ticker,date,open,high,low,close,news
DXCM,2005-04-13,3.0,3.0,3.0,3.0,
DXCM,2005-04-14,3.02,3.05,2.7025,2.935,
DXCM,2005-04-15,2.9125,2.925,2.5575,2.5625,
DXCM,2005-04-18,2.625,2.705,2.6,2.625,
DXCM,2005-04-19,2.75,2.75,2.64,2.645,
DXCM,2005-04-20,2.6375,2.675,2.625,2.65,
DXCM,2005-04-21,2.65,2.6575,2.625,2.625,
DXCM,2005-04-22,2.69,2.7425,2.625,2.63,
DXCM,2005-04-25,2.665,2.6875,2.6275,2.6375,
DXCM,2005-04-26,2.6275,2.6625,2.625,2.625,
DXCM,2005-04-27,2.625,2.635,2.4025,2.4475,
DXCM,2005-04-28,2.4175,2.54,2.4175,2.475,
DXCM,2005-04-29,2.5,2.575,2.5,2.5,
DXCM,2005-05-02,2.47,2.525,2.4675,2.4775,
DXCM,2005-05-03,2.495,2.525,2.475,2.5,
DXCM,2005-05-04,2.5,2.525,2.475,2.525,
DXCM,2005-05-05,2.5025,2.5225,2.475,2.475,
DXCM,2005-05-06,2.475,2.5,2.475,2.5,
DXCM,2005-05-09,2.5225,2.525,2.475,2.475,
DXCM,2005-05-10,2.6175,2.9375,2.525,2.8475,
DXCM,2005-05-11,2.8525,2.9375,2.825,2.8675,
DXCM,2005-05-12,2.875,2.925,2.7375,2.8275,
DXCM,2005-05-13,2.8975,2.915,2.84,2.9075,
DXCM,2005-05-16,2.9,3.225,2.8775,3.1425,
DXCM,2005-05-17,3.185,3.685,3.1075,3.4875,
DXCM,2005-05-18,3.5575,3.575,3.4125,3.4975,
DXCM,2005-05-19,3.5,3.5075,3.4825,3.4975,
DXCM,2005-05-20,3.5,3.51,3.4475,3.47,
DXCM,2005-05-23,3.5,3.505,3.3425,3.5,
DXCM,2005-05-24,3.5075,3.55,3.475,3.5,
DXCM,2005-05-25,3.4625,3.5375,3.375,3.5125,
DXCM,2005-05-26,3.4875,3.65,3.4875,3.5025,
DXCM,2005-05-27,3.555,3.5625,3.5,3.55,
DXCM,2005-05-31,3.58,3.58,3.4225,3.5,
DXCM,2005-06-01,3.5625,3.565,3.395,3.4775,
DXCM,2005-06-02,3.46,3.46,3.375,3.39,
DXCM,2005-06-03,3.385,3.4525,3.375,3.435,
DXCM,2005-06-06,3.46,3.5,3.4375,3.5,
DXCM,2005-06-07,3.5125,3.6475,3.505,3.6475,
DXCM,2005-06-08,3.645,3.77,3.645,3.725,
DXCM,2005-06-09,3.725,3.8225,3.615,3.7225,
DXCM,2005-06-10,3.74,3.895,3.6625,3.77,
DXCM,2005-06-13,3.8975,3.9975,3.8,3.85,
DXCM,2005-06-14,3.975,3.975,3.7375,3.77,
DXCM,2005-06-15,3.73,3.875,3.73,3.8475,
DXCM,2005-06-16,3.8475,3.875,3.7675,3.8125,
DXCM,2005-06-17,3.875,3.875,3.75,3.8,
DXCM,2005-06-20,3.825,3.825,3.725,3.7525,
DXCM,2005-06-21,3.7375,3.75,3.5025,3.61,
DXCM,2005-06-22,3.5625,3.565,3.3075,3.3825,
DXCM,2005-06-23,3.32,3.3625,3.125,3.1825,
DXCM,2005-06-24,3.12,3.245,3.0,3.0,
DXCM,2005-06-27,3.04,3.05,2.8775,2.9875,
DXCM,2005-06-28,3.0625,3.13,2.9875,3.125,
DXCM,2005-06-29,3.1625,3.1625,3.0625,3.0925,
DXCM,2005-06-30,3.0825,3.125,3.06,3.1,
DXCM,2005-07-01,3.1,3.125,3.1,3.11,
DXCM,2005-07-05,3.125,3.1325,3.075,3.13,
DXCM,2005-07-06,3.1375,3.1375,2.9775,3.045,
DXCM,2005-07-07,3.0125,3.0125,2.9475,2.9475,
DXCM,2005-07-08,2.935,3.01,2.8875,3.01,
DXCM,2005-07-11,3.0,3.125,2.9375,3.0875,
DXCM,2005-07-12,3.05,3.075,2.9375,2.995,
DXCM,2005-07-13,3.04,3.04,2.9,2.93,
DXCM,2005-07-14,2.9375,2.94,2.85,2.8875,
DXCM,2005-07-15,2.9325,2.9375,2.83,2.885,
DXCM,2005-07-18,2.935,2.935,2.885,2.905,
DXCM,2005-07-19,2.9125,2.9425,2.875,2.88,
DXCM,2005-07-20,2.91,2.9375,2.7625,2.8,
DXCM,2005-07-21,2.785,2.9425,2.775,2.8125,
DXCM,2005-07-22,2.8575,2.8975,2.805,2.87,
DXCM,2005-07-25,2.9025,2.9025,2.5975,2.6075,
DXCM,2005-07-26,2.625,2.9,2.625,2.75,
DXCM,2005-07-27,2.7975,2.7975,2.69,2.75,
DXCM,2005-07-28,2.75,2.75,2.7075,2.75,
DXCM,2005-07-29,2.75,2.755,2.6825,2.755,
DXCM,2005-08-01,2.7975,2.9775,2.79,2.9,
DXCM,2005-08-02,2.9,2.9375,2.8575,2.9325,
DXCM,2005-08-03,2.9325,2.9375,2.865,2.9,
DXCM,2005-08-04,2.9,2.9175,2.7525,2.77,
DXCM,2005-08-05,2.8625,2.8625,2.705,2.7125,
DXCM,2005-08-08,2.71,2.71,2.5,2.5975,
DXCM,2005-08-09,2.725,2.725,2.56,2.5625,
DXCM,2005-08-10,2.565,2.6125,2.4875,2.55,
DXCM,2005-08-11,2.5875,2.5875,2.475,2.5,
DXCM,2005-08-12,2.525,2.5625,2.485,2.53,
DXCM,2005-08-15,2.5625,2.5625,2.5,2.5625,
DXCM,2005-08-16,2.5625,2.625,2.5225,2.5625,
DXCM,2005-08-17,2.5375,2.5875,2.4625,2.535,
DXCM,2005-08-18,2.5275,2.925,2.5275,2.8875,
DXCM,2005-08-19,2.935,3.055,2.935,2.9375,
DXCM,2005-08-22,2.9725,3.0275,2.945,3.0225,
DXCM,2005-08-23,3.0725,3.35,3.0,3.095,
DXCM,2005-08-24,3.1875,3.23,3.05,3.08,
DXCM,2005-08-25,3.08,3.135,3.025,3.085,
DXCM,2005-08-26,3.0575,3.0675,2.915,2.9225,
DXCM,2005-08-29,2.945,3.0375,2.9375,2.975,
DXCM,2005-08-30,3.0,3.05,2.9875,3.025,
DXCM,2005-08-31,3.085,3.11,3.035,3.11,
DXCM,2005-09-01,3.1175,3.125,3.015,3.025,
DXCM,2005-09-02,3.0125,3.1225,3.0125,3.105,
DXCM,2005-09-06,3.07,3.145,3.07,3.145,
DXCM,2005-09-07,3.13,3.155,3.06,3.125,
DXCM,2005-09-08,3.1725,3.1975,3.05,3.0875,
DXCM,2005-09-09,3.095,3.135,3.095,3.1125,
DXCM,2005-09-12,3.0875,3.175,3.0625,3.0625,
DXCM,2005-09-13,3.1025,3.1375,3.04,3.0775,
DXCM,2005-09-14,3.115,3.1525,3.0875,3.12,
DXCM,2005-09-15,3.1125,3.1125,3.075,3.1,
DXCM,2005-09-16,3.1,3.1075,3.075,3.1075,
DXCM,2005-09-19,3.1025,3.105,3.015,3.0325,
DXCM,2005-09-20,3.0125,3.035,2.9575,2.99,
DXCM,2005-09-21,3.0275,3.125,2.97,3.0775,
DXCM,2005-09-22,3.06,3.06,3.0025,3.0475,
DXCM,2005-09-23,3.0625,3.1425,3.0625,3.07,
DXCM,2005-09-26,3.0625,3.1675,3.04,3.115,
DXCM,2005-09-27,3.125,3.125,3.035,3.035,
DXCM,2005-09-28,3.0175,3.025,2.875,2.935,
DXCM,2005-09-29,2.8775,2.9425,2.875,2.9425,
DXCM,2005-09-30,2.9225,2.94,2.875,2.905,
DXCM,2005-10-03,2.8875,3.1375,2.8875,2.975,
DXCM,2005-10-04,2.9625,3.1125,2.955,3.0375,
DXCM,2005-10-05,3.015,3.025,2.9725,3.0025,
DXCM,2005-10-06,3.0025,3.075,3.0,3.04,
DXCM,2005-10-07,3.05,3.085,3.0425,3.0425,
DXCM,2005-10-10,3.075,3.1,3.0,3.075,
DXCM,2005-10-11,3.03,3.0375,2.8875,2.955,
DXCM,2005-10-12,2.92,2.94,2.7775,2.81,
DXCM,2005-10-13,2.825,2.845,2.7075,2.71,
DXCM,2005-10-14,2.7325,2.7525,2.6775,2.7525,
DXCM,2005-10-17,2.7275,2.8775,2.5,2.855,
DXCM,2005-10-18,2.8875,2.8975,2.8275,2.8525,
DXCM,2005-10-19,2.825,2.955,2.825,2.93,
DXCM,2005-10-20,2.935,2.935,2.8925,2.9025,
DXCM,2005-10-21,2.8875,2.9375,2.8875,2.9375,
DXCM,2005-10-24,2.905,2.9975,2.8925,2.99,
DXCM,2005-10-25,2.9975,3.1125,2.9725,3.1125,
DXCM,2005-10-26,3.1125,3.2125,3.025,3.1975,
DXCM,2005-10-27,3.2425,3.2425,3.0725,3.11,
DXCM,2005-10-28,3.125,3.1775,3.0875,3.1525,
DXCM,2005-10-31,3.1575,3.285,3.1575,3.2525,
DXCM,2005-11-01,3.2875,3.3875,3.2625,3.3625,
DXCM,2005-11-02,3.335,3.5,3.1175,3.42,
DXCM,2005-11-03,3.4275,3.475,3.425,3.45,
DXCM,2005-11-04,3.44,3.4425,3.27,3.3175,
DXCM,2005-11-07,3.35,3.355,3.275,3.275,
DXCM,2005-11-08,3.2375,3.24,3.1875,3.215,
DXCM,2005-11-09,3.23,3.355,3.23,3.3475,
DXCM,2005-11-10,3.375,3.4,3.325,3.335,
DXCM,2005-11-11,3.325,3.425,3.325,3.3825,
DXCM,2005-11-14,3.3825,3.5825,3.3825,3.53,
DXCM,2005-11-15,3.5675,3.595,3.4475,3.4775,
DXCM,2005-11-16,3.485,3.495,3.4525,3.475,
DXCM,2005-11-17,3.44,3.5875,3.44,3.5475,
DXCM,2005-11-18,3.615,3.615,3.495,3.5975,
DXCM,2005-11-21,3.6225,3.75,3.61,3.72,
DXCM,2005-11-22,3.75,3.7525,3.555,3.7525,
DXCM,2005-11-23,3.7375,3.9125,3.705,3.8,
DXCM,2005-11-25,3.8,3.85,3.7875,3.8,
DXCM,2005-11-28,3.8175,3.8175,3.525,3.5275,
DXCM,2005-11-29,3.6375,3.6875,3.48,3.49,
DXCM,2005-11-30,3.5075,3.5625,3.475,3.505,
DXCM,2005-12-01,3.5625,3.575,3.5,3.5075,
DXCM,2005-12-02,3.5,3.6425,3.4725,3.6425,
DXCM,2005-12-05,3.6,3.6375,3.5,3.535,
DXCM,2005-12-06,3.5025,3.6,3.5,3.565,
DXCM,2005-12-07,3.6,3.6,3.5725,3.575,
DXCM,2005-12-08,3.5425,3.575,3.53,3.5575,
DXCM,2005-12-09,3.54,3.625,3.54,3.6225,
DXCM,2005-12-12,3.6125,3.715,3.5075,3.54,
DXCM,2005-12-13,3.5675,3.5675,3.4975,3.525,
DXCM,2005-12-14,3.4525,3.525,3.4525,3.5,
DXCM,2005-12-15,3.5,3.82,3.5,3.82,
DXCM,2005-12-16,3.8125,3.875,3.8,3.8575,
DXCM,2005-12-19,3.8775,4.0425,3.85,3.9875,
DXCM,2005-12-20,4.0,4.0175,3.99,3.9975,
DXCM,2005-12-21,4.0225,4.0225,3.8525,3.89,
DXCM,2005-12-22,3.8825,3.975,3.8525,3.8775,
DXCM,2005-12-23,3.875,4.015,3.865,3.895,
DXCM,2005-12-27,3.8675,3.9075,3.8675,3.8875,
DXCM,2005-12-28,3.91,3.935,3.8775,3.9,
DXCM,2005-12-29,3.91,3.9225,3.8025,3.8025,
DXCM,2005-12-30,3.8225,3.8225,3.7075,3.73,
DXCM,2006-01-03,3.745,3.745,3.625,3.625,
DXCM,2006-01-04,3.66,3.95,3.65,3.8125,
DXCM,2006-01-05,3.8575,3.96,3.7875,3.95,
DXCM,2006-01-06,3.995,4.065,3.9125,3.9125,
DXCM,2006-01-09,3.9375,4.05,3.895,3.895,
DXCM,2006-01-10,3.8875,3.9425,3.8025,3.9025,
DXCM,2006-01-11,3.9025,3.9425,3.85,3.855,
DXCM,2006-01-12,3.855,4.0,3.7825,3.8125,
DXCM,2006-01-13,3.775,3.9225,3.6875,3.77,
DXCM,2006-01-17,3.7225,3.7575,3.65,3.6775,
DXCM,2006-01-18,3.7075,3.7475,3.5775,3.675,
DXCM,2006-01-19,3.735,3.8,3.6,3.7,
DXCM,2006-01-20,3.7425,3.895,3.725,3.7675,
DXCM,2006-01-23,3.79,3.79,3.73,3.7475,
DXCM,2006-01-24,3.77,3.7875,3.7,3.7175,
DXCM,2006-01-25,3.7425,3.8975,3.725,3.8975,
DXCM,2006-01-26,3.935,4.195,3.9225,4.075,
DXCM,2006-01-27,4.075,4.1375,3.9725,4.06,
DXCM,2006-01-30,4.05,4.5,3.9975,4.43,
DXCM,2006-01-31,4.425,4.8575,4.3925,4.75,
DXCM,2006-02-01,4.75,4.75,4.57,4.6025,
DXCM,2006-02-02,4.6025,4.6875,4.3375,4.5,
DXCM,2006-02-03,4.495,4.585,4.365,4.47,
DXCM,2006-02-06,4.5,4.575,4.475,4.5,
DXCM,2006-02-07,4.5,4.525,4.4625,4.465,
DXCM,2006-02-08,4.4575,4.525,4.4025,4.5,
DXCM,2006-02-09,4.5,4.6575,4.485,4.5,
DXCM,2006-02-10,4.43,4.52,4.2875,4.4925,
DXCM,2006-02-13,4.5,4.5475,4.395,4.41,
DXCM,2006-02-14,4.41,4.44,4.3375,4.3725,
DXCM,2006-02-15,4.355,4.4125,4.2725,4.3125,
DXCM,2006-02-16,4.3075,4.375,4.225,4.3125,
DXCM,2006-02-17,4.3375,4.3875,4.22,4.3175,
DXCM,2006-02-21,4.34,4.35,4.2375,4.2425,
DXCM,2006-02-22,4.26,4.5375,4.2575,4.3275,
DXCM,2006-02-23,4.35,4.5,4.2375,4.26,
DXCM,2006-02-24,4.2825,4.2825,4.1525,4.25,
DXCM,2006-02-27,4.25,4.2675,4.1475,4.2475,
DXCM,2006-02-28,4.25,4.375,4.07,4.3625,
DXCM,2006-03-01,4.36,4.625,4.2975,4.55,
DXCM,2006-03-02,4.51,4.765,4.51,4.73,
DXCM,2006-03-03,4.7,4.71,4.475,4.55,
DXCM,2006-03-06,4.5375,4.585,4.425,4.525,
DXCM,2006-03-07,4.5,4.505,4.4325,4.465,
DXCM,2006-03-08,4.46,4.5425,4.44,4.53,
DXCM,2006-03-09,4.545,4.6575,4.525,4.5875,
DXCM,2006-03-10,4.5725,4.665,4.565,4.64,
DXCM,2006-03-13,4.6675,4.71,4.6,4.67,
DXCM,2006-03-14,4.6875,4.9125,4.6875,4.8825,
DXCM,2006-03-15,4.8975,5.2225,4.8975,5.2,
DXCM,2006-03-16,5.2275,5.2275,5.0,5.0125,
DXCM,2006-03-17,5.035,5.0625,4.8,4.82,
DXCM,2006-03-20,4.835,4.85,4.5775,4.61,
DXCM,2006-03-21,4.645,4.755,4.5,4.6225,
DXCM,2006-03-22,4.6375,4.825,4.625,4.665,
DXCM,2006-03-23,4.67,4.855,4.6625,4.8125,
DXCM,2006-03-24,4.825,4.9725,4.72,4.9525,
DXCM,2006-03-27,5.495,5.925,5.16,5.3,
DXCM,2006-03-28,5.4875,5.5,5.0875,5.265,
DXCM,2006-03-29,5.28,5.35,5.11,5.1525,
DXCM,2006-03-30,5.1475,5.175,4.915,5.0625,
DXCM,2006-03-31,5.08,5.125,5.015,5.0675,
DXCM,2006-04-03,5.1025,5.215,5.0325,5.14,
DXCM,2006-04-04,5.175,5.3625,5.145,5.1525,
DXCM,2006-04-05,5.185,5.2675,5.1,5.15,
DXCM,2006-04-06,5.0,5.1,4.9475,5.055,
DXCM,2006-04-07,5.035,5.07,4.825,4.9275,
DXCM,2006-04-10,4.9275,4.985,4.75,4.965,
DXCM,2006-04-11,4.9675,4.9875,4.7775,4.825,
DXCM,2006-04-12,4.8175,5.16,4.79,5.0775,
DXCM,2006-04-13,5.1075,5.2625,5.065,5.095,
DXCM,2006-04-17,5.13,5.2,5.06,5.1625,
DXCM,2006-04-18,5.1625,5.4225,5.15,5.405,
DXCM,2006-04-19,5.3925,5.455,5.295,5.4525,
DXCM,2006-04-20,5.4275,5.5775,5.3475,5.5625,
DXCM,2006-04-21,5.5825,5.8675,5.5575,5.825,
DXCM,2006-04-24,5.8025,5.92,5.7225,5.875,
DXCM,2006-04-25,5.875,6.3,5.845,6.2475,
DXCM,2006-04-26,6.1875,6.2325,5.89,6.2175,
DXCM,2006-04-27,6.4225,6.675,6.19,6.255,
DXCM,2006-04-28,6.2675,6.31,6.1875,6.29,
DXCM,2006-05-01,6.29,6.38,6.225,6.2625,
DXCM,2006-05-02,6.25,6.3125,6.225,6.2825,
DXCM,2006-05-03,6.255,6.415,6.155,6.3175,
DXCM,2006-05-04,6.2575,6.4625,6.2575,6.45,
DXCM,2006-05-05,6.475,6.5,6.2675,6.3125,
DXCM,2006-05-08,6.2875,6.295,6.0125,6.1375,
DXCM,2006-05-09,6.105,6.105,5.7775,5.87,
DXCM,2006-05-10,5.87,5.9875,5.6875,5.8025,
DXCM,2006-05-11,5.825,5.9375,5.55,5.575,
DXCM,2006-05-12,5.575,5.615,5.425,5.5125,
DXCM,2006-05-15,5.5125,5.5375,5.3025,5.4525,
DXCM,2006-05-16,5.125,5.5875,5.08,5.51,
DXCM,2006-05-17,5.5,5.5125,5.375,5.46,
DXCM,2006-05-18,5.4825,5.495,5.295,5.295,
DXCM,2006-05-19,5.2975,5.3475,5.2075,5.25,
DXCM,2006-05-22,5.2125,5.2625,5.1,5.18,
DXCM,2006-05-23,5.215,5.47,5.16,5.26,
DXCM,2006-05-24,5.25,5.29,5.0875,5.205,
DXCM,2006-05-25,5.255,5.2625,5.0375,5.15,
DXCM,2006-05-26,5.19,5.19,4.6875,4.95,
DXCM,2006-05-30,5.015,5.075,4.9,4.9375,
DXCM,2006-05-31,4.925,5.0,4.8475,4.865,
DXCM,2006-06-01,4.865,4.94,4.7725,4.9375,
DXCM,2006-06-02,5.0,5.4025,4.965,5.2925,
DXCM,2006-06-05,5.2625,5.405,5.25,5.3075,
DXCM,2006-06-06,5.3025,5.335,5.215,5.275,
DXCM,2006-06-07,5.2675,5.325,5.065,5.0825,
DXCM,2006-06-08,5.04,5.0575,4.6075,4.725,
DXCM,2006-06-09,4.7375,4.83,4.6625,4.675,
DXCM,2006-06-12,4.665,4.715,4.19,4.2075,
DXCM,2006-06-13,3.8025,4.115,3.2775,3.4925,
DXCM,2006-06-14,3.4975,3.5225,3.205,3.475,
DXCM,2006-06-15,3.47,3.585,3.3125,3.3725,
DXCM,2006-06-16,3.365,3.3975,3.29,3.38,
DXCM,2006-06-19,3.3975,3.5125,3.3575,3.395,
DXCM,2006-06-20,3.4125,3.465,3.3375,3.36,
DXCM,2006-06-21,3.3625,3.3625,3.1925,3.2075,
DXCM,2006-06-22,3.21,3.2275,2.945,3.025,
DXCM,2006-06-23,3.0225,3.1825,2.98,3.115,
DXCM,2006-06-26,3.105,3.1375,3.0225,3.06,
DXCM,2006-06-27,3.055,3.06,2.925,2.9725,
DXCM,2006-06-28,2.975,3.1975,2.975,3.16,
DXCM,2006-06-29,3.165,3.2775,3.1625,3.2775,
DXCM,2006-06-30,3.3,3.425,3.2275,3.395,
DXCM,2006-07-03,3.3675,3.4875,3.3625,3.4475,
DXCM,2006-07-05,3.425,3.4375,3.255,3.335,
DXCM,2006-07-06,3.3575,3.375,3.23,3.25,
DXCM,2006-07-07,3.235,3.265,3.175,3.22,
DXCM,2006-07-10,3.2225,3.4425,3.2075,3.3125,
DXCM,2006-07-11,3.2925,3.325,3.11,3.1925,
DXCM,2006-07-12,3.18,3.2125,3.0775,3.0925,
DXCM,2006-07-13,3.08,3.1025,2.9675,3.005,
DXCM,2006-07-14,2.9925,3.045,2.95,3.0325,
DXCM,2006-07-17,3.0275,3.05,2.85,2.91,
DXCM,2006-07-18,2.9125,2.96,2.8825,2.92,
DXCM,2006-07-19,2.9325,3.1375,2.9125,3.1125,
DXCM,2006-07-20,3.1325,3.175,3.005,3.015,
DXCM,2006-07-21,2.9825,2.99,2.725,2.82,
DXCM,2006-07-24,2.8375,2.8775,2.735,2.7475,
DXCM,2006-07-25,2.7575,2.8525,2.5875,2.81,
DXCM,2006-07-26,2.8,2.8625,2.77,2.8475,
DXCM,2006-07-27,2.88,3.0,2.7125,2.755,
DXCM,2006-07-28,2.77,3.085,2.77,2.98,
DXCM,2006-07-31,2.965,2.9875,2.875,2.9725,
DXCM,2006-08-01,2.9625,2.9725,2.86,2.92,
DXCM,2006-08-02,2.93,3.0,2.9025,2.925,
DXCM,2006-08-03,2.91,2.975,2.85,2.925,
DXCM,2006-08-04,2.9625,2.98,2.87,2.8925,
DXCM,2006-08-07,2.87,2.875,2.715,2.845,
DXCM,2006-08-08,2.85,2.88,2.7875,2.8325,
DXCM,2006-08-09,2.8525,2.855,2.7425,2.7725,
DXCM,2006-08-10,2.7425,2.8675,2.7375,2.8375,
DXCM,2006-08-11,2.825,2.885,2.745,2.7975,
DXCM,2006-08-14,2.775,2.885,2.725,2.8825,
DXCM,2006-08-15,2.885,3.06,2.885,2.9375,
DXCM,2006-08-16,2.945,3.1225,2.945,3.04,
DXCM,2006-08-17,3.0225,3.11,3.0,3.055,
DXCM,2006-08-18,3.1325,3.5875,3.1275,3.545,
DXCM,2006-08-21,3.5625,3.6,3.34,3.4175,
DXCM,2006-08-22,3.4025,3.4175,3.325,3.3375,
DXCM,2006-08-23,3.35,3.3675,3.2325,3.25,
DXCM,2006-08-24,3.245,3.2625,3.1925,3.23,
DXCM,2006-08-25,3.2325,3.265,3.2075,3.2325,
DXCM,2006-08-28,3.25,3.25,3.2,3.2175,
DXCM,2006-08-29,3.25,3.25,3.0825,3.2025,
DXCM,2006-08-30,3.1925,3.31,3.175,3.2625,
DXCM,2006-08-31,3.2925,3.3375,3.2,3.21,
DXCM,2006-09-01,3.2125,3.2125,2.9,2.915,
DXCM,2006-09-05,2.8975,3.0375,2.82,3.0,
DXCM,2006-09-06,2.9875,3.0225,2.845,2.9125,
DXCM,2006-09-07,2.885,2.8925,2.7625,2.7875,
DXCM,2006-09-08,2.8,2.8675,2.7975,2.8625,
DXCM,2006-09-11,2.8625,2.895,2.8375,2.8925,
DXCM,2006-09-12,2.8775,2.9175,2.875,2.885,
DXCM,2006-09-13,2.875,2.8975,2.7575,2.7725,
DXCM,2006-09-14,2.7525,2.77,2.6625,2.68,
DXCM,2006-09-15,2.7,2.7375,2.6075,2.6575,
DXCM,2006-09-18,2.6525,2.71,2.61,2.615,
DXCM,2006-09-19,2.615,2.625,2.5125,2.5575,
DXCM,2006-09-20,2.555,2.675,2.5525,2.6425,
DXCM,2006-09-21,2.645,2.6925,2.5625,2.6775,
DXCM,2006-09-22,2.6775,2.77,2.59,2.615,
DXCM,2006-09-25,2.625,2.6625,2.5475,2.6375,
DXCM,2006-09-26,2.6475,2.685,2.6125,2.675,
DXCM,2006-09-27,2.6825,2.8025,2.6575,2.735,
DXCM,2006-09-28,2.755,2.755,2.685,2.695,
DXCM,2006-09-29,2.685,2.8475,2.68,2.7825,
DXCM,2006-10-02,2.775,2.8225,2.725,2.755,
DXCM,2006-10-03,2.7375,2.7475,2.625,2.6675,
DXCM,2006-10-04,2.65,2.7075,2.5925,2.6725,
DXCM,2006-10-05,2.6875,2.8125,2.65,2.8025,
DXCM,2006-10-06,2.7825,2.92,2.7725,2.7875,
DXCM,2006-10-09,2.7825,2.8375,2.76,2.785,
DXCM,2006-10-10,2.785,3.0,2.7775,2.9775,
DXCM,2006-10-11,2.9975,3.0425,2.84,2.885,
DXCM,2006-10-12,2.91,2.9525,2.8625,2.885,
DXCM,2006-10-13,2.9,2.9,2.785,2.805,
DXCM,2006-10-16,2.8,2.8,2.72,2.7425,
DXCM,2006-10-17,2.7475,2.7625,2.6875,2.745,
DXCM,2006-10-18,2.77,2.77,2.6125,2.6375,
DXCM,2006-10-19,2.6375,2.65,2.4875,2.55,
DXCM,2006-10-20,2.55,2.57,2.4225,2.45,
DXCM,2006-10-23,2.4525,2.4975,2.425,2.4475,
DXCM,2006-10-24,2.2875,2.325,2.15,2.2575,
DXCM,2006-10-25,2.2525,2.285,2.2375,2.255,
DXCM,2006-10-26,2.25,2.345,2.2425,2.295,
DXCM,2006-10-27,2.2775,2.3125,2.1925,2.2875,
DXCM,2006-10-30,2.27,2.27,2.1675,2.195,
DXCM,2006-10-31,2.1875,2.2125,2.1175,2.2,
DXCM,2006-11-01,2.21,2.2125,2.0875,2.155,
DXCM,2006-11-02,2.1625,2.2525,2.125,2.2275,
DXCM,2006-11-03,2.25,2.31,2.15,2.2875,
DXCM,2006-11-06,2.24,2.3875,2.24,2.33,
DXCM,2006-11-07,2.32,2.425,2.3,2.305,
DXCM,2006-11-08,2.3025,2.31,2.235,2.265,
DXCM,2006-11-09,2.2625,2.48,2.24,2.3,
DXCM,2006-11-10,2.325,2.445,2.305,2.4275,
DXCM,2006-11-13,2.45,2.5675,2.44,2.5575,
DXCM,2006-11-14,2.575,2.6725,2.5725,2.6475,
DXCM,2006-11-15,2.6375,2.6575,2.5625,2.625,
DXCM,2006-11-16,2.6325,2.665,2.5825,2.62,
DXCM,2006-11-17,2.62,2.6575,2.5625,2.6425,
DXCM,2006-11-20,2.6325,2.755,2.625,2.7075,
DXCM,2006-11-21,2.72,2.9925,2.705,2.925,
DXCM,2006-11-22,2.9225,2.9375,2.825,2.825,
DXCM,2006-11-24,2.81,2.9375,2.775,2.935,
DXCM,2006-11-27,2.93,2.945,2.725,2.75,
DXCM,2006-11-28,2.735,2.7575,2.615,2.645,
DXCM,2006-11-29,2.665,2.8375,2.65,2.7375,
DXCM,2006-11-30,2.73,2.845,2.7125,2.815,
DXCM,2006-12-01,2.815,2.9,2.7925,2.8775,
DXCM,2006-12-04,2.8975,3.0375,2.8775,2.9225,
DXCM,2006-12-05,2.9375,2.95,2.8525,2.8775,
DXCM,2006-12-06,2.875,2.905,2.825,2.9,
DXCM,2006-12-07,2.9025,3.0075,2.8525,2.8775,
DXCM,2006-12-08,2.865,2.8875,2.835,2.85,
DXCM,2006-12-11,2.835,2.895,2.8075,2.8475,
DXCM,2006-12-12,2.835,2.9725,2.815,2.825,
DXCM,2006-12-13,2.835,2.8925,2.705,2.745,
DXCM,2006-12-14,2.74,2.74,2.575,2.6475,
DXCM,2006-12-15,2.65,2.76,2.605,2.6825,
DXCM,2006-12-18,2.7075,2.7875,2.6075,2.6375,
DXCM,2006-12-19,2.63,2.75,2.6,2.6975,
DXCM,2006-12-20,2.7075,2.7825,2.67,2.755,
DXCM,2006-12-21,2.7525,2.7625,2.55,2.555,
DXCM,2006-12-22,2.5625,2.5925,2.465,2.5,
DXCM,2006-12-26,2.505,2.6,2.505,2.5775,
DXCM,2006-12-27,2.5725,2.5775,2.5125,2.5575,
DXCM,2006-12-28,2.56,2.57,2.475,2.5175,
DXCM,2006-12-29,2.51,2.5125,2.43,2.465,
DXCM,2007-01-03,2.49,2.5275,2.4375,2.47,
DXCM,2007-01-04,2.455,2.4725,2.3975,2.4475,
DXCM,2007-01-05,2.4325,2.475,2.3625,2.42,
DXCM,2007-01-08,2.415,2.5125,2.3875,2.41,
DXCM,2007-01-09,2.4075,2.4325,2.35,2.355,
DXCM,2007-01-10,2.34,2.37,2.295,2.3675,
DXCM,2007-01-11,2.3375,2.38,2.2,2.29,
DXCM,2007-01-12,2.275,2.2875,2.2,2.2475,
DXCM,2007-01-16,2.2475,2.25,2.125,2.15,
DXCM,2007-01-17,2.1525,2.2375,2.13,2.2025,
DXCM,2007-01-18,2.1975,2.205,2.125,2.1325,
DXCM,2007-01-19,2.1275,2.19,2.0075,2.1775,
DXCM,2007-01-22,2.18,2.18,2.0875,2.1075,
DXCM,2007-01-23,2.1,2.1325,2.0775,2.13,
DXCM,2007-01-24,2.1275,2.2425,2.1075,2.2275,
DXCM,2007-01-25,2.2425,2.26,2.16,2.25,
DXCM,2007-01-26,2.25,2.285,2.1875,2.2525,
DXCM,2007-01-29,2.24,2.395,2.215,2.3,
DXCM,2007-01-30,2.3,2.31,2.2475,2.2775,
DXCM,2007-01-31,2.27,2.27,2.1875,2.225,
DXCM,2007-02-01,2.2475,2.26,2.2025,2.2375,
DXCM,2007-02-02,2.2375,2.275,2.2125,2.225,
DXCM,2007-02-05,2.23,2.3125,2.205,2.25,
DXCM,2007-02-06,2.2525,2.2625,2.205,2.2225,
DXCM,2007-02-07,2.2175,2.23,2.2025,2.2125,
DXCM,2007-02-08,2.2075,2.22,2.165,2.2,
DXCM,2007-02-09,2.2,2.215,2.1625,2.195,
DXCM,2007-02-12,2.2,2.2,2.125,2.1575,
DXCM,2007-02-13,2.1525,2.2475,2.13,2.245,
DXCM,2007-02-14,2.24,2.2625,2.17,2.2,
DXCM,2007-02-15,2.2125,2.22,2.1775,2.215,
DXCM,2007-02-16,2.2175,2.235,2.165,2.205,
DXCM,2007-02-20,2.1975,2.26,2.1975,2.25,
DXCM,2007-02-21,2.2375,2.2475,2.165,2.185,
DXCM,2007-02-22,2.1825,2.2325,2.1525,2.1775,
DXCM,2007-02-23,2.1775,2.3475,2.1775,2.3125,
DXCM,2007-02-26,2.33,2.33,2.2525,2.265,
DXCM,2007-02-27,2.2525,2.2575,2.06,2.12,
DXCM,2007-02-28,2.125,2.155,2.0,2.0225,
DXCM,2007-03-01,2.0,2.0825,1.9475,1.985,
DXCM,2007-03-02,1.9675,2.0,1.6725,1.695,
DXCM,2007-03-05,1.67,1.675,1.5425,1.625,
DXCM,2007-03-06,1.625,1.75,1.6175,1.7425,
DXCM,2007-03-07,1.735,1.855,1.7175,1.845,
DXCM,2007-03-08,1.8025,1.8575,1.8,1.8325,
DXCM,2007-03-09,1.8425,1.8575,1.7925,1.8125,
DXCM,2007-03-12,1.8825,1.8875,1.8325,1.855,
DXCM,2007-03-13,1.83,1.8525,1.8125,1.8375,
DXCM,2007-03-14,1.84,1.84,1.7825,1.835,
DXCM,2007-03-15,1.825,1.825,1.7775,1.8125,
DXCM,2007-03-16,1.8175,1.8475,1.7,1.75,
DXCM,2007-03-19,1.76,1.79,1.7175,1.735,
DXCM,2007-03-20,1.7325,1.76,1.725,1.75,
DXCM,2007-03-21,1.75,1.75,1.7325,1.75,
DXCM,2007-03-22,1.76,1.82,1.76,1.8025,
DXCM,2007-03-23,1.8025,1.8875,1.8,1.825,
DXCM,2007-03-26,1.8225,1.8425,1.81,1.825,
DXCM,2007-03-27,1.8225,1.8575,1.8125,1.8225,
DXCM,2007-03-28,1.8175,1.845,1.8,1.8125,
DXCM,2007-03-29,1.835,1.945,1.8075,1.925,
DXCM,2007-03-30,1.9375,1.97,1.9325,1.965,
DXCM,2007-04-02,1.97,1.97,1.9,1.93,
DXCM,2007-04-03,1.935,1.985,1.9125,1.9725,
DXCM,2007-04-04,1.9675,1.9675,1.91,1.915,
DXCM,2007-04-05,1.9125,1.9275,1.8875,1.91,
DXCM,2007-04-09,1.95,2.285,1.95,2.2075,
DXCM,2007-04-10,2.2125,2.265,2.13,2.1675,
DXCM,2007-04-11,2.1725,2.1725,2.0575,2.0775,
DXCM,2007-04-12,2.0775,2.1475,2.0775,2.1025,
DXCM,2007-04-13,2.1175,2.12,2.0275,2.0425,
DXCM,2007-04-16,2.06,2.105,2.0,2.0875,
DXCM,2007-04-17,2.0975,2.1275,2.0625,2.0875,
DXCM,2007-04-18,2.085,2.09,2.05,2.0625,
DXCM,2007-04-19,2.065,2.0825,1.98,1.985,
DXCM,2007-04-20,2.0175,2.0825,1.9725,2.0625,
DXCM,2007-04-23,2.05,2.0625,1.9825,2.0375,
DXCM,2007-04-24,2.05,2.07,1.975,1.995,
DXCM,2007-04-25,2.0,2.085,2.0,2.04,
DXCM,2007-04-26,2.0425,2.07,1.99,2.065,
DXCM,2007-04-27,2.0325,2.075,2.03,2.0425,
DXCM,2007-04-30,2.055,2.07,1.985,1.9925,
DXCM,2007-05-01,1.9925,1.9925,1.9125,1.93,
DXCM,2007-05-02,1.94,1.9525,1.9025,1.925,
DXCM,2007-05-03,1.9225,1.9275,1.8475,1.8675,
DXCM,2007-05-04,1.875,1.875,1.78,1.845,
DXCM,2007-05-07,1.84,1.89,1.84,1.88,
DXCM,2007-05-08,1.8875,1.9125,1.8025,1.85,
DXCM,2007-05-09,1.825,1.8925,1.825,1.8825,
DXCM,2007-05-10,1.8375,1.95,1.835,1.9325,
DXCM,2007-05-11,1.945,1.9775,1.8725,1.9075,
DXCM,2007-05-14,1.9,1.9325,1.8525,1.8675,
DXCM,2007-05-15,1.86,1.8875,1.8,1.8,
DXCM,2007-05-16,1.81,1.85,1.7525,1.7875,
DXCM,2007-05-17,1.7875,1.7875,1.725,1.7275,
DXCM,2007-05-18,1.735,1.7525,1.7075,1.7175,
DXCM,2007-05-21,1.7175,1.8275,1.7175,1.775,
DXCM,2007-05-22,1.775,1.835,1.775,1.82,
DXCM,2007-05-23,1.82,1.8425,1.7675,1.8275,
DXCM,2007-05-24,1.82,1.8225,1.725,1.7775,
DXCM,2007-05-25,1.7875,1.85,1.765,1.7975,
DXCM,2007-05-29,1.8075,1.8225,1.745,1.755,
DXCM,2007-05-30,1.7375,1.7525,1.6575,1.675,
DXCM,2007-05-31,1.675,1.6875,1.595,1.64,
DXCM,2007-06-01,1.775,1.785,1.6125,1.6225,
DXCM,2007-06-04,1.62,1.655,1.61,1.64,
DXCM,2007-06-05,1.6525,1.6625,1.615,1.6425,
DXCM,2007-06-06,1.6125,1.6625,1.6025,1.6425,
DXCM,2007-06-07,1.6375,1.6575,1.6275,1.655,
DXCM,2007-06-08,1.6225,1.69,1.6,1.635,
DXCM,2007-06-11,1.6325,1.6625,1.6125,1.64,
DXCM,2007-06-12,1.635,1.6825,1.6025,1.655,
DXCM,2007-06-13,1.6625,1.6625,1.605,1.6375,
DXCM,2007-06-14,1.645,1.6975,1.6325,1.6925,
DXCM,2007-06-15,1.725,1.725,1.6875,1.705,
DXCM,2007-06-18,1.705,1.715,1.675,1.6825,
DXCM,2007-06-19,1.675,1.7225,1.6575,1.7125,
DXCM,2007-06-20,1.7225,1.895,1.7125,1.8625,
DXCM,2007-06-21,1.8975,1.9325,1.83,1.925,
DXCM,2007-06-22,1.935,1.9875,1.885,1.9575,
DXCM,2007-06-25,1.9475,2.05,1.9375,2.0325,
DXCM,2007-06-26,2.035,2.08,1.93,2.07,
DXCM,2007-06-27,2.055,2.0875,1.99,2.0225,
DXCM,2007-06-28,2.0,2.0625,1.9675,1.9875,
DXCM,2007-06-29,1.9875,2.075,1.9875,2.0475,
DXCM,2007-07-02,2.0475,2.11,2.0475,2.095,
DXCM,2007-07-03,2.1025,2.1225,2.05,2.105,
DXCM,2007-07-05,2.1,2.125,2.0275,2.085,
DXCM,2007-07-06,2.0925,2.1375,2.0825,2.1325,
DXCM,2007-07-09,2.1325,2.345,2.1275,2.3025,
DXCM,2007-07-10,2.3975,2.3975,2.3,2.315,
DXCM,2007-07-11,2.345,2.3525,2.2625,2.28,
DXCM,2007-07-12,2.2925,2.375,2.27,2.3525,
DXCM,2007-07-13,2.3525,2.435,2.3525,2.42,
DXCM,2007-07-16,2.42,2.44,2.3725,2.3775,
DXCM,2007-07-17,2.3625,2.4125,2.36,2.3775,
DXCM,2007-07-18,2.365,2.4125,2.34,2.35,
DXCM,2007-07-19,2.41,2.435,2.34,2.3625,
DXCM,2007-07-20,2.365,2.39,2.315,2.38,
DXCM,2007-07-23,2.3875,2.3875,2.23,2.2575,
DXCM,2007-07-24,2.0775,2.215,2.0225,2.145,
DXCM,2007-07-25,2.1725,2.275,2.06,2.155,
DXCM,2007-07-26,2.1575,2.17,1.9925,2.0825,
DXCM,2007-07-27,2.085,2.085,2.0225,2.045,
DXCM,2007-07-30,2.0425,2.1,2.02,2.075,
DXCM,2007-07-31,1.955,2.075,1.95,2.0075,
DXCM,2007-08-01,2.0,2.0075,1.8275,1.8575,
DXCM,2007-08-02,1.8775,1.95,1.7625,1.9475,
DXCM,2007-08-03,1.945,2.0325,1.885,1.925,
DXCM,2007-08-06,1.925,1.9275,1.825,1.8825,
DXCM,2007-08-07,1.88,2.0575,1.865,2.0075,
DXCM,2007-08-08,2.0575,2.38,1.965,2.3,
DXCM,2007-08-09,2.285,2.5125,2.285,2.39,
DXCM,2007-08-10,2.3125,2.33,2.1025,2.18,
DXCM,2007-08-13,2.1825,2.1825,1.9375,2.105,
DXCM,2007-08-14,2.125,2.135,1.9875,2.0125,
DXCM,2007-08-15,2.0075,2.04,1.995,2.0025,
DXCM,2007-08-16,2.015,2.1825,1.98,2.14,
DXCM,2007-08-17,2.1175,2.26,2.1175,2.2475,
DXCM,2007-08-20,2.255,2.2875,2.23,2.2825,
DXCM,2007-08-21,2.27,2.3025,2.25,2.2825,
DXCM,2007-08-22,2.2975,2.3175,2.2175,2.2975,
DXCM,2007-08-23,2.2975,2.3075,2.215,2.225,
DXCM,2007-08-24,2.2275,2.2275,2.175,2.2025,
DXCM,2007-08-27,2.185,2.2025,2.1075,2.1875,
DXCM,2007-08-28,2.1875,2.275,2.1875,2.23,
DXCM,2007-08-29,2.2375,2.25,2.1875,2.24,
DXCM,2007-08-30,2.23,2.2675,2.2275,2.2325,
DXCM,2007-08-31,2.2525,2.3275,2.1875,2.3,
DXCM,2007-09-04,2.2825,2.31,2.2725,2.2975,
DXCM,2007-09-05,2.2875,2.37,2.235,2.3025,
DXCM,2007-09-06,2.3225,2.35,2.28,2.3275,
DXCM,2007-09-07,2.295,2.36,2.295,2.35,
DXCM,2007-09-10,2.3475,2.41,2.3325,2.405,
DXCM,2007-09-11,2.405,2.44,2.375,2.3875,
DXCM,2007-09-12,2.3875,2.45,2.31,2.3625,
DXCM,2007-09-13,2.3675,2.4325,2.3275,2.35,
DXCM,2007-09-14,2.36,2.435,2.3025,2.315,
DXCM,2007-09-17,2.305,2.38,2.305,2.355,
DXCM,2007-09-18,2.385,2.4025,2.3375,2.3575,
DXCM,2007-09-19,2.385,2.43,2.375,2.4275,
DXCM,2007-09-20,2.4125,2.4575,2.3175,2.34,
DXCM,2007-09-21,2.3425,2.4175,2.325,2.41,
DXCM,2007-09-24,2.435,2.4425,2.3675,2.375,
DXCM,2007-09-25,2.37,2.4275,2.37,2.4025,
DXCM,2007-09-26,2.4125,2.4225,2.365,2.3925,
DXCM,2007-09-27,2.42,2.4825,2.395,2.425,
DXCM,2007-09-28,2.4375,2.5,2.4125,2.5,
DXCM,2007-10-01,2.5,2.7275,2.48,2.61,
DXCM,2007-10-02,2.6275,2.7025,2.57,2.59,
DXCM,2007-10-03,2.585,2.66,2.5625,2.645,
DXCM,2007-10-04,2.6675,2.685,2.575,2.585,
DXCM,2007-10-05,2.615,2.675,2.5825,2.6625,
DXCM,2007-10-08,2.6525,2.6625,2.5875,2.6525,
DXCM,2007-10-09,2.655,2.685,2.6225,2.665,
DXCM,2007-10-10,2.66,2.66,2.55,2.6025,
DXCM,2007-10-11,2.6075,2.6575,2.51,2.5625,
DXCM,2007-10-12,2.5575,2.5925,2.5,2.5175,
DXCM,2007-10-15,2.425,2.45,2.3175,2.3225,
DXCM,2007-10-16,2.31,2.31,2.2025,2.21,
DXCM,2007-10-17,2.225,2.2725,2.165,2.245,
DXCM,2007-10-18,2.2175,2.285,2.0825,2.2675,
DXCM,2007-10-19,2.27,2.275,2.1475,2.1475,
DXCM,2007-10-22,2.1525,2.27,2.1275,2.21,
DXCM,2007-10-23,2.2325,2.325,2.2075,2.315,
DXCM,2007-10-24,2.2875,2.31,2.235,2.29,
DXCM,2007-10-25,2.29,2.3275,2.2575,2.3,
DXCM,2007-10-26,2.3225,2.3225,2.1,2.11,
DXCM,2007-10-29,2.1375,2.2375,2.1,2.15,
DXCM,2007-10-30,2.1225,2.1975,2.03,2.03,
DXCM,2007-10-31,2.0425,2.3875,2.0425,2.325,
DXCM,2007-11-01,2.285,2.295,2.23,2.265,
DXCM,2007-11-02,2.2825,2.2825,2.1725,2.235,
DXCM,2007-11-05,2.1975,2.21,2.1275,2.1825,
DXCM,2007-11-06,2.2,2.21,2.105,2.1975,
DXCM,2007-11-07,2.175,2.1875,2.12,2.12,
DXCM,2007-11-08,2.1375,2.1375,2.08,2.1,
DXCM,2007-11-09,2.0875,2.155,2.065,2.1525,
DXCM,2007-11-12,2.1475,2.1625,2.1,2.1125,
DXCM,2007-11-13,2.1275,2.16,2.1225,2.15,
DXCM,2007-11-14,2.1625,2.285,2.1625,2.285,
DXCM,2007-11-15,2.27,2.2775,2.22,2.2225,
DXCM,2007-11-16,2.25,2.495,2.225,2.26,
DXCM,2007-11-19,2.2475,2.2475,2.16,2.19,
DXCM,2007-11-20,2.185,2.2,2.095,2.15,
DXCM,2007-11-21,2.1275,2.13,2.0775,2.0825,
DXCM,2007-11-23,2.095,2.105,2.0775,2.1,
DXCM,2007-11-26,2.0975,2.155,2.0475,2.14,
DXCM,2007-11-27,2.14,2.14,2.06,2.0725,
DXCM,2007-11-28,2.085,2.1525,2.0375,2.14,
DXCM,2007-11-29,2.1325,2.16,2.0775,2.1225,
DXCM,2007-11-30,2.1425,2.245,2.14,2.1625,
DXCM,2007-12-03,2.1575,2.25,2.1425,2.175,
DXCM,2007-12-04,2.15,2.25,2.1175,2.1875,
DXCM,2007-12-05,2.21,2.21,2.0875,2.1075,
DXCM,2007-12-06,2.11,2.2825,2.1025,2.2825,
DXCM,2007-12-07,2.2825,2.38,2.25,2.335,
DXCM,2007-12-10,2.3325,2.4125,2.315,2.325,
DXCM,2007-12-11,2.37,2.37,2.2075,2.225,
DXCM,2007-12-12,2.25,2.25,2.11,2.13,
DXCM,2007-12-13,2.1175,2.13,2.015,2.0875,
DXCM,2007-12-14,2.0875,2.0875,1.9925,1.995,
DXCM,2007-12-17,1.9925,2.055,1.93,1.955,
DXCM,2007-12-18,1.97,1.9975,1.8875,1.9175,
DXCM,2007-12-19,1.905,1.96,1.9,1.9025,
DXCM,2007-12-20,1.915,2.1325,1.915,2.0375,
DXCM,2007-12-21,2.0725,2.23,2.0725,2.23,
DXCM,2007-12-24,2.2325,2.395,2.2025,2.345,
DXCM,2007-12-26,2.345,2.4,2.2875,2.3125,
DXCM,2007-12-27,2.3075,2.3675,2.2575,2.275,
DXCM,2007-12-28,2.285,2.31,2.135,2.1675,
DXCM,2007-12-31,2.1575,2.275,2.1575,2.2075,
DXCM,2008-01-02,2.2625,2.3175,2.205,2.2375,
DXCM,2008-01-03,2.23,2.2575,2.2025,2.21,
DXCM,2008-01-04,2.1975,2.2025,2.1225,2.175,
DXCM,2008-01-07,2.195,2.2675,2.1025,2.125,
DXCM,2008-01-08,2.1175,2.1175,2.035,2.07,
DXCM,2008-01-09,2.06,2.14,1.9675,2.065,
DXCM,2008-01-10,2.0675,2.2025,2.005,2.15,
DXCM,2008-01-11,2.1275,2.2075,2.125,2.1375,
DXCM,2008-01-14,2.165,2.25,2.145,2.2125,
DXCM,2008-01-15,2.1875,2.3425,2.1875,2.34,
DXCM,2008-01-16,2.3425,2.505,2.28,2.4025,
DXCM,2008-01-17,2.4025,2.46,2.265,2.3675,
DXCM,2008-01-18,2.36,2.3625,2.2175,2.225,
DXCM,2008-01-22,2.255,2.2775,2.2075,2.2625,
DXCM,2008-01-23,2.2475,2.3325,2.15,2.255,
DXCM,2008-01-24,2.255,2.295,2.015,2.065,
DXCM,2008-01-25,2.02,2.265,2.0,2.2525,
DXCM,2008-01-28,2.24,2.3025,2.2075,2.27,
DXCM,2008-01-29,2.2725,2.2775,2.215,2.235,
DXCM,2008-01-30,2.22,2.2725,2.14,2.14,
DXCM,2008-01-31,2.135,2.205,2.1025,2.1025,
DXCM,2008-02-01,2.0725,2.1975,2.0725,2.16,
DXCM,2008-02-04,2.175,2.22,2.0975,2.11,
DXCM,2008-02-05,2.1025,2.125,2.055,2.0725,
DXCM,2008-02-06,2.075,2.09,2.0,2.0175,
DXCM,2008-02-07,2.005,2.04,1.9175,2.015,
DXCM,2008-02-08,2.0175,2.0475,1.9125,1.9975,
DXCM,2008-02-11,1.98,2.075,1.975,2.075,
DXCM,2008-02-12,2.0975,2.1275,2.065,2.1025,
DXCM,2008-02-13,2.065,2.25,2.065,2.2375,
DXCM,2008-02-14,2.23,2.255,2.0175,2.07,
DXCM,2008-02-15,2.05,2.08,1.9925,2.0,
DXCM,2008-02-19,2.025,2.195,2.025,2.1225,
DXCM,2008-02-20,2.085,2.1025,1.975,1.975,
DXCM,2008-02-21,1.99,2.0,1.945,2.0,
DXCM,2008-02-22,1.98,1.995,1.915,1.9425,
DXCM,2008-02-25,1.9125,2.025,1.9125,1.9575,
DXCM,2008-02-26,2.01,2.0325,1.9275,1.9375,
DXCM,2008-02-27,1.9425,1.9775,1.9175,1.945,
DXCM,2008-02-28,1.9375,1.9375,1.87,1.885,
DXCM,2008-02-29,1.88,1.92,1.815,1.8425,
DXCM,2008-03-03,1.8275,1.8625,1.725,1.7425,
DXCM,2008-03-04,1.7325,1.93,1.69,1.8725,
DXCM,2008-03-05,1.8775,1.8975,1.8125,1.8375,
DXCM,2008-03-06,1.81,1.835,1.715,1.73,
DXCM,2008-03-07,1.7075,1.7675,1.7075,1.7475,
DXCM,2008-03-10,1.7325,1.7375,1.4975,1.5125,
DXCM,2008-03-11,1.555,1.555,1.38,1.42,
DXCM,2008-03-12,1.36,1.3725,1.03,1.165,
DXCM,2008-03-13,1.125,1.215,1.0675,1.12,
DXCM,2008-03-14,1.1975,1.2625,1.165,1.17,
DXCM,2008-03-17,1.195,1.2275,1.04,1.0575,
DXCM,2008-03-18,1.0975,1.1275,0.9275,0.9625,
DXCM,2008-03-19,0.93,1.0425,0.9225,0.925,
DXCM,2008-03-20,0.93,1.0825,0.925,0.995,
DXCM,2008-03-24,1.0,1.1175,0.9775,1.08,
DXCM,2008-03-25,1.0725,1.09,1.0275,1.05,
DXCM,2008-03-26,1.05,1.1625,1.025,1.0725,
DXCM,2008-03-27,1.08,1.1725,1.05,1.155,
DXCM,2008-03-28,1.1475,1.185,1.01,1.0175,
DXCM,2008-03-31,1.05,1.0975,1.015,1.035,
DXCM,2008-04-01,1.025,1.07,0.9925,0.9975,
DXCM,2008-04-02,1.005,1.0125,0.985,1.0,
DXCM,2008-04-03,1.0075,1.05,0.99,1.0425,
DXCM,2008-04-04,1.035,1.12,1.0225,1.11,
DXCM,2008-04-07,1.135,1.3675,1.125,1.285,
DXCM,2008-04-08,1.2925,1.385,1.25,1.37,
DXCM,2008-04-09,1.36,1.48,1.35,1.4225,
DXCM,2008-04-10,1.41,1.4875,1.375,1.4675,
DXCM,2008-04-11,1.445,1.485,1.4,1.4525,
DXCM,2008-04-14,1.4525,1.4525,1.355,1.41,
DXCM,2008-04-15,1.4025,1.4125,1.3125,1.3325,
DXCM,2008-04-16,1.33,1.4825,1.305,1.4625,
DXCM,2008-04-17,1.45,1.545,1.4,1.4525,
DXCM,2008-04-18,1.5725,1.825,1.5675,1.7625,
DXCM,2008-04-21,1.7075,1.8675,1.66,1.83,
DXCM,2008-04-22,1.83,1.84,1.7575,1.7975,
DXCM,2008-04-23,1.815,1.86,1.7925,1.8375,
DXCM,2008-04-24,1.8225,1.86,1.7925,1.8525,
DXCM,2008-04-25,1.845,1.9625,1.8375,1.955,
DXCM,2008-04-28,1.955,2.05,1.9125,2.0025,
DXCM,2008-04-29,1.985,2.0175,1.9025,1.9525,
DXCM,2008-04-30,1.95,2.015,1.9075,1.925,
DXCM,2008-05-01,1.9325,1.9725,1.9,1.97,
DXCM,2008-05-02,1.975,1.975,1.7925,1.81,
DXCM,2008-05-05,1.82,1.87,1.795,1.85,
DXCM,2008-05-06,1.87,1.89,1.8175,1.8675,
DXCM,2008-05-07,1.8725,1.875,1.6825,1.7,
DXCM,2008-05-08,1.705,1.7175,1.6525,1.7125,
DXCM,2008-05-09,1.6675,1.6775,1.58,1.6,
DXCM,2008-05-12,1.6075,1.8325,1.6075,1.8,
DXCM,2008-05-13,1.8125,1.815,1.7375,1.815,
DXCM,2008-05-14,1.8275,1.895,1.78,1.785,
DXCM,2008-05-15,1.795,1.9975,1.795,1.8925,
DXCM,2008-05-16,1.8925,1.9525,1.845,1.87,
DXCM,2008-05-19,1.87,1.985,1.87,1.9075,
DXCM,2008-05-20,1.91,1.99,1.8775,1.945,
DXCM,2008-05-21,1.955,1.96,1.8825,1.8875,
DXCM,2008-05-22,1.9175,2.0,1.885,1.955,
DXCM,2008-05-23,1.9725,1.9725,1.85,1.8925,
DXCM,2008-05-27,1.875,1.975,1.875,1.9625,
DXCM,2008-05-28,1.965,2.0,1.925,1.995,
DXCM,2008-05-29,1.985,2.0125,1.9675,1.99,
DXCM,2008-05-30,1.98,2.0675,1.965,1.9725,
DXCM,2008-06-02,1.98,1.9975,1.9275,1.945,
DXCM,2008-06-03,1.9425,1.98,1.84,1.885,
DXCM,2008-06-04,1.8575,1.88,1.775,1.815,
DXCM,2008-06-05,1.8125,1.8575,1.7725,1.8325,
DXCM,2008-06-06,1.8225,1.9175,1.8025,1.8725,
DXCM,2008-06-09,1.8725,1.9075,1.815,1.825,
DXCM,2008-06-10,1.8,1.835,1.775,1.7775,
DXCM,2008-06-11,1.765,1.785,1.725,1.755,
DXCM,2008-06-12,1.7775,1.8325,1.775,1.8075,
DXCM,2008-06-13,1.8375,2.0,1.82,2.0,
DXCM,2008-06-16,2.0,2.0,1.875,1.955,
DXCM,2008-06-17,1.9575,1.9575,1.8775,1.9125,
DXCM,2008-06-18,1.91,1.92,1.865,1.8975,
DXCM,2008-06-19,1.905,1.905,1.8475,1.8675,
DXCM,2008-06-20,1.8525,1.8775,1.82,1.8325,
DXCM,2008-06-23,1.85,1.88,1.8175,1.8575,
DXCM,2008-06-24,1.85,1.85,1.7625,1.7925,
DXCM,2008-06-25,1.8075,1.8075,1.6975,1.72,
DXCM,2008-06-26,1.6975,1.6975,1.5775,1.6725,
DXCM,2008-06-27,1.66,1.7025,1.5575,1.5925,
DXCM,2008-06-30,1.5875,1.615,1.51,1.51,
DXCM,2008-07-01,1.505,1.51,1.395,1.47,
DXCM,2008-07-02,1.4625,1.485,1.3925,1.4275,
DXCM,2008-07-03,1.43,1.435,1.335,1.4175,
DXCM,2008-07-07,1.42,1.435,1.34,1.42,
DXCM,2008-07-08,1.43,1.61,1.43,1.605,
DXCM,2008-07-09,1.6,1.6,1.4625,1.4625,
DXCM,2008-07-10,1.4575,1.5625,1.44,1.4975,
DXCM,2008-07-11,1.48,1.65,1.45,1.65,
DXCM,2008-07-14,1.65,1.6875,1.4825,1.535,
DXCM,2008-07-15,1.515,1.6925,1.4525,1.6825,
DXCM,2008-07-16,1.6925,1.75,1.625,1.7375,
DXCM,2008-07-17,1.75,1.85,1.7425,1.8025,
DXCM,2008-07-18,1.8125,1.8475,1.68,1.6825,
DXCM,2008-07-21,1.6875,1.76,1.6375,1.7375,
DXCM,2008-07-22,1.73,1.9225,1.7075,1.9175,
DXCM,2008-07-23,1.9175,1.9725,1.76,1.7925,
DXCM,2008-07-24,1.82,1.88,1.79,1.7975,
DXCM,2008-07-25,1.835,1.945,1.745,1.7575,
DXCM,2008-07-28,1.745,1.77,1.695,1.715,
DXCM,2008-07-29,1.7175,1.8125,1.695,1.8025,
DXCM,2008-07-30,1.8175,1.87,1.74,1.745,
DXCM,2008-07-31,1.725,1.755,1.65,1.68,
DXCM,2008-08-01,1.68,1.735,1.63,1.715,
DXCM,2008-08-04,1.71,1.71,1.6375,1.67,
DXCM,2008-08-05,1.71,1.875,1.6525,1.8,
DXCM,2008-08-06,1.75,1.78,1.5175,1.575,
DXCM,2008-08-07,1.56,1.695,1.5075,1.695,
DXCM,2008-08-08,1.6925,1.8275,1.5775,1.815,
DXCM,2008-08-11,1.81,1.81,1.665,1.685,
DXCM,2008-08-12,1.6725,1.68,1.585,1.6125,
DXCM,2008-08-13,1.625,1.685,1.575,1.63,
DXCM,2008-08-14,1.635,1.7375,1.635,1.7375,
DXCM,2008-08-15,1.765,1.7875,1.685,1.74,
DXCM,2008-08-18,1.74,1.76,1.6325,1.6475,
DXCM,2008-08-19,1.6275,1.66,1.535,1.5625,
DXCM,2008-08-20,1.55,1.55,1.415,1.4625,
DXCM,2008-08-21,1.435,1.51,1.4225,1.5025,
DXCM,2008-08-22,1.51,1.615,1.5075,1.5925,
DXCM,2008-08-25,1.5875,1.6,1.5325,1.5475,
DXCM,2008-08-26,1.5475,1.61,1.525,1.6075,
DXCM,2008-08-27,1.605,1.73,1.605,1.72,
DXCM,2008-08-28,1.72,1.7875,1.6375,1.7775,
DXCM,2008-08-29,1.7775,1.82,1.7075,1.72,
DXCM,2008-09-02,1.755,1.755,1.605,1.6075,
DXCM,2008-09-03,1.61,1.6725,1.5825,1.6025,
DXCM,2008-09-04,1.585,1.6575,1.5625,1.57,
DXCM,2008-09-05,1.5625,1.75,1.5,1.7175,
DXCM,2008-09-08,1.75,1.8125,1.7275,1.75,
DXCM,2008-09-09,1.7575,1.86,1.69,1.7075,
DXCM,2008-09-10,1.7125,1.745,1.525,1.61,
DXCM,2008-09-11,1.5925,1.5925,1.525,1.5675,
DXCM,2008-09-12,1.63,1.6425,1.54,1.605,
DXCM,2008-09-15,1.555,1.655,1.5475,1.6425,
DXCM,2008-09-16,1.6075,1.7075,1.59,1.685,
DXCM,2008-09-17,1.6675,1.695,1.49,1.685,
DXCM,2008-09-18,1.7025,1.86,1.565,1.8425,
DXCM,2008-09-19,1.9225,1.975,1.73,1.7875,
DXCM,2008-09-22,1.81,1.815,1.6275,1.635,
DXCM,2008-09-23,1.6325,1.7125,1.565,1.5875,
DXCM,2008-09-24,1.5925,1.72,1.585,1.655,
DXCM,2008-09-25,1.6675,1.74,1.515,1.5825,
DXCM,2008-09-26,1.5575,1.61,1.5275,1.58,
DXCM,2008-09-29,1.5625,1.6175,1.5025,1.5025,
DXCM,2008-09-30,1.5225,1.6525,1.5025,1.5475,
DXCM,2008-10-01,1.5375,1.615,1.4975,1.5275,
DXCM,2008-10-02,1.5225,1.575,1.475,1.48,
DXCM,2008-10-03,1.5025,1.6175,1.4375,1.4425,
DXCM,2008-10-06,1.41,1.4975,1.285,1.4475,
DXCM,2008-10-07,1.4625,1.4625,1.3,1.3075,
DXCM,2008-10-08,1.27,1.325,1.2025,1.2125,
DXCM,2008-10-09,1.2375,1.28,0.975,1.0,
DXCM,2008-10-10,0.9925,1.175,0.9075,1.0,
DXCM,2008-10-13,1.0,1.26,0.985,1.245,
DXCM,2008-10-14,1.275,1.375,1.1175,1.1875,
DXCM,2008-10-15,1.1725,1.2275,0.905,1.065,
DXCM,2008-10-16,1.0725,1.2075,0.995,1.1675,
DXCM,2008-10-17,1.1375,1.295,1.0025,1.08,
DXCM,2008-10-20,1.105,1.2075,1.105,1.125,
DXCM,2008-10-21,1.105,1.175,1.0625,1.105,
DXCM,2008-10-22,1.0775,1.125,1.0325,1.0325,
DXCM,2008-10-23,1.0375,1.0925,0.99,1.0225,
DXCM,2008-10-24,0.9775,1.0225,0.9425,0.9425,
DXCM,2008-10-27,0.94,1.005,0.915,1.005,
DXCM,2008-10-28,0.9525,1.1475,0.9525,1.13,
DXCM,2008-10-29,1.1575,1.1575,1.0375,1.0525,
DXCM,2008-10-30,1.065,1.1725,1.0275,1.0675,
DXCM,2008-10-31,1.0475,1.2075,1.0475,1.13,
DXCM,2008-11-03,1.125,1.1775,1.0925,1.12,
DXCM,2008-11-04,1.1675,1.1675,1.07,1.1,
DXCM,2008-11-05,1.09,1.15,1.0275,1.045,
DXCM,2008-11-06,1.0375,1.06,0.945,0.95,
DXCM,2008-11-07,0.96,1.0275,0.9375,0.9425,
DXCM,2008-11-10,0.995,1.0,0.895,0.895,
DXCM,2008-11-11,0.8825,0.935,0.6775,0.6875,
DXCM,2008-11-12,0.685,0.7,0.5375,0.5375,
DXCM,2008-11-13,0.55,0.6225,0.4425,0.5125,
DXCM,2008-11-14,0.5125,0.565,0.5075,0.52,
DXCM,2008-11-17,0.5175,0.565,0.4925,0.4975,
DXCM,2008-11-18,0.5,0.5125,0.4525,0.46,
DXCM,2008-11-19,0.5,0.5125,0.44,0.44,
DXCM,2008-11-20,0.45,0.45,0.34,0.3475,
DXCM,2008-11-21,0.355,0.405,0.355,0.385,
DXCM,2008-11-24,0.405,0.5325,0.4,0.4875,
DXCM,2008-11-25,0.5075,0.5525,0.4625,0.4925,
DXCM,2008-11-26,0.435,0.505,0.4275,0.5,
DXCM,2008-11-28,0.4925,0.5075,0.4825,0.5,
DXCM,2008-12-01,0.5725,0.5725,0.475,0.4875,
DXCM,2008-12-02,0.5,0.505,0.4825,0.5,
DXCM,2008-12-03,0.4875,0.5,0.4575,0.4975,
DXCM,2008-12-04,0.51,0.905,0.5,0.7475,
DXCM,2008-12-05,0.7275,0.83,0.64,0.825,
DXCM,2008-12-08,0.8375,0.91,0.7875,0.91,
DXCM,2008-12-09,0.8875,0.9575,0.8225,0.9025,
DXCM,2008-12-10,0.945,0.945,0.725,0.8225,
DXCM,2008-12-11,0.8025,0.905,0.76,0.7975,
DXCM,2008-12-12,0.7825,0.8825,0.75,0.8825,
DXCM,2008-12-15,0.885,0.8975,0.765,0.785,
DXCM,2008-12-16,0.795,0.875,0.7075,0.79,
DXCM,2008-12-17,0.785,0.7875,0.7,0.755,
DXCM,2008-12-18,0.7825,0.785,0.6275,0.6375,
DXCM,2008-12-19,0.675,0.725,0.5975,0.6575,
DXCM,2008-12-22,0.6575,0.6675,0.6175,0.625,
DXCM,2008-12-23,0.5725,0.695,0.5725,0.6375,
DXCM,2008-12-24,0.6325,0.645,0.5875,0.62,
DXCM,2008-12-26,0.6225,0.6425,0.59,0.5975,
DXCM,2008-12-29,0.595,0.595,0.5425,0.565,
DXCM,2008-12-30,0.57,0.63,0.55,0.63,
DXCM,2008-12-31,0.63,0.71,0.5875,0.69,
DXCM,2009-01-02,0.69,0.705,0.655,0.69,
DXCM,2009-01-05,0.7,0.825,0.6725,0.82,
DXCM,2009-01-06,0.815,1.18,0.8125,0.9175,
DXCM,2009-01-07,0.95,0.9675,0.85,0.8525,
DXCM,2009-01-08,0.8725,0.885,0.8525,0.88,
DXCM,2009-01-09,0.8825,0.8825,0.81,0.8125,
DXCM,2009-01-12,0.8125,0.9875,0.79,0.7975,
DXCM,2009-01-13,0.8,0.88,0.79,0.835,
DXCM,2009-01-14,0.8225,0.8225,0.7575,0.775,
DXCM,2009-01-15,0.78,0.8175,0.725,0.7825,
DXCM,2009-01-16,0.7825,0.905,0.7825,0.875,
DXCM,2009-01-20,0.9025,0.9175,0.7525,0.7575,
DXCM,2009-01-21,0.7725,0.81,0.765,0.805,
DXCM,2009-01-22,0.785,0.83,0.7625,0.82,
DXCM,2009-01-23,0.795,0.8025,0.7725,0.7875,
DXCM,2009-01-26,0.7875,0.835,0.7725,0.805,
DXCM,2009-01-27,0.805,0.8725,0.75,0.835,
DXCM,2009-01-28,0.8525,0.875,0.805,0.8175,
DXCM,2009-01-29,0.805,0.8475,0.76,0.78,
DXCM,2009-01-30,0.75,0.875,0.75,0.8075,
DXCM,2009-02-02,0.8125,0.85,0.775,0.84,
DXCM,2009-02-03,0.8475,0.85,0.79,0.81,
DXCM,2009-02-04,0.8125,0.855,0.7975,0.835,
DXCM,2009-02-05,0.83,0.84,0.81,0.8275,
DXCM,2009-02-06,0.825,0.9475,0.82,0.9225,
DXCM,2009-02-09,0.92,0.9475,0.92,0.92,
DXCM,2009-02-10,0.8925,0.9225,0.8425,0.8525,
DXCM,2009-02-11,0.8575,0.9825,0.825,0.955,
DXCM,2009-02-12,0.9325,0.9325,0.8725,0.8925,
DXCM,2009-02-13,0.895,0.9225,0.89,0.8925,
DXCM,2009-02-17,0.8525,0.9,0.8325,0.8525,
DXCM,2009-02-18,0.8625,0.865,0.8025,0.85,
DXCM,2009-02-19,0.8625,0.9075,0.855,0.9025,
DXCM,2009-02-20,0.8825,0.9875,0.7975,0.9625,
DXCM,2009-02-23,0.97,1.0125,0.9225,0.9525,
DXCM,2009-02-24,0.965,1.1,0.91,1.0425,
DXCM,2009-02-25,1.055,1.055,0.9675,0.9675,
DXCM,2009-02-26,0.975,1.07,0.9425,0.9425,
DXCM,2009-02-27,0.935,1.015,0.9,1.0125,
DXCM,2009-03-02,0.9975,0.9975,0.9,0.9,
DXCM,2009-03-03,0.915,0.985,0.9,0.9375,
DXCM,2009-03-04,0.9525,1.0,0.95,0.9775,
DXCM,2009-03-05,0.9475,1.0125,0.81,0.8175,
DXCM,2009-03-06,0.795,0.9225,0.795,0.8275,
DXCM,2009-03-09,0.8225,0.895,0.8225,0.865,
DXCM,2009-03-10,0.885,0.9625,0.8275,0.9575,
DXCM,2009-03-11,0.9675,0.9925,0.88,0.9375,
DXCM,2009-03-12,0.93,1.035,0.93,1.025,
DXCM,2009-03-13,1.025,1.0625,0.9725,1.0225,
DXCM,2009-03-16,1.0375,1.0725,0.9625,1.0075,
DXCM,2009-03-17,1.01,1.055,0.995,1.025,
DXCM,2009-03-18,1.025,1.0875,1.025,1.0575,
DXCM,2009-03-19,1.07,1.11,1.045,1.075,
DXCM,2009-03-20,1.075,1.1125,1.0375,1.04,
DXCM,2009-03-23,1.08,1.1625,1.075,1.1625,
DXCM,2009-03-24,1.1475,1.1625,1.1025,1.105,
DXCM,2009-03-25,1.1175,1.16,1.005,1.1,
DXCM,2009-03-26,1.1225,1.17,1.0875,1.16,
DXCM,2009-03-27,1.135,1.1525,1.06,1.065,
DXCM,2009-03-30,1.0325,1.035,0.96,1.0075,
DXCM,2009-03-31,1.025,1.0425,0.9975,1.035,
DXCM,2009-04-01,1.0175,1.135,1.0125,1.1,
DXCM,2009-04-02,1.1275,1.15,1.0975,1.1075,
DXCM,2009-04-03,1.11,1.18,1.09,1.15,
DXCM,2009-04-06,1.1375,1.1625,1.12,1.14,
DXCM,2009-04-07,1.1175,1.1875,1.0925,1.15,
DXCM,2009-04-08,1.1625,1.1625,1.085,1.1,
DXCM,2009-04-09,1.13,1.175,1.0925,1.17,
DXCM,2009-04-13,1.15,1.1725,1.1125,1.145,
DXCM,2009-04-14,1.1225,1.14,1.09,1.1075,
DXCM,2009-04-15,1.0975,1.195,1.0975,1.1925,
DXCM,2009-04-16,1.2,1.2225,1.1375,1.1775,
DXCM,2009-04-17,1.1825,1.1825,1.1275,1.1425,
DXCM,2009-04-20,1.125,1.1525,1.0925,1.1375,
DXCM,2009-04-21,1.1325,1.1875,1.1025,1.1525,
DXCM,2009-04-22,1.135,1.215,1.1275,1.1425,
DXCM,2009-04-23,1.145,1.1625,1.055,1.1,
DXCM,2009-04-24,1.11,1.145,1.0725,1.1125,
DXCM,2009-04-27,1.095,1.1025,0.9725,1.0075,
DXCM,2009-04-28,1.0,1.05,0.995,1.035,
DXCM,2009-04-29,1.0475,1.1025,1.025,1.0725,
DXCM,2009-04-30,1.0875,1.12,1.06,1.12,
DXCM,2009-05-01,1.1125,1.1125,1.0475,1.05,
DXCM,2009-05-04,1.06,1.1,1.0125,1.0225,
DXCM,2009-05-05,1.0175,1.025,0.9675,1.0,
DXCM,2009-05-06,1.0175,1.06,1.0,1.0175,
DXCM,2009-05-07,1.03,1.075,0.96,0.97,
DXCM,2009-05-08,0.9825,1.02,0.935,1.0,
DXCM,2009-05-11,0.98,1.0,0.965,0.98,
DXCM,2009-05-12,0.985,0.985,0.895,0.9575,
DXCM,2009-05-13,0.9375,0.945,0.8925,0.93,
DXCM,2009-05-14,0.935,0.9725,0.8825,0.9475,
DXCM,2009-05-15,0.9575,1.0575,0.9475,1.0125,
DXCM,2009-05-18,1.0525,1.15,1.045,1.13,
DXCM,2009-05-19,1.125,1.15,1.08,1.145,
DXCM,2009-05-20,1.1525,1.2,1.1425,1.1525,
DXCM,2009-05-21,1.135,1.1925,1.1225,1.1525,
DXCM,2009-05-22,1.1575,1.2,1.1575,1.1875,
DXCM,2009-05-26,1.1725,1.2725,1.1575,1.2525,
DXCM,2009-05-27,1.245,1.3675,1.2025,1.3275,
DXCM,2009-05-28,1.335,1.335,1.2125,1.2625,
DXCM,2009-05-29,1.2675,1.39,1.2625,1.39,
DXCM,2009-06-01,1.38,1.49,1.38,1.41,
DXCM,2009-06-02,1.4075,1.435,1.355,1.365,
DXCM,2009-06-03,1.3525,1.38,1.265,1.305,
DXCM,2009-06-04,1.31,1.3725,1.295,1.365,
DXCM,2009-06-05,1.385,1.3925,1.325,1.3625,
DXCM,2009-06-08,1.3625,1.5575,1.3575,1.3925,
DXCM,2009-06-09,1.4,1.4175,1.375,1.3825,
DXCM,2009-06-10,1.3925,1.425,1.38,1.4225,
DXCM,2009-06-11,1.4225,1.4725,1.39,1.4425,
DXCM,2009-06-12,1.4475,1.565,1.43,1.555,
DXCM,2009-06-15,1.47,1.6075,1.47,1.59,
DXCM,2009-06-16,1.565,1.64,1.5575,1.6125,
DXCM,2009-06-17,1.6075,1.7625,1.5975,1.675,
DXCM,2009-06-18,1.6925,1.705,1.5675,1.57,
DXCM,2009-06-19,1.5975,1.5975,1.4925,1.5,
DXCM,2009-06-22,1.495,1.565,1.465,1.5075,
DXCM,2009-06-23,1.5275,1.5975,1.5125,1.5675,
DXCM,2009-06-24,1.5775,1.6225,1.53,1.5625,
DXCM,2009-06-25,1.5525,1.5975,1.54,1.575,
DXCM,2009-06-26,1.56,1.5875,1.52,1.56,
DXCM,2009-06-29,1.5725,1.575,1.5225,1.56,
DXCM,2009-06-30,1.5575,1.59,1.5125,1.5475,
DXCM,2009-07-01,1.5675,1.595,1.545,1.555,
DXCM,2009-07-02,1.5425,1.5425,1.45,1.47,
DXCM,2009-07-06,1.465,1.465,1.3525,1.405,
DXCM,2009-07-07,1.41,1.415,1.32,1.3225,
DXCM,2009-07-08,1.3325,1.385,1.3125,1.3375,
DXCM,2009-07-09,1.3425,1.365,1.3125,1.3325,
DXCM,2009-07-10,1.325,1.395,1.315,1.3325,
DXCM,2009-07-13,1.3375,1.355,1.3125,1.35,
DXCM,2009-07-14,1.345,1.3925,1.3275,1.38,
DXCM,2009-07-15,1.3975,1.4525,1.3975,1.4375,
DXCM,2009-07-16,1.425,1.445,1.395,1.425,
DXCM,2009-07-17,1.43,1.43,1.365,1.3775,
DXCM,2009-07-20,1.39,1.4125,1.375,1.4025,
DXCM,2009-07-21,1.415,1.415,1.35,1.3625,
DXCM,2009-07-22,1.36,1.415,1.35,1.3975,
DXCM,2009-07-23,1.3925,1.4475,1.385,1.4225,
DXCM,2009-07-24,1.425,1.4825,1.3475,1.45,
DXCM,2009-07-27,1.4525,1.5,1.375,1.4925,
DXCM,2009-07-28,1.4775,1.5425,1.45,1.54,
DXCM,2009-07-29,1.5475,1.645,1.49,1.6425,
DXCM,2009-07-30,1.6525,1.74,1.6225,1.69,
DXCM,2009-07-31,1.6775,1.6825,1.585,1.615,
DXCM,2009-08-03,1.6225,1.6875,1.5925,1.67,
DXCM,2009-08-04,1.6525,1.8625,1.645,1.7825,
DXCM,2009-08-05,1.7925,1.8025,1.69,1.7,
DXCM,2009-08-06,1.7175,1.7225,1.6725,1.6725,
DXCM,2009-08-07,1.7,1.75,1.66,1.71,
DXCM,2009-08-10,1.69,1.725,1.6375,1.6625,
DXCM,2009-08-11,1.6475,1.705,1.625,1.63,
DXCM,2009-08-12,1.6275,1.7,1.6275,1.69,
DXCM,2009-08-13,1.695,1.74,1.6275,1.705,
DXCM,2009-08-14,1.7075,1.73,1.665,1.725,
DXCM,2009-08-17,1.6875,1.735,1.64,1.705,
DXCM,2009-08-18,1.71,1.8175,1.6875,1.8075,
DXCM,2009-08-19,1.7875,1.915,1.785,1.9025,
DXCM,2009-08-20,1.8925,1.9775,1.875,1.9675,
DXCM,2009-08-21,1.995,2.24,1.9025,2.0925,
DXCM,2009-08-24,2.12,2.16,2.0175,2.0525,
DXCM,2009-08-25,2.07,2.0775,2.02,2.055,
DXCM,2009-08-26,2.0675,2.0725,2.0175,2.05,
DXCM,2009-08-27,2.0325,2.0775,1.9825,2.0325,
DXCM,2009-08-28,2.0375,2.0525,1.9625,1.9875,
DXCM,2009-08-31,1.9725,1.9875,1.84,1.9525,
DXCM,2009-09-01,1.9325,2.005,1.9,1.9225,
DXCM,2009-09-02,1.9075,1.945,1.8925,1.9275,
DXCM,2009-09-03,1.9375,2.0225,1.9125,2.01,
DXCM,2009-09-04,2.01,2.03,1.99,2.0225,
DXCM,2009-09-08,2.03,2.0475,1.9875,2.03,
DXCM,2009-09-09,2.035,2.0975,2.0275,2.09,
DXCM,2009-09-10,2.0775,2.135,2.025,2.12,
DXCM,2009-09-11,2.1175,2.1175,2.0475,2.0625,
DXCM,2009-09-14,2.0625,2.0775,2.0075,2.05,
DXCM,2009-09-15,2.04,2.04,1.995,2.01,
DXCM,2009-09-16,2.0225,2.0225,1.9425,2.005,
DXCM,2009-09-17,2.0,2.0175,1.9625,1.98,
DXCM,2009-09-18,1.9875,2.0025,1.9725,2.0,
DXCM,2009-09-21,1.985,2.0275,1.955,2.0,
DXCM,2009-09-22,2.01,2.065,1.9875,2.0075,
DXCM,2009-09-23,2.0175,2.0375,1.9875,1.9925,
DXCM,2009-09-24,2.0,2.0325,1.9325,1.9525,
DXCM,2009-09-25,1.9425,1.955,1.8775,1.93,
DXCM,2009-09-28,1.9425,2.0175,1.8975,1.995,
DXCM,2009-09-29,1.99,2.025,1.9775,2.0,
DXCM,2009-09-30,2.0,2.0,1.91,1.9825,
DXCM,2009-10-01,1.9775,1.9875,1.9075,1.9075,
DXCM,2009-10-02,1.875,1.9075,1.8125,1.88,
DXCM,2009-10-05,1.895,2.065,1.895,2.055,
DXCM,2009-10-06,2.0625,2.0625,1.9825,2.005,
DXCM,2009-10-07,1.99,2.0,1.95,1.97,
DXCM,2009-10-08,1.975,1.98,1.9125,1.92,
DXCM,2009-10-09,1.9025,1.975,1.9,1.97,
DXCM,2009-10-12,1.9825,2.0,1.925,1.935,
DXCM,2009-10-13,1.9375,1.9375,1.88,1.9075,
DXCM,2009-10-14,1.9375,1.9475,1.895,1.9325,
DXCM,2009-10-15,1.9125,1.99,1.8875,1.9625,
DXCM,2009-10-16,1.9425,1.9625,1.8875,1.93,
DXCM,2009-10-19,1.9425,1.97,1.8775,1.965,
DXCM,2009-10-20,1.965,1.9875,1.9325,1.945,
DXCM,2009-10-21,1.9375,1.9975,1.8875,1.8975,
DXCM,2009-10-22,1.895,1.9375,1.8825,1.93,
DXCM,2009-10-23,1.93,1.9475,1.855,1.875,
DXCM,2009-10-26,1.8725,1.9225,1.8225,1.8325,
DXCM,2009-10-27,1.8325,1.875,1.79,1.8325,
DXCM,2009-10-28,1.835,1.85,1.74,1.7425,
DXCM,2009-10-29,1.765,1.7825,1.7375,1.7575,
DXCM,2009-10-30,1.75,1.7675,1.6325,1.715,
DXCM,2009-11-02,1.735,1.735,1.6625,1.695,
DXCM,2009-11-03,1.6775,1.7275,1.65,1.725,
DXCM,2009-11-04,1.73,1.7625,1.7275,1.735,
DXCM,2009-11-05,1.745,1.85,1.745,1.8325,
DXCM,2009-11-06,1.805,1.8725,1.7925,1.8475,
DXCM,2009-11-09,1.87,1.915,1.8425,1.8525,
DXCM,2009-11-10,1.8425,1.8575,1.7875,1.825,
DXCM,2009-11-11,1.8475,1.875,1.8225,1.8425,
DXCM,2009-11-12,1.845,1.8625,1.7475,1.755,
DXCM,2009-11-13,1.77,1.875,1.77,1.8225,
DXCM,2009-11-16,1.8325,1.9225,1.8325,1.895,
DXCM,2009-11-17,1.8925,1.9025,1.85,1.8825,
DXCM,2009-11-18,1.8775,1.8925,1.8375,1.855,
DXCM,2009-11-19,1.845,1.86,1.8125,1.8175,
DXCM,2009-11-20,1.81,1.865,1.7975,1.8175,
DXCM,2009-11-23,1.8475,1.885,1.835,1.8475,
DXCM,2009-11-24,1.845,1.845,1.8,1.82,
DXCM,2009-11-25,1.835,1.86,1.815,1.8175,
DXCM,2009-11-27,1.7625,1.8,1.75,1.75,
DXCM,2009-11-30,1.76,1.845,1.76,1.8125,
DXCM,2009-12-01,1.82,1.8525,1.7775,1.8,
DXCM,2009-12-02,1.8,1.8325,1.79,1.81,
DXCM,2009-12-03,1.8225,1.885,1.7825,1.79,
DXCM,2009-12-04,1.8325,1.875,1.795,1.8675,
DXCM,2009-12-07,1.8225,1.8575,1.8125,1.825,
DXCM,2009-12-08,1.8075,1.83,1.7825,1.7825,
DXCM,2009-12-09,1.79,1.835,1.7625,1.8325,
DXCM,2009-12-10,1.8425,1.9,1.84,1.875,
DXCM,2009-12-11,1.8875,1.9375,1.855,1.8975,
DXCM,2009-12-14,1.9125,1.9175,1.8625,1.915,
DXCM,2009-12-15,1.905,1.9675,1.8725,1.9275,
DXCM,2009-12-16,1.95,1.95,1.9025,1.9275,
DXCM,2009-12-17,1.9175,1.9625,1.8425,1.885,
DXCM,2009-12-18,1.9025,1.9125,1.8025,1.82,
DXCM,2009-12-21,1.835,1.87,1.785,1.8075,
DXCM,2009-12-22,1.8075,1.86,1.78,1.8325,
DXCM,2009-12-23,1.8375,1.8975,1.8375,1.8875,
DXCM,2009-12-24,1.9,1.94,1.895,1.9325,
DXCM,2009-12-28,1.945,1.975,1.9125,1.9675,
DXCM,2009-12-29,1.9725,2.02,1.95,2.0125,
DXCM,2009-12-30,1.9975,2.03,1.9725,2.03,
DXCM,2009-12-31,2.035,2.06,2.01,2.0175,
DXCM,2010-01-04,2.0525,2.14,2.0525,2.14,
DXCM,2010-01-05,2.13,2.1975,2.115,2.1725,
DXCM,2010-01-06,2.1775,2.2775,2.16,2.2375,
DXCM,2010-01-07,2.255,2.335,2.2275,2.3025,"[""Stocks That Created New 52 Week Highs (TDSC, ARMH, ARUN, BBBY, DXCM)"", ""Stocks That Created New 52 Week Highs (TDSC, ARMH, ARUN, BBBY, DXCM)"", ""Stocks That Created New 52 Week Highs (TDSC, ARMH, ARUN, BBBY, DXCM)""]"
DXCM,2010-01-08,2.3,2.325,2.2425,2.26,
DXCM,2010-01-11,2.28,2.31,2.235,2.2525,
DXCM,2010-01-12,2.2425,2.365,2.225,2.365,
DXCM,2010-01-13,2.3675,2.395,2.255,2.305,
DXCM,2010-01-14,2.3075,2.34,2.2975,2.305,
DXCM,2010-01-15,2.3725,2.4725,2.32,2.425,"[""Benzinga\u2019s Top Upgrades (CMA, OMX, SPLS, DXCM, INTC, DRQ)"", ""Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)"", ""Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)"", ""Benzinga\u2019s Top Upgrades (CMA, OMX, SPLS, DXCM, INTC, DRQ)"", ""Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)"", ""Benzinga\u2019s Top Upgrades (CMA, OMX, SPLS, DXCM, INTC, DRQ)""]"
DXCM,2010-01-19,2.4125,2.55,2.4125,2.5175,
DXCM,2010-01-20,2.5075,2.5475,2.48,2.5025,
DXCM,2010-01-21,2.51,2.51,2.365,2.4375,
DXCM,2010-01-22,2.4225,2.4275,2.3025,2.34,
DXCM,2010-01-25,2.365,2.385,2.2775,2.3425,
DXCM,2010-01-26,2.3275,2.375,2.31,2.3175,
DXCM,2010-01-27,2.3075,2.4,2.3025,2.3875,
DXCM,2010-01-28,2.385,2.385,2.27,2.31,
DXCM,2010-01-29,2.325,2.395,2.2625,2.265,
DXCM,2010-02-01,2.2975,2.3425,2.275,2.34,
DXCM,2010-02-02,2.335,2.3725,2.31,2.335,
DXCM,2010-02-03,2.3175,2.3575,2.275,2.31,
DXCM,2010-02-04,2.285,2.3025,2.235,2.2475,
DXCM,2010-02-05,2.265,2.265,2.195,2.2475,
DXCM,2010-02-08,2.2625,2.2725,2.2125,2.215,
DXCM,2010-02-09,2.25,2.2625,2.18,2.2075,
DXCM,2010-02-10,2.2025,2.305,2.165,2.305,
DXCM,2010-02-11,2.31,2.3725,2.2525,2.365,
DXCM,2010-02-12,2.3325,2.42,2.3125,2.4125,
DXCM,2010-02-16,2.4375,2.465,2.385,2.4325,
DXCM,2010-02-17,2.4475,2.4625,2.4025,2.4375,
DXCM,2010-02-18,2.4375,2.45,2.3575,2.445,
DXCM,2010-02-19,2.445,2.445,2.335,2.34,
DXCM,2010-02-22,2.34,2.375,2.3025,2.3575,
DXCM,2010-02-23,2.36,2.37,2.2825,2.3175,
DXCM,2010-02-24,2.3175,2.345,2.2775,2.315,
DXCM,2010-02-25,2.2775,2.28,2.2275,2.2775,
DXCM,2010-02-26,2.2825,2.2825,2.225,2.26,
DXCM,2010-03-01,2.26,2.3025,2.25,2.3025,
DXCM,2010-03-02,2.3125,2.375,2.3075,2.355,
DXCM,2010-03-03,2.3675,2.3675,2.3125,2.3175,
DXCM,2010-03-04,2.325,2.325,2.2625,2.2725,
DXCM,2010-03-05,2.295,2.37,2.295,2.37,
DXCM,2010-03-08,2.3625,2.445,2.3625,2.4175,
DXCM,2010-03-09,2.425,2.5,2.3925,2.4225,
DXCM,2010-03-10,2.43,2.5625,2.4025,2.56,
DXCM,2010-03-11,2.55,2.58,2.5,2.5275,
DXCM,2010-03-12,2.5475,2.5475,2.4025,2.45,
DXCM,2010-03-15,2.4325,2.465,2.36,2.4425,
DXCM,2010-03-16,2.445,2.455,2.3375,2.3825,
DXCM,2010-03-17,2.395,2.4375,2.38,2.4075,
DXCM,2010-03-18,2.39,2.4375,2.3775,2.4325,
DXCM,2010-03-19,2.4475,2.5,2.4025,2.4625,
DXCM,2010-03-22,2.4475,2.6,2.42,2.58,
DXCM,2010-03-23,2.5975,2.71,2.575,2.705,
DXCM,2010-03-24,2.7,2.7375,2.63,2.64,
DXCM,2010-03-25,2.6525,2.68,2.53,2.5325,
DXCM,2010-03-26,2.5375,2.57,2.45,2.4575,
DXCM,2010-03-29,2.4725,2.5375,2.47,2.4925,
DXCM,2010-03-30,2.4975,2.545,2.445,2.4625,
DXCM,2010-03-31,2.4475,2.4825,2.43,2.435,
DXCM,2010-04-01,2.445,2.495,2.425,2.4825,
DXCM,2010-04-05,2.4825,2.5625,2.46,2.5025,
DXCM,2010-04-06,2.485,2.525,2.46,2.4675,
DXCM,2010-04-07,2.475,2.5025,2.34,2.39,
DXCM,2010-04-08,2.39,2.395,2.3525,2.3775,
DXCM,2010-04-09,2.375,2.4825,2.365,2.48,
DXCM,2010-04-12,2.4825,2.5525,2.4825,2.5275,
DXCM,2010-04-13,2.5275,2.6175,2.5125,2.605,
DXCM,2010-04-14,2.625,2.7025,2.625,2.7,
DXCM,2010-04-15,2.705,2.75,2.7025,2.7475,
DXCM,2010-04-16,2.7475,2.75,2.675,2.715,
DXCM,2010-04-19,2.7125,2.72,2.63,2.67,
DXCM,2010-04-20,2.6875,2.7425,2.665,2.74,
DXCM,2010-04-21,2.745,2.745,2.6425,2.7425,
DXCM,2010-04-22,2.7125,2.775,2.6875,2.7525,
DXCM,2010-04-23,2.7675,2.8,2.5975,2.6425,
DXCM,2010-04-26,2.6375,2.675,2.5875,2.6425,
DXCM,2010-04-27,2.6375,2.7125,2.6375,2.6925,
DXCM,2010-04-28,2.7125,2.74,2.68,2.7375,
DXCM,2010-04-29,2.75,2.8425,2.7325,2.8275,
DXCM,2010-04-30,2.8275,2.845,2.705,2.7375,
DXCM,2010-05-03,2.7375,2.8475,2.7325,2.8375,
DXCM,2010-05-04,2.7975,2.7975,2.685,2.7175,
DXCM,2010-05-05,2.6625,2.725,2.575,2.63,
DXCM,2010-05-06,2.575,2.5825,2.4275,2.47,
DXCM,2010-05-07,2.47,2.54,2.2875,2.3175,
DXCM,2010-05-10,2.4625,2.4625,2.35,2.38,
DXCM,2010-05-11,2.3525,2.555,2.32,2.5175,
DXCM,2010-05-12,2.5325,2.6775,2.5325,2.6675,
DXCM,2010-05-13,2.675,2.815,2.675,2.73,
DXCM,2010-05-14,2.705,2.7525,2.6725,2.7375,
DXCM,2010-05-17,2.74,2.79,2.6475,2.7425,
DXCM,2010-05-18,2.7825,2.8,2.655,2.67,
DXCM,2010-05-19,2.6775,2.79,2.6775,2.7325,
DXCM,2010-05-20,2.6675,2.7075,2.5325,2.555,
DXCM,2010-05-21,2.505,2.5875,2.4325,2.58,
DXCM,2010-05-24,2.57,2.57,2.48,2.4875,
DXCM,2010-05-25,2.4175,2.5325,2.385,2.5225,
DXCM,2010-05-26,2.53,2.64,2.475,2.4875,
DXCM,2010-05-27,2.555,2.6075,2.4925,2.5975,
DXCM,2010-05-28,2.5825,2.65,2.5225,2.6325,
DXCM,2010-06-01,2.585,2.5875,2.3325,2.45,
DXCM,2010-06-02,2.4525,2.5725,2.425,2.5625,"[""Piper Jaffray Reiterates Buy Rating On DexCom Despite FDA Warnings (DXCM)"", ""Piper Jaffray Reiterates Buy Rating On DexCom Despite FDA Warnings (DXCM)"", ""Piper Jaffray Reiterates Buy Rating On DexCom Despite FDA Warnings (DXCM)""]"
DXCM,2010-06-03,2.5525,2.625,2.535,2.595,
DXCM,2010-06-04,2.515,2.6125,2.39,2.3975,
DXCM,2010-06-07,2.41,2.4575,2.31,2.3225,
DXCM,2010-06-08,2.33,2.355,2.23,2.305,
DXCM,2010-06-09,2.3375,2.4925,2.315,2.4325,
DXCM,2010-06-10,2.48,2.495,2.4,2.4525,
DXCM,2010-06-11,2.405,2.5325,2.405,2.5325,
DXCM,2010-06-14,2.565,2.6025,2.51,2.5325,
DXCM,2010-06-15,2.5525,2.65,2.5025,2.64,
DXCM,2010-06-16,2.6275,2.9325,2.5775,2.9125,
DXCM,2010-06-17,2.9325,2.935,2.805,2.8475,
DXCM,2010-06-18,2.8525,2.875,2.7975,2.8675,
DXCM,2010-06-21,2.9,2.975,2.84,2.865,
DXCM,2010-06-22,2.8675,2.91,2.7775,2.785,
DXCM,2010-06-23,2.7825,2.8225,2.7175,2.7725,
DXCM,2010-06-24,2.7475,2.775,2.6875,2.6975,
DXCM,2010-06-25,2.71,2.795,2.6325,2.795,
DXCM,2010-06-28,2.7525,2.9,2.725,2.8525,
DXCM,2010-06-29,2.8,2.835,2.7375,2.775,
DXCM,2010-06-30,2.7825,3.005,2.775,2.89,
DXCM,2010-07-01,2.8875,2.8875,2.67,2.8225,
DXCM,2010-07-02,2.85,2.9025,2.77,2.865,
DXCM,2010-07-06,2.905,2.9425,2.7225,2.7575,
DXCM,2010-07-07,2.7775,2.8475,2.7525,2.8425,
DXCM,2010-07-08,2.87,2.87,2.7575,2.81,
DXCM,2010-07-09,2.7975,2.8725,2.775,2.8625,
DXCM,2010-07-12,2.8575,2.89,2.76,2.7675,Can second-quarter reports repair technical damage Monday's analysis
DXCM,2010-07-13,2.8125,2.8375,2.7775,2.825,
DXCM,2010-07-14,2.805,2.9,2.8025,2.8875,
DXCM,2010-07-15,2.8875,2.8875,2.8025,2.83,
DXCM,2010-07-16,2.7975,2.8025,2.705,2.72,
DXCM,2010-07-19,2.73,2.7625,2.6925,2.7425,
DXCM,2010-07-20,2.6975,2.785,2.6975,2.7825,"[""Mad Money Lightning Round OT (BRCM, MGA, JCI, DXCM, ABT)"", ""Mad Money Lightning Round OT (BRCM, MGA, JCI, DXCM, ABT)""]"
DXCM,2010-07-21,2.81,2.815,2.685,2.69,"Mad Money Lightning Round OT (BRCM, MGA, JCI, DXCM, ABT)"
DXCM,2010-07-22,2.7425,2.8125,2.7425,2.7975,
DXCM,2010-07-23,2.7825,2.9075,2.6975,2.875,
DXCM,2010-07-26,2.895,2.965,2.875,2.95,
DXCM,2010-07-27,2.975,3.015,2.9425,2.975,
DXCM,2010-07-28,2.96,2.96,2.865,2.87,
DXCM,2010-07-29,2.9075,2.9125,2.7625,2.78,
DXCM,2010-07-30,2.73,2.8275,2.7275,2.79,
DXCM,2010-08-02,2.8325,2.9225,2.8225,2.91,
DXCM,2010-08-03,2.9025,2.9675,2.8425,2.93,
DXCM,2010-08-04,3.0075,3.0875,2.9425,3.065,"[""William Blair Reiterates Outperform on DexCom (DXCM)"", ""DexCom Meets, Beats on Sales - Analyst Blog"", ""DexCom Meets, Beats on Sales - Analyst Blog"", ""William Blair Reiterates Outperform on DexCom (DXCM)"", ""DexCom Meets, Beats on Sales - Analyst Blog"", ""William Blair Reiterates Outperform on DexCom (DXCM)""]"
DXCM,2010-08-05,3.0275,3.0275,2.96,2.975,
DXCM,2010-08-06,2.935,2.935,2.835,2.9275,
DXCM,2010-08-09,2.9525,3.0175,2.9075,3.0125,
DXCM,2010-08-10,2.97,3.1,2.9525,3.0825,
DXCM,2010-08-11,3.0025,3.085,3.0025,3.0225,
DXCM,2010-08-12,2.9725,3.0575,2.93,3.0375,
DXCM,2010-08-13,3.025,3.14,3.0225,3.07,"[""DXCM Expects To Reach Profitability On Existing And Milestone Cash"", ""DXCM Expects To Reach Profitability On Existing And Milestone Cash"", ""DXCM Expects To Reach Profitability On Existing And Milestone Cash""]"
DXCM,2010-08-16,3.0425,3.2075,3.0425,3.1825,"[""Breakout Stocks: SPDR Gold Trust, Netflix"", ""Breakout Stocks: SPDR Gold Trust, Netflix"", ""Breakout Stocks: SPDR Gold Trust, Netflix""]"
DXCM,2010-08-17,3.2325,3.3275,3.14,3.1475,
DXCM,2010-08-18,3.1525,3.245,3.0725,3.1675,
DXCM,2010-08-19,3.14,3.1875,3.06,3.1125,
DXCM,2010-08-20,3.0875,3.145,3.01,3.12,
DXCM,2010-08-23,3.125,3.175,3.05,3.125,
DXCM,2010-08-24,3.0825,3.1225,3.0125,3.0275,
DXCM,2010-08-25,3.005,3.105,3.005,3.09,
DXCM,2010-08-26,3.0975,3.16,3.025,3.06,
DXCM,2010-08-27,3.11,3.2,3.0375,3.185,
DXCM,2010-08-30,3.18,3.235,3.1525,3.155,
DXCM,2010-08-31,3.1425,3.2125,3.0575,3.0575,
DXCM,2010-09-01,3.1175,3.22,3.1175,3.205,
DXCM,2010-09-02,3.195,3.2825,3.1625,3.275,
DXCM,2010-09-03,3.3,3.3575,3.1925,3.2775,
DXCM,2010-09-07,3.2725,3.3175,3.225,3.2425,
DXCM,2010-09-08,3.2375,3.35,3.2375,3.28,
DXCM,2010-09-09,3.3375,3.4175,3.305,3.37,
DXCM,2010-09-10,3.3725,3.39,3.2475,3.2675,
DXCM,2010-09-13,3.315,3.34,3.245,3.305,
DXCM,2010-09-14,3.2925,3.335,3.27,3.28,
DXCM,2010-09-15,3.275,3.3725,3.265,3.3525,
DXCM,2010-09-16,3.3525,3.3525,3.2825,3.3225,
DXCM,2010-09-17,3.365,3.375,3.26,3.3375,
DXCM,2010-09-20,3.3575,3.47,3.325,3.4575,
DXCM,2010-09-21,3.465,3.4875,3.415,3.45,
DXCM,2010-09-22,3.445,3.4975,3.4325,3.4625,
DXCM,2010-09-23,3.425,3.4825,3.3575,3.4,
DXCM,2010-09-24,3.455,3.545,3.4125,3.515,
DXCM,2010-09-27,3.525,3.525,3.405,3.4175,
DXCM,2010-09-28,3.4175,3.4625,3.3425,3.3825,
DXCM,2010-09-29,3.3625,3.4,3.345,3.3475,
DXCM,2010-09-30,3.3825,3.3825,3.2225,3.305,
DXCM,2010-10-01,3.34,3.34,3.265,3.315,
DXCM,2010-10-04,3.315,3.35,3.25,3.3175,
DXCM,2010-10-05,3.35,3.3725,3.3025,3.3225,
DXCM,2010-10-06,3.3225,3.3575,3.295,3.33,
DXCM,2010-10-07,3.3375,3.355,3.3025,3.34,
DXCM,2010-10-08,3.3325,3.435,3.3025,3.4125,
DXCM,2010-10-11,3.41,3.5725,3.41,3.5125,
DXCM,2010-10-12,3.49,3.5275,3.45,3.5,
DXCM,2010-10-13,3.5175,3.6175,3.4825,3.5725,
DXCM,2010-10-14,3.5625,3.6175,3.5025,3.55,
DXCM,2010-10-15,3.5975,3.5975,3.4775,3.525,
DXCM,2010-10-18,3.545,3.59,3.5,3.5875,
DXCM,2010-10-19,3.525,3.6175,3.5,3.5325,
DXCM,2010-10-20,3.5475,3.5975,3.4875,3.5175,
DXCM,2010-10-21,3.545,3.5525,3.4275,3.4575,
DXCM,2010-10-22,3.4675,3.5375,3.43,3.5375,
DXCM,2010-10-25,3.575,3.58,3.465,3.515,
DXCM,2010-10-26,3.505,3.5825,3.485,3.5375,
DXCM,2010-10-27,3.515,3.56,3.47,3.5025,
DXCM,2010-10-28,3.54,3.54,3.455,3.465,
DXCM,2010-10-29,3.47,3.505,3.4325,3.4475,
DXCM,2010-11-01,3.4525,3.495,3.35,3.385,
DXCM,2010-11-02,3.4325,3.49,3.385,3.4625,
DXCM,2010-11-03,3.455,3.5,3.42,3.4775,
DXCM,2010-11-04,3.53,3.5875,3.4525,3.4775,"[""DexCom Inc. Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.23"", ""DexCom Shares Plummet 20% After Hours (DXCM)"", ""DexCom Shares Plummet 20% After Hours (DXCM)"", ""DexCom Inc. Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.23"", ""DexCom Shares Plummet 20% After Hours (DXCM)"", ""DexCom Inc. Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.23""]"
DXCM,2010-11-05,2.5625,2.9225,2.4775,2.7125,"[""DexCom Plummets 21% On Earnings And Revenue Miss(DXCM)"", ""DexCom Falls Out of Bed (DXCM)"", ""DexCom Falls Out of Bed (DXCM)"", ""DexCom Plummets 21% On Earnings And Revenue Miss(DXCM)"", ""Stocks Mixed at Mid-Day, Despite Positive Jobs Report, as Investors Consolidate Gains Despite early positive sentiment thanks to a better-than-expected jobs report, stocks have moved into mixed territory at mid-day as investors try to read the tea leaves on the economy in the latest jobs data. Before the bell, the U.S. Department of Labor reported that non-farm payroll gains totaled 151,000, more than double the 70,000 gain expected. Private-sector employment gained 159,000. The jobless rate held at 9.6%. The unemployment rate has stayed above 9% since May of 2009--just before the recession officially ended, according to MarketWatch. Past-months' readings were also revised up. The payrolls count in August and September was revised higher by a cumulative 110,000. Payrolls fell a revised 1,000 in August, instead of a 57,000 drop, and by 41,000 in September, instead of a 95,000 decline. Average hourly earnings increased 5 cents, or 0.2% to $22.73. Profit-taking also likely contributed to the decline in the major indexes a day after the DJIA ended at its highest point since just before Lehman Bros. filed for bankruptcy in September 2008, widely seen as the pivotal event of the financial sector collapse. In company news, Bank of America Corp. ( BAC ) and Citigroup ( C ) are looking at whether they will allow their employees to use Apple's ( AAPL ) iPhone as a business phone and alternative to Research in Motion's ( RIMM ) BlackBerry, Bloomberg reported. The bank's are currently testing software for the iphone to make sure it is secure enough for company messages, the report says. The move by BofA and Citi are a sign that RIM may be losing its grip on the corporate mobile phone market, the report said. American International Group ( AIG ) said it expects to finish the sale of its Taiwan life-insurance unit within a year as the company is divesting assets to pay back the U.S. bailout of the firm. AIG had earlier said it would look at scaling back the company's operations after a deal to divest it fell apart in September, but the company said in a statement today that it believes a sale will be completed in six months, the report said. BHP Billiton ( BHP ), the largest mining company in the world, is higher as momentum established yesterday continues. Yesterday shares soared after the Canadian government rejected the company's $39 hostile bid to acquire Potash Corporation of Saskatchewan ( POT ). Traders are viewing this action as favorable for BHP shares as an acquisition of such immense size is seen as risky. Fablyn, a bone drug from Pfizer ( PFE ) that did not win approve from U.S. regulators due to safety questions, reportedlt reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, Bloomberg reported. According to the report, women taking the medicine had a 79% lower chance of breast cancer compared with those on placebo, the report said. Meanwhile, Pfizer leads a race against three rivals to sell the first new pill for rheumatoid arthritis in 10 years, according to another Bloomberg report. BP plc ( BP ) shares gained in London trading by the close of trading there Friday on talk that Exxon Mobil ( XOM ) was considering a bid for the oil company, Reuters reported. BP ADRs are trading lower at the NYSE while Exxon is logging gains. BP declined to comment on the rumor. A spokesman for Exxon said it is \""not our practice to comment on market speculation, rumors or media reports,\"" the report said. Shareholder advisory firm ISS is recommending that shareholders of Barnes & Noble ( BKS ) renew its anti-takeover poison pill when the bookstore chain holds a special meeting on Nov. 17, Reuters reported. The poison pill was originally adopted last year after shareholder Ron Burkle doubled his stake within a matter of days, the report said. Coca-Cola Co. ( KO ) shares are lower following Thursday news the soft drink maker hit the market with its largest debt offering ever of $4.5 billion, including a three-year tranche at one of the lowest interest rate in high-grade corporate bonds, Reuters reported. The company is looking to shorten the average length of time to maturity its debt holds, the report said. In the latest earnings news: --Washington Post ( WPO ) shares are higher after the company said it earned $9.12 per share from continuing operations in Q3, above the Thomson Reuters mean for $4.44. Sales were $1.1897 billion, versus estimates for $1.26317 billion. The results came from gains at its higher-education unit, which is receiving government scrutiny. The company also saw a pickup in advertising revenues at its newspaper business. --Starbucks ( SBUX ) is higher after reporting fourth quarter earnings of 37 cents per share, better than the 32-cent expectation. Same-store sales for the quarter rose an impressive 8%. The company also raised its guidance for 2011 profit to $1.41 to $1.47 per share versus the current $1.43 consensus. --DexCom ( DXCM ) is down after it said late Thursday total Q3 sales were $11.7 million, below the Thomson Reuters mean for $13.2 million. Net loss was $0.23 per share. Less items, the loss was $0.22 per share, wider than the mean Bloomberg estimate. --Activision Blizzard Inc ( ATVI ) is higher after the video game maker reported better-than-expected third quarter results. The company also raised its full-year outlook as sales for titles such as World of Warcraft and StarCraft II surged. Commodities are mixed. December gold contracts are up $9, or 0.58%, to $1,391 an ounce while December crude contacts are down 0.31%, or $0.28, at $86.21 a barrel. In energy ETFs, the United States Oil Fund ( USO ) is down 0.6% to $37.27 and the United States Natural Gas fund ( UNG ) is down 0.72% to $5.55. In precious metal ETFs, the SPDR Gold Trust ( GLD ) is down 0.28% to $135.65. Market Vectors Gold Miners ( GDX ) is down 0.37% to $59.81. iShares Silver Trust ( SLV ) is up 0.94% to $25.91. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Day Update: Investors Seek Clear Direction Despite Positive Jobs Data; Indexes Mixed Here's where markets stand at mid-day: -NYSE down 3.95 (-0.06%) to 7,778.52 -DJIA down 21 (-0.18%) to 11,413.84 -S&P 500 up 1.18 (+0.11%) to 1,222.41 -Nasdaq down 6.04 (-0.24%) to 2,571.31 GLOBAL SENTIMENT Hang Seng up 1.39% Nikkei up 2.86% FTSE up 0.04% MID-DAY NYSE INDEX WATCH NYSE Energy down 0.37% at 11,787.55 NYSE Financial up 0.45% at 4,968.41 NYSE Health Care down 0.51% at 6,509.34 NYSE Arca Tech 100 down 0.04% at 1,045.34 UPSIDE MOVERS (+) JAZZ (+12.7%) continues evening jump that followed convincing earnings, guidance beat. (+) SBUX (+4.2%) continues firmer trading after earnings beat, guidance that straddles Street view. (+) LVS (+3.3%) gets favorable analyst coverage. (+) BEBE (+11.5%) upgraded. (+) STT (+2.5%) upgraded. (+) BZH (+4.9%) swings to loss. DOWNSIDE MOVERS (-) RRGB (-11.2%) continues evening decline seen after earnings miss, pulled guidance. (-) CROX (-4.5%) turns lower after initial evening gain followed earnings beat. (-) AMKR (-9.8%) continues evening slide that followed disappointing results, guidance. (-) YRCW (-12.4%) reports wider-than-expected loss. (-) LLNW (-7.3%) down despite earnings beat. (-) NTRS (-0.23%) down as Goldman strips Conviction Buy rating. (-) AIG (-1.2%) swings to loss. (-) TM (-0.11%) boosts profit forecast. MARKET DIRECTION Despite early positive sentiment thanks to a better-than-expected jobs report, stocks have moved into mixed territory at mid-day as investors try to read the tea leaves on the economy in the latest jobs data. Before the bell, the U.S. Department of Labor reported that non-farm payroll gains totaled 151,000, more than double the 70,000 gain expected. Private-sector employment gained 159,000. The jobless rate held at 9.6%. The unemployment rate has stayed above 9% since May of 2009--just before the recession officially ended, according to MarketWatch. Past-months' readings were also revised up. The payrolls count in August and September was revised higher by a cumulative 110,000. Payrolls fell a revised 1,000 in August, instead of a 57,000 drop, and by 41,000 in September, instead of a 95,000 decline. Average hourly earnings increased 5 cents, or 0.2% to $22.73. Profit-taking also likely contributed to the decline in the major indexes a day after the DJIA ended at its highest point since just before Lehman Bros. filed for bankruptcy in September 2008, widely seen as the pivotal event of the financial sector collapse. In company news, Bank of America Corp. ( BAC ) and Citigroup ( C ) are looking at whether they will allow their employees to use Apple's ( AAPL ) iPhone as a business phone and alternative to Research in Motion's ( RIMM ) BlackBerry, Bloomberg reported. The bank's are currently testing software for the iphone to make sure it is secure enough for company messages, the report says. The move by BofA and Citi are a sign that RIM may be losing its grip on the corporate mobile phone market, the report said. American International Group ( AIG ) said it expects to finish the sale of its Taiwan life-insurance unit within a year as the company is divesting assets to pay back the U.S. bailout of the firm. AIG had earlier said it would look at scaling back the company's operations after a deal to divest it fell apart in September, but the company said in a statement today that it believes a sale will be completed in six months, the report said. BHP Billiton ( BHP ), the largest mining company in the world, is higher as momentum established yesterday continues. Yesterday shares soared after the Canadian government rejected the company's $39 hostile bid to acquire Potash Corporation of Saskatchewan ( POT ). Traders are viewing this action as favorable for BHP shares as an acquisition of such immense size is seen as risky. Fablyn, a bone drug from Pfizer ( PFE ) that did not win approve from U.S. regulators due to safety questions, reportedlt reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, Bloomberg reported. According to the report, women taking the medicine had a 79% lower chance of breast cancer compared with those on placebo, the report said. Meanwhile, Pfizer leads a race against three rivals to sell the first new pill for rheumatoid arthritis in 10 years, according to another Bloomberg report. BP plc ( BP ) shares gained in London trading by the close of trading there Friday on talk that Exxon Mobil ( XOM ) was considering a bid for the oil company, Reuters reported. BP ADRs are trading lower at the NYSE while Exxon is logging gains. BP declined to comment on the rumor. A spokesman for Exxon said it is \""not our practice to comment on market speculation, rumors or media reports,\"" the report said. Shareholder advisory firm ISS is recommending that shareholders of Barnes & Noble ( BKS ) renew its anti-takeover poison pill when the bookstore chain holds a special meeting on Nov. 17, Reuters reported. The poison pill was originally adopted last year after shareholder Ron Burkle doubled his stake within a matter of days, the report said. Coca-Cola Co. ( KO ) shares are lower following Thursday news the soft drink maker hit the market with its largest debt offering ever of $4.5 billion, including a three-year tranche at one of the lowest interest rate in high-grade corporate bonds, Reuters reported. The company is looking to shorten the average length of time to maturity its debt holds, the report said. In the latest earnings news: --Washington Post ( WPO ) shares are higher after the company said it earned $9.12 per share from continuing operations in Q3, above the Thomson Reuters mean for $4.44. Sales were $1.1897 billion, versus estimates for $1.26317 billion. The results came from gains at its higher-education unit, which is receiving government scrutiny. The company also saw a pickup in advertising revenues at its newspaper business. --Starbucks ( SBUX ) is higher after reporting fourth quarter earnings of 37 cents per share, better than the 32-cent expectation. Same-store sales for the quarter rose an impressive 8%. The company also raised its guidance for 2011 profit to $1.41 to $1.47 per share versus the current $1.43 consensus. --DexCom ( DXCM ) is down after it said late Thursday total Q3 sales were $11.7 million, below the Thomson Reuters mean for $13.2 million. Net loss was $0.23 per share. Less items, the loss was $0.22 per share, wider than the mean Bloomberg estimate. --Activision Blizzard Inc ( ATVI ) is higher after the video game maker reported better-than-expected third quarter results. The company also raised its full-year outlook as sales for titles such as World of Warcraft and StarCraft II surged. Commodities are mixed. December gold contracts are up $9, or 0.58%, to $1,391 an ounce while December crude contacts are down 0.31%, or $0.28, at $86.21 a barrel. In energy ETFs, the United States Oil Fund ( USO ) is down 0.6% to $37.27 and the United States Natural Gas fund ( UNG ) is down 0.72% to $5.55. In precious metal ETFs, the SPDR Gold Trust ( GLD ) is down 0.28% to $135.65. Market Vectors Gold Miners ( GDX ) is down 0.37% to $59.81. iShares Silver Trust ( SLV ) is up 0.94% to $25.91. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Falls Out of Bed (DXCM)"", ""DexCom Plummets 21% On Earnings And Revenue Miss(DXCM)""]"
DXCM,2010-11-08,2.695,2.7725,2.5575,2.7525,"[""DexCom Announces the Sale of 2.85 Million Shares"", ""DexCom EPS Meets but Sales Misses - Analyst Blog"", ""DexCom EPS Meets but Sales Misses - Analyst Blog"", ""DexCom Announces the Sale of 2.85 Million Shares"", ""DexCom EPS Meets but Sales Misses - Analyst Blog"", ""DexCom Announces the Sale of 2.85 Million Shares""]"
DXCM,2010-11-09,2.82,3.025,2.8025,2.98,"[""Benzinga's Volume Movers (ATLS, DXCM, APEI, BSFT)"", ""Benzinga's Volume Movers (ATLS, DXCM, APEI, BSFT)"", ""Benzinga's Volume Movers (ATLS, DXCM, APEI, BSFT)""]"
DXCM,2010-11-10,2.99,3.04,2.9025,3.035,
DXCM,2010-11-11,3.0,3.025,2.95,2.9775,
DXCM,2010-11-12,2.95,2.9925,2.915,2.9275,
DXCM,2010-11-15,2.93,2.99,2.93,2.97,
DXCM,2010-11-16,2.9625,3.025,2.925,2.9625,
DXCM,2010-11-17,2.98,2.98,2.8975,2.9125,
DXCM,2010-11-18,2.9425,2.995,2.915,2.9725,
DXCM,2010-11-19,2.9775,3.095,2.975,2.9825,
DXCM,2010-11-22,2.96,3.035,2.9225,2.9675,
DXCM,2010-11-23,2.9325,2.965,2.9025,2.9525,
DXCM,2010-11-24,2.97,2.9975,2.9475,2.99,
DXCM,2010-11-26,2.965,2.9875,2.9475,2.97,
DXCM,2010-11-29,2.9475,2.955,2.81,2.8725,
DXCM,2010-11-30,2.845,2.905,2.805,2.82,
DXCM,2010-12-01,2.88,3.0275,2.88,2.9775,
DXCM,2010-12-02,2.985,3.0,2.93,2.9375,
DXCM,2010-12-03,2.92,2.9725,2.92,2.95,
DXCM,2010-12-06,2.9375,3.0125,2.9375,3.0,
DXCM,2010-12-07,2.9725,3.0875,2.945,3.04,
DXCM,2010-12-08,3.0525,3.0825,3.0075,3.0275,
DXCM,2010-12-09,3.05,3.0725,3.0025,3.04,
DXCM,2010-12-10,3.0525,3.065,3.0325,3.05,
DXCM,2010-12-13,3.0575,3.0675,3.0175,3.0175,
DXCM,2010-12-14,3.02,3.24,3.0,3.24,
DXCM,2010-12-15,3.2275,3.2625,3.1975,3.2075,
DXCM,2010-12-16,3.22,3.305,3.22,3.285,
DXCM,2010-12-17,3.27,3.3,3.2125,3.2775,
DXCM,2010-12-20,3.32,3.4,3.2875,3.38,"[""Takeover Candidates In Medical Tech"", ""Takeover Candidates In Medical Tech"", ""Takeover Candidates In Medical Tech""]"
DXCM,2010-12-21,3.4,3.425,3.3575,3.405,
DXCM,2010-12-22,3.4,3.4575,3.3775,3.455,
DXCM,2010-12-23,3.36,3.49,3.3475,3.4025,
DXCM,2010-12-27,3.405,3.445,3.375,3.4275,
DXCM,2010-12-28,3.44,3.45,3.385,3.435,
DXCM,2010-12-29,3.435,3.495,3.3975,3.49,
DXCM,2010-12-30,3.4775,3.5125,3.41,3.4425,
DXCM,2010-12-31,3.4325,3.4575,3.3775,3.4125,
DXCM,2011-01-03,3.435,3.4425,3.3675,3.4275,
DXCM,2011-01-04,3.4425,3.46,3.285,3.33,
DXCM,2011-01-05,3.3325,3.425,3.3275,3.425,
DXCM,2011-01-06,3.4175,3.4425,3.39,3.425,
DXCM,2011-01-07,3.44,3.4575,3.3925,3.4325,
DXCM,2011-01-10,3.405,3.435,3.3575,3.425,
DXCM,2011-01-11,3.4275,3.5125,3.405,3.5025,
DXCM,2011-01-12,3.5,3.8,3.5,3.7925,
DXCM,2011-01-13,3.7675,3.88,3.715,3.855,"Stocks Seeing Unusual Volume, With Bullish Options Sentiment Compiled by Luis Gonzalez: The following is a list of stocks seeing unusually high trading volume during Thursday's session. For each stock we'll list the Relative Volume indicator, which expresses today's volume as a multiple of the three month average. In addition, all of these stocks have a large number of open call option positions relative to put option positions, i.e. bullish options market sentiment. This list might offer an interesting starting point to momentum investors. Options data sourced from Schaeffer's, relative volume data sourced from Finviz. Analyze These Ideas (Tools Will Open In A New Window) 1. Access a thorough description of all companies mentioned 2. Compare analyst ratings for all stocks mentioned below 3. Visualize monthly and annual returns for all stocks mentioned The list has been sorted by the Put/Call ratio. 1. AEGON N.V. (AEG): Life Insurance Industry. Market cap of $11.38B. Relative volume at 4.6. Call open interest at 656 contracts vs. put open interest at 107 contracts (Put/Call ratio at 0.16). Short float at 0.12%, which implies a short ratio of 2.17 days. The stock has lost -6.59% over the last year. 2. Northern Dynasty Minerals Ltd. (NAK): Gold Industry. Market cap of $1.6B. Relative volume at 5.09. Call open interest at 12,648 contracts vs. put open interest at 2,648 contracts (Put/Call ratio at 0.21). Short float at 1.05%, which implies a short ratio of 1.38 days. The stock has gained 81.04% over the last year. 3. Acuity Brands, Inc. (AYI): Diversified Electronics Industry. Market cap of $2.36B. Relative volume at 3.67. Call open interest at 4,568 contracts vs. put open interest at 1,033 contracts (Put/Call ratio at 0.23). Short float at 10.01%, which implies a short ratio of 10.6 days. The stock has gained 45.01% over the last year. 4. Cell Therapeutics, Inc. (CTIC): Biotechnology Industry. Market cap of $317.76M. Relative volume at 3.57. Call open interest at 56,360 contracts vs. put open interest at 14,713 contracts (Put/Call ratio at 0.26). Short float at 7.35%, which implies a short ratio of 15.34 days. The stock has lost -66.67% over the last year. 5. Powell Industries, Inc. (POWL): Industrial Electrical Equipment Industry. Market cap of $445.39M. Relative volume at 4.26. Call open interest at 427 contracts vs. put open interest at 113 contracts (Put/Call ratio at 0.26). Short float at 3.54%, which implies a short ratio of 4.76 days. The stock has gained 18.69% over the last year. 6. El Paso Corp. (EP): Oil & Gas Pipelines Industry. Market cap of $9.72B. Relative volume at 5.3. Call open interest at 159,502 contracts vs. put open interest at 43,837 contracts (Put/Call ratio at 0.27). Short float at 1.96%, which implies a short ratio of 2.12 days. The stock has gained 30.07% over the last year. 7. IDT Corporation (IDT): Diversified Communication Services Industry. Market cap of $607.84M. Relative volume at 3.33. Call open interest at 5,309 contracts vs. put open interest at 1,663 contracts (Put/Call ratio at 0.31). Short float at 6.68%, which implies a short ratio of 3.21 days. The stock has gained 542.58% over the last year. 8. Macquarie Infrastructure Company LLC (MIC): Basic Materials Wholesale Industry. Market cap of $948.69M. Relative volume at 8.06. Call open interest at 1,338 contracts vs. put open interest at 430 contracts (Put/Call ratio at 0.32). Short float at 0.85%, which implies a short ratio of 2.41 days. The stock has gained 56.25% over the last year. 9. Williams Companies, Inc. (WMB): Oil & Gas Pipelines Industry. Market cap of $15.14B. Relative volume at 3.68. Call open interest at 403,124 contracts vs. put open interest at 132,589 contracts (Put/Call ratio at 0.33). Short float at 1.84%, which implies a short ratio of 1.42 days. The stock has gained 21.44% over the last year. 10. EXCO Resources Inc. (XCO): Independent Oil & Gas Industry. Market cap of $4.11B. Relative volume at 3.89. Call open interest at 56,720 contracts vs. put open interest at 19,135 contracts (Put/Call ratio at 0.34). Short float at 4.64%, which implies a short ratio of 3.06 days. The stock has lost -2.37% over the last year. 11. ON Semiconductor Corp. (ONNN): Semiconductor Industry. Market cap of $4.92B. Relative volume at 4.16. Call open interest at 23,667 contracts vs. put open interest at 8,415 contracts (Put/Call ratio at 0.36). Short float at 4.41%, which implies a short ratio of 2.86 days. The stock has gained 32.36% over the last year. 12. TTM Technologies Inc. (TTMI): Printed Circuit Boards Industry. Market cap of $1.17B. Relative volume at 7.19. Call open interest at 2,423 contracts vs. put open interest at 871 contracts (Put/Call ratio at 0.36). Short float at 7.83%, which implies a short ratio of 8.04 days. The stock has gained 28.47% over the last year. 13. Banco Bilbao Vizcaya Argentaria, S.A. (BBVA): Foreign Regional Banks Industry. Market cap of $38.6B. Relative volume at 5.41. Call open interest at 41,143 contracts vs. put open interest at 15,132 contracts (Put/Call ratio at 0.37). Short float at 0.14%, which implies a short ratio of 1.79 days. The stock has lost -42.9% over the last year. 14. North American Palladium Ltd. (PAL): Industrial Metals & Minerals Industry. Market cap of $1.07B. Relative volume at 4.39. Call open interest at 35,243 contracts vs. put open interest at 12,971 contracts (Put/Call ratio at 0.37). Short float at 3.2%, which implies a short ratio of 1.09 days. The stock has gained 64.16% over the last year. 15. Keegan Resources Inc. (KGN): Gold Industry. Market cap of $385.05M. Relative volume at 3.48. Call open interest at 447 contracts vs. put open interest at 169 contracts (Put/Call ratio at 0.38). Short float at 0.09%, which implies a short ratio of 0.49 days. The stock has gained 23.28% over the last year. 16. National Grid plc (NGG): Gas Utilities Industry. Market cap of $30.23B. Relative volume at 4.49. Call open interest at 1,466 contracts vs. put open interest at 558 contracts (Put/Call ratio at 0.38). Short float at 0.05%, which implies a short ratio of 0.5 days. The stock has lost -13.1% over the last year. 17. DexCom, Inc. (DXCM): Medical Instruments & Supplies Industry. Market cap of $890.93M. Relative volume at 3.04. Call open interest at 2,459 contracts vs. put open interest at 950 contracts (Put/Call ratio at 0.39). Short float at 7.13%, which implies a short ratio of 8.44 days. The stock has gained 64.53% over the last year. 18. PPL Corporation (PPL): Electric Utilities Industry. Market cap of $12.86B. Relative volume at 4.71. Call open interest at 11,543 contracts vs. put open interest at 4,585 contracts (Put/Call ratio at 0.4). Short float at 1.27%, which implies a short ratio of 1.57 days. The stock has lost -14.03% over the last year. 19. Sanmina-SCI Corp. (SANM): Printed Circuit Boards Industry. Market cap of $1.02B. Relative volume at 4.33. Call open interest at 11,130 contracts vs. put open interest at 4,791 contracts (Put/Call ratio at 0.43). Short float at 8.45%, which implies a short ratio of 5.65 days. The stock has gained 9.47% over the last year. 20. AMERCO (UHAL): Rental & Leasing Services Industry. Market cap of $1.74B. Relative volume at 3.71. Call open interest at 597 contracts vs. put open interest at 266 contracts (Put/Call ratio at 0.45). Short float at 3.85%, which implies a short ratio of 4.16 days. The stock has gained 95.56% over the last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2011-01-14,3.8675,3.9025,3.805,3.8475,
DXCM,2011-01-18,3.8625,4.0125,3.805,3.9475,
DXCM,2011-01-19,3.965,4.015,3.705,3.78,
DXCM,2011-01-20,3.75,3.7525,3.6625,3.68,
DXCM,2011-01-21,3.6775,3.7325,3.58,3.6,
DXCM,2011-01-24,3.63,3.735,3.5925,3.69,
DXCM,2011-01-25,3.6775,3.73,3.585,3.625,
DXCM,2011-01-26,3.595,3.72,3.595,3.625,
DXCM,2011-01-27,3.6275,3.695,3.6025,3.6225,
DXCM,2011-01-28,3.615,3.625,3.4325,3.525,
DXCM,2011-01-31,3.5525,3.6175,3.4875,3.5275,
DXCM,2011-02-01,3.535,3.635,3.515,3.5325,
DXCM,2011-02-02,3.525,3.5725,3.4525,3.465,
DXCM,2011-02-03,3.4675,3.535,3.4425,3.535,
DXCM,2011-02-04,3.5025,3.6325,3.5025,3.58,
DXCM,2011-02-07,3.57,3.685,3.56,3.6425,
DXCM,2011-02-08,3.6325,3.6775,3.5325,3.665,
DXCM,2011-02-09,3.6725,3.7375,3.5875,3.6875,
DXCM,2011-02-10,3.65,3.6925,3.6125,3.6825,
DXCM,2011-02-11,3.66,3.69,3.6325,3.6875,
DXCM,2011-02-14,3.675,3.72,3.6525,3.6725,
DXCM,2011-02-15,3.675,3.7,3.625,3.665,
DXCM,2011-02-16,3.6625,3.6875,3.63,3.68,
DXCM,2011-02-17,3.68,3.73,3.63,3.73,
DXCM,2011-02-18,3.745,3.745,3.6225,3.705,
DXCM,2011-02-22,3.6525,3.6975,3.5675,3.5875,
DXCM,2011-02-23,3.5625,3.6225,3.485,3.5425,
DXCM,2011-02-24,3.5475,3.5625,3.5025,3.56,
DXCM,2011-02-25,3.59,3.6875,3.575,3.6825,
DXCM,2011-02-28,3.72,3.76,3.58,3.6575,
DXCM,2011-03-01,3.7125,3.7325,3.535,3.545,
DXCM,2011-03-02,3.5325,3.59,3.4925,3.585,
DXCM,2011-03-03,3.595,3.6925,3.595,3.645,"[""DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results"", ""DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results"", ""DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results""]"
DXCM,2011-03-04,3.6825,3.8175,3.6625,3.7825,"[""Piper Jaffray Reiterating Overweight On DexCom (DXCM)"", ""Piper Jaffray Reiterating Overweight On DexCom (DXCM)"", ""Piper Jaffray Reiterating Overweight On DexCom (DXCM)""]"
DXCM,2011-03-07,3.785,3.79,3.5125,3.6025,"[""DexCom's 4Q Loss Trims - Analyst Blog"", ""DexCom's 4Q Loss Trims - Analyst Blog"", ""DexCom's 4Q Loss Trims - Analyst Blog""]"
DXCM,2011-03-08,3.5925,3.6275,3.5225,3.575,
DXCM,2011-03-09,3.51,3.5975,3.51,3.56,
DXCM,2011-03-10,3.5125,3.6175,3.4325,3.475,
DXCM,2011-03-11,3.4675,3.49,3.415,3.4675,
DXCM,2011-03-14,3.38,3.47,3.375,3.4,
DXCM,2011-03-15,3.2775,3.375,3.25,3.35,
DXCM,2011-03-16,3.34,3.3825,3.2775,3.34,
DXCM,2011-03-17,3.375,3.4225,3.32,3.325,
DXCM,2011-03-18,3.35,3.355,3.3,3.3375,
DXCM,2011-03-21,3.495,3.5725,3.47,3.565,
DXCM,2011-03-22,3.5825,3.64,3.565,3.6275,
DXCM,2011-03-23,3.625,3.6575,3.565,3.57,
DXCM,2011-03-24,3.6,3.64,3.545,3.6325,
DXCM,2011-03-25,3.6425,3.72,3.6375,3.66,
DXCM,2011-03-28,3.6775,3.7525,3.6625,3.7075,
DXCM,2011-03-29,3.76,3.915,3.74,3.9025,"[""Jefferies Initiates DexCom At Buy, $17 PT"", ""Jefferies Initiating Coverage On DexCom At Buy"", ""Jefferies Initiating Coverage On DexCom At Buy"", ""Jefferies Initiates DexCom At Buy, $17 PT"", ""Jefferies Initiating Coverage On DexCom At Buy"", ""Jefferies Initiates DexCom At Buy, $17 PT""]"
DXCM,2011-03-30,3.9175,3.9675,3.8625,3.9375,
DXCM,2011-03-31,3.96,3.9725,3.8775,3.88,
DXCM,2011-04-01,3.9075,4.0675,3.89,4.0675,
DXCM,2011-04-04,4.08,4.1325,4.0275,4.035,
DXCM,2011-04-05,4.035,4.105,3.99,4.09,
DXCM,2011-04-06,4.0925,4.165,4.0475,4.125,
DXCM,2011-04-07,4.1175,4.2125,4.0775,4.0775,
DXCM,2011-04-08,4.1125,4.1625,4.045,4.0525,
DXCM,2011-04-11,4.045,4.125,4.0175,4.0875,
DXCM,2011-04-12,4.0625,4.0825,4.0,4.025,"[""Medtronic Deals with Diabetes Better - Analyst Blog"", ""Medtronic Deals with Diabetes Better - Analyst Blog"", ""Medtronic Deals with Diabetes Better - Analyst Blog""]"
DXCM,2011-04-13,4.0425,4.065,4.0,4.0625,
DXCM,2011-04-14,4.0025,4.03,3.9425,3.99,
DXCM,2011-04-15,4.015,4.02,3.9125,4.0025,
DXCM,2011-04-18,3.945,3.985,3.8775,3.945,
DXCM,2011-04-19,3.9575,3.9725,3.84,3.9525,
DXCM,2011-04-20,4.0125,4.1475,3.985,4.145,
DXCM,2011-04-21,4.1925,4.1925,4.0675,4.0975,
DXCM,2011-04-25,4.0975,4.13,4.0,4.1225,
DXCM,2011-04-26,4.13,4.21,4.065,4.065,
DXCM,2011-04-27,4.0625,4.0925,3.99,4.0875,
DXCM,2011-04-28,4.085,4.17,4.085,4.165,
DXCM,2011-04-29,4.1825,4.2075,4.1475,4.1625,
DXCM,2011-05-02,4.175,4.2175,4.1475,4.18,
DXCM,2011-05-03,4.1725,4.2275,4.0325,4.125,"[""DexCom Announces Board Additions; Names Kevin Sayer President (DXCM)"", ""DexCom Announces Board Additions; Names Kevin Sayer President (DXCM)"", ""DexCom Announces Board Additions; Names Kevin Sayer President (DXCM)""]"
DXCM,2011-05-04,4.1175,4.1775,4.0625,4.105,"[""DexCom Misses but Losses Trim - Analyst Blog"", ""UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM)"", ""Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results"", ""Jefferies Reiterates Buy On DexCom, Raises PT To $19.50 (DXCM)"", ""Jefferies Reiterates Buy On DexCom, Raises PT To $19.50 (DXCM)"", ""UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM)"", ""Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results"", ""DexCom Misses but Losses Trim - Analyst Blog"", ""Jefferies Reiterates Buy On DexCom, Raises PT To $19.50 (DXCM)"", ""UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM)"", ""Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results"", ""DexCom Misses but Losses Trim - Analyst Blog""]"
DXCM,2011-05-05,3.825,3.85,3.6825,3.725,
DXCM,2011-05-06,3.73,3.7925,3.7225,3.7525,
DXCM,2011-05-09,3.745,3.7975,3.7275,3.77,
DXCM,2011-05-10,3.8,3.8475,3.7775,3.8325,
DXCM,2011-05-11,3.825,3.855,3.7975,3.83,
DXCM,2011-05-12,3.8275,3.915,3.7975,3.9,
DXCM,2011-05-13,3.9025,3.925,3.7875,3.85,
DXCM,2011-05-16,3.815,3.8575,3.775,3.8125,
DXCM,2011-05-17,3.82,3.82,3.74,3.785,
DXCM,2011-05-18,3.75,3.8925,3.745,3.8275,
DXCM,2011-05-19,3.8625,3.875,3.7875,3.8625,
DXCM,2011-05-20,3.835,3.87,3.7975,3.85,
DXCM,2011-05-23,3.78,3.8,3.7075,3.76,
DXCM,2011-05-24,3.765,3.7675,3.615,3.65,
DXCM,2011-05-25,3.635,3.77,3.6275,3.745,
DXCM,2011-05-26,3.75,3.83,3.71,3.8125,"[""DexCom Reaffirmed Neutral - Analyst Blog"", ""Piper Jaffray Highlights DXCM's Early Continuous Glucose Management Data"", ""Piper Jaffray Highlights DXCM's Early Continuous Glucose Management Data"", ""DexCom Reaffirmed Neutral - Analyst Blog"", ""Piper Jaffray Highlights DXCM's Early Continuous Glucose Management Data"", ""DexCom Reaffirmed Neutral - Analyst Blog""]"
DXCM,2011-05-27,3.8375,3.85,3.805,3.825,
DXCM,2011-05-31,3.85,3.9475,3.82,3.9425,
DXCM,2011-06-01,3.9325,3.9375,3.775,3.7925,
DXCM,2011-06-02,3.7575,3.8925,3.7075,3.75,
DXCM,2011-06-03,3.6875,3.7625,3.6225,3.6475,
DXCM,2011-06-06,3.64,3.6675,3.5075,3.5225,
DXCM,2011-06-07,3.5525,3.605,3.525,3.525,
DXCM,2011-06-08,3.55,3.55,3.465,3.4775,
DXCM,2011-06-09,3.4975,3.5325,3.47,3.5025,
DXCM,2011-06-10,3.4775,3.5025,3.35,3.375,
DXCM,2011-06-13,3.3925,3.405,3.295,3.3025,
DXCM,2011-06-14,3.3425,3.3975,3.315,3.39,
DXCM,2011-06-15,3.3475,3.385,3.2525,3.2625,
DXCM,2011-06-16,3.2625,3.3575,3.225,3.29,
DXCM,2011-06-17,3.3325,3.4125,3.315,3.35,
DXCM,2011-06-20,3.34,3.4575,3.3375,3.43,
DXCM,2011-06-21,3.4675,3.6425,3.4375,3.635,
DXCM,2011-06-22,3.605,3.77,3.605,3.675,
DXCM,2011-06-23,3.6175,3.675,3.57,3.67,
DXCM,2011-06-24,3.6675,3.7175,3.605,3.65,
DXCM,2011-06-27,3.635,3.7175,3.5875,3.6975,"[""Piper Jaffray Reiterates Overweight and PT of $20 on DexCom"", ""Piper Jaffray Reiterates Overweight and PT of $20 on DexCom"", ""Piper Jaffray Reiterates Overweight and PT of $20 on DexCom""]"
DXCM,2011-06-28,3.6825,3.7075,3.655,3.685,
DXCM,2011-06-29,3.7,3.7,3.6125,3.6225,
DXCM,2011-06-30,3.625,3.6575,3.61,3.6225,"[""Wedbush Reiterates Outperform and PT of $18 on DexCom"", ""Wedbush Reiterates Outperform and PT of $18 on DexCom"", ""Wedbush Reiterates Outperform and PT of $18 on DexCom""]"
DXCM,2011-07-01,3.6275,3.7375,3.6175,3.6525,
DXCM,2011-07-05,3.6625,3.7425,3.6325,3.7325,
DXCM,2011-07-06,3.7175,3.775,3.6925,3.7425,
DXCM,2011-07-07,3.78,3.8975,3.7575,3.8825,
DXCM,2011-07-08,3.805,3.875,3.7925,3.8675,
DXCM,2011-07-11,3.8175,3.875,3.7725,3.7975,
DXCM,2011-07-12,3.7775,3.8775,3.775,3.8025,
DXCM,2011-07-13,3.8225,3.87,3.8175,3.835,
DXCM,2011-07-14,3.8425,3.91,3.8075,3.89,
DXCM,2011-07-15,3.9075,3.9425,3.87,3.915,
DXCM,2011-07-18,3.905,3.9125,3.87,3.9075,Top Picks in Medical Devices for Earnings St. Jude and DexCom have catalysts and opportunities.
DXCM,2011-07-19,3.85,3.87,3.7725,3.815,"[""Hearing Negative Twitter Chatter on DexCom"", ""Hearing Negative Twitter Chatter on DexCom"", ""Hearing Negative Twitter Chatter on DexCom""]"
DXCM,2011-07-20,3.8275,3.8675,3.78,3.8275,
DXCM,2011-07-21,3.85,3.885,3.8025,3.86,
DXCM,2011-07-22,3.8675,3.8675,3.8275,3.8575,
DXCM,2011-07-25,3.855,3.86,3.7925,3.7975,
DXCM,2011-07-26,3.88,3.88,3.64,3.655,
DXCM,2011-07-27,3.6275,3.6275,3.48,3.5225,
DXCM,2011-07-28,3.505,3.58,3.5,3.5425,
DXCM,2011-07-29,3.55,3.575,3.4975,3.545,
DXCM,2011-08-01,3.635,3.635,3.455,3.5325,
DXCM,2011-08-02,3.525,3.5825,3.325,3.325,
DXCM,2011-08-03,3.36,3.405,3.2075,3.3475,
DXCM,2011-08-04,3.11,3.19,2.74,2.74,
DXCM,2011-08-05,2.8625,2.87,2.6925,2.81,"[""DexCom Meets, Cuts Losses - Analyst Blog"", ""DexCom Meets, Cuts Losses - Analyst Blog"", ""DexCom Meets, Cuts Losses - Analyst Blog""]"
DXCM,2011-08-08,2.7025,2.8025,2.5625,2.575,
DXCM,2011-08-09,2.665,2.795,2.4575,2.79,
DXCM,2011-08-10,2.885,2.885,2.5675,2.5775,
DXCM,2011-08-11,2.6,2.7825,2.565,2.7375,
DXCM,2011-08-12,2.775,2.8125,2.6975,2.785,
DXCM,2011-08-15,2.8275,2.8975,2.7825,2.885,
DXCM,2011-08-16,2.91,2.9225,2.81,2.8375,"[""Feltl Upgrades DexCom To Buy, PT Raised To $15.85"", ""UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35"", ""UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35"", ""Feltl Upgrades DexCom To Buy, PT Raised To $15.85"", ""UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35"", ""Feltl Upgrades DexCom To Buy, PT Raised To $15.85""]"
DXCM,2011-08-17,2.8625,2.9225,2.78,2.8275,
DXCM,2011-08-18,2.7325,2.75,2.645,2.685,
DXCM,2011-08-19,2.605,2.765,2.57,2.71,"[""DexCom Remains Neutral - Analyst Blog"", ""Pre-Market Losers; Cincinnati Bell Down 13%"", ""Pre-Market Losers; Cincinnati Bell Down 13%"", ""DexCom Remains Neutral - Analyst Blog"", ""Pre-Market Losers; Cincinnati Bell Down 13%"", ""DexCom Remains Neutral - Analyst Blog""]"
DXCM,2011-08-22,2.7975,2.8075,2.6375,2.7275,
DXCM,2011-08-23,2.6325,2.84,2.63,2.8375,
DXCM,2011-08-24,2.8175,2.9375,2.7475,2.93,
DXCM,2011-08-25,2.955,2.955,2.81,2.8275,
DXCM,2011-08-26,2.755,2.92,2.755,2.9175,
DXCM,2011-08-29,2.9275,3.1,2.9275,3.095,
DXCM,2011-08-30,3.0775,3.095,2.99,3.02,
DXCM,2011-08-31,3.025,3.0725,2.935,3.0075,
DXCM,2011-09-01,2.9225,3.0825,2.895,2.94,
DXCM,2011-09-02,2.9,3.005,2.8625,2.88,
DXCM,2011-09-06,2.765,2.84,2.7475,2.84,
DXCM,2011-09-07,2.9025,3.0375,2.8525,3.02,
DXCM,2011-09-08,2.99,3.08,2.98,3.0,
DXCM,2011-09-09,2.955,3.0,2.8825,2.91,
DXCM,2011-09-12,2.8525,2.945,2.8275,2.895,
DXCM,2011-09-13,2.9125,3.0225,2.8325,3.0125,
DXCM,2011-09-14,3.05,3.15,3.0025,3.09,
DXCM,2011-09-15,3.125,3.2,3.0525,3.1775,
DXCM,2011-09-16,3.1875,3.1975,3.135,3.1975,
DXCM,2011-09-19,3.13,3.235,3.125,3.1925,
DXCM,2011-09-20,3.26,3.4225,3.17,3.2725,"[""Morgan Keegan Maintains Outperform on DexCom"", ""Top Narrow Based Indexes For September 20"", ""Top Narrow Based Indexes For September 20"", ""Morgan Keegan Maintains Outperform on DexCom"", ""Top Narrow Based Indexes For September 20"", ""Morgan Keegan Maintains Outperform on DexCom""]"
DXCM,2011-09-21,3.2825,3.3375,3.14,3.15,
DXCM,2011-09-22,3.0375,3.1625,2.9125,2.9725,
DXCM,2011-09-23,2.9025,3.075,2.9025,2.9725,
DXCM,2011-09-26,3.0,3.105,2.8875,3.0,
DXCM,2011-09-27,3.09,3.26,3.0125,3.2125,
DXCM,2011-09-28,3.2025,3.2575,3.0525,3.055,
DXCM,2011-09-29,3.1525,3.185,3.045,3.1375,
DXCM,2011-09-30,3.075,3.13,2.995,3.0,
DXCM,2011-10-03,2.955,3.03,2.8025,2.84,
DXCM,2011-10-04,2.805,3.06,2.805,3.05,
DXCM,2011-10-05,3.0625,3.1075,3.0125,3.055,
DXCM,2011-10-06,3.05,3.0725,2.9825,3.0225,
DXCM,2011-10-07,3.06,3.0725,2.7675,2.775,
DXCM,2011-10-10,2.845,2.885,2.7975,2.8725,
DXCM,2011-10-11,2.845,2.92,2.835,2.8675,
DXCM,2011-10-12,2.895,2.9475,2.805,2.8225,
DXCM,2011-10-13,2.7975,2.8275,2.775,2.8125,
DXCM,2011-10-14,2.8625,2.8725,2.7575,2.8075,
DXCM,2011-10-17,2.7625,2.8975,2.6425,2.655,
DXCM,2011-10-18,2.6625,2.7125,2.6125,2.685,
DXCM,2011-10-19,2.6875,2.7275,2.565,2.58,
DXCM,2011-10-20,2.595,2.67,2.475,2.565,
DXCM,2011-10-21,2.63,2.66,2.53,2.565,
DXCM,2011-10-24,2.5825,2.7625,2.58,2.7575,
DXCM,2011-10-25,2.7375,2.755,2.61,2.62,
DXCM,2011-10-26,2.67,2.67,2.5325,2.545,
DXCM,2011-10-27,2.5775,2.6525,2.2825,2.35,
DXCM,2011-10-28,2.3625,2.53,2.2825,2.51,
DXCM,2011-10-31,2.45,2.495,2.425,2.4475,
DXCM,2011-11-01,2.3525,2.4025,2.335,2.35,
DXCM,2011-11-02,2.35,2.525,2.2875,2.45,"[""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Inc. Reports Operating Results (10-Q)""]"
DXCM,2011-11-03,1.8625,2.1425,1.8325,1.9675,
DXCM,2011-11-04,1.9625,2.0,1.885,1.9075,
DXCM,2011-11-07,1.9025,1.93,1.8325,1.8525,"[""DexCom Misses Completely - Analyst Blog"", ""DexCom Misses Completely - Analyst Blog"", ""DexCom Misses Completely - Analyst Blog""]"
DXCM,2011-11-08,1.86,1.8625,1.7775,1.845,
DXCM,2011-11-09,1.7825,1.83,1.7675,1.7775,
DXCM,2011-11-10,1.8075,1.8375,1.755,1.77,
DXCM,2011-11-11,1.795,1.84,1.77,1.835,
DXCM,2011-11-14,1.825,1.825,1.745,1.75,
DXCM,2011-11-15,1.7475,1.81,1.725,1.8025,
DXCM,2011-11-16,1.775,1.8025,1.7575,1.76,
DXCM,2011-11-17,1.755,1.775,1.7375,1.75,
DXCM,2011-11-18,1.8125,1.8375,1.765,1.775,
DXCM,2011-11-21,1.7425,1.75,1.7175,1.735,"[""DexCom Hits 52-Week Low of $6.89"", ""DexCom Hits 52-Week Low of $6.89"", ""DexCom Hits 52-Week Low of $6.89""]"
DXCM,2011-11-22,1.74,1.7575,1.715,1.7275,"[""DexCom Hits 52-Week Low of $6.86"", ""DexCom Hits 52-Week Low of $6.86"", ""DexCom Hits 52-Week Low of $6.86""]"
DXCM,2011-11-23,1.6875,1.7525,1.6875,1.7375,"[""DexCom Hits 52-Week Low of $6.75"", ""DexCom Hits 52-Week Low of $6.75"", ""DexCom Hits 52-Week Low of $6.75""]"
DXCM,2011-11-25,1.7275,1.75,1.71,1.7325,
DXCM,2011-11-28,1.775,1.8525,1.7725,1.8525,
DXCM,2011-11-29,1.85,1.8925,1.85,1.8775,
DXCM,2011-11-30,1.965,2.0075,1.945,2.005,
DXCM,2011-12-01,2.0025,2.02,1.975,2.0,
DXCM,2011-12-02,2.0275,2.085,2.005,2.06,
DXCM,2011-12-05,2.095,2.12,2.0625,2.09,
DXCM,2011-12-06,2.09,2.14,2.0425,2.1075,
DXCM,2011-12-07,2.095,2.14,2.0175,2.0425,
DXCM,2011-12-08,2.025,2.035,1.99,2.0,
DXCM,2011-12-09,2.0475,2.0975,1.99,2.0775,
DXCM,2011-12-12,2.0775,2.1625,2.0,2.02,
DXCM,2011-12-13,2.045,2.0875,2.0,2.01,
DXCM,2011-12-14,2.0025,2.025,1.995,2.01,
DXCM,2011-12-15,2.045,2.0825,2.025,2.0525,
DXCM,2011-12-16,2.0825,2.1325,2.0525,2.07,
DXCM,2011-12-19,2.0575,2.1125,2.0225,2.0275,
DXCM,2011-12-20,2.0675,2.1575,2.0675,2.1525,"[""McNicoll Lewis & Vlak Initiates DexCom at Buy"", ""MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT"", ""MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT"", ""McNicoll Lewis & Vlak Initiates DexCom at Buy"", ""MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT"", ""McNicoll Lewis & Vlak Initiates DexCom at Buy""]"
DXCM,2011-12-21,2.1525,2.1875,2.1025,2.1775,
DXCM,2011-12-22,2.155,2.225,2.15,2.1825,
DXCM,2011-12-23,2.185,2.19,2.1425,2.145,
DXCM,2011-12-27,2.135,2.175,2.12,2.1625,
DXCM,2011-12-28,2.1625,2.1875,2.125,2.135,
DXCM,2011-12-29,2.1725,2.3725,2.15,2.35,"[""5 Under-$10 Stocks Set to Soar"", ""Wunderlich Securities Initiates DexCom at Buy, $12 PT"", ""UPDATE: Wunderlich Initiates Coverage on DexCom at Buy"", ""Afternoon Movers; Positive US News"", ""Afternoon Movers; Positive US News"", ""UPDATE: Wunderlich Initiates Coverage on DexCom at Buy"", ""Wunderlich Securities Initiates DexCom at Buy, $12 PT"", ""5 Under-$10 Stocks Set to Soar"", ""Afternoon Movers; Positive US News"", ""UPDATE: Wunderlich Initiates Coverage on DexCom at Buy"", ""Wunderlich Securities Initiates DexCom at Buy, $12 PT"", ""5 Under-$10 Stocks Set to Soar""]"
DXCM,2011-12-30,2.3275,2.3925,2.305,2.3275,
DXCM,2012-01-03,2.38,2.405,2.3425,2.36,
DXCM,2012-01-04,2.33,2.3575,2.2775,2.3,
DXCM,2012-01-05,2.2875,2.2925,2.225,2.23,
DXCM,2012-01-06,2.2275,2.26,2.19,2.2075,
DXCM,2012-01-09,2.2125,2.2475,2.16,2.21,
DXCM,2012-01-10,2.255,2.2575,2.205,2.215,
DXCM,2012-01-11,2.2125,2.5425,2.16,2.5325,"[""Oppenheimer Reiterates Perform on DexCom"", ""Feltl and Company Lowers PT on DexCom to $9"", ""Piper Jaffray Reiterates Overweight Rating on DexCom"", ""Piper Jaffray Reiterates Overweight Rating on DexCom"", ""Feltl and Company Lowers PT on DexCom to $9"", ""Oppenheimer Reiterates Perform on DexCom"", ""Piper Jaffray Reiterates Overweight Rating on DexCom"", ""Feltl and Company Lowers PT on DexCom to $9"", ""Oppenheimer Reiterates Perform on DexCom""]"
DXCM,2012-01-12,2.53,2.5775,2.47,2.5675,
DXCM,2012-01-13,2.5325,2.5575,2.475,2.5025,
DXCM,2012-01-17,2.4525,2.56,2.4425,2.54,"[""Brean Murray Initiates DexCom at Buy"", ""UPDATE: Brean Murray Carret Initiates Buy, $12.50 Target on DexCom"", ""UPDATE: Brean Murray Carret Initiates Buy, $12.50 Target on DexCom"", ""Brean Murray Initiates DexCom at Buy"", ""UPDATE: Brean Murray Carret Initiates Buy, $12.50 Target on DexCom"", ""Brean Murray Initiates DexCom at Buy""]"
DXCM,2012-01-18,2.56,2.6725,2.535,2.6675,
DXCM,2012-01-19,2.6675,2.73,2.66,2.705,
DXCM,2012-01-20,2.7175,2.7175,2.66,2.68,
DXCM,2012-01-23,2.6875,2.725,2.6225,2.6425,
DXCM,2012-01-24,2.6275,2.705,2.6125,2.685,
DXCM,2012-01-25,2.665,2.7575,2.615,2.7325,
DXCM,2012-01-26,2.745,2.765,2.6575,2.7475,
DXCM,2012-01-27,2.7475,2.8075,2.7,2.7625,
DXCM,2012-01-30,2.745,2.7625,2.6775,2.75,
DXCM,2012-01-31,2.77,2.7825,2.72,2.7425,
DXCM,2012-02-01,2.765,2.8525,2.76,2.8225,
DXCM,2012-02-02,2.8125,2.9125,2.8125,2.8825,
DXCM,2012-02-03,2.935,2.97,2.9025,2.925,
DXCM,2012-02-06,2.895,2.955,2.85,2.94,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-02-07,2.9225,2.9525,2.87,2.9275,
DXCM,2012-02-08,2.93,2.955,2.8275,2.8425,
DXCM,2012-02-09,2.7675,2.895,2.765,2.8425,
DXCM,2012-02-10,2.81,2.8375,2.755,2.78,
DXCM,2012-02-13,2.8175,2.8175,2.7825,2.8,
DXCM,2012-02-14,2.7775,2.8725,2.75,2.795,
DXCM,2012-02-15,2.79,2.8,2.725,2.735,
DXCM,2012-02-16,2.78,2.9625,2.74,2.95,
DXCM,2012-02-17,2.965,2.975,2.8875,2.9,
DXCM,2012-02-21,2.8975,2.9375,2.835,2.8625,
DXCM,2012-02-22,2.865,2.8775,2.77,2.7975,
DXCM,2012-02-23,2.9075,2.9075,2.755,2.7975,"[""DexCom Inc. Reports Operating Results (10-K)"", ""DexCom Announces Acquisition of SweetSpot Diabetes Care for $4.5M"", ""DexCom Reports Q4 EPS $(0.18) vs $(0.17) Est; Revenues $22.40M vs $21.63M Est"", ""DexCom Reports Q4 EPS $(0.18) vs $(0.17) Est; Revenues $22.40M vs $21.63M Est"", ""DexCom Announces Acquisition of SweetSpot Diabetes Care for $4.5M"", ""DexCom Inc. Reports Operating Results (10-K)"", ""DexCom Reports Q4 EPS $(0.18) vs $(0.17) Est; Revenues $22.40M vs $21.63M Est"", ""DexCom Announces Acquisition of SweetSpot Diabetes Care for $4.5M"", ""DexCom Inc. Reports Operating Results (10-K)""]"
DXCM,2012-02-24,2.8,2.8375,2.6625,2.7,"[""DexCom's EPS Misses, Sales Beat - Analyst Blog"", ""Wunderlich Securities Maintains DexCom at Buy, Raises PT from $12 to $15"", ""Brean Murray Carret & Co. Maintains DexCom at Buy, Raises PT from $12.5 to $13.5"", ""UPDATE: Wunderlich Securities Raises Price Target on DexCom to $15"", ""UPDATE: Canaccord Genuity Raises Target on DexCom to $11.50"", ""UPDATE: Brean Murray Carret Raises Target on DexCom to $13.50"", ""UPDATE: Brean Murray Carret Raises Target on DexCom to $13.50"", ""UPDATE: Canaccord Genuity Raises Target on DexCom to $11.50"", ""UPDATE: Wunderlich Securities Raises Price Target on DexCom to $15"", ""Brean Murray Carret & Co. Maintains DexCom at Buy, Raises PT from $12.5 to $13.5"", ""Wunderlich Securities Maintains DexCom at Buy, Raises PT from $12 to $15"", ""DexCom's EPS Misses, Sales Beat - Analyst Blog"", ""DexCom's EPS Misses, Sales Beat - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth-quarter 2011 loss per share of 18 cents, higher than both the Zacks Consensus Estimate of a loss of 17 cents and the year-ago loss of 16 cents per share. Net loss for the quarter increased 24.9% year over year to $12.3 million. For fiscal 2011, loss per share of 68 cents was also above the Zacks Consensus Estimate of a loss of 67 cents but much lower than the year-ago loss of 97 cents per share. Revenues Sales increased sharply 43% year over year to $22.4 million in the fourth quarter, beating the Zacks Consensus Estimate of $22 million. Revenue was $76.3 million in fiscal 2011, up 57% year over year, surpassing the Zacks Consensus Estimate of $75 million. Product sales climbed 54% to $20.9 million while development grant and other revenues were down 27% to $1.5 million in the reported quarter. Margins and Expenses Gross margin improved to 47.7% in the fourth quarter from 44.7% a year ago. Cost of sales moved up 35.6% year over year to $11.7 million on account of higher cost of product sales. Operating expenses increased 36.1% year over year to $23 million on account of higher R&D spending and selling, general and administrative expenses, which grew 33.8% and 37.7%, respectively, in the quarter. Balance Sheet At the end of the quarter, DexCom had cash and short-term marketable securities of $81.9 million, up 74% y/y. Our Take We believe DexCom is poised to gain a major share of the glucose monitoring market, driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to a stricter regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UPDATE: Brean Murray Carret Raises Target on DexCom to $13.50"", ""UPDATE: Canaccord Genuity Raises Target on DexCom to $11.50"", ""UPDATE: Wunderlich Securities Raises Price Target on DexCom to $15"", ""Brean Murray Carret & Co. Maintains DexCom at Buy, Raises PT from $12.5 to $13.5"", ""Wunderlich Securities Maintains DexCom at Buy, Raises PT from $12 to $15"", ""DexCom's EPS Misses, Sales Beat - Analyst Blog""]"
DXCM,2012-02-27,2.68,2.6925,2.565,2.6775,
DXCM,2012-02-28,2.68,2.7775,2.67,2.7725,
DXCM,2012-02-29,2.7825,2.8,2.6925,2.6975,
DXCM,2012-03-01,2.735,2.8,2.6775,2.6825,
DXCM,2012-03-02,2.6775,2.7,2.555,2.5925,
DXCM,2012-03-05,2.595,2.63,2.5625,2.5875,
DXCM,2012-03-06,2.565,2.59,2.52,2.525,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-03-07,2.5525,2.5875,2.535,2.56,
DXCM,2012-03-08,2.5775,2.595,2.5375,2.5875,"[""Reaffirming DexCom at Neutral - Analyst Blog"", ""Reaffirming DexCom at Neutral - Analyst Blog"", ""Reaffirming DexCom at Neutral - Analyst Blog We remain Neutral on DexCom ( DXCM ), a prominent player in the continuous glucose monitoring market. Its fourth-quarter fiscal 2011 loss per share of 18 cents was a penny higher than the Zacks Consensus Estimate. Losses widened year over year despite solid double-digit growth in the top line. Revenues zoomed 43% year over year to $22.4 million, beating the Zacks Consensus Estimate. Product sales spiked 54% to $20.9 million in the quarter. DexCom is focused on the development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. The diabetes market is large and growing. An important component of effective diabetes management is frequent monitoring of blood glucose levels. DexCom's product has a comparative advantage in terms of both patient convenience and quality of data generated vis-\u00e0-vis traditional diagnostic tests. We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement and increased need for continuous glucose monitoring. Increased awareness and acceptance of the need for continuous glucose monitoring and more favorable reimbursement coverage should help drive sales for DexCom's products. Other potential catalysts include the FDA approval and launch of new products under the company's collaborative agreements with several companies including Insulet Corporation. DexCom plans to file a Premarket Approval (\""PMA\"") for the Gen4 sensor system at the end of the first quarter or early second quarter of 2012. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. We also feel that the company's recent move to buy healthcare IT company SweetSpot Diabetes may allow it to better compete with Medtronic ( MDT ) through better data management systems. However, competition in the glucose monitoring market is fierce and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to a strict regulatory environment. Our recommendation on the stock is supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reaffirming DexCom at Neutral - Analyst Blog""]"
DXCM,2012-03-09,2.5925,2.6075,2.53,2.555,
DXCM,2012-03-12,2.55,2.59,2.5275,2.545,
DXCM,2012-03-13,2.55,2.58,2.5175,2.5625,
DXCM,2012-03-14,2.555,2.6125,2.5525,2.5975,
DXCM,2012-03-15,2.615,2.745,2.595,2.7225,
DXCM,2012-03-16,2.73,2.7425,2.6775,2.7075,
DXCM,2012-03-19,2.6725,2.75,2.6725,2.7075,
DXCM,2012-03-20,2.69,2.7075,2.6275,2.63,
DXCM,2012-03-21,2.6375,2.6725,2.5975,2.625,
DXCM,2012-03-22,2.6025,2.6025,2.5475,2.5675,
DXCM,2012-03-23,2.565,2.6025,2.5525,2.5875,
DXCM,2012-03-26,2.595,2.705,2.5875,2.6875,
DXCM,2012-03-27,2.705,2.7475,2.6775,2.68,
DXCM,2012-03-28,2.6875,2.6875,2.575,2.63,
DXCM,2012-03-29,2.5975,2.6325,2.585,2.625,
DXCM,2012-03-30,2.6325,2.6525,2.58,2.6075,
DXCM,2012-04-02,2.5875,2.6775,2.57,2.6575,
DXCM,2012-04-03,2.6525,2.71,2.6475,2.6875,
DXCM,2012-04-04,2.6675,2.69,2.65,2.6775,
DXCM,2012-04-05,2.655,2.665,2.61,2.6125,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-04-09,2.5575,2.58,2.505,2.505,
DXCM,2012-04-10,2.5075,2.5275,2.35,2.3725,
DXCM,2012-04-11,2.405,2.4375,2.3725,2.4125,
DXCM,2012-04-12,2.4225,2.4825,2.4225,2.445,
DXCM,2012-04-13,2.4275,2.4475,2.34,2.3775,
DXCM,2012-04-16,2.39,2.4125,2.3625,2.38,
DXCM,2012-04-17,2.405,2.45,2.39,2.41,
DXCM,2012-04-18,2.39,2.4175,2.37,2.395,
DXCM,2012-04-19,2.3925,2.455,2.38,2.4,
DXCM,2012-04-20,2.4525,2.4525,2.395,2.4,
DXCM,2012-04-23,2.37,2.4275,2.3575,2.42,
DXCM,2012-04-24,2.4175,2.4575,2.405,2.425,
DXCM,2012-04-25,2.4675,2.4825,2.4375,2.4625,
DXCM,2012-04-26,2.4625,2.4775,2.445,2.4625,
DXCM,2012-04-27,2.48,2.51,2.45,2.4925,
DXCM,2012-04-30,2.4975,2.4975,2.4425,2.445,
DXCM,2012-05-01,2.445,2.5025,2.445,2.45,
DXCM,2012-05-02,2.4225,2.5275,2.4075,2.5275,"[""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q1 EPS $-0.21 vs $-0.19 Est; Revenues $20.1M vs $19.88M Est"", ""DexCom Reports Q1 EPS $-0.21 vs $-0.19 Est; Revenues $20.1M vs $19.88M Est"", ""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q1 EPS $-0.21 vs $-0.19 Est; Revenues $20.1M vs $19.88M Est"", ""DexCom Inc. Reports Operating Results (10-Q)""]"
DXCM,2012-05-03,2.5,2.525,2.4375,2.5025,"[""Feltl and Company Maintains DexCom at Hold, Raises PT from $9 to $Sat Dec 30 1899 08:15:00 GMT-0800 (PST)"", ""McNicoll Lewis Vlak Maintains DexCom at Hold, Raises PT from $9 to $10"", ""McNicoll Lewis Vlak Maintains DexCom at Hold, Raises PT from $9 to $10"", ""Feltl and Company Maintains DexCom at Hold, Raises PT from $9 to $Sat Dec 30 1899 08:15:00 GMT-0800 (PST)"", ""McNicoll Lewis Vlak Maintains DexCom at Hold, Raises PT from $9 to $10"", ""Feltl and Company Maintains DexCom at Hold, Raises PT from $9 to $Sat Dec 30 1899 08:15:00 GMT-0800 (PST)""]"
DXCM,2012-05-04,2.4975,2.55,2.4525,2.505,
DXCM,2012-05-07,2.5,2.5475,2.48,2.525,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Misses on EPS, Losses Mount - Analyst Blog"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Misses on EPS, Losses Mount - Analyst Blog"", ""DexCom Misses on EPS, Losses Mount - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per share. Net loss for the quarter increased 18.7% year over year to $14.1 million (21 cents per share). Revenues Sales increased sharply 41.8% year over year to $20.1 million in the first quarter, narrowly beating the Zacks Consensus Estimate of $20 million. Product sales jumped 42% to $18.6 million while development grant and other revenues were up 42.7% to $1.5 million in the reported quarter. Margins and Expenses Gross margin picked up to 46.7% in the first quarter from 36.1% a year ago. Cost of sales moved up 18.2% year over year to $10.7 million mostly on account of higher cost of product sales. Operating expenses increased 45.9% year over year to $24.8 million on account of higher R&D spending and selling, general and administrative expenses, which grew 55% and 40.6%, respectively, in the reported quarter. Balance Sheet DexCom exited the quarter with cash and short-term marketable securities of $70.2 million, down 14.3% on a sequential basis. Our Take We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to a stricter regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Misses on EPS, Losses Mount - Analyst Blog""]"
DXCM,2012-05-08,2.5,2.5875,2.4875,2.5825,
DXCM,2012-05-09,2.5425,2.615,2.5375,2.605,
DXCM,2012-05-10,2.6225,2.6375,2.585,2.625,
DXCM,2012-05-11,2.5975,2.6425,2.5625,2.59,
DXCM,2012-05-14,2.56,2.5975,2.545,2.5625,
DXCM,2012-05-15,2.5575,2.6225,2.5575,2.61,
DXCM,2012-05-16,2.6325,2.7075,2.6175,2.625,
DXCM,2012-05-17,2.625,2.6325,2.595,2.605,
DXCM,2012-05-18,2.6,2.64,2.5825,2.6025,
DXCM,2012-05-21,2.605,2.685,2.5975,2.6725,
DXCM,2012-05-22,2.6725,2.705,2.6075,2.6425,
DXCM,2012-05-23,2.605,2.6625,2.565,2.66,
DXCM,2012-05-24,2.6575,2.6725,2.595,2.6225,
DXCM,2012-05-25,2.6225,2.7,2.6225,2.6975,
DXCM,2012-05-29,2.71,2.84,2.7,2.7725,
DXCM,2012-05-30,2.7475,2.7675,2.6375,2.6575,
DXCM,2012-05-31,2.6525,2.6975,2.595,2.69,
DXCM,2012-06-01,2.6125,2.7425,2.575,2.6925,
DXCM,2012-06-04,2.7,2.71,2.65,2.675,
DXCM,2012-06-05,2.6525,2.7175,2.6525,2.675,
DXCM,2012-06-06,2.6775,2.7625,2.665,2.7025,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-06-07,2.6725,2.75,2.6725,2.7025,
DXCM,2012-06-08,2.69,2.9125,2.69,2.905,
DXCM,2012-06-11,2.9275,2.985,2.8875,2.89,"[""DexCom Retained at Neutral - Analyst Blog"", ""DexCom Retained at Neutral - Analyst Blog"", ""DexCom Retained at Neutral - Analyst Blog We remain Neutral on DexCom ( DXCM ). Its first-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus Estimate. Losses widened year over year despite solid double-digit revenue growth. Sales increased sharply 41.8% year over year to $20.1 million in the first quarter, narrowly beating the Zacks Consensus Estimate. Product sales jumped 42% to $18.6 million while development grant and other revenues were up 42.7% to $1.5 million in the reported quarter. The diabetes market is large and growing. An important component of effective diabetes management is frequent monitoring of blood glucose levels. DexCom's product has a comparative advantage in terms of both patient convenience and quality of data generated vis-\u00e0-vis traditional diagnostic tests. We believe DexCom is poised to gain a share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement and increased need for continuous glucose monitoring. Increased awareness and acceptance of the need for continuous glucose monitoring and more favorable reimbursement coverage should help drive sales for DexCom's products. Other potential catalysts include the FDA approval and launch of new products under the company's collaborative agreements with several companies including Insulet Corporation. The company revealed that it filed for a pre-market approval (PMA) for its Gen4 sensor in the first quarter of 2012. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. We also feel that the company's move to buy healthcare IT company SweetSpot Diabetes may allow it to compete more effectively with Medtronic ( MDT ) through better data management systems. However, competition in the glucose monitoring market is fierce. Moreover, DexCom has incurred losses since inception and its efforts are made more difficult by a stringent regulatory environment. We are currently Neutral on the stock, supported by a short-term Zacks #3 Rank (Hold). DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Retained at Neutral - Analyst Blog""]"
DXCM,2012-06-12,2.8975,2.95,2.88,2.95,
DXCM,2012-06-13,2.93,3.0675,2.93,3.025,
DXCM,2012-06-14,3.0225,3.115,2.99,3.1025,"[""Echo Therapeutics to Join Russell Microcap Index - Analyst Blog"", ""Dexcom Receives CE Mark Approval for the Dexcom G4 Continuous Glucose Monitoring System"", ""Dexcom Receives CE Mark Approval for the Dexcom G4 Continuous Glucose Monitoring System"", ""Echo Therapeutics to Join Russell Microcap Index - Analyst Blog"", ""Echo Therapeutics to Join Russell Microcap Index - Analyst Blog On June 13, Echo Therapeutics ( ECTE ), a transdermal medical device company, announced that it anticipates being included in the Russell Microcap Index. It expects the inclusion on June 25, 2012, when Russell Investments rebalances its set of U.S. indexes. This assumption is based on a preliminary list of additions posted by Russell on June 8, 2012. Management is enthusiastic about this opportunity as it . The inclusion in the Russell Microcap Index is expected to enhance awareness of the company to a larger number of institutions and investors by increasing the visibility and volume trading of the stock. It will mark a keystone as the Russell Microcap Index is an important weighted index that examines trends in relatively smaller companies. This should also enhance Echo's shareholder base. The annual recalculation of the Index can be relied upon to avoid any distortion in presenting the performance of Echo Therapeutics. The Russell Microcap Index is well regarded and proactively used by investment managers as well as institutional investors. It serves as a benchmark for all investment strategies with assets worth $3.9 trillion in the institutional marketplace. The index covers almost 98% of the global investable market across 83 countries for more than 10,000 securities. Membership in the Russell Microcap Index for its equity indexes depends on the market capitalization, objectives and style attributes of the company. This membership lasts for one year and implies inclusion in the appropriate growth and value style indexes. The annual reconstitution of the Russell Indexes covers the largest 4000 stocks in the U.S. as of the end of May. The stocks are ranked according to the total market capitalization to create the Russell 3000 index and Russell Microcap Index. Echo Therapeutics specializes in the production of medical devices with advanced skin permeation technology. Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. The stock currently retains a Zacks #4 Rank, which translates into a short-term Sell rating. ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Receives CE Mark Approval for the Dexcom G4 Continuous Glucose Monitoring System"", ""Echo Therapeutics to Join Russell Microcap Index - Analyst Blog""]"
DXCM,2012-06-15,3.1,3.195,3.0725,3.1725,"[""DexCom Wins CE Mark - Analyst Blog"", ""DexCom Wins CE Mark - Analyst Blog"", ""DexCom Wins CE Mark - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, recently reported that it received a CE Mark for its 4 th generation continuous glucose monitoring system. This recognition for the DexCom G4 system permits its launch in EU as well as certain Latin American and Asian nations, where the CE Mark is recognized. Diabetes is a chronic condition, and a major cause of fatality and disability, which affects over 350 million individuals across the globe, as per the International Diabetes Federation. It can lead to serious negative outcomes such as end-stage renal failure, blindness and amputation of limbs. The DexCom G4 is intended to aid diabetics to better monitor their glucose levels. The company stated that the DexCom G4 system's strong performance is duly evident in the information recently submitted by it to the American Diabetes Association's 72nd Scientific Sessions. DexCom is developing a plan for a phased product commercialization in overseas markets. The diabetes market is large and growing. An important component of effective diabetes management is frequent monitoring of blood glucose levels. DexCom's ambulatory product has a comparative advantage in terms of both patient convenience and quality of data generated vis-\u00e0-vis traditional diagnostic tests. We believe DexCom is poised to gain a share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement and increased need for continuous glucose monitoring. Increased awareness and acceptance of the need for continuous glucose monitoring and more favorable reimbursement coverage should help drive sales for DexCom's products. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes may allow it to compete more effectively with Medtronic ( MDT ) through better data management systems. However, competition in the glucose monitoring market is fierce. Moreover, DexCom has incurred losses since inception and its efforts are made more difficult by a stringent regulatory environment. We are currently Neutral on the stock, supported by a short-term Zacks #3 Rank (Hold). DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Wins CE Mark - Analyst Blog""]"
DXCM,2012-06-18,3.1625,3.285,3.15,3.21,
DXCM,2012-06-19,3.235,3.2775,3.2125,3.2675,
DXCM,2012-06-20,3.275,3.3,3.24,3.2575,
DXCM,2012-06-21,3.2575,3.29,3.13,3.1575,
DXCM,2012-06-22,3.1825,3.2875,3.16,3.2575,
DXCM,2012-06-25,3.2125,3.23,3.1425,3.1575,
DXCM,2012-06-26,3.1625,3.18,3.065,3.1175,
DXCM,2012-06-27,3.1325,3.2525,3.1325,3.215,
DXCM,2012-06-28,3.1975,3.255,3.0975,3.1675,
DXCM,2012-06-29,3.2325,3.25,3.215,3.24,
DXCM,2012-07-02,3.24,3.27,3.225,3.245,
DXCM,2012-07-03,3.2675,3.28,3.235,3.265,
DXCM,2012-07-05,3.2625,3.2725,3.2375,3.245,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-07-06,3.2125,3.2425,3.18,3.1975,
DXCM,2012-07-09,3.1975,3.225,3.135,3.2225,
DXCM,2012-07-10,3.2525,3.265,3.225,3.255,
DXCM,2012-07-11,3.2525,3.3025,3.24,3.2775,
DXCM,2012-07-12,3.245,3.25,3.15,3.18,
DXCM,2012-07-13,3.2,3.2525,3.19025,3.2425,
DXCM,2012-07-16,3.225,3.25,3.1825,3.235,"[""McNicoll Lewis Vlak Suspends Coverage on DexCom"", ""McNicoll Lewis Vlak Suspends Coverage on DexCom"", ""McNicoll Lewis Vlak Suspends Coverage on DexCom""]"
DXCM,2012-07-17,3.28,3.28,3.2075,3.225,
DXCM,2012-07-18,3.21,3.2425,3.1825,3.195,
DXCM,2012-07-19,3.22,3.225,3.175,3.1925,
DXCM,2012-07-20,3.16,3.175,2.9975,3.0025,
DXCM,2012-07-23,2.94,2.9775,2.9025,2.94,
DXCM,2012-07-24,2.945,3.005,2.8625,2.875,
DXCM,2012-07-25,2.8875,2.8875,2.815,2.82,
DXCM,2012-07-26,2.875,2.9,2.8225,2.85,
DXCM,2012-07-27,2.8625,2.93,2.83,2.9175,
DXCM,2012-07-30,2.9125,2.945,2.805,2.835,
DXCM,2012-07-31,2.8225,2.864,2.7475,2.7525,
DXCM,2012-08-01,2.7675,2.8125,2.6625,2.775,
DXCM,2012-08-02,2.74,2.87,2.74,2.835,
DXCM,2012-08-03,2.8625,2.935,2.84,2.925,
DXCM,2012-08-06,2.92,3.005,2.92,2.9675,"[""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q2 EPS $-0.21 vs $-0.20 Est; Revenues $23.5M vs $22.24M Est"", ""DexCom Reports Q2 EPS $-0.21 vs $-0.20 Est; Revenues $23.5M vs $22.24M Est"", ""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q2 EPS $-0.21 vs $-0.20 Est; Revenues $23.5M vs $22.24M Est"", ""DexCom Inc. Reports Operating Results (10-Q)""]"
DXCM,2012-08-07,2.9825,3.035,2.9175,2.9975,"[""DexCom Misses on EPS, Losses Climb - Analyst Blog"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""Jefferies & Company Maintains DexCom at Buy, Raises PT from $14 to $15"", ""Jefferies & Company Maintains DexCom at Buy, Raises PT from $14 to $15"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Misses on EPS, Losses Climb - Analyst Blog"", ""DexCom Misses on EPS, Losses Climb - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share. Net loss for the quarter jumped 99.4% year over year to $14.7 million (21 cents per share). Revenues Sales grew 9.4% year over year to $23.5 million in the first quarter, beating the Zacks Consensus Estimate of $22 million. Product sales increased 41.8% to $21.5 million while development grant and other revenues were down 69.1% to $1.9 million in the reported quarter. Margins and Expenses Gross margin declined to 47.9% in the second quarter from 55.4% a year ago. Cost of sales increased 27.9% year over year to $12.2 million, mostly on account of higher cost of product sales. Operating expenses moved up 34.4% year over year to $25.9 million due to higher R&D spending and selling, general and administrative expenses, which grew 49.6% and 25.7%, respectively, in the reported quarter. Balance Sheet DexCom ended the quarter with cash and short-term marketable securities of $105 million, down 41.7% on a year over year basis. Our Take We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to an increasingly strict regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Jefferies & Company Maintains DexCom at Buy, Raises PT from $14 to $15"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Misses on EPS, Losses Climb - Analyst Blog""]"
DXCM,2012-08-08,2.9775,3.01,2.935,3.0,
DXCM,2012-08-09,3.0,3.095,2.97,3.0875,
DXCM,2012-08-10,3.095,3.1375,3.06525,3.125,
DXCM,2012-08-13,3.11,3.135,3.0825,3.135,
DXCM,2012-08-14,3.145,3.195,3.1325,3.1675,
DXCM,2012-08-15,3.1675,3.2125,3.165,3.2075,
DXCM,2012-08-16,3.195,3.2475,3.16,3.21,
DXCM,2012-08-17,3.1975,3.245,3.1925,3.245,
DXCM,2012-08-20,3.2275,3.245,3.18,3.225,
DXCM,2012-08-21,3.235,3.2625,3.13,3.16,
DXCM,2012-08-22,3.145,3.2025,3.04,3.1025,
DXCM,2012-08-23,3.11,3.1125,3.055,3.0925,
DXCM,2012-08-24,3.0775,3.1525,3.05,3.13,
DXCM,2012-08-27,3.1425,3.145,3.11,3.1425,"[""DexCom Remains Neutral - Analyst Blog"", ""DexCom Remains Neutral - Analyst Blog"", ""DexCom Remains Neutral - Analyst Blog We reiterate our Neutral recommendation on DexCom Inc. ( DXCM ). Its second-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus Estimate of a loss of 20 cents per share. Net loss widened 99.4% year over year to $14.7 million, despite healthy revenue growth. San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DexCom is well placed in the industry that it serves. The comparison of the exponential rise of diabetes in recent years to the fraction of population using continuous glucose monitors implies that the market for the company's offerings remains considerably underpenetrated. Further, the company can gain significant operating leverage from expansion of its footprint into new geographies as statistics suggest that the market in developing countries present a sizeable market opportunity. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). We believe that the company's move to buy healthcare IT company SweetSpot Diabetes may allow it to compete more effectively with Medtronic through better data management systems. DexCom is still in its early stage of operations and has incurred losses since inception in 1999. It is exposed to an increasingly strict regulatory environment. Also worth mentioning in this context is the high reimbursement risk which the company faces in the domestic market. We still believe that DexCom is poised to gain a major share of the glucose monitoring market, driven by sustained product development initiatives, collaborations and increased need for continuous glucose monitoring. Our Neutral recommendation on the stock is backed by a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Remains Neutral - Analyst Blog""]"
DXCM,2012-08-28,3.1325,3.15,3.09,3.14,
DXCM,2012-08-29,3.14,3.2175,3.13275,3.1975,
DXCM,2012-08-30,3.185,3.195,3.1525,3.165,
DXCM,2012-08-31,3.2,3.325,3.1875,3.325,
DXCM,2012-09-04,3.3375,3.4625,3.265,3.4425,
DXCM,2012-09-05,3.4275,3.505,3.4,3.475,
DXCM,2012-09-06,3.4875,3.615,3.4775,3.54,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 15,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 15,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 15,000 Shares""]"
DXCM,2012-09-07,3.565,3.565,3.46,3.475,
DXCM,2012-09-10,3.46,3.49125,3.3625,3.37,
DXCM,2012-09-11,3.3825,3.455,3.37525,3.42,
DXCM,2012-09-12,3.42,3.47,3.3875,3.4325,
DXCM,2012-09-13,3.43,3.5825,3.4225,3.5025,
DXCM,2012-09-14,3.48,3.48,3.315,3.375,
DXCM,2012-09-17,3.355,3.3925,3.2575,3.38,
DXCM,2012-09-18,3.38,3.53,3.37,3.51,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares""]"
DXCM,2012-09-19,3.51,3.6,3.5,3.57,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares""]"
DXCM,2012-09-20,3.58,3.705,3.565,3.6825,"[""Jefferies & Company Maintains DexCom at Buy, Raises PT from $15 to $18"", ""Piper Jaffray Maintains DexCom at Overweight, Raises PT from $14 to $17"", ""Piper Jaffray Maintains DexCom at Overweight, Raises PT from $14 to $17"", ""Jefferies & Company Maintains DexCom at Buy, Raises PT from $15 to $18"", ""Piper Jaffray Maintains DexCom at Overweight, Raises PT from $14 to $17"", ""Jefferies & Company Maintains DexCom at Buy, Raises PT from $15 to $18""]"
DXCM,2012-09-21,3.735,3.735,3.6425,3.725,"[""Option Alert: Dexcom October 15 Call; Block Trade: 2,500 Contracts @$0.65"", ""Option Alert: Dexcom October 15 Call; Block Trade: 2,500 Contracts @$0.65"", ""Option Alert: Dexcom October 15 Call; Block Trade: 2,500 Contracts @$0.65""]"
DXCM,2012-09-24,3.72,3.77,3.66375,3.7375,
DXCM,2012-09-25,3.7575,3.7625,3.7,3.715,
DXCM,2012-09-26,3.7175,3.7525,3.6975,3.7125,
DXCM,2012-09-27,3.7125,3.76,3.6675,3.75,
DXCM,2012-09-28,3.725,3.765,3.7105,3.7575,
DXCM,2012-10-01,3.775,3.8325,3.705,3.7375,
DXCM,2012-10-02,3.7725,3.87,3.7025,3.7375,
DXCM,2012-10-03,3.7325,3.75,3.7,3.7125,
DXCM,2012-10-04,3.7125,3.7375,3.67,3.7,
DXCM,2012-10-05,3.7175,3.7575,3.68,3.69,"[""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-10-08,3.6875,3.7725,3.57,3.575,"[""U.S. FDA Approves the Dexcom G4 PLATINUM Continuous Glucose Monitor"", ""Canaccord Maintains DexCom at Buy, Raises PT from $14 to $20"", ""Feltl and Company Maintains DexCom at Hold, Raises PT from $10.75 to $14"", ""Feltl and Company Maintains DexCom at Hold, Raises PT from $10.75 to $14"", ""Canaccord Maintains DexCom at Buy, Raises PT from $14 to $20"", ""U.S. FDA Approves the Dexcom G4 PLATINUM Continuous Glucose Monitor"", ""Feltl and Company Maintains DexCom at Hold, Raises PT from $10.75 to $14"", ""Canaccord Maintains DexCom at Buy, Raises PT from $14 to $20"", ""U.S. FDA Approves the Dexcom G4 PLATINUM Continuous Glucose Monitor""]"
DXCM,2012-10-09,3.575,3.575,3.4125,3.4525,"[""Wedbush Securities Maintains DexCom at Outperform, Raises PT from $15 to $16"", ""Wedbush Securities Maintains DexCom at Outperform, Raises PT from $15 to $16"", ""Wedbush Securities Maintains DexCom at Outperform, Raises PT from $15 to $16""]"
DXCM,2012-10-10,3.4475,3.5025,3.4125,3.4925,
DXCM,2012-10-11,3.51,3.5275,3.4225,3.445,"[""FDA Nod for Dexcom G4 Platinum - Analyst Blog"", ""FDA Nod for Dexcom G4 Platinum - Analyst Blog"", ""FDA Nod for Dexcom G4 Platinum - Analyst Blog DexCom ( DXCM ), a provider of continuous glucose monitoring systems, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its new continuous glucose monitoring system, the DexCom G4 Platinum. The company has started taking orders and will start shipments in the coming weeks. DexCom received the CE Mark for its G4 system in June 2012 and already markets the product in the European Union as well as certain Latin American and Asian nations, where the CE Mark is recognized. Clinical data validates the improved performance of G4 Platinum over the company's Seven Plus with a 19% increase in overall accuracy for glucose monitoring. Trials also indicate a 30% improvement in accuracy when blood glucose level is below 70mg/dl (for hypoglycemia relevance range). The inbuilt features of the G4 Platinum make it the most innovative system for continuous glucose monitoring in the market. The increased accuracy for hypoglycemic range and ease of use will enhance the standard of care for diabetic patients. Given the burgeoning diabetes population in the U.S., the G4 Platinum presents considerable market opportunity. The commercialization of G4 in the U.S. could just be the catalyst that the company needs to gain share in the market it serves. Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company expects to introduce its products in India by year end. It also plans to expand its footprint in China and Japan next year. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. Competition in the glucose monitoring market is fierce. DexCom competes with Roche Diabetes Care, a division of Roche ( RHHBY ) and LifeScan under Johnson & Johnson ( JNJ ) for its Seven Plus offering. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes may allow it to compete more effectively through better data management systems. Despite increasing revenues, DexCom remains a loss making entity and its efforts are made more difficult by a stringent regulatory environment. We currently have a long-term Neutral recommendation on the stock, supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FDA Nod for Dexcom G4 Platinum - Analyst Blog""]"
DXCM,2012-10-12,3.4375,3.485,3.3925,3.4,
DXCM,2012-10-15,3.415,3.44,3.3925,3.435,
DXCM,2012-10-16,3.46,3.5275,3.46,3.525,
DXCM,2012-10-17,3.5225,3.5725,3.5,3.5275,
DXCM,2012-10-18,3.515,3.5475,3.5,3.53,
DXCM,2012-10-19,3.505,3.545,3.41,3.42,
DXCM,2012-10-22,3.4125,3.425,3.3225,3.345,
DXCM,2012-10-23,3.315,3.36,3.255,3.345,
DXCM,2012-10-24,3.355,3.365,3.295,3.3625,
DXCM,2012-10-25,3.39,3.41175,3.3175,3.35,
DXCM,2012-10-26,3.36,3.4015,3.315,3.3425,
DXCM,2012-10-31,3.34,3.3625,3.2175,3.275,
DXCM,2012-11-01,3.2875,3.375,3.2625,3.2675,"[""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q3 EPS $-0.25 vs $-0.22 Est"", ""DexCom Reports Q3 EPS $-0.25 vs $-0.22 Est"", ""DexCom Inc. Reports Operating Results (10-Q)"", ""DexCom Reports Q3 EPS $-0.25 vs $-0.22 Est"", ""DexCom Inc. Reports Operating Results (10-Q)""]"
DXCM,2012-11-02,3.2575,3.3175,3.165,3.2275,"[""Jefferies & Company Maintains DexCom at Buy, Lowers PT from $18 to $16.50"", ""Canaccord Maintains DexCom at Buy, Lowers PT from $20 to $19"", ""UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom"", ""UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom"", ""Canaccord Maintains DexCom at Buy, Lowers PT from $20 to $19"", ""Jefferies & Company Maintains DexCom at Buy, Lowers PT from $18 to $16.50"", ""UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom"", ""Canaccord Maintains DexCom at Buy, Lowers PT from $20 to $19"", ""Jefferies & Company Maintains DexCom at Buy, Lowers PT from $18 to $16.50""]"
DXCM,2012-11-05,3.2175,3.29,3.165,3.2525,"[""DexCom Continues to Incur Loss - Analyst Blog"", ""DexCom Continues to Incur Loss - Analyst Blog"", ""DexCom Continues to Incur Loss - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, higher than the Zacks Consensus Estimate of a loss of 22 cents per share and the year-ago loss of 20 cents a share. Net loss for the quarter soared 30% year over year to $17.3 million. Revenues Revenues surged 26.5% year over year to $23.1 million in the third quarter, marginally beating the Zacks Consensus Estimate of $23 million. Product sales increased almost 27% to $21.1 million while development grant and other revenues improved 25.6% to $2 million in the reported quarter. Margins and Expenses Gross margin dipped to 36.4% in the third quarter from 44.7% a year ago. Operating expenses increased 19.8% year over year to $25.7 million due to higher R&D spending and selling, general and administrative expenses, which grew 28.6% and 14.4%, respectively, in the reported quarter. Research and development expenditure shot up on account of incremental clinical trials costs while selling, general and administrative expenses increased due to additional marketing initiatives. Balance Sheet DexCom exited the third quarter with cash and short-term marketable securities of $53.4 million, down 45.1% on a year-over-year basis. Our Take DexCom is well placed in the industry that it serves. Given the burgeoning diabetes population in the U.S., its G4 Platinum presents considerable market opportunity. Successful commercialization of G4 in the U.S. could just be the catalyst that the company needs to gain share in the market it serves. Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company expects to introduce its products in India by year end. It also plans to expand its footprint in China and Japan next year. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. Competition in the glucose monitoring market is fierce. DexCom competes with Roche Diabetes Care, a division of Roche ( RHHBY ) and LifeScan under Johnson & Johnson ( JNJ ) for its Seven Plus offering. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes Care, may allow it to compete more effectively through better data management systems. Despite increasing revenues, DexCom remains a loss making entity and its efforts are made more difficult by a stringent regulatory environment. We currently have a long-term 'Neutral' recommendation on the stock, supported by a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Continues to Incur Loss - Analyst Blog""]"
DXCM,2012-11-06,3.2725,3.335,3.2275,3.255,
DXCM,2012-11-07,3.2125,3.25,3.1425,3.1875,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-11-08,3.19,3.235,3.1775,3.2025,
DXCM,2012-11-09,3.18,3.28,3.1675,3.1925,
DXCM,2012-11-12,3.1975,3.3,3.1825,3.2725,
DXCM,2012-11-13,3.2625,3.30175,3.18,3.18,
DXCM,2012-11-14,3.1975,3.1975,3.06,3.0875,
DXCM,2012-11-15,3.075,3.15,3.0525,3.085,"[""Still Neutral on DexCom - Analyst Blog"", ""Still Neutral on DexCom - Analyst Blog"", ""Still Neutral on DexCom - Analyst Blog Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom ( DXCM ), a provider of continuous glucose monitoring systems, with a target price of $13.00. Even though the company's international expansion and pipeline development remains on track, it remains a loss-making entity which operates in a highly competitive landscape. DexCom missed the bottom-line consensus for the fifth consecutive time in the third quarter of 2012. Its loss per share of 25 cents was higher than the Zacks Consensus Estimate of a loss of 22 cents per share as well as the year-ago loss of 20 cents a share. During the conference call, DexCom issued a ballpark estimate of $89 million for full year 2012 revenues compared with the current Zacks Consensus Estimate of $95 million for the 2012 revenues. The company also asserted that it will continue to develop its GEN5 system. The joint development of Edwards Lifesciences ' ( EW ) next-generation in-hospital glucose monitoring system is almost complete and the company expects CE Mark approval in Europe before the end of 2012. Overseas territories contributed 10% to the company's product revenues in the most recent quarter. We expect international revenues to strengthen as DexCom ventures into new territories. The company recently gained approval in Australia, while it anticipates approval in Canada and India. DexCom also plans to gain a foothold in other Asian countries like China and Japan. The comparison of the exponential rise of diabetes in developing countries to the fraction of the population using continuous glucose monitors implies that the market for DexCom's products remains largely underpenetrated in these geographies. Last month, the U.S. Food and Drug Administration (FDA) cleared DexCom's new continuous glucose monitoring system, the DexCom G4 Platinum. The company received the CE Mark for its G4 system in June 2012 and already markets the product in the European Union as well as certain Latin American and Asian nations where the CE Mark is recognized. The commercialization of G4 in the U.S. could just be the catalyst that the company needs to gain share. On the flip side, DexCom faces aggressive competition from large players with deeper pockets. The company competes with Roche Diabetes Care, a division of Roche ( RHHBY ) and LifeScan under Johnson & Johnson ( JNJ ) for its Seven Plus offering. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. Moreover, reluctance on the part of physicians and patients to adopt DexCom's products may make it challenging for the company to expand share. This is mainly because the company's glucose monitoring device is more invasive than other self-monitored glucose testing systems. Additionally, manufacturing constraints might hamper the supply continuum of the company. We still believe that DexCom is poised to gain a major share of the glucose monitoring market, driven by sustained product development initiatives, collaborations and increased need for continuous glucose monitoring. The stock carries a short-term Zacks #3 Rank (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Still Neutral on DexCom - Analyst Blog""]"
DXCM,2012-11-16,3.0775,3.17,3.0075,3.15,
DXCM,2012-11-19,3.22675,3.22675,3.1125,3.18,
DXCM,2012-11-20,3.1675,3.225,3.1325,3.1525,
DXCM,2012-11-21,3.15,3.2,3.1225,3.135,
DXCM,2012-11-23,3.125,3.145,3.0925,3.095,
DXCM,2012-11-26,3.07,3.1125,3.0625,3.095,
DXCM,2012-11-27,3.09,3.14,3.055,3.0825,
DXCM,2012-11-28,3.055,3.09,3.0125,3.0625,
DXCM,2012-11-29,3.105,3.18,3.07,3.175,
DXCM,2012-11-30,3.265,3.275,3.235,3.27,
DXCM,2012-12-03,3.2525,3.445,3.2525,3.4275,"[""8 Stocks Soaring on Unusual Volume"", ""8 Stocks Soaring on Unusual Volume"", ""8 Stocks Soaring on Unusual Volume""]"
DXCM,2012-12-04,3.4225,3.54,3.398,3.5375,
DXCM,2012-12-05,3.5025,3.555,3.46,3.465,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 5,000 Shares""]"
DXCM,2012-12-06,3.455,3.5025,3.405,3.4075,
DXCM,2012-12-07,3.4075,3.4525,3.392,3.41,
DXCM,2012-12-10,3.415,3.48875,3.3975,3.485,
DXCM,2012-12-11,3.495,3.585,3.4775,3.56,
DXCM,2012-12-12,3.5775,3.62,3.49,3.495,"[""DexCom, Inc. (DXCM) VP, CFO Jess Roper sells 8,715 Shares"", ""DexCom, Inc. (DXCM) VP, CFO Jess Roper sells 8,715 Shares"", ""DexCom, Inc. (DXCM) VP, CFO Jess Roper sells 8,715 Shares""]"
DXCM,2012-12-13,3.505,3.525,3.4025,3.41,
DXCM,2012-12-14,3.3875,3.4,3.3125,3.315,"[""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares"", ""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares"", ""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares""]"
DXCM,2012-12-17,3.3225,3.3575,3.275,3.305,"[""DexCom Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares"", ""DexCom Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares"", ""DexCom Inc. (DXCM) CTO Jorge A Valdes sells 31,872 Shares""]"
DXCM,2012-12-18,3.278,3.3525,3.278,3.325,
DXCM,2012-12-19,3.3325,3.405,3.2775,3.3975,
DXCM,2012-12-20,3.3925,3.425,3.3275,3.3825,
DXCM,2012-12-21,3.3675,3.3825,3.28,3.3325,
DXCM,2012-12-24,3.325,3.374,3.29,3.33,
DXCM,2012-12-26,3.33,3.35,3.28,3.315,
DXCM,2012-12-27,3.31,3.33,3.295,3.3125,
DXCM,2012-12-28,3.2925,3.3825,3.2875,3.305,
DXCM,2012-12-31,3.305,3.41,3.29,3.3975,
DXCM,2013-01-02,3.4725,3.5,3.4225,3.4625,
DXCM,2013-01-03,3.475,3.515,3.435,3.49275,
DXCM,2013-01-04,3.515,3.555,3.465,3.5425,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares""]"
DXCM,2013-01-07,3.5475,3.7375,3.5425,3.6,"[""Dexcom Names Kevin Sayer as COO; Sees Q4 Product Sales $31.6M, FY13 Sales $120-130M"", ""Dexcom Names Kevin Sayer as COO; Sees Q4 Product Sales $31.6M, FY13 Sales $120-130M"", ""Dexcom Names Kevin Sayer as COO; Sees Q4 Product Sales $31.6M, FY13 Sales $120-130M""]"
DXCM,2013-01-08,3.6,3.665,3.565,3.62,
DXCM,2013-01-09,3.6375,3.675,3.58,3.65,
DXCM,2013-01-10,3.6425,3.735,3.6375,3.7325,
DXCM,2013-01-11,3.73,3.745,3.6975,3.705,
DXCM,2013-01-14,3.705,3.725,3.64,3.66,"[""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $18.00"", ""UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom"", ""UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom"", ""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $18.00"", ""UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom"", ""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $18.00""]"
DXCM,2013-01-15,3.645,3.6675,3.62,3.65,
DXCM,2013-01-16,3.65,3.6525,3.6125,3.62,
DXCM,2013-01-17,3.64,3.655,3.61,3.6225,
DXCM,2013-01-18,3.6275,3.695,3.61,3.695,
DXCM,2013-01-22,3.6775,3.7225,3.66,3.72,
DXCM,2013-01-23,3.7075,3.7425,3.6925,3.71,
DXCM,2013-01-24,3.705,3.7175,3.6625,3.6925,
DXCM,2013-01-25,3.7425,3.8875,3.715,3.875,
DXCM,2013-01-28,3.88,3.8875,3.815,3.82,
DXCM,2013-01-29,3.8125,3.8325,3.7525,3.78875,
DXCM,2013-01-30,3.775,3.82,3.735,3.765,
DXCM,2013-01-31,3.7675,3.83,3.7325,3.8075,
DXCM,2013-02-01,3.7975,3.9025,3.75,3.8775,
DXCM,2013-02-04,3.82,3.8875,3.73,3.7475,
DXCM,2013-02-05,3.7325,3.7975,3.7,3.75,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares""]"
DXCM,2013-02-06,3.72,3.785,3.6925,3.77,
DXCM,2013-02-07,3.77125,3.77125,3.6675,3.695,
DXCM,2013-02-08,3.71,3.715,3.645,3.6975,
DXCM,2013-02-11,3.6975,3.7075,3.6475,3.6525,
DXCM,2013-02-12,3.665,3.6875,3.6225,3.6325,
DXCM,2013-02-13,3.6425,3.675,3.5275,3.6175,
DXCM,2013-02-14,3.615,3.66,3.57,3.65,
DXCM,2013-02-15,3.685,3.6875,3.5975,3.6025,"[""Earnings Preview: Medtronic - Analyst Blog"", ""Earnings Preview: Medtronic - Analyst Blog"", ""Earnings Preview: Medtronic - Analyst Blog We expect leading medical devices company - Medtronic ( MDT ) to beat expectations when it reports third-quarter 2013 results on Feb 19. Why a Likely Positive Surprise? Our proven model shows that Medtronic is likely to beat earnings because it has the right combination of two key ingredients. Positive Zacks ESP: Earnings ESP (Read: Zacks Earnings ESP: A Better Method ), which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is at +2.20%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares. Zacks #2 Rank (Buy): Note that stocks with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of beating earnings. The sell rated stocks (#4 and #5) should never be considered going into an earnings announcement. The combination of Medtronic's Zacks Rank # 2 (Buy) and ESP of +2.20% makes us very confident in looking for a positive earnings beat on Feb 19. What is Driving the Better Than Expected Earnings? Medtronic is enjoying market share gain on the back of the Resolute Integrity DES for the treatment of coronary artery disease. Other recently launched products are also contributing to overall growth. The company also reiterated its aim of returning 50% of free cash flow to shareholders and is targeting suitable acquisitions to augment growth. Meanwhile, Medtronic has increased its focus on the emerging markets and is targeting higher revenues from this region. Other Stocks to Consider Here are some other companies that warrant a look as these have the right ingredients to report possible earnings beat this quarter: DENTSPLY International Inc. ( XRAY ), Earnings ESP of +1.82% and Zacks Rank #3 (Hold) DexCom, Inc. ( DXCM ), Earnings ESP of +11.77% and Zacks Rank #3 (Hold) Walgreen Co. ( WAG ), Earnings ESP of +2.11% and Zacks Rank #3 (Hold). About Earnings ESP Would you like to own more stocks likely to beat their next earnings report? And avoid stocks likely to disappoint? If yes, then it's time you learn about the Earnings ESP score available on Zacks.com. DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Earnings Preview: Medtronic - Analyst Blog""]"
DXCM,2013-02-19,3.615,3.675,3.59,3.6725,
DXCM,2013-02-20,3.6675,3.68,3.585,3.59625,
DXCM,2013-02-21,3.5875,3.625,3.5125,3.5325,"[""DexCom, Inc. Reports Q4 EPS of $(0.12) vs $(0.16) Est; Revenue of $33.30M vs $31.09M Est"", ""DexCom, Inc. Reports Q4 EPS of $(0.12) vs $(0.16) Est; Revenue of $33.30M vs $31.09M Est"", ""DexCom, Inc. Reports Q4 EPS of $(0.12) vs $(0.16) Est; Revenue of $33.30M vs $31.09M Est""]"
DXCM,2013-02-22,3.6875,3.935,3.6575,3.9325,"[""DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog"", ""UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues"", ""UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues"", ""DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog"", ""DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth quarter 2012 adjusted loss per share of 14 cents, better than the Zacks Consensus Estimate of a loss of 16 cents per share. For 2012, DexCom reported adjusted loss per share of 81 cents better than the Zacks Consensus Estimate of a loss of 84 cents per share. Net loss for the quarter dropped 30.3% year over year to $8.5 million (or loss of 12 cents per share). Revenues Revenues surged 48.7% year over year to $33.3 million in the fourth quarter, beating the Zacks Consensus Estimate of $29 million. For 2012, revenues rose 30.9% to $99.9 million surpassing the Zacks Consensus Estimate of $96 million. Product sales increased almost 51.7% to $31.7 million while development grant and other revenues improved 6.7% to $1.6 million in the reported quarter. Margins and Expenses Gross margin improved to 52.6% in the fourth quarter from 47.8% a year ago. Operating expenses increased 13.1% year over year to $25.9 million due to higher selling, general and administrative expenses, which grew 25.5% in the reported quarter. The company reduced its operating loss year over year. Balance Sheet DexCom exited the fourth quarter with cash and short-term marketable securities of $48.7 million, down 40.6% on a year-over-year basis. Long-term debt (net of current portion) amounted to $6.8 million, up from zero in the year-ago period. Our Take DexCom is well placed in the industry that it serves. Given the burgeoning diabetes population in the U.S., its G4 Platinum presents considerable market opportunity. Successful commercialization of G4 in the U.S. could just be the catalyst that the company needs to gain share in the market it serves. Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company is eyeing prospects in the vast markets of India, China and Japan. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. Competition in the glucose monitoring market is fierce. DexCom competes with Roche Diabetes Care, a division of Roche ( RHHBY ) and LifeScan under Johnson & Johnson ( JNJ ) for its Seven Plus offering. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes Care, may allow it to compete more effectively through better data management systems. Despite increasing revenues, DexCom remains a loss making entity and its efforts are made more difficult by a stringent regulatory environment. The stock currently holds a Zacks Rank #3 (Hold). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues"", ""DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog""]"
DXCM,2013-02-25,3.94,3.99125,3.775,3.78,
DXCM,2013-02-26,3.7675,3.7875,3.72,3.755,
DXCM,2013-02-27,3.75,3.8675,3.715,3.745,
DXCM,2013-02-28,3.73,3.7825,3.715,3.73,
DXCM,2013-03-01,3.6925,3.8075,3.6575,3.8025,
DXCM,2013-03-04,3.7075,3.8575,3.7075,3.8425,"[""Reiterate DexCom at Neutral - Analyst Blog"", ""Reiterate DexCom at Neutral - Analyst Blog"", ""Reiterate DexCom at Neutral - Analyst Blog On Feb 28, 2013, we retained DexCom ( DXCM ) at Neutral after the company beat Zacks Consensus Estimates for earnings and revenue for fourth quarter 2012. Why the Retention? DexCom released its results for the fourth quarter on Feb 21. The company posted adjusted loss per share of 14 cents per share, better than the Zacks Consensus Estimate of a loss of 16 cents a share. Revenues in the reported quarter surged 48.7% year over year to $33.3 million, beating the Zacks Consensus Estimate of $29 million. Over the past 30 days, the Zacks Consensus Estimate for 2013 has moved down by 6 cents to (54) cents and for 2014 it has dropped by 4 cents to (20) cents during the same timeframe. DexCom is well placed in the industry that it serves. Given the burgeoning diabetes population in the U.S., its G4 Platinum presents considerable market opportunity. Successful commercialization of G4 Platinum in the U.S. could just be the catalyst that the company needs to gain share in the market it serves. Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company is eyeing prospects in the vast markets of India, China and Japan. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes Care, may allow it to compete more effectively through better data management systems. Despite increasing revenues, DexCom remains a loss-making entity and its efforts are made more difficult by a stringent regulatory environment. Competition in the glucose monitoring market is fierce. DexCom currently holds a Zacks Rank #3 (Hold). Other Stocks to Consider Cyberonics Inc. ( CYBX ) and ABIOMED, Inc. ( ABMD ) carry a Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy), respectively, and are expected to do well. In addition, Sirona Dental Systems Inc. ( SIRO ) retains a Zacks Rank #2 (Buy) and warrants a look. ABIOMED INC (ABMD): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SIRONA DENTAL (SIRO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reiterate DexCom at Neutral - Analyst Blog""]"
DXCM,2013-03-05,3.86,3.91875,3.8075,3.905,"[""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares"", ""DexCom, Inc. (DXCM) CEO Terrance H Gregg sells 9,000 Shares""]"
DXCM,2013-03-06,3.91,3.9175,3.7975,3.815,
DXCM,2013-03-07,3.8025,3.85,3.765,3.85,
DXCM,2013-03-08,3.8875,3.9875,3.8375,3.9875,
DXCM,2013-03-11,3.9375,3.9875,3.8525,3.8925,
DXCM,2013-03-12,3.9525,4.265,3.945,4.2475,"[""DexCom Reports $1 Million Insider Buy"", ""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 24,054 Shares"", ""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 24,054 Shares"", ""DexCom Reports $1 Million Insider Buy"", ""DexCom Reports $1 Million Insider Buy DexCom Inc. ( DXCM ) reported on Monday that Director, Dr. Jay Skyler, invested over $1 million back into DexCom. This marks the first insider buy for DexCom since March of last year. Skyler added 70,000 shares at $15.50 to his stake on March 11 costing him a total of $1,085,000. Skylar now holds 274,036 shares of DexCom. Since this transaction the cost of each share is up 5.48%. Dr. Jay Skyler, M.D. is a Professor of Medicine, Pediatrics, and Psychology at the University of Miami. Dr. Skyler specializes in diabetes research. He researches the clinical aspects of diabetes, especially improving the care of type 1 diabetes through glycemic control. Skyler is a former President of the American Diabetes Association and the International Diabetes Immunotherapy Group. He was the founding Editor-in-Chief of Diabetes Care and is currently the Senior Editor of Diabetes Technology & Therapeutics . DexCom is a medical device company based out of San Diego, Calif. The company develops and markets continuous glucose monitoring systems for people with diabetes. The primary source of product revenue comes from DexCom's SEVEN PLUS continuous glucose monitoring system. DexCom reported that for 2012 product revenue grew to $93 million demonstrating a 41% increase from the $65.9 million product revenue in 2011. The company also reported a net loss of $54.5 million or $0.79 per share for 2012. On Feb. 21, DexCom was named the 5 th most Innovative Companies in Healthcare by Fast Company . Director Jay Skyler is not the only one making insider trades in DexCom this year. CEO Gregg Terrance has sold 27,000 of his shares this year and Executive Vice President Steven Pacelli sold 75,000 shares on Feb. 28. For more information on DexCom's insider trades, look at DexCom's Insider Trade History . DexCom is currently owned by the following eight gurus followed by GuruFocus: Manning & Napier Advisors (1,971,560 shares), RS Investment Management (1,139,043 shares), Ron Baron (1,250,000 shares), Pioneer Investments (329,800 shares), Mario Gabelli (76,000 shares), Jim Simons (108,843 shares), Steven Cohen (1,200 shares), and Stanley Druckenmiller (265,000 shares). For more information on these gurus' shares in DexCom look at DexCom's Guru Trades. With its shares up 8.86% this afternoon, DexCom trades at $16.95.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom, Inc. (DXCM) CTO Jorge A Valdes sells 24,054 Shares"", ""DexCom Reports $1 Million Insider Buy""]"
DXCM,2013-03-13,4.2375,4.2425,4.105,4.1775,"[""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $20.00"", ""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $20.00"", ""Wunderlich Maintains Buy on DexCom, Inc., Raises PT to $20.00""]"
DXCM,2013-03-14,4.12,4.29,4.12,4.19,
DXCM,2013-03-15,4.175,4.18,4.0375,4.0825,
DXCM,2013-03-18,4.04,4.0925,4.005,4.0375,
DXCM,2013-03-19,4.0575,4.09,4.0475,4.075,
DXCM,2013-03-20,4.1075,4.135,4.07075,4.115,
DXCM,2013-03-21,4.0875,4.1375,4.015,4.065,
DXCM,2013-03-22,4.09,4.1675,4.075,4.1575,
DXCM,2013-03-25,4.1625,4.2275,4.145,4.1775,
DXCM,2013-03-26,4.205,4.275,4.155,4.21,
DXCM,2013-03-27,4.1925,4.265,4.16,4.2625,
DXCM,2013-03-28,4.2675,4.28,4.1725,4.18,
DXCM,2013-04-01,4.1875,4.34,4.185,4.28,
DXCM,2013-04-02,4.305,4.405,4.2725,4.3125,
DXCM,2013-04-03,4.315,4.315,4.1175,4.1875,
DXCM,2013-04-04,4.24,4.2425,4.1475,4.1825,
DXCM,2013-04-05,4.11,4.1225,4.0275,4.105,
DXCM,2013-04-08,4.1275,4.1275,4.045,4.1225,
DXCM,2013-04-09,4.1725,4.1975,4.1175,4.1175,
DXCM,2013-04-10,4.1525,4.1625,4.0625,4.0775,
DXCM,2013-04-11,4.065,4.13,4.045,4.045,
DXCM,2013-04-12,4.0325,4.0975,4.0275,4.065,
DXCM,2013-04-15,4.03,4.105,3.895,3.9025,
DXCM,2013-04-16,3.925,3.995,3.87,3.94,
DXCM,2013-04-17,3.9475,3.95,3.84,3.855,
DXCM,2013-04-18,3.8975,3.92,3.77,3.78,"[""DexCom, Inc. (DXCM) Brings Apple Like \""Design\"" to Medical Devices"", ""DexCom, Inc. (DXCM) Brings Apple Like \""Design\"" to Medical Devices"", ""DexCom, Inc. (DXCM) Brings Apple Like \""Design\"" to Medical Devices""]"
DXCM,2013-04-19,3.785,3.91,3.76,3.875,
DXCM,2013-04-22,3.8825,3.9,3.7925,3.8175,
DXCM,2013-04-23,3.815,3.8575,3.7725,3.8025,
DXCM,2013-04-24,3.7875,3.8775,3.7625,3.8525,
DXCM,2013-04-25,3.845,3.9,3.835,3.8725,
DXCM,2013-04-26,3.87,3.91,3.8625,3.8875,
DXCM,2013-04-29,3.9075,3.9725,3.8825,3.9625,
DXCM,2013-04-30,3.955,4.1275,3.945,4.1025,
DXCM,2013-05-01,4.125,4.3,3.98,4.225,"[""DexCom, Inc. Reports Q1 EPS of $(0.16) vs $(0.17) Est; Revenue of $29.60M vs $28.33M Est"", ""DexCom, Inc. Reports Q1 EPS of $(0.16) vs $(0.17) Est; Revenue of $29.60M vs $28.33M Est"", ""DexCom, Inc. Reports Q1 EPS of $(0.16) vs $(0.17) Est; Revenue of $29.60M vs $28.33M Est""]"
DXCM,2013-05-02,4.3125,4.6,4.2825,4.5125,"[""DexCom Loss Narrower than Est. - Analyst Blog"", ""DexCom Loss Narrower than Est. - Analyst Blog"", ""DexCom Loss Narrower than Est. - Analyst Blog DexCom, Inc. ( DXCM ), a player in the glucose monitoring market, reported first quarter 2013 adjusted loss per share of 16 cents, narrower than the Zacks Consensus Estimate of a loss of 17 cents per share. Revenues Revenues surged 47% year over year to $29.6 million in the first quarter, beating the Zacks Consensus Estimate of $28 million. Product sales increased about 49% to $27.8 million while development grant and other revenues improved 20% to $1.8 million in the reported quarter. Margins and Expenses Gross margin improved to 55.7% in the first quarter from 46.8% a year ago. Operating expenses increased 10.5% year over year to $27.4 million due to higher selling, general and administrative expenses, which grew 17.5% in the reported quarter. The company reduced its operating loss year-over-year. Balance Sheet DexCom exited the first quarter with cash and short-term marketable securities of $45.3 million, down 7% on a sequential basis. Long-term debt (net of current portion) amounted to $6.3 million, down 7.4% sequentially. Our Take DexCom is well placed in the industry that it serves. Given the burgeoning diabetes population in the U.S., its products present a considerable market opportunity. Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company is eyeing prospects in the vast markets of India, China and Japan. In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings. We believe that the company's move to buy healthcare IT company SweetSpot Diabetes Care, may allow it to compete more effectively through better data management systems. Despite increasing revenues, DexCom remains a loss making entity and its efforts are made more difficult by a stringent regulatory environment. The stock currently holds a Zacks Rank #3 (Hold). Abiomed, Inc. ( ABMD ), Accuray Incorporated ( ARAY ) and Cepheid ( CPHD ) each carry a Zacks Rank #2 (Buy) and are expected to do well. ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report CEPHEID INC (CPHD): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Loss Narrower than Est. - Analyst Blog""]"
DXCM,2013-05-03,4.5775,4.67,4.5125,4.65,
DXCM,2013-05-06,4.645,4.645,4.5175,4.53,
DXCM,2013-05-07,4.595,4.6125,4.4775,4.6125,
DXCM,2013-05-08,4.605,4.755,4.5825,4.735,
DXCM,2013-05-09,4.7425,4.9475,4.735,4.885,
DXCM,2013-05-10,4.9,5.0175,4.88,4.95,
DXCM,2013-05-13,4.85,5.0425,4.835,4.98,
DXCM,2013-05-14,4.975,5.04125,4.9525,4.995,
DXCM,2013-05-15,4.995,5.0275,4.89,4.8975,
DXCM,2013-05-16,4.875,4.8875,4.8125,4.8625,
DXCM,2013-05-17,4.865,5.2975,4.865,5.295,
DXCM,2013-05-20,5.2625,5.4225,5.25,5.31,
DXCM,2013-05-21,5.295,5.335,5.195,5.2825,
DXCM,2013-05-22,5.28,5.375,5.0725,5.09,
DXCM,2013-05-23,5.0075,5.105,4.9975,5.0675,"[""DexCom Stays at Neutral - Analyst Blog"", ""DexCom Stays at Neutral - Analyst Blog"", ""DexCom Stays at Neutral - Analyst Blog On May 22, 2013, we reiterated DexCom, Inc. ( DXCM ) at Neutral based on its first quarter 2013 earnings results. On May 1, DexCom announced results for the reported quarter. The company incurred adjusted loss per share of 16 cents, narrower than the Zacks Consensus Estimate of a loss of 17 cents per share. Revenues surged 47% year over year to $29.6 million in the first quarter, beating the Zacks Consensus Estimate of $28 million. Product sales increased about 49% to $27.8 million while development grant and other revenues improved 20% to $1.8 million in the reported quarter. Going forward, its G4 Platinum offering is expected to fuel growth. DexCom has collaborative agreements with several companies including Tandem Diabetes Care, Inc. and Animas Corporation (a subsidiary of Johnson & Johnson). On the negative side, competition in the glucose monitoring market is fierce. Moreover, DexCom has incurred losses since inception and its efforts are made more difficult by a stringent regulatory environment. The Zacks Consensus Estimate has improved by a penny over the past month to a loss of 54 cents for 2013. The Zacks Consensus Estimate for 2014 has improved by a penny to a loss of 21 cents over the same timeframe. The stock carries a Zacks Rank #3 (Hold). We are more optimistic about CryoLife Inc. ( CRY ) and Heartware International Inc. ( HTWR ) each of which carries a Zacks Rank #2 (Buy) and are expected to do well. In addition, Conceptus, Inc. ( CPTS ) carries a Zacks Rank #1 (Strong Buy) and warrants a look. CONCEPTUS INC (CPTS): Free Stock Analysis Report CRYOLIFE INC (CRY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report HEARTWARE INTL (HTWR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Stays at Neutral - Analyst Blog""]"
DXCM,2013-05-24,5.055,5.105,5.015,5.075,
DXCM,2013-05-28,5.1225,5.2525,5.1125,5.205,
DXCM,2013-05-29,5.1575,5.2275,5.1075,5.125,
DXCM,2013-05-30,5.13,5.1725,5.0575,5.1225,
DXCM,2013-05-31,5.0775,5.325,5.0625,5.2075,
DXCM,2013-06-03,5.2075,5.39,5.17,5.375,
DXCM,2013-06-04,5.375,5.4875,5.3225,5.4075,
DXCM,2013-06-05,5.39,5.495,5.38,5.4525,
DXCM,2013-06-06,5.4425,5.525,5.4025,5.4825,
DXCM,2013-06-07,5.4925,5.62,5.4925,5.6,
DXCM,2013-06-10,5.5075,5.58,5.475,5.535,"[""Wunderlich Downgrades DexCom, Inc. to Hold, Maintains $20.00 PT"", ""UPDATE: Wunderlich Securities Downgrades DexCom to Hold on Valuation"", ""UPDATE: Wunderlich Securities Downgrades DexCom to Hold on Valuation"", ""Wunderlich Downgrades DexCom, Inc. to Hold, Maintains $20.00 PT"", ""UPDATE: Wunderlich Securities Downgrades DexCom to Hold on Valuation"", ""Wunderlich Downgrades DexCom, Inc. to Hold, Maintains $20.00 PT""]"
DXCM,2013-06-11,5.4575,5.6275,5.3825,5.605,
DXCM,2013-06-12,5.615,5.66,5.56,5.585,
DXCM,2013-06-13,5.57,5.57,5.30675,5.525,"[""Feltl & Co. Downgrades DexCom, Inc. to Sell"", ""Feltl & Co. Downgrades DexCom, Inc. to Sell"", ""Feltl & Co. Downgrades DexCom, Inc. to Sell""]"
DXCM,2013-06-14,5.5,5.57,5.465,5.5375,
DXCM,2013-06-17,5.5325,5.6475,5.5275,5.64,
DXCM,2013-06-18,5.665,5.7425,5.6175,5.7,
DXCM,2013-06-19,5.6875,5.7075,5.325,5.36,
DXCM,2013-06-20,5.3175,5.372,5.01625,5.045,
DXCM,2013-06-21,5.0625,5.24,4.9825,5.235,
DXCM,2013-06-24,5.195,5.45875,5.1275,5.435,"[""Canaccord Genuity Maintains Buy on DexCom, Inc., Raises PT to $25.00"", ""UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead"", ""UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead"", ""Canaccord Genuity Maintains Buy on DexCom, Inc., Raises PT to $25.00"", ""UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead"", ""Canaccord Genuity Maintains Buy on DexCom, Inc., Raises PT to $25.00""]"
DXCM,2013-06-25,5.495,5.5,5.4125,5.44,
DXCM,2013-06-26,5.485,5.6275,5.4825,5.4925,
DXCM,2013-06-27,5.535,5.6725,5.455,5.6425,
DXCM,2013-06-28,5.6425,5.71125,5.5575,5.6125,
DXCM,2013-07-01,5.655,5.775,5.625,5.7075,
DXCM,2013-07-02,5.7075,5.73,5.58,5.605,
DXCM,2013-07-03,5.58,5.6225,5.5425,5.6,
DXCM,2013-07-05,5.6475,5.72,5.5215,5.72,
DXCM,2013-07-08,5.7525,5.805,5.7125,5.7425,
DXCM,2013-07-09,5.7875,5.8175,5.5175,5.5675,
DXCM,2013-07-10,5.55,5.6475,5.4875,5.5425,
DXCM,2013-07-11,5.6275,5.8775,5.589,5.8675,
DXCM,2013-07-12,5.8425,6.0025,5.7975,5.9425,
DXCM,2013-07-15,5.965,6.09,5.8875,5.8925,
DXCM,2013-07-16,5.885,5.9625,5.685,5.695,
DXCM,2013-07-17,5.7125,5.81625,5.5275,5.6275,
DXCM,2013-07-18,5.6525,5.775,5.6,5.695,
DXCM,2013-07-19,5.6725,5.685,5.57,5.6175,
DXCM,2013-07-22,5.6325,5.705,5.6,5.6925,
DXCM,2013-07-23,5.7525,5.8725,5.725,5.8025,
DXCM,2013-07-24,5.53,5.655,5.445,5.555,"[""Northland Securities Downgrades DexCom, Inc. to Underperform, Raises PT to $17.00"", ""Northland Securities Downgrades DexCom, Inc. to Underperform, Raises PT to $17.00"", ""Northland Securities Downgrades DexCom, Inc. to Underperform, Raises PT to $17.00""]"
DXCM,2013-07-25,5.5425,5.74,5.5425,5.74,
DXCM,2013-07-26,5.69,5.75,5.635,5.655,
DXCM,2013-07-29,5.665,5.725,5.6175,5.6225,
DXCM,2013-07-30,5.66,5.825,5.5675,5.575,
DXCM,2013-07-31,5.5775,5.633,5.44,5.445,
DXCM,2013-08-01,5.505,5.6025,5.485,5.5725,
DXCM,2013-08-02,5.57,5.7075,5.54,5.655,
DXCM,2013-08-05,5.63,5.74,5.585,5.6025,
DXCM,2013-08-06,5.5725,5.66,5.5125,5.62,
DXCM,2013-08-07,5.5875,5.665,5.4625,5.495,"[""DexCom, Inc. Reports Q2 EPS of $(0.14) vs $(0.16) Est; Revenue of $35.80M vs $31.13M Est"", ""DexCom, Inc. Reports Q2 EPS of $(0.14) vs $(0.16) Est; Revenue of $35.80M vs $31.13M Est"", ""DexCom, Inc. Reports Q2 EPS of $(0.14) vs $(0.16) Est; Revenue of $35.80M vs $31.13M Est""]"
DXCM,2013-08-08,6.25,6.99,6.25,6.665,"[""DexCom Sess Narrower Loss - Analyst Blog"", ""Wunderlich Suspends Hold Rating on DexCom, Inc., Removes $20.00 PT"", ""Jefferies Maintains Buy on DexCom, Inc., Raises PT to $27.00"", ""UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results"", ""Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally"", ""Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally"", ""UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results"", ""Jefferies Maintains Buy on DexCom, Inc., Raises PT to $27.00"", ""Wunderlich Suspends Hold Rating on DexCom, Inc., Removes $20.00 PT"", ""DexCom Sess Narrower Loss - Analyst Blog"", ""DexCom Sess Narrower Loss - Analyst Blog DexCom, Inc. ( DXCM ) reported a narrower loss of $1.1 million or 2 cents per share in the second quarter of the year compared with $14.7 million or 21 cents in the same quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 16 cents per share. Including $9.0 million in non-cash expenses, comprising primarily of share-based compensation, depreciation, and amortization, reported loss was $10.1 million or 14 cents in the quarter. DexCom's total revenue soared 53.0% to $35.8 million, exceeding the Zacks Consensus Estimate of $31.0 million. Product revenues surged 65.1% to $35.5 million while development grant and other revenues fell drastically to $0.3 million from $1.9 million in the prior year quarter. Product gross profit was $21.8 million in the quarter, which more than doubled compared to $10.6 million in the second quarter of 2012. Total cost of sales rose nearly 14.0% to $13.9 million compared to $12.2 million in the second quarter of 2012. Product cost of sales increased 25.7% to $13.7 million from $10.9 million in the comparable quarter of 2012, primarily due to increased volumes of product sales. Research and development expenses rose 11.0% to $11.1 million in the quarter compared to $10.0 million for the second quarter of 2012. The higher research and development expenses were stemmed from additional payroll costs and share-based compensation. Selling, general and administrative expense increased 30.2% to $20.7 million in the second quarter from $15.9 million in the previous year quarter. The increase was attributable to additional payroll costs, share-based compensation and commissions. DXCM had cash and cash equivalents of $28.2 million as of Jun 30, 2013, significantly up from $8.1 million as of Dec 31, 2012. Total debt was flat at $7.0 million as of Jun 30, 2013 compared with the same as of Dec 31, 2012. Calif.-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The company relies significantly on its base of recurring revenue which reflects increasing usage rate with existing patients. Thus, higher patient base will bolster top-line for DexCom. DXCM currently retains a Zacks Rank #4 (Sell). Currently, other medical stocks that are performing well include Thoratec Corporation ( THOR ) and Cyberonics ( CYBX ), both with a Zacks Rank #1 (Strong Buy), and IDEXX Laboratories, Inc. ( IDXX ) with a Zacks Rank #2 (Buy). CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Healthcare Stocks Holding Late Gains; DexCom Climbs to 52-Week High After Narrowed Q2 Net Loss Top Healthcare Stocks JNJ -0.41% PFE -0.36% ABT -0.04% MRK -0.03% AMGN -1.83% Healthcare stocks are ending slightly higher with the NYSE Healthcare Sector Index climbing about 0.3% while shares of healthcare companies in the S&P 500 are up 0.2% as a group. In company news, DexCom Inc. ( DXCM ) is up more than 23% at $27.11 a share, earlier setting a 52-week high of $27.96 after the medical device company narrowed its Q2 net loss compared to its year-ago results and revenue surged. The maker of continuous glucose monitors reported Q2 revenue of $35.8 million, up 53% from the year-ago quarter. The net loss was $0.14, a 33% decline from last year's $0.21 per share loss. Analysts, on average, were looking for a $0.13 per share net loss on $32.4 million in revenue. In other sector news, (+) XON, Synthetic-biology startup soars over 50% after pricing an upsized initial public offering of 10 million shares at $16 each. (-) ARRY, Narrows fiscal Q4 net loss compared to last year's results, also beating analyst estimates. Revenue climbs 22.7% year over year to $25.4 million, also beating expectations. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Sector Update: Healthcare Healthcare stocks are ending slightly higher with the NYSE Healthcare Sector Index climbing about 0.3% while shares of healthcare companies in the S&P 500 are up 0.2% as a group. In company news, DexCom Inc. ( DXCM ) is up more than 23% at $27.11 a share, earlier setting a 52-week high of $27.96 after the medical device company narrowed its Q2 net loss compared to its year-ago results and revenue surged. The maker of continuous glucose monitors reported Q2 revenue of $35.8 million, up 53% from the year-ago quarter. The net loss was $0.14, a 33% decline from last year's $0.21 per share loss. Analysts, on average, were looking for a $0.13 per share net loss on $32.4 million in revenue. In other sector news, (+) XON, Synthetic-biology startup soars over 50% after pricing an upsized initial public offering of 10 million shares at $16 each. (-) ARRY, Narrows fiscal Q4 net loss compared to last year's results, also beating analyst estimates. Revenue climbs 22.7% year over year to $25.4 million, also beating expectations. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally The U.S. stock market rose on Thursday after a series of declines in the wake of uncertainty over the Federal Reserve's timeline for tapering its quantitative easing program. Although the gains were muted, the rally snapped a 3-day losing streak for U.S. equities. Crude oil futures fell for the fifth consecutive session while strength was seen in precious metals on Thursday. The U.S. Dollar recorded moderate losses while long-term Treasury prices rose modestly. Major Averages The Dow Jones Industrial Average rose around 28 points, or 0.18 percent, to close at 15,498. The S&P 500 added a little less than 7 points, or 0.39 percent, to 1,697. The Nasdaq gained 15 points, or 0.41 percent, to 3,669. Jobless Claims Initial jobless claims increased from 328,000 for the week ending July 27 to 333,000 for the week ending August 3. This compared to consensus estimates calling for an increase to 340,000. Continuing claims rose from 2.951 million for the week ending July 20 to 3.018 million for the week ending July 27. The consensus expected continuing claims to rise to 2.975 million. Related: Is Tesla overvalued? Commodities Crude oil prices declined on Thursday. At last check, NYMEX crude futures were trading down 0.80 percent to $103.53. Brent futures had lost 0.63 percent to $106.76. Natural gas futures rose a little better than 2 percent on the session to $3.31. Precious metals prices moved up strongly on Thursday. Near the close of equities, COMEX gold futures were up better than 2 percent while silver futures had climbed around 4 percent. Gold was last trading at $1,313.00 while silver contracts were trading hands at $20.30. The grains complex was mostly higher on the day, although wheat futures recorded a loss. At last check, corn was up 0.33 percent while wheat had shed 0.35 percent. Movers in soft commodities included cocoa and cotton, with each gaining around 1 percent. Bonds Long-term Treasury prices had recorded moderate gains late on Thursday . Heading into the closing bell for equities, the iShares Barclays 20+ Year Treasury Bond ETF (NYSE: TLT ) was up around 0.19 percent to $107.00. Treasury yields were as follows on Thursday afternoon: The 2-Year Note was yielding 0.30 while the 5-Year Note yield was at 1.36 percent. The 10-Year Note and 30-Year Bond were yielding 2.59 percent and 3.67 percent, respectively. Related: Currencies Late in the day, the U.S. Dollar was sitting on moderate losses. Near the close, the PowerShares DB US Dollar Index Bullish ETF (NYSE: UUP ), which tracks the performance of the greenback versus a , was down 0.32 percent to $21.91. The closely watched EUR/USD pair was up 0.41 percent to $1.3387. Other movers included the USD/CAD, which fell 1.03 percent, and the AUD/USD, which climbed 1.46 percent. Volatility and Volume The CBOE Volatility Index (VIX) pulled back from its recent highs as stocks rose on Thursday, snapping a 3-day streak of declines. Late in the day, the VIX was down 2.23 percent to 12.69. Volume picked up on the session, but remained well-below the 3-month average. Around 81 million SPDR S&P 500 ETF (NYSE: SPY ) shares traded hands compared to a 3-month average of almost 133 million. Stock Movers Investors reacted to Q2 earnings results and full-year guidance from Orbitz Worldwide (NYSE: OWW ) by pushing the stock up more than 37 percent on Thursday afternoon. DexCom (NASDAQ: DXCM ) surged more than 21 percent after the company released its fiscal Q2 earnings results. Shares of online daily deals site Groupon (NASDAQ: GRPN ) were trading after the company reported better-than-expected fiscal second-quarter financial results. Strong Q2 results propelled shares of Wageworks (NYSE: WAGE ) up more than 19 percent near Thursday's close. Tesla Motors with a 14 percent gain after the company's fiscal second-quarter financial results. Tower Group International (NASDAQ: TWGP ) fell around 24 percent on the day after the company postponed its second-quarter earnings release. A wider-than-expected loss in the company's fiscal fourth-quarter sent shares of Fusion-IO skidding on Thursday. The stock was last trading down almost 24 percent near the close. Investors dumped shares of Imperva (NYSE: IMPV ) after the company reported less-than-stellar results for its fiscal second-quarter. The stock fell around 15 percent on the session. Halcon Resources (NYSE: HK ) lost around 11 percent after the company priced a secondary offering of common stock. Disappointing Q2 results from Tumi Holdings (NYSE: TUMI ) sent that stock down almost 12 percent on Thursday. Related: (c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally"", ""UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results"", ""Jefferies Maintains Buy on DexCom, Inc., Raises PT to $27.00"", ""Wunderlich Suspends Hold Rating on DexCom, Inc., Removes $20.00 PT"", ""DexCom Sess Narrower Loss - Analyst Blog""]"
DXCM,2013-08-09,6.625,6.8925,6.5775,6.7725,"[""DexCom, Inc. (DXCM) Enters Overbought Territory - Tale of the Tape"", ""DexCom, Inc. (DXCM) Enters Overbought Territory - Tale of the Tape"", ""DexCom, Inc. (DXCM) Enters Overbought Territory - Tale of the Tape DexCom, Inc. ( DXCM ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because DXCM is now in overbought territory with an RSI value of 70.97. Furthermore, estimates for the DexCom, Inc. have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth. DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom, Inc. (DXCM) Enters Overbought Territory - Tale of the Tape""]"
DXCM,2013-08-12,6.77,6.8325,6.695,6.73,
DXCM,2013-08-13,6.755,6.86,6.6525,6.8525,
DXCM,2013-08-14,6.8375,6.9475,6.785,6.79,
DXCM,2013-08-15,6.725,6.79475,6.63,6.64125,
DXCM,2013-08-16,6.6075,6.62,6.46,6.53,
DXCM,2013-08-19,6.4925,6.665,6.44,6.57,
DXCM,2013-08-20,6.536,6.7275,6.536,6.685,
DXCM,2013-08-21,6.655,6.7275,6.595,6.67,
DXCM,2013-08-22,6.7025,6.9275,6.665,6.895,
DXCM,2013-08-23,6.915,6.915,6.7625,6.8075,
DXCM,2013-08-26,6.8125,7.0425,6.805,6.925,
DXCM,2013-08-27,6.8575,6.87,6.5675,6.6025,
DXCM,2013-08-28,6.595,6.7625,6.565,6.6875,
DXCM,2013-08-29,6.6525,6.875,6.6525,6.785,
DXCM,2013-08-30,6.765,6.8325,6.715,6.7625,
DXCM,2013-09-03,6.7825,6.86,6.6075,6.695,
DXCM,2013-09-04,6.685,6.7475,6.605,6.6675,
DXCM,2013-09-05,6.6525,6.795,6.6525,6.7425,
DXCM,2013-09-06,6.795,6.795,6.52,6.6675,
DXCM,2013-09-09,6.6925,6.8475,6.6675,6.8475,
DXCM,2013-09-10,6.9,7.0275,6.9,6.9975,
DXCM,2013-09-11,7.0,7.12,6.8975,6.9875,
DXCM,2013-09-12,6.98,6.9875,6.87,6.8775,
DXCM,2013-09-13,6.9575,7.0025,6.835,6.835,"[""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT"", ""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT"", ""Benzinga's Top Initiations"", ""UPDATE: J.P. Morgan Initiates Coverage on DexCom on Market Leader Position"", ""UPDATE: J.P. Morgan Initiates Coverage on DexCom on Market Leader Position"", ""Benzinga's Top Initiations"", ""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT"", ""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT"", ""UPDATE: J.P. Morgan Initiates Coverage on DexCom on Market Leader Position"", ""Benzinga's Top Initiations"", ""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT"", ""JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces $32.00 PT""]"
DXCM,2013-09-16,6.9375,6.962,6.73,6.7325,
DXCM,2013-09-17,6.7425,6.9225,6.6975,6.905,
DXCM,2013-09-18,6.89,7.03,6.8375,7.0125,
DXCM,2013-09-19,7.015,7.1075,7.0025,7.085,
DXCM,2013-09-20,7.125,7.125,7.01625,7.0325,
DXCM,2013-09-23,7.0075,7.105,6.95,7.075,
DXCM,2013-09-24,7.065,7.1375,6.97,7.0025,
DXCM,2013-09-25,6.9925,7.065,6.81,6.87,
DXCM,2013-09-26,6.9125,7.31,6.9075,7.2975,
DXCM,2013-09-27,7.185,7.2825,6.3725,6.8075,
DXCM,2013-09-30,6.715,7.0875,6.665,7.055,"[""Dexcom Retained at Neutral - Analyst Blog"", ""Dexcom Retained at Neutral - Analyst Blog"", ""Dexcom Retained at Neutral - Analyst Blog On Sep 27, we reiterated our Neutral recommendation on Dexcom, Inc. ( DXCM ). The medical device company focuses on the development of continuous glucose monitoring systems but remains a loss-making entity despite soaring revenues. However, we are impressed by its better than expected results. Why the Retention? On Aug 7, DexCom reported a narrower loss of $1.1 million or 2 cents per share in the second quarter of 2013 compared with a loss of $14.7 million or 21 cents in the year-ago quarter, as well as the Zacks Consensus Estimate of a loss of 16 cents per share. The company's total revenues soared 53.0% to $35.8 million, also exceeding the Zacks Consensus Estimate of $31.0 million. Following the earnings release, the Zacks Consensus Estimate for 2013 inched down marginally by 1.9% to 52 cents per share, over the last 30 days. However, the estimate for 2014 remained unchanged at 20 cents over the same period. Currently, the stock has a Zacks Rank #3 (Hold). Going forward, the new U.S. Food and Drug Administration (FDA)-cleared G4 Platinum and international expansion are expected to accelerate growth. Increased awareness of the need for continuous glucose monitoring, new products and data supporting blood glucose monitoring should also help drive sales. In addition, DexCom has also been active on the collaboration front in order to enhance the functions of existing products. Its business fundamentals rely on a recurring revenue base. Nevertheless, competition in the glucose monitoring market continues to be fierce. Reimbursement risks and a stringent regulatory environment also pose potential challenges for DXCM in the near term. Other Stocks to Consider While we remain on the sidelines regarding DexCom, medical instruments stocks that warrant a look include Cynosure ( CYNO ), Given Imaging ( GIVN ) and Luminex Corporation ( LMNX ). All these stocks carry a Zacks Rank #2 (Buy). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report GIVEN IMAGING (GIVN): Get Free Report LUMINEX CORP (LMNX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Retained at Neutral - Analyst Blog"", ""DexCom, Insulet Unmoved by Medtronic Medtronic's insulin device doesn't materially challenge DexCom and Insulet.""]"
DXCM,2013-10-01,7.0525,7.09225,6.94,7.0425,
DXCM,2013-10-02,6.955,7.2375,6.9475,7.1825,
DXCM,2013-10-03,7.1875,7.2925,6.985,7.0925,
DXCM,2013-10-04,7.0925,7.23,7.0075,7.01,
DXCM,2013-10-07,6.9875,7.075,6.94,6.9625,
DXCM,2013-10-08,6.9575,7.0775,6.8,6.82,
DXCM,2013-10-09,6.845,6.865,6.67,6.7,"[""Will AngioDynamics (ANGO) Beat Earnings Estimates? - Analyst Blog"", ""Mindray Medical Remains Neutral - Analyst Blog"", ""Mindray Medical Remains Neutral - Analyst Blog"", ""Will AngioDynamics (ANGO) Beat Earnings Estimates? - Analyst Blog"", ""Will AngioDynamics (ANGO) Beat Earnings Estimates? - Analyst Blog We expect the leading medical devices provider AngioDynamics Inc. ( ANGO ) to beat expectations when it reports fiscal 2014 first quarter results after the closing bell on Oct 10. Why a Likely Positive Surprise? Our proven model shows that AngioDynamics is likely to beat earnings estimates because it has the right combination of two key ingredients. Positive Zacks ESP:Earnings ESP , the difference between the Most Accurate estimate of 4 cents and the Zacks Consensus Estimate of 3 cents, stands at +33.33%. Zacks Rank #3 (Hold): ANGO currently retains a Zacks Rank #3 (Hold). The combination of the stock's Zacks Rank #3 (Hold) and +33.33% ESP makes us confident of a positive earnings beat on Oct 10. What is Driving the Better than Expected Earnings? AngioDynamics enjoys leading market share in several of its operating segments including angiographic products and thrombolytic catheters and products. The market served by ANGO is in excess of $1 billion, and continues to grow. AngioDynamics has delivered solid earnings results in the fourth quarter of fiscal 2013. It has reported more than twofold year-over-year increase in adjusted earnings to 7 cents per share for the quarter, surpassing the Zacks Consensus Estimate by 2 cents. For fiscal 2013, adjusted earnings surged 66.7% to 35 cents per share and beat the Zacks Consensus Estimate by a penny AngioDynamics expects fiscal 2014 revenues in the range of $346 million-$352 million, up 3% at the top range of the previous guidance. Adjusted earnings per share are expected in the range of 31 cents to 35 cents for the fiscal year, taking into account the impact from the medical device tax. Other Stocks to Consider AngioDynamics is not the only bullish company this earnings season. We also see likely earnings beats coming from the following industry peers: DexCom Inc. ( DXCM ): Earnings ESP of +15.39% and Zacks Rank #2 (Buy). Sunshine Heart Inc. ( SSH ): Earnings ESP of +32.50% and Zacks Rank #3 (Hold). Techne Corp. ( TECH ): Earnings ESP of +1.25% and Zacks Rank #3 (Hold). ANGIODYNAMICS (ANGO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SUNSHINE HEART (SSH): Free Stock Analysis Report TECHNE CORP (TECH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mindray Medical Remains Neutral - Analyst Blog On Oct 8, we reiterated our Neutral recommendation on Mindray Medical International Limited ( MR ). Although the medical device company's domestic sales remain robust, it is currently facing a difficult environment in developed international markets. Why the Retention? On Aug 5, Mindray posted a 17.8% rise in second-quarter 2013 adjusted earnings per share to $0.53 from $0.45 a year ago and met the Zacks Consensus Estimate. Net revenues grew 14.7% to $307.2 million but missed the Zacks Consensus Estimate of $319 million. The company's earnings have beaten the Zacks Consensus Estimate in 2 out of the last 4 quarters, while meeting the same in the last reported quarter, thus maintaining an average surprise of 5.42%. Following the earnings release, the Zacks Consensus Estimate for 2013 earnings inched up 1.5% to $2.01 and then 1.0% to $2.03 per share. However, the estimate for 2014 earnings declined 1.8% to $2.20 and then 0.9% to $2.18 over the same period. Furthermore, the acquisition of ZONARE in July has led management to raise its year-over-year rise in revenues guidance to at least 18% from 17%. However, MR reiterated adjusted net earnings guidance, anticipating at least 15% rise over 2012. Mindray is a bellwether in the Chinese medical devices industry. The company has a large domestic sales infrastructure, which gives it better access to medium-sized county hospitals. In China, it beats other multinationals on price and defeats local players, who have cheaper products, on brand recognition. In western markets, MR targets mid-market and price-sensitive customers. Although it has entered the premium segment globally, its competitive advantage is still unclear. Uncertainties in healthcare reforms in the U.S. have reduced demand for Mindray's products. Moreover, competition is fierce and threatens price erosion over time. Other Stocks to Consider Medical instruments stocks that warrant a look include Dexcom, Inc. ( DXCM ), Masimo Corporation ( MASI ) and MAKO Surgical Corp. ( MAKO ). All these stocks carry a Zacks Rank #2 (Buy). DEXCOM INC (DXCM): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mindray Medical Remains Neutral - Analyst Blog"", ""Will AngioDynamics (ANGO) Beat Earnings Estimates? - Analyst Blog""]"
DXCM,2013-10-10,6.8,6.96,6.71,6.865,
DXCM,2013-10-11,6.835,6.905,6.7675,6.8625,"[""Masimo Presents Encouraging Study - Analyst Blog"", ""Masimo Presents Encouraging Study - Analyst Blog"", ""Masimo Presents Encouraging Study - Analyst Blog Masimo Corporation ( MASI ), a leader in non-invasive monitoring technology for patient care, recently revealed encouraging results from a multi-center study of its rainbow Acoustic Monitoring (RAM). This positive piece of news should boost investor confidence in the stock. The company's stock returned a solid 22.3% to its investors on a year-to-date basis. The study had analyzed the efficacy of RAM in comparison to capnography (nasal cannula) in post-surgical pediatric patient population. Results revealed that, despite having similar accuracy like capnography, RAM displayed better patient tolerance. The multi-center trial results were announced in Pediatric Anesthesia and conducted by researchers at Cincinnati Children's Hospital Medical Center, University of Arizona Medical Center, and Children's Medical Center at Dallas. RAM is used to measure respiratory rates in a non-invasive manner (with a cloth adhesive sensor worn around the neck), thereby allowing better comfort for children. Researchers concluded that acoustic monitoring is a safer option to continuously monitor respiration rate in pediatric patients. Positive results from the clinical trial have highlighted MASI's capabilities in developing products that are safe and reliable. In September, MASI had entered into an agreement to sell its Masimo Patient SafetyNet to U.S.-based Saint Alphonsus Regional Medical Center. The 387-bed facility will install the device in patient rooms on orthopedic, general surgery, and neurology floors. Earlier, Masimo had forged an alliance with University Children's Hospital in Basel, Switzerland. The hospital was the first pediatric institution in the region to utilize the Masimo Patient SafetyNet in its general wards. Currently, Masim haso a Zacks Rank #2 (Buy). MASI had reported earnings of 30 cents per share that beat the Zacks Consensus Estimate by 3 cents in the last reported quarter. Its revenues (including royalties) went up almost 12.0% to $137.4 million, also exceeding the Zacks Consensus Estimate of $136 million. Apart from MASI, other medical instrument stocks that warrant a look include Mindray Medical International Ltd ( MR ), MAKO Surgical Corp. ( MAKO ) and Dexcom, Inc. ( DXCM ). All these stocks carry a Zacks Rank #2 (Buy). DEXCOM INC (DXCM): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Masimo Presents Encouraging Study - Analyst Blog""]"
DXCM,2013-10-14,6.84,7.2775,6.8125,7.26,
DXCM,2013-10-15,7.3475,7.6175,7.2875,7.3675,"[""Benchmark Initiates Coverage on DexCom, Inc. at Buy, Announces $37.00 PT"", ""UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor"", ""UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor"", ""Benchmark Initiates Coverage on DexCom, Inc. at Buy, Announces $37.00 PT"", ""UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor"", ""Benchmark Initiates Coverage on DexCom, Inc. at Buy, Announces $37.00 PT""]"
DXCM,2013-10-16,7.4075,7.5225,7.37,7.435,"Picks to Play Johnson & Johnson Trends Wedbush cites St. Jude Medical, DexCom and Medtronic."
DXCM,2013-10-17,7.41,7.625,7.355,7.5525,
DXCM,2013-10-18,7.6325,7.795,7.5525,7.72,"[""Intuitive Surgical Q3 Revenue Miss Hurts Stock"", ""Intuitive Surgical Q3 Revenue Miss Hurts Stock"", ""Intuitive Surgical Q3 Revenue Miss Hurts Stock""]"
DXCM,2013-10-21,7.685,7.75,7.5375,7.5875,
DXCM,2013-10-22,7.6325,7.685,7.46,7.4675,
DXCM,2013-10-23,7.4425,7.56,7.2275,7.5325,
DXCM,2013-10-24,7.52,7.595,7.4425,7.4675,
DXCM,2013-10-25,7.4975,7.5125,7.345,7.4475,
DXCM,2013-10-28,7.4625,7.785,7.41,7.6525,
DXCM,2013-10-29,7.6575,7.9225,7.3825,7.48,
DXCM,2013-10-30,7.465,7.6175,7.305,7.3075,
DXCM,2013-10-31,7.25,7.295,7.175,7.1825,
DXCM,2013-11-01,7.1625,7.215,7.0025,7.1,
DXCM,2013-11-04,7.1275,7.1725,7.0375,7.11,
DXCM,2013-11-05,7.02,7.165,7.005,7.135,
DXCM,2013-11-06,7.17,7.2375,6.775,6.81,"[""DexCom, Inc. Reports Q3 EPS of $(0.08) vs $(0.13) Est; Revenue of $42.90M vs $35.87M Est"", ""DexCom, Inc. Reports Q3 EPS of $(0.08) vs $(0.13) Est; Revenue of $42.90M vs $35.87M Est"", ""DexCom, Inc. Reports Q3 EPS of $(0.08) vs $(0.13) Est; Revenue of $42.90M vs $35.87M Est""]"
DXCM,2013-11-07,8.425,8.4325,7.9125,8.3075,"[""DexCom Beats, Sees Narrower Loss - Analyst Blog"", ""GDP Data Boosts Stock Futures; NationStar Mortgage Crumbles"", ""Northland Securities Upgrades DexCom, Inc. to Market Perform, Raises PT to $30.00"", ""Wedbush Maintains Outperform on DexCom, Inc., Raises PT to $39.00"", ""Market Wrap For November 7: Markets Take A Breather As Twitter Takes Center Stage"", ""Market Wrap For November 7: Markets Take A Breather As Twitter Takes Center Stage"", ""Wedbush Maintains Outperform on DexCom, Inc., Raises PT to $39.00"", ""Northland Securities Upgrades DexCom, Inc. to Market Perform, Raises PT to $30.00"", ""DexCom Beats, Sees Narrower Loss - Analyst Blog"", ""GDP Data Boosts Stock Futures; NationStar Mortgage Crumbles"", ""DexCom Beats, Sees Narrower Loss - Analyst Blog DexCom, Inc. ( DXCM ) reported a narrower loss of $6.0 million or 8 cents per share in the third quarter of the year compared with $17.3 million or 25 cents in the comparable quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 13 cents. DexCom's total revenue surged 85.7% to $42.9 million, topping the Zacks Consensus Estimate of $36.0 million, on product revenues that more than doubled to $42.5 million from $21.1 million a year ago. Meanwhile, development grant and other revenues plunged 80.0% to $0.4 million from $2.0 million in the prior year quarter. Product gross profit more than tripled to $27.7 million in the quarter from $7.7 million in the third quarter of 2012. Total gross profit increased in the same magnitude to $27.6 million from $8.4 million a year ago while gross margin improved significantly to 64.3% from 36.4% in the 2012-quarter. Product cost of sales rose 10.4% to $14.8 million from $13.4 million for the third quarter in 2012, driven by higher volume of product sales. Total cost of sales grew 4.1% to $15.3 million from $14.7 million for the third quarter of 2012. Research and development expenses increased 14.6% to $11.8 million from $10.3 million in the third quarter of 2012. Selling, general and administrative expense soared 40.3% to $21.6 million from $15.4 million a year ago, due to additional payroll costs, share-based compensation and commissions. DXCM had cash and cash equivalents of $33.4 million as of Sep 30, 2013, significantly up from $8.1 million as of Dec 31, 2012. Total debt remained flat at $7.0 million as of Sep 30, 2013 compared with the same as of Dec 31, 2012. Calif.-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The company relies significantly on its base of recurring revenue which reflects increasing usage rate with existing patients. Thus, higher patient base will bolster top-line for DexCom. DXCM currently retains a Zacks Rank #3 (Hold). Currently, other medical stocks that are performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), CryoLife, Inc. ( CRY ) and Natus Medical Inc. ( BABY ). All of them carry a Zacks Rank #1 (Strong Buy). NATUS MEDICAL (BABY): Free Stock Analysis Report CRYOLIFE INC (CRY): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Market Wrap For November 7: Markets Take A Breather As Twitter Takes Center Stage"", ""Wedbush Maintains Outperform on DexCom, Inc., Raises PT to $39.00"", ""Northland Securities Upgrades DexCom, Inc. to Market Perform, Raises PT to $30.00"", ""DexCom Beats, Sees Narrower Loss - Analyst Blog"", ""GDP Data Boosts Stock Futures; NationStar Mortgage Crumbles""]"
DXCM,2013-11-08,8.3075,8.4675,8.2175,8.2625,
DXCM,2013-11-11,8.25,8.3875,7.965,8.2525,
DXCM,2013-11-12,8.2375,8.455,8.135,8.3675,
DXCM,2013-11-13,8.275,8.5975,8.275,8.4175,
DXCM,2013-11-14,8.4175,8.4325,8.02,8.1275,
DXCM,2013-11-15,8.12,8.2575,8.08,8.14,
DXCM,2013-11-18,8.0,8.025,7.8375,7.8725,"[""Agilent Technologies (A) Catches Eye: Stock Jumps 8.7% - Tale of the Tape"", ""Agilent Technologies (A) Catches Eye: Stock Jumps 8.7% - Tale of the Tape"", ""Agilent Technologies (A) Catches Eye: Stock Jumps 8.7% - Tale of the Tape Agilent Technologies Inc. ( A ) was a big mover last session, as the company saw its shares rise by nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The sudden jump breaks the recent trend of the company, as the stock is now trading above the volatile price range of $50.05 to $52.99 in the past one-month time frame. This bio-analytical and electronic measurement solutions provider has seen a mixed track record when it comes to estimate revisions. While 6 estimates moved north, 4 estimates were revised lower over the past one month. The Zacks Consensus Estimate moved a notch higher in the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future. Agilent currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative. Some better performing stocks from the broader medical industry include Align Technology Inc. ( ALGN ), Medtronic, Inc. ( MDT ) and DexCom, Inc. ( DXCM ). While Align Technology holds a Zacks Rank #1 (Strong Buy), Medtronic and DexCom carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> AGILENT TECH (A): Free Stock Analysis Report ALIGN TECH INC (ALGN): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Agilent Technologies (A) Catches Eye: Stock Jumps 8.7% - Tale of the Tape""]"
DXCM,2013-11-19,7.9025,8.1425,7.8125,8.04,
DXCM,2013-11-20,8.06,8.0875,7.9575,8.055,
DXCM,2013-11-21,8.0775,8.235,8.0375,8.1925,
DXCM,2013-11-22,8.185,8.2325,8.055,8.1025,
DXCM,2013-11-25,8.0975,8.2425,8.0125,8.1,
DXCM,2013-11-26,8.095,8.2025,8.0775,8.1325,
DXCM,2013-11-27,8.1675,8.3225,8.1425,8.32,
DXCM,2013-11-29,8.315,8.4375,8.2725,8.2725,
DXCM,2013-12-02,8.2175,8.9925,8.2175,8.5075,
DXCM,2013-12-03,8.47,8.65,8.3775,8.5775,"[""DexCom Hits New 52-Week High - Analyst Blog"", ""DexCom Hits New 52-Week High - Analyst Blog"", ""DexCom Hits New 52-Week High - Analyst Blog Shares of San Diego-based medical instruments maker DexCom, Inc. ( DXCM ) reached a new 52-week high of $35.97 in mid-day trading yesterday. Shares of the company closed at $34.03 on the same day, representing a solid one-year and year-to-date returns of 148.2% and 145.7%, respectively. DXCM has a market cap of $2.4 billion. Average volume of shares traded over the last three months stood at approximately 595.9K. Shares of DexCom started escalating following its promising third quarter results on Nov 6. The company reported a narrower loss of $6.0 million or 8 cents per share in the quarter compared with $17.3 million or 25 cents in the comparable quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 13 cents. DXCM's total revenues surged 85.7% to $42.9 million, topping the Zacks Consensus Estimate of $36.0 million, on product revenues that more than doubled to $42.5 million from $21.1 million a year ago. Meanwhile, development grant and other revenues plunged 80.0% to $0.4 million from $2.0 million in the prior year quarter. Product gross profit more than tripled to $27.7 million in the quarter from $7.7 million in the third quarter of 2012. Total gross profit increased in the same magnitude to $27.6 million from $8.4 million a year ago while gross margin improved significantly to 64.3% from 36.4% in the 2012-quarter. DexCom had cash and cash equivalents of $33.4 million as of Sep 30, 2013, significantly up from $8.1 million as of Dec 31, 2012. Total debt remained flat at $7.0 million as of Sep 30, 2013 compared with the same as of Dec 31, 2012. Currently, DXCM retains a Zacks Rank #2 (Buy). Other medical instrument stocks that are also worth a look include Cynosure, Inc. ( CYNO ), Natus Medical Inc. ( BABY ), and AngioDynamics Inc. ( ANGO ). Cynosure and Natus Medical carry a Zacks Rank #1 (Strong Buy) while AngioDynamics carries a Zacks Rank #2 (Buy). ANGIODYNAMICS (ANGO): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Hits New 52-Week High - Analyst Blog""]"
DXCM,2013-12-04,8.56,8.8685,8.5,8.645,"S&P 500 holds the near-term uptrend Focus: Crude Oil, USO, MSFT, SLCA, DXCM, AGU, OTEX U.S. stocks are slightly higher to start Wednesday following a stronger-than-expected private-sector employment report. Against this backdrop, the S&P 500 has initially drawn buyers at its 20-day moving average, a widely-tracked near-term trending indicator."
DXCM,2013-12-05,8.6425,8.8425,8.5925,8.61,
DXCM,2013-12-06,8.6475,8.7025,8.4675,8.6625,
DXCM,2013-12-09,8.6875,8.7,8.5125,8.5675,
DXCM,2013-12-10,8.565,8.565,8.2575,8.325,
DXCM,2013-12-11,8.37,8.52,8.2875,8.39,
DXCM,2013-12-12,8.5,8.77,8.4075,8.65,
DXCM,2013-12-13,8.64,8.725,8.535,8.625,
DXCM,2013-12-16,8.625,8.725,8.515,8.595,"Is it wise to own stock in a company with no profits? When one is talking biotechs, it is often a case of a company that has yet to make money, but does that mean you should turn a blind eye? In this case, absolutely not."
DXCM,2013-12-17,8.6,8.625,8.465,8.5675,
DXCM,2013-12-18,8.6175,8.6975,8.5,8.585,
DXCM,2013-12-19,8.5625,8.6475,8.22,8.355,
DXCM,2013-12-20,8.4025,8.64,8.3825,8.5925,
DXCM,2013-12-23,8.64,8.7475,8.4025,8.47,
DXCM,2013-12-24,8.4525,8.55,8.41325,8.5125,
DXCM,2013-12-26,8.5275,8.6875,8.435,8.655,
DXCM,2013-12-27,8.6975,8.8475,8.66,8.765,
DXCM,2013-12-30,8.7825,8.9425,8.6975,8.8325,
DXCM,2013-12-31,8.8225,8.9825,8.8025,8.8525,
DXCM,2014-01-02,8.8125,8.90975,8.533,8.6875,
DXCM,2014-01-03,8.6225,8.7875,8.6225,8.7,
DXCM,2014-01-06,8.755,8.8625,8.675,8.7525,
DXCM,2014-01-07,8.7025,8.895,8.7025,8.8675,
DXCM,2014-01-08,8.875,8.895,8.8025,8.87,
DXCM,2014-01-09,8.8675,9.1725,8.8175,9.16,
DXCM,2014-01-10,9.1775,9.315,9.125,9.2625,
DXCM,2014-01-13,9.21,9.5325,9.195,9.3125,
DXCM,2014-01-14,9.3875,9.46,9.0575,9.23,"[""DexCom, Inc. Sees Q3 Sales $51.0M vs $45.80M Est"", ""DexCom, Inc. Sees FY2014 Sales $205.0M-225.0M vs $212.70M Est"", ""DexCom, Inc. Sees Q3 Sales $51.0M vs $45.80M Est"", ""DexCom, Inc. Sees FY2014 Sales $205.0M-225.0M vs $212.70M Est"", ""DexCom, Inc. Sees Q3 Sales $51.0M vs $45.80M Est"", ""DexCom, Inc. Sees FY2014 Sales $205.0M-225.0M vs $212.70M Est""]"
DXCM,2014-01-15,9.295,9.345,9.1275,9.2675,
DXCM,2014-01-16,9.275,9.45,9.2475,9.4075,
DXCM,2014-01-17,9.425,9.43,9.23,9.34,
DXCM,2014-01-21,9.36,9.5,9.28,9.42,"[""Echo Therapeutics Applies for CE Mark - Analyst Blog"", ""Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape"", ""Echo Therapeutics Applies for CE Mark - Analyst Blog"", ""Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape"", ""Echo Therapeutics Applies for CE Mark - Analyst Blog Shares of Echo Therapeutics, Inc. ( ECTE ) rose 10% since the announcement of its submission of Conformite Europeenne (CE) Mark Technical File in order to obtain the market approval for its Symphony continuous glucose monitoring (CGM) system. According to a study, Symphony CGM is capable of monitoring glucose levels as it did on 32 patients in critical care units at four hospitals. CE Marking implies a medical device's compliance with European Union (EU) legislation and directives with respect to safety, health, environmental and consumer protection. It is necessary for commercialization in countries in the EU. ECTE expects to receive the CE Marking in the second quarter of the year. Last month, Echo Therapeutics reached a collaboration agreement with Hong Kong-based Medical Technologies Innovation Asia (MTIA), Ltd., through which its Symphony continuous glucose monitoring (CGM) system will be developed, manufactured, marketed and distributed in China, Hong Kong, Macau and Taiwan. The collaboration agreement includes a license arrangement and equity investment in ECTE. Under the licensing, MTIA will bear the development, manufacturing and marketing costs for bringing Symphony CGM System in the Chinese market. MTIA has established sales channels in more than 1,000 hospitals across the China provinces. Theglobal marketfor glucose monitoring systems is measured at roughly $10 billion. The glucose monitoring devices include blood glucose meters and test strips which provide single blood glucose values. Based in Philadelphia, PA, Echo Therapeutics is a medical device company aimed at developing enhanced skin permeation technology Prelude SkinPrep System, and non-invasive, wireless, and glucose monitoring system. ECTE stated that it will apply for market approval of Symphony CGM system in the European Union in the fourth quarter of this year. ECTE posted a narrower loss of 49 cents per share for the third quarter of the year compared with $1.07 in the comparable quarter of 2012 as well as the Zacks Consensus Estimate of 56 cents. The decrease in loss was attributable to lower shares outstanding at the end of the quarter. Net loss, in fact, increased 22.8% to $5.2 million from $4.3 million a year ago. Revenues in the quarter slid 27.1% to $22.6 thousand, significantly lower than the operating expenses of $4.95 million. This resulted in operating loss of $4.9 million compared with $3.6 million in the third quarter of 2012. Echo Therapeutics' research and development expenses rose 28.8% to $2.8 million from $2.1 million in the third quarter of 2012. The increase was attributable to higher development, regulatory and clinical expenses, as well as manufacturing preparation costs. Currently, ECTE retains a Zacks Rank #2 (Buy). Other players in the medical instruments industry that are also worth a look include Natus Medical Inc. ( BABY ), DexCom, Inc. ( DXCM ), and AngioDynamics Inc. ( ANGO ). Natus Medical and DexCom carry a Zacks Rank #1 (Strong Buy) while AngioDynamics carries a Zacks Rank #2 (Buy). ANGIODYNAMICS (ANGO): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape Pacific Biosciences of California, Inc. ( PACB ) was a big mover last session, as the company saw its shares rise by over 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.87 to $5.98 in the past one-month time frame. This medical instruments company has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future. Pacific Biosciences of California currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. Some better-ranked stocks in the same industry include Natus Medical Inc. ( BABY ), CryoLife Inc. ( CRY ) and DexCom, Inc. ( DXCM ). All these stocks hold a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> NATUS MEDICAL (BABY): Free Stock Analysis Report CRYOLIFE INC (CRY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Echo Therapeutics Applies for CE Mark - Analyst Blog"", ""Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape""]"
DXCM,2014-01-22,9.455,9.55,9.2825,9.3,
DXCM,2014-01-23,9.2875,9.2875,9.065,9.1925,
DXCM,2014-01-24,9.255,9.3125,8.965,9.17,
DXCM,2014-01-27,9.1875,9.3175,9.035,9.0375,
DXCM,2014-01-28,9.0175,9.3375,9.0,9.275,"[""Will Quest Diagnostics (DGX) Miss This Quarter? - Analyst Blog"", ""Will Quest Diagnostics (DGX) Miss This Quarter? - Analyst Blog"", ""Will Quest Diagnostics (DGX) Miss This Quarter? - Analyst Blog Quest Diagnostics Inc. ( DGX ) is scheduled to report its fourth-quarter 2013 results before the opening bell on Jan 30. Last quarter, Quest Diagnostics had posted a negative earnings surprise of 1.92%. Let's see how things are shaping up for this announcement. Factors at Play Quest Diagnostics has delivered negative earnings surprises in all of the last four quarters with an average miss of 5.73%. Although the company's massive organizational restructuring strategy implemented since Jan 2013 to increase operational efficiency and restore growth is encouraging, near-term visibility remains a matter of concern. In addition, Quest Diagnostics is continuously witnessing challenges with respect to testing volume. Moreover, lower healthcare utilization and reimbursement pressure from government and other payers continue to pose threats. Meanwhile, Quest Diagnostics has been focusing on high-potential areas such as gene-based esoteric testing for cancer, cardiovascular disease, infectious disease and neurological disorders. Earnings Whispers? Our proven model does not conclusively show that Quest Diagnostics is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below. Zacks ESP: Earnings ESP for Quest Diagnostics is 0.00% since the Most Accurate estimate stands at $0.94, in line with the Zacks Consensus Estimate. Zacks Rank: Quest Diagnostics' Zacks Rank #4 (Sell) when combined with a 0.00% ESP, makes surprise prediction difficult. Other Stocks to Consider Here are some other companies you may want to consider as our model shows that they have the right combination of elements, i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3. DexCom, Inc. ( DXCM ) has an Earnings ESP of +14.29% and holds a Zacks Rank #2 (Buy). DexCom is expected to report its fourth quarter earnings on Feb 20. Cardinal Health, Inc. ( CAH ) has an Earnings ESP of +2.41% and holds a Zacks Rank #2. Cardinal Health will report second quarter fiscal 2014 earnings on Jan 30. Symmetry Medical, Inc. ( SMA ) has an Earnings ESP of +14.29% and holds a Zacks Rank #3 (Hold). Symmetry Medical will be reporting fourth quarter earnings on Feb 20. CARDINAL HEALTH (CAH): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYMMETRY MEDICL (SMA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Quest Diagnostics (DGX) Miss This Quarter? - Analyst Blog""]"
DXCM,2014-01-29,9.18,9.4575,9.1325,9.39,"[""Will Zimmer (ZMH) Miss Earnings Estimates? - Analyst Blog"", ""Will Zimmer (ZMH) Miss Earnings Estimates? - Analyst Blog"", ""Will Zimmer (ZMH) Miss Earnings Estimates? - Analyst Blog Zimmer Holdings Inc. ( ZMH ) is scheduled to report its fourth-quarter 2013 results before the opening bell on Jan 30. Last quarter, the company delivered a positive earnings surprise of 0.81%. Let's see how things are shaping up for this announcement. Factors at Play Barring the second quarter, Zimmer had posted positive earnings surprises in all of the last four quarters with an average beat of 0.54%. In order to streamline its business, Zimmer is continuing with its global restructuring program. A number of new products are slated for launch that will have a positive impact on the top line. After several quarters of challenging market conditions in the form of reduced procedure volume and pricing pressure, the company is gradually witnessing stability in the global musculoskeletal market with better-than-expected sales growth in certain geographies. However, pricing continues to remain a major headwind for Zimmer. Moreover, with continued weakening of yen, the company is expected to face negative currency impact on its sales. Earlier, while updating its growth outlook for 2013, Zimmer expected currency movement to lower revenues by 1.5% resulting in 2.0% revenue growth on a reported basis. Earnings Whispers? Our proven model does not conclusively show that Zimmer is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below. Zacks ESP: Earnings ESP for Zimmer is 0.00% since the Most Accurate estimate stands at $1.61, in line with the Zacks Consensus Estimate. Zacks Rank: Zimmer's Zacks Rank #3 (Hold) when combined with a 0.00% ESP, makes surprise prediction difficult. Other Stocks to Consider Here are some other companies you may want to consider as our model shows that they have the right combination of elements, i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3. DexCom, Inc. ( DXCM ) has an earnings ESP of +14.29% and holds a Zacks Rank #2 (Buy). DexCom is expected to report its fourth-quarter earnings on Feb 20. Cardinal Health, Inc. ( CAH ) has an earnings ESP of +2.41% and holds a Zacks Rank #1 (Strong Buy). Cardinal Health will report second-quarter fiscal 2014 earnings on Jan 30. Symmetry Medical, Inc. ( SMA ) has an earnings ESP of +14.29% and holds a Zacks Rank #3. Symmetry Medical will be reporting fourth-quarter earnings on Feb 20. CARDINAL HEALTH (CAH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYMMETRY MEDICL (SMA): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Zimmer (ZMH) Miss Earnings Estimates? - Analyst Blog""]"
DXCM,2014-01-30,9.475,9.815,9.465,9.8125,
DXCM,2014-01-31,9.7175,10.13,9.69,10.115,"[""Cepheid Reports Q4 Loss, Beats on Revs - Analyst Blog"", ""Cepheid Reports Q4 Loss, Beats on Revs - Analyst Blog"", ""Cepheid Reports Q4 Loss, Beats on Revs - Analyst Blog Cepheid ( CPHD ) reported adjusted loss of 8 cents per share in the fourth quarter of 2013, a substantial decrease from year-ago adjusted income of 11 cents a share. The Zacks Consensus Estimate of 10 cents remains below the quarter's adjusted figure. The adjustments include restructuring expense including impairment of certain assets and amortization of acquired intangible assets (we have considered stock-based compensation as regular expense). For full year 2013, adjusted net loss was 15 cents per share, up by 11 cents, from the adjusted net loss figure in 2012. It remains ahead of the Zacks Consensus Estimate of 17 cents. Reported fourth-quarter net loss was 10.3 million or loss of 15 cents per share. For full year 2013, reported net loss was $18 million or loss of 27 cents per share. Revenue in Detail Revenues improved 22.6% year over year to $113.3 million in the fourth quarter, surpassing the Zacks Consensus Estimate of $102 million. For the full year, revenues increased 21.2% year over year to $401.3 million, surpassing the Zacks Consensus Estimate of $390 million. This increase came on the back of strong market adoption of GeneXpert Systems and broadening reach of the Xpert test portfolio. Growth was also driven by strong business in High Burden Developing Countries (HBDC) and improved performance in the commercial clinical business. Segments in Detail The Clinical segment (up 22.9% year over year to $101 million) contributed about 89.1% to total revenue in the reported quarter. The Clinical segment comprises Clinical Systems (up 50.7% year over year to $20.2 million) and Clinical Reagents (up 17.4% year over year to $80.8 million). Commercial Clinical also showcased record sequential performance in terms of dollar growth in the company's history. It recorded sequential growth of 16%. On the other hand, Cepheid's Non-Clinical & Other business revenues rose 20.6% year over year to $12.3 million. On a geographic basis, product sales from the mainstay North American market grew 10.5% year over year to $69.7 million. The overseas market recorded a 48.8% year-over-year growth to $43.6 million in the reported quarter. During the reported quarter, Cepheid placed 205 GeneXpert systems in its commercial Clinical business. Moreover, it placed additional 178 GeneXpert systems as part of its HBDC program. Including the HBDC systems, a cumulative total of 5509 systems have been placed worldwide as of Dec 31, 2013. Operational Update Cepheid's adjusted gross margin (considering stock-based compensation as regular expense) was 49.2% in the reported quarter, down 610 basis points (bps) year over year. The margin contraction was on account of unfavorable mix toward the lower margin HBDC business. Adjusted COGS during the quarter spiked 39.2% to $57.5 million. In the reported quarter, adjusted operating expenses amounted to $57.8 million, up 36.3% year over year. Accordingly, adjusted operating loss was $2 million in the quarter, down from adjusted operating income of $8.7 million in the year-ago quarter. Financial Update Cepheid exited the quarter with cash and cash equivalents and short-term investment of $74.9 million compared with $95.8 million at the end of the same quarter previous year. In 2013, Cepheid generated $15 million in cash flow from operations, compared to $2.9 million in the year-ago period. Capital expenditure increased 104.7% year over year to $47.5 million. Guidance The company declared its business outlook for 2014. It expects total revenue to be in the range of $446-$461 million. The Zacks Consensus Estimate falls at the lower-end of the guidance range. Further, it anticipates adjusted net income in the range of 24-29 cents per share. The current Zacks Consensus Estimate is pegged at 7 cents per share of net income. Our Take Cepheid is a leading molecular diagnostics company that is dedicated to bring about healthcare improvement by developing, manufacturing and marketing accurate yet easy-to-use molecular systems and tests. The non-performance of the Non-clinical business in 2013 remains a concern for the company. However, with growing adoption of high throughput Infinity system, expanding molecular diagnostics test menu and strategies to expand in emerging markets like India and China, we believe that the company holds the potential to do well in 2014. Currently, Cepheid carries a Zacks Rank #2 (Buy). Other stocks worth considering in the broader healthcare sector are Natus Medical Inc. ( BABY ), AngioDynamics Inc. ( ANGO ) and DexCom, Inc. ( DXCM ). Natus Medical sports a Zacks Rank #1 (Strong Buy) while AngioDynamics and DexCom carry the same rank as Cepheid. ANGIODYNAMICS (ANGO): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report CEPHEID INC (CPHD): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cepheid Reports Q4 Loss, Beats on Revs - Analyst Blog""]"
DXCM,2014-02-03,10.1175,10.3,9.73,9.745,"[""FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System"", ""Innovative Dexcom G4\u00ae PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2-17 Years"", ""Innovative Dexcom G4\u00ae PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2-17 Years"", ""FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System"", ""Innovative Dexcom G4\u00ae PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2-17 Years"", ""FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System""]"
DXCM,2014-02-04,10.2575,10.54,9.67,9.715,"[""Natus Medical Upped to Strong Buy - Analyst Blog"", ""Natus Medical Upped to Strong Buy - Analyst Blog"", ""Natus Medical Upped to Strong Buy - Analyst Blog On Jan 31, Zacks Investment Research upgraded Natus Medical Inc. ( BABY ) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Natus Medical has been witnessing rising earnings estimates owing to impressive fourth-quarter 2013 results and an increased guidance for 2014. Moreover, this medical devices maker also delivered positive earnings surprises in all of the last 4 quarters. On Jan 29, Natus Medical reported fourth-quarter 2013 adjusted earnings per share of 37 cents, surpassing the Zacks Consensus Estimate of 32 cents by 15.6%. The fourth-quarter earnings also steered ahead of the prior-year quarter figure of 29 cents by 27.6%. BABY registered impressive growth on the back of improved revenues from the European as well as the international market. Based on its progress, the company raised its earnings per share projection for full-year 2014 to $1.14 -$1.18 from the previous guidance of $1.12 -$1.16. On the other hand, revenues are expected to be in the range of $345 million to $350 million for the full year. The Zacks Consensus Estimate for 2014 increased 1.8% to $1.16 per share as all estimates were revised higher over the last 30 days. The current Zacks Consensus Estimate falls within the guidance range provided by Natus Medical. The company's prime focus is to expand through organic growth. BABY also seeks to achieve its operating objectives through increased focus on earnings and healthy cash generation. We believe that the consistent focus of management to eventually occupy a leading position in both the Newborn Care and Neurology products market reinforces investors' confidence in the growth potential of Natus Medical. Other stocks to Consider Investors interested in the medical instruments industry can look at better-ranked stocks like Cyberonics Inc. ( CYBX ) DexCom, Inc. ( DXCM ) and Echo Therapeutics, Inc . ( ECTE ). While DexCom and Echo Therapeutics carry a Zacks Rank #2 (Buy), Cyberonics has the same Zacks Rank as BABY. NATUS MEDICAL (BABY): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Natus Medical Upped to Strong Buy - Analyst Blog""]"
DXCM,2014-02-05,9.8595,10.0225,9.65525,10.0,
DXCM,2014-02-06,10.0075,10.125,9.63,9.68,"[""FDA Approval for DexCom's G4 PLATINUM - Analyst Blog"", ""FDA Approval for DexCom's G4 PLATINUM - Analyst Blog"", ""FDA Approval for DexCom's G4 PLATINUM - Analyst Blog DexCom, Inc ( DXCM ) recently secured the U.S. Food and Drug Administration's (FDA) approval for its continuous glucose monitoring (CGM) device - DexCom G4 PLATINUM (Pediatric). This CGM device is designed for use in children affected with diabetes aged between 2 and 17 years. The device had earlier been FDA approved for use among adults 18 years and older. DexCom's shares shot up as much as 8% in the trading session following the announcement. The stock has been up 2.6% since the news release. Currently, the DexCom G4 PLATINUM (Pediatric) is the only available CGM system that has been approved for children as young as 2 years old. The DexCom G4 PLATINUM can continuously track glucose levels for 7 consecutive days throughout the 24-hour period. This user-friendly wireless technology system facilitates viewing of the glucose levels as and when needed. Unlike the conventional blood glucose meter, DexCom G4 PLATINUM CGM system displays the moving trends of the glucose levels, which in turn helps the user to undertake correct choices in proper diabetes management. Uncontrolled glucose levels pose potential health complications and can even lead to death. To battle this concern the CGM system is fitted with an in-built alarm that alerts when the glucose levels either rise or fall to dangerous levels. DexCom has designed the product with a tiny sensor and wireless transmitter to make it easy for use in children. The DexCom G4 PLATINUM is also believed to be one of the smallest and lightest CGMs available in the market. The FDA approval of the new DexCom G4 PLATINUM for use in children comes as a respite for parents who can easily monitor glucose levels on a regular basis without being bothered about the child being at home, or away at school, or even participating in sports activities. Effective management of diabetes is essential as it is often associated to have long-term impacts on the health of people. It has been observed that ype 1 diabetes is more prevalent both in children as well as in young adults. With the availability of such a unique device, children are likely to better manage their diabetes going into adulthood. At the same, they will also be cautious about incorporating necessary lifestyle changes right from their early years. The FDA approval for the DexCom G4 PLATINUM is a remarkable achievement in the field of diabetes management in the past 40 years, as diabetes is a grave health issue in the U.S as well as in other countries. We believe that with the achievement of the FDA approval for this device, DexCom will gain access to a huge market, as various studies indicate that diabetes among children is alarmingly on the rise in the U.S. Currently, DexCom carries a Zacks Rank #2 (Buy). Investors interested in the medical instruments industry can also look at other well-placed stocks like Natus Medical Inc . ( BABY ), Echo Therapeutics, Inc. ( ECTE ) and Cyberonics Inc. ( CYBX ). While Natus Medical carries a Zacks Rank #1 (Strong Buy) both Echo Therapeutics and Cyberonics carry a Zacks Rank #2 (Buy). NATUS MEDICAL (BABY): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FDA Approval for DexCom's G4 PLATINUM - Analyst Blog""]"
DXCM,2014-02-07,9.68,9.8375,9.32,9.4275,
DXCM,2014-02-10,9.44,9.935,9.4375,9.9325,"[""Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP"", ""Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape"", ""Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP"", ""Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape"", ""Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP Top 3 MedTech Stocks, Poised to Gain on Earnings The medical devices industry, once acclaimed for its high-paying jobs and research and development opportunities, has been facing the threat of both the 2.3% medical device excise tax since its enactment in the beginning of 2013 and sequestration-related spending cuts to the U.S. federal budget. In fact, these factors have significantly restricted the industry's bottom-line improvement this past year. To make matters worse, this year, more spending cuts are expected to come into effect which will last through 2021. The medical devices spending cut, if not repealed, may take a grave turn in 2014, leading to serious consequences like delaying progress in medical breakthroughs, deterioration in job creation, and tempering of economic growth. The imposition of medical device excise tax as part of the Obamacare roll-out is taking a heavy toll on the medical devices sector, hurting pricing decisions of participants and subjecting them to tremendous margin pressure. However, as a ray of hope amid this difficult scenario, National Institutes of Health (NIH) recently won a $1 billion or 3.5% increase in its fiscal 2014 budget from the previous year's post-sequestration budget (according to fiscal 2014 Omnibus Appropriations bill released on Jan 13, 2014). As per a recent report published in lexology.com, this hike - although not sufficient - is expected to result in 385 million new grant opportunities for researchers. Apart from NIH, the National Institutes of Standards and Technology and The National Science Foundation (NSF) are some others who stand to gain from this bill. The U.S. Food and Drug Administration (FDA) has also managed a $217 million increase in its 2014 budget over the previous year. However, things are not at all cheery for the Centers for Medicare and Medicaid Services (CMS). While the bill includes $3.7 billion for the CMS, this was $195 million less than what was enacted in the previous fiscal. Despite the overall negative sentiment, it might be a good idea to bet on a handful of medical device stocks that are likely to beat earnings estimates this quarter. An earnings beat will translate into rapid price appreciation for these stocks. This will give you above-average return as you are getting these stocks at a cheaper price due to the overall negative sentiment in the sector. How to Choose the Best? With the existence of a number of industry players, finding the right stocks that have the potential to beat earnings estimates could appear to be a difficult task, but our proprietary methodology makes it fairly simple for you. You could narrow down the list of choices by looking at stocks that have the combination of a favorable Zacks Rank - Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - and a positive Zacks Earnings ESP . Earnings ESP is our proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. Our research shows that for stocks with this combination, the chance of positive earnings surprise is as high as 70%. 3 Stocks Set to Beat Earnings Here are three medical stocks that have the right combination of elements to post an earnings beat this quarter: Henry Schein Inc. ( HSIC ), based in Melville, N.Y., is a leading distributor of health care products and services to office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites across the globe. The stock carries a Zacks Rank #1 with an Earnings ESP of +1.44%. The Zacks Consensus Estimate for earnings in the fourth quarter is pegged at $1.39. Henry Schein delivered positive earnings surprises in three of the last four quarters with an average beat of 1.21%. Based on favorable market dynamics, the company's animal health and dental business is expected to deliver strong sales. Over the past several quarters, the company has demonstrated consistent growth via both organic and inorganic means. Henry Schein will be reporting fourth-quarter 2013 earnings on Feb 11. Cyberonics Inc. ( CYBX ) is a Zacks Rank #2 stock and has an Earnings ESP of +4.08%. The Zacks Consensus Estimate for the fourth quarter is 49 cents. Cyberonics is a medical technology company with core expertise in neuromodulation. The company provides Vagus Nerve Stimulation (VNS) therapy for the treatment of refractory epilepsy and treatment-resistant depression (TRD). The company has delivered positive earnings surprises in the trailing four quarter. Cyberonics continued to gain from a solid foothold in the epilepsy market and strong overseas business. Further penetration in the still untapped epilepsy market should also catalyze growth. The company's lucrative pipeline is another upside. Cyberonics will be reporting fourth-quarter fiscal 2014 earnings on Feb 20. DexCom, Inc. ( DXCM ), based in San Diego, Calif., is a Zacks Rank #2 (Buy) stock with an Earnings ESP of +14.29%. The Zacks Consensus Estimate for the fourth quarter is pegged at a loss of 7 cents. DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. These are designed particularly for ambulatory use for people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. The company has delivered positive earnings surprises in the training four quarters with an average beat of 17.34%. The company's G4 Platinum is expected to do well in the fourth quarter. Increased awareness of the need for continuous glucose monitoring, new products and data supporting blood glucose monitoring should help drive sales. Dexcom will be reporting fourth-quarter 2013 earnings on Feb 20. The Bottom Line In order to sustain the current precarious condition within the MedTech space, key players are trying every possible means to change their business models and cost structures. They are undertaking various restructuring initiatives to counter costs associated with the implementation of the new tax. This renewed focus could result in continued mergers and acquisitions (M&A) and expansion to emerging markets going forward. They are also trying to divest their nonpaying operations in order to weather the tax burden. Nevertheless, you could safely rely on the industry outperformers that still possess earnings strength. CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP"", ""Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape""]"
DXCM,2014-02-11,9.9475,10.13,9.82,10.0625,"[""Cepheid Down to Strong Sell - Analyst Blog"", ""Cepheid Down to Strong Sell - Analyst Blog"", ""Cepheid Down to Strong Sell - Analyst Blog On Feb 4, Zacks Investment Research downgraded Cepheid ( CPHD ) to a Zacks Rank #5 (Strong Sell). Why the Downgrade? On Jan 30, Cepheid reported fourth-quarter 2013 adjusted loss of 8 cents per share, narrower than the Zacks Consensus Estimate of a loss of 10 cents per share. The adjusted loss excludes restructuring expenses including impairment of certain assets and amortization of acquired intangible assets (considering stock-based compensation as regular expense). For full-year 2014, Cepheid expects net loss in the range of 21 cents to 26 cents per share. The current Zacks Consensus Estimate for 2014 stands at a loss of 23 cents per share. On the other hand, revenues are expected in the range of $446-$461 million. The Zacks Consensus Estimate for revenues is pegged at $457 million, well within the guidance provided by the company. Cepheid anticipates a weak capital spending environment given persistent weak macro-economic conditions. Additionally, the austerity measures in Europe are expected to affect the growth prospects particularly in the overseas markets. A stiff competitive scenario is another cause of concern as other players in the market boast of stronger resources, capitalizing on which they can garner greater market share. This can prove detrimental for Cepheid's revenues going ahead. Cepheid has witnessed downward estimate revisions following the announcement of its fourth-quarter results. Three estimates moved down in the past 30 days, while no upward revision was observed over the same time span. Other Stocks To Consider Better-ranked stocks in the medical instruments industry include Natus Medical Inc. ( BABY ) , Cyberonics Inc. ( CYBX ) and DexCom, Inc. ( DXCM ). While Natus Medical sports a Zacks Rank #1 (Strong Buy), Cyberonics and DexCom carry a Zacks Rank #2 (Buy). NATUS MEDICAL (BABY): Free Stock Analysis Report CEPHEID INC (CPHD): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cepheid Down to Strong Sell - Analyst Blog""]"
DXCM,2014-02-12,10.095,10.325,10.0675,10.275,
DXCM,2014-02-13,10.275,10.7125,10.22,10.64,"[""Teleflex Recalls Tracheal Tube - Analyst Blog"", ""Teleflex Recalls Tracheal Tube - Analyst Blog"", ""Teleflex Recalls Tracheal Tube - Analyst Blog Teleflex Medical Incorporated ( TFX ) has declared a worldwide voluntary recall of its ISIS HVT Tracheal Tube Cuffed with subglottic secretion suction port (with and without Preloaded Stylet). Teleflex communicated the product recall to its U.S. customers by means of a letter on Jan 6, 2014, clearly stating that customers should discontinue use of the said device and return all unused ISIS products to Teleflex with immediate effect. The product codes have also been clearly indicated for the convenience of the customers. Teleflex ISIS HVT is a comprehensive, convertible endotracheal tube designed to provide airway access. Attached with a suction port and a separate line for subglottic secretion suctioning, the Teleflex ISIS HVT is designed for patients who need both short - and long-term ventilation. Patients are not required to change tubes with the Teleflex ISIS HVT. However, Teleflex made a voluntary recall of the ISIS HVT following complaints that it can kink during patient use. This makes it dangerous to use, as any such occurrence can deprive the patient of adequate ventilation, in turn, leading to hypoxic injury or anoxia. The U.S. Food and Drug Administration (FDA) has classified this action as a Class I recall which is defined as a situation where there is a considerable chance of adverse health consequence or even death resulting from the use of a violative product. Any product recall may have an impact on the company's bottom line and dampen its reputation in the market. Teleflex must handle this recall deftly to ensure that its competitors in the MedTech industry do not take advantage of the situation. As a result, Teleflex should take appropriate steps to help retain customer satisfaction and trust in the company's products. Superior customer satisfaction can eventually support the growth prospects of Teleflex in the market, going forward. Currently, Teleflex carries a Zacks Rank #2 (Buy). Investors interested in the medical instruments industry can look at other stocks like Natus Medical Inc. ( BABY ), Cyberonics Inc. ( CYBX ) and DexCom, Inc. ( DXCM ). While BABY carries a Zacks Rank #1 (Strong Buy), CYBX and DXCM hold the same Zacks Rank as Teleflex. NATUS MEDICAL (BABY): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Teleflex Recalls Tracheal Tube - Analyst Blog""]"
DXCM,2014-02-14,10.6575,10.8975,10.5188,10.855,"[""Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape"", ""Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape"", ""Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape DexCom, Inc. ( DXCM ) has been on the move lately as the stock has risen by 10.9% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors' minds right now is; can this trend continue? While there can be no telling for sure, it is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on DXCM is moving in the right direction. In fact, the stock currently has a Zacks Rank #2 (Buy), suggesting that the recent run could certainly continue for this in-focus company. DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape""]"
DXCM,2014-02-18,10.9625,11.05,10.7825,10.9825,
DXCM,2014-02-19,10.9925,11.26,10.98,11.1325,
DXCM,2014-02-20,11.0825,11.085,10.51,10.8575,"[""Feltl & Co. Downgrades DexCom, Inc. to Sell"", ""DexCom, Inc. Reports Q4 EPS of $(0.04) vs $(0.07) Est; Revenue of $51.70M vs $48.53M Est"", ""DexCom, Inc. Reports Q4 EPS of $(0.04) vs $(0.07) Est; Revenue of $51.70M vs $48.53M Est"", ""Feltl & Co. Downgrades DexCom, Inc. to Sell"", ""DexCom, Inc. Reports Q4 EPS of $(0.04) vs $(0.07) Est; Revenue of $51.70M vs $48.53M Est"", ""Feltl & Co. Downgrades DexCom, Inc. to Sell""]"
DXCM,2014-02-21,11.7325,11.935,10.6375,10.7775,"[""Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook"", ""Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook"", ""Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook Following the market opening Friday, the Dow traded up 0.32 percent to 16,184.28 while the NASDAQ surged 0.27 percent to 4,278.99. The S&P also rose, gaining 0.25 percent to 1,844.33. Leading and Lagging Sectors In trading on Friday, technology shares were relative leaders, up on the day by about 0.37 percent. Meanwhile, top gainers in energy sector included Microvision (NASDAQ: MVIS ), with shares up 20.2 percent, and Aruba Networks (NASDAQ: ARUN ), with shares up 7.1 percent. Shares of Aruba surged after the company reported quarterly results and announced an additional $200 million share repurchase authorization. Energy sector was the leading decliner in the US market today. Energy shares fell around 0.05 percent in today's trading. Among the energy stocks, Endeavour International (NYSE: END ) was down more than 9.5 percent, while Cabot Oil & Gas (NYSE: COG ) tumbled around 4.5 percent. Top Headline After the closing bell Thursday, Groupon (NASDAQ: GRPN ) projected a surprise loss for the first quarter. For the first quarter, Groupon expected an adjusted loss of $0.02 to $0.04 per share on revenue of $710 to $760 million. However, analysts were projecting a profit of $0.06 per share on revenue of $668.7 million. Groupon posted a quarterly net loss of $81.2 million, versus a year-ago loss of $81.1 million. On a per share basis, it lost $0.12 per share. Excluding items, Groupon earned $0.04 per share. Its revenue climbed to $768.4 million. However, analysts projected earnings of $0.02 per share on revenue of $718 million. Equities Trading UP Emeritus (NYSE: ESC ) shot up 37.37 percent to $29.48 after the company and Brookdale Senior Living (NYSE: BKD ) signed a definitive merger agreement. Shares of CommScope Holding Company (NASDAQ: COMM ) got a boost, shooting up 18.19 percent to $22.42 after the company reported Q4 results. Analysts at Jefferies upgraded the stock from Hold to Buy and lifted the price target from $17.50 to $25. DexCom (NASDAQ: DXCM ) was also up, gaining 7.21 percent to $46.56 after the company reported better-than-expected fourth-quarter results. Equities Trading DOWN Shares of Fleetmatics Group PLC (NYSE: FLTX ) were down 11.39 percent to $35.40 after the company issued a weak profit forecast. Groupon (NASDAQ: GRPN ) shares tumbled 15.75 percent to $8.66 after the company projected a surprise quarterly loss. Acacia Research (NASDAQ: ACTG ) was down, falling 8.26 percent to $13.67 on weaker-than-expected Q4 results. Commodities In commodity news, oil traded down 0.10 percent to $103.21, while gold traded up 0.42 percent to $1,322.40. Silver traded up 0.30 percent Friday to $21.75, while copper fell 0.06 percent to $3.26. Eurozone European shares were mostly higher today. The Spanish Ibex Index fell 0.06 percent, while Italy's FTSE MIB Index declined 0.12 percent. Meanwhile, the German DAX climbed 0.11 percent and the French CAC 40 climbed 0.34 percent while U.K. shares gained 0.22 percent. Economics Sales of existing homes declined 5.1% to an annual rate of 4.62 million in January, according to the National Association of Realtors. However, economists were projecting a rate of 4.67 million. (c) 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook""]"
DXCM,2014-02-24,10.8125,11.3825,10.8125,11.24,
DXCM,2014-02-25,11.17,11.5,11.0025,11.25,"[""DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog"", ""DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog"", ""DexCom Larger Than S&P 500 Component Cliffs Natural Resources In the latest look at stocks ordered by largest market capitalization, Russell 3000 component DexCom Inc (Symbol: DXCM) was identified as having a larger market cap than the smaller end of the S&P 500, for example Cliffs Natural Resources, Inc. (Symbol: CLF), according to The Online Investor . Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much - that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true \""apples-to-apples\"" comparison of the value of two stocks. In the case of DexCom Inc (Symbol: DXCM), the market cap is now $3.23B, versus Cliffs Natural Resources, Inc. (Symbol: CLF) at $3.11B. Below is a three month price history chart comparing the stock performance of DXCM vs. CLF: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which indices will include the stock, and which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and \""tosses out\"" the biggest 100 companies so as to focus solely on the 400 smaller \""up-and-comers\"" (which in the right environment can outperform their larger rivals). And ETFs that directly follow an index like the S&P 500 will only own the underlying component of that index, selling companies that lose their status as an S&P 500 company, and buying companies when they are added to the index. So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at TheOnlineInvestor.com find value to putting together these looks at comparative market capitalization daily. At the closing bell, DXCM is up about 0.1%, while CLF is trading flat on the day Tuesday. The 20 Largest U.S. Companies By Market Capitalization \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog""]"
DXCM,2014-02-26,11.2025,11.54,11.18,11.365,
DXCM,2014-02-27,11.33,11.615,11.28,11.56,
DXCM,2014-02-28,11.61,11.775,11.1725,11.275,
DXCM,2014-03-03,11.1875,11.3,10.9,11.27,
DXCM,2014-03-04,11.4275,11.905,11.3775,11.7225,"Is DexCom (DXCM) a Great Growth Stock? - Tale of the Tape Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors' attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is DexCom, Inc. ( DXCM ). This firm, which is in the Medical Instruments industry space, saw EPS growth of 48.2% last year, and is looking great for this year too. In fact, the current growth estimate for this year calls for earnings-per-share growth of 79.7%. Furthermore, the long-term growth rate is currently an impressive 32.5%, suggesting pretty good prospects for the long haul. And if this wasn't enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 36.1%. Thanks to this rise in earnings estimates, DXCM has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DXCM. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for DXCM as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-03-05,11.715,12.3025,11.625,12.2825,
DXCM,2014-03-06,12.4275,12.4575,11.755,11.885,
DXCM,2014-03-07,11.8625,11.9672,11.57,11.855,
DXCM,2014-03-10,11.91,11.91,11.3555,11.535,
DXCM,2014-03-11,11.5,11.89,11.345,11.43,
DXCM,2014-03-12,11.2525,11.4575,11.0675,11.455,
DXCM,2014-03-13,11.4375,11.7475,11.16,11.2625,
DXCM,2014-03-14,11.2,11.34,10.97,11.175,
DXCM,2014-03-17,11.1775,11.505,11.0862,11.41,
DXCM,2014-03-18,11.46,11.865,11.43,11.855,"[""Varian to Acquire Velocity Medical SW - Analyst Blog"", ""Varian to Acquire Velocity Medical SW - Analyst Blog"", ""Varian to Acquire Velocity Medical SW - Analyst Blog Calif.-based medical instruments maker Varian Medical Systems ( VAR ) entered an agreement to acquire the Velocity software from Atlanta-based Velocity Medical Solutions, LLC. However, the news failed to entice investors as stock price stayed almost the same (just a 0.1% slide) since the announcement. The Velocity software is designed to help clinicians making informed decisions for treating their patients by presenting a comprehensive view of a patient's diagnostic imaging and treatment history, regardless of their previous location of treatment or previous technology used for the treatment. The software is capable of accessing and aggregating unstructured treatment and imaging data from diverse systems. The privately-held Velocity Medical Solutions was founded by some eminent clinicians in order to transform unstructured data into meaningful clinical knowledge. The Velocity software has already been used at over 200 cancer treatment centers globally. Post-acquisition, Varian expects its global sales, service and support network will lead to better market penetration for the Velocity software. The company intends to develop this oncology software platform with the Velocity team in Atlanta, GA. The acquisition is expected to close in the fiscal third quarter. VAR posted a 5.8% rise in net earnings per share to 91 cents for the first quarter of fiscal 2014 from 86 cents in the prior fiscal quarter, and edged past the Zacks Consensus Estimate by a penny. With this, VAR also met its own guidance of a 6-7% rise in earnings per share to 87-91 cents for the quarter. Revenues in the quarter escalated nearly 5.0% to $711.5 million during the quarter, but lagged the Zacks Consensus Estimate of $718 million. The growth was attributable to the continued strong demand for Oncology services and X-ray imaging components during the quarter. For fiscal 2014, VAR expects revenues to grow by 6-8% compared with the earlier guidance of 6-7%. However, the company reiterated its earnings per share guidance between $4.22 and $4.34 for the year. The current Zacks Consensus Estimate of $4.29 lies within the guided range. For the second quarter of fiscal 2014, VAR expects revenues to be flat on a year-over-year basis. However, it expects earnings per share for the quarter in the range of $1.00 to $1.04. The current Zacks Consensus Estimate of $1.02 lies within the guided range. Currently, VAR carries a Zacks Rank #3 (Hold). Some better-ranked medical instrument stocks that currently worth a look include Cynosure Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ), and DexCom, Inc. ( DXCM ). Both Cynosure and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Varian to Acquire Velocity Medical SW - Analyst Blog""]"
DXCM,2014-03-19,11.9125,11.9625,11.6225,11.65,
DXCM,2014-03-20,11.73,11.7825,11.5025,11.6075,"[""FDA Clears Volcano Corp's iFR Modality - Analyst Blog"", ""FDA Clears Volcano Corp's iFR Modality - Analyst Blog"", ""FDA Clears Volcano Corp's iFR Modality - Analyst Blog Precision-guided therapy tools provider Volcano Corporation ( VOLC ) recently received the U.S. Food and Drug Administration's (FDA) approval for the company's proprietary iFR (instant wave-Free Ratio) Modality. Subsequently, the company initiated the limited market release of the product in the U.S. According to Volcano Corp., iFR Modality can be performed with the same pressure wires and equipment used for Fractional Flow Reserve (FFR). However, it does not inject hyperemic agents into the patient's body that cause stress to the heart. Moreover, iFR reduces timing costs per procedure and makes physiology guidance fast and routine during multi-vessel disease cases. Combined with the company's recently-introduced Verrata Pressure Guide Wire, the iFR Modality can be used most efficiently. The iFR Modality, which was earlier introduced in Europe and Japan, has shown a strong adoption rate. Currently, this product is installed on more than 300 systems globally, including Europe and Japan. According to the company, this latest U.S. FDA clearance will boost the adoption rate further leading to upgradation of more than 90% of Volcano's worldwide installed base of multi-modality systems. Volcano Corp. is currently progressing well with the rollout of iFR Modality in Europe and Japan. According to the company, the recent release of two studies, ADVISE II and ADAPT-DES with their positive outcomes, will help increase iFR and FFR adoption and IVUS penetration in more complex cases. According to the company, the broader market for intra-body imaging and sensing products is expected to grow from $332 million in 2006 to $2.7 billion by 2021, representing a CAGR of 15% approximately. Within this broader market, the current market for IVUS, FFR and Axsun products will capture only $750 million reflecting high growth potential in the coming period. We note that the current growth trend in the IVUS and FFR markets are impressive at approximately 3.5% and 20-30% respectively. The stock currently carries a Zacks Rank #4 (Sell). Well-placed medical stocks worth considering include ABIOMED, Inc. ( ABMD ), Cyberonics Inc. ( CYBX ) and DexCom, Inc. ( DXCM ). All the three stocks hold a Zacks Rank #2 (Buy). ABIOMED INC (ABMD): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FDA Clears Volcano Corp's iFR Modality - Analyst Blog""]"
DXCM,2014-03-21,11.575,11.6812,10.995,11.1225,
DXCM,2014-03-24,11.1725,11.2375,10.385,10.7725,"[""Why DexCom (DXCM) Could Be a Potential Winner - Tale of the Tape"", ""Why DexCom (DXCM) Could Be a Potential Winner - Tale of the Tape"", ""Why DexCom (DXCM) Could Be a Potential Winner - Tale of the Tape It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors' radar screens for a reason, though there are some hidden gems that could be worth uncovering by those with a high risk tolerance. One way to find these underappreciated stocks is by looking at companies that haven't seen their share prices move higher lately, but have observed analysts raising earnings estimates for their stock. This trend could signal that investors haven't quite embraced the rising estimate story yet, but that the potential for a big move higher is definitely there. One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is DexCom, Inc. ( DXCM ). This medical instrument company stock has actually seen its current year loss estimates narrow from loss of 13 cents to loss of 9 cents over the past month. But that is not yet reflected in its price, as the stock gained only 2.44% over the same time frame. You should not be concerned about the price remaining muted going forward. This year's expected earnings growth over the prior year is 79.65%, which should ultimately translate into price appreciation. And if this isn't enough, DXCM currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance ). So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider DexCom. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for DXCM and that now might be an interesting buying opportunity. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom (DXCM) Could Be a Potential Winner - Tale of the Tape""]"
DXCM,2014-03-25,10.5675,11.18,10.5525,10.7625,"[""DexCom Wins FDA Warning Letter for Admin Deficiencies, Will Submit Materials to Demonstrate Compliance, Says No Sanctions Levied by FDA"", ""DexCom Wins FDA Warning Letter for Admin Deficiencies, Will Submit Materials to Demonstrate Compliance, Says No Sanctions Levied by FDA"", ""DexCom Wins FDA Warning Letter for Admin Deficiencies, Will Submit Materials to Demonstrate Compliance, Says No Sanctions Levied by FDA""]"
DXCM,2014-03-26,10.7825,10.9325,10.5775,10.5775,
DXCM,2014-03-27,10.475,10.515,9.96,10.125,"[""DexCom Inc. (DXCM): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report"", ""DexCom Inc. (DXCM): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report"", ""DexCom Inc. (DXCM): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Summary: Dexcom remains a loss-making entity despite increasing revenues primarily due to surging operating expenses. Nevertheless, in the third quarter of 2014, the company's losses remained flat on a year-over-year basis. Revenues surged 60.8% to $69 million on a solid 60% rise in product revenues and also topped the Zacks Consensus Estimate of $61 million. The growing installed base of customers using the G4 Platinum system continues to drive product revenues and margins. DexCom has a robust product pipeline which contributes to the growth trajectory of this company. However, the market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions, which remains a potent headwind. Thus, we reaffirm our Neutral recommendation on DexCom with a target price of $64.00. Overview: San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. DexCom's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels. The company's first product, STS Continuous Glucose Monitoring System, was designed for up to three days of continuous use. This product was removed from the market when DexCom received U.S. Food and Drug Administration (FDA) approval for its second generation continuous glucose monitoring system, the DexCom SEVEN, named for its design for up to seven days of continuous use. DexCom discontinued sales of SEVEN in the U.S. following the launch of its third generation continuous glucose monitoring system, the SEVEN PLUS, which received approval for up to seven days of continuous use. In Oct 2012, DexCom had gained approval for its continuous glucose monitoring system, G4 Platinum, and began commercialization of the product in the fourth quarter of 2012. In Feb 2014, the Dexcom G4 Platinum system received FDA approval for pediatric indication in the U.S., while the device was cleared for professional use in Jun 2014. The company reported total revenues of $160 million in 2013, up 60.2% year over year. Total revenues for the nine months ended Sep 30, 2014 stood at $174.9 million, up 61.5% year over year. During this period, product revenues shot up 63.3% year over year to $172.8 million. DexCom Inc. (DXCM): Read the Full Research Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""First Week of DXCM May 17th Options Trading Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the May 17th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the DXCM options chain for the new May 17th contracts and identified one put and one call contract of particular interest. The put contract at the $40.00 strike price has a current bid of $2.15. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $40.00, but will also collect the premium, putting the cost basis of the shares at $37.85 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $41.11/share today. Because the $40.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 5.38% return on the cash commitment, or 38.47% annualized - at Stock Options Channel we call this the YieldBoost . Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $40.00 strike is located relative to that history: Top YieldBoost Calls of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Inc. (DXCM): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report""]"
DXCM,2014-03-28,10.0925,10.275,9.9275,10.01,
DXCM,2014-03-31,10.0875,10.41,9.9175,10.34,"[""Balanced View on Hologic - Analyst Blog"", ""Balanced View on Hologic - Analyst Blog"", ""Balanced View on Hologic - Analyst Blog""]"
DXCM,2014-04-01,10.2975,10.4375,10.205,10.3225,"[""Balanced View on Haemonetics - Analyst Blog"", ""Balanced View on Haemonetics - Analyst Blog"", ""Balanced View on Haemonetics - Analyst Blog""]"
DXCM,2014-04-02,10.38,10.5725,10.1662,10.4875,"[""Balanced View on Cyberonics - Analyst Blog"", ""Balanced View on Cyberonics - Analyst Blog"", ""Balanced View on Cyberonics - Analyst Blog""]"
DXCM,2014-04-03,10.53,10.615,10.145,10.195,"[""DexCom Shares Fall on FDA Warning - Analyst Blog"", ""DexCom Shares Fall on FDA Warning - Analyst Blog"", ""DexCom Shares Fall on FDA Warning - Analyst Blog Shares of San-Diego, CA-based DexCom, Inc. ( DXCM ) tumbled after it revealed the warning letter issued by the U.S. Food and Drug Administration (FDA) regarding administrative deficiencies in its Medical Device Reports (MDR). Although the FDA had sent the warning letter on Mar 14, the company disclosed it only early last week. Since the revelation of the warning letter, DexCom's shares dropped 5.7% to close at $41.95 yesterday. FDA's Charges The federal watchdog agency conducted an inspection of DexCom's San-Diego facility in Nov 2013 after which it determined that the company was not in compliance with the MDR regulations that were recently updated in Jul 2013. The FDA warning letter held that the glucose monitoring company failed to report at least 4 incidences of low blood sugar (i.e. hypoglycemia) requiring medical treatment that were not correctly detected by the firm's blood glucose monitoring device. The company also failed to report one instance which reasonably suggests that DexCom's blood glucose monitor malfunctioned and shocked a patient. The referenced medical interventions to treat hypoglycemia are considered medical interventions necessary to prevent permanent impairment of a body function or permanent damage to a body structure. According to the letter, DexCom failed to submit an MDR for each referenced event. However, the FDA did not impose any sanctions in the warning letter. DexCom's Claims Dexcom disclosed the FDA warning letter, saying only that the letter flagged \""deficiencies in filing MDRs involving the company's continuous glucose monitoring system.\"" Before the end of Apr 2014, Dexcom expects to submit all materials necessary to maintain compliance with the FDA's reporting obligations, in an effort to resolve any remaining deficiencies and have the warning letter repealed in due course. According to Dexcom, the warning is not likely to affect its current operations or its ability to manufacture and sell its G4 Platinum systems and sensors. Neither is it expected to impact any of its pending or future bids for approval from the FDA. Our Stance Though the last two weeks have been witness to a downtrend in DexCom's share price, we believe it is well-positioned for future earnings growth. DexCom reported strong top and bottom-line results for the fourth quarter of 2013, topping the Zacks Consensus Estimates on both fronts. Following the earnings release on Feb 20, shares of this medical device company depicted an uptrend. Moreover, over the past two months, the company has seen 9 positive estimate revisions for the current year causing the Zacks Consensus Estimate to improve 30.8% to its current level of a loss of 9 cents per share from a loss of 13 cents for 2014. Furthermore, long-term growth for the stock is currently pegged at an impressive 32.5% compared to the industry average of 17.3%. DexCom currently retains a Zacks Rank #2 (Buy). Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). All the three stocks sport a Zacks Rank #1 (Strong Buy). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Fall on FDA Warning - Analyst Blog""]"
DXCM,2014-04-04,10.415,10.415,9.42,9.4975,
DXCM,2014-04-07,9.4275,9.46,8.7325,8.92,
DXCM,2014-04-08,8.9375,9.38,8.8775,9.18,"[""DexCom (DXCM) is now in Oversold Territory - Tale of the Tape"", ""DexCom (DXCM) is now in Oversold Territory - Tale of the Tape"", ""DexCom (DXCM) is now in Oversold Territory - Tale of the Tape DexCom, Inc. 's ( DXCM ) share price has entered into oversold territory with an RSI value of 28.5. The Zacks Consensus Estimate for DexCom for the full year period has improved 4 cents over the past two months to -9 cents per share. Currently, DexCom has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( DXCM ) after its recent drop. DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) is now in Oversold Territory - Tale of the Tape""]"
DXCM,2014-04-09,9.2025,9.5925,9.1,9.57,
DXCM,2014-04-10,9.83,9.87,9.005,9.0125,"[""Delcath Systems Shares Tank on Stock Split - Analyst Blog"", ""Sterne Agee Upgrades DexCom, Inc. to Buy, Maintains $50.00 PT"", ""Sterne Agee Upgrades DexCom, Inc. to Buy, Maintains $50.00 PT"", ""Delcath Systems Shares Tank on Stock Split - Analyst Blog"", ""Delcath Systems Shares Tank on Stock Split - Analyst Blog Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. According to an SEC filing, the stock split trimmed Delcath shares to roughly 9.4 million from 150.9 million. Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device. FDA determined that the risks associated with the company's Melblez device are higher than the benefits for patients with unresectable ocular melanoma metastatic to the liver. In Oct last year, Delcath's shares turned red after the announcement of raising about $7.5 million through sales of common stock. The New York-based medical device maker also announced several layoffs as part of its restructuring plan. However, Delcath's financial results for the 2013-fourth quarter showed improvement. The company posted a narrower loss of 4 cents per share for the quarter compared with 14 cents in the fourth quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 5 cents per share. Revenues in the quarter surged 69% to $338 million. Operating expenses dipped 52% to $5.8 million from $12.0 million for the fourth quarter of 2012. The decline is primarily attributable to a significant reduction in expenses related to the company's NDA submission to the FDA, as well as the cost reduction measures. Operating loss was narrower at $5.5 million (including non-cash stock-based compensation income of $0.3 million) compared with $11.8 million (including $0.9 million in non-cash stock-based compensation expense) for the fourth quarter of 2012. Currently, Delcath retains a Zacks Rank #1 (Strong Buy). Other players in the medical instruments industry that are also worth a look include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ), and DexCom, Inc. ( DXCM ). Cynosure and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Sterne Agee Upgrades DexCom, Inc. to Buy, Maintains $50.00 PT"", ""Delcath Systems Shares Tank on Stock Split - Analyst Blog""]"
DXCM,2014-04-11,9.0,9.127,8.6475,8.905,
DXCM,2014-04-14,8.965,9.0675,8.725,8.8225,
DXCM,2014-04-15,8.8825,8.8825,8.07,8.54,
DXCM,2014-04-16,8.545,9.095,8.545,9.0075,
DXCM,2014-04-17,9.0025,9.2475,8.8375,9.145,
DXCM,2014-04-21,9.175,9.22125,8.9275,9.0175,
DXCM,2014-04-22,9.03,9.1875,8.9575,9.03,"[""Balanced Outlook on Accuray - Analyst Blog"", ""Balanced Outlook on Accuray - Analyst Blog"", ""Balanced Outlook on Accuray - Analyst Blog On April 16, we have updated our research report on Accuray Incorporated ( ARAY ). Despite being a loss-making company, we expect the company's product revenues to improve further as medical centers continue to adopt the company's innovative radiosurgery and radiation therapy systems on a global basis. Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter compared with a loss of $25.5 million, or 35 cents per share for the same quarter in the prior fiscal year as well as the Zacks Consensus Estimate of a loss of 20 cents per share. The narrower loss can be attributed to higher revenues and a substantial fall in operating expenses during the quarter. Total revenues grew 20.4% to $93.6 million, surpassing the Zacks Consensus Estimate of $81.0 million significantly. Product revenues surged 36.1% to $45.1 million while Service revenues rose 8.7% to $45.5 million. The improvement in Product revenues was attributable to impressive rise in product orders. Gross product orders almost doubled (102%) to $80.3 million in the quarter while net product orders (gross orders less cancellations and age-outs) soared 232% to $59.4 million in the second quarter. At the end of the quarter, product backlog was $362 million, up roughly 30% from the backlog at the end of the fiscal 2013-second quarter. The increase in Service revenues was driven by the higher installed base and conversion of customers to emerald and diamond service contracts. For fiscal 2014 ending June this year, Accuray upgraded its revenue guidance to a range of $340 to $350 million from the prior range of $325 to $345 million based on its performance in the first half of fiscal 2014 and optimism triggered by the continued momentum of converting orders to revenues. The current Zacks Consensus Estimate of $344 million lies within the guided range. However, Accuray expects lower net orders in second half of fiscal 2014 compared with the net orders in the first half of the fiscal year. With this, Accuray expects to end the fiscal year with net product orders of $215 to $225 million, reflecting 25-31% growth over the prior fiscal year. Currently, Accuray retains a Zacks Rank #2 (Buy). The company expects to release its fiscal 2014-third quarter results on April 29. Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). Delcath Systems and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Balanced Outlook on Accuray - Analyst Blog""]"
DXCM,2014-04-23,9.005,9.075,8.8975,9.0025,
DXCM,2014-04-24,9.0725,9.25,8.505,8.67,
DXCM,2014-04-25,8.605,8.63,8.3275,8.345,
DXCM,2014-04-28,8.4,8.4975,8.005,8.165,
DXCM,2014-04-29,8.165,8.4875,8.075,8.115,
DXCM,2014-04-30,8.115,8.1975,7.935,8.11,
DXCM,2014-05-01,8.0625,8.26,7.9675,8.1875,"[""DexCom, Inc. Reports Q1 EPS of $(0.17) vs $(0.08) Est; Revenue of $47.10M vs $44.15M Est"", ""DexCom, Inc. Reports Q1 EPS of $(0.17) vs $(0.08) Est; Revenue of $47.10M vs $44.15M Est"", ""DexCom, Inc. Reports Q1 EPS of $(0.17) vs $(0.08) Est; Revenue of $47.10M vs $44.15M Est""]"
DXCM,2014-05-02,8.1725,8.485,7.0225,7.96125,
DXCM,2014-05-05,7.7525,7.98,7.725,7.8725,
DXCM,2014-05-06,7.8175,7.94,7.6175,7.625,"[""DexCom Misses, Sees Broader Q1 Loss - Analyst Blog"", ""DexCom Misses, Sees Broader Q1 Loss - Analyst Blog"", ""DexCom Misses, Sees Broader Q1 Loss - Analyst Blog DexCom, Inc. ( DXCM ) reported a broader loss of $12.5 million or 17 cents per share in the first quarter of 2014 compared with $11.1 million or 16 cents in the comparable quarter of 2013 as well as the Zacks Consensus Estimate of a loss of 8 cents. The broader loss can be attributable to a significant increase in operating expenses in the quarter, mainly on account of a substantial rise in non-cash share-based compensation. Revenues DexCom's total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million, on a handsome 68.0% rise in product revenues to $46.7 million. However, a development grant and other revenues plunged 77.8% to $0.4 million in the quarter. Expenses and Margins Product gross profit nearly doubled to $29.8 million while product gross margin surged 760 basis points (bps) to 63.3% in the first quarter of 2014. The company continues to expect improvement in gross margin in the year as volumes continue to rise, mainly consumable product sales. Operating expenses in the quarter jumped 53.6% to $42.1 million, driven by increased share-based compensation due to an uptrend in share price. Dexcom's non-cash equity related charges soared 86.8% to $9.9 million for the quarter from $5.3 million in the first quarter of 2013. Research and development (R&D) expenses spiked 55.9% to $14.5 million in the quarter. The increase is partially attributable to a $2.1 million increase in non-cash equity related expense. The remaining increase in R&D expenses relates to continued investment in the product pipeline, focusing upon higher accuracy, better connectivity, patient convenience and lower cost. In the quarter, Dexcom conducted a number of clinical studies related to future technology, new sensors, new algorithms, enhance labeling, failure connectivity and general product improvements. The company has a few pending submissions with the FDA, including DexCom SHARE, the DexCom G4 system for professional use, the SweetSpot cloud-based system. Selling, general and administrative (SG&A) expenses went up 52.5% to $27.6 million in the quarter, driven by increased headcount for commercial infrastructure. The increase in both R&D and SG&A expenses led to a broader operating loss of $12.3 million compared with $10.9 million loss in the 2013-first quarter. Financial Status DexCom had cash and cash equivalents of $45.7 million as of Mar 31, 2014 compared with $43.2 million as of Dec 31, 2013. Total long-term debt went down to $6.3 million from $6.8 million as of Dec 31, 2013. Our Take CA-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The company relies significantly on its base of recurring revenue which reflects increasing usage rate with existing patients. Thus, higher patient base will bolster top-line for DexCom. However, we are concerned about its widening losses and disappointed about its earnings miss in the first quarter. DexCom currently retains a Zacks Rank #4 (Sell). Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Natus Medical carry a Zacks Rank #2 (Buy). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Misses, Sees Broader Q1 Loss - Analyst Blog""]"
DXCM,2014-05-07,7.6,7.6325,7.17,7.42,
DXCM,2014-05-08,7.4175,7.7,7.34,7.525,
DXCM,2014-05-09,7.455,7.8875,7.385,7.88,
DXCM,2014-05-12,7.88,8.165,7.855,8.0225,
DXCM,2014-05-13,7.96,8.165,7.87,7.965,
DXCM,2014-05-14,7.925,8.1875,7.8725,7.9525,
DXCM,2014-05-15,7.8875,7.96,7.695,7.9375,"[""Jim Cramer Interviews CEO Terrance H. Gregg of DexCom on Mad Money"", ""DexCom CEO Gregg: 'Our Products Allow Patients to Have Constant Monitoring of Glucose Levels'"", ""DexCom CEO Gregg: 'The Individuals Who Have Diabetes Make the Choice and they Choose Us'"", ""DexCom CEO Gregg: 'Our Long-Term Goal is to Replace Finger Sticks'"", ""DexCom CEO Gregg: 'Our Long-Term Goal is to Replace Finger Sticks'"", ""DexCom CEO Gregg: 'The Individuals Who Have Diabetes Make the Choice and they Choose Us'"", ""DexCom CEO Gregg: 'Our Products Allow Patients to Have Constant Monitoring of Glucose Levels'"", ""Jim Cramer Interviews CEO Terrance H. Gregg of DexCom on Mad Money"", ""DexCom CEO Gregg: 'Our Long-Term Goal is to Replace Finger Sticks'"", ""DexCom CEO Gregg: 'The Individuals Who Have Diabetes Make the Choice and they Choose Us'"", ""DexCom CEO Gregg: 'Our Products Allow Patients to Have Constant Monitoring of Glucose Levels'"", ""Jim Cramer Interviews CEO Terrance H. Gregg of DexCom on Mad Money""]"
DXCM,2014-05-16,7.9325,8.1575,7.8875,8.105,
DXCM,2014-05-19,8.0975,8.2175,8.0025,8.14,
DXCM,2014-05-20,8.0875,8.1425,7.7625,7.825,"Interesting DXCM Put And Call Options For July 19th Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the July 19th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the DXCM options chain for the new July 19th contracts and identified one put and one call contract of particular interest. The put contract at the $30.00 strike price has a current bid of $1.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $28.70 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $31.84/share today. Because the $30.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 4.33% return on the cash commitment, or 26.36% annualized - at Stock Options Channel we call this the YieldBoost . Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $30.00 strike is located relative to that history: Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-05-21,7.9175,8.2225,7.885,7.9825,
DXCM,2014-05-22,7.9925,8.1725,7.9625,8.0875,
DXCM,2014-05-23,8.0975,8.3525,8.0175,8.295,
DXCM,2014-05-27,8.365,8.645,8.2625,8.64,
DXCM,2014-05-28,8.65,8.745,8.5425,8.545,
DXCM,2014-05-29,8.5575,8.64,8.5425,8.605,
DXCM,2014-05-30,8.6075,8.6625,8.395,8.44,
DXCM,2014-06-02,8.41,8.4475,8.12,8.31,
DXCM,2014-06-03,8.195,8.2925,8.035,8.145,
DXCM,2014-06-04,8.44,8.7275,8.3125,8.72,"[""FDA Nod for DexCom's G4 PLATINUM System - Analyst Blog"", ""Shares of Dexcom Moving Higher Following CEO Gregg's Appearance on CNBC's Fast Money"", ""Shares of Dexcom Moving Higher Following CEO Gregg's Appearance on CNBC's Fast Money"", ""FDA Nod for DexCom's G4 PLATINUM System - Analyst Blog"", ""FDA Nod for DexCom's G4 PLATINUM System - Analyst Blog San-Diego, CA-based DexCom, Inc. ( DXCM ) received U.S. Food and Drug Administration (FDA) approval for its DexCom G4 PLATINUM Professional Continuous Glucose Monitoring (CGM) System. The Professional CGM System is a powerful, analytical tool that allows healthcare experts to treat patients who suffer from frequent hypoglycemia (low blood sugar), struggle to meet glycemic goals, or have wide fluctuations in glycemic variability. Continuous glucose monitoring is extremely important for diabetes management. It helps regulate the glucose level by providing information on the direction and rate of glucose change and also alerts users in case of major fluctuations in the glucose level. The PLATINUM Professional CGM System is the first and only real-time professional CGM which provides unblinded feedback, thus allowing patients to experience the benefits of real-time glucose monitoring. Through real-time visibility of dynamic glucose changes, clinicians can coach their patients to better outcomes. The professional CGM System allows clinicians to retrospectively alter treatment after viewing the effects that specific foods, exercise, stress and medications have on their patients' glucose level. How it Works? The DexCom G4 PLATINUM Professional CGM consists of a medical practice-owned professional CGM system and sensors. Patients are placed on a professional CGM for a period of seven days - this involves minimal training and setup time. During this period, dynamic and comprehensive data is collected that can be shared with the patients. Such information helps patients to understand the impact of their behavior on their glucose levels. It thus provides the doctor with an opportunity to review glucose data retrospectively with the patients to make therapeutic treatment recommendations. By taking at least two calibrations from a blood glucose meter daily, the DexCom G4 PLATINUM Professional CGM provides continuous readings on the rate and direction of glucose change up to every five minutes. The system can also be customized for personalized glucose targets and alerts and has an alarm feature to alert the user if glucose levels rise or fall to dangerous levels. Going Forward DexCom's mission is to provide doctors, patients and caregivers new medical technology to improve their understanding and management of diabetes. The currently available professional CGM systems offer only retrospective, blinded information on the glucose level of patients. The novel DexCom G4 PLATINUM Professional CGM will enable clinicians to gain real-time insight into their patients' glycemic profiles leading to improved glucose control. Over the long run, DexCom remains focused on replacing finger stick meters, the traditional standard-of-care for glucose monitoring, with CGM. Zacks Rank DexCom currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the medical instruments industry are Alphatec Holdings, Inc. ( ATEC ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). While Alphatec Holdings and RTI Surgical sport a Zacks Rank #1 (Strong Buy), Accuray carries a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ALPHATEC HLDGS (ATEC): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of Dexcom Moving Higher Following CEO Gregg's Appearance on CNBC's Fast Money"", ""FDA Nod for DexCom's G4 PLATINUM System - Analyst Blog""]"
DXCM,2014-06-05,8.885,9.12,8.875,9.0325,
DXCM,2014-06-06,9.15,9.1825,9.01,9.18,
DXCM,2014-06-09,9.1375,9.37,9.0925,9.345,
DXCM,2014-06-10,9.295,9.38,9.1275,9.27,
DXCM,2014-06-11,9.21,9.23875,8.9775,9.0575,
DXCM,2014-06-12,9.0325,9.1225,8.865,9.0025,
DXCM,2014-06-13,9.0475,9.2645,8.8225,9.0,
DXCM,2014-06-16,9.0375,9.4675,9.0095,9.4575,"[""DexCom Collaborates with Insulet Corporation - Analyst Blog"", ""DexCom Collaborates with Insulet Corporation - Analyst Blog"", ""DexCom Collaborates with Insulet Corporation - Analyst Blog CA-based glucose monitoring systems provider DexCom, Inc. ( DXCM ) and diabetes products supplier Insulet Corporation ( PODD ) have announced their intention to integrate data from Insulet's OmniPod System into DexCom's mobile App platform. DexCom's mobile App platform is currently under development. It will be the first version of a mobile App that is capable of incorporating glucose and other diabetes-related data from patients' devices, which will be displayed through a smartphone App. The decision to integrate Insulet's OmniPod System data into DexCom's mobile App platform is a part of DexCom's open architecture approach to diabetes-related data. The approach will include an \""approved by DexCom\"" indication to validate the authenticity of devices and Apps integrating DexCom CGM data. DexCom's mobile App platform will provide Insulet's OmniPod users increased access to data, improving diabetes management. It will help diabetic people achieve better control on their disease. Dexcom reported a broader loss of $12.5 million or 17 cents per share in the first quarter of 2014 compared with $11.1 million or 16 cents in the comparable quarter of 2013 as well as the Zacks Consensus Estimate of a loss of 8 cents. The broader loss can be attributable to significant increase in operating expenses in the quarter, mainly on account of a substantial rise in non-cash based share-based compensation. DexCom's total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million, on a handsome 68.0% rise in product revenues to $46.7 million. However, development grant and other revenues plunged 77.8% to $0.4 million in the quarter. DexCom currently retains a Zacks Rank #4 (Sell). Some better-ranked stocks in the medical instruments sector include Alphatec Holdings, Inc. ( ATEC ) and Luminex Corporation ( LMNX ). Both of them sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report LUMINEX CORP (LMNX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ALPHATEC HLDGS (ATEC): Free Stock Analysis Report INSULET CORP (PODD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Monday's ETF Movers: IHI, FM In trading on Monday, the iShares U.S. Medical Devices ETF ( IHI ) is outperforming other ETFs, up about 1.5% on the day. Components of that ETF showing particular strength include shares of Covidien ( COV ), up about 19.3% and shares of Dexcom ( DXCM ), up about 3.2% on the day. And underperforming other ETFs today is the iShares MSCI Frontier 100 ETF ( FM ), off about 2.3% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Pampa Energia ( PAM ), lower by about 6.9%, and shares of Bbva Banco Frances (BFR), lower by about 6.7% on the day. VIDEO: Monday's ETF Movers: IHI, FM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Collaborates with Insulet Corporation - Analyst Blog""]"
DXCM,2014-06-17,9.4875,9.995,9.311,9.80375,
DXCM,2014-06-18,9.7725,9.9775,9.7575,9.9725,
DXCM,2014-06-19,9.98,10.005,9.8325,9.9975,
DXCM,2014-06-20,9.9175,10.265,9.9175,10.25,
DXCM,2014-06-23,10.2425,10.3875,10.1312,10.2275,
DXCM,2014-06-24,10.1525,10.3975,10.1475,10.185,
DXCM,2014-06-25,10.1225,10.245,10.05,10.2025,
DXCM,2014-06-26,10.22,10.245,10.0375,10.1,
DXCM,2014-06-27,10.0425,10.0625,9.835,9.9125,
DXCM,2014-06-30,9.875,10.0525,9.8575,9.915,
DXCM,2014-07-01,9.9825,10.02,9.8425,9.92,
DXCM,2014-07-02,9.9275,10.1275,9.875,9.9325,
DXCM,2014-07-03,10.0,10.025,9.8375,9.9575,
DXCM,2014-07-07,9.92,9.92,9.46,9.4825,"[""8-K from Dexcom Shows Co. Entered Settlement, License Deal July 2nd with Abbott Diabetes, Party Not Acquired in Change of Control to Be Paid $25M"", ""8-K from Dexcom Shows Co. Entered Settlement, License Deal July 2nd with Abbott Diabetes, Party Not Acquired in Change of Control to Be Paid $25M"", ""8-K from Dexcom Shows Co. Entered Settlement, License Deal July 2nd with Abbott Diabetes, Party Not Acquired in Change of Control to Be Paid $25M""]"
DXCM,2014-07-08,9.435,9.455,8.81,8.8375,
DXCM,2014-07-09,8.845,9.075,8.845,9.0425,
DXCM,2014-07-10,8.73,9.0975,8.6675,8.9825,
DXCM,2014-07-11,8.9525,9.185,8.9,9.1525,
DXCM,2014-07-14,9.2725,9.2925,9.0675,9.25,
DXCM,2014-07-15,9.27,9.3575,9.0715,9.1025,
DXCM,2014-07-16,9.1625,9.205,9.0025,9.1325,
DXCM,2014-07-17,9.035,9.2125,8.9275,8.97,
DXCM,2014-07-18,8.93,9.2,8.875,9.18,"[""5 New Medical Technologies For Diabetics"", ""5 New Medical Technologies For Diabetics"", ""5 New Medical Technologies For Diabetics""]"
DXCM,2014-07-21,9.1125,9.32,9.03,9.2375,
DXCM,2014-07-22,9.3025,9.595,9.2375,9.4575,
DXCM,2014-07-23,9.475,9.6425,9.47,9.625,
DXCM,2014-07-24,9.605,9.695,9.5125,9.6075,"First Week of March 2015 Options Trading For DexCom (DXCM) Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the March 2015 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the DXCM options chain for the new March 2015 contracts and identified one put and one call contract of particular interest. The put contract at the $35.00 strike price has a current bid of $4.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $35.00, but will also collect the premium, putting the cost basis of the shares at $31.00 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $38.39/share today. Because the $35.00 strike represents an approximate 9% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 11.43% return on the cash commitment, or 17.45% annualized - at Stock Options Channel we call this the YieldBoost . Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $35.00 strike is located relative to that history: Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-07-25,9.5075,9.8225,9.465,9.7625,
DXCM,2014-07-28,9.8,9.86,9.525,9.8275,
DXCM,2014-07-29,9.8275,10.095,9.75,9.97,
DXCM,2014-07-30,10.05,10.235,9.9025,10.0275,
DXCM,2014-07-31,9.855,9.89,9.415,9.42,
DXCM,2014-08-01,9.43,9.5425,9.1325,9.3075,
DXCM,2014-08-04,9.37,9.645,9.2975,9.605,
DXCM,2014-08-05,9.565,9.8725,9.487,9.775,
DXCM,2014-08-06,9.6525,9.875,9.5375,9.5525,"[""DexCom, Inc. Reports Q2 EPS of $(0.09) vs $(0.10) Est; Revenue of $58.80M vs $52.45M Est"", ""DexCom, Inc. Reports Q2 EPS of $(0.09) vs $(0.10) Est; Revenue of $58.80M vs $52.45M Est"", ""DexCom, Inc. Reports Q2 EPS of $(0.09) vs $(0.10) Est; Revenue of $58.80M vs $52.45M Est""]"
DXCM,2014-08-07,10.06,10.995,9.955,10.8525,"[""DexCom Sees Narrower Q2 Loss; Revenues Top Estimates - Analyst Blog"", ""DexCom Sees Narrower Q2 Loss; Revenues Top Estimates - Analyst Blog"", ""DexCom Sees Narrower Q2 Loss; Revenues Top Estimates - Analyst Blog DexCom, Inc. ( DXCM ) reported a narrower loss of $7.0 million or 10 cents per share in the second quarter of 2014 compared with $10.1 million or 14 cents in the comparable quarter of 2013. The loss was in line with the Zacks Consensus Estimate. Dexcom, Inc - Earnings Surprise | FindTheBest DexCom's total revenues surged 64.2% to $58.8 million, topping the Zacks Consensus Estimate of $53.0 million. The upside was driven by a significant 63.9% rise in product revenues to $58.2 million and a 100% growth in development grant and other revenues to $0.6 million in the quarter. Expenses and Margins Product gross profit spiked 81.2% to $39.5 million while product gross margin expanded 650 basis points (bps) to 67.9% in the second quarter of 2014. Research and development (R&D) expenses rose 24.3% to $13.8 million in the quarter owing to additional payroll and consulting costs. Selling, general and administrative (SG&A) expenses went up 49.3% to $30.9 million in the quarter, driven by additional payroll costs and commissions. Despite the increase in both R&D and SG&A expenses, operating loss narrowed to $4.8 million from the year-ago level of $9.9 million. As a result, operating (loss) margin reduced significantly by 1950 bps to 8.2% from 27.7% in the second quarter of 2013. Financial Status DexCom had cash and cash equivalents of $49.5 million as of Jun 30, 2014, up 14.6% from $43.2 million as of Dec 31, 2013. Total long-term debt went down 14.7% to $5.8 million from $6.8 million as of Dec 31, 2013. Consequently, the long-term-debt-to-capitalization ratio declined 200 bps to 5.5% from 7.5% as of Dec 31, 2013. Our Take We are encouraged by DexCom's narrower loss in the second quarter as well as the revenue beat. However, the company needs to keep a check on its rising operating expenses mainly buoyed by additional payroll costs, consulting costs, commissions and share-based compensations. Nevertheless, DexCom exited the quarter with an improved financial position as indicated by a higher cash balance and reduced long-term debt. DexCom presently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the medical instruments sector include Accuray Inc. ( ARAY ), Alphatec Holdings, Inc. ( ATEC ) and RTI Surgical Inc. ( RTIX ). All these stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ALPHATEC HLDGS (ATEC): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Sees Narrower Q2 Loss; Revenues Top Estimates - Analyst Blog""]"
DXCM,2014-08-08,10.8125,11.1075,10.755,11.0625,
DXCM,2014-08-11,11.1275,11.235,10.9425,10.9625,
DXCM,2014-08-12,10.9275,10.9825,10.695,10.7225,
DXCM,2014-08-13,10.785,11.0675,10.65,10.9725,
DXCM,2014-08-14,10.9175,11.11,10.84,10.9825,"[""DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog"", ""DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog"", ""DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog Shares of CA-based glucose monitoring systems provider DexCom, Inc. ( DXCM ) have climbed nearly 14.6% since the announcement of its encouraging 2014-second quarter results last week followed by the revelation of its data integration relationship with Silicon Valley-based manufacturer of Asante Snap Insulin Pump, Asante Solutions, Inc. Dexcom collaborated with privately-held Asante to integrate insulin data from the Asante Snap Insulin Pump into its mobile app platform to facilitate simplified diabetes management. The platform provides timely and accurate data, supporting effective diabetes control for patients. DexCom's first-of-its-kind mobile app platform, designed to aggregate glucose and other diabetes-related data from patients' devices and display the integrated data on a smart phone, is currently under development. Asante Snap Insulin Pump is the second insulin delivery device to be integrated into the Dexcom mobile app, the first being Insulet Corporation's ( PODD ) OmniPod System. Notably, DexCom's mobile app platform will provide Insulet's OmniPod users a wider access to data, thus improving diabetes administration. It will also help diabetic people achieve better control on their disease. Earlier, in June, DexCom disclosed its intentions to adopt an \""open architecture\"" approach to diabetes-related data. The approach will include an \""approved by DexCom\"" indication to validate the authenticity of devices and apps integrating DexCom CGM data. DexCom posted a narrower loss of $7.0 million or 10 cents per share in the second quarter of 2014 compared with $10.1 million or 14 cents in the comparable quarter of 2013. The loss was in line with the Zacks Consensus Estimate. DexCom's total revenues escalated 64.2% to $58.8 million, topping the Zacks Consensus Estimate of $53.0 million. The upside was driven by a significant 63.9% rise in product revenues to $58.2 million and 100% growth in development grant and other revenues to $0.6 million. Moreover, DexCom exited the quarter with a higher cash balance of $49.5 million as of Jun 30, 2014, compared with $43.2 million as of Dec 31, 2013. Also, the total long-term debt went down 14.7% to $5.8 million from $6.8 million as of Dec 31, 2013. Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments sector include Alphatec Holdings, Inc. ( ATEC ) and RTI Surgical Inc. ( RTIX ) Both the stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report ALPHATEC HLDGS (ATEC): Free Stock Analysis Report INSULET CORP (PODD): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog""]"
DXCM,2014-08-15,11.0925,11.0925,10.7225,10.905,
DXCM,2014-08-18,10.975,11.105,10.875,11.1025,
DXCM,2014-08-19,11.0925,11.3625,11.0758,11.23,"DexCom Moves Up In Market Cap Rank, Passing Graham Holdings In the latest look at stocks ordered by largest market capitalization, Russell 3000 component DexCom Inc (Symbol: DXCM) was identified as having a larger market cap than the smaller end of the S&P 500, for example Graham Holdings Co. (Symbol: GHC), according to The Online Investor . Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much - that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true ""apples-to-apples"" comparison of the value of two stocks. In the case of DexCom Inc (Symbol: DXCM), the market cap is now $3.39B, versus Graham Holdings Co. (Symbol: GHC) at $3.32B. Below is a three month price history chart comparing the stock performance of DXCM vs. GHC: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which indices will include the stock, and which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and ""tosses out"" the biggest 100 companies so as to focus solely on the 400 smaller ""up-and-comers"" (which in the right environment can outperform their larger rivals). And ETFs that directly follow an index like the S&P 500 will only own the underlying component of that index, selling companies that lose their status as an S&P 500 company, and buying companies when they are added to the index. So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at TheOnlineInvestor.com find value to putting together these looks at comparative market capitalization daily. At the closing bell, DXCM is up about 1.1%, while GHC is trading flat on the day Tuesday. The 20 Largest U.S. Companies By Market Capitalization » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-08-20,11.16,11.2275,10.905,11.035,
DXCM,2014-08-21,11.05,11.0575,10.7438,10.885,
DXCM,2014-08-22,10.9025,11.2025,10.75,11.02,"[""Top Insider Sells Highlight: Dexcom Inc."", ""Top Insider Sells Highlight: Dexcom Inc."", ""Top Insider Sells Highlight: Dexcom Inc. CEO, 10% Owner of Dexcom Inc ( DXCM ) Terrance H Gregg sold 23,893 shares on 08/21/2014 at an average price of $44.36. The total transaction amount was $1,059,893. Dexcom Inc is a Delaware corporation, founded in May 1999. Dexcom Inc has a market cap of $3.29 billion; its shares were traded at around $43.60 with and P/S ratio of 15.90. Articles on GuruFocus.COM. Gregg joined the board of directors in 2005, became the president and CEO in 2007 and finally was appointed CEO in 2011. Prior to Dexcom Inc, Gregg was the president of Metronic MiniMed Inc. Dexcom Inc. announced its 2014 second quarter financial results. The Company reported revenues of $58.8 million and net loss of $6.0 million. Joel Greenblatt Undervalued Stocks Joel Greenblatt Top Growth Companies Joel Greenblatt High Yield stocks GuruFocus guru Joel Greenblatt initiated his position in Dexcom Inc. He bought 8,033 shares. Ron Baron ( Trades , Portfolio) and Mario Gabelli (Trades, Portfolio) both kept their positions in DXCM unchanged. Baron owns 1,348,572 shares and Gabelli owns 70,500 shares. Gregg sold 260,000 shares of DXCM stock in August. VP/CFO Jess Roper sold 40,000 shares of DXCM stock from April to August. director Barbara Kahn, Sr. VP. Worldwide Sales Richard Doubleday, Sr. VP/general counsel John Lister, President/COO Kevin R Sayer, and SVP, Regulatory and Clinical Andrew K Balo sold 55,553 shares of DXCM stock in August. About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members . This article first appeared on GuruFocus . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top Insider Sells Highlight: Dexcom Inc.""]"
DXCM,2014-08-25,11.195,11.195,10.885,10.9775,
DXCM,2014-08-26,10.9625,11.5925,10.9575,11.4725,
DXCM,2014-08-27,11.3975,11.53,11.2325,11.295,
DXCM,2014-08-28,11.2175,11.355,11.035,11.07,
DXCM,2014-08-29,11.005,11.2325,11.005,11.05,
DXCM,2014-09-02,11.1325,11.235,11.005,11.205,
DXCM,2014-09-03,11.155,11.1625,10.83,10.895,
DXCM,2014-09-04,10.885,10.9872,10.625,10.67,
DXCM,2014-09-05,10.6325,10.8025,10.48,10.7125,
DXCM,2014-09-08,10.67,10.8225,10.6475,10.7975,"3 Reasons Medtronic Inc. Stock Could Rise Last month, Medtronic 's first-quarter earnings topped consensus estimates on the top and bottom lines, as revenue rose 5% year over year to $4.27 billion and non-GAAP diluted earnings climbed 6% to $0.93 per share. Medtronic posted positive sales growth across all three business groups -- cardiac and vascular, restorative therapies, and diabetes -- with the diabetes group posting impressive 13% growth thanks to strong sales of the MiniMed 530G. Source: YCharts Despite those robust earnings, Medtronic stock has remained nearly unchanged since the report, so investors are likely wondering if the stock will rise or fall in the near future. In a previous article, I discussed three reasons Medtronic stock could fall . In this article, I'll highlight three reasons that it could also rise. The Covidien acquisition could lead to a higher dividend Medtronic's proposed $42.9 billion acquisition of Dublin-based Covidien will benefit the company in two ways -- a lower corporate tax bill and a much larger, $3.7 billion per year footprint across high-growth, emerging markets. However, an additional benefit could be a higher dividend. Since Medtronic is currently based in the U.S., all of its foreign profits (54% of its bottom line before taxes) must be repatriated to the U.S. before they can be used to pay dividends. That causes them to be taxed at the 35% U.S. corporate income tax rate, minus any foreign taxes already paid. If Medtronic moves to Ireland, that rate drops to 12.5%. Since Medtronic pays out nearly a third of its profits as dividends, that move would likely result in a much higher dividend for shareholders. Attracting more income investors would definitely fit into Medtronic's long-term strategy, since the company has raised its dividend for 37 consecutive years. In June, the company raised its quarterly dividend 9% to $0.305 per share, increasing its forward annual dividend yield to 2%. While that rate is definitely better than rival St. Jude Medical , which pays 1.6%, it's still significantly lower than Johnson & Johnson 's rate of 2.8%. The massive growth potential of the CGM market Medtronic's MiniMed 530G with Enlite, which the FDA approved last September, consists of a continuous glucose monitor, or CGM, which commands an insulin pump to shut off insulin delivery when glucose levels fall below a preset threshold, making it the first ""wearable artificial pancreas"" in history. This allowed Medtronic to simultaneously gain market share in the CGM and insulin pump markets. Since the MiniMed 530G's introduction, the diabetes group has posted double-digit sales gains for three consecutive quarters. MiniMed 530G. Source: Medtronic The global CGM market is expected to grow from $194.8 million in 2012 to $568.5 million by 2020, according to Allied Market Research. That growth is expected to be driven by a preference of CGMs over conventional devices and a rise in diabetes cases across the world. The MiniMed 530G could soon face competition from Johnson & Johnson and Dexcom 's Animas Vibe, which could soon be approved by the FDA. However, the CGM market has such strong growth potential that there could be plenty of room for both products as well as other competitors. Meanwhile, Medtronic's next generation MiniMed 640G, which can predictively shut off insulin before low thresholds are met, could keep it a step ahead of the competition. Competitive pressure will lead to more innovative products Competitive pressure means that Medtronic will keep launching cutting-edge devices to remain ahead of the competition. Medtronic's fierce rivalry with St. Jude Medical yielded two of the company's most innovative products -- the Reveal LINQ miniaturized implantable cardiac monitor, or ICM, and Activa ""brain pacemaker."" The Reveal LINQ is about one-third the size of a triple-A battery and about 80% smaller than comparable ICMs. The device is smaller than St. Jude's battery-size pacemaker, which the company gained through its acquisition of Nanostim last October. Both devices are leadless (they don't require wires that connect to the heart) and implanted through the femoral artery in the thigh. During Medtronic's conference call , CEO Omar Ishrak attributed the 4% growth of the cardiac rhythm and heart failure business -- a level not achieved in four years -- directly to strong demand for the Reveal LINQ. Medtronic's Activa brain pacemaker uses deep brain stimulation, DBS, to treat neurological disorders like Parkinson's disease. DBS systems helped Medtronic's neuromodulation revenue rise 11% year over year to $479 million last quarter. St. Jude is also competing against Medtronic in this field with similar DBS devices. Stronger competition in ICMs, DBS systems, and artificial pancreases should encourage Medtronic to launch innovative new devices which could generate strong sales and keep it ahead of its rivals. A Foolish final word In conclusion, Medtronic is a solid company which still has plenty of opportunities for fresh growth. A bigger dividend, a growing presence in the insulin pump and CGM market, and newer products on the horizon are just three reasons that Medtronic could still be a great long-term investment, even as the stock flirts with all-time highs. Top dividend stocks for the next decade The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now . The article 3 Reasons Medtronic Inc. Stock Could Rise originally appeared on Fool.com. Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-09-09,10.8075,10.8825,10.585,10.625,
DXCM,2014-09-10,10.66,10.905,10.635,10.825,
DXCM,2014-09-11,10.72,10.9625,10.6325,10.9225,
DXCM,2014-09-12,10.89,11.0175,10.615,10.6275,
DXCM,2014-09-15,10.65,10.65,10.1405,10.2075,
DXCM,2014-09-16,10.2,10.37,10.0908,10.2675,
DXCM,2014-09-17,10.2575,10.45,10.2093,10.39,
DXCM,2014-09-18,10.47,10.655,10.3875,10.5625,
DXCM,2014-09-19,10.605,10.62,10.3675,10.445,
DXCM,2014-09-22,10.395,10.4125,9.975,10.1125,
DXCM,2014-09-23,10.045,10.1975,9.9775,10.085,
DXCM,2014-09-24,10.13,10.4075,10.03,10.345,
DXCM,2014-09-25,10.3325,10.3325,10.0875,10.1475,
DXCM,2014-09-26,10.1725,10.2975,10.1475,10.25,
DXCM,2014-09-29,10.125,10.4175,10.03,10.3475,
DXCM,2014-09-30,10.305,10.3575,9.995,9.9975,
DXCM,2014-10-01,9.945,9.96,9.7,9.77,"DexCom Breaks Below 200-Day Moving Average - Notable for DXCM In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $38.92, changing hands as low as $38.80 per share. DexCom Inc shares are currently trading down about 2.3% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $26.68 per share, with $49.8299 as the 52 week high point - that compares with a last trade of $39.08. According to the ETF Finder at ETF Channel, DXCM makes up 2.04% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 1.9% on the day Wednesday. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-10-02,9.765,10.255,9.6925,10.1625,
DXCM,2014-10-03,10.3125,10.7325,10.295,10.6475,
DXCM,2014-10-06,10.705,10.7475,10.31,10.3125,
DXCM,2014-10-07,10.1575,10.285,10.065,10.0925,
DXCM,2014-10-08,10.085,10.5125,10.0,10.4825,
DXCM,2014-10-09,10.4725,10.63,10.1625,10.1675,
DXCM,2014-10-10,10.1,10.51,10.0725,10.125,
DXCM,2014-10-13,10.155,10.43,9.9125,10.13,
DXCM,2014-10-14,10.1375,10.42,10.1375,10.2475,
DXCM,2014-10-15,10.0825,10.4825,9.7275,10.3725,
DXCM,2014-10-16,10.2125,10.605,10.15,10.345,
DXCM,2014-10-17,10.505,10.505,10.16,10.165,
DXCM,2014-10-20,10.1375,10.5475,10.0975,10.5,"[""FDA Approves Dexcom SHARE"", ""FDA Approves Dexcom SHARE"", ""FDA Approves Dexcom SHARE""]"
DXCM,2014-10-21,10.72,11.035,10.6225,11.02,
DXCM,2014-10-22,11.0375,11.145,10.53,10.71,
DXCM,2014-10-23,10.8325,11.1325,10.7075,11.02,
DXCM,2014-10-24,11.055,11.1325,10.7875,10.8275,
DXCM,2014-10-27,10.8275,10.8275,10.6425,10.775,"Forget MannKind Corporation: 3 Better Stocks Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of our top analysts to weigh in on which companies they believe could outpace Mannkind going forward. Read on to learn what they think. Brian Orelli : MannKind and Agios have market caps a little over $2 billion, and both biotechs have large partners to help sell their drugs. But that's about where the similarities end. MannKind's Afrezza is already approved in the U.S.; Agios' drugs aren't out of phase 1 yet. Despite the early stage, which admittedly makes it risky, I think Agios has more potential. Just look at when their drugs were partnered: Sanofi licensed Afrezza after it was approved, and Celgene teamed up with Agios before its drugs were even in the clinic. The amount of money they got upfront -- $150 million for MannKind and $130 million including an equity investment for Agios -- was also fairly similar, despite the difference in development stage. Agios' drugs are designed to attack cancer in a novel way by blocking altered metabolic activity caused by mutated proteins in cancer cells. If the drugs work, it won't be hard to convince doctors to use them, because the biology is straightforward. For MannKind's Afrezza, doctors are very comfortable with the way insulin helps diabetics, but they may not be nearly as comfortable delivering it through the lungs, especially since the FDA slapped a black box warning on the drug. George Budwell : MannKind's Afrezza might go on to perform well commercially, but Novavax looks to me like the better company. Novavax is a small-cap biopharma focusing on the development of nanoparticle-based vaccines and adjuvants for a host of common diseases in need of new therapeutic options -- such as respiratory syncytial virus (RSV), seasonal and pandemic flu types, among many others. While vaccines tend to have razor-thin margins, the dearth of commercially available treatments for RSV suggests that this program could have more pricing power. Perhaps the main reason I prefer Novavax over MannKind, though, is the lead role its platform should play in the future of vaccine development in general -- which to my mind gives the company more upside than a stock which is based really around one drug. MannKind, by contrast, simply isn't in the game of developing ""breakthrough"" therapies that could influence clinical outcomes across a wide diversity of diseases. Source: Dexcom. Todd Campbell : MannKind's Afrezza is an intriguing drug, but Dexcommay be a better bet . Dexcom makes and sells the G4 Platinum, a continuous glucose monitor, or CGM, that provides diabetics with glucose levels every five minutes as well as displays the diabetics' glucose trend. Those sensors transmit data to a small device resembling a smartphone, allowing patients better insight into determining whether they should eat or take insulin. Since using Dexcom devices should reduce blood sugar highs and lows, Dexcom could play a big role in slowing disease progression to more life-threatening conditions, such as heart disease. Demand for Dexcom systems is growing quickly, with second-quarter sales jumping 64% to $58 million, and that's driving sales of Dexcom's high-margin disposable sensors. Rising sensor sales helped profit the company's gross margin climb from 66% exiting 2013 to 68% in Q2 (up from 61% last year). According to analysts, margin expansion will help Dexcom turn profitable next year, and if so, investors may find Dexcom's $3 billion market cap is too small relative to its total addressable market. According to research conducted by the University of Chicago, the number of diabetics in the U.S. is expected to double to 44 million people over the next 20 years. This coming blockbuster will make every biotech jealous The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW . The article Forget MannKind Corporation: 3 Better Stocks originally appeared on Fool.com. Brian and George don't have positions in the companies mentioned. Todd is long Celgene.The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-10-28,10.8125,11.1325,10.795,11.04,
DXCM,2014-10-29,11.0675,11.215,11.0363,11.125,
DXCM,2014-10-30,11.0975,11.375,10.9875,11.1925,
DXCM,2014-10-31,11.5,11.56,11.23,11.2375,
DXCM,2014-11-03,11.2875,11.2875,10.9625,10.99,
DXCM,2014-11-04,11.0725,11.35,11.025,11.12,
DXCM,2014-11-05,11.25,11.2925,10.9725,11.0,
DXCM,2014-11-06,10.865,11.1925,10.8625,11.1575,"[""FDA Approves Dexcom Software With Artificial Pancreas Algorithm"", ""FDA Approves Dexcom Software With Artificial Pancreas Algorithm"", ""FDA Approves Dexcom Software With Artificial Pancreas Algorithm""]"
DXCM,2014-11-07,11.6975,13.02,11.6525,12.7325,"[""Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog"", ""Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape"", ""Midday Gainers From November 7: Channel Advisor, Eaton Vance, Envestnet, Interval Leisure, DexCom"", ""Dexcom Registers 89.3K Shares For Sale"", ""Dexcom Registers 89.3K Shares For Sale"", ""Midday Gainers From November 7: Channel Advisor, Eaton Vance, Envestnet, Interval Leisure, DexCom"", ""Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog"", ""Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape"", ""Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape Foundation Medicine, Inc. ( FMI ) saw a big move last session, as the company's shares fell by nearly 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for FMI as the stock is now up around 30% in the past one-month time frame. The molecular information products provider has seen a flat track record when it comes to current year estimate revisions over the past few weeks (0 increases, 0 decreases), and the consensus for loss hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump. FMI currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical sector include AngioDynamics Inc. ( ANGO ), ABIOMED, Inc. ( ABMD ) and DexCom, Inc. ( DXCM ). While AngioDynamics sports a Zacks Rank #1 (Strong Buy), ABIOMED and DexCom carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FOUNDATION MED (FMI): Free Stock Analysis Report ANGIODYNAMICS (ANGO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog Hologic Inc. ( HOLX ) reported fourth-quarter fiscal 2014 adjusted earnings of 43 cents per share, up 10.3% from the year-ago equivalent of 39 cents. Moreover, adjusted earnings surpassed the Zacks Consensus Estimate of 37 cents by a solid 16.2% and also steered ahead of the company's guidance range of 36\u221237 cents. Year-over-year top line improvement coupled with an encouraging operational performance contributed to this better-than-anticipated bottom-line growth. On a reported basis, the company recorded net income of $28.2 million or 10 cents per share, registering a massive improvement over the net loss of $1,113.9 million or $4.11 per share reported in the prior-year quarter. Full-year adjusted net income was $419.7 million or $1.51 per share, reflecting an improvement of 3.2% or 0.7% over the year-ago net income of $406.5 million or $1.50 per share. Hologic, Inc - Earnings Surprise | FindTheBest Revenues in Detail Revenues were $660.6 million in the quarter, up 6.2% year over year. The top line also exceeded the Zacks Consensus Estimate of $636 million by 3.9% as well as the company's guidance range of $630\u2212$640 million. During the fourth quarter, Hologic entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic. Excluding this one-time revenue benefit, Hologic's fourth-quarter revenues rose 2.8% on a constant currency basis to $640 million. Year over year improvement in Hologic's top line growth was driven by revenue growth across all its four segments in the reported quarter . For full-year 2014, Hologic's revenues came in at $2.53 billion, reflecting an improvement of 0.7% from the year-ago adjusted revenues of $2.51 billion (adjustment primarily related to blood screening collaboration). Full year revenues also exceeded the company's guided range of $2.50\u2212$2.51 billion. Segments in Detail Revenues in the Diagnostic segment (46.4% of total revenue) rose 2.4% year over year to $293.1 million (excluding the one time revenue benefit of $20.1 million) in the quarter. The revenue growth was primarily driven by an increase in the company's molecular diagnostics franchise and blood screening franchise, owing to the Japanese Red Cross deal. However, a consistent decline in U.S. ThinPrep pap test sales on account of interval expansion, partially offset these improvements. Breast Health segment (37.7%) improved 3.1% year over year to $241.5 million. Revenue improvement was driven by strong growth in 3D mammography system sales, as well as service revenue growth from the growing installed base of digital mammography systems. However, the sales decline of 2D mammography systems, as transition of customers to Hologic's 3D systems continued (as Hologic expected), partially neutralized this improvement. The GYN Surgical business (12.3%) recorded revenues of $78.5 million, up 2.3% from the comparable prior-year period. This increase was owing to strong growth in global MyoSure system sales, partially neutralized by declines observed in U.S. NovaSure system sales. Revenues from Skeletal Health (3.7%) increased 10.4% year over year to $23.4 million, owing to growing sales of Hologic's new Horizon platform and to a lesser extent, an increase in sales of mini C-arm system sales. Operational Update Hologic's gross margin was 52.2% in the reported quarter, up 550 basis points (bps) year over year from the year-ago equivalent tally of 46.7%. The margin expansion was primarily driven by favorable product revenue mix. In the reported quarter, adjusted operating expenses amounted to $204.1 million, up 17.6% year over year. Hologic's adjusted operating margin in the fourth quarter came in at 24%, reflecting an expansion of 550 bps year over year, owing to better-than-expected top line growth. Financial Update Hologic exited the quarter with cash and cash equivalents of $741.6 million compared with $829.4 million at the end of fiscal 2013. Total long-term debt (net of current portion) as on Sep 27, 2014 was $4.15 billion, down 2.1% year over year. Guidance Hologic provided its business outlook for fiscal 2015. The company expects revenue growth (excluding the impact of foreign currency) of approximately 2% to 3.5% over fiscal 2014, in the coming fiscal. Including an expected 1% negative impact from foreign currency, Hologic expects reported growth of approximately 1% to 2.5%, resulting in reported revenues in the range of $2.54 billion to $2.57 billion. The current Zacks Consensus Estimate for revenues for fiscal 2015 is pegged at $2.56 billion, which lies within the guidance range. Hologic expects adjusted EPS in the range of $1.50 to $1.54, reflecting year-over-year growth of 3%-5.5%. The current Zacks Consensus Estimate for adjusted EPS is pegged at $1.53, which lies within the guidance range. For first-quarter fiscal 2015, Hologic expects year-over-year revenue growth, excluding the impact of foreign currency, of approximately 3% to 4.5%. Including an expected 1% negative impact from foreign currency, the company expects reported revenue of $625 million-$635 million (growth of approximately 2% to 3.5%). Adjusted EPS is expected in the range of 35-36 cents (year-over-year growth of approximately 3% to 6%). The current Zacks Consensus Estimate for revenues and EPS are pegged at $631 million and 37 cents, respectively. Our Take Hologic's impressive performance in the fiscal fourth-quarter surpassed expectations on both the earnings and revenue fronts. In the reported quarter, all of Hologic's four business segments delivered positive growth for the first time. Management expects this progressive momentum of Hologic to continue over the long term as well. Recently, CMS has increased the reimbursement rates for Hologic's 3D mammography screening and diagnostic services. Per management, this will not only elevate Hologic's financial position but will also expand patient accessibility for this advanced technology, in the long run. We believe Hologic will be able to achieve its near-term as well as long-term goals, banking on an efficient management team coupled with high-tech diagnostic products. Currently, Hologic carries a Zacks Rank #3 (Hold). Some well-ranked stocks in the medical instruments industry are AngioDynamics Inc. ( ANGO ), ABIOMED, Inc. ( ABMD ) and DexCom, Inc. ( DXCM ). While AngioDynamics sports a Zacks Rank #1 (Strong Buy), ABIOMED and DexCom carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HOLOGIC INC (HOLX): Free Stock Analysis Report ANGIODYNAMICS (ANGO): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Registers 89.3K Shares For Sale"", ""Midday Gainers From November 7: Channel Advisor, Eaton Vance, Envestnet, Interval Leisure, DexCom"", ""Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog"", ""Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape""]"
DXCM,2014-11-10,12.6975,13.375,12.5175,13.375,"[""Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape"", ""DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog"", ""DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog"", ""Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape"", ""DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog DexCom, Inc. ( DXCM ) recently revealed the U.S. Food and Drug Administration (FDA) approval for a new algorithm designed for its G4 PLATINUM Continuous Glucose Monitoring (CGM) system. Following the announcement, shares of DexCom shot up nearly 14.12% to close at $50.93 in the last trading session. This latest software enhancement to DexCom G4 Platinum will make the performance level of blood glucose monitoring comparable to finger stick meters, the traditional standard-of-care for the same. With this new technology, the G4 Platinum system approaches a MARD (Mean Absolute Relative Difference) measurement of 9%, making it the first and only CGM system in the market with a single-digit MARD. The new algorithm will be made available free of charge to existing adult patients using G4 Platinum and will be preloaded onto the new DexCom receivers. The combination of the latest software with CGM advantages of real-time trends, speed and direction, will allow healthcare providers, patients and caregivers to have a complete picture of the patient's glucose activity. Management is extremely optimistic with regard to the new algorithm for the G4 Platinum system, which according to them, represents a significant potential to support the company's ultimate goal of replacing finger-sticks altogether. In fact, since its launch in Oct 2012, the G4 Platinum CGM system has been driving superior product revenue growth at DexCom. Notably, DexCom's average year over year quarterly revenue growth has been approximately 63% since the launch. The recently reported third-quarter 2014 also saw a significant 60% rise in product revenues, on the back of continued growth in the installed base of customers using the G4 Platinum system. Other highlights of the quarter are provided below. Third-Quarter Results DexCom reported a loss of 8 cents per share in the third-quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 5 cents. However, losses during the quarter remained flat on a year-over-year basis. DexCom's total revenue surged 60.8% to $69 million, topping the Zacks Consensus Estimate of $61 million. The upside was driven by an impressive 60% rise in product revenues to $68 million and a $0.7 million increase in development grant and other revenues to $1.1 million. Gross margin expanded 450 basis points year over year to 69.5%, primarily due to increased revenue and greater sales of the high margin G4 Platinum system. Both selling, general and administrative (SG&A) and research and development (R&D) expenses rose 56% and 56.8% year over year, respectively, owing to higher cost of sales, increased marketing expenses, additional payroll and consulting costs and other key expenses for commercial infrastructure. Despite the increase in both R&D and SG&A expenses, operating loss narrowed to $5 million from the year-ago level of $5.8 million, riding on strong revenue growth and higher gross margin base. DexCom had cash and cash equivalents of $63.2 million as of Sep 31, 2014, higher than $49.5 million as of Jun 30, 2014. Total long-term debt went down to $5.2 million from $5.8 million as of Jun 30, 2014. Our Take We are encouraged with DexCom's revenue beat and narrower operating losses in the third quarter. DexCom also boasts a robust product pipeline with the recent launch of DexCom SHARE - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM System. However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. Currently, DexCom carries a Zacks Rank #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape DexCom, Inc . ( DXCM ) was a big mover last session, as the company saw its shares rise over 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock has gained over 21% in the past one-month time frame. This developer of continuous glucose monitoring systems has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in trend either. Friday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future. Dexcom currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. Better-ranked stocks worth considering in the Med-Instruments industry include AngioDynamics Inc. ( ANGO ), ABIOMED, Inc. ( ABMD ) and Edwards Lifesciences Corp. ( EW ). While AngioDynamics sports a Zacks Rank #1 (Strong Buy), ABIOMED and Edwards Lifesciences carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report ANGIODYNAMICS (ANGO): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog"", ""Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape""]"
DXCM,2014-11-11,13.27,13.5,13.125,13.285,"[""DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog"", ""DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog"", ""DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog Shares of DexCom, Inc. ( DXCM ) closed at a new 52-week high of $53.50 on Nov 10, translating into a solid one-year return of roughly 62%. In fact, shares of this CA-based glucose monitoring systems provider have been on the rise since the beginning of this year, posting an impressive year-to-date return of around 51%. DexCom has a market cap of around $4 billion while average volume of shares traded over the last three months stands at roughly 0.6 million. Catalysts for Growth Impressive third-quarter 2014 results indicating double-digit top-line growth, a string of U.S. Food and Drug Administration (FDA) approvals for its new products over the last few months along with a robust product pipeline contribute to the growth trajectory of this company, creating good momentum for 2015 as well. This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%. With this new technology, the G4 Platinum system approaches a MARD (Mean Absolute Relative Difference) measurement of 9%, making it the first and only CGM system in the market with a single-digit MARD. Last month, the FDA cleared DexCom's CGM remote mobile communications device - DexCom SHARE, which enables wireless transmission of a patient's glucose information to the G4 Platinum receiver. Following the approval, DexCom launched the device, making significant advances toward extending CGM to mobile devices. In the recently reported third-quarter 2014, the company's losses remained flat on a year-over-year- basis. Revenues, on the other hand, surged 60.8% driven by continued growth in the installed base of customers using the G4 Platinum system. Gross margins also expanded primarily due to greater sales of the high margin G4 Platinum system. Higher gross margin base, along with strong revenue growth further led to narrower operating losses in the quarter. Going forward, DexCom expects to drive greater sales volume and improved margins as it makes significant investments and launches new products. It is extremely optimistic with regard to its G4 Platinum system which has been driving superior product revenue growth. However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. Currently, DexCom carries a Zacks Rank #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog""]"
DXCM,2014-11-12,13.175,13.5425,13.1625,13.5025,
DXCM,2014-11-13,13.375,13.625,13.34,13.4075,
DXCM,2014-11-14,13.35,13.405,13.0625,13.1825,
DXCM,2014-11-17,13.195,13.27,12.9175,12.935,
DXCM,2014-11-18,12.8925,13.15,12.87,12.8975,"DexCom Larger Than S&P 500 Component Bemis In the latest look at stocks ordered by largest market capitalization, Russell 3000 component DexCom Inc (Symbol: DXCM) was identified as having a larger market cap than the smaller end of the S&P 500, for example Bemis Co Inc (Symbol: BMS), according to The Online Investor . Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much - that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true ""apples-to-apples"" comparison of the value of two stocks. In the case of DexCom Inc (Symbol: DXCM), the market cap is now $3.95B, versus Bemis Co Inc (Symbol: BMS) at $3.90B. Below is a three month price history chart comparing the stock performance of DXCM vs. BMS: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which indices will include the stock, and which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and ""tosses out"" the biggest 100 companies so as to focus solely on the 400 smaller ""up-and-comers"" (which in the right environment can outperform their larger rivals). And ETFs that directly follow an index like the S&P 500 will only own the underlying component of that index, selling companies that lose their status as an S&P 500 company, and buying companies when they are added to the index. So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at TheOnlineInvestor.com find value to putting together these looks at comparative market capitalization daily. At the closing bell, DXCM is down about 0.3%, while BMS is trading flat on the day Tuesday. The 20 Largest U.S. Companies By Market Capitalization » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2014-11-19,12.89,12.9355,12.6075,12.62,
DXCM,2014-11-20,12.5825,12.775,12.525,12.7125,
DXCM,2014-11-21,12.93,12.93,12.46,12.5925,
DXCM,2014-11-24,12.6025,12.815,12.515,12.795,
DXCM,2014-11-25,12.8525,12.95,12.6075,12.6775,
DXCM,2014-11-26,12.7075,12.885,12.6575,12.8375,
DXCM,2014-11-28,13.0425,13.06,12.8375,12.865,
DXCM,2014-12-01,12.7475,13.0,12.635,12.825,
DXCM,2014-12-02,12.8525,13.37,12.85,13.3625,
DXCM,2014-12-03,13.3625,13.7875,13.2925,13.625,
DXCM,2014-12-04,13.5775,13.7725,13.475,13.6475,
DXCM,2014-12-05,13.6375,13.925,13.62,13.8275,
DXCM,2014-12-08,13.84,14.15,13.6675,14.015,"[""Cowen & Company Initiates Coverage on DexCom, Inc. at Outperform, Announces $65.00 PT"", ""Cowen & Company Initiates Coverage on DexCom, Inc. at Outperform, Announces $65.00 PT"", ""Cowen & Company Initiates Coverage on DexCom, Inc. at Outperform, Announces $65.00 PT""]"
DXCM,2014-12-09,13.87,14.58,13.8675,14.575,
DXCM,2014-12-10,14.535,14.5375,13.875,13.885,
DXCM,2014-12-11,13.915,13.985,13.525,13.5825,
DXCM,2014-12-12,13.4075,13.6575,13.2525,13.415,
DXCM,2014-12-15,13.43,13.5475,13.1,13.2125,
DXCM,2014-12-16,13.2675,13.56,13.1502,13.315,
DXCM,2014-12-17,13.435,13.96,13.27,13.935,
DXCM,2014-12-18,14.1525,14.22,13.955,14.2125,
DXCM,2014-12-19,14.23,14.3,14.0688,14.1375,
DXCM,2014-12-22,14.1925,14.195,14.025,14.11,
DXCM,2014-12-23,14.1825,14.225,13.38,13.4875,
DXCM,2014-12-24,13.5775,13.875,13.49,13.735,
DXCM,2014-12-26,13.7675,13.9,13.675,13.7875,
DXCM,2014-12-29,13.98,14.17,13.86,14.0325,
DXCM,2014-12-30,13.945,14.0538,13.6912,13.8,
DXCM,2014-12-31,13.84,14.095,13.7425,13.7625,"IWO, GPK, ULTI, DXCM: Large Inflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected an approximate $93.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 46,550,000 to 47,200,000). Among the largest underlying components of IWO, in trading today Graphic Packaging Holding Co (Symbol: GPK) is down about 0.2%, Ultimate Software Group, Inc. (Symbol: ULTI) is trading flat, and DexCom Inc (Symbol: DXCM) is higher by about 1.2%. For a complete list of holdings, visit the IWO Holdings page » The chart below shows the one year price performance of IWO, versus its 200 day moving average: Looking at the chart above, IWO's low point in its 52 week range is $120.67 per share, with $144.60 as the 52 week high point - that compares with a last trade of $144.04. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-01-02,13.905,14.1525,13.555,13.6275,
DXCM,2015-01-05,13.5225,14.02,13.5225,13.865,"[""New chief at DexCom"", ""DexCom Inc Names Kevin Sayer As President, CEO; Terry Gregg Assumes Role Of Executive Chairman"", ""DexCom Inc Names Kevin Sayer As President, CEO; Terry Gregg Assumes Role Of Executive Chairman"", ""New chief at DexCom"", ""DexCom Inc Names Kevin Sayer As President, CEO; Terry Gregg Assumes Role Of Executive Chairman"", ""New chief at DexCom""]"
DXCM,2015-01-06,13.8,13.9475,13.475,13.5525,"[""Sterne Agee Downgrades DexCom to Neutral, Removes $56.00 PT"", ""Sterne Agee Downgrades DexCom to Neutral, Removes $56.00 PT"", ""Sterne Agee Downgrades DexCom to Neutral, Removes $56.00 PT""]"
DXCM,2015-01-07,13.6575,13.9025,13.325,13.9,
DXCM,2015-01-08,14.06,14.6575,13.9,14.5925,
DXCM,2015-01-09,14.6325,14.7335,14.3575,14.5475,
DXCM,2015-01-12,14.6075,14.87,14.605,14.7575,
DXCM,2015-01-13,15.1275,15.7125,14.7875,14.9975,"[""DexCom reports preliminary revenue and provides outlook for 2015"", ""From 8-K: DexCom Sees FY2014 Sales $257.0M vs $250.0M Est"", ""From 8-K: DexCom Sees FY2014 Sales $257.0M vs $250.0M Est"", ""DexCom reports preliminary revenue and provides outlook for 2015"", ""From 8-K: DexCom Sees FY2014 Sales $257.0M vs $250.0M Est"", ""DexCom reports preliminary revenue and provides outlook for 2015""]"
DXCM,2015-01-14,14.875,15.1338,14.7,14.785,"[""DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog"", ""DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog"", ""DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog Developer of continuous glucose monitoring systems, DexCom Inc. ( DXCM ), recently announced preliminary product revenues for fourth quarter and full year 2014. DexCom anticipates fourth quarter product revenues to surge an impressive 64% on a year-over-year basis to $84 million. The stated figure is higher than the current Zacks Consensus Estimate which is pegged at $82 million. Notably, product revenues have grown over 60% on a year-over-year basis for six consecutive quarters. The company's average year-over-year quarterly revenue growth has been 65% since the launch of G4 PLATINUM. For 2014, revenues are estimated to soar 64% on a year-over-year basis to $257 million, in line with the current Zacks Consensus Estimate. According to DexCom's estimates, the company's patient base in the U.S. grew by more than 50% in 2014. DexCom is riding high on the back of a number of FDA approvals as well as a robust pipeline. DexCom has received clearances from the FDA for G4 Platinum Continuous Glucose Monitoring (CGM) system and the CGM remote mobile communications device - DexCom SHARE. The company also remains focused on introducing a steady stream of innovative products related to its sensor technology. DexCom's revenues have been outperforming the Zacks Consensus Estimate for quite some time now and going by the preliminary estimations, we hope to see another beat. For 2015, DexCom expects product revenues in the range of $340-$360 million. The current Zacks Consensus Estimate for the year is pegged at $350 million, which lies within the company's guidance range. We believe DexCom will continue to generate significant top-line growth on the back of strong performance by G4 Platinum coupled with innovative product launches. Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. Currently, DexCom carries a Zacks Rank #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog""]"
DXCM,2015-01-15,14.8625,14.905,14.2325,14.355,"Some of the Nasdaq’s leading lights have begun to dim The action in the Nasdaq overall has not been good for speculators, and the action in some of the leading speculative stocks has been highly questionable, making a large cash position perhaps the best way to go for now."
DXCM,2015-01-16,14.33,14.759,14.14,14.7425,
DXCM,2015-01-20,14.8,14.8125,14.16,14.375,
DXCM,2015-01-21,14.2875,14.4575,13.9875,14.06,
DXCM,2015-01-22,14.2025,14.5275,13.9825,14.5275,
DXCM,2015-01-23,14.365,14.69,14.2825,14.485,"[""Dexcom OK to market glucose monitoring app"", ""'FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring'"", ""'FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring'"", ""Dexcom OK to market glucose monitoring app"", ""'FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring'"", ""Dexcom OK to market glucose monitoring app""]"
DXCM,2015-01-26,14.7425,15.7025,14.645,15.695,"[""FDA clears DexCom glucose monitoring system receiver"", ""Cell MedX Takes Another Step Forward (TNDM, CMXC, DXCM)"", ""Cell MedX Takes Another Step Forward (TNDM, CMXC, DXCM)"", ""FDA clears DexCom glucose monitoring system receiver"", ""Cell MedX Takes Another Step Forward (TNDM, CMXC, DXCM)"", ""FDA clears DexCom glucose monitoring system receiver""]"
DXCM,2015-01-27,15.5675,15.89,15.455,15.58,"[""Dexcom's Smart Glucose Monitoring System Receives FDA Approval"", ""DexCom: More Good News For Diabetes Patients And Shareholders"", ""DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape"", ""Dexcom's Smart Glucose Monitoring System Receives FDA Approval"", ""DexCom: More Good News For Diabetes Patients And Shareholders"", ""DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape"", ""DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape DexCom, Inc. ( DXCM ) was a big mover last session, as the company saw its shares rise over 8% on the day. The upside was owing to the receipt of the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share. This development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $54.21 to $59.99. This developer of continuous glucose monitoring systems has witnessed two positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday's rally can turn into more strength down the road. Dexcom currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive. A better-ranked stock in the Med-Instruments industry is ABIOMED, Inc. ( ABMD ) which carries a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom's Smart Glucose Monitoring System Receives FDA Approval"", ""DexCom: More Good News For Diabetes Patients And Shareholders"", ""DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape""]"
DXCM,2015-01-28,15.72,15.8575,15.09,15.1475,"[""FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog"", ""Dexcom's Smart Glucose Monitoring System Receives FDA Approval"", ""FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog"", ""Dexcom's Smart Glucose Monitoring System Receives FDA Approval"", ""FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog Developer of continuous glucose monitoring systems, DexCom, Inc. ( DXCM ), recently received the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses a secure wireless connection between a patient's receiver and an app on the patient's smartphone. With the help of this connection, which will be established via Bluetooth Low Energy (BLE), the receiver will be able to transfer glucose information to apps on the mobile devices of up to five recipients. The recipients, or followers, can then supervise a patient's glucose information and get alert notifications from anywhere via their Apple ( AAPL ) iPhone or iPod touch. The \""Share\"" and \""Follower\"" apps will be available on the Apple App Store at no additional charge. The company plans to extend this service to the Android platform as well. DexCom is riding high on the back of a number of FDA approvals received over the past few months. In Nov 2014, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring system. Prior to that, DexCom Share was cleared by the regulator in Oct 2014. We view that the company is making significant progress in extending Continuous Glucose Monitoring to mobile devices, in a bid to enhance customer convenience. We feel these approvals will benefit DexCom's long-term prospects. Once the approved products are rolled out in the market, these will help drive significant top-line growth. Notably, DexCom announced preliminary product revenues for fourth quarter and full year 2014. DexCom anticipates fourth quarter product revenues to surge an impressive 64% on a year-over-year basis to $84 million. Zacks Rank Currently, DexCom retains a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include Inogen ( INGN ), Synergetics USA ( SURG ). Both sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report INOGEN INC (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog"", ""Dexcom's Smart Glucose Monitoring System Receives FDA Approval""]"
DXCM,2015-01-29,15.15,15.25,14.85,15.25,"[""Engineering Probiotics to Treat Diabetes and Other Diabetes Stock News (CRTOF, ASND, DXCM & CMXC)"", ""Engineering Probiotics to Treat Diabetes and Other Diabetes Stock News (CRTOF, ASND, DXCM & CMXC)"", ""Engineering Probiotics to Treat Diabetes and Other Diabetes Stock News (CRTOF, ASND, DXCM & CMXC)"", ""FDA gives investors another reason to like DexCom Already a leader in the glucose-monitoring space, the FDA recently approved one of the company\u2019s devices which should help propel shares higher, even after a fantastic 2014.""]"
DXCM,2015-01-30,15.1225,15.3375,14.92,14.945,
DXCM,2015-02-02,15.0,15.3575,14.975,15.3275,
DXCM,2015-02-03,15.335,15.46,14.985,15.305,"[""Oil Is In Recovery Mode - Cramer's Mad Money (2/2/15)"", ""Oil Is In Recovery Mode - Cramer's Mad Money (2/2/15)"", ""Oil Is In Recovery Mode - Cramer's Mad Money (2/2/15)""]"
DXCM,2015-02-04,15.2525,15.45,15.1325,15.2475,
DXCM,2015-02-05,15.3175,15.515,15.2175,15.5038,
DXCM,2015-02-06,15.58,15.9125,15.4075,15.62,
DXCM,2015-02-09,15.61,15.8125,15.1875,15.3975,"[""Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog"", ""3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP"", ""Good News For Apple Watch: FDA Steps Back From App Regulation"", ""Good News For Apple Watch: FDA Steps Back From App Regulation"", ""3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP"", ""Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog"", ""Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog CVS Health Corporation ( CVS ) - formerly known as CVS Caremark - is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10. Last quarter, the company had posted a positive earnings surprise of 0.88% while the four-quarter trailing average beat is pegged at 0.41%. Let's see how things are shaping up prior to this announcement. Factors at Play Barring an unimpressive first quarter of 2014, CVS Health delivered two successive quarters of earnings and revenue beat in 2014. However, this being the first quarter that will see the full financial effect of the company's decision to exit the tobacco category, CVS expects profit growth in the fourth quarter to be somewhat lower than the sequentially previous numbers. However, we are encouraged that based on 15 successful selling seasons; the company has invested incrementally in the next season to ensure a successful migration of new customers. Over the quarters, the Pharmacy Services segment has been positively impacted by growth in specialty pharmacy and favorable purchasing economics while the Retail Pharmacy segment has benefited from increased sales and an improved margin rate, partially offset by incremental store operating costs associated with operating more number of stores. In the fourth quarter, within the retail segment, CVS expects revenues to be up 0.25% to 1.75% year over year. Adjusted script comps are expected to increase in the range of 3.5% to 4.5% while total same store sales growth are projected to remain in the range of negative 1% to positive 0.5%. The company expects front store same store sales to reflect a negative impact of approximately 900 basis points relative to the tobacco exit in the fourth quarter. On the bright side, the company expects expansion in retail gross margins in the fourth quarter driven by better purchasing economics which includes the quarterly payment from Cardinal Health as well as the exit from the tobacco business. In the PBM segment, the company expects revenues to increase 16.75% to 18.25% with adjusted claims to remain between 270 million and 275 million. However, the company expects a significant decline in PBM gross margins during the fourth quarter due to price compression and drug mix. Earnings Whispers? Our proven model does not conclusively show that CVS Health is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. That is, however, not the case here as you will see below. Zacks ESP: CVS Health's earnings ESP is 0.00%, as both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.21. Zacks Rank: CVS Caremark has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. However, a 0.00% ESP makes surprise prediction difficult. Note that we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26. Actavis plc ( ACT ) has an earnings ESP of +4.38% and carries a Zacks Rank #2. Actavis is scheduled to report fourth-quarter earnings on Feb 18. DexCom, Inc. ( DXCM ) has an earnings ESP of +100% and retains a Zacks Rank #3 (Hold). DexCom is expected to report fourth-quarter earnings on Feb 19. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP 2015 is forecasted to be a transition year for the medical instruments sector. Healthcare providers are expected to spend more on the backdrop of an improving U.S. economy, which will eventually drive top-line growth. Additionally, the recent legislation to repeal a much debated 2.3% federal excise tax under Obamacare is good news for these companies, as it will improve their bottom line. However, to date, the Oct-Dec quarter results failed to show any significant improvement for these companies. Meanwhile, the overall earnings trend shows that a strong dollar is negatively impacting profitability. Most of the companies (particularly with International exposure) are expected to revise down their 2015 guidance due to unfavourable foreign exchange. Also, capital spending from hospitals and other medical centers are yet to show significant improvement that will offset this currency headwind. In fact, the revenue trend reflects that healthcare providers are pretty reluctant in making big ticket instrument purchases, primarily owing to reimbursement uncertainties. Despite the uncertainty currently looming over the medical instrument space, it might be a good idea to bet on a handful of stocks that are likely to beat earnings estimates this quarter. An earnings beat will naturally translate into rapid price appreciation for these stocks. How to Choose the Right Stock? With the existence of a number of industry players, finding the right stocks that have the potential to beat earnings estimates could pose a difficult task. Our proprietary methodology, however, makes it fairly simple for you. You could narrow down the list of choices by looking at stocks that have the combination of a favourable Zacks Rank - Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - and a positive Earnings ESP . Earnings ESP is our proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate. Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%. 3 Stocks Set to Beat Earnings Given below are three medical instrument providers that have the right combination of elements to post an earnings beat this quarter: DexCom Inc ( DXCM ) - The stock currently carries a Zacks Rank #3 and has an earnings ESP of +100%. This developer of continuous glucose monitoring systems recently reported preliminary product revenues for fourth-quarter 2014, which stands higher than the Zacks Consensus Estimate. DexCom anticipates fourth-quarter product revenues to surge an impressive 64% on a year-over-year basis to $84 million. The company is riding high on the back of a number of FDA approvals as well as a robust pipeline. DexCom has received clearances from the FDA for G4 Platinum Continuous Glucose Monitoring (CGM) system and the CGM remote mobile communications device - DexCom SHARE. The company also remains focused on introducing a steady stream of innovative products related to its sensor technology. GenMark Diagnostics ( GNMK ) is yet another Zacks Rank #3 stock that has an earnings ESP of +10.71%. This provider of automated, multiplex molecular diagnostic testing systems recently announced preliminary fourth-quarter results. The company anticipates revenues of $9.8 million, which highlights a 52% rise from the year-ago quarter figure. During the quarter, the company installed 38 XT-8 analyzers, which brought the total installed base to 540 analyzers within the U.S. market. GenMark also completed the development stage of the ePlex sample-to-answer system in the quarter. It expects to launch ePlex in Europe sometime around the middle of the year. The company plans to file for 510(k) approval with the FDA in the second half of the year. GenMark is set to report its fourth-quarter fiscal 2015 financial results on Feb 24. Tandem Diabetes Care ( TNDM ) has a Zacks Rank #3 with an earnings ESP of +2.47%. This manufacturer of t:slim insulin pumps recently gained FDA approval to market t:flex Insulin Pump. At 480 units, t:flex's insulin reservoir has the largest capacity currently available in the U.S. The large capacity of the new pump will help the company to address the needs of teenagers with type 1 diabetes and many with type 2 diabetes. We believe that Tandem's diabetes management product portfolio keeps it well positioned to gain from rising diabetic population worldwide. Conclusion Despite currency volatility and sluggish spending environment, we believe that rising demand for better healthcare at affordable cost will be a key growth driver for medical instrument suppliers in 2015. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report TANDEM DIABETES (TNDM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Good News For Apple Watch: FDA Steps Back From App Regulation"", ""3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP"", ""Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog""]"
DXCM,2015-02-10,15.5775,15.7,15.1725,15.6725,
DXCM,2015-02-11,15.6775,15.995,15.6,15.8475,
DXCM,2015-02-12,15.9475,15.9925,15.4475,15.485,
DXCM,2015-02-13,15.53,15.7675,15.47,15.67,
DXCM,2015-02-17,15.7825,15.7825,15.35,15.6025,
DXCM,2015-02-18,15.5,15.67,15.325,15.6525,"[""Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape"", ""Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape"", ""Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape Investors are always looking for stocks that are poised to beat at earnings season and DexCom, Inc. ( DXCM ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because DXCM is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings-with the most up-to-date information possible-is a pretty good indicator of some favorable trends underneath the surface for DXCM in this report. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 1 cent per share for DXCM, compared to a broader Zacks Consensus Estimate, which is at a loss of 3 cents per share. This suggests that analysts have very recently bumped up their estimates for DXCM, giving the stock a Zacks Earnings ESP of 66.67% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ). Given that DXCM has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for DexCom, and that a beat might be in the cards for the upcoming report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is a Surprise Coming for DexCom (DXCM) This Earnings Season? - Tale of the Tape""]"
DXCM,2015-02-19,15.64,15.8425,15.5775,15.76,
DXCM,2015-02-20,15.785,16.11,15.58,16.105,"[""Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms"", ""Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms"", ""Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms""]"
DXCM,2015-02-23,16.16,16.16,15.6925,15.8825,"[""Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog"", ""Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog"", ""Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog We expect DexCom Inc. ( DXCM ) to post a narrower-than-expected loss figure when it reports fourth quarter and full year 2014 results on Feb 25. However, in the last quarter, the company's loss of 8 cents per share was wider than the Zacks Consensus Estimate by 3 cents. Let's see how things are shaping up for this announcement. What is Driving the Better-than-Expected Earnings? Last month, DexCom announced its preliminary fourth-quarter 2014 results. The company anticipates product revenues to surge an impressive 64% on a year-over-year basis to $84 million. DexCom is riding high on the back of a number of FDA approvals as well as a robust product pipeline. Meanwhile, the company has received clearances from the FDA for G4 Platinum Continuous Glucose Monitoring (CGM) system and the CGM remote mobile communications device - DexCom SHARE. DexCom is also focused on introducing a steady stream of innovative products related to its sensor technology. We believe DexCom will generate significant top-line growth on the back of strong performance by the G4 Platinum system coupled with other innovative product launches. Why a Likely Positive Surprise? Our proven model shows that DexCom is likely to post narrower loss because it has the right combination of two key ingredients. Zacks ESP : DexCom's Earnings ESP stands at +66.67%. This is because the company's Most Accurate estimate stands at a loss of a penny, whereas the Zacks Consensus Estimate is pegged at a loss of 3 cents. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive surprise. Zacks Rank : DexCom currently has a Zacks Rank #3 (Hold). Note that stocks with Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings estimates. Conversely, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement. The combination of DexCom's Zacks Rank #3 and +66.67% ESP makes us reasonably confident of the company surpassing estimates this quarter. Other Stocks to Consider Here are some other companies you may want to consider as our model shows these have the right combination of elements to post an earnings beat this quarter: Impax Laboratories ( IPXL ) has an earnings ESP of +27.27% and a Zacks Rank #1. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Hyperion Therapeutics ( HPTX ) has an earnings ESP of +15.38% and a Zacks Rank #2. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog""]"
DXCM,2015-02-24,15.8675,15.8675,15.2675,15.4025,"[""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close""]"
DXCM,2015-02-25,15.4825,15.84,15.265,15.835,"[""DexCom's (DXCM) CEO Kevin Sayer on Q4 2014 Results - Earnings Call Transcript"", ""DexCom Reports Fourth Quarter EPS of $0.02"", ""DexCom Reports Fourth Quarter EPS of $0.02"", ""DexCom's (DXCM) CEO Kevin Sayer on Q4 2014 Results - Earnings Call Transcript"", ""DexCom Reports Fourth Quarter EPS of $0.02"", ""DexCom's (DXCM) CEO Kevin Sayer on Q4 2014 Results - Earnings Call Transcript""]"
DXCM,2015-02-26,15.835,15.9075,15.0375,15.49,"[""DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog"", ""DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog"", ""DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog DexCom Inc. ( DXCM ) reported fourth-quarter 2014 EPS of 2 cents per share, which compares favorably with the Zacks Consensus Estimate of a loss of 3 cents and year-ago loss of 4 cents per share. Dexcom Inc. - Earnings Surprise | FindTheCompany The impressive result was driven by a 64.3% surge in revenues, which totaled $84.3 million, much ahead of the Zacks Consensus Estimate of $79 million. The upside was driven by an impressive 63.1% jump in product revenues. Quarter Details Gross margin expanded 400 basis points (bps) year over year to 70.5%, primarily on the back of improving product mix, which was roughly 30% durable and 70% consumable in the quarter. Average selling price (ASP) for sensors remained constant at approximately $73 per sensor and the ASP for Dexcom's hardware stayed at approximately at $850 to $900 per starter kit. Both selling, general and administrative (SG&A) and research and development (R&D) expenses rose 52.1% and 71.4% year over year, respectively, owing to increased marketing expenses, higher sales commissions, additional payroll related costs and expenses related to work on near-term product pipeline as well as advanced product suite. Despite the increase in both R&D and SG&A expenses, DexCom reported operating income of $1.6 million compared with the year-ago loss of $2.3 million, riding on strong revenue growth and higher gross margin base. DexCom had cash and cash equivalents of $71.8 million as of Dec 31, 2014, higher than $63.2 million as of Sep 30, 2014. Total long-term debt went down to $4.6 million from $5.2 million at the end of the fourth quarter of 2013. Product Update DexCom launched a total of five new products in 2014, compared to three worldwide product launches in the previous two years combined. Management plans at least five more launches in 2015. Depending upon execution and regulatory time frame, DexCom expects the count to increase to as many as ten products in 2015. In January, DexCom received the FDA approval for its G4 PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses Bluetooth Low Energy (BLE) to connect patient's receiver and an app on the patient's smartphone. With this, the receiver will be able to transfer glucose information to apps on the mobile devices of up to five recipients. The recipients, or followers, can then supervise a patient's glucose information and receive alert notifications from anywhere via their Apple ( AAPL ) iPhone, iPad or iPod touch. The company plans to extend this service to the Android platform as well. DexCom also announced that the Share Receiver will be compatible with the G5 mobile system. Most recently, the company submitted its G5 mobile PMA supplement to the FDA. The company expects an approval by the end of 2015. Outlook DexCom expects product revenues to be in the range of $340 million to $360 million. Approximately 40% to 45% of this revenue is expected to be generated in the first half, while the remaining is likely to come in the back half, much similar to the 2014 trend. First-quarter 2015 revenues are expected to be approximately 20% of full-year revenues. However, first-quarter results are expected to be negatively impacted by seasonality as well as the financial impact of the launch of Share Receiver upgrade program. DexCom expects product gross margin to be down sequentially in the first quarter, but margins are likely to return to normal over the course of 2015. For 2015, R&D expenses are expected to jump almost 25% on a reported basis, owing to higher overhead and share-based compensation expenses. Our Take DexCom reported profits for the first time in its history in the fourth quarter. The company's revenue beat is also encouraging. The company boasts a robust product pipeline with the recent launch of DexCom SHARE - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM System. DexCom is riding high on the back of a number of FDA approvals received over the past few months. In Nov 2014, the FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring system. We feel these approvals will benefit DexCom's long-term prospects. Once the approved products are launched in the market, these will help drive significant top-line growth. However, intensifying competition and a tepid first-quarter outlook will remain overhangs on the stock. Zacks Rank and Other Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include Abiomed ( ABMD ) and Luminex ( LMNX ). Both the companies sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog""]"
DXCM,2015-02-27,15.5075,15.74,15.13,15.185,
DXCM,2015-03-02,15.15,15.2525,14.77,14.915,
DXCM,2015-03-03,14.7625,14.9325,14.36,14.7625,
DXCM,2015-03-04,14.7175,15.0475,14.525,14.97,
DXCM,2015-03-05,15.0,15.2125,14.9425,15.1375,
DXCM,2015-03-06,14.95,15.0875,14.755,14.8975,
DXCM,2015-03-09,14.9675,14.9825,14.6075,14.9025,
DXCM,2015-03-10,14.7475,14.8625,14.47,14.625,"Commit To Buy DexCom At $50, Earn 10.8% Annualized Using Options Investors eyeing a purchase of DexCom Inc (Symbol: DXCM) stock, but tentative about paying the going market price of $58.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $50 strike, which has a bid at the time of this writing of $2.85. Collecting that bid as the premium represents a 5.7% return against the $50 commitment, or a 10.8% annualized rate of return (at Stock Options Channel we call this the YieldBoost ). Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $50 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless DexCom Inc sees its shares decline 14.3% and the contract is exercised (resulting in a cost basis of $47.15 per share before broker commissions, subtracting the $2.85 from $50), the only upside to the put seller is from collecting that premium for the 10.8% annualized rate of return. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $50 strike for the 10.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 252 trading day closing values as well as today's price of $58.38) to be 42%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Tuesday, the put volume among S&P 500 components was 754,604 contracts, with call volume at 967,913, for a put:call ratio of 0.78 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today . Top YieldBoost Puts of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-03-11,14.6275,15.0075,14.4875,14.9775,
DXCM,2015-03-12,14.73,15.0,14.475,14.93,
DXCM,2015-03-13,14.755,15.0575,14.755,15.0075,
DXCM,2015-03-16,15.14,16.0,15.13,15.75,
DXCM,2015-03-17,15.7275,15.825,15.475,15.5775,"[""5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years"", ""5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years"", ""5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years""]"
DXCM,2015-03-18,15.59,15.875,15.36,15.625,
DXCM,2015-03-19,15.57,15.9175,15.4925,15.86,
DXCM,2015-03-20,15.87,16.0,15.405,15.4925,
DXCM,2015-03-23,15.43,15.4625,15.2175,15.3825,
DXCM,2015-03-24,15.5,15.5975,15.25,15.305,
DXCM,2015-03-25,15.46,15.46,14.875,14.9425,
DXCM,2015-03-26,14.89,14.935,14.455,14.5925,
DXCM,2015-03-27,14.5625,15.14,14.5625,15.04,
DXCM,2015-03-30,15.2025,15.635,15.1125,15.495,
DXCM,2015-03-31,15.4225,15.715,15.35,15.585,
DXCM,2015-04-01,15.47,15.545,15.2,15.3725,
DXCM,2015-04-02,15.405,15.7475,15.25,15.7375,
DXCM,2015-04-06,15.5825,15.8925,15.5,15.845,
DXCM,2015-04-07,15.7988,16.05,15.7575,15.8025,
DXCM,2015-04-08,15.755,16.125,15.72,16.0525,
DXCM,2015-04-09,16.0675,16.2975,15.9875,16.25,
DXCM,2015-04-10,16.325,17.1225,16.255,16.9725,"[""DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog"", ""DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog"", ""DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog Shares of DexCom Inc.DXCM rallied to a new 52-week high of $65.19 on Apr 9, eventually closing a tad bit lower at $65.00. This represents a strong one-year return of about 80.3%. The S&P 500 also jumped almost 14.1% during the same period. We note that this Zacks Rank #3 (Hold) stock has a market cap of $5.04 billion and a long-term expected EPS growth rate of 32.5%. Key Growth Catalysts DexCom reported profit for the first time in its history in the fourth quarter of 2014. The company has a robust product pipeline with the latest launch of DexCom Share - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM System. The company is riding high on the back of a number of FDA approvals received over the past few months. DexCom expects product revenues in the range of $340 million to $360 million. Approximately 40% to 45% of this revenue is expected to be generated in the first half, while the remaining is likely to come in the back half, much similar to the 2014 trend. First-quarter 2015 revenues are expected to be approximately 20% of full-year revenues. However, first-quarter results are expected to be negatively impacted by seasonality as well as the financial impact of the launch of Share Receiver upgrade program. DexCom expects product gross margin to be down sequentially in the first quarter, but margins are likely to return to normal over the course of 2015. Estimate Revisions The Zacks Consensus Estimate for 2015 increased by a penny to stand at $0.02 over the past 60 days, which reflects significant growth as compared with 30 cents of loss reported in 2014. Similarly, the consensus estimate for fiscal 2016 surged 14.3% (6 cents) to 48 cents over the same period. Stocks to Consider Better-ranked stocks in the sector are Inogen INGN , Abiomed ABMD and Luminex LMNX . While Inogen sports a Zacks Rank #1 (Strong Buy), Abiomed and Luminex carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report INOGEN INC (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog""]"
DXCM,2015-04-13,16.995,17.2275,16.695,16.855,"[""DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog"", ""DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog"", ""DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog Developer of continuous glucose monitoring systems, DexCom Inc.DXCM recently announced that its G4 PLATINUM Continuous Glucose Monitoring (CGM) System with Share app will be available on Apple Watch. Technology giant Apple Inc.'s (AAPL) much anticipated device, Apple Watch, is set to hit the stores on Apr 24. Following the announcement, shares of DexCom climbed as much as 5.4% to touch an intra-day high of $68.49 on Apr 10, pulling back to close the day at $67.89. We note that shares of this San Diego, CA-based company have gained nearly 23% so far this year. Notably, DexCom CGM and its mobile apps - Share 2 and Follow - are already approved by the FDA and allow both users and followers to view glucose data directly on their Apple iPhone or iPod Touch. The \""Share\"" and \""Follower\"" apps, which are currently available on the Apple App Store at no additional charge will also be available for free download from the Apple Watch App Store starting Apr 24. With the availability of CGM apps on the Apple Watch, caregivers and people with diabetes will have the opportunity to track their glucose levels and trends in a convenient and discreet manner right from their wrist. Additionally, patients or \""Sharers\"" will be allowed to invite up to five people to view their glucose information and send an alert when the sharer's glucose levels are outside the normal range. We feel that DexCom is making significant efforts to provide its patients with access to the most current technology to better manage diabetes. As technology is becoming a more relevant and indispensable part of people's lives, we feel that such business opportunities will go a long way in enhancing the visibility of DexCom's products and services. Moreover, strategic deals with companies like Apple, which have a vast global presence, will boost DexCom's business scale massively. By expanding its range of solutions and services, DexCom will not only improve its international presence but will also enhance its top-line growth opportunities. Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include Inogen INGN , Abiomed ABMD and Fluidigm Corp FLDM . While Inogen sports a Zacks Rank #1 (Strong Buy), both Abiomed and Fluidigm carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report FLUIDIGM CORP (FLDM): Free Stock Analysis Report INOGEN INC (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog""]"
DXCM,2015-04-14,16.8575,17.0275,16.6925,16.975,
DXCM,2015-04-15,17.0025,17.1975,16.795,17.1225,"Johnson & Johnson Trends Favor Four Stocks The firm’s results and earnings call were positive for Intuitive Surgical, St. Jude Medical, Masimo and DexCom."
DXCM,2015-04-16,17.1475,17.21,16.8475,16.9825,
DXCM,2015-04-17,16.8175,16.9075,16.67,16.85,
DXCM,2015-04-20,17.0575,17.175,16.79,17.105,
DXCM,2015-04-21,17.165,17.6348,17.035,17.5825,
DXCM,2015-04-22,17.6,17.72,17.1525,17.32,
DXCM,2015-04-23,17.315,17.81,17.255,17.64,"[""Apple Watch Puts These 3 Health Stocks in Focus - Analyst Blog"", ""Apple Watch Puts These 3 Health Stocks in Focus - Analyst Blog"", ""Apple Watch Puts These 3 Health Stocks in Focus - Analyst Blog Over the last couple of years, the very mention of the word \""apple\"" first draws up a sleek, white, bitten-off reflection of the fruit rather than the red and juicy illustration of it. That's precisely how popular the company Apple Inc.AAPL has grown to be. Planted way back in 1976, Apple has revolutionized the way the world looks at computing. Today, this consumer electronics company is set to alter the face of the healthcare industry with its latest fruit - the Apple Watch - ripe to be plucked. Apple's smartwatch, announced in Sep 2014 and made available for pre-order on Apr 10, 2015, is already anticipated to be seen on more than 2.3 million wrists, once shipping begins on Apr 24. Interestingly, this translates to more sales than that recorded by all Android smartwatch manufacturers in 2014. Until now, the smartwatch was seen as a niche product appealing only to hardcore tech users and calorie-counting fitness buffs. However, thanks in large part to the positive reception of the Apple Watch, one can be sure that the company's latest device will make smartwatches mainstream. As this technology becomes more commonplace in the world of consumer electronics, it will also make inroads into the medical world, where it has a lot to offer. Healthcare Getting Smarter Healthcare, often viewed as an industry that is slow to adopt the latest technology, is actually standing on the threshold of transformative change. Currently valued at $2.9 trillion, the U.S. healthcare industry is more concerned than ever about monitoring a patient's health outside the walls of the hospital through intelligently connected devices. A number of technology companies are releasing wearable devices that can double as health trackers. From headsets that measure brainwaves to clothes that incorporate sensing devices to smartwatches that allow fitness tracking, personal health monitoring is the wave of the future. In the medical world, where pagers and landline phones are still widely used by doctors to coordinate care, an effective wrist-based communication tool allows for continuous monitoring of a patient's health. The use of smartwatches in healthcare communication, in particular, has the potential to improve the speed and quality of care delivery. While the monitoring of activity, sleep cycles, pulse rate and other physiological parameters has become state of the art in today's smartwatches, the latest devices have a dozen other applications that can not only help people to keep fit, but in extreme cases to stay alive. Specific applications designed for select groups like heart patients, diabetic patients and epileptic patients can actually be used by doctors to continuously track the patient's health vitals, flagging clinicians when signs fall below normal, thus allowing them to adjust treatments accordingly and deliver better patient outcomes. A Bite into the Apple Watch Apple Watch, which pairs with the users' iPhones via Wi-Fi or Bluetooth, is being endorsed as a comprehensive health and fitness device. While it allows users to send and receive text messages, speak into the phone to search content and answer calls, health monitoring is actually believed to be a major feature of the watch. From collecting data in new ways to helping hospitals reduce costly emergency room visits, the potential of Apple's smartwatch in healthcare is something that cannot be ignored. Although reception to smart watches from device makers like Samsung and Sony has been tepid, healthcare companies are not the ones to dismiss a new offering from Apple as it brings with it a new level of technological power, not to mention brand appeal. To tap the power of Apple's latest device, a number of healthcare companies are seen developing and announcing a plethora of medical apps for the Apple Watch platform. We believe that Apple will, in fact, need the support of these app developers, health care companies and medical technology companies to create the functions to give people a reason to want to wear a computer around their wrist all the time. By way of this rationale, as the Apple Watch begins to shine on people's wrists, it will throw some spotlight on the healthcare industry as a whole. 3 Healthcare Stocks in Focus As healthcare stands to greatly benefit from the adoption of smartwatches, we feel the time is ripe for investors to enter the arena and ride the approaching wave of growth. Several health and health care companies came out to show off their new Apple Watch apps at the 2015 Healthcare Information Management Systems Society (HIMSS) conference held at Chicago this month. While all the apps need to prove their worth in order to reserve a spot on the tiny wrist-based screen, we believe that the Apple Watch apps of the following three companies stand a good chance to do so. A favorable Zacks Rank and an impressive Growth Score (for explanation, please see our style score system ) lend additional credence to the growth prospects of these companies: DexCom Inc.DXCM Developer of continuous glucose monitoring (CGM) systems, DexCom has made its G4 PLATINUM CGM System with Share app available on the Apple Watch. Being among the first in the category to be approved by the U.S. Food and Drug Administration, DexCom's app will allow diabetic patients to track their blood glucose statistics right from their wrist. The app will also allow them to share this information with caregivers, parents, doctors, or other authorized individuals and send an alert when the glucose levels are beyond the normal range. Flaunting a Growth Score of 'A,' DexCom has seen solid activity on the earnings estimate revision front as well, suggesting that analysts are gaining more confidence on its prospects in both the short and the long term. Over the past 60 days, estimates for the current year have doubled from a penny to 2 cents a share, while for the next year it has improved 9.5% to 46 cents a share. Currently, DexCom carries a Zacks Rank #3 (Hold). athenahealth Inc.ATHN One of the leading providers of cloud-based services and electronic health records (EHR) for hospitals and clinics, athenahealth introduced a new care coordination and communication Apple Watch app - AthenaText. The app is designed to help providers quickly locate and communicate with other members of a patient's care team and support staff. The AthenaText app can sync care coordination activities and information across multiple devices so that the patient record is always up to date. Providers will also be able to refer a patient across town, request a peer consult, or ask for a specialist's recommendation. While the initial version of the app will provide read-only capabilities, athenahealth is expected to add interactive capabilities in June. Currently, athenahealth sports a Zacks Rank #1 (Strong Buy) and a Growth Score of 'B'. Moreover, the firm has also been enjoying positive estimate revisions over the past month which has caused the Zacks Consensus Estimate to climb 4.5% to its current level of 23 cents a share for the current year and 2.2% to its current level of 46 cents per share for fiscal 2016. Cerner Corp.CERN Healthcare information technology company, Cerner, launched its patient engagement app - HealtheLife - on the Apple Watch. The app, designed with push notification reminders to track health data and a display dashboard for tracked metrics, will help patients manage their own health, thus building a healthier community. With patients' consent, the data will be sent directly to the Cerner Millennium EHR which will help providers focus on personalized patient care and population health management. Cerner's population health management and care coordination offerings are important growth catalysts for the company. We believe that an expansion of such services will enhance the company's visibility, which, in turn, will drive top-line growth. Moreover, it is worth mentioning that Cerner, holding a Zacks Rank #3 and a Growth Score of 'B,' has an expected long-term earnings growth of 17.3%, higher than the industry growth of 16.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report CERNER CORP (CERN): Free Stock Analysis Report ATHENAHEALTH IN (ATHN): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Apple Watch Puts These 3 Health Stocks in Focus - Analyst Blog""]"
DXCM,2015-04-24,17.7025,17.7582,17.3,17.3575,"[""The Zacks Analyst Blog Highlights: Apple, DexCom, athenahealth and Cerner - Press Releases"", ""The Zacks Analyst Blog Highlights: Apple, DexCom, athenahealth and Cerner - Press Releases"", ""The Zacks Analyst Blog Highlights: Apple, DexCom, athenahealth and Cerner - Press Releases For Immediate Release Chicago, IL - April 24, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Apple Inc. ( AAPL ), DexCom Inc. ( DXCM ), athenahealth Inc. ( ATHN ) and Cerner Corp. ( CERN ). Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free . Here are highlights from Thursday's Analyst Blog: Apple Watch Puts These Health Stocks in Focus Over the last couple of years, the very mention of the word \""apple\"" first draws up a sleek, white, bitten-off reflection of the fruit rather than the red and juicy illustration of it. That's precisely how popular the company Apple Inc. ( AAPL ) has grown to be. Planted way back in 1976, Apple has revolutionized the way the world looks at computing. Today, this consumer electronics company is set to alter the face of the healthcare industry with its latest fruit - the Apple Watch - ripe to be plucked. Apple's smartwatch, announced in Sep 2014 and made available for pre-order on Apr 10, 2015, is already anticipated to be seen on more than 2.3 million wrists, once shipping begins on Apr 24. Interestingly, this translates to more sales than that recorded by all Android smartwatch manufacturers in 2014. Until now, the smartwatch was seen as a niche product appealing only to hardcore tech users and calorie-counting fitness buffs. However, thanks in large part to the positive reception of the Apple Watch, one can be sure that the company's latest device will make smartwatches mainstream. As this technology becomes more commonplace in the world of consumer electronics, it will also make inroads into the medical world, where it has a lot to offer. Healthcare Getting Smarter Healthcare, often viewed as an industry that is slow to adopt the latest technology, is actually standing on the threshold of transformative change. Currently valued at $2.9 trillion, the U.S. healthcare industry is more concerned than ever about monitoring a patient's health outside the walls of the hospital through intelligently connected devices. A number of technology companies are releasing wearable devices that can double as health trackers. From headsets that measure brainwaves to clothes that incorporate sensing devices to smartwatches that allow fitness tracking, personal health monitoring is the wave of the future. In the medical world, where pagers and landline phones are still widely used by doctors to coordinate care, an effective wrist-based communication tool allows for continuous monitoring of a patient's health. The use of smartwatches in healthcare communication, in particular, has the potential to improve the speed and quality of care delivery. While the monitoring of activity, sleep cycles, pulse rate and other physiological parameters has become state of the art in today's smartwatches, the latest devices have a dozen other applications that can not only help people to keep fit, but in extreme cases to stay alive. Specific applications designed for select groups like heart patients, diabetic patients and epileptic patients can actually be used by doctors to continuously track the patient's health vitals, flagging clinicians when signs fall below normal, thus allowing them to adjust treatments accordingly and deliver better patient outcomes. A Bite into the Apple Watch Apple Watch, which pairs with the users' iPhones via Wi-Fi or Bluetooth, is being endorsed as a comprehensive health and fitness device. While it allows users to send and receive text messages, speak into the phone to search content and answer calls, health monitoring is actually believed to be a major feature of the watch. From collecting data in new ways to helping hospitals reduce costly emergency room visits, the potential of Apple's smartwatch in healthcare is something that cannot be ignored. Although reception to smart watches from device makers like Samsung and Sony has been tepid, healthcare companies are not the ones to dismiss a new offering from Apple as it brings with it a new level of technological power, not to mention brand appeal. To tap the power of Apple's latest device, a number of healthcare companies are seen developing and announcing a plethora of medical apps for the Apple Watch platform. We believe that Apple will, in fact, need the support of these app developers, health care companies and medical technology companies to create the functions to give people a reason to want to wear a computer around their wrist all the time. By way of this rationale, as the Apple Watch begins to shine on people's wrists, it will throw some spotlight on the healthcare industry as a whole. 3 Healthcare Stocks in Focus As healthcare stands to greatly benefit from the adoption of smartwatches, we feel the time is ripe for investors to enter the arena and ride the approaching wave of growth. Several health and health care companies came out to show off their new Apple Watch apps at the 2015 Healthcare Information Management Systems Society (HIMSS) conference held at Chicago this month. While all the apps need to prove their worth in order to reserve a spot on the tiny wrist-based screen, we believe that the Apple Watch apps of the following three companies stand a good chance to do so. A favorable Zacks Rank and an impressive Growth Score (for explanation, please see our style score system ) lend additional credence to the growth prospects of these companies: DexCom Inc. ( DXCM ) Developer of continuous glucose monitoring (CGM) systems, DexCom has made its G4 PLATINUM CGM System with Share app available on the Apple Watch. Being among the first in the category to be approved by the U.S. Food and Drug Administration, DexCom's app will allow diabetic patients to track their blood glucose statistics right from their wrist. The app will also allow them to share this information with caregivers, parents, doctors, or other authorized individuals and send an alert when the glucose levels are beyond the normal range. Flaunting a Growth Score of 'A,' DexCom has seen solid activity on the earnings estimate revision front as well, suggesting that analysts are gaining more confidence on its prospects in both the short and the long term. Over the past 60 days, estimates for the current year have doubled from a penny to 2 cents a share, while for the next year it has improved 9.5% to 46 cents a share. Currently, DexCom carries a Zacks Rank #3 (Hold). athenahealth Inc. ( ATHN ) One of the leading providers of cloud-based services and electronic health records (EHR) for hospitals and clinics, athenahealth introduced a new care coordination and communication Apple Watch app - AthenaText. The app is designed to help providers quickly locate and communicate with other members of a patient's care team and support staff. The AthenaText app can sync care coordination activities and information across multiple devices so that the patient record is always up to date. Providers will also be able to refer a patient across town, request a peer consult, or ask for a specialist's recommendation. While the initial version of the app will provide read-only capabilities, athenahealth is expected to add interactive capabilities in June. Currently, athenahealth sports a Zacks Rank #1 (Strong Buy) and a Growth Score of 'B'. Moreover, the firm has also been enjoying positive estimate revisions over the past month which has caused the Zacks Consensus Estimate to climb 4.5% to its current level of 23 cents a share for the current year and 2.2% to its current level of 46 cents per share for fiscal 2016. Cerner Corp. ( CERN ) Healthcare information technology company Cerner launched its patient engagement app - HealtheLife - on the Apple Watch. The app, designed with push notification reminders to track health data and a display dashboard for tracked metrics, will help patients manage their own health, thus building a healthier community. With patients' consent, the data will be sent directly to the Cerner Millennium EHR which will help providers focus on personalized patient care and population health management. Cerner's population health management and care coordination offerings are important growth catalysts for the company. We believe that an expansion of such services will enhance the company's visibility, which, in turn, will drive top-line growth. Moreover, it is worth mentioning that Cerner, holding a Zacks Rank #3 and a Growth Score of 'B,' has an expected long-term earnings growth of 17.3%, higher than the industry growth of 16.8%. Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free . About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks \""Profit from the Pros\"" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ATHENAHEALTH IN (ATHN): Free Stock Analysis Report CERNER CORP (CERN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Zacks Analyst Blog Highlights: Apple, DexCom, athenahealth and Cerner - Press Releases""]"
DXCM,2015-04-27,17.39,17.53,16.645,16.89,
DXCM,2015-04-28,16.8875,17.1625,16.45,17.0075,"[""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close""]"
DXCM,2015-04-29,16.8375,17.0825,16.5625,16.7825,"[""DexCom (DXCM) Kevin Ronald Sayer on Q1 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q1 2015 Results - Earnings Call Webcast"", ""DexCom misses by $0.06, beats on revenue"", ""DexCom (DXCM) Kevin Ronald Sayer on Q1 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q1 2015 Results - Earnings Call Webcast"", ""DexCom misses by $0.06, beats on revenue"", ""DexCom (DXCM) Kevin Ronald Sayer on Q1 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q1 2015 Results - Earnings Call Webcast"", ""DexCom misses by $0.06, beats on revenue""]"
DXCM,2015-04-30,16.55,17.4125,16.45,16.8925,"[""DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog"", ""DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog"", ""DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog DexCom Inc.DXCM reported net loss of 17 cents per share in the first quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 10 cents per share. However, net loss per share remained flat on a year-over-year basis. Dexcom Inc. - Earnings Surprise | FindTheCompany Following the release of the company's first-quarter results, shares tumbled nearly 4.36% or $2.93 in afterhours trading to close at $64.20. Quarter Details First-quarter revenues surged nearly 55% year over year and totaled $72.8 million, marginally higher than the Zacks Consensus Estimate of $72 million. The upside was driven by an impressive 56% jump in product revenues. New patient growth on a year-over-year basis exceeded revenue growth in the first quarter. Average selling price (ASP) for sensors remained constant at the range of roughly $70\u2212$75 per sensor and the ASP for Dexcom's hardware stayed at approximately at $850 to $900 per starter kit. Gross margin expanded 60 basis points (bps) year over year to 64%, primarily on the back of a favorable product mix, which was roughly 30% durable and 70% consumable in the quarter. Margins were partly offset by the additional cost of goods sold related to the upgrade of the G4 PLATINUM with Share during the quarter. Selling, general and administrative (SG&A) and research and development (R&D) expenses rose 42.8% and 36.6% year over year, respectively, owing to increased marketing expenses, higher sales commissions, additional payroll related costs and expenses related to work on near-term product pipeline as well as advanced product suite. DexCom reported operating loss of $12.7 million, higher than the year-ago operating loss of $12.3 million due to rising operating expenses. DexCom had cash and cash equivalents of $54.2 million as of Mar 31, 2015, lower than $71.8 million as of Dec 31, 2014. Total long-term debt went down to $4.1 million from $4.6 million as of Dec 31, 2014. Product Update In Jan 2015, DexCom received the FDA approval for its G4 PLATINUM Continuous Glucose Monitoring (CGM) System with Share and launched the same in March. The company also launched it G4 PLATINUM CGM with Share app on the Apple (AAPL) watch in April. The company is scheduled to release the Android DexCom Follow app for the Android community in early summer this year. DexCom also announced that the Share Receiver will be compatible with the G5 mobile system. The company submitted its G5 mobile PMA supplement to the FDA in February and expects an approval by the end of 2015. Outlook DexCom continues to expect product revenues in the range of $340 million to $360 million in 2015. Approximately 40% to 45% of this revenue is expected to be generated in the first half, while the remaining is likely to come in the back half, much similar to the 2014 trend. For 2015, R&D expenses are expected to jump almost 25% on a reported basis, owing to higher overhead and share-based compensation expenses. Our Take DexCom's robust product pipeline with the recent launch of DexCom SHARE - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM System are impressive. DexCom is riding high on the back of a number of FDA approvals received over the past few months and plans to launch several new products in 2015. We feel that these approvals will benefit DexCom's long-term prospects. Once the approved products are launched in the market, these will help drive significant top-line growth. However, we feel that higher product development costs and R&D expenses will continue to hurt margins in the near term. Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include RTI Surgical RTIX , Inogen INGN and Abiomed ABMD . While RTI Surgical sports a Zacks Rank #1 (Strong Buy), both Inogen and Abiomed carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report INOGEN INC (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog""]"
DXCM,2015-05-01,17.04,17.12,16.64,16.78,
DXCM,2015-05-04,16.685,17.1575,16.665,17.0475,
DXCM,2015-05-05,16.9525,17.1225,16.44,16.55,
DXCM,2015-05-06,16.56,16.685,16.3475,16.58,
DXCM,2015-05-07,16.5275,17.09,16.475,16.87,"The Best Company for Investing in the Diabetes Market The Centers for Diseases Control and Prevention estimates that 29.1 million Americans suffer from diabetes, with that number reaching as high as 387 million around the globe. By 2035, the worldwide number is estimated to grow to as many 592 million patients. Diabetes is a chronic disease caused by the body's inability to produce or effectively utilize insulin, which prevents the body from adequately regulating blood glucose levels. Diabetes is typically classified into two major groups: type 1 and type 2. Type 1 diabetes is an autoimmune disorder characterized by the body attacking its own insulin-producing cells of the pancreas. Without any natural insulin production, patients with type 1 diabetes must rely on frequent insulin injections in order to regulate and maintain blood glucose levels. As of 2012, about 1.25 million American had been diagnosed with Type 1 diabetes. Type 2 diabetes is a metabolic disorder that results when the body is unable to produce sufficient amounts of insulin or becomes insulin resistant, and this type is much more common than type 1. About 19 million Americans have been diagnosed with type 2 diabetes, and a further 8.1 million have type 2 but remain undiagnosed. Treating diabetes is both complicated and costly. The most recent estimates from the American Diabetes Association indicate that total costs to treat diabetes in the U.S. reached $245 billion in 2012 alone, up from $174 billion in 2007. It's no surprise that a market with that level of spending has attracted investors' attention. There are plenty of ways for investors to gain exposure to the diabetes treatment market, such as Big Pharma companies like Sanofi , Novo Nordisk , and Eli Lilly , who produce a range of drugs used to treat the disease. On the opposite end of the diversity spectrum, MannKind Incorporated joined the game recently with its launch of Afrezza, an innovative inhaled insulin that eliminates the need for patients to take shots. Since MannKind has only this one drug approved, it is higher risk than its larger competitors, but it is more of a pure play on the diabetes treatment market. On the drug delivery side, investors can take a stake in insulin pump manufactures like Medtronic , Insulet , or Tandem Diabetes , all of which have products on the market for insulin delivery to diabetics. However, there is another company I've had my eye on for a few years, and its been one of my biggest mistakes as an an investor that I've never personally bought shares. The company has been a massive long winner, up a market-crushing 560% since going public in 2005 , leaving investor favorite MannKind in the dust. That company is Dexcom . Dexcom produces and sell a product called a continuous glucose monitor, which is a two-part device designed to shows users what their blood glucose level is continuously . Currently, most patients with diabetes check their glucose levels with a meter that requires the user to add a drop of blood to a strip to get a point-in-time reading. The problem with this method is that patients and providers do not get an accurate reading on what is happening with the patient's blood sugars throughout the day, as glucose levels can fluctuate rapidly. Dexcom's system shows a continuous graph of the patient's blood sugars levels, which can lead to better decisions about insulin dosages, ultimately providing for much better blood sugar control. Dexcom's solution has enjoyed rapid adoption since launching in 2006, and full-year revenue jumped an impressive 62% in 2014 to $259.2 million. Gross margins for the company have been going up, and in Q4 2014, they hit a very impressive 70%, which allowed the company to generate a profit for the first time ever. The balance sheet is strong as well, with $83 million in cash and equivalents versus $3 million in debt. Huge opportunity ahead Dexcom is giving investors plenty of reasons to believe growth will remain strong in the years ahead. The system received expanded approval in February 2014 for the pediatric market, providing a meaningful tailwind for the company. The company also has announced partnerships with several insulin pump manufacturers that will allow for the displaying of Dexcom's sensor readings directly on the pump itself, which eliminates the need to carry a separate Dexcom receiver. Source: Animas Animas Corp.'s Vibe insulin pump has this feature built in and received FDA approval in December 2014. Tandem DiabetesCare 's T:Slim pump is slated to have this feature as well, and this version is currently pending FDA approval. Dexcom has also announced a similar agreement with InsuletCorp. 's OmniPod system. Dexcom is only scratching the surface internationally, as well -- the company only generated 14% of its revenue outside the U.S. in 2014. Lastly, Dexcom has announced that its system will work with the Apple Watch, giving patients a much more convenient way to monitor what is happening with their blood sugar. Analysts predict the good times are going to continue to roll, with revenue expected to climb another 39% this year to $360 million and reach $489 million in 2016. As the company matures and economies of scale set in, margins should expand nicely, providing a big boost to the bottom line. All for a price Dexcom shares can hardly be called cheap, as they are currently trading at about 20 times 2014 sales . However, given the opportunity presented by such a large market, Wall Street is understandably excited about the company's future, and it's been bidding up shares to match the opportunity, particularly given that the company is finally profitable. There is a chance the stock price has gotten ahead of itself, but given that Dexcom has proven its technology is well-liked by patients and providers, and has plenty of room for growth ahead, the company remains my favorite way to invest in diabetes. The next billion-dollar Apple secret Apple forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering Apple's brand-new gadgets and the coming revolution in technology. And its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article The Best Company for Investing in the Diabetes Market originally appeared on Fool.com. Brian Feroldi owns shares of Apple and Insulet. The Motley Fool recommends Apple and Insulet. The Motley Fool owns shares of Apple. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-05-08,17.0575,17.245,16.79,16.975,
DXCM,2015-05-11,16.94,17.18,16.85,16.9,
DXCM,2015-05-12,16.7525,17.145,16.5375,17.02,
DXCM,2015-05-13,17.0525,17.065,16.625,16.9425,
DXCM,2015-05-14,17.0075,17.45,16.6375,17.2325,
DXCM,2015-05-15,17.2525,17.305,16.93,17.0975,
DXCM,2015-05-18,17.075,17.5925,16.9825,17.525,
DXCM,2015-05-19,17.5,17.595,17.3175,17.4475,
DXCM,2015-05-20,17.5525,17.585,17.185,17.2925,
DXCM,2015-05-21,17.2425,17.3025,16.945,17.0625,
DXCM,2015-05-22,17.0325,17.22,16.97,17.17,
DXCM,2015-05-26,17.0,17.29,16.92,17.1625,
DXCM,2015-05-27,17.1575,17.9325,17.055,17.91,
DXCM,2015-05-28,17.86,17.95,17.59,17.8175,"[""DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog"", ""DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog"", ""DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog Shares of DexCom Inc. DXCM rallied to a new 52-week high of $71.73 on May 27, eventually closing a tad bit lower at $71.64. This represents a strong one-year return of about 108.1%. The S&P 500 also jumped almost 10.6% during the same period. We note that this Zacks Rank #3 (Hold) stock has a market cap of $5.44 billion and a long-term expected EPS growth rate of 32.5%. Key Growth Catalysts DexCom reported loss in the first quarter of 2015 primarily owing to higher operating expenses. The reported net loss of 17 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents per share. However, the company's top-line growth was encouraging. Revenues surged nearly 55% year over year and totaled $72.8 million, marginally higher than the Zacks Consensus Estimate of $72 million. The upside was driven by an impressive 56% jump in product revenues. New patient growth on a year-over-year basis exceeded revenue growth in the first quarter. The latest launch of DexCom Share - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM system will continue to drive top-line growth for the rest of 2015. DexCom has a robust pipeline that comprises the upcoming G5 mobile system (expected to be launched in late 2015), next generation G6 system (scheduled to launch in the first half of 2017), insulin dose plan for current system (under consideration with FDA) and insertion system. However, higher product development costs, research & development (R&D) and marketing expenses will continue to hurt margins in the near term. DexCom continues to expect product revenues in the range of $340 million to $360 million for 2015. Approximately 40% to 45% of this revenue is expected to be generated in the first half, while the remaining is likely to come in the back half, much similar to the 2014 trend. Estimate Revisions The Zacks Consensus Estimate for 2015 currently stands at a loss of 2 cents per share, which has remained steady over the past 7 days. Similarly, the consensus estimate for fiscal 2016 has remained steady at 45 cents over the same period. Stocks to Consider Better-ranked stocks in the sector are LDR Holding LDRH , Globus Medical GMED and Masimo MASI . While LDR Holding sports a Zacks Rank #1 (Strong Buy), Globus Medical and Masimo carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report LDR HOLDING (LDRH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog""]"
DXCM,2015-05-29,17.75,18.18,17.6875,17.93,
DXCM,2015-06-01,17.9025,18.25,17.7975,18.0875,
DXCM,2015-06-02,18.0075,18.3475,17.875,18.1475,"[""Dexcom Reports Follow App Available/Compatible with Android Devices"", ""Dexcom Reports Follow App Available/Compatible with Android Devices"", ""Dexcom Reports Follow App Available/Compatible with Android Devices""]"
DXCM,2015-06-03,18.2325,18.2475,17.96,18.12,"[""DexCom's (DXCM) Follow CGM App Now on Android Devices - Analyst Blog"", ""DexCom's (DXCM) Follow CGM App Now on Android Devices - Analyst Blog"", ""DexCom's (DXCM) Follow CGM App Now on Android Devices - Analyst Blog Developer of continuous glucose monitoring systems, DexCom Inc.DXCM recently announced that the DexCom Follow app - a component of the Dexcom G4 PLATINUM Continuous Glucose Monitor (CGM) System with Share - is now available for Android devices. Notably, DexCom CGM is the industry's first mobile-connected CGM system. We note that DexCom CGM and its mobile apps - Share 2 and Follow - are already approved by the FDA and allow both users and followers to view glucose data directly on their iOS-enabled devices. The Follow app, which is now compatible with Android devices, offers caregivers and people with diabetes the opportunity to track their glucose levels and trends in a convenient and discreet manner on their smart devices. Additionally, patients or \""Sharers\"" can invite up to five people to view their glucose information and send an alert when the Sharer's glucose levels are beyond the normal range. By enabling more users to conveniently share glucose readings, DexCom aims to provide its patients and their families with access to the most current technology to better manage diabetes. The company announced that the app, which is available for free download from the Apple AAPL App Store and the Apple Watch App Store, will now be available for free download on the Google GOOGL Play store for Android users as well. We feel that DexCom is making significant efforts to provide its patients with access to the most current technology to better manage diabetes. As technology is becoming a more relevant and indispensable part of people's lives, we feel that such business opportunities will go a long way in enhancing the visibility of DexCom's products and services. Moreover, strategic deals with companies like Apple and Google, which have a vast global presence, will boost DexCom's business scale massively. By expanding its range of solutions and services, DexCom will not only improve its international presence but will also enhance its top-line growth opportunities. DexCom also has a robust pipeline which is a key growth catalyst in our view. The company's pipeline comprises the upcoming G5 mobile system (expected to be launched in late 2015), next generation G6 system (scheduled to launch in the first half of 2017), insulin dose plan for current system (under consideration with FDA) and insertion system. However, higher product development costs, research & development and marketing expenses will continue to hurt margins, which is a concern in the near term. Stock to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). A better-ranked stock in the medical instruments industry is LDR Holding Corp LDRH with a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report LDR HOLDING (LDRH): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom's (DXCM) Follow CGM App Now on Android Devices - Analyst Blog""]"
DXCM,2015-06-04,18.0275,18.0975,17.6475,17.965,
DXCM,2015-06-05,17.99,18.2175,17.8575,18.1525,"Notable ETF Outflow Detected - IWO, ISIS, DXCM, BLUE Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected an approximate $107.3 million dollar outflow -- that's a 1.5% decrease week over week (from 46,700,000 to 46,000,000). Among the largest underlying components of IWO, in trading today Isis Pharmaceuticals, Inc. (Symbol: ISIS) is up about 1.9%, DexCom Inc (Symbol: DXCM) is down about 0.1%, and bluebird bio Inc (Symbol: BLUE) is up by about 2.5%. For a complete list of holdings, visit the IWO Holdings page » The chart below shows the one year price performance of IWO, versus its 200 day moving average: Looking at the chart above, IWO's low point in its 52 week range is $120.67 per share, with $155.69 as the 52 week high point - that compares with a last trade of $153.40. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-06-08,18.1175,18.2075,17.89,17.935,
DXCM,2015-06-09,17.9725,17.9725,17.505,17.725,
DXCM,2015-06-10,17.855,18.125,17.6475,18.0425,
DXCM,2015-06-11,18.0675,18.375,17.9875,18.3475,
DXCM,2015-06-12,18.2625,18.3375,18.025,18.11,
DXCM,2015-06-15,17.8475,18.1175,17.505,18.0925,
DXCM,2015-06-16,18.005,18.335,17.95,18.1975,
DXCM,2015-06-17,18.265,18.8725,18.255,18.7425,"[""InsiderInsights.com Daily Round Up 6/16/15: RAI, GAIN, NPS, VRX"", ""InsiderInsights.com Daily Round Up 6/16/15: RAI, GAIN, NPS, VRX"", ""InsiderInsights.com Daily Round Up 6/16/15: RAI, GAIN, NPS, VRX""]"
DXCM,2015-06-18,18.755,19.4175,18.755,19.35,
DXCM,2015-06-19,19.4075,19.495,19.2175,19.405,
DXCM,2015-06-22,19.595,19.595,19.26,19.4525,
DXCM,2015-06-23,19.45,19.5,19.3125,19.4825,
DXCM,2015-06-24,19.4925,19.525,19.19,19.275,
DXCM,2015-06-25,19.435,19.5425,19.255,19.44,
DXCM,2015-06-26,19.5425,19.9975,19.3875,19.9,
DXCM,2015-06-29,19.6225,20.1425,19.4825,19.775,"[""Stocks Hitting 52-Week Highs"", ""Stocks Hitting 52-Week Highs"", ""Stocks Hitting 52-Week Highs""]"
DXCM,2015-06-30,19.975,20.0575,19.84,19.995,
DXCM,2015-07-01,20.1425,20.35,19.8275,19.9425,"[""Stocks Hitting 52-Week Highs"", ""Stocks Hitting 52-Week Highs"", ""Stocks Hitting 52-Week Highs""]"
DXCM,2015-07-02,19.97,20.025,19.7325,19.84,
DXCM,2015-07-06,19.695,20.0975,19.5,19.9275,
DXCM,2015-07-07,19.9875,20.2925,19.5,20.2675,
DXCM,2015-07-08,20.405,20.405,19.7625,19.8775,"[""Baird Initiates Coverage on DexCom at Outperform, Announces $95.00 PT"", ""Baird Initiates DexCom, Tandem Diabetes At Outperform On Large Growth Expectations"", ""Benzinga's Top Initiations"", ""Benzinga's Top Initiations"", ""Baird Initiates DexCom, Tandem Diabetes At Outperform On Large Growth Expectations"", ""Baird Initiates Coverage on DexCom at Outperform, Announces $95.00 PT"", ""Benzinga's Top Initiations"", ""Baird Initiates DexCom, Tandem Diabetes At Outperform On Large Growth Expectations"", ""Baird Initiates Coverage on DexCom at Outperform, Announces $95.00 PT""]"
DXCM,2015-07-09,20.04,20.195,19.99,20.04,"[""Healthcare ratings roundup"", ""Healthcare ratings roundup"", ""Healthcare ratings roundup""]"
DXCM,2015-07-10,20.2575,20.385,20.14,20.3625,
DXCM,2015-07-13,20.565,20.7775,20.41,20.5025,"[""Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc."", ""Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc."", ""Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc.""]"
DXCM,2015-07-14,20.5175,20.745,20.455,20.565,"[""Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM"", ""Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM"", ""Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM""]"
DXCM,2015-07-15,20.585,20.6512,20.1475,20.2275,
DXCM,2015-07-16,20.3225,20.9575,20.32,20.9175,
DXCM,2015-07-17,20.9325,21.02,20.735,20.9475,
DXCM,2015-07-20,21.0525,21.08,20.78,20.87,"[""Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc."", ""Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc."", ""Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc.""]"
DXCM,2015-07-21,20.87,21.1525,20.6375,21.1325,"[""Insider Weekends - July 17, 2015"", ""Insider Weekends - July 17, 2015"", ""Insider Weekends - July 17, 2015""]"
DXCM,2015-07-22,21.0125,21.445,21.0125,21.3525,
DXCM,2015-07-23,21.3425,21.55,21.145,21.2825,
DXCM,2015-07-24,21.205,21.3625,20.7025,20.7725,
DXCM,2015-07-27,20.615,20.625,20.2,20.425,
DXCM,2015-07-28,20.595,20.875,20.22,20.8525,
DXCM,2015-07-29,20.9,20.98,20.4425,20.89,
DXCM,2015-07-30,20.8475,21.07,20.5,20.98,
DXCM,2015-07-31,21.125,21.52,20.865,21.1625,
DXCM,2015-08-03,21.25,21.4425,20.8337,21.1325,
DXCM,2015-08-04,21.17,21.3925,21.025,21.2325,"[""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close"", ""FXH, DXCM, HNT, ABC: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $125.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 59,000,002 to 60,800,002). Among the largest underlying components of FXH, in trading today DexCom Inc (Symbol: DXCM) is up about 1.1%, Health Net, Inc. (Symbol: HNT) is up about 0.8%, and AmerisourceBergen Corp. (Symbol: ABC) is higher by about 0.8%. For a complete list of holdings, visit the FXH Holdings page \u00bb The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $51.50 per share, with $70.72 as the 52 week high point - that compares with a last trade of $69.93. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable earnings after Wednesday's close"", ""Four Medical Picks With Healthy Earnings Outlooks DexCom, Intersect ENT, AxoGen and Cardica all report this week and are boosted by positive trends.""]"
DXCM,2015-08-05,21.2825,21.75,21.175,21.4875,"[""DexCom misses by $0.02, beats on revenue"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Webcast"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Transcript"", ""DexCom Reports Q2 EPS $(0.05) vs. Est. $(0.03), Rev. $93.2M vs. Est. $84.81M"", ""DexCom Reports Q2 EPS $(0.05) vs. Est. $(0.03), Rev. $93.2M vs. Est. $84.81M"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Webcast"", ""DexCom misses by $0.02, beats on revenue"", ""DexCom Reports Q2 EPS $(0.05) vs. Est. $(0.03), Rev. $93.2M vs. Est. $84.81M"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q2 2015 Results - Earnings Call Webcast"", ""DexCom misses by $0.02, beats on revenue""]"
DXCM,2015-08-06,23.675,24.395,22.865,23.3275,"[""DexCom (DXCM) Q2 Loss Wider than Expected, Revenues Beat - Analyst Blog"", ""DexCom (DXCM) Q2 Loss Wider than Expected, Revenues Beat - Analyst Blog"", ""DexCom (DXCM) Q2 Loss Wider than Expected, Revenues Beat - Analyst Blog DexCom Inc.DXCM reported net loss of 5 cents per share in the second quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 3 cents. However, net loss per share was narrower than the year-ago equivalent of 9 cents. Quarter Details Second-quarter revenues surged nearly 58.5% year over year to $93.2 million, which handily beat the Zacks Consensus Estimate of $85 million. The upside was driven by an impressive 59.6% jump in product revenues. Average selling price (ASP) for sensors was at the high end of the company's stated range of $70\u2212$75 per sensor while ASP for Dexcom's hardware stayed at approximately at $850 to $900 per starter kit. Gross margin expanded 290 basis points (bps) year over year to 70.8%, primarily on the back of higher revenues and a favorable product mix, comprising roughly 30% durable and 70% consumable in the quarter. Selling, general and administrative (SG&A) and research and development (R&D) expenses rose 46.3% and 64.9% year over year to $45.2 million and $24.4 million, respectively, owing to increased marketing expenses, additional payroll related costs and expenses related to work on near-term product pipeline as well as an advanced product suite. DexCom reported operating loss of $3.6 million, lower than the year-ago operating loss of $5.8 million, thanks to higher revenues, offset by increasing operating expenses. DexCom had cash and cash equivalents of $67.7 million as of Jun 30, 2015, higher than $54.2 million as of Mar 31, 2015. Product Pipeline DexCom expects to launch G5 mobile system for both pediatrics and adults in 2015. The company is well on track to conduct a pre-pivotal study with its gen 6 sensors later this year. Following that, the company will look to commence a pivotal study. DexCom expects to launch gen 6 in early 2017. The company is initiating investments in its real-time analytics platform, given that G4 PLATINUM is gaining significant market traction. Outlook DexCom raised its revenue guidance from a range of $340-$360 million to a range of $350-$375 million. The company expects to make additional investments prior to the rollout of the G5 mobile system. Hence, SG&A expenses are expected to increase 25% on a year-over-year basis in 2015. In the near term, DexCom expects gross margin to remain at about 70%, but gross margin on hardware is expected to be lower, going forward, due to the roll out of the G5 mobile transmitter. Management expects the product mix between durable and consumable products to remain steady at 30% and 70%, respectively. Our Take DexCom's healthy product pipeline is a major positive. The company plans to launch several new products in 2015. We feel the pipeline approvals and their subsequent launches will benefit DexCom's long-term prospects and drive significant top-line growth. However, higher product development costs and R&D expenses will continue to hurt margins in the near term. Zacks Rank Currently, DexCom has a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Agios Pharmaceuticals AGIO , NuVasive NUVA and Abaxis ABAX . All the three stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABAXIS INC (ABAX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 Loss Wider than Expected, Revenues Beat - Analyst Blog""]"
DXCM,2015-08-07,23.1225,23.2775,22.655,22.94,
DXCM,2015-08-10,22.87,23.0475,22.38,22.5725,
DXCM,2015-08-11,23.0,24.0475,22.85,23.9775,"[""DexCom teams up with Google on next-gen glucose monitors"", ""DexCom Reports Collaboration with The Life Sciences Team at Google Related to Breakthrough Technologies to Change Future of Diabetes Mgmt"", ""DexCom Reports Collaboration with The Life Sciences Team at Google Related to Breakthrough Technologies to Change Future of Diabetes Mgmt"", ""DexCom teams up with Google on next-gen glucose monitors"", ""DexCom Taps Google to Build Miniature Diabetes Sensors Source: DexCom DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet. Improving care There are 387 million diabetic people worldwide and that number is estimated to grow to nearly 600 million by 2035. Because diabetes can lead to life-threatening conditions, such as heart disease, it is one of the most worrisome healthcare epidemics on the planet. In an attempt to reduce the risk of developing these life-threatening diseases, it's incredibly important to help keep blood sugar in check. Unfortunately, DexCom estimates that an average diabetic spends greater than 70% of his or her time outside of a healthy blood glucose range. For that reason, glucose monitors like those sold by DexCom are being increasingly more widely used by both type 1 and type 2 diabetics to get real-time insight into their blood sugar, including trending data that can be sent directly to a smartphone like handset. Using this data, diabetes patients can more accurately determine whether or not to eat or take their insulin, reducing the risks of blood sugar highs and lows. Currently, sensors used in these devices are inserted under the skin, but with the help of Google's miniature electronics research, DexCom hopes to create tiny bandage-sized sensors that are cheap and disposable. If the company can do that, then these sensors could displace the need for finger sticks for most, if not all, patients. \""This partnership has the potential to change the face of diabetes technology forever,\"" said Kevin Sayer, president and chief executive officer of DexCom. \""Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes.\"" Details of the deal DexCom is paying Google $35 million in DexCom stock up front as well as potential milestones up to $65 million in cash or stock and single-digit royalties on any sales above $750 million. In exchange, DexCom will gain access to Google's vast expertise in miniaturizing electronics and information delivery. Google's glucose monitoring expertise comes courtesy of GoogleX, a company research lab that developed a contact lens that uses miniature electronics and a glucose sensor to monitor sugar levels in a patient's tears. The contact lens evaluates the tears using glitter-sized processing chips and then transmits the findings to a device, such as a smartphone, via an antenna that's thinner than human hair. DexCom and Google hope to leverage that expertise to build and then connect bandage-sized sensors automatically to the cloud, allowing data collected by them to be easily shared to any Internet-connected device or platform. DexCom expects the first products from this collaboration to hit the market in the coming three years with additional products coming in five years. Looking ahead Because developing a cloud-based sensor could conceivably make DexCom's sensors device-agnostic, it could significantly broaden the company's share of the glucose monitoring market to more type 2 diabetics, and since these sensors will be disposable, these sensors could create an important and ongoing revenue stream for the company. Given the size of the global diabetes market, tapping into the larger type 2 market could significantly grow DexCom's already fast-growing business. Last year, the company's sales grew 62% to $259.2 million and that momentum carried over into 2015 with DexCom reporting sales of $165.7 million through the first six months, up 58% year over year. Since DexCom is a much smaller company than Google and the potential market for these sensors is large, this deal could prove to be more shareholder-friendly to DexCom investors than to Google investors. For that reason, I think DexCom is worth considering for long-haul portfolios. Because Google is willing to accept shares in DexCom as payment, it would seem that the company agrees. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article DexCom Taps Google to Build Miniature Diabetes Sensors originally appeared on Fool.com. Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Google (A shares) and Google (C shares). The Motley Fool owns shares of Google (A shares) and Google (C shares). Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Collaboration with The Life Sciences Team at Google Related to Breakthrough Technologies to Change Future of Diabetes Mgmt"", ""DexCom teams up with Google on next-gen glucose monitors""]"
DXCM,2015-08-12,23.7425,24.0575,23.4225,23.955,"[""DexCom Shares Gain on Google Deal: Should You Consider?"", ""DexCom Shares Gain on Google Deal: Should You Consider?"", ""DexCom Shares Gain on Google Deal: Should You Consider? Shares of DexCom Inc. DXCM rallied 6.2% ($5.62) to close at $95.91 on Aug 11 after the continuous glucose monitoring (CGM) device maker announced a partnership with Google's life sciences team. DexCom and Google are teaming up to develop a series of CGM devices that will be compact (\""bandage-sized sensor\""), easy to use and more economic than existing products. The devices will be disposable and can be used by all types of diabetes patients. Per the partnership agreement, DexCom will hold the exclusive sales and distribution rights of the devices. However, the company will be obligated to make an upfront payment as well as milestone payments during the development process. Post launch, Google will receive revenue-based royalties once the products garner a certain level of revenue. As technology is becoming a more relevant and indispensable part of people's lives, we feel that the Google collaboration will go a long way in enhancing the brand value of DexCom's products and services. The combination of Google's miniaturized electronics platform with DexCom's superior sensor technology is expected to develop CGMs that will help patients manage diabetes better. In this regard, we note that DexCom enjoys a strong market presence with its G4 PLATINUM System being industry's first mobile connected CGM system. DexCom's CGM and its mobile apps - Share 2 and Follow - are approved by the FDA and allow both users and followers to view glucose data directly on Android and iOS-enabled devices. Moreover, strategic deals with technology providers like Apple and Google, which boast a vast global presence, is expected to boost DexCom's business scale massively. By expanding its range of solutions and services, DexCom will not only improve its international presence but will also enhance its top-line growth opportunities. DexCom also has a robust pipeline which is a key growth catalyst in our view. The company expects to launch G5 mobile system for both pediatrics and adults in 2015. It is well on track to conduct a pre-pivotal study with its gen 6 sensors later this year. Following that, the company will look to commence a pivotal study. Meanwhile, DexCom also expects to launch gen 6 in early 2017. However, high product development costs, research & development as well as marketing expenses will continue to hurt margins, which is a concern in the near term. Zacks Rank & Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include Masimo MASI , Mazor Robotics MZOR and RTI Surgical RTIX . All the three stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report MAZOR ROBOTICS (MZOR): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Gain on Google Deal: Should You Consider?""]"
DXCM,2015-08-13,24.0225,24.5725,23.83,24.2675,
DXCM,2015-08-14,24.5025,24.7125,24.31,24.545,
DXCM,2015-08-17,24.58,24.6075,23.8175,24.5275,
DXCM,2015-08-18,24.3625,24.7,24.13,24.165,
DXCM,2015-08-19,24.1,24.2525,23.5,23.875,"[""Baron Funds Comments on DexCom Inc."", ""Baron Funds Comments on DexCom Inc."", ""Baron Funds Comments on DexCom Inc.""]"
DXCM,2015-08-20,23.625,23.745,22.625,22.645,
DXCM,2015-08-21,22.4475,22.725,22.085,22.5025,
DXCM,2015-08-24,19.6475,21.955,19.115,21.3725,"[""Google to Spin Off Life Sciences into an Alphabet Subsidiary"", ""Google to Spin Off Life Sciences into an Alphabet Subsidiary"", ""Google to Spin Off Life Sciences into an Alphabet Subsidiary Google Inc.GOOGL has been rather quiet after its announcement regarding the restructure and the formation of a new holding company called Alphabet. Recently, Google co-founder and Alphabet President Sergey Brin stated that Google X - the research unit behind projects like self-driven cars, delivery drones and Internet balloons - will spin off the life sciences group into a standalone company within Alphabet. Currently, life sciences group develops next-generation health products in the nanodiagnostics space such as glucose-reading smart contact lenses. CEO Andy Conrad, who has been the head of this business since 2013, will continue to lead it. Though complete details about the companies under Alphabet are not available yet, as of now it includes Life Sciences (contact lenses to test diabetes from tear drops, etc.), thermostat maker Nest (smart thermostats and related products) and age longevity company, Calico. Alphabet management will also be responsible for Google Fiber (for high speed Internet access), robots and Google Capital and Google Ventures (investments in startups). Brin stated that the new Life sciences business will continue to partner with other life sciences companies and focus on taking the medical devices from early research to the clinical testing stage. Google has been trying to expand into the healthcare space. Recently, the online search giant partnered with continuous glucose monitoring (CGM) device maker, DexCom DXCM , to develop a series of compact (\""bandage-sized sensor\""), easy to use and economic CGM devices for diabetes patients. Last year, the company formed a joint venture with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories, to formulate treatments for cancer and Alzheimer's disease. Google also launched Google Fit health data platform, an open multi-OS API for fitness apps and devices. The program allows developers to track fitness data, sync it across devices and store it in a central place. Similar services have recently been introduced by Apple and Samsung. The recent move will help Google to focus more on developing technologies that make is easier for users to track health-related data and expand further in the growing healthcare space. Apart from strengthening its presence in the ever-expanding field of medicine, Google will be able to create high revenue generating prospects in its life sciences division. Google has a Zacks Rank #2 (Buy). A couple of other technology stocks worth considering are Manhattan Associates, Inc. MANH and Open Text Corporation OTEX , both sporting a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report OPEN TEXT CORP (OTEX): Free Stock Analysis Report MANHATTAN ASOC (MANH): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Google to Spin Off Life Sciences into an Alphabet Subsidiary""]"
DXCM,2015-08-25,23.0,23.0775,21.75,22.3925,"[""Keeping A Small Nest Egg From Cracking"", ""FDA Approves Dexcom G5\u00ae Mobile Continuous Glucose Monitoring System"", ""FDA Approves Dexcom G5\u00ae Mobile Continuous Glucose Monitoring System"", ""Keeping A Small Nest Egg From Cracking"", ""FDA Approves Dexcom G5\u00ae Mobile Continuous Glucose Monitoring System"", ""Keeping A Small Nest Egg From Cracking""]"
DXCM,2015-08-26,22.91,22.9975,22.29,22.8825,"[""Panic-Proofing the Small Investor"", ""DexCom Wins FDA Approval for G5 CGM System; Stock Up"", ""Panic-Proofing the Small Investor"", ""DexCom Wins FDA Approval for G5 CGM System; Stock Up"", ""DexCom Wins FDA Approval for G5 CGM System; Stock Up Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and solitary CGM system permitted by the FDA for use in both adults and children above two years of age. The transmitter, with in-built Bluetooth, sends essential glucose information directly to an app on iOS-enabled devices for instantaneous diabetes supervision. The company intends to launch the app for android devices in early 2016. Per the company's management, shipment of the G5 Mobile system will commence in late September, this year. Meanwhile, the upgrade charge will be low for systems under warranty period. However, purchasers of DexCom's G4 Platinum with Share system, from Aug 1, 2015 till the shipment of G5 Mobile system, will be able to upgrade without incurring extra cost. Like its forerunner, the G5 system allows users to choose up to five recipients or 'followers', who can distantly keep tabs on a patient's glucose information and receive alerts from anywhere. DexCom, of late, has been reasonably focused on improving diabetes management by rolling out technologies for continuous glucose monitoring devices. In January this year, the company received the FDA approval for its DexCom G4 PLATINUM Continuous Glucose Monitoring System with Share. Following that, the company launched the app for Apple AAPL watch in April. In the month of June, the app was made available for the android community as well. We believe that the G5 system will allow DexCom to gain better market traction. The company has already raked in good business on the back of its G4 Platinum platform. Moreover, the glucose monitoring market represents significant commercial opportunity for DexCom as the diabetes market is large and growing. Prevalence of the disease has increased as a result of the ageing population, inappropriate diet and increasingly sedentary lifestyles. DexCom also boasts an extensive product pipeline including the next generation G6 system (expected to launch in the first half of 2017), insulin dose plan for current system (under FDA consideration) and insertion system. However, on the flip side, higher product development costs, R&D and marketing expenses are expected to hurt margins in the near term. Zacks Rank Currently DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include Masimo MASI and Thoratec THOR . Both the stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report THORATEC CORP (THOR): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Little-Known Medtech Stocks Investors Ought To Consider Biotech stocks may have gotten the bulk of investor attention in the past year, but plenty of mid and small cap medtech companies have been rallying too. Given the recent market sell-off, companies like these three may be offering investors an opportunity to buy. Source: Masimo Corp No. 1: Masimo Corporation Masimo manufactures medical devices used to monitor patient health, including pulse oximeters that are used to measure oxygen levels in patient blood. The company generates its sales directly and via royalties earned on sales of products by companies licensing its technology, including GE Medical and Medtronic . In the second quarter, Masimo's product revenue rose 10.6% to $147.6 million, leading to total revenue, including royalty payments, of $155.7 million, up 10.5% year over year. In addition to growing its top line by a double digit percentage, Masimo is leveraging growth for bottom line upside, too. Second quarter non-GAAP net income improved to $23.1 million, or $0.43, from $14.1 million, or $0.25 last year. Because sales and profit have (so far) outpaced its internal forecast this year, Masimo upped its full year outlook in August and, based on that guidance, Masimo expects to deliver top line and GAAP bottom line results of $621 million and $1.43 per share, respectively, up from prior guidance for $608 million and $1.33 per share, respectively. Since Masimo shares have retreated about 9% in the past week, it could be the perfect time to sprinkle some shares of this medtech company into portfolios. Source: Abiomed No. 2: Abiomed A 60% jump in U.S. sales of Abiomed's Impella line of blood pumping devices used in heart disease patients continues a string of rapid growth that has been driving shares in the company higher. The company's success is being supported this year by the recent launch of the Impella 2.5, which expands Abiomed's position in high risk heart procedures. In its most recently reported fiscal first quarter, Abiomed notched sales of $73.4 million, up 50% from last year, and delivered EPS of $0.20, which was handily north of analysts $0.08 forecast. Following that performance, Abiomed now expects its full year sales will eclipse $300 million in 2015, up from its prior estimates for sales of at least $285 million. If Abiomed delivers on that revenue goal, then it should have little trouble rewarding investors with earnings growth. In the past month, analysts have boosted their fiscal 2016 full year EPS forecast to $0.75 from $0.60 and increased their 2017 full year EPS forecast to $1.10 from $0.87. Although those increases aren't enough to make Abiomed a cheap stock, its rapid growth and debt-free balance sheet could make it worth buying; especially if it continues to drop. Source: DexCom No. 3: DexCom Few healthcare trends are likely to provide the tailwinds for demand for care than the rising diabetes prevalence. The International Diabetes Federation estimates that there are 387 million people with diabetes worldwide and that there will be 592 million people with diabetes by 2035. That's a shocking forecast, but if it proves to be true, then there will be exponentially greater demand in the future for devices like DexCom's, which are used by both type 1 and type 2 diabetes patients to track and chart their blood sugar levels. By tracking blood sugar continuously, patients are better able to manage when to administer insulin, which may help reduce the likelihood of diabetes related diseases, such as heart disease, that can be caused by poorly controlled blood sugar over time. The potential to better control diabetes is already resonating with doctors and patients. Last year, DexCom's sales grew 62% to $259.2 million and sales total $165.7 million through the first six months of this year, up 58% from a year ago. That's impressive, but ongoing innovation could lead to sensors that are placed on the skin like a Band-Aid, rather than inserted under the skin, and that could result in even greater growth. Earlier this month, DexCom inked a deal with Google to develop next generation miniature electronics that could be used to create smaller and less intrusive sensors than exist today. With a strong balance sheet, a growing installed customer base, and demographics offering significant potential market growth, DexCom could also be a profit friendly long haul investment worth considering. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article 3 Little-Known Medtech Stocks Investors Ought To Consider originally appeared on Fool.com. Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of General Electric Company and Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Panic-Proofing the Small Investor"", ""DexCom Wins FDA Approval for G5 CGM System; Stock Up""]"
DXCM,2015-08-27,23.3975,23.7375,23.0,23.435,
DXCM,2015-08-28,23.2025,23.9175,23.2025,23.5475,
DXCM,2015-08-31,23.325,24.06,23.275,23.535,"[""This Top Diabetes Stock Just Extended Its Lead The G5 announcement has a great chance of helping the company accelerate its already torrid growth rate, which could allow the stock to continue its market-beating ways from today's nosebleed valuation. However, as bullish as I am on the company's competitive position in the market and its huge opportunity ahead, its stock is simply far too richly valued for my taste. Until the company trades at a more reasonable valuation, I'm content to keep my distance from the stock and will continue to root from the sidelines for this diabetes winner to keep on advancing. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article This Top Diabetes Stock Just Extended Its Lead originally appeared on Fool.com. Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Google to work with Sanofi to fight diabetes Google Inc. said Monday its health-care-research unit agreed to work with European pharmaceutical major Sanofi SA on new ways to monitor and treat diabetes. The companies declined to say how much they are investing in the partnership. Sanofi is a leading maker of diabetes medication, as well as many other drugs.""]"
DXCM,2015-09-01,22.745,23.0675,21.8475,21.955,
DXCM,2015-09-02,22.2975,22.505,21.86,22.3425,"[""InsiderInsights.com Daily Round Up 9/1/15: Diamondback Energy, Gap, NuStar, Opko Health"", ""InsiderInsights.com Daily Round Up 9/1/15: Diamondback Energy, Gap, NuStar, Opko Health"", ""InsiderInsights.com Daily Round Up 9/1/15: Diamondback Energy, Gap, NuStar, Opko Health""]"
DXCM,2015-09-03,22.4725,22.66,21.955,22.0025,
DXCM,2015-09-04,21.75,22.245,21.6625,22.0775,
DXCM,2015-09-08,22.4725,22.8425,22.2,22.7625,
DXCM,2015-09-09,22.925,22.975,22.5625,22.71,
DXCM,2015-09-10,22.62,24.45,22.579,24.1075,"[""Premarket Biotech Digest: Cancer Hallmarks, Gilead's Truvada For HIV Prevention, MannKind Downgraded"", ""Dexcom Spikes to High on Volume"", ""Dexcom Spikes to High on Volume"", ""Premarket Biotech Digest: Cancer Hallmarks, Gilead's Truvada For HIV Prevention, MannKind Downgraded"", ""Dexcom Spikes to High on Volume"", ""Premarket Biotech Digest: Cancer Hallmarks, Gilead's Truvada For HIV Prevention, MannKind Downgraded""]"
DXCM,2015-09-11,23.9175,24.4875,23.6025,24.3525,"[""DexCom - Getting Connected"", ""DexCom - Getting Connected"", ""DexCom - Getting Connected""]"
DXCM,2015-09-14,24.4775,24.6425,23.7575,23.9325,
DXCM,2015-09-15,24.0,24.275,23.8325,24.18,"[""Top Weekly Insider Sells Highlights"", ""Top Weekly Insider Sells Highlights"", ""3 MedTech Stocks to Sprinkle Into Your Portfolios Image Source: Intuitive Surgical. While biotech stock tends to dominate the healthcare headlines, another part of the healthcare sector quietly goes about its ways, and investors in this space have banked great returns during the years. What is this lesser known part of the healthcare industry? Medical devices. Unlike pharmaceuticals, medical devices are not nearly as susceptible to generic competition, and their often high learning curves can help to create high switching costs among their users, which can lead to favorable economics. Better yet, the wind is at their backs as an industry; aging populations and the growth of emerging markets factor nicely into this industry's long-term playbook. We asked our team of Motley Fool contributors to pitch a medical equipment or device stock that they believe could make a nice addition to your portfolio. Read below why we think that DexCom , Intuitive Surgical , and RTI Surgical might be worth buying. Todd Campbell : The convergence of technology and medicine is leading to a wave of innovation designed to improve health, including the use of data analytics to track and report real-time blood-sugar levels in diabetics. At the forefront of this emerging trend is DexCom , a maker of glucose monitoring sensors and devices. DexCom's products are used by type 1 and type 2 diabetics to better control their diseases, and sales are soaring. In Q2, DexCom reports sales jumped 59%, to $93.2 million. You're right to think that DexCom's growth is impressive, but even better days may lie ahead of it. According to the International Diabetes Federation, the number of diabetics globally is going to jump by 205 million people during the next 20 years. If they're right, there's going to be a massive need for medtech products like DexCom's that may slow the disease's progression. To address that opportunity, DexCom announced last month that it's partnering with Google to develop inexpensive miniaturized electronics that can be used in small, bandage-sized, disposable sensors. If that effort pans out, then it will serve as yet another reason why DexCom is one medtech company worth owning. Brian Feroldi : One of my favorite reasons that I like to invest in MedTech stocks is that they tend to offer high switching costs. After all, once a healthcare provider goes through the arduous process of learning how to use the device, they will likely be highly reluctant to switch to another device, even if there's a cost savings to doing so. One of my favorite companies in the space that offers tremendous switching costs is Intuitive Surgical , the worldwide leader in robotic surgery. Once a hospital takes on the expense of installing a machine, and one of its doctors is trained for hours on how to operate it, you can bet that they would be extremely resistant to learning another system. Intuitive Surgical produces the da Vinci surgical systems, which allow physicians to remotely control robotic arms that allow for minimally invasive surgical procedures. The system offers doctors greater access and visibility into a variety of surgical procedures, and it offers patients fewer scars, less blood loss, and a shorter stay at the hospital. Intuitive offers investors a terrific razor/razor blade business model that creates revenue from both sales of the systems themselves, as well as from consumables used in every procedure performed. In addition, the company inks a high-margin service contract along with every system sold that helps to juice the bottom line, which creates a nice one, two, three punch that should keep the dough flowing into shareholders' pockets for years. Shares in this best-of-breed medical-device maker rarely come cheap; even now, the shares are trading for a steep 38 times trailing earnings. However, Intuitive is a leader in the space, and is nicely positioned to continue to dominate the growing robotic surgery market. Investors who want in on this long-term trend might want to add some shares to their portfolios today, and add more on any weakness in the share price. George Budwell : RTI Surgical is an under-the-radar global surgical-implant company with high-growth potential, and a manageable risk profile that investors may want to check out. The company has three core business segments, namely biologic-based allograft and xenograft implants, hardware composed of metal and synthetic-based implants, and focused products such as nanOss advanced bone graft substitute, Fortiva porcine dermis, and map3 allograft. The key reason to keep an eye on this small-cap medtech company is that management has outlined a bold plan to grow its revenue by 92%, and improve operating margins by more than 300% from 2014 levels. To achieve this goal, management believes that focused products will lead the way, along with an expanding international footprint, especially in Asia. The good news is that RTI posted a 10% increase in total revenues, to $71.6 million in the second quarter compared to a year ago, on a constant-currency basis. And its gross profits edged higher by low single digits, as well, in the first half of 2015, relative to a year ago. Management therefore appears to be delivering -- at least so far -- on its stated goal of reaching $500 million in revenue, and improving profitability, making this an intriguing stock to watch in the crowded medtech space. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article 3 MedTech Stocks to Sprinkle Into Your Portfolios originally appeared on Fool.com. Brian Feroldi owns shares of Intuitive Surgical. George Budwell has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool owns and recommends Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top Weekly Insider Sells Highlights According to GuruFocus Insider Data , the largest insider sells during the past week were DexCom Inc. ( NASDAQ:DXCM ), Gilead Sciences Inc. ( NASDAQ:GILD ), Palo Alto Networks Inc. ( NYSE:PANW ) and Salesforce.com Inc. ( CRM ). The overall trend of insiders is illustrated in the chart below: DexCom Inc.: Executive Chairman Terrance H. Gregg sold 160,001 shares DexCom Executive Chairman Terrance H. Gregg sold 160,001 shares during the past week at an average price of $95.73 per share. Warren Buffett Recent Buys DexCom designs, develops and commercializes glucose monitoring systems for ambulatory use by people with diabetes. The company has a market cap of $7.67 billion; its shares were traded at around $95.73 with and P/S ratio of 23.24. The company has released its second quarter 2015 results. In this period, the company grew total revenue to $93.2 million, an increase of 59% over the same quarter in 2014. Total gross profit was $66 million, compared to $39.9 million for the prior year quarter. Net loss was $3.7 million, or $0.05 per share for the second quarter of 2015 compared to a net loss of $6.0 million, or $0.08 per share last year. Director Jonathan T. Lord also recently sold shares of DXCM stock. Gilead Sciences Inc.: President and COO John F. Milligan sold 100,000 shares President and COO John F. Milligan sold 100,000 shares of GILD stock on Sept. 8 at the average price of $103.39 per share. Milligan owns at least 1,029,108 shares now. The price of the stock has increased by 5.76% since. Gilead Sciences has a market cap of $160.48 billion; its shares were traded at around $109.35 with a P/E ratio of 11.48 and P/S ratio of 5.92. The dividend yield of Gilead Sciences stocks is 0.39%. Gilead Sciences had an annual average earnings growth of 27.20% over the past five years. For its second quarter of 2015, Gilead reported total revenues of $8.24 billion and net income of $4.5 billion. This compares to revenues of $6.54 billion and net income of $3.66 billion in the same quarter of last year. Diluted EPS for its second quarter of 2015 were $2.92. Chairman and CEO John C. Martin and multiple other insiders recently have sold shares of GILD stock. Palo Alto Networks Inc.: CFO Steffan Tomlinson sold 60,000 shares Palo Alto Networks CFO Steffan Tomlinson sold 60,000 shares on Sept. 9 at an average price of $179.54 per share. Palo Alto Networks has a market cap of $15.02 billion, and its shares were traded at around $179.54 with and P/S ratio of 17.54. The company has recently reported its fiscal fourth quarter 2015 results ended July 31. Total revenue for this quarter improved 59% year-over-year to $283.9 million, and non-GAAP net income per share increased to $0.28 from $0.11 in the year-ago quarter. CTO Nir Zuk sold 30,000 shares of PANW stock on Sept. 8 at the average price of $164.49. Salesforce.com Inc.: CFO Mark J. Hawkins sold 103,494 shares Salesforce.com CFO Mark J. Hawkins sold 103,494 shares during the past week at an average price of $69.89 per share. Salesforce.com has a market cap of $46.13 billion; its shares were traded at around $69.89 with a P/S ratio of 7.57. The company had an annual average earnings growth of 14.20% over the past 10 years. Salesforce.com has released its fiscal second quarter 2016 results ended July 31. For this quarter, non-GAAP diluted EPS were $0.19 and revenue was $1.63 billion. Deferred revenue was $3.03 billion, an increase of 29% over the prior year quarter. Chairman of the Board and CEO Marc Benioff and multiple other insiders also have sold shares of CRM stock. For the complete list of stocks that bought/sold by their company executives, go to: Insider Buys. About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members . This article first appeared on GuruFocus . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top Weekly Insider Sells Highlights""]"
DXCM,2015-09-16,24.1475,24.4175,23.9025,24.3675,
DXCM,2015-09-17,24.53,25.8225,24.42,25.4775,
DXCM,2015-09-18,25.0575,25.6675,24.9775,25.0,
DXCM,2015-09-21,25.2725,25.4,24.5875,24.9725,
DXCM,2015-09-22,24.74,24.74,24.0625,24.3625,
DXCM,2015-09-23,24.3325,25.18,24.07,25.1375,
DXCM,2015-09-24,25.0275,25.0525,23.8875,24.26,
DXCM,2015-09-25,24.56,24.57,22.6975,23.015,"[""With Valuation Looking Stretched, DexCom Is Getting Risky"", ""With Valuation Looking Stretched, DexCom Is Getting Risky"", ""With Valuation Looking Stretched, DexCom Is Getting Risky""]"
DXCM,2015-09-28,22.56,22.855,20.56,21.2075,
DXCM,2015-09-29,21.145,21.645,20.515,20.7475,
DXCM,2015-09-30,21.075,21.4925,20.865,21.465,
DXCM,2015-10-01,21.4025,21.505,20.9575,21.42,
DXCM,2015-10-02,21.5875,21.7425,20.92,21.6775,"Are Medtronic's Competitors Finally Catching Up? Medical device juggernaut Medtronic is a big player in the world of healthcare, and it holds strong competitive positions in a huge number of diseases including cardiac care, minimally invasive surgery, spinal surgery, and more. One division that is certainly an important long-term growth driver for Medtronic's business is its diabetes franchise, as the diabetes market is simply huge. The American Diabetes Association estimates that about 29 million Americans had either type 1 or type 2 diabetes in 2012, and the numbers get bigger in a hurry when you include the rest of the world. Medtronic is currently the leader in selling medical devices that help patients control their blood sugar levels, as the company has long dominated the market for both insulin pumps and continuous glucose monitoring devices. In fiscal year 2015, which ended for the company in April, Medtronic reported preliminary net sales of more than $1.7 billion from its diabetes division, up more than 9% over the previous year on a constant currency basis, making it one of the faster-growing divisions in the company. More recently, diabetes pump upstart Tandem Diabetes announced that the FDA has approved the sale of its t:slim G4 pump that works with the Dexcom's G4 system. Since its launch, Tandem has been attracting customers at a rapid pace, as its sleek insulin pump features a touchscreen interface many patients find appealing. Source: Tandem Diabetes. The company has been chipping away at market share of the pump market since its launch, and it managed to ship an impressive 3,331 pumps in the second quarter alone, up a sharp 49% over the year-ago period, and that was without having a continuous glucose monitor hooked up to it. Now that the t:slim G4 insulin pump is approved, Tandem should see sales accelerate from their already torrid pace, which could cause a flood of patients to move away from Medtronic's offerings. Another player in the space that has been a thorn in Medtronic's side for years is Insulet Corporation , which offer patients a tubeless insulin pump. While it looks like it will still be some time before this company will incorporate a continuous glucose monitor directly into its handheld receiver, they have already announced that they are working with -- you guessed it -- Dexcom on doing just that. 640G insulin pump. Source: Medtronic. Medtronic fights back Mind you, Medtronic isn't exactly sitting still as these smaller players offer unique features that set them apart from the giant. It has announced a new system it calls the 640G, which is currently being sold overseas and looks to finally bring the look of the company's pump into the 21st century. It features a brand-new layout and color screen that should appeal to its customers who have been choosing more user-friendly options, though it should be noted that it will not feature a touchscreen. However, this new pump may still help set it apart from competitors, as it will feature the ability to suspend delivery of insulin as a patient's glucose levels get low, and resume pumping once glucose levels have a chance to recover. If the company can get that approved, it would certainly be an important step in the race to create an artificial pancreas. The pump will also work with a newer version of the company's sensor, dubbed the Enhanced Enlite, that promises greater accuracy and increased patient comfort. The 640G is currently available for sale overseas, but the device has not yet been submitted to the FDA, as phase 3 clinical trials for the device are currently under way. Now what? Competition in the space continues to look fierce as these companies battle head-to-head for dominance in the space. Medtronic is still far and away the leader, and the odds look good that it will continue to hold that title for the foreseeable future, but it's by no means my favorite name for investing in the space. Medtronic investors would be wise to watch these smaller competitors closely. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here . The article Are Medtronic's Competitors Finally Catching Up? originally appeared on Fool.com. Brian Feroldi owns shares of Insulet. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-10-05,21.8375,22.1825,20.9025,21.14,
DXCM,2015-10-06,21.1975,21.1975,19.5675,20.03,
DXCM,2015-10-07,20.105,20.1625,19.4325,19.665,
DXCM,2015-10-08,19.6475,19.8,18.6875,19.4975,
DXCM,2015-10-09,19.61,19.6175,19.035,19.3875,
DXCM,2015-10-12,19.3825,19.785,18.9775,19.49,
DXCM,2015-10-13,19.235,19.3175,18.7875,18.86,
DXCM,2015-10-14,18.7475,18.795,17.5725,17.6625,"[""After Hours Gainers / Losers"", ""DEXCOM"", ""DexCom Reports Q3 Prelim Revs $105M vs Est $97.47M"", ""5 After-Hours Movers: Netflix, MBIA And More"", ""5 After-Hours Movers: Netflix, MBIA And More"", ""DexCom Reports Q3 Prelim Revs $105M vs Est $97.47M"", ""DEXCOM"", ""After Hours Gainers / Losers"", ""DXCM Makes Notable Cross Below Critical Moving Average In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $73.57, changing hands as low as $70.31 per share. DexCom Inc shares are currently trading down about 5.7% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $38.91 per share, with $103.29 as the 52 week high point - that compares with a last trade of $71.23. According to the ETF Finder at ETF Channel, DXCM makes up 4.20% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading relatively unchanged on the day Wednesday. Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 After-Hours Movers: Netflix, MBIA And More"", ""DexCom Reports Q3 Prelim Revs $105M vs Est $97.47M"", ""DEXCOM"", ""After Hours Gainers / Losers""]"
DXCM,2015-10-15,19.955,21.35,19.1225,21.0875,"[""DexCom (DXCM) Leaps on Q3 Numbers"", ""DexCom (DXCM) Crumbles: Stock Falls by 6.4%"", ""Stock Futures Up, Paring Gains; Seagate, Garmin, Valeant Tumble"", ""Premarket Gainers / Losers as of 9:10 am"", ""Midday Gainers / Losers"", ""Sterne Agee CRT Upgrades DexCom to Buy, Announces $90.00 PT"", ""Leerink Swann Upgrades DexCom to Outperform, Raises PT to $100.00"", ""Benzinga's Top #PreMarket Gainers"", ""Morning Market Gainers"", ""Benzinga's Top Upgrades"", ""Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates"", ""Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher"", ""Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results"", ""Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results"", ""Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher"", ""Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates"", ""Benzinga's Top Upgrades"", ""Morning Market Gainers"", ""Benzinga's Top #PreMarket Gainers"", ""Leerink Swann Upgrades DexCom to Outperform, Raises PT to $100.00"", ""Sterne Agee CRT Upgrades DexCom to Buy, Announces $90.00 PT"", ""Midday Gainers / Losers"", ""DexCom (DXCM) Leaps on Q3 Numbers"", ""Stock Futures Up, Paring Gains; Seagate, Garmin, Valeant Tumble"", ""Premarket Gainers / Losers as of 9:10 am"", ""DexCom (DXCM) Crumbles: Stock Falls by 6.4%"", ""Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results Toward the end of trading Thursday, the Dow traded up 1.04 percent to 17,100.39 while the NASDAQ climbed 1.44 percent to 4,851.56. The S&P also rose, gaining 1.21 percent to 2,018.35. Leading and Lagging Sectors In trading on Thursday, healthcare shares jumped by 1.77 percent. Top gainers in the sector included DexCom, Inc. (NASDAQ: DXCM ), up 20 percent, and Dyax Corp. (NASDAQ: DYAX ), up 16 percent. In trading on Thursday, basic materials shares rose by just 0.14 percent. Meanwhile, top losers in the sector included HORSEHEAD HOLDING CORP. (NASDAQ: ZINC ), down 12 percent, and KMG Chemicals, Inc. (NYSE: KMG ), off 9 percent. Top Headline Citigroup Inc (NYSE: C ) reported better-than-expected earnings for the third quarter on Thursday. The New York-based bank posted a quarterly profit of $4.29 billion, or $1.35 per share, versus $2.84 billion, or $0.88 per share, in the year-ago period. Excluding accounting adjustments, Citigroup earned $1.31 per share. Its revenue dropped to $18.69 billion from $19.69 billion, while revenue excluding accounting adjustments fell 8 percent to $18.5 billion. Analysts were expecting a profit of $1.28 per share on revenue of $18.5 billion. Equities Trading UP Five Prime Therapeutics Inc (NASDAQ: FPRX ) shares shot up 64 percent to $27.74 following announcement of worldwide license, collaboration agreement on CSF1R antibody program with Bristol-Myers Squibb Co (NYSE: BMY ). Shares of Keryx Biopharmaceuticals (NASDAQ: KERX ) got a boost, shooting up 7 percent to $3.98 after the company reported a $125 million private placement of Convertible Senior Notes due 2020, with the Baupost Group. DexCom, Inc. (NASDAQ: DXCM ) shares were also up, gaining 20 percent to $84.62 after the company reported preliminary unaudited revenue for the third quarter of roughly $105 million, up 52 percent year-over-year. Equities Trading DOWN Imprivata Inc (NYSE: IMPR ) shares tumbled 33 percent to $11.56 after the company reported preliminary third quarter financial results. Shares of Garmin Ltd. (NASDAQ: GRMN ) were down 14 percent to $31.68 on weak Q3 preliminary results. Netflix, Inc. (NASDAQ: NFLX ) was down, falling 9 percent to $100.75 after the company reported Q3 results. The company added 3.62 million streaming subscribers during the recent quarter. It added 0.88 million new US members in the latest quarter. Commodities In commodity news, oil traded down 0.19 percent to $46.55, while gold traded up 0.59 percent to $1,186.80. Silver traded up 0.33 percent Thursday to $16.17, while copper rose 0.58 percent to $2.43. Eurozone European shares were higher today. The eurozone's STOXX 600 climbed 1.46 percent, the Spanish Ibex Index rose 0.64 percent, while Italy's FTSE MIB Index surged 1.74 percent. Meanwhile, the German DAX climbed 1.50 percent, and the French CAC 40 jumped 1.44 percent, while U.K. shares rose 1.10 percent. Economics The consumer price index dropped 0.2 percent in September, versus economists' expectations for a 0.2 percent decline. US jobless claims declined 7,000 to 255,000 in the week ended October 10. Economists were estimating claims to total 270,000. The Empire State manufacturing index increased to negative 11.36 in October, compared to negative 14.67 in September. Economists were expecting a reading of negative 8. The Philadelphia Fed manufacturing index gained to a reading of negative 4.5 in October, versus a reading of negative 6.0 in September. Economists were expecting a reading of negative 1.0. Crude supplies gained 7.6 million barrels for the week ended October 9, the U.S. Energy Information Administration said. However, analysts were estimating supplies to rise by 1.8 million barrels. Gasoline supplies declined 2.6 million barrels, while distillate stockpiles shrank 1.5 million barrels last week. \u00a9 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Crumbles: Stock Falls by 6.4% DexCom, Inc.DXCM saw a big move last session, as the company's shares fell by over 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for DXCM, as the stock is now down nearly 27% in the past one-month time frame. The company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks, and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump. DXCM currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%. Investors interested in the Medical Instruments industry may consider better-ranked stock like Masimo MASI , which carries a Zacks Rank #1 (Strong Buy). Is DXCM going up? Or down? Predict to see what others think: Up or Down Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Dexcom Inc is Soaring Today What: Shares of Dexcom , a company that makes continuous glucose monitors that help people with diabetes monitor their blood glucose levels, were up more than 13% this morning after the company releases preliminary results for its third quarter. So what: The company expects to report third quarter revenue of roughly $105 million, which would be a 52% jump over the year ago period. That number is far higher than analysts were expecting, as the pros were modeling for revenue only landing around $97 million during the period. Investors cheered the revenue beat, sending shares much higher today. Now what: Customers apparently are thrilled with the company's new system , called the G5 mobile, as Kevin Sayer, Dexcom's President and Chief Executive Officer, noted in the release: Chances are good that the good times will continue to roll for the company as well, as both Tandem Diabetes and Animas, a division of Johnson & Johnson , have received FDA approval to sell insulin pumps that talk directly to Dexcom's sensor, which is a key feature that up until recently Medtronic's diabetes division has had all to itself . Once again, Dexcom simply knocked the cover off the ball. Investors with an interest in the diabetes space might want to consider adding a few shares of this long term winner to their portfolio. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article Why Dexcom Inc is Soaring Today originally appeared on Fool.com. Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates Following the market opening Thursday, the Dow traded up 0.38 percent to 16,988.88 while the NASDAQ climbed 0.83 percent to 4,822.54. The S&P also rose, gaining 0.52 percent to 2,004.58. Leading and Lagging Sectors In trading on Thursday, technology shares jumped by 0.72 percent. Top gainers in the sector included Advanced Semiconductor Engineering (ADR) (NYSE: ASX ), up 8 percent, and LG Display Co Ltd. (ADR) (NYSE: LPL ), up 7 percent. In trading on Thursday, basic materials shares slipped by 0.28 percent. Meanwhile, top losers in the sector included Koppers Holdings Inc. (NYSE: KOP ), down 9 percent, and KMG Chemicals, Inc. (NYSE: KMG ), off 7 percent. Top Headline Citigroup Inc (NYSE: C ) reported better-than-expected earnings for the third quarter on Thursday. The New York-based bank posted a quarterly profit of $4.29 billion, or $1.35 per share, versus $2.84 billion, or $0.88 per share, in the year-ago period. Excluding accounting adjustments, Citigroup earned $1.31 per share. Its revenue dropped to $18.69 billion from $19.69 billion, while revenue excluding accounting adjustments fell 8 percent to $18.5 billion. Analysts were expecting a profit of $1.28 per share on revenue of $18.5 billion. Equities Trading UP Five Prime Therapeutics Inc (NASDAQ: FPRX ) shares shot up 49 percent to $25.15 following announcement of worldwide license, collaboration agreement on CSF1R antibody program with Bristol-Myers Squibb Co (NYSE: BMY ). Shares of Keryx Biopharmaceuticals (NASDAQ: KERX ) got a boost, shooting up 12 percent to $4.19 after the company reported a $125 million private placement of Convertible Senior Notes due 2020, with the Baupost Group. DexCom, Inc. (NASDAQ: DXCM ) shares were also up, gaining 12 percent to $79.13 after the company reported preliminary unaudited revenue for the third quarter of roughly $105 million, up 52 percent year-over-year. Equities Trading DOWN Imprivata Inc (NYSE: IMPR ) shares tumbled 36 percent to $11.00 after the company reported preliminary third quarter financial results. Shares of Garmin Ltd. (NASDAQ: GRMN ) were down 11 percent to $32.77 on weak Q3 preliminary results. Manitowoc Company Inc (NYSE: MTW ) was down, falling 13 percent to $14.18 after the company issued preliminary Q3 results. Commodities In commodity news, oil traded down 1.82 percent to $45.79, while gold traded up 0.12 percent to $1,181.20. Silver traded down 0.32 percent Thursday to $16.07, while copper fell 0.31 percent to $2.41. Eurozone European shares were higher today. The eurozone's STOXX 600 climbed 1.29 percent, the Spanish Ibex Index rose 0.58 percent, while Italy's FTSE MIB Index surged 1.36 percent. Meanwhile, the German DAX climbed 1.51 percent, and the French CAC 40 jumped 1.42 percent, while U.K. shares rose 1.11 percent. Economics The consumer price index dropped 0.2 percent in September, versus economists' expectations for a 0.2 percent decline. US jobless claims declined 7,000 to 255,000 in the week ended October 10. Economists were estimating claims to total 270,000. The Empire State manufacturing index increased to negative 11.36 in October, compared to negative 14.67 in September. Economists were expecting a reading of negative 8. The Philadelphia Fed manufacturing index gained to a reading of negative 4.5 in October, versus a reading of negative 6.0 in September. Economists were expecting a reading of negative 1.0. \u00a9 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results"", ""Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher"", ""Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates"", ""Benzinga's Top Upgrades"", ""Morning Market Gainers"", ""Benzinga's Top #PreMarket Gainers"", ""Leerink Swann Upgrades DexCom to Outperform, Raises PT to $100.00"", ""Sterne Agee CRT Upgrades DexCom to Buy, Announces $90.00 PT"", ""Midday Gainers / Losers"", ""DexCom (DXCM) Leaps on Q3 Numbers"", ""Stock Futures Up, Paring Gains; Seagate, Garmin, Valeant Tumble"", ""Premarket Gainers / Losers as of 9:10 am"", ""DexCom (DXCM) Crumbles: Stock Falls by 6.4%""]"
DXCM,2015-10-16,21.0975,21.5375,20.5325,20.82,"[""Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies"", ""Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies"", ""Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies Shares of DexCom Inc. DXCM surged 19.4% ($13.70) to close at $84.35 on Oct 15, after the company announced an encouraging revenue forecast for the third quarter of 2015 that ended on Sep 30. The company is set to report third-quarter results on Nov 4. DexCom expects revenues to rise an impressive 52% on a year-over-year basis to $105 million, much higher than the current Zacks Consensus Estimate of $98 million. The Zacks Consensus Estimate for earnings is currently pegged at a breakeven for the quarter. DexCom is riding high on the back of its healthy product portfolio and innovative pipeline. We note that the company enjoys a strong market presence, thanks to G4 PLATINUM System, which is the industry's first mobile connected continuous glucose monitoring (CGM) system. Meanwhile, DexCom's CGM and mobile apps - Share 2 and Follow - are approved by the FDA and allow both users and followers to view glucose data directly on Android and iOS-enabled devices. In late August, the FDA approved the G5 Mobile CGM System of the company. The fully portable product is the first and solitary CGM system permitted by the FDA for use in both adults and children above two years of age. The transmitter, with in-built Bluetooth, sends essential glucose information directly to an app on iOS-enabled devices for instantaneous diabetes supervision. The company intends to launch the app for android devices in early 2016. The company has already started shipping the device. It is also well on track to conduct a pre-pivotal study with its gen 6 sensors later this year. Following that, the company will look to commence a pivotal study. Meanwhile, DexCom expects to launch gen 6 in early 2017. Apart from innovative product launches, strategic partnerships with the likes of Apple and Google, which boast a vast global presence, are expected to boost DexCom's business scale massively. In August, the company entered into a partnership with Google's life sciences team to develop a series of CGM devices that will be compact (\""bandage-sized sensor\""), easy to use and more economic than the existing products. The devices will be disposable and can be used by all types of diabetes patients. As technology is becoming a more relevant and indispensable part of people's lives, we feel that the Google collaboration will go a long way in enhancing the brand value of DexCom's products and services. The combination of Google's miniaturized electronics platform with DexCom's superior sensor technology is expected to develop CGMs that will help patients manage diabetes better. Moreover, by expanding its range of solutions and services, DexCom improves its international presence that will enhance top-line growth. However, high product development costs, research & development as well as marketing expenses will continue to hurt margins, which is a concern for the near term. Uncertainty over reimbursement also remains a headwind in our view. Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include Masimo MASI , Mazor Robotics MZOR and Cyberonics CYBX . All the three stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report MAZOR ROBOTICS (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sponsored Links Want to know more? click here chestnutcarbon.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Likely Winners in a Medical Device Tax Repeal? Prepare to Be Surprised Medtronic's Twin Cities marathon (Source: Flickr, Creative Commons). If you listen to its critics, the controversial 2.3% Obamacare medical device tax has been a kick in the pants to the entire U.S. medical device industry. In its most recent 10K, med-tech behemoth Medtronic said it shelled out $135 million on the tax in its 2015 fiscal year. Medtronic has been vocal that the tax is onerous, eroding its ability to create jobs and expand research. The company also leads the pack in cranking up its lobbying on Capitol Hill, with over $5 million in lobbying expenses last year. But healthcare -- and healthcare reform -- is extremely complicated. Those who are paying the most for the tax aren't necessarily suffering the most. In fact, overall net profits reported by the 102 largest U.S.-based med-tech companies increased a comfortable 7% from 2013 to 2014, and a downright off-the-hook 19% the year before that, according to a survey of company data by the Government Accountability Office. Drilling down a little further If you look deeper, however, you'll find another story. And this one isn't nearly so rosy. Unlike the pharmaceutical industry, a large number of smaller device companies with one or two products characterize the device industry. These companies don't have the pricing edge of a Medtronic or Johnson & Johnson , which are the go-to sellers of a wide range of medical supplies. Smaller companies are much more sensitive to the impact of the device tax, since they are less able to simply pass on the tax to their customers. In addition, since the tax is on sales , not profit, the tariff eats up most of the profits of many of these small players, if they have any. We're not talking only pie-in-the-sky start-ups here. Because of the lengthy and somewhat unpredictable regulatory process that must be negotiated before a medical device can be sold, it can take from $70 million to $100 million in total sales before a med-tech becomes profitable. Statistics bear this out. While leading U.S. med-techs are logging record profits, smaller device companies are feeling tremendous margin pressure. In a survey done by the U.S. Government Accountability Office, nearly all of the reported increase in net profit for the 102 companies surveyed came from the 30 big caps with sales of over $1 billion per year. By contrast, the 72 smaller companies surveyed reported an overall net loss over the same years. What's the real risk of this tax? Probably the key argument against the medical device tax is that it throttles small-company innovation. Medical device firms that are entering the market have a harder time becoming profitable with the additional cost of this excise tax. In turn, this would give an advantage to larger, more established firms, reducing the competitiveness of the industry. As Boston-based AbioMed's CEO Michael Minogue told NPR: \""I don't think taxing the innovators and taxing the group of companies that provide innovation for healthcare is a smart idea, but the biggest concern I have, and what's unprecedented, is to tax companies that are not yet profitable, and in our industry where 70% of the companies are not yet profitable, this is going to have detrimental effects in their job growth, in their survival.\"" Whether it's in the realm of point-of-care technology or personalized medicine, it's these under-the-radar companies that are likely to solve some of the major issues healthcare faces today. Unfortunately, when the profits of an early stage medical device company are wiped out, it can also snuff out their ability to fund research and development activities that could ultimately greatly benefit those who need their devices. Mark Throdahl is the CEO of privately held OrthoPediatrics, the world's only company specializing in making orthopedic equipment for children. Throdahl said on the matter: \""This is a very burdensome tax because it is based on sales, not profits. In terms of magnitude, the tax is about the size of our entire product development budget.\"" Other companies are in worse straits. \""We're actually borrowing money to pay the excise tax,\"" said Tom Allen, CEO of another privately held device maker, Iconacy Orthopedic Patients. Like most of their peers, both these CEOs believe a tax on profit would be more fair -- and certainly more manageable for smaller medical device makers. Rather than seeing the glass as half empty, however, let's look at the other side. Here's who could win big if a repeal passes the finish line. The lives of tens of thousands of children have been strikingly transformed by pediatric medical devices and services. (Photo courtesy of Flickr, Creative Commons) Two fast-growing small caps that could hugely benefit In other words, while the big caps would net the highest dollar volume gain, it's the fast-growing smaller medical device stocks that should feel the greatest impact from a repeal. One such company is Dexcom , which recently nabbed FDA approval of a continuous glucose monitoring device to compete with Medtronic's similar device . Dexcom saw revenue growth of 58.5% last quarter and earnings growth of 38.33%, on a year-over-year basis. But its profit margins were a negative 3.97% in the quarter. While that's an improvement compared to 10.20% loss for the same quarter last year, a repeal could help nudge Dexcom into the black. Another example of a small medical device company that would benefit hugely from a repeal of the tax is Inogen , an innovator in oxygen therapy. Inogen's shares managed to float even higher in the recent sell-off and are up 61% since the beginning of the year. Inogen also saw its revenue grow 45% last quarter, over the same quarter last year. Inogen sells a portable oxygen concentrator that uses a chemical process to separate oxygen from nitrogen in the surrounding air. That means users don't have to drag along a heavy tank that only provides air for two to three hours. Inogen's device lasts nine hours and is rechargeable by plugging into a typical outlet. Like many small med-techs, however, Inogen relies heavily on domestic sales, so the medical device tax cuts deep. Inogen sells overseas, but the company experiences its strongest sales growth in the U.S., with domestic sales growing 80.5% last quarter. 1%-5% projected lift for industry leader Medtronic Of course, the larger companies in the industry would also gain from a repeal. When discussing the tax, Medtronic's CFO Gary Ellis said Medtronic would make \""trade-offs\"" and that \""we won't have as much to invest going forward.\"" Thus far, the trade-offs appear to have succeeded. Last fiscal year, Medtronic saw its net profit margins exceed 20%, putting it on par with many pharmaceutical giants. In the face of that, a 2.3% tax doesn't seem onerous. Still, while the company seems to have successfully passed on the cost of the tax to the hospitals that purchase its devices, hospitals are becoming more cost-conscious. While it's hard to put a dollar amount to how much of an impact a repeal could have, Bernstein Research has noted that a repeal of the tax could boost the medical device companies' profits by 1% to 5%. He also named Medtronic as a key beneficiary. Can a Senate repeal override the expected veto? The House has already voted to repeal the device tax. The next hurdle is a Senate vote before it reaches President Obama's desk. A Senate repeal seems highly likely, since last year in a non-binding Senate vote, 34 Democrats and 45 Republicans voted against it, saying it's a tax on innovation. Very much up in the air, however, is whether backers in the Senate can gain enough votes to override the expected presidential veto. President Obama has made it clear he believes the tax is necessary to pay for Obamacare. And even those most eager for repeal realize it's going to be hard to come up with a $30 billion offset to replace what the tax is projected to generate over 10 years. The takeaway Despite bipartisan protests, the medical device tax survived last year. While repeal looks more likely this year, Capitol Hill is always unpredictable. Investors should also note that a possible repeal could already be priced into the major med-tech stocks. The market typically prices in political events before reality confirms them. Still, there are stocks in this group that are worth watching. In particular, while EPS estimates for 2015 are mostly mediocre for med-tech, there are a handful of smaller stocks that expect spectacular growth. If you see the repeal gaining steam and grabbing headlines, you might want to look closer at the two small caps already mentioned, or RTI Surgical a small cap medtech which has a bold plan to grow its revenue by 92%. While these stocks are more volatile than large, established healthcare companies, they are also where an actual repeal could have the greatest impact. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article The Likely Winners in a Medical Device Tax Repeal? Prepare to Be Surprised originally appeared on Fool.com. Cheryl Swanson owns shares of Johnson & Johnson. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies""]"
DXCM,2015-10-19,20.845,21.225,20.54,20.8125,
DXCM,2015-10-20,20.685,20.9675,19.8875,20.145,
DXCM,2015-10-21,20.275,20.6125,19.405,19.9025,
DXCM,2015-10-22,20.05,20.1625,18.91,19.51,
DXCM,2015-10-23,19.6075,20.6575,19.5,20.625,
DXCM,2015-10-26,20.5325,21.015,20.28,20.63,
DXCM,2015-10-27,20.4475,20.9575,20.29,20.8975,
DXCM,2015-10-28,20.92,21.2075,20.46,21.0175,
DXCM,2015-10-29,20.945,21.125,20.4,20.6125,
DXCM,2015-10-30,20.66,21.0525,20.4275,20.83,
DXCM,2015-11-02,21.1475,21.8325,21.015,21.7025,"[""Morgan Stanley Initiates Coverage on DexCom at Overweight, Announces $106.00 PT"", ""Morgan Stanley Initiates Coverage on DexCom at Overweight, Announces $106.00 PT"", ""Morgan Stanley Initiates Coverage on DexCom at Overweight, Announces $106.00 PT""]"
DXCM,2015-11-03,21.5525,22.19,21.14,21.8575,
DXCM,2015-11-04,21.8475,22.16,21.5,21.7625,"[""Dexcom Reports Q3 Adj. EPS $(0.07) vs $(0.01) Est., Sales $105.2M vs $99.9M Est."", ""Dexcom Reports Q3 Adj. EPS $(0.07) vs $(0.01) Est., Sales $105.2M vs $99.9M Est."", ""Dexcom Reports Q3 Adj. EPS $(0.07) vs $(0.01) Est., Sales $105.2M vs $99.9M Est.""]"
DXCM,2015-11-05,20.155,21.4725,20.155,21.2025,"DexCom Q3 Loss Wider than Expected, Revenues Beat DexCom Inc.DXCM reported net loss of 7 cents per share in the third quarter of 2015, wider than the Zacks Consensus Estimate of loss of a penny. However, net loss per share was narrower than the year-ago equivalent of loss of 8 cents. Dexcom Inc. (DXCM) - Earnings Surprise | FindTheCompany Quarter Details Third-quarter revenues surged nearly 52.5% year over year to $105.2 million, which beat the Zacks Consensus Estimate of $100 million. The upside was driven by an impressive 53.5% jump in product revenues. Revenues in the third quarter were in line with the company's expectation. Average selling price (ASP) was in the range of $70−$75 per sensor while ASP for Dexcom's hardware stood at approximately $850 to $850 per starter kit. Gross margin expanded 260 basis points (bps) year over year to 71% primarily on the back of higher revenues and a favorable product mix, comprising roughly 30% of durable and 70% of consumable in the quarter. Selling, general and administrative (SG&A) expenses rose 55.2% on a year-over-year basis to $52.3 million. The upside may be attributed to increased head count in the company's organization (including both field sales and internal sales support staff). Additional marketing expenses were also a major reason behind the year-over-year increase. Research and development (R&D) expenses amounted to $64.8 million, as compared with $18.5 million in the year-ago quarter. The increase can be attributed to increased additional payroll related costs and expenses with respect to work on near-term product pipeline as well as an advanced product suite. DexCom reported operating loss of $42.4 million, much higher than the year-ago operating loss of $5.2 million, owing to escalating operating expenses. DexCom exited the third quarter with cash and cash equivalents of $85.3 million. Product Pipeline DexCom continues to make considerable progress with advanced Sensor technologies, including Gen 6. DexCom is also working on a new insertion system, new low-cost, high-quality receiver, and several generations of transmitters, which are designed to be more suitable for patients. The new insertion system will be used initially with the G5 sensor and algorithm. The company plans to launch the new receiver and insertion system in the U.S. in the second half of next year. Outlook DexCom expects revenues to exceed the top-end of the $350-$375 million range in 2015. Our Take DexCom has a healthy product portfolio and innovative pipeline, which we feel is a major growth catalyst. However, high product development costs, research & development as well as marketing expenses will continue to hurt margins, which is a concern for the near term. Uncertainty over reimbursement is another potent headwind. Zacks Rank & Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are Masimo MASI , Natus Medical BABY and Cesca Therapeutics KOOL . All the stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report CESCA THERAP (KOOL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-11-06,21.19,21.2675,20.7975,21.18,
DXCM,2015-11-09,20.99,21.31,20.7525,21.2575,
DXCM,2015-11-10,21.26,21.4375,20.9925,21.23,
DXCM,2015-11-11,21.3775,21.5175,21.015,21.185,
DXCM,2015-11-12,21.0775,21.1075,20.7275,20.8475,
DXCM,2015-11-13,20.7325,21.3075,20.67,21.105,
DXCM,2015-11-16,21.1275,21.2,20.565,20.75,
DXCM,2015-11-17,20.7325,20.97,20.62,20.7275,
DXCM,2015-11-18,20.8525,21.2875,20.655,21.245,
DXCM,2015-11-19,21.2,21.5825,21.1075,21.1525,
DXCM,2015-11-20,21.275,21.995,21.275,21.5725,
DXCM,2015-11-23,21.4575,21.7075,21.3275,21.5675,"[""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM"", ""Why Warren Buffett Would Pay 2X Current Market Price To Own CASM""]"
DXCM,2015-11-24,21.5625,21.7375,21.4,21.715,
DXCM,2015-11-25,21.75,22.0325,21.75,21.85,
DXCM,2015-11-27,21.8575,22.36,21.8575,22.2075,"Giving Thanks, Healthcare Style The end of November is certainly a time set aside for giving thanks. Many of us are thankful for our family and friends. But there are so many others out there -- healthcare workers and caregivers -- dedicating their lives to serving and enhancing the health of others. There are also pharmaceutical companies like Gilead Sciences , or medical device companies like Dexcom , and other healthcare entities doing 'heroic' advances in the industry, tirelessly working day in, day out with the noble mission of finding treatment for HIV or different forms of cancer. This holiday, we're thankful for innovation, passion, and greater purpose in the healthcare sector. A full transcript follows the video. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Kristine Harjes: Giving thanks, healthcare style. This is Industry Focus. Hi everyone, welcome to Industry Focus. I'm Kristine Harjes and I am thankful to be joined by Todd Campbell. We're recording this episode a little bit in advance, but Thanksgiving is still less than a week away. By the time you listeners are hearing this, you'll probably be practically smelling the turkey. I know, I for one am very thankful for being able to take a few days off to spend with my family, eat some great food, and hopefully come out of it with some amazing leftovers. How about you Todd? What are you feeling thankful for? Todd Campbell: Oh definitely anticipating those leftovers without a doubt. Harjes: It's so funny how that's like kind of the best part. Campbell: Oh, I know. There's nothing better than that big bulky sandwich the day after Thanksgiving. Harjes: Yeah just oozing gravy and stuffing. Oh my, I can't wait. Campbell: Yeah well in addition to the leftovers there's a few things that I'm thankful for healthcare-style. Of course one of them is the great team that we have here at the Motley Fool. You know, I've been in the business a long time and you guys, what we do here on the program is wonderful. And it's great having a wonderful teammate like you too Kristine. Harjes: Aw thanks, Todd. Yeah I'm so thankful that I get to talk to you and do this show every week. And even everybody that I get to work with at this company, you know from the writers, to the tech people that put on these shows. It's a really great place and I just say, I'm also thankful to work for a place that I can really get behind the mission. I mean the Motley Fool, everybody here wants to help the world invest better. And that is such a beautiful thing that I can be in a place that believes in this wholeheartedly, and everybody is so wicked smart and applying themselves to that mission. So cool. I'm thankful for that. Campbell: Absolutely. We started off today's episode by saying that we wanted to approach this with giving thanks healthcare style. In preparation for filming today and recording this episode, I started spending a lot of time thinking about what it is that's happening in healthcare that I'm really thankful for. And you know, one of the things that jumps to the top of my mind is how thankful I am that there are so many doctors and nurses and caregivers that are out there working tirelessly day in and day out to help patients understand their disease, figure out their treatment options, and you know, deal with the side effects that often can come with those treatment options. And it doesn't matter if it's a surgeon that's helping out a patient at a major hospital or if it's the nurse practitioner that's helping out people at the CVS ' Minute Clinics. These people are a godsend if you will. And our lives are certainly better off having them as a part of them. Harjes: Yeah everybody working in the industry is a superhero and I'm certainly thankful for how hard all of our doctors work and everybody. You know, like you said, it doesn't matter if you are a surgeon or if you're the person at the CVS Minute Clinic. These people in the healthcare industry are working tirelessly and we're all so much better off for it. It goes beyond just the interaction between patients and their caregivers too. It goes all the way toward the drug developers, the people who run the insurance companies, it's a huge, huge industry and I like to think it's one where everybody can really believe in the mission of health. I mean that's something we can get behind and so I'm definitely thankful for the passion that everybody working in the industry has. Campbell: Right. We mentioned CVS and Minute Clinics and just go back to what you just said about if your focus is on health first, it's like anything else, right? I suppose if you love what you do, you will succeed, right? So at CVS health, I mean not only are they making healthcare more affordable to everybody and accessible to everybody by opening up clinics in their stores right down the street, but you know, their decision to stop selling tobacco and put I guess patient health before profit. You know, they gave up $2 billion in sales in that decision. Harjes: Yeah we look into it and we try to financially justify it because we're investors, but what it comes down to is just mission alignment. That's what it is. Campbell: Yeah. I mean it's that kind of thoughtfulness and I guess innovation the way that they approach their businesses that make us thankful not only as patients, people, but also as investors. The Motley Fool is helping everyone come up with new ways of approaching their investment portfolios figuring out what kind of companies they want to own. And certainly if you're putting your mission first, I think you have a much better likelihood of succeeding long-term. It doesn't matter if you're talking about a company like CVS and what they're doing on affordability, accessibility, it also applies to drug makers and what they're doing as far as coming up with truly game changing new medicines. Harjes: Yeah I mean you mention the word innovation and that's at the heart of it. Oh my gosh, there are so many drug makers and they're taking a lot of heat lately. But truly they are revolutionizing patient care. It's amazing. Campbell: I think we forget sometimes each one of these companies there's this team of scientists -- people just like everyone else -- who day in and day out are doing the hard work of digging into understanding the body's anatomy and how it will react to different medicines and creating those medicines that can truly help us live longer, healthier lives. Look what's been accomplished at Gilead Sciences in the past decade in both HIV and Hepatitis C. You know, HIV is no longer the death sentence that it once was. Now people are living long, healthier lives because of treatments that have come out of Gilead Sciences. In Hepatitis C these have created what amounts to a functional cure for a disease that no cure had previously existed for. Harjes: Yeah indeed. I mean and not only is it a cure, but the patient experience when you're going through Hepatitis C treatment, is so, so much better than the older generation of treatments. Campbell: Yeah 90% plus curates, easier to tolerate dosing regimens. I mean these are things that again, putting people first turns into a good -- it's just good business overall. Harjes: Yeah. So there are so many examples that we could touch on with drug makers, but let's not forget about medical device makers too. I mean there's been some really great innovations there. Todd can you think of any particular ones that you would say you're thankful for that innovation? Campbell: I know, and I'm sure you do too, a lot of people have diabetes. And you know one of the things that I've spent a lot of time, and we've touched upon past in the show, is a company called Dexcom. And what Dexcom is doing is they're developing new ways to better track and report sugar levels in patients so that they can control those blood sugar levels and hopefully delay the progression of their disease so that they are living longer, healthier lives. So yeah, I mean like you said, it's not just the drug makers who are innovating in these ways. It's also med tech companies like Dexcom that are improving patient lives. Harjes: Yeah Dexcom was a great example to use right there. I mean they are making a continuous glucose monitoring device so that you're not just getting a reading here and there and trying to manage your disease in a spotty sort of way. But it really is continual. It's a way of looking at your glucose levels and being able to really understand what's going on with your body. So that hopefully you can better manage your disease. And there's so much that goes into treating diabetes and it's awesome to see that there's so many different companies approaching the disease and trying to make the patient burden a little bit lighter. Campbell: These are all chronic diseases that were, we need to make big inroads on over the next 30 years. Millions and millions of people are going to be suffering from heart disease, diabetes, various other conditions, Alzheimer's, and we need to continue to I guess move the ball forward and make sure that we've got that long-term focus. How are we going to address this problem in the long-term? And when you start thinking long-term it makes me think of other things that I'm thankful for in lessons that I've learned over my career or have been taught in my career not only by mentors but also by my family. I mean my father is a former banker and at an early age he taught me the value of saving, dollar-cost averaging, and now those lessons today are helping ensure my family's financial security. Harjes: That's amazing. Yeah I mean family is at the heart of everything. I mean I can also look at my parents and immediately see how they've helped me become who I am today as a person and also financially. Just to keep somewhat on-topic, I mean I would give the shout-out to my father for teaching me how to have an eye for detail and how to work with numbers from a young age. And my mother is the one that got me interested in healthcare to begin with. She's always worked in healthcare and she's always been a model for me for taking care of yourself and just how important health is. So the combination there, it's pretty easy to see how I ended up doing what I'm doing right now -- applying numbers and analysis to the world of healthcare. Campbell: Right, being able to take the lessons that we learned early on. I suppose this is something that I know that I'm sharing it now with my children. It's a generational thing. Earlier, and earlier, and earlier you're educating them about these things that could have a big impact on their lives. And you know, I look at it, I said, ""Yeah, if you start earlier, start investing continuously. Look what I've done, and if you even start earlier than I did, look where you could be financially when it gets to that point when you're retiring."" My mother, she was a social scientist so she taught me a lot about how to handle and deal with emotion. And you know, one thing that I think that investors are always dealing with is, ""How do I balance the emotional reaction that I get when I see something come across my newsfeed versus my long-term investing thesis?"" So all of those skills that they taught me, I appreciate and value and I'm thankful for as well. Harjes: Yeah, I think we can both say that we're so thankful for all the people in our lives who have shaped us and taught us so many amazing things. And I would be remiss if I didn't throw a shout-out to those that are working behind the scenes to put this podcast together. So thank you to Austin, just gave him a wave out there. He does all of our taping. Danny who does the behind-the-scenes on the episodes. There are so many other people that come together to make this show what it is. Todd, thank you for doing this every week with me. I have learned so much from you and we always have such a good time. Campbell: It's wonderful and something I look forward to every week and hopefully so do the people who are turning in. Harjes: Yeah and speaking of, thank you so much to our listeners. I mean this podcast would be all for nothing without those of you who tune in every week. Send us your questions and comments at IndustryFocus@Fool.com . You guys are the reason that we come together to put this show on. So thanks to you guys and I hope everybody has a fantastic Thanksgiving! The article Giving Thanks, Healthcare Style originally appeared on Fool.com. Kristine Harjes owns shares of Gilead Sciences. Todd Campbell owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends CVS Health. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-11-30,22.1475,22.1575,21.07,21.255,
DXCM,2015-12-01,21.115,21.5975,21.0875,21.5425,"Curing the World: A Shout Out to Healthcare Innovators Many of us like to complain about the companies involved in the healthcare industry. In the wake of Thanksgiving, we're taking the opposite approach to discuss the benefits big companies in the sector have brought to the world. Two such entities are Gilead Sciences and Dexcom . The pair has released numerous innovative treatments over the past decade, and they aren't slowing down anytime soon. This Thanksgiving, Motley Fool analyst Kristine Harjes and Fool contributor Todd Campbell give a shout-out to some of the industry's major innovators. A full transcript follows the video. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . This podcast was recorded on 11/25/15. Kristine Harjes: You mention the word ""innovation,"" and that's at the heart of it. Oh my gosh, there are so many drugmakers and they're taking a lot of heat lately. But truly, they are revolutionizing patient care. It's amazing. Todd Campbell: I think we forget sometimes each one of these companies there's this team of scientists -- people just like everyone else -- who day in and day out are doing the hard work of digging into understanding the body's anatomy and how it will react to different medicines and creating those medicines that can truly help us live longer, healthier lives. Look what's been accomplished at Gilead Sciences in the past decade in both HIV and hepatitis C. You know, HIV is no longer the death sentence that it once was. Now people are living long, healthier lives because of treatments that have come out of Gilead Science. In hepatitis C, these have created what amounts to a functional cure for a disease that no cure had previously existed for. Harjes: Yeah, indeed. I mean, and not only is it a cure, but the patient experience when you're going through hepatitis C treatment, is so, so much better than the older generation of treatments. Campbell: Yeah, 90%-plus cure rates, easier-to-tolerate dosing regimens. I mean, these are things that, again, putting people first turns into a good -- it's just good business overall. Harjes: Yeah. So there are so many examples that we could touch on with drugmakers, but let's not forget about medical-device makers too. I mean, there's been some really great innovations there. Todd, can you think of any particular ones that you would say you're thankful for that innovation? Campbell: I know, and I'm sure you do, too, a lot of people have diabetes. And you know, one of the things that I've spent a lot of time, and we've touched upon past in the show, is a company called Dexcom. And what Dexcom is doing is they're developing new ways to better track and report sugar levels in patients so that they can control those blood sugar levels and hopefully delay the progression of their disease so that they are living longer, healthier lives. So, yeah, I mean, like you said, it's not just the drugmakers who are innovating in these ways. It's also med-tech companies like Dexcom that are improving patient lives. Harjes: Yeah, Dexcom was a great example to use right there. I mean, they are making a continuous glucose monitoring device so that you're not just getting a reading here and there and trying to manage your disease in a spotty sort of way. But it really is continual. It's a way of looking at your glucose levels and being able to really understand what's going on with your body, so that hopefully you can better manage your disease. And there's so much that goes into treating diabetes, and it's awesome to see that there's so many different companies approaching the disease and trying to make the patient burden a little bit lighter. Campbell: These are all chronic diseases that were, we need to make big inroads on over the next 30 years. Millions and millions of people are going to be suffering from heart disease, diabetes, various other conditions, Alzheimer's, and we need to continue to, I guess, move the ball forward and make sure that we've got that long-term focus. The article Curing the World: A Shout Out to Healthcare Innovators originally appeared on Fool.com. Kristine Harjes owns shares of Gilead Sciences. Todd Campbell owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2015-12-02,21.595,21.83,21.4875,21.555,
DXCM,2015-12-03,21.605,21.79,20.875,20.985,
DXCM,2015-12-04,21.135,21.9675,21.135,21.9425,
DXCM,2015-12-07,21.845,21.9275,21.6,21.8075,
DXCM,2015-12-08,21.6525,21.9825,21.575,21.8175,
DXCM,2015-12-09,21.695,21.7425,21.18,21.3125,
DXCM,2015-12-10,21.3575,21.495,20.95,21.24,
DXCM,2015-12-11,21.02,21.1875,20.3375,20.4425,
DXCM,2015-12-14,20.42,20.865,20.4163,20.74,
DXCM,2015-12-15,20.89,20.9975,19.625,19.795,
DXCM,2015-12-16,20.0125,20.62,19.995,20.505,
DXCM,2015-12-17,20.575,20.745,20.3575,20.4325,
DXCM,2015-12-18,20.4475,20.8625,20.265,20.5275,
DXCM,2015-12-21,20.5875,20.84,20.3625,20.4075,
DXCM,2015-12-22,20.4775,20.67,19.945,20.6425,
DXCM,2015-12-23,20.665,20.73,20.365,20.4675,
DXCM,2015-12-24,20.3,20.4125,20.065,20.2825,
DXCM,2015-12-28,20.265,20.4475,20.125,20.425,
DXCM,2015-12-29,20.425,20.8075,20.3675,20.5825,
DXCM,2015-12-30,20.5425,20.76,20.4375,20.59,
DXCM,2015-12-31,20.465,20.7575,20.35,20.475,
DXCM,2016-01-04,20.07,20.0826,19.4428,19.6225,
DXCM,2016-01-05,19.6475,20.245,19.625,20.19,
DXCM,2016-01-06,19.86,20.185,19.705,19.8475,"The Ensign Group Buys 3 Nursing Facilities in South Carolina The Ensign Group Inc. ENSG recently announced the acquisition of three skilled nursing facilities - Compass Post Acute Rehabilitation, Las Calinas Post Acute Rehabilitation and Opus Post Acute Rehabilitation - in South Carolina. The centers will add 285 beds to The Ensign Group's operations and have a combined occupancy rate of 65%. Management expects the acquisitions to be mildly accretive to earnings in 2016. Acquisitions have been a key growth catalyst for The Ensign Group for years. In the third quarter of 2015, the company acquired 12 skilled nursing operations, 20 assisted and independent living operations, one home health business and one hospice agency. As a result of these frequent acquisitions, the company now operates 185 healthcare facilities, 13 hospice agencies, 15 home health agencies, three home care businesses and 17 urgent care clinics across 14 states. However, despite frequent acquisitions, the company's balance sheet remains strong as reflected by the adjusted net-debt-to-EBITDAR ratio of 3.27x at the end of the third quarter. We believe that a strong balance sheet and sufficient liquidity will help the company pursue acquisitions that will expand its customer base and market share going forward. Meanwhile, The Ensign Group provided a positive outlook for 2015 and 2016. For 2015, the company raised its revenue guidance to the range of $1.31-$1.33 billion and earnings to $2.53-$2.58 per share. For 2016, the company projects revenues in the range of $1.53-1.58 billion. Earnings are forecasted at $2.87-$3.01 per share. The Ensign Group also announced a share buyback program worth $15 million that will further accelerate earnings growth over the next 12 months. Stocks to Consider Currently, The Ensign Group carries a Zacks Rank #2 (Buy). Other favorably ranked stocks include Abiomed ABMD , DexCom DXCM and Fresenius Medical Care FMS . All the three stocks carry the same Zacks Rank as The Ensign Group. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report ENSIGN GROUP (ENSG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-01-07,19.72,20.4825,19.53,20.4475,
DXCM,2016-01-08,20.6975,20.9675,19.85,19.9,
DXCM,2016-01-11,20.105,20.1525,19.08,19.455,"[""Community Health Quorum Spin-Off on Hold, Slated for 1H16 Community Health Systems, Inc.CYH recently announced that it has postponed the proposed spin-off of Quorum Health Corporation considering the current market conditions. The transaction is now expected to close in the first half of 2016, instead of the previously planned first quarter. Earlier in Aug 2015, the company had announced plans to establish a new publicly traded hospital company, by spinning off 38 of its hospitals along with Quorum Health Resources - its hospital management and consulting business. The new independent company, with a portfolio of 38 hospitals and 3,635 licensed beds, is planned to have its headquarters in Middle Tennessee. It will operate in markets where hospitals are the solitary provider of acute care services. We believe that the postponement is a setback for Community Health, at least in the near term. However, positive share price movement following the news suggests that investors are not overly worried over the rescheduling. Meanwhile, Community Health continues to divest hospitals on a regular basis, which will in turn, help it to focus on large hospitals that operate on higher margins. Last month, the company completed the sale of Bartow Regional Medical Center, along with related outpatient services, to subsidiaries of BayCare Health System. Community Health also announced a definitive agreement to divest the assets of The Memorial Hospital of Salem County along with related outpatient services to Prime Healthcare Foundation. In conjunction with the divestures, Community Health is focused on pursuing acquisitions that will benefit its overall business model. The company recently inked a definitive agreement to buy majority stake in two reputed hospitals. Community Health, the nation's largest hospital operator (by hospital count), will be buying an 80% stake in IU Health La Porte Hospital in La Porte and IU Health Starke Hospital in northwestern Indiana. The transaction will take Community Health's Indiana hospital tally to 11. We believe the strategic buyouts will drive the company's penetration into the healthcare services market, which in turn, will enhance its competitive position as well as drive significant growth. Zacks Rank and Key Picks Currently, Community Health carries a Zacks Rank #4 (Sell). Better-ranked stocks in the medical space are Exactech EXAC , DexCom DXCM and Fresenius Medical Care FMS . While Exactech sports a Zacks Rank #1 (Strong Buy), both DexCom and Fresenius Medical Care have a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""RTI Surgical's (RTIX) Preliminary Q4 Results Impress RTI Surgical Inc.RTIX is set to beat the Zacks Consensus Estimate on the top-line front, going by the company's recently announced preliminary fourth-quarter 2015 results. The company is scheduled to report fourth-quarter results on Feb 16, 2016. RTI Surgical's fourth-quarter revenue is roughly $76.1 million, way ahead of the Zacks Consensus Estimate of $68 million. The top line reflects growth of 7.2% on a year-over-year basis and is also higher than management's guided range of $68-$69 million. The fourth-quarter performance will be largely influenced by increased orders from commercial distributors. Meanwhile, the commercial business, per management, continues to be unpredictable owing to unfavorable timing of distributor orders. Revenues generated from the domestic market amounted to $70.6 million, which reflects year-over-year growth of almost 8%. International revenues, on the other hand, stands unchanged at $5.5 million. On a constant currency basis, international revenues increased 11% from the year-ago quarter. For full-year 2015, revenues amounted to $282.3 million and improved 7.4% on a year-over-year basis. Domestic revenues increased nearly 9% to $260.4 million, while international revenues fell 8.4% (up 4% at constant currency) to $21.9 million. The stock has seen a 13.7% fall in its price since Dec 24, 2015. The impressive top-line performance is expected to boost investor confidence on the stock. We are impressed with RTI Surgical's business in the domestic market, which is a key growth catalyst. However, the volatility in the commercial business raises concern. An unfavorable foreign exchange rate is also expected to hinder growth in the near term. Zacks Rank and Key Picks Currently, RTI Surgical has a Zacks Rank #4 (Sell). Better-ranked stocks in the medical instruments industry are Exactech EXAC , DexCom DXCM and Fresenius Medical Care FMS . While Exactech sports a Zacks Rank #1 (Strong Buy), both DexCom and Fresenius Medical Care have a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2016-01-12,19.5725,20.515,19.4425,19.4725,"[""InsiderInsights.com Daily Round Up 1/11/16: APC, PSX, SRE, XLRN"", ""8-K from DexCom Shows Expecting Q4 Unaudited Sales ~$129M vs $120M Est."", ""UPDATE: DexCom Sees FY15 Unaudited Sales of ~$400M vs $391M Est."", ""UPDATE: DexCom Sees Global Patient Base 140-150K as of Dec. 31, '15"", ""UPDATE: DexCom Sees Global Patient Base 140-150K as of Dec. 31, '15"", ""UPDATE: DexCom Sees FY15 Unaudited Sales of ~$400M vs $391M Est."", ""8-K from DexCom Shows Expecting Q4 Unaudited Sales ~$129M vs $120M Est."", ""InsiderInsights.com Daily Round Up 1/11/16: APC, PSX, SRE, XLRN"", ""Abiomed's Preliminary Q3 Results Hint at Impressive Sales Abiomed, Inc.ABMD recently announced preliminary results for the third quarter of fiscal 2016, wherein the top line is expected to beat the Zacks Consensus Estimate. The company is scheduled to release full financial results on Feb 4, 2016. The provider of heart support technologies estimates revenues of roughly $85.8 million for the third quarter, reflecting year-over-year growth of 38%. Moreover, the figure is expected to outpace the Zacks Consensus Estimate of $79 million. Per management, domestic revenues from Impella products are expected to surge 45% on a year-over-year basis to $75 million. In the quarter under review, U.S. patient usage is expected to improve 45%. We are impressed with Abiomed's preliminary results. If the company manages to outpace the Zacks Consensus Estimate in the third quarter of fiscal 2016, it will mark the sixth consecutive beat. Abiomed's Impella utilization is accelerating at a remarkable pace with an increasing number of hospitals and customer sites purchasing the same, asserting that the Impella product line is a significant growth catalyst. In the second quarter of fiscal 2016, Impella revenues grew 53% to $71.7 million, which helped generate 47% top-line growth. At the end of the second quarter of fiscal 2016, Impella 2.5 had been installed at 1000 of about 1400 targeted hospital sites. Impella CP, on the other hand, has been placed at 739 hospital sites. We are also upbeat about Abiomed's healthy product pipeline which includes Abiomed's upcoming products - Impella ECP (Expandable Cardiac Power), the Next Generation Impella CP, the Impella 5.5 and the longer term Impella BTR (Bridge to Recovery). Zacks Rank & Other Stocks to Consider Currently, Abiomed carries a Zacks Rank #2 (Buy). Other well-placed stocks in the medical space are Exactech EXAC , DexCom DXCM and Fresenius Medical Care FMS . While Exactech sports a Zacks Rank #1 (Strong Buy), both DexCom and Fresenius Medical Care have a Zacks Rank #2. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Greatbatch Unveils 2015 Preliminary Results & 2016 Outlook Greatbatch, Inc.GB recently announced preliminary results for 2015 and unveiled the outlook for 2016. The manufacturer of medical devices estimates sales of around $1.44 billion in 2015, reflecting a decline of 8% on a year-over-year basis. Notably, the sales figure in 2015 and 2014 incorporates the Lake Region merger (completed in Oct 27, 2015) and Nuvectra spin-off (expected in 2016). Per management, adjusted EBITDA in 2015 is expected to be $312 million, reflecting a year-over-year increase of 1.6%. Adjusted EBITDA margin, on the other hand, is estimated to expand 70 basis points (bps) to 21.6%. For 2016, Greatbatch expects sales to be about $1.47 billion. Adjusted EBITDA is likely to be around $327 million while adjusted EBITDA margin is projected at 22.3%. In 2016, management will focus on expanding margins and also on generating significant organic growth. We are not overtly impressed with the preliminary results, given that the top line is expected to take a hit. However, the expected EBITDA margin expansion is a positive. Moreover, the recent Lake Region buyout has important long-term prospects for the company. The acquisition is also anticipated to provide significant operating synergies, which will, in turn, boost earnings. In fact, management at Greatbatch expects the acquisition to help adjusted earnings per share achieve double-digit growth rate in 2016. Post that, it is expected to be even more accretive. Additionally, net annual synergy for operating profit is projected at around $25 million in 2016 and is likely to increase to at least $60 million by 2018. The combined company is also poised to generate significant cash flow, which will strengthen the balance sheet. Again, the proposed spin-off of its neuromodulation device business (QiG Group) is expected to help Greatbatch operate more effectively by proper allocation of resources. Post spin-off, the new entity is going to be known as Nuvectra Corp, which will primarily emphasize on the development & marketization of the Algovita spinal cord stimulation system. Zacks Rank & Other Stocks to Consider Currently, Greatbatch sports a Zacks Rank #1 (Strong Buy). Other well-placed stocks in the medical space are Exactech EXAC , DexCom DXCM and Fresenius Medical Care FMS . While Exactech sports a Zacks Rank #1, both DexCom and Fresenius Medical Care have a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report GREATBATCH INC (GB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Pacific Biosciences Foresees Lower Sequel Shipment in 1H16 Pacific Biosciences of California Inc PACB recently provided an update on its new Sequel system, launched in October last year. The company received 49 orders for the system and shipped 10 during the recently concluded fourth quarter of 2015. Sequel system is a nucleic acid sequencing platform based on Single Molecule, Real-Time (SMRT) technology that was developed under the company's partnership with Roche. Sequel is a more powerful device as compared to the company's legacy PacBio RS II system. However, Pacific Biosciences noted that the new SMRT cells - provided by its prototype chip vendor - for the Sequel Systems will be in limited supply through the first half of 2016. Hence, shipment of the system will be slower during the period. Pacific Biosciences added that it is in the process of outsourcing the manufacturing of the cells to a high volume producer, which will be completed by the middle of the year. The company expects to ramp up shipments in the later half with the increase in supply of SMRT cells. However, this assurance failed to cheer investors as the share price plunged 9.4% to close at $11.42 on Jan 11. The delay in shipment will surely impact Pacific Biosciences' top-line growth in the first half of 2016. Nevertheless, we are encouraged by the growing adoption rate of the system. Pacific Biosciences noted that more than 40% of the Sequel systems ordered in the quarter were from new customers. The upcoming software and chemistry update will further improve the features of the new system. Moreover, the legacy PacBio RS II continues to win orders (three in the quarter), which is positive in our view. We believe that Pacific Biosciences has significant growth prospects in plant and animal as well as human genome sequencing. The company's leading position in microbial sequencing also presents it a significant growth opportunity in the infectious disease market. Zacks Rank & Key Picks Currently, Pacific Biosciences has a Zacks Rank #3 (Hold). Better-ranked stocks in the same space are Exactech EXAC , Abiomed ABMD and Dexcom DXCM . While Exactech sports a Zacks Rank #1 (Strong Buy), both Abiomed and Dexcom carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED INC (ABMD): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UPDATE: DexCom Sees Global Patient Base 140-150K as of Dec. 31, '15"", ""UPDATE: DexCom Sees FY15 Unaudited Sales of ~$400M vs $391M Est."", ""8-K from DexCom Shows Expecting Q4 Unaudited Sales ~$129M vs $120M Est."", ""InsiderInsights.com Daily Round Up 1/11/16: APC, PSX, SRE, XLRN""]"
DXCM,2016-01-13,19.4175,19.5475,17.5375,17.83,"[""Can Big Data Fix Healthcare? (Part II)"", ""Can Big Data Fix Healthcare? (Part II)"", ""Stryker's (SYK) Preliminary Results Hint at In-Line Q4 Sales Stryker CorporationSYK recently announced preliminary results for fourth quarter and full-year 2015, per which net sales are expected to be in line with the Zacks Consensus Estimate. In addition, Stryker raised its full-year adjusted earnings per share (EPS) guidance. Adjusted EPS is now expected to lie in the band of $5.09-$5.12, as compared to the previous range of $5.07-$5.12. Adjusted EPS growth rate on a year-over-year basis is projected at 7.6%-8.2%. Unfavorable foreign exchange rate is expected to create a headwind of 4 cents in the fourth quarter of 2015. Stryker anticipates net sales increase of 3.7% on a year-over-year basis to $2.7 million in the fourth quarter of 2015. Excluding the effect of foreign exchange rate and acquisitions, net sales are expected to exhibit a growth rate of 6.4%. Organic growth for full-year 2015 is expected to be 6.1%. Sales in the U.S. are expected to be $2 billion in the fourth quarter of 2015, reflecting a year-over-year increase of 8.4%. International sales, on the other hand, are estimated to decline 6.9% (up 3.7% at constant currency) to $744 million. Sales from the Orthopedics segment are expected to increase 3.3% to $1.1 billion. Sales of the company's MAKO RIO Robotic Arm Interactive System are expected to total 31 units in the fourth quarter of 2015, compared to 20 in the year-ago quarter. Excluding the impact of acquisitions, sales are estimated to jump 7.1% at constant currency. MedSurg sales are anticipated to be roughly $1.1 billion in the fourth quarter, indicating an increase of 3%. In constant currency and excluding the impact of acquisitions, sales are expected to improve 4.2%. Neurotechnology and Spine sales are estimated at around $483 million, representing an improvement of 6.5%. At constant currency and excluding the impact of acquisitions, sales are projected to rise 9.9%. Stryker bought back shares worth $700 million in 2015, with remaining open authorization of $1.9 billion. We believe that strong growth momentum at the Trauma & Extremities, Spine and Neurotechnology businesses will help drive top-line growth in the near term. Growing adoption of MAKO will also boost sales in the orthopedic and reconstructive surgery market. However, a strong U.S. dollar will continue to hurt sales in the near term. Zacks Rank & Stocks to Consider Currently, Stryker carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are Exactech EXAC , DexCom DXCM and Fresenius Medical Care FMS . While Exactech sports a Zacks Rank #1 (Strong Buy), both DexCom and Fresenius Medical Care have a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Big Data Fix Healthcare? (Part II)""]"
DXCM,2016-01-14,17.875,18.47,16.5775,18.1,"[""InsiderInsights.com Daily Round Up 1/13/16: Tuesday Morning, Conn's, Barnes & Noble Education, Phillips 66"", ""Baron Funds Comments on DexCom Inc."", ""Baron Funds Comments on DexCom Inc."", ""InsiderInsights.com Daily Round Up 1/13/16: Tuesday Morning, Conn's, Barnes & Noble Education, Phillips 66"", ""Baron Funds Comments on DexCom Inc. Another health care holding, DexCom, Inc. , ( NASDAQ:DXCM ) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom's fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company's new product pipeline remains robust and will lead to further adoption among the growing population of diabetics. From the Baron Funds Small Cap Fund winter newsletter 2016 . HMHC 15-Year Financial Data The intrinsic value of HMHC Peter Lynch Chart of HMHC PGND 15-Year Financial Data The intrinsic value of PGND Peter Lynch Chart of PGND Warning! GuruFocus has detected 3 Warning Sign with BFAM. Click here to check it out. BFAM 15-Year Financial Data The intrinsic value of BFAM Peter Lynch Chart of BFAM Warning! GuruFocus has detected 1 Warning Sign with DXCM. Click here to check it out. DXCM 15-Year Financial Data The intrinsic value of DXCM Peter Lynch Chart of DXCM Read More: Winter newsletter 2016 Baron Funds Comments on Bright Horizons Family Solutions Inc. About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members . This article first appeared on GuruFocus . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Baron Funds Comments on DexCom Inc."", ""InsiderInsights.com Daily Round Up 1/13/16: Tuesday Morning, Conn's, Barnes & Noble Education, Phillips 66""]"
DXCM,2016-01-15,17.5,17.72,17.1025,17.56,
DXCM,2016-01-19,17.6225,18.2325,17.59,18.1075,
DXCM,2016-01-20,17.84,18.825,17.5875,18.51,"[""4 Ways Google Is Good For You"", ""4 Ways Google Is Good For You"", ""4 Ways Google Is Good For You""]"
DXCM,2016-01-21,18.4925,18.6825,18.11,18.12,
DXCM,2016-01-22,18.14,18.58,18.0075,18.505,
DXCM,2016-01-25,18.44,18.5075,18.11,18.165,
DXCM,2016-01-26,18.2225,18.3975,17.7175,18.3025,"[""InsiderInsights.com Daily Round Up 1/25/16: APC, RDUS, SSRG, UBA"", ""InsiderInsights.com Daily Round Up 1/25/16: APC, RDUS, SSRG, UBA"", ""InsiderInsights.com Daily Round Up 1/25/16: APC, RDUS, SSRG, UBA""]"
DXCM,2016-01-27,18.2725,18.555,17.7625,17.83,
DXCM,2016-01-28,18.64,18.64,17.045,17.385,"[""InsiderInsights.com Daily Round Up 1/27/16: Simmons First National, Hooper Holmes, Kinder Morgan, Veeva Systems"", ""InsiderInsights.com Daily Round Up 1/27/16: Simmons First National, Hooper Holmes, Kinder Morgan, Veeva Systems"", ""InsiderInsights.com Daily Round Up 1/27/16: Simmons First National, Hooper Holmes, Kinder Morgan, Veeva Systems""]"
DXCM,2016-01-29,17.34,18.0475,17.34,17.82,
DXCM,2016-02-01,17.7525,18.1025,17.5058,18.0075,
DXCM,2016-02-02,17.805,18.2087,17.57,17.66,
DXCM,2016-02-03,17.6375,17.9088,17.2,17.4725,
DXCM,2016-02-04,17.51,17.8238,17.2762,17.6575,
DXCM,2016-02-05,17.635,17.9388,15.35,15.495,"[""Sterne Agee CRT Defending DXCM, Says Buy on Weakness, Says Co Has Industry Leading Product And Strong Product Pipeline"", ""Sterne Agee CRT Defending DXCM, Says Buy on Weakness, Says Co Has Industry Leading Product And Strong Product Pipeline"", ""Sterne Agee CRT Defending DXCM, Says Buy on Weakness, Says Co Has Industry Leading Product And Strong Product Pipeline""]"
DXCM,2016-02-08,14.985,14.995,11.98,13.43,"[""Baird Downgrades DexCom to Neutral, Lowers PT to $74.00"", ""Benzinga's Top Downgrades"", ""Cowen Defending DXCM, Says Incorrect Reports Circulating Are Driving Selloff"", ""Cowen Defending DXCM, Says Incorrect Reports Circulating Are Driving Selloff"", ""Benzinga's Top Downgrades"", ""Baird Downgrades DexCom to Neutral, Lowers PT to $74.00"", ""Why DexCom, Inc. Shares Fell 21% Today Image source: DexCom. What: After investment firm Robert W. Baird downgraded the stock from outperform to neutral, shares in DexCom were down 21.5% at 2:00 p.m. ET today. So what: Despite reporting at the J.P. Morgan healthcare conference last month that unaudited revenue from the sale of DexCom's continous glucose monitors jumped 54% to approximately $400 million in 2015, the company's shares have fallen 40.5% this year. Contributing to investors' concern is DexCom's spending plans. DexCom plans to build a new factory, expand in the EU, and funnel more money into R&D this year, and that means the company's operating margin may take a short-term hit in 2016. As a result, industry watchers have reduced their EPS forecast to a loss of $0.05 in 2016, down from a gain of $0.20 90 days ago. Now what At the J.P. Morgan healthcare conference, DexCom forecast sales of $540 million to $565 million in 2016, up at least 35% from last year. That projection suggests a slowing in year-over-year growth, but it's still healthy enough to make this company intriguing, particularly given that Baird's new $74 price target is still nicely higher than shares are trading today. Overall, investors might want to consider stepping up and buying shares on this sell-off, because DexCom has seen a tenfold increase in revenue since 2011, yet it's only penetrated a small slice of this massive addressable market. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . The article Why DexCom, Inc. Shares Fell 21% Today originally appeared on Fool.com. Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright \u00a9 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Analysts Expect JKH Will Reach $170 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Morningstar Mid-Cap Growth ETF (Symbol: JKH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $170.32 per unit. With JKH trading at a recent price near $132.80 per unit, that means that analysts see 28.25% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of JKH's underlying holdings with notable upside to their analyst target prices are Team Health Holdings Inc (Symbol: TMH), Office Depot, Inc. (Symbol: ODP), and DexCom Inc (Symbol: DXCM). Although TMH has traded at a recent price of $35.35/share, the average analyst target is 76.57% higher at $62.42/share. Similarly, ODP has 66.56% upside from the recent share price of $5.09 if the average analyst target price of $8.48/share is reached, and analysts on average are expecting DXCM to reach a target price of $100.21/share, which is 61.68% above the recent price of $61.98. Below is a twelve month price history chart comparing the stock performance of TMH, ODP, and DXCM: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cowen Defending DXCM, Says Incorrect Reports Circulating Are Driving Selloff"", ""Benzinga's Top Downgrades"", ""Baird Downgrades DexCom to Neutral, Lowers PT to $74.00""]"
DXCM,2016-02-09,13.23,13.9675,12.8625,13.345,"[""Best And Worst Q1'16: Health Care ETFs, Mutual Funds And Key Holdings"", ""Best And Worst Q1'16: Health Care ETFs, Mutual Funds And Key Holdings"", ""Best And Worst Q1'16: Health Care ETFs, Mutual Funds And Key Holdings""]"
DXCM,2016-02-10,13.5,14.7125,13.4375,14.565,
DXCM,2016-02-11,14.1325,14.5375,13.835,14.0625,
DXCM,2016-02-12,14.335,14.3725,13.625,14.03,
DXCM,2016-02-16,14.2075,15.0925,14.0575,14.815,
DXCM,2016-02-17,14.9375,15.625,14.7675,15.455,
DXCM,2016-02-18,15.585,15.7975,15.375,15.425,
DXCM,2016-02-19,15.29,16.0475,15.125,15.7975,
DXCM,2016-02-22,15.9125,16.135,15.7488,15.8925,"[""Notable earnings after Tuesday's close"", ""Notable earnings after Tuesday's close"", ""Notable earnings after Tuesday's close""]"
DXCM,2016-02-23,15.8925,16.575,15.7175,15.8175,"[""DexCom beats by $0.01, beats on revenue"", ""DexCom (DXCM) Q4 2015 Results - Earnings Call Webcast"", ""DexCom (DXCM) Kevin Ronald Sayer on Q4 2015 Results - Earnings Call Transcript"", ""DexCom Reports Q4 Adj. EPS $(0.26) vs $0.01 Est., Sales $130.8M vs $123.7M Est."", ""DexCom Reports Q4 Adj. EPS $(0.26) vs $0.01 Est., Sales $130.8M vs $123.7M Est."", ""DexCom (DXCM) Kevin Ronald Sayer on Q4 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q4 2015 Results - Earnings Call Webcast"", ""DexCom beats by $0.01, beats on revenue"", ""Earnings Reaction History: DexCom, Inc., 83.3% Follow-Through Indicator, 8.7% Sensitive Expected Earnings Release: 02/23/2016, After-hours Avg. Extended-Hours Dollar Volume: $2,163,704 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 7.1% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 7.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 1.9% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.9% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for February 23, 2016 : EIX, VRSK, EXR, JAZZ, Y, FSLR, WTR, DXCM, CPRT, CAR, HLS, CONE The following companies are expected to report earnings after hours on 02/23/2016. Visit our Earnings Calendar for a full list of expected earnings releases. Edison International ( EIX ) is reporting for the quarter ending December 31, 2015. The electric power utilities company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.60. This value represents a 43.40% decrease compared to the same quarter last year. In the past year EIX has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 8.18%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EIX is 16.86 vs. an industry ratio of 8.20, implying that they will have a higher earnings growth than their competitors in the same industry. Verisk Analytics, Inc. ( VRSK ) is reporting for the quarter ending December 31, 2015. The business info service company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.75. This value represents a 15.38% increase compared to the same quarter last year. In the past year VRSK has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 10.39%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VRSK is 22.75 vs. an industry ratio of 17.60, implying that they will have a higher earnings growth than their competitors in the same industry. Extra Space Storage Inc ( EXR ) is reporting for the quarter ending December 31, 2015. The reit company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.87. This value represents a 27.94% increase compared to the same quarter last year. In the past year EXR has met analyst expectations once and beat the expectations the other three quarters. The days to cover, as reported in the 1/29/2016 short interest update, increased 155.50% from previous report on 1/15/2016. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EXR is 27.47 vs. an industry ratio of 12.70, implying that they will have a higher earnings growth than their competitors in the same industry. Jazz Pharmaceuticals plc ( JAZZ ) is reporting for the quarter ending December 31, 2015. The drug company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.66. This value represents a 22.43% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for JAZZ is 22.56 vs. an industry ratio of -8.70, implying that they will have a higher earnings growth than their competitors in the same industry. Alleghany Corporation ( Y ) is reporting for the quarter ending December 31, 2015. The insurance (property & casualty) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $6.81. This value represents a 12.80% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for Y is 15.48 vs. an industry ratio of 13.30, implying that they will have a higher earnings growth than their competitors in the same industry. First Solar, Inc. ( FSLR ) is reporting for the quarter ending December 31, 2015. The solar company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.80. This value represents a 57.67% decrease compared to the same quarter last year. FSLR missed the consensus earnings per share in the 1st calendar quarter of 2015 by -113.79%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for FSLR is 15.15 vs. an industry ratio of -13.30, implying that they will have a higher earnings growth than their competitors in the same industry. Aqua America, Inc. ( WTR ) is reporting for the quarter ending December 31, 2015. The water supply company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.29. This value represents a 3.57% increase compared to the same quarter last year. WTR missed the consensus earnings per share in the 3rd calendar quarter of 2015 by -2.56%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for WTR is 24.76 vs. an industry ratio of 9.80, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. ( DXCM ) is reporting for the quarter ending December 31, 2015. The medical instruments company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.00. This value represents a 100.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for DXCM is -227.04 vs. an industry ratio of -7.50. Copart, Inc. ( CPRT ) is reporting for the quarter ending January 31, 2016. The auction company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.44. This value represents a 10.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for CPRT is 19.16 vs. an industry ratio of 24.50. Avis Budget Group, Inc. ( CAR ) is reporting for the quarter ending December 31, 2015. The business services company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.18. This value represents a 21.74% decrease compared to the same quarter last year. CAR missed the consensus earnings per share in the 3rd calendar quarter of 2015 by -0.5%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for CAR is 9.37 vs. an industry ratio of 18.90. HealthSouth Corporation ( HLS ) is reporting for the quarter ending December 31, 2015. The medical (outpatient/home care) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.59. This value represents a 7.27% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for HLS is 16.06 vs. an industry ratio of 22.30. CyrusOne Inc ( CONE ) is reporting for the quarter ending December 31, 2015. The reit company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.57. This value represents a 18.75% increase compared to the same quarter last year. In the past year CONE has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 3.64%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for CONE is 17.80 vs. an industry ratio of 12.70, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Q4 Adj. EPS $(0.26) vs $0.01 Est., Sales $130.8M vs $123.7M Est."", ""DexCom (DXCM) Kevin Ronald Sayer on Q4 2015 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q4 2015 Results - Earnings Call Webcast"", ""DexCom beats by $0.01, beats on revenue""]"
DXCM,2016-02-24,15.01,16.225,14.13,16.1125,"DexCom Posts Earnings in Q4, Sales Beat, FY16 View Bright DexCom Inc. DXCM reported earnings of 2 cents per share in the fourth quarter of 20Array5, better than the Zacks Consensus Estimate of a break-even and in line with the year-ago quarter figure. Fourth-quarter revenues surged nearly 55% year over year to $Array30.8 million, which beat the Zacks Consensus Estimate of $Array28 million. Revenues surged 55.Array% year over year to $402 million in full-year 20Array5. The company reported loss of 72 cents per share, which was much wider than loss of 30 cents reported in full-year 20Array4. International business generated $Array6 million in revenues during the quarter. Average selling price (ASP) was in the range of $70−$75 per sensor while ASP for Dexcom's hardware stood at approximately $850 to $850 per starter kit. Gross margin contracted 70 basis points (bps) year over year to 69.7% primarily due to unfavorable product mix. Selling, general and administrative (SG&A) expenses rose 68.8% on a year-over-year basis to $6Array.Array million. The upside may be attributed to increased head count in the company's organization (including both field sales and internal sales support staff). Additional marketing expenses were also a major reason behind the year-over-year upside. Research and development (R&D) expenses increased 3Array.9% year over year to $28.5 million. The rise can be attributed to increased additional payroll-related costs and expenses with respect to work on near-term product pipeline as well as an advanced product suite. DexCom reported operating income of $Array.6 million, which remained flat on a year-over-year basis. Product Details DexCom launched its next-generation G5 Mobile CGM system both in the U.S. and Europe in 20Array5. According to management, ""G5 Mobile system is the first and only CGM system approved by the FDA for both adults and children as young as two years of age that sends glucose data directly to a smartphone."" Meanwhile, the company plans to launch the Android version of the G5 Mobile later this year and note that the Android follow application is already available. DexCom also plans to submit and possibly launch an enhanced version of G5 Mobile app to provide for additional features and functionality, such as insulin onboard data obtained from the company's pump partners in 20Array6. In this regard, the company noted that it expects to gain a FDA approval for the insulin dosing claim during the second half of 20Array6. With respect to Gen 6, after a series of pre-submission meetings with the FDA, DexCom expects to submit its IDE in the next two weeks and plans to commence a pivotal study in the second quarter of 20Array6. Guidance For fiscal 20Array6, DexCom expects revenues in the range of $540 million to $565 million, reflecting growth of approximately 35% to 40% from 20Array5. The company expects 55%--60% of these revenues to be generated in the second half of the year. DexCom noted that gross margin will be impacted slightly in 20Array6 by higher costs related to manufacturing capacity expansion project. The company expects gross margin between 67% and 70% for the full year. First-quarter gross margin is likely to decline sequentially on lower volumes due to seasonality. DexCom expects approximately 20% to 25% year-over-year increase in cash-based operating expenses. Cash-based expenditures are expected to be approximately $40 million in 20Array6. Our Take DexCom's healthy product portfolio and innovative pipeline are the major catalysts for 20Array6 and beyond. The company's recently launched direct-to-consumer marketing campaign as well as signing of Pharmacy contracts with United Healthcare and Anthem ANTM are a positive in our view. However, high product development costs, research & development as well as marketing expenses will continue to hurt margins, which is a concern for the near term. Uncertainty over reimbursement is another potent headwind. Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are Abiomed ABMD and CryoLife CRY . Both the stocks sport a Zacks Rank #Array (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED INC (ABMD): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report CRYOLIFE INC (CRY): Free Stock Analysis Report ANTHEM INC (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-02-25,16.2275,17.035,16.2275,16.8025,
DXCM,2016-02-26,16.8125,17.17,16.23,16.48,
DXCM,2016-02-29,16.5425,16.9625,16.1725,16.265,
DXCM,2016-03-01,16.4675,16.4675,15.9275,16.4125,
DXCM,2016-03-02,16.4575,16.6225,16.19,16.44,"[""Navigating This Market - Cramer's Mad Money (3/1/16)"", ""Navigating This Market - Cramer's Mad Money (3/1/16)"", ""Navigating This Market - Cramer's Mad Money (3/1/16)""]"
DXCM,2016-03-03,16.3525,16.63,16.135,16.6,
DXCM,2016-03-04,16.565,16.95,16.527,16.7075,
DXCM,2016-03-07,16.665,17.2175,16.5575,17.095,
DXCM,2016-03-08,16.97,17.2275,16.47,16.525,
DXCM,2016-03-09,16.5475,16.5717,15.5952,16.1325,
DXCM,2016-03-10,16.1325,16.3225,15.315,15.6525,"JKH's Underlying Holdings Imply 16% Gain Potential Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Morningstar Mid-Cap Growth ETF (Symbol: JKH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $167.15 per unit. With JKH trading at a recent price near $144.34 per unit, that means that analysts see 15.80% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of JKH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Office Depot, Inc. (Symbol: ODP), and ServiceNow Inc (Symbol: NOW). Although DXCM has traded at a recent price of $64.53/share, the average analyst target is 43.97% higher at $92.90/share. Similarly, ODP has 34.56% upside from the recent share price of $5.18 if the average analyst target price of $6.97/share is reached, and analysts on average are expecting NOW to reach a target price of $79.12/share, which is 30.81% above the recent price of $60.49. Below is a twelve month price history chart comparing the stock performance of DXCM, ODP, and NOW: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-03-11,15.86,16.3575,15.7725,16.2875,
DXCM,2016-03-14,15.6175,16.1475,15.6175,16.01,
DXCM,2016-03-15,15.845,15.905,15.455,15.49,"DexCom Launches G5 PLATINUM CGM App on Apple Watch DexCom Inc.DXCM recently announced that its G5 PLATINUM Continuous Glucose Monitoring (CGM) System with Share app will be available on Apple's AAPL Watch. Notably, DexCom CGM and its mobile apps - Share 2 and Follow - are already approved by the FDA and allow both users and followers to view glucose data directly on their Apple iPhone or iPod Touch. Additionally, the G5 app for iPhone will offer a new feature - Today view - which will allow users to access CGM information without opening the app or even unlocking the phone. With the availability of G5 CGM app on the Apple Watch, caregivers and people with diabetes will have the opportunity to track glucose levels and trends in a convenient and discreet manner right from their wrist. Additionally, patients or ""Sharers"" will be allowed to invite up to five people to view their glucose information and send an alert when the sharer's glucose levels are beyond the normal range. We feel that DexCom is making noteworthy efforts to provide its patients with access to the most current technology to better manage diabetes. As technology is becoming a more pertinent and essential part of people's lives, we feel that such business prospects will go a long way in improving the visibility of DexCom's products and services. Moreover, strategic deals with companies like Apple that have a vast global presence will boost DexCom's business scale massively. By expanding its range of solutions and services, DexCom will not only improve its international presence but will also enhance its top-line opportunities. It is to be noted that in 2015, the company's revenues surged 55.1% on a year-over-year basis to $402 million. Zacks Rank and Key Picks Currently, DexCom has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are Abiomed ABMD and Luminex LMNX . Both the stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report ABIOMED INC (ABMD): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-03-16,15.495,15.7425,14.985,15.06,
DXCM,2016-03-17,15.01,15.14,14.6125,14.85,
DXCM,2016-03-18,14.925,15.3175,14.72,15.1825,
DXCM,2016-03-21,15.045,15.2925,14.82,14.8775,
DXCM,2016-03-22,14.855,15.7925,14.855,15.6725,
DXCM,2016-03-23,15.5175,15.57,15.255,15.2875,
DXCM,2016-03-24,15.14,15.185,14.7975,14.99,
DXCM,2016-03-28,14.935,15.0025,14.758,14.865,
DXCM,2016-03-29,15.0,15.81,14.725,15.72,
DXCM,2016-03-30,15.805,16.5625,15.805,16.375,
DXCM,2016-03-31,16.305,17.28,16.275,16.9775,
DXCM,2016-04-01,16.865,17.3425,16.5,16.9075,
DXCM,2016-04-04,17.0375,18.0275,16.9075,17.6225,
DXCM,2016-04-05,17.375,17.47,16.89,16.9475,
DXCM,2016-04-06,16.84,17.245,16.83,17.18,
DXCM,2016-04-07,17.0875,17.245,16.9525,17.1075,
DXCM,2016-04-08,17.2525,17.3575,16.7525,17.02,
DXCM,2016-04-11,17.0,17.0675,16.6225,16.7,
DXCM,2016-04-12,16.63,16.6975,16.035,16.3225,
DXCM,2016-04-13,16.3825,16.6125,16.225,16.4675,
DXCM,2016-04-14,16.4375,16.975,16.4,16.76,"[""BTIG Research Initiates Coverage on DexCom at Buy, Announces $80.00 PT, Says 'Valuation is Hyperglycemic, But We See More Quarterly Beats'"", ""BTIG Research Initiates Coverage on DexCom at Buy, Announces $80.00 PT, Says 'Valuation is Hyperglycemic, But We See More Quarterly Beats'"", ""BTIG Research Initiates Coverage on DexCom at Buy, Announces $80.00 PT, Says 'Valuation is Hyperglycemic, But We See More Quarterly Beats'""]"
DXCM,2016-04-15,16.7675,16.8975,16.5325,16.7025,
DXCM,2016-04-18,16.595,17.0088,16.57,16.915,
DXCM,2016-04-19,16.925,16.975,16.63,16.7,
DXCM,2016-04-20,16.725,16.89,16.475,16.765,
DXCM,2016-04-21,16.8175,17.0225,16.77,16.92,"[""Dexcom's Diabetes Market Play"", ""Dexcom's Diabetes Market Play"", ""Dexcom's Diabetes Market Play""]"
DXCM,2016-04-22,16.875,17.2175,16.875,17.1075,
DXCM,2016-04-25,17.0775,17.445,17.0675,17.2825,"Notable Monday Option Activity: CYNO, DXCM, RATE Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cynosure Inc (Symbol: CYNO), where a total volume of 1,327 contracts has been traded thus far today, a contract volume which is representative of approximately 132,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46% of CYNO's average daily trading volume over the past month, of 288,240 shares. Especially high volume was seen for the $50 strike call option expiring May 20, 2016 , with 1,070 contracts trading so far today, representing approximately 107,000 underlying shares of CYNO. Below is a chart showing CYNO's trailing twelve month trading history, with the $50 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 3,170 contracts thus far today. That number of contracts represents approximately 317,000 underlying shares, working out to a sizeable 42.2% of DXCM's average daily trading volume over the past month, of 752,010 shares. Particularly high volume was seen for the $70 strike call option expiring May 20, 2016 , with 2,104 contracts trading so far today, representing approximately 210,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $70 strike highlighted in orange: And Bankrate Inc (Symbol: RATE) options are showing a volume of 5,041 contracts thus far today. That number of contracts represents approximately 504,100 underlying shares, working out to a sizeable 40.2% of RATE's average daily trading volume over the past month, of 1.3 million shares. Especially high volume was seen for the $10 strike call option expiring June 17, 2016 , with 5,000 contracts trading so far today, representing approximately 500,000 underlying shares of RATE. Below is a chart showing RATE's trailing twelve month trading history, with the $10 strike highlighted in orange: For the various different available expirations for CYNO options , DXCM options , or RATE options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-04-26,17.275,17.4675,17.1288,17.465,
DXCM,2016-04-27,17.2675,17.7,16.95,17.1025,"[""DexCom (DXCM) Kevin Ronald Sayer on Q1 2016 Results - Earnings Call Transcript"", ""DexCom Reports Q1 EPS $(0.23) vs. Est. $(0.20), Rev. $116.2M vs. Est. $110.38M"", ""DexCom Reports Q1 EPS $(0.23) vs. Est. $(0.20), Rev. $116.2M vs. Est. $110.38M"", ""DexCom (DXCM) Kevin Ronald Sayer on Q1 2016 Results - Earnings Call Transcript"", ""DexCom Reports Q1 EPS $(0.23) vs. Est. $(0.20), Rev. $116.2M vs. Est. $110.38M"", ""DexCom (DXCM) Kevin Ronald Sayer on Q1 2016 Results - Earnings Call Transcript""]"
DXCM,2016-04-28,16.76,17.25,16.425,16.49,"Are DexCom's Best Days Behind It, or Still to Come? Image source: Dexcom, Inc. Worry that its valuation had run too far, too fast has resulted in DexCom 's shares tumbling from more than $100 last September to less than $70. However, the maker of medical devices that help diabetics better track their blood sugar has only begun to penetrate a big and growing market. Can DexCom expand itself from a niche maker of products for type 1 diabetes into a much larger company, or is this as good as it gets? Some background Diabetics with type 1 disease have been using finger sticks to manage their blood sugar levels for decades, but according to DexCom, that approach isn't nearly as effective as it may seem. Despite patients being well educated on the risks associated with being out of their desired ranges, the average person with diabetes is outside of their target blood glucose range 70% of the time. Because blood sugar highs and lows can lead to diabetes progressing to a point where it can cause heart disease and other life-threatening complications, innovating new strategies that allow patients to more accurately track and manage their blood sugar levels is critical. Image source: Dexcom, Inc. Capitalizing on a new approach Rather than evaluating blood glucose levels via random finger sticks, DexCom has developed a blood glucose monitor that uses sensors to continuously track and report levels to patients. Because DexCom's devices provide a level of clarity that has previously been lacking, increasing use by patients eager to chart their levels has led to increasingly larger sales of monitors and the disposable sensors necessary to use them. Although payer reimbursement headwinds have limited the adoption to type 1 patients and out-of-pocket purchasers, DexCom reports that sales still increased 60% to $116.2 million in the first quarter. That performance comes on top of a 55% increase in sales to $402 million last year. That growth is impressive, but it may just be the beginning. An estimated 500,000 people under age 14 are living with type 1 diabetes, and the number of people with type 1 is growing 3% annually. Since DexCom's penetration is measured in the tens of thousands of patients, it's arguably only scratching the surface of its addressable market. Looking ahead DexCom's weakest quarter has historically been the first quarter, and according to management, this year's results were in line with its expectations. As such, the C-suite reiterated prior guidance for revenue of at least $540 million this year. If the company can hit that target, it should help put DexCom on the path to profitability. However, headwinds that could delay profitability include an increase in investments to boost capacity and spending related to R&D. For example, the company inked a collaboration deal with Verily last year to develop next-generation, smaller, and less-burdensome sensors and transmitters. Technological innovation that improves the patient's experience will help drive customer retention and, thus, sensor sales, especially as the installed base of devices grows. However, an even bigger impact on future revenue could come from a labeling change to DexCom's devices by the FDA. As it stands today, a confirmatory finger stick is required by the label. However, DexCom believes it has a good shot at removing that requirement, and the FDA has agreed to put the matter in front of an advisory committee in July. Assuming the advisory committee agrees with the company, an eventual label change could clear the way to Medicare reimbursement. That would be a big win, because a significant number of elderly diabetics forego buying the device because of its cost. Additionally, the majority of DexCom's sales are generated within the U.S., and efforts to win reimbursement in other major markets overseas, such as Germany and France, are progressing. If those markets open up, international sales could climb far beyond their current $19 million. Overall, DexCom's sales pace demonstrates that its products resonate with consumers, and the more global payers that sign on to reimburse its products, the better it will be for investors. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here . The article Are DexCom's Best Days Behind It, or Still to Come? originally appeared on Fool.com. Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-04-29,16.4175,16.4175,15.66,16.095,"DexCom (DXCM) Q1 Loss Wider than Expected, Stock Down Shares of DexCom Inc. DXCM fell 3.6% to close at $65.96 on Apr 28, following a disappointing first-quarter 2016 earnings release. The company reported loss of 23 cents per share in the quarter, a penny wider than the Zacks Consensus Estimate. DexCom had reported a loss of 17 cents in the year-ago quarter. Dexcom Inc. - Earnings Surprise | FindTheBest Revenues surged 59.6% year over year to $116.2 million, beating the Zacks Consensus Estimate of $110 million. Average selling price (ASP) was in the range of $70−$75 per sensor while ASP for Dexcom's hardware stood at approximately $850 to $850 per starter kit. International business generated $19 million in revenues. The company is gearing up for the inauguration of its European headquarters in Scotland post which it plans to expand its team in the continent. Gross margin expanded 80 basis points (bps) year over year to 64.6%. The modest growth can be attributed to lower sales due to seasonality, higher warranty expenses and unfavorable product mix. Selling, general and administrative (SG&A) expenses rose 57.6% on a year-over-year basis to $62.1 million. Research and development (R&D) expenses also increased 62.6% year over year to $32.2 million. Overall, operating expenses surged 59.3% year over year to $94.3 million. The higher expenses may be attributed to increased head count in the company's organization (including both field sales and internal sales support staff). Additional marketing expenses were a major factor driving the year-over-year increase. DexCom spent less than $10 million on its four key strategic initiatives - the Verily partnership, manufacturing capacity expansion, international expansion, and investment in advanced data platforms. The company plans to spend a total of $40 million on these four initiatives through full-year 2016. DexCom reported an operating loss of $19.2 million as compared to an operating loss of $12.7 million in the year-ago quarter. FDA Action On Feb 23, 2016, DexCom issued a customer notification in its website and certified mail to patients that alerted customers of a potential issue affecting the audible alarms and alerts associated with the speaker component of certain receivers. The company started voluntary recall (class II) of those affected receivers that were experiencing problems with audible alarms and alerts. After an inspection in late March, the FDA classified the recall as Class I due to the extreme importance of alerts and alarms in a continuous glucose monitoring (CGM) system. Accordingly, DexCom issued a press release on Apr 11 and also posted the class I recall notice on its website. DexCom hopes to solve the issue by replacing the current speaker with a more efficient one and has already sought approval from the FDA. The company is also evaluating a software upgrade for the current receiver to systematically test its audio functionality on a regular basis. Depending on the timing of the FDA approval for these corrective measures, DexCom noted that it may need to write-off its currently stocked receiver inventory, which will cost approximately $5 million. Product Details DexCom launched its next-generation G5 Mobile CGM system in the U.S. and Europe in 2015. According to management, ""G5 Mobile system is the first and only CGM system approved by the FDA for both adults and children as young as two years of age that sends glucose data directly to a smartphone."" The company plans to launch the Android version of the G5 Mobile later this year. DexCom also plans to submit and possibly launch an enhanced version of G5 Mobile app to provide additional features and functionality, such as insulin onboard data obtained from the company's pump partners in 2016. In this regard, the company noted that it expects to gain a FDA approval for the insulin dosing claim in the second half of 2016. With respect to Gen 6, DexCom expects to obtain IDE approval in the coming weeks and plans to commence a pivotal study in the late second quarter or early third quarter of 2016. Guidance For fiscal 2016, DexCom projects revenues in the range of $540 million to $565 million, reflecting growth of approximately 35% to 40% from 2015. The company expects 55%--60% of these revenues to be generated in the second half of the year. DexCom noted that gross margin will be impacted slightly in 2016 by higher costs related to manufacturing capacity expansion project. The company expects gross margin between 67% and 70% for the full year. Our Take DexCom's healthy product portfolio and innovative pipeline are the major catalysts for 2016 and beyond. The company's ongoing direct-to-consumer marketing campaign as well as signing of Pharmacy contracts with United Healthcare and Anthem ANTM are a positive in our view. However, higher warranty expenses related to the product recall will continue to hurt margins in the near term. Moreover, uncertainty over timing of the FDA approval for the corrective measures on the affected receivers will drag down the shares in the near term. Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are Inogen INGN and Exactech EXAC . Both the stocks carry a Zacks Rank #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report INOGEN INC (INGN): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ANTHEM INC (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-05-02,16.03,16.4725,15.8975,16.275,"[""Dexcom Reports Purchase of Nintamed, Co.'s Distributor in Germany, Switzerland, Austria, No Terms Disclosed"", ""Dexcom Reports Purchase of Nintamed, Co.'s Distributor in Germany, Switzerland, Austria, No Terms Disclosed"", ""Dexcom Reports Purchase of Nintamed, Co.'s Distributor in Germany, Switzerland, Austria, No Terms Disclosed""]"
DXCM,2016-05-03,15.95,16.23,15.5375,15.77,
DXCM,2016-05-04,15.6925,15.6925,15.2675,15.35,"[""Ira Sohn Conference 2016: The Live Blog"", ""Sohn Idea Contest Winner Unveils Short Thesis On DexCom"", ""Sohn Idea Contest Winner On DexCom Short, Says Co. Has Insulin Pump Competition From Medtronic And Abbott"", ""DexCom Shares Falling ~2% Off Sohn Idea Contest Winner's Short Thesis"", ""Sohn Contest Winner Says Future Revenue Miss Is 'Key Catalyst' To DexCom Short Thesis"", ""Sohn Contest Winner Says Future Revenue Miss Is 'Key Catalyst' To DexCom Short Thesis"", ""DexCom Shares Falling ~2% Off Sohn Idea Contest Winner's Short Thesis"", ""Sohn Idea Contest Winner On DexCom Short, Says Co. Has Insulin Pump Competition From Medtronic And Abbott"", ""Sohn Idea Contest Winner Unveils Short Thesis On DexCom"", ""Ira Sohn Conference 2016: The Live Blog"", ""Sohn Contest Winner Says Future Revenue Miss Is 'Key Catalyst' To DexCom Short Thesis"", ""DexCom Shares Falling ~2% Off Sohn Idea Contest Winner's Short Thesis"", ""Sohn Idea Contest Winner On DexCom Short, Says Co. Has Insulin Pump Competition From Medtronic And Abbott"", ""Sohn Idea Contest Winner Unveils Short Thesis On DexCom"", ""Ira Sohn Conference 2016: The Live Blog""]"
DXCM,2016-05-05,15.32,15.465,15.21,15.35,
DXCM,2016-05-06,15.34,15.455,15.0175,15.3275,
DXCM,2016-05-09,15.3,15.7375,15.2725,15.61,
DXCM,2016-05-10,15.7325,15.735,15.425,15.6225,
DXCM,2016-05-11,15.7175,16.2,15.6675,15.8625,
DXCM,2016-05-12,15.9625,15.985,15.075,15.29,
DXCM,2016-05-13,15.22,15.3575,15.0325,15.1575,"[""Short Dexcom: Sohn Investment Idea Contest Winner"", ""Short Dexcom: Sohn Investment Idea Contest Winner"", ""Short Dexcom: Sohn Investment Idea Contest Winner""]"
DXCM,2016-05-16,15.2375,15.7375,15.2025,15.7,
DXCM,2016-05-17,15.6475,15.805,15.4,15.4775,
DXCM,2016-05-18,15.45,15.5275,15.2728,15.46,
DXCM,2016-05-19,15.4075,15.7925,15.295,15.5675,
DXCM,2016-05-20,15.675,16.02,15.6088,15.955,"Better Buy: MannKind Corp. vs. Dexcom Without profits, we have to look at DexCom's price-to-sales multiple. At 11 times trailing sales, and over 9 times this year's estimates, DexCom stock still has a lot of optimism baked in. I'm sure its products will remain popular with people who can afford them, but that might not be enough to haul this company to Profit Town. While I'd strongly recommend waiting until DexCom can show sustainable profitability, at least it's not depending on the summer's most successful product launch to avoid bankruptcy. That makes it a much better buy than MannKind, hands down. There's something big happening this Friday I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was the best performing in the U.S. as reported by The Wall Street Journal )* and his brother, Motley Fool CEO Tom Gardner, are going to reveal their next stock recommendations this Friday. Together, they've tripled the stock market's return over the last 13 years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas. Click here to be among the first people to hear about David and Tom's newest stock recommendations. *""Look Who's on Top Now"" appeared in The Wall Street Journal in Aug. 2013, which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-05-23,15.7875,16.1025,15.72,15.87,
DXCM,2016-05-24,15.9825,16.43,15.7125,16.2525,
DXCM,2016-05-25,16.195,16.435,16.065,16.33,
DXCM,2016-05-26,16.3025,16.3025,15.7275,15.7875,
DXCM,2016-05-27,15.7675,16.3575,15.575,16.3225,
DXCM,2016-05-31,16.3125,16.3225,15.8975,16.1225,
DXCM,2016-06-01,15.8775,16.4,15.67,16.1875,
DXCM,2016-06-02,16.1475,16.9175,15.8975,16.9175,"Noteworthy Thursday Option Activity: RLYP, CAR, DXCM Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Relypsa, Inc (Symbol: RLYP), where a total volume of 17,580 contracts has been traded thus far today, a contract volume which is representative of approximately 1.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.6% of RLYP's average daily trading volume over the past month, of 3.2 million shares. Especially high volume was seen for the $20 strike call option expiring September 16, 2016 , with 3,170 contracts trading so far today, representing approximately 317,000 underlying shares of RLYP. Below is a chart showing RLYP's trailing twelve month trading history, with the $20 strike highlighted in orange: Avis Budget Group Inc (Symbol: CAR) saw options trading volume of 15,170 contracts, representing approximately 1.5 million underlying shares or approximately 52.2% of CAR's average daily trading volume over the past month, of 2.9 million shares. Particularly high volume was seen for the $31 strike call option expiring July 15, 2016 , with 3,021 contracts trading so far today, representing approximately 302,100 underlying shares of CAR. Below is a chart showing CAR's trailing twelve month trading history, with the $31 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 4,098 contracts thus far today. That number of contracts represents approximately 409,800 underlying shares, working out to a sizeable 51.1% of DXCM's average daily trading volume over the past month, of 801,815 shares. Especially high volume was seen for the $55 strike put option expiring September 16, 2016 , with 2,000 contracts trading so far today, representing approximately 200,000 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $55 strike highlighted in orange: For the various different available expirations for RLYP options , CAR options , or DXCM options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-06-03,16.8825,16.98,16.6425,16.8775,"[""Tandem Diabetes Care: Still A High Growth Well-Positioned Medical Device Name"", ""Tandem Diabetes Care: Still A High Growth Well-Positioned Medical Device Name"", ""Tandem Diabetes Care: Still A High Growth Well-Positioned Medical Device Name""]"
DXCM,2016-06-06,16.7175,17.225,16.6475,17.1425,
DXCM,2016-06-07,17.0725,17.27,17.005,17.265,
DXCM,2016-06-08,17.265,18.365,17.0696,18.335,
DXCM,2016-06-09,18.3325,18.6775,17.87,18.1675,
DXCM,2016-06-10,18.0675,18.235,17.7825,17.9775,
DXCM,2016-06-13,17.86,18.7125,17.645,18.02,
DXCM,2016-06-14,18.0575,18.45,17.7927,18.35,
DXCM,2016-06-15,18.45,18.7,18.1425,18.2375,
DXCM,2016-06-16,18.175,18.2275,17.87,18.1225,
DXCM,2016-06-17,18.0875,18.2175,17.9025,18.15,
DXCM,2016-06-20,18.7225,19.405,18.4812,19.31,"[""JPMorgan Bullish On Dexcom Heading Into July 21 FDA Panel"", ""JPMorgan Bullish On Dexcom Heading Into July 21 FDA Panel"", ""DexCom (DXCM) Shares Cross Above 200 DMA In trading on Monday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $74.68, changing hands as high as $76.67 per share. DexCom Inc shares are currently trading up about 5% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $47.92 per share, with $103.29 as the 52 week high point - that compares with a last trade of $76.16. According to the ETF Finder at ETF Channel, DXCM makes up 1.92% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading up by about 1.8% on the day Monday. Click here to find out which 9 other stocks recently crossed above their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""JPMorgan Bullish On Dexcom Heading Into July 21 FDA Panel""]"
DXCM,2016-06-21,19.435,19.435,18.8875,19.3775,"[""InsiderInsights.com Daily Round Up 6/20/16: Imperva, Goldman Sachs MLP & Energy Renaissance Fund, MLP Income Opportunities Fund, Bioscri, Applied Optoelectronics"", ""Diabetes Panel For DexCom And Alere"", ""Diabetes Panel For DexCom And Alere"", ""InsiderInsights.com Daily Round Up 6/20/16: Imperva, Goldman Sachs MLP & Energy Renaissance Fund, MLP Income Opportunities Fund, Bioscri, Applied Optoelectronics"", ""Diabetes Panel For DexCom And Alere"", ""InsiderInsights.com Daily Round Up 6/20/16: Imperva, Goldman Sachs MLP & Energy Renaissance Fund, MLP Income Opportunities Fund, Bioscri, Applied Optoelectronics""]"
DXCM,2016-06-22,19.3325,19.4425,19.0425,19.3725,
DXCM,2016-06-23,19.4375,19.5425,19.115,19.3975,"The Next Big Thing in Diabetes Treatment May Not Be a Drug, But a Device Ever year, 5 million people die from diabetes, and with hundreds of millions of people expected to develop the disease in the coming decades, there's a significant need for new treatment approaches. One promising approach that could revolutionize treatment is the use of next-generation technology to track a diabetes patient's blood sugar levels and determine the proper dosage of diabetes medicine for them. For example, DexCom (NASDAQ: DXCM) is using technology to create systems that allow patients and care givers to better chart their glucose levels so that they can more effectively manage their disease. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analysts Kristine Harjes and Gaby Lapera are joined by Todd Campbell to talk about how medical devices like this are harnessing technology to improve outcomes in diabetes patients. A transcript follows the video. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . {%video%} This podcast was recorded on Jun. 15, 2016. Kristine Harjes: One other element, too, investing in this space from a treatment perspective that I find intriguing, is in medical devices, because convenience is super important, as this is a chronic condition. Gaby Lapera: Absolutely. That really helps people manage it. Devices help people manage their diabetes a lot better than they did before. There is a new, well, I guess, a new-ish class of device that can be inserted on the body, on the skin somewhere, and it continuously monitors your blood sugar, and will administer insulin depending on what your current blood sugar level is. Harjes: These are called CGMs, continuous glucose monitors. The big company that's making them right now that I know is one of your favorites, Todd, to talk about is DexCom. Todd Campbell: Right. DexCom is making these continuous monitors that are allowing you to basically chart your blood sugar over time, which is amazing. Gaby, you brought up the fact that if you put on a shirt, you feel it at first. Then you don't feel it the rest of the day. Yes, you may be able to tell when you're out of sorts or when your blood sugar is off, but DexCom has found that 70% of the time, most diabetics are outside of their desired range in blood sugar. I think the analogy makes sense to be used here, too. You just don't know sometimes what you're getting in creeping up closer to those problem zones that that's actually happening. By charting the data, being able to keep better track of it in this way, then you can better control it. If you can better control it, maybe then you can delay the progression of the disease and delay things like cardiovascular events. Harjes: Another point to make here is that this is becoming a pretty high-tech space, where you get companies that are coming in and want you to be able to see your continuous glucose levels on your iPhone, and to be able to send that to your doctors, send that to your parents, send that to the people that really matter. I had a conversation earlier this year with the CEO of a company called Livongo -- they're a privately held company. You might recognize the CEO's name, Glen Tullman. He's the former CEO of Allscripts . Anyway, this is also mentioned in a March interview that I did with MuleSoft, for those of you who have been listening to the podcast for a couple of months now or longer. Anyhow, Livongo is making a ... What their goal here is to monitor chronic conditions remotely via a connected device. Then you can send the data to your doctors for analysis. You can share it with people that matter to you, as we were just mentioning. They also have a staff of coaches that's available for support and monitoring. This is a company that has a reach in general chronic conditions, but they started off just in diabetes, mostly because it's such a humongous disease. It really, really matters. Plus, 70% of people with diabetes that are 50 years or older have one or more other chronic diseases. You get companies that are coming into this space because they recognize that there's a huge unmet need. They're really changing the way that we treat this disease and the lives of the people that have to manage it every single day. Editor's note: CGMs at this point do not administer insulin. Gaby Lapera has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-06-24,18.665,19.4575,18.2925,19.365,
DXCM,2016-06-27,19.2075,19.365,18.6475,18.9775,"[""Insider Weekends: June 24, 2016"", ""Insider Weekends: June 24, 2016"", ""Insider Weekends: June 24, 2016""]"
DXCM,2016-06-28,19.125,19.5794,19.055,19.51,"[""InsiderInsights.com Daily Round Up 6/27/16"", ""Weekly CFO Sells Highlights"", ""Weekly CFO Sells Highlights"", ""InsiderInsights.com Daily Round Up 6/27/16"", ""Weekly CFO Sells Highlights"", ""InsiderInsights.com Daily Round Up 6/27/16""]"
DXCM,2016-06-29,19.525,20.3075,19.5025,19.75,"S&P 500 absorbs Brexit, reclaims the 2,040 breakdown point Focus: Crude oil weathers a volatility spike, USO, ETE, DXCM, RMD, GIS U.S. stocks are firmly higher early Wednesday, building on this week’s sharp post-Brexit reversal. In the process, the S&P 500 has nearly immediately reclaimed its breakdown point — S&P 2,040 — reaching firmer technical ground."
DXCM,2016-06-30,19.815,19.97,19.585,19.8325,
DXCM,2016-07-01,19.905,20.055,19.745,19.9075,
DXCM,2016-07-05,19.88,19.88,19.62,19.7625,
DXCM,2016-07-06,19.75,19.7875,19.4925,19.6725,
DXCM,2016-07-07,19.645,19.72,19.0528,19.5525,
DXCM,2016-07-08,19.75,19.75,19.3225,19.7175,
DXCM,2016-07-11,19.8725,19.955,19.66,19.85,
DXCM,2016-07-12,19.975,20.25,19.85,19.95,
DXCM,2016-07-13,20.03,20.1175,19.76,19.8325,
DXCM,2016-07-14,20.005,20.02,19.26,19.5275,
DXCM,2016-07-15,19.525,19.625,19.19,19.3875,
DXCM,2016-07-18,19.575,19.63,19.19,19.5475,
DXCM,2016-07-19,19.8,21.5875,19.7375,20.76,"[""Dexcom Reports FDA Posted Briefing Doc Ahead of Panel Meeting"", ""Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates"", ""Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting"", ""Benzinga's Volume Movers"", ""10 Biggest Mid-Day Gainers For Tuesday"", ""10 Biggest Mid-Day Gainers For Tuesday"", ""Benzinga's Volume Movers"", ""Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting"", ""Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates"", ""Dexcom Reports FDA Posted Briefing Doc Ahead of Panel Meeting"", ""Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates Following the market opening Tuesday, the Dow traded down 0.07 percent to 18,519.32 while the NASDAQ declined 0.35 percent to 5,038.16. The S&P also fell, dropping 0.26 percent to 2,161.24. Leading and Lagging Sectors On Tuesday, healthcare shares rose by 0.02 percent. Top gainers in the sector included DexCom, Inc. (NASDAQ: DXCM ) and Cerus Corporation (NASDAQ: CERS ). In trading on Tuesday, basic materials shares fell by 1.28 percent. Meanwhile, top losers in the sector included Vale SA (ADR) (NYSE: VALE ), down 4 percent, and Rio Tinto plc (ADR) (NYSE: RIO ), down 4 percent. Top Headline Goldman Sachs Group Inc (NYSE: GS ) reported stronger-than-expected results for its second quarter on Tuesday. The bank posted quarterly earnings $3.72 per share on revenue of $7.93 billion. However, analysts were expecting earnings of $3 per share on sales of $7.58 billion. Its revenue from trading fixed income, commodities and currencies climbed 20 percent to $1.93 billion, while revenue from trading increased 2 percent to $3.68 billion in the quarter. Equities Trading UP Bridgeline Digital Inc (NASDAQ: BLIN ) shares shot up 24 percent to $1.12 as the company reported that one of the nation's largest franchise systems has selected its iAPPS for Intranet. Shares of Hudson Technologies, Inc. (NASDAQ: HDSN ) got a boost, shooting up 33 percent to $5.05 after the company reported that it has been awarded a Department of Defense contract with an estimated maximum value of $400 million. Cerulean Pharma Inc (NASDAQ: CERU ) shares were also up, gaining 19 percent to $2.71 as the company reported that it has received the FDA Fast Track designation for CRLX101 for the treatment of platinum-resistant ovarian cancer. Equities Trading DOWN Super Micro Computer, Inc. (NASDAQ: SMCI ) shares dropped 29 percent to $18.81 after the company lowered its Q4 forecast and announced a $100 million buyback plan. Shares of Netflix, Inc. (NASDAQ: NFLX ) were down 13 percent to $85.59. Netflix posted upbeat earnings for its second quarter, but the company reported weak subscriber growth for the quarter. Netflix added 1.7 million subscribers worldwide during the quarter, well short of the company's projections. SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) was down, falling around 16 percent to $11.15. SciClone Pharma reported that it is no longer speaking with acquirers and plans to remain an independent company. The company projects FY2016 earnings of $0.70 to $0.74 per share on sales of $158.0 million to 163.0 million. Commodities In commodity news, oil traded down 0.07 percent to $45.21 while gold traded up 0.03 percent to $1,329.70. Silver traded down 0.50 percent Tuesday to $19.98, while copper rose 0.45 percent to $2.25. Eurozone European shares were mostly lower today. The eurozone's STOXX 600 declined 0.63 percent, the Spanish Ibex Index slipped 0.68 percent, while Italy's FTSE MIB Index dropped 1.50 percent. Meanwhile the German DAX declined 0.92 percent, and the French CAC 40 declined 0.79 percent, while U.K. shares rose 0.07 percent. Economics U.S. housing starts rose 4.8 percent to an annual pace of 1.19 million in June. However, economists were expecting a 1.17 million pace. Building permits increased 1.5 percent to an annual pace of 1.15 million. The Treasury is set to auction 4-week and 52-week bills at 11:30 a.m. ET. \u00a9 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why MGIC Investment, Dexcom, and F5 Networks Jumped Today Insuring mortgages can be a risky but rewarding business. Image source: Getty Images. On Tuesday, the stock market saw a break in its recent upward momentum, and major market benchmarks finished the day mixed. The Dow finished with modest gains to set another all-time record high, but the broader S&P 500 fell from its high-water mark set yesterday. Investors were somewhat nervous after some negative quarterly financial reports from major U.S. companies threw cold water on what had been an auspicious start to earnings season, and uncertainties about the future direction of the global economy were enough to cause at least a short pause in stocks' record run. However, some stocks still managed to keep up their positive momentum, and MGIC Investment (NYSE: MTG) , Dexcom (NASDAQ: DXCM) , and F5 Networks (NASDAQ: FFIV) were among the best performers on the day. MGIC gets good news from the mortgage world MGIC Investment rose 7% after the mortgage insurance specialist reported solid results in its second-quarter financial report. The mortgage insurer said that mortgage policy sales rose 10% during the quarter, but more importantly, costs of claims fell by roughly half. With the housing market having supported higher prices, fewer properties have left borrowers underwater on their mortgages, and that has helped reduce the need for MGIC to pay out on policies in the event of default. In addition, favorable data from the Commerce Department showed that new-home construction rose at a nearly 5% rate in June, which was faster than expected and pointed to the continued strength of the housing market. As long as the health of housing stays strong, MGIC will be in a position to work off potentially problematic policies and write new business that stands a better chance of avoiding future losses. Dexcom hopes for a favorable FDA review Dexcom gained 6% as investors speculated about the chances that the company will approve a change in intended use of one of its medical products. The company issued a press release on Tuesday saying that the Food and Drug Administration had published briefing documents in advance of this Thursday's planned meeting of a panel of its Medical Devices Advisory Committee that concentrates on clinical chemistry and toxicology devices. Dexcom hopes that the panel will recommend approval of its premarket approval application supplement, with which it proposes to allow patients to use its G5 Mobile CGM System to make diabetes treatment decisions based on reported concentrations of glucose in interstitial fluid. Investors can expect further comments from Dexcom on Friday morning at a conference call to discuss what happens at the meeting, but investors are already excited about the potential for faster growth from the San Diego-based medical device maker. Could F5 Networks get bought out? Finally, F5 Networks gained 4%. The networking specialist could be the latest reported target of private equity investors at Thoma Bravo, according to reports from the New York Post . F5 struggled during the last half of 2015 and early 2016, but the stock posted sizable gains recently as the company has reportedly worked with investment bankers to try to field acquisition offers and determine which might be the best fit for F5. With the lack of any definitive confirmation from F5, investors need to realize that at this point, there could be serious consequences if the networking company doesn't manage to find a buyer in the near future. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""10 Biggest Mid-Day Gainers For Tuesday"", ""Benzinga's Volume Movers"", ""Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting"", ""Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates"", ""Dexcom Reports FDA Posted Briefing Doc Ahead of Panel Meeting""]"
DXCM,2016-07-20,20.9725,21.28,20.885,21.1575,
DXCM,2016-07-21,21.16,21.16,21.16,21.16,"[""FDA Ad Comm backs use of Dexcom's G5 CGM as a replacement for blood glucose meter"", ""FDA panel review underway for Dexcom diabetes monitor, Alere POC diabetes test on deck for tomorrow"", ""FDA Ad Comm backs use of Dexcom's G5 CGM as a replacement for blood glucose meter"", ""FDA panel review underway for Dexcom diabetes monitor, Alere POC diabetes test on deck for tomorrow"", ""FDA Ad Comm backs use of Dexcom's G5 CGM as a replacement for blood glucose meter"", ""FDA panel review underway for Dexcom diabetes monitor, Alere POC diabetes test on deck for tomorrow""]"
DXCM,2016-07-22,21.99,22.2625,21.5775,21.9725,"[""DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System"", ""DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System"", ""DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System""]"
DXCM,2016-07-25,21.91,21.9648,21.755,21.95,
DXCM,2016-07-26,22.0075,22.17,21.875,22.08,
DXCM,2016-07-27,22.035,22.3075,21.79,22.165,
DXCM,2016-07-28,22.21,22.6512,22.0875,22.39,
DXCM,2016-07-29,22.5825,23.0975,22.425,23.0575,
DXCM,2016-08-01,23.1725,23.315,22.825,23.1625,"[""Notable earnings after Tuesday's close"", ""BMO Capital Highlights This Week's MedTech Earnings"", ""BMO Capital Highlights This Week's MedTech Earnings"", ""Notable earnings after Tuesday's close"", ""Look at Aug 2 Medical Instrument Earnings: IDXX, DXCM, CGNT As we get into the thick of the Q2 earning season, we observe that the magnitude of the earnings decline, which we had expected at the beginning of the reporting cycle, is slowly changing for better though only slightly. With more than 60% of the reports already out, we are optimistic of this improving trend to continue through the season. Nevertheless, growth is still unlikely and the analysts are, by now, quite certain this will be the fifth straight quarter of an earnings decline for the S&P 500 index. As per our latest Earnings Preview report, around 317 S&P 500 members (73.5% of the index's total market capitalization) have released their results, and the scorecard shows 3.3% year-over-year decline in the index' Q2 earnings on 0.9% lower revenues. Medical, one of the 16 broader Zacks sectors, has however exhibited a promising performance so far. Earnings growth rate stood at 5.4% year over year on account of a 1.2% rise in revenues. For the remaining the season, earnings are expected to grow 3.4%, driven by impressive top-line growth expectation of 7.7% in this sector. What's in Store for the Med-Instrument Space? Medical Instrument, a specialized sub-sector within the broader Medical sector, is showing a lot of potential as of now. This is impressive given the severe economic instability, fierce competition, and increasing cost related hazards leading to regulatory complexities. The success of the medical instrument industry comes on the back of successful execution of some top strategic priorities, which include R&D and product development; strategic M&A and alliances and a focus on emerging market expansion. Needless to say that factors like the recent exemption of the Medical Device Excise tax for the next two years has also come in as a much-needed breather for these Medical instrument stocks. We believe this exemption, albeit temporary, has boosted the positive sentiment in the medical device investment world, as most analysts believe it to be sufficient for companies to address pressing issues such as a lack of opportunity for R&D, innovation, pipeline development, and to make investments needed to accelerate patient and provider access to innovative health care products. Let's take a look at the Medical Instruments stocks slated to release their quarterly reports on Aug 2: IDEXX Laboratories, Inc.IDXX Headquartered in Delaware NJ, IDEXX is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry along with water testing and dairy markets. IDEXX's robust worldwide commercial capabilities and best-in-class products, which include the next-generation chemistry analyzer - Catalyst One, are the key growth drivers over the near term. IDEXX is scheduled to report second-quarter 2016 numbers on Aug 2. The company currently carries a Zacks Rank #3 (Hold) and has a positive Earnings ESP of 1.61%. That is because both the Most Accurate estimate stands higher at 63 cents per share as compared to the Zacks Consensus Estimate which remains at 62 cents. We note that while a favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise, a bullish Zacks rank #1 (Strong Buy), 2 (Buy) or #3 (Hold) increases the predictive power of the ESP. We also observe that IDEXX' trailing 12-month earnings surprise is 6.33%. IDEXX LABS INC Price and EPS Surprise IDEXX LABS INC Price and EPS Surprise | IDEXX LABS INC Quote DexCom, Inc.DXCM San Diego, CA-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). The large and growing diabetes market, strong product portfolio, innovative product pipeline, collaborative agreements with several companies and focus on international markets are key catalysts for Dexcom. Dexcom is scheduled to report second-quarter 2016 numbers on Aug 2. However, our proven model does not conclusively show that Dexcom is likely to beat earnings this quarter. This is because Dexcom currently carries a Zacks Rank #3 (Hold) and has a negative Earnings ESP of 36.36%. That is because both the Most Accurate Estimate remains at loss of 15 cents which the Zacks Consensus Estimate remains higher at a loss of 11 cents per share. We also note that Dexcom's trailing 12-month earnings surprise is a negative 223.74%. DEXCOM INC Price and EPS Surprise DEXCOM INC Price and EPS Surprise | DEXCOM INC Quote Cogentix Medical, Inc.CGNT This medical device provider catering to urology market and flexible endoscopy is scheduled to report second-quarter 2016 earnings on Aug 2. While a favorable Zacks Rank #3 (Hold) increases the predictive power of the ESP, a 0.00% ESP makes a surprise prediction difficult. We also note in the last reported quarter, the company registered an earnings miss of 33.33%. However, the trailing 12-month average surprise came in at a positive 24.17%. COGENTIX MEDICL Price and EPS Surprise COGENTIX MEDICL Price and EPS Surprise | COGENTIX MEDICL Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX LABS INC (IDXX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $91.31, changing hands for $92.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised. There are 12 different analyst targets contributing to that average for DexCom Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $56.75. And then on the other side of the spectrum one analyst has a target as high as $112.00. The standard deviation is $13.704. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $91.31/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $91.31 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BMO Capital Highlights This Week's MedTech Earnings"", ""Notable earnings after Tuesday's close""]"
DXCM,2016-08-02,23.1225,23.215,22.745,23.195,"[""DexCom EPS of -$0.24"", ""DexCom (DXCM) Kevin Ronald Sayer on Q2 2016 Results - Earnings Call Transcript"", ""DexCom -5.7% as loss widens in Q2"", ""DexCom Reports Q2 GAAP EPS $(0.24) vs $(0.05) in Same Qtr. Last Year, Sales $137.3M vs $132.6M Est."", ""DexCom Reports Q2 GAAP EPS $(0.24) vs $(0.05) in Same Qtr. Last Year, Sales $137.3M vs $132.6M Est."", ""DexCom (DXCM) Kevin Ronald Sayer on Q2 2016 Results - Earnings Call Transcript"", ""DexCom -5.7% as loss widens in Q2"", ""DexCom EPS of -$0.24"", ""Earnings Reaction History: DexCom, Inc., 85.7% Follow-Through Indicator, 7.8% Sensitive Expected Earnings Release: 08/02/2016, After-hours Avg. Extended-Hours Dollar Volume: $2,241,855 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 5.6% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (4 events) the stock posted additional gains in the following regular session by an average of 5.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 1.9% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.9% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Q2 GAAP EPS $(0.24) vs $(0.05) in Same Qtr. Last Year, Sales $137.3M vs $132.6M Est."", ""DexCom (DXCM) Kevin Ronald Sayer on Q2 2016 Results - Earnings Call Transcript"", ""DexCom -5.7% as loss widens in Q2"", ""DexCom EPS of -$0.24""]"
DXCM,2016-08-03,21.96,23.625,21.875,22.7175,"DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down Shares of DexCom Inc. DXCM fell 5.7% in after-hours trading on Aug 2, following another disappointing earnings release. The company reported loss of 24 cents per share in the second quarter of 2016, much wider than the Zacks Consensus Estimate of a loss of 11 cents. DexCom had reported a loss of 5 cents in the year-ago quarter. Revenues surged 47.3% year over year to $137.3 million, beating the Zacks Consensus Estimate of $133 million. Average selling price (ASP) was in the range of $70−$75 per sensor while ASP for Dexcom's hardware was stable (approximately $850 to $850 per starter kit) in the quarter. International revenues surged 45% year over year to $18 million in the quarter. DexCom bought its distributor Nintamed, which operated in Germany, Austria and Switzerland. DexCom also established direct team in the U.K. Notably, in Germany, the G-BA agreed to provide reimbursement for the company's continuous glucose monitoring (CGM) device. The reimbursement approval is anticipated to benefit DexCom's top-line growth beginning 2017. Dexcom Inc. - Earnings Surprise | FindTheBest Operational Details Gross margin contracted 850 basis points (bps) year over year to 62.3%. The gross margin was affected chiefly by increased warranty expense as well as a write-down of excess and obsolete inventory of approximately $3.5 million related to the company's receiver recall. Selling, general and administrative (SG&A) expenses surged 53.3% on a year-over-year basis to $69.3 million. Research and development (R&D) expense also jumped 48.8% year over year to $36.3 million. Overall, operating expenses were up 51.7% year over year to $105.6 million. The higher expenses can be attributed to increased payroll related costs and expenses related to work on the company's product pipeline. DexCom also incurred considerable expense related to its Verily partnership. DexCom also spent more on its four key strategic initiatives - the Verily partnership, manufacturing capacity expansion (in Arizona), international expansion, and investment in advanced data platforms. The company plans to spend a total of $40 million on these four initiatives through full-year 2016. DexCom reported an operating loss of $20.1 million compared with an operating loss of $3.6 million in the year-ago quarter. DEXCOM INC Price, Consensus and EPS Surprise DEXCOM INC Price, Consensus and EPS Surprise | DEXCOM INC Quote Regulatory Action On Feb 23, 2016, DexCom issued a customer notification in its website and certified mail to patients that alerted customers of a potential issue affecting the audible alarms and alerts associated with the speaker component of certain receivers. The company started voluntary recall (class II) of those affected receivers that were experiencing problems with audible alarms and alerts. After an inspection in late March, the U.S. Food and Drug Administration (FDA) classified the recall as Class I due to the extreme importance of alerts and alarms in a CGM system. Accordingly, DexCom issued a press release on Apr 11 and also posted the class I recall notice on its website. During the second quarter, DexCom received FDA approval for a more robust speaker for the current receiver. The company is in the process of planning the production of this newly configured receiver. DexCom also filed its next generation touchscreen receiver with the FDA during the quarter. The company also submitted for a firmware update on the transmitter and a software update for its mobile app that will enhance the performance and reliability of the G5 Mobile transmitter. While recently, the Clinical Chemistry and Clinical Toxicology Devices Panel of the FDA voted in favor of the proposed non-adjunctive indication for DexCom's G5 Mobile CGM system. This indication would designate the G5 Mobile CGM system as a replacement to finger-stick glucose testing for diabetes treatment decisions. DexCom had filed a pre-market approval (PMA) supplement with the FDA for this indication, for which the review by the advisory committee was conducted on Jul 21. Product Details DexCom launched its next-generation G5 Mobile CGM system in the U.S. and Europe in 2015. According to management, ""G5 Mobile system is the first and only CGM system approved by the FDA for both adults and children as young as two years of age that sends glucose data directly to a smartphone."" DexCom plans to launch the Android version of the G5 Mobile app in the third quarter. The U.S. Android launch is now dependent upon the transmitter firmware revision that the company filed for the FDA approval in the second quarter. The company now expects the U.S. Android launch to happen in late 2016 or early 2017. DexCom also plans to submit and possibly launch an enhanced version of G5 Mobile app to provide additional features and functionality, such as insulin onboard data obtained from the company's pump partners in 2016. The new G5 insertion system and transmitter is expected to be filed for the FDA approval within the next few weeks. With respect to Gen 6, DexCom obtained IDE approval in the second quarter. Guidance For fiscal 2016, DexCom now projects revenues in the range of $550 million to $575 million as compared with previous guidance of $540 million to $565 million. DexCom anticipates warranty costs as a percentage of sales to decline in the third quarter of 2016 and is expected to normalize before the end of the year. DexCom forecasts gross margin to be in the mid-to-upper 60% range for the second half of the year and in the mid-60% for the full year of 2016. Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #2 (Buy). Better-ranked stocks in the medical sector are Cepheid CPHD , Masimo Corp MASI and Natus Medical BABY . All the three stocks sport a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CEPHEID INC (CPHD): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-08-04,22.875,22.9425,22.66,22.875,
DXCM,2016-08-05,22.755,23.055,22.6975,22.8075,"[""You Need A Web Presence - Cramer's Mad Money (8/4/16)"", ""You Need A Web Presence - Cramer's Mad Money (8/4/16)"", ""You Need A Web Presence - Cramer's Mad Money (8/4/16)""]"
DXCM,2016-08-08,22.8125,22.93,22.62,22.665,
DXCM,2016-08-09,22.75,22.8625,22.6275,22.775,
DXCM,2016-08-10,22.565,22.7412,22.2925,22.56,
DXCM,2016-08-11,22.7175,22.79,22.605,22.73,
DXCM,2016-08-12,22.75,22.75,22.5,22.6325,
DXCM,2016-08-15,22.625,22.825,22.5475,22.72,"Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised) Medical device major Medtronic plc's ( MDT ) MiniMed 630G system with SmartGuard technology - a new insulin pump that facilitates diabetes care - recently won the U.S. FDA (Food and Drug Administration) approval for its commercial launch in the U.S. This system will be useful particularly on people aged sixteen years or more. The MiniMed 630G basically combines SmartGuard technology which is already featured in the MiniMed 530G system with a brand new user-friendly design. We note that, the SmartGuard technology acts against low blood sugar and is the only system at present to reduce the frequency of night-time low episodes by one third. We believe this system will receive huge market acceptance taking into consideration the fact that up to 75% of severe hypoglycemia occurs during night time while patients are asleep. MiniMed 630G has a user-friendly design which enables personalized diabetes management and also provides advanced clinical performance. Apart from that, this system, unlike the other members of the MiniMed family uses the Contournext Link 2.4, the blood glucose meter of Ascensia Diabetes Care which claims to provide accurate blood glucose test results. We note that, with rapidly rising incidents of diabetes across the U.S., healthcare organizations are now focused on innovating technologies that will effectively help the nation's 29.1 million diabetics manage their health conditions. Remarkably, diabetes has been growing at an exponential rate lately with the global diabetic population expected to reach 552 million by 2030 from 366 million in 2011. With such a scenario looming, disease management and providing optimal therapy has become a major challenge for healthcare providers. Medtronic is leaving no stone unturned to consolidate its position as a leading holistic diabetes management company in the U.S. In this regard, we should refer to the company's global, multi-year collaboration with Qualcomm Life, a wholly-owned subsidiary of Qualcomm Incorporated, to jointly develop future generation continuous glucose monitoring (CGM) systems that aspire to improve health outcomes for people with diabetes. Other major medical device companies that are prominent players in the diabetic space are Becton, Dickinson and Company ( BDX ), DexCom, Inc. ( DXCM ) and Abbott Laboratories ( ABT ), among others. (We are reissuing this article to correct a mistake. The original article, issued earlier today, August 15, 2016, should no longer be relied upon.) Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-08-16,22.7475,22.7475,22.5502,22.655,
DXCM,2016-08-17,22.6375,22.6775,22.4875,22.5725,
DXCM,2016-08-18,22.5625,22.8575,22.5625,22.725,
DXCM,2016-08-19,22.625,22.8325,22.4875,22.735,"[""The Difference Between DexCom (DXCM) and Fitbit (FIT) is Why Biotricity (BTCY) is Compelling"", ""The Difference Between DexCom (DXCM) and Fitbit (FIT) is Why Biotricity (BTCY) is Compelling"", ""The Difference Between DexCom (DXCM) and Fitbit (FIT) is Why Biotricity (BTCY) is Compelling""]"
DXCM,2016-08-22,22.6625,22.8672,22.5075,22.64,"[""Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update"", ""Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update"", ""Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update""]"
DXCM,2016-08-23,22.585,23.0625,22.5075,23.0225,"[""InsiderInsights.com Daily Round Up 8/22/16: WisdomTree Investments, Zosano Pharma, Vishay Precision, Chicago Bridge"", ""InsiderInsights.com Daily Round Up 8/22/16: WisdomTree Investments, Zosano Pharma, Vishay Precision, Chicago Bridge"", ""InsiderInsights.com Daily Round Up 8/22/16: WisdomTree Investments, Zosano Pharma, Vishay Precision, Chicago Bridge""]"
DXCM,2016-08-24,22.93,23.4675,22.56,22.5875,
DXCM,2016-08-25,22.6375,22.945,22.5,22.655,
DXCM,2016-08-26,22.6425,22.865,22.563,22.81,
DXCM,2016-08-29,22.895,23.16,22.6346,22.9125,
DXCM,2016-08-30,22.9125,23.1175,22.8425,23.0373,
DXCM,2016-08-31,22.9325,23.0,22.6925,22.7725,
DXCM,2016-09-01,22.825,22.9825,22.5775,22.9275,
DXCM,2016-09-02,23.0,23.1975,22.8325,23.0225,
DXCM,2016-09-06,23.145,23.875,23.045,23.5775,
DXCM,2016-09-07,23.6125,23.9513,23.545,23.755,"[""Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany"", ""Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany"", ""Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany""]"
DXCM,2016-09-08,23.7025,24.095,23.5588,23.95,
DXCM,2016-09-09,23.76,23.85,23.19,23.24,
DXCM,2016-09-12,23.04,23.31,22.8,23.26,"8 Risky Stocks That Are Worth the Risk Want big returns? Take on big risks. So goes the inescapable calculus of investing. With so many investors focused on safety and income these days, we decided to take a contrarian approach by looking for risky companies that have the potential to deliver big payoffs. We've identified eight risky stocks that we believe are worth the risk. Several of these companies, we feel, have the potential to be game-changers in their industries--the proverbial ""next Google."" But in exchange for the possibility of a big payoff down the road, investors must be content forgoing profits for the time being (only one of our picks pays a dividend). Others on the list are already profitable and show great potential, but come with other unusual or notable risks. Consider stashing a small portion of your play money into each of these names, then ignoring them for a few years. Chances are not all will succeed. But the one or two (or more) winners on the list could win big. Symbol: BABA Share price: $99.62 Market capitalization: $246.3 billion 52-week range: $57.20 - $104.30 Annual sales: $17 billion Estimated earnings for the fiscal year ending March 2017: $3.28 per share Estimated earnings for the fiscal year ending March 2018: $4.21 per share Price-earnings ratio: 29 Year-to-date return: 23% What does the company do? Often called ""the eBay of China,"" Alibaba is the dominant online retailer in China. Alibaba's business model is slightly different than those of the U.S. companies it's often compared to, combining elements of eBay ( EBAY ), Amazon.com ( AMZN ) and PayPal ( PYPL ). Its websites are essentially large online marketplaces, linking buyers with sellers and earning fees from advertising and payment processing. But unlike eBay, it doesn't operate auctions, and unlike Amazon, it doesn't sell products itself. Why is the stock risky? ""It's risky because we don't know where China is going,"" says Benjamin Segal, manager of the Neuberger Berman International Equity Fund, which owns the stock. Economic growth in China has been slowing, the Shanghai Composite index has fallen more than 40% since June 2015, and economists have been warning of risks in the country's ""shadow banking"" sector, in which lightly regulated financial companies have been selling trillions of dollars in risky products. Why is it worth the risk? A slowing Chinese economy is still a growing Chinese economy. The country is gradually shifting to a consumer-driven economy from one in which investment spending--including government investments in infrastructure and spending by state-sponsored and private enterprises--has been the main driver of growth. That should spell more business for retailers. Moreover, China doesn't have the vast array of brick-and-mortar stores that the U.S. does, making newly minted members of the middle class more likely to turn to online shopping first. Alibaba's profits have grown almost tenfold in the past three years, and analysts expect them to increase by a still-brisk 28% annual pace over the next three to five years. ""In an economy that will, in time, be comparable to if not bigger than the U.S., here is eBay, PayPal and Amazon all wrapped into one,"" says Segal. Compared with, say, Amazon.com's P/E ratio of 101, Alibaba, trading at 29 times estimated year-ahead profits, looks cheap. SEE ALSO: The Best Stocks From Around the World Symbol: ATHN Share price: $120.12 Market capitalization: $4.7 billion 52-week range: $114.59 - $170.42 Annual sales: $1 billion Estimated 2016 earnings: $1.77 per share Estimated 2017 earnings: $2.23 per share Price-earnings ratio: 62 Year-to-date return: -25% What does the company do? Athenahealth offers web-based health care software for physicians and hospitals. The software helps health care providers track and collect reimbursements from insurers, store patients' electronic health records, and coordinate overall office-management tasks. Athenahealth earns its money by charging a percentage of collections, which aligns its incentives with clients and often works out to be cheaper for users than alternative systems. Why is the stock risky? The company is barely profitable, and the health care sector is slow-moving and fraught with bureaucracy, meaning providers may be slow to adopt a new way of doing things. Its chief executive officer, Jonathan Bush (nephew to the 41st U.S. President and cousin to the 43rd), is considered controversial because of his tendency to divulge too much information about the inner workings and struggles of his company. And the stock is hardly cheap. Why is it worth the risk? Sure, health care companies are slow to adopt change, but the slow-moving, costly existing process of health care billing is ripe for a makeover, and Athenahealth's products are the most compelling on the market. Cathie Wood, CEO of ARK Investment Management, says the company's strategy is reminiscent of that of Amazon.com--forgoing near-term profits in an effort to stake out a dominant market position. ""This could be a winner-take-most situation,"" says Wood. Investors will need to be patient with the stock, but Athenahealth could be worth the wait. See Also: 12 Stocks to Get Dividends Every Month Symbol: BLUE Share price: $53.43 Market capitalization: $2.1 billion 52-week range: $35.37 - $143.08 Annual sales: Not meaningful Estimated 2016 earnings: -$6.15 per share Estimated 2017 earnings: -$6.52 per share Year-to-date return: -17% What does the company do? Bluebird develops gene therapies, an up-and-coming medical treatment that entails introducing ""corrected"" genes into a patient's body, in order to treat or even cure a genetic condition. Bluebird is developing gene therapies to target certain types of genetically caused anemia: severe sickle cell disease and beta thalassemia. The company also has a gene therapy in the works to treat a rare nervous-system disorder and is in the early stages of developing immunotherapies for certain types of cancer. Why is the stock risky? All of Bluebird's products are still in clinical trials, so the company does not yet earn money from selling its products, let alone generate any profits. There's always the risk that the company burns through its cash before it brings any products to market. Why is it worth the risk? Bluebird's therapies have seen some inspiring results. Although the company's drug trials have thus far included relatively small numbers of people, in a few cases patients appear to have been cured of all symptoms of a life-threatening genetic condition with just one course of treatment. ""Bluebird's treatments have the potential to be life-changing,"" says Dennis Wassung, a portfolio manager with Cabot Wealth Management who owns the stock in separately managed accounts. Results haven't been uniformly perfect for any of Bluebird's therapies, but all three of its gene therapies hold promise. It's hard to come up with an appropriate price tag for such an early-stage company. But with the stock down 73% from its May 2015 peak of $197.35--because of some unexpected setbacks in trial results and also because of overall weakness among biotech stocks--investors might one day look back at the current share price and see a screaming buying opportunity. See Also: 7 Battered Biotech Stocks to Buy Symbol: DXCM Share price: $92.96 Market capitalization: $7.7 billion 52-week range: $47.92 - $103.29 Annual sales: $490 million Estimated 2016 earnings: -$0.57 per share Estimated 2017 earnings: $0.26 per share Year-to-date return: 14% What does the company do? Dexcom makes continuous glucose monitoring systems for patients with diabetes. An alternative to conventional finger-prick tests, Dexcom's products essentially provide moment-by-moment tracking of glucose levels, using a sensor that is inserted under the skin. The device automatically transmits data to a small, iPod-like instrument, which allows patients to watch trends on their blood sugar and receive alerts if their glucose levels enter dangerous territory. Why is the stock risky? Dexcom has yet to turn profitable, and it's not the only company offering this type of technology. Plus, the stock has already enjoyed a large run-up--soaring by more than 13 times since November 2011. On a price-to-sales basis, Dexcom trades at a ""meaningful premium"" to its peers, says Wassung. Why is it worth the risk? Dexcom leads competitors in terms of market share and accuracy of its products, so it deserves a premium valuation. Only 15% of patients with type-1 diabetes are using continuous glucose monitoring systems, Wassung says, so an enormous untapped opportunity set remains. ""Dexcom's technology has really just started to hit the mainstream market in the last few years, and is receiving a lot of support from the medical community,"" he adds. Analysts expect the company to turn profitable in the fourth quarter of 2016, earn $0.26 per share next year and $0.98 per share in 2018. Symbol: ESLT Share price: $96.70 Market capitalization: $4.0 billion 52-week range: $72.05 - $103.28 Annual sales: $3.2 billion Actual 2015 earnings: $4.74 per share Estimated 2016 earnings: Not available Estimated 2017 earnings: Not available Year to date return: 10.8% What does the company do? Elbit Systems makes drones, technology systems for aircrafts, and intelligence-gathering and military communications systems. The company, which is based in Haifa, Israel, sells its products all over the world, with no one country or geographic area dominating its revenues. Why is the stock risky? Elbit is based in a tough and volatile neighborhood. Trade with Israel is vulnerable to shifting political winds. And although the shares trade on Nasdaq, Elbit's shares are not as liquid as a typical U.S. stock. Why is it worth the risk? Elbit's growth prospects are excellent thanks to its broad geographic diversification. For example, in the first half of 2016, sales to Europe increased by 31% compared with the same period in 2015, as European members of NATO boosted spending on their militaries because of concerns about Russia's expansionist aims. The company's high-tech focus should continue to give it an edge; it recently signed contracts for delivery of thermal-imaging observation systems and tactical communication systems. The company has a backlog of orders worth $6.8 billion, equivalent to more than two years of annual revenue. First-half profits of $106 million ($2.49 per share) were up 18% from the first six months of 2015. The stock has been on a tear, more than tripling since August 2012, but we think it still has room to run. Elbit is the only company on our list that pays a dividend. The stock yields 1.7%. See Also: Great Foreign Stocks That Pay Big Dividends Symbol: SKX Share price: $23.48 Market capitalization: $3.7 billion 52-week range: $22.50 - $49.58 Annual sales: $3.4 billion Estimated 2016 earnings: $1.83 per share Estimated 2017 earnings: $2.14 per share Price-earnings ratio: 12 Year-to-date return: -22% What does the company do? Known mainly for its sneakers, Skechers also makes other casual footwear, such as boots and sandals Why is the stock risky? Skechers' shoes haven't been, well, cool, in a long time. The brand's heyday was in the late '90s and early aughts, arguably peaking in 2001, when Brittany Spears appeared on the cover of Forbes in a pair of Skechers (alongside a story proclaiming that the company might be the ""next Nike""). Since then, sales have grown at a respectable 8.9% per year, but Skechers has made missteps in its quest to regain its former trendiness. In 2012, for example, the company settled charges with the Federal Trade Commission that its Shape Up shoes (endorsed by Kim Kardashian) would help wearers lose weight and tone their backsides. The stock has sunk 27% since July 21, when the company reported second-quarter results that came in below analysts' estimates. Why is it worth the risk? Skechers may never again be the hottest must-have shoe. Instead, the company has shifted its strategy to offering a lot of inexpensive versions of popular styles, aiming to capture a portion of market share in a variety of categories rather than focusing on a single trendy shoe. In 2015, Skechers surpassed Adidas to become the second-biggest seller of athletic footwear in the U.S., behind only Nike ( NKE ). Sales and earnings have grown robustly in recent years. Sales rose an annualized 26% from 2012 through 2015, and profits skyrocketed from $10 million to $232 million. The streak came to a halt in the second quarter, with sales expanding by only 10% from the same period in 2015 and earnings actually slipping by 7%. However, much of the slowdown was due to onetime issues. Wassung says investors have been too hard on the stock in the past month and a half, and he sees a buying opportunity. Symbol: TSLA Share price: $194.47 Market capitalization: $28.9 billion 52-week range: $141.05 - $271.57 Annual sales: $4.6 billion Estimated 2016 earnings: -$0.95 per share Estimated 2017 earnings: $1.71 per share Price-earnings ratio: Not meaningful Year-to-date return: -19% What does the company do? Tesla is best known for its sleek electric vehicles, and almost all of its revenues come from selling cars and related products and services. But the ambitions of Elon Musk, the company's enigmatic CEO, don't stop at high-end cars. Tesla is in the process of acquiring SolarCity ( SCTY ), a maker of solar panels, and Musk has said he wants Tesla to become a one-stop shop to help consumers power their households. He plans to accomplish this by selling panels along with efficient batteries for storing generated energy (because solar panels generate a lot of energy at certain times of day, and none at others). Why is the stock risky? Tesla has yet to turn a profit, although analysts expect it to earn money in the current quarter. And lofty expectations are already baked into the stock, which trades at 185 times estimated year-ahead earnings (profits are so low, the P/E isn't especially meaningful). Moreover, Tesla's proposed acquisition of SolarCity has been criticized as a bailout of the solar company, which came close to running out of cash this year and has been unable to persuade other potential suitors to invest. Tesla has itself reported in regulatory filings that it will need to issue additional stock or debt before the end of the year, in part to bankroll the merger. Why is it worth the risk? Few companies can truly lay claim to having the potential to change the world, but Tesla is one of them. Musk has said he expects the company to be producing 1 million electric vehicles per year by 2020, as Tesla works on making its factories more efficient. That would put its output at roughly one-seventh of the annual output of Ford Motor ( F ). The company is also investing heavily in its battery technology, which has the potential to serve applications far beyond vehicles and solar-powered homes. ""Lots of investors don't like the fact that they can't hang their hat on certain quarterly numbers,"" says Wood, of ARK Investment Management, a firm that runs actively managed exchange-traded funds and owns the stock. ""We don't mind because we see the big picture."" QUIZ: How Well Do You Know Dividends? Symbol: TUBE Share price: $8.99 Market capitalization: $326 million 52-week range: $8.75 - $14.46 Annual sales: $202 million Estimated 2016 earnings: -$0.58 per share Estimated 2017 earnings: -$0.31 per share Year-to-date return: -34% What does the company do? TubeMogul develops self-service advertising software that allows advertisers and advertising agencies to directly purchase TV, online and mobile ad spots. Its business model represents a dramatic shift for the advertising industry. Print, online and broadcast ads have traditionally been bought and sold through a laborious and costly process of soliciting requests for proposals, with layers of middlemen taking cuts of deals. Why is the stock risky? The company is not yet profitable. Analysts, on average, don't expect it to make money until 2018, but it could remain in the red for longer than investors expect. Why is it worth the risk? ""Disruption"" is a buzzword that gets wildly overused in the world of start-ups, but TubeMogul's business model does seem to have the potential to be a game-changer for digital advertising. It's a cheaper model for advertisers and it allows them to, with a few clicks, target the exact demographic groups they want to reach on the exact mediums they want to use. And it provides up-to-the-moment analytics on whether an ad campaign is reaching the right people. Plus, the stock looks reasonable on the basis of its price-to-sales ratio. The shares sell at 1.7 times the past 12 months' sales, matching the price-to-sales ratio for industrial companies in Standard & Poor's 500-stock index. SEE ALSO: 5 Good Dividend Stocks to Buy While They Are Cheap The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-09-13,23.175,23.3425,22.835,22.97,"[""Feasibility study underway for Insulet's artificial pancreas system"", ""Feasibility study underway for Insulet's artificial pancreas system"", ""Feasibility study underway for Insulet's artificial pancreas system""]"
DXCM,2016-09-14,22.66,23.2,22.5933,22.9475,"[""BTIG Research Downgrades DexCom to Neutral"", ""BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued"", ""BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued"", ""BTIG Research Downgrades DexCom to Neutral"", ""BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued"", ""BTIG Research Downgrades DexCom to Neutral""]"
DXCM,2016-09-15,22.88,23.4625,22.7025,23.1875,
DXCM,2016-09-16,23.245,23.5325,23.165,23.265,"[""Healthcare ratings roundup - upgrades/downgrades"", ""Desjardins Upgrades DexCom to Buy"", ""Benzinga's Top Upgrades"", ""Benzinga's Top Upgrades"", ""Desjardins Upgrades DexCom to Buy"", ""Healthcare ratings roundup - upgrades/downgrades"", ""Benzinga's Top Upgrades"", ""Desjardins Upgrades DexCom to Buy"", ""Healthcare ratings roundup - upgrades/downgrades""]"
DXCM,2016-09-19,23.35,23.43,23.075,23.265,
DXCM,2016-09-20,23.2925,23.3738,23.025,23.1825,
DXCM,2016-09-21,23.25,23.4225,23.1025,23.375,
DXCM,2016-09-22,23.5,23.6975,23.4225,23.5025,
DXCM,2016-09-23,23.5,23.56,23.4338,23.4775,
DXCM,2016-09-26,23.3975,23.4625,23.2125,23.29,
DXCM,2016-09-27,23.2425,23.475,23.2335,23.43,"[""B. Riley Initiates Coverage on DexCom at Neutral, Announces $97.00 PT"", ""Benzinga's Top Initiations"", ""Benzinga's Top Initiations"", ""B. Riley Initiates Coverage on DexCom at Neutral, Announces $97.00 PT"", ""Benzinga's Top Initiations"", ""B. Riley Initiates Coverage on DexCom at Neutral, Announces $97.00 PT""]"
DXCM,2016-09-28,23.3875,23.43,21.18,22.435,"[""InsiderInsights.com Daily Round Up 9/27/16: EIGI, IDSY, HY"", ""Shares of DexCom Down 7% For The Session At $87.43/Share"", ""Dexcom Sells off to Low of $86.77 on Volume"", ""BZ NOTE: Shares of Tandem Diabetes Care, DexCom Both Down ~7% On Medtronic's Earlier Approval Of Automated Insulin Delivery Device For Type 1 Diabetes"", ""Hearing JP Morgan Defending DexCom"", ""Hearing JP Morgan Defending DexCom"", ""BZ NOTE: Shares of Tandem Diabetes Care, DexCom Both Down ~7% On Medtronic's Earlier Approval Of Automated Insulin Delivery Device For Type 1 Diabetes"", ""Shares of DexCom Down 7% For The Session At $87.43/Share"", ""Dexcom Sells off to Low of $86.77 on Volume"", ""InsiderInsights.com Daily Round Up 9/27/16: EIGI, IDSY, HY"", ""Hearing JP Morgan Defending DexCom"", ""BZ NOTE: Shares of Tandem Diabetes Care, DexCom Both Down ~7% On Medtronic's Earlier Approval Of Automated Insulin Delivery Device For Type 1 Diabetes"", ""Shares of DexCom Down 7% For The Session At $87.43/Share"", ""Dexcom Sells off to Low of $86.77 on Volume"", ""InsiderInsights.com Daily Round Up 9/27/16: EIGI, IDSY, HY""]"
DXCM,2016-09-29,22.4725,22.495,21.565,21.95,
DXCM,2016-09-30,22.09,22.255,21.7025,21.9125,"[""Healthcare ratings roundup - new coverage"", ""Medtronic's Artificial Pancreas Leads The Field"", ""Medtronic's Artificial Pancreas Leads The Field"", ""Healthcare ratings roundup - new coverage"", ""Medtronic's Artificial Pancreas Leads The Field"", ""Healthcare ratings roundup - new coverage""]"
DXCM,2016-10-03,21.7275,21.9525,21.0225,21.245,"DexCom Enters Oversold Territory Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $85.58 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 49.8. A bullish investor could look at DXCM's 28.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $47.92 per share, with $96.38 as the 52 week high point - that compares with a last trade of $85.93. According to the ETF Finder at ETF Channel, DXCM makes up 4.44% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 1% on the day Monday. Find out what 9 other oversold stocks you need to know about » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-04,21.2475,21.3712,20.145,20.4825,"New Strong Sell Stocks for October 4th Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: • DexCom, Inc.DXCM is developing continuous glucose monitoring systems for people with diabetes. The Zacks Consensus Estimate for its current year earnings has been revised 3% downward over the last 30 days. • Syntel, Inc.SYNT is a worldwide provider of advanced technology services to Fortune 1000 companies, as well as to government entities. The Zacks Consensus Estimate for its current year earnings has declined 2.5% over the last 30 days. • FTD Companies, Inc.FTD provides floral, gift and related products and services to consumers, retail florists, and other retail. It has seen the Zacks Consensus Estimate for its current year earnings being revised 3.5% downward over the last 30 days. • China Southern Airlines Co. Ltd.ZNH is one of the leading air transportation enterprises in China, especially in passenger volume and the total amount of tax and profit for the past three years. The Zacks Consensus Estimate revision for its current year earnings was a negative of 1.8% over the last 30 days. • Sonic Corp.SONC operates and franchises one of the largest chain of drive-in restaurants in the U.S. The Zacks Consensus Estimate for its current year earnings has moved 6.6% lower over the last 30 days. View the entire Zacks Rank #5 List . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CHINA SOUTH-ADR (ZNH): Free Stock Analysis Report SYNTEL INC (SYNT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report FTD COS INC (FTD): Free Stock Analysis Report SONIC CORP (SONC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-05,20.6375,21.2138,20.445,20.8425,"Analysts Expect USSD Will Reach $28 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree Strong Dollar U.S. Equity Fund ETF (Symbol: USSD), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.96 per unit. With USSD trading at a recent price near $25.51 per unit, that means that analysts see 9.62% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of USSD's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), CenterPoint Energy, Inc (Symbol: CNP), and Aqua America Inc (Symbol: WTR). Although DXCM has traded at a recent price of $81.93/share, the average analyst target is 18.02% higher at $96.70/share. Similarly, CNP has 11.81% upside from the recent share price of $22.36 if the average analyst target price of $25.00/share is reached, and analysts on average are expecting WTR to reach a target price of $33.20/share, which is 11.67% above the recent price of $29.73. Below is a twelve month price history chart comparing the stock performance of DXCM, CNP, and WTR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-06,20.8625,21.0475,20.5925,20.77,"How DexCom Can Fight Back Against Medtronic's Artificial Pancreas Image source: Medtronic plc. Medtronic plc (NYSE: MDT) got an FDA green-light last week to begin marketing its artificial pancreas, the MiniMed 670G, and management is planning to launch the device early next year. Will the 670G dent demand for DexCom 's(NASDAQ: DXCM) continuous glucose monitors in 2017? Read on to find out how DexCom plans to keep growing. A game-changing innovation Insulin is a hormone produced in the pancreas that is used to break down sugar into energy. However, in 1.25 million Americans who are diagnosed with type 1 diabetes, the pancreas fails to produce insulin, forcing patients to monitor their blood sugar levels and dose themselves insulin as necessary. The burden associated with managing type 1 diabetes is heavy, and as a result, most diabetics' blood sugar levels are out of the desired range most of the time. That's worrisome because blood sugar highs and lows can lead to life-threatening illnesses, such as heart disease. To reduce the risk of blood sugar highs and lows, Medtronic developed the 670G, a system that uses a blood glucose sensor, an insulin pump, and an infusion patch to automatically keep a type 1 diabetes patient's blood sugar levels on target. Once patients program their information into the device, the 670G manages insulin levels by automatically checking blood sugar every five minutes and dosing insulin at the appropriate levels when needed. Mealtime insulin doses are automatically calculated based on each patient's programmed insulin to carbohydrate ratio and the amount of carbohydrates that will be eaten. Image source: DexCom. Upcoming threat Until now, DexCom's continuous glucose monitors (CGM) have been the biggest advance in type 1 diabetes treatment. The company's latest-generation CGM, the G5, automatically streams blood glucose levels to a patient's device or smartphone, and by charting blood sugar peaks and valleys, patients can better control their disease. The advantages of CGMs have been a boon to DexCom and its investors. The company's sales jumped 47% year over year and 18% quarter over quarter to $137 million in Q2. However, DexCom's rapid growth could come under pressure if Medtronic's G70 hits the ground running next spring. That's because the G70 uses Medtronic's own CGM and sensors, not DexCom's. Navigating the threat Fortunately for DexCom, the risk posed by the G70 may not last long. Sales headwinds won't be felt until after the G70 launch early next year, and until the device wins EU approval, DexCom should be able to keep growing its international sales rapidly. DexCom's international revenue was $18 million in Q2, up 45% from a year ago. If the G70 launch does go off without a hitch, DexCom's type 1 market share will only take a hit in adults. Initially, the G70 is only approved for use in patients aged 14 and up. Most type 1 patients are adults, but roughly 200,000 patients are younger than 18, and ostensibly, many of those patients are younger than 14. DexCom could begin to win back any market share lost to the G70 in relatively short order if collaborations with Medtronic's competitors pan out. DexCom is sharing its technology with various insulin pump makers that are developing their own artificial pancreases, including Insulet , Animas (a Johnson & Johnson company), Tandem , and the privately-held Bigfoot biomedical, which was founded by Jeffrey Brewer, the former CEO of JDRF International, a global type 1 diabetes advocacy group. Insulet plans to begin clinical trials for its artificial pancreas this year, and it's eyeing potential commercialization in 2018; Tandem also hopes to begin clinical trials this year, and it's targeting a launch in late 2017; and Bigfoot biomedical just enrolled its first patient in a clinical trial. In addition to those high-profile relationships, DexCom has teamed up with Alphabet 's life sciences spin-off Verily on next-generation diabetes technology. Verily is amassing a team of leaders in diabetes research, and it recently hired Insulet's Howard Zissler, who helped spearhead Insulet's artificial pancreas program. Tying it together Medtronic's first-to-market advantage might be short-lived, and the impact on DexCom's growth will depend a great deal on the official launch date of the G70 and how quickly DexCom's partners get their similar systems through the FDA. Assuming that its partners are successful in developing a competing product, I think that the artificial pancreas market could support multiple players -- and that's good news for DexCom, given its system agnostic approach. Forty thousand Americans are newly diagnosed with type 1 diabetes annually, and up to 5 million Americans may be living with type 1 diabetes by 2050. Overall, the coming year could be one of transition in the type 1 treatment space, and that could mean that DexCom's shares experience more than their fair share of volatility. If that volatility includes a drop in the company's share price, then I'll be looking for a chance to buy for the long haul. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.The Motley Fool owns shares of and recommends Alphabet (C shares). The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet and Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-07,20.745,20.875,20.4975,20.7325,
DXCM,2016-10-10,20.8375,21.2825,20.785,20.98,
DXCM,2016-10-11,20.8575,20.8575,20.25,20.4725,
DXCM,2016-10-12,20.55,20.845,20.36,20.505,
DXCM,2016-10-13,20.3975,20.6125,20.0025,20.495,
DXCM,2016-10-14,20.5225,20.625,20.2675,20.42,"Stock Exchange: Charts For WB, DDD, DXCM And APD Deserve A Look By Jeff Miller : Each week Felix and Oscar host a poker game. We listen in on current trading ideas in the few minutes before the game starts. They like to call this their ""Stock Exchange."" I am the only human present, and the only one using fundamental analysis. Their methods are excellent, as you will learn if you join us for a few weeks. Since the time frames and risk profiles differ, so do the stock ideas. Do the markets predict future events? Or should you use fundamentals to predict the markets? That is an ongoing debate at the Stock Exchange. This Week's Ideas Our technical experts have some very aggressive ideas this week. Felix I look for long-term themes, and I have a great one this week. This week I am revisiting technology, specifically Weibo Corp. ( WB ). There are not too many social media platforms that are available for trading, but this is one that is (we hear) popular in China. It sounds pretty interesting and maybe (if not, already) will show up here soon. Just look at the chart. What a strong momentum play!! Our question for this week's post is from Sedona7 of SeekingAlpha, as follows: I really appreciate your work Jeff (and group). Felix (and Jeff), I am wrestling with my current position in Bristol-Myers Squibb ( BMY ) ... should I stay or should I go? Felix responds: BMY is on my sell list (a negative rating). There are many better choices. [Jeff] The 20 multiple is pretty rich for the stodgy recent growth rate. 3% dividend is OK. If the expected earnings growth for 2016-17 comes through, it is probably fairly valued. I agree with Felix that there are better choices. [Felix] Please keep your questions coming. I could use the overtime pay! Oscar It seems like every week that we have some crashing, dynamic stock that we can liken to a pinch hitter or an offensive lineman. My choice for this week is a change of pace. Take a look at the moving averages on 3D Systems ( DDD ) below. This reminds me of the long, smooth strokes you see from the US Olympic Rowing team. Sure, it may not be as exciting as the MLB Division series - but it sure is pretty. Here we've got steady, sustainable growth from a major name in the broader sector of 3D printing. What's not to like? The chart is very encouraging. Breakout coming? [Jeff] [Oscar] I am good at speculating. Holmes I am the rebounding specialist. Here is a ""fetching"" opportunity, DexCom ( DXCM ) hit an all-time high around $97 in September of 2015; sold off to a low of 53 before rebounding back to $95; this most recent selloff gives us a nice technical entry into this name looking for a run back to $95, with a stop around the 200d MA ($75.17). [Jeff] [Holmes] What's a multiple? [Jeff] It stands for ""not meaningful."" You see it when a stock has no earnings. It is important for determining value. [Holmes] I get paid nicely for stock rebounds whether there are earnings or not. The chart tells the story. Athena I have a very interesting choice this week, Air Products and Chemicals ( APD ). [Jeff] That has a familiar sound. Didn't we just discuss that pick? [Holmes] Yes! It was my choice last week. She is copying. I was stopped out with a small loss. [Jeff] I did not care for it last week, and I still don't. The price is a bit lower, but not low enough for me. [Athena] I need not copy from humans and dogs. The Holmes rebound play did not work. APD fits my style just fine. My average holding period is about four months. We can revisit this after some time. Here is the updated chart. (click to enlarge) Questions If you want an opinion about a specific stock or sector, even those we did not mention, just ask! Put questions in the comments. Address them to a specific expert if you wish. Each has a specialty. Who is your favorite? (You are allowed to choose me, although my feelings will not be hurt very much if you prefer one of the models). Cast of Characters Felix is fussy, precise, and very cautious. He looks for what is working, but it also must have upside potential. He is an investor who thinks long term. Felix will not usually announce new picks, but he will answer questions, saying what he thinks about specific stocks. He will also comment on favorite themes and sectors. Oscar is naturally optimistic and a bit excitable. He definitely likes to go with winners, and focuses on a one-month time frame. He trades either sector ETFs, or a basket of stocks (equally weighted) that reflect a sector. Oscar will mention a favorite sector each week, and will also answer questions about sectors. Holmes is a trader, but a cautious one. Holmes emphasizes asset protection through profit taking, stops, and trailing stops. He is careful in selecting new positions, and generally looks at an intermediate time frame. While he does not know the definition of ""mean reversion,"" he loves rebounds! There is no set holding period, but two or three months is not unusual. Holmes will tell us one stock recommended that week. For those who sign up for his email list (no charge, privacy respected, holmes at newarc dot com) he will report exits with a one-day delay. Athena trades more frequently than the others, but still limits risk. Her inspiration helps to find good ideas. Her excellent quant skills find attractive risk/reward opportunities. Her wisdom leads her to exit trades that are not working. Athena will provide a new idea each week. Jeff usually has some comments about stock or market fundamentals. Unlike the other witty participants, he sounds like an old prof. An Important Note to Readers - from Jeff All of the characters (except me!) are models, carefully engineered and tested by one of the leading developers of the last thirty years. I humanize them to make it easier to understand the characteristics in their design. I always remind readers that my posts are informational, not investment advice, and that is especially true here. While we are trading based upon all four models, we are always watching and can act quickly when necessary. The models are not suitable for all investors. If you like the approach, reach out to us (info at newarc dot com) and we will provide more information. The conversation is light-hearted, but the stock analysis is serious. We own positions in each of the stocks mentioned. Finding great stock picks need not be boring. Please enjoy the banter and join in. See also Altria: The Good Old Days Are Back on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-17,20.475,20.5925,20.275,20.4925,
DXCM,2016-10-18,20.625,20.76,20.5375,20.63,"[""InsiderInsights.com Daily Round Up 10/17/16: GTXI, SITO, CNBKA, LE"", ""InsiderInsights.com Daily Round Up 10/17/16: GTXI, SITO, CNBKA, LE"", ""InsiderInsights.com Daily Round Up 10/17/16: GTXI, SITO, CNBKA, LE""]"
DXCM,2016-10-19,20.5775,20.7325,20.4675,20.5,"[""Deja Vu All Over Again: 2016 OC3 Reminiscent Of 1984 Apple Macintosh Release"", ""Deja Vu All Over Again: 2016 OC3 Reminiscent Of 1984 Apple Macintosh Release"", ""Deja Vu All Over Again: 2016 OC3 Reminiscent Of 1984 Apple Macintosh Release""]"
DXCM,2016-10-20,20.4875,20.665,20.4475,20.625,
DXCM,2016-10-21,20.575,20.575,20.0725,20.17,
DXCM,2016-10-24,20.19,20.7875,20.0975,20.6275,
DXCM,2016-10-25,20.49,20.49,19.92,20.055,"Think You've Seen Crazy Valuations? You Haven't Seen These 3 Stocks While stock valuations are often more art than science, it is easy to spot the outliers. That goes both ways, with some stocks trading at nosebleed values while others are ridiculously cheap. This is certainly the case with these three stocks, which run the gamut from insanely expensive to surprisingly cheap: Dexcom (NASDAQ: DXCM) , GrubHub (NYSE: GRUB) , and Williams Partners (NYSE: WPZ) . DXCM Revenue (TTM) data by YCharts . While Dexcom is a stock that I've had on my radar for some time, the company's nosebleed valuation has always kept me on the sidelines. Even today I can't help but feel that shares are far too richly priced. Right now shares are trading for more than 14 times sales , and that's after dropping nearly 20% from their recent high. Granted, sales have grown so quickly over the last few years that you could easily argue that the company has earned its premium valuation. Next year analysts are projecting that sales will grow by another 40%, so the prosperity is expected to continue. While I'm hopeful that the company can maintain its rapid growth rate, I do think that caution is warranted, given that Medtronic (NYSE: MDT) just got the green light from the FDA on the first artificial pancreas . If demand for Medtronic's device impacts DexCom's growth even slightly, then it is possible that shares could take a tumble. We won't know the answer to that question until Medtronic officially launches the product for sale next year. In the meantime, I think that Dexcom's crazy valuation provides ample reason to remain cautious. Overvaluing food delivery Evan Niu, CFA : Within the tech space, it's not too hard to find a company that seems to be asking a lot in terms of its valuation relative to its prospects. I believe that GrubHub is overvalued: The online food-delivery service currently trades at 8.9 times sales and 90.7 times earnings. While those valuation multiples aren't as high as those of other tech companies that deliver online services, they still suggest that investors are baking in hefty growth expectations. GrubHub's trailing twelve-month sales growth over the past year has been 34% -- solid but perhaps undeserving of such optimism. None of this is to say that the business is crumbling. Active diners in the second quarter rose 24% to 7.35 million, which helped gross food sales jump 29% to $733 million. Orders have hit all-time highs despite seasonal headwinds. My problem with GrubHub is the lack of a competitive advantage or differentiator. Sure, the company's app and service are easy to use and make ordering deliveries much more convenient, but an app is not an advantage; anyone can build an intuitive app. Merchants pay more to enjoy higher rankings in search results, but rivals can also potentially undercut GrubHub with lower fees. The current valuation prices in a much more resilient business that can withstand the test of time. Keep in mind that shares have traded as high as $48 and as low as $18 over the past two years, so volatility should be expected. Volatility and lofty valuation multiples go hand in hand, after all. Shares have recovered and are marching back toward highs, but investors will want to be on the lookout ahead of third-quarter earnings, which are expected on Oct. 26. When expectations are running high, so is the risk of disappointment. This pipeline stock is crazy cheap Matt DiLallo : I'm going to take the contrarian approach here and propose a company that looks expensive but is actually trading at a ridiculously cheap valuation. In the following chart, pipeline company Williams Partners appears to trade at a nosebleed valuation compared to its pipeline peers: KMI EV to EBITDA (TTM) data by YCharts . However, that seemingly expensive valuation is largely the result of recording an impairment charge associated with its Canadian operations, which it recently sold. Adjusting for that charge, Williams Partners expects to generate $4.3 billion in EBITDA (earnings before interest, taxes, depreciation and amortization) this year. Given its approximately $44 billion enterprise value (EV), this implies a valuation of slightly more than 10 times EBITDA, which is well below its pipeline rivals. Further, Williams Partners has several fee-based expansion projects currently under construction that should boost its annual EBITDA by $630 million next year alone, pushing it up to a run rate of $5 billion. Those earnings imply a forward valuation of just 8.8 times EV-to-EBITDA. That's crazy cheap compared to its peers, and one reason why Williams Partners' parent company is investing billions to increase its stake. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Brian Feroldi has no position in any stocks mentioned. Evan Niu, CFA has no position in any stocks mentioned. Matt DiLallo and The Motley Fool own shares of Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-10-26,19.9275,19.96,18.8575,19.3125,
DXCM,2016-10-27,19.3425,19.3675,18.8075,18.855,"[""All About Demand - Cramer's Mad Money (10/26/16)"", ""All About Demand - Cramer's Mad Money (10/26/16)"", ""Notable Two Hundred Day Moving Average Cross - DXCM In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $75.25, changing hands as low as $75.23 per share. DexCom Inc shares are currently trading down about 2.4% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $47.92 per share, with $96.38 as the 52 week high point - that compares with a last trade of $75.42. According to the ETF Finder at ETF Channel, DXCM makes up 4.56% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 2.7% on the day Thursday. Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""All About Demand - Cramer's Mad Money (10/26/16)""]"
DXCM,2016-10-28,18.8,19.48,18.7962,19.175,
DXCM,2016-10-31,19.28,19.7087,19.1075,19.56,"[""Notable earnings after Tuesday's close"", ""BTIG Research Upgrades DexCom, Inc. - Common Stock to Buy"", ""BTIG Research Upgrades DexCom, Inc. - Common Stock to Buy"", ""Notable earnings after Tuesday's close"", ""Medical Product Nov 1 Earnings Lineup: CERN, IDXX, DXCM, BIO With Q3 earnings reports already out from more than 58.2% of the S&P 500 members (291 companies), our latest Earnings Preview has exhibited an improving trend so far. Approaching the second half of the earnings reporting cycle, we are further assured about this quarter turning out to be the first to witness earnings growth after five back-to-back quarters of earnings declines for the S&P 500 index. Total earnings for these 291 companies are up 2.2% year over year on 1.3% higher revenues, with 73.5% beating EPS estimates and 57.4% coming ahead of revenue estimates. As per the report, Medical is one of the 12 broader sectors among the 16 Zacks sectors which are expected to report earnings growth. The sector is likely to deliver 6% earnings growth on the back of 7.3% higher revenues in the third quarter. What's in Store for the Med-Product Space? Medical product, a niche area under the medical device subcategory within the broader Medical sector, holds a lot of promise at the moment thanks to the temporary two-year suspension of the controversial 2.3% medical device excise tax which took a toll on the entire MedTech industry since its enactment in 2013. In addition, the recent change in consumer demand and market dynamics led to a dramatic transformation in the entire healthcare system. This is evident from the growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care, and the shift of the payment system to a value-based model among others. Let's take a look at the major Medical Product stocks slated to release their quarterly reports on Nov 1: Cerner CorporationCERN This health information technologies company is scheduled to report its third-quarter 2016 earnings on Nov 1. We believe that Cerner's strong product portfolio will help boost its customer base. The frequent contract wins reflect growing traction. Moreover, the company has strong growth opportunities in the revenue cycle management (RCM) and ambulatory market. However, our proven model does not conclusively show that Cerner is likely to beat earnings this quarter as along with a Zacks Rank #3 (Hold), it has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 56 cents. We note that while a favorable Zacks Rank #3 increases the predictive power of the ESP, a 0.00% ESP makes surprise prediction difficult. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.(Read More: Can Cerner Spring a Surprise this Earnings Season? ) CERNER CORP Price and EPS Surprise CERNER CORP Price and EPS Surprise | CERNER CORP Quote IDEXX Laboratories, Inc.IDXX Headquartered in Delaware NJ, IDEXX Laboratories is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. We note that IDXX's continued strong instrument placements, global lab momentum reflecting leverage of expanded commercial capability as well as strong test menu expansion remained the key highlights for the company's business in the first half of 2016. However, high dependence on third-party distributors and intense competition continue to pose threats. The company is scheduled to report third-quarter 2016 numbers on Nov 1. IDEXX currently has an Earnings ESP of 0.00% along with a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Note that stocks with a Zacks Rank #1, 2 (Buy) or 3 have a significantly higher chance of beating earnings estimates. Conversely, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. IDEXX LABS INC Price and EPS Surprise IDEXX LABS INC Price and EPS Surprise | IDEXX LABS INC Quote DexCom, Inc.DXCM This medical device company is focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). The large and growing diabetes market, strong product portfolio, innovative product pipeline, collaborative agreements with several companies and focus on international markets are key positives. On the other hand, intensifying competition, entry of new products, reluctance on the part of physicians and patients to adopt DexCom's products, reimbursement risks, supply constraints and working capital problems are key concerns. DexCom, which is scheduled to report third-quarter 2016 numbers on Nov 1, currently has a Zacks Rank #3 and an Earnings ESP of -35.71%. That is because the Most Accurate estimate stands at a loss of 19 cents while the Zacks Consensus Estimate is pegged at a loss of 14 cents. Hence, we cannot conclusively predict that DexCom is likely to beat estimates this quarter. DEXCOM INC Price and EPS Surprise DEXCOM INC Price and EPS Surprise | DEXCOM INC Quote Bio-Rad Laboratories, Inc.BIO This medical product company is a provider of a broad range of innovative products and solutions for the life science research and clinical diagnostic markets.The company is scheduled to report third-quarter 2016 numbers on Nov 1. Bio-Rad is expected to release its third-quarter fiscal 2016 financial numbers on Nov 1. The company carries a Zacks Rank #5 (Strong Sell) and an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 51 cents. BIO-RAD LABS -A Price and EPS Surprise BIO-RAD LABS -A Price and EPS Surprise | BIO-RAD LABS -A Quote Looking for Ideas with Even Greater Upside? Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CERNER CORP (CERN): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BTIG Research Upgrades DexCom, Inc. - Common Stock to Buy"", ""Notable earnings after Tuesday's close""]"
DXCM,2016-11-01,19.4875,19.8625,19.3425,19.48,"[""DexCom misses by $0.09, beats on revenue"", ""DexCom Reports Q3 non-GAAP Loss/Share $0.07 vs $0.13 Est, Rev $148.6M vs $146.26M Est"", ""DexCom Reports Q3 non-GAAP Loss/Share $0.07 vs $0.13 Est, Rev $148.6M vs $146.26M Est"", ""DexCom misses by $0.09, beats on revenue"", ""DexCom Reports Q3 non-GAAP Loss/Share $0.07 vs $0.13 Est, Rev $148.6M vs $146.26M Est"", ""DexCom misses by $0.09, beats on revenue""]"
DXCM,2016-11-02,15.6975,16.615,15.25,15.7325,"[""DexCom (DXCM) Q3 2016 Results - Earnings Call Transcript"", ""Insulet and DexCom feel Tandem's pain; shares slump 11% and 20%, respectively"", ""18 Stocks Moving In Wednesday's Pre-Market Session"", ""Dexcom -19.78% Premarket @$62.51 Following Tuesday's Earnings Miss, Multiple PT Cuts by Analysts"", ""Dexcom Shares Spike to High of $65.25 Following Positive Jim Cramer/CNBC Mention"", ""18 Biggest Mid-Day Losers For Wednesday"", ""18 Biggest Mid-Day Losers For Wednesday"", ""Dexcom Shares Spike to High of $65.25 Following Positive Jim Cramer/CNBC Mention"", ""Dexcom -19.78% Premarket @$62.51 Following Tuesday's Earnings Miss, Multiple PT Cuts by Analysts"", ""18 Stocks Moving In Wednesday's Pre-Market Session"", ""Insulet and DexCom feel Tandem's pain; shares slump 11% and 20%, respectively"", ""DexCom (DXCM) Q3 2016 Results - Earnings Call Transcript"", ""Here's Why DexCom, Inc. Is Plunging Today Image source: DexCom. What happened Shares of DexCom (NASDAQ: DXCM) , a medical-device company focused on diabetes, dropped by 18% as of 12:45 p.m. EDT on Wednesday, after the company reported its third-quarter results. So what Dexcom reported $148.6 million in revenue for the third quarter, which was up 41% over the year-ago period and was $2 million more than analysts were expecting. However, the company struggled to translate the top-line beat into success on the bottom line. Dexcom reported a quarterly net loss of $18.8 million, or $0.22 per share, which was quite a bit worse than the $0.14 loss that the pros were expecting. On its conference call with investors, management stated that its net loss exceeded its internal expectations primarily due to the build-out of its customer service infrastructure. In addition, management said that it increased its marketing spending and added to its executive head count in the third quarter, both of which drove up costs. Looking ahead, management stated that it expects to hit the \""mid to upper end\"" of its guidance revenue range for the full year, which is $550 million to $575 million. However, the company stated that it does not expect to exceed the top end of the range. With Wall Street currently projecting full-year revenue of $576 million, this is a disappointing forecast. It's also worth remembering that Dexcom had a long history of exceeding Wall Street's targets, which earned the company a premium valuation . Given the higher-than-expected quarterly loss and lower-than-hoped-for guidance, it is no wonder shares are tumbling today. Now what Looking beyond the numbers, it's likely that the markets are feeling jittery about Dexcom's prospects given that Medtronic (NYSE: MDT) , its primary competitor, recently got FDA approval for the first \"" artificial pancreas .\"" Kevin Sayer, Dexcom's CEO, addressed these concerns right up front during the company's conference call, noting: Medtronic expects to officially launch the 670G for sale early next year, so it will still be some time before investors learn whether this product dampens Dexcom's growth prospects. While I personally believe that the company will be able to grow at above-average rates for the foreseeable future, I continue to think that the smart move is to remain cautious. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Insulet Corporation Is Plunging Today Image source: Insulet What happened Shares of Insulet Corporation (NASDAQ: PODD) , a medical device maker primarily focused on diabetes, dropped by 11% as of 2:30 p.m. EDT on Wednesday. So what Given that we are in the middle of earnings season, you'd likely assume that the drop is being caused by the company's weak quarterly results, but that's simply not the case. The insulin pump maker isn't set to report third-quarter earnings until the market closes on Thursday. Rather, today's plunge is likely because two other diabetes-focused medical device companies posted disappointing quarterly results. First, Tandem Diabetes Care -- an insulin pump manufacturer and one of Insulet's direct competitors -- reported a 22% decline in sales in the third quarter. While the company actually managed to grow its insulin pump shipments year over year, a large number of customers took advantage of its \""Technology Upgrade Program,\"" which deferred $8.4 million of sales. Investors are not taking the news well, pushing shares down more than 55% in afternoon trading. Second, shares of Dexcom (NASDAQ: DXCM) are also under a lot of selling pressure today. The continuous glucose monitoring company reported strong revenue growth in the third quarter, but expenses came in much higher than the markets were expecting. To add insult to injury, it said that its full-year revenue was going to come in a bit shy of Wall Street's projections. The market appears to be taking a \""guilty by association\"" approach to Insulet's stock today, hence shares are dropping. Now what The biggest unknown for Insulet's investors heading into 2017 is how the company will be affected by Medtronic 's(NYSE: MDT) recently approved \"" artificial pancreas .\"" For what it's worth, Dexcom CEO Kevin Sayer believes that the media hype surrounding the approval is overselling the capabilities of the technology, saying: Unfortunately, Insulet's investors still have some waiting to do before they learn what kind of impact Medtronic's new device could have on its business. The device doesn't officially start shipping until early next year. I'd advise Insulet's long-term investors to listen in on its conference call on Thursday afternoon to hear what management has to say about the new device and the potential impact on its business. While it is possible that Insulet's tube-free design will help to insulate it from the upcoming competition, until we know more, the smart move is to remain cautious. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here . Brian Feroldi owns shares of Insulet.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""18 Biggest Mid-Day Losers For Wednesday"", ""Dexcom Shares Spike to High of $65.25 Following Positive Jim Cramer/CNBC Mention"", ""Dexcom -19.78% Premarket @$62.51 Following Tuesday's Earnings Miss, Multiple PT Cuts by Analysts"", ""18 Stocks Moving In Wednesday's Pre-Market Session"", ""Insulet and DexCom feel Tandem's pain; shares slump 11% and 20%, respectively"", ""DexCom (DXCM) Q3 2016 Results - Earnings Call Transcript""]"
DXCM,2016-11-03,15.715,15.9,14.8675,15.02,
DXCM,2016-11-04,15.04,15.84,15.04,15.475,"[""High Sugar Bloodbath For Tandem And Dexcom"", ""High Sugar Bloodbath For Tandem And Dexcom"", ""Commit To Buy DexCom At $55, Earn 11.8% Annualized Using Options Investors eyeing a purchase of DexCom Inc (Symbol: DXCM) stock, but cautious about paying the going market price of $62.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $55 strike, which has a bid at the time of this writing of $4.00. Collecting that bid as the premium represents a 7.3% return against the $55 commitment, or a 11.8% annualized rate of return (at Stock Options Channel we call this the YieldBoost ). Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $55 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless DexCom Inc sees its shares fall 11.8% and the contract is exercised (resulting in a cost basis of $51.00 per share before broker commissions, subtracting the $4.00 from $55), the only upside to the put seller is from collecting that premium for the 11.8% annualized rate of return. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $55 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2017 put at the $55 strike for the 11.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 252 trading day closing values as well as today's price of $62.78) to be 45%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Friday, the put volume among S&P 500 components was 680,315 contracts, with call volume at 680,315, for a put:call ratio of 0.71 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today . Top YieldBoost Puts of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""High Sugar Bloodbath For Tandem And Dexcom""]"
DXCM,2016-11-07,15.565,15.94,15.315,15.75,"[""Insulet Continues Pushing Forward In Diabetes Market"", ""Insulet Continues Pushing Forward In Diabetes Market"", ""Insulet Continues Pushing Forward In Diabetes Market""]"
DXCM,2016-11-08,15.7475,15.9325,15.485,15.66,
DXCM,2016-11-09,15.5425,15.9975,15.035,15.4975,
DXCM,2016-11-10,15.6275,15.9375,15.3525,15.6325,"DexCom (DXCM) Incurs Wider Loss in Q3, Beats on Revenue DexCom Inc.DXCM reported loss of 22 cents per share in the third quarter of 2016, much wider than the Zacks Consensus Estimate of a loss of 14 cents. DexCom had reported a loss of 7 cents in the year-ago quarter. Revenues surged 4.1% year over year to $148.6 million, beating the Zacks Consensus Estimate of $147.0 million. FindTheCompany | Graphiq Operational Details In the reported quarter, cost of sales increased to $47.5 compared to $30.5 million for the same quarter in 2015. This was primarily due to an increase in sales volume. Research and development expense decreased by $20.9 million from the year-ago quarter to $43.9 million. The decrease in research and development expense was primarily due to the absence of a non-cash charge related to Verily Collaboration Agreement incurred during the third quarter of 2015. This was partially offset by additional payroll costs and additional non-cash share-based compensation during the third quarter of 2016. Selling, general and administrative expense increased by $23.4 million from the third quarter of 2015 to $75.7 million. The increase primarily was due to additional payroll, marketing cum consulting costs, and non-cash share-based compensation. In the reported quarter, gross profit totaled $101.1 million compared with $74.7 million in the comparable quarter of 2015. GAAP net loss was $18.8 million for the third quarter of 2016 compared with GAAP net loss of $42.5 million in the year-ago quarter. Financial Condition As of Sep 30, 2016, DexCom had $127.3 million in cash, cash equivalents and short-term marketable securities versus $115.2 million as of Dec 31, 2015. DEXCOM INC Price, Consensus and EPS Surprise DEXCOM INC Price, Consensus and EPS Surprise | DEXCOM INC Quote Zacks Rank & Key Picks DexCom currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical space include Anika Therapeutics Inc. ANIK , Cambrex Corporation CBM and IDEXX Laboratories, Inc. IDXX . Notably, all the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Anika Therapeutics represents a strong long-term expected growth rate of 15.00%. Notably, the company has a positive one-year return of almost 3%. Cambrex Corporation has a positive one-year return of 4.8%. The company also has a promising long-term expected growth rate of 15.00%. IDEXX Laboratories represents a promising one-year return of 56.4%. The company has a long-term expected growth rate of almost 14.96%. The Best Place to Start Your Stock Search Today, you are invited to download the full list of 220 Zacks Rank #1 """"Strong Buy"""" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 """"Strong Sells"""" and other private research. See these stocks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX LABS INC (IDXX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-11-11,15.68,16.5575,15.485,16.295,
DXCM,2016-11-14,16.575,17.715,16.5625,17.1975,"[""Dexcom Reports Health Canada Approval for G5 Mobile CGM System"", ""JP Morgan Says DexCom Data Over The Weekend Was 'Way Above' Expectations"", ""JP Morgan Says DexCom Data Over The Weekend Was 'Way Above' Expectations"", ""Dexcom Reports Health Canada Approval for G5 Mobile CGM System"", ""JP Morgan Says DexCom Data Over The Weekend Was 'Way Above' Expectations"", ""Dexcom Reports Health Canada Approval for G5 Mobile CGM System""]"
DXCM,2016-11-15,17.19,18.265,17.1675,17.8825,
DXCM,2016-11-16,17.7925,18.025,17.595,17.8225,"[""8 Stocks That Rallied Three Days On Increasing Volume"", ""8 Stocks That Rallied Three Days On Increasing Volume"", ""8 Stocks That Rallied Three Days On Increasing Volume""]"
DXCM,2016-11-17,17.6575,18.275,17.6575,18.0025,"[""Exclusive: Dexcom CEO Talks Health Canada Approval, International Markets, Investments And Competition"", ""Exclusive: Dexcom CEO Talks Health Canada Approval, International Markets, Investments And Competition"", ""Exclusive: Dexcom CEO Talks Health Canada Approval, International Markets, Investments And Competition""]"
DXCM,2016-11-18,18.1025,18.285,17.845,17.85,"[""Stock Exchange: How To Spot A Great Chart"", ""Stock Exchange: How To Spot A Great Chart"", ""Stock Exchange: How To Spot A Great Chart By Jeff Miller : Technical analysts dominate the daily discussion of stocks. Fundamental concepts change slowly. Chart patterns change constantly. Usually the calls are dramatic, because no one cares about advice that says, \""all is well, keep holding.\"" Traders live on stock charts, but investors also pay close attention. Everyone wants to know whether a stock is breaking down, breaking out, or stuck in a trading range. Here is the key question: How do you spot a good chart? We have several great charts this week. The Stock Exchange provides an expert-level debate on technical and fundamental analysis. (Important background is available here ). Comments, dissent, and specific stock questions are welcome! This Week - Is Felix right about KHC? One issue with charts is the wide difference in interpretation. Do analysts see what they want to see? Are the interpretive criteria constant and objective? This week (without telling him), I searched for other opinions on one of our expert selections, Felix's choice of The Kraft Heinz Company ( KHC ). The same principles would apply to all the picks, but this is a convenient example. Before turning to Felix, let's look at other approaches. This one provides a complex chart and plenty of additional points of interest. It makes a lot of specific predictions, suggesting many trades with moves of less than one point. (click to enlarge) Here is another , one-year term and 50-day MA. This is a much longer time frame with an implied criterion reflecting that. And here is a dramatically different time frame from the same source . Instead of a 50-day MA, we now have two hours. And one more site, which invites predictions . I am not sure what conclusion you would reach, but the participants have many different conclusions. Let's see what Felix has to say, and also check out my own conclusion to this article. Felix I look for long-term themes, and I have a great one this week. I have a pick without an army: KHC. It is my lone soldier of the week, a strong company. The recent selloffs provide a good point of entry with the rebounds already underway. This should be good for another 5 points. I've had a question Question from Fred Barone: Any opinion on CVR Energy ( CVI ) thank you. Felix: This is a stock I won't be holding for a while; it has been going downhill since 2013. There hasn't been much upside. On the other hand, it does rank in the top 25% of my universe, so it is not terrible. I would take a guess that you have been holding this for a while? [F] Please keep your questions coming. I could use the overtime pay. And by the way, Jeff. Are we working next Thursday? [J] Next Thursday the market is closed and we are all taking a day off to give thanks and spend time with family. [F] I don't have a family and I could use the overtime bonus. Athena I hope I'm not too late to the party on this one. Teck Resources Ltd. ( TCK ) has been on a solid rise since March. We've had the stock price quadruple since then, which is remarkable to say the least. While I don't expect to cash in on that kind of return in the next few weeks, there is still a tidy profit to be had here. [J] This pick is not completely hopeless. The company has some earnings. There is plenty of fluctuation but excellent growth expectations. This might work. (click to enlarge) [A] The market is sending a message that it will work. I listen, Jeff, and so should you! Oscar While I focus on sectors, sometimes ideas get as narrow as a single country ETF. My regular sports channels had a brief blurb about some guy named Abe meeting with Trump. Some of my sources suggested that I should check out the WisdomTree Japan Hedged Equity ETF ( DXJ ) this week. Much like Japan's national sport, sumo wrestling, this pick is all about momentum off the bottom. [J] So you are telling us that you have been following the visit of Japanese Prime Minister Abe ? The first foreign leader to meet with President-Elect Trump? [O] Not exactly \""following.\"" It was on my Facebook news feed. [J] Why did you choose the Wisdom Tree ETF, which is adjusted for currency variation? [O] Variation? [J] Yen for each dollar. [O] I'm not sure, but on my last visit, dollars were welcome. Holmes This week I'm picking DexCom ( DXCM ) a specialty health stock. After a sharp decline on November 1st, this stock has proceeded to consolidate and slowly climb back up from a low of 61.00. I will put in a stop at 62.50. I bought this stock at 70.96, looking for a nice rebound to the low 80s or even higher. If we start to rally, I'll be moving up my stop aggressively. My major concern is that move is based on perceived changes in medical policies from Washington, vs. improvement in the outlook of this company. I'll be very tight on the trigger if the stock starts to drift lower day after day. (click to enlarge) [H] How have I been doing? [J] Your picks have been profitable. I also like your frequent decisions to take profits and move on. You are not overstaying your welcome. [H] That is a very honest assessment. I like that in a human. Next you must learn to be more intuitive. Sometimes stocks rebound before the fundamentals confirm. I often spot such cases. [J] Are you really considering policy changes from Washington? [H] Of course not. The price and volume reflect that information! Background on the Stock Exchange Each week Felix and Oscar host a poker game for some of their friends. Since they are all traders they love to discuss their best current ideas before the game starts. They like to call this their \"" Stock Exchange .\"" (Check it out for more background). Their methods are excellent, as you know if you have been following the series. Since the time frames and risk profiles differ, so do the stock ideas. You get to be a fly on the wall from my report. I am the only human present, and the only one using any fundamental analysis. The result? Several expert ideas each week from traders, and a brief comment on the fundamentals from the human investor. The models are named to make it easy to remember their trading personalities. Each week features a different expert or stock. Questions If you want an opinion about a specific stock or sector, even those we did not mention, just ask! Put questions in the comments. Address them to a specific expert if you wish. Each has a specialty. Who is your favorite? (You can choose me, although my feelings will not be hurt very much if you prefer one of the models). Conclusion My first job in the investment business involved a wide variety of research tasks. My boss, a clever fellow, became suspicious of conclusions from our technical analyst. He asked me to create some stock charts with the data inverted. He presented one group to our analyst, and got a verdict of bullish on all fronts. A bit later he presented the same charts, with the pattern inverted. As he suspected, those were also deemed to be bullish! Technical analysis is interesting, but usually lacks rigorous testing. In today's example, I do not know precisely why Felix likes KHC, but here are three ideas: The stock chart is like those I have seen before - descent from a prior high, a new base, and often an uptick. Some might see this as a \""cup-and-handle\"" but not all such patterns qualify for Felix. When we get a pick, it represents thousands of similar training cases, and hundreds of test cases. It is not just an idea with an argument, but a scientific conclusion. You cannot identify a \""good chart\"" unless you have many, many comparisons. See also Popeye Goes To Washington on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stock Exchange: How To Spot A Great Chart""]"
DXCM,2016-11-21,17.8175,18.3925,17.8125,18.295,
DXCM,2016-11-22,18.215,18.365,17.09,17.5575,"7 Feast or Famine Stocks to Buy for Thanksgiving InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Name two of the greatest turnarounds in U.S. business history? At the top of the list would have to be Steve Job's successful return to Apple Inc. (NASDAQ: AAPL ) in 1996, more than a decade after the co-founder was shown the door. AAPL stock gained more than 9,000% over the next 14 years. Source: Sweet Ice Cream Photography Via Unsplash Next, would have to be Lee Iacocca's rescue of FiatChrysler Automobiles NV (NYSE: FCAU ) back in 1979 before it was owned by Fiat. Fresh off the Mustang creator's firing from the Ford Motor Company (NYSE: F ), Iacocca did whatever it took, including creating the now ubiquitous minivan, to revive the fortunes of the Motor City's No. 3 carmaker. This is the stuff that legends are made of. On the brink, down and out, struggling to survive, Jobs and Iacocca will always be viewed as great leaders despite their human failings. At a time when we give thanks, it's important that we remember their great work. Who are the turnaround messiahs of today? Those CEOs whose companies are losing money, but are one big break away from salvation. The 10 Best S&P 500 Blue-Chip Dividend Stocks to Buy Now During Thanksgiving week, it's appropriate that we consider seven feast or famine stocks to buy. Feast or Famine Stocks to Buy: Pure Storage (PSTG) Source: Christopher Bowns via Flickr It's been a little more than a year since the data storage company went public, and even though Pure Storage Inc (NYSE: PSTG ) proclaimed at the time to have the fastest growth in ""storage industry history,"" PSTG stock has floundered, down 14.1% since its Oct. 5, 2015, IPO. Big Data is a huge deal, so it's certainly playing in a potentially explosive segment of the technology sector. Unfortunately, when you have enterprises continuing to debate how to store all their information, you never know if you're one hit product away from success or failure. Since launching its FlashArray product in 2012, Pure Storage has racked up more than $600 million in operating losses over 42 months. Yet, you can't help but be impressed by its revenues, which have grown tenfold in the past two years alone. In the second quarter of 2016, PSTG increased revenues 93% year-over-year to $163.2 million, growing its customers by 107% year-over-year to more than 2,300. The big news: It began shipping FlashBlade, its follow-up product to FlashArray. Despite the significant operating losses it's racked up, PSTG could finally deliver the promise so many believed it had coming to market last October. With the stock down 13 months after going public, now is the time for it to really break out. FlashBlade could be just the ticket to make that move happen. Feast or Famine Stocks to Buy: XPO Logistics (XPO) Source: via XPO Logistics (Modified) The serial acquirer of transportation and logistics businesses - more than a dozen acquisitions since 2011 - including Con-way Inc., which it acquired last year for $3 billion - recently sold Con-way's truckload business to Canadian trucking firm TransForce Inc (OTCMKTS: TFIFF ) for $558 million in a move to reduce the $5 billion in debt taken on to make all of these acquisitions. Not a pivotal piece of Con-way's business, TransForce's offer was simply too good to pass up. If you thought Pure Storage was a big revenue grower, XPO Logistics Inc (NYSE: XPO ) is out of this world, having growing its revenues from $177 million in 2011 to a top ten global transportation and logistics company with $10.9 billion in revenue through the first three quarters of fiscal 2016 and estimated full-year revenues of more than $15 billion. Most importantly, XPO generated free cash flow in Q3 2016 of $65 million and expects to be free cash flow positive for the entire year. Amazingly, it's got a good chance to reach its adjusted Ebitda goal of $1.6 billion by fiscal 2018. And only seven years after CEO Bradley Jacobs and investors put $150 million into XPO, then called Express-1 Expedited Solutions, to gain majority control. Today, Jacobs Private Equity owns approximately 15% of XPO's shares and 23% of the votes. The Top 10 Mutual Funds to Buy for 2017 On the precipice of making money, XPO Logistics shareholders can expect more good things to happen with Jacobs at the helm. Feast or Famine Stocks to Buy: DexCom (DXCM) Source: Alden Chadwick Via Flickr How you view DexCom, Inc. 's (NASDAQ: DXCM ) latest quarter depends on whether you're a glass half-full or glass half empty type of person. The maker of continuous glucose monitoring (CGM) systems announced its Q3 2016 earnings Nov. 1; it lost 22 cents per share on $148.6 million in revenue. If you're a half full kind of person, you'll view its 41% year-over-year increase in revenue and 55% reduction in its quarterly loss to $18.6 million, as real progress towards sustainable profitability. If you're a half empty person, in the red is in the red, no matter the number. Working on bringing its CGM systems to the diabetes world since 1999, DexCom has yet to make a profit, but whose revenues will likely hit $1 billion within the next five years. If hope were all you needed to make money on a stock, DexCom would be at the top of anyone's list. DexCom's argument when it comes to managing diabetes is that intermittent, finger-stick glucose monitoring isn't enough. Patients tend to spend a great deal of their day outside a healthy glycemic range between 80 and 140 milligrams of glucose for every deciliter of blood. So, constant monitoring is the better alternative. There are three million insulin intensive patients in the U.S. - 30 million patients if you include T2 non-insulin and non-intensive patients - and only a small percentage of those patients are using CGM. Despite intense competition from Medtronic PLC (NYSE: MDT ), DexCom continues to improve its gross margins and generate free cash flow, a key ingredient to most successful and profitable businesses. Good things are just around the corner. Feast or Famine Stocks to Buy: Splunk (SPLK) Source: Web Summit Via Flickr Earlier this year, Splunk Inc (NASDAQ: SPLK ) stock traded in the low $30s, a level not seen since early 2013. If you were lucky enough to have bought SPLK stock at those prices you've done well, because it's doubled in value since then. What happened to reignite the analyzer of big data? Like many software companies, it's in the middle of transitioning from software licenses to the cloud. That transition's been anything but smooth in terms of both top- and bottom-line growth. In early February, as some other cloud companies delivered disappointing results , Splunk stock went splat in sympathy with those stocks. However, the downward trend was short-lived. Splunk announced Q1 2016 earnings in late February that were much better than analyst expectations. And SPLK stock was off to the races, gaining 12% in March alone. But now analysts fear the move to the cloud has become a big headwind to Splunk's historical growth - revenues have grown six-fold in past five years - and expect its Q3 2016 results to be a big disappointment leaving SPLK stock to flounder once more. Splunk Cloud uptake will limit upside and expect ""another deceleration relative to historical growth rate,"" MKM Partners' analyst Kevin Buttigieg recently said about Splunk's upcoming Q3 earnings. ""While investors had understood that the transition to the cloud could have a negative effect on margins, they are now grappling with its negative effect on top-line growth as well."" 5 Retail Stocks That May Not Be Around Next Christmas Still not making money on an annual basis, but generating positive free cash flow, SPLK stock might be expensive at 10 times sales, eventually, the opportunities in Big Data analytics will pay handsomely. Splunk included. Feast or Famine Stocks to Buy: Autodesk (ADSK) Source: Scott Lewis via Flickr The maker of 3D modeling software made the decision to transition to a subscription-based business model from a licensed-based one back in 2013 . As part of that transition, it's accepted operating losses, as the price it has to pay to remain competitive. Since 2013, Autodesk, Inc. (NASDAQ: ADSK ) operating profit has disappeared going from $305 million, or $1.32 per share, in fiscal 2013 to a company projected loss of at least $608 million, or $2.74 per share. On a non-GAAP basis, it's less painful, with an estimated loss of between 55 cents and 70 cents per share. But it's a loss nonetheless. The subscription model, when done well, can lead to higher revenue and profits. Adobe Systems Incorporated (NASDAQ: ADBE ) migrated to a subscription-based model starting in 2013, operating profits went from $1.2 billion in fiscal 2012 to $413 billion in fiscal 2014 - then the turnaround took hold. Adobe will likely generate operating profits of $1.4 billion or more in fiscal 2017, with operating margins returning to historical norms. The big problem for Autodesk: It needs to speed up the transition. Adobe's subscription revenues really took off over the past two fiscal years - $1.1 billion in 2013 to $3.2 billion in 2015 - while maintaining operating expenses at the same level. Over the past two years, Autodesk's subscription revenues have increased by $200 million or about 20%. It has got to do better. Keep the faith, ADSK shareholders. A couple of figures in its Q2 2016 report provide hope. First, new model annualized recurring revenue increased 82% in the second quarter to $371 million. That's a sign customers are slowly getting on board. The second sign things will get better is deferred revenue - up 23% to $1.5 billion in Q2 - the subscription fees to be paid in future months in order for customers to continue to use the software. If these two keep going up on a quarterly basis and at a decent clip there's no reason why it too can't generate record profits just like Adobe. Feast or Famine Stocks to Buy: Workday (WDAY) Source: JD Hancock via Flickr Are you starting to sense a pattern here? It seems all of these cloud companies are growing revenues at a significant pace without much hope for immediate profits or even those on the horizon. Workday Inc (NYSE: WDAY ) definitely fits into that category. The cloud-based enterprise software company was founded in 2005 and went public in October 2012 at $28 per share. Trading above $80, IPO investors still holding have done well although WDAY stock has traded in a fairly tight range since April 2014. What's going to get it unstuck? Continue to grow subscriptions while slowing the amounts spent on marketing and product development which accounted for about 65% of its Q2 2016 operating expenses. Cut both of those by 25% while increasing subscription revenues by 30-40% per quarter and presto, you've got significant operating profits, not losses. Financially, Workday's business is getting stronger. Its trailing 12-month free cash flow is $178.1 million or about 13% of its revenue over those same 12 months. Adobe's current trailing 12-month free cash flow is 31% of revenue. Clearly, WDAY has work to do (no pun intended) but it's getting there. As it continues to win new customers in both the human capital management and financial segments, many of whom are global powerhouses, WDAY should gain pricing power as its customers become attached at the hip to its cloud-based products. 7 A-Rated Healthcare Stocks to Buy Before Trump Takes Office When that happens, and it will, and Workday continues to maintain control over its expenses, the margins will go through the roof. And so will WDAY stock. Feast or Famine Stocks to Buy: Tesla (TSLA) Source: Mike Lau via Flickr (Modified) It's hard to believe but Tesla Motors Inc (NASDAQ: TSLA ) actually made a profit in the third quarter, its first in more than three years. More importantly, it generated $176 million in free cash flow from the production of 25,185 vehicles. Its business is getting profitable just in time to begin producing the Model 3, Tesla's version of the commuter car. Orders for new Model S and Model X vehicles were up 68% in Q3 while actual production jumped 92% year-over-year. Tesla expects to deliver 50,000 new vehicles from June 2016 through the end of the year with slightly more than half that number in Q4. So, although Tesla generated its first profit in a long time and business is looking up, it's still going to lose in the order of $800 million in 2016, a substantial amount. Not to mention its profit only came after a $139 million in California zero emission credits which are almost 100% pure profit. CEO Elon Musk has rolled the dice merging SolarCity Corp for $2.6 billion figuring the two businesses go together like peanut butter and jelly. It remains to be seen whether his vision will be correct. What we do know is they'll both require a lot of cash until the potential synergies can be effectively - and profitably - exploited. Of all the seven feast or famine stocks, Tesla is easily my favorite. Not because I think you'll make the most amount of money but because Elon Musk is an innovator like no other - except maybe Jeff Bezos. As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. The post 7 Feast or Famine Stocks to Buy for Thanksgiving appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-11-23,17.615,18.085,17.4575,18.0475,
DXCM,2016-11-25,18.31,18.545,17.9125,18.205,
DXCM,2016-11-28,18.1875,18.4825,17.5875,17.6775,
DXCM,2016-11-29,17.7475,17.7475,16.8,17.0175,"[""Insulet Investors Being Kept In The Dark, CEO Alleged To Encourage Questionable Sales Techniques: Significant Downside Remains"", ""PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio"", ""New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'"", ""New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'"", ""PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio"", ""Insulet Investors Being Kept In The Dark, CEO Alleged To Encourage Questionable Sales Techniques: Significant Downside Remains"", ""New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'"", ""PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio"", ""Insulet Investors Being Kept In The Dark, CEO Alleged To Encourage Questionable Sales Techniques: Significant Downside Remains""]"
DXCM,2016-11-30,17.1275,17.2925,15.91,16.3225,
DXCM,2016-12-01,16.25,16.455,15.6662,15.835,"[""Caution On Acacia - Cramer's Lightning Round (11/30/16)"", ""Biotricity (BTCY) Hits the Target Apple (AAPL) and Fitbit (FIT) Missed"", ""Biotricity (BTCY) Hits the Target Apple (AAPL) and Fitbit (FIT) Missed"", ""Caution On Acacia - Cramer's Lightning Round (11/30/16)"", ""2 Longs And 2 Shorts To Watch This December Oasis Petroleum Inc. (OAS) had a big day on Wednesday, up 3.25, or 28%, to 14.97, on 34 million shares traded, as oil stocks benefited from news of OPEC's production cut. The stock has been climbing all year since its January bottom at 3.40. It held channel support in its dip in early August before resuming it upmove. The long-term chart indicates this could very well make a run to around the 18 range and then the mid-20\u2019s intermediate-term. U.S. Silica Holdings, Inc. (SLCA) broke out of a wedge pattern on Wednesday, up 5.42, or 12%, to 50.61, on 6 million shares traded. Shares in the frack sand supplier for oil and natural gas recovery hit a new multi-year high at 51.31. Watch for a move towards the channel top in the high-50's. DexCom, Inc. (DXCM), which gapped down sharply in early November, fought its way back to its declining topsline in a rising flag all month. However, the stock has broken down in the last three sessions on a pick-up in volume, falling another 2.78, or 4%, to 65.29, on 5.4 million shares traded Wednesday. That\u2019s huge downside volume for this stock. Watch for a test of the early November low around 59, and eventually 52. Mercadolibre, Inc. (MELI) has also broken down from a rising bear flag after traversing from the bottom of its channel to the top in recent weeks. The stock dropped 5.09, or 3%, to 157.82, on 2.5 million shares traded, a dramatic pick-up in volume. The next level to watch is the recent low around 145, followed by the June low near 125. See Harry's video chart analysis on these and other stocks. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Biotricity (BTCY) Hits the Target Apple (AAPL) and Fitbit (FIT) Missed"", ""Caution On Acacia - Cramer's Lightning Round (11/30/16)""]"
DXCM,2016-12-02,15.8925,16.1288,15.7325,15.9675,"[""SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'"", ""SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'"", ""SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'""]"
DXCM,2016-12-05,16.1275,16.44,15.9225,16.1125,
DXCM,2016-12-06,16.1725,16.4325,15.945,16.37,
DXCM,2016-12-07,16.25,16.4225,15.5225,15.76,
DXCM,2016-12-08,15.6825,16.2,15.605,16.1525,"Peek Under The Hood: IYH Has 19% Upside Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $169.28 per unit. With IYH trading at a recent price near $141.94 per unit, that means that analysts see 19.26% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and Bio-Rad Laboratories Inc (Symbol: BIO). Although DXCM has traded at a recent price of $63.04/share, the average analyst target is 34.61% higher at $84.86/share. Similarly, RARE has 33.29% upside from the recent share price of $71.33 if the average analyst target price of $95.08/share is reached, and analysts on average are expecting BIO to reach a target price of $225.00/share, which is 27.29% above the recent price of $176.76. Below is a twelve month price history chart comparing the stock performance of DXCM, RARE, and BIO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-12-09,16.115,16.41,16.0575,16.2525,
DXCM,2016-12-12,16.1,16.365,16.0588,16.32,
DXCM,2016-12-13,16.4075,16.6175,16.11,16.25,"[""Why WEAR, And Why WEAR It Now?"", ""Why WEAR, And Why WEAR It Now?"", ""Why WEAR, And Why WEAR It Now?""]"
DXCM,2016-12-14,16.2575,16.2825,15.8325,16.035,
DXCM,2016-12-15,16.36,16.36,15.8175,15.93,"[""B. Riley Upgrades DexCom to Buy"", ""B. Riley Upgrades DexCom to Buy"", ""B. Riley Upgrades DexCom to Buy""]"
DXCM,2016-12-16,15.9,16.2225,15.78,15.8525,
DXCM,2016-12-19,15.975,16.32,15.75,15.8775,"[""Continuous Glucose Monitoring Systems - A Growing Market"", ""Today's healthcare analyst action"", ""Oppenheimer Upgrades DexCom to Outperform, Maintains $84.00 Target"", ""Benzinga's Top Upgrades, Downgrades For December 19, 2016"", ""15 Biggest Mid-Day Gainers For Monday"", ""15 Biggest Mid-Day Gainers For Monday"", ""Benzinga's Top Upgrades, Downgrades For December 19, 2016"", ""Oppenheimer Upgrades DexCom to Outperform, Maintains $84.00 Target"", ""Today's healthcare analyst action"", ""Continuous Glucose Monitoring Systems - A Growing Market"", ""These 3 Stocks Are Up Over 500% Over the Last 5 Years The S&P 500 has risen more than 105% over the last five years, if you account for dividend reinvestment. That's a big enough gain to turn a $10,000 investment into a cool $20,500. While that's a great five-year run, a handful of stocks have left the famous index in the dust over this same time period. Here's a closer look at three such stocks -- Ionis Pharmaceuticals (NASDAQ: IONS) , Teligent (NASDAQ: TLGT) , and Dexcom (NASDAQ: DXCM) -- that are each up at least 500% over the last five years. Ionis Pharmaceuticals: Up 632% This biotech's claim to fame was developing an innovative process called antisense that it uses to develop drugs. Ionis' technology allows compounds to be created that target and bind to RNA, which is what pumps out the proteins that cause diseases. Ionis' drugs can be used to reduce the amount of troublesome protein that end up in the body, thereby helping to treat the underlying disease. What's great about this technology is that Ionis can quickly churn out new drugs once a troublesome RNA target is identified. That has allowed the company to pack its pipeline full of dozens of drugs that are aimed a treating a wide range of diseases. That provides investors with multiple shots on goal. Beyond the broad pipeline, Ionis has been such a terrific investment over the last few years thanks to its ability to make believers out of other big pharma companies. Currently, the company boasts partnerships with Biogen , GlaxoSmithKline , Bayer , AstraZeneca , Roche , and more. Better still, these partners have been willing to shower Ionis with huge up-front cash payments to get their hands on the company's technology, which has kept the company's cash burn rates quite low. DXCM Revenue (TTM) data by YCharts . With diabetes rates climbing around the world, Dexcom should have plenty of room left to grow in the years ahead. Now that the company's crazy valuation has become more reasonable, it might be a great time to give this company's stock a closer look. 10 stocks we like better than Ionis Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Ionis Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of Nov. 7, 2016. Brian Feroldi owns shares of Ionis Pharmaceuticals.Like this article? Follow him on Twitter, where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this. The Motley Fool owns shares of and recommends Biogen and Ionis Pharmaceuticals. The Motley Fool recommends AstraZeneca. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""15 Biggest Mid-Day Gainers For Monday"", ""Benzinga's Top Upgrades, Downgrades For December 19, 2016"", ""Oppenheimer Upgrades DexCom to Outperform, Maintains $84.00 Target"", ""Today's healthcare analyst action"", ""Continuous Glucose Monitoring Systems - A Growing Market""]"
DXCM,2016-12-20,15.8375,16.9498,15.155,15.89,"[""FDA OKs expanded use for DexCom's G5 glucose monitoring system; shares up 3%"", ""Traders Attributing Recent Strength In Dexcom To FDA Release Highlighting Approval Of Dexcom's G5 Mobile Continuous Glucose Monitoring System Non-Adjunctive Label Claim"", ""FDA Approval of Dexcom's Non-Adjunctive Indication Triggers a New Era in Diabetes Management"", ""FDA Approval of Dexcom's Non-Adjunctive Indication Triggers a New Era in Diabetes Management"", ""Traders Attributing Recent Strength In Dexcom To FDA Release Highlighting Approval Of Dexcom's G5 Mobile Continuous Glucose Monitoring System Non-Adjunctive Label Claim"", ""FDA OKs expanded use for DexCom's G5 glucose monitoring system; shares up 3%"", ""FDA Approval of Dexcom's Non-Adjunctive Indication Triggers a New Era in Diabetes Management"", ""Traders Attributing Recent Strength In Dexcom To FDA Release Highlighting Approval Of Dexcom's G5 Mobile Continuous Glucose Monitoring System Non-Adjunctive Label Claim"", ""FDA OKs expanded use for DexCom's G5 glucose monitoring system; shares up 3%""]"
DXCM,2016-12-21,16.145,16.4675,15.8975,15.935,"DexCom (DXCM) Gains FDA Approval for G5 Mobile CGM System San Diego, CA-based DexCom, Inc.DXCM , a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system. Notably, G5 Mobile is the only CGM system that enables daily diabetes treatment without frequent pricking of the finger. Per management, the approval is expected to establish a new benchmark in glucose monitoring for diabetes management. For the last six months, the company has a negative return of almost 18%, wider than the Zacks categorized Medical Instruments sub-industry's decline of roughly 2.9%. However, DexCom witnessed a nominal increase of roughly 0.3% to close at $63.56 yesterday, breaking the dismal market trend. On the brighter side, DexCom's long-term fundamentals are compelling. The company recorded a three-year CAGR of 59% for revenues, a strong positive in our view. Meanwhile, a long-term expected earnings growth of 32.5% instills investor confidence. Additionally, the Zacks Rank #3 (Hold) company promises sales growth of 41.9% for the current year, comparing favorably with the industry's 6.3%. Coming back to the development, the go-ahead paved way for an appropriate replacement to the traditional finger stick glucose treatment procedures in diabetes management. Notably, in Jul 2016, a panel of experts selected by the FDA marked the G5 Mobile CGM system safe. DEXCOM INC Price DEXCOM INC Price | DEXCOM INC Quote Of the other products in the CGM pipeline, the DexCom G4 Platinum product line has been a flagship and is significantly boosting the company's top line since long. Our Take The G5 Mobile CGM system has emerged as the first and only non-adjunctive CGM system in the U.S. We believe the non-adjunctive indication of this system should fortify the company's foothold in the continuous glucose monitoring markets. Meanwhile, the niche markets are forecasted to reach a worth of $568.5 million globally by 2020, multiplying at a CAGR of 14.8% (Allied Market Research). However, the market for blood glucose monitoring devices is highly competitive, subject to rapid change and is significantly affected by product introductions. On this note, DexCom competes directly with bigwigs like Roche Diabetes Care - a division of Roche Diagnostics and LifeScan, Inc. - a division of Johnson & Johnson. Other Key Picks Other favorably ranked stocks in the broader medical sector include Addus HomeCare Corporation ADUS , LHC Group, Inc. LHCG and IDEXX Laboratories, Inc. IDXX . Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1. Meanwhile, LHC Group carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 50.4%. LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 22.2% in the last three months. IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of 62.3%. Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX LABS INC (IDXX): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report LHC GROUP LLC (LHCG): Free Stock Analysis Report ADDUS HOMECARE (ADUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2016-12-22,15.9,16.165,15.3825,15.525,
DXCM,2016-12-23,15.585,15.73,15.4225,15.6275,
DXCM,2016-12-27,15.5525,15.65,15.3375,15.6,
DXCM,2016-12-28,15.675,15.9425,15.225,15.2525,
DXCM,2016-12-29,15.3175,15.3538,15.07,15.16,
DXCM,2016-12-30,15.145,15.31,14.84,14.925,
DXCM,2017-01-03,14.875,14.9122,14.44,14.5625,"[""Morgan Stanley Downgrades DexCom to Neutral, Lowers price target to $66.00"", ""Morgan Stanley Downgrades DexCom to Neutral, Lowers price target to $66.00"", ""Morgan Stanley Downgrades DexCom to Neutral, Lowers price target to $66.00""]"
DXCM,2017-01-04,14.575,15.2875,14.42,15.18,
DXCM,2017-01-05,15.2225,16.1375,15.1325,15.665,
DXCM,2017-01-06,15.7925,15.9775,15.6225,15.8075,
DXCM,2017-01-09,15.875,15.9725,15.6175,15.6225,
DXCM,2017-01-10,15.715,17.3725,15.6075,16.76,"[""DexCom sees 2016 top line up 42% to $570M"", ""A Quiet Year For Mid-Size Medtech"", ""JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString"", ""DexCom Sees Prelim. Q4 Rev. ~$168M vs. Est. $167M, FY16 Rev. ~$570M vs. Est. $569M; FY17 Rev. $710-$740M vs. Est. $753M"", ""DexCom Sees Prelim. Q4 Rev. ~$168M vs. Est. $167M, FY16 Rev. ~$570M vs. Est. $569M; FY17 Rev. $710-$740M vs. Est. $753M"", ""JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString"", ""A Quiet Year For Mid-Size Medtech"", ""DexCom sees 2016 top line up 42% to $570M"", ""DexCom Sees Prelim. Q4 Rev. ~$168M vs. Est. $167M, FY16 Rev. ~$570M vs. Est. $569M; FY17 Rev. $710-$740M vs. Est. $753M"", ""JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString"", ""A Quiet Year For Mid-Size Medtech"", ""DexCom sees 2016 top line up 42% to $570M""]"
DXCM,2017-01-11,16.8225,17.355,16.575,17.2575,"DexCom Looking Forward to Strong Revenues in Q4 and 2016 San Diego, CA-based DexCom, Inc.DXCM , a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016. This reflects an increase of 28% over the fourth quarter of 2015. For fiscal 2016, total preliminary, unaudited revenue is expected to be $570 million, implying an estimated increase of 42% over 2015. However, for the last six months, the company posted a negative return of almost 16%, wider than the Zacks categorized Medical Instruments sub-industry's decline of roughly 6.1%. However, DexCom witnessed an increase of roughly 6.6% to close at $67.04 yesterday, breaking the dismal market trend. Meanwhile, the estimate revision trend has been unfavorable as 12 estimates moved south over the past two months with no movement in the opposite direction. In fact, the current year estimates for the stock decreased by a penny to a loss of 77 cents per share as another estimate moved down last month. Coming back to the news, the upside expected in revenues was due to an estimated 80,000 to 90,000 new patients adopting DexCom Continuous Glucose Monitoring (CGM) worldwide. The company ended the year with approximately 200,000 patients globally, up from approximately 140,000 at the end of 2015. On the brighter side, DexCom's long-term fundamentals are compelling. The company recorded a three-year CAGR of 59% for revenues, a strong positive in our view. Meanwhile, a long-term expected earnings growth of 32.5% instills confidence in investors. DexCom develops and markets continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers. Zacks Rank & Key Picks Currently, DexCom has a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector include Glaukos Corporation GKOS , Dextera Surgical Inc. DXTR and Penumbra Inc. PEN . Notably, Glaukos Corporation and Penumbra sport a Zacks Rank #1 (Strong Buy) while Dextera carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 52.1%. Dextera Surgical has posted a positive earnings surprise of 8.3% in the last reported quarter. Additionally, a long-term expected earnings growth rate of 25% raises investor confidence. Penumbra has a long-term expected earnings growth rate of 20%. Notably, the stock represents an impressive one-year return of almost 29.7%. Zacks' Top 10 Stocks for 2017 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Glaukos Corporation (GKOS): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-01-12,17.25,17.43,16.82,16.9025,
DXCM,2017-01-13,19.84,22.2,19.655,21.2825,"[""CMS OKs reimbursement for DexCom's CGM system"", ""Technical Alert: Dexcom Leaps After Raised Q4 Guidance"", ""Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher"", ""DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage"", ""DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage"", ""Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher"", ""Technical Alert: Dexcom Leaps After Raised Q4 Guidance"", ""CMS OKs reimbursement for DexCom's CGM system"", ""Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher Toward the end of trading Friday, the Dow traded down 0.13 percent to 19,864.29 while the NASDAQ climbed 0.48 percent to 5,573.96. The S&P also rose, gaining 0.13 percent to 2,273.27. Leading and Lagging Sectors Healthcare shares gained around 0.43 percent in trading on Friday. Meanwhile, top gainers in the sector included DexCom, Inc. (NASDAQ: DXCM ), and Array Biopharma Inc (NASDAQ: ARRY ). In trading on Friday, utilities shares fell by 0.33 percent. Meanwhile, top losers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG ), down 3 percent, and Companhia Paranaense de Energia (ADR) (NYSE: ELP ), down 3 percent. Top Headline JPMorgan Chase & Co. (NYSE: JPM ) reported better-than-expected earnings for its fourth quarter on Friday. JPMorgan said it earned $1.71 per share in the fourth quarter on revenue of $23.4 billion. Wall Street analysts were expecting the company to earn $1.44 per share on revenue of $24.0 billion. Equities Trading UP Naked Brand Group Inc (NASDAQ: NAKD ) shares shot up 56 percent to $1.62 after the company announced plans to to merge with Bendon Limited. Shares of Sanchez Energy Corp (NYSE: SN ) got a boost, shooting up 28 percent to $11.11. Anadarko Petroleum Corporation (NYSE: APC ) announced the sale of Eagleford Shale assets to Sanchez Energy and Blackstone Energy Partners for $2.3 billion. Telenav Inc (NASDAQ: TNAV ) shares were also up, gaining 16 percent to $8.15 after the company reported the settlement of patent lawsuit. The company projects Q2 revenue of $51 million to $52 million and loss of $0.30 per share to $0.28 per share. Equities Trading DOWN Uranium Resources, Inc. (NASDAQ: URRE ) shares dropped 19 percent to $2.55 after the company reported the pricing of $9.7 million public offering. Shares of Skyline Medical Inc (NASDAQ: SKLN ) were down around 15 percent to $2.39. Skyline Medical priced its stock and warrant offering for gross proceeds of $3.9 million. Inventure Foods Inc (NASDAQ: SNAK ) was down, falling around 13 percent to $6.30. DA Davidson downgraded Inventure Foods from Buy to Neutral and lowered the price target from $10.00 to $8.00. Commodities In commodity news, oil traded down 1.19 percent to $53.20 while gold traded down 0.26 percent to $1,196.70. Silver traded down 0.21 percent Friday to $16.79, while copper rose 0.64 percent to $2.69. Eurozone European shares closed higher today. The eurozone's STOXX 600 rose 0.95 percent, the Spanish Ibex Index gained 1.11 percent, while Italy's FTSE MIB Index climbed 1.87 percent. Meanwhile the German DAX climbed 0.94 percent, and the French CAC 40 rose 1.20 percent while U.K. shares rose 0.62 percent. Economics The producer price index increased 0.3 percent in December, matching economists' expecttaions for a 0.3 percent growth. U.S. retail sales rose 0.6 percent for December, versus economists' expectations for a 0.7 percent growth U.S. business inventories rose 0.70 percent for November, versus economists' expectations for a 0.50 percent growth. The University of Michigan's consumer sentiment index slipped to 98.10 in January, versus a prior reading of 98.20. Economists were expecting a reading of 98.10. \u00a9 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Shares Cross Above 200 DMA In trading on Friday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $75.47, changing hands as high as $85.85 per share. DexCom Inc shares are currently trading up about 23.3% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $47.92 per share, with $96.38 as the 52 week high point - that compares with a last trade of $83.94. According to the ETF Finder at ETF Channel, DXCM makes up 2.19% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading up by about 1.3% on the day Friday. Click here to find out which 9 other stocks recently crossed above their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom, Inc. Stock Surged Higher Today Image source: Getty Images. What happened Shares of the medical device company DexCom (NASDAQ: DXCM) gained as much as 31% today as of 2:30 p.m. EST. The stock's surge higher was fueled by the Centers for Medicare and Medicaid Services (CMS) defining continuous glucose monitors (CGM) as \""therapeutic\"" under Medicare Part B. This favorable ruling qualifies the company's G5 mobile CGM system for coverage under Medicaid and Medicare. So what Prior to this regulatory ruling, Medicare beneficiaries with diabetes needed to be covered by a third-party payer with a policy adopting CGM devices, or simply pay out of pocket to gain access to this ground-breaking technology. So with CGM systems now being covered by Medicaid and Medicare, DexCom's sales should rise dramatically within this sizable segment of the diabetes patient population. Now what Over the past five years, DexCom has been one of the fastest-growing medical device companies in the world, reflecting both the sheer size of the diabetes product market and the growing demand for more efficient ways to manage the disease. So it's not totally surprising that market has built in a substantial premium into the company's valuation. That said, there may not be much more upside potential -- at least in the near term -- remaining in this stock after today's hefty move northwards. DexCom's shares, after all, are now trading at something along the lines of nine to 10 times its 2017 estimated revenue haul, and that's taking into account the company's forthcoming expansion into the Medicare population. Put simply, it might be best to wait until this high-flying stock cools off before grabbing shares. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of January 4, 2017 George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Sanchez Energy, DexCom, and Pandora Media Jumped Today The stock market finished the week on a mixed note on Friday, as the Nasdaq and S&P 500 climbed higher, even as the Dow Jones Industrials (DJINDICES: ^DJI) finished with a slight loss of just five points. Earnings season has begun, and solid results from major U.S. banks set a generally positive tone for the market. Investors responded favorably to optimistic guidance about the financial industry's prospects for 2017, and some other companies also had extremely good news that helped to offset some weakness in the consumer segment of the economy. Three of the top-performing stocks on the day were Sanchez Energy (NYSE: SN) , DexCom (NASDAQ: DXCM) , and Pandora Media (NYSE: P) . Below, we'll look more closely at these stocks to tell you why they did so well. Image source: Sanchez Energy. Sanchez boosts its big bet on the Eagle Ford Sanchez Energy soared 29% after the energy company reported that it had entered into a strategic partnership with private equity giant Blackstone Energy Partners. The 50/50 venture was formed to purchase a working interest in about 318,000 acres in the lucrative Eagle Ford area of Texas from peer Anadarko Petroleum (NYSE: APC) , with the partnership paying $2.3 billion for the assets. The Anadarko property is next to assets that Sanchez already works on in the Eagle Ford, and current production will provide immediate cash flow while extensive proved reserves and resource potential show plenty of future promise. CEO Tony Sanchez III noted that, \""this accretive and transformative acquisition more than doubles our drilling inventory,\"" and it will triple its exposure to the favorable trends in sections of the Eagle Ford that Sanchez has already successfully developed. Investors are excited that Sanchez was able to make a smart strategic partnership to capitalize on what could be a strong opportunity. DexCom gets a key regulatory win DexCom jumped 26% in the wake of a favorable classification decision from the Centers for Medicare and Medicaid Services (CMS) last Thursday. The producer of continuous glucose monitors said that the CMS had assigned the DexCom G5 Mobile system as a therapeutic continuous glucose monitor, which allows medical professionals to make treatment decisions using the device. Currently, the company's system is the only one that has earned this classification, and DexCom CEO Kevin Sayer described how big a breakthrough this is for the company, saying, \""This landmark CMS ruling will make available the most important technology in diabetes management to the Medicare population.\"" Investors expect the move to have dramatic impacts on DexCom's financials going forward, justifying the big share-price gain. Pandora cuts jobs, but gives favorable guidance Finally, Pandora Media picked up 6%. The streaming audio company said that it would cut its workforce in the U.S. by about 7% in response to increasing competition in the music-streaming niche, with the goal of cutting operational costs. However, Pandora also said that it expects to top its previous guidance for revenue for the fourth quarter, citing strong advertising performance and an increase in paid subscription customer counts. CEO Tim Westergren put the gains into context, saying that, \""with all the elements of our strategy in place, we are in the best position possible to expand our listener base, drive engagement, and deliver significant value to all of our stakeholders.\"" Whether the gains will continue depends on whether the introduction of Pandora Premium goes as well as Westergren and Pandora hope, but for now, investors seem optimistic about Pandora's future. 10 stocks we like better than Anadarko Petroleum When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Anadarko Petroleum wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of January 4, 2017 Dan Caplinger has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Pandora Media. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage"", ""Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher"", ""Technical Alert: Dexcom Leaps After Raised Q4 Guidance"", ""CMS OKs reimbursement for DexCom's CGM system""]"
DXCM,2017-01-17,21.3675,21.685,21.1525,21.3725,"Notable Tuesday Option Activity: DXCM, ANET, EMN Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 11,388 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 61.7% of DXCM's average daily trading volume over the past month of 1.8 million shares. Particularly high volume was seen for the $85 strike put option expiring January 20, 2017 , with 5,477 contracts trading so far today, representing approximately 547,700 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $85 strike highlighted in orange: Arista Networks Inc (Symbol: ANET) options are showing a volume of 3,816 contracts thus far today. That number of contracts represents approximately 381,600 underlying shares, working out to a sizeable 61.5% of ANET's average daily trading volume over the past month, of 620,660 shares. Especially high volume was seen for the $90 strike put option expiring January 20, 2017 , with 1,729 contracts trading so far today, representing approximately 172,900 underlying shares of ANET. Below is a chart showing ANET's trailing twelve month trading history, with the $90 strike highlighted in orange: And Eastman Chemical Co (Symbol: EMN) options are showing a volume of 6,230 contracts thus far today. That number of contracts represents approximately 623,000 underlying shares, working out to a sizeable 58.4% of EMN's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $75 strike call option expiring January 20, 2017 , with 6,004 contracts trading so far today, representing approximately 600,400 underlying shares of EMN. Below is a chart showing EMN's trailing twelve month trading history, with the $75 strike highlighted in orange: For the various different available expirations for DXCM options , ANET options , or EMN options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-01-18,21.5,21.5475,21.0225,21.04,
DXCM,2017-01-19,21.04,21.16,20.31,20.3975,
DXCM,2017-01-20,20.4,20.565,19.9075,20.0525,"[""Have Faith In Trump's Agenda - Cramer's Mad Money (1/19/17)"", ""Baillie Gifford Reports 7.25% Passive Stake In Dexcom"", ""Baillie Gifford Reports 7.25% Passive Stake In Dexcom"", ""Have Faith In Trump's Agenda - Cramer's Mad Money (1/19/17)"", ""Baillie Gifford Reports 7.25% Passive Stake In Dexcom"", ""Have Faith In Trump's Agenda - Cramer's Mad Money (1/19/17)""]"
DXCM,2017-01-23,19.9125,20.115,19.7525,19.995,
DXCM,2017-01-24,19.575,20.0125,19.075,19.9375,
DXCM,2017-01-25,20.0325,20.5725,19.965,20.225,
DXCM,2017-01-26,20.1925,20.3825,19.7875,19.88,"[""Dowling & Yahnke Llc Buys Sempra Energy, Evolent Health Inc, Koninklijke Ahold Delhaize NV, ..."", ""Dowling & Yahnke Llc Buys Sempra Energy, Evolent Health Inc, Koninklijke Ahold Delhaize NV, ..."", ""Dowling & Yahnke Llc Buys Sempra Energy, Evolent Health Inc, Koninklijke Ahold Delhaize NV, ...""]"
DXCM,2017-01-27,19.8625,20.0025,19.7288,19.87,
DXCM,2017-01-30,19.79,19.9062,19.4075,19.6375,
DXCM,2017-01-31,19.7125,19.99,19.5175,19.7875,"[""Delphi Private Advisors LLC Buys Schwab International Equity, Schwab International Small-Cap ..."", ""Movers And Shakers In Diabetes Management - Where Will Medtech In 2017 Take Us?"", ""Movers And Shakers In Diabetes Management - Where Will Medtech In 2017 Take Us?"", ""Delphi Private Advisors LLC Buys Schwab International Equity, Schwab International Small-Cap ..."", ""Movers And Shakers In Diabetes Management - Where Will Medtech In 2017 Take Us?"", ""Delphi Private Advisors LLC Buys Schwab International Equity, Schwab International Small-Cap ...""]"
DXCM,2017-02-01,19.9525,20.0475,19.6675,19.86,"[""Lean Long-Term Growth Portfolio - January 2017 Update"", ""Lean Long-Term Growth Portfolio - January 2017 Update"", ""Lean Long-Term Growth Portfolio - January 2017 Update""]"
DXCM,2017-02-02,19.96,20.085,19.58,19.89,
DXCM,2017-02-03,19.8825,20.3775,19.795,20.345,
DXCM,2017-02-06,20.25,20.4825,19.805,19.9175,"[""Dexcom: Spearhead Of A New Disruptive Technology In Diabetes"", ""Dexcom: Spearhead Of A New Disruptive Technology In Diabetes"", ""3 of the Highest-Growth Stocks in the Market Today Every investor dreams of getting in on the next great growth stock. However, it can be quite difficult to invest in companies that promise extreme growth rates because they are often bid up to premium valuations that can make them quite risky to own. Still, fast growth can often flame out. Regardless, it can be worthwhile to build a watchlist of potential multi-baggers. To help you do just that, I ran a screen to identify companies with the following characteristics: Market cap over $300 million Sales growth of at least 30% over the past five years Estimated EPS growth of at least 30% over the next five years Of the companies identified by the screen, three stood out to me as poised for exceptional growth: Paycom Software (NYSE: PAYC) , T-Mobile US (NASDAQ: TMUS) , and Dexcom (NASDAQ: DXCM) . Are any of them worth buying today? Read on to learn more about these companies so you can make that call for yourself. A payroll processing disruptor Payroll is a boring but mission-critical task for every business. The market for this service is mature and extremely competitive, but Paycom Software has been rapidly rising up in this industry since its founding in 1998. What makes Paycom's product offering stand apart from more established competitors? First, Paycom's platform is provided exclusively through the cloud. That makes it easy to implement and access from anywhere. Second, Paycom offers far more than just simple payroll processing solutions. The company's platform is an all-in-one human capital management software solution that assists with many other HR tasks such as time management, performance reviews, recruiting, training, and more. This unique combination is helping Paycom grow like wildfire. Revenue has grown by more than 40% annually over the past five years, which has allowed the company's bottom line to swell. Better yet, 98% of the company's revenue is recurring, which gives the company a predictable base to grow from. The only knock against Paycom is that Wall Street is aware of the company's potential and has priced its stock accordingly. Trading for nearly 65 times trailing earnings, Paycom stock is far from cheap, so if the company's growth engine stalls, shareholders could be in for a world of pain. Still, fast-growing stocks that are already profitable don't come along every day, so I think this is one growth stock worth paying up to own . A wireless carrier with attitude The U.S. wireless market is mature and dominated by AT&T and Verizon , so you'd be forgiven for assuming that there isn't any room for anyone else to grow. I thought so, too, which is why I was surprised to learn that T-Mobile showed up on my screen. If you live in the U.S., then you are likely familiar with T-Mobile's \""Un-carrier\"" messaging. The company has been calling out other wireless carriers for using hidden fees and charges to jack up their customers' bills. By contrast, T-Mobile promises customers great service, unlimited access to data, and transparent pricing terms that are free of hidden costs. DXCM Revenue (TTM) data by YCharts . Amazingly, these extreme growth rates have been achieved without reimbursement access from Medicare. Thankfully, the Centers for Medicare & Medicaid Services recently announced that it was changing its policy and will begin offering coverage for Dexcom's G5 Mobile system. That's big news that promises to open up a massive new group of patients to Dexcom's system. Like Paycom, the markets have caught on to Dexcom's growth potential and have awarded it a crazy valuation . Still, diabetes isn't going away anytime soon, and Dexcom looks well-positioned for fast growth ahead. Time could prove that paying up to own this company's stock is well worth it. 10 stocks we like better than T-Mobile When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and T-Mobile wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of January 4, 2017. Brian Feroldi owns shares of Paycom Software. The Motley Fool owns shares of and recommends Paycom Software. The Motley Fool recommends T-Mobile US and Verizon Communications. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom: Spearhead Of A New Disruptive Technology In Diabetes""]"
DXCM,2017-02-07,19.8775,20.19,19.876,19.95,
DXCM,2017-02-08,19.8375,20.02,19.7225,19.81,"[""Marble Harbor Investment Counsel, LLC Buys eBay, Vodafone Group PLC, DexCom, Sells Target, Dell ..."", ""Marble Harbor Investment Counsel, LLC Buys eBay, Vodafone Group PLC, DexCom, Sells Target, Dell ..."", ""Marble Harbor Investment Counsel, LLC Buys eBay, Vodafone Group PLC, DexCom, Sells Target, Dell ...""]"
DXCM,2017-02-09,19.8375,20.1425,19.765,19.845,
DXCM,2017-02-10,19.825,20.075,19.705,20.0,"[""NIH Trials Set Up Artificial Pancreas Market Battle"", ""Mitsubishi UFJ Trust & Banking Corp Buys SPDR Bloomberg Barclays Short Term High Yield ..."", ""NIH Trials Set Up Artificial Pancreas Market Battle"", ""Mitsubishi UFJ Trust & Banking Corp Buys SPDR Bloomberg Barclays Short Term High Yield ..."", ""NIH Trials Set Up Artificial Pancreas Market Battle"", ""Mitsubishi UFJ Trust & Banking Corp Buys SPDR Bloomberg Barclays Short Term High Yield ...""]"
DXCM,2017-02-13,19.955,20.2188,19.955,20.055,
DXCM,2017-02-14,20.125,20.34,19.8875,20.265,"[""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ..."", ""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ..."", ""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ...""]"
DXCM,2017-02-15,20.25,21.0,20.2425,20.8138,"Notable Wednesday Option Activity: DXCM, PBPB, STMP Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 6,197 contracts has been traded thus far today, a contract volume which is representative of approximately 619,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60.7% of DXCM's average daily trading volume over the past month, of 1.0 million shares. Particularly high volume was seen for the $85 strike call option expiring February 17, 2017 , with 3,574 contracts trading so far today, representing approximately 357,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $85 strike highlighted in orange: Potbelly Corp (Symbol: PBPB) options are showing a volume of 990 contracts thus far today. That number of contracts represents approximately 99,000 underlying shares, working out to a sizeable 60.1% of PBPB's average daily trading volume over the past month, of 164,820 shares. Especially high volume was seen for the $13 strike put option expiring April 21, 2017 , with 655 contracts trading so far today, representing approximately 65,500 underlying shares of PBPB. Below is a chart showing PBPB's trailing twelve month trading history, with the $13 strike highlighted in orange: And Stamps.com Inc. (Symbol: STMP) saw options trading volume of 1,087 contracts, representing approximately 108,700 underlying shares or approximately 56.1% of STMP's average daily trading volume over the past month, of 193,890 shares. Especially high volume was seen for the $115 strike put option expiring February 17, 2017 , with 626 contracts trading so far today, representing approximately 62,600 underlying shares of STMP. Below is a chart showing STMP's trailing twelve month trading history, with the $115 strike highlighted in orange: For the various different available expirations for DXCM options , PBPB options , or STMP options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-02-16,21.1525,21.2075,20.03,20.3475,"[""Dexcom Shares Tick Below $83 Level Over Last Few Mins as Hearing Piper Jaffray Negative on Name"", ""Downside in Dexcom Shares Intensifies as $82 Level Support Level Breaks; Shares Down 1.3% Over Last Few Mins, Down 2.7% for Session, Down 4.3% Since Open"", ""DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected"", ""DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected"", ""Downside in Dexcom Shares Intensifies as $82 Level Support Level Breaks; Shares Down 1.3% Over Last Few Mins, Down 2.7% for Session, Down 4.3% Since Open"", ""Dexcom Shares Tick Below $83 Level Over Last Few Mins as Hearing Piper Jaffray Negative on Name"", ""DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected"", ""Downside in Dexcom Shares Intensifies as $82 Level Support Level Breaks; Shares Down 1.3% Over Last Few Mins, Down 2.7% for Session, Down 4.3% Since Open"", ""Dexcom Shares Tick Below $83 Level Over Last Few Mins as Hearing Piper Jaffray Negative on Name""]"
DXCM,2017-02-17,20.265,20.665,20.145,20.4725,
DXCM,2017-02-21,20.2675,20.5575,19.92,19.975,"[""The Mobile Health Wearables Market Finally Matures, Gives Consumers What They Want"", ""DexCom finance chief bids adieu"", ""DexCom finance chief bids adieu"", ""The Mobile Health Wearables Market Finally Matures, Gives Consumers What They Want"", ""DexCom finance chief bids adieu"", ""The Mobile Health Wearables Market Finally Matures, Gives Consumers What They Want""]"
DXCM,2017-02-22,19.97,19.9725,19.505,19.6475,
DXCM,2017-02-23,19.6225,19.795,19.275,19.49,"DexCom Shares Cross Below 200 DMA In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $77.37, changing hands as low as $77.10 per share. DexCom Inc shares are currently trading down about 0.8% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $56.52 per share, with $96.38 as the 52 week high point - that compares with a last trade of $77.96. According to the ETF Finder at ETF Channel, DXCM makes up 1.99% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading relatively unchanged on the day Thursday. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-02-24,19.2725,19.7275,19.215,19.625,"DexCom (DXCM) Q4 Earnings: What to Expect from the Stock? DexCom, Inc.DXCM is set to report fiscal fourth-quarter 2017 results on Feb 28. DexCom does not have an impressive track of beating estimates in the four trailing quarters. In the last reported quarter, it recorded a negative earnings surprise of 57.14%, bringing the four-quarter average to a negative 59.96%. However, in the past three months, DexCom gained almost 7.95%, outperforming the Zacks categorized Medical Instruments sub-industry's gain of roughly 6.74%. Let's see how things are shaping up prior to this announcement. Factors at Play We believe the glucose monitoring and diabetes market represents significant commercial opportunity for DexCom, and are likely to be the key catalysts for the company in the fourth quarter. The medical device company expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016. This reflects an increase of 28% over the fourth quarter of 2015. The upside expected in revenues was due to an estimated 80,000 to 90,000 new patients adopting DexCom Continuous Glucose Monitoring (CGM) worldwide. The company continues to witness flat pricing, owing to price discounting in larger accounts, limited product offerings and international price cuts. Further, DexCom derives a significant part of total revenue from international operations, which is adversely affected by fluctuations in foreign currency exchange rates. Moreover, overall activities of DexCom during the fourth quarter were inadequate to win analysts' confidence. As a result, the Zacks Consensus Estimate for the quarter to be reported fell two cents to a loss of nine cents per share in the last 90 days. Earnings Whispers However, our proven model does not conclusively show that DexCom is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below: Zacks ESP: DexCom currently has an Earnings ESP of -66.67%. That is because the Most Accurate estimate stands at a loss of 15 cents and the Zacks Consensus Estimate is pegged at a loss of 9 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . DexCom, Inc. Price and EPS Surprise DexCom, Inc. Price and EPS Surprise | DexCom, Inc. Quote Zacks Rank: DexCom currently carries a Zacks Rank #3 (Hold) which increases the predictive power of ESP. However, the company's -66.67% ESP makes surprise prediction difficult. We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks to Consider Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat: Masimo CorporationMASI has an Earnings ESP of +3.51% and a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here . Exelixis, Inc.EXEL has an Earnings ESP of +200.00% and a Zacks Rank #2. Zynerba Pharmaceuticals, Inc.ZYNE has an Earnings ESP of +2.74% and a Zacks Rank #2. Zacks' Top 10 Stocks for 2017 In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Zynerba Pharmaceuticals, Inc. (ZYNE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-02-27,19.5525,19.835,18.8825,19.805,"[""Notable earnings after Tuesday's close"", ""Should You Buy DexCom (DXCM) Ahead of Earnings?"", ""Notable earnings after Tuesday's close"", ""Should You Buy DexCom (DXCM) Ahead of Earnings?"", ""Notable earnings after Tuesday's close"", ""Should You Buy DexCom (DXCM) Ahead of Earnings?""]"
DXCM,2017-02-28,19.785,19.785,19.3097,19.54,"[""DexCom (DXCM) Q4 2016 Results - Earnings Call Transcript"", ""DexCom beats by $0.01, beats on revenue"", ""DexCom Reports Q4 EPS $(0.09) vs $(0.10) Est., Sales $171.2M vs $167.97M Est."", ""DexCom Reports Q4 EPS $(0.09) vs $(0.10) Est., Sales $171.2M vs $167.97M Est."", ""DexCom (DXCM) Q4 2016 Results - Earnings Call Transcript"", ""DexCom beats by $0.01, beats on revenue"", ""Earnings Reaction History: DexCom, Inc., 71.4% Follow-Through Indicator, 6.4% Sensitive Expected Earnings Release: 02/28/2017, After-hours Avg. Extended-Hours Dollar Volume: $2,574,716 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 5.4% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 5.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 60% Average next regular session additional loss: 2.2% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.2% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for February 28, 2017 : CRM, ROST, PANW, UHS, TSRO, JAZZ, AR, DXCM, EPR, LOGM, ACAD, BUFF The following companies are expected to report earnings after hours on 02/28/2017. Visit our Earnings Calendar for a full list of expected earnings releases. Salesforce.com Inc ( CRM ) is reporting for the quarter ending January 31, 2017. The computer software company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.04. This value represents a 300.00% increase compared to the same quarter last year. CRM missed the consensus earnings per share in the 1st calendar quarter of 2016 by -75%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CRM is 354.52 vs. an industry ratio of 62.10, implying that they will have a higher earnings growth than their competitors in the same industry. Ross Stores, Inc. ( ROST ) is reporting for the quarter ending January 31, 2017. The discount retail company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.75. This value represents a 13.64% increase compared to the same quarter last year. In the past year ROST has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ROST is 24.61 vs. an industry ratio of 15.70, implying that they will have a higher earnings growth than their competitors in the same industry. Palo Alto Networks, Inc. ( PANW ) is reporting for the quarter ending January 31, 2017. The information technology services company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.38. This value represents a 54.22% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for PANW is -148.03 vs. an industry ratio of 9.50. Universal Health Services, Inc. ( UHS ) is reporting for the quarter ending December 31, 2016. The hospital company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.79. This value represents a 4.68% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for UHS is 17.28 vs. an industry ratio of 13.20, implying that they will have a higher earnings growth than their competitors in the same industry. TESARO, Inc. ( TSRO ) is reporting for the quarter ending December 31, 2016. The drug company's consensus earnings per share forecast from the 12 analysts that follow the stock is $-1.96. This value represents a 3.70% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for TSRO is -25.29 vs. an industry ratio of 6.60. Jazz Pharmaceuticals plc ( JAZZ ) is reporting for the quarter ending December 31, 2016. The drug company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.65. This value represents a 27.31% decrease compared to the same quarter last year. In the past year JAZZ has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 37.58%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for JAZZ is 22.38 vs. an industry ratio of 6.60, implying that they will have a higher earnings growth than their competitors in the same industry. Antero Resources Corporation ( AR ) is reporting for the quarter ending December 31, 2016. The oil (us exp & production) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.13. This value represents a no change for the same quarter last year. In the past year AR has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 200%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for AR is 67.00 vs. an industry ratio of -8.80, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. ( DXCM ) is reporting for the quarter ending December 31, 2016. The medical instruments company's consensus earnings per share forecast from the 14 analysts that follow the stock is $-0.10. This value represents a 600.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for DXCM is -100.27 vs. an industry ratio of 3.40. EPR Properties ( EPR ) is reporting for the quarter ending December 31, 2016. The reit company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.23. This value represents a 4.24% increase compared to the same quarter last year. In the past year EPR has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for EPR is 16.16 vs. an industry ratio of 16.50. LogMein, Inc. ( LOGM ) is reporting for the quarter ending December 31, 2016. The computer services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.36. This value represents a 2.86% increase compared to the same quarter last year. In the past year LOGM has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 14.29%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for LOGM is 90.14 vs. an industry ratio of 26.40, implying that they will have a higher earnings growth than their competitors in the same industry. ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.65. This value represents a 44.44% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. Blue Buffalo Pet Products, Inc. ( BUFF ) is reporting for the quarter ending December 31, 2016. The consumer company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.18. This value represents a 12.50% increase compared to the same quarter last year. In the past year BUFF has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 10%. The \""days to cover\"" for this stock exceeds 12 days. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BUFF is 31.01 vs. an industry ratio of -5.60, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Q4 EPS $(0.09) vs $(0.10) Est., Sales $171.2M vs $167.97M Est."", ""DexCom (DXCM) Q4 2016 Results - Earnings Call Transcript"", ""DexCom beats by $0.01, beats on revenue""]"
DXCM,2017-03-01,19.6,21.0225,19.6,20.3675,"[""Lean Long-Term Growth Portfolio - February 2017 Update"", ""Lean Long-Term Growth Portfolio - February 2017 Update"", ""Lean Long-Term Growth Portfolio - February 2017 Update""]"
DXCM,2017-03-02,20.375,20.735,20.2075,20.26,"Billionaire George Soros Bought These 2 Biotech Stocks Billionaire super-investor George Soros may have stepped away from actively managing his namesake fund, but the firm's quarterly activity still garners significant interest within the investing community. The Soros Fund Management, after all, has been one of world's most active and profitable investing firms over its 47-year history. The secret to the Soros fund's success is its core philosophy, which centers around identifying emerging trends early on and subsequently exploiting them to the fullest. So it's fairly common to see the fund buy small chunks of a company in one quarter, and then either ratchet up its position or sell it off entirely in the next quarter. Keeping this theme squarely in mind, the most recent 13-F filings revealed that the Soros fund bought shares of both Celgene (NASDAQ: CELG) and DexCom (NASDAQ: DXCM) in the fourth quarter of 2016. Do these two buys indicate that these stocks are about to heat up? Let's dig deeper to find out. Celgene's R&D efforts are paying dividends Celgene is known mostly for Revlimid, Abraxane, and Pomalyst, its trio of top flight blood cancer drugs. However, the company has successfully used its core expertise in blood cancer to delve into other lucrative disease markets of late, such as chronic inflammatory diseases. Celgene's relatively new plaque psoriasis medicine Otezla, for instance, was able to achieve blockbuster status in less than two years after its original approval, and is set to generate upwards of $1.7 billion in sales this year. This stunning level of revenue growth for both Otezla and its flagship hematology products has enabled the biotech to form numerous external partnerships, and aggressively pursue M&A opportunities to vastly broaden its clinical portfolio over the last few years. As a direct result, Celgene is on track to announce a jaw-dropping 19 Phase 3 data readouts over the next two years. The best part, though, is that this onslaught of pivotal data readouts also contains some extremely high-value disease targets. The experimental drug ozanimod, for instance, sports megablockbuster potential as a treatment for relapsing multiple sclerosis (RMS), ulcerative colitis, and Crohn's disease. And so far, the drug is performing as expected in trials. Earlier this month, Celgene reported that ozanimod met both its primary and secondary endpoints in its first late-stage trial as an oral therapy for RMS. The drug's second late-stage readout is forecast to hit the Street sometime in the second quarter of this year. If warranted, the company plans on filing ozanimod's regulatory application with the FDA before year's end, perhaps giving Celgene its next franchise-level drug as soon as mid to late 2018. In all, Celgene is an ultra high-growth biotech that's nearing several major clinical milestones. So there's definitely good reason to keep a close eye on this blue-chip biotech in 2017, and perhaps even pick up some shares ahead of these upcoming catalysts. DexCom is a leader in diabetes management Dexcom is a medical device company with enormous aspirations. The short story is that this mid-cap company wants to completely displace finger sticks with its continuous glucose monitoring (CGM) systems as the gold standard for glucose monitoring in diabetes patients. The basic idea is that more accurate glucose monitoring should lead to better overall diabetes management, and hence lower incidence rates of serious complications from the disease such as kidney failure, heart attacks, and strokes. And with over 422 million adults already living with diabetes across the globe and incidence rates only continuing to rise, Dexcom is unquestionably pursuing a monstrous commercial opportunity. The really exciting part about this biotech's growth story, though, is that the company isn't just targeting a sizable commercial opportunity, but actually making major strides at capturing the lion's share of the CGM market. Dexcom's revenues over the past couple years, for example, have grown by leaps and bounds: DXCM Revenue (Annual) data by YCharts Adding fuel to the fire, the Centers for Medicare and Medicaid Services recently defined CGM systems as ""therapeutic"" under Medicare Part B, allowing them to be covered by Medicaid and Medicare. This favorable regulatory decision, combined with growing demand for CGM systems in general, is expected to drive Dexcom's sales up by another 25% to 30% this year to around $710 to $740 million. The drawback is that Dexcom's rocket-like growth hasn't gone unnoticed, with its shares trading at a price to sales ratio in excess of 12.5 right now. But with the diabetes market growing hand-in-hand with the rising global population, this biotech's hefty premium may be worth the price of admission. 10 stocks we like better than Celgene When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of February 6, 2017 George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-03-03,19.995,20.4225,19.875,20.11,"DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues DexCom Inc.DXCM reported loss of 9 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents. DexCom had reported earnings of two cents in the year-ago quarter. In the reported quarter, total revenue grew to $171.2 million, reflecting an increase of 31% from $130.8 million in the year-ago quarter. This also came in higher than the Zacks Consensus Estimate of $168.0 million. Stock Performance The price performance of the stock has been favorable in the last three months. DexCom registered a stable return of 25.74%, outpacing the Zacks classified Medical - Instruments sub-industry's gain of almost 10.73%. Operational Details In the reported quarter, cost of sales increased to $54.5 from $39.6 million in fourth-quarter 2015. This was primarily due to an increase in sales volume. Research and development expense increased to $29.0 million in the year-ago quarter to $44.0 million. The decrease in research and development expense was primarily due to the absence of a non-cash charge related to Verily Collaboration Agreement incurred in 2015. This was partially offset by additional payroll costs and additional non-cash share-based compensation. Selling, general and administrative expense totaled $79 million in the reported quarter compared with $61 million during the same quarter in 2015. The rise was primarily due to year-over-year increases in head count in customer support organizations, higher marketing expenses and IT cost. In the reported quarter, gross profit totaled $117 million, generating a gross margin of 68% compared with a gross profit of $91 million and a gross margin of 70% for the same quarter in the prior year. On a year-over-year basis, gross margin was negatively impacted by sales of G5 Mobile transmitter. Financial Condition As of Dec 31, 2016, DexCom had $123.7 million in cash, cash equivalents and short-term marketable securities versus $115.2 million as of Dec 31, 2015. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector include Glaukos Corporation GKOS , Avinger, Inc. AVGR and Fluidigm Corporation FLDM . Notably, all the stocks carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 184.6%. Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter. Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 1.23% over the last three months. Zacks' Top Investment Ideas for Long-Term Profit How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fluidigm Corporation (FLDM): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Avinger, Inc. (AVGR): Free Stock Analysis Report Glaukos Corporation (GKOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-03-06,19.9425,20.06,19.405,19.59,"[""Raymond James Institutional Investors Conference Begins Today; Presenters Include Ruth's Hospitality, DexCom, MAYCOM, Rayonier, TD Ameritrade, & Envision Healthcare"", ""Raymond James Institutional Investors Conference Begins Today; Presenters Include Ruth's Hospitality, DexCom, MAYCOM, Rayonier, TD Ameritrade, & Envision Healthcare"", ""Raymond James Institutional Investors Conference Begins Today; Presenters Include Ruth's Hospitality, DexCom, MAYCOM, Rayonier, TD Ameritrade, & Envision Healthcare""]"
DXCM,2017-03-07,19.6775,19.75,19.36,19.6475,"[""Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio"", ""Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio"", ""Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio""]"
DXCM,2017-03-08,19.6975,19.9275,19.5225,19.56,
DXCM,2017-03-09,19.5125,19.75,19.2525,19.3875,"Better Buy: MannKind Corp. vs. Dexcom America spends more than $322 billion each year treating the 29 million patients who have diabetes or prediabetes. That's a staggering number, so it's not hard to understand why several companies have chosen to specialize in treating this disease. MannKind (NASDAQ: MNKD) and Dexcom (NASDAQ: DXCM) are two such businesses. Both companies have launched innovative products that are designed to make it far easier for patients to manage their disease. But which company is the better bet for new money today? Let's take a closer look at both of them to see if we can ascertain an answer. The case for MannKind Many people with diabetes are forced to inject themselves with insulin multiple times each day in order to keep their blood sugar levels in an acceptable range. While this has been the standard of care treatment for generations, many patients do not like to give themselves injections. MannKind's big idea was to make insulin inhalable, thereby providing patients with a needle-free way to meet their fast-acting insulin needs. After years of research, the FDA finally gave the green light to the company's product -- called Afrezza -- in 2014. Unfortunately, MannKind has faced numerous obstacles in commercializing the drug. Sanofi -- Mannkind's former partner -- priced Afrezza at a big premium to other insulins, which caused many insurers to place restrictions on its use. That made it quite difficult for patients to access the drug. The situation got so bad thatSanofi threw in the towel less than a year into the launch. Predictably, that caused MannKind's stock to tank. MNKD data by YCharts . The terrible launch and loss of a deep-pocketed partner put MannKind in a tough position. Over the last year, the company has been scrambling to cut costs, raise capital, and relaunch the product. Thankfully, MannKind has made a number of moves that have greatly enhanced its financial position. The company recently received a $30 million cash injection from Sanofi. It also sold one of its buildings for $16 million. When adding in other ways to access capital, MannKind has given itself a little bit of breathing room. The company also executed a reverse stock split earlier this month that should alleviate the threat of being delisted from the Nasdaq for having a share price under $1.00. Of course, the only thing that matters from here is how fast MannKind can ramp sales of Afrezza. Third-quarter sales of the drug were only $573,000, which is a still just a pittance. Only time will tell if MannKind will be successful with its attempts to relaunch the product. The case for Dexcom Unlike MannKind, Dexcom has been a market darling for years. This company's success can be traced to the rapid uptake by the diabetes community of its innovative continuous glucose monitoring (CGM) system. This disposable device is worn on the body for up to seven days and constantly uploads a patient's blood sugar levels to a receiver or phone. This provides patients with a convenient way for them to track their glucose levels in real time, enabling them to better manage their disease. What's wonderful about this business is that Dexcom operates a razor-and-blades business model. Each consumer that signs up gets locked into buying the company's high-margin consumables for years. With more patients signing up every day, Dexcom's revenue growth has been extraordinary. In turn, the stock price has soared. DXCM Revenue (TTM) data by YCharts . Thankfully, even today Dexcom believes that it has still only scratched the surface of what's possible. While roughly 200,000 patients are active Dexcom users, that's still just a tiny fraction of the 29 million Americans that have diabetes. The opportunity looks even bigger when you zoom out to include the rest of the world. On the downside, Wall Street has caught on to Dexcom's growth potential and has priced its shares accordingly. The company is currently trading at 13 times sales , which is an unbelievably expensive premium. With medical device giant Medtronic gearing up to launch the first artificial pancreas , it is possible that Dexcom's growth rate could start to slow. If true, then traders might find Dexcom's nose-bleed valuation to be too rich, and shares could take a tumble. The better buy While some investors might find MannKind's tiny share price to be attractive, I for one think its stock is too risky to touch. That's why I'd vastly prefer to buy Dexcom instead, even though the company's stretched valuation makes it a risky stock, too. Still, Dexcom is rapidly expanding, nearing profitability, and has a debt-free balance sheet. That makes it the better buy in my book. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of February 6, 2017 Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-03-10,19.4275,19.625,19.2125,19.585,
DXCM,2017-03-13,19.4425,19.625,19.225,19.4,
DXCM,2017-03-14,19.29,19.6175,19.225,19.3675,"[""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ..."", ""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ..."", ""John Paulson Buys Time Warner, Harman International Industries, B/E Aerospace, Sells American ...""]"
DXCM,2017-03-15,19.2625,19.5825,19.2625,19.3025,
DXCM,2017-03-16,19.42,19.545,19.1875,19.345,"[""The Fed Acted Rationally - Cramer's Mad Money (3/15/17)"", ""Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma"", ""Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma"", ""The Fed Acted Rationally - Cramer's Mad Money (3/15/17)"", ""Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma"", ""The Fed Acted Rationally - Cramer's Mad Money (3/15/17)""]"
DXCM,2017-03-17,19.32,19.8475,19.1175,19.7225,"3 Top Diabetes Care Stocks to Buy in 2017 Nearly 30 million Americans have diabetes -- a condition where the body fails to properly metabolize sugar. Left untreated, that sugar builds up in the bloodstream and the body, which can lead to a number of serious additional health problems such as cardiovascular disease, kidney disease and eye disease. Treating diabetes is expensive, costing America alone some $322 billion each year. Naturally, a market that big has attracted plenty of companies to focus on the disease state. Novo Nordisk (NYSE: NVO) , Insulet (NASDAQ: PODD) , and DexCom (NASDAQ: DXCM) are three such businesses, and I think that they all could be great choices for investors. The value play Many people who have diabetes take drugs to help keep their blood sugar levels in check. One of the long-term leaders in the industry is Novo Nordisk, a Danish drugmaker that has been selling insulin for nearly a century. Novo's top line has charged upward for years as it brought new treatments to market. Recent hits include Tresiba, a long-acting insulin that has been taking share from Sanofi 's megahit Lantus, and Victoza, a GLP-1 inhibitor that lowers blood sugar levels and tends to help some patients lose weight. Novo also boasts a number of new drugs that should be coming to market soon, such as the recently FDA-approved Xultophy, which combines Victoza and Tresiba, and Fiasp, an ultra-fast rapid-acting mealtime insulin. And yet, despite its long history of successful drug development and its leadership position in treating an increasingly common disease, Novo's share price and valuation have been crushed over the past year. NVO data by YCharts What gives? You can blame the decline on increasing pricing pressure from insurers on the company's legacy products. To maintain its market share, Novo has been offering discounts. As a result, management dropped its long-term profit growth target from 10% to 5%. While the waning profit growth is disappointing, I can't help but think that the markets have overreacted. Novo's still cranking out profits, and it has a huge tailwind at its back, so I can't help but like its long-term prospects. With shares trading at a discount and offering up a dividend yield approaching 4%, I think this is a top stock for conservative investors to consider. No tubes for you Not every person who has diabetes requires insulin injections to stay healthy, but millions of them do. Those daily injections can be a pain, and dosing with precision can be difficult, which is why many insulin-dependent patients prefer instead to use an insulin pump. However, wearing a pump presents its own issues. Traditional insulin pumps require tubing, which can easily get snagged or tangled during everyday living. To solve that problem, Insulet launched a patch pump called the OmniPod that is worn directly on the body and disposed of after three days of use. The device is also waterproof and features automatic cannula insertion, which makes it far easier for patients to place it in tough to reach spots. Insulet's unique tube-free system has allowed it to gobble up market share over the last decade. Better yet, the company's ""razor-and-blade"" business model creates a lot of recurring revenue. When combined, the company's top-line -- and share price -- have soared. PODD Revenue (TTM) data by YCharts While Insulet is still losing money, there's reason to believe that profits could finally be on the horizon. Revenue from the company's core OmniPod business is still growing by double-digit percentages both stateside and abroad. Meanwhile, the other drug delivery business is growing nicely, powered mostly by the company's partnership with Amgen . Margins are also on the rise and are expected to continue to push higher. Longer term, CEO Patrick Sullivan expects the company to pump out more than $1 billion in revenue. If the company can hit that ambitious target, its top line would nearly triple. Of course, Wall Street is aware of the company's potential and has priced shares at more than seven times sales. While that's a pricey valuation, if the company can deliver on its growth targets, I could easily see shares continuing to outperform from here. I sense a good opportunity Many people with diabetes are required to measure their blood sugar levels at various times during the day in order to ensure it is within a healthy range. For most, this requires a finger prick to obtain a small blood sample that is tested on a monitor. As you may guess, this isn't a process that many people like. In an effort to ease this burden, Dexcom launched a small medical device a decade ago that is worn on the body for up to seven days and continuously measures blood glucose levels. This information is then uploaded directly to a smartphone or other receiver, making it far easier for users to track their blood sugar, and allowing them to do it in real time. This product -- now called the Dexcom G5 Mobile Continuous Glucose Monitoring System -- has been wildly successful. Like Insulet, Dexcom also benefits from a razor-and-blade business model, which has allowed the company's revenue to soar. In turn, long-term shareholders have been extremely well rewarded. DXCM Revenue (TTM) data by YCharts Despite its history of success, there's reason to believe that DexCom's growth engine is just getting warmed up. The company only counts 200,000 patients as active users, just a small fraction of the 415 million people with diabetes worldwide. While Dexcom is still losing money, that's expected to change in 2017. However, Wall Street has caught on to this growth story and is valuing the company at 11 times sales. Despite that nose-bleed valuation, I still think shares could be worth owning since the company is closing in on profitability and staring down a massive growth opportunity. Share prices are likely to remain volatile for the foreseeable future, but if you are a growth investor at heart, I think that DexCom is certainly worthy of a closer look. 10 stocks we like better than Novo Nordisk When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of February 6, 2017 Brian Feroldi owns shares of Insulet. The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-03-20,19.7225,20.0156,19.5825,19.905,
DXCM,2017-03-21,19.965,20.1825,19.0275,19.1225,
DXCM,2017-03-22,19.075,19.3,18.7775,19.225,
DXCM,2017-03-23,19.0375,19.39,18.9475,19.02,
DXCM,2017-03-24,19.705,21.0775,19.6925,20.655,"[""Medicare clarifies criteria for coverage of DexCom's G5 CGM System; shares ahead 9%"", ""Medicare clarifies criteria for coverage of DexCom's G5 CGM System; shares ahead 9%"", ""Medicare clarifies criteria for coverage of DexCom's G5 CGM System; shares ahead 9%""]"
DXCM,2017-03-27,20.53,20.9,20.395,20.85,"DexCom Gains as CMS Announces Criteria for G5 Mobile CGM The markets seem to be happy with South San Francisco, CA-based DexCom, Inc.DXCM . The company's stock price rallied 4.8% to close at $82.62 yesterday following its announcement, that the Centers for Medicare & Medicaid Services (CMS) published an article clarifying the criteria for coverage of its DexCom G5 Mobile CGM (continuous glucose monitoring) system for patients with diabetes and on intensive insulin therapy. DexCom G5 Mobile is the only FDA approved glucose measurement device for therapeutic decision making. Per management, CMS has mentioned four criteria for patients to be covered by the G5 Mobile therapeutic system. Eligible patients must have either Type 1 or Type 2 diabetes and require daily injections of insulin or the use of a continuous subcutaneous insulin infusion pump. Furthermore, patients should have been using a home blood glucose monitor and performing frequent blood glucose monitoring testing for a long time. The DexCom G5 Mobile CGM has been significantly boosting the company's top line over the recent past. Interestingly, the platform has a number of FDA submissions on track that include a reliable touch screen receiver, a new insertion system and corresponding smaller transmitter and an Android platform, which is expected to be launched in the U.S. by mid-2017. DexCom, Inc. Price DexCom, Inc. Price | DexCom, Inc. Quote Stock Performance A glimpse at the share price trend over the past three months reveals a promising scenario. DexCom gained a stellar 35.5%, outshining the Zacks classified Medical Instruments sub-industry's return of 8.03%. Furthermore, the current return of the stock is well ahead of the S&P 500's return of 16.4% over the same time frame. On the flip side, the estimate revision trend looks dismal. For the full year, 12 analysts moved south over the last two months compared to no movement in the opposite direction. As a result, the current year estimates are pegged at a loss of 57 cents per share, 128% wider than a loss of 25 cents estimated two months ago. Despite the bullish price trend, the disappointing analyst sentiments indicate looming concerns ahead. Notably, DexCom has a Zacks Rank #3 (Hold). Bottom Line We believe the glucose monitoring market represents significant commercial opportunity for DexCom. Furthermore, the diabetes market is booming at the moment, courtesy of the ageing population, inappropriate dietary habits and increasingly sedentary lifestyles. To substantiate the sentiment, a research report by the Allied Market Research reveals that the global markets for Continuous Glucose Monitoring is expected to reach a worth of $568.5 million by 2020, multiplying at a CAGR of 14.8%, with North America being a key market segment. However, cut-throat competition in the market for blood glucose monitoring devices is a major headwind. The introduction of products by other companies will also make it challenging for DexCom. Stocks to Consider Better-ranked stocks in the broader medical sector include Inogen Inc. INGN , Avinger, Inc. AVGR and Fluidigm Corporation FLDM . Notably, Inogen sports a Zacks Rank #1 (Strong Buy) while Fluidigm and Avinger carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 89.4%. Avinger projects sales growth of 30.63% for the current year. Additionally, the company has projected earnings per share growth rate of 39.53% for the current year. Fluidigm has a long-term expected earnings growth rate of 25%. The stock posted a positive earnings surprise of 1.6% in the last reported quarter. Zacks' Top 10 Stocks for 2017 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inogen, Inc (INGN): Free Stock Analysis Report Avinger, Inc. (AVGR): Free Stock Analysis Report Fluidigm Corporation (FLDM): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-03-28,20.7875,21.075,20.7328,21.0025,
DXCM,2017-03-29,21.08,21.58,20.94,21.2975,
DXCM,2017-03-30,21.3025,21.3725,21.0279,21.2575,
DXCM,2017-03-31,21.1725,21.4175,21.12,21.1825,
DXCM,2017-04-03,21.1875,21.33,20.7325,20.9925,
DXCM,2017-04-04,20.9375,21.195,20.3772,20.475,"3 Hot Stocks to Buy in April It's natural for investors to shy away from buying high-flying stocks. However, sometimes a stock takes off because of thesis-changing news. When that happens, it can sometimes make sense to buy, even after a stock has gone on a big run. Dexcom (NASDAQ: DXCM) , Shopify (NYSE: SHOP) , and Portola Pharmaceuticals (NASDAQ: PTLA) are three stocks that have all soared at least 40% since the start of the year. Here's why investors can believe that the good times will continue from here. Dexcom: Up 42% Shareholders of the diabetes-focused medical-device company can thank two big announcements for the stock's big year-to-date rally. First, Dexcom provided investors with a sneak peek at its fourth-quarter results during the 2017 J.P. Morgan Healthcare conference . Management said revenue would be about $168 million, representing 28% growth over the year-ago period. The company also guided for revenue to grow another 25% to 30% in 2017. Those figures compared favorably with what Wall Street had expected, sending shares screaming higher. A few months later, Dexcom shared the wonderful news that people with diabetes who have Medicare can finally obtain reimbursement for the company's continuous glucose-monitoring system. In addition, Dexcom's G5 Mobile is currently the only system that fits the FDA's criteria to justify coverage. That fact should provide Dexcom with a near monopoly among this patient population. It's worth pointing out that Dexcom's management team gave 2017 revenue guidance before the Medicare news hit the wire. That could mean management didn't bake that information into its forecast, so revenue might sail past that already lofty projection. If true, it wouldn't surprise me to see shares continue their upward trajectory. Shopify: Up 68% While the brick-and-mortar retail landscape is currently in a funk, the e-commerce retail space continues to be red hot. One company greatly benefiting from the shifting consumer landscape is Shopify, a leading provider of cloud-based e-commerce software for small- and medium-sized businesses. Shopify helps hundreds of thousands of businesses conduct business online. The company's software makes it easy for these businesses to create a website, process payments, manage inventory, track shipping, and more. Accessing these services requires a monthly fee that starts at $29, which is a low enough price point to attract even price-sensitive customers. When Shopify reported its fourth-quarter results, investors were blown away to learn that the company's customer count soared to 375,000 businesses. That's up sharply from the 243,000 it recorded in the fourth quarter last year, which helped drive total revenue up 86% year over year. Despite its success, Shopify believes it has still only scratched the surface of what's possible. The company estimates that 11 million businesses could use its product just in the areas it currently operates in. Zoom out to the entire world, and that number jumps to 46 million. If the company can continue to produce outstanding quarterly reports, I wouldn't be shocked at all to see shares continue to rise. Portola Pharmaceuticals: Up 74% 2016 was a rough year for Portola Pharmaceuticals. Shares nosedived after the FDA gave the thumbs-down to AndexXa, the company's antidote to Factor Xa inhibitors such as Johnson & Johnson 's Xarelto and Bristol-Myers Squibb and Pfizer 's Eliquis. Mixed results from a phase 3 trial involving Portola's own Factor Xa inhibitor betrixaban only added to the worries. When added together, shares plunged by more than 50%. Since then, a handful of upbeat announcements from 2017 has reversed the stock's decline. First, management told investors it expects to resubmit AndexXa to the FDA in the second quarter. That could put it on pace for an approval by late 2017 or early 2018. Next, Portola got some good news from the FDA related to its pending approval of betrixaban. The agency told Portola that it didn't identify any issues that would require an advisory committee meeting. Given that betrixaban has been granted both fast-track designation and priority review, investors took this news to mean that the drug stands a good chance of winning the thumbs-up by its PDUFA date of June 24. Finally, investors cheered the company's decision to raise $150 million through a non-dilutive royalty agreement. The terms provided Portola with a $50 million upfront payment and an additional $100 million if the FDA approves AndexXa. In exchange, the company agreed to pay a tiered, mid-single-digit royalty based on worldwide sales. When coupled with the company's $319 million in cash at year's end, Portola looks to have plenty of financing lined up. These events set up Portola to potentially announce the approval and launch of both AndexXa and betrixaban over the next 12 months. If everything goes according to plan, then I could easily see more gains ahead. 10 stocks we like better than Shopify When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Shopify wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of February 6, 2017 Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Johnson and Johnson and Shopify. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-04-05,20.51,20.5748,19.9475,20.0125,
DXCM,2017-04-06,20.075,20.1125,19.65,20.0625,
DXCM,2017-04-07,19.9375,19.9875,19.61,19.69,
DXCM,2017-04-10,19.5475,19.7575,19.51,19.525,
DXCM,2017-04-11,19.625,19.6525,19.0125,19.2725,
DXCM,2017-04-12,19.2375,19.3675,19.1312,19.1925,
DXCM,2017-04-13,18.695,19.1325,18.155,19.015,"Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes? Last fall, Medtronic (NYSE: MDT) won FDA approval of a closed-loop system that automatically tracks blood sugar levels and delivers insulin as necessary. The system is being heralded as a major advance in treating diabetes, because it significantly reduces the need for finger sticks and insulin shots. Will this new device be a hit? Solving a big problem There are about 1.25 million Americans with Type 1 diabetes, and for these patients, managing their blood sugar levels can seem like a full-time job. Type 1 diabetes patients must regularly check their blood sugar levels with finger sticks, and then dose themselves with insulin when blood sugar levels require it. Unfortunately, this scattershot approach to managing the disease results in many patients failing to maintain appropriate blood glucose levels, especially at night, or when exercising. Because time spent outside of desired blood sugar ranges can accelerate disease progression and lead to life-threatening conditions, inadequately controlled diabetes remains a big problem. Fortunately, medical device makers have developed new technology like insulin pumps and continuous glucose monitors that help patients better control their disease, however, until now, there wasn't a FDA-approved closed-loop system for the monitoring and dosing of insulin available. The FDA gave Medtronics MiniMed 670G a green light after trial results showed that it helped patients remain within their desired blood sugar range over a three-month period. The trial included both adults and children with Type 1 diabetes, and A1C levels fell from 7.7% to 7.1% in children and from 7.3% to 6.8% in adults. There also was a 44% decline in time spent with blood glucose below 70 mg/dL and a 40% decline in time spent with dangerous hypoglycemia, or levels below 50 mg/dL. What it does The MiniMed 670G uses sensors to automatically monitor blood glucose levels every five minutes and it uses a pump to automatically administer insulin as it's needed. A daily finger-stick is still required to calibrate the system, and the insulin pump needs to be refilled every few days, but the system still significantly reduces the treatment burden on patients. The MiniMed 670G system includes a sensor that's attached to the body and that must be changed weekly, an insulin pump that's worn on the waist, and an infusion patch that connects to the pump to administer insulin via a catheter. Medtronic's device is an important advance in automating diabetes treatment, but it's not approved for use in Type 1 diabetes patients who are younger than 14 (yet), it still requires some patient involvement, and it's arguably a bit bulkier of a solution for active patients, who may prefer wireless pumps, such as Insulet 's(NASDAQ: PODD) Omnipod. Omnipod is a tubeless insulin management system that delivers insulin for up to three days using a wireless programming device. Oftentimes, patients pair Omnipod up with a continuous glucose monitor, such as those made by DexCom (NASDAQ: DXCM) , to provide even better control of their disease. What's next Medtronic only began shipping the MiniMed 670G to patients recently, so the verdict isn't in on whether it will win away consumers from these other solutions. If it does, then it could be an important new source of revenue for Medtronic. However, that tailwind could only be temporary, because the MiniMed 670G may face stiff competition soon. Insulet, for example, is working on its own closed-loop system that incorporates DexCom's sensors, and if trials are successful, its system could be available as soon as next year. Similar systems are also being developed by Tandem and Bigfoot Biomedical, so you'll want to pay attention to their progress, too. 10 stocks we like better than Medtronic When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medtronic wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of April 3, 2017 Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-04-17,19.0575,19.1525,18.7925,18.81,
DXCM,2017-04-18,18.7625,18.825,18.36,18.44,"DexCom is Now Oversold (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $73.44 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 43.3. A bullish investor could look at DXCM's 28.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $57.68 per share, with $96.38 as the 52 week high point - that compares with a last trade of $73.85. According to the ETF Finder at ETF Channel, DXCM makes up 1.71% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading relatively unchanged on the day Tuesday. Find out what 9 other oversold stocks you need to know about » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-04-19,18.45,18.6275,18.185,18.525,"Add Up The Parts: FXH Could Be Worth $68 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDEX Fund ETF (Symbol: FXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $67.51 per unit. With FXH trading at a recent price near $61.52 per unit, that means that analysts see 9.74% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FXH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), United Therapeutics Corp (Symbol: UTHR), and ABIOMED, Inc. (Symbol: ABMD). Although DXCM has traded at a recent price of $73.76/share, the average analyst target is 18.67% higher at $87.53/share. Similarly, UTHR has 14.89% upside from the recent share price of $121.08 if the average analyst target price of $139.11/share is reached, and analysts on average are expecting ABMD to reach a target price of $137.17/share, which is 13.20% above the recent price of $121.17. Below is a twelve month price history chart comparing the stock performance of DXCM, UTHR, and ABMD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-04-20,18.5875,19.0625,18.525,18.975,
DXCM,2017-04-21,18.9325,19.03,18.7987,18.8075,
DXCM,2017-04-24,19.0975,19.2175,18.7025,18.7225,
DXCM,2017-04-25,18.75,18.9825,18.6675,18.735,
DXCM,2017-04-26,18.8425,19.073,18.6475,18.92,
DXCM,2017-04-27,19.2025,19.8558,19.1725,19.4825,"[""William Blair Initiates Coverage On DexCom with Outperform Rating"", ""Benzinga's Top Upgrades, Downgrades For April 27, 2017"", ""Benzinga's Top Upgrades, Downgrades For April 27, 2017"", ""William Blair Initiates Coverage On DexCom with Outperform Rating"", ""Benzinga's Top Upgrades, Downgrades For April 27, 2017"", ""William Blair Initiates Coverage On DexCom with Outperform Rating""]"
DXCM,2017-04-28,19.705,19.745,19.3475,19.49,
DXCM,2017-05-01,19.475,19.98,19.4504,19.9,"Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More The first-quarter earnings season has gathered pace, with results from 288 S&P 500 members or 63.8% of the index's total market capitalization already out (as of April 28). As per the latest Earnings Preview , total earnings for these companies are up 13.7% from the same period last year on 8.2% higher revenues, with 76.4% beating EPS estimates and 68.1% beating revenue estimates. The proportion of companies beating both EPS and revenue estimates is 55.2%. For the remaining 212 index members (combined with the already reported 288 index members), earnings are estimated to improve 11.2% on 6.2% higher revenues this season. Notably, this could be the third straight quarter of earnings growth after five quarters of back-to-back decline. The current week is set to see a plethora of earnings releases as many bigwigs are lined up to report their quarterly numbers. This week will bring in results from more than 1000 companies, including 126 from the S&P 500 index. Coming to the Medical universe, this is one of the major broader sectors among the 16 Zacks sectors in the S&P 500 cohort that are expected to report earnings growth in the first quarter. The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things. Furthermore, cost-effective products and techniques targeting emerging markets raise optimism. Here, we take a sneak peek into four Medical stocks set to report their quarterly figures on May 2: Based in Franklin Lakes, NJ, Becton, Dickinson and CompanyBDX , commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. Our proven model conclusively shows that Becton, Dickinson is likely to beat on earnings in first-quarter fiscal 2017. This is because the company currently has an Earnings ESP of +0.45% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . BD's innovative product line, number of regulatory approvals both in the U.S. and international markets, and strategic partnerships are likely to boost its growth trajectory (read more: Is a Surprise Coming for Becton This Earnings Season? ). Becton, Dickinson and Company Price and EPS Surprise Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote DexCom, Inc.DXCM is scheduled to report first-quarter 2017 numbers on May 2. This medical device company is focused on the design, development and commercialization of continuous glucose monitoring systems. Intensifying competition, entry of new products, reluctance on the part of physicians and patients to adopt DexCom's products, reimbursement risks, supply constraints and working capital problems are the key concerns. DexCom currently has a Zacks Rank #3 (Hold) and an Earnings ESP of -10.91%. That is because the Most Accurate estimate stands at a loss of 61 cents while the Zacks Consensus Estimate is pegged at a loss of 55 cents. Hence, we cannot conclusively predict that DexCom is likely to beat estimates this quarter. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . DexCom, Inc. Price and EPS Surprise DexCom, Inc. Price and EPS Surprise | DexCom, Inc. Quote Owens & Minor, Inc.OMI is set to report first-quarter figures on May 2, after market close. This is a global healthcare services company that provides vital supply chain services to healthcare providers and manufacturers of healthcare products. It also provides logistics services across the spectrum of medical products from disposable medical supplies to devices and implants. Our proven model does not conclusively show that Owens & Minor is likely to beat on earnings in first-quarter fiscal 2017. This is because the company currently has an Earnings ESP of 0.00% and a Zacks Rank #3. This makes surprise prediction difficult. Owens & Minor, Inc. Price and EPS Surprise Owens & Minor, Inc. Price and EPS Surprise | Owens & Minor, Inc. Quote Halyard Health Inc.HYH is expected to release first-quarter fiscal 2017 financial numbers on May 2. Headquartered in Alpharetta, GA, Halyard develops, manufacture and market clinical solutions that improve medical outcomes and business performance in more than 100 countries. Halyard Health is unlikely to surprise as it currently has a Zacks Rank #4 (Sell) and an Earnings ESP of 0.00%. Both the Most Accurate estimate and the Zacks Consensus Estimate stands at 43 cents. Also, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement. Halyard Health, Inc. Price and EPS Surprise Halyard Health, Inc. Price and EPS Surprise | Halyard Health, Inc. Quote Sell These Stocks. Now. Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks """"Strong Sells"""" absolutely free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Owens & Minor, Inc. (OMI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report Halyard Health, Inc. (HYH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-05-02,19.9625,20.4775,19.666,20.4125,"[""DexCom Reports Q1 EPS $(0.49) vs $(0.50) Est., Sales $142.3M vs $144.47M Est."", ""DexCom Reports Q1 EPS $(0.49) vs $(0.50) Est., Sales $142.3M vs $144.47M Est."", ""DexCom Reports Q1 EPS $(0.49) vs $(0.50) Est., Sales $142.3M vs $144.47M Est.""]"
DXCM,2017-05-03,18.625,19.125,18.175,18.4775,"[""Bank of New York Mellon Corp Buys Citigroup Inc, iShares Core S&P Small-Cap, GGP Inc, Sells ..."", ""BTIG Research Downgrades DexCom to Neutral"", ""BTIG Research Downgrades DexCom to Neutral"", ""Bank of New York Mellon Corp Buys Citigroup Inc, iShares Core S&P Small-Cap, GGP Inc, Sells ..."", ""DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss DexCom Inc.DXCM reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents. However, the figure was wider than the loss of 23 cents reported in the year-ago quarter. Interestingly, Dexcom posted a positive earnings surprise in the last quarter as well. Getting back to the quarter, total revenue grew to $142 million, reflecting an increase of 22.4% from $116 million in the year-ago quarter. However, the figure lagged the Zacks Consensus Estimate of $144 million. Dexcom Inc. - Earnings Surprise | FindTheBest Operational Details DexCom generated a gross margin (as a percentage of revenues) of 66%, compared with 65% for the same quarter in the prior year. Notably, gross margin was slightly below management's anticipated range for the quarter, thanks to a drop in first-quarter sales. International business showed continued year-over-year growth in the quarter, generating $26 million in revenues, up 37% on a year-over-year basis. Notably, international business represented 18% of total revenue in the first quarter. Particularly, Germany fueled almost 37% growth outside the U.S. in the quarter. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Research and development (R&D) expenses totaled $48 million in the quarter, compared with $32 million a year ago. The company's R&D investments include the G6 pivotal study and related submissions with the FDA. Selling, general and administrative expenses totaled $86 million in the reported quarter, compared with $62 million in the same quarter of 2016. The rise was primarily due to year-over-year increases in head count in customer support organizations, higher marketing expenses and escalating IT costs. Financial Update As of Mar 31, 2017, DexCom had $181.1 million in cash, cash equivalents and short-term marketable securities. Guidance This Zacks Rank #3 (Hold) company projects global revenues in the band of $710 million to $740 million, reflecting growth of approximately 25% to 30%. For the full year, DexCom anticipates gross margin at the low end of the 67% to 70% guidance. Key Picks Better-ranked stocks in the broader medical sector include Neovasc Inc. NVCN , Hologic, Inc. HOLX and Sunshine Heart Inc SSH . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 33.7%. Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock recorded a stellar EPS growth rate (last 3-5 years of actual earnings) of almost 22%. Neovasc saw a stellar gain of 12.5% over the last three months. The company projects sales growth of 102.88% for the current year. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis Report Neovasc Inc. (NVCN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BTIG Research Downgrades DexCom to Neutral"", ""Bank of New York Mellon Corp Buys Citigroup Inc, iShares Core S&P Small-Cap, GGP Inc, Sells ...""]"
DXCM,2017-05-04,18.65,18.8825,18.28,18.8438,
DXCM,2017-05-05,19.0875,19.6225,18.9125,19.0525,
DXCM,2017-05-08,18.8,18.9675,18.205,18.35,
DXCM,2017-05-09,18.25,18.25,17.985,17.9975,
DXCM,2017-05-10,17.9825,18.1675,17.5675,17.775,
DXCM,2017-05-11,17.8,18.08,17.215,17.235,"Why Apple Inc. (AAPL) Stock Can Count on the Apple Watch InvestorPlace - Stock Market News, Stock Advice & Trading Tips Apple Inc.'s (NASDAQ: AAPL ) Apple Watch was released in 2015 to much fanfare and analyst interaction. The smartwatch has changed the market and absolutely dominated a growing industry. The company doesn't release sales figures, but industry experts have highlighted just how big of a lead it has for smartwatches. New reports on Apple getting into the glucose monitoring market via the Apple Watch could boost sales of the watch even further. If it can win here, it would make the Apple Watch and AAPL stock both must-owns for many. Source: Apple In April, the Apple Watch celebrated its two year anniversary as one of many innovative Apple products that have become must-haves for technology lovers and users who like the easy to use items from the company. Once considered a horrible idea or a flop, the Apple Watch has actually outsold Rolex over the last 12 months. To find out just how popular the watch is and what impact it has on the finances of AAPL stock, you have to dig a little deeper. Apple does not break out the individual performance of the Apple Watch, rather placing it in a category called Other Products with the iPod, Airpods and Beats headphones. In AAPL's first fiscal quarter, the company saw record sales of the iPhone, Mac and Apple Watch. Company CEO Tim Cook said , ""It was also our best quarter ever for Apple Watch, both units and revenues, with holiday demand so strong that we couldn't make enough."" Research firm Strategy Analytics estimates that AAPL shipped 5.2 million Apple Watch units and had 63% market share for smartwatches during the important holiday quarter. What Can the Apple Watch Do for AAPL? Apple reported second-quarter earnings last week and showed the dominance of the Apple Watch in its category again. Sales of the watch nearly doubled from the prior year and helped boost the performance of the Other Products category once again. Apple CEO Tim Cook called the performance ""phenomenal growth"" and said, ""We couldn't be more satisfied with it"". Interestingly enough, if AAPL's Other Products category was its own company, sales of the Apple Watch, Airpods and Beats would be enough to make it a Fortune 500 company. 7 Stocks to Buy on the Next Big Market Dip The Other Products category saw quarterly revenue of $2.9 billion. While that was a far cry from the $33.2 billion seen in sales from the iPhone in the quarter, the Other Products led the way in terms of growth. The category, which includes the Apple Watch, saw a year-over-year increase of 31%, compared to gains of 18% for Services and 14% for Mac. Revenue from iPhones grew only 1% and sales of the iPad fell 12%. Recently, the Apple Watch gained more attention as CNBC highlighted Apple's secret plans on making the device a potential entrant in the glucose monitoring market. AAPL has a small team of engineers developing glucose sensors over the last five years. The glucose sensor market was a long-term vision of former Apple founder Steve Jobs. The former CEO saw wearables as a possible way for the company to be involved in the life sciences market. Jobs thought wearables could eventually track oxygen levels, heart rates and blood glucose levels. Apple entering the diabetes market shouldn't come as a big surprise to the industry or investors. Large technology companies continue to diversify and invest where there is money to be made as technology evolves. Rival Alphabet Inc (NASDAQ: GOOG , NASDAQ: GOOGL ) is working on a diabetes project of its own, which I covered here recently. Alphabet's Verily Life Sciences division is working with Novartis AG (ADR) (NYSE: NVS ) on a smart lenses project that would help diabetics track their blood glucose levels. Sony Corp (ADR) (NYSE: SNE ), Samsung (OTCMKTS: SSNNF ) and other companies are also working on their own versions of smart lenses. The diabetes market continues to be one of the largest in terms of revenue possibilities for companies. With limited treatment options, it is also one of several holy grails for the industry. In my Alphabet article, I pointed out that diabetes is one of the leading causes of deaths with more than 70,000 a year in the U.S. In 2015, around 50% of the U.S. adult population was diabetic or pre-diabetic, representing a huge market. The global diabetic care device market was worth $18.5 billion in 2015 and is seen rising to $26 billion, according to Zion Market Research . Investors have already recognized how valuable the glucose monitoring market is. Small cap DexCom, Inc. (NASDAQ: DXCM ) has watched its stock soar 636% in the last five years. The device maker company now sports a market capitalization of $6.5 billion and is up 28% in 2017. DexCom saw its DexCom G5 device approved as the only mobile CGM (constant glucose monitor) on the market. The device places a small sensor underneath the skin and then sends constant glucose readings to the person's device, cutting out the need to prick a finger every hour or monitor gaps in testing due to work or school. In the most recent first quarter, DexCom saw revenue grow 22% to $142.3 million. International sales increased 37%. The DexCom G5 is covered by Medicare and picking up coverage as a leading option for diabetic patients. Imagine if Apple can get a product similar to this to the masses with its huge distribution network, retail stores and brand appeal. Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Bounce Now DexCom stock may not be done running either. The company has ambitious goals and a partnership with Alphabet's Verily division. The goal is to bring a mini glucose monitor to the market and by 2021 has an even smaller disposable glucose monitor the size of a band-aid. With the company's strong relationship with Verily, DexCom is likely more of an acquisition by Alphabet than Apple, but keep a close watch here. Bottom Line on AAPL Stock While analysts and investors may think The Apple Watch having relevance in the diabetes testing market may be a long ways off, it could be much closer than thought. AAPL is currently doing feasibility studies and has hired consultants to help with the regulatory path for the Apple Watch being approved as a testing device. Apple has hired biotechnology experts from other companies to help in this process. An Apple Watch device that can monitor blood glucose levels with a good degree of accuracy will make the product a possible must own for diabetics. This should be music to the ears of owners of APPL stock. While the iPhone is the company's bread and butter, other areas like services, Apple TV and the Apple Watch are helping the company diversify and provide a better glimpse into the future of one of the world's most valuable companies. As of this writing, Chris Katje did not hold a position in any of the aforementioned securities. More From InvestorPlace 7 Stocks to Sell Thanks to TERRIBLE Seasonality 7 Stocks That Will Get Crushed in The Next Crash The Tesla Inc (TSLA) Solar Roof Is Available ... And Cheaper! The post Why Apple Inc. (AAPL) Stock Can Count on the Apple Watch appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-05-12,17.235,17.655,17.1775,17.605,
DXCM,2017-05-15,17.6625,18.04,17.5675,17.8825,"What's Alphabet Got to Do With Healthcare? Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) has a treasure trove of data at its fingertips, and it's been more than willing to spend its financial firepower to take moonshots that could disrupt industries. These moonshots include collaborations with healthcare companies, including Medtronic (NYSE: MDT) and Dexcom (NASDAQ: DXCM) , that could eventually reshape healthcare. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell discuss Alphabet's efforts to create new devices that could help patients live longer. A full transcript follows the video. 10 stocks we like better than Alphabet When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of May 1, 2017 This video was recorded on May 10, 2017. Kristine Harjes:Novartis is working with Alphabet's Google's Verily, which was formerly Google Life Sciences, on a smart contact lens that you put in your eye like a normal contact, and it measures blood sugar levels from your tears. So what they're hoping to do is have it change color if the levels aren't within normal range. That's straight sci-fi right there. Todd Campbell: That is crazy. That is fascinating. And then, of course, you have Verily, which is part of Alphabet/Google, however you want to refer to them. Verily is working on a program with Dexcom to create sensors that peel off like little Band-Aids. Obviously, this is going to become a much, like you said, less invasive way of being able to track a disease and provide more information, and then hopefully that information can be used by the patient to at least delay disease progression so that they're not ending up with cardiac risk and risk of death later on in life. Harjes: Right. This is another example of a tech specialist, Google, working with a healthcare-device specialist, which is Dexcom. Dexcom, in case you're not familiar with them, are a continuous glucose monitor, CGM, specialist. Dexcom has all these awesome CGMs that they've already developed, and now they see this tremendous advantage in being able to harness Google's analytic capabilities to make this better. They're working with Verily on developing a CGM that's no bigger than a Band-Aid. There would still be some insertion, because their system is based on a wire, but they're looking at ways other than a needle to insert it, which would not just be a better experience, but hopefully take the cost down. Campbell: You know what's fascinating to me, Google is always on the cutting edge, in the way that they're doing research and discovering new ways and new approaches. They're not just a search engine. A few years ago, they came out with Google Glass. I don't know if our listeners remember Google Glass. Maybe some of them still have them kicking around. It's a head-up display that you attach to your glasses that allows you to access the internet, access information, and communicate with, say, your computer or PC. There are companies out there today that are still using Google Glass to improve healthcare. For example, there's a small company out in California called Augmentix. Augmentix works with physicians. Physicians will walk in to a primary care appointment wearing Google Glass; they'll be able to, through a scribe back at Augmentix HQ, be able to communicate and spend more time with the patient and spend less time on the paperwork. So basically, the scribe is writing down what's occurring, or taking care of the EHR, or electronic [health] medical record component of a physician's job, via the use of Google Glass. There's all sorts of ways that we're not even contemplating that wearables, be it from Google or Fitbit or Apple , or even [ Amazon.com ], could impact and change healthcare over the course of the coming decades. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Kristine Harjes owns shares of Apple. Todd Campbell owns shares of Amazon and Apple. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, and Fitbit. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-05-16,17.8125,17.8125,17.3675,17.425,"[""Option Alert: Dexcom Jun 70.0 Puts: 500 @ Above Ask! $2.85: 1305 traded vs 1384 OI: Earnings 8/1 After Close (est) $69.65 Ref"", ""Benzinga's Option Alert Recap From May 16"", ""Benzinga's Option Alert Recap From May 16"", ""Option Alert: Dexcom Jun 70.0 Puts: 500 @ Above Ask! $2.85: 1305 traded vs 1384 OI: Earnings 8/1 After Close (est) $69.65 Ref"", ""Will Wearable Technology Make Us Healthier? The potential to improve how we treat patients with chronic diseases, including diabetes, is a massive market opportunity for wearable-technology companies including Fitbit (NYSE: FIT), Apple (NASDAQ: AAPL) , and Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , and collaborations with leading healthcare companies, including Medtronic (NYSE: MDT) , suggest that work is already under way to create wearable technology for patients. In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell discuss the market potential of wearables in healthcare and the challenges facing developers of this technology. A full transcript follows the video. 10 stocks we like better than Apple When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Apple wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of May 1, 2017 This video was recorded on May 10, 2017. Kristine Harjes: Welcome to Industry Focus , the podcast that dives into a different sector of the stock market every day. Today is May 10, and I'm your Healthcare show host, Kristine Harjes. I'm here at Fool HQ just outside of Washington D.C., and I have Motley Fool healthcare contributor Todd Campbell calling in from New Hampshire. Todd, welcome. What is the most interesting thing you've written since the last time we talked? Todd Campbell: I don't know what the most interesting thing I have written is. I like to think all of what I write is interesting, and all of what you can find on The Motley Fool is fascinating. [laughs] But I think today's show is going to be absolutely interesting. Harjes: Yeah, I hope so. We've talked on the show before about the intersection between technology and healthcare. One show that comes to mind in particular was when I had Motley Fool analyst Simon Erickson come on while he was at South by Southwest, which is a tech conference, but with each passing year it seems like there's more more interest in healthcare from the tech world. So today, we wanted to dive in to one particular area where tech companies are working in the healthcare space, and that is diabetes. Campbell: This is going to be a very interesting show, because we're going to be talking about the future, or what the future could look like, in treating diseases like diabetes using wearables, things that we have on our wrists every day already. Harjes: Exactly. This is an enormous opportunity, which is why the tech world is so interested in it. If you look at America, one-third of people in the United States are obese, and 9.3% of them have diabetes already. And this is a problem that's only getting bigger. Campbell: No pun intended, right? Harjes: Yeah, that was no pun intended at all. Campbell: One-point-nine billion adults over 18 are overweight. Six hundred million adults obese. Thirteen percent of the adult population, obese. The prevalence of obesity has more than doubled between 1980 and 2014. Clearly, there's a need for things that help us get moving and help us monitor how good of a job we're doing in getting the exercise we need every day to prevent diseases. That's really why we're talking about it on a Healthcare show. We're not talking about companies like Fitbit because we're interested, necessarily, from the technology standpoint. We're also interested in how these devices can be used to change clinical outcomes. Diabetes and obesity, there is a link. Harjes: The way that I see it, there are two different sides to this story. You have the obesity side, where if you can get yourself living a more healthy lifestyle, you lower your risk of diabetes, or you can better manage your disease. Then, there's also the blood sugar level monitoring, which, if you already have diabetes, is absolutely key. So you see a lot of partnerships and a lot of work being done between healthcare companies and tech companies that are trying to combine data from both of those different sides of this puzzle, to see what is the relationship between activity levels and glucose levels and management of disease. Campbell: What's interesting is that the sensors we're developing now, we have a much better understanding how the body works. The body is such an amazing, incredibly sophisticated system, and we can actually determine how our bodies are doing, as far as their normal processes, by evaluating things like blood sugar in the blood, or evaluating changes in what we excrete through our sweat. Sensors are becoming more and more sensitive, and as a result, they're being able to be used in increasingly more helpful ways. But taking that one step further, these sensors are now getting to a point where they're getting smaller, less intrusive, more easily used by patients. So we're not talking about this big, bulky thing you have to lug around with us anymore. Harjes: Right, and that's important not just because it makes patients' lives easier, but because in theory, that could boost compliance. Campbell: Compliance, let's admit it, it's a big deal. Let's just look at Fitbit. Fitbit has been around for 10 years, and they've sold 63 million devices. There's so many of these devices around, and maybe many of our listeners are wearing them right now. But what's intriguing to me is, as I was researching for today's show, only one in 10 are wearing them on a daily basis, Harjes: Yeah, I believe it. I think Fitbit in general is struggling with not so much initial adoption, but actually sticking with their product. But if they want to really dive into being able to integrate their wearables tracker with something like a continuous glucose monitor, which is something they're working on with Medtronic regularly. You can just tell the people who were just sitting there shaking up and down all day long and counting that as steps. And that's fine if you're doing something like a step competition with your friends -- well, it's not fine, it's not great, but it doesn't have the consequences that it would if somebody is using it in a medical way. And that's not to say that people are trying to cheat their medical data. But even something as simple as brushing your teeth, people sometimes log that as steps, and that's problematic when your doctor is looking at that data. Campbell: Yeah. I was reading one study, Kristine, where a care provider, a hospital system provided a bunch of older patients, I think they were in their 80s, with devices that could be used to measure how much activity they were doing and their heart rate and all of this stuff, and frankly, most of them forgot that they were even wearing them within a few days of wearing them, and forgot to put them on. We have to, obviously, be able to develop systems that are sensitive and give us new insights into, for example, blood sugar levels, so that people can stay within their desired range more frequently throughout the day. But we also have to make it so it becomes something like your watch, where you're actually looking at it every once in awhile. Again, I suppose watches aren't being worn as much as they used to be anyway, because now we have smartphones. How often are you checking your watch? It's going to be like a text message; you're going to have to actually pick up the phone and look at your texts and say, \""I moved this many feet, and my heart rate is this, but what do I do with this information?\"" I think that's part of what Medtronic is trying to accomplish in its push here, is to take all the information it has, from being a huge player in medical devices, especially in diabetes, and be able to marry that with the information that's being collected by the user who's wearing the device, and then being able to take that one step further and actually provide actionable insight that either the caregiver, be it the primary physician or the patient, can use to actually improve their lifestyle, or something. Harjes: Yeah, you're absolutely correct. Medtronic right now is staring down a mountain of data and looking at it and saying, \""We have so much information; how do we derive useful conclusions out of it?\"" They have a partnership with IBM that was announced in April of 2015 that will leverage the artificial-intelligence powers of Watson, which is the supercomputer that won Jeopardy! With Watson, they're going to analyze all these electronic medical record data, I think it's 10,000 EMRs, and they're going to use this population information to develop a real-time personalized care. Todd, as you were saying, it's going to need to come from an app or your phone or something telling you, \""You're showing abnormal patterns,\"" or, \""We've noticed this.\"" That's exactly what they're trying to develop. They created something called Sugar IQ, which is a personalized assistant that can detect patterns of behavior, and it can protect diabetic events hours before they happen, which is really pretty incredible. And it seems to me like they're only getting started with this. Campbell: You know what's interesting, too, is that Massachusetts General Hospital did something where they gave pedometers to patients, and they linked that up with a text-messaging system that would basically say, \""Here's how you're doing; here's some tips.\"" They actually look at the weather, all sorts of things that they put together to try to figure out the best way to make it relevant to the patients. Sure enough, the patients who are receiving these daily tips did better overall in achieving whatever their goal was for their blood sugar levels. So yes, we have all of this information out there, all of this data. On the healthcare side of things, we have companies like Medtronic that have tons of experience in creating medical devices. Then we have the consumer-electronics companies, who have tons of experience generating devices that people want to use. Then, we have healthcare providers who are trying to figure out how can they take all of this, marry it together, and make it into something they can actually use to reduce these rates of obesity, to keep people who are pre-diabetic -- because there are over 80 million Americans who are pre-diabetic -- to keep those from becoming full-blown cases of diabetes and ultimately make it to the cardiovascular disease is no longer the No. 1 killer worldwide. Harjes: This is a multi-faceted problem, which is why it's so interesting to see different types of companies coming at it from all of their angles of expertise. All right, let's turn to a company that I don't think we've mentioned yet on the show but is working in the space, and that's Apple. Campbell: Apple is obviously on the cutting edge when it comes to developing easy-to-use consumer electronics that resonate with people. That's the whole thing, the whole experience. So we were talking before the break, being able to figure out, we want to marry healthcare outcomes with technology with the information we've collected -- how do we do that in a way that really resonates with consumers? And one of the ways that Apple is trying to do that is through its Apple Watch. Harjes: Right. The Apple Watch is a really interesting product, but right now it's kind of a luxury product. And I think if they're able to find a way to make it a must-have for diabetics, that's going to be a game-changer for this product. Campbell: You have apps that tie into both your Apple phone, your Watch. Some of those are healthcare related. You have access to things like heart rate through these devices, being able to track those things. But wouldn't it be great, Kristine, if you could be wearing your Apple Watch and, at the same time that you're wearing it, it's measuring your blood glucose level? Harjes: Absolutely, yeah. One of the big step changes with this project -- which, by the way, Apple is working on this. Despite Apple being shrouded in secrecy about what's next sometimes, a very credible journalist from CNBC reports that they are working in this area. So the step change that I see in this project is that they're looking at a non-invasive continuous glucose monitor sensor. When you talk about reading your glucose levels, it always involves some sort of prick to the finger, or something that is invasive to the body, What they're trying to do is figure out how the Apple Watch could incorporate an optical sensor to read glucose levels just by shining light through the skins, and integrating that with the data that you have on your Apple Watch. Campbell: Which is pretty amazing. I guess the question would be, will that be shining continuously and measuring it continuously? Or will that only be shining at specific intervals? And how often will those intervals be? And that's going to create all sorts of design problems, because you're going to have to figure out, how do you make the battery lights last long enough to be able to do that, potentially? Harjes: What happens when you're charging? Campbell: Yeah. If we go back in time for a second, we've already made huge advances in doing this, as far as, you have companies like Medtronic that now have an artificial pancreas where you have continuous glucose monitoring occurring from a small sensor that is inserted underneath the skin, that you wear in a pump that's delivering blood glucose on demand as it needs to. You have other companies like Dexcom (NASDAQ: DXCM) that are out there that are making huge advances in sensor technology, that are providing real-time, truly continuous readings that people are able to use to chart up and down their blood glucose levels to help them better figure out when they might be crashing, when they might need insulin or not need insulin, or whatever. So Apple, I think you're right, it's a fascinating concept to be able to just use light, and be able to evaluate blood glucose. But it's not as simple as just saying, \""Yeah, we're going to do this.\"" I suppose that's why they haven't rolled it out yet, and why they're being so secretive. Supposedly, they're in the initial test phases of this to try to see whether or not this makes sense. They went out a couple years ago and bought a company that was working on sensors for healthcare to try and give them a little bit more experience in that area. It's hard for me to imagine, honestly, Kristine, that we get, 10, 20 years from now, and it's almost like going to be like we're having our doctor with us on demand. We're going to have so much information, so much data, that we're going to be able to collect just from the clothes we're wearing -- you can buy compression shirts and sleeves now that do a lot of these evaluations, too. They're looking at various different disease indications, being able to measure levels of certain proteins in your sweat to be able to see how your kidneys are performing, all sorts of interesting things that theoretically we could discover and be able to track over the course of the next 10 or 20 years. I think what Apple is saying is, \""We want to make sure we don't get left behind in that movement.\"" Harjes: Exactly. Here's another crazy one: Novartis is working with Alphabet's Google's Verily, which was formerly Google Life Sciences, on a smart contact lens that you put in your eye like a normal contact, and it measures blood sugar levels from your tears. So what they're hoping to do is have it change color if the levels aren't within normal range. That's straight sci-fi right there. Campbell: That is crazy. That is fascinating. And then, of course, you have Verily, which is part of Alphabet/Google, however you want to refer to them. Verily is working on a program with Dexcom to create sensors that peel off like little Band-Aids. Obviously, this is going to become a much, like you said, less invasive way of being able to track a disease and provide more information, and then hopefully that information can be used by the patient to at least delay disease progression so that they're not ending up with cardiac risk and risk of death later on in life. Harjes: Right. This is another example of a tech specialist, Google, working with a healthcare-device specialist, which is Dexcom. Dexcom, in case you're not familiar with them, are a continuous glucose monitor, CGM, specialist. Dexcom has all these awesome CGMs that they've already developed, and now they see this tremendous advantage in being able to harness Google's analytic capabilities to make this better. They're working with Verily on developing a CGM that's no bigger than a Band-Aid. There would still be some insertion, because their system is based on a wire, but they're looking at ways other than a needle to insert it, which would not just be a better experience, but hopefully take the cost down. Campbell: You know what's fascinating to me, Google is always on the cutting edge, in the way that they're doing research and discovering new ways a new approaches. They're not just a search engine. A few years ago, they came out with Google Glass. I don't know if our listeners remember Google Glass. Maybe some of them still have them kicking around. It's a head-up display that you attach to your glasses that allows you to access the internet, access information, and communicate with, say, your computer or PC. There are companies out there today that are still using Google Glass to improve healthcare. For example, there's a small company out in California called Augmentix. Augmentix works with physicians. Physicians will walk in to a primary care appointment wearing Google Glass; they'll be able to, through a scribe back at Augmentix HQ, be able to communicate and spend more time with the patient and spend less time on the paperwork. So basically, the scribe is writing down what's occurring, or taking care of the EHR, or electronic [health] medical record component of a physician's job, via the use of Google Glass. There's all sorts of ways that we're not even contemplating that wearables, be it from Google or Fitbit or Apple, or even [ Amazon.com ], could impact and change healthcare over the course of the coming decades. Harjes: Right. It does feel incredibly nascent right now. One company that I want to mention, because you just reminded me that we haven't mentioned them yet, is Amazon. They, right now, have this diabetes challenge, which is specifically the name of the Echo woman, the voice, I've been told by our listeners that we shouldn't say that during the podcast, because saying her voice will trigger her, and it'll stop what you're doing and wait for a new command. So hopefully you know the girl's name that's I'm talking about. The Echo woman. Anyway, Amazon is partnered with Merck , and they have challenged developers to create an Echo-powered solution to help type 2 diabetics. They are, in July of this year, going to announce the five finalists, then throw them into this virtual accelerator to try to develop the best thing that they can. The winner will end up with $125,000, and that will be announced in September. So, definitely looking forward to seeing what they come up with. Campbell: The Innovation that's going on in these contests, who knows how we'll use our Echo, how Echo and some of these other consumer devices that we wouldn't think of as healthcare devices are going to reshape. The things that we're going to have to remember, remind all of our listeners, because obviously we're coming across as pretty excited about the future of this space, right, Kristine, is that there are some concerns. We have the accuracy of the data. There are some concerns that some of these devices, the information they're collecting, isn't healthcare-quality accurate. We have security and privacy concerns, the sharing of information, who gets to see it, who doesn't get to see it. And then, of course, as we touched on previously, that whole patient adherence component of it, are they going to have that wearable on them all the time or enough of the time to be able to come to good conclusions? Harjes: Yes, and even patient willingness, particularly as it concerns their security and their privacy. There's a whole 'nother level of attachment to your healthcare information that you don't have to, say, how many steps you took in a day. You might be willing to share that across your friend network on the Fitbit app. But do you really want to share it as it pertains to your medical status? Campbell: Kristine, forget about pre-existing conditions. We're talking about previous to existing conditions. Harjes: Yeah, exactly. It'll be interesting. It's definitely a very early stage market. Looking at this from an investing standpoint, it seems to me like all these tech companies that we talked about, most of them are great stocks, but I wouldn't necessarily invest money in them because of their healthcare initiatives, because they're too small at this point. They could be huge opportunities downstream, but I think it's going to be a long time before, say, Apple's healthcare initiatives end up being a meaningful contributor to the business. Campbell: We don't know who the winners or losers will be. It's just way too early, as you said. We know who, so far, the market share leaders are in some of these wearables, Fitbit and Apple being No. 1 and No. 3. Harjes: Yeah, there's actually a pretty big Chinese company that's in the mix, too. Campbell: Yeah, No. 2. Funny thing is, and this shows you -- I'm up in New Hampshire and I don't get out very often -- I had never even heard of the company prior to doing the research on this. Harjes: Actually, I hadn't, either, but I think that's just because they don't really have a big lodging in the U.S. But they're huge in Asia, and they're actually really cheap devices. Campbell: Yeah, they're a private Chinese company called Xiaomi. Harjes: Yeah. So it'll be interesting to keep an eye on. Todd, any final thoughts before I close out? Campbell: No. I think, like you said, we're an investing show, and I think the investing takeaway is, stay tuned. I don't think you can go out and buy any of these stocks based on what we just discussed today. But I think it's definitely worth tracking how this industry is progressing, paying attention to the news flow on it, because at some point, this is going to become very big business for somebody. Harjes: Yeah. And it is really interesting to me to see how these different sectors overlap. Even just in a portfolio allocation sense, if I have my money in, say, Alphabet, and all of a sudden healthcare becomes half of their business, does that change how I think about that investment? I don't know. Remains to be seen. But like I said, we are just in the early stages, so stay tuned. That will just about do it for today's show. If anyone has questions or comments for the team, we love hearing from our listeners. You can reach us at industryfocus@fool.com , also in the Motley Fool Podcasts Facebook group or at Twitter , @MFIndustryFocus. As always, people on the program may have interests in the stocks that they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. For Todd Campbell, I'm Kristine Harjes. Thanks a bunch to our producer, Austin Morgan, who proved himself today to be a champion knockerballer, and it was awesome. Congrats, Austin, and Fool on, everyone! Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Kristine Harjes owns shares of Apple. Todd Campbell owns shares of Amazon, Apple, Facebook, and Twitter. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Facebook, Fitbit, and Twitter. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Benzinga's Option Alert Recap From May 16"", ""Option Alert: Dexcom Jun 70.0 Puts: 500 @ Above Ask! $2.85: 1305 traded vs 1384 OI: Earnings 8/1 After Close (est) $69.65 Ref""]"
DXCM,2017-05-17,17.375,17.3812,16.9325,17.0125,
DXCM,2017-05-18,16.975,17.235,16.7775,17.165,
DXCM,2017-05-19,17.1975,17.25,16.7275,16.915,
DXCM,2017-05-22,17.19,17.2875,16.9088,17.2125,"[""PiperJaffray Reinstates Overweight on DexCom, Announces $78.00"", ""PiperJaffray Reinstates Overweight on DexCom, Announces $78.00"", ""PiperJaffray Reinstates Overweight on DexCom, Announces $78.00""]"
DXCM,2017-05-23,17.2125,17.3525,16.87,16.905,
DXCM,2017-05-24,16.945,17.0875,16.7775,17.065,
DXCM,2017-05-25,17.125,17.3375,16.975,17.2875,"[""Noteworthy Thursday Option Activity: YUMC, DXCM, FDC Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Yum China Holdings Inc (Symbol: YUMC), where a total of 12,242 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 52.7% of YUMC's average daily trading volume over the past month of 2.3 million shares. Especially high volume was seen for the $37.50 strike call option expiring October 20, 2017 , with 2,060 contracts trading so far today, representing approximately 206,000 underlying shares of YUMC. Below is a chart showing YUMC's trailing twelve month trading history, with the $37.50 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 6,405 contracts thus far today. That number of contracts represents approximately 640,500 underlying shares, working out to a sizeable 44.5% of DXCM's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $65 strike put option expiring July 21, 2017 , with 3,259 contracts trading so far today, representing approximately 325,900 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $65 strike highlighted in orange: And First Data Corp (Symbol: FDC) options are showing a volume of 13,651 contracts thus far today. That number of contracts represents approximately 1.4 million underlying shares, working out to a sizeable 42.5% of FDC's average daily trading volume over the past month, of 3.2 million shares. Especially high volume was seen for the $16 strike call option expiring July 21, 2017 , with 6,014 contracts trading so far today, representing approximately 601,400 underlying shares of FDC. Below is a chart showing FDC's trailing twelve month trading history, with the $16 strike highlighted in orange: For the various different available expirations for YUMC options , DXCM options , or FDC options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Analysts Predict 10% Gains Ahead For The Holdings of EQWM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares Russell Midcap Equal Weight Portfolio ETF (Symbol: EQWM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.43 per unit. With EQWM trading at a recent price near $43.89 per unit, that means that analysts see 10.34% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of EQWM's underlying holdings with notable upside to their analyst target prices are AutoZone, Inc. (Symbol: AZO), Sally Beauty Holdings Inc (Symbol: SBH), and DexCom Inc (Symbol: DXCM). Although AZO has traded at a recent price of $590.99/share, the average analyst target is 43.13% higher at $845.86/share. Similarly, SBH has 34.64% upside from the recent share price of $17.38 if the average analyst target price of $23.40/share is reached, and analysts on average are expecting DXCM to reach a target price of $90.93/share, which is 33.22% above the recent price of $68.26. Below is a twelve month price history chart comparing the stock performance of AZO, SBH, and DXCM: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2017-05-26,17.3375,17.365,17.03,17.1625,
DXCM,2017-05-30,17.17,17.1725,16.9675,17.095,
DXCM,2017-05-31,17.135,17.1575,16.54,16.71,
DXCM,2017-06-01,16.595,16.8725,16.5775,16.7125,
DXCM,2017-06-02,16.7925,17.0025,16.6725,16.92,"DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound? A month has gone by since the last earnings report for DexCom, Inc.DXCM . Shares have lost about 9.6% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. DexCom Q1 Loss Narrower than Expected, Revenues Miss DexCom Inc. DXCM reported a loss of $0.49 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $0.55. However, the figure was wider than the loss of $0.23 reported in the year-ago quarter. Interestingly, Dexcom posted a positive earnings surprise in the last quarter as well. Getting back to the quarter, total revenue grew to $142 million, reflecting an increase of 22.4% from $116 million in the year-ago quarter. However, the figure lagged the Zacks Consensus Estimate of $144 million. Operational Details DexCom generated a gross margin (as a percentage of revenues) of 66%, compared with 65% for the same quarter in the prior year. Notably, gross margin was slightly below management's anticipated range for the quarter, thanks to a drop in first-quarter sales. International business showed continued year-over-year growth in the quarter, generating $26 million in revenues, up 37% on a year-over-year basis. Notably, international business represented 18% of total revenue in the first quarter. Particularly, Germany fueled almost 37% growth outside the U.S. in the quarter. Research and development (R&D) expenses totaled $48 million in the quarter, compared with $32 million a year ago. The company's R&D investments include the G6 pivotal study and related submissions with the FDA. Selling, general and administrative expenses totaled $86 million in the reported quarter, compared with $62 million in the same quarter of 2016. The rise was primarily due to year-over-year increases in head count in customer support organizations, higher marketing expenses and escalating IT costs. Financial Update As of Mar 31, 2017, DexCom had $181.1 million in cash, cash equivalents and short-term marketable securities. Guidance The company projects global revenues in the band of $710 million to $740 million, reflecting growth of approximately 25% to 30%. For the full year, DexCom anticipates gross margin at the low end of the 67% to 70% guidance. How Have Estimates Been Moving Since Then? Following the release, investors have witnessed a downward trend in fresh estimates. There has been one revision higher for the current quarter compared to eight lower. While looking back an additional 30 days, we can see even more downward momentum. There have been nine moves down in the last two months. In the past month, the consensus estimate has shifted downward by 49.4% due to these changes. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote VGM Scores Currently, DexCom's stock has an average Growth Score of 'C', though it is lagging a lot on the momentum front with an 'F'. Charting a somewhat similar path, the stock was allocated a grade of 'D' on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in. The company's stock is suitable solely for growth based on our styles scores. Outlook Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-06-05,16.83,18.0912,16.705,17.7975,"[""DexCom Shares Now Up 3.3%"", ""DexCom Shares Spike Higher as Co. Named During Apple Watch Presentation at WWDC"", ""DexCom Shares Now Up 3.3%"", ""DexCom Shares Spike Higher as Co. Named During Apple Watch Presentation at WWDC"", ""DexCom (DXCM) Stock Rallies on Apple Watch Partnership Shares of DexCom DXCM popped nearly 5% in afternoon trading Monday after Apple AAPL announced that it has partnered with the company to deliver glucose monitoring on its latest Apple Watch operating system. The latest Apple Watch news, which included a full introduction to Watch OS 4, was announced earlier today at Apple's annual Worldwide Developers Conference. Among several other updates, Watch OS 4 with feature glucose data that is pulled from DexCom monitors. Based out of San Diego, California, DexCom is a leader in continuous glucose monitoring systems for diabetes management. The company's latest platform, the G5 Mobile CGM System, provides real-time glucose readings every five minutes and is the only FDA-approved CGM system that does not require pricking your finger. Watch OS 4 will also deliver several new Watch faces, improvements to the device's Activity functions, and new \""Monthly Challenges\"" for exercise. There were also several announced compatibilities with various types of equipment. For example, Apple promised data exchange between the Watch and one's surfboard, allowing for real-time wave high readouts and calorie burning results. The Watch OS 4 announcement also included new updates to the music player, as well as a new docking system. The dev preview will be available today, with a free update available for all Watch users in the fall. Make sure to check back here for the latest news from WWDC! Want morestock market analysisfrom this author? Make sure to follow @ Ryan_McQueeney on Twitter! Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Now Up 3.3%"", ""DexCom Shares Spike Higher as Co. Named During Apple Watch Presentation at WWDC"", ""Dexcom shares soar 4% after Apple speaks to Apple Watch partnership on continuous glucose monitors"", ""Stock market closes lower as geopolitics hamper equity benchmark\u2019s record run Dow, S&P 500, Nasdaq dial back from records U.S. stocks struggle to find direction Monday, losing hold of a slight boost following remarks from President Donald Trump on revamping the country\u2019s air-traffic control system, as investors grapple with a variety of geopolitical issues, both domestic and abroad.""]"
DXCM,2017-06-06,17.5325,17.6525,17.1225,17.435,"[""Company News for June 06, 2017"", ""Company News for June 06, 2017"", ""Company News for June 06, 2017 \u2022 Shares of Herbalife Ltd HLF declined 6.6% after the company projected revenues to decline between 2% and 6% for the second quarter, higher than its previous projected declines of 0.5% to 4.5% \u2022 Pandora Media Inc's P shares gained 1.9% after reports that Verizon Communications VZ considers investment of $100 million in the music streaming service \u2022 Shares of Puma Biotechnology Inc PBYI gained 2.1% after the company declared positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 \u2022 DexCom, Inc.'s DXCM shares increased 5.2% after Apple AAPL declared that it has partnered with DexCom to deliver glucose monitoring on Apple Watch operating system Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pandora Media, Inc. (P): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report Herbalife LTD. (HLF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Company News for June 06, 2017""]"
DXCM,2017-06-07,17.595,17.7475,17.0975,17.3175,"[""DarioHealth: Disruption Is Valuable"", ""DexCom Reports FDA Approval of G5 Mobile App for Android Devices"", ""DexCom Reports FDA Approval of G5 Mobile App for Android Devices"", ""DarioHealth: Disruption Is Valuable"", ""DexCom Reports FDA Approval of G5 Mobile App for Android Devices"", ""DarioHealth: Disruption Is Valuable"", ""DexCom wins FDA approval for G5 mobile app for android devices DexCom Inc. said Wednesday it has won approval from the U.S. Food and Drug Administration for its G5 mobile app for android devices. The San Diego-based company said the app allows people with diabetes to view and monitor their glucose levels on their mobile devices. The company already launched an app for iOS devices in 2016. Shares rose 0.5% in premarket trade, and have gained 17% in 2017, while the S&P 500 has gained 8.5%.""]"
DXCM,2017-06-08,17.34,17.6575,17.1719,17.525,
DXCM,2017-06-09,17.5825,17.8825,16.92,17.2475,"3 Growth Stocks for Ambitious Investors If you've got big, bold plans for your portfolio, then stocks that also exhibit such ambition can help you achieve them. It's not necessary to delve into penny stocks or other such risky endeavors -- just choose companies that possess the right qualities. We asked three top Motley Fool contributors to identify a stock that an ambitious investor might appreciate, and they came up with Dexcom (NASDAQ: DXCM) , Autodesk (NASDAQ: ADSK) , and Vista Outdoor (NYSE: VSTO) . Read on to find out why they hold such promise. A diabetes darling Brian Feroldi(Dexcom): The American Diabetes Association estimates that more than 29 million Americans have diabetes and another 86 million are at risk of developing the disease. Given the prevalence, perhaps it isn't a big surprise to learn that dozens of companies have developed products aimed at treating this condition. One of my favorites is Dexcom, a leading provider of continuous glucose monitors. Dexcom's stock has been a Wall Street favorite for years as demand for the company's product continuous to soar. So what is a continuous glucose monitor? Traditionally, if a person with diabetes wanted to know what their blood sugar level was, they would have to prick their finger and apply a drop of blood to a meter. While this data was useful, it was also burdensome to gather. In addition, the number didn't tell the user anything about which direction their blood sugar was heading. Dexcom's solution to this problem was to insert a small sensor under the skin that continuously measured glucose levels. Those readings would then be constantly uploaded to a monitor, which provided people with diabetes with a real-time view of their glucose levels. What's more, Dexcom's sensors need to be changed out every few days, which provides the company with a recurring revenue stream. Since the product's launch, the diabetes community has welcomed Dexcom's device with open arms. Better yet, Dexcom's razor-and-blade business model has allowed its top line to soar, taking long-term shareholders on a very profitable ride. DXCM Revenue (TTM) data by YCharts . While Dexcom's growth is impressive, the company's system is currently being used by about 200,000 patients. That number is still quite small when compared to the 29 million Americans with the disease. The only knock against Dexcom is that Wall Street values its stock at nearly 10 times sales. While that's expensive, if you count yourself as an ambitious investor, I certainly wouldn't fault you for taking a small position in Dexcom today. Picture these profits Demitri Kalogeropoulos(Autodesk): Autodesk might not look like a growth stock given that both its top and bottom lines are heading in the wrong direction right now. The design software specialist's sales fell slightly in 2015 before diving 19% last year. Its annual losses ballooned to $582 million from $330 million over the same time. Both of those figures were heavily impacted by Autodesk's choice to abandon its one-time purchase model and replace it with subscription offerings. Yet while these new cloud-based purchases carry much smaller initial contract prices, they make up for that weakness by delivering higher-margin recurring revenue. The business model shift has made subscriber figures the key number to watch lately. And by that metric, Autodesk is doing a great job. The company grew its customer base by 21% last year and the solid momentum carried on into its fiscal first quarter on the strength of new cloud-based offerings that helped subscription plan recurring revenue double to $692 million. Ambitious investors should consider investing in this business ahead of what could be a significant operating rebound. Management is targeting a 20% subscription gain this year as recurring revenue expands by as much as 26% to account for a growing proportion of the total sales base. Yes, sales and profits are both likely to show just minor improvements over last year, but surging subscription sales are laying the groundwork for much better growth down the road. Ready to shoot out the lights Rich Duprey(Vista Outdoor): Although its stock sits nearly 60% below its 52-week high, an ambitious investor might just find Vista Outdoor a company to train their sights on. The shooting sports and outdoor gear retailer has been hit by twin forces that it had not prepared for: the election of Donald Trump as president and a wave of retail bankruptcies. The outcome of the presidential election surprised most everyone and sucked the wind out of the sails of the gun industry. In part driven by the fear of greater gun control legislation getting introduced, gun sales had soared in recent years, but the election of a purported gun-friendly president and Congress helped deflate such worries. Vista called it an ""unprecedented"" drop in demand. At the same time, the bankruptcy of sporting goods retailers like Sports Authority and Gander Mountain hurt sales of recreational outdoors gear, as the stores were big sellers of its products. In Vista's most recent earnings report, it said a write-off of $17 million worth of receivables from a bankrupt retail customer lopped off $0.18 from Vista's per-share earnings. That was likely Gander Mountain, as its March bankruptcy filing listed it as owing Vista nearly $15.2 million. But the gun market is booming and the FBI just reported the month of May was its busiest May ever for background checks of potential gun buyers, with some 1.9 million investigations conducted. All year long it has shown the big drop off in demand following the election was more of a one-off event than a trend. Vista still expects it to take time for demand to recover to where it was, but everything points to greater growth again. While the retail landscape remains dicey, Dick's Sporting Goods (NYSE: DKS) scooped up a bunch of Gander Mountain stores and the retailer's new owner Camping World has said it is rebranding the chain as Gander Outdoor. Guns won't be quite as prominent as they were previously, but it's a hopeful sign Vista will have a new outlet once more. Trading at just 13 times next year's estimated earnings and a fraction of its sales, Vista Outdoor's depressed stock appears ripe to grow. An investor willing to bide his time during some likely short-term turbulence could enjoy some ambitious returns in the future. 10 stocks we like better than Autodesk When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Autodesk wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 5, 2017 Brian Feroldi has no position in any stocks mentioned. Demitrios Kalogeropoulos has no position in any stocks mentioned. Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends Camping World Holdings. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-06-12,17.2975,18.0325,17.1125,17.92,
DXCM,2017-06-13,17.9075,18.495,17.808,18.205,
DXCM,2017-06-14,18.18,18.695,18.04,18.6675,
DXCM,2017-06-15,18.5,18.9225,18.49,18.9025,
DXCM,2017-06-16,19.0325,19.1725,18.81,19.065,
DXCM,2017-06-19,19.14,19.6825,19.0954,19.49,
DXCM,2017-06-20,19.4875,19.62,19.3425,19.46,
DXCM,2017-06-21,19.4425,19.7625,19.4425,19.5825,
DXCM,2017-06-22,19.55,19.8275,19.55,19.67,
DXCM,2017-06-23,19.6175,19.7625,19.3175,19.3325,
DXCM,2017-06-26,19.4,19.5375,18.9775,19.4375,
DXCM,2017-06-27,19.4525,19.5,18.5238,18.735,
DXCM,2017-06-28,18.7725,18.92,18.5,18.82,
DXCM,2017-06-29,18.8175,18.8175,18.125,18.3175,
DXCM,2017-06-30,18.42,18.44,18.13,18.2925,
DXCM,2017-07-03,18.29,18.545,17.9513,18.13,
DXCM,2017-07-05,18.13,18.3875,17.7925,18.29,
DXCM,2017-07-06,18.2375,18.2987,17.7725,17.7925,
DXCM,2017-07-07,17.8175,18.0925,17.7025,18.0875,"[""MedTech Thriving on Consolidation & Expansion: Stocks to Buy"", ""MedTech Thriving on Consolidation & Expansion: Stocks to Buy"", ""MedTech Thriving on Consolidation & Expansion: Stocks to Buy""]"
DXCM,2017-07-10,18.04,18.075,17.625,17.74,
DXCM,2017-07-11,17.725,17.88,17.38,17.8725,
DXCM,2017-07-12,17.985,18.205,17.82,17.9475,
DXCM,2017-07-13,17.5,17.704,17.0837,17.51,
DXCM,2017-07-14,17.5625,18.0962,17.49,17.93,
DXCM,2017-07-17,17.9775,18.026,17.4575,17.6725,
DXCM,2017-07-18,17.675,17.6875,17.4125,17.4925,
DXCM,2017-07-19,17.485,17.5925,17.35,17.5,"Swell Investing: Building A Portfolio Of Companies Make The World A Better Place “Social responsibility” probably isn’t the first phrase that comes to many people's minds when thinking of publicly traded companies. But for Swell Investing — an investment platform backed by Pacific Life that launched May 16 — it’s a specialty. Swell Investing charges a 0.75 percent annual fee and requires a minimum account value of $500, and the fund has portfolios for companies operating in renewable energy, green tech, disease eradication, clean water, zero waste, and healthy living. We spoke with founder and CEO Dave Fanger about how he’s formed a portfolio for investors who want their dollars to make a difference. Benzinga: Where did the idea for Swell come from? Fanger: It really was from my work in the M&A area — you’re looking and talking to many leaders as you go through the process for an acquisition. You get to know the cultures and values as a leader. I realized there wasn’t really an opportunity in the investment world to invest with your values in mind. For me, there was a personal standpoint: I’ve been a Type 1 diabetic since I was 9, and my family has had a battle with cancer. Benzinga: What’s the company’s relationship with Pacific Life? Fanger: I was working at Pacific Life in the M&A space when I came up with the idea, and they eventually provided the capital behind this. We’re a fully owned subsidiary of Pacific Life, and they have incubated the idea here. They got behind the mission of the business and the value that’s in this space. I’ve worked there since 2008 and I’ve gotten to know the senior leadership quite well. As we’ve gone through, they’ve provided great support from both a regulatory and legal standpoint, but also, as you can imagine, Pacific Life has 150 years of experience in financial services, and that helps us to offer institutional-quality portfolio management. In their history, they’ve also incubated other asset managers. One of their other well-known ones was PIMCO. Benzinga: How do you evaluate a company’s social impact? Fanger: That’s one of the most critical parts of the entire process. We’re unapologetically selective when it comes to choosing companies. Roughly 300 companies make the cut. If you think about all the publicly traded securities, that’s quite stringent. When we look at impact, we take a very different approach from others in the space. We want to see that the companies first have a minimum threshold for an environmental social governance rating. It can range from a CCC all the way to an AAA. We select companies from BB and above. Volkswagen is a CCC. On the other hand, an AAA would be a Tesla Inc (TSLA). These ratings are conducted by third parties. We also want to make sure you’re making revenue within this sustainable scene. We want to see that you’re a company like Xylem Inc (XYL) that actually produces a product and service. We want to make sure you’re earning revenue in your business in line with the theme. Finally, we want to make sure your target goals and your corporate social responsibility are aligned with the U.N. sustainable development goals. You’ve got to make it through each of those steps from an impact perspective, and then we look at it from the portfolio management side of things. Benzinga: Are investors increasingly asking about what the end impact of their dollars will be? Fanger: Certainly we’ve seen in a lot of our own consumer research and studies that there’s been a strong interest by consumers for impacting investing. Recent studies show that millennial interest in impact investing [falls at] around 75 to 80 percent [of those surveyed]. Even more broadly than millennials, in the broader investing universe, of those who say ‘I’m interested in impact investing,’ it’s close to 71 percent. Almost three out of four people are asking for it. There’s a lot of consumer demand — we’ve seen the numbers. Benzinga: Could you give a few examples from the Swell portfolio of ways public companies are making the world a better place? Fanger: One that’s really cool is Vestas. They’re in our renewable energy portfolio and so is another called Enel. They’re leading the way in green energy. Those two are great examples. One of the other areas is solar panels and solar energy systems, and a company like First Solar, Inc. (FSLR), that’s also in our renewable energy space. I’m fond of Trex, known for their eco-friendly decks made from recyclable materials. Benzinga: What about companies working on disease eradication? Fanger: We go through that same in-depth process from an impact standpoint. When we’re looking at disease eradication — that has to align with the U.N. sustainable development goal No. 3, which is their health and well-being sustainable development goal. You’ll see companies in the portfolio addressing cancer and diabetes. DexCom, Inc. (DXCM) helps in the monitoring of many diabetics with their blood sugar. I use their product myself. It’s good to hear from consumers when they take a look at these listings and point out they’re seeing companies that are close to them and their values. Benzinga: How does it feel to go to work everyday with a portfolio that has an altruistic impact? Fanger: It feels absolutely wonderful. The team’s excited. We’ve got so many people who apply for positions here as we grow. They’re seeing an environment and a workspace where they’re able to touch the impact space and they want to do that. Each person who has joined the this team has really exuded that kind of thinking and interest in impact. It’s about making the planet a better place and knowing we’re helping everyone out there with their values as they think about investing. This article is exclusive to Nasdaq.com and has been edited for clarity and brevity. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-07-20,17.595,17.68,17.46,17.5025,
DXCM,2017-07-21,17.42,17.63,17.27,17.38,
DXCM,2017-07-24,17.3275,17.6175,17.2975,17.425,
DXCM,2017-07-25,17.445,17.7475,17.2175,17.5,
DXCM,2017-07-26,17.4625,17.6,17.185,17.1875,
DXCM,2017-07-27,17.265,17.265,16.5625,16.62,
DXCM,2017-07-28,16.6025,16.8425,16.5,16.7625,
DXCM,2017-07-31,16.755,16.84,16.57,16.6525,
DXCM,2017-08-01,16.75,16.885,16.705,16.71,"[""Dexcom Reports Q2 Loss/Share $(0.16) vs. $(0.21) Est., Sales $170.6M vs. $166.3M Est."", ""DexCom Names Quentin Blackford CFO Effective September 1, 2017"", ""DexComn Reports Adj. EPS $(0.16) vs $(0.21) Est., Sales $170.6M vs $166.3M Est."", ""DexCom Names Quentin Blackford CFO Effective September 1, 2017"", ""DexComn Reports Adj. EPS $(0.16) vs $(0.21) Est., Sales $170.6M vs $166.3M Est."", ""Dexcom Reports Q2 Loss/Share $(0.16) vs. $(0.21) Est., Sales $170.6M vs. $166.3M Est."", ""Earnings Reaction History: DexCom, Inc., 77.8% Follow-Through Indicator, 6.8% Sensitive Expected Earnings Release: 08/01/2017, After-hours Avg. Extended-Hours Dollar Volume: $4,072,602 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 4.9% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 4.9%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (4 events) the stock dropped further, adding to the extended-hours losses by an average of 2.0% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Names Quentin Blackford CFO Effective September 1, 2017"", ""DexComn Reports Adj. EPS $(0.16) vs $(0.21) Est., Sales $170.6M vs $166.3M Est."", ""Dexcom Reports Q2 Loss/Share $(0.16) vs. $(0.21) Est., Sales $170.6M vs. $166.3M Est.""]"
DXCM,2017-08-02,17.9125,17.9425,17.435,17.825,"[""DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat"", ""DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat"", ""DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat DexCom Inc.DXCM reported a loss of 16 cents per share in the second quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 23 cents. Also, the figure improved from the loss of 24 cents reported in the year-ago quarter. Total revenue grew to $170.6 million, reflecting an increase of 24% from $137.3 million in the year-ago quarter. Also, the figure came ahead of the Zacks Consensus Estimate of $166.0 million. Operational Details DexCom generated gross margin (as a percentage of revenues) of 69%, compared with 62% for the same quarter in the prior year. Notably, gross margin rebounded year-over-year due to an improvement in warranty rate, primarily within receiver lines. International business displayed continued year-over-year growth in the quarter, generating $30 million in revenues, up 69% on a year-over-year basis. Notably, international business represented 17% of total revenue in the second quarter. Germany contributed almost 25% of international business in the quarter. Research and development (R&D) expenses totaled $45 million in the quarter compared with $36 million a year ago. The company's R&D investments include the G6 pivotal study and related submissions with the FDA. Selling, general and administrative expenses totaled $86 million in the reported quarter compared with $69 million in the prior-year quarter. The rise was primarily due to year-over-year increases in head count in field sales cum customer support organizations, and higher patient-focused marketing expenses. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Financial Update As of Jun 30, DexCom had $497 million in cash, cash equivalents and short-term marketable securities versus $124 million at the end of 2016. During the quarter, the company raised $400 million in gross proceeds from its convertible notes offering and paid $75 million outstanding on its $200 million credit facility. Guidance This Zacks Rank #3 (Hold) company projects global revenues in the band of $710 million to $740 million, reflecting growth of approximately 25% to 30%. For the full year, DexCom anticipates gross margin at the low end of the 67% to 70% guidance. Key Picks Some better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation EW , Abiomed Inc. ABMD and Fresenius Medical Care Corporation FMS . Notably, Fresenius Medical Care and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Abiomed has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has a one-year return of 1.5%. Abiomed delivered a strong return of 23.4% over the last one year. The stock has a long-term expected earnings growth rate of 30.5%. Fresenius Medical Care represents an impressive return of 2.5% over the last one year. The company delivered a solid earnings surprise of 20.5% in the last reported quarter. More Stock News: Tech Opportunity Worth $386 Billion in 2017 From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat""]"
DXCM,2017-08-03,17.8225,17.9975,17.535,17.685,"[""DexCom (DXCM) in Focus: Stock Moves 6.7% Higher"", ""Dowling & Yahnke Llc Buys iShares S&P Small-Cap 6\u2026\u2026 Growth ETF, Altaba Inc, SPDR ..."", ""Dowling & Yahnke Llc Buys iShares S&P Small-Cap 6\u2026\u2026 Growth ETF, Altaba Inc, SPDR ..."", ""DexCom (DXCM) in Focus: Stock Moves 6.7% Higher"", ""DexCom (DXCM) in Focus: Stock Moves 6.7% Higher DexCom, Inc. DXCM was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company-as the stock is now down 1.7% in the past one-month time frame. The move came after the company reported better-than-expected third quarter, 2017 results. The company has seen three negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last. DexCom currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote A better-ranked stock in the Medical - Instrumentsindustry is Fresenius Medical Care Corporation FMS , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Is DXCM going up? Or down? Predict to see what others think: Up or Down More Stock News: Tech Opportunity Worth $386 Billion in From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dowling & Yahnke Llc Buys iShares S&P Small-Cap 6\u2026\u2026 Growth ETF, Altaba Inc, SPDR ..."", ""DexCom (DXCM) in Focus: Stock Moves 6.7% Higher""]"
DXCM,2017-08-04,17.7412,17.8925,17.7125,17.785,
DXCM,2017-08-07,17.745,17.9025,17.7175,17.8275,
DXCM,2017-08-08,17.8,17.955,17.7575,17.8275,
DXCM,2017-08-09,17.735,17.91,17.6378,17.885,
DXCM,2017-08-10,17.8425,17.8775,17.4125,17.45,
DXCM,2017-08-11,17.4175,17.57,17.2625,17.4,
DXCM,2017-08-14,17.58,18.0625,17.475,17.905,
DXCM,2017-08-15,17.9225,17.9225,17.6675,17.805,"[""Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet"", ""Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet"", ""Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet""]"
DXCM,2017-08-16,17.945,18.3675,17.795,18.265,"Bullish Two Hundred Day Moving Average Cross - DXCM In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $72.93, changing hands as high as $73.47 per share. DexCom Inc shares are currently trading up about 2.6% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $57.68 per share, with $96.38 as the 52 week high point - that compares with a last trade of $73.06. According to the ETF Finder at ETF Channel, DXCM makes up 1.77% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading up by about 0.4% on the day Wednesday. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-08-17,18.2425,18.4175,18.1758,18.195,
DXCM,2017-08-18,18.145,18.6225,18.0325,18.2875,
DXCM,2017-08-21,18.2875,18.4125,18.0425,18.265,"[""DexCom Reports Publication Of New Study Showing People With Type-2 Diabetes On MDI Insulin Therapy Benefit From Use Of CGM: 'Participants in the study achieved significant A1C reduction...'"", ""DexCom Reports Publication Of New Study Showing People With Type-2 Diabetes On MDI Insulin Therapy Benefit From Use Of CGM: 'Participants in the study achieved significant A1C reduction...'"", ""DexCom Reports Publication Of New Study Showing People With Type-2 Diabetes On MDI Insulin Therapy Benefit From Use Of CGM: 'Participants in the study achieved significant A1C reduction...'""]"
DXCM,2017-08-22,18.3925,19.73,18.265,18.9775,
DXCM,2017-08-23,18.8275,18.995,18.6975,18.7975,
DXCM,2017-08-24,18.79,18.9725,18.6625,18.875,
DXCM,2017-08-25,18.9175,19.0275,18.81,18.88,
DXCM,2017-08-28,18.8075,18.955,18.6788,18.8625,
DXCM,2017-08-29,18.8,18.885,18.7175,18.8075,
DXCM,2017-08-30,18.7625,18.7625,18.4925,18.535,
DXCM,2017-08-31,18.4775,18.91,18.4775,18.6525,
DXCM,2017-09-01,18.685,18.795,18.4475,18.74,
DXCM,2017-09-05,18.6225,18.98,18.4525,18.9625,
DXCM,2017-09-06,19.0475,19.097,18.525,18.7825,
DXCM,2017-09-07,18.7375,18.8569,17.7725,17.8075,"[""Fitbit, Dexcom to Develop Continuous Glucose Monitoring Experience for People Living with Diabetes"", ""Fitbit, Dexcom to Develop Continuous Glucose Monitoring Experience for People Living with Diabetes"", ""Why Cabela's, Fitbit, and AbbVie Jumped Today The stock market was mixed on Thursday, with the major U.S. indexes closing the session almost flat. Concerns about the damage Hurricane Irma will inflict when it hits the Florida coast this weekend continued to weigh on certain sectors, but a moment of bipartisanship in Washington made generated some optimism about the potential for progress on the White House's domestic agenda later this year. Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you what propelled their gains. Cabela's sale looks like a go Cabela's stock jumped 14.3% after the retailer got positive news on the regulatory front related to its proposed merger with outdoor gear peer Bass Pro Shops . The Federal Reserve approved the sale of Cabela's credit card division to Synovus Financial (NYSE: SNV) , which was the last obstacle in the way of the larger merger transaction. The stock's move brings its price to within $1 of the proposed $61.50 per share in cash that Cabela's shareholders are slated to receive under the terms of the agreement. Many watchers now expect the deal to get completed before its initial deadline in early October. Fitbit joins the fight against diabetes Fitbit shares climbed 9.8% in the wake of the wearables company's announcement that it was forging a new partnership in the fight against diabetes. The fitness-tracking device manufacturer said it will collaborate with glucose-monitoring specialist DexCom (NASDAQ: DXCM) to put important information for those suffering from diabetes on its new Ionic smartwatch. With the holiday shopping season coming up, Fitbit is looking for strategies that can boost its flagging sales; adding a feature that meets the specific needs of a large, well-defined group of potential customers could be just what the doctor ordered for building up sales momentum over the rest of the year. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. The drug maker said that its candidate treatment upadacitinib had met its primary endpoint in a phase 2b study in treating atopic dermatitis, showing a greater mean percentage of changes from the baseline in eczema area and severity compared to a placebo. Upadacitinib also helped 50% of patients achieve clear or almost clear skin, and reductions in itching were also positives for the drug. AbbVie management saw the news as good, and with the drug also in phase 3 trials as a treatment for rheumatoid arthritis and psoriatic arthritis, upadacitinib has several potential routes that could lead to it becoming a blockbuster. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!* Tom and David just revealed their ten top stock picks for investors to buy right now. Click here to get access to the full list! *Stock Advisor returns as of September 5, 2017 Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fitbit. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Fitbit Stock Is Soaring Today What happened Shares of fitness wearables company Fitbit (NYSE: FIT) surged on Thursday following the announcement of a partnership with medical-device maker DexCom (NASDAQ: DXCM) related to glucose monitoring. The two companies will develop a continuous glucose monitoring experience that will put DexCom data on Fitbit's upcoming Ionic smartwatch. Fitbit stock was up about 10% at 11:45 a.m. EDT, while shares of DexCom were down 1.7%. So what With Fitbit suffering from a steep drop-off in demand for its fitness trackers, the Ionic smartwatch needs to be a success for the company to turn itself around. Ionic is set to begin shipping in October for $300, slightly less expensive than the base Series 2 Apple Watch, but slightly more expensive than the first-generation Series 1. DexCom's continuous glucose monitoring (CGM) products currently allow users to view data on Android and iOS devices. The Fitbit deal will put that data on the Ionic smartwatch, allowing users to quickly view important health information. \""The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days, coupled with Dexcom's market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,\"" said Fitbit CEO James Park. DexCom data is expected to be available on the Ionic sometime in 2018. Further collaboration between the two companies is possible, although nothing concrete has been announced. Now what The 10% move in Fitbit stock seems like a major overreaction. This deal puts data already available on smartphones on Fitbit's Ionic. DexCom's mobile app is already integrated with the Apple Watch and Android Wear devices, meaning that this partnership is nothing more than Fitbit playing catch-up, trying to make its smartwatch platform a viable alternative. Whether Fitbit's Ionic succeeds will depend on the willingness of consumers to buy a smartwatch with a nascent app ecosystem. The deal with DexCom doesn't change the story. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of September 5, 2017 Timothy Green has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple and Fitbit. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Breaks Below 200-Day Moving Average - Notable for DXCM In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $73.44, changing hands as low as $71.09 per share. DexCom Inc shares are currently trading off about 5.2% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $57.68 per share, with $96.38 as the 52 week high point - that compares with a last trade of $71.23. According to the ETF Finder at ETF Channel, DXCM makes up 72299.39% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading up by about 0.6% on the day Thursday. Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Fitbit, Dexcom to Develop Continuous Glucose Monitoring Experience for People Living with Diabetes"", ""Fitbit shares jump almost 10% on news to work with Dexcom on diabetes product Shares of fitness tracker Fitbit Inc. surged almost 10% in early trade Thursday, after the company said it is working with Dexcom Inc. to help people manage diabetes. Dexcom makes products to allow for continuous glucose monitoring and Fitibit is aiming to develop ways for diabetes patients to get a reading on their glucose levels on their wrist, without needing a smart phone or an app. \""The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days1, coupled with Dexcom's market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,\"" said James Park, CEO of Fitbit. Fitbit shares are down 11.5% in 2017, while the S&P 500 has gained 10%.""]"
DXCM,2017-09-08,17.78,17.8275,17.4325,17.8175,"[""Fitbit Tracking Higher After Deal With Dexcom"", ""Fitbit Tracking Higher After Deal With Dexcom"", ""Fitbit Tracking Higher After Deal With Dexcom"", ""Fitbit shares close up 10% on diabetes-monitoring partnership in new smartwatch Fitness-tracker company shares hit highest prices since January after detailing collaboration with DexCom glucose monitors Fitbit Inc. shares rally Thursday to close at levels not seen since late January after the fitness-tracker company announces a collaboration with glucose-monitoring device company DexCom Inc. to allow diabetics to monitor their blood sugar through Fitbit\u2019s new smartwatch.""]"
DXCM,2017-09-11,17.9525,18.3125,17.725,18.2825,"3 Stocks to Gain as Internet of Things Weaves Into Our Lives InvestorPlace - Stock Market News, Stock Advice & Trading Tips Everyone knows by now what Internet of Things (IoT) is. It has already become an integral part of everyday life, thanks to an ever-increasing number of connected products. At the consumer level, the IoT market is dominated by techs such as Amazon.com, Inc. (NASDAQ: AMZN ) and Alphabet Inc. (NASDAQ: GOOGL , NASDAQ: GOOG ) whose Echo and Home, respectively, are ruling the market. Also, activity-tracking products and advanced in-car technology are other products already available. On the commercial side, a number of industrial manufacturers have started installing sensors inside machines to track performance and efficiency. IoT Market: Strong Growth Projections Market observers recognize IoT as a booming space. According to a recent report by research firm Gartner, worldwide spending on endpoints and services of connected objects is expected to reach nearly $2 trillion in 2017 from $737 billion in 2016. There will be about 8.4 billion connected objects (IoT objects) in use globally by the end of this year, a rise of 31% from the year ago. This figure is likely to reach around 20.4 million by 2020. Notably, North America, Western Europe and Greater China region will dominate 67% of total globally IoT-installed bases in 2017. As per a Gartner report, Businesses will represent 57% of total IoT spending this year to $964 billion. Consumer applications will amount to $725 billion in 2017. The research firm has estimated that hardware spending from both segments will reach almost $3 trillion by 2020. According to another research firm IDC, the IoT market could nearly triple in the coming years. In 2014, the global IoT market was worth $655.8 billion. However, it has the potential to reach up to $1.7 trillion by 2020. Given such impressive projected numbers in the IoT space, investors should definitely consider adding IoT stocks to their portfolios. Let's take a closer look at the three IoT stocks that have the right combination to outperform. Stocks to Gain as Internet of Things Weaves Into Our Lives: Cypress Semiconductor Corporation (CY) Cypress Semiconductor Corporation (NASDAQ: CY ) manufactures embedded system solutions for automotive, industrial, home automation and appliances, consumer electronics and medical products. Last year, the company acquired Broadcom's Wireless Internet of Things business to gain leadership in the IoT segment. Also, the company laid off 8% of its global workforce to focus on the growth areas like the IoT segment. Recently, Cypress' IoT connectivity platform teamed up with Arrow Electronics to deliver pioneering solutions to facilitate new, inventive business models for the IoT market. The company has a Zacks Rank #2 (Buy) and has a long-term expected earnings growth rate of 10.0%. Although CY has returned only 17.7% on a year-to-date basis compared to the industry 's gain of 18.2%, we believe that strong growth potential of its IoT initiatives will help the stock rebound going forward. Stocks to Gain as Internet of Things Weaves Into Our Lives: Texas Instruments Incorporated (TXN) Semiconductor giant Texas Instruments Incorporated (NASDAQ: TXN ) has substantial opportunities stemming from the increasing demand for its microcontrollers - low cost, low power, embedded chips that have programming, and data memory. Its focus on gaining share in the infotainment and advanced driver assistance system (ADAS) segments of the automotive market are likely to spur growth in 2017. The company's IoT profile falls under its Embedded Processors division, which includes the Connectivity, Microcontrollers, and Processors categories. Its Embedded Processors segment witnessed growth of 8.1% sequentially and 15% year over year in its last reported second-quarter results. We believe that increasing number of connected devices is expected to drive demand for these chips in 2017 and beyond that will boost top-line growth. The stock currently carries a Zacks Rank #2 (Buy) and has a long-term expected earnings growth rate of 9.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . However, Texas Instruments has also underperformed the industry it belongs to on a year-to-date basis. The stock has returned approximately 11.5% compared with the industry's growth of roughly 15.0%. Stocks to Gain as Internet of Things Weaves Into Our Lives: Fitbit Inc (FIT) Fitbit Inc FIT - Although the company's growth has been slowed by massive competition in the wearables space, this is one of the few IoT pureplays that should perform well in the near future. Fitbit has devices at varying prices for individual and corporate uses. The company pursues corporate healthcare plans and has registered some major wins in the area. Recently, the company introduced its sleek tech-filled wristwatch, the Ionic, which could help the company gain some share in the IoT market. Moreover, Fitbit has partnered with glucose monitoring device company, Dexcom Inc. (DXCM), to help users monitor their glucose levels on its new wristwatch Ionic. The deal will definitely help Fitbit to counter some competition in the IoT market. It has also undergone significant executive shakeup and cost structuring recently. The company currently carries a Zacks Rank #3 (Hold). The stock has a long-term expected earnings growth rate of 22.5%. However, Fitbit has also underperformed the industry it belongs to on a year-to-date basis. The stock has lost approximately 14.1% compared with the industry's growth of roughly 8.7%. Bottom Line The above mentioned stocks have made great progress in the segment and will play a big role in shaping the market going forward. Undoubtedly, these IoT stocks can't not be ignored. 4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really take off. See Stocks Now>> The post 3 Stocks to Gain as Internet of Things Weaves Into Our Lives appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-09-12,18.3775,18.475,18.1475,18.4025,"Why Fitbit Inc (FIT) Stock Is Rising on the Latest Ionic Update InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fitbit Inc (NYSE: FIT ) got a nice boost when it finally announced its Ionic smartwatch at the end of August. But more good news about the Ionic has lifted Fitbit stock even more: The company is partnering with DexCom, Inc. (NASDAQ: DXCM ) to bring blood glucose monitoring to the Fitbit Ionic. Source: Dexcom, Fitbit With the ability to see their blood glucose levels on their wrist, in real time, the new Fitbit smartwatch will go beyond fitness to offer people suffering from diabetes a real reason to buy. And while the fitness market is big, the health market is huge . Fitbit Announces Dexcom Partnership for Fitbit Ionic Last week, Fitbit announced it was partnering with Dexcom , the leading manufacturing of continuous glucose monitoring (CGM) devices. The partnership will mean people suffering from diabetes who use one of Dexcom's CGM sensors, will be able to view that data on their Fitbit Ionic smartwatch starting in 2018. It's important to note that this doesn't mean that Fitbit has mastered the technology needed for an optical blood glucose sensor. Apple Inc. (NASDAQ: AAPL ) has reportedly assembled a team that is hard at work on that technology for its Apple Watch , but it has not yet succeeded in cracking that very difficult problem. Instead, the Dexcom CGM has a sensor that is inserted under the wearer's skin to take blood glucose readings. It's attached to a wireless transmitter. The transmitter sends data to a receiver. In the case of the Fitbit Ionic, the CGM sensor would send data wirelessly to the smartwatch, so the wearer could see results on their wrist, along with their other health and fitness data, including heart rate and blood oxygen level. That's not as convenient or unobtrusive as an optical CGM would be, but it's the current state of technology. And besides, incorporating an optical CGM on a smartwatch would likely mean having to deal with an onerous Food and Drug Administration approval process that would wreak havoc with Fitbit's product release schedule. Fitbit Stock Reacts to the Potential Fitbit is a leader - although no longer number one - when it comes to wearables. The company's growth has been driven by consumers who are obsessed with tracking their fitness and activity, but that market is a relatively small subset of the population. In the last quarter, Fitbit sold 3.4 million activity trackers. 10 Products Apple Inc. (AAPL) Has Killed The Fitbit Ionic is expected to expand the target demographic by adding smartwatch fans to the mix. Fitbit stock got a bump on the Ionic announcement based on the possibility that some potential Apple Watch buyers might be tempted by a FIT smartwatch. Health monitoring -and in particular diabetes- is a whole other story. Worldwide, it's estimated that over 400 million people are diabetic. The key to maintaining their health is managing blood sugar levels and the way to do that is through blood glucose monitoring. Turning the Fitbit Ionic into a handy display for a Dexcom CGM is a quick way to turn the Fitbit smartwatch into an attractive accessory for a huge market. That's why Fitbit stock popped 7% on the announcement of the partnership. Reality Check The Dexcom CGM partnership is big news for Fitbit. However, the arrangement isn't exclusive. In fact, Dexcom has supported the Apple Watch since 2015 … Apple CEO Tim Cook has been spotted wearing a CGM to track his blood sugar levels on an Apple Watch , and if it isn't a Dexcom model he's using, it's something similar. FIT does have an advantage, though, in the Ionic's superior battery battery life. That would support wearing the Fitbit Ionic at night, while most Apple Watch users will have to skip the Dexcom connection to recharge their smartwatch. The wildcard here is the Apple Watch Series 3, which is expected to be unveiled today at Apple's big iPhone event. Is Alphabet Inc (GOOGL) About to Buy HTC's Smartphone Business? Apple hasn't said a whole lot publicly about its own capabilities in this area, but given the fact that Tim Cook has been wearing a CGM and Fitbit has gone ahead and made this announcement, it's possible that Apple might just feature that CGM support when it shows off the new Apple Watch Series 3. Just to knock FIT back down a peg. With that new Apple Watch expected to make an appearance today to counter the Fitbit Ionic, keep a watch on Fitbit stock. It's going to react to what Apple announces… As of this writing, Brad Moon did not hold a position in any of the aforementioned securitie s. More From InvestorPlace 10 Electric Cars the Tesla Inc (TSLA) Model 3 Needs to Beat The 10 Best Tech Stocks from Top-Ranked Analysts Fibit Inc (FIT) Ionic vs. Apple Inc. (AAPL) Apple Watch: Which Is Best? The post Why Fitbit Inc (FIT) Stock Is Rising on the Latest Ionic Update appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-09-13,18.335,18.86,18.335,18.74,
DXCM,2017-09-14,18.6075,18.6075,18.055,18.0875,
DXCM,2017-09-15,17.985,18.1225,17.525,17.5725,"[""Barclays Initiates Coverage On DexCom with Equal-Weight Rating, Announces $76.00 Price Target"", ""Benzinga's Top Upgrades, Downgrades For September 15, 2017"", ""Benzinga's Top Upgrades, Downgrades For September 15, 2017"", ""Barclays Initiates Coverage On DexCom with Equal-Weight Rating, Announces $76.00 Price Target"", ""Benzinga's Top Upgrades, Downgrades For September 15, 2017"", ""Barclays Initiates Coverage On DexCom with Equal-Weight Rating, Announces $76.00 Price Target"", ""Apple and Fitbit expected to boost sales of smartwatches and other wearable tech IDC predicts sales will grow an average 17% a year through 2021 As Apple Inc. and Fitbit Inc. plan launches of new smartwatches, sales of wearable electronic devices are expected to continue growing strongly for at least the next four years.""]"
DXCM,2017-09-18,17.69,17.7525,17.22,17.315,
DXCM,2017-09-19,17.31,17.3975,17.02,17.365,
DXCM,2017-09-20,17.32,17.5675,17.23,17.5575,
DXCM,2017-09-21,17.58,17.6107,17.31,17.375,
DXCM,2017-09-22,17.43,17.57,17.2738,17.4975,
DXCM,2017-09-25,17.5,17.5425,17.1488,17.2875,
DXCM,2017-09-26,17.3475,17.3525,16.9675,16.98,"[""Hearing Northland Securities Initiates Coverage On DexCom with Outperform Rating, Announces $85.00 Price Target"", ""Hearing Northland Securities Initiates Coverage On DexCom with Outperform Rating, Announces $85.00 Price Target"", ""Fitbit Inc (FIT) Stock Looks Good for the Very Short Term InvestorPlace - Stock Market News, Stock Advice & Trading Tips I've been bearish for some time on Fitbit Inc (NYSE: FIT ) stock. But I'm now reconsidering this view - at least for the short run. One reason is that, well, the sentiment probably cannot get any worse. During the past few years, the company has gone from a tech darling to a has-been. Keep in mind that - back in the summer of 2015 - the shares were fetching nearly $50. Right now, they are at about $6. Source: Via Fitbit As a result, the valuation metrics are starting to look attractive, especially for a value investor. Consider that the price-to-sales multiple is a mere .84X. Hey, it is actually 0.45 when you strip out the $675 million in cash. But valuation is not the only factor. FIT stock also should benefit from year-over-year comparisons. The reason is the last year's holiday season was an absolute disaster. Revenue plunged by 19% to $573.8 million and the net loss came to 56 cents a share. Note that the Street consensus was calling for the top-line to hit $736.4 million. 7 Beaten-Down Stocks to Buy Now So yes, the bar is set fairly low for the upcoming Q4. It is also encouraging that there are already signs of an improvement in the business. During Q2, the company reported revenues of $587 million, up from $400 million in the same period a year ago, and the earnings came to 12 cents a share. Analysts were forecasting revenues of $578 million and earnings of 11 cents a share. But going forward, the main driver for FIT stock will be the rollout of its smartwatch, which is called Ionic. This is the result of three acquisitions - such as for Coin, Pebble and Vector - and heavy investments in R&D. Granted, FIT has been late to the game and the competitive environment is intense. Just some of the rivals include Apple Inc. (NASDAQ: AAPL ), Garmin Ltd. (NASDAQ: GRMN ) and Xiaomi. But for FIT, the company has been smart to focus on its core competencies in the fitness category. Some the Ionic smartwatch features include: An SpO2 sensor that allows for in-depth tracking, GPS tracking, water resistance of up to 50 meters, wireless headphones, a virtual personal trainer (which provides workouts that are personalized to your activities and health condition), mobile payments and a battery life of over 4 days. True, the Ionic device is not without its issues and flaws. For example, while you can receive texts, you cannot send them! Also the overall design could probably be sleeker and the app store is no where near the depth of iTunes or Alphabet Inc's (NASDAQ: GOOGL ) Play. But then again, for a first version, the Ionic is still impressive and is likely to get attention in the marketplace. The 7 Best Stocks for Your Golden Years Bottom Line On FIT Stock Keep in mind that the Ionic smartwatch is not just about the consumer market. FIT is also leveraging the device into the healthcare category. To this end, the company has struck a partnership with DexCom, Inc. (NASDAQ: DXCM ), that will allow for the monitoring of a person's glucose levels. No doubt, there is a great need for such a product, as there are over 400 million people across the world who suffer from diabetes. And finally, FIT stock may benefit from the lackluster buzz from the new Apple Watch 3. According to various reviews, it appears that the device is having issues with its cellular features, such as connection with LTE networks as well as problems with the draining of the battery. But again, even with some of the recent positive news for Fitbit stock, the sentiment is still fairly dour. Yet the Ionic smartwatch has a good chance of getting traction, which is likely to gin up much more interest in the shares. Tom Taulli runs the InvestorPlace blog IPO Playbook and is also the author of High-Profit IPO Strategies , All About Commodities and All About Short Selling . Follow him on Twitter at @ttaulli . As of this writing, he did not hold a position in any of the aforementioned securities. More from InvestorPlace 7 'Strong Buy' Stocks Wall Street Is 100% Sure Of 6 A-Rated Dividend Stocks to Buy The 7 Best Dow Jones Stocks to Buy Today The post Fitbit Inc (FIT) Stock Looks Good for the Very Short Term appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Hearing Northland Securities Initiates Coverage On DexCom with Outperform Rating, Announces $85.00 Price Target""]"
DXCM,2017-09-27,17.105,17.2125,16.84,16.8675,
DXCM,2017-09-28,11.9725,12.0,10.655,11.36,"[""JP Morgan Downgrades DexCom to Neutral"", ""Raymond James Downgrades DexCom to Market Perform"", ""Dexcom Shares Fall 22% Premarket Following FDA Approval of Abbott's Blood Glucose Monitoring Device, Analyst Downgrades"", ""The Market In 5 Minutes: The Market Wakes Up To The Trump Tax Plan"", ""Tandem Diabetes Reports 1/3 Of t:slim X2 Pump Users Already Updated Their Pumps Via Personal Computer To Add New Dexcom G5 CGM Integration"", ""20 Stocks Moving In Thursday's Pre-Market Session"", ""Benzinga's Top Upgrades, Downgrades For September 28, 2017"", ""5 Biggest Price Target Changes For Thursday"", ""Canaccord Stick With Buy Rating On Dexcom Following Abbott's Libre Receiving Unexpected Label Addition To Include Insulin Dosing Indication"", ""Mid-Morning Market Update: Markets Edge Lower; BlackBerry Tops Q2 Expectations"", ""Mid-Day Market Update: Exa Corp Rises On Acquisition News; Comtech Shares Plunge"", ""Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition"", ""18 Biggest Mid-Day Losers For Thursday"", ""Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerba Pharmaceuticals Shares Spike Higher"", ""Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerba Pharmaceuticals Shares Spike Higher"", ""18 Biggest Mid-Day Losers For Thursday"", ""Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition"", ""Mid-Day Market Update: Exa Corp Rises On Acquisition News; Comtech Shares Plunge"", ""Mid-Morning Market Update: Markets Edge Lower; BlackBerry Tops Q2 Expectations"", ""Canaccord Stick With Buy Rating On Dexcom Following Abbott's Libre Receiving Unexpected Label Addition To Include Insulin Dosing Indication"", ""5 Biggest Price Target Changes For Thursday"", ""Benzinga's Top Upgrades, Downgrades For September 28, 2017"", ""20 Stocks Moving In Thursday's Pre-Market Session"", ""Tandem Diabetes Reports 1/3 Of t:slim X2 Pump Users Already Updated Their Pumps Via Personal Computer To Add New Dexcom G5 CGM Integration"", ""The Market In 5 Minutes: The Market Wakes Up To The Trump Tax Plan"", ""Dexcom Shares Fall 22% Premarket Following FDA Approval of Abbott's Blood Glucose Monitoring Device, Analyst Downgrades"", ""Raymond James Downgrades DexCom to Market Perform"", ""JP Morgan Downgrades DexCom to Neutral"", ""Pre-Market Most Active for Sep 28, 2017 : ERIC, ZYNE, RAD, BBRY, DXCM, EXA, ITCI, DB, SAN, TEVA, NKE, BAC The NASDAQ 100 Pre-Market Indicator is down -5.16 to 5,932.63. The total Pre-Market volume is currently 8,345,631 shares traded. The following are the most active stocks for the pre-market session : Ericsson ( ERIC ) is unchanged at $5.66, with 1,856,837 shares traded. As reported in the last short interest update the days to cover for ERIC is 8.338379; this calculation is based on the average trading volume of the stock. Zynerba Pharmaceuticals, Inc. ( ZYNE ) is +4.88 at $11.07, with 1,122,853 shares traded. ZYNE's current last sale is 158.14% of the target price of $7. Rite Aid Corporation ( RAD ) is -0.08 at $2.20, with 942,132 shares traded. Seeking Alpha Reports: Your Daily Pharma Scoop: Celgene's CELMoD Potential, Allergan's Senate Troubles, Abbott Approval Surge BlackBerry Limited ( BBRY ) is +0.67 at $9.90, with 903,413 shares traded. Market Realist Reports: A Look at the Qualcomm-Apple Dispute DexCom, Inc. ( DXCM ) is -18.7 at $48.77, with 712,619 shares traded. As reported in the last short interest update the days to cover for DXCM is 10.332882; this calculation is based on the average trading volume of the stock. Exa Corporation ( EXA ) is +7.19 at $24.15, with 690,957 shares traded., following a 52-week high recorded in prior regular session. Intra-Cellular Therapies Inc. ( ITCI ) is -1.51 at $15.15, with 662,425 shares traded. As reported in the last short interest update the days to cover for ITCI is 7.874596; this calculation is based on the average trading volume of the stock. Deutsche Bank AG ( DB ) is +0.41 at $16.98, with 298,142 shares traded. DB's current last sale is 119.58% of the target price of $14.2. Banco Santander, S.A. ( SAN ) is +0.06 at $6.91, with 211,800 shares traded. SAN's current last sale is 95.97% of the target price of $7.2. Teva Pharmaceutical Industries Limited ( TEVA ) is +0.19 at $17.81, with 184,291 shares traded. TEVA's current last sale is 80.04% of the target price of $22.25. Nike, Inc. ( NKE ) is -0.13 at $52.54, with 176,255 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending May 2018. The consensus EPS forecast is $0.66. NKE's current last sale is 85.43% of the target price of $61.5. Bank of America Corporation ( BAC ) is +0.12 at $25.53, with 172,104 shares traded. As reported by Zacks, the current mean recommendation for BAC is in the \""buy range\"". The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Is Getting Crushed Today What happened Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. Patients using DexCom's G5 Mobile device, on the other hand, need to perform up to two finger-sticks per day for the purposes of calibration. Abbott's shares were up by more than 4% on the back of this positive regulatory development. So what DexCom's stock has skyrocketed in the last few years because of its dominant position in the rapidly growing glucose-monitoring market. In fact, sales of its G5 mobile CGM were forecast to grow by another 25% to 30% this year after the Centers for Medicare and Medicaid Services ruled that the device was indeed \"" therapeutic ,\"" and could therefore be covered under Medicare Part B. With the entry of Abbott's more user-friendly device, though, DexCom's blistering levels of growth may start to taper off. Now what Can Abbott's newly approved CGM device truly disrupt the market and steal a significant chunk of the market share away from DexCom? Based on the performance of DexCom's shares Thursday, the overwhelming sentiment among investors appears to be \""yes,\"" and I happen to agree with the market's initial assessment. Unfortunately, DexCom is about a year away from bringing a similar no-calibration (and hence, no finger-stick) device to market, and that lag could spell disaster for the CGM specialist. A first-mover advantage, after all, should translate into a formidable economic moat against follow-on devices -- putting DexCom in a bad position. So while it might be tempting to grab some shares in the wake of this dramatic decline, I'd caution against it for the time being. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of September 5, 2017 George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Becomes Oversold (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 12.0, after changing hands as low as $42.62 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 62.8. A bullish investor could look at DXCM's 12.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $42.62 per share, with $89.98 as the 52 week high point - that compares with a last trade of $43.22. According to the ETF Finder at ETF Channel, DXCM makes up 1.08% of the SPDR S&P Health Care Equipment ETF (Symbol: XHE) which is trading lower by about 1.1% on the day Thursday. Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 09/28/2017: LOXO,ZYNE,DXCM Top Health Care Stocks JNJ -0.33% PFE +0.38% ABT +2.82% MRK -0.50% AMGN +0.26% Health care stocks were unable to hold on to most of their earlier rise, with the NYSE Health Care Index still showing a 0.3% increase this afternoon while shares of health care companies in the S&P 500 were up just 0.1% as a group. In company news, Loxo Oncology ( LOXO ) surged on Thursday after the specialty drugmaker last night said it was selected for a late-breaking presentation of its LOXO-292 prospective treatment for genetically defined lung cancer at an industry conference beginning Oct. 15 in Yokohama, Japan. According to the company, the upcoming presentation will focus on the two patients with RET-fusion lung cancer treated with LOXO-292. While both patients had their disease continue to progress while they were treated with multi-kinase inhibitors, LOXO-292 produced partial responses in both patients. One of the patients received 20 milligrams daily of the highly selective RET inhibitor while the other patient whose cancer had previously progressed to their brain was treated twice daily with doses ranging between 20 to 100 milligrams. Both patients are still alive, Loxo said last night. In other sector news, (+) ZYNE, ZYN002 cannabidiol gel meets primary endpoint during Phase II testing, with 46% of the pediatric and adolescent patients with Fragile X syndrome showing statistically significant improvement in their anxiety, depression and mood symptoms after 12 weeks of treatment. (-) DXCM, Reduced to Neutral from Overweight at JP Morgan, which also cut its price target for the company's stock by $22 to $71 a share. Raymond James and Northland Capital both lower investment ratings to Market Perform from Outperform. Wedbush trims price target by $9 to $75 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Morning Movers: Endo Slumps, Hain Jumps, Philip Morris Rises Stocks look set for a lower open today as Trump's tax plan continues to dominate the news. Getty Images S&P 500 futures have declined 0.2%, while Dow Jones Industrial Average futures have fallen 0.2%. Nasdaq Composite futures have dropped 0.4%. Accenture (ACN) has fallen 1.6% to $134.50 after its earnings and sales topped analyst forecasts. Archer Daniels Midland (ADM) has dropped 2.9% to $41.80 after getting cut to Neutral from Buy at Citigroup. BlackBerry (BBRY) has climbed 7.8% to $9.95 after its earnings topped second-quarter forecasts. DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. Abbott has gained 3.8% to $54.15. Endo International (ENDP) has dropped 2.7% to $8.80 after Goldman Sachs started it as a Sell. Hain Celestial Group (HAIN) has jumped 8.8% to $44 after reaching an agreement with Engaged Capitalto reconstitute its board, and agreed to explore strategic alternatives. McDonald's (MCD) has advanced 0.9% to $155.51 after getting upgraded to Buy from Neutral at Longbow. McCormick (MKC) has risen 2.7% to $99.01 after beating earnings forecasts and offering above-consensus full-year guidance. Mallinckrodt (MNK) has gained 3.4% to $36.60 after getting started at Buy at Buy at Goldman Sachs. Philip Morris International (PM) has risen 1.2% to $113 after Goldman Sachs added the tobacco company to its Conviction Buy list. Pier 1 Imports (PIR) has tumbled 9.8% to $4.06 after beating earnings forecasts but offering below-consensus guidance. Sherwin-Williams (SHW) has declined 1.4% to $345.02 after cutting its third-quarter earnings guidance due to the recent hurricanes. Thor Industries (THO) has gained 3.9% to $124.65 after beating earnings forecasts. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Happened in the Stock Market Today Stocks gained on Thursday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) closing up and the S&P 500 (SNPINDEX: ^GSPC) setting a new record. Today's stock market Data source: Yahoo! Finance. Homebuilders climbed in advance of some earnings announcements, and the iShares US Home Construction ETF (NYSEMKT: ITB) rose 1.3%. Small-cap stocks rose again, with the iShares Russell 2000 ETF (NYSEMKT: IWM) closing up 0.3% to a record high. As for individual stocks, DexCom (NASDAQ: DXCM) plummeted on news from a big competitor, and Rite Aid (NYSE: RAD) disappointed investors once again. DexCom gets crushed on news of competition Shares of diabetes monitor maker DexCom got whacked by 32.7% today after medical products giant Abbott Laboratories announced that the FDA has approved its continuous glucose monitor (CGM) that requires no finger pricks, a first in the market. Abbott's stock rose 2.9% on the news. Abbott's device, called FreeStyle Libre, uses a sensor about the size of two stacked quarters that attaches to the back of the arm and passes blood glucose data wirelessly to a receiver that tracks glucose levels minute by minute. DexCom sells a similar system, but it requires two finger pricks per day for calibration. The freedom from needing to take blood samples could be a game changer for the 30 million people with diabetes in America. Abbott plans to sell the device at all major retail pharmacies before the end of the year, and likely at a lower price than the DexCom system. DexCom has had a head start in the CGM market in the U.S., with an 18% jump in domestic revenue in the most recent quarter. It also won a positive reimbursement decision from Medicare, which will start augmenting sales in the current quarter. What's more, DexCom has already been competing against FreeStyle Libre outside the U.S., where the device is being sold in 40 countries. DexCom's international sales rose 69% last quarter, and in the last conference call, a DexCom executive said that when the devices are reimbursed and therefore the lower cost of Abbott's product is not a factor, patients have been switching from the Libre to DexCom's device because of higher accuracy. But investors are clearly concerned that Abbott's marketing clout and the convenience of FreeStyle Libre will ultimately trump any other advantages DexCom may have. Rite Aid continues to struggle Struggling pharmacy chain Rite Aid reported its fiscal second-quarter results today, and investors did not like what they heard, sending the stock down 11%. While the company has recently received regulatory approval to sell 1,932 of its 4,507 stores to Walgreens Boots Alliance (NASDAQ: WBA) , the company is already shrinking on its own, reporting a revenue decline of 4.4% to $7.7 billion, and an adjusted net loss of $0.01 per share, compared with a per-share profit of $0.03 in the period a year earlier. Same-store sales decreased 3.4%, reflecting a 4.6% decline in pharmacy sales and a 0.9% drop in front-end sales. The contraction in pharmacy sales was blamed on the negative impact of generic drug introductions and a 1.8% fall in the number of prescriptions filled, due in part to exclusion from pharmacy networks that the company had participated in previously. It's hard to imagine things getting much worse for Rite Aid's shareholders, who have seen the stock lose 75% of its value in 2017. The store sale to Walgreens for $4.375 billion in cash will allow the company to pay off a good chunk of its $7 billion in debt and help it get back to profitability. But given that Walgreens will be picking up stores with the least competitive exposure to its existing store base, leaving Rite Aid with stores most threatened by the now-stronger competitor, there are still more questions than answers about the future of the company. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!* Tom and David just revealed their ten top stock picks for investors to buy right now. Click here to get access to the full list! * Stock Advisor returns as of Sept. 5, 2017. Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 09/28/2017: ANGO,ZYNE,DXCM Top Health Care Stocks JNJ +0.01% PFE +0.55% ABT +3.23% MRK -0.25% AMGN +0.53% Health care stocks were outpacing most other sectors, with the NYSE Health Care Index showing a 0.6% increase this afternoon while shares of health care companies in the S&P 500 were up nearly 0.4% as a group. In company news, AngioDynamics ( ANGO ) fell Thursday, with the company's shares sinking as much as 19% to reach a session low of $15.20 each after the surgical and diagnostic devices manufacturer reported a slump for its fiscal Q1 adjusted net income and revenue compared with the same quarter last year and also missing Wall Street expectations. Excluding one-time items, the company earned $0.12 per share during the three months ended Aug. 31, down from $0.17 per share during the year-ago period and trailing the Capital IQ consensus by $0.04 per share. Net sales declined 3.1% to $85.4 million, also lagging the $86.1 million Street view. Looking ahead to the 12 months ending next May, the company is projecting adjusted FY18 net income in a range of $0.64 to $0.68 per share, straddling the analyst mean expecting $0.67 per share. It also sees net sales this year coming in between $352 million to $359 million, in-line with the $355.5 million consensus. In other sector news, (+) ZYNE, (+63.7%) ZYN002 cannabidiol gel meets primary endpoint during Phase II testing, with 46% of the pediatric and adolescent patients with Fragile X syndrome showing statistically significant improvement in their anxiety, depression and mood symptoms after 12 weeks of treatment. (-) DXCM, (-35.7%) Falls to three-year low following downgrade to Neutral from Overweight at JP Morgan, which also cut its price target for the company's stock by $22 to $71 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerba Pharmaceuticals Shares Spike Higher"", ""18 Biggest Mid-Day Losers For Thursday"", ""Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition"", ""Mid-Day Market Update: Exa Corp Rises On Acquisition News; Comtech Shares Plunge"", ""Mid-Morning Market Update: Markets Edge Lower; BlackBerry Tops Q2 Expectations"", ""Canaccord Stick With Buy Rating On Dexcom Following Abbott's Libre Receiving Unexpected Label Addition To Include Insulin Dosing Indication"", ""5 Biggest Price Target Changes For Thursday"", ""Benzinga's Top Upgrades, Downgrades For September 28, 2017"", ""20 Stocks Moving In Thursday's Pre-Market Session"", ""Tandem Diabetes Reports 1/3 Of t:slim X2 Pump Users Already Updated Their Pumps Via Personal Computer To Add New Dexcom G5 CGM Integration"", ""The Market In 5 Minutes: The Market Wakes Up To The Trump Tax Plan"", ""Dexcom Shares Fall 22% Premarket Following FDA Approval of Abbott's Blood Glucose Monitoring Device, Analyst Downgrades"", ""Raymond James Downgrades DexCom to Market Perform"", ""JP Morgan Downgrades DexCom to Neutral""]"
DXCM,2017-09-29,11.4375,12.29,11.4025,12.2312,"[""16 Stocks Moving In Friday's Pre-Market Session"", ""16 Stocks Moving In Friday's Pre-Market Session"", ""16 Stocks Moving In Friday's Pre-Market Session""]"
DXCM,2017-10-02,12.33,12.5775,12.1875,12.415,
DXCM,2017-10-03,12.4275,12.495,11.5775,11.795,
DXCM,2017-10-04,11.705,12.0375,11.6325,12.025,
DXCM,2017-10-05,11.9925,12.2075,11.7675,11.9975,
DXCM,2017-10-06,12.05,12.1,11.8875,11.94,"Why Fitbit Stock Rose 15.4% in September What happened Shares of Fitbit (NYSE: FIT) climbed 15.4% in September, according to data from S&P Global Market Intelligence . The jump in the company's share price can mostly be attributed to optimism surrounding the unveiling and launch of its Ionic smartwatch line. So what Fitbit unveiled the Ionic smartwatch on Aug. 28, highlighting features including a four-day battery life, new health-tracking technologies, and contactless payments. Fitbit also announced a partnership with DexCom to bring glucose-monitoring technology to the Ionic line of watches. The Ionic is an important step for the company as it attempts to expand beyond activity trackers and get a bigger foothold in the broader wearables market. Fitbit stock also got a lift following a Sept. 26 announcement that the company was one of nine that had been approved for a Food and Drug Administration program that will ease the regulatory approval measures for health and wellness apps, thereby speeding development processes. Faster development timelines could be significant as the company looks to build on the health and wellness functionality of its devices and develop an app ecosystem for its smartwatches. Now what The Ionic smartwatch went on sale Oct. 1 at a retail price of $300. Rather than opt to use a third-party operating system such as Alphabet 's Android, Fitbit has developed its own operating system for its smartwatches. This move gives the company greater control over the hardware platform, however it also means that there will be fewer apps available for the devices, which could ultimately impact consumer adoption. Fitbit's sales have slipped by double digits in each of the last three quarters, and the company expects that revenue for the year will be down between 22% and 29% despite Ionic's fourth-quarter launch. The smartwatch will likely be the deciding factor in whether Fitbit can return to growth next year, so investors should keep a close eye on its performance. 10 stocks we like better than Fitbit When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Fitbit wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of September 5, 2017 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Noonan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends GOOGL, GOOG, and Fitbit. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-10-09,11.9675,12.0162,11.7688,11.825,"[""DexCom's Quiet Consolidation After Huge Decline"", ""DexCom's Quiet Consolidation After Huge Decline"", ""DexCom's Quiet Consolidation After Huge Decline""]"
DXCM,2017-10-10,11.8025,11.8733,11.44,11.525,
DXCM,2017-10-11,11.595,11.805,11.5375,11.8,
DXCM,2017-10-12,11.8125,11.875,11.5575,11.71,
DXCM,2017-10-13,11.5725,11.6275,11.4325,11.51,
DXCM,2017-10-16,11.45,11.4925,11.1425,11.2425,
DXCM,2017-10-17,11.31,11.3738,10.9675,11.2475,
DXCM,2017-10-18,11.2188,11.335,11.0075,11.2375,
DXCM,2017-10-19,11.245,11.3025,10.9738,11.245,
DXCM,2017-10-20,11.275,11.3775,11.115,11.195,
DXCM,2017-10-23,11.1275,11.47,11.1275,11.1925,"[""Detailed Research: Economic Perspectives on DexCom, Pier \u2013 Imports, Gilead Sciences, Fitbit, ..."", ""Detailed Research: Economic Perspectives on DexCom, Pier \u2013 Imports, Gilead Sciences, Fitbit, ..."", ""Detailed Research: Economic Perspectives on DexCom, Pier \u2013 Imports, Gilead Sciences, Fitbit, ...""]"
DXCM,2017-10-24,11.1225,11.2425,11.0025,11.1375,
DXCM,2017-10-25,11.1025,11.25,11.0,11.1725,
DXCM,2017-10-26,11.1425,11.24,10.94,11.115,
DXCM,2017-10-27,11.115,11.195,11.03,11.14,
DXCM,2017-10-30,11.1175,11.3225,10.935,11.31,"[""Vanguard Health Care Fund Buys 6 New Stocks in the 'rd Quarter"", ""Vanguard Health Care Fund Buys 6 New Stocks in the 'rd Quarter"", ""Vanguard Health Care Fund Buys 6 New Stocks in the 3rd Quarter The Vanguard Health Care Fund ( Trades , Portfolio ), managed my Jean Hynes, bought six new positions in the third quarter, it revealed Monday. The new positions represented two industries equally: biotech, and medical diagnostics and research. The three from biotech were: bluebeard bio Inc. ( BLUE ), BeiGene Ltd. ( BGNE ) and Galapagos NV ( GLPG ). Medical instruments and diagnostics companies were: Essilor International SA ( EI ), DexCom Inc. ( DXCM ) and PRA Health Sciences Inc. (PRAH). The portfolio of the Vanguard Health Care Fund (Trades, Portfolio) had 80 positions as of the end of the third quarter. Together, they had a value of $46.56 billion. Since inception in 1984, the fund has gleaned a 16.58% average annual return. New Buys Essilor International SA ( EI ) The fund purchased 1,957,406 shares of the company, giving it a 0.52% portfolio weight. The stock's price averaged 106.21 euros per share for the third quarter. Essilor International SA has a market cap of $23.24 billion; its shares were traded around $107.30 with a P/E ratio of 30.14 and P/S ratio of 3.31. The trailing 12-month dividend yield of Essilor International SA stocks is 1.40%. The forward dividend yield of Essilor International SA stocks is 1.40%. Essilor International SA had an annual average earnings growth of 11.10% over the past 10 years. GuruFocus rated Essilor International SA the business predictability rank of 5-star. DexCom Inc. ( DXCM ) The fund purchased 2,606,600 shares of the company, giving it a 0.27% portfolio weight. The stock's price averaged $71 per share for the third quarter. bluebeard bio Inc. ( BLUE ) The fund purchased 378,528 shares of bluebeard bio Inc., giving it a 0.11% portfolio weight. The stock's price averaged $107 per share for the third quarter. PRA Health Sciences Inc. (PRAH) The fund purchased 601,636 shares of the company, giving it a 0.1% portfolio weight. The stock's price averaged $76 per share for the third quarter. BeiGene Ltd. ( BGNE ) The fund purchased 305,865 shares of the company, giving it a 0.07% portfolio weight. The stock's price averaged $74 per share for the third quarter. Galapagos NV ( GLPG ) The fund purchased 282,879 shares of the company, giving it a 0.06% portfolio weight. The stock's price averaged 74 euro per share for the third quarter. See the portfolio of the Vanguard Health Care Fund (Trades, Portfolio) here. Premium Members This article first appeared on GuruFocus . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Vanguard Health Care Fund Buys 6 New Stocks in the 'rd Quarter""]"
DXCM,2017-10-31,11.3225,11.48,11.2125,11.2425,
DXCM,2017-11-01,11.28,11.4075,11.125,11.215,"[""DexCom Q3 Adj. EPS $(0.04) vs $(0.16) Est., Sales $184.6M vs $184.2M Est."", ""DexCom Q3 Adj. EPS $(0.04) vs $(0.16) Est., Sales $184.6M vs $184.2M Est."", ""DexCom Q3 Adj. EPS $(0.04) vs $(0.16) Est., Sales $184.6M vs $184.2M Est.""]"
DXCM,2017-11-02,11.8,12.575,11.6025,11.93,"[""DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet"", ""DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet"", ""Why Fitbit Inc Stock Can Climb Back Out of Its Grave InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's only a glimmer of hope right now, but Fitbit Inc (NYSE: FIT ) is starting to get back on track. FIT stock is currently down roughly 3% in early morning trading after reporting earnings yesterday, but it's important for investors to remember something before they jump the gun. The company has been innovating its product roadmap with increased discipline in its cost structure. Despite the early morning fall, I still think there is a value opportunity here for patient investors. FIT Stock: Earnings Breakdown The adjusted loss was 1-cent-per-share and revenues came to $392.5 million. By comparison, the consensus estimate was for a 3 cent loss on FIT stock and revenues of $392 million. As for the outlook for the full-year, the company is forecasting a loss of 27 cents to 23 cents-per-share and revenues of $1.62 billion and $1.65 billion. The Street, on the other hand, was looking for a loss of 31 cents and revenues $1.62 billion. But again, the key is the progress with the product line. And the latest quarter does provide some encouraging metrics. For example, on a sequential basis, there was a 7% increase in device shipments to 3.6 million. This is an indication that FIT is finding ways to deal with the competitive threats from mega operators like Apple Inc. (NASDAQ: AAPL ), Samsung Electronics and Xiaomi Inc. During the quarter, FIT launched its Ionic smartwatch. It includes features like GPS tracking, heart-rate tracking, water resistance (up to 50 meters), a SpO2 sensor, contactless payments and battery life of over four days. And in terms of customer traction, there are certainly positive signs for FIT stock. Note that the Ionic device has an average of 4.2 stars on Amazon.com, Inc.'s (NASDAQ: AMZN ) website. This actually represents the best reception for any Fitbit product in its history. 5 Tech Stocks to Buy With Monster Yields The Ionic device is also attracting interest from third-party developers; 1,400 have already signed on to build apps for the platform. Something else: The Fitbit Flyer wireless headset is also seeing robust demand. In the quarter, there was a 14% attach rate with Ionic purchases (this is from FIT's website sales). FIT and the Healthcare Opportunity One of FIT stock's biggest advantages is its database . There are 90 billion hours of heart rate data, 167 billion minutes of exercise information and 85 trillion steps. In other words, the FIT platform has the potential to allow for detecting health issues. To this end, the company recently struck a deal with DexCom, Inc. (NASDAQ: DXCM ), which is the leader in continuous glucose monitoring. The partnership will involve developing products to help people manage their diabetes, which is a disease that affects over 400 million people across the globe. Apple Inc. Faces Another Fire With Apple Watch 3 Display Problems Next, the U.S. Food and Drug Administration's (FDA) chose FIT as one of nine companies to be a part of a precertification pilot. By doing this, the company is likely to benefit from faster approvals. Bottom Line on the FIT Stock Price In terms of valuation, the FIT stock price is fairly cheap. Consider that the price-to-sales ratio is 0.8X. In fact, when you strip out the $659 million in cash, the multiple is a mere 0.45X. But more importantly, the company looks poised to get a lift from its Ionic device, which could mean a strong holiday season for FIT stock. What's more, in the meantime, there should be growth from the healthcare business. Again, a rapid turnaround is probably not in the cards. But for investors with a long-term perspective on things, FIT could prove a profitable turnaround opportunity. Tom Taulli is the author of High-Profit IPO Strategies , All About Commodities and All About Short Selling . Follow him on Twitter at @ttaulli . As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace 10 Zombie Stocks to Buy Before They Return From the Grave 10 Cheap Stocks to Buy With Only $12 7 Blue-Chip Stocks to Sell in November The post Why Fitbit Inc Stock Can Climb Back Out of Its Grave appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet DexCom, Inc.DXCM reported a loss of 3 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 15 cents. Also, the figure improved from a loss of 22 cents reported in the year-ago quarter. Total revenues grew 24.2% to $184.6 million from $148.6 million in the year-ago quarter. Revenues met the Zacks Consensus Estimate. Segmental details Sensor revenues (71% of total revenues) grew 24% on a year-over-year basis to $131.1 million. Transmitter revenues (21%) increased 20% from the prior-year quarter to $38.2 million. Receiver revenues (8%) grew 15% year over year to $14.4 million. Other revenues (including revenues from services, freight, accessories, etc.), accounting for the rest, totaled $0.9 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Operational Details DexCom generated gross margin (as a percentage of revenues) of 68.8%, compared with 68% in the same quarter of the prior year. Notably, gross margin expanded 76 basis points (bps) year over year. International business displayed continued to grow in the quarter, generating $33.3 million in revenues, up 83% on a year-over-year basis. Notably, international business represented 18% of total revenues in the third quarter. Research and development (R&D) expenses totaled $43.3 million in the quarter, contracting 1.4% from $43.9 million a year ago. Selling, general and administrative expenses totaled $84.2 million in the reported quarter, increasing 11.2% from $75.7 million in the prior-year quarter. Financial Update As of Sep 30, DexCom had $525.8 million in cash, cash equivalents and short-term marketable securities versus $496.6 million at the end of the second quarter of 2017. Guidance The company expects global revenues to come in at the low end of its previously issued guidance of $710 million to $740 million. For the full year, DexCom reaffirmed the low end of the 67% to 70% gross margin guidance. Zacks Rank & Key Picks DexCom has a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Luminex Corporation LMNX and Intuitive Surgical, Inc. ISRG . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter's 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter. Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. The company's revenues in the quarter increased almost 4.1% year over year to $74.1 million. Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% year over year. Also, revenues increased 18% year over year to $806.1 million. Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades\u2026 from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet""]"
DXCM,2017-11-03,11.9275,12.345,11.745,12.28,"[""Why 2017 was a Year to Forget for Fitbit Inc. Fitbit (NYSE: FIT) shares fell 3% on Nov. 1 after the wearables maker reported its third quarter earnings. Its revenue fell 22% annually to $393 million, marking its fourth straight quarter of double-digit sales declines, and it posted a non-GAAP net loss of $0.01 per share, versus a profit of $0.19 per share a year ago. However, those headline numbers beat analyst expectations for $392 million in revenues and a loss of $0.04 per share. For the fourth quarter, Fitbit forecasts -1% to 5% sales growth, and for its non-GAAP earnings to come in between a loss of $0.03 and a profit of $0.01. For the full year, Fitbit expects a 24%-26% sales decline, and a net loss between $0.23-$0.27 per share compared to a loss of $0.12 per share in 2016. Those estimates all either matched or beat analyst expectations, but investors clearly weren't impressed with Fitbit's overall performance. As a result, the stock remains down about 15% for the year, and more than 50% over the past 12 months -- making 2017 a year to forget for the struggling wearables maker. Let's take a look at why Fitbit fell off a cliff, and whether or not it could ever rebound. What happened to Fitbit? Fitbit's fitness trackers made it one of the hottest brands on Wall Street when it launched its IPO over two years ago. Sales were up 255% in 2013, 175% in 2014, and 149% in 2015. Analysts gushed over the rosy future of wearable devices, and the stock surged from its IPO price of $20 to nearly $30 on its first day of trading. Today, the stock is worth about $6. Three big problems torpedoed Fitbit's high-flying stock. First, other companies like Xiaomi and Garmin commoditized the fitness tracker market with cheaper devices. Second, companies like Samsung and Apple (NASDAQ: AAPL) launched pricier smartwatches with built-in fitness tracking capabilities. Fitbit, once the largest wearables maker in the world by market share, slipped to third place behind Xiaomi and Apple, according to IDC's second quarter numbers. Between the second quarters of 2016 and 2017, Fitbit's market share plunged from 24.1% to 12.9%. Lastly, wearables remained a niche market that didn't come anywhere close to matching smartphones or tablets as a new product category. As a result, Fitbit's revenue rose just 17% last year, and is now headed for its first annual decline this year. To lift sales, Fitbit cut prices and invested more in the development and marketing of new products. That caused its margins to contract and resulted in four straight quarters without a profit. Source: YCharts. What's Fitbit's turnaround plan? Things look bleak for Fitbit, but the company still has other irons in the fire . The first big effort is Ionic, its first full-featured smartwatch. The Ionic faces fierce competition from the Apple Watch 3, but the Ionic's lengthy battery life of about four days crushes the Apple Watch's single-day battery life, and it's slightly cheaper at $300. During last quarter's conference call, Fitbit CEO James Park claimed that the Ionic and the older \""smartwatch-like\"" Blaze were respectively the first and second best-selling smartwatches on Amazon in the US. The Ionic is also intended to become the foundation of a new ecosystem for Fitbit. The device supports its new mobile payments platform Fitbit Pay. It also recently partnered with medical device maker Dexcom (NASDAQ: DXCM) to sync its glucose monitoring devices to the Ionic's display, which could encourage other medical device makers to share their data with Fitbit. Fitbit is also expanding its app ecosystem. It already reaches millions of users with its flagship app, but it's also developing a full app store for the Ionic, which could lock in users and become a new stream of revenue for the company. It also purchased smartwatch maker Pebble's assets and high-end smartwatch maker Vector to expand its hardware and software capabilities. Fitbit is also diversifying away from standard wearable devices with new products like the Fitbit Flyer wireless headphones and the Aria 2 smart scale, but revenue from those products should remain low compared to best-selling wearable products like the Charge 2. But will these efforts pay off? Fitbit faces a tough uphill battle, and it's unclear when its sales and earnings will start growing again. But for now, the stock looks fairly cheap at 0.8 times sales, and about 20% of shares were still being shorted as of Oct. 24. This means that expectations are currently so low that any good news could cause this beaten-down stock to jump. 10 stocks we like better than Fitbit When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Fitbit wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of October 9, 2017 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Leo Sun owns shares of AMZN. The Motley Fool owns shares of and recommends AMZN, Apple, and Fitbit. The Motley Fool has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Surprising Analyst 12-Month Target For EQWM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares Russell Midcap Equal Weight Portfolio ETF (Symbol: EQWM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.70 per unit. With EQWM trading at a recent price near $45.82 per unit, that means that analysts see 12.83% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of EQWM's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), NCR Corp (Symbol: NCR), and HanesBrands Inc (Symbol: HBI). Although DXCM has traded at a recent price of $47.72/share, the average analyst target is 47.81% higher at $70.53/share. Similarly, NCR has 45.14% upside from the recent share price of $30.66 if the average analyst target price of $44.50/share is reached, and analysts on average are expecting HBI to reach a target price of $26.92/share, which is 34.04% above the recent price of $20.08. Below is a twelve month price history chart comparing the stock performance of DXCM, NCR, and HBI: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2017-11-06,12.3,12.5225,12.2375,12.485,"3 Stocks Changing the Future of Healthcare The healthcare sector is in the midst of an unprecedented technological boom at the moment. Despite major advancements across several medical fields, though, this innovation bonanza is, quite literally, showing no signs of slowing down. Armed with this insight, we asked three of our Motley Fool investors which companies they think are on the cusp of changing healthcare as we know it. They suggested Bellicum Pharmaceuticals (NASDAQ: BLCM) , Apple (NASDAQ: AAPL) , and Novocure (NASDAQ: NVCR) . Read on to find out why. A hidden gem in immuno-oncology George Budwell (Bellicum Pharmaceuticals): Genetically modified cell-based cancer therapies are now a reality following the back-to-back approval of both Gilead Sciences ' Yescarta and Novartis ' Kymriah earlier this year. But while Gilead and Novartis' respective CAR-T therapies did show unprecedented abilities to treat hard-to-treat forms of blood cancers in clinical trials, they also both produced some serious -- even potentially deadly -- side effects that may keep them from becoming frontline anti-cancer therapies. The small-cap clinical-stage biotech Bellicum Pharmceuticals, however, may have a way to circumvent these problematic side effects. Bellicum has developed a molecular switch mechanism that can induce either apoptosis (programmed cell death), or proliferation (to enhance potency) of their genetically modified cell therapies following infusion. Gilead and Novartis, by contrast, are limited to treating patients experiencing life-threatening side effects -- such as cytokine release syndrome -- with standard immunosuppressants, and this ad hoc approach hasn't always worked unfortunately. The one glaring problem with Bellicum's value proposition, though, is that the company is a few years away from grabbing a major regulatory approval capable of making it a cash flow positive operation. And that fact almost certainly means that Bellicum will eventually tap the public markets for funds at least a few more times in the years ahead. That being said, Bellicum is developing a well-differentiated anti-cancer technology that could become the gold standard in cell-based therapies down the road. So while the biotech does need to shore up its long-term financial outlook, Bellicum's novel cell therapy platform also gives it a real shot at reshaping the entire field in the not-so-distant future. This tech giant is making waves in the healthcare sector Sean Williams(Apple): There are a number of companies doing wonders in the healthcare field. For instance, cancer immunotherapy drug developers are giving advanced cancer patients a new lease on life, while medical device makers are improving the quality of life for diabetes patients. But one company with deep pockets that could change the game is a bit untraditional : Apple. Apple, which is best known for its iPhone, iPad, and Macbook, announced its entrance in to the health space in 2014 when it introduced the Health app with its launch of iOS. The Health app allows users to keep track of their wellness in four key areas: activity, sleep, mindfulness, and nutrition. While the Health app is continually a work in progress, it's a step toward increasing wellness awareness with the public, and shuffling consumers toward that next step: cloud-based sharing. The advent of the Apple Watch and other wearable technology may one day allow your doctor to collect real-time data that could improve your personalized wellness plan. CNBC pointed out in April of this year that Apple's been working on a blood-glucose measurement device for diabetics that'll work without the need for a needle. Considering how often patients have to test their blood sugar, this would be a major quality of life advancement. A proprietary model appears to have been tested out by Apple CEO Tim Cook. In June, Apple forged a partnership with blood glucose monitoring device maker Dexcom (NASDAQ: DXCM) that'll link Dexcom's device with the Apple Watch. Apple's Bluetooth technology that allows devices to link to its Watch isn't unique to Dexcom (it'll potentially work with other devices), but it's just another example of how Apple can use wearables, technology, and/or the cloud to personalize the treatment process. While it could be a nascent revenue generator for years, look for healthcare to slowly grow into a notable portion of Apple's revenue stream in the decades to come. A new weapon in the cancer fight Brian Feroldi (Novocure): While we've made tremendous progress in the war against cancer, more than half a million Americans still die each year as a result of their diagnosis. Clearly, there's still plenty of work left to do. Novocure is one company that's blazing new trails in the fight. The company figured out a few years ago that cancerous tumors can't replicate themselves as easily when an electric field is nearby. That unique insight lead the company to create a product called Optune, which is a FDA-approved medical device that treats brain cancer. Optune looks like a swimmers cap that has a cord coming out of the back. To use it, a patient simply puts the device on their head and hooks it up to a portable electronics kit. Once turned on, Optune creates a series of electric fields that go to work on the brain cancer while leaving the rest of the body unscathed. It might sound like Optune is too good to be true, but the company has the data to prove that the device is the real deal. The company published data from a long-term study that showed that adding Optune to standard-of-care therapy chemotherapy more than doubled survival rates at five years. That's an impressive result for an incredibly hard to treat cancer. While Optune's appeal has allowed Novocure to grow like crazy , there's reason to believe that the party is just getting started. Novocure is currently running trials to prove that Optune works in lung, pancreatic, and ovarian cancers, too. If they succeed then the sky is the truly the limit for this company's growth potential. Brian Feroldi owns shares of Apple and NovoCure. George Budwell has no position in any of the stocks mentioned. Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple and Gilead Sciences. The Motley Fool has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-11-07,12.5,12.6725,12.365,12.5275,
DXCM,2017-11-08,12.525,12.6,12.225,12.2475,
DXCM,2017-11-09,12.4025,12.66,12.2925,12.595,
DXCM,2017-11-10,12.7275,12.8625,12.45,12.6875,
DXCM,2017-11-13,12.5825,12.9775,12.5225,12.8875,
DXCM,2017-11-14,12.8875,13.11,12.8875,12.8875,
DXCM,2017-11-15,12.8425,13.1475,12.7856,13.0,
DXCM,2017-11-16,13.0625,13.29,12.8675,13.255,"[""PPG, Dexcom Shares Ticking Modestly Higher Here Amid Report Out Of Chatroom Co.'s Will Be Featured On CNBC's 'Mad Money'"", ""PPG, Dexcom Shares Ticking Modestly Higher Here Amid Report Out Of Chatroom Co.'s Will Be Featured On CNBC's 'Mad Money'"", ""PPG, Dexcom Shares Ticking Modestly Higher Here Amid Report Out Of Chatroom Co.'s Will Be Featured On CNBC's 'Mad Money'""]"
DXCM,2017-11-17,13.24,13.5225,13.05,13.5025,"[""Thursday Was About Wal-Mart And Cisco - Cramer's Mad Money (11/16/17)"", ""Thursday Was About Wal-Mart And Cisco - Cramer's Mad Money (11/16/17)"", ""Thursday Was About Wal-Mart And Cisco - Cramer's Mad Money (11/16/17)""]"
DXCM,2017-11-20,13.5,13.8525,13.4212,13.665,
DXCM,2017-11-21,13.7725,13.9025,13.465,13.7775,"[""DexCom teams up with Lilly to combine CGM into insulin lineup"", ""Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem"", ""Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem"", ""DexCom teams up with Lilly to combine CGM into insulin lineup"", ""Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem"", ""DexCom teams up with Lilly to combine CGM into insulin lineup""]"
DXCM,2017-11-22,13.8025,13.96,13.6488,13.8375,"[""Lilly Inks Deal to Include Dexcom Products in Diabetes System Eli Lilly and CompanyLLY announced that it has inked a development deal with DexCom, Inc. DXCM to integrate the latter's continuous glucose monitoring (CGM) products and tools into Lilly's Connected Diabetes Ecosystem. A Connected Diabetes Ecosystem connects devices and technologies to provide solutions that can cater to an individual's unique needs in managing diabetes. In fact, devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools can link patients and their care teams to deal with the disease in a better way. The Connected Diabetes Ecosystem will depend on Lilly's core diabetes expertise along with the devices and tools provided by Dexcom. Per Lilly, the agreement with Dexcom will enable the company to reduce the daily burden for people with diabetes. Studies are expected to begin by the end of 2017. So far this year, shares of Lilly have increased 13.5% compared with the industry 's gain of 14.8%. Lilly has a strong portfolio of diabetes treatments including Trulicity (GLP-1), Jardiance (SGLT-2), Trajenta, Humulin, Basaglar, Humalog, and Glyxambi. Also, it has a diabetes alliance with Boehringer Ingelheim for many of these products. The company is seeking label expansion of some of these drugs. Zacks Rank & Stocks to Consider Lilly carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks in the same space are Sucampo Pharmaceuticals SCMP and Ligand Pharmaceuticals LGND carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Sucampo's earnings per share estimates have moved up from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 15.63%. Ligand's earnings per share estimates have climbed $3.68 to $3.70 for 2018 over the last 60 days. The company pulled off a positive earnings surprise in two of the trailing four quarters, with an average beat of 8.22%. The share price of the company has increased 27.9% year to date. Wall Street's Next Amazon Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom-Lily Partnership to Boost CGM Platform, Customer Base DexCom, Inc.DXCM recently announced the signing of a development agreement with Eli Lilly and Company LLY . Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added to Lilly's Connected Diabetes Ecosystem. Through the integration of CGM with Lily's smart insulin delivery devices, DexCom aims to provide a holistic approach to diabetes management for its customers. Notably,clinical trials are expected to begin by the end of 2017. DexCom's FDA-cleared CGM system - the DexCom G4 Platinum - is contributing significantly to the top line. DexCom G4 Platinum is the most innovative CGM system in the market. In June, DexCom had announced the FDA approval of the DexCom G5 mobile app for Android devices. Moreover, DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product use. In September 2017, DexCom announced a tie-up with leading wearables brand Fitbit to develop and market products to help people better manage diabetes and get a clearer picture of their overall health. The first planned initiative is to bring DexCom CGM data to Fitbit's new smartwatch, Fitbit Ionic. The companies aim to make the smartwatch available in 2018 and will continue to explore ways to develop tools to improve diabetes management. We believe the glucose monitoring market represents significant commercial opportunity for DexCom. Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%. Also, the International Diabetes Federation (IDF) estimates that by 2035, the worldwide incidence of people suffering from diabetes will reach 592 million. Recently, management at DexCom confirmed that the company is well poised to congregate the unmet demand in the global diabetic space, especially when it comes to CGM. DexCom's increased patient convenience, enhanced connectivity, data analytics, and lower cost platforms fortify the company's foothold in the global diabetic space. However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. In this space, Abbott recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Share Price Performance DexCom has been gaining investor confidence on consistently positive results. Over the last month, the company's share price outperformed the broader industry . The stock has gained 23.1%, as compared with the broader industry's 1%. The company has also outperformed the 0.9% gain of the S&P 500 market. Zacks Rank & Key Pick DexCom carries a Zacks Rank #3 (Hold). A better-ranked medical stock is PetMed Express, Inc. PETS , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 80.9% in a year. Wall Street's Next Amazon Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2017-11-24,14.0025,14.0025,13.75,13.8875,
DXCM,2017-11-27,13.875,14.025,13.7,13.8875,"3 Top Diabetes Stocks to Buy Now Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs associated with diabetes are projected to increase by more than 50% by 2030. But where there's a problem, there's also an opportunity. Healthcare companies continue to develop innovative new approaches to treating and managing diabetes. This innovation in turn creates value for investors. At least 15 publicly traded companies have current products addressing diabetes either on the market or in development. A few of these stocks hold the potential to generate market-beating returns for investors. I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Here's why these are three top diabetes stocks to buy now. Abbott Labs Abbott Labs claims a market cap of close to $98 billion. The company's primary focus in the past has been on branded generic drugs, diagnostic systems and tests, nutritional products, and cardiovascular and neuromodulation medical devices. Abbott's diabetes care unit revenue wasn't even listed separately in the company's financial statements. However, diabetes should be much more important to Abbott in the future. In September, the U.S. Food and Drug Administration (FDA) approved the company's FreeStyle Libre Flash Glucose Monitoring System. It's the first continuous glucose monitoring (CGM) system approved by the FDA that doesn't require a finger-stick blood sample. As you might imagine, the potential for the FreeStyle Libre system is huge. DexCom (NASDAQ: DXCM) has been the leader in of the fast-growing CGM market so far. FDA approval for Abbott's FreeStyle Libre system caused DexCom stock to plummet because of the threat from Abbott. Although DexCom is developing its own no-finger-stick device, it's about a year away from being able to market the product. That gives Abbott a nice head start. Abbott was already enjoying a fantastic year even before the FDA decision. The stock is up more than 40% year to date, driven in large part by the company's acquisition earlier this year of St. Jude Medical. This acquisition made Abbott an even more formidable force in the medical device market. There's also a lot for investors to like about Abbott's dividend. Its yield currently stands at 1.91%. Abbott has increased its dividend for 45 consecutive years and has paid a dividend every quarter since 1924. Becton, Dickinson and Company Becton, Dickinson and Company's market cap of nearly $52 billion makes it the smallest of these three top diabetes stocks. However, the company will grow close in size to the other two on the list once it finalizes a planned $24 billion acquisition of C. R. Bard, Inc. (NYSE: BCR) . Around 13% of Becton, Dickinson and Company's total revenue stems from its diabetes care segment. BD's diabetes products include insulin pumps, insulin syringes, pen needles, and sharps containment. Sales for its diabetes care segment is growing by low-single-digit percentages, held back in part because of austerity measures in some European countries. The addition of C. R. Bard will provide a big boost to BD's revenue and earnings. However, Bard focuses on vascular, urology, and oncology products. BD's diabetes care unit won't be impacted much, if any, by the deal. BD stock has been a big winner so far in 2017, with shares jumping close to 40% year to date. In addition, the company pays a dividend, which currently yields 1.33%. Like Abbott, both BD and C. R. Bard are Dividend Aristocrats , with BD increasing its dividend every year since 1972. Johnson & Johnson Johnson & Johnson is the giant of the group, with a market cap of over $370 billion. J&J's diabetes care unit is a big business on track to generate sales of around $1.6 billion in 2017, but that's only a small sliver of the company's total revenue. However, the company's pharmaceutical segment markets diabetes drug Invokana, which should add another $1.1 billion or so to J&J's total diabetes-related revenue this year. There's an asterisk needed with Johnson & Johnson, though. Were it not for Invokana, J&J might not be classified as a diabetes stock for much longer. The company announced that it was exiting the insulin pump business. J&J is also evaluating strategic options for its other diabetes care businesses. These options include selling the units and forming partnerships or joint ventures with other companies. Still, J&J certainly qualifies as a diabetes stock now. And it should be a good one to own over the long run, albeit more because of its pharmaceutical lineup than its diabetes care products. Cancer drugs Darzalex and Imbruvica combined with autoimmune-disease drug Stelara are enjoying strong sales growth. The acquisition of Swiss drugmaker Actelion earlier this year has added a successful pulmonary hypertension franchise to the company's roster. J&J also has one of the best drug pipelines in the biopharmaceutical industry , with promising candidates including prostate cancer drug apalutamide. Don't forget Johnson & Johnson's dividend, either. Its dividend yields 2.37% right now. J&J is also a Dividend Aristocrat and has raised its dividend for an impressive 55 years in a row. Best pick? I don't think investors would go wrong by buying any or all of these diabetes stocks. All three pay great dividends, and all three have decent growth prospects. If I could only pick one of them, though, I'd go with Abbott. Wall Street analysts project higher earnings growth over the next five years for Abbott than they do for BD or J&J. I suspect they're right. The acquisition of St. Jude Medical was a smart move for Abbott, in my view. I'm also excited about the potential for the FreeStyle Libre CGM system. If you're looking for a growth stock with a solid dividend that's also going to significantly impact how diabetes is managed, I think Abbott Labs is the best option. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of Nov. 6, 2017 Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool recommends Becton Dickinson. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-11-28,14.455,14.5625,14.455,14.455,
DXCM,2017-11-29,14.5,15.225,14.4525,14.845,"[""DexCom up 4% on potential CGM opportunity with UnitedHealth"", ""Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals"", ""Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals"", ""DexCom up 4% on potential CGM opportunity with UnitedHealth"", ""Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals"", ""DexCom up 4% on potential CGM opportunity with UnitedHealth""]"
DXCM,2017-11-30,14.755,14.895,14.235,14.6075,
DXCM,2017-12-01,14.5475,14.71,14.18,14.505,
DXCM,2017-12-04,14.665,14.935,14.4275,14.47,
DXCM,2017-12-05,14.4375,14.7062,14.3525,14.5025,
DXCM,2017-12-06,14.5475,14.82,14.42,14.7,
DXCM,2017-12-07,14.735,15.0775,14.655,14.9925,
DXCM,2017-12-08,15.005,15.47,14.9775,15.3825,
DXCM,2017-12-11,15.3075,15.5875,14.4275,14.6125,"[""DexCom 13G From Wellington Mgmt. Group Shows Raised Stake From ~7.97M Shares To ~8.7M Shares, Or 10.05% Stake"", ""DexCom 13G From Wellington Mgmt. Group Shows Raised Stake From ~7.97M Shares To ~8.7M Shares, Or 10.05% Stake"", ""DexCom 13G From Wellington Mgmt. Group Shows Raised Stake From ~7.97M Shares To ~8.7M Shares, Or 10.05% Stake""]"
DXCM,2017-12-12,14.7,14.8775,14.31,14.3125,
DXCM,2017-12-13,14.2875,14.71,14.1425,14.6275,
DXCM,2017-12-14,14.695,14.855,14.4225,14.5575,
DXCM,2017-12-15,14.5525,14.7775,14.1975,14.26,
DXCM,2017-12-18,14.38,14.615,14.18,14.5875,
DXCM,2017-12-19,14.575,14.7162,14.4625,14.53,
DXCM,2017-12-20,14.6275,14.635,14.17,14.1825,"DexCom (DXCM) Banks on Collaborations, Competition Rife On Dec 19, we issued an updated research report on DexCom, Inc.DXCM . The company has been trading above the broader industry over the past month. The stock has gained 5.5%, higher than the broader industry's gain of 0.8%. We believe the glucose monitoring market represents significant opportunity for DexCom. The diabetes market is large and growing. In the third quarter of 2017, management at Dexcom confirmed that the company is well poised to meet the unmet demand in the global diabetic space, especially when it comes to the continuous glucose monitoring facility. DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio. In this regard, DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit to develop and market products for better management of diabetes and get a clearer picture of overall health with easy-to-use mobile tools. DexCom continues to focus on international markets, especially Germany. The company is also eyeing the sizeable markets of India, China and Japan. Given the demographic trends and lifestyle in countries outside the United States and Europe, we believe that DexCom has bountiful opportunities in the international market. However, the company faces reimbursement risks owing to efforts to control healthcare expenses. Further, with an increasing demand for its offerings, DexCom might face supply constraints in the near term. The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by product launches. With respect to the G4 Platinum system, DexCom competes directly with Roche Diabetes Care - a division of Roche Diagnostics; LifeScan, Inc. - a division of Johnson & Johnson; the MediSense and TheraSense divisions of Abbott Laboratories; and Bayer Corporation. Zacks Rank & Key Picks DexCom carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are athenahealth, Inc. ATHN , Align Technology, Inc. ALGN and Luminex Corporation LMNX . Notably, athenahealth, and Align Technology sport a Zacks Rank #1 (Strong Buy) while Luminex carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. athenahealth has a long-term expected earnings growth rate of 22.3%. The stock has rallied roughly 17.1% over a year. Align Technology has a long-term expected earnings growth rate of 28.9%. The stock has gained 134.5% in a year. Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 4.6% in the past three months. 5 Medical Stocks to Buy Now Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits. Click here to see the 5 stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-12-21,14.23,14.295,13.77,13.9325,
DXCM,2017-12-22,13.95,14.0975,13.8425,14.03,"[""4 MedTech Stocks to Explode in 2018"", ""4 MedTech Stocks to Explode in 2018"", ""4 MedTech Stocks to Explode in 2018 The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax. The MedTech fraternity is leaving no stone unturned to permanently do away with the dreadful tax - but has not been able to. Interestingly, the year 2017 has been quite an eventful one, courtesy of a series of socio-political occurrences that favored the space. The year witnessed the much talked-about election wherein Donald Trump took over the nation's charge as President. Not only were the new administration's health schemes thoroughly criticized but the reforms that were brought in taxation schemes became a much talked-about subject. Needless to say, these developments kept investors on their toes. Standing at the threshold of 2018 it is imperative for the investors thus to find the means which can dilute the macroeconomic woes and help them gain more. But before guiding you to make prudent investments for the year let's take a look at the various developments that have taken place within the space and see what awaits the investors in the coming year. Health Policy Qualms to Continue in 2018 : It has already been a year since trump became the President. However, his policies continue to be the most debated issue in the space. The new administration's Obamacare 'repeal & replacement' effort through Congress and the latest 'Executive Order', which apparently has been designed to provide quality healthcare to the nation at affordable rate, has already posed a serious threat to the healthcare community. Per critics, this order, forsaking the consideration of pre-existing health conditions has been designed to push people into \""junk\"" insurance plans. The American Hospital Association has put forward an extremely bearish view on the executive order related to promote health care choice and competition. The association apprehends that the executive order will solely allow health insurance plans that cover fewer benefits and give lesser consumer protections. Tax-Reform May Hit Hard in 2018 : According a report by Business Insider, the Republican tax plan repeals an itemized deduction that applies to healthcare expenses. If the new bill gets implemented, families with high healthcare expenditure will be impacted as these expenses will no longer be deducted from their taxes. Hence, people will no longer be interested in expensive healthcare or MedTech procedures. A report by The Hill says that the Section 4303 of the Republican tax bill plan imposes a 20% excise tax on goods manufactured overseas by subsidiaries of U.S. companies. Under the U.S. tax code, Puerto Rico is considered a foreign land which implies that U.S. parent companies will have to pay excise taxes if they purchase from their subsidiaries in the island. In this regard, the FDA recently found that around 30% of Puerto Rico's gross domestic product was driven by pharmaceuticals and medical devices in 2016. Undoubtedly, the latest tax plan has created an uproar among MedTech players who might witness a huge reduction in their turnover with the approval of the bill. Medical Device Tax Returns in 2018 : The medical community was extremely hopeful about Trump's regulatory agenda as it promised to abolish the infamous 2.3% medical device tax that was first was included in the 2010 health care reform law. The dreaded tax, imposed on the selling price instead of net profit and amounting to a stupendous sum, wiped out almost a quarter of the profit of medical technology companies. Realizing this, the U.S. House and Senate temporarily suspended it for two years at the beginning of 2015. Going by the available data, it is quite evident that this partial two-year repeal of the medical device tax has benefited the sector's development. Per data provided by the medical device trade group (in a Ken Blackwell article published by The Daily Caller), within this period, there was roughly an 83% rise in research and development (R&D) investments by MedTech players. The Republicans however have tightlipped on this tax raising the probability of its return in 2018. Undoubtedly, its comeback will be an additional burden for the MedTech fraternity, largely discouraging R&D activities. Per an article by Matt Murphy in wbur, sectors which are going to be hampered most by reimposition of this levy are X-ray and MRI machines, surgical instruments and pacemakers. Use of 'PRO' Concept May Delay Regulatory Process in 2018 : The Center for Devices and Radiological Health's (CDRH) strategic priorities have been recently published where it has elaborately discussed the Value and Use of Patient Reported Outcomes (PROs) in Assessing Effects of Medical Devices. According to a Medcitynews article by John Speer, CDRH, the umbrella organization at the FDA, talked about a plan that would entitle patients to have access to high-quality, safe and effective medical devices. PRO basically means a patient's assessment of their own health status or quality of life. This is especially impactful because the majority of medical devices in the United States are cleared by FDA via the 510(k) premarket submission where patients have no voice as such. With the new PRO concept, this is no longer going to be valid. Per the report, \""given the expected behavior of the FDA by industry, it might increase the time taken to get through the regulatory process and increase costs to produce Class II devices.\"" This is because, now they will have to conduct some sort of PRO study if this becomes a requirement. Also they will need additional funding to support the study activities. FDA User Fee Increase, May Pose a Threat : Per an Emergo Group report, the FDA's 2018 user fees, established by the Medical Device User Fee Amendments of 2017 (MDUFA IV), will increase for all registration-related categories, including a sizeable fee increase for 510(k) premarket notification submissions by larger companies. In addition, FDA Establishment Registration fees will jump 37% to $4,642 for the 2018 fiscal from $3,382 in 2017. This implementation may pose a huge burden for the digital health industry and small companies in the medical device space. 4 Stocks to Brave the Threats In such a tumultuous scenario, to save investors from the time-taking process of identifying the powerful MedTech stocks who may brave the industry threats in 2018, we have taken the help of the Zacks Stock Screener . Here we have highlighted four MedTech stocks with market cap of $500 million or more with a Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive estimate revision trend of more than 5% for fiscal 2018. Based on strong fundamentals and positive vital metrics, these stocks have ample credential to return more to shareholders amid eco-political threats.(Looking for the Best Stocks for 2018? Be among the first to see our Top Ten Stocks for 2018 portfolio here . ) Bio-Rad Laboratories, Inc.BIO : Over the years, this $7300 billion market-cap stock has successfully demonstrated solid top-line growth driven by strong sales of Droplet Digital PCR instruments and consumables, cell biology and food safety products in the life science group. Additionally, the company has a strong cash balance that enables it to carry out share repurchases and provide solid returns to investors. The expansion in gross and operating margin also buoys optimism. The company is also constantly investing in R&D for product innovation. Based on this bullish sentiment, over the past four weeks the company's EPS estimate for the upcoming fiscal has improved 6.08%. The stock sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. Bio-Rad Laboratories, Inc. Price Bio-Rad Laboratories, Inc. Price | Bio-Rad Laboratories, Inc. Quote Mazor Robotics Ltd.MZOR : Market is particularly upbeat about the company's CE Mark approval for its Mazor X Surgical Assurance platform. The approval will allow Mazor Robotics and its partner Medtronic to commercialize, co-promote and market the Mazor X platformin countries that recognize CE Mark. This development should get reflected in Mazor's 2018 performance. This $1384 billon stock has a Zacks Rank #2. Over the past month, estimates for the company have moved 9.57% north for the next fiscal. Mazor Robotics Ltd. Price Mazor Robotics Ltd. Price | Mazor Robotics Ltd. Quote Tactile Systems Technology, Inc.TCMD : This $522-billion company develops and markets at-home therapy devices that treat lymphedema and chronic venous insufficiency. The company's offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinical staff. Meanwhile, the figures for Tactile Systems' next year are quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a 40.4% rise over the said frame. The stock flaunts a Zacks Rank #1. Tactile Systems Technology, Inc. Price Tactile Systems Technology, Inc. Price | Tactile Systems Technology, Inc. Quote DexCom, Inc.DXCM : DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio. In this regard, DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit (FIT) to develop and market products for better management of diabetes and get a clearer picture of overall health with easy-to-use mobile tools. In November 2017, the company partnered with Eli Lilly and Company (LLY). Per the agreement, DexCom's flagship continuous glucose monitoring system will be added to Lilly's Connected Diabetes Ecosystem. This Zacks Rank #2 stock with a market cap of $4.93 billion is a valuable pick for 2018. Over a month, estimates for the company have moved 9.76% north for the next fiscal. DexCom, Inc. Price DexCom, Inc. Price | DexCom, Inc. Quote Where Do Zacks' Investment Ideas Come From? You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 \""Strong Buy\"" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 \""Strong Sells\"" and other private research. See the stocks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report Tactile Systems Technology, Inc. (TCMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""4 MedTech Stocks to Explode in 2018""]"
DXCM,2017-12-26,14.065,14.3312,14.0375,14.235,"The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom For Immediate Release Chicago, IL - December 26, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bio-Rad Laboratories, Inc.BIO , Mazor Robotics Ltd.MZOR , Tactile Systems Technology, Inc.TCMD , Eli Lilly and CompanyLLY and DexCom, Inc.DXCM . Here are highlights from Friday's Analyst Blog: 4 MedTech Stocks to Explode in 2018 The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax. The MedTech fraternity is leaving no stone unturned to permanently do away with the dreadful tax - but has not been able to. Interestingly, the year 2017 has been quite an eventful one, courtesy of a series of socio-political occurrences that favored the space. The year witnessed the much talked-about election wherein Donald Trump took over the nation's charge as President. Not only were the new administration's health schemes thoroughly criticized but the reforms that were brought in taxation schemes became a much talked-about subject. Needless to say, these developments kept investors on their toes. Standing at the threshold of 2018 it is imperative for the investors thus to find the means which can dilute the macroeconomic woes and help them gain more. But before guiding you to make prudent investments for the year let's take a look at the various developments that have taken place within the space and see what awaits the investors in the coming year. Health Policy Qualms to Continue in 2018 : It has already been a year since trump became the President. However, his policies continue to be the most debated issue in the space. The new administration's Obamacare 'repeal & replacement' effort through Congress and the latest 'Executive Order', which apparently has been designed to provide quality healthcare to the nation at affordable rate, has already posed a serious threat to the healthcare community. Per critics, this order, forsaking the consideration of pre-existing health conditions has been designed to push people into ""junk"" insurance plans. The American Hospital Association has put forward an extremely bearish view on the executive order related to promote health care choice and competition. The association apprehends that the executive order will solely allow health insurance plans that cover fewer benefits and give lesser consumer protections. Tax-Reform May Hit Hard in 2018 : According a report by Business Insider, the Republican tax plan repeals an itemized deduction that applies to healthcare expenses. If the new bill gets implemented, families with high healthcare expenditure will be impacted as these expenses will no longer be deducted from their taxes. Hence, people will no longer be interested in expensive healthcare or MedTech procedures. A report by The Hill says that the Section 4303 of the Republican tax bill plan imposes a 20% excise tax on goods manufactured overseas by subsidiaries of U.S. companies. Under the U.S. tax code, Puerto Rico is considered a foreign land which implies that U.S. parent companies will have to pay excise taxes if they purchase from their subsidiaries in the island. In this regard, the FDA recently found that around 30% of Puerto Rico's gross domestic product was driven by pharmaceuticals and medical devices in 2016. Undoubtedly, the latest tax plan has created an uproar among MedTech players who might witness a huge reduction in their turnover with the approval of the bill. Medical Device Tax Returns in 2018 : The medical community was extremely hopeful about Trump's regulatory agenda as it promised to abolish the infamous 2.3% medical device tax that was first was included in the 2010 health care reform law. The dreaded tax, imposed on the selling price instead of net profit and amounting to a stupendous sum, wiped out almost a quarter of the profit of medical technology companies. Realizing this, the U.S. House and Senate temporarily suspended it for two years at the beginning of 2015. Going by the available data, it is quite evident that this partial two-year repeal of the medical device tax has benefited the sector's development. Per data provided by the medical device trade group (in a Ken Blackwell article published by The Daily Caller), within this period, there was roughly an 83% rise in research and development (R&D) investments by MedTech players. The Republicans however have tightlipped on this tax raising the probability of its return in 2018. Undoubtedly, its comeback will be an additional burden for the MedTech fraternity, largely discouraging R&D activities. Per an article by Matt Murphy in wbur, sectors which are going to be hampered most by reimposition of this levy are X-ray and MRI machines, surgical instruments and pacemakers. Use of 'PRO' Concept May Delay Regulatory Process in 2018 : The Center for Devices and Radiological Health's (CDRH) strategic priorities have been recently published where it has elaborately discussed the Value and Use of Patient Reported Outcomes (PROs) in Assessing Effects of Medical Devices. According to a Medcitynews article by John Speer, CDRH, the umbrella organization at the FDA, talked about a plan that would entitle patients to have access to high-quality, safe and effective medical devices. PRO basically means a patient's assessment of their own health status or quality of life. This is especially impactful because the majority of medical devices in the United States are cleared by FDA via the 510(k) premarket submission where patients have no voice as such. With the new PRO concept, this is no longer going to be valid. Per the report, ""given the expected behavior of the FDA by industry, it might increase the time taken to get through the regulatory process and increase costs to produce Class II devices."" This is because, now they will have to conduct some sort of PRO study if this becomes a requirement. Also they will need additional funding to support the study activities. FDA User Fee Increase, May Pose a Threat : Per an Emergo Group report, the FDA's 2018 user fees, established by the Medical Device User Fee Amendments of 2017 (MDUFA IV), will increase for all registration-related categories, including a sizeable fee increase for 510(k) premarket notification submissions by larger companies. In addition, FDA Establishment Registration fees will jump 37% to $4,642 for the 2018 fiscal from $3,382 in 2017. This implementation may pose a huge burden for the digital health industry and small companies in the medical device space. 4 Stocks to Brave the Threats In such a tumultuous scenario, to save investors from the time-taking process of identifying the powerful MedTech stocks who may brave the industry threats in 2018, we have taken the help of the Zacks Stock Screener . Here we have highlighted four MedTech stocks with market cap of $500 million or more with a Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive estimate revision trend of more than 5% for fiscal 2018. Based on strong fundamentals and positive vital metrics, these stocks have ample credential to return more to shareholders amid eco-political threats.(Looking for the Best Stocks for 2018? Be among the first to see our Top Ten Stocks for 2018 portfolio here . ) Bio-Rad Laboratories, Inc. : Over the years, this $7300 billion market-cap stock has successfully demonstrated solid top-line growth driven by strong sales of Droplet Digital PCR instruments and consumables, cell biology and food safety products in the life science group. Additionally, the company has a strong cash balance that enables it to carry out share repurchases and provide solid returns to investors. The expansion in gross and operating margin also buoys optimism. The company is also constantly investing in R&D for product innovation. Based on this bullish sentiment, over the past four weeks the company's EPS estimate for the upcoming fiscal has improved 6.08%. The stock sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. Mazor Robotics Ltd. : Market is particularly upbeat about the company's CE Mark approval for its Mazor X Surgical Assurance platform. The approval will allow Mazor Robotics and its partner Medtronic to commercialize, co-promote and market the Mazor X platformin countries that recognize CE Mark. This development should get reflected in Mazor's 2018 performance. This $1384 billon stock has a Zacks Rank #2. Over the past month, estimates for the company have moved 9.57% north for the next fiscal. Tactile Systems Technology, Inc. : This $522-billion company develops and markets at-home therapy devices that treat lymphedema and chronic venous insufficiency. The company's offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinical staff. Meanwhile, the figures for Tactile Systems' next year are quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a 40.4% rise over the said frame. The stock flaunts a Zacks Rank #1. DexCom, Inc. : DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio. In this regard, DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit (FIT) to develop and market products for better management of diabetes and get a clearer picture of overall health with easy-to-use mobile tools. In November 2017, the company partnered with Eli Lilly and Company. Per the agreement, DexCom's flagship continuous glucose monitoring system will be added to Lilly's Connected Diabetes Ecosystem. This Zacks Rank #2 stock with a market cap of $4.93 billion is a valuable pick for 2018. Over a month, estimates for the company have moved 9.76% north for the next fiscal. Where Do Zacks' Investment Ideas Come From? You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 ""Strong Buy"" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 ""Strong Sells"" and other private research. See the stocks free >> Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report Tactile Systems Technology, Inc. (TCMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2017-12-27,14.1875,14.3188,14.12,14.22,
DXCM,2017-12-28,14.1975,14.34,14.1,14.3325,
DXCM,2017-12-29,14.3325,14.4925,14.28,14.3475,
DXCM,2018-01-02,14.405,14.8825,14.385,14.4975,
DXCM,2018-01-03,14.4925,14.55,14.3225,14.5175,
DXCM,2018-01-04,13.495,13.555,12.76,13.06,"[""DexCom down 10% on Medicare coverage for Abbott's FreeStyle Libre CGM"", ""Dexcom Shares Ticking Lower As Hearing Northland Issued Mid-Day Downgrade On Stock"", ""Northland Securities Downgrades DexCom to Underperform"", ""Dexcom Shares Down 8%, Potentially Following News Abbott's CGM System, FreeStyle Libre Is Now Available To Medicare Patients; Northland Issued Mid-Day Downgrade On Stock"", ""Dexcom Shares Down 8%, Potentially Following News Abbott's CGM System, FreeStyle Libre Is Now Available To Medicare Patients; Northland Issued Mid-Day Downgrade On Stock"", ""Northland Securities Downgrades DexCom to Underperform"", ""Dexcom Shares Ticking Lower As Hearing Northland Issued Mid-Day Downgrade On Stock"", ""DexCom down 10% on Medicare coverage for Abbott's FreeStyle Libre CGM"", ""Dexcom Shares Down 8%, Potentially Following News Abbott's CGM System, FreeStyle Libre Is Now Available To Medicare Patients; Northland Issued Mid-Day Downgrade On Stock"", ""Northland Securities Downgrades DexCom to Underperform"", ""Dexcom Shares Ticking Lower As Hearing Northland Issued Mid-Day Downgrade On Stock"", ""DexCom down 10% on Medicare coverage for Abbott's FreeStyle Libre CGM""]"
DXCM,2018-01-05,13.0975,13.4625,12.9512,13.315,"[""36 Biggest Movers From Yesterday"", ""36 Biggest Movers From Yesterday"", ""36 Biggest Movers From Yesterday""]"
DXCM,2018-01-08,13.3175,13.94,13.05,13.86,"[""DexCom sees $218M in Q4 sales"", ""DexCom Sees Q4 Sales ~$218M vs $212.7M Est.; FY17 Sales ~$715M vs $710.2M Est."", ""DexCom Sees FY18 Sales ~$830M-$850M vs $854.6M Est."", ""DexCom Sees FY18 Sales ~$830M-$850M vs $854.6M Est."", ""DexCom Sees Q4 Sales ~$218M vs $212.7M Est.; FY17 Sales ~$715M vs $710.2M Est."", ""DexCom sees $218M in Q4 sales"", ""Fibit Inc Invests in Blood Glucose Monitoring Startup InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fitbit Inc (NASDAQ: FIT ) confirmed that it has made its first investment in a startup, in an effort to beat Apple Inc.'s (NASDAQ: AAPL ) Apple Watch. The Fitbit investment is in a company called Sano, which aims to develop a wearable, coin-sized blood sugar monitor for diabetics. The Sano patch would feed this data into a wearable for display - presumably the Fitbit Ionic smartwatch (or its successor). FIT stock popped on the news on Friday morning, but is now down 2.5% shortly after the bell Monday morning. The Fitbit Investment In Sano CNBC broke the news on Friday that Fitbit was investing $6 million in Sano , a startup focused on developing a blood glucose monitoring patch. 10 Best ETFs of 2017 Speaking about the Fitbit investment, CEO James Park told CNBC : \""This fits into our strategy of looking beyond the device and thinking more about (health) solutions. I think the complete solution comes in the form of having some monitoring solution that is coupled with a display, and a wearable that can give you the interventions at the right moment.\"" According to the report, the Sano patch won't be ready to ship for about a year. It's not non-invasive tech - it uses needles that penetrate the skin. Sano claims, however, that their needles don't penetrate as far as current solutions, making it \""painless.\"" The Sano patch will also be less expensive and much smaller than currently available blood glucose monitoring technology. Why The Fascination With Blood Glucose Monitoring? This Fitbit investment is driven by the current trend toward health and fitness for smartwatch sales. With the first wave of early smartwatch adopters in the rear view mirror, people concerned with health and fitness tracking are the next big market. Apple noted this, then switched the focus of its smartwatch and was rewarded with surging Apple Watch sales . Apple's move hit Fitbit, which was focused on wearables but lacked a true smartwatch. Since the Apple Watch was released, Fitbit has been in a slump - FIT stock is down nearly 88% since its 2015 heights. Apple sees the health market as the key to drive Apple Watch sales to an entirely new level. And diabetes monitoring is a potential gold mine. Hundreds of millions of people worldwide suffer from diabetes. The World Health Organization (WHO) says that in 2015, 8.5% of adults 18 or older were diabetic. WHO is also predicting that globally, the disease will be the 7th leading cause of death by 2030 . Effective blood glucose monitoring is key to managing diabetes. Currently, this means frequent and painful pricks with a needle to draw and then test blood. It's no secret that Apple has been hard at work on a non-invasive blood sugar monitor that would feed into the Apple Watch. If consumers turn to Apple to monitor their diabetes, that could drive massive Apple Watch sales, with health insurance companies potentially footing the bill. Potential Upside for FIT Stock The Fitbit investment in Sano is an attempt to take advantage of that massive market for diabetes management. And while the Sano patch does involve needles - as opposed to the optical sensor solution Apple is reportedly working toward - it appears to be further along in development than anything Apple has. Fitbit recently announced its trackers had been chosen for use in the National Institute of Health's \""All of Us\"" program . And both Fitbit and Apple already partner with a number of existing companies offering blood glucose monitoring technology, including DexCom, Inc, (NASDAQ: DXCM ). But these existing monitors are relatively bulky and expensive. 10 Awful Stocks to Kick to the Curb If the Fitbit investment in Sano pays off, Fitbit would have a coin-sized, wearable blood sugar monitor that feeds data to the Fitbit Ionic smartwatch. And the impact of beating Apple to such a huge potential market is going to have a significant upside for FIT stock. That explains the pop, but why the drop in FIT stock? The Sano patch is still a year out, and a lot can happen in that time. Realization that the patch still requires needles may also have scared off some investors. With their investment in Sano, however, Fitbit has made it clear it has no intention of letting the Apple Watch take over the developing market for health wearables the same way it steamrolled the smartwatch market. As of this writing, Brad Moon did not hold a position in any of the aforementioned securitie s. More From InvestorPlace: Huawei Guns for Apple Inc and Samsung in 2018 With Planned U.S. Push How Costly Will the Apple Inc. HomePod Delay Be? 10 Tech Stocks That Will Disappear by 2027 Compare Brokers The post Fibit Inc Invests in Blood Glucose Monitoring Startup appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Sees FY18 Sales ~$830M-$850M vs $854.6M Est."", ""DexCom Sees Q4 Sales ~$218M vs $212.7M Est.; FY17 Sales ~$715M vs $710.2M Est."", ""DexCom sees $218M in Q4 sales""]"
DXCM,2018-01-09,13.9875,13.99,13.005,13.65,"[""DexCom (DXCM) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow"", ""JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics"", ""DexCom Shares Down 3.048%; Earlier Co. Presented At JP Morgan Health Care Conf., Reported FY18 Outlook, Sees Sales $830M-$850M vs $853.06M Est."", ""DexCom Shares Down 3.048%; Earlier Co. Presented At JP Morgan Health Care Conf., Reported FY18 Outlook, Sees Sales $830M-$850M vs $853.06M Est."", ""JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics"", ""DexCom (DXCM) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow"", ""Fitbit for Kids? FIT Considering Smartwatch for Children InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fitbit Inc (NYSE: FIT ) is reportedly working on a version of Fibit for kids. Source: Shutterstock A recent report claims that the company has been working for months to develop a version of Fitbit for kids. Several unnamed sources spoke about the matter, but didn't provide details on how the devices would differ from current ones. The idea of developing a version of Fitbit for kids makes sense. There's already been parents using wearables as a way to track their children and that behavior is only expected to increase over time. A Fitbit device with kids in mind could make this easier for parents to do while still letting the kids get their own advantages from it. While we still don't know much about a possible version of Fitbit for kids, Bloomberg claims that it may have the ability to track glucose levels. The company has been working to expand its fitness tracker into a health-monitoring device and has been working with glucose monitoring company DexCom, Inc. (NASDAQ: DXCM ). 6 Stocks That Will Hit a Trillion Dollars There's a large market that a version of Fitbit for kids could tap into. This is due to the current age recommendations for Fitbit. The company currently only suggests users of its wearable devices to be 13 or older . However, the release of a device for kids could help it grow its users well beyond its current level. Either way, the product is still in early development and won't likely come out for some time yet. FIT stock was up slightly as of Thursday afternoon. More From InvestorPlace 10 Startups to Watch in 2018 10 Stocks That Could Surprise in 2018 5 Dividend Growth Stocks to Buy for Bigger Returns As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Fitbit for Kids? FIT Considering Smartwatch for Children appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Down 3.048%; Earlier Co. Presented At JP Morgan Health Care Conf., Reported FY18 Outlook, Sees Sales $830M-$850M vs $853.06M Est."", ""JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics"", ""DexCom (DXCM) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow""]"
DXCM,2018-01-10,13.745,14.67,13.7028,14.65,"[""DexCom Estimates Strong Revenue Figures for Q4 and 2017"", ""UnitedHealthcare, Dexcom Report Will Bring Wearable Technology Solution, 1-on-1 Coaching To People Battling Type-2 Diabetes"", ""UnitedHealthcare, Dexcom Report Will Bring Wearable Technology Solution, 1-on-1 Coaching To People Battling Type-2 Diabetes"", ""DexCom Estimates Strong Revenue Figures for Q4 and 2017"", ""DexCom Estimates Strong Revenue Figures for Q4 and 2017 DexCom, Inc.DXCM reported preliminary, unaudited revenues of approximately $218 million for the fourth quarter ended Dec 31, 2017. The revenue figure is higher than the Zacks Consensus Estimate of $211.9 million, which reflects an improvement of 28% from the fourth quarter of 2016. For fiscal 2017, total preliminary, unaudited revenues are expected to total $715 million, up 25% over 2016 levels. The full-year figure is well above the Zacks Consensus estimate of $710.63 million. Meanwhile, the estimate revision trend has been favorable as one estimate moved south over the past two months, with two movements in the opposite direction. In fact, the current year estimates narrowed down 2 cents to a loss of 63 cents per share. The stock has a Zacks Rank #3 (Hold). DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote 2018 Outlook For 2018, DexCom estimates total revenues in the range of $830-$850 million, courtesy of strong sensor volumes, international revenues and the expansion of DexCom's worldwide patient base. Meanwhile, the Zacks Consensus Estimate for 2018 revenues is pegged at $856 million at the moment. Dexcom's launch of G6 sensor platform and expansionary moves in the Medicare and international markets are likely to boost revenues in 2018. However, cutthroat competition in the niche space is likely to mar the top line. Shares Fall However, the market is not really happy with DexCom's preliminary results for the fourth quarter and full-year 2017. Following the announcement, the stock tumbled 1.5% in the last trading session to close at $54.60. The company is likely to report full financial results on Feb 27, 2018, after the market closes . DexCom's price movement in the past year has been unimpressive. The company reported a negative return of 20.9%, comparing unfavorably with the industry 's rally of 26%. The current level is also lower than the S&P 500's gain of 23.7% over the same time frame. DexCom's glucose monitoring devices are more invasive and better than other self-monitored glucose testing systems. Moreover, reports suggest that patients are unwilling to realize the benefits of continuous glucose monitoring at the moment. Reluctance on the part of physicians and patients to adopt DexCom's products may make it challenging for the company to expand market share. Key Picks A few better-ranked stocks in the broader medical sector are Integer Holdings Corporation ITGR , Bio-Rad Laboratories, Inc. BIO and Intuitive Surgical, Inc. ISRG . Bio-Rad Laboratories flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25%. Integer Holdings has a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2 (Buy). Intuitive Surgical has a long-term expected earnings growth rate of 9.2%. The stock carries a Zacks Rank #2. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UnitedHealthcare, Dexcom Report Will Bring Wearable Technology Solution, 1-on-1 Coaching To People Battling Type-2 Diabetes"", ""DexCom Estimates Strong Revenue Figures for Q4 and 2017""]"
DXCM,2018-01-11,14.7475,14.795,14.33,14.555,
DXCM,2018-01-12,14.555,14.555,13.9675,14.1875,"3 Stellar Stocks With Very Bullish News Sentiment What’s the effect of news—goodorbad—on a stock’s price? A recent study by data scientists at the Fed revealed that positive news stories increase stock returns quickly. Specifically, positive news affects stock prices within a week. The Nasdaq Smart Portfolio aims to let investors capitalize on this by enabling individual investors to pinpoint stocks with a specific news sentiment. Investors can combine this with other types of data sources to bring an edge to their strategy. Here, for example, we used the Portfolio’s stock screener to scan for mega/ large cap stocks with substantial Street support and Very Bullish news sentiment signal. The analyst consensus is based on the last three months of ratings by over 4,700 analysts tracked by the screener. From the results this search generated we set out to find the most compelling stocks with soaring shares and a strong outlook. Now with this in mind let’s dig down into three of the market’s hottest stocks: Alibaba Group Holding Limited (BABA) Chinese e-commerce giant Alibaba is buzzing right now. The media is busy digesting the fact that BABA shares almost doubled in 2017. For example, a recent report by the Nikkei Asian Review states that Tencent and Alibaba topped Asia’s market cap ranking in 2017. And BABA isn’t about to give up this leadership position anytime soon. As many articles point out, the company has multiple strategies up its sleeve to keep growth soaring. For instance, BABA plans to speed up the roll out of its Hema online-offline supermarkets. On January 9, the news broke that BABA will open 30 new Hema stores in Beijing in 2018. Consumers can shop, order groceries for home delivery and eat in-store, all via a Hema app connected to BABA’s Alipay. At the same time, Quartz reported on January 5 that BABA has a new goal: to deliver its cloud computing tech to China’s 6 million convenience stores. Using its Ling Shou Tong retail platform, BABA can advise independent retails how to optimize their stores to achieve maximum sales. The Street certainly approves of BABA’s impressive tactics and execution. Only a couple of days ago, on January 9, top Nomura analyst Jialong Shi reiterated his BABA buy rating with a $219 price target. This indicates 15.4% upside from the current share price. According to Shi, BABA’s e-commerce business stands to benefit from the increasingly powerful force of younger Chinese consumers. He expects BABA revenue to grow 50% year-over-year in the fiscal third quarter, with a 45% year-over-year gain for specifically Chinese retail. As for BABA’s Hema roll out, Shi has this to say: “JD.com, Meituan and some offline supermarkets are opening stores similar to Ali- backed Hema, which suggests to us that the Hema model is an effective approach to penetrate fresh produce categories. We believe Ali’s investments in new retail initiatives could accelerate in CY18F to secure better locations and properties in advance of competitors for its brick-and-mortar stores. Hema announced plans to open 30 stores in Beijing alone this year, even more than the 25 it opened in China in 2017.” As we can see from the chart below, BABA has a ‘Strong Buy’ analyst consensus rating with 17 consecutive buy ratings in the last three months. UnitedHealth Group (UNH) Healthcare behemoth UNH is the sixth largest company in the US on the Fortune 500. The company offers both health care products and insurance services. Indeed, UNH has just launched a very innovative diabetes management system with the help of glucose specialist DexCom, Inc (DXCM). On January 10, at the massive Las Vegas electronics show CES, UnitedHealth revealed a new initiative that uses wearable technology and personalized support to help members manage Type 2 diabetes. “Continuous glucose monitoring can be a game changer for people enrolled in our Medicare Advantage plans, as the data can be translated into personalized information that can be acted upon in real time” stated UNH CEO Brian Thompson. The company wants to use computers, smartphones and wearables to simplify the ‘healthcare experience’ for consumers. Note that UNH also scores 100% Street support with 10 back-to-back buy ratings in three months. Meanwhile the average analyst price target of $249 suggests 11% upside potential from the current share price. Earlier this month, Goldman Sachs’ Stephen Tanal initiated coverage of UNH with a bullish Buy rating and $269 price target (20% upside potential). He likes the stock because of its: 1) significant lead in national scale 2) favorable business mix, and 3) impressive adjusted earnings at 20% from 2017-2020. FedEx (FDX) The world’s largest express transportation company is already up 42% from this time last year. And following strong fiscal second-quarter results in late December the outlook continues to appear promising. ""Boy we had it right this year so far, knock on wood” is one quote from the company’s post-earning results call. In particular, F2Q18 (November-end) revenue grew 9.3% year-over-year with adjusted EPS of $3.18 (up 15% y/y) significantly topping consensus of $2.88. Given these figures, perhaps it’s not surprising that FedEx has just announced that it is opening a new Shanghai hub to cope with increased express demand. “The Asia Pacific region remains the growth driver of the world,” says David Cunningham, CEO of FedEx Express. The huge facility, which apparently cost over $100 million, can process an incredible 36,000 documents and packages per hour. Overall, we can see from TipRanks that FDX’s Strong Buy analyst consensus rating breaks down into 17 buy ratings vs just 2 hold ratings. Barclays analyst Brandon Oglenski even calls FDX a ‘top pick’. He reiterated his buy rating and $310 price target on the stock (16% upside potential) on January 8. Our database covers over 5,000 stocks. Find your own “Strong Buy” stocks in the sector that interests you the most. Go to the Nasdaq Smart Portfolio stock screener now. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-01-16,14.27,14.35,14.0175,14.1025,
DXCM,2018-01-17,14.1025,14.2875,13.8575,14.08,
DXCM,2018-01-18,14.0825,14.2075,13.81,14.07,"[""Weakness In Dexcom Being Attributed To New Coverage Policy From Cigna That Cover Abbott's Libre Glucose Monitoring System"", ""Weakness In Dexcom Being Attributed To New Coverage Policy From Cigna That Cover Abbott's Libre Glucose Monitoring System"", ""Weakness In Dexcom Being Attributed To New Coverage Policy From Cigna That Cover Abbott's Libre Glucose Monitoring System""]"
DXCM,2018-01-19,14.0475,14.175,13.91,14.0125,
DXCM,2018-01-22,13.9075,13.9438,13.7025,13.775,
DXCM,2018-01-23,13.6775,13.985,13.5875,13.9375,
DXCM,2018-01-24,13.98,14.5725,13.92,14.435,
DXCM,2018-01-25,14.5375,14.715,14.3575,14.705,
DXCM,2018-01-26,14.65,14.6609,14.4275,14.52,"This Explains Why Senseonics Holdings Inc. Is Falling Today What happened In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday. So what Senseonics announced on late Thursday afternoon that it wanted to raise capital from a convertible notes offering. The company succeeded and announced the terms of the deal on Friday morning: $50 million of convertible notes were sold with an interest rate of 5.25%. The underwriters of the deal were granted a 30-day option to purchase an additional $7.5 million worth of notes. The notes mature on Feb. 1, 2023, and can be converted into common stock at a price of $3.40 per share. The deal is expected to net Senseonic $48 million, or $55.3 million if the underwriter exercises their option in full. That $3.40 conversion price is above Thursday's closing price of $3.20, so why are shares falling on this pricing news? The most likely answer is that they are not reacting to the pricing details at all. Instead, the markets are probably focusing on the preliminary quarterly results that were provided on late Thursday afternoon as part of the proposal letter. Management stated on Thursday that its fourth-quarter revenue is expected to be approximately $2.9 million. While that's sharply higher than the $0.3 million that was recorded in the year-ago period, it trails the $2.96 million that Wall Street had expected. Traders appear to be slamming shares today based on the disappointing revenue result. Now what Senseonics' continuous glucose monitoring system is called Eversense and it stands apart from other devices because it is implantable and can last for up to 90 days. While the device has not yet received FDA approval, Senseonics is already selling the device in Europe. Will the Eversense be a hit in the U.S. if it wins approval? That's tough to say. The company will face a healthy amount of competition from the market leaderDexcom (NASDAQ: DXCM) , not to mention medical device giant Medtronic and newcomerAbbott Laboratories . While the 90-day wear time is appealing, the device does have to be implanted underneath the skin to work. That might be an unappealing prospect for many patients. On the other hand, the market for diabetes is so huge that all four of these companies might post growth as adoption of continuous glucose monitoring systems continues to grow. Personally, I think that Senseonics' device does look compelling, but this company is losing money hand-over-fist right now, so I have no interest in buying this stock. Still, the technology looks promising, so I plan on remaining attentive to this company's progress. 10 stocks we like better than Senseonics Holdings, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of January 2, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-01-29,14.52,14.7475,14.3575,14.41,
DXCM,2018-01-30,14.4375,14.915,14.2875,14.8275,
DXCM,2018-01-31,14.825,14.9725,14.53,14.55,
DXCM,2018-02-01,14.495,14.6675,14.35,14.4675,
DXCM,2018-02-02,14.3925,14.6475,14.215,14.32,
DXCM,2018-02-05,14.3075,14.5425,13.9825,14.0475,
DXCM,2018-02-06,13.8075,14.155,13.5888,13.9025,"[""Reynders McVeigh Capital Management, LLC Buys Stryker Corp, Biogen Inc, Gilead Sciences Inc, ..."", ""Reynders McVeigh Capital Management, LLC Buys Stryker Corp, Biogen Inc, Gilead Sciences Inc, ..."", ""Reynders McVeigh Capital Management, LLC Buys Stryker Corp, Biogen Inc, Gilead Sciences Inc, ...""]"
DXCM,2018-02-07,13.9,13.965,13.6875,13.71,
DXCM,2018-02-08,13.75,13.87,13.58,13.63,
DXCM,2018-02-09,13.7075,13.7925,13.2299,13.5875,
DXCM,2018-02-12,13.5675,13.835,13.465,13.6725,
DXCM,2018-02-13,13.67,13.74,13.425,13.6675,
DXCM,2018-02-14,13.545,14.0325,13.545,13.935,
DXCM,2018-02-15,14.05,14.2225,13.88,14.1775,
DXCM,2018-02-16,14.1975,14.445,14.09,14.335,"Commit To Purchase DexCom At $45, Earn 8.2% Annualized Using Options Investors considering a purchase of DexCom Inc (Symbol: DXCM) stock, but cautious about paying the going market price of $57.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $45 strike, which has a bid at the time of this writing of $2.20. Collecting that bid as the premium represents a 4.9% return against the $45 commitment, or a 8.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost ). Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $45 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless DexCom Inc sees its shares decline 21.5% and the contract is exercised (resulting in a cost basis of $42.80 per share before broker commissions, subtracting the $2.20 from $45), the only upside to the put seller is from collecting that premium for the 8.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $45 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $45 strike for the 8.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 253 trading day closing values as well as today's price of $57.11) to be 53%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Friday, the put volume among S&P 500 components was 2.26M contracts, with call volume at 2.67M, for a put:call ratio of 0.85 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today . Top YieldBoost Puts of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-02-20,14.3,14.4675,14.205,14.2825,
DXCM,2018-02-21,14.3275,14.5225,14.0075,14.22,
DXCM,2018-02-22,14.2825,14.58,14.07,14.1,
DXCM,2018-02-23,14.135,14.22,13.8702,14.09,"[""Why DexCom (DXCM) Might Surprise This Earnings Season"", ""Why DexCom (DXCM) Might Surprise This Earnings Season"", ""Why DexCom (DXCM) Might Surprise This Earnings Season Investors are always looking for stocks that are poised to beat at earnings season and DexCom, Inc.DXCM may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because DexCom is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for DXCM in this report. In fact, the Most Accurate Estimate for the current quarter is currently at 9 cents per share for DXCM, compared to a broader Zacks Consensus Estimate of 3 cents per share. This suggests that analysts have very recently bumped up their estimates for DXCM, giving the stock a Zacks Earnings ESP of +175.00% heading into earnings season. DexCom, Inc. Price and EPS Surprise DexCom, Inc. Price and EPS Surprise | DexCom, Inc. Quote Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ). Given that DXCM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Clearly, recent earnings estimate revisions suggest that good things are ahead for DexCom, and that a beat might be in the cards for the upcoming report. Zacks Top 10 Stocks for 2018 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018? Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys. Access Zacks Top 10 Stocks for 2018 today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom (DXCM) Might Surprise This Earnings Season""]"
DXCM,2018-02-26,14.0625,14.2662,13.925,14.2425,"[""Will Admissions Drive Universal Health's (UHS) Q4 Earnings?"", ""The Future Of Health"", ""Notable earnings after Tuesday's close"", ""Notable earnings after Tuesday's close"", ""The Future Of Health"", ""Will Admissions Drive Universal Health's (UHS) Q4 Earnings?"", ""Patterson Companies (PDCO) Q3 Earnings: What's in Store? Patterson Companies, Inc. PDCO is scheduled to release third-quarter fiscal 2018 results on Mar 1. The company anticipates a decline in the Dental Supply segment - one of its major revenue components. While this can majorly dampen earnings, an expected improvement in Animal Segment operating income should drive results. Notably, Patterson Companies reported adjusted earnings of 51 cents per share in second-quarter fiscal 2018, missing the Zacks Consensus Estimate of 54 cents. Net sales fell 2.3% from the year-ago quarter to $1.39 billion and lagged the Zacks Consensus Estimate of $1.42 billion. Let us take a look at how things are shaping up before the release. Dental-Supply Segment to Decline in Q3 The Zacks Consensus Estimate for the Dental Supply segment is $592 million for third-quarter fiscal 2018. This reflects a decline of almost 5.4% year over year. The loss of exclusive distribution rights with Dentsply Sirona XRAY forced the company to shift to a new enterprise resource planning system to efficiently manage inventory. However, the system is creating short-term challenges. Undoubtedly, the termination of the contract presents new opportunities for Patterson Companies to expand distribution platform to a wider range of product offerings. However, the company continues to witness heavy initial impact from the loss of this deal. Patterson Companies, Inc. Price and EPS Surprise Patterson Companies, Inc. Price and EPS Surprise | Patterson Companies, Inc. Quote The company's decision to end exclusive distribution will affect results through fiscal 2018. In fact, dental segment sales have been sluggish over the last couple of quarters. Management has provided a dull guidance for the coming quarters as well. In the last quarter, dental sales (40% of total sales) fell 8.4% at constant currency (cc) year over year to approximately $553.6 million. The downside was caused by lower sales of CEREC and digital technology products. Management expects headwinds in the technology-based equipment business to persist through fiscal 2018, adding to the company's woes. Other Factors at Play Estimates & Guidance For the third quarter, the Zacks Consensus Estimate for adjusted earnings is pegged at 51 cents, reflecting a decline of 12.1% year over year. Management anticipates headwinds in its technology equipment business to persist through fiscal 2018. This is primarily because of Patterson Companies' initiatives to transit its sales model to an expanded technology product portfolio. Further, the Zacks Consensus Estimate for revenues is pegged at $1.38 billion, showing a decline of 1.1% year over year. In the last quarter, the company estimated adjusted earnings per share for fiscal 2018 in the range of $2.00-$2.10, way below the previous band of $2.25-$2.40. Patterson Companies expects deal amortization expenses of $25.3 million or 27 cents per share. The company projects integration and business restructuring expenses at $5.3 million or 6 cents per share. Animal Health Segment Animal Health is the second important contributor to revenues for Patterson Companies after the dental unit. Steady growth in this unit is expected to be a long-term growth driver. Management expects solid margin improvement in the segment on the back of enhanced partnerships with product manufacturers and strong sales execution. The Zacks Consensus Estimate for operating income from the Animal Health unit is pegged at $30.9 million, reflecting an improvement of 33.1% from the last quarter. However, the Zacks Consensus Estimate for net sales is $786 million, reflecting a decline of 4.6% year over year. Our quantitative model does not show an earnings beat for Patterson Companies this quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. This is not the case here, as you will see below. Zacks ESP: The Earnings ESP for Patterson Companies is -0.65%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Patterson Companies carries a Zacks Rank #2. Key Picks Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. The Cooper Companies Inc. COO has an Earnings ESP of +0.04% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here . DexCom, Inc. DXCM has an Earnings ESP of +126.5% and a Zacks Rank #3. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Admissions Drive Universal Health's (UHS) Q4 Earnings? Universal Health Services, Inc.UHS is set to report fourth-quarter 2017 results on Feb 28 after market close. Last quarter, the company reported adjusted earnings of $1.64 per share, having missed the Zacks Consensus Estimate by 3.5%. The bottom line, however, grew 2.5% year over year on higher revenues. Let's see, how things are shaping up for this announcement. Why a Likely Positive Surprise? Our proven model shows that Universal Health has the right combination of the following two key ingredients to beat estimates this quarter. Zacks ESP : Universal Health has an Earnings ESP of +0.39%. A stock's positive ESP raises confidence about an earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Universal Health Services, Inc. Price and EPS Surprise Universal Health Services, Inc. Price and EPS Surprise | Universal Health Services, Inc. Quote Zacks Rank : Universal Health carries a Zacks Rank #2 (Buy), which increases the predictive power of ESP as stocks with a favorable Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have significantly higher chances of an earnings beat. Conversely, we caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is witnessing negative estimate revisions. Q4 Expectations Both segments of Universal Health namely Acute Care and Behavioral Health, have been delivering strong results over the past many quarters. Notably, the segments have also been continuously witnessing a rise in admissions, licensed beds and patient days, leading to higher revenues in turn. Moreover, the fourth quarter is likely to have experienced this favorable trend. The Zacks Consensus Estimate for total revenues in the to-be-reported quarter is pegged at $2.6 billion, reflecting year-over-year growth of 6%. Our consensus estimate for revenues from Acute Care and Behavioral Health segments stands at $1.4 billion and $1.2 billion, up 6% and 6.7% respectively, year over year. The average number of licensed beds in the Acute Care hospitals and Behavioral Health centers kept increasing since 2012. Our consensus estimate for Average Licensed Beds in Acute Care and Behavioral Health is pegged at 6.1 billion and 23.1 billion, up 0.5% and 5.7% year over year, respectively. An increase in number of beds at both the facilities will likely drive up admission volumes. The Zacks Consensus Estimate for Admissions in Acute Care and Behavioral Health is pegged at 73.2 billion and 116.3 billion respectively, up 5.4% and 4.7% year over year, respectively. In addition, the company's continuous focus to enhance shareholders' value through share repurchases might have boosted its bottom line by limiting share count in the fourth quarter. However, rising costs related to interest payment, reserves for settlements, legal judgments and lawsuits plus impairments of long-lived assets are likely to have weighed on margins. Other Stocks to Consider Here are some other stocks also worth considering from the medical sector with the right combination of elements to come up with an earnings beat this time around: Aerie Pharmaceuticals, Inc. AERI is set to report fourth-quarter earnings on Feb 28. The company has an Earnings ESP of +41.20% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here . Bio-Rad Laboratories, Inc. BIO , which is set to release fourth-quarter earnings on Feb 27, has an Earnings ESP of +2.61% and a Zacks Rank of 2 . DexCom, Inc. DXCM has an Earnings ESP of +126.47% and is a Zacks #3 Ranked player. The company is set to announce fourth-quarter earnings on Feb 27. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""George Soros Just Bought These 2 Biotech Stocks. Should You? Billionaire George Soros' namesake fund, Soros Fund Management, has consistently beat the broader markets over the past 40-plus years. The fund's quarterly buys and sells are therefore must-read material for any serious investor. What was the fund buying in the fourth quarter of 2017? In the high-growth biotech space, the fund initiated new, albeit modest, positions in both the diabetes device maker DexCom (NASDAQ: DXCM) and the clinical-stage drugmaker AnaptysBio, Inc. (NASDAQ: ANAB) , according to the latest 13F filings with the U.S. Securities and Exchange Commission. Should investors take a cue from this elite money management firm and buy these two biotech stocks? Let's dig deeper to find out. Time to buy this falling knife? DexCom is a top player in the relatively new field of continuous blood glucose sensing devices. Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. As Abbott's continuous glucose monitoring device is both cheaper than the G5 Mobile and doesn't need to be calibrated, DexCom's G5 Mobile system is clearly at a competitive disadvantage at this point. So it's not entirely surprising that investors are growing more and more concerned about DexCom's future growth prospects. Despite this new competitive threat, however, DexCom's sales are still expected to climb by an impressive 18.7% to $846 million this year. The company is also on track to reportedly launch its own \""no-calibration\"" G6 continuous glucose monitoring device later this year, and its G5 system did reportedly outperform Abbott's FreeStyle Libre System in terms of the time required to detect hypoglycemia in people with type 1 diabetes in a head-to-head study earlier this year. The downside is that DexCom's shares remain on the expensive side even after this latest pullback. The company's trailing price-to-sales ratio, for example, currently stands at a sky-high 7.32. So you have to be willing to pay a fairly sizable premium if you want to buy into DexCom's supercharged growth story. Can this rocket-like trajectory continue? AnaptysBio's shares have quadrupled in value in the just the past 12 months. The catalyst? ANAB data by YCharts . Investors are apparently excited about AnaptysBio's experimental atopic dermatitis (eczema) candidate ANB020. This clinical-stage drug works by inhibiting the cell signaling molecule interleukin-33, which is known to play a key role in numerous inflammatory disorders. Recently, the company reported overwhelmingly positive results for ANBO20 in a small mid-stage study in adult patients with moderate-to-severe atopic dermatitis. And based on this encouraging outcome, AnaptysBio is planning to evaluate the drug's safety and efficacy in a much larger mid-stage study for atopic dermatitis later this year. The company is also currently assessing ANBO20 in adult patients with peanut allergies and eosinophilic asthma. The big idea, if you will, is that ANBO20 may be able to grab the lion's share of the $4 billion skin disorder market if it proves to be as potent as advertised. That's a tall order for any experimental anti-inflammatory drug, but the initial results do appear to back this claim thus far. Are either of these biotechs worth buying right now? DexCom and AnaptysBio both have incredibly enticing long-term growth trajectories, but they also come with a hefty dose of risk. After all, there's no guarantee that DexCom can continue to grab market share in an increasingly competitive space, and the company will also have to constantly innovate to stay ahead of the field. AnaptysBio, for its part, still has a lot to prove in terms of the efficacy and safety of ANBO20 -- its most valuable product candidate. No matter how profound, small mid-stage trial results should always be taken with a rather large grain of salt. What's the verdict? These two mid-cap biotech stocks might be appealing to risk-tolerant investors on the hunt for unusual growth opportunities. But conservative investors should probably keep their distance because of their highly uncertain outlooks. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of Feb. 5, 2018 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable earnings after Tuesday's close"", ""The Future Of Health"", ""Will Admissions Drive Universal Health's (UHS) Q4 Earnings?""]"
DXCM,2018-02-27,14.245,14.55,13.885,13.93,"[""Imminent Healthcare Device Launch Could Send Little BTCY Soaring"", ""DexCom beats by $0.07, beats on revenue"", ""DexCom (DXCM) Q4 2017 Results - Earnings Call Transcript"", ""DexCom Q4 Earnings Preview"", ""DexCom Reports Q4 EPS $0.10 vs. $0.03 Est., Sales $221M vs. $$215.87M Est."", ""DexCom Reports Q4 EPS $0.10 vs. $0.03 Est., Sales $221M vs. $$215.87M Est."", ""DexCom Q4 Earnings Preview"", ""DexCom (DXCM) Q4 2017 Results - Earnings Call Transcript"", ""DexCom beats by $0.07, beats on revenue"", ""Imminent Healthcare Device Launch Could Send Little BTCY Soaring"", ""Earnings Reaction History: DexCom, Inc., 75.0% Follow-Through Indicator, 5.8% Sensitive Expected Earnings Release: 02/27/2018, After-hours Avg. Extended-Hours Dollar Volume: $6,479,314 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 3% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.0%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 60% Average next regular session additional loss: 2.2% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.2% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reports Q4 EPS $0.10 vs. $0.03 Est., Sales $221M vs. $$215.87M Est."", ""DexCom Q4 Earnings Preview"", ""DexCom (DXCM) Q4 2017 Results - Earnings Call Transcript"", ""DexCom beats by $0.07, beats on revenue"", ""Imminent Healthcare Device Launch Could Send Little BTCY Soaring""]"
DXCM,2018-02-28,13.9225,14.3538,13.605,14.035,
DXCM,2018-03-01,14.0325,14.0459,13.375,13.5075,"[""DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4"", ""DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4"", ""DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4 DexCom, Inc. DXCM reported earnings per share (EPS) of 10 cents in the fourth quarter of 2017, beating the Zacks Consensus Estimate by 233.3%. Also, the figure improved from a loss of 9 cents in the year-ago quarter. Full-year 2017 loss of 58 cents was narrower than the loss of 78 cents in the year-ago quarter. The figure was also better than the Zacks Consensus Estimate of a loss of 63 cents. Total revenues grew 29.1% to $221 million from $171.2 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $217.8 million. Full-year 2017 revenues came in at $718.5 million, beating the Zacks Consensus Estimate of $715.3 million. The figure also improved from the year-ago number by 25.3%. Segmental details Sensor revenues & other revenues (73% of total revenues) grew 30% on a year-over-year basis to $160.6 million. Transmitter revenues (19%) increased 31% from the prior-year quarter to $42.4 million. Receiver revenues (8%) grew 21% year over year to $18 million. Operational Details DexCom generated gross margin (as a percentage of revenues) of 69.5%, an expansion of 129 basis points (bps) year over year. International business displayed continued growth in the quarter, generating $33.2 million in revenues, up 58% on a year-over-year basis. Notably, international business represented 15% of total revenues in the fourth quarter. Research and development (R&D) expenses totaled $48.7 million in the quarter, up 11.4% year over year. Selling, general and administrative expenses totaled $92.8 million in the reported quarter, increasing 17.3% year over year. Financial Update Full-year 2017, DexCom had $548.6 million in cash, cash equivalents and short-term marketable securities versus $123.7 million at the end of 2016. Guidance DexCom reaffirmed the full-year 2018 guidance. The company expects full-year 2018 revenues in the range of $830-$850 million. Gross profit margin is projected in the band of 65% to 68%. Reported operating expenses, excluding investments in non-intensive programs, is expected to increase 10% from 2017. Our Take DexCom exited the fourth quarter on a solid note. The year-over-year growth in revenues and earnings is encouraging. The expansion in gross margin buoys optimism. The company is also focusing on product and innovation through R&D. Peer Performance Some medical stocks that reported solid results this earnings season are PetMed Express PETS , PerkinElmer PKI and Becton, Dickinson and Company BDX . PetMed reported third-quarter fiscal 2018 results. Adjusted EPS of 44 cents were up 88.3% from the prior-year quarter. Revenues rose 13.7% to $60.1 million. PerkinElmer reported fourth-quarter 2017 adjusted EPS of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter. Becton, Dickinson reported first-quarter 2018 adjusted EPS of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4""]"
DXCM,2018-03-02,13.4375,13.7625,13.325,13.7225,
DXCM,2018-03-05,13.7075,14.06,13.61,13.93,
DXCM,2018-03-06,13.935,15.03,13.895,14.96,
DXCM,2018-03-07,14.8725,15.2875,14.855,15.21,
DXCM,2018-03-08,15.2675,15.3925,14.855,15.05,"[""Dexcom comes up short in challenge to WaveForm patents; shares down 1%"", ""WaveForm Receives Favorable Decision On Glucose Monitoring Patents, PTAB Haqs Ruled Two Early Patents Held By WaveForm Are Not Invalid; Watch For Downside In Dexcom"", ""WaveForm Receives Favorable Decision On Glucose Monitoring Patents, PTAB Haqs Ruled Two Early Patents Held By WaveForm Are Not Invalid; Watch For Downside In Dexcom"", ""Dexcom comes up short in challenge to WaveForm patents; shares down 1%"", ""WaveForm Receives Favorable Decision On Glucose Monitoring Patents, PTAB Haqs Ruled Two Early Patents Held By WaveForm Are Not Invalid; Watch For Downside In Dexcom"", ""Dexcom comes up short in challenge to WaveForm patents; shares down 1%""]"
DXCM,2018-03-09,15.0075,15.2412,14.695,15.0325,
DXCM,2018-03-12,14.95,16.0525,14.8775,16.0225,"[""Dexcom: Breaking A Paradigm"", ""Dexcom: Breaking A Paradigm"", ""Dexcom: Breaking A Paradigm""]"
DXCM,2018-03-13,16.01,16.475,15.875,16.2275,
DXCM,2018-03-14,16.275,16.4725,15.8925,16.23,
DXCM,2018-03-15,16.245,16.5,16.0375,16.2225,
DXCM,2018-03-16,16.28,16.5175,16.11,16.3975,
DXCM,2018-03-19,16.3775,16.555,16.06,16.28,
DXCM,2018-03-20,16.315,16.5025,16.1725,16.3975,
DXCM,2018-03-21,16.415,17.1525,16.2125,16.9275,
DXCM,2018-03-22,16.8125,17.31,16.6825,16.685,
DXCM,2018-03-23,17.095,17.73,17.0875,17.2,"[""Baird Upgrades DexCom to Outperform"", ""Baird Upgrades DexCom to Outperform"", ""Baird Upgrades DexCom to Outperform""]"
DXCM,2018-03-26,17.3575,17.5775,17.215,17.5425,
DXCM,2018-03-27,17.63,18.1875,17.43,17.4975,"[""FDA OKs DexCom G6 integrated CGM system"", ""DexCom Shares Spike ~$0.50 As Traders Circulate FDA.gov Alert Showing Approval For G6 iCGM System For Determining Sugar Levels In Children 2+, Adults With Diabetes"", ""DexCom Shares Spike ~$0.50 As Traders Circulate FDA.gov Alert Showing Approval For G6 iCGM System For Determining Sugar Levels In Children 2+, Adults With Diabetes"", ""FDA OKs DexCom G6 integrated CGM system"", ""DexCom Shares Spike ~$0.50 As Traders Circulate FDA.gov Alert Showing Approval For G6 iCGM System For Determining Sugar Levels In Children 2+, Adults With Diabetes"", ""FDA OKs DexCom G6 integrated CGM system""]"
DXCM,2018-03-28,17.5825,18.495,17.5,18.32,"[""Institutional Top Ideas Series: Deerfield Management"", ""DexCom Shares Indicated Up 3.5% Near Tues. High Around $72.50; A Co. Press Release Tues. Evening Confirmed Marketing Authorization For Co.'s New G6 CGM System"", ""28 Stocks Moving In Wednesday's Pre-Market Session"", ""28 Stocks Moving In Wednesday's Pre-Market Session"", ""DexCom Shares Indicated Up 3.5% Near Tues. High Around $72.50; A Co. Press Release Tues. Evening Confirmed Marketing Authorization For Co.'s New G6 CGM System"", ""Institutional Top Ideas Series: Deerfield Management"", ""DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System DexCom, Inc.DXCM recently announced that the FDA has granted a de novo approval for the marketing of the new Dexcom G6 CGM monitoring system to check blood sugar levels in children and adults without pricking fingers for diabetes management. This is the first glucose monitoring system permitted by the FDA that can be used as a standalone Continuous Glucose Monitoring (CGM) and for integration into automated insulin dosing (AID) systems. What is 'de novo'? Per FDA, a de novo classification for a particular product/platform establishes a new device type along with classification, necessary controls and product code. Further, a device that has de novo approval is eligible for a 510(k)-approval submission. The large and expanding diabetes market, strong product portfolio and positive tidings at the regulatory front are likely to provide DexCom with a competitive edge in the U.S. MedTech sector. CGM - a Prominent Space in MedTech CGM provides continuous insight into glucose levels throughout the day and night. Per CISION, the global CGM market is estimated to reach $4 Billion by 2024. Per the report, United States is the leader in the global CGM market. DexCom is a leading player in the global CGM markets. Other than G6 CGM, DexCom's FDA-cleared G4 Platinum platform is significantly boosting the company's top line. The inbuilt features of the G4 Platinum make it the most innovative system in the market. In 2017, DexCom announced the receipt of FDA's approval of the DexCom G5 mobile app for android devices. By the end of fourth quarter of 2017, the company confirmed the development of a fully disposable real-time CGM system with Verily. This is expected to be completed by the end of 2017. The company is confident about its G6 sensor. Lacklustre Price Performance DexCom's price movement in the past year has been unimpressive. The company reported a negative return of 17.8%, comparing unfavorably with the industry 's rally of 21.9%. The current level is also lower than the S&P 500 Index's gain of 14.3%. Zacks Rank & Key Picks DexCom carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO , athenahealth, Inc. ATHN and Edwards Lifesciences Corporation EW . Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%. athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%. Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank of 2 (Buy). Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""28 Stocks Moving In Wednesday's Pre-Market Session"", ""DexCom Shares Indicated Up 3.5% Near Tues. High Around $72.50; A Co. Press Release Tues. Evening Confirmed Marketing Authorization For Co.'s New G6 CGM System"", ""Institutional Top Ideas Series: Deerfield Management""]"
DXCM,2018-03-29,18.2825,18.825,18.21,18.54,"[""Stocks Generating Improved Relative Strength: Dexcom"", ""BMO Increases DexCom Price Target From $68 To $78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call"", ""Benzinga's Top Analyst Calls From March 29, 2018"", ""Benzinga's Top Analyst Calls From March 29, 2018"", ""BMO Increases DexCom Price Target From $68 To $78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call"", ""Stocks Generating Improved Relative Strength: Dexcom"", ""Benzinga's Top Analyst Calls From March 29, 2018"", ""BMO Increases DexCom Price Target From $68 To $78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call"", ""Stocks Generating Improved Relative Strength: Dexcom""]"
DXCM,2018-04-02,18.55,18.8925,18.47,18.6325,"[""Dexcom Reaches 80-Plus Relative Strength Rating Benchmark"", ""DexCom Is A Takeover Candidate - Cramer's Lightning Round (3/29/18)"", ""Dexcom Reaches 80-Plus Relative Strength Rating Benchmark"", ""DexCom Is A Takeover Candidate - Cramer's Lightning Round (3/29/18)"", ""Dexcom Reaches 80-Plus Relative Strength Rating Benchmark"", ""DexCom Is A Takeover Candidate - Cramer's Lightning Round (3/29/18)""]"
DXCM,2018-04-03,18.5825,18.7675,18.425,18.6725,
DXCM,2018-04-04,17.75,18.2862,17.3775,18.04,"[""Goldman Sachs Initiates Coverage On DexCom with Sell Rating, Announces $57.00 Price Target"", ""Guggenheim Initiates Coverage On DexCom with Neutral Rating"", ""Guggenheim Initiates Coverage On DexCom with Neutral Rating"", ""Goldman Sachs Initiates Coverage On DexCom with Sell Rating, Announces $57.00 Price Target"", ""Here's Why Senseonics Holdings Inc. Is Rising Today What happened After receiving a buy rating and an upbeat price target from a Wall Street analyst, shares of Senseonics Holdings (NYSEMKT: SENS) , a small-cap medical device company focused on glucose-monitoring solutions for people with diabetes , jumped as much as 10% in afternoon trading on Wednesday. Shares were up 9% as of 3:05 p.m. EDT. So what Senseonics bulls can thank Christopher Pasquale from Guggenheim for today's jump. Pasquale reiterated his buy rating on the company's stock and also set a price target of $6 per share. That represents an almost exact double from yesterday's closing price of about $3 per share. Traders responded to the bullish analyst note by bidding up the share price. Now what Senseonics shareholders have enjoyed a prosperous 2018 thus far. The company shored up its balance sheet in January by raising about $48 million through a convertible note offering . More recently, we learned that the Food and Drug Administration (FDA) voted unanimously that its Eversense system is safe, effective, and the benefits of its use outweigh the risks. When combined with today's positive analyst commentary, Sensonics' shares have jumped more than 25% since the start of the year. So is now a smart time to buy into Sensonics' growth story? That's a tougher call. On the plus side, the 90-day wear time of the Eversense system will likely be attractive to many patients. On the negative side, the device is going to have a heck of a time challenging the current market leader Dexcom (NASDAQ: DXCM) , even if it wins approval. After all, Dexcom just won FDA approval for its G6 system that can be worn for 10 days, communicate directly with a smartphone or smartwatch, and requires no finger sticks for calibration. It's hard to say whether or not the Eversense system will be able to effectively compete against those benefits. I know firsthand just how hard it can be to successfully launch a medical device in the diabetes industry against an incumbent, so I continue to believe that skepticism is warranted. That's why I'll continue to track Senseonics' progress from the safety of the sidelines. 10 stocks we like better than Senseonics Holdings, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of April 2, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Guggenheim Initiates Coverage On DexCom with Neutral Rating"", ""Goldman Sachs Initiates Coverage On DexCom with Sell Rating, Announces $57.00 Price Target""]"
DXCM,2018-04-05,18.1125,18.44,18.005,18.07,
DXCM,2018-04-06,18.03,18.14,17.5025,17.5375,
DXCM,2018-04-09,17.7175,17.9875,17.495,17.595,
DXCM,2018-04-10,17.7225,17.97,17.67,17.82,
DXCM,2018-04-11,17.74,17.9125,17.6825,17.74,
DXCM,2018-04-12,17.74,18.4575,17.74,18.175,
DXCM,2018-04-13,18.23,18.2725,17.8825,18.095,
DXCM,2018-04-16,18.2125,18.3725,18.095,18.2675,
DXCM,2018-04-17,18.315,18.5675,18.0925,18.355,
DXCM,2018-04-18,18.3075,18.6556,18.3038,18.375,
DXCM,2018-04-19,18.3275,18.375,18.0725,18.185,
DXCM,2018-04-20,18.19,18.355,18.0088,18.1175,
DXCM,2018-04-23,18.24,18.46,18.14,18.325,"[""5 Health Care Stocks in Gurus' Portfolios"", ""5 Health Care Stocks in Gurus' Portfolios"", ""Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the U.S. equity market, the SPDR S&P Health Care Equipment ETF (XHE) is a smart beta exchange traded fund launched on 01/26/2011. What Are Smart Beta ETFs? The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market. A good option for investors who believe in market efficiency, market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta. This kind of index follows this same mindset, as it attempts to pick stocks that have better chances of risk-return performance; non-cap weighted strategies base selection on certain fundamental characteristics, or a mix of such characteristics. While this space offers a number of choices to investors, including simplest equal-weighting, fundamental weighting and volatility/momentum based weighting methodologies, not all these strategies have been able to deliver superior results. Fund Sponsor & Index Because the fund has amassed over $239.12 M, this makes it the largest ETF in the Health Care ETFs. XHE is managed by State Street Global Advisors. Before fees and expenses, XHE seeks to match the performance of the S&P Health Care Equipment Select Industry Index. This Index represents the health care equipment and supplies sector of the S&P Total Market Index. The Index is one of nineteen S&P Select Industry Indices, each designed to measure the performance of a narrow sub-industry or group of sub-industries as defined by the GICS.The Health Care Index is a modified equal weight index. Cost & Other Expenses Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. With the least expensive product in the space, this ETF has annual operating expenses of 0.35%. XHE's 12-month trailing dividend yield is 0.02%. Sector Exposure and Top Holdings ETFs offer diversified exposure and thus minimize single stock risk, but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis. XHE's heaviest allocation is in the Healthcare sector, which is about 100% of the portfolio. Taking into account individual holdings, Dexcom Inc. (DXCM) accounts for about 1.82% of the fund's total assets, followed by Glaukos Corp (GKOS) and Insulet Corporation (PODD). The top 10 holdings account for about 17.55% of total assets under management. Performance and Risk XHE has gained about 10.84% so far this year, and as of 04/21/2018, it's up approximately 27.13% in the last one year. In the past 52-week period, the fund has traded between $56.42 and $72.27. The fund has a beta of 0.90 and standard deviation of 16.59% for the trailing three-year period, which makes XHE a medium choice in this particular space. With about 71 holdings, it effectively diversifies company-specific risk. Alternatives SPDR S&P Health Care Equipment ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. IShares U.S. Medical Devices ETF (IHI) tracks Dow Jones U.S. Select Medical Equipment Index. The fund has $1.71 B in assets. IHI has an expense ratio of 0.44%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. Bottom Line To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ISHARS-US MED D (IHI): ETF Research Reports SPDR-SP HC EQPT (XHE): ETF Research Reports Glaukos Corporation (GKOS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Insulet Corporation (PODD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 Health Care Stocks in Gurus' Portfolios""]"
DXCM,2018-04-24,18.355,18.7675,18.2725,18.6075,
DXCM,2018-04-25,18.525,18.5825,18.26,18.4325,
DXCM,2018-04-26,18.4325,18.7975,18.21,18.6225,
DXCM,2018-04-27,18.6875,18.735,18.3512,18.5625,
DXCM,2018-04-30,18.6625,18.82,18.2575,18.295,"[""Tandem Diabetes Care's t:slim X2 CE Mark'd"", ""Tandem Diabetes Care's t:slim X2 CE Mark'd"", ""Tandem Diabetes Care's t:slim X2 CE Mark'd""]"
DXCM,2018-05-01,18.155,18.61,18.15,18.3475,"[""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close"", ""Notable earnings after Wednesday's close""]"
DXCM,2018-05-02,18.37,18.6175,18.3125,18.5775,"[""DexCom beats by $0.01, beats on revenue"", ""DexCom Q1 revenues up 30%; guidance raised; shares up 3% after hours"", ""DexCom (DXCM) Q1 2018 Results - Earnings Call Transcript"", ""DexCom Q1 Adj. EPS $(0.32) Beats $(0.33) Est., Sales $184.40M Beats $172.08M Est."", ""DexCom Raises FY18 Outlook From $830M-$850M To $850M-$860M vs $842.79M Est."", ""DexCom Raises FY18 Outlook From $830M-$850M To $850M-$860M vs $842.79M Est."", ""DexCom Q1 Adj. EPS $(0.32) Beats $(0.33) Est., Sales $184.40M Beats $172.08M Est."", ""DexCom (DXCM) Q1 2018 Results - Earnings Call Transcript"", ""DexCom Q1 revenues up 30%; guidance raised; shares up 3% after hours"", ""DexCom beats by $0.01, beats on revenue"", ""DexCom Raises FY18 Outlook From $830M-$850M To $850M-$860M vs $842.79M Est."", ""DexCom Q1 Adj. EPS $(0.32) Beats $(0.33) Est., Sales $184.40M Beats $172.08M Est."", ""DexCom (DXCM) Q1 2018 Results - Earnings Call Transcript"", ""DexCom Q1 revenues up 30%; guidance raised; shares up 3% after hours"", ""DexCom beats by $0.01, beats on revenue""]"
DXCM,2018-05-03,19.5,21.3125,19.3845,20.9525,"[""Here's Why DexCom Is Surging Today What happened Investors in DexCom (NASDAQ: DXCM) are having a pleasant start to the day. Shares of the diabetes-focused medical device company jumped as much as 14% in early morning trading on Thursday after the company reported strong first-quarter results. The stock was up about 8% as of 10:22 a.m. EDT. So what Here's a review of the key numbers from Dexcom's first quarter: Revenue jumped 30% to $184.4 million. That was far higher than the $172.1 million in revenue that Wall Street had expected. Non-GAAP net loss was $28.3 million, or $0.32 per share. That was a penny better than what analysts had projected. Cash balance at quarter end was $534 million. The strong start to the year caused management to raise its revenue guidance by $20 million for the full year. The company now expects revenue to land between $850 million to $860 million, which implies a growth rate of 19% at the midpoint. Given the better-than-expected results and guidance boost, it is easy to understand why traders are feeling giddy. Now what Dexcom's stock has now fully recovered from the drubbing that it took in late 2017 after the FDA approved Abbott 's new FreeStyle Libre System. Anyone who was smart enough to buy shares after the huge plunge has made a killing in a short period of time. Can Dexom keep the momentum up? I'd argue that the answer is yes. The company just won FDA approval for its G6 system which boasts a number of improvements over its current system. In addition, the diabetes market is so huge that Dexcom should be able to continue growing quickly even if Abbott or Senseonics Holdings have successful product launches. Count me as a bull. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of April 2, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Close Update: U.S. Stocks Wobble Into Close, Paring Losses Ahead of Monthly Payrolls Report Wall Street pared losses and the benchmarks ended mixed Thursday as the Dow Jones Industrial Average swung about 400 points to hang on for a marginal gain that stemmed its losing skid at four days heading into the key jobs report early Friday. A recovery in information technology and industrials stocks helped the measures mitigate their losses on a day that saw geopolitics curb sentiment on U.S.-China trade tensions and as mixed earnings results from a heavy slate of releases drove much of the price action. The Dow had 11 of its 30 blue chips post gains, led by a 2% rise in Boeing ( BA ). On the downside, Nike ( NKE ) slumped 2% On the S&P 500, just three of the 11 sectors ended higher, with materials up 0.2% and tech rising 0.1%. On the downside, health care slumped 1.1% as Cardinal Health ( CAH ) skidded 21% in the S&P's sharpest loss when the company lowered its forecast for full-year earnings as missed estimates in fiscal Q3. The Dow and the S&P fell below their 200-day moving averages on an intraday basis during the selling Thursday, testing the key support level before recouping some of the losses. Investors could see \""choppy-to-higher\"" price trends in the next few weeks as they \""deal with not-so-stellar guidance (earnings have been solid...), higher rates, and ongoing geopolitical uncertainty,\"" said Janney technical analyst Dan Wantrobski. Political jitters both domestic and foreign were adding pressure as investors watched key trade meetings between the US and China and mulled the potential impact of new revelations made about President Trump and payments made to an adult film actress who alleged she was intimate with him. But attention Friday will turn elsewhere in Washington, D.C., as the Department of Labor releases April's nonfarm payrolls report. The consensus on Econoday is for 191,000 additions from 103,000 in March. The unemployment rate is seen ticking down to 4% from 4.1% with average hourly earnings up 0.2% on the month. Here's where the markets stood by the close: US MARKETS Dow Jones Industrial Average was up 5.17 points (+0.02%) S&P 500 was down 5.94 points (-0.23%) Nasdaq Composite Index was down 12.75 points (-0.18%) GLOBAL SENTIMENT FTSE 100 was down 0.54% Nikkei 225 was closed Hang Seng Index was down 1.34% Shanghai China Composite Index was up 0.65% UPSIDE MOVERS (+) STAA (+26.27%) Reported upbeat Q1 results with 33% revenue growth and 200% gain in net income (+) DXCM (+12.78%) Price target lifted at Oppenheimer after Q1 beat (+) LOGI (+8.85%) Fiscal Q4 results beat expectations (+) EXEL (+7.76%) Q1 income, revenue surges (+) TPX (+3.29%) Q1 sales beat Wall Street estimates DOWNSIDE MOVERS (-) ANIK (-24.68%) Q1 revenue fell 9%, missing estimates, announced product recall (-) HABT (-16.1%) Reported negative comparable store sales (-) CRIS (-10.9%) Files for $200 million mixed shelf offering (-) HII (-10.59%) Reports Q1 earnings well below Street views (-) SPOT (-5.61%) Q1 revenue up YoY, but misses expectations The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2018-05-04,20.75,21.02,20.0225,20.865,"[""DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""55 Biggest Movers From Yesterday"", ""55 Biggest Movers From Yesterday"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View"", ""DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View DexCom, Inc. DXCM reported loss of 32 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate. Also, the figure was narrower than the loss of 49 cents reported in the year-ago quarter. The stock has a Zacks Rank #3 (Hold). Total revenues grew 29.6% to $184.4 million from $142.3 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $173 million. Segmental Details Sensor revenues & other revenues (72% of total revenues) grew 30% on a year-over-year basis to $131.9 million. Transmitter revenues (20%) increased 28% from the prior-year quarter's tally to $37.7 million. Receiver revenues (8%) grew 26% year over year to $14.8 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Operational Details DexCom generated gross margin (as a percentage of revenues) of 64.5%, which contracted 160 basis points (bps) year over year. Margins were under pressure due to an inventory change and shift toward OUS and Medicare. International business displayed continued growth in the quarter, up 49% on a year-over-year basis. Research and development (R&D) expenses totaled $44.8 million in the quarter, down 6.9% year over year. Selling, general and administrative expenses totaled $104.8 million in the reported quarter, increasing 21.3% year over year. Guidance DexCom raised full-year 2018 guidance. The company expects 2018 revenues in the range of $850-$860 million, up from the previous range of $830-$850 million. Meanwhile, the Zacks Consensus Estimate for revenues is currently pegged at $843.7 million, which is significantly lower than the guided estimate. Gross profit margin is projected in the band of 65% to 68%. Reported operating expenses, excluding investments in non-intensive programs, is expected to increase 10% from 2017. In Conclusion DexCom's first-quarter 2018 adjusted earnings met the Zacks Consensus Estimate. Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues are key catalysts at the moment. The glucose monitoring market represents significant commercial opportunity for DexCom. DexCom's opportunities in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide the company a competitive edge in the MedTech space. Further, the company's next-generation fully-disposable CGM systems is also in progress On the flip side, cutthroat competition in the market for blood & glucose monitoring devices is a headwind for DexCom at the moment. We believe the company's margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Lower expected margins on transmitter sales are also a cause of concern. Q1 Earnings of MedTech Majors at a Glance A few better-ranked stocks in the broader medical space, which reported solid earnings this season, are Baxter International Inc. BAX , Varian Medical Systems, Inc. VAR and Intuitive Surgical, Inc. ISRG . While Intuitive Surgical and Varian sport a Zacks Rank #1 (Strong Buy), Baxter carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Intuitive Surgical reported adjusted earnings of $2.44 per share, which surpassed the Zacks Consensus Estimate by 22.6%. Revenues totaled $848 million, which beat the Zacks Consensus Estimate by 10.6%. Varian reported second-quarter fiscal 2018 adjusted earnings of $1.15 per share, which beat the Zacks Consensus Estimate of $1.06. Adjusted earnings improved 27.8% on a year-over-year basis. Baxter reported first-quarter 2018 adjusted earnings per share of 70 cents, which beat the Zacks Consensus Estimate by 12.9% and improved from the year-ago quarter's figure of 58 cents. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""55 Biggest Movers From Yesterday"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View""]"
DXCM,2018-05-07,20.75,22.0225,20.481,21.3975,
DXCM,2018-05-08,21.3075,21.545,21.2125,21.3025,"[""Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure"", ""Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure"", ""Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure""]"
DXCM,2018-05-09,21.3,21.3,21.0325,21.1975,
DXCM,2018-05-10,21.315,21.4725,21.08,21.14,
DXCM,2018-05-11,21.2275,21.7675,21.1875,21.7,"[""Domini Social Investments LLC Buys DexCom Inc, Itron Inc, Atlassian Corporation PLC, Sells ..."", ""Bank of America Initiates Coverage On DexCom with Buy Rating, Announces $100 Price Target"", ""Bank of America Initiates Coverage On DexCom with Buy Rating, Announces $100 Price Target"", ""Domini Social Investments LLC Buys DexCom Inc, Itron Inc, Atlassian Corporation PLC, Sells ..."", ""Bank of America Initiates Coverage On DexCom with Buy Rating, Announces $100 Price Target"", ""Domini Social Investments LLC Buys DexCom Inc, Itron Inc, Atlassian Corporation PLC, Sells ...""]"
DXCM,2018-05-14,21.5775,22.15,21.5775,21.985,"[""Prosight Management, LP Buys Shire PLC, Teligent Inc, Cigna Corp, Sells Chimerix Inc, uniQure ..."", ""Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'"", ""Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'"", ""Prosight Management, LP Buys Shire PLC, Teligent Inc, Cigna Corp, Sells Chimerix Inc, uniQure ..."", ""Here's Why Tandem Diabetes Care, Inc. Is Rising Today What happened In response to an analyst upgrade, shares of Tandem Diabetes Care (NASDAQ: TNDM) , a medical device company focused on insulin pumps, rose 16% as of 11:30 a.m. EDT on Monday. So what Tandem's shareholders can thank JP McKim, an analyst at Piper Jaffray, for today's double-digit jump. McKim upgraded Tandem's stock from neutral to overweight on Monday and increased his price target on the stock to $13.00. That's substantially higher than his prior price target of $8.00 and also well above the stock's closing price of $8.90 on Friday. McKim's decision to upgrade the stock was based on his belief that the company will boast a \""superior closed loop system for several years\"" enabling the company to continue to grab market share at a rapid pace. A \""closed loop\"" system is another name for an artificial pancreas , which is a combination device that will monitor a patient's blood glucose levels and use an algorithm to dose them with insulin when needed. Tandem has been working with its partner DexCom (NASDAQ: DXCM) for many years to bring such a device to market. Traders are bidding up the share price today based on McKim's bullish statements. Now what Tandem's stock has been on a massive tear since it bottomed out earlier this year. It's up more than 346% since January, which is a remarkable move in a short period of time. The optimism has been fueled in part by a great first-quarter report . The huge run in recent months might make you conclude that this has been a great stock to own. However, if you zoom out to include the company's entire history on the public markets, you'd get a different story: TNDM data by YCharts . McKim may be correct when he says that Tandem will be a leader in the race to get the first truly closed-loop system to market. If that happens and the company can maintain its edge for several years, then the stock could be poised for a big run. However, the company faces steep competition from the likes of Medtronic and Insulet , both of which are gunning to introduce artificial pancreases of their own to market as soon as possible. I'm not quite as confident as McKim that Tandem will be able to get there first and maintain its edge for long. In the meantime, Tandem's financial statements are likely to remain ugly for quite some time. Last year, it lost $73 million, and it's guiding for another considerable loss in 2018 as well. That likely means that it won't be long before the company taps shareholders yet again to keep the business afloat. Overall, I think that Tandem has a great product, and I admit that the company could be poised to continue growing rapidly from here. However, it's been an awful long-term investment and its financial situation remains extremely dicey. For that reason, I'll be keeping this stock far away from my portfolio for the foreseeable future. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of April 2, 2018 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of April 2, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'"", ""Prosight Management, LP Buys Shire PLC, Teligent Inc, Cigna Corp, Sells Chimerix Inc, uniQure ...""]"
DXCM,2018-05-15,21.7975,21.9475,21.3575,21.815,
DXCM,2018-05-16,21.8875,21.925,21.575,21.635,"[""Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?"", ""Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?"", ""Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now? A smart beta exchange traded fund, the SPDR S&P Health Care Equipment ETF (XHE) debuted on 01/26/2011, and offers broad exposure to the Health Care ETFs category of the U.S. equity market. What Are Smart Beta ETFs? The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market. A good option for investors who believe in market efficiency, market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns. There are some investors, though, who think it's possible to beat the market with great stock selection; this group likely invests in another class of funds known as smart beta, which track non-cap weighted strategies. These indexes attempt to select stocks that have better chances of risk-return performance, based on certain fundamental characteristics or a combination of such characteristics. Methodologies like equal-weighting, one of the simplest options out there, fundamental weighting, and volatility/momentum based weighting are all choices offered to investors in this space, but not all of them can deliver superior returns. Fund Sponsor & Index Because the fund has amassed over $259.84 M, this makes it the largest ETF in the Health Care ETFs. XHE is managed by State Street Global Advisors. This particular fund, before fees and expenses, seeks to match the performance of the S&P Health Care Equipment Select Industry Index. This Index represents the health care equipment and supplies sector of the S&P Total Market Index. The Index is one of nineteen S&P Select Industry Indices, each designed to measure the performance of a narrow sub-industry or group of sub-industries as defined by the GICS.The Health Care Index is a modified equal weight index. Cost & Other Expenses Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. With the least expensive product in the space, this ETF has annual operating expenses of 0.35%. XHE's 12-month trailing dividend yield is 0.02%. Sector Exposure and Top Holdings ETFs offer diversified exposure and thus minimize single stock risk, but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis. This ETF has heaviest allocation in the Healthcare sector - about 100% of the portfolio. Looking at individual holdings, Inogen Inc. (INGN) accounts for about 2.29% of total assets, followed by Dexcom Inc. (DXCM) and Quidel Corporation (QDEL). Its top 10 holdings account for approximately 18.93% of XHE's total assets under management. Performance and Risk XHE has added roughly 15.28% so far this year, and as of 05/16/2018, is up about 29.47% in the last one year. In the past 52-week period, the fund has traded between $56.42 and $74.71. The fund has a beta of 0.87 and standard deviation of 16.53% for the trailing three-year period, which makes XHE a medium choice in this particular space. With about 71 holdings, it effectively diversifies company-specific risk. Alternatives SPDR S&P Health Care Equipment ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. IShares U.S. Medical Devices ETF (IHI) tracks Dow Jones U.S. Select Medical Equipment Index. The fund has $1.80 B in assets. IHI has an expense ratio of 0.44%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. Bottom Line To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ISHARS-US MED D (IHI): ETF Research Reports SPDR-SP HC EQPT (XHE): ETF Research Reports Inogen, Inc (INGN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?""]"
DXCM,2018-05-17,21.5675,21.985,21.455,21.7275,
DXCM,2018-05-18,21.67,21.8125,21.5311,21.6625,
DXCM,2018-05-21,21.775,21.9625,21.5088,21.7275,
DXCM,2018-05-22,21.685,21.685,21.465,21.5725,
DXCM,2018-05-23,21.4725,21.835,21.44,21.75,
DXCM,2018-05-24,21.7925,21.9175,21.58,21.87,
DXCM,2018-05-25,21.98,22.1,21.765,22.0,"3 Top Stocks That Aren't on Wall Street's Radar Great companies come in all shapes and sizes. That makes it tough for Wall Street to stay on top of every stock, especially when so many investors focus on short-term returns, rather than the long-term opportunity for a company. We asked some Motley Fool investors to scour their universe for names that they think are underappreciated by Wall Street, and they responded with DexCom Inc. (NASDAQ: DXCM) , HUYA Inc. (NYSE: HUYA) , and Control4 Corp. (NASDAQ: CTRL) . Are these stocks savvy buys for your portfolio? Read on to learn more about what makes them compelling investments. A medtech stock for the long haul Todd Campbell(DexCom): The number of Wall Street analysts with a ""hold"" rating on this diabetes medtech stock has increased from three to seven since February. And given analysts' reluctance toward ""sell"" ratings, that's a pretty pessimistic -- and I'd argue incorrect -- assessment of DexCom's opportunity. Yes, DexCom's shares have rallied significantly since FDA approval of its latest continuous glucose monitor (CGM) for diabetes, but long-term investors might be better off focusing on the fact that the addressable market for CGMs is massive, and likely to get even bigger in the coming decade. In the U.S. alone, over 30 million people are living with diabetes. And because 84 million Americans have prediabetes, or elevated blood sugar levels, the addressable patient population is expected to skyrocket to nearly 55 million by 2030. Currently, most of the demand for CGMs is coming from type 1 diabetes patients, who are at the greatest risk of life-threatening complications. However, a much bigger opportunity for DexCom is emerging in type 2 patients, who represent about 95% of diabetics in the United States. In Q1 2018, DexCom's sales grew 30% year over year to $184 million. And as the company's monitors gain more-widespread adoption by payers and patients in type 1 and type 2 diabetes, management expects its full-year sales to exceed $850 million, up from $719 million in 2017. There are about 40,000 new type 1 diagnoses and 1.5 million total diabetes patients diagnosed annually in the U.S. So there's a very long runway ahead of this company that can support its future sales growth and, eventually, profitability. Overall, given an increasing diabetes market and the likelihood of DexCom delivering advances that give patients even greater control over their disease, I believe this is a great stock to add to growth portfolios. A pure play on the esports market Leo Sun(Huya): Chinese video streaming company YY (NASDAQ: YY) recently spun off its game-streaming unit, Huya, in an IPO that raised $180 million. The stock then went on a roller-coaster ride , surging from $12 per share to almost $24, before sliding back to the high teens. Very few Wall Street analysts have chimed in about Huya, but its growth is stunning. Its average monthly active users (MAUs) rose 30% annually to 83.4 million last year, as its mobile MAUs jumped 75% to 36.2 million. Huya's total number of paying users rose 63% annually to 2.9 million during the fourth quarter, as its monthly active broadcasters climbed 11% to 610,000. Huya's revenue rose 174% annually to 2.18 billion yuan ($355.8 million) last year, with 107% sales growth in the fourth quarter. Its net loss narrowed from 625.6 million yuan in 2016 to 81 million yuan ($12.4 million) in 2017. It posted a net profit of 4.98 billion yuan ($765 million) during the fourth quarter, compared to a loss of 137.6 million yuan a year earlier. China's esports market reached 229 million gamers last year, according to market research firm Frost & Sullivan, and that figure is expected to hit 537 million by 2022. If Huya stays at the top of this market, it could experience explosive growth over the next few years. But at $19, this stock trades at about 11 times sales -- which indicates a lot of growth is already baked in. International growth Daniel Miller (Control 4 Corp.): One stock flying under Wall Street's radar is Control 4 . It takes time to get noticed by Wall Street, and with a market capitalization of only $630 million, it'll be a bit before Control 4 is a household name. And becoming a household name is precisely the company's business. Control 4 provides a plethora of products and services for the high-end smart-home market. We're talking professionally installed systems that can cost upward of $50,000 all told. These solutions include anything and everything: smart lighting, audio, multiroom video, remote controls, doors, thermostats, as well as platform products to make everything work seamlessly. The company's future is intriguing for two reasons: its balance sheet and growth prospects. Starting with its balance sheet, consider that Control 4 ended the second quarter with more than $76 million in cash and no debt. The pristine balance sheet is even more impressive considering its history of acquisitions. Among other smart-home suppliers, it acquired CardAccess in 2014, Leaf in 2015, Pakedge in 2016, and ihiji in 2018. It has successfully integrated these, and with no debt can pounce on any opportunity that appears to be a good fit and can drive its top line higher. Control 4's growth prospects are tantalizing as well. Management estimates a 1.5% penetration of the U.S. market, with even more potential internationally. In 2011, international authorized dealers (a fancy way of saying dealers that sell the full Control 4 lineup) accounted for only 17% of total authorized dealers. At the end of 2017, international authorized dealers accounted for almost 30% of the total. With a balance sheet that enables Control 4 to pounce on more acquisitions, juicy international growth prospects, and a stock that jumped 192% in 2017 , it won't be long before Wall Street's radar detects this smart-home company. 10 stocks we like better than Control4 When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Control4 wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of May 8, 2018 Daniel Miller has no position in any of the stocks mentioned. Leo Sun has no position in any of the stocks mentioned. Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of Control4. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-05-29,21.8575,22.1425,21.6375,21.7875,
DXCM,2018-05-30,21.945,22.1525,21.8266,21.8725,
DXCM,2018-05-31,21.7525,22.35,21.7188,21.9975,
DXCM,2018-06-01,22.025,23.3875,22.025,23.05,"[""DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?"", ""DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?"", ""DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue? A month has gone by since the last earnings report for DexCom, Inc.DXCM . Shares have added about 17.7% in that time frame. Will the recent positive trend continue leading up to its next earnings release, or is DXCM due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Recent Earnings DexCom reported loss of 32 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate. Also, the figure was narrower than the loss of 49 cents reported in the year-ago quarter. Total revenues grew 29.6% to $184.4 million from $142.3 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $173 million. Segmental Details Sensor revenues & other revenues (72% of total revenues) grew 30% on a year-over-year basis to $131.9 million. Transmitter revenues (20%) increased 28% from the prior-year quarter's tally to $37.7 million. Receiver revenues (8%) grew 26% year over year to $14.8 million. Operational Details DexCom generated gross margin (as a percentage of revenues) of 64.5%, which contracted 160 basis points (bps) year over year. Margins were under pressure due to an inventory change and shift toward OUS and Medicare. International business displayed continued growth in the quarter, up 49% on a year-over-year basis. Research and development (R&D) expenses totaled $44.8 million in the quarter, down 6.9% year over year. Selling, general and administrative expenses totaled $104.8 million in the reported quarter, increasing 21.3% year over year. Guidance DexCom raised the full-year 2018 guidance. The company expects 2018 revenues in the range of $850-$860 million, up from the previous range of $830-$850 million. Gross profit margin is projected in the band of 65% to 68%. Operating expenses, excluding investments in non-intensive programs, are expected to increase 10% from 2017. How Have Estimates Been Moving Since Then? It turns out, fresh estimates have trended downward during the past month. There have been four revisions higher for the current quarter compared to seven lower. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote VGM Scores At this time, DXCM has an average Growth Score of C. Its Momentum is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Our style scores indicate that the stock is more suitable for momentum investors than growth investors. Outlook Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, DXCM has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?""]"
DXCM,2018-06-04,22.9325,23.4025,22.75,23.365,
DXCM,2018-06-05,23.28,23.61,23.05,23.6075,
DXCM,2018-06-06,23.75,23.935,23.3462,23.5475,
DXCM,2018-06-07,23.55,23.56,21.9225,22.3725,"[""Dexcom Shares Down 4.2% Thurs.; Traders Attributing Weakness To Earlier Circulation Apple Planning Device To Help Monitor Blood Pressure"", ""Dexcom Shares Down 4.2% Thurs.; Traders Attributing Weakness To Earlier Circulation Apple Planning Device To Help Monitor Blood Pressure"", ""Dexcom Shares Down 4.2% Thurs.; Traders Attributing Weakness To Earlier Circulation Apple Planning Device To Help Monitor Blood Pressure""]"
DXCM,2018-06-08,23.2075,23.4375,22.9325,23.25,"[""CORRECTION: JP Morgan Upgrades DexCom to Overweight"", ""A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street"", ""Benzinga's Top Upgrades, Downgrades For June 8, 2018"", ""The Market In 5 Minutes: China, ZTE, McDonald's And More"", ""30 Stocks Moving In Friday's Mid-Day Session"", ""30 Stocks Moving In Friday's Mid-Day Session"", ""The Market In 5 Minutes: China, ZTE, McDonald's And More"", ""Benzinga's Top Upgrades, Downgrades For June 8, 2018"", ""A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street"", ""CORRECTION: JP Morgan Upgrades DexCom to Overweight"", ""JP Morgan Upgrades DexCom to Overweight"", ""30 Stocks Moving In Friday's Mid-Day Session"", ""The Market In 5 Minutes: China, ZTE, McDonald's And More"", ""Benzinga's Top Upgrades, Downgrades For June 8, 2018"", ""A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street"", ""CORRECTION: JP Morgan Upgrades DexCom to Overweight"", ""JP Morgan Upgrades DexCom to Overweight""]"
DXCM,2018-06-11,23.185,23.9625,23.015,23.7525,"[""Andrew Left Goes Long Fitbit, Sees 130% Upside"", ""Andrew Left Goes Long Fitbit, Sees 130% Upside"", ""SPDR S&P Health Care Equipment ETF Experiences Big Inflow Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Health Care Equipment ETF (Symbol: XHE) where we have detected an approximate $70.9 million dollar inflow -- that's a 19.6% increase week over week in outstanding units (from 4,600,000 to 5,500,000). Among the largest underlying components of XHE, in trading today DexCom Inc (Symbol: DXCM) is trading flat, Inogen, Inc (Symbol: INGN) is up about 0.3%, and Penumbra Inc (Symbol: PEN) is lower by about 1.3%. For a complete list of holdings, visit the XHE Holdings page \u00bb The chart below shows the one year price performance of XHE, versus its 200 day moving average: Looking at the chart above, XHE's low point in its 52 week range is $57.93 per share, with $79.69 as the 52 week high point - that compares with a last trade of $78.84. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Andrew Left Goes Long Fitbit, Sees 130% Upside"", ""Fitbit stock jumps nearly 15% after Citron praises health opportunity Shares have gained 35% in June amid strong early signs for Versa smartwatch Investors appear to be betting that Fitbit Inc. is ready for a comeback, sending shares to their highest levels since early 2017 on Monday.""]"
DXCM,2018-06-12,24.0,25.375,23.985,24.695,"[""Dexcom G6 CGM System receives CE mark"", ""Dexcom Reports Co. Received CE Mark For Dexcom G6 System For People With Diabetes Ages 2 Years And Up"", ""William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta"", ""William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta"", ""Dexcom Reports Co. Received CE Mark For Dexcom G6 System For People With Diabetes Ages 2 Years And Up"", ""Dexcom G6 CGM System receives CE mark"", ""William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta"", ""Dexcom Reports Co. Received CE Mark For Dexcom G6 System For People With Diabetes Ages 2 Years And Up"", ""Dexcom G6 CGM System receives CE mark""]"
DXCM,2018-06-13,24.7825,24.9112,24.6,24.705,"DexCom Stock History DexCom, Inc. (NASDAQ: DXCM) is a medical device company that pioneered the development of continuous glucose monitors (CGM) used by diabetics to more accurately track their blood glucose levels and control their disease. Founded in 1999, DexCom competes against industry titans Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) in an addressable market that totals more than 30 million diabetics in the United States alone. Given there are 1.5 million new cases of diabetes diagnosed every year in America, and the number of people with diabetes is expected to eclipse 50 million by 2030, does DexCom deserve to be a top stock for growth investors to buy? What is diabetes? When functioning normally, the pancreas releases insulin after we eat to convert glucose into stored energy. However, in patients with diabetes, the pancreas either doesn't produce any or enough insulin (type 1 diabetes) or the body has developed a resistance to the insulin it produces (type 2 diabetes). Resulting from genetic or environmental factors, type 1 diabetes is typically diagnosed in childhood or in adolescence. A lifelong disease, type 1 diabetes requires chronic blood glucose monitoring and regular insulin dosing to prevent the buildup of blood sugar that can lead to a series of health problems. Type 2 diabetes is usually diagnosed later in life than type 1 and while the cause of type 2 diabetes isn't fully understood, a person's genetics and lifestyle are considered contributing factors to developing insulin resistance. The most common type of diabetes, type 2 diabetes accounts for about 95% of diabetes patients. While type 2 patients don't have as intensive of a regimen for monitoring their blood sugar, these patients often progress to requiring insulin and ongoing analysis of blood sugar levels is critical. Absent adequate monitoring and the correct use of insulin, diabetes patients are at risk of developing a variety of health problems, including nerve damage that can lead to amputation, vision loss that can lead to blindness, and life-threatening kidney disease and cardiovascular disease. According to the World Health Organization (WHO), adults with diabetes have a two- to threefold higher risk of heart attack and stroke than their nondiabetic peers. Diabetes is the seventh leading cause of death and overall, the average life expectancy of someone with diabetes at age 50 is reduced by nearly nine years. How big is the diabetes market There are 30.3 million Americans living with diabetes in America, according to the Centers for Disease Control (CDC), and globally, the addressable patient population eclipses 422 million, up from 108 million in 1980, according to WHO. The number of people with diabetes is expected to increase substantially over the coming decade, and as a result, the total costs associated with treating it is forecast to skyrocket. Research from the Institute for Alternative Futures (IAF) concludes that the number of people with diagnosed or undiagnosed diabetes in the U.S. will reach 54.9 million by 2030 and that spending on diabetes will increase to $622 billion in 2030 from $408 billion in 2015. A need for better monitoring Medications, including metformin, are widely used to help keep blood glucose levels from causing life-threatening problems in type 2 patients, but the most critical component of keeping diabetes in check for type 1 patients is accurate monitoring and insulin dosing to avoid dangerously high (hyperglycemia) or low (hypoglycemia) levels of blood sugar. Usually, type 1 and type 2 diabetes patients evaluate their blood sugar levels by using finger sticks to collect a small blood sample that can be analyzed by a glucose meter. Because type 1 diabetics produce very little or no insulin, they undergo this routine four to 10 times per day, including prior to eating, before and after exercising, and before falling asleep. Regular checks of blood sugar during the night aren't uncommon, either. Type 2 diabetics don't require as intensive of monitoring but they still check their blood sugar levels often, including around mealtimes. Despite regularly checking blood sugar with finger sticks, studies show most diabetes patients spend 70% of every day outside of the healthy range for blood sugar, and as a result, are at a greater risk of diabetes causing life-threatening problems. Recognizing that finger sticks and glucose metering fall short for many people, DexCom was founded in 1999 with a singular mission: to develop medical devices that continuously monitor blood glucose levels so that patients can better determine when they should be taking their insulin. Dexcom's history of innovation Until 2003, DexCom's research focused primarily on developing implantable sensors that could remain in the body for an extended time. But in 2004, growing concern that the company would face challenges gaining approval for a long-term implant solution that was more invasive and costly than traditional finger sticks, led to the development of short-term, temporary sensors that can be attached to the skin. In 2005, DexCom raised $56.4 million in an IPO on the Nasdaq to fund clinical trials of its short- and long-term system. The short-term sensor and CGM solution -- the STS continuous glucose monitoring (CGM) system -- won FDA approval in 2006 after trials demonstrated patients spent less time outside a normal healthy blood sugar range while using it. The long-term implant solution, however, was halted after the company ""evaluated several months of data from feasibility studies"" and determined the product ""didn't warrant investing in a large pivotal trial."" In short, creating a reliable long-term device that would pass muster with regulators, payers, and patients was too difficult a challenge to overcome, particularly given the successful launch of the short-term sensor solution, which was a revolutionary advance in its own right. The short-term STS system used tiny wire-like sensors that were inserted by the patient just under the skin that could be worn for three days. Data collected by these sensors was reported wirelessly to the STS receiver, where it was charted and displayed in a graph to patients. To help patients know when their blood glucose levels were too high or too low, the STS system also included a feature that triggered alerts. The company's second-generation product, the seven-day STS CGM system, got the FDA's nod in 2007. That system increased the time sensors could be worn by diabetics from three to seven days and it included a feature that allowed patients to download their glucose level data to a computer for review. These early systems provided revolutionary insight to patients but didn't begin to gain widespread adoption until 2008, when results from a Juvenile Diabetes Research Foundation trial were unveiled. In its 322-person trial, CGMs significantly improved glucose control without hypoglycemia. The study was important because it reduced worry that the use of CGM's could cause patients to take too much insulin. Thanks in part to a growing body of evidence supporting the use of CGMs, DexCom's sales began to accelerate. In 2008, sales climbed 76% to $8.1 million and by 2011, sales were topping $40 million. The rapid run-up in sales allowed DexCom to plow more money into research and development, and that spending led to the development of its next generation of CGMs, the G-series. The company's first G-series CGM was the G4 Platinum, which won FDA approval in 2012. The G4 was smaller than the STS systems preceding it, and it improved hypoglycemic accuracy by 30%. The improvement in accuracy is important because CGM's don't measure glucose levels through the bloodstream. Instead, they do so through the interstitium, a fluid-filled space just under the skin. Because CGM sensors are inserted into the interstitium, the CGM's software contains code that deduces actual blood sugar levels from the sensor readings at points in time. Absent greater accuracy, patients were still at risk of taking too much insulin, which can cause hypoglycemia. The G4 also offered a longer transmission range between its sensors and the receiver and a more user-friendly color LCD display than previous devices. In 2015, DexCom followed up the G4 with the G5. The G5 allowed patients to see real-time data on either a DexCom receiver or on any compatible device, including smartphones, via an app. The G5 also included an option to securely share real-time data with a caregiver, such as a parent, and it provided access to a cloud-based repository where data could be stored for review. Importantly, the G5 was the first DexCom CGM to do away with the need to confirm CGM readings with finger sticks prior to taking insulin. Although finger sticks were still necessary every 12 hours to calibrate the system, the advance significantly reduced the burden of finger sticks on patients. Ongoing technological advances, such as the G4 and G5, alongside growing acceptance of CGMs generally, has been a boon to the company's top line. Since 2008, DexCom's annual sales have increased from less than $10 million to $718.5 million in 2017 -- a compounded annual growth of nearly 57%. DXCM Revenue (Annual) data by YCharts . Competition heats up DexCom isn't the only company profiting from continuous glucose monitoring systems. Medtronic and Abbott Labs are deep-pocketed foes and each has recently launched compelling new devices for diabetes that challenge DexCom. After securing an unexpected early approval in 2016, Medtronic launched its MiniMed 670G in 2017. The MiniMed 670G is the world's first closed-loop monitoring and insulin dosing system to win the regulatory green light. It combines Medtronic's Guardian CGM and Medtronic's insulin pump in a system that automatically measures blood glucose levels every five minutes and then, automatically doses insulin when it's necessary. The MiniMed 670G marks a major advance in treating diabetics requiring extensive monitoring and so far, it's a hit. In Medtronic's 2018 fiscal fourth quarter, diabetes revenue rose 26% to $645 million because of the system. Abbott Labs is also riding a wave of growing demand following the approval of its latest CGM , the Freestyle Libre. When the Freestyle Libre won FDA approval in 2017, it became the first CGM approved that didn't require daily finger sticks for calibration. The device's sensors do have a 12-hour warm-up period in which data isn't recorded, however, so finger sticks are necessary during that period. The Freestyle Libre launched at a lower price point than DexCom's G5 and since it eliminated the need for finger sticks for calibration, it's become a commercial success. As of March 2018, 650,000 patients were using the Freestyle Libre and 50,000 new patients were being added monthly. Abbott hasn't said specifically how much money the Freestyle Libre's contributing to its top-line, but it has said that it was responsible for a 30% increase in its diabetes revenue in Q1 2018. Abbott Labs reports its diabetes sales in its ""other"" category and in Q1 2018, ""other"" revenue accounted for $430 million of Abbott Labs $7.4 billion in total sales. DexCom's future As you can see in the following chart, the 2017 approval of Abbott's Freestyle Libre took a toll on DexCom's share price. However, the sell-off proved temporary as the company's shares rallied sharply following the FDA approval of DexCom's latest CGM, the G6, in March 2018. DXCM data by YCharts . The G6 is arguably more feature-rich than the Freestyle Libre. Like the Freestyle Libre, DexCom's G6 eliminates the need for finger sticks, but unlike Abbott Labs' CGM, the G6's sensors only have a two-hour warm-up period. The G6 automatically communicates data between its sensors and a receiver and the receiver can be a smartphone or similar device, too. Alternatively, Abbott's receiver has to be held within 1.5 inches of its sensors to transfer data and there's no app yet that allows patients to use a smartphone or tablet as the receiver. Furthermore, the G6 warns patients of dangerous glucose readings with an alarm, while the Freestyle Libre doesn't. The G6 system uses smaller sensors than DexCom's G5 and its sensors can be applied to the skin with a new one-touch applicator that's easier to use. Additionally, the G6's sensors can be worn for 10 days while the G5 sensors are only approved for seven days of use. G6's features could help DexCom outcompete the Freestyle Libre, but what's most exciting about the G6 is that it's the first CGM to win FDA approval as a stand-alone system or as a CGM for use in automated insulin dosing systems. Currently, Medtronic is the only company marketing a closed-loop monitoring and insulin dosing system (the aforementioned MiniMed 670G), but insulin pump makers Insulet (NASDAQ: PODD) and Tandem Diabetes (NASDAQ: TNDM) are working on their own closed-loop systems and those systems are being designed for use with DexCom's CGMs. Studies for a system that pairs up the G5 with Insulet's Omnipod insulin pump are underway, and according to management, its closed-loop system could reach the market as soon as late 2019. Meanwhile, Tandem Diabetes is even closer to the finish line. Its t:slim X2 insulin pump is the only pump approved for use with DexCom's G5 that doesn't require finger sticks prior to dosing insulin, and Tandem says an FDA approval of a closed-loop system using the G5 could come as soon as the summer of 2018. An OK for a system that incorporates the G6 could be available by the end of 2018 or early 2019, too. The potential associated with DexCom's G6 isn't limited to those two solutions, though. DexCom is looking at pairing it up with other solutions, such as smart insulin pens or apps, too. DexCom's innovation isn't going to stop with the G6, either. The company's working closely with Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) healthcare spinoff Verily on disposable CGM solutions that could find their way to the market in 2020. Is DexCom a stock to buy? DexCom is at the forefront of CGM technology and its strategy of working with any insulin delivery system could help it win more market share over time. The company isn't profitable yet, though, and there's no guarantee its sales will reach the levels necessary to produce consistent earnings. Nevertheless, the sheer size of the addressable market for diabetes medical devices and a single-digit penetration rate for CGMs in that market suggest there's plenty of potential for revenue to climb high enough for DexCom to eventually reward shareholders with profits. Undeniably, DexCom's got heavyweight competition from Medtronic and Abbott Labs, but unlike those companies, it's a pure player in this market. If CGMs become a standard used alongside insulin delivery to treat diabetes patients, then its investors could benefit substantially. For that reason, I think it's worth owning. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of May 8, 2018 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell owns shares of Alphabet (C shares). His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-06-14,24.8425,25.525,24.515,24.6325,"Fitbit Inc May Still Have 30% Upside – Despite Massive Rally InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Fitbit Inc (NYSE: FIT ) have been on fire, with Fitbit stock rising roughly 40% in June alone. It's obviously been a massive rally and has led to an overbought condition in the stock. But there's reason for some investors to believe that it could have more room to run. So what's sparking this run? Stocks don't just rally 40% in two weeks and 65% from the April lows without a catalyst. What's Moving Fitbit Stock In late April, Fitbit announced it's teaming up with Alphabet Inc (NASDAQ: GOOGL )(NASDAQ: GOOG ) for healthcare purposes. With Google's help, Fitbit can leverage the cloud, machine learning and other technologies to bolster its technology offering. The company's focus on healthcare is what's helping drive it higher. 20 Long-Term Value Stocks With Hulking Upside The company reported its quarterly results in May and they were better than expected, but certainly not great. Revenue fell 17% year-over-year and FIT reported a loss-per-share rather than earnings-per-share. But overall, the outlook for Fitbit was mixed, to be honest. But the company's conference call played an important role, especially when it came to its healthcare potential. Co-founder, chairman and CEO James Park said: ""We continue to make progress on deepening our reach into health care and see ongoing evidence that payers are embracing wearable devices and beginning to provide financial incentives to consumers that change their behaviors."" ""We believe that technology in wearable devices had flipped the traditional narrative in health care, empowering consumers with real information about their health. We believe this presents an opportunity to leverage our brand, engage consumers and change their behaviors."" They talked about partnerships with UnitedHealth Group Inc (NYSE: UNH ) and emphasized how its partnership with Google would allow for increased efficiency. They also talked about how valuable their healthcare data will become as their devices and software gains in usage. Indeed partnering with Google, insurance companies and DexCom, Inc. (NASDAQ: DXCM ) - one of the largest glucose monitoring companies - leaves the door wide open for Fitbit. Potential for FIT Stock So what does all this mean for Fitbit stock? In May, several analysts slapped an $8 price target on the stock. That leaves about 10% upside from current levels on the table. Right before earnings, another analyst slapped a $10 price target on Fitbit stock. That was Alex Fuhrman of Craig-Hallum and even after the big rally, it still implies more than 30% upside from here. The one that really got Fitbit stock moving came from Citron Research. Andrew Left argues that Fitbit stock is going to $15 this year. That is, unless another company swoops in and snatches it up. Can Fitbit stock do it? He argues that Fitbit is transitioning from a ""dead"" step-counting fitness tracker to a high-potential med-tech device company. If so, its $1.5 billion market cap (plus a premium) is a relatively low price to pay for an acquirer - especially considering the market-leading Apple Watch from Apple Inc. (NASDAQ: AAPL ) isn't something M&A buyers will ever pry away from Apple. Could it be Google? Perhaps, as it's shown to not be afraid of acquisitions in the past. We'll have to see how Fitbit's progress goes with its current initiatives. Trading Fitbit Stock Click to Enlarge Fitbit stock has been on a massive rally, but it needs to rest in my mind. Sporting an RSI (blue circle) north of 80 doesn't mean it will pullback. But it makes adding to the current gains that much harder. This month alone, Fitbit stock has pushed through the $6 and $7 level, the latter of which is quite significant. From a bulls' perspective, it would be great to see FIT stock consolidate between $7 and $7.50. That will give it time to work off its overbought condition and recharge for another leg higher. The key, though, is $7. Should it fail, there's no definitive level of support below. If that happens, we'll need to see how it shakes out and if Fitbit stock can reclaim $7 again. But for now, let's go one step at a time and first see if support holds and Fitbit stock can cool off. The 10 Stocks That Will Push the Dow Over 30K With a short interest of almost 15% - although likely lower now - FIT could have more upside if bulls can get a short-squeeze going again. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . As of this writing, Bret Kenwell was long AAPL. More From InvestorPlace 20 Stocks With Renewed Bull Cases After Trump-Kim Summit 7 Stocks That Could Take a Trade-War Hit 7 Women-Led S&P 500 Companies to Own for the Long Haul The 10 Stocks That Will Push the Dow Over 30K Compare Brokers The post Fitbit Inc May Still Have 30% Upside - Despite Massive Rally appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-06-15,24.2175,25.1275,24.0719,24.93,"[""Buy Lockheed Martin On Weakness - Cramer's Lightning Round (6/14/18)"", ""Buy Lockheed Martin On Weakness - Cramer's Lightning Round (6/14/18)"", ""Buy Lockheed Martin On Weakness - Cramer's Lightning Round (6/14/18)""]"
DXCM,2018-06-18,24.885,25.2987,24.7031,25.2225,"[""Can Fitbit Be Worth $15 By The End Of The Year?"", ""Can Fitbit Be Worth $15 By The End Of The Year?"", ""Can Fitbit Be Worth $15 By The End Of The Year?""]"
DXCM,2018-06-19,25.2175,25.4498,24.8725,25.2025,
DXCM,2018-06-20,25.3225,25.475,25.0788,25.1625,"Why the Outlook for Fitbit Stock Is Positive in Any Scenario InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fitbit (NYSE: FIT ) bears believe that Fitbit stock is overvalued, citing the company's falling market share and revenue, as well as tough competition in the wearables space. But as I've pointed out in the past, the company's smartwatches are actually superior to Apple's (NASDAQ: APPL ) Apple Watch in many ways, while its partnerships with health insurers should enable it to greatly increase its revenue and its alliance with Alphabet's (NASDAQ: GOOG )(NASDAQ: GOOGL ) Google and Dexcom (NASDAQ: DXCM ) should result in great innovations. Meanwhile, the upbeat reviews for the company's new Versa smartwatch should cause more people to give the Fitbit product a chance- enabling them to see how it is superior to Apple Watch. The company has also released Ace, the first and - as far as I know - so far the only smartwatch geared for kids. 7 Small-Cap Stocks to Consider for the Second Half of 2018 Here's a look at three different scenarios - bear, base and bull - for Fitbit stock to enable investors to get an idea of the risk/reward outlooks going forward: Bear Scenario for Fitbit Stock Revenue from the Versa ends up being only 20% to 30% higher than those of the Ionic as Apple's higher marketing dollars and great reputation, along with cheaper imports from Chinese companies, keep a lid on sales of Fitbit's new device. However, enough diabetic patients, women who want to utilize Fitbit's new female health tracking system, Android users, and smartwatch enthusiasts who like its lower price, long battery life and Coach app buy the Versa to keep sales of the product from crashing. Revenue from the company's Coach app also rises around 20% annually, and FIT sells around 300,000 Ace devices per year. A few more health insurers and major companies incentivize their customers/employees to use Fitbit products. The collaboration with Google doesn't result in any major innovations. And additional wearables released by Fitbit are not nearly as popular as the Versa. In this scenario, rising revenue from slightly higher sales of Versa, Ace, and the Coach app, along with increased revenue from employee and insurer incentivization programs, will be largely, although not completely, offset by lower tracker sales. Fitbit's revenue will increase around 10% per year. Investors will realize the company is not going to thrive - but isn't going bankrupt anytime soon. In this scenario, Fitbit stock will reach around $10 per share in early 2019. FIT could be acquired for around 20% more than in 2019 or 2020. Base Scenario for Fitbit Stock Versa gathers a great deal of buzz and becomes quite popular among the groups mentioned previously. Revenue from the Versa is about four times that of the Ionic in 2018 and rises to six times its level during the holiday season of 2018 and in early 2019 as the device takes a great deal of market share from Apple Watch and other rivals. About 20% of U.S. health insurers and 5% of major U.S. employers incentivize their customers/employees to use FIT devices. Revenue from apps quadruple year-over-year, becoming significant. Ace sells at an annualized pace of 1 million. Due to incentives offered by employers and insurers, and the buzz around Fitbit, tracker sales remain little changed. Innovations created by Fitbit in tandem with Google and Dexcom cause 10% of doctors to start advocating some of their patients use the device. Fitbit's revenue doubles in the fourth quarter of 2018 and the first quarter of 2019, enabling it to become significantly profitable. Fitbit stock reaches around $25 by April 2019. Bullish Scenario for Fitbit Stock Versa becomes by far the world's best-selling smartwatch by the holiday season, obtaining market share of around 70%. It is one of the five ""must-have"" products of the holiday season. About 50% of health insurers and 15% of major U.S. employers incentivize their customers/employees to use Fitbit devices as the products' diagnostic capabilities and their ability to promote people's health become much more widely accepted. Contributing to the latter sentiment are blockbuster innovations made by Fitbit and its partners. In the wake of these innovations, about 25% of U.S. doctors recommend that at least some of their patients use a Fitbit device. Ace sells at an annual rate of 4 million. New wearables released by Fitbit also generate strong sales. In this scenario, Fitbit revenue would quadruple and its annualized net income would reach about $1.5 billion. Fitbit stock would jump to at least $45 by April 2019. The company could be acquired by the end of 2019 for as much as $80 per share. 3 Stocks to Buy on Weakness As you can see from these scenarios, the risk/reward ratio for Fitbit stock is quite positive. Consequently I recommend buying FIT stock. As of this writing, Larry Ramer owned shares of FIT stock. More From InvestorPlace 7 Best Tech Stock Ideas for 2018 7 Stocks That Could Take a Trade-War Hit 3 More Fintech Stocks to Put On Your Wish List 3 Cheap Stocks Under $3 to Consider Now Compare Brokers The post Why the Outlook for Fitbit Stock Is Positive in Any Scenario appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-06-21,25.09,25.2712,24.44,24.935,"[""FDA OKs Senseonics Eversense CGM device; shares up 1%"", ""FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours"", ""FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours"", ""FDA OKs Senseonics Eversense CGM device; shares up 1%"", ""FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours"", ""FDA OKs Senseonics Eversense CGM device; shares up 1%""]"
DXCM,2018-06-22,25.08,25.4675,24.865,24.89,"Big News Sends Tandem Diabetes Soaring 10.2% Today What happened After the Food and Drug Administration greenlit the use of software that can suspend insulin when its insulin pump is used in conjunction with DexCom 's (NASDAQ: DXCM) continuous glucose monitor (CGM), shares of Tandem Diabetes Care (NASDAQ: TNDM) are rallying 10.2% at 12:45 p.m. EDT on Friday. So what Historically, diabetes patients can spend up to 70% of their day outside their desired blood glucose range, and as a result, they're at risk of seeing their disease progress to a point where it causes life-threatening complications. In a bid to better control blood sugar levels, doctors and patients are increasingly embracing monitors that can track blood sugar levels in real time and pumps that provide background insulin. The use of these systems together can conceivably automate insulin dosing. However, software that can predict future blood sugar levels to avoid the risk of hypoglycemia, or ultra-low levels of blood sugar that can be life-threatening, is necessary for that to happen. For this reason, the approval of Tandem Diabetes Care's latest upgrade to its insulin pumps is important. In trials, using Tandem's Basal-IQ algorithm to predict blood sugar levels 30 minutes into the future resulted in a 31% relative reduction in time spent by patients with blood glucose levels below 70 mg/dL when compared to a CGM and an insulin pump alone. Tandem Diabetes Care's suspend feature works by automatically stopping insulin delivery when low blood sugar is expected and then automatically restarting it when blood glucose levels trend back upward. Now what Until now, Medtronic 's (NYSE: MDT) MiniMed 670G was the only approved automated monitoring and insulin pump delivery system available to patients, but when Tandem Diabetes Care launches its new feature in August, it will provide stiff competition. Medtronic doesn't break out MiniMed 670G sales specifically, but the revenue opportunity associated with this advance in treatment is significant. The number of users of the MiniMed 670G increased from about 20,000 people in December 2017 to 70,000 exiting March 2018 and Medtronic cites the MiniMed 670G as major reason behind its low 20% year-over-year growth in its diabetes segment. Medtronic's diabetes sales totaled $2.1 billion in fiscal 2018. Unexpectedly, Tandem Diabetes Care's FDA approval includes the use of its new feature alongside DexCom's latest CGM , the G6. A more feature-rich CGM than its predecessor, the G6 removes the need for finger sticks for calibration and its sensors can be worn for 10 days rather than seven days. Pairing the G6 with Tandem Diabetes Care's t:slim insulin pump out of the gate could make Tandem's solution even more attractive, and investors should therefore seriously consider adding this stock to their growth portfolios. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-06-25,24.7325,24.8512,23.48,23.86,
DXCM,2018-06-26,23.8075,24.0125,23.5225,23.825,
DXCM,2018-06-27,23.95,24.05,22.6525,23.085,
DXCM,2018-06-28,23.075,23.6675,22.6775,23.5675,
DXCM,2018-06-29,23.6525,23.83,23.335,23.745,
DXCM,2018-07-02,24.1675,24.75,23.7775,24.6125,"[""Premarket analyst action - healthcare"", ""The Market In 5 Minutes: More Trade Threats, July PDUFA Dates, Tesla's Goal And More"", ""Benzinga's Top Upgrades, Downgrades For July 2, 2018"", ""DexCom Shares Up 2% Following Earlier Upgrade From Market Perform To Outperform At Raymond James"", ""DexCom Shares Up 2% Following Earlier Upgrade From Market Perform To Outperform At Raymond James"", ""Benzinga's Top Upgrades, Downgrades For July 2, 2018"", ""The Market In 5 Minutes: More Trade Threats, July PDUFA Dates, Tesla's Goal And More"", ""Premarket analyst action - healthcare"", ""What's in Store for AngioDynamics (ANGO) in Q4 Earnings? AngioDynamicsIncANGO is set to report fourth-quarter fiscal 2018 results on Jul 11, before market open. In the last reported quarter, the company reported adjusted earnings of 25 cents per share, which beat the Zacks Consensus Estimate by 25% and improved 31.6% year over year. Net sales fell almost 2% year over year to $83.9 million, missing the Zacks Consensus Estimate of $86 million. The company delivered a average positive earnings surprise of 9.79% in the trailing four quarters. For the quarter to be reported, the Zacks Consensus Estimate for earnings is pegged at 21 cents, reflecting a rise of10.5% year over year. Further, the Zacks Consensus Estimate for sales isat $89 million, showing an increase of 2.4% year over year Let's see how things are shaping up prior to this announcement. AngioDynamics, Inc. Price and Consensus AngioDynamics, Inc. Price and Consensus | AngioDynamics, Inc. Quote Factors to Drive Q4 Results AngioDynamics' expanding product pipeline, international market expansion and cost saving initiatives will provide considerable growth opportunities in the fourth quarter. AngioDynamics is a leading provider of minimally invasive medical devices used for vascular access, surgery, peripheral vascular disease and oncology. The company's product lines include ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. These are expected to boost the company's sales in the quarter to be reported. Further, the company continues to witness healthy demand for its coveted NanoKnife system for treating tumors. Increased penetration of the device contributed to revenues in the company's Oncology division. In fact, the recent regulatory approval of VOLTA, a radiofrequency ablation device in Japan, is also a significant positive for the quarter to be reported. The company is already looking to broaden its commercial opportunities. Along with Germany and Denmark, the company is also looking forward to achieve the same in Europe and the United Kingdom. The Deterrents However, in the third quarter, growth in the Fluid and Thrombus Management product lines was offset by declines in the Venous Insufficiency and Angiographic Catheter businesses. Further, declines in PICCs product line and lower sales related to the discontinued RFA product line dampened sales growth. We believe that these headwinds will persist in the fourth quarter. What Our Model Predicts? However, our quantitative model does not conclusively show earnings beat for AngioDynamics in this quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. This is not the case here, as you will see below. Zacks ESP: AngioDynamics currently has an Earnings ESP of 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 21 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: AngioDynamics currently carries a Zacks Rank #3, which increases the predictive power of ESP. However, an ESP of 0.00% makes surprise prediction difficult. We caution against stocks with a Zacks Rank #4 and 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks to Consider Here are some companies you may want to consider as our model shows that they have the right combination of elements to post earnings beat this quarter. Wright Medical Group N.V. WMGI has an Earnings ESP of +60.2% and a Zacks Rank #3. Varian Medical Systems, Inc. VAR has an Earnings ESP of +1.08% and a Zacks Rank #3. DexCom, Inc. DXCM has an Earnings ESP of +39.7% and a Zacks Rank #3. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Up 2% Following Earlier Upgrade From Market Perform To Outperform At Raymond James"", ""Benzinga's Top Upgrades, Downgrades For July 2, 2018"", ""The Market In 5 Minutes: More Trade Threats, July PDUFA Dates, Tesla's Goal And More"", ""Premarket analyst action - healthcare""]"
DXCM,2018-07-03,24.615,24.8438,24.15,24.53,"3 Best Diabetes Stocks of 2018 So Far Stocks of biopharmaceutical companies making diabetes drugs haven't been huge winners in 2018 so far. But it's a much different story for medical device companies that focus on monitoring and treating diabetes. Several of these stocks soared in the first half of the year. Which were the biggest winners? Tandem Diabetes Care (NASDAQ: TNDM) , DexCom (NASDAQ: DXCM) , and Senseonics Holdings (NYSEMKT: SENS) stocks enjoyed tremendous success during the first six months of 2018. Here's why these are the three best diabetes stocks of 2018 so far -- and if they're still smart picks for investors. 1. Tandem Diabetes Care Tandem Diabetes Care focuses on developing and marketing insulin pumps. Its stock has skyrocketed close to 790% so far this year. There have been two key catalysts for Tandem in 2018. One is the company's continued financial improvement. Tandem reported a 42% year-over-year jump in sales in its Q1 results announced in April. The company's t:slim X2 insulin pump was the star performer. Tandem's sales have been boosted by the exit of Animas from the insulin pump market in Oct. 2017. The other big catalyst for Tandem was Food and Drug Administration approval in June for the company's t:slim X2 insulin pump with Basal-IQ technology. This Basal-IQ technology uses algorithms to predict 30 minutes into the future where insulin levels will be. It then adjusts insulin delivery based on the predictions. Tandem anticipates launching the new product in August. Integration with DexCom's G6 continuous glucose monitoring (CGM) system should especially help make the new t:slim X2 insulin pump a success. With both sales and gross margins growing, Tandem hopes to reach breakeven cash flow by the second half of 2019. 2. DexCom While Tandem Diabetes Care handles delivering insulin into patients' bloodstreams, DexCom makes the CGM systems that monitor blood sugar levels for determining when insulin is needed. DexCom stock is up close to 70% year to date. The reasons behind DexCom's tremendous stock performance are similar to those of Tandem. DexCom announced FDA approval of its new G6 CGM on March 27. Shares had already been rising in the weeks leading up to the announcement in anticipation of the approval decision. On May 3, DexCom stock soared again after the company reported Q1 results that were better than analysts expected. DexCom also increased its full-year 2018 revenue guidance by $20 million. DexCom has been a leader in continuous glucose measurement, but its G6 system should greatly improve the company's competitive position. Unlike previous CGMs, the G6 requires no finger sticks and no calibration. Its integration with other leading devices, including Tandem's insulin pump, should add to its appeal. 3. Senseonics Senseonics is much smaller than DexCom, but the company hopes to be just as successful with its own CGM system. Its stock has jumped nearly 60% higher so far this year. Like both Tandem and DexCom, regulatory approvals have been the keys for Senseonics stock's success thus far in 2018. In February, Senseonics announced European approval and a launch in European markets for its Eversense CGM system. The system includes a sensor implanted beneath the skin with a transmitter worn over the sensor that sends data to an app on a smartphone. The company also announced in June that the FDA had approved the Eversense CGM system. This followed an advisory committee's unanimous vote in March recommending approval for the system. That vote played a role in prompting Guggenheim analyst Christopher Pasquale to hike his price target for Senseonics to $6 per share in early April -- resulting in a nice bounce for the stock . Senseonics thinks that Eversense CGM will be attractive to customers for a couple of key reasons. The company claims that its CGM has a higher accuracy than other systems. Senseonics also believes that individuals with diabetes will prefer an implanted sensor that lasts up to 80 days instead of having weekly sensor insertions required by other CGM systems. Are they still buys? I wouldn't necessarily count on these three stocks producing gains in the second half of 2018 as they have in the first half. However, I think that Tandem, DexCom, and Senseonics could continue to be winners over the long run. The diabetes market is enormous. Each of these companies provides innovative products that should achieve solid commercial success. I think Tandem could give medical device giant Medtronic a run for its money. In my view, the CGM market is large enough for several companies to succeed, including both DexCom and Senseonics. Senseonics is the riskiest of the three, since it's just getting started with commercialization of Eversense. Still, I like the prospects for all three of these stocks. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-07-05,24.6625,24.715,24.2038,24.38,
DXCM,2018-07-06,24.4275,24.8625,24.0709,24.7425,"[""Med devices group joins broad rally"", ""Med devices group joins broad rally"", ""Med devices group joins broad rally""]"
DXCM,2018-07-09,24.7875,25.215,24.5725,25.095,"[""Dexcom And The Missing Connection Between Stock Price And Fundamental Business"", ""Dexcom And The Missing Connection Between Stock Price And Fundamental Business"", ""2 Stocks That Turned $1,000 Into More Than $8,000 This Year Over the past three years, the stock market has gained about 36%, but it remains virtually unchanged so far this year. Volatility has become the norm as big moves take the Dow Jones Industrial Average and the S&P 500 on a roller coaster ride. Yet in 2018, there are two stocks that would have taken a $1,000 investment on Jan. 1 and turned it into more than $8,000 in less than six months. Let's see why NII Holdings (NASDAQ: NIHD) and Tandem Diabetes Care (NASDAQ: TNDM) have rocketed higher this year. TNDM data by YCharts. NII Holdings (up 713%) It would have taken a big leap of faith to invest in Latin America's Nextel wireless service provider NII Holdings at the start of the year. For one thing, it was trading as a penny stock at the end of 2017, going for less than $0.50 per share, burning through its cash, and with significant debt. Its business was a mess for years as the world moved on to 3G and 4G networks and it was still offering only 2G service. In 2014, it filed for bankruptcy, and emerged the following year, having shed over $4 billion worth of debt. The devaluation of Brazil's real weighed heavily on its finances, though, as it sold off operations in Argentina, Mexico, Chile, and Peru leaving Brazil as its only market. The company only launched a 4G network in 2017, but by then it faced a lot of competitors. Its finances were once again a disaster and it was also in danger of losing its Nasdaq market listing, though that risk is now seemingly past. So what caused its stock to suddenly reverse course and zoom to such outrageous gains? It seems Brazil's National Telecommunications Agency will consider raising the cap on how much spectrum that telecoms can own, which might allow NII Holdings to sell off assets or be acquired. It's hired an advisor to sell its remaining 70% stake in Nextel Brazil, having previously sold a 30% position in order to raise $50 million. There was an option by the buyer to increase its stake to 60% for an additional $150 million, but the owner chose not to exercise it, and instead sold its 30% stake to another buyer for $70 million. During the company's conference call with analysts to discuss NII's earnings, CFO Dan Freiman said: \""When enacted, these changes and our better operational performance may open up new opportunities for us to unlock the value of our assets. We will proactively explore alternatives as the process evolves.\"" The company expects the regulatory process to be completed by the third or fourth quarter of 2018. While there's been some financial improvement following a restructuring of its debt, there's no real reason to invest in NII Holdings. It was a precariously positioned company beforehand. And whatever benefits it may enjoy should this regulatory change come through have likely already been priced into the stock. Just because a stock has done well doesn't mean you should feel like you've missed out. A blind squirrel can still stumble on an acorn. Betting on a penny stock like NII Holdings would have been exactly that: gambling. And that's not the way you should invest your money. Tandem Diabetes Care (up 859%) Investors would have done much better keeping an eye on Tandem Diabetes Care, a small, promising -- yet still risky -- medical products company that is growing sales, but also losing money. In the first quarter, it sold a few thousand of its next-generation insulin pump, the t:slim X2, and says it needs an installed base of 80,000 pumps to break even on a cash flow basis, though it believes it can hit that milestone some time next year. Because diabetes is a huge growth market, with the incidence of the disease expected to grow 165% in the U.S. by 2050, Tandem has a promising technology that analysts believe, if successful, could challenge Medtronic (NYSE: MDT) for industry leadership. Medtronic offers a competing technology called a continuous glucose monitor (CGM) that tracks a patient's blood sugar over time to let them better manage their disease. As diabetics seek alternatives to insulin injections to regulate their condition, Tandem has partnered with DexCom to bring its insulin pump system (that works with DexCom's monitoring system) to market early next year. The artificial pancreas monitors patients' blood glucose levels and uses an algorithm to know when to deliver an appropriate dose of insulin. At least one analyst thinks highly of Tandem's prospects for being able to grab market share when its system is commercialized. He upgraded the stock , which sent shares soaring. Although Medtronic is many times larger than Tandem, its CGM device is also much larger than Tandem's t:slim X2, and thus more cumbersome. And DexCom's monitors, which work with both systems, can be used for longer periods of time with Tandem's pump, making them more convenient. Also, the need for finger pricks for dosing decisions isn't needed with the t:slim X2 whereas they're still necessary with Medtronic's MiniMed system. While the potential for Tandem Diabetes Care may be more promising than for NII Holdings, it also is a risky proposition. Even though the FDA just approved Tandem's pump with its newest technology that predicts where insulin level needs and adjusts production accordingly, Medtronic also received regulatory approval for its own enhanced CGM system that now allows for treating patients between ages seven and 13. It removes a competitive advantage Tandem had with its pump being able to be used on those as young as six. Tandem's finances are probably not going to look pretty either for awhile yet. Still, by the t:slim X2 getting approved for use with DexCom's more feature-rich monitoring technology, a development that wasn't expected, there's good reason why Tandem Diabetes Care shares are soaring. Pull back the lens While the run-up experienced by both companies this year has been extraordinary, it's becoming more clear that only one of them is really worth considering. That's what happens when you take risks with your investments, especially with penny stocks . Although both NII Holdings and Tandem Diabetes Care have destroyed shareholder value over the past three years, each losing around 80% of their value, which actually includes their amazing gains this year, only Tandem has the potential to become a profitable long-term investment. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom And The Missing Connection Between Stock Price And Fundamental Business""]"
DXCM,2018-07-10,25.19,25.62,24.8925,25.0,
DXCM,2018-07-11,24.72,25.7338,24.72,25.6775,"3 Top Growth Stocks to Buy in July Ideally, you want to buy and hold shares of companies that will grow at a healthy pace for a long time. Paying a premium for a growth stock makes sense if that growth both materializes and leads to solid profits down the road. There are a lot of growth stocks out there, but three of our Motley Fool contributors have identified three that would be great additions to your portfolio in July. Here's what you need to know about Texas Roadhouse (NASDAQ: TXRH) , Kulicke & Soffa Industries (NASDAQ: KLIC) , and DexCom (NASDAQ: DXCM) . A steakhouse slowly aged to perfection Nicholas Rossolillo(Texas Roadhouse): The restaurant industry is a challenging one. Consumers have plenty of choices, and keeping diners loyal to a brand can be a tough task. To make matters worse, the industry has had to cope with self-inflicted pain the past few years as over-expansion has caused foot traffic at the average store to decline the last few years. Bucking the trend is casual steakhouse chain Texas Roadhouse. The restaurant has avoided the struggle most of its peers have experienced by staying true to its primary market: underserved suburban America. Providing big portions at fair prices to working-class families is still only part of the story, though. While many chains out there have put together aggressive expansion plans, Roadhouse has stayed disciplined and opened new locations at a more modest rate. Only 30 new stores will be opened this year, only about a 5% increase in total count -- which includes a new sports bar brand called Bubba's 33 that is being tested in select markets. The stock has also been a slow-and-steady story for over a decade now, but the results have been impressive nonetheless. Shares have doubled nearly five times over at this point, but there's reason to believe they're still a good buy even close to an all-time high. When management reported on progress a couple months ago, same-store sales growth was accelerating. This metric, which measures a combination of average guest ticket and foot traffic, is one of the most important factors driving a restaurant's profit margins. A month into the second quarter of 2018, and same-store sales were up an impressive 8.5% compared to a 4.9% increase in the first quarter . With Texas Roadhouse keeping tight control over expenses and getting the most out of its existing stores, this stock is one of the best restaurant buys out there right now. A small-cap semiconductor company Tim Green(Kulicke & Soffa Industries): Kulicke & Soffa manufactures equipment used by the semiconductor industry to package semiconductor components. It's a small company, with annual revenue of about $800 million. The semiconductor equipment industry is cyclical, so Kulicke & Soffa's results can swing up and down along with demand. But the long-term growth of the semiconductor industry, as well as the company's efforts to diversify into advanced packaging, should keep the numbers moving in the right direction in the long run. Kulicke & Soffa sees its available market growing from $2.2 billion in 2017 to $2.7 billion in 2021. Its core business will drive some of this growth, but demand for advanced packaging and equipment used for automotive products like sensors and cameras will be the key drivers. Kulicke & Soffa also has plenty of cash at its disposal to make strategic acquisitions. The company's balance sheet featured over $600 million of net cash at the end of its latest quarter. Kulicke & Soffa doesn't trade like a growth stock . Backing out the net cash, the stock trades for less than 8 times the average analyst estimate for 2018 earnings. Since earnings tend to fluctuate, this earnings multiple makes the stock look a bit cheaper than it truly is. Average earnings over the next few years could be lower if the current boom in sales dissipates. But even so, with plenty of long-term growth potential, Kulicke & Soffa is a solid growth stock pick. This diabetes stock's revolutionizing treatment Todd Campbell (DexCom): The diabetes market is getting bigger, and technology that helps patients better track blood sugar levels and dose their insulin is going to play a big role in the future. According to the Institute for Alternative Futures, the number of Americans with diabetes will increase from about 30 million today to nearly 55 million in 2030, and as a result, spending on diabetes is expected to soar. A good piece of that spending could find its way to DexCom's top line. DexCom's a leading manufacturer of continuous glucose monitors (CGM) that track real-time changes in blood sugar to help patients avoid dangerous highs and lows that can accelerate diabetes progression. CGMs use sensors, software, and hardware to record, analyze, and report blood sugar levels in real time, and they're already winning over patients who require frequent insulin injections. In 2017, DexCom's sales grew 25% to $718 million. Last year's performance was solid, but I think sales could increase by more this year following the launch of DexCom's newest CGM, the G6. In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. Abbott's advantage disappeared earlier this year when the FDA approved the G6. Importantly, the G6 is arguably a better system. The G6's sensors can be worn longer than those used with the Freestyle Libre, it includes alarms for blood sugar highs and lows that the Freestyle Libre doesn't, it has a shorter warm up time than the Freestyle Libre, and unlike the Freestyle Libre, it automatically sends data to a device for display. Those advantages could spark sales growth, but the use of CGMs in new automated insulin delivery systems is what really excites me about DexCom's CGM opportunity. Recently, Tandem Diabetes won an FDA green light for a system that combines DexCom's CGM with its insulin pump to administer insulin automatically, and DexCom's CGMs are also being evaluated in a similar system that's being developed by Insulet (NASDAQ: PODD) . If these systems win widespread use, and I think they will, then it could be a boon to DexCom investors. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Nicholas Rossolillo owns shares of Texas Roadhouse. Timothy Green owns shares of Kulicke & Soffa Industries. Todd Campbell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Texas Roadhouse. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-07-12,25.75,26.365,25.53,26.16,"[""Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial"", ""Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial"", ""Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial""]"
DXCM,2018-07-13,25.97,25.97,25.075,25.1125,"[""Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering"", ""Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering"", ""Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering""]"
DXCM,2018-07-16,25.1825,25.1825,24.65,24.8625,"[""'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care"", ""'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care"", ""'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care""]"
DXCM,2018-07-17,24.6925,25.5275,24.545,25.435,"[""Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?"", ""Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?"", ""Merit Medical (MMSI) to Report Q2 Earnings: What's in Store? Merit Medical Systems, Inc MMSI is scheduled to report second-quarter 2018 earnings on Jul 23, after the market closes . The company's acquisition-driven strategy is expected to boost growth by expanding existing product offerings across all business segments in the quarter. Strong prospects in the HeRO product line are a positive. In the last reported quarter, Merit Medical's adjusted earnings came in at 31 cents, which beat the Zacks Consensus Estimate by 6.9%. Earnings rose 10.7% from the prior-year quarter's tally. In the quarter, worldwide revenues totaled $203 million on a reported basis, beating the Zacks Consensus Estimate by 4.6%. The company posted an average positive earnings surprise of 10.2% in the trailing four quarters. For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $214.5 million, reflecting a rise of 15%. The same for adjusted earnings is at 40 cents, mirroring a 11.1% increase. Merit Medical Systems, Inc. Price and Consensus Merit Medical Systems, Inc. Price and Consensus | Merit Medical Systems, Inc. Quote Let's delve into the factors that are likely to impact Merit Medical's upcoming quarterly results. Acquisitions to Drive Growth Merit Medical has been leveraging on bolt-on buyouts to drive inorganic growth. On May 2, the company announced a worldwide distribution agreement with NinePoint Medical, Inc and the development of a strategic alliance between the Merit Endotek division and NinePoint Medical. The alliance is likely to combine the highly exclusive gastrointestinal and pulmonary medical devices from Merit Endotek with the ground-breaking Optical Coherence Tomography (OCT) platform from NinePoint Medical. Leadership Change Merit Medical witnessed a major change in its leadership in the second quarter. On May 31, the company announced that Bernard Birkett has resigned as the chief financial officer. In his replacement, Raul Parra, a veteran who has already served the company for more than eight years, has been appointed as the new interim chief financial officer. The company's shares have significantly improved since then. FDA Approvals Of the major approvals, the company's recently-approved Prelude Ideal product by the FDA deserves a mention. It is a unique vascular sheath. Strong demand for this product has bolstered the company's prominence in the MedTech markets. Apart from Prelude Ideal, the company recently received a 510(k) for a distal access SYNC and the Merit Pursue Microcatheter. Positive feedbacks and approvals from the top-notch regulatory bodies is likely to boost the top line in the second quarter with an expanded customer base. Notably, by the end of the first quarter of 2018, Merit Medical confirmed that it has almost 50 active R&D products in its portfolio. HeRO to Drive Growth Merit Medical's HeRO product line has been a key contributor to growth. HeRO Graft, Super HeRO Adapter and HeRO Ally Revision Kit are the three platforms within the HeRO family of dialysis devices. Considering the solid global prospects of hemodialysis solutions, the HeRO product line is likely to provide Merit Medical with a competitive edge in the MedTech markets in the quarter to be reported. Earnings Whispers Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the fiscal third quarter. This is not the case here as you will see below. Zacks ESP: Merit Medical has an Earnings ESP of -7.11. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: The company carries a Zacks Rank #2. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. Bio-Rad Laboratories BIO has an Earnings ESP of +7.41% and a Zacks Rank of 2. Baxter International Inc BAX has an Earnings ESP of +0.42% and a Zacks Rank of 2. DexCom, Inc. DXCM has an Earnings ESP of +12.84% and a Zacks Rank of 3. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?""]"
DXCM,2018-07-18,25.5,25.945,25.2825,25.88,"[""DXCM: A Leader In The Shift From Prick To Click"", ""DXCM: A Leader In The Shift From Prick To Click"", ""DXCM: A Leader In The Shift From Prick To Click""]"
DXCM,2018-07-19,25.885,26.1172,25.5275,25.635,"[""Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?"", ""Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?"", ""Will Global Industrial Unit Boost Ecolab's (ECL) Q2 Earnings? Ecolab Inc. ECL is scheduled to report second-quarter 2018 results on Jul 31, before the market opens. Solid performance in the Global Industrial segment is likely to drive the top line. Further, an expected improvement in revenues in other segments is likely to help the company generate solid results. However, the company faces pricing pressure in the Energy segment, which is likely to dampen profits in the upcoming quarterly results. In the last reported quarter, the company posted adjusted earnings of 91 cents per share, which beat the Zacks Consensus Estimate by 3.4%. Earnings also rose 13.8% on a year-over-year basis. Adjusted quarterly net sales were $3.47 billion, up 9.8% from the year-ago quarter's figure. Also, net sales beat the Zacks Consensus Estimate of $3.37 billion.Ecolab delivered an average positive earnings surprise of 1.1% in the past four quarters. For the second quarter, the Zacks Consensus Estimate for revenues is pegged at $3.7 million, reflecting growth of 7% on a year-over-year basis. The Zacks Consensus Estimate for earnings is pegged at 1.27 cents, indicating an increase of 12.4% year over year. Let's delve deeper. Ecolab Inc. Price and EPS Surprise Ecolab Inc. Price and EPS Surprise | Ecolab Inc. Quote Global Industrial to Drive Q2 Global Industrial accounted for 35.7% of total revenues in the last reported quarter. Sales in the segment grew 5% year over year to almost $1.24 billion. The upside was driven by major gains in Water, Food & Beverage and Life Sciences unit. Europe, North America and Latin America propelled growth in the segment. For the upcoming quarterly results, the Zacks Consensus Estimate for Global Industrial segment is pegged at $1.32 billion. The figure reflects an increase of 17.6% from the year-ago quarter's figure. The Global Industrial segment primarily provides water treatment and process applications. Operating units within the Global Industrial reportable segment include Nalco Water, Food & Beverage, Paper, Textile Care and Life Sciences. Recently, the company acquired New York-based Cascade Water Services Inc - a privately-held company - that provides water treatment programs and services to the U.S. institutional market. Notably, acquisition broadens services and improves opportunities in strategic water treatment market in the Global Industrial unit. Other Factors Impacting Q2 Global Institutional - a Key Contributor The segment accounted for 35.2% of total revenues in the last reported quarter. Sales increased 9% to $1.22 billion led by strong growth in the Specialty business line. The segment witnessed solid growth in North America and Asia Pacific. The segment provides specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, healthcare, government, education and retail industries. Operating units within the Global Institutional segment include Institutional, Specialty and Healthcare. Management expects second-quarter 2018 results to surpass first-quarter 2018 numbers with solid growth in the U.S. business. Further, the China business within the Global Institutional unit has been growing steadily at double digits or high single digits and is expected to sustain the pace, which will be reflected in the upcoming quarterly result. The Zacks Consensus Estimate for the Global Institutional segment is pegged at $1.31 billion, up 7.6% year over year. Global Energy in Focus Global Energy accounted for 24% of total revenues in the last reported quarter. Sales rose 9% to $847.1 million on strong growth in the well stimulation business and modest gains in the downstream business. The segment operates under the moniker - Nalco Champion. Global Energy caters to the process chemical and water treatment needs of the global petroleum and petrochemical industries in upstream as well as downstream applications. Management announced margin improvements and operating income growth in the energy business in the last reported quarter. Solid estimate revision trends in the Global Energy segment buoy optimism. The Zacks Consensus Estimate for the Global Energy segment is pegged at $855 million, reflecting an improvement of 8% on a year-over-year basis. View Up For the second quarter of 2018, Ecolab expects adjusted earnings per share in the range of $1.23-$1.29. The current outlook reflects an increase of 10-15% year over year. Adjusted gross margin for the quarter is expected at around 42% of net revenues. Issues Pertaining to ERP Adoption The company is in the process of adopting enterprise resource planning (ERP) and human resources software systems. The changes will incur one-time implementation costs that will mar earnings in the upcoming quarterly results. The new ERP system will be in North America. Management confirmed that the company has a lot of experience in ERP roll out. However, the completion of the process requires time and huge expenditures. What Does Our Model Predict? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the fiscal third quarter. This is not the case here as you will see below. Earnings ESP: Ecolab has an Earnings ESP of -0.71%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Ecolab carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. Bio-Rad Laboratories BIO has an Earnings ESP of +7.41% and a Zacks Rank of 2. Baxter International Inc BAX has an Earnings ESP of +0.90% and a Zacks Rank of 2. DexCom, Inc DXCM has an Earnings ESP of +12.84% and a Zacks Rank of 3. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings? PerkinElmer, Inc 's PKI second-quarter 2018 results, expected to release after the market closes on Aug 1, are likely to reflect steady growth in the core Diagnostics business. While this might prove to be a major driver, let's take a quick look at the other factors which will drive the upcoming results. In the first quarter of 2018, the company reported adjusted earnings of 63 cents per share, beating the Zacks Consensus Estimate by 3.3%. PerkinElmer reported adjusted revenues of approximately $644 million, which beat the Zacks Consensus Estimate of $616 million. Revenues also improved 25.3% from the year-ago quarter's tally. Notably, for the second quarter, the Zacks Consensus Estimate for earnings is pegged at 86 cents, reflecting year-over-year growth of 28.4%. The same for revenues is pinned at $693.8 million, indicating 26.8% growth. PerkinElmer delivered an average positive earnings surprise of almost 2% in the trailing four quarters. Let's delve into the factors that are likely to have an impact on second-quarter results. PerkinElmer, Inc. Price and EPS Surprise PerkinElmer, Inc. Price and EPS Surprise | PerkinElmer, Inc. Quote Diagnostics Revenues to Drive Q2 Diagnostic revenues have been fortifying the company's market position in terms of exclusiveness of services in the respective markets. The segment accounted for 38.4% of total revenues in the last reported quarter. Adjusted operating income in the segment came in at $52.7 million, up from $44.7 million in the first quarter of 2017. Revenues were $247.5 million compared with $156.8 million a year ago, up 62% on a year-over-year basis. This indicates an improvement of 7% organically. For the Diagnostics market, the company offers products that are used to detect genetic disorders. PerkinElmer also provides digital x-ray flat panel detectors and infectious disease testing solutions in its Diagnostics portfolio. The second-quarter results are likely to reflect strong growth in the Diagnostic segment, particularly in the infectious disease business and reproductive health business. However, the applied genomics business, which was down on a year-over-year basis due to lesser-than-expected micro fluidic sales in the first quarter, may continue to be soft in the second quarter as well. It is also encouraging to note that the Zacks Consensus Estimate for the Diagnostics segment is pegged at $274 million, up 10.9% sequentially. What Are the Other Factors Driving Q2? DAS - a Key Contributor PerkinElmer has formulated a 'DAS Growth Strategy' that focuses on finalizing the organizational changes associated with the life sciences business under Discovery & Analytical Solutions (\""DAS\"") segment. The company continues to leverage on its informatics and OneSource service offerings to improve the pharmaceutical customer's lab productivity in the DAS unit. Another important component of the DAS growth strategy is to accelerate growth in China and other emerging markets with increased investments. In the last reported quarter, Discovery and Analytical Solutions represented 61.2% of the company's total sales. Revenues from DAS totaled $247.5 million, up 62% year over year. Recently, the company collaborated with Helix to develop and commercialize exome sequencing-based tests that will help consumers make proactive health management decisions. Buoyed by the solid prospects, the Zacks Consensus Estimate for revenues is pegged at $418 million, reflecting an improvement of 21.2% sequentially. Improving Margin Trend to Continue PerkinElmer's gross and operating margin continues to improve primarily on the back of productivity initiatives and volume leverage. The new product introductions are expected to improve product mix and enhance gross margin. This along with stringent cost control will continue to drive operating margin in the second quarter. In the first quarter of 2018, adjusted gross profit in the quarter came in at $313.3 million, up 25.8% year over year. Adjusted gross margin, as a percentage of revenues, was 48.6% in the quarter, up 20 basis points (bps) year over year. The company expects significant gross margin expansion over the next three years. Guidance Raised For 2018, PerkinElmer expects adjusted earnings of $3.60 per share, which is significantly higher than the previous guidance of $3.50. Notably, the Zacks Consensus Estimate for earnings is also pegged at $3.60. The company expects revenues of $2.8 billion in 2018, up from the earlier range of $2.72-$2.74 billion. The Zacks Consensus Estimate is currently pegged at $2.8 billion. Thus, PerkinElmer is confident about improving growth trajectory, which is likely to drive the second-quarter results. What Does Our Model Predict? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the fiscal third quarter. This is exactly the case here as you will see below. Earnings ESP: PerkinElmer has an Earnings ESP of +1.03. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: PerkinElmer carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Other Stocks Worth a Look Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. Bio-Rad Laboratories BIO has an Earnings ESP of +7.41% and a Zacks Rank of 2. Baxter International Inc BAX has an Earnings ESP of +0.90% and a Zacks Rank of 2. DexCom, Inc DXCM has an Earnings ESP of +12.84% and a Zacks Rank of 3. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?""]"
DXCM,2018-07-20,25.735,25.8675,25.4975,25.5575,"[""Beauty Lies In The Eye Of The Investor - Cramer's Mad Money (7/19/18)"", ""Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?"", ""Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?"", ""Beauty Lies In The Eye Of The Investor - Cramer's Mad Money (7/19/18)"", ""Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings? Express Scripts Holding Company ESRX is scheduled to report second-quarter 2018 results on Aug 1, after the market closes . Solid performance by the Pharmacy Benefit Management segment (\""PBM\"") is likely to drive the company's top line. However, the company is getting acquired by Cigna Corporation by the end of 2018. Express Scripts delivered an average positive earnings surprise of almost 1.3% in the trailing four quarters. In the last reported quarter, Express Scripts posted adjusted earnings of $1.77 per share, which beat the Zacks Consensus Estimate by a penny. Further, adjusted earnings improved 33% year over year. Revenues of $24.78 billion beat the Zacks Consensus Estimate of $24.76 billion and inched up 0.5% year over year. For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $25.34 billion, reflecting a nominal fall of 0.01%. The Zacks Consensus Estimate for earnings is pegged at $2.20, indicating an increase of 27.2%. Let's delve into the factors that are likely to have an impact on second-quarter 2018 results. Express Scripts Holding Company Price and EPS Surprise Express Scripts Holding Company Price and EPS Surprise | Express Scripts Holding Company Quote PBM in Focus Express Scripts is the largest PBM in North America. The company has been consistently trying to expand the core PBM business. The Zacks Consensus Estimate for PBM revenues is pegged at $23.63 billion, indicating a rise of2% sequentially. We believe that the company's unique offerings of home-delivery pharmacy care, specialty pharmacy care, specialty benefit management and medical as well as drug data analysis services buoy optimism. The Zacks Consensus Estimate for PBM Product-Home Delivery is pegged at $11.26 billion, showing a rise of6.3% sequentially. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. The Zacks Consensus Estimate for these PBM Services is pegged at $342 million, indicating a rise of11.4% on a sequential basis. Coming to the suite of developments in the PBM unite, on Apr 12, Express Scripts announced the launch of a new, innovative 12-month pilot for a performance-based retail pharmacy network for commercial plans designed to optimize medication therapy. In 2018, Accredo specialty pharmacy, a subsidiary of Express Scripts, has earned URAC's accreditation at its primary dispensing locations like, Warrendale, New Castle and Indianapolis. This is likely to enhance the company's customer base. Other Factors at Play Long-term View Buoyed by strong results in the last reported quarter, Express Scripts' enterprise value initiative is estimated to cost $600-$650 million as of now. Notably, management expects cumulative savings of nearly $1.2 billion by 2021. Further, the company's targeted compounded annual adjusted EBITDA growth rate for the core business from 2017-2020 of 2-4% is a tailwind. Thus, Express Scripts is confident about improving growth trajectory, which is likely to drive second-quarter results. Recently, the company launched the most innovative approach to value-based contracting in the industry, a system that made hepatitis C treatments cheaper and ensured patient access and superior clinical outcomes. Also, in the case of inflammatory conditions and multiple sclerosis the system will ensure that payers can get their money back when drugs are ineffective. In this regard, Express Scripts and Walgreens Boots Alliance, Inc. announced that they are expanding group purchasing efforts to include the procurement of specialty brand drugs in February. This collaboration is a strategic one and the yield will be reflected in the quarter to be reported,owing to the massive savings potential by biosimilars. Express Scripts Getting Acquired After declaring that Express Scripts is losing its biggest customer - the leading health insurer Anthem Inc - the company recently announced that it is getting acquired by Cigna, a global health insurance company.The acquisition is expected to be completed by Dec 31, 2018. Per the definitive agreement, Cigna will take over Express Scripts in a cash and stock transaction worth $67 billion. Notably, this includes Cigna's assumption of approximately $15 billion debt of Express Scripts. In fact, Moody's Investors Service, the rating services arm of Moody's Corporation, is worried about the company's high customer concentration and pricing pressure. Per Moody's, Express Scripts is likely to experience declining script volume and higher-than-typical customer losses in the days to come. Other challenges include fewer generic drug introductions, softening mail order growth trends, client focus on cost savings and transparency. What Does Our Model Predict? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. This is not the case here as you will see below. Earnings ESP: Express Scripts has an Earnings ESP of -0.04%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Express Scripts carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. Bio-Rad Laboratories BIO has an Earnings ESP of +7.41% and a Zacks Rank of 2. Baxter International Inc BAX has an Earnings ESP of +0.90% and a Zacks Rank of 2. DexCom, Inc DXCM has an Earnings ESP of +12.84% and a Zacks Rank of 3. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Top Healthcare Stocks to Buy in July It could be the perfect time to add Tandem Diabetes Care (NASDAQ: TNDM) , IQVIA Holdings (NYSE: IQV) , and Gilead Sciences (NASDAQ: GILD) to portfolios. Why? Because these Motley Fool investors think the launch of a new game-changing device for diabetes will send Tandem's sales soaring; increased spending on drug development will be a boon to IQVIA; and pipeline data could cure Gilead Sciences' ailing share price. Read on to see if these stocks are right for your portfolio. A big advance in diabetes treatment Todd Campbell(Tandem Diabetes Care): One of the most intriguing healthcare stocks I'm interested in adding to my portfolio this month is Tandem Diabetes, an insulin pump maker that plans to launch its automated insulin delivery system in August. Tandem currently markets the t:slim X2, an insulin pump that patients can use instead of multiple daily insulin injections. Usually, patients pair up these pumps with DexCom 's (NASDAQ: DXCM) continuous glucose monitor (CGM), but until now, the two couldn't automatically monitor and dose insulin as necessary. That will change in August when Tandem Diabetes launches Basal-IQ, a feature that automatically pauses insulin delivery when CGM readings predict blood sugar levels could become too low. The ability to prevent hypoglycemia, a life-threatening condition, clears the way for patients to use these devices to automatically treat diabetes and, perhaps, delay its progression. Tandem's insulin system will be the second such automated system to become available. The first system, Medtronic 's (NYSE: MDT) MiniMed 670G, has been a big success with 70,000 people who were using it as of March, up from 20,000 people in December. Because over 1 million people have type 1 diabetes and could benefit from these systems, there's reason to think that Tandem's sales could head materially higher following its debut -- especially because the t:slim X2 is smaller than the MiniMed 670G and, when paired up with DexCom's newest CGMs, it offers patients the ability to change sensors and check their blood sugar with finger sticks less often than with the MiniMed 670G. Tandem's a lot smaller company than Medtronic, but it's a pure play on this next-generation solution. And because the addressable market is so big, I can't help but think it makes sense to stash some Tandem shares away in growth portfolios. A hidden healthcare winner Brian Feroldi (IQVIA Holdings): Developing a new drug from scratch is an extremely difficult and expensive process that is fraught with risk. That's why many biotech companies choose to partner up with a contract research organization (CRO) when they think they have found a potential winner. Doing so gives the compound the best chance of success. IQVIA Holdings is the go-to CRO partner for many biotech companies. The reason is that IQVIA employs a worldwide army of researchers who specialize in running clinical trials and compiling data. That deep experience is highly prized by biotech executives, who want to make sure that the clinical development process goes as smoothly as possible. For investors, what's great about IQVIA's business is that the company gets paid no matter how the drug in development fares during the trial. Better yet, since the drug development process takes years to complete, IQVIA's revenue becomes highly predictable as new compounds are added to its pipeline. For example, last quarter the company reported that it had more than $15 billion worth of projects in its research and development backlog. Another fact to applaud is that IQVIA also helps its customers to commercialize drugs that do find their way to market. The company does this by selling access to its one-of-a-kind database of patient records and prescriptions that help biotech and pharma companies with targeting. All told, IQVIA boasts a highly attractive business model that should enable double-digit revenue growth for the foreseeable future. With shares currently trading for less than 17 times next year's earnings estimates, I think this is a great company for healthcare investors to get to know. Good news should be on the way Keith Speights (Gilead Sciences): Once upon a time, Gilead Sciences was a high-flying biotech stock with the wind at its back. That hasn't been the case for a while, though. Plunging sales for its hepatitis C virus (HCV) franchise has dragged down Gilead's revenue, earnings, and share price. But good news should be on the way for Gilead. The biotech expects the HCV sales deterioration to stabilize this year. The HCV market has boiled down to a one-on-one matchup between Gilead and AbbVie (NYSE: ABBV) . Price cuts were a common theme over the past couple of years, but that shouldn't be a major factor anymore. It will just be Gilead versus AbbVie competing for a smaller number of hepatitis C patients. That's actually a much-improved scenario than Gilead has faced in recent years. If HCV doesn't weigh on total revenue and earnings nearly as much, that means investors will focus more on Gilead's HIV drugs. They should like what they see with Biktarvy, Gilead's latest HIV drug, launched in the first quarter. Biktarvy's sales should ramp up quickly and eventually reach $6 billion or more annually. Then there's the pipeline. Gilead should soon announce late-stage results for filgotinib in treating rheumatoid arthritis. Filgotinib could become the company's first immunology blockbuster drug. Gilead also has selonsertib, a strong candidate for treating nonalcoholic steatohepatitis (NASH), and is pursuing additional indications for cancer therapy Yescarta. Like I said, good news should be on the way. That makes Gilead a great stock to buy in July, in my view. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Brian Feroldi has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie and Gilead Sciences. Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?"", ""Beauty Lies In The Eye Of The Investor - Cramer's Mad Money (7/19/18)""]"
DXCM,2018-07-23,25.6725,26.205,25.5075,26.0825,"[""Sonar Might Be The Future"", ""Sonar Might Be The Future"", ""Sonar Might Be The Future""]"
DXCM,2018-07-24,26.0675,26.2032,25.3875,25.4375,
DXCM,2018-07-25,25.3525,25.9975,25.2575,25.9275,
DXCM,2018-07-26,25.815,25.8492,25.2,25.495,
DXCM,2018-07-27,25.08,25.35,23.1725,23.8375,"[""Med tech stocks mired in the red following Edwards, Mettler-Toledo results"", ""Med tech stocks mired in the red following Edwards, Mettler-Toledo results"", ""Med tech stocks mired in the red following Edwards, Mettler-Toledo results""]"
DXCM,2018-07-30,23.8325,24.0075,23.0825,23.3475,"[""Netflix re-releases documentary critical of medical device industry"", ""Netflix re-releases documentary critical of medical device industry"", ""Netflix re-releases documentary critical of medical device industry""]"
DXCM,2018-07-31,24.18,24.18,23.52,23.7825,"[""Notable earnings after Wednesday's close"", ""The Smart Way To Invest In Growth Stocks"", ""The Smart Way To Invest In Growth Stocks"", ""Notable earnings after Wednesday's close"", ""Why Tandem Diabetes Care Is Rallying by 11.3% Today What happened After reporting second-quarter financial results and updating its full-year sales forecast, Tandem Diabetes Care (NASDAQ: TNDM) saw its shares soar 11.3% by 3 p.m. EDT. So what Tandem Diabetes' second-quarter financial results show that it's continuing to make progress toward profitability. The company reported that a 59% year-over-year increase in insulin pump shipments propelled sales 60% higher to $34.1 million, and that its operating margin improved from -89% in Q2 2017 to -41% in Q2 2018. It's important to note that the company says that it continues to generate about half its sales from patients who are new to insulin pumps and that it's chipping away at the lead held by competitors, including Medtronic (NYSE: MDT) . On Tandem's quarterly conference call, management pegged its market share at about 12%. The company also updated its outlook for the rest of the year. Historically, sales pick up into the end of the year as people reach their out-of-pocket maximum levels for their insurance plan. This year isn't expected to be any different. Management's forecasting that revenue will be between $140 million to $148 million this year, up 30% to 38% from 2017. Now what Tandem Diabetes recently won a Food and Drug Administration OK to begin marketing a closed-loop insulin system that combines its T:slim X2 pump and its Basal-IQ algorithm with Dexcom 's (NASDAQ: DXCM) new G6 continuous glucose monitor (CGM). The Basal-IQ algorithm can predict blood sugar levels 30 minutes in advance and shut off insulin if a patient is at risk of hypoglycemia (blood glucose levels that are too low). In trials, Basal-IQ reduced the amount of time patients spend with dangerously low blood glucose readings by 31%, compared to the use of an insulin pump and CGM alone. The Basal-IQ feature, which is expected to be available in August, will make Tandem Diabetes only the second diabetes company to offer such an automated insulin solution. Previously, the market was owned by Medtronic's MiniMed 670G, a system that launched early in 2017. The MiniMed 670G has been a success, with the number of people using it climbing to 70,000 at the end of March, from 20,000 at the end of 2017. However, Tandem Diabetes' solution might be a better than Medtronic's, because it virtually eliminates the need for finger sticks to check blood sugar for calibration, and its blood glucose sensors can be worn for 10 days rather than seven. It remains to be seen if Tandem Diabetes' system can elbow away market share from the MiniMed 670G, but management appears confident. It expects to reach cash flow breakeven next year, and that could mean that profitability is around the corner. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Smart Way To Invest In Growth Stocks"", ""Notable earnings after Wednesday's close""]"
DXCM,2018-08-01,23.5325,24.1175,23.4425,23.86,"[""DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates"", ""DexCom (DXCM) Q2 2018 Results - Earnings Call Transcript"", ""After Hours Gainers / Losers (08/01/2018)"", ""Nemaura Medical up 21%"", ""DexCom Q2 Adj. EPS $(0.10) Beats $(0.18) Estimate, Sales $242.5M Beat $205.68M Estimate"", ""DexCom Raises FY18 Sales Outlook From $850-$860M To $925M vs $862.25M Est."", ""DexCom Executive Chairman and Director Terry Gregg Retires, President and CEO Kevin Sayer Appointed Chairman of the Board"", ""DexCom Shares Gain20% After Hours; Co. Beat Q2 EPs And Sales Estimates, Raised FY18 Sales Guidance Above Estimates"", ""DexCom Shares Gain20% After Hours; Co. Beat Q2 EPs And Sales Estimates, Raised FY18 Sales Guidance Above Estimates"", ""DexCom Executive Chairman and Director Terry Gregg Retires, President and CEO Kevin Sayer Appointed Chairman of the Board"", ""DexCom Raises FY18 Sales Outlook From $850-$860M To $925M vs $862.25M Est."", ""DexCom Q2 Adj. EPS $(0.10) Beats $(0.18) Estimate, Sales $242.5M Beat $205.68M Estimate"", ""DexCom (DXCM) Q2 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates"", ""After Hours Gainers / Losers (08/01/2018)"", ""Nemaura Medical up 21%"", ""Commit To Purchase DexCom At $85, Earn 14.8% Annualized Using Options Investors eyeing a purchase of DexCom Inc (Symbol: DXCM) stock, but tentative about paying the going market price of $94.22/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2019 put at the $85 strike, which has a bid at the time of this writing of $7.80. Collecting that bid as the premium represents a 9.2% return against the $85 commitment, or a 14.8% annualized rate of return (at Stock Options Channel we call this the YieldBoost ). Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $85 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless DexCom Inc sees its shares decline 10.4% and the contract is exercised (resulting in a cost basis of $77.20 per share before broker commissions, subtracting the $7.80 from $85), the only upside to the put seller is from collecting that premium for the 14.8% annualized rate of return. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $85 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the March 2019 put at the $85 strike for the 14.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 252 trading day closing values as well as today's price of $94.22) to be 53%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Wednesday, the put volume among S&P 500 components was 1.54M contracts, with call volume at 1.54M, for a put:call ratio of 0.70 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today . Top YieldBoost Puts of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable Wednesday Option Activity: DXCM, BEAT, CLH Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 6,353 contracts has been traded thus far today, a contract volume which is representative of approximately 635,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.6% of DXCM's average daily trading volume over the past month, of 818,545 shares. Especially high volume was seen for the $95 strike call option expiring August 17, 2018 , with 1,376 contracts trading so far today, representing approximately 137,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $95 strike highlighted in orange: BioTelemetry Inc (Symbol: BEAT) options are showing a volume of 3,112 contracts thus far today. That number of contracts represents approximately 311,200 underlying shares, working out to a sizeable 76.7% of BEAT's average daily trading volume over the past month, of 405,490 shares. Particularly high volume was seen for the $55 strike call option expiring November 16, 2018 , with 1,330 contracts trading so far today, representing approximately 133,000 underlying shares of BEAT. Below is a chart showing BEAT's trailing twelve month trading history, with the $55 strike highlighted in orange: And Clean Harbors Inc (Symbol: CLH) saw options trading volume of 2,342 contracts, representing approximately 234,200 underlying shares or approximately 75.4% of CLH's average daily trading volume over the past month, of 310,490 shares. Especially high volume was seen for the $60 strike call option expiring October 19, 2018 , with 1,657 contracts trading so far today, representing approximately 165,700 underlying shares of CLH. Below is a chart showing CLH's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for DXCM options , BEAT options , or CLH options , visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 Connected Devices Stocks for a High-Tech Portfolio InvestorPlace - Stock Market News, Stock Advice & Trading Tips The market for connected devices has been around for a lot longer than most people think. You've probably had one such device around for your whole life - a telephone. But with the emergence of megatrends like mobile, cloud and big data, there has been a major transformation. Connected devices are becoming ubiquitous, appearing throughout our homes, cars, hospitals and factories. Essentially, any device can be tethered with sensors, WiFi or cellular systems. And the growth is enormous. According to a report from LM Ericsson (NASDAQ: ERIC ), the number of connected devices is forecast to hit 29 billion by 2022. So how can investors capitalize on this? Well, the good news is that there are many companies that are pushing innovation in this market - and should be long-term winners. 10 Best Tech Stocks to Buy on This Dip Here's a look at five that stand out: Connected Devices Stocks: ForeScout Technologies (FSCT) While there are many benefits to connected devices, there are also some downsides. Perhaps the biggest is the threat of hacks. This is where a company like ForeScout Technologies (NASDAQ: FSCT ) comes in. Yes, it's a cybersecurity operator that focuses on managing the risks of connected devices in an organizations networks. But to do this, FSCT takes a much different approach. Note that during the past decade the company has developed so-called agentless technology that discovers intrusions in real-time. The system also can handle complex environments, such as wired/wireless networks and virtual/cloud infrastructures. As a testament to the technology, the U.S. Department of Defense recently awarded the company with an enterprise-wide blanket purchase agreement. In terms of the growth, it has certainly been robust for FSCT. In the latest quarter , revenues jumped by 42% to $59.7 million and operating cash flows came to a hefty $24.5 million, up 41%. Connected Devices Stocks: NXP Semiconductors (NXPI) NXP Semiconductors (NASDAQ: NXPI ) has gone through quite a bit of drama lately. Of course, Qualcomm (NASDAQ: QCOM ) dropped its acquisition of the company because it could not get approval with Chinese authorities. The result is that NXPI stock has taken a hit, going from $125.50 in February to $95. But then again, this does look like a good opportunity to pick up shares in a company that is likely to benefit from the trend of connected devices. Note that the company develops a broad array of chips, such as for power management, security, digital processing and mixed signal solutions for RF (radio frequency). All these have proven quite effective for autos, mobile phones and consumer applications. For example, the company has the No. 1 positions in bank card identification, auto safety and mobile NFC (which is for payments). While the failed QCOM acquisition was a distraction, it is important to keep in mind that NXPI got a $2 billion break-up fee. Besides, QCOM's interest was a big-time validation of NXPI's technology. RBC Capital: 10 Leaders and Laggards for 2025 Something else to consider: NXPI stock is fairly cheap, at 12.5X. The company also recently announced a $5 billion buyback. Connected Devices Stocks: SAP (SAP) SAP (NYSE: SAP ), which was founded in the early 1970.s, is one of largest players in the enterprise application market. At the core of the company is its ERP (Enterprise Resource Planning) system, which handles critical areas like HR, inventory and financials. Consider that the customer base is more than 404,000 and there are over 150 million users of its cloud applications. But the market is fairly mature. So to find growth, SAP has been investing in other markets like databases. There have also been a spate of acquisitions, such as for Ariba, Concur, Sybase, Business Objects and SuccessFactors. Now with this massive platform, SAP has been building out its IoT (Internet of Things) business as well - which is essentially another way of describing connected devices. Part of this has been retooling the existing technology. But SAP has also introduced is own standalone system, called Leonardo. These initiatives are in the early stages - but they are quickly gaining traction. A notable example of this is Cisco (NASDAQ: CSCO ). By using Leonard, the company has been able to identify a whopping $1 billion in new business opportunities. Connected Devices Stocks: Alarm.com (ALRM) In a sense, the home and business security industry is an early example of connected devices. But next-generation technologies have definitely been supercharging things. One of the standouts in the category is Alarm.com (NASDAQ: ALRM ), which has created a platform for intelligently connected properties. Some of the functions include video monitoring, energy management and intelligent automation. Last year, Alarm.com's system processed more than 100 billion data points from over 80 million connected devices. Growth has also been solid. In the latest quarter, revenues rose by 25% to $92.8 million and adjusted EBITDA came to $23 million, up from $14.1 million on a year-over-year basis. Granted, the market is intensely competitive. After all, mega tech operators like Amazon.com (NASDAQ: AMZN ) and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ) have been making a play for the opportunity. However, ALRM is really more focused on the higher-end of the market - that is, the company uses more advanced systems and cameras. There is also a network of 7,000 service providers. 5 High-Growth Stocks Headed for a Brick Wall And besides, the market opportunity is massive. According to Gartner , the spending on connected homes - on a global basis - is expected to go from $45 billion in 2017 to $146 billion by 2021. Connected Devices Stocks: DexCom (DXCM) When it comes to connected devices, there is significant opportunity in the healthcare industry. Real-time monitoring can certainly be a key driver in improving the outcomes for patients. Just look at DexCom (NASDAQ: DXCM ), which is the pioneer of continuous glucose monitors that do not require finger sticks for calibration. For example, its G5 Mobile system is seamlessly connected to a person's iPhone, iPad or Android device. There is also a cloud platform that provides reporting and personalized advice. Diabetes is definitely a terrible problem across the globe. According to the The International Diabetes Federation , there are over 425 million people with the disease. It's actually the seventh leading cause of death in the U.S. Now as for DXCM, the company has been able to continue to innovate and get approvals from the FDA. The growth has also been strong. In the most recent quarter, revenues grew by 30% to $184.4 million and GAAP net income was $24.2 million. Tom Taulli is the author of High-Profit IPO Strategies , All About Commodities and All About Short Selling . Follow him on Twitter at @ttaulli . As of this writing, he did not hold a position in any of the aforementioned securities. Compare Brokers The post 5 Connected Devices Stocks for a High-Tech Portfolio appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Shares Gain20% After Hours; Co. Beat Q2 EPs And Sales Estimates, Raised FY18 Sales Guidance Above Estimates"", ""DexCom Executive Chairman and Director Terry Gregg Retires, President and CEO Kevin Sayer Appointed Chairman of the Board"", ""DexCom Raises FY18 Sales Outlook From $850-$860M To $925M vs $862.25M Est."", ""DexCom Q2 Adj. EPS $(0.10) Beats $(0.18) Estimate, Sales $242.5M Beat $205.68M Estimate"", ""DexCom (DXCM) Q2 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates"", ""After Hours Gainers / Losers (08/01/2018)"", ""Nemaura Medical up 21%""]"
DXCM,2018-08-02,29.85,31.4125,28.7025,31.1725,"[""Premarket Gainers as of 9:05 am (08/02/2018)"", ""DexCom up 24% premarket on Q2 beat"", ""Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/02/2018)"", ""Midday Gainers / Losers (08/02/2018)"", ""32 Stocks Moving In Thursday's Pre-Market Session"", ""Benzinga Pro's 5 Stocks To Watch Today"", ""BMO Capital Maintains Outperformer on DexCom, Raises Price Target to $125"", ""The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter"", ""Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $127"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $125"", ""Jefferies Maintains Buy on DexCom, Raises Price Target to $125"", ""65 Stocks Moving In Thursday's Mid-Day Session"", ""Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher"", ""Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher"", ""65 Stocks Moving In Thursday's Mid-Day Session"", ""Jefferies Maintains Buy on DexCom, Raises Price Target to $125"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $127"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $125"", ""Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations"", ""The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter"", ""BMO Capital Maintains Outperformer on DexCom, Raises Price Target to $125"", ""Benzinga Pro's 5 Stocks To Watch Today"", ""32 Stocks Moving In Thursday's Pre-Market Session"", ""Midday Gainers / Losers (08/02/2018)"", ""Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/02/2018)"", ""Premarket Gainers as of 9:05 am (08/02/2018)"", ""DexCom up 24% premarket on Q2 beat"", ""Why Dexcom Is Soaring Today What happened Shares of Dexcom (NASDAQ: DXCM) , a medical device maker focused on diabetes , surged 23% as of 11 a.m. EDT on Thursday. The huge jump is attributable to the release of second-quarter results that smashed expectations and featured a huge boost to guidance. So what Here's a review of the key figures from Dexcom's second quarter: Revenue jumped 42% to $242.5 million. For perspective, Wall Street was only expecting revenue of $204.9 million, so the company handily beat estimates. Non- GAAP net loss was $9.2 million, or $0.10 per share. That was also much better than the $0.18 loss that market watchers were expecting. The better-than-expected results also allowed management to significantly boost its guidance for the year. The company now expects full-year revenue of about $925 million. That's much higher than its prior range of $850 million to $860 million. Given the significant beat-and-raise, it isn't hard to figure out why shares are flying high today. Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. Instead, Dexcom just reported an acceleration in its revenue growth rate, which suggests that the total market is large enough for both companies' products to coexist. Looking to the future, Dexcom's partnerships with Tandem Diabetes Care and Insulet should keep on serving as catalysts to drive continued adoption. In other words, investors have plenty of reasons to believe that this company's growth engine is still warming up. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations Following the market opening Thursday, the Dow traded down 0.44 percent to 25,221.80 while the NASDAQ declined 0.02 percent to 7,705.79. The S&P also fell, dropping 0.22 percent to 2,807.27. Leading and Lagging Sectors Thursday morning, the consumer staples shares climbed 0.01 percent. Meanwhile, top gainers in the sector included Nature's Sunshine Products, Inc. (NASDAQ: NATR ) up 9 percent, and Sprouts Farmers Market, Inc. (NASDAQ: SFM ) up 12 percent. In trading on Thursday, materials shares fell 1.45 percent. Top Headline Aetna Inc. (NYSE: AET ) reported stronger-than-expected earnings for its second quarter. Earnings came in at $3.43 per share, beating market estimates of $3.04 per share. Sales came in at $15.56 billion, beating estimates of $15.5 billion. Equities Trading UP Boingo Wireless, Inc. (NASDAQ: WIFI ) shares shot up 32 percent to $30.65 after reporting a second-quarter earnings beat. Boingo Wireless also announced the purchase of Elauwit Networks for $28 million in cash. Shares of STAAR Surgical Company (NASDAQ: STAA ) got a boost, shooting up 22 percent to $39.00 after the company posted upbeat Q2 earnings and raised FY18 sales growth guidance. DexCom, Inc. (NASDAQ: DXCM ) shares were also up, gaining 22 percent to $116.18 after the company reported better-than-expected results for its second quarter and raised its FY18 sales guidance. Equities Trading DOWN Cross Country Healthcare, Inc. (NASDAQ: CCRN ) shares dropped 28 percent to $8.571 after posting downbeat Q2 results. Shares of ION Geophysical Corporation (NYSE: IO ) were down 27 percent to $18.92 after the company announced weak quarterly financial results. Floor & Decor Holdings, Inc. (NYSE: FND ) was down, falling around 15 percent to $40.80 after the company announced its quarterly financial results and trimmed its full-year guidance. Commodities In commodity news, oil traded down 0.78 percent to $67.13 while gold traded down 0.43 percent to $1,222.30. Silver traded down 0.34 percent Thursday to $15.40, while copper fell 0.95 to $2.7215. Eurozone European shares were lower today. The eurozone's STOXX 600 declined 0.92 percent, the Spanish Ibex Index fell 1.19 percent, while Italy's FTSE MIB Index slipped 1.81 percent. Meanwhile the German DAX dropped 1.61 percent, and the French CAC 40 fell 0.74 percent while U.K. shares fell 0.94 percent. Economics U.S. initial jobless claims rose 1,000 to 218,000 in the latest week. However, economists were expecting a reading of 220,000. U.S. factory orders rose 0.7 percent for June, versus economists' expectations for a 0.7 percent gain. The Energy Information Administration's weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET. Data o money supply for the recent week will be released at 4:30 p.m. ET. \u00a9 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What DexCom Just Said About Its Future DexCom, Inc. 's (NASDAQ: DXCM) continuous glucose monitors (CGM) are increasingly being used by diabetics to track their blood glucose levels, and based on the company's second-quarter results, the company's sales momentum is accelerating following the approval of its newest device, the G6. Is this stock worth adding to your portfolio? Here's what management's saying about its business today and its potential in the future. What they do Normally, beta cells in the pancreas produce insulin that turns glucose in the blood into energy; however, people with type 1 diabetes don't produce insulin, and type 2 patients have developed a resistance to insulin. There are an estimated 30 million people with diabetes in the U.S. alone, including about 1.5 million people with type 1 diabetes. In the past, patients with type 1 disease and many patients with type 2 diabetes have relied upon finger sticks to draw blood, blood glucose monitors to measure blood sugar levels, and insulin injections to bring blood glucose readings down to a normal range. More recently, patients requiring multiple insulin doses per day have been reducing their need for finger sticks by using CGMs, including those made by DexCom, to track and report blood glucose levels in real time. These devices include the use of wearable sensors that record the data and a receiver, or in the case of DexCom, an app, that communicates with the sensors, tracks the data, and reports it to patients and caregivers. A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. The approval of the Freestyle Libre did away with that requirement, significantly reducing patient burden and, in the process, giving Abbott Labs an edge in the CGM market. However, Abbott's advantage didn't last very long. In March, the FDA approved DexCom's G6, which similarly does away with finger sticks for calibration. Importantly, the G6 packs features the Freestyle Libre doesn't, which could tilt market share back in DexCom's favor. Specifically, the G6 doesn't require a stand-alone receiver, and its sensors automatically communicate data to a user's app or another compatible device. Abbott requires a receiver (there's no app yet), and it has to be held within 1.5 inches of its sensors to transfer data. The G6 also has an alarm to alert patients of dangerous glucose readings that the Freestyle Libre doesn't. Those advantages appear to be resonating with patients. Although the G6 was only available for part of the quarter, DexCom's sales jumped 42% year over year to $242.5 million in Q2 2018. As a result, after backing out gains associated with DexCom's equity investments, the company's adjusted loss improved to $0.10, which was $0.08 better than industry watchers were expecting. What's on tap from here There was plenty to like about the company's second-quarter performance, including a 78% year-over-year increase in international sales, but what's really moving the needle for investors is the company's potential to profit from its inclusion in next-generation, closed-loop, automated-insulin delivery systems that pair its CGMs with insulin pumps. Last year, Medtronic (NYSE: MDT) won FDA approval for the first closed-loop monitoring and insulin pump solution, the MiniMed 670G. A DexCom competitor, Medtronic built its system using its own Guardian CGM and pump. The system has been a success, with Medtronic reporting 70,000 users at the end of March, up from 20,000 exiting December. Soon, though, the MiniMed 670G is going to face stiff competition from Tandem Diabetes (NASDAQ: TNDM) t:slim X2 system, which relies on DexCom's G6 and Tandem's own insulin pump. The FDA gave Tandem Diabetes the OK to market its automated solution in June when it approved Basal-IQ, an algorithm that shuts off insulin delivery from Tandem's pump when blood glucose levels are predicted to get too low in the future. Tandem says it's on track to launch its system with the G6 this month. The availability of Tandem's automated-insulin system could benefit DexCom in two ways: It could increase G6 demand in the coming year, and since DexCom has a $55 million equity stake in Tandem Diabetes, a successful launch could increase the value of its investment. For consideration, DexCom's cost basis in Tandem is only $5 million. Tandem isn't the only manufacturer using DexCom's G6, though. DexCom's CGMs are also being evaluated as part of automated insulin systems being developed at Insulet (NASDAQ: PODD) and Eli Lilly (NYSE: LLY) . Is DexCom a stock to buy? DexCom's profitability has been a question mark, but that's due in part to the company's international expansion plans and research and development efforts. If those investments pay off, then earnings should follow. Because international revenue grew more quickly than U.S. revenue last quarter, overseas sales now represent 22% of revenue, up from 17% of revenue in Q2 2017. Due to greater global demand for its CGMs, management now thinks its full year 2018 sales will be approximately $925 million, and that's significantly higher than its prior range of between $850 million to $860 million. Given that reports suggest CGMs have only penetrated about 20% of the addressable market for type 1 patients, and even less in type 2 patients, there's good reason to think DexCom's future is bright enough for it to warrant being included in investors' portfolios. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 08/02/2018: INSM,DXCM,IRTC,EXAS Top Health Care Stocks JNJ -0.96% PFE -0.59% ABT -0.25% MRK -0.36% AMGN +0.14% Health care stocks lost some ground this afternoon, including a more than 0.1% decline Thursday for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were up over 0.4% as a group while the Nasdaq Biotechnology index still was climbing over 0.8% today. Among health care stocks moving on news: + Insmed Inc ( INSM ) advanced almost 14% on Thursday after the specialty drug maker reported a Q2 net loss of $1.00 per share, expanding on a $0.72 per share loss during the year-ago period but beating the Capital IQ consensus expecting an $1.08 per share net loss. It had no revenue during the quarter, as expected. The company also said the U.S. Food and Drug Administration will issue a decision on the its ALIS experimental treatement for adult patients with NTM lung disease by Sept. 28 during the agency's priority review program. An advisory panel is slated to meet August 7 to review the drug candidate. In other sector news: + DexCom ( DXCM ) hit a record high on Thursday, climbing over 30% to a best-ever $124.74 a share after the medical device company raised its FY18 revenue forecast to $925 million, or $63 million above the $862 million Street view. It also reported a smaller Q2 net loss than analysts were expecting and above-consensus quarterly revenue, prompting analysts at Oppenheimer to raise their price target for the company by $40 to $125 a share. + iRhythm Technologies ( IRTC ) climbed to a best-ever $90.40 a share on Thursday, rising nearly 19%, after the cardiac care company reported better-than-expected Q2 revenue. It also is projecting FY18 revenue in a range of $138 million to $141 million, exceeding the analyst mean by at least $4.21 million. - Exact Sciences ( EXAS ) dropped almost 19% on Thursday after the molecular diagnostics company reported Q2 revenue lagging the $104.4 million Street view by around $1.5 million. It also recorded a net loss of $0.30 per share for the April-to-June reporting period, expanding on a $0.27 per share loss last year but beating the Street view expecting a $0.33 per share net loss. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher Toward the end of trading Thursday, the Dow traded down 0.01 percent to 25,332.52 while the NASDAQ climbed 1.14 percent to 7,794.97. The S&P also rose, gaining 0.46 percent to 2,826.31. Leading and Lagging Sectors Thursday afternoon, the information technology shares climbed 1.34 percent. Meanwhile, top gainers in the sector included Quarterhill Inc. (NASDAQ: QTRH ) up 27 percent, and Internap Corporation (NASDAQ: INAP ) up 23 percent. In trading on Thursday, materials shares fell 0.71 percent. Top Headline Aetna Inc. (NYSE: AET ) reported stronger-than-expected earnings for its second quarter. Earnings came in at $3.43 per share, beating market estimates of $3.04 per share. Sales came in at $15.56 billion, beating estimates of $15.5 billion. Equities Trading UP Boingo Wireless, Inc. (NASDAQ: WIFI ) shares shot up 40 percent to $32.58 after reporting a second-quarter earnings beat. Boingo Wireless also announced the purchase of Elauwit Networks for $28 million in cash. Shares of InnSuites Hospitality Trust (NYSE: IHT ) got a boost, shooting up 52 percent to $1.94 after the nano-cap REIT said it reached an agreement to sell its Yuma Hospitality Property for $16.25 million. DexCom, Inc. (NASDAQ: DXCM ) shares were also up, gaining 29 percent to $122.84 after the company reported better-than-expected results for its second quarter and raised its FY18 sales guidance. Equities Trading DOWN Cross Country Healthcare, Inc. (NASDAQ: CCRN ) shares dropped 30 percent to $8.25 after the company posted downbeat second-quarter results. Shares of ION Geophysical Corporation (NYSE: IO ) were down 28 percent to $18.647 after the company announced weak quarterly financial results. Synthetic Biologics, Inc. (NYSE: SYN ) was down, falling around 34 percent to $0.13 after the company announced a 1:35 reverse stock split. Commodities In commodity news, oil traded up 2.22 percent to $69.16 while gold traded down 0.59 percent to $1,220.30. Silver traded down 0.43 percent Thursday to $15.385, while copper fell 0.18 to $2.7425. 2.1 Eurozone European shares closed lower today. The eurozone's STOXX 600 declined 0.82 percent, the Spanish Ibex Index fell 1.03 percent, while Italy's FTSE MIB Index slipped 1.73 percent. Meanwhile the German DAX dropped 1.50 percent, and the French CAC 40 fell 0.68 percent while U.K. shares fell 1.01 percent. Economics U.S. initial jobless claims rose 1,000 to 218,000 in the latest week. However, economists were expecting a reading of 220,000. U.S. factory orders rose 0.7 percent for June, versus economists' expectations for a 0.7 percent gain. Domestic supplies of natural gas climbed 35 billion cubic feet for the week ended July 27, the U.S. Energy Information Administration reported. Analysts projected a gain of 45 billion cubic feet. Data on money supply for the recent week will be released at 4:30 p.m. ET. \u00a9 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 08/02/2018: DXCM,IRTC,EXAS Top Health Care Stocks JNJ -0.76% PFE -0.08% ABT -0.31% MRK -0.32% AMGN +0.54% Health care stocks were broadly higher, including a less than 0.1% rise for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were up almost 0.5% as a group while the Nasdaq Biotechnology index was climbing over 0.9%. Among health care stocks moving on news: + DexCom ( DXCM ) hit a record high, climbing over 30% to a best-ever $124.74 a share after the medical device company beat analyst projections with its Q2 financial results and also raised its FY18 revenue forecast at least $63 million above the $862 million Street view. It trimmed its Q2 net loss by $0.04 compared with last year and beat the Capital IQ consensus expecting an $0.18 per share net loss. Revenue grew 42% year over year to $242.5 million, also exceeding the $205.8 million Street view. In other sector news: + iRhythm Technologies ( IRTC ) climbed to a best-ever $90.40 a share, rising nearly 19%, after the cardiac care company reported better-than-expected Q2 revenue. It also is projecting FY18 revenue in a range of $138 million to $141 million, exceeding the analyst mean by at least $4.21 million. - Exact Sciences ( EXAS ) dropped almost 19% after the molecular diagnostics company reported Q2 revenue lagging the $104.4 million Street view by around $1.5 million. It also recorded a net loss of $0.30 per share for the April-to-June reporting period, expanding on a $0.27 per share loss last year but beating the Street view expecting a $0.33 per share net loss. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher"", ""65 Stocks Moving In Thursday's Mid-Day Session"", ""Jefferies Maintains Buy on DexCom, Raises Price Target to $125"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $127"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $125"", ""Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations"", ""The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter"", ""BMO Capital Maintains Outperformer on DexCom, Raises Price Target to $125"", ""Benzinga Pro's 5 Stocks To Watch Today"", ""32 Stocks Moving In Thursday's Pre-Market Session"", ""Midday Gainers / Losers (08/02/2018)"", ""Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/02/2018)"", ""Premarket Gainers as of 9:05 am (08/02/2018)"", ""DexCom up 24% premarket on Q2 beat"", ""Dexcom stock surges 30% on better-than-expected revenue results DexCom Inc. shares surged nearly 30% in extremely heavy Thursday trade after the company reported a second-quarter revenue beat and narrower-than-expected loss. Earnings for the latest quarter rose to $30.2 million, or 34 cents per share, after $2.9 million, or 3 cents per share in the year-earlier period. The company said it had an adjusted loss per share of 10 cents, excluding 48 cents per share in income from an investment in Tandem Diabetes Care as well as interest expense on senior convertible notes. The FactSet consensus was a loss of 18 cents per share. Revenue rose to $242.5 million from $170.6 million, above the FactSet consensus of $205.8 million. The company attributed its latest earnings to significant adoption of continuous glucose monitors, which patients use to manage their diabetes more easily. The performance was \""particularly notable\"" because the company's G6 platform -- a new iteration of the device that integrates with a smartphone, has a sensor that lasts 10 days and doesn't require a fingerstick test to measure blood sugar levels -- was only launched late in the quarter, Chief Executive Kevin Sayer noted. DexCom also raised its 2018 revenue guidance from a range of $850 million to $860 million to about $925 million. Company shares have lifted 66% over the last three months, compared with a 7.2% rise in the S&P 500 and a 5.8% rise in the Dow Jones Industrial Average .""]"
DXCM,2018-08-03,31.03,31.2475,29.75,30.8325,"[""DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View"", ""75 Biggest Movers From Yesterday"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $130"", ""DexCom shares are trading down 3.5% despite strong Q2 results reported Wednesday and positive analyst activity over past two days."", ""10 Biggest Price Target Changes For Friday"", ""Stocks Which Set New 52-Week High Yesterday, August 2nd"", ""Stocks Which Set New 52-Week High Yesterday, August 2nd"", ""10 Biggest Price Target Changes For Friday"", ""DexCom shares are trading down 3.5% despite strong Q2 results reported Wednesday and positive analyst activity over past two days."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $130"", ""75 Biggest Movers From Yesterday"", ""DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View"", ""DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View DexCom, Inc. DXCM reported loss of 10 cents per share in the second quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 20 cents. Also, the figure improved from a loss of 16 cents in the year-ago quarter. The stock has a Zacks Rank #3 (Hold). Total revenues rallied 42.1% to $242.5 million from $170.6 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $205 million. Segmental Details Revenues in the Sensor segment (74% of total revenues) surged 47% on a year-over-year basis to $179.4 million. Transmitter revenues (18%) increased 26% year over year to $43.9 million. Receiver revenues (8%) rallied 36% year over year to $19.1 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Operational Details DexCom generated gross margin (as a percentage of revenues) of 63.3%, which contracted 560 basis points (bps) year over year. Margins were under pressure due to an inventory change and shift toward OUS and Medicare. International business displayed consistent growth in the quarter, up 78% on a year-over-year basis to $52.9 million. Research and development (R&D) expenses totaled $47.2 million in the quarter, up4.2% year over year. Selling, general and administrative expenses totaled $111.3 million in the reported quarter, increasing 29.7% year over year. Guidance DexCom raised 2018 guidance. The company expects revenues of $925 million, up from the previous range of $850-$860 million. Meanwhile, the Zacks Consensus Estimate for revenues is currently pegged at $861.2 million, which is significantly lower than the guidance. Reported operating expenses, excluding investments in non-intensive programs, are expected to increase 14% from 2017 level, significantly higher than the previous forecast of 10%. However, gross profit margin is projected to be 64%, lower than the previous guidance of 65-68%. In Conclusion DexCom reported loss in second-quarter2018, narrower than the Zacks Consensus Estimate of a loss. Solid contributions from the Sensor, Transmitter and Receiver segments are key catalysts. The glucose monitoring market presents significant commercial opportunity for DexCom. The company's opportunities in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide the company a competitive edge in the MedTech space. Further, the company's next-generation fully-disposable CGM systems are also in progress. On the flip side, cutthroat competition in the market for blood & glucose monitoring devices is a headwind for DexCom at the moment. We believe that the company's margins will continue to be under pressure in the coming quarters, thanksto high product development costs and rising expenditures on the R&D front. Lower expected margins on transmitter sales are also a cause of concern. Q2 Earnings of MedTech Majors at a Glance A few better-ranked stocks in the broader medical space, which reported solid earnings this season are Stryker Corporation SYK , Intuitive Surgical, Inc ISRG and Illumina, Inc ILMN . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Stryker carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Intuitive Surgical reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted earnings improved 38% year over year. Stryker reported second-quarter 2018 adjusted earnings per share of $1.76, beating the Zacks Consensus Estimate by 1.7%. Earnings improved 15% year over year and also exceeded the high end of the company's guidance. Illumina reported adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.11. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Crosses Above Average Analyst Target In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $99.93, changing hands for $124.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised. There are 15 different analyst targets contributing to that average for DexCom Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $55.00. And then on the other side of the spectrum one analyst has a target as high as $118.00. The standard deviation is $19.396. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $99.93/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $99.93 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Which Set New 52-Week High Yesterday, August 2nd"", ""10 Biggest Price Target Changes For Friday"", ""DexCom shares are trading down 3.5% despite strong Q2 results reported Wednesday and positive analyst activity over past two days."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $130"", ""75 Biggest Movers From Yesterday"", ""DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View""]"
DXCM,2018-08-06,30.9025,31.8275,30.0925,30.46,"[""Premarket analyst action - healthcare"", ""Berenberg Upgrades DexCom to Buy"", ""Berenberg Upgrades DexCom to Buy"", ""Premarket analyst action - healthcare"", ""Berenberg Upgrades DexCom to Buy"", ""Premarket analyst action - healthcare""]"
DXCM,2018-08-07,30.6125,31.6375,30.545,31.19,"[""Stocks Which Set New 52-Week High Yesterday, August 6th"", ""Stocks Which Set New 52-Week High Yesterday, August 6th"", ""Stocks Which Set New 52-Week High Yesterday, August 6th""]"
DXCM,2018-08-08,31.3275,31.5,30.7675,31.0875,
DXCM,2018-08-09,31.0125,31.5,30.7875,30.7975,
DXCM,2018-08-10,30.5,31.44,30.39,30.8375,"[""Stock Exchange: Is This The Calm Before The Storm?"", ""Stock Exchange: Is This The Calm Before The Storm?"", ""Stock Exchange: Is This The Calm Before The Storm?""]"
DXCM,2018-08-13,30.71,31.235,30.5,30.965,
DXCM,2018-08-14,31.0075,31.9125,30.9125,31.8575,
DXCM,2018-08-15,31.975,32.2725,30.855,30.975,"[""The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $145"", ""Stocks Which Set New 52-Week High Yesterday, August 14th"", ""Stocks Which Set New 52-Week High Yesterday, August 14th"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $145"", ""The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue"", ""Stocks Which Set New 52-Week High Yesterday, August 14th"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $145"", ""The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue""]"
DXCM,2018-08-16,31.25,32.1125,31.23,32.0775,"[""FDA streamlines voluntary device malfunction reporting"", ""Stocks Which Set New 52-Week High Yesterday, August 15th"", ""Stocks Which Set New 52-Week High Yesterday, August 15th"", ""FDA streamlines voluntary device malfunction reporting"", ""Stocks Which Set New 52-Week High Yesterday, August 15th"", ""FDA streamlines voluntary device malfunction reporting""]"
DXCM,2018-08-17,31.92,32.775,31.9,32.74,
DXCM,2018-08-20,32.745,33.195,32.6575,33.0375,
DXCM,2018-08-21,33.19,34.085,33.15,34.0075,"[""The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows"", ""Stocks Which Set New 52-Week High Tues., Aug. 21, 2018"", ""Stocks Which Set New 52-Week High Tues., Aug. 21, 2018"", ""The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows"", ""Stocks Which Set New 52-Week High Tues., Aug. 21, 2018"", ""The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows""]"
DXCM,2018-08-22,34.0,34.81,33.85,34.5225,"[""DexCom acquires TypeZero Tech"", ""The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin"", ""Stocks Which Set New 52-Week High Yesterday, August 21st"", ""Dexcom To Acquire TypeZero Tech, No Financial Terms Disclosed"", ""Dexcom To Acquire TypeZero Tech, No Financial Terms Disclosed"", ""Stocks Which Set New 52-Week High Yesterday, August 21st"", ""The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin"", ""DexCom acquires TypeZero Tech"", ""Dexcom To Acquire TypeZero Tech, No Financial Terms Disclosed"", ""Stocks Which Set New 52-Week High Yesterday, August 21st"", ""The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin"", ""DexCom acquires TypeZero Tech""]"
DXCM,2018-08-23,35.6875,36.1512,34.5062,35.55,"[""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $150"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $160"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $160"", ""The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero"", ""10 Biggest Price Target Changes For Thursday"", ""Stocks Which Set New 52-Week High Yesterday, August 22nd"", ""Stocks Which Set New 52-Week High Yesterday, August 22nd"", ""10 Biggest Price Target Changes For Thursday"", ""The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $160"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $160"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $150"", ""Stocks Which Set New 52-Week High Yesterday, August 22nd"", ""10 Biggest Price Target Changes For Thursday"", ""The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $160"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $160"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $150""]"
DXCM,2018-08-24,35.51,35.7225,33.765,34.0825,"[""The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict"", ""Stocks Which Set New 52-Week High Yesterday, August 23rd"", ""Stocks Which Set New 52-Week High Yesterday, August 23rd"", ""The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict"", ""Stocks Which Set New 52-Week High Yesterday, August 23rd"", ""The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict"", ""Why Dan Chung Likes Microsoft, Puma, and Roper Technologies The Fred Alger Management CEO discusses stocks that are winning big in Internet 3.0""]"
DXCM,2018-08-27,34.25,35.2675,34.105,35.1575,"[""I Got 43% Return On My Obesity-Themed Portfolio. Janus Henderson Investors Did Better With SLIM."", ""Dexcom Acquires TypeZero Technologies For Diabetes Management Tech"", ""Dexcom Acquires TypeZero Technologies For Diabetes Management Tech"", ""I Got 43% Return On My Obesity-Themed Portfolio. Janus Henderson Investors Did Better With SLIM."", ""Dexcom Acquires TypeZero Technologies For Diabetes Management Tech"", ""I Got 43% Return On My Obesity-Themed Portfolio. Janus Henderson Investors Did Better With SLIM.""]"
DXCM,2018-08-28,35.25,35.635,34.935,35.3975,"Here's Why You Should Hold On to DexCom (DXCM) Stock Now With a market capitalization of approximately $12.05 billion, DexCom, Inc.DXCM is expected to benefit from lucrative prospects in the diabetes market, strong product portfolio, collaborative agreements with several companies and focus on international markets. However, the company's margins were under pressure in the last reported quarter. Which Way are the Estimates Treading? For the current quarter, the Zacks Consensus Estimate is pegged at a loss of 10 cents per share, reflecting a decline of 150% on a year-over-year basis. The same for the revenues is pegged at $239.5 million, reflecting an increase of 29.7% year over year. For 2018, the Zacks Consensus Estimate for revenues is pegged at $929.1million, reflecting growth of 29.3%. The stock has a Zacks Rank #3 (Hold). Here we take a quick look at the primary factors that have been plaguing DexCom and henceforth discuss the prospects that ensure near-term recovery of the stock. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote What's Deterring DexCom? DexCom reported loss in second-quarter 2018, narrower than the Zacks Consensus Estimate. The company's second-quarter gross profit totaled $154 million generating a gross margin of 63.3%, down 320 basis points (bps) year over year on an adjusted basis. Escalating non-recurring expenses, as the company ramped production volumes faster than anticipated, resulted in lackluster margin trends. Further, earlier-than-anticipated G6 launch resulted in unexpected excess and obsolete charges related to DexCom's G5 hardware. Owing to the lackluster trends, DexCom lowered margin guidance for 2018. Gross profit margin is projected to be just 64% of net revenues in 2018, lower than the previous guidance of 65-68%. Why Should You Still Hold? In 2017, DexCom announced the receipt of FDA approval of the Dexcom G5 mobile app for Android devices. Coming to the G6 CGM System, in June, the company announced that it has received CE Mark for its DexCom G6 System for people with diabetes aged two years and above. The company is optimistic about its G6 sensor. By the end of the second quarter of 2018, management announced that DexCom G6 represents the most important and complex launch in the company's history. DexCom G6 is highly exclusive in the market because it functions without finger-stick calibrations. Share Price Performance DexCom's shares have outperformed the industry in a year's time. Notably, the company's shares have surged 86.9%, against the industry's decline of 4%. The current level is also higher than the S&P 500 index's rise of 19%. Want More from the MedTech Space? A few better-ranked stocks in the MedTech space are Penumbra, Inc. PEN , Integer Holdings Corporation ITGR and Illumina, Inc. ILMN . All the companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Penumbra has a long-term expected earnings growth rate of 20%, while the same for Integer Holdings and Illumina is pinned at 15% and 22.1%, respectively. Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-08-29,35.3325,36.0125,35.18,35.555,"Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? The First Trust Mid Cap Growth AlphaDEX Fund (FNY) was launched on 04/19/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Mid Cap Growth segment of the US equity market. The fund is sponsored by First Trust Advisors. It has amassed assets over $235.43 M, making it one of the average sized ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth With market capitalization between $2 billion and $10 billion, mid cap companies usually contain higher growth prospects than large cap companies, and are considered less risky than their small cap counterparts. These types of companies, then, have a good balance of stability and growth potential. Growth stocks have higher than average sales and earnings growth rates. While these are expected to grow faster than the broader market, they also have higher valuations. Also, growth stocks are a type of equity that carries more risk compared to others. They are likely to outperform value stocks in strong bull markets but over the longer-term, value stocks have delivered better returns than growth stocks in almost all markets. Costs Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same. Annual operating expenses for this ETF are 0.70%, making it one of the most expensive products in the space. It has a 12-month trailing dividend yield of 0.11%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 25.50% of the portfolio. Healthcare and Consumer Discretionary round out the top three. Looking at individual holdings, Molina Healthcare, Inc. (MOH) accounts for about 0.92% of total assets, followed by Dexcom, Inc. (DXCM) and Trex Company, Inc. (TREX). The top 10 holdings account for about 8.51% of total assets under management. Performance and Risk FNY seeks to match the performance of the Nasdaq AlphaDEX Mid Cap Growth Index before fees and expenses. The NASDAQ AlphaDEX Mid Cap Growth Index is an enhanced which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 600 Mid Cap Growth Index. The ETF has gained about 18.96% so far this year and was up about 34.85% in the last one year (as of 08/29/2018). In the past 52-week period, it has traded between $34.91 and $46.62. The ETF has a beta of 0.96 and standard deviation of 14.61% for the trailing three-year period, making it a medium risk choice in the space. With about 225 holdings, it effectively diversifies company-specific risk. Alternatives First Trust Mid Cap Growth AlphaDEX Fund holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, FNY is an outstanding option for investors seeking exposure to the Mid Cap ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the iShares Russell Mid-Cap Growth ETF (IWP) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $8.27 B in assets, iShares Russell Mid-Cap Growth ETF has $9.53 B. IJK has an expense ratio of 0.25% and IWP charges 0.25%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FT-MC GROWTH AD (FNY): ETF Research Reports Trex Company, Inc. (TREX): Free Stock Analysis Report ISHARS-RS M GR (IWP): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report ISHARS-SP MC GR (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-08-30,35.4025,36.3675,35.4025,36.1,
DXCM,2018-08-31,36.1775,36.4865,36.0025,36.095,"[""DexCom (DXCM) Up 15.8% Since Last Earnings Report: Can It Continue?"", ""Stocks Which Set New 52-Week High Yesterday, August 30th"", ""Stocks Which Set New 52-Week High Yesterday, August 30th"", ""DexCom (DXCM) Up 15.8% Since Last Earnings Report: Can It Continue?"", ""Stocks Which Set New 52-Week High Yesterday, August 30th"", ""DexCom (DXCM) Up 15.8% Since Last Earnings Report: Can It Continue?""]"
DXCM,2018-09-04,36.025,36.5675,35.8112,36.515,"[""Stocks Which Set New 52-Week High Friday, August 31"", ""Stocks Which Set New 52-Week High Friday, August 31"", ""Stocks Which Set New 52-Week High Friday, August 31""]"
DXCM,2018-09-05,36.55,36.565,35.0225,35.4975,"[""The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results"", ""Stocks Which Set New 52-Week High Yesterday, September 4th"", ""Stocks Which Set New 52-Week High Yesterday, September 4th"", ""The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results"", ""Stocks Which Set New 52-Week High Yesterday, September 4th"", ""The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results""]"
DXCM,2018-09-06,35.6875,36.3,35.2325,35.7,
DXCM,2018-09-07,35.3325,36.7775,35.2692,35.87,"[""Tech Is Defenseless - Cramer's Mad Money (9/6/18)"", ""Tech Is Defenseless - Cramer's Mad Money (9/6/18)"", ""Tech Is Defenseless - Cramer's Mad Money (9/6/18)""]"
DXCM,2018-09-10,35.8375,36.46,35.395,36.2875,"[""Stocks Which Set New 52-Week High Friday, September 7th"", ""Stocks Which Set New 52-Week High Friday, September 7th"", ""Stocks Which Set New 52-Week High Friday, September 7th""]"
DXCM,2018-09-11,36.3375,37.12,36.1302,36.7175,
DXCM,2018-09-12,37.12,37.12,35.875,36.56,"[""Northland Securities Upgrades DexCom to Market Perform"", ""Benzinga's Top Upgrades, Downgrades For September 12, 2018"", ""Stocks Which Set New 52-Week High Yesterday, September 11th"", ""Stocks Which Set New 52-Week High Yesterday, September 11th"", ""Benzinga's Top Upgrades, Downgrades For September 12, 2018"", ""Northland Securities Upgrades DexCom to Market Perform"", ""Stocks Which Set New 52-Week High Yesterday, September 11th"", ""Benzinga's Top Upgrades, Downgrades For September 12, 2018"", ""Northland Securities Upgrades DexCom to Market Perform""]"
DXCM,2018-09-13,36.7675,37.1395,36.1575,36.25,
DXCM,2018-09-14,36.16,36.525,35.4675,35.7575,"[""Stocks Which Set New 52-Week High Yesterday, September 13th"", ""Once Again, Baird Predicts End To Tandem's 'Fantastic' Run"", ""Once Again, Baird Predicts End To Tandem's 'Fantastic' Run"", ""Stocks Which Set New 52-Week High Yesterday, September 13th"", ""10 Boring Stocks Growing Like Weeds InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most investors love a good story - or should I say, a sexy story. In looking for stocks to buy, they like the stories of the companies that are transforming an entire industry or are exploiting a niche that no one even knew existed 20 minutes ago. It's the rags-to-riches tale, the ground-floor-stock temptation. But generally speaking, for real, long-term investors, you want a lot more than wings - you want roots. Stocks that are proven. Stocks that have history. Stocks that have been around for decades, even though few people even know that they're publicly traded. Even hot-shot tech companies have to grind out their quarterly numbers after all the hype leaves them. Giant growth can be a fickle asset as a company matures, since double- and triple-digit growth is never sustainable in the long run. 10 Tech Dividend Stocks With Growth Potential These 10 boring stocks growing like weeds will not only endure, but they will thrive. They may not impress your friends on the golf course, but they'll certainly keep your portfolio heading in the right direction. Boring Stocks to Buy: SVB Financial Group (SIVB) Source: Shutterstock SVB Financial Group (NASDAQ: SIVB ) is a bank, but it's a unique kind of bank - the SVB stands for Silicon Valley Bank. It has become kind of a boutique investment bank for some of its customers. Say you launched a start-up and got bought out for a few million dollars. A customer like you is in a very special place to launch new firms similar to the one that you have already successfully launched. And SIVB can provide that capital to seed those new firms. And now SIVB is expanding across the U.S. In a tech driven world, this bank has big potential, which is why it's up 86% in the past year. Boring Stocks to Buy: IAC (IAC) Source: Rob Thurman Via Flickr IAC/InterActiveCorp (NASDAQ: IAC ) is certainly not a name that rolls off the tongue. But behind this imposing name lies some of the most familiar apps that the romantically inclined use regularly. IAC runs the The Match Group (NASDAQ: MTCH ), as in the dating sites Match.com, Tinder, PlentyOfFish and OkCupid. Another division runs home services sites Homeadvisor and Angie's List. And yet another division runs Vimeo. And it has a publishing segment that run The Daily Beast, Ask.com, Dictionary.com and others. 7 Stocks to Buy to Actually Make America Great Again The fact is, IAC is an online subscription and advertising-based behemoth. It's no surprise that IAC stock is up 90% in the past year. The cross-pollination of all these divisions means it is creating a self-sustaining information and entertainment empire for digital natives. Boring Stocks to Buy: Paycom (PAYC) Source: Microsoft Paycom Software (NYSE: PAYC ) is a cloud-based SaaS (software as a service) company that specializes in human capital management software. Basically, that means it outsources most human resources needs from recruitment to retirement. As small businesses continue to expand, one of the biggest challenges is building out a human resources department. Most business owners know their trade but understand little about the laws and procedures governing HR. And this can impact the scalability of a business. That's where PAYC comes in. Business owners can contract out this piece of the business and concentrate on what they do best. PAYC stock is up a whopping 103% year to date, and the momentum is continuing to grow. Boring Stocks to Buy: Texas Pacific Land Trust (TPL) Source: Shutterstock Texas Pacific Land Trust (NYSE: TPL ) has been around since 1888, when it was created as a holding company when the Texas and Pacific Railway Company was reorganized. It took over 3.5 million acres of land. Now, it manages 888,333 acres of that land. That's land that has oil and gas on it. Land that has housing, commercial and government development on it. And all those royalties and rents are managed by TPL. As the shale boom continues, especially in Texas, TPL is at the epicenter of its boom times. 15 Digital Ad Stocks to Buy for the Long Run TPL is up 86% so far this year and as Texas continues to boom, the stock will grow. Boring Stocks to Buy: DexCom (DXCM) Source: Shutterstock DexCom (NASDAQ: DXCM ) was the No. 2 company last year in Forbes' list of Most Innovative Growth Companies last year. The year before it was No. 4. The point is, DXCM isn't just sitting on its laurels, it's continuing to dominate a growing niche that is dying for better tech. DXCM makes continuous glucose monitoring solutions (CGM) for diabetics. Sadly, this is a growth business. But up until now, the old monitoring solutions - pricking your finger and putting your blood on a test strip that measures glucose levels on a device - was the only game in town. There were some CGMs out there, but they have been a bit clunky - and clunky for a child makes it a tough option. DXCM in a game-changer in this sector and now has devices that can be read off an app on your phone or smart watch. It's up 148% year to date and has plenty of headroom left. Boring Stocks to Buy: Callaway Golf (ELY) Source: Shutterstock Callaway Golf (NYSE: ELY ) is one of the most well-known brands in golf. From its revolutionary oversized drivers that have now become the standard on the pro tour and the public links to its line of clothes and bags, ELY is a niche brand that has a devoted and diverse following. While every year, there is hand-wringing about the demise of the sport with younger generations, the numbers show just the opposite . Golfers' numbers continue to grow. Youth participation is up. And ELY continues to adapt to the new generation of golfers that come along. This is not a stodgy, \""clubby\"" brand. It has always been known for innovation, and that continues to this day. 9 Marijuana Stocks to Play the Pot Craze The fact that the stock is up 64% in the past year is proof enough that ELY is still finding opportunity on and off the course. Boring Stocks to Buy: Chart Industries (GTLS) Chart Industries (NASDAQ: GTLS ) has a classic tag line for a \""boring\"" stock: \""You may never use the products we make, but everyone uses the products we make possible.\"" And that is certainly accurate, if not heart pounding. GTLS makes cryogenic equipment that are used to separate gasses and other compounds out of liquified natural gas (LNG). This is a crucial phase of \""refining\"" for LNG. And it means that as the economy grows and energy (and materials production) demands grow, so will GTLS. GTLS stock is up over 110% in the past year and the economy is just getting started, which means so is this stock. Boring Stocks to Buy: Synalloy (SYN) Source: Shutterstock Synalloy Corporation (NASDAQ: SYNL ) has been around since 1945, yet it's likely you've never heard of it. Based in Richmond, Virginia, it makes stainless steel and nickel alloy pipe, liquid storage systems and heavy wall seamless pipes and tubing. Think storage tanks and equipment for oil and gas exploration and production. SYNL also has a chemicals division that supports the metals, mining, carpet, automotive and other industries. 7 Trucking Stocks to Buy as Retail Markets Shift Into Higher Gear The fact is, while it has a core business that has kept it chugging along since the '40s, it thrives when the economy is expanding - like now. SYNL stock is up over 100% in the past year. Boring Stocks to Buy: Kimbell Royalty Partners (KRP) Source: Shutterstock Kimbell Royalty Partners LP (NYSE: KRP ) is a relative newcomer to the oil and gas exploration and production (E&P) game in Texas, having organized just a few short years ago. But if there's a time to be in the E&P game, this is it. Domestic energy production is booming and the current political climate is getting rid of regulation, so it's more profitable than ever to be a part of the U.S. energy business. While KRP has been operating as a private company for nearly two decades, it has truly come into its own recently. As of July, it now holds 11.1 million gross acres in 28 states. It has 84,000 wells on its properties, with 34,000 wells in the Permian Basin alone. Up 40% year to date, this limited partnership has a bright future. And its 7.5% dividend is a nice addition to the growth. Boring Stocks to Buy: Ladder Capital (LADR) Source: Shutterstock Ladder Capital (NASDAQ: LADR ) is an interesting real estate investment trust (REIT). Usually REITs own properties and then distribute their after tax profits to shareholders in the form of dividends. While LADR does have a generous 7.6% dividend, it doesn't derive most of its revenue from leases. It specializes in commercial real estate financing solutions. It is a lender to companies looking to lease properties. Granted, it has a few properties, but the bulk of its operations are funded by its financing arm. And with a recovering economy, this is a very good spot to be in. 7 Dividend Stocks to Buy Amid This Tough Market Environment LADR stock is up 26% year to date, and that doesn't include the dividend. This isn't hot tech-stock growth, but for a REIT in a unique niche, this is a very tempting total return play for the long term. Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor , Breakthrough Stocks , Accelerated Profits and Platinum Growth . His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com . Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. Compare Brokers The post 10 Boring Stocks Growing Like Weeds appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Once Again, Baird Predicts End To Tandem's 'Fantastic' Run"", ""Stocks Which Set New 52-Week High Yesterday, September 13th""]"
DXCM,2018-09-17,35.71,35.9975,34.1825,34.4825,"[""My Best Performers Of The Year"", ""My Best Performers Of The Year"", ""Strange: Bullish DXCM Analysts Actually See -2.12% Downside Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM - averaging the work of 15 analysts - reveals an average price target of $140.00/share. That's a whopping -2.12% below where DXCM has been trading recently at $143.03/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.39 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that - a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $170.00. And then on the other side of the spectrum one analyst has a target as low as $100.00. The standard deviation is $18.224. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes - much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $140.00/share, the -2.12% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""My Best Performers Of The Year""]"
DXCM,2018-09-18,34.6375,35.265,34.6375,34.8275,"[""Sonos Is Inconsistent - Cramer's Lightning Round (9/17/18)"", ""Jim Cramer Gives His Opinion on McDonald's, PayPal And More"", ""Jim Cramer Gives His Opinion on McDonald's, PayPal And More"", ""Sonos Is Inconsistent - Cramer's Lightning Round (9/17/18)"", ""Jim Cramer Gives His Opinion on McDonald's, PayPal And More"", ""Sonos Is Inconsistent - Cramer's Lightning Round (9/17/18)"", ""Non-diabetics are using diabetes technology to track their blood sugar and improve their health Glucose tracking can help people understand their health, from diet to exercise and energy levels, they say \u2018I think the value is unbelievable,\u2019 one entrepreneur told MarketWatch.""]"
DXCM,2018-09-19,34.91,35.3125,33.8028,34.77,"Interesting DXCM Put And Call Options For September 21st Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the September 21st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the DXCM options chain for the new September 21st contracts and identified one put and one call contract of particular interest. The put contract at the $130.00 strike price has a current bid of 20 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $130.00, but will also collect the premium, putting the cost basis of the shares at $129.80 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $138.42/share today. Because the $130.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 93%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 0.15% return on the cash commitment, or 28.08% annualized - at Stock Options Channel we call this the YieldBoost . Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $130.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $140.00 strike price has a current bid of 90 cents. If an investor was to purchase shares of DXCM stock at the current price level of $138.42/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $140.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 1.79% if the stock gets called away at the September 21st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $140.00 strike highlighted in red: Considering the fact that the $140.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.65% boost of extra return to the investor, or 118.66% annualized, which we refer to as the YieldBoost . The implied volatility in the put contract example is 68%, while the implied volatility in the call contract example is 71%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $138.42) to be 60%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-09-20,35.0375,35.35,34.7375,34.8525,"[""Senseonics Revenues Are Set To Explode"", ""Senseonics Revenues Are Set To Explode"", ""Senseonics Revenues Are Set To Explode""]"
DXCM,2018-09-21,34.5375,35.0925,34.5375,34.875,"[""Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?"", ""Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?"", ""Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Designed to provide broad exposure to the Mid Cap Growth segment of the US equity market, the First Trust Mid Cap Growth AlphaDEX Fund (FNY) is a passively managed exchange traded fund launched on 04/19/2011. The fund is sponsored by First Trust Advisors. It has amassed assets over $254.74 M, making it one of the average sized ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Compared to large and small cap companies, mid cap businesses tend to have higher growth prospects and are less volatile, respectively, with market capitalization between $2 billion and $10 billion. These types of companies, then, have a good balance of stability and growth potential. Growth stocks have higher than average sales and earnings growth rates. While these are expected to grow faster than the broader market, they also have higher valuations. Also, growth stocks are a type of equity that carries more risk compared to others. Compared to value stocks, growth stocks are a safer bet in a strong bull market, but don't perform as strongly in almost all other financial environments. Costs When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal. Annual operating expenses for this ETF are 0.70%, making it one of the most expensive products in the space. It has a 12-month trailing dividend yield of 0.11%. Sector Exposure and Top Holdings ETFs offer a diversified exposure and thus minimize single stock risk but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 25.80% of the portfolio. Healthcare and Consumer Discretionary round out the top three. Looking at individual holdings, Dexcom, Inc. (DXCM) accounts for about 1.03% of total assets, followed by Molina Healthcare, Inc. (MOH) and Trex Company, Inc. (TREX). The top 10 holdings account for about 9.1% of total assets under management. Performance and Risk FNY seeks to match the performance of the Nasdaq AlphaDEX Mid Cap Growth Index before fees and expenses. The NASDAQ AlphaDEX Mid Cap Growth Index is an enhanced which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 600 Mid Cap Growth Index. The ETF has added about 18.19% so far this year and was up about 29.38% in the last one year (as of 09/21/2018). In the past 52-week period, it has traded between $35.69 and $47.12. The ETF has a beta of 0.97 and standard deviation of 14.16% for the trailing three-year period, making it a medium risk choice in the space. With about 225 holdings, it effectively diversifies company-specific risk. Alternatives First Trust Mid Cap Growth AlphaDEX Fund holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, FNY is an excellent option for investors seeking exposure to the Mid Cap ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the iShares Russell Mid-Cap Growth ETF (IWP) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $8.30 B in assets, iShares Russell Mid-Cap Growth ETF has $9.58 B. IJK has an expense ratio of 0.25% and IWP charges 0.25%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FT-MC GROWTH AD (FNY): ETF Research Reports Trex Company, Inc. (TREX): Free Stock Analysis Report ISHARS-RS M GR (IWP): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report ISHARS-SP MC GR (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?""]"
DXCM,2018-09-24,34.76,35.7,34.48,35.525,
DXCM,2018-09-25,35.735,36.425,35.585,36.1975,"[""Dexcom Investors Are Whistling Past The Graveyard"", ""Dexcom Investors Are Whistling Past The Graveyard"", ""DXCM Crosses Above Average Analyst Target In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $141.67, changing hands for $142.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised. There are 15 different analyst targets contributing to that average for DexCom Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $100.00. And then on the other side of the spectrum one analyst has a target as high as $170.00. The standard deviation is $19.334. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $141.67/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $141.67 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Investors Are Whistling Past The Graveyard""]"
DXCM,2018-09-26,36.175,36.625,35.315,35.705,
DXCM,2018-09-27,35.8575,36.1175,35.295,35.99,"Investing in Diabetes Stocks: A Beginner's Guide Roughly 1 out of every 10 Americans -- or more than 30 million people -- have diabetes. Another 84 million Americans have prediabetes, which means they are dangerously close to developing diabetes. The numbers get even more mind-boggling when you zoom out to include the rest of the world. The World Health Organization estimated that more than 422 million people had diabetes in 2014. Millions more are diagnosed every year. These numbers show why many healthcare experts consider diabetes to be an epidemic. Treating diabetes is enormously expensive. A study published in the medical journal The Lancet in 2016 estimated the global cost of diabetes is more than $825 billion per year. Given these numbers, it should come as no surprise to see that treating diabetes has turned into a big business. Below, we'll take a look at everything that investors need to know about how to put money to work in the disease state. What is diabetes? Diabetes occurs when the body loses its ability to properly regulate glucose levels in the blood. That's a big problem because glucose is the body's main source of fuel. Maintaining healthy glucose levels is a delicate balancing act that is normally managed by the liver and the pancreas. Too little glucose in the blood -- which is called hypoglycemia -- can lead to dizziness, fainting, and even death in extreme cases. On the flip side, too much glucose in the blood -- which is known as hyperglycemia -- isn't good either. Excess glucose can damage major organs, such as the kidneys, heart, and eyes. Normally, the pancreas combats rising glucose levels by releasing insulin into the bloodstream. Insulin is a hormone that enables cells to convert glucose into energy. However, people with diabetes either no longer make enough insulin to satisfy their needs or they have lost the ability to use the insulin their bodies produce effectively. Broadly speaking, there are three main types of diabetes: Type 1: This type of diabetes occurs when the immune system mistakenly attacks and destroys its own insulin-producing cells in the pancreas. While Type 1 diabetes can occur at any age, it usually happens in children and young adults. That's why it used to be referred to as ""juvenile diabetes"" for many years . However, that terminology has since been dropped since adults can be diagnosed with Type 1, too. With Type 1 diabetes, a person no longer makes any insulin at all and must regularly receive artificial insulin in order to stay alive. Only about 5% all people with diabetes have Type 1. Type 2: This type of diabetes occurs when the body no longer makes enough insulin to meet its needs or fails to utilize the insulin that is produced naturally effectively. Type 2 diabetes can also occur at any age, but is most commonly diagnosed in middle-aged people and senior citizens. There is also a strong link between obesity and Type 2 diabetes. Type 2 is by far the most common form of diabetes. Gestational diabetes: This type of diabetes occurs in some women when they become pregnant. Thankfully, gestational diabetes usually disappears after the baby is delivered. However, patients with gestational diabetes are often at a greater risk of being diagnosed with Type 2 diabetes down the road. In addition, sometimes patients are mistakenly diagnosed with gestational diabetes when in fact they actually have Type 2 diabetes. Treating diabetes All people who have Type 1 diabetes and gestational diabetes require treatment. Most patients with Type 2 diabetes receive regular care as well. Here's an overview of the tools and methods that are used in modern-day diabetes management: Glucose monitoring: People with diabetes need to constantly monitor their blood glucose levels to ensure that they are in a healthy range. Most patients track their levels by using a meter that provides a point-in-time reading when a drop of blood is applied to a disposable strip (the blood is usually obtained from a finger prick). In recent years several companies have introduced continuous glucose monitors that track blood sugar levels directly in real time. Diet and exercise: Many people with Type 2 diabetes can keep their blood sugar levels in a healthy range by adopting a lifestyle that features healthy eating habits and regular exercise. Medication: A huge variety of drugs are available to help people with Type 2 diabetes reach their goals when dieting and exercising alone is not enough. Some of these drugs lower blood glucose levels by increasing the body's sensitivity to insulin (such as metformin and thiazolidinediones). Other drugs work by stimulating the pancreas to increase its insulin production (sulfonylureas and meglitinides). Some other drugs help to slow digestion and reduce blood sugar spikes after meals (DPP-4 inhibitors and GLP-1 receptor agonists). The newest generation of diabetes drugs helps the body to excrete more glucose through urine (SGLT2 inhibitors). Insulin: Every patient with Type 1 diabetes and many patients with Type 2 diabetes need artificial insulin to control their blood sugar levels. The majority of patients who take insulin inject it into their body by using a syringe or insulin pen. However, some patients choose to get insulin delivery by using a pump. Insulin pumps came in a variety of styles but are generally worn continuously and infuse insulin directly into the patient's body. Companies that make diabetes products A multitude of private and public companies make products that are used to treat diabetes. Here's are some of the biggest and best-know publicly traded diabetes companies: DATA SOURCE: YAHOO! FINANCE. MARKET CAP DATA AS OF 9/25/2018. You've likely noticed that several of these are massive healthcare companies. Johnson & Johnson, Sanofi, and Medtronic all boast market capitalization in excess of $100 billion and sell products in a multitude of disease states, including diabetes. That's why many of them are not great options for investors who want to buy pure-play diabetes companies. For example, Medtronic's diabetes division should pull in about $2 billion in annual revenue in fiscal 2018 from the sale of insulin pumps and continuous glucose monitors. While that's a big number in absolute terms, it makes up only about 6% of the company's total sales. Investors who are looking for direct exposure to the diabetes market are probably better served by looking elsewhere. So which diabetes companies are the top stocks for investors? Here's a closer look at three companies that I believe are worthy of consideration. Novo Nordisk You'd be forgiven if you assumed that Novo Nordisk, with a market cap of $116 billion, is a giant drugmaker that has its hands in several different disease states. In fact, the overwhelming majority of Novo's revenue comes from selling drugs that treat diabetes. In 2017, diabetes products sales comprised 81% of Novo's top line, which makes it as close to a pure play on diabetes as it gets in big pharma. Novo sells a number of popular drugs that are used to treat all three types of diabetes. Its insulin business sells brand-name products such as NovoLog, Tresiba, Levemir, Xultophy, and Fiasp. While all of the company's insulins lower glucose levels, they differ in how quickly they reduce glucose levels, their maximum impact, and how long they remain active in the body. Novo also markets a number of branded medicines that are used to treat Type 2 diabetes, such as NovoNorm, Ozempic, and Victoza. Novo's focus on diabetes has made it a wonderful stock to own for many years. However, the last few years have been a challenging time for the business. U.S. insurers have put a tremendous amount of pressure on the company to reduce prices on its insulin products in order to maintain favorable formulary coverage. That pricing pressure became so great that management eventually dialed back its long-term growth rate projections in 2016. More recently, Novo's business has been on an upswing thanks to several successful drug launches. Expense control and label expansion claims have also helped the company to move its bottom line in the right direction . Novo's profits should continue to lurch forward at a modest rate as next-generation drugs from its pipeline are steadily introduced to the market. While this company probably won't be posting fast growth anytime soon, it remains a low-risk way for investors to beef up their diabetes exposure. Income investor will also like that Novo pays out a dividend yield of about 2.8%. Insulet Corporation Insulin pumps are a great tool for insulin-dependent diabetes patients to control their glucose levels. Insulin pumps have been around for decades, and they work by delivering fast-acting insulin into a patient's body 24 hours a day. Modern pumps can be programmed to deliver different amounts of insulin at different times of the day to more closely match a patient's needs. At mealtime, patients can give themselves additional insulin to control their blood sugar spikes. While insulin pumps can greatly help a patient to manage their diabetes, only a minority of patients use them. One reason for the disconnect is that the majority of insulin pumps require patients to wear tubing. That's an unappealing prospect for many patients because tubing can easily get snagged or tangled with everyday activities. Insulet's solution to this lifestyle problem was to launch a patch pump that is worn directly on the body. This unique device is called the Omnipod , and it has been a huge hit with patients ever since it was launched for sale in 2005. For investors, the beauty of Insulet's Omnipod System is that the patch portion of the pump needs to be replaced every three days. This razor-and-blade business model -- which is a strategy that involves first selling a durable product (razor) to help drive sales of a consumable product (blades) -- makes the company's revenue highly predictable as new users adopt the system. Insulet has also innovated new uses for its drug delivery technology. The company has a partnership in place with Amgen in which the Omnipod is used to deliver the cancer drug Neulasta to patients. The company also continues to explore other drugs that may benefit from its tubing-free delivery system. Between its diabetes and other drug business, Insulet's CEO is calling for the company's revenue to exceed $1 billion by 2021. That's more than double what the company produced in 2017. If Insulet can deliver on its ambitious growth targets, then it is likely that its share price will continue to rally . Dexcom DexCom has been a red-hot growth stock ever since it won approval for its first continuous glucose-monitoring system back in 2006 . This innovative device allowed patients with diabetes to track their blood sugar levels in near real time, making it much easier for them to stay within a healthy range. DexCom has made several important improvements to its product over the years, including the recent FDA approval of its sixth-generation system . This newest product enables patients to make therapy decisions without having to prick their finger, and it's the first DexCom product to win such a claim. This innovative product should allow the company's ultra-fast revenue growth rate to continue. Another potential positive for investors is that DexCom has struck up numerous partnership agreements with insulin pump manufacturers such as Insulet and Tandem Diabetes Care . The aim of these agreements is to eventually introduce an artificial pancreas to market. An artificial pancreas would continuously sense a patient's blood glucose level and automatically dose insulin into the body. This would keep a patient's glucose levels in a healthy range at all times without any input at all from the patient. If achieved, this technology promises to revolutionize diabetes care. Like Insulet, DexCom operates using a razor-and-blade business model. This helps to ensure that the company's revenue will continue to grow over time as more users make the switch. DexCom estimates that 6 million patients in the U.S. and EU alone are on intensive insulin therapy. However, less than 10% of them are currently using a continuous glucose-monitoring system. That provides the company with a tremendous runway for growth even as competition in the space continues to heat up . Should you invest in diabetes stocks? It's an unfortunate truth that diabetes is one of the fastest-growing diseases in the world . The number of patients with diabetes has increased by nearly fourfold since 1980. If current trends persist, the number of people with diabetes is expected to exceed 640 million by 2040 with 150 million of them living in China alone. While the opportunity ahead is huge, there are risks for investors to consider. Regulators have to give the thumbs-up to devices and drugs before they can be marketed, but approvals aren't always guaranteed. Pharmaceutical sales can also evaporate when a drug loses patent protection and a cheaper generic version of the drug is launched. That risk now exists for biologic drugs, too, now that biosimilars -- copycat drugs that are made inside a living organism -- have been given the go-ahead in the U.S. Also, competition has been heating up in the disease state, which gives governments and insurers firepower to negotiate pricing concessions . Given these risks, diabetes investors shouldn't place all of their chips on a single stock. Instead, taking a basket approach makes sense. A long-term time horizon is also required since many of these stocks can be highly volatile . Until a cure is finally invented, the best option for many patients with diabetes is to manage their disease by using the most effective diabetes products and treatments. That puts innovative companies like Novo Nordisk, Insulet, and DexCom in a great position to continue delivering for shareholders and patients alike. 10 stocks we like better than Novo Nordisk When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of June 4, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of Johnson & Johnson and Medtronic and has the following options: short October 2018 $135 calls on Johnson & Johnson. The Motley Fool recommends Amgen, Becton Dickinson, Insulet, and Novo Nordisk. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-09-28,35.8875,36.2535,35.475,35.76,
DXCM,2018-10-01,35.225,35.4275,32.8725,33.4425,"[""Abbott's next-gen FreeStyle Libre CGM CE Mark'd"", ""Novo Nordisk Announces First Global Launch Of Connected Insulin Pens"", ""Novo Nordisk Announces First Global Launch Of Connected Insulin Pens"", ""Abbott's next-gen FreeStyle Libre CGM CE Mark'd"", ""Novo Nordisk Announces First Global Launch Of Connected Insulin Pens"", ""Abbott's next-gen FreeStyle Libre CGM CE Mark'd""]"
DXCM,2018-10-02,33.565,33.9,32.44,32.575,
DXCM,2018-10-03,32.6175,32.7537,31.23,31.535,
DXCM,2018-10-04,31.25,31.5262,30.69,31.2675,"[""Steven Cohen Plunges Into Nevro"", ""Daily Insider Ratings Round Up 10/1/18"", ""US Diabetes Market Gaining Momentum: 3 Stocks in Focus"", ""Steven Cohen Plunges Into Nevro"", ""US Diabetes Market Gaining Momentum: 3 Stocks in Focus"", ""Daily Insider Ratings Round Up 10/1/18"", ""US Diabetes Market Gaining Momentum: 3 Stocks in Focus Diabetes is one of the most challenging health conditions in the United States. About 1.4 million new cases of diabetes are diagnosed every year in the country, thanks to rise in the geriatric population, urbanization and poor lifestyle practices. Per Allied Market Research, the global diabetes therapeutics market is estimated to reach a worth of $186,842 million by 2023, at a CAGR of 16%. Thus, companies involved in the development of medical devices for diabetes are most likely to draw investors' attention. Artificial Intelligence - A Mega Trend in Diabetes Care Digitization has made big data technologies more relevant in healthcare, the diabetes care space being no exception. Smart apps have made self-management and monitoring of diabetes affordable. These applications can show real-time data on patients' blood glucose levels on these apps. Consumer fitness brand Fitbit FIT also entered the sapce by a $6-million investment in Sano. Additionally, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ, a cognitive mobile personal assistant app that aims to provide real-time actionable glucose insights and predictions for patients with diabetes. Per Research and Market, theglobal marketfor artificial intelligence in diabetes management is expected to see a CAGR of 50.7% between 2017 and 2023. Treatment Procedures Continuous Glucose Monitoring (CGM) Blood glucose monitoring is a way of testing the concentration of glucose in the blood. Self-monitoring by patients is the easiest and the most widely adopted method of glucose monitoring across the world. This has encouraged companies in the MedTech industry to focus on the development of glucose monitoring devices. Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to see a CAGR of 8% between 2018 and 2024. Insulin Patients diagnosed with Type I diabetes frequently require insulin injections. The procedure involves use of needles, syringes, insulin pens or insulin pumps. Medtronic's MiniMed Insulin Pump therapy deserves a special mention here. Meanwhile, drugs like Metformin and Sulfonylureas are used to treat Type II diabetes. Research by Market Watch suggests that the global human insulin drugs and devices market will cross a value of $45.36 billion by 2022, at a CAGR of 8%. Set against this backdrop, let's take a look at a few companies which are raking in billions by providing quality diabetes care. Stocks to Watch We have zeroed in on three stocks, each with a Zacks Rank #3 (Hold). We believe each of these companies can tap into the promising prospects of the diabetes device market. These stocks have also outperformed their respective industries in the past year. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our first pick is Abbott LaboratoriesABT . The Illinois-based MedTech giant is dedicated to developing innovative products that make glucose testing easier and more accurate. The company's products like Freestyle Libre, Freestyle Navigator II, Freestyle Lite, Freestyle Insulinx can be used by patients for personal glucose monitoring. Abbott has also launched mobile applications like Librelink and Librelinkup. It is encouraging to note that earlier this year, the company announced the availability of FreeStyle LibreLink app in Europe for use on smartphones (both iPhone and Android). The stock has rallied 31.1% compared with the industry 's 22% rise. Next on our list is New Jersey-based Becton, Dickinson and CompanyBDX , also known as BD. The medical technology bigwig's products are designed to provide effective diabetes care. BD's FlowSmart technology enables a new infusion set with a unique design to help reduce unplanned flow interruptions and keep patients' diabetes management on track. The company also offers a wide array of insulin syringes like BD 1-mL conventional insulin syringes, SafetyGlide 6mm insulin syringe, Safety-Lok insulin syringe. Moreover, BD's pen needles are compatible with leading diabetes medication pens in the United States. This range includes AutoShield Duo pen needle, Nano 4mm pen needle and Ultra-Fine pen needles. The stock has gained 31.1% compared with the industry 's increase of 15.8%. Investors may also keep an eye on DexCom, Inc.DXCM . The California-based medical device company is known for designing, developing and commercializing CGM systems. The company's FDA-cleared CGM system - the DexCom G4 Platinum - is significantly boosting the top line. The inbuilt features of G4 Platinum make it the most innovative CGM system in the market. Last year, DexCom announced the FDA approval of the Dexcom G5 mobile app for Android devices. In fact, the FDA recently granted a De Novo request for the DexCom G6 CGM System. In June, DexCom announced the receipt of CE Mark for its DexCom G6 System for people with diabetes ages two years and above. In August, DexCom acquired TypeZero Technologies, whose inControl diabetes management system is designed to provide personalized diabetes management solutions. In fact, Tandem Diabetes TNDM plans to launch its new FDA-approved t:slim X2 Insulin Pump with DexCom's G6 CGM system. The stock has rallied 162.8% compared with the industry 's 25.7% rise. 5 Companies Verge on Apple-Like Run Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Steven Cohen Plunges Into Nevro"", ""US Diabetes Market Gaining Momentum: 3 Stocks in Focus"", ""Daily Insider Ratings Round Up 10/1/18""]"
DXCM,2018-10-05,31.09,32.3425,30.645,31.61,"[""Notable ETF Inflow Detected - FNX, DXCM, OLLI, ZEN Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Mid Cap Core AlphaDEX Fund (Symbol: FNX) where we have detected an approximate $202.8 million dollar inflow -- that's a 21.6% increase week over week in outstanding units (from 13,400,002 to 16,300,002). Among the largest underlying components of FNX, in trading today DexCom Inc (Symbol: DXCM) is up about 1%, Ollie's Bargain Outlet Holdings Inc (Symbol: OLLI) is up about 0.4%, and Zendesk Inc (Symbol: ZEN) is up by about 0.1%. For a complete list of holdings, visit the FNX Holdings page \u00bb The chart below shows the one year price performance of FNX, versus its 200 day moving average: Looking at the chart above, FNX's low point in its 52 week range is $61.57 per share, with $73.11 as the 52 week high point - that compares with a last trade of $69.96. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""How The Pieces Add Up: SPLG Targets $37 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio Large Cap ETF (Symbol: SPLG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $37.31 per unit. With SPLG trading at a recent price near $33.84 per unit, that means that analysts see 10.26% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPLG's underlying holdings with notable upside to their analyst target prices are CyrusOne Inc (Symbol: CONE), DexCom Inc (Symbol: DXCM), and BOK Financial Corp (Symbol: BOKF). Although CONE has traded at a recent price of $62.37/share, the average analyst target is 13.41% higher at $70.73/share. Similarly, DXCM has 13.27% upside from the recent share price of $125.07 if the average analyst target price of $141.67/share is reached, and analysts on average are expecting BOKF to reach a target price of $108.78/share, which is 12.69% above the recent price of $96.53. Below is a twelve month price history chart comparing the stock performance of CONE, DXCM, and BOKF: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2018-10-08,31.31,31.515,30.32,30.8525,"[""Medical device makers in the red"", ""Wearable Medical Device Boom Puts These 3 Stocks in Focus"", ""Medical device makers in the red"", ""Wearable Medical Device Boom Puts These 3 Stocks in Focus"", ""Wearable Medical Device Boom Puts These 3 Stocks in Focus More than half of the American populace uses wearable devices to track calories, measure oxygen saturation (SpO2), monitor sleep, fetal monitoring, pulse rate analysis, maintain blood pressure and self-glucose monitoring. Per a recent research report by the BrandEssence, the wearable medical devices market was valued at $6.58 billion in 2017 and is expected to reach a worth of $25.46 Billion before 2024, at a CAGR of about 21.32%. Considering the trends, analysts and tech enthusiasts are expecting significant growth in the wearable medical devices market. Thus, companies involved in the development of wearable medical devices are likely to draw investors' attention. Tech Behemoths Reigning the Space Since the advent of the smartphone, tech companies have been working to apply medical uses to phone-connected, body-mounted sensors. After the release of Apple 's AAPL FDA-approved Watch Series 4 that captures an electrocardiogram seamlessly, Fitbit, Inc.FIT recently announced that its latest wearable, Charge 3, is available globally. The product, priced at $149.95, features 24/7 PurePulse heart rate technology that is more advanced, with more than nine trillion minutes of heart rate data. Further, it includes SpO2 sensor that tracks oxygen level in blood, sleeping disorders, allergies and asthma. Let us take a quick look at three companies from the MedTech space that are gaining momentum in the wearable devices space. 3 MedTech Companies Gaining Momentum We have zeroed in on three MedTech stocks that have significant exposure towearable technology and are raking in billions. Masimo Corporation MASI : Masimo is a strong player in the U.S. MedTech space. The company's wide exposure to wireless technology is supported by its SET Pulse Oximetry platform. The company's flagship Radius 7 platform is small, lightweight and wearable for untethered monitoring as well as ambulation. It is used for measuring SpO2 and monitoring pulse rate. The platform leverages on Masimo's SET Measure-through Motion and Low Perfusion pulse oximetry platform. Masimo's shares have outperformed the industry in the past year. The stock has rallied 40.4% compared with the industry's increase of 22.9%. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Medtronic PLC MDT : Medtronic announced integration with a popular fitness wearable company, Garmin International Inc., a unit of Garmin Ltd.GRMN . The company will leverage on Garmin's wearable device data for remote patient monitoring. Medtronic integrated Garmin data directly into Medtronic Care Management Services' (MCMS) platform. The collaboration is revolutionary as it synced Garmin v\u00edvofit series activity tracker data into the MCMS NetResponse mobile application. This enabled patients and physicians to better manage health conditions from home. Also, it gave healthcare providers to check on patients' activities at home post discharge from hospital. In 2016, Medtronic partnered with Fitbit to integrate health and activity tracking for patients suffering from diabetes as well as their physicians and care teams. The stock has a Zacks Rank #3 (Hold). Medtronic's shares have returned 26.3% in a year's time compared with the industry 's return of 20.5%. DexCom, IncDXCM : The company's FDA-cleared CGM system - the Dexcom G5 mobile app - for Android devices is a compact CGM System that works seamlessly to display real-time glucose activity on smart phones or watches, tablets and other compatible devices. This makes DexCom's solutions easy, user friendly and propels its demand. Apart from this, the company has a very unique application - DexCom Follow App - which enables 5 people to remotely monitor the patient's glucose data and trends. DexCom's shares have outperformed the industry in a year's time. Notably, the company's shares have surged 167.4% compared with the industry's rise of 22.8%. The stock has a Zacks Rank #3. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Garmin Ltd. (GRMN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medical device makers in the red"", ""Wearable Medical Device Boom Puts These 3 Stocks in Focus""]"
DXCM,2018-10-09,30.76,31.73,30.395,30.625,"[""The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom"", ""The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom"", ""The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom For Immediate Release Chicago, IL -October 9, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Masimo CorporationMASI , Medtronic PLCMDT , Garmin Ltd.GRMN and DexCom, IncDXCM . Here are highlights from Monday's Analyst Blog: Wearable Medical Devices Boom Puts These 3 Stocks in Focus More than half of the American populace uses wearable devices to track calories, measure oxygen saturation (SpO2), monitor sleep, fetal monitoring, pulse rate analysis, maintain blood pressure and self-glucose monitoring. Per a recent research report by the BrandEssence, the wearable medical devices market was valued at $6.58 billion in 2017 and is expected to reach a worth of $25.46 Billion before 2024, at a CAGR of about 21.32%. Considering the trends, analysts and tech enthusiasts are expecting significant growth in the wearable medical devices market. Thus, companies involved in the development of wearable medical devices are likely to draw investors' attention. Tech Behemoths Reigning the Space Since the advent of the smartphone, tech companies have been working to apply medical uses to phone-connected, body-mounted sensors. After the release of Apple's FDA-approved Watch Series 4 that captures an electrocardiogram seamlessly, Fitbitrecently announced that its latest wearable, Charge 3, is available globally. The product, priced at $149.95, features 24/7 PurePulse heart rate technology that is more advanced, with more than nine trillion minutes of heart rate data. Further, it includes SpO2 sensor that tracks oxygen level in blood, sleeping disorders, allergies and asthma. Let us take a quick look at three companies from the MedTech space that are gaining momentum in the wearable devices space. 3 MedTech Companies Gaining Momentum We have zeroed in on three MedTech stocks that have significant exposure towearable technology and are raking in billions. Masimo Corporation : Masimo is a strong player in the U.S. MedTech space. The company's wide exposure to wireless technology is supported by its SET Pulse Oximetry platform. The company's flagship Radius 7 platform is small, lightweight and wearable for untethered monitoring as well as ambulation. It is used for measuring SpO2 and monitoring pulse rate. The platform leverages on Masimo's SET Measure-through Motion and Low Perfusion pulse oximetry platform. Masimo's shares have outperformed the industry in the past year. The stock has rallied 40.4% compared with the industry's increase of 22.9%. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Medtronic PLC : Medtronic announced integration with a popular fitness wearable company, Garmin International Inc., a unit of Garmin Ltd. . The company will leverage on Garmin's wearable device data for remote patient monitoring. Medtronic integrated Garmin data directly into Medtronic Care Management Services' (MCMS) platform. The collaboration is revolutionary as it synced Garmin v\u00edvofit series activity tracker data into the MCMS NetResponse mobile application. This enabled patients and physicians to better manage health conditions from home. Also, it gave healthcare providers to check on patients' activities at home post discharge from hospital. In 2016, Medtronic partnered with Fitbit to integrate health and activity tracking for patients suffering from diabetes as well as their physicians and care teams. The stock has a Zacks Rank #3 (Hold). Medtronic's shares have returned 26.3% in a year's time compared with the industry 's return of 20.5%. DexCom, Inc : The company's FDA-cleared CGM system - the Dexcom G5 mobile app - for Android devices is a compact CGM System that works seamlessly to display real-time glucose activity on smart phones or watches, tablets and other compatible devices. This makes DexCom's solutions easy, user friendly and propels its demand. Apart from this, the company has a very unique application - DexCom Follow App - which enables 5 people to remotely monitor the patient's glucose data and trends. DexCom's shares have outperformed the industry in a year's time. Notably, the company's shares have surged 167.4% compared with the industry's rise of 22.8%. The stock has a Zacks Rank #3. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Garmin Ltd. (GRMN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom""]"
DXCM,2018-10-10,30.55,30.89,29.4575,29.52,
DXCM,2018-10-11,29.3,31.0975,29.0025,30.6,"[""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $150"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $150"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $150""]"
DXCM,2018-10-12,31.15,31.9825,30.93,31.7675,
DXCM,2018-10-15,31.8825,32.0,30.9462,31.2925,
DXCM,2018-10-16,31.4925,33.4975,31.3825,33.3,
DXCM,2018-10-17,33.21,33.6725,32.655,33.16,"[""Market Rallies When Fed Is Absent - Cramer's Mad Money (10/16/18)"", ""Market Rallies When Fed Is Absent - Cramer's Mad Money (10/16/18)"", ""Market Rallies When Fed Is Absent - Cramer's Mad Money (10/16/18)""]"
DXCM,2018-10-18,32.92,33.6175,32.565,33.2125,"[""Dexcom G6 will be available to medicare beneficiaries with diabetes in early 2019"", ""Dexcom Announces G6 Continuous Glucose Monitoring System Will Be Available To Medicare Beneficiaries With Diabetes In Early 2019"", ""Dexcom Announces G6 Continuous Glucose Monitoring System Will Be Available To Medicare Beneficiaries With Diabetes In Early 2019"", ""Dexcom G6 will be available to medicare beneficiaries with diabetes in early 2019"", ""DexCom Launches CLARITY Mobile App, Strengthens CGM Profile DexCom, Inc.DXCM recently launched its mobile application, CLARITY. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. In fact, patients can now view the same on their phones. Clearly, this latest development is likely to fortify DexCom's foothold in the CGM space. About DexCom's CGM Profile Based in California, this medical device company is known for designing, developing and commercializing CGM systems. Currently, DexCom's FDA-cleared CGM system - the DexCom G4 Platinum - is driving its top line significantly. Its inbuilt features like the G4 Platinum make the DexCom G4 Platinum the most innovative CGM system in the market. Last year, DexCom announced the FDA approval of the Dexcom G5 mobile app for Android devices. Diabetes Care Adopts Cloud-Based Services Smart apps have made self-management and continuous monitoring of diabetes affordable through the use of cloud-based applications. These applications can show real-time data on patients' blood glucose levels on these apps. For instance, consumer fitness brand Fitbit FIT entered the space by a $6-million investment in Sano. Moreover, MedTech giant Medtronic MDT collaborated with IBM to develop Sugar.IQ - a cognitive mobile personal assistant app. This application intends to provide real-time actionable glucose insights and predictions for patients with diabetes. Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Abbott's products like Freestyle Libre, Freestyle Navigator II, Freestyle Lite, FreestyleInsulinx can be used by patients for personal glucose monitoring. Market Prospects In the United States, about 1.4 million new cases of diabetes are diagnosed every year. Going by an article of Allied Market Research, the global CGM systems market is expected to see a CAGR of 22.9% between 2018 and 2024. It also predicts that, theglobal marketfor artificial intelligence in diabetes management is expected to witness a CAGR of 50.7% between 2017 and 2023. Thus, DexCom's latest move has been a well-timed one. Wall Street's Next Amazon Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Announces G6 Continuous Glucose Monitoring System Will Be Available To Medicare Beneficiaries With Diabetes In Early 2019"", ""Dexcom G6 will be available to medicare beneficiaries with diabetes in early 2019""]"
DXCM,2018-10-19,34.0,34.1425,32.1775,32.25,"[""Goldman Sachs Upgrades DexCom to Neutral, Announces $125 Price Target"", ""Benzinga's Top Upgrades, Downgrades For October 19, 2018"", ""Benzinga's Top Upgrades, Downgrades For October 19, 2018"", ""Goldman Sachs Upgrades DexCom to Neutral, Announces $125 Price Target"", ""Benzinga's Top Upgrades, Downgrades For October 19, 2018"", ""Goldman Sachs Upgrades DexCom to Neutral, Announces $125 Price Target""]"
DXCM,2018-10-22,32.1825,33.0175,31.7375,32.86,"[""Senseonics up 8% after hours on Aetna coverage for Eversense"", ""Senseonics up 8% after hours on Aetna coverage for Eversense"", ""Senseonics up 8% after hours on Aetna coverage for Eversense""]"
DXCM,2018-10-23,32.445,32.9025,31.545,32.7875,
DXCM,2018-10-24,32.785,33.3675,31.1025,31.21,
DXCM,2018-10-25,31.18,31.8512,29.825,31.415,
DXCM,2018-10-26,30.6,31.6925,29.6525,31.3425,
DXCM,2018-10-29,31.83,32.5912,30.705,31.16,
DXCM,2018-10-30,31.085,32.18,30.7038,31.3525,
DXCM,2018-10-31,31.6425,33.965,31.25,33.1925,
DXCM,2018-11-01,33.3875,34.4112,32.8025,34.0025,
DXCM,2018-11-02,34.2825,34.5,32.7875,33.165,"7 Straight-A Stocks to Build a Portfolio Around InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's no doubt that October was a crazy month. After a decent run through the third quarter, the markets decided it was time to re-evaluate valuations across the board. This happens sometimes. But it doesn't mean that the markets are heading toward a bear market or a significant reckoning. There are still good stocks to buy. As you have seen in the first couple of days in November, there is a lot of talk from politicians to get the market back in the headlines for good reasons. And the economy is also delivering good numbers on employment and wage growth. The latter has been a sticking point up to now, as low-end service jobs have been growing but employers haven't been raising their wages. That is starting to change now. 7 Best Stocks to Buy as You Recalibrate Your Compass The seven straight-A stocks to buy to build a portfolio around that are featured below have come down in price but not possibilities. They are less expensive now, yet promise outsized long-term growth. What's more, each stock here has received A ratings across three categories (quantitative, sales growth and earnings growth) by Portfolio Grader . Source: Shutterstock Amazon (AMZN) Amazon (NASDAQ: AMZN ) can't be ignored for an article like this. It is about as disruptive a company as is out there today. That's true not only for its ever-growing expansion into new markets, but it's true for its sheer size and impact on everything it does. For example, after getting sustained criticism for its low-wage warehouse jobs, AMZN announced that it was raising minimum wages to $15 an hour. This was as much good business as good press. It now pays more than top retailers like Walmart and Target for its warehouse workers. That makes it a bigger draw for the best talent. And it pressures its competitors to raise their wages without hurting their margins. AMZN is just getting started. This is a long-term foundation play that is a bit cheaper now. Source: Shutterstock Netflix (NFLX) Netflix Inc (NASDAQ: NFLX ) is another one of those disruptive companies spawned from simple beginnings that is now developing into a global force that is challenging legacy entertainment companies at every turn. Just five years ago, NFLX launched its first original series, House of Cards . Later that year, it launched its second, Hemlock Grove and then Orange Is the New Black . Today, just five years later, NFLX is looking at 700 original TV series and 80 movies, just in 2018. From a mail-delivery DVD movie rental company to one of the largest and most powerful global entertainment companies in the world is some serious growth. And the fact is, NFLX has yet to tap into two of the most significant entertainment markets around - India and China. 7 Canadian Stocks to Buy Now (And Only 2 Are Pot Stocks) Even when NFLX missed its subscriber numbers in Q2 analysts stayed bullish. And that paid off in Q3 when the numbers came in well above estimates yet again. Source: Rob Thurman Via Flickr IAC/InterActiveCorp (IAC) IAC/InterActiveCorp (NASDAQ: IAC ) is one of the top internet and media services companies around. While its name doesn't usually ring many bells, its subsidiaries usually do: Match.com, Tinder, PlentyOfFish, OKCupid, as well as Home Advisor and Angie's List. It also has a video division that features Vimeo and a publications sector that runs The Daily Beast, Dictionary.com and CityGrid, to name a few. This is a vertically integrated media services company built especially for Gen Xers and millennials. There are few companies that have diversified their holding like IAC, which makes it a unique and compelling investment. Plus, the way it is structured, it can cross-sell to its subscribers and derives revenue from a variety of sources, not just advertising. For example, Match Group Inc (NASDAQ: MTCH ) is a separately traded company that specializes in dating apps and online educational services of which IAC owns a controlling share. MTCH is up 73% year to date and its parent is up 68% year to date. Source: Shutterstock Abiomed (ABMD) Abiomed Inc (NASDAQ: ABMD ) is a medical equipment company with a $17 billion market cap. It's not usually put into articles that talk about stocks to build your portfolio around. However, there are two important things about ABMD that make it different. First is the sector. The medical equipment sector is going through the kind of tech revolution that is going on in every other sector of the economy. And as the US healthcare system (as well as others around the globe) looks to bring down costs without raising problems for patients, better equipment is becoming an of great interest from healthcare providers and insurance companies. Second, ABMD is fundamentally a 1-product company. It makes heart pumps to help an ailing or failing heart. This kind of equipment will be in greater demand as baby boomers begin to age and average ages rise across the developed world. 5 Stocks to Sell In November Amid Elections and Earnings This is a one-trick pony that has a very unique and important trick that has a decade of growth ahead of it. Source: Alden Chadwick Via Flickr DexCom (DXCM) DexCom Inc (NASDAQ: DXCM ) is a medical device maker that specializes in continuous glucose monitoring (CGM) equipment. As increasing numbers of Americans test positive for diabetes, there has been a boom in the cottage industry of glucose monitoring. Part of the reason for this is the new drugs on the market, while generally effective, are not available as generics yet and are very expensive. While losing weight and getting exercise can help manage diabetes, diet is important. And as diabetics continue to live with the disease, glucose levels can become increasingly erratic. CGM is very helpful in allowing diabetics to keep an eye on their levels using a smartwatch or smartphone. What's more, even non-diabetics are starting to track their glucose levels to see if there are any correlations to their energy levels, athletic performance, etc. App-based health information is transformative to allowing people to manage their conditions on a regular basis, so they don't have to spend so much time at the doctor or hospital. Up 136% year to date, DXCM has plenty of headroom. Source: Shutterstock Paycom (PAYC) Paycom Software Inc (NASDAQ: PAYC ) is part of the decentralization that going on in small and medium-sized businesses. It used to be that someone with a skill set and a good idea would start a business, hire people to grow the business and hire staff to manage the business. Generally speaking, most business owners are skilled in the building or managing a product or project, but don't have much experience running payroll, managing hiring and keeping up with taxes, personnel balancing receivables with liabilities. And until recently, that meant having to hire more than couple people to pull all this together. But now, this whole part of the operation can be outsourced to a company like PAYC. This allows the principal to do what she or he does best - grow the business. PAYC has a $7 billion market cap, so it's big enough to be a player in the new HR space, but it is small enough to be flexible and see real benefits from its growth. 3 Blue-Chip Stocks to Buy for Future Growth Up 57% year to date, PAYC has plenty of opportunities to grow and is also the ideal size for a bigger firm to snap it up a healthy premium. Source: Social Woodlands via Flickr (Modified) Medifast (MED) Medifast Inc (NYSE: MED ) is a weight loss diet company that was founded by a physician in Baltimore, Maryland, in 1980. Initially, the meal plans were sold through doctors' offices to patients that needed special diets for chronic diseases or to lose weight. To this day, Medifast is sold directly by physicians. But it is also now part of the huge dietetic meal industry and people can buy products off the website or join its wholly owned subsidiary Optavia . Optavia is the new face of the program Take Shape for Life, which offers specialized programs, counseling and support for customers looking for a more intensive experience on their road to healthy eating. And the Optavia division has been the big growth engine for MED in recent quarters. MED is logging huge numbers - up 203% year to date - compared to its more famous competitors. With rising income and a recovering economy, MED has a lot of potential to continue this growth for years to come. Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor , Breakthrough Stocks , Accelerated Profits and Platinum Growth . His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com . Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 7 Canadian Stocks to Buy Now (And Only 2 Are Pot Stocks) 5 Stocks to Sell In November Amid Elections and Earnings 3 Retail Stocks to Buy Despite All the Fearmongering Compare Brokers The post 7 Straight-A Stocks to Build a Portfolio Around appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-11-05,33.165,33.4562,32.4825,32.71,"[""Notable earnings after Tuesday's close"", ""Notable earnings after Tuesday's close"", ""Notable earnings after Tuesday's close""]"
DXCM,2018-11-06,32.8775,33.38,32.2375,33.23,"[""DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates"", ""DexCom Q3 revenues up 45%"", ""DexCom beats by $0.26, beats on revenue"", ""The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering"", ""DexCom, Inc. Q3 EPS $0.17 Beats $(0.10) Estimate, Sales $266.7M Beat $241.3M Estimate"", ""DexCom Raises FY18 Sales Guidance From $925M To $975M vs $930.8M Estimate"", ""DexCom, Inc. Q3 EPS $0.17, Sales $266.7M Beat $241.3M Estimate"", ""DexCom, Inc. Q3 EPS $0.17, Sales $266.7M Beat $241.3M Estimate"", ""DexCom Raises FY18 Sales Guidance From $925M To $975M vs $930.8M Estimate"", ""DexCom, Inc. Q3 EPS $0.17 Beats $(0.10) Estimate, Sales $266.7M Beat $241.3M Estimate"", ""The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering"", ""DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates"", ""DexCom Q3 revenues up 45%"", ""DexCom beats by $0.26, beats on revenue"", ""DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 241.67%. A quarter ago, it was expected that this medical device company would post a loss of $0.20 per share when it actually produced a loss of $0.10, delivering a surprise of 50%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $266.70 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 10.17%. This compares to year-ago revenues of $184.60 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have added about 128% since the beginning of the year versus the S&P 500's gain of 2.4%. What's Next for DexCom? While DexCom has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $259.72 million in revenues for the coming quarter and -$0.49 on $929.31 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Earnings Reaction History: DexCom, Inc., 77.8% Follow-Through Indicator, 8.8% Sensitive Expected Earnings Release: 11/06/2018, After-hours Avg. Extended-Hours Dollar Volume: $8,467,631 DexCom, Inc. ( DXCM ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in DXCM indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 100% Average next regular session additional gain: 5.6% Over the prior three fiscal years (12 quarters), when shares of DXCM rose in the extended-hours session in reaction to its earnings announcement, history shows that 100.0% of the time (5 events) the stock posted additional gains in the following regular session by an average of 5.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2% Over that same historical period, when shares of DXCM dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.0% by the following regular session close. Data provided by the MT Pro service at MTNewswires.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for November 6, 2018 : PXD, DXC, PAA, DVN, GDDY, JKHY, FANG, DXCM, LNT, JAZZ, XEC, KAR The following companies are expected to report earnings after hours on 11/06/2018. Visit our Earnings Calendar for a full list of expected earnings releases. Pioneer Natural Resources Company ( PXD ) is reporting for the quarter ending September 30, 2018. The oil (us exp & production) company's consensus earnings per share forecast from the 18 analysts that follow the stock is $1.69. This value represents a 252.08% increase compared to the same quarter last year. PXD missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -8.44%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for PXD is 21.52 vs. an industry ratio of 0.60, implying that they will have a higher earnings growth than their competitors in the same industry. DXC Technology Company ( DXC ) is reporting for the quarter ending September 30, 2018. The information technology services company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.96. This value represents a 1.55% increase compared to the same quarter last year. In the past year DXC has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 10.29%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for DXC is 8.84 vs. an industry ratio of 45.00. Plains All American Pipeline, L.P. ( PAA ) is reporting for the quarter ending September 30, 2018. The oil/gas company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.37. This value represents a 76.19% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for PAA is 13.96 vs. an industry ratio of 3.70, implying that they will have a higher earnings growth than their competitors in the same industry. Devon Energy Corporation ( DVN ) is reporting for the quarter ending September 30, 2018. The oil (us exp & production) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.43. This value represents a 6.52% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DVN is 22.21 vs. an industry ratio of 0.60, implying that they will have a higher earnings growth than their competitors in the same industry. GoDaddy Inc. ( GDDY ) is reporting for the quarter ending September 30, 2018. The internet services company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.18. This value represents a 157.14% increase compared to the same quarter last year. In the past year GDDY has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for GDDY is 137.74 vs. an industry ratio of 28.00, implying that they will have a higher earnings growth than their competitors in the same industry. Jack Henry & Associates, Inc. ( JKHY ) is reporting for the quarter ending September 30, 2018. The electrical company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.93. This value represents a 22.37% increase compared to the same quarter last year. JKHY missed the consensus earnings per share in the 3rd calendar quarter of 2017 by -3.8%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for JKHY is 37.16 vs. an industry ratio of 27.50, implying that they will have a higher earnings growth than their competitors in the same industry. Diamondback Energy, Inc. ( FANG ) is reporting for the quarter ending September 30, 2018. The oil (us exp & production) company's consensus earnings per share forecast from the 17 analysts that follow the stock is $1.52. This value represents a 14.29% increase compared to the same quarter last year. FANG missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -3.05%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for FANG is 18.01 vs. an industry ratio of 0.60, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. ( DXCM ) is reporting for the quarter ending September 30, 2018. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $-0.12. This value represents a 200.00% decrease compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DXCM is -267.27 vs. an industry ratio of 2.50. Alliant Energy Corporation ( LNT ) is reporting for the quarter ending September 30, 2018. The electric power utilities company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.84. This value represents a 12.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for LNT is 20.07 vs. an industry ratio of 17.30, implying that they will have a higher earnings growth than their competitors in the same industry. Jazz Pharmaceuticals plc ( JAZZ ) is reporting for the quarter ending September 30, 2018. The drug company's consensus earnings per share forecast from the 2 analysts that follow the stock is $2.98. This value represents a 1.71% increase compared to the same quarter last year. JAZZ missed the consensus earnings per share in the 4th calendar quarter of 2017 by -5.49%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for JAZZ is 13.85 vs. an industry ratio of -4.20, implying that they will have a higher earnings growth than their competitors in the same industry. Cimarex Energy Co ( XEC ) is reporting for the quarter ending September 30, 2018. The oil (us exp & production) company's consensus earnings per share forecast from the 19 analysts that follow the stock is $1.52. This value represents a 39.45% increase compared to the same quarter last year. XEC missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -3.05%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for XEC is 12.05 vs. an industry ratio of 0.60, implying that they will have a higher earnings growth than their competitors in the same industry. KAR Auction Services, Inc ( KAR ) is reporting for the quarter ending September 30, 2018. The retail company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.71. This value represents a 24.56% increase compared to the same quarter last year. In the past year KAR has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.8%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for KAR is 19.50 vs. an industry ratio of 15.20, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom, Inc. Q3 EPS $0.17, Sales $266.7M Beat $241.3M Estimate"", ""DexCom Raises FY18 Sales Guidance From $925M To $975M vs $930.8M Estimate"", ""DexCom, Inc. Q3 EPS $0.17 Beats $(0.10) Estimate, Sales $266.7M Beat $241.3M Estimate"", ""The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering"", ""DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates"", ""DexCom Q3 revenues up 45%"", ""DexCom beats by $0.26, beats on revenue""]"
DXCM,2018-11-07,34.25,36.25,33.12,36.1625,"[""DexCom (DXCM) Q3 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q3 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q3 2018 Results - Earnings Call Transcript""]"
DXCM,2018-11-08,35.9,38.035,35.75,37.1025,"[""IBD Stock Of The Day Flirts With Breakout And Nears Annual Profitability"", ""IBD Stock Of The Day Flirts With Breakout And Nears Annual Profitability"", ""DexCom (DXCM) Catches Eye: Stock Jumps 8.8% DexCom, Inc.DXCM was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 17.2% in the past one-month time frame. The move came after the company reported solid third-quarter 2018 results. The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future. DexCom currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative. DexCom, Inc. Price DexCom, Inc. Price | DexCom, Inc. Quote Investors interested in the Medical - Instruments industry may consider Penumbra, Inc. PEN , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Is DXCM going up? Or down? Predict to see what others think: Up or Down Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""IBD Stock Of The Day Flirts With Breakout And Nears Annual Profitability""]"
DXCM,2018-11-09,37.0275,37.91,36.175,37.365,"DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $147.86, changing hands for $148.41/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised. There are 14 different analyst targets contributing to that average for DexCom Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $125.00. And then on the other side of the spectrum one analyst has a target as high as $170.00. The standard deviation is $14.373. But the whole reason to look at the average DXCM price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $147.86/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $147.86 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . The Top 25 Broker Analyst Picks of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-11-12,36.8175,37.375,35.1425,35.4525,"Charting a failed technical test: S&P 500, Nasdaq violate 200-day average Focus: Biotech sector stalls at the breakdown point, XBI, DXCM, XLNX, FN, WELL U.S. stocks are firmly lower early Monday, pressured as Apple, Inc. approaches its 200-day moving average, and with General Electric refusing to find a floor. Against this backdrop, the S&P 500 has ventured back under its 200-day moving average, currently 2,762.5, a downturn punctuating last week’s failed retest of well-defined resistance."
DXCM,2018-11-13,35.8575,36.4975,34.81,35.6825,"DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View DexCom, Inc.DXCM reported adjusted earnings of 17 cents per share in the third quarter of 2018, beating the Zacks Consensus Estimate of a loss of 12 cents. Also, the figure improved from a loss of 4 cents in the year-ago quarter. The stock sports a Zacks Rank #1 (Strong Buy). Total revenues rallied 44.5% to $266.7 million on a year-over-year basis. The figure surpassed the Zacks Consensus Estimate of $242 million. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote Segmental Details Revenues in the Sensor segment (73% of total revenues) surged 47% on a year-over-year basis to $194 million. Transmitter revenues (18%) increased 27% year over year to $48.5 million. Receiver revenues (9%) rallied 68% year over year to $24.2 million. Geographical Details U.S. revenues (76% of total revenues) surged 34% on a year-over-year basis to $202.4 million. International revenues (24%) rocketed 93% year over year to $64.3 million Operational Details. Gross Profit in the quarter totaled $168.6 million, up 32.8% year over year. DexCom generated gross margin (as a percentage of revenues) of 63.2%, which contracted 560 basis points (bps) year over year. Margins were under pressure due to an inventory change as well as shift toward OUS and Medicare. Research and development (R&D) expenses totaled $50.1 million in the quarter, up 15.7% year over year. Selling, general and administrative expenses totaled $104.6 million in the reported quarter, up 24.2% year over year. The company reported net operating expenses of $154.7 million, up 21% year over year. As a percentage of revenues, DexCom generated operating margin of 5.2% in the third quarter. Guidance DexCom raised 2018 guidance. The company expects revenues of $975 million, up from the previous projection of $925 million. Meanwhile, the Zacks Consensus Estimate for revenues is currently pegged at $967.4 million, which is significantly lower than the guidance. Reported operating expenses, excluding investments in non-intensive programs, are expected to increase 18% from 2017 level. The estimate is significantly higher than the previous forecast of 14%. However, gross profit margin is projected to be 64%, in line with the prior guidance. Wrapping Up DexCom exited the third quarter on a strong note, beating the Zacks Consensus Estimate for earnings and revenues. Impressive contributions from the Sensor, Transmitter and Receiver segments are key catalysts. A raised guidance instills investors' optimism. The glucose monitoring market presents significant commercial opportunity for DexCom. The company's opportunities in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. On the flip side, cutthroat competition in the market for blood & glucose monitoring devices is a headwind. We believe that the company's margins will continue to remain under pressure in the upcoming quarters, thanks to high product development costs and rising expenditures on the R&D front. Lower expected margins on transmitter sales are add to the concerns. Q3 Earnings of MedTech Majors at a Glance Other top-ranked stocks from the broader Medical space that delivered robust results this earnings season are Intuitive Surgical ISRG , Stryker Corporation SYK and Merit Medical Systems, Inc MMSI . Notably, each of the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Intuitive Surgical reported third-quarter 2018 adjusted earnings per share (EPS) of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, which outpaced the consensus mark of $918.6 million. Stryker posted third-quarter 2018 adjusted EPS of $1.69, which outpaced the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps. Merit Medical reported third-quarter 2018 adjusted EPS of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus mark of $218 million. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce """"the world's first trillionaires,"""" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-11-14,35.7675,36.245,34.4175,34.7075,"[""Here's Why You Should Buy Integer Holdings (ITGR) Stock Now"", ""Here's Why You Should Buy Integer Holdings (ITGR) Stock Now"", ""Here's Why You Should Buy Integer Holdings (ITGR) Stock Now Integer Holdings Corporation ITGR is currently one of the best-performing stocks in the Medical Instruments industry. In fact, its solid focus on portfolio management and operational excellence are commendable. Moving ahead, the company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets. Integer Holdings has a Zacks Rank #2 (Buy). Impressive Share Price Performance A glimpse at the company's price trend reveals that Integer Holdings has outperformed its industry in a year's time. The stock has surged 77.8%, significantly higher than the industry's 14.9% rally and the S&P 500 index's 6.2% gain. Let us take a quick look at three important factors that make Integer Holdings a solid pick for now. Factors at Play Strong Q3 Results Integer Holdings wrapped up the third quarter on a solid note, with earnings and revenues beating the respective Zacks Consensus Estimate. Also, the company continues to gain from its Cardio & Vascular product line. Third-quarter adjusted earnings came in at $1.06 per share, outpacing the consensus mark by 15.2%. The bottom-line also improved 16.5% on a year-over-year basis. On a reported basis, revenues improved 6.9% year over year to $305.1 million and surpassed the Zacks Consensus Estimate of $292 million. Operational Excellence Integer Holdings have been witnessing an increase in profits since the last couple of quarters, courtesy of its consistent efforts to streamline operations. In the third quarter, the company generated gross profit of $91.9 million, up 3.1% year over year. Total operating income amounted to $41.5 million, up 15.7% year over year. Adjusted operating margin was 14.9%, up 30 bps year over year. Upbeat Guidance For 2018, the company expects revenues in the band of $1,195-$1,210 million, mirroring 6-7% growth from the previous year's tally (on an adjusted basis). Adjusted earnings are expected in the range of $3.55-$3.70 per share, indicating a 15-20% rise from the figure registered a year ago. Which Way Are Estimates Treading? The Zacks Consensus Estimate for third-quarter earnings is pegged at 92 cents, reflecting a year-over-year decrease of 4.2%. The same for revenues stands at $279.9 million, indicating 28.3% decline year over year. For the full year, the Zacks Consensus Estimate for earnings is pegged at $3.66, reflecting growth of 30.3% from a year ago. The same for revenues stands at $1.30billion. Integer Holdings Corporation Price and Consensus Integer Holdings Corporation Price and Consensus | Integer Holdings Corporation Quote Bottom Line Integer Holdings has a stable foothold in the cardiac, orthopedics, vascular and advanced surgical markets. Buoyed by solid prospects, the stock currently has a VGM Score of B . The VGM score (V stands for Value, G for Growth and M for Momentum) essentially highlights critical factors in a stock that have the potential to drive its price higher in the near term. Our research shows that stocks, with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, are better picks than most. Key Picks Some other top-ranked stocks in the broader medical space are Abiomed, Inc. ABMD , Masimo Corporation MASI and DexCom, Inc. DXCM . Abiomed has a long-term expected earnings growth rate of 34.3%. The stock carries a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank stocks here . Masimo's long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank #2. With a Zacks Rank #1, DexCom has an average four-quarter positive earnings surprise of 131.3%. 3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline. So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it. See them today for free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Buy Integer Holdings (ITGR) Stock Now""]"
DXCM,2018-11-15,34.465,34.9925,33.2525,33.9375,
DXCM,2018-11-16,33.7275,35.0425,33.3842,34.5375,
DXCM,2018-11-19,34.25,34.4725,30.0475,30.3275,"[""Alphabet Halts Glucose Lens Work to Focus on Other Projects"", ""Alphabet Halts Glucose Lens Work to Focus on Other Projects"", ""Alphabet Halts Glucose Lens Work to Focus on Other Projects Alphabet 's GOOGL healthcare division Verily has put a pause to its Smart Lens program in a bid to allocated resources more efficiently. Notably, this major project of Verily was being developed in collaboration with Novartis' eye-care division, Alcon since 2014. Notably, the project was related to the creation of a glucose-measuring contact lens for diabetic patients. This would enable the patients in managing their disease more efficiently, in turn inventing a non-invasive diabetes monitoring technology. However, the amalgamation of technology and live science in this project witnessed limitations due to correlation discrepancies between tear glucose and blood glucose concentrations. Consequently, Verily along with Alcon halted the project recently. Although the move does not bode well for the company's heavy investments in the project under review, it provides the scope of diversifying resources to other valuable projects. Shift in Focus With the latest move, Verily's focus on other eye-related technology deepens. The company has decided to concentrate more on the proper development of the other two 'Smart Lens' projects. While one is related to the creation of contact lens for the people with presbyopia, the other one is the development of intraocular lens that would improve the eye sight post cataract surgery. We believe this shift in focus is likely to help the company in achieving optimal usage of its wealth, skill and expertise. Additionally, Alphabet will be able to reap benefits from the rapidly growing market for contact lens globally. The market is reportedly expected to witness a CAGR of 7.8% between 2018 and 2024 to reach $18 billion by 2024. Further, the company will be able to bolster footprint in the intraocular lens space which as per a report from MarketsandMarkets is projected to hit $4.56 billion by 2022 at a CAGR of 5.4% between 2017 and 2022. Coming to the price performance, shares of Alphabet have returned 1.5% on a year-to-date basis against the industry 's decline of 22.5%. Intensifying Battle We notice that Alphabet is not the only tech company which is trying to expand presence in the vast healthcare sector. Another tech giant, Apple AAPL is also aggressively pursuing development of non-invasive techniques for diabetes management. The iPhone maker has a secret team comprising biomedical engineers who are engaged in developing sensors that would assist in monitoring blood sugar levels. Alphabet's recent move might seem to be in the wrong direction in the light of Apple's robust efforts. However, Verily has announced that it is continuously working on the development of non-intrusive glucose-measuring devices. The company is currently working with Dexcom DXCM on the creation of a miniaturized glucose monitor. Further, Verily has formed a joint venture with Sanofi SNY called Onduo and intends to help people living with Type 2 diabetes by integrating devices, software, medicine and professional care all together. All these strong endeavors are likely to aid Alphabet's competitive position in the diabetes management space. Currently, Alphabet carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Alphabet Inc. Revenue (TTM) Alphabet Inc. Revenue (TTM) | Alphabet Inc. Quote Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Alphabet Halts Glucose Lens Work to Focus on Other Projects""]"
DXCM,2018-11-20,29.3275,30.67,28.8825,29.9575,"[""Dexcom giving $250M in stock to Verily in amended license deal"", ""Dexcom giving $250M in stock to Verily in amended license deal"", ""Noteworthy ETF Inflows: FXH, I, HCA, DXCM Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $532.8 million dollar inflow -- that's a 33.0% increase week over week in outstanding units (from 22,000,002 to 29,250,002). Among the largest underlying components of FXH, in trading today Intelsat SA (Symbol: I) is down about 5.6%, HCA Healthcare Inc (Symbol: HCA) is up about 0.4%, and DexCom Inc (Symbol: DXCM) is lower by about 3%. For a complete list of holdings, visit the FXH Holdings page \u00bb The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $66.88 per share, with $85.3074 as the 52 week high point - that compares with a last trade of $72.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom giving $250M in stock to Verily in amended license deal""]"
DXCM,2018-11-21,30.28,31.091,29.765,30.4025,"[""DexCom Is Priced For Perfection"", ""Dexcom files prospectus to offer 3.87M shares"", ""The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO"", ""The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO"", ""Dexcom files prospectus to offer 3.87M shares"", ""DexCom Is Priced For Perfection"", ""Here's Why Tandem Diabetes Care Is Jumping 16% Today What happened After investment bank Baird upped its rating on the insulin pump maker to a buy, shares of Tandem Diabetes Care (NASDAQ: TNDM) shot up by 16% at 1:15 p.m. EST on Wednesday. So what Tandem Diabetes' sells insulin pumps that type 1 diabetics and insulin-intensive type 2 diabetics can use to manage their disease. The company faces stiff competition from the likes of Medtronic (NYSE: MDT) and Insulet (NASDAQ: PODD) , but it made a big headway toward capturing a more meaningful share of the pump market this summer when it launched a new automated insulin system that pairs its pumps with a continuous glucose monitor made by DexCom (NASDAQ: DXCM) . In the past, insulin pump users needed to consult with their CGM and, often, confirm blood sugar readings with a finger stick, but next-generation systems like the one sold by Tandem Diabetes automatically track your blood glucose readings and dose insulin as required. In Tandem Diabetes system, its Basal-IQ algorithm predicts blood sugar levels 30 minutes in advance and it can shut off insulin if someone's at risk of having a blood glucose level that's dangerously low. The launch of this new system has put Tandem Diabetes on a path toward profitability. In the third quarter, its pump shipments grew 118% to 8,434 and its sales jumped 71.5% to $46.3 million. Based on that performance, management told investors during its conference call that it's \""well-positioned to reach our breakeven target for adjusted EBITDA in Q4 of this year.\"" The upbeat outlook and the fact that Tandem Diabetes shares have tumbled from a peak of about $50 in September to roughly $33 as of this writing appears to have been enough to convince Baird that shares offer upside. This morning, the company lifted its rating to outperform from neutral and set a price target of $46. Now what The company estimates its market share to be about 12%, but that's likely to increase given the third-quarter results and the potential for its system to make insulin dosing easier on patients. Having said that, Medtronic's got its own similar system on the market and Insulet is developing an automated system, too, so Tandem Diabetes will still have to compete aggressively for sales in the future. The potential associated with disrupting the diabetes market shouldn't be understated, though. There are over 30 million people with diabetes, including more than 1 million with type 1 diabetes, in the U.S., and increasingly more people who could eventually benefit from automated insulin systems are being diagnosed every year. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO"", ""Dexcom files prospectus to offer 3.87M shares"", ""DexCom Is Priced For Perfection""]"
DXCM,2018-11-23,29.91,31.2525,29.91,31.07,
DXCM,2018-11-26,31.4425,32.2325,30.755,31.4975,"[""DexCom launches $750M convertible debt offering"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now"", ""DexCom launches $750M convertible debt offering"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now DexCom, Inc. DXCM is currently one of the best-performing stocks in the Medical Instruments industry. The large and growing diabetes market, strong product portfolio, collaborative agreements with several companies and focus on international markets are key drivers of the stock at the moment. DexCom sports a Zacks Rank #1 (Strong Buy). Impressive Share Price Performance A glimpse at the company's price trend reveals that DexCom has outperformed its industry in a year's time. The stock has soared 123.8%, significantly outperforming the industry's 8% growth and the S&P 500 index's 1.1% gain. Let us take a quick look at three important factors that make DexCom a solid pick for now. Factors at Play Deal With Verily In a bid to fortify its foothold in the Type 2 diabetes space, DexCom recently announced a new amendment to its license deal with Verily- the life sciences unit of Alphabet GOOGL . With this deal, DexCom is expected to deliver its next generation CGM (Continuous Glucose Monitoring) platform by the end of 2020. DexCom will make an initial payment of $250 million in stock. Moreover, additional payments of up to $280 million may become due and payable through product launch and revenue milestones. DexCom is likely to pay $275 million of the milestones in stock as well (read more: DexCom Amends Deal With Verily to Launch Advanced CGM by 2020 ). Solid Q3 Results DexCom reported adjusted earnings of 17 cents per share in the third quarter of 2018, which surpassed the Zacks Consensus Estimate of a loss of 12 cents. Total revenues rallied 44.5% to $266.7 million on a year-over-year basis and also surpassed the Zacks Consensus Estimate of $242 million. Buoyed by solid third-quarter results, DexCom raised the 2018 guidance. The company expects revenues of $975 million, up from $925 million anticipated earlier. Reported operating expenses, excluding investments in non-intensive programs, are expected to increase 18% from the 2017 level. The projection is significantly higher than the previous forecast of 14%. Gross profit margin is projected at 64%, in line with the prior guidance. Strong International Foothold DexCom continues to focus on international markets, primarily on Germany. It is eyeing the sizeable markets of India, China and Japan as well. In the third quarter of 2018, DexCom's international revenues skyrocketed 93% year over year to $64.3 million, with all major markets nearly doubling from the prior-year quarter. Notably, the company received approvals in Japan and Korea. Management sees robust growth opportunities in some of the European Union countries as well. Which Way Are Estimates Treading? The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 14 cents, reflecting a year-over-year increase of 40%. The same for revenues stands at $283.1 million, indicating 28.1% decline year over year. For the full year, the Zacks Consensus Estimate is pegged at a loss of 12 cents. The same for revenues stands at $977.4 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote Bottom Line DexCom's solid foothold in international markets is commendable. Furthermore, the company exhibits a VGM Score of B. Markedly, the VGM Score (V stands for Value, G for Growth and M for Momentum) essentially highlights critical factors in a stock that have the potential to drive its price higher in the near term. Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy) are better picks. Other Stocks to Consider Some other top-ranked stocks in the broader medical space are Abiomed, Inc. ABMD and Masimo Corporation MASI . Abiomed has a long-term expected earnings growth rate of 34.3%. The stock carries a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank stocks here . Masimo's long-term earnings growth rate is projected at 14.6%. The stock has a Zacks Rank #2. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom launches $750M convertible debt offering"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now""]"
DXCM,2018-11-27,30.6725,31.405,30.0162,30.9975,"[""4 Profitable Stocks Boasting Amazingly High Net Income Ratio"", ""4 Profitable Stocks Boasting Amazingly High Net Income Ratio"", ""4 Profitable Stocks Boasting Amazingly High Net Income Ratio Profitability analysis is considered one of the best possible ways to assess the prospects of a company. This analysis is used to identify a profitable company from a loss-making one. In this context, it can be inferred that a profitable company generally has a high level of sales surplus, which will help it meet all its operating and non-operating costs and still offer high returns. In this context, it may be wise to invest in shares of a company with a high level of profitability as it normally ensures high returns. As a result, the simplest and most transparent way of checking a company's profitability is by using accounting ratios. There are a variety of profitability ratios, from which we have selected net income ratio here as it is the most useful and simplest profitability metric. Net Income Ratio There are a variety of profit ratios like gross income ratio, operating income ratio, pretax profit margin and net income ratio, which can be used to find out a company's profit generating abilities. But net income ratio is widely accepted as the most conservative of the above-mentioned ratios. Net income in simple words is total earnings a company makes after deducting all the expenses from its sales revenue. Net income ratio or net profit margin is a ratio of a company's net income and sales revenue. A high net income ratio shows that the company is able to effectively manage all its business activities, including production, administration, selling, etc. Screening Parameters Net income ratio is one of our key screening parameters. However, to find out the sure winners, we have added a few additional criteria to arrive at an efficient strategy. Zacks Rank equal to #1: Only Strong Buy stocks are allowed. With the Zacks Rank proving itself to be one of the best rating systems out there, this is a great way to start things off. % Rating Strong Buy greater than 70%: This indicates that 70% of the analysts covering these stocks are optimistic. 12-Month Trailing Net Income Ratio Higher than X Industry: High net income ratio indicates a company's solid profitability. 12-Month Trailing Sales and Net Income Growth Higher than X Industry: Stocks that possess higher sales and net income growth in the last 12 months showcase better financial performance. These few parameters narrowed down the universe of over 7,712 stocks to only 12. Here are four of the 12 stocks that qualified the screen: DexCom, Inc. DXCM is a medical device company. It has an average four-quarter positive earnings surprise of more than 100%. E*TRADE Financial Corporation ETFC is a financial services company. It has an average four-quarter positive earnings surprise of 10.5%. MCBC Holdings, Inc. MCFT is a designer of sport boats and outboard boats in North America and globally. It has an average four-quarter positive earnings surprise of 20.4%. Quidel Corporation QDEL is a developer of diagnostic testing solutions for applications. It has an average four-quarter positive earnings surprise of 34%. You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today . Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks' portfolios and strategies are available at: https://www.zacks.com/performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report MCBC Holdings, Inc. (MCFT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""4 Profitable Stocks Boasting Amazingly High Net Income Ratio""]"
DXCM,2018-11-28,30.875,31.72,30.4175,31.175,"[""DexCom prices $750M convertible senior notes"", ""Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel"", ""UBS Initiates Coverage On DexCom with Neutral Rating, Announces $135 Price Target"", ""UBS Initiates Coverage On DexCom with Neutral Rating, Announces $135 Price Target"", ""Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel"", ""DexCom prices $750M convertible senior notes"", ""UBS Initiates Coverage On DexCom with Neutral Rating, Announces $135 Price Target"", ""Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel"", ""DexCom prices $750M convertible senior notes""]"
DXCM,2018-11-29,31.465,32.7775,31.2225,32.49,"[""5 Stocks to Gain as Fed Chair \""Blinks\"" on Rates"", ""FDA issues new draft guidance for blood glucose monitors"", ""FDA issues new draft guidance for blood glucose monitors"", ""5 Stocks to Gain as Fed Chair \""Blinks\"" on Rates"", ""5 Stocks to Gain as Fed Chair \""Blinks\"" on Rates On Nov 29, Fed Chair Jerome Powell's comments helped the Dow post its largest one-day gains in eight months. Powell unequivocally stated that rates were close to neutral, a clear departure from comments made two months ago. On that occasion, his statements had sent the S&P 500 into correction mode. But now Jerome Powell has indicated that the Fed may be at the end of its three-year tightening cycle. This is in keeping with market expectations and addresses President Trump's repeated criticism of the Fed Chair's stance on rates. With trade tensions also likely to be addressed over the weekend, markets are likely to shrug the volatility which has gripped stocks in recent times. Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks. Powell \""Blinks\"" on Rates Speaking at The Economic Club of New York, Powell said that interest rates are still at historical lows. At the same time, they are currently only a shade below \""the level that would be neutral for the economy.\"" His closely watched speech was a clear departure from comments made around two months ago. Powell's speech was in consonance with comments made by Fed Vice Chair Richard Clarida on Nov 27. Underlining the importance of a data-dependent approach to monetary policy, Clarida said interest rates were \""much closer\"" to a neutral level. On that occasion, the Fed Chair had said that rates were a \""long way from neutral.\"" Following his remarks, the S&P 500 entered correction mode. Subsequently, his stance on rates has come in for sharp criticism from President Trump. On Nov 27, Trump said that he was \""not even a little bit happy\"" with his choice of Powell as Fed Chair. Commenting on Powell's change in stance, CNBC's Jim Cramer tweeted that the Fed Chair had \""blinked\"" on rates. \""Powell sees the global slowdown and knows that it could hurt us,\"" tweeted Cramer, attributing the change in stance to this factor. Trade Tensions Likely to be Addressed, GDP Robust Meanwhile, The New York Times has reported that President Trump is concerned about the impact of lingering trade tensions with China on equity markets and the economy. This could lead to the President seeking a compromise on trade on the sidelines of the G-20 summit starting in Argentina this weekend. This is clear divergence from Trump's recent stance on trade relations with China. In fact, they are more in keeping with recent comments from U.S. National Economic Council Director Larry Kudlow. On Nov 27, Kudlow said the U.S. government has reopened negotiations on trade issues with China at several high-powered levels. Additionally, the economy remains robust as can be gleaned from the latest GDP numbers. The Department of Commerce's second estimate kept third-quarter GDP unrevised at a 3.5% pace. A spike in inventories and business investment has been the primary catalyst to the strong pace of growth witnessed during the quarter. Our Choices Powell's change in stance comes as a welcome surprise for markets which have been weighed down by fears about a tougher rate environment. Meanwhile, a trade deal between the United States and China is likely to be worked out on the sidelines of the G-20 summit this weekend. With most lingering concerns likely to be addressed shortly, markets are all set to resume their long-standing rally. At this stage, investment in stocks with strong growth potential will be lucrative. Our selection is backed by a Zacks Growth Score of A and a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 or 2 (Buy) offer the best opportunities in the Growth-investing space. We have handpicked five such stocks with a Zacks Rank #1 and Growth Style Score of A. DexCom, Inc.DXCM is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. DexCom has expected earnings growth of 79.8% for the current year. The Zacks Consensus Estimate for the current year has improved by 75% over the last 30 days. The Mosaic CompanyMOS is a leading producer and marketer of concentrated phosphate and potash for the global agriculture industry. The Mosaic Company has expected earnings growth of 71.9% for the current year. The Zacks Consensus Estimate for the current year has improved by 9.2% over the last 30 days. Amedisys, Inc.AMED provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. Amedisys has expected earnings growth of 62% for the current year. The Zacks Consensus Estimate for the current year has improved by 5.6% over the last 30 days. Genomic Health, Inc.GHDX is a global cancer company with a focus on advanced molecular diagnostics. Genomic Health's expected earnings growth for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 96.7% over the last 30 days. Fossil Group, Inc.FOSL is a designer and manufacturer of clothing and accessories. Fossil Group's expected earnings growth for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved by 32.9% over the last 30 days. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Mosaic Company (MOS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Fossil Group, Inc. (FOSL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FDA issues new draft guidance for blood glucose monitors"", ""5 Stocks to Gain as Fed Chair \""Blinks\"" on Rates""]"
DXCM,2018-11-30,32.385,33.085,31.84,32.3975,
DXCM,2018-12-03,33.41,34.3525,32.8925,34.1475,
DXCM,2018-12-04,34.0625,34.6475,30.4425,31.9775,"[""DexCom down 10% as Investor Day proceeds"", ""DexCom down 10% as Investor Day proceeds"", ""DexCom down 10% as Investor Day proceeds""]"
DXCM,2018-12-06,31.75,32.44,31.015,32.3675,"DexCom (DXCM) Down 11.6% Since Last Earnings Report: Can It Rebound? It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 11.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is DexCom due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. DexCom Q3 Earnings & Revenues Beat, International Sales Rise Y/Y DexCom reported adjusted earnings of 17 cents per share in the third quarter of 2018, beating the Zacks Consensus Estimate of a loss of 12 cents. Also, the figure improved from a loss of 4 cents in the year-ago quarter. Total revenues rallied 44.5% to $266.7 million on a year-over-year basis. The figure surpassed the Zacks Consensus Estimate of $242 million. Segmental Details Revenues in the Sensor segment (73% of total revenues) surged 47% on a year-over-year basis to $194 million. Transmitter revenues (18%) increased 27% year over year to $48.5 million. Receiver revenues (9%) rallied 68% year over year to $24.2 million. Geographical Details U.S. revenues (76% of total revenues) surged 34% on a year-over-year basis to $202.4 million. International revenues (24%) rocketed 93% year over year to $64.3 million. Operational Details Gross Profit in the quarter totaled $168.6 million, up 32.8% year over year. DexCom generated gross margin (as a percentage of revenues) of 63.2%, which contracted 560 basis points (bps) year over year. Margins were under pressure due to an inventory change as well as shift toward OUS and Medicare. Research and development (R&D) expenses totaled $50.1 million in the quarter, up 15.7% year over year. Selling, general and administrative expenses totaled $104.6 million in the reported quarter, up 24.2% year over year. The company reported net operating expenses of $154.7 million, up 21% year over year. As a percentage of revenues, DexCom generated operating margin of 5.2% in the third quarter. Guidance DexCom expects revenues of $975 million, up from the previous projection of $925 million. Reported operating expenses, excluding investments in non-intensive programs, are expected to increase 18% from 2017 level. The estimate is significantly higher than the previous forecast of 14%. However, gross profit margin is projected to be 64%, in line with the prior guidance. How Have Estimates Been Moving Since Then? It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 1888.31% due to these changes. VGM Scores At this time, DexCom has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise DexCom has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2018-12-07,32.045,32.665,30.0675,30.3525,"[""Stock Exchange: More Unnerving Face-Rippers Ahead?"", ""Stock Exchange: More Unnerving Face-Rippers Ahead?"", ""Stock Exchange: More Unnerving Face-Rippers Ahead?""]"
DXCM,2018-12-10,30.475,30.9875,29.91,30.8625,"[""What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)"", ""What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year? Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of DXCM and the rest of the Medical group's stocks. DexCom is one of 841 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. DXCM is currently sporting a Zacks Rank of #1 (Strong Buy). Over the past three months, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 74.28% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Based on the most recent data, DXCM has returned 111.55% so far this year. At the same time, Medical stocks have gained an average of 1.12%. This shows that DexCom is outperforming its peers so far this year. Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 93 individual stocks and currently sits at #76 in the Zacks Industry Rank. This group has gained an average of 11.92% so far this year, so DXCM is performing better in this area. Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Falling Estimates & Price Mean for Alphatec Holdings (ATEC) Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Alphatec Holdings, Inc.ATEC , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in ATEC. A key reason for this move has been the negative trend in earnings estimates revisions. For the full year, we have seen one estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss 61 cents a share a month ago to its current level of loss of 67 cents. Also, for the current quarter, Alphatec Holdings has seen one downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 12 cents a share from a loss of 7 cents over the past 30 days. The stock has also seen some pretty dismal trading lately, as the share price has dropped 17.9% in the past month. Alphatec Holdings, Inc. Price and Consensus Alphatec Holdings, Inc. Price and Consensus | Alphatec Holdings, Inc. Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. If you are still interested in the Medical - Instruments industry, you may instead consider a better-ranked stock - DexCom, Inc. DXCM . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today's Zacks #1 Rank stocks here . Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Alphatec Holdings, Inc. (ATEC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)""]"
DXCM,2018-12-11,31.2975,32.3882,30.1625,30.7575,
DXCM,2018-12-12,31.3,31.61,30.8888,31.13,"[""5 Stocks That Popped More Than 100% in 2018 Defying All Odds"", ""5 Stocks That Popped More Than 100% in 2018 Defying All Odds"", ""3 Top Medical Device Stocks to Buy Now Healthcare providers tend to stay brand-loyal to medical devices after they've been trained on how to use them. This product stickiness is a key reason the industry is a great place to hunt for investment ideas. Align Technology (NASDAQ: ALGN) , NovoCure (NASDAQ: NVCR) , and DexCom (NASDAQ: DXCM) are three great examples of medical device makers that have already produced huge returns for shareholders. Here's why each of them is a great buy today. Align Technology Align is the company behind the Invisalign system. The company sells a series of clear aligners to patients with misaligned teeth, which is an attractive alternative to metal-and-wire braces. Beyond selling directly to consumers, Align also sells an intra-oral scanner called iTero to orthodontists that produces 3D images of patients' teeth. Those images make it easy for dental practices to get their patients started on Invisalign. Align's products have proven to be a massive hit with patients and dental professionals alike. The company's revenue, profits, and stock price have all soared in response. The great news for investors is that Align's management team believes that it has still only captured about 13% of its current addressable market. If that number is anywhere close to accurate, then it means that this company's days of hypergrowth are far from over. Meanwhile, the company's stock is currently down by more than 40% from its recent high. The huge reversal can be blamed on fears of rising competition from SmileDirectClub and a slower-than-hoped-for growth forecast . Should investors worry about the incoming competition? I don't think so, for a few reasons. First, the two companies are targeting different types of customers: people who visit the orthodontist and those who do not. Second, Align is a direct investor in SmileDirectClub and is an exclusive supplier, meaning buying Align gives investors exposure to growth of SmileDirectClub. And third, the market opportunity is so large that I think these two businesses can coexist. Wall Street appears to agree with my assessment. Current projections call for Align's profits to grow in excess of 24% annually over the next five years. With shares currently trading around 38 times next year's earnings estimates, I think right now is a great time for investors to get in. NovoCure Researchers have been looking for new ways to fight cancer for decades. While most of that effort has been focused on developing better drugs, an innovative company called NovoCure took a different approach. The company discovered that highly-tuned electric fields could be used to inhibit cell division in cancerous tumors, meaning it slows down the speed at which the tumor grows. When this technology is combined with traditional treatment methods, it leads to better outcomes . What's more, using electric fields to fight cancer is virtually free of side effects -- a highly appealing prospect for patients and providers alike. NovoCure decided to focus its initial efforts on treating a deadly form of brain cancer called glioblastoma multiforme. The company secured its first Food and Drug Administration (FDA) approval in 2011, and sales have grown like gangbusters ever since . For investors, the exciting thing about NovoCure is that the company believes that its technology can fight a wide range of other cancers. It is awaiting FDA approval to treat mesothelioma and is in various stages of development in treating lung cancer, ovarian cancer, pancreatic cancer, and others. Expansion into any of these indications down the road could allow its hypergrowth to continue. NovoCure hasn't reached profitability yet, but it is very close. The company has more than $220 million in cash, so it shouldn't need to tap investors to get there. While NovoCure is packed with potential, the recent marketwide sell-off has hit its stock hard. Shares are currently down more than 30% from their all-time high. You still can't call the share price \""cheap\"" (it's currently about 14 times sales), but the potential upside is massive if NovoCure can successfully win FDA approval in new indications. I think the odds of that happening are very good since its device has already proven effective in brain cancer and is virtually free of side effects. I also love the fact that this company has no competition . DexCom The market for diabetes products is massive and grows every year . While that's a terrible trend for the health of society, it is a great backdrop for diabetes companies like DexCom. DexCom makes a continuous glucose monitor (CGM) that enables people with diabetes to track changes in their blood glucose levels in real time. That's important because diabetes can cause a person's blood glucose levels to fluctuate wildly throughout the day. If levels are too high or too low, it can cause short and long-term health problems. Being able to monitor changing glucose levels in real time allows patients to take action to avoid issues down the road. The allure of DexCom's solution has translated into mind-boggling growth. Sales have grown from $259 million in 2014 to an estimated $976 million in 2018. The huge gains are allowing the company to finally start producing profits. DexCom has numerous partnerships that should drive its next phase of growth. The company is working to integrate its technology with insulin pumps made by both Tandem Diabetes Care and Insulet . It is also working with Alphabet 's healthcare arm to develop next-generation CGM technology. When you combine these opportunities with the fact that CGM penetration rates are still very low, DexCom looks poised for massive growth. Market watchers currently project that its earnings will grow in excess of 140% annually over the next five years. While the triple-digit growth projection is mostly a result of starting from a small base, that's still an eye-popping number. If the company can deliver on those lofty expectations, then its sky-high P/E ratio, which is currently 257, will fall very quickly. That makes me believe that investors who buy today will be handsomely rewarded for paying up to own this stock. 10 stocks we like better than Align Technology When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Align Technology wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Alphabet (A shares), Alphabet (C shares), and NovoCure. The Motley Fool owns shares of and recommends Align Technology, Alphabet (A shares), and Alphabet (C shares). The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 Stocks That Popped More Than 100% in 2018 Defying All Odds""]"
DXCM,2018-12-13,31.225,31.43,30.2788,30.755,
DXCM,2018-12-14,30.4875,30.83,29.85,30.165,
DXCM,2018-12-17,29.7375,29.8625,28.2525,28.425,"[""Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look"", ""4 Medical Device Stocks That More Than Doubled in 2018"", ""Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional."", ""Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional."", ""Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look"", ""4 Medical Device Stocks That More Than Doubled in 2018"", ""Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look Medical Instrument companies Abiomed, Inc.ABMD and DexCom, Inc.DXCM are two solid contenders in the U.S. MedTech space, which is expected to reach a worth of $409.5 billion by 2023 at a CAGR of 4.5%. Notably, analysts believe that 2019 is likely to prove profitable for U.S. medical device companies, courtesy of the 2.3% Medical Device tax abatement along with focus on Artificial Intelligence and cybersecurity. Against this backdrop, it is difficult to choose between the above-mentioned companies as they have similar business models. Making things more difficult, the scales apparently look balanced as Abiomed carries a Zacks Rank #2 (Buy), while DexCom sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . However, we make a detailed analysis of the companies' fundamentals to determine which has a slight edge over the other. Massachusetts-based Abiomed is engaged in developing, manufacturing and marketing medical products, designed to assist or replace the pumping function of the failing heart. Meanwhile, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). Price Performance Over the past year, Abiomed's shares have gained 66.4% compared with DexCom's 106.7% rally. The Medical Instruments industry has rallied 8.2% in the same time frame. Meanwhile, the S&P 500 index has declined 3.5%. Which Way Are Estimates Headed? Earnings The Zacks Consensus Estimate for Abiomed's current-quarter earnings per share stands at 93 cents, suggesting an improvement of 32.9% year over year. The same for DexCom is projected at 13 cents, showing year-over-year growth of 30%. ABIOMED, Inc. Price and Consensus ABIOMED, Inc. Price and Consensus | ABIOMED, Inc. Quote Sales The Zacks Consensus Estimate for Abiomed's current-quarter revenues is pegged at $194.88 million, suggesting growth of 26.5% from the previous year. The same for DexCom is pegged at $283.08 million, reflecting a rise of 28.1%. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote What's Favoring the Stocks? Abiomed currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2, are better picks than most. Over the past four years, the company's revenues have seen a CAGR of 37.2% to $594 million. DexCom also has a Growth Score of A. Over the past four years, the company's revenues have seen a CAGR of 40.5% to $719 million. Other Key Picks Other top-ranked stocks in the broader medical space are Stryker Corporation SYK and Surmodics, Inc. SRDX . Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2. Surmodics' long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank #2. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional."", ""Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look"", ""4 Medical Device Stocks That More Than Doubled in 2018""]"
DXCM,2018-12-18,28.8525,29.095,28.215,28.6525,
DXCM,2018-12-19,28.8175,29.71,28.12,28.37,"[""4 Healthcare Stocks That Popped More Than 100% in 2018"", ""DexCom Option Alert: Fri $120 Calls Sweep (2) near the Ask: 540 @ $1.75 vs 283 OI; Ref=$116.85"", ""DexCom Option Alert: Fri $120 Calls Sweep (2) near the Ask: 540 @ $1.75 vs 283 OI; Ref=$116.85"", ""4 Healthcare Stocks That Popped More Than 100% in 2018"", ""DexCom Option Alert: Fri $120 Calls Sweep (2) near the Ask: 540 @ $1.75 vs 283 OI; Ref=$116.85"", ""4 Healthcare Stocks That Popped More Than 100% in 2018""]"
DXCM,2018-12-20,28.21,28.483,27.0875,27.515,
DXCM,2018-12-21,27.7425,27.7975,26.2625,27.08,
DXCM,2018-12-24,26.9725,27.5375,26.4275,26.9925,"[""DexCom Sees Hammer Chart Pattern: Time to Buy?"", ""DexCom Sees Hammer Chart Pattern: Time to Buy?"", ""Analysts Expect ESGU To Hit $68 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG MSCI USA ETF (Symbol: ESGU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $67.74 per unit. With ESGU trading at a recent price near $52.85 per unit, that means that analysts see 28.17% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of ESGU's underlying holdings with notable upside to their analyst target prices are Caterpillar Inc. (Symbol: CAT), DexCom Inc (Symbol: DXCM), and CSX Corp (Symbol: CSX). Although CAT has traded at a recent price of $120.07/share, the average analyst target is 38.97% higher at $166.87/share. Similarly, DXCM has 37.86% upside from the recent share price of $108.32 if the average analyst target price of $149.33/share is reached, and analysts on average are expecting CSX to reach a target price of $80.25/share, which is 32.21% above the recent price of $60.70. Below is a twelve month price history chart comparing the stock performance of CAT, DXCM, and CSX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Sees Hammer Chart Pattern: Time to Buy? DexCom, Inc.DXCM has been struggling lately, but the selling pressure may be coming to an end soon. That is because DXCM recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. What is a Hammer Chart Pattern? A hammer chart pattern is a popular technical indicator that is used in candlestick charting. The hammer appears when a stock tumbles during the day, but then finds strength at some point in the session to close near or above its opening price. This forms a candlestick that resembles a hammer, and it can suggest that the market has found a low point in the stock, and that better days are ahead. Other Factors Plus, earnings estimates have been rising for this company, even despite the sluggish trading lately. In just the past 60 days alone 12 estimates have gone higher, compared to none lower, while the consensus estimate has also moved in the right direction. Estimates have actually risen so much that the stock now has a Zacks Rank #1 (Strong Buy) suggesting this relatively unloved stock could be due for a breakout soon. This will be especially true if DXCM stock can build momentum from here and find a way to continue higher of off this encouraging trading development. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Sees Hammer Chart Pattern: Time to Buy?""]"
DXCM,2018-12-26,27.16,29.1925,27.16,29.1175,
DXCM,2018-12-27,28.6275,29.5,28.25,29.485,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has DexCom (DXCM) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. DexCom is one of 838 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DXCM is currently sporting a Zacks Rank of #1 (Strong Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 74.28% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. According to our latest data, DXCM has moved about 102.94% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.70%. This means that DexCom is performing better than its sector in terms of year-to-date returns. Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 92 individual stocks and currently sits at #65 in the Zacks Industry Rank. This group has gained an average of 4.65% so far this year, so DXCM is performing better in this area. Investors with an interest in Medical stocks should continue to track DXCM. The stock will be looking to continue its solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2018-12-28,29.625,30.1425,28.96,29.57,
DXCM,2018-12-31,29.805,30.44,29.635,29.95,
DXCM,2019-01-02,29.2525,29.5925,28.5,28.795,"[""The Best Performing Stocks Of 2018"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $135"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $135"", ""The Best Performing Stocks Of 2018"", ""Here's Why Tandem Diabetes Care Is Dropping Today What happened Shares of Tandem Diabetes Care (NASDAQ: TNDM) , a medical device company focused on diabetes, fell about 10% as of 2:15 p.m. EST on Wednesday. The decline is most likely attributable to negative sentiment from Wall Street related to a few of the company's peers. So what Here's an overview of some of the news that is impacting diabetes-focused medical device companies today: An analyst at Morgan Stanley lowered their price target on Insulet (NASDAQ: PODD) -- which competes directly with Tandem -- from $105 to $90 in a research report issued on Wednesday. Insulet's stock is down about 8% today in response. Morgan Stanley also lowered its price target on DexCom (NASDAQ: DXCM) -- a diabetes company focused on continuous glucose monitoring that works with Tandem -- to $135 from $150. Dexcom's stock is down about 4% in resopnse. An analyst at Citigroup lowered their rating on Medtronic (NYSE: MDT) -- which makes both insulin pumps and continuous glucose monitors -- to \""Neutral\"" from \""Buy,\"" and the price target was lowered to $96 from $109. Shares are falling about 3% in response. A paper was published in the journal Cell Metabolism stating that researchers have found that a new cocktail of drugs can help the body to reactivate insulin-producing cells. While it is still very early, this research could be an important step in curing diabetes. Add it all up, and it isn't surprising to see that Tandem's stock is getting whacked today, too. Now what 2018 was a remarkable year for Tandem, so it is possible that its shares are taking a step back today thanks to profit-taking now that investors won't be on the hook for capital gains tax until 2020. Regardless of the reason for today's drop, I see nothing that suggests the company is any different today than it was at the end of 2018. If you were bullish on Tandem just a few days ago, then there doesn't seem to be a reason to change your tune today. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $135"", ""The Best Performing Stocks Of 2018""]"
DXCM,2019-01-03,28.5725,29.0975,27.5825,28.065,"[""Here's Why Investors Should Bet on DexCom (DXCM) Right Now"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now"", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now DexCom, Inc.DXCM is currently one of the best-performing stocks in the Medical Instruments industry. Promising agreements with several companies and a strong guidance for 2018 are key drivers for the stock at the moment. DexCom currently carries a Zacks Rank #2 (Buy). Impressive Share Price Performance Over the past year, DexCom's shares have rallied 98.4% outperforming the industry's 5% gain. The current level also compares favorably with the S&P 500 index's 7.4% decline. What's Favoring the Stock? Bullish Outlook DexCom's raised 2018 guidance instill investors' optimism in the stock. Notably, the company expects revenues of $975 million, up from the previous projection of $925 million. The lucrative glucose monitoring industry also represents significant commercial opportunity for the company. Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to see a CAGR of 8% by 2024. Strategic Deals In a bid to fortify its foothold in the Type 2 diabetes space, DexCom recently announced a new amendment to its license deal with Verily - the life sciences unit of Alphabet GOOGL . With this deal, DexCom is expected to deliver its next-generation CGM (Continuous Glucose Monitoring) platform by the end of 2020. (read more: DexCom Amends Deal With Verily to Launch Advanced CGM by 2020 ). Last year, the company, along with UnitedHealthcare, announced an individualized glucose management pilot program driven by wearable technology to help people with Type 2 diabetes manage their condition in real time. Which Way Are Estimates Treading? The Zacks Consensus Estimate for DexCom's fourth-quarter 2018 earnings is pegged at 13 cents, reflecting a year-over-year increase of 30%. The same for revenues stands at $283.1 million, indicating a 28.1% decline year over year. For 2018, the Zacks Consensus Estimate is pegged at a loss of 12 cents. The same for revenues stands at $977.4 million. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote Bottom Line Buoyed by the solid prospects, the stock has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 are better picks than most. Other Key Picks Other top-ranked stocks in the broader medical space are Veeva Systems Inc. VEEV and Integer Holdings Corporation ITGR . Veeva Systems' long-term earnings growth rate is projected at 19.5%. The stock currently flaunts a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. Integer projects earnings growth rate of 31.2% for the fourth quarter. It currently carries a Zacks Rank #1. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Bet on DexCom (DXCM) Right Now""]"
DXCM,2019-01-04,28.545,29.57,28.2525,29.06,
DXCM,2019-01-07,31.3825,33.195,31.0,32.4875,"[""DexCom +4.1% as prelim Q4 revenue beats consensus"", ""AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife"", ""DexCom"", ""DexCom"", ""DexCom Sees FY2019 Sales $1.18B-1.23B vs $1.18B Est"", ""DexCom shares are trading higher after the company announced it expects preliminary Q4 sales to have increased 50% since last year."", ""DexCom shares are trading higher after the company announced it expects preliminary Q4 sales to have increased 50% since last year."", ""DexCom Sees FY2019 Sales $1.18B-1.23B vs $1.18B Est"", ""DexCom"", ""DexCom"", ""AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife"", ""DexCom +4.1% as prelim Q4 revenue beats consensus"", ""AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife AngioDynamics Inc.ANGO reported second-quarter fiscal 2019 adjusted earnings of 22 cents per share, which edged past the Zacks Consensus Estimate by a penny. The bottom line also surged 29.4% on a year-over-year basis. Revenues totaled $91.5 million, surpassing the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the metric increased 5.5%. A glimpse of the company's price trend reveals that AngioDynamics has outperformed the industry in a year's time. The stock has rallied 29.2% compared with the industry's 1.5% growth. The current level also compares favorably with the S&P 500 index's 7.6% decline. The stock currently carries a Zacks Rank #3 (Hold). Geographical Analysis In the quarter under review, U.S. net revenues totaled $71.9 million, up 5.2% year over year and at constant currency (cc). International revenues summed $19.6 million, up 6.6% year over year and 7.8% at cc. AngioDynamics, Inc. Price, Consensus and EPS Surprise AngioDynamics, Inc. Price, Consensus and EPS Surprise | AngioDynamics, Inc. Quote Segmental Analysis Vascular Interventions and Therapies (VIT) Business VIT revenues in the quarter grossed $52.4 million, up 2.2% from the year-ago quarter's figure. Per management, Fluid Management and AngioVac saw strong growth but were partially offset by a decelerating decline in the Venous Insufficiency business. Vascular Access (VA) Business Revenues at this segment amounted to $23.7 million, which surged 5.1% on a year-over-year basis. Per management, strong revenues of Ports and Dialysis products were slightly offset by a decline in revenues of PICCs. Oncology/Surgery Business Revenues at the Oncology segment improved 19.8% year over year to $15.3 million backed by strong NanoKnife revenues in both capital and disposables. The segment also saw positive contributions from the two recent acquisitions of BioSentry and RadiaDyne, which was somewhat offset by decreased revenues of the company's Thermal Ablation products. Excluding the impact of transition from the company's Acculis Microwave product to its Solero Microwave product, its Oncology business grew 28.7% year over year. Margin Analysis In the quarter under review, gross profit totaled $49.1 million, up 14.9% from the year-ago quarter number. Gross margin was 53.7%, up 440 basis points (bps). Adjusted operating income totaled $12.1 million, up 20% year over year. Adjusted operating margin was 13.2%, up 150 bps year over year. Guidance Retained For fiscal 2019, AngioDynamics continues to expect revenues in the range of $354-$359 million. The Zacks Consensus Estimate is pegged at $357.1 million, within the guided range. Adjusted earnings per share is expected between 82-86 cents. The Zacks Consensus Estimate is pinned at 85 cents, within the guided range. Free cash flow is projected within $26-$31 million for fiscal 2019. Wrapping Up AngioDynamics exited the fiscal second quarter on a solid note, with both earnings and revenues beating estimates. The company continues to gain from its core Oncology business unit that witnessed solid growth, courtesy of strong NanoKnife business. Per management, Fluid Management, AngioVac and Ports and Dialysis products also saw growth in the quarter. Recent acquisitions of BioSentry and RadiaDyne are contributing to the company's results as well. Targeted investments in the thrombus management portfolio indicate focus on innovation. Significant expansion in gross and operating margins is an added positive. The company retained its fiscal 2019 outlook. On the flip side, headwinds in the company's Venous Insufficiency business and sluggish show by the radiofrequency ablation products raise concerns. However, management stated that declines in Venous business line are decelerating. Additionally, PICCs revenues dipped in the quarter. Key Picks A few better-ranked stocks in the broader medical space are Veeva Systems Inc VEEV , athenahealth ATHN and DexCom DXCM . Veeva Systems' long-term earnings growth rate is projected at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . athenahealth's long-term earnings growth rate is projected at 17.7%. The stock carries a Zacks Rank #2 (Buy). DexCom's current-quarter earnings growth rate is projected at 30%. The stock carries a Zacks Rank of 2. 3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline. So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it. See them today for free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why DexCom Traded 11.8% Higher Today What happened After DexCom (NASDAQ: DXCM) reported preliminary fourth-quarter and full-year results for 2018, its shares rallied 11.8% higher at 3:30 p.m. EST on Monday. So what The leading manufacturer of continuous glucose monitors (CGM) used to monitor blood sugar levels in diabetics unveiled preliminary financial results for last quarter and the full year at the J.P. Morgan Healthcare Conference earlier today. The company expects to deliver $331 million in sales for Q4, up at least 50% year over year and significantly higher than the consensus Wall Street analyst estimate of $285 million. For the full year, revenue is forecast to exceed $1.025 billion, up over 42% from 2017. Additionally, it's guiding for revenue to increase 15% to 20% to between $1.175 billion to $1.225 billion in 2019. For perspective, analysts were projecting $1.18 billion in sales in 2019. The results reflect rising demand for its G6 CGM, a device that won approval last spring and that's included as part of Tandem Diabetes (NASDAQ: TNDM) t:slim X2 automated insulin delivery solution. Tandem's system relies on its t:slim X2 pump, DexCom's G6 CGM, and a sophisticated algorithm to automatically control insulin dosing based on real-time blood sugar data. Now what DexCom will report official results on Feb. 21 after the market closes , but it's unlikely that those figures will differ materially from the preliminary results reported today. The ability to automatically track blood sugar and dose insulin is a game-changing advance because it may help delay disease progression by helping patients remain within their desired glucose range more often. Currently, DexCom's only available with Tandem's automatic solution, but that could change in the future because it's also expected to be included in solutions being developed by insulin drug developer Eli Lilly & Co. (NYSE: LLY) and insulin pump maker Insulet (NASDAQ: PODD) . Also, DexCom is working on next-generation CGMs it's developing with Verily, a healthcare company backed by Alphabet . If those CGMs are cost-effective, it could expand DexCom's market beyond type 1 diabetics to type 2 patients who require multiple daily injections. A development like that would be significant given 30 million people have type 2 diabetes compared to 1.25 million with type 1 diabetes. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Todd Campbell owns shares of DexCom. His clients may have positions in the companies mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom shares are trading higher after the company announced it expects preliminary Q4 sales to have increased 50% since last year."", ""DexCom Sees FY2019 Sales $1.18B-1.23B vs $1.18B Est"", ""DexCom"", ""DexCom"", ""AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife"", ""DexCom +4.1% as prelim Q4 revenue beats consensus""]"
DXCM,2019-01-08,32.865,34.05,32.6525,32.88,
DXCM,2019-01-09,33.2175,34.79,33.2175,34.6875,
DXCM,2019-01-10,34.6875,35.505,34.5225,35.475,"FXH, DXCM, IONS, MD: Large Outflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $96.4 million dollar outflow -- that's a 4.6% decrease week over week (from 29,050,002 to 27,700,002). Among the largest underlying components of FXH, in trading today DexCom Inc (Symbol: DXCM) is up about 0.8%, Ionis Pharmaceuticals Inc (Symbol: IONS) is off about 0.6%, and Mednax, Inc. (Symbol: MD) is lower by about 0.5%. For a complete list of holdings, visit the FXH Holdings page » The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $63.8401 per share, with $85.3074 as the 52 week high point - that compares with a last trade of $71.28. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-01-11,35.475,35.685,34.95,35.275,"[""Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More"", ""Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More"", ""3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN The U.S. Medical Services industry is likely to embark onto a new era with the latest federal rule that has taken effect for hospitals since Jan 1. The rule mentions certain price transparency requirements for the U.S. hospitals, which are now asked to post a list of 'charge prices' on thousands of services. Analysts believe this will benefit patients as they would know the cost of medical services before committing to those. Meanwhile, over the past year, the Medical Services industry has rallied 13.7% against the S&P 500 index's 6.4% decline. Let's also find out some other factors that make the Medical Services space a prospective one for investors. Home-Based Care Boosts Medical Services The Medical Services industry essentially comprises third-party service providers and care givers that are appointed by core healthcare companies. Notably, these providers offer home-based services as well which have been slowly gaining popularity, backed by the growing old population in the United States. This includes medical social services, nursing care, home health aides and others. In fact, players from outside the space have joined as well. In 2018, retail bigwig Amazon AMZN also acquired online pharmacy PillPack, with an aim to offer prescription coordination and home delivery to consumers. Going by a report in CNBC, each day, about 10,000 seniors turn 65 in the United States. This has boosted the demand for home-based care in the country. Zion Market Research predicts the global home healthcare market to generate revenues of $391.41 billion by 2021, at a CAGR of 9.4%. The research further shows that North America has, by far, the largest share in the space and is set to continue its dominance till 2021. Reduced Regulatory and Tax Burdens Create Scope A significant reduction in regulatory and tax burden on U.S. healthcare companies is creating opportunities for mobile and wireless medical technology companies. DexCom's DXCM G6 Continuous Glucose Monitoring System deserves a mention in this regard. This apart, treatments are also becoming less invasive with shorter recovery times. Accordingly, terms like 'bed less hospitals' have become trend of the future. Third-party laboratory testing providers and contract research organizations are also recording increasing demand, thanks to the rising need for complex tests, services and clinical research. Clearly, medical services companies have opportunities of raking in huge profits. Choosing the Winning Stocks In a backdrop like this, the Zacks Rank and the Momentum Score come in handy. Using the Zacks Stock Screener , we have zeroed in on three Medical Services stocks. Notably, each of these stocks carry a Zacks Rank #2 (Buy) and have a Momentum Score of A or B. This reflects possibilities of outperformance at the moment. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Our research shows that stocks with a Momentum Score of A or B, when combined with a Zacks Rank #1 or 2, are better picks than most. Our first pick is HealthEquity, Inc.HQY which has a Momentum Score of A. The Utah-based healthcare services provider's fourth-quarter earnings growth rate is projected at a whopping 233.3%. HealthEquity is an Internal Revenue Service approved non-bank custodian of HSA, which is a medical savings account available to taxpayers in the United States. Interestingly, it has clinched the top position in the HSA (Health Savings Account) industry through its first-mover advantage, focus on innovation and differentiated capabilities. Additionally, for 2019, HealthEquity projects revenues of $281-$285 million, up from $279-$285 million anticipated earlier. Next on our list is Apollo Medical Holdings, Inc.AMEH having a Momentum Score of A. The California-based provider of healthcare services offers integrated care, inpatient and physician alignment solutions. The company's data-enabled clinical platform provides care for patients continuously, whether they are in the hospital, in a skilled nursing facility or at home. The company recently announced that its wholly-owned subsidiary, APA ACO, generated $12.96 million in gross savings in the first performance year (2017) and that, as a result, it achieved $5.90 million in shared savings from the Centers for Medicare & Medicaid Services. Investors may also consider OpGen, Inc.OPGN which has a Momentum Score of B. The Maryland-based microbial genetics analysis company's fourth-quarter earnings growth rate is projected at 68.4%. The company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. Last month, the company announced the submission of the final report for completion of the contract from the Centers for Disease Control and Prevention to develop smartphone-based clinical decision support solutions for antimicrobial stewardship and infection control in low and middle-income countries. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report HealthEquity, Inc. (HQY): Free Stock Analysis Report OpGen, Inc. (OPGN): Free Stock Analysis Report Apollo Medical Holdings, Inc. (AMEH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More""]"
DXCM,2019-01-14,35.1075,35.8275,35.0025,35.685,
DXCM,2019-01-15,35.87,37.1,35.5,36.7625,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Device makers in the green after BSX and EW settle patent fights"", ""Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?"", ""Varian Medical (VAR) to Report Q1 Earnings: What's in Store?"", ""Device makers in the green after BSX and EW settle patent fights"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?"", ""Varian Medical (VAR) to Report Q1 Earnings: What's in Store?"", ""3 Top Diabetes Stocks to Watch in January Diabetes affects tens of millions of Americans, and even more are at risk of developing diabetes, as they suffer from prediabetes. With such a large population suffering from the condition, it's clearly a disease that gets much attention and investment. We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . Diabetes and a lot more Keith Speights (Abbott Laboratories): While the broader market floundered in 2018, Abbott Labs turned in a great performance. Shares of the medical device company soared nearly 27%. The diabetes market was key to Abbott's success. In Abbott's Q3 earnings call in October, CEO Miles White highlighted the great launch for the company's Freestyle Libre continuous glucose monitoring (CGM) system that doesn't require finger sticks. White said that more than 1 million customers now use the product, an impressive number to achieve in a relatively short time. Sales for Freestyle Libre more than doubled year over year to over $300 million. Expect Freestyle Libre to continue to drive growth for Abbott in the future. The company also hopes to win U.S. approval to launch version two of the product, which includes an alarm feature that lets users know when their glucose levels are too low or too high. But Abbott Labs has a lot more going for it. The company is the global leader in minimally invasive surgical solutions for leaky heart valves. And Abbott continues to generate growth from its established pharmaceuticals, nutrition, and electrophysiology businesses. Abbott has two products to watch in addition to Freestyle Libre. The first is its MitraClip device for mitral valve repair. There's a lot of growth potential for MitraClip, especially if Abbott wins an expanded indication for the device (approval from the FDA for use in more situations). The company also has a pivotal study underway for a new product, Tendyne, that could enable the replacement of damaged mitral heart valves without open-heart surgery. Innovations like Freestyle Libre in diabetes and Tendyne in structural heart devices make Abbott Labs a stock to keep your eyes on -- in January and beyond. $40 million to $1 billion in 8 years Todd Campbell(DexCom): What does disruption look like to an investor? How about going from $40 million in annual sales to over $1 billion in annual sales in eight years? That's impressive, but it may only hint at the revenue opportunity ahead for DexCom, the leading maker of continuous glucose monitors (CGMs) for diabetes patients. In the past, patients with insulin-intensive diabetes had to rely on many finger sticks to provide point-in-time insight into blood sugar. Historically, the haphazard insight offered by finger sticks meant the average patient spent 70% of their time outside their desired blood sugar range, which put them at risk of new symptoms including cardiovascular disease, nerve damage, and blindness -- or even death. That's not the case anymore. Today, DexCom's CGMs provide real-time insight into blood sugar without the need for finger sticks, giving patients, caregivers, and doctors an unprecedented ability to manage disease. DexCom estimates its current addressable market of insulin-intensive type and type 2 diabetes patients is 3.2 million; however, advances that will make CGMs smarter, smaller, and cheaper could increase that market significantly. Addressing the gestational diabetes market could increase its target market by about 800,000 patients; monitoring patients in hospitals would add about 10 million patients; and serving the entire type 2 diabetes population expands the addressable population to roughly 27 million in the U.S alone. DexCom's $1.03 billion in sales grew 42% year over year, in part because its newest CGM, the G6, is a part of the automated insulin delivery device from Tandem Diabetes Care (NASDAQ: TNDM) . In 2019 sales are expected to grow up to 20% as the G6 launch spreads. Sales could accelerate even faster when DexCom's next CGM -- the G7 -- is launched in 2020. With double-digit growth on tap and a massive and growing market, I think DexCom's a great stock to consider adding to portfolios now. The biggest player in the insulin market Chuck Saletta(Novo Nordisk): Diabetes happens either because your own body can't produce insulin (type 1) or because your body has become resistant to the insulin it does produce (type 2). For patients suffering from type 1 diabetes and many who suffer from type 2, treatment with insulin is a critical part of managing the disease. With over 100 million Americans suffering from either diabetes or prediabetes, it's clearly a huge disease -- and insulin is a huge part of fighting it. That's what makes Novo Nordisk an incredibly important company to watch. Novo Nordisk produces about half the insulin sold commercially around the world. That makes it something of a barometer when it comes to the overall state of the diabetes industry, and certainly makes it worth watching for investors interested in treating the condition. Its large market position in the fight against a huge disease gives Novo Nordisk a certain amount of pricing power. It recently increased prices on its insulin products by around 5%, showcasing its belief that it will be able to maintain its strong market position despite those higher prices. While there's talk of a potential cure for Type 1 diabetes on the horizon, the unfortunate likelihood is that diabetes will be with us for a long time to come. And should a cure actually come about, chances are decent that Novo Nordisk will play a role there too. That makes Novo Nordisk a contender for consideration not just for this month, but for the long haul as well. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Chuck Saletta has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. Todd Campbell owns shares of DexCom. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Varian Medical (VAR) to Report Q1 Earnings: What's in Store? Varian Medical Systems Inc. 's VAR first-quarter fiscal 2019 results are scheduled to release on Jan 23, after market close. A strong overseas presence and product launches are likely to favor the company's fiscal first-quarter results. Last-Quarter Results In the las t report ed quarter, Varian Medical's adjusted earnings of $1.16 per share missed the Zacks Consensus Estimate of $1.19. Adjusted earnings however improved 11.5% on a year-over-year basis. Revenues totaled $801.6 million, which beat the consensus mark of $762.7 million. On a year-over-year basis, revenues rose 11.1% or 12% at constant currency. Which Way Are Estimates Treading? Currently, the Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $717.9 million, reflecting a rise of 5.8%. The same for adjusted earnings is pinned at $1.06. Let's discuss the factors that are likely to impact Varian Medical's upcoming quarterly results. Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Strong International Presence Varian Medical enjoys a significant global presence. Last November, the company's coveted Halcyon system has been approved by the China National Medical Product Administration. (Read More: Varian Medical's Halcyon Gets NMPA Approval in China ) In October, Varian Medical's Advanced Radiotherapy Clinical School will run courses at India-based Reliance Group's flagship Kokilaben Dhirubhai Ambani Hospital (KDAH) in Mumbai. (Read More: Varian & Reliance Group Tie Up to Enhance Cancer Care ) In September, the company collaborated with Kenya's Mediheal Group of Hospitals to expand radiotherapy access in the country. (Read More: Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals ) Product Launches Last October, Varian Medical announced a new single-room proton therapy system, ProBeam 360\u00b0, which enables efficient Intensity Modulated Proton Therapy and faster treatment by minimizing patient repositioning and re-imaging. Additionally, the company launched Bravos system for High Dose Rate (HDR) brachytherapy treatments, a result of five years of in-clinic research. Notably, the system is designed to improve patient and clinic experience by simplifying brachytherapy treatment. Reflective of these factors, Varian Medical has issued a solid fiscal 2019 guidance, with revenue growth expected in the range of $3.06-$3.15 billion, reflecting 5-8% growth year over year. The Zacks Consensus Estimate for revenues is pegged at $3.10 billion, within the guided range. Adjusted earnings per share are projected in the range of $4.60-$4.75. The Zacks Consensus Estimate for earnings is pegged at $4.96, within the range. Earnings Whispers Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below. Earnings ESP: Varian Medical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Varian Medical carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. PerkinElmer PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. Baxter International BAX has an Earnings ESP of +1.15% and a Zacks Rank #3. DexCom DXCM has an Earnings ESP of +23.03% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Device makers in the green after BSX and EW settle patent fights"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?"", ""Varian Medical (VAR) to Report Q1 Earnings: What's in Store?""]"
DXCM,2019-01-16,36.9625,37.3575,36.41,36.7625,"[""Here's Why Momentum Investors Will Love DexCom (DXCM)"", ""Here's Why Momentum Investors Will Love DexCom (DXCM)"", ""Here's Why Momentum Investors Will Love DexCom (DXCM)""]"
DXCM,2019-01-17,36.805,37.745,36.6575,37.375,
DXCM,2019-01-18,37.6875,38.1725,37.295,37.38,
DXCM,2019-01-22,37.25,38.11,36.85,37.705,"ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio ResMed Inc.RMD recently expanded its AirFit mask portfolio with the introduction of its first top-of-head-connected nasal CPAP mask, AirFit N30i, in the United States. The product is already available across Canada, Australia, New Zealand and most of Europe with more launches planned in other geographies, scheduled for late 2019. AirFit N30i in Detail This device has a top-of-head connection that keeps tubing out of the wearers' way, letting them comfortably move and sleep in any position. Its nasal cradle cushion reduces facial markings and irritation. Per the company, in comparison to other popular nasal top-of-head masks, three of four users preferred AirFit N30i over the traditional ones. Market Potential Globally, over 100 million are estimated to be afflicted with sleep apnea (per an article published in The Sleep Zone). This increasing incidence has driven demand for sleep apnea devices. Per a MarketsandMarkets report by, the global sleep apnea devices market is expecting a CAGR of 7.8% to reach $6.49 billion between 2018 and 2023. Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with expanded treatment options are anticipated to continue driving demand for sleep apnea devices. In view of this data, we believe, the latest development will help ResMed cash in on opportunities in this niche market. Stress on Innovation In order to maintain its leadership position in the sleep disordered breathing (SDB) market and to boost its sales base, ResMed is focusing on product development and innovation. In this regard, the company earlier unveiled its first minimal-contact full face CPAP mask - AirFit F30. Further, ResMed consistently sees a strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally. Share Price Performance Over the past year, shares of ResMed have outperformed its industry . The stock has rallied 17.5% against the industry's decline of 3.2%. Zacks Rank and Key Picks ResMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Veeva Systems VEEV , Omnicell, Inc. DXCM and Illumina, Inc. ILMN . Veeva Systems' long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Omnicell's long-term earnings growth rate is projected at 11.8%. The stock carries a Zacks Rank #2 (Buy). Illumina's long-term earnings growth rate is expected at 23.4%. The stock has a Zacks Rank of 2. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-01-23,37.5,37.865,35.69,36.635,"Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings? PerkinElmer, Inc.PKI is expected to release fourth-quarter 2018 results on Jan 31, after market close. The quarterly result should reflect steady growth in the core Diagnostics business. Meanwhile, a raised earnings view for 2018 is encouraging. Q3 Results at a Glance PerkinElmer reported third-quarter 2018 adjusted earnings per share of 90 cents, which fell short of the Zacks Consensus Estimate by 2.2%. However, the bottom line grew 23.3% from the year-ago quarter figure. Revenues in the quarter came in at $674.3 million, missing the Zacks Consensus Estimate by 0.02% but improved 21.7% on a year-over-year basis. Adjusted revenues totaled $674.5 million, which increased 21.6% year over year. In the trailing four quarters, PerkinElmer delivered average positive earnings surprise of 2.5%. Which Way Are Estimates Treading? For the quarter to be reported, the Zacks Consensus Estimate for earnings per share is pegged at $1.16, mirroring 19.6% improvement year over year. The same for revenues stands at $746.2 million, reflecting growth of 16.3% year over year. Let's see how things are shaping up before the earnings results. PerkinElmer, Inc. Price and EPS Surprise PerkinElmer, Inc. Price and EPS Surprise | PerkinElmer, Inc. Quote Diagnostics Revenues: A Key Catalyst We expect PerkinElmer's Diagnostics segment to be the major growth driver for fourth-quarter 2018 results. Notably, the company's immunodiagnostics and applied genomics business lines are the key contributors to Diagnostics revenues. Acquisitions of Tulip and Haoyuan should also play a major role. PerkinElmer also provides digital x-ray flat panel detectors and infectious disease testing solutions in its Diagnostics portfolio. In the las t report ed quarter, the segment accounted for 38.8% of total revenues, which grew 58.8% on a year-over-year basis. It is encouraging to note that for the fourth quarter, the Zacks Consensus Estimate for the segment's revenues is pinned at $290 million, mirroring 50.3% improvement year over year. Other Factors at Play Fourth-Quarter Guidance For the fourth quarter of 2018, management forecasts reported revenues of $745 million, representing 16% year-over-year growth. The guidance assumes approximately 5% core organic revenue growth and $102 million sales from EUROIMMUN. Earnings is predicted to come in at $1.16, indicating 20% increase on a year-over-year basis. This forecast includes an additional 4-cent headwind from foreign exchange. DAS - A Key Contributor PerkinElmer has been consistently experiencing strong customer uptake of both new imaging and analytical instrumentation in the Discovery & Analytical Solutions (DAS) segment. This trend is likely to continue in the to-be-reported quarter as well. Additionally, the fourth quarter is likely to witness strength in life sciences and applied end markets in DAS. Life sciences strength is likely to be driven by solid performance in the pharma biotech end market. Notably, PerkinElmer's new in vivo imaging products, launched in late 2017, should also bolster the DAS segment's performance in the fourth quarter. For investors' notice, DAS accounted for 60.2% of revenues in the last reported quarter. Revenues at this segment totaled $406.2 million, reflecting a 5.4% rise from the year-ago quarter. Per management, the segment saw organic growth of 7% in the third quarter. For the quarter to be reported, the Zacks Consensus Estimate for the segment's revenues stands at $457 million, reflecting a 2% improvement year over year. What Does Our Model Say? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is precisely the case here. Earnings ESP : PerkinElmer has an Earnings ESP of +0.77%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank : PerkinElmer carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter. Intuitive Surgical, Inc. ISRG has an Earnings ESP of +2.63% and a Zacks Rank #2. Illumina, Inc. ILMN has an Earnings ESP of +1.83% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here . DexCom DXCM has an Earnings ESP of +0.90% and a Zacks Rank #2. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs. See Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Get Free Report DexCom, Inc. (DXCM): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-01-24,36.795,36.975,35.9475,36.02,"[""Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally"", ""PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong"", ""NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y"", ""Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid"", ""Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?"", ""Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?"", ""What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?"", ""Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?"", ""NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y"", ""What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?"", ""Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?"", ""Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally"", ""PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong"", ""Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid"", ""NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y NextGen Healthcare, IncNXGN reported third-quarter fiscal 2019 adjusted earnings of 20 cents per share, up from 15 cents reported in the year-ago quarter. Under ASC 605, the company registered pro forma adjusted earnings of 18 cents per share. Notably, both the metrics exceeded the Zacks Consensus Estimate of 15 cents. Revenues totaled $130.9 million, down 0.6% year over year. Under ASC 605, revenues for the fiscal third quarter summed $130.3 millionon a pro forma basis. The Zacks Consensus Estimate stands at $130.8 million. Bookings Update Per management, this Zacks Rank #3 (Hold) company witnessed consistent momentum in quarterly bookings, which improved 8% year over year to $32.8 million in the reported quarter. Management stated that the company's growing pipeline and coveted RCM (Revenue Cycle Management) services platform mainly drove bookings. However, bookings decreased on a sequential basis. Segment Details The company reported third-quarter fiscal 2019 revenues under the following segments: Total Recurring revenues grossed $117.4 million, down 1.3% from the year-ago quarter's figure. Meanwhile, total Software, hardware and other non-recurring revenues came in at $13.42 million, up 5.5% on a year-over-year basis. This uptick was driven by large professional consulting engagements. Gross Margin In the quarter under review, gross profit totaled $69.2 million, down 1.3% from the prior-year quarter's tally. Gross margin was 52.9%, down 30 basis points (bps). Per management, the company shifted away from high margin maintenance revenues toward the lower margin services. Fiscal 2019 View For fiscal 2019, NextGen expects revenues of $525-$535 million, in line with the previously-issued guidance. The Zacks Consensus Estimate for revenues is pegged at $530.4 million, which is within the current guidance. Full-year earnings per share is expected between 72 cents and 76 cents, higher than the previous projection of 70 cents and 74 cents. Summing Up NexGen ended the fiscal third quarter on a positive note, with adjusted earnings exceeding the Zacks Consensus Estimate. NextGen rides on Software, hardware and other non-recurring unit. Management presently foresees solid growth prospects in the RCM pipeline as well. Moreover, the NextGen population health analytics suite and NextGen mobile platform registered significant growth. Solid bookings too deserves a mention. For investors' notice, the company expects high-single digit revenue growth by fiscal 2020, mirroring strong leverage in 2021 and 2022 as well. For fiscal 2022, the company expects 20% operating margin. However, the plummeting gross profit is a negative. Sluggishness in the recurring revenue segment in recent times adds to the woes. Additionally, NextGen faces stiff rivalry in the MedTech space. Upcoming Releases A few better-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for adjusted earnings per share is pegged at 42 cents and the same for revenues is $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted earnings per share is pegged at 94 cents and for revenues it stands at $200.6 million. The stock has a Zacks Rank #2 (Buy). DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for fourth-quarter adjusted EPS is pinned at 14 cents and for revenues it stands at $330.6 million. The stock carries a Zacks Rank of 2. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's Setting the Tone for Hologic's (HOLX) Q1 Earnings? Hologic, Inc.HOLX is slated to report first-quarter fiscal 2019 results on Jan 30, after the closing bell. The company's earnings surpassed the Zacks Consensus Estimate in two of the past four quarters, the average beat being 3.5%. Let's see how things are shaping up prior to this announcement. Key Catalyst Hologic recently announced preliminary revenue results for first-quarter fiscal 2019. The company projects an impressive performance in the quarter and expects to surpass its expectations on the revenue front. Per the preliminary announcement, Hologic expects total revenues to increase approximately 5% (up 5.7% at constant exchange rate or CER) on a year-over-year basis to $831 million in the to-be-reported quarter, well ahead of the Zacks Consensus Estimate of $818.4 million. This also exceeds the company's earlier provided revenue guidance of $800-$815 million. Solid top line is primarily expected on the back of growth across a majority of Hologic's segments. (Please read: Hologic Stock Rides on Impressive Preliminary Q1 Result ) Hologic is optimistic about riding on strength in the Breast Health segment in the to-be-reported quarter. There has been consistent rise in market share within Breast Health on the back of direct-to-consumer initiatives, introduction of products, and software and services along with strong mammography systems portfolio. Hologic, Inc. Price and EPS Surprise Hologic, Inc. Price and EPS Surprise | Hologic, Inc. Quote Management seems upbeat about the buyout of Focal Therapeutics and Faxitron Bioptics. These acquisitions are aimed to broaden the Breast Health portfolio and strengthen Hologic's position in the breast-conserving surgery market. Additionally, the company's adoption of mammography systems, 3Dimensions and 3D Performance encourages us. These products started to leverage the company's Genius brand and encouraged customers to upgrade their existing 2D systems. In this regard, the receipt of PMA from the FDA for Clarity HD high-resolution 3D imaging and Intelligent 2D imaging technology is noteworthy. These products are now available in the 3Dimensions breast tomosynthesis system. Further, global sales of interventional breast products - mainly biopsy systems and disposables - have been rising consistently. Increase in Affirm prone table sales is another positive. The company projects that Brevera, new real-time biopsy system, will continue to drive growth in fiscal 2018. Hologic also has a CE Mark for the Brevera breast biopsy system, with CorLumina imaging technology, real-time breast biopsy and verification system. As per the preliminary result, Hologic expects to report Breast Health (39.1% of total revenues) revenues of $325 million, up 12.8% on a year-over-year basis. The Zacks Consensus Estimate for interventional breast solutions revenues is pegged at $61 million, marking rise of 17.3% from the prior-year quarter. The consensus estimate for Mammography/Breast Care revenues is pegged at $319 million, which reflects an increase of 10.8% from the year-ago quarter. Other factors that are likely to influence Hologic's results in the fiscal first quarter are as follows: The company expects the Diagnostics segment to maintain a stellar performance on strength in the Molecular Diagnostics business. In the United States, it is likely to gain from increasing market share and utilization of the Panther system along with market expansion by conforming to testing guidelines. Global growth in the Molecular Diagnostics segment can be attributed to the Panther system, Hologic's fully-automated molecular diagnostics instrument. In October, Hologic boosted its portfolio of respiratory assays available for Panther Fusion, with the receipt of CE mark for its Panther Fusion Bordetella assay. Moreover, the company's receipt of FDA approval for its Group B Streptococcus (GBS) assay on the Panther Fusion system encourages us. The frequent utilization of Aptima women's health assays is another catalyst. Notably, Aptima assays gained a huge customer base, with respect to testing for chlamydia and gonorrhea, HPV (human papillomavirus), and trichomonas. We are also hopeful about Hologic's expanded market for sexually transmitted disease testing. The company is seeing strong demand for virology tests as well. A similar trend is expected to be maintained in the to-be-reported quarter. As per the preliminary result, Hologic expects to report Diagnostics (35.7% of total revenues) revenues of $297 million, up 4.2% on a year-over-year basis. The Zacks Consensus Estimate of $160 million for Molecular Diagnostics revenues reflects an increase of 7.4% from the year-ago quarter. Management is highly optimistic about international performance as well. During the fourth quarter of fiscal 2018, international revenues rose 4.5%, primarily on strong contribution from the Molecular Diagnostics, Breast Health and Gyn Surgical businesses. This trend is expected to continue in the to-be-reported quarter. On the flip side, Hologic has faced challenges like unfavorable foreign currency movement over the past few quarters. Escalating operating expenses and intense competition, particularly in the tomosynthesis market, are persisting headwinds. What Our Model Suggests Per the proven Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has higher chances of beating estimates if it also has a positive Earnings ESP . Hologic currently has a Zacks Rank #3 and an Earnings ESP of +2.19%. The combination hints that the company is likely to post a beat for this earnings season. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . The Zacks Consensus Estimate for earnings of 57 cents reflects 3.6% rise on a year-over-year basis. Other Stocks Worth a Look Here are a few other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter. PerkinElmer PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. Illumina, Inc. ILMN has an Earnings ESP of +0.32% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings? Baxter International Inc.BAX is scheduled to report fourth-quarter 2018 earnings on Jan 31, before the market opens. We expect the company to see steady growth on the back of strength in its core Renal Care segment. A strong earnings view for 2018 also buoys optimism. Q3 Results at a Glance In the las t report ed quarter, Baxter posted adjusted earnings per share of 80 cents, which surpassed the Zacks Consensus Estimate by 8.1% and improved from the year-ago quarter by 25%. Revenues totaled $2.77 billion, which marginally missed the Zacks Consensus Estimate of $2.79 billion. Revenues improved 2.2% on a year-over-year basis and 3% at constant currency (cc). Baxter has an average positive earnings surprise of 9.5% for the trailing four quarters. Which Way Are Q4 Estimates Treading? The Zacks Consensus Estimate for fourth-quarter earnings per share is pegged at 73 cents, showing a year-over-year increase of 14.1%. The same for revenues is pinned at $2.80 billion, reflecting a rise of 1% year over year. Let's see how things are shaping up before the earnings results. Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Renal Care in Focus Baxter's Renal Care segment, which offers improved dialysis solutions for patients, is expected to drive fourth-quarter results. In the last reported quarter, revenues in the unit grossed $910 million, accounting for 32.9% of the quarterly sales. It is encouraging to note that, the Zacks Consensus Estimate for the unit's fourth-quarter revenues is pegged at $951 million, reflecting a sequential rise of 4.5%. The Zacks Consensus Estimate for the segment's U.S. revenues is pinned at $212 million, up 1.4% sequentially. Meanwhile, the same for the segment's international sales stands at $728 million, mirroring a sequential rise of 3.9%. In fact, last October, Baxter and Mayo Clinic inked a collaboration agreement to form an outpatient clinic for chronic kidney disease management. (Read More: Baxter Collaborates With Mayo Clinic to Open Renal Care Center ) Additionally, management expects Renal Care to see revenue growth of 3-4% in 2018. Other Factors at Play View Impressive For the quarter to be reported, Baxter expects adjusted earnings per share within 71-73 cents. Clinical Nutrition & Advanced Surgery Likely to Drive Q4 Baxter's Clinical Nutrition and Advanced Surgery segments form a major part of the company's business. In the last reported quarter, Clinical Nutrition revenues totaled $218 million, contributing 7.9% to quarterly sales, while Advanced Surgery sales were $200 million, accounting for 7.2%. It is encouraging to note that, the Zacks Consensus Estimate for the Clinical Nutrition's fourth-quarter sales stands at $223 million, while the same for Advanced Surgery is pinned at $202 million. For Advanced Surgery, Baxter estimates revenue growth of 10% at constant currency. Additionally, these segments have seen developments in recent times. For instance, last October, Baxter and the American Society for Parenteral and Enteral Nutrition (ASPEN) launched an educational video series on the appropriate use of parenteral nutrition (PN). (Read More: Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition ) Last November, Baxter unveiled Peri-Strips Dry stapler and Tisseel Prima syringe at the 2018 American Society for Metabolic and Bariatric Society Obesity Week meeting. (Read More: Baxter Launches Peri-Strips & Tisseel Prima, Shares Up ) We believe such trends are likely to favor the company this season. What Does Our Model Say? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. This is exactly the case here. Earnings ESP: Baxter has an Earnings ESP of +1.83%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Baxter carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision. Other Stocks Worth a Look Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter. Intuitive Surgical ISRG has an Earnings ESP of +2.63% and a Zacks Rank #2. PerkinElmer PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally Varian Medical Systems, Inc. 's VAR first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate. Adjusted earnings were in line with the year-ago quarter figure. Revenues totaled $741 million, which outpaced the consensus mark of $717.9 million. On a year-over-year basis, revenues rose 9.2% and 10% at constant currency (cc). Quarterly revenues were negatively impacted by $8 million. Meanwhile, the Zacks Rank #3 (Hold) stock has rallied 12.1% compared with the industry 's 4.1% rise. The current level also compares favorably with the S&P 500 index's 7.1% decline. Let's delve deeper into the company's quarterly results. Halcyon Drives Revenues In the first quarter, the Halcyon platform received 20 new orders. Since its launch, Varian has received 202 orders worldwide. The recent approval from China National Medical Product Administration has expanded the global availability of Halcyon. Varian Medical Systems, Inc. Price, Consensus and EPS Surprise Varian Medical Systems, Inc. Price, Consensus and EPS Surprise | Varian Medical Systems, Inc. Quote Segment Details Oncology Systems: In the first quarter, revenues in the segment totaled $702.5 million, up 8% year over year and 9% at cc. Excluding the impact of tariffs, revenues were up 9% year over year. Varian's worldwide net installed base had 8,918 units, up 322 units on a year-over-year basis. As a whole, gross orders grew 16% from the year-ago quarter, marking the highest growth in a decade. Geographically, gross orders in Americas increased 12% on a year-over-year basis. In EMEA, gross orders rose 15% year over year, marking the sixth consecutive quarter of double-digit growth. In APAC, gross orders increased 25% year over year on strength in China. Operating earnings in the segment declined 10% year over year owing to the impact of tariffs. Proton Solutions: Revenues at the segment climbed 32% on a year-over-year basis to $38.5 million. Per management, this was driven by clinical handovers, representing an important future recurring revenue source for the segment. Margins Total gross profit in the reported quarter was $316.1 million, up 4.4% year over year. Gross margin in the reported quarter was 42.7% of net revenues, down 190 basis points (bps) on a year-over-year basis. Research and development expenses rose 8.9% year over year to $60.9 million. Selling, general and administrative expenses fell 4% year over year to $120.5 million. Adjusted operating income in the fiscal first quarter totaled $120.2 million, down 4.6% year over year. As a percentage of revenues, adjusted operating margin was 16.2% down 240 bps. Guidance Reiterated Varian has kept its guidance for fiscal 2019 intact. For fiscal 2019, year-over-year revenue growth is expected in the range of $3.06-$3.15 billion, up 5-8% year over year. The Zacks Consensus Estimate for revenues is pegged at $3.10 billion, within the guided range. Adjusted operating earnings, as a percentage of revenues, is projected in the band of 17-18%. Adjusted ne t earnings per share are expected in the range of $4.60 to $4.75. The Zacks Consensus Estimate for earnings is pegged at $4.69, within the guided range. Cash flow from operations is expected in the band of $460-$510 million for the fiscal. Wrapping Up Varian ended the first quarter of fiscal 2019 on a strong note. While earnings met estimates, revenues outpaced the same. The company continues to gain from its core Oncology Segment, which saw solid overseas growth in the quarter. Strength in China buoys optimism. In fact, management foresees tremendous opportunities in China for Varian's radiation therapy products. The company's flagship Halcyon system was granted exclusion from tariffs which is a major positive. Additionally, new proton therapy products are slowly building momentum for Varian's Proton Solutions business. On the flip side, Varian's gross and operating margins contracted in the quarter. The U.S.-China tariffs also impacted the top line. Resultantly, the Oncology segment's operating income declined in the quarter. The company competes with large electronic companies as well as smaller and more specialized radiation therapy equipment manufacturers. Key Picks A few better-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for the period's adjusted earnings per share is pegged at 42 cents and the same for revenues is $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 94 cents and for revenues it stands at $200.6 million. The stock has a Zacks Rank #2 (Buy). DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for adjusted EPS for the to-be-reported quarter is 14 cents and for the top line, it stands at $330.6 million. The stock carries a Zacks Rank of 2. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong PetMed Express, Inc.PETS announced earnings per share (EPS) of 38 cents in the third quarter of fiscal 2019, down from the year-ago quarter's 44 cents. The year-over-year decline was largely due to a drop in gross profit margin. Net sales in the reported quarter remained flat year over year at $60.1 million. In the reported quarter, reorder sales increased 4.6% to $53.3 million on a year-over-year basis, while new order sales declined 26.1% to $6.8 million. Per the company, growing online rivalry affected new order sales. Average order value was approximately $84 in the quarter compared with $86 a year ago. The decline can be attributed to more aggressive pricing. Per the company, the seasonality in its business is mainly because of the proportion of flea, tick and heartworm medications in the product mix. Spring and summer are considered peak seasons, while fall and winter represent off-seasons. PetMed Express, Inc. Price, Consensus and EPS Surprise PetMed Express, Inc. Price, Consensus and EPS Surprise | PetMed Express, Inc. Quote During the quarter under review, PetMed acquired 81,000 new customers compared with 106,000 a year ago. Gross margin contracted 420 basis points (bps) year over year to 32.3% in the quarter under review. The contraction was mainly led by extra discounts provided to the consumers. General and administrative expenses remained almost flat year over year at $5.8 million. However, advertising expenses declined 12.2% to $3.6 million. Adjusted operating margin (without including depreciation expenses) declined 340 bps to 16.6% from the year-ago quarter. PetMed exited the fiscal third quarter with cash and cash equivalents of $93.2 million, compared with $87.1 million at the end of second-quarter fiscal 2019. The company also declared a quarterly dividend of 27 cents per share, payable to shareholders on record as of Feb 15, 2019. Our Take PetMed's fiscal third-quarter earnings were hit by growing competition which forced the company to offer additional discounts to customers. This also had a negative impact on gross margin. However, the company expects to gain momentum in the online market by opting for more aggressive pricing and promotion strategies and shelling out more on advertisements. Key Picks A few top-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for the period's adjusted EPS is 42 cents and for revenues, $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 94 cents and for revenues stands at $200.6 million. The stock has a Zacks Rank #2 (Buy). DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for adjusted EPS for the to-be-reported quarter is 14 cents and for the top line, $330.6 million. The stock carries a Zacks Rank of 2. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. The bottom line improved 9.5% year over year and fell within the company's guided range of 80-82 cents. Reported earnings from continuing operation in the quarter came in at 37 cents against the year-ago loss of 48 cents per share. Full-year adjusted EPS was $2.88, a 15.2% improvement from the year-ago period. However, it missed the Zacks Consensus Estimate by a penny. Fourth-quarter worldwide sales came in at $7.77 billion, up 2.3% year over year on a reported basis. The top line remained slightly below the Zacks Consensus Estimate of $7.79 billion. On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments), sales increased 6.4% year over year in the reported quarter. For 2018, sales were $30.6 billion, up 11.6% on a reported basis and up 7.3% on an organic basis from 2017. The top line remained in line with the Zacks Consensus Estimate. Quarter in Detail Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion. This included an 8.4% adverse impact from currency fluctuations. Sales in the key emerging markets declined 6.2% year over year on a 10.5% adverse impact of foreign exchange. Organically, sales improved 4.3% in this market. The Medical Devices business sales increased 6.7% on a reported basis to $2.92 billion. On an organic basis, sales grew 9%. Cardiovascular and Neuromodulation sales reportedly (up 4.8% on an organic basis) rose 6.7% on double-digit growth in Electrophysiology and Structural Heart.In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation catheters. Within Structural Heart, growth was driven by several product areas across Abbott's broad portfolio, including AMPLATZERPFO Occluder and MitraClip. Diabetes Care sales improved 28.3% (up 32.4% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. Nutrition sales were down 0.4% year over year on a reported basis (up 3.6% on an organic basis) to $1.78 billion. Pediatric Nutrition sales increased 3.7% on an organic basis. Adult Nutrition sales were up 3.5% organically. Diagnostics sales were up 2.9% year over year on a reported basis (up 7.4% on a comparable operational basis) to $1.96 billion. Core Laboratory Diagnostics sales grew 9.4% while Point of Care Diagnostics slipped 5.1%, on an organic basis. Molecular Diagnostics sales were up 3.8% banking on strong growth in the infectious disease testing business. Rapid Diagnostics recorded sales of $548 million, driven by solid contributions from cardiometabolic testing. 2019 Guidance Abbott has initiated its 2019 guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are expected in the band of $3.15-$3.25. The Zacks Consensus Estimate of $3.19 remains within this projected range. Organic sales growth is expected in the range of 6.5% -7.5%. The Zacks Consensensus Estimate for the top line is pegged at $32.03 billion. The company has also provided first-quarter 2019 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 60-62 cents. The consensus mark of 66 cents falls outside the predicted range. Our Take Abbott exited the fourth quarter on a mixed note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark on a close margin. Increasing currency headwinds to some extent dented the company's international performance. Overall, we are optimistic about Abbott's strong and consistent EPD and Medical Devices performance organically. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Also, solid contributions from the company's other two businesses encourage us. Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments. Zacks Rank & Key Picks Abbott currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for the period's adjusted EPS is 42 cents and for revenues, $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy). ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 94 cents and for revenues stands at $214 million. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for adjusted EPS for the to-be-reported quarter is 14 cents and for the top line, $330.5 million. The stock carries a Zacks Rank of 2. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?"", ""NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y"", ""What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?"", ""Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?"", ""Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally"", ""PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong"", ""Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid""]"
DXCM,2019-01-25,36.1525,36.82,35.6925,36.2525,"[""What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?"", ""What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?"", ""ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates ResMed Inc. RMD announced second-quarter fiscal 2019 adjusted earnings per share (EPS) of $1, in line with the year-ago number. The adjusted earnings, however, beat the Zacks Consensus Estimate by 5.3%. Including one-time items, ResMed delivered EPS of 86 cents in the quarter under review as compared to 7 cents a year ago. A Closer View of the Top Line Revenues in the reported quarter increased 8% year over year (up 9% at constant exchange rate or CER) to $651.1 million. The figure, however, missed the Zacks Consensus Estimate of $667 million. On a geographic basis, excluding Software as a Service, revenues in the United States, Canada and Latin America totaled $358.5 million, reflecting a 9% increase over the prior-year period. Revenues from Software as a Service in the quarter under consideration summed $63.2 million, up 63% year over year. Revenues in the combined EMEA and APAC region were $229.4 million, highlighting a 1% rise at CER from the year-earlier tally. ResMed Inc. Price, Consensus and EPS Surprise ResMed Inc. Price, Consensus and EPS Surprise | ResMed Inc. Quote Excluding the MatrixCare purchase accounting deferred revenue fair value adjustment, the adjusted gross margin for the fiscal second quarter was 59.1%, a 90-basis point expansion from the year-ago number. Selling, general and administrative expenses were up 6.4% year over year to $161.6 million while Research and Development expenses increased 6.1% to $43.1 million. This in turn, induced a 6.4% rise in adjusted operating expenses, which amounted to $204.7 million. However, adjusted operating margin in the reported quarter rose 133 bps to 27.5%. Financial Updates ResMed exited second-quarter fiscal 2019 with cash and cash equivalents of $149.5 million compared with $230.2 million at the end of fiscal 2018. Year to date, the company generated $177.6 million of cash flow from operations compared with the year-ago figure of $226.5 million. Along with the earnings release of fiscal second quarter, ResMed approved a quarterly dividend of 37 cents per share, same as the previous payout. The dividend is payable Mar 14, 2018 to shareholders of record as of Feb 7, 2018. Given its recent acquisitions including MatrixCare and Propeller Health, the company has suspended its share buyback program. Outlook Assuming current exchange rates and likely trends in product and geographic mix, ResMed expects its gross margin for the second half of fiscal 2019 to be broadly consistent with its year-ago gross margin.SG&A as a percentage of revenues is expected to be within 25% for the second half of the current fiscal year. Meanwhile, R&D expenses as a percentage of revenues is projected to be in the range of 7-8% for the second half of fiscal 2019. Our Take ResMed exited the second quarter of fiscal 2019 on a dull note with earnings matching the Zacks Consensus Estimate and revenues missing the mark. The company registered growth at CER across all geographical regions. However, in this quarter, device sales in France and Japan were impacted as customers completed their connected device upgrade programs.The company expects this impact to persist in the next few quarters. Overall, the company achieved high-single-digit global revenue growth in the reported quarter, led by strong sales from Software-as-a-Service businesses as well as new mask products and devices. Within Software-as-a-Service, the company recorded steady growth in Brightree service offerings and incremental contribution from the buyouts of MatrixCare and HEALTHCAREfirst. Zacks Rank & Key Picks ResMed carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are BioTelemetry, Inc. BEAT , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . BioTelemetry is expected to release fourth-quarter 2018 results on Feb 28. The Zacks Consensus Estimate for the period's adjusted EPS is 42 cents and for revenues, $103.02 million. The stock sports a Zacks Rank #1 (Strong Buy). ABIOMED is expected to release fourth-quarter fiscal 2018 results on Jan 31. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 94 cents and for revenues stands at $214 million. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. DexCom is slated to release fourth-quarter 2018 results on Jan 26. The Zacks Consensus Estimate for adjusted EPS in the to-be-reported quarter is 14 cents and for the top line, $330.5 million. The stock carries a Zacks Rank of 2. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards? AmerisourceBergen Corporation 's ABC first-quarter fiscal 2019 results are scheduled to release on Jan 31. While the company's core Pharmaceutical Distribution unit is likely to drive growth, stiff competition is likely to mar prospects. Fiscal Q4 Results AmerisourceBergen posted adjusted earnings of $1.45 per share in fourth-quarter fiscal 2018, which exceeded the Zacks Consensus Estimate of $1.44 and improved 9% year over year. Revenues increased almost 10.7% to $43.29 billion but missed the Zacks Consensus Estimate of $43.53 billion. The company delivered a positive earnings surprise in the trailing four quarters, the average being 6.9%. Which Way Are Q1 Estimates Treading? For the quarter to be reported, the Zacks Consensus Estimate for revenues is pegged at $43.52 billion, reflecting 7.5% growth year over year. The same for earnings stands at $1.50, indicating year-over-year decline of 3.2%. Let's delve deeper to analyze how things are shaping up before the earnings announcement. Pharmaceutical Distribution Unit to Drive Q1 Increasing volume and an expanding customer base at this segment are likely to boost revenues. This segment serves healthcare providers in the pharmaceutical supply channel. Not to forget, the Pharmaceutical Distribution segment accounted for 96.4% of the company's net revenues in the las t report ed quarter. Moreover, the segment's revenues grew 3.9% on a year-over-year basis to $41.73 billion. The Zacks Consensus Estimate for Pharmaceutical Distribution stands at $40.46 billion, mirroring an improvement of 11.5% from the year-ago quarter number. Per management, the segment surpassed the company's expectations in the past few of quarters. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, improved economic conditions and population demographics should reflect in first-quarter fiscal 2019 results. AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Other Factors to Consider Other Segment This segment consists of Global Commercialization Services and Animal Health, and includes World Courier, AmerisourceBergen Consulting and MWI. In the last reported quarter, the Other segment contributed 3.7% to the company's net revenues. Notably, revenues at the segment improved 7.9% year over year to $1.60 billion in the fiscal fourth quarter. We expect the segment to witness robust growth in the quarter to be reported. The Zacks Consensus Estimate for first-quarter revenues is pegged at $1.64 billion, up 6.1% year over year. World Courier unit The World Courier unit, in particular, is likely to be one of the key growth drivers of the Other segment. The World Courier business delivered excellent results, with record gains in the last reported quarter. The unit witnessed outstanding operating income growth as well. We expect similar trends in the fiscal first quarter. What Does Our Model Say? Our proven model clearly indicates that a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to deliver a positive earnings surprise. This is not the case here. Earnings ESP : AmerisourceBergen has an Earnings ESP of -0.95%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank : AmerisourceBergen carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in the upcoming releases: PerkinElmer, Inc. PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. Illumina, Inc. ILMN has an Earnings ESP of +0.32% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""\""the world's first trillionaires,\""\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's in Store for Edwards Lifesciences' (EW) Q4 Earnings? Edwards Lifesciences CorporationEW is slated to report fourth-quarter 2018 results, after market close on Jan 31. Last quarter, the company's earnings beat the Zacks Consensus Estimate by 5.9%. Moreover, Edwards Lifesciences delivered positive earnings surprises in the trailing four quarters, the average beat being 7.8%. Let's see how things are shaping up prior to this announcement. Key Catalyst Similar to the prior quarter, Edwards Lifesciences is expected to gain from strength in Critical Care product group. The segment has been seeing solid growth across all product categories. Edwards Lifesciences is also set to keep gaining from Critical Care technologies with the rollout of HemoSphere monitoring platform supported by new group purchasing organization contracts in the United States. Last December, the company announced that the HemoSphere advanced hemodynamic monitoring platform received FDA approval for the Acumen suite of intelligent decision-support solutions. Edwards Lifesciences Corporation Price and EPS Surprise Edwards Lifesciences Corporation Price and EPS Surprise | Edwards Lifesciences Corporation Quote TheZacks Consensus Estimate for Critical Care product group sales of $171 million shows an increase of 4.3% from the year-ago quarter. We are also upbeat about the Surgical Structural Heart product group which should continue to see solid uptake of its new premium aortic valves along with solid aortic unit volume. Further, the company has initiated the launch of its INSPIRIS RESILIA aortic valve in Japan which is likely to contribute to the top line in the to-be-reported quarter. Moreover, buoyed by continued adoption of INTUITY Elite valve system, management expects it to continue to drive the top line in the fourth quarter. This apart, INSPIRIS RESILIA aortic valve is witnessing encouraging demand in the United States since its rollout initiated last January. TheZacks Consensus Estimate for Surgical Structural Heart product sales of $208 million reflects a rise of 1.5% from the year-ago quarter. Here are a few other factors that might influence Edwards Lifesciences' fourth-quarter results: Edwards Lifesciences has been seeing consistent performance by the Transcatheter Heart Valve Therapy (THVT) segment. However, during the third-quarter earnings announcement, Edwards Lifesciences noted that it is expecting the 2018 underlying sales growth in THVT to remain sluggish, at around 12.5% because of limited contribution from Cardioband Tricuspid Annular Reduction System and a newly-revised controlled rollout strategy for SAPIEN 3 Ultra. Notably, in transcatheter tricuspid repair, constrained by supply, clinicians are treating a limited number of patients in Europe with Cardioband. With this, in the third quarter, sales were limited to $1 million in both mitral and tricuspid programs. Management expects this trend to continue in the fourth quarter as well. Meanwhile, last November, Edwards Lifesciences received CE mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients. Accordingly, the Zacks Consensus Estimate for total THV sales of $594 million shows an increase of 10% from the year-ago quarter. Overall, the company projects sales between $950 million and $1 billion in the to-be-reported quarter. Our consensus estimate for fourth-quarter total revenues is pegged at $973.7 million, showing a rise of 9.6% from the prior-year quarter. What Our Model Suggests According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Edwards Lifesciences has a Zacks Rank #3 and an Earnings ESP of +0.86%, a combination that suggests a beat for the company this earnings season. The Zacks Consensus Estimate for earnings of $1.17 reflects a 24.5% rise on a year-over-year basis. Other Stocks Worth a Look Here are a few other medical stocks worth considering as these also have the right combination of elements to post an earnings beat in the to-be-reported quarter. PerkinElmer PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. Illumina, Inc. ILMN has an Earnings ESP of +0.32% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?""]"
DXCM,2019-01-28,36.0725,36.2475,35.0275,35.34,"[""Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?"", ""Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?"", ""Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?"", ""Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?"", ""Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?"", ""Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?"", ""Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?"", ""Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?"", ""Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings? Zimmer Biomet Holdings, Inc. ZBH is set to report fourth-quarter 2018 results on Feb 1, before the market opens. The company delivered an earnings surprise of 1.87% in the las t report ed quarter. Its earnings topped the consensus mark in three of the preceding four reported quarters, the average beat being 1.54%. Let's take a look at how things are shaping up prior to this announcement. Key Catalysts Zimmer Biomet is again expected to report strong top-line numbers for its S.E.T. (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) arm, backed by a firm focus on priority areas like quality remediation, supply recovery and product launches. The company is receiving a consistent positive feedback on the already marketed products. Within Sports, Comprehensive Baseplate, Sidus Stem-Free Shoulder and jogger stitch are anticipated to see a positive response. Within Extremities and Trauma subcategories, the company is investing a lot as well. We are also optimistic about a strong customer uptake of the company's Comprehensive Augmented Baseplate. Zimmer Biomet Holdings, Inc. Price and EPS Surprise Zimmer Biomet Holdings, Inc. Price and EPS Surprise | Zimmer Biomet Holdings, Inc. Quote Management keeps envisioning a better show within S.E.T. during the second half of 2018 as compared to the first half. However, the company earlier noted that, it is going to deal with a much more challenging comps in the fourth quarter as compared to the third. This apart, the sequentially last reported quarter reaped notable timing benefits with regard to both tenders and capital sales on the tender front, both in Asia-Pacific and EMEA. This benefit is seemingly not visible in the yet-to-be-reported quarter. Meanwhile, the company's S.E.T business has been of late massively hit by supply issues and a persistent pricing pressure. We expect all these factors to impact the company's fourth-quarter top line. The Zacks Consensus Estimate for S.E.T. revenues of $455 million remains marginally above $454 million, recorded in fourth-quarter 2017. Looking at the focused execution of Zimmer Biomet's sales teams, we expect the global adoption rate of the flagship personalized knee system - Persona - to be impressive.The company is seeing a very good uptake of the more recently released Persona Trabecular Metal Tibia. The Zacks Consensus Estimate for Knee revenues stands at $730 million as compared to $731 million in the prior-year quarter. Within Hip business, we anticipate the company to render a sturdy performance in the Asia-Pacific region. In the previously reported quarter, the company registered 8.6% sales growth at constant currency exchange rate within Hip in the aforementioned geography. Our consensus estimate for Hip revenues from Asia Pacific is pegged at $136 million, which reflects a 28.3% rise from the year-ago quarter. The Zacks Consensus Estimate of $500 million for Hip revenues shows a 0.2% rise from the year-ago level. However, Zimmer Biomet was grappled with pricing pressure of approximately (2.5%) during the fourth quarter. In absence of any favorable changes along these lines, the headwinds might affect the company's impending quarterly results. Overall, fourth-quarter total revenues are projected at $2.06 billion, indicating a 0.67% decline from the year-earlier quarter. What Our Quantitative Model Suggests: Our proven Zacks model clearly shows that a company with a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zimmer Biomet has a Zacks Rank #3, which increases the predictive power of ESP. It also has an Earnings ESP of +0.05%, together which a likely earnings surprise is predicted. Other Stocks Worth a Look Here are a few other medical stocks worth considering from the same space as these too comprise the right mix of elements to exceed expectations this reporting cycle. DexCom, Inc. DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . MacroGenics, Inc. MGNX has an Earnings ESP of +8.15% and a Zacks Rank of 2. NanoString Technologies, Inc. NSTG has an Earnings ESP of +4.64% and is a Zacks #2 Ranked stock. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NanoString Technologies, Inc. (NSTG): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report MacroGenics, Inc. (MGNX): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings? IDEXX Laboratories, Inc.IDXX is scheduled to report fourth-quarter 2018 results on Feb 1, before the opening bell. In the las t report ed quarter, the company delivered a positive earnings surprise of 7.14%. Notably, the stock outperformed the Zacks Consensus Estimate in each of the preceding four reported quarters, the average being 6.37%. Let's take a look at how things are shaping up prior to this announcement. Key Catalysts IDEXX should continue with its momentum in the fourth quarter, courtesy of a strong global rise in Companion Animal Group (CAG) Diagnostics' revenues. In the third quarter, this upside was driven by strong consistent gains from recurring CAG revenues, high premium CAG instrument placements and consistent high growth in digital business. This trend is expected to be retained further. In terms of 2018 outlook, IDEXX expects to deliver full-year organic growth trend in CAG Diagnostic recurring revenues to be around 13.2%, supported by steady strong growth in the United States and expanding international consumable revenues. IDEXX Laboratories, Inc. Price and EPS Surprise IDEXX Laboratories, Inc. Price and EPS Surprise | IDEXX Laboratories, Inc. Quote The Zacks Consensus Estimate of $474 million for CAG Diagnostics revenues represents an 9.4% improvement over the last reported quarter. For the fourth quarter, the company anticipates revenue growth in the range of 7-9%, net of an estimated 2% foreign exchange headwind. IDEXX hopes to retain high recurring CAG Diagnostic revenue gains in the quarter under review, aided by sustaining strong trends in the United States. The company is projecting moderate overall organic growth in the 9-11% band related to tough prior-year comparisons in global instrument placements and expectations for lower revenues in LPD (Livestock and Poultry Diagnostics) business. In this regard, the company forecasts mid to high single-digit revenue declines in LPD organic revenues for the fourth quarter. Other Factors We pin considerable hopes on progress in the Water Business, lying on a growth trajectory of late on the back of encouraging test results in the United States and benefits drawn from the global go-direct initiatives. Moreover, the business witnessed 9% organic strength in the last reported quarter. The company earlier stated that it is perfectly on track for a continued high-single digit organic revenue boost in this business through 2018. The consensus mark for Water revenues stands at $30.98 million for the yet-to-be-reported period, translating into a 7.3% improvement from the year-ago number. IDEXX constantly expands its global footprint. It has been significantly getting advantages from bountiful opportunities in the emerging companion animal diagnostics markets. Further, management's regular share buybacks underscore the company's robust free cash flow reserve. On the flip side, adverse foreign currency movement is a major headwind. Another concern is the company's heavy reliance on third-party distributors. The purchasing dynamics of distributors leave a significant impact on the company's sales of instrument consumables and its rapid assay products. Moreover, IDEXX has been witnessing a rise in operating expenses due to increased head count along with higher investments in portfolio development as well as expansion in the United States and internationally. Additionally, a competitive landscape in the domestic and overseas markets weighs on IDEXX's performance. Thus, the struggle to gain market traction might be a drag, which in turn, can hurt fourth-quarter results. Here's what the quantitative model predicts: Our proven Zacks model clearly shows that a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has higher chances of beating estimates if it also has a positive Earnings ESP . IDEXX has a Zacks Rank #3, which increases the predictive power of ESP. However, it has an Earnings ESP of -0.28%, which leaves surprise prediction inconclusive as the company also needs a positive ESP to be confident about a likely surprise. Thus, this combination fails to suggest an earnings beat for the stock this season. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Stocks Worth a Look Here are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle. DexCom, Inc. DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . MacroGenics, Inc. MGNX has an Earnings ESP of +8.15% and a Zacks Rank of 2. NanoString Technologies, Inc. NSTG has an Earnings ESP of +4.64% and is a Zacks #2 Ranked stock. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX): Get Free Report DexCom, Inc. (DXCM): Free Stock Analysis Report MacroGenics, Inc. (MGNX): Get Free Report NanoString Technologies, Inc. (NSTG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings? Becton, Dickinson and Company 's BDX , popularly known as BD, first-quarter fiscal 2019 results are scheduled to release on Feb 5, before market opens. While the results are likely to show steady growth in the core BD Medical segment, BD Life Sciences may partially mar results. Fiscal Q4 Results at a Glance In the las t report ed quarter, BD posted earnings of $2.93 per share which surpassed the Zacks Consensus Estimate by a penny. The bottom line improved 22.1% on a year-over-year basis and 24.6% at constant currency (cc). Revenues totaled $4.4 billion and outpaced the Zacks Consensus Estimate of $4.36 billion. The reported figure surged 39% from the year-ago quarter number, primarily owing to the acquisition of C. R. Bard. At cc, revenues rose 8.4%. BD has an average positive earnings surprise of 0.4% for the trailing four quarters. Which Way Are Q1 Estimates Treading? For the quarter to be reported, the Zacks Consensus Estimate for BD's earnings per share is pegged at $2.59, showing a year-over-year increase of 4.4%. The same for revenues stands at $4.10 billion, reflecting an increase of 33.3% year over year. Let's see how things are shaping up prior to the earnings release. BD Medical Likely to Drive Q1 Earnings BD Medical, one of the major revenue drivers of the company, is expected to drive the fiscal first-quarter results. Strong year-over-year growth of revenues from needles, syringes and intravenous catheters for medication delivery, prefilled IV flush syringes, syringes and pen needles for diabetes care and others are likely to boost the segment. In the last reported quarter, BD Medical accounted for 53.4% of the company's net revenues. The segment posted sales worth $2.35 billion, up 20.7% from the year-ago quarter and 10.1% at cc. It is encouraging to note that, for the fiscal first quarter, the Zacks Consensus Estimate for the segment's revenues is pegged at $2.11 billion, showing a year-over-year rise of 3.5%. Management expects BD Medical revenues to grow between 5% and 6% in fiscal 2019. Coming to the subsegments, Medication Surgical Systems revenues grew 5.9% in the fourth quarter. The Zacks Consensus Estimate for first-quarter revenues is pegged at $957 million, up 3.5% on a year-over-year basis. Diabetes Care revenues grew 1.7% in the fourth quarter. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $27 million, flat when compared to the year-ago period. At Pharmaceutical Systems , revenues grew 9.4% in the fourth quarter. However, the Zacks Consensus Estimate for the fourth quarter is pinned at $243 million, down 0.4% on a year-over-year basis. Becton, Dickinson and Company Price and EPS Surprise Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote Other Factors at Play Preliminary Results Prior to the earnings release, BD posted impressive preliminary first-quarter results, which instils optimism in the stock. Notably, revenues of $4.16 billion reflect a growth of 35.1% year over year and 5.2% at cc. Preliminary adjusted earnings per share of $2.70 reflect a growth of 8.9% on a year-over-year basis and 14.9% at cc. Resultantly, the company continues to expect fiscal 2019 revenue growth of 8.5-9.5%, driven by the C. R. Bard acquisition. At cc, revenues are anticipated to increase 5-6%. The Zacks Consensus Estimate for the same is pegged at $17.43 billion. Fiscal 2019 adjusted earnings per share are expected in the band of $12.05-$12.15, mirroring growth of 10% from fiscal 2018. The Zacks Consensus Estimate stands at $12.11 per share. Developments BD has witnessed several developments in recent times which are expected to positively impact the quarter-to-be-reported results. Last November, the company received FDA 510(k) clearance for its Phoenix CPO detect test. This will allow hospitals to identify infections caused by carbapenemase-producing organisms. (Read More: BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems ) Moreover, management at BD remains optimistic about new products like Alaris Pump and Pyxis ES, BD MAX, BD FACSLyric, BD Horizon Brilliant dyes, Lutonix AV and Covera. Headwinds BD's Life Sciences unit, which accounted for 25.2% of net sales in the last reported quarter, is likely to see a soft fiscal first quarter. Notably, the Zacks Consensus Estimate for the segment's first-quarter revenues is pinned at $1.04 billion, reflecting a decline of 0.5% year over year. Additionally, management foresees some other headwinds which may dent results in fiscal 2019. For instance, raw material pricing pressure, which increased in 2018, is expected to accelerate into fiscal 2019 primarily due to resin price increases. Additionally, the round of tariffs enacted last September is likely to act against the company. What Does Our Model Say? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. However, this is not the case here. Earnings ESP: BD has an Earnings ESP of -1.05%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: BD carries a Zacks Rank #2. Meanwhile, we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. PerkinElmer PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Baxter International BAX has an Earnings ESP of +1.83% and a Zacks Rank #3. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Core Business Units Boost McKesson's (MCK) Q3 Earnings? McKesson Corporation 's MCK third-quarter fiscal 2019 results are scheduled to release on Jan 31. The company's core business units - U.S. Pharmaceutical and Specialty Solutions, and European Pharmaceutical Solutions - are likely to boost the company's quarterly performance. Fiscal Q2 Results McKesson reported second-quarter fiscal 2019 earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.28. Adjusted earnings improved 10% year over year. Sales came in at $53.08 billion, which missed the Zacks Consensus Estimate of $53.56 billion. However, the metric rose 1.9% on a year-over-year basis. In the trailing four quarters, McKesson has delivered a positive avera ge earnings surprise of 6.4%. McKesson Corporation Price and EPS Surprise McKesson Corporation Price and EPS Surprise | McKesson Corporation Quote Which Way Are Q3 Estimates Headed? The Zacks Consensus Estimate for McKesson's fiscal third-quarter earnings is pegged at $3.18, mirroring a 6.7% decline year over year. The same for revenues stands at $55.27 billion, reflecting an increase of 3.1% year over year. Let's see how things are shaping up prior to the earnings release. Core Business Units to Drive Q3 Results McKesson's Pharmaceutical wing is likely to act as a key catalyst in boosting the company's fiscal third-quarter results. Notably, the segment is likely to gain momentum on the back of its branded, generic and over-the-counter pharmaceuticals. This apart, McKesson's Specialty business is likely to be a major top-line contributor, with strong growth in specialty drug distribution. Not to forget, the company's U.S. Pharmaceutical and Specialty Solutions contributed 70.4% to the company's net revenues in the fiscal second quarter. For the quarter to be reported, the Zacks Consensus Estimate for the U.S. Pharmaceutical and Specialty Solutions is pegged at $43.01 billion, showing a sequential rise of 3.4%. Other Factors at Play European Pharmaceutical Solutions Interestingly, despite stiff competition in France, the European Pharmaceutical revenues contributed 12.5% to McKesson's net revenues in the fiscal second quarter. The Zacks Consensus Estimate for European Pharmaceutical's third-quarter revenues is pinned at $6.85 billion, indicating a sequential increase of 3.2%. Medical Surgical Solutions This segment delivers laboratory supplies including reagents, lab equipment, lab glassware, eye wash solution, specimen collection and lab supplies. In the las t report ed quarter, the unit contributed 3.7% to the company's net revenues. For the quarter to be reported, the Zacks Consensus Estimate for the segment's sales stands at $1.98 billion, reflecting a sequential increase of 1.7%. What Does Our Model Say? Our proven model clearly indicates that a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to deliver a positive earnings surprise. This is not the case here. Earnings ESP : McKesson has an Earnings ESP of -0.08%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank : McKesson carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in the upcoming releases: PerkinElmer, Inc. PKI has an Earnings ESP of +0.77% and a Zacks Rank #3. Illumina, Inc. ILMN has an Earnings ESP of +0.02% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PerkinElmer, Inc. (PKI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?"", ""Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?"", ""Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?"", ""Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?""]"
DXCM,2019-01-29,35.265,35.535,34.575,35.0125,
DXCM,2019-01-30,35.2075,36.1025,35.1325,35.9025,
DXCM,2019-01-31,36.0575,36.5825,34.945,35.2575,"[""Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?"", ""Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?"", ""Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth? Boston Scientific Corporation BSX is scheduled to report fourth-quarter 2018 results, before the opening bell on Feb 6. In the las t report ed quarter, the company's earnings per share beat the Zacks Consensus Estimate by 2.94%. Moreover, it delivered positive earnings surprises in three of the trailing four reported quarters, the average beat being 7.5%. Let's see, how things are shaping up prior to this announcement. Preliminary Results at a Glance Notably, Boston Scientific recently projected an impressive fourth-quarter performance and expects to meet the upper end of its own expectations on the revenue front. In the to-be-reported quarter, Boston Scientific expects total revenue growth of 6.3% (up 8.2% on operational basis after excluding the impact of foreign currency fluctuations) on a year-over-year basis to $2.56 billion, in line with the current Zacks Consensus Estimate. However, this meets the upper end of the company's earlier provided revenue guidance of $2.525-$2.565 billion. A firm top line is primarily expected on the back of growth across all the company's segments and geographical regions. (Read more: Boston Scientific Gains on Impressive Preliminary Q4 Results ). Key Catalysts Alike the prior quarter, we are upbeat about strong contributions from Boston Scientific's Cardiovascular business group, which comprises Interventional Cardiology (IC) and Peripheral Interventions (PI). In the last reported quarter, the company generated around 38% of its total revenues from this highest revenue generating segment. Boston Scientific Corporation Price and EPS Surprise Boston Scientific Corporation Price and EPS Surprise | Boston Scientific Corporation Quote We are optimistic about the IC business that will help the company maintain impressive global growth, courtesy of an innovative portfolio and robust commercial teams. Complex PCI ( percutaneous coronary intervention) products within IC are growing strongly on successful global expansion efforts. According to Boston Scientific, the global Complex PCI results are largely offsetting the recent decline in the company's coronary drug-eluting stent business. Within Structural Heart, we are looking forward to Boston Scientific's WATCHMAN, ACURATE and IRIS product lines that are expected to contribute to the top line in the to-be-reported quarter. The company expects revenues from WATCHMAN and ACURATE TAVR franchise to total approximately $450 million in 2018. This apart, the recent acquisition of Claret Medical should largely aid Structural Heart's top line. Notably, Claret Medical brought Sentinel (the only cerebral embolic protection system approved in the United States and Europe) to Boston Scientific's Structural Heart portfolio. Per the preliminary fourth-quarter result, sales from the company's IC were up 5.1% on a reported basis (up 7.6% operationally) on a year-over-year basis. The Zacks Consensus Estimate for IC revenues is pegged at $669 million, indicating an increase of 5.2% on a year-over-year basis. In recent quarters, the PI business consistently demonstrated a solid uptick across segments like peripheral arterial disease, venous and interventional oncology. In the last reported quarter, the company commenced the launch of Eluvia in the United States. According to Boston Scientific, Eluvia has significant market opportunity, given the large addressable patient population, differentiated, sustained-release technology and superior clinical outcomes with reduced need for reintervention. We believe, this launch will be accretive to the company's fourth-quarter results. Meanwhile, the preliminary release highlights the fact that in the fourth quarter, the Peripheral Interventions business was up 9.3% (up 11.4%). Accordingly, the Zacks Consensus Estimate for fourth-quarter PI revenues stands at $295 million, reflecting a 6.5% rise year over year. Other Factors at Play Among the other segments, MedSurg is estimated to demonstrate a steady performance led by endoscopy. Urology and Pelvic Health are also projected to surpass market levels, driven by investment strategies in the key international geographies. Within endoscopy, the company is expected to display sturdy results, riding on a promising EndoChoice performance, particularly in pathology and infection prevention. Urology and Pelvic Health business should also continue to maintain its growth momentum on robust global performance. Boston Scientific's recent acquisitions have added several products (though many are under development) with immense potential to its portfolio. The buyouts of Apama MedicalSecurus Medical in Electrophysiology, Augmenix in Urology along with EmCision in Endoscopy deserve special mention. The company is gradually fortifying its presence in the emerging markets of Brazil, Russia, India and China (BRIC). In third-quarter 2018, business from the emerging markets registered 20% growth owing to a commendable progress in China and Latin America. Boston Scientific is gaining traction in India as well. It is currently targeting about 10 emerging markets for additional emphasis. The company is also pinning hopes on its core cardiology segment, which is gradually stabilizing with growth in the BRIC nations. This trend is expected to sustain in the to-be-reported quarter as well. However, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports have raised concerns for major MedTech players as a single adverse move might affect top-line numbers in the coming quarters. Overall, the Zacks Consensus Estimate for total revenues of $2.56 billion represents an increase of 6.24% from the prior-year quarter. Also, earnings estimates of 37 cents reflect an 8.8% rise on a year-over-year basis. What Our Quantitative Model Predicts Our proven Zacks model clearly shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has high chances of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Boston Scientific has a Zacks Rank #2, which increases the predictive power of ESP. However, the company has an Earnings ESP of 0.00%, which makes surprise prediction difficult. Thus, this combination fails to suggest any likely earnings beat for the stock this earnings season. Stocks Worth a Look Here are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle. DexCom, Inc. DXCM has an Earnings ESP of +8.93% and a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank stocks here . MacroGenics, Inc. MGNX has an Earnings ESP of +8.15% and is a Zacks #2 Ranked player. NanoString Technologies, Inc. NSTG has an Earnings ESP of +4.64% and a Zacks Rank of 1. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report NanoString Technologies, Inc. (NSTG): Free Stock Analysis Report MacroGenics, Inc. (MGNX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings? Myriad Genetics, Inc.MYGN is scheduled to report second-quarter fiscal 2019 results on Feb 5, after the closing bell. Last quarter, the company posted a positive earnings surprise of 43.3%. Moreover, Myriad Genetics beat the Zacks Consensus Estimate in the trailing four quarters, the average being 25.6%. Let's take a look at how things are shaping up prior to this announcement. Myriad Genetics, Inc. Price and EPS Surprise Myriad Genetics, Inc. Price and EPS Surprise | Myriad Genetics, Inc. Quote Factors at Play Similar to last quarter, Myriad Genetics is expected to gain from strong Molecular Diagnostics performance, led by solid contributions from the GeneSight, EndoPredict and Prolaris tests. GeneSight Test Per the company, as the GeneSight test is placed in a highly under-penetrated preventive care market, the product has huge market potential. In first-quarter fiscal 2019, Myriad Genetics saw a 28% year-over-year rise in GeneSight testing volumes. Management expects consistent growth in revenues from this test. EndoPredict Test Over the last few months, Myriad Genetics has been making steady progress with the EndoPredict test. Revenues from the test rose 33.3% year over year in the las t report ed quarter. During the second quarter of fiscal 2018, the company announced the finalization of LCD from Noridian for EndoPredict, thereby expanding the test's coverage to around 90% of the U.S. market. Further, the National Institute for Health and Care Excellence (NICE) in the United Kingdom issued a revised Diagnostics Consultation Document (DCD) that covers EndoPredict as one of the three approved prognostic tests. Notably, the company projects more than 26,000 breast cancer patients in the United Kingdom annually, which would be eligible for breast cancer prognostic signature. Also, in December 2018, NICE included EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for patients with ER-positive, HER2-negative early breast cancer and are lymph node-negative. These new developments should add to the top-line in the to-be-reported quarter. Prolaris Test Prolaris testing volumes grew 59% year over year in the last reported quarter. We are encouraged by the company's receipt positive reimbursement medical coverage decision from Blue Shield of California. Per management, with this development, another 4 million people got commercial coverage under the scope of Prolaris testing, resulting in coverage for 56% of prostate cancer patients. Furthermore, Myriad Genetics' receipt of seven new commercial coverage decisions for the Prolaris test is expected to contribute to the top line in the to-be-reported quarter. Hereditary Cancer Testing We expect Myriad Genetics to continue to see year-over-year growth in Hereditary Cancer volumes. The fiscal fourth quarter was the seventh consecutive quarter in which the company witnessed year-over-year Hereditary cancer volume growth. Further, Myriad Genetics is also witnessing impressive demand for metastatic breast cancer testing. In October, Myriad Genetics announced the receipt of FDA approval for using its BRACAnalysis CDx as a companion diagnostic with Pfizer's PARP (poly ADP ribose polymerase) inhibitor, TALZENNA (talazoparib). Fortifying its foothold internationally, the company has been receiving encouraging response for its BRACAnalysis CDx in Japan for metastatic breast cancer. All these factors are expected to maintain the momentum in the to-be-reported quarter as well. Vectra DA Myriad Genetics is upbeat about its consistent product diversification strategy which shows significant momentum in Vectra DA volumes. The company is optimistic about the strong clinical evidence for Vectra DA. In this regard, the company announced results from two studies confirming Vectra test's ability to significantly predict response to tofacitinib and track response to rituximab in patients with rheumatoid arthritis in October. Moreover, Myriad Genetics informed about endorsement of its Vectra testing for adults with rheumatoid arthritis by large professional organization empowering community rheumatologists - Bendcare - in the United States in the same month. All these developments are likely to boost contribution from the test in the fiscal second quarter's earnings results. Management has provided the guidance for the second quarter of fiscal 2018. The company estimates adjusted earnings per share of 36-38 cents on total revenues of $216-$218 million. Further, the Zacks Consensus Estimate for second-quarter revenues of $218.5 million reflects a rise of 12.6% from the year-ago quarter. What Does Our Model Say? Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. However, this is not the case here. Earnings ESP: Myriad Genetics has an Earnings ESP of -4.26%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Myriad Genetics carries a Zacks Rank #3. Stocks Worth a Look Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter. Becton, Dickinson and Company BDX has an Earnings ESP of +0.49% and a Zacks Rank #2. DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Cardinal Health, Inc. CAH has an Earnings ESP of +2.75% and a Zacks Rank #3. Looking for Stocks with Skyrocketing Upside? Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Get Free Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?""]"
DXCM,2019-02-01,35.175,35.465,34.195,35.445,
DXCM,2019-02-04,35.4575,36.155,35.2775,36.1225,"[""Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings? Laboratory Corporation of America HoldingsLH also known as LabCorp, is slated to report fourth-quarter 2018 results on Feb 7, before the market opens. In the las t report ed quarter, the company's adjusted earnings lagged the Zacks Consensus Estimate by 4.53%. However, average trailing four-quarter beat was 1.55%. Let's see how things are shaping up for this announcement. Factors at Play Within Diagnostics, the previous reported quarter witnessed trouble related to certain ransomware attack last July and an adverse impact of hurricane Florence. This induced lower-than-expected organic revenues for that quarter. To counter this effect, LabCorp has come up with its initiative to make certainorganizational changes for strengthening its leadership and operational performance. The company is also on track to launch the next phase of Diagnostics LaunchPad, which will result in multiyear cost savings of a similar magnitude like LaunchPad Phase I (under the drug development business). In the fourth quarter, LabCorp is expected to particularly gain from its collaboration with Walgreens. Per the company, this partnership underpins the LabCorp-Walgreens channel, which is uniquely positioned to deliver a wide range of personalized, integrated, consumer-facing services over time. We are also looking forward to the company's alliance with European provider of clinical laboratory testing, Unilabs. This collaboration has started to broaden the network of laboratories used by biopharmaceutical companies to support companion diagnostic development and commercialization. Per LabCorp, companion diagnostics is a global opportunity and the tie-up with Unilabs is the first step toward extending its companion Dx offering worldwide. Laboratory Corporation of America Holdings Price and EPS Surprise Laboratory Corporation of America Holdings Price and EPS Surprise | Laboratory Corporation of America Holdings Quote Overall, from the fourth quarter itself, the company expects to deploy more capital for near- and long-term value creation including internal capital investments and strategic acquisitions and partnerships within its Diagnostics wing. However, how much this can contribute to the company's top line in the quarter to be reported is unclear. The company currently projects to report LabCorp Diagnostics revenues for the full year in the range of 2.1-2.5%, a reduction from the earlier-provided band of3-3.5%. Within Covance Drug Development, we note that after suffering a dull phase for several quarters, the segment started to gross higher revenues exactly a year ago on the back of Chiltern acquisition and a strong organic growth profile besides a favorable foreign currency translation. The Chiltern buyout proved accretive to LabCorp's portfolio with the addition of highly complementary capabilities to the company's offerings including scale expansion in the Asia Pacific region, a broader reach in the rapidly-growing emerging and mid-tier biopharma customer segments a well as the company's expertise in the oncology drug development. Apart from Chiltern, LabCorp continues to add Covance's offerings to its portfolio through targeted tuck-in acquisitions and partnerships. The latest on this list is the comprehensive laboratory collaboration with Baptist Health, the largest not-for-profit system in Kentucky. As part of this association, the company will utilize its fully standardized laboratory solutions, operational expertise and a comprehensive test menu to support the delivery of care across eight hospital-based labs. This apart, the company's consolidation of Sciformix Corporation, a scientific process outsourcing company, is projected to cement LabCorp's position in the later phases of drug and device development, particularly for post-marketing pharmacovigilance and market access solutions. All these factors should together constantly benefit the top line at LabCorp's Covance Drug Development in the yet-to-be reported quarter. The company is also optimistic about the development regarding its multi-year project, LaunchPad. LabCorp currently remains on track to deliver $150 million of net savings from Covance LaunchPad by the end of 2020 and $30 million of cost synergies from the integration of Chiltern by the end of 2019. Overall, the company currently expects 2018 Covance Drug Development revenue growth within 24-26%. Per LabCorp's modified guidance for 2018, revenue rise is anticipated in the 9.9-10.3% band from 2017. Adjusted EPS forecast for the current year lies within the $10.95-$11.05 range. What the Quantitative Model Suggests Our proven Zacks model conclusively shows that a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP . LabCorp has a Zacks Rank #3 (Hold), which increases the predictive power of ESP. However, its Earnings ESP of 0.00% makes surprise prediction difficult. The Zacks Consensus Estimate for fourth-quarter earnings of $2.48 reflects 1.22% growth year over year. Revenue increase is pegged at $2.78 billion, a 0.46% slip year over year. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Stocks to Consider Here are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle. DexCom, Inc. DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . MacroGenics, Inc. MGNX has an Earnings ESP of +8.15% and is a Zacks #2 Ranked player. NanoString Technologies, Inc. NSTG has an Earnings ESP of +4.64% and a Zacks Rank of 2. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MacroGenics, Inc. (MGNX): Free Stock Analysis Report NanoString Technologies, Inc. (NSTG): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Shares Soared 17.7% in January What happened After reporting preliminary revenue for the fourth quarter on Jan. 7 that was better than expected and offering up guidance for additional sales growth in 2019, DexCom (NASDAQ: DXCM) saw its shares jumped 17.7% in January, according to S&P Market Intelligence . So what DexCom markets continuous glucose monitors (CGM) that diabetics use to better track their blood glucose levels. And thanks to the launch last spring of the G6, its latest system, 2018 was a banner year for the company. Preliminary figures unveiled in early January show sales increased 42% year over year to $1.025 billion in 2018, including sales of $331 million in the fourth quarter, up over 50% from Q4 2017. The figures were particularly surprising given that management had said in early December it expected sales of just $975 million for 2018, implying fourth-quarter revenue of $281.4 million based on sales through the first nine months of the year. Management also outlined a goal for sales in 2019 to grow between 15% to 20% -- or between $1.175 billion and $1.225 billion. That's in keeping with its outlook for compound annual revenue growth of 15% through 2023. Now what Typical insulin-dependent diabetics spend about 70% of their day outside their desired blood sugar range. And since inadequate control of their blood sugar can lead to life-threatening disease progression, technology that can improve insight into highs and lows is important to achieving better outcomes. In the future, DexCom aims to launch cheap, disposable sensors that could expand its market opportunity from about 3 million insulin-intensive people in the U.S. today to over 30 million type 1 and type 2 patients. If it can deliver on this target, then DexCom's peak revenue opportunity could be significantly higher than it is today. For perspective, management's growth-rate target translates into roughly a doubling of revenue over the coming five years. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of November 14, 2018 Todd Campbell owns shares of DexCom. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2019-02-05,36.3575,37.365,36.25,37.185,"[""3 Medical Instruments Stocks Likely to Beat Estimates in Q4"", ""3 Medical Instruments Stocks Likely to Beat Estimates in Q4"", ""3 Medical Instruments Stocks Likely to Beat Estimates in Q4 The Medical Instruments stock earnings are likely to grow on rapid innovation and strong R&D focus in the fourth quarter. Further, rampant M&As and the modernization of 510 (k)-clearance pathway is likely to help the dominant Medical Instruments players gain leverage in the space. Factors to Drive Q4 Earnings Emerging Economies: Strong performance of Medical Instruments companies in emerging economies, especially in the Asia/Pacific and Western Europe markets, is likely to fuel fourth-quarter results. These companies are likely to benefit from an expanding customer base, relaxed regulations, cheap skilled labor, increasing wealth and government focus on healthcare infrastructure. Favorable Tax Reforms: Sector participants are expected to gain from the slashed tax rate to 21% from 35%, dropping the U.S. combined rate from 38.9% to 25.7%. This has aided margin growth and the trend is likely to continue in this quarter. Also, a bipartisan two-year suspension of a 2.3% excise tax on Medical Instruments and Medical Device manufacturers at the beginning of 2018 has encouraged massive investments in the Medical Instruments sector. Both the developments are expected to boost hiring and investment among U.S.-based Medical Instruments manufacturers. Modernization of 510 (k): Last November, the FDA attempted to modernize the 510(k)-clearance pathway. For investors' knowledge, the 510(k) is a premarket submission made by MedTech companies to the FDA to validate a medical device as safe and effective. According to a December article published in Investing News, \""the changes are meant to create a safer product for patients while holding companies accountable for any safety discrepancies, all while holding on to the FDA's gold standard for safety.\"" This is likely to favorably impact fourth-quarter results to some extent. Increase in Healthcare Expenditure: Favorable consumer behavior and improving expenditure patterns are likely to benefit Medical Instruments manufacturers in the fourth quarter. It is encouraging to note that the U.S. healthcare expenditures are expected to rise from $3.3 trillion in 2016 to $5.7 trillion in 2026 (Mercer Capital), indicating average annual growth of 5.5%. This apart, America's exceptional purchasing power along with solid demand for medical products, medical instruments, medical services and lab equipment has provided the nation a leading position in the global Medical Instruments space. Factor to Worry About The U.S.-China trade war has triggered a short-term downtrend in the Medical Instruments sector. According to a survey conducted by the Medical Imaging & Technology Alliance (\""MITA\""), tariffs will cost Medical Instruments companies nearly $138 million every year. This might show on Medical Instruments companies' fourth-quarter results. For instance, Varian Medical VAR reported first-quarter fiscal 2019 results last month. The company's revenues were negatively impacted by $8 million due to U.S.-China trade war. Total operating earnings and earnings per share were declined by $11 million. Moreover, the core Oncology segment's operating earnings declined 10% year over year due to tariffs. Zacks Methodology Given the high degree of diversity in the Medical Instruments industry, finding the right stocks with the potential to beat estimates might be quite a daunting task. However, our proprietary Zacks methodology, makes this routine fairly simple for investors. Investors can narrow down the choices by focusing on stocks that have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can see the complete list of today's Zacks #1 Rank stocks here . Our research shows that for stocks with this combination, chances of a positive earnings surprise are significantly as high as 70%. Earnings ESP is our proven methodology for identifying stocks that have high chances of surprising with their nex t earnings announcement. This key element provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Here we present three stocks that are expected to beat earnings estimates in this reporting cycle. DexCom, Inc.DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. The company continues to focus on international markets, with strong emphasis on Germany. Currently, it is eyeing the sizeable markets of India, China and Japan. Given the demographic trend and lifestyle in countries outside the United States and Europe, we believe that DexCom has a strong international market opportunity. The company is slated to release fourth-quarter 2018 earnings results on Feb 21. The Zacks Consensus Estimate for fourth-quarter earnings stands at 14 cents, mirroring year-over-year growth of 40%. The same for revenues is pegged at $330.6 million, reflecting 49.6% improvement year over year. DexCom, Inc. Price and EPS Surprise DexCom, Inc. Price and EPS Surprise | DexCom, Inc. Quote Masimo CorporationMASI has an Earnings ESP of +1.04% and a Zacks Rank #3. Strong sales in Masimo's flagship Signal Extraction Technology (SET) pulse oximetry unit is likely to drive the company's fourth-quarter 2018 results. The platform successfully eliminates the limitations of conventional pulse oximeters. At present, Masimo's rainbow SET technology is gaining traction owing to rapid product development. The device has been clinically proven to reliably detect critical congenital heart disease in newborns. The company is slated to release fourth-quarter earnings results on Feb 26. The Zacks Consensus Estimate for earnings stands at 72 cents, which remains flat year over year. The same for revenues is pegged at $220 million, indicating a 2.3% decline year over year. Masimo Corporation Price and EPS Surprise Masimo Corporation Price and EPS Surprise | Masimo Corporation Quote Wright Medical Group N.V.WMGI has an Earnings ESP of +18.18% and a Zacks Rank #2. Solid performance by the company's upper and the lower extremity segments buoy optimism. Moreover, the FDA approval of the AUGMENT Injectable Bone Graft is a major positive. The company has also witnessed strong growth by the Perform Reversed Glenoid platform. Further, contribution from the company's SIMPLICITI shoulder system is noteworthy. The company is slated to release fourth-quarter 2018 earnings results on Feb 26. The Zacks Consensus Estimate for earnings stands at 6 cents, mirroring a 40% decline year over year. The same for revenues is pinned at $237.4 million, showcasing a 9.1% decline year over year. Wright Medical Group N.V. Price and EPS Surprise Wright Medical Group N.V. Price and EPS Surprise | Wright Medical Group N.V. Quote Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Get Free Report DexCom, Inc. (DXCM): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Medical Instruments Stocks Likely to Beat Estimates in Q4""]"
DXCM,2019-02-06,37.0075,37.4425,36.01,36.29,
DXCM,2019-02-07,36.0775,36.4425,35.55,35.99,"[""HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors"", ""Top Stocks Share Many Common Traits, But This One Might Be The Most Important"", ""Top Stocks Share Many Common Traits, But This One Might Be The Most Important"", ""HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors"", ""HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors Prior to the fiscal fourth-quarter earnings release, HealthEquity, Inc.HQY announced preliminary results for fiscal 2019, wherein the total number of HSAs (Health Savings Account) for which it serves as a non-bank custodian was 4 million. This reflects an increase of 17% from fiscal 2018. Investors Cheerful HealthEquity's fiscal fourth-quarter preliminary results seem to impress investors. Following the announcement, share price of this Zacks Rank #3 (Hold) company climbed 2.2% to $66.45 at close. If the company manages to outpace the Zacks Consensus Estimate in the fiscal fourth quarter, it will mark the second consecutive quarterly beat. Over the past month, shares of HealthEquity have rallied 25.7%, higher than the industry 's 12.5% growth. The current level is also higher than the S&P 500's rally of 6.4%. HSA Details By the end of fiscal 2019, total custodial assets held by HSA Members totaled $8.1 billion, up 19% from the earlier year. HealthEquity, Inc. Price and Consensus HealthEquity, Inc. Price and Consensus | HealthEquity, Inc. Quote In fiscal 2019, the company set a record by opening 674,000 new HSAs which helped HAS members add $1.3 billion worth of custodial assets. Outlook For fiscal 2019, management at HealthEquity anticipates revenues within $284 million and $287 million. The midpoint of the latest guidance of $285.5 million is above the Zacks Consensus Estimate of $284.3 million. Adjusted earnings per share are projected between $1.13 and $1.17, higher than the Zacks Consensus Estimate of $1.12. Additionally, the company provided fiscal 2020 revenue guidance. Revenues are expected in the range of $333 million to $339 million, below the Zacks Consensus Estimate of $341.3 million. Key Picks A few better-ranked stocks in the broader medical space arePenumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM .Each of these stocks currently carries a Zacks Rank #2 (Buy).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20%. Wright Medical's long-term earnings growth rate is expected at 11%. DexCom's next-quarter earnings per share are projected to grow at 56.3%. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs. See Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report DexCom, Inc. (DXCM): Get Free Report HealthEquity, Inc. (HQY): Get Free Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top Stocks Share Many Common Traits, But This One Might Be The Most Important"", ""HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors""]"
DXCM,2019-02-08,35.69,36.6775,35.6875,36.3825,"[""Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?"", ""The Diabetes Landscape Is Changing \u2014 Can This Stock Lead The Pack?"", ""The Diabetes Landscape Is Changing \u2014 Can This Stock Lead The Pack?"", ""Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?"", ""Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance Prior to the fourth-quarter earnings release, Ecolab Inc.ECL announced preliminary fourth-quarter results, wherein adjusted earnings per share (EPS) is likely to increase 11.6% year over year to $1.54. This is marginally below the Zacks Consensus Estimate of $1.55. On a full-year basis, adjusted EPS is expected to climb 12.2% to $5.25 from 2017, in line with the Zacks Consensus Estimate. The fourth-quarter 2018 results are scheduled to release on Feb 19, before market opens. Ecolab's preliminary fourth-quarter results weren't applauded by investors. Following the announcement, shares of the Zacks Rank #3 (Hold) company fell 0.4% to $158.61 at close. Over the past year, shares of Ecolab have rallied 24.2%, higher than the industry 's 5.6% growth. The current level is also better than the S&P 500's rally of 6.2%. Outlook Ecolab expects revenues to be strong in 2019, with growth across all segments. On a full-year basis, the company expects adjusted EPS within $5.80 to $6.00, mirroring growth of 10-14% from 2018. The midpoint of the latest guidance of $5.90 is marginally below the Zacks Consensus Estimate of $5.91. Other Major Developments Ecolab plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020. This is likely to make the Upstream Energy business a market-leading pure-play global provider of oil and gas production, drilling, and completion product and service solutions. For investors' notice, the Upstream Energy sub-unit currently forms part of Ecolab's core Energy segment. For 2018, Ecolab expects sales of $2.4 billion and operating income of $170 million from the sub unit. Additionally, Ecolab raised the target for its previously announced efficiency initiative. The benefits of the efficiency initiative are now estimated at $325 million compared with the previous forecast of $200 million. These additional savings are expected to build through 2019 with greater impact in 2020 and 2021. Key Picks A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM . Each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20%. Wright Medical's long-term earnings growth rate is expected at 11%. DexCom's next-quarter earnings per share are projected to grow 56.3%. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""the world's first trillionaires,\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL): Get Free Report Penumbra, Inc. (PEN): Get Free Report DexCom, Inc. (DXCM): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings? Computer Programs And Systems, Inc. CPSI fourth-quarter 2018 results are scheduled for release on Feb 15. The company's strong diversified portfolio of RCM solutions is likely to drive top-line growth in the quarter to be reported. Computer Programs' RCM suite of services, which include Accounts Receivable Management Services, Private Pay, medical coding and more, are added positives. Each of these offerings has a client penetration rate between 10% and 20%. Q3 Results at a Glance In the las t report ed quarter, Computer Programs delivered adjusted earnings of 79 per share, which surpassed the Zacks Consensus Estimate of 48 cents. Meanwhile, revenues came in at $69.3 million, missing the Zacks Consensus Estimate of $71 million. The company has an average four-quarter positive earnings surprise of 30.2%. Computer Programs and Systems, Inc. Price and EPS Surprise Computer Programs and Systems, Inc. Price and EPS Surprise | Computer Programs and Systems, Inc. Quote Which Way Are Q4 Estimates Trending? The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 58 cents, reflecting a 7.9% decline year over year. For revenues, the same is pinned at $74.4 million, mirroring a 4.7% decline year over year. Let's delve deeper. Other Factors at Play TruBridge to Drive Growth TruBridge platform's solid bookings trend, good client retention rate and huge recurring revenue base are likely to significantly boost Computer Systems' results in the fourth quarter. Also, the company is expected to benefit from its acute and postacute EHR client base. Notably, of the $7.3 million in TruBridge bookings in the third quarter, 82% stemmed from cross sales into acute and postacute EHR client base. In the meantime, Computer Systems' pipeline remains strong as it is expected to generate 25 to 30 new EHR system contracts on an annual basis. This, in turn, is likely to have a positive impact on the company's performance in the fourth quarter. American HealthTech (\""AHT\"") Per management at Computer Systems, the AHT solution has been witnessing positive client feedback. In the last reported quarter, the first phase of the AHT 18 plan had been executed, which is currently available at 150 customer sites at the moment. The AHT platform's solid prospects should prove beneficial to the company in the to-be-reported quarter. What Does Our Model Say? Our proven model clearly indicates that a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to deliver a positive earnings surprise. This is not the case here. Earnings ESP: Computer Systems has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: Computer Systems carries a Zacks Rank #3. Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks Worth a Look DexCom DXCM has an Earnings ESP of +8.93% and a Zacks Rank #2. Medidata Solutions, Inc. MDSO has an Earnings ESP of +0.54% and a Zacks Rank #2. Wright Medical Group N.V. WMGI has an Earnings ESP of +58.24% and a Zacks Rank #2. The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce \""\""the world's first trillionaires,\""\"" but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Computer Programs and Systems, Inc. (CPSI): Free Stock Analysis Report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Diabetes Landscape Is Changing \u2014 Can This Stock Lead The Pack?"", ""Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?""]"
DXCM,2019-02-11,36.915,38.33,36.8232,37.8075,
DXCM,2019-02-12,38.33,38.9625,37.515,38.1825,"[""Medical devices maintain strength, IHI up 11% ytd"", ""Medical devices maintain strength, IHI up 11% ytd"", ""DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $149.20, changing hands for $151.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised. There are 15 different analyst targets contributing to that average for DexCom Inc, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $125.00. And then on the other side of the spectrum one analyst has a target as high as $170.00. The standard deviation is $14.253. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $149.20/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $149.20 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on DXCM - FREE . The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medical devices maintain strength, IHI up 11% ytd""]"
DXCM,2019-02-13,38.13,38.4125,36.2725,37.2625,"[""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?"", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?"", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards? DexCom, Inc. DXCM fourth-quarter 2018 results are scheduled for release on Feb 21, after market close. The large and growing diabetes market, solid sensor volumes and international-revenue growth are expected to provide a boost to the quarterly results. Q3 Results at a Glance DexCom reported adjusted earnings of 17 cents per share in the third quarter of 2018, outpacing the Zacks Consensus Estimate of a loss of 12 cents. Also, the figure improved from a loss of 4 cents registered in the year-ago quarter. Total revenues rallied 44.5% to $266.7 million on a year-over-year basis. The top-line figure surpassed the Zacks Consensus Estimate of $242 million. Furthermore, the company has an average four-quarter positive earnings surprise of 37.6%. Which Way are Estimates Trending? The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 14 cents, reflecting 40% growth year over year. The same for revenues is pinned at $330.6 million, mirroring 49.6% improvement year over year. Let's delve deeper. Sensor Segment to Boost Q4 Results DexCom's unique sensor technology has provided it a competitive edge in the MedTech space. In the third quarter, revenues at the Sensor segment (73% of total revenues) surged 47% on a year-over-year basis to $194 million. The company is expected to gain from strong demand for the G6 sensors. In fact, these sensors are likely to rake in huge profits in the quarter to be reported. By the end of the third quarter of 2018, management at DexCom announced that the G6 system is available in 14 countries and the company will continue to roll it globally in 2019. Meanwhile, DexCom's Insulet and Lilly diabetes management products continue to progress well. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $209 million, reflecting 29.8% growth year over year. Other Factors at Play Preliminary Results DexCom expects preliminary, unaudited revenues for the fourth quarter to exceed $331 million, mirroring 50% growth year over year. For 2018, total preliminary, unaudited revenues are expected to outpace $1.03 billion, up 42% year over year. In the meantime, management remains optimistic about DexCom's strong growth in G6 CGM platform both in the United States and internationally. Transmitter Revenues & Receiver Revenues Transmitter revenues (18% of total revenues) increased 27% year over year to $48.5 million in the third quarter. The Zacks Consensus Estimate for the segment is pegged at $45.9 million for the fourth quarter, up 8.3% year over year. In the third quarter, Receiver revenues (9% of total revenues) rallied 68% year over year to $24.2 million. The Zacks Consensus Estimate for the segment stands at $45.9 million for the fourth quarter, up 49.3% year over year. What Does Our Model Say? Our proven model clearly indicates that a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to deliver a positive earnings surprise. This is not the case here. Earnings ESP: DexCom has an Earnings ESP of -14.3%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Zacks Rank: DexCom carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here . Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions. DexCom, Inc. Price and EPS Surprise DexCom, Inc. Price and EPS Surprise | DexCom, Inc. Quote Stocks Worth a Look Masimo Corporation MASI has an Earnings ESP of +1.04% and a Zacks Rank #3. AxoGen, Inc. AXGN has an Earnings ESP of +14.29% and a Zacks Rank #3. Wright Medical Group N.V. WMGI has an Earnings ESP of +58.24% and a Zacks Rank #2. 3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline. So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it. See them today for free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report AxoGen, Inc. (AXGN): Get Free Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?""]"
DXCM,2019-02-14,37.075,37.4075,36.7275,36.9575,"[""DexCom (DXCM) Earnings Expected to Grow: Should You Buy?"", ""Here's Why Investors Should Buy CONMED (CNMD) Stock Now"", ""DexCom (DXCM) Earnings Expected to Grow: Should You Buy?"", ""Here's Why Investors Should Buy CONMED (CNMD) Stock Now"", ""DexCom (DXCM) Earnings Expected to Grow: Should You Buy? Wall Street expects a year-over-year increase in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on February 21, 2019, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This medical device company is expected to pos t quarterly earnings of $0.14 per share in its upcoming report, which represents a year-over-year change of +40%. Revenues are expected to be $330.57 million, up 49.6% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.02% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for DexCom? For DexCom, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -14.29%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination makes it difficult to conclusively predict that DexCom will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the las t report ed quarter, it was expected that DexCom would post a loss of $0.12 per share when it actually produced earnings of $0.17, delivering a surprise of +241.67%. Over the last four quarters, the company has beaten consensus EPS estimates three times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to bea t earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. DexCom doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Buy CONMED (CNMD) Stock Now CONMED CorporationCNMD is one of the top players in the MedTech space. A solid fourth-quarter show and consistent focus on Research and Development (R&D) are working in favor of the stock. In a year's time, this Zacks Rank #2 (Buy) stock has rallied 18.1% against the industry 's 2.6% decline. The current level is also significantly higher than the S&P 500's 1.9% rise. What's Favoring CONMED? In the recently reported fourth quarter of 2018, CONMED posted adjusted earnings per share of 73 cents, in line with the Zacks Consensus Estimate. Also, the figure improved 5.8% from the year-ago quarter. It is encouraging to note that the company expects 2019 sales growth in the range of 5-6% at cc. Adjusted diluted ne t earnings per share for 2019 are projected in the range of $2.42 to $2.47, representing growth of 11-13% over 2018. CONMED's steady focus on innovation instills investor confidence. By the end of fourth-quarter 2018, management at CONMED announced that solid organic R&D pipeline and product innovation will be lending the company a competitive edge. In the quarter, the company's R&D expenses totaled $10.4 million or 4.3% of total sales, which shows a 23.8% increase over $8.4 million recorded in the prior-year quarter. Additionally, management at CONMED confirmed that it will continue to increase investments in R&D, which should be between 4.5% and 5% of net sales in 2019. CONMED Corporation Price and Consensus CONMED Corporation Price and Consensus | CONMED Corporation Quote Which Way Are Estimates Treading? The Zacks Consensus Estimate for first-quarter 2019 earnings is pegged at 54 cents, reflecting growth of 1.9% on a year-over-year basis. The same for the revenues stands at $209.9 million, mirroring a 3.9% improvement year over year. For 2019, the Zacks Consensus Estimate for revenues is pegged at $898.4 million, reflecting growth of 4.5%. The same for adjusted earnings is pinned at $2.44, indicating a year-over-year rise of 11.9%. Other Key Picks Other top-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20%. Wright Medical's long-term earnings growth rate is estimated at 11%. DexCom's next-quarter earnings per share is projected to grow at 56.3%. Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Earnings Expected to Grow: Should You Buy?"", ""Here's Why Investors Should Buy CONMED (CNMD) Stock Now""]"
DXCM,2019-02-15,37.4775,37.5625,36.835,37.1225,"[""FDA issues draft guidance on non-binding feedback on inspections"", ""The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings"", ""The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings"", ""FDA issues draft guidance on non-binding feedback on inspections"", ""The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings"", ""FDA issues draft guidance on non-binding feedback on inspections""]"
DXCM,2019-02-19,37.265,37.5475,36.8375,36.975,
DXCM,2019-02-20,36.7725,37.045,36.1075,36.385,"[""DexCom Q4 2018 Earnings Preview"", ""Stocks Near Buy Points Ahead Of Earnings Thursday: Investing Action Plan"", ""DexCom Q4 2018 Earnings Preview"", ""Stocks Near Buy Points Ahead Of Earnings Thursday: Investing Action Plan"", ""DexCom Q4 2018 Earnings Preview"", ""Stocks Near Buy Points Ahead Of Earnings Thursday: Investing Action Plan""]"
DXCM,2019-02-21,36.385,36.875,35.975,36.5625,"[""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q4 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q4 Earnings and Revenues Top Estimates"", ""DexCom Q4 revenue up 53%"", ""DexCom beats by $0.37, beats on revenue"", ""Masimo and Saudi Arabia MOH Collaborate for CCHD Screening"", ""The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan"", ""DexCom Q4 Adj. EPS $0.54 May Not Compare To $0.17 Estimate, Sales $338M Beat $299.67M Estimate"", ""DexCom Q4 Adj. EPS $0.54 May Not Compare To $0.17 Estimate, Sales $338M Beat $299.67M Estimate"", ""The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q4 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q4 Earnings and Revenues Top Estimates"", ""DexCom Q4 revenue up 53%"", ""DexCom beats by $0.37, beats on revenue"", ""Masimo and Saudi Arabia MOH Collaborate for CCHD Screening"", ""Masimo and Saudi Arabia MOH Collaborate for CCHD Screening Masimo CorporationMASI recently announced a collaboration with the Saudi Arabia Ministry of Health (\""MOH\"") to implement a solution designed to streamline the process of critical congenital heart disease (\""CCHD\"") screening of newborns, using Masimo SET. Notably, Saudi Arabia commenced a mandatory CCHD screening program for all newborns, using the Masimo Eve Newborn Screening Application on the Radical-7 Pulse CO-Oximeters in 2016. In 2018, Eve on Rad-97 Pulse CO-Oximeters was added to the program. It is encouraging to note that in last June, the UAE Ministry of Health & Prevention adopted Masimo's flagship Eve application for CCHD screening in newborns. (Read More: MOHAP Selects Masimo's Eve for CCHD Screening in UAE ) In the recent past, Eve received the CE marking. (Read More: Masimo's Eve Gets CE Mark, Bolsters CCHD Diagnosis ) About Eve Masimo's Eve combines the power of Masimo SET Measure-through Motion and Low Perfusion pulse oximetry with a pre-ductal to post-ductal synchronization algorithm designed to reduce calculation errors. This cost-effective application is available on the Radical-7 Pulse CO-Oximeter. Studies have shown that Masimo SET pulse oximetry can improve CCHD screening, helping to save many newborns' lives while reducing the cost of care. Prospects CCHD affects approximately 2-3 newborns per 1000 births and requires intervention soon after birth to prevent significant morbidity or mortality. ResearchAndMarkets opines that the global pulse oximetry market is likely to grow at a CAGR of 6.2% between 2019 and 2025. Hence, the latest development has been a well-timed one for Masimo. Masimo Rides on Developments In recent times, MedTech company, based in California, has seen a slew of developments. In February, Masimo announced the launch of Doctella, the home-based patient engagement and remote care automation platform, to provide end-to-end home care solution, allowing clinicians to create and manage treatment plans. In the last month, Masimo announced FDA clearance of the measurement of respiration rate from the pleth (RRp) on the MightySat Rx spot-check fingertip pulse oximeter. Moreover, Masimo's Iris Device Management System has been recently launched in the United States. Notably, the system is designed to streamline management of Masimo devices used in a hospital. Shares Up Reflective of the above developments, shares of the Zacks Rank #2 (Buy) company have rallied 50.8% compared with the industry 's 10.1% growth and the S&P 500 index's 3% return, in a year. Other Key Picks Some other top-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected to be 20%. Wright Medical's long-term earnings growth rate is projected to be 11%. DexCom's fourth-quarter earnings is projected to grow 56.3%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Luminex Hurt By Segmental Sluggishness, Stiff Competition On Feb 20, we issued an updated research report on Luminex CorporationLMNX . A weak fourth quarter and stiff competition in the Medtech space currently plague the company. The stock currently carries a Zacks Rank #4 (Sell). What's Deterring the Stock? Luminex saw some sluggishness in the recently-reported fourth quarter of 2018. Earnings per share in the fourth quarter dropped on a year-over-year basis. Per management, the departure of LabCorp impacted results. Additionally, Luminex's assay and molecular diagnostic revenues declined year over year in the quarter, impacted by LabCorp. Notably, assay revenues fell 11.7%, while molecular diagnostic revenues declined 11% year over year. Moreover, Luminex's Other segment saw a revenue decline of 14% year over year in the quarter. In addition to this, Luminex operates in the highly competitive life sciences industry. The industry is characterized by rapid and continuous technological innovation. Currently, it is facing significant competitive headwinds in the respiratory market. The company's dependence on its partners for revenue generation may add to the woes. Luminex's customers include clinical diagnostic, pharmaceutical, biotechnological, chemical and industrial companies. Reduced spending on research and diagnostics by these companies is likely to dent demand for Luminex's products. Price Performance Despite the hurdles, shares of Luminex have rallied 28.1% compared with the industry 's 10.1% gain over the past year. The current level also compares favorably with the S&P 500 index's 3% rally. Key Picks Some better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20%. Wright Medical's long-term earnings growth rate is expected at 11%. DexCom's next-quarter earnings per share are projected to grow 56.3%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Luminex Corporation (LMNX): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q4 Earnings and Revenues Top Estimates DexCom (DXCM) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 237.50%. A quarter ago, it was expected that this medical device company would post a loss of $0.12 per share when it actually produced earnings of $0.17, delivering a surprise of 241.67%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $338 million for the quarter ended December 2018, surpassing the Zacks Consensus Estimate by 2.18%. This compares to year-ago revenues of $221 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call . DexCom shares have added about 21.5% since the beginning of the year versus the S&P 500's gain of 11.1%. What's Next for DexCom? While DexCom has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power o f earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $246.13 million in revenues for the coming quarter and $0.27 on $1.23 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for February 21, 2019 : INTU, KHC, BIDU, ED, HPE, SBAC, PBA, BMRN, KEYS, DXCM, ATUS, LNT The following companies are expected to repor t earnings after hours on 02/21/2019. Visit our Earnings Calendar for a full list of expected earnings releases. Intuit Inc. ( INTU ) is reporting for the quarter ending January 31, 2019. The computer software company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.56. This value represents a 600.00% increase compared to the same quarter last year. In the past year INTU has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 85%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for INTU is 44.86 vs. an industry ratio of 56.10. The Kraft Heinz Company ( KHC ) is reporting for the quarter ending December 31, 2018. The food company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.93. This value represents a 3.33% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for KHC is 13.37 vs. an industry ratio of 6.50, implying that they will have a higher earnings growth than their competitors in the same industry. Baidu, Inc. ( BIDU ) is reporting for the quarter ending December 31, 2018. The internet services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.16. This value represents a 38.95% decrease compared to the same quarter last year. In the past year BIDU has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 17.44%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BIDU is 21.48 vs. an industry ratio of 9.10, implying that they will have a higher earnings growth than their competitors in the same industry. Consolidated Edison Inc ( ED ) is reporting for the quarter ending December 31, 2018. The electric power utilities company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.76. This value represents a 5.00% decrease compared to the same quarter last year. In the past year ED has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 5.41%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ED is 18.33 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry. Hewlett Packard Enterprise Company ( HPE ) is reporting for the quarter ending January 31, 2019. The computer company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.34. This value represents a no change for the same quarter last year. In the past year HPE has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 4.65%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for HPE is 10.22 vs. an industry ratio of -9.10, implying that they will have a higher earnings growth than their competitors in the same industry. SBA Communications Corporation ( SBAC ) is reporting for the quarter ending December 31, 2018. The reit company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.83. This value represents a 99.82% decrease compared to the same quarter last year. In the past year SBAC has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.87%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for SBAC is 25.59 vs. an industry ratio of 15.70, implying that they will have a higher earnings growth than their competitors in the same industry. Pembina Pipeline Corp. ( PBA ) is reporting for the quarter ending December 31, 2018. The oil (production/pipeline) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.48. This value represents a 7.69% decrease compared to the same quarter last year. The last two quarters PBA had negative earnings surprises; the lates t report they missed by -2.13%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for PBA is 21.33 vs. an industry ratio of 1.40, implying that they will have a higher earnings growth than their competitors in the same industry. BioMarin Pharmaceutical Inc. ( BMRN ) is reporting for the quarter ending December 31, 2018. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.09. This value represents a 70.00% increase compared to the same quarter last year. BMRN missed the consensus earnings per share in the 4th calendar quarter of 2017 by -25%. The \""days to cover\"" for this stock exceeds 10 days. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BMRN is -431.71 vs. an industry ratio of -7.70. Keysight Technologies Inc. ( KEYS ) is reporting for the quarter ending January 31, 2019. The electrical instrument company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.72. This value represents a 63.64% increase compared to the same quarter last year. In the past year KEYS has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 14.29%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for KEYS is 23.17 vs. an industry ratio of 12.00, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. ( DXCM ) is reporting for the quarter ending December 31, 2018. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.16. This value represents a 60.00% increase compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DXCM is -1323.09 vs. an industry ratio of -0.60. Altice USA, Inc. ( ATUS ) is reporting for the quarter ending December 31, 2018. The communications company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.14. This value represents a 0.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ATUS is -303.00 vs. an industry ratio of 11.40. Alliant Energy Corporation ( LNT ) is reporting for the quarter ending December 31, 2018. The electric power utilities company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.36. This value represents a 9.09% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for LNT is 20.82 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Q4 Adj. EPS $0.54 May Not Compare To $0.17 Estimate, Sales $338M Beat $299.67M Estimate"", ""The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q4 2018 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q4 Earnings and Revenues Top Estimates"", ""DexCom Q4 revenue up 53%"", ""DexCom beats by $0.37, beats on revenue"", ""Masimo and Saudi Arabia MOH Collaborate for CCHD Screening""]"
DXCM,2019-02-22,38.4225,39.04,33.805,34.215,"[""DexCom's G6 CGM OK'd in Canada"", ""DexCom's G6 CGM OK'd in Canada"", ""Dexcom Inc (DXCM) Q4 2018 Earnings Conference Call Transcript Dexcom Inc (NASDAQ: DXCM) Q4 2018 Earnings Conference Call Feb. 21, 2019 , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom Fourth Quarter and Full Year 2018 Earnings Release Call. My name is Adrian and I'll be your operator for today's call. At this time all participants are in a listen-only mode. Later we will conduct question-and-answer session. (Operator Instructions) Please note this conference is being recorded. I'll now turn the call over to Matt Dolan, Vice President of Corporate Development. Please go ahead sir. Matthew Dolan -- Vice President, Corporate Development Thank you operator and welcome to the DexCom's Fourth Quarter 2018 Earnings Call. We will begin our prepared remarks with Kevin Sayer, DexCom's Chairman, President and CEO who will provide a summary of the quarter and fiscal year; this will be followed by a review of our financials and 2019 outlook from Quentin Blackford, our Executive Vice President and CFO; and then a strategic update from Steve Pacelli, our Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we'll open up the call for your questions. (Operator Instructions) With that let's review our Safe Harbor statement. Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom and are subject to various risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP results. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the Investor Relations portion of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I'll turn it over to Kevin. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Thank you for joining us today as we discuss our year-end results. Simply put, 2018 was an incredible year for DexCom on several fronts. First and foremost we broke through $1 billion in annual revenue. Very few if any medical device companies have reached the $1 billion revenue mark, while growing revenues organically at greater than 40% year-over-year. Clearly, the fourth quarter exceeded our expectations, delivering growth of over 50% compared to the same period a year ago. The Company also posted its most profitable non-GAAP fourth quarter and full year on record, as we continue to focus on growth while demonstrating leverage. Beyond the numbers, we received FDA approval for our G6 system in late March with G6 becoming a Class II system and being the first to meet the agency's newly established Special Controls for iCGM. We launched G6 in the U.S. around mid-year and continue to roll it out to additional markets globally. Initial patient feedback for G6 has been outstanding. G6 has truly redefined best-in-class CGM and provides us with a platform that we believe will drive continued growth opportunities for DexCom. Beyond G6, we saw significant increases in adoption in both the Medicare and international markets, both of which remain significantly under penetrated. We advanced our interoperability and decision support initiatives, including the acquisition of TypeZero and we solidified our product pipeline by amending our agreement with Verily and strengthened our balance sheet with the convertible note financing that we did late in the fourth quarter. All of these accomplishments have positioned us for continued success in 2019 and beyond. The team at DexCom has worked incredibly hard for this achievements. And I must recognize all of the effort needed to make this happen. The organization is achieving milestones that few companies ever do which is gratifying and comes with significant dedication and determination from our team. But going forward that will not be enough. We must put the infrastructure in place for this business to scale to its full potential. This need in part drove the additional announcement that we made today. In light of our meaningful uptick in demand we have set the aggressive internal goal to double our G6 production capacity by year-end. We need to expand our footprint dedicated to manufacturing within the Arizona facility both to meet our G6 goals and in anticipation of a late 2020 launch of G7. Similar to our scaling and manufacturing capacity, we have had to rethink how we build our customer-facing infrastructure to better serve our rapidly growing patient base not just for today but also to build a sustainable infrastructure for the future. We have therefore expanded and reorganized our customer support efforts which includes an increase in resources on our new Philippines location, as well as outsourcing other functions through third parties. This move will provide the ability to serve our customers with the same high-level of quality that they have become accustomed to and grow in a much more efficient manner. This expansion will result in organizational changes, including a reduction in certain staff at both our San Diego and Arizona facilities despite an expected overall increase in employee numbers in these locations this year. These types of decisions are always difficult as we've had to increase our support staff significantly over the past several years and have relied on such individuals to meet the demand of our customers. This is a necessary step to continue to adapt and further differentiate our business by maintaining our focus on the patient experience. These changes will occur during a transition period and we have taken the necessary steps to ensure that they occur as seamlessly as possible, while being open with our employees and supporting those impacted over the next several months. Quentin, will walk you through the financial implications of this effort. To sum up DexCom continues to deliver strong results and our recent initiatives leave us well positioned to execute over the next several years. I'll now turn the call over to Quentin, for financial update. Quentin Blackford -- Chief Financial Officer Thank you Kevin. As a reminder some of the figures that I will refer to on a non-GAAP basis and reconciliations to our GAAP results are available on our website. Today, we reported record worldwide revenue of $338 million for the fourth quarter of 2018 compared to $221 million for the same quarter in 2017, representing growth of 53% over the same quarter a year ago on both reported and constant-currency basis; a clear acceleration that drove us to $1.032 billion in revenue for the year. Sequentially, revenue was up 27% over the third quarter. This growth was driven by the sustained ramp in awareness that we saw building throughout 2018 particularly in our U.S. commercial business which was the primary driver of the upside. Notably, this growth materialized despite a decline in revenue per patient which was in line with our expectations provided on the third quarter call. As a result of our continued shift in channel mix, including continued growth of the International and Medicare businesses, as well as our proactive attempt to move commercial payer contracts into the pharmacy channel, we expected to see some overall pressure on revenue per patient. Nonetheless, we realized accelerating growth throughout the back half of the year as we saw these headwinds begin to play out and delivered an outstanding 2018. And we're particularly pleased with achieving 50% growth in our U.S. business in the fourth quarter. International sales in the quarter were consistent with our expectations and were up 72% over Q4 2017 on a reported basis or 75% excluding the impact of foreign exchange rate changes. Consistent with the first three quarters of the year, our fourth quarter growth continued to be driven by our direct markets. Fourth quarter gross margins improved from the third quarter as expected to 66%, resulting in a gross profit of $223 million. Operating expenses were $387 million for Q4 2018, including a $218 million one-time non-cash research and development charge related to the amendment of our Verily agreement. Apart from this non-recurring charge, fourth quarter operating expenses were $170 million compared to $142 million in Q4 2017. This reflects an increase of 20% year-over-year and compares favorably to our 53% revenue growth in the quarter. For the full year, we realized growth of 44% while non-GAAP operating expenses which adjust for the non-cash charge related to amended agreement with Verily, grew at less than half of that rate at 18%. In addition to the better-than-expected revenue result, this organization did a great job of controlling spend in 2018 and delivered meaningful improvements in our profitability profile. Importantly, adjusted EBITDA which excludes the impact of share-based compensation and the non-cash research and development fee was $86.3 million or 25.5% of revenue for the fourth quarter, demonstrating the profitability profile that this business is capable of consistently producing over time. Our non-GAAP net income was $48.9 million or $0.54 per share. We're incredibly happy with the progress being made on the profitable front and remain comfortable with the long-term financial goals laid out at our Investor Day back in December of 2018. We fortified our balance sheet, having ended the quarter with nearly $1.4 billion in cash and equivalents which includes roughly $700 million in net proceeds following our convertible note offering and share repurchase in Q4 of 2018. This offering provides the financial stability and flexibility we need to invest in our key strategic initiatives. We continue to have full availability of our $200 million revolving line of credit. Turning to 2019, as we provided in early January, we anticipate full year revenues of between $1.175 billion and $1.225 billion. This outlook assumes a higher rate of patient volume growth offset by headwinds associated with the decreased revenue per patient related to shifting channel mix. As you saw in our press release and as Kevin summarized, we announced a corporate initiative earlier today that will better position us to meet the increasing demands of growth in our business. As a result, we expect to incur roughly $25 million in restructuring-related charges that will primarily be incurred in the first half of 2019 and will be excluded from our non-GAAP financial results going forward. With that consideration we anticipate the following full year 2019 non-GAAP financial results. Gross margin improving to approximately 65%; operating margin increasing to approximately 5.5%; and adjusted EBITDA margin expanding to roughly 18%. We have included a reconciliation of GAAP versus non-GAAP results in our website, as well as historical trend presenting non-GAAP financial results on a consistent basis for comparability purposes. With that I'll now turn the call over to Steve for a strategic update. Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Thank you Quentin. The continued rollout of G6 remains a primary strategic priority for DexCom at the outset of 2019. In the U.S. we plan to begin shipping G6 to our Medicare patients in the near term and we have multiple OUS introductions planned for the balance of the year. 2018 was a year of great progress for our insulin delivery partners and we look forward to the launch of Tandem's Control-IQ system later this year, which includes our G6 sensor platform, as well as our recently acquired hybrid closed-loop algorithm from TypeZero. We're excited about the continued progress we're making with Insulet on the Horizon platform, as well as Lily, as they look to bring both connected pumps and pens to market. Our smart pen and integration program with Nova Nordisk continues to advance since we announced that partnership in October. We will continue to push these and other collaborations forward in 2019 and expect to see DexCom integrated smart pen systems that are commercially available in 2020.(ph)As we nearly saw in November, we amended our collaboration agreement with Verily, strengthening our product development goals and further aligning our interest as we work toward the commercialization of a fully disposable real-time CGM. This amendment eliminates all future royalty payments, significantly improving our long-term profitability outlook. Our next-generation or G7 system remains on track for a late 2020 or early 2021 release. With G7 on the horizon, we continue to collaborate on(ph)Paleo efforts in the non-intensive Type 2 population, working with United Healthcare, Onduo and others as they utilize CGM as a core tool and programs to drive health and economic benefits for people with Type 2 diabetes. In addition, we are on track to kick off study this year for applications in both the hospital and gestational markets. Both of these represent new markets in which uncontrolled glucose presents a major impediment to patient health and an economic burden to the health system. While we remain in the early stages, we are well positioned to leverage G6 as a platform technology that enables us to answer key questions and determine next steps. We look forward to providing updates as these studies progress. As you can see we continue to drive a number of important strategic initiatives and we're excited about the pipeline and market expansion opportunities ahead. With that I'll pass it back to Kevin. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Thank you Steve. 2018 will stand as the year of historic milestone for DexCom. And in diabetes technology in general. Our outlook for 2019 contemplates the growing awareness in the value of CGM. Our leadership position based on G6 technology be increasingly competitive landscape and our own proactive moves to optimize distribution channels and position DexCom for long-term operating efficiency. Given the growing awareness of the benefits of CGM and our accelerating growth throughout 2018, we entered 2019 with excitement around the opportunity that lies ahead. I would now like to open up the call for Q&A. Matt? Matthew Dolan -- Vice President, Corporate Development Thank you Kevin. (Operator Instructions) Operator, please provide the complete Q&A instructions. Questions and Answers: Operator (Operator Instructions) And our first question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Robert W. Baird -- Analyst Thank you. Good evening guys, can you hear me OK? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Yes, no problem. Jeff Johnson -- Robert W. Baird -- Analyst Alright, great. Thanks for taking the call. So I'm sure there is going to be some revenue questions and things like that. So I was thinking I was going to be deeper in the queue but so my question is pretty simple, just have you heard anything from Medicare on any kind of updated hospital CGM use initiatives that they could be looking to put in place that you guys could participate in over the next year or two? Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Yeah, nothing specifically -- Jeff, this is Steven, nothing specifically in terms of programs but we are aware that CMS has a particular focus on glucose control in the in-patient setting that we think will absolutely lend itself to that business evolving in the relatively near term. You've heard mention before of readmissions as a result of poor glucose control not being paid for. We are seeing hypoglycemia as a new focal point for CMS. And then you should expect that that would obviously trickle down into the core commercial payers as well. So it's a pretty exciting opportunity. It's still early but we're -- we're all aware of it. Jeff Johnson -- Robert W. Baird -- Analyst Yes. And then Quentin, we're two months into the quarter and obviously the 2019 guidance looks to a lot of us to be at least somewhat conservative here. Just any kind of update than gating and should we be thinking of kind of higher first half growth versus second half? Or just how we should be setting that model to this point? Thanks. Quentin Blackford -- Chief Financial Officer Yeah. I think we feel good about where we're at as we start to get into 2019 here. I think just given the tougher comps that we're up against in the back half of 2019 given the accelerating growth we saw over the course of 2018, you naturally would see lower growth rate. So I think you should expect higher growth rates in the first half, lower in the back half. In terms of the cadence, I would just point out we would expect the seasonal trends in the business to reflect more of what we saw in 2016 and 2017. 2018 was a year of tremendous acceleration and the growth profile over the course of the year which caused the seasonality trend to look a little bit different. So I think thinking about 20% or so of revenue in the first quarter which is in line with 2016 and 2017 is probably the right way to think about it. Operator And our next question comes from Margaret Kaczor from William Blair. Your line is open. Margaret Kaczor -- William Blair -- Analyst Hi, good afternoon guys. Thanks for taking the question. Maybe just to start off with -- just to follow-up on the guidance question. You guys obviously delivered 2x the original 2018 growth guidance. So as you look at 2019, I'm in the assumption that you guys made, how do those differ this year relative to last year including kind of the risk-weighting as you were, Quentin you were looking into last year relative to this year? Quentin Blackford -- Chief Financial Officer Well, I think if you go back to the beginning of last year, we laid out some of the headwinds that we anticipated may show up in the business over the course of the year. I think when you start to look back at it those headwinds did in fact show up but they showed up much later in the year than what we originally anticipated. So we're very clear early on we expected that there could be revenue per patient headwinds in the business. We didn't start to really see those until the third quarter and then really a full quarter's worth in the fourth quarter. So I think we were contemplating all the right things. It's just a timing of when they started to be impactful was probably a little bit later than we originally expected. When I think about 2019, we are approaching the year in a somewhat similar manner with respect to how we think about that revenue per patient headwinds that we know are in the business, although what's different now is we know they are playing out. We saw it Q4. We expect they're going to continue to play into 2019. And so when you look at the absolute dollar growth in our guidance, we are guiding to about $150 million to $200 million of absolute dollar growth but we've been clear there's about $100 million of revenue per patient headwinds in that guidance. So if you were to normalize back for that you've actually got a gross increase of about $300 million over the course of the year which is more or less right in line with what we just delivered in 2018. So the absolute dollar growth is pretty consistent. The growth rate is coming down obviously a much more difficult base that we're growing off of. But I think it starts to make a lot of sense when you look at it that way. Margaret Kaczor -- William Blair -- Analyst Okay. That's helpful. And then just kind of I guess a little bit going on that vein as a follow up, can you guys give us an update on the percent-wise that are under pharmacy right now? I think it was about 20% last quarter. And then as you're seeing that grow as a percentage of the mix coverage, have you seen any change in terms of the patient ad mix driven by pharmacy yet? And how do you expect that plays out throughout 2019? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman I'll take that Margaret, this is Kevin. Our covered lives are over 50% now slightly above that. And again let me remind you just because we have the covered lives over 50% doesn't mean they'll process through pharmacy. Most of our pharmacy plans have a dual benefit with DME pharmacy. Then it's up to us to drive awareness, so physicians and patients know that they can be covered through that vehicle. We expect that to continue to accelerate over the course of the year. We've had some very good discussions and some wins with the local, regional and national payer level over the past several months and have some really exciting things untapped going into 2019. And I think as Quentin talked about earlier channel mix, we are expecting channel mix to a shift in that direction. We see a tremendous opportunity for patients if they can pick their product up in the drugstore rather than call us and go through the DME process which is alive and well in the first quarter. We're in a much better position. So we're definitely driving and shifting the business there and encouraging our field team to do so as well. Operator And our next question comes from Raj Denhoy from Jefferies. Raj Denhoy -- Jefferies -- Analyst Hi, good afternoon. Wondered, if I could ask about the international performance. Again very strong in the quarter. Are there other countries contemplated in the near term in terms of establishing reimbursement or is it still mostly coming from Germany and some of the markets you're already in? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Yeah, the growth in our guidance is primarily coming from the existing countries that we are operating within. I think we've talked about the fact that we are seeing opportunities open up into countries like Japan, Korea where there has been regulatory approval more recently. We don't expect those to be big contributors to the overall revenue number in 2019. And I think we'll let the product get into the market and see how it performs and then we can start to think about how it becomes additive to the overall numbers, but it's all incremental opportunity as far as work and we look out into the future. Raj Denhoy -- Jefferies -- Analyst Are there specific countries though that you've targeted here for 2019 where you expect to establish more routine reimbursement that could be larger contributors? I think in the past you mentioned UK and some other large markets that might open up? Quentin Blackford -- Chief Financial Officer We're certainly making progress in the U.K. We continue to make progress in Italy. There are couple geographies where there are large government-funded CGM initiatives where they're announcing funding over several years and expanding the available population where CGM is available. For example, many of these countries will fund CGM for (inaudible) only and now they're saying OK, we'll expand this to adults and cover more. So we'll take advantage of those opportunities. There are competitive bidding situation, so I'm not going to go into those details and say where they all are but we will aggressively pursue those opportunities. We had a situation for example in Australia several years ago where they opened it up for bid and said they were going to cover not even 10 million in CGM. And within 60 days we have eaten up pretty much that entire budget as patients flocked to DexCom CGM. So we take advantage of those opportunities rapidly and we'll take care of the advantage of those where we can next year. Operator And the next question comes from Steven Lichtman from Oppenheimer. Steven Lichtman -- Oppenheimer & Co. -- Analyst Thank you. Hi guys, you've talked in the past that your discussions with payers revolve around the pharmacy course and I think also expanding into intensive Type 2s, I want to ask the second opportunity. How much progress are you making on getting coverage for intensive Type 2s and could that start becoming more of a revenue contributor this year? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman We think that it will become more of a revenue contributor. The Medicare coverage decision has been helpful but it takes awhile to get that Medicare coverage decision pushed down to all the individual payers and expend access. A lot of this is in conjunction with all of our pricing and overall access discussions as we ask for access to more patients than what is the pricing model, what is the business model for these people. And so all of these variables are in play and they've been -- we've been talking through all of them. We believe we'll increase our Type 2 intensive access. I'd love it to be faster than it is. But in all candid with Medicare Type 2 intensive insulin access, you have a very large portion of the Type 2 insulin intensive using population covered already. We just need really to increase awareness within patients and physicians that they can have access to that technology now under Medicare coverage. Steven Lichtman -- Oppenheimer & Co. -- Analyst Got it. And then as a follow up, will we potentially get any update on the United non-intensive study and outcomes there this year? Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Again, we've said this before Steve, it's not really it, don't think of it as a study with a principal investigator and something that's going to be published into a medical journal. This is real world. The work we're doing not just with United but on a number of fronts on the Type 2 non-intensive kind of Type 2 non-insulin taking patient is really real world, think of them as real world, but very, really large pilot study. Frankly, the last thing any of these guys want to do is share their findings with the rest of the world, right, because these guys are all competitors and they hold this data and the programs that are evolving out of these pilot to be very proprietary. And so I don't think you're going to see or certainly we're not going to be permitted to publish anything about the United pilot. I can't imagine United is going to be too vocal about it. So I think the answer is probably not. Operator And our next question comes from Danielle Antalffy from Leerink. Your line is open. Danielle Antalffy -- Leerink Partners LLC -- Analyst Hi, good afternoon guys, thanks so much for taking the question. Just curious and I guess, it's -- more specific to Europe right now than the U.S. but any change in the competitive landscape that you're seeing. I mean, obviously it is not impacting your growth trajectory. That's the first question specifically as it relates to the updated Abbott product? And then the follow-up question I have is how do we think about pricing longer-term in the U.S.? So I appreciate what you're saying here for 2019. Is it right to think that that sort of pricing headwind will repeat itself each year and get incrementally worse? Or is this kind of like and we're at the bottom for price increase guys? Thanks so much. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman This is Kevin. I'll try and take that Danielle. That's a very good question. With respect to competition, we take competition seriously all the time. While it hasn't slowed our growth trajectory, I would say if anything our vision and our focus on the competitive environment is much greater than it's been before. And as we design our products and our future pipeline we want to take advantage of those things that we do well to continue to toward competition. With respect to pricing in the U.S., as Quentin often says, pricing by channel for us has remained relatively consistent. But as we move more business into other channels for example, the pharmacy channel and currently the Medicare channel that's lower priced than we recognized in the past. We are preparing as we talked at our Analyst Day, over long-term to be a viable competitor in the pricing environment whatever it turns out to be. We talked about doubling the capacity of Arizona factory for G6. We talked about building at the G7 lines. As we look at our cost profile going forward we're preparing for whatever the market brings. We believe CGM is a very valuable technology. And the fact is what we've seen in Europe so far is the reimbursement as way of recognize the value of our technology over others on the market and we've continued to get a premium price. We will work to those models. We will work to those models in the U.S. We will grow and adapt to where it ends but we do think our product with its accuracy, its performance, its connectivity and its features has been worthy of the premium price that we have received and so for the payers have been amicable to that. That being said as we've also talked about if we can increase access and make it easier for patients to get and decrease our operating expenses through better channel mix, we're all for it. And we will take advantage of those opportunities as well. Quentin Blackford -- Chief Financial Officer Danielle I would just add I think we're still early in the opportunity of converting folks from traditional fingersticks to CGM. That the opportunity in the way of volume growth from the adoption of CGM technology is so significant that while there is going to be revenue per patient headwinds over time, I think the volume opportunity significantly more outweighs any of those headwinds. And I think as you open up some of these other markets that go beyond the intensive world of diabetes, you may see a different revenue per patient profile there but the volume numbers are again so significant that I think there is tremendous runway in front of us from a growth perspective for years to come. Danielle Antalffy -- Leerink Partners LLC -- Analyst Got it. Thanks so much guys. Operator And our next question comes from Kyle Rose from Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great, thank you very much. Can you hear me alright? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Yeah. Quentin Blackford -- Chief Financial Officer Yeah. Kyle Rose -- Canaccord Genuity -- Analyst Great. So I just wanted to dig back into the product cadence here over the course of next 12 to 18 months. I mean, obviously the G6 rollout globally and into Medicare is a priority. I think you reaffirmed that the G7 time lines for late 2020, early 2021. I'm just kind of wondering is there anything that we should be expecting over the interim period there whether it be the lower cost transmitter, G6 professional version potentially getting an extended wear time on the G6. Just kind of help us understand what some of the near-term product milestones may be? And then I just have one more question on longer-term margins. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman That's a great question and certainly a fun one for me. We always look at interim improvements for our product. If you look at everything we've ever done every generation we launch we come for example with an algorithm that significantly improves performance. Not long after we launch because once we have all these data we can really go model and figure out where it is. So we are exploring new algorithms with our G6 technology. We're also exploring longer wear time. We have the caveat around meeting iCGM standards with that longer wear time and we want to make sure we can meet iCGM standards for that full longer period whatever that may be. We do have the lower cost transmitter that will be out certainly in broad scale during the second half of 2019. We've got thought through the inventory they have now but that will certainly be a cost reduction and a help for us. And remember one of our key features and differentiators is the patient experience and our ability to iterate through software changes. We are really focusing tremendously on software development and offering our patients a better experience and better tools to manage their condition. Certainly not tomorrow but as we look at the TypeZero acquisition and the tools they develop for decision support and offering patients information to manage their condition better we intend to bring those tools to market. If we can get them done with G6, we'll get them done and get them in there if we have to wait till G7, we will do so. But make no mistake about it we want to make this patient experience more meaningful and better for them each and every day. Kyle Rose -- Canaccord Genuity -- Analyst Thank you. And then from an operating perspective, obviously taking some near-term charges to expanding operations internationally, but may be Quentin, can you kind of help us understand how we should think about going to a lower cost region when you're building up some of those operational capabilities. Just how that should impact margins over the long-term? And then any CapEx guidance this year as you invest in the manufacturing capacity? Quentin Blackford -- Chief Financial Officer Yeah, sure. So I think consistent with what we kind of talked about back at our Investor Day in December, gross margin expectations for us are to continue in that mid-60s range over the next five years or so. There are several levers that will allow us to improve that in terms of taking cost out of the product, including this lower cost transmitter that we expect later in the year but we also assume that there's going to be lower revenue per patient headwinds that we're going to be dealing with as well. And so I think the cost savings will ultimately offset the -- those benefits will offset headwinds that come from the lower revenue per patient. So think about that as being relatively consistent with where we're at now. And if we can deliver or execute better than great there is upside to it. I think one of the big areas of opportunity and Kevin hit on it is really focusing on how we double our capacity over the course of the year. We see tremendous opportunities in the markets in front of us. Markets that were not yet in but believe there is real potential to be in and we want to make sure that we have the capacity to address that. So you're going to see some significant CapEx spend over the course of this year, well north of $100 million to build out automated lines, stand up incremental clean rooms at our Mesa facility and ensure that we're building out capacity just as fast as we possibly can. So I think that's the way to think about it. In terms of operating margin cadence we laid out a plan to get to 15% over a five-year horizon. That's roughly 300 basis points a year. We are not committed to 300 basis points necessarily each and every year but I think we're making great progress toward it here in 2019 with our guidance that delivers roughly 200 basis points. And that's in the midst of a year that we are incredibly focused on getting G7 far down the pathway in getting that to market in late 2020, as well as the fact that we laid out this reorganization today. And I think it's important that we all understand. We are committed to ensuring that the patient experience is a good one through this transition. And therefore we're not looking at any reduction in workforce along the way until we are performing at equivalent or better levels than what we are performing in the Company today and then resources can start to come down. And so you got a bit of cost in the P&L this year that I would call duplicative. Just to ensure that there is a smooth transition here. Otherwise, you would see more leverage coming through the P&L this year alone. But we feel great about where are at. We're confident we can get to that long-term plan that we laid out and feel good about it. Operator And our next question comes from David Lewis, Morgan Stanley. Your line is open. Morgan Stanley -- -- Analyst Hi, this is (inaudible) for David. Congrats on the quarter. Just one for me and one follow-up I've got. Is there any update on the trials for the 14-day sensor for G6 and is that something we could see an approval for later this year? Quentin Blackford -- Chief Financial Officer We are not going to comment specifically on the timing but it's certainly something that's in the near-term pipeline. Morgan Stanley -- -- Analyst Okay. And then the pharmacy channel that you had 50% covered lives today, 40% last quarter. Should we think about 10 percentage point increase quarterly going forward? Or would you expect that pace to increase over the course of the year? Quentin Blackford -- Chief Financial Officer It's just not that predicable. I mean, we continue to push as hard as we can to transition the business into the pharmacy channel. And remember important thing Kevin said it, but the important thing to remember is when we say we had 50% of the commercial lives that have a pharmacy benefit that doesn't mean we're processing 50% of our commercial business through the pharmacy channel yet. So it's not just the addition of additional covered lives under contract. It's also then transitioning those folks into the pharmacy channel through education and otherwise. Operator And our next question comes from Travis Steed from Bank of America. Travis Steed -- Bank of America Merrill Lynch -- Analyst Alright. Thanks for taking the questions. I had a question about iCGM. I think we can debate all day if another competitor can better or not. But just wanted to ask on a big picture if one of your larger competitors does get iCGM, how do you think that changes the conversation for payers, patients and physicians? Does that have an impact on the conversation that you're having with those customers? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Yes. This is Kevin. I'll take that. And honestly the iCGM designations set some wonderful standards for us to get products approved and get them through the system quicker. I don't believe as I sit here today as we butt up against our competitors in the various payer channel and payer meetings that they really know that much about what iCGM means other than they know about the performance of DexCom sensor. Where iCGM becomes extremely relevant is on two fronts as I said earlier. Standards for us to shoot forward when we get future product iterations improved. For example, the 14-day product we're talking about, we know exactly how many data points we need to have and how that product needs to perform before we file up with the FDA to get that designation. We love the clarity and we intend to (technical difficulty) operate in that space. Number 2, when we get into interoperability, with various software systems with software around insulin pen, software around the sensor-augmented pump systems and sensor-assisted pump systems and various AP algorithms. Then with an iCGM you can drop in a different CGM into different systems if they are already approved. And this will give us and others if they can attain that designation the opportunity to go partner with more people. We are evaluating that designation. We already partnered with a number of people. And it helps us go faster than (inaudible). We try and help our partners go faster all the time now anyway. When it becomes significant is when we change our technology so when we go to the G7 platform for example, or we go to a 14-day platform somebody like Tandem, because we're iCGM or Insulet when they are out on the market can immediately incorporate our iCGM technolgoty into their system without running another clinical study, just showing that the sensor works properly. In the past, we literally sat in meetings with former partners and they chose not to integrate our technology with future offerings because they want to do a trial and run a filing and do a filing. So this -- that's where the iCGM comes in. I don't know that it is a big driver on the sales side. DexCom performance has always been a driver and we've always led with that. Travis Steed -- Bank of America Merrill Lynch -- Analyst And a question, one of your competitors is also talking about preferred co-pays. Is that something you're seeing gaining traction in the payer community at all and how important do you think that is in changing customer behavior? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman I think there is some of that that probably goes both ways quite honestly between the different competitors that are out there. I think keep in mind there is well north of 1,000 different payer policies and contracts that we're all working through. There is nothing of significance that we could point to in either direction where we've been advantaged or any other competitor has been advantaged to our knowledge. So we hear rumblings of it here or there, usually it's on a very small scale. So I'm sure it is out there in pockets but nothing of significance and nothing that concerns us. Operator And our next question comes from JP McKim from Piper Jaffray. Your line is open. J. P. McKim -- Piper Jaffray & Co -- Analyst Hi, thanks for taking the question. I wanted to ask just given kind of Tandem's strength from days like you now that you connect with that and then come and control like you. Have you seen any difference in your patient adds from MDI, pumps, any notable shift in the recent months? Quentin Blackford -- Chief Financial Officer Yes. No, I think, I mean, what we've been seeing, we did see a shift over the last several years where historically, we had been more heavily weighted to pump users I think. Again, it's mostly anecdotal, we don't have perfect data but it appears that we're basically tracking our patient adds to what the market represents which is in the U.S. kind of 65%, 70% of our new patients are in MDI patients and the balance are pump patients. J. P. McKim -- Piper Jaffray & Co -- Analyst Okay. That's helpful. Then just one on the pharmacy. You hear more and more of these walgreens and these large centers that are actually stocking the G6 in-house and so I'm wondering how much of, I don't want to say revenue contributor or how much of a strategy push that is? Is it material enough to call out at this point? Or is it just kind of the strategy you have and you'll see how it evolves going forward? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Yeah, look we -- there has been no shift in our business model toward stocking distributors or no incremental contribution that would skew the results in any way from stocking-type relationships or orders that would have come through. As a matter of fact, if they were significant enough and meaningful enough you would see us call those out in our MD&A of our Qs and our Ks and that's not the case. So we don't have any of that driving the results at this point. You go back into the fourth quarter I think what was most encouraging is the number of new patient additions was well beyond what we had anticipated. And honestly, it's accelerated every single quarter of the year. So the momentum has been tremendous there. And I think that's well as the driver. There is not anything from a stocking perspective that's drove any of these results. Operator And our next question comes from Joanne Wuensch from BMO Capital. Your line is open. Matt -- BMO Capital Markets (United States) -- Analyst Yes, hi, this is Matt on for Joanne. My question is with regards to expanding the capacity in Arizona. How is that going to impact gross margins in 2019 and 2020? Are you guys able to quantify that? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman What I'll lay out for you is kind of how we think about the different moving pieces. In 2019, if there is not a lot of incremental weight being put on the gross margin profile from standing up that Mesa Arizona facility it's already been stood up to degree and we're just adding incremental capacity into there at a faster clip but the unit production is increasing with it. So you're absorbing all that incremental cost. So you don't get any incremental weight put on your gross margin. What you have playing out over the course of 2019 is really you're going to get a benefit as a result of this lower cost transmitter that we've designed and will rollout in the back of the year. That benefit though will be offset by the headwinds associated with the revenue per patient impacts as channel mix continues to shift. Not getting to far ahead out into 2020 but now you are going to have a full year of 2020 with the benefit of the lower cost transmitter, you're going to have more full year impact of the Mesa facility but you will continue to have some of the channel shifts as the international business grows faster, as you now have a full year of pharmacy transitioned probably baked into the results. And again, I think the right way to think about the long-term gross margin is in that mid-60s but you will have those different levers playing out over time. Matt -- BMO Capital Markets (United States) -- Analyst That's helpful. And then just my follow-up. One of your competitors made an announcement that they are partnering up with Novo Nordisk, as well. Does that have any impact with your strategy with them and thank you for taking the questions? Quentin Blackford -- Chief Financial Officer No. Not at all. I mean, as you know they just announced that relationship. We announced our relationship with Novo back in October. And I can tell you we've been working with Novo for far longer than that. We continue to push forward to develop software tools, robust software tools to integrate our CGM together with their intelligent insulin pen technologies that will be coming to market. So I don't think that announcement earlier this week has any impact. Operator And our next question comes from Robbie Marcus from JP Morgan. Your line is open. Christen -- JP Morgan -- Analyst Hi, thank you. This is actually Christen on for Robbie. Just had a question on how you think about the development of the overall CGM market. Abbott put out that they now have 1.3 million active users. I know it's been harder for you to track user numbers. But where do see overall penetration levels for Type 1 diabetics for CGM in the markets you compete in? And where do you see that moving to over the course of 2019 versus the very rapid acceleration we saw in 2018? Thanks and then I just have one follow-up. Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development I mean, I'm not going to comment specifically on Abbott's patient numbers because I think much of that will come down to how you actually define what is an active patient using your technology. But what we've seen we contract the Abbott prescriptions here in the U.S. and kind of what we know about our patient base I think from a Type 1 perspective, we're probably pushing 30% penetration, far lower than that in the intensive and non-intensive Type 2 space. It's a little harder to track in Europe. I think Abbott has been a bit longer in Europe, so their patient install base is probably a little larger over there but kind of hard to tell. I think we still really the story is that we're all still in our infancy here in terms of addressable patients. So we've got a long way to go. Christen -- JP Morgan -- Analyst And then my follow-up is just you know you have the launch of Control-IQ coming up midway through this year with Tandem. How should we be thinking about that launch in terms of ASP of sensors that you will sell through that system? And have you baked in any incremental sales for the launch of Control-IQ of, uptick in the business that you do with Tandem versus your other partners? Thanks. Quentin Blackford -- Chief Financial Officer Yes. So we're not going to break down the components of our guidance. Certainly, that launch is one of the many things that is anticipated in the guidance that we gave you for this year. But in terms of ASPs on the sensors there will be no change whatsoever. I mean, the way we process through either the pharmacy or DME won't change with respect to the product, at least in the relatively near term so there wouldn't be any delta there. Operator And our next question comes from Ravi Misra from Berenberg Capital. Your line is open. Ravi Misra -- Berenberg Capital Markets -- Analyst Hi, thanks for taking the questions. So Quentin, just I wanted to kind of get you -- you have a kind of a range on revenues but a point figure on gross margin. So I guess, my first kind of question is, how do we think about that between the kind of bottom of the range, top of the range, any of the cadence there? And is it right to kind of think of OK, well you're taking a little bit of a haircut on a per patient revenue but your margin year-over-year is essentially flat because of these lower cost transmitters. I mean, is that kind of like-for-like reduction? And then my follow-up is around the restructuring. If you could just help us understand a little bit more around, give us the upfront investment that you're putting forward in the severances there. What kind of savings are you expecting there? And then how does that tie into as you look at risk to continue the tremendous growth that you have in driving? Thank you. Quentin Blackford -- Chief Financial Officer Yes, so there is a lot there. I'll try to hit on it and you can remind me if I don't hit on a part of it. With respect to the lower cost transmitter and how that's playing through the margins, we're only getting the back half of the benefit for that and that's kind of offsetting a full year impact of the continued transition through the pharmacy channel or toward the pharmacy channel. So it's not a like-for-like one-for-one necessarily if it was a full year annualized basis of all items being considered. In terms of the range on revenue and the point on the gross margin, I think we came out and said approximately 65%. I think, you'll find it's going to round into their based upon the different revenue ranges. So we could flex a little bit but we feel pretty good it's going to right around that 65% whether it was on the low end or the high end of that range. With respect to the reorganization that we talked about today, there's going to be about $25 million of restructuring cost that we will incur this year that's primarily related to both severance and retention. Most of that's going to be incurred in the first half of the year as we work through the transition. And most of those costs are triggered when we identify the individuals impacted and we've set a date which most of that has now happened or happened today. So you've triggered a good part of that expense upon that communication. Therefore it's going to happen or the expenses is going to be recorded in the first half although those people will continue to be with us over the course of some part of the year until I like mentioned earlier we get performance metrics in line or better than what we currently run at today. So we did not separate out any of the duplicative costs. We left all of those in our non-GAAP results. We're holding ourselves accountable to those to managing those well. But first and foremost is ensuring a good experience for the patients through this transition. And then we'll start to remove costs where it make sense. We're not going to quantify exactly what that is. We are not going to quantify that benefit for 2020 at this point but it certainly will be a nice enabler of helping us to achieve that longer-term 15% operating margin goal and 25% EBITDA margin goal we put out there over that five-year horizon. Operator And our next question comes from Doug Schenkel from Cowen and Company. Your line is open. Ronald -- Cowen And Company -- Analyst Hi, this is Ronald for Doug, thanks for taking my questions. It appears like your install base grew 50% in 2018. Is that correct? I'm looking at 2019 even factoring in the revenue per patient headwinds -- the headwinds, the high-end of your guidance seems to imply that install base growth(ph)disallow the decent amount versus that 50% this year. Is that correct? And if so why did that occur? I know it's a tough comparison but it doesn't seem like momentum is slowing? Quentin Blackford -- Chief Financial Officer Yes, we're not going to talk about the install base or the patient number. I think Steve laid out earlier the differences in how each of the different players in the market tend to look at it and everyone has got a different definition tied into it. I think the way to think about it and we've been pretty clear in our guidance, our volume assumptions in our guidance is about 25% to 30% growth. We've layered on top of that the 10 points of potential headwinds coming from revenue per patient or price headwinds that take that down to the 15% or 20%. So our guidance from a volume perspective up 25% to 30% on yes what was much stronger in 2018 but I think you got to keep in mind a couple different things. You got a much different base that you're growing off of. It was much more difficult in 2019 growing off of 44% growth base than what 2018 was that grew off of 25% base. And you also had the G6 launch in 2018 that we don't repeat in 2019. So there is couple reasons why it might slow a bit. I still think 25% to 30% volume growth is something we're going to be very happy with. And if you can deliver more than that then terrific. There's a lot of opportunities there. Ronald -- Cowen And Company -- Analyst Okay. And then can you talk about on Onduo's expansion plans for 2019? How broadly do you expect them to expand in the U.S.? And can you talk about how they're using DexCom CGM within their program? How often annually per patient on average? And is this only for a specific high-risk patients or more broadly? Thank you. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman We are not privy all of Onduo's plans. We do talk to them. Work with them. We provide them sensors. I believe they'll go as quickly as they possibly can. Their use of CGM is very much as an educational tool and something to reset the bar for people with Type 2 diabetes. Similar to other programs that we work with the Type 2 patient typically has not had any information like a CGM ever to help the manager condition their tool. He loves to exercise more and take your pills. And when you get on a CGM you can figure out well, gee, this is what exercise more does, this is what Eli Lilly different does. And this is what happens when I take my medications or when I change my medications. We believe CGM will be a critical component in all Type 2 diabetes management. There's nothing that can give a patient the information that CGM does. Absolutely nothing. And if we present it properly in a manner where patients can implement this information to make changes in their lifestyle and routines, it's going to be fantastic. The question then becomes how many a year do they use and what is the business model. And I think that's going to be worked out by a number of players through studies over time. And will be worked out by us as we look at potentially different product offerings to serve this market. We view it as a big one and we view it as something that can make a huge difference. Operator And our next question comes from Isaac Ro from Goldman Sachs. Your line is open. Isaac Ro -- Goldman Sachs -- Analyst Good afternoon. Thank you guys. Maybe first question, if you can just give us an update for -- on the Verily program. In loose terms, what some of the key milestones are for development this calendar year in terms of what's making your expectations that will be a great starting point. Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Yeah, so Isacc, this is Steve. What you heard us talk about in the prepared remarks was G7 and committing to the time line of launching G7 by the end of next year or the first part of 2020 and that remains on track. That is will be the first launch of a product that incorporates our technology together with Verily. We're not referring to it specifically as the Verily platform anymore. It's really, it's a DexCom product and we're going to call it G7 going forward. In terms of milestones we're not going to comment specifically on the -- in terms of clinical trial or regulatory filings at this point but we'll probably update you guys as the year goes on. Isaac Ro -- Goldman Sachs -- Analyst That's fine. Thank you. And then Quentin, a question for you on the guidance. Just given the velocity of top line growth, if we combine that with all the moving parts on the P&L from pharmacy and just funding the growth of the business. Can you help us think a little bit about the quarterly cadence of operating margin this year? Can you say that may or may not be kind of aligned with revenue seasonality. Can you just help if there's any kind of revenue to expense mismatch this year that could be a little bit non-obvious to us here in the beginning of the year? Thank you. Quentin Blackford -- Chief Financial Officer Yeah, I think back to this whole point of ensuring that we have a smooth transition in the workforce into our Philippines and third-party service providers, we're going to be willing to run duplicative cost through the P&L for a period of time which really starts in the first half of the year and is going to continue to be that way through the first half and then start to alleviate towarrds the mid part, the late part of Q3 and into Q4. So with those headwinds I don't think that you should necessarily expect you're going to have significant improvements in operating margin year-over-year in the first half of the year but you ought to see sequential improvements in operating margin take place over the course of the year. Operator Your next question comes from Matt Taylor from UBS. Your line is open. Quentin Blackford -- Chief Financial Officer Hey Matt, are you there? Operator Okay. We will move on. Next question comes from Chris Pasquale from Guggenheim. Your line is open. Chris Pasquale -- Guggenheim -- Analyst Thanks. I appreciate the sensitivity around the install base number but you guys have also provided some new color on new patient adds in the past. And I would think at least there definitions would be pretty consistent. Anything you're willing to share for 2018 to help us true up our models on that metric? Quentin Blackford -- Chief Financial Officer I would tell you that new patient adds were the primary driver of overall growth but very similar to the install base. I think the definition of a new patient is very different across the players in this space. We don't consider a new patient really a patient of ours until they are actually repurchasing and buying a normal purchase patterns for a period of time. I'm not sure if that's consistent across the universe. So even how we define new patients I think is very different across the players in this space. Chris Pasquale -- Guggenheim -- Analyst Okay. And then Quentin, just trying to nail down the impact of the transmitter and how that flows through. Can you share anything in terms of actually quantifying the magnitude of the cost reduction on the transmitter from where you're today to what this next gen looks like? Quentin Blackford -- Chief Financial Officer Yeah, we haven't quantified where it can go. It's significant I'll tell you that. The problem with it is the more volume that you're able to push through the plant and the more that you're absorbing in the way of cost, the better it gets. So we're not going to see the full benefit of it in 2019 as we get the full production capacity with it in '20 it becomes more meaningful to us. But we're not going to identify the complete difference or the total difference in that new structure -- new cost structure. Operator And our next question comes from Matt Lismund(ph)from Raymond James. Matt Lismund -- Raymond James & Associates, Inc -- Analyst Hi, thanks for the questions. I'm on for Jayson Bedford. My question is really about retention levels. So are you seeing with the G6 increased complaints among user base relative to G5 and G4 and how is it here trended? And do you still kind of see room for improved retention levels going forward maybe with the G7? Thanks. Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Our retention levels we've been very pleased with what we've seen with G6 and the teams here have done a really nice job being focused on it and watching it. We have seen some improvements in our ability to retain folks although we've always done a really nice job retaining patients once they've got on to our DexCom technology. But there has been a bit of improvement there. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman This is Kevin. The one thing I will add is our retention is largely been a factor of economic circumstances as well. And what will be interesting for us is as we map and charge G6 particularly as the majority of those patients use the phone app much more than our G5 patients before, I think we can have better pictures going forward in time as we look at what happens in the first quarter where our co-pays and deductibles reset. I think G6 anecdotally we hear everybody likes it a lot better. We still need more data. I mean with all those sales in Q4 we don't know whether those patients are coming back yet. And the biggest reason we lose a patient is money. It's not been the product performance. It's what they can afford and what they can do. Are we still there? Matt Lismund -- Raymond James & Associates, Inc -- Analyst Oh, thanks, that was my only question, I'm sorry. Operator I'm sorry. Your next question comes from Suraj Kalia from Northland Securities. Suraj Kalia -- Northland Capital Markets -- Analyst Sure, good afternoon everyone. So Kevin, a lot of pointers you'll have provided and I'm trying to get my hands around it. Let's assume FY '19 around(ph)$1.025 billion right revenues. Can you give us directionally in terms of what the expectation is for the pharmacy channel? And the subpart of that question is, I don't remember you guys giving us a delta between the DME and the pharmacy channel. I guess the reason I'm trying to ask is from let's say six quarters ago to now, gross margins are down roughly 500 bps. I understand the channel mix. I understand the movement of manufacturing, how you're all trying to move OpEx line item agreed. Help us understand or reconcile how your outlook is for the pharmacy channel? And what the price delta is so that we can at least kind of put it into a model and makes sense of that. Thanks for taking my questions. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman This is Kevin. I'll take that one. I'll go back to my old CFO days Quentin, but I won't throw a bunch of numbers out. At the end of the day when we talk about channel mix and channel shifting and the effect on margin, average revenue per patient is not just the pharmacy channel. Again, a larger percentage of our business continues to go through foreign markets. And those foreign markets do have lower average revenue per patient per year. And as that increases, our margins in fact do come down. Medicare as we started was a lower-average revenue per year per patient based on the goods that we ship them versus other. And that was kind of a margin deterrent in the beginning. We think overtime as our costs come down Medicare margins will be very good. With respect to pharmacy and DME mix, we've never disclosed that and there is no magic formula for what the difference is between DME and pharmacy. It literally varies contract. The contract and how we structure each of these arrangements. I think we can do it overtime. Quentin Blackford -- Chief Financial Officer Yes, Suraj, I would just add to it. The pharmacy model is a very attractive model to us. From an operating margin perspective we're convinced we can make more profit dollars in that business than we can at the DME channel. So we will continue to push for it hard. And while it might weigh on the gross margin a bit, it's going to ultimately be a tailwind for the operating margin. So at the end of the day it's the right thing to be looking at and it's going to be of value creator for us over the long term. Operator And the next question comes from Matt Taylor from UBS. Your line is open. UBS -- -- Analyst Hi, this is (inaudible) on for Matt. Sorry, I was on mute. Thanks for taking my questions. I have two quick ones. So first, what's the percentage of patients currently on G6 versus earlier generation of device? And also can you give us more color on the feedback you received so for for your pilot activities, with if possible G6 CGM? Thank you. Quentin Blackford -- Chief Financial Officer Well, I can tell you the G6 in the U.S. business, the majority of folks have moved toward G6 in our U.S. commercial business. Obviously, Medicare is still a G5 product. And then the international space we still have a lot of markets that utilize G5 but transitioning into G6. But in the U.S. it's now moved into the majority of folks on G6 in the U.S. You're going to have to repeat your second question. I didn't get it. UBS -- -- Analyst I'm sorry. So the second question is just the feedback you've got so far from your pilot activities with your disposable G6 CGM? Kevin Sayer -- Chief Executive Officer, President & Executive Chairman It's really very small. Nothing really to report there. UBS -- -- Analyst Okay, thank you. Operator And that concludes the question-and-answer session. I'll turn the call back over to Kevin Sayer for final comments. Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Thank you everybody for participating in our call today. Something you may not know is this year is actually DexCom's 20th birthday anniversary. We launched our first product in 2006 and after 10 years of commercial activity we hit the $500 million in annual revenues. But we picked up the next $500 million in annual revenues over the last two years. We're positioning the Company for the next billion dollars in revenues and beyond and I know it's going to go much faster. This is never easy but we are fully, fully committed to having the ideal technology in our pipeline to capitalize on this massive opportunity. As you heard today much of our focus this year in addition to growing our business and pushing the product pipeline is to build the infrastructure necessary to enable us to meet those goals. We look forward to a great 2019 and want to thank everybody once again. Have a great day. Operator Thank you ladies and gentlemen. This concludes today's conference. Thank you for participating and you may now disconnect. Duration: 65 minutes Call participants: Matthew Dolan -- Vice President, Corporate Development Kevin Sayer -- Chief Executive Officer, President & Executive Chairman Quentin Blackford -- Chief Financial Officer Steven R. Pacelli -- Executive Vice President, Strategy & Corporate Development Jeff Johnson -- Robert W. Baird -- Analyst Margaret Kaczor -- William Blair -- Analyst Raj Denhoy -- Jefferies -- Analyst Steven Lichtman -- Oppenheimer & Co. -- Analyst Danielle Antalffy -- Leerink Partners LLC -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Morgan Stanley -- -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst J. P. McKim -- Piper Jaffray & Co -- Analyst Matt -- BMO Capital Markets (United States) -- Analyst Christen -- JP Morgan -- Analyst Ravi Misra -- Berenberg Capital Markets -- Analyst Ronald -- Cowen And Company -- Analyst Isaac Ro -- Goldman Sachs -- Analyst Chris Pasquale -- Guggenheim -- Analyst Matt Lismund -- Raymond James & Associates, Inc -- Analyst Suraj Kalia -- Northland Capital Markets -- Analyst UBS -- -- Analyst More DXCM analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see ourTerms and Conditionsfor additional details, including our Obligatory Capitalized Disclaimers of Liability. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 31, 2019 Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom's G6 CGM OK'd in Canada""]"
DXCM,2019-02-25,34.4875,35.3675,34.4875,35.225,"[""Dexcom Sees Composite Rating Improve To 96"", ""DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $160"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $160"", ""Dexcom Sees Composite Rating Improve To 96"", ""DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up"", ""DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up DexCom, Inc. DXCM reported adjusted earnings of 54 cents per share in the fourth quarter of 2018, which outpaced the Zacks Consensus Estimate of 16 cents. The figure also improved from 10 cents registered in the year-ago quarter. Total revenues rallied 53% to $338 million on a year-over-year basis and also surpassed the Zacks Consensus Estimate by 2.2%. Segmental Details Revenues at the Sensor segment (75% of total revenues) surged 57% on a year-over-year basis to $252.8 million. Transmitter revenues (17%) increased 39% year over year to $59 million. Receiver revenues (8%) rallied 46% year over year to $26.3 million. Geographical Details U.S. revenues (83% of total revenues) surged 50% on a year-over-year basis to $281 million. International revenues (17%) skyrocketed 72% year over year to $57 million. Margin Analysis Gross profit in the quarter under review totaled $222.8 million, up 45.1% year over year. However, DexCom generated gross margin (as a percentage of revenues) of 65.9%, which contracted 360 basis points (bps) year over year. Margins were under pressure due to an inventory change as well as shift toward OUS and Medicare. Research and development (R&D) expenses amounted to $50.1 million in the quarter, up 15.7% year over year. Selling, general and administrative expenses totaled $104.6 million in the reported quarter, up 24.2% year over year. The company reported adjusted operating expenses of $169.7 million, up 19.9% year over year. As a percentage of revenues, DexCom generated adjusted operating margin of 50.2% in the fourth quarter. Guidance DexCom expects revenues in the range of $1.18-$1.23billion. The Zacks Consensus Estimate for revenues is currently pegged at $1.23billion, in line with the upper end of the guided range. However, gross profit margin is projected to be 65% of net revenues. While adjusted operating margin is expected to be 5.5% of net revenues, adjusted EBITDA margin is expected to be 18%. Wrapping Up DexCom exited the fourth quarter on a strong note, beating the Zacks Consensus Estimate for earnings and revenues. Impressive contributions from the Sensor, Transmitter and Receiver segments were key catalysts. A strong guidance also instills investors' optimism in the stock. In addition, the glucose monitoring market presents significant commercial opportunity for this Zacks Rank #2 (Buy) company. DexCom's opportunities in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. On the flip side, cutthroat competition in the market for blood & glucose monitoring devices is worrisome. We believe that the company's margins will continue to remain under pressure in the upcoming quarters due to high product development costs and rising expenditures on the R&D front. Lower expected margins on transmitter sales are added concerns. Earnings of MedTech Majors at a Glance Some other top-ranked MedTech stocks that posted solid quarterly results are Varian Medical Systems VAR , AngioDynamics ANGO and CONMED Corporation CNMD . Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2. AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock sports a ZacksRank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million exceeded the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2. This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities. These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month. Click here to see these breakthrough stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Invest in Illumina (ILMN) Stock Now Illumina, Inc.ILMN has been gaining investor confidence on consistently positive results. Over the past year, shares of Illumina have rallied 29% compared with the S&P 500 index's 0.5% gain. This renowned sequencing and array-based genetic analysis solution provider has a market cap of $44.26 billion. The company has an earnings growth rate of 21.5% for the next three to five years. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. What Makes the Stock an Attractive Pick? Worldwide Expansion to Drive Growth Apart from North America, Illumina markets and distributes products to customers in Europe, Latin America, and the Asia-Pacific region, either through its direct selling force or through distributors that specialize in life science products. In the fourth quarter, Illumina witnessed impressive growth in the Asia-Pacific region propelled by 28% sequencing growth (adjusting for the tariff impact) in Greater China. Obviously, among the emerging markets, China currently offers the maximum scope for growth to Illumina. Strategic Partnerships to Strengthen Business We are optimistic about Illumina's expansion strategy through the enhancement of its portfolio of sequencing products, and the development of strategic partnerships with therapeutic and diagnostic services providers. For instance, within clinical markets, extended RAS companion diagnostic kit was developed by Illumina in partnership with Amgen to identify patients who are eligible for treatment of metastatic colorectal cancer with Vectibix. In 2018, Illumina announced the acquisition of Edico Genome to strengthen the next-generation sequencing (NGS) platform. The acquisition is expected to help Illumina provide an enhanced data analysis experience to NGS users along with an expanded customer base. Growth in Oncology Space Lately, to catalyze clinical markets, Illumina has adopted a strategy to deliver market-leading technologies and tailored solutions that will enable customers to personalize patient care through genomics. The company is seeing a rise in the number of liquid biopsy and clinical commercial customers. In 2018, the NovaSeq platform consistently demonstrated strong momentum on solid performance by the S1, S2 and S4 flow cells. Riding on NovaSeq platform strength, the company recorded sequencing system revenues of $159 million in the fourth quarter, a new quarterly record for Illumina. While the HiSeq replacement cycle is under process, the company is optimistic to note that majority of HiSeq and HiSeq X customers have placed NovaSeq orders. Which Way Are Estimates Heading? For the current quarter, the Zacks Consensus Estimate for earnings is pegged at $1.34. The same for revenues stands at $834.29 million, mirroring a year-over-year improvement of 6.7%. For 2019, the Zacks Consensus Estimate for earnings is pinned at $6.53, reflecting 14.2% year-over-year growth. The same for revenues is pegged at $3.77 billion. Other Key Picks Other top-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom, Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20%. Wright Medical's long-term earnings growth rate is expected at 11%. DexCom's second-quarter earnings per share are projected to grow 160%. This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities. These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98% , +119% and +164% gains in as little as 1 month. Click here to see these breakthrough stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $160"", ""Dexcom Sees Composite Rating Improve To 96"", ""DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up""]"
DXCM,2019-02-26,35.075,35.17,34.1725,34.8975,"Here's Why Investors Should Buy DexCom (DXCM) Stock Now DexCom, Inc.DXCM is one of the top players in the MedTech space. It is likely to gain from a solid fourth-quarter performance and robust growth at the Sensor, Transmitter and Receiver segments. In the past three months, this Zacks Rank #2 (Buy) stock has rallied 13.4% compared with the S&P 500's 6.2% increase. What's Favoring the Stock? DexCom exited the fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate. Revenues at the Sensor segment (75% of total revenues) surged 57% on a year-over-year basis to $252.8 million. Transmitter revenues (17%) increased 39% year over year to $59 million. Receiver revenues (8%) rallied 46% year over year to $26.3 million. For 2019, the company expects revenues in the range of $1.18-$1.23 billion. However, gross profit margin is projected to be 65% of net revenues. While adjusted operating margin is expected to be 5.5% of net revenues, adjusted EBITDA margin is expected to be 18%. DexCom recently announced that it has received Health Canada approval for the next generation Dexcom G6 CGM System for people with diabetes aged two years and older. Earlier, Dexcom G6 was introduced in the United States, the United Kingdom, Ireland and several other European countries, and has witnessed solid sales. In 2019, DexCom plans the G6 commercial launch in Canada as the company continues to build capacity for supporting global launch plans. These apart, DexCom announced an amendment to its previously-announced collaboration with Verily. The revised terms are likely to expand DexCom's product development goals. By the end of fourth-quarter 2018, management at DexCom announced that the company has been witnessing significant increases in adoption in both the Medicare and international markets. Also, the company advanced its interoperability and decision support initiatives including the acquisition of TypeZero and solidified its product pipeline by amending the agreement with Verily. Which Way Are Estimates Trending? The Zacks Consensus Estimate for 2019 revenues is pegged at $1.23 billion, reflecting an 18.8% growth. The same for adjusted earnings is pinned at 28 cents, indicating a year-over-year decline of 6.7%. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here . Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2. Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-02-27,35.025,35.9425,34.88,35.0225,"[""Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses"", ""DexCom (DXCM) Gets Health Canada Approval for G6 CGM System"", ""DexCom (DXCM) Gets Health Canada Approval for G6 CGM System"", ""Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses"", ""DexCom (DXCM) Gets Health Canada Approval for G6 CGM System DexCom, Inc.DXCM announced that its next generation G6 CGM system has received an approval from Health Canada, a regulatory authority. The device is designed to cater to diabetes patients in Canada, aged two years and above. The G6 commercial launch in Canada is slated to occur in late 2019. Interestingly, DexCom is already planning for the worldwide launch of the product in the near future. About G6 CGM DexCom's G6 CGM system is a diabetes management device. G6 was initially launched in the markets of United States, United Kingdom, Ireland and several other European nations, where it registered robust sales figures in the las t report ed quarter. For investors' notice, G6 is an upgradation of DexCom's flagship G5 mobile system. The G5 mobile system is used to measure glucose levels with a sensor that is fitted just underneath the skin. DexCom is also gearing up for the launch of the G7 system in late 2020 or early 2021. With G7, the company aims to deliver cost-effective health benefits to people suffering from non-intensive Type 2 diabetes. Market Prospects Per Allied Market Research, the global market of CGM systems is projected to reach $4,921 million by 2024, multiplying at a CAGR of 22.9% (from 2018 to 2024). Considering the bountiful prospects, the launch of the G6 CGM system by DexCom is considered to be strategically timed. Not to forget, the CGM systems market is an integral part of the broader diabetic devices space, which also includes blood glucose meters and insulin delivery devices. Other Recent Developments In November 2018, DexCom amended the collaboration and licensing agreement with Verily for the development of a fully disposable real-time CGM. The agreement enabled DexCom to more efficiently deal with Type 2 diabetes. DexCom has been making solid progress with Insulet for developments on its Horizon platform. DexCom announced a development agreement with Lilly to incorporate CGM into the latter's Connected Diabetes Ecosystem. This will enable Dexcom to introduce both connected pumps and pens to the market. In October 2018, the company announced the collaboration of its smart pen and integration program with Novo Nordisk. The company plans to continue investing in several other similar partnerships throughout 2019 and expects DexCom integrated smart pen systems to become commercially accessible to consumers by 2020. Price Performance The stock has outperformed the S&P 500 Index over the past three months. The stock has gained 10.8% compared with the index's growth of 4.5%. Zacks Rank & Other Key Picks Currently, DexCom has a Zacks Rank #2 (Buy). Other top-ranked stocks in the broader medical space include ABIOMED, Inc., ABMD , Penumbra, Inc., PEN , and Masimo, Inc. MASI , each carrying a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . ABIOMED's long-term earnings growth rate is expected to be 27.67%. Penumbra's long-term earnings growth rate is projected to be 20%. Masimo's long-term earnings are projected to grow 15.6%. Is Your Investment Advisor Fumbling Your Financial Future? See how you can more effectively safeguard your retirement with a new Special Report, \""4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.\"" Click to get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Gets Health Canada Approval for G6 CGM System"", ""Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses""]"
DXCM,2019-02-28,35.005,35.6588,34.7975,34.8325,"[""Here's Why You Should Invest in Chemed (CHE) Stock Right Now"", ""Here's Why You Should Invest in Chemed (CHE) Stock Right Now"", ""Here's Why You Should Invest in Chemed (CHE) Stock Right Now Chemed CorporationCHE has been gaining investor confidence on continued positive results. In the past six months, the company has been consistently outperforming the S&P 500 market. The stock has gained 3.2% versus the market's 3.6% decline. This Cincinnati, OH-based company has a market cap of $5.20 billion. The company has an expected earnings growth rate of 13.9% for the next three to five years. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. What Makes the Stock an Attractive Pick? VITAS Holds Potential Chemed has seen strong performance from the VITAS business over the past few quarters. During fourth-quarter 2018, VITAS admissions generated from hospitals rose 2% and made up 50% of total admissions. Also, home-based admissions rose 2.5%. Overall, VITAS revenues rose 4.9% on a 1.1% rise in geographically-weighted average Medicare reimbursement rate and a 7.3% increase in average daily census. For 2019, the company projects VITAS Healthcare revenue growth (prior to Medicare Cap) of 5.5-6%. Roto-Rooter Continues to Grow Roto-Rooter is currently the nation's leading provider of plumbing and drain cleaning services. Through its network of company-owned branches, independent contractors and franchises, Roto-Rooter offers plumbing and drain cleaning services to more than 90% of the U.S. population. During fourth-quarter 2018, Roto-Rooter reported 10.6% growth year over year. This business displayed robust performance in the core plumbing and drain cleaning service segments as well as solid growth in water restoration. We currently look forward to Roto Rooter's recently-made acquisition of certain franchises in California. Shareholders' Return Chemed's capital deployment policy is based on suitable acquisitions and solid return of cash to shareholders through dividends and buybacks. Chemed exited 2018 with total cash and cash equivalents of $4.83 million, showing a significant decline from $11.1 million at the end of 2017. The company had total debt of $89.2 million at the end of 2018, which again reflected a decline from $101.2 million at the end of 2017. At 2018-end, net cash provided by operating activities was $287.1 million compared with $162.5 million at 2017-end. During the fourth quarter, the company repurchased shares worth $36.9 million. As of Dec 31, 2018, the company had $47 million of remaining share repurchase authorization under this plan. Which Way Are Estimates Treading? For the current quarter, the Zacks Consensus Estimate for earnings is pegged at $2.98, reflecting year-over-year growth of 9.6%. The same for revenues stands at $456 million, mirroring 3.8% improvement year over year. For 2019, the Zacks Consensus Estimate for earnings is pinned at $12.7, reflecting 7% year-over-year growth. The same for revenues is pegged at $1.87 billion, indicating a rise of 4.7%. Other Key Picks Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Tandem Diabetes Care, Inc. TNDM and DexCom, Inc DXCM . Notably, each of these stocks currently carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is expected at 8%. Tandem Diabetes' long-term earnings growth rate is expected at 20%. DexCom's second-quarter earnings per share are projected to grow 160%. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Invest in Chemed (CHE) Stock Right Now""]"
DXCM,2019-03-01,35.13,36.01,34.525,35.8725,
DXCM,2019-03-04,35.9725,36.226,34.5125,35.375,"[""Here's Why You Should Snap Up Abbott (ABT) Stock Right Now"", ""US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'"", ""US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'"", ""Here's Why You Should Snap Up Abbott (ABT) Stock Right Now"", ""Here's Why You Should Snap Up Abbott (ABT) Stock Right Now Abbott Laboratories ABT has been gaining investor confidence on continued positive results. The company's share price has outperformed the S&P 500 over the past year. The stock has gained 32.6% in comparison to the market's 3% rise in the said period. This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $124.96 billion. The company has an expected earnings growth rate of 11.8% for the next three to five years. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. What's Working in Favor of the Stock? Diagnostics Arm Grows on Alinity Within Diagnostics, sales have been growing substantially over the past few quarters. Alinity, the family of highly differentiated instruments, is achieving accelerated growth and strong competitive win rates in Europe. The global rollout of Alinity positions this business for consistent above-market growth in the years to come. Alere Integration Synergies Impressive The integration of Alere has added Rapid Diagnostics to Abbott's existing leadership position in the $50-billion global diagnostics market. Alere's complementary portfolio of diagnostic products, comprising tests for infections such as HIV, tuberculosis, malaria and dengue will be added to Abbott's portfolio. Over the past few months, Abbott has made solid progress with the integration of this business and continues to see several levers for growth acceleration, including opportunities for geographic, platform and test menu expansion. Progress With Diabetes Business This business achieved growth of 35% in 2018 led by FreeStyle Libre which achieved global sales of more than $1 billion in 2018, an increase of 100% from the prior year. As of 2018-end, there are now approximately 1.3 million active users worldwide, of which approximately two-thirds are type 1 diabetics and one-third type 2. In the United States, there has been an accelerating trend of new users as Abbott is ramping up its awareness efforts during the second half of the year. Other Key Picks Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc DXCM . Notably, each of these stocks currently carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is expected at 8%. Illumina'slong-term earnings growth rate is expected at 21.5%. DexCom's second-quarter earnings per share are projected to grow 160%. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs. See Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'"", ""Here's Why You Should Snap Up Abbott (ABT) Stock Right Now""]"
DXCM,2019-03-05,35.4075,37.4575,34.75,36.7425,"[""Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now"", ""Hologic (HOLX) Receives Global Nods for Omni Hysteroscope"", ""'Diabetes-tech giant Dexcom plans to lay off 13% of its workers and outsource jobs. People who rely on the products say it's endangering a key part of its business.' -Business Insider Earlier Reported"", ""Dexcom Discussed As New Short Idea By Hedgeye"", ""Hearing Hedgeye Sees Over 305 Downside In Dexcom; Likes Co. And Its Products But Believe Stock Has 'Gotten Ahead Of Itself'"", ""Hearing Hedgeye Sees Over 305 Downside In Dexcom; Likes Co. And Its Products But Believe Stock Has 'Gotten Ahead Of Itself'"", ""Dexcom Discussed As New Short Idea By Hedgeye"", ""'Diabetes-tech giant Dexcom plans to lay off 13% of its workers and outsource jobs. People who rely on the products say it's endangering a key part of its business.' -Business Insider Earlier Reported"", ""Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now"", ""Hologic (HOLX) Receives Global Nods for Omni Hysteroscope"", ""Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now Hologic, Inc. HOLX has been on a healthy growth trajectory of late. The company's progress in the domestic and international markets, a strong pipeline of products as well as huge prospects of the GYN Surgical and Molecular Diagnostics segments make it an attractive pick. Thus, this Zacks Rank #2 (Buy) stock has solid prospects in the near term. Over the past year, the company's share price has outperformed its industry . The stock has gained 22.7% in comparison with the industry's 12.2% rise and the S&P 500's 3.2% increase. The stock has a market cap of $13.68 billion. The company's expected growth rate for three to five years is 8.9%. Let's find out whether the recent favorable trend is a sustainable one. What's Working in Favor of the Stock? Molecular Diagnostics Sees Consistent Growth Hologic's management is impressed with continued growth in the core Molecular Diagnostics sub-segment, which accounted for roughly 55.4% of total Diagnostics revenues in the fiscal first quarter. Molecular Diagnostics sales increased 11.2% at CER. Global growth was driven by expanding market share and utilization of fully automated Panther system along with continued solid uptake of Aptima women's health products. Per management, the company has more than 15 FDA-cleared or CE-marked tests to run on the Panther or Panther Fusion platforms. In January, Hologic received FDA approval for Aptima Mycoplasma genitalium assay. GYN Surgical Continues to See Growth After a dull performance in the first half of fiscal 2018, the company has been showing gradual improvement in the GYN Surgical business. Although NovaSure sales declined, we are upbeat about the solid quarterly show by MyoSure. New leadership, easier comparisons and revamped sales and marketing efforts along with product launches are expected to drive growth. Per Hologic, MyoSure has gained the reputation of being the largest product line in the Surgical business. This product line has been consistently delivering strong performance and has seen high-single-digit growth in the fiscal first quarter. Hologic expects its surgical business to witness strong growth on continued expansion of MyoSure suite of products, stability in NovaSure and growing international business. Growth Initiatives In order to streamline operations and reduce cost of revenue, Hologic has been adopting strategies over the past few years. The company has invested in commercial areas where management has recognized solid returns. In this regard, Hologic has invested in the Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain market share with NovaSure. Per management, these initiatives are paying off through increased brand awareness, market share gains and price stability, all of which will result in higher sales. Other Key Picks Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc DXCM . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is projected at 8%. Illumina'slong-term earnings growth rate is expected at 21.5%. DexCom's second-quarter earnings per share are estimated to grow 160%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Hologic (HOLX) Receives Global Nods for Omni Hysteroscope In line with Hologic, Inc. 's HOLX focus to grow within the promising space of GYN Surgical, the company recently announced encouraging global regulatory approvals for its Omni hysteroscope. In this regard, Health Canada issued a medical device license for Hologic's Omni hysteroscope, an advanced three-in-one modular scope. Furthermore, the company received CE mark for the same. Omni Hysteroscope in Details Hologic claims Omni hysteroscope to have advanced visualization capabilities for both diagnostic and therapeutic hysteroscopic procedures. The company in this regard noted that a direct visualization of the uterine cavity in women with abnormal bleeding is very useful. This allows accurate identification and collection of quality samples and remove pathology in a safer and more effective manner than traditional methods like blind biopsy and curettage. In December 2018, Hologic announced the U.S. launch of Omni hysteroscope. According to Hologic, the device is compatible with all MyoSure tissue removal offerings, including MyoSure REACH, MyoSure XL, MyoSure LITE and MyoSure MANUAL devices. Market Potential Hologic's strategy to gain traction from the GYN Surgical segment seems to be aligned with data provided by Prescient & Strategic Intelligence. Per the report, the global hysteroscope market is expected to witness a CAGR of 4.5% between 2016 and 2022. It is further believed that increasing female geriatric population, growing uterine cancer cases, rising female infertility incidences, increasing cases with abnormal uterine bleeding and rising customer needs of minimally-invasive treatments will boost the global hysteroscope market. In view of these encouraging factors, we believe that the company's development regarding the Fluent system is strategic and it is likely to broaden customer base. GYN Surgical at a Glance After a dull performance in the first half of fiscal 2018, the company has been showing gradual improvement in the GYN Surgical business. Although NovaSure sales declined, we are upbeat about the solid quarterly show by MyoSure. New leadership, easier comparisons and revamped sales and marketing efforts along with product launches are expected to drive growth. However, Novasure sales declined mid-single digit from the prior-year period. Per Hologic, Myosure has gained the reputation of being the largest product line in the Surgical business. This product line has been consistently delivering strong performance and has seen high-single digit growth in the fiscal first quarter. We are upbeat about the commercial launch of MyoSure MANUAL device in the United States. Notably, in addition to MyoSure MANUAL, the Myosure products portfolio consists of MyoSure, MyoSure REACH, MyoSure XL, and MyoSure LITE devices. Going forward, Hologic expects its surgical business to witness strong growth on continued expansion of MyoSure suite of products, stability in NovaSure and growing international business. Share Price Movement Hologic has consistently outperformed its industry over the past year. The stock has gained 22.8% in comparison with the 12.3% rise of the industry. Zacks Rank & Other Key Picks Hologic currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is expected at 8%. Illumina'slong-term earnings growth rate is expected at 21.5%. DexCom's second-quarter earnings per share are projected to grow 160%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Hearing Hedgeye Sees Over 305 Downside In Dexcom; Likes Co. And Its Products But Believe Stock Has 'Gotten Ahead Of Itself'"", ""Dexcom Discussed As New Short Idea By Hedgeye"", ""'Diabetes-tech giant Dexcom plans to lay off 13% of its workers and outsource jobs. People who rely on the products say it's endangering a key part of its business.' -Business Insider Earlier Reported"", ""Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now"", ""Hologic (HOLX) Receives Global Nods for Omni Hysteroscope""]"
DXCM,2019-03-06,36.74,37.0162,35.6125,35.8525,"[""GNC Forms Joint Venture With IVC to Improve Cost Efficiency"", ""GNC Forms Joint Venture With IVC to Improve Cost Efficiency"", ""GNC Forms Joint Venture With IVC to Improve Cost Efficiency GNC Holdings, Inc.GNC recently announced forming a strategic joint venture with a vitamins and nutritional supplement manufacturer - International Vitamin Corporation (\""IVC\""). Through the joint venture, GNC will integrate its manufacturing division with IVC. Per management, IVC's consistent supply of raw materials at reasonable prices, strong manufacturing processes and the buying power of both organizations will help GNC achieve increased cost savings. The joint venture will be manufacturing the products produced by the Nutra manufacturing facility. Financial Details of the Deal GNC is expected to retain an initial 43% ownership in the joint venture and slated to receive an aggregate of $101 million from IVC in exchange of Nutra manufacturing facility and the Anderson facility's net assets. Depending on the joint venture's future performance and subject to adjustments, GNC will receive an additional $75 million from IVC over the next four years as IVC's ownership in the joint venture increases to 100%. GNC's Nutra business is included within the Manufacturing/Wholesale segment. As a result of this joint venture, the company expects decline of roughly $25-$30 million in the segment's EBITDA in the near term. GNC's Other Joint Ventures GNC has recently completed a transaction to form a joint venture with Harbin Pharmaceutical Group to strengthen its presence in China's huge supplements market. The company is now set to launch two joint ventures with Harbin- Hong Kong-based China joint venture and China joint venture. Per management, these joint ventures will make a wide distribution network accessible to GNC and enhance the company's manufacturing ability in China. Notably, the Hong Kong-based China joint venture, operating the existing cross-border e-commerce business was formed along with the closing of the Harbin investment. Furthermore, GNC is ready to complete the China joint venture in a short span of time, and it will comprise the retail stores in China and the pharmacy distribution channel. On finalization of the joint venture, Harbin will contribute $20 million of working capital to the newly formed entity. The joint venture will also aggressively invest in marketing and is expected to deliver $200 million in revenues over the next three years. Share Price Movement GNC has outperformed its industry in the past three months. The stock has gained 2.3%, against the industry's 21.4% decline. Zacks Rank and Key Picks GNC Holdings currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is projected at 8%. Illumina'slong-term earnings growth rate is expected at 21.5%. DexCom's second-quarter earnings per share are estimated to grow 116.7%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""GNC Forms Joint Venture With IVC to Improve Cost Efficiency""]"
DXCM,2019-03-07,35.895,36.4912,35.175,35.7675,"[""GNC Holdings to Expand Portfolio With Alani Nutrition Deal"", ""GNC Holdings to Expand Portfolio With Alani Nutrition Deal"", ""Tandem's Global Growth a Boost, Operating Losses a Bane On Mar 6, 2019, we issued an updated research report on Tandem Diabetes Care, Inc.TNDM . Tandem Diabetes' expansion initiatives in the global market s are a major positive. However, the company's heavy dependence on the sales of insulin pumps and its recurring operating losses pose concerns for the stock. Tandem Diabetes currently carries a Zacks Rank #3 (Hold). The company has outperformed the industry in the past three months. The stock has soared 91% compared with the industry 's 3.6% rise. Notably, the company fared well on the top-line front with better-than-expected results in fourth-quarter 2018. Strength in domestic sales along with the launch of the t:slim X2 Insulin Pump in selected international markets bode well for the company. In the fourth quarter, the company witnessed a strong rollout of this system globally. The sales guidance for 2019 looks promising. Also, favorable demographics in the diabetes market are expected to boost demand for Tandem Diabetes' products. Tandem Diabetes Care, Inc. Price Tandem Diabetes Care, Inc. Price | Tandem Diabetes Care, Inc. Quote As a major milestone, t:slim X2 Insulin Pump obtained a commercial license in Canada during the fourth quarter. Also, the FDA classified it under the first and a new device category called alternate controller enabled infusion pumps, in short, referred to as ACE pumps. Moreover, the same is related to the FDA's interoperability initiative, which the company previously termed as an iPump. Tandem Diabetes is also working on a mobile application, currently designed to use the Bluetooth radio capability to wirelessly upload pump data to t:connect, receive notification of pump alerts and alarms plus integrate other health-related information from third-party sources. The company is consistently focusing on strengthening its global presence. In 2018, it informed about entering into agreements with independent distributors for markets in Australia, New Zealand, Italy, Scandinavia, South Africa, Spain and the United Kingdom. On the flip side, excessive reliance on sales of insulin pumps and persistent operating losses pose threats to the company. Moreover, the company's operations are likely to be affected by a tough competitive environment. Key Picks Some better-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc. DXCM , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian's long-term earnings growth rate is projected at 8%. Illumina's long-term earnings growth rate is expected at 21.5%. DexCom's second-quarter fiscal 2019 earnings per share are estimated to grow 116.7%. Is Your Investment Advisor Fumbling Your Financial Future? See how you can more effectively safeguard your retirement with a new Special Report, \""4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.\"" Click to get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""GNC Holdings to Expand Portfolio With Alani Nutrition Deal""]"
DXCM,2019-03-08,35.39,35.8525,34.8988,35.81,"[""Align Technology-Benco Dental Deal to Expand iTero Reach"", ""Align Technology-Benco Dental Deal to Expand iTero Reach"", ""Is DexCom a Buy? DexCom (NASDAQ: DXCM) has been a home run stock for early investors. Its shares have thrashed the S&P 500 over the last one, three, and five years, showing no signs of slowing. Can this winner keep thriving? Let's dig into the bull and bear cases for the California-based company to find out. The business DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. This device is worn on the body and constantly monitors a patient's blood glucose levels. That data is uploaded to a handheld controller, smartphone, or smartwatch that provides information needed to keep blood glucose levels in a healthy range. DexCom operates on a razor-and-blade business model . The permanent \""razor\"" is the company's handheld device that receives and displays the data, while the disposable \""blades\"" are its sensors that are inserted directly into a patient's body. After 10 days of use, they need to be properly tossed and replaced, thus providing a dependable source of recurring revenue. This business model has allowed DexCom's top line to grow at a breakneck pace as it brings on new patients over time. DXCM revenue (TTM) . Data by YCharts . Reasons for optimism DexCom's revenue growth has been incredibly impressive, and it remains strong to this day. In 2018, its top line rose by 44%, sending it over the $1 billion mark. Can the company keep its double-digit growth rate going? The odds look good for a number of reasons: Dexcom has captured less than 20% of the 3.2 million patients in the U.S. who require intensive insulin therapy. The penetration rate looks even smaller when you factor in the international opportunity. According to the company, several other groups of patients could benefit from CGM therapy. This includes people with gestational diabetes, those who require non-intensive insulin therapy, and intermittent CGM use in the hospital setting. Together, these opportunities add up to tens of millions of potential users in the U.S. alone. Dexcom has struck up numerous partnerships with other diabetes companies like Tandem Diabetes Care , Insulet , Eli Lilly , and Novo Nordisk to help get the word out. The company has teamed up with Alphabet 's healthcare division, Verily, to develop a next-generation sensor, which aims to be smaller, cheaper, and fully disposable. Management forecasts that the company will pull in between $2 billion and $2.5 billion in total revenue by 2023 and improve profitability significantly. If those numbers prove to be anywhere close to accurate, shareholders should be nicely rewarded. Reasons for caution Dexcom would be a no-brainer investment if the company had the CGM market all to itself. Unfortunately, it faces a fair amount of competition. Its primary competitor is medical device giant Medtronic (NYSE: MDT) , which has enjoyed a strong foothold in the diabetes market for decades, through its insulin pump division. It also launched a combination insulin pump/CGM system a few years ago, a device thath increased patient convenience and has proven quite popular with patients. Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The Libre was the first CGM system that did not require its users to perform daily finger sticks for calibration, and was also marketed at a much lower price point than DexCom's CGM. The Freestyle Libre has experienced a lot of market success . Thus far, DexCom hasn't had any problems growing even with the competition from these well-funded giants, but it's possible that could change. Another potential pitfall that could work against investors who buy today is Dexcom's generous valuation. The company is currently trading for more than 12 times sales and about 150 times next year's earnings estimates. Those figures suggest that Wall Street is pricing in a lot of growth. If it fails to deliver on its ambitious growth targets, shareholders could be in a for a world of hurt. Is DexCom a buy? While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company. Its product is innovative, and the company has secured numerous partnership agreements, which should ensure it continues to win more than its fair share of the new business. What's more, the diabetes market is so huge that it could easily support multiple winners. If you're a growth-focused investor who doesn't mind paying up for a high-growth business, DexCom could be a nice addition to your portfolio. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Align Technology-Benco Dental Deal to Expand iTero Reach In an attempt to widen iTero customer base, Align Technology, Inc.ALGN recently announced a distribution agreement with Benco Dental. Per the agreement, starting Apr 1, Benco Dental will begin distributing iTero Element scanners in the United States.Notably, Benco Dental is a leading privately-owned dental distributor in the United States. Market Potential Per a Research And Markets report, the global 3D dental scanner market is expected to see a CAGR of 10.2% in the 2017-2021 period. The latest developments will help Align Technology cash in on the opportunities. iTero Portfolio in Focus Expanding the iTero suite, Align Technology recently announced the launch of its first intraoral scanner with near-infrared imaging technology - iTero Element 5D Imaging System. The system has been made commercially available in Canada, European Union countries acknowledging CE mark (excluding Greece), Switzerland, Norway, Australia, New Zealand, Hong Kong and Thailand. However, the iTero Element 5D Imaging System is currently not available in the United States or Latin America. Align Technology has begun manufacturing the iTero Element intraoral scanner in China post-receipt of Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration. The company is seeing rising Scanner and Services business sales globally, including Italy, Japan and China. Align Technology is also gaining from the adoption of the iTero platform by dental service organizations or DSO partners. We are also upbeat about the company's expansion of the iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States and majority of European countries, including France, Germany, Italy, Spain and the United Kingdom. Share Price Movement Over the past three months, Align Technology's share price has outperformed its industry . The stock has gained 6.5% against the industry's 0.3% fall. Zacks Rank & Key Picks Align Technology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Varian'slong-term earnings growth rate is projected at 8%. Illumina'slong-term earnings growth rate is expected at 21.5%. DexCom's second-quarter earnings per share are estimated to grow 116.7%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Align Technology-Benco Dental Deal to Expand iTero Reach""]"
DXCM,2019-03-11,35.75,36.2625,35.4825,36.0225,"[""How To Increase Return And Control Market Risk With Momentum Stocks"", ""How To Increase Return And Control Market Risk With Momentum Stocks"", ""The Best And Worst Stocks of the 10-Year Bull Market It has been 10 years since the U.S. stock market touched its post financial crisis nadir on Mar 9, 2009. Since then, American stocks have gained despite concerns about global economic growth, anxieties related to central bank policies and tit-for-tat trade war threats. Having said that, the United States and China's initiative to reach a deal, stabilize interest rates and an uptick in consumer confidence have surely provided the required impetus to stocks. The current bull run has lifted both the S&P 500 and the Dow Jones index by more than 400%. Since the financial crisis, increase in share prices and dividends helped the broader S&P 500, in particular, add nearly $21 trillion to its value, per the S&P Dow Jones Indices. In the meantime, the tech-laden Nasdaq has risen more than 500%, mostly led by fast-growing tech bigwigs including the FAANGs. For instance, Apple Inc. AAPL has given its shareholders a 1,373.7% return since the financial crisis, while Netflix, Inc.NFLX returned 6,396.7%. In other words, if you had bought $100,000 in Netflix stock on Mar 9, 2009, you would have been a millionaire by now! Not all stocks, however, have performed well over the course of the past decade. And the disparity between the top performers and the worst is rather shocking. Some companies, in fact, saw their shares tumble around 90%. Let us take a look at some of the market's top and bottom dwellers during the 10-year bull phase. Top Stocks of the Past Decade The biggest gainer in the past decade, a whopping 23,296.6%, is none other than Jazz Pharmaceuticals plcJAZZ . Around 10 years back, the company was struggling to get approval for its drugs. Its antidepressant Luvox was encountering hurdles, while narcolepsy drug Xyrem needed to gain traction. And how can we forget that the company was compelled to trim 24% of its workforce in 2008 due to earnings pressure. But things have changed for the better. Xyrem is now the company's primary brand and Defitelio used for cancer treatment is picking up. Jazz Pharmaceuticals also bought the rights to Defitelio in 2014. The company currently has a Zacks Rank #3 (Hold). In the past 60 days, Jazz Pharmaceuticals has seen nine earnings estimates move up, while none moved down for the current year. The Zacks Consensus Estimate for earnings rose 3.6% in the same period. The company is estimated to gain more than 5% in both the current and next quarter. The company has already gained 8.8% in the past month, more than the Medical - Drugs industry's rise of 2.7%. Lululemon Athletica Inc .'s LULU shares in the past 10 years scaled an amazing 6,541%. But, the company had its share of ups and downs. It had to recall a few of its black yoga pants due to transparency issue in 2013, compelling the then-CEO Chip Wilson to step down. However, the company managed to notch double-digit growth, purely on brand strength. The company currently has a Zacks Rank #2 (Buy). In the past 60 days, Lululemon Athletica has seen 14 earnings estimates move up, while none moved down for the current year. The Zacks Consensus Estimate for earnings rose 2.2% in the same period. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . The company's expected earnings growth rate for the current year is nearly 46%, more than the Textile - Apparel industry's projected rise of 23.3%. The company has outperformed the broader industry in the past year (+77.4% vs +16.1%). As said earlier, among the prominent names, Netflix is definitely one. It has been a pioneer in the field of streaming video. It boasts 146.5 million subscribers and by the middle of last year, Netflix had a 51% share of the U.S. streaming market with its nearest rival being Amazon Prime at a 33%. The company currently has a Zacks Rank #3. In the past 30 days, Netflix has seen one earnings estimate move north, while none moved south for the current year. The Zacks Consensus Estimate for earnings rose 0.5% in the same period. The company's expected earnings growth rate for the current year is 51.1%, in contrast to the Broadcast Radio and Television industry's projected decline of 4.5%. The company has outperformed the broader industry so far this year (+30.6% vs +20.8%). ABIOMED, Inc . ABMD has been a publicly trading company since 1987. It has made a noteworthy difference for cardiac patients by introducing the first artificial heart to the market. And the company saw its shares jump an incredible 6,108% over the past decade, with the rally picking up in 2017. Impella's sales growth was predominantly responsible for the rally. The company currently has a Zacks Rank #2. In the past 60 days, ABIOMED has seen six earnings estimates move up, while one moved down for the current year. The Zacks Consensus Estimate for earnings rose 0.4% in the same period. DexCom, Inc.DXCM , a key name within the glucose monitor market, yielded a staggering return of 4,044.8% over the past decade. Its partnership with Roche Holding AG RHHBY , acquisition of SweetSpot and FDA approval of the DexCom G4 Platinum, a glucose monitor, are some of the few developments boosting its shares. The company currently has a Zacks Rank #2. In the past 60 days, DexCom has seen 10 earnings estimates move up, while two moved down for the current year. The Zacks Consensus Estimate for earnings soared 91.7% in the same period. The company's expected earnings growth rate for the current year is 53.3%, more than the Medical - Instruments industry's projected increase of 15.9%. The company has outperformed the broader industry over the past year (+123.5% vs +2.7%). The Not So Lucky Ones! Weatherford International plcWFT , Transocean Ltd . RIG and Chesapeake Energy CorporationCHK , to name few, were the worst performers over the past decade. All of them saw their shares plunge more than 70% during the said period. While huge debt burden was responsible for Weatherford International's downfall, the arrival of fracking, drop in oil prices and increase in cost of deepwater drilling affected offshore contract drilling service provider Transocean. Chesapeake is another energy player that took extensive beating when oil prices tanked in 2014-15. The company unfortunately couldn't recover from the setback completely. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Netflix, Inc. (NFLX): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Weatherford International PLC (WFT): Free Stock Analysis Report Transocean Ltd. (RIG): Free Stock Analysis Report Chesapeake Energy Corporation (CHK): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick? Medical instrument companies Hologic, Inc.HOLX and DexCom, Inc.DXCM are solid contenders in the U.S. MedTech space, which is expected to reach a worth of $409.5 billion by 2023 at a CAGR of 4.5%. Analysts believe that 2019 will prove profitable for U.S. medical device companies, courtesy of the 2.3% Medical Device tax abatement along with focus on AI and cybersecurity. Meanwhile, it is difficult to make a choice between the above-mentioned companies as both carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . However, we make a detailed analysis of the companies' fundamentals to determine which has a slight edge over the other. Massachusetts-based Hologic develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women. The company is focused on building mammography systems for breast examination and osteoporosis assessment. Meanwhile, California-based DexComis a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). Price Performance Over the past year, Hologic's shares have gained 19.8% compared with DexCom's 123.5% rally. The Medical Instruments industry has rallied 2.7% in the same time frame. Meanwhile, the S&P 500 index has declined 1.3%. Which Way Are Estimates Headed? The Zacks Consensus Estimate for Hologic's current-year earnings per share stands at $2.41, suggesting an improvement of 8.1% year over year. The same for DexCom is projected at 46 cents, showing year-over-year growth of 53.3%. Hologic, Inc. Price and Consensus Hologic, Inc. Price and Consensus | Hologic, Inc. Quote The Zacks Consensus Estimate for Hologic's current-year revenues is pegged at $3.32 billion, suggesting growth of 3.2% from the previous year. The same for DexCom is pegged at $1.21 billion, reflecting a rise of 17.5%. DexCom, Inc. Price and Consensus DexCom, Inc. Price and Consensus | DexCom, Inc. Quote What's Favoring the Stocks? Hologic currently has a Growth Score of C. Meanwhile, DexCom has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2, are better picks than most. DexCom's FDA-cleared CGM system - the DexCom G4 Platinum - is significantly boosting the company's top line. Moreover, the company continues to focus on international markets, Germany in particular. The company is eyeing the sizeable markets of Korea, India, China and Japan as well. Over the past four years, Hologic's revenues have seen a CAGR of 19% to $3.22 billion. Meanwhile, DexCom's revenues have seen a CAGR of 156.7% to $1.03 billion. Wrapping Up The above analysis shows that despite being close contenders, DexCom scores higher than Hologic when it comes to growth projections and fundamentals. Key Picks A few other top-ranked stocks in the broader medical space are Veeva Systems Inc VEEV and Integer Holdings Corporation ITGR . Veeva Systems' long-term earnings growth rate is projected at 14.8%. The stock flaunts a Zacks Rank #2. Integer Holdings projects earnings growth rate of 31.2% for the first quarter. It currently carries a Zacks Rank #2. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""How To Increase Return And Control Market Risk With Momentum Stocks""]"
DXCM,2019-03-12,35.9825,36.168,35.0875,35.9475,"[""The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom"", ""Tech Snaps Market Out of Slump"", ""The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom"", ""Tech Snaps Market Out of Slump"", ""Varian & Tata Trust Tie Up to Boost Radiotherapy in India Varian Medical Systems, Inc.VAR recently announced signing of a three-year agreement with Tata Trust. The deal aims at increasing patient access to advanced radiation therapy treatments in India. This apart, Varian's ARIA oncology information system and Eclipse treatment planning system will be implemented to help improve the level of care. Following the announcement, shares of the Zacks Rank #2 (Buy) company gained 0.5% to $134.60 at close. About the Agreement The latest agreement is a part of a program undertaken by Tata Trusts with the goal of creating patient-centric cancer institutions and providing affordable care closer to patients' homes across different regions in India. This is likely to fortify Varian's foothold in the Asia-Pacific radiation therapy market as India is expected to witness 1.8 million new cancer cases a year by 2025. Varian's Presence in India It is encouraging to note that Mumbai's first Varian Edge radiosurgery system was installed in 2016. In the same year, this California-based MedTech giant was selected by India's Apollo Hospitals Group for the supply of 12 advanced medical linear accelerators and five brachytherapy systems to replace traditional cancer treatment machines. The company's Advanced Radiotherapy Clinical School is currently running courses at the Reliance Group's flagship Kokilaben Dhirubhai Ambani Hospital in Mumbai. (Read More: Varian & Reliance Group Tie Up to Enhance Cancer Care ) Additionally, last October, the first lung cancer patient in India was treated with Varian's popular Halcyon system in Gujarat's Sterling Cancer Hospital. Another MedTech company that has a solid presence in the Indian cancer care space is Accuray Incorporated ARAY . Notably, the company's flagship Radixact system currently experiences robust demand across the country. Market Prospects Market Data Forecast predicts that the Asia-Pacific radiotherapy market is expected to witness a CAGR of 6.8% to reach $1.79 billion by 2023. Growth of the aging population, technological innovations in radiotherapy products and increasing cases of cancer are currently fueling the market's growth. In this scenario, we believe the latest development to be a well-timed one for Varian. Price Performance In a year's time, the stock has rallied 6.4% compared with the industry 's 4.4% growth. The current level is also higher than the S&P 500 index's 1.3% decline. Other Key Picks Other top-ranked stocks in the broader medical space are Stryker Corporation SYK and DexCom DXCM , each carrying a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Stryker's long-term earnings growth rate is projected at 10%. DexCom's current-quarter earnings growth rate is expected to be 46.9%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom For Immediate Release Chicago, IL - March 12, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Jazz Pharmaceuticals plc JAZZ , Lululemon Athletica Inc. LULU , ABIOMED, Inc. ABMD and DexCom, Inc. DXCM . Here are highlights from Monday's Analyst Blog: The Best Stocks of the 10-Year Bull Market It has been 10 years since the U.S. stock market touched its post financial crisis nadir on Mar 9, 2009. Since then, American stocks have gained despite concerns about global economic growth, anxieties related to central bank policies and tit-for-tat trade war threats. Having said that, the United States and China's initiative to reach a deal, stabilize interest rates and an uptick in consumer confidence have surely provided the required impetus to stocks. The current bull run has lifted both the S&P 500 and the Dow Jones index by more than 400%. Since the financial crisis, increase in share prices and dividends helped the broader S&P 500, in particular, add nearly $21 trillion to its value, per the S&P Dow Jones Indices. In the meantime, the tech-laden Nasdaq has risen more than 500%, mostly led by fast-growing tech bigwigs including the FAANGs. For instance, Apple has given its shareholders a 1,373.7% return since the financial crisis, while Netflix returned 6,396.7%. In other words, if you had bought $100,000 in Netflix stock on Mar 9, 2009, you would have been a millionaire by now! Not all stocks, however, have performed well over the course of the past decade. And the disparity between the top performers and the worst is rather shocking. Some companies, in fact, saw their shares tumble around 90%. Let us take a look at some of the market's top and bottom dwellers during the 10-year bull phase. Top Stocks of the Past Decade The biggest gainer in the past decade, a whopping 23,296.6%, is none other than Jazz Pharmaceuticals plc . Around 10 years back, the company was struggling to get approval for its drugs. Its antidepressant Luvox was encountering hurdles, while narcolepsy drug Xyrem needed to gain traction. And how can we forget that the company was compelled to trim 24% of its workforce in 2008 due to earnings pressure. But things have changed for the better. Xyrem is now the company's primary brand and Defitelio used for cancer treatment is picking up. Jazz Pharmaceuticals also bought the rights to Defitelio in 2014. The company currently has a Zacks Rank #3 (Hold). In the past 60 days, Jazz Pharmaceuticals has seen nine earnings estimates move up, while none moved down for the current year. The Zacks Consensus Estimate for earnings rose 3.6% in the same period. The company is estimated to gain more than 5% in both the current and next quarter. The company has already gained 8.8% in the past month, more than the Medical - Drugs industry's rise of 2.7%. Lululemon Athletica Inc. 's shares in the past 10 years scaled an amazing 6,541%. But, the company had its share of ups and downs. It had to recall a few of its black yoga pants due to transparency issue in 2013, compelling the then-CEO Chip Wilson to step down. However, the company managed to notch double-digit growth, purely on brand strength. The company currently has a Zacks Rank #2 (Buy). In the past 60 days, Lululemon Athletica has seen 14 earnings estimates move up, while none moved down for the current year. The Zacks Consensus Estimate for earnings rose 2.2% in the same period. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The company's expected earnings growth rate for the current year is nearly 46%, more than the Textile - Apparel industry's projected rise of 23.3%. The company has outperformed the broader industry in the past year (+77.4% vs +16.1%). ABIOMED, Inc. has been a publicly trading company since 1987. It has made a noteworthy difference for cardiac patients by introducing the first artificial heart to the market. And the company saw its shares jump an incredible 6,108% over the past decade, with the rally picking up in 2017. Impella's sales growth was predominantly responsible for the rally. The company currently has a Zacks Rank #2. In the past 60 days, ABIOMED has seen six earnings estimates move up, while one moved down for the current year. The Zacks Consensus Estimate for earnings rose 0.4% in the same period. The company's expected earnings growth rate for the current year is 106.1%, more than the Medical - Instruments industry's projected rise of 15.9%. The company has outperformed the broader industry over the past one-year period (+6.6% vs +2.7%). DexCom, Inc. , a key name within the glucose monitor market, yielded a staggering return of 4,044.8% over the past decade. Its partnership with Roche Holding AG (RHHBY), acquisition of SweetSpot and FDA approval of the DexCom G4 Platinum, a glucose monitor, are some of the few developments boosting its shares. The company currently has a Zacks Rank #2. In the past 60 days, DexCom has seen 10 earnings estimates move up, while two moved down for the current year. The Zacks Consensus Estimate for earnings soared 91.7% in the same period. The company's expected earnings growth rate for the current year is 53.3%, more than the Medical - Instruments industry's projected increase of 15.9%. The company has outperformed the broader industry over the past year (+123.5% vs +2.7%). Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom"", ""Tech Snaps Market Out of Slump""]"
DXCM,2019-03-13,35.56,37.5375,35.3775,36.865,
DXCM,2019-03-14,36.805,36.8825,36.1188,36.7125,
DXCM,2019-03-15,36.7375,38.07,36.5,37.75,
DXCM,2019-03-18,38.005,38.72,36.3775,36.5375,"[""Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4"", ""Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4"", ""Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4""]"
DXCM,2019-03-19,36.555,36.905,36.125,36.735,"[""Inogen's Prospects in Europe Solid Amid Trade-Related Tension"", ""Inogen's Prospects in Europe Solid Amid Trade-Related Tension"", ""Inogen's Prospects in Europe Solid Amid Trade-Related Tension On Mar 18, we issued an updated research report on Inogen, Inc.INGN . A strong fourth-quarter show and solid prospects in Europe currently favor the stock. On the contrary, trade-related uncertainties plague this Zacks Rank #3 (Hold) company. What's Favoring the Stock? In the recently-reported fourth quarter of 2018, Inogen posted earnings of 44 cents per share, which surpassed the Zacks Consensus Estimate of 25 cents. The bottom line improved from a net loss of 3 cents in the year-ago quarter. Revenues came in at $86.5 million, which trumped the Zacks Consensus Estimate of $82 million. On a year-over-year basis, the top line climbed 35.7%. Reflective of this, Inogen retained its revenue and EBITDA outlook for 2019. Notably, the company continues to expect revenues between $430 million and $440 million, representing 20.1-22.9% growth over 2018. Full-year adjusted EBITDA is projected between $67 million and $71 million, representing 9.3-15.9% growth year over year. Moreover, Inogen is optimistic about its prospects in Europe. In the fourth quarter of 2018, Inogen's business-to-business unit saw international revenues of $18.5 million, up 54.5% year over year on continued adoption by the company's European partners. Per management, Europe sales represented 87.8% of fourth-quarter international sales. Deterrents Despite a better-than-expected fourth quarter, Inogen trimmed its 2019 net income guidance range to $40-$44 million from the previously-issued $48-$52 million. Per management, the slashed guidance is due to a fall in estimated provision for income taxes related to excess tax benefits recognized from stock-based compensation. Additionally, the company's guidance assumes a full impact of the tariffs on applicable Chinese sourced materials since the increase of China import tax has been currently delayed by the United States, giving rise to trade-related uncertainties. Price Performance Over the past year, shares of Inogen have declined 23.5% against the industry 's 9.8% gain. The current level is also lower than the S&P 500 index's 4.3% rally. Key Picks A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Wright Medical Group N.V. WMGI and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20.9%. Wright Medical's long-term earnings growth rate is estimated at 11.3%. DexCom's next-quarter earnings per share are projected to grow 120%. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%. See Latest Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inogen, Inc (INGN): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Inogen's Prospects in Europe Solid Amid Trade-Related Tension""]"
DXCM,2019-03-20,36.75,37.02,36.2775,36.54,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year? Investors focused on the Medical space have likely heard of DexCom (DXCM), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of DXCM and the rest of the Medical group's stocks. DexCom is a member of the Medical sector. This group includes 833 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DXCM is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 98.22% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. According to our latest data, DXCM has moved about 22.65% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 10.46% on average. This means that DexCom is performing better than its sector in terms of year-to-date returns. Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 90 individual stocks and currently sits at #100 in the Zacks Industry Rank. This group has gained an average of 17.95% so far this year, so DXCM is performing better in this area. Investors in the Medical sector will want to keep a close eye on DXCM as it attempts to continue its solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2019-03-21,36.375,36.895,35.08,35.54,"[""'Amazon-exclusive medical brand Choice expands services with One Drop partnership' -Digiday Reported On Tuesday"", ""Spruce Point Sees 60% Downside In Dexcom (approximately $65-$85/Share)"", ""Spruce Point: Dexcom Could Fall 45-60%"", ""Spruce Point: Dexcom Could Fall 45-60%"", ""Spruce Point Sees 60% Downside In Dexcom (approximately $65-$85/Share)"", ""'Amazon-exclusive medical brand Choice expands services with One Drop partnership' -Digiday Reported On Tuesday"", ""Here's Why You Should Hold on to Cerner (CERN) Stock for Now A slew of developments and a strong view for 2019 are working in favor of Cerner CorporationCERN at present. However, an intensely competitive industry is concerning. Over the past year, the Zacks Rank #3 (Hold) stock has lost 3.1% against the industry 's 7.2% rally. The current level also compares unfavorably with the S&P 500 index's 4.6% gain. What's Deterring the Stock? Cerner faces cutthroat competition from Healthcare IT bigwigs like athenahealth and Allscripts Healthcare Solutions, which might affect both pricing and margins. Additionally, for the first quarter of 2019, business bookings are expected in the range of $1.10-$1.30 billion. The midpoint of this range reflects a 14% decline year over year. Why Should You Retain Cerner? Developments Cerner has been witnessing a slew of developments in recent times. Recently, the company expanded its reach in the Alabama rural health care market through a new collaboration with the Escambia County Healthcare Authority. Notably, D.W. McMillan Memorial Hospital in Brewton and Atmore Community Hospital in Atmore are to switch to the Cerner Millennium EHR (Electronic Health Record) platform. Last month, Massachusetts-based Sturdy Memorial Hospital signed a seven-year agreement to upgrade its EHR with Cerner Millennium. Additionally, Florida-based BayCare Health System is using Cerner's advanced technologies and services to increase access to care and improve the health status of its patients. View Strong For the first quarter of 2019, Cerner expects revenues between $1.37 billion and $1.42 billion. Adjusted earnings per share are expected in the band of 60-62 cents. For 2019, revenues are expected between $5.65 billion and $5.85 billion. Adjusted earnings per share are expected between $2.57 and $2.67. Which Way Are Estimates Treading? For the first quarter, the Zacks Consensus Estimate for earnings is pegged at 62 cents, reflecting a year-over-year increase of 6.9%. The same for revenues is pinned at $1.39 billion, showing an increase of 7.6% year over year. For 2019, the Zacks Consensus Estimate for revenues is pinned at $5.75 billion, mirroring growth of 7.1%. The same for earnings stands at $2.62, indicating growth of 6.9% from the previous year. Cerner Corporation Price and Consensus Cerner Corporation Price and Consensus | Cerner Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Veeva Systems VEEV and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20.9%. Veeva System's long-term earnings growth rate is estimated at 14.8%. DexCom's next-quarter earnings per share are projected to grow 120%. This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities. These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month. Click here to see these breakthrough stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here\u2019s What the Apple Watch Means for AAPL Stock InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's become increasingly clear over the past few months that Apple (NASDAQ: AAPL ) can no longer rely on the iPhone alone. That realization initially tanked Apple stock, which dropped nearly 40% between early October and late December. Of late, however, investors have become more comfortable with that pivot: AAPL stock already has gained nearly 20% so far in 2019. Source: Shutterstock The bull case for Apple stock, as Luke Lango argued this month, is that services revenue can offset hardware pressure . With Apple stock still cheap (it trades at less than 15x forward earnings), even modest growth is enough. Add in the fact that Apple still has more cash on its balance sheet than any company in history , and it doesn't take smashing success for AAPL to move higher. The bear case, which I laid out in detail last year, is that the iPhone simply is too important . The product still drives 60% of revenue. And with Apple's market capitalization nearly $900 billion, what would be a hit for another company barely moves the needle for Apple. 7 Beaten-Up Stocks to Buy as They Reverse Course The Apple Watch is an interesting microcosm of that bull/bear debate. And news this week of a landmark study involving the product adds an intriguing layer to the argument. From one standpoint, the Apple Watch could be a key part of the transformation of Apple and AAPL stock. From another, it hardly matters at all. The Apple Watch Study On Monday, researchers from Apple and Stanford Medicine released the results of a massive study involving the Apple Watch. Some 419,000 subjects participated over eight months. Those individuals wore the target smartwatches with the capability to detect abnormal heartbeats. The results aren't conclusive. Roughly 0.5% of the participants received notice of an irregular pattern. Unsurprisingly, the rate was higher in older patients. Of those who received a notice, only about 20% followed up by wearing a patch to confirm the diagnosis. Of that group, 34% received a confirmed diagnosis. But in a smaller group of subjects who wore both a patch and the Apple Watch, 84% of atrial fibrillation cases detected by the path were also picked up by the Watch. On the whole, the study does seem like good news for Apple (and for patients). There are concerns about false positives from the technology. However, the innovation is constantly improving and will benefit from further tweaking. As one cardiologist told CNBC , the results were \""moderately good for a screening tool, but not amazing.\"" That description could change over time, and more studies should give a better understanding of just how effective the Apple Watch is. The study doesn't prove that the Apple Watch can be a successful cardiac screening tool, at least not yet. A two-in-three false positive rate might be too problematic for some (or most) doctors. But at the least, the study does show that Apple might be on the right path in terms of developing life-saving - and profitable - technology. Does It Matter for AAPL Stock? From an investment standpoint, the question is whether even success here is enough. Again, this is a nearly $900 billion company. Fitbit (NYSE: FIT ), whose smartwatch category the Apple Watch has taken over, has an enterprise value well under $1 billion. Apple hasn't broken out its smartwatch revenue. But sales of \""other products\"" - including Apple Watch, AirPods, Apple TV, Beats and other smaller lines - in fiscal year 2018 were $17.4 billion, according to the 10-K . CFO Luca Maestri last year said AirPods and Apple Watch combined were driving over $10 billion annually in revenue. That's a big number. But the revenue from other products (now called \""Wearables, Home and Accessories\"") still is about 7% of trailing-twelve-month revenue after driving 8.7% of first-quarter sales. Assuming its smartwatch revenue is $7-8 billion (roughly half of that category), it still drives maybe 3% of total corporate revenue. Even modest declines in iPhone revenue will more than offset growth in the Apple Watch. The Services Case for Apple Stock So it's easy perhaps to argue that the smartwatch division simply isn't enough. But where the story gets interesting is not just in hardware sales, but how the company can monetize the services side of the product. Healthcare giant Johnson & Johnson (NYSE: JNJ ) is joining in the next controlled study of the Apple Watch. And the product itself could be the tip of the spear in the company's healthcare strategy. Back in January, Dana Blankenhorn detailed that strategy and the ways in which AAPL stock could profit from healthcare services. Monitoring revenues could be large. DexCom (NASDAQ: DXCM ) is a $13 billion company built off the back of a continuous glucose monitoring system for diabetes. Other tech giants, including Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), are looking to profit from the intersection of medicine and technology. However, the Apple Watch puts the company into millions of homes, a huge head start. I still question whether it's enough. Even the development of a DexCom-sized business adds less than 2% to Apple's market capitalization. But combined with efforts elsewhere in services, in content, and through share buybacks, there's an argument that Apple can keep profits intact in the near-term before eventually driving growth again. That's the strategy needed to keep AAPL stock moving higher, particularly with the year-to-date rally. How investors view the potential of the Apple Watch given recent developments might show how they will view the possibilities of Apple's larger pivot away from its reliance on hardware \u2026 and just how successful that strategy is going to be. As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 7 Specialty Retail ETFs to Buy the Industry's Disruption 5 Stocks To Buy for the Happiest Employees 3 Out-of-Favor Consumer Stocks to Buy Compare Brokers The post Here's What the Apple Watch Means for AAPL Stock appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Spruce Point: Dexcom Could Fall 45-60%"", ""Spruce Point Sees 60% Downside In Dexcom (approximately $65-$85/Share)"", ""'Amazon-exclusive medical brand Choice expands services with One Drop partnership' -Digiday Reported On Tuesday""]"
DXCM,2019-03-22,35.17,35.2375,31.975,32.2575,"[""Bull of the Day: DexCom (DXCM)"", ""Why Dexcom Faces 45-60% Downside Risk From Abbot's New Libre 2 Product"", ""DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day"", ""Here's Why You Should Retain Ecolab Stock in Your Portfolio"", ""HMS Holdings Gains on PI & TPM Solutions, Competition Rife"", ""DexCom shares trading lower following a nearly 3 percent decline on Thursday amid a negative report from Spruce Point. Shares traded below the $140 level Friday."", ""41 Stocks Moving In Friday's Mid-Day Session"", ""41 Stocks Moving In Friday's Mid-Day Session"", ""DexCom shares trading lower following a nearly 3 percent decline on Thursday amid a negative report from Spruce Point. Shares traded below the $140 level Friday."", ""HMS Holdings Gains on PI & TPM Solutions, Competition Rife"", ""Here's Why You Should Retain Ecolab Stock in Your Portfolio"", ""DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day"", ""Why Dexcom Faces 45-60% Downside Risk From Abbot's New Libre 2 Product"", ""Bull of the Day: DexCom (DXCM)"", ""DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL - March 22, 2019 - Zacks Equity Research DexCom DXCM as the Bull of the Day, comScore SCOR as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Lululemon LULU , Nike NKE and Under Armour UAA . Here is a synopsis of all five stocks: Bull of the Day : DexCom is a $13 billion med-tech developer of continuous glucose monitoring (CGM) systems for people with diabetes. DXCM became a Zacks #2 Rank after a strong beat and raise quarter reported on 2/21. DexCom delivered Q4 adjusted EPS of 54 cents vs the consensus of 17-c for a giant 217% beat. And Q4 revenues of $338 million beat the consensus view of $307.5 million by a healthy 10%. Much of the good news was baked in as the company had preannounced the coming strong results. But they even beat those numbers. As you probably know, diabetes patients must stick their finger several times per day to monitor their blood sugar. Dexcom is changing that with a device called a continuous glucose monitor (CGM). These devices track glucose levels throughout the day rather than rely on bloody finger sticks and test strips. And this, as you might guess, gives patients and their care providers more accurate data to measure and understand daily ebbs and flows in blood glucose levels. In February, DexCom received Health Canada approval for its G6 CGM System. Dexcom announced that the Health Canada thumbs up for its next generation CGM system was for people with diabetes ages two years and up. It was previously introduced into the U.S, U.K., Ireland, and several other European countries and has seen strong sales so the G6 commercial launch in Canada, planned for late 2019, is much anticipated. Analysts Hail the Innovation and the Growth Here were analyst reactions to DexCom's Feb 21 report after the company offered 2019 revenue guidance of $1.175 billion to $1.225 billion, representing 19% growth over last year, and gross profit margin of approximately 65%... Cowen & Co: Analyst Doug Schenkel raised his price target on DexCom to $175 from $150 following its \""blowout\"" Q4 results. The analyst believes its guidance leaves plenty of room for top and bottom line upside, though he admits a new competitor product could provide headline risk. He views the shares as a long-term core holding. Schenkel reiterated his Outperform rating on DexCom shares. Canaccord Genuity: Analyst Kyle Rose raised his price target on DexCom to $160 from $140 following its strong Q4 results. The analyst expects its exceptional growth to continue, supported by strong growth in sensor volumes, continued worldwide adoption of CGM, and the ongoing launch of G6, which is just now moving into additional territories and Medicare. Rose views DexCom as one of the best pure growth assets across the med-tech space. Piper Jaffray: Analyst JP McKim told investors in a research note that he believes DexCom is positioning itself for the next $1B in sales to be \""solid, profitable growth.\"" The restructuring allows the company to scale quicker and at a lower cost over the longer term, McKim says. He reiterated an Overweight rating on DexCom with a $165 price target. Oppenheimer analysts raised their 2019 sales estimate to $1.22 billion from $1.13 billion, with US growth in the mid-teens and elsewhere up ~30%. Their EPS projection rose to $0.59 from $0.25 on solid operating leverage and their price target goes to $167 from $150. Leerink Swann analysts explained why DXCM could continue to commance a premium valuation. Their $170 price target applies a ~9.5X price-to-sales multiple to their $1.512 billion 2020 revenue estimate. DXCM shares currently trade at about 10X their $1.22 bilion 2019 sales estimate, which is a premium to comparable small-cap MedTech companies. Bear of the Day : comScore is a Zacks Rank #5 (Strong Sell) and checks in with an F for the Value Style Score and a D for the Growth Style Score. The company posted a beat of the Zacks Consensus Estimate on February 28, but it is now the Bear of the Day. Let's take a look at why that is the case. Description comScore, Inc. is a global leader in measuring the digital world. This capability is based on a massive, global cross-section of more than two million consumers who have given comScore permission to confidentially capture their browsing and transaction behavior, including online and offline purchasing. comScore panelists also participate in survey research that captures and integrates their attitudes and intentions. Through its proprietary technology, comScore measures what matters across a broad spectrum of behavior and attitudes. comScore analysts apply this deep knowledge of customers and competitors to help clients design powerful marketing strategies and tactics that deliver superior ROI. comScore services are used by global leaders such as AOL, Microsoft, Yahoo!, Verizon, Best Buy, The Newspaper Association of America, Tribune Interactive, ESPN, Fox Sports, Nestle, MBNA, Starcom USA, Universal McCann, the United States Postal Service, Merck and Expedia. Recent Earnings Although the chart show that SCOR bea t earnings , I see other data that suggest that SCOR missed in a big way. I see a loss of $0.46 compared to an expected loss of $0.21 on the bottom line. Revenue of $109M was good for 6% growth and topped the $104.8M estimate. Prior to this report, Zacks shows that SCOR missed the prior three quarter with an average negative earnings surprise of 52%. Estimates The estimate data on the detailed estimate page is not fully functioning at the moment, but I do see that there were negative revisions over the last 30 and 60 days. If you look at the agreement section, you can see there were negative earnings estimate revisions for this quarter, next quarter and for the full year. Valuation Without a positive earnings number, there is no PE, but I do see a 2.3x book multiple which is where value players should be happy. They tend to like a book multiple below 3x. A price to sales multiple of 3x is fairly rich considering the low growth profile. Margins are negative, but they are moving in the right direction. That said, SCOR will likely not post positive earnings this year or next. Why lululemon (LULU) Looks Like a Buy Heading into Q4 Earnings Lululemon shares popped over 3% Thursday heading into the release of its fourth quarter financial results, as part of its larger 2019 climb. The yoga apparel and athleisure giant's bottom-line looks set to surge as it expands its menswear business, its global reach, and more. Recent News Barclays analysts earlier this week elaborated on why they are high on Lululemon as it tries to grab market share from Nike and Under Armour-which has struggled to roll out compelling athleisure offerings. The firm currently has an \""overweight\"" rating on Lululemon stock and a $200 a share price target, which represents roughly 39% upside compared to LULU's $144.35 a share closing price on Wednesday. Analyst Matthew McClintock said that Canadian company \""has a significantly larger [total addressable market] than even the most optimistic estimates likely expect.\"" \""We continue to believe Lululemon's [total addressable market] is ever-expanding as the company has entered into men's in a meaningful way, has seen success in office, travel [and] commute offerings and continues to see a significant amount of opportunity in bras and outerwear.\"" Company Overview As the Barclays analyst mentioned, the firm has expanded far beyond its original women's yoga apparel in recent years. Lululemon currently sells men's and women's jackets for as much as $600 as it tries to compete against other higher-end brands. Lululemon now boasts a lineup of outwear, shoes, accessories, as well as more work-appropriate and fashion-focused offerings for both men and women-which will likely become a key growth area for LULU as companies around the country relax their dress codes. Earlier this month, Lululemon also signed NFL quarterback Nick Foles as its first men's ambassador in an effort to attract consumers away from more traditional sportswear brands. The company closed Q3 with 426 stores around the world. Investors should also note that LULU's e-commerce comps surged 46%. Going forward, the company's ability to expand its digital commerce business will likely become even more important in the internet-crazed retail age. This expansion includes the firm's presence across social media outlets, where brands are now built from scratch and consumers shop directly. Outlook & Earnings Trends As we alluded to at the top, shares of Lululemon have jumped over 22% this year to outpace the S&P 500's 13% climb, its industry's 18% average, and Nike. LULU stock rested up 3.10% through mid-afternoon trading Thursday at $148.82 a share. This marked a roughly 10% downturn from its 52-week high of $164.79 a share, which gives the stock some room to run. Before we look at what to expect from LULU's Q4 financial results, it is worth noting that company management raised its quarterly guidance earlier this year on the back of strong holiday period sales. The Vancouver, Canada-based firm upped its guidance based on total comparable sales growth in the mid-to-high teens, up from high-single to low-double digits comps expansion. With that said, Lululemon's Q4 revenues are projected to jump 23.7% to reach $1.15 billion, based on our current Zacks Consensus Estimate. This would top Q3's 21% top-line growth. Meanwhile, the firm's full-year revenues are projected to surge roughly 26% from fiscal 2017's $2.65 billion to reach $3.27 billion. Last year, total full-year revenue popped just 13%. Moving on, Lululemon is projected to see its adjusted Q4 earnings soar 30.8% to touch $1.74 a share. Plus, the athletic apparel company's full-year EPS figure is expected to surge 44.4% to reach $3.74 a share. We should also note that LULU has seen some positive earnings estimate revision activity recently. Bottom Line Lululemon is currently a Zacks Rank #2 (Buy) based, in part, on its recent earnings estimate revision activity. The company also boasts an \""A\"" grade for Growth in our Style Scores system. And Lululemon executives have reaffirmed its goal to reach $4 billion in revenue by 2020, which includes hitting $1 billion in menswear sales. LULU is scheduled to release its Q4 and full-year 2018 financial after the closing bell on Wednesday, March 27. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs. See Stocks Today >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com https://www.zacks.com Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks \""Terms and Conditions of Service\"" disclaimer. www.zacks.com/disclaimer . Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report comScore, Inc. (SCOR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report Under Armour, Inc. (UAA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""HMS Holdings Gains on PI & TPM Solutions, Competition Rife On Mar 20, we issued an updated research report on HMS Holdings Corp.HMSY . The company has an encouraging earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average being 24%. Notably, this trend of consecutive beats underlines its operating efficiency. HMS Holdings is likely to benefit from solid prospects in its Payment Integrity (\""PI\"") and Total Population Management (\""TPM\"") solutions. The company is consistently boosting margins and profitability. PI comes under HMS Holdings' unique suite of Analytical Services. The company's PI services ensure accurate and appropriate healthcare payments. These services are applicable to all customers HMS Holdings serves, including federal and state governments, commercial health plans and other at-risk or self-insured entities. Notably, PI revenues grew more 32.5% in the fourth quarter of 2018 on a year-over-year basis (excluding Medicare RAC). The company's TPM services consist of population risk analytics, and consumer engagement and care management solutions, driven by internal product development and acquisitions of Essette and Eliza in 2016 and 2017, respectively. TPM has been a significant top-line contributor for HMS Holdings. TPM revenues grew 15.1% on a year-over-year basis in the fourth quarter. For 2019, the company expects revenues between $640 million and $650 million. This depicts year-over-year growth of 8.4-10.2%. On the flip side, the company faces a highly regulated environment in almost every state it operates. This apart, stiff competition in the U.S. healthcare insurance benefit cost containment industry is a concern. Bottom Line In a year's time, shares of HMS Holdings have gained 96.6% compare with the industry 's 9.4% growth. The current level also compares favorably with the S&P 500 index's decline of 4.4% over the same time frame. HMS Holdings currently has a Zacks Rank #3 (Hold). The company has an impressive Growth Style Score of B. Our Growth Style Score highlights all the vital metrics of a company's financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 offer the best investment opportunities. Key Picks A few better-ranked stocks from the MedTech space are DexCom, Inc. DXCM , Varian Medical Systems, Inc. VAR and Masimo Corp. MASI , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%. Varian Medical has long-term earnings growth rate of 8%. Masimo has long-term earnings growth rate of 15.6%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Ecolab Stock in Your Portfolio Ecolab Inc.ECL has been gaining investors' confidence on continued robust performance. The company issued an impressive guidance for 2019. However, intensifying competition and integration risks are primary headwinds for the company as of now. In a year's time, the stock has gained 31.1% compared with the industry 's 5.7% growth. Moreover, the company has an interesting earnings surprise history, having outpaced the Zacks Consensus Estimate in three of the trailing four quarters, the average being 0.5%. Notably, this trend of consecutive beats underlines the company's operating efficiency. So let us take a quick look at the primary factors plaguing this Zacks Rank #3 (Hold) company and discuss the prospects that ensure near-term recovery. Deterrents Ecolab operates in highly competitive markets. Notably, the company faces competition from bigwigs like P&G, Unilever, PuroClean and ChemStation. The company's U.S. Cleaning & Sanitizing and International divisions face stiff competition from Clorox and Church & Dwight. Factors That Bode Well View Impressive Ecolab issued an impressive guidance for 2019. Notably, the company expects 2019 adjusted earnings per share (EPS) of $5.80 to $6.00, rising 10-14% from the 2018 figure. Adjusted tax rate is expected to be 20-21%. For the first quarter of 2019, adjusted EPS is projected between 98 cents and $1.06, reflecting year-over-year growth of 8-16%. Cost Efficiency Program Ecolab recently announced an efficiency program that will generate $325 million of run rate savings by 2021. Earlier, the company predicted it to be $200 million. These additional savings are likely to have a strong impact on 2019, 2020 and 2021 results. For boosting its G&A solutions, Ecolab will be strengthening its Workday and SAP platforms by consolidating systems, back offices and third-party vendors. Product-Portfolio Solid The company has major launches underway. Ecolab also continues to invest significantly in customer-facing technology and infrastructure technology. The company's new Health Department Intelligence (HDI) platform also helps foodservice operators better understand their health inspection results, improve health inspection performance and better manage food safety risks across multiple sites. In recent times, Ecolab launched a Life Sciences cleanroom program in North America, developed specially for pharmaceutical manufacturing. The program provides comprehensive cleaning and disinfection for both sterile and non-sterile applications. Ecolab has been gaining traction in digital technology markets also. The company expects to invest largely in the coming quarters to enhance its digital portfolio. New customer-digital programs like SMARTPOWER, 3D CIP, 3D TRASAR, new QSR and FRS digital safety platforms continue to improve field efficiency, customer service and capability. Per management, new additions to its portfolio will help Ecolab reach its mid-teens EPS growth goal beyond 2019. Which Way Are Estimates Heading? The Zacks Consensus Estimate for first-quarter 2019 earnings is pegged at $1.02, reflecting year-over-year increase of 12.1%. The same for revenues stands at $3.57 billion, indicating 12.6% rise. For 2019, the Zacks Consensus Estimate for earnings is at $5.91, reflecting rise of 13%. The same for revenues stands at $15.46 billion, indicating 5.4% rise. Ecolab Inc. Price and Consensus Ecolab Inc. Price and Consensus | Ecolab Inc. Quote Bottom Line Despite cutthroat competition in the niche markets, Ecolab seems to be positioned for growth on strong guidance and solid product portfolio. The company's long-term earnings growth rate of 12.6% also supports this view. Key Picks A few better-ranked stocks from the MedTech space are DexCom, Inc. DXCM , Varian Medical Systems, Inc. VAR and Masimo Corp. MASI , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%. Varian Medical has long-term earnings growth rate of 8%. Masimo Corporation has long-term earnings growth rate of 15.6%. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why DexCom Shares Are Dropping Today What happened Shares of DexCom (NASDAQ: DXCM) , a diabetes company focused on continuous glucose monitoring, fell as much as 10% in afternoon trading on Friday. The stock was down about 8% as of 3:14 p.m. EDT. So what The drop is directly traceable to a bearish report that was released today by an analyst named Ben Axler, at a hedge fund named Spruce Point Capital Management. Axler published a report stating that DexCom's stock could be cut in half from today's levels. Here are the key points of his argument: DexCom is starting to saturate its core type-1 diabetes market in the U.S. It recently stopped reporting patient growth, which is a bad sign. Abbott Laboratories (NYSE: ABT) is on the verge of launching its second-generation FreeStyle Libre product. This updated device promises to be much more competitive with DexCom and will cost about 80% less. The incoming competition could crimp DexCom's revenue growth rate and margins. Traders are selling off DexCom's stock in response. Now what Bearish analys t report s should always be viewed with skepticism when the author is short the security prior to publication. That's certainly true of this report as Axler and/or Spruce Point Capital Management are currently short shares of DexCom. That doesn't mean that this report should be dismissed, as it does raise some valid points. Abbott is a huge medical device company with vast resources, and its new FreeStyle Libre looks quite compelling. It could be a serious contender considering that it will be priced at a substantial discount to DexCom's products. That premium might not matter much to patients who are on intensive insulin therapy and demand the very best, but it will likely be a huge selling point for patients who require less-intensive forms of therapy and are price sensitive. On the flip side, DexCom hasn't slowed down at all since the FreeStyle Libre was launched a few years ago, so it is possible that the updated version won't impact its growth rates, either. It is also worth noting that DexCom management is on record stating that it will pull in between $2 billion and $2.5 billion in total revenue by 2023. They knew that the next-generation FreeStyle Libre was waiting in the wings when they made that forecast, so they didn't think it will hamper their growth. My view is that total diabetes pie is big enough to support multiple winners, so I don't think DexCom's bulls need to panic. But there's no doubt that the competition in the space is heating up. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""41 Stocks Moving In Friday's Mid-Day Session"", ""DexCom shares trading lower following a nearly 3 percent decline on Thursday amid a negative report from Spruce Point. Shares traded below the $140 level Friday."", ""HMS Holdings Gains on PI & TPM Solutions, Competition Rife"", ""Here's Why You Should Retain Ecolab Stock in Your Portfolio"", ""DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day"", ""Why Dexcom Faces 45-60% Downside Risk From Abbot's New Libre 2 Product"", ""Bull of the Day: DexCom (DXCM)""]"
DXCM,2019-03-25,32.0,32.06,30.375,31.02,"[""AMN Healthcare Down on Soft Locum Tenens Business, Dull View"", ""60 Biggest Movers From Friday"", ""60 Biggest Movers From Friday"", ""AMN Healthcare Down on Soft Locum Tenens Business, Dull View"", ""AMN Healthcare Down on Soft Locum Tenens Business, Dull View On Mar 20, we issued an updated research report on AMN Healthcare Services IncAMN . The company's soft Locum Tenens Business and a dull 2019 view are concerning factors at the moment. Shares Down Over the past year, the Zacks Rank #4 (Sell) stock has declined 16.5% against its industry 's 15.2% rally. The current level is also lower than the S&P 500 index's 6.4% gain. Estimates Plummet For the first quarter, four estimates have moved down over the last 60 days, compared to no movement in the opposite direction. For 2019, five estimates have moved south. Reflective of this, AMN Healthcare's current-quarter earnings per share projection plunged 18.6% to 70 cents over the past two months. Meanwhile, current-year earnings per share estimate moved 33.6% to down $2.98 over the same time frame. AMN Healthcare Services Inc Price and Consensus AMN Healthcare Services Inc Price and Consensus | AMN Healthcare Services Inc Quote What's Deterring the Stock? In the recently-reported fourth quarter of 2018, Locum Tenens revenues declined 24% to $82 million, far wider than management's expectation of a 14% fall. Per management, there were larger-than-expected declines in the emergency medicine and hospital specialties due to a drop in demand. Hence, first-quarter 2019 Locum Tenens revenues are expected to deteriorate year over year. Furthermore, the company expects 2019 organic revenues to decline 6% owing to expectations of lower contributions from the Locum Tenens business. Additionally, Nurse and Allied segment revenues are expected to decline about 1-2% year over year. Lastly, AMN Healthcare outsources certain critical applications or business processes to external providers, including cloud-based, credentialing and data processing services. Hence, the failure or inability to perform by one or more of these critical suppliers could cause significant disruptions and raise costs for the company. However, it is encouraging to note that the company's acquisition of MedPartners has proven accretive in recent times. Key Picks A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Veeva Systems VEEV and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Penumbra's long-term earnings growth rate is expected at 20.9%. Veeva Systems' long-term earnings growth rate is estimated at 14.8%. DexCom's next-quarter earnings per share are projected to grow 120%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BD Remains Confident About LUTONIX DCB Despite FDA Letter Becton, Dickinson and CompanyBDX , popularly known as BD, announced that it has received a 'warning' letter from the FDA on Mar 15, 2019, regarding the increased long-term mortality of its LUTONIX drug-coated balloon (\""DCB\""). Notably, the FDA's concern follows a solid preliminary analysis of long-term data of the LUTONIX DCB. BD's flagship LUTONIX DCB is a paclitaxel-coated device that is used to treat peripheral arterial disease in the femoropopliteal artery. Following the news release, the share price of BD inched down 1.8% yesterday. The stock has a Zacks Rank #3 (Hold). Three Major Factors Supporting BD Per the recent press release issued by BD, it seems that the company is still optimistic about the LUTONIX DCB. Here's Why: Favorable Pre-clinical and Clinical data Investors should notice that BD has issued a statement indicating the \""robustness of its pre-clinical and clinical data\"" of LUTONIX DCB. Management at BD claims to have evidence from seven separate studies that successfully demonstrated the safety and efficacy of these products. This apart, BD has analyzed and reviewed all available data about the LUTONIX DCB over the past several months, all of which had favorable outcomes. Becton, Dickinson and Company Price and Consensus Becton, Dickinson and Company Price and Consensus | Becton, Dickinson and Company Quote The LEVANT 2 study BD conducted a LEVANT 2 study to evaluate the possibilities of the long-term mortality risks of LUTONIX DCB. The study enrolled 1,189 patients - a sample that is significantly more than the pooled dataset by the FDA. BD confirmed that the company did not witness any abnormalities or an indication of long-term mortality in this large patient cohort. Underlying Cause Not Mentioned by the FDA Interestingly, the FDA has accepted that the underlying cause pertaining to the increased risk of mortality for LUTONIX DCB is yet to be decoded. In fact, the amount of long-term data analyzed by the FDA was also limited, which might have created inconsistency in estimating mortality risk. Further, the data was not intended to be pooled. Collaborations With Other Global Regulators BD is trying to collaborate with global regulators, academic societies and other thought leaders to support an independent patient-level meta-analysis and further investigate the importance of safety and DCBs. Furthermore, the company added that it is currently working with the FDA and VIVA Physicians Group. BD plans to complete these independent investigations before the FDA's Advisory Committee Meeting (panel) that is anticipated to take place in mid-June 2019. Key Picks A few better-ranked stocks from the MedTech space are DexCom, Inc. DXCM , Varian Medical Systems, Inc. VAR and Masimo Corporation MASI , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%. Varian Medical has a long-term earnings growth rate of 8%. Masimo Corporation has a long-term earnings growth rate of 15.6%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Big Stock Charts for Monday: Twitter, UnitedHealth Group and Philip Morris InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pow! A little fear went a long way on Friday, exacerbated by Thursday's surprisingly big advance. When all was said and done, the S&P 500 lost 1.9% on the last trading day of last week. Yet, it's still above all the key moving average lines. Assume nothing. Nokia (NYSE: NOK ) did the most damage, losing more than 6% following reports that it was investigating the terms and conditions of a business acquisition made in 2016 . Though not likely, any discovery of issues could lead to penalties. DexCom (NASDAQ: DXCM ) logged a much bigger loss though, off more than 9% after analysts with Spruce Point suggests DXCM shares could be cut in half as competition within the glucose monitoring system market heats up. Verizon Communications (NYSE: VZ ) tried to resist the tide, advancing 2.5% as investors get fired up over its brewing rollout of 5G connectivity. There weren't enough names like Verizon to keep the broad market even close to a breakeven on Friday, however. As the new trading week kicks off, it's the stock charts of Twitter (NYSE :TWTR ), UnitedHealth Group (NYSE: UNH ) and Philip Morris International (NYSE: PM ) that are worth some technical scrutiny. Here's why, and what to look for. Philip Morris International (PM) It has been a good run. Philip Morris International shares are up more than 28% from their December low. But the weight of the big gain is starting to bear down on the stock, and it's doing so at the point that's most opportune for the bears. 7 Beaten-Up Stocks to Buy as They Reverse Course A pullback wouldn't necessarily have to be a permanent condition though, and it's pretty clear where the bulls would regroup if PM shares suffer the setback being flagged here. Click to Enlarge \u2022 The make-or-break ceiling is around $92.80, where the stock peaked last week but also peaked in October. \u2022 Zooming out to the weekly chart, we can see shares are stochastically overbought and ripe for profit-taking. \u2022 While a setback may be in the works, the convergence of the purple 50-day, the gray 100-day and the white 200-day moving average line could readily combine to act as a floor. Twitter (TWTR) For the past several months, the bears have been trying to upend Twitter but have been unable to do it. That has given the stock time to regroup, and even move into a position to stage a full recovery. That's not happened yet, but one or two more good days could do the trick. And, that effort is taking shape with a very encouraging backdrop. Click to Enlarge \u2022 The foundation for the renewed bullish effort is the support supplied at $26.30, where shares made a double bottom in the latter part of last year. \u2022 But the big buy trigger here is a move above the white 200-day moving average line and above the falling resistance lines that has tagged all the major peals since December. It's plotted in yellow on both stock charts. \u2022 Fanning the bullish flames - at least partially - is the big bearish gap left behind in July. The upper edge of the gap range is just above the $42 mark. UnitedHealth Group (UNH) Finally, in late February UnitedHealth Group gave a second - and pretty decisive - selloff that largely confirmed a major downturn was in the works. That panned out as expected, with UNH stock making a few more days of selling. The bulls did push back, but that effort crumbled and turned back into a downtrend right where one would expect. The renewal of the downtrend at the ideal ceiling sets up a third bearish leg that could end up turning into a bigger selloff than the last couple of setbacks have been. Click to Enlarge \u2022 The rally effort was stopped and reversed just as the white 200-day moving average line was bumped. That reversal is highlighted on the daily chart. \u2022 The big floor from here is around $235, in line with the past two major bottoms UNH has made. That support is plotted with a red dashed line. \u2022 The weekly chart puts things in perspective. The three-year advance was amazing, but arguably overcooked. A little more weakness could easily turn into a lot of profit-taking. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com , or follow him on Twitter , at @jbrumley. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 7 A-Rated Stocks to Buy in the Second Quarter 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock 7 ETFs for a Millennial Portfolio Compare Brokers The post 3 Big Stock Charts for Monday: Twitter, UnitedHealth Group and Philip Morris appeared first on InvestorPlace . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Relative Strength Alert For DexCom Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $121.50 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 55.0. A bullish investor could look at DXCM's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $68.86 per share, with $156.16 as the 52 week high point - that compares with a last trade of $126.14. Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Crosses Below Key Moving Average Level In trading on Monday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $127.62, changing hands as low as $121.50 per share. DexCom Inc shares are currently trading down about 2.6% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $68.86 per share, with $156.16 as the 52 week high point - that compares with a last trade of $125.68. Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""60 Biggest Movers From Friday"", ""AMN Healthcare Down on Soft Locum Tenens Business, Dull View""]"
DXCM,2019-03-26,31.1775,31.4,30.035,30.2375,"[""Fresenius Medical to Make Huge Investments, Competition Rife"", ""Allscripts' FollowMyHealth Partners Ephraim McDowell Health"", ""Allscripts' FollowMyHealth Partners Ephraim McDowell Health"", ""Fresenius Medical to Make Huge Investments, Competition Rife"", ""Allscripts' FollowMyHealth Partners Ephraim McDowell Health In a bid to strengthen its enterprise and mobile patient engagement platform, Allscripts Healthcare Solutions Inc.MDRX recently announced that its flagship platform, FollowMyHealth, will partner with Ephraim McDowell Health. Per management, this partnership is likely to enhance the patient experience for millions of people and drive the digital transformation process in the U.S. healthcare industry. FollowMyHealth - A Key Catalyst FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians. It also offers a mobile, enterprise patient engagement tool for hospitals and health systems. It is encouraging to note that, in 2018, FollowMyHealth's total connected patients reached over 17 million with portal alone. Furthermore, Allscripts recently integrated the HealthGrid capabilities into the FollowMyHealth platform. This is likely to enable organizations to reach 100% of their patient populations, both pre-visit and post-visit. Taking into consideration the expanded HealthGrid platform, total connected patients are now 40 million, which might see an improvement in the coming days. Leveraging on FollowMyHealth, clients are expecting up to 70% of patients actively engaged. Allscripts has been a leading player in the Patient Engagement solutions as well. The company is gaining prominence with other platforms like FollowMyHealth Achieve and FollowMyHealth Telemedicine. Other Recent Developments Earlier this month, Allscripts announced a strategic partnership with Opargo, a SaaS platform, to strengthen Allscripts Practice Management revenue cycle software. Opargo leverages on predictive analytics to ensure that critical patients have hospital slots available, even at the last minute. Adoption of these solutions is likely to have a solid impact on Allscripts customer base and the health care industry as a whole. Moreover, Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution - a comprehensive revenue cycle management solution for physician's practices and large hospital organizations (read more: Allscripts Partners With Opargo to Boost Practice Management ). This apart, Allscripts has strengthened its strategic relationship with Pulse8 - a leading player in healthcare analytics and technology. Pulse8 is likely to boost Allscripts' flagship platform, Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members. Veradigm is also likely to leverage on Pulse8's newly combined offering of clinical data exchange solutions, cutting-edge analytics and point-of-care engagement tools to maximize return on investment. Price Performance Shares of this Zacks Rank #4 (Sell) company have lost 17.2% against the industry 's 7.6% growth. The current level also compares unfavorably with the S&P 500 index's 7.5% gain over the same time frame. However, Allscripts is on a spree of positive developments and strategic deals, which might provide it with a solid ground to perform better in the days to come. Stocks to Consider A few better-ranked stocks from the MedTech space are DexCom, Inc. DXCM , Varian Medical Systems, Inc. VAR and Masimo Corporation MASI , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%. Varian Medical has a long-term earnings growth rate of 8%. Masimo Corporation has a long-term earnings growth rate of 15.6%. Is Your Investment Advisor Fumbling Your Financial Future? See how you can more effectively safeguard your retirement with a new Special Report, \""4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.\"" Click to get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allscripts Healthcare Solutions, Inc. (MDRX): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Allscripts' FollowMyHealth Partners Ephraim McDowell Health"", ""Fresenius Medical to Make Huge Investments, Competition Rife""]"
DXCM,2019-03-27,30.165,30.23,28.6912,28.885,"[""Varian Medical (VAR) Collaborates With Korea-Based Hospital"", ""Varian Medical (VAR) Collaborates With Korea-Based Hospital"", ""Varian Medical (VAR) Collaborates With Korea-Based Hospital Varian Medical Systems, Inc. 's VAR recent tie-up with Korea University Medical Center Anam Hospital led to the first treatment by the company's flagship Halcyon system in the country. Notably, Varian Medical's ARIA oncology information system and Eclipse treatment planning software will also be used by the hospital. Following the announcement, shares of this Zacks Rank #2 (Buy) company rose 3% to $139.12 at close. The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care, streamlining every aspect of image-guided volumetric intensity modulated radiotherapy. Meanwhile, the ARIA oncology information system is a comprehensive information and image management solution that lets patients oversee all aspects of oncology care. Eclipse is an integrated treatment planning system, supporting a variety of treatment options including protons, electrons, external beam, low-dose-rate brachytherapy and cobalt therapy. Operations in Asia Varian Medical enjoys a significant presence in Asia. In the las t report ed quarter, orders in Southeast Asia and Korea nearly doubled. Notably, the company received two Halcyon orders from Korea. Further, APAC revenues shot up 7% on a year-over-year basis. In March, the company signed a three-year agreement with Tata Trust for increasing patient access to advanced radiation therapy treatments in India. (Read More: Varian & Tata Trust Tie Up to Boost Radiotherapy in India ) Last December, the company's Halcyon radiotherapy system, which are manufactured in China, received approval from the United States Trade Representative for its exclusion from Section 301 tariffs. (Read More: Varian Medical's Halcyon Excluded From Trade Tariffs ) Additionally, the Halcyon system was granted approval by the China National Medical Product Administration, expanding its global availability. (Read More: Varian Medical's Halcyon Gets NMPA Approval in China ) Notably, the system was introduced to the China market earlier this year. Market Prospects The Newsmates suggests that the global radiation therapy equipment market will see a CAGR of 6.4% between 2019 and 2023. Another key player in the space is Accuray Incorporated ARAY , whose subsidiary Accuray Asia recently formed a joint venture with CNNC High Energy Equipment Co., a subsidiary of China Isotope and Radiation Corporation. Price Performance Over the past year, shares of Varian Medical have rallied 14.1% compared with the industry 's 12.6% gain. The current level is also higher than the S&P 500 index's 7.9% rise. Other Key Picks Other top-ranked stocks in the broader medical space are Veeva Systems VEEV and DexCom. Inc. DXCM . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Veeva Systems' long-term earnings growth rate is estimated at 14.8%. DexCom's second-quarter earnings per share are projected to grow 120%. Today's Best Stocks from Zacks Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Varian Medical (VAR) Collaborates With Korea-Based Hospital""]"
DXCM,2019-03-28,28.825,29.9725,28.16,29.595,"First Week of April 18th Options Trading For DexCom (DXCM) Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading this week, for the April 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new April 18th contracts and identified one put and one call contract of particular interest. The put contract at the $105.00 strike price has a current bid of $1.20. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $105.00, but will also collect the premium, putting the cost basis of the shares at $103.80 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $118.63/share today. Because the $105.00 strike represents an approximate 11% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 86%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.14% return on the cash commitment, or 19.86% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $120.00 strike price has a current bid of $4.60. If an investor was to purchase shares of DXCM stock at the current price level of $118.63/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $120.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.03% if the stock gets called away at the April 18th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.88% boost of extra return to the investor, or 67.40% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 57%, while the implied volatility in the call contract example is 52%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $118.63) to be 51%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-03-29,29.75,29.9725,29.28,29.775,"[""Stocks To Watch: Dexcom Sees Relative Strength Rating Jump To 83"", ""Why Veeva Systems (VEEV) is an Attractive Pick Right Now?"", ""Here's Why Investors Should Retain NextGen Healthcare Stock"", ""Stocks To Watch: Dexcom Sees Relative Strength Rating Jump To 83"", ""Why Veeva Systems (VEEV) is an Attractive Pick Right Now?"", ""Here's Why Investors Should Retain NextGen Healthcare Stock"", ""Stocks To Watch: Dexcom Sees Relative Strength Rating Jump To 83"", ""Why Veeva Systems (VEEV) is an Attractive Pick Right Now?"", ""Here's Why Investors Should Retain NextGen Healthcare Stock""]"
DXCM,2019-04-01,29.9875,30.2462,28.5,28.7925,"[""Here's Why You Should Retain ABIOMED Stock in Your Portfolio"", ""Here's Why You Should Retain ABIOMED Stock in Your Portfolio"", ""Integer Holdings Gets Positive Outlook & B+ Rating From S&P Integer Holdings CorporationITGR recently announced that Standard & Poor(S&P)revised its outlook from \""stable\"" to \""positive\"". The new outlook is based on Integer's debt reduction and expected targeted debt-to-adjusted EBITDA leverage ratio of 2.5X-3.5X. Investors should also notice that S&P raised its issuer credit rating from B to B+, and Moody's Investors Service upgrades its corporate family rating from B3 to B2. In a year's time, Integer has gained 36.8%, significantly higher than the S&P 500 index's increase of 10%. The current return is also higher than the broader industry 's 17.2% rally over the same time period. Details of the S&P's Outlook An obligator rated B+ by the S&P means that the company has a strong capacity to meet its financial commitments. However, adverse business, financial, or economic conditions might impair the company's capacity or willingness to meet its financial commitments. The best rating is 'AAA', which means it is highly likely that the borrower will repay its debt. The worst rating is 'D,' which means the issuer has already defaulted. Positive outlook for the company indicates that the current rating may be raised. Reasons Behind the Outlook Integer has strengthened its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end. In the third quarter of 2018, Integer paid down its debt balance by $548 million from the sale of its Advanced Surgical & Orthopedic product line. Integer expects to generate continued strong free cash flow and pay down its outstanding debt by an additional $105-$115 million in 2019. Solid Guidance For 2019, adjusted earnings are expected to be $4.05-$4.25 per share, indicating a 7-12% rise from the previous year. Integer expects earnings per share in the $2.77-$2.97 band on a reported basis, mirroring 7-12% growth on a year-over-year basis. Integer anticipates 2019 revenues between $1.26 billion and $1.28 billion, mirroring 4-5% growth year over year. On an adjusted basis, the company expects revenues in the same band, reflecting a 4-6% improvement from the previous year. Adjusted income from operations is anticipated between $141 million and $275 million, showing a year-over-year rise of 8-13%. Zacks Rank & Other Stocks to Consider Integer carries a Zacks Rank #2 (Buy). Other top-ranked stocks from the MedTech space are DexCom, Inc. DXCM , Varian Medical Systems, Inc. VAR and Masimo Corporation MASI , each carrying a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%. Varian Medical has a long-term earnings growth rate of 8%. Masimo Corporation has a long-term earnings growth rate of 15.6%. Zacks' Top 10 Stocks for 2019 In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs. See Stocks Today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain ABIOMED Stock in Your Portfolio""]"
DXCM,2019-04-02,29.245,29.4275,28.3775,29.245,
DXCM,2019-04-03,29.4625,29.6962,28.73,29.4225,
DXCM,2019-04-04,29.6125,29.785,29.0262,29.29,"[""Dexcom Scores Relative Strength Rating Upgrade; Hits Key Benchmark"", ""Dexcom Scores Relative Strength Rating Upgrade; Hits Key Benchmark"", ""Here's Why DexCom Shares Slumped 14.5% in March What happened After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence. So what DexCom's continuous glucose monitors (CGMs) help diabetics track their blood glucose levels better, reducing dangerous blood sugar highs and lows and potentially slowing disease progression. IMAGE SOURCE: GETTY IMAGES. In 2018, DexCom sales soared 44% year over year to $1.032 billion following the launch of its latest system, the G6. In 2019, sales could be harder to come by, though, according to short-seller Spruce Point Capital Management. In a report released last month, Spruce Point said the launch of Abbott Labs' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. Currently, DexCom competes against Medtronic's Guardian brand of CGMs and the first-generation Freestyle Libre, a CGM that, unlike DexCom's G6, still requires patients to prick their fingers during the first 11 hours of wear to confirm readings -- and doesn't include blood glucose high and low alarms. Abbott's already next-generation finger-stick-less Freestyle Libre has launched overseas, and while there's no timeline for a potential launch in the U.S., an eventual release could challenge DexCom because G6 sensors are approved for only 10 days of wear, while Freestyle Libre's sensors can be worn for 14 days. The longer wear can reduce patient's costs, making it attractive to patients with limited insurance coverage for the G6. Now what In 2019, DexCom doesn't expect to deliver growth similar to 2018, but it's still targeting revenue to increase by 15% to 20% to $1.175 billion- $1.225 billion. DexCom's also said its plan is to grow sales at a compounded annual rate of 15% through 2023. Although more type 1 diabetics are using CGMs than ever before, the opportunity to penetrate the market for type 2 patients and others in need of monitoring, such as patients with gestational diabetes, is significant. Only 12.5% of the roughly 200 million people with diabetes worldwide achieve their desired blood glucose target. The G6 is the only CGM to have secured an FDA approval for interoperability, so it stands to benefit from next-generation blood glucose control systems, including automated insulin devices from Tandem Diabetes and Insulet, and smart pen solutions at Eli Lilly and Novo Nordisk, the two largest manufacturers of insulin products. Tandem launched its first automated system last year; Insulet's system is expected next year; and Eli Lilly and Novo Nordisk's solutions are on deck. Furthermore, DexCom could benefit from the anticipated launch of its G7 in 2020. Developed with help from Verily, a healthcare technology company spun off from Alphabet, the G7 is expected include a low-cost, disposable sensor that may allow DexCom to penetrate the type 2 market more effectively. The threat posed by Abbott Labs shouldn't be ignored, but the size of this market and the potential advances in the next 12 to 24 months could make buying shares on this sell-off wise. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell owns shares of Alphabet (C shares) and DexCom. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why DexCom Shares Slumped 14.5% in March What happened After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence . So what DexCom's continuous glucose monitors (CGMs) help diabetics track their blood glucose levels better, reducing dangerous blood sugar highs and lows and potentially slowing disease progression. In 2018, DexCom sales soared 44% year over year to $1.032 billion following the launch of its latest system, the G6. In 2019, sales could be harder to come by, though, according to short-seller Spruce Point Capital Management. In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. Currently, DexCom competes against Medtronic 's Guardian brand of CGMs and the first-generation Freestyle Libre, a CGM that, unlike DexCom's G6, still requires patients to prick their fingers during the first 11 hours of wear to confirm readings -- and doesn't include blood glucose high and low alarms. Abbott's already next-generation finger-stick-less Freestyle Libre has launched overseas, and while there's no timeline for a potential launch in the U.S., an eventual release could challenge DexCom because G6 sensors are approved for only 10 days of wear, while Freestyle Libre's sensors can be worn for 14 days. The longer wear can reduce patient's costs, making it attractive to patients with limited insurance coverage for the G6. Now what In 2019, DexCom doesn't expect to deliver growth similar to 2018, but it's still targeting revenue to increase by 15% to 20% to $1.175 billion- $1.225 billion. DexCom's also said its plan is to grow sales at a compounded annual rate of 15% through 2023. Although more type 1 diabetics are using CGMs than ever before, the opportunity to penetrate the market for type 2 patients and others in need of monitoring, such as patients with gestational diabetes, is significant. Only 12.5% of the roughly 200 million people with diabetes worldwide achieve their desired blood glucose target. The G6 is the only CGM to have secured an FDA approval for interoperability, so it stands to benefit from next-generation blood glucose control systems, including automated insulin devices from Tandem Diabetes and Insulet , and smart pen solutions at Eli Lilly and Novo Nordisk , the two largest manufacturers of insulin products. Tandem launched its first automated system last year; Insulet's system is expected next year; and Eli Lilly and Novo Nordisk's solutions are on deck. Furthermore, DexCom could benefit from the anticipated launch of its G7 in 2020. Developed with help from Verily, a healthcare technology company spun off from Alphabet , the G7 is expected include a low-cost, disposable sensor that may allow DexCom to penetrate the type 2 market more effectively. The threat posed by Abbott Labs shouldn't be ignored, but the size of this market and the potential advances in the next 12 to 24 months could make buying shares on this sell-off wise. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell owns shares of Alphabet (C shares) and DexCom. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Scores Relative Strength Rating Upgrade; Hits Key Benchmark""]"
DXCM,2019-04-05,29.4525,29.6375,29.075,29.23,"[""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know"", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know"", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know DexCom (DXCM) closed the most recent trading day at $116.92, moving -0.2% from the previous trading session. This change lagged the S&P 500's 0.46% gain on the day. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.59%. Heading into today, shares of the medical device company had lost 18.11% over the past month, lagging the Medical sector's gain of 0.72% and the S&P 500's gain of 3.24% in that time. DXCM will be looking to display strength as it nears its nex t earnings release, which is expected to be May 1, 2019. On that day, DXCM is projected to report earnings of -$0.17 per share, which would represent year-over-year growth of 46.88%. Our most recent consensus estimate is calling for quarterly revenue of $246.45 million, up 33.65% from the year-ago period. DXCM's full-year Zacks Consensus Estimates are calling for earnings of $0.46 per share and revenue of $1.23 billion. These results would represent year-over-year changes of +53.33% and +19.13%, respectively. It is also important to note the recent changes to analyst estimates for DXCM. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DXCM is holding a Zacks Rank of #2 (Buy) right now. Looking at its valuation, DXCM is holding a Forward P/E ratio of 252.41. This represents a premium compared to its industry's average Forward P/E of 32.11. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 43% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know""]"
DXCM,2019-04-08,29.2875,29.4275,28.39,28.7375,
DXCM,2019-04-09,28.55,29.0388,28.5,28.805,
DXCM,2019-04-10,28.7625,29.9512,28.5625,29.72,"[""DexCom shares are trading higher. Not currently seeing any company-specific news."", ""DexCom shares are trading higher. Not currently seeing any company-specific news."", ""DexCom shares are trading higher. Not currently seeing any company-specific news.""]"
DXCM,2019-04-11,29.8025,30.3625,29.3705,29.825,"5 Top Medical Device Stocks for 2019 You might look back at 2018 as a dismal year for stocks. After all, both the Dow Jones and S&P 500 indexes were down for the year. But for many medical device stocks, 2018 was a fantastic year, with at least a dozen medical device stocks racking up gains of more than 25%. There's no way to know whether medical device stocks will perform as well in 2019 as they did last year. However, there are still quite a few stocks that should be long-term winners and have a decent shot at delivering nice gains this year. Here's what you need to know about the top medical device stocks for 2019. Image source: Getty Images. Overview of the medical device industry The most important thing to understand about the medical device industry is probably its product diversity. The U.S. Food and Drug Administration (FDA) defines a medical device in broad terms. This definition includes any ""instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory"" that is used in diagnosing, curing, preventing, or treating a disease. With a definition that expansive in scope, you'd expect that there would be a lot of companies making medical devices. And you'd be right. There are around 5,500 medical device companies in the U.S. alone, making products that range from artificial joints to bedpans to robotic surgical systems. Some of these medical device companies are large and very profitable. However, over 70% of these companies have fewer than 20 employees. Many of them are still in the development stage and have no consistent revenue. The competitive dynamics for these companies vary greatly depending on the type of product they make. Simple medical devices such as surgical supplies tend to compete primarily on price and typically have low profit margins. On the other hand, medical devices that use advanced technology often have little competition, can be very expensive, and in turn generate high profit margins. All medical devices in the U.S. are regulated by the FDA. The agency places a medical device into one of three classes: Data source: FDA. The regulatory hurdles that a medical device company must clear depends on the class its medical device is assigned to. Class I devices usually only require registering with the FDA, and there's no approval process. For a small number of Class I devices, though, a regulatory filing called a 510(k) notification must be submitted to the FDA. This filing shows the FDA that the medical device is at least as safe and effective as an already-approved product that didn't require more extensive approval. It's the opposite scenario for Class II devices. Just a few get by through only registering with the FDA, while most require the filing of a 510(k) notification. The regulatory process for Class III devices is more involved. Companies must submit a premarket approval (PMA) application to the FDA, with clinical data that shows the medical device is safe and effective. The FDA reviews these PMA applications closely, and sometimes enlists the help of outside experts in the review process. Class III medical devices can only be marketed after receiving FDA approval. Growth prospects for the medical device industry The medical device industry should benefit from aging demographic trends for years to come. An aging population translates to more cases of chronic disease and a greater demand for all types of medical devices. In addition, the emergence of larger middle classes in developing nations should increase opportunities for some segments within the medical device industry. Overall, the global medical device market is projected to grow by a compound annual growth rate (CAGR) of 4.5% through 2023 to $409.5 billion, according to market researcher Lucintel. However, medical devices that use advanced technology should grow even more. The global high-tech medical device market is projected to grow at a CAGR of 29.2% through 2026 to reach $252 billion, according to Research and Markets. This rapid growth is expected to be bolstered by emerging technologies such as the Internet of Things (IoT) -- the connection of all types of devices to the Internet for the purpose of collecting data, tracking usage, and automating systems. What to look for in medical device stocks There are three primary things you should evaluate before buying a medical device stock: Financial position Competitive advantages Growth potential The most important aspect of a medical device company's financial position to consider is its profitability. Many up-and-coming medical device makers don't yet have profitable operations. As a result, they must raise the capital needed to fund operations, typically through either borrowing money or by issuing new shares -- both of which can have negative consequences. When a company takes on additional debt, its interest expenses increase. This reduces the amount of money available to spend in other areas like reinvesting in the business. Issuing new shares dilutes the value of existing shares. The company's total value doesn't change when more shares are issued, so dividing that value into more shares makes each share worth less. Another key component of a medical device maker's financial position is its available cash, including cash equivalents and short-term investments. For companies that aren't yet profitable, the amount of cash available is directly related to how long it will be before additional capital must be raised through debt or issuing new shares. For profitable companies, the cash stockpile is important in providing flexibility for expanding through acquisitions or other business development deals. Over the long term, competitive advantages will matter even more than a company's current financial position. When evaluating a medical device stock, research how its products compare to that of its competitors. The stocks of companies with medical devices that offer significantly more functionality than rivals or provide significant total cost advantages over rivals are more likely to be successful. It's possible that a medical device company has a strong financial position and solid competitive advantages but weak growth potential. How? Some medical devices can have a small total addressable market or a market that is already saturated with little room for additional growth. Check out the potential markets for a medical device stock before buying to make sure that there's plenty of room for long-term growth. Top medical device stocks for 2019 The top medical device stocks for 2019 illustrate the diversity of the medical device industry, with products as simple as clear plastic aligners for straightening teeth to robotic-assisted surgical systems. But these stocks have two key things in common. They all have solid competitive advantages. And they all have exceptional growth prospects. Here are five top medical devices stocks to consider buying in 2019: Data sources: Yahoo! Finance, company presentations. 1. Abiomed Abiomed focuses on medical devices for treating cardiovascular diseases. Around 25,000 of its Impella heart pumps are implanted in patients annually. The company celebrated its 100,000th patient in the fourth quarter of 2018. Revenue has more than tripled since 2014. Abiomed boosted its full-year 2019 guidance, calling for a revenue increase this year of around 31%. And its earnings per share are growing even faster. All of this has put Abiomed in an enviable financial position. The company reported cash of around $450 million in its latest quarterly update and the company has zero debt. Abiomed created the field of heart recovery using temporary heart pumps. The company really doesn't have a direct competitor in this market. That's the kind of competitive advantage that investors love. The growth prospects for Abiomed continue to look very good. Abiomed estimates that its current total addressable market in the U.S. is around $6 billion annually. It has only penetrated 11% of that market so far but expects to capture all of it. Outside of the U.S., Abiomed has penetrated 17% of the total addressable market in Germany and 1% in Japan. And these markets continue to grow as the country's populations age. 2. Align Technology Align Technology's flagship product is the Invisalign clear dental aligner. The company also sells iTero intraoral scanners that dental professionals use to create 3D images of patients' teeth, which are then used to development Invisalign treatment plans. Strong revenue and earnings growth has been a common theme in Align's quarterly updates, although its earnings growth trajectory has slowed somewhat recently. The company continues to be highly profitable and has amassed a cash stockpile of $744.5 million, including cash, cash equivalents, and marketable securities. Align pioneered the use of clear aligners for straightening teeth. The company continues to develop new products to treat more serious cases of malocclusion (misalignment of teeth). Align has also created a strong network of orthodontists and dentists who recommend Invisalign to their patients. While some competitors have entered the clear aligner market, Align Technology isn't too worried about them. Actually, the company owns a significant stake in one of its top rivals in the direct-to-consumer market, SmileDirectClub. Even though Align has been tremendously successful, there remains a huge untapped market. The company currently claims a market share of only 14% of the current addressable market. With new products on the way to treat more difficult cases, Align should be able to expand its addressable market significantly as well. 3. DexCom DexCom focuses on developing and marketing continuous glucose monitoring (CGM) systems for individuals with diabetes. The company has been a leader in the CGM market for several years. Sales have soared for DexCom, with an impressive CAGR of 44% from 2011 through 2018. The company reached profitability in 2018 and appears likely to keep the earnings flowing. DexCom also has plenty of cash on hand, reporting cash, cash equivalents, and marketable securities totaling nearly $1.4 billion as of Dec. 31, 2018. DexCom's latest CGM system, the G6, enjoys several competitive advantages over rival products. G6 is the only system that meets all of the FDA's integrated CGM special controls for accuracy in determining glucose levels. It's the first CGM that doesn't not require any finger sticks -- a huge plus for patients with diabetes. The system also integrates with leading insulin pumps, smart insulin pens, and insulin patch pumps. The market potential for DexCom is huge. DexCom has plenty of room to grow by focusing on its core patient population in the U.S. of 3.2 million individuals who require continuous glucose monitoring. However, there are an estimated 415 million people with diabetes worldwide. Only 6% of them achieve their desired outcomes, presenting a large potential opportunity for DexCom. The company also has an even more advanced product on the way -- the G7. This CGM system will be fully disposable and cost-effective for patients and payers. DexCom CEO Kevin Sayer said in the company's Q4 conference call that the G7 is on track to launch in late 2020 or early 2021. 4. Intuitive Surgical Intuitive Surgical pioneered the use of robotic surgical systems with its da Vinci system. More than 6 million procedures have been performed using the da Vinci, with around 1 million of those procedures occurring just last year. The company is in great financial shape. Intuitive's revenue jumped nearly 19% last year to $3.7 billion, while earnings soared 68% year over year to more than $1.1 billion. The company ended 2018 with a cash stockpile of $4.8 billion. Intuitive Surgical enjoys a couple of significant competitive advantages. First, it has a large base of customers who are motivated to maximize their return on investment with da Vinci rather than look for a new system. Second, the handful of companies with products that could potentially challenge Intuitive don't have the long track record that da Vinci has. CEO Gary Guthart noted in the company's Q4 earnings conference call that there have been nearly 1,500 peer-reviewed clinical journal articles for the da Vinci system. But can Intuitive Surgical continue to generate strong growth? It seems likely. Many surgical procedures still have way too many complications resulting from differences in the skill of surgeons. Robotic surgical systems like da Vinci help reduce these issues. The long-term demographic trend of aging global populations also should increase the numbers of procedures performed in the types of surgeries for which da Vinci is most used. Also, Intuitive Surgical is investing heavily in research and development. The company's latest system, ION, enables lung biopsy using minimally invasive robotic technology. Investors can expect more advances from Intuitive in the future. 5. Tandem Diabetes Care Like DexCom, Tandem Diabetes Care focuses squarely on the diabetes market. Instead of CGM systems, though, Tandem develops and sells insulin pumps. Tandem's sales have been growing at a phenomenal rate, jumping 71% in 2018. And the company posted a profit for the first time in the fourth quarter of 2018. As of Dec. 31, 2018, Tandem had cash, cash equivalents, and short-term investments of $129 million. While there are other insulin pumps on the market, Tandem's newest product, the t:slim X2, has several competitive advantages. For one thing, it integrates with DexCom's G6 CGM system. It also is the smallest insulin pump on the market, which makes it more convenient for users to wear. Also, the pump's Basal-IQ technology helps predict when insulin levels are about to move outside of thresholds before they do. Tandem has a big growth opportunity in the U.S. The company thinks that it will be able to increase the number of Americans with diabetes who use insulin pumps from around 550,000 to 900,000. Tandem also is targeting another 3 million people with type 1 diabetes who live outside the U.S. Risks The greatest risk for these medical device stocks is the threat of competition. The medical device industry is constantly changing, with new and improved technology regularly introduced. Align Technology and Intuitive Surgical enjoyed virtual monopolies for several years, but now both companies face new rivals. The other companies are also likely to see stiffer competition in the future. Several of the companies also could be hurt if global trade issues aren't resolved. In particular, U.S.-China trade tensions could present challenges for medical device companies that either already have a presence in China or hope to establish operations there. There's also a risk that new products in development could fail to secure FDA approval or encounter delays in receiving clearance for marketing, as well as the risk for product liability lawsuits and legal action if any of the medical devices turn out to be less safe than once thought. Looking ahead Despite these risks, the future appears to be bright for the medical device industry -- and particularly for companies with high-tech medical devices. Abiomed, Align Technology, DexCom, Intuitive Surgical, and Tandem Diabetes Care should be in great shape to succeed in 2019 and beyond. 10 stocks we like better than Intuitive Surgical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Intuitive Surgical wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 1, 2019 Keith Speights owns shares of Align Technology and Intuitive Surgical. The Motley Fool owns shares of and recommends Abiomed, Align Technology, and Intuitive Surgical. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-04-12,29.88,30.0725,29.45,29.47,"Top IoT Stocks to Buy in 2019 Most of us would probably describe the internet as a vast network of websites, social networks, and videos that users can virtually access with computers and mobile devices. While this would undoubtedly describe the ways most of us interact with the internet, it fails to encompass its vast array of connections and reach. The internet is much more than a collection of billions of web addresses; it is the digital network connecting each website to billions of connected devices. The IoT might consist of 75 billion devices by 2025. Image source: Getty Images. What is the Internet of Things? The internet has expanded to now connect a number of devices beyond our familiar computers, tablets, and smartphones. Collectively, these connected devices make up the Internet of Things (IoT), a network of billions of appliances and gadgets that collect, receive, and transmit data. These devices can be used to automate, control, monitor, or track a wide range of formerly ""dumb"" devices -- things that once did not communicate to other devices or connect to the internet -- such as: Automobiles Lights Medical devices (e.g., advanced hearing aids, heart monitors, etc.) Refrigerators Security systems Smart speakers Televisions Thermostats Transportation infrastructure devices (e.g., electronic toll collections, smart traffic controls, etc.) Wearables And more What are smart devices? These appliances, when capable of communicating with users, other devices, or the internet, are often referred to as ""smart devices."" The adjective ""smart"" generally means the device is part of the IoT and, as such, is generally capable of more than what the appliance is traditionally known for doing. For instance, a smart TV means the television can browse the internet, download apps, or be controlled by other devices. A smart doorbell might send a push notification to your smartphone when rung. A smart refrigerator can order food that is running low. Popular smart-home devices Several of today's largest companies are now making smart-home speakers that can control the rest of the home's smart devices from one central location. For instance, Amazon.com (NASDAQ: AMZN) sold a ""record-breaking number"" of devices powered by Alexa, its AI platform in the 2018 holiday season quarter, with the Echo Dot, its voice-controlled speaker, being the highest-selling unit globally. The Alexa platform now has 50,000 skills, ranging from streaming music, citing facts, playing games, and of course, ordering products from Amazon. Many of today's largest tech companies have entered the smart-home space as the category gains in popularity with consumers. Image source: Getty Images. Alphabet's (NASDAQ: GOOGL)(NASDAQ: GOOG) Google Home devices also sold millions of units in 2018 and can work with more than 5,000 different smart-home devices across 150 different brands. (Even The Motley Fool works with Google Home!) Alphabet brags that the device was used to make 16 million recipes during the 2018 holiday season. Apple's (NASDAQ: AAPL) HomePod, powered by Siri, has not enjoyed nearly the same popularity as the Google Home or Echo Dot devices, probably owing to its much higher price point. That said, Apple continues to believe there is a market for a smart-home speaker that prioritizes privacy and sound quality above all else. How big is the IoT? There are many contrasting projections concerning the growth of the installed device base of the IoT over the coming years. IHS Markit, a global information provider, estimates that the total number of IoT devices will surge from 27 billion in 2017 to 125 billion by 2030. Cisco estimates that it will be much higher by then, believing that 500 billion devices will be connected to the internet in 2030. Global consulting firm Bain believes spending on the IoT will grow to $520 billion in 2021, more than double the $235 billion that was spent in 2017. When it comes to investing, the better approach is often to be generally right than precisely wrong. In other words, the important takeaway from these statistics isn't the exact number of devices that will be connected in a certain year or the precise spending that companies will invest in this industry. Rather, the relevant fact is that the IoT is still growing by leaps and bounds, with a long runway still ahead of it. The biggest pros and cons of investing in the IoT One of the biggest tailwinds for the IoT is the coming of 5G wireless networks. 5G, the fifth generation of wireless networks, will bring: Faster network speeds -- some experts claim up to 100 times as fast as 4G networks. Lower latency (the delay between sending and receiving a signal). Greater data capabilities, meaning more data will be able to be carried across mobile signals at once. By increasing wireless networks' speed and reliability, 5G will enable a whole host of applications, including autonomous vehicles, mobile payments, and virtual reality. This will literally increase the real-world number and use of IoT devices. The greatest risk facing the IoT is that while it is big and growing, its future growth rate remains a projection. Nothing is certain to come to pass. 5G networks might launch slower than anticipated. Fully autonomous vehicles might prove to be decades away. Virtual reality may never see mass adoption among consumers. Industries may never find uses or ways to analyze the troves of data IoT can give them. ETFs, the easy way to invest in the Internet of Things With all of the money pouring into the IoT in the years ahead, it's only natural for investors to wonder how to capitalize on this huge trend. While we'll discuss individual stocks shortly, there is another, easier way to attempt to profit: The Global X Internet of Things ETF (NASDAQ: SNSR). An ETF, or exchange-traded fund, is a basket of equities that are grouped together under one trading entity. Many, as in this case, are grouped together under common sectors and themes. The Global X IoT ETF contains large holdings in a wide range of diverse companies, including: DexCom (NASDAQ: DXCM), which designs and produces health-care monitoring devices for diabetics. ADT, the alarm company. And Skyworks Solutions (NASDAQ: SWKS), an analog semiconductor maker whose chips enable devices to connect to wireless networks. In other words, buying this ETF can instantly diversify investors across industries, yet still be centered on the common theme of the IoT. Investing in ETFs can also be a smart way to mitigate risk through diversification as well as take advantage of macro trends without the heavy time investment that studying individual stocks involves. While this ETF could very well beat the S&P 500 index in the years ahead, I believe there are still better ways for investors to profit from the Internet of Things. The best IoT stocks for 2019 Data source: Google Finance. Let's take a closer look at some of these companies to see why they make such good investments today. DexCom: Continuous monitoring for diabetics DexCom is a health-care device company that designs and develops continuous glucose monitoring (CGM) systems for diabetics. A small sensor, placed just under the skin, measures glucose levels every five minutes. An adhesive patch holds the sensor in place throughout the day. A small transmitter then sends the readings to a compatible mobile device, usually an Android or iOS smartphone. DexCom makes sensors that provide continuous glucose monitoring for diabetics. Image source: DexCom Inc. DexCom's CGM solutions are shown to reduce users' A1C scores (a blood test that shows your average glucose levels over the past three months), reduce hypoglycemia, and provide active monitoring at night, making them an extremely attractive value proposition for diabetics. The company expects to grow revenue by 15% annually through 2023, a reflection of its huge total addressable market and the number of patients it has yet to reach. Over the same period, it expects to grow its operating margin from negative 3% to 15% through a variety of cost controls and the winding down of research projects. GrubHub: The food-delivery app GrubHub is the country's largest digital platform for placing restaurant take-out and delivery orders. As the devices that connect to the internet increase in number, mobile platforms for ordering delivery should only grow more ubiquitous. In addition to being a huge mobile platform, GrubHub is also one of the best ways to invest in the growing food-delivery boom. The company finished 2018 with 17.7 million active diners, the number of unique diner accounts that have placed an order on the company's platform in the past year. During that same time, there were also 467,500 daily average grubs, or DAGs, which the company calculates by taking the number of total orders and dividing it by the number of days in the measured period. Both figures were up approximately 20% from 2017 totals. GrubHub is constantly working to improve its mobile interface so hungry diners can find exactly what they're looking for in a quick and seamless process. In a 2018 conference call, founder and CEO Matthew Maloney stated: Continuous improvement of our diner-facing product remains a priority and a source of growth for us. Recently, we reengineered our mobile experience implementing a new, cleaner tile layout for restaurant search as well as improvements to navigation and a more photo-forward approach to discovery. GrubHub is also providing mobile support for many of its partners, including Yum! Brands' Taco Bell and KFC chains. In late 2017, the company partnered with the two iconic fast-food brands to become their exclusive digital online and mobile ordering platform. When asked if GrubHub would be integrating its platform with the restaurants' mobile apps as well, Maloney responded: [W]e're powering their white label for everything. All transactions and their websites ... We are not only supporting their restaurants on our marketplaces and across our affiliate network, but we are also supporting them on all of their white label properties. We're providing order management, including pickup and delivery for KFC and Taco Bell ... It's a very close, unique partnership in the space because we're extremely aligned and both parties are agnostic to what channel the order comes in on. It doesn't take a crystal ball to see that more restaurants, especially smaller chains and stand-alone locations would want to outsource their mobile offerings to GrubHub as well. While the company faces competition from the likes of DoorDash and Uber Eats, GrubHub seems to be one of the few winners that will emerge from the pack for mobile ordering of food delivery and takeout. Mastercard and Visa: The credit-card networks Mastercard and Visa sport similar business models, essentially collecting tiny fees for every transaction facilitated over their respective networks. While they obviously compete with each other and other credit-card networks for market share, their primary rival remains cash. Mastercard CEO Ajay Banga estimates that about 80% of the world's transactions are still facilitated with currency. As such, trends like e-commerce have been a boon for Mastercard and Visa. Visa CFO Vasant Prabhu explained at a recent analyst conference that online purchases have been a huge boon for credit-card companies: E-commerce is growing five times as fast as face-to-face transactions. And in an e-commerce transaction, the propensity to use a Visa card is twice as high as a face-to-face transaction. So something growing five times as fast where your propensity to be used is twice what it might have been. That's phenomenal. Mobile commerce should propel electronic forms of payment and be a boon for Mastercard and Visa. Image source: Getty Images. Not only does mobile commerce continue this trend, it accelerates it. The more devices connected to the internet, the easier it will be to make electronic payments where cash was previously used. This can be done through apps, such as those hosted by Domino's and GrubHub, or even via sensors on your vehicle's gas tank that will automatically pay for the gas as you pump. As more devices come online, transactions that traditionally had to be negotiated using cash -- think parking meters, toll-booth collections, etc. -- will now be facilitated with digital payments. Skyworks Solutions: Connecting the Internet of Things (IoT) For those not familiar with the company, Skyworks Solutions designs analog semiconductors, a key component for any connected device to wireless networks such as LTE or Wi-Fi. Most of Skyworks' revenue comes from smartphones, and its biggest customer by far is Apple. As the advent of 5G approaches, more devices will be connected than ever before. For payments purposes, this includes things from smartwatches that wearers can use to make purchases at stores to cars that will automatically pay the pump once the nozzle is inserted in the vehicle's gas tank. All of these devices will need to connect to a network to make the payment, and the more of these connected devices there are, the more the world will need Skyworks' chips. In a 2019 conference call, CEO Liam Griffin specifically called out several industrial and consumer applications as catalysts for IoT device growth once 5G network coverage spreads: With expanded 5G network capacity on the horizon, we expect 75 billion devices will be connected by 2025. That's three times today's installed base. Leveraging our leadership across all major wireless standards, including ... 4G LTE and 5G, we are well-positioned to capture a disproportionate share of this growth, particularly with the advent of autonomous vehicles, virtual reality, Industrial IoT, and frictionless commerce. Skyworks has shown a clear ability to profitably grow as smartphone architecture grows in complexity and connected devices in numbers. In the 2018 fiscal year, Skyworks' non-GAAP EPS was $7.22, more than triple its 2013 total of $2.20. That's greater than 27% annual growth over a six-year time frame. Verizon: The 5G wireless network leader The faster network speeds that the next generation of wireless coverage offers are essential to the growth of the IoT. While other networks have begun to close the U.S. wireless coverage gap between their own infrastructure and Verizon's, I believe Verizon will deploy 5G coverage in more major domestic markets sooner than the rest. As the 5G race between the telecom carriers really heats up, I believe Verizon's quality will, once again, clearly surpass its competitors'. Verizon looks poised to be the first telecom carrier with nationwide 5G wireless coverage. There are several reasons I think Verizon occupies the inside lane in this race. For starters, Verizon was the first to launch a commercial 5G service. In late 2018, Verizon launched 5G Home, a 5G-internet service for residences in Houston, Indianapolis, Los Angeles, and Sacramento. This will give Verizon a head start over its rivals as it figures out the best way to install and maintain this type of service. In a recent conference call, CFO Matt Ellis explained, ""And we've seen performance as we've expected since we started doing those installs, the technology works. Our customers are getting the experience they expected."" In tests leading up to the 5G Home launch, Verizon engineers were pleasantly surprised by the real-world capabilities of the network. For instance, in an interview with Motley Fool contributor Nicholas Rossolillo, Verizon Vice President of Network Engineering Mike Haberman stated, ""Some of the examples we use were it got higher up buildings, up to the 19th floor of buildings, when we didn't think it would reach that high. We were seeing locations 2,000 feet from the cell site and still having good speeds."" Verizon also has higher aspirations for its 5G networks than just faster smartphone speeds, such as its smart-city initiatives, where the company is working with specific municipalities to use the technology to solve different pain points around the city. What might make Verizon a particularly interesting stock for some investors is that it sports a dividend yield that is consistently over 4%. For income investors looking to invest in the growing mobile payments trend, Verizon might be their best bet. IoT: A trend from which all investors can profit Since the inception of the internet, mankind's tendency to use technology to make the world a smaller, more connected place has only accelerated. I do not think this race to connect to the world around us will slow down, much less cease, any time soon. The IoT represents one of the best ways to invest in this trend. As you can see, there are a number of great companies to choose from that have exposure to this sector, ranging from the tech companies making the smart devices, to the makers of the components, to the providers of the services that will be offered through these devices. These companies also encompass the different styles of investing. For income investors, there are stocks such as Apple and Verizon that pay growing and hefty dividend yields. Value investors might be interested in beaten-up semiconductor stocks or undervalued telecom carriers that stand to benefit from IoT's growth. Growth investors will probably be attracted to the big tech and payments companies. No matter your style of investing, I am confident this trend can help all investors profit and beat the market in the years ahead. 10 stocks we like better than Apple When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Apple wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 31, 2019 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Matthew Cochrane owns shares of Alphabet (A shares), Amazon, Mastercard, Skyworks Solutions, and Verizon Communications. The Motley Fool owns shares of and recommends Alphabet (A and C shares), Amazon, Apple, Mastercard, and Skyworks Solutions. The Motley Fool owns shares of Visa and has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-04-15,29.3675,30.0025,29.1675,29.7425,
DXCM,2019-04-16,30.17,30.2175,29.22,29.44,
DXCM,2019-04-17,29.45,29.45,27.44,27.845,"[""Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid"", ""Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional."", ""Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional."", ""Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid"", ""Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional."", ""Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid""]"
DXCM,2019-04-18,27.965,28.7025,26.86,28.5725,
DXCM,2019-04-22,28.4325,29.215,28.2988,29.1525,
DXCM,2019-04-23,29.3125,29.84,28.5775,29.5075,
DXCM,2019-04-24,29.445,29.96,29.058,29.705,"[""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release"", ""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release"", ""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release""]"
DXCM,2019-04-25,29.815,30.029,29.3125,29.53,
DXCM,2019-04-26,29.715,31.1238,29.715,31.0425,"[""Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More"", ""Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More"", ""Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More""]"
DXCM,2019-04-29,31.2075,31.36,30.3825,31.1075,"[""Dexcom Clears Key Benchmark, Hitting 80-Plus RS Rating"", ""Dexcom Clears Key Benchmark, Hitting 80-Plus RS Rating"", ""20 High-Growth Stocks For The Next 20 Years It's been shown that long-term investing outperforms short-term trading and historically, some of the stock markets best performing stocks have been those delivering break-neck revenue growth. There's no telling which stocks will be the next big winners, but disruptive, fast-growing companies could position you best for market-beating returns. If so, then these 20 high-growth companies could be top stocks to stash away for the long haul. No. 1 Alarm.com Alarm.com (NASDAQ: ALRM) is a modern-day security guard for increasingly smarter homes. Its suite of security and safety-oriented products are digitally connected for homeowners by installation pros. Want to control your heating and lights from your smartphone while you're at work? No problem. Want to see who is knocking on your door or see when your teens are coming or going? Alarm.com's got you covered. Sales were $421 million in 2018, up 24% from 2017, yet only 6 million of the over 120 millions homes in North America are protected by Alarm.com, suggesting there's still plenty of room for future growth. IMAGE SOURCE: GETTY IMAGES. No. 2: Alteryx Data scientists use Alteryx (NYSE: AYX) to inform their merchandising, fuel hedging, clinical-trial management, and derivatives modeling. It's tough to find an industry where there isn't a use case for Alteryx's data mining software. Alteryx's customer count has increased at an 82% compounded annual pace since Q1, 2015 and growing use by existing customers and new accounts resulted in sales of $254 million in fiscal 2018, up 55% from fiscal 2017. Even better, Alteryx's already profitable, earning $0.82 per share last fiscal year. Alteryx expects revenue of $345 million in fiscal 2019, up 36%, but it's long-term opportunity could be much bigger. The big data and analytics market is valued at $49 billion worldwide, according to IDC. No. 3: Anaplan Decision-makers are increasingly turning to Anaplan's (NYSE: PLAN) budgeting and forecasting tools to see the impact of changing assumptions in real-time. Anaplan's ability to translate ideas into money-saving initiatives helped its revenue grow 43% to $240.6 million in fiscal 2019. Revenue is expected to eclipse $310 million in fiscal 2020. The company's working with 250 of the Fortune 2000 companies but its addressable market is north of $20 billion annually, so the potential for additional revenue growth is significant. IMAGE SOURCE: GETTY IMAGES. No. 4. Aurora Cannabis The second-largest Canadian cannabis company, Aurora Cannabis (NYSE: ACB) could win a large share of the $150 billion global marijuana market as more sales move to regulated retailers from the black market. Canada's national recreational marijuana market opened last year, giving Aurora Cannabis an opportunity to capture the 5 billion Canadian dollars spent illegally there every year. In the fourth quarter, it sold about 7,000 kilograms of marijuana, resulting in sales of CA$54 million, up 362% year over year. As of March, Aurora Cannabis' operating at a 120,000 kilograms per year pace. Importantly, projects are planned that could increase production to 700,000 kilos or more per year, which will enable it serve new markets, such as the United States, if marijuana legalization spreads. No. 5: bluebird bio Delivering genetic fixes for genetic disorders using deactivated viruses is a game changing scientific advance. Gene therapy is in its infancy, but bluebird bio (NASDAQ: BLUE) has one of the most advanced pipelines of these revolutionary treatments. In 2019, it expects European approval of its first gene therapy, Zynteglo, which inserts a functional copy of the B-globin gene in a patient's stem cells, restoring hemoglobin production in beta-thalassemia patients. If approved, it could eliminate the need for regular blood transfusions for thousands of people. A second therapy in its pipeline that's fast-approaching is bb2121, which targets multiple myeloma, a common blood cancer. There's no guarantee bluebird bio's gene therapies will win approval, but if they get an OK, these one-time treatments could generate billions of dollars in sales. No. 6: Canopy Growth The global marijuana markets biggest player, Canopy Growth (NYSE: CGC) is a vertically integrated cannabis company that grows its own marijuana and manufactures and sells its own marijuana products. In January 2019, it became the first large marijuana company to announce plans to enter the $50 billion U.S. marijuana market through a hemp-focused venture in New York. Canopy Growth's revenue skyrocketed 283% year over year to CA$83 million thanks to CA$58 million in Canadian recreational, adult-use sales. A $4 billion investment by wine and beer giant Constellation Brands (NYSE: STZ) gives it the more financial firepower than any other publicly traded pot stock, suggesting it has ample financial flexibility to take advantage of growing momentum to legalize marijuana worldwide. IMAGE SOURCE: GETTY IMAGES. No. 7: DexCom Diabetes is a life-threatening condition characterized by an inability to produce insulin (type 1) or a resistance to insulin (type 2), a protein created by the pancreas that helps the body transform glucose sugar in a future source of energy. Globally, over 420 million people have diabetes, including nearly 100 million people in the U.S. and Europe. Left untreated, diabetes can cause cardiovascular disease, blindness, and nerve loss. Historically, diabetics relied on point-in-time finger sticks to measure blood sugar to determine insulin dosing. However, diabetics spend an average of 70% of their day outside their target glucose range, indicating new approaches, including DexCom's (NASDAQ: DXCM) continuous glucose monitors (CGM), are necessary. DexCom's CGMs provide real-time glucose readings and high-low glucose alerts that improve insulin decisions. Its sales increased 44% year over year to $1.032 billion in 2018 and while it faces stiff competition from Abbott Labs (NYSE: ABT), DexCom is still guiding for 14% growth this year. No. 8: Diamondback Energy Global energy demand is climbing and that should help drive revenue higher at Diamondback Energy (NASDAQ: FANG), the third largest oil and gas producer in the prolific Permian Basin in Western Texas and Nevada. In 2007, it had about 4,000 acres in the Permian. Today, it has approximately 604,367 gross acres there, including 231,100 acres in the Midland Basin and approximately 232,143 acres in the Delaware Basin. Using horizontal drilling, Diamondback Energy is producing increasingly more oil and gas at attractive yields. It completed its first horizontal wells in 2012 and now, it operates nearly 1,200 horizontal wells. Diamondback's Permian Basin net production was 47,610 MBOE in 2018, comprising 72% oil, 16% natural gas liquids, and 12% natural gas. It drilled 189 gross wells in 2018 and in 2019, it expects to complete at least 290 horizontal wells. Revenue was $2.2 billion in 2018, up from $527 million in 2016, and given estimated proved oil and natural gas reserves of 992,001 MBOE, Diamondback could be one of the best oil stocks for long-term investors to own. No. 9: Elastic N.V. Elastic N.V. (NYSE: ESTC) is the Google of corporate search. It allows workers to instantly access a treasure trove of valuable information that could otherwise be difficult to find or make sense of. Sales were $159.9 million in fiscal 2018 and they're expected to reach $265 million in fiscal 2019. In fiscal 2020, the consensus estimate is for sales to increase to $365 million, which is more than double its fiscal 2018 revenue. There's no telling if the company will deliver on those estimates, but its leadership is undoubtedly motivated. Altogether, the company's founders and C-suite officers own nearly 40% of the company. No. 10: Exact Sciences Colonoscopies are expensive and the pre-test regimen keeps many from getting this life-saving colon cancer test. Fortunately, now there's an alternative. In 2016, Exact Sciences (NASDAQ: EXAS) launched Cologuard, a screening kit that allows people to mail a stool sample to a lab for an evaluation. So far, the response from consumers has been terrific. Revenue was $454 million in 2018, up 70% year over year. In 2019, it's modeling for revenue of between $710 million to $730 million. Currently, it only has 4% market share, but it believes it will eventually reach 40% market share. If so, that means Cologuard could generate $4 billion or more in annual revenue. Exact Sciences isn't stopping there, either. It's working with the Mayo Clinic on liquid biopsy tests with the hope of catching cancer in its earliest stages, when it's easiest to defeat. IMAGE SOURCE: GETTY IMAGES. No. 11: Guardant Health We're at the cusp of a revolutionary change in how we treat cancer. Rather than targeting cancer by the location of its origin, we're discovering new ways to leverage genetic insight to find the treatments that are most likely to work. Guardant Health's (NASDAQ: GH) liquid biopsy tests are at the forefront of technology enabling this shift to personalized medicine. Currently, its blood tests provide insight for patients with tough-to-treat cancer, particularly when there's little tissue to test, but in the future, liquid biopsy could become the standard for all patients. In 2018, Guardant Health's sales were $50 million, up 82%, and according to management, its addressable market in advanced cancer is worth $6 billion. No. 12: Insulet Insulet's (NASDAQ: PODD) Omnipod insulin pump is a hit with insulin-intensive patients who want the flexibility of a tubeless insulin pump. In 2018, its sales were $564 million, up 22% from 2017. In the short-term, sales growth could slow because of the launch of Tandem Diabetes (NASDAQ: TNDM) automated-insulin system, which pairs Tandem's pump with a DexCom CGM, but the company still expects to deliver sales of between $662 to $687 million in 2019, representing growth of at least 17%. Furthermore, Insulet hopes to launch its own automated insulin system in 2020. Given Insulet's tubeless advantage and the growing size of the diabetes market, Insulet could be the company best-positioned to capitalize on the shift to automated insulin from finger sticks and injections. No. 13: Intuitive Surgical Robotic surgery isn't science fiction. It's already being commonly used in various procedures, including urology and gynecology. The market leader by miles, Intuitive Surgical's (NASDAQ: ISRG) installed over 5,000 of its surgical robots worldwide. As more systems have been installed and advances have opened up the use of its systems in new areas, such as hernia repair, procedure volume has been growing at a double-digit pace, which is driving sales of instruments and consumables used in surgeries. Intuitive Surgical's sales more than tripled to $3.7 billion in 2018 from 2008 and as providers increasingly recognize advantages associated with robotic surgery, including fewer complications and faster recovery times, sales ought to continue higher. IMAGE SOURCE: GETTY IMAGES. No. 14: Invitae Corporation Cancer isn't the only disease that can be better informed by genetic insight. Invitae's (NYSE: NVTA) gene screening tests are being used to provide genetic profiles for parents-to-be, newborns, and people with or at risk of rare disease. Its goal is to drive the cost of genetic screening so low that everybody will be able to understand their risks of genetic disease. In 2018, it completed 303,000 tests and in 2019, it expects to complete over 500,000 tests. If so, its revenue will increase to $220 million, up 48% from 2018. No. 15: MongoDB Companies have essentially been using the same rows and columns style databases to house information for decades and increasingly, those legacy databases are falling short as corporate data morphs from solely letters and numbers to unstructured information, like images. Addressing today's database needs requires a 21st century solution that's more flexible and dynamic than predecessors. In steps MondoDB (NASDAQ: MDB), a company founded by ex-Doubleclick executives to displace the use of traditional structured query language (SQL) databases with an unstructured, NoSQL, solution. MongoDB's the mostwidely used NoSQL solution and its revenue is growing thanks to rising subscription demand for its cloud-based offering, Atlas. In fiscal 2019, MongoDB's total revenue was $254 million, up 64% year-over-year and because Atlas revenue increased over 400%, it now accounts for 34% of companywide sales. IMAGE SOURCE: GETTY IMAGES. No. 16: 2U, Inc. Education on demand is getting better thanks to 2U (NASDAQ: TWOU), an education technology provider that could be the best way to profit from growing adoption of online education. 2U creates private label online graduate programs and certificate programs that major universities market to students worldwide. Currently, it works with 35 universities, including the University of Southern California, which accounts for 21% of revenue. Universities pay 2U a fixed percentage of tuition and fees and generally, sign contracts of 10 years or longer. In 2018, 2U Inc. revenue increased 44% to $412 million and revenue is expected to grow to $547 million in 2019. If you believe that the future is education anywhere, then 2U Inc. is a smart bet, particularly since America's graduate education market collects nearly $80 billion in tuition payments every year. No. 17: Twilio Connecting customers to your services in a digital world means having a robust app that can easily handle messaging, voice, and video communication. If your receiving an offer via text, speaking with a customer service chat-bot, taking an online survey, or awaiting a ride-share then there's a good chance Twilio's (NYSE: TWLO) technology is powering it. The company's the leading solution used for in-app communications with over 64,000 active customers. In 2018, revenue totaled $650 million, up 63% from the full year 2017, and its expected to surpass $1 billion this year. With 5G technology opening doors to even better ways of communicating in the future, it wouldn't surprise if this company's sales continue marching higher. No. 18: ZenDesk Customer services is one of the biggest pain points facing any business. Dissatisfied customers mean lost sales and a dinged reputation. Also, opportunities to increase sales by leveraging successful conversations with customers are lost. To keep customers returning and boost potential revenue, Zendesk (NYSE: ZEN) offers digital customer service tools, including customer service prioritizing, live chat, and Q&A solutions. It generates nearly half its sales overseas and in 2018, revenue grew 39% to $599 million. Future sales could come from new solutions and bundling existing solutions. For example, customers can begin with Zendesk support, then add Zendesk Chat, or other services, such as its recently launched customer relationship management tool, Zendesk Sunshine. In 2019, management's targeting sales of at least $795 million. IMAGE SOURCE: GETTY IMAGES. No. 19: Zoom Video Communications Connecting partners, clients, and stakeholders remain key to business success and perhaps, no company is more successfully facilitating conversations than Zoom Video (NASDAQ: ZM). Its conferencing solutions are increasingly becoming the go-to choice for institutions and growing demand for video communication because of travel costs and an increasingly global marketplace should allow that to continue. Zoom, which had its IPO in April 2019, posted sales of $331 million in fiscal 2019, up 118%, year over year. Importantly, the company's already tilting toward consistent profitability, reporting $7.6 million in net income last year. With a net expansion rate of 118% in fiscal 2019, a founder CEO at the helm, and a growing appetite for simple, reliable video communication, Zoom Video's an enticing long-term stock to buy. No. 20: Zscaler Protecting corporate data from unwanted eyes used to be as simple as building a wall around valuable information and limiting access via gates. Today, it's not that easy. People are accessing data from various devices from all over the world and that data isn't housed in only one place. Because Zscaler (NASDAQ: ZS) addresses challenges associated with securing data in an increasingly complex work environment, its revenue has grown from $54 million in fiscal 2015 to $190 million in fiscal 2018. Last year, revenue increased 51% and in fiscal 2019, revenue is expected to grow another 50% to $289 million. That could only be the beginning, though, because the companies only working with about 200 of Forbes Global 2000 companies. 10 stocks we like better than Zoom Video Communications When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zoom Video Communications wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell owns shares of 2U, Anaplan Inc, Bluebird Bio, DexCom, Intuitive Surgical, Invitae, and Twilio. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends 2U, Alphabet (A shares), Alteryx, Bluebird Bio, Guardant Health, Intuitive Surgical, MongoDB, Twilio, Zendesk, and Zscaler, Inc. The Motley Fool recommends Alarm.com Holdings, Constellation Brands, and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Clears Key Benchmark, Hitting 80-Plus RS Rating""]"
DXCM,2019-04-30,31.04,31.435,30.24,30.2675,"[""UBS Maintains Neutral on DexCom, Inc. - Common Stock, Lowers Price Target to $140"", ""UBS Maintains Neutral on DexCom, Inc. - Common Stock, Lowers Price Target to $140"", ""UBS Maintains Neutral on DexCom, Inc. - Common Stock, Lowers Price Target to $140""]"
DXCM,2019-05-01,30.63,31.1975,29.3075,29.655,"[""DexCom Q1 Earnings Preview"", ""DexCom Q1 EPS $(0.05) May Not Compare To $(0.16) Estimate, Sales $280.5M Beat $246.39M Estimate"", ""Dexcom Guides FY19 Revenues Of $1.25-1.3B Vs. $1.23B Estimate"", ""Dexcom Guides FY19 Revenues Of $1.25-1.3B Vs. $1.23B Estimate"", ""DexCom Q1 EPS $(0.05) May Not Compare To $(0.16) Estimate, Sales $280.5M Beat $246.39M Estimate"", ""DexCom Q1 Earnings Preview"", ""Dexcom Guides FY19 Revenues Of $1.25-1.3B Vs. $1.23B Estimate"", ""DexCom Q1 EPS $(0.05) May Not Compare To $(0.16) Estimate, Sales $280.5M Beat $246.39M Estimate"", ""DexCom Q1 Earnings Preview""]"
DXCM,2019-05-02,29.6175,30.925,29.5,30.0925,"[""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2019 Results - Earnings Call Transcript"", ""Raymond James Maintains Outperform on DexCom, Inc. - Common Stock, Lowers Price Target to $150"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 financial results and announced 2019 EPS guidance above the analyst consensus estimate."", ""BMO Capital Maintains Outperform on DexCom, Inc. - Common Stock, Raises Price Target to $172"", ""BMO Capital Maintains Outperform on DexCom, Inc. - Common Stock, Raises Price Target to $172"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 financial results and announced 2019 EPS guidance above the analyst consensus estimate."", ""Raymond James Maintains Outperform on DexCom, Inc. - Common Stock, Lowers Price Target to $150"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2019 Results - Earnings Call Transcript"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2019 Results - Earnings Call Transcript"", ""DexCom (DXCM) Q1 2019 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q1 2019 Earnings Call May. 01, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom first-quarter 2019 earnings release conference call. My name is Adrianne, and I'll be your operator for today's call. [Operator instructions] Please note, this conference is being recorded. I'll now turn the call over to Matt Dolan. Matt Dolan, you may begin. Matt Dolan -- Vice President Corporate Development Thank you, operator, and welcome to DexCom's first-quarter 2019earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will provide a summary of the quarter; followed by a financial review and outlook from Quentin Blackford, our executive vice president and CFO; and then a strategic update from Steve Pacelli, our executive vice president of strategy and corporate development. Following our prepared remarks, we'll open up the call for your questions. [Operator instructions] Please note that there are also slides available related to our first-quarter performance on the DexCom Investor Relations website on the Events & Presentations page. With that, let's review our safe harbor. Some of the statements that we'll make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom and are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to confirm these forward-looking statements to actual results. Additionally, during the call, we'll discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release in the Investor Relations portion of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn the call over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Matt, and thank you, everyone, for joining us. We are off to a great start in 2019 with much of the momentum that we experienced in 2018 continuing into our first quarter. First-quarter revenues grew to $280 million, a 52% increase over the first quarter of 2018. Once again, this strong performance was broad-based, as increased volumes in both our U.S. and OUS businesses drove results above our expectations, even as we absorbed the pricing headwinds that we have anticipated. We have spent s developing our innovative technology and demonstrating real-world clinical outcomes. And as awareness builds, demand for DexCom CGM is very strong among both new and existing patients. We remain confident that the company is well-positioned to drive toward our long-term targets. Particularly, as we expand the rollout of G6 and improve access to CGM. With this growing demand in mind, we are on track to meet our goal of doubling our G6 capacity by the end of 2019. From a cost perspective, we are demonstrating good expense control with revenue growth outpacing the increase in operating expense growth by more than two times. We continue to believe that patient outcomes demonstrate the true value of a CGM. In the first quarter, we showed real-world data that demonstrates the effectiveness of our Urgent Low Soon alert in the G6, which provides an actionable warning in advance of a dangerous hypoglycemic low. Not only have we seen a further decrease in hypoglycemia among G6 users with this feature, but this has been achieved regardless of a user's frequency of screen views. We also show the correlation between users of DexCom SHARE and Follow apps and better timing range for children and adolescents with diabetes. Once again highlighting the importance of this feature to our user base. It is outcomes such as these that have contributed to DexCom's great reputation among clinicians and allow us to capitalize on the increasing global awareness around CGM technology. The kind of demand we are experiencing can also bring certain challenges. This is especially the case in the first quarter of every year as we must reconfirm benefits and document clinical necessity for each patient. The process can be burdensome at times with our teams going back-and-forth with clinicians and payers on the patient's behalf. To our customers, we understand the fundamental importance of DexCom CGM in your life and are working around the clock to make sure that you are cared for. We saw improvement in our ability to meet demand and serve our customers as the quarter progressed and believe that the initiatives that we introduced to expand our customer's volume per structure are progressing well, with several areas showing meaningful productivity improvements. Considering the significant level of demand for DexCom CGM and the strength of our first quarter, we are very pleased to be able to increase our revenue outlook for 2019. I will now turn the call over to Quentin who will provide detail on this outlook, as well as a review of our financials. Quentin Blackford -- Executive Vice President and Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics that I discuss today will be presented on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. Today, we reported worldwide revenue of $280.5 million for the first quarter of 2019, compared to $184.4 million for the same quarter in 2018, representing growth of 52% on a reported basis and 53% on a constant-currency basis or $96 million of absolute dollar growth. Clearly the growing awareness for CGM has continued into the New Year . Geographically, U.S. and international revenues both demonstrated strong growth of 45% and 79%, respectively, over the first quarter of 2018. International revenues grew 86%, excluding the impact of currency, at least 25% of total company revenues in the first quarter, representing a high-water mark for the business and tracking toward the long-term expectations that we highlighted at our Investor Day late last year. We have seen continued success in shifting to the pharmacy channel consistent with our expectations at the start of the year , and we will continue to prioritize this initiative as we seek to drive improved access to DexCom CGM. Our first-quarter gross profit was $168.8 million or 60.2% of sales. The sequential decline from the fourth quarter of 2018 was consistent with what we've seen in prior years. Relative to this first quarter of 2018, gross margin was negatively impacted by incremental investments to scale infrastructure as we drive significant capacity expansion in 2019 and the continued shift in our mix toward the U.S. pharmacy, and International business. As demand continues to exceed expectations, we're accelerating investments to increase capacity, which is putting some additional pressure on gross margins. We now expect gross margins for the year of 64% to 65% as we speed up our capacity ramp to meet the growing demand. We remain confident in our ability to bring cost out of the system as the year progresses and over the long term, beginning with the introduction of our new G6 transmitter, and continued to implementation of automation into the manufacturing process, which will allow us to exit this year with gross margins approaching 70%. These improvements provide us with the strategic flexibility to be proactive with payers and to navigate future uncertainties and the pricing environment as we continue to push for greater access to CGM. Operating expenses were $176.4 million for the first-quarter 2019, compared to $147.6 million in the same period last year. This reflects an increase of 20% year-over-year and compares favorably to 52% revenue growth in the quarter, resulting in significant operating expense leverage from the prior year. Operating loss $7.6 million in the first quarter of 2019, compared to $28.7 million in the same quarter of 2018. Our improved operational discipline resulted in a 1,290-basis-point improvement in operating margins from prior year. Adjusted EBITDA was $26.1 million or 9.3% of revenue for the first quarter, compared to $4.5 million or 2.4% of revenue for the first quarter of 2018. As we said throughout 2018, we believe there is an opportunity to drive significant operating leverage toward our long-term targets in both of our first-quarter adjusted EBITDA and operating margin reflect great progress toward these goals. However, we are not pursuing this leverage at the expense of the growth in our business. We remain confident in the opportunity that lies ahead, not only for our core business, but also the application of CGM technology to new markets. We will continue to invest in these initiatives, our R&D pipeline, and other strategic opportunities in order to maximize DexCom's long-term potential. Our net loss was $4.6 million or $0.05 per share and our balance sheet remains strong having ended the quarter with approximately $1.4 billion in cash and equivalents and no borrowing against our $200 million revolving line of credit. As mentioned, we continue to prioritize investment into our capacity expansion initiatives and automation of manufacturing, which led to $39 million of capex in the first quarter. Looking at the remainder of the year, given the strength of our first-quarter performance and the growing demand that we are seeing for DexCom real-time CGM, we are increasing our full-year revenue expectations by $75 million and we now anticipate total revenue of approximately $1.25 billion to $1.3 billion for the year, reflecting reported growth of 21% to 26%. As I mentioned previously, we anticipate full-year gross margins to approximate 64% to 65% for 2019, showing meaningful improvement in the back half of the year as we look to exit the year approaching 70%. We now expect operating margins of approximately 6% and remain comfortable with our original target of adjusted EBITDA margins of approximately 18%. Our restructuring efforts associated with setting up operations in the Philippines are progressing well with nearly 200 employees now on the ground in Manila. We have been extremely pleased with early indications demonstrating significant efficiency and scaling benefits. We now expect the restructuring-related costs to come in at approximately $15 million to $20 million, with the majority in the first half and now slightly below our original estimates. With that, I will now turn the call over to Steve for a strategic update. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Thank you, Quentin. As our first-quarter performance indicates, global awareness and demand for real-time CGM continues to increase dramatically, not only in the U.S., but also in international markets like Germany, the U.K. and Australia. In February, DexCom stood front and center at the annual Advanced Technologies & Treatments for Diabetes or ATTD conference, with DexCom product utilized in numerous clinical studies and presentations from key leaders in the diabetes community. As anyone in attendance can attest, there is genuine excitement toward our efforts around Decision Support, app enhancement and of course, the G6 platform. The global rollout of G6 remains a key strategic objective in 2019. As Kevin noted, we are doubling G6 capacity by the end of 2019. Given the level of performance and ease-of-use that the G6 system brings, we expect G6 to continue to function as a platform product for DexCom for many years to come, even certain markets beyond the launch of our next-gen G7 product. Yet as we push the rollout in production of G6, our teams are also making significant progress toward finalizing G7, and we remain on track for a late 2020 or early 2021 initial launch. As a reminder, G7 will be an entirely new sensor platform for DexCom. One that meets the iCGM standards and further extends our leadership with a significantly reduced form factor and extended wear in a fully disposable one-piece wearable. Strong, therapeutic, cost-saving outcomes utilizing CGM continue to present themselves across the healthcare landscape. For several quarters, we have discussed CGM usage in non-intensive type 2 diabetes, prediabetes, gestational diabetes, broad potential deployment in the hospital, and application in overall wellness. While it is now time for an increased focus in investment in these areas, particularly since we know that these opportunities will require completely different business models and distribution channels, in order to lead this effort, I'm pleased to announce that we have pointed Matt Dolan as General Manager of New Markets. As many of you are already aware through his involvement with our Investor Relations and Corporate Development Efforts, Matt is a great leader and we are confident that he and his dedicated team are the right people to guide these key growth initiatives for DexCom. Turning back to our core business, we have now proven ourselves to be early advocates of the principle of interoperability and patient choice, having established partnerships with multiple insulin delivery players, and we will continue to leverage the iCGM designation. We're seeing significant progress from these collaborations and look forward to the launch of a few of these connected products over the next 12 months. We are especially thrilled for our patients as these innovative products stand ready to minimize the burden of diabetes management. And we are proud that DexCom stands at the center of this progress. With that, I'll pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Steve. This is obviously an exciting time to work at DexCom. Not only are we working hard to bring our technology to the increasing number of people with diabetes, who see the benefit of real-time CGM, but we are very actively exploring possible applications of our sensor technology to additional populations. My personal expectations for New Markets group are very high. We need to gather as much clinical cost-based evidence as possible with our G6 platform so that we are truly prepared to attack these markets in a big way with G7. In the meantime, we are capitalizing on the continued momentum in our core business, leading to a significant increase in our annual revenue guidance. With this success, we have to put everybody on the DexCom team to roll out in the first quarter, from the commercial team, to manufacturing, to customer support, to R&D and beyond. We know you have worked incredibly hard, and we thank you. In summary, we are pleased with DexCom's performance to start the year , and believe that we are well positioned for another great of revenue growth, technology advancement and increasing profitability. I would now like to open the call up for Q&A. Matt? Matt Dolan -- Vice President Corporate Development Thank you, Kevin. [Operator instructions] Operator? Questions & Answers: Operator [Operator instructions] Our first question comes from Jayson Bedford from Raymond James. Jayson Bedford -- Raymond James -- Analyst I'll ask my question and related follow-up upfront here. First, Quentin, just implied in the initial guidance was about $100 million in assumed pricing headwinds due to the mix in the pharmacy, international, etc. Is that -- what's still baked into the new guidance? And second, in terms of the move to the pharmacy I realize the inherent benefits for existing users migrating to what should be a lower-cost setting but receiver growth continues to be quite strong. So my question is, do you think the move to the pharmacy has stimulated incremental growth in new patient adds? And any color that you could provide around the pharmacy dynamic in the quarter would be great. Quentin Blackford -- Executive Vice President and Chief Financial Officer Sure. So yes, Jason, to you point, the $100 million that we talked about on the initial call for the year setting the original expectations, that's still consistent with how we think about it over the course of the year, so no change there. Obviously, we've got a concerted effort in place to move to the pharmacy channel, and that's playing out about just like we anticipated that it would. Your point on new patient growth, I am certain that the pharmacy channel makes access more easy and more convenient for folks. I'm certain that's a part of the driver. And when you look at that overall growth in the company, there is no question that the primary driver of our growth is new patient volume. So I am sure it's connected. Operator And our next question comes from Travis Steed from Bank of America. Travis Steed -- Bank of America Merrill Lynch -- Analyst Just looking at your Q1 revenue, it seems typical seasonality, so that's 20% Q1 for the full year. Just trying to think about that suggested $100 million more than you're guiding to for 2019. So is that just the typical conservatism that you have or is there anything else we should consider as we model out 2019? Kevin Sayer -- Chairman, President, and Chief Executive Officer I think the right way to think about it, and I know we talked about 20% back on the last call. I think a few things came through in the quarter. We talked about the strength in the fourth quarter being really driven by new patient additions that came in late in the quarter. Now if you recall, at that point in time, we shared that we expected those folks -- maybe back with their next reorder really early in the second quarter. We saw a lot of that end up coming through in the month of March was a bit ahead of our expectation, a great signal and great outcome. But at the end of the day, that was a bit of the upside surprise. I think the other thing to keep in mind just around seasonality is that, as we continue to move more into the pharmacy channel, and as we continue to see the OUS business become a bigger part of the overall business, and as that Medicare continues to grow faster than the commercial business, all of those have very different seasonal patterns to them, generally, which might have more revenue early in the year. So we're just trying to be thoughtful around all of those different dynamics in the business, as we set expectations for the full year, surely not trying to signal anything. We know what your math would indicate that you laid out, but we're just being mindful of some of the shifts in the mix of the business. Travis Steed -- Bank of America Merrill Lynch -- Analyst All right. No, that's helpful. And then I want to make sure I heard you correctly. You're exiting the with 70% roughly gross margins? Just kind of give us a little bit more info on how you're going to get there, and is that sustainable into next year? And also, does it give you a little bit more flexibility on pricing, if needed? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. So, I think, this is -- the 70% ability to get into that number by the end of the year is in line with the plans that we've always had around our gross margins progression into the future. You go back to our Investor Day and we laid out the path that arguably could take us up north of 70%, and then you have the headwinds that continue to play in with the revenue per patient, mix challenges that we envision as we continue to move into the pharmacy. OUS becomes more significant. So there's nothing out of the ordinary here. It's right in line to what we've planned to be able to do. The big enabler for us, and we've talked about this lower cost design transmitter for some time now, you're going to see that start to play through in the fourth quarter. So the teams have done an incredible job of designing cost out of the system. We'll start to produce that in the back half of the year. You'll actually see it start to get produced in the third quarter. That will get hung up in inventory a bit. We'll start to sell through it in the fourth quarter, and the benefit will start to play through. So it's in line with the plans that we've had. I think in terms of next year -- I would just tell you, let's stick in the mid-60s at this point in time. I think it absolutely gives us the flexibility to continue to navigate the pricing environment and do what we need to do to ultimately generate the most significant growth for the company. But it's these kind of things that give us the strategic opportunities to be flexible on how we think about positioning ourselves. Operator And our next question comes from Robbie Marcus with JP Morgan. Robbie Marcus -- J.P. Morgan -- Analyst Congrats on the great quarter. I want to address the question that's been impacting the stock and clearly, top of mind for investors lately, and what's the potential impending approval of your competitor's Libre 2.0 product? And there's a lot of questions out there about -- what does it look like? Does it get iCGM? And how those alerts and alarms will compare as a product versus G6 today and eventually G7? So I'd love to get your thoughts here. And any clarity or insight you can give us would be much appreciated? Kevin Sayer -- Chairman, President, and Chief Executive Officer Robbie, this is Kevin. I'll take that one. Thanks. Let's go back a bit, it was about a year ago at this time that we talked about the iCGM standards for the first time. And we remain very bullish on the fact that the FDA did give us guidance and standards by which we can develop products in the future that will be safe and in the best interest of our patient. And we stand by that. We've wanted standards and guidance for years so we know what the bars to shoot at, and we actively look at that. We never assumed when we started this process that we would be the only iCGM company in the world, that eventually others would up their game to get that approval. And in the event that Abbott does get approval on the iCGM standards, that's -- they've obviously provided enough clinical evidence to do so with the FDA. If you look back at the history of our company, and we were reminiscing about this today as we were preparing for the call. Ever since I've been here, we've always had a competitive offering from another company in the field that claim to be as good as a DexCom. But you'll notice the claims of those companies have always been, \""We're as good as a DexCom.\"" Never as good as somebody else. We're as good as a DexCom. Real life use in field has proven over and over again that our technology leads the way snd that our actual real-world clinical performance, on-body and on-patients, has always been the best and has always survived and given us the position to do that. We're very confident that our product will remain top-of-the-line and will do -- and will be extremely well received. We have not seen a lot of Libre 2 in Europe where it's been launched, so we don't have a lot of answers. And we're not going to speak to the characteristics of their product. We know a lot about ours. We have enhancements coming for G6 over the course of the year that will make it an even better product offering. And over time, as we offer theDecision Support and other things for our patients, we intend to have the best experience that a patient could possibly have with G6. When we move to G7 and it's size advantage, the body wearable, the one-piece component where we don't have to put a transmitter in the system anymore. The lightweight nature of it. And many of you know, I wear the G7 quite a bit now as I've always been a sensor snob, it is a patient experience. It's a bigger leap than from G5 to G6 has been in our previous history. So we know that product will be wildly competitive and have all the features and benefits of the current G6 system and more. So we -- our pipeline is fabulous. It's a great market opportunity and there's room for a number of participants and a number of products, not just one. Robbie Marcus -- J.P. Morgan -- Analyst That's really clear. I appreciate the thoughts, Kevin, and then just a follow-up. Maybe not too far off of this, but can you give us some flavor of what your discussions with payers are like? Are the payers focused on cost avoidance of diabetes, adverse events, and improving patient outcomes or are they just simply focused on moving reimbursement to the lowest-cost dominator? I appreciate it. Kevin Sayer -- Chairman, President, and Chief Executive Officer It depends on the meeting and it depends on the payer. We have been very successful in our payer discussions over the past several months and have had wins on numerous payer discussions. For example, Cigna just gave us pharmacy coverage and pharmacy benefit. We do not issue press releases every time we have a win because that's our job, that's normal course of business for us. But we have great coverage there and some local payers and pharmacy coverage. We do spend a lot of time discussing outcomes and educating payers. And I think over time, as we get more data and as we can build a better case, we can get those type of contracts in place. I would put the onus for that back on us rather than on the payers. We just need better measurables and better data. It's taken us years to develop that clinical evidence. The DIaMonD study that we talked about for the first time a couple of years ago was really our first endeavor to do just that. And now, with all this data coming to our servers, to our mobile platforms, we believe we'll be able to make some very strong real-world evidence just from our patients as we look at time and range statistics, and compliance with the system and how well they do on hypo avoidance. I have an example in my prepared remarks of the predictive alert that we have in the G6 system and how we're seeing a significant reduction in hypoglycemia because of that alert. That type of evidence is something we really haven't presented in the past, and we will do that going forward now that we have so much data from the mobile systems. We're very comfortable playing in that realm because we know the outcomes that our device provides to patients are outstanding. Operator And our next question comes from Danielle Antalffy from Leerink. Danielle Antalffy -- Leerink -- Analyst Congrats on a really good quarter. Just a question, and this is sort of following up on the question around the impact of a competitor potentially getting iCGM. But just curious if you can give any color directionally or what have you on the percent of your installed base domestically today and/or new patient adds that are MDI versus pumpers? I think historically you've said, the majority of the patients coming on to the DexCom are MDI and not actually pumpers. Anything you can say to that? Kevin Sayer -- Chairman, President, and Chief Executive Officer The majority of our new adds now are MDI patients, Danielle, by a reasonable margin. As we're getting a much larger patient base, we're going over into those who are not on the pump systems for more of the new adds. But I anticipate, as our partners get new systems out, that we will see significant growth in that segment, as well as these systems do more than just deliver insulin but actually have algorithms that can improve outcomes. Right now our new patient adds are primarily MDI patients. That's most of them. Danielle Antalffy -- Leerink -- Analyst Got it. OK. That's helpful. And then just a question on the G7, and I want to make sure I'm understanding correctly how pricing is going to change with G7. I know you guys haven't sort of outlined your go-to-market strategy per se, but I think you've said in the past that at some point, you're expecting to be at -- well, tell me if this is correct. Are you expecting to eventually be pricing at parity with the competition as we look down -- further down the line to G7 and beyond? Or do you think that even with G7, you'll still be pricing at a premium? Kevin Sayer -- Chairman, President, and Chief Executive Officer I'm not going to outline all the specific details regarding that. But here is our strategy and here's how we look at that. We look at the annual revenue per patient per -- and what is the appropriate amount to charge a patient. For example, as we've gone from G7 to G6, that's how we look at that product offering as annual revenue per year rather than pricing on the individual components. With respect to how we price G7, there's a lot of variables involved there. If we have Decision Support tools that lead to better outcomes. Does that justify a premium? Does it not? I think we'll have to see it over time. What's most important for the investment community to know is from a cost basis, we have a lot of flexibility with G7. We designed that product for manufacturing. We designed that to be a lower cost product offering than we have today, particularly with the extended wear. We're prepared for what the market will do, but we will study this at great length and have a very detailed go-to-market strategy before we go, but I can't commit to anything specifically now. We're very optimistic about all the directions we can go. Operator And our next question comes from JP McKim from Piper Jaffray. JP McKim -- Piper Jaffray -- Analyst I wanted to ask, one, just, Kevin, you made a comment that you -- that I think you're wearing a G7 now. So it feels a little more real me. And so, I don't know, maybe initial thoughts on it. And then, will we see a trial start for G7 this year or is that still something that will happen in 2020? Kevin Sayer -- Chairman, President, and Chief Executive Officer Look, we run trials with G7 all the time. But they're small trials that we're gathering data to learn and fine tune the features of the system. With respect to the experience, the regulatory people are probably going to kill me if the legal guy doesn't first, but it really is spectacular. The wearable is pretty much nonexistent on your body. As I look at projects we've started and innovation that we've attempted during my term at this company, this is the biggest leap we've ever taken. And it's a huge leap. And kudos to all the people involved in it because if I were to design what I'd hope CGM would have been when I started in this business, 25 years ago this week, I would have designed this. And so we're finally here. JP McKim -- Piper Jaffray -- Analyst That's really helpful. And then maybe just on -- if I could ask one on just the non-intensive programs. There are several trials that we should see some data at ADA around. I mean, either Matt or Kevin, like how do you -- how to define success in those trials? Is it -- are payers really akin on recent amount of medications or are they'd sort of give the time, the range of the metrics? Or -- I guess, how do you -- how should we look at those trials as successful? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. I would say, you have to take the individual markets and kind of look market-by-market. So certainly, in the non-insulin-using, non-intensive type 2 market, reduction of drug cost is paramount, right? In the hospital, things like length of stay -- reduce nursing time is important but reducing length of stay, getting people out of the ICU down to a step-down ward, into the general ward and out of the hospital. And actually, as important these days, prevention of hypoglycemia in a hospital setting is becoming increasingly important, it's on CMS's radar as a key metric for hospitals. So reduction of hypoglycemia is going to be important going forward in that market. Gestational diabetes, we're still early in exploring opportunities. I'd love to tell you that at some point, the CGM session will actually replace the oral glucose tolerance test. That's going to take some time and effort and some clinical trial work on our part, so there's no kind of one size fits all in the new markets' development opportunities, but Matt has developed and will continue to develop a pretty robust team to tackle all these markets. And clearly, over the next several s, three-years to five-years time horizon, those markets becoming increasingly important for us. Operator And our next question comes from David Lewis, Morgan Stanley. David Lewis -- Morgan Stanley -- Analyst Just 2 from me. Quentin, just want to come back to the gross margins. I appreciate your commentary about the 70% for the back half of the year in mid-60s next year. But if I take the LRP, which obviously as you're aware with 65% in 2023. Scaling and innovation, about 700 basis points of that. So it actually feels like both of those factors are playing a pretty powerful role on the back half of '19. So is it safe to assume the 65% 2023 number, given you're seeing earlier scaling and innovation is a -- is now a conservative number and we should think about that number being kind of materially higher? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. I don't want to get out to five years out from now and talk about whether it's conservative or aggressive. I think what we tried to lay out for you is that we have very clear lines of sight to some very specific improvement efforts that will drive the gross margin higher over time. What becomes a bit more of a variable that we're prepared to be able to address is the revenue per patient headwind. And as the mix shifts between different channels, we're going to have more than enough leverage flowing through the COGS profile of our business to be able to address that very aggressively and still produce a very attractive gross margin profile. So we're happy with where things are at. The lower-cost transmitter coming in the back half of this year had always been something that we planned for and knew that we'd see a nice benefit from -- to Kevin's point earlier, you're going to see an incremental benefit coming from G7, as well as that's been designed to be even more cost-effective. So there's a lot of nice levers in front of us that give us the opportunity to combat some of the headwinds that might be out there. David Lewis -- Morgan Stanley -- Analyst OK. And just a quick follow-up on just the pharmacy benefit, the [Inaudible], can you just update us, Steve, maybe on where you are into the pharmacy benefit coverage. I think it was 50% last quarter. And more specifically, a lot has been made, sort of, intra-quarter about first provider or primary provider relationships. Can you just sort of talk about whether preferential provider or formerly relationships are having any impacts on U.S. demand? And sort of how you see the future of preferred provider relationships in the channel, so the -- who you are in mix and we would say I'm preferred provider? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development I'll answer the second part of that question first, which the answer is no. I mean, we've seen some isolated instances of companies trying to negotiate for preferred status, but that's certainly not something we're seeing as a trend as we move to the pharmacy benefit. As for commercial lives under coverage, we're certainly north of 50%. We haven't given a more granular number than that, and we're still not processing. In terms of commercial business, we're not processing close to 50% through the pharmacy channel at this point. We're working hard to move more and more patients into that channel. So when we say we have north of 50% of the commercial lives covered, we're certainly still not processing 50%. Operator And our next question comes from Joanne Wuensch from BMO Capital Markets. Joanne Wuensch -- BMO Capital Markets -- Analyst Very nice quarter. Two questions really. At the ADA meeting in June, can you give us a feel for what we should be looking for there? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. Steve, why don't you take that one? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I mean, I would say the most exciting data set, if you will, that we hope to see at ADA will be really a combined data set together with Tandem, where we should get a, at least, a first peak if not a full-blown view of the iDCL data. So that's -- again, that's Tandem's X2 pump with the DexCom G6 and the DexCom/type 0 algorithm running a hybrid close loop systems. So that's probably the highlight for us and for Tandem collectively at ADA. There will be a number of additional kind of poster and some podium presentations, but from a data perspective that's really what we're looking forward to. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. I'd just add. The other thing, Joanne, that we're going to continue to see is anybody who stands up to speak starts talking about CGM. Every outcome, every trial, everything going on, CGM is clearly becoming the standard of evaluation -- of evaluating diabetes care across the board. And I believe that trend is going to continue at ADA, and you will see CGM pretty much interwoven everywhere with everything that's done. Joanne Wuensch -- BMO Capital Markets -- Analyst That's helpful. And then my second question has to do with the OUS market. Growth was strong there again this quarter, and I'm just trying to get an idea of sustainability and into what other regions you might be looking to venture into? Kevin Sayer -- Chairman, President, and Chief Executive Officer You were talking about the OUS market? Matt Dolan -- Vice President Corporate Development Internationally, yes? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes, yes. Kevin Sayer -- Chairman, President, and Chief Executive Officer Clearly, the growth was strong there, and I think, you look at overall adoption of CGM in that overall marketplace is probably still sub-10% in terms of the long range opportunities. And so there's a huge amount of runway that continues to exist in front of us. And our core markets continue to drive the primary growth for us today. Germany was another standout performer in the quarter leading the way for us. But there is significant other new markets that are coming online. We just saw significant growth coming out of the Nordic markets, for example. We saw incremental reimbursement approved in Australia that allowed significant amount of contribution over the course of later part of this year into next year. And then you get into some of the Asian markets, where we haven't started to see the contribution yet, but expect nice tailwinds coming out of Japan and Korea, for example. So there are several new market opportunities, or even markets that we're in today, that it is growing at incredible rates, in paces of growth and a relatively untapped market opportunity. So I think there's several channels for overall growth in that international business that -- to get it to the point where in our long-range plans, we talked about it being closer to 30%, 35% of the overall business, which means it's going to be growing faster than the U.S. business. I think there's a lot of channels that will continue to make that available to us. Operator And our next question comes from Margaret Kaczor from William Blair. Margaret Kaczor -- William Blair -- Analyst So first one from me is more a bigger picture prospective, because we've now seen several quarters of strong patients growth. So what I'm curious about is whether you guys are seeing a change in prescription patterns in the market? Whether it's [Inaudible] or patients, and irrespective more of pharmacy or G6, but is CGM really becoming widely expected and a go-to from those type 1 patients? Kevin Sayer -- Chairman, President, and Chief Executive Officer Margaret, this is Kevin. I believe it's becoming much more widely accepted and prescription patterns are rising across the board. That -- it's just becoming the tool of the manager insulin delivery. And it's not -- while it is becoming a tool and more accepted, penetration rates are still not at the point where we need to step back and worry. In the type 1 market, we think the penetration rates in the U.S. are still in the 30% range across the board. And type 2 intensive insulin using it is still not that big a number either. So over time, there's plenty of market runway here to continue to go on the international front. Penetration rates in the intensive population are close to being at that high but we think it is much more accepted than it was before. And we think G6 has had a very positive impact for us in these new markets, because it's much easier to use. There's no calibration feature, the easier insertion, the direct-to-phone connectivity. All the things we've built into G6 were designed to drive this market and we're seeing the benefits of that as we go forward. Margaret Kaczor -- William Blair -- Analyst And so just to follow up on that. It seems like you guys have got nice improvements. So the indoors saw selecting patients that they think that will see the most benefits from that. And what else maybe do you need, I know you mentioned new connected product launches this year. I don't know if those are digital software or hardware? Kevin Sayer -- Chairman, President, and Chief Executive Officer It's interesting. I just spent some time with several of the folks from the field. And I would tell you, a lot of this varies territory to territory. It varies practice to practice still. There is not a standard guideline where all the doctors are identifying different patients and having different criteria. I would say like anything, that it's changing rapidly. When I first went out on the field, when I started here, the only patient recommended for CGM was a pumper. I would ask doctors, who do you put on CGM? They'd say somebody with a pump is where we start. That certainly is not the case anymore. And so it varies across the board, but it is much more prevalent than it used to be. There's still plenty of room. Operator And our next question comes from Jeff Johnson from Baird. Jeff Johnson -- Baird -- Analyst Kevin, I want to go back and ask you a question on the MDI versus pump mix that was talked about earlier. Especially within the MDI category, are you seeing any change in that patient base? Are you winning any competitive converts there? Or are those all native first-time users of CGM that you're winning on that MDI side? Kevin Sayer -- Chairman, President, and Chief Executive Officer I don't have a good piece of data here. Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes, I would say -- I would say, anecdotally, just honestly coming out of our national sales meeting and talking to our field force, who really they're on the front line, that you hear anecdotal stories that yes, people would try Libre and then if they are content with an on-body experience, with a sensor experience that they do migrate to a DexCom, but we don't have any real metrics to kind of give you as to what sort of conversion rate we have on Abbott to DexCom. With respect to Medtronic, they've launched a stand-alone system, but we -- honestly, we just don't do that system out in the marketplace at all. Jeff Johnson -- Baird -- Analyst Yes. Fair enough. And then on Medicare, I just -- we didn't get much color on that this quarter. Any update there on stick rates, on demand trends, things like that. I know G6 is pushed till later this in that channel. Has that been impacting near-term demand? Just any updates would be helpful? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. No change in trends there, Jeff. I would say our stick rates remain very, very high. I mean we're incredibly encouraged by what we're seeing there. And the new patient funnel continues to be very full. So pushing the G6 launch out into later in the year has not impacted any trends that we've seen in that Medicare business right now. Operator And our next question comes from Doug Schenkel from Cowen. Unknown speaker This is Ryan on for Doug. And first off, Matt, congrats on the new role. You referenced G6 enhancements coming this year and earlier in the call and talked about new algorithms on the last quarterly call. Can you provide any more details? Should we expect the new algorithm to noticeably improve the performance metrics of G6 during 2019? And then should we expect extended wear for G6 during 2019? Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what, let us -- we're going to keep that close to the vest and not lay out the -- the road map. In the U.S., I can tell you in 2019, we don't expect extended wear for the G6 in 2019. The decisions that we are making around things that would require extensive trials of that nature are very interesting. Do we commit those resources to G6? Or do we commit those resources to accelerating G7? And in many cases, we're choosing the G7 acceleration over that. But there are new features coming out in the fall on G6, and we'll kind of wait a while before we lay what all those are out to everybody. Operator And your next question comes from Chris Pasquale from Guggenheim. Chris Pasquale -- Guggenheim Securities -- Analyst I just want to follow up on the comment about the gross margin, Quentin, and why we shouldn't assume that 70% is a good number going forward? I'm assuming some of that has to do with the continuation of the pharmacy dynamic next year but just kind of flush out how much you have to sort of swim upstream to maintain margins in the mid-60s? And what you're thinking about over the next -- call it, 18 months? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. Without getting into specifics around 2020, maybe I'll just point you to one of the dynamics that we feel in the business right now, which is somewhat considerable to what we saw last as well. For the full year, when we set margin expectations, we talked about there being roughly a 200-basis-point headwind relative to the revenue per patient impact of moving into some of these other channels, both pharmacy and OUS. I think based upon what we know at that point in time, that's probably the right way to continue to think about that headwind as we roll into next year. Clearly, we'll refine that as we learn more as we exit the year but they start to push up into the 70s with the lower-priced transmitter. It clearly gives us opportunities to be more thoughtful around pricing strategies into the future. So that's why I come back into the mid-60s for the time being. But in terms of the pressure we're feeling from mixed channel, a couple of hundred basis points right now it's what we're seeing. So you can model from there where you want. But I still think the mid-60s is right way to think about it over the long-term. Chris Pasquale -- Guggenheim Securities -- Analyst That's helpful. And then on the new markets, I'm assuming it's going to be a little while before we see some real data in some of these new indications. But at this point, is there a lead candidate that you guys think is most promising or that you -- you think you want to go after first? Kevin Sayer -- Chairman, President, and Chief Executive Officer I would say, we're -- look, we're already commercial to some extent in the non-intensive type 2. I mean we've characterized some of the work we're doing, particularly with UnitedHealthcare as pilot studies, but we're talking about multiple thousands of patients. So there are large pilot studies. With respect to the work being done by United, Onduo, etc. You're not going to see any data. In fact, they hold some of the findings and the learnings there to be highly proprietary, so they're not going to share that with anybody. To the extent we run a more formalized clinical protocol for a hospital indication or a gestational indication or something like that, that data may become available. But right now, I don't think we have any plans to -- really, to tip our hat to our potential competitors in those markets as well. Operator And our next question comes from Raj Denhoy from Jefferies. Raj Denhoy -- Jefferies -- Analyst Just really wanted to ask about the leverage, the middle of the income statement you guys are talking about. And I appreciate the comments on the increase to the folks in the Philippines now. So a couple of questions there. One is, if you think about the environment getting potentially more competitive, one of the concerns is that customer service for you guys has always been such a really strong shoot and as you move that now -- offshore and how you maintain that? And so I'm curious if you have any kind of really data or anything you can offer in terms of how that transition is going. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. Raj, we've been incredibly impressed by the team that's being built over there. And we pay very close attention to, not only quantitative assessment and performance metrics, but also qualitative. And so, we try to take the opportunity with every single patient as they work with our folks over there to get feedback from them -- on how the calls went and what we can do better. And I can tell you out of the gate, our qualitative scores are higher than what we've seen in our domestic teams. So we're seeing great results and something that we're paying very close attention to. From an efficiency perspective, we've been beyond, to be quite honest, what we anticipated we might be able to recognize in the early stages there. You look at some of the work coming off our customer advocacy or complaints area, our tech support and other back-office functions, and the efficiencies are significant that lead us to believe that it's going to make it much easier to scale, much more quickly and clearly, more effectively. So we couldn't be more encouraged by what -- we're seeing out of that effort there. I believe that over time, that becomes a real strategic asset to this company and allows us to be more aggressive in how we think about other strategic opportunities in markets we might want to pursue. Or how we just compete in the local markets that we're in already. So very encouraged by what we're seeing there. Operator And your next question comes from Ravi Misra from Berenberg Capital. Ravi Misra -- Berenberg Capital -- Analyst So my first one is again on gross margins. Just hoping, Quentin, maybe you could give us a little bridge between the first-quarter and fourth-quarter ramp? And then on the first quarter, what are the headwinds that showed up in that margin that are going to fall away, maybe break it down versus year-over-year versus mix-shift or underutilized overhead? Quentin Blackford -- Executive Vice President and Chief Financial Officer Ravi, when you're talking fourth quarter, you're talking about from Q1 this year to Q4 of '19? Ravi Misra -- Berenberg Capital -- Analyst Right. Yes, actually. Quentin Blackford -- Executive Vice President and Chief Financial Officer Sure. So I think -- let me just talk year-over-year real fast, Q1-to-Q1 around some of the headwinds that we had. There was about 200 basis points of impact related to the continued shift toward pharmacy, and the OUS business being a bigger part of the overall contribution. And then there's about 200 basis points associated with -- really, our focus on doubling capacity. And we talked about the fact that with the demand being beyond what we had anticipated, we're accelerating some of that spend. So we pulled some of that forward. Not all of that is capitalizable or inventoriable. And so it's run through the P&L a bit earlier than what we had anticipating. So I think you'll see Q1 will be that low-water mark. I think you'll start to see it improve a bit in Q2 and see some real improvement in Q3 and onto Q4. And really what drives that, in Q3, you're going to start to get just the benefit of levering the fixed overhead that we put in place right now to design the automated manufacturing capabilities. In Q4, while you're getting some of the benefit of that leverage or the fixed overhead, you're really going to start to get the play-through of the benefit on the low-cost transmitter. So hopefully that gives you a bit of a bridge over the course of the year in terms of what the contributing factors are. But I think for us, we can see a clear line of sight of getting close to that 70% range as we exit this year. Ravi Misra -- Berenberg Capital -- Analyst Great. I can add some follow-ups offline. And then my second question is, just around type 2 usage and kind of some of the commentary you had around moving patients from the ward -- from ward to ward, just curious, what's the take on the proposed rule changes around new technology add-on payments? I mean do you see a space for your CGM products to fit into that designation? And what could that mean from a reimbursement or payment perspective? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. Absolutely, and particularly in the hospital setting, as I mentioned, CMS has a renewed focus and has identified hypoglycemia in the inpatient setting as a huge problem. And so you're not going to detect hypoglycemia with finger sticks, even if you're taking a couple of finger sticks an hour, right? So I think that the CGM plays into that environment. And we've long known that referring hyperglycemia in the hospital is a problem leads to reduced healing times. We can get CGM put on this -- the idea would be to get CGM put on these patients potentially pre-op, get them into the hospital with the sensor already on, get their blood sugar under control before a procedure and get them in and out of the hospital as quickly as possible. So yes, we think there's great application here. We think also the disposable nature of G7 is the perfect product opportunity there. Operator And our next question is from Matt Taylor from UBS. Matt Taylor -- UBS -- Analyst So I wanted to ask, Quentin, a question, see if you could give us a little bit more detail on what changes here sequentially in terms of some of the assumptions that are embedded in the revenue guidance for the year? Did address a little bit of this in the earlier question about the pricing headwinds, but can you just give us a sense for what has changed? And if you could provide broad strokes on the different components, that would be helpful? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. I think -- it's really quite simple. To be honest with you, it's not a lot of different moving pieces. It comes down to new patient volume more than anything else. I think the demand that we continue to see in the business coming off at Q4 and the strong Q1 continues to increase our confidence in the adoption of the technology in the marketplace, and so it's really new patient volumes that are driving the incremental growth. I think you'll see a lot of that come thru on the commercial business through the pharmacy channel. From our experience, we believe that's where the majority ends up showing up, and then the international business is a bit strong as well. So those two channels are the primary drivers. And at the end of the day, it's all new patient volumes that are driving it. The pricing assumption, I talked about earlier, no change in terms of the $100 million headwind. Matt Taylor -- UBS -- Analyst OK. And then maybe just a follow-up with the Head of New Markets here or just for the team, can you talk about which of the new markets you think is really going to be able to bear fruit for the company in the near term? Anything that you can share on the strategy there that's changed since -- you talked about some of the things at Investor Day? Kevin Sayer -- Chairman, President, and Chief Executive Officer This is Kevin. I'll take that. I'm not as concerned about bearing fruit on the revenue side, as I am building a long-term case. So our efforts this year go -- as we rolled this stuff out, as I said earlier in my prepared remarks, are to develop the outcomes, the cost base evidence that show these are markets where we're going to save patient's money and deliver better outcomes. So it will be largely developing that evidence in those business models, establishing relationships we need to go to distribute into these markets and taking some steps like that over 2019 and early 2020. And then when we roll out G7, we expect to roll that out to these other places as well. And that becomes more of a commercial thing right now. And again, I will echo something that Steve said earlier. We haven't just been sitting around on this and not working. We've had some of our best people working on these fronts for quite some time. Now what we've done is formalized the structure and said, you guys have a home, you have a group, you have some goals, go get this done. And we're going to start measuring that progress more, rather than just as projects. And that's what we're expecting in the near-term. Operator And our next question comes from Steve Lichtman from Oppenheimer. Steve Lichtman -- Oppenheimer -- Analyst Kevin, on intensive type 2s, where do you think we're at penetration-wise today? And any updated color on your discussions with commercial payers and expanding access to those patients? Kevin Sayer -- Chairman, President, and Chief Executive Officer We continue to pursue that with the payers and certainly, using the CMS ruling as a basis for that. It gives us a very good start. I don't think penetration is very deep there right now. I can give you a number, I think it's less than 10%, in general. However, a lot of those type 2 intensive patients are Medicare patients. And as we launch -- as we look at launching G6 into Medicare later in this year, for example, we think we have an opportunity to grow that significantly, and that's a nice opportunity for us going forward in the future. I can't tell you that the type 2 intensive patients on the system, Quentin referred to the stickiness of our Medicare patients. It's been extremely good so far. So they're getting very good outcomes, those who use it. So we're happy with it. It is a tremendous opportunity for us and I -- we look forward to for more coverage. It's a chore. Getting the insurance companies to pay more and spend more money is never simple. Steve Lichtman -- Oppenheimer -- Analyst Got it. And then, you also talked about the positive results you're seeing from the predictive hypo alerts. When do you think we could see data aggregated and published around the benefits there? Kevin Sayer -- Chairman, President, and Chief Executive Officer I believe, Steve, that our predictive hypo alert paper was presented at ATTD. So that's already out, the G6 system, the patients that experience less hypoglycemia with the predictive alert. Operator And our next question comes from Suraj Kalia from Northland Securities. Suraj Kalia -- Northland Securities -- Analyst Congrats on a great quarter. So Quentin, a lot of my questions have been asked. Maybe I'll just kind of lump both my questions into one. And forgive me if you all have mentioned this on the call. What are the expectations for U.S. versus OUS contribution in FY '19? I'd love to get some perspective on how you'll see the margins for these two different buckets. I mean roughly speaking, the math tells me that roughly $400 million -- a little over $400 million would be OUS, the remaining would be U.S. Maybe you can kind of parse out for as what the -- how we should think about this? How the gross margins for the different buckets would be? And finally, this transmitter that is expected to bump up gross margins to 70% in Q4, what is the incremental gross margins contribution from this transmitter? I'd love to get some color, if possible? Quentin Blackford -- Executive Vice President and Chief Financial Officer Sure. So in terms of U.S. versus OUS split, on the full year, our OUS business is expected to grow in the mid- to high-30s range, which -- the U.S. business is growing in the teens, the 20%-or-so. That's about what we've expected on the course of the full year. We haven't given specific gross margin data points on the U.S. or OUS business and we're not going to put that out there. And that shifts, honestly, quarter to quarter just based upon the mix of revenue within -- so, OUS, where you've got a direct marketing, you've got a distributor business as well. So it just fluctuates based upon the mix. But we haven't put those data points out there, nor are we going to right now. In terms of the incremental benefit associated with the transmitter, the G6 low-cost transmitter, without giving you the exact specific cost differential, we can tell you it's more than 50% cheaper than what the G6 existing transmitter is today. So in terms of orders of magnitude, I think that it's clearly a very significant benefit for us that drives the overall improvement in the gross margin in that fourth-quarter time frame we've talked about. Operator And that concludes the question-and-answer session. I'll now turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you very much, and thanks everyone for being on the call today. I actually wanted to stop the call at 52% growth and $95 million-plus in incremental revenue over Q1 of last year, but we decided we would keep going. Much of the discussion around this call and recent months has focused upon 2 things: The pricing environment and anticipated competitive offerings in the space. And I think too often we forgot one thing. This market opportunity is huge. It is extremely large, not only in the intensive insulin space, but ultimately, in the type 2 space and the other areas, so we're looking at all the way down to health and wellness. We continue to see people now buying our system, getting a prescription, because they want to manage the nutrition on the side and they're paying cash and using it, but seeing some very interesting things. We truly see today when CGM, in multiple configurations and forms, becomes a very useful tool across all of healthcare and truly the standard of care in the intensive management of diabetes. With respect to pricing, our channel and payer teams are doing very well at DexCom. I talked earlier about the recent win with Cigna. We are -- we're hitting all cylinders here and that team has gone very well. Given the size of the opportunity with respect to the competitive environment, I said earlier, we didn't expect to remain the sole voice of CGM forever. We always knew others would come. An increased awareness generated by all parties move patients to the technology that best meets their needs, and that technology remains DexCom. With G6, our planned enhancements coming later this ; our next-gen G7 offering, and the technologies that will be following that, we expect to be the leader in this industry, in this the space for a very long time. Thanks again everybody and have a great day. Operator [Operator signoff] Duration: 66 minutes Call participants: Matt Dolan -- Vice President Corporate Development Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin Blackford -- Executive Vice President and Chief Financial Officer Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Jayson Bedford -- Raymond James -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Danielle Antalffy -- Leerink -- Analyst JP McKim -- Piper Jaffray -- Analyst David Lewis -- Morgan Stanley -- Analyst Joanne Wuensch -- BMO Capital Markets -- Analyst Margaret Kaczor -- William Blair -- Analyst Jeff Johnson -- Baird -- Analyst Unknown speaker Chris Pasquale -- Guggenheim Securities -- Analyst Raj Denhoy -- Jefferies -- Analyst Ravi Misra -- Berenberg Capital -- Analyst Matt Taylor -- UBS -- Analyst Steve Lichtman -- Oppenheimer -- Analyst Suraj Kalia -- Northland Securities -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Analysts Expect DWAQ To Hit $124 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA NASDAQ Momentum ETF (Symbol: DWAQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $123.65 per unit. With DWAQ trading at a recent price near $112.45 per unit, that means that analysts see 9.96% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of DWAQ's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Mirati Therapeutics Inc (Symbol: MRTX), and Sage Therapeutics Inc (Symbol: SAGE). Although DXCM has traded at a recent price of $118.62/share, the average analyst target is 32.80% higher at $157.53/share. Similarly, MRTX has 27.58% upside from the recent share price of $60.00 if the average analyst target price of $76.55/share is reached, and analysts on average are expecting SAGE to reach a target price of $202.73/share, which is 21.57% above the recent price of $166.76. Below is a twelve month price history chart comparing the stock performance of DXCM, MRTX, and SAGE: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BMO Capital Maintains Outperform on DexCom, Inc. - Common Stock, Raises Price Target to $172"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 financial results and announced 2019 EPS guidance above the analyst consensus estimate."", ""Raymond James Maintains Outperform on DexCom, Inc. - Common Stock, Lowers Price Target to $150"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2019 Results - Earnings Call Transcript"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2019 Results - Earnings Call Transcript""]"
DXCM,2019-05-03,30.3625,31.4388,29.9112,30.7375,"[""Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results."", ""Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results."", ""Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results.""]"
DXCM,2019-05-06,29.6625,30.8925,29.6625,30.5525,
DXCM,2019-05-07,30.2775,30.5425,29.4125,29.9025,
DXCM,2019-05-08,29.74,30.2,29.275,29.5575,"[""Jim Cramer Weighs In On CVS, Starbucks, Tilray And More"", ""Jim Cramer Weighs In On CVS, Starbucks, Tilray And More"", ""Jim Cramer Weighs In On CVS, Starbucks, Tilray And More""]"
DXCM,2019-05-09,29.1975,29.5788,28.875,29.3025,
DXCM,2019-05-10,29.23,29.805,28.61,29.6975,
DXCM,2019-05-13,29.04,29.3312,28.685,29.0625,
DXCM,2019-05-14,29.1375,30.3,29.1375,30.0625,"[""Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks."", ""Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks."", ""Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.""]"
DXCM,2019-05-15,29.7275,30.845,29.5985,30.3725,"[""3 \""Internet of Things\"" Stocks to Buy Right Now"", ""IBD Stock Of The Day Flirts With A Breakout As It Takes On Medtronic"", ""IBD Stock Of The Day Flirts With A Breakout As It Takes On Medtronic"", ""3 \""Internet of Things\"" Stocks to Buy Right Now"", ""IBD Stock Of The Day Flirts With A Breakout As It Takes On Medtronic"", ""3 \""Internet of Things\"" Stocks to Buy Right Now""]"
DXCM,2019-05-16,30.2425,30.84,29.8025,29.8525,
DXCM,2019-05-17,29.6625,29.8425,29.1625,29.51,
DXCM,2019-05-20,29.2525,29.945,28.8538,29.6175,
DXCM,2019-05-21,29.8275,30.21,29.6425,29.6475,
DXCM,2019-05-22,29.4675,29.7275,29.3425,29.6875,
DXCM,2019-05-23,29.425,29.45,28.4075,28.615,
DXCM,2019-05-24,28.79,29.7475,28.5975,29.7425,
DXCM,2019-05-28,29.75,30.7112,29.75,30.1775,
DXCM,2019-05-29,29.8275,29.9245,28.975,29.65,
DXCM,2019-05-30,29.6525,30.2725,29.2075,29.975,"[""This Is Not The End Of The Bull Market; An Agile Trader Can Be Successful Today"", ""This Is Not The End Of The Bull Market; An Agile Trader Can Be Successful Today"", ""This Is Not The End Of The Bull Market; An Agile Trader Can Be Successful Today""]"
DXCM,2019-05-31,29.7475,30.58,29.2675,30.325,"[""Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?"", ""Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?"", ""Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?""]"
DXCM,2019-06-03,30.27,30.835,29.97,30.24,"Implied QUS Analyst Target Price: $92 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR MSCI USA StrategicFactors ETF (Symbol: QUS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $91.72 per unit. With QUS trading at a recent price near $81.72 per unit, that means that analysts see 12.23% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of QUS's underlying holdings with notable upside to their analyst target prices are Steel Dynamics Inc. (Symbol: STLD), Vistra Energy Corp (Symbol: VST), and DexCom Inc (Symbol: DXCM). Although STLD has traded at a recent price of $25.15/share, the average analyst target is 62.52% higher at $40.88/share. Similarly, VST has 35.11% upside from the recent share price of $23.56 if the average analyst target price of $31.83/share is reached, and analysts on average are expecting DXCM to reach a target price of $160.87/share, which is 32.62% above the recent price of $121.30. Below is a twelve month price history chart comparing the stock performance of STLD, VST, and DXCM: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-06-04,30.3775,31.2175,30.2275,31.1875,
DXCM,2019-06-05,31.25,31.6828,30.755,30.865,
DXCM,2019-06-06,30.7575,30.8125,29.605,30.1738,"[""Here's Why You Should Invest in DexCom (DXCM) Stock Now"", ""Dexcom Shares Volatile Over Last Few Mins. Following Senseonics FDA Doc On Eversense, Very Large Volume Spike As Doc Was Circulated By Traders; Piper Jaffray Noted Co. Also Has A Non-Adjunctive Claim"", ""Dexcom Shares Volatile Over Last Few Mins. Following Senseonics FDA Doc On Eversense, Very Large Volume Spike As Doc Was Circulated By Traders; Piper Jaffray Noted Co. Also Has A Non-Adjunctive Claim"", ""Here's Why You Should Invest in DexCom (DXCM) Stock Now"", ""Dexcom Shares Volatile Over Last Few Mins. Following Senseonics FDA Doc On Eversense, Very Large Volume Spike As Doc Was Circulated By Traders; Piper Jaffray Noted Co. Also Has A Non-Adjunctive Claim"", ""Here's Why You Should Invest in DexCom (DXCM) Stock Now""]"
DXCM,2019-06-07,30.3125,31.6625,30.1088,31.495,
DXCM,2019-06-10,31.7575,35.32,31.625,34.61,"[""DexCom shares are trading higher on elevated volume. Not seeing any fundamental news to justify price action."", ""DexCom shares are trading higher on elevated volume. Not seeing any fundamental news to justify price action."", ""Why DexCom Stock Jumped Today What happened Shares of DexCom (NASDAQ: DXCM) jumped 9.9% on Monday after rising more than 12% earlier in the day. The nice gain appears to be related to a couple of factors. One is continued momentum from Medtronic's (NYSE: MDT) announcement on Friday that it will develop insulin pumps that will be interoperable with the DexCom G6 continuous glucose monitoring (CGM) system. And over the weekend, Tandem Diabetes Care (NASDAQ: TNDM) presented highly anticipated results from the International Diabetes Closed Loop (iDCL) trial of the DexCom G6 and Tandem's t:Slim X2 insulin pump at the American Diabetes Association (ADA) meeting. So what Currently, the CGM system integrates with Tandem's t:Slim X2 insulin pump in what's called a \""closed loop\"" system, where the CGM monitors glucose levels and lets the pump know when to administer insulin. Medtronic's decision to launch insulin pumps that are interoperable with the G6 system should expand the potential market for DexCom. The DexCom G6 continuous glucose monitoring system. Image source: DexCom. Tandem's presentation of data from the iDCL study was also great news for DexCom. This was the first large-scale study of a closed-loop system that included a dedicated control group. In DexCom's Q1 conference call in May, Steve Pacelli, the company's executive vice president for strategy and corporate development, said that this data would \""probably be the highlight\"" for DexCom at the ADA meeting. And it was indeed a highlight. Probably the most impressive result from the iDCL study was that the time that patients were in an acceptable range for glucose levels was 76% for those using the closed-loop system compared with only 59% for patients in the control group. The popularity of the G6 CGM system is a big reason DexCom stock has soared nearly 50% over the last 12 months. Now what DexCom should have more good news for its G6 system later this year. The company plans to roll out new features this fall. It hopes to launch the G6 CGM with Medicare later this year. But the G6 will be the big story for DexCom for a limited time only. The company is working on its next-generation G7 system and plans to launch the new CGM by late 2020 or early 2021. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom shares are trading higher on elevated volume. Not seeing any fundamental news to justify price action.""]"
DXCM,2019-06-11,34.1425,35.0,34.1425,34.6325,"[""DexCom Shares Closed Up Nearly 10% On Mon.; Piper Jaffray Analyst JP McKim Tells Benzinga Upside Attributed To 'Positive Developments At The American Diabetes Association'"", ""DexCom Shares Closed Up Nearly 10% On Mon.; Piper Jaffray Analyst JP McKim Tells Benzinga Upside Attributed To 'Positive Developments At The American Diabetes Association'"", ""DexCom Shares Closed Up Nearly 10% On Mon.; Piper Jaffray Analyst JP McKim Tells Benzinga Upside Attributed To 'Positive Developments At The American Diabetes Association'""]"
DXCM,2019-06-12,34.8025,36.3275,34.8025,36.3175,
DXCM,2019-06-13,36.25,36.875,36.115,36.58,
DXCM,2019-06-14,36.58,37.12,36.2825,37.01,"[""5 Top-Ranked Stocks Crushing the Market in June"", ""3 \""Internet of Things\"" Stocks to Buy Right Now"", ""3 \""Internet of Things\"" Stocks to Buy Right Now"", ""5 Top-Ranked Stocks Crushing the Market in June"", ""3 \""Internet of Things\"" Stocks to Buy Right Now"", ""5 Top-Ranked Stocks Crushing the Market in June""]"
DXCM,2019-06-17,37.1475,37.8425,37.0,37.585,"[""Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day"", ""Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day"", ""Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day""]"
DXCM,2019-06-18,38.0475,38.3475,37.735,38.135,"[""Leading Companies In The Development Of The Internet Of Things"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""Leading Companies In The Development Of The Internet Of Things"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""Leading Companies In The Development Of The Internet Of Things""]"
DXCM,2019-06-19,38.2125,38.525,37.685,38.445,
DXCM,2019-06-20,38.74,39.375,38.541,38.915,"[""IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday"", ""IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday"", ""IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday""]"
DXCM,2019-06-21,38.525,38.7875,37.5825,37.7,
DXCM,2019-06-24,37.7075,37.99,36.75,36.915,
DXCM,2019-06-25,37.0075,37.0275,35.8325,35.88,
DXCM,2019-06-26,36.0675,36.25,34.8075,35.3825,
DXCM,2019-06-27,35.6175,36.77,35.565,36.4575,"[""DexCom Shares Do Not Appear To Be Impacted Following Earlier Article Highlighting Possible Competitor In Diabetes Space 'Apple continues expanding into health care by selling its first diabetes product in stores'"", ""DexCom Shares Do Not Appear To Be Impacted Following Earlier Article Highlighting Possible Competitor In Diabetes Space 'Apple continues expanding into health care by selling its first diabetes product in stores'"", ""DexCom Shares Do Not Appear To Be Impacted Following Earlier Article Highlighting Possible Competitor In Diabetes Space 'Apple continues expanding into health care by selling its first diabetes product in stores'""]"
DXCM,2019-06-28,36.675,37.5775,36.4575,37.46,"[""DexCom: High Growth, Intense Competition, Extreme Valuation"", ""China Trade War Cease-Fire Could Be Catalyst For Swing Trading"", ""China Trade War Cease-Fire Could Be Catalyst For Swing Trading"", ""DexCom: High Growth, Intense Competition, Extreme Valuation"", ""China Trade War Cease-Fire Could Be Catalyst For Swing Trading"", ""DexCom: High Growth, Intense Competition, Extreme Valuation""]"
DXCM,2019-07-01,37.8725,38.2662,37.735,37.8575,
DXCM,2019-07-02,37.955,37.955,36.085,36.4175,
DXCM,2019-07-03,36.4975,36.745,35.8025,35.84,"[""ETF & Stock Winners of Longest US Economic Expansion"", ""ETF & Stock Winners of Longest US Economic Expansion"", ""ETF & Stock Winners of Longest US Economic Expansion""]"
DXCM,2019-07-05,35.5275,36.8325,35.3275,36.7475,"[""Will MedTech Ease Investors' Concern & Outperform? 4 Picks"", ""Will MedTech Ease Investors' Concern & Outperform? 4 Picks"", ""Will MedTech Ease Investors' Concern & Outperform? 4 Picks""]"
DXCM,2019-07-08,36.62,37.125,36.0325,36.405,
DXCM,2019-07-09,36.2275,36.9725,35.9933,36.945,
DXCM,2019-07-10,37.0225,38.2375,37.02,37.72,
DXCM,2019-07-11,37.88,38.21,37.225,38.125,"[""All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy"", ""All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy"", ""All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy""]"
DXCM,2019-07-12,38.085,38.1375,36.4725,37.2925,"[""3 Internet of Things Stocks to Buy for July"", ""3 Internet of Things Stocks to Buy for July"", ""3 Internet of Things Stocks to Buy for July""]"
DXCM,2019-07-15,37.43,38.0725,37.015,37.7775,"3 Top Diabetes Stocks to Watch in July Diabetes is one of the most common diseases across the globe, and its prevalence is expected to rise due to the unchecked obesity epidemic. As a result, the demand for diabetes products has been going through the roof over the past decade, especially among next-generation medical devices. Which diabetes-oriented healthcare companies are in the best position to benefit from this global trend? We asked three of our Motley Fool contributors this question, and they picked DexCom, Inc. (NASDAQ: DXCM), Insulet (NASDAQ: PODD), and Tandem Diabetes Care (NASDAQ: TNDM). Here's why these three medtech diabetes companies should be on your radar this month. Image source: Getty Images. A medtech company with more room to run George Budwell (DexCom, Inc.): Single-product companies with stocks that sport stately price-to-sales ratios over 12 are rarely compelling buys. However, the continuous glucose monitoring (CGM) device company DexCom is an oddball in this regard. Despite its over-the-top valuation and limited product portfolio, this diabetes medtech titan remains an attractive growth play, even at these elevated levels. What's the lowdown? DexCom launched its factory-calibrated G6 CGM device last year to rave reviews by end users. In fact, the company has barely been able to keep up with demand since launch, resulting in its first-quarter revenues growing by an astounding 52% to $280 million compared to the same period a year ago. And as the G6 launch matures, DexCom expects its gross margins to improve to a healthy 70%, perhaps by the end of 2019. The company, in turn, recently upped its annual revenue guidance by $75 million for the full year, thanks to the strong demand for the G6 system, in conjunction with its steadily improving profit margins. DexCom's growth story, however, is only getting started. The company expects to roll out its next CGM device, the G7, in late 2020 or early 2021. The G7 will feature a slimmer design, an entirely new sensor platform, and a far more customer-friendly price. The main goal with this next-generation CGM device is to greatly expand the market beyond type 1 or type 2 diabetes patients. DexCom envisions a day where individuals simply at risk of developing diabetes will be outfitted with one of their CGM devices. That's a lofty goal, but one that could exponentially growth DexCom's target market in the coming decade. Down (with) the tubes Keith Speights (Insulet): Most diabetes patients don't have to wear insulin pumps. But for those who do, the long tubes associated with most insulin pumps on the market today can be a hassle. That's not the case for Insulet's OmniPod, though. Insulet stock has already been a big winner so far in 2019. Shares soared after the company posted better-than-expected sales growth in its first-quarter results. Although Insulet doesn't announce its Q2 financial results until Aug. 5, 2019, don't be surprised if the stock runs up in advance of its next quarterly update. The company thinks that year-over-year sales growth in the second quarter will be at least as high as the 29% growth delivered in Q1. Insulet CEO Shacey Petrovic predicts that the company is on track to achieve $1 billion in revenue in 2021 with a 70% gross margin and an operating margin in the midteens. To put that revenue figure in perspective, it's nearly double the total revenue that Insulet made in 2018. A big reason for this optimism is the strong launch of the OmniPod DASH insulin management system in the U.S. Initial adopters of OmniPod DASH have praised its ease of use. And fewer prescribing restrictions have opened up access for more patients to use the insulin pump system. Insulet looks really expensive if you look at earnings-based valuation metrics. But the company's earnings should grow rapidly. Insulet definitely appears to be a diabetes stock to keep your eyes on in July and beyond. It could be a great time to buy this pump player, too Todd Campbell (Tandem Diabetes): I agree with Keith that tubeless pumps offer advantages that make them desirable, but I'd also add that there's a good reason to cozy up to shares in the leading tubed-pump player, Tandem Diabetes. Unlike Insulet, Tandem Diabetes' pump is FDA approved for use in tandem with DexCom's continuous glucose monitors to form a first-generation automated insulin dosing system. This system, which won the go-ahead last summer, disables the pump from dosing additional insulin when real-time data from the CGM shows dangerous blood sugar lows. Since approval, demand for Tandem's pumps have taken off. In Q1 2019 the company shipped 14,732 pumps, up 75% from Q3 2018, and sales totaled $66 million, up 142% year over year. What's really remarkable about that performance is that the first quarter is typically weak because patients usually wait until later in the year, when their deductible is met, to buy equipment like this. Since we're already in the second half of the year, I suspect more people meeting their deductibles will further accelerate pump shipments and revenue into the end of the year. Results could also benefit from the expected rollout later this year of next-generation software that will allow Tandem's system to make decisions based on high glucose readings, too. This additional feature will make Tandem's automated system much more helpful to many more patients. Importantly, pump makers are only scratching the surface of the market. Only about 30% of the 1.5 million type 1 diabetics in the U.S. are using pump therapy currently, and Tandem's market share is only about 12%. Given that tailwinds may strengthen from here this year, buying this tubed-pump player this month could be profit-friendly. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 George Budwell has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. Todd Campbell owns shares of DexCom. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-07-16,37.8825,38.25,37.2,37.4625,
DXCM,2019-07-17,37.4025,37.4025,36.1925,36.8925,
DXCM,2019-07-18,36.92,38.9975,36.605,38.3475,
DXCM,2019-07-19,38.4275,38.7595,37.975,38.145,"Charting a bull-trend pullback, S&P 500 maintains 20-day average Focus: Gold and silver digest headline breakouts, IBM takes flight, GLD, SLV, GDX, IBM, PEGA, DXCM U.S. stocks are mixed early Friday, treading water after Thursday’s seemingly conflicting Federal Reserve policy remarks, and following a strong earnings report from Dow 30 component Microsoft Corp. Against this backdrop, the S&P 500 has maintained near-term support (2,973) an area currently matching the 20-day moving average."
DXCM,2019-07-22,38.1325,39.25,38.1325,38.7775,
DXCM,2019-07-23,37.9875,39.1175,37.88,37.9875,
DXCM,2019-07-24,38.1325,38.4675,37.55,38.24,"[""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release"", ""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release"", ""DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release""]"
DXCM,2019-07-25,38.0025,38.365,37.6688,37.8725,"[""What's in the Offing for DexCom's (DXCM) Earnings in Q2?"", ""What's in the Offing for DexCom's (DXCM) Earnings in Q2?"", ""What's in the Offing for DexCom's (DXCM) Earnings in Q2?""]"
DXCM,2019-07-26,38.23,38.7825,37.805,38.4425,
DXCM,2019-07-29,38.4625,38.745,37.4802,38.385,"[""Tech Stocks Hit Hard, But Several Top Growth Stocks Hold Near Buy Points"", ""Looking At Signs That The Market Is Stalling Out. Sell Before Powell's Interest Rate Cut News"", ""Tech Stocks Hit Hard, But Several Top Growth Stocks Hold Near Buy Points"", ""Looking At Signs That The Market Is Stalling Out. Sell Before Powell's Interest Rate Cut News"", ""Tech Stocks Hit Hard, But Several Top Growth Stocks Hold Near Buy Points"", ""Looking At Signs That The Market Is Stalling Out. Sell Before Powell's Interest Rate Cut News""]"
DXCM,2019-07-30,38.025,39.275,38.025,39.0975,"[""Dow Jones Holds Above This Key Price Level; These 5 Growth Stocks Aim For Market Leadership"", ""Dexcom Receives Composite Rating Upgrade"", ""Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More"", ""Fed Rate Cut, China Trade Talks, 5 Top Stocks Near Buy Points With Earnings Due: Action Plan"", ""Dow Jones Holds Above This Key Price Level; These 5 Growth Stocks Aim For Market Leadership"", ""Dexcom Receives Composite Rating Upgrade"", ""Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More"", ""Fed Rate Cut, China Trade Talks, 5 Top Stocks Near Buy Points With Earnings Due: Action Plan"", ""Dow Jones Holds Above This Key Price Level; These 5 Growth Stocks Aim For Market Leadership"", ""Dexcom Receives Composite Rating Upgrade"", ""Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More"", ""Fed Rate Cut, China Trade Talks, 5 Top Stocks Near Buy Points With Earnings Due: Action Plan""]"
DXCM,2019-07-31,39.3725,40.0,38.621,39.2175,"[""DexCom, Inc. 2019 Q2 - Results - Earnings Call Slides"", ""DexCom Q2 top line up 39%, guidance raised"", ""DexCom EPS beats by $0.08, beats on revenue"", ""Apple Breaks Out Again, Dow Jones Reverses Lower; This Social Media Stock Crosses New Buy Point"", ""The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster"", ""Stocks That Managed to Breach 52-Week Highs Wednesday Morning"", ""DexCom Q2 EPS $0.08 Beats $0.01 Estimate, Sales $336.4M Beat $307.04M Estimate"", ""Dexcom Raises FY19 Sales Guidance From $1.25B-$1.3B To $1.325B-$1.375B vs $1.29B Estimate"", ""DexCom shares are trading lower despite the company reporting strong Q2 earnings."", ""DexCom shares are trading lower despite the company reporting strong Q2 earnings."", ""Dexcom Raises FY19 Sales Guidance From $1.25B-$1.3B To $1.325B-$1.375B vs $1.29B Estimate"", ""DexCom Q2 EPS $0.08 Beats $0.01 Estimate, Sales $336.4M Beat $307.04M Estimate"", ""Stocks That Managed to Breach 52-Week Highs Wednesday Morning"", ""The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster"", ""DexCom, Inc. 2019 Q2 - Results - Earnings Call Slides"", ""DexCom Q2 top line up 39%, guidance raised"", ""DexCom EPS beats by $0.08, beats on revenue"", ""Apple Breaks Out Again, Dow Jones Reverses Lower; This Social Media Stock Crosses New Buy Point"", ""DexCom shares are trading lower despite the company reporting strong Q2 earnings."", ""Dexcom Raises FY19 Sales Guidance From $1.25B-$1.3B To $1.325B-$1.375B vs $1.29B Estimate"", ""DexCom Q2 EPS $0.08 Beats $0.01 Estimate, Sales $336.4M Beat $307.04M Estimate"", ""Stocks That Managed to Breach 52-Week Highs Wednesday Morning"", ""The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster"", ""DexCom, Inc. 2019 Q2 - Results - Earnings Call Slides"", ""DexCom Q2 top line up 39%, guidance raised"", ""DexCom EPS beats by $0.08, beats on revenue"", ""Apple Breaks Out Again, Dow Jones Reverses Lower; This Social Media Stock Crosses New Buy Point""]"
DXCM,2019-08-01,39.2525,40.325,35.125,37.08,"[""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q2 2019 Results - Earnings Call Transcript"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $172"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $160"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $186"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $185"", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $185"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $186"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $160"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $172"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q2 2019 Results - Earnings Call Transcript"", ""What You'll Want to Know About DexCom's Q2 Earnings Results DexCom (NASDAQ: DXCM) has taken investors on a roller-coaster ride so far in 2019, with shares rising more than 25% earlier in the year, giving up all of those gains and then some, then bouncing back to move even higher than before. Investors were spooked after a bearish report about the company was released in March, but the worries soon faded away. There wasn't anything spooky about DexCom's latest quarterly figures. The company announced its second-quarter results after the market closed on Wednesday. Here are the highlights from DexCom's Q2 update. Image Source: Getty Images. By the numbers DexCom's Q2 revenue jumped 39% year over year to $336.4 million. Analysts estimated that the company's revenue for the second quarter would come in at a little over $307 million. The company announced a net loss in the second quarter on a generally accepted accounting principles (GAAP) basis of $10.5 million, or $0.12 per share. This reflected deterioration from the prior-year period when the company announced GAAP net income of $30.2 million, or $0.34 per share. DexCom reported non-GAAP adjusted net income of $7.8 million, or $0.08 per share. This represented a significant improvement from the prior-year period adjusted net loss of $6.5 million, or $0.07 per share. Wall Street analysts estimated that DexCom would post adjusted earnings per share of $0.01 in the quarter. Behind the numbers It's apparent from DexCom's strong revenue growth in Q2 that its G6 continuous glucose monitoring (CGM) systems remain very popular with customers who have diabetes. The company said that increased awareness of real-time CGM is a key factor in driving higher sales volumes. This revenue growth came from all geographic regions where DexCom sells its products. U.S. sales soared 40% year over year to $266.3 million. International sales jumped 33% higher to $70.1 million. You might wonder, though, why DexCom's bottom line looked so much worse than the prior-year period. There were two primary culprits. One was that the company's interest expense increased significantly from a year ago. However, the biggest factor was a $42.7 million gain from an equity investment posted in the second quarter of 2018 that resulted in a temporary profit on a GAAP basis. That one-time equity gain was adjusted out of DexCom's non-GAAP net income figures. As a result, the company's non-GAAP comparisons looked much better. Looking ahead DexCom now anticipates revenue to be between $1.325 billion and $1.375 billion in full-year 2019, up from its previous guidance of $1.25 billion to $1.30 billion. The company projected 2019 non-GAAP operating margin of 7%, compared to 6% provided in its previous outlook. CEO Kevin Sayer said that the company remains \""confident in DexCom's long-term growth opportunity.\"" Investors will want to watch closely, though, to see how the future launch of Abbott Lab's new version of its FreeStyle Libre CGM system impacts sales of DexCom's G6 CGM. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 2019 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q2 2019 Earnings Call Jul 31, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom second-quarter 2019 earnings release conference call. My name is Adrian, and I'll be the operator for today's call. [Operator instructions] Please note this conference is being recorded. I'll now turn the call over to Sean Christensen. Sean Christensen, you may begin. Sean Christensen -- Senior Investor Relations Manager Thank you, operator, and welcome to DexCom second-quarter 2019earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will provide a summary of the quarter followed by a financial review and outlook from Quentin Blackford, our executive vice president and CFO; and then a strategic update from Steve Pacelli, our executive vice president of strategy and corporate development. Following our prepared remarks, we will open up the call for your questions. [Operator instructions] Please note that there are also slides available related to our second quarter performance on the DexCom investor relations website on the events and presentations page. With that, let's review our safe harbor statement. Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom and are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on form 10-K, quarterly reports on form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our second quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measures. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us today. We are pleased to report another outstanding quarter for DexCom with awareness of DexCom CGM continuing to rise within the diabetes community and beyond. Second-quarter revenue grew to $336 million, a 40% increase over the second quarter of 2018 on a constant currency basis, continuing the momentum that we're seeing for the past five quarters. As we have observed in previous quarters, the primary driver of our growth in all channels including our U.S. commercial business, Medicare and other OUS businesses remains volume growth attributable to new patients. In fact, new patient additions once again reached a record level in the second quarter. And as our results indicate, the volume growth that we are experiencing is more than offsetting the pricing pressure that we anticipated with lower revenue for patient associated with our move to the pharmacy channel, as well as the continued expansion of our Medicare and OUS businesses. While attending the American Diabetes Association Conference in San Francisco in early June, two conclusions became increasingly clear to me. First, awareness of real-time CGM is quickly progressing and driving CGM toward standard of care status. We've been on record for years stating that the future is CGM First, and we believe that future is here. At ADA, CGM was no longer a minor presence relative to the various drug therapies. Instead, DexCom CGM featured prominently in standing room only product presentations, academic papers and as the driver of automated insulin delivery devices, all of which reflect the growing market awareness that we are seeing. Timing range is quickly becoming the most important metric to assess glucose control with new timing range guidelines being established this year. Only CGM can provide these types of metrics, it is very clear to us that CGM as a diagnostic tool will become another large market for us in the future. This is well-planned with the recent submission of our G6 pro product, which we expect to launch in 2020. With significant room for further adoption in both the Type 1 and intensive Type 2 populations, we are ever more confident in the growth opportunity that lies ahead for these core business segments. Second, we are just scratching the surface of the potential for DexCom CGM. Discussions around CGM and ADA were not limited to traditional intensive insulin-using populations, was extended to preliminary studies on use in pregnancy and inpatient settings. And as we stated on our last call, we are exploring applications of our technology into these settings as we position DexCom to maximize its long-term growth opportunity. To support these significant opportunities, our team's operational performance remains critically important. At the start of the year, we established the ambitious goal of doubling our G6 production capacity, and I'm pleased to report that we are on track to achieve that goal. We are excited about the fact that we have initiated production of our low-cost transmitter in our San Diego and Mesa locations. We are now building inventory as we prepare for launch. Based on the hard work of our operations teams in both San Diego and Mesa, we continue to strengthen our G6 capacity. This positions us well to expand the launch of G6 in the second half of this year. We look forward to bringing G6 to Canada later this year and driving the ongoing transition to G6 in additional OUS markets. We remain committed to G6 launch for our Medicare patients later this year and believe that this should drive incremental demand in patient satisfaction in an already strong category. Also on the Medicare front as a number of you have seen, CMS recently differentiated reimbursement between Class 2 and Class 3 CGMs. And while the rate for the G6 system will be less than Class 3 CGM, please keep in mind that we will ship fewer centers and no BGM supplies with the future G6 bundle. Based on our better-than-expected second-quarter performance, we are pleased again to be able to increase our revenue outlook for 2019, as well as our full-year operating margin and adjusted EBITDA targets. I will now turn the call over to Quentin, who will provide detail on this outlook, as well as review of our financials. Quentin Blackford -- Executive Vice President and Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. Today, we reported worldwide revenue of $336.4 million for the second quarter of 2019, compared to $242.5 million for the same quarter in 2018, representing growth of 39% on a reported basis. Our momentum continues to be strong with this being the third consecutive quarter that we have added more than $90 million in absolute dollar growth on a year-over-year basis. And as Kevin stated, another quarterly record of new patient addition for the company. On a geographic basis, our revenue growth continued to be strong in both our U.S. and OUS businesses, which grew at 40% and 37%, respectively on a constant currency basis in the second quarter. I'd like to remind you that our growth comps in both our U.S. and OUS businesses were meaningfully more difficult in the second quarter than the first quarter and will continue through the remainder of the year. Our second-quarter gross profit was $206.5 million or 61.4% of revenue, representing a 120 basis point sequential improvement over the first quarter of 2019, while increasing our G6 capacity and was in line with our expectations. On a year-over-year basis, gross margin was negatively impacted by our ongoing investments to drive capacity expansion, as well as the increasing mix in both our OUS and pharmacy channels. Our full-year gross margin expectations remain unchanged. As we invest in the long term, our team has done an excellent job of introducing automation and innovation into the sensor manufacturing process, and therefore, decreasing the cost profile of our systems. We are confident that we can continue to do this both within the G6 platform and as we progress toward the launch of G7, providing the company with flexibility, as we evaluate future growth opportunities. Operating expenses were $200.3 million for Q2 2019, compared to $155.8 million in Q2 2018. This reflects an increase of 29% year over year. As a result of our continued outperformance on the top line, we realized an uptick in our variable operating expenses for the quarter. In addition, the second quarter included two sources of higher-than-expected expense that we expect to normalize in the near term. First, we made a number of investments in the quarter toward the development of G7 as we continue to prepare for launch. We made good progress in the quarter, which triggered a small incentive charge of $3.2 million to barely for accelerating development work. Even as we continued the worldwide rollout of our G6 system, we are beginning to invest aggressively in the product, in manufacturing innovation, which will ensure rapid introduction of our G7 product when launched. Second, we incurred duplicative costs within our customer service organization as we ramped our operations in Manila. We've been willing to incur these costs to this transition and believe we've built a world-class team in our DexCom Manila location. However, we recognize that our third-party service capabilities have not met our expectations and are working to bring them up to the same level. Normalizing for these individual items, operating expense growth would've been approximately half the rate of revenue. Overall, we are on track to demonstrate good operating leverage this year and anticipate continued improvement in operating margins in the second half of the year. Operating income was $6.2 million in the second quarter of 2019, compared to an operating loss of $2.2 million in the same quarter of 2018. Even with the second-quarter expenses that I just highlighted, we achieved nearly 300 basis points of year-over-year operating margin expansion in the quarter. Adjusted EBITDA was $45.9 million or 13.6% of revenue for the second quarter, compared to $24.5 million or 10.1% of revenue for the second quarter of 2018. We remain well-positioned to achieve our long-term margin targets that we established at our investor day in late 2018, while generating cash to invest in the next wave of innovation that will extend our growth trajectory. This includes our investment in the G7 platform, as well as our exploration of the value of the CGM in new markets. Our net income was $7.8 million or $0.08 per share. We ended the second quarter in strong cash position with nearly $1.4 billion on our balance sheet providing the company with significant financial and strategic flexibility. For now, as evidenced by the $47 million of capital expenditures in the second quarter, our priority remains expansion of our production capacity. And as Kevin stated in his remarks, we are tracking toward our target of doubling G6 capacity this year while beginning to invest for G7 production. Given the strength of our first-half performance and the continued demand that we're seeing for DexCom real-time CGM, we now anticipate 2019 total revenue of approximately $1.325 billion to $1.375 billion, reflecting reported growth of 28% to 33% for the year, up from our prior outlook of 21 to 26%. As I mentioned previously, our full-year gross margin expectations stand at 64 to 65% and approaching 70% as we exit the year, driven primarily by the broad introduction of our lower-cost G6 transmitter in the back half of the year. In light of our better-than-expected revenue growth, we now expect operating margins of approximately 7% and adjusted EBITDA margins of approximately 18.5%, reflecting an increase of 100 basis points and 50 basis points, respectively, from prior guidance. With that, I'll now turn the call over to Steve for strategic update. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Thank you, Quentin. We had another great quarter in the books. We are excited about the growing acceptance of CGM around the world as a first-line technology for people with diabetes on intensive insulin therapy. Despite a number of rapidly changing market dynamics, DexCom is capitalizing on massive growth opportunity, and we are confident that the business is well-positioned to succeed over the long term. One of the core strategic objectives in early 2019 was to expand access to DexCom CGM. Within the U.S. market, our teams have been focused on two primary areas. First, as we have discussed in detail, we are making a strong push to ensure that patients have access to DexCom CGM through the pharmacy channel. Although this has not been a primary driver for our volume growth in the first half of the year, we are confident that it is the most efficient channel for patients, clinicians and for DexCom over the long term. The second area where we have thought to expand access is in the intensive insulin Type 2 population with an estimated more than 1.5 million people with Type 2 diabetes using real-time insulin. This population effectively doubled the addressable market of our core business in the U.S. Most importantly, CMS recognized when they first approved our CGM for the Medicare population. This is a group of patients that clearly stands to benefit from our technology for better glucose management and safer insulin dosing. Our proactive effort to drive these two initiatives will be crucial in driving CGM to the standard of care over the long term and has also been the primary factor behind the pricing headwinds that we've detailed throughout the year. While it will take time to realize the full benefit of these strategic priorities, we are pleased to report that we are gaining steady traction in both of these efforts. Our insulin delivery partners are progressing well toward the commercialization of integrated products. On the product side, both Tandem Diabetes and Insulet presented encouraging results at ADA related to their respective automated insulin delivery systems. We believe that these solutions will not only gain share among pump users, but will attract those interested in pump therapy. At ADA, we also announced our intent to integrate the DexCom G6 into Type 2. This represents yet another example of DexCom support of patient choice and interoperability in the diabetes ecosystem as we leverage our ICGM designation. We remain excited about our partnerships with Novo Nordisk on the smart pen side and with Eli Lilly on the development of both the smart pen and connected pump. As a reminder, the majority of people with diabetes on intensive insulin therapy around the world continue to choose insulin pens as their preferred means of insulin delivery, which highlights the importance of our smart pen relationships. In early June, we also announced a collaboration with smart pen maker, Companion Medical, which allows us to integrate insulin data from Companion's pen users into DexCom's Clarity software. We are committed to helping people, manage their diabetes by bringing together the two critical components of treatment decisions, glucose levels and insulin dosing to give patients and clinicians a comprehensive picture for their diabetes management. We intend to continue delivering additional sources of insulin data into the DexCom ecosystem over time. As Quentin mentioned, even as we roll out G6 to additional markets, the development of our G7 platform remains the key strategic objective for the company with a significantly reduced form factor, our market defining accuracy and a one-piece disposable wearable, we are confident that G7 will be highly desirable to our existing and prospective patients, as well as a product that accelerates our entrance into new markets outside of our core intensive insulin business. On this front, we are pleased to reaffirm our time lines for a limited launch in late 2020 and a broader launch in 2021. With that, I'll pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Steve. Any time you exit the first half of the year having reached full-year revenue guidance by $150 million or more than 10%, you know that the year must be going well and it has truly been a great first half of 2019 for DexCom. To grow at our current scale, there are a lot of things you have to come together, and this is a great testament to the team that we have here at DexCom to those in the field, in the clean rooms, and those thinking years down the road asking what's next. Thank you for your commitment to DexCom and to the people we serve. There is still a huge growth opportunity for DexCom's core business in diabetes and beyond. The technology that we worked so hard to develop positions us well to go after any significant market opportunity that we choose. In summary, it's been a great first half of 2019, but we're just getting started and we will not rest. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Senior Investor Relations Manager As a reminder, we ask the audience to limit themselves to only one question and one follow-up. Operator, please provide the complete Q&A instructions. Questions & Answers: Operator [Operator instructions] And the first question comes from Robbie Marcus with JP Morgan. Your line is open. Robbie Marcus -- J.P. Morgan -- Analyst Great. And congratulations on an another really nice quarter here. Maybe I could start, and I don't want to get greedy here and this is for Quentin. But after the big beats and raises you put up in the first half of the year with north of 45% growth in the first half of the year, guidance implies 17 to 25% growth in the back part of the year. I know there's a lot of moving parts here in terms of pricing as you switch from DME to pharmacy, Medicare international, but maybe as a catchall question here, Quentin, help us understand some of the moving pieces here and the impact that each of them have on guidance for the back part of the year? Quentin Blackford -- Executive Vice President and Chief Financial Officer Sure, Robbie. You point out the decelerating growth in the back half of the year, which is accurate. I think probably the most important thing just to draw everybody's attention to is the fact that comps get meaningfully more difficult in the back half of the year to the tune of roughly 15 to 20% percentage points of headwinds in the third and fourth quarter, respectively. So if you think back to the launch of G6 last year, you saw a growth in the back half of the year starting to get up into the mid-40s, even north of 50% in the fourth quarter. We are now anniversary-ing that and it creates a meaningful comp headwind. So I think you start to normalize for that and you get growth rates back into the ranges that you've seen in the first half of the year. So you have to be mindful of that aspect. And then, certainly, from a price perspective, we continue to anticipate double -- see those headwinds throughout the course of the back half of the year even probably accelerating just a bit in the fourth quarter when you start to contemplate some of the incremental moves that CMS has made with the Medicare business that will create a little bit of an incremental headwind from a pricing perspective. Although from a margin perspective, we feel pretty good that over time it's actually going to be beneficial to us as we no longer have to provide all the BGM supply. So we feel good about where that goes longer term, but it's going to create a bit of headwind. So I think those are the big moving pieces, but the biggest one being that the tougher comps. Robbie Marcus -- J.P. Morgan -- Analyst Okay. Great. And then follow-up question. Everybody's focus is ahead all the way to G7 as we sit here today. Can you lay out just the time lines of what we should expect? I know it's an ICGM filing that's going to be different than what we have historically seen for your different iterations. But give us sort of the time lines of what we'll see, when we'll see it, whether it's data presentations or manufacturing, ramping up and product out there? Now help us understand the time lines from here on now. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes, Robbie, this is Kevin. I'll take that one. We continue a lot on the development side on G7. We're making some very big decisions over the next couple of months before we lock in design and go. As far as clinical trial presentations in all Canada, we probably will not have much till the product is approved and the pivotal has been submitted to the FDA because we really don't want to play our hand. We are running small trials all over the place right now, looking at configurations and things we can consider putting in that product. But none of those are really contemplated for publication. [indiscernible] since our ICGM standards is we know what the outcome has to look like. Therefore, we're going to run a trial that will meet those outcome points and no one should be overly surprised or confident that the G7 platform will perform very well. We have some really wonderful things going into it and technology that we've been developing for years. As far as the launch, as Steve said in his remarks, it'll be a limited launch in late 2020. We will not have the capacity to roll it out to everyone in the fourth quarter and we are not going to try, and we do not want to -- we've learned enough about capacity this year. We are not going to relearn those lessons in even bigger way. We will then -- once we get approved, roll this thing out as we get our manufacturing plant up and fully ready to go to whereby we can support significant volumes. And other lesson we've learned on G6 from G5 is the conversions with new technology can actually be very fast. We probably underestimated the rate at which our patients will convert from G5 to G6 just given what we know about our patient behavior. We are not going to underestimate this conversion is going to go fast and it is going to be a wonderful product. So 2021, we really want the capacity to be able to swap everybody out. We will continue to support G6 in specific markets and with integrated products and such, the G7 becomes our flagship product by the end of 2021 with G6 supporting entirely different roles. Robbie Marcus -- J.P. Morgan -- Analyst Thanks a lot. Appreciate it. Operator And the next question comes from JP McKim from Piper Jaffray. Your line is open. JP McKim -- Piper Jaffray -- Analyst Hi, good afternoon. Thank you for taking the question. I'd like to just touch on the pharmacy, if you could just give us an update on where you are in terms of coverage and maybe volume going that way, and if you could touch a little bit on the Walgreens announcement? It was in the PowerPoint, but you didn't talk about it in your prepared remarks. So maybe talk about that partnership and what that could do for you guys going forward? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development I'll speak to the pharmacy question, and Kevin will give you an update on the Walgreen. We continue to make good progress on the pharmacy front in terms of adding vibes that are able to access the products through pharmacy coverage. So we continue to move down that path. I think, importantly, the new patients that continue to come into the company continue to come in through the pharmacy channel. We see good progress being made there. Obviously, we've got an existing business that we've put in place over the years. I've trained folks how to navigate through the DME channel and they're still accustomed to that. So that shift out of DME in the pharmacy on the existing base has gone a bit more slowly than what we see coming in with the new patients. So we fully anticipate that the business model over time will be through the pharmacy channel. We continue to push the organization down that pathway. We're making good progress, but there's still a lot of runway ahead of us, there's still a lot of room to go. So we'll continue to focus on it. You'll hear we talk about it for quite some time, I'm sure. Kevin Sayer -- Chairman, President, and Chief Executive Officer And with respect to Walgreens and that announcement, Walgreens has been a good partner of ours for quite a while. In fact, as we started pharmacy coverage for patients, one of our best distribution outlets in the early days was the Walgreens specialty pharmacies where our patients were -- could very easily get access to the technology via pharmacy benefit. Going forward, with all the data we gather from our patients and all the data we gather from our patients and other devices and other centers and such going forward. With Walgreens, they've and we view this as opportunity to be a very strong data partner for general healthcare. While we have certainly [indiscernible] ambitions and we need to partner in relationship. We think it'll be a great place for patients to get their product over time. And we're looking forward to working much closer together. So this is the beginning. And if you take a look at their website and how they've talked about this, it's pretty front and center, so we're very happy. JP McKim -- Piper Jaffray -- Analyst That's helpful. And Quentin, if he could just address like the delta and the growth rate between the segments, on transmitter, receivers, -- especially on the receiver side was down 4%. So I assume it has to do with international and the move into the pharmacy, but if you could just maybe give people some expectations around why the growth rate should be so different across the various products? Quentin Blackford -- Executive Vice President and Chief Financial Officer It's a great question, and to your point, the receiver is actually down from a dollar perspective in the reported figures. I can tell you from a unit basis, they were up significantly. And as Kevin pointed out in his prepared remarks, our new patient numbers were at record levels, an all-time record for us, again, in the second quarter. So volumes continue to trend very well. What you're seeing play out there is really a dynamic in how we think about strategically pricing the product for the future, both as we move into the pharmacy, but as well as we start to think about new product iterations like G7 over time, that start to remove the transmitter or the receiver component altogether. And so, where the values of getting placed is a bit different from a category perspective, but it's not reflective of the underlying volume growth in the business. So I think that's what are you seeing play out there. It's certainly something that we have made very distinct decisions around in terms of how we set up these pricing strategies. And you're now seeing it start to play through in the categories from a dollar perspective, but nothing that would indicate any underlying concerns or anybody needs to pay attention to. Volume growth is incredibly strong, new patient growth is strong as it has ever been. JP McKim -- Piper Jaffray -- Analyst Thank you. Operator And the next question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. Can you hear me OK? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah. Jeff Johnson -- Robert W. Baird and Company -- Analyst All right. Maybe I'll follow up on that question there and trying to move away from looking at centers versus transmitters versus receiver revenue. Conceptually, we thought of you guys kind of generate maybe $3,000 per year per patient in kind of ex-receiver revenue anyway. With G7 launching late next year into 2021 and going for maybe 10 to 14 or more likely, I think, 15 days, what do you think that $3,000 per year per patient revenue? How does that -- what are the puts and takes on where that could go? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes, Jeff, we're not going to get into the specifics of that price point. I think importantly, as we sit down with payers and negotiate positions, we tend to look at this from an average value per patient on an annual basis and so to the degree that we are going to give that information, we've put the playbook out there in front of everybody to see, particularly the payers, and you can imagine that since this is out there, you're going straight there. I think the important thing to note is that we understand the configuration of G7 when it comes into the marketplace. It's very different than the G6 product. We are having discussions with payers today around how we structure these contracts, so the G7 can come in very seamlessly and we move right into it. And so, the revenue does start to change across each of the buckets. And it does start to come down on an annual basis on a per user perspective. So as we move further into the pharmacy, we know it has to come down over time. And I would just point you back to our long-term goals. When we put out the 2 to $2.5 million of revenue, we absolutely anticipated that the revenue per patient has to come down over time, and we are playing right along the path where what we anticipated that might look like. We're executing nicely on that front and feel very good about the progress being made. Jeff Johnson -- Robert W. Baird and Company -- Analyst All right. Fair enough. And then on your fourth-quarter comments around Medicare and with that Class 2 bundle down, I think, 13 or 14% or something like that, you size that as one of the impacts why 4Q maybe modestly impacted or the guidance implies maybe a little bit slower growth then. How do we think about that into 2020, understanding you're not giving 2020 guidance, but is that around in there as we start thinking about 2020? Is that something we need to put a finer point on in our models thinking about next year's revenue growth, just that change in the Medicare dollars? Quentin Blackford -- Executive Vice President and Chief Financial Officer I think we need to be mindful of it. It is going to be a headwind for us as we now will have a full year of the impact relative to just one quarter of 2019. So it's certainly something that we'll speak more about as we get closer to the end of the year and start talking about 2020. But you're going to want to be mindful of it. I think importantly the ability to eliminate the BGM supply from the bundle or no longer having to provide that actually puts us in a position where it becomes margin accretive relative to the current position that we're in with Medicare channel. So overall, we view it as an opportunity from a margin perspective to show some improvement. It's not going to move the needle in a significant way, but it does become the headwind then. Jeff Johnson -- Robert W. Baird and Company -- Analyst Fair enough. Thank you. Operator And our next question comes from Margaret Kaczor from William Blair. Your line is open. Margaret Kaczor -- William Blair and Company -- Analyst Hey guys. Thanks for taking the questions. And maybe one for me switching over to the OUS dynamic a little bit. If you could walk us through the near- and long-term outlook and really what are the two or three scenarios for you guys in a bear and bull case? Where and when will market penetration be outside the U.S. above 20%, above 50% penetration? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I mean, look, I think for us Europe is lagging a little behind our penetrations in the U.S., but there is no reason that -- particularly in the reimbursed markets in Western Europe that over time, Western Europe should look a whole lot like our U.S business, as frankly should Japan and Canada and Australia and the other developed markets. We're not going to give obviously specifics on when and how quickly we think we can get to those levels of penetration. But it's coming. The European business, one comment I would make on the European business in revenues, particularly in the second quarter, is that our -- we've said this time and again on our calls that the European business because it's still predominantly through third-party distribution, tends to be a little more choppy. We don't have the same seasonality from DME deductibles that reset in the first quarter, and in the European distribution network, the order patterns just tend to be a little choppier. So the European business is still humming along. It's a big price buck for us, and we expect it to continue to be great from a growth perspective. Margaret Kaczor -- William Blair and Company -- Analyst Yes. And then Quentin, just wanted to follow up a little bit on some of the outsourced support organization and some of the commentary you guys had on that. Walk us through what you guys maybe have missed? What you guys are doing to fix it? And over kind of what time horizon should we still assume that we can contract toward the operating margin goal long term? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. I don't think you should have or walk away from the call with any incremental concern being added to an operating margin goal. We are tracking incredibly well from that perspective, and we feel great about the decision that we made there and it's going to be a really nice leverage point for us over time. I think the difference is when we stood up that Philippines operation, we started with really two paths. There was a direct DexCom employee base that has performed incredibly well and then there's a third-party outsourced component that we've utilized as well. And I think what we've learned is the standard that we hold ourselves to honestly is just not the same standard that other parties probably hold themselves to. And so, the question or the issue that we're starting to remedy is to get into those situations, elevate the standard that we expect and hold them accountable to deliver that for us and to us. I think it's going to be a few months here as we work through it. It's front and center, it is a priority for the team. We've got our resources all over it. The reality is we can do better. And I think that's what we're trying say here, is we understand the challenge. The experience can get better for our patients, we know that, and we're after it. And so, we're committed to investing and improving in that. I don't -- you shouldn't look at that as a significant investment beyond the current spend rate that you see us executing until now. Margaret Kaczor -- William Blair and Company -- Analyst Great, thanks. Operator And the next question comes from Joanne Wuensch from BMO. Your line is open. Joanne Wuensch -- BMO Capital Markets -- Analyst Thank you for taking the question. I just want to get my head around the move to the pharmacy channel a little bit more. It sounds like last quarter, you were able to announce a share that the Cigna had granted pharmacy benefit. Are there any other larger insurers that we -- you can give us an update on? Or another way to look at it, a percent coverage moment? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes, I'll take that. We haven't had any large contracts that we disclosed that have come to fruition this quarter, but we continue to roll along really well. One of the things we're struggling with, in all honesty, is having to find how much -- how many covered lines we have because we -- as we look at all the payers we have or our competitor may have, we're way about the same, but we don't really want to disclose that same percentage. We know we are well over 50%. We're always getting where we want to be. The more important factor, Margaret -- I mean, not Margaret, Joanne, I'm sorry, in this situation is we got to give patients move to the coverage that we have. And we continue to flow the new patients through there, that would be helpful. And as we continue to -- we'll just continue to have programs and you'll see a lot of effort there in the future. Our strategy has been working very well as we go before payers, and I've gone before a couple of them. Our presentation has been very strong, and we've been able to get the reimbursement that we're wanting and very frequently get to the pharmacy channel. So we -- but we've just have to keep knocking them out. Joanne Wuensch -- BMO Capital Markets -- Analyst Just as a follow-up. If I calculate this correctly on a dollar basis, your international revenue was flat sequentially. Am I looking at that right? And is there something going on there I should know about? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. You're looking at it correctly. I don't think there's anything there that you need to particularly be concerned about. I think from a sequential perspective, your point is accurate. To Steve's point earlier, this is a lumpy business. Nearly half of it is still close to the distributor channel, and I can tell you in a market or two, the matter of an order coming through in the first quarter or second quarter or falling into the third quarter, it can cross over from time to time. So we did have a little bit of that played out in the second quarter that would change the sequential trend. I think the important thing is when you look at new patient adoption, you look at existing patients' performance in these markets, it's consistent with what we've seen. There is no change in that trend. So I think you're seeing more of a timing issue when you look at it from a sequential perspective. In terms of the year over year, I think the other thing just to point out is you've got a meaningfully more difficult comp in the second quarter than what you had in the first quarter in this international business, nearly 30 points of incremental growth that showed up in Q2 of last year versus Q1, which again, I think, just kind of comes back and demonstrates the lumpiness in the international business. So nothing that we are concerned about playing out there. We still are incredibly bullish on the international business. The new patient opportunities continue to be strong and probably, most importantly, the overall adoption of our technology in the market is still quite liked, which leaves a lot of room to run. Joanne Wuensch -- BMO Capital Markets -- Analyst Thank you. Nice quarter. Operator And our next question comes from Danielle Antalffy from SVB. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hey, good afternoon, guys. Thanks so much for taking the question. Congrats on another really, really strong quarter. Quentin, I was hoping if you can give a little bit more color on the pricing headwind that you've seen so far year to date? I know you guys talked about 100 million for the year. How much that's been absorbed thus far? And how much incremental should we expect in the second half? And I have a follow-up. Quentin Blackford -- Executive Vice President and Chief Financial Officer Yes. So I think if you go back to the first quarter, we commented then it was a bit less than the $20 million. Here in the second quarter, it's closer to the 25 million that we've had commented on, on a per quarter basis. I would tell you it was right in line with expectations. I think in the back half of the year, we expect that to accelerate a bit. I think importantly, there's a couple of dynamics playing out. Certainly, the move into the pharmacy is a big priority for us, and we've talked very clearly around our intent to allow price to come down a bit to open up that channel. You've got the Medicare revision in their rates. That will play a bit into -- a bit of a headwind there as well. And then I think importantly, we're also seeing willingness and opportunity with the payers to continue to even move into DME channel to create easier access to product and technology. And so, we're willing to give a bit of price in that scenario as well, knowing that over time, it's going to have to walk itself down. So in those negotiations generally what happens is you're negotiating for easier access to the technology, less paperwork, less requirements in terms of logging glucose levels. Those are the kind of things that if we can make that easier for the patient, we are willing to concede pricing a bit because we understand that volumes are likely to pick up, and we certainly have seen that play out. So we've got that base into the back half as well. That should give you some color on the incremental price in the back half versus first. Danielle Antalffy -- SVB Leerink -- Analyst OK, that's helpful. And then my follow-up is at a very high level, Kevin. I don't know if you want to take this one, but you talked about, it's not necessarily been the pharmacy efforts in driving the outperformance. And I'm just curious if you can talk about, like, what has been driving the outperformance, what level of visibility do you have? You've raised guidance $150 million, but you've only beat consensus year to date by $65 million. So you clearly have some level of visibility into that, I would expect. And it sounds like it's expanded access, could you quantify at all, like how much over the last 12 months access has actually expanded as the percentage of your addressable patient population has increased by a certain percent or something? Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what, I'll walk through that. And if Steve and Quentin have anything they want to add, they're welcome to. I think there's a couple of factors. I think awareness has become a huge factor in our marketplace. Many more people are aware of CGM and what it can do now than ever been before. As we do our own marketing research and ask about our brand awareness and CGM awareness, the responses are much, much better than we've ever seen. I would tell you also, the G6 is a big deal. Those patients have learned about G6 and learned the experience they can have and all that it does. This has been extremely helpful in our growth. There's other well things, Tandem having an approved pump that's integrated with our system. It's certainly been helpful in driving new patients at DexCom, the growth in the international markets. And it's interesting. Oftentimes, we would look at growth, and I look back in the old days. I look at Steve. You all had asked us, what about peds? Is peds driving growth? Or -- and then recently, is Medicare driving growth? Every segment is growing. Every single business line is growing and growing nicely. Commercial business, the Medicare business, you look at peds and adults, they're both growing. You look at Europe, it's very much across the board. It is really driven by CGM awareness and the fact that people really are figuring out that this is something they really need to control and manage their diabetes. I don't know you if you guys have anything you want to add on that. Danielle Antalffy -- SVB Leerink -- Analyst Thanks so much. Operator And our next question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good afternoon. Just a couple for me. Maybe first quarter for Quentin. So Quentin, I think ADA was the first time you offered some qualitative specifics around what G7 COGS could be. I think, specifically, you said you think G7 COGS can get down to competitor levels at scale. I just want to be sure, there's a couple of things. What you think those levels are? How do you define scale from a revenue perspective? And what's diving your confidence now in kind of providing that kind of qualitative commentary? Kevin Sayer -- Chairman, President, and Chief Executive Officer This is Kevin. I'll take that, David. When we started the G7 project back in 2015, one of the things we put on the table was cost target. That was very aggressive, and we didn't think we'd ever be able to meet. But we marched through that cost target going forward. We know when we roll the thing out the door. In the beginning, we're not getting to that target. But over time, as we look at the cost of the electronics, the battery, the manufacturing processes, we're implementing that are different than anything we've done before. Even the number of parts in the insertion system, everything has been designed not only to perform at our standard, but it's been designed to manufacture. It's been designed to manufacture at a lower cost in a more reliable way. So we're very confident we can get to lower COGS. Quite honestly, I said in the meeting yesterday, our G6 COGS, as we get to volumes next year and as we increase our manufacturing capacity and fill out our initial plan, are going to come out significantly as well. Our COGS are moving in the right direction. It's just taking more time. And as we've invested dollars to expand before the expansion, you think it's getting a little bit tough on the absorption side. But as we fill that plant and keep working hard in San Diego, we're very confident we'll get there. But G7 is just designed completely different than anything we've ever done. David Lewis -- Morgan Stanley -- Analyst OK. Very helpful, Kevin. The second thing is just pharmacy coverage percentage. I think you said 50% last quarter. Can you just sort of update us what that number is today? I think one of your competitors shared that they were at 75% this quarter. So where are you guys today? And could you just -- can you give us any sense by year-end what percent of revenue you think will come through the pharmacy? And just a sense of scale on that number, what that number could be perhaps in a year from now? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah, this is Kevin. I'll go into a year from now because I think that's easier than today. We would be -- I can set a goal. We certainly would want to be in the 80% range as far as coverage a year from now. And that certainly is what we're shooting for. As far as where we are today, we know we're above 50%. We've gotten some more contracts. Having -- it's better than it was last quarter, but there's some -- we haven't a lot of these calculations. We've -- I've heard one number, 57%. I've heard others, above 60%. I don't have the perfect number for you, David, but we're comfortable where we. And like I said earlier in our comments, we've gone through each payer. We do this on a regular basis. What do we have, what do the rest of the market have? We don't see a lot of difference there. So maybe we compute our lives different over there. It doesn't matter. We're making the progress that we want to make. As far as the percentage of our business going through, I'll reiterate Quentin's comments. We've never disclosed that percentage, and we won't until it becomes very obvious. At the end of the day, our new patients are very much going over there. We have not launched a major effort to move the existing patients over there. And again, this relates to people being comfortable with how they process things in the past, having good insurance and coverage in DME. This is going to be a process that's going to take time, but we'll get there. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah. I mean, David. As we were talking in our preparations earlier today, Kevin pointed out, we spent 13 or 14 years, the last 13 or 14 years building a big DME business, and it's just not going to shift overnight. Our doctors, our field sales force, our patients are used to processing the existing business. So you'll see new patients shift to the pharmacy much quicker because we're, obviously, opening every new patient who comes in the door to see if we have pharmacy coverage, but transitioning the DME base over to pharmacy is going to take some time. David Lewis -- Morgan Stanley -- Analyst Great. Thank you. Nice quarter. Operator And your next question comes from Travis Steed from the Bank of America. Your line is open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Congrats on a great quarter again. So we've heard a lot about the capacity constraints, but both of you and from patients. So wanted to get a sense for how much the limiting factor capacity has actually been on adding new patients in the first half of the year and what you could see from a tailwind as you double capacity in the second half. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'll start. We don't think we've lost many new patients for capacity. The issue that we've had, literally, is timing of shipments and we've delayed things a bit. And at the end of the quarter, we really had filled pretty much everything. Patient-wise and direct patient-wise, that was on the books. The double capacity, the goals they have in place by the end of the year, we will not have double capacity running as we go through the rest of the year. That's a process that is ongoing, and we got some new processes. For example, we have our first fully automated G6 lines up and running here in San Diego, and we'll then replicate those lines over in Arizona over the next several months to get those things up and running. And the fully automated G6 processes really exciting leases for me to see. Over the course of the end of the year, again, you can see capacity is constrained just a bit. Still, we are delaying the Medicare launch till the fourth quarter. We have Canada coming online in the second half of the year, but it's not coming out immediately. And there are some other international geographies we want to be in with G6 as well when we last swap out the G5 patients, particularly those in our European markets and in our existing Medicare base. So we're still a bit constrained on all the things we would like to do. But we'll work through it, and we think by then end of the year, we'll be in a very good place. Travis Steed -- Bank of America Merrill Lynch -- Analyst Great. And Quentin, gross margin in the first half of the year, low 60% range, and still committing to that, approaching 70% by Q4. Anything you can give us confidence on to -- really in the ramp in the back half in gross margin. How much of that is coming from the lower-cost transmitter versus other things? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yeah, sure. It's a great question. And the vast majority of our ability to get that 70% range in the fourth quarter is really tied to that lower-cost transmitter. So I think what you want to plan to see is Q3 will step probably somewhat in line with what you saw Q2 over Q1b. I think you'll see that same kind of sequential improvement. I think you'll see the nice improvement in the fourth quarter to 70%. In terms of trying to deliver a little bit of confidence or help you become more confident in that number, we've got our first low-cost units off the production lines as we speak. So we're producing them now in San Diego. They've come off the lines in Mesa. We have a high degree of confidence in being able to scale that up and ramp it. And so, our confidence level is quite high that we can get to these numbers. Operator And our next question comes from Doug Schenkel from Cowen. Your line is open. Ryan Blicker -- Cowen and Company -- Analyst Hi. This is Ryan, on for Doug. You talked of making steady progress, expanding coverage for intensively managed Type 2 patients in the U.S. Is there anything more quantitive you can say? I believe Medicare represents about a third of this patient population. How much progress have you made within commercial payers, specifically? Do 50% of commercial labs have coverage, or anything close to 50%? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development It's a great question. I'm not -- I don't know that we have a specific answer for you. We continue to make progress, certainly as we push to move into pharmacy, pushing for greater access for intensively managed Type 2 is right at the top of the list. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah. And an example I can give you is in the past, as you go back a couple of years, one of the things we would give up to get better access for our Type 1 patients was Type 2 access sometimes in our contractual pricing discussions. That's not going on now. We are pushing aggressively to get the Type 2 insulin users covered. And quite honestly, having CMS issue that type of guidance has been very helpful for us. It's been a catalyst for us to go to payers and say, \""Look, if Medicare patients get this, so should the others.\"" So we're making progress, but we're not there yet. Ryan Blicker -- Cowen and Company -- Analyst OK, that's helpful. And then I apologize if I missed this. I think, previously, you had talked about launching a decision support system for MDI patients, along with the smart pen partner around late this year or early next year. Is that still on track? Or has that been pushed out a little bit? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah. So our first commercial smart pen launch will be together with Companion, right, where we're doing a -- it's really a retrospective review of insulin data together with CGM data in our clarity system. With respect to a real-time display of insulin in the DexCom app, that's still could happen later this year or first part of next year. We haven't been specific with who and what that product might look like, but we're still making good progress. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'll just add to that. We don't view that as a revenue driver as we sit here today. That would be nice to have. Operator And the next question comes from Jayson Bedford from Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Thanks. Just a couple of quick ones here. In terms of the new transmitter, I realize the COGS benefit to DexCom, but are there features and benefits to users? Kevin Sayer -- Chairman, President, and Chief Executive Officer It's identical to the existing G6 transmitter. But I will add, we couldn't go to direct to- pple Watch until we get to this new configuration. So there is some better electronics we'll be able to use the features on and get some new firmware in, and such. But as far as performance, that's, I guess, I -- it's my understanding, the range is a little bit longer, but it's not a huge change. Jayson Bedford -- Raymond James -- Analyst OK. And then I just want to get back to the international commentary about kind of flat sequential. You mentioned that half the business goes through distributors. Did you see more consistency from the direct business? And I guess, the other question is have you seen any change in market dynamics in Europe? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yeah. We do see more consistency in that direct business. That revenue cycle is a little bit different. We're recognizing revenue upon the sales to the end-user, whereas the distributor, generally, they'll take inventory positions, work though inventory, replenish and so forth. So you get a bit more lumpiness in that distributor business than you do in the direct. In terms of end market trends or anything changing, no, and I think we were pretty clear with the comments earlier. The new patient numbers continue to be a very nice for us, continue to track in terms of what we've seen historically from the overall international business. Existing patient trends, from an overall international perspective, looking very good as well. And so, again, I come back to, it's a bit of lumpiness. You got a tough comp. Honestly, you're going to have a tough comp in the third quarter as well in the international business. Last year, the third-quarter growth rate was even beyond what it was in Q2. So I think you'll see this again for another quarter. And then I think you'll start to see it pick up again in the fourth quarter. But nothing unusual here, nothing that is drawing our concern. We stayed very close to it. We understand the patient dynamics quite well and we're very encouraged with what we see. Operator And your next question comes from Raj Denhoy from Jefferies. your line is open. Raj Denhoy -- Jefferies -- Analyst I guess I -- it's late in the call, but I figure I'll ask the question anyway, just on competition, right? So that's been asked on most conference calls. We're still waiting for Libra 2.0 to get approved here. I guess do you any updated thoughts on that product or the competitive landscape and really anything about the delay on the product getting approved? Kevin Sayer -- Chairman, President, and Chief Executive Officer No, we don't. And we're not going to give them our air time. We've dealt with competition ever since we've been here, and we'll deal with that one when it comes. So no, we don't have anything to add. Raj Denhoy -- Jefferies -- Analyst Fair enough. For my second question, I just wanted to ask about your expectations around -- and you mentioned some of the pump partnerships, and I guess, over the next several months, we're going to see the first automated insulin delivery systems with your CGM. Do you have any thoughts on what that could do to CGM adoption or your growth really into next year? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development You mean, I'll somewhat defer to Tandem. But their latest public guidance is that their in control system would launch in Q4 of this year. So that will be a DexCom G6 sensor with a DexCom/TypeZero algorithm running on the Tandem X2 pump. The beauty -- as I said before, the beauty of the architecture of that -- the current system with Basal-IQ is that patients who are already taking advantage of the G6 system with Basal-IQ will be able to field-upgrade their system. So many of their existing patients are already joint patients that are already using the G6 system. It remains to be seen as -- I've said this a number -- on a number of occasions, do these automated insulin delivery systems -- as we get more automation, does that kind of reinvigorate, reaccelerate growth in the pump market? And I think we're optimistic that it does, and so to the extent we attract new patients and do pump therapy, be it Tandem, Insulet, that's obviously a benefit for all of us. Raj Denhoy -- Jefferies -- Analyst OK, that's helpful. Thank you. Operator And the next question comes from Chris Pasquale from Guggenheim. Your line is open. Chris Pasquale -- Guggenheim Partners LLC -- Analyst Yeah, thanks. Quentin, I want to follow up on the question about gross margins. You had talked about not assuming that the level with every office is a sustainable one for you in 2020 given ongoing pricing pressure. Could you just update thoughts on where gross margin shakes out over the course of the next 12 to 18 months? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yeah. Again, we're not going to get on into setting the expectation for 2020 just yet. Obviously, you'll see where the fourth quarter is expected to exit. And again, we feel very good about that number approaching the 70% range. So I think it talks to the potential that we have in front of us, but we are trying to be very transparent about the fact that the pricing headwinds are going to continue to exist. We're going to continue to navigate toward the pharmacy channel. We know Medicare is a bit of a headwind from a top line, but from a margin perspective without giving the CGM supplies, we actually feel like that could be a bit accretive. So we'll get more color as we start to get closer to the end of the year or exit the year, but I don't think you should anticipate it being up at that 70% range that we see in Q4. I think that's a fine starting point, but then you start model in the pricing headwinds that we talked about and the pressure that comes from the shifting mix of the business even as OUS becomes a bigger component, you can start to work yourself into a number, but we're not going to give any more specifics than that at this point. It's too early. Chris Pasquale -- Guggenheim Partners LLC -- Analyst That's fine. That's helpful. And then if I do a little bit of math here on the duplicative cost piece that you talked about. It looks like it was about 7 or $8 million in the quarter by my math. Is that in the right ballpark? And how does that trend over the back half of the year? Does it stay in there? Or does it gradually come out? Quentin Blackford -- Executive Vice President and Chief Financial Officer Yeah. I think you're a little bit high, to be honest with you. You're not meaningfully off, but you're bit on the higher end of where that is. So I wouldn't look at that and annualize that per se, but you're getting down the right path. We do think that that start still alleviate a bit in the back half of the year. So one of the things that we said that we would do and be very careful about was we would ensure that we have the capabilities stood up in our new facility before we let resources go here. And we are now demonstrating that. We have had a wave of resources go or two. We'll see that continue to play out in Q3. And so, the duplicative costs will start to step down in the back half of the year. Operator And the next question comes from Steven Lichtman from Oppenheimer. Your line is open. Steven Lichtman -- Oppenheimer Thank you. Hi, guys. As you continue to move toward G7, I was wondering if you can give update us on your latest thoughts on how you see the usage model within the non-intensive patient population. Do you still expect it to be intermittent use? Just related thoughts overall and moving into that large channel long term. Kevin Sayer -- Chairman, President, and Chief Executive Officer Long term, if we had a device that would be we reimbursed that patient could wear all the time, I think they would wear it. The issue becomes what is going to be reimbursed and what type of model is going to serve those patients best from a cost perspective. I can't tell you and give you feedback on at least three programs we're aware of or intermittent use of G6 is going on right now. And different levels of intermittent use. Some wear for three months straight, some wear one. Some wear it for one month, depending upon where they are. And the outcomes in these patients exceed anything ever in a Type 2 patient in any drug. They learn more from wearing the sensor than any pharmaceutical product that's ever been introduced in that market. We're very optimistic we can make a big difference there. And we will continue to work on that business model with our G6 platforms and with those parties we're working with, the programmatic people, the payers and such to develop the right model. So when we're ready, we're ready to go. And we would -- and quite honestly, we would walk away from an opportunity if somebody wants to use G6. It's just not the perfect product with the reusable three-month live transmitter to attack out, but we're learning a lot. We've committed a lot of resources to this. We're very confident we can make a huge difference, but the business model has yet to be developed. Steven Lichtman -- Oppenheimer Great. That's helpful, Kevin. And then just secondly, on international, Steve, you mentioned Japan briefly. I was just wondering if you could provide an update on that opportunity and when you think you can start becoming a personal and not just professional use there? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah, we're still working through the regularly aspects of G6 in Japan. So if you remember, we actually launched in Japan with a professional version, utilizing the G4/G5 sensor platform. So I would tell you, it's probably not before the end of this year, but probably sometime. I'm hoping in the first part of next year, we're launching G6 as a direct-to-patient consumer use product. Operator And our next question comes from Suraj Kalia from Northland Securities. Your line is open. Suraj Kalia -- Northland Capital Good afternoon everyone. Thanks for taking my question. Kevin, can you hear me all right? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah, I can hear you fine. Suraj Kalia -- Northland Capital Perfect. So just one question. Most of the questions have been asked, but maybe this is better positioned for Quentin. Quentin, I know this whole thing about you all have been consistent about Q4 margins stepping up to 70%, at least the math you have suggested is Q3 is going to be give or take 63% and then it steps up to 70%. Can you help us fill in the blanks here? So I just did some rough math. If the transmitters, those are the ones that are going to cost a step change, am I right that they have to be 80%-plus gross margins on that? How should we think about that because I'm not getting to that 70%? Any additional fill in the blanks would be greatly appreciated. Quentin Blackford -- Executive Vice President and Chief Financial Officer Yeah. I don't think, Suraj. We've never given specific gross margin profiles of any particular product of ours. But I would tell you, the cost reduction that we have in that transmitter from where it was is significant. It is orders of magnitude less cost than what it used to be. So we're not going to give you the specifics, but it was a very meaningful reduction. The team did an incredible job, really both the R&D teams and operations teams combined in designing cost out from a design perspective, but also just the process of manufacturing the product with the whole team effort that generated incredible benefit. Operator And that concludes the question-and-answer session. I'll now turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, operator. I guess I want to talk about one other recurring theme at ADA that kept coming to me over and over again. I met numerous people there that I've known for a number of years who have Type 1 diabetes, and I literally heard the same thing over and over again. I haven't stuck my finger for six months, I haven't stuck my finger for eight months. I heard a story from one patient who said he rubbed his wife on the -- on her shoulder, and she said for the first time in many, many years, his fingers didn't have scales on them or weren't rough. Other patient said I've never been healthier in my life because this is so easy to use. One well-known position, actually, we took the opportunity to make me aware of the responsibility we have as a company because these patients relying now only on G6 to manage all their diabetes, and no one sticks their finger anymore. These are great stories. But to assume that type of responsibility, we have to be really good. And we have to continue to perform on the financial side, so we can meet our goals on the technology, manufacturing and operations side. There are things we have to do better. As Quentin said earlier, we will address our customer service area, particularly outside service, and we will get that in line with all of the wonderful experiences our patients have with our product. We appreciate everybody's continued support, our patients, the physician community, our investors and especially our employees. Our sustained performance -- and this actual performance we have over the first half of the year only shines a brighter light on what we think is going to happen in the future. Thank you. Operator [Operator signoff] Duration: 66 minutes Call participants: Sean Christensen -- Senior Investor Relations Manager Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin Blackford -- Executive Vice President and Chief Financial Officer Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Robbie Marcus -- J.P. Morgan -- Analyst JP McKim -- Piper Jaffray -- Analyst Jeff Johnson -- Robert W. Baird and Company -- Analyst Margaret Kaczor -- William Blair and Company -- Analyst Joanne Wuensch -- BMO Capital Markets -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst David Lewis -- Morgan Stanley -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Ryan Blicker -- Cowen and Company -- Analyst Jayson Bedford -- Raymond James -- Analyst Raj Denhoy -- Jefferies -- Analyst Chris Pasquale -- Guggenheim Partners LLC -- Analyst Steven Lichtman -- Oppenheimer Suraj Kalia -- Northland Capital More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Bank of America Maintains Buy on DexCom, Raises Price Target to $185"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $186"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $160"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $172"", ""DexCom, Inc. (DXCM) CEO Kevin Sayer on Q2 2019 Results - Earnings Call Transcript""]"
DXCM,2019-08-02,37.2775,37.2775,35.44,36.0525,"[""CAM Group Holding A Buys MSCI Inc, Anthem Inc, Teleflex Inc, Sells Johnson & Johnson, ..."", ""S&P 500 Breaks Support Level Of 2,950; Next Stop: 2,900. Meanwhile Buy Square"", ""CAM Group Holding A Buys MSCI Inc, Anthem Inc, Teleflex Inc, Sells Johnson & Johnson, ..."", ""S&P 500 Breaks Support Level Of 2,950; Next Stop: 2,900. Meanwhile Buy Square"", ""CAM Group Holding A Buys MSCI Inc, Anthem Inc, Teleflex Inc, Sells Johnson & Johnson, ..."", ""S&P 500 Breaks Support Level Of 2,950; Next Stop: 2,900. Meanwhile Buy Square""]"
DXCM,2019-08-05,35.3725,35.8575,34.8825,35.5325,"[""MannKind: Afrezza Scripts And New Marketing"", ""MannKind: Afrezza Scripts And New Marketing"", ""Implied VONG Analyst Target Price: $179 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 1000 Growth ETF (Symbol: VONG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $179.46 per unit. With VONG trading at a recent price near $163.12 per unit, that means that analysts see 10.02% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VONG's underlying holdings with notable upside to their analyst target prices are Lions Gate Entertainment Corp (Symbol: LGF.A), DexCom Inc (Symbol: DXCM), and IAC/InterActiveCorp (Symbol: IAC). Although LGF.A has traded at a recent price of $12.64/share, the average analyst target is 67.13% higher at $21.12/share. Similarly, DXCM has 19.13% upside from the recent share price of $144.21 if the average analyst target price of $171.80/share is reached, and analysts on average are expecting IAC to reach a target price of $280.21/share, which is 18.35% above the recent price of $236.77. Below is a twelve month price history chart comparing the stock performance of LGF.A, DXCM, and IAC: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""MannKind: Afrezza Scripts And New Marketing""]"
DXCM,2019-08-06,35.795,36.9875,35.795,36.9125,"[""Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance."", ""Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance."", ""Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.""]"
DXCM,2019-08-07,36.6025,37.0,35.88,36.8275,
DXCM,2019-08-08,37.17,38.9275,37.17,38.55,"[""DexCom shares are trading higher on seemingly no company-specific news."", ""DexCom shares are trading higher on seemingly no company-specific news."", ""DexCom shares are trading higher on seemingly no company-specific news.""]"
DXCM,2019-08-09,38.26,39.09,38.26,38.86,"[""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating"", ""Dexcom Clears Technical Benchmark, Hitting 90-Plus RS Rating""]"
DXCM,2019-08-12,38.47,38.75,37.6575,37.9825,"[""Dexcom: An Interested Bet On CGM Dominance"", ""Dexcom: An Interested Bet On CGM Dominance"", ""Dexcom: An Interested Bet On CGM Dominance""]"
DXCM,2019-08-13,38.4075,39.55,37.6735,39.325,"[""DexCom (DXCM) Investor Presentation - Slideshow"", ""\ufeffShares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products."", ""Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products."", ""DexCom (DXCM) Investor Presentation - Slideshow"", ""Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products."", ""DexCom (DXCM) Investor Presentation - Slideshow""]"
DXCM,2019-08-14,38.5625,38.7425,37.81,38.375,"[""Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession."", ""Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession."", ""Noteworthy Wednesday Option Activity: MDCO, DXCM, URBN Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Medicines Co (Symbol: MDCO), where a total of 6,696 contracts have traded so far, representing approximately 669,600 underlying shares. That amounts to about 63% of MDCO's average daily trading volume over the past month of 1.1 million shares. Particularly high volume was seen for the $31 strike put option expiring August 16, 2019, with 1,483 contracts trading so far today, representing approximately 148,300 underlying shares of MDCO. Below is a chart showing MDCO's trailing twelve month trading history, with the $31 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 5,375 contracts thus far today. That number of contracts represents approximately 537,500 underlying shares, working out to a sizeable 59.9% of DXCM's average daily trading volume over the past month, of 897,050 shares. Particularly high volume was seen for the $175 strike call option expiring September 20, 2019, with 1,203 contracts trading so far today, representing approximately 120,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $175 strike highlighted in orange: And Urban Outfitters, Inc. (Symbol: URBN) saw options trading volume of 12,261 contracts, representing approximately 1.2 million underlying shares or approximately 58.3% of URBN's average daily trading volume over the past month, of 2.1 million shares. Particularly high volume was seen for the $22 strike put option expiring August 23, 2019, with 5,165 contracts trading so far today, representing approximately 516,500 underlying shares of URBN. Below is a chart showing URBN's trailing twelve month trading history, with the $22 strike highlighted in orange: For the various different available expirations for MDCO options, DXCM options, or URBN options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.""]"
DXCM,2019-08-15,38.375,39.6875,38.375,39.6325,"[""DexCom: G7 Will Change Everything"", ""DexCom: G7 Will Change Everything"", ""DexCom: G7 Will Change Everything""]"
DXCM,2019-08-16,39.795,41.2725,39.635,40.92,"[""Stocks That Hit 52-Week Highs On Friday"", ""Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal."", ""Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal."", ""Stocks That Hit 52-Week Highs On Friday"", ""Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal."", ""Stocks That Hit 52-Week Highs On Friday""]"
DXCM,2019-08-19,41.5825,41.915,40.56,40.8975,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Stocks That Hit 52-Week Highs On Monday"", ""Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war."", ""Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war."", ""Stocks That Hit 52-Week Highs On Monday"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war."", ""Stocks That Hit 52-Week Highs On Monday"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Charting a bullish reversal, S&P 500 extends rally from major support Focus: Utilities break to record territory, XLU, WEN, DXCM, ITRI, SONO, ALLK U.S. stocks are firmly higher early Monday, rising amid renewed trade-related optimism, as well as China\u2019s stimulus move, signaled over the weekend. Against this backdrop, the S&P 500 has extended its bullish reversal from major support (2,817), punctuating its third successful retest in as many weeks.""]"
DXCM,2019-08-20,40.86,42.365,40.6175,42.07,"Forget the Inverted Yield Curve, These 3 Stocks Just Hit All-Time Highs You've probably heard the phrase ""inverted yield curve"" more over the last week than you have during the last three years. Some are now worried that a recession could be imminent. While inverted yield curves can be predictors of oncoming recessions, it's important to note that those recessions sometimes don't happen for several years. And the yield curve can quickly reverse its inversion. It's already happened earlier this year. More importantly, stocks can continue to perform very well even while bond yields appear to be out of whack. Three healthcare stocks are proving this point and then some. DexCom (NASDAQ: DXCM), Edwards Lifesciences (NYSE: EW), and West Pharmaceutical Services (NYSE: WST) just hit all-time highs. Here's why these stocks continue to soar despite overall market uncertainty and whether they're smart picks to buy now. Image source: Getty Images. 1. DexCom Back in March, a short-seller published a report that predicted DexCom's shares would plunge 50% or more with the company's leadership in the continuous glucose monitoring (CGM) market threatened. While that report temporarily caused DexCom stock to drop, its predictions haven't panned out so far. DexCom is up close to 40% so far this year. The reason behind DexCom's great performance is that business is booming for its G6 CGM system. In DexCom's second-quarter results announced three weeks ago, the company easily beat Wall Street revenue and earnings estimates. DexCom reported year-over-year revenue growth of 39% thanks to higher sales for the G6 CGM system. CEO Kevin Sayer stated in the company's Q2 conference call that DexCom is ""just scratching the surface of the potential"" for its CGM technology. Thus far, CGM has focused on patients with diabetes who require intensive glucose monitoring to regulate insulin administration. However, the company is exploring the use of its CGM system beyond these traditionally intensive insulin-using patients by conducting studies for the use of CGM in pregnancy and inpatient settings. The company also is developing the successor to the G6 CGM. Sayer stated that DexCom expects a limited launch of the new G7 CGM system in late 2020 with a broader launch in 2021. The G7 system will be a fully disposable CGM that's significantly smaller than the G6, less expensive, and will have a longer extended-wear period. 2. Edwards Lifesciences Edwards Lifesciences is another medical device stock that's having a great year so far. Its shares are up over 40% year to date, with no signs of investor fatigue yet. Like DexCom, Edwards Lifesciences reported strong second-quarter results driven by increasing demand for its products. The company posted 15% year-over-year revenue growth, topping analysts' projections. Edwards' success has been fueled mainly by its transcatheter aortic valve replacement (TAVR) artificial heart valves, its surgical structural heart and critical care solutions, and its new Pascal transcatheter mitral system. Innovation is key to Edwards Lifesciences' growth. The company already launched its Sapien 3 Ultra heart valve in Europe and won U.S. Food and Drug Administration (FDA) approval for the TAVR artificial heart valve this week. The company also thinks that increased adoption of TAVR therapy will be a tailwind in the future. Edwards Lifesciences CEO Mike Mussallem said in the company's Q2 conference call that ""we are increasingly confident that there are many patients who would benefit from TAVR and who are not diagnosed, referred, or treated today."" Mussallem also noted that the company anticipates solid international growth because of relatively low TAVR therapy adoption outside of the U.S. 3. West Pharmaceutical Services West Pharmaceutical Services has delivered the most impressive year-to-date performance of these three healthcare stocks at all-time highs. Shares have jumped nearly 50% so far in 2019. West specializes in making containment and delivery systems for injectable medicines. The company doesn't usually generate spectacular growth. However, West has consistently beaten Wall Street earnings estimates this year and boosted its full-year 2019 revenue and earnings guidance in July. The company's NovaPure and Westar components have been especially popular with customers that develop biologic drugs, which are made from living organisms. That's great news because biologic drugs themselves have become more prevalent. Eight of the top 10 best-selling drugs last year were biologics. West Pharmaceutical Services is also growing through acquisitions. The company recently acquired its distributor in South Korea to establish a more direct presence in the important Asian market. CEO Eric Green stated in the Q2 conference call that the company will ""continuously look at bolt-on technologies that will enhance our current portfolio."" Are they buys? I like two of these three high-flying stocks. My view is that DexCom should have plenty of room to run, with continued momentum for its G6 CGM and tremendous potential for its new G7 CGM on the way. I also think that Edwards Lifesciences' prospects look great, especially now that it's won FDA approval for the Sapien 3 Ultra heart valve. But while I like West Pharmaceutical Services as a business, I'm not convinced the stock can keep its upward trajectory going for too much longer. Shares trade at more than 42 times expected earnings. West isn't growing fast enough to deserve that lofty valuation, in my opinion. 10 stocks we like better than Edwards Lifesciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Edwards Lifesciences wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-08-21,42.5,43.35,42.1525,43.2975,"[""Bridger Management, Llc Buys Alcon Inc, Humana Inc, HCA Healthcare Inc, Sells Laboratory Corp ..."", ""The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform"", ""Bridger Management, Llc Buys Alcon Inc, Humana Inc, HCA Healthcare Inc, Sells Laboratory Corp ..."", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform"", ""Bridger Management, Llc Buys Alcon Inc, Humana Inc, HCA Healthcare Inc, Sells Laboratory Corp ...""]"
DXCM,2019-08-22,43.3325,43.8725,42.77,43.5925,"[""Aubrey Capital Management Ltd Buys Noah Holdings, Sea, CareDx Inc, Sells Huazhu Group, Momo ..."", ""MannKind - 'Fireside' Chat With CEO Mike Castagna"", ""The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study"", ""MannKind - 'Fireside' Chat With CEO Mike Castagna"", ""Aubrey Capital Management Ltd Buys Noah Holdings, Sea, CareDx Inc, Sells Huazhu Group, Momo ..."", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study"", ""MannKind - 'Fireside' Chat With CEO Mike Castagna"", ""Aubrey Capital Management Ltd Buys Noah Holdings, Sea, CareDx Inc, Sells Huazhu Group, Momo ...""]"
DXCM,2019-08-23,43.685,44.1475,43.1112,43.3875,"[""Dexcom prevails in patent dispute with WaveForm Tech"", ""Stocks That Hit 52-Week Highs On Friday"", ""Court Rules That Patents Asserted Against Dexcom CGM Systems Are Invalid"", ""Court Rules That Patents Asserted Against Dexcom CGM Systems Are Invalid"", ""Stocks That Hit 52-Week Highs On Friday"", ""Dexcom prevails in patent dispute with WaveForm Tech"", ""Court Rules That Patents Asserted Against Dexcom CGM Systems Are Invalid"", ""Stocks That Hit 52-Week Highs On Friday"", ""Dexcom prevails in patent dispute with WaveForm Tech""]"
DXCM,2019-08-26,43.75,43.875,43.2125,43.6725,"Notable ETF Outflow Detected - FXH, PODD, DXCM, UHS Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $40.9 million dollar outflow -- that's a 3.6% decrease week over week (from 15,150,002 to 14,600,002). Among the largest underlying components of FXH, in trading today Insulet Corp (Symbol: PODD) is up about 1.3%, DexCom Inc (Symbol: DXCM) is up about 0.8%, and Universal Health Services, Inc. (Symbol: UHS) is higher by about 0.1%. For a complete list of holdings, visit the FXH Holdings page » The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $63.8401 per share, with $85.3074 as the 52 week high point — that compares with a last trade of $74.77. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-08-27,44.04,44.5875,43.6125,43.75,"[""Stocks That Hit 52-Week Highs On Tuesday"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The 52-Week Highs You Never Heard About The fear-mongering media had quite a few factors to scare investors with last Friday: the U.S.-China trade war, President Trump\u2019s latest tweets, and the plummeting S&P 500. Underneath the big selloff, would you ever guess that plenty of stocks made new 52-week highs that very same day? No, I\u2019m not talking about the good old \u201cFANG\u201d stocks \u2013 Facebook (NASDAQ:), Amazon (NASDAQ:), Netflix (NASDAQ:) and Google (NASDAQ:), which fell 2.4%, 3%, 1.8% and 3.2%, respectively. In fact, the FANG stocks have been well off their highs for at least a month \u2013 if not 10 or 11 months! However, several of my stocks did hit new 52-week highs\u2026including DexCom, Inc. (NASDAQ:), Lockheed Martin Corp. (NYSE:) and NextEra Energy, Inc. (NYSE:), one of my Top 5 Stocks in my Growth Investor service. A medical device maker, a defense contractor, and a power company\u2026what a motley crew. Well \u2013 what do these stocks have in common? Take a look at how these companies measure up in my Portfolio Grader and I think you\u2019ll spot the common thread: Yep, this diverse group of stocks from different corners of the U.S. economy all earned an \u201cA\u201d for their Quantitative Grade. That formula is one of the most important aspects of the stock-picking system behind Portfolio Grader. And it\u2019s responsible for all the best wins of my investing career \u2013 so let me explain what I\u2019m measuring here: Essentially, a stock\u2019s Quantitative Grade lets you know whether or not it is experiencing strong buying pressure. Simply put, I believe in \u201cfollowing the money.\u201d If the \u201csmart money\u201d on Wall Street, like hedge funds and mutual funds, is pouring into a stock, that provides great momentum to keep the stock moving higher, all in itself. If the smart money is avoiding a stock \u2013 that\u2019s a major red flag. For example, most all of the FANG stocks currently have a \u201cC\u201d for their Quantitative Grade. Not terrible\u2026but DXCM, LMT and NEE are simply better favored on Wall Street, as shown by their \u201cA\u201d grades. And the new 52-week highs demonstrate that. Energy stocks, on the other hand, are racking up lots of \u201cDs\u201d and even \u201cFs\u201d for their Quantitative Grade. So, while many of them have juicy dividend yields, the incredibly weak stock performance cancels out that thesis for investing in energy at this time. This all being the case\u2026it won\u2019t surprise you to learn that at , we\u2019re largely avoiding energy. By focusing on companies with strong fundamentals, and popularity on Wall Street \u2013 even if they don\u2019t receive much press \u2013 we\u2019ve been able to ride stocks like DXCM, LMT and NEE to new 52-week highs, despite the volatile market. In fact, at , we\u2019ve enjoyed such strong relative performance that we haven\u2019t had to sell any stocks in three months. So would I recommend that you respond to the trade-war terrors by dumping your stocks? No. I would recommend, however, that you . For example, you might not want a portfolio that\u2019s overly exposed to Europe \u2013 given that President Trump has proposed tariffs on EU goods as well. While the \u201cbig fish\u201d is Airbus (OTCMKTS:), the European rival to The Boeing Company (NYSE:), consumer staples like olive oil, wine and cheese may also incur the extra tax. Tariffs or no, I say \u201cbuy American\u201d is the way to go, anyway. When you get down to it, the United States is not only the country with the largest economy \u2013 but we also have some of the best growth prospects as well. At this point, countries from Sweden to Japan and even Germany are even willing to resort to negative interest rates to juice their growth. This is largely why global capital is pouring into the U.S. bond market\u2026and the U.S. stock market has been the oasis for quite some time already, and clearly, it still is today. As you see below, the S&P 500 (with its 14% year-to-date gain) is beating other global indexes by a mile. Out of those 500 stocks \u2013 which becomes more like 5,000 when you factor in the whole U.S. market \u2013 how do we find the cr\u00e8me de la cr\u00e8me? Well, . You already saw Step 1 earlier: \u201cfollow the money.\u201d to profit and protect yourself. These days, if you want to invest with the \u201csmart money,\u201d you\u2019ve got to have a healthy weighting in bulletproof stocks like my . Not only did these stocks earn an A in my Portfolio Grader, thanks to strong buying pressure and great fundamentals\u2026 The stocks also earn an A in my Dividend Grader. These stocks are able to pay great yields \u2013 and have the strong business model to back it up! All in all, I\u2019ve got 27 strong dividend growth stocks for you, almost all of which yield more than the S&P 500. These stocks are poised to do well as we continue to see international capital flow to the U.S. markets. , and how you can get great performance out of YOUR portfolio \u2013 come what may. Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system \u2014 with . In his latest feat, Louis discovered the \u201cMaster Key\u201d to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. The post appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Tuesday""]"
DXCM,2019-08-28,43.22,44.6125,43.0,43.7975,
DXCM,2019-08-29,44.45,44.45,42.8775,43.015,"[""Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists"", ""DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $195"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $195"", ""Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists"", ""DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $195"", ""Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists"", ""DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?""]"
DXCM,2019-08-30,43.0975,43.2575,42.27,42.9025,"[""DexCom: The Best Medical Equipment Stock To Buy Now"", ""DexCom: The Best Medical Equipment Stock To Buy Now"", ""DexCom: The Best Medical Equipment Stock To Buy Now""]"
DXCM,2019-09-03,42.5,43.15,42.325,43.065,"[""BMO Capital Maintains Outperform on DexCom, Raises Price Target to $190"", ""10 Biggest Price Target Changes For Tuesday"", ""10 Biggest Price Target Changes For Tuesday"", ""BMO Capital Maintains Outperform on DexCom, Raises Price Target to $190"", ""5 Internet of Things Stocks to Buy Now The internet of things has been a hot topic for years now, but with a 5G revolution right around the corner, connected devices are garnering more and more attention. Trade tension with China has made the market shaky, especially in the tech space. However, when it comes to picking stocks to buy in the technology sector, the internet of things is a great place to start. Here\u2019s a look at five stocks that offer exposure to the fast-growing internet of things market. Internet of Things Stocks to Buy: AT&T (T) Source: Roman Tiraspolsky / Shutterstock.com If you\u2019re looking for internet of things stocks to buy, the first place to look is network providers. None of the connectivity needed would be possible without telecoms building and maintaining infrastructure to support it. If everything goes according to plan and T-Mobile (NASDAQ:) and Sprint (NYSE:S) merge, there are only three names to choose from on that list \u2014 T-Mobile, AT&T (NYSE:) and Verizon (NYSE:VZ). A lot of people point to Verizon as the winner of the three, but the only telecom I\u2019d be willing to bet on right now is T. T stock is cheap because the firm is weighed down by a massive debt pile that it acquired beefing up its content library in preparation for a new streaming service. Not everyone believes in AT&T\u2019s path forward, which explains the firm\u2019s ultra-low valuation. However, I think T stock\u2019s future looks bright in the streaming space and its position in 5G means the company has a definite future growth catalyst. With a near 6% dividend yield and a forward price-to-earnings ratio of just 9.7, T stock is a cheap way to buy into the revolution. Honeywell International (HON) Source: josefkubes / Shutterstock.com Another internet of things stock that can\u2019t be overlooked is Honeywell (NYSE:), an American company responsible for a wide range of connected household devices. Honeywell not only makes everything from connected fire alarms to thermostats for consumers, but the firm also delivers a wide range of connected solutions at the enterprise level as well. There\u2019s a lot to like about HON stock from its modest P/E of 18.4 to its respectable 2% dividend yield to the fact that it\u2019s been able to grow its earnings per share by 14% annually for the past three years. However, what I find most compelling about Honeywell is the fact that the firm is making big moves into the internet of things space in an unprecedented way. HON is pushing forward with , a strategy that combines connected wearables with cloud-based applications in order to assist customers in creating more efficient organizations. DexCom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com It would be irresponsible to talk about internet of things stocks to buy without mentioning at least one healthcare play. The healthcare space holds a lot of potential for growth when it comes to connected devices because data collection is such an important part of the industry. DexCom (NASDAQ:) makes glucose monitors for people living with diabetes. DXCM stock is up 43% so far this year, though it\u2019s been a bumpy ride for investors. In just two years, DXCM is up 128% as its devices gained notoriety and investors started to take notice. Of course there is some risk buying into a stock that\u2019s been on a run up, but DexCom looks likely to keep climbing in the years ahead as it rolls out new devices at more affordable price points. DexCom is that will be smaller than the firm\u2019s G6 model. Its lower manufacturing costs mean it will be less expensive for consumers. Management is hoping that the new G7 model will help the firm break into other markets beyond glucose monitoring which would create an entirely new growth runway. Skyworks Solutions (SWKS) Source: madamF / Shutterstock.com Another industry that can\u2019t be overlooked when it comes to the internet of things is the semiconductor space. The chips that power connected devices and the networks themselves are an integral part of the overall future of the internet of things. However, choosing which semiconductor stocks to buy right now is a tricky business as the industry has been up against some pretty strong headwinds in recent months. My pick here is Skyworks Solutions (NASDAQ:), a Massachusetts-based semiconductor firm whose share price has been on a roller coaster ride for the past year. The government\u2019s ban on sales to Huawei has hurt SWKS stock significantly \u2014 in the third quarter the firm saw its revenue fall 14% and EPS were down a whopping 47%. However, the firm appears to be faring well in areas unaffected by the trade tension. The company is becoming a major player in the 5G space, and its connected chips including soundbars and smartwatches. The firm\u2019s tech is also included in Oculus headsets, Facebook\u2019s (NASDAQ:) virtual reality arm. So, although you\u2019re taking on a lot of risk considering that the trade war with China looks unlikely to let up anytime soon, SWKS could offer a great deal of reward as well. Not only will its connected chips drive growth in the future, but the firm\u2019s comparisons in 2020 will be much easier after the dismal year it\u2019s had. That means investors who can stomach the risk could see a payoff in just a few months time. Visa (V) Source: Tada Images / Shutterstock.com Payment processors will be another big beneficiary of a more connected world. As more and more devices make their way online, online payments will continue to rise. Part of the reason connected devices are gaining traction is that they reduce friction in people\u2019s lives. Cash has become friction for many people, leading developers to look for easier ways to allow people to pay for things without ever taking out their wallets. The two largest credit card networks, Visa (NYSE:) and Master Card (NYSE:MA) will be able to continue building their networks as people continue to opt for cashless payments. Don\u2019t get me wrong, V stock is expensive \u2014 it trades at almost 29 times its future earnings, but that extra cost is worth it. Visa makes money every time someone uses their credit or debit cards, and with trillions of dollars changing hands in Visa\u2019s name each year, that translates into some pretty impressive revenue figures. Guggenheim Securities analyst Jeff Cantwell in Visa\u2019s business to business payments arm. Cantwell pointed out that V stock will benefit significantly as contactless payments spread and Visa pushes its way further into cross-border transactions, a $100 trillion market. As of this writing Laura Hoy was long FB and T. The post appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""10 Biggest Price Target Changes For Tuesday"", ""BMO Capital Maintains Outperform on DexCom, Raises Price Target to $190""]"
DXCM,2019-09-04,43.1725,43.24,42.2925,42.4075,
DXCM,2019-09-05,42.5975,42.8562,41.6275,41.9175,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.7 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.7 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.7 million of Shares""]"
DXCM,2019-09-06,41.92,41.92,40.0588,40.1225,
DXCM,2019-09-09,40.015,40.29,36.21,36.3425,"[""DexCom down 6% on bearish comments at investor conference"", ""Hearing DexCom At Morgan Stanley Healthcare Conference Says Still Sees Pressure On Q3 Comps"", ""DexCom shares are trading lower after the company said it still sees pressure on Q3 comps at the Morgan Stanley Healthcare Conference."", ""DexCom shares are trading lower after the company said it still sees pressure on Q3 comps at the Morgan Stanley Healthcare Conference."", ""Hearing DexCom At Morgan Stanley Healthcare Conference Says Still Sees Pressure On Q3 Comps"", ""DexCom down 6% on bearish comments at investor conference"", ""DexCom shares are trading lower after the company said it still sees pressure on Q3 comps at the Morgan Stanley Healthcare Conference."", ""Hearing DexCom At Morgan Stanley Healthcare Conference Says Still Sees Pressure On Q3 Comps"", ""DexCom down 6% on bearish comments at investor conference""]"
DXCM,2019-09-10,35.95,36.745,34.57,36.31,"[""Trade Desk, Elastic, Twilio, Okta, Workday Down +20%, What The Heck's Going On? Look To The Charts"", ""Shares of companies in the diagnostics and research space are trading lower, potentially on continued weakness after DexCom provided bearish commentary at a Morgan Stanley healthcare conference on Monday."", ""Shares of companies in the diagnostics and research space are trading lower, potentially on continued weakness after DexCom provided bearish commentary at a Morgan Stanley healthcare conference on Monday."", ""Trade Desk, Elastic, Twilio, Okta, Workday Down +20%, What The Heck's Going On? Look To The Charts"", ""Analysts Forecast 10% Gains Ahead For IWF Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 1000 Growth ETF (Symbol: IWF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $177.10 per unit. With IWF trading at a recent price near $161.27 per unit, that means that analysts see 9.82% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IWF's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), EXACT Sciences Corp. (Symbol: EXAS), and Atlassian Corp PLC (Symbol: TEAM). Although DXCM has traded at a recent price of $145.37/share, the average analyst target is 22.30% higher at $177.78/share. Similarly, EXAS has 20.73% upside from the recent share price of $108.74 if the average analyst target price of $131.28/share is reached, and analysts on average are expecting TEAM to reach a target price of $144.92/share, which is 14.77% above the recent price of $126.27. Below is a twelve month price history chart comparing the stock performance of DXCM, EXAS, and TEAM: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of companies in the diagnostics and research space are trading lower, potentially on continued weakness after DexCom provided bearish commentary at a Morgan Stanley healthcare conference on Monday."", ""Trade Desk, Elastic, Twilio, Okta, Workday Down +20%, What The Heck's Going On? Look To The Charts""]"
DXCM,2019-09-11,36.4675,37.2075,36.2625,36.675,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares""]"
DXCM,2019-09-12,36.8625,37.3275,36.5325,36.79,"[""Dexcom Inc (DXCM) EVP CFO Quentin S. Blackford Sold $\u2013.5 million of Shares"", ""Dexcom Inc (DXCM) EVP CFO Quentin S. Blackford Sold $\u2013.5 million of Shares"", ""Dexcom Inc (DXCM) EVP CFO Quentin S. Blackford Sold $\u2013.5 million of Shares""]"
DXCM,2019-09-13,36.395,36.79,36.025,36.565,"[""IoMT Becomes the Buzzword in New Age MedTech Investing"", ""IoMT Becomes the Buzzword in New Age MedTech Investing"", ""IoMT Becomes the Buzzword in New Age MedTech Investing""]"
DXCM,2019-09-16,36.3725,37.4175,36.195,37.17,
DXCM,2019-09-17,37.7425,38.96,37.27,38.425,"[""New operating chief at DexCom"", ""IBD Rating Upgrades: Dexcom Shows Improved Relative Price Strength"", ""Dexcom Reports Quentin Blackford Promoted As COO"", ""Dexcom Reports Quentin Blackford Promoted As COO"", ""New operating chief at DexCom"", ""IBD Rating Upgrades: Dexcom Shows Improved Relative Price Strength"", ""Dexcom Reports Quentin Blackford Promoted As COO"", ""New operating chief at DexCom"", ""IBD Rating Upgrades: Dexcom Shows Improved Relative Price Strength""]"
DXCM,2019-09-18,37.865,39.4188,37.865,39.2325,"First Week of DXCM January 2022 Options Trading Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the January 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new January 2022 contracts and identified one put and one call contract of particular interest. The put contract at the $150.00 strike price has a current bid of $32.70. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $150.00, but will also collect the premium, putting the cost basis of the shares at $117.30 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $154.98/share today. Because the $150.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 21.80% return on the cash commitment, or 9.30% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $170.00 strike price has a current bid of $34.90. If an investor was to purchase shares of DXCM stock at the current price level of $154.98/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $170.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 32.21% if the stock gets called away at the January 2022 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $170.00 strike highlighted in red: Considering the fact that the $170.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 39%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 22.52% boost of extra return to the investor, or 9.60% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 48%, while the implied volatility in the call contract example is 46%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $154.98) to be 46%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-09-19,39.3775,39.3775,38.37,38.7475,"[""Stocks To Watch: Dexcom Sees Relative Strength Rating Rise To 83"", ""Stocks To Watch: Dexcom Sees Relative Strength Rating Rise To 83"", ""Stocks To Watch: Dexcom Sees Relative Strength Rating Rise To 83""]"
DXCM,2019-09-20,38.7525,39.4625,38.035,38.6,
DXCM,2019-09-23,38.8,39.6225,38.5522,38.8325,"[""Stocks & ETF to Invest in Healthcare Robotics and Innovation"", ""Stocks & ETF to Invest in Healthcare Robotics and Innovation"", ""Stocks & ETF to Invest in Healthcare Robotics and Innovation""]"
DXCM,2019-09-24,38.7575,39.1475,37.8275,38.365,
DXCM,2019-09-25,38.4425,38.625,37.325,38.44,"[""DexCom Still Has Significant Upside Potential"", ""DexCom Still Has Significant Upside Potential"", ""DexCom Still Has Significant Upside Potential""]"
DXCM,2019-09-26,38.6125,38.783,37.4075,37.4725,"Interesting DXCM Put And Call Options For November 15th Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading today, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new November 15th contracts and identified one put and one call contract of particular interest. The put contract at the $145.00 strike price has a current bid of $6.90. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $145.00, but will also collect the premium, putting the cost basis of the shares at $138.10 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $152.59/share today. Because the $145.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.76% return on the cash commitment, or 34.71% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $145.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $155.00 strike price has a current bid of $9.20. If an investor was to purchase shares of DXCM stock at the current price level of $152.59/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $155.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.61% if the stock gets called away at the November 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considering the fact that the $155.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 50%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.03% boost of extra return to the investor, or 43.98% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 50%, while the implied volatility in the call contract example is 47%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $152.59) to be 46%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-09-27,37.6375,37.9925,36.775,37.1275,
DXCM,2019-09-30,37.14,37.7475,36.6575,37.31,
DXCM,2019-10-01,37.4025,37.6882,37.0,37.2125,
DXCM,2019-10-02,37.0475,37.4988,36.4475,37.2225,
DXCM,2019-10-03,37.3475,39.5725,36.4012,39.3525,
DXCM,2019-10-04,39.3025,40.33,39.3025,40.0925,"[""Silverleafe Capital Partners, LLC Buys DexCom Inc, ishares Gold Trust, The Walt Disney Co, ..."", ""Stock Upgrades: Dexcom Shows Rising Relative Strength"", ""Silverleafe Capital Partners, LLC Buys DexCom Inc, ishares Gold Trust, The Walt Disney Co, ..."", ""Stock Upgrades: Dexcom Shows Rising Relative Strength"", ""Silverleafe Capital Partners, LLC Buys DexCom Inc, ishares Gold Trust, The Walt Disney Co, ..."", ""Stock Upgrades: Dexcom Shows Rising Relative Strength""]"
DXCM,2019-10-07,39.7838,40.4638,39.4875,39.8625,
DXCM,2019-10-08,39.5825,39.82,37.52,37.6025,"[""FDA OKs Dexcom G6 Pro CGM system"", ""FDA OKs Dexcom G6 Pro CGM system"", ""FDA OKs Dexcom G6 Pro CGM system""]"
DXCM,2019-10-09,38.02,38.7475,37.3875,38.475,"[""DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval"", ""DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval"", ""DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval""]"
DXCM,2019-10-10,38.185,38.8875,37.825,38.615,
DXCM,2019-10-11,39.24,39.975,38.775,38.8375,"SIZE's Holdings Imply 13% Gain Potential Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Edge MSCI USA Size Factor ETF (Symbol: SIZE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $100.72 per unit. With SIZE trading at a recent price near $88.87 per unit, that means that analysts see 13.33% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SIZE's underlying holdings with notable upside to their analyst target prices are Teleflex Incorporated (Symbol: TFX), DexCom Inc (Symbol: DXCM), and ServiceNow Inc (Symbol: NOW). Although TFX has traded at a recent price of $317.10/share, the average analyst target is 21.44% higher at $385.09/share. Similarly, DXCM has 15.10% upside from the recent share price of $154.46 if the average analyst target price of $177.78/share is reached, and analysts on average are expecting NOW to reach a target price of $301.35/share, which is 14.50% above the recent price of $263.18. Below is a twelve month price history chart comparing the stock performance of TFX, DXCM, and NOW: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-10-14,38.94,40.535,38.775,40.045,
DXCM,2019-10-15,39.0,39.18,36.595,38.2425,"[""DexCom down 6% on Abbott/Tandem deal"", ""DexCom shares are trading lower after the company's competitor Abbott announced a partnership to develop a glucose monitoring system with Tandem Diabetes."", ""DexCom shares are trading lower after the company's competitor Abbott announced a partnership to develop a glucose monitoring system with Tandem Diabetes."", ""DexCom down 6% on Abbott/Tandem deal"", ""Notable Tuesday Option Activity: WDC, NFLX, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Western Digital Corp (Symbol: WDC), where a total of 44,603 contracts have traded so far, representing approximately 4.5 million underlying shares. That amounts to about 112.6% of WDC's average daily trading volume over the past month of 4.0 million shares. Particularly high volume was seen for the $59 strike put option expiring October 25, 2019, with 18,821 contracts trading so far today, representing approximately 1.9 million underlying shares of WDC. Below is a chart showing WDC's trailing twelve month trading history, with the $59 strike highlighted in orange: Netflix Inc (Symbol: NFLX) saw options trading volume of 104,785 contracts, representing approximately 10.5 million underlying shares or approximately 111.5% of NFLX's average daily trading volume over the past month, of 9.4 million shares. Especially high volume was seen for the $285 strike call option expiring October 18, 2019, with 4,980 contracts trading so far today, representing approximately 498,000 underlying shares of NFLX. Below is a chart showing NFLX's trailing twelve month trading history, with the $285 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 6,739 contracts thus far today. That number of contracts represents approximately 673,900 underlying shares, working out to a sizeable 107.2% of DXCM's average daily trading volume over the past month, of 628,465 shares. Particularly high volume was seen for the $160 strike call option expiring October 18, 2019, with 3,114 contracts trading so far today, representing approximately 311,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $160 strike highlighted in orange: For the various different available expirations for WDC options, NFLX options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom shares are trading lower after the company's competitor Abbott announced a partnership to develop a glucose monitoring system with Tandem Diabetes."", ""DexCom down 6% on Abbott/Tandem deal""]"
DXCM,2019-10-16,38.9475,39.8688,37.62,38.4675,
DXCM,2019-10-17,38.635,39.615,38.435,39.1675,
DXCM,2019-10-18,38.875,39.3725,38.295,39.23,"[""DexCom: A Leader In A Lucrative Market But May Be A Little Overvalued"", ""DexCom: A Leader In A Lucrative Market But May Be A Little Overvalued"", ""DexCom: A Leader In A Lucrative Market But May Be A Little Overvalued""]"
DXCM,2019-10-21,39.2475,39.9022,39.0182,39.155,"[""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast)"", ""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast)"", ""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast)""]"
DXCM,2019-10-22,39.33,39.58,37.63,37.7225,"[""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast Transcript)"", ""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast Transcript)"", ""Earnings Speak To Continued Equity Upside, Says Bill Gunderson (Podcast Transcript)""]"
DXCM,2019-10-23,38.105,38.5,36.5275,36.615,"[""Sell-siders upgrade Biogen on aducanumab prospects, Raymond James doubts"", ""Stifel Initiates Coverage On DexCom with Buy Rating, Announces $190 Price Target"", ""Stifel Initiates Coverage On DexCom with Buy Rating, Announces $190 Price Target"", ""Sell-siders upgrade Biogen on aducanumab prospects, Raymond James doubts"", ""Stifel Initiates Coverage On DexCom with Buy Rating, Announces $190 Price Target"", ""Sell-siders upgrade Biogen on aducanumab prospects, Raymond James doubts""]"
DXCM,2019-10-24,37.0525,37.3225,36.615,36.7425,
DXCM,2019-10-25,36.73,37.4775,36.3075,36.8475,
DXCM,2019-10-28,36.88,38.0725,36.88,37.9075,
DXCM,2019-10-29,37.9575,38.92,37.365,38.71,"[""Fitbit: Unlikely Deal Below $10"", ""Fitbit: Unlikely Deal Below $10"", ""Fitbit: Unlikely Deal Below $10""]"
DXCM,2019-10-30,38.9625,39.2375,38.27,38.935,"[""Dexcom Earns Relative Strength Rating Upgrade; Hits Key Threshold"", ""Dexcom Earns Relative Strength Rating Upgrade; Hits Key Threshold"", ""Dexcom Earns Relative Strength Rating Upgrade; Hits Key Threshold""]"
DXCM,2019-10-31,38.8475,39.3593,37.7775,38.56,
DXCM,2019-11-01,38.9,40.0125,38.66,39.325,"[""DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?"", ""DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?"", ""DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?""]"
DXCM,2019-11-04,39.7,39.8375,38.975,39.635,
DXCM,2019-11-05,39.6225,39.9675,37.6025,38.39,"[""DexCom Q3 2019 Earnings Preview"", ""DexCom Q3 2019 Earnings Preview"", ""DexCom Q3 2019 Earnings Preview""]"
DXCM,2019-11-06,38.4975,39.3138,38.0662,38.28,"[""DexCom Q3 sensor sales up 64%; shares up 15% after hours"", ""ROKU, DXCM, PBYI, FOSL, and AERI among after hour movers"", ""DexCom, Inc. 2019 Q3 - Results - Earnings Call Presentation"", ""DexCom EPS beats by $0.45, beats on revenue"", ""Dow Jones Futures: Time To Reset Roku? These 4 Stocks Are Testing Buy Points On Earnings"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""DexCom, Inc.'s (DXCM) CEO Kevin Sayer on Q3 2019 Results - Earnings Call Transcript"", ""The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings"", ""DexCom Q3 EPS $0.65 Beats $0.21 Estimate, Sales $396.3M Beat $348.12M Estimate"", ""DexCom Raises FY2019 Sales Guidance from $1.325B-1.375B to $1.425B-1.45B"", ""DexCom Raises FY2019 Sales Guidance from $1.325B-1.375B to $1.425B-1.45B"", ""DexCom Q3 EPS $0.65 Beats $0.21 Estimate, Sales $396.3M Beat $348.12M Estimate"", ""The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings"", ""DexCom, Inc.'s (DXCM) CEO Kevin Sayer on Q3 2019 Results - Earnings Call Transcript"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dow Jones Futures: Time To Reset Roku? These 4 Stocks Are Testing Buy Points On Earnings"", ""ROKU, DXCM, PBYI, FOSL, and AERI among after hour movers"", ""DexCom Q3 sensor sales up 64%; shares up 15% after hours"", ""DexCom, Inc. 2019 Q3 - Results - Earnings Call Presentation"", ""DexCom EPS beats by $0.45, beats on revenue"", ""DexCom (DXCM) Q3 2019 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q3 2019 Earnings Call Nov 06, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom third-quarter 2019 earnings release conference call. My name is Erin, and I'll be your operator for today's call. [Operator instructions] Please note that this conference is being recorded. I will now turn the call over to Sean Christensen. Sean, you may begin. Sean Christensen -- Senior Investor Relations Manager Thank you, operator, and welcome to DexCom's third-quarter 2019earnings call Our agenda begins with Kevin Sayer, Dexcom's chairman, president, and CEO, who will provide a summary of the quarter; followed by a financial review and outlook from Quentin Blackford, our COO, and CFO; and then a strategic update from Steve Pacelli, our executive vice president of strategy and corporate development. Following our prepared remarks, we will open the call up for your questions. [Operator instructions] Please note that there are also slides available related to our third-quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third-quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us today. The third quarter was another great period of growth for DexCom. There are many things that we can highlight today, but let me give you three key statistics that point to the strength of our business. The third quarter represents our highest U.S. growth rate since the first quarter of 2016 when the business was much smaller. The third quarter included the highest absolute dollar growth in the history of our company, increasing nearly $130 million over the third quarter of 2018. We not only achieved profitability in the third quarter, but for the first time ever, through nine months, we are profitable on both a GAAP and non-GAAP basis. The explanation for this performance remains relatively simple. More and more people are becoming aware of the value of DexCom's real-time CGM. And with G6, we have the right product to meet their needs. We often highlight access and awareness as the primary answers for the growth that we are experiencing, but this is the result of years of work from the DexCom team. It is the result of many people embracing our core value to think big. We think big in the way we design our products, the way we serve our patients, our approach to device integration and empowering user choice, and the way we structure our business to meet the expectations of our patients, our employees and our shareholders. Thinking big includes thinking about long-term profitability. As I stated earlier, through the first nine months of the year, we find ourselves profitable on both a GAAP and non-GAAP basis and on our way to our first GAAP profitable year. But even as we embrace this visionary mindset, it has not come without challenges. This explosive growth continues to leave supply levels much tighter than we expected as we ramp capacity. And because of these supply constraints, our customer-facing infrastructure has been stretched to its limits. As Quentin will explain later, our guidance considers these challenges. I can assure you that as we think about DexCom's opportunities in diabetes and beyond, we are continuing to think big. In addition, as many of you have recently seen, we've had some key developments over the past few months. In September, we began selling G6 in Canada and have seen a great response to this launch. In early October, we officially began shipping G6 to our Medicare patients. Toward this end, we are partnering with Walgreens to ensure that all Medicare patients can fill their prescriptions for DexCom CGM through any of Walgreens' nationwide retail locations. This provides a wonderful opportunity to improve upon the DexCom experience for our Medicare patients and is an important step in our long-term move to the pharmacy as our primary distribution channel. As you can see, we are innovating beyond great product design and focusing on the customer experience that we create around the product. Whether this involves DexCom directly or work with our valued partners, we are thinking with the interest of our patients in mind. We continue to make excellent progress with our insulin delivery partners. As Tandem Diabetes said on their call, they are on the verge of launching their advanced hybrid closed loop with Control-IQ system. On top of that, Insulet is making great progress with their Horizon closed-loop pump with DexCom G6 integration. The combination of Insulet and DexCom will provide a unique and compelling user experience and form factor. Our strategy for the intensive insulin delivery business is playing out according to our plan, and in fact, vastly exceeding our initial expectations. As we look to the future, we continue to gather data on markets to pursue outside of our core intensive insulin business. We are investing in our new markets team to execute on this strategy and expect to increase investment there in the future. Time and time again, we are learning that our product has an incredible impact in these markets. Doctors all over the world are clamoring for real-time CGM use in the hospital to improve patient outcomes and streamline workflows for healthcare professionals in this environment. We continue to believe that the opportunity for expanded use of DexCom in pregnancy is significant and are aware of several independent studies in progress around the world that will demonstrate the importance of CGM in this patient population. And finally, with respect to type two non-intensive diabetes and pre-diabetes, data from CGM usage continues to point to promising outcomes, including potential long-term cost reductions for this costly patient group. The experience here reminds us of where we were many years ago when we started our CGM First campaign for the intensive insulin market. While there may be many use cases for these patients, we believe that CGM will be the primary tool to drive improved outcomes in the type two non-intensive and pre-diabetes populations. And we all know the size of these markets. Overall, 2019 continues to exceed our expectations. Based on the strong third-quarter results, we are pleased again to be able to increase our revenue outlook, as well as our full-year operating margin and adjusted EBITDA targets. I will now turn the call over to Quentin, who will provide detail on this outlook, as well as a review of our financials. Quentin? Quentin Blackford -- Chief Operating Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. Today, we reported worldwide revenue of $396.3 million for the third quarter of 2019, compared to $266.7 million for the same quarter in 2018, representing growth of 49% on both a reported and constant-currency basis. Our momentum has continued, driven by strong new patient additions and customer satisfaction with G6. As Kevin mentioned, these factors drove absolute dollar growth of nearly $130 million versus the prior year, a new DexCom record and significantly above anything we've seen in the past. The U.S. business grew 53% in the third quarter, the fastest pace since early 2016, as the rapid adoption of CGM in the U.S. across all of our major channels, continues to exceed our expectations and has been the primary driver of our outperformance this year. We continue to gain traction in our effort to prioritize customer access in our commercial business and believe that our efforts to remove upfront barriers across all channels, including the pharmacy, are contributing to new patient growth. Our OUS business continues to grow very well, ahead of our internal expectations. In the third quarter, we came up against our highest OUS growth comp in the past six years, with 93% year-over-year growth in the third quarter of 2018. Despite that, we were still able to grow at 39% on a constant-currency basis or 36% on a reported basis, both of which represented a nice sequential uptick with solid increases across the board for both our direct and distributor markets. Our third-quarter gross profit was $246.9 million or 62.3% of sales, compared to 63.2% of sales in the third quarter of 2018. The Q3 sequential improvement of 90 basis points was in line with our expectations that we noted on the second-quarter call. While pricing remains consistent with our expectations and we are gaining the cost benefit of our new transmitter design, we did experience challenges with one of our automated G6 sensor production lines late in the third quarter which temporarily lowered production levels. This lower production output, combined with the strong product demand, have left inventory levels tight as we head into the fourth quarter. As a result, the remaining transition from G5 to G6 for certain channels of our business will be slower than originally anticipated. We still expect a strong sequential improvement in gross margin in the fourth quarter, but the magnitude will be less than original expectations. We now expect full-year gross margin of approximately 63%, slightly lower than prior guidance. Operating expenses were $187.8 million for Q3 2019, compared to $153.9 million in Q3 2018. This reflects an increase of 22% year over year. The business continues to demonstrate excellent operating leverage, with third-quarter revenue growth once again exceeding the growth in operating expenses by more than two times. As a result of our continued focus on operational discipline and commitment to process improvement, robotics, automation in our Manila location, we are achieving leverage while maintaining investments into research and development of our core business while also increasing investments in new market opportunities. Operating income was $59.1 million or 14.9% of revenue in the third quarter of 2019, compared to $14.7 million or 5.5% of revenue in the same quarter of 2018. This reflects a year-over-year improvement of 940 basis points in operating margins for the quarter. Adjusted EBITDA was $92.5 million or 23.3% of revenue for the third quarter of 2019, compared to $48 million or 18% of revenue for the third quarter of 2018. As our operating margin and adjusted EBITDA margin indicate, we are making great progress toward our profitability targets, and we see these as strong indicators for the long-term cash flow potential of the business. Net income for the third quarter was $60.4 million or $0.65 per share. Through the first nine months of the year, we are now GAAP profitable for the first time in our company's history, and we are on track to deliver our first-ever full year of GAAP profitability. We remain in a strong cash position with greater than $1.4 billion of cash and cash equivalents on the balance sheet at the end of the third quarter. Our immediate priority remains the expansion of our G6 production capacity, as well as capital investment in preparation for the eventual launch of G7. We also continue to have flexibility as we invest to lengthen our growth runway, including our investments in support of our new markets team. Turning to guidance. Given the incredible growth that we have experienced through the first nine months of the year, we now anticipate 2019 total revenue of $1.425 billion to $1.450 billion, an increase of greater than $85 million at the midpoints of our prior incurring guidance, respectively. Importantly, and unlike prior guidance, this contemplates the production capability that we currently anticipate for the fourth quarter. The revised revenue guidance implies an annual growth of 38% to 41%, which is an impressive organic growth number for a company of our size. As I mentioned previously, we now expect full-year gross margin of approximately 63%, improving sequentially in the fourth quarter as we start to realize the benefit of a full quarter of our new low-cost transmitter. In light of our better-than-expected revenue growth, we now expect operating margins of approximately 9% and adjusted EBITDA margins of approximately 19.5%, reflecting increases of 200 basis points and 100 basis points, respectively, from our prior guidance. With that, I will now turn the call over to Steve for a strategic update. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Thanks, Quentin. Our great results in the third quarter are a validation of our strategic efforts, and we remain well-positioned to take advantage of our long-term growth opportunity. As some of you may have seen at September's EASD Conference in Barcelona, the full three-year results of our Comisair study showed that DexCom CGM, when paired with either insulin pumps or pens, drove an average increase of more than 20% to time and range. That is nearly five hours per day of improved glycemic control. Another clear validation of DexCom CGM as the first-line defense for people with diabetes and that CGM connected devices are here to stay. Our insulin delivery partners continue to make progress on CGM-enabled integrated systems. As Kevin mentioned, with the pending approval and launch of Control-IQ, we are thrilled to be bringing our first advanced hybrid closed-loop technology to market and commend Tandem on their progress to date and their dedication to bring this best-in-class platform to reality. DexCom is proud to provide the enabling CGM and AP algorithm technology for this platform. Together, these tools helped keep the system in a closed-loop mode 92% of the time during the pivotal study. Similarly, Eli Lilly, Novo Nordisk and Companion Medical are all making progress in their efforts to commercialize connected smartpens. We are seeing more and more interest from additional insulin delivery companies that recognize the value of connectivity to CGM, and we will continue to be the demonstrated leader in these efforts. As we expand the rollout of G6, we are simultaneously taking steps to prepare the way for G7 which we still plan to launch on a limited basis in late 2020 and more broadly in 2021. We intend to be very thoughtful on the rollout of G7 as we scale the infrastructure necessary to support the anticipated demand for this exciting new platform. On our previous call, we announced the FDA submission of our G6 Pro product, and we were pleased to announce its approval in early October. This is another strong example of the streamlined review process enabled by our iCGM designation, giving us the opportunity to quickly iterate products to serve the needs of different customer segments. The G6 Pro represents the first disposable professional CGM product that is indicated for either blinded or unblinded real-time use. In blinded mode, the product is available for all people, ages two and up. In unblinded mode, G6 Pro is indicated for all people with diabetes, ages two and up. Both options provide valuable insights into the impact of activity, food choices, medications and other factors on people's glucose levels. It also provides clinicians a wonderful tool to introduce their patients to real-time CGM and to adjust or optimize treatment based on observable patterns and time and range. We've spoken at length this year about our efforts to improve access for our patients, whether advocating for coverage for type two intensive patients, pushing for ways to reduce the upfront cost to our patients or negotiating for the removal of administrative hurdles for patients to start on CGM. As you can see from various public and private data sources, we are making good progress with the long-term transition of the U.S. business to the pharmacy channel. As we've noted previously, this is a complex task. We have long-standing relationships with our DME distributors and many of our patients have grown accustomed to their process through the DME channel. With these challenges noted, our field team is doing solid work, and we look forward to continued expansion through the pharmacy channel. Specific to formulary placement, we don't plan to comment on every contract win, as this is a normal part of our business operations. What we will say, as many of you have likely seen, is that we have good momentum here in our efforts. The value of DexCom CGM speaks for itself, and payers and PBMs continue to demonstrate their understanding of what our product brings to the customer. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Steve. It is hard to continue to put words around the growth that we have seen since the launch of G6, and the third quarter is certainly no exception. At DexCom, we have the stated mission to empower people to take control of diabetes. As this quarter, and clinical studies like Comisair continues to demonstrate, we have a product that is enabling people to do just that. It seems like every day we hear stories have people gaining confidence with their help. Children and patients living with less fear and overall quality of lives improving. These are the stories of people being empowered. To wrap up, 2019 has proven to be a wonderful year thus far, and we remain excited for the long road ahead. To the DexCom team, let's finish the year strong. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Senior Investor Relations Manager Thank you, Kevin. [Operator instructions] Questions & Answers: Operator [Operator instructions] And your first question comes from Danielle Antalffy from SVB. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hey good afternoon guys, thanks so much for taking the questions. Congrats on what can only be described as a phenomenal quarter. I'll keep it to -- I'll follow instructions and keep it to one question. Kevin, you mentioned capacity -- some capacity challenges and the line that went down during the quarter. Can you give some additional color on how that factors into your guidance for the remainder of the year? And why you weren't concerned about meeting increasing demand going forward? Thanks so much. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks for the question, Danielle. Give a little history here. We launched G6 a year ago, and we launched it earlier than we planned. And we've been chasing this ever since we started. As you look at 2019, we've grown over $300 million in the first three quarters and $130 million in the last quarter. And while we've experienced large growth percentages in the past, we've never experienced anything like this. We committed to doubling our capacity this year. And by the time we exit the year, in all fairness, we will have double the capacity to build G6 product that we had before. We're doing everything we can to put additional capacity in place to meet the demand for the fourth quarter. As we talked about, our manufacturing line went down in September, late in the third quarter and for some time early in the fourth quarter. That's production we can't make up today. We do have some levers to pull and some things that might come on board in December. We can see some upside to making that up. And in our worst case, we assume in our guidance this year that we're not going to make that up. We're not going to plan on that. And if we do, there's some upside there. So by the time we exit the year, we will have doubled our G6 capacity. And I can tell you we have more automated lines coming on, some in the first quarter, more in the second quarter to the point by the time you get to the middle of 2020, we will have doubled our capacity again and be able to serve everybody. We're confident we have enough capacity to meet the numbers that we've given you. We believe we have an opportunity to do more if certain things go well, and then we'll go from there. Operator And your next question comes from Margaret Kaczor from William Blair. Your line is open. Margaret Kaczor -- William Blair & Company -- Analyst Hey, guys, good afternoon, and thanks for taking the question. First one for me. It's a little bit tagging answer, and from Danielle, in terms of the marketplace demand that you're seeing. Given the capacity constraints you have, I assume a lot of the growth that you're seeing is actually push-driven, meaning that patients are educated and they're reaching out to you versus you trying to convince them. So is that true? And then should we assume that patient add growth is still growing at the same pace or better than U.S. revenue growth and why or why that shouldn't change going forward? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what, let me start with that. And if Quentin, Steve want to jump in, they can. With respect to new patients, Q3 was very comparable to Q2. We had a very good new patient, third quarter. And so that has not been an issue with respect to patients reordering. We have not seen a change in reordering patterns from our patients. They're ordering what and when they can and when their insurance will reimburse for them. So there's no real difference here as to what we've experienced in the past. In reality, what we're experiencing, what we're working through is getting product out to them as quickly as we can. Sometimes they wait just an extra day for the product, sometimes it's as long as a week. But we are getting product to everybody. We'd like to get it to them sooner, and we'd like to have more at our discretion here. But we're keeping up with everything. And we're doing well. Quentin Blackford -- Chief Operating Officer I think Margaret, the only thing I would add is it's a combination of both, right? I mean patients continue to become more and more aware of the technology and find their way to the device. And clearly, our commercial team continues to do just an outstanding job of creating opportunities as well. So it's a bit of both. And the new patient additions continue to outpace overall revenue growth. So it's a strong indicator of where the business is heading. Margaret Kaczor -- William Blair & Company -- Analyst Perfect. Thank you, guys. Operator And your next question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. I was -- I wanted to ask -- I know, Steve, you said you're not going to say a lot on formulary status, but we've seen a few positive moves with the sizable payers for 2020 with regards to DexCom's placement. So I'm wondering, what's driving that favorable treatment into next year? Maybe how does some of your tiering placements for next year compared to your lower price competitor? And Quentin, are you still comfortable with the $100 million to $125 million pricing headwind next year as you give up some price to move into pharmacy? Or are these big wins, maybe push that expectation a little bit higher in trade-off or volume? Thank you. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development So I'll start off, and then I'll turn it over to Quentin on the numbers. Yes. Look, I mean, this is what we told you guys. We're executing on exactly what we told you we would do, which is why it was somewhat tongue in cheek, the prepared remarks, that we're not going to put a press release out every time we get a new pharmacy win. But this is what we told you we would do. We've been telling you we would do this, and we're executing on our plans. And with respect to pricing, Quentin you can comment? Quentin Blackford -- Chief Operating Officer Yes. No. It's right in line with what we have always anticipated, Jeff. I don't, at this point, see any need to kind of revise the expectation we've put out there. I think that $100 million to $125 million of headwinds is something that we'll continue to see throughout the course of next year. But we aren't changing our strategy here. I think what's being demonstrated is that our plan is being effective. It's working, and the payers are seeing the value of our products. And they understand it for the premium product that it is, and we're opening doors. So no change there. Operator And your next question is from Ryan Blicker with Cowen. Your line is open. Ryan Blicker -- Cowen and Company -- Analyst Hi, thanks for taking my questions. For G7, how much progress have you made working on automating your manufacturing processes over the past few months? And is there still a significant amount of work to be done, nailing down your exact manufacturing process? And then for G7 overall, what are the biggest steps in the development process you hope to accomplish over the next few months? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Hi, this is Kevin. I'll take that. G7 is on schedule as we sit right now with the schedule that we put together on all fronts. We are now in the process of evaluating the final tweaks to the configuration to lock down the entire design. The majority of the design is locked down, but we've got a -- as always, when we get to this point in the sensor, what's that exact sensor configuration going to be, and then we've got some algorithm and some effort to do, but none of that will slow down the clinical study. With respect to the total automation of the G7 plant, Steve, very, very truthfully said we're going to do a limited launch in 2020 and be careful how we launch in 2021. We don't want to put ourselves in a position we're talking about today, because we see that as a product that we can market to the world at great, great -- with great, great success. So our automated lines are in design. They're being built. The equipment's not all in yet because the process isn't completely done. But things like ordering molds which have a long lead time and things of that nature are happening. And you will see significant capital expenditures by us over the next several months as we get these lines up and running. We have a great automation team. We have good processes that we're counting on. They'll certainly be adjusted as the product becomes more mature. The product was designed to be more manufacturable than G6. So we think these processes could be simpler over time. And I'll just add one other thing. We're not just asking the guys to automate G7, at the same time, they're automating the G6 factory, as well as we have automated lines for the assembly of our G6 product going up both in San Diego and in our Mesa facility. So we've got a lot on our plate manufacturing-wise. We're confident with the progress we're making, what the guys are doing, and expect a very successful launch in product. Operator And your next question comes from David Lewis with Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good afternoon, and congrats on a great quarter. Yes, Quentin, just in terms of just the fourth-quarter guidance, you typically guide a fair amount of sequential deceleration, kind of in line with historical precedent. And in the fourth quarter, it's a little heavier than normal coming off a very, very strong third quarter. Is there anything from a timing perspective or pull-forward perspective for the fourth quarter that's worth calling out? Kevin Sayer -- Chairman, President, and Chief Executive Officer Let me just talk through the fourth quarter for a second and give you a little bit of color on it. There's nothing significant in terms of timing that, I think, changes the impact of either Q3 or Q4. But one thing to keep in mind is the OUS business is a bit more choppy than the rest of our business. The sequential trends there can move around a little bit. If you look historically, international has typically been flat to slightly down in the fourth quarter, and we continue to expect that's how it will play out this year. I think the other thing to keep in mind is that as we continue to move more and more of the business toward a subscription-based model, the historic seasonality is going to play a little bit differently in the current year than what we've seen throughout history. So we're trying to model that as well. I think the other thing just to keep in mind is, Q3 was truly a remarkable quarter for us. We were up 18% sequentially from Q2, whereas, historically, we've been up 8% to 10%. So for us to look at that and call it a trend and anticipate that we're going to see the same sequential increase into the fourth quarter, that's a bit premature. We want to see this play out a little bit longer than just 90 days worth of experience in the third quarter. So we're trying to be mindful of that. And I think the other thing just that is worth noting, and Kevin has hit on it, we are capacity -- we're at the top end of the capacity in our guidance range. And if we can pull some of these incremental opportunities forward in terms of production lines, then terrific. There's going to be opportunity to exceed what we set the expectation for. Worst-case scenario, as those lines come up in the very early part of January, and we're off and running at that point. But if we can get those brought forward, then there's potential upside. Operator And your next question comes from Robbie Marcus with J.P. Morgan. Your line is open. Robbie Marcus -- J.P. Morgan -- Analyst Thanks, and congrats on a great quarter. I was wondering if you could just help parse out what the drivers of growth were, clearly breaking down the barriers of costs that the pharmacy is having a big impact. But anything you could add on Medicare versus pharmacy versus DME would be really helpful. Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Our big driver this quarter was the U.S. commercial business. Our U.S. commercial business, not Medicare, but our U.S. commercial patients and our U.S. commercial revenues grew at a rate faster than any quarter we've ever seen. And that was the primary driver. Medicare growth continues to be good. But in all fairness, in the third quarter, we know there's some pent-up demand for patients to shift over to G6. We expect Medicare to really take off next year as we roll out our Walgreens and pharmacy delivery mechanism for the Medicare patients and make it much easier for them and get them all over to G6. International was also a great quarter. The growth sequentially there was very strong. Quentin talked about the fact that we're comparing to a 93% growth quarter internationally last year, and we still grew 39% over that number. So the international markets were good as well. I really can't tell you whether it's DME or pharmacy that's driving it. I think just the drive is awareness. And people are becoming much more aware of CGM, and what it can do for them and having great experiences with the product that we have. Operator And your next question comes from Kyle Rose with Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you very much for taking the questions and congrats on a terrific quarter. You talked a little bit -- or talked at length about some of the capacity from a manufacturing perspective. But if we look back at some of the last two years, when you think about some of the growth you've had, you've also been somewhat constrained just from a customer support perspective. Given the surge in growth from a new patient perspective, maybe help us understand just what other investments and infrastructure changes you're making from a customer support perspective, both currently now with the G6. I know you went to OUS or offshore in some of that support earlier this year, but also in prep for G7 in 2020 and then 2020 and beyond. And then I'll hop back in queue. Thank you. Quentin Blackford -- Chief Operating Officer Yes. Well, certainly, the operation that we've set up in Manila has turned into a real corporate asset of ours. I think you look at the performance that we're seeing there, both from a quantitative, qualitative perspective, quite honestly, we're operating at some of the highest levels that we've ever seen in the company's history. And that's allowing us to scale more aggressively than what we have historically and address some of the increasing demand that we see. I think another thing that we spend a tremendous amount of time looking for opportunities in the organization is just around what we call RPA or robotic automation and taking processes that are incredibly labor-intensive and finding those aspects of those processes and automating those, so that the folks who are doing those things can focus really more on value-added capabilities to the organization and serving the patients or even our commercial team in a much better way. And I think, encouragingly, we're seeing NPS scores start to reach some of their highest levels here in recent weeks than what we've seen over the last 18 to 24 months, even before we started down the path of taking some of the things outside the States and into the Philippines. So we're encouraged by what we're seeing. We continue to make investments in those ways. I think as we continue to head into the future, the more we can automate the patient experience with us and eliminate the need for a live person to be on the other end of every phone call, the greater we're going to have an ability to scale and improve the patient experience along the way. So those are the things we're focused on. We're encouraged by what we're seeing. But to be fair and truthful, it has been a challenge over the time that the growth has really put pressure on it. And we're doing everything we can to stay out ahead of it. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'd just add one other thing. We have an opportunity with G7 to reset the bar as to how we're going to act with patients and what distribution and reimbursement channels we'll pursue. Everything we're doing with G6 is positioning us to put G7 in its most accessible light to make sure patients can get right to it. Again, our Walgreens announcement with the Medicare patients to whereby Medicare patients will be able to go to Walgreens and get their monthly supplies, rather than calling us and being on the phone with us or our distributors, is a major win. I was on the phone with a physician just a couple of weeks ago, and he explained to me his frustration with -- we have three or four Medicare distributors on ourselves, and all three of those ask -- all of those ask for different paperwork. We think we can make this much more efficient for our patients with that move. And that's part of the innovation and thinking big I was referring to. We're going to make this easier. And so everything we're doing with G6 is going to fly right into G7, and we are preparing to become a company that serves several million patients, not just several hundred thousand. Operator And your next question comes from Jayson Bedford with Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Thanks, and good afternoon. So I guess, just given the U.S. growth, I think it begs the question around traction in people with insulin-dependent type 2 diabetes. So can you just comment on what you're seeing in this patient population and the impact the pharmacy has had on penetrating this opportunity? Quentin Blackford -- Chief Operating Officer I'll take that, Jason. We are growing in that space, but in all fairness, we do not have the broad reimbursement for insulin-using type 2 patients that we so desire. Medicare covers those patients. And some of the payers have come along, and some of them have not. We think it will continue to grow over time. But even with our pharmacy contracts, there are sometimes limitations as to what insulin-using patients can have access to our technology. We are negotiating through that. We are willing to give, for example, willing to give price to have those patients covered if they will cover them. The Medicare patients do have coverage. And that's where a large portion of this population exists. And we will be able to get those and go after them. But it's still a chore and it's still not -- certainly not the majority of our business, even the majority of our Medicare patients at this point in time. It's a great growth opportunity for us. Operator And your next question comes from Travis Steed with Bank of America. Your line is open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Hi. Congratulations on an outstanding quarter. So it's been almost a year since you laid out the various non-core market opportunities at your Analyst Day. You've got a dedicated team looking at that and doing research there. Just love to hear kind of what you've learned over the last year if there's anything you can elaborate on in terms of different business models or any different views on the market sizes there? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. This is Kevin. I'll let Steve and Quentin take a little more of that, too, because we've all had interesting experiences. As this has evolved, we've gone from -- we're going to have a complicated type two program to using other programs, to having payers run the thing, to how is this model going to go. And the one learning that I've seen that I'll share with you is, it doesn't matter what the model is. CGM is what drives it. And I think there's going to be opportunities across the board, directly with payers, directly with the programmatic entities, directly with employers, directly with clinics to better manage these patients. And you'll see CGM usage vary from model to model. There are some who think you need a specific number per year, but the most recent group I talked to said, \""I just put them on them on it all the time because we get such good results.\"" We don't know how it's going to play out. But again, look at the size of that market and look at the amount of dollars spent taking care of those patients. Look at the cost of drugs for those patients and their effectiveness. We think there's a cost savings play here that might be even greater than what we're saving in the type 1 space and intensive insulin using space, when all is said and done, if we can develop the right algorithms to get into the right groups. I don't know, Steve, Quentin, you got to anything? Quentin Blackford -- Chief Operating Officer No. I think you hit it just right. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I don't have anything to add to that. Operator And your next question comes from JP McKim from Piper Jaffray. Your line is open. Unknown speaker Good afternoon, and thanks for taking my questions. It's actually Matt on for JP. So as I look back at the business on the top line over the last five years, you guys haven't grown less than 25% per year in any of those last five. In the last two, it's been much, much faster than that. So as we think forward a little bit, I know you've got a little bit of capacity constraint at the moment, but it seems like you've got a lot of tailwinds here on the Medicare side and the pharmacy side. So is there anything specifically that could keep you from that level of growth as we look forward? Quentin Blackford -- Chief Operating Officer Yes. I think, Matt, more than anything else, as that business gets larger and you get into kind of the law of large numbers, the growth rate continues to come under pressure. I think that you look at -- last year, we grew $300 million year-over-year in terms of absolute dollar growth this year. At the midpoint, we're talking about $400 million of absolute dollar growth, yet the growth rate is arguably a little bit slower, still at elevated levels, but arguably slower. So I think that as we continue to move into the future, the rates' going to just be pressured from the tougher and tougher comps that we have and a larger base of business. But you hit the nail on the head. There's a lot to be bullish about. And we couldn't be more bullish around the opportunities that sit in front of us within the core business itself, the alternative market opportunities. I mean these markets are enormous. And I think what we learn more and more every day is that at the end of the day, it's CGM device that really opens up the opportunity to either impact cost, improve a patient's life, whatever it might be. It comes right back to our device. So we couldn't be more bullish about the future. But at the same time, we're not going to get ahead of ourselves. We're going to be thoughtful, but we're going to pursue every one of those growth opportunities as far as we can. Operator And your next question comes from Mathew Blackman with Stifel. Your line is open. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everyone. You guys spent a lot of time answering questions about the pricing implications of pharmacy access. I was hoping you could talk a bit about the potential profitability implications of increasing mix running through the pharmacy. Quentin Blackford -- Chief Operating Officer Yes. I think the pharmacy is a very, very attractive business model for us. Obviously, it reduces the burden that a patient and a physician and even our back-office staff here has to work through to get a patient onto the technology. So it's attractive from that perspective. But it's also very attractive from a profitability perspective. We firmly believe that we can make more profit dollars per patient through the pharmacy channel than we can to the DME channel. So -- and much of that comes by way of reducing the back office effort and just reducing the amount of time that it takes to get that patient on to the product. And then it clearly opens up by having easier access, the opportunity to address more of the market. So for all those reasons, pharmacy is very attractive to us, but from a profitability perspective, it's going to deliver profit dollars on a per-patient basis that are higher than the DME channel. Operator And your next question comes from Steven Lichtman with Oppenheimer. Steven, your line is open. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. Yes. Just following up on the very strong international performance. Were there any standouts in particular that stood out? Or was it across the board? And what was the -- what are some of the big new opportunities you're focused on ahead outside of the U.S.? Thanks. Quentin Blackford -- Chief Operating Officer I'll speak to the quarter itself. I mean it's pretty simple, and maybe Steve or Kevin can speak to the opportunities. But within the quarter, it was very widespread. It was across our direct markets, it was across our distributor markets and it was across all of the regions. There wasn't anyone country, in particular, that far and away led the pack. There wasn't anyone country that was far and away behind the pack either. So it continues to be very broad-based strength across each and every one of our markets and the teams' are doing a remarkable job with it. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'd just add, I spoke a bit about the Canadian launch in September. And that launch was a great success and win for our Canadian team. If I depict one other geography, the one I'll call out is the U.K. They had a month in December that far exceed -- I mean, September, that far exceeded anything that had ever done. And we're pretty proud of the results. And we got an email, \""Hey, we just hit this mark.\"" And it's pretty exciting because we don't have widespread reimbursement in the U.K., it's regional, and there's a lot of cash pay. We think as we grow in the U.K., we can get widespread reimbursement, and then this becomes a much greater market for us. So kudos to the U.K. team as well. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I think the only final add for me would be, as you guys are building models, don't build anything significant this year from Japan. But Kevin and I just spent some time over in Japan. And kind of detailed G6 for the first time, G6 is filed in Japan. And we expect to launch it there, probably the first half of next year. And there's some real excitement around that product. So we'll get you guys updated when the time comes. But that's still really a nonexistent market for us at this point. Operator [Operator instructions] Your next question comes from Chris Pasquale from Guggenheim. Your line is open. Chris Pasquale -- Guggenheim Partners LLC -- Analyst Thanks, and congrats on the quarter, guys. Quentin, the SG&A leverage this quarter was very impressive. Can you talk about the sustainability of that? You didn't raise EBITDA guidance by quite as much as I thought you may have given the progress this quarter. So I'm just wondering if there was anything in terms of timing of spend that may have shifted some dollars from Q3 into Q4. Quentin Blackford -- Chief Operating Officer No. Nothing specific around the timing of spend, although I will tell you, in the fourth quarter, we're going to start to see some incremental spend, particularly around the development efforts of automating these G7 lines. We have the product pretty well dialed in, in terms of its design. Now it's all about designing these lines. And conceptually, we know what the lines need to look like, what they need to produce. Now it's fine-tuning that work and making sure that we have them up ready to start to roll. So you've got that cost coming through in the fourth quarter that you didn't necessarily have in the third quarter. To your point, on a year-to-date basis, we made incredible traction from a profitability perspective. OPEX has levered over 1,000 basis points. And on a full-year basis, we're going to see tremendous leverage from both an operating margin and EBITDA margin, even though it might not have been raised in line with what you were expecting. It's still tremendous improvements. I think what it tells you is that this business has the capability to perform very appealing profitability measures if you will. There's nothing structurally in the business model that keeps us from being able to do that. I think what we want to be able to do is balance the investments that are going to open up all these new growth opportunities, that we continue to become more convicted are real. And so we're going to balance that over time. But we remain committed to those long-term profitability goals we've laid out. We're making tremendous progress toward them and feel good about where we're at today. So we're pleased with the progress that's being made. Operator And there are no questions at this time. Kevin Sayer -- Chairman, President, and Chief Executive Officer All right. This is Kevin. I'm going to close up as I usually do. We want to thank everybody for participating on the call this quarter. In closing, I want to acknowledge the contribution of all of our team members to get to this point. $130 million in growth in this quarter combined with our best financial results ever. We've never delivered a quarter like this. And we've asked our people to go above and beyond in 2019 to achieve these things. While our year-to-date revenue growth is near 50%, I can assure you all that our volume growth, of all product components, far exceeds that number. And we've been running all year to keep up. And while we see a light at the end of the tunnel, it's just not as quickly as we'd hoped for. Our commercial teams have hit on all cylinders this year. International growth remains strong and a great opportunity going forward for us is global access and awareness continues to improve. We also talked about the effectiveness of our U.S. reimbursement team and positioning us for the future, enabling our shift to more efficient distribution channels with numerous contract wins and our relationships throughout our distribution channels have been nothing but strengthen over the course of the year. And finally, our U.S. sales team, both internal and external. They've navigated through some very difficult situations with respect to our supply constraints, yet remain engaged and effective. There isn't a better group anywhere. Many of our accomplishments this year can be measured by numbers, all of the letters and emails of lives that we've changed. Standing up a facility and a business in the Philippines over the past 9 months that's grown to a nearly 700-person workforce of people who have committed to this company, as everybody here in the States, and who demonstrate the commitment to patients that we've always had that have made DexCom the company than it is today. We look forward to continuing this success in the future. Thank you. Operator [Operator signoff] Duration: 50 minutes Call participants: Sean Christensen -- Senior Investor Relations Manager Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin Blackford -- Chief Operating Officer Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Danielle Antalffy -- SVB Leerink -- Analyst Margaret Kaczor -- William Blair & Company -- Analyst Jeff Johnson -- Robert W. Baird and Company -- Analyst Ryan Blicker -- Cowen and Company -- Analyst David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Jayson Bedford -- Raymond James -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Unknown speaker Mathew Blackman -- Stifel Financial Corp. -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Chris Pasquale -- Guggenheim Partners LLC -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable Wednesday Option Activity: GOOG, NVDA, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alphabet Inc (Symbol: GOOG), where a total of 13,387 contracts have traded so far, representing approximately 1.3 million underlying shares. That amounts to about 104.5% of GOOG's average daily trading volume over the past month of 1.3 million shares. Particularly high volume was seen for the $1310 strike call option expiring November 08, 2019, with 626 contracts trading so far today, representing approximately 62,600 underlying shares of GOOG. Below is a chart showing GOOG's trailing twelve month trading history, with the $1310 strike highlighted in orange: NVIDIA Corp (Symbol: NVDA) options are showing a volume of 77,274 contracts thus far today. That number of contracts represents approximately 7.7 million underlying shares, working out to a sizeable 97.4% of NVDA's average daily trading volume over the past month, of 7.9 million shares. Particularly high volume was seen for the $210 strike call option expiring November 08, 2019, with 8,674 contracts trading so far today, representing approximately 867,400 underlying shares of NVDA. Below is a chart showing NVDA's trailing twelve month trading history, with the $210 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 5,773 contracts, representing approximately 577,300 underlying shares or approximately 88.9% of DXCM's average daily trading volume over the past month, of 649,725 shares. Particularly high volume was seen for the $155 strike put option expiring November 15, 2019, with 668 contracts trading so far today, representing approximately 66,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $155 strike highlighted in orange: For the various different available expirations for GOOG options, NVDA options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Raises FY2019 Sales Guidance from $1.325B-1.375B to $1.425B-1.45B"", ""DexCom Q3 EPS $0.65 Beats $0.21 Estimate, Sales $396.3M Beat $348.12M Estimate"", ""The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings"", ""DexCom, Inc.'s (DXCM) CEO Kevin Sayer on Q3 2019 Results - Earnings Call Transcript"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dow Jones Futures: Time To Reset Roku? These 4 Stocks Are Testing Buy Points On Earnings"", ""ROKU, DXCM, PBYI, FOSL, and AERI among after hour movers"", ""DexCom Q3 sensor sales up 64%; shares up 15% after hours"", ""DexCom, Inc. 2019 Q3 - Results - Earnings Call Presentation"", ""DexCom EPS beats by $0.45, beats on revenue""]"
DXCM,2019-11-07,46.3,50.2,45.7875,48.675,"[""Dow Jones Today: China Trade Chatter Points Market Toward New Highs; Elf, Baidu, Dexcom Eye Breakouts; Disney Reports Late"", ""BIDU, IQ among premarket gainers"", ""Dow Jones Soars 858 Points In Q4; Why This Market Leader Surpassed An Alternate Buy Point"", ""Dow Jones Futures: Don't Fight China Trade News; Disney Soars Late After Dexcom, Alibaba, Costco Break Out"", ""IBD Stock Of The Day Breaks Out To Record High After Crushing Earnings Views"", ""Dow Jones Futures Rally On China Trade News; Roku Dives, But These 4 Stocks Are Testing Breakouts"", ""The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $185"", ""30 Stocks Moving in Thursday's Pre-Market Session"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $215"", ""23 Healthcare Stocks Moving In Thursday's Pre-Market Session"", ""DexCom shares are trading higher after the company reported better-than-expected Q3 results and raised FY19 sales guidance."", ""Baird Maintains Outperform on DexCom, Raises Price Target to $240"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $202"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stifel Nicolaus Maintains Buy on DexCom, Raises Price Target to $200"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $195"", ""Piper Jaffray Maintains Overweight on DexCom, Raises Price Target to $200"", ""75 Stocks Moving In Thursday's Mid-Day Session"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $189"", ""Mid-Day Market Update: Crude Oil Up Over 2%; Party City Shares Fall After Downbeat Q3 Results"", ""Mid-Afternoon Market Update: DexCom Gains Following Strong Q3 Results; Obseva Shares Plunge"", ""Mid-Afternoon Market Update: DexCom Gains Following Strong Q3 Results; Obseva Shares Plunge"", ""Mid-Day Market Update: Crude Oil Up Over 2%; Party City Shares Fall After Downbeat Q3 Results"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $189"", ""75 Stocks Moving In Thursday's Mid-Day Session"", ""Piper Jaffray Maintains Overweight on DexCom, Raises Price Target to $200"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $195"", ""Stifel Nicolaus Maintains Buy on DexCom, Raises Price Target to $200"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $202"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $240"", ""DexCom shares are trading higher after the company reported better-than-expected Q3 results and raised FY19 sales guidance."", ""23 Healthcare Stocks Moving In Thursday's Pre-Market Session"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $215"", ""30 Stocks Moving in Thursday's Pre-Market Session"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $185"", ""The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs"", ""Dow Jones Futures: Don't Fight China Trade News; Disney Soars Late After Dexcom, Alibaba, Costco Break Out"", ""IBD Stock Of The Day Breaks Out To Record High After Crushing Earnings Views"", ""Dow Jones Soars 858 Points In Q4; Why This Market Leader Surpassed An Alternate Buy Point"", ""Dow Jones Today: China Trade Chatter Points Market Toward New Highs; Elf, Baidu, Dexcom Eye Breakouts; Disney Reports Late"", ""BIDU, IQ among premarket gainers"", ""Dow Jones Futures Rally On China Trade News; Roku Dives, But These 4 Stocks Are Testing Breakouts"", ""Health Care Sector Update for 11/07/2019: VIVO,NVRO,DXCM,RDNT Top Health Care Stocks JNJ +0.10% PFE -0.87% ABT -0.08% MRK -0.52% AMGN +0.42% Health care stocks turned narrowly mixed this afternoon, with the NYSE Health Care Index falling almost 0.1% while the shares of health care companies in the S&P 500 still were hanging on for a nearly 0.1% gain. The Nasdaq Biotechnology index also was slipping more than 0.1% in late trade, reversing a mid-day advance. Among health care stocks moving on news: (+) Meridian Bioscience (VIVO) dropped more than 18% on Thursday after the diagnostic test kits company projected non-GAAP FY20 net income badly missing Wall Street estimates. Excluding one-time items, the company is expecting to earn between $0.28 to $0.34 per share, well under the Capital IQ consensus looking for a $0.51 per share adjusted profit during the 12 months ending next September. In other sector news: (+) DexCom (DXCM) soared more than 30% to a record high of $200.80 per share on Thursday after the medical device company raised its FY19 revenue outlook above analyst projections after reporting a 48.6% year-over-year increase in Q3 revenue to $396.3 million, also topping the $349 million Street view. Excluding one-time items, the company also earned $0.65 per share, up from $0.18 per share during the year-ago period and crushing the Capital IQ consensus expecting $0.20 per share. (+) Nevro (NVRO) rose almost 27% to a best-ever $108.20 a share after the medical device company reported a smaller-than-expected Q3 net loss of $0.58 per share, beating the Capital IQ consensus expecting an $0.84 per share GAAP loss. Revenue grew 5% over year-ago levels to $100.2 million, also topping the $92.3 million Street view. It also increased its FY19 revenue forecast and said chief financial officer Andrew Galligan plans to retire but will stay in the post until a successor is named and then work in a transitional role for an unspecified period. (-) RadNet (RDNT) was down almost 2% in Thursday trade after the diagnostic imaging services company announced a partnership with a privately held artificial intelligence company to boost patient compliance and operational protocols during mammogram exams. Radnet has licensed selected AI tools from Whiterabbit.ai and also made an unspecified investment in the company as part of the new partnership. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 11/07/2019: NVRO,DXCM,RDNT Top Health Care Stocks JNJ +0.91% PFE -0.44% ABT +0.24% MRK +0.13% AMGN +0.29% Health care stocks were edging higher this afternoon, with the NYSE Health Care Index climbing almost 0.1% while the shares of health care companies in the S&P 500 also were up more than 0.2% as a group. The Nasdaq Biotechnology index also was climbing nearly 0.3%. Among health care stocks moving on news: (+) Nevro (NVRO) rose almost 27% to a best-ever $108.20 a share after the medical device company reported a smaller-than-expected Q3 net loss of $0.58 per share, beating the Capital IQ consensus expecting an $0.84 per share GAAP loss. Revenue grew 5% over year-ago levels to $100.2 million, also topping the $92.3 million Street view. It also increased its FY19 revenue forecast and said chief financial officer Andrew Galligan plans to retire but will stay in the post until a successor is named and then work in a transitional role for an unspecified period. In other sector news: (+) DexCom (DXCM) soared 31% to a record high of $200.80 per share on Thursday after the medical device company raised its FY19 revenue outlook above analyst projections after reporting a 48.6% year-over-year increase in Q3 revenue to $396.3 milion, also topping the $349 million Street view. Excluding one-time items, the company also earned $0.65 per share, up from $0.18 per share during the year-ago period and crushing the Capital IQ consensus expecting $0.20 per share. (-) RadNet (RDNT) was down almost 2% in Thursday trade after the diagnostic imaging services company announced a partnership with a privately held artificial intelligence company to boost patient compliance and operational protocols during mammogram exams. Radnet has licenced selected AI tools from Whiterabbit.ai and also made an unspecified investment in the company as part of the new partnership. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Is Surging Today What happened After reporting blowout quarterly results, shares of DexCom (NASDAQ: DXCM), a diabetes company focused on continuous blood sugar tracking, jumped 29% as of 10:32 a.m. EST on Thursday. So what The headline numbers from the quarter were great: Revenue soared 49% to $396 million. GAAP operating margin expanded by 890 basis points to 14% of revenue. GAAP net income was $45.8 million, or $0.50 per share. Non-GAAP net income almost quadrupled to $60.4 million, or $0.65 per share. That blew past the $0.20 that analysts had been expecting. Image source: Getty Images. Management also boosted its full-year guidance in response to the upbeat result: Revenue is now expected to land between $1.425 billion and $1.450 billion. This represents growth of about 40% at the midpoint, which is much higher than its prior forecast of about 30% growth. It's also nicely above the $1.37 billion that Wall Street was looking for. Gross profit margin is expected to be about 63%, down slightly from management's prior expectation of 64% to 65%. Non-GAAP operating margin is expected to be about 9%, up from management's previous expectation of 7%. Non-GAAP adjusted EBITDA margin is expected to be approximately 19.5%, up from management's prior forecast of 18.5%. Traders are bidding up the share price in response to the nearly flawless quarterly report. Now what These results should help to prove that DexCom isn't having any problems growing quickly even with increasing competition. What's more, the company is now solidly profitable, which is great to see. DexCom's stock remains extremely expensive -- shares are trading for more than 14 times sales and 138 times next year's earnings estimates -- but that doesn't mean that this winner can't continue to win. If you're a growth stock investor, DexCom deserves a spot on your radar. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Keep An Eye On IFRX, VNDA, DXCM\u2026 (RTTNews) - What's moving these stocks? 1. InflaRx N.V. (IFRX) InflaRx is a clinical-stage biopharmaceutical company. The stock closed Wednesday's trading at $2.59, and was up 32.43% after-hours. News: The company reported positive results from the phase IIb study of lead drug candidate IFX-1. IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody is under phase IIb study dubbed SHINE in patients with moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease. Yesterday, InflaRx announced positive results from the open-label extension (OLE) part of the study. 2.Vanda Pharmaceuticals Inc. (VNDA) Vanda Pharmaceuticals is a revenue genrating biopharmaceutical company The stock closed Wednesday's trading at $13.14, and was up 19.86% after-hours. News: The company announced better-than-expected financial results for the third quarter ended September 30, 2019 and provided full-year revenue guidance. Net income in the third quarter was $100.42 million or $1.84 per share compared with $7.17 million or $0.13 per share in the corresponding quarter last year. Third-quarter earnings were favored by an income tax benefit of $88.1 million. Analysts earnings expectation was $0.07 per share. Revenue in the third quarter rose to $59.49 million from $49.14 million in the same quarter a year ago. Looking forward to full year, the company expects revenue to be in the range of $215 million to $225 million. Analysts currently expect the company to report revenue of $224.8 million. 3.DexCom, Inc. (DXCM) DexCom is a medical device company, focusing on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. The stock closed Wednesday's trading at $153.12, and was up 19.51% after-hours. News: The company reported Street-beating earnings in the third quarter ended September 30, 2019, and raised FY2019 revenue outlook. Net income was $45.8 million, or $0.50 per share, for the third quarter compared with $46.6 million, or $0.52 per share, for the same quarter last year. Net income on an adjusted basis rose to $60.4 million, or $0.65 per share from $15.9 million, or $0.18 per share in the year-earlier period. Analysts had a consensus earnings estimate of $0.20 per share. Revenue in the third quarter grew 49% to $396.3 million, from $266.7 million in the year-earlier quarter. The company has raised its revenue expectation to the range of $1.425 billion to $1.450 billion compared to previous expectations of $1.325 billion to $1.375 billion. Analysts forecast revenue of $1.37 billion. 4.Livongo Health, Inc. (LVGO) Livongo Health is a medical device company that provides digital health management solutions to patients with chronic conditions. The stock closed Wednesday's trading at $21.20, and was up 14.76% after-hours. News: The company reported upbeat financial results for the third quarter ended September 30, 2019, and provided robust fourth-quarter and full-year revenue outlook. Net loss for the third quarter was $19.73 million or $0.27 per share compared with net loss of $10.56 million or $0.64 per share in the same quarter a year ago. On a non-GAAP basis, net loss narrowed to $3.38 million or $0.05 per share from $9.08 million or $0.55 per share in the prior-year quarter. Analysts had expected a loss of $0.13 per share. Total revenue for the quarter was $46.66 million, up 148% year-over-year from $18.78 million. Looking forward to fourth quarter, the company expects revenue in the range of $49.0 million and $49.5 million. The consensus estimate is $45.85 million. For 2019, the company sees revenue in the range of $168.5 million and $169.0 million, compared with the consensus estimate of $161.89 million. 5.Career Education Corporation (CECO) Career Education Corporation is an educational services company. The stock closed Wednesday's trading at $14.90, and was up 13.15% after-hours. News: The company reported strong financial results for the third quarter ended September 30, 2019, announced share buyback, and provided fourth-quarter and full-year outlook. Third-quarter net income rose to $18.2 million or $0.25 per share from $14.9 million or $0.21 per share for the prior-year quarter. Adjusted earnings per share were $0.33 in the third quarter versus $0.25 in the year-ago quarter. Analysts had estimated $0.24 per share. Revenue in the third quarter increased 6.4 percent to $155.0 million as compared to $145.7 million in the year-earlier period. Looking forward to fourth quarter, the company expects adjusted earnings per share to be in the range of $0.27 to $0.29. This is compared with the street estimate of $0.24 per share. For the full year, the company sees adjusted earnings to be in the range of $1.32 to $1.34 per share and revenue growth is expected between 6.0 percent and 6.5 percent. The consensus estimate for earnings is at $1.24 and for revenue growth is at 5 percent. On November 4, 2019, the Board of Directors of the company approved a new stock repurchase program of up to $50 million of outstanding common stock. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Mid-Afternoon Market Update: DexCom Gains Following Strong Q3 Results; Obseva Shares Plunge"", ""Mid-Day Market Update: Crude Oil Up Over 2%; Party City Shares Fall After Downbeat Q3 Results"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $189"", ""75 Stocks Moving In Thursday's Mid-Day Session"", ""Piper Jaffray Maintains Overweight on DexCom, Raises Price Target to $200"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $195"", ""Stifel Nicolaus Maintains Buy on DexCom, Raises Price Target to $200"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $202"", ""Baird Maintains Outperform on DexCom, Raises Price Target to $240"", ""DexCom shares are trading higher after the company reported better-than-expected Q3 results and raised FY19 sales guidance."", ""23 Healthcare Stocks Moving In Thursday's Pre-Market Session"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $215"", ""30 Stocks Moving in Thursday's Pre-Market Session"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $185"", ""The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs"", ""Dow Jones Futures: Don't Fight China Trade News; Disney Soars Late After Dexcom, Alibaba, Costco Break Out"", ""IBD Stock Of The Day Breaks Out To Record High After Crushing Earnings Views"", ""Dow Jones Soars 858 Points In Q4; Why This Market Leader Surpassed An Alternate Buy Point"", ""Dow Jones Today: China Trade Chatter Points Market Toward New Highs; Elf, Baidu, Dexcom Eye Breakouts; Disney Reports Late"", ""BIDU, IQ among premarket gainers"", ""Dow Jones Futures Rally On China Trade News; Roku Dives, But These 4 Stocks Are Testing Breakouts""]"
DXCM,2019-11-08,48.525,49.906,48.375,49.52,"[""DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?"", ""Stock Upgrades: Dexcom Shows Rising Relative Strength"", ""DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3"", ""Westfield Capital Management Co Lp Buys Fidelity National Information Services Inc, Global ..."", ""Jennison Associates Llc Buys Shopify Inc, DexCom Inc, American Tower Corp, Sells Alexion ..."", ""94 Biggest Movers From Yesterday"", ""The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut"", ""The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut"", ""94 Biggest Movers From Yesterday"", ""Westfield Capital Management Co Lp Buys Fidelity National Information Services Inc, Global ..."", ""Jennison Associates Llc Buys Shopify Inc, DexCom Inc, American Tower Corp, Sells Alexion ..."", ""Stock Upgrades: Dexcom Shows Rising Relative Strength"", ""DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?"", ""DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3"", ""DXCM Crosses Above Average Analyst Target In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $179.47, changing hands for $194.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 15 different analyst targets contributing to that average for DexCom Inc, but the average is just that \u2014 a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $125.00. And then on the other side of the spectrum one analyst has a target as high as $200.00. The standard deviation is $17.983. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $179.47/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $179.47 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut"", ""94 Biggest Movers From Yesterday"", ""Westfield Capital Management Co Lp Buys Fidelity National Information Services Inc, Global ..."", ""Jennison Associates Llc Buys Shopify Inc, DexCom Inc, American Tower Corp, Sells Alexion ..."", ""Stock Upgrades: Dexcom Shows Rising Relative Strength"", ""DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?"", ""DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3""]"
DXCM,2019-11-11,49.0,51.4815,48.65,51.42,"[""What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?"", ""Dexcom: Material Deceleration On The Horizon"", ""Stocks That Hit 52-Week Highs On Monday"", ""These Are The Winners Of The Inaugural WeTrader Paper Trading Competition"", ""These Are The Winners Of The Inaugural WeTrader Paper Trading Competition"", ""Stocks That Hit 52-Week Highs On Monday"", ""What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?"", ""Dexcom: Material Deceleration On The Horizon"", ""These Are The Winners Of The Inaugural WeTrader Paper Trading Competition"", ""Stocks That Hit 52-Week Highs On Monday"", ""What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?"", ""Dexcom: Material Deceleration On The Horizon""]"
DXCM,2019-11-12,51.01,52.05,50.7225,51.535,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Healthcare Stocks That Hit New Highs (DXCM, ZLAB, PODD) (RTTNews) - The following are the healthcare stocks that hit a new 52-week high on Monday. 1. Zai Lab Limited (ZLAB) hit a new high of $39.49 in intraday trading on Monday, before closing at $39.40. The stock is up nearly 70% year-to-date. Zai Lab is a commercial stage biopharmaceutical company. The company has a broad late-stage pipeline in oncology and infectious disease, including: Durlobactam, in combination with sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by A.baumannii that the company is co-developing with Entasis Therapeutics is under a phase III study. Acinetobacter baumannii is an opportunistic bacterial pathogen primarily associated with hospital-acquired infections. Ripretinib, in-licensed by Zai Lab from Deciphera Pharmaceuticals Inc. (DCHP) for the development and potential commercialization into mainland China, Hong Kong, Macau, and Taiwan the Greater China region, is under phase III trial in second-line Gastrointestinal Stromal Tumors (GIST) patients, dubbed INTRIGUE. A pivotal Phase 3 study of Ripretinib in patients with fourth-line and fourth-line plus GIST, dubbed INVICTUS is also underway. Positive top-line data were reported in August. Margetuximab, for the treatment of HER2-positive metastatic breast cancer patients, successfully completed a phase III study, dubbed SOPHIA, in February of this year. Margetuximab was licensed from MacroGenics Inc. (MGNX) in November 2018. Zai Lab has rights for this drug candidate in mainland China, Hong Kong, Macau, and Taiwan. MacroGenics expects to submit a biologics license application for Margetuximab to the U.S. FDA for HER2-positive metastatic breast cancer this year. Bemarituzumab for the treatment of patients with previously-untreated advanced gastric cancer is under an international phase III trial, dubbed FIGHT. The Company licensed Bemarituzumab from Five Prime (FPRX) in December 2017. Zai Lab is responsible for the China portion of the FIGHT study. Zai Lab had revenues of $3.42 million during the six months ended June 30, 2019, compared to nil in the corresponding period last year. 2. DexCom, Inc. (DXCM) recorded a new high of $205.93 in intraday trading on Monday, before closing at $205.68. The stock has gained 70% year-to-date. DexCom is a medical device company, focusing on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Recent event: The company reported upbeat earnings in the third quarter on November 7, 2019, and raised full-year revenue outlook. Net income on an adjusted basis rose to $60.4 million or $0.65 per share from $15.9 million or $0.18 per share in the year-earlier period. Analysts had a consensus earnings estimate of $0.20 per share. Revenue in the third quarter grew 49% to $396.3 million from $266.7 million in the year-earlier quarter. The company has raised its full-year revenue expectation to a range of $1.425 billion to $1.450 billion from its previous forecast range of $1.325 billion to $1.375 billion. Analysts expect the company to report revenue of $1.37 billion. 3. Insulet Corporation (PODD) jumped to a new high of $174.18 in intraday trading on Monday, before closing at $173.99. The stock is up nearly 120% year-to-date. Insulet Corporation is a medical device company developing insulin delivery systems. Recent event: The company reported better-than-expected revenue in the third quarter on November 5, 2019, and raised full-year revenue guidance. Third-quarter revenue was $192.1 million, up 27%, compared to $151.1 million in the prior-year quarter. Net income was $0.9 million, or $0.01 per share, compared with $1.7 million, or $0.03 per share, in the year-ago quarter. In the third quarter, Insulet started the installation of its new highly-automated manufacturing facility in the U.S., with production on this line expected to commence in 2020. For the fourth quarter, the company expects revenue in the range of $193 million to $201 million. The analysts' expectation is $199.08 million. The company foresees full-year revenue in a range of $722 million to $730 million, representing growth of 28% to 29% compared to 24% to 27%, guided earlier. Analysts see revenue of $725.67 million for the year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2019-11-13,51.055,51.6325,49.994,50.725,"[""5 Relative Price Strength Stocks to Buy for Optimum Returns"", ""The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher"", ""The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher"", ""5 Relative Price Strength Stocks to Buy for Optimum Returns"", ""The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher"", ""5 Relative Price Strength Stocks to Buy for Optimum Returns""]"
DXCM,2019-11-14,51.2025,51.6312,49.6763,50.7025,"[""NextGen's Medfusion Buyout to Improve Patient Experience"", ""Dexcom: Prepare To Be Greedy When Fear Strikes Back"", ""5 Companies Hit 5\u2014-Week Highs"", ""Dexcom: Prepare To Be Greedy When Fear Strikes Back"", ""5 Companies Hit 5\u2014-Week Highs"", ""NextGen's Medfusion Buyout to Improve Patient Experience"", ""Dexcom: Prepare To Be Greedy When Fear Strikes Back"", ""5 Companies Hit 5\u2014-Week Highs"", ""NextGen's Medfusion Buyout to Improve Patient Experience""]"
DXCM,2019-11-15,50.8475,52.095,50.505,52.0925,"[""Abiomed, DexCom, Quidel, Other Medical Equipment Stock Buys"", ""Abiomed, DexCom, Quidel, Other Medical Equipment Stock Buys"", ""Abiomed, DexCom, Quidel, Other Medical Equipment Stock Buys""]"
DXCM,2019-11-18,52.3025,53.62,52.205,53.445,"[""DexCom Continues To Soar After Earnings"", ""Piper likes DexCom in premarket analyst action"", ""Stocks That Hit 52-Week Highs On Monday"", ""Stocks That Hit 52-Week Highs On Monday"", ""DexCom Continues To Soar After Earnings"", ""Piper likes DexCom in premarket analyst action"", ""Is Tandem Diabetes Care Stock a Buy? One promising area for biotech investors looking for growth is the diabetes market. More than 425 million adults around the world have been diagnosed with the condition, a figure that will only continue to grow over the coming years. Because diabetes has a relatively low mortality rate and an increasing patient population, many biotech stocks that focus on this market have quickly become compelling investments. One of these is Tandem Diabetes Care (NASDAQ: TNDM), a leading manufacturer of insulin pumps used by patients with type 1 diabetes to manage their blood sugar levels. Shares of Tandem have almost doubled since the start of the year as sales continue to skyrocket. Let's take a look at some reasons Wall Street considers Tandem Diabetes a buy and whether these reasons are justified. IMAGE SOURCE: GETTY IMAGES. The market for insulin pumps Type 1 diabetes patients require insulin on a consistent basis, usually administered either by multiple daily injections (the most common method) or by continuous subcutaneous insulin infusions, also referred to as just insulin pump therapy. This second option, which is becoming increasingly popular among type 1 diabetes patients, relies on a portable pump that automatically delivers insulin in a way that mimics the bodily process of a nondiabetic person. Although only a portion of type 1 diabetes patients use insulin pumps, not needing to take multiple daily injections is a major convenience factor that will likely convince many to give insulin pumps a try. At the same time, the fact that most patients aren't using insulin pumps yet means there's plenty of room for the limited number of insulin pump manufacturers, such as Tandem Diabetes, to grow significantly. Surging sales Tandem's sales really started to take off after it received approval from the U.S. Food and Drug Administration to use its latest insulin pump, t:slim X2, alongside the Basal-IQ glucose monitor from DexCom. This combination almost completely automates the insulin dosing process for patients, which is a significant selling point over other competitors that haven't integrated glucose monitors yet. Specifically, the FDA ended up classifying the t:slim X2 as an ACE pump (alternative controller enabled infusion pump), a designation that allows integration with other externally produced components. Since this approval, sales of Tandem's insulin pumps have skyrocketed. In its most recent Q3 financial results, the company saw insulin pump shipments surge by 105% worldwide, growing from 8,434 in Q3 2018 to an impressive 17,893 pumps in Q3 2019. At the same time, Tandem's margins have seen a significant improvement, rising from negative 34% to negative 6% since last year. The company currently estimates that its 2019 sales will come in at $365 million, compared to the $89.8 million seen back in 2018 and the $44.1 million of 2017. A recent setback? Tandem experienced a little bit of a setback recently when the FDA reported the death of a patient who was using the company's t:slim X2 pump in October. More specifically, the coroner found that the patient's blood sugar was extremely low at the time of death. While shares of Tandem slid in light of this news, the company provided an update to the case, saying that the death wasn't caused by a pump malfunction. Considering the automated nature of these insulin pumps, patients trust that they will operate perfectly, as a malfunction or outright failure in insulin dosing can easily lead to hypoglycemia and other emergency conditions such as diabetic ketoacidosis. While why exactly the man died remains a mystery, especially since privacy reasons prevent Tandem from clarifying the cause further, the most important thing for investors to know was that the t:slim X2 pump wasn't the cause. \""While this event is certainly tragic, unfortunately some patients experience such issues and ultimately expire while on insulin pumps,\"" said Piper Jaffray analyst J.P. McKim in a research note following this news. Looking at the competition While Roche and Johnson & Johnson used to be competitors in the insulin pump market, both companies sold their pump businesses in 2016 and 2017. This leaves only a couple of major players, one of the most notable being Tandem's rival insulin pump manufacturer Insulet (NASDAQ: PODD). A comparatively positioned and similarly sized competitor to Tandem, Insulet has also seen strong sales growth over the past year. Revenue has gone up by 27% in comparison to the previous year, according to its third-quarter results, and its omnipod insulin pump has also received an ACE designation from FDA to start incorporating glucose monitors. While Insulet's new glucose-monitoring insulin pumps won't be ready until sometime in 2020, Tandem will have to prepare for a new competing product that might chip away at its market share. However, considering the sheer size of the type 1 diabetes population, the number of potential insulin pump users, and the relative lack of competition beyond a handful of companies, there's enough room in this market for both companies to grow without stifling each other too much. The main risk The biggest concern insulin pump makers like Tandem Diabetes have to worry about is the prospect of a potential type 1 diabetes drug. While there's no miracle cure on the horizon as of yet, there are some treatments that help slow down the onset of the disease in patients who are at high risk of becoming diabetic. Most notable is Provention Bio's Teplizumab. This drug candidate, which is specifically designed for type 1 diabetes patients, is currently in a phase 3 clinical trial that has shown promising results so far. The drug has shown to be able to delay or even prevent the eventual onset of type 1 diabetes in patients considered to be at high risk of developing the condition. However, Teplizumab is a preventative drug at its core and doesn't target patients who already have full-blown diabetes, meaning most of the current diabetic market won't be eligible for the treatment. At the same time, even if all goes well with the FDA, Teplizumab likely won't be available until 2022 at the earliest, when its phase 3 trial concludes. That gives insulin pump makers plenty of time to continue growing with little concern. Is Tandem Diabetes a buy right now? Tandem Diabetes has seen stellar revenue growth over the past year and shows no signs of slowing down. With just a handful of competitors in a rapidly growing market, the company is an extremely compelling growth stock at this moment. While future diabetes drugs such as Teplizumab could end up hurting Tandem's growth figures, such a situation is still fairly far in the future. For the next 12 to 24 months, there's nothing stopping Tandem from continuing its growing spree. For those comfortable with investing in a small, high-growth, high-risk biotech stock, Tandem Diabetes is an excellent addition to your portfolio. Just don't put all your eggs in this one basket, and make sure Tandem is just one part in a larger, diversified portfolio. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool recommends Insulet and Johnson & Johnson. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Monday"", ""DexCom Continues To Soar After Earnings"", ""Piper likes DexCom in premarket analyst action""]"
DXCM,2019-11-19,53.6125,54.7325,53.1275,54.395,"[""5 Winning Stocks Halfway Through Q4"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""5 Winning Stocks Halfway Through Q4"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""5 Winning Stocks Halfway Through Q4""]"
DXCM,2019-11-20,54.13,55.8125,54.125,55.3325,"[""The Zacks Analyst Blog Highlights: comScore, Communications Systems, Vista Outdoor, Forterra and DexCom"", ""The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data"", ""The Zacks Analyst Blog Highlights: comScore, Communications Systems, Vista Outdoor, Forterra and DexCom"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data"", ""The Zacks Analyst Blog Highlights: comScore, Communications Systems, Vista Outdoor, Forterra and DexCom""]"
DXCM,2019-11-21,55.26,55.61,53.765,54.7025,"[""Healthcare On The March"", ""Digital Health Gaining Momentum: 3 MedTech Stocks in Focus"", ""The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon"", ""The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon"", ""Healthcare On The March"", ""Digital Health Gaining Momentum: 3 MedTech Stocks in Focus"", ""The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon"", ""Healthcare On The March"", ""Digital Health Gaining Momentum: 3 MedTech Stocks in Focus""]"
DXCM,2019-11-22,54.3675,55.879,54.2555,55.4625,
DXCM,2019-11-25,56.0,56.88,55.425,56.6975,"[""Dexcom Inc (DXCM) EVP Quality and Regulatory Aff Donald Abbey Sold $\u2014.6 million of Shares"", ""MEDNAX (MD) Ties Up With Homestead to Expand in Florida"", ""Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?"", ""Stocks That Hit 52-Week Highs On Monday"", ""Stocks That Hit 52-Week Highs On Monday"", ""Dexcom Inc (DXCM) EVP Quality and Regulatory Aff Donald Abbey Sold $\u2014.6 million of Shares"", ""MEDNAX (MD) Ties Up With Homestead to Expand in Florida"", ""Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?"", ""Stocks That Hit 52-Week Highs On Monday"", ""Dexcom Inc (DXCM) EVP Quality and Regulatory Aff Donald Abbey Sold $\u2014.6 million of Shares"", ""MEDNAX (MD) Ties Up With Homestead to Expand in Florida"", ""Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?""]"
DXCM,2019-11-26,56.6375,56.9585,55.8025,56.0175,"[""5 Best-Performing, Top-Ranked Growth Stocks of November"", ""The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug"", ""5 Best-Performing, Top-Ranked Growth Stocks of November"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug"", ""5 Best-Performing, Top-Ranked Growth Stocks of November""]"
DXCM,2019-11-27,56.06,57.2112,55.9822,56.855,"[""The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen"", ""Noteworthy Wednesday Option Activity: DXCM, EXPE, CLVS Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 7,617 contracts has been traded thus far today, a contract volume which is representative of approximately 761,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53.3% of DXCM's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $210 strike put option expiring December 20, 2019, with 6,477 contracts trading so far today, representing approximately 647,700 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $210 strike highlighted in orange: Expedia Group Inc (Symbol: EXPE) options are showing a volume of 24,775 contracts thus far today. That number of contracts represents approximately 2.5 million underlying shares, working out to a sizeable 52% of EXPE's average daily trading volume over the past month, of 4.8 million shares. Particularly high volume was seen for the $105 strike call option expiring January 17, 2020, with 1,691 contracts trading so far today, representing approximately 169,100 underlying shares of EXPE. Below is a chart showing EXPE's trailing twelve month trading history, with the $105 strike highlighted in orange: And Clovis Oncology Inc (Symbol: CLVS) saw options trading volume of 61,890 contracts, representing approximately 6.2 million underlying shares or approximately 51% of CLVS's average daily trading volume over the past month, of 12.1 million shares. Especially high volume was seen for the $12 strike call option expiring December 20, 2019, with 5,179 contracts trading so far today, representing approximately 517,900 underlying shares of CLVS. Below is a chart showing CLVS's trailing twelve month trading history, with the $12 strike highlighted in orange: For the various different available expirations for DXCM options, EXPE options, or CLVS options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen""]"
DXCM,2019-11-29,56.525,57.4225,56.3175,56.8275,"[""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ..."", ""5 Screaming Hot Strong Buy Stocks"", ""Top Ranked Momentum Stocks to Buy for November 29th"", ""6 Top Momentum Stocks in November With More Room to Run"", ""DexCom, Inc. (DXCM) Shares March Higher, Can It Continue?"", ""5 Best Bets in View Before the Curtain Falls on November"", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks That Hit 52-Week Highs On Friday"", ""5 Screaming Hot Strong Buy Stocks"", ""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ..."", ""DexCom, Inc. (DXCM) Shares March Higher, Can It Continue?"", ""Top Ranked Momentum Stocks to Buy for November 29th"", ""5 Best Bets in View Before the Curtain Falls on November"", ""6 Top Momentum Stocks in November With More Room to Run"", ""Stocks That Hit 52-Week Highs On Friday"", ""5 Screaming Hot Strong Buy Stocks"", ""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ..."", ""DexCom, Inc. (DXCM) Shares March Higher, Can It Continue?"", ""Top Ranked Momentum Stocks to Buy for November 29th"", ""5 Best Bets in View Before the Curtain Falls on November"", ""6 Top Momentum Stocks in November With More Room to Run""]"
DXCM,2019-12-02,54.5375,56.1325,54.275,55.98,"[""DexCom down 2% on G6 app glitches"", ""Dow Jones Futures: Apple, AMD, DexCom Stand Tall As Stock Market Stumbles; Coupa Earnings Top"", ""Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data."", ""Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data."", ""Dow Jones Futures: Apple, AMD, DexCom Stand Tall As Stock Market Stumbles; Coupa Earnings Top"", ""DexCom down 2% on G6 app glitches"", ""What Happened in the Stock Market Today Major benchmarks fell on Monday after President Trump reinstated tariffs on steel and aluminum imports from Brazil and Argentina. Also, a report from the Institute for Supply Management indicated that the manufacturing sector contracted in November for the fourth straight month, further dampening sentiment. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closed down, with the real estate sector seeing the biggest losses due to rising long-term interest rates. Today's stock market Data source: Yahoo! Finance. As for individual stocks, Apache (NYSE: APA) issued an exploration update that rattled investors, and an outage at DexCom (NASDAQ: DXCM) is affecting alerts from its devices. Image source: Getty Images. Apache's update on an exploratory well spooks investors Shares of Apache fell 12.3% after the company issued an update on its exploratory well off the coast of Suriname and investors interpreted the release as bad news. The company didn't comment on test results and said it would drill deeper than originally planned. Apache started drilling the Maka Central Number One well in late September with an expected drill time of 30 to 60 days and a target depth of 6,325 meters. Today's press release said that after reaching 6,200 meters, Apache is conducting tests on two plays and will keep digging down to 6,900 meters. Investors took the lack of detail on findings so far and the decision to dig deeper as bad signs. Apache has high hopes for the project, saying last month that its exploration program in the large block near massive finds being developed by ExxonMobil is \""potentially transformational.\"" The stock has been under pressure lately, and new doubt around the first of three exploratory wells planned for the company's most promising opportunity had investors heading for the exits today. DexCom outage stretches into third day DexCom, maker of continuous glucose monitoring (CGM) systems, reported an outage of its \""Follow\"" app, which alerts parents when their diabetic children have life-threatening blood sugar levels. The stock, a favorite of growth investors, fell 1.5%. The company reported the disruption on its Facebook page Saturday morning, and as of 10:25 a.m. PST Monday, the service had still not been fully restored. According to DexCom, \""[A] server overload occurred due to an unexpected system issue that generated a massive backlog, which our system was unable to handle.\"" DexCom's CGM system monitors blood glucose levels every five minutes using a small sensor under the skin, eliminating the need for finger pricks to collect blood samples. This service outage highlights the potential issues of \""connected\"" medical devices and the reliance that patients and their caregivers put on them, but the trend is clearly here to stay. DexCom's stock has been hitting new highs as investors bet on the company's accelerating sales growth. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor, has quadrupled the S&P 500!* Tom and David just revealed their ten top stock picks for investors to buy right now. Click here to get access to the full list! *Stock Advisor returns as of June 1, 2019. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jim Crumly owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Industry Focus: What We're Thankful For In this special Thanksgiving edition of Industry Focus: Energy, The Motley Fool's Nick Sciple and Jason Hall share some things they're thankful for -- investors and investments they've learned from, financial personas that don't get enough credit, products and services that make life so much easier and better, college football teams and players that fans can't not be thankful for, and more. And thanks to you for tuning in! To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video. 10 stocks we like better than Walmart When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks {% render_component 'sa-returns-as-of' type='rg'%} This video was recorded on Nov. 21, 2019. Nick Sciple: Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day. Today is Thanksgiving, and as is appropriate, we're giving thanks. I'm your host Nick Sciple, and today I'm joined by Motley Fool contributor Jason Hall via Skype. Jason, what's up? Jason Hall: Nick, thank you for having me on today, and happy Thanksgiving! Sciple: Thank you for joining me and happy Thanksgiving. And just so our listeners know, we're not crazy people. We're not at work on Thanksgiving. We're prerecording this on November 21st. But we thought it'd be fun to give you all a nice little Thanksgiving show. Jason, you just moved into a new house. What are your plans for your first Thanksgiving in your new home? Are you going to be there? Are you going to the grandparents? What's going on? Hall: My plan is to get out of this house and to get out of this state and find my sanity. Moving is horrible. Moving with a three-year-old is especially painful. So I will be, thankfully, in the beautiful little coastal town of Panacea, Florida -- about 45 minutes south of Tallahassee for anybody that's not familiar. It's kind of in the elbow of the Gulf Coast. We're down there with family. Some family goes every year, and we try to go every other year. Very excited about that, to be on the Gulf Coast for Thanksgiving. Sciple: Going to God's country, the Gulf Coast, man. As a Mobile, Alabama native, really, really jealous you're going to make it down there. This will be the first year, actually, I haven't made it down to Alabama for Thanksgiving. Going to be spending Thanksgiving with my girlfriend up here in the D.C. area. Excited to do that, but also going to be missing family a little bit. I hope you enjoy the Gulf Coast as much as I enjoyed growing up there. We're going to run through some fun little list of that stuff we're thankful for. The first one that I want us to do is, Jason, what is the product or service that you are most thankful for in your life? Hall: Disney+, buddy. It's changing lives, I'm telling you. Disney+ is changing people's lives every day. OK, all right, no, I'm sort of kidding. As a consumer, Amazon (NASDAQ: AMZN). There's no doubt about it. It is truly something that has given me back hours of my life. As someone who hates going to stores, it's so much easier just to flip open the app and just buy whatever I need, and know that it's going to be at my house the next day or the day after that. That's fantastic. I'm going to do one more. You know me, I can't just do one of anything. Professionally, Stock Advisor, the Motley Fool stock-picking service that was launched by Tom and David. I can truly say that this changed my life. I started with The Motley Fool as a paid subscriber to Stock Advisor. Got really involved on the message boards. This service played a huge role in helping me develop as an investor, and is actually the thing that opened the door to me ending up on this podcast with you right here. It's truly changed my life. Sciple: We didn't pay him to say that, folks. [laughs] I would say for me, to echo your sentiments there, The Motley Fool podcasts. I mean, that's why I'm here. That's how I ended up here at this company. But my product that I will say is Google (NASDAQ: GOOG) (NASDAQ: GOOGL). I don't know how my life would be like without Google. It changed the bar conversation forever. There's no more debating anything anymore. I've got the answer right at my fingertips. I can't tell you the number of things I google every day. Google probably knows more about me, and probably every person that's listening to this show, than I know about myself. I get so much value out of it. The way I picture Google is, the internet has every bit of information you could ever think of in the world, right? Before the internet, where you needed to go to get that information is, like, your local library. Now, imagine if you walked into that library, and nothing was in order. You couldn't find anything. Well, that's what the internet's like without Google. The internet's really not that useful without a search engine that can let you find what you need in this massive pile of information, quickly. I think it's brought so much value to me and lots of folks around the world. So, I'm going to go with Google. Hall: Did you watch the Matrix movies? Sciple: Of course. Hall: To me, in my head, even to this day, I imagine that Google is actually just a white room with a person that's inside of it. It's the Oracle. That's Google. That's it. It's not computers. It's the Oracle. Hall: That's quite possible. All right, our next thing we're most thankful for. We're going to talk about, what is the investor you're most thankful for, Jason? Hall: Charlie Munger. Absolutely Charlie Munger, no doubt about it. I don't think he gets anywhere near enough street cred. He is a huge reason Berkshire has created so many billionaires. I still don't think he gets anywhere near enough credit for Buffett's evolution as an investor. I still read these articles to this day, and it makes me cringe when somebody calls Buffett a value investor. Buffett hasn't been a value investor in 30 years. Buffett likes to pay a fair price, but because of Charlie Munger, Warren Buffett's focus for years and years has been more on buying high-quality businesses that have competitive advantages and have these real durable strengths, the moat that he talks about, something that's going to allow them to continue to grow their business and generate an adequate rate of return over the long term. And Charlie Munger, I think there's a good chance that the Warren Buffett would have remained a cigar-butt investor if it wasn't for Charlie Munger. Sciple: Yeah, absolutely. Charlie Munger would be my 1-B here. When you talk about that, moving away from value investing, I think what Charlie Munger really did is moving Buffett from value as a quantitative methodology to value as an analytical style, of thinking, paying less for what you buy than what it's worth relative to saying, because of this number, this company is undervalued. I think that's been transformational. And that's a much more scalable style when you get to tens and tens of billions of dollars than it is trying to find cigar butts, as Buffett did coming up. Hall: Nick, you know, also, Charlie Munger is an attorney. Sciple: Yeah. We have a theme here. I was going to say, we have a theme here. My investor I'm most thankful for is also an attorney, Peter Thiel, at for a few reasons. The first is more personal to me. When I first got started in investing, I was in law school, doing that sort of thing. And one observation Peter Thiel had, I think was super influential to me. He went to law school at Stanford, went to work at a big firm in New York. Famously made it three months, and he said, from the outside, the law firm was a place that everybody wanted to get in. And from the inside, it was a place that everybody wanted to get out. I didn't really realize that that was explaining my observations until I'd really read that observation, and it really just clicked with me, and is a big part of why I'm here doing what I'm doing right now. In addition to that, on the more investing side of things, I think Zero to One is probably the best investing book I've ever read. Really kind of transformed the way I think about companies. One of his conceptualizations is, where most people would say competitive advantage, he says monopoly. I want these companies that have a monopoly on their brand or a monopoly on this asset, versus having a competitive advantage. What does this company have that no one else has? Another analytical thing to think about is, what do you believe that most people would disagree with you on? I think, if you're an investor, you really have to disagree with most people to find any sort of value in the market. If you're not doing something contrarian to the market, you're just getting the market's return. So, that has been super valuable to me. And then one other thing, it's exposed me to mimetic theory. For folks that haven't been exposed to that, read up on it. Really, it's a theory of everything. I can't really explain it to you here. But, read up on. Has really changed the way I view the world in a significant way. We talked on this show a while back about T. Boone Pickens. I think Peter Thiel shares some of the political controversy that T. Boone Pickens has. But, like T. Boone Pickens, an incredible number of lessons, an incredibly clear thinker, and I think everyone can learn from him about his observations both on life and investing. Hall: Yeah. I want to just tie this together real quick. I think it's really interesting, you think about Munger, you think about Thiel, think about you, and think about, I'll include in this, John Maxfield, one of our colleagues that rights for The Motley Fool. You're all attorneys. And, other attorneys I've known in my life -- I have an uncle -- if you want to learn how to really ask good questions, make good friends with an attorney. You will become so much better at asking the right questions, to get to not the answers that you want, but to learn. So, I'm going to mix you in there with Mr. Munger and Mr. Thiel, too. Something about that law training that teaches you really how to get to the crux of things. It's so powerful. Sciple: So what Jason is saying is, everybody be nicer to lawyers. Hall: Well, no. You don't have to be nice to them. Sciple: [laughs] All right, let's move on to, what is the investment you're most thankful for, Jason? Hall: It's an investment that has cost me a substantial amount of capital over the years. In terms of dollars invested, it's one of my largest. Bought my way out of a really ugly position. It's Clean Energy Fuels (NASDAQ: CLNE). And the reason I'm picking Clean Energy Fuels is because I've learned so much. This is one that, I look at the capital losses I've taken over time as a great tuition. It's a great education. It's taught me a lot about how to analyze companies. Also, I've learned some really valuable lessons. Even great ideas don't always work out exactly as you planned. And sometimes, things work that you expect to work, but other things prevent them from necessarily being profitable investments. I think this is a great case for that. That's why I picked it. I didn't pick the one that's made me the most money. I didn't pick Netflix or Amazon, that have made me the most money. But I've learned more about being a good investor from Clean Energy Fuels than any other stock I've ever owned. Sciple: Jason, I'm not as enlightened as you. I picked the stock that's been my best performer since I've owned it, and that's Dexcom (NASDAQ: DXCM). It's not just because it's been my best performer, although, of course, that really helps. But it's one of those cases where observing what happens in the world, I think, was more valuable to me than observing what had happened in the market. When I bought that stock, it had just sold off pretty significantly because one of its competitors, I believe Medtronic, had come out -- for background, Dexcom makes continuous glucose monitors. These are, for someone with Type One Diabetes, will be typically an implantable sensor that will go in your upper arm usually, and it measures your glucose over time to track to make sure you're not too high, not too low. It was a pioneer in that device, and they continue to be one of the leaders in the space. Well, the stock had really sold off significantly because Medtronic had introduced a continuous glucose monitor that was the first one on the market that didn't have to be calibrated every day. You didn't have to stick your finger and draw blood to make sure the sensor was measuring properly. The market came out and said, basically, they're going to take away the market, and all these other competitors are gone. Well, the reason I bought Dexcom, I talked to several people who had the sensor and said, \""Are you going to switch over to this new product?\"" And they said no. They said no for a few reasons. The reason why I think Dexcom still a great stock today, they have the most accurate sensor on the market. When it comes to keeping yourself in the proper glucose range, the more accurate you can be, obviously, the better, going through highs and lows. They also were the only product on the market, at least at the time, that had the seamless integration with your iPhone. So, you could easily monitor your glucose and those sorts of things through your phone. If you talk about parents who have young children that have Type One Diabetes, it lets them get alerts whenever their child would hit a high or low. So it really adds a lot of utility to folks there. And then third, that competing product that I mentioned to you, you could only use that CGM with their insulin pump. What Dexcom really is, it's a product that is agnostic. You can use all kinds of different pump options with them. So, it's one of those things where the market really overreacted. But, talking to people and learning how people actually used the product was able to make a decision that led to a great investment, which was particularly valuable. Hall: A little Peter Lynch here. Let's go ahead and bring it a little One Up On Wall Street here, talk about using what you observe in the world to identify potential opportunities. Nick, good job, buddy. Well done! Sciple: Yeah. The other one would be Phil Fisher, the Scuttlebutt method. I think there's a lot of scuttlebutt there involved in that thesis. I really encourage folks when they're making investment decisions to talk to people who actually use these products. Pay attention to the world. When you go to a restaurant and there's a line out the door, maybe that's a good sign. Or, if you go to a restaurant, and maybe it looks really cheap from a valuation point of view when you look at the numbers, but there's nobody in the restaurant when you go there, you don't like the product, and that sort of thing ... trust the people who actually use these products when you make these decisions, and I think you'll be rewarded over time. Hall: Well done! Sciple: OK, for this last one, I want to talk about, every time I have you on the show, Jason, we like to talk about a little bit of college football. Thanksgiving is a notoriously big NFL day. And, that Saturday is always the biggest rivalry weekend of the year. I know I would always have to build my Thanksgiving plans around, how can I get back to Tuscaloosa or Auburn for the Iron Bowl that weekend? So, in that vein, Jason, what or who is the college football player you're most thankful for? Hall: You know me, I can't do just one of anything. I'm going to say the strength of Georgia's team this season by far has been defense. I'm going to go with J. R. Reid. Safety. One of the true greats. Georgia strong safety. Just got nominated for the Bronko Nagurski award for the best defensive player in college football. That's pretty big deal. Did you know that Georgia's defense has not given up a single rushing touchdown this season? Sciple: I know now. Hall: Through 10 games! Not a single one. On offense, I'm going to go with Andrew Thomas, the superstar blindside offensive tackle. Probably going to be the first offensive tackle, probably the first offensive lineman drafted this year. He's a junior, I'm sure he's going to leave early. He's an Outland Trophy semifinalist for the best offensive lineman. I also want to point out that, did you know that the University of Alabama did not have a single offensive lineman nomination for the Outland Trophy? I don't think that's happened in like six or seven years. That's a big deal. Auburn's got one. Sciple: Well, darn... Hall: [laughs] OK, so, Georgia is also ranked higher than Auburn in the college football playoff standings. Sciple: That is accurate. That is accurate. All right. [laughs] I have a few. I'll give you some honorable mentions. A. J. McCarron, huge part of my early college career. From my hometown? His tattoo choices, I don't know about that. Folks who are unfamiliar with that, maybe Google that. But, I think, a college football player I'm really most appreciative of, and I don't think there will ever be a moment that will match, the National Championship a couple years ago, Tua Tagovailoa. It's very rare that someone is one of the best at what they do and also one of the nicest people that do what they do. I think Tua is one of those people. It's really unfortunate, his injury that happened a couple weeks ago. He dislocated his hip. But I think he's just one of the nicest, most genuine people, and also probably the best quarterback to ever play at Alabama throughout history. Again, I was at that National Championship game. Second and 26 is probably the greatest football moment of my college football career. Jason may not agree. Really, so appreciative of what he stands for and he's represented the University and just college football in general. Really thankful for Tua. Hall: Yeah, I think it stinks that his college career could have ended on a fluke, weird kind of thing like that. And there's risk to his professional career. Here's the question I have. I agree, great choice. Tua Tagovailoa. Do you think there's any chance, if he's healthy, he comes back for his senior year? Sciple: There's always a chance! I don't want to get my hopes up too much, but there's always a chance. The factor that I've seen some folks talk about is, he does have an insurance policy if he falls in the draft. So, there's not a significant economic reason for him to do so, as some I think. But, we'll just have to see. Whether he does or doesn't, super thankful about how he's represented the University and, like I said, college football in general. Jason, all our listeners, I hope you have a happy Thanksgiving. We will see you next week. Hall: Happy Thanksgiving, everybody! Sciple: As always, people on the program may own companies discussed on the show, and The Motley Fool may have formal recommendations for or against the stocks discussed, so don't buy or sell anything based solely on what you hear. Thanks to Austin Morgan for his work behind the glass. For Jason Hall, I'm Nick Sciple, thanks for listening and Fool on! John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Jason Hall owns shares of Alphabet (A shares), Amazon, Clean Energy Fuels, Netflix, and Walt Disney. Nick Sciple owns shares of Alphabet (C shares) and DexCom. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Berkshire Hathaway (B shares), Netflix, and Walt Disney. The Motley Fool recommends Clean Energy Fuels and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), long January 2021 $60 calls on Walt Disney, short January 2020 $220 calls on Berkshire Hathaway (B shares), and short January 2020 $130 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data."", ""Dow Jones Futures: Apple, AMD, DexCom Stand Tall As Stock Market Stumbles; Coupa Earnings Top"", ""DexCom down 2% on G6 app glitches""]"
DXCM,2019-12-03,55.335,57.441,55.0795,57.165,"[""How To Find Top Momentum Stocks In Healthcare"", ""Dow Jones Futures Fall As Trump Says He Might Favor China Trade Deal After 2020 Election"", ""Dow Jones Futures Fall As Trump Says He Might Favor China Trade Deal After 2020 Election"", ""How To Find Top Momentum Stocks In Healthcare"", ""Dow Jones Futures Fall As Trump Says He Might Favor China Trade Deal After 2020 Election"", ""How To Find Top Momentum Stocks In Healthcare""]"
DXCM,2019-12-04,57.2,57.7125,56.504,57.295,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2014 million of Shares"", ""The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2014 million of Shares"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2014 million of Shares""]"
DXCM,2019-12-05,57.705,58.0,56.6725,56.7,"[""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?"", ""The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?"", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?""]"
DXCM,2019-12-06,57.1,57.565,55.9025,56.19,"[""DexCom (DXCM) Up 16.5% Since Last Earnings Report: Can It Continue?"", ""The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend"", ""The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend"", ""DexCom (DXCM) Up 16.5% Since Last Earnings Report: Can It Continue?"", ""The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend"", ""DexCom (DXCM) Up 16.5% Since Last Earnings Report: Can It Continue?""]"
DXCM,2019-12-09,56.2375,56.9075,55.225,55.25,"[""This Fund Manager Seeks Stocks To Invest In That Are Cutting-Edge Companies"", ""This Fund Manager Seeks Stocks To Invest In That Are Cutting-Edge Companies"", ""Here's Why Dexcom Stock Jumped 47% in November What happened Shares of Dexcom (NASDAQ: DXCM), a leader in the growing market for blood sugar trackers, jumped 47.4% in November, according to data from S&P Global Market Intelligence. Another quarterly report filled with positive signals was the spark that started the rally. So what Glucose monitors that sync with smartphones are gaining popularity fast, and Dexcom's third-quarter earnings report suggests its G6 system is leading the pack. Compared with the prior-year period, revenue grew 49% to $396 million. Beneath the top line, it looks like the company's easy-to-use solutions are flying off shelves all by themselves. Third-quarter operating expenses rose just 23% to $191 million. Image source: Getty Images. Dexcom also raised its expectations for the rest of 2019. Instead of a range of $1.33 billion to $1.38 billion, total revenue is expected to reach between $1.43 billion and $1.45 billion this year. On the bottom line, adjusted operating earnings are expected to reach 9% of total sales instead of the 7% operating margin the company had been expecting just a few months earlier. Now what There's no shortage of glucose monitoring options for diabetes patients to choose from, but Dexcom's devices could command a leading share of the market for the foreseeable future. In October, the company officially started selling everything needed to begin using a G6 to Medicare patients in partnership with Walgreens. Keeping glucose levels in a normal range has been shown to reduce the risk of problems common among diabetes patients, such as vision loss. That means Medicare can save a bundle over the long run by providing Dexcom's devices. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The DXCM Paradox: Analysts Bullish But Forecast -10.29% Fall Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM \u2014 averaging the work of 16 analysts \u2014 reveals an average price target of $201.62/share. That's a whopping -10.29% below where DXCM has been trading recently at $224.76/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.39 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that \u2014 a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $240.00. And then on the other side of the spectrum one analyst has a target as low as $125.00. The standard deviation is $25.439. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes \u2014 much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $201.62/share, the -10.29% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""This Fund Manager Seeks Stocks To Invest In That Are Cutting-Edge Companies""]"
DXCM,2019-12-10,55.125,55.7425,53.5975,53.8825,
DXCM,2019-12-11,53.48,53.95,52.8325,53.09,"3 Biotech Stocks That Can Double Your Money in 2020 While the world of biotech has always been an interesting one, now's an especially exciting time to consider investing in the sector. There are many potential blockbuster drugs awaiting U.S. Food and Drug Administration (FDA) approval, with a number of treatments having already received a thumbs-up earlier this year. For the companies that have been behind these breakthrough solutions, their financial prospects have never been better. Specifically, Amarin (NASDAQ: AMRN), Portola Pharmaceuticals (NASDAQ: PTLA), and Tandem Diabetes Care (NASDAQ: TNDM) are all likely to see their stock prices rise dramatically in the coming year due to treatments they are developing or have already developed. Image source: Getty Images. 1. Amarin The excitement behind Amarin has only further jumped after an FDA committee recommended its fish oil drug, Vascepa. This drug has already been approved to treat patients with elevated levels of triglycerides, but not necessarily those at risk of adverse cardivoascular events such as heart attacks and strokes. However, results from a new study have shown promising results in Vascepa's effectiveness as a way to help patients with these conditions. Amarin hopes that the FDA will widen Vascepa's potential use for patients at high-risk of having a heart attack or stroke, a decision which would substantially increase Vascepa's potential addressable market. A five-year trial involving over 8,000 patients considered at risk of cardiovascular events found that patients who took a two gram dose of Vascepa twice daily had significantly reduced changes of either having a heart attack or a stroke. Specifically, the fish oil drug produced a 31% reduction in the chance of heart attack, a 28% reduced chance of suffering a stroke, and a 20% reduced chance of death due to cardiovascular failure. For this reason, investors were paying close attention to the FDA committee scheduled in mid-November to review Vascepa. The results were overwhelmingly positive and gave Amarin's drug a major thumbs-up. Now, investors are waiting to see if the FDA will extend Vascepa an expanded indication for high-risk cardiovascular patients on Dec. 28. Many analysts on Wall Street are already considering Vascepa to be the next blockbuster drug in the cardiovascular disease sector, with some expecting peak revenues to exceed $4 billion annually by 2028. Considering that Amarin's third-quarter 2019 revenue came in at only $112.4 million for the quarter, Vascepa's potential approval would be a game-changer for the company. At the same time, major healthcare organizations such as the American Heart Association, American Diabetes Association, the European Society of Cardiology have all recommended Vascepa as an effective way to lower LDL cholesterol in patients. When one looks at these recommendations, as well as the thumbs-up from the FDA committee in November, it's not surprising to see why the odds seem to be in Amarin's favor for Vascepa's official approval later this month. 2. Portola Pharmaceuticals Portola Pharmaceuticals is developing the only anticoagulant reversal agent on the market, something that can be a lifesaver for patients who suffer from uncontrollable bleeding often seen as a side effect of today's generation of blood thinners (also known as anticoagulants). Specifically, Portola's drug treats patients using Johnson & Johnson's rivaroxaban and Pfizer's apixaba, two of the most prevalent blood thinners on the market. This drug, Andexxa, has already received a number of designations from the FDA, including the all-important Breakthrough Therapy designation, and has earned approval for commercial production in the U.S. earlier this year. Although Andexxa is a relatively expensive treatment, costing $27,500 per patient dose, the fact that it would be the sole treatment to an otherwise life-threatening side effect means that cost won't prove much of a deterrent until a cheaper replacement to Andexxa is produced (which doesn't seem to be imminent). In 2017, there were 140,000 hospital admissions due to uncontrollable bleeding due to anticoagulants, which are prescribed to patients to lower the risk of blood clots.. Assuming a $27,500 average price point per patient dose, this would put the American market for Andexxa in the $3.85 billion range, if not more. Thus, it's not surprising that this one drug could catapult Portola, a $2.2 billion market value company, into a much higher valuation. 3. Tandem Diabetes Care Tandem Diabetes is different from the other two biotech stocks mentioned above. Instead of offering a revolutionary new drug candidate, Tandem is a leading manufacturer of insulin pumps for patients with type 1 diabetes. These pumps help automate insulin dosing in patients and managing their blood sugar levels. Shares of Tandem have already more than doubled since the start of the year, but there's still plenty of long-term potential for the company. Sales for Tandem's newest insulin pump -- t:sim X2, which incorporates a continuous glucose monitor from DexCom -- have been surging and show little signs of slowing down. Worldwide pump shipments jumped by 112% worldwide from last year, while the company's profit margins have improved steadily, from negative 34% to just negative 6% during the same period. Tandem's year-end projections put its 2019 sales somewhere around the $365 million ballpark. This is a significant increase from the $183.9 million revenue in 2018 and the $107.6 million figure in 2017. The market for insulin pumps is still quite far from being saturated, with plenty of room for Tandem to grow in the coming years. This is especially true in international markets, with other countries such as Canada having recently announced regulatory approval for Tandem to sell t:slim X2. Overall, Tandem's strong growth so far seems likely to continue for at least a few more years before slowing down, with investors likely to enjoy significant gains from the stock in the meantime. 10 stocks we like better than Amarin When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amarin wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2019-12-12,52.9675,53.27,50.3925,50.5,"[""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ..."", ""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ..."", ""3 of the Fastest-Growing Large-Cap Stocks on the Planet Historically speaking, value stocks have outpaced growth stocks over the long run, although both have produced handsome returns for buy-and-hold investors. A Bank of America/Merrill Lynch report released in 2016 found that the average annual return for value stocks was 17% between 1926 and 2016, compared to 12.6% for growth stocks over the same 90-year period. Yet, here's something investors will find interesting: Since the Great Recession, growth stocks have run circles around value stocks. The historically low-interest-rate environment has encouraged lending and borrowing, which is great news for rapidly expanding growth stocks. And with rates expected to remain low for the foreseeable future, it leaves the door open for ongoing outperformance. Though you might be tempted to look for growth stocks in the small-cap and mid-cap arena, don't forget about large-cap stocks (those with markets caps of at least $10 billion). Despite often being viewed as mature businesses that left their growth phase in the rearview mirror a long time ago, the following three companies would respectively disagree. In fact, these three large-cap stocks are some of the fastest-growing companies on the planet. Image source: Getty Images. DexCom Although Wall Street estimates can be incredibly fluid, continuous glucose monitoring (CGM) system manufacturer DexCom (NASDAQ: DXCM) is expected to see its sales grow from $1 billion in 2018 to $2.5 billion by 2022, with the company's earnings per share (EPS) on track to grow 11-fold, from $0.30 per share in 2018 to $3.62 (estimated) by 2022. Make no mistake about it, DexCom isn't a cheap company at 119 times next year's projected EPS, but that's not scaring away Wall Street or investors. That's because diabetes is a serious and growing problem in the U.S., with the Centers for Disease Control and Prevention finding that 30.3 million Americans (more than 9% of the population) had diabetes in 2015. Further, more than 84 million people aged 18 and over had prediabetes, which, if left untreated. could lead to diabetes years down the line. This presents a massive market opportunity for DexCom and its monitoring devices to help diabetics take better control of their health. With DexCom continuing to innovate, it should be able to grow its core U.S. CGM market share, which currently sits at a little less than 20%. Look for the launch of the G7 in 2020 or 2021 as the next major growth driver for a company that's on track for 40% full-year sales growth in 2019. Image source: Getty Images. Shopify The tech sector is another area where you're bound to find high-growth companies, and large-cap Shopify (NYSE: SHOP) does not disappoint. The software-as-a-service (SaaS) cloud company is expected by Wall Street to grow sales from $1.07 billion in 2018 to around $3.6 billion in 2022. At the same time, full-year EPS will climb from $0.38 in 2018 to an estimated $2.92 over the same period. The beauty of Shopify is that its business model offers two ways to grow. There's the higher-margin SaaS services, such as website hosting and file storage, which have seen growth taper a bit in recent years but does an excellent job of avoiding client churn. There's also the faster-growing merchant solutions, which helps with in-house payment processing and shipping, and even provides cash advances to merchants. Even though merchant solutions is a lower-margin segment than subscription services, it requires considerably less upkeep and marketing to drive this growth, making it an indispensable operating segment. Similar to DexCom, Shopify isn't cheap at 400 times next year's EPS, but few cloud companies of its size ($43 billion market cap) are expected to grow sales as quickly. With Shopify even acting as a point-of-sale platform for cannabis operators in Canada, it's bound to remain a popular stock among growth investors. Image source: Square. Square Speaking of growth you can bank on, point-of-sale solutions provider Square (NYSE: SQ) is projected by Wall Street to see its sales skyrocket from $1.59 billion in 2018 to a cool $4.8 billion by 2022. At the same time, EPS for the company should nearly quadruple from $0.47 in 2018 to $1.75 by 2022. Square is quickly becoming a juggernaut in the payment processing space as an alternative to traditional merchant solutions providers Visa and Mastercard. In the most recent quarter, Square processed $28.2 billion in gross purchasing volume (GPV), ultimately helping the company generate 44% year-over-year net revenue growth. What's really impressive is that GPV from large sellers rose 34% from the prior-year quarter (Q3 2019 vs. Q3 2018), with these large sellers now accounting for 55% of the company's total GPV. Translation: Square isn't just for small- and medium-sized businesses anymore. This is also a company reliant on financial innovation to drive growth. The company's Cash App, which allows users to send, store, and even invest money, generated year-over-year net revenue growth of 115% in the third quarter. The Cash App ecosystem is clearly working wonders for Square, and with Cash App's margins improving in each of the past two years, it should not be surprising if the company remains among the fastest-growing large-cap stocks for the foreseeable future. 10 stocks we like better than Square When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Square wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Sean Williams owns shares of Bank of America. The Motley Fool owns shares of and recommends Mastercard, Shopify, Square, and Visa and recommends the following options: short January 2020 $70 puts on Square. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio ...""]"
DXCM,2019-12-13,50.5,51.5325,49.88,50.9575,"[""FDA OKs Tandem's Control-IQ; shares up 1%"", ""Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology"", ""Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology"", ""FDA OKs Tandem's Control-IQ; shares up 1%"", ""Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology"", ""FDA OKs Tandem's Control-IQ; shares up 1%""]"
DXCM,2019-12-16,51.535,53.2312,51.34,53.1025,"[""DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System"", ""DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System"", ""DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System""]"
DXCM,2019-12-17,53.31,54.4625,52.125,54.3325,"[""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $225"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $225"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $225""]"
DXCM,2019-12-18,54.2075,55.2562,54.0275,54.6625,"[""Here's Why You Should Add DexCom (DXCM) to Your Portfolio"", ""DexCom Shares Down 0.2%; BofA Earlier Issued Note Calling Stock 'A top idea for 2020,' Raised Price Target From $220 To $250"", ""Bank of America Reiterates Buy on DexCom, Raises Price Target to $250"", ""UPDATE: Bank Of America On Dexcom Notes 'We do not expect a potential Libre 2 approval to be a major negative with G7 coming, with DXCM winning preferred payer agreements, and with out-of-pocket costs quickly narrowing between G6 and Libre'"", ""UPDATE: Bank Of America Reiterates Buy On Dexcom, Raises Target To $250, Names A Top Idea For 2020 Notes 'Street estimates remain too low in our view, and the stock likely works into a year-end G7 launch'"", ""UPDATE: Bank Of America On Dexcom Notes 'We do not expect a potential Libre 2 approval to be a major negative with G7 coming, with DXCM winning preferred payer agreements, and with out-of-pocket costs quickly narrowing between G6 and Libre'"", ""UPDATE: Bank Of America Reiterates Buy On Dexcom, Raises Target To $250, Names A Top Idea For 2020 Notes 'Street estimates remain too low in our view, and the stock likely works into a year-end G7 launch'"", ""Bank of America Reiterates Buy on DexCom, Raises Price Target to $250"", ""DexCom Shares Down 0.2%; BofA Earlier Issued Note Calling Stock 'A top idea for 2020,' Raised Price Target From $220 To $250"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio"", ""Tandem Diabetes' New Tech Is Cool, but It Will Face a Crowded Market The impressive headlines were enough to grab investors' attention last week. Not only did Tandem Diabetes (NASDAQ: TNDM) win the U.S. Food and Drug Administration's clearance of its new insulin pump management platform, but it even spurred the FDA's creation of a whole new category of insulin-dosing technology. The Control-IQ technology is a complete automated insulin dosing (AID) system that offers interoperability with other manufacturers' insulin monitoring devices. In this case, Control-IQ works with Dexcom's (NASDAQ: DXCM) G6 continuous glucose monitoring tool. Other diabetes-management tech companies could make compatible devices in the future. The rub is that rivals are already nipping at Tandem's heels. In fact, a sizable piece of the insulin-dosing market is rooted in open-source options and do-it-yourself solutions that make a diabetic's smartphone the centerpiece of their self-management effort. Image Source: Getty Images. The good news Last week, the FDA cleared Tandem's Control-IQ technology for use with its t:slim X2 insulin pump and Dexcom's G6 CGM, creating the first-ever hybrid closed loop that delivers automatic correction doses to prevent high or low blood sugar levels. The exciting innovation here is the fact that Control-IQ's software is 'interoperable,' meaning this device is compatible with hardware from other manufacturers of diabetes devices. To people who don't have diabetes, the detail might mean little. But for the 1 million people in the U.S. who have type 1 diabetes, this initially looks like the long-overdue answer to a significant need for reliable insulin-management solutions using devices from multiple makers. Other stand-alone solutions like the MiniMed 670G insulin pump from Medtronic (NYSE: MDT) were initially seen as similar game-changers. But research by the Boston Children's Hospital in 2017 and 2018 revealed roughly one-third of its sample patients -- people with diabetes between the ages of 14 and 25 -- discontinued use of the pump because it was too complicated to manage. Tandem's Control-IQ is different in that it removes the need for constant manual adjustment of the pump and it does so in a clinically verified way. At stake is a piece of a digital diabetes management market that's estimated to be worth $12 billion by 2025, growing at an annualized pace of more than 20% to reach that figure. The emergence of closed-loop systems like the ones Medtronic and now Tandem Diabetes created is expected to be one of the diabetes management market's key growth drivers. The bad news The FDA's green light for Tandem's Control-IQ platform marks a milestone for the company and for the diabetes management movement. Theoretically, the pump/monitor/software combo could be a mostly automated solution that offers people with diabetes a variety of choices with very little hassle. It's not a selling point Tandem Diabetes will have to itself for much longer, though, if Medtronic's plans pan out. Its next-generation MiniMed 780G automated insulin dosing system, expected to launch in the coming year, will also make the corrective doses that Control-IQ facilitates. Perhaps even more marketable is that the 780G can connect with smartphones, providing easy access to information about a user's glucose levels. Beyond that, the Omnipod Horizon from Insulet (NASDAQ: PODD) is expected to become available in the latter half of 2020. As is stands now, that insulin pump will be entirely manageable from a smartphone rather than requiring a device attached to a pump and monitor. France's Diabeloop has also seemingly toyed with the idea of marketing its EU-approved DBLG1 closed-loop insulin monitoring and pump system. Medtronic's 670G is available in Europe, but Diabeloop's DBLG1 is the first and only such system that -- like Tandem Diabetes' technology -- offers interoperability with other companies' hardware and devices. Clearly the FDA is now OK with the idea. Other healthcare companies are likely to start eyeing this innovation now that Tandem has validated the idea. Despite the FDA's warning in May 2019 that DIY solutions for diabetes management can be dangerous, the DIY diabetes management community has organized which in turn, gave rise to free availability of the open-source artificial pancreas software that makes this development possible using older, sometimes secondhand equipment. A nonprofit called Tidepool is also working on open-source software called Loop, which will initially work with Insulet's Omnipod, Medtronic's MiniMed, and Dexcom's G6 and is also intended to be an FDA-regulated platform. Aside from the sheer cost of new and fully branded closed-loop systems, some people with diabetes simply like the idea of nonproprietary options, which tend to offer more functionality than regulator-approved ones. Whatever the motivation, it all works against demand for Tandem's Control-IQ. Bottom line Such closed-loop systems are the future to be sure, and adding interoperability is a nice touch. As it stands now, though, it doesn't look like this innovation will be enough to rekindle the slowing growth comparison that made Tandem such a strong performer last year. That's not necessarily disastrous. Its fiscal trajectory should still push it out of the red next year, and analysts' profit estimates for the following year are compelling. It's progress the market can latch onto. But even at its present pace, Tandem Diabetes' current company value is more than 100 times 2021's expected earnings. That's rich even for a high-growth name like Tandem. It's especially pricey when the company's latest breakthrough is already slated to face stiff competition that could alter growth expectations in the meantime. Data source: Thomson Reuters. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UPDATE: Bank Of America On Dexcom Notes 'We do not expect a potential Libre 2 approval to be a major negative with G7 coming, with DXCM winning preferred payer agreements, and with out-of-pocket costs quickly narrowing between G6 and Libre'"", ""UPDATE: Bank Of America Reiterates Buy On Dexcom, Raises Target To $250, Names A Top Idea For 2020 Notes 'Street estimates remain too low in our view, and the stock likely works into a year-end G7 launch'"", ""Bank of America Reiterates Buy on DexCom, Raises Price Target to $250"", ""DexCom Shares Down 0.2%; BofA Earlier Issued Note Calling Stock 'A top idea for 2020,' Raised Price Target From $220 To $250"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio""]"
DXCM,2019-12-19,54.77,55.2475,53.7225,54.0825,
DXCM,2019-12-20,54.2975,54.5775,52.5925,53.355,"[""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $255"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $255"", ""Notable Friday Option Activity: DXCM, TTWO, NDLS Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 4,319 contracts have traded so far, representing approximately 431,900 underlying shares. That amounts to about 43.8% of DXCM's average daily trading volume over the past month of 986,665 shares. Particularly high volume was seen for the $220 strike call option expiring January 17, 2020, with 970 contracts trading so far today, representing approximately 97,000 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $220 strike highlighted in orange: Take-Two Interactive Software, Inc. (Symbol: TTWO) saw options trading volume of 4,772 contracts, representing approximately 477,200 underlying shares or approximately 43.6% of TTWO's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $120 strike put option expiring December 27, 2019, with 800 contracts trading so far today, representing approximately 80,000 underlying shares of TTWO. Below is a chart showing TTWO's trailing twelve month trading history, with the $120 strike highlighted in orange: And Noodles & Co (Symbol: NDLS) options are showing a volume of 1,386 contracts thus far today. That number of contracts represents approximately 138,600 underlying shares, working out to a sizeable 43.3% of NDLS's average daily trading volume over the past month, of 320,420 shares. Especially high volume was seen for the $7.50 strike call option expiring May 15, 2020, with 1,006 contracts trading so far today, representing approximately 100,600 underlying shares of NDLS. Below is a chart showing NDLS's trailing twelve month trading history, with the $7.50 strike highlighted in orange: For the various different available expirations for DXCM options, TTWO options, or NDLS options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $255""]"
DXCM,2019-12-23,53.4175,54.405,53.1175,54.0975,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2019-12-24,54.2325,54.7875,54.02,54.1,"[""6 MedTech Stocks That are Set to Beat the Market in 2020"", ""6 MedTech Stocks That are Set to Beat the Market in 2020"", ""6 MedTech Stocks That are Set to Beat the Market in 2020""]"
DXCM,2019-12-26,54.1625,54.6125,53.4175,53.83,
DXCM,2019-12-27,54.3625,54.8318,53.505,54.5275,"[""Here's Why You Should Retain OPKO Health (OPK) Stock for Now"", ""Here's Why You Should Retain OPKO Health (OPK) Stock for Now"", ""Here's Why You Should Retain OPKO Health (OPK) Stock for Now""]"
DXCM,2019-12-30,54.3025,54.69,53.4125,54.0475,"[""Here's Why You Should Invest in Patterson Companies Stock Now"", ""Here's Why You Should Invest in Patterson Companies Stock Now"", ""Here's Why You Should Invest in Patterson Companies Stock Now""]"
DXCM,2019-12-31,54.12,55.1725,54.0325,54.685,"[""Here's Why You Should Hold on to Intuitive Surgical for Now"", ""Here's Why You Should Hold on to Intuitive Surgical for Now"", ""Here's Why You Should Hold on to Intuitive Surgical for Now""]"
DXCM,2020-01-02,54.64,55.6575,53.4218,54.845,"[""Top-Ranked ETFs, Stocks From Top Sector of the Last Decade"", ""Top-Ranked ETFs, Stocks From Top Sector of the Last Decade"", ""3 Healthcare Stocks Primed for 2020 Gains Not all stocks are equal. Some will generate returns, while others will harvest losses. Some will soar magnificently, while others will crash and find it hard to reignite. The eternal question for the intrepid investor remains unchanged, though; which are the ones bound for fortune and, conversely, which are the ones to avoid. While nothing is certain, there are ways to help make the right decision. TipRanks\u2019 Best Stocks to Buy tool tracks 8 key metrics and uses the results to score stocks accordingly. The tool displays the most compelling investments and gives them a Smart Score; from 1, down in the doldrums, all the way up to a \u201cPerfect 10\u201d at the peak of the summit. In this case, the data crunching tool recognized 3 healthcare stocks, which not only display Strong Buy status but also earned a \u201cPerfect 10\u201d Smart Score. Let\u2019s take a closer look at the data at hand. Horizon Therapeutics (HZNP) In the rollercoaster world of healthcare so much hinges on the FDA\u2019s approval or rejection of a new drug. Of course, it\u2019s imperative to look at the bigger picture, and realize what these companies are trying to achieve in terms of their respective therapies. There is no doubt, though, that especially in this sector, the market reacts dramatically to both good and bad news. One such company looking forward to an FDA decision in the new year is biopharma Horizon Therapeutics. The company\u2019s focus is on rare and rheumatic conditions, and a PDUFA date of March 8 will determine the future of Horizon\u2019s teprotumumab drug, a treatment for active thyroid eye disease (TED). The disease can potentially lead to loss of vision and the drug could be the first treatment for TED to gain approval from the FDA. Clinical trials in both Phases 2 and 3 have displayed positive data, and an approval will add the treatment to a portfolio that the company thinks will generate between $1.28 billion and $1.31 billion in net sales in 2019. Piper Jaffray\u2019s David Amsellem believes Horizon is \""on the cusp of a seminal milestone.\"" The analyst reveals in a note to clients that a recent physician survey indicated positive feedback for the drug and the approval of teprotumumab will lead to a \""relatively high probability of wide adoption.\"" Amsellem sees \""ample room for significant further value creation\u201d and thinks Horizon shares are set for multiple expansion. Unsurprisingly, then, Amsellem reiterated his Overweight rating and raised his price target from $36 to $49, which represents a potential upside of 36% from current levels. (To watch Amsellem\u2019s track record, click here) The rest of the Street backs the Piper Jaffray analyst unanimously; all the analysts, 7 to be precise, tracked over the last 3 months, rate the biopharma a Buy; Therefore, Horizon has a Strong Buy consensus rating. The average price target of $40.57 indicates upside potential of 12%. (See Horizon stock analysis on TipRanks) Aravive Inc (ARAV) While the market has provided plentiful returns in 2019, not many have performed better than biotech Aravive. The micro-cap, which is focused on treatments for life threatening diseases, has added almost 300% to its share price throughout the year. Aravive\u2019s lead candidate is AVB-500, a treatment for ovarian cancer and IgA nephropathy (kidney fibrosis). Recent data from a Phase 1b clinical trial of the drug in platinum-resistant recurrent ovarian cancer patients displayed positive results, with the study showing that women taking the drug exhibited higher rates of progression free survival. It is still early, though, and the trial was small, with only 31 patients. The company recently began a Phase IIa study of AVB-500 in IgA nephropathy patients, and Piper Jaffray\u2019s Edward Tenthoff noted the predictive modeling shows that AVB-500 \""should provide sufficient exposure for therapeutic efficacy and may support a pivotal trial start next year.\u201d The 5-star analyst reiterated an Overweight rating, alongside a price target of $31. This implies upside potential of an excellent 125%. (To watch Tenthoff\u2019s track record, click here) Further adding to the bull\u2019s case is Cantor Fitzgerald\u2019s Louise Chen, who believes \u201cpositive data readouts from Aravive's pipeline will drive shares higher.\u201d Chen rates ARAV an Overweight alongside a $30 price target. (To watch Chen\u2019s track record, click here) Over the last three months, two other analysts have joined the bullish pair with an opinion on Aravive. Both also rate the biotech a Buy, which grants Aravive a Strong Buy consensus rating. The average price target of $28.50 implies upside potential of 109%. (See Aravive stock analysis on TipRanks) DexCom Inc (DXCM) The synergy between technology and healthcare is constantly on the rise. The development of new tech enables treatment focused companies to break new ground and solve people\u2019s day to day issues in ways not possible only a few years ago. This brings us to DexCom, the maker of the CGM (continuous glucose monitoring) system. The system enables diabetics to track and manage sugar levels by inserting a small sensor underneath the skin. The sensor measures glucose levels and through a transmitter which is fastened on top, wirelessly sends the data to a smart device. Statistics have shown that over 30 million people had diabetes in 2015 (over 9% of the population) and a further 84 million adults have had prediabetes, which if not treated, is a possible gateway to full blown diabetes. Although the numbers are alarming, they present significant market opportunity for Dexcom\u2019s sugar monitoring products. The company has had an excellent 2019 and its share price skyrocketed over 80%. The recent third-quarter report helped continue the upward trend, with revenue of $396 million exhibiting growth of 49% from the previous year\u2019s same period. Merrill Lynch\u2019s Travis Steed thinks Dexcom\u2019s 2019 performance is set to continue in the new year and rates the stock a \u201ctop idea for 2020.\u201d The 5-star analyst highlights the company\u2019s \u201ccompetitive moat\u201d and thinks DexCom is undervalued by the Street. Therefore, Steed reiterated a Buy rating on DXCM and raised his price target to $250 from $220. This conveys the analyst\u2019s confidence in the company\u2019s ability to add 14% to its share price over the next 12 months. (To watch Steed\u2019s track record, click here) Steed is not alone in his bullish thesis, as 12 Buys and a single Hold bestow Strong Buy status on the groundbreaking glucose tracker. The average price target of $220.82, though, implies only small upside of 1%. This could mean that the analysts haven\u2019t updated their models yet to reflect its 2019 gain. (See DexCom stock analysis on TipRanks) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top-Ranked ETFs, Stocks From Top Sector of the Last Decade""]"
DXCM,2020-01-03,54.1975,54.8812,53.8025,54.675,"[""Here's Why You Should Hold on to Becton, Dickinson Stock Now"", ""Here's Why You Should Hold on to Becton, Dickinson Stock Now"", ""Here's Why You Should Hold on to Becton, Dickinson Stock Now""]"
DXCM,2020-01-06,54.48,56.7938,54.1875,56.4975,"[""Growth Stocks Near A Buy Zone: Look For Breakouts From These 3 Leaders"", ""Dow Jones Futures: Key Sector Rejoins Stock Market Leadership; These 6 Stocks Just Entered Buy Zones"", ""Manager After Manager, This T. Rowe Price Fund Outperforms \u2014 With These Special Stocks"", ""Growth Stocks Near A Buy Zone: Look For Breakouts From These 3 Leaders"", ""Dow Jones Futures: Key Sector Rejoins Stock Market Leadership; These 6 Stocks Just Entered Buy Zones"", ""Manager After Manager, This T. Rowe Price Fund Outperforms \u2014 With These Special Stocks"", ""The 10 Best Performing Stocks of the Decade Now that the 2010s are over, we're going to look at the decade's 10 best performing stocks. Why? Such a review could help investors with their stock picking. Lists of past huge winners are often great places to look for future winners if you subscribe to the theory that \""winners often keep winning.\"" Moreover, such a review might spark some insight as to what makes for a big long-term winner. Image source: Getty Images. The 10 top-performing stocks of the 2010s The stocks are listed by descending order of their return over the just-ended decade. (To avoid listing stocks that were quite tiny and obscure 10 years ago, only stocks that ended the decade with market caps of at least $10 billion, meaning they're \""large caps,\"" are on the list.) RANK COMPANY MARKET CAP WALL STREET'S PROJECTED 5-YEAR AVERAGE ANNUAL EPS GROWTH 1 Netflix (NASDAQ: NFLX) $143 billion 41.7% 2 Domino's Pizza (NYSE: DPZ) $12.1 billion 12.8% 3 MarketAxess Holdings (NASDAQ: MKTX) $14.4 billion 14.8% 4 Exact Sciences (NASDAQ: EXAS) $14 billion 20% 5 DexCom (NASDAQ: DXCM) $20 billion 78% 6 Cheniere Energy (NYSEMKT: LNG) $16 billion 27.8% 7 TransDigm Group (NYSE: TDG) $30.9 billion 13.4% 8 Broadcom (NASDAQ: AVGO) $125 billion 13.3% 9 Fair Isaac (NYSE: FICO) $11.1 billion 19.3% 10 United Rentals (NYSE: URI) $12.5 billion 2.2% S&P 500 -- -- Data sources: Yahoo! Finance and YCharts. EPS = earnings per share. 7 of the 10 companies are profitable If singer Meat Loaf is right that \""two out of three ain't bad,\"" then the profitability profile of our group is slightly better than \""ain't bad.\"" Seven of the 10 are profitable on a trailing-12-month basis, while Exact Sciences (No. 4), DexCom (No. 5), and Cheniere Energy (No. 6) are not. 2 household names top the list There are probably just two companies among the decade's 10 best performers that the vast majority of Americans would know -- Netflix and Domino's Pizza -- and they top our list. This is probably not entirely coincidental. There's a reason these consumer-focused companies are so well known: They sell products or services that are extremely popular. That strong demand for their offerings has driven their financial performances, which in turn, has powered their stocks' performances. While Netflix and Domino's are in entirely different businesses, they have a key commonality that's at the core of their immense success: They're both pioneers. Netflix's pioneering of video streaming disrupted the massive cable TV and movie theater industries and largely put video rental stores out of business. Investors should monitor competition, which continues to heat up. Notably, Disney launched a broad streaming offering in November. Domino's pioneered pizza delivery on a large scale. It offered a key service feature that set it apart from the largely mom-and-pop pizza delivery competition: guaranteed delivery in less than 30 minutes. Its stores are also open considerably later than most independent pizza shops, so it can be the only option for many consumers who get a late-night hankering for pizza delivery. The 2 financial sector stocks -- one is a Warren Buffett stock MarketAxess (No. 3) and Fair Isaac (No. 9) could be described as financial-tech companies, though one also might consider Fair Isaac a tech company. MarketAxess operates the leading electronic bond-trading platform for institutional investors and dealers. It's been benefiting from the shift in bond trading to online platforms. Fair Isaac describes itself as a \""leading analytics software company.\"" While the company might not be a household name, its flagship product -- the FICO credit score -- is quite well known. Fair Isaac also offers a wide range of other products and services for various industries aimed at helping management run their businesses better. Legendary investor Warren Buffett owns the stock in his Berkshire Hathaway portfolio, which is certainly a good endorsement. The 2 healthcare stocks With stocks ranking No. 4 (Exact Sciences) and No. 5 (DexCom), the healthcare sector makes a healthy showing on the decade's list of stock champs. While both these stocks are unprofitable on a trailing-12-month basis, DexCom recently achieved solid quarterly profitability. In 2014, Exact Sciences launched its initial product, Cologuard, the first stool DNA test for colorectal cancer. It aims to build the \""world's leading advanced cancer diagnostics company,\"" according to CEO Kevin Conroy. The company made a notable step toward that goal in November when it closed on its $2.8 billion acquisition of Genomic Health, which makes tests for breast, colon, and prostate cancer that use advanced genomic science to optimize cancer treatment decisions. DexCom makes a continuous glucose monitoring (CGM) system, the G6, for people living with diabetes. G6 has been a big winner for the company, with third-quarter revenue soaring 49% year over year. With the global population getting older and heavier, the incidence of diabetes is on track to continue to increase. The others The remaining big winners on our list include one energy stock (No. 6, Cheniere Energy), two industrial stocks (No. 7, TransDigm, and No. 10, United Rentals), and one technology stock (No. 8, Broadcom). Cheniere Energy is an energy company primarily engaged in liquid natural gas (LNG)-related businesses. It \""owns and operates the Sabine Pass LNG receiving terminal and Creole Trail Pipeline located in Louisiana, through [its] general partner ownership interest in and management agreements with Cheniere Energy Partners,\"" according to its website. It has several development projects under way. TransDigm is a leading global designer and manufacturer of highly engineered aerospace components, systems, and subsystems. It got notably larger last year thanks to its acquisition of Esterline Technologies. A big thing to like about TransDigm is that its operating margin is significantly higher than others in its industry. Broadcom is focused on semiconductor and infrastructure software solutions. It targets seven markets: data center, networking, software, broadband, wireless, storage, and industrial. United Rentals is the largest equipment rental company in the world with locations across the U.S. and Canada. Its stock can be expected to be quite cyclical since it largely serves the construction industry. Wall Street expects the company's earnings growth to slow from a 24% average annual rate over the last five years to just 2.2% annually over the next half decade. Find out why Netflix is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. Netflix is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of December 1, 2019 Beth McKenna has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares), Fair Isaac, MarketAxess Holdings, Netflix, TransDigm Group, and Walt Disney. The Motley Fool recommends Broadcom Ltd and Exact Sciences and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), long January 2021 $60 calls on Walt Disney, short January 2020 $220 calls on Berkshire Hathaway (B shares), and short April 2020 $135 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Growth Stocks Near A Buy Zone: Look For Breakouts From These 3 Leaders"", ""Dow Jones Futures: Key Sector Rejoins Stock Market Leadership; These 6 Stocks Just Entered Buy Zones"", ""Manager After Manager, This T. Rowe Price Fund Outperforms \u2014 With These Special Stocks""]"
DXCM,2020-01-07,56.2525,58.6075,56.2525,57.8625,"[""Dow Jones Futures Dive On Iranian Missile Attack Report; Micron Leads 5 'Live' Winners"", ""Nasdaq Leads Mixed Stock Market As Chip Stocks Outperform"", ""Dexcom Earns Membership In 95-Plus Composite Rating Club"", ""Dow Jones Futures Dive On Iranian Missile Attack Report; Micron Leads 5 'Live' Winners"", ""Nasdaq Leads Mixed Stock Market As Chip Stocks Outperform"", ""Dexcom Earns Membership In 95-Plus Composite Rating Club"", ""The 10 Best Healthcare Stocks of the Decade This list is a snapshot of the best healthcare stocks for an entire decade, from 2010 to 2020. As such, some magnificent stocks are excluded, simply because of the measurement period. For instance, Axsome Therapeutics had an amazing 3,578% return in 2019. And yet Axsome's fantastic 2019 return was predicated on an investor buying at the bottom in January. Measured from its IPO price at $9 a share, Axsome was a 10-bagger for the decade. That's a good return, of course, but not impressive enough to make this list. Our top 10 is filled with medical device makers and companies that are providing services to the healthcare industry. Only three drug companies made it to the top. If you invested $1,000 in each of these 10 companies on Jan. 4, 2010, 10 years later your portfolio would be worth $247,607. And here are the mightiest healthcare stocks over the last decade. Image source: Getty Images 10. Jazz Pharmaceuticals (up 1,699%) Jazz Pharmaceuticals (NASDAQ: JAZZ) is an Irish biotech company that focuses on drugs for sleep disorders, as well as oncology/hematology and other unmet medical needs. Its marketed products include Xyrem for excessive daytime sleepiness, as well as Erwinaze and Vyxeos for leukemia. It also has drugs for sleep apnea and Parkinson's disease in its pipeline. The $8 billion biotech is highly profitable, with margins of 29%. 9. Abiomed (up 1,782%) Abiomed (NASDAQ: ABMD) was $8.86 a share at the open on Jan. 4, 2010. Fast forward a decade, and on Jan. 3, 2020, the stock was trading for $166.82 a share. (And it's down 47% off its highs!) So that's a fantastic return for long-term shareholders. It's almost a 19-bagger. Abiomed is a medical device company focused on creating artificial pumps for failing hearts. Its major device, the Impella, is a micro-pump that can replace heart function for six hours. 8. NeoGenomics (up 1,790%) NeoGenomics (NASDAQ: NEO) was trading for $1.55 at the beginning of the decade. Ten years later, its shares are trading hands for $29.31. The company specializes in running advanced genomics tests for hospitals and doctors in the oncology space. It's a $3 billion small-cap. In its most recent quarter, Neo grew revenues at 50% year over year. (Some of that growth was due to its acquisition of Genoptix in Dec. 2018). 7. Accelerate Diagnostics (up 1,813%) Accelerate Diagnostics (NASDAQ: AXDX) was a penny stock ten years ago, trading for $0.89 a share. Investors who put in $1,000 at the beginning of the decade (1,123 shares) are sitting on $19,124 now. (Let your winners run!) Accelerate is a medical device company that specializes in infectious diseases. Its devices help doctors quickly determine if a patient has been exposed to a deadly bacteria or fungus. The company's not profitable yet, but revenues increased 68% in the most recent quarter. 6. Simulations Plus (up 2,001%) Simulations Plus (NASDAQ: SLP) was a tiny micro-cap ten years ago. Today it's worth $500 million. The company provides simulation software and services to drug companies to help with drug discovery and development. Using the company's software, scientists can simulate in vitro experiments over many molecules at once. The software will predict various properties of molecules, including absorption rates and interactions with other drugs. Simulations Plus has 25% profit margins and revenue growth of 20% in its most recent quarter. 5. Repligen (up 2,123%) Repligen (NASDAQ: RGEN) is a bioprocess developer with a market cap of almost $5 billion. Repligen is a picks-and-shovels play on the rise of biotechnology. Instead of taking the risks of drug discovery and drug failure, you can invest in Repligen, a company that provides equipment to a multitude of companies so that biologic drugs can be manufactured. Repligen has an estimated 95% market share in producing the proteins that go into vaccines and gene therapy. 4. DexCom (up 2,563%) DexCom (NASDAQ: DXCM) is now a massive $20 billion healthcare company. But 10 years ago, it was a tiny medical device company. DexCom specializes in continuous glucose monitoring (CGM) systems for people with diabetes. Right now the company is in a hot competition with Abbott Labs in the CGM market. The company's recently achieved profitability and its top-line growth is still blistering at 49% year over year. 3. Exact Sciences (up 2,612%) Exact Sciences (NASDAQ: EXAS) is a large-cap ($14 billion) company focused on molecular diagnostics for oncology. The company's main product is Cologuard, a non-invasive DNA screening test taken from a stool sample. Profitability is still elusive but the company has fantastic top-line growth. Revenues are up 85% year over year. And profitability is definitely in the cards as the company has 80% gross margins on a pro forma basis. 2. ACADIA Pharmaceuticals (up 2,956%) ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biotech that is focused on disorders of the central nervous system. Its leading pharmaceutical is Nuplazid, which is used to treat hallucinations and delusions caused by Parkinson's. The company hopes to expand the label to include other forms of dementia. 1. Neurocrine Biosciences (up 3,863%) Neurocrine Biosciences (NASDAQ: NBIX) is the top healthcare stock over the last decade. Investors who bought 361 shares at $2.77 a share are now sitting on almost $40,000. The $10 billion biotech has two drugs on the market: Ingrezza, a drug for involuntary muscle movement, and Orilissa, a hormone therapy for women's health. COMPANY PRICE JAN. 4, 2010 PRICE JAN. 3, 2020 PERCENTAGE GAIN Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. Many of these names came out of nowhere to give astounding returns to the investors who bought and held them. And despite these very large returns, many of these stocks are still attractive going forward. My favorite is Accelerate Diagnostics, but I think several of these names will easily defeat the S&P 500 over the next decade. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Taylor Carmichael owns shares of Axsome Therapeutics. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool owns shares of NeoGenomics, Inc. The Motley Fool recommends Exact Sciences, Neurocrine Biosciences, and Repligen. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Top Medical Device Stocks to Buy in January Medical device stocks were sizzling hot in 2019. The iShares U.S. Medical Devices ETF soared 32%, easily beating the S&P 500's performance. This medical device exchange-traded fund (ETF) also trounced the 18% gain delivered by the Health Care Select Sector SPDR ETF, which includes stocks from across the healthcare sector. Will 2020 be another great year for medical device stocks? I think so. Here are three top medical device stocks you can buy in January to profit from the booming industry. Image source: Getty Images. 1. Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. While Abbott's 20% return in 2019 lagged behind the broader market indexes and many other medical device stocks, I expect 2020 will be a big year for the healthcare giant. The biggest catalyst for Abbott should be the anticipated FDA clearance for the new version of its popular Freestyle Libre continuous glucose monitoring (CGM) system. This new version of Freestyle Libre supports interoperability with other devices and will include alarms, features that will enable Abbott to compete even more effectively against DexCom's G6 CGM. But Freestyle Libre isn't the only thing Abbott has going for it. The company markets a wide range of products that generated close to $32 billion in sales last year. Among those were several new products that, along with Freestyle Libre, are important growth drivers for Abbott, including Alinity diagnostic systems and MitraClip mitral regurgitation devices. Investors should also like Abbott Labs' dividend. The company recently boosted its dividend by 12.5%, marking its 48th consecutive year of dividend increases. Abbott's dividend currently yields close to 1.7%. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year. The robotic surgical systems maker delivered a gain of more than 23%, which isn't too shabby but wasn't quite as good as some medical device stocks. But my view is that Intuitive should remain one of the steadiest winners on the market. The key reason behind my long-term optimism about Intuitive Surgical is its 21st-century version of the old razor-and-blades business model. Intuitive derives over 70% of its total revenue from recurring sources, primarily replacement instruments and accessories for its da Vinci robotic surgical systems. This recurring revenue continues to grow as the company sells and leases more systems and as customers use robotic surgery for more procedures. Procedure volumes will almost certainly increase due to two key factors: demographic trends and product innovation. With aging populations in the U.S. and across the world, more surgeries that are ideally suited for robotic assistance will be performed. Intuitive Surgical also continues to launch new products like its Ion robotic system for lung biopsy and da Vinci SP for transoral surgery, which expands the types of procedures for which its technology can be used. I also expect that robotic surgery will gain more widespread acceptance and adoption with new rivals entering the market. Although increased competition usually isn't great news for a stock, my view is that the moves by Medtronic and others to launch new products will expand the robotic surgery market and benefit Intuitive Surgical over the long run. 3. ShockWave Medical Unlike Abbott Labs and Intuitive Surgical, ShockWave Medical (NASDAQ: SWAV) handily beat the broader market indexes last year, with the stock skyrocketing 44%. The small medical device company took investors on a roller-coaster ride, however, more than doubling by May, losing all those gains by late September, and then rebounding. I like ShockWave because I like the potential for its technology. The company uses intravascular lithotripsy (IVL) to break up calcium deposits in patients with atherosclerosis, or hardening of the arteries. It's a simple process and arguably a safer approach than traditional methods used to treat the problem, such as balloons and minimally invasive surgery. And lithotripsy has been used for decades to break up kidney stones made of calcium without harming surrounding tissues. ShockWave also has a huge potential market. Different types of atherosclerosis that the company is targeting combined represent an annual sales opportunity of more than $6 billion. ShockWave plans to launch new products in 2020 and expand into new international markets this year, both of which represent key catalysts for the stock. There are a couple of downsides for ShockWave, though. It isn't profitable yet and could have to issue more shares in the future to raise cash (as it did in November 2019), a move that would dilute the value of existing shares. Also, the stock is valued at a steep premium, with shares trading at nearly 36 times trailing-12-month sales. Any bumps in the road will likely cause ShockWave's share price to plunge. Still, my view is that the growth prospects for ShockWave make it a stock for aggressive investors to seriously consider buying. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of Health Care SPDR and Intuitive Surgical. The Motley Fool owns shares of and recommends Intuitive Surgical and ShockWave Medical. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dow Jones Futures Dive On Iranian Missile Attack Report; Micron Leads 5 'Live' Winners"", ""Nasdaq Leads Mixed Stock Market As Chip Stocks Outperform"", ""Dexcom Earns Membership In 95-Plus Composite Rating Club""]"
DXCM,2020-01-08,57.695,58.94,57.2025,58.3075,"[""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know"", ""The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results"", ""The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results"", ""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?"", ""The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results"", ""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?""]"
DXCM,2020-01-09,58.7525,60.196,57.78,59.8175,"[""The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results"", ""Strange: Bullish DXCM Analysts Actually See -7.44% Downside Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM \u2014 averaging the work of 16 analysts \u2014 reveals an average price target of $215.88/share. That's a whopping -7.44% below where DXCM has been trading recently at $233.23/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 14 14 14 11 Buy ratings: 1 1 1 1 Hold ratings: 3 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.39 1.39 1.39 1.47 The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.39 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that \u2014 a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $255.00. And then on the other side of the spectrum one analyst has a target as low as $125.00. The standard deviation is $34.893. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes \u2014 much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $215.88/share, the -7.44% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Thursday"", ""The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results""]"
DXCM,2020-01-10,60.36,60.535,58.9775,59.325,"[""Stock Market Gives Back Early Gains After Weakish Jobs Data; These Chinese Growth Stocks Continue To Rise"", ""Here's Why You Should Add Cerner (CERN) to Your Portfolio"", ""IBD Stock Of The Day Dexcom Is Breaking Out To A Record High \u2014 Here's Why"", ""The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx"", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks That Hit 52-Week Highs On Friday"", ""The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx"", ""Stock Market Gives Back Early Gains After Weakish Jobs Data; These Chinese Growth Stocks Continue To Rise"", ""IBD Stock Of The Day Dexcom Is Breaking Out To A Record High \u2014 Here's Why"", ""Here's Why You Should Add Cerner (CERN) to Your Portfolio"", ""Stocks That Hit 52-Week Highs On Friday"", ""The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx"", ""Stock Market Gives Back Early Gains After Weakish Jobs Data; These Chinese Growth Stocks Continue To Rise"", ""IBD Stock Of The Day Dexcom Is Breaking Out To A Record High \u2014 Here's Why"", ""Here's Why You Should Add Cerner (CERN) to Your Portfolio""]"
DXCM,2020-01-13,58.75,59.02,56.0025,58.96,"[""DexCom Sees Prelim. Q4 Sales ~$457M vs $431.47M Est., Prelim. FY19 Sales $1.47B vs $1.44B Est.; Sees FY20 Sales $1.725B-$1.775B vs $1.75B Est."", ""DexCom Sees Prelim. Q4 Sales ~$457M vs $431.47M Est., Prelim. FY19 Sales $1.47B vs $1.44B Est.; Sees FY20 Sales $1.725B-$1.775B vs $1.75B Est."", ""DexCom and Livongo Health Team up in Glucose Data Deal Two companies active in the diabetes segment, DexCom (NASDAQ: DXCM) and Livongo Health (NASDAQ: LVGO) announced on Monday they were collaborating on user data dissemination. In a joint press release, the two companies said that users of Livongo's health information platform would be able to sync their data from DexCom's G6 glucose (blood sugar) monitoring system. The two companies said this will allow Livongo users to utilize that data with other information tracked by the platform, such as weight and blood pressure, to obtain a deeper understanding of the state of their health. Image source: Getty Images \""Livongo can now aggregate data from the Dexcom G6, cross-reference with proprietary blood pressure and weight data from its connected devices, and then use advanced data science to interpret that data and offer Members personalized health insights, or Health Nudges, based on their comprehensive health profile,\"" the companies wrote in their announcement. At the end of September, the Livongo software platform had over 770 customers. The system allows users to monitor and manage chronic illnesses, particularly type 2 diabetes. It can also track developments in hypertension, among other health issues. DexCom is a specialist in continuous glucose monitoring (CGM); its G6 is a product that takes readings from a small sensor inserted just under the skin. The readings are transmitted wirelessly and can be monitored on a display device such as a smartphone. DexCom and Livongo did not provide the terms or the financial details of their new arrangement. On Monday, the paths of the two healthcare stocks diverged. Livongo's shares closed up by nearly 6%. In contrast, DexCom's were down, albeit only marginally. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Sees Prelim. Q4 Sales ~$457M vs $431.47M Est., Prelim. FY19 Sales $1.47B vs $1.44B Est.; Sees FY20 Sales $1.725B-$1.775B vs $1.75B Est.""]"
DXCM,2020-01-14,59.0375,60.4888,58.435,58.765,"[""DexCom (DXCM) Dips More Than Broader Markets: What You Should Know"", ""ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View"", ""DexCom (DXCM) Dips More Than Broader Markets: What You Should Know"", ""ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View"", ""DexCom (DXCM) Dips More Than Broader Markets: What You Should Know"", ""ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View""]"
DXCM,2020-01-15,58.86,58.9375,57.325,58.585,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.4 million of Shares"", ""Inogen (INGN) Announces Preliminary Q4 Results, Slashes View"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.4 million of Shares"", ""Inogen (INGN) Announces Preliminary Q4 Results, Slashes View"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.4 million of Shares"", ""Inogen (INGN) Announces Preliminary Q4 Results, Slashes View""]"
DXCM,2020-01-16,58.68,59.4075,57.555,58.6025,"[""Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results"", ""Allscripts Expands Partnership With PIH Health Through 2025"", ""Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results"", ""Allscripts Expands Partnership With PIH Health Through 2025"", ""Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results"", ""Allscripts Expands Partnership With PIH Health Through 2025""]"
DXCM,2020-01-17,59.0475,59.2025,57.565,57.6975,"[""Diabetes Management Gains FDA Attention: 3 Stocks in Focus"", ""How These Hot Investors Find Stocks That 'Make Their Own Luck'"", ""Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy"", ""Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy"", ""How These Hot Investors Find Stocks That 'Make Their Own Luck'"", ""Diabetes Management Gains FDA Attention: 3 Stocks in Focus"", ""Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy"", ""How These Hot Investors Find Stocks That 'Make Their Own Luck'"", ""Diabetes Management Gains FDA Attention: 3 Stocks in Focus""]"
DXCM,2020-01-21,57.675,58.9925,57.45,57.905,"[""Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now"", ""Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now"", ""Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now""]"
DXCM,2020-01-22,58.4325,59.8302,58.4325,58.885,"[""Here's Why You Should Add DexCom (DXCM) to Your Portfolio"", ""Stryker (SYK) to Report Q4 Earnings: What's in the Cards?"", ""Stryker (SYK) to Report Q4 Earnings: What's in the Cards?"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio"", ""2 Growing Healthcare Stocks You Should Know If you were asked to name the greatest healthcare stocks of the last decade, do you think you could? When I was researching an article on the subject, I was surprised by the winners. I had no idea that any of these companies had run up so far. But at least I had heard of most of these stocks; companies like DexCom, Abiomed, and Exact Sciences are familiar to a lot of Fools. On the other hand, two of the best healthcare stocks over the past decade were complete mysteries to me. Both of these companies were micro-caps in 2010, and they went on to have magnificent runs. Accelerate Diagnostics (NASDAQ: AXDX) had a 19-bagger for the decade, and Simulations Plus (NASDAQ: SLP) returned 2,000% to its investors. Let's dig a little deeper into them. Image source: Getty Images. Speeding up diagnosis of infectious disease Accelerate Diagnostics is a fascinating medical device company. Accelerate sells a device called the Accelerate Pheno, a small machine that tests for bacteria and fungus infections right in the hospital. The status quo is to run a test on a patient, send it off to a lab, and get the response back in two to three days. With Accelerate Pheno, the doctors can get a response back in a matter of hours, and that speed makes a big difference in treatment. When you are invaded with bacteria or fungus, your body can have an extreme immune response, called sepsis. About 270,000 people die from sepsis every year in the United States. Sepsis also costs hospitals an estimated $27 billion each year \u2014 it's the No.1 cause of hospitalizations in the U.S. Most of these sepsis deaths are preventable if the doctors know what the infection is. Speed is paramount in these situations, and the Accelerate Pheno cuts the wait time by 75%. It's over 40 hours faster than traditional methods. It's early in the company's story. Right now, it's broadening its focus from selling to the top hospitals (influencers) to selling to all hospitals. In the last quarter, Accelerate reported 167 instruments sold so far in 2019. There are 6,146 hospitals in the U.S., so there's a huge runway for growth. One exciting thing about Accelerate Diagnostics is that the company has a razor-and-blades business model. It sells its Accelerate Pheno in a one-time purchase, and then racks up recurring revenue from the use of the device. Once the hospital buys the machine, high-margin future revenue is pretty much assured -- consumables (the recurring revenues from the use of the device) are growing by 150%. Accelerate recently hired a new chief operating officer, Jack Phillips, who will become CEO when Lawrence Mehren retires next month. Phillips was the CEO of Roche Diagnostics, a subsidiary of Roche. Roche is a mega-cap ($275 billion), so to have the chief executive of its diagnostic division step down to become COO of a tiny company deserves attention. Sales are expected to start ramping this year, and insiders are getting excited. Tom Brown, a member of the board of directors and a former executive at Abbott Laboratories, recently bought $136,000 worth of shares on the open market, at a price of $14 a share. Using computer models to predict how drugs will do in the lab Simulations Plus has been around for 24 years, growing from a tiny micro-cap into a $600 million small cap. Its modeling software is used by 19 of the top 20 pharmaceutical companies, as well as many biotechs and regulatory agencies. Simulation Plus offers an array of software, including its flagship product, Gastro Plus, a modeling platform that simulates various absorption rates of molecules through all the major dosing routes. It's faster and cheaper to do these tests on the computer than in the lab. One of the modules of Gastro Plus allows scientists to test for drug-drug interactions. The company also sells ADMET Predictor, a software that analyzes absorption, distribution, metabolism, excretion, and toxicity of various molecules. The company rang up $8 million in revenue in its most recent quarter, growing its top line about 20% from the same period the previous year. Its profit margin sits at 25%, with $11 million in cash and no debt. One worry with Simulations Plus is how expensive the stock is, with a trailing price-to-earnings ratio of 70 and a PEG ratio (price-to-earnings growth) over 4. . But it's clearly a well-respected name in the pharmaceutical space. If the company can fortify its current business with new offerings, the stock should continue to advance. Which stock is the winner? Right now it seems that Accelerate Diagnostics has a much larger market opportunity than Simulations Plus. The vast majority of hospitals don't have a Pheno yet, so most of the company's revenue is still ahead of it. In addition, once those sales are made, Accelerate will have continuous revenue streams into the future. Simulations Plus, on the other hand, has already made sales to 19 of the top 20 pharmaceutical companies. That's an enviable record, but it also makes you wonder if the company has any room to make new sales. Simulations Plus will either have to make additional sales to existing customers or sell its software to smaller and smaller firms. Also worrisome is that Simulations Plus' software is not based in the cloud; its model is the old \""one and done\"" software sale, with a buyer who installs the software and owns a perpetual license. And some of the company's revenue comes from consulting fees, a business that doesn't scale well at all. Nonetheless, it might be an outstanding acquisition for a larger player like Veeva Systems. Simulations Plus is definitely a stock to keep on your watch list. But the stock I prefer as a buying opportunity today is the one I recently bought myself: Accelerate Diagnostics. 10 stocks we like better than Accelerate Diagnostics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Accelerate Diagnostics wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Taylor Carmichael owns shares of Accelerate Diagnostics. The Motley Fool owns shares of and recommends Abiomed and Veeva Systems. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stryker (SYK) to Report Q4 Earnings: What's in the Cards?"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio""]"
DXCM,2020-01-23,59.0075,59.4475,57.9225,58.9,"[""What's in Store for Varian Medical (VAR) in Q1 Earnings?"", ""Best Thematic ETF for 2020: Cloud, Internet of Things & More"", ""Best Thematic ETFs for 2020: Cloud, Internet of Things & More"", ""Best Thematic ETF for 2020: Cloud, Internet of Things & More"", ""Best Thematic ETFs for 2020: Cloud, Internet of Things & More"", ""What's in Store for Varian Medical (VAR) in Q1 Earnings?"", ""Best Thematic ETF for 2020: Cloud, Internet of Things & More"", ""Best Thematic ETFs for 2020: Cloud, Internet of Things & More"", ""What's in Store for Varian Medical (VAR) in Q1 Earnings?""]"
DXCM,2020-01-24,59.4425,59.675,58.2712,58.485,"[""What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?"", ""NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3"", ""Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?"", ""What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?"", ""NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?"", ""What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?"", ""NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3""]"
DXCM,2020-01-27,57.2525,59.1062,56.6812,58.8625,"[""What's in Store for Thermo Fisher (TMO) in Q4 Earnings?"", ""Stocks To Watch: Medical Stock With 261% Growth Retries Breakout"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""Stocks To Watch: Medical Stock With 261% Growth Retries Breakout"", ""What's in Store for Thermo Fisher (TMO) in Q4 Earnings?"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""Stocks To Watch: Medical Stock With 261% Growth Retries Breakout"", ""What's in Store for Thermo Fisher (TMO) in Q4 Earnings?""]"
DXCM,2020-01-28,58.9625,59.4425,58.46,58.735,"[""PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates"", ""Baxter (BAX) to Report Q4 Earnings: What's in the Cards?"", ""PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates"", ""Baxter (BAX) to Report Q4 Earnings: What's in the Cards?"", ""PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates"", ""Baxter (BAX) to Report Q4 Earnings: What's in the Cards?""]"
DXCM,2020-01-29,59.0675,60.0538,58.145,59.635,"[""Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates"", ""This IBD Stock Of The Day Broke Out And Is Now Eyeing Profitability"", ""Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?"", ""This IBD Stock Of The Day Broke Out And Is Now Eyeing Profitability"", ""Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?"", ""Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates"", ""This IBD Stock Of The Day Broke Out And Is Now Eyeing Profitability"", ""Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?"", ""Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates""]"
DXCM,2020-01-30,59.4625,59.9425,58.0,59.7325,"[""Varian (VAR) Earnings and Revenues Miss Estimates in Q1"", ""Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid"", ""McKesson (MCK) to Report Q3 Earnings: What's in the Offing?"", ""Align Technology (ALGN) Earnings Beat in Q4, Margins Rise"", ""Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid"", ""McKesson (MCK) to Report Q3 Earnings: What's in the Offing?"", ""Varian (VAR) Earnings and Revenues Miss Estimates in Q1"", ""Align Technology (ALGN) Earnings Beat in Q4, Margins Rise"", ""Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid"", ""McKesson (MCK) to Report Q3 Earnings: What's in the Offing?"", ""Varian (VAR) Earnings and Revenues Miss Estimates in Q1"", ""Align Technology (ALGN) Earnings Beat in Q4, Margins Rise""]"
DXCM,2020-01-31,59.705,61.835,59.5025,60.1875,"[""CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4"", ""Stocks To Watch: Friday's New Highs Screen Includes These 3 Earnings Winners"", ""Beacon Investment Advisory Services, Inc. ..."", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks To Watch: Friday's New Highs Screen Includes These 3 Earnings Winners"", ""Beacon Investment Advisory Services, Inc. ..."", ""CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4"", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks To Watch: Friday's New Highs Screen Includes These 3 Earnings Winners"", ""Beacon Investment Advisory Services, Inc. ..."", ""CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4""]"
DXCM,2020-02-03,60.26,60.96,59.1125,59.2725,"[""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know"", ""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?"", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know"", ""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?"", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know"", ""DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?""]"
DXCM,2020-02-04,59.7275,61.315,59.4175,60.925,"[""What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?"", ""What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?"", ""What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?""]"
DXCM,2020-02-05,61.085,61.085,59.25,59.635,"Why DexCom Stock Gained 10% in January What happened Shares of the diabetes medical device giant DexCom (NASDAQ: DXCM) gained a noteworthy 10% during the month of January, according to data from S&P Global Market Intelligence. Its stock is now trading at all-time highs as a result of this latest double-digit rally. What caused DexCom's stock to catch fire yet again in January? The short answer is that the stock has been on an absolute tear ever since the company reported third-quarter earnings back in early November 2019. In fact, DexCom's stock has gained an astounding 59% since its last earnings report. Image source: Getty Images. So what Investors appear to be gobbling up this medical device stock for two interrelated reasons: DexCom's continuous glucose monitoring (CGM) franchise -- headed up by the groundbreaking G6 CGM system -- has transformed the company into a juggernaut. Over the past 12 months, the company's annual revenue has risen by a staggering 42% to $1.47 billion. In 2020, DexCom is expected to have another banner year, with its top line rising by 21.4%. A key component of DexCom's wildly successful growth story is a new partnership with diabetes drugmaker Eli Lilly (NYSE: LLY). In late December, the two companies announced a non-exclusive agreement to integrate DexCom's CGM platform into Lilly's personalized diabetes management system. As Lilly is one of the biggest diabetes players in the world, this deal should provide a major competitive advantage for DexCom in the years ahead. Now what Is DexCom stock worth buying at these lofty levels? At 16.5 times trailing-12-month sales, this red-hot growth stock may have trouble printing fresh highs anytime soon. Put simply, DexCom's stupendous sales growth appears to be baked into its valuation at this point. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-02-06,60.43,60.605,59.285,59.75,
DXCM,2020-02-07,59.8325,60.2475,58.7525,60.055,"[""What's in the Cards for DaVita (DVA) This Earnings Season?"", ""Med Stock Dexcom In Buy Range Ahead Of Earnings"", ""Med Stock Dexcom In Buy Range Ahead Of Earnings"", ""What's in the Cards for DaVita (DVA) This Earnings Season?"", ""Med Stock Dexcom In Buy Range Ahead Of Earnings"", ""What's in the Cards for DaVita (DVA) This Earnings Season?""]"
DXCM,2020-02-10,60.1475,61.8575,60.0165,61.73,"[""Silvant Capital Management LLC Buys Facebook Inc, NVIDIA Corp, DexCom Inc, Sells Adobe Inc, Las ..."", ""Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?"", ""Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings"", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?"", ""Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment"", ""Topping The S&P 500, This Mutual Fund Seeks Cyclical And GARP Stocks"", ""Silvant Capital Management LLC Buys Facebook Inc, NVIDIA Corp, DexCom Inc, Sells Adobe Inc, Las ..."", ""Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?"", ""Topping The S&P 500, This Mutual Fund Seeks Cyclical And GARP Stocks"", ""Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment"", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?"", ""Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings"", ""The DXCM Paradox: Analysts Bullish But Forecast -4.17% Fall Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM \u2014 averaging the work of 15 analysts \u2014 reveals an average price target of $230.20/share. That's a whopping -4.17% below where DXCM has been trading recently at $240.22/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 14 14 14 14 Buy ratings: 1 1 1 1 Hold ratings: 3 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.39 1.39 1.39 1.39 The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.39 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that \u2014 a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $258.00. And then on the other side of the spectrum one analyst has a target as low as $185.00. The standard deviation is $26.197. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes \u2014 much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $230.20/share, the -4.17% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Silvant Capital Management LLC Buys Facebook Inc, NVIDIA Corp, DexCom Inc, Sells Adobe Inc, Las ..."", ""Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?"", ""Topping The S&P 500, This Mutual Fund Seeks Cyclical And GARP Stocks"", ""Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment"", ""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?"", ""Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings""]"
DXCM,2020-02-11,61.7725,62.01,60.635,61.98,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.5 million of Shares"", ""Medtronic (MDT) to Report Q3 Earnings: What's in Store?"", ""The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.5 million of Shares"", ""Medtronic (MDT) to Report Q3 Earnings: What's in Store?"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.5 million of Shares"", ""Medtronic (MDT) to Report Q3 Earnings: What's in Store?""]"
DXCM,2020-02-12,62.0025,62.67,60.86,61.5,"[""5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow"", ""Shopify (SHOP) Q4 Earnings and Revenues Top Estimates"", ""Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates"", ""Barrick Gold (GOLD) Q4 Earnings and Revenues Beat Estimates"", ""Lithia Motors (LAD) Lags Q4 Earnings Estimates"", ""Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More"", ""The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data"", ""Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More"", ""5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow"", ""Shopify (SHOP) Q4 Earnings and Revenues Top Estimates"", ""Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates"", ""Barrick Gold (GOLD) Q4 Earnings and Revenues Beat Estimates"", ""Lithia Motors (LAD) Lags Q4 Earnings Estimates"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data"", ""Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More"", ""5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow"", ""Shopify (SHOP) Q4 Earnings and Revenues Top Estimates"", ""Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates"", ""Barrick Gold (GOLD) Q4 Earnings and Revenues Beat Estimates"", ""Lithia Motors (LAD) Lags Q4 Earnings Estimates""]"
DXCM,2020-02-13,61.005,63.675,60.5675,63.0525,"[""Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+"", ""The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services"", ""Dow Jones Futures: Stock Market Resilient; Nvidia, Roku, Dexcom Lead Key Earnings Movers"", ""Earnings Scheduled For February 13, 2020"", ""The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO"", ""DexCom Q4 Adj. EPS $1.15 Beats $0.74 Estimate, Sales $462.8M Beat $442.38M Estimate"", ""DexCom Sees FY20 Sales $1.725B-$1.775B vs $1.77B Estimate"", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""DexCom Sees FY20 Sales $1.725B-$1.775B vs $1.77B Estimate"", ""DexCom Q4 Adj. EPS $1.15 Beats $0.74 Estimate, Sales $462.8M Beat $442.38M Estimate"", ""The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO"", ""Earnings Scheduled For February 13, 2020"", ""Dow Jones Futures: Stock Market Resilient; Nvidia, Roku, Dexcom Lead Key Earnings Movers"", ""Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+"", ""The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services"", ""DexCom Reports Q4 Earnings, Beats EPS and Revenue Targets On Thursday afternoon, DexCom (NASDAQ: DXCM) announced its fourth-quarter and full-year financial results. The maker of continuous glucose monitoring systems for diabetes management reported an overall strong quarter during which key metrics beat Wall Street's expectations. Revenue came in at $462.8 million, up 37% from the $338 million it brought in during Q4 2018. While sales growth in the U.S. market was strong, its biggest increase came from international markets, where sales rose by 52%. The domestic market still provides for 81% of the company's total income, however. DexCom's GAAP net income was $92.7 million in Q4, a marked turnaround from the $179.7 million GAAP net loss it produced in the year-ago period. Image source: Getty Images. One metric that changed noticeably for the worse was DexCom's cash position, which fell from $1.14 billion at the close of 2018 to just $446.2 million as of the end of 2019. For the most part, however, the company has exceeded analysts' expectations. Wall Street had expected $441.0 million in quarterly revenue for the company, a figure that DexCom beat handily, while analysts' consensus EPS forecast of $0.74 turned out to be well below the GAAP EPS of $1.00 that the biotech company reported. Further details DexCom is a medical device manufacturer known for its diabetes monitoring systems, and its technology is a core feature in the products of a number of insulin pump makers, such as Tandem Diabetes Care. DexCom's stock rose 4.9% in after-hours trading Thursday following the quarterly release. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""DexCom Sees FY20 Sales $1.725B-$1.775B vs $1.77B Estimate"", ""DexCom Q4 Adj. EPS $1.15 Beats $0.74 Estimate, Sales $462.8M Beat $442.38M Estimate"", ""The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO"", ""Earnings Scheduled For February 13, 2020"", ""Dow Jones Futures: Stock Market Resilient; Nvidia, Roku, Dexcom Lead Key Earnings Movers"", ""Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+"", ""The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services""]"
DXCM,2020-02-14,70.95,73.75,68.976,70.9775,"[""Top Software Stocks, Chip Leader Nvidia Ride Post-Earnings Rally To New Highs"", ""Stock Market Turns Mixed On Retail Sales; Dexcom, Nvidia, Roku Jump On Earnings, But Datadog Plunges"", ""This Diabetes Stock Just Threw Down A Gauntlet \u2014 Can Rivals Catch Up?"", ""Dow Jones Eases, But Visa, American Express Buck The Trend; 3 Stocks Move Bullishly On Earnings"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $300"", ""30 Stocks Moving in Friday's Pre-Market Session"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $275"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $288"", ""The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering"", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""10 Biggest Price Target Changes For Friday"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $285"", ""Stocks That Hit 52-Week Highs On Friday"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $300"", ""CFRA Maintains Hold on DexCom, Raises Price Target to $258"", ""50 Stocks Moving In Friday's Mid-Day Session"", ""50 Stocks Moving In Friday's Mid-Day Session"", ""CFRA Maintains Hold on DexCom, Raises Price Target to $258"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $300"", ""Stocks That Hit 52-Week Highs On Friday"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $285"", ""10 Biggest Price Target Changes For Friday"", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $288"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $275"", ""30 Stocks Moving in Friday's Pre-Market Session"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $300"", ""Top Software Stocks, Chip Leader Nvidia Ride Post-Earnings Rally To New Highs"", ""Dow Jones Eases, But Visa, American Express Buck The Trend; 3 Stocks Move Bullishly On Earnings"", ""Stock Market Turns Mixed On Retail Sales; Dexcom, Nvidia, Roku Jump On Earnings, But Datadog Plunges"", ""This Diabetes Stock Just Threw Down A Gauntlet \u2014 Can Rivals Catch Up?"", ""Health Care Sector Update for 02/14/2020: DCPH,DXCM,IMGN,PLSE Top Health Care Stocks JNJ -0.45% PFE -1.27% ABT -0.06% MRK +0.24% AMGN -0.48% Health care stocks were mostly lower, with the NYSE Health Care Index declining 0.3% on Friday while the shares of health care companies in the S&P 500 also were down 0.1% as a group. The Nasdaq Biotechnology index was climbing 0.4%. Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. Net proceeds will be used to fund more research and development of its drug candidates, clinical trials and commercialization efforts and other general corporate purposes. In other sector news: (+) ImmunoGen (IMGN) climbed 29% to its best share price since October 2018 at $7.07 apiece after the biotechnology company reported a surprise Q4 profit and a more than three-fold increase in revenue compared with year-ago levels, also exceeding Wall Street estimates. Looking forward, it sees FY20 revenue in a range of $60 million to $65 million, topping the $44.7 million analyst mean. (+) DexCom (DXCM) rose 13% after the medical device company late Thursday reported non-GAAP Q4 net income and revenue topping year-ago levels, earning $1.15 per share during the three months ended Dec. 31, more than doubling its $0.56 per share adjusted profit last year while revenue rose 36.9% to $462.8 million. Analysts, on average, had been looking for a $0.72 per share profit, excluding one-time items, on $457.1 million in revenue. (-) Pulse Biosciences (PLSE) fell over 42% soon after Friday's opening bell, dropping to a three-year low of $7.00 a share after the US Food and Drug Administration said the company has not demonstrated its CellFX non-thermal cellular dermatology treatment was substantially equivalent to its predicate device. Pulse said it was prepared to provide the agency with more clinical data to obtain 510(k) market clearance for the device. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 02/14/2020: DXCM,IMGN,PLSE Top Health Care Stocks JNJ -0.45% PFE -1.27% ABT -0.06% MRK +0.24% AMGN -0.48% Health care stocks were mostly lower, with the NYSE Health Care Index declining 0.4% on Friday while the shares of health care companies in the S&P 500 also were down 0.3% as a group. The Nasdaq Biotechnology index was climbing 0.2%. Among health care stocks moving on news: (+) DexCom (DXCM) rose 15% after the medical device company late Thursday reported non-GAAP Q4 net income and revenue topping year-ago levels, earning $1.15 per share during the three months ended Dec. 31, more than doubling its $0.56 per share adjusted profit last year while revenue rose 36.9% to $462.8 million. Analysts, on average, had been looking for a $0.72 per share profit, excluding one-time items, on $457.1 million in revenue. In other sector news: (+) ImmunoGen (IMGN) climbed 29% to its best share price since October 2018 at $6.92 apiece after the biotechnology company reported a surprise Q4 profit and a more than three-fold increase in revenue compared with year-ago levels, also exceeding Wall Street estimates. Looking forward, it sees FY20 revenue in a range of $60 million to $65 million, topping the $44.7 million analyst mean. (-) Pulse Biosciences (PLSE) fell over 42% soon after Friday's opening bell, dropping to a three-year low of $7.00 a share after the US Food and Drug Administration said the company has not demonstrated its CellFX non-thermal cellular dermatology treatment was substantially equivalent to its predicate device. Pulse said it was prepared to provide the agency with more clinical data to obtain 510(k) market clearance for the device. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Friday's ETF with Unusual Volume: PDP The Invesco DWA Momentum ETF is seeing unusually high volume in afternoon trading Friday, with over 150,000 shares traded versus three month average volume of about 113,000. Shares of PDP were up about 0.5% on the day. Components of that ETF with the highest volume on Friday were Advanced Micro Devices, trading up about 1.2% with over 22.7 million shares changing hands so far this session, and Nvidia, up about 8% on volume of over 16.5 million shares. Dexcom is the component faring the best Friday, higher by about 15.5% on the day, while Mirati Therapeutics is lagging other components of the Invesco DWA Momentum ETF, trading lower by about 2.1%. VIDEO: Friday's ETF with Unusual Volume: PDP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Shares Are Flying Higher Today What happened Shares of DexCom (NASDAQ: DXCM) were flying 15.4% higher as of 11:44 a.m. EST on Friday. The big gain came following the company's announcement of its 2019 fourth-quarter and full-year results after the market closed on Thursday. DexCom reported Q4 revenue of $462.8 million, up 37% year over year and well above the average analysts' estimate of $442.4 million. It also announced adjusted earnings of $106.5 million, or $1.15 per share. This reflected significant improvement from adjusted earnings of $50.2 million, or $0.56 per share, posted in the prior-year period. It also blew past the consensus Wall Street earnings estimate of $0.74 per share. Image source: Getty Images. So what When a company beats estimates the way DexCom did with its Q4 results, its stock is bound to jump. The key question to ask, though, is: Why did the company top estimates? In DexCom's case, the answer is simple. The company's G6 continuous glucose monitoring (CGM) systems continue to enjoy strong customer demand. And that strong demand isn't just in the U.S. DexCom's international sales grew even faster than its U.S. sales did in the fourth quarter. This momentum seems likely to continue. Diabetes remains a serious problem across the world. Real-time CGM offers a way for patients to keep their diabetes under control. Now what DexCom's nice jump today probably won't fade away. The company projects strong full-year 2020 revenue growth. With sales for the G6 device soaring and a new G7 CGM coming in the future, DexCom appears to be one of the most promising healthcare stocks on the market. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q4 2019 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q4 2019 Earnings Call Feb 13, 2020, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom fourth-quarter 2019 earnings release conference call. My name is Cheryl, and I will be your operator for today's call. [Operator instructions] Please note that this conference call is being recorded. I will now turn the call over to Sean Christensen. Sir, you may begin. Sean Christensen -- Senior Investor Relations Manager Thank you, operator, and welcome to DexCom's fourth-quarter and full-year 2019earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will provide a summary of the quarter and full-year 2019, followed by a financial review and outlook from Quentin Blackford, our COO and CFO, and then a strategic update from Steve Pacelli, our executive vice president of strategy and corporate development. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our fourth-quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our fourth-quarter and full-year earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. 2019 was another fantastic year for DexCom. I want to take a few minutes to highlight some of our accomplishments before we turn our attention to 2020. This was the second consecutive year that our organic growth exceeded 40%. To put this into perspective, given that we started the year on a revenue base greater than $1 million, this means that we added more than $440 million of absolute growth in the year. New patients continue to be the primary driver behind the growth and includes growing traction in the insulin-dependent type 2 market, where we continue to expand access in addition to our existing coverage in Medicare. We ended the year approaching 650,000 net active patients globally who are benefiting from DexCom CGM technology. And as a reminder, we only count someone as a patient when they are consistently reordering product. We are also achieving this growth with operational and spending discipline as an organization. 2019 was the most profitable year in DexCom's history and represented our first full year of GAAP profitability. We are demonstrating great operating leverage, even as we doubled G6 capacity in 2019 and continued to invest in R&D to drive our future growth. As we grow, we are building and adapting our infrastructure to serve meaningfully more patients. In the U.S., we are making great progress in our effort to transition to the pharmacy channel as we expanded covered lives by more than 50% in 2019. We are now fully under way in the launch of G6 into Medicare and look forward to those patients having access to the no fingerstick G6 technology. We have built an extensive global business services team in Manila in 2019, exiting the year with progress on all of our key customer service metrics. Our business services team will be a great asset for us as we continue to scale the company and strive to offer our customers the best possible experience. We are also transparent with you and our customers about the things we must improve. As many of you heard in late November, we experienced a temporary server outage that impacted the ability of family and friends to monitor glucose levels of loved ones via our SHARE and Follow apps. I told our customers, healthcare providers and shareholders that we needed to do better. We needed a system in place to greatly improve communication with our customers. In the weeks since, we have taken significant steps to do just that. We have launched a system status page on our website ahead of schedule. This provides real-time updates on system functionality, 24 hours a day, seven days a week. We are also in the final stages of rolling out an in-app messaging system that will provide quick communication with our customers. As you can see, we are not sitting still, even with the rapid growth that we've experienced since the launch of G6. The reason for this is simple, we believe that there is a huge opportunity still ahead of us for our sensor platform. For our core markets, we remain confident in the underlying shift from fingersticks to CGM as the standard of care. Outside of our core markets, our excitement for the potential of DexCom CGM to address broader global health issues continues to grow. We are beginning to see great early stage data demonstrating the value of CGM for all people with type 2 diabetes, including those not on insulin therapy. Our work with UnitedHealth Group has progressed very well, and we look forward to the expanded use of DexCom CGM in their type 2 populations in 2020. We will look to extend the presence of DexCom CGM for type 2 customers through additional partnerships with programs offered by digital health players like Onduo, Livongo and WellDoc, all integrating CGM data into their respective coaching platforms. And we continue to work directly with providers. As we recently discussed at an investor conference, our initial pilot work for non-insulin-using type 2 customers with Intermountain Healthcare revealed gross cost savings of nearly $5,000 per member per year for those using DexCom CGM relative to those using fingersticks. We look forward to providing additional details like these related to type 2 and other new markets as we progress in 2020. With all of this G6-driven growth in our core markets and ongoing learnings in our new markets, we enter 2020 with an eye toward the biggest product launch in DexCom's history, G7. We have a busy year ahead, but the team has done a great job thus far for us to progress toward our goal of a full-scale launch in 2021. To summarize, 2019 was another great year for DexCom, but we're pressing forward to capitalize and execute in 2020 on these many long-term opportunities. I will now turn the call over to Quentin for a review of our financials. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the fourth quarter of 2019, we reported worldwide revenue of $462.8 million, compared to $338 million for the fourth quarter of 2018, representing growth of 37% on both the reported and constant-currency basis. As a reminder, the fourth quarter of 2018 represented the most difficult comp for the entire year of 2019 for both our worldwide and U.S. business. New patients adopting our technology remained the primary driver of our growth as people continue to gain awareness of the value of DexCom CGM. As Kevin noted, we've been pleased to see that this new patient growth includes steady traction among the type 2 population, where we continue to push for increased market access. Throughout 2019, these increasing patient volumes and strong customer satisfaction with G6 are fueling our momentum. Despite the most difficult quarterly growth comp in 2018, our U.S. business continued to grow very well, with growth of 34% in the fourth quarter of 2019. As our revenue indicates, our volume growth initiatives are more than offsetting the lower revenue per patient that accompanies our transition to the pharmacy channel. Similar to what we saw in the first nine months of the year, this growth came from all of our U.S. channels as expanding CGM awareness is driving strong growth in Medicare, DME and our growing pharmacy business. We saw great performance from our international business in the fourth quarter as well, with 54% constant-currency growth compared to the fourth quarter of 2018. The response to the launch of G6 has exceeded our expectations. We continue to see excellent growth in direct markets like Germany and the U.K., and our distributor markets are also growing very well with strength across the board. Of note, for the first time in our company's history, we launched our e-commerce platform in Canada and were more than pleased with the results as we saw the number of new patients nearly double in the fourth quarter. Our fourth-quarter gross profit was $309.3 million or 66.8% of revenue, compared to 65.9% of revenue in the fourth quarter of 2018. As anticipated, we saw a significant sequential step-up in our gross margin in the 66.8% for the quarter, representing the highest point since 2017. The year-over-year margin improvement was in line with our expectations noted on the third-quarter call. Our teams continue to focus on designing incremental improvements that reduced product cost and increase automated manufacturing, giving us flexibility in our efforts to improve patient access and prioritize efficient channels without meaningfully compromising gross margin. As we head into 2020 and transition the Medicare customer base to G6 from G5, we will receive the full cost benefit of our new G6 transmitter design, which helps offset certain items such as the cost to scale up G6 and G7 manufacturing lines. Operating expenses were $205.7 million for Q4 2019, compared to $168.4 million in Q4 2018. This reflects an increase of 22% year over year and a 540-basis-point reduction as a percentage of revenue from the fourth quarter in 2018. The expense growth in the fourth quarter was primarily driven by incremental R&D spend related to our G7 efforts as we advance toward our launch plans. For the full year, the 23% growth in operating expenses remained well below our 43% total revenue growth, even as we invested significantly to capitalize on DexCom's long-term growth opportunity. Operating income was $103.6 million or 22.4% of revenue in the fourth quarter of 2019, compared to $54.4 million or 16.1% of revenue in the same quarter of 2018. This reflects a year-over-year improvement of 630 basis points in operating margin for the quarter. Adjusted EBITDA was $141.7 million or 30.6% of revenue for the fourth quarter, compared to $83.6 million or 24.7% of revenue for the fourth quarter of 2018. Given the strength of the fourth quarter, our full-year operating margin of 10.9% and adjusted EBITDA margin of 20.7% came in well ahead of our revised full-year guidance of 9% and 19.5%, respectively, as provided on the third-quarter call. As these numbers support, we remain confident in our leverage potential and the discipline that we're exhibiting as an organization. But we will also continue to invest opportunistically as we scale manufacturing for both G6 and G7 in 2020 and explore the use of our real-time CGM in new markets. Net income for the fourth quarter was $106.5 million or $1.15 per share. In 2019, we also established for the first time in our company's history, our first full year of GAAP profitability with full-year GAAP net income of $101.1 million. We remain in a strong cash position with greater than $1.5 billion of cash and cash equivalents on the balance sheet as we exit the year. Given the growth opportunities that are ahead of us, our priority continues to be capital allocation that supports our organic growth opportunity. Turning to 2020 guidance. As we stated last month, we anticipate full-year revenues of between $1,725,000,000 and $1,775,000,000, representing growth of 17% to 20%. This growth contemplates many of the same factors that we navigated in 2019, including a higher rate of volume growth as access and awareness of DexCom CGM continue to grow, our expanded launch of G6 to populations like Medicare and new DexCom integrated systems that come to market. These tailwinds are offset by the continued realization of a reduction in average annual revenue per patient as we navigate toward channels with lower prices, as well as considerations surrounding the competitive environment. Turning to margins. We continue to track well toward our long-term targets established at our 2018 Investor Day. For 2020, we anticipate the following non-GAAP results: Gross margins improving to approximately 64%. Given that we remain in the early stages of patient adoption of our technology in our core market, as well as validation in our patient base that type 2 patients are realizing the value of our technology, we must begin to plan and invest for growth beyond our San Diego and Mesa manufacturing centers. Included in our gross margin guidance are costs associated with identifying and beginning to set up a third manufacturing site that will reside outside of the United States. This third site will further our efforts to reduce the overall production cost of our products, better support our international expansion strategy and support our long-term gross margin expectations of the mid-60s. We expect operating margins to increase to approximately 13%, which contemplates the continued benefits of our global shared services center in the Philippines, offset by increasing investments in our DTC and G7 efforts. Finally, we expect that adjusted EBITDA margins will expand to approximately 23%. As you can imagine, with our ambition to double G6 capacity in the first half of the year, invest in the scale-up of G7 and expand our manufacturing footprint outside of the United States, 2020 will require capital expenditures in excess of what we saw in 2019. With that, I will now turn the call over to Steve for a strategic update. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Thanks, Quentin. As our 2018 and 2019 results indicated, G6 has been a game changer for people with diabetes, with 2019 revenue more than doubling from the year before G6 was launched. Customer satisfaction with G6 remains very high, and we look forward to the benefits of the capacity expansion that we achieved throughout the course of 2019 and continuing into 2020. We plan to double capacity again in the first half of 2020, enabling us to expand our G6 launch in our existing markets, as well as new geographies and to ramp our efforts in these new markets with direct-to-consumer marketing. We are now more than 1.5 years into the launch of G6, and we still have a long way to go to realize its full potential. As Quentin mentioned, the launch of our e-commerce platform in Canada has been a great success and we look forward to expanding the rollout of this platform to additional markets throughout 2020. We expect to complete the transition of our Medicare base to G6 by mid-2020. Many of these customers have waited a long time for G6, and we are thrilled to be providing it to them. As well as the many more Medicare patients who stand to benefit from access to G6 as soon as possible. We will continue to push for expanded market access and look forward to the introduction of G6 in markets like Japan and South Korea later this year. Our payer and market access teams have done a great job to position us for continued momentum in 2020, including their efforts to open up pharmacy access, both for people with type 1 and type 2 diabetes on insulin. As a reminder, the process of transitioning our DME customer base to pharmacy will not happen overnight, even with the progress we have made for customer lives covered through the pharmacy. But we believe we are well-positioned to make meaningful progress in this transition in 2020, which we have contemplated in our guidance. We're excited to be in the position to drive multiple DexCom integrated insulin delivery systems in 2020. We're very excited about the work that we are doing with Insulet in the HORIZON integrated system. In December, Insulet began the pivotal trial, and they remain on track for a launch later in the year. Our commercial agreement with Eli Lilly was officially signed in December and represents another step forward in bringing their system to market with G6, which will initially focus on a smart pen offering. In January, Tandem launched their latest integrated pump offering, the Control-IQ system, incorporating the DexCom G6 sensor and our TypeZero algorithm to automate insulin delivery. This is the first integrated system to offer automated correction boluses based off the customer's CGM reading and our AP algorithm. These are the kind of achievements that do not happen overnight simply because we obtain the regulatory designation of an iCGM or an ACE pump or an iController. In fact, our relationship with each of the companies that I just mentioned goes back multiple years. It takes hard work and significant time to integrate CGM with insulin delivery systems, and DexCom remains the leader in the effort to bring innovative technologies to the diabetes community. Even with the ongoing success of G6, much of our attention is turning toward G7. With G7, we are moving the performance of DexCom real-time CGM into a fully disposable product that is only slightly larger than a nickel. And we believe that customers are going to love the result. As Kevin mentioned, we affirmed our G7 time line today for a full rollout in 2021. We are currently focused on the G7 clinical trial, which we expect to be much larger than the size of the trial that we ran for G6, and we are initiating the scale-up of manufacturing for G7 to support the launch time lines that we have mentioned. From the outset, G7 has been designed for scale to support our belief in the market potential for real-time CGM, which we continue to think has opportunity to address far greater numbers of customers and disease states than we currently serve. From product development and the expansion of DexCom CGM into our existing markets, to new geographies, to the ongoing development of new market opportunities, our strategy is focused as we head into 2020. And with that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Steve. Last year, I spoke on this call and talked about 2018 as a year of milestones. 2019 was a year of continued momentum, but there was a lot of work behind the scenes to ensure that momentum. We're entering 2020 as excited as ever for the opportunity that lies ahead, and with DexCom very well-positioned. We are in our best inventory position since the launch of G6 and are focused on the right channels for efficient growth and learning each day about how to expand the use of DexCom CGM to additional customers. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Senior Investor Relations Manager Thank you, Kevin. [Operator instructions] Operator, please provide the Q&A instructions. Questions & Answers: Operator Thank you. [Operator instructions] Our first question comes from Jeff Johnson from Baird. Your line is now open. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. Congratulations on the year. Can you hear me OK? Kevin Sayer -- Chairman, President, and Chief Executive Officer We can hear you. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Absolutely. Jeff Johnson -- Robert W. Baird and Company -- Analyst All right. Hey, great. Kevin, I guess, with my one question, a lot of places I could go, but let me focus maybe on the U.S. commercial business. Would love to hear how you feel about the mix of new patient adds this year with MDI versus maybe competitive share gains. And specifically, would love to hear maybe your thoughts with some of the formulary changes we've seen at the start of this year, how you think that might help sensor volumes this year? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer That's a pretty complicated one question so I'll deal with those as best I can. With respect to the new patient adds this year, there was a majority of our new patient adds, a pretty significant majority of our new patient adds, who are multiple daily injection patients, who are using pens and insulin to control their insulin delivery. We still have a number of pump patients as well, but to expand the way we've expanded and to grow as quickly as we've grown, do the math, we have to be getting patients on multiple daily injections. On the competitive front, we're very pleased with our growth in the number of insulin-using patients that we're picking up here. It was just a great year all around on the new patient front. With respect to the formulary and the increased access that we see coming, there's a couple of things we think that will be very good for next year that we see right now. The first is more increased type 2 intensive insulin access for many of our patients. And under many of the plans, plans are starting to open up and follow the Medicare guidelines there. That really opens a lot of doors for us, and that will be good. And then increased pharmacy coverage. While our pharmacy rollout has been a bit choppy as we're trying to learn here how to do that best, that has not been our core business going to the drug store since we started. We'll learn to be better and get better there. But as we can make the product more accessible and easy to get, over and over again, we see the utilization is higher and retention is better. So all those things point to a very strong 2020 for us. Operator Thank you. Our next question comes from Jayson Bedford from Raymond James. Your line is now open. Jayson Bedford -- Raymond James -- Analyst Hi, good afternoon. I'll ask an uncomplicated question. In terms of -- and I'm not sure -- I missed part of the call, but G7 timing, is your expectation that you get it approved here in 2020? Kevin Sayer -- Chairman, President, and Chief Executive Officer Our expectation is that we launch it full-scale in 2021. And we've spoken several times about a limited launch in 2020, and that's still one of our primary goals and objectives, but we don't want anybody believing that this rollout is going to happen in 2020. We need to get the trial done, the filing in and reviewed, and our manufacturing scaled up and apply those lessons we learned with G6 to G7. So our big focus and the focus we want everybody to focus on is that launch in 2021. As we get more information, we can share, we'll share it. But that's our time line and that's our commercialization time line for now. We're really not giving any filing or trial time lines today. We can talk more about that as we go on. Operator Thank you. Our next question comes from Travis Steed from Bank of America. Your line is now open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Great. Congratulations on a great year. So I had a question for Quentin. You've got goals for operating margins of 15% by 2023, which looks a lot more conservative now than it did before. And if revenues end up coming on better this year, you could potentially achieve that this year. So just trying to think about the long-term profitability of this business, is there anything long term, as you have more business to the pharmacy channel, G7 is at scale, is there anything that would be structurally inhibiting this business from being at a 25% to 30% operating margin? And additionally, is there anything about G7 launching that where gross margins would step back? Or can you manage through that? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yeah. It's a good question. When we put out the 15% operating margin guidance. At that point in time, we were just trying to draw a reference out in the future that we were confident we could navigate toward, but it was never an end goal that we had in mind. It was more along the lines of the progress we thought we could make. And if you recall, when we did that that was 1,500 basis points away from where we were at that point in time. So to your point, we've closed the gap quite considerably even faster than what we anticipated. But there's nothing structurally in this business that won't allow us to go beyond the 15%. We're not ready to revise kind of those long-term expectations of where we can go. We couldn't be more bullish and excited about the investment opportunities in these new markets that are in front of us. You think about the hospital, gestational, the non-intensive type 2s, the international expansion, all of these things are incredible opportunities that we're going to make sure we're investing into to make sure that we open them up, but none of that is going to keep us from being able to get to the 15% and then on beyond that in time. So no, there's nothing structurally that concerns us whatsoever. G7, I would just remind you. That product was designed from the very beginning with cost in mind. And the idea was to be able to produce that at a very low-cost profile that will go far below even where G6 we've been able to get it to. So from my perspective, all that does is open up even greater opportunity to compete in lower-priced channels if we need to, to be aggressive in the marketplace to push volumes in a way that we need to. But all of it complements the long-term profitability profile that we're trying to achieve here. So I think, very complementary to what we're trying to do. Operator Thank you. Our next question comes from Robbie Marcus from JP Morgan. Your line is now open. Robbie Marcus -- J.P. Morgan -- Analyst Thanks. And I'll echo congrats on a really nice quarter and year. Quentin, we've looked over the past two years and you've meaningfully exceeded your initial guidance range. We see something similar in 2020. Maybe if you could just help us understand why this is the right place to start off the year? And then I remember last year, you kind of walked us through what volume versus mix versus price would be. If you could do the same and maybe break down U.S. versus international and what's assumed in the guidance range, that would be really helpful. Thank you. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Sure. So we continue to be very bullish on the opportunity that sits in front of us from a revenue perspective, just in the core markets that we participate in today. I think we're very early in the adoption of the technology, which leaves a lot of runway. But we also know there are very different patient profiles in that adoption cycle and how quickly they come on to the technology or how long it takes to convince them. It's hard to predict, and we're not going to get ahead of ourselves in that respect. I think if you look at our guidance, the way we thought about it is from an absolute dollar perspective, our guidance assumes a $250 million to $300 million increase year over year. And we've been very clear that there are price headwinds that continue to be contemplated in that guidance. As we walk, average revenue per patient down over time is contemplated in the numbers we put out there. That's about $150 million in 2020. So if you add that back to the net increase that we've guided to, that takes the gross revenue increase on an apples-to-apples basis versus prior year, it's about a $400 million to $450 million increase. You compare that to what we just did in 2019 of a $444 million increase and I think you start to get your mind wrapped around the guidance that we've provided. So we feel good about it. We think there's incredible opportunity. It doesn't make sense to get ahead of ourselves at this point in time, and feel like we've got guidance dialed-in appropriately. Operator Thank you. Our next question comes from Margaret Kaczor from William Blair. Your line is now open. Malgorzata Kaczor -- William Blair and Company -- Analyst Hey, good afternoon, guys. Thanks for taking the question. Maybe first, I wanted to elaborate a little bit on some of the partnerships and updates that you guys have had over the last several months because there have been a lot, including some of the data at J.P. Morgan and so on. So how should we think about some of those? Are there more in the pipeline beyond that this year, especially since, Kevin, you talked about thinking really, really big. And how should we think about the timing to those partnerships becoming more material commercial activity. Thanks. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah. I mean, I think you have to look -- this is Steve. I think you need to kind of bifurcate the partnerships into kind of our core intensive insulin business, both U.S. and OUS. We've got Tandem currently launching Control-IQ, Insulet launching HORIZON later this year. Tandem with Basal-IQ in Europe and hopefully, I don't want to speak for Tandem on their time lines, but hopefully, Control-IQ at some point later this year. So those are all meaningful near-term revenue contributors, right? Because these are folks who are going on their -- many of them are probably already our patients or some portion are already DexCom patients as they go on these systems. But there will certainly be incremental new patient additions as a result of those product launches. So those are really exciting. The update with Lilly, we're still some period of time out before we launch the first really product, but we're definitely making some progress there. The partnerships and the data that we talked about really on the non-intensive side of the business at J.P. Morgan, that's still really early stage. I mean, the way we're trying to frame that, Margaret, is that a year ago around J.P. Morgan, we kind of talked about this new market opportunity strategy, particularly in the non-insulin-using type 2 space. We kind of followed that up, the goal is that this year J.P. Morgan was to follow that up with really some early stage, but concrete evidence that there's a real opportunity here, right? Between the work we're doing with United, the cost savings we showed with Intermountain with one of the payer systems we're working with. So I wouldn't look to -- certainly, not 2020 as a meaningful revenue contribution from really that non-insulin-using type 2 business, but we're super excited about it. The data supporting that there's a huge opportunity there. And I think in the out-years, and you start thinking about '21, '22, '23, I think there's going to be a much more significant revenue contribution from businesses outside of kind of our core intensive insulin business. Operator Thank you. Our next question comes from Ryan Blicker from Cowen. Your line is now open. Ryan Blicker -- Cowen and Company -- Analyst Hi, thanks for taking my questions. You talked about strong and growing contributions from the intensely managed type 2 patient population. Is there anything you can quantify for us on that front, either how big that population is now as a proportion of the installed base or new patient additions? And then just overall, do you expect new patient adds to grow in 2020 versus 2019? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah, this is Kevin. I'll take that. We won't really break out the type 2 patients in the patient base. We don't stratify it between Medicare, peds, those types of things right now. We did give everybody a patient number this year and I think it's a good place for everybody to start. Second part of the -- yeah, why don't you take that one? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Second question. I think the growth rate probably slows a bit, but the absolute number continues to be comparable, if not up slightly, is the way to think about it. Operator Thank you. Our next question comes from Danielle Antalffy from SVB Leerink. Your line is now open.Danielle Joy AntalffyHey, good afternoon, everyone. Thanks for taking the question, and congrats on a really fantastic year. Quentin, I just wanted to ask about seasonality as we look at Q1 specifically and how to think about moving through the year. Is there anything we need to be cognizant of as we go into Q1, which I think is usually a seasonally weak quarter. Any color you can give on the quarterly cadence would be helpful on modeling. Thanks so much. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Sure, yeah. I think at this point in time, historic seasonality that we've seen in the business that generally would have Q1 represent close to 20% of the full year is probably the right way to think about it. We've seen where the street has modeled currently 2020, I think we feel good about that. So I think you guys have got to dialed in pretty well in terms of how you're thinking about seasonality. I do think, over time, as the business continues to mature, as you get more revenue flowing through the pharmacy channel, as Medicare continues to represent a bigger part of the overall business, that seasonality may begin to change a bit, but probably not in 2020. I think historic trends are a good way to think about it, and roughly 20% is probably the right way to model. Operator Thank you. Our next question comes from David Lewis from Morgan Stanley. Your line is now open. David Lewis -- Morgan Stanley -- Analyst Thanks. Quentin, just a follow-up on the 2020 guidance. I mean if I look at the implied leverage for 2020 relative to '18 and '19, the implied leverage for '20 is a little lower just looking at revenue dollars versus the Op expense. Is the right way to think about this year kind of the guidance reflects the expenses that are sort of dialed in for the year and that incremental upside, if there is going to be incremental upside to revenue, that is likely to fall down at a higher rate? Thanks so much. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yeah. So I think what you'll see is we'll continue to be very disciplined in how we manage the business. David, to your point, in the last 24 months, we've driven about 2,200 basis points of opex leverage in this business. So the team has been very thoughtful, accountable, disciplined in how we steward our resources, but we also see some significant opportunities sitting in front of us to really pour some investment into. For example, in '19, we never really poured the fuel on the fire from a DTC spend perspective in the commercial business. We didn't have the capacity from a manufacturing perspective to really open that channel up and support the demand that we thought it might create. We will open DTC up in a meaningful way in 2020, and that is contemplated in our spend. As that drives revenue, if it drives it beyond kind of how we guided, then I think to your point, we'd be very thoughtful and disciplined around how we let that flow through. And yes, I would think that it would drive incremental margin. But we want to make sure we're not passing on the investment opportunities around things like DTC, what we're learning in the new market efforts, particularly around that non-intensive population and knowing that we can take cost out of caring for these patients. We're going to make sure we set that up for success into the future. So that's where we're investing at. If revenue outperforms, then I think you'll see us perform well on the margin front. Operator Thank you. Our next question comes from Kyle Rose from Canaccord. Your line is now open.Kyle William RoseGreat. Thank you very much for taking the questions, and congrats on a strong year and quarter. Steve, you talked a little bit about some of the non-intensive type 2 opportunities. But at the Analyst Day, you also you broke out opportunities like hospital use and gestational use. It looks like there will be some gestational data at next week's ATTD, but just wanted to kind of understand how we should think about when those potential opportunities start flowing through the model in 2021 and beyond? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah. So if you're asking specifically about opportunities outside of non-intensive non-insulin-using type 2s, certainly, there's work being done. There's research being done. You're going to see basically a cascade. As we've kind of done some preliminary work in the clinical side, we've recognized that type 2 non-intensive would be the next logical kind of lowest-hanging fruit for us. So that's where you're going to see us -- what you're going to see us go after first with probably hospital being a close second. In terms of gestational, like you said, it's an exciting market, but a little bit more limited in terms of touch points in the OB/GYN's offices and things like that. So we're working on a strategy there as well. We need to update our labeling, certainly, for hospital and for pregnancy, and there's some initiatives under way there. But you're going to see a cascade of what I would say, incremental increasing contribution over the next several years in all of those categories. Operator Thank you. Our next question comes from Matthew O'Brien from Piper Jaffray. Your line is now open. Matthew O'Brien -- Piper Sandler -- Analyst Thank you. It's actually Piper Sandler. But would love to ask a multipart question that I'm sure Kevin will hate. But I just want to follow-up a little bit more on the non-intensive type 2 commentary. First of all, you're not signaling any kind of concern about a slowdown in your traditional intensive managed group? And then secondly, I don't know if it's for Steve or not. But if you kind of frame up the opportunity that you're thinking about there. There's 1.5 million type 1s, 1.7 million MDI patients. Is this non-intensive group around that level? And can you access that group without some level of reimbursement? Kevin Sayer -- Chairman, President, and Chief Executive Officer This is Kevin. And I can take both of those. We do not believe at all that our intensive business is going to slow down. And in fact, as we look at our strategy, our first pillar is to continue to serve that patient base and continue to grow there. With CGM penetration still, on a combined basis, in the 35% to 40% range in the U.S. and much less than that in other geographies, there is plenty of room to grow. And as CGM becomes a standard of care here, again, I've said for a number of years, I think 80% market penetration is possible and I will hold to that certainly here in the U.S. So there's plenty of room to grow in the intensive business, particularly as we get more automated integrated systems out on the market. With respect to the type 2 non-intensive business, no, we're not talking 1.5 million to 1.7 million people, we're talking 30 million people in the U.S. and hundreds of million of people around the world. I'll address that a little bit more of my closing comments and things that we've learned, but we believe CGM has a tremendous, tremendous benefit there. And we're going to make sure that we can maximize that in the space. But thanks, it's a good question. Operator Thank you. Our next question comes from Mathew Blackman from Stifel. Your line is now open.Mathew Justin BlackmanGood afternoon, everyone. Thanks for taking the question. Quentin, you called out DTC as an investment priority in 2020. So can you talk about the magnitude of returns you get on DTC investment dollars? And then how quickly do you typically see those returns manifesting in revenues? Thanks. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yeah. So you'll see us start to turn DTC spend on really in the back half of the year. Our goal from a capacity perspective is to double where we exited 2019 by the time we get to the mid part of 2020. So we will double capacity once again by the mid part. Once we are there, we feel like we've built enough supply that we can handle any demand that might come from the DTC efforts. It's one of the highest returns on any investment we can make in the company. We monitor it very closely. It's not something that I'm going to disclose in terms of exactly what that rate is, but I will tell you, it's one of the best investments we make. And typically, it's going to take a couple of months to start to see that turn back up into real tangible results in the business, but you could see some benefit in the back part of the year. Operator Thank you. Our next question comes from Raj Denhoy from Jefferies. Your line is now open. Raj Denhoy -- Jefferies -- Analyst Hi, good evening. Quentin, I have a question, actually, coming into 2019, you had talked about kind of absorbing 10 points of mix, price mix offset due to the channel mix that you're experiencing. I guess, this year, it sounds like $150 million, it's roughly another 10 points. When do you imagine that settles out? Is there a point at which the price of the sensor is at a point where you're more normalized and perhaps are not absorbing that level of impact every year? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yeah. Well, I think what we've demonstrated, Raj, is that our strategy to walk price down over time and have volume more than offset that has played out incredibly well. We started to walk price down, really two years ago. And we walked it down again last year. You're going to feel that impact this year. But we've got a price point or a revenue per patient point in mind that we're trying to get to. And there's probably a couple more years, 2020 being one of those that we'll continue to feel this from. And I think volume will more than offset it, but then we're at a very, very good price point that we feel great when you consider the fact that we'll be bringing G7 into the market at that price point. We feel like we're set up to compete incredibly well. So there's probably a couple of years here that we'll continue to navigate through it and have volume more than offset it, but then we're at a point where we think is quite sustainable into the future with an incredible product being G7. Operator Thank you. Our next question comes from Ravi Misra with Berenberg Capital. Your line is now open.Ravi MisraHi, good afternoon. So just a question on -- just a little bit on the transmitter revenues, pretty strong quarter there on that line item more so than we had expected. Can you just walk us a little bit through what was the reason behind that strength in terms of reorders or new patient starts? Thanks. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yeah, I think you continue to see the strength of the new patient numbers show up there. I will point out the fact that if you just look at it from a comp perspective, there was a bit of an easier comp on the transmitter line than there was on the sensor line in the fourth quarter. So if you go back a year ago and look at sensor versus transmitter revenue, there was an easier comp sitting on that transmitter line that drove a little bit of that growth. I would just make sure you contemplate that. And then keep in mind, as we continue to evolve as a company, as we continue to think through our pricing strategy and position ourselves in a way that we can very easily step into the G7 product, which is a very different form factor, where the sensor and the transmitter are one unit versus two distinct units in G6, it ends up in account -- having a bit of an impact on how we account for the revenue in each one of those buckets. So we're going to have to contemplate the revenue buckets that we continue to report into the future. We want to make sure we're giving you something that is the right way to think about the business and model it. But what you're seeing play through that right now is just a little bit of an accounting nuance in how we allocate revenue based upon these new pricing strategies. Operator Thank you. Our next question comes from Steven Lichtman from Oppenheimer. Your line is now open. Steven Lichtman -- Oppenheimer and Co. Inc. -- Analyst Thank you. Hi, guys. On international, obviously, it's been very strong, and there's been a lot of breadth there. As you look ahead, just one of the countries, I think, later this year, Steve, you mentioned is Japan. Can you talk a little bit more about when you think you'll have that launched and what the opportunity is on the personnel side in Japan looking ahead? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah, so the hope is to have a personal-use CGM in G6 approved in the first half of this year. Kind of the big still unknown, if you will, is whether -- and to what extent we get reimbursement for that product. So if it comes in this cycle. That's great. If not, it could come next year or the year after. So I would tell you that growth, like in all of our outside of the U.S. markets, growth is really instigated by reimbursement. So we're taking a little bit of a wait and see approach there. And we're certainly going to launch the product in Japan once we get approval. But as you know, in the cash pay world, it's not always as easy. So I'd say wait for updates on the reimbursement front on Japan is really what you're looking for. Operator Thank you. And our final question comes from Marie Thibault from BTIG. Your line is now open. Marie Thibault -- BTIG -- Analyst Thanks for taking the question. Nice to see such a great year. I'll wrap it up. I wanted to hear a little bit more about details on your plans for the third manufacturing site OUS. And what cadence or milestones we should be looking for throughout 2020 as it impacts the gross margin line? Kevin Sayer -- Chairman, President, and Chief Executive Officer Sure. So we couldn't be more excited about the opportunity that sits in front of us in our core business, but as well, the international business. We're very early in the stages of really taking advantage of that market. We probably have sub 15% of that opportunity. And I think over time, you're going to see us put a lot of focus and effort there and standing up a manufacturing capability that gets much closer to the end user is a very strategic move on our part while also identifying locations where we can ultimately reduce the overall cost of production that will let us compete in the lower price environment. So strategically, it makes a tremendous amount of sense. You'll hear us talk more about it over the course of the year as we settle in on exactly where we select to start to build out that capability. But what we know is that these things take multiple years to stand up. We won't be producing out of that facility for a couple of years here. But we've got to start the work now to ensure that once we get the full capacity in our San Diego and Mesa facilities, we're ready to step right into that international opportunity and ensure that we have no impact on supply. So we're getting ahead of it, ensuring that we don't hold up the business, and we're excited about what it can do for us. Operator And that concludes our question-and-answer session. At this time, I would like to turn the call back over to Kevin Sayer for closing comments. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you very much, and thanks, everybody, for participating today. Last week, we had all of the leaders of our company around the world here in San Diego for a leadership summit. We wanted to accomplish a couple of things. The first thing we wanted to do is celebrate 2019 like we did today on this call for the amazing year that we had. And the theme is universal around that group. We did have an amazing year, but growth like this is hard. And I want to thank our people for all their hard work. The second thing we wanted to do is lay out our plans to our group, and what we intend to do and what we expect for the future, similar to how we have in our investor conferences, that we will never leave our core markets and we'll continue to care for our intensively managed patients and offer the best alternative there and then move this great technology to other applications with a focus on type 2 diabetes. As I left that summit, oftentimes, we get them -- things reaffirm what you said and what you tell people. Not long after leaving the summit on the intensive management side, we got to note from a provider about one of their patients, a young woman who had an A1c above 13. And she was wondering if she would ever have children because she was afraid what would happen to the child because of her poor diabetes control. After six months on DexCom, her A1c is down to five, and she is expecting her first child. Great outcome, and that's why we're committed to this business. On the type 2 side, in the past two weeks, I've had conversations with a couple of physicians and asked the following question, how often should people with type 2 diabetes be wearing a CGM? Because we hear numerous answers as we go about on the community, and to my surprise, both of them looked at me and said, all the time. They should be wearing this thing all the time. You need to figure out a way to do it. Hence, another facility, hence, we continue to grow and expand, and hence, we continue to invest in our business on the R&D side and on the commercial side. We couldn't be more bullish about our company than we are today, and thanks, everybody, for listening. Operator [Operator signoff] Duration: 50 minutes Call participants: Sean Christensen -- Senior Investor Relations Manager Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Jeff Johnson -- Robert W. Baird and Company -- Analyst Jayson Bedford -- Raymond James -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Malgorzata Kaczor -- William Blair and Company -- Analyst Ryan Blicker -- Cowen and Company -- Analyst David Lewis -- Morgan Stanley -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Raj Denhoy -- Jefferies -- Analyst Steven Lichtman -- Oppenheimer and Co. Inc. -- Analyst Marie Thibault -- BTIG -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Reasons Why DexCom's Q4 Update Delighted Investors When you're hot, you're hot. And DexCom (NASDAQ: DXCM) is hot. The diabetes-focused medical-device stock skyrocketed 83% last year. DexCom got off to a good start in 2020, as well, with a double-digit gain by early February. Investors looking for another catalyst received one when the company announced its fiscal 2019 fourth-quarter and full-year results after the market closed on Thursday. DexCom's shares jumped around 5% in after-hours trading following the release of its latest results. Here are three reasons why the company's Q4 update delighted investors. Image source: DexCom. 1. Impressive revenue growth DexCom reported revenue in the fourth quarter of $462.8 million. This reflected year-over-year growth of 37%. It also easily topped the average analyst estimate of $442.4 million. There's no question why the company's sales continue to rise. DexCom's G6 continuous glucose monitoring (CGM) system is attracting more and more patients as they become aware of the benefits of real-time CGM. The company's U.S. revenue jumped 34% year over year to $375.9 million, making up 81% of DexCom's total revenue in the fourth quarter. However, DexCom grew sales even faster in international markets, with revenue soaring 52% year over year to $86.9 million. 2. Better-than-expected earnings DexCom announced fourth-quarter net income of $92.7 million, or $1 per diluted share, based on generally accepted accounting principles (GAAP). That's a huge improvement from the company's GAAP net loss of $179.7 million, or $2.03 per diluted share, in the prior-year period. The company's adjusted non-GAAP earnings looked even better. DexCom posted non-GAAP net income of $106.5 million, or $1.15 per share. This result reflected a big jump from non-GAAP earnings of $50.2 million, or $0.56 per diluted share, in the same period of 2018. It also trounced the consensus Wall Street earnings estimate of $0.74 per share. To be fair, DexCom's GAAP net loss in the prior-year period included a $217.7 million non-cash charge related to its amended agreement with Alphabet subsidiary Verily. But the non-GAAP earnings figure in Q4 of 2018 excluded this charge. DexCom's adjusted earnings improvement was really as good as it appeared to be. 3. Solid 2020 guidance Investors in healthcare stocks (for that matter, investors in any kind of stocks) are more interested in the future than the past. DexCom's future looks quite good based on the company's full-year 2020 guidance. The company maintained its previous full-year 2020 revenue outlook of between $1.725 billion and $1.775 billion. The average analyst's revenue estimate for the year is $1.77 billion, near the upper end of DexCom's range. But Wall Street analysts know that DexCom tends to sandbag with its revenue guidance. For example, the company projected full-year 2019 revenue of between $1.175 billion and $1.225 billion but delivered actual 2019 revenue of $1.476 billion. DexCom also provided more detailed guidance for other financial metrics in full-year 2020. The company expects a gross profit margin of around 64% and a non-GAAP operating margin of around 13%. DexCom looks for non-GAAP adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of close to 23%. Looking ahead DexCom CEO Kevin Sayer stated, \""We have taken significant steps to prepare the business for long-term growth and believe we are well-positioned as we enter 2020.\"" The company's Q4 performance appears to justify his optimism. Some, and perhaps many, healthcare stocks could face increased volatility in 2020 with the U.S. presidential campaign heating up. DexCom, though, shouldn't be impacted too much by political pressures. The company appears to be in good shape to continue delighting investors well into the future. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares). The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""50 Stocks Moving In Friday's Mid-Day Session"", ""CFRA Maintains Hold on DexCom, Raises Price Target to $258"", ""Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $300"", ""Stocks That Hit 52-Week Highs On Friday"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $285"", ""10 Biggest Price Target Changes For Friday"", ""DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results."", ""The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $288"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $275"", ""30 Stocks Moving in Friday's Pre-Market Session"", ""Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to $300"", ""Top Software Stocks, Chip Leader Nvidia Ride Post-Earnings Rally To New Highs"", ""Dow Jones Eases, But Visa, American Express Buck The Trend; 3 Stocks Move Bullishly On Earnings"", ""Stock Market Turns Mixed On Retail Sales; Dexcom, Nvidia, Roku Jump On Earnings, But Datadog Plunges"", ""This Diabetes Stock Just Threw Down A Gauntlet \u2014 Can Rivals Catch Up?""]"
DXCM,2020-02-18,71.1,74.5,70.345,74.0,"[""76 Biggest Movers From Friday"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $270"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $270"", ""76 Biggest Movers From Friday"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $270"", ""76 Biggest Movers From Friday""]"
DXCM,2020-02-19,74.565,75.4175,72.1212,72.92,"[""The Top 5 Buys of Steve Mandel's Lone Pine Capital"", ""Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System"", ""The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA"", ""Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System"", ""The Top 5 Buys of Steve Mandel's Lone Pine Capital"", ""Why Senseonics Holdings Shares Jumped Today What happened Shares of Senseonics Holdings (NYSEMKT: SENS) were jumping 10.4% higher as of 2:49 p.m. EST on Wednesday after rising as much as 31.6% earlier in the day. The nice gain came following the medical device maker's announcement on Tuesday that Cigna (NYSE: CI) began covering the Eversense continuous glucose monitoring (CGM) system effective Feb. 15, 2020. So what Senseonics has already lined up several major payers to provide coverage for the Eversense CGM, including Aetna (which is now owned by CVS Health) and Humana. The addition of Cigna to the list holds the potential to boost sales for Eversense. Cigna claims over 17 million members across the U.S. Image source: Getty Images. Eversense is the only long-term implantable CGM system on the market for individuals with diabetes. It competes against popular CGM systems from Abbott Labs and DexCom. The two bigger rivals have already made major inroads in securing payer reimbursement for their devices. Senseonics' win with Cigna should position it to compete more effectively. So far, though, Senseonics hasn't made a lot of money with its Eversense CGM. The company reported a 17% year-over-year revenue decline in the third quarter of 2019 with total sales of $4.3 million. Most of that revenue came from outside the U.S. Now what Senseonics' fortunes could pick up in 2020 if Eversense gains momentum in the U.S. The key to success for the healthcare stock will be to convert its positive coverage decisions into provider and patient adoption of its CGM. 10 stocks we like better than Senseonics Holdings, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Insulet Announces Agreements With Abbott and DexCom On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Shares of Insulet were up by more than 2% on the news as of 2 p.m. EST. The integrated systems will allow patients to have their insulin delivery controlled automatically according to their blood glucose levels using disposable CGMs and Insulet's wearable, tubeless insulin delivery pods. The systems will use Insulet's Omnipod Horizon system, which it expects to launch in the second half of 2020. Image source: Getty Images. The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. Wednesday's press release announced a commercialization agreement between the companies, but the terms were not disclosed. The bigger news regarded the agreement with Abbott. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product. Abbott's FreeStyle Libre CGM is the market leader, and could be more important to Insulet's business than DexCom's devices. Core to the growth strategy of the rapidly expanding diabetes company is international expansion, and the massive Abbott already has 2 million FreeStyle Libre users in 46 countries. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom's Stock a Buy? Diabetes is a growing problem in the U.S. and around the world. In the U.S., researchers estimate that nearly 55 million Americans will have either type 1 or type 2 diabetes by 2030. In the U.S., costs related to diabetes, both healthcare and societal, will reach $622 billion, which is a 53% increase from 2015. That's why buying shares of a company that helps patients with diabetes can make for a sound, long-term investment. One company that has stood out in this area is DexCom (NASDAQ: DXCM). But with the stock having achieved significant gains and up more than 400% in just the past two years, investors may be wondering whether it's still a good buy or whether it has peaked. Let's take a look. The company is coming off a strong earnings beat DexCom released its fourth-quarter and full-year results for 2019 on Feb. 13, and it beat analyst expectations for both revenue and earnings. Sales in Q4 were up 37% year over year. And for the full year, its top line increased by 43% from 2018, reaching $1.5 billion in revenue. It was the second straight year where sales grew by at least 40%. But the company expects revenue for 2020 to grow at a slower rate, between 17% and 20%. It also expects its gross margin to remain at around 64%, which is in line with 2019. Image Source: DexCom This year was also the first full year that the company recorded a positive net income, with profits totaling $101 million. In 2018, DexCom incurred a loss of $127 million, and it had a $50 million loss the year before that. Why there's still lots of growth left One of the reasons the company is likely to keep growing is that it continues to enhance and improve its products. The company's continuous glucose monitoring (CGM) system is driving its growth as DexCom credits the growing awareness of its real-time CGM as one of the reasons for its strong performance in Q4. Its latest product, the DexCom G6 CGM, provides patients with real-time glucose readings and does not use finger sticks, which the previous G5 product required for calibration. Medicare does cover the G6, but DexCom notes in its earnings release that it only began shipping the product to Medicare patients in Q4. It is available at Walgreens locations, and continuing to raise awareness and rolling out the product to more patients is a key initiative for DexCom in 2020. Another initiative the company is focusing on is a new G7 product, with DexCom looking to offer patients a slimmer, less expensive product. The company does not expect a full commercial launch of the G7 until 2021. With better, more discreet ways to monitor glucose levels that are less invasive than before, DexCom's products become attractive options for people with diabetes who are looking for more innovative solutions. And with the number of people with diabetes growing, the market for the company's products will only get larger. Abbott Labs' competing product, the FreeStyle Libre, generated worldwide sales of $534 million in the company's recent fourth-quarter results, which was a 58.5% improvement from the prior-year quarter. Medtronic, another competitor, offers both integrated and stand-alone CGM products. In its third-quarter earnings released on Feb. 18, the company noted that sales for its CGM products grew in the \""mid-teens.\"" However, the company's total diabetes sales of $610 million were flat from the prior-year quarter. Tandem Diabetes is another diabetes company that had revenue of $94.7 million in its third-quarter, which is more than double the sales the company recorded in the prior-year quarter. Tandem's flagship product is the t:slim X2 insulin pump and one of its features is the ability to integrate with the DexCom G6. While there are many CGM products available on the market, and many are cheaper than DexCom's, the company's impressive sales numbers suggest that's not a concern, at least not yet. Should you buy DexCom today? In 2019, shares of DexCom soared 82%, eclipsing the S&P 500's returns of 30%. The stock's been a high performer, and it's trading at its 52-week high. But that's what can happen when a company is doing very well, and it shouldn't be a deterrent from buying shares. But a concern for value-oriented investors is that the stock trades at some hefty multiples. With a forward price-to-earnings ratio of over 94, investors are paying a steep price for future earnings. And with sales of $1.5 billion in its most recent fiscal year, investors are also paying about 16 times sales as well. DexCom isn't a cheap stock, and given how bullish the markets are today, a slowdown could hurt its price. With the company expecting its growth to slow in 2020, paying more than 90 times earnings or 16 times sales is a bit excessive. While the company's growth opportunities are encouraging, the shares' valuation would have to come down to more reasonable levels (around 25 to 30 times forward earnings) for the healthcare stock to be a good buy. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stock Alert: DexCom Touches New High (RTTNews) - Shares of continuous glucose monitoring (CGM) systems maker DexCom, Inc. (DXCM) climbed $12.09 or 4.26% on Tuesday to touch a new high of $298. The stock gained $1.50 in extended trading. On February 13, DexCom had reported positive earnings surprise for its fourth quarter. The stock has gained nearly 18% since then. Net income in the fourth quarter was $92.7 million, or $1.00 per share, compared with net loss of $179.7 million, or $2.03 per share, for the same quarter a year ago. Excluding items, EPS was $1.15 that beat average estimates of analysts polled by Thomson Reuters by $0.41. Revenue grew 37% year-over-year to $462.8 million. Revenue for the full-year is expected between $1.725 billion and $1.775 billion. Analysts estimate revenue of $1.78 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA"", ""Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System"", ""The Top 5 Buys of Steve Mandel's Lone Pine Capital""]"
DXCM,2020-02-20,73.0825,76.6775,71.8075,75.6275,"[""Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?"", ""Why DexCom (DXCM) Stock Might be a Great Pick"", ""Dexcom Inc (DXCM) EVP Operations Jeffrey Moy Sold $\u2013.9 million of Shares"", ""The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study"", ""The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study"", ""Dexcom Inc (DXCM) EVP Operations Jeffrey Moy Sold $\u2013.9 million of Shares"", ""Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?"", ""Why DexCom (DXCM) Stock Might be a Great Pick"", ""The Growth Opportunity That Will Move Medtronic Ahead of Its Rivals One of the world's largest medical device companies, Medtronic (NYSE: MDT), has seen a more than 55% rise in its stock price over the past five years. The 71-year-old company serves more than 150 countries worldwide, with success in diagnostic tools for heart disease, surgery, restorative therapies, and diabetes. Over the past 12 months alone, the stock is up nearly 24%. Can this momentum continue? There is one key division that may offer clues to Medtronic's long-term growth. Image Source: Getty Images. A major growth opportunity Medtronic is broken down into four key divisions, as seen in the table below. DIVISION PRODUCT FOCUS PERCENTAGE OF REVENUE, YEAR TO DATE (Q1-Q3 2020) PERCENTAGE OF REVENUE, FY 2019 PERCENTAGE OF REVENUE, FY 2018 PERCENTAGE OF REVENUE, FY 2017 CHANGE (FY2017- FY2019) Cardiac and Vascular Group Heart failure, coronary heart disease, surgical tools 36.9% 37.7% 37.9% 35.3% 9.6% Minimally Invasive Therapies Group Surgical tools; therapies for lungs, stomach, kidneys 28% 27.7% 29.1% 33.4% (14.5%) Restorative Therapies Group Therapies for spine, neurological disorders, and pain 27.2% 26.8% 25.9% 24.8% 11.1% Diabetes Group Insulin pumps, blood sugar monitors (continuous glucose monitoring), therapy management software 7.9% 7.8% 7.1% 6.5% 24.1% Source: Medtronic. Of the four, the diabetes division shows the most promise for Medtronic investors. Diabetes affects roughly 30.3 million people, or 9.4% of the population, in the United States; worldwide, about 425 million adults live with the condition. Diabetes impairs the body's ability to process sugar, and patients must continually monitor their blood sugar levels and manage them with a hormone called insulin. At Medtronic, the diabetes division includes key products such as MiniMed insulin pumps and accessories, Guardian continuous glucose monitoring (CGM), and therapy management software. Worldwide, sales of insulin pumps and CGM across all manufacturers are expected to grow at a compound annual growth rate (CAGR) of more than 12%, and as the table shows, divisional revenue at Medtronic is up 24.1% since 2017 -- the highest increase of the four divisions. The company's most recent earnings report, for the third quarter of fiscal 2020, showed that Medtronic's strength is in theglobal market-- worldwide sales accounted for approximately half of the total, resulting in 16% growth year over year and offsetting some U.S. revenue challenges from increased competition. Global strength in CGM The CGM market showed strong results in both integrated and stand-alone products. CGM products that are integrated with Medtronic's MiniMed insulin pump led sales, with a particular boost from new patient acquisitions in international markets. The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). DexCom has an advantage over its competitors in the U.S. market, with growth coming from CGM orders by Medicare plans, durable medical equipment (DME) suppliers, and pharmacy orders. DexCom continues to expand in these areas, but there's still room to grow for rivals like Medtronic, too. New products with additional capabilities and accuracy may help Medtronic regain market share, and its position as UnitedHealthcare's preferred insulin pump provider should help it expand in the integrated CGM market both domestically and internationally. Dominance in the insulin pump space Medtronic's MiniMed pumps have been a major sales driver in the past, and the international markets provide growth opportunities that should offset a U.S. revenue decline brought on by increased competition. Medtronic already sells its insulin pumps in Western Europe and many emerging markets, and a key catalyst will come this week, when the company is set to present data on its new insulin pump at the International Conference on Advanced Technologies and Treatments for Diabetes. This data should advance the creation of a timeline for milestones and eventual approval of the new 780G insulin pump by the U.S. Food and Drug Administration (FDA). The 780G already has a European Commission mark of approval (CE mark) and has achieved conformity for products sold in the European Economic Area (EEA), and investors should gear up for more data in June, which will discuss results from a feasibility study for in-home use of the 780G to automate insulin delivery in patients with diabetes. Positive results from this study would allow the device to progress toward FDA approval, which would create an additional growth driver for Medtronic and improve its competitiveness in the market for insulin pumps. Medtronic also has a plan in place to retain many of its current users -- the Next Tech Pathway program allows purchasers of the former 670G product to upgrade their device for free when the 780G arrives. This will be a key factor in improving U.S. sales and should allow Medtronic to stay at the forefront of the competition. Medtronic boasts roughly 60% ofglobal marketshare in the insulin pump market, where it squares off against competitors such as Tandem Diabetes Care (NASDAQ: TNDM) and Insulet Corporation (NASDAQ: PODD). Its partnership with UnitedHealthcare (NYSE: UNH) is key here, and Medtronic can also expect growth from its continuing outcomes-based agreements with select healthcare providers such as Aetna; these value-based plans pay providers based on patient outcomes and quality of services performed, and Medtronic's participation could improve brand awareness and recognition among consumers and strengthen U.S. market share. A recent recall of two MiniMed products because of safety concerns may have short-term effects, but it's unlikely to change the long-term growth trajectory. The diabetes division makes up just 8% of Medtronic's revenue, and the potential financial consequences of litigation and replacement will be offset in the short term by revenue from the company's diversified portfolio of other products. When considering longer-term prospects, the growth of the insulin pump market in international markets along with integrated and stand-alone CGM sales will contribute to further revenue streams, offsetting declines in other divisions (including the minimally invasive therapies division). In addition, the release of new products such as the 780G pump will improve Medtronic's strength in the U.S. market, where it's currently struggling because of competitive challenges. Long-term opportunities Medtronic's diabetes division offers a window into the company's long-term prospects. Currently, the division makes up less than 10% of the company's revenue, meaning there's significant opportunity for growth here -- especially with a CAGR of 12% for both insulin pumps and CGM. Given its solid partnerships and agreements with healthcare providers and the opportunities presented in international markets, Medtronic has an opportunity to remain the market leader in insulin pumps over the long term. As the company dominates in the diabetes segment, shareholders and healthcare investors should see results on both the company's top and bottom lines. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Amar Khatri has no position in any of the stocks mentioned. The Motley Fool recommends Insulet and UnitedHealth Group. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study"", ""Dexcom Inc (DXCM) EVP Operations Jeffrey Moy Sold $\u2013.9 million of Shares"", ""Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?"", ""Why DexCom (DXCM) Stock Might be a Great Pick""]"
DXCM,2020-02-21,76.46,76.4925,71.565,72.8125,"[""Insulet Partners With Abbott and Dexcom on Diabetes"", ""Earnings Watch: Best Buy Stock Resilient Ahead Of Results; Palo Alto Networks, Square Also Strong"", ""National Pension Service Buys TC Energy Corp, Bristol-Myers Squibb Company, Truist Financial ..."", ""The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion"", ""The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion"", ""Insulet Partners With Abbott and Dexcom on Diabetes"", ""Earnings Watch: Best Buy Stock Resilient Ahead Of Results; Palo Alto Networks, Square Also Strong"", ""National Pension Service Buys TC Energy Corp, Bristol-Myers Squibb Company, Truist Financial ..."", ""3 Great Diabetes-Focused Stocks In this episode of Industry Focus: Wild Card, Nick Sciple and Brian Feroldi take a look at the healthcare sector, specifically diabetes CGM (Continuous Glucose Monitoring) devices. These administer small doses of insulin to maintain the blood glucose level in patients. We discover which new technologies are making this process more patient-friendly and how the three companies we're discussing today are making this possible. To catch full episodes of all of The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video. 10 stocks we like better than Walmart When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks {% render_component 'sa-returns-as-of' type='rg'%} This video was recorded on Feb. 19, 2020. Nick Sciple: It's Wednesday, February 19th. Welcome to Industry Focus. I'm your host Nick Sciple, and for Wild Card Wednesday, we're going back to the healthcare well and we're going to be talking about diabetes stocks. I've got Brian Feroldi here with me today. Brian, how are you doing? Brian Feroldi: Hey, Nick, how are you? Sciple: I'm doing great. You know we're talking about healthcare today. You said you went to a doctor's appointment this morning. How are you feeling? Feroldi: Oh, I'm feeling good, but the funny thing is, I just go to a local small family physician. It was my annual physical. And of course, I walk in the door, and what do I have immediately handed to me? A paper and a pencil to refill out my name, my address, my phone number -- even though I've been going to the same doctor for about a decade now. So [it] just shows you how much room there is for innovation in the healthcare space. Sciple: Oh, absolutely. And I think that's something we're going to be talking about today. When it comes to innovation and healthcare, that's diabetes, specifically the CGM (Continuous Glucose Monitoring) market and the insulin -- that's exactly what we're going to talk about today when it comes to innovation in healthcare in the diabetes space. I know a lot of folks are probably familiar with diabetes on a surface level. But just to start off, before we dive into these companies, Brian, can you give us a high-level overview of what diabetes is and how it affects patients? Feroldi: Sure. So diabetes is when the body loses its ability to make enough insulin to satisfy its needs. And insulin is a hormone that's secreted by the pancreas into the blood. And insulin greatly assists with the absorption of glucose, which is also going to sugar into the liver, fat and most importantly, the other muscular cells. So without enough insulin in the body, sugar can't be absorbed properly by the muscles. And all of that excess sugar that's in the bloodstream just continues to build up and up and up and up, and that can lead to a huge range of health problems, both in the short-term -- such as if you have really high blood glucose levels your vision can become blurry, you can have excessive thirst or hunger, you can get tired very easily. And more importantly, over the long term, if you consistently have high blood sugar levels, you can lose a significant amount of waste and you triple your chances of having a heart disease or a stroke. So broadly speaking, there are two main types of diabetes. The first is called Type 1, and that's an autoimmune disease where your body attacks and kills the insulin-producing cells that are in the pancreas. And when that happens, the person completely loses the ability to produce any insulin at all, and in that scenario, a patient with Type 1 has to take artificial insulin to survive. And just to throw some numbers around there, there's about roughly 1.5 million Americans that have Type 1 diabetes. Type 2 diabetes is when the pancreas doesn't make enough insulin to satisfy its needs or the body becomes resistant to the insulin that it does make naturally -- and that is usually as a result of obesity. And Type 2 diabetes is far more prevalent than Type 1. In America, there's about 28 million Americans that have Type 2 diabetes. And there's another 84 million Americans that are at risk of developing diabetes -- that's called prediabetes. So diabetes is a major health problem. Sciple: Yeah, absolutely. When you talk about these patients, about 95% of those are the Type 2 diabetics, that it's primarily tracked back to diet, dietary choices, and that sort of thing. Type 1 diabetics, it's autoimmune, this is congenital. There's really not that much we can do about that. But to your point, diabetes, when it is not well-treated, can lead to some of the most expensive healthcare events that a patient can have. It's one of the leading causes of kidney failure, one of leading causes of amputation. For most diabetes patients, whether or not they have one of these huge complications, it's still a large number of patients that are affected. I pulled a stat. We're going to talk about Dexcom (NASDAQ: DXCM) later today. Dexcom CEO at the JPMorgan Healthcare Conference cited that only 6% of people with diabetes actually don't suffer from complications. So most patients suffer these issues. Now, traditionally how diabetes was monitored was through the traditional finger pricks. Each day, you would prick your finger and check your blood sugar level, make sure it's in the appropriate range. However, the technology we're going to talk about today has really changed the standard of care for how, at least for Type 1 patients are handling their diabetes today. Can you talk a little bit about that? Feroldi: Yeah. So to your point. So for decades, the way that a person with diabetes would monitor their blood sugar levels was with a finger stick. So, they would prick their finger and take a drop of blood, apply it to a strip that went on a glucose monitor and a point in time reading would then be produced. That sounds good and useful, but the truth is that blood sugar levels change rapidly throughout the day based on a whole range of factors. So eating food, exercising, your mood -- all those things can actually greatly increase or reduce, greatly impact your blood sugar levels. So finger sticks, where the compliance would be to say, \""Prick your finger four times per day.\"" Well, even that much information -- which not everybody with diabetes would even do -- was still nowhere near enough to accurately figure out what was happening with a person's glucose levels 24 hours a day. So about a decade ago, the first continuous glucose monitors came to market. And these were devices that are attached directly to the skin. They're small, say, about half the size of a box of Tic Tacs, and they are worn. They put a little sensor underneath the skin and they continuously upload a blood sugar reading to a wireless handheld device 24 hours a day. So many of them give readings, say, every five minutes. And with that much data, suddenly a patient could get a much better idea of how their blood sugar levels are changing throughout the day and they could make therapeutic decisions based on that to keep their blood sugar in a much healthier range than they could have before. Sciple: Absolutely. When healthcare providers are treating folks with diabetes, one of the No. 1 things they want to target is how long can we keep our patients in the targeted range of glucose levels. And when you look at a finger prick, even if you do that four times a day, that is a limited insight into how your glucose is fluctuating throughout the day. So what these CGM's allow patients and providers to do is get a more accurate picture of how often they're staying within that target range. And that tends to lead toward better outcomes for patients, which is very important, obviously, from a patient's point of view, not having to prick your finger every day, getting a better perspective of your health condition is valuable. But it's also valuable for these insurance payers, because we talked about earlier how significant the expense of diabetes treatment is. And that's only really increased over the past decade. But if we can get a better picture of how glucose levels change throughout the day, can keep patients in that target range over a longer period, that should be better for patients and they'll have better outcomes from a healthcare point of view, and better for insurance payers in that the risk of these high-expense complications like amputations, kidney failure, that sort of thing, really reduces. So, both from the patient's perspective and from the payer perspective, this therapy really has a lot of appeal. Feroldi: Yeah, completely. And one point that we need to make sure our listeners are aware of is, when you have diabetes, as we said, your blood sugar can constantly move up and down based on what you're doing. The traditional way to bring your blood sugar down is, if you have Type 2 diabetes, with diet and exercise changes or by taking drugs. If you have Type 1, the only way to bring your blood sugar level down is to take artificial insulin. Now, that's good if you have high blood sugar and you're taking insulin to bring it down, but figuring out the proper dose is critical. If you take too much insulin, then your blood sugar can drop well below a healthy level and you can pass out and go into a coma immediately. So it's really tricky for people to -- it's a balancing act between too much insulin and not enough insulin that people have to walk on the tightrope. And what CGM devices allow people to do is to see that they're going to be heading in a trouble zone before it actually happens, and they can take action to prevent those extremes from happening. And CGM devices are more expensive than traditional blood glucose monitoring, but if you can just keep a patient out of a hospital one time in, say, a decade, then the therapy pays for itself. Sciple: Yeah, absolutely. I think we list out these benefits of CGM, and there is significant growth in the space, but we need to note that penetration is still relatively low. Among the Type 1 population, we're still looking at 35% to 40% penetration. You'd expect penetration to be lower among Type 2 -- these are folks who are [on] less intensive insulin therapy -- but that's still really looking at 15% penetration. So really a lot of growth opportunity in this space. And that's what is going to transition us to talking about the first stock we're going to talk about today is Dexcom, which is one of the earliest pioneers in CGM. And if you look at the stock, it has just been an incredible performer over the past 10 years, five years, one year, anyway you look at it. Over the past 10 years, the stock is up 2,500%. It's a triple over the last five years, it's a double over the past year. Brian, when you look at this company, what's been driving this growth? Feroldi: Yes. So Dexcom has kind of been the leader in the CGM space for more than a decade. There are other competitors that they've gone up against, most notably would be Medtronic, which used to completely own and dominate the diabetes-device space. But Dexcom has always been one step ahead of them with a very critical component of CGM, which is accuracy. Having the most accurate results is critical to being able to make therapeutic changes when necessary, and Dexcom has solely focused on continuous glucose monitoring space, and that has helped to keep them one step ahead of the competition. And as you alluded to before, this company has been a monster winner for investors because they consistently attract new users to their device. And Dexcom actually has a business model that I personally love, which is the razor and blade. So Dexcom not only sells the handhold controller, which is used to actually receive the data, but the sensors that they wear on their body must be changed every 10 days. So this is a razor-and-blade model. So as this company adds new users every year, its revenue has just soared. Sciple: Yeah. If you look at their most recent quarter, they called out 650,000 active regularly reordering Dexcom users. So these are patients who are using their CGM. Every 10 days they need a new Dexcom sensor to replace their existing one. The huge launch for growth over the past couple of years has been Dexcom's G6 product they released in 2018. That was their first product that came to market that didn't require calibration, which has been huge for the CGM space. So prior to the Dexcom G6 and also the Abbott Labs FreeStyle Libre that came out just a little bit before Dexcom G6 product. Even CGM wearers, at least twice a day would have to prick their finger and calibrate the sensor to make sure it was accurately reading. However, in the past couple of years, we've seen this influx of no-calibration sensors, which has really grown the market that much more, it makes the appeal from a patient point of view that much better. You don't have to prick your fingers at all, which has led to some massive growth for the business. Feroldi: Yeah. That is something that held up adoption for a couple of years, where as you said, even though patients were willing to upgrade, were willing to wear the sensor 24 hours a day. They did still have to manually prick their finger and manually enter results into their CGM to actually calibrate it, so that it was as accurate as possible. Dexcom has continually advanced its sensor with each new generation. And as you said, the growth has been explosive in the last few years with the launch of the device that does not require any finger pricks. And you can easily see how that would be extremely compelling for anybody with diabetes to go with a device because you completely give up finger sticks with the most up-to-date sensors. Sciple: Yeah. Another thing we need to note about Dexcom's positioning in the market. You know, I called out Abbott FreeStyle Libre, the other no-cal CGM product on the market today. Abbott's strategy is more going toward the low-price segment of the market. They have the lowest cost. However, Dexcom's strategy is a little bit different. You mentioned earlier, they are focused on accuracy. They're particularly focused on accuracy in the hypoglycemia area -- that's those issues we mentioned where your glucose can plummet, and it's really scary for patients because they make you pass out or go into a coma. Another area they focused on, is focused more toward pediatric -- younger patients. They are the only device on the market today that offers the alerts. My cousin, as a matter of fact, is a Dexcom wearer, my uncle has these alerts on his phone. So if over the night the child falls out of their glucose range, an alert will go off on the child's phone or in the parent's phone to alert them to that low-in-range status to get them some food or what have you to keep them out of that low glucose range. So for a parent, it's particularly valuable having those alerts, could lead you to why you would adopt Dexcom over the other product. They also believe that Dexcom's product is approved for people [age] 2 and up, but if you look at Abbott Libre product, it's only approved for older patients. So Dexcom has been positioning themselves in this premium segment of the market, targeting really easy-to-use products with alerts and that sort of thing, and targeting younger folks, which has really been a good opportunity for them. Feroldi: Yeah. To your point, Abbott launched its Libre product a few years ago. This is a lower priced product that isn't as accurate as Dexcom, but because they price themselves at such a low and affordable range, they have taken significant market share and their device has been a huge success. So, it is nice to see that patients do have options when it comes to see CGM, and it's also nice to see that price that Abbott came to market with was such a low-price device that it makes the technology that much more affordable. Sciple: Absolutely, and even with this price competition, when you look at Dexcom results, there's been plenty of room for growth for all these players in this space. So if you look at 2019, Dexcom revenue up 43% for the year. Roughly doubled their revenue over the past couple of years when both of these products came to market. If you look at, even over a longer term, look at their five-year revenue CAGR [compound annual growth rate], over 40%. So just massive growth in this area, as new patients have been moving into adopting CGM. Another big development was Medicare coverage added in the past couple of years, which has really opened up the population. So even as there has been continued competition on price, which Dexcom expects to continue, as the size of the patient population has grown that has increased opportunities for them. Feroldi: Yeah. And that was a big concern for investors a few years ago when the Libre was initially approved. When the day that that happened, Dexcom's stock got absolutely walloped. I think it fell 30% or 40%, because investors were so fearful that the lower-price device would just eat their market share. But we've seen exactly the opposite -- we've actually seen both of these companies do extremely well, just because the market for these types of devices has been so huge. And as you alluded to at the top of the show, the penetration rates are still not where they could ultimately go. So this market is so big and diabetes is so prevalent that there is space for more than one winner, and that's exactly what we've seen. Sciple: Yeah, to your [point], Brian, I mean, that's when I actually went and bought Dexcom after that 30% selldown. I had some close family and friends, as I mentioned, that are users of the product. I asked them whether they were going to switch over. And because of those issues, when it comes to accuracy of the sensor, as well as those alerts and things, if you have younger patients who use the sensor, we actually haven't seen as many people switch over. Now, for new adopters who are price conscious, that's been a concern. But again, we've just seen massive growth. The other thing is in 2019, Dexcom swung over into GAAP [generally accepted accounting principles] profitability for the first time. Expect to continue that going forward. As you look toward further growth, you mentioned this G7 product coming out. As we evaluate the opportunity for continued growth in the CGM space, how should we be thinking about that, as investors? Feroldi: Yeah. So one of the biggest opportunities for these companies -- for both of these companies moving forward -- it's just continued adoption. I mean, as the technology continues to improve and more patients learn about the benefits of going to CGM, especially in international markets where the adoption rates are still infinitesimally small when compared to developed markets like the U.S. and Europe, there's still lots of room for these companies to grow. But with Dexcom, in particular, one thing that they're doing to kind of make sure that they have a growing market share is they are actually been very active on the partnership front. So what we've talked about so far has been the CGM side, the Continuous Glucose Monitoring side, but that's just getting the diagnostics. From there, you still have to take an action once your blood sugar is too high or too low. And if your blood sugar is too high, one of the common ways that people that are insulin-dependent to control their blood sugar is with the use of an insulin pump, and that is something that Dexcom has been very active with partnering with some of the leading insulin pump providers -- to have an integrated system that not only lets patients monitor their blood sugars, but also allows them to take action to make sure they're in a healthy range. Sciple: Yeah, I think one thing Dexcom calls out repeatedly is that they are the only product on the market -- at least as of the most recent quarter -- that has iCGM (integrated Continuous Glucose Monitoring) designation, which really allows them some flexibility as they integrate with other platforms, which has really been a godsend for them. You mentioned these partnerships, the big ones on the pump side, are Tandem Diabetes (NASDAQ: TNDM) and Insulet (NASDAQ: PODD). First off, Tandem Diabetes, when we drive into that one, what should we know about it? That's another one that's just been a monster performer. Feroldi: Yeah, so Tandem Diabetes is an insulin pump company. And so, an insulin pump, again, has traditionally been a pager-sized device that's worn on the patient's body 24 hours a day. It has a tube that attaches to an infusion set, and through that tube, the insulin pump consistently pushes small doses of insulin into the body throughout the day. And then when a patient eats and requires a larger dose of insulin, they can give themselves a bigger bolus of insulin over time. And pumps have done a great job at mimicking the pancreas to keep the blood sugar in healthy ranges. However, historically, patients have had to do all the work and all the calculations themselves. So they have to be there with therapy decisions whenever they're about to eat. And that's a big burden for patients who are wearing these devices. It's much better than the other option, which is just to continuously take shots throughout the day, but they're still being onerous on these companies to do so. So what Tandem has done is they've made a very consumer-friendly device that has a touchscreen on it. It's been smaller than other pumps that are historically available. And they've really gone with consumer-friendly messaging to just make the device as easy to use as possible. And that messaging and the device have really become hugely popular with patients. This company has produced eye-popping growth in the number of units that it shipped for a couple of years. I mean, just in the most recent quarter, their number of pumps shipped and their revenue grew over 100%, and that's on top of growing at 100% for a few years in a row. So this company has been extremely impressive with the execution. It's still not profitable, it's rapidly approaching profitability as the volume continues to grow. But Tandem has been another monster winner for investors over the last couple of years. Sciple: Yeah, I just pulled up the chart. Over the past three years, 35-bagger for this stock. I mean -- and it was one of those things, too, Brian, before it had this big run-up -- the stock was really languishing. I mean, it was almost in penny-stock territory. What really launched this turnaround for the company to send the stock to the moon? Feroldi: Yeah, I will tell you that I personally wrote this company off as dead a few years ago. I mean, they were just sucking wind, they were running out of cash, they had completely exhausted all of their financial resources. And I actually have friends still in the diabetes space, which I used to work in, and they were asking me about this stock under $1, and everything that I looked at just screamed, \""Stay away.\"" But they have mounted a comeback like I have never seen in my life. They did a capital raise, which shored up their balance sheet. And their execution to get their pump out has been phenomenal. I mean, this company has produced growth rates like I have not seen in the device space for a long time. In reality, Wall Street was pricing them as if they needed a miracle turnaround, and believe it or not, that's exactly what the company produced. Sciple: To your point, Tandem has just massively exploded since they've come out with some of these integrated products that have allowed them to talk to the Dexcom sensor and to administer insulin without intervention from the patient. Another one of those pump competitors for Tandem is Insulet. That's a company that you worked at for a number of years, Brian. What should we know about Insulet? Feroldi: Yeah. So Insulet is also in the insulin pump space. And their innovation in the market was to make the insulin pumps tubeless. So rather than have a pager-like device with a tube attached to it that goes into an infusion set, Insulet actually miniaturized all of the pumping mechanisms and put them into a device that's the size of about a box of Tic Tacs that sticks directly onto the skin. And there's no buttons on it -- it's completely waterproof and it's worn on the body 24 hours a day. And the device actually receives instructions from a wireless remote control. So this device has been highly attractive to patients that are interested in pump therapy but don't want a lot of the lifestyle negatives that come from wearing a traditional pump. And if you look at their growth, about three-quarters of the patients that are going to Insulet's Omnipod system, the majority of them would not have actually gone with pump therapy at all if it wasn't for the tubeless nature of the device. So they've done a great job at expanding the market. But at its core, the Insulet's Omnipod system works very similar to the other insulin pumps that came before it. So it constantly administers a small dose of insulin 24 hours a day. And then when a patient is going to eat and they need a large dose of insulin, they just pull up their wireless controller and then tell it how much to deliver. But both Insulet and Tandem have partnered with Dexcom to make what's called a closed-loop system. So that would be a true device that you put on your body and then there's really no thinking involved. The device itself would constantly measure your blood sugar and administer insulin doses based on your readings. That has been the holy grail of diabetes treatment for decades basically. And getting this device to market has proven to be hugely challenging. But we're finally at the point where we're actually getting really close to the first closed-loop systems being involved. So Insulet, its closed-loop system is going to be called the Omnipod Horizon. That's going to, as we said, deliver insulin into the patient's body whenever high glucose levels are detected. It works directly with the Dexcom system. And this device is estimated to be launched later this year. And actually today, before we started recording, Dexcom and Insulet announced that they were expanding their partnership so that Dexcom's next-generation system, its G7 system, would work directly with Omnipod's next-generation system to provide the first closed-loop insulin pump combination device that would actually work with somebody's smartphone. So innovation is alive and well in diabetes, and these devices are doing great things to make living with diabetes as easy as possible. Sciple: Yeah, to your point, Brian, I mean, the software has just been huge for them because they had this system, this tubeless system in place for a long time, which added convenience to patients, but now they can match with their competitors, are matching on the convenience side when it comes to the closed-loop system. So really a big development for Insulet. When you look at these partnerships with Dexcom, what advantage does that give them? When you look at Medtronic, Abbott Labs, these are big medical-device companies that are going to partner with their own pumps and that sort of thing. When you look at this kind of agnostic player, does that give any advantages to Dexcom as the CGM player, that has these shots on goal with lots of other pump manufacturers? Feroldi: Yeah, I think so. I think that that's going to -- the partnerships with the pump companies is something that separates Dexcom from Abbott, and it should keep it in that premium leadership position. To your point before, I do think that there is going to be pressure on Dexcom moving forward to lower the cost of their device and reduce it because adoption is growing just so rapidly. And now that the Libre is out there and obviously a market success, you could see insurers starting to put the screws to Dexcom to lower their prices. But Dexcom's next-generation system is supposed to be a lower-cost system. So I do think that there's going to be enough cost savings in the device to not only lower prices for patients and providers, but also for Dexcom to maintain strong margins. But there's no doubt that its partnerships that it has in place with both Insulet and Tandem should help to differentiate it in the CGM space. Sciple: Yeah, Dexcom's management has actually called this out -- that they expect revenue per patient to decline moving into 2020 as they move deeper into international markets, as you mentioned, as they push deeper into Medicare. Obviously, Medicare has a lot of leverage to squeeze companies on prices. That's something they're calling out. However, just massive growth when it comes to patient adoption. I think that they doubled production this year. They're expecting to double production going into 2020. I believe, I looked up, Abbott Labs is looking to triple to five times production of their FreeStyle Libre system. So just across the board, massive growth. One area we didn't mention when it came to CGM, but I think we should touch on at least briefly. When you look at these pump providers and just the traditional target market for CGMs is these insulin intensive Type 1 diabetics, that we mentioned earlier. As you look at this Type 2 diabetes market, that's starting to grow their presence in CGM and other kinds of more advanced diabetes therapies. How do you assess the opportunity there for these businesses, both on the pump side and the CGM side for growth in Type 2 diabetes? Feroldi: Well, historically speaking, most people with Type 2 diabetes, only a fraction of them actually require insulin. And of those [who] require insulin, only a fraction of those actually require intensive insulin management -- which is when you're taking, say, two, three, or four shots per day. So that limits the numbers that you see in the market. So, like, right now, if we're talking about, say, 30 million Americans with Type 2 diabetes, only about, say, 2 million or 3 million of them are on intensive insulin therapy. However, the [...] there is so huge that even if you account for a small fraction of them to be eventually eligible to receive a pump or a continuous glucose monitor, the numbers are so big that there's still a huge room for both Dexcom and Insulet to grow substantially in the space. So I do think that, as insurers learn more about the benefits and as the technology continues to improve, they will gradually make it easier and easier for patients with Type 2 to adopt pump therapy and CGM therapy. So I do think that that is going to drive all of these companies' growth in the 2020s. Sciple: Yeah, I think if you look at the TAM [total addressable market] for these businesses we've mentioned, that as penetration in existing Type 1 patients has increased over time, we're at 35% to 40% penetration today. It is a clear trajectory of that trending toward the standard of care, particularly as we see the emergence of these closed-loop systems, no calibration CGM systems that really make it that much more convenient for patients, as well as all the things we mentioned as far as bringing down the cost of treating these folks over time. The other thing we have to think about, as well, on the Type 2 side is just the number of people with diabetes is growing significantly over time. So when you look at a company like Dexcom or these pump players, not only are we seeing growth as these products become standard of care for existing patients, but the number of patients is growing meaningfully year over year. So when you look at this opportunity going forward, Brian, I mean, Dexcom is at 18 times revenue, so really richly valued. But when you look at these opportunities, it grows over time, how excited would you be to buy the stock today at that valuation? Feroldi: Well, there's no doubt that investors are paying a premium to get into the stock today, but it does show you that Wall Street really values and is excited about what this company is doing. Valuation has always been a concern with Dexcom the entire way up. So I would say that if Dexcom or Insulet or Tandem excite you as an investor, I mean, all three of these companies are trading at 16- to 20-times sales. So Wall Street is pricing in enormous growth. And all of them, I think, have deserved their premium valuation. So if I was interested in any of these stocks or if our listeners were interested, I would say these are great stocks to buy in thirds, so you don't go all-in at once, given the huge valuation. You buy a tiny little bit, you wait and see how it goes, and then you add from there. Sciple: Yeah, I totally agree with that. I tell you, when I first bought Dexcom a couple of years back, I thought it was a little pricey then. Again, that was right after this big new competition came on from the FreeStyle Libre that really scared a lot of folks out of the stock. However, I mean this growth has been massive. If you look back at this company, it's very rare you can see a company that's posted pretty much a decade worth a plus-40% revenue growth with really no signs of slowing up in any significant way. Prices are coming down, that's a concern, but as the patient population grows in a really significant [way], there's big opportunities for these companies. I don't know that I would be -- to your point -- taking a full possession at 18 times sales, but this is a company I would really consider buying in thirds. It is my belief that over time, CGM and pump therapy for the average diabetes patient is going to become standard of care. Feroldi: Yeah, I think that that's correct. The real challenge that these companies are going to have to face is they're going to also have to maintain their profitability. And as they continue to grow and become standard of care and there's likely to be a big pressure on them to continually reduce price. So far, these companies have had no problem dealing with that issue. The big question moving forward to me is, will they be able to continue to do so? I still have questions about that personally, so again, I wouldn't go whole hog in any of these stocks. But again, the addressable market here is so massive, and it's still growing, that there's reason for investors to be excited about all of these companies. Sciple: Yeah, I think, regardless of whether you're comfortable investing in these companies today, this is an area of the healthcare industry to really pay attention to. The American Diabetes Association calls out that 1 in 7 healthcare dollars spent in the U.S. are related to diabetes or diabetes complications. So these are going to be real important businesses going forward. I don't think diabetes, as a condition, is going away. So before we go away, I want to ask our listeners one small favor. We're taking a survey and we'd like you to participate. It helps us learn more about our listeners. No matter how long you've been listening or how frequently you listen to the show. It's quick, it's anonymous. So if you can take a few minutes to help us out, we would really appreciate it. And you can find the listener survey in [the] description of this episode. Brian, thanks, as always, for coming on Industry Focus, sharing your knowledge, and I hope to have you on again soon. Feroldi: Sounds like a plan, Nick... have a great day. Sciple: As always, people on the program may own companies discussed on the show, and The Motley Fool may have formal recommendations for or against the stocks discussed, so don't buy or sell anything based solely on what you hear. Thanks to Austin Morgan for his work behind the glass. For Brian Feroldi, I'm Nick Sciple, thanks for listening and Fool on! Brian Feroldi has no position in any of the stocks mentioned. Nick Sciple owns shares of DexCom. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Want to Get Rich Investing in Healthcare? Check Out These Diabetes Stocks The healthcare sector hasn't been a big winner for investors over the last 12 months. Shares of the largest healthcare-focused exchange-traded fund (ETF), Health Care Select SPDR ETF, are lagging well behind the performance of the S&P 500. But not all areas within the healthcare sector are performing poorly. Three diabetes stocks in particular continue to be sizzling hot. If you want to get rich investing in healthcare, you definitely need to check out DexCom (NASDAQ: DXCM), Insulet (NASDAQ: PODD), and Tandem Diabetes Care (NASDAQ: TNDM). Image source: Getty Images. 1. DexCom Shares of DexCom have more than doubled over the last 12 months. The key reason for the stock's fantastic performance is fast-growing sales of the company's G6 continuous glucose monitoring (CGM) system. DexCom's latest quarterly results show just how successful the company's G6 CGM is right now. The company's revenue jumped 37% year over year in Q4 2019 to $462.8 million, well above the consensus Wall Street estimate. This strong revenue growth helped DexCom to also trounce analysts' fourth-quarter earnings estimate. The company benefited from its launch of the G6 into the U.S. Medicare market. It expanded its global operations. DexCom also partnered with major healthcare organizations like UnitedHealth Group to increase the use of its CGM system by individuals with type 2 diabetes. 2. Insulet If you liked DexCom's big gains, you'll love Insulet's performance. The stock has skyrocketed more than 140% over the past 12 months, powered by rapidly growing demand for its OmniPod insulin pumps for individuals with Type 1 or Type 2 diabetes who require insulin. Insulet won't report its fourth-quarter results until next week, but the company's Q3 update in November underscored the tremendous momentum for OmniPod. Sales for the insulin pump jumped 34% year over year to $177.2 million, accounting for over 92% of the company's total revenue. OmniPod is much more convenient than traditional insulin shots, with one \""pod\"" replacing up to 14 injections each day. It's also differentiated from other leading insulin pumps because it's tubeless, waterproof, and easily hidden beneath clothing. 3. Tandem Diabetes Care Insulet isn't the only insulin pump maker that's on a roll. Shares of Tandem Diabetes Care are up more than 70% over the past 12 months, thanks primarily to continued success for the company's t:slim X2 insulin pumps. Like Insulet, Tandem is scheduled to report its fourth-quarter results next week. It seems likely that the company will continue its momentum from Q3, when it announced that its revenue more than doubled from the prior-year period to $94.7 million, with especially strong growth in international markets. Tandem's strategy has been to focus heavily on introducing innovative new products based on its core t:slim platform. The company has launched six new insulin pump versions over the last six years. Tandem's slogan for t:slim X2 -- \""the pump that gets updated, not outdated\"" -- highlights one of its competitive advantages. In addition, t:slim X2 is smaller than other leading insulin pumps and already integrates with DexCom's CGM systems. Why these diabetes stocks could get even hotter Investing in healthcare stocks that focus on diabetes should be a winning strategy for the future based on demographic trends alone. There are around 463 million people across the world with diabetes -- and that number is growing. Only around 6% of individuals with diabetes don't develop complications. This creates a massive opportunity for medical devices that help effectively manage diabetes. All three of the diabetes stocks mentioned have catalysts on the way that should enable them to succeed in 2020 and beyond. DexCom is launching the G6 CGM in more international markets and plans to conduct the biggest product launch in its history on a full scale in 2021 with its new G7 CGM system. Insulet recently announced plans to integrate with DexCom's G6 and G7, as well as Abbott Labs' popular Freestyle Libre CGM. Tandem just launched its latest version of the t:slim X2 insulin pump, which is the first system to deliver automatic correction boluses of insulin and adjust insulin levels to keep blood sugar levels within thresholds. There's no guarantee that you'll get rich investing in DexCom, Insulet, and Tandem. But these three diabetes stocks appear to be on a track to continue generating strong gains for long-term investors. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of Health Care SPDR. The Motley Fool recommends Insulet and UnitedHealth Group. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion"", ""Insulet Partners With Abbott and Dexcom on Diabetes"", ""Earnings Watch: Best Buy Stock Resilient Ahead Of Results; Palo Alto Networks, Square Also Strong"", ""National Pension Service Buys TC Energy Corp, Bristol-Myers Squibb Company, Truist Financial ...""]"
DXCM,2020-02-24,69.5025,73.7578,68.75,73.5125,"[""Insulet Partners With Dexcom for Automated Insulin Delivery"", ""Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown."", ""Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown."", ""Insulet Partners With Dexcom for Automated Insulin Delivery"", ""Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown."", ""Insulet Partners With Dexcom for Automated Insulin Delivery""]"
DXCM,2020-02-25,74.36,75.4575,69.6775,70.99,
DXCM,2020-02-26,71.1775,74.46,68.775,69.5625,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Dow Jones Pares Big Gains As Stock Market Rally Fades; Watch This FANG Stock"", ""Dow Jones Pares Big Gains As Stock Market Rally Fades; Watch This FANG Stock"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Diabetes Stock Insulet Drops 8.5% on Earnings Miss and Softer-Than-Expected Outlook Insulet (NASDAQ: PODD) reported fourth quarter and full year 2019 results after the market closed on Tuesday, Feb. 25. The tubeless insulin pump specialist's revenue grew 27%, and its earnings per share declined 50% year over year. Shares of the Massachusetts-based healthcare company fell 8.5% on Wednesday. We can attribute the market's reaction to earnings missing Wall Street's consensus estimate, along with guidance for both the first quarter and full year 2020 coming in lower than analysts had been projecting. Over the last year, Insulet stock has doubled, while the S&P 500 has returned 13.7%. Image source: Insulet. Insulet's key numbers METRIC Q4 2019 Q4 2018 CHANGE Revenue $209.4 million $164.9 million 27% Operating income $18.2 million $16.2 million 12% Net income $5.0 million $9.9 million (49%) Earnings per share (EPS) $0.08 $0.16 (50%) Data source: Insulet. Revenue easily beat Insulet's guidance range of $193 million to $201 million. For context, in the first, second, and third quarters, year over year revenue growth was 43%, 29%, and 27%, respectively. Wall Street was looking for EPS of $0.11 on revenue of $195.5 million. So the company fell short on the bottom line, but surpassed the top line expectation. What happened with Insulet? In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million. U.S. Omnipod revenue jumped 36% to $126.7 million. International Omnipod revenue rose 20% to $65.8 million. Drug delivery revenue edged up 1% to $16.9 million. Fourth quarter gross margin was 64%, down from 66.9% in the year-ago period, and slightly lower than last quarter's 64.1%. As with last quarter, the year over year decline was due to the ramp-up of the company's manufacturing capabilities at its new U.S. facility, located in Massachusetts. The company installed a second U.S. manufacturing line, with commercial production on this line expected by mid-year 2020. It \""entered pivotal trial for the Omnipod Horizon automated insulin delivery system, including 240 participants ages 6 to 70 years old,\"" according to the earnings release. This system, expected to launch late this year, uses a DexCom continuous glucose monitor (CGM) to dose insulin. The company \""broadened collaboration with DexCom to integrate its G6 and future G7 continuous glucose monitoring systems into the Omnipod Horizon system.\"" It \""expanded partnership with Abbott [Laboratories] to integrate its next-generation Libre glucose sensing technology into the next-generation Omnipod Horizon system.\"" What management had to say Here's what CEO Shacey Petrovic had to say in the press release: 2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results. With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth. As we look ahead to 2020, Insulet has a clear trajectory to strengthen our leadership position and make even greater treatment options a reality for the large and underserved global diabetes market. We are well on track to meet our 2021 financial targets of $1 billion in revenue, 70% gross margin and mid-teens operating margin, and remain focused on advancing our mission to ease the burden of people living with diabetes. Looking ahead Insulet ended a great year with a solid quarter. Management issued first quarter and full year revenue guidance: Q1: Revenue growth 17% to 20% year over year. 2020: Revenue growth of 14% to 18% over 2019. Going into earnings, Wall Street had been modeling for year over year revenue growth of 27.4% in the first quarter and 20.8% for 2020. So, Insulet's outlook for both periods came in lighter than analysts expected. This was surely a big factor in the stock's decline on Wednesday. Insulet has a great track record of beating its quarterly revenue guidance and increasing its annual guidance several times each year. So, the revenue growth outlooks for the first quarter and 2021 are probably quite conservative. 10 stocks we like better than Insulet When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Insulet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dow Jones Pares Big Gains As Stock Market Rally Fades; Watch This FANG Stock"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2020-02-27,68.385,73.4925,67.5028,70.37,
DXCM,2020-02-28,69.1825,69.685,66.667,69.0,"[""This IBD Stock Of The Day Is Weathering Coronavirus Better Than Its Rivals"", ""This IBD Stock Of The Day Is Weathering Coronavirus Better Than Its Rivals"", ""This IBD Stock Of The Day Is Weathering Coronavirus Better Than Its Rivals""]"
DXCM,2020-03-02,69.525,71.625,69.275,71.4325,"[""Look Who's Got Lots Of Leaderboard, IBD 50 Stocks"", ""Dow Jones Futures: Apple, Microsoft Lead Strong Market Rally, But It's Still A Coronavirus Stock Market Correction; Watch These Leaders"", ""Dow Jones Futures: Apple, Microsoft Lead Strong Market Rally, But It's Still A Coronavirus Stock Market Correction; Watch These Leaders"", ""Look Who's Got Lots Of Leaderboard, IBD 50 Stocks"", ""Dow Jones Futures: Apple, Microsoft Lead Strong Market Rally, But It's Still A Coronavirus Stock Market Correction; Watch These Leaders"", ""Look Who's Got Lots Of Leaderboard, IBD 50 Stocks""]"
DXCM,2020-03-03,71.5782,72.221,67.05,68.22,"[""Here's Why You Should Invest in Integer Holdings Stock Now"", ""Stocks Close Sharply Lower Despite Interest Rate Cut; Where Investors Are Fleeing"", ""Stocks Close Sharply Lower Despite Interest Rate Cut; Where Investors Are Fleeing"", ""Here's Why You Should Invest in Integer Holdings Stock Now"", ""Stocks Close Sharply Lower Despite Interest Rate Cut; Where Investors Are Fleeing"", ""Here's Why You Should Invest in Integer Holdings Stock Now""]"
DXCM,2020-03-04,69.455,71.05,68.25,70.9675,
DXCM,2020-03-05,70.485,72.9637,69.805,71.7425,"[""Here's Why You Should Hold on to OPKO Health Stock for Now"", ""Dow Jones Futures: Apple, Tesla, Lead Nine Stocks To Watch In Coronavirus Stock Market Correction"", ""Citigroup Initiates Coverage On DexCom with Buy Rating, Announces $330 Price Target"", ""Benzinga's Top Upgrades, Downgrades For March 5, 2020"", ""Benzinga's Top Upgrades, Downgrades For March 5, 2020"", ""Citigroup Initiates Coverage On DexCom with Buy Rating, Announces $330 Price Target"", ""Dow Jones Futures: Apple, Tesla, Lead Nine Stocks To Watch In Coronavirus Stock Market Correction"", ""Here's Why You Should Hold on to OPKO Health Stock for Now"", ""Benzinga's Top Upgrades, Downgrades For March 5, 2020"", ""Citigroup Initiates Coverage On DexCom with Buy Rating, Announces $330 Price Target"", ""Dow Jones Futures: Apple, Tesla, Lead Nine Stocks To Watch In Coronavirus Stock Market Correction"", ""Here's Why You Should Hold on to OPKO Health Stock for Now""]"
DXCM,2020-03-06,71.735,71.9675,69.09,71.56,"[""Lipper Award Winners Pick Healthcare and Technology Stocks Amidst Coronavirus Downturn"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $305"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $305"", ""Lipper Award Winners Pick Healthcare and Technology Stocks Amidst Coronavirus Downturn"", ""Why Diabetes Stock Dexcom Jumped 14.6% in February While the Market Dropped What happened Shares of medical device maker Dexcom, Inc. (NASDAQ: DXCM) gained 14.6% in February, according to data from S&P Global Market Intelligence. That performance is even stronger than it might initially seem considering the S&P 500 index dropped 8.2% last month due to concerns that the novel coronavirus, COVID-19, could blunt global economic growth. Dexcom stock is up a whopping 95.1% over the one-year period through March 5, compared to the broader market's 10.6% return over this period. Image source: Dexcom. So what We can attribute Dexcom stock's strong performance last month to the healthcare company's Feb. 13 release of fourth-quarter 2019 results that pleased investors. Shares soared 12.6% the next day. In Q4, revenue jumped 37% year over year to $462.8 million, driven by the continued robust demand from people living with diabetes for the company's G6 continuous glucose monitoring (CGM) systems. That result easily topped the $442.4 million Wall Street consensus estimate. Adjusted earnings came in at $106.5 million, or $1.15 per share, up from $50.2 million, or $0.56 per share, in the year-ago period. That result also sprinted by the analyst expectation, which was $0.74. Data by YCharts. Now what Dexcom reaffirmed its guidance for full-year 2020. It expects revenue of $1.73 billion to $1.78 billion, representing growth of 17% to 20% year over year. It also projects adjusted operating margin of approximately 13%, compared to 10.9% in 2019. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $305"", ""Lipper Award Winners Pick Healthcare and Technology Stocks Amidst Coronavirus Downturn""]"
DXCM,2020-03-09,65.445,69.745,65.0,66.63,
DXCM,2020-03-10,67.9125,70.45,65.885,69.8,"3 Profitable Healthcare Stocks That Are Trouncing the Market During the Coronavirus Correction It's hard to swim against the current. But it's not impossible to do so. Most stocks have fallen hard in the current market correction that was initially caused by worries about the coronavirus and is now being worsened by plunging oil prices. There are exceptions, though. Three profitable healthcare stocks have trounced the overall market indexes and could be poised to continue outperforming the market. Here's which stocks are swimming against the current -- and why they're winning. Image source: Getty Images. 1. Regeneron Pharmaceuticals Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are up more than 20% over the past month, a period where the S&P 500 index tanked by 17%. Regeneron has defied stock market gravity thanks to three pieces of good news. First, the biotech announced on Feb. 4 that it's working with the U.S. Department of Health and Human Services (HHS) to develop a treatment for the novel coronavirus. Regeneron already developed an antiviral drug for treating Ebola and has worked with HHS on developing a treatment for MERS, which is also a member of the coronavirus family. Second, Regeneron announced better-than-expected fourth-quarter results two days later. Its eye-disease drug Eylea generated 11% year-over-year sales growth. Sales for cancer immunotherapy Libtayo more than quintupled compared to the prior-year period. Third, Regeneron announced positive results on Feb. 8 from a late-stage clinical study evaluating Eylea in treating moderately severe to severe non-proliferative diabetic retinopathy (NPDR). Although this was the least of the catalysts boosting Regeneron's shares, the results could set the stage for the company to pick up another approved indication in the future for its blockbuster drug. 2. Gilead Sciences Gilead Sciences (NASDAQ: GILD) stock is up around 5% over the last four weeks, a much better performance than the major market indexes. Like Regeneron, Gilead benefited from news about its antiviral program targeting COVID-19, the disease caused by the novel coronavirus. There's a good reason to view Gilead as the leader in the coronavirus race. A World Health Organization (WHO) official stated in late February that Gilead's antiviral drug remdesivir is the ""one drug right now that we think may have efficacy."" Gilead has already started two late-stage clinical studies evaluating remdesivir in treating COVID-19. But its coronavirus program hasn't been the only news for Gilead in recent days. The company announced on March 2, that it plans to acquire clinical-stage biotech Forty Seven (NASDAQ: FTSV) for $4.9 billion. Forty Seven's lead candidate is experimental blood cancer drug magrolimab. The purchase of Forty Seven fits perfectly with Gilead's strategy of making bolt-on acquisitions of small-to-medium-sized biotechs. And with Gilead Sciences CEO Daniel O'Day's background in oncology development, Gilead's scooping up of a cancer-focused small biotech like Forty Seven makes sense. 3. DexCom It's not just big biotech stocks that are beating the market. Shares of DexCom (NASDAQ: DXCM) have jumped close to 10% over the last month. And the medical device company managed to achieve this gain without having any positive ties to coronavirus programs. DexCom's shares are performing well because its business is performing well. The company announced good news across the board with its Q4 results. Revenue soared 37% year over year with continued momentum for DexCom's G6 continuous glucose monitoring (CGM) system. DexCom's adjusted earnings in Q4 blew past Wall Street estimates. Some companies could experience a negative fallout from the coronavirus outbreak or from lower oil prices, but not DexCom. The medical device maker looks for a strong year in 2020 as its G6 CGM system gains momentum, especially in international markets. DexCom also reported even more good news for its G6 CGM system on Feb. 19. The company is teaming up with Insulet (NASDAQ: PODD) to integrate the G6 CGM with Insulet's insulin pumps. DexCom and Insulet also agreed to integrate the not-yet-released G7 CGM system with Insulet's insulin pumps. Continued momentum? Regeneron, Gilead, and DexCom should be able to continue their momentum and keep outperforming the overall market. For Regeneron and Gilead, the primary catalyst is likely to be progress with their respective COVID-19 programs. For DexCom, it's all about the company's G6 CGM sales. Over the long run, I like the prospects for Gilead and DexCom the most. Gilead could soon win approval for filgotinib, an immunology drug with huge sales potential. DexCom's rollout of the G7 CGM should keep the company at the forefront in diabetes management. The worries about the coronavirus will likely fade over time, but my view is that the opportunities for Gilead and DexCom won't. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-03-11,67.8275,68.25,61.255,63.105,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares""]"
DXCM,2020-03-12,54.6275,63.75,53.75,61.91,"[""Stocks Off Session Lows; Dow Wipes Out All Gains From 2018 Low"", ""DexCom (DXCM) Stock Moves -1.89%: What You Should Know"", ""Dow Jones Dives Deeper Into Bear Market After Trump Coronavirus Response, Fed Stimulus"", ""DexCom (DXCM) Stock Moves -1.89%: What You Should Know"", ""Dow Jones Dives Deeper Into Bear Market After Trump Coronavirus Response, Fed Stimulus"", ""Stocks Off Session Lows; Dow Wipes Out All Gains From 2018 Low"", ""DexCom (DXCM) Stock Moves -1.89%: What You Should Know"", ""Dow Jones Dives Deeper Into Bear Market After Trump Coronavirus Response, Fed Stimulus"", ""Stocks Off Session Lows; Dow Wipes Out All Gains From 2018 Low""]"
DXCM,2020-03-13,64.08,64.75,55.0,61.005,"[""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?"", ""Stocks Trade Near Lowest Levels Of Session As Gains Thin Out"", ""Dexcom Inc (DXCM) EVP Strategy and Corporate Dev Steven Robert Pacelli Sold $\u2014. ..."", ""DexCom shares are trading lower despite market strength. Not currently seeing negative company-specific news."", ""DexCom shares are trading lower despite market strength. Not currently seeing negative company-specific news."", ""Dexcom Inc (DXCM) EVP Strategy and Corporate Dev Steven Robert Pacelli Sold $\u2014. ..."", ""Stocks Trade Near Lowest Levels Of Session As Gains Thin Out"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?"", ""DexCom shares are trading lower despite market strength. Not currently seeing negative company-specific news."", ""Dexcom Inc (DXCM) EVP Strategy and Corporate Dev Steven Robert Pacelli Sold $\u2014. ..."", ""Stocks Trade Near Lowest Levels Of Session As Gains Thin Out"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?"", ""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?""]"
DXCM,2020-03-16,53.75,54.725,50.5,50.575,"[""Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy."", ""Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy."", ""Why DexCom Stock Is Getting Trounced Today What happened Shares of the diabetes-oriented medical device maker DexCom (NASDAQ: DXCM) are tanking in lockstep with the broader market today. Specifically, DexCom's stock was down by an eye-catching 13.8% as of 10:37 a.m. EDT Monday morning. DexCom, along with most other U.S. stocks, is reacting negatively to both the Federal Reserve's emergency rate cut over the weekend and the fallout resulting from the continued spread of COVID-19 across the globe. The bottom line is that the global economy appears headed for a prolonged rough patch. In turn, investors are selling off stocks this morning, presumably in favor of cold hard cash. Image source: Getty Images. So what DexCom was one of the hottest growth stocks in the entire healthcare sector prior to this dramatic sell-off. Fueled by skyrocketing sales of its G6 continuous glucose monitoring (CGM) system, the company's shares were up by nearly 90% year-over-year at the start of March. As such, DexCom's stock might be getting singled out for particularly harsh punishment today. In brief, the company's shares were trading at an astronomical 94 times next year's projected earnings at one point earlier this month, thanks to its meteoric rise over the course of 2019 to early 2020. Now what Should bargain hunters take advantage of today's weakness? The short answer is no. DexCom's game-changing CGM system has been selling like hot cakes, but a noteworthy portion of this growth has been coming from international markets in recent quarters. Unfortunately, there's no way to predict how COVID-19 will impact the sales of medical devices abroad. Thus, it might be best to watch this falling knife from the safety of the sidelines for the time being. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.""]"
DXCM,2020-03-17,51.3125,51.8025,45.5175,49.685,"[""The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital"", ""The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital"", ""DexCom (DXCM) Shares Cross Below 200 DMA In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $189.56, changing hands as low as $182.07 per share. DexCom Inc shares are currently trading off about 7.9% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $107.44 per share, with $306.71 as the 52 week high point \u2014 that compares with a last trade of $188.38. Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Add Up The Parts: SUSL Could Be Worth $60 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG MSCI USA Leaders ETF (Symbol: SUSL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $60.34 per unit. With SUSL trading at a recent price near $42.52 per unit, that means that analysts see 41.90% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SUSL's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), NiSource Inc. (Symbol: NI), and Alexandria Real Estate Equities Inc (Symbol: ARE). Although DXCM has traded at a recent price of $202.30/share, the average analyst target is 44.87% higher at $293.06/share. Similarly, NI has 44.46% upside from the recent share price of $20.94 if the average analyst target price of $30.25/share is reached, and analysts on average are expecting ARE to reach a target price of $175.28/share, which is 43.31% above the recent price of $122.31. Below is a twelve month price history chart comparing the stock performance of DXCM, NI, and ARE: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET iShares ESG MSCI USA Leaders ETF SUSL $42.52 $60.34 41.90% DexCom Inc DXCM $202.30 $293.06 44.87% NiSource Inc. NI $20.94 $30.25 44.46% Alexandria Real Estate Equities Inc ARE $122.31 $175.28 43.31% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital""]"
DXCM,2020-03-18,47.3825,56.25,46.75,47.79,"[""Dow Falls 5,800 Points In March, Boeing Crashes 64%; Trump Plan Fails To Stanch Selling"", ""DexCom shares are trading higher despite overall market weakness. Not currently seeing company-specific news."", ""DexCom shares are trading higher despite overall market weakness. Not currently seeing company-specific news."", ""Dow Falls 5,800 Points In March, Boeing Crashes 64%; Trump Plan Fails To Stanch Selling"", ""DexCom shares are trading higher despite overall market weakness. Not currently seeing company-specific news."", ""Dow Falls 5,800 Points In March, Boeing Crashes 64%; Trump Plan Fails To Stanch Selling""]"
DXCM,2020-03-19,47.805,54.9125,47.79,51.56,"[""Dow Jones Futures Fall: Can Coronavirus Stock Market Rally Count To Two? Tesla Fremont Plant To Close; Boeing's Bailout Blues"", ""Dow Jones Futures Fall: Can Coronavirus Stock Market Rally Count To Two? Tesla Fremont Plant To Close; Boeing's Bailout Blues"", ""Why Novocure, Insulet, and Dexcom Are Rising Today What happened Shares of Novocure (NASDAQ: NVCR), Insulet (NASDAQ: PODD), and Dexcom (NASDAQ: DXCM) all rose by double digits in afternoon trading on Thursday. As of 3:15 p.m. EDT, these healthcare stocks were up 10%, 7%, and 10%, respectively. So what The major U.S. stock indexes all started the day down but rallied in afternoon trading on Thursday. The S&P 500 and Dow Jones Industrial Average were up more than 2%, while the tech-heavy Nasdaq was up more than 4%. Dozens of beaten-down, high-growth companies are outpacing the market's strong returns today, even though they didn't produce any market-moving news. Novocure, Insulet, and Dexcom were included in that group. All three of these medical-device markets are growing their top lines at a double-digit rate and have been sold off hard in the COVID-19-inspired bear market. And yet, none of these companies released any noteworthy information today. Image source: Getty Images. What's mystifying about these companies' stock jumps is that the strength is not being experienced by the entire medical-device industry. The iShares U.S. Medical Devices ETF (NYSEMKT: IHI) -- which is an exchange-traded fund that holds positions in 56 medical-device companies -- is trading down slightly today. Now what Novocure, Insulet, and Dexcom have been walloped over the past month. Even including today's bumps, all three of these stocks are still down more than 30% from their February highs. The good news for investors is that all three of the companies are still firmly in high-growth mode. Novocure, which makes a medical device that's primarily used to treat brain cancer, reported sales growth of 42% in 2019 to $351 million. That strong growth helped to shrink the company's net loss by almost 90% to just $7 million for the full year. With several clinical trials underway that could significantly increase its commercial potential, Novocure could remain in expansion mode for years to come. Insulet, which markets a tubeless insulin pump that's used to treat diabetes, also had a banner 2019. Sales grew 31% to $738 million, and the company produced net income of $11.6 million. Management is targeting $1 billion in revenue by 2021 and a \""mid-teens operating margin.\"" If these numbers are achievable, then Insulet's profitability is poised to significantly expand over the next few years. Dexcom, which makes a continuous glucose monitor that's used by people with diabetes, grew its top line 43% in 2019 to $1.48 billion. Dexcom also recently crossed into the black, posting $100 million in profit for the full year. Management expects growth to slow in 2020 but is still targeting top-line growth between 17% and 20%. That's quite impressive, given this company's size. Valuing high-growth companies is tricky when times are good but nearly impossible when volatility is high. That makes it likely that all three of these businesses are going to continue to experience huge share-price swings based on the latest COVID-19 news of the day. Longer term, all three of these industry disruptors continue to look poised for more market-beating growth. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Brian Feroldi owns shares of Novocure. The Motley Fool owns shares of and recommends Novocure. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dow Jones Futures Fall: Can Coronavirus Stock Market Rally Count To Two? Tesla Fremont Plant To Close; Boeing's Bailout Blues""]"
DXCM,2020-03-20,52.0775,55.8325,50.83,52.375,"[""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know"", ""DexCom (DXCM) Gains As Market Dips: What You Should Know""]"
DXCM,2020-03-23,52.3875,55.3725,49.1412,52.575,"[""Stephens & Co. Maintains Overweight on DexCom, Lowers Price Target to $240"", ""Stephens & Co. Maintains Overweight on DexCom, Lowers Price Target to $240"", ""Stephens & Co. Maintains Overweight on DexCom, Lowers Price Target to $240""]"
DXCM,2020-03-24,54.1925,59.8015,54.0,59.0525,Three stocks that are ‘part of the solution’ to the coronavirus crisis Money manager Amy Zhang of Alger zeroes in on short- and long-term opportunities Money manager Amy Zhang of Alger zeroes in on short- and long-term opportunities.
DXCM,2020-03-25,59.9175,63.5,59.2525,59.8325,"[""US Government Reaches Deal on Stimulus Package: 5 Top Picks"", ""US Government Reaches Deal on Stimulus Package: 5 Top Picks"", ""US Government Reaches Deal on Stimulus Package: 5 Top Picks""]"
DXCM,2020-03-26,60.9875,63.375,59.8026,62.5525,"[""What Stocks Move After the Stimulus Bill Passes?"", ""Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors."", ""Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors."", ""What Stocks Move After the Stimulus Bill Passes?"", ""Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors."", ""What Stocks Move After the Stimulus Bill Passes?""]"
DXCM,2020-03-27,61.5075,67.5,60.1525,65.74,"[""Coronavirus Stock Market Crash: New Stock Market Leaders Will Share This Common Trait"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $278"", ""DexCom shares are trading higher despite market weakness. Morgan Stanley analysts today maintained an Equal-Weight rating on the stock and raised the price target from $270 to $278."", ""DexCom shares are trading higher despite market weakness. Morgan Stanley analysts today maintained an Equal-Weight rating on the stock and raised the price target from $270 to $278."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $278"", ""Coronavirus Stock Market Crash: New Stock Market Leaders Will Share This Common Trait"", ""DexCom shares are trading higher despite market weakness. Morgan Stanley analysts today maintained an Equal-Weight rating on the stock and raised the price target from $270 to $278."", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $278"", ""Coronavirus Stock Market Crash: New Stock Market Leaders Will Share This Common Trait"", ""Charting a bull-bear technical test, S&P 500 pauses amid potential key reversal Focus: Crude oil\u2019s dead-cat bounce leaves prices vulnerable, Semiconductors reach key test amid relative strength, Select pockets of individual strength persist U.S. stocks are firmly lower early Friday, pressured in the wake of the biggest three-day market rally since 1933. Against this backdrop, the S&P 500 has topped slightly under its 200-week moving average (2,644) as it nonetheless vies to register a striking bullish reversal pattern, a key reversal, on the weekly chart.""]"
DXCM,2020-03-30,66.3275,70.2424,63.7675,69.5,"[""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now"", ""Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""These 2 Stocks Are Trading at a Once-in-a-Lifetime Price The coronavirus has been bad news for U.S. stock prices. The Dow Jones Industrial Average has given back most of its gains during the Donald Trump presidency, and scores of blue-chip equities are now trading at multiyear lows as a result. Despite this historic marketwide drop in stock prices, however, most equities still aren't worth buying right now. The unfortunate truth is that the pandemic is probably several weeks away from hitting a peak in the United States, making it virtually impossible to open up the broader economy. So with little to no economic activity on the near-term horizon, stock prices are bound to print lower lows as this public health crisis deepens during the month of April. But there are a few bright spots in this dour market. Companies that produce products essential to daily life, such as medical devices and pharmaceuticals, should eventually separate themselves from the pack. Keeping with this theme, the diabetes medical device specialist DexCom (NASDAQ: DXCM) and the pharmaceutical titan Pfizer (NYSE: PFE) are both trading at once-in-a-lifetime prices right now. Here's why investors may want to add these two top healthcare stocks to their portfolios soon. Image source: Getty Images. DexCom: a V-shaped rebound is already taking shape DexCom is a medical device specialist focused on battling another global pandemic: diabetes. There are an estimated 463 million adults living with diabetes at the moment. What's more, the adult diabetic population is forecast to grow at an alarming rate during the current decade, thanks to the global rise in obesity and sedentary lifestyles. DexCom, for its part, is pitching in to help in the fight against diabetes with its game-changing G6 continuous glucose monitoring (CGM) system. By allowing patients to carefully monitor their glucose levels, this device should ultimately have a significant impact on the prevalence of diabetes-related complications such as nerve degeneration, cardiovascular disease, kidney failure, and blindness. And so far, the G6 CGM is a smashing commercial success. Driving this point home, DexCom's annual revenue rose by an astonishing 43% year over year in 2019 to a whopping $1.47 billion, due in no small part to the enormous demand for the G6 CGM system. Moreover, the company expects this upward trend to continue in 2020, with annual sales forecast to increase to $1.72 billion to $1.74 billion for the full year. With such a strong near-term outlook, it's no surprise that DexCom's shares have bucked the broader marketwide downturn in 2020 by gaining 20.2% so far this year. Still, the medical device giant's shares remain well off their 52-week highs. Now, DexCom is facing some stiff competition in the CGM market, and its shares are trading in the area of 12 times next year's projected sales right now. These two issues are important risk factors that investors shouldn't simply brush aside. That said, DexCom is a proven innovator, its target market is massive and growing, and the company has a long way to go before its G6 CGM system hits a commercial peak. As such, it might be a smart idea to buy this medical device stock while its shares are still down by a healthy 13% from their 52-week high. Pfizer: a top value and income play Big pharma titan Pfizer has had a dismal year. The company's shares have shed over 20% of their value and are now trading close to their five-year low as a result. Apart from the coronavirus-induced sell-off, Pfizer's shares have also suffered from a lack of confidence among investors and Wall Street analysts alike. The main reason is Pfizer's plan to spin off its generic-drug business Upjohn and pair it with Mylan to form a new entity called Viatris. As this move will slash the company's annual revenues by a significant amount, investors appear to be concerned about the sustainability of Pfizer's top-notch dividend (current yield of 4.79%), along with its prospects as a growth-oriented branded drug company. All of these concerns, however, are likely way overblown. First off, current Pfizer shareholders will own a piece of Viatris. That's important because the combined yield of Pfizer and Viatris should at least equal -- and quite possibly exceed -- the company's present annualized payout. Secondly, Pfizer has laid out a strong case explaining why its five core growth products, consisting of Vyndaqel, Ibrance, Xeljanz, Eliquis, and Prevnar, should deliver no less than 6% top-line growth per year for the next five years. What's more, Pfizer also sports one of the deepest and most robust clinical pipelines in the industry. So this initial 6% top-line growth target will likely turn out to be a conservative estimate. Bottom line: Pfizer's stock has gotten slammed for no good reason in 2020. So once this viral pandemic fades into the background, this top value and income play should come roaring back. 10 stocks we like better than Pfizer When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell owns shares of Pfizer. The Motley Fool recommends DexCom and Mylan. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?""]"
DXCM,2020-03-31,68.1575,69.2695,65.7575,67.3175,"[""Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now"", ""Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now""]"
DXCM,2020-04-01,63.8775,65.985,63.045,63.7025,"[""Dow Jones Futures: Keep Your Distance From Coronavirus Bear Market As Covid-19 Cases Surge"", ""Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities."", ""Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities."", ""Dow Jones Futures: Keep Your Distance From Coronavirus Bear Market As Covid-19 Cases Surge"", ""Got $5,000 to Invest? 3 Great Medical Device Stocks to Buy Right Now Sure, many stocks have bounced back somewhat from their lows during the massive market meltdown caused by the coronavirus pandemic. However, there are still lots of attractive opportunities for long-term investors. One of the best places to invest over the last five years has been in medical device stocks. The iShares U.S. Medical Devices ETF has more than tripled the performance of the S&P 500 index during the period. I think medical device stocks will continue to beat the overall market throughout this decade. But which stocks are the best picks? If you have $5,000 to invest (or even less), here are three great medical device stocks to buy right now. Image source: Getty Images. 1. Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. It definitely helped that the company received emergency use authorization last week from the FDA to launch the fastest molecular point-of-care test for diagnosing novel coronavirus disease COVID-19. I fully expect this new test, which will run on the already-popular ID NOW testing platform, will be an enormous winner for Abbott. But as difficult as the challenges are right now, the COVID-19 crisis will only be temporary. Abbott's primary growth drivers lie in addressing health issues that won't go away. Wall Street analysts project that Abbott will increase its earnings by more than 10% on average annually over the next five years. One key to achieving that growth is the company's successful continuous glucose monitoring (CGM) system Freestyle Libre. Abbott hopes to soon win FDA clearance for a new version of the device that should pave the way for an even greater market opportunity. In addition to its strong growth prospects, Abbott reigns as one of the more attractive dividend stocks around. The company has increased its dividend for 48 consecutive years and has paid a dividend for a remarkable 384 consecutive quarters. That's 96 years of steady dividends. Abbott's dividend currently yields around 1.8%. 2. DexCom DexCom's (NASDAQ: DXCM) shares have also made a solid comeback. Although the company doesn't have any products that can be used in the fight against COVID-19, it does have one important thing in common with Abbott Labs. Like Abbott, DexCom markets a super-successful CGM device. DexCom's G6 has become one of the most popular tools for individuals with diabetes to monitor and manage their condition. The G6 is the first FDA-approved integrated CGM that's interoperable with other medical devices such as insulin pumps. DexCom has an even more promising product on the way. CEO Kevin Sayer stated in the company's Q4 conference call in February that the G7 CGM, which will be less expensive and smaller than the G6, should be \""the biggest product launch in DexCom's history.\"" The company expects to launch the new device in 2021. Analysts think that DexCom will grow its earnings by an average of nearly 55% annually over the next five years. That kind of growth doesn't seem farfetched considering the likely market opportunity for the company's G7 device. 3. ShockWave Medical ShockWave Medical (NASDAQ: SWAV) stock took a bigger beating during the coronavirus market sell-off than either Abbott or DexCom. That's not surprising considering that ShockWave is smaller and not yet profitable. But like the larger medical device makers, ShockWave's share price has bounced back in a major way even though it's still down year to date. The company took an old idea and applied it in an innovative new way. Lithotripsy has been used for decades as a way to break up calcium in kidney stones using sound waves. ShockWave uses intravascular lithotripsy (IVL) to crack calcium in arteries. This IVL approach reduces some of the major risks associated with current therapies for treating atherosclerosis. For example, balloons and surgery can cause perforations to blood vessels and tissue damage. IVL's sound waves expand blood vessels under low pressure, lowering the risk of perforation and minimizing the chances of harming soft tissue. ShockWave estimates that its market opportunity tops $6 billion annually. The company should generate around $75 million in revenue this year. It's not surprising that Wall Street analysts project tremendous growth for ShockWave over the next few years. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends ShockWave Medical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities."", ""Dow Jones Futures: Keep Your Distance From Coronavirus Bear Market As Covid-19 Cases Surge""]"
DXCM,2020-04-02,62.5,67.7425,62.5,66.595,"[""Dow Jones Futures: After Strong Market Rally, Tesla Leaps On Q1 Deliveries, But These 4 Leaders Eye Buy Points"", ""Dow Jones Futures: After Strong Market Rally, Tesla Leaps On Q1 Deliveries, But These 4 Leaders Eye Buy Points"", ""Dow Jones Futures: After Strong Market Rally, Tesla Leaps On Q1 Deliveries, But These 4 Leaders Eye Buy Points""]"
DXCM,2020-04-03,65.905,68.1194,64.2675,65.1875,"[""Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?"", ""Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?"", ""Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?""]"
DXCM,2020-04-06,68.0925,68.0925,65.25,67.3275,"[""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?"", ""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?"", ""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?""]"
DXCM,2020-04-07,68.2425,70.0,62.5025,62.6775,"[""Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods"", ""IBD Stock Of The Day Tops 2 Buy Points On A 'Rare Event' Amid Covid-19"", ""Dow Jones Futures: A Coronavirus Stock Market Rally Test To Save Your Portfolio; Vertex, Amazon, TAL In Focus"", ""Dow Jones Futures: A Coronavirus Stock Market Rally Test To Save Your Portfolio; Vertex, Amazon, TAL In Focus"", ""IBD Stock Of The Day Tops 2 Buy Points On A 'Rare Event' Amid Covid-19"", ""Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods"", ""Dow Jones Futures: A Coronavirus Stock Market Rally Test To Save Your Portfolio; Vertex, Amazon, TAL In Focus"", ""IBD Stock Of The Day Tops 2 Buy Points On A 'Rare Event' Amid Covid-19"", ""Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods""]"
DXCM,2020-04-08,63.845,65.0975,62.565,64.5025,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dow Jones Futures: Coronavirus Stock Market Rally Lacks Two Key Qualities; Analyzing Apple, Amazon, Microsoft, Dexcom, Nvidia, Costco"", ""There's A 'Bold, Flashing' Sign Above Dexcom Amid Covid Pandemic"", ""Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign."", ""Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign."", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dow Jones Futures: Coronavirus Stock Market Rally Lacks Two Key Qualities; Analyzing Apple, Amazon, Microsoft, Dexcom, Nvidia, Costco"", ""There's A 'Bold, Flashing' Sign Above Dexcom Amid Covid Pandemic"", ""Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign."", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2013.6 million of Shares"", ""Dow Jones Futures: Coronavirus Stock Market Rally Lacks Two Key Qualities; Analyzing Apple, Amazon, Microsoft, Dexcom, Nvidia, Costco"", ""There's A 'Bold, Flashing' Sign Above Dexcom Amid Covid Pandemic""]"
DXCM,2020-04-09,64.9875,69.1538,64.65,68.8175,"[""Large Number Of Users Helps Dexcom, But Patient Growth At Risk"", ""Dow Jones Jumps Again, Extends Weekly Gain To More Than 2,800 Points; Top Retailer Falls Despite Strong Sales"", ""Here's Why You Should Retain HealthEquity Stock for Now"", ""Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race."", ""Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race."", ""Large Number Of Users Helps Dexcom, But Patient Growth At Risk"", ""Dow Jones Jumps Again, Extends Weekly Gain To More Than 2,800 Points; Top Retailer Falls Despite Strong Sales"", ""Dow Jones Jumps Again, Extends Weekly Gain To More Than 2,800 Points; Top Retailer Falls Despite Strong Sales"", ""Here's Why You Should Retain HealthEquity Stock for Now"", ""Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race."", ""Large Number Of Users Helps Dexcom, But Patient Growth At Risk"", ""Dow Jones Jumps Again, Extends Weekly Gain To More Than 2,800 Points; Top Retailer Falls Despite Strong Sales"", ""Dow Jones Jumps Again, Extends Weekly Gain To More Than 2,800 Points; Top Retailer Falls Despite Strong Sales"", ""Here's Why You Should Retain HealthEquity Stock for Now""]"
DXCM,2020-04-13,69.97,71.4475,67.5275,68.315,"[""PRA Health Unit to Offer Free Access to Metys COVID-19 Module"", ""USA Financial Portformulas Corp Buys Activision Blizzard Inc, NVIDIA Corp, Biogen Inc, Sells ..."", ""Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?"", ""USA Financial Portformulas Corp Buys Activision Blizzard Inc, NVIDIA Corp, Biogen Inc, Sells ..."", ""PRA Health Unit to Offer Free Access to Metys COVID-19 Module"", ""Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?"", ""USA Financial Portformulas Corp Buys Activision Blizzard Inc, NVIDIA Corp, Biogen Inc, Sells ..."", ""PRA Health Unit to Offer Free Access to Metys COVID-19 Module"", ""Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?""]"
DXCM,2020-04-14,69.1975,71.3125,68.5137,70.1675,"[""Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?"", ""Here's Why You Should Retain Allscripts in Your Portfolio Now"", ""Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?"", ""Here's Why You Should Retain Allscripts in Your Portfolio Now"", ""Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?"", ""Here's Why You Should Retain Allscripts in Your Portfolio Now""]"
DXCM,2020-04-15,69.725,75.0,69.4075,72.9225,"[""Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month"", ""Amedisys Gains on Expanding Hospice Arm, Favorable Demography"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?"", ""Dow Jones Futures: Coronavirus Stock Market Rally Faces Key Test Amid New Breakouts; Apple, Tesla Near Technical High"", ""Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?"", ""What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?"", ""Dow Jones Futures: Coronavirus Stock Market Rally Faces Key Test Amid New Breakouts; Apple, Tesla Near Technical High"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?"", ""What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?"", ""Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?"", ""Amedisys Gains on Expanding Hospice Arm, Favorable Demography"", ""Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month"", ""Dow Jones Futures: Coronavirus Stock Market Rally Faces Key Test Amid New Breakouts; Apple, Tesla Near Technical High"", ""Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?"", ""What's in Store for Intuitive Surgical (ISRG) Q1 Earnings?"", ""Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?"", ""Amedisys Gains on Expanding Hospice Arm, Favorable Demography"", ""Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month""]"
DXCM,2020-04-16,73.75,77.2725,73.75,76.5688,"[""Dow Jones Futures Jump On Gilead, Boeing News: Ride The Coronavirus Stock Market Rally Wave With These Eight Sectors"", ""Here's Why You Should Retain OPKO Health in Your Portfolio"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Dow Jones Futures Jump On Gilead, Boeing News: Ride The Coronavirus Stock Market Rally Wave With These Eight Sectors"", ""Here's Why You Should Retain OPKO Health in Your Portfolio"", ""DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $286.75, changing hands for $291.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 16 different analyst targets contributing to that average for DexCom Inc, but the average is just that \u2014 a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $190.00. And then on the other side of the spectrum one analyst has a target as high as $330.00. The standard deviation is $32.904. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $286.75/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $286.75 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 15 15 14 14 Buy ratings: 1 1 1 1 Hold ratings: 3 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.37 1.37 1.39 1.39 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Thursday"", ""Dow Jones Futures Jump On Gilead, Boeing News: Ride The Coronavirus Stock Market Rally Wave With These Eight Sectors"", ""Here's Why You Should Retain OPKO Health in Your Portfolio""]"
DXCM,2020-04-17,77.7175,82.3975,75.8325,80.85,"[""Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?"", ""Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y"", ""The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement"", ""Stocks That Hit 52-Week Highs On Friday"", ""Stocks That Hit 52-Week Highs On Friday"", ""The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement"", ""Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?"", ""Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y"", ""Stocks That Hit 52-Week Highs On Friday"", ""The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement"", ""Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?"", ""Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y""]"
DXCM,2020-04-20,80.7175,82.1325,79.0,80.8175,"[""Masimo Collaborates With Samsung to Help Fight Coronavirus"", ""Here's Why You Should Hold on to Cerner (CERN) Stock Now"", ""Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?"", ""Here's Why You Should Retain Accuray in Your Portfolio"", ""Masimo Collaborates With Samsung to Help Fight Coronavirus"", ""Here's Why You Should Hold on to Cerner (CERN) Stock Now"", ""Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?"", ""Here's Why You Should Retain Accuray in Your Portfolio"", ""Masimo Collaborates With Samsung to Help Fight Coronavirus"", ""Here's Why You Should Hold on to Cerner (CERN) Stock Now"", ""Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?"", ""Here's Why You Should Retain Accuray in Your Portfolio""]"
DXCM,2020-04-21,80.1025,80.73,76.75,77.0975,
DXCM,2020-04-22,77.8725,80.8875,77.835,80.1575,"[""Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?"", ""Breakout Watch: 52 A+ Funds Inject New Life Into This Medical Supplies Stock"", ""Here's Why You Should Retain NextGen Healthcare Stock Now"", ""Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow"", ""Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash."", ""Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash."", ""Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow"", ""Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?"", ""Breakout Watch: 52 A+ Funds Inject New Life Into This Medical Supplies Stock"", ""Here's Why You Should Retain NextGen Healthcare Stock Now"", ""3 Stocks Hitting All-Time Highs All three of the major U.S. stock market indices are down by double digits from the all-time highs they set in February. That marketwide weakness has knocked down the share price of almost every stock, but a few dozen companies have managed to sidestep the sell-off and are currently trading at all-time highs. Abbott Laboratories (NYSE: ABT), Dexcom (NASDAQ: DXCM), and MarketAxess Holdings (NASDAQ: MKTX) have never been more highly valued than they are today. Here's why investors can't get enough of these stocks. Image source: Getty Images. Abbott Laboratories Abbott Laboratories is a broadly diversified healthcare company that has been in the news a lot recently. It recently launched three diagnostic tests for COVID-19, including a molecular test that can tell whether you have COVID-19 in five minutes. The company is ramping up production of these tests, and CVS Health announced that it's using drive-up stations in its parking lots as part of the innovative system. Abbott's rapid innovation in response to COVID-19 is wonderful -- but it's only a tiny part of its overall business. The company is a big player in numerous healthcare markets, including pharmaceuticals, diagnostics, nutritional offerings, and products to help with cardiovascular issues. Abbott's recently announced first-quarter results looked good. Revenue jumped 2.5% to $7.7 billion, and adjusted net income rose 3% to $0.65 per share. The nutrition division was the star of the show, posting growth of 7.3%, likely in response to people stocking up in response to shelter-in-place orders. While these figures were below Abbott's original forecast, they exceeded Wall Street's estimates on both fronts. Management decided to withdraw its original guidance for the full year, which makes sense, but the company's broadly diversified portfolio should help it easily handle the crisis. The company should also be able to continue its 47-year streak of boosting its dividend payment, which will be music to dividend-focused investors' ears. Dexcom Diabetes is a massive health problem. More than 34 million Americans have diabetes, and another 88 million Americans are at risk of developing it. The numbers only skyrocket from there when you zoom out to include the rest of the world. Treating diabetes requires blood glucose monitoring, which has historically required a blood sample obtained from a finger prick. More than a decade ago, Dexcom launched a wearable sensor that continuously monitors glucose levels, which is helpful because readings can fluctuate wildly throughout the day. Dexcom's system has been a massive success. Revenue has grown by more than 3,680% over the last decade to reach $1.47 billion last year. This amazing growth propelled Dexcom's stock to new heights all along the way, which made the company one of the best-performing healthcare stocks you could have owned over the past decade. Dexcom expects to grow its top line by at least 17% in 2020, and it has a new sensor in development that should prove popular with the diabetes community. Wall Street clearly believes in this company's potential, which is why shares are (once again) trading at a fresh all-time high. MarketAxess Holdings The odds are good that you've never heard of MarketAxess. The company specializes in electronic fixed-income trading at the institutional level, so it's not one most consumers come into contact with. Believe it or not, electronic fixed-income trading -- buying and selling fixed-income securities such as Treasuries or bonds over the Internet -- has still not been widely adopted. On an average day, more than $67 billion worth of fixed-income securities trade hands. Last year, electronic fixed-income platforms only processed about $8 billion worth of trades per day. The remainder take place via one-on-one phone calls or by email, both of which are slow, illiquid, and inefficient. With a penetration rate of less than 12%, there's lots of market share left for MarketAxess to grab. MarketAxess is already producing jaw-dropping financial results at its current market share; it cranked out a stunning 47% operating margin in the fourth quarter of 2019. The company's balance sheet is in tip-top shape, too, boasting $500 million in cash and investments and no long-term debt. MarketAxess is so obscenely profitable that it can easily afford to make the occasional acquisition, buy back stock, and pay a growing dividend all at the same time. Trading activity tends to pick up when markets go haywire, so it wasn't surprising to see that MarketAxess reported a 50% year-over-year increase in credit trading volume in March. That sets the stage for this company to have a very prosperous 2020. Combine the current environment with the company's long-term potential, and it's no surprise to see traders bidding up shares of this amazing growth stock to new heights. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Brian Feroldi owns shares of MarketAxess Holdings. The Motley Fool owns shares of and recommends MarketAxess Holdings. The Motley Fool recommends CVS Health and DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash."", ""Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow"", ""Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?"", ""Breakout Watch: 52 A+ Funds Inject New Life Into This Medical Supplies Stock"", ""Here's Why You Should Retain NextGen Healthcare Stock Now""]"
DXCM,2020-04-23,79.6425,82.225,79.285,80.51,"[""Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?"", ""Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?"", ""Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?""]"
DXCM,2020-04-24,81.8575,83.5675,81.122,83.11,"[""ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?"", ""3 Medical Product Stocks Set to Beat This Earnings Season"", ""What's in Store for Juniper (JNPR) This Earnings Season?"", ""Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings"", ""Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates"", ""What's in Store for Juniper (JNPR) This Earnings Season?"", ""Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings"", ""Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates"", ""ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?"", ""3 Medical Product Stocks Set to Beat This Earnings Season"", ""What's in Store for Juniper (JNPR) This Earnings Season?"", ""Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings"", ""Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates"", ""ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?"", ""3 Medical Product Stocks Set to Beat This Earnings Season""]"
DXCM,2020-04-27,85.885,86.1375,82.5,83.7625,"[""Why DexCom (DXCM) Might Surprise This Earnings Season"", ""Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis"", ""Stryker (SYK) to Report Q1 Earnings: What's in the Offing?"", ""Baxter (BAX) to Report Q1 Earnings: What's in the Offing?"", ""Stocks That Hit 52-Week Highs On Monday"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $350"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $350"", ""Stocks That Hit 52-Week Highs On Monday"", ""Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis"", ""Baxter (BAX) to Report Q1 Earnings: What's in the Offing?"", ""Stryker (SYK) to Report Q1 Earnings: What's in the Offing?"", ""Why DexCom (DXCM) Might Surprise This Earnings Season"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $350"", ""Stocks That Hit 52-Week Highs On Monday"", ""Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis"", ""Baxter (BAX) to Report Q1 Earnings: What's in the Offing?"", ""Stryker (SYK) to Report Q1 Earnings: What's in the Offing?"", ""Why DexCom (DXCM) Might Surprise This Earnings Season""]"
DXCM,2020-04-28,83.7525,84.5,78.0375,78.3825,"[""DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates"", ""The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update"", ""DexCom Q1 EPS $0.440 May Not Compare To $0.140 Estimate, Sales $405.100M Beat $358.620M Estimate"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""23 Stocks Moving In Tuesday's After-Hours Session"", ""23 Stocks Moving In Tuesday's After-Hours Session"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""DexCom Q1 EPS $0.440 May Not Compare To $0.140 Estimate, Sales $405.100M Beat $358.620M Estimate"", ""The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update"", ""DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates"", ""Nasdaq 100 Movers: DXCM, NXPI In early trading on Tuesday, shares of NXP Semiconductors topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.0%. Year to date, NXP Semiconductors has lost about 19.1% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 5.0%. DexCom is showing a gain of 45.5% looking at the year to date performance. Two other components making moves today are Vertex Pharmaceuticals, trading down 4.8%, and United Airlines Holdings, trading up 5.3% on the day. VIDEO: Nasdaq 100 Movers: DXCM, NXPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""23 Stocks Moving In Tuesday's After-Hours Session"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""DexCom Q1 EPS $0.440 May Not Compare To $0.140 Estimate, Sales $405.100M Beat $358.620M Estimate"", ""The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update"", ""DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates""]"
DXCM,2020-04-29,85.0,86.5525,82.0901,86.3675,"[""35 Stocks Moving in Wednesday's Pre-Market Session"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $360"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $360"", ""The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $377"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $360"", ""Stifel Maintains Buy on DexCom, Raises Price Target to $385"", ""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $375"", ""Citigroup Maintains Buy on DexCom, Raises Price Target to $361"", ""82 Stocks Moving In Wednesday's Mid-Day Session"", ""Guggenheim Maintains Buy on DexCom, Raises Price Target to $395"", ""Guggenheim Maintains Buy on DexCom, Raises Price Target to $395"", ""82 Stocks Moving In Wednesday's Mid-Day Session"", ""Citigroup Maintains Buy on DexCom, Raises Price Target to $361"", ""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $375"", ""Stifel Maintains Buy on DexCom, Raises Price Target to $385"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $360"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $377"", ""The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $360"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $360"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""35 Stocks Moving in Wednesday's Pre-Market Session"", ""BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Spotify, Blue Apron Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street looked set to jump at open on Wednesday after Gilead Sciences GILD.O reported an encouraging update on a potential COVID-19 treatment, while upbeat earnings reports from Google-parent Alphabet and Boeing boosted the mood. .N At 8:56 ET, Dow e-minis 1YMc1 were up 1.82% at 24,482. S&P 500 e-minis ESc1 were up 1.74% at 2,917, while Nasdaq 100 e-minis NQc1 were up 1.76% at 8,873. The top three NYSE percentage gainers premarket .PRPG.NQ: ** FTS Internationl Inc FTSI.K, up 33.7% ** R.R. Donnelley & Sons Co RRD.N, up 29.6% ** Hovnanian Enterprises Inc HOV.N, up 25.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Blue Apron Holding Inc APRN.K, down 24.7% ** Roper Technologies Inc ROP.N, down 18.3% ** CoreSite Realty Corp COR.N, down 11.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** NXT-ID Inc NXTD.O, up 86.4% ** Zions Bancorporation ZIONW.O, up 48.1% ** Iconix Brand Group Inc ICON.O, up 46.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Lantronix Inc LTRX.O, down 27.8% ** Yatra Online Inc YTRA.O, down 15.3% ** Creative Realities Inc CREX.O, down 13.5% ** PepsiCo Inc PEP.O: up 0.5% premarket BUZZ-Street View: PepsiCo's snacks could help crunch some of coronavirus impact ** resTORbio Inc TORC.O: up 23.8% premarket BUZZ-resTORbio: Surges on merger with privately-held Adicet ** iRobot Corp IRBT.O: down 5.0% premarket BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain ** Hasbro Inc HAS.O: down 3.9% premarket BUZZ-Hasbro Inc: Drops on flagging weak Q2 over coronavirus concerns ** Humana Inc HUM.N: up 4.0% premarket BUZZ-Humana Inc: Rises on upbeat Q1 profit and revenue ** Callaway Golf Co ELY.N: down 5.9% premarket BUZZ-Callaway Golf drops on $200 mln convertible debt deal ** WW International Inc WW.O: up 12.4% premarket BUZZ-WW International: Rises on lesser-than-expected Q1 loss, gain in digital subscribers ** Mastercard Inc MA.N: up 5.1% premarket BUZZ-Mastercard: Rises on better-than-expected Q1 profit ** Chevron Corp CVX.N: up 2.3% premarket ** Exxon Mobil Corp XOM.N: up 2.8% premarket ** Whiting Petroleum Corp WLL.N: up 12.9% premarket ** Occidental Petroleum COrp OXY.N: up 3.4% premarket ** Marathon Oil Corp MRO.N: up 5.8% premarket ** Callon Petroleum CPE.N: up 9.9% premarket ** Apache Corp APA.N: up 6.4% premarket ** Schlumberger NV SLB.N: up 4.6% premarket ** Halliburton Co HAL.N: up 7.4% premarket ** TechnipFMC Plc FTI.N: up 6.3% premarket BUZZ-Oil and gas cos rise on smaller-than-feared U.S. inventories build ** NXP Semiconductors NV NXPI.O: up 2.4% premarket BUZZ-NXP Semiconductors: Gains as brokerages raise PTs on inventory risk mitigation ** United Parcel Service Inc UPS.N: up 0.8% premarket BUZZ-Street View: UPS to deliver more to homes even in Q2 ** Merck & Co Inc MRK.N: up 1.0% premarket BUZZ-Street View: Profit forecast cut puts spotlight on 'defensive' Merck ** Spotify Technology SA SPOT.N: up 9.5% premarket BUZZ-Spotify: Rises after co adds more paid subscribers than expected ** Fuwei Films Co Ltd FFHL.O: up 30.6% premarket BUZZ-Fuwei Films: Jumps on Q4 profit, specialty films sales growth ** Alphabet Inc GOOGL.O: up 8.4% premarket BUZZ-Street View: Alphabet to come out stronger on other side of coronavirus outbreak ** Pfizer Inc PFE.N: up 1.6% premarket BUZZ-Street View: Pfizer among best-positioned to develop coronavirus vaccine ** Blue Apron Holdings Inc APRN.N: down 24.7% premarket BUZZ-Blue Apron: Revenue misses despite surge in stay-at-home orders ** Akamai Technologies Inc AKAM.O: down 4.0% premarket BUZZ-Akamai falls after pulling 2020 forecast ** DeXcom Inc DXCM.O: up 7.9% premarket BUZZ-Dexcom Inc: Up on strong quarterly profit, revenue beat ** General Electric Co GE.N: down 2.9% premarket BUZZ-General Electric: Slips on Q1 profit miss, sees further damage ** Mondelez International inc MDLZ.O: up 0.4% premarket BUZZ-Street View: Mondelez's short-term hurdles to fade in the long run ** Ford Motor Co F.N: down 2.6% premarket BUZZ-Street View: Ford has enough liquid fuel but cash burn worries linger ** Southwest Airlines Co LUV.N: down 1.5% premarket BUZZ-Southwest Airlines boosts capital raise >50%, reaps $4 bln ** 3M Co MMM.N: up 1.0% premarket BUZZ-Street View: Demand for 3M masks to cushion COVID-19 blow, dividend eyed ** iRobot Corp IRBT.O: down 5.0% premarket BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Liberty Oilfield, MRC Global, Capricor Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street jumped on Wednesday as Gilead Sciences gave an encouraging update on a potential COVID-19 treatment and upbeat earnings from Google-parent Alphabet boosted shares of other technology and internet giants..N At 11:19 ET, the Dow Jones Industrial Average .DJI was up 2.08% at 24,602.06. The S&P 500 .SPX was up 2.41% at 2,932.31 and the Nasdaq Composite .IXIC was up 3.02% at 8,868.055. The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 18.2% ** Royal Caribbean Cruises Ltd , up 14.1% ** Carnival Corp , up 13.4% The top three S&P 500 .PL.INX percentage losers: ** Akamai Technologies Inc , down 7% ** C.H. Robinson Worldwide Inc , down 6.5% ** Walmart Inc , down 3.9% The top three NYSE .PG.N percentage gainers: ** SM Energy Co , up 36.8% ** Sonic Automotive Inc , up 32.3% ** Brinker International Inc , up 29.9% The top three NYSE .PL.N percentage losers: ** Franklin FTSE South Africa ETF , down 33.1% ** Blue Apron Holdings Inc , down 21.7% ** Fresh Del Monte Produce Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Capricor Therapeutics Inc , up 161% ** Chimerix Inc , up 55.6% ** BiondVax Pharmaceuticals Equity Warrants , up 42.2% The top three Nasdaq .PL.O percentage losers: ** Creative Realities Inc , down 23.1 % ** Fangdd Network Group Ltd , down 15.5 % ** Pluristem Therapeutics Inc , down 15.1 % ** Boeing Co BA.N, RIC: up 6.79% BUZZ-Boeing shares jump as planemaker downplays liquidity concerns ** Gilead Sciences Inc GILD.O: up 4.6% BUZZ-Gilead: Jumps after positive update on potential COVID-19 treatment BUZZ-Street View: Data suggest Gilead's remdesivir has role in treating COVID-19 ** Liberty Oilfield Services Inc LBRT.N: up 26.7% BUZZ-Liberty Oilfield Services: Gains on surprise Q1 profit ** Sun Communities Inc SUI.N: down 2.9% BUZZ-REIT Sun Communities dims on upsized stock deal ** Enterprise Products Partners EPD.N: up 8.0% BUZZ-Enterprise Products Partners: Climbs on first-quarter profit beat, capex cut ** Juniper Networks Inc JNPR.N: down 1.9% BUZZ-Juniper Networks rises after 8 brokerages lift PT on strong orders ** MRC Global Inc MRC.N: up 29.1% BUZZ-MRC Global Inc: Soars on surprise Q1 profit ** ONEOK Inc OKE.N: up 4.2% BUZZ-ONEOK: Rises on Q1 profit beat, capex reduction ** Zoom Video Communications Inc ZM.O: down 4.5% BUZZ-Google challenges Zoom with free video conferencing ** Capricor Therapeutics Inc CAPR.O: up 161.0% BUZZ-Capricor Therapeutics eyes best day on COVID-19 treatment data ** resTORbio Inc TORC.O: up 17.2% BUZZ-resTORbio: Surges on merger with privately-held Adicet ** iRobot Corp IRBT.O: down 6.3% BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain ** Hasbro Inc HAS.O: down 2.4% BUZZ-Hasbro Inc: Drops on flagging weak Q2 over coronavirus concerns ** Humana Inc HUM.N: up 5.1% BUZZ-Humana Inc: Rises on upbeat Q1 profit and revenue ** Callaway Golf Co ELY.N: down 1.2% BUZZ-Callaway Golf drops on $200 mln convertible debt deal ** WW International Inc WW.O: up 16.6% BUZZ-WW International: Rises on lesser-than expected Q1 loss, gain in digital subscribers ** Mastercard Inc MA.N: up 6.5% BUZZ-Mastercard: Rises on better-than-expected Q1 profit ** Chevron Corp CVX.N: up 4.9% ** Exxon Mobil Corp XOM.N: up 4.3% ** Whiting Petroleum Corp WLL.N: up 13.1% ** Occidental Petroleum COrp OXY.N: up 7.9% ** Marathon Oil Corp MRO.N: up 7.8% ** Callon Petroleum CPE.N: up 8.4% ** Apache Corp APA.N: up 13.2% ** Schlumberger NV SLB.N: up 9.9% ** Halliburton Co HAL.N: up 11.2% ** TechnipFMC Plc FTI.N: up 9.2% BUZZ-Oil and gas cos rise on smaller than feared U.S. inventories build ** Starbucks Corp SBUX.O: down 1.9% BUZZ-Street View: Can Starbucks mirror China recovery in U.S.? BUZZ-Starbucks slips on grim China sales forecast ** NXP Semiconductors NV NXPI.O: up 6.0% BUZZ-NXP Semiconductors: Gains as brokerages raise PTs on inventory risk mitigation ** United Parcel Service Inc UPS.N: down 2.4% BUZZ-Street View: UPS to deliver more to homes even in Q2 ** Merck & Co Inc MRK.N: down 1.8% BUZZ-Street View: Profit forecast cut puts spotlight on 'defensive' Merck ** Spotify Technology SA SPOT.N: up 13.4% BUZZ-Spotify: Jumps on better-than-expected surge in paid subscribers ** Fuwei Films Co Ltd FFHL.O: up 8.2% BUZZ-Fuwei Films: Jumps on Q4 profit, specialty films sales growth ** Alphabet Inc GOOGL.O: up 8.6% BUZZ-Street View: Alphabet to come out stronger on other side of coronavirus outbreak ** Blue Apron Holdings Inc APRN.N: down 21.5% BUZZ-Blue Apron: Revenue misses despite surge in stay-at-home orders ** Akamai Technologies Inc AKAM.O: down 7.0% BUZZ-Akamai falls after pulling 2020 forecast ** DeXcom Inc DXCM.O: up 7.6% BUZZ-Dexcom Inc: Up on strong quarterly profit, revenue beat ** General Electric Co GE.N: down 2.4% BUZZ-General Electric: Slips on Q1 profit miss, sees further damage ** Mondelez International inc MDLZ.O: down 0.2% BUZZ-Street View: Mondelez's short-term hurdles to fade in the long run ** Ford Motor Co F.N: up 0.4% BUZZ-Street View: Ford has enough liquid fuel but cash burn worries linger ** Southwest Airlines Co LUV.N: up 4.3% BUZZ-Southwest Airlines boosts capital raise >50%, reaps $4 bln ** iRobot Corp IRBT.O: down 6.3% BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain The 11 major S&P 500 sectors: Communication Services .SPLRCL up 4.63% Consumer Discretionary .SPLRCD up 2.41% Consumer Staples .SPLRCS down 0.59% Energy .SPNY up 5.49% Financial .SPSY up 3.30% Health .SPXHC up 0.49% Industrial .SPLRCI up 1.83% Information Technology .SPLRCT up 3.48% Materials .SPLRCM up 2.68% Real Estate .SPLRCR up 1.43% Utilities .SPLRCU down 0.45% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Blue Apron, iRobot Corp, General Electric Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Wednesday, bolstered by solid earnings reports from Google-parent Alphabet and Boeing that provided some optimism as the country moved cautiously to ease lockdowns, while investors braced for data which could reveal a sharp contraction in the domestic economy. .N At 7:56 ET, Dow e-minis 1YMc1 were up 0.54% at 24,175. S&P 500 e-minis ESc1 were up 0.49% at 2,881.25, while Nasdaq 100 e-minis NQc1 were up 0.71% at 8,781.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** R.R. Donnelley & Sons Co RRD.N, up 23.2% - ** Capital Senior Living Corp CSU.N, up 17.9% ** QEP Resources Inc QEP.N, up 16.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Blue Apron Holdings Inc APRN.K, down 19.9% - ** Tupperware Brands Corp TUP.N, down 11.2% ** Callaway Golf Co ELY.N, down 5.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** NXT-ID Inc NXTD.O, up 78.4% ** ResTORbio Inc TORC.O, up 38.5% ** Chimerix Inc CMRX.O, up 37.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Net Element Inc NETE.O, down 13% ** Creative Realities Inc CREX.O, down 12.3% ** Criteo SA CRTO.O, down 9.8% ** resTORbio Inc TORC.O: up 38.5% premarket BUZZ-resTORbio: Surges on merger with privately-held Adicet ** Starbucks Corp SBUX.O: down 1.6% premarket BUZZ-Street View: Can Starbucks mirror China recovery in U.S.? ** NXP Semiconductors NV NXPI.O: up 1.0% premarket BUZZ-NXP Semiconductors: Gains as brokerages raise PTs on inventory risk mitigation ** United Parcel Service Inc UPS.N: up 0.1% premarket BUZZ-Street View: UPS to deliver more to homes even in Q2 ** Merck & Co Inc MRK.N: up 0.1% premarket BUZZ-Street View: Profit forecast cut puts spotlight on 'defensive' Merck ** Spotify Technology SA SPOT.N: up 8.0% premarket BUZZ-Spotify: Rises after co adds more paid subscribers than expected ** Fuwei Films Co Ltd FFHL.O: up 22.9% premarket BUZZ-Fuwei Films: Jumps on Q4 profit, specialty films sales growth ** Alphabet Inc GOOGL.O: up 7.4% premarket BUZZ-Street View: Alphabet to come out stronger on other side of coronavirus outbreak ** Pfizer Inc PFE.N: up 1.4% premarket BUZZ-Street View: Pfizer among best-positioned to develop coronavirus vaccine ** Blue Apron Holdings Inc APRN.N: down 19.9% premarket BUZZ-Blue Apron: Revenue misses despite surge in stay-at-home orders ** Akamai Technologies Inc AKAM.O: down 4.6% premarket BUZZ-Akamai falls after pulling 2020 forecast ** DeXcom Inc DXCM.O: up 7.5% premarket BUZZ-Dexcom Inc: Up on strong quarterly profit, revenue beat ** General Electric Co GE.N: down 5.1% premarket BUZZ-General Electric: Slips on Q1 profit miss, sees further damage ** Mondelez International Inc MDLZ.O: down 0.5% premarket BUZZ-Street View: Mondelez's short-term hurdles to fade in the long run ** Ford Motor Co F.N: down 3.9% premarket BUZZ-Street View: Ford has enough liquid fuel but cash burn worries linger ** Southwest Airlines Co LUV.N: down 1.3% premarket BUZZ-Southwest Airlines boosts capital raise >50%, reaps $4 bln ** 3M Co MMM.N: up 0.4% premarket BUZZ-Street View: Demand for 3M masks to cushion COVID-19 blow, dividend eyed ** iRobot Corp IRBT.O: down 7.6% premarket BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Capricor Therapeutics, Liberty Oilfield, Blue Apron Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks jumped to seven-week highs on Wednesday as Gilead Sciences gave an encouraging update on a potential COVID-19 treatment and upbeat earnings from Google-parent Alphabet boosted shares of other technology and internet giants. .N At 12:36 ET, the Dow Jones Industrial Average .DJI was up 2.41% at 24,682.31. The S&P 500 .SPX was up 2.65% at 2,939.15 and the Nasdaq Composite .IXIC was up 3.45% at 8,904.909. The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 19.8% ** Alliance Data Systems Corp , up 15.3% ** Discover Financial Services , up 14.4% The top three S&P 500 .PL.INX percentage losers: ** Akamai Technologies Inc , down 5.3% ** C.H. Robinson Worldwide Inc , down 4.7% ** Coty Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** SM Energy Co , up 40.2% ** Liberty Oilfield Services Inc , up 31.2% ** MRC Global Inc , up 29.9% The top three NYSE .PL.N percentage losers: ** Altisource Asset Management Corp , down 36.1% ** Franklin FTSE South Africa ETF , down 33.1% ** Empire State Realty OP , down 28.9% The top three Nasdaq .PG.O percentage gainers: ** Capricor Therapeutics Inc , up 241.2% ** BiondVax Pharmaceuticals Equity Warrants , up 61.1% ** Chimerix Inc , up 45% The top three Nasdaq .PL.O percentage losers: ** Creative Realities Inc , down 27.5% ** Martin Midstream Partners L.P , down 15.7% ** Fangdd Network Group Ltd , down 14.9% ** Chimerix Inc CMRX.O: up 45.0% BUZZ-Chimerix Inc: Surges on launch of COVID-19 treatment study ** Brinker International Inc EAT.N: up 28.3% BUZZ-Brinker International, Dine Brands surge on encouraging results ** Catalent Inc CTLT.N: up 9.7% ** Johnson & Johnson JNJ.N: down 0.4% BUZZ-Catalent: Jumps on COVID-19 vaccine supply agreement with Johnson and Johnson ** Boeing Co BA.N, RIC: up 9.49% BUZZ-Boeing shares jump as planemaker downplays liquidity concerns ** Gilead Sciences Inc GILD.O: up 6.7% BUZZ-Gilead: Jumps after positive update on potential COVID-19 treatment BUZZ-Street View: Data suggest Gilead's remdesivir has role in treating COVID-19 ** Liberty Oilfield Services Inc LBRT.N: up 31.2% BUZZ-Liberty Oilfield Services: Gains on surprise Q1 profit ** Sun Communities Inc SUI.N: down 2.1% BUZZ-REIT Sun Communities dims on upsized stock deal ** Enterprise Products Partners EPD.N: up 9.6% BUZZ-Enterprise Products Partners: Climbs on first-quarter profit beat, capex cut ** MRC Global Inc MRC.N: up 30.2% BUZZ-MRC Global Inc: Soars on surprise Q1 profit ** ONEOK Inc OKE.N: up 3.4% BUZZ-ONEOK: Rises on Q1 profit beat, capex reduction ** Zoom Video Communications Inc ZM.O: down 5.8% BUZZ-Google challenges Zoom with free video conferencing ** Capricor Therapeutics Inc CAPR.O: up 241.2% BUZZ-Capricor Therapeutics eyes best day on COVID-19 treatment data ** resTORbio Inc TORC.O: up 15.6% BUZZ-resTORbio: Surges on merger with privately-held Adicet ** Hasbro Inc HAS.O: down 3.0% BUZZ-Hasbro Inc: Drops on flagging weak Q2 over coronavirus concerns ** Humana Inc HUM.N: up 5.2% BUZZ-Humana Inc: Rises on upbeat Q1 profit and revenue ** Callaway Golf Co ELY.N: down 0.7% BUZZ-Callaway Golf drops on $200 mln convertible debt deal ** WW International Inc WW.O: up 18.3% BUZZ-WW International: Rises on lesser-than expected Q1 loss, gain in digital subscribers ** Mastercard Inc MA.N: up 6.7% BUZZ-Mastercard: Rises on better-than-expected Q1 profit ** Chevron Corp CVX.N: up 4.3% ** Exxon Mobil Corp XOM.N: up 4.2% ** Whiting Petroleum Corp WLL.N: up 9.9% ** Occidental Petroleum COrp OXY.N: up 6.8% ** Marathon Oil Corp MRO.N: up 7.4% ** Callon Petroleum CPE.N: up 10.1% ** Apache Corp APA.N: up 12.7% ** Schlumberger NV SLB.N: up 9.6% ** Halliburton Co HAL.N: up 10.0% ** TechnipFMC Plc FTI.N: up 7.9% BUZZ-Oil and gas cos rise on smaller-than-feared U.S. inventories build ** Starbucks Corp SBUX.O: down 1.4% BUZZ-Street View: Can Starbucks mirror China recovery in U.S.? BUZZ-Starbucks slips on grim China sales forecast ** NXP Semiconductors NV NXPI.O: up 7.9% BUZZ-NXP Semiconductors: Gains as brokerages raise PTs on inventory risk mitigation ** United Parcel Service Inc UPS.N: down 1.5% BUZZ-Street View: UPS to deliver more to homes even in Q2 ** Spotify Technology SA SPOT.N: up 12.3% BUZZ-Spotify: Jumps on better-than-expected surge in paid subscribers ** Fuwei Films Co Ltd FFHL.O: up 13.3% BUZZ-Fuwei Films: Jumps on Q4 profit, specialty films sales growth ** Alphabet Inc GOOGL.O: up 8.9% BUZZ-Street View: Alphabet to come out stronger on other side of coronavirus outbreak ** Pfizer Inc PFE.N: up 0.4% BUZZ-Street View: Pfizer among best-positioned to develop coronavirus vaccine ** Blue Apron Holdings Inc APRN.N: down 25.2% BUZZ-Blue Apron: Revenue misses despite surge in stay-at-home orders ** Akamai Technologies Inc AKAM.O: down 5.2% BUZZ-Akamai falls after pulling 2020 forecast ** DeXcom Inc DXCM.O: up 8.6% BUZZ-Dexcom Inc: Up on strong quarterly profit, revenue beat ** General Electric Co GE.N: down 1.2% BUZZ-General Electric: Slips on Q1 profit miss, sees further damage ** Mondelez International inc MDLZ.O: up 0.3% BUZZ-Street View: Mondelez's short-term hurdles to fade in the long run ** Ford Motor Co F.N: up 0.2% BUZZ-Street View: Ford has enough liquid fuel but cash burn worries linger ** Southwest Airlines Co LUV.N: up 5.2% BUZZ-Southwest rises after $4 bln liquidity boost; airlines rally ** iRobot Corp IRBT.O: down 3.4% BUZZ-iRobot Corp: Slumps as coronavirus hits sales, upends supply chain ** BeyondSpring Inc BYSI.O: up 10.4% BUZZ-BeyondSpring Inc: Up after changing goal for neutropenia drug study The 11 major S&P 500 sectors: Communication Services .SPLRCL up 5.09% Consumer Discretionary .SPLRCD up 2.65% Consumer Staples .SPLRCS up 0.26% Energy .SPNY up 5.53% Financial .SPSY up 3.60% Health .SPXHC up 1.20% Industrial .SPLRCI up 2.29% Information Technology .SPLRCT up 3.79% Materials .SPLRCM up 2.85% Real Estate .SPLRCR up 1.60% Utilities .SPLRCU up 0.64% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q1 2020 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q1 2020 Earnings Call Apr 28, 2020, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom first-quarter 2020 earnings release conference call. My name is Adrian, and I'll be your operator for today's call. [Operator instructions] Please note this conference is being recorded. I'll now turn the call over to Sean Christensen. Sean, you may begin. Sean Christensen -- Senior Investor Relations Manager Thank you, operator, and welcome to DexCom's first-quarter 2020earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will provide a summary of the quarter, followed by a financial review and outlook from Quentin Blackford, our COO and CFO; and then a strategic update from Steve Pacelli, our executive vice president of strategy and corporate development. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our first-quarter performance on the DexCom investor relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance, including statements with respect to the impacts of the COVID-19 pandemic on DexCom and the potential timing of updated 2020 annual guidance. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 All forward-looking statements included in this presentation are made as of the date hereof, based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our first-quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Let me start by expressing my gratitude for the many healthcare workers and first responders that are supporting all of us at this time. We certainly stand with you in this effort and our thoughts are with you and those who have been impacted by COVID-19. As a quick summary, the first quarter was another very strong quarter for DexCom, continuing the growth momentum that we've delivered for much of the past two years. First-quarter revenue grew to $405 million, representing 44% growth over the first quarter of 2019 or greater than $120 million of absolute dollar growth. This performance was driven by strength in new patient additions in both the U.S. and international businesses, even as we saw some impact to new patient opportunities related to COVID-19 beginning in mid-March. We will address first-quarter performance in a moment. But first and foremost, we wanted to discuss the impact of COVID-19 and DexCom's response. The past few months have brought and likely will continue to bring unprecedented challenges to global health and economic systems as a result of the virus. While this has been an incredibly difficult humanitarian crisis, we have also seen many encouraging examples of collaboration around the world from public and private entities. We have seen people working to bring care to those in need, protect the health of the vulnerable and support the well-being of workers and families. From the outset, we recognize that DexCom has an important role to play. Our customers rely on our CGM technology to safely manage blood glucose and deliver insulin. In many cases, these are people with diabetes who have relied on DexCom CGM since diagnosis, meaning they haven't known a world without the peace of mind of real-time continuous glucose monitoring. People of diabetes are also at heightened risk for complications with COVID-19, highlighting the importance of good glycemic control during these challenging times. We set out with three core priorities: keep our employees safe, continue to serve our patients and work to help our communities. To meet this challenge and support these core priorities, we set in motion several initiatives. We quickly moved the majority of our global employees to home-base work arrangements. This transition enhances safety of all of our employees, including our teams who remain on-site and benefit from a less dense work environment. Our IT and emergency response teams have done an excellent job to enable this shift and provide necessary resources for our teams to continue to function effectively and care for our patients. I could share numerous examples of DexCom teams going above and beyond to ensure that our customers receive product and the support that they need. But I'll share one that stands out to me. In order to ensure that our products were supplied in a timely manner, we had members of our IT teams, who were willing to sleep on-site to meet the needs of our employees and our patients. As this story demonstrates, our employees care deeply for our patients, and we continue to work on new ways to enhance customer support in these unique times. This includes our announcement yesterday of a program to provide financial assistance to our existing patients who have lost or may lose access to insurance coverage for their DexCom supplies as a result of COVID-19. This program, which we plan to launch in the next several weeks, will provide up to two 90-day supply shipments for only $45 each and provide relief to our patients in what is clearly a very challenging time. As it pertains to our customers, both the patient and the clinician, we are working on ways to ensure we have the appropriate infrastructure to support their evolving needs. Our extensive virtual resources for patient and clinician training and customer support are proving to be especially important as the world embraces the increasing use of telemedicine platforms. As a reminder, more than 70% of our historical new patient additions have self-trained using the resources that we provide, demonstrating the value of these resources and the easier use of our CGM systems. Even prior to the global spread of the virus, our procurement and operations teams work to access and mitigate any potential risk to the supply chain for existing products. Because of their effort, we have seen very little disruption with our manufacturing sites as both San Diego and Mesa remain fully operational. Our manufacturing teams have worked seamlessly to make sure that our customers get the CGM systems they rely on. We've implemented additional safety measures to reduce the number of people on-site at any given time. We have implemented shift separations and added additional sanitation and safety measures on top of our existing procedures, including thermal scanning. With the supply chain and manufacturing operations currently in good shape, we continue to be in a strong inventory position to meet the current demand for both existing patients and new patients. We have seen some customer interest in stocking up on the product, but have worked to keep customers supplied in line with the provisions of their insurance providers. This also applies to our DME suppliers and wholesalers. We did not see a material positive impact from customer stocking on our first-quarter sales performance. We have also looked at ways that DexCom could play its part in providing solutions that benefit our communities during the COVID outbreak. When avenues already played out as hospital systems came under increasing pressure and had limited personal protective equipment, we began to feel the number of requests for our G6 sensors. In the ICU, hospital personnel often need to monitor patients with fingersticks as much as every half hour. In response to the request, we worked with the FDA to temporarily allow for the use of G6 in the hospital setting, and we quickly set out to supply product to key regions battling the COVID crisis. Because of our real-time connectivity, our CGM systems allow healthcare providers to remotely monitor a patient's glucose levels in real time, reducing the need for fingersticks. As a result, there are fewer physical interactions between healthcare providers and patients, which limits viral exposure for hospital staff and preserves personal protective equipment. We are already seeing promising evidence of these benefits from the initial sites. Recently, the FDA removed the three-hour delay requirement for CGM data into our CLARITY software, allowing for faster data integration. As we roll this out in the coming weeks, our remote monitoring solutions will be further enhanced in both the hospital setting and for telehealth consultations for people with diabetes. We expect to continue supporting hospitals in areas of the country most impacted by the COVID-19 emergency, although our top priority remains serving our existing patients without interruption. The drastic, but necessary steps to mitigate the spread of the virus have also created some areas of unpredictability for us as we continue in our second quarter and the remainder of 2020. As I briefly noted above, we have seen some impact to new patient opportunities since the broader social distancing measures were put in place in mid-March. We are hopeful that this impact may be mitigated as clinicians enhance their telemedicine capabilities, and our team is certainly working hard to ensure patient access for those who needed DexCom CGM. Quentin will provide more detail around how we have contemplated this uncertainty relative to our 2020 guidance. Another area of unpredictability right now is around the timing of large clinical trials like we need to run for G7. We remain confident in our ability to deliver G7, but acknowledge that the timing of the pivotal trial will be delayed due to the pausing of new trials at most clinical sites. We currently expect a minimum delay of approximately six months for the pivotal trial. This is obviously a challenging time across the globe, but I'm very proud of the way the DexCom teams have responded. I will now turn the call over to Quentin for a review of our financials. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the first quarter of 2020, we reported worldwide revenue of $405.1 million compared to $280.5 million for the first quarter of 2019, representing growth of 44% on a reported basis and 45% on a constant currency basis. The growth performance reflects the strength of our new patient additions throughout 2019 and the first quarter of 2020 as we continue to see growing awareness of the value of DexCom CGM for both type 1 and type 2 patients. The U.S. business grew 39% in the first quarter of 2020 over the first quarter of 2019 with strong growth from each channel, durable medical equipment, pharmacy and Medicare. Pharmacy continues to be the fastest-growing channel for us, and realize the strongest sequential uptick in utilization to date as a result of the significant access improvements that our team has driven over the past year. Our international business also put up a great first quarter, growing 63% on a constant currency basis relative to the same quarter in 2019. The $112.8 million in revenues for our international business represents an increase of more than $25 million from our previous quarterly high watermark. Strength was across the board, including both direct and distributor markets. Our first-quarter gross profit was $258.7 million or 63.9% of revenue compared to 60.2% in the first quarter of 2019. The 370 basis point improvement to year-over-year gross margin reflects the focused work of our teams to take cost out of our product design and manufacturing processes. As Kevin mentioned, our procurement team has done a great job of keeping our supply chain functioning, well with little impact to our ability to produce product as well as our product cost thus far. We will continue to monitor this closely as the situation evolves globally. Operating expenses were $215.4 million for Q1 2020 compared to $176.4 million in Q1 2019. This reflects an increase of 22% year-over-year and a nearly 1,000 basis point reduction as a percentage of revenue from the first quarter of 2019. We continue to prioritize key areas of investment, including our efforts to scale G6 manufacturing, progressing toward our goal of doubling capacity again in the first half of this year. We are also continuing our preparation for the scale-up of our G7 manufacturing lines and looking to support our sales growth with increasing direct-to-consumer advertising as greater clarity evolves from the current global situation. Our non-GAAP results exclude some incremental costs that we experienced toward the end of the quarter in both cost of goods sold and operating expenses as a result of COVID-19. As Kevin noted, the safety of our employees remains our No. 1 priority. However, as an essential provider of medical devices, there are certain functions that must be performed on-site despite shelter-in-place orders to ensure continuity of supply. As a result, we are incurring incremental costs to assist our employees and ensure their safety to the greatest extent possible and expect to continue to do so in the near-term as we support our people through this crisis. We expect to continue to incur costs related to our COVID-19 response until macro business conditions return to normal. Operating income was $43.3 million or 10.7% of revenue in the first quarter of 2020 compared to a loss of $7.6 million or negative 2.7% of revenue in the same quarter of 2019. This reflects a year-over-year improvements of nearly 1,300 basis points in operating margin for the quarter. Similarly, adjusted EBITDA margin improved by nearly 1,000 basis points to 19.2% of revenue or $77.8 million for the first quarter of 2020 compared to 9.3% of revenue or $26.1 million for the first quarter of 2019. As our operating margin and adjusted EBITDA margin performance indicate, we are doing a good job managing our expenses and gaining leverage from our strong top line results. Net income for the first quarter was $41.4 million or $0.44 per share. Our balance sheet remains very strong with more than $1.5 billion in cash and equivalents at the end of the first quarter, leaving us in a strong net cash position. The capital structure that we have put in place, along with our improved profitability profile that demonstrates the cash earnings potential of this business, provides us the flexibility to not only navigate the current environment, but also be opportunistic when needed. Our convertible notes are not due until 2022 and 2023, respectively, and are convertible in either cash or stock at our discretion. We have worked hard and are fortunate to be in this position, recognizing that there are many companies that are less fortunate and struggling to support their employees. Therefore, although we are potentially entitled to stimulus funds as a healthcare provider, we have chosen not to accept these funds and hope that they could be allocated to other American businesses and employees who are in greater need. Turning to 2020 guidance. Given the unpredictable current economic and global health environment, we have chosen to temporarily suspend 2020 guidance until we have greater visibility on the outlook. To be clear, this decision does not necessarily imply upside or downside to our prior guidance. Our first-quarter performance was above our expectations. And apart from the uncertainty created by COVID-19, we would be in a position to raise our guidance today. Ultimately, we believe the underlying demand for CGM has not changed despite the situation with COVID-19. In these early days, we have seen the benefits in the shift to telemedicine because DexCom's real-time CGM is connected, it has become one of the primary methods for physicians to monitor their patients and get newly diagnosed patients up and running. Further to this, as Kevin noted, the FDA has recently removed the three-hour delay requirement for our CLARITY system, which will further differentiate DexCom CGM in its remote monitoring capability. In addition, as noted earlier, we've seen the FDA move quickly to enable the use of DexCom CGM in the hospital setting, further increasing demand for our product. On the other hand, as we've seen office visits decline across healthcare, new patient starts could be impacted in Q2 and into the back half of the year depending on how COVID-19 situation plays out. We will also monitor the macroeconomic environment to gauge employment levels and the ultimate impact of our financial assistance program. Further, while our global supply chain has remained stable, it is less predictable in the current environment and could experience interruption. Predicting all of these future variables has been difficult, and we found it prudent to temporarily suspend our guidance until visibility improves. We will continue to monitor the situation closely and keep you updated as things evolve, and we can provide greater clarity. With that, I will now turn the call over to Steve for a strategic update. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Thanks, Quentin. Given our strong financial position and the growing opportunity ahead of us, we continue to press forward with the strategic initiatives that we outlined at the start of the year. As the COVID-19 pandemic has played out, we looked how DexCom could play a role in delivering an impactful solution. Kevin already walked you through the incredible work being done in the hospital setting. Recent data published in the Journal of Diabetes Science and Technology shows the clear need for glucose control in the hospital and cements the reason we are so committed to assisting in this crisis. The study found that the COVID-19 mortality rate for people with diabetes or hyperglycemia, even in nondiabetics, during their stay was more than four times greater than patients without diabetes or hyperglycemia. Even more alarming, for those who had no evidence of diabetes prior to hospitalization who developed hyperglycemia during their stay, 42% died in the hospital. These are sobering statistics and have served as a constant reminder to our team as we work around the clock to assist frontline workers. As we look forward, our commercial team has begun leveraging our extensive data platforms, which should prove especially valuable for patients and clinicians in an environment where telemedicine business are quickly becoming the norm. As an example, an article published last week in Diabetes Technology & Therapeutics showed great results for two newly diagnosed type 1 patients, one a 20-year-old male and another a 12-month-old female, who were given a G6 and treated with telemedicine during the COVID-19 stay at home orders. Using the G6 and our software tools, clinicians at the Barbara Davis Center in Colorado were able to significantly improve the glucose levels of these patients through virtual care. Stepping back, the fundamentals of our business remain sound, and there were several encouraging developments during the first quarter. As our sales growth indicates, the momentum behind our no fingerstick G6 technology continued in the first quarter. And as we have said multiple times before, we continue to believe that there are significantly more people on intensive insulin therapy who stand to benefit from a transition to our real-time CGM. At the end of the first quarter, we have now transitioned a majority of our Medicare base over to G6. As the only Class II iCGM on the market and the lowest cost CGM for the Medicare channel, we look forward to bringing G6 to people both with type 1 and intensively managed type 2 diabetes, who are eligible for Medicare. We are also pleased that UnitedHealthcare recently began coverage for their intensive insulin type 2 patient population. Combined with Medicare, this demonstrates the increasing traction that we are gaining in the type 2 intensive market. In January, we introduced additional data demonstrating the value of DexCom CGM in the type 2 nonintensive market. This includes our direct work with UnitedHealthcare, digital health programs like Welldoc, Onduo and Livongo; and integrated health systems like Intermountain, where our preliminary pilot showed significant savings with the full-time use of DexCom G6 relative to standard of care, self-monitored blood glucose. We are excited to be expanding access to DexCom CGM throughout all of these channels and look forward to sharing additional results as we progress in our type 2 efforts. The opportunity for growth is also extensive when we look outside the U.S., where use of CGM remains far less than that of fingersticks. In February, we obtained regulatory approvals for G6 in Australia, South Korea and Japan and are progressing toward extending the G6 launch to each of these markets later this year. In support of our continued growth, and in particular, the service of our international markets, we recently finalized a decision to develop a third manufacturing site in Malaysia. This will be another significant investment for DexCom and demonstrates our belief in the long-term opportunity ahead of us. We continue to advance the regulatory pathway for use of CGM in pregnancy, attaining CE Mark for wear on the back of the arm, and we removed the pregnancy warning for G6 for use in type 1, type 2 and gestational diabetes. Following this approval, we launched G6 in the U.K. for pregnant women with diabetes and are currently working to broaden the clinical evidence to support the use of DexCom CGM for the management of gestational diabetes. Finally, our efforts as a forerunner in interoperability and our support of patient choice and their method of insulin delivery has us well positioned to benefit from multiple commercial systems over the next couple of years, whether through automated insulin delivery or connected smart pens. As you can see, there are many exciting things that the DexCom teams are driving forward, even as we navigate the unprecedented time that we are now experiencing. With that, I'll turn it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Steve. This has certainly been a challenging season for all of us. I know that there are many that I have met and people on this call that have been personally impacted by COVID-19. And as I mentioned earlier, our thoughts are certainly with you. I've been grateful to see the unified response of so many companies to work toward innovative solutions, including some of the companies that we traditionally compete with. I am also proud of the response of the DexCom team, who have worked selflessly to bring continuity to our business and assurance to our customer base in a time of heightened anxiety. We are pressing forward in 2020 with resilience in the current environment and continue to hope for the opportunity that lies ahead for DexCom. I would now like to open the call up for Q&A. Sean? Sean Christensen -- Senior Investor Relations Manager Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions & Answers: Operator Thank you. [Operator instructions] And our first question comes from Robbie Marcus from JP Morgan. Your line is open. Robbie Marcus -- J.P. Morgan -- Analyst Thanks and congrats on a great quarter. I have a lot of questions I could ask you about the first-quarter performance. But unfortunately, I'm going to address the elephant in the room with COVID-19. You pulled guidance, but you do have a month of performance here, what's happened in April. I was wondering if you could just walk us through? I don't know if it's Quentin, if you want to take it or how you split it up. But maybe walk us through how we should think about the expectations for 2Q? And how to think about the impact to prescribing in a recovery? How remote telehealth can help or hurt prescriptions of new patients? And how to think about the impact down the P&L as new sales might be disrupted, offset by some of the new venues that you've been able to secure here with testing? Kevin Sayer -- Chairman, President, and Chief Executive Officer Robbie, this is Kevin. I'll start. If I gave you a whole much April color, then I'd be giving you guidance, and that's what we just said that we weren't going to do. That being said, we remain very bullish on our business, as you can see by the first-quarter results. And we have learned very much that the impact of the connectivity of our device with telemedicine is becoming very, very well-known by within the physician community. We hosted a webinar last week and had 900 participants sign up. We don't get 900 people to anything here. That was a huge win for us as we talk and learn more about that. So we think particularly with our system where it goes directly to a phone and a directly at CLARITY and physicians can pull CLARITY up wherever they are working, that is a big win for patients. We know that diabetes, and I'll talk about this a little more later, but it's not going to go away. And these patients need to be cared for. We think we solve a very serious problem by getting data to patients and their caregivers in a very timely basis. You heard us also talk about getting CLARITY more toward a real-time platform that could literally give patient the opportunity to call their doctor and say, \""Hey, what's going on with me?\"" And caregivers aren't on share follow all the time. A more real-time CLARITY is going to give that caregiver a good answer. So we see a situation where we have a very good answer. We're bullish on the business going forward. Things are just a little different now. I don't know, Quentin, if you want to add a little more to that? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. No, I think you described it well. I think, Robbie, the thing is coming out of the quarter or over the course of the first quarter, the strength in the core business, the underlying business was incredibly strong. And I think from our perspective, we're as bullish as we've ever been on where we're at in this opportunity, the runway that exists in front of us. And probably even more so now when you think about the long term, just with the hospital opportunity opening probably sooner than what we anticipated. The whole play in telehealth, telemedicine, we know we have a device that works better there than anything else in the marketplace. And folks seem to be understanding that. To Kevin's point, the 900 folks that joined the webinar, it was a webinar specifically directed toward telehealth, telemedicine. So there's a real interest out there. So I think long term, we feel incredibly bullish about where we're at. In April, yes, the new patient starts were down a bit. We noted that coming out of Q1. We have seen it start to rebound a bit in April. I think it continues to build over time. But we need to see that play out and have some certainty there before we can get back to where we feel comfortable providing guidance. There's just too many things that are uncertain at this point in time that we need that greater clarity on. But I would just reiterate, the underlying strength, the fact that folks are recognizing the value of this product and what it means in the marketplace. From a long-term perspective, we're as bullish as we've ever been. Operator And the next question comes from Danielle Antalffy from Leerink. Your line is open. Danielle Antalffy -- SVB Leerink-- Analyst Hey. Good afternoon, guys. Thanks so much for taking the question. Congrats on a really strong quarter. And I guess just a follow-up. And I was wondering if you could talk a little bit about? So I appreciate the commentary point and thank you on new patient adds in April and without coming down, seeing a uptick a little bit. Can you talk a little bit about how new patient adds, patient training, things like that could look post COVID, if we are in a world where telehealth is a more prominent part of patient management, specifically for diabetes? I would think that, that ultimately would favor CGM, but just curious about how you think, if that could change your long-term expectations around penetration in these markets? And maybe a little bit of color of post COVID, what things might look like based on what you're seeing today? And that's my question. Kevin Sayer -- Chairman, President, and Chief Executive Officer Danielle, I think we'll tag team this one, too, and I'll start. First of all, as we talked about in our call, 70% of our patients train themselves with the material that we provide. And we've also had remote coaching services through DexCom care to help these patients as well. We've anticipated a day like this with respect to training for a long, long time, which is why we moved away from the model we previously had to whereby we could make this easier and get patients on the system. So we don't see that changing much at all. As far as new patient opportunities and new patients coming in, whereas in the past many times that was a result of an office visit. Now it's coming in possibly through a telemedicine conference with a healthcare provider. They could also be coming in through our direct-to-consumer marketing. Our online efforts are all the things that we have and then we have to turn around and figure out a way to get the proper paperwork from the healthcare provider. One of the other things that's key to remember in Quentin's remarks, he talked about how our move to the pharmacy is accelerating. As we go to the pharmacy, the paperwork requirements for healthcare providers come down significantly, so again making the whole process easier. And that's been our goal from the beginning, to get this process easy enough to whereby we can get the penetration that we thought we could get. And I've said for years that 80% penetration in intensive insulin users for CGM should be our long-term goal, and it still is. And the easier we make it, the faster penetration will go. And those efforts have not changed and won't change as a result of COVID. As far as post COVID world and what I see is demand, I think, if anything, people are going to be more concerned about controlling their diabetes to make sure they're healthy. So if something like this happens again, that will not become a complicating factor because their diabetes is in control, not running rampant. So again, we see this as an opportunity to almost increase retention and increase usage within our current patient base as much as it is to grab new. And so I don't want to sound too opportunistic about this. But we have an answer to a serious problem here, and we think people will come to it. Steve, Quentin, if you have anything more to add. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer You covered it all. Kevin Sayer -- Chairman, President, and Chief Executive Officer OK. Operator And our next question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Baird -- Analyst Thank you. Good afternoon, guys. Maybe moving over to the hospital setting. Kevin, a nice win by getting the CGM G6 into the hospital setting. Wondering what this means maybe longer term? Any discussions with the FDA on whether data you'll collect in these COVID patients could be used to maybe accelerate a broader approval down the road for hospital use? Do you think you'd still have to go through the lengthy pivotal that seem like it might have pushed hospital approval out two to three years from now or one to two years out anyway. Is there a way to accelerate that with some of this data that you'll be collecting here over the next six months with the COVID pandemic? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer No. Thank you. We actually have had discussions with the FDA about this very subject. And it is our hope to gather as much data as we can from these patients as they're in this hospital with various compounds being injected and to take care of their help to see how our sensor performs in this environment, how well connectivity is and what we can learn. Our commitment to the agency is with this opportunity, we'll gather as much data as we can, and we're going to share what we learn and see if we can, in fact, accelerate that path and get this device approved for use as a glucose monitoring technology in the hospital environment rather than what they're doing with fingersticks. And as we gather data, we'll take advantage of this opportunity. I think, Jeff, the learnings we've had so far are standing to us as we're into a different channel, with a different physician group, with different caregivers who haven't seen CGM before, with rules and regulations around hospital IT departments and connecting a phone within their security system. We've had learnings that we would have never anticipated. We will be so much more ready to go to this market when it's time. The commitment we've made here from a dollar perspective is large. We put a lot of time and effort, and the hospital team has literally worked around the clock to get this going. And so we'll gather the data. We'll file what we see or at least share what we see and then determine the course of action after that. If we see highly positive results, it's not unthinkable that they would give us an accelerated time frame or cut back on the work that we have to do or possibly change a label to allow us to get there sooner. We're open to all that, and we will look at every one of those opportunities once we're done. But we're really taking this opportunity very seriously. Operator And our next question comes from Matthew O'Brien from Piper Jaffray. Your line is open. Matthew O'Brien -- Piper Jaffray -- Analyst Afternoon. Thanks for taking the questions. Can we just talk about G7 for a second. I think most people have expected a bit of a delay here, but it's a 14-day trial. So the six-month delay, I think, is a little bit longer than some had expected. So I guess the question would be, what would have to happen for it to be pushed out that entire six months? Or what could happen to where that delay is not necessarily that long? Kevin Sayer -- Chairman, President, and Chief Executive Officer I'll start. Again, I'll let the other guys chime in. It's not just a 14-day study. If we could run a 14-day study and put several hundred people on it for 14 days, that would be relatively simple. These trials are not that simplistic. There's going to be at least four in clinic days where blood is drawn for 12 hours, and we can only handle two to three patients at a time at a clinic per day. So these trials are very well orchestrated and scheduled from a logistics perspective. We do not know when clinics who run these trials are going to open back up and allow patients in, to run these kind of studies, nor do we know when patients are going to run and allow themselves to be subjected to this kind of study. So we're putting that time in there knowing there's going to be a while before things get back to normal in these large clinics. And many large clinics where we do these studies aren't even letting patients come in the door now, let alone patients come in for clinical trials. So we've put this time frame on it. How could it, in fact, accelerate? It could accelerate if we found data on the system that would enable us to statistically reduce the size of the trial. But let us, again, remind you, we're not shooting for just anything. We're shooting for iCGM standards, and that is a high bar. That is not an arbitrary bar set by the FDA. That's a high bar. We've met it with G6, and we executed a perfect study to get that done. We've got to execute perfection again. So we've given ourselves this time frame to make sure all our plans are locked down, that we can get the centers open, that can go and do this, and we'll be methodical and thoughtful about it. If there's some way we can accelerate that, we would. But we gave you this because we typically are prudent in our guidance and what we speak and what we think, and that's what we see right now. That's it. Operator And our next question comes from Travis Steed from Bank of America. Travis Steed -- Bank of America Merrill Lynch -- Analyst Congratulations on a strong Q1. Just want to get a little more color on the impact of the patient support program and also the mix headwind and I'd assume would happen as patients move from commercial to Medicaid coverage. So any color there of how to think about the headwind for those two programs? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes, Travis, this is Quentin. I think what you're asking is exactly what we struggle with in terms of defining any certainty around what it's going to be. As we continue to see the fallout from an unemployment perspective in the states and even globally, how that ultimately shows up or translates into our numbers, it's hard for us to predict. You take an existing patient who has been paying in line with their program or their plan, they've been on for some period of time, and all of a sudden they fall into the patient assistance program. You're right, there is going to be a mix impact on the business. And I think that's part of the challenge with we're trying to draw the line on exactly where that's going to be. And until we have greater color on where those rates, unemployment rates ultimately fall out and the impacts ultimately fall out to our patient base, it's hard to predict. So that's what leads to putting us in a position where we ultimately feel best at this point, just to pull guidance. Again, we couldn't be more bullish around what's going on inside the business, but we know there's going to be mix impacts and shifts over the next several months. So right now, the visibility is limited. Operator And our next question comes from Margaret Kaczor from William Blair. Your line is open. Margaret Kaczor -- William Blair & Company -- Analyst Good afternoon, guys. Just wanted to follow up with some more specific question about the hospital. So when we look at the sensors that are going out there, can you give us some sort of information in terms of the data sharing agreements that you guys have with the hospitals trialing this? So what data are you targeting again? What endpoints are the hospitals and yourselves interested in? And are patients consenting to you or the hospital using the data at least on a de-identified basis, so you can get kind of a larger national registry at least? Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I would say, Margaret, this is Steve. Don't read too much into it at this early stage. This is something that literally the hospital team work 24/7 to get product into the hospital to reduce the risks to caregivers, right? They weren't able to take fingersticks because they'd have to, really, they have to actually change out their PP every time they would have to go pick a finger and they couldn't do it. So right now, we're capturing data. This is all about being able to remotely monitor these patients to help the caregivers in the hospital provide better care. To the extent we have data down the road that we're obviously retaining, we'll look to see what we do with it. But right now, we've not made any plans to do anything specifically with the data, either with a hospital or on an anonymized basis or otherwise. Kevin Sayer -- Chairman, President, and Chief Executive Officer We have a couple that are under IRB, but it's not... Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Most of them are... Kevin Sayer -- Chairman, President, and Chief Executive Officer Most of them are getting this thing up and running to take care of people right now. But Steve is right, we're continuing to work on that. Operator Our next question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good afternoon. Just want to come back to the first quarter a little bit here. And Kevin, you touched on this briefly in your preamble. We think about the effect of stocking and the effect of inpatient use. I'm assuming inpatient use was pretty minimal in the first quarter. But both these positive offsets potentially was stocking several million or tens of millions, and was the inpatient opportunity here recently several million or bigger than that? Just trying to get some sense of the framework of some of those positive drivers here. Thanks so much. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'll let Quentin take that. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer David, this is Quentin. Yes. With respect to the inpatient, that was minimal. I mean it didn't move the needle at all. On the stocking side, you're talking several millions, not tens of millions by any stretch at all. It was on the lower end. I think the point that we were making in our prepared remarks was there are several questions out there around whether or not stocking is driving results in the first quarter. And the point is there are several distributors who would have liked to have had the opportunity to stock up ahead of some of the uncertainty that they saw. But frankly, we weren't in the position or we weren't enabling that to take place. We monitor this very closely. We have provisions in our agreements with those distributors that limit amount of days of inventory on hand that they can carry, and so we monitor that. And so while there was an expressed interest to stock to a greater degree, we did not enable that and therefore it was not a driver of the results. And that was the point we're trying to get across. Operator And our next question comes from Joanne Wuensch from Citibank. Joanne Wuensch -- Citi -- Analyst Good evening our afternoon and thanks for taking the question. I'm curious what you have seen either in the month of April or in previous recessions when it comes to attrition. And do patients start going back to traditional fingersticks? And anything you could say because many of us on this call did not cover the stock back in '08/'09 or '01/'02 would be helpful if it's relevant? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Steve, you are the only one here... Steve Pacelli -- Executive Vice President of Strategy and Corporate Development What I would tell you is, no, I mean, we've obviously had a very strong quarter driven by both existing patient base and new patients back. If you remember back in the '08/'09 time frame, we were still on the seven and the seven-plus, which those technologies just weren't really ready for prime time. It really wasn't. If you remember, it wasn't until we launched the Gen-4 platinum in the, I think it was Q4 of 2012 that you really saw the inflection in this business. We really moved to a must-have versus a nice-to-have in terms of our technology. So I don't know that you could possibly make a comparison to back that. I mean back in those days, it was Terry and I just trying to raise money, every opportunity we could to keep the lights on. So it's just a different. It's not even the comparable business at this point. Kevin Sayer -- Chairman, President, and Chief Executive Officer About the only thing I could add to that is we have done everything we can to make it easier for our patients to get CGM even during these tough times. In '08/'09, we had 0 Medicaid coverage. We had no Medicare coverage. We had no pharmacy benefit where the co-pay is typically significantly lower than it is through DME, and pricing has been somewhat lower. So I think we've done everything we can to position our business to be more successful during a time like this and to help our patients continue on the therapy. But again, now you have what may be a recession tied to a healthcare event, we may see exactly the opposite. The patients absolutely have to have this to remain healthier, believe that they do. Again, part of the unknowns that we're trying to work through and trying to manage. Operator And our next question comes from Kyle Rose of Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you very much for taking the questions. So I appreciate the additional commentary with respect to the G7 clinical trial. But maybe help us understand what you can do over the course of the next six months from a manufacturing perspective to help accelerate maybe the launch timing? Because if I remember correctly, you're going to get approval before year-end, but the launch wasn't really going to take place until you had capacity, and that was a 2021 event. Maybe help us understand what happens behind the scenes while the trial might not be going and how that might help the eventual commercial pace when it does launch? Kevin Sayer -- Chairman, President, and Chief Executive Officer Let's be clear, we never said we'd have approval by year-end, and we said we expected a 2021 launch with a limited launch by the end of 2020, was our goal without meaningful financial impact in 2020, if we had a limited launch. There are things we can do to accelerate those studies possibly. On the manufacturing side, we have similar circumstances to what Quentin described earlier about the core business. We have suppliers that we're not in control of who are rapidly putting equipment together and building things for us. We have orders for this equipment all over the world, waiting for it to come in, to get those lines up and running. We will remain committed to the fact we will not do a full-scale launch of this product until we're ready to go completely. And on top of that, while we wait and sometimes we forget, we have a fantastic product with what we have in G6, and so we will continue to refine and make that better. I don't know, Quentin, if you have any other things we can do on manufacturing? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer No, I think the teams are doing a great job of pushing forward as well as we can, as fast as we can on on G7 and just the automation capability from a production perspective. Clearly, having folks out of the office creates some challenging disruptions in the pace at which you move. But I think overall, we're navigating it quite well. At the same time, our supply chain is one where it's global in nature. We rely on folks from all over the world to help us produce our product. And we've done a great job of managing G6 to date. G7, we've managed through it as well, but there have been situations where you have a temporary impact here and there, and you got to quickly navigate through it to make sure everything stays on track and on time. And to date, we've done that well. But that's some of the uncertainty that starts to get introduced in the environment that we find ourselves navigating through. So to date, we're handling it well, but there's a lot of balls in the air, and we're doing the best that we possibly can. And if we can pull it forward to Kevin's point, we certainly will look at those sorts of things. Operator And our next question comes from Mathew Blackman from Stifel. Your line is open. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everyone. Thanks for taking the question. You did mention accelerating pharmacy channel mix. So I'm curious, if you had any feedback from payers, I'm talking particularly about holdout payers that may now be more willing to accommodate pharmacy access for DexCom? And similarly, has there been any impact in the last six weeks or so on the insurance verification process? Is that moving along smoothly? Is it so much to the pace you've seen in the past, faster or slower? Any help there would be appreciated. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin, do you want to go ahead? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. So I think from a pharmacy perspective, the comments that we made were clear that we've seen the uptick in that pharmacy channel progress at a very rapid pace. And it's one channel that we always thought just has tremendous potential for us, and we've proved that out over the course of the first quarter. As a matter of fact, we talk about new patients being a driver of growth. For the first time, we saw record new patients in the first quarter despite the fact that we saw it slow down in the very back end of the quarter. And I attribute a good part of that to the pharmacy channel. We haven't seen payers or at least I couldn't speak to any particular payers here in the last several weeks who have opened up more incremental pharmacy access, but we have seen payers who are willing to think differently around the requirements that they might have on patients ordering product, such as clinical site visits or coming in to see the clinician. They're allowing that through telehealth now, telemedicine. We see more and more payers who are moving in that direction each and every week. So we are seeing a changing dynamic from a payer perspective. Haven't seen it so much in terms of opening incremental pharmacy access in the last several weeks, but there is an appetite for change here. Operator And our next question comes from Raj Denhoy from Jefferies. Your line is open. Raj Denhoy -- Jefferies -- Analyst Hi. Good afternoon. I wonder if I could maybe ask about international a little bit, so the $41 million increase, 60-plus percent was notably strong. And so I'm curious if there was particular markets in which you saw that growth? And as a related question, as we think about Germany, the U.K. being some of the more impacted markets with COVID, what are your thoughts around how those will trend over the next several quarters? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. Raj, great question. International was clearly a bright spot in the quarter. And really, it was across the entire international region whether it was Europe, Asia, both regions performed incredibly well. Canada was a driver of the overall growth. With the e-commerce platform we put in place there, we couldn't be more happy with the results that we see. I think one of the interesting data points coming out of the quarter, while Germany is a large market for us, continues to have great success. The U.K. also growing quite aggressively, very significantly outpaced most other major markets, which was nice to see. So a lot of runway continue to exist in all of these markets, but really strength across the board, even through Asia and Australia. So there's not one country to really pull out and attribute all the success to. It was performance across the entire slate that led to the overall outcome that we communicated. Operator Our next question comes from Jayson Bedford from Raymond James. Jayson Bedford -- Raymond James -- Analyst Good afternoon. I hope everyone is healthy. I hate to blow my one question on a yes or no question. But Quentin, I think I just heard you say that you generated record new patients in 1Q. Is that correct? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. Jayson Bedford -- Raymond James -- Analyst So meaning you generated more new patients in 1Q '20 than in any other quarter? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. Correct. The first quarter of 2020 was a record number of new patients to the company versus any other quarter in history. That's right. Operator And the next question comes from Ryan Blicker from Cowen. Your line is open. Ryan Blicker -- Cowen and Company -- Analyst Thanks for taking my questions. Two reimbursement ones. So subsequent to your NH coverage, is there any quantification you could provide on where commercial payer coverage for intensively managed type 2 patients is in the U.S. today? And then, could you also give us an update on the reimbursement environment in Japan and South Korea as you plan to launch later this year? Kevin Sayer -- Chairman, President, and Chief Executive Officer The reimbursement with intensive type 2 is, obviously, most of them are Medicare patients, and we have that covered. After that, it has really been payer by payer. We announced UnitedHealthcare type 2 coverage today. We also have had another large payer expand their type 2 intensive use policy that just hit us today, that will be another win for us. I think a lot of the payers as we go to the pharmacy, have actually included type 2s as we've gone there as well. But it's a gradual thing. It's not going to happen overnight. We keep having wins in our payer team is doing a good job staying on top of that, and we're kind of getting the message out that an insulin user is an insulin user, and they all need access to this. So our type 2 intensive use patient base is growing significantly and becoming a much larger part of our business. Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Yes. I don't have a great update for you, new update for you anyway on Korea. But with respect to Japan, we did get our G6 approval. So that's an approval for consumer use as to a professional use clinician product. We don't currently have reimbursement. So when we launch that product in the consumer channel before the end of this year, it will be a cash pay product. What we've elected not to do is follow a competitor and accept really some part reimbursement based on kind of fingerstick level pricing. We're just not going to go there with that. We're going to do our work, provide the Japanese government with the appropriate data, outcomes data and establish real reimbursement for real-time CGM. So that won't be this year, but we'll give you an update when we have more. Operator And our next question comes from Chris Pasquale from Guggenheim. Your line is open. Chris Pasquale -- Guggenheim Securities -- Analyst Thanks. Can you quantify at all the impact on new patient starts in April? Just looking for a rough sense for how significant the disruption has been. And then Quentin, I just want to make sure I heard you right that you're already seeing those numbers begin to rebound. That seems a little fast. I'm wondering whether you have any sense for why that is or physicians getting better at telemedicine? It seems like most areas are still pretty locked down. Thanks. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. We're not going to comment specifically on where it's at. I think there's been a lot of research, a lot of surveys that have been done that we've seen that would indicate new patient starts might be 40% or 50% of what they previously were. We haven't seen it to that extent, but they certainly have been impacted. And to the point I made earlier, we have seen it start to come back a bit. I think folks are just getting comfortable understanding that there's other means of being able to interact with their physician, learn about the product and obviously, get the product on to them. And that's the telehealth, telemedicine capability that continues to develop. I'll point you back to the webinar that we had just two weeks ago. Over 900 physicians dialed into that webinar to learn of the value and ways to introduce CGM through telehealth. I think that speaks to the interest level that's out there. So I think it will continue to build over time. How quickly it goes, it's hard to say, and that's part of why the uncertainty exists and gives us pause on the guidance that's out there and leaving it there. But overall, I think down the road, telehealth, telemedicine is going to play a much bigger part than what we've seen historically. Operator And our next question comes from Steven Lichtman from Oppenheimer & Company. Your line is open. Steven Lichtman -- Oppenheimer and Company -- Analyst Hi, guys. You talked about the strong cash position you're in, which is particularly important during this time. You also mentioned being opportunistic with the cash. Can you provide any color on where that cash can be put to use for growth initiatives beyond the manufacturing expansion? Any other broader thoughts on potential use of cash that you can provide? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what? Quentin, you take first stab, then we kind of look at each other. Go ahead. Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Well, I think certainly, the new market opportunities that we've been after for a while now with Dolan and team leading that effort, we've been very clear around hospital. Is there a way to accelerate that? There certainly seems to be an interest level beyond hours now sitting on the other side, whether it's the hospital or the FDA, we want to make sure we're opportunistic and think about that in a way that can accelerate it. I think that there's, potentially in that space, even more than just the device itself, but how do you improve efficiency in the hospital setting. So even from an IT capability perspective, thinking about those sorts of things, you think about gestational diabetes, pregnancy, the whole type 2 non-intensive space, I think that that market remains significant. And I think we're seeing each and every day that there's a validated opportunity in that space, and we want to go fast. So we're keeping our eyes open out there in those spaces around the opportunities that exist. And if there's opportunities to kind of really put the foot on the gas pedal, we're going to look at those sorts of things. So that's what we mean by being opportunistic. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. I'd just add one more thing as far as cash because I'm the one driving Quentin and his team on this. We talk about doubling manufacturing capacity before the first half of the year is over. We're pushing that, but that's a lot of capital equipment as we go to a lot of G6 automated lines and getting those up and running and get more lines up at our contract manufacturers. We then have a significant capital investment in the G7 equipment that will be coming, and we talked about investing in a third manufacturing site in Malaysia. So there's going to be a lot of capital equipment that we purchased. The other place that we will definitely be using cash as we invest in our business is just on our infrastructure in our systems. If we've learned anything through this, we need to make some more investments on that side, too. Our team has been fantastic with the tools they have when you get in some more tools. So we have a lot of capital use for that money for organic growth as well. Operator And our next question comes from Ravi Misra from Berenberg Capital. Your line is open. Ravi Misra -- Berenberg Capital Markets -- Analyst I hope everyone over there and their families are OK. Just a question about the financial assistance program. You're providing about six months' worth of supply to patients. Can you just help us understand kind of would that be something that would be shipped out immediately if someone signs up? And also, how do we think about it if the economy continues to kind of show these unemployment numbers? How willing is the company to kind of extend these programs for beyond that six-month period? Is there anything that would be gating you to do that? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, we'll start with our six-month period. And as we got to that conclusion, as we've modeled that out, we're certainly comfortable with that. We're very comfortable with, again, helping our patient base out. These are the people who have built our company and made it what it is. And as I said in my prepared remarks, the more I traveled before this pandemic, the more I learned, there are a lot of people who have no idea how to manage their diabetes without a CGM. So we will continue to try and get product to patients. We'll evaluate the economic consequences of what we do as we roll this out over time. Three years ago, if we had to do this, it would have been even much more difficult because we had very little Medicaid. And we didn't even have Medicare up and running. Now with Medicare approval and Medicaid, there are some states where these patients have better employed can go to Medicaid programs. But it's very inconsistent and sporadic, even though we have, I want to say, 60% of Medicaid programs cover us, some only covers for kids and some make it very difficult. So we will continue to push for more Medicaid coverage during this time to try and mitigate that, and we'll see how it goes, and we'll keep track. But it's important that we make sure these people can stay on the system, and we think this is a really good opportunity for us. So we will continue to do that. Operator And our last question comes from Chris Cooley from Stephens. Your line is open. Chris Cooley -- Stephens Inc. -- Analyst Thank you. Congrats on the record new patient starts. Just at this point, from my perspective, maybe Quentin, could you help us out a little bit with as we look at the operating expenses trending forward, you alluded to better managing the supply chain, we'd assume you'd keep higher levels of safety stock, have higher costs in the shorter run and appropriately so on the labor side. Just maybe help us when we look at the first quarter, was that reflected in the 1Q results? Or just any way you can maybe help us better understand how we should think about maybe the margin structure as we start to go through the year ex the capacity build-out? And maybe similarly from the DTC effort, what you're looking for there that to kick that up just from change in the COVID-19 situation? Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Yes. I think if you go back to the guidance that we set coming into the year, we spoke about some of the different levers that were in there. And certainly, some of the things that we're going to weigh on the organization being specific to G7 trials, development of the automation lines, ramping G6 as quickly as we can and doubling it, and DTC being a significant investment. I think while we've walked away from guidance on the full year, those sorts of drivers are still going to be in the spend profile and they're going to be more heavily weighted in the back half of the year. So while you're seeing a 1,300 basis point improvement in operating margin in Q1, it's not likely that you're going to see that same sort of improvement in the back half of the year because there's going to be all these incremental investments that we know that we need to make, and that will set the company up for growth far into the future, and we're going to commit ourselves to invest in those ways. So I think you're going to continue to see some good leverage in the first half of the year. I think in the back half of the year, you're going to see the P&L start to look a little bit differently as we make some of these key investments into what I think all of us understand to be critical growth drivers of the future. So I'll leave it at that. The P&L profile will shift a little bit. But overall, we still remain committed to the longer-term goals that we put out there at Analyst Day, just a year and a half ago or so. Operator And that concludes the question-and-answer session. I'll turn the call back over to the speakers for final remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer This is Kevin. I'll finish up today. We want to thank all of you for participating on our call. Assuredly under circumstance is far different from what you'd envision during our 2019 Q4 and year-end call last February. As I watch the news, night in and out, I've seen the toll that this virus is taken on communities all over the world and recognize that when this pandemic ends, our world, human interaction and the administration of healthcare will be forever changed. DexCom is very fortunate to be in a strong position during this pandemic, and I personally feel a sense of obligation to operate from that strength to serve the needs of others in this time of heightened anxiety. With stay-at-home orders and school closures, we realize our employees' day-to-day lives have been appended causing significant stress. We've attempted to reduce that stress by offering increased pay to essential on-site workers and promoting increased safety measures to best protect all DexCom employees. We recognize that diabetes doesn't take a break even for pandemics, economic slowdowns or high unemployment. Now more than ever, we have a responsibility to patients that have supported DexCom over the years and made us the company that we are today. We're therefore working quickly on the rollout of our patient assistance program to provide access to DexCom CGM for the many individuals who have lost their jobs as a result of COVID-19. In addition, we realized helping a patient staying can control their blood glucose, also assist family members and clinicians providing immediate relief to our healthcare system. Our core belief remains unchanged. If we do our best to take care of our patients, the business will always move in the right direction. Every intensive insulin-using patient should have access to real-time CGM. We'll work tirelessly to make that happen. COVID-19 has had a disproportionate impact on the diabetes community. This awful virus is also attacking the pancreas of people without diabetes. As a result, brave frontline responders are having to repeatedly gown up with full PPE to administer fingersticks to test patient's blood glucose levels. We worked hard with the FDA to provide these heroes with better tools to treat patients and reduce healthcare workers' overall risk infection. How our employees have rallied to this cause has been nothing short of amazing. In short order, we've created new training materials, stood up a specialized technical support group, procured and configured thousands of cellphones for use in this environment at a cost in excess of $1 million, and developed a separate commercial structure to launch G6 in this market at significantly reduced prices. We are making a significant investment here. Our commitment to connectivity, enable multiple platforms to consume our data and cloud-based tools for healthcare providers has become even more important than we envision when we blaze this trail many, many years ago. As the work from the team at the Barbara Davis Center in Colorado indicates, the unique features of our CGM and connected software solutions are playing an important role in driving care from newly diagnosed people with diabetes during this crisis. We are hopeful that the expanded use of telemedicine during the crisis can ultimately provide avenues for greater access to healthcare over the long-term with DexCom CGM providing an essential tool in the process. In addition, our efforts to assist hospitals worldwide is a big investment, as I said earlier. We intend to take all of the data that we can gather, generated during this time, to accelerate the development and launch of a hospital-based system that better meets the needs of healthcare providers in our current ambulatory product. It's often during difficult times that the two character of an individual or company is revealed. Our hope is that our efforts during this time will provide comfort to the many stakeholders that we serve and that our character of DexCom will stand out brightly. On behalf of our employees, I'm proud to lead these efforts. Thanks. Goodbye. Operator [Operator signoff] Duration: 67 minutes Call participants: Sean Christensen -- Senior Investor Relations Manager Kevin Sayer -- Chairman, President, and Chief Executive Officer Quentin Blackford -- Chief Operating Officer and Chief Financial Officer Steve Pacelli -- Executive Vice President of Strategy and Corporate Development Robbie Marcus -- J.P. Morgan -- Analyst Danielle Antalffy -- SVB Leerink-- Analyst Jeff Johnson -- Baird -- Analyst Matthew O'Brien -- Piper Jaffray -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Margaret Kaczor -- William Blair & Company -- Analyst David Lewis -- Morgan Stanley -- Analyst Joanne Wuensch -- Citi -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Raj Denhoy -- Jefferies -- Analyst Jayson Bedford -- Raymond James -- Analyst Ryan Blicker -- Cowen and Company -- Analyst Chris Pasquale -- Guggenheim Securities -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Ravi Misra -- Berenberg Capital Markets -- Analyst Chris Cooley -- Stephens Inc. -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Guggenheim Maintains Buy on DexCom, Raises Price Target to $395"", ""82 Stocks Moving In Wednesday's Mid-Day Session"", ""Citigroup Maintains Buy on DexCom, Raises Price Target to $361"", ""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $375"", ""Stifel Maintains Buy on DexCom, Raises Price Target to $385"", ""JP Morgan Maintains Overweight on DexCom, Raises Price Target to $360"", ""Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $377"", ""The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda"", ""Oppenheimer Maintains Outperform on DexCom, Raises Price Target to $360"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $360"", ""DexCom shares are trading higher after the company reported better-than-expected Q1 sales results."", ""35 Stocks Moving in Wednesday's Pre-Market Session"", ""How Hedge Funds Beat the S&P 500 in the First Quarter Hedge funds quickly lowered their exposure to risk in February, data from Jefferies shows."", ""Here are the stock market\u2019s biggest winners on Wednesday as investors see new hope Good news from Gilead Sciences and a statement from the Federal Reserve offset some grim economic numbers Good news from Gilead Sciences and a statement from the Federal Reserve offset some grim economic numbers""]"
DXCM,2020-04-30,85.75,87.7425,83.75,83.8,"[""108 Biggest Movers From Yesterday"", ""The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $335"", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $335"", ""The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1"", ""108 Biggest Movers From Yesterday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""UBS Maintains Neutral on DexCom, Raises Price Target to $335"", ""The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1"", ""108 Biggest Movers From Yesterday""]"
DXCM,2020-05-01,82.75,85.8175,82.099,85.38,"[""The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO"", ""Watching Dexcom Shares As Hearing David Einhorn Q1 Letter To Greenlight Investors Shows Covered Short In Stock"", ""Watching Dexcom Shares As Hearing David Einhorn Q1 Letter To Greenlight Investors Shows Covered Short In Stock"", ""The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO"", ""3 \""Non-Coronavirus Stocks\"" That Would Have Doubled Your Money Over the Last Year \""Coronavirus stocks,\"" the stocks of companies that make products and provide services that are experiencing strong demand stemming from the COVID-19 pandemic, have been getting a ton of attention. (Indeed, like many financial writers, I recently wrote an article on the topic, outlining 8 top coronavirus stocks.) However, some stocks that don't fall into this category have also been strong performers in recent months, as well as over the long term. For instance, you'd have more than doubled your money had you invested in these \""non-coronavirus stocks\"" a year ago: diabetes specialists Insulet and DexCom and real estate investment trust Safehold. Image source: Getty Images. Three non-coronavirus stocks: Key stats COMPANY MARKET CAP FORWARD P/E PROJECTED ANNUALIZED 5-YEAR EPS GROWTH* YTD 2020 RETURN (LOSS) 1-YEAR RETURN 10-YEAR RETURN Insulet (NASDAQ: PODD) $12.6 billion 357 172% 16.7% 132% 1,350% DexCom (NASDAQ: DXCM) $31 billion 155 52% 53.2% 177% 2,960% Safehold (NYSE: SAFE) $2.9 billion 44.3 36.9% 46.9% 133% N/A S&P 500 -- -- -- (9.3%) 0.9% 202% Data sources: Yahoo! Finance and YCharts. Data as of April 30, 2020. P/E = price-to-earnings ratio. EPS = earnings per share. YTD = year to date. *Wall Street's consensus estimate. The diabetes stocks If you're looking for a growth market in which to invest, I'd suggest the diabetes space. Unfortunately, the incidence of the disease (both type 1 and type 2) has been rising around the world. Indeed, many healthcare experts consider diabetes an epidemic in the United States and many other countries. Two top names in the diabetes space are medical-device makers Insulet and DexCom. Insulet makes the leading tubeless insulin pump, the Omnipod, and DexCom produces a continuous glucose monitoring (CGM) system, the G6. In fact, these two companies are partners. In the second half of this year, Insulet plans to launch its Horizon automated insulin delivery system, which uses a DexCom CGM. Moreover, the Horizon system's insulin pump will be controlled by a smartphone. On Tuesday, DexCom reported its first-quarter 2020 results, which crushed Wall Street's expectations. Sales rose 44% year over year to $405.1 million, sailing by the $357.6 million analyst consensus estimate. Adjusted earnings per share (EPS) landed at $0.44, compared to the year-ago period's loss of $0.05 per share. This result demolished the consensus estimate of $0.14. Insulet is scheduled to report first-quarter results on Thursday, May 7, after market close. Image source: Getty Images. Safehold Safehold is a real estate investment trust (REIT) that specializes in commercial property (but no retail) ground leases in the 25 largest markets in the U.S. It buys the land underlying commercial real estate projects, which it leases back to the owners of the structures on the land. The company uses the rental income to grow the business and pay shareholders a modest dividend, currently yielding 1.2%. Safehold was founded in 2016 and held its initial public offering in 2017, so it's relatively small for a REIT and doesn't have much of a track record. That said, it seems worth watching. Like most companies, Safehold expects to have some near-term pain due to the pandemic. By the end of the first quarter, deals were largely on hold across the commercial real estate market. However, management also believes the company should bounce back quickly once the dust settles a bit. Here's what CEO Jay Sugarman had to say during the April 23 first-quarter earnings call: We continue to be engaged in conversations with customers on a number of fronts, and would expect our better price, more efficient capital to be in demand once there's more clarity about the future. We expect deals put on hold may very well come back, and that existing customers will find the opportunities to deploy capital and seek our help in capitalizing those opportunities. ... As for the existing portfolio, all of our ground leases paid [their rent] in April. In the first quarter, Safehold's revenue soared 84% year over year to $40.2 million. Net income jumped 56% to $17.4 million, which translated to earnings per share coming in flat with the year-ago period at $0.36. (The number of shares outstanding increased, which is why EPS was only flat while net income rose significantly.) 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Watching Dexcom Shares As Hearing David Einhorn Q1 Letter To Greenlight Investors Shows Covered Short In Stock"", ""The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO""]"
DXCM,2020-05-04,85.765,88.21,84.8575,88.1275,"[""How This Top Mutual Fund Found Stocks That Defied The Covid-19 Downturn"", ""How This Top Mutual Fund Found Stocks That Defied The Covid-19 Downturn"", ""How This Top Mutual Fund Found Stocks That Defied The Covid-19 Downturn""]"
DXCM,2020-05-05,89.9875,93.6025,87.7731,91.07,"[""The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout"", ""Stocks That Hit 52-Week Highs On Tuesday"", ""Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session."", ""Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session."", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout"", ""Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session."", ""Stocks That Hit 52-Week Highs On Tuesday"", ""The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout""]"
DXCM,2020-05-06,92.81,95.3444,91.3804,91.63,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares"", ""Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More"", ""The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""S&P Dow Jones Indices Announces 'DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600'"", ""S&P Dow Jones Indices Announces 'DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600'"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle"", ""Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares"", ""Salesforce.com To Replace Allergan In S&P100 (RTTNews) - S&P Dow Jones Indices said that S&P 500 constituent Salesforce.com (CRM) will replace Allergan in the S&P 100. DexCom Inc. (DXCM) will replace Allergan plc (AGN) in the S&P 500. S&P 500 and 100 constituent AbbVie Inc. (ABBV) is acquiring Allergan in a transaction expected to be completed soon pending final conditions. S&P MidCap 400 constituent Domino's Pizza Inc. (DPZ) will replace Capri Holdings Ltd. (CPRI) in the S&P 500, STORE Capital Corp. (STOR) will replace Domino's Pizza in the S&P MidCap 400, and Capri Holdings will replace Acorda Therapeutics Inc. (ACOR) in the S&P SmallCap 600. S&P Dow Jones Indices will make the changes effective prior to the opening on Tuesday, May 12. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P Dow Jones Indices Announces 'DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600'"", ""Stocks That Hit 52-Week Highs On Wednesday"", ""The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle"", ""Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.\u2013 million of Shares"", ""Domino's Pizza, DexCom to join S&P 500 S&P Dow Jones Indices said late Wednesday that Domino's Pizza Inc. will join the S&P 500 index , replacing Capri Holdings Ltd. . With the change, Store Capital Corp. will move to the S&P MidCap 400, S&P said. Additionally, DexCom Inc. will replace Allergan Plc in the S&P 500, and S&P 500 constituent Salesforce.com will replace Allergan in the S&P 100, the company said. AbbVie Inc. is buying Allergan in a deal expected to be completed soon. The changes are effective before the bell on May 12, S&P Dow Jones said.""]"
DXCM,2020-05-07,97.9575,102.122,97.2525,101.09,"[""The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500"", ""DexCom shares are trading higher after S&P Dow Jones Indices announced DexCom is set to join the S&P 500."", ""Stocks That Hit 52-Week Highs On Thursday"", ""Stocks That Hit 52-Week Highs On Thursday"", ""DexCom shares are trading higher after S&P Dow Jones Indices announced DexCom is set to join the S&P 500."", ""The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500"", ""Stock Aleret: DexCom Touches New High (RTTNews) - Shares of DexCom, Inc. (DXCM), that makes continuous glucose monitoring systems have touched its 52 week high of $400.79 on Thursday. The stock is currently at 393.69, more than 7% up. DexCom will be added to the S&P 500, effective Tuesday, May 12, replacing Allergan (AGN). On May 4, the company said, its G6 Continuous Glucose Monitoring has been temporarily authorized by Health Canada to monitor patients during the COVID-19 pandemic. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Thursday"", ""DexCom shares are trading higher after S&P Dow Jones Indices announced DexCom is set to join the S&P 500."", ""The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500""]"
DXCM,2020-05-08,101.775,103.658,99.5543,101.375,"[""GQ Asset Management, LLC Buys Dollar General Corp, Tesla Inc, DexCom Inc, Sells iShares Core U. ..."", ""The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda"", ""The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda"", ""GQ Asset Management, LLC Buys Dollar General Corp, Tesla Inc, DexCom Inc, Sells iShares Core U. ..."", ""Coronavirus Pandemic Propels User Growth for Livongo Health Shares of Livongo Health (NASDAQ: LVGO), maker of remote patient-monitoring solutions, soared 12% to an all-time high Thursday after the company reported first-quarter results. Revenue grew 115% to $68.8 million, better than the preliminary results of $65.5 million to $66.5 million that the company released a month ago. GAAP net loss was $5.6 million, or $0.06 per share, as compared to a $14.4 million loss in the period a year ago. Excluding amortization, some one-time tax charges, and over $8 million in stock compensation expense, the company had non-GAAP earnings of $0.03, while analysts were expecting a loss on that basis. Livongo makes a virtual-care platform that enables remote monitoring of patients with chronic health problems. Its smartphone-based software collects information from wirelessly connected monitors, provides information to patients, and connects them to health coaches and medical professionals. The company has partnered with DexCom for blood glucose monitoring in diabetes patients and connects to blood-pressure monitors for patients with hypertension (high blood pressure). Image source: Getty Images. COVID-19 is accelerating Livongo's virtual-care solutions The company said on the conference call that the pandemic accelerated the virtual-care delivery model, and the company's user numbers certainly bear that out. Livongo enrolled 105,827 new members in the first quarter after adding only 14,868 in Q4. There are now 328,510 enrolled Livongo members, about twice the total of a year ago. People with chronic health conditions such as diabetes and hypertension are at greater risk for complications with COVID-19, so Livongo's corporate clients, which are healthcare systems and employers that sign contracts to make the platform available to their members, looked to the company to help protect their most vulnerable populations. Livongo signed a record 380 new clients in the quarter for a total of 1,252 -- 77% growth year over year. The company also said it had recently signed one of the largest contracts in its history. The company was selected by the Government Employee Health Association, a non-profit provider of medical and dental plans covering over 2 million federal employees, retirees, and their dependents. Livongo has added solutions for diabetes prevention and behavioral health, and growth from those new products should add to strong growth in the company's core product for diabetes monitoring. According to the chief financial officer, 18% of its clients have bought more than one solution from Livongo, indicating that it's having some success cross-selling its newer offerings. Looking forward Livongo expects the rapid growth to continue this year. The company guided for revenue in the second quarter between $73 million and $75 million, compared with the analyst consensus of $73.7 million. For the full year, Livongo raised its revenue forecast to $290 million to $303 million, or growth of 70% to 78%, compared with the 73% growth Wall Street is expecting. The company says that it expects to be profitable in 2021 on an \""adjusted EBITDA [earnings before interest, taxes, depreciation, and amortization]\"" basis, which many people would say doesn't quite meet the standard of real profit. But the company is in strong financial condition, with $219 million in cash and no long-term debt, and it only consumed $10 million in operating cash flow in Q1. Livongo was on a path of rapid growth before this, but results in the first quarter showed that the COVID-19 pandemic is another strong tailwind for the healthcare company. Investors were appreciating that and bidding up the stock price Thursday. 10 stocks we like better than Livongo Health Inc When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Livongo Health Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Crumly owns shares of DexCom. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda"", ""GQ Asset Management, LLC Buys Dollar General Corp, Tesla Inc, DexCom Inc, Sells iShares Core U. ...""]"
DXCM,2020-05-11,101.012,107.0,100.9,105.34,"[""' Stocks Growing Capex Fast"", ""Aft, Forsyth & Company, Inc. Buys DexCom Inc, Akamai Technologies Inc, CSL, Sells iShares U. ..."", ""DexCom Announces Proposed Offering of $850M of Convertible Senior Notes"", ""Stocks That Hit 52-Week Highs On Monday"", ""'Jim Cramer reviews top 10 stocks 'for this difficult moment' on the 'Cramer Covid-19 Index'' -CNBC"", ""Stocks That Hit 52-Week Highs On Monday"", ""DexCom Announces Proposed Offering of $850M of Convertible Senior Notes"", ""Aft, Forsyth & Company, Inc. Buys DexCom Inc, Akamai Technologies Inc, CSL, Sells iShares U. ..."", ""' Stocks Growing Capex Fast"", ""After Hours Most Active for May 11, 2020 : CPRI, STOR, DXCM, DBX, DPZ, EBAY, CMCSA, CHNG, PFE, CBAY, LC, KGC The NASDAQ 100 After Hours Indicator is down -7.13 to 9,291.79. The total After hours volume is currently 104,276,665 shares traded. The following are the most active stocks for the after hours session: Capri Holdings Limited (CPRI) is +0.35 at $14.66, with 12,668,284 shares traded. CPRI's current last sale is 69.81% of the target price of $21. STORE Capital Corporation (STOR) is unchanged at $20.00, with 9,233,211 shares traded. STOR's current last sale is 80% of the target price of $25. DexCom, Inc. (DXCM) is -1.7 at $419.66, with 8,666,899 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2020. The consensus EPS forecast is $0.28. , following a 52-week high recorded in today's regular session. Dropbox, Inc. (DBX) is -0.18 at $22.76, with 4,274,115 shares traded. As reported by Zacks, the current mean recommendation for DBX is in the \""buy range\"". Domino's Pizza Inc (DPZ) is -0.48 at $377.01, with 4,115,569 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2020. The consensus EPS forecast is $2.02. As reported by Zacks, the current mean recommendation for DPZ is in the \""buy range\"". eBay Inc. (EBAY) is unchanged at $42.13, with 3,780,449 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2020. The consensus EPS forecast is $0.66. EBAY's current last sale is 97.98% of the target price of $43. Comcast Corporation (CMCSA) is -0.16 at $36.00, with 3,177,209 shares traded. As reported by Zacks, the current mean recommendation for CMCSA is in the \""buy range\"". Change Healthcare Inc. (CHNG) is -0.001 at $11.55, with 2,670,927 shares traded. CHNG's current last sale is 64.16% of the target price of $18. Pfizer, Inc. (PFE) is -0.01 at $38.09, with 2,647,791 shares traded. PFE's current last sale is 96.43% of the target price of $39.5. CymaBay Therapeutics Inc. (CBAY) is +0.45 at $2.29, with 2,215,620 shares traded. GlobeNewswire Reports: CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update LendingClub Corporation (LC) is unchanged at $5.81, with 2,142,685 shares traded. LC's current last sale is 27.02% of the target price of $21.5. Kinross Gold Corporation (KGC) is unchanged at $6.90, with 1,794,530 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2020. The consensus EPS forecast is $0.14. KGC's current last sale is 97.18% of the target price of $7.1. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Rocketed Higher in April What happened Medical device company DexCom (NASDAQ: DXCM) saw its shares gain a stately 31.5% during the month of April, according to data from S&P Global Market Intelligence. The company's shares burst higher last month for two inter-related reasons. So what First up, DexCom's stock lost as much as 30% of its value in March in response to the COVID-19 sell-off. Bargain hunters clearly viewed this dip as a once-in-a-lifetime buying opportunity. Underscoring this point, the biotech's shares have now gained an astounding 112% since hitting a two-year low in late March. That's a nearly unheard of type of move for a large-cap stock. Image Source: Getty Images. Secondly, DexCom crushed Wall Street's consensus first-quarter revenue forecast toward the end of April. Thanks to strong demand for its continuous glucose monitoring (CGM) devices, DexCom topped analysts' Q1 revenue estimate by a staggering 13.3%. While the company couldn't rule out negative impacts from the ongoing COVID-19 pandemic, DexCom has yet to experience any significant headwinds from this outbreak. Not many large-cap healthcare companies can make that claim right now. Now what Is DexCom's stock still a strong buy? That's a hard question to answer. DexCom's stock has repeatedly defied conventional wisdom when it comes to classic valuation metrics. As proof, the company's shares have consistently been valued at over 15 times forward-looking sales. DexCom's incredible run, however, may be close to hitting a high-water mark after this latest surge. The stock, after all, is now valued at an astronomical 17.3 times 2021 projected sales. That's an exceedingly rich valuation, even for an ultra high-growth company like DexCom. As such, it might be a good idea to wait for a more attractive entry point. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""'Jim Cramer reviews top 10 stocks 'for this difficult moment' on the 'Cramer Covid-19 Index'' -CNBC"", ""Stocks That Hit 52-Week Highs On Monday"", ""DexCom Announces Proposed Offering of $850M of Convertible Senior Notes"", ""Aft, Forsyth & Company, Inc. Buys DexCom Inc, Akamai Technologies Inc, CSL, Sells iShares U. ..."", ""' Stocks Growing Capex Fast""]"
DXCM,2020-05-12,105.075,105.442,102.525,102.7,"[""Winners Keep On Winning: Investing In Outperforming Stocks"", ""'Jim Cramer reviews top 10 stocks 'for this difficult moment' on the 'Cramer Covid-19 Index'' -CNBC"", ""The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings"", ""The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings"", ""Winners Keep On Winning: Investing In Outperforming Stocks"", ""The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings"", ""Winners Keep On Winning: Investing In Outperforming Stocks""]"
DXCM,2020-05-13,103.232,103.632,100.5,101.8,"[""Andra AP-fonden Buys Centene Corp, Truist Financial Corp, ViacomCBS Inc, Sells ViacomCBS Inc, ..."", ""Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?"", ""Andra AP-fonden Buys Centene Corp, Truist Financial Corp, ViacomCBS Inc, Sells ViacomCBS Inc, ..."", ""Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?"", ""Andra AP-fonden Buys Centene Corp, Truist Financial Corp, ViacomCBS Inc, Sells ViacomCBS Inc, ..."", ""Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?""]"
DXCM,2020-05-14,100.388,102.178,99.18,100.762,"[""Wells Fargo Initiates Coverage On DexCom with Equal-Weight Rating, Announces Price Target of $420"", ""Benzinga's Top Upgrades, Downgrades For May 14, 2020"", ""Benzinga's Top Upgrades, Downgrades For May 14, 2020"", ""Wells Fargo Initiates Coverage On DexCom with Equal-Weight Rating, Announces Price Target of $420"", ""Benzinga's Top Upgrades, Downgrades For May 14, 2020"", ""Wells Fargo Initiates Coverage On DexCom with Equal-Weight Rating, Announces Price Target of $420""]"
DXCM,2020-05-15,99.7625,104.745,99.2125,104.432,"[""Jackson Square Capital, Llc Buys Bristol-Myers Squibb Company, Adobe Inc, Zoom Video ..."", ""Jackson Square Capital, Llc Buys Bristol-Myers Squibb Company, Adobe Inc, Zoom Video ..."", ""Jackson Square Capital, Llc Buys Bristol-Myers Squibb Company, Adobe Inc, Zoom Video ...""]"
DXCM,2020-05-18,106.255,107.148,103.309,103.61,"[""Here's Why You Should Retain Masimo Stock (MASI) For Now"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Stocks That Hit 52-Week Highs On Monday"", ""Stocks That Hit 52-Week Highs On Monday"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Here's Why You Should Retain Masimo Stock (MASI) For Now"", ""Strange: Bullish DXCM Analysts Actually See -14.21% Downside Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM \u2014 averaging the work of 18 analysts \u2014 reveals an average price target of $358.39/share. That's a whopping -14.21% below where DXCM has been trading recently at $417.73/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 15 15 15 14 Buy ratings: 1 1 1 1 Hold ratings: 4 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.45 1.37 1.37 1.39 The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.45 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that \u2014 a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $420.00. And then on the other side of the spectrum one analyst has a target as low as $190.00. The standard deviation is $49.147. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes \u2014 much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $358.39/share, the -14.21% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. The Top 25 Broker Analyst Picks of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks That Hit 52-Week Highs On Monday"", ""Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?"", ""Here's Why You Should Retain Masimo Stock (MASI) For Now""]"
DXCM,2020-05-19,102.98,104.521,99.9225,101.142,"[""The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering"", ""The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering"", ""The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering""]"
DXCM,2020-05-20,102.448,102.746,98.7837,99.99,"[""Here's Why You Should Retain Merit Medical (MMSI) for Now"", ""Here's Why You Should Retain Merit Medical (MMSI) for Now"", ""Here's Why You Should Retain Merit Medical (MMSI) for Now""]"
DXCM,2020-05-21,99.8275,100.802,97.7125,99.8425,
DXCM,2020-05-22,99.185,101.385,96.78,101.312,
DXCM,2020-05-26,102.122,102.938,95.02,95.4475,"[""Frank Sands Adds 5 Stocks to Portfolio"", ""Trump Says Reached 'Breakthrough' Agreement On Cost Of Insulin"", ""Trump Says Reached 'Breakthrough' Agreement On Cost Of Insulin"", ""Frank Sands Adds 5 Stocks to Portfolio"", ""BUZZ-U.S. STOCKS ON THE MOVE-Alliance Data Systems, Alibaba Group, Dexcom, Can Fite Biofarma, U.S. travel firms Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks jumped and the S&P 500 breached 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions .N At 10:44 ET, the Dow Jones Industrial Average .DJI was up 2.49% at 25,073.63. The S&P 500 .SPX was up 1.89% at 3,011.35 and the Nasdaq Composite .IXIC was up 1.14% at 9,431.314. The top three S&P 500 .PG.INX percentage gainers: ** Alliance Data Systems Corp , up 16% ** Norwegian Cruise Line Holdings Ltd , up 13.2% ** United Airlines Holdings Inc , up 12.7% The top three S&P 500 .PL.INX percentage losers: ** Dexcom Inc , down 4.3% ** Take-Two Interactive Software Inc , down 3.6% ** Regeneron Pharmaceuticals Inc , down 3.5% The top two NYSE .PG.N percentage gainers: ** Amplify Seymour Cannabis ETF , up 24.7% ** Fly Leasing Ltd , up 23.3% The top three NYSE .PL.N percentage losers: ** ProShares UltraShort MSCI Brazil Capped , down 19.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 17.4% ** Can Fite Biofarma Ltd , down 15.3% The top three Nasdaq .PG.O percentage gainers: ** MMtec Inc , up 97.3% ** Luckin Coffe Inc , up 62.6% ** Argenx SE , up 34.1% The top three Nasdaq .PL.O percentage losers: ** Qualigen Therapeutics Inc, down 29.7% ** Genetic Technologies Ltd , down 16.3% ** Medigus Ltd , down 13.6% ** American Airlines Groups Inc AAL.O: up 10.3% ** United Airlines Holdings Inc UAL.O: up 12.7% ** Expedia Group Inc EXPE.O: up 9.0% BUZZ-U.S. travel firms fly on hopes of easing travel restriction in Europe ** JPMorgan Chase & Co JPM.N: up 5.2% ** Goldman Sachs Group Inc GS.N: up 6.2% BUZZ-U.S. Banks: Rise as yields edge higher ** Hewlett Packard Enterprise Co HPE.N: up 3.8% BUZZ-Rises as JPM upgrades on IT spending recovery ** Novavax Inc NVAX.O: up 11.8% BUZZ-Surges after starting clinical trial of COVID-19 vaccine candidate ** Tuesday Morning Corp TUES.O: down 17.5% BUZZ-Plunges on report of bankruptcy filing preparations ** Merck & Co Inc MRK.N: up 1.8% BUZZ-Shares rise on plans to develop COVID-19 vaccine, antiviral drug ** Exxon Mobil Corp XOM.N: up 3.0% ** Chevron Corp CVX.N: up 4.2% ** Halliburton Co HAL.N: up 2.8% ** Occidental Petroleum Corp OXY.N: up 2.9% BUZZ-Oil and gas stocks gain as confidence in supply cut grows ** Alibaba Group Holdings Inc BABA.N: up 2.6% BUZZ-Street View: Alibaba's robust growth remains very well intact ** Regeneron Pharmaceuticals Inc REGN.O: down 3.5% BUZZ-Buyback of stake from Sanofi positive for both companies - analysts BUZZ-Street View: Sanofi's Regeneron stake sale positive, unsurprising ** Sorrento Therapeutics Inc SRNE.O: up 5.3% BUZZ-Sorrento rises on FDA nod for clinical trial of protein deposition disorder treatment ** BioLine RX Ltd BLRX.O: down 30.1% BUZZ-BioLine RX drops on deep-discounted stock deal ** DouYu International Holdings Ltd DOYU.N: up 15.3% BUZZ-Rises on quarterly revenue beat ** Duke Energy Corp DUK.N: up 0.8% ** CenterPoint Energy Inc CNP.N: up 4.9% BUZZ-Utilities sector: Left behind but holding up well - CS ** Sky Solar Holdings Ltd SKYS.O: up 18.9% BUZZ-Surges on buyout proposal ** Johnson & Johnson JNJ.N: up 1.2% BUZZ-Bowel syndrome drug cost surpasses budget impact threshold- ICER ** Diffusion Pharmaceuticals Inc DFFN.O: up 16.9% BUZZ-Diffusion Pharma up on FDA's response to proposed COVID-19 treatment trial plan ** Cellectar Biosciences Inc CLRB.O: up 10.6% BUZZ-Cellectar rises on FDA fast-track tag for cancer therapy ** IZEA Worldwide Inc IZEA.O: up 38.5% BUZZ-IZEA Worldwide surges on strong sales, marketing service deal The 11 major S&P 500 sectors: Communication Services .SPLRCL up 1.53% Consumer Discretionary .SPLRCD up 1.84% Consumer Staples .SPLRCS up 1.15% Energy .SPNY up 3.54% Financial .SPSY up 4.42% Health .SPXHC up 0.65% Industrial .SPLRCI up 3.98% Information Technology .SPLRCT up 0.91% Materials .SPLRCM up 2.63% Real Estate .SPLRCR up 2.79% Utilities .SPLRCU up 2.30% (Compiled by Shradha Singh in Bengaluru) ((Shradha.Singh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tuesday Sector Laggards: Healthcare, Technology & Communications The worst performing sector as of midday Tuesday is the Healthcare sector, up 1.1%. Within that group, DexCom Inc (Symbol: DXCM) and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) are two of the day's laggards, showing a loss of 5.8% and 5.4%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.7% on the day, and down 1.13% year-to-date. DexCom Inc, meanwhile, is up 74.60% year-to-date, and Regeneron Pharmaceuticals, Inc. is up 43.65% year-to-date. Combined, DXCM and REGN make up approximately 2.1% of the underlying holdings of XLV. The next worst performing sector is the Technology & Communications sector, higher by 1.5%. Among large Technology & Communications stocks, Take-Two Interactive Software, Inc. (Symbol: TTWO) and Activision Blizzard, Inc. (Symbol: ATVI) are the most notable, showing a loss of 5.5% and 3.5%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is up 0.7% in midday trading, and up 6.42% on a year-to-date basis. Take-Two Interactive Software, Inc., meanwhile, is up 8.48% year-to-date, and Activision Blizzard, Inc. is up 19.38% year-to-date. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, nine sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Financial +6.2% Industrial +5.4% Materials +5.0% Consumer Products +3.9% Services +3.7% Energy +3.7% Utilities +2.3% Technology & Communications +1.5% Healthcare +1.1% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-IZEA Worldwide, Diffusion Pharma, DouYu International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks jumped and the S&P 500 crossed 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions. .N At 12:59 ET, the Dow Jones Industrial Average .DJI was up 2.67% at 25,119.36. The S&P 500 .SPX was up 1.89% at 3,011.19 and the Nasdaq Composite .IXIC was up 1.00% at 9,417.757. The top three S&P 500 .PG.INX percentage gainers: ** Alliance Data Systems Corp ADS.N, up 17.5% ** Norwegian Cruise Line Holdings Ltd NCLH.N, up 15.1% ** United Airlines Holdings Inc UAL.O, up 14.3% The top three S&P 500 .PL.INX percentage losers: ** Dexcom Inc DXCM.O, down 5.6% ** Take-Two Interactive Software Inc TTWO.O, down 5.2% ** Newmont Corp NEM.N, down 4.8% The top three NYSE .PG.N percentage gainers: ** Fly Leasing Ltd FLY.N, up 33.9% ** Emerald Holding Inc EEX.N, up 28.6% ** Amplify ETF Tr/Seymour Cannabis ETF CNBS.N, up 26.1% The top three NYSE .PL.N percentage losers: ** Direxion Daily S&P 500 High Beta Bear 3X Shares HIBS.N, down 18.6% ** ProShares UltraShort MSCI Brazil Capped BZQ.N, down 15.5% ** Can Fite Biofarma Ltd CANF.N, down 15.3% The top three Nasdaq .PG.O percentage gainers: ** MMtec Inc MTC.O, up 84.5% ** Luckin Coffee Inc LK.O, up 52.2% ** Argenx SE ARGX.O, up 36.6% The top three Nasdaq .PL.O percentage losers: ** Wins Finance Holdings Inc WINS.O, down 31.4% ** Qualigen Therapeutics Inc QLGN.O, down 29.5% ** Medigus Ltd MDGS.O, down 16.2% ** IZEA Worldwide Inc IZEA.O: up 27.4% BUZZ-Surges on strong sales, marketing service deal ** Cellectar Bioscience Inc CLRB.O: up 4.2% BUZZ-Rises on FDA fast-track tag for cancer therapy ** Diffusion Pharmaceutical Inc DFFN.O: up 8.7% BUZZ-Up on FDA's response to proposed COVID-19 treatment trial plan ** Goldman Sachs Group Inc GS.N: up 7.4% ** JPMorgan Chase & Co JPM.N: up 7.2% ** Citigroup Inc C.N: up 9.0% ** Wells Fargo & Co WFC.N: up 7.8% ** Bank of America Corp BAC.N: up 7.0% ** Morgan Stanley MS.N: up 7.0% BUZZ-U.S. banks: Rise as yields edge higher ** Sky Solar Holdings Ltd SKYS.O: up 17.7% BUZZ-Surges on buyout proposal ** DouYu International Holdings Ltd DOYU.O: up 20.0% BUZZ-Rises on quarterly revenue beat ** Kala Pharmaceuticals Inc KALA.O: up 0.9% BUZZ-Up on FDA nod to resubmitted application for eye drug ** Sorrento Therapeutics Inc SRNE.O: up 3.9% BUZZ-Rises on FDA nod for clinical trial of protein deposition disorder treatment ** Johnson & Johnson JNJ.N: up 0.9% BUZZ-Bowel syndrome drug cost surpasses budget impact threshold- ICER ** Adapthealth Corp AHCO.O: up 5.1% BUZZ-Gains on agreement to acquire diabetes device supplier ** 1Life Healthcare Inc ONEM.O: down 9.7% BUZZ-Falls on planned $250 mln convertible offering ** Marvell Technology Group Ltd MRVL.O: up 3.3% BUZZ-Hits over 14-yr high as Susquehanna lifts PT on 5G boost ** AutoZone Inc AZO.N: up 1.1% BUZZ-Rises as same-store sales improve ** Hibbett Sports Inc HIBB.O: up 2.6% BUZZ-Rises as retailer says current-quarter sales are \""robust\"" ** Anaplan Inc PLAN.N: down 6.5% BUZZ-Falls on tepid Q2 revenue forecast ** Novavax Inc NVAX.O: up 10.0% BUZZ-Surges after starting clinical trial of COVID-19 vaccine candidate ** Gilead Sciences Inc GILD.O: up 1.1% BUZZ-SunTrust upgrades on remdesivir sales potential ** Hewlett Packard Enterprise Co HPE.N: up 3.1% BUZZ-Rises as JPM upgrades on IT spending recovery ** Tuesday Morning Corp TUES.O: down 7.0% BUZZ-Plunges on report of bankruptcy filing preparations ** Merck & Co Inc MRK.N: up 2.3% BUZZ- Rises on plans to develop COVID-19 vaccine, antiviral drug ** Chevron Corp CVX.N: up 3.2% ** Exxon Mobil Corp XOM.N: up 2.9% ** Apache Corp APA.N: up 3.9% ** WPX Energy Inc WPX.N, RIC: up 1.3% ** Callon Petroleum Co CPE.N: up 1.4% ** Occidental Petroleum Corp OXY.N: up 1.1% ** Schlumberger NV SLB.N: up 4.6% ** Halliburton Co HAL.N: up 2.6% ** TechnipFMC FTI.N: up 6.0% ** Baker Hughes Co BKR.N: up 4.7% BUZZ-Oil and gas stocks gain as confidence in supply cut grows ** Alibaba Group Holdings Inc BABA.N: up 1.8% BUZZ-Street View: Alibaba's robust growth remains very well intact ** American Airlines Groups Inc AAL.O: up 13.8% ** United Airlines Holdings Inc UAL.O: up 14.3% ** Expedia Group Inc EXPE.O: up 6.9% ** Tripadvisor Inc TRIP.O: up 14.0% ** Marriott International Inc MAR.O: up 4.7% BUZZ-U.S. travel firms fly on hopes of easing travel restriction in Europe The 11 major S&P 500 sectors: Communication Services .SPLRCL up 1.34% Consumer Discretionary .SPLRCD up 1.69% Consumer Staples .SPLRCS up 1.02% Energy .SPNY up 2.95% Financial .SPSY up 5.12% Health .SPXHC up 0.71% Industrial .SPLRCI up 4.47% Information Technology .SPLRCT up 0.78% Materials .SPLRCM up 2.94% Real Estate .SPLRCR up 2.99% Utilities .SPLRCU up 1.90% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: REGN, NCLH In early trading on Tuesday, shares of Norwegian Cruise Line Holdings topped the list of the day's best performing components of the S&P 500 index, trading up 14.5%. Year to date, Norwegian Cruise Line Holdings has lost about 72.8% of its value. And the worst performing S&P 500 component thus far on the day is Regeneron Pharmaceuticals, trading down 5.2%. Regeneron Pharmaceuticals is showing a gain of 43.9% looking at the year to date performance. Two other components making moves today are DexCom, trading down 3.0%, and Carnival, trading up 12.9% on the day. VIDEO: S&P 500 Movers: REGN, NCLH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tuesday's ETF with Unusual Volume: SUSL The iShares ESG MSCI USA Leaders ETF is seeing unusually high volume in afternoon trading Tuesday, with over 1.3 million shares traded versus three month average volume of about 124,000. Shares of SUSL were up about 1.8% on the day. Components of that ETF with the highest volume on Tuesday were Norwegian Cruise Line, trading up about 13.8% with over 48.1 million shares changing hands so far this session, and Delta Air Lines, up about 9.8% on volume of over 41.9 million shares. Dexcom is lagging other components of the iShares ESG MSCI USA Leaders ETF Tuesday, trading lower by about 5.4%. VIDEO: Tuesday's ETF with Unusual Volume: SUSL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Trump Says Reached 'Breakthrough' Agreement On Cost Of Insulin"", ""Frank Sands Adds 5 Stocks to Portfolio""]"
DXCM,2020-05-27,95.05,95.05,84.065,89.9075,"[""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $450"", ""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $450"", ""BUZZ-U.S. STOCKS ON THE MOVE-Mersana, Moderna, StoneCo Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh A selloff in technology stocks dragged on the S&P 500 and Nasdaq on Wednesday, with investors also cautious about brewing U.S.-China tensions at a time when policymakers are attempting to revive the global economy from a coronavirus-driven slump..N At 11:01 ET, the Dow Jones Industrial Average .DJI was up 0.51% at 25,122.27. The S&P 500 .SPX was down 0.33% at 2,981.9 and the Nasdaq Composite .IXIC was down 1.91% at 9,161.87. The top three S&P 500 .PG.INX percentage gainers: ** Nordstrom Inc , up 10.6% ** Discover Financial Services , up 8.6% ** Gap Inc , up 7.8 % The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 11.6% ** Nvidia Corp , down 7.7% ** ServiceNow Inc , down 7.4% The top three NYSE .PG.N percentage gainers: ** UBS AG London B/ETRACS Monthly Pay , up 32.8% ** Microsectors U S Big Banks Index 3X EFN , up 32% ** Moog Inc , up 17.1% The top three NYSE .PL.N percentage losers: ** Microsectors U S Big Banks Index 3x , down 39.3% ** Renren Inc , down 18.5% ** Vapotherm Inc , down 14.5% The top three Nasdaq .PG.O percentage gainers: ** Euroseas Ltd , up 31.6% ** Mersana Therapeutics Inc , up 31.8% ** Liberty Media Corp , up 30.9% The top three Nasdaq .PL.O percentage losers: ** Arcturus Therapeutics Holdings Inc , down 32.6% ** Oasis Midstream Partners LP , down 24.2% ** La Jolla Pharmaceutical Co , down 24.1% ** HEICO Corp HEI.N: up 4.6% BUZZ-Jumps as margins hold steady even as sales fall ** Mersana Therapeutics Inc MRSN.O: up 32% BUZZ-Up on positive data from cancer therapy study ** Papa John's International Inc PZZA.O: up 1.6% ** Domino's Pizza Inc DPZ.N: up 1.0% BUZZ-Pizza chains heat up on upbeat comparable sales numbers ** Twitter Inc TWTR.N: down 4.6% ** Facebook Inc FB.O: down 3.9% BUZZ-Fall after Trump threatens to shutter social media ** Moderna Inc MRNA.O: down 16.5% BUZZ-Extends losses after COVID-19 vaccine news ** Ralph Lauren Corp RL.N: up 1.2% BUZZ-Rises on upbeat China outlook ** Photronics Inc PLAB.O: down 10.2% BUZZ-Falls on Q2 revenue miss, tepid forecast ** Novavax Inc NVAX.O: down 11.8% BUZZ-Down after $167 mln acquisition to boost COVID-19 vaccine production ** StoneCo Ltd STNE.O: up 21.3% BUZZ-Surges on growth in payment volume ** WPX Energy Inc WPX.N: down 2.0% ** Parsley Energy Inc PE.N: down 3.3% ** Concho Resources Inc CXO.N: down 2.3% ** Antero Resources Corp AR.N: down 3.1% ** Laredo Petroleum Inc LPI.N: down 6.6% ** Chesapeake Energy Corp CHK.N: down 2.7% BUZZ-GS recommends WPX Energy, Concho, Parsley among well-hedged E&P stocks ** Dentsply Sirona Inc XRAY.O: up 3.2% BUZZ-In solid post-COVID position vs peers; upgrades- Evercore ** Vipshop Holdings Ltd VIPS.N: up 3.1% BUZZ-Rises after Q1 sales exceed forecast ** Zoetis Inc ZTS.N: up 0.4% BUZZ-Jefferies starts with 'buy' on innovation, demand for pet health products ** TransMedics Group Inc TMDX.O: down 16.1% BUZZ-Slips after co prices upsized $70 mln stock offering USN ** American Airlines Group Inc AAL.O: up 3.3% ** Delta Air Lines Inc DAL.N: down 0.6% ** United Airlines Holdings Inc UAL.O: up 0.4% ** Southwest Airlines Co LUV.N: down 0.7% ** Spirit Airlines Inc SAVE.N: up 4.4% ** JetBlue Airways Corp JBLU.O: up 0.6% ** Alaska Air Group Inc ALK.N: up 1.3% BUZZ-U.S. airlines: Set to gain some lost ground as lockdowns ease ** Dorian LPG Ltd LPG.N: up 5.6% BUZZ-Climbs on Q1 profit beat, revenue surge ** Arcus Biosciences Inc RCUS.N: down 12.8% BUZZ-Drops after Gilead investment comes at no premium ** Goldman Sachs Group Inc GS.N: up 3.8% ** JPMorgan Chase & Co JPM.N: up 4.1% ** Citigroup Inc C.N: up 5.1% ** Wells Fargo & Co WFC.N: up 3.9% ** Bank of America Corp BAC.N: up 4.0% ** Morgan Stanley MS.N: up 4.8% BUZZ-U.S. Banks: Track rise in yields as risk appetite improves ** Innovative Industrial Properties Inc IIPR.N: down 3.6% BUZZ-Falls after pricing share offering ** Fiverr International Ltd FVRR.N: down 14.6% BUZZ-Falls on $100 mln shares offering The 11 major S&P 500 sectors: Communication Services .SPLRCL down 1.24% Consumer Discretionary .SPLRCD down 0.88% Consumer Staples .SPLRCS up 0.72% Energy .SPNY down 0.56% Financial .SPSY up 2.91% Health .SPXHC down 1.29% Industrial .SPLRCI up 1.88% Information Technology .SPLRCT down 1.91% Materials .SPLRCM up 0.08% Real Estate .SPLRCR up 0.08% Utilities .SPLRCU up 0.67% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: DXCM, SIRI In early trading on Wednesday, shares of Sirius XM Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.8%. Year to date, Sirius XM Holdings has lost about 19.0% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 9.1%. DexCom is showing a gain of 58.6% looking at the year to date performance. Two other components making moves today are NVIDIA, trading down 5.4%, and Microchip Technology, trading up 4.9% on the day. VIDEO: Nasdaq 100 Movers: DXCM, SIRI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: DXCM, JWN In early trading on Wednesday, shares of Nordstrom, topped the list of the day's best performing components of the S&P 500 index, trading up 10.9%. Year to date, Nordstrom has lost about 54.4% of its value. And the worst performing S&P 500 component thus far on the day is DexCom trading down 6.0%. DexCom is showing a gain of 64.1% looking at the year to date performance. Two other components making moves today are ResMed, trading down 5.7%, and Discover Financial Services, trading up 10.8% on the day. VIDEO: S&P 500 Movers: DXCM, JWN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $450""]"
DXCM,2020-05-28,90.155,94.6725,89.9088,90.4575,"[""DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?"", ""Here's Why You Should Retain Inogen in Your Portfolio Now"", ""Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector."", ""Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector."", ""DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?"", ""Here's Why You Should Retain Inogen in Your Portfolio Now"", ""S&P 500 Analyst Moves: DXCM The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #63 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. Looking at the stock price movement year to date, DexCom is showing a gain of 70.5%. VIDEO: S&P 500 Analyst Moves: DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector."", ""DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?"", ""Here's Why You Should Retain Inogen in Your Portfolio Now"", ""Picking a Long/Short Fund Isn\u2019t Easy, but It Can Be Profitable Long/short funds can differ dramatically in how they\u2019re managed, which can lead to some pretty dramatic differences in returns. How to evaluate, and four good funds.""]"
DXCM,2020-05-29,91.87,94.7725,91.0,94.5775,"Nasdaq 100 Movers: UAL, ZM In early trading on Friday, shares of Zoom Video Communications topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.7%. Year to date, Zoom Video Communications registers a 154.1% gain. And the worst performing Nasdaq 100 component thus far on the day is United Airlines Holdings, trading down 3.7%. United Airlines Holdings Inc is lower by about 68.4% looking at the year to date performance. Two other components making moves today are Trip.com Group, trading down 3.4%, and DexCom, trading up 2.6% on the day. VIDEO: Nasdaq 100 Movers: UAL, ZM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-01,95.625,95.9694,93.03,94.675,"DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $368.22, changing hands for $378.31/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 18 different analyst targets contributing to that average for DexCom Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $190.00. And then on the other side of the spectrum one analyst has a target as high as $475.00. The standard deviation is $59.814. But the whole reason to look at the average DXCM price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $368.22/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $368.22 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: RECENT DXCM ANALYST RATINGS BREAKDOWN » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 15 15 15 14 Buy ratings: 1 1 1 1 Hold ratings: 4 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.45 1.37 1.37 1.39 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM — FREE. The Top 25 Broker Analyst Picks of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-02,94.0025,95.1875,92.1025,93.9375,"[""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.' million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.' million of Shares"", ""Dexcom Inc (DXCM) President, CEO and Chairman Kevin R Sayer Sold $\u2014.' million of Shares""]"
DXCM,2020-06-03,93.5,94.185,90.0075,91.465,"Wednesday Sector Laggards: Healthcare, Utilities In afternoon trading on Wednesday, Healthcare stocks are the worst performing sector, not showing much of a gain. Within the sector, DexCom Inc (Symbol: DXCM) and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) are two large stocks that are lagging, showing a loss of 3.8% and 3.3%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.5% on the day, and up 0.61% year-to-date. DexCom Inc, meanwhile, is up 65.29% year-to-date, and Regeneron Pharmaceuticals, Inc. is up 59.07% year-to-date. Combined, DXCM and REGN make up approximately 2.1% of the underlying holdings of XLV. The next worst performing sector is the Utilities sector, up 1.4%. Among large Utilities stocks, WEC Energy Group Inc (Symbol: WEC) and Dominion Energy Inc (Symbol: D) are the most notable, with WEC showing a loss of 0.1% and D up 0.3%. One ETF closely tracking Utilities stocks is the Utilities Select Sector SPDR ETF (XLU), which is up 1.2% in midday trading, and down 4.03% on a year-to-date basis. WEC Energy Group Inc, meanwhile, is up 3.21% year-to-date, and Dominion Energy Inc is up 5.58% year-to-date. Combined, WEC and D make up approximately 11.9% of the underlying holdings of XLU. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, eight sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Financial +4.2% Industrial +3.5% Services +3.2% Materials +3.2% Energy +2.8% Consumer Products +2.7% Technology & Communications +1.6% Utilities +1.4% Healthcare -0.0% 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-04,90.915,91.2075,85.085,86.2125,"[""DexCom shares are trading lower, not currently seeing company-specific news for the session. NOTE: Stock has gained on heavy momentum this year and appears to be giving back some gains following run up."", ""DexCom shares are trading lower, not currently seeing company-specific news for the session. NOTE: Stock has gained on heavy momentum this year and appears to be giving back some gains following run up."", ""BUZZ-U.S. STOCKS ON THE MOVE- Cinedigm, Ebay Inc, Anavex Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indices,S&P 500 and Nasdaq edged lower in choppy trading on Thursday, as a rally fueled by hopes of a post-coronavirus economic recovery fizzled out even with weekly jobless claims dipping below 2 million for the first time since mid-March..N At 11:30 ET, the Dow Jones Industrial Average .DJI was down 0.01% at 26,267.22. The S&P 500 .SPX was down 0.29% at 3,113.76 and the Nasdaq Composite .IXIC was down 0.44% at 9,639.846. The top three S&P 500 .PG.INX percentage gainers: ** American Airlines Group , up 24.3% ** United Airlines Holding , up 13% ** Delta Air Lines , up 10.3% The top three S&P 500 .PL.INX percentage losers: ** Dexcom , down 5.3% ** Marketaxess Holdings , down 4% ** J M Smucker , down 3.7% The top three NYSE .PG.N percentage gainers: ** Ashford Inc , up 37.2% ** Medley Llc , up 31.9% ** Seacor Marine Holding , up 26.4% The top three NYSE .PL.N percentage losers: ** Empire State Realty , down 44.6% ** Smartsheet Inc , down 22.3% ** Navios Maritime , down 13% The top three Nasdaq .PG.O percentage gainers: ** Rosehill Resources , up 215.7% ** Cinedigm Corp , up 172.9% ** Kezar Life Sciences , up 108.5% The top three Nasdaq .PL.O percentage losers: ** Cassava Sciences Inc , down 23.7% ** Summit Wireless Technologies , down 21.3% ** Fsd Pharma , down 19.1% ** Goldman Sachs Group Inc GS.N: up 0.6% ** JPMorgan Chase & Co JPM.N: up 1.3% ** Citigroup Inc C.N: up 1.7% ** Wells Fargo & Co WFC.N: up 3.5% ** Bank of America BAC.N: up 2.0% ** Morgan Stanley MS.N: up 1.6% BUZZ-U.S. big banks rise as yields tick up on European stimulus, U.S. jobs report ** Cinedigm Corp CIDM.O: up 172.9% BUZZ-Eyes best day ever on deal for OTT channel distribution ** Autodesk Inc ADSK.O: down 0.2% BUZZ-Brokerages hike PT on rising demand from construction industry ** Aldeyra Therapeutics ALDX.O: up 3.4% BUZZ-Gains on FDA agreement for eye disease treatment ** Ebay Inc EBAY.O: up 6.2% BUZZ-:Hits record high on upbeat Q2 outlook ** G-III Apparel Group GIII.O: up 10.2% BUZZ-Jumps on plan to cut losses with store closures ** Alpine Income Property PINE.N: up 1.1% BUZZ-:Rises as BTIG starts coverage with 'buy' ** Charles Schwab SCHW.N: up 1.6% ** TD Ameritrade Holding Corp AMTD.O: up 4.7% BUZZ-Charles Schwab, TD Ameritrade rise after all-stock deal gets DOJ approval ** American Airlines AAL.O: up 24.3% BUZZ-Soars on plans to boost flights in July as economy reopens ** Anavex Life Sciences AVXL.O: up 7.3% BUZZ-Anavex rises on approval to expand Alzheimer's study to Canada, UK ** Cloudera Inc CLDR.N: down 12.2% BUZZ-Drops on downbeat revenue forecast ** Royal Caribbean Cruises RCL.N: up 0.7% BUZZ-Falls co launches $2 bln convertible, notes offerings ** J M Smucker co SJM.N: down 3.7% BUZZ-Falls on gloomy fiscal 2021 sales forecast ** Kirkland's Inc KIRK.O: down 12.1% BUZZ-Falls as Q1 adjusted loss widens on coronavirus-led store closures ** Planet Fitness PLNT.N: down 3.0% BUZZ-Falls as Raymond James downgrades on stretched valuation ** Smartsheet Inc SMAR.N: down 22.3% BUZZ-Sinks, analysts say sell-off overdone ** NMI Holdings Inc NMIH.O: down 1.0% BUZZ-Falls after pricing $200 mln stock offering ** Nio Inc NIO.N: up 7.1% BUZZ-Gains on \""record\"" May deliveries ** BioXcel Therapeutics Inc BTAI.O: up 11.6% BUZZ-Guggenheim starts coverage with 'buy' ** Freeport-McMoRan Inc FCX.N: up 0.4% BUZZ-: Jefferies sees stock doubling next year amid global recovery ** Sabre Corp SABR.O: up 1.9% BUZZ-Rises on plans to cut 800 jobs ** Michaels Companies Inc MIK.O: down 3.4% BUZZ- : Drops on surprise quarterly loss due to virus hit ** JinkoSolar Holding Co JKS.N: up 4.5% BUZZ-: Jumps on favorable decision in U.S. ITC patent investigation The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.48% Consumer Discretionary .SPLRCD down 0.24% Consumer Staples .SPLRCS down 0.18% Energy .SPNY down 0.75% Financial .SPSY up 0.87% Health .SPXHC down 0.69% Industrial .SPLRCI up 0.50% Information Technology .SPLRCT down 0.50% Materials .SPLRCM up 0.11% Real Estate .SPLRCR down 1.42% Utilities .SPLRCU down 1.01% (Reporting by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: ZM, EBAY In early trading on Thursday, shares of eBay topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.9%. Year to date, eBay registers a 36.2% gain. And the worst performing Nasdaq 100 component thus far on the day is Zoom Video Communications, trading down 2.4%. Zoom Video Communications is showing a gain of 221.2% looking at the year to date performance. Two other components making moves today are DexCom, trading down 2.3%, and United Airlines Holdings, trading up 4.1% on the day. VIDEO: Nasdaq 100 Movers: ZM, EBAY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Thursday Sector Laggards: Utilities, Healthcare The worst performing sector as of midday Thursday is the Utilities sector, showing a 2.2% loss. Within that group, Ameren Corp (Symbol: AEE) and NextEra Energy Inc (Symbol: NEE) are two large stocks that are lagging, showing a loss of 3.3% and 3.3%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 2.3% on the day, and down 6.24% year-to-date. Ameren Corp, meanwhile, is down 3.54% year-to-date, and NextEra Energy Inc is up 4.81% year-to-date. Combined, AEE and NEE make up approximately 17.1% of the underlying holdings of XLU. The next worst performing sector is the Healthcare sector, showing a 0.5% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Edwards Lifesciences Corp (Symbol: EW) are the most notable, showing a loss of 5.8% and 3.5%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.7% in midday trading, and up 0.19% on a year-to-date basis. DexCom Inc, meanwhile, is up 57.58% year-to-date, and Edwards Lifesciences Corp, is down 7.23% year-to-date. Combined, DXCM and EW make up approximately 2.1% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Thursday. As you can see, six sectors are up on the day, while three sectors are down. SECTOR % CHANGE Industrial +1.1% Energy +1.1% Financial +1.0% Services +0.4% Consumer Products +0.2% Materials +0.2% Technology & Communications -0.3% Healthcare -0.5% Utilities -2.2% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom shares are trading lower, not currently seeing company-specific news for the session. NOTE: Stock has gained on heavy momentum this year and appears to be giving back some gains following run up.""]"
DXCM,2020-06-05,85.0125,91.8538,84.005,91.1225,
DXCM,2020-06-08,90.5625,92.56,88.0675,92.155,"S&P 500 Movers: DXCM, CCL In early trading on Monday, shares of Carnival topped the list of the day's best performing components of the S&P 500 index, trading up 15.0%. Year to date, Carnival has lost about 51.3% of its value. And the worst performing S&P 500 component thus far on the day is DexCom, trading down 3.1%. DexCom is showing a gain of 61.5% looking at the year to date performance. Two other components making moves today are Fortinet, trading down 3.1%, and Coty, trading up 14.9% on the day. VIDEO: S&P 500 Movers: DXCM, CCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-09,93.25,97.3312,93.25,95.125,"[""Raymond James Maintains Outperform on DexCom, Raises Price Target to $395"", ""10 Biggest Price Target Changes For Tuesday"", ""10 Biggest Price Target Changes For Tuesday"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $395"", ""BUZZ-U.S. STOCKS ON THE MOVE-Vroom, Amazon, Applied DNA Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's S&P 500 and Dow Jones indexes fell on Tuesday, while the tech-heavy Nasdaq hit a record high for the third straight session, as investors eyed this week's Federal Reserve meeting for signs on how it views a restarting economy. .N At 13:00 ET, the Dow Jones Industrial Average .DJI was down 0.73% at 27,372.21. The S&P 500 .SPX was down 0.57% at 3,213.91 and the Nasdaq Composite .IXIC was up 0.52% at 9,976.129. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices , up 5.4% ** Dexcom , up 4.5% ** SBA Communications Corp , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Marathon Oil , down 10% ** Concho Resources , down 9.9% ** American Airlines Group , down 9.8% The top three NYSE .PG.N percentage gainers: ** Planet Green Holdings , up 32.5% ** Microsectors US Big Oil Index , up 14.4% ** ishrares Currently Hedged MscI EAFE Small-Cap , up 13.8% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 54.4% ** Whiting Petroleum Corp , down 22.1% ** Tupperware Brands , down 21.6% The top three Nasdaq .PG.O percentage gainers: ** Immuron Ltd , up 596.2% ** Vroom Inc , up 109.4% ** Fangdd Netwrk Group , up 93% The top three Nasdaq .PL.O percentage losers: ** Fossil Group Inc , down 28.9% ** Genius Brands International , down 25.5% ** Conns Inc , down 22.8% ** Chesapeake Energy Corp CHK.N: down 54.4% BUZZ-Shares slide premarket after meteoric gains in last session ** Continental Resources CLR.N: down 9.4% BUZZ-MKM Partners downgrades on valuation concerns ** Adobe Inc ADBE.O: up 0.4% BUZZ-Cowen & Co increases PT on higher sector valuation ** Chesapeake Energy Corp CHK.N: down 54.4% ** Hertz Global Holding HTZ.N: down 12.7% ** Whiting Petroleum corp WLL.N: down 22.0% BUZZ-Back to earth: Hertz, Whiting, Chesapeake ** Boxlight corp BOXL.O: down 20.1% BUZZ-Plunges on discounted, dilutive share sale offer ** EBay Inc EBAY.O: up 2.1% BUZZ-Wells Fargo hikes PT, upgrades on strong e-commerce growth ** Stitch Fix Inc SFIX.O: down 5.9% BUZZ-Falls on Q3 revenue miss ** Yext Inc YEXT.N: down 1.8% BUZZ-Berenberg downgrades to \""hold\"" as execution, cost-cut strategy not clear ** Macy's Inc M.N: down 4.1% BUZZ-Rises as reopened stores outperform retailer's expectations ** Aqua Metals Inc AQMS.O: up 10.8% BUZZ-Shines as CEO raises stake in company ** Blackstone Mortgage Trust BXMT.N: down 6.6% BUZZ-Falls on $282 mln stock offer ** Uber Technologies Inc UBER.N: down 0.2% ** Lyft Inc LYFT.O: down 2.8% BUZZ-Wedbush raises PT on Uber, Lyft as demand improves ** AMC Entertainment Holdings AMC.N: down 5.5% BUZZ-Falls as California caps attendance at cinemas ** Lovesac Co LOVE.O: up 25.0% BUZZ-Soars on Q1 revenue jump, smaller loss ** GrubHub Inc GRUB.N: up 1.4% BUZZ-Jefferies hikes PT on reports of possible M&A ** Spirit Realty Capital Inc SRC.N: down 10.2% BUZZ-Drops on 8 mln share offering ** Tesla Inc TSLA.O: up 0.3% BUZZ-Pares losses on billionaire investor's comment ** Aimmune Therapeutics Inc AIMT.O: down 0.6% BUZZ-Street View: Post-pandemic challenges remain for Aimmune peanut allergy therapy ** OpGen Inc OPGN.O: up 8.0% BUZZ-Jumps as device rapidly detects bacterial infection in COVID-19 patients ** Immuron Ltd IMRN.O: up 596.2% BUZZ-Up on plans to start mid-stage studies testing diarrhea drug ** Signet Jewelers SIG.N: down 14.3% BUZZ-Falls as Q1 sales miss, announces hundreds of store closures ** Ceridian HCM Holding Inc CDAY.N: down 8.9% BUZZ-HR software firm falls from record high as sponsor, CEO sell shares ** Cerecor Inc CERC.O: down 14.6% BUZZ-Biopharma Cerecor falls on $33 mln equity raise ** Genasys Inc GNSS.O: up 3.8% BUZZ-Rises on $1.9 mln follow-on order from U.S. Army ** MoneyGram International MGI.O: up 15.3% BUZZ-Gains as digital transactions jump over two-fold in May ** Tiffany & Co TIF.N: up 1.7% BUZZ-Says it's in compliance with debt covenants, shares rise ** RealReal Inc REAL.O: up 2.7% BUZZ-Rises on recovery signals ** Fate Therapeutics FATE.O: up 22.6% BUZZ-Surges on upsized equity raise; JNJ to buy shares ** MarketAxess MKTX.O: up 0.7% BUZZ-Rises as Credit Suisse raises PT, EPS estimate ** Occidental Petroleum corp OXY.N: down 6.3% BUZZ-BofA upgrades to 'buy' on oil price rebound, co's cash-saving plans ** Anthem Inc ANTM.N: down 1.8% BUZZ-Stephens hikes PT after co expects to generate 70% of adj EPS in H1 ** Vroom Inc VRM.O: up 109.4% BUZZ-Vroom races higher in IPO debut ** Amazon.com AMZN.O: up 3.7% BUZZ-Rises as brokerages see better Q2 on strong online demand ** Urstadt Biddle Properties UBA.N: down 16.9% BUZZ-Falls on dividend cut, weaker revenue ** Brown-Forman BFb.N: up 2.8% BUZZ-Reverses course as management points to recovery ** Applied DNA APDN.O: up 1.1% BUZZ-Rises on $40,000 grant for COVID-19 program The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.15% Consumer Discretionary .SPLRCD up 0.41% Consumer Staples .SPLRCS down 0.93% Energy .SPNY down 3.47% Financial .SPSY down 2.09% Health .SPXHC down 0.32% Industrial .SPLRCI down 2.16% Information Technology .SPLRCT up 0.57% Materials .SPLRCM down 0.97% Real Estate .SPLRCR down 0.97% Utilities .SPLRCU down 2.57% (Reporting by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: UAL, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.9%. Year to date, DexCom registers a 76.8% gain. And the worst performing Nasdaq 100 component thus far on the day is United Airlines Holdings, trading down 10.5%. United Airlines Holdings is lower by about 50.5% looking at the year to date performance. Two other components making moves today are Marriott International, trading down 4.4%, and Advanced Micro Devices, trading up 4.5% on the day. VIDEO: Nasdaq 100 Movers: UAL, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: OXY, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 4.9%. Year to date, DexCom registers a 76.8% gain. And the worst performing S&P 500 component thus far on the day is Occidental Petroleum, trading down 11.8%. Occidental Petroleum is lower by about 47.8% looking at the year to date performance. Two other components making moves today are Coty, trading down 10.8%, and Advanced Micro Devices, trading up 4.5% on the day. VIDEO: S&P 500 Movers: OXY, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Signet Jewelers, OpGen, Cerecor Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks opened lower on Tuesday as investors turned cautious ahead of a Federal Reserve meeting that could offer views on the recent signs of economic recovery that drove the tech-heavy Nasdaq to an all-time high. .N At 9:30 ET, the Dow Jones Industrial Average .DJI was down 1.17% at 27,249.83. The S&P 500 .SPX was unchanged at 0 and the Nasdaq Composite .IXIC was down 0.44% at 9,881.416. The top three S&P 500 .PG.INX percentage gainers: ** Dexcom Inc , up 4.4% ** Hanesbrands Inc , up 2.9% ** Marketaxess Holdings Inc , up 1.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum , down 11.2% ** Americn Airlines Group , down 8.5% ** United Airlines Holding , down 8.1% The top three NYSE .PG.N percentage gainers: ** Latam Airlines Group , up 18.2% ** Can-Fite Biopharma Ltd , up 17.2% ** Direxion Daily S&P 500 High Beta Bear , up 9.1% The top three NYSE .PL.N percentage losers: ** Hertz Global Holding , down 35.8% ** Whiting Petroleum Corp , down 28.2% ** Transocean Ltd , down 21.3% The top three Nasdaq .PG.O percentage gainers: ** Immuron Ltd , up 379.5% ** Izea Worldwide Inc , up 90.5% ** Neonode Inc , up 36.1% The top three Nasdaq .PL.O percentage losers: ** Piedmont Lithium Ltd , down 21.9% ** Cerecor Inc , down 18.3% ** Zagg Inc , down 14.7% ** Continental Resources CLR.N: down 7.9% BUZZ-MKM Partners downgrades on valuation concerns ** Adobe Inc ADBE.O: down 0.3% BUZZ-Cowen & Co increases PT on higher sector valuation ** Hertz Global Holding HTZ.N: down 35.8% ** Whiting Petroleum corp WLL.N: down 28.0% BUZZ-Back to earth: Hertz, Whiting, Chesapeake ** Boxlight corp BOXL.O: down 20.5% BUZZ-Plunges on discounted, dilutive share sale offer ** EBay Inc EBAY.O: up 1.0% BUZZ-Wells Fargo hikes PT, upgrades on strong e-commerce growth ** Stitch Fix Inc SFIX.O: down 5.1% BUZZ-Falls on Q3 revenue miss ** Yext Inc YEXT.N: down 4.0% BUZZ-Berenberg downgrades to \""hold\"" as execution, cost-cut strategy not clear ** Macy's Inc M.N: up 7.2% BUZZ-Rises as reopened stores outperform retailer's expectations ** Aqua Metals Inc AQMS.O: up 20.3% BUZZ-Shines as CEO raises stake in company ** Blackstone Mortgage Trust BXMT.N: down 5.6% BUZZ-Falls on $282 mln stock offer ** Uber Technologies Inc UBER.N: down 0.7% ** Lyft Inc LYFT.O: down 4.9% BUZZ-Wedbush raises PT on Uber, Lyft as demand improves ** AMC Entertainment Holdings AMC.N: down 5.9% BUZZ-Falls as California caps attendance at cinemas ** Lovesac Co LOVE.O: up 21.5% BUZZ-Soars on Q1 revenue jump, smaller loss ** GrubHub Inc GRUB.N: up 0.5% BUZZ-Jefferies hikes PT on reports of possible M&A ** Spirit Realty Capital Inc SRC.N: down 7.5% BUZZ-Drops on 8 mln share offering ** Tesla Inc TSLA.O: down 1.9% BUZZ-Pares losses on billionaire investor's comment ** Aimmune Therapeutics Inc AIMT.O: down 4.2% BUZZ-Street View: Post-pandemic challenges remain for Aimmune peanut allergy therapy ** OpGen Inc OPGN.O: up 10.0% BUZZ-Jumps as device rapidly detects bacterial infection in COVID-19 patients ** Immuron IMRN.O: up 379.5% BUZZ-Up on plans to start mid-stage studies testing diarrhea drug ** Signet Jewelers SIG.N: down 10.0% BUZZ-Falls as Q1 sales miss, announces hundreds of store closures ** Ceridian HCM Holding Inc CDAY.N: down 4.0% BUZZ-HR software firm falls from record high as sponsor, CEO sell shares ** Cerecor Inc CERC.O: down 18.3% BUZZ-Biopharma Cerecor falls on $33 mln equity raise The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.27% Consumer Discretionary .SPLRCD down 0.74% Consumer Staples .SPLRCS down 0.90% Energy .SPNY down 4.22% Financial .SPSY down 2.24% Health .SPXHC up 0.05% Industrial .SPLRCI down 2.14% Information Technology .SPLRCT down 0.42% Materials .SPLRCM down 1.55% Real Estate .SPLRCR down 1.54% Utilities .SPLRCU down 1.84% (Reporting by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""4 Industries That'll Thrive in the New Bull Market Fasten your seatbelts, folks, because the stock market has been on one heck of an emotional roller-coaster over much of the past four months. Initially, panic and uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic sent the broad-based S&P 500 down 34% in less than five weeks. But in the subsequent 11 weeks, we've witnessed roughly 80% of this initial drop clawed back by equities, with Wall Street appearing to enter a new bull market. Although swoons in the stock market are inevitable, history has decisively shown that opportunistic long-term investors who buy during these periods of weakness tend to make money. It's never really a question of whether you should invest when a new bull market emerges, but where you should park your capital. Assuming a new bull market has been established, the following four industries look set to thrive (and dominate) for a long time to come. Image source: Getty Images. Cybersecurity One of the bigger beneficiaries of the COVID-19 pandemic is cybersecurity. To be perfectly clear, cybersecurity was already growing at a healthy pace well before the coronavirus shut down nonessential businesses across much of the country. But with more employees being forced to work remotely than ever before, the need to secure cloud-based data is taking on added importance. Essentially, COVID-19 took an existing trend and gave it a shot of adrenaline. Hands down, my favorite company in this space is Palo Alto Networks (NYSE: PANW), which I pegged on April 9, 2020, as one of five stocks that could be a 10-bagger (i.e., deliver 1,000%-plus returns) by 2030. Aside from the fact that enterprise cloud demand continues to pick up, Palo Alto benefits from the fact that it's pushing subscription and support-based solutions as opposed to hardware. Subscriptions generate much better margins than hardware, and cash flow is far more predictable as Palo Alto is unlikely to see customer churn for what's effectively a basic-need service for any business. Over the past year, Palo Alto's subscription and support revenue has grown to account for 68% of total sales, up from approximately 62% in the prior-year quarter. Image source: Getty Images. Cloud computing Building off of cybersecurity, the hottest thing since sliced bread in the new bull market is going to be anything having to do with cloud computing. This could mean the infrastructure players that are responsible for aiding businesses in creating their cloud, platform-as-a-service providers that allow enterprises to build, manage, and deploy applications, and software-as-a-service companies, which operate and sell ready-to-use apps for businesses and consumers. Interestingly, some of the most prominent names in the cloud space are the United States' largest publicly traded companies: Amazon (NASDAQ: AMZN) with Amazon Web Services (AWS), Microsoft with Azure, and Alphabet with Google Cloud. I don't see how investors can't get excited about Amazon in the new bull market. Even putting aside its e-commerce dominance, AWS continues to grow at about twice the pace of its retail/ad operations, and it produces considerably better margins. With Amazon's cloud services now accounting for 13.5% of total sales in Q1 2020 and a majority of its operating income, it's no wonder Wall Street expects a near-tripling in the company's operating cash flow by 2023. Image source: Getty Images. Personalized medicine The new bull market will also feature an ongoing push toward personalized medicine. By personalized medicine, I'm referring to the idea of tailoring treatment for each individual rather than offering generalized medical solutions. Most personalized medicine leans on the increased use of technology, the cloud, and innovative new devices. For example, another 10-bagger stock I singled out in April is Livongo Health (NASDAQ: LVGO), a provider of personalized health solutions. Using mountains of collected data and artificial intelligence, Livongo sends tips to members with diabetes in order to help them make meaningful behavioral changes that result in them living longer and healthier lives. It also doesn't hurt that Livongo's solutions can potentially work hand in hand with other wireless diabetes devices (e.g., insulin pumps), meaning patients don't have to leave the comfort of their homes to convey sensitive data to their physicians. Maybe the best thing about Livongo Health and the personalized medicine push is that it's not all talk. Livongo's Diabetes member count doubled from the prior-year quarter to more than 328,000, and it's already generated two consecutive quarters of profitability despite significant reinvestment into its solutions. If Livongo is already turning the corner to profitability with less than 1% of U.S. diabetes market share, just imagine its potential when it expands to treat other chronic illnesses, like hypertension. Image source: Getty Images. Internet of Things Finally, look for the Internet of Things (IoT) to finally realize its full potential in the new bull market. By IoT, I'm talking about wireless devices being able to connect and communicate with one another and data centers. Examples might include a smart thermostat that learns your heating and cooling preferences to conserve energy usage in your home, or an automobile that automatically reorders a defective or soon-to-be-defective component. It's not uncommon for Wall Street and investors to overestimate the impact of new technology and be left disappointed. This is sort of what happened with IoT stocks in the latter half of the 2010s. But with an increased reliance on work-from-home, the cloud, and even personalized medicine, the value of IoT is rising like never before. To build off of the previous industry (personalized medicine), DexCom (NASDAQ: DXCM) is the perfect example of IoT in action. Dexcom, which happens to have a deal in place with Livongo Health, is a producer of continuous glucose monitoring devices for diabetics. DexCom's devices can provide patients with real-time blood-glucose levels, communicate with insulin pumps to administer or hold off on the administration of insulin, and aid in producing reports that can be sent to a primary care provider. IoT has applications in virtually every industry, and the new bull market should showcase that fact. 10 stocks we like better than Amazon When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Amazon and Livongo Health Inc. The Motley Fool owns shares of and recommends Alphabet (A and C shares), Amazon, Livongo Health Inc, Microsoft, and Palo Alto Networks. The Motley Fool recommends DexCom and recommends the following options: long January 2021 $85 calls on Microsoft, short January 2021 $115 calls on Microsoft, short January 2022 $1940 calls on Amazon, and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""10 Biggest Price Target Changes For Tuesday"", ""Raymond James Maintains Outperform on DexCom, Raises Price Target to $395"", ""11 High-Growth Stocks to Ride Out the Recession Barron\u2019s screened each sector of the S&P 500 for stocks with the highest long-term growth rate, paired with year-to-date returns."", ""It\u2019s Time to Talk About Stock Market Bubbles After a nearly 50% rally, the Dow Jones Industrial Average is down more than 250. Is it just a pullback or something more ominous?""]"
DXCM,2020-06-10,96.305,96.9275,92.965,96.2925,
DXCM,2020-06-11,94.5,95.3925,90.2295,90.6775,
DXCM,2020-06-12,92.1497,96.4725,90.7425,92.5575,
DXCM,2020-06-15,90.75,99.885,89.67,99.6875,"[""BUZZ-U.S. STOCKS ON THE MOVE-CAI International, Carrols Restaurant, 58.com Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were mixed in choppy afternoon trading on Monday, with the benchmark S&P 500 paring early losses to trade flat as investors weighed the economic outcome of a spike in new coronavirus cases in China and parts of the United States. .N At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.05% at 25,618.84. The S&P 500 .SPX was down 0.05% at 3,039.93 and the Nasdaq Composite .IXIC was up 0.80% at 9,665.954. The top three S&P 500 .PG.INX percentage gainers: ** ViacomCBS Inc , up 10% ** Oneok Inc , up 7.5% ** DexCom Inc , up 7% The top three S&P 500 .PL.INX percentage losers: ** Cabot Oil & Gas corp , down 3.7% ** Bristol Myers Squibb Co , down 2.6% ** Concho Resources , down 2.6% The top three NYSE .PG.N percentage gainers: ** Leaf Group Ltd , up 21.8% ** Gsx Techedu Inc , up 20.7% ** Oneconnect Financial Technology Co , up 20.3% The top three NYSE .PL.N percentage losers: ** Hertz Global Holding , down 21.4% ** China Rapid Finance , down 13.1% ** Core Laboratories Nv , down 11.4% The top three Nasdaq .PG.O percentage gainers: ** Urban One Inc , up 105.4% ** Edesa Biotch Inc , up 110% ** Net Element Inc , up 76% The top three Nasdaq .PL.O percentage losers: ** Us Ecolgy Inc WT , down 17.6% ** Atlas Technical Consultanats Inc , down 17.3% ** Imara Inc , down 15.8% ** Sunnova Energy NOVA.N: up 10.6% BUZZ-CS upgrades to 'outperform' on lower cost of capital ** eHealth Inc EHTH.O: up 4.5% BUZZ-starts coverage on eHealth, says tech-savvy customers to drive growth ** Extraction Oil & Gas XOG.O: down 10.7% BUZZ-Slumps on bankruptcy filing ** Exxon Mobil Corp XOM.N: down 0.1% ** Chevron Corp CVX.N: down 1.6% BUZZ-Oil and gas cos: Fall on fears of second wave of virus hitting demand recovery ** JinkoSolar Holding Corp JKS.N: down 7.6% BUZZ-Falls as Q2 revenue outlook below Street estimate ** Moderna Inc MRNA.O: up 5.3% BUZZ-Rises after report says Israel in talks to buy co's COVID-19 vaccine ** Twilio TWLO.N: up 4.4% BUZZ-Piper Sandler upgrades to 'overweight' on favorable digital trends ** Fluidigm Corp FLDM.O: up 9.0% BUZZ-Jumps on seeking FDA emergency use clearance for COVID-19 test ** Shopify SHOP.N: up 6.3% BUZZ-Gains as Walmart partners to expand marketplace platform ** China XD Plastics Company CXDC.O: up 10.6% BUZZ-Rises on go-private deal ** Brickell Biotech Inc BBI.O: up 51.6% BUZZ-surges as study meets main goal to treat excess sweating ** China's 58.Com WUBA.N: up 9.3% BUZZ-Rises on report of Warburg Pincus-backed buyout deal ** CarMax KMX.N: up 2.0% BUZZ-Credit Suisse sees upbeat Q1, hikes PT ** IVERIC bio Inc ISEE.O: up 11.0% BUZZ-Surges on positive data from eye disorder treatment study ** Hertz Global Holding HTZ.N: down 21.6% BUZZ-In reverse after co files to sell $500 mln in shares ** Catalent CTLT.N: up 2.4% BUZZ-Jumps on COVID-19 vaccine supply agreement with AstraZeneca ** Intel Corp INTC.O: up 0.3% BUZZ-KeyBanc sees Intel staging comeback, upgrades ** Edesa Biotech EDSA.O: up 110.0% BUZZ-surges on nod to start COVID-19 treatment trial ** Venus Concept VERO.O: up 8.9% BUZZ-Jumps as FDA clears use of laser hair removal device ** iRobot IRBT.O: up 12.3% BUZZ-up on upbeat Q2 sales forecast as home cleaning product demand rises ** Top Ships TOPS.O: down 7.2% BUZZ-Slides after pricing stock offering at discount ** General Electric GE.N: up 0.6% BUZZ-Falls as aviation chief set to retire ** Adamis Pharma ADMP.O: up 9.9% BUZZ-Rises on commercial license for experimental COVID-19 drug ** Valaris VAL.N: up 0.9% BUZZ-Delays $13 mln interest payment, shares fall ** Antero Resources AR.N: up 14.9% BUZZ-Gains on $402 mln overriding royalty deal ** Genius Brands International GNUS.O: up 9.4% BUZZ-shares jump as Arnold Schwarzenegger to invest ** Net Element NETE.O: up 76.0% BUZZ-Hits over 2-year high on potential merger with Mullen Technologies ** Coffee Holding JVA.O: up 7.9% BUZZ-Jumps as co swings to Q2 profit ** China's 58.com WUBA.N: up 9.3% BUZZ-rises on $8.7 billion take-private deal ** CAI International CAI.N: down 7.9% BUZZ-Tumbles after deciding against sale ** Ribbon Communications RBBN.O: up 6.7% BUZZ-Northland Capital upgrades on strong demand, shares rise ** Carrols Restaurant Group TAST.O: up 5.0% BUZZ-Rises as Burger King comparable sales turn positive The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.39% Consumer Discretionary .SPLRCD up 0.13% Consumer Staples .SPLRCS up 0.33% Energy .SPNY up 0.01% Financial .SPSY up 0.51% Health .SPXHC down 0.25% Industrial .SPLRCI up 0.66% Information Technology .SPLRCT up 0.26% Materials .SPLRCM up 0.51% Real Estate .SPLRCR up 0.23% Utilities .SPLRCU up 0.58% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Monday Sector Leaders: Services, Healthcare Looking at the sectors faring best as of midday Monday, shares of Services companies are outperforming other sectors, higher by 1.3%. Within the sector, ViacomCBS Inc (Symbol: VIAC) and Lennar Corp (Symbol: LEN) are two large stocks leading the way, showing a gain of 9.8% and 5.4%, respectively. Among the largest ETFs, one ETF closely following services stocks is the iShares U.S. Consumer Services ETF (Symbol: IYC), which is down 0.2% on the day, and down 4.67% year-to-date. ViacomCBS Inc, meanwhile, is down 38.96% year-to-date, and Lennar Corp is up 12.35% year-to-date. VIAC makes up approximately 0.5% of the underlying holdings of IYC. The next best performing sector is the Healthcare sector, higher by 1.1%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Universal Health Services, Inc. (Symbol: UHS) are the most notable, showing a gain of 7.8% and 4.9%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.5% in midday trading, and down 3.36% on a year-to-date basis. DexCom Inc, meanwhile, is up 82.46% year-to-date, and Universal Health Services, Inc., is down 29.97% year-to-date. Combined, DXCM and UHS make up approximately 1.1% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, nine sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Services +1.3% Healthcare +1.1% Technology & Communications +1.1% Financial +1.0% Energy +1.0% Materials +0.9% Consumer Products +0.8% Industrial +0.8% Utilities +0.6% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Monday Option Activity: DXCM, PEN, RAD Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 5,939 contracts has been traded thus far today, a contract volume which is representative of approximately 593,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of DXCM's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $400 strike call option expiring June 19, 2020, with 444 contracts trading so far today, representing approximately 44,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $400 strike highlighted in orange: Penumbra Inc (Symbol: PEN) options are showing a volume of 938 contracts thus far today. That number of contracts represents approximately 93,800 underlying shares, working out to a sizeable 41.4% of PEN's average daily trading volume over the past month, of 226,460 shares. Especially high volume was seen for the $140 strike put option expiring July 17, 2020, with 401 contracts trading so far today, representing approximately 40,100 underlying shares of PEN. Below is a chart showing PEN's trailing twelve month trading history, with the $140 strike highlighted in orange: And Rite Aid Corp (Symbol: RAD) saw options trading volume of 12,166 contracts, representing approximately 1.2 million underlying shares or approximately 40.5% of RAD's average daily trading volume over the past month, of 3.0 million shares. Particularly high volume was seen for the $13.50 strike call option expiring June 19, 2020, with 2,169 contracts trading so far today, representing approximately 216,900 underlying shares of RAD. Below is a chart showing RAD's trailing twelve month trading history, with the $13.50 strike highlighted in orange: For the various different available expirations for DXCM options, PEN options, or RAD options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FXH, NVST, DXCM, BIO: ETF Outflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $102.8 million dollar outflow -- that's a 5.7% decrease week over week (from 21,200,002 to 20,000,002). Among the largest underlying components of FXH, in trading today Envista Holdings Corp (Symbol: NVST) is up about 2.3%, DexCom Inc (Symbol: DXCM) is up about 2%, and Bio-Rad Laboratories Inc (Symbol: BIO) is lower by about 1.5%. For a complete list of holdings, visit the FXH Holdings page \u00bb The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $60.6994 per share, with $91.67 as the 52 week high point \u2014 that compares with a last trade of $84.80. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-General Electric, Adamis Pharmaceuticals, Net Element Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks dropped on Monday after a spike in new coronavirus cases in China and parts of the United States dampened hopes of a swift economic recovery that had driven a sharp rise in Wall Street's main indexes over the past month. .N At 11:30 ET, the Dow Jones Industrial Average .DJI was down 1.24% at 25,286.77. The S&P 500 .SPX was down 0.82% at 3,016.27 and the Nasdaq Composite .IXIC was down 0.23% at 9,566.683. The top three S&P 500 .PG.INX percentage gainers: ** ViacomCBS Inc , up 7.1% ** Dexcom Inc , up 6.2% ** Fortinet Inc , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 6.3% ** Norwegian Cruise Line , down 5.9% ** Alliance Data Systems Corp , down 5.8% The top three NYSE .PG.N percentage gainers: ** Gsx Techedu Inc , up 25.5% ** China Green Agriculture , up 22.1% ** EQM Midstream Partners , up 16% The top three NYSE .PL.N percentage losers: ** China Rapid Finance , down 24% ** Hertz Global Holding , down 22.3% ** CAI International Inc , down 14.3% The top three Nasdaq .PG.O percentage gainers: ** Edesa Biotch Inc , up 169.3% ** Urban One Inc , up 137.5% ** Net Element , up 94.6% The top three Nasdaq .PL.O percentage losers: ** Atlas Technical Consultants , down 21% ** Kbs Fashion Group , down 18.9% ** Art's Way Manufacturing Co , down 18.3% ** Sunnova Energy NOVA.N: up 9.2% BUZZ-CS upgrades to 'outperform' on lower cost of capital ** eHealth Inc EHTH.O: up 3.5% BUZZ-Evercore starts coverage on eHealth, says tech-savvy customers to drive growth ** Extraction Oil & Gas XOG.O: down 15.3% BUZZ-Slumps on bankruptcy filing ** Exxon Mobil Corp XOM.N: down 1.9% ** Chevron Corp CVX.N: down 3% BUZZ-Oil and gas cos: Fall on fears of second wave of virus hitting demand recovery ** JinkoSolar Holding Corp JKS.N: down 9.1% BUZZ-Falls as Q2 revenue outlook below Street estimate ** Moderna Inc MRNA.O: up 3.7% BUZZ-Rises after report says Israel in talks to buy co's COVID-19 vaccine ** Twilio TWLO.N: up 5.1% BUZZ-Piper Sandler upgrades to 'overweight' on favorable digital trends ** Fluidigm Corp FLDM.O: up 7.1% BUZZ-Jumps on seeking FDA emergency use clearance for COVID-19 test ** Shopify SHOP.N: up 4.8% BUZZ-Gains as Walmart partners to expand marketplace platform ** China XD Plastics Company CXDC.O: up 6.8% BUZZ-Rises on go-private deal ** Brickell Biotech Inc BBI.O: up 43.7% BUZZ-Surges as study meets main goal to treat excess sweating ** China's 58.Com WUBA.N: up 9.9% BUZZ-Rises on report of Warburg Pincus-backed buyout deal ** CarMax KMX.N: up 0.1% BUZZ-Credit Suisse sees upbeat Q1, hikes PT ** IVERIC bio Inc ISEE.O: up 15.9% BUZZ-Surges on positive data from eye disorder treatment study ** Hertz Global Holding HTZ.N: down 22.3% BUZZ-In reverse after co files to sell $500 mln in shares ** Catalent CTLT.N: up 1.6% BUZZ-Jumps on COVID-19 vaccine supply agreement with AstraZeneca ** Edesa Biotech EDSA.O: up 169.3% BUZZ-Surges on nod to start COVID-19 treatment trial ** Venus Concept VERO.O: up 6.8% BUZZ-Jumps as FDA clears use of laser hair removal device ** iRobot IRBT.O: up 12.7% BUZZ-Up on upbeat Q2 sales forecast as home cleaning product demand rises ** Top Ships TOPS.O: down 8.5% BUZZ-Slides after pricing stock offering at discount ** General Electric GE.N: down 2.8% BUZZ-Falls as aviation chief set to retire ** Adamis Pharmaceuticals ADMP.O: up 12.2% BUZZ-Rises on commercial license for experimental COVID-19 drug ** Valaris VAL.N: down 3.7% BUZZ-Delays $13 mln interest payment, shares fall ** Antero Resources AR.N: up 12.3% BUZZ-Gains on $402 mln overriding royalty deal ** Genius Brands International GNUS.O: up 13.5% BUZZ-Shares jump as Arnold Schwarzenegger to invest ** Net Element NETE.O: up 94.6% BUZZ-Hits over 2-year high on potential merger with Mullen Technologies ** Coffee Holding JVA.O: up 8.1% BUZZ-Jumps as co swings to Q2 profit The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.52% Consumer Discretionary .SPLRCD down 1.00% Consumer Staples .SPLRCS down 0.38% Energy .SPNY down 2.11% Financial .SPSY down 1.08% Health .SPXHC down 1.00% Industrial .SPLRCI down 1.16% Information Technology .SPLRCT down 0.63% Materials .SPLRCM down 0.77% Real Estate .SPLRCR down 0.57% Utilities .SPLRCU down 0.54% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle The most popular constant glucose monitor in America is getting a long-awaited upgrade. The FDA has finally cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system from Abbott (NYSE: ABT) for type 1 diabetes patients 4 and older. It has been more than two years since the next-generation iCGM earned CE Mark clearance in Europe, but Abbott's experience with U.S. regulators wasn't nearly as smooth. The FreeStyle Libre 2 adds Bluetooth capability; the Libre 1 model could only transmit information about a patient's blood sugar levels wirelessly using NFC (near-field communication) protocols. Image source: Getty Images. Over the past couple of years, another iCGM, the G6 from Dexcom (NASDAQ: DXCM), has gained significant popularity, partly because its Bluetooth functionality makes it easier for patients (and their caregivers) to receive alerts on their smartphones the moment their blood sugar reaches a dangerous level. Why diabetes patients may favor the Freestyle Libre 2 Insurers and government payers have quickly learned that replacing frequent finger-pokes with disposable, stick-on glucose monitors improves diabetes patients' outcomes and reduces their hospitalizations. During the first three months of 2020, worldwide Libre sales rose 59.3% year over year to more than $600 million, which works out to around 20% of Abbott's total revenue at the moment. Despite the fact that the Libre 1 was less able to interact with popular mobile devices, Abbott hasn't had any trouble holding onto a large share of the U.S. iCGM market with its low-priced device. And given that the Libre 2's sensor has been approved to remain applied to patients for 14 days at a time, its new iCGM could have a leg up on Dexcom's G6 and its 10-day sensor. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-06-16,100.5,100.842,96.57,98.25,"S&P 500 Movers: DXCM, LLY In early trading on Tuesday, shares of Eli Lilly topped the list of the day's best performing components of the S&P 500 index, trading up 11.8%. Year to date, Eli Lilly registers a 20.4% gain. And the worst performing S&P 500 component thus far on the day is DexCom, trading down 1.9%. DexCom is showing a gain of 78.9% looking at the year to date performance. Two other components making moves today are T-Mobile US, trading down 1.8%, and Vulcan Materials, trading up 10.1% on the day. VIDEO: S&P 500 Movers: DXCM, LLY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-17,99.63,101.835,98.9178,100.795,"[""Wednesday Sector Leaders: Healthcare, Technology & Communications In afternoon trading on Wednesday, Healthcare stocks are the best performing sector, higher by 0.7%. Within the sector, DexCom Inc (Symbol: DXCM) and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) are two large stocks leading the way, showing a gain of 3.3% and 2.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.6% on the day, and down 0.65% year-to-date. DexCom Inc, meanwhile, is up 85.55% year-to-date, and Vertex Pharmaceuticals, Inc. is up 28.35% year-to-date. Combined, DXCM and VRTX make up approximately 2.8% of the underlying holdings of XLV. The next best performing sector is the Technology & Communications sector, up 0.5%. Among large Technology & Communications stocks, Activision Blizzard, Inc. (Symbol: ATVI) and Applied Materials, Inc. (Symbol: AMAT) are the most notable, showing a gain of 4.1% and 2.9%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is up 0.8% in midday trading, and up 13.09% on a year-to-date basis. Activision Blizzard, Inc., meanwhile, is up 28.63% year-to-date, and Applied Materials, Inc., is down 0.61% year-to-date. AMAT makes up approximately 0.8% of the underlying holdings of XLK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, three sectors are up on the day, while five sectors are down. SECTOR % CHANGE Healthcare +0.7% Technology & Communications +0.5% Utilities +0.3% Industrial 0.0% Consumer Products -0.1% Services -0.1% Materials -0.2% Financial -0.5% Energy -2.4% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Beyond Meat, BioSig Technologies, The Alkaline Water Co Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Wednesday, rising for a fourth straight session, as signs of more stimulus bolstered hopes of a quick economic rebound, even as six U.S. states saw a record rise in new coronavirus cases. .N At 9:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.31% at 26,370.55. The S&P 500 .SPX was up 0.32% at 3,134.6 and the Nasdaq Composite .IXIC was up 0.62% at 9,957.382. The top three S&P 500 .PG.INX percentage gainers: ** Lowes Companies Inc , up 3% ** Dexcom Inc , up 2.1% ** Electronic Arts Inc , up 1.9% The top three S&P 500 .PL.INX percentage losers: ** Norwegian Cruise Line , down 8.1% ** Royal Caribbean Cruises , down 6.1% ** Carnival Corp , down 4.8% The top three NYSE .PG.N percentage gainers: ** Nuverra Environmental Solutions , up 149.7% ** American Shared Hospital Services , up 55.9% ** Ntn Buzztime Inc , up 47.9% The top three NYSE .PL.N percentage losers: ** Corecivic Inc , down 18.1% ** Document Security Systems Inc , down 17.1% ** Norwegian Cruise Line , down 8.1% The top three Nasdaq .PG.O percentage gainers: ** Carver Bancorp , up 612.4% ** Urban One Inc , up 127.3% ** Clearsign Technologies Inc , up 45.3% The top three Nasdaq .PL.O percentage losers: ** Chembio Diagnostics , down 62% ** Proficient Alpha Acquisition Corp , down 47.3% ** Urban One Inc , down 28.5% ** InnerWorkings INWK.O: up 37.3% BUZZ-Soars as expenses fall, EBITDA rises ** Norwegian Cruise Line NCLH.N: down 8.1% BUZZ-Drops after extending voyage suspensions ** Mastercard Inc MA.N: up 0.5% ** Visa Inc V.N: up 0.6% BUZZ-Citi Research raises PT on Mastercard, Visa as payments recovery starts ** Energous WATT.O: up 46.2% BUZZ-Rises on partnership to make wireless charging batteries ** DraftKings Inc DKNG.O: down 3.7% BUZZ-Drops after co launches $1.3 bln stock offering ** KKR & Co KKR.N: up 1.5% BUZZ-Piper Sandler starts with 'overweight' on co's upbeat strategy ** AVEO Oncology AVEO.O: down 14.9% BUZZ-Drops on $44.6 mln stock offering ** Aclaris Therapeutics ACRS.O: up 35.8% BUZZ-Jumps on FDA approval for COVID-19 treatment study ** The Alkaline Water Co WTER.O: up 21.6% BUZZ-Jumps on strong Q4 revenue, upbeat Q1 forecast ** XpressSpa XSPA.O: down 12.2% BUZZ-Slides on stock and warrants offerings half of public float ** Beyond Meat Inc BYND.O: up 5.5% BUZZ-Rises on launch of plant-based burger value pack ** Hexo Corp HEXO.N: down 11.9% BUZZ-Pot producer Hexo plans C$34.5 mln equity raise, shares fall ** BioSig Technologies BSGM.O: up 5.4% BUZZ-Rises as enrollment for COVID-19 drug trial starts ** Armata Pharmaceuticals ARMP.A: up 20.9% BUZZ-Gains on U.S. defense department funding for drug development The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.10% Consumer Discretionary .SPLRCD up 0.84% Consumer Staples .SPLRCS up 0.44% Energy .SPNY down 0.93% Financial .SPSY up 0.03% Health .SPXHC up 0.37% Industrial .SPLRCI down 0.06% Information Technology .SPLRCT up 0.64% Materials .SPLRCM up 0.46% Real Estate .SPLRCR down 0.18% Utilities .SPLRCU down 0.57% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-06-18,101.278,101.852,99.78,100.478,
DXCM,2020-06-19,101.288,103.062,100.78,102.34,"3 Diabetes Monitoring Companies That Are Recession-Proof Companies that make continuous glucose monitors (CGMs) -- devices that diabetic patients wear to monitor the level of glucose in their blood -- have been largely unaffected by the COVID-19 concerns that have slammed other medical device companies. Diabetic patients don't have the option of putting off care. Daily monitoring of blood sugar levels is essential to controlling the disease, which is the seventh-leading cause of death in the U.S., according to the Centers for Disease Control and Prevention (CDC). The CDC says that in the past 20 years, the number of adults diagnosed with diabetes has more than doubled as Americans have aged and become, on average, more obese. IMAGE SOURCE: GETTY IMAGES If you're looking for recession-proof healthcare stocks, makers of CGMs are good options. Here are three that have been soaring this year. DexCom is keeping people away from doctors' offices The key product for DexCom (NASDAQ: DXCM) is its G6 monitoring device, a CGM system with an unobtrusive patch that attaches to a person's skin and gives constant glucose readings that are then sent to a smartphone app. Patients don't have to prick their fingers for blood samples. Besides being convenient, it also requires fewer trips to the doctor's office -- a good thing during a pandemic, as care providers can access the patient's glucose readings remotely. Convenience is apparently good for business. As of Thursday's close, DexCom's share price is up 84% for the year. The company said its first-quarter revenue was $405 million, up 44% year over year. The report shows that a big part of that revenue -- $305 million -- comes not from the hardware but from its devices' sensors, which have to be replaced every 10 days at minimum. The San Diego company reported its first-quarter net income as $19.9 million, a big jump from the $29.6 million loss it reported the same quarter a year ago. Livongo is a rising star in the industry Livongo (NASDAQ: LVGO) has only been around for six years, and its stock didn't go public until last year. As of Thursday, the Mountain View, Calif., company's stock was up 179.8% year to date. What caused that jump? As with DexCom, Livongo's digital platform is perfect for remote use. It allows physicians to track clients' glucose levels for diabetes and their blood pressure for hypertension without office visits. That has become a big plus during the coronavirus pandemic, but it's also a trend that's likely to continue. It's also a good blend for Livongo, because many people with diabetes also suffer from high blood pressure. Livongo announced in January that it was entering into a partnership with DexCom, using that company's G6 CGM device with the Livongo Applied Health Signals platform. Livongo's revenue is built around adding to its client base and then using artificial intelligence to coach members toward better health choices. As of the last quarter, the company said it had 1,252 clients, up 44% over the fourth quarter of 2019. (Each client represents a group of members; total member count is over 300,000.) The company isn't making a profit yet, but in the first quarter it reported revenue of $68.8 million, which was a rise of 115% over the $32.1 million it made during Q1 2019. The company also kept its guidance and said it expected to make $290 million to $303 million this year. While Livongo lost $5.6 million in the first quarter on a generally accepted accounting principles (GAAP) basis, it said it had non-GAAP net income of $3.9 million, worth $0.03 per diluted share. With a GAAP net margin of 73.7% in the first quarter, it won't be long until Livongo consistently turns a profit. Insulet has new profits on the horizon Like DexCom, Insulet (NASDAQ: PODD), which is based in Acton, Mass., has an impressive product that will drive sales. The tubeless insulin pump manufacturer presented its newest product, the Omnipod 5, at the American Diabetes Association's 80th Scientific Sessions earlier this month. It hopes to bring it to market in early 2021. According to Insulet, the Omnipod 5 combines a disposable closed-loop insulin pump with DexCom's G6 monitor. The product is small, waterproof, and wearable, attaching to a patient's back. The closed-loop system dispenses small amounts of glucose regulated by a smartphone app. It is also capable of dispensing other medication. The company's current products -- two wireless insulin pumps called Omnipod PDM and Omnipod DASH -- brought in $673.5 million last year in revenue. Through Thursday, Insulet's share price was up 10.7% year to date. The company's first-quarter numbers showed revenue of $198 million, a year-over-year rise of 24%. The report did, however, show a net loss in the quarter of $2.1 million, as opposed to the $4.4 million in net income it made in the first quarter of 2019. In the company's first-quarterearnings call CFO Wayde McMillan said that some of those losses were due to the company's bringing a second manufacturing site online. It's still easy to be bullish on Insulet. Last year, it had $11.9 billion in net income, up from $3.29 million the year before. In the long run, it appears to be on a good trend. It's hard to make a bad choice All three companies present excellent opportunities. However, I like DexCom because its G6 CGM appears to be the state-of-the-art system that other companies are pairing with, and the company has a longer record of making a profit. Livongo may present the best long-term option of the three, however, as it is a younger company that's growing at a faster clip. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Jim Halley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-22,103.758,103.872,101.195,101.582,"Interesting DXCM Put And Call Options For August 21st Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new August 21st contracts and identified one put and one call contract of particular interest. The put contract at the $400.00 strike price has a current bid of $32.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $400.00, but will also collect the premium, putting the cost basis of the shares at $367.70 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $405.98/share today. Because the $400.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.07% return on the cash commitment, or 49.12% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $400.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $410.00 strike price has a current bid of $36.00. If an investor was to purchase shares of DXCM stock at the current price level of $405.98/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $410.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.86% if the stock gets called away at the August 21st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $410.00 strike highlighted in red: Considering the fact that the $410.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 46%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 8.87% boost of extra return to the investor, or 53.94% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 63%, while the implied volatility in the call contract example is 60%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $405.98) to be 57%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-23,101.842,103.642,101.25,101.725,"Noteworthy ETF Outflows: FXH, DXCM, NVST, SGEN Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $424.1 million dollar outflow -- that's a 23.5% decrease week over week (from 20,000,002 to 15,300,002). Among the largest underlying components of FXH, in trading today DexCom Inc (Symbol: DXCM) is up about 1%, Envista Holdings Corp (Symbol: NVST) is up about 1.2%, and Seattle Genetics Inc (Symbol: SGEN) is up by about 1.1%. For a complete list of holdings, visit the FXH Holdings page » The chart below shows the one year price performance of FXH, versus its 200 day moving average: Looking at the chart above, FXH's low point in its 52 week range is $60.6994 per share, with $91.67 as the 52 week high point — that compares with a last trade of $90.89. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-06-24,101.44,102.93,96.755,98.575,"How This Bond Fund Has Beaten the Stock Market Over 25 Years TheAllianzGI Convertible fund, which invests in convertible bonds with a growth tilt, has delivered a 10.3% annualized return since its 1993 inception."
DXCM,2020-06-25,98.8025,99.6725,95.017,99.5225,
DXCM,2020-06-26,99.985,101.14,93.81,95.765,
DXCM,2020-06-29,96.9225,99.6375,94.22,99.55,
DXCM,2020-06-30,99.45,102.185,97.9562,101.35,
DXCM,2020-07-01,102.24,102.24,98.825,100.052,"If You Invested $1,000 in Dexcom's IPO, This Is How Much Money You'd Have Now Dexcom (NASDAQ: DXCM) went public on April 14, 2005. The stock opened at $12.08 a share. At that price, an investment of $1,000 would have gotten you 82 shares. That investment would have been a leap of faith, as the company had no revenues at that point. But in a year, Dexcom would release its first commercial product, the STS Continuous Glucose Monitoring System. It consisted of a tiny device inserted under the skin of a diabetes patient. Dexcom's system provided real-time glucose measurements, alerting the user if their blood sugar levels were too high or too low. Image source: Getty Images The stock went up -- and then way, way down At first, the stock market reacted favorably to the introduction of Dexcom's first commercial product. By 2006, an IPO investor would have doubled their money. In a little over a year, that $1,000 investment would be worth over $2,000, as the share price hit $25 a share in May. Unfortunately, the stock crashed at that point. It fell back under the IPO price later that year, hitting $9 a share in October. In 2007, the stock stayed under the IPO price all year, so early investors were still underwater. In 2008, the entire stock market crashed, sending Dexcom shares down to penny stock territory. The share price dropped all the way to $1.42. What could you do? Of course, as a stock investor, there are only three things you can do: buy, sell, or hold. If you admitted defeat, you would have sold your shares and taken your losses. Dexcom would have been a horrible investment for you. What if you bought more? You might've realized that the stock market crash of 2008 had little to do with diabetes. Maybe you were a user of Dexcom's device and loved the product . Perhaps you saw this market panic as an opportunity, and you invested another $1,000 in the company, picking up another 704 shares. So, if you were a crazy optimist, you held 786 shares of Dexcom, the penny stock. What if you didn't want to admit defeat, but you weren't feeling optimistic, either? After three years of investing in Dexcom, you'd lost almost 90% of your money. Your IPO investment in Dexcom would now be worth $116.44. Maybe at this point you just shrug and do nothing. ACTION IN 2008 SHARE COUNT TOTAL INVESTMENT SHARE PRICE IN 2020 RESULT Sell shares 0 $1,000 $383.06 ($883.56) Invest another $1,000 786 $2,000 $383.06 $301,085 Do nothing 82 $1,000 $383.06 $31,410 Share price from Yahoo! Finance Why was Dexcom such a fantastic stock? Diabetes is a killer. According to the Centers for Disease Control and Prevention (CDC), diabetes is the seventh-leading cause of death in the U.S. The CDC says that regular blood sugar monitoring is the most important thing you can do to manage your diabetes. Monitoring your glucose levels can ""help delay or prevent diabetes complications such as heart attack, stroke, kidney disease, blindness, and amputation."" Continuous glucose monitoring is a big improvement over the prior standard of care. In the past, patients had to needle-stick themselves and measure their blood sugar periodically. With Dexcom's device, diabetes patients can track their blood sugar at any time, all the time. There are no gaps in monitoring, and the device warns the patient when glucose levels are too high or too low. In 2014, after nine years in the stock market, Dexcom saw demand for its continuous glucose monitoring systems rise. Sales rose 62%. While the company was not yet profitable, it was cash flow positive, and shares were trading for $35.90. At that point, Dexcom wasn't a secret anymore. It was obvious that continuous glucose monitoring was an innovation that was winning in the marketplace. Dexcom rode that wave. IPO investors were sitting on a triple. What about the brave investors who bought in the dark days of 2008? They saw a 25-bagger. Still, it wasn't too late to buy Dexcom stock in 2014. Even the people who sold out of fear could still buy back in. Investors who bought Dexcom's stock in 2014 -- nine years after the IPO -- would be rewarded with a nice 10-bagger over the next six years. Buying great companies at the IPO is nice. Buying great companies that are getting killed in a stock market crash is even nicer. But the most important thing in stock investing is to buy strong companies. Regardless of when investors bought Dexcom in its early years, they are sitting on huge profits now. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-07-02,100.555,103.869,99.515,101.838,
DXCM,2020-07-06,103.05,108.224,102.202,105.795,"[""Notable Monday Option Activity: DXCM, ADBE, FCX Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 5,344 contracts has been traded thus far today, a contract volume which is representative of approximately 534,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 41% of DXCM's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $450 strike call option expiring July 17, 2020, with 1,275 contracts trading so far today, representing approximately 127,500 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $450 strike highlighted in orange: Adobe Inc (Symbol: ADBE) options are showing a volume of 13,445 contracts thus far today. That number of contracts represents approximately 1.3 million underlying shares, working out to a sizeable 40.6% of ADBE's average daily trading volume over the past month, of 3.3 million shares. Especially high volume was seen for the $460 strike call option expiring July 10, 2020, with 540 contracts trading so far today, representing approximately 54,000 underlying shares of ADBE. Below is a chart showing ADBE's trailing twelve month trading history, with the $460 strike highlighted in orange: And Freeport-McMoran Copper & Gold (Symbol: FCX) saw options trading volume of 87,778 contracts, representing approximately 8.8 million underlying shares or approximately 40.3% of FCX's average daily trading volume over the past month, of 21.8 million shares. Especially high volume was seen for the $11 strike call option expiring July 17, 2020, with 15,894 contracts trading so far today, representing approximately 1.6 million underlying shares of FCX. Below is a chart showing FCX's trailing twelve month trading history, with the $11 strike highlighted in orange: For the various different available expirations for DXCM options, ADBE options, or FCX options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The 3 Best S&P 500 Stocks So Far in 2020 The stock market's been absolutely crazy in 2020, with huge ups and downs. Halfway through the year, those who invest in the S&P 500 (SNPINDEX: ^GSPC) are still down on the year, but most are breathing a big sigh of relief after having suffered far larger losses earlier in the year. Even in the face of the downturn, there's a select group of stocks have risen dramatically so far in 2020. Here, we'll look at the three top performers with an eye toward figuring out what the future's likely to bring for them. DXCM data by YCharts. DexCom, up 86% In some ways, it's questionable whether DexCom (NASDAQ: DXCM) truly deserves a place on this list. The company has been public for 15 years, but it just joined the S&P 500 Index in May. DexCom's success has come from its revolutionary products. The medical device maker is behind the STS Continuous Glucose Monitoring System, which helps diabetes patients get continuous real-time glucose measurements and can provide alerts if glucose levels reach troubling levels. Unfortunately, diabetes is affecting more patients than ever, and that's made DexCom a key provider in helping people fight the disease without having to do repeated glucose checks on their own all the time. Image source: DexCom. Investors like DexCom because demand for its products isn't sensitive to economic conditions. That's made it a solid play, and the growth potential has helped give DexCom extraordinary performance as well. Regeneron Pharmaceuticals, up 66% The biotech industry has been a hotbed of interest in 2020, because many companies in the space have looked for ways to apply their therapies to fight the COVID-19 pandemic. Regeneron Pharmaceuticals (NASDAQ: REGN) is one of those companies. It's gotten plenty of growth recently as well from non-coronavirus treatments like eye disorder treatment Eylea and eczema drug Dupixent. Investors have their eyes on REGN-COV2, a COVID-19 treatment candidate that seeks to prevent the coronavirus from entering host cells. Human trials of REGN-COV2 began just last month, so it'll be a while before data becomes available. However, with a history that includes the successful Ebola virus treatment it developed, Regeneron has medical professionals feeling optimistic about the company's prospects for coming out with a sequel. PayPal Holdings, up 64% COVID-19 has had a hugely disruptive impact on the economy, but there've still been some companies that have done well during the pandemic. PayPal Holdings (NASDAQ: PYPL) has benefited from greater adoption of e-commerce channels, for which customers generally need electronic payment systems like PayPal's to make purchases. PayPal faces plenty of competition, but it has worked hard to distinguish itself from the crowd and make itself a leader in the electronic payments industry. Most recently, PayPal has stressed the development of contactless payment features, which will allow both merchants and consumers to pay without having to actually touch any surfaces at a storefront. That could prove more important than ever for health and safety purposes. It's also persuaded some businesses to shift to PayPal, and that comes at the same time that online checkout market share for the payment network has been on the rise. With industry-leading experience and a strong brand, PayPal has staying power in the cutthroat electronic payment space. What's next for the S&P? Even with the S&P still down for the year, many investors are optimistic about the future. That's particularly true for these three high-growth stocks. PayPal, Regeneron, and DexCom all have the potential to keep riding the wave higher even if the broader stock market stays in the doldrums. 10 stocks we like better than Regeneron Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Regeneron Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends PayPal Holdings. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $75 calls on PayPal Holdings. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-07-07,106.85,109.872,106.045,106.465,
DXCM,2020-07-08,107.315,108.85,106.522,108.778,
DXCM,2020-07-09,108.95,111.38,107.125,110.125,
DXCM,2020-07-10,109.832,110.682,108.25,109.91,"DexCom Shares Hit All-time High, Up Over 100% Year-to-Date (RTTNews) - Shares of medical device company DexCom Inc. (DXCM) closed at an all-time high of $440.50 yesterday, and that reflects a gain of over 100 percent year-to-date. DexCom is a maker of continuous glucose monitoring (CGM) systems like DexCom G6, DexCom G6 Pro, DexCom G5 Mobile, and DexCom G4 PLATINUM that help people to take control of diabetes. The Company's current target market consists primarily of people with Type 1 and Type 2 diabetes who utilize insulin pump therapy or who utilize multiple daily insulin injections. The Company's first product to be commercialized was the STS Continuous Glucose Monitoring System, and it was launched in the year 2006. Over the years, DexCom has launched a number of innovative products for continuous glucose monitoring, all of which are being well received by customers. In 2006, the year in which DexCom became a commercial-stage company, its revenue was just $2.17 million. Since then, in each subsequent year, revenue has significantly increased, and in 2018, for the first time, passed the billion-dollar revenue mark. The Company's revenue was $1.03 billion in 2018, and it further increased to $1.48 billion in 2019. Moreover, 2019 also marked the first full year of GAAP profitability, wherein the net income was $101.1 million or $1.10 per share compared to a net loss of $127.1 million or $1.44 per share in 2018. In the first quarter ended March 30, 2020, revenue was $405.1 million, up 44% over the year-ago quarter. At the time of reporting Q1 results, citing uncertainties related to the COVID-19 pandemic, the Company temporarily suspended the 2020 guidance that it had issued in February. The financial results for the second quarter of 2020 are scheduled to be reported on July 28, 2020. Analysts polled by Thomson Reuters are expecting earnings of $0.34 per share and revenue of $415.39 million for the quarter. Will DexCom's Q2 results meet or beat analysts' estimates and will the Company reinstate guidance with its earnings announcement? Sponsored Links Chuck Norris In His 80's Says: ""Try This Once A Day For More Energy"" America Morning Supply Watch now The stock is regularly covered by rttnews.com and the last time we alerted readers to it was on February 19, 2020, when it was trading around $298. (Stock Alert: DexCom Touches New High) DXCM has traded in a range of $138.28 to $445.52 in the last 1 year. The stock closed Thursday's trading at $440.50, up 1.24%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-07-13,110.358,111.625,100.612,101.058,"[""Nasdaq Sinks 227 Points as Zoom, Other Investor Favorites Reverse and Fall Hard The Nasdaq Composite (NASDAQINDEX: ^IXIC) has had a great run, rising to record highs. But at least for a few hours, investors decided to forget about the future promise of many of the companies whose shares trade on Nasdaq stock market and instead weighed their profits. After having been up significantly for much of the day, the Composite and the Nasdaq-100 index fell almost 2%. To be clear, not all Nasdaq stocks suffered declines. But the majority of the Nasdaq-100 did, and many of the companies that have flown the highest saw big declines seemingly based on nothing more than just fatigue at the pace of their past advances. Image source: Getty Images. Some big declines There were plenty of stocks that posted sizable one-day drops: Zoom Video Communications (NASDAQ: ZM), which has been one of the best-performing stocks in the market so far in 2020, fell almost 6% after having been up more than 2% at points earlier in the day. DocuSign (NASDAQ: DOCU), which has seen demand for its electronic signature service soar during the coronavirus pandemic, slumped 9%. DexCom (NASDAQ: DXCM) -- maker of continuous glucose monitoring medical devices for diabetes patients -- suffered an 8% drop. Data analytics specialist Datadog (NASDAQ: DDOG) sank 10%, just one of many software-as-a-service (SaaS) companies caught up in the downdraft. For the most part, there wasn't any fundamental news that sent these stocks down, along with the countless others that lost ground on Monday. Instead, it's useful to look the psychology of the market right now for hints to explain the big reversal. The higher they rise, the harder they fall In the long run, stocks tend to rise in conjunction with the strength of their underlying businesses. That's why relatively few people have been surprised at the fact that high-flying stocks have been able to defy the coronavirus bear market and gain ground. Specifically, each of these companies has found tremendous growth opportunities in recent months. Zoom has hundreds of millions of people using its video collaboration platform for the first time in 2020. DocuSign has filled the void created by people not being able to meet in person to sign important legal documents. DexCom's monitoring devices have become even more valuable in helping to keep diabetes patients from having to visit treatment centers for assessments. And Datadog and its SaaS peers have helped to give their enterprise clients the ability to make the most of the information they're collecting while letting workers be productive from remote locations. What's less clear, though, is whether the size of the stock-price gains in these companies has been warranted. In the short run, what defines how much a stock goes up is popularity among investors and buying demand for its shares. Short-term moves rarely move solely in one direction, with inevitable zigs and zags to keep shareholders on their toes. Always be ready for volatility Last but not least, investors who've owned these stocks for a while shouldn't let a day's losses lure them away from their long-term investment strategies. If you still believe that Datadog, DexCom, DocuSign, or Zoom will be an important player and grow in the future, then a significant decline like today's is a better sign that you should think about adding to positions rather than taking away from them. There's no guarantee that the stocks won't lose more ground on Tuesday, later this week, or during the rest of 2020. But if the businesses do well, then these big names and the many strong tech stocks that make up much of the Nasdaq-100 should have further to climb. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Datadog, DocuSign, and Zoom Video Communications. The Motley Fool recommends DexCom and recommends the following options: short August 2020 $130 calls on Zoom Video Communications. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""37 Stocks to Buy in the Second Half of 2020 Our Roundtable experts identify stocks left behind in the rebound but poised to emerge even stronger after the crisis.""]"
DXCM,2020-07-14,99.14,102.83,95.28,102.585,
DXCM,2020-07-15,103.75,104.998,101.808,104.485,
DXCM,2020-07-16,103.282,104.055,100.178,103.305,"Is Dexcom Stock a Buy? There's a simple, straightforward argument for investing in Dexcom (NASDAQ: DXCM). The company specializes in the development of continuous glucose monitoring (CGM) systems, which help diabetes patients keep track of their blood glucose levels. Diabetes is the seventh leading cause of death in the country, according to the U.S. Centers for Disease Control and Prevention (CDC). About one person in 10 in the U.S. has diabetes, and 88 million have pre-diabetes. Monitoring blood glucose levels is critical for those who suffer from this condition, meaning Dexcom's services are in high demand. Perhaps as a result of these factors, the company's stock has performed well recently. Year to date, Dexcom's shares are up by 88%. Still, there's more to consider before pulling the trigger. Let's take a closer look at Dexcom's business, financial results, and competition, and decide whether it is worth buying its shares today. DXCM data by YCharts Dexcom's first-quarter results Dexcom's main growth driver is the G6 CGM System. This digital device allows diabetes patients to monitor their blood sugar levels continually. As such, it presents several advantages over the old-fashioned glucose monitoring system. Traditionally, those with diabetes had to rely on pesky fingersticks that could only tell one's blood glucose level at a particular point in time. The G6 System (and other devices like it) is more convenient. Dexcom's crown jewel continues to make significant headway, and as a result the company has been posting strong financial results. During the first quarter, Dexcom recorded revenue of $405 million, representing 44% year-over-year growth. The company also reported operating income of $33.6 million, compared with the operating loss of $14.4 million it reported during the year-ago period. Lastly, DexCom's net income per share of $0.22 was significantly better than the net loss per share of $0.30 it recorded during the prior-year quarter. ""Our strong first-quarter results demonstrate the continued momentum in our business, driven by growing awareness and customer satisfaction with our G6 CGM technology,"" said Dexcom CEO Kevin Sayer. Image source: Getty Images. There is a lot of room to grow for Dexcom, both in the U.S. and abroad. Domestically, the company estimates that the type 2 diabetes space remains underpenetrated, with its total market size reaching about 27 million patients. In international markets, the use of CGM systems ""remains far less than that of fingersticks,"" according to Dexcom executive vice president Steve Pacelli. Further, the company is currently developing a successor to its G6, appropriately named the G7. The G7 will present several advantages over the G6. For instance, it will be smaller and last longer than its predecessor. This device is currently undergoing a pivotal clinical trial, and despite a delay caused by the COVID-19 pandemic, Dexcom has high hopes for the G7. Thanks to the market opportunities in the U.S. and abroad, and the potential launch of the G7 in the future, Dexcom could have a bright future ahead. Challenges Dexcom faces stiff competition within the CGM market. Two of the company's peers within this segment are Abbott Laboratories and Medtronic. Abbott's Freestyle Libre is a CGM system that continues to make significant headway. During the first quarter, sales of this device soared by more than 60% year over year, according to the company. Meanwhile, Medtronic's MiniMed 670G is an insulin pump that comes with its own CGM. The company also offers other devices within its diabetes group business. During its latest reported quarter, Q3 2020, Medtronic's diabetes segment recorded revenue of $610 million, which remained flat compared to the prior-year quarter. But thanks to the increased adoption of the MiniMed 670G abroad, Medtronic's revenue in international markets grew by 13.7% year over year. The competition from Abbott, Medtronic, and others will continue to present a strong challenge for Dexcom. The verdict Dexcom's potential market remains vast, and the company will likely continue to make steady progress within its niche thanks to its ability to innovate. And while I think investors should keep an eye on the competition, I believe Dexcom is poised to remain a leader in the CGM business, and the company will continue to outperform the market in the long run. In short, Dexcom is a healthcare stock worth buying today. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-07-17,104.165,107.438,103.312,106.108,
DXCM,2020-07-20,107.69,109.25,106.848,108.092,
DXCM,2020-07-21,108.092,108.75,105.095,107.255,
DXCM,2020-07-22,107.705,108.685,104.42,106.538,
DXCM,2020-07-23,106.815,109.418,104.01,105.002,
DXCM,2020-07-24,105.115,106.219,100.662,105.438,"Notable ETF Inflow Detected - VOT, DXCM, LULU, SPLK Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap Growth ETF (Symbol: VOT) where we have detected an approximate $108.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 45,267,122 to 45,888,819). Among the largest underlying components of VOT, in trading today DexCom Inc (Symbol: DXCM) is down about 0.8%, lululemon athletica inc (Symbol: LULU) is up about 0.3%, and Splunk Inc (Symbol: SPLK) is lower by about 1.1%. For a complete list of holdings, visit the VOT Holdings page » The chart below shows the one year price performance of VOT, versus its 200 day moving average: Looking at the chart above, VOT's low point in its 52 week range is $106.0746 per share, with $177.31 as the 52 week high point — that compares with a last trade of $172.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-07-27,107.04,107.04,102.895,105.858,
DXCM,2020-07-28,105.792,107.884,104.15,104.448,
DXCM,2020-07-29,107.458,111.18,102.92,106.77,"[""Noteworthy Wednesday Option Activity: OMC, DXCM, HES Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Omnicom Group, Inc. (Symbol: OMC), where a total volume of 14,293 contracts has been traded thus far today, a contract volume which is representative of approximately 1.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64.5% of OMC's average daily trading volume over the past month, of 2.2 million shares. Especially high volume was seen for the $47.50 strike put option expiring August 21, 2020, with 13,641 contracts trading so far today, representing approximately 1.4 million underlying shares of OMC. Below is a chart showing OMC's trailing twelve month trading history, with the $47.50 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 5,286 contracts thus far today. That number of contracts represents approximately 528,600 underlying shares, working out to a sizeable 55.8% of DXCM's average daily trading volume over the past month, of 947,375 shares. Especially high volume was seen for the $420 strike call option expiring January 21, 2022, with 508 contracts trading so far today, representing approximately 50,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $420 strike highlighted in orange: And Hess Corp (Symbol: HES) options are showing a volume of 10,745 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 50.2% of HES's average daily trading volume over the past month, of 2.1 million shares. Particularly high volume was seen for the $41 strike put option expiring August 28, 2020, with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of HES. Below is a chart showing HES's trailing twelve month trading history, with the $41 strike highlighted in orange: For the various different available expirations for OMC options, DXCM options, or HES options, visit StockOptionsChannel.com. Sponsored Links The US States People Are Fleeing And The Ones They Are Moving To Forbes Read More Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""How DexCom More Than Doubled Wall Street's Q2 Earnings Estimate Some stocks might be struggling in 2020, but not DexCom (NASDAQ: DXCM). As of earlier this month, it even ranked as the best-performing stock in the S&P 500 Index so far this year. DexCom, which makes continuous glucose monitoring (CGM) systems for diabetes management, announced its second-quarter results after the market closed on Tuesday, and there was plenty of good news for investors. Here are the highlights. Blood sugar information on a smartphone. Image source: Getty Images. By the numbers DexCom reported second-quarter revenue of $451.8 million. This reflected a 34% increase from the prior-year period's revenue total of $336.4 million. The consensus among Wall Street analysts projected Q2 revenue of $415.74 million. The company announced Q2 net income of $46.3 million, or $0.48 per share, based on generally accepted accounting principles (GAAP). This represented a huge improvement from the net loss of $10.5 million, or $0.12 per share, reported in the same quarter of 2019. DexCom posted adjusted net income of $77.1 million, or $0.79 per share, in the second quarter. This was a big increase from adjusted earnings of $7.8 million, or $0.08 per share, in the prior-year period. It also trounced the average analyst earnings estimate of $0.35 per share. Behind the numbers Demand continued to be exceptionally strong for DexCom's G6 CGM system. The company attributed its success to increased \""awareness of real-time CGM.\"" An increase in sales was only one factor behind the tremendous bottom-line improvement, though. The company's gross profit margin rose to 62.8% in Q2 from 61.4% in the prior-year period. DexCom also held the line on spending. Total operating expenses increased by only 4.3% year over year to $216.3 million. When operating expenses rise at a much slower rate than revenue rises, higher earnings are usually a slam dunk. Thanks to its strong performance in the second quarter and a convertible note offering, DexCom padded its already-impressive cash stockpile. The company reported cash, cash equivalents, and short-term marketable securities of over $2.5 billion, up from $1.53 billion at the end of 2019. Looking ahead DexCom reinstated its full-year 2020 guidance. It projects revenue will increase 25% year over year to around $1.85 billion. The company expects its adjusted gross profit margin will be at least 65% with an adjusted operating margin of at least 14%. The margin for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) is anticipated to be 24% or higher. The COVID-19 pandemic doesn't appear to be a concern at all for DexCom's growth. Perhaps the only question for the healthcare stock is how increased competition from Abbott Laboratories' recently approved FreeStyle Libre 2 integrated CGM system will impact G6 sales. Find out why DexCom is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of June 2, 2020 Sponsored Links Chuck Norris In His 80's Says: \""Try This Once A Day For More Energy\"" America Morning Supply Watch now Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Inc (DXCM) Q2 2020 Earnings Call Transcript Image source: The Motley Fool. Dexcom Inc (NASDAQ: DXCM) Q2 2020 Earnings Call Jul 28, 2020, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom Second Quarter 2020 Earnings Release Conference Call. My name is Adrienne, and I'll be your operator for this call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] Please note this conference call is being recorded. I'll now turn the call over to Sean Christensen. Sean, you may begin. Sean Christensen -- Senior Investor Relations Manager Thank you, operator and welcome to DexCom's second quarter 2020earnings call Our agenda begins with Kevin Sayer, DexCom's Chairman, President and CEO, who will provide a summary of the quarter followed by a financial review and outlook from Quentin Blackford, our COO and CFO and then a strategic update from Steve Pacelli, our Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call up for your questions. At that time we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today. Please note, there are also slides available related to our second quarter performance on the DexCom Investor Relations website on the Events & Presentations page. With that let's review our Safe Harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties and actual results could differ materially from those anticipated in these forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our second quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Sean and thank you everyone for joining us today. We entered the second quarter with several areas of uncertainty as COVID-19 quickly spread and I am incredibly proud of how the DexCom teams have responded. We established three pillars for our organization to ensure the safety of our employees, to maintain service continuity for our customers who rely on their G6 CGM systems and third to do our part to assist our communities as we address this novel virus. We are executing well on all three of these measures and the results are indicated in our second quarter financial and operational performance. Total revenue grew 35% on a constant currency basis in the second quarter, driven by our significant growth in new patient additions over the past year. This represents more than $115 million of absolute dollar growth over the same period in 2019. This growth includes steady traction in the type 2 market, where we continue to see strong new patient additions as coverage expands. As of the close of the second quarter, the type 2 patient population exceeds 20% of our total US patient base, reflecting our growing traction as market access expands. Even with rising CGM awareness there remain many people who continue to rely on finger sticks to manage diabetes and we believe that there remains a significant opportunity for growth ahead in our core type 1 and type 2 intensive markets. As we discussed in April, new patients were slowed at the start of the quarter as clinicians transitioned to support their patients via telemedicine. We did see a nice recovery in new patient additions in late April and over the remainder of the quarter. Especially in the US with our sales and patient care teams doing a great job to ensure that both customers and clinicians were aware of the full set of DexCom tools to enable virtual care. The strength of our core business also reflects our focus on the service experience that we provide. Whether through our pharmacy channel initiative, the scaling of our customer support organization or the user interface and tools we've built to our software solution, we are prioritizing the needs of our customers. We are now two years into the launch of our G6 system and the feedback that we continue to receive from our patients is incredible. In fact, net promoter scores for G6 have now reached all-time highs according to both third-party industry analysis as well as our own internal measurements. This includes the most recent dQ&A industry survey of type 1 and type 2 intensive patients in which G6 received a net promoter score of 83, well ahead of our competitors and in line with the initial results that we saw immediately after the launch of G6 in 2018. Our scores have been especially high among new Medicare customers where the transition to our no fingerstick G6 system has been very well received by both type 1 and type 2 intensive users. Our customers are achieving these results while paying an out-of-pocket cost that is comparable or often less than the out-of-pocket cost of our largest competitor. As we've mentioned before, G6 has the lowest out-of-pocket cost for Medicare patients and will be at parity with any other CGM classified as Class II iCGM by the FDA. The pharmacy channel has also proven to be a wonderful option for many of our customers and remains our preferred long term channel. For customers using pharmacy benefits now, nearly 70% have an out-of-pocket cost less than $60 per month and 30% pay no out-of-pocket cost. Notably this data is based upon the first five months of 2020 when patients are more likely to have deductibles still outstanding. As you can see our products continue to demonstrate their ability to perform in real-world settings and drive patient outcomes at affordable levels. This includes the use of DexCom CGM in additional populations beyond those with insulin intensive diabetes. As we mentioned on the first quarter call, on April 1st we received an allowance from the FDA to provide DexCom CGM to hospitals during the COVID crisis, allowing for remote monitoring on any of their hospitalized patients. Our primary goal in this initiative was and continues to be the assistance of front line workers during the pandemic and the team has been working continually with sites to get CGM implemented. We've made great progress to date in training hospitals and the feedback we have received from the care teams has been great. An example, near to us in San Diego, Scripps Health published a case study on their use of DexCom G6 since the start of the COVID pandemic and highlighted several encouraging points. The use of G6 was eagerly embraced by the hospital and nursing teams with high rates of satisfaction among patients as well. Early data indicates a trend toward reduced incidence of low and high glucose values across all patients who used CGM. And specific to COVID-19 patients, visits into the patients' rooms have been decreased by 30% to 50% during the length of stay, saving valuable equipment and also reducing viral exposure for the hospital staff. As we stated previously, our hospital efforts were not a material driver of revenue in the second quarter and we do not expect it to be for the current year. But the data that we are generating is invaluable as we assess the regulatory pathway forward for this important market, whether it is the shift to telemedicine, the hospital initiative or our efforts to expand access for the type 2 population with our various partnerships, our team continues to press forward in the midst of the challenges brought on by COVID. We've successfully doubled G6 capacity in the first half of the year, putting us in a great position operationally to address the significant market opportunities ahead of us. G6 is a platform technology. During the past 12 months, we have seen the launch of a very successful automated insulin delivery system at Tandem, significant progress at Insulet and other automated insulin delivery partners, introduction of the first billing [Phonetic] enabled MDI systems utilization of an app developed specifically for the type 2 diabetes program at UnitedHealthcare and the recent launch of G6 Pro to meet a very important market need. We plan for numerous customer experience and product enhancement, as well as new market opportunities for this platform over the next two years. And many of these initiatives will be incorporated into the G7 platform going forward. And finally onto G7 where we are pressing forward on several fronts. As we said on the last call, COVID-19 has affected our timelines on this project, specifically pivotal studies would be delayed for at least six months due to uncertainty at the clinics. And we are going to be fully ready for G6 conversion when we launch. Some G7 manufacturing scale activities have been delayed as some of our vendors shut down for a meaningful periods of time. And let me remind you, we are going to be fully ready for a G7 conversion when we launch and a very small amount of G6 equipment can be used for G7. I am not going to provide you with specific clinical trial, filing and launch dates today. In this competitive world, we have no interest in sharing our playbook with the entire industry. There will not be a limited launch of G7 in 2020. Such a launch would not provide a meaningful financial impact and rushing to accommodate such a launch would ultimately delay our long-term plans. Design of the hardware, sensor and electronics is locked and the G7 algorithm is complete. We have used our extra time to add some great enhancements to this system. We are back in the clinics. We are in the process of finalizing clinical sites and timing for the US and OUS pivotal studies. Our first fully automated G7 line is up in San Diego. Additional G7 automation equipment is arriving regularly in San Diego and Mesa and at third-party contract manufacturers. I will now turn the call over to Quentin for a review of our financials. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the second quarter of 2020, we reported worldwide revenue of $451.8 million compared to $336.4 million for the second quarter of 2019, representing an absolute dollar increase of more than $115 million and growth of 34% on a reported basis and 35% on a constant currency basis. The strong growth continued despite some of the challenges posed early in the quarter by the pandemic with continued new patient growth reflecting the overall momentum behind real-time CGM in both the type 1 and type 2 patient populations. As Kevin noted, we are meeting this shift toward real-time CGM with a product in G6 that customers love leading to our record net promoter score levels. Our US business remained very strong in the second quarter with growth of 38% over the second quarter of 2019. This growth extended across all three of our primary US channels, pharmacy, DME and Medicare. Pharmacy remains the fastest-growing channel among the three and our teams continue to prioritize this as a key component of our long-term strategy based on the benefits provided to DexCom, clinicians and especially our customers. The majority of national plans and PBMs are now covering DexCom via the pharmacy benefit with many incorporating a dual pharmacy and DME benefit. Our international business grew 22% in the second quarter on a constant currency basis with consistent growth across our direct and distributor markets. We did see a greater impact to new patients and certain international markets as a result of COVID in the second quarter compared to the US. Unlike the first quarter, the reduced access for in-clinic visits for new patients did not allow us to offset our anticipated second quarter price impact with the same degree of volume gains. However, we remain confident in our long-term strategy, as we saw improvement throughout the quarter with new patient growth recovering and our direct markets returning to strong growth in June as well as distributor orders beginning to rebound early in the third quarter. We are creating streamlined pathways for new patients to access DexCom CGM through different channels in our international markets. Building from the successful launch of a Canadian e-commerce platform, which drove record new patient growth following its launch in 2019, we recently expanded the e-commerce opportunity to our UK market and are encouraged by the similar early results. Canada and the UK were among our highest growth markets in the second quarter. Our second quarter gross profit was $289.7 million or 64.1% of revenue compared to 61.4% of revenue in the second quarter of 2019. Gross margin was sequentially consistent with our Q1 performance and consistent with the expectations that we noted on the Q1 call for a more muted improvement between Q1 and Q4 of 2020 as we continue to ramp cost associated with the introduction of our G7 lines. Importantly, we now have our first G7 line in place and producing product for clinical trials. The 270 basis point year-over-year margin improvement was driven primarily by product design developments, most notably our lower cost transmitter. Operating expenses were $213 million for Q2 2020 compared to $200.3 million in Q2 2019. This reflects an increase of 6% year-over-year and a 1,240 basis point reduction as a percent of revenue from the second quarter of 2019. As an organization, we continue to make great strides as we invest in the initiatives that will DexCom's long-term growth while also remaining disciplined as an organization and this is evident in our second quarter results. Just as COVID did impact our top line, it also had an impact on certain spending activities, which resulted in some of the operating margin improvement during the quarter and was therefore temporary in nature. As a result, we expect moderation in the year-over-year margin comparisons in the second half of the year as we invest in several key initiatives for the Company, including the G7 clinical trials, G7 manufacturing scale-up, our new market efforts and direct-to-consumer advertising that we began to accelerate late in the second quarter. Operating income was $76.7 million or 17% of revenue in the second quarter of 2020 compared to $6.2 million or 1.8% of revenue in the same quarter of 2019. This reflects a year-over-year improvement of more than 1,500 basis points in operating margin for the quarter. Adjusted EBITDA was $122.6 million or 27.1% of revenue for the second quarter compared to $45.9 million or 13.6% of revenue for the second quarter of 2019. Net income for the second quarter was $77.1 million or $0.79 per share. Over the past two years, we have made tremendous progress toward becoming a profitable company. As a result, it is now becoming evident that we are going to be able to utilize the significant historic tax benefits that we have accrued over time and we are approaching a position where in the near future we expect to release the valuation allowance that we have been required to place against many of our tax benefits in the past. This is something that we have been in front of and planning for, including the implementation of a global tax structure over the last couple of years that will allow us to continue to expand rapidly and efficiently on a global basis. As we set expectations for 2021, we will look to provide clarity around our annual tax rate expectations and leverage the benefits associated with the tax structure we put in place in contemplation of such an event. In early May, we took advantage of market conditions to further solidify our balance sheet with a new convertible note offering. On the strength of the offering, we closed the quarter in a great financial position with more than $2.5 billion of cash. Utilizing a combination of the cash generated from the convertible note offering, as well as DexCom stock, we redeemed the majority of our 2022 convertible notes in the second quarter and will redeem the remainder later this week. Our cash position leaves us in great shape to pursue the growth opportunities ahead of us, including support of the development of new markets, opportunistic investment in capabilities that complement our growth and capital allocation into our G7 scale-up in Malaysian manufacturing facility. As we look to the second half of the year, there remain several areas of uncertainty as we contemplate the continuation of the COVID pandemic and its global impact, including employment rates and uptake of our patient assistance program in the US. Nevertheless, based on our experience in the second quarter, the tools that our teams have developed to support virtual patient care and a growing clinical awareness of the value of CGM, particularly in the current environment, we believe there is enough visibility to reinstate full-year guidance. We now expect 2020 revenue to be approximately $1.85 billion, representing growth of 25% over 2019. This represents an increase of $100 million from the midpoint of our initial 2020 guidance resulting from the strength of the business in the first half of the year. Our teams have responded well and continue to drive new patient adoption and ensure the satisfaction of our existing patients. Given the recent uptick in COVID cases globally and in the US in particular, our guidance assumes approximately 75% to 80% of our original expectations for global new patients in the back half of the year, which was consistent with what we had experienced in late March and into April at the outset of the COVID outbreak globally. Turning to margins, we now anticipate the following non-GAAP results to meet or exceed the following levels, which are ahead of what we established at the start of the year, including increasing gross margin expectations to meet or exceed 65%, representing a steady improvement over 2019. This includes costs associated with the initial development of our Malaysia manufacturing facility in support of the growth of our international business and is in line with our long-term expectations for gross margins in the mid 60%s. We are now increasing operating margin expectations to meet or exceed 14%. This revised guidance contemplates the increased second half spending associated with the initiatives that I previously mentioned yet still demonstrating annually year-over-year improvement as we leverage our strong top line results. Finally, we are increasing our expected adjusted EBITDA margins to meet or exceed 24% for the year. Our team has done a great job to execute on our goal of doubling G6 capacity in the first half of 2020 despite an extraordinarily difficult and unanticipated operating environment putting the Company in its best position since the launch of G6 to meet the many opportunities in front of us and we now look forward to replicating that momentum with the scale-up of our G7 lines. With that, I will now turn the call over to Steve for a strategic update. Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Thanks, Quentin. We continue to make great strides in executing on our strategic priorities, even as we navigate the current environment with the utmost care for the health of our employees, the continued service of our patients and assistance to our communities. The doubling of G6 capacity in the first half of the year has placed us in a great position to creatively target new customers and extend the launch of G6 in several of our existing markets. We are getting steady traction among type 2 insulin intensive customers building from our efforts to drive expanded access beyond Medicare into the commercial payers as we've seen with UnitedHealthcare and more recently Aetna, both of which now provide access through the pharmacy. At the recent virtual ADA conference, we presented encouraging data on a subset of our type 2 intensive patients after their first 12 weeks of usage of G6. The data demonstrated average A1C reduction of 1.5%, significant improvement to quality of life metrics and 95% customer satisfaction with G6. COVID has also brought a clear focus to the long-term potential for CGM and the importance of glycemic control. We've spoken at length about the large market opportunities ahead for DexCom, including our focus on the broader type 2 market, hospital use and use during pregnancy. The fact that all three of these populations have now received exemptions to allow for broader access to DexCom CGM during the pandemic provides validation for these new market expansions. In early April the FDA made special allowance to permit the use of CGM in the hospital setting. In early May, we saw a special ruling from CMS to allow access to all people with diabetes who are diagnosed with COVID-19. And earlier this month, Health Canada issued an interim order for the use of G6 for all women with diabetes who are pregnant during the pandemic, and more and more data continue to emerge supporting these decisions and the value of CGM beyond the intensive insulin using population. At ADA, our partners at Onduo presented data comparing the impact of CGM versus non-CGM use in their virtual diabetes clinic. While both cohorts of patients ultimately saw a significant A1C decrease, the group using DexCom G6 saw a reduction nearly two times as much as those not using CGM. In addition, earlier this month UnitedHealthcare announced the expansion of their level two digital health therapy to more than 230,000 people with type 2 diabetes. This program, which utilizes G6 as a core component, saw great results in United's initial pilot work, including clinically significant A1C reduction for those with a baseline A1C greater than 8 [Phonetic] and significant reductions to medication usage with some participants even achieving remission and no longer needing medication. We are pressing forward in support of our various partnerships to reach the whole type 2 population, including our work with UnitedHealthcare, Intermountain Healthcare, Livongo, Welldoc, Onduo and others. We are also excited about the launch of our G6 professional products which has several appealing use cases as we explore the full value of our CGM platform. We are also excited about the launch of our G6 professional product which has several appealing use cases as we explore the full value of our CGM platform. The product provides a natural extension into the type 2 non-intensive market by leveraging the strong existing reimbursement framework for professional CGM with a tool that empowers clinicians. G6 Pro gives doctors the flexibility to assess a patient's glycemic health in real time for all patients with diabetes. As a single-use product G6 Pro will also serve as a great introduction for a patient looking to experience the functionality of DexCom CGM. G6 Pro can also be prescribed for use in blinded mode where the patient does not see the real-time data to all people, ages two years and up, not just people with diabetes, providing all people with the opportunity to assess their glycemic health. Our strategy of prioritizing interoperability and patient choice continues to leave us well positioned as the insulin delivery market shifts toward commercial connected devices. In early May, we signed an agreement to collaborate with Ypsomed, adding another key partner to our existing partners in Eli Lilly, Insulet, Novo Nordisk and Tandem Diabetes. Sean Christensen -- Senior Investor Relations Manager Thank you, Steve. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Adrienne, please provide the Q&A instructions. Questions and Answers: Operator Thank you. [Operator Instructions] And our first question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Baird -- Analyst Thank you. Good afternoon, guys. Can you hear me OK? Kevin Sayer -- Chairman, President and Chief Executive Officer We can. Perfect. Jeff Johnson -- Baird -- Analyst Great. Thanks for all the information on the call and congratulations on the quarter. So, Kevin and Steve, you both touched on the hospital and pregnancy gestational use. I guess what I'd love to hear an update on is maybe the pathway and timeline to maybe extending some of those reimbursements to more of a permanent nature whether that's Canada, the UK where we've seen some of the movement on gestational over the last year or even in the US. Just again pathway and timelines on how we should think about when those could become more permanent contributors to the model. Thank you. Kevin Sayer -- Chairman, President and Chief Executive Officer You bet. I'll take that, Jeff. On the hospital side, we are really now just starting to gather data from the centers that use CGM. When we started the whole hospital initiative, it was just let's get the product out there and help the staff at the hospitals and also make patients healthier and we navigated through a series of things that we really didn't anticipate very well, such as the IT systems at the hospital and things of that nature. So we're now starting to gather data. We also have learned interestingly enough that a lot of the hospitals, even though they all got the same product had different protocols and different way they use CGM. Some of these centers would put it on anybody with diabetes, somebody would put [Phonetic] anybody with elevated glucose levels and others would take the approach, we're not going to do this until somebody is really sick. So we're going to learn more about the protocols and how it was used and start gathering data about the center and how it work and all. So we're going to try and gather data with respect to how these patients were treated from a drug side as well. Anecdotally, what we've heard is our product performed in the hospital the way we thought it would, that its accuracy and performance really wasn't affected by the compounds used to treat these patients. And we should have a pretty good picture of where it is. We've not had any additional discussions with the agency on hospital data yet, because we really haven't had anything in a form that we could present that would start us down a path. As far as next steps in the hospital, we will take a -- we still have the ability to use the product in the system and with COVID not going away, I think we'll be able to gather more data. And now that we've been through this initial wave of learning, we'll probably get better data and more data and know what we're looking for going forward and put together data. We will present that to the FDA and at the same time we'll present them what the plan as to what we think we need to do next. That's going to be a while and -- but we've got some time to gather more data. On the gestational side and the pregnancy side, we have seen some countries open up and say, hey, let's go do this, the UK and Canada that you pointed out. We've had very detailed discussions with the FDA as to what we need to do on the pregnancy side to get that label and we are working on that. We all know, the product works very well in pregnancy. All you got to do is go to social media and see all the DexCom patients who have had a child that they never thought they would have who have diabetes. Our type 1 patients on gestational side, we think our opportunity is outstanding, not only from a manage those patients who have gestational diabetes as a predictor of those who may in fact get it. And again we are running studies. There are studies being run by many others to determine what that model looks like. I think our first step there, Jeff, is we need to get just a pregnancy indication with the FDA, rather than a specific gestational one and then head down the line to develop a product and a platform that fits into that market on a cost-effective and a positive outcome basis. But we're very optimistic that it will. Operator And our next question comes from Kyle Rose with Canaccord. Your line is open. Kyle Rose -- Canaccord -- Analyst Great. Thank you very much for taking the questions. I just wanted to talk a little bit about the quarter and maybe just kind of understand any differences you're seeing in underlying the patient behavior or patient demand in states or geographies that have high levels of COVID currently or any states or geographies that don't. I'm just trying to understand how much of an impact we saw to new patient starts with respect to COVID in the quarter and how we should think about the potential for the rising case volumes, potentially increase in the second half of the year? Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, we didn't quantify exactly what we believe the impact to be in the second quarter, but we tried to give some color and it's the foundation for how we thought about the back half of the year as well. If you look at the end of March and into April, new patient starts when COVID was really starting to ramp at that point in time was roughly 75% of kind of that normal range that we would have expected. So you saw about a 25% impact on the new patient starts at that point in time. Now I will say over the course of the quarter, end of June, we saw that rebound nicely back in line with previous expectations, as things started to come under a bit of control. Now we saw it pick up a little bit in July as the COVID cases have increased a bit more that we're all aware of, and we were very clear in our guidance that we're assuming roughly 75% to 80% of new patient starts throughout the back half of the year. That's the best data point we have at this point in time. So I would just take you back to that reference point of 75% to 80% roughly new patient starts throughout the month of April is kind of how we saw the impact in the quarter. Operator And our next question comes from Ryan Blicker from Cowen. Your line is open. Ryan Blicker -- Cowen and Company -- Analyst Hi. Thank you for taking my question. Can you talk a bit more about the recent launch of UnitedHealthcare's level 2 program? How significant of a catalyst is this for non-intensive type 2 adoption in the US? And do you believe that this program together with Intermountain data that you've shared suggests that CGM use will be more frequent and sustained among non-intensive type 2 patients over the long term than the intermittent use case you've historically discussed? Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Yeah. I think it's -- this is Steve. It's certainly evolving, but I think these are all validating points for us, right, that certainly, UnitedHealthcare serves more than 230,000 non-insulin taking type 2 patients and we would hope that over time, that program is expanded pretty dramatically beyond where it is today. We're in the midst of just continuing to capture data and prove out the value of this technology in the non-intensive patient population. We know we have something there. We know it's important. Whether it becomes a real-time all-the-time use case over time, it very well could be. We're seeing some very positive outcomes for people using it for, frankly, a longer period of time than maybe we would have cited previously. So there is an opportunity. Reimbursement is still in its infancy in the non-insulin using patient population. So we've not only got to prove the outcomes, we've got to get the product paid for. So it's still not even the balance of this year, not going to be a material piece of the business, but it's going to continue to grow over the coming years, for sure. Operator And our next question comes from Robbie Marcus from JPMorgan. Your line is open. Robbie Marcus -- JP Morgan -- Analyst Thanks. Appreciate the question and congrats on a good quarter. Quen, I want to maybe spend a little bit on the guidance here. You touched on new patient expectations. Usually at the beginning of the year, at JPMorgan, when you give guidance, you give us a little flavor for how we should think about revenue per patient and the headwind expected there for throughout the year as you shift into pharmacy and restructure some of your negotiations on price and international. So I was wondering if you could give us a little bit more flavor as we're halfway through the year, what's baked into guidance? And also, if you could spend some time walking us through the bottom line expectations. You put up a fantastic adjusted EBITDA this quarter. How much of that really is the new baseline? And if you could quantify how much was just deferred spending that we should expect in the back part of the year. Thanks. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Great. So with respect to the first part of that question around top line and revenue per patient or maybe the pricing headwinds that we've talked about historically, certainly we came into the year with an expectation that that was going to be somewhere around $125 million to $150 million, likely being closer to that $150 million range. I can tell you that based upon where we saw price coming in in Q2, it was right in line with our expectation. We have not changed our pricing assumption and our full year guidance at this point in time. We still expect it to be around the $150 million range. So not anything significant in terms of a change there. The strategy we've put in place to step this down over time continues to play out exactly as we had expected. So that continues to be consistent. With respect to the bottom line, we've made incredible progress from a profitability perspective really over the last, call it, four or five quarters now with nearly 1,500 basis points of improvement in operating margin profile in Q2 alone. There's no question that some of the spending was impacted in the quarter, particularly around efforts like DTC as we started to pull back some of that early in the quarter just with the uncertainty around how COVID was going to impact things over the course of the quarter and into the back part of the year. I will tell you, we did start that back up in early Q3. So you're going to see incremental spending in the back half of the year around things like DTC. The other thing to keep in mind that's going to impact your spending trends that won't allow the same kind of improvement in Q2 to play through in the back half of the year is the fact that we're starting up the G7 trials. We've been very open and deliberate about the spend that's going to go into that. We're putting forward quite a bit of resources around standing up those manufacturing capabilities and ensuring that capacity is going to be there right out of the gate. We do have the first line-up. There's incremental lines coming right behind it as we speak and building out that entire supply chain capability. And then finally, we've already spent some time talking about it on the call today, but you look at opportunities like hospital, gestational, those are significant revenue drivers for us into the future. We're going to make sure that we're spending in those areas to ensure that open those up and provide for growth into the future. So we are going to spend in the back part of the year. You're not going to see the same sort of improvement. But at the same time, we're committed that over time, we will continue to mature as an organization. We're going to step toward the long-term goals of profitability that we've laid out. And I think we've made great progress toward it, but you're not going to see these sorts of improvement every single quarter. I think you need to look at it over a period of time. Operator And our next question comes from comes from Margaret Kaczor from William Blair. Margaret Kaczor -- William Blair & Company -- Analyst Hey. Good afternoon, guys. Thanks for taking the question. I wanted to follow up on the type 2 mix this quarter. The 20% number seemed pretty strong and it seems like it's increasing. So, can you guys give us any sense around where these patients are coming from? Are they top prescribers for DexCom or other T1s or anything on patient profile, new to CGM or early adopters? Long story short, as we look at that T2 growth, even within the intensive population going into the back end of this year and into next, is it push or pull or is it getting easier at all? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Well, this is Kevin. I'll take that. It is getting easier. And I think the biggest catalyst in all this was when we got Medicare approval a while ago, and now we're getting Medicare awareness with these insulin-using patients because a large number of insulin-using patients in this type 2 population are, in fact, Medicare patients. So, that has been a big catalyst for growth, particularly as we've gotten better at serving and taking care of those patients. I think the other catalyst is just the approvals we were seeing from some of the large payers. Steve pointed out, UnitedHealthcare. United has been covering type 2 patients on intensive insulin recently, again, giving more patients access to it. As these patients are having positive outcomes, access is growing and they're matching the CMS approvals that we've already received. So, it's coming across the board and it's not coming just from our primary prescribers, they are coming from everywhere. Many of these patients don't even see endocrinologists. So, they're finding out about DexCom and coming to us directly because of our marketing efforts and because what they've heard word of mouth or what they've seen from others. We've always felt this would be a great use of our technology, and it's proving to be exactly that. Operator And our next question comes from Jayson Bedford from Raymond James. Jayson Bedford -- Raymond James -- Analyst Hi. Good afternoon. Thanks for taking the questions. So, I guess, just on the international business, it looks like that's probably the only place you could really pick at here. Quentin, can you just summarize why the growth was a bit slower than historical trend? You seem to infer that trends in the direct market picked up in June and in distributor markets in July. Can we assume that you expect a greater than seasonal impact in international sales in the second half? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, it's a fair question. I think it's a bit premature to speak to that fact in terms of playing out over the course of Q3 with respect to the distributor orders. Certainly, we saw those orders start to come through and in the third quarter, I think the question becomes based upon what was happening with COVID in the broader environment today, do we see that actually rebound and double up in terms of the orders in Q3 or does everything just kind of defer and push a bit. Our guidance would contemplate the fact that it pushes at this point in time just based upon the best information that we have. If it were to all come in then terrific, I think we'd be very happy. Just a little bit of color around that OUS result. I think what you're seeing there is very comparable to what the broader marketplace and the industry realized over the course of the quarter as well. I think if you look at the data points that have been put out there by our competitors, thus far, they saw a slowdown in growth in Q2 in their international business, just as we did sequentially, absolute dollars step down from Q1 into Q2, which we certainly saw as well, but the broad market saw the same thing. So, I don't think you're seeing anything that's unique to DexCom. I think over time, we remain as bullish as ever on the international opportunity. We've stated the fact that we're going to step down price over time in the international space as well. And when you have a quarter like Q2 where the ability for new patients to get into the clinic and come on to the product becomes a bit muted, you see a bit more of a pronounced impact. So, that's all part of a long-term strategy that we believe in and are very bullish around. So, we're still very, very optimistic and excited about that international business, but that's a bit of color that played out in Q2. And with respect to Q3, our view is that things probably push. But if we see it rebound, it's been great, there's upside to the number. Operator And the next question comes from Joanne Wuensch from Citibank. Your line is open. Joanne Wuensch -- Citibank -- Analyst Good afternoon and nice quarter. ADA seems like 1 million years ago now, June, but can you give us an idea of what the key things were that you walked away from that you think we'll be talking about over the next 18 months? Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, I'll take that one. I think, again, the walk away from ADA is how important CGM has become in all this. Almost every presentation you went through every presentation we saw the performance of drugs, the performance of other systems is based on CGM data. From DexCom's perspective, obviously, the drive of the automated insulin delivery systems was largely driven by DexCom sensors, regardless of who the presenter was up at the pulpit other than Medtronic and we can see our sensor can drive great outcomes there. I think the other takeaway is we're not stopping innovation in diabetes. Everybody is still pushing forward, and we still think there's better ways to attack this. This is a big cost and healthcare problem in our country and around the world. And I don't think anybody is going to slow down. But our biggest takeaway, compare that to your first ADA, Joanne, where we had to beg for anybody even listened to us. And now every place we go and just our industry goes, CGM has become the dominant technology here across all of the diabetes treatments and we're looking forward to just continuing to be better. Operator And our next question comes from Matt O'Brien from Piper Sandler. Your line is open. Jason -- Piper Sandler -- Analyst Hi. Good afternoon. This is Jason [Phonetic] on for Matt. Thanks for taking the questions. Congrats on a nice quarter here. Kevin or Steve, a higher-level question on the non-intensive side. Appreciate some of the comments you made, but hope you can discuss maybe how you perceive these models or programs evolving over the next few years? Do you expect the revenue model to be similar to what you see with the intensely managed population? Or do you expect it to take different forms with maybe some possible risk-sharing or shared cost saving developments? Just anything you can offer there and how you see the contracts coming together over time, now that you've been engaged with payers and other partners on various models. Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. This is Kevin. I'll add a bit to Steve's comments earlier. We don't see one solution yet. We are working with a number of partners on the payer front. We're working with clinics. We're working with a lot of these diabetes management systems as well to provide CGM data to that to figure out what the best model for these patients is. We're not only working with these partners, but we're doing a lot of market research on our own. In one of Steve's comments that is becoming very evident in all the work that we do is type 2 patients are more than open to wearing CGM and learning what's going on with their bodies. They want a different experience than we offer today for the type 1 patients connecting to insulin pumps and Bluetooth pens and sophisticated predictive alerts and alarms and things like that we have today are not as important to that group. But what is important to that group is that they're healthy and that we can reduce their meds, that we can reduce their costs, that we can make their physician visits more productive and we can make changes in their help that save them these complications over the years. So I think what you'll see is we'll continue to pursue all these models, at the same time, we're going to pursue the proper product configuration and reimbursement models for us. I've been in numerous discussions where we ask, if we get paid X for an intensive patient for a year, what should we -- what should be the reimbursement rate for non-intensive type 2 because the fact is we aren't saving their life on a near-term basis. With an alert and alarm, we are not giving them something that determines their drug dosing decision, but we are giving information to better manage their lives. So, we think there may ultimately be a different class of product here and a different form of reimbursement even if patients wear them all the time, which is, again, another reason we're investing so much in scale here, because we like these things everywhere. I think the market is developing nicely and the constant threat [Phonetic] coming from all these approaches, if this thing works. Operator And the next question comes from Travis Steed from Bank of America. Your line is open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Hi. Thanks for taking the questions. Just wanted to touch on the hospital channel a bit more. I'd just love to hear how you're going to approach the commercial aspect longer term, you don't really have reps in the hospital. Do you need a partner there or are you planning to build out a separate sales force? And also, I don't know if you're willing to say the revenues generated in the hospital this quarter if that was a few million dollars or more than that? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer The revenues in the hospital wouldn't have a significant impact on the financials. The costs far exceeded the revenue. So, we'll leave it at that. With respect to the channel, we've not made a decision there as far as how we'd pursue that. We are early enough in this process that we're not ready to adopt a commercial model. We want to leave our options open. We would explore partners. We would explore doing it ourselves. But we'll figure out where to best use our dollars and then we haven't made a decision there yet. Operator And the next question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good afternoon. Thanks for taking the question. Quentin, just a quick follow-up here for you on guidance. So, in the second half, you're effectively assuming that new patient start rates are similar to sort of the trough of COVID, even though there probably has been some improvement and you're not assuming any distributors sort of recoup in ex-US markets. And just kind of related to that, can you just give us a sense ex-US whether this was country-specific or just broadly ex-US? Because our sense is maybe Germany performed differently than Canada, performed differently than France. So, those two quick ones? Thank you. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah. I think in the prepared remarks, we were pretty clear with the fact that we saw COVID did impact certain countries a little bit differently than others. UK and Canada performed incredibly well, particularly on the e-commerce platform that we had put in place. Germany certainly was impacted and our distributor markets were certainly impacted. On the distributor point, again, I think it's just too early to tell if that's going to double up in Q3 or if that's just going to be simply something that pushes out over the course of the remainder of the year. I think at some point in time, it will catch up to itself, and we'll be back on that same trajectory. It's just too hard to predict if that happens in the next six months or not. And our guidance would be based off the fact that it does not, that it's been pushed. That's kind of how we thought about it. So -- and then your point on just the new patient starts in the back half of the year. Like I said, we're trying to create some clarity for you guys in the back half of the year around what we're confident that we can deliver on. We're using the best data points that we have from our experience. And that 75% to 80% new patients start is what we realized early in the second quarter as COVID was kind of starting to really gain some traction. We've seen COVID numbers increasing here recently in the third quarter as well. And so that's the best data point that we have. So, that's how we went about putting the numbers together. Obviously, if we can navigate through that more effectively or to a better degree, then there's going to be opportunity in the guidance number, but we don't want to get ahead of ourselves at this point. Operator And the next question comes from Larry Biegelsen from Wells Fargo. Larry Biegelsen -- Wells Fargo -- Analyst Hey, good afternoon, guys. Thanks for taking the question. Kevin, as you mentioned upfront, Medicare is not enforcing the clinical criteria for CGM during the pandemic. It's unclear if this applies to all type 1 and type 2 patients or just those affected by COVID. How broadly have physicians interpreted this rule and what impact have you seen in the market? And do you expect CMS to continue to allow this exception through next year? Thanks for taking the question. Kevin Sayer -- Chairman, President and Chief Executive Officer You bet. We do not believe it's had an exceptional impact on our business, as far as bringing more Medicare patients to the table. And -- but they are coming. On a broad scale basis, as we look at the Medicare ruling, we would be very pleased if we could get the criteria for Medicare patients much more condensed and much more realistic. We actually met on that this morning. And one of the things pointed out yet again to me is, Medicare requires our patients to document that they do four fingersticks a day before they go to CGM and our patients only reimbursed for three fingersticks a day by CMS. So there are large inconsistencies there. And this is a product that has tremendous impact with these patients. It would certainly be our goal to have these coverage criteria and the steps that patients have to go through to get CGM simplified and more broadly applied across all of diabetes. But that's something we're working on now, and I can't anticipate where CMS is going to go. But it certainly makes sense that we do that. Operator And our next question comes from Danielle Antalffy from SVB Leerink. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hey. Good afternoon, guys. Thanks so much for taking the question. Congrats on another very strong quarter. Just a quick question on the type 2s. I think you mentioned it's now 20%. I think you said of your installed base, correct me if I'm wrong, maybe you said new patient adds. But how has that changed versus the year-ago period? Just trying to get a sense of how that might be growing. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. No, it's certainly increasing nicely, particularly as we continue to focus in that particular area. The 20% is of the installed base. So we didn't give a sense in terms of the overall growth in that particular area. But we've talked about our focus there in opening up those channels. And I think the fact that we're now talking about it just indicates the progress that we're making there. So that's the extent of the detail we've given around it. Operator And our next question comes from Mathew Blackman from Stifel. Your line is open. Mathew Blackman -- Stifel -- Analyst Good afternoon, everyone. Thanks for the question. And Quentin, thanks for the color on new patient start headwinds. I was hoping you could extend those comments, the installed base. Any notable change in attrition or utilization rates during the quarter or the first half of '20? And are you making any changes to how you're thinking about those same attrition utilization risks in this new guidance? Thanks. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah. Great question. We didn't really see anything over the course of Q2. But to be fair, I think, it's probably a bit early to really understand whether or not we will see an impact. And therefore, we have contemplated something in our guidance in the back part of the year around our patient assistance program or attrition. And keep in mind, we announced during the second quarter that we would be putting in place a patient assistance program, but that wasn't going to be effective until the third quarter. Our view is that, if a patient were going to a trip, they would likely fall into that program. So when we talk about guidance in the back half of the year, you've got a couple of things playing out there. You've got the new patient starts that we've been very clear. 75% to 80% is how we've modeled it. But then we also are assuming that we're going to see some impact on attrition, and they're going to fall into this patient assistance program, which is going to mean quite a bit less revenue to us, obviously, than what we might have normally received from them. So that's playing out in the back part as well. Operator And the next question comes from Chris Pasquale from Guggenheim. Chris Pasquale -- Guggenheim -- Analyst Thanks. Quentin, two quick model questions. First, just any numbers you could put around the expense shift from 2Q into the back half of the year. The leverage was really impressive. It would be great to have a better sense for how much of that was one time. And then can you give us any broad strokes on what you're thinking in terms of the tax rate once you start reporting one from an income statement perspective? Thanks. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah. We're not going to talk to the tax rate just yet. I think we need to get to the point where we flip that valuation allowance. We don't know exactly when that's going to be just yet, but we know that it's coming here in the near future. And the last thing I want to do is like I said, put a couple of $100 million gain through the financial statements that surprises everybody in the particular period. I think it's important to know we're out in front of this. We anticipate it. We've put a tax structure in place that's going to allow us to have a very efficient global tax structure and grow globally in a very efficient way with a very attractive tax rate. So we've been well in front of this for quite some time, and the point is just to start to put it on your radar. With respect to the other question, sorry, remind me what the other question was. Opex in the back part of the year. Chris Pasquale -- Guggenheim -- Analyst Yeah. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer So there wasn't a significant impact that moved the needle meaningfully in the second quarter. I mean, call it, roughly $10 million or so of spend that likely would have showed up in the quarter had we not been impacted. But I think importantly, the back half of the year is where you're going to see a significant ramp in the overall spend profile, particularly with G7 clinical trials getting go and G7 scale really taking off. And then turning on the DTC spigot for the first time in a significant way. I think one of the things that maybe is not as appreciated by folks is that historically, we've always been constrained from an inventory position. We exited Q2 in the strongest inventory position that we've been in with respect to G6 in our Company's history. That allows us to start to open up opportunities like DTC in a significant way that we believe can drive growth into the future. So you're going to see that play out. Spending is going to be significantly higher in the back half. When you do your modeling, it's going to be almost $100 million of spend higher in the back half. We recognize that and realize it. But those things that I just indicated are going to be the areas that we primarily focus on in our spending. Operator [Operator Instructions] And Ravi Misra, your line is open from Berenberg Capital. Ravi Misra -- Berenberg Capital -- Analyst Hi. How are you doing? It's Misra. I hope everyone is OK. I just want to pick your brains a little bit more around the reimbursement for some of this less intensive insulin management patients, Steve or Kevin, can you help out to think about what's the index comps control in terms of what you think you need to do to establish that use case in a kind of payment? Thanks. Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Obviously, first and foremost, it's to build, as Kevin mentioned, to build the right products for this patient population. We think the products are going to be different. They're not going to have all the -- there won't be nearly as -- I don't want to say nearly as robust because the performance of the underlying sensor will be the same. But having some of the bells and whistles that we need for the intensive insulin population just don't apply to type 2. The software experience needs to be different. So those types of things are within our control or even, frankly, within the control of some of our partners that we've talked about, right? Livongo offers a patient experience to their patients. United, the Level 2 program is an experience that we've developed together with United, but it's really a UnitedHealthcare patient experience. So we're not going to -- there's not going to be a one-size-fits-all here. We're going to offer our own tools. We do offer our own tools today, and we're going to enable multiple players in this business to offer the appropriate tools to this patient population, because we know it's such a massive opportunity that it would used as to [Phonetic] just make our sensors available to anybody who's a viable company. Operator And the next question comes from Steven Lichtman from Oppenheimer. Your line is open. Steven Lichtman -- Oppenheimer -- Analyst Thank you. Hi, guys. Wondering if you could provide some more color on the e-commerce initiatives that you mentioned are expanding internationally. In what ways has it helped in Canada and now UK during COVID in terms of driving new patients and getting them started on CGM? Kevin Sayer -- Chairman, President and Chief Executive Officer Well, certainly, I think from an access perspective, it just makes it very easy for the patient to be able to find our product available right on the web in their particular country. And in many ways, it becomes something we can scale relatively easily. And we choose new countries to take it into. And I think that when folks are searching or trying to learn about the product and then they have the ability to purchase it, right there at their fingertips in a web platform, it just makes it naturally easier to come on to the technology. And I think you see what played out in Canada in terms of record number of new patients shortly after we launched it. The early success in the UK clearly speaks to the benefit of the e-commerce platform as well. So I think it's something that we can scale over time as we take into new countries and it clearly has the benefits with it. I think you heard in the prepared remarks, nearly 70% of all of our patients come on to our product for their first time through some sort of either virtual training or online training capability or in-app capability. So the e-commerce platform kind of lends itself very naturally into that ability to come on to the product. Operator And our next question comes from Matt Taylor from UBS. Your line is open. Yem -- UBS -- Analyst Thanks. This is actually Yem [Phonetic] in for Matt. Maybe a question on the DTC ads. Can you talk a little bit about the impact that might have on second half growth? What's the focus in terms of the patient segment or geographically, are you able to take advantage of lower ad rates to go a little bit more aggressive on that? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. This is Kevin. I'll take that. With respect to the ad rates and the spending, I don't get too involved in that one anymore. I leave that to the other guys. But our team is very targeted with respect to the ads that we develop, where we run them, when we run them, and we have tremendous systems in place to monitor the leads that come in from those ads. We have, again, a team in place that if you watch our ad and email us and want of information, we get back to those patients very quickly. They don't wait for several days. It's a matter of hours and we give back those patients and let them know we are here and we will help them and educate them and who to get their insurance information, their doctor information, everything that patient might need. We do track that spending and where we spend it, we track the results from it, and then we invest in those places where we think it will be better. But we are seeing -- working from home now, we see DexCom ads whenever we watch television a lot more than we used to. And I think they've been very successful and our team is really good at this. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer And I would just say, from a return on investment perspective, there's not a better investment that we can make inside of these four walls today than direct-to-consumer spending. It's amazing, the capability that the team has put together in the targeted effort there to drive results. Operator Thank you, ladies and gentlemen, this concludes today's Q&A session. I will now turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you very much, operator, and thanks everybody again for being on our call today. We saw a headline come across our phones while we're sitting here what pandemic, DexCom rocks here. I just want to tell everybody that we did have a great quarter, but we were affected by this like everybody else. Our commercial teams had to completely change the way they worked. And I had a town hall meeting with our team in the Philippines last week and the stories of some people who literally kept themselves locked up in the city for two months, away from their families to help patients are incredibly inspiring. We've all been affected by this and working from homes. And it's safe to say like everybody else, we've never experienced anything or planned for anything like this. But what an amazing six-month this Company has had in this environment? I just want to list a few accomplishments over the last six months in closing today. And we completed a financing that gives us the balance sheet strength necessary to accomplish all of our long-term goals. We achieved an absolute -- worldwide absolute dollar sales growth increase of $240 million during this chaotic time. Our type 2 business on the intensive insulin side is demonstrating strength and the outcomes we always said we'd have with these patients. We've waited a long time to execute on this plan, and we finally got into the hospital and we think that will be a great market for us. Our financial performance is exceeding all of our plans on the bottom line, providing us with operating cash to reinvest in our business as we talked about money that we need to spend over the next six months of the year. Our G6 satisfaction scores are at all-time highs again during this period of chaos. We have a great product supported by a very dedicated team. Let's not forget our pipeline. G7 progress is excellent. As I said earlier in the call, the groups working on this project are hitting on all cylinders. And there is nothing more exciting at DexCom than the sense of urgency related to a platform change like this that's such a monumental effort. We are redoing everything that we do now to bring this incredible product to market. G7 is not the only thing in our pipeline. We're spending numerous hours talking about G8, 9 and 10 and whatever else comes in the future, but we're also making sure we don't ignore G6. We have numerous product improvements and patient experience improvements with G6 that will be out over the next couple of years. We don't ever sit still. I just completed a series of virtual presentations for various groups here at DexCom. And one of the questions I was asked to answer is, why has the company been so successful? And I narrowed my answer down to a very simple statement. We provide a solution to a very serious problem and we do it better than anybody else ever has. As we look to the future, we can continue to do that only, we can do it much better than we do it today, and we believe we can solve many more problems in the same manner. It's going to thrill the healthcare community. And more importantly, we're going to save patients, caregivers, healthcare professional and payers' time, money, and we're going to continue to save lives. Thank you, everybody. Operator [Operator Closing Remarks] Duration: 63 minutes Call participants: Sean Christensen -- Senior Investor Relations Manager Kevin Sayer -- Chairman, President and Chief Executive Officer Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Jeff Johnson -- Baird -- Analyst Kyle Rose -- Canaccord -- Analyst Ryan Blicker -- Cowen and Company -- Analyst Robbie Marcus -- JP Morgan -- Analyst Margaret Kaczor -- William Blair & Company -- Analyst Jayson Bedford -- Raymond James -- Analyst Joanne Wuensch -- Citibank -- Analyst Jason -- Piper Sandler -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Mathew Blackman -- Stifel -- Analyst Chris Pasquale -- Guggenheim -- Analyst Ravi Misra -- Berenberg Capital -- Analyst Steven Lichtman -- Oppenheimer -- Analyst Yem -- UBS -- Analyst More DXCM analysis All earnings call transcripts {%sfr%} Find out why DexCom is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of June 2, 2020 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-07-30,105.838,108.058,104.06,107.84,
DXCM,2020-07-31,108.695,110.532,106.252,108.885,
DXCM,2020-08-03,110.155,112.362,108.098,110.918,"[""The DXCM Paradox: Analysts Bullish But Forecast -2.05% Fall Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with DexCom Inc (Symbol: DXCM). The average 12-month price target for DXCM \u2014 averaging the work of 18 analysts \u2014 reveals an average price target of $426.61/share. That's a whopping -2.05% below where DXCM has been trading recently at $435.54/share. With this kind of downside potential (should DXCM fall to that price target), one might expect to see a high concentration of \""hold\"" or even \""sell\"" ratings on the stock. Yet, take a look at the bullishness: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 15 15 15 15 Buy ratings: 1 1 1 1 Hold ratings: 4 4 4 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.45 1.45 1.45 1.37 The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.45 for DXCM leans strongly towards the bullish end of the spectrum, yet the DXCM price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at DexCom Inc. Of course, the average price target is just that \u2014 a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $540.00. And then on the other side of the spectrum one analyst has a target as low as $190.00. The standard deviation is $84.229. But the whole reason to look at the average in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes \u2014 much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with DXCM trading so far above that average target price of $426.61/share, the -2.05% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good \""signal\"" to investors in DXCM to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for DexCom Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stocks Robinhood Investors Should Buy With $1,000 The coronavirus disease 2019 (COVID-19) pandemic has made this one of the wildest year on record for the stock market. In a five-month stretch, we've witnessed the fastest bear-market descent in history, the strongest quarterly rally in 22 years, and the tech-heavy Nasdaq Composite log more than two dozen all-time highs. Suffice it to say that it's been volatile. Generally speaking, volatility can be a great thing for investors. That's because it allows long-term-minded investors to buy into great companies at a discount. Image source: Getty Images. However, increased periods of volatility also have a knack for bringing short-term and novice investors out of the woodwork. Online investing platform Robinhood, which is known for attracting millennial and/or novice investors, is the current posterchild for this short-term thinking. In recent months, we've witnessed Robinhood investors pile into Hertz following its Chapter 11 bankruptcy filing, Eastman Kodak after being awarded a $765 million government loan, and Nikola, despite the electric-truck manufacturer having not collecting a cent in revenue. Robinhood's leaderboard (i.e., a list of the platform's most-held stocks) is a minefield of generally awful companies or stocks that are hot for a very short period of time. The thing is, Robinhood absolutely has the potential to be a platform that kick-starts young investors on their path toward financial freedom. But in order to do so, Robinhood investors will need to think for the long-term and focus on buying higher-quality businesses. It's also important for young investors to understand that starting capital isn't a constraint. If Robinhood investors are working with $1,000 of investment capital, they have more than enough to buy game-changing stocks for the long haul. Here are three perfect examples for Robinhood's members to consider buying. Image source: Square. Square First of all, forget chasing bankrupt companies and penny stocks when you have the ability to buy a financial technology powerhouse like Square (NYSE: SQ). Most folks probably know Square best for its seller ecosystem, which provides point-of-sale devices to small and medium-sized merchants. For years, this seller ecosystem has allowed Square to collect merchant fees. What's really interesting, though, is that this point-of-sale platform isn't just for small businesses any longer. During the March-ended quarter, 52% of the gross payment volume (GPV) that traversed Square's network came from larger businesses, which by Square's definition entails at least $125,000 in annualized GPV. Making inroads with bigger businesses should lead to higher merchant fees and less of a payment processing drop-off when the next economic contraction strikes. However, it's Square's Cash App that'll be its primary sales growth and profitability driver throughout the decade. Cash App is a peer-to-peer payment platform that can be used to transfer money to and from a traditional bank account, and can also be linked to Cash Card for more traditional purchasing activity. It's become especially popular during the pandemic as people shift away from using cash. Furthermore, Robinhood's younger investors will appreciate that Cash App allows forbitcoin exchangeand direct investments. Exchanging fiat currency for bitcoin is actually one of the most profitable functions for Cash App. Wall Street is counting on Square to more than quadruple its sales between 2019 and 2023, which makes it a fintech stock Robinhood investors are going to want to own. Image source: Getty Images. DexCom A second high-growth stock whose potential isn't fleeting is medical-device maker DexCom (NASDAQ: DXCM). And don't let its nearly $440 share price scare you off -- it has plenty of upside still to come. DexCom is a manufacturer of continuous glucose monitoring systems (CGM) for patients with diabetes. Instead of patients pricking their fingers on a regular basis to test their blood sugar levels, a CGM provides consistent readouts that can be used two ways. Either the real-time data can be displayed on a DexCom wireless device, a smartphone, or a smartwatch for the patient to act on (if need be), or it can be sent wirelessly to an insulin pump, which will dispense doses of insulin on an as-needed basis. Aside from the simplicity of use, DexCom's CGMs are fueling patient convenience and treatment personalization. The company's Clarity software allows diabetics to aggregate their blood glucose readings into easy-to-read digital reports that can be sent to a primary care physician or specialist. This can be especially helpful during a pandemic, with diabetics not having to leave their house to get critical data to their doctor. Investors should also understand what a monstrous market opportunity CGMs are in the United States. According to the Centers for Disease Control and Prevention, 34.2 million people in the U.S. have diabetes (75% of which know it), with another 88 million exhibiting symptoms of prediabetes. DexCom's potential patient pool is enormous, and it continues to grow every year. Although DexCom isn't what you'd call a fundamentally cheap stock, it is a company that's expected to deliver 20%-plus growth on an annual basis for many years to come. Image source: Getty Images. Facebook A third stock Robinhood investors should scoop up is social media giant Facebook (NASDAQ: FB). It may not be the sexiest pick, considering there are other high-growth social media platforms folks could invest in, but its consistency is unmatched. Last week, Facebook reported its second-quarter operating results, ended June 30. Even with COVID-19 as a serious headwind -- remember, most U.S. states and developed countries were on lockdown throughout much of April and some portion of May -- Facebook saw its monthly active user count grow by approximately 100 million to 2.7 billion from the sequential first quarter, with family monthly active people surpassing 3 billion to hit 3.14 billion. On a year-over-year basis, family monthly active people grew by 14%. The point is, no social media platform offers access to more eyeballs than Facebook. Though there may be other sites with faster active user growth, it's Facebook that advertisers are going to seek out for targeted campaigns. This gives Facebook a ridiculous amount of ad-pricing power. Another exciting aspect of Facebook is that the company is still in the relatively early innings of its growth. Though this might sound like a head-scratcher of a statement for a company that might generate $78 billion in sales in 2020, you should know that Facebook still hasn't monetized Facebook Messenger or WhatsApp. Once Facebook begins monetizing these highly popular platforms, it should see a significant surge in sales and cash flow. As one final note, don't overlook Facebook's non-ad-based revenue potential. In the second quarter, \""other\"" revenue spiked 40% from the previous year to $366 million. This \""other\"" category includes the sale of Oculus virtual reality headsets and Portal, the company's smart video calling device. These innovations, along with Facebook Pay, could be sneaky growth drivers this decade. 10 stocks we like better than Facebook When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Facebook wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Facebook and Square. The Motley Fool owns shares of and recommends Facebook and Square. The Motley Fool recommends DexCom and recommends the following options: short September 2020 $70 puts on Square. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-04,110.524,110.705,108.659,110.472,
DXCM,2020-08-05,110.438,113.75,109.151,112.948,
DXCM,2020-08-06,113.102,113.222,107.39,109.75,
DXCM,2020-08-07,110.22,114.058,108.755,110.175,
DXCM,2020-08-10,109.828,109.958,101.553,105.305,"[""BUZZ-U.S. STOCKS ON THE MOVE-Eastman Kodak, Trevena, Seres Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow rose on Monday, as investors rotated into value stocks from heavyweight tech-focused companies while awaiting word on progress in the fiscal support bill for the country's battered economy. .N At 12:59 ET, the Dow Jones Industrial Average .DJI was up 1.00% at 27,708.02. The S&P 500 .SPX was up 0.11% at 3,354.97 and the Nasdaq Composite .IXIC was down 0.37% at 10,970.489. The top three S&P 500 .PG.INX percentage gainers: ** MGM Resorts International , up 13.5% ** Royal Caribbean Cruises Ltd , up 9.9% ** Wynn Resorts Ltd , up 8.9 % The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 4.9% ** Tyler Technologies, Inc , down 4.5% ** Fiserv Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Biomx Inc , up 53.2% ** John Hancock Multifactor Materials ETF , up 42.1% ** Seritage Growth Properties , up 18.2% The top three NYSE .PL.N percentage losers: ** Navidea Biopharmaceuticals Inc , down 30.8% ** Eastman Kodak Company , down 27.3% ** Universal Security Instruments Inc , down 11.7% The top three Nasdaq .PG.O percentage gainers: ** Seres Therapeutics, Inc , up 353.3% ** Omeros Corp , up 51.4% ** Adamas Pharmaceuticals Inc , up 36.2% The top three Nasdaq .PL.O percentage losers: ** Scworx Corp , down 44.1% ** Reata Pharmaceuticals Inc , down 33.3% ** Hycroft Mining Holding Equity Warrants , down 32.3% ** Ocugen Inc OCGN.O: up 25.1% BUZZ-Rises on fourth orphan drug status for eye disease therapy ** Canopy Growth Corp CGC.N: up 8.9% BUZZ-Jumps on smaller-than-expected loss ** Nikola Corp NKLA.O: up 18.7% BUZZ-Jumps on new 2,500 EV garbage truck order ** PPL Corp PPL.N: up 5.3% BUZZ-Rises after initiating sale process for UK business ** MGM Resorts International MGM.N: up 13.5% BUZZ-Jumps on IAC stake, online gaming scope ** Virgin Galactic Holdings Inc SPCE.N: up 6.1% BUZZ-Rebounds after Abu Dhabi's Mubadala discloses 7% stake ** NewAge Inc NBEV.O: down 9.6% BUZZ-Falls after Q2 revenue misses estimates ** Chevron Corp CVX.N: up 2.4% ** Exxon Mobil Corp XOM.N: up 1.9% ** Callon Petroleum Co CPE.N: up 5.8% ** Marathon Oil Corp MRO.N: up 3.7% ** Whiting Petroleum Corp WLL.N: up 7.2% ** Cabot Oil & Gas Corp COG.N: up 1.6% ** Occidental Petroleum Corp OXY.N: up 4.1% ** Schlumberger NV SLB.N: up 3.1% ** Halliburton Co HAL.N: up 3.8% BUZZ-Oil stocks gain on positive China data, hopes for U.S. stimulus ** Northern Dynasty Minerals Ltd NAK.N: down 3.5% BUZZ-Falls as Biden opposes Alaska mine project ** Exelon Corp EXC.O: down 1.6% BUZZ-Drops after major explosion in Baltimore ** Radius Health Inc RDUS.O: up 6.2% BUZZ-Rises on better-than-expected Q2 results ** Eastman Kodak Co KODK.N: down 27.3% BUZZ-Plunges as $765 mln U.S. loan put on hold after recent allegations ** Twitter Inc TWTR.N: up 2.2% BUZZ-Jumps on reports co expressed interest in TikTok's U.S. operations ** Simon Property Group Inc SPG.N: up 8.0% BUZZ-Up on report of turning mall space into Amazon distribution centers ** Brookdale Senior Living Inc BKD.N: up 4.3% BUZZ-Jefferies sees higher Q2 costs due to COVID-19 ** Humana Inc HUM.N: up 0.8% BUZZ-Stephens sees strong 2021 growth on Medicare investment strategy ** Trevena Inc TRVN.O: up 27.5% BUZZ-Surges as FDA approves opioid painkiller ** Mallinckrodt Plc MNK.N: up 3.8% BUZZ-Rises as FDA grants priority review for skin therapy ** Seres Therapeutics Inc MCRB.O: up 353.3% BUZZ-Surges as lead drug meets main goal of late-stage study ** Foot Locker Inc FL.N: up 6.0% BUZZ-Soars on surprise rise in same-store sales ** Omeros Corp OMER.O: up 51.4% BUZZ-Jumps on positive data from COVID-19 drug in small study ** Aquestive Therapeutics Inc AQST.O: up 11.3% BUZZ-Up as FDA gives \""fast track\"" tag to allergic reaction drug candidate ** Vaxart Inc VXRT.O: up 5.2% BUZZ-Shares up as co plans to advance COVID-19 vaccine into human trials ** Hoth Therapeutics Inc HOTH.O: up 14.3% BUZZ-Up as co gets licensing rights to potential COVID-19 test ** Wynn Resorts Ltd WYNN.O: up 8.9% ** MGM Resorts International MGM.N: up 13.5% ** Melco Resorts & Entertainment Ltd MLCO.O: up 9.2% ** Las Vegas Sands Corp LVS.N: up 8.0% BUZZ-Casino stocks rise as Macau to partially resume tourist visa scheme ** Reata Pharmaceuticals Inc RETA.O: down 33.3% BUZZ-Drops as FDA asks for genetic disorder drug's second trial ** Majesco MJCO.O: up 23.4% BUZZ-Surges after Thoma Bravo raises offer to buy company The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.40% Consumer Discretionary .SPLRCD up 0.63% Consumer Staples .SPLRCS up 0.22% Energy .SPNY up 2.28% Financial .SPSY up 0.44% Health .SPXHC down 0.37% Industrial .SPLRCI up 1.97% Information Technology .SPLRCT down 0.28% Materials .SPLRCM up 0.67% Real Estate .SPLRCR down 0.04% Utilities .SPLRCU down 0.22% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Eastman Kodak, Trevena, Omeros Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street indexes opened a touch higher on Monday after President Donald Trump signed executive orders over the weekend to support the country's economy through the coronavirus crisis until more concrete stimulus could be passed. .N At 10:46 ET, the Dow Jones Industrial Average .DJI was up 0.96% at 27,697.02. The S&P 500 .SPX was up 0.22% at 3,358.69 and the Nasdaq Composite .IXIC was down 0.73% at 10,930.733. The top three S&P 500 .PG.INX percentage gainers: ** MGM Resorts International , up 13.9% ** American Airlines Group Inc , up 9.7% ** Royal Caribbean Cruises Ltd , up 9.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 4.6% ** Advanced Micro Devices Inc , down 4.5% ** FleetCor Technologies Inc , down 4% The top three NYSE .PG.N percentage gainers: ** Xtant Medical Holdings Inc , up 105.5% ** John Hancock Multifactor Materials ETF , up 42.1% ** Seritage Growth Properties , up 26.7% The top three NYSE .PL.N percentage losers: ** Navidea Biopharmaceuticals Inc , down 35.7% ** Eastman Kodak Company , down 30.7% ** Universal Security Instruments Inc , down 11.7% The top three Nasdaq .PG.O percentage gainers: ** Seres Therapeutics, Inc , up 500.4% ** Omeros Corp , up 54% ** Trevena Inc , up 30.9% The top three Nasdaq .PL.O percentage losers: ** Scworx Corp , down 56.6% ** Addex Therapeutics Ltd , down 28% ** Recro Pharma Inc , down 25.9% ** Ocugen Inc OCGN.O: up 25.2% BUZZ-Rises on fourth orphan drug status for eye disease therapy ** Canopy Growth Corp CGC.N: up 9.6% BUZZ-Jumps on smaller-than-expected loss ** Kandi Technologies Group Inc KNDI.O: down 3.7% BUZZ-Falls on drop in Q2 EV parts sales ** Nikola Corp NKLA.O: up 13.0% BUZZ-Jumps on new 2,500 EV garbage truck order ** PPL Corp PPL.N: up 3.8% BUZZ-Rises after initiating sale process for UK business ** MGM Resorts International MGM.N: up 13.9% BUZZ-Jumps on IAC stake, online gaming scope ** Virgin Galactic Holdings Inc SPCE.N: up 5.1% BUZZ-Rebounds after Abu Dhabi's Mubadala discloses 7% stake ** NewAge Inc NBEV.O: down 4.5% BUZZ-Falls after Q2 revenue misses estimates ** Eastman Kodak Co KODK.N: down 30.6% BUZZ-Plunges as $765 mln U.S. loan put on hold after recent allegations ** Twitter Inc TWTR.N: up 1.9% BUZZ-Jumps on reports co expressed interest in TikTok's U.S. operations ** Simon Property Group Inc SPG.N: up 6.9% BUZZ-Up on report of turning mall space into Amazon distribution centers ** Brookdale Senior Living Inc BKD.N: up 4.8% BUZZ-Jefferies sees higher Q2 costs due to COVID-19 ** Trevena Inc TRVN.O: up 30.9% BUZZ-Surges as FDA approves opioid painkiller ** Mallinckrodt Plc MNK.N: up 3.7% BUZZ-Rises as FDA grants priority review for skin therapy ** Seres Therapeutics Inc MCRB.O: up 500.4% BUZZ-Surges as lead drug meets main goal of late-stage study ** Foot Locker Inc FL.N: up 8.1% BUZZ-Soars on surprise rise in same-store sales ** Omeros Corp OMER.O: up 54.0% BUZZ-Jumps on positive data from COVID-19 drug in small study ** Aquestive Therapeutics Inc AQST.O: up 8.3% BUZZ-Up as FDA gives \""fast track\"" tag to allergic reaction drug candidate ** Vaxart Inc VXRT.O: up 5.1% BUZZ-Shares up as co plans to advance COVID-19 vaccine into human trials ** Hoth Therapeutics Inc HOTH.O: up 10.1% BUZZ-Up as co gets licensing rights to potential COVID-19 test ** Wynn Resorts Ltd WYNN.O: up 9.1% ** MGM Resorts International MGM.N: up 13.9% ** Melco Resorts & Entertainment Ltd MLCO.O: up 8.0% ** Las Vegas Sands Corp LVS.N: up 8.1% BUZZ-Casino stocks rise as Macau to partially resume tourist visa scheme ** Reata Pharmaceuticals Inc RETA.O: down 25.8% BUZZ-Drops as FDA asks for genetic disorder drug's second trial ** Majesco MJCO.O: up 23.6% BUZZ-Surges after Thoma Bravo raises offer to buy company The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.58% Consumer Discretionary .SPLRCD up 0.14% Consumer Staples .SPLRCS up 0.41% Energy .SPNY up 2.67% Financial .SPSY up 1.01% Health .SPXHC down 0.25% Industrial .SPLRCI up 2.06% Information Technology .SPLRCT down 0.79% Materials .SPLRCM up 0.89% Real Estate .SPLRCR down 0.19% Utilities .SPLRCU up 0.10% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Monday Option Activity: CCL, DXCM, DIN Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Carnival Corp (Symbol: CCL), where a total of 154,095 contracts have traded so far, representing approximately 15.4 million underlying shares. That amounts to about 45.9% of CCL's average daily trading volume over the past month of 33.6 million shares. Particularly high volume was seen for the $16 strike call option expiring August 14, 2020, with 9,944 contracts trading so far today, representing approximately 994,400 underlying shares of CCL. Below is a chart showing CCL's trailing twelve month trading history, with the $16 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 4,088 contracts thus far today. That number of contracts represents approximately 408,800 underlying shares, working out to a sizeable 45.6% of DXCM's average daily trading volume over the past month, of 896,560 shares. Especially high volume was seen for the $430 strike call option expiring August 21, 2020, with 576 contracts trading so far today, representing approximately 57,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $430 strike highlighted in orange: And Dine Brands Global Inc (Symbol: DIN) options are showing a volume of 3,199 contracts thus far today. That number of contracts represents approximately 319,900 underlying shares, working out to a sizeable 44.4% of DIN's average daily trading volume over the past month, of 721,015 shares. Especially high volume was seen for the $40 strike put option expiring March 19, 2021, with 1,111 contracts trading so far today, representing approximately 111,100 underlying shares of DIN. Below is a chart showing DIN's trailing twelve month trading history, with the $40 strike highlighted in orange: For the various different available expirations for CCL options, DXCM options, or DIN options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-11,103.752,104.802,100.788,102.788,"After 150 days of the COVID-19 pandemic, here are the best- and worst-performing stocks The tech sector is still in the lead, but consumer-discretionary group trails only slightly The tech sector is still in the lead, but consumer-discretionary group trails only slightly."
DXCM,2020-08-12,103.05,107.605,103.05,106.972,"[""Wednesday Sector Leaders: Utilities, Healthcare Looking at the sectors faring best as of midday Wednesday, shares of Utilities companies are outperforming other sectors, up 1.7%. Within that group, American Water Works Co, Inc. (Symbol: AWK) and NextEra Energy Inc (Symbol: NEE) are two large stocks leading the way, showing a gain of 3.1% and 2.7%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 2.0% on the day, and down 3.61% year-to-date. American Water Works Co, Inc., meanwhile, is up 20.88% year-to-date, and NextEra Energy Inc is up 19.02% year-to-date. Combined, AWK and NEE make up approximately 19.6% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, higher by 1.4%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Hologic Inc (Symbol: HOLX) are the most notable, showing a gain of 4.3% and 3.7%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 1.8% in midday trading, and up 6.12% on a year-to-date basis. DexCom Inc, meanwhile, is up 96.09% year-to-date, and Hologic Inc is up 30.69% year-to-date. Combined, DXCM and HOLX make up approximately 1.4% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, seven sectors are up on the day, while two sectors are down. SECTOR % CHANGE Utilities +1.7% Healthcare +1.4% Technology & Communications +1.4% Energy +0.8% Consumer Products +0.6% Services +0.4% Industrial +0.2% Materials -0.1% Financial -0.7% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Stein Mart, Trevena, Cellular Biomedicine Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Wednesday, with the S&P 500 crawling towards a record high in a broad rally led by tech stocks, although some investors were cautious following a stalemate over the new coronavirus relief bill. .N At 10:29 ET, the Dow Jones Industrial Average .DJI was up 0.90% at 27,937.07. The S&P 500 .SPX was up 1.10% at 3,370.46 and the Nasdaq Composite .IXIC was up 1.82% at 10,979.554. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices, Inc , up 4.7% ** FedEx Corporation , up 4.2% ** DexCom Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Wynn Resorts, Limited , down 3.3% ** Las Vegas Sands Corp , down 3% ** Carnival Corp , down 2.8% The top three NYSE .PG.N percentage gainers: ** Universal Security Instruments, Inc , up 35.8% ** Cornerstone Building Brands Inc , up 21.3% ** Lightinthebox Holding Co Ltd , up 17.1% The top three NYSE .PL.N percentage losers: ** Jumia Technologies AG , down 29% ** Document Security Systems, Inc , down 14.7% ** Griffon Corporation , down 12.9% The top three Nasdaq .PG.O percentage gainers: ** Biofrontera AG , up 85.8% ** Summer Infant, Inc , up 35.7% ** Cellular Biomedicine Group Inc , up 35% The top three Nasdaq .PL.O percentage losers: ** Onespan Inc , down 31.2% ** Super League Gaming, Inc , down 21.8% ** Virtra Inc , down 20% ** K12 Inc LRN.N: down 8.0% BUZZ-Climbs on Q4 profit beat, co sees higher student enrollments ahead ** American Eagle Outfitters Inc AEO.N: up 4.7% BUZZ-Rises as J.P. Morgan upgrades on lingerie brand's promise ** Lemonade Inc LMND.N: down 1.6% BUZZ-Drops as guidance misses in first post-IPO report ** Stein Mart Inc SMRT.O: down 44.7% BUZZ-Sinks on bankruptcy filing ** Trevena Inc TRVN.O: down 17.0% BUZZ-Retreats after pricing $50 mln share offering ** Epam Systems Inc EPAM.N: up 4.8% BUZZ-MS sees demand rising to pre-COVID-19 levels, upgrades ** Moderna Inc MRNA.O: up 1.7% BUZZ-More contracts possible after U.S. COVID-19 vaccine deal - Jefferies ** Overstock.com Inc OSTK.O: down 6.4% BUZZ-Falls after pricing upsized equity offering ** Pacific Ethanol Inc PEIX.O: up 17.1% BUZZ-Surges on qtrly profit vs year-ago loss ** Plug Power Inc PLUG.O: down 6.2% BUZZ-Drops on $300 mln stock offering ** Cellular Biomedicine Group Inc CBMG.O: up 35.0% BUZZ-Jumps on take-private deal ** ResMed Inc RMD.N: up 1.4% BUZZ-Benefiting from higher ventilator sales -GlobalData ** Montage Resources Corp MR.N: down 9.4% BUZZ-Down as rival Southwestern to buy co at discounted price ** JPMorgan Chase & Co JPM.N: up 0.5% ** Citigroup Inc C.N: up 0.3% ** Wells Fargo & Co WFC.N: down 0.2% ** Goldman Sachs Group Inc GS.N: up 1.0% ** Bank of America Corp BAC.N: up 0.6% ** Morgan Stanley MS.N: up 2.3% BUZZ-U.S. big banks gain on stimulus hopes, oil price rise ** Omeros Corp OMER.O: down 11.6% BUZZ-Down after pricing public offering at a discount ** Crown Crafts Inc CRWS.O: up 15.1% BUZZ-Rises on reinstated dividend, strong results ** Marathon Petroleum Corp MPC.N: up 2.3% BUZZ-Cowen upgrades to \""outperform\"" on Speedway sale ** Staffing 360 Solutions Inc STAF.O: down 22.6% BUZZ-Falls on wider Q2 loss ** Home Depot Inc HD.N: up 1.5% ** Lowe's Companies Inc LOW.N: up 1.0% BUZZ-Home Depot, Lowe's rise as analysts raise sales growth forecasts The 11 major S&P 500 sectors: Communication Services .SPLRCL up 1.68% Consumer Discretionary .SPLRCD up 1.17% Consumer Staples .SPLRCS up 1.08% Energy .SPNY up 0.18% Financial .SPSY up 0.62% Health .SPXHC up 1.42% Industrial .SPLRCI up 0.75% Information Technology .SPLRCT up 1.74% Materials .SPLRCM up 1.13% Real Estate .SPLRCR up 0.98% Utilities .SPLRCU up 0.88% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: FLIR, IVZ In early trading on Wednesday, shares of Invesco topped the list of the day's best performing components of the S&P 500 index, trading up 5.5%. Year to date, Invesco has lost about 35.8% of its value. And the worst performing S&P 500 component thus far on the day is FLIR Systems, trading down 2.3%. FLIR Systems, is lower by about 28.1% looking at the year to date performance. Two other components making moves today are Royal Caribbean Group, trading down 2.2%, and DexCom, trading up 3.5% on the day. VIDEO: S&P 500 Movers: FLIR, IVZ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-13,108.2,109.997,107.685,108.82,"[""DXCM Crosses Above Average Analyst Target In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $426.61, changing hands for $427.89/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 18 different analyst targets contributing to that average for DexCom Inc, but the average is just that \u2014 a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $190.00. And then on the other side of the spectrum one analyst has a target as high as $540.00. The standard deviation is $84.229. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $426.61/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $426.61 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 15 15 15 15 Buy ratings: 1 1 1 1 Hold ratings: 4 4 4 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.45 1.45 1.45 1.37 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Top Diabetes Stocks to Buy in August Diabetes is a huge concern in the United States. According to the Centers for Disease Control and Prevention (CDC), more than 34 million people in the United States have diabetes, and 20% of them don't know they have it. That doesn't count the 88 million people in the United States who the CDC says are in the prediabetic stage. The CDC said the number of people living with diabetes has more than doubled over the past 20 years, so the market presents a huge opportunity for companies that concern themselves with treating the disease. The most common form of diabetes is type 2, which CDC research says occurs in 90%-95% of diabetes patients. If you're looking to invest in companies treating diabetes, DexCom (NASDAQ: DXCM), Tandem Diabetes Care (NASDAQ: TNDM), and Novo Nordisk (NYSE: NVO) are worth looking at this month in the healthcare space. Image source: Getty Images. Until last week, I also would have included Livongo Health (NASDAQ: LVGO) on this list. As I said two months ago, the company's virtual-care monitoring system has fostered growth that should continue. However, it was announced last week that Teladoc would acquire Livongo, which, in the short term at least, may actually depress Livongo's share prices. The stock is down 9% in the past week. DexCom is having a great year despite the pandemic Shares of DexCom, which makes continuous glucose monitoring (CGM) systems to help manage diabetes, are up 97% for the year, as of Wednesday. The company announced second-quarter results July 29, and it was all green lights. Reported revenue in the quarter was $451.8 million, a growth of 34% year over year. The big number was $46.2 million -- that was DexCom's quarterly net income, compared with a $10.5 million loss the same quarter last year. Things are going so well that the company reinstated guidance for 2020 with a predicted $1.9 billion in yearly revenue, which represents a 25% improvement over 2019. DexCom's CGM devices eliminate the need for constant finger pricking to measure one's glucose levels. They can easily be worn on the stomach, lower back, or upper arm (though the last method is not yet approved by the U.S. Food and Drug Administration, or FDA) and give readouts on smartphones. Compared with finger sticks, DexCom's devices have an ease of wear and high tech that have helped bring in new patients, the company said. Where DexCom has really benefited is in the revenue related to the replaceable sensors that come with its CGM devices. While hardware revenue was up 2% year over year and 38.5% compared with the same quarter in 2018, sensor-related revenue was up 39.9% year over year and 103% over the same quarter two years ago. Tandem Diabetes Care continues its run of growth A recent report on the insulin pump market predicts a 9.4% compound annual growth rate (CAGR) through 2026. Tandem is well placed to take advantage of that momentum because it has an easy-to-use pump that is gaining market share. Fast-growing companies are a great way for investors to make money, and Tandem fits that bill. In the second quarter, the company's reported sales were $109.2 million, a 17% increase over the same quarter in 2019. The company said it shipped 14,735 pumps in the United States in the quarter, a 15% jump year over year and nearly as many as the 17,000 the company delivered in the entire year of 2017. The market has taken notice, sending Tandem's shares up more than 80% year to date. While the company hasn't turned a profit yet, it lost $24.8 million last year, down from a $122.6 million loss the year before, so it appears on its way. More importantly, it has been growing revenue, with a CAGR of 37.8% over the past five years. Novo Nordisk has found itself a nice niche in diabetes care Novo Nordisk, a pharmaceutical company based in Denmark, specializes in diabetes care, plus treating other chronic diseases such as obesity and rare blood and endocrine disorders. While the company has seen some headwinds because of the coronavirus pandemic, its diabetes business remains solid. The company's share prices are up more than 25% year to date. Novo Nordisk has had three consecutive years of growth in revenue and net income. In its second-quarter report, announced Thursday, it said revenue was $4.8 million, largely flat year over year, while net income was $1.7 billion, an 11% rise over the same period in 2019, beating analysts' estimates. Especially encouraging: the rise of the company's new type 2 diabetes drugs, Ozempic and Rybelsus, both of which are forms of semaglutide, which the company says increases the body's own insulin production. Ozempic, a once-weekly injectable, brought in $1.7 billion globally last year compared with $264 million in 2018, the year it was introduced in the United States. In the first half of the year, it brought in nearly $1.1 billion, a 156% rise over the same period last year. The company really sees big things for Rybelsus, a once-daily pill, which has brought in $64.5 million in revenue in the first six months since it was launched. Rybelsus was approved by the FDA last fall. Like Ozempic, it's used to lower glucose levels and has additional cardiovascular benefits. Novo Nordisk also raised its dividend to $0.52 a share, a 15% raise over last year, offering a yield of 1.36%. DXCM data by YCharts Investing in a growing field of care All three companies present themselves as good opportunities for investment this month. I especially like DexCom because diabetes is a difficult disease to manage, and the company's CGM device makes things easier for patients and gives doctors more information. Tandem has a similar edge because its pump is gaining ground on competitors. Novo Nordisk, however, may be the best long-term option because it is working on drugs to not only manage diabetes but, in some cases, prevent it. 10 stocks we like better than Novo Nordisk When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jim Halley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-14,109.125,110.112,105.776,106.29,"Friday Sector Laggards: Utilities, Healthcare Looking at the sectors faring worst as of midday Friday, shares of Utilities companies are underperforming other sectors, showing a 0.5% loss. Within the sector, Sempra Energy (Symbol: SRE) and AES Corp. (Symbol: AES) are two large stocks that are lagging, showing a loss of 2.1% and 1.6%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.7% on the day, and down 4.97% year-to-date. Sempra Energy, meanwhile, is down 11.60% year-to-date, and AES Corp., is down 9.85% year-to-date. Combined, SRE and AES make up approximately 5.9% of the underlying holdings of XLU. The next worst performing sector is the Healthcare sector, showing a 0.2% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Illumina Inc (Symbol: ILMN) are the most notable, showing a loss of 2.4% and 2.1%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.1% in midday trading, and up 5.70% on a year-to-date basis. DexCom Inc, meanwhile, is up 94.31% year-to-date, and Illumina Inc is up 4.36% year-to-date. Combined, DXCM and ILMN make up approximately 2.3% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, six sectors are up on the day, while two sectors are down. SECTOR % CHANGE Energy +1.3% Financial +1.0% Services +0.8% Materials +0.7% Consumer Products +0.6% Industrial +0.5% Technology & Communications -0.0% Healthcare -0.2% Utilities -0.5% 25 Dividend Giants Widely Held By ETFs » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-08-17,107.242,110.46,106.856,110.23,
DXCM,2020-08-18,111.29,111.578,108.521,109.305,
DXCM,2020-08-19,109.68,110.32,107.26,108.22,
DXCM,2020-08-20,107.978,110.265,107.875,107.97,"[""How Has DexCom Stock Performed in 2020 So Far? Few things will both propel a stock and obliterate expectations during a time when the rest of the industry is struggling. DexCom (NASDAQ: DXCM), maker of continuous blood glucose monitors that free diabetics from pricking their fingers, has done that with each earnings report in 2020, and shares have risen 98%, making it the third-best performer in the S&P 500 Index. As the COVID-19 pandemic was beginning to unfold in the first quarter, DexCom crushed expectations by growing revenue 44% and reporting non-generally accepted accounting principles (GAAP) earnings per share (EPS) of $0.44, compared with a loss in the period a year earlier. Second-quarter results, reported on July 28, also humbled a few analysts when the company posted 34% top-line growth and EPS of $0.79. The consensus estimate was for revenue growth of 24% and EPS of $0.35. Image source: Getty Images. The advantage of continuous glucose monitors (CGMs) is not only convenience but better control of glucose levels around the clock and therefore better health for diabetes patients, a big reason why insurance payers are getting on board to cover them. New patient starts and highly satisfied customers are driving growth of its latest line of CGMs, the G6, and design improvements are taking costs out and raising gross margin. DexCom's outlook for the rest of 2020 and 2021 is excellent. The pandemic caused about a 25% decrease in patient starts in Q2. Although the company is planning for that situation to continue, eventually new patient acquisition will rebound. Next year, the company will unveil its next-generation CGM, the G7, which should give results another boost. DexCom reinstated full-year guidance in Q2, raising its earlier estimate of 17% to 20% revenue growth to 25% and giving investors more reason to own shares of this successful growth stock. Find out why DexCom is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of August 1, 2020 Jim Crumly owns shares of DexCom. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""VO, DXCM, CNC, SPLK: Large Inflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $131.8 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 193,758,259 to 194,502,261). Among the largest underlying components of VO, in trading today DexCom Inc (Symbol: DXCM) is up about 1.1%, Centene Corp (Symbol: CNC) is off about 1.2%, and Splunk Inc (Symbol: SPLK) is up by about 1.2%. For a complete list of holdings, visit the VO Holdings page \u00bb The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $110.05 per share, with $186.74 as the 52 week high point \u2014 that compares with a last trade of $177.09. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-21,108.22,108.701,106.0,106.725,
DXCM,2020-08-24,106.934,107.248,103.625,105.698,
DXCM,2020-08-25,102.852,107.675,102.773,107.518,
DXCM,2020-08-26,106.41,108.38,105.758,106.422,
DXCM,2020-08-27,106.318,107.805,103.255,106.938,"[""These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020 In the days and weeks leading up to the start of the coronavirus pandemic, the S&P 500 index was hitting all-time highs. On Feb. 19 of this year, it achieved a record peak since the Great Recession of 2008, closing at 3,386.15. Then the bottom fell out. By March 23, the S&P 500 had hit a record low, closing at just 2,237.40 -- a more than 1,100-point drop from its high just a month earlier. While this has undoubtedly been an extremely rough year for the stock market, we've seen an impressive rally since March thanks to increased optimism regarding a successful vaccine, the distribution of coronavirus stimulus funds (and hopes for a second round), and low interest rates. On Monday, the S&P 500 closed at its new all-time high of 3,431.28. Throughout the pandemic stock market's highs and lows, some surprising winners have emerged among the S&P 500. Healthcare companies Dexcom (NASDAQ: DXCM), Abiomed (NASDAQ: ABMD), West Pharmaceutical Services (NYSE: WST), Regeneron Pharmaceuticals (NASDAQ: REGN), and IDEXX Laboratories (NASDAQ: IDXX) have flourished while others have fallen to abysmal lows -- and each has a uniquely promising growth story to tell. Let's take a closer look. Image Source: Getty Images. 1. Dexcom A leader in diabetes care, San Diego-based Dexcom makes continuous glucose monitoring systems. In 2018, the American Diabetes Association reported that 10.5% of the U.S. population, or more than 34 million Americans, was diabetic. The World Health Organization reports that in 2016, diabetes was the cause of 1.6 million fatalities across the globe. Diabetes is also one of the conditions associated with a heightened likelihood of severe illness or death from COVID-19. Given these facts, it's not surprising that the demand for Dexcom's products not only boomed but exploded during the pandemic. Dexcom released its first-quarter 2020 results on April 28, reporting a 44% increase in revenue from Q1 2019. Revenue growth in international markets was up 61% in Q1 2020, while domestic U.S. revenue rose by 39% in the quarter, which ended on March 31. On July 28, Dexcom released its financial results for the second quarter ending on June 30. Q2 revenue was up 34% year-over-year. . Its operating income according to generally accepted accounting principles (GAAP) totaled $67.8 million, representing 15% of the company's total revenue for Q2 2020 ($451 million). Dexcom is projecting a 25% increase in revenue for full-year 2020 to $1.9 billion. Dexcom has also made its continuous glucose monitoring products accessible to providers in the U.S. and Canada in an effort to increase the safety of frontline medical workers while ensuring diabetes patients receive the care and attention they need during the pandemic. Shares of Dexcom held firm when the wider market fell in March, and have risen steadily since April. The stock is up nearly 93% year to date. 2. Abiomed With a market capitalization of nearly $14 billion, Abiomed is a large-cap company that develops and manufactures medical devices. The company is known for its Impella system, featuring the smallest heart pump in the world. There's been a fair share of controversy surrounding the company's Impella RP device in particular over the past year. The U.S. Food and Drug Administration (FDA) sent a letter to healthcare providers on Feb. 4, 2019, warning of an increased risk of mortality in patients who received the Impella RP -- more than had been detected in prior premarket clinical studies. However, a subsequent letter sent in May 2019 revealed that subjects showing higher incidence of mortality would not have met the eligibility requirements for premarket clinical studies. This past June, the FDA granted the Impella RP an emergency use authorization (EUA) for cardiovascular patients who have contracted the novel coronavirus. In fiscal 2020, Abiomed reported a 9% increase in revenue to $840.9 million. Its operating income increased nearly 11%. The company also marked the close of fiscal 2020 with zero outstanding debt and more than $650 million in cash. Abiomed's revenue in the first fiscal quarter of 2021 was down about 21% from fiscal Q1 2020, with operating income having decreased 44%. Global sales of Impella were also down 22% in the quarter. Due to the uncertainty regarding the impact of the COVID-19 pandemic on the 2021 fiscal year, Abiomed is keeping mum about its full-year revenue guidance. However, despite its mixed financial performance, the stock is up by more than 80% from its closing price on Jan. 2. Shares of the company have been hovering at about $300 since July. DXCM data by YCharts 3. West Pharmaceutical Services West Pharmaceutical Services fills a void in a less-talked-about side of the healthcare industry. The company makes delivery systems and packaging for pharmaceutical products. It has a market capitalization of nearly $20 billion and pays a modest dividend of about 0.24%. The company is a relative newbie to the S&P 500, having just joined the index in May. Shares of West Pharmaceutical closed at $269.67 on Monday, not far from their 52-week high of $279.54. The stock is up nearly 78% since the beginning of the year. West Pharmaceutical reported strong sales growth in both the first and second quarters of this year. In Q1, the company's net sales increased by nearly 11%; in Q2, that number was more than 12%. The company also boosted its full-year net sales guidance in its Q2 report, anticipating between $2 billion and $2.1 billion. In the first half of the year, West Pharmaceutical's free cash flow was up 42% compared to the first six months of 2019 and totaled $136 million. The company's incredible resilience during a recession isn't surprising. Its wide-ranging product lineup, which includes cartridge systems, vial containers, and intradermal delivery methods, are all essential healthcare solutions in high demand during regular times -- and even more so during the pandemic. 4. Regeneron Pharmaceuticals Shares of Regeneron Pharmaceuticals have climbed steadily since February, up an impressive 59% year to date. The stock doesn't come cheap; one share will run you close to $600. Regeneron reported year-over-year revenue increases of 33% ($1.8 billion) and 24% ($2 billion) in the first and second quarters, respectively. The company's blockbuster drug Eylea, which treats neovascular (wet) age-related macular degeneration, diabetic retinopathy, and other retinal diseases, recorded U.S. net sales of $1.2 billion in Q1 and $1.1 billion in Q2. Another key revenue driver this year has been eczema medication Dupixent, the product of Regeneron's long-standing antibody drug collaboration with Sanofi (NASDAQ: SNY). Notably, sales of Dupixent were up 129% in the first quarter of 2020. The drug was also recently approved by the FDA for children between 6 and 11 who are suffering from mild to severe atopic dermatitis. Regeneron has several products in its pipeline for investors to have hope about. Perhaps the most closely watched is the dual antibody cocktail solution for COVID-19, REGN-COV2, that it's developing and manufacturing in partnership with Roche Holdings (OTC: RHHBY). Under the terms of the agreement, Regeneron would manage domestic distribution of REGN-COV2 while Roche would handle its distribution in international markets. After receiving a positive safety review following the phase 1 study, REGN-COV2 is now being evaluated in multiple late-stage trials. Two phase 2/3 studies are assessing the candidate's efficacy as a potential treatment, and a separate phase 3 study is evaluating its ability to prevent illness in subjects whose household members have contracted COVID-19. Regeneron entered into a $450 million contract with the Biomedical Advanced Research and Development Authority (BARDA) back in July to supply the government with both treatment doses and preventative doses from the initial lots of REGN-COV2. Of course, this is pending the success of REGN-COV2 in late-stage clinical studies and the FDA's issuance of an EUA or approval. 5. IDEXX Laboratories The final stock on our list that has continued to flex its muscles throughout 2020 is IDEXX Laboratories. The company fills a unique niche in animal healthcare, offering a variety of products and services including livestock software monitoring systems, microbiological water tests, software for veterinarians, and pet diagnostic tests. IDEXX's stock has experienced more than 44% growth since the start of 2020, despite an initial 31% dip when the market fell in March. IDEXX is contributing to the fight against COVID-19. The company announced in April that it was launching its IDEXX SARS-CoV-2 (COVID-19) RealPCR Test, a coronavirus diagnostic test for pets. In May, the FDA issued an EUA to IDEXX's subsidiary OPTI Medical Systems, Inc., for a laboratory test kit for humans that identifies the presence of SARS-CoV-2, the disease that causes COVID-19. The test has also received the European Union's CE Mark regulatory certification. As for the company's balance sheet, IDEXX reported $2.4 billion in revenue last year, boosted by 11% recurring revenue in its companion animal group diagnostics (CAG) division. Revenue was up 9% in Q1 to reach $626 million, and in Q2 it rose another 3% to hit $638 million. Both results were also bolstered by its CAG segment, despite the lockdown's adverse impact on routine veterinary visits, which caused delays in diagnostic testing. IDEXX closed the second quarter of 2020 reporting a gross margin of nearly 60% (up 180 basis points year over year) and operating margin over 30% (up 380 basis points year over year). 10 stocks we like better than Regeneron Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Regeneron Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed and Idexx Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020 Although the coronavirus crisis is far from over, it has already transformed the way healthcare players operate. Some companies have seen record demand for their essential medicines, while others have only recently seen their revenues rebound after shutdowns and stay-at-home orders wreaked havoc on their business. In spite of the ups and downs of the year, the timing has actually never been better for investors to get into the market. The top healthcare stocks in the S&P 500 index have returned between 23% and 96% year to date, making the benchmark's 6.6% rally look pretty measly. In a market where winners keep winning and losers keep losing, the best way to ensure the safety of your capital is to buy stocks that are proven performers with future growth potential. Here are the 10 biggest healthcare winners in the S&P 500 index so far this year, and the reasons why they will enrich your portfolio for years to come. Image source: Getty Images. 1. DexCom DexCom (NASDAQ: DXCM) creates continuous glucose monitoring systems that can transform how patients with diabetes manage their condition. To date, the company has captured more than 20% of the type 2 diabetes patient market in the U.S. In its quarter ended June 30, the company's revenue grew by 34% to $451.8 million from the second quarter of 2019. The stock is currently trading at $427, up a whopping 95% year to date. 2. Abiomed Abiomed (NASDAQ: ABMD) is the distributor and manufacturer of Impella, the world's smallest heart pump. The company's product is protected by over 884 patents, with an additional 759 pending. The U.S. Food and Drug Administration (FDA) recently approved Impella for the treatment of certain types of heart failure in patients with COVID-19, which should create strong demand for the device in the near future. Abiomed has no debt and about $600 million in cash on its balance sheet. The company's stock has been handsomely rewarded for this performance, up almost 80% so far this year. 3. West Pharmaceutical Services West Pharmaceutical Services (NYSE: WST) plays a critical role in producing injectable drugs and drug delivery systems. The company is poised to package billions of doses of COVID-19 vaccines as they clear clinical trials. Demand for its services has increased significantly due to the pandemic, and West Pharmaceutical Services is now expecting up to $4.25 earnings per share by the end of the year, which is up from $3.62 in the previous quarter. The stock is trading at 11 times sales, showing that investors are expecting a lot of growth out of the coronavirus vaccine opportunity. 4. Regeneron A notable entry on this list is large-cap biotech Regeneron (NASDAQ: REGN), which markets a diverse portfolio of biologics. The drug Eylea, which is used to treat retinal diseases, generates about $1.75 billion in revenue per quarter. Newly commercialized products, such as Dupixent, used in the treatment of specific allergies, and Libtayo, a cancer treatment drug, generated a stunning $1 billion and $80 million in sales just a few years after their approvals. Regeneron has accumulated about $5.7 billion in cash and investments to offset its $1.5 billion in debt. Year to date, the company's stock has jumped from about $370 to $606. For all its impressive growth, the company is trading at just nine times sales. 5. IDEXX Laboratories As one of the world's largest providers of veterinary and livestock products, IDEXX Laboratories' (NASDAQ: IDXX) financial results have captivated investors. During the second quarter of 2020, the company's annual earnings per share increased by 23% to $1.72. In June, its diagnostics business saw 30% growth compared to May. The company's share price is up 47% this year to $383. IDEXX should continue to benefit from an impressive long-term trend in pet spending; U.S. pet expenditures have gone up every single year for the past 25 years. 6. Bio-Rad Laboratories Bio-Rad Laboratories (NYSE: BIO) is a leader in life science research and clinical diagnostics development. Last quarter, the company recorded $536.9 million in revenue and $48.3 million in earnings from strong growth in sales from its COVID-19 and medical tests. The company is in a superb financial position, with $1.03 billion in cash and investments, which is enough to offset its $438.7 million in debt. At seven times price-to-sales, this is a good deal for investors looking for growth at a reasonable price. 7. Hologic Women's health and technology company Hologic (NASDAQ: HOLX) stock has been on a tear this year due to the popularity of its COVID-19 diagnostic tests. There are now 13 million of the company's tests utilized per week, accounting for more than 25% of the total COVID-19 testing market. Hologic can manufacture up to one million tests per week, which helps the company generate about $324 million per quarter in revenue. At $66.11, or 27 times price-to-sales, the company's stock may have more room to appreciate based on continued demand for coronavirus testing. 8. Danaher Medical conglomerate Danaher (NYSE: DHR) received an uptick in orders for its medical instruments as part of the efforts to fight the pandemic. Overall revenue grew by 3.5% annually to $5.3 billion in the second quarter of 2020. Danaher also netted $1.44 in earnings per share, representing a 30% improvement from Q2 2019. Year to date, the company's share price has grown from around $155 to $207.57. 9. Thermo Fisher Scientific Thermo Fisher Scientific (NYSE: TMO) is a life science company providing scientific instruments, reagents, consumables, and various software and services. During Q2 2020, the company's revenue increased by 10% year over year to $6.92 billion. It grew its earnings per share to $3.89, an increase of 28%. The pandemic continues to help boost demand for the company's services by about $1.3 billion per quarter. The stock is worth $422.29 per share, up about 30% from the beginning of 2020. BIO data by YCharts 10. Vertex Pharmaceuticals Finally, biotech Vertex Pharmaceuticals (NASDAQ: VRTX) has seen its revenue and bottom line skyrocket since its triple combination therapy, Trikafta, came to market as a treatment of cystic fibrosis patients with a critical gene mutation. The drug is likely to capture up to 90% of the global cystic fibrosis market. During Q2 2020, the company's revenue increased by 62% year over year to $1.52 billion. Meanwhile, its net income more than doubled to $1.36 billion compared to the same period last year. Vertex Pharmaceuticals is trading at $272.35, up 23.5% this year. 10 stocks we like better than Vertex Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed and Idexx Laboratories. The Motley Fool recommends DexCom and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-08-28,107.08,107.755,104.45,104.738,
DXCM,2020-08-31,104.51,106.958,103.15,106.352,
DXCM,2020-09-01,105.755,107.822,104.976,105.548,
DXCM,2020-09-02,105.978,112.495,103.255,111.928,"[""Noteworthy Wednesday Option Activity: SQ, CYTK, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Square Inc (Symbol: SQ), where a total of 103,536 contracts have traded so far, representing approximately 10.4 million underlying shares. That amounts to about 87% of SQ's average daily trading volume over the past month of 11.9 million shares. Particularly high volume was seen for the $180 strike call option expiring September 04, 2020, with 6,984 contracts trading so far today, representing approximately 698,400 underlying shares of SQ. Below is a chart showing SQ's trailing twelve month trading history, with the $180 strike highlighted in orange: Cytokinetics Inc (Symbol: CYTK) saw options trading volume of 6,914 contracts, representing approximately 691,400 underlying shares or approximately 83.5% of CYTK's average daily trading volume over the past month, of 828,505 shares. Particularly high volume was seen for the $30 strike call option expiring October 16, 2020, with 3,200 contracts trading so far today, representing approximately 320,000 underlying shares of CYTK. Below is a chart showing CYTK's trailing twelve month trading history, with the $30 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 5,144 contracts, representing approximately 514,400 underlying shares or approximately 80.8% of DXCM's average daily trading volume over the past month, of 637,015 shares. Especially high volume was seen for the $430 strike call option expiring October 16, 2020, with 526 contracts trading so far today, representing approximately 52,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $430 strike highlighted in orange: For the various different available expirations for SQ options, CYTK options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Jumped Today What happened Shares of DexCom (NASDAQ: DXCM) were jumping 5.7% higher as of 3:02 p.m. EDT on Wednesday. The maker of continuous glucose monitoring (CGM) systems didn't announce any news. Instead, DexCom's gains appear to be the result of investors' general optimism about the economy as the overall stock market rose on Wednesday. So what Most stocks tend to move higher when the major market indexes rise. The strongest stocks, though, usually generate gains that are well above the indexes'. And DexCom qualifies as one of the strongest on the market, with the healthcare stock more than doubling so far in 2020. Image source: Getty Images. The most important thing for investors to understand is why DexCom has performed so well. That question can be answered with one letter and one numeral: G6. Sales continue to soar for DexCom's G6 CGM system. The company reported a 34% year-over-year revenue jump in the second quarter. DexCom's growth could pick up even more in the second half of the year with fewer headwinds from the COVID-19 pandemic. Now what Competition in the CGM market has intensified with Abbott Labs winning FDA clearance for its Freestyle Libre 2 CGM in June. However, DexCom appears to be in a good position to continue delivering strong growth with its G6 system and should experience a sales boost when it launches its new G7 system in the future. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-09-03,109.0,111.615,102.25,103.238,
DXCM,2020-09-04,103.16,103.705,94.3375,99.56,"[""Friday Sector Laggards: Technology & Communications, Healthcare In afternoon trading on Friday, Technology & Communications stocks are the worst performing sector, showing a 1.9% loss. Within that group, NVIDIA Corp (Symbol: NVDA) and Salesforce.com Inc (Symbol: CRM) are two large stocks that are lagging, showing a loss of 6.0% and 5.3%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 2.7% on the day, and up 27.90% year-to-date. NVIDIA Corp, meanwhile, is up 108.21% year-to-date, and Salesforce.com Inc is up 54.38% year-to-date. Combined, NVDA and CRM make up approximately 6.7% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 1.1% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and ABIOMED, Inc. (Symbol: ABMD) are the most notable, showing a loss of 5.0% and 4.6%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 1.1% in midday trading, and up 4.13% on a year-to-date basis. DexCom Inc, meanwhile, is up 79.35% year-to-date, and ABIOMED, Inc. is up 64.41% year-to-date. Combined, DXCM and ABMD make up approximately 1.3% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, two sectors are up on the day, while seven sectors are down. SECTOR % CHANGE Financial +0.5% Materials +0.1% Consumer Products -0.1% Industrial -0.3% Utilities -0.6% Energy -0.6% Services -0.9% Healthcare -1.1% Technology & Communications -1.9% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom, Livongo Health, and Teladoc Health Stocks Are Tumbling Today What happened Investors could be hearing the sound of a bubble popping. Major stock market indexes plunged on Thursday, with the declines continuing into Friday. And the overall market sell-off is pulling down several of 2020's biggest healthcare winners. Shares of DexCom (NASDAQ: DXCM) were tumbling 5.9% lower as of 11:43 a.m. EDT on Friday. Livongo Health (NASDAQ: LVGO) and Teladoc Health (NYSE: TDOC) stocks were both down 5.8%. So what What should investors make of the declines today? There's a pretty good argument that the overall market pullback presents great buying opportunities for DexCom, Livongo, and Teladoc. Image source: Getty Images. DexCom continues to deliver tremendous sales growth thanks to the success of its G6 continuous glucose monitoring system. The company reported revenue of $451.8 million in the second quarter, up 34% year over year. This momentum doesn't seem likely to slow down. It could even accelerate as the impact of the COVID-19 pandemic on physician visits fades. Livongo and Teladoc stocks are already joined at the hip. The two companies announced on Aug. 5 that they plan to merge. Because of how the deal is structured, their stock prices will basically move in lockstep. Although some investors initially didn't like that Livongo and Teladoc will merge, the combination of the companies will create a powerful player in the healthcare sector. Livongo brings its digital health platform for chronic disease management to the table, while Teladoc reigns as the leader in telehealth. The overall stock market drop on Friday shouldn't affect any of these companies' long-term growth prospects. Demand for their products and services should remain strong. And, in the case of Livongo and Teladoc, a worsening of the pandemic could even fuel higher demand for their virtual-care offerings. Now what All three of these healthcare stocks could be volatile throughout the rest of 2020 and perhaps even into next year. But investors will be better off focusing on the businesses instead of the stock performances. The main things to look forward to are each company's next quarterly update and the anticipated closing of the Teladoc-Livongo merger in the fourth quarter of this year. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of Livongo Health Inc and Teladoc Health. The Motley Fool owns shares of and recommends Livongo Health Inc and Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Healthcare Stocks You Should Buy, According to Wall Street It hasn't necessarily been easy to find winning stocks this year. The effects of the COVID-19 pandemic have shaken several companies to their core, and some simply aren't surviving the long-term economic implications of extended lockdowns. On the flip side, some winners have risen to the top of the pile. Although the healthcare sector has been less embattled during the coronavirus pandemic than other industries, stocks in this arena certainly haven't been immune to its economic pitfalls. When analysts set their sights on a winning healthcare stock, it's usually worth taking a second look. These are two top healthcare stocks you should buy, according to Wall Street. Image source: Getty Images. Teladoc It was already the biggest and oldest telehealth entity in the country before the pandemic, and Teladoc Health's (NYSE: TDOC) revenue has soared to new heights this year. Growth was impressive in 2019, with a 32% year-over-year revenue increase to $553 million and a 57% increase in visits on its platform. But 2020 so far is blowing all that away, with a 92% increase in visits during the first three months of the year and a 203% year-over-year escalation of patient visits during the second quarter. Between the beginning of January and the end of June, Teladoc attained 63% revenue growth and surpassed total earnings of more than $421 million for 2020's first half. The company expects to boost its domestic paid membership base to as many as 51 million individuals during the third quarter and projects up to $995 million in revenue for all of 2020. Teladoc was already a superior growth stock before the pandemic, but now there's no telling how far the company could expand. Its recent decision to acquire Livongo (NASDAQ: LVGO) and create a telehealth mega-giant is expected to bring the new company pro forma revenue growth of 85% for 2020. TDOC data by YCharts. Dexcom Shares of diabetes-care company Dexcom (NASDAQ: DXCM) are up 147% from just 12 months ago. DexCom's position in the continuous glucose monitoring (CGM) market, a sector expected to achieve a compound annual growth rate (CAGR) of 22% between 2019 and 2027, has helped it stay the distance throughout the pandemic. In July, the company's G6 continuous glucose-monitoring system received a temporary authorization from Health Canada for use by pregnant women with diabetes. In May, Health Canada had already temporarily authorized the device for expanded use in hospitals to help providers evaluate very sick patients while limiting face-to-face contact. The company has also proffered its CGM systems for U.S. medical providers. Dexcom's revenue shot up by 44% year over year in the first quarter of 2020, with 39% domestic earnings growth and 61% growth in other markets. Investors knew the true test of Dexcom's mettle would be in its Q2 earnings, which it released July 28, and they weren't disappointed. During the second quarter, revenue was up 34% year over year -- 21% outside the U.S. and 38% domestically. The company is anticipating its 2020 earnings to jump by 25% to $1.9 billion for the whole year. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc and Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here are the biggest stock-market losers on Thursday as the tech sector tanks All S&P 500 sectors ended lower Thursday\u2019s decline was broad, with all sectors of the S&P 500 ending lower.""]"
DXCM,2020-09-08,97.7225,99.0449,95.795,97.2975,
DXCM,2020-09-09,99.6125,100.965,97.56,100.42,
DXCM,2020-09-10,101.332,101.418,97.1375,97.505,"3 Stocks for Robinhood Investors to Buy During a Stock Market Crash This has been a year like none other for the investment community. In a roughly six-month span, Wall Street crammed in the steepest and quickest bear market decline in history, as well as the fastest rebound from a bear market low to record highs. Perhaps the only constant in 2020 has been the inability to predict short-term stock movements with any long-lasting success. But just because equities have ascended to new all-time highs doesn't mean volatility has been put to bed. Late last week, equities ""hiccuped"" after a multi-month rally, with the technology-heavy Nasdaq Composite shedding more than 6% of its value in two days and the broad-based S&P 500 losing over 4% in the same stretch. Image source: Getty Images. Volatility can be a double-edged sword. If you're a long-term investor, volatility is actually great news. That's because it allows you to buy into great companies at a perceived discount. As long as your intention is to hold for multiple years and trust your investment theses, a little near-term volatility isn't a concern. Then again, if you're a short-term investor or day trader, volatility can be a temptation, but also a nightmare. Online investing app Robinhood, which is well-known for its commission-free trading platform and gifts of shares to new members, has been particularly adept at attracting these shortsighted investors. The average Robinhood customer is in their early 30s and has limited knowledge of investing in equities. Worse yet, the platform doesn't appear to provide the tools necessary for young investors to succeed. As a result, Robinhood's leaderboard (i.e., the most-held stocks on the platform) is a smorgasbord of penny stocks, awful companies, and whatever stocks Wall Street is chasing this week. But it doesn't have to be this way. Robinhood investors have access to fractional share purchases, so they don't need to start with a fortune to make one. They simply need the discipline to trust their investment theses over the long run and to understand the opportunities stock market crashes and corrections present. If last week's stock market dip were to turn into a full-fledged correction or crash, Robinhood investors would be wise to consider buying into the following three stocks. Image source: Facebook. Facebook One of the smartest moves Robinhood investors can make is to purchase shares of the dominant social media company on the planet, Facebook (NASDAQ: FB). Perhaps the most amazing stat I can offer about Facebook is this: During the pandemic-impacted second quarter, this almost entirely ad-based company still managed to grow advertising revenue by a double-digit percentage. Facebook draws in 1.79 billion people each day, and the platform has 3.14 billion family monthly active people (including Facebook's other owned social media sites). Advertisers fully understand that they can't go anywhere else and reach so many eyeballs at once, which is what gives Facebook the upper hand when it comes to ad pricing power. This summer's ongoing advertising boycott didn't seem to have much of an impact. Another crazy thing to consider is that Wall Street forecasts that Facebook will generate approximately $80 billion in revenue this year, even though the company isn't anywhere close to fully monetizing its family of products. The lion's share of this revenue is derived from ad placement on Facebook and Instagram. The company has yet to scratch the surface on monetizing Facebook Messenger or WhatsApp. Facebook owns four of the seven most-visited social media sites and is only generating significant revenue from two of them. Facebook also has opportunities to expand its revenue channels beyond advertising. The company already offers payment service Facebook Pay. Plus, Facebook may be the perfect platform to host some sort of paid streaming service in the future. If a stock market crash occurs, scooping up shares of Facebook could be a smart move. Image source: Getty Images. Freshpet Buying shares of organic and natural pet food maker Freshpet (NASDAQ: FRPT) is another relatively surefire way for Robinhood investors to put their money to work if the stock market crashes. All eyes might be on high-growth work-from-home trends like cybersecurity and cloud computing, but it's the pet industry that's been the unbreakable rock for more than a quarter of a century. Data from the American Pet Products Association finds that year-on-year expenditures on companion animals haven't declined for at least 25 years, with spending in 2020 expected to hit $99 billion -- $38.4 billion of which will be spent on food and treats. We're witnessing the same trends in the pet food realm as in traditional grocery stores. Pet owners are willing to spend more on organic and natural foods for their pets if doing so leads to a higher quality of life. Just as organic human foods in grocery stores have been a significant source of growth, so has Freshpet's focus on higher-quality foods and treats. Despite facing one of the ugliest quarters for U.S. economic growth on record, Freshpet's second-quarter sales surged 33% to $80 million. Freshpet is benefiting from the introduction of new products, access to more retail locations, an increase in repeat customers, and juicier margins associated with its pricier organic and natural products. After generating $246 million in full-year sales in 2019, Freshpet is expected to more than double its revenue to north of $600 million by 2023. In other words, it's a growth stock with both bark and bite for investors. Image source: Getty Images. DexCom Robinhood investors would also be wise to pick up shares of medical device maker DexCom (NASDAQ: DXCM) if the stock market crashes. DexCom is best known for manufacturing and selling continuous glucose monitoring (CGM) systems used by diabetics. The potential patient pool for DexCom's CGM's is massive. The Centers for Disease Control and Prevention estimates there to be 34.2 million diabetics in the U.S., with another 88 billion showing prediabetic symptoms. These statistics alone suggest incredible growth opportunity in maintenance and applied health signal devices for diabetics. Just how good has DexCom's growth been? Full-year sales rocketed from $49 million in 2010 to $1.48 billion by 2019. According to Wall Street, DexCom seems on track for ongoing compound annual sales growth of roughly 20% through at least 2023. That'll take its full-year sales to around $3.3 billion and more than likely result in an expansion of the company's earnings before interest, taxes, depreciation, and amortization (EBITDA) margin. Although DexCom's stock remains pricey, its large patient pool and cutting-edge innovation support its premium. As long as the number of diabetic patients who could benefit from a CGM device continues to grow, DexCom's market share has nowhere to go but up. {%sfr) 10 stocks we like better than Facebook When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Facebook wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook and Freshpet. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-09-11,99.0125,99.8512,94.4525,95.865,
DXCM,2020-09-14,96.5525,99.9325,96.525,98.4025,
DXCM,2020-09-15,99.645,100.121,97.9958,99.4925,
DXCM,2020-09-16,99.9575,100.992,97.88,98.48,
DXCM,2020-09-17,95.655,97.4,93.905,96.5525,"[""If You Invested $5,000 in Dexcom During the Coronavirus Market Crash, This Is How Much Money You'd Have Now The March market crash and volatility that's followed have revealed the stocks that are recession-proof champions, while pulling back the curtain on companies far more vulnerable to economic adversity. Among healthcare companies that have continued to achieve profitable returns, Dexcom (NASDAQ: DXCM) is top-of-mind. The company is known for manufacturing and marketing continuous glucose monitoring (CGM) devices. Dexcom has consistently surpassed the S&P 500's performance this year, experiencing substantial and relatively consistent gains during a roller-coaster year. As of Sept. 16, Dexcom has gained 82% year-to-date compared to the S&P 500's return of about 5.5%. If you're curious about what a $5,000 investment in Dexcom back in March would be worth today, you've come to the right place. Let's dig deeper into Dexcom's performance over the past six months. Image source: Getty Images. $5,000 would be worth... Shares of Dexcom dipped only moderately in the March market crash. The stock closed at $219.38 on Jan. 2., the first trading day of the year. Shares hit their lowest point on March 17, when Dexcom closed at $191.16, down about 13% from the start of 2020. The stock started to recover at the end of March and has risen with momentum ever since. Let's suppose that you invested in Dexcom on March 17, when the stock hit its low. With $5,000 to spend, you would have been able to purchase around 26 shares of the company. Today, that investment would be worth over $10,200. Not many stocks give you the opportunity to more than double your money in just six months. The explanation for Dexcom's resilience in the face of extreme market headwinds isn't all that complicated. The company is a prominent manufacturer of CGM devices, which are in considerable demand despite adverse market conditions and serve a huge population of healthcare consumers. It's been estimated that roughly 34.2 million people, or about 11% of the entire American population, has diabetes. The CGM market is projected to realize a compound annual growth rate (CAGR) of more than 12% between 2020 and 2026. Diabetes patients are also among those most at risk of suffering serious complications from COVID-19, which has only heightened demand for Dexcom's products since the pandemic began. DXCM data by YCharts A key leader in the continuous glucose monitoring device market Dexcom's star product is its G6 system, a one-touch applicator that generates blood glucose levels in real-time. The company recently concluded the launch of its G6 Pro system, marketed as \""the first and only single-use, professional CGM available in blinded and unblinded modes.\"" In blinded mode, patients won't have access to their glucose readings, alarms, or other G6 app health alerts. This setting allows care providers to capture patients' health information while they are behaving normally, without the influence of a CGM. Unblinded mode allows patients full access to their glucose levels and other tracked information on the Dexcom G6 app. Dexcom grew its first quarter revenue by 44% and recent second quarter revenue by 34% year over year. In the second quarter, which ended on June 30, Dexcom saw 38% domestic revenue growth and 21% revenue growth in markets outside the U.S. The company also reported gross profit margins on the basis of generally accepted accounting principles (GAAP) of more than 63% in Q1 and 62.9% in Q2. Management expects the company to increase its annual revenue by 25% compared to 2019, achieving total revenues of $1.9 billion and a gross profit margin of 65% or greater for the full year. As of June 30, Dexcom reported cash and marketable securities equivalent to $2.5 billion, which positively outweighs its total liabilities of $2.2 billion. Currently, the company doesn't pay a dividend, which frees up a considerable portion of its cash reserves to work on paying off existing debt. Should you take the plunge? Analysts are optimistic about Dexcom's growth trajectory over the next few years. They project that the company will boost its earnings by more than 55% per year through 2025. In fact, Dexcom was popular with investors for its consistent earnings growth before the pandemic, and has continued its streak in the worst economic recession since the Great Depression. The company has consistently grown its annual earnings by double digits over the past five years alone: 2015 (55%), 2016 (43%), 2017 (25%), 2018 (44%), and 2019 (43%). Dexcom's stellar balance sheet and excellent cash-to-debt ratio also set the company up for success, and its addressable market for diabetes management in the U.S. and abroad is poised for continued growth. For all of these reasons, I believe that investors should scoop up shares of the growth stock now, before it soars even higher. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is The Rally Over For DexCom Near $400? DexCom\u00e2\u0080\u0099s stock (NASDAQ:DXCM) trades at $397 currently and it has gained 80% in value so far this year. It traded at a pre-Covid high of $302 in February, and it is currently 30% higher than that level. Also, DXCM stock has gained 87% from the low of $210 seen in March 2020, as the demand for its G6 continuous glucose monitoring device remained high, and it helped the company post a solid 34% jump in Q2 sales even in these challenging times. That said, in view of the strong rally in DXCM stock since late March, we believe that the stock has little room for growth in the near future. Our conclusion is based on our detailed analysis of DexCom\u00e2\u0080\u0099s stock performance during the current crisis with that during the 2008 recession\u00c2 in an interactive dashboard analysis. 2020 Coronavirus Crisis Timeline of 2020 Crisis So Far: 12/12/2019: Coronavirus cases first reported in China 1/31/2020: WHO declares a global health emergency. 2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high 3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, as Covid-19 cases accelerate outside China. Doesn\u00e2\u0080\u0099t help that oil prices crash in mid-March amid Saudi-led price war Since 3/24/2020: S&P 500 recovers 49% from the lows seen on Mar 23, as the Fed\u00e2\u0080\u0099s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system. DexCom Performance During 2020 Coronavirus DXCM stock declined from levels of around $292 in mid February (pre-crisis peak) to levels of around $210 as of March 23 (as the markets bottomed out), implying DXCM stock lost 28% from its approximate pre-crisis peak. It then rallied to levels of about $395 currently, rising by 87% since March 23. It is also up 80% from levels of $219 seen in early January. S&P 500 Index Performance During 2020 Coronavirus/Oil Price War Crisis The S&P 500 index declined from levels of around 3,386 in mid Feb (pre-crisis peak) to levels of around $2,237 as of Mar 23 (as the markets bottomed out), implying the index lost 34% of its value from its approximate pre-crisis peak. It then rallied to levels of about 3,341 currently, rising by 49% since Mar 23. It is also up 3% from levels of 3,231 seen in early January. 2007-08 Financial Crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 \u00e2\u0080\u0093 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) DexCom Stock Performance Over 2007-08 Financial Crisis We see DXCM stock declined from levels of around $10 in September 2007 (pre-crisis peak) to levels of around $4 in March 2009 (as the markets bottomed out), implying DXCM stock lost 61% from its approximate pre-crisis peak. It recovered post the 2008 crisis, to levels of about $8 in early 2010, rising by 99% between March 2009 and January 2010. S&P 500 Performance Over The 2007-08 Financial Crisis S&P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied to levels of 1,124, rising by about 48% between March 2009 and January 2010. Fundamentals How Do DexCom\u00e2\u0080\u0099s Fundamentals Look In Recent Years? DexCom\u00e2\u0080\u0099s Revenues grew a stellar 4x from $0.4 billion in 2015 to $1.5 billion in 2019, primarily led by the increased adaption of its CGM devices. DexCom\u00e2\u0080\u0099s CGM device \u00e2\u0080\u0093 G6 \u00e2\u0080\u0093 is FDA approved to make diabetes treatment decisions without a need for a finger prick. With strong growth in revenues, the company was able to expand its margins meaningfully, and it turned profitable in 2019 with earnings of $1.11 per share, compared to a loss of $0.72 in 2015. Survival Check Does DexCom Have A Sufficient Cash Cushion To Meet Its Obligations Through The Coronavirus Crisis? DexCom\u00e2\u0080\u0099s total debt increased from $0.3 billion in 2017 to $1.1 billion in 2019, while its total cash remained around $0.4 billion over the same period. The company also generated close to $314 million in cash from its operations, and it appears to be in a good position to weather the crisis. CONCLUSION Phases of COVID-19 crisis: Early- to mid-March 2020:\u00c2 Fear\u00c2 of the coronavirus outbreak spreading rapidly translates into\u00c2 reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020:\u00c2 Fed stimulus\u00c2 suppresses near-term survival anxiety May-June 2020:\u00c2 Recovery of demand, with gradual lifting of lockdowns \u00e2\u0080\u0093 no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued\u00c2 improvement in demand\u00c2 and\u00c2 a decline in the number of new cases\u00c2 and progress with vaccine development buoy expectations Going by the historical performance and in view of the strong rally in DexCom stock since late March, we believe that the stock has little room for growth in the near future. What if instead you are looking for a more balanced portfolio? Here\u00e2\u0080\u0099s a top quality portfolio to outperform the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk. It has outperformed the broader market year after year, consistently. See all\u00c2 Trefis Price Estimates\u00c2 and\u00c2 Download\u00c2 Trefis Data\u00c2 here What\u00e2\u0080\u0099s behind Trefis? See How It\u00e2\u0080\u0099s Powering New Collaboration and What-Ifs For\u00c2 CFOs and Finance Teams\u00c2 |\u00c2 Product, R&D, and Marketing Teams \u00c2 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-09-18,97.705,100.265,95.2525,97.3275,
DXCM,2020-09-21,96.25,98.3025,95.4137,97.9225,
DXCM,2020-09-22,98.045,99.6575,95.43,99.5325,
DXCM,2020-09-23,98.7775,99.6275,95.655,96.5175,
DXCM,2020-09-24,95.25,96.9472,94.2025,95.5075,"[""Dexcom and University of Virginia to Advance Diabetes Research Together A leading manufacturer of automated insulin delivery systems, Dexcom (NASDAQ: DXCM) signed a five-year collaboration agreement with the University of Virginia on Thursday . The company will fund research at the university that could expand its addressable patient population. Dexcom already has clinical trial evidence that shows its constant glucose monitoring (CGM) technology reduces the amount of time Type 1 diabetes patients spend with blood sugar levels that are too high or too low. Through its collaboration with the university, the company will test its CGM technology for use among people with Type 2 and gestational diabetes, as well as for hospitalized patients. Image source: Getty Images. The University of Virginia's Center for Diabetes Technology will lead the research efforts, but the collaboration will employ experts from multiple disciplines across the University of Virginia System. This isn't the first time these two have conducted research as partners. In 2019, the collaboration partners presented successful results of a trial with Type 1 diabetes patients that used Dexcom's CGM technology to control their blood sugar levels.\u00c2 In 2020, Dexcom expects revenue to grow by about 25% to around $1.85 billion. While there has been some uptake of Dexcom's CGM systems among insulin-dependent Type 2 patients, the relative lack of evidence of a benefit is severely limiting the company's total revenue. In 2017, the American Diabetes Association estimated the number of Type 1 diabetes cases in the U.S. at 1.3 million. In 2012, it estimated the number of Type 2 diabetes patients at 27.8 million. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks \u00c2 *Stock Advisor returns as of August 1, 2020 \u00c2 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Solid Stocks to Get You Through a Market Crash This has been a wild year in the stock markets. After a devastating market crash in March, major stock indexes quickly recovered their losses and rallied into uncharted territory in August, only to suffer yet another market correction due to excessive speculation in tech stocks in the past weeks. There is no way of knowing whether the ongoing market correction will develop into a full-blown bear market or if stocks will simply bounce back and reach new highs. Regardless of what happens, no investors seem to like the current market uncertainty regarding whether to buy, sell, or stay away altogether. Keep in mind, though, that the stock market has recovered from every single downturn in history. If investors do decide to buy the dip, here are the top three stocks to hold through the current environment. Image Source: Getty Images. 1. Apple Tech giant Apple (NASDAQ: AAPL) had a fantastic second quarter this year, with its revenue up 11% year over year to $59.7 billion and earnings per share at $0.645, up 18% over Q2 2019. The increase was driven by overwhelming consumer satisfaction with its iPhone 11 series. The company's MacBook launches were also well-received, with revenue up 31% year over year to $6.6 billion. That's not all; the company added 130 million paid subscribers compared to Q2 2019 for its Apple TV, Arcade, News, and credit card services. Currently, the stock is trading for a premium of 7 times sales and 33 times earnings. Overpaying just a little for a superb blue-chip stock, however, is rarely a bad idea. Year to date, the company's shares have proven pandemic-proof, and are up over 45%. On Aug. 31, Apple's stock went through a 4-to-1 stock split in order to make shares more accessible for purchase. That undoubtedly fueled a spectacular run-up and sell-off, with shares now down close to 20% from all-time-highs. 2. DexCom This year, shares of continuous glucose monitoring (CGM) manufacturer DexCom (NASDAQ: DXCM) rallied by nearly 80% as the COVID-19 pandemic forced many diabetes patients to turn to at-home management of the chronic condition, sharply increasing the demand for the company's devices. Its mobile gadgets handle insulin delivery for patients and analyze key metrics such as blood sugar levels in real time for healthcare professionals. Patients with diabetes who use DexCom's CGMs have significantly lower glucose levels in their blood than patients who are treated under regular care, and the company's product provides an estimated $5,000 in health savings per patient per year. Only 15% to 40% of patients with diabetes in the U.S. are using CGMs, paving the way for the company to capture more market share. DexCom expects to bring in $1.85 billion in revenue this year, considerable growth from the $1.47 billion in sales it generated in 2019. If healthcare investors are looking for a company that can both grow its revenue consistently and thrive against economic downturns brought by the COVID-19 pandemic, DexCom is a top choice. 3. Scotts Miracle-Gro Scotts Miracle-Gro (NYSE: SMG) is an industry leader in providing lawn, gardening, and indoor agricultural growth products. During the third quarter of 2020, sales were up 28% year over year to $3.24 billion, with sales in its cannabis subsidiary, Hawthorne, up by a whopping 72% from last year. That growth is partly due to the fact that more U.S. states are joining the bandwagon for legalizing recreational and medical marijuana, which stimulated purchases of nutrients and lightings for raising cannabis plants. Another pillar of growth lies in the increasing demand for gardening/stay-at-home projects in the face of COVID-19 related lockdowns and quarantines. There are six states with recreational pot legalization on the ballot in November. Meanwhile, the U.S. cannabis market is expected to reach $73.6 billion by 2027, up from just $9.1 billion in 2019. That's a huge market opportunity for Scotts Miracle-Gro. For the entire year, the company expects to generate over $4 billion in revenue and $6.85 in earnings per share, compared to $3.2 billion in revenue and $4.47 in EPS in 2019. Those are some impressive results for a company valued at only 2 times price-to-sales and 26 times price-to-earnings. Scotts Miracle-Gro produces enough profit each year to pay a dividend, with an annual yield of 1.6%. For the past five years, its stock gained an impressive 142%, beating the S&P 500's 69.5% return. 10 stocks we like better than Apple When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Apple wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple and Scotts Miracle-Gro. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-09-25,94.9459,100.632,94.1925,100.59,
DXCM,2020-09-28,99.75,100.375,96.7525,100.048,"BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Bank of America, Eiger BioPharmaceuticals, Pangaea Logistics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks jumped on Monday, bouncing back from the longest weekly losing streak in a year for the S&P 500 and the Dow, with technology, banks and travel shares leading the advance..N At 12:21 ET, the Dow Jones Industrial Average .DJI was up 1.72% at 27,642.62. The S&P 500 .SPX was up 1.44% at 3,345.95 and the Nasdaq Composite .IXIC was up 1.07% at 11,030.094. The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ** Ambow Education Holding Ltd , up 115.5% ** Ashford Hospitality Trust Inc , up 58.7% ** Amer Shared Hospital Services , up 30.4% The top three NYSE .PL.N percentage losers: ** Annovis Bio Inc ANVS.N, down 10% ** Great Ajax Corp AJX.N down 9.33% ** PG&E Corp PCG.N, down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Piedmont Lithium Ltd , up 316.1% ** Oxbridge Re Holdings Ltd , up 245.8% ** Perceptron Inc , up 66.1% The top three Nasdaq .PL.O percentage losers: ** Aquestive Thrapeutics Inc , down 34.5% ** Inovio Pharmaceuticals Inc , down 26% ** Sky Solar Holdings Ltd , down 18.8% ** Boeing Co BA.N: up 6.7% BUZZ-Rises as Alembic Global upgrades on hopes of 737 MAX return ** Bank of America Corp BAC.N: up 3.2% BUZZ-Bank stocks lift Wall Street amid global recovery hopes ** Piedmont Lithium Ltd PLL.O: up 316.1% BUZZ-U.S.-listed shares hit record high on Tesla supply deal ** Masimo Corp MASI.O: up 2.1% BUZZ-Gains after FDA clears its pulse oximeter ** Eiger BioPharmaceuticals Inc EIGR.O: down 13.0% BUZZ-Slips after Lambda fails as possible COVID-19 treatment ** Sorrento Therapeutics Inc SRNE.O: up 4.8% BUZZ-Rises on positive early data from knee pain therapy study ** Plug Power Inc PLUG.O: up 11.9% BUZZ-Gains as Morgan Stanley raises FY24 revenue estimate, upgrades rating ** Pangaea Logistics Solutions Ltd PANL.O: up 4.7% BUZZ-Gains after raising stake in Nordic Bulk Holding ** Exxon Mobil Corp XOM.N: up 3.2% BUZZ-Oil stocks gain tracking crude prices ** Chevron Corp CVX.N: up 3% BUZZ-Oil stocks gain tracking crude prices ** Tessco Technologies Inc TESS.O: up 4% BUZZ-Up after founder urges to remove directors ** Natera Inc NTRA.O: up 2.2% BUZZ-Gains after Morgan Stanley starts coverage with 'overweight' ** Virgin Galactic Holdings Inc SPCE.N: up 19.8% BUZZ-Soars as two more bulls board ** Abbott Laboratories ABT.N: up 1% BUZZ-Up on EU approval for smallest version of glucose monitoring device ** Chesapeake Utilities Corp CPK.N: up 12% BUZZ-Rises as set join S&P SmallCap 600 ** OpGen Inc OPGN.O: up 6% BUZZ-Rises on potential use of tool to detect COVID-19 co-infections ** Perceptron Inc PRCP.O: up 66.1% BUZZ-Gains on takeover offer from Sweden's Atlas Copco ** United Parcel Service Inc UPS.N: up 2.6% BUZZ-Eyes record high open after KeyBanc upgrade ** Hologic Inc HOLX.O: up 1.5% BUZZ-Rises as FDA allows emergency use of asymptomatic COVID-19 test ** AbbVie Inc ABBV.N: up 1.5% BUZZ-Gains on orphan drug, fast track tag for spinal cord injury treatment ** Staffing 360 Solutions Inc STAF.O: up 13.7% BUZZ-Gains on sale of recruitment business unit ** Heron Therapeutics Inc HRTX.O: up 5.4% BUZZ-Rises on European marketing approval for non-opioid painkiller ** Virgin Galactic Holdings Inc SPCE.N: up 19.0% BUZZ-Soars after BofA says 'buy' ** American Airlines Group Inc AAL.O: up 4.8% BUZZ-Rises after securing $5.5 bln Treasury loan ** CBL & Associates Properties Inc CBL.N: down 1.7% BUZZ-Falls after restructuring petition extention ** Tesla Inc TSLA.O: up 2.7% BUZZ-Set to rise for third straight session ** Pinterest Inc PINS.N: up 2.2% BUZZ-Up as Guggenheim starts coverage with ""buy"" rating ** Quotient Ltd QTNT.O: up 3.3% BUZZ-Rises as FDA approves emergency use of its COVID-19 antibody test ** WPX Energy Inc WPX.N: up 16.4% BUZZ-Jumps after shale producers agree to merger deal ** Devon Energy Corp DVN.N: up 12.3% BUZZ-Jumps after shale producers agree to merger deal ** Mallinckrodt PLC MNK.N: down 23.3% BUZZ-Falls after report says drugmaker weeks away from filing for bankruptcy ** MobileIron Inc MOBL.O: up 5.6% BUZZ-Rises on $872 mln deal to go private ** Snap Inc SNAP.N: up 3.6% BUZZ-U.S. tech stocks: Guggenheim hikes PTs on 'sustainable' strength ** Ford Motor Co F.N: up 2.9% BUZZ-Taps into German coronavirus relief aid - Handelsblatt ** Xpeng Inc XPEV.N: up 5.3% BUZZ-Surges on plans to open new car factory in China ** Aquestive Therapeutics Inc AQST.O: down 34.5% BUZZ-Slumps after FDA declines co's treatment for seizures ** Uber Technologies Inc UBER.N: up 3.4% BUZZ-Uber jumps as co wins legal bid to restart London operations ** Sina Corp SINA.O: up 6.1% BUZZ-Rises on $2.6 bln deal to go private ** Expedia Group Inc EXPE.O: down 0.9% BUZZ-RBC downgrades as survey suggests slow travel recovery ** Weibo Corp WB.O: up 6.7% BUZZ-Rises on Q2 revenue beat ** Square Inc SQ.N: up 1.3% BUZZ-Gains after Credit Suisse raises price target ** Cleveland-Cliffs Inc CLF.N: up 10.5% BUZZ-Rises on purchase of ArcelorMittal's U.S. assets The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.73% Consumer Discretionary .SPLRCD up 1.39% Consumer Staples .SPLRCS up 1.33% Energy .SPNY up 3.08% Financial .SPSY up 2.86% Health .SPXHC up 0.90% Industrial .SPLRCI up 2.37% Information Technology .SPLRCT up 0.97% Materials .SPLRCM up 2.15% Real Estate .SPLRCR up 1.69% Utilities .SPLRCU up 1.01% (Compiled by Niket Nishant in Bengaluru) ((Niket.Nishant@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-09-29,99.9475,102.389,99.4875,100.545,
DXCM,2020-09-30,100.602,103.908,99.3775,103.058,
DXCM,2020-10-01,104.27,105.0,102.458,103.46,
DXCM,2020-10-02,99.2475,100.4,94.7775,96.13,"[""BUZZ-U.S. STOCKS ON THE MOVE-Academy Sports and Outdoors, Workhorse Group, Telenav, Janus Henderson Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday after two straight sessions of gains as news that President Donald Trump had contracted COVID-19 stirred up political uncertainty just weeks before the election. .N At 12:33 p.m. ET, the Dow Jones Industrial Average .DJI was down 0.19% at 27,764.19. The S&P 500 .SPX was down 0.59% at 3,360.89 and the Nasdaq Composite .IXIC was down 1.67% at 11,136.82. The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy , up 7% ** Invesco Ltd , up 6.8% ** LyondellBasell Industries NV , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Dexcom Inc DXCM.O, down 6.8% ** Incyte Corp INCY.O, down 4.7% ** Take-Two Interactive Software Inc TTWO.O, down 4.5% The top NYSE .PG.N percentage gainers: ** American Renal Associates Holdings Inc ARA.N, up 67.2% ** IDT Corp IDT.N, up 38.5% The top three NYSE .PL.N percentage losers: ** Scully Royalty Ltd SRL.N, down 20.7% ** Electromed Inc ELMD.N, down 10.7% ** Oneconnect Financial Technology Co Ltd OCFT.N, down 9.3% The top three Nasdaq .PG.O percentage gainers: ** C4 Therapeutics Inc CCCC.O, up 36.4% ** Nano-X Imaging Ltd NNOX.O, up 35.8% ** Thryv Holdings Inc THRY.O, up 32% The top three Nasdaq .PL.O percentage losers: ** Benitec Biopharma Inc BNTC.O, down 35.3% ** Mesoblast Ltd MESO.O, down 32.3% ** Lixiang Education Holding Co Ltd LXEH.O, down 18.5% ** Twilio Inc TWLO.N: up 13.6% BUZZ-Twilio: Jumps as Q3 sales outlook enthuses Street ** Protara Therapeutics Inc TARA.O: up 0.9% BUZZ-Protara Therapuetics: Rises after hedge fund reports 5.8% passive stake ** Nu Skin Enterprises Inc NUS.N: up 11.1% BUZZ-Extends gains as brokerages bullish after Q3 forecast raise ** Casella Waste Systems Inc CWST.O: up 1.4% BUZZ-Casella Waste Systems acquires Pinto Trucking; shares up ** Crocs Inc CROX.O: up 1.0% BUZZ-Jumps as Justin Bieber teases collaboration on Instagram ** Tesla Inc TSLA.O: down 5.4% BUZZ-Shares fall as Model 3 deliveries underwhelm bulls ** Mesoblast Ltd MESO.O: down 32.3% BUZZ-Mesoblast: Slumps as FDA declines to approve transplant rejection treatment ** Bloom Energy Corp BE.N: down 7.3% BUZZ-Bloom Energy down as Morgan Stanley markets large block ** Activision Blizzard Inc ATVI.O: down 4.4% BUZZ-Slips on delay of new \""World of Warcraft\"" game ** Assured Guaranty Ltd AGO.N: up 16.0% BUZZ-Assured Guaranty: Rises as co to join S&P 600 small cap index ** Invesco Ltd IVZ.N: up 6.8% ** Janus Henderson JHG.N: up 15.8% BUZZ-Janus Henderson: Hits near four-month high as Trian buys stake ** DPW Holdings Inc DPW.A: up 10.2% BUZZ-DPW Holdings soars after unit launches new EV charger ** Synthetic Biologics Inc SYN.A: down 33.0% BUZZ-Synthetic Biologics scraps irritable bowel treatment trial, shares drop ** Ibio Inc IBIO.A: up 1.5% BUZZ-Ibio: Gains on deal with Safi Biosolutions ** Laboratory Corporation of America Holdings LH.N: up 1.2% BUZZ-LabCorp: Up as FDA authorizes method to improve speed of COVID-19 molecular test ** Co-Diagnostics Inc CODX.O: up 2.1% BUZZ-Up on FDA approving saline oral rinse COVID-19 test ** IDT Corp IDT.N: up 38.5% BUZZ-Set for seven-month high on higher Q4 earnings ** Arcutis Biotherapeutics ARQT.O: down 14.2% BUZZ-Arcutis Biotherapeutics drops on equity raise ** American Renal Associates Holdings Inc ARA.N: up 67.2% BUZZ-American Renal surges on near $400 mln buyout deal from Nautic Partners ** Humanigen Inc HGEN.O: up 2.1% BUZZ-Jumps after drug shows promise in treating COVID-19 patient ** Hycroft Mining HYMC.O: down 15.8% BUZZ-Hycroft Mining slides after co prices equity offering ** Nano-X Imaging Ltd NNOX.O: up 35.8% BUZZ-Nano-X Imaging surges after co announces live tech demonstration ** Workhorse Group Inc WKHS.O: down 4.5% ** Nio Inc NIO.N: down 1.5% ** Arcimoto Inc FUV.O: down 7.5% BUZZ-EV stocks fall in tandem with Tesla's slide ** Conagra Brands CAG.N: up 2.3% BUZZ-Rises after analysts lift price targets ** Telenav Inc TNAV.O: up 17.7% BUZZ-Jumps on buyout offer from CEO-led company ** Golar LNG GLNG.O: down 1.3% BUZZ-Petrobras flags Golar JV's high \""risk grade\"", casts doubt on unit's offer ** Benitec Biopharma Inc BNTC.O: down 35.3% BUZZ-Hits record low on discounted stock deal ** C4 Therapeutics Inc CCCC.O: up 36.4% BUZZ-C4 Therapeutics: Surges 40% in market debut ** Academy Sports and Outdoors Inc ASO.O: down 2.8% BUZZ-KKR-backed Academy Sports and Outdoors slips nearly 7% in market debut ** Immunome Inc IMNM.O: up 8.3% BUZZ-Jumps 30.5% in Nasdaq debut ** Oncorus Inc ONCR.O: down 1.3% BUZZ-Oncorus Inc: Rises 3% in Nasdaq debut ** Noble Energy Inc NBL.O: up 1.3% BUZZ-Noble Energy: Rises on shareholder nod for $4.2 bln sale to Chevron ** Valvoline Inc VVV.N: up 2.8% BUZZ-Valvoline: Rises on deals to purchase 33 service centers The 11 major S&P 500 sectors: Communication Services .SPLRCL down 1.58% Consumer Discretionary .SPLRCD down 0.90% Consumer Staples .SPLRCS down 0.71% Energy .SPNY up 1.12% Financial .SPSY up 0.90% Health .SPXHC down 0.44% Industrial .SPLRCI up 1.35% Information Technology .SPLRCT down 2.04% Materials .SPLRCM up 1.27% Real Estate .SPLRCR up 1.05% Utilities .SPLRCU up 0.68% (Compiled by C Nivedita in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Is Slipping Today What happened Shares of DexCom (NASDAQ: DXCM) were slipping 6.3% lower as of 11:29 a.m. EDT on Friday. The decline came after Wells Fargo analyst Larry Biegelsen downgraded the stock to underweight from equal weight and cut his price target to $350 from $420. So what Analysts routinely downgrade stocks. Sometimes they're right, and sometimes they're wrong. The main thing for investors to understand is why an analyst formed a more negative opinion. Image source: Getty Images. In this case, Biegelsen is concerned about increased competition for DexCom's G6 continuous glucose monitoring (CGM) system. Abbott Labs (NYSE: ABT) recently won approval of its Freestyle Libre 3 CGM in Europe. Abbott's device is priced at less than half that of DexCom's G6. Biegelsen views this as problematic for DexCom since Libre 3 closes much of the functionality gap with the G6 system. The Wells Fargo analyst's reasoning makes sense. However, the CGM market is growing so rapidly that DexCom should continue to enjoy momentum for the G6 system. More importantly, the company has its own new CGM product -- G7 -- on the way. Now what It remains to be seen how much of an impact Abbott's Libre 3 will make on DexCom's G6 sales. The big question for investors is how long it will be before DexCom launches its G7 system. CEO Kevin Sayer stated in the company's Q2 conference call that there won't be a limited launch of the new product this year as some expected. The COVID-19 pandemic has pushed back DexCom's timelines for the G7. The healthcare stock could remain volatile until more clarity about the G7 launch timing is available. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks \u00c2 *Stock Advisor returns as of September 24, 2020 \u00c2 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Invesco, Mesoblast, Assured Guaranty, IDT Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes tumbled at the open on Friday after President Donald Trump tested positive for COVID-19 weeks before the election, with an elusive fiscal stimulus and a slowdown in the domestic economic recovery also denting sentiment. .N At 9:42 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.76% at 27,605.87. The S&P 500 .SPX was down 0.94% at 3,349.07 and the Nasdaq Composite .IXIC was down 1.34% at 11,174.332. The top three S&P 500 .PG.INX percentage gainers: ** Invesco Ltd IVZ.N, up 5.9% ** Paycom Software Inc PAYC.N, up 3.9% ** Conagra Brands Inc CAG.N, up 2.2% The top three S&P 500 .PL.INX percentage losers: ** Dexcom Inc DXCM.O, down 4% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 3.2% ** Tapestry Inc TPR.N, down 3.1% The top NYSE .PG.N percentage gainers: ** Xtant Medical Holdings Inc XTNT.N, up 172.7% ** American Renal Associates Holdings Inc ARA.N, up 64.2% The top three NYSE .PL.N percentage losers: ** Electromed Inc ELMD.N, down 11.1% ** Select Energy Services, Inc WTTR.N, down 9.7% ** Gray Television Inc GTNa.N, down 8.5% The top Nasdaq .PG.O percentage gainers: ** Nano-X Imaging Ltd NNOX.O, up 26.2% ** Houghton Mifflin Harcourt Co HMHC.O, up 19.4% The top three Nasdaq .PL.O percentage losers: ** Benitec Biopharma Inc BNTC.O, down 37.7% ** Mesoblast Ltd MESO.O, down 35.8% ** Arcutis Biotherapeutics Inc ARQT.O, down 14.7% ** Twilio Inc TWLO.N: up 7.4% BUZZ-Twilio: Jumps as Q3 sales outlook enthuses Street ** Protara Therapeutics Inc TARA.O: up 1.2% BUZZ-Protara Therapuetics: Rises after hedge fund reports 5.8% passive stake ** Nu Skin Enterprises Inc NUS.N: up 9.0% BUZZ-Extends gains as brokerages bullish after Q3 forecast raise ** Tesla Inc TSLA.O: down 3.4% BUZZ-Tesla: Set to snap two-day winning streak UPDATE 4-Tesla reports record quarterly deliveries, but Model 3 sales underwhelm bulls ** JPMorgan Chase & Co JPM.N: down 0.9% ** Morgan Stanley MS.N: down 0.1% ** Goldman Sachs Group Inc GS.N: down 0.5% ** Citigroup Inc C.N: down 0.8% ** Wells Fargo & Co WFC.N: down 1.0% ** Bank of America Corp BAC.N: down 1.5% BUZZ-U.S. big banks track broader market fall as Trump tests COVID-19 positive ** ExxonMobil Corp XOM.N: down 1.1% ** Chevron Corp CVX.N: down 1.1% ** Diamondback Energy Inc FANG.O: up 1.6% ** ConocoPhillips COP.N: down 1.0% ** Apache Corp APA.O: down 0.9% ** Callon Petroleum Co CPE.N: down 2.1% ** Halliburton Co HAL.N: down 2.6% ** Patterson-UTI Energy Inc PTEN.O: down 1.6% ** Marathon Petroleum Corp MPC.N: down 2.0% BUZZ-U.S. energy shares: Dragged lower as Trump tests positive for coronavirus ** Mesoblast Ltd MESO.O: down 35.8% BUZZ-Mesoblast: Slumps as FDA declines to approve transplant rejection treatment ** Bloom Energy Corp BE.N: down 7.3% BUZZ-Bloom Energy down as Morgan Stanley markets large block ** Activision Blizzard Inc ATVI.O: down 1.9% BUZZ-Slips on delay of new \""World of Warcraft\"" game ** Assured Guaranty Ltd AGO.N: up 13.2% BUZZ-Rises as co to join S&P 600 small cap index ** Sasol Ltd SSL.N: down 6.2% BUZZ-Slips on U.S. unit's stake sale plans to LyondellBasell for $2 bln ** Invesco Ltd IVZ.N: up 5.9% BUZZ-Gains on activist Trian stake purchase, possible push for deals ** DPW Holdings Inc DPW.A: up 14.2% BUZZ-DPW Holdings soars after unit launches new EV charger ** American Airlines Group Inc AAL.O: down 1.6% ** United Airlines Holdings Inc UAL.O: down 2.3% ** Southwest Airlines Co LUV.N: down 2.6% ** Alaska Air Group ALK.N: down 3.1% ** Delta Air Lines Inc DAL.N: down 2.5% ** JetBlue Airways Corp JBLU.O: down 2.1% ** Spirit Airlines Inc SAVE.N: down 2.9% BUZZ-U.S. airlines fall as positive Trump COVID-19 test raises uncertainty ** Synthetic Biologics Inc SYN.A: down 36.3% BUZZ-Synthetic Biologics scraps irritable bowel treatment trial, shares drop ** Ibio Inc IBIO.A: up 3.9% BUZZ-Ibio: Gains on deal with Safi Biosolutions ** Co-Diagnostics Inc CODX.O: up 14.2% BUZZ-Up on FDA approving saline oral rinse COVID-19 test ** Chembio Diagnostics Inc CEMI.O: up 2.5% BUZZ-Rises after FDA approves rapid HIV-Syphilis test ** IDT Corp IDT.N: up 23.5% BUZZ-Set for seven-month high on higher Q4 earnings ** Arcutis Biotherapeutics ARQT.O: down 14.7% BUZZ-Arcutis Biotherapeutics drops on equity raise The 11 major S&P 500 sectors: Communication Services .SPLRCL down 1.08% Consumer Discretionary .SPLRCD down 1.27% Consumer Staples .SPLRCS down 0.45% Energy .SPNY down 1.03% Financial .SPSY down 0.73% Health .SPXHC down 0.30% Industrial .SPLRCI down 0.48% Information Technology .SPLRCT down 1.52% Materials .SPLRCM down 0.16% Real Estate .SPLRCR down 0.85% Utilities .SPLRCU down 0.54% (Compiled by C Nivedita in Bengaluru) ((c.nivedita@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-10-05,97.0,97.4388,94.6838,95.6275,
DXCM,2020-10-06,94.9175,97.3375,93.3525,93.7225,
DXCM,2020-10-07,94.1875,98.6075,94.1875,98.455,
DXCM,2020-10-08,99.165,99.95,96.7925,96.875,
DXCM,2020-10-09,98.3825,99.245,96.3,96.5,
DXCM,2020-10-12,98.13,100.458,97.005,98.545,
DXCM,2020-10-13,99.625,100.725,98.625,100.235,"3 Must-Own Growth Stocks for Robinhood Investors Investing in 2020 has been quite the adventure -- and there's still 2-1/2 months to go before we close out the year. Thus far, we've witnessed a record-breaking tumble of 34% in the S&P 500 that took less than five weeks, as well as the fastest rebound in history to fresh highs from a bear market bottom. While this volatility has been a gift for long-term investors, it's also proved quite the lure for short-term traders. Image source: Getty Images. Online investing app Robinhood, which is known for offering commission-free trades, fractional-share investing, and free shares of random stock to new members, has been particularly adept at signing up these short-sighted traders, many of whom are young or novice investors. On the one hand, it's excellent news that young people are putting their money to work in the stock market. After all, there's been no better wealth creator over the long haul than stocks. However, Robinhood has failed to provide these newer investors with the knowledge and tools they need to succeed over the long term. As a result, far too many of its members are left chasing so-called growth stocks that turn out to be awful companies. Piling into growth stocks is a fantastic strategy for younger investors as long as they intend to hang onto them long term. Since millennials have time on their side, buying into innovative high-growth companies gives them their best chance to generate game-changing investment returns. With this in mind, here are three growth stocks I consider to be must-owns for Robinhood investors. Image source: Square. Square Fintech stock Square (NYSE: SQ) is perhaps the most exciting stock in the entire market right now, and it isn't a company you'll have to twist arms to encourage young investors to buy. That's because Square's peer-to-peer payment platform Cash App caters to a younger audience to begin with. Square's bread-and-butter business segment is its seller ecosystem. The company has been providing point-of-sale devices, loans, and analytics to businesses for almost a decade. Between 2012 and 2019, gross payment volume (GPV) on its platform grew from a mere $6.5 billion to $106.2 billion. Since Square's seller ecosystem is primarily driven by merchant fees, growing GPV and higher usage by medium and large businesses could really pump up fee collection. But it's Cash App that'll be Square's knight in shining armor over the long run. We were already witnessing a push toward digital payments well before the coronavirus disease 2019 (COVID-19) pandemic hit. With cash now viewed as not only outdated but also as a harbinger of germs, the desire to go digital is even greater. In a 30-month stretch between the end of 2017 and June 2020, Cash App's monthly active users more than quadrupled to 30 million. Additionally, 7 million users are now using Cash Card -- a traditional debit card that links to users' Cash App balance. Cash App allows Square to collect merchant fees via Cash Card. Square also uses it to reap transfer fees to and from Cash App and traditional bank accounts, as well as investment/exchange fees tied to bitcoin. Square could well be the fastest-growing financial stock this decade, which makes it a must-own for young investors. Image source: Getty Images. DexCom Within the healthcare space, Robinhood investors would be wise to scoop up shares of medical-device maker DexCom (NASDAQ: DXCM). Though medical-device companies are constantly battling commoditization and competition, these aren't big concerns for DexCom, which is a leading global manufacturer of continuous glucose monitoring (CGM) systems. DexCom's CGM devices allow diabetic patients to monitor their blood glucose levels continuously without finger pricks. These devices help patients better control their blood glucose levels, and work hand in hand with an insulin pump. Why DexCom? While I don't wish poor health on anyone, the fact is that there are 34.2 million diabetics in the U.S. alone (that's more than 10% of the U.S. population), with another 88 million people aged 18 and over showing signs of prediabetes. The number of people with diabetes is climbing, not falling, which suggests that DexCom's devices will find a growing audience in the years to come. Best of all, DexCom is set up as a monthly subscription service. Subscription revenue is highly transparent and predictable; it's responsible for keeping DexCom's gross profit margin nicely above the 60% threshold. Investors should expect DexCom's innovation and high-margin revenue stream to push sales up by close to 20% a year for the foreseeable future. That's growth young investors can appreciate. Image source: Getty Images. CrowdStrike Holdings A final must-own growth stock for Robinhood investors is cloud-native cybersecurity company CrowdStrike Holdings (NASDAQ: CRWD). Cybersecurity companies are offering what's become a basic-need service. Hackers and robots don't take vacation days, nor do they care if the global economy is experiencing a recession. The coronavirus pandemic has pushed more businesses than ever into an online/cloud setting, and they'll rely more than ever on cybersecurity solution providers like CrowdStrike to protect their and their customers' data. CrowdStrike's cloud-based Falcon platform has helped it stand out. Falcon is powered by artificial intelligence, growing smarter with each new CrowdStrike customer. Also, being cloud-native allows for seamless responses to threats at generally lower costs than in-office cloud protection. Signing up new clients is great, and CrowdStrike has had no issue doing so over the past four years. Yet it's the spending growth of existing clients that's most impressive. In the first quarter of fiscal 2018, only 9% of its clients had at least four cloud module subscriptions. As of the second quarter of fiscal 2021, 57% of its clients had at least four cloud module subscriptions. CrowdStrike grows with its clients, with CrowdStrike's margins receiving their biggest boost from existing client add-ons. Between fiscal 2020 and fiscal 2023, Wall Street expects the company to roughly triple sales, which makes it the perfect innovative tech stock for young and novice investors to buy. 10 stocks we like better than CrowdStrike Holdings, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and CrowdStrike Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 24, 2020 Sean Williams owns shares of Square. The Motley Fool owns shares of and recommends CrowdStrike Holdings, Inc. and Square. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-10-14,100.085,100.818,97.585,98.5025,
DXCM,2020-10-15,97.7675,100.115,97.1328,99.895,
DXCM,2020-10-16,100.79,104.498,99.735,101.25,"BUZZ-U.S. STOCKS ON THE MOVE-Coffee Holding, Boeing, Hertz, Pfizer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street bounced back on Friday after three straight days of losses as Pfizer said it could apply for emergency use of its COVID-19 vaccine candidate as early as November, while data showed stronger-than-expected retail sales growth last month. .N At 10:15 AM ET, the Dow Jones Industrial Average .DJI was up 0.77% at 28,713.12. The S&P 500 .SPX was up 0.57% at 3,503.04 and the Nasdaq Composite .IXIC was up 0.66% at 11,791.371. The top three S&P 500 .PG.INX percentage gainers: ** Laboratory Corp , up 4.3% ** Vontier Corp , up 3.8% ** Dexcom Inc , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Citizens Financial Group , down 6.5% ** Schlumberger Ltd , down 5.7% ** J.B. Hunt Transport Services Inc , down 5.1% The top three NYSE .PG.N percentage gainers: ** CIT Group Inc , up 22.5% ** Navistar International Corp , up 20.8% ** Badger Meter Inc , up 13.4% The top three NYSE .PL.N percentage losers: ** Ntn Buzztime Inc , down 10.2% ** Daqo New Energy Corp , down 9.7% ** Citizens Financial Group Inc , down 6.5% The top three Nasdaq .PG.O percentage gainers: ** Kaixin Auto Holdings , up 163.2% ** SG Block Inc , up 42.1% ** Nano Dimension Ltd , up 33.7% The top three Nasdaq .PL.O percentage losers: ** Calyxt Inc , down 20.4% ** Biomerica Inc , down 18.2% ** Del Taco Restaurants Inc , down 16.7% ** Gilead GILD.O: down 0.6% BUZZ- Dips as WHO study raises doubts on remdesivir's benefits against COVID-19 ** Yandex N.V YNDX.O: down 1.4% BUZZ-Russia's Yandex terminates Tinkoff buyout talks, shares down ** MMTEC Inc MTC.O: up 14.9% BUZZ- Rises on strong half-year revenue ** Snap SNAP.N: up 0.1% BUZZ- Set to extend gains for 4th day after analysts hike PT ahead of results ** Amarin AMRN.O: up 1.2% BUZZ- Rises on positive data from heart drug study ** Chewy Inc CHWY.N: up 2.8% BUZZ- Gains as Jefferies upgrades to 'buy' ** Pfizer Inc PFE.N: up 2.4% ** BioNTech SE BNTX.O: up 2.3% BUZZ-Pfizer seeks U.S. emergency use nod for COVID-19 vaccine in November, shares rise ** Schlumberger SLB.N: down 5.7% BUZZ- Down after Q3 revenue plunges on demand hit ** CIT Group CIT.N: up 22.5% BUZZ- Rises on First Citizens buyout deal ** Orchard Therapeutics ORTX.O: up 15.7% BUZZ- Rises after EU panel endorses co's gene therapy ** SG Blocks Inc SGBX.O: up 42.1% BUZZ- Jumps on deal with Blink Charging ** Hertz HTZ.N: up 92.2% BUZZ- Rips higher on $1.65 bln DIP funding ** Calyxt Inc CLXT.O: down 20.4% BUZZ- Drops on deep-discounted direct stock deal ** Lazydays Holdings Inc LAZY.O: up 7.1% BUZZ-Lazydays Holdings rebounds after co scraps equity offering ** Boeing BA.N: up 2.9% BUZZ-Boeing takes flight as 737 MAX nears European safety approval ** Navistar NAV.N: up 20.8% BUZZ- Soars on report of nearing deal with Volkswagen's Traton ** J.B. Hunt Transport Services JBHT.O: down 5.2% BUZZ- Down on Q3 profit miss ** NanoVibronix NAOV.O: up 0.5% BUZZ- Up on launch of next generation pain management device ** Coffee Holding Co JVA.O: up 16.2% BUZZ- Jumps as co to launch CBD-infused coffee The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.81% Consumer Discretionary .SPLRCD up 0.76% Consumer Staples .SPLRCS up 0.63% Energy .SPNY down 1.95% Financial .SPSY down 0.37% Health .SPXHC up 1.34% Industrial .SPLRCI up 0.87% Information Technology .SPLRCT up 0.50% Materials .SPLRCM up 0.58% Real Estate .SPLRCR down 0.29% Utilities .SPLRCU up 0.35% (Compiled by Dania Nadeem in Bengaluru) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-10-19,100.902,102.5,98.755,99.375,
DXCM,2020-10-20,99.36,101.05,97.4075,98.1198,"2 Unstoppable Stocks That Are Better Buys Than Apple If you owned shares of Apple throughout the past decade, you are undoubtedly a happy investor now. Over the past 10 years, the tech giant's stock has soared by a little over 950% -- vastly outpacing the S&P 500's 196% gain in the same period. But all that growth means that Apple is now one of the largest companies in the world. There's no doubt the iPhone maker can keep finding ways to grow, and in my view, its shares are still worth buying. But given its market cap of more than $2 trillion, investors seekiong stocks with explosive, long-term growth potential may want to look elsewhere. Here are two stocks that fit the bill: DexCom (NASDAQ: DXCM) and Teladoc (NYSE: TDOC). Find out why these healthcare companies have a bright future ahead. DXCM data by YCharts 1. DexCom: Helping diabetes patients live better lives DexCom develops continuous glucose monitoring (CGM) systems, which help diabetes patients perform an essential task -- keeping track of their blood glucose levels. Whereas blood glucose meter (BGM) options can only measure a patient's glucose level at the specific moments they're taken, CGMs allow those with diabetes to track their blood glucose levels continuously, with alerts if the reading gets too low or too high. BGMs and their pesky fingersticks are also often painful to use, but CGMs aren't. The convenience of CGMs continues to help DexCom deliver great financial results. During its second quarter, which ended June 30, the company's revenue grew by 34% to $451.8 million. DexCom attributed its top-line growth to increasing awareness of CGMs. The company's GAAP gross margin also increased to 62.9%, up from 61.4%; non-GAAP gross profit grew to 64.1%, up from 61.4%. The higher revenue and higher gross profit led to a higher bottom line for DexCom. The company's net income for the quarter was $46.3 million, after it recorded a $10.5 million net loss during last year's second quarter. Image source: Getty Images. DexCom makes the bulk of its revenue in the U.S., where there's plenty of room to penetrate the CGM space. Management estimates that its core market -- people on intensive insulin therapy (ITT) -- numbers roughly 3.3 million U.S. patients. Add in several other countries (including Australia and Canada) where DexCom does business, and its core ITT market jumps to between 7 million and 8 million people. And there is a significantly larger untapped opportunity beyond these places, in countries where DexCom's presence is currently either minimal or nonexistent, but where those on ITT could benefit from its products. With a long history of innovations and a growing presence abroad, DexCom is in a good position to grow for years to come. Its market cap is $38.3 billion, which is tiny compared to Apple, giving the healthcare company a long runway for growth. Buying shares of DexCom today and holding them for the long haul would be a great move. 2. Teladoc: Leading the telemedicine revolution If you had reservations about going to see a doctor at the height of the coronavirus pandemic, you weren't alone. Most healthcare facilities put nonessential procedures on pause as they dealt with the worst of COVID-19. Thankfully, Teladoc was there to offer some basic medical care -- including consultations with qualified physicians -- from the comfort of one's home, all thanks to the magic of telemedicine. The company's virtual care visits famously spiked earlier this year, both from those whose health insurance plans covered telehealth costs and from those who had to pay a fee per visit. Naturally, Teladoc's revenue also grew significantly as a result. During its second quarter ending June 30, the company's revenue jumped by 85% year over year to $241 million, while its total visits skyrocketed by 203% to 2.8 million. This could be just the beginning. There are excellent reasons to think the telehealth craze will continue long after the outbreak is over. According to a Doctor.com poll of more than 1,800 adults, 83% of patients say they are likely to use telemedicine even after the pandemic ends. Meanwhile, Grand View Research has estimated that the telemedicine market will hit $155.1 billion by 2027, up from $41.4 billion in 2019. Image source: Getty Images. Let's not forget that in August, Teladoc initiated a move to acquire Livongo Health (NASDAQ: LVGO) in a cash-and-stock transaction valued at $18.5 billion. Livongo focuses on providing tools to help those with chronic conditions, particularly diabetes, achieve better health outcomes. The combined market opportunity for these two companies in the U.S. alone is $121 billion, which means they haven't even begun to scratch the surface of these segments -- Teladoc currently has a market cap of $18.4 billion, while Livongo's is $14.4 billion. The combined entity will be minuscule compared to Apple, and with a long runway for growth ahead, it will continue to reward shareholders for many years to come. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 24, 2020 Prosper Junior Bakiny owns shares of Livongo Health Inc and Teladoc Health. The Motley Fool owns shares of and recommends Apple, Livongo Health Inc, and Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-10-21,98.4725,99.1988,96.2725,96.96,
DXCM,2020-10-22,96.625,99.5625,96.465,98.9488,
DXCM,2020-10-23,99.5,102.802,99.2412,102.75,"VO, DXCM, DOCU, VEEV: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $113.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 194,905,482 to 195,518,309). Among the largest underlying components of VO, in trading today DexCom Inc (Symbol: DXCM) is up about 2.5%, DocuSign Inc (Symbol: DOCU) is up about 0.3%, and Veeva Systems Inc (Symbol: VEEV) is higher by about 3.3%. For a complete list of holdings, visit the VO Holdings page » The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $110.05 per share, with $187.5399 as the 52 week high point — that compares with a last trade of $185.76. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-10-26,101.415,104.748,100.875,104.5,
DXCM,2020-10-27,98.8075,99.5,95.0275,95.1575,"[""Dexcom Inc (DXCM) Q3 2020 Earnings Call Transcript Image source: The Motley Fool. Dexcom Inc (NASDAQ: DXCM) Q3 2020 Earnings Call Oct 27, 2020, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom Third Quarter 2020 Earnings Release Conference Call. My name is Adrian, and I'll be your operator for today's call. [Operator Instructions] I'll now turn the call over to Sean Christensen. Sean Christensen, you may begin. Sean Christensen -- Director of Corporate Affairs Thank you, operator. And welcome to DexCom's third-quarter 2020earnings call Our agenda begins with Kevin Sayer, DexCom's Chairman, President, and CEO, who'll provide a summary of the quarter followed by a financial review and outlook from Quentin Blackford, our COO and CFO, and then a strategic update from Steve Pacelli, our Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question, so we can provide an opportunity for everyone participating today. Please note that, there are also slides available related to our third quarter performance on the DexCom Investor Relations website on the Events and Presentations page. Before we dive in, I'm also pleased to announce that DexCom will be hosting it's Biennial Investor Day on Wednesday, December 9th, where we will discuss our business and long-term outlook in more detail. This will be a fully virtual event available by webcast. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof, based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP, with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Sean. And thank you everyone for joining us. Well, we've got a bit different route over the past 24 hours compared to our usual earnings reports, but I'm very glad to be with you today. Most of you probably saw that we pre-announced revenue after market closed yesterday, in conjunction with the announcement of the retirement of Rick Doubleday, our Chief Commercial Officer. I'll have more to say about Rick and what is he accomplished later in this call. We chose to provide the revenue pre-announcement in order to remove any market uncertainty about the strength of our business in conjunction with our notification of Rick's retirement. Our strong third quarter results reflect the resilience of our business and the importance of DexCom CGM to our growing customer base, even as the world continues to navigate the challenges prepended by the COVID pandemic. Based on this performance, we are pleased to be in a position once again to raise our 2020 revenue guidance in the year-end. Total revenue grew 26% in the third quarter, driven by our strong new-patient growth over the past year. This patient growth continued in the third quarter with our pharmacy and Medicare channels exhibiting the strongest growth in the quarter. We continue to see some impact in new patients relative to our expectations, as a result from the pandemic, however, as our updated guidance indicates, the impact was not as significant as we expected and communicated on our second quarter call. We also officially introduced our Patient Assistance Program at the start of the third quarter, extending our support to our customers who've lost coverage during this trying time. We saw a small handful of people utilize the program during the quarter, but it did not have a material impact on our performance. We've made excellent progress on the access front with nearly all people with type 1 diabetes in the U.S. now having access to DexCom CGM as well as a quickly increasing amounts of people with type 2 diabetes on intensive insulin therapy. We recently entered into a governmentwide contract for the sale of DexCom CGM to eligible government buyers, including the VA. This contract will facilitate easier and more convenient access to DexCom CGM as they may allow for pharmacy access to DexCom CGM for eligible veterans, another example of how we're making it easier for patients to take control of their diabetes at an affordable price. In addition, our team is doing great work to expand access outside of the U.S., including the recent publication of our U.K. cost-effectiveness study that showed the clear economic benefits associated with use of DexCom CGM. Based on studies like these, we are hopeful that we will be able to drive near term access wins on behalf of people with diabetes with government payers on a global basis. With customer feedback related to G6 continuing to trend at record levels, we have several initiatives under way to extend the DexCom growth opportunity and bring DexCom CGM to more people who stand to benefit from enhanced knowledge of their glucose levels. For our intensive business, many of you likely saw our press release with Eli Lilly earlier this month, announcing our co-marketing efforts of our G6 CGM with Lilly's new ultra rapid-acting insulin. This collaboration is a great example of our strong partnership with the Lilly team and should provide a nice boost to our efforts to expand awareness of DexCom CGM among practicing clinicians including primary care physicians. We are making great progress on our efforts to extend DexCom CGM to non-intensive type 2 customers as well. Intermountain Healthcare recently published the results of the first pilot using DexCom CGM, which demonstrated annual cost savings of approximately $5,000 per member for DexCom users relative to standard-of-care fingersticks. We are thrilled to say the large expansion of this trial with Intermountain is now well under way and we are excited about our work with UnitedHealth, as they extend their rollout of the Level2 program, although it is still early in the commercial rollout, our teams are working together very well to ensure the kind of patient experience that we expect for any users of our CGM systems. We continue to support hospitals and help protect patients and frontline workers during the pandemic, with more than 200 hospitals, reaching out to us about DexCom CGM during this crisis. We remain focused on generating evidence, potentially expedite approval for the use of CGM for patient monitoring. Along these lines, early feedback on the performance of our CGM has been positive, including several recently published articles documenting use of the product during the pandemic. In September, we also announced the creation of hospital registry to allow us to collect data on Dexcom CGM performance efficiently during this time. As we press forward these initiatives with a great customer satisfaction with G6, our teams internally are intently focused on the next steps with G7. We commenced approval support trials for G7 in the mid-October. This timing remains consistent with our previous discussions around the impact of COVID to our clinical trial timeline. Although all of us are eager for you to experienced G7, we are committed to doing this in the right way and ensuring that the trials are run efficiently and that we bring to market a product that delivers the best-in-class customer experience for DexCom users. We expect to launch G7 in the several key markets during the second half of 2021. Given the growth of the business and our expanding patient base, the expansion G7 into all of our core markets will likely extend into 2022, as we continue to scale manufacturing to support these markets in the right way. There is one change to G7 from our previous discussions. After extensive evaluation in several pre-market studies, we have made the decision to launch G7 first as the 10-day product, with a clear pathway to extend the wear duration shortly. Our customers' lives are heavily dependent upon DexCom CGM and we have high standards to ensure that we meet our commitments to our customers. For example, while our 15-day configuration demonstrates survival rates in the 70%-plus range, we don't believe this is good enough for our patients. With that I will turn it over to Quentin for our financial review. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the third quarter of 2020, we reported worldwide revenue of $529 million compared to $396.3 million for the third quarter of 2019, representing growth of 26% of the reported and constant currency basis. Our U.S. business maintained strong performance in the third quarter despite facing the toughest quarterly comparison for all of 2020, as we lapped the 53% growth in the third quarter of 2019. U.S. revenue totaled $398.6 million for the quarter, compared to $308.8 million in the third quarter of 2019, representing growth of 29%. All three of our channels contributed to the year-over-year growth in the U.S. with pharmacy and Medicare standing out as the strongest contributors, in line with our strategic emphasis and our efforts to streamline access for our customers over the last several years. Our Net Promoter Scores approached record levels among our users and in particular, our Medicare customers, including those with type 2 diabetes and on intensive insulin therapy, a testament to the simplicity of our DexCom G6 system in the value of real-time CGM knowledge. Our international business grew 17%, versus the prior year, in the third quarter to $102.3 million and increased 21% on a sequential basis from the second quarter. The impact of a COVID pandemic on new-patients starts continued be felt more acutely in our international markets, especially, as some of our core international markets have experienced increased case rates toward the end of summer and into the fall. This is primarily in those markets that have higher administrative requirements to accessing technology, which are much more difficult with COVID-related restrictions. However, in markets where administrative burdens are limited, we continue to see strong growth in momentum with the U.K. and Canada, especially standing out. In addition, we are continuing to benefit from the increased manufacturing capacity that we've driven over the past year, enabling us to extend the G6 offering to additional international markets, including our most recent launches into Belgium and Turkey at the start of the fourth quarter. Our third quarter gross profit was $340.7 million or 68% of revenue, compared to 62.3% of revenue in the third quarter of 2019. Despite the increased pricing pressure that we've been talking about, this represents our highest quarterly gross margin since we launched G6 in 2018. Our teams have done a terrific job designing cost out of our products and manufacturing processes in addition to driving greater manufacturing efficiencies as volume continues to increase. We are more excited than ever about where we believe we can take the cost profile of our products over time, further enabling our ability to successfully navigate the lower pricing environment that accompanies our push to enables easier access to our product for our customers through the pharmacy channel. Operating expenses were $245.7 million for Q3 2020 compared to $187.8 million in Q3 2019, inline with our previous commentary. This reflects an increase of approximately 170 basis points as a percent of sales as we invested into some of our key initiatives in the third quarter. The increased spend in research and development is primarily focused on the G7 clinical trials in addition to finalizing manufacturing readiness in anticipation of our future G7 launch. Within sales and marketing, we are prioritizing our direct-to-consumer marketing efforts, given the continued momentum with CGM awareness and the adoption runway ahead, with the results of our early campaigns delivering an excellent return to DexCom. On a go-forward basis, we continue to anticipate an elevated level of operating expenses in the fourth quarter and into 2021 as we move forward with our G7 pivotal trials, manufacturing scale-up, and direct-to-consumer efforts. Importantly, general and administrative expenses continue to lever nicely in the quarter. Operating income was $95 million or 19% of revenue in the third quarter of 2020, compared to $59.1 million or 14.9% of revenue in the same quarter of 2019. This reflects a year-over-year improvement of 410 basis points in operating margin for the quarter. Adjusted EBITDA was $146.9 million or 29.3% of revenue for the third quarter compared to $92.5 million or 23.3% of revenue for the third quarter of 2019, an improvement of 600 basis points. Net income for the third quarter was $93.6 million or $0.94 per share. We closed the quarter in a great financial position with more than $2.6 billion in cash and cash equivalents. This leaves us with plenty of liquidity to continue our capacity expansion initiatives for G6 and G7 in conjunction with growing CGM demand, while also being opportunistic with our investment strategy as we contemplate the long-term growth potential for our technology. We continue to anticipate some volatility to new patients in the fourth quarter of the year as COVID case rates rise and fall in certain of our areas of operations and the global economy fluctuates. But, with the strong third-quarter results, we are in a good position to once again raise our outlook for the remainder of the fiscal year. We now expect 2020 revenue to be approximately $1.9 billion, representing a growth of 29% over 2019. This represents an increase of $50 million from our previous guidance and $150 million from the midpoint of our guidance at the outset of the year, despite the impact from COVID over the past few quarters. As Kevin mentioned, new patient starts came in slightly ahead of the levels that we anticipated for the second half of the year and communicated on our second-quarter call. Although, they were still down relative to our pre-pandemic expectations. For the fourth quarter, we expect new patient starts to be approximately 90% of our original expectations, before the impact of COVID. Turning to margins. We now anticipate the following non-GAAP results to meet or exceed the following levels. Gross margins to meet or exceed 66%, representing an increase of approximately 300 basis points versus 2019, despite the pricing pressures that we have realized primarily as a result of our emphasis on the pharmacy channel. We expect operating margins to meet or exceed 16%, an increase of approximately 500 basis points from the prior year. Finally, we expect that adjusted EBITDA margins will expand to meet or exceed 26% for the year, also, an increase of approximately 500 basis points from the prior year. Our margin profile is clearly reflecting the strong revenue growth over the past several years and our ability to drive strong operating leverage from our key strategic drivers. We have also benefited to a certain degree this year from some near-term operating expense benefits associated with COVID related impacts to clinical trials, industry conferences and other normal work practices. We anticipate that some of the investments will begin to generate returns in the fourth quarter and then 2021. In addition, we will continue to invest to maximize our growth potential for the long term and we believe that as COVID-related restrictions to free up, there will be a return to spend in certain areas. So, while we expect the organization to continue to progress, the gains of margin expansion may not continue at the same magnitude or with the same predictability as we've seen this year. With that, I will now turn the call over to Steve for a strategic update. Steve Pacelli -- Executive Vice President, Strategy and Corporate Development Thank you, Quentin. Even with the ongoing impact of the COVID pandemic in our communities, our focus of DexCom remains largely business as usual. This means that we are focused on our patients, striving to ensure that they are cared for and empowered by DexCom's CGM in this time where glucose control is as important as ever. This also means that our teams are focused on executing on our core strategic priorities to best position DexCom to capitalize on our growth opportunity. The significant capacity expansions that our teams have worked tirelessly for since the start of 2019, has left us in a great position to aggressively target new patients, be at different strategic marketing pathways, including enhanced direct-to-consumer marketing, and as of very recently, the ability to offer product samples to healthcare providers so that their patients can experience first-hand the benefits of DexCom CGM. While we are being strategic about these investments in light of the impact of COVID, our inventory position has us well positioned to take advantage of these new opportunities and provide full support to the efforts of our field sales force. In September, we announced a new five-year research collaboration with the University of Virginia, my own[[Phonetic] monitor, of course. This agreement enables additional resources for our Charlottesville team as we look to innovate our artificial pancreas algorithm technology. We look forward to developing additional tools to offer our part -- and smart Pen partners to simplify the experience of managing diabetes for our collective customers. We'll also use the collaboration to advance our data analytics capabilities and research programs as we demonstrate the clinical value of DexCom CGM for customers outside of our core intensive insulin using population. This includes our efforts in non-intensive Type 2 diabetes, pre-diabetes, pregnancy, and the hospital market. We are making good progress in our efforts to extend the use of DexCom CGM to the broad Type 2 population. This includes continued traction in our Type 2 intensive segments, where the recent VA contract adds to our significant reimbursement progress thus far in 2020. With Medicare, UnitedHealthcare, Aetna, and the VA, and others now covering DexCom for the Type 2 intensive population, we are confident that this will be a nice growth driver for the company and a great outcome for those with Type 2 diabetes on intensive insulin therapy. But we are equally excited about the work we are conducting to demonstrate the value of DexCom CGM for the non-intensive Type 2 community. In addition to our work with Level 2 and Intermountain Healthcare, which Kevin mentioned, we will kick off commercial pilot programs with several of our key digital health partners in the fourth quarter. Our automated insulin delivery partnership strategy continues to support our growth and position DexCom to lead the shift toward connected devices for people with diabetes on intensive insulin therapy. Tandem's Control-IQ became the first automated insulin delivery system driven by DexCom technology earlier this year and has quickly generated great momentum for both companies, and more importantly, great outcomes for users of the system. As we draw closer to the start of 2021, we are excited for the anticipated launch of Insulet's Omnipod 5 system in the first half of next year. This represents another important step for DexCom, as we will have integrated systems commercially available that are arguably best-in-class solutions for both tubed and patch pump technologies. And with our integration work with Eli Lilly, Novo Nordisk, and Ypsomed progressing as well, we believe the DexCom is well-positioned to support our core markets for users of insulin pump and smart pen systems in the years ahead. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, Chief Executive Officer Thanks, Steve. As we head toward the equation of 2020, I want to take a moment to extend my gratitude to Rick Doubleday, our Chief Commercial Officer, who plans to retire at the end of this year and continue with us in a consulting role through 2021. Rick joined DexCom in 2009, leading our sales organization from approximately $49 million in sales in this first full year to the $1.9 billion that we're closing in on now. I can't think of many examples where a commercial leader has overseeing compounded growth of greater than 40% over a 10-year period, but that is what Rick was accomplished here in DexCom. He is a great leader and a great friend who has developed a solid plan to execute as we progress into 2021, and the launch of our G7 system. Rick has also worked extensively to develop a very talented commercial team. So we are in a great position as we press forward to execute on our goals in 2021 and beyond. So I hope you will join me in expressing appreciation for Rick's outstanding leadership at DexCom and best wishes as he embraces well deserved time spent with his family. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Director of Corporate Affairs Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions and Answers: Operator Thank you. We will now begin the question-and-answer session. [Operator Instructions] And our first question comes from Robbie Marcus from JP Morgan. Your line is open. Robert Marcus -- JP Morgan Chase -- Analyst Thank you, and congrats on a nice quarter. Kevin, the topic de jure that I think is the focus most investors now is the competitive environment and the pricing environment, particularly between you and Abbott. You both have great products and it's a large market. We've got a lot of product updates, both from your competitor and today with G7 moving into trials here and a launch in second half of next year, now with a 10-day product. How should people think about the increasing -- I know, I don't want to put the word out there but similarity of the options from the two products and how to think about the ongoing price differential in the pharmacy? I know, you've talked about this before but I just think it's important to reiterate the answer here given the focus for investors. Thanks. Kevin Sayer -- Chairman, President, Chief Executive Officer No, I appreciate that, Robbie. With respect to pricing, I think our results very clearly demonstrate how well we've managed this process as we moved a great deal of our business through the pharmacy channel, I am sure, Quent will get into that more later as we are into more questions, as you look at our margins as great as they are with volumes significantly higher than they were before and prices coming down, we've clearly proven that we can scale here. So we definitely understand how that works. With respect to products and features and things of that nature, let me start with G6 before we move to G7. This is an incredible product and it has incredible features and has truly been a market leader. It has taken us a while to get out to scale manufacturing G6 and get to capacity that we need and we have that now. And so, we will push G6 very hard and very competitively until G7 gets here, G6 is what we have today. With respect to our future products. I can't speak to what our competitors have. I know what G7 is and what it does. There are many features in there we have not shared with everybody that will delight the world. We went through the 10-day life for exactly the reasons I said on the call and it really leads into what is going to be the differentiation. We did this because we want the patient experience to be what we committed to. We have learned in our extensive research the most important thing for us is still to deliver what we say and as we were getting out to 15 days, particularly with our algorithm with that sensor, we saw too many of them not making it and while it performed great at the longer time, it wasn't great enough for us. So we shorten the life for now. We're very confident with changes we can make, to make it last longer. What the difference will be over time and we're investing significant resources, is on the experience side. The concept that one CGM experience fits all, it's just not going to work going forward, as you look at the AID Systems, as you look at people that are type 2 intensive insulin users who have migrated to CGM later in life. They may want different information and different experience. I think as we get the physical features of the product, exactly where patients want them and very comfortable with G7, what's going to be most important is the learning the experience that keeps them engaged and leads to better outcomes and we're very confident that we can win that though. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer And Robbie, just to add on to that and hit on Kevin's point of the pharmacy, I think it's important for folks to recognize that in the pharmacy channel, our product is not priced all that differently from Libre with respect to what the patients coming out of pocket for greater than 70% of our patients are able to get onto our product at less than $60 per month. Many of them with no out of pocket on a per-month basis. So from a patient perspective, it's priced very competitively. Operator And our next question comes from Danielle Antalffy from SVB Leerink. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hi, good afternoon guys. Thanks so much for taking the question. Just a question on -- I'm sorry to harp on the competitive landscape, but I'll ask more specifically, you saw growth in Europe did -- was slower than I believe one of your competitors and they did launch a competitive product and -- in Europe and I guess, if you could give us a little bit of color on what's happening, is anything there? is the first part of your question? The second part of the question is, just as a whole you grew slower than the competitor that's been on top of mind for a lot of investors today and I'm just curious that, how much of that is supply constraint being a little bit more constrained and not really pushing G6 as much as you could or will be doing in the future versus any real competitive dynamics here. Thanks so much. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Sure. Danielle, I'll take that. Let me hit OUS first. From an OUS perspective, our performance in the quarter was right in line with our expectations. I think if you go back and look historically at seasonal trends in that international business, Q3 is typically up around that 20% range and we were up 21% sequentially this year in Q3 coming off of Q2. To be a bit more clear with it though, we certainly saw some mixed results at the country level and in those countries where the patients required to be in the physician office to train on, to go through the administrative process through all the paperwork that's required, we certainly have seen that be a slower uptick in getting back to normal volumes in the midst of this COVID environment. Clearly COVID has impacted the ability to be in the office. Contrary to that though in markets where we have our e-commerce platform in place, for example, U.K., Canada, we're seeing record numbers of new patients coming onto our technology and just some tremendous growth there. So I really believe it's more a story of what the model looks like and how COVID is impacting that or not in terms of the patient's ability to get on to the product. And I think if you looked across the competitive landscape and you go back to some of the commentary that's been put out there over the course of the quarter, for those folks who are more focused in the IIT space, which happens to be where we're primarily focused today in our international business, I think you've heard them speak to some softness in the international business as well. So I think what you saw come together for us was right in line with what the market is seeing. We feel good about it. Again, it was in line with our expectations. To your point in terms of growing overall at a slower rate than one of our competitors. I think you have to keep in mind, we're navigating through a price headwind right now as we start to step price down and move more into the pharmacy channel and we are making terrific progress on that front, even a bit ahead of our expectations and if you were to look at the third quarter in particular and the 26% revenue dollar growth that we put up, if you were to look at that on a unit volume perspective, I believe we put up market leading unit growth in the quarter itself, growing nearly 40% from a unit perspective that's better than anything else out in the marketplace right now. So I think when you adjust for price, which is a bit specific to us and you really look at patients and unit volume, I think we're putting up market leading performance. Operator Your next question comes from Mathew Blackman from Stifel. Your line is open. Mathew Blackman -- Stifel Nicolaus -- Analyst Good afternoon, everyone. Thanks for the question. I wanted to touch on the comment from Steve about sampling and if you'll indulge -- I'll just have to intertwine questions on the topic. The first one is, how should we think about the potential impact of sampling on type 2s versus type 1s, would you expect it to be more impactful for Type 2s than type 1 and then the follow-on to that is, we actually did talk to a doc last week that I'll say very briefly us you had begun sampling his practice for the first time and he said he expected something like 50% conversion of this first call 20 patients or so into paying customers that sounds like that would be a home run. If that was broadly true, but help us understand how you're going to measure success or ROI on this new initiatives. Thanks. Kevin Sayer -- Chairman, President, Chief Executive Officer Well, this is Kevin. I will take that. We're thrilled to be able to sample at this point in time and to be doing it in a manner that we think can be very large scale. For years patients have wanted to try DexCom and see what they can do and given our status with our direct business and all the things we're doing, there were constraints around our ability to do that, we've removed those constraints as we work through the distribution channel. We believe that it's going to affect patients across the board, not only type 1s, but I think your comment on type 2 intensive insulin users is a very good one. They might be a bit more resistant to the technology because they've been dealing with diabetes longer and do I really want to do that. If you have the experience of wearing a G6 and having being able to see what happens, this becomes very easy. And so we're really excited about it. We expect the results will be good, if not fantastic. And if you look at the payback for us, you look at the revenue we get from a patient per year, if we convert 50% of these people to full-time use that is beyond spectacular program, we know you have to come close to that number for this to be a spectacular result for us, but I think the recognition and the ability for a physician to say, look, I have an answer for you, let's try this, it's really important to us and we think it's going to be a big initiative for us this year. Operator And your next question comes from Jeff Johnson from Baird. Your line is open. Jeffrey Johnson -- Robert W. Baird -- Analyst Good afternoon, all. Just want to do, weave a couple of points into a single question maybe we've been discussing recently some fairly tangible evidence that we think exists, anyway that you guys might be looking to dramatically expand our sales force over the coming months. So what I'm wondering I guess more than anything is one is that true? Two, does Rick's departure at all signal maybe he wasn't on board with that or anything else in the direction of the commercial organization and three, we don't typically think of sales reps in your business being a key driver of sales. So what might be driving that planned expansion if it is under way or plan to take place here over coming months. Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer I'll take that one. Let me address the Rick issue first. This has nothing to do with Rick's deciding to retire if anything, this all our sales reps, right now, are Rick's plans and he does get us even through to the end of the year while he will be working with us through year-end. So these events are completely unrelated. We are planning several things on the sales and marketing front over the next year. We will not reveal all of them, but what we do believe is we do need more coverage in the field, particularly as we look at the HCP community and those who are not endocrinologist, as you get into primary care physicians who are seeing more and more of these patients. We need some access there and we need some more feet, I'm speaking to them. We are very cognizant of the return our sale force has for us and I would disagree with you. Our sales team is great and they do provide a lot of benefit to our Company, they are a great voice and really are face of the Company in many of these geographies. So that I disagree with. We are fully on board with what we're going forward with and look forward to measuring results of it. Operator And our next question comes from Joanne Wuensch from Citibank. Your line is open. Joanne Wuensch -- Citi -- Analyst Good afternoon, and thank you for taking the question. Can we pause for a little bit on your comments regarding pricing versus unit volume? At one stage, I think, we were looking at a little over $100 million headwind in terms of pricing in 2020. Is that sort of the same number that we're thinking about? And then the second part of that is at what stage do you close the gap on pricing so that unit volume strength really shines through? Thank you. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, Joanne, this is Quentin. As we spoke about price this year, just coming off of last quarter, for example, we were talking about $150 million headwind in the business. So I think we were north of $100 million you had referred to. That was something that was probably a year old, to be honest with you, as we were starting to navigate through it last year, so it was a bit higher than that. As we've made terrific progress on the pharmacy side, we've actually seen price to be a little bit more of a headwind, then what that $150 million would have represented. I think it's going to be closer to $175 million for the year, we saw stronger price headwinds come through in Q3 that were embedded in that 26%. And obviously, if you do the unit volume at nearly 40%, you can kind of understand what the impact was in the quarter. But the majority of that is being realized as a result of us opening up that pharmacy channel, which we believe in the long term is the much better channel to be putting patients onto the product through for various reasons. It increases access, makes it easier for folks to get onto the product, and importantly, from a profitability perspective over time, will be a much more profitable business model for us. And I think just looking at the quarter itself, seeing gross margin reach record levels of 68% while the quarter represents the greatest amount of mix in that pharmacy channel, just demonstrates our ability to really get after the cost profile of our product and compete in that segment quite aggressively. In terms of how long it takes to ultimately get to the price point or the mix of the pharmacy channel, we're not going to speak to that today, I think you're going to hear more from us as we get to our Analyst Day around just how far we are into that pharmacy channel and where we see that going, but we're making terrific progress there, very happy with what we're seeing. Operator And your next question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Hey, Quent, just a follow-up there. Just thinking about the fourth quarter guide. It basically implies around kind of, 20 points in momentum deceleration that's probably 5 points heavier than you guided sort of into the fourth quarter last year. Anything you'd call out, U.S. or ex-U.S. we should be thinking about into the fourth quarter and perhaps it just reflects frankly that incremental $25 million of price as you exit out the year? Thanks so much. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah. Thanks, David. Let me talk through a little bit of the assumptions that we've made as we head into Q4. I think we continue to operate in an environment where there is not a great deal of clarity with respect to how COVID is ultimately going to impact the business and we want to be prudent and thoughtful around how we set those expectations. First and foremost, as we move more and more business into the pharmacy model as well as the Medicare business continues to grow at a strong rate, the seasonal impact in the business is going to shift, you're not going to see nearly as much revenue show up in the fourth quarter as the patients no longer really incentivize to take advantage of a scenario where they might have already met the deductible and they're going to load up on product as they exit the year. So the seasonal trends in the business are going to look a little bit different as the mix in the business shifts. With respect to COVID in particular, our best estimate at this point in time is that we're going to see about a 10% impact to new patient starts in the fourth quarter. If we navigate that more successfully, then terrific, there's going to be some upside to the number, but that's our best estimate at this point in time. And then I think that, the other thing to consider is the fact that we've put in place the Patient Assistance Program that really hasn't had an impact on the overall results just yet. We saw it start to take place in Q3, but it didn't impact us in a material way. But if you think about it, that was put in place to help those patients who ended up being unemployed or just couldn't afford the product in general. And most of that started to happen back in the second quarter as COVID really started to take place. And if you think through that scenario, we've got patients who would go on to COBRA for a period of two or three months, they typically would make their last purchase of a quarters worth of supplies, so another three months of product. And that put them right into the fourth quarter when they're going to be making their next purchase, which is when they would now be coming on to the Patient Assistance Program. So our belief that that's going to be a bit more impactful in the fourth quarter than what we've seen in other quarters. I think when you take those sorts of things into consideration and you try to quantify those, if you were to exclude them, you'd see a growth rate right back in line with what you've seen year-to-date. Operator And your next question comes from Matthew O'Brien from Piper Sandler. Your line is now open. Matthew O'Brien -- Piper Sandler -- Analyst Afternoon. Thanks for taking the question. Kevin, the comment that you made about not seeing what you wanted to see from day 10 to day 15, is that because you can't hit the iCGM designation, or was it just the key levels that working the algos and quite right, what exactly does that mean, do you think you're going to have an iCGM designation for this, for G7 when you get out to 15 days? And then on the 10-day sensor, is it going to be a cheaper sensor because I know cost is a big gating factor for some people? Thank you. Kevin Sayer -- Chairman, President, Chief Executive Officer So let me start with pricing. Again we currently sell a 10-day sensor and pricing is very much based upon the cost per month, whether you buy two sensors or three sensors. As we been these contracts, CGM is a monthly cost, it really doesn't get down to the unit. Particularly, if you look at the way our contracts are negotiated with respect to transmitter and receiver prices and you get into rebates on various components, so the cost per individual sensor really doesn't matter, it's what we can make and what we get reimbursed for in a given month. With respect to getting out from 10 to 15 days, for us this is a problem that we can solve. In order to meet iCGM standards, the way our algorithm works is we turn the sensors off when the data, we believe isn't necessarily good enough for iCGM standards. Many of our patients would argue that the data is just fine when we shut them off, but that's how we look at this and how we run it. We saw that we're basically shutting off more sensors than we wanted to right now and we needed to perform better. As I said earlier, we can get 70% of them to 15 days without any trouble, but 70% in our minds is not good enough for our patients. We'd rather have a better reliability number and go 10 days. It is a cost issue more than anything else and over time, when we get the 15, the COGS will obviously be less. But as you look at our G6 performance with our 10-day sensor now and the cost profile that our ops team, Quentin and the team have created, we've -- we're very happy with that and we're very comfortable going forward with G7 with 10. We'd like to make it 15 and we'll work on that as soon as we're done with the 10 filing. We expect everything we do to have an iCGM designation by the way, so there won't be any backing off on that. Operator And our next question comes from Travis Steed from the Bank of America. Travis Steed -- Bank of America -- Analyst Hi. Thanks for taking the questions. Just wanted to get a little bit more color on the G7 timelines. The -- you mentioned key markets in the second half of next year, does the U.S. fall in the second half, or is that going to be more 2022? And then on the U.S. pivotal trial, when do you expect that to actually finish enrolling? Kevin Sayer -- Chairman, President and Chief Executive Officer We're not going to give all those timeline details out for competitive reasons, more than anything else. Our policy in the past is more to announce approvals rather than to give a bunch of details on the studies. I did say that we started our studies with respect to generating data for approvals. By saying multiple geographies that obviously means there'll be international launches. To the extent we launch in other places has yet to be determined. Right now we're focused on a number of efforts getting ready for that and the complexity of G7 for us is actually, it's kind of a blast. It's very exciting to go through changes big as we're doing, but literally, every single process in building this is different than what we've done before. And so, we are getting factories and capacity up and running, the lines we've fully automated, we want to be completely ready to manufacture tens of millions of these things at launch rather than just a few. And in fairness to our commercial team and everybody in the field, we've spent all of '19 living on about three days to finish goods and we're not doing that again. That won't be, I have very -- every confidence that will not be through the way on launch, it will be getting all the approvals in but we'll launch it in the appropriate time frames and give color as the situation evolves. Operator And your next question comes from Margaret Kaczor from William Blair. Your line is open. Margaret Kaczor -- William Blair -- Analyst Hey, good afternoon, guys. Thanks for taking the question. Yeah. I wanted to follow-up on the G7 launch. And just operationally, have you guys been able to start working through some of those payor contracts, or they asking you to wait and I ask just because of that lack of the transmitter, whether that's going to then structure that G7 sales cycle on an annual revenue basis for maybe days per sensor don't matter as you extend further into the life of that or is it going to be sensor only? Kevin Sayer -- Chairman, President, Chief Executive Officer We've contemplated the G7 launch ever since we started negotiating contracts for G6. We don't view this as a big change over for us. If anything -- our team will be more than ready to do this in the field when time happens. And as it gets closer, as we go through the next billing cycle, inevitably, our team will -- well for G7 there will be some payers who will do dual-pricing even though G7 is not approved others, will want to wait till the products approved. The policies vary across the board, but we've contemplated the G7 launch and all the G6 work that we've done. So we have a model going forward that will be easy to repeat. Operator And next question comes from Ray[Phonetic] Denhoy from Jefferies. Your line is open. Raj Denhoy -- Jefferies -- Analyst Hey, thank you. Maybe, Quent, one for you about the gross margin, it's been pretty impressive to see the gross margin expansion, even as you guys are absorbing all of this price. And I guess the question is, where there or really how long you can keep doing that? Is there a level at which gross margin can -- has to stop going up and actually starts to go the other direction as pricing continues to come down? And I appreciate G7 represents kind of a step-change in that, but as we're still on G6, how long does this keep growing? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, Raj, great question. We couldn't be more excited about where we've been able to take the cost profile of our G6 products. And keep in mind, we're doing that at a time where we've created record inventory levels for the company, which just opened up more and more growth potential and growth avenues for the organization that we can start to pursue. So we're excited about that. We're currently at our lowest cost point-to-date on G6. And I think there's quite a bit of runway still in front of us with respect to take cost out of that product, particularly as we keep pushing significant volumes through the plant. As you look at the cost profile, I believe we can get to a profile that is less than $1 of day, of cost for the product, regardless of whether that's G6 or G7, keep in mind, G7 from the very beginning of time was designed with cost in mind and the ability to get to a lower cost profile than G6. And so, while we're making tremendous progress on G6, the ability to replicate that and do even better with G7 is something that we fully believe in our ability to do. That being said, G7 will be more expensive in the early stages as we're ramping capacity, but at scale, it will be a lower cost profile for us than G6. So, I think there's still quite a bit of a good runway in front of us. The teams are focused on driving costs out of the product. We're redesigning, manufacturing process where we can take manual efforts and move them to automated efforts. We're moving into lower-cost jurisdictions. We've renegotiated cost points with many of our vendors as they've taken advantage of larger volumes as well. We've redesigned the logistics and distribution model that we utilize as well as taking cost out. So, I don't think we're anywhere close to having realized the full benefit of all of that just yet, but you're starting to see it play through. To the degree that we continue to navigate through price headwinds will somewhat impact how high that gross margin can go, but at the very least it, let us come back those sorts of things. So we're excited about where we're on the cost side. Operator And your next question comes from Steven Lichtman from Oppenheimer & Company. Your line is open. Steven Lichtman -- Oppenheimer & Co. -- Analyst Thank you. Hi, guys. I was wondering if you could update us on progress in intensive Type 2. Are you seeing momentum now on the commercial side with the win, you talked about with United and more recently with Aetna. And where do you think we are in terms of the market-intensive Type 2 CGM penetration? Kevin Sayer -- Chairman, President and Chief Executive Officer I'll refer to Steve, to Quentin on the market penetration. I can just tell you, anecdotally, what we're hearing is very much as these patients are getting covered, the technology is getting to them. We've always had Type 2 intensive insulin used coverage in Medicare. In that respect, I think our biggest barrier there and again it talks to the sales force expansion and messaging, because we're getting physicians to recommend it to those patients and making everybody aware. So we're happy with that, we're not. On the penetration, Steve... Quentin Blackford -- Chief Financial Officer and Chief Operating Officer What we said on the last call is that, that our Type 2 business was exceeding 20% of our patient base. I don't think we're prepared to update that today, but the other -- the point that I would want to make on the -- even just the intensive Type 2 spaces of the addressable market is simply larger, right. So whether you're looking at the U.S. business, or even looking at the European, or the other foreign markets, in the U.S., we're looking at a patient opportunity of probably pushing like 2 million patients where we used to use a number of maybe like 1.5 million in the U.S., I think the data that we have suggest that, that market opportunity is a lot bigger. So, our penetration certainly isn't there, we're making great progress on the insurance front and it's a huge market opportunity as we look to continue to expand the intensive business. Operator And your next question comes from Chris Pasquale for Guggenheim. Your line is open. Chris Pasquale -- Guggenheim Guggenheim Securities -- Analyst Thanks. Two quick ones from me. One, I was hoping you could give us a little bit more on the significance of the government contract you mentioned in the U.S., what impact that could have on the business? And then, I just want to follow up on the question about international. I'm curious, if the situation is improving in the countries that have lagged due to COVID or if you actually think that might give a little bit worse here in 4Q as virus case counts increase in some of those places. Thanks. Kevin Sayer -- Chairman, President, Chief Executive Officer The government contracts really important to us, particularly on the VA side, there is a much higher incidence of diabetes with that group of patients than the general population, being able to get access to G6 through a pharmacy benefit at zero copay, we think is a wonderful benefit for that group. I think it's just part of the general blocking and tackling that we do to continue to grow. So I can't quantify, these are the types of wins that you've seen DexCom generated over the past several years and we are looking forward to serving this patient base much easier than we have before. I'll let, Quentin, talk about the international piece. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah. With respect to international, early signs are starting to point to the fact that new patient numbers are starting to step back up, clearly not back at the levels they used to be at, but we are seeing those start to trend back up the way we would expect them to overtime. So, we're seeing some good progress there and, clearly, that's in those markets that have the administrative burdens placed upon that are a bit heavier in those markets where you're utilizing something like e-commerce platform. We've seen terrific results there so. Operator And your next question comes from Chris Cooley from Stephens. Your line is open. Chris Cooley -- Stephens -- Analyst Good evening, and thank you for taking the questions. Just may be at this point from me lets get to, when you think about the UVA collaboration and you talk about the advanced analytics, DexCom already essentially owns and controls the data to the generation. You have the algorithms in place. How's there on maybe, a future revenue stream from -- what do we want to call this an IT management or some type of here just ways that you can, sort of, leverage the data that you have in-house now to further enhance the margin profile longer term. Steve Pacelli -- Executive Vice President, Strategy and Corporate Development Yeah, no, it's a great question and we've spent time exploring ways to monetize the data today. And quite frankly at this point, to the extent we can help our partners, be more competitive with the algorithms that we provide to them and that we provide to our patients, just from a patient capture and patient retention perspective, I think we're pretty happy with that. The UVA collaboration, in particular, you guys all know we bought type zero a few years back, that algorithm, in particular, is commercialized in the Tandem Control-IQ product today. Really when we look at the opportunity at UVA, it's really to expand to next-generation algorithms, whether they'd be for automated insulin delivery, which we would probably do in conjunction with our folks at TypeZero or even beyond to the intensive insulin patients who don't use an insulin pump and even beyond that, whether it's Type 2 more broadly, health and wellness, pre-diabetes, even in the hospital. So we're looking at kind of ample opportunity over the next five years to really work closely with UVA who has been responsible together with our folks at TypeZero for developing these best-in-class algorithms. Operator And your next question comes from Kyle Rose from Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great, thank you for taking the questions. Just two from me, both on the commercial side. First on the DTC program. If you can help us understand, I guess the ongoing effectiveness of the program and where you're at with respect to rolling it out and realizing the value and the return on investment from those DTC investments? And then secondarily, are you seeing changes with respect to your referring physician mix, obviously, you talked about maybe making some salesforce investments as we move more into the non-Endo, just trying to understand how that was different channels to have different sales and marketing needs. Kevin Sayer -- Chairman, President, Chief Executive Officer Well, as respect to DTC, we have rolled that out and we're going very strong here in the fourth quarter. Our return on our DTC investments has been very, very good to date. In fact, compared to other ones, we've seen in other companies, our returns are extremely high still. So that program has not capped as far as effectiveness. So we'll continue to investigate and you will see more from us going forward this quarter and first of next year. We have a lot of fun things planned for you on the DTC front. With respect to more channels and referring physicians, again as Quinton said earlier, we had tremendous new patient numbers this quarter, so we're still getting referrals, obviously in the Endocrinology community and the communities where we served. Traditionally, we just feel they need to go deeper and to visit with more healthcare professionals and help them better treat their patients as well. One of the things we learned from COVID with respect to our CLARITY system, as physicians had to do mobile appointments or tele appointments, they can pull CLARITY data up on the screen. Those appointments become very effective and there is a large group of physicians who don't have access to CLARITY or haven't been using it. We need to get out and get our message out there. So that's our plan, is go deeper and to help our people focus more on those territories where they work. Operator And your next question comes from Jayson Bedford from Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Good afternoon. I hate to get granular here, but I thought I heard Kevin say that new patient growth continued in the third quarter. There is a couple of ways to interpret that comment. So my question is did you add more new patients in 3Q '20 than you did in 3Q '19? Kevin Sayer -- Chairman, President and Chief Executive Officer Yes, Jayson, just to be clear Q3 2020 was a record number of new patient adds for us. So it was the highest quarterly new patient add of any quarter in our history. Operator And your next question comes from Ravi Misra from Berenberg Capital. Your line is open. Iris Long -- Berenberg Capital Markets -- Analyst Hi, there. This is Iris calling for Ravi. Thanks for taking the question. So if you can talk about CGM coverage under Medicaid, so as we think about the macro economy, the unemployment rate is high and maybe there are more people moving to Medicaid from other insurances. So can you talk about CGM coverage under Medicaid and do you think the shift to Medicaid would reduce patients' access to CGM or increase pricing pressure. Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, this is Kevin. I will take that. We have Medicaid coverage in approximately 40 of the 50 states as we sit here today and I would be in full disclosure. It's spotty in some states, it's very easy in some states, they make it very hard as they're very budget conscious and they worry about spending dollars. We believe and we have various pricing arrangements throughout all the states. There's a wide range of pricing there. I don't -- if we had coverage in all 50 states and everything were equal and almost every device business, Medicaid pricing ends up being lower than everything else and we're prepared to do that. We believe these patients, serve access to our technology as well. But really the challenge for us has been getting it across the finish line in a manner to whereby patients can get the technology and it's just too hard, right now. We are trying hard to be better. We've had some major wins on that front. But there is a couple of states where we just keep knocking on the door and keep -- I mean there are some states where we get across the finish line and then they've attached Medicaid coverage to some other thing in the State Legislature and we get thrown out. It's been a very frustrating thing for me in particularly because so many of those patients are children and really deserve access to DexCom CGM, deserve access to share and follow all the things that we have to offer. So we continue to fight that battle. I hope we have it in every state and we will make sure that we can compete competitively on the pricing side. We're not going to give the Medicaid business up, we want patients to have access to us. Operator And your next question comes from Ryan Blicker from Cowen. Your line is open. Ryan Blicker -- Cowen and Company -- Analyst Hi, thanks for taking my question. You've always said that at some point competitors will close the gap versus DexCom on performance and connectivity. Assuming this happen at some point over the next one or 2 years, do you believe DexCom can differentiate versus its competitors via the software around the CGM and accordingly sustain some degree of premium priced long-term, you're clearly making significant investments here as demonstrated with TypeZero and the UVA collaboration. But again, do you believe DexCom can differentiate via software over time instead of the hardware differentiation you've enjoyed since 2012 and if so when will we start to hear more about your software product pipeline. Thank you. Kevin Sayer -- Chairman, President, Chief Executive Officer Well, you will hear more about our software product pipeline as we launch those products over time and let's be clear on the hardware differentiation side. While we've said that gap is going to close, it still hasn't and we still lead in connectivity and connectivity with multiple devices and their operability and data sharing and all of those things. That infrastructure has taken us a long time to build, and it comes a lot to support. I think over the next several years, software will be a key thing delivering the experience of the patient that will keep them engaged and provide a great outcome. I was at dinner with a longtime diabetes patient the other night and we sort of talking about experiences and the guy looked at me, and goes, so wait a minute, you don't think one size fits all? I said, no I don't. I think at some point in time, you'll see -- I know you'll see from DexCom different software offering. So stay tuned on that one. I think the other thing that everybody needs to understand also about this market is really kind of the next several years is just the challenge of scale and we've lived through this. As we continue to invest in factories, we've got G6 pretty much built out now, that took us a couple of years and now we're investing heavily in G7. You are looking at somewhere between $0.5 billion to $1 billion in capital investment on our part to do this, to get to where it needs to be to get these products at the cost basis they need to be, but also automated and at scale so we can deliver the volumes that we need and that will be a differentiator as well, if companies aren't investing in that scale and that's can be difficult. So as I look out over time, connectivity and the hardware experience that we provide, we still believe we will be best-in-class over everybody else, but the software experience we can create based on the mentality that we have is as close as we are to our patients. Really it is going to be differentiator. As far as premium pricing over time, we will continue to work toward that end. We've done very well in the pricing -- in our pricing schemes now but as Quentin alluded to earlier, with our shift to the pharmacy, many of our patients to Medicare that's becoming our pricing models have moved in the way that we thought they would. I do think there are things we have CGMs to do that are worth more than other things and as I look to this in the future, I do see an experience. This is just me personally, that is worth a higher price, than some other experience and conversely, I see some other experiences, it may not be worth as much as what we charge today. So stay tuned on that. We -- as I mentioned, some of the other day, we've kind of created this industry from 2012 to now and it's going to be fun to evolve over the next several years as well. Operator And your next question comes from Larry Biegelsen from Wells Fargo. Your line is open. Lawrence Biegelsen -- Wells Fargo -- Analyst Hey guys, thanks for fitting me in. Quentin, any color or preliminary thoughts on 2020 -- how we should think about 2021 relative to 2020. The 29% top line growth you're guiding to in 2020 and the operating margin of greater than 16%, any high-level thoughts? Thanks for taking the question. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, Larry. We're not going to talk about 2021 on the call today. Clearly, we believe there is tremendous opportunity for growth in front of us given just the fact that there is so much awareness to continue to be had around our product, I think we've been clear from a profitability side, we're going to be disciplined in this organization and we're going to make the right investments where we need to open up new growth channels into the future and all of that will be contemplated in the guidance that we ultimately end up providing for '21, but we're not going to do that today. Operator And that concludes the question-and-answer session. I will turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you. I again want to thank everybody for participating onearnings calltoday. I really can't emphasize enough how strong our teams performed during these incredibly unstable times. $0.5 billion in quarterly worldwide sales at a time when our field teams have had very limited access to clinicians and have had to be very creative to figure out how to get the message out to patients. We've raised our guidance now for three straight quarters. We have gross margins approaching 70% during a period of managed price reduction, combined with unit volumes being more than double what they were two years ago and significantly higher than last year at this time. We have operating and net income levels higher than we've ever had before. During a period when our customers' satisfaction scores are also at all time highs, as far and excess of those of our competitors. We are doing our best on our commitment to our patients. Innovation continues to thrive here. I personally learn more about sensor technology in 2020 then any of the other years I've been here. All of this is pushing toward tremendous innovation going forward and as we see the use of CGM in other applications and some of the things, some of our data partners.our payor partners are going to be able to do with this data going forward, never been more bullish about innovation and what's coming in the future. And barriers for new markets are coming down as we've navigated our way through the hospital experience and learned there, our type 2 efforts with the program, Steve, talked about earlier, we're making progress in multiple markets for the future, so we'll be able to address those. You can't do all these things without a remarkable team. I want to express my gratitude to everybody on the DexCom family at this time. But I'll remind everybody of one thing, we are still at the very beginning of this journey and it's only going to get faster from here. Thank you, everybody. Operator [Operator Closing Remarks] Duration: 64 minutes Call participants: Sean Christensen -- Director of Corporate Affairs Kevin Sayer -- Chairman, President and Chief Executive Officer Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Steve Pacelli -- Executive Vice President, Strategy and Corporate Development Kevin Sayer -- Chairman, President, Chief Executive Officer Robert Marcus -- JP Morgan Chase -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Mathew Blackman -- Stifel Nicolaus -- Analyst Jeffrey Johnson -- Robert W. Baird -- Analyst Joanne Wuensch -- Citi -- Analyst David Lewis -- Morgan Stanley -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Travis Steed -- Bank of America -- Analyst Margaret Kaczor -- William Blair -- Analyst Raj Denhoy -- Jefferies -- Analyst Steven Lichtman -- Oppenheimer & Co. -- Analyst Chris Pasquale -- Guggenheim Guggenheim Securities -- Analyst Chris Cooley -- Stephens -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Jayson Bedford -- Raymond James -- Analyst Iris Long -- Berenberg Capital Markets -- Analyst Ryan Blicker -- Cowen and Company -- Analyst Lawrence Biegelsen -- Wells Fargo -- Analyst More DXCM analysis All earnings call transcripts 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Tumbles: Tech Stocks Gain but Everything Else Falls The S&P 500 index (SNPINDEX: ^GSPC) closed down 10 points, or about 0.3%, on Oct. 27 as stocks diverged into two groups: the tech stocks that went higher, and everything else that fell. Both the tech and communications sectors gained today, while every other sector closed lower. In total, 381 of the 503 stocks in the index closed lower today. Today's biggest gainers -- no surprise -- were tech stocks. Xilinx (NASDAQ: XLNX) shares picked up 8.6% following the official announcement that Advanced Micro Devices (NASDAQ: AMD) was paying $35 billion to acquire its smaller rival. Shares of F5 Networks (NASDAQ: FFIV) gained 8.5% on earnings. Companies reporting earnings led the charge lower. Shares of Franklin Resources (NYSE: BEN) fell 13.6% after the company announced quarterly results that failed to meet expectations. Joining Franklin on the slide lower were Dexcom (NASDAQ: DXCM), Raytheon Technologies (NYSE: RTX), and Eli Lilly (NYSE: LLY), all down 7% or more. Image source: Getty Images. Big tech the lone bright spot Xilinx shares gained on the announcement of the AMD deal, which will pay Xilinx investors 1.7234 AMD shares for each share of Xilinx they own, attaching a $35 billion value to the smaller company. The acquisition is expected to help AMD step up its game in the high-growth data center segment where Intel has a commanding presence. F5 Networks shares gained following the company's fourth-quarter earnings report and earnings call. F5 reported strong growth in its burgeoning subscription software business, and CEO Frank Pelzer said software sales would grow 35% this year. This growth is helping the company transition away from a hardware and software sales model that's in decline, as more companies move to software-as-a-service. The biggest of the big tech stocks also gained today, with Apple (NASDAQ: AAPL), Amazon (NASDAQ: AMZN), and Microsoft (NASDAQ: MSFT) all posting modest gains ahead of earnings. Microsoft reported after market close, delivering some $14 billion in profits. Apple and Amazon are set to report later this week. Amazon also announced today that it would need to hire another 100,000 seasonal workers to support demand through the holiday shopping season. Earnings woes sent these stocks lower Recent earnings excitement has turned a bit negative, with the four worst-performing S&P stocks today all falling on earnings. Franklin Resources Franklin Resources shares declined sharply after it reported earnings of $0.56 per share, well below expectations, while investors also cast their doubts about the near-term prospects for the money manager and financial services company, which is still working through combining Legg Mason, which it recently acquired. Eli Lilly Pharma giant Eli Lilly shares also fell today following an underwhelming (at least for Wall Street's expectations) quarter. Revenue was up 5% to $5.7 billion, but analysts wanted to see $5.9 billion, and $1.54 adjusted earnings per share didn't meet the $1.71 per share Wall Street was looking for. In short, today's decline is the result of Wall Street trying to gild the lily. Today's sell-off could represent an opportunity to buy shares of a quality company at a respectable price. Raytheon Defense and aerospace giant Raytheon shares fell as the company's commercial aviation business continues to struggle under the weight of the coronavirus pandemic. The company said it would cut almost 20,000 employees and contractors, mostly in its commercial aviation-focused units. It will also cut more than 20% of its existing infrastructure as part of its cost-cutting efforts. The depth of the cuts, both to headcount and the company's facilities, indicates Raytheon management expects commercial aviation will struggle to return to normal for a number of years. Dexcom The glucose monitoring devices company reported 26% revenue growth, a solid increase in operating income, and set guidance for 29% growth this fiscal year. By most accounts that's a solid result, but it wasn't released until after market close today. The company pre-released third-quarter revenue results on Oct. 26, while also announcing the retirement of Chief Commercial Officer Rick Doubleday, who joined Dexcom in 2009 and played a major role in building what is on track to be a $2 billion sales business this year. Looking ahead: Earnings season heating up More than 100 S&P 500 companies are set to report earnings before the end of the week. This includes six of the eight biggest companies, with Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) and Facebook (NASDAQ: FB) reporting Wednesday, and Visa (NYSE: V) reporting tomorrow along with Mastercard (NYSE: MA). Investors should expect this massive dump of new information -- and traders looking to make money before and after the reports -- to add to the recent volatility. What happens over the next few days is impossible to predict. But looking at the bigger picture, and further into the future, I think it's a reasonable conclusion that investors can still count on stocks as the best way to create wealth over the long term. Find out why Amazon is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. Amazon is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of October 20, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jason Hall owns shares of Alphabet (A shares), Mastercard, and Visa. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Facebook, Mastercard, Microsoft, and Visa. The Motley Fool recommends DexCom and Xilinx and recommends the following options: long January 2021 $85 calls on Microsoft, short January 2021 $115 calls on Microsoft, short January 2022 $1940 calls on Amazon, and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Tiffany, Eli Lilly, Harley-Davidson, Energy Transfer, Advanced Micro Devices Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow fell on Tuesday, dragged down by a string of earnings disappointments and doubts about a coronavirus stimulus package before Election Day, although Nasdaq rose ahead of results from mega-cap technology companies .N At 12:25 ET, the Dow Jones Industrial Average .DJI was down 0.21% at 27,626.17. The S&P 500 .SPX was up 0.11% at 3,404.76 and the Nasdaq Composite .IXIC was up 0.64% at 11,431.183. The top three S&P 500 .PG.INX percentage gainers: ** Xilinx Inc , up 8.7% ** F5 Networks Inc , up 7.5% ** Tiffany & Co , up 4.5% The top three S&P 500 .PL.INX percentage losers: ** Franklin Resources Inc , down 10.4% ** Dexcom Inc , down 6.5% ** Roper Technologies Inc , down 6.2% The top three NYSE .PG.N percentage gainers: ** Weidai Ltd , up 60.3% ** 1847 Goedeker Inc , up 55.5% ** Harley-Davidson Inc , up 26.6% The top three NYSE .PL.N percentage losers: ** Sequans Communications SA , down 15.2% ** Knoll Inc , down 14.9% ** Scorpio Bulkers Inc , down 12.9% The top three Nasdaq .PG.O percentage gainers: ** Scholar Rock Holding Corp , up 80.6% ** Siyata Mobile Inc , up 30.6% ** Synalloy Corp , up 29.6% The top three Nasdaq .PL.O percentage losers: ** Galera Therapeutics, Inc , down 15.1% ** Kala Pharmaceuticals, Inc., down 14.7% ** Diamondpeak Holdings Corp , down 14.2% ** Twilio Inc TWLO.N: down 2.4% BUZZ-Twilio Inc: Falls on Q4 loss forecast ** Chegg Inc CHGG.N: down 9.5% BUZZ-Down as Q3 loss widens ** F5 Networks Inc FFIV.O: up 7.5% BUZZ-Rises on upbeat Q1 sales forecast ** Catabasis Pharmaceuticals Inc CATB.O: down 70.4% BUZZ-Eyes record low as muscle disorder drug fails late-stage study ** AudioCodes Ltd AUDC.O: down 2.8% BUZZ-AudioCodes: Jumps on third-quarter revenue, profit beat ** Energy Transfer ET.N: down 7.5% BUZZ-Energy Transfer drops after distribution falls below estimates ** Crocs Inc CROX.O: up 1.9% BUZZ-Rises on third-quarter revenue beat, strong Q4 forecast ** Advanced Micro Devices Inc AMD.O: down 4.0% BUZZ-Drops; co plans to buy chipmaker Xilinx in $35 bln deal - Reuters News ** Harley-Davidson HOG.N: up 26.6% BUZZ-Up on upbeat Q3 results ** Eli Lilly LLY.N: down 5.7% BUZZ-Slides as Q3 profit hit by weak demand for drugs ** SPI Energy Co SPI.O: up 8.9% BUZZ-Jumps on board approval to spin off EV charging unit ** Anaptysbio Inc ANAB.O: up 7.5% BUZZ-Brokerages cheer royalty stream from amended GSK deal ** Varonis Systems Inc VRNS.O: up 5.0% BUZZ-Varonis hits record high as analysts hike PTs after upbeat Q3 ** Novavax Inc NVAX.O: up 1.0% BUZZ-Rises on COVID-19 vaccine candidate update ** Build-A-Bear Workshop Inc BBW.N: up 10.4% BUZZ-Jumps on upbeat third-quarter revenue forecast ** PJT Partners Inc PJT.N: up 6.3% BUZZ-Up on Q3 profit beat, boosts buyback ** Moelis & Co MC.N: up 4.0% BUZZ-Up on quarterly dividend raise, Q3 revenue beat ** Nektar Therapeutics NKTR.O: down 1.1% BUZZ-Nektar Therapeutics: Potential COVID-19 drug trial to begin, however investors not impressed ** Raytheon Technologies RTX.N: down 4.6% BUZZ-Falls after defense unit sales disappoint ** DTE Energy DTE.N: up 2.4% BUZZ-Climbs on plans to divest midstream ops, upbeat outlook ** 3M Co MMM.N: down 1.3% BUZZ-3M: Slips on uncertain outlook even as Q3 results beat estimates ** CASI Pharma CASI.O: up 20.3% BUZZ-Rises on deal with BioInvent to develop, market cancer drug The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.27% Consumer Discretionary .SPLRCD up 0.51% Consumer Staples .SPLRCS up 0.48% Energy .SPNY down 0.69% Financial .SPSY down 1.09% Health .SPXHC down 0.04% Industrial .SPLRCI down 1.41% Information Technology .SPLRCT up 0.71% Materials .SPLRCM down 0.23% Real Estate .SPLRCR down 0.07% Utilities .SPLRCU up 0.66% (Compiled by Rithika Krishna) ((rithika.krishna@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Twitter, Harley-Davidson, Chegg Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was little changed on Tuesday after a sharp pull back in the prior session as investors parsed through a slew of mixed corporate earnings, while awaiting progress on U.S. fiscal stimulus. .N At 10:48 ET, the Dow Jones Industrial Average .DJI was down 0.23% at 27,622.47. The S&P 500 .SPX was down 0.23% at 3,393.14 and the Nasdaq Composite .IXIC was up 0.57% at 11,424.019. The top three S&P 500 .PG.INX percentage gainers: ** Xilinx Inc XLNX.O, up 10.2% ** F5 Networks Inc FFIV.OQ, up 7.9% ** Twitter Inc TWTR.N, up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Franklin Resources Inc BEN.N, down 8.1% ** Eli Lilly and Co LLY.N, down 5.5% ** Dexcom Inc DXCM.O, down 5.4% The top three NYSE .PG.N percentage gainers: ** 1847 Goedeker Inc GOED.N, up 82.3% ** Harley-Davidson Inc HOG.N, up 26.4% ** Build-A-Bear Workshop Inc BBW.N, up 19.2% The top three NYSE .PL.N percentage losers: ** Knoll Inc KNL.N, down 12.1% ** Comfort Systems USA Inc FIX.N, down 10.3% ** Chegg Inc CHGG.N, down 10.2% The top two Nasdaq .PG.O percentage gainers: ** Scholar Rock Holding Corp SRRK.O, up 87.3% ** Harbor Custom Development Inc HCDI.O, up 27.7% The top three Nasdaq .PL.O percentage losers: ** Genfit SA GNFT.O, down 13.3% ** Galera Therapeutics Inc GRTX.O, down 12.9% ** Amkor Technology Inc AMKR.O, down 11.8% ** American International Group AIG.N: up 2.3% BUZZ-AIG: Operational split, CEO succession bring cheer ** Twilio Inc TWLO.N: down 1.7% BUZZ-Twilio Inc: Falls on Q4 loss forecast ** Chegg Inc CHGG.N: down 10.2% BUZZ-Down as Q3 loss widens ** TriNet Group < TNET.N>: down 6.2% BUZZ-TriNet Group: Jumps as Q3 results top expectations ** F5 Networks Inc FFIV.O: up 7.8% BUZZ-Rises on upbeat Q1 sales forecast ** Catabasis Pharmaceuticals Inc CATB.O: down 68.4% BUZZ- Eyes record low as muscle disorder drug fails late-stage study ** Energy Transfer ET.N: down 5.9% BUZZ-Energy Transfer drops after distribution falls below estimates ** Crocs Inc CROX.O: up 1.6% BUZZ-Crocs: Rises on third-quarter revenue beat, strong Q4 forecast ** Advanced Micro Devices Inc AMD.O: down 3.1% BUZZ-AMD plans to buy chipmaker Xilinx in $35 bln deal ** Harley-Davidson HOG.N: up 26.4% BUZZ-Harley-Davidson up on upbeat Q3 results ** Eli Lilly LLY.N: down 5.5% BUZZ-Slides as Q3 profit hit by weak demand for drugs ** Staffing 360 Solutions STAF.O: up 8.8% BUZZ-Jumps on completion of its debt restructuring ** Pfizer < PFE.N>: down 1.2% BUZZ-Down after Q3 sales drop ** SPI Energy Co SPI.O: up 17.3% BUZZ-Jumps on board approval to spin off EV charging unit ** Anaptysbio Inc ANAB.O: up 7.5% BUZZ-Brokerages cheer royalty stream from amended GSK deal The 11 major S&P 500 sectors: Communication Services .SPLRCL up 0.41% Consumer Discretionary .SPLRCD up 0.58% Consumer Staples .SPLRCS up 0.31% Energy .SPNY down 1.07% Financial .SPSY down 0.91% Health .SPXHC down 0.05% Industrial .SPLRCI down 1.08% Information Technology .SPLRCT up 0.45% Materials .SPLRCM down 0.25% Real Estate .SPLRCR down 0.21% Utilities .SPLRCU up 0.31% (Compiled by Rithika Krishna) ((rithika.krishna@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stock Alert: DexCom Down 6% (RTTNews) - Shares of DexCom, Inc. (DXCM), a medical device company, are losing almost 6 percent or $24.77 in Tuesday's morning trade at $393.23. U.S. stocks are little changed on Tuesday following the sell-off seen in the previous sesion, which came amid concerns about a renewed spike in coronavirus cases. Investors remained cautious as they monitored corporate earnings results and merger news. Monday, DexCom said that Rick Doubleday, the company's executive vice president and chief commercial officer, will retire at the end of 2020 in order to spend more time with his family. Rick joined DexCom in 2009. DexCom also announced preliminary third-quarter revenues of $500.9 million, representing growth of 26 percent year over year. Analysts polled by Thomson Reuters have a consensus revenue estimate of $476.75 million. DexCom will provide a full presentation of its quarterly results on Tuesday, October 27. DexCom has traded in a range of $149.46 to $456.23 in the past 52 weeks. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""4 Smart Stocks That'll Make Robinhood Investors Rich When the curtain falls on 2020, it'll go down as one of the most volatile years on record. During the first quarter, we watched as uncertainty surrounding the coronavirus pandemic pushed the CBOE Volatility Index to its highest reading in history. We also saw a ferocious rally from the March 23 bear market low. Generally speaking, when volatility soars, young and/or novice investors take it as their cue to pile into the stock market. Image source: Getty Images. Online investing app Robinhood, which is known best for its commission-free trading, gifting of free shares of stock to new members, and fractional-share investing, has seen its membership skyrocket in 2020. That's because Robinhood is a popular destination of millennial and novice investors, with the average age of its members being only 31. On the bright side, young investors putting their money to work in the stock market should be commended. With time as their ally, they have the leverage to compound their initial investment many times over before and after retirement. But at the same time, Robinhood has done a poor job of prepping its users for success. Without the proper tools and education, many of its members are focused on penny stocks or downright awful companies, rather than putting their money to work over the long run in potentially game-changing businesses. If Robinhood investors want to get rich the right way, here are four smart stocks they can buy right now and hang on to for many years to come. Image source: Getty Images. Datadog One company that looks like a no-brainer buy for investors with a long horizon is cloud-based software-as-a-service provider Datadog (NASDAQ: DDOG). With COVID-19 completely disrupting the traditional office environment, anything and everything having to do with cloud-based data, including monitoring, has come into focus. Long after the pandemic has passed (whenever that may be), Datadog's application performance monitoring solutions, especially for consumer-facing businesses, will remain in high demand. Just how impressive has Datadog been? In the second quarter, the U.S. economy saw its biggest decline in gross domestic product in decades. Comparatively, Datadog delivered sales growth of 68% from the prior-year period, along with another quarter of adjusted profits. Perhaps most important, the company's growth was especially pronounced among bigger businesses. Datadog ended June with 1,015 subscribing customers with at least $100,000 in annual recurring revenue (ARR). That's up from 594 customers with an ARR over $100,000 in the prior-year period. Datadog's key to rapid margin growth is getting its existing clients to spend more, which is pretty clearly what we're seeing happen. Look for Datadog to double its sales a couple of times this decade. Image source: Getty Images. Innovative Industrial Properties Since the Robinhood platform bars its members from buying over-the-counter-listed stocks, one of the few smart names Robinhood investors can buy in the marijuana space is Innovative Industrial Properties (NYSE: IIPR). Innovative Industrial Properties is a real estate investment trust (REIT) that acquires and leases medical marijuana cultivation and processing sites in the United States. Through the beginning of October, IIP owned 63 properties in 16 states, and had more than 99% of its owned square footage leased for a weighted-average length of 16.2 years. Even though the company stopped reporting its average yield on invested assets in the first quarter, I suspect it'll take around six years for the company to recoup its invested assets, with everything afterward being gravy. Innovative Industrial Properties has particularly benefited due to its sale-leaseback program. With access to financial institutions limited for U.S. marijuana stocks, IIP steps in to purchase properties for cash. In return, it immediately leases these assets back to the seller for an extended period of time. The operator receives much-needed cash, while IIP lands a longtime tenant. With the U.S. being the No. 1 cannabis market in the world, the future remains bright for Innovative Industrial Properties. Image source: Getty Images. DexCom Buying great stocks is sometimes as easy as playing a numbers game. That's why medical device company DexCom (NASDAQ: DXCM) has the opportunity to make patient Robinhood investors rich. Specifically, DexCom is focused on developing and selling continuous glucose monitoring (CGM) systems for diabetics. Instead of patients regularly pricking their fingers to check their blood glucose levels, DexCom's CGMs provide pertinent data to the patient and/or physician via a wireless device. It can even be linked with certain insulin pumps to improve glycemic balance. When I said that buying great stocks is sometimes as easy as playing a numbers game, I meant standing behind a company whose patient pool consists of 34.2 million diabetics in the U.S., and another 88 million U.S. adults with pre-diabetes. The number of Americans with this chronic illness has continued to climb over the decades, providing a growing pool of patients for an indication with no cure. Furthermore, because the service DexCom provides is subscription-based, it reduces the likelihood of client churn and provides exceptionally high margins. DexCom isn't a fundamentally cheap stock, but its consistent double-digit growth rate makes it well worth the premium. Image source: Sea Limited. Sea Limited A final smart stock that has the potential to make Robinhood investors rich is Singapore-based Sea Limited (NYSE: SE). Sea has had a monstrous run-up this year, but looks to be just clearing its throat in terms of long-term growth potential. Made of up three operating segments, Sea's gaming arena is responsible for the bulk of its sales -- for now. Sea's mobile hit game Free Fire saw its number of paying customers more than double in July 2020 from July 2019, with over 100 million daily peak active users. All told, 10% of quarterly active users (for the entire digital entertainment segment) are now paying customers. But it's not gaming that has the investment community so excited. Sea Limited has the opportunity to become in Southeast Asia what MercadoLibre became in South America. Sea's Shopee e-commerce platform saw gross orders increase by 150% during the second quarter, with adjusted revenue nearly tripling. This is a region with a burgeoning middle class that, like the rest of the world, is seeking convenient consumption options during the pandemic. The online Shopee platform has been the prime beneficiary, and should continue to be so, well after the pandemic is over. The feather in Sea's cap is that it's also disrupting traditional finance with its SeaMoney solutions. More than 15 million people are already paying mobile wallet customers. Like Datadog, Sea should be capable of doubling its sales every three to four years. 10 stocks we like better than Sea Limited When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sea Limited wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Datadog, Innovative Industrial Properties, MercadoLibre, and Sea Limited. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-10-28,91.585,92.0,82.655,87.28,"[""Stock Alert: DexCom Slips 10% (RTTNews) - Shares of DexCom, Inc. (DXCM) are currently slipping over 10% despite the medical device company's third-quarter results beating Wall Street estimates. U.S. stocks are trading down on Wednesday morning as investors are worried about the economic impact of spike in coronavirus cases lately. DXCM is currently trading at $340.21, up $40.42 or 10.62%, on the Nasdaq. Tuesday, DexCom reported third-quarter profit of $72.2 million or $0.73 per share, up from $45.8 million or $0.50 per share last year. Adjusted earnings increased to $0.94 per share from $0.65 per share last year. Analysts polled by Thomson Reuters estimated earnings of $0.64 per share. Revenues for the quarter grew 26% to $500.9 million from $396.3 million last year. Analysts had a consensus estimate of $476.75 million. Looking forward, DexCom expects revenues of about $1.90 billion for the full year. Analysts currently estimate revenues of $1.87 billion. On Monday, DexCom said that Rick Doubleday, the company's executive vice president and chief commercial officer, will retire at the end of 2020. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Titan Pharma, Community Health Systems, MediaAlpha Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow hit their lowest levels since late-September on Wednesday as coronavirus cases surged globally and fears of a contested U.S. presidential election next week added to worries..N At 13:10 ET, the Dow Jones Industrial Average .DJI was down 3.16% at 26,595.47. The S&P 500 .SPX was down 2.88% at 3,292.97 and the Nasdaq Composite .IXIC was down 3.29% at 11,055.084. The top three S&P 500 .PG.INX percentage gainers: ** General Electric Co , up 9.2 % ** Automatic Data Processing Inc , up 6 % ** Trane Technologues PLC Ord , up 4.6 % The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 11.8 % ** C.H. Robinson Worldwide , down 10.1 % ** Akamai Technologies Inc , down 9 % The top three NYSE .PG.N percentage gainers: ** Tupperware Brands Corp , up 33.6 % ** MediaAlpha Inc , up 33.4 % ** Community Health Systems , up 32.8 % The top three NYSE .PL.N percentage losers: ** Callaway Golf , down 22.4 % ** Universal Insurance Holdings Inc , down 17.9 % ** Renren Inc , down 15.5 % The top three Nasdaq .PG.O percentage gainers: ** Astrotech Corp , up 28.4 % ** Scholar Rock Holding Corp , up 25.2 % ** Applied UV Inc , up 24 % The top three Nasdaq .PL.O percentage losers: ** Biodesix Inc , down 20.6 % ** Akerna Corp , down 20.5 % ** Chefs' Warehouse Inc , down 19.7 % ** EQT Corp EQT.N: down 2.3% BUZZ-EQT: Down on plans to buy Chevron's Appalachia assets for $735 mln ** Microsoft Corp MSFT.O: down 4.2% BUZZ-Microsoft shares gyrate after Q1 report ** Caesars Entertainment Inc CZR.O: down 4.1% BUZZ-Caesars Entertainment to sell Tropicana Evansville operations for $480 mln ** ExxonMobil Corp XOM.N: down 2.7% ** Chevron Corp CVX.N: down 3.4% ** TechnipFMC Plc FTI.N: down 5.4% ** Halliburton Co HAL.N: down 7.3% ** Diamondback Energy Inc FANG.O: down 4.6% ** Marathon Oil Corp MRO.N: down 5.2% ** Conocophillips COP.N: down 3.0% ** Apache Corp APA.O: down 5.1% ** Devon Energy Corp DVN.N: down 5.4% ** Callon Petroleum Co CPE.N: down 5.3% ** Occidental Petroleum Corp OXY.N: down 2.8% ** Phillips 66 PSX.N: down 3.8% BUZZ-U.S. energy shares dive: WTI crude sinks on COVID-19 case spike ** Fiverr International Ltd FVRR.N: up 6.5% BUZZ-Fiverr International: Jumps on third-quarter revenue beat ** Microsoft Corp MSFT.O: down 4.2% BUZZ-Street View: Microsoft likely on track for solid growth ahead ** Lyft Inc LYFT.O: down 3.6% BUZZ-Lyft: Cowen & Co cuts PT ahead of Q3 earnings ** General Electric Co GE.N: up 9.2% BUZZ-GE: Shares rise on smaller Q3 loss ** First Solar Inc FSLR.O: up 11.1% BUZZ-First Solar jumps after strong Q3, upbeat forecast; JP Morgan hikes PT ** Intel Corp INTC.O: down 2.2% BUZZ-Intel: Falls; brokerage lowers PT after AMD-Xilinx deal ** Goldman Sachs Group Inc GS.N: down 3.0% ** JPMorgan Chase & Co JPM.N: down 2.3% ** Morgan Stanley MS.N: down 1.7% ** Bank of America Corp BAC.N: down 2.0% ** Wells Fargo & Co WFC.N: down 2.3% ** Citigroup Inc C.N: down 1.6% ** U.S Bancorp USB.N: down 2.2% BUZZ-U.S. bank shares slide; Treasury yields dip on virus jitters ** Spirit Airlines Inc SAVE.N: down 5.1% ** Southwest Airlines Co LUV.N: down 4.2% ** Alaska Air Group Inc ALK.N: down 4.7% ** Delta Air Lines Inc DAL.N: down 4.5% ** American Airlines Group Inc AAL.O: down 2.2% ** Royal Caribbean Cruises Ltd RCL.N: down 4.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 7.6% ** Carnival Corp CCL.N: down 8.0% ** Hilton Worldwide Holdings Inc HLT.N: down 2.9% ** Hyatt Hotels Corp H.N: down 1.8% ** Mariott International Inc MAR.O: down 2.8% ** TripAdvisor Inc TRIP.O: down 3.4% ** Booking Holdings Inc BKNG.O: down 3.7% ** Expedia Group Inc EXPE.O: down 2.3% BUZZ-Travel stocks tumble on fears of more COVID-19 lockdowns ** Bunge Ltd BG.N: up 3.3% BUZZ-Bunge Ltd: Surges on Q3 revenue beat ** Tupperware Brands Corp TUP.N: up 33.6% BUZZ-Tupperware Brands: Gains as quarterly sales jump ** Bed Bath & Beyond Inc BBBY.O: down 11.5% Bed Bath & Beyond: Sinks as sales forecast fails to impress Street ** Advanced Micro Devices Inc AMD.O: down 2.7% BUZZ-Street View: AMD unlocks expanded market opportunity with Xilinx deal **Hess Corp HES.N: down 1.3% BUZZ-Hess: Falls on wider-than-expected Q3 loss, cuts FY production outlook ** Six Flags Entertainment Corp SIX.N: down 7.8% BUZZ-Six Flags Entertainment: Drops after revenue misses estimates ** ** MSCI Turkey ETF TUR.O: down 3.7% BUZZ-Turkey-focused ETF drops; lira hits record low as traders' bearishness grows ** Deutsche Bank AG DB.N: down 1.5% BUZZ-Deutsche Bank's U.S. shares rise on surprise Q3 net profit ** Omnicom Group Inc OMC.N: down 5.5% BUZZ-Omnicom: MoffettNathanson upgrades to \""neutral\"" on growth prospects for 2021 ** Mastercard Inc MA.N: down 7.1% BUZZ-Mastercard: Set to open at 3-mth low on Q3 profit slump ** Barrick Gold Corp GOLD.N: down 4.8% ** AngloGold Ashanti Ltd AU.N: down 5.9% ** Agnico Eagle Mines Ltd AEM.N: down 5.3% ** Gold Fields Ltd GFI.N: down 8.0% BUZZ-Gold miners slip as stronger dollar hits bullion prices ** Akerna Corp KERN.O: down 20.5% BUZZ-Akerna Corp: Falls on $12 mln discounted offering ** Dine Brands Global Inc DIN.N: up 2.5% BUZZ-Dine Brands: Rises as quarterly earnings beat estimates ** Summit Materials Inc SUM.N: down 13.2% BUZZ-Summit Materials: Drops as low cement sales hit Q3 results ** Chefs' Warehouse Inc CHEF.O: down 19.7% BUZZ-Chefs' Warehouse: Falls on bigger-than-expected Q3 loss ** Chewy Inc CHWY.N: up 5.1% BUZZ-Chewy Inc: Rises on launch of telehealth service for pets ** Tenable Holdings Inc TENB.O: down 3.2% BUZZ-Tenable Holdings: Rises as brokerages hike PTs after strong forecast ** Callaway Golf Co ELY.N: down 22.4% BUZZ-Callaway Golf: Hits 4-month low on deal to buy rest of Topgolf ** Hawaiian Holdings Inc HA.O: down 9.9% BUZZ-Hawaiian Holdings slides as pandemic hits Q3 results, outlook ** Biogen Inc BIIB.O: down 2.7% BUZZ-Biogen's aducanumab unlikely to get FDA green light: Baird ** Enterprise Products Partners LP EPD.N: down 1.4% BUZZ-Enterprise Products Partners: Falls on Q3 rev miss, drop in crude shipment volumes ** Marine Products Corp MPX.N: down 9.5% BUZZ-Marine Products set for worst day in over a month on weak sales ** Anthem Inc ANTM.N: down 3.5% BUZZ-Anthem down after warning of higher costs in Q4 ** Titan Pharmaceuticals Inc TTNP.O: up 58.3% BUZZ-Titan Pharma: Jumps on deal to buy drug to treat chronic itching ** MiRagen Therapeutics Inc MGEN.O: up 117.3% BUZZ-MiRagen Therapeutics: Surges on Viridian acquisition ** Root Inc ROOT.O: up 2.6% BUZZ-Root Inc: Falls nearly 4% in Nasdaq debut ** MediaAlpha Inc MAX.N: up 33.4% BUZZ-MediaAlpha Inc: Rises 21% in NYSE debut ** Enphase Energy Inc ENPH.O: up 4.1% BUZZ-Enphase Energy: Gains on multiple PT raises, Q3 results beat ** Biodesix Inc BDSX.O: down 20.6% BUZZ-Biodesix Inc: Slumps 24.5% in Nasdaq debut ** Community Health Systems Inc CYH.N: up 32.8% BUZZ-Community Health Systems jumps after strong results, CEO change The 11 major S&P 500 sectors: Communication Services .SPLRCL down 3.66% Consumer Discretionary .SPLRCD down 2.96% Consumer Staples .SPLRCS down 2.80% Energy .SPNY down 3.07% Financial .SPSY down 2.42% Health .SPXHC down 2.82% Industrial .SPLRCI down 2.47% Information Technology .SPLRCT down 3.82% Materials .SPLRCM down 2.61% Real Estate .SPLRCR down 2.30% Utilities .SPLRCU down 2.36% (Compiled by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Chefs' Warehouse, Chewy Inc, Polaris Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow hit their lowest levels since late-September on Wednesday as a surge in coronavirus cases in the United States and Europe dashed hopes of a quick global economic recovery. .N At 11:37 a.m. ET, the Dow Jones Industrial Average .DJI was down 2.89% at 26,670.59. The S&P 500 .SPX was down 2.87% at 3,293.46 and the Nasdaq Composite .IXIC was down 2.85% at 11,105.621. The top three S&P 500 .PG.INX percentage gainers: ** General Electric Co , up 8.2 % ** Automatic Data , up 6 % ** Trane Technologies PLC , up 4.3 % The top three S&P 500 .PL.INX percentage losers: ** Dexcom , down 10.2 % ** C.H. Robinson Worldwide , down 9 % ** Carnival Corp , down 8.9 % The top three NYSE .PG.N percentage gainers: ** Tupperware Brands , up 33.1 % ** Community Health Systems , up 28.2 % ** Proshars Trst Ii , up 16.2 % The top three NYSE .PL.N percentage losers: ** Callaway Golf , down 21.2 % ** Universal Holdings , down 15.3 % ** Renren Inc , down 15.3 % The top three Nasdaq .PG.O percentage gainers: ** Applied UV Inc , up 28 % ** Astrotech Corp , up 22.4 % ** Socket Mobile Inc , up 18.1 % The top Nasdaq .PL.O percentage losers: ** Big 5 Sporting , down 21.4 % ** Rekor System Inc , down 17 % ** EQT Corp EQT.N: up 1.7% BUZZ-EQT: Down on plans to buy Chevron's Appalachia assets for $735 mln ** Microsoft Corp MSFT.O: down 3.6% BUZZ-Microsoft shares gyrate after Q1 report ** FireEye Inc FEYE.O: down 2.3% BUZZ-FireEye: Rises on strong Q3 results, higher forecasts ** Caesars Entertainment Inc CZR.O: down 4.3% BUZZ-Caesars Entertainment to sell Tropicana Evansville operations for $480 mln ** ExxonMobil Corp XOM.N: down 3.2% ** Chevron Corp CVX.N: down 3.8% ** TechnipFMC Plc FTI.N: down 6.5% ** Halliburton Co HAL.N: down 7.6% ** Diamondback Energy Inc FANG.O: down 5.8% ** Marathon Oil Corp MRO.N: down 6.7% ** Conocophillips COP.N: down 4.4% ** Apache Corp APA.O: down 6.2% ** Devon Energy Corp DVN.N: down 6.9% ** Callon Petroleum Co CPE.N: down 6.8% ** Occidental Petroleum Corp OXY.N: down 4.1% ** Phillips 66 PSX.N: down 5.4% BUZZ-U.S. energy shares dive: WTI crude sinks on COVID-19 case spike ** Fiverr International Ltd FVRR.N: up 4.4% BUZZ-Fiverr International: Jumps on third-quarter revenue beat ** Merck & Co Inc MRK.N: down 1.8% BUZZ-Street View: Keytruda still represents growth pillar for Merck ** Microsoft Corp MSFT.O: down 3.6% BUZZ-Street View: Microsoft likely on track for solid growth ahead ** Lyft Inc < LYFT.O>: down 5.6% BUZZ-Lyft: Cowen & Co cuts PT ahead of Q3 earnings ** General Electric Co GE.N: up 8.2% BUZZ-GE: Shares rise on smaller Q3 loss ** First Solar Inc FSLR.O: up 11.9% BUZZ-First Solar jumps after strong Q3, upbeat forecast; JP Morgan hikes PT ** Intel Corp INTC.O: down 2.5% BUZZ-Intel: Falls; brokerage lowers PT after AMD-Xilinx deal ** Goldman Sachs Group Inc GS.N: down 2.5% ** JPMorgan Chase & Co JPM.N: down 2.7% ** Morgan Stanley MS.N: down 2.0% ** Bank of America Corp BAC.N: down 2.6% ** Wells Fargo & Co WFC.N: down 4.0% ** Citigroup Inc C.N: down 2.3% ** U.S Bancorp USB.N: down 2.8% BUZZ-U.S. bank shares slide; Treasury yields dip on virus jitters ** Spirit Airlines Inc SAVE.N: down 6.1% ** Southwest Airlines Co LUV.N: down 5.9% ** Alaska Air Group Inc ALK.N: down 6.1% ** Delta Air Lines Inc DAL.N: down 6.1% ** American Airlines Group Inc AAL.O: down 4.2% ** Royal Caribbean Cruises Ltd RCL.N: down 6.2% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 8.6% ** Carnival Corp CCL.N: down 8.9% ** Hilton Worldwide Holdings Inc HLT.N: down 3.6% ** Hyatt Hotels Corp H.N: down 3.6% ** Mariott International Inc MAR.O: down 4.2% ** TripAdvisor Inc TRIP.O: down 3.9% ** Booking Holdings Inc BKNG.O: down 3.1% ** Expedia Group Inc EXPE.O: down 4.0% BUZZ-Travel stocks tumble on fears of more COVID-19 lockdowns ** Bunge Ltd BG.N: up 4.9% BUZZ-Bunge Ltd: Surges on Q3 revenue beat ** Tupperware Brands Corp TUP.N: up 33.1% BUZZ-Tupperware Brands: Gains as quarterly sales jump ** Bed Bath & Beyond Inc BBBY.O: down 12.5% Bed Bath & Beyond: Sinks as sales forecast fails to impress Street ** Advanced Micro Devices Inc AMD.O: down 2.4% BUZZ-Street View: AMD unlocks expanded market opportunity with Xilinx deal **Hess Corp HES.N: down 3.3% BUZZ-Hess: Falls on wider-than-expected Q3 loss, cuts FY production outlook ** Six Flags Entertainment Corp SIX.N: down 8.8% BUZZ-Six Flags Entertainment: Drops after revenue misses estimates ** Ryder System Inc R.N: down 2.4% BUZZ-Ryder System: set for 9-mth high on surprise Q3 profit ** ** MSCI Turkey ETF TUR.O: down 3.0% BUZZ-Turkey-focused ETF drops; lira hits record low as traders' bearishness grows ** Deutsche Bank AG DB.N: down 0.3% BUZZ-Deutsche Bank's U.S. shares rise on surprise Q3 net profit ** Omnicom Group Inc OMC.N: down 4.5% BUZZ-Omnicom: MoffettNathanson upgrades to \""neutral\"" on growth prospects for 2021 ** Garmin Ltd GRMN.O: up 1.1% BUZZ-Garmin: Rises on Q3 results beat, strong annual revenue forecast ** Mastercard Inc MA.N: down 6.0% BUZZ-Mastercard: Set to open at 3-mth low on Q3 profit slump ** Barrick Gold Corp GOLD.N: down 4.4% ** AngloGold Ashanti Ltd AU.N: down 5.5% ** Agnico Eagle Mines Ltd AEM.N: down 5.3% ** Gold Fields Ltd GFI.N: down 7.0% BUZZ-Gold miners slip as stronger dollar hits bullion prices ** Akerna Corp KERN.O: down 16.4% BUZZ-Akerna Corp: Falls on $12 mln discounted offering ** Dine Brands Global Inc DIN.N: up 1.0% BUZZ-Dine Brands: Rises as quarterly earnings beat estimates ** Summit Materials Inc SUM.N: down 13.9% BUZZ-Summit Materials: Drops as low cement sales hit Q3 results ** 3M Co MMM.N: down 1.1% BUZZ-Street View: N95 boost temporary, but 3M yet to recover in other segments ** Chefs' Warehouse Inc CHEF.O: down 16.9% BUZZ-Chefs' Warehouse: Falls on bigger-than-expected Q3 loss ** Chewy Inc CHWY.N: up 5.4% BUZZ-Chewy Inc: Rises on launch of telehealth service for pets ** Polaris Inc PII.N: up 1.5% BUZZ-Polaris gains on strong Q3 earnings ** Tenable Holdings Inc TENB.O: down 3.1% BUZZ-Tenable Holdings: Rises as brokerages hike PTs after strong forecast ** Callaway Golf Co ELY.N: down 21.2% BUZZ-Callaway Golf: Hits 4-month low on deal to buy rest of Topgolf The 11 major S&P 500 sectors: Communication Services .SPLRCL down 3.03% Consumer Discretionary .SPLRCD down 2.58% Consumer Staples .SPLRCS down 2.24% Energy .SPNY down 3.87% Financial .SPSY down 2.68% Health .SPXHC down 2.58% Industrial .SPLRCI down 2.37% Information Technology .SPLRCT down 3.39% Materials .SPLRCM down 2.68% Real Estate .SPLRCR down 2.09% Utilities .SPLRCU down 1.81% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""How DexCom Trounced Wall Street Estimates in Q3 DexCom (NASDAQ: DXCM) rebounded quickly from the coronavirus-fueled market meltdown earlier this year. But while its shares are up more than 70% year to date, the stock has mostly been in a holding pattern in recent months. The diabetes care technology provider announced its third-quarter results after the market closed on Tuesday. Were those results enough to provide a nice bump for the stock? Here are the highlights from DexCom's Q3 update. Image source: Getty Images. By the numbers DexCom reported Q3 revenue of $500.9 million, a 26% increase from the $396.3 million reported in the same quarter of the previous year. This result easily topped analysts' average revenue estimate of $476.75 million. The company announced net income in the third quarter of $72.2 million, or $0.73 per share, based on generally accepted accounting principles (GAAP). This was a big jump from DexCom's GAAP earnings in the prior-year period of $45.8 million, or $0.50 per share. DexCom recorded adjusted net income in Q3 of $93.6 million, or $0.94 per share, compared to $60.4 million, or $0.65 per share, in the year-ago period. This handily beat the consensus Wall Street earnings estimate of $0.64 per share. Behind the numbers Earlier this month, Wells Fargo analyst Larry Biegelsen downgraded DexCom and slashed his one-year price target on the stock because he was concerned about increased competition for the company's G6 continuous glucose monitoring (CGM) system. Although the G6 certainly does have stiffer competition from Abbott Labs' FreeStyle Libre 2, DexCom's Q3 results showed that its CGM device continues to attract plenty of customers. DexCom reported strong volume growth for its G6 device driven by new patient additions. It's not all that surprising that the CGM market is big enough to support multiple winners. However, year-over-year sales growth is slowing for DexCom. That's true both in the U.S. and in international markets. On the other hand, hardware revenue growth appears to be accelerating. DexCom reported 20% year-over-year hardware revenue growth in Q3 compared to 9% growth in the prior-year period. Looking ahead DexCom again raised its full-year 2020 guidance. The company now anticipates revenue of $1.9 billion in full-year 2020, up from its previous outlook of $1.85 billion. The healthcare stock could enjoy a boost if a new partnership pays off with higher sales. After the end of the third quarter, DexCom and Eli Lilly announced a program for U.S. healthcare providers that teams DexCom's G6 devices with Lilly's new rapid-acting mealtime insulin Lyumjev. Investors should also keep their eyes on what DexCom does with its growing cash stockpile. The company reported cash and marketable securities totaling $2.6 billion at the end of the third quarter. DexCom noted that this strong cash position provides a lot of flexibility as it \""continues to expand production capacity and explore new market opportunities.\"" 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Akerna, Mastercard, gold miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street main indexes slumped on Wednesday as a surge in coronavirus cases in the United States and Europe dashed hopes of a quick global economic recovery..N At 10:14 a.m. ET, the Dow Jones Industrial Average .DJI was down 2.19% at 26,862.64. The S&P 500 .SPX was down 2.08% at 3,320.27 and the Nasdaq Composite .IXIC was down 2.48% at 11,148.411. The top three S&P 500 .PG.INX percentage gainers: ** General Elec Co , up 8.7 % ** Automatic Data , up 6.9 % ** Trane Tchnlg Ord , up 5.2 % The top three S&P 500 .PL.INX percentage losers: ** Dexcom , down 9.3 % ** Akamai Tech Inc , down 7.9 % ** Ch Robinson Ww , down 6.8 % The top three NYSE .PG.N percentage gainers: ** Cmnty Hlth Sys , up 30.8 % ** Tupperware Brnds , up 28.9 % ** Systemax Inc , up 17.3 % The top three NYSE .PL.N percentage losers: ** Callaway Golf , down 18 % ** Summit Materials , down 15.7 % ** Renren Inc Adr , down 15.1 % The top three Nasdaq .PG.O percentage gainers: ** Appld Uv Inc Ord , up 34.5 % ** Socket Moble Inc , up 24 % ** Scholar Rock Hld , up 18.5 % The top three Nasdaq .PL.O percentage losers: ** Akerna Corp , down 20.8 % ** Lrdstwn Mtrs Wnt , down 19.5 % ** Key Tronic Cp , down 16.2 % ** EQT Corp EQT.N: down 1.0% BUZZ-EQT: Down on plans to buy Chevron's Appalachia assets for $735 mln ** Microsoft Corp MSFT.O: down 3.5% BUZZ-Microsoft shares gyrate after Q1 report ** FireEye Inc FEYE.O: up 0.2% BUZZ-FireEye: Rises on strong Q3 results, higher forecasts ** Caesars Entertainment Inc CZR.O: down 2.0% BUZZ-Caesars Entertainment to sell Tropicana Evansville operations for $480 mln ** ExxonMobil Corp XOM.N: down 2.9% ** Chevron Corp CVX.N: down 3.5% ** TechnipFMC Plc FTI.N: down 5.1% ** Halliburton Co HAL.N: down 5.7% ** Diamondback Energy Inc FANG.O: down 6.7% ** Marathon Oil Corp MRO.N: down 5.7% ** Conocophillips COP.N: down 4.9% ** Apache Corp APA.O: down 5.9% ** Devon Energy Corp DVN.N: down 6.7% ** Callon Petroleum Co CPE.N: down 7.6% ** Occidental Petroleum Corp OXY.N: down 4.5% ** Phillips 66 PSX.N: down 3.5% BUZZ-U.S. energy stocks fall as WTI slides on stock build, rising COVID-19 cases ** Fiverr International Ltd FVRR.N: up 4.0% BUZZ-Fiverr International: Jumps on third-quarter revenue beat ** Merck & Co Inc MRK.N: down 1.3% BUZZ-Street View: Keytruda still represents growth pillar for Merck ** Microsoft Corp MSFT.O: down 3.5% BUZZ-Street View: Microsoft likely on track for solid growth ahead ** Lyft Inc < LYFT.O>: down 4.4% BUZZ-Lyft: Cowen & Co cuts PT ahead of Q3 earnings ** General Electric Co GE.N: up 8.7% BUZZ-GE: Shares rise on smaller Q3 loss ** First Solar Inc FSLR.O: up 15.5% BUZZ-First Solar jumps after strong Q3, upbeat forecast; JP Morgan hikes PT ** Intel Corp INTC.O: down 1.4% BUZZ-Intel: Falls; brokerage lowers PT after AMD-Xilinx deal ** Goldman Sachs Group Inc GS.N: down 2.3% ** JPMorgan Chase & Co JPM.N: down 1.9% ** Morgan Stanley MS.N: down 2.3% ** Bank of America Corp BAC.N: down 2.2% ** Wells Fargo & Co WFC.N: down 3.9% ** Citigroup Inc C.N: down 1.7% ** U.S Bancorp USB.N: down 1.9% BUZZ-U.S. bank shares slide; Treasury yields dip on virus jitters ** Spirit Airlines Inc SAVE.N: down 4.4% ** Southwest Airlines Co LUV.N: down 4.6% ** Alaska Air Group Inc ALK.N: down 4.7% ** Delta Air Lines Inc DAL.N: down 4.9% ** American Airlines Group Inc AAL.O: down 4.1% ** Royal Caribbean Cruises Ltd RCL.N: down 3.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 5.7% ** Carnival Corp CCL.N: down 6.1% ** Hilton Worldwide Holdings Inc HLT.N: down 2.6% ** Hyatt Hotels Corp H.N: down 3.6% ** Mariott International Inc MAR.O: down 3.1% ** TripAdvisor Inc TRIP.O: down 4.5% ** Booking Holdings Inc BKNG.O: down 2.3% ** Expedia Group Inc EXPE.O: down 3.5% BUZZ-Travel stocks tumble on fears of more COVID-19 lockdowns ** Bunge Ltd BG.N: up 7.7% BUZZ-Bunge Ltd: Surges on Q3 revenue beat ** Tupperware Brands Corp TUP.N: up 28.9% BUZZ-Tupperware Brands: Gains as quarterly sales jump ** Bed Bath & Beyond Inc BBBY.O: down 10.4% Bed Bath & Beyond: Sinks as sales forecast fails to impress Street ** Advanced Micro Devices Inc AMD.O: down 2.9% BUZZ-Street View: AMD unlocks expanded market opportunity with Xilinx deal **Hess Corp HES.N: down 4.4% BUZZ-Hess: Falls on wider-than-expected Q3 loss, cuts FY production outlook ** Six Flags Entertainment Corp SIX.N: down 10.2% BUZZ-Six Flags Entertainment: Drops after revenue misses estimates ** Ryder System Inc R.N: up 0.1% BUZZ-Ryder System: set for 9-mth high on surprise Q3 profit ** ** MSCI Turkey ETF TUR.O: down 3.1% BUZZ-Turkey-focused ETF drops; lira hits record low as traders' bearishness grows ** Deutsche Bank AG DB.N: down 0.1% BUZZ-Deutsche Bank's U.S. shares rise on surprise Q3 net profit ** Omnicom Group Inc OMC.N: down 3.4% BUZZ-Omnicom: MoffettNathanson upgrades to \""neutral\"" on growth prospects for 2021 ** Garmin Ltd GRMN.O: up 1.3% BUZZ-Garmin: Rises on Q3 results beat, strong annual revenue forecast ** Mastercard Inc MA.N: down 6.3% BUZZ-Mastercard: Set to open at 3-mth low on Q3 profit slump ** Barrick Gold Corp GOLD.N: down 3.6% ** AngloGold Ashanti Ltd AU.N: down 4.7% ** Agnico Eagle Mines Ltd AEM.N: down 4.5% ** Franco-Nevada Corp FNV.V: !RIC {FNV.V} is invalid ** Gold Fields Ltd GFI.N: down 6.2% BUZZ-Gold miners slip as stronger dollar hits bullion prices ** Akerna Corp KERN.O: down 20.8% BUZZ-Akerna Corp: Falls on $12 mln discounted offering ** Dine Brands Global Inc DIN.N: up 3.3% BUZZ-Dine Brands: Rises as quarterly earnings beat estimates ** Summit Materials Inc SUM.N: down 15.7% BUZZ-Summit Materials: Drops as low cement sales hit Q3 results ** 3M Co : down 0.2% BUZZ-Street View: N95 boost temporary, but 3M yet to recover in other segments The 11 major S&P 500 sectors: Communication Services .SPLRCL down 2.54% Consumer Discretionary .SPLRCD down 2.03% Consumer Staples .SPLRCS down 1.30% Energy .SPNY down 3.53% Financial .SPSY down 1.99% Health .SPXHC down 1.87% Industrial .SPLRCI down 1.50% Information Technology .SPLRCT down 2.94% Materials .SPLRCM down 2.24% Real Estate .SPLRCR down 1.32% Utilities .SPLRCU down 0.50% (Compiled by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here are Wednesday\u2019s biggest losers in the stock market as 97% of S&P 500 companies dropped Cruise lines took a beating as new coronavirus cases in the U.S. rose to a record Cruise lines took a beating as new coronavirus cases in the U.S. rose to a record.""]"
DXCM,2020-10-29,88.19,88.5975,83.0925,83.8225,
DXCM,2020-10-30,84.185,84.5,79.375,79.895,"These are the worst-performing stocks in October as Big Tech slumps The information technology sector fell over 5% for the month, the biggest drop for any industry The information technology sector fell over 5% for the month, the biggest drop for any industry."
DXCM,2020-11-02,82.135,82.135,76.4075,78.0,
DXCM,2020-11-03,78.7525,83.375,78.7525,82.9425,"Which Biotech Stocks Are a Buy on Earnings? InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s no denying that the biotechnology sector has prospered amid the coronavirus pandemic. Source: Shutterstock In fact, a basket of stocks that tracks the biotech, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), surged 9.3% this year and has more than tripled the performance of the S&P 500’s 2.2% over the same time period. Just take a look at the chart below. Many biotech and healthcare stocks are releasing their earnings reports this week, which includes more well-known pharmaceutical stocks like Pfizer (NYSE:PFE), Gilead Sciences (NASDAQ:GILD) and Moderna (NASDAQ:MRNA). So, let’s take a quick look at their earnings results. Pfizer is one of the world’s largest pharmaceutical companies and develops a variety of medicines and vaccines, including one for COVID-19. For its third quarter, PFE reported slightly better-than-expected adjusted earnings of $0.72 per share, which topped analysts’ expectations for adjusted earnings of $0.70 by 2.9%. This was still down 4% year-over-year from the $0.75 earned in the third quarter of 2019. Third-quarter revenue of $12.13 billion missed estimates calling for $12.3 billion. Folks might associate Gilead Sciences with its remdesivir drug, as it is an approved treatment for COVID-19 by the FDA. However, it also creates treatments for HIV and hepatitis, as well as moderate to severe rheumatoid arthritis (RA) and lymphoma, just to name a few. Moderna is also producing its own COVID-19 vaccine and is now very close to approval for widespread use. For the third quarter, MRNA reported a per share loss of $0.59, a wider-than-expected loss of $0.38. The company beat the expected revenue of $80.6 million, nearly doubling to $157.9 million. The company’s increase in revenue but steeply declining earnings per share is due to of the rise of research and development costs for the COVID-19 vaccine. Now, let’s see how they stack up in my Portfolio Grader: All three companies receive low marks for their Fundamental Grade, which isn’t surprising given the mixed third-quarter earnings reports. So, if you’re interested in high-growth biotech companies with superior fundamentals, you’ll want to consider looking elsewhere. My Growth Investor biotech stocks — DexCom, Inc. (NASDAQ:DXCM), IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Quidel Corporation (NASDAQ:QDEL) are a great place to start. They also reported their earnings results this week, and I’m pleased to say that they all knocked it out of the park. Let’s take a look … DexCom, Inc. (DXCM) DexCom, Inc. has been innovating the continuous glucose monitoring (CGM) industry since 1999. With DXCM’s technology, a diabetic does not need to prick their finger to test their blood glucose levels. Instead, they insert a small sensor under the skin. They will then be notified via a display device when their glucose levels are either too low or high. It is simple, user-friendly and pain-free. The CGM market is expanding rapidly and DXCM is seeing a strong demand for its products and services right now. This was evident in the company’s third quarter report. DXCM crushed analysts’ earnings and revenue estimates for the third quarter and, in turn, increased its full-year outlook. During the third quarter, revenue increased 26% year-over-year to $500.9 million, compared to $396.3 million in the same quarter a year ago. Third-quarter earnings soared 55% year-over-year to $93.6 million, or $0.94 per share, up from $60.4 million, or $0.65 per share, in the third quarter of 2019. The consensus estimate called for earnings of $0.64 per share on $476.75 million, so DexCom posted a 46.9% earnings surprise and a 5.1% revenue surprise. Looking ahead to full-year 2020, DexCom now expects revenue to grow 29% year-over-year to $1.9 billion. That’s up from previous forecasts for revenue of $1.85 billion. The stock fell over 20% this week on some profit-taking, which is perfectly normally following its strong run over the past year, so I’m not concerned. IDEXX Laboratories, Inc. (IDXX) IDXX is a leading provider of veterinary products and services. IDEXX Labs also offers equine health products, livestock and poultry diagnostics, dairy testing and water testing solutions. In fact, the company’s products offer reliable diagnosis and treatments for more than 50 diseases that are prevalent in cows, pigs, chickens and horses. And its diagnostic tests evaluate the quality and safety of water and milk. It also developed a COVID-19 diagnostic test for animals. Shares of IDEXX Laboratories, Inc. surged on Thursday to a new 52-week high of $453.20 after the company posted double-digit earnings and revenue growth for its third quarter. IDXX noted that strong recurring revenue from its Companion Animal Group Diagnostics business (23%) helped drive the company’s overall results during the quarter. Third-quarter revenue rose 19% year-over-year to $722 million, while earnings per share jumped 36% year-over-year to $1.69. The analyst community was expecting earnings of $1.43 per share on $672.53 million, so IDXX topped earnings estimates by 18.2% and revenue forecasts by 7.4%. Quidel Corporation (QDEL) Quidel Corporation develops diagnostic testing solutions that provide quick test results and, in turn, reduce healthcare costs and improve patient outcomes. So, it’s not too surprising that Quidel has developed a diagnostic test for COVID-19. With coronavirus cases on the rise, Quidel announced that will increase the production of its rapid antigen test. In fact, the company recently doubled its production of the Sofia rapid antigen test to about two million tests per week. The company unveiled blowout third-quarter earnings and revenue results on Thursday afternoon. Company management stated, “Our strong third-quarter results serve as a preamble for what will be a truly remarkable finish to 2020.” For the third quarter, Quidel achieved total revenue of $476.1 million, up 276% from the $126.5 million in the same quarter a year ago. Third-quarter earnings surged 725.7% year-over-year to $5.78 per share, compared to $0.70 per share in the third quarter of 2019. The analyst community was expecting earnings of $4.75 per share on revenue of $450.39 million, so Quidel beat earnings estimates by 21.7% and revenue forecasts by 5.7%. Now let’s see how my Growth Investor stocks stack up in Portfolio Grader: Not only do these Growth Investor biotech stocks rank better than PFE, GILD and MRNA overall, they have outperformed them, year-to-date, too. Moderna is neck-and-neck with Quidel Corporation, but as you can see in the chart above, DXCM, QDEL and IDXX all trounced PFE and GILD. This is what happens when you invest in the fundamentally superior stocks. And this is just biotechnology. My Growth Investor Buy Lists are chock full of stocks from other sectors with similar potential. I have 43 stocks on my Growth Investor High Growth Buy List that range from technology to insurance to retailers and much, much more. I just added three new stocks to my Growth Investor Buy Lists in yesterday’s Growth Investor November Monthly Issue — including another biotech company — so there are plenty of stocks to choose from! I also released my latest Top 5 Stocks list, reviewed some of my companies’ latest earnings results (there were a lot of them!) and previewed next week’s earnings reports. There was a lot to talk about, and you can catch up here. Note: The Editor hereby discloses that as of the date of this email, the Editor, directly or indirectly, owned the following securities that are the subject of the commentary, analysis, opinions, advice, or recommendations in, or which are otherwise mentioned in, the essay set forth below: Dexcom, Inc. (DXCM), IDEXX Laboratories, Inc. (IDXX), Quidel Corporation (QDEL), Pfizer Inc (PFE) Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the “Master Key” to profiting from the biggest tech revolution of this (or any) generation. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Daily Picks: Stocks to Buy Ahead of the Election The post Which Biotech Stocks Are a Buy on Earnings? appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-11-04,86.5025,87.59,83.825,86.125,
DXCM,2020-11-05,88.455,91.5612,87.4525,88.7775,
DXCM,2020-11-06,89.095,91.265,87.2756,90.33,
DXCM,2020-11-09,90.3325,91.51,85.775,85.96,
DXCM,2020-11-10,84.0525,85.315,81.715,84.8825,"Why DexCom Stock Crumbled in October What happened Shares of the diabetes management giant DexCom (NASDAQ: DXCM) lost 23% of their value over the course of October, according to data from S&P Global Market Intelligence. DexCom's stock dipped last month for two core reasons: Early in the month, Wells Fargo analyst Larry Biegelsen slashed his 12-month price target on the stock from $420 to $350. Biegelsen cited increased competition and pricing pressure in the continuous glucose monitoring (CGM) space following the approval of Abbott Labs' Freestyle Libre 3 CGM in Europe. Abbott's CGM system is reportedly priced at $1,066 per year, whereas DexCom's G6 device runs about $2,496 per year. That's a major price difference, perhaps justifying Biegelsen's rather pessimistic outlook. Second, most healthcare stocks pulled back from their recent highs last month due to the uncertainty surrounding the U.S. presidential election. DexCom's shares clearly couldn't escape this marketwide trend. Most of the stock's hefty decline, after all, occurred in the final days of October. Image source: Getty Images. So what DexCom's shares were at an all-time high of $456.23 per share earlier this year, thanks to the monstrous sales growth of its CGM products. However, the company's stock was valued at a sky-high price-to-sales ratio of 32. Now, DexCom's stock still isn't cheap following this healthy pullback. But the company's price-to-sales ratio is at least more reasonable at 21.5. In short, DexCom's stock was arguably due for a correction. Now what Is DexCom stock a worthwhile buy at these levels? This large-cap medical device company is a proven winner. Yes, the CGM space probably isn't going to support supercharged levels of growth for much longer. But DexCom's strong balance sheet should allow it to expand into other areas of diabetes care in the near future, and that's great news for long-term shareholders. All told, patient investors may indeed want to grab some shares of this elite healthcare giant soon. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-11-11,85.7125,88.12,85.125,86.875,
DXCM,2020-11-12,87.1175,89.82,83.505,84.175,"[""S&P 500 Movers: CCL, NOW In early trading on Thursday, shares of ServiceNow topped the list of the day's best performing components of the S&P 500 index, trading up 3.8%. Year to date, ServiceNow registers a 85.1% gain. And the worst performing S&P 500 component thus far on the day is Carnival, trading down 5.1%. Carnival is lower by about 69.7% looking at the year to date performance. Two other components making moves today are Wynn Resorts, trading down 4.9%, and DexCom, trading up 1.9% on the day. VIDEO: S&P 500 Movers: CCL, NOW The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 Top Healthcare Stocks to Buy in November Compared to other sectors of the market, stocks in the healthcare industry have performed remarkably well this year. Many healthcare stocks have mirrored or surpassed the gains of the S&P 500 amid the market's recovery following the March crash. Given the vital products and services that companies in the healthcare industry provide, from life-saving medications and medical devices to insurance and potential vaccines, it's not surprising that a number of stocks in this sector have remained recession and volatility-proof. If you're worried about another market crash and thinking about beefing up your portfolio in November, these are five stocks worthy of your consideration. Let's dive right in. Image source: Getty Images 1. Teladoc A leader in the ongoing telehealth revolution, Teladoc (NYSE: TDOC) has gained 116% year to date. Teladoc was breaking records well before the pandemic -- the company reported 32% year-over-year revenue growth in 2019 while growing visits on its platform by more than 50%. The company's merger with applied health signals leader Livongo Health, which was completed on Oct. 30, will be a game-changer. When Teladoc announced the merger in August, management reported that the combined companies would generate pro forma revenue of more than $1 billion in 2020 alone. Management had previously projected in the company's Q1 earnings report full-year revenue between $800 million and $825 million. Management also forecasted that the merger would produce pro forma adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) equivalent to a $120 million. In the third quarter, which ended on Sep. 30, the company reported 109% revenue growth year over year, along with a 206% increase in patient visits on its platform. The company's third-quarter gross margin totaled 63.3%. Management expects the company to report between $294 million and $304 million in revenue for the fourth quarter of 2020. Very few companies have been able to boast about double-digit growth amid the pandemic, much less triple-digit growth, but Teladoc has managed to accomplish the impossible this year. 2. Dexcom Shares of continuous glucose monitoring (CGM) device maker Dexcom (NASDAQ: DXCM) are up almost 60% from January. The nature of Dexcom's business and the high demand for its products have enabled it to thrive during the pandemic with double-digit revenue growth. The majority of diabetics who require CGM devices have been diagnosed with type 1 diabetes. The American Diabetes Association reported that as of 2018, roughly 1.6 million individuals were living with the disease. The healthcare stock has had an exceptional few quarters with consistent year-over-year revenue growth -- 44% in the first quarter, 34% in the second, and 26% in the third. During the third quarter ending on Sep. 30, the company's revenues in the U.S. alone burgeoned by a robust 29%. Dexcom also reported exceptional third-quarter gross profits equivalent to 68% of its total sales for the period. Management has said that it expects the company's full-year 2020 revenues to grow by 29% from 2019 and total roughly $1.9 billion. 3. Becton, Dickinson Like the previous two picks on this list, Becton, Dickinson (NYSE: BDX) serves a very specific niche of the healthcare field. The company develops and sells medical devices and reagents. During the final fiscal quarter of 2020, which closed on Sep. 30, Becton, Dickinson's revenues increased 4.4% year over year to $4.8 billion. However, the company reported $17.1 billion in revenue for the full fiscal year 2020, a 1% year-over-year decline from 2019. Sales of Becton, Dickinson's diagnostic COVID-19 tests, which include a 15-minute rapid detection test and two real-time reverse transcription polymerase chain reaction (rRT-PCR) tests, did help to offset this revenue decline to a certain extent. During the fourth quarter alone, sales of the company's COVID-19 tests totaled $440 million. Becton, Dickinson pays a modest dividend that currently yields about 1.3%. Despite mixed financial results in fiscal 2020, the company's strong portfolio of core products should help it to recover from these near-term headwinds. Given that the stock is down approximately 11% compared to its January trading price, now may be an excellent time to buy this stock at a discount. TDOC data by YCharts 4. UnitedHealth Group Shares of health insurance stock UnitedHealth Group (NYSE: UNH) have soared by more than 19% year to date. The stock is also a good choice for investors seeking dividend income -- it pays a nice yield of 1.4%. UnitedHealth Group impressed investors when it released its third-quarter earnings on Oct. 14 for the three-month period ending on Sep. 30. During Q3, the company boosted its revenues by 8% year over year, part of which was attributable to the 21% growth in revenues from its Optum division. Adjusted earnings per share (EPS) dropped 10% during the quarter, indicating a drop in the company's overall net earnings, although management noted that \""care patterns disrupted by the pandemic moved closer to normal levels.\"" The company anticipates reporting adjusted EPS in the range of $16.50 to $16.75 for the full-year 2020. The company had previously demonstrated the strength of its core businesses during the second quarter (ending on June 30), in which it reported revenues up by a whopping $1.5 billion. UnitedHealth Group was able to avoid extreme financial fallout from the COVID-19 pandemic due to \""deferred care in the risk-based businesses,\"" the positive effect of which carried over into the most recent quarter. Analysts also seem confident in UnitedHealth Group's future growth prospects, projecting that the company will increase its earnings by 13% per year over the next five years. 5. Vertex Pharmaceuticals A market leader in cystic fibrosis (CF) medications, Vertex Pharmaceuticals (NASDAQ: VRTX) has stayed the course this year despite broader market volatility. The company currently has four approved products -- Symdeko, Trikafta, Orkambi, and Kalydeco -- all of which treat CF. When the U.S. Food and Drug Administration (FDA) approved Trikafta last October, it was hailed as a \""new breakthrough therapy\"" and \""the first triple combination therapy available to treat patients with the most common CF mutation.\"" During the third quarter of 2020 ending Sep. 30, Trikafta alone brought in revenues of $960 million, while Symdeko, Orkambi, and Kalydeco amassed revenues of $156 million, $226 million, and $193 million respectively. Vertex's total third-quarter revenues came to $1.5 billion, representing a 62% year-over-year increase from its revenues in the third quarter of last year. The company grew its cash position to $6.2 billion in the third quarter, while raising its full-year product revenue guidance to the range of $6 billion to $6.2 billion. Vertex Pharmaceuticals has a promising product pipeline of therapies, including candidates for the treatment of CF and sickle cell disease. The company also recently entered into a new partnership with vaccine-maker Moderna (NASDAQ: MRNA) to develop gene-editing therapy delivery systems for CF. Given its place at the forefront of the CF market, Vertex Pharmaceuticals is well-positioned for future, continued growth. 10 stocks we like better than Teladoc Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool recommends Becton, Dickinson, DexCom, UnitedHealth Group, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-11-13,85.705,86.6475,83.6675,84.1,"S&P 500 Analyst Moves: DXCM The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #65 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. Looking at the stock price movement year to date, DexCom is showing a gain of 56.6%. VIDEO: S&P 500 Analyst Moves: DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-11-16,84.1,86.115,83.2375,85.0075,
DXCM,2020-11-17,84.2125,84.6625,83.31,83.5875,"[""VO, DXCM, LULU, DOCU: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $489.4 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 195,518,309 to 198,002,982). Among the largest underlying components of VO, in trading today DexCom Inc (Symbol: DXCM) is off about 1.1%, lululemon athletica inc (Symbol: LULU) is down about 0.7%, and DocuSign Inc (Symbol: DOCU) is higher by about 2.4%. For a complete list of holdings, visit the VO Holdings page \u00bb The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $110.05 per share, with $197.70 as the 52 week high point \u2014 that compares with a last trade of $195.11. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Better Buy: Abbott Laboratories vs. DexCom Medical device makers Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) are hoping small products can have a big effect for patients and investors alike; both companies have new, sleeker continuous glucose monitoring devices (CGMs) in the works. Diabetes is one of the most prevalent diseases in the world, with 700 million people expected to be living with it by 2045, according to the International Diabetes Federation. There are 34 million diabetics in the United States, with 1.5 million people newly diagnosed each year. Many diabetics are turning to CGMs -- which provide real-time monitoring, rather than requiring a finger prick -- to ensure their blood sugar is at a healthy level. Companies that sell CGMs can expect both growth and competition in the space; the compound annual growth rate is expected to be roughly 22% through 2027, according to one study. Image source: Getty Images. The case for DexCom DexCom stock is up more than 56% this year, but in the past three months, it has dropped by more than 19%. This is despite some very good third-quarter figures that included revenue of $500.9 million, a rise of 26% year over year; net income of $72.2 million, up 58.6%; and $138.4 million in net income so far this year. (Last year, the company made a profit for the first time, finishing with $101.1 million in net income.) There are several explanations for the stock's recent decline. For one, it's facing increased competitive pressure in the CGM space from Abbott, which recently launched its Freestyle Libre 3 device in Europe and will do so in the U.S. soon. DexCom's current GCM model, the G6, uses sensors that must be replaced every 10 days, with a cost that can run to $3,828 per year before insurance. Abbott's Freestyle Libre 2 and Libre 3 have sensors that are designed to be changed every 14 days, so the annual cost for the sensors is typically $2,398. However, DexCom said it expects to launch its G7 GCM device early next year; this one is also designed to be worn for two weeks, making its sensors less expensive. It will also be very small, about the size of a nickel (Abbott's Libre 3 is said to be the size of two stacked pennies). Another factor that may be weighing on DexCom stock is analyst concern about healthcare reform -- specifically, the worry that President-elect Joe Biden's administration will target the high costs of CGM devices. The most likely reason for the stock's fall, however, is that its earnings, as good as they have been, don't justify the stock's price. Its price-to-earnings (P/E) ratio is sky-high compared with industry competitors Abbott and Medtronic. However, that P/E of 140 is misleading by itself, because it doesn't take into account DexCom's anticipated growth. If you look at its forward price-to-earnings-to-growth ratio of 0.633, the company's share price is actually not out of line, although it's still higher than Abbott's. MDT PE Ratio data by YCharts The case for Abbott Laboratories Abbott's market cap is six times larger than DexCom's, and the former company is more diverse. It has four divisions: nutrition, diagnostics, established pharmaceuticals, and medical devices. CGMs are just part of the company's medical device sales. The company said its diabetes care offerings brought in $843 million in the third quarter, a little bit more than 9.4% of its $8.9 billion in overall sales. All that size will likely limit stratospheric growth, however. That $8.9 billion was a 9.6% better than the year before; Abbott's net earnings of $2.3 billion, meanwhile, were down 11.7% year over year. The company's most effective division in the quarter was diagnostics, which it said saw 38.2% growth year over year, primarily because of a boost from its COVID-19 diagnostic tests. During the quarter, Abbott launched FreeStyle Libre 2 in the United States and obtained Europe's CE Mark approval for the FreeStyle Libre 3. One big advantage in Abbott stock is it comes with one of the industry's most consistent dividends. A Dividend Aristocrat, the company has raised its dividend every year for the past 48 years. This year, it increased its quarterly payout to $0.36 per share; at current prices, that works out to a yield of about 1.3% and a sustainable payout ratio of 44.4% (trailing 12 months). Abbott's diversity and greater size give it an edge While it may not see the rapid growth that could yet come for DexCom, Abbott's other healthcare divisions divisions give it strength to weather financial storms. Also, comparing the two stocks, it's easy to make the case that its stock is better priced. On top of that, the company's dividend, though not overly generous, is consistent, safe, and gives investors another reason to hold onto the stock for the long run. However, DexCom is more of a growth stock, and if its new G7 launch is successful, its stock has a lot more short-term upside than Abbott's. Which one is better for you may depend on how risk-averse you are. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Jim Halley has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-11-18,83.8112,83.9563,81.8925,82.3025,"[""The Math Shows FXH Can Go To $112 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDEX Fund ETF (Symbol: FXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.96 per unit. With FXH trading at a recent price near $101.91 per unit, that means that analysts see 9.86% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FXH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Alnylam Pharmaceuticals Inc (Symbol: ALNY), and Jazz Pharmaceuticals plc (Symbol: JAZZ). Although DXCM has traded at a recent price of $334.35/share, the average analyst target is 33.53% higher at $446.47/share. Similarly, ALNY has 26.76% upside from the recent share price of $129.30 if the average analyst target price of $163.90/share is reached, and analysts on average are expecting JAZZ to reach a target price of $182.50/share, which is 24.76% above the recent price of $146.28. Below is a twelve month price history chart comparing the stock performance of DXCM, ALNY, and JAZZ: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET First Trust Health Care AlphaDEX Fund ETF FXH $101.91 $111.96 9.86% DexCom Inc DXCM $334.35 $446.47 33.53% Alnylam Pharmaceuticals Inc ALNY $129.30 $163.90 26.76% Jazz Pharmaceuticals plc JAZZ $146.28 $182.50 24.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""These 3 Medical Device Stocks Leave Biotech in the Dust Even though the biotech sector's coronavirus vaccine efforts have dominated the 2020 news cycle, those stocks don't always beat the market. When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run. In particular, DexCom (NASDAQ: DXCM), Medtronic (NYSE: MDT), and Abiomed (NASDAQ: ABMD) have beaten the NASDAQ Biotechnology Index handily over the last five years. And, while they may not have had triple or quadruple-digit gains this year like a few of the coronavirus vaccine stocks out there, they still have plenty of room to grow. Furthermore, there are upcoming catalysts for growth that are worth keeping a close eye on. MDT data by YCharts DexCom's glucose monitor revenue exceeds expectations If you had to check your blood glucose level a few times per day, you'd probably grow tired of pricking your finger to draw a drop of blood. Using DexCom's continuous glucose monitors (CGMs) means that patients living with diabetes only need to check their smartphone application to check their blood glucose levels. Once people start using the system, they have to purchase replacement sensors for every 10-day period, meaning that DexCom's revenue has a significant recurring component. Strong sales of the latest monitor, the G6, have driven yearly total revenue to grow at least 34% year over year since the start of 2018. In fact, growth has been so strong that it exceeded management's revenue and profitability estimates. As of its most recent earnings report, the company expects to earn around $50 million more than it predicted for this year. Plus, its healthy gross margin and operating margin will be slightly larger too. DexCom isn't content to rest on its laurels, however -- the next CGM device is already in development. Given that only around 20% of the people with type 2 diabetes in the U.S. have a continuous monitoring device, it's clear that revenue will grow for years to come as DexCom expands its reach into its massive target market. Innovation at a breakneck pace is normal for Medtronic Competing in many different medical markets is second nature for Medtronic, so it's no surprise that it is now planning to manufacture medical robotics and digital surgery systems. With its recently announced Touch Surgery platform, clinicians can transform video taken during surgeries into interactive computer generated images. Then, these images can be used to train new surgeons, analyze results, and provide other critical information. This new product line will dovetail perfectly with Medtronic's minimally invasive therapies (MIT) segment, which earned the company $1.8 billion (of $6.5 billion total sales) in the most recent quarter alone. It'll also drive fresh revenue growth in a market that is becoming increasingly crowded. In the future, the MIT segment may even offer products in every element of the surgery value chain. Until then, expect it to retain the top spot in the markets for defibrillators, surgical staplers, and pacemakers. Image source: Getty Images Abiomed is becoming a market leader in cardiac support Abiomed is the smallest of the companies I'll discuss today, but it still massively outperformed the biotech sector over the last five years. The company's main product is its line of Impella heart pumps, which keep a patient's blood circulating during heart surgery. These pumps were the largest contributor to its $841 million in revenue during its 2020 fiscal year. Impella sales are expanding rapidly, with a sequential increase of 29% compared to last quarter, contributing to year-over-year quarterly earnings growth of 376%. Abiomed has continually reinvested in the Impella since it became the first U.S. Food and Drug Administration (FDA)-approved cardiac pump for high-risk heart surgeries in 2015. Now, the pumps are used in several new surgical niches in addition to what they were initially approved for. While it expects to eventually face competition from larger players like Abbott Laboratories (NYSE: ABT), Abiomed is the dominant actor in the market for the time being. When the real competition starts, Abiomed will still have a major advantage that others won't: specialization. Few companies will be willing to spend upwards of $98 million per year in research and development (R&D) efforts on cardiac pumps alone. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-11-19,81.725,83.6,81.0675,82.66,"Could DexCom Be a Millionaire-Maker Stock? Between its life-changing continuous glucose monitors, consistent growth, and sound fundamentals, DexCom (NASDAQ: DXCM) has many of the hallmarks of a good investment. And, with its manufacturing capacity ramping up while further research and development efforts push forward to make even more sophisticated products, the future appears quite bright. But will these beneficial tailwinds be enough to make new investors into millionaires in the next few years? It's unlikely because the stock won't be experiencing triple-digit growth anytime soon. Nonetheless, it could still be a worthwhile investment, so let's explore why this company is worthy of your attention. Image source: Getty Images. DexCom's product is a great fit for its market DexCom's wearable continuous glucose monitoring (CGM) products help people with diabetes to manage their conditions without the pain of repeatedly pricking their fingers to take glucose measurements from droplets of blood. Wearable sensors pierce the patient's skin only once, after which they can wear it for up to 10 days. The sensor then uploads data to a smartphone application, which helps patients to calibrate their intake of glucose-stabilizing medicines as well as food. For patients with an obsession for data, there's also a suite of charting tools that can be applied to historical blood glucose readings. The target market for the sensors is patients on intensive insulin therapy (IIT). These patients are the most likely to require an extensive number of finger sticks to measure their blood glucose level in a given day, so they stand to benefit the most. Of the 3.3 million patients who need IIT in the U.S., 40% of those with type 1 diabetes and 20% of those with type 2 diabetes currently use a continuous glucose monitor. This means that DexCom's target market has plenty of room to grow, which is good news. Outside of the U.S., the potential for growth is even larger. In the future, management plans to penetrate the non-intensive market, which it estimates to be around 27 million people in the U.S. There are a few important financial metrics that are trending in favor of significant long-term growth. The first of these is the profit margin, which is at a healthy 12.69%. This indicates that DexCom can sustainably serve its existing customer base despite making technologically sophisticated products and spending a significant amount on research and development. Similarly, the company's year-over-year quarterly revenue growth is strong at 26.4%, as is its quarterly earnings growth at 57.6%. While revenue growth has slowed somewhat this year, total revenues topped $500 million in the third quarter, which is a new record for the company. Finally, DexCom has $1.82 billion in debt, which isn't too overwhelming when compared to its cash holdings of $2.6 billion and its trailing free cash flow of $62.46 million. As long as its debts don't balloon, they won't negatively affect investments in growth. Why you won't make millions with this stock Despite its positive qualities, I don't think that the stock is about to make anyone into a millionaire. First, it probably can't continue to expand its revenue as rapidly as it has in the past, now that large and powerful competitors like Abbott Laboratories (NYSE: ABT) are staking their claims in the CGM market. Abbott's lineup of CGM products is larger, and it may be able to lock consumers into its product ecosystem. More importantly, DexCom's valuation appears to be quite inflated. The median price-to-earnings ratio of companies in the medical diagnostics and research industry is 36.05, whereas DexCom's is 137.87. This means that each share is expensive compared to the earnings that it commands, which will likely dissuade many investors from purchasing the stock, preventing its price from rising consistently. There's no law that says that the stock won't grow because its ratio is too high, but you'll probably need to wait until the price drops to a less inflated level before the company's future growth has a chance of making you into a millionaire. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-11-20,82.7875,83.0697,78.885,78.9675,
DXCM,2020-11-23,79.7475,81.25,78.6565,80.2725,
DXCM,2020-11-24,80.7491,80.7491,78.13,78.33,
DXCM,2020-11-25,78.77,80.035,77.7527,78.1375,
DXCM,2020-11-27,79.4075,79.915,78.0025,79.5525,
DXCM,2020-11-30,79.3925,80.4825,78.3451,79.92,
DXCM,2020-12-01,80.3375,82.2775,79.7925,81.93,"Medtronic or Dexcom: Which Medical Device Stock Is Poised To Deliver Higher Gains? 2020 has been quite a roller coaster ride for the stock markets. The recent positive developments regarding two COVID-19 vaccine candidates has been a drag on the work-from-home stocks but bodes well for many sectors that were crushed due to lower demand amid shelter-at-home mandates. Several medical device makers will likely gain from the success of COVID-19 vaccines as these companies have been seeing weak demand, as the world’s attention shifted from elective and other medical procedures to the unprecedented health crisis. Amid rising hopes of a recovery, we will use the TipRanks Stock Comparison tool to stack up Medtronic against Dexcom and see which medical devices company offers a better investment opportunity. Medtronic (MDT) Leading medical device maker Medtronic boasts the Street’s support as several analysts are optimistic about its long-term growth prospects despite the pandemic weighing down sales in recent quarters. The company has an impressive product pipeline and has won over 180 regulatory approvals in the US, Europe, Japan and China this year. These approvals include devices to treat cardiac complications, chronic pain, urinary incontinence, brain-related disorders and diabetes. Medtronic is supplementing its organic growth with tuck-in acquisitions to strengthen its position in several areas like robotics. Its recent acquisitions include Ai Biomed to expand the ENT portfolio, Medicrea International and Digital Surgery to bolster the robotics portfolio and Avenu Medical to enhance its endovascular solutions. (See MDT stock analysis on TipRanks) The company is also addressing its weakness in lucrative areas like diabetes. Its recently launched MiniMed 780G insulin pump is receiving a favorable response in Europe. Medtronic also commenced the limited release of the 770G insulin pump in the US in November. In September, the company acquired Companion Medical, the maker of InPen—a smart insulin pen system paired with an integrated diabetes management app. Meanwhile, last week, Medtronic reported its 2Q FY21 (ended Oct. 30) results and stated that it was seeing “a faster-than-expected recovery and approaching year-over-year growth.” The company fared better-than-expected but 2Q organic revenue was still down 1.5% and adjusted EPS fell 22%. Following the 2Q conference call, BTIG analyst Ryan Zimmerman increased the price target on Medtronic to $124 from $119 and reiterated a Buy rating. Zimmerman noted, “Near-term commentary on procedural trends was encouraging with weekly sales in November improving over October as mgmt. signaled that pre-earnings FY3Q21 Consensus estimates for MDT's top-line were below guidance (-1% vs. flat to up slightly in FY3Q21).” “Further, with mgmt. seeing no change to its expectations for FY4Q21, which assumes a normalization to sales, investors are likely assured that MDT should continue on its trajectory for the entire 2H of FY21. It seems that most investor focus though is looking past FY2H21 and onto FY22. As procedural dynamics stabilize and forthcoming pipeline products take hold, we believe the investments made in FY21 (which limited adj. OMs [operating margins]) should provide increased leverage through the P&L allowing adj. OM's to get back to pre-COVID levels (~29%),” added the analyst. Overall, a Strong Buy analyst consensus on Medtronic is backed by 17 Buys versus 3 Holds and 1 Sell. Shares are currently trading at the start of the year levels. The average price target of $125.90 reflects an upside potential of 10.7% in the months ahead. Dexcom (DXCM) Dexcom produces continuous glucose monitoring (or CGM) systems, which help diabetes patients track their blood glucose levels continually, unlike the traditional monitoring devices that reflect blood glucose levels at a particular point in time. While other medical device companies suffered over recent quarters due to COVID-led slowdowns, Dexcom delivered better-than-anticipated results thanks to higher sales of disposable sensors for its CGM systems. Despite strong volumes and new patient additions, Dexcom investors are concerned about pricing headwinds and rising competition. In October, shares took a hit when Wells Fargo analyst Larry Biegelsen downgraded the stock to Sell from Hold and slashed the price target to $350 from $420. Biegelsen feels that the recent approval of Abbott's Libre 3 in Europe will put downward pressure on Dexcom's pricing at a faster rate than anticipated by the Street as Libre 3 further closes the gap between the two companies' CGM technology. The analyst points out that Dexcom's G6 CGM is currently priced at a 134% premium to Abbott’s Libre. He believes that with the growing adoption of the CGM category, customers around the world will become increasingly price-sensitive, thus putting pressure on Dexcom. (See DXCM stock analysis on TipRanks) Meanwhile, Dexcom is positive about the demand for its products and recently raised its forecast to reflect full-year revenue growth of 29%. It is also gearing up to launch the G7 device (currently in clinical trials) in several key markets during the second half of 2021. Dexcom sees tremendous international growth opportunities as diabetes is rising at an alarming rate. It has ramped up its manufacturing capacity to extend the G6 CGM offering to additional international markets, including recent launches in Belgium and Turkey. Currently, the Street’s cautiously optimistic Moderate Buy analyst consensus for Dexcom is based on 8 Buys, 3 Holds and 1 Sell. Shares have gained 46.1% year-to-date and the average price target of $449.60 suggests further upside potential of 40.6% from current levels. Conclusion Medtronic is surely an attractive long-term play with a diverse product portfolio that focuses on 70 health conditions. Also, it pays a quarterly dividend of $0.57 and has a dividend yield of 2.05%. That said, Dexcom’s strong prospects in the diabetes market and the stock’s significant upside potential compared to Medtronic make it a more favorable pick currently, though its high valuation could be a deterrent for some investors. To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-12-02,81.67,83.4645,80.655,83.3,
DXCM,2020-12-03,83.35,87.2675,82.8147,86.1575,
DXCM,2020-12-04,85.8425,87.49,84.54,87.0075,
DXCM,2020-12-07,87.685,88.4568,83.9838,84.35,
DXCM,2020-12-08,84.6125,87.07,83.3325,87.04,
DXCM,2020-12-09,86.9525,87.375,82.4,83.3475,"[""Wednesday Sector Laggards: Technology & Communications, Healthcare In afternoon trading on Wednesday, Technology & Communications stocks are the worst performing sector, showing a 1.4% loss. Within that group, Qorvo Inc (Symbol: QRVO) and Fortinet Inc (Symbol: FTNT) are two large stocks that are lagging, showing a loss of 5.7% and 5.0%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 1.8% on the day, and up 36.88% year-to-date. Qorvo Inc, meanwhile, is up 37.97% year-to-date, and Fortinet Inc is up 17.22% year-to-date. Combined, QRVO and FTNT make up approximately 0.3% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 0.8% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Bio-Rad Laboratories Inc (Symbol: BIO) are the most notable, showing a loss of 4.4% and 3.8%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.6% in midday trading, and up 11.16% on a year-to-date basis. DexCom Inc, meanwhile, is up 52.19% year-to-date, and Bio-Rad Laboratories Inc is up 45.46% year-to-date. Combined, DXCM and BIO make up approximately 0.7% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, none of the sectors are up on the day, while nine sectors are down. SECTOR % CHANGE Consumer Products -0.3% Services -0.4% Utilities -0.4% Energy -0.4% Financial -0.5% Industrial -0.5% Healthcare -0.8% Materials -0.8% Technology & Communications -1.4% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""One of My Stocks Just Sold Off Big on No News. Now What? Over two market days last month, online marketplace operator Fiverr (NYSE: FVRR) lost more than 27% of its value. There was no company-specific news to explain the decline. This left some investors wondering what to make of it all. On this episode of Fool Live that aired on Nov. 10, \""The Wrap\"" host Jason Hall and Fool.com contributors Danny Vena and Brian Feroldi provide a potential explanation for the sharp sell-off and share timeless advice to help investors avoid making a common -- and costly -- investing mistake. Find out why Fiverr International is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. Fiverr International is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of November 20, 2020 Jason Hall: Randy is asking us about Fiverr ticker FVRR. Danny Vena, can you talk to us about Fiverr? Danny Vena: I'm going to pull up a chart here because I think it explains far better than I could what's going on with Fiverr. I did not see any company specific news, but what I'm seeing is here's a company who before this rotation out of tech began in earnest was up 700%, so far in 2020. It's dropped down a little bit. Now, it's up nearly 500%. Danny Vena: No company-specific news, you just need to know that this is a company that is going to be extremely volatile. I don't remember off the top of my head, it has a small $5 billion market cap. When you're talking about a company that size, that has grown that fast in that short of a period of time, and also when you're talking about the fact that the entire stock market has just been discounting tech stocks and fast growers. There's nothing specific going on with Fiverr. It's just part of \""taking the tech stocks out behind the woodshed\"" phenomenon that's going on right now. Jason Hall: Sometimes it happens. Great stocks do incredibly well and then a bunch of people look at their portfolio and are like, \""Wow. I've got to take money off the table,\"" and they take money off the table even though in my opinion, a totally nonsensical way to view your portfolio because you're not at the blackjack table. It's your money, it's your company that you own a part of, but that's part of how people think about it. Danny Vena: Jason, I made similar mistakes when I was a young investor. I thought Netflix (NASDAQ: NFLX) had doubled and I sold off part of my Netflix shares. To date, the hundred and some dollars that I made in gains would be worth $38,000. It's just a mistake that young investors make and I would say, don't feel obliged to follow suit. Jason Hall: I've made similar mistakes as an old investor, but it happens. Brian Feroldi: I sold Dexcom (NASDAQ: DXCM) for seven bucks. Jason Hall: It's still a little better than. Was it a couple of hundred bucks per share now, something like that? Brian Feroldi: It's like 350. Jason Hall: Yeah, it happens. Brian Feroldi owns shares of Fiverr International and Netflix. Danny Vena owns shares of Fiverr International and Netflix. Jason Hall has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fiverr International and Netflix. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Has a Lot to Prove in 2021 As the adage goes, two things in life are inevitable: death and taxes. Experienced growth investors might want to add a third inescapable truth to that list: Companies with a high-margin, fast-growing market to themselves will eventually see their space invaded by competition. This is the situation with DexCom (NASDAQ: DXCM). The company was the first mover into the market for continuous glucose monitors (CGMs). These wearable devices allow people with diabetes to watch glucose levels without sticking their fingers to get blood samples. With such obvious advantages over existing methods for controlling insulin dosage and a growing incidence of diabetes, it's no wonder DexCom has delivered rapid growth, increasing revenue by 43% in 2019. Competition isn't new for DexCom. However , investors are concerned about the success Abbott Laboratories (NYSE: ABT) is having with its second-generation CGM, FreeStyle Libre 2, which was approved in Europe in October 2018 and launched in the U.S. last quarter. Abbott is also in the process of launching a FreeStyle Libre 3 in Europe now. The U.S. could see that product within the next year or two. Is it time for investors to bail on DexCom? Image source: DexCom. Will DexCom maintain a technological advantage with its hardware? DexCom introduced its first product in 2006. With that first-mover position has come a technological advantage that put Abbott and other competitors in catch-up mode. The latest model, the G6, came out in 2018. It was accurate enough to be the first CGM approved by the U.S. Food and Drug Administration (FDA) for use in an integrated system with other devices, such as insulin pumps. The disposable sensor is good for 10 days. The transmitter beams send readings every five minutes to mobile devices such as tablets, smartphones, or smartwatches, and can trigger predictive alerts to avoid low blood sugar events. Those features make the G6 the premium model CGM, but Abbott's FreeStyle Libre 2 is a step toward closing the gap. The FreeStyle Libre 2 sends readings every minute to a reader device, has real-time alerts, and a sensor that lasts 14 days. While the device still isn't approved for use in automated insulin dosing systems and the smartphone app hasn't yet been approved by the FDA, the company claims the Libre 2's accuracy is superior to the competition. DexCom has said all along that the technology gap will narrow over time. It has an answer in the works. The G7 is in clinical trials and the company expects it to launch in the second half of 2021. DexCom disappointed observers in the last conference call by saying that it will launch G7 with a 10-day sensor life instead of the 15 days analysts had expected. The company said it will work on increasing the sensor's life after the launch. Other details of the G7's features are still under wraps, so investors will be very interested to see how the product stacks up against the competition. Will DexCom be able to maintain premium pricing? DexCom's customers have been willing to pay up for the advantages of its products. One effect of increasing competition, however, has been pressure on the selling price. The company is pushing to increase sales through pharmacies -- a channel already utilized by Abbott and one that requires lower prices than the distributor channel. DexCom estimates that pricing will be a $175 million headwind to total revenue in 2020, which it's expecting will come to about $1.9 billion. Again, DexCom has anticipated the pricing shift and has done an excellent job so far of bringing down the manufacturing costs of the G6 while maintaining its position as the premium product. Gross margin actually expanded in the latest quarter to 68%, compared with 62.3% in the period a year earlier. The company also raised its full-year guidance for gross margin by a full point to 66%. DexCom says that the coming G7 was designed with low cost in mind, and that the model will give it some flexibility to further lower price while keeping profits up. Abbott only started selling FreeStyle Libre 2 in the U.S. midway through the last quarter. DexCom is still expecting a strong top line in Q4, but the full impact of the competitive pressure hasn't hit yet. Investors will be watching for the warning signs of volume deceleration or margin compression in the next few quarters. How valuable are DexCom's integrations, software, and data? DexCom maintains that it'll continue to have the best CGM hardware on the market as it innovates. It also says that the user experience delivered by its software platform will be the big differentiator in the future. The company has amassed a huge amount of data from connected devices in its cloud-based reporting system that it can use to create personalized diabetes treatment plans by analyzing trends. The company has the lead in collaborations and integrations with other devices for automated insulin delivery. What are these non-hardware assets worth? No one really knows at this point, but they're partly why DexCom stock gets a premium valuation, and could partly account for why the company has maintained its growth in the face of competition. The threat is real, however. Abbott will pursue the same opportunities. Investors shouldn't assume that the company's size gives it an advantage, though. Abbott is diversified across various businesses, including pharmaceuticals and nutrition, that are competing for investment dollars. Its diabetes business contributes only about 10% of sales. DexCom is focused entirely on the space, has a first-mover advantage in CGMs, and is willing to invest 17% of revenue on research and development, compared with only 7% for the healthcare giant. Is the market big enough for two or more big players? This question is the only one on this list with a clear answer: yes. The incidence of diabetes is growing worldwide, and CGMs are still in their early days. Most monitors are sold to patients with Type 1 diabetes on intensive insulin therapy. Type 2 diabetes is much more prevalent and drives much of the growth in healthcare expenditures. Selling CGMs to new populations of potential users, including those in underserved markets outside the U.S., represents huge opportunity for all the players. Abbott is already selling more CGMs than DexCom is, but that's hardly made a dent in G6 sales. FreeStyle Libre sales in 2019 were $1.8 billion, overshadowing DexCom's total 2019 revenue of $1.5 billion. DexCom's top line has grown 34% in the first nine months of 2020, despite the decline in selling price for the G6. The company said on the latest conference call that unit growth in the most recent quarter was nearly 40%. Is DexCom stock a buy? There are enough questions about the impact of growing competition for DexCom that investors were probably justified in driving the share price down 26% from their all-time high earlier this year. The stock isn't cheap at 14 times analyst estimates of 2021 sales. That valuation for this quality growth stock could easily continue, though, unless the answers to these questions start turning negative. I own shares of both companies with no plans to sell. I think DexCom will continue to grow at a rapid pace, but I'll probably hold off on buying new shares until the competitive picture becomes clearer, which could happen in the next few quarters. Aggressive investors may see a buying opportunity in DexCom here, but more conservative ones might want to consider adding some shares of Abbott instead. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Jim Crumly owns shares of Abbott Laboratories and DexCom. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2020-12-10,83.0,87.3574,82.5225,86.7975,"Thursday Sector Leaders: Energy, Healthcare Looking at the sectors faring best as of midday Thursday, shares of Energy companies are outperforming other sectors, higher by 2.7%. Within that group, Occidental Petroleum Corp (Symbol: OXY) and Apache Corp (Symbol: APA) are two large stocks leading the way, showing a gain of 8.1% and 7.6%, respectively. Among energy ETFs, one ETF following the sector is the Energy Select Sector SPDR ETF (Symbol: XLE), which is up 2.2% on the day, and down 28.65% year-to-date. Occidental Petroleum Corp, meanwhile, is down 47.15% year-to-date, and Apache Corp, is down 35.60% year-to-date. Combined, OXY and APA make up approximately 3.2% of the underlying holdings of XLE. The next best performing sector is the Healthcare sector, up 0.3%. Among large Healthcare stocks, Hologic Inc (Symbol: HOLX) and DexCom Inc (Symbol: DXCM) are the most notable, showing a gain of 5.4% and 4.5%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.2% in midday trading, and up 11.27% on a year-to-date basis. Hologic Inc, meanwhile, is up 45.03% year-to-date, and DexCom Inc is up 59.32% year-to-date. Combined, HOLX and DXCM make up approximately 1.2% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Thursday. As you can see, two sectors are up on the day, while six sectors are down. SECTOR % CHANGE Energy +2.7% Healthcare +0.3% Technology & Communications 0.0% Services -0.2% Financial -0.6% Consumer Products -0.8% Utilities -0.9% Materials -0.9% Industrial -1.0% 25 Dividend Giants Widely Held By ETFs » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-12-11,85.6125,87.875,85.4338,86.9275,
DXCM,2020-12-14,87.2875,89.735,87.0088,88.3975,
DXCM,2020-12-15,89.1625,89.345,86.25,88.5525,
DXCM,2020-12-16,88.05,89.205,87.22,88.0875,
DXCM,2020-12-17,88.8425,89.8875,88.135,89.4775,"Up 60% In 2020, Here's Why DexCom Is Just Getting Started More than 34 million Americans have diabetes and an additional 88 million are at risk of developing the disease, according to the American Diabetes Association. In this world of data, automation, and availability of information, it's hard to wrap your mind around the idea that roughly 10% of the U.S. population has diabetes and an additional 25% are at risk. Diabetes is a chronic problem worldwide and there are many companies seeking to help diabetes patients. DexCom (NASDAQ: DXCM), a San Diego-based medical technology company is one that has been disrupting the industry. DexCom's continuous glucose monitoring (CGM) system allows diabetes patients to track their glucose levels via a wearable device that transmits biometrics to a smart device every five minutes. Its stock has risen more than 60% year to date, compared to the S&P 500's growth of nearly 15% over the same period. Over a five-year period, DexCom's stock has increased 344% compared to the broader market which rose 81%. The question for investors heading into 2021 is whether the good times for DexCom will keep going and if it's a strong buy today. Image source: Getty Images. Convenience and comfort make CGMs ideal Traditional glucose monitoring products are difficult to use and painful, requiring a finger stick from a pricking device. The patient has to carry the testing equipment with them. The convenience of the DexCom sensor is life-altering for patients because of convenience, elimination of pain, and most importantly, real-time glucose levels that can provide insights and analytics. CGM technology has made the finger-stick method obsolete for many patients and its popularity has propelled stocks like DexCom and its competitors higher in recent years. DexCom is not the only company that sells a CGM system. Abbott Laboratories (NYSE: ABT), Medtronic (NYSE: MDT), and Roche (OTC: RHHBY) all have competing products in their diabetes management businesses. But DexCom's net promoter scores are significantly better than their competitors, meaning the patients utilizing the products prefer the freedom offered by the DexCom G6 CGM. DexCom introduced the G6 in 2018 and since then, CGMs have become the standard of care for patients with diabetes. The company is actively working on its G7 version, which is in clinical trials. The new product is expected to launch in the second half of 2021. CEO Kevin Sayer said in the Q3 2020 earnings call that the ""G7 will be more expensive in the early stages as we're ramping capacity, but at scale, it will be a lower cost profile for us than G6. So, I think there's still quite a bit of a good runway in front of us."" Partnership strategy and other advantages Management has been astute by partnering with Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), as well as with Tandem Diabetes Care (NASDAQ: TNDM). Tandem utilizes DexCom's G6 CGM in its t:slim X2 insulin pump device which is widely used by diabetes patients. DexCom's CEO has an 87% approval rating on Glassdoor, showing employees have confidence in the company's leader. DexCom's Q3 revenue was $501 million and revenue growth was 26% year over year, despite headwinds from the COVID-19 pandemic. The company has been disrupting the diabetes market for years and G7 should have a significantly positive impact as the company reduces manufacturing costs and drives penetration into the type 2 diabetes market. Most of DexCom's patients have type 1 diabetes but this is changing as the cost of sensors improves and insurance companies include CGM devices in their coverage. DexCom's market penetration in the U.S. for type 1 diabetes is 40% and just 15% for type 2 diabetes, which represents a large future opportunity for the company. While DexCom continues to rapidly grow in the U.S., it has ample global opportunity. Management is working to develop a strategy for growth in international markets and believes that awareness and sharing CGM technology will help it win more patients. The other advantage that DexCom has over its competitors is the ability to allocate higher research and development spend to innovate. Its larger and more diversified competitors have to allocate resources across a plethora of competing opportunities, hence R&D spending tends to be lacking. Is DexCom a buy today? With the disruptive technology of a small monitoring device, a diabetes patient has seamless monitoring of their glucose levels to their smart device. This technology will continue to drive growth for healthcare companies that recognize the way people want to live vs. traditional devices that are large and cumbersome. DexCom will be a company to watch for many years to come as it continues to innovate and drive smaller and smarter devices for patients. DXCM data by YCharts DexCom thumped the market in 2020 and outpaced all its competitors. This is definitely a company deserving of future investment consideration for all kinds of investors. With continued innovation and new product introductions on the horizon, DexCom is a healthcare stock that should continue to beat the market for many years. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Jonathan Waldron owns shares of Apple and Tandem Diabetes Care. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Apple. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-12-18,90.364,91.375,88.37,89.6425,
DXCM,2020-12-21,88.1675,88.7325,86.66,87.2125,"Noteworthy Monday Option Activity: RCL, LMT, DXCM Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Royal Caribbean Group (Symbol: RCL), where a total volume of 30,050 contracts has been traded thus far today, a contract volume which is representative of approximately 3.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.1% of RCL's average daily trading volume over the past month, of 5.3 million shares. Especially high volume was seen for the $66 strike put option expiring December 31, 2020, with 3,934 contracts trading so far today, representing approximately 393,400 underlying shares of RCL. Below is a chart showing RCL's trailing twelve month trading history, with the $66 strike highlighted in orange: Lockheed Martin Corp (Symbol: LMT) saw options trading volume of 8,738 contracts, representing approximately 873,800 underlying shares or approximately 55.9% of LMT's average daily trading volume over the past month, of 1.6 million shares. Especially high volume was seen for the $530 strike call option expiring January 21, 2022, with 427 contracts trading so far today, representing approximately 42,700 underlying shares of LMT. Below is a chart showing LMT's trailing twelve month trading history, with the $530 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 6,757 contracts, representing approximately 675,700 underlying shares or approximately 55% of DXCM's average daily trading volume over the past month, of 1.2 million shares. Particularly high volume was seen for the $300 strike put option expiring January 15, 2021, with 5,358 contracts trading so far today, representing approximately 535,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $300 strike highlighted in orange: For the various different available expirations for RCL options, LMT options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-12-22,87.2375,88.5625,86.3575,88.5575,
DXCM,2020-12-23,89.2925,91.2475,88.995,88.9975,
DXCM,2020-12-24,89.135,89.5698,87.93,88.755,
DXCM,2020-12-28,88.8475,91.345,88.0925,90.5775,
DXCM,2020-12-29,91.9162,92.1725,88.1375,89.225,
DXCM,2020-12-30,89.94,90.7875,88.51,90.6925,"4 High-Growth Trends You'll Want to Invest in for 2021 A new year brings new opportunities for the investment community. Following one of the most volatile years in history for the stock market, investors are looking forward to the young bull market stretching its legs in 2021. Though a stock market crash or correction is always possible, there are ample tailwinds to suggest that equities can continue marching higher. Lending rates should remain at or near historic lows for the foreseeable future, which is going to encourage growth stocks to borrow. This extra cash can be used to hire, innovate, and acquire other businesses. As we ready to say goodbye to 2020, here are four high-growth trends for 2021. Image source: Getty Images. Precision medicine We've learned a lot in 2020 about where the future of healthcare is headed. There's little question that you'll want to invest in precision medicine. By precision medicine, I'm talking about drugs, devices, and services that are designed to personalize a previously one-size-fits-all treatment process. A good example is telemedicine giant Teladoc Health (NYSE: TDOC), which saw virtual visits more than triple from the prior-year period in each of the past two quarters. Teladoc fully understands that virtual visits are more convenient for patients and physicians. They're also usually cheaper for health insurers than office visits. With the addition of fast-growing applied health signals company Livongo Health, Teladoc is on the leading edge of treatment personalization. Investors might also consider a leader in medical devices like DexCom (NASDAQ: DXCM). DexCom produces and sells continuous glucose monitoring (CGM) systems that help diabetics monitor their blood sugar levels. DexCom's CGMs can also be used to provide instant data to physicians. Considering that there are 34.2 million people with diabetes in the U.S., and another 88 million with prediabetes, DexCom should remain busy. Image source: Getty Images. Cloud infrastructure Prior to the coronavirus disease 2019 (COVID-19) pandemic, businesses big and small were steadily building online presences and increasingly sharing data via the cloud. The pandemic has simply accelerated this trend and demonstrated the importance of cloud building-block infrastructure. One of the more obvious key players in cloud infrastructure is e-commerce giant Amazon (NASDAQ: AMZN). Retail comprises the bulk of Amazon's total sales, but most of its operating income comes from cloud infrastructure platform Amazon Web Services (AWS). AWS currently has an annual sales run rate of $46 billion. It should be responsible for tripling Amazon's operating cash flow over the next four years. Don't overlook Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), either. Ad placement on Google, its internet search platform, is Alphabet's key growth driver. Yet the company's fastest-growing segment is Google Cloud, with 45% sales growth in Q3 2020. Cloud has an annual sales run rate approaching $14 billion. Alphabet's deep pockets and the Google brand name should be more than enough to give Amazon a run for its money. Image source: Getty Images. U.S. cannabis Growth seekers would also be wise to consider putting their money to work in U.S. marijuana stocks in 2021. The U.S. is the largest cannabis market in the world. 2021 looks as if it'll be the year vertically integrated multistate operators (MSO) push into recurring profitability. Additional state-level legalizations could further bolster industry sentiment. Green Thumb Industries (OTC: GTBIF) is one MSO on the cusp of going green for good. The company generates approximately two-thirds of its revenue from derivatives (i.e., edibles, infused beverages, vapes, topicals, and concentrates). These derivatives boast considerably higher margins than dried cannabis flower, which will help Green Thumb beat some of its peers to the profit column. Green Thumb has 50 operational dispensaries at the moment, but holds enough licenses to open 96 total stores in a dozen states. Cresco Labs (OTC: CRLBF) should also be on track for a banner year. Nearly half of the company's 19 open dispensaries are in the limited license state of Illinois. The Land of Lincoln opened the door to recreational pot sales on Jan. 1, 2020, and looks well on its way to north of $1 billion in annual sales by 2024. Further, Cresco has a massive wholesale presence in California that gives it access to more than 575 dispensaries. California is the largest cannabis market in the world by annual sales. Image source: Getty Images. Companion animals A fourth and final high-growth trend that investors should be all over is pet ownership. According to the American Pet Products Association, nearly 85 million households own a pet today, with $99 billion expected to be spent on companion animals in 2020. At no point over the last quarter-century have U.S. pet expenditures declined year over year. Pet health insurer Trupanion (NASDAQ: TRUP) is one of the biggest opportunities in its industry. Trupanion has been building up rapport with veterinarians at the clinic level for two decades, which gives it a priceless advantage over other competitors entering the pet insurance space. At the moment, only 1% of U.S. pet owners have health insurance on their furry family member. Ongoing pet owner education at the clinic level should help drive these penetration rates significantly higher in years to come. Freshpet (NASDAQ: FRPT) is yet another fast-growing company in the companion pet space. Like grocers who latched onto the organic and natural foods growth phase of the 2000s, Freshpet understands that pet owners will pay for higher-quality pet food and treats. Freshpet is still in its marketing infancy, yet has already found its way into over 22,000 retail doors. A sustainable double-digit growth opportunity lies ahead. 10 stocks we like better than Alphabet (A shares) When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet (A shares) wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Amazon and Teladoc Health. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Cresco Labs Inc., Freshpet, Green Thumb Industries, Teladoc Health, and Trupanion. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2020-12-31,91.2375,92.66,90.3868,92.43,
DXCM,2021-01-04,91.5175,92.3675,87.96,89.435,
DXCM,2021-01-05,89.51,92.6475,88.805,92.1875,"[""3 Recession-Proof Healthcare Stocks to Buy for 2021 Healthcare was one of the few industries to emerge from 2020 relatively unscathed in comparison to much harder-hit sectors such as retail, travel, or energy. The top-performing healthcare stocks in 2020 have a few prominent characteristics. Many of them rely on a diversified portfolio of products that attract consistent demand or target specific consumer populations, such as the rare disease market or diabetes care. Whether or not you're concerned about another market crash in 2021, it's still important to limit your portfolio's exposure to excess risk by filling your basket of stocks with recession-proof buys. And if you're the type of investor who likes to spice things up with a handful of riskier stocks, these pandemic stalwarts can provide some equilibrium to the rest of your portfolio. Let's take a look at three recession-proof healthcare stocks that were at the top of their game in 2020 and are excellent buys for 2021. Image source: Getty Images. DexCom Shares of DexCom (NASDAQ: DXCM) have gained nearly 350% over the past five years and shot up 65% in the last 12 months alone. DexCom makes continuous glucose monitoring (CGM) devices, and its flagship product is the G6 CGM system. The company is one of the most prominent players in the CGM market. Its system \""sends glucose readings to your compatible smart device and receiver every five minutes with no fingersticks necessary\"" and \""features a 10-day wear sensor that is designed to be water-resistant and easy-to-insert with an auto-applicator.\"" The company is also planning to release its G7 CGM device in the latter part of 2021. The new system was originally slated for release in 2020, but manufacturing and other delays caused by the coronavirus pandemic held back its launch. The G7 will be released with a 10-day wear sensor like the G6, but management said on the company's third-quarter earnings call that it expects to increase the device's wearability period. Given the astronomical success of the G6 CGM device, the next-generation system should be poised for equal or even greater success. DexCom has faced challengers to its foothold on the CGM device market over the past few years, particularly in Abbott Labs' (NYSE: ABT) FreeStyle Libre system, but its balance sheet continues to reflect rock-solid growth. In the 2016-2019 period, the company reported double-digit revenue increases every year: 43%, 25%, 44%, and 43%, respectively. DexCom's financial performance has been equally impressive throughout the pandemic. The company reported first, second, and third-quarter year-over-year revenue increases of 44%, 34%, and 26%, respectively. DexCom also has about $2.6 billion in cash and marketable securities, and only $506 million in total current liabilities, so the company doesn't have any concerning debt issues to contend with in 2021. DexCom isn't the only strong presence in the CGM device market, but when you consider that nearly half a billion people worldwide have diabetes, it doesn't need to be. The company meets a constant and ever-growing need with its life-saving devices. For this reason, DexCom is a recession-proof stock that you can easily buy and hold for the next few decades. Data source: YCharts. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) also targets a very specific niche in healthcare with its rare disease portfolio comprised entirely of cystic fibrosis (CF) drugs. The company has its finger on the pulse of the CF drug market, most notably with its triple-combination therapy Trikafta. The U.S. Food and Drug Administration's (FDA) approval of the drug in October 2019 was monumental, making Trikafta the first-ever prescription medicine that roughly 90% of CF sufferers can take. Vertex has three other approved products in its stable besides Trikafta: Orkambi, Symdeko, and Kalydeco, all of which have achieved considerable commercial success. Vertex Pharmaceuticals has a solid track record of consistent, above-average revenue growth. In 2019, its top line spiked 37% year over year. And the pandemic hasn't slowed Vertex's growth at all. The company reported product revenues of approximately $1.5 billion in each of the first three quarters of 2020, representing year-over-year increases of 77%, 62%, and 62%. Trikafta has quickly achieved blockbuster status, and amassed $2.8 billion in total product revenue in the first nine months of 2020. Orkambi, Symdeko, and Kalydeco raked in total product revenues of $700 million, $500 million, and $600 million, respectively, during this time frame. Vertex Pharmaceuticals isn't resting on its laurels. The company continues to seek expanded approvals for its existing panel of drugs while pursuing additional growth opportunities. Management announced on Dec. 21 that the FDA had issued new indications for Trikafta, Kalydeco, and Symdeko for CF patients with specific rare mutations. The company also inked a partnership agreement with Skyhawk Therapeutics on Dec. 22, \""aimed at the discovery and development of novel small molecules that modulate RNA splicing for the treatment of serious diseases.\"" This new collaboration will only further Vertex's presence in the rare disease treatment space, as should its robust pipeline of drug candidates for conditions including CF, sickle cell disease, Duchenne muscular dystrophy, type 1 diabetes, and a rare blood disorder called beta thalassemia. If you're in the market for a recession-proof healthcare stock with minimal competition to affect future growth over the next five to 10 years, now looks like a great time to jump on this screaming buy. Regeneron Shares of Regeneron (NASDAQ: REGN) once nearly soared 80% in 2020, before exiting the year with a 27% increase. The company reported double-digit year-over-year revenue growth in each of the first three quarters of 2020 (33%, 24%, and 32%), thanks in large part to the continued success of Dupixent. The blockbuster drug, which is approved to treat several conditions including moderate-to-severe atopic dermatitis, is the product of Regeneron's long-standing partnership with French company Sanofi (NASDAQ: SNY). Sales of Dupixent alone raked in $855 million in the first quarter, followed by $945 million in the second quarter and $1.07 billion in the third. Regeneron's Eylea, a medication used to treat macular degeneration, has also been a major cash cow. The drug brought in well over $3 billion in sales during the first nine months of 2020. Regeneron's COVID-19 antibody cocktail could also turn out to be a significant source of income for the company over the next few years. The cocktail, which is a mixture of two monoclonal antibodies called casirivimab and imdevimab, was authorized for emergency use by the FDA on Nov. 21. The authorization applies to adults with mild or moderate cases of COVID-19, and children aged 12 and above who weigh 40 kg or more, tested positive for the virus, and are in danger of becoming seriously ill or requiring in-hospital treatment. The antibody cocktail is currently enrolled in numerous ongoing late-stage clinical trials assessing its safety and efficacy for both hospitalized and non-hospitalized patients, as well as to prevent infection after exposure to the disease. Regeneron previously inked a $450 million contract with the U.S. government under the Operation Warp Speed program, so an initial batch of 300,000 doses will be provided to patients free of charge. However, Regeneron is planning to manufacture millions of additional doses in 2021 and beyond if its antibody cocktail gains regulatory approval. The company already reached an agreement with Swiss pharmaceutical company Roche (OTC: RHHBY), who would make and distribute the antibody cocktail internationally if it is approved. With each dose of Regeneron's COVID-19 treatment costing an estimated $1,500, the company could easily have another blockbuster on its hands. In addition to its current portfolio and potential success in the COVID-19 treatment space, Regeneron has a robust pipeline featuring a host of antibody therapies it's studying for the treatment of multiple myeloma, non-small cell lung cancer, heart failure, and more. And despite incurring higher-than-usual research and development costs during the third quarter, Regeneron still closed the three-month period with nearly $6 billion in cash and marketable securities, and just $2 billion in long-term debt. The company's balance sheet is in great shape, and it's growth potential over the next few years is huge, with or without the success of its COVID-19 antibody cocktail. Investors should consider buying in now before shares potentially spike even higher in the coming months. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now\u2026 and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Nasdaq 100 Stocks That Can Make You a Boatload of Money in 2021 Investors were taken on the ride of their lives in 2020. After getting pummeled in the first quarter, the broader market proved unstoppable in the nine months to end the year. This was especially true of the technology-heavy and growth-focused Nasdaq 100. When the curtain closed, the market cap-weighted Nasdaq 100 ended the year higher by nearly 48%. That's triple the return of the benchmark S&P 500 in 2020 and almost six times the gain posted by the iconic Dow Jones Industrial Average. What you might be surprised to learn is that there's still some serious value hiding in plain sight. The following three Nasdaq 100 stocks all have the potential to make you a boatload of money in 2021, and beyond. Image source: Getty Images. Vertex Pharmaceuticals By all accounts, specialty drug stock Vertex Pharmaceuticals (NASDAQ: VRTX) had a down year. Despite finishing higher by almost 8%, the company closed the latter half of 2020 by losing almost a fifth of its value. This stemmed from a pipeline update in October that saw the company discontinue phase 2 studies of promising alpha-1 antitrypsin deficiency (AATD) drug VX-814 after elevated liver enzyme levels were seen in some trial participants. While it was unfortunate to see one of Vertex's promising pipeline products fail, it's the nature of the drug-development process and in no way tarnishes Vertex's history of success on the development front. The biggest differentiating factor for Vertex is the company's overwhelming success in helping patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and lungs. There currently is no cure. Vertex has developed multiple generations of gene-specific treatments for CF patients. The latest, Trikafta, was approved five months ahead of schedule after the drug improved predicted forced expiratory volume in one second by 3.7 percentage points in trial participants. As the most-effective treatment option for the most common mutation of CF (F508del), Trikafta looks to be well on its way to eventually surpassing $6 billion in annual sales. Beyond the failed VX-814, Vertex has a half-dozen other experimental therapies in clinical trials, and a number of other preclinical programs under way. CTX001 as a treatment for sickle cell disease and beta thalassemia, along with VX-864 as a treatment for AATD, are among the most promising. It'd be great if Vertex's revenue stream were less reliant on CF, but it's a mistake to discount the company's stock just because of its overwhelming success in a single indication. Look for Vertex to bounce back in 2021 and make shareholders a boatload of money. Image source: Getty Images. DexCom Another healthcare stock that should continue to shine in 2021 is medical-device maker DexCom (NASDAQ: DXCM). Unlike Vertex, DexCom powered higher by 69% last year. However, it's retraced by 18% since hitting an all-time closing high in early August. What makes DexCom such an intriguing company is its focus on helping patients with diabetes. DexCom develops continuous glucose monitoring (CGM) systems. A CGM system can help diabetics take better control of their glycemic balance, while reducing or eliminating the need for repeated finger-prick tests. A patients' real-time blood glucose reading can be displayed wirelessly on a host of devices (smartphone, smartwatch, or a DexCom wireless display), and in select instances DexCom's devices can be linked to an insulin pump. Just as important, DexCom's CGMs come with its Clarity software. Clarity allows patients to easily aggregate their blood glucose readings in digital reports, which can then be sent to a primary physician or specialist. The value of Clarity has been especially notable during the coronavirus pandemic, where at-risk patients, such as diabetics, are purposefully avoiding office visits. DexCom can also benefit from the sheer size of the U.S. diabetes market. According to the Centers for Disease Control and Prevention, more than 34 million people have diabetes today (75% of which know they have the disease), and another 88 million Americans are exhibiting the symptoms of prediabetes. The company's potential pool of patients continues to climb, which is why a 20% growth rate is perfectly sustainable. Image source: Getty Images. Facebook Just because Facebook (NASDAQ: FB) is a $778 billion company doesn't mean that it's exceptional growth potential is now in the past. Let's start with the basics: Facebook is the go-to for social media advertising. At the end of September, Facebook had 2.74 billion monthly active users, along with 3.21 billion monthly family active people. This family figure includes owned platforms WhatsApp and Instagram. Advertisers fully understand that there isn't anywhere they can go to reach such a huge targeted audience. This means exceptional ad-pricing power for Facebook, year in and year out. Something else that often gets overlooked with Facebook is that the company is nowhere near done monetizing its assets. While it's been generating plenty of ad revenue from Facebook and Instagram, WhatsApp and Facebook Messenger haven't been monetized in a meaningful way. Facebook owns four of the six most-visited social platforms in the world, yet it's only generating meaningful revenue from two of them. When the company does monetize WhatsApp and Facebook Messenger, expect sales growth and operating cash flow to pick up big-time. Facebook also has innovation potential that extends beyond advertising. For instance, it'll be launching its own cryptocurrency (Libra) sometimes this year, which may help drum up interest for Facebook Pay. I believe some sort of streaming service could lie in its future, as well. Based on its operating cash flow, Facebook looks to be about as cheap as it's ever been. This suggests substantial upside is still to come. 10 stocks we like better than Facebook When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Facebook wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook. The Motley Fool recommends DexCom and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-01-06,92.7425,96.1275,91.6725,93.98,"DexCom (DXCM) Shares Cross Above 200 DMA In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $373.09, changing hands as high as $384.51 per share. DexCom Inc shares are currently trading up about 3% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $182.07 per share, with $456.23 as the 52 week high point — that compares with a last trade of $379.92. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-07,94.175,97.4,94.175,96.79,"Charting January breakouts, U.S. benchmarks tag round-number milestones Focus: Financials and regional banks take flight amid surging Treasury yields, Health care sector tags record highs, XLF, KRE, XLV, AMAT, SWKS, DXCM U.S. stocks are firmly higher early Thursday, rising to punctuate an early-week whipsaw. Against this backdrop, each big three U.S. benchmark has tagged its latest record high as well as a round-number milestone — S&P 3,800, Nasdaq 13,000 and Dow 31,000."
DXCM,2021-01-08,97.3175,99.245,95.3175,97.0225,
DXCM,2021-01-11,93.4975,93.875,90.7925,92.66,"BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Tesla, Twitter, GeoVax Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes slipped from record levels on Monday as investors locked in gains after a strong rally, with prospects of President Donald Trump's impeachment trial stoking fears of a delay in further pandemic relief. .N At 12:46 ET, the Dow Jones Industrial Average .DJI was down 0.06% at 31,078.4. The S&P 500 .SPX was down 0.27% at 3,814.38 and the Nasdaq Composite .IXIC was down 0.55% at 13,129.635. The top three S&P 500 .PG.INX percentage gainers: ** Eli Lilly and Company , up 11.5% ** Biogen Inc , up 8.5% ** Etsy Inc , up 5.6% The top three S&P 500 .PL.INX percentage losers: ** Universal Health Services , down 5.1% ** Tesla Inc , down 4.9% ** Dexcom Inc , down 4.4% The top three NYSE .PG.N percentage gainers: ** Star Peak Energy Transition , up 19.6% ** Cynergistek , up 18% ** Navios Maritime Holdings , up 17.4% The top three NYSE .PL.N percentage losers: ** Turquoise Hill Resources , down 19.8% ** China Green Agriculture , down 13% ** Silvergate Capital Corp , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Property Solutions Acquisition , up 103.8% ** GeoVax Labs , up 62.8 % ** Sify Technologies Limited , up 53.5 % The top three Nasdaq .PL.O percentage losers: ** Diginex Equity Warrants , down 25.1 % ** Applied DNA Sciences , down 21.8% ** Bit Digital Inc , down 20.1% ** Lyft Inc LYFT.O: up 2.1% ** Zillow group Inc ZG.O: up 1.2% BUZZ- U.S. Internet: Jefferies says Facebook tops large-cap pick for 2021 ** Bluebird bio BLUE.O: up 3.0% BUZZ-Rises on plans for cancer drug unit spin-off ** Eli Lilly and co LLY.N : up 11.5% BUZZ- Rises as Alzheimer's drug slows clinical decline in mid-stage trial ** Callon Petroleum CPE.N: down 2.0% ** Apache Corp APA.O: down 0.4% ** Occidental Petroleum OXY.N: down 0.1% ** Schlumberger NV SLB.N : down 0.1% BUZZ- Oil cos decline on renewed lockdowns, stronger dollar ** Anaplan Inc PLAN.N: up 2.8% BUZZ- Up, brokerages raise rating on back-office makeover trend ** Boot Barn Holdings BOOT.N: up 8.7% BUZZ-Street cheers holiday momentum with PT hikes ** Boeing Co BA.N: down 2.0% BUZZ- Drops after Sriwijaya Air crash involving older 737 jet ** Exicure Inc XCUR.O : up 17.5% BUZZ- Gains on fast-track tag for potential skin cancer drug ** Tesla Inc TSLA.O: down 4.9% BUZZ-Tesla: Drops; set to snap 11 consecutive sessions of gains ** Property Solutions Acquisition PSAC.O: up 18.1% BUZZ- Gains on reports of merger talks with Faraday ** Nio Inc NIO.N : up 9.4% BUZZ-Set for a record high after JPM raises PT BUZZ-Nio Inc: Launches first sedan to take on Tesla; JPM raises PT ** STAAR surgical co STAA.O: up 0.1% BUZZ-Poised for growth, says BTIG ** Mesoblast Limited MESO.O: up 45.5% BUZZ- Gains on positive additional data from heart failure therapy study ** Royal Gold Inc RGLD.O : up 1.3% BUZZ-RBC says co leads red carpet in precious metals industry; upgrades ** Crocs Inc CROX.O: up 12.6% BUZZ- Crocs jumps after raising revenue outlook ** ODP Corp ODP.O: up 16.5% BUZZ- ODP Corp gains after Staples' $2.1 bln buyout offer ** Albemarle Corp ALB.N : down 3.0% BUZZ- Falls as Chile threatens legal action ** Lordstown Motors RIDE.O : up 19.0% BUZZ- Up as co receives 100,000 pre-orders of electric pickup truck ** Exxon Mobil Corp XOM.N : up 3.1% BUZZ- Morgan Stanley prefers Exxon Mobil over Chevron for 2021 ** GeoVax Labs GOVX.O : up 62.8% BUZZ- Surges after grant for COVID-19 vaccine development ** ASLAN Pharma ASLN.O : up 1.0% BUZZ- Gains on approval to expand eczema treatment study ** Southern Copper Corp SCCO.N : down 0.6% ** Freeport-McMoRan Inc FCX.N : down 2.5% BUZZ- Copper miners fall as demand worries weigh on metal prices ** DexCom DXCM.O : down 4.4% BUZZ-Falls as 2021 revenue view below Street estimates ** Build-A-Bear Workshop BBW.N : up 4.7% BUZZ- Rising COVID-19 cases hurt quarterly sales ** Riot Blockchain RIOT.O : down 13.3% ** Marathon Patent Group MARA.O : down 11.3% ** Overstock.com OSTK.O : down 1.4% ** MicroStrategy Inc MSTR.O : down 5.3% BUZZ- Cryptocurrency stocks dive as Bitcoin plunges 19% ** Twitter TWTR.N : down 4.4% BUZZ-Shares slump after Trump's account suspension ** Dave & Buster's Entertainment PLAY.O : up 4.5% BUZZ- Jumps on better-than-expected Q4 revenue forecast ** Remark Holdings Inc MARK.O : up 14.4% BUZZ- At over 6-month high on share repurchase, revenue outlook ** Tillys Inc TLYS.N : up 2.7% BUZZ-Rises as online surge boosts holiday-period sales ** Exact Sciences EXAS.O : up 14.8% BUZZ-Rises as Q4 revenue forecast above estimates The 11 major S&P 500 sectors: Communication Services .SPLRCL down 0.97% Consumer Discretionary .SPLRCD down 0.87% Consumer Staples .SPLRCS down 0.49% Energy .SPNY up 1.49% Financial .SPSY up 0.30% Health .SPXHC up 0.59% Industrial .SPLRCI up 0.14% Information Technology .SPLRCT down 0.23% Materials .SPLRCM up 0.29% Real Estate .SPLRCR down 1.64% Utilities .SPLRCU down 1.31% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-12,92.8425,92.8775,89.065,90.0425,"2 Healthcare Stocks That Crushed the Market Last Year -- And Still Have Room to Grow Coming into 2020, stocks were riding the wave of one of the longest bull markets in history. But the economic fallout of the COVID-19 pandemic brought that streak to a close. The market fell sharply in early 2020 as recorded cases of the disease grew in the U.S. and abroad, although it recovered nicely during the second half of the year. The S&P 500 was up 16.3% last year, a respectable performance considering the volatility. However, some stocks managed to perform much better than that. For instance, shares of Tandem Diabetes Care (NASDAQ: TNDM) rose by 60.5% in 2020, while DexCom's (NASDAQ: DXCM) stock gained 69% in the same period. These two healthcare companies have something else in common: They develop and market products that help diabetes patients manage their illnesses. This market is already quite large: Roughly 34.2 million Americans have diabetes, and 88 million more have prediabetes. And studies indicate that these numbers will continue to increase. Companies that help people manage this disease are likely to remain in high demand. Tandem Diabetes Care and DexCom are both well positioned to make a mark in this space. Read on to find out why both would be excellent additions to your portfolio. 1. DexCom One of the most critical aspects of managing diabetes is monitoring blood sugar levels, and patients have several options available. One such option is a blood glucose meter (BGM) that uses fingersticks. This method does have significant drawbacks, however. First, fingersticks are somewhat painful, and second, BGMs can only measure blood sugar levels at a particular point in time. Another method is known as continuous glucose monitoring (CGM). CGM systems are small devices that continually keep track of a person's blood glucose level, often using a sensor inserted into the skin. While fingersticks may still be needed to calibrate the device properly, CGMs reduce the frequency at which a patient uses them. Indeed, DexCom's G6 CGM System eliminates the need for fingersticks altogether, and in a survey of G6 users, 84% said the initial sensor insertion was painless. In other words, the G6 CGM System presents significant advantages over the first method. This factor has helped DexCom perform well. During the nine-month period ending Sept. 30, the company's revenue jumped by 34% year over year to $1.4 billion. Management attributed this growth to an increased ""awareness of real-time CGM."" Image source: Getty Images. It is worth noting that DexCom is working on a successor to the G6, appropriately named the G7. This new, thinner model will bring significant reductions in manufacturing costs. The G7 is currently undergoing clinical trials, and it should be launching in key markets during the second half of the year. Speaking of which, DexCom's core markets are North America, Australia, and a few other developed counties. The company estimates that this total population is comprised of roughly 10 million potential customers and remains underpenetrated -- and that's to say nothing of the opportunities that lie beyond. In such a landscape, DexCom will likely continue to grow its revenue and earnings, and its stock price will follow suit. Putting money into this healthcare stock right now would be a great move. 2. Tandem Diabetes Care Tandem Diabetes develops insulin pumps and accessories. The company's crown jewel is the t:slim X2 insulin pump, which works in tandem with DexCom's G6 to continuously monitor blood glucose levels and uses an automated delivery system to maintain a patient's blood sugar level within a pre-defined range. This helps reduce hypoglycemia, a dangerous condition for those with diabetes. It's not surprising, then, that consumers have flocked to Tandem Diabetes' innovative product, as evidenced by the company's revenue growth. The chart below shows the healthcare company's quarterly top-line growth for the past three years. TNDM Revenue (Quarterly) data by YCharts Can Tandem Diabetes maintain this momentum? Yes, it can, and here is why. Just like DexCom, the company has a massive untapped market opportunity ahead of it. In the U.S., most diabetes patients still rely on multiple daily injections rather than insulin pumps, even though the latter method is less painful and less prone to human errors. The opportunity abroad is even larger for Tandem Diabetes, since the proportion of patients with diabetes who use innovative pumps like the t:slim X2 is even smaller outside the U.S. Tandem Diabetes plans on having 500,000 customers by the end of 2024, up from 190,000 as of its third quarter of 2020, which ended Sept. 30. Analysts estimate that the company will keep growing its revenue at an annual rate of 53.2% throughout the next five years. What's more, the company isn't resting on its laurels, with several products currently in development to better assist diabetes patients. These factors will help the healthcare company maintain the momentum it had last year, and those who buy its shares will be glad they did so down the road. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-13,89.98,91.11,86.97,90.6375,
DXCM,2021-01-14,90.545,91.0685,87.5099,88.02,"Nasdaq 100 Movers: XEL, KLAC In early trading on Thursday, shares of KLAC topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.3%. Year to date, KLAC registers a 21.4% gain. And the worst performing Nasdaq 100 component thus far on the day is Xcel Energy, trading down 1.8%. Xcel Energy is lower by about 4.2% looking at the year to date performance. Two other components making moves today are DexCom, trading down 1.4%, and Applied Materials, trading up 7.6% on the day. VIDEO: Nasdaq 100 Movers: XEL, KLAC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-15,88.0575,89.1875,86.8975,88.55,
DXCM,2021-01-19,89.6225,90.0125,87.0062,89.41,"Abbott vs Dexcom: Which “Strong Buy” Stock Could Deliver Higher Returns in 2021? With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is growing rapidly worldwide—sedentary lifestyles being a key reason for that. A recent report by the World Health Organization (WHO) revealed that deaths from diabetes surged 70% globally between 2019 and 2020. Abbott and Dexcom are some of the names that are developing diabetes monitoring systems. Using the TipRanks Stock Comparison tool, we will place Abbott and Dexcom alongside each other and pick the stock reflecting a more compelling play. Abbott Laboratories (ABT) Abbott has a diversified business that includes four segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceutical Products (which generates revenue from the sale of branded generic pharmaceutical products outside of the US). Since the pandemic's onset, Abbott has been in the news for the multiple COVID-19 tests developed by the company. Most recently, BinaxNOW COVID-19 Ag Test Card was granted the FDA’s emergency use authorization for virtually guided at-home use. Coming to diabetes, Abbott sees tremendous growth in the area, especially through its FreeStyle Libre technology, which is a sensor-based continuous glucose monitoring system. Sales of FreeStyle Libre systems grew 37.9% in 3Q 2020. Moreover, in 3Q 2020, the company’s FreeStyle Libre 3 system secured CE Mark for use by diabetic patients in Europe. The FreeStyle Libre 3 provides real-time glucose readings automatically delivered to the user’s smartphone every minute, offering unsurpassed 14-day accuracy and real-time glucose alarms. The company also won CE Mark for its Libre Sense Glucose Sport Biosensor, which helps athletes “better understand the efficacy of their nutritional choices on training and athletic performance.” Furthermore, Abbott’s FreeStyle Libre 2 received approval in December 2020 by Health Canada for adults and children (4 and older) with diabetes. (See ABT stock analysis on TipRanks) Last month, Raymond James analyst Jayson Bedford reiterated a Buy rating for Abbott following a call with the company’s management. Bedford stated that the company is working through the reimbursement channels in Europe and expects to launch Libre 3 in the “coming months,” while the analyst had anticipated a December launch. Bedford also specified that management did not lay out a timeline for Libre 3 roll out in the US, but he estimates the launch could happen in 2021. The analyst also noted that the app for the Libre 2 system has not yet been approved, but management is optimistic about the submission. Commenting on the prospects of the COVID-19 testing portfolio, Abbott’s management anticipates the testing market to remain strong into mid-2021 and then start to decline in the second half of this year. To back his bullish stance on Abbott, the analyst concluded, “The 'third wave' of CV-19 has raised the near-term uncertainty level (for the group), but ABT remains well positioned given its diversified portfolio, and the CV-19 testing tailwind, which lessens the near-term risk profile. Management is executing well, and enters 2021 with momentum.” Overall, consensus among analysts is a Strong Buy based on 8 Buys versus 2 Holds. Abbott shares have risen 25.1% over the past year and the average price target of $120.57 suggests upside potential of 8.3% in the months ahead. Dexcom (DXCM) Diabetes is growing rapidly and so is the need for continuous glucose monitoring (CGM) systems, which Dexcom specializes in. The company's G6 CGM system is FDA-permitted for use by people with Type 1 and Type 2 diabetes. Last week, the company announced better-than-anticipated preliminary results for 4Q 2020, which calls for revenue to meet or exceed $567 million. This implies year-over-year growth of 23%, with U.S. revenue expected to rise about 20% to $451 million and international revenue to grow about 33% to $116 million. (See DXCM stock analysis on TipRanks) Overall, the company expects to meet or exceed revenue of $1.925 billion in 2020, reflecting a gain of over 30%. As for the initial 2021 outlook, Dexcom calls for top-line growth in the range of 15%-20%. The company’s outlook is based on an increase in its sensor volumes, driven by the growing CGM awareness for people with Type 1 and Type 2 diabetes, continued expansion beyond the US, shifting channel mix and overall market dynamics. Covering Dexcom for Oppenheimer, analyst Steven Lichtman notes that the company’s international business was the primary driver of the revenue beat, owing to new initiatives including direct-to-consumer and e-commerce channel. Indeed, Dexcom is pursuing international growth and has extended its G6 CGM offering to additional markets, including the rollout in Belgium and Turkey in 4Q 2020. Commenting on the 2021 outlook, Lichtman noted that the company has maintained a conservative stance when it comes to its guidance in the past two years. The analyst assumes that the impact of competition from Abbott's Libre franchise is factored into the forecast. He believes that growth drivers for 2021 include “big new opportunities in T2 [Type 2 diabetes] and international expansion along with the G7 launch.” On the 3Qearnings call Dexcom stated that it expects to launch G7 in several key markets in the second half of 2021, and then expand its reach into all of its core markets in 2022. Overall, Lichtman continues to be bullish on Dexcom and maintained a Buy rating with a $445 price target. Currently, Dexcom scores a Strong Buy analyst consensus based on 9 Buys and 2 Holds. The average price target stands at $456.11, indicating upside potential of 28.8% from current levels. Shares have already risen 53.5% over the past 52 weeks. Bottom line Abbott’s diversified business model and exposure to major growth areas like diabetes are its key strengths. Dexcom is completely focused on meeting the growing need for its CGM systems in the domestic as well as international markets. While the Street is bullish on both companies, right now, the average price target indicates a higher upside potential for Dexcom stock. To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-20,89.8575,91.8225,89.49,91.03,
DXCM,2021-01-21,91.675,92.6975,90.425,91.875,
DXCM,2021-01-22,91.9075,93.4975,91.32,92.53,
DXCM,2021-01-25,93.3875,94.5,91.115,94.0975,"[""Are These The Best Health Care Stocks To Watch This Week? 3 In Focus Do You Have These Top Health Care Stocks On Your Watchlist? In the stock market today, health care stocks are in the limelight. For one thing, it is a part of the stock market which investors flock to in good times and bad. This is because we will always require health care as long as there is sickness. In general, the health care industry consists of a plethora of companies that produce and market medical products and services. The likes of which consist of biotechnology companies who have been hard at work producing treatments and drugs. Aside from that, there are also virtual health care companies that have been catering to the general public who are stuck at home. Admittedly, a healthy immune system is vital in the fight against the current pandemic. Investors could be looking to add the top health care stocks to their portfolios. As most investors know, top biotech stocks such as Moderna (NASDAQ: MRNA) have been on a tear in the past year. This is mostly due to their part in developing the coronavirus vaccine. Additionally, we have also seen the rise of companies that provide home health care solutions to people in need. Take Dexcom (NASDAQ: DXCM) for example. The company produces continuous glucose monitoring (CGM) systems. Dexcom\u2019s diabetic clients rely heavily on its CGMs to monitor their glucose levels in real-time. Thanks to the company, they are now able to monitor their health safely from home. In turn, DXCM stock is up by over 90% since the March lows. All in all, there is a wide range of health care stocks for investors to choose from. In a time where health is more important than ever, it does make for an enticing opportunity for investors as well. Well if you think so, here is a list of the top health care stocks to watch this week. Read More Top 5 Things To Watch In The Stock Market This Week 3 Renewable Energy Stocks To Watch Before February 2021 Best Health Care Stocks to Watch Right Now Eli Lilly And Company (NYSE: LLY) Neuronetics (NASDAQ: STIM) Teladoc Health (NYSE: TDOC) Eli Lilly And Company Starting us off is Indiana-based pharmaceutical company, Eli Lilly. The company\u2019s products are sold across 125 countries. Notably, LLY stock has surged since the year started with gains of over 23% and closed last week at a new all-time high. As LLY stockholders must be excited now, could they anticipate more gains this week? Just last week, the company made two positive announcements. First, Eli Lilly reported that its coronavirus treatment, bamlanivimab, significantly reduced the risk of contracting symptomatic COVID-19 by 80%. In detail, residents, and staff from long-term care facilities across the U.S. were tested with the help of the National Institutes of Health (NIH). Furthermore, the company also announced the completed acquisition of Prevail Therapeutics (NASDAQ: PRVL). Eli Lilly is looking to employ Prevail\u2019s expertise in neuroscience to establish a new gene therapy program. If anything, it seems that Eli Lilly is firing on all cylinders as we move into February. In its recent quarter fiscal posted in October, the company reported solid figures all around. It brought in $5.74 billion in total revenue for the quarter. On top of that, it saw a 129% jump in cash on hand which added up to $3.6 billion. Considering the ongoing health care disruptions brought on by the pandemic, Eli Lilly continues to deliver. Would you be watching LLY stock ahead of its upcoming quarterly results announcement on January 29? [Read More] 3 Top 5G Stocks To Watch This Week Neuronetics Neuronetics is another top health care stock to watch right now. The Pennsylvania-based biotech company develops non-invasive treatments for chronic psychiatric and neurological disorders. To point out, a recent update on its Major Depressive Disorder (MDD) treatment has sent STIM stock on a tear. The company\u2019s shares are looking at gains of over 40% since the announcement on January 19. To elaborate, its NeuroStar Advanced Therapy (NSAT) outcomes registry hit a 10,000-patient milestone. This makes it the largest outcomes registry in the world for MDD. Importantly, the registry was created to collect and analyze data from MDD patients who are treated with NSAT. Along with this groundbreaking achievement, Neuronetics also announced the latest results from its registry. It found that 73% of patients treated with NSAT experienced significant improvement in their symptoms. CEO Keith Sullivan said, \u201cWe are confident that the Outcomes Registry data is laying the groundwork for future advancements and treatment protocols.\u201d Not only is Neuronetics treatment showing results, but it is also contributing vital information towards the field of MDD. Given the growing emphasis on mental health, investors could see STIM stock having long-term growth potential. In its recent quarter fiscal report in November, the company reported total revenue of $12.45 million. It also ended the quarter with $50.72 million in cash on hand. Given the coronavirus-related impacts on its business, the company is seeing a strong sequential rebound. With the recent success of Neuronetics\u2019 flagship MDD treatment, could STIM stock be in for another great year? Your guess is as good as mine. [Read More] Top Dividend Stocks To Buy In 2021? 6 For Your List Teladoc Health Teladoc is a leading virtual health care company. Its telemedicine services have come to be a vital resource for the general population stuck at home. Naturally, this is because its telehealth services allow Teladoc to provide for customers\u2019 health care needs in a safe manner. As a result, TDOC stock is up by over 174% in the past year. In fact, it just hit a new all-time high at last week\u2019s closing bell at the price of $263 a share. Given its current value, it would be normal for investors to wonder if it still has room to grow. Back in October, the company reported strong financial figures for its third-quarter fiscal. Teladoc saw year-over-year surges of 109% in total revenue and 149% in cash on hand. CEO Jason Gorevic said, \u201cOur strong third-quarter results exceeded expectations, driven by broad-based strength across the business and building on the momentum we saw in the first half of the year,\u201d In addition to its merger with Livongo, the company has also been bolstering its offerings. According to Teladoc, this move made it the \u201conly consumer and health care provider partner to span a person\u2019s entire health journey.\u201d Should things go as planned, I could see why investors look at TDOC stock with long-term gains in mind. In recent news, the company also presented at the 39th annual JPMorgan Health Care Conference on January 11. Gorevic announced a collaboration with Dexcom to bring its proprietary CGM technology to existing customers for free. Adding to that, he also revealed that the company had launched pilots of its virtual primary care offering, Teladoc Primary 360. With Teladoc expanding and bolstering its existing services, it could be a busy time ahead for the company. Do you think this means big gains for TDOC stock in the future? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Analysts Forecast 10% Upside For FTLB Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Hedged BuyWrite Income ETF (Symbol: FTLB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $22.49 per unit. With FTLB trading at a recent price near $20.46 per unit, that means that analysts see 9.88% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTLB's underlying holdings with notable upside to their analyst target prices are Osisko Gold Royalties Ltd (Symbol: OR), Wheaton Precious Metals Corp (Symbol: WPM), and DexCom Inc (Symbol: DXCM). Although OR has traded at a recent price of $11.93/share, the average analyst target is 35.54% higher at $16.17/share. Similarly, WPM has 35.16% upside from the recent share price of $40.42 if the average analyst target price of $54.63/share is reached, and analysts on average are expecting DXCM to reach a target price of $445.65/share, which is 20.41% above the recent price of $370.12. Below is a twelve month price history chart comparing the stock performance of OR, WPM, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET First Trust Hedged BuyWrite Income ETF FTLB $20.46 $22.49 9.88% Osisko Gold Royalties Ltd OR $11.93 $16.17 35.54% Wheaton Precious Metals Corp WPM $40.42 $54.63 35.16% DexCom Inc DXCM $370.12 $445.65 20.41% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""FOCUS-Alphabet's Verily bets on long-term payoff from virus-testing deals By Paresh Dave OAKLAND, Calif., Jan 25 (Reuters) - For Alphabet Inc's GOOGL.O Verily, a healthcare venture that is one the tech giant's most prominent \""other bets,\"" the coronavirus pandemic offered an immediate business opportunity. Starting last February, the company shifted many of its about 1,000 employees to developing software for governments and employers to manage coronavirus testing. It quickly landed major customers including the state of California, which records show paid Verily $49.6 million to use its Baseline software to schedule virus tests. Smaller deals included a previously unreported $3.1 million grant from the National Foundation for the Centers for Disease Control and Prevention to operate California testing sites. Verily executives said the pandemic work was a chance to demonstrate the company's capabilities, and attract new customers. \""The conversations are naturally flowing in that way,\"" said Dr. Jessica Mega, Verily's chief medical and scientific officer. Critics say the effort has been another distraction for Verily, which has bounced between dozens of projects without producing a stable revenue stream. The venture has drawn more than $1.8 billion in funding from Alphabet and outside investors including private equity firm Silver Lake. Converting temporary buyers into long-term clients may be wishful thinking, four industry analysts said. Two former executives and a current employee criticized the company for taking on another one-off opportunity instead of focusing on attracting recurring subscribers to its software for clinical research, disease management and other tasks. \""I don't think COVID will give them significant tailwinds,\"" said one of the people, speaking on the condition of anonymity. Chief Executive Andy Conrad has told employees Verily is driving toward an initial public offering, and more consistent sales would be essential for a successful Wall Street debut. Verily's overall sales are not disclosed by Alphabet. Evercore ISI analyst Kevin Rippey estimated 2020 \""other bets\"" overall revenue at about $650 million, with Verily contributing under $175 million. The former executives described Verily's actual revenue as higher, and another analyst suggested $200 million to $300 million as more realistic. 'WE HAD TO HELP' Spun out of Google in 2015, Verily develops devices and software aimed at improving data collection, treatment, research and patient care. It has enjoyed bursts of revenue from collaborations with healthcare companies, including work with DexCom Inc DXCM.O on a miniaturized blood glucose monitor and a scuttled, high-profile experiment with Alcon AG ALCC.S to create a smart contact lens for similar measurements. But Verily's financial future hinges on software products led by Baseline, which helps drugmakers enroll participants for clinical trials and analyze study data. It aims to reduce paperwork and site visits compared with traditional methods. Mega said the company refashioned Baseline to schedule coronavirus tests after governments such as California started asking for help. The software also powers scheduling for 460 Rite Aid Corp RAD.N pharmacies, which provide testing as part of a partnership with the Department of Health and Human Services. Baseline enabled about 2 million people to get tests nationwide last year, she said, a fraction of the 250 million administered overall. Dr. Vivian Lee, Verily's president of health platforms, said government COVID-19 projects helped jumpstart separate testing software dubbed Healthy at Work and Healthy at School. The new tools have 20 customers between them, including Brown University and some biotech companies, Verily said. The University of Alabama, Birmingham has spent $6.9 million on Healthy at School, according to previously unreported records. Ralph Zottola, an assistant vice president at the university, said it is considering Verily for software to validate whether students have been vaccinated because the company has been \""a good partner.\"" When the need for coronavirus testing software ends, Verily aims to transition some new customers to Onduo, one of its core offerings alongside Baseline. The program includes sensors, diet coaching and other personalized tools that insurers and employers can provide for managing chronic diseases and general wellness. Onduo counts Walgreens Boots Alliance Inc WBA.O and insurers such as CareFirst as customers. Still, both Onduo and Baseline remain very small players in medical software markets researchers say are worth over $100 billion in the United States annually, and some larger rivals like Teladoc Health Inc's TDOC.N Livongo and Omada Health Inc did not divert resources to the pandemic last year. Livongo, which directly competes with Onduo, reported sales more than doubled to $267 million during the first three quarters of 2020 compared with same period a year earlier. Mega defended Verily's moves during the greatest public health crisis in a century. \""Across the company, we've raised our hands,\"" she said. \""There was an opportunity, we had to help, but it's accelerating our core business.\"" (Reporting by Paresh Dave; Editing by Jonathan Weber and Bill Berkrot) ((paresh.dave@thomsonreuters.com; 415-565-1302;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-01-26,94.4225,94.46,90.065,90.355,
DXCM,2021-01-27,89.925,90.3025,87.25,87.41,"Forget FAANG, Buy These 2 Ultra-High Growth Stocks Instead Investing in FAANG stocks -- Facebook, Apple, Amazon, Netflix, and Google (Alphabet) -- is often an easy decision for growth investors. These are the top tech stocks in the world and they continue to rise in value. They all soundly outperformed the S&P 500 and its 16% returns in 2020, with the worst-performing stock, Alphabet, rising 31% while Apple soared 81%. But the problem with investing in those stocks is that they may not have as much growth potential left. Apple, for example, posted an incredible $274.5 billion in revenue in its most recent fiscal year, but that was just 5.5% higher from the previous year's total. For even better growth opportunities, investors should look outside of FAANG. Two stocks that look to be more promising buys are Roku (NASDAQ: ROKU) and Teladoc Health (NYSE: TDOC). Image source: Getty Images. 1. Roku Roku's streaming platform and devices have been rising in popularity amid the COVID-19 pandemic. Sales of $1.1 billion over the past three quarters are up 57.2% from the same period a year ago. Revenue from its hardware (or player segment) have grown by 40.3% while sales related to its streaming platform are up by 65.6%. On Jan. 6, the company announced it reached a milestone in 2020 -- ending the year with more than 50 million active accounts (51.2 million in total). For all of 2020, users streamed 58.7 billion hours of content, which was a year-over-year increase of 55%. And there could be even more growth ahead for the California-based business. It recently announced that it acquired Quibi's distribution rights all over the world. Quibi focuses on content that's no more than 10 minutes in length. And although it never gained much popularity since launching in April, it will likely bring more eyeballs to Roku's platform, and it could bring in more ad revenue for the company. There is tons of growth potential for Roku, certainly more than you might get from a FAANG stock, and that's why this is a company that you should consider adding to your portfolio today. 2. Teladoc Health Telehealth giant Teladoc has enjoyed strong growth amid the pandemic as patients make the most of its convenient technology. Through virtual visits, they can connect with physicians even if they're unable to physically visit the doctor's office due to shutdowns and COVID-19-related restrictions. But Teladoc isn't just a good investment during the pandemic. The growth in the telehealth sector could be here to stay, even if COVID-19 isn't a concern anymore. Fortune Business Insights estimates that the telehealth market will grow to a value of $559.52 billion by 2027, which is more than nine times the $61.4 billion it was worth in 2019. And after merging with Livongo Health last year in an $18.5 billion deal, Teladoc is in an even stronger position to benefit from that growth. Its business was more general in nature, focusing on regular, day-to-day visits with the doctor. But Livongo's business is more specialized, focusing on chronic care and providing services like diabetes coaching for its patients to help them stay on top of their illnesses. Combined, the companies can provide patients with a broader scope of telehealth services. Earlier this month, the company also announced it would be partnering with DexCom, which makes continuous glucose monitoring (CGM) systems. Teladoc will now provide its users with ""CGM-powered insights"" to help them see and monitor their glucose levels. What's impressive is that while Teladoc will benefit from the aforementioned partnerships, its core business is also still showing strong growth. The company released its third-quarter earnings on Oct. 28, 2020 (just days before it officially closed on its deal with Livongo). Sales for the period ended Sept. 30, 2020, totaled $288.8 million, more than double the $138 million it posted in the prior-year period. The total number of telehealth visits of 2.8 million grew by a staggering 206%. Teladoc is an exciting healthcare stock, not only because the business is benefiting from growth in the telehealth sector, it's also making key moves to fortify its market share. Last year, its shares soared 139% and this year it's already up over 40% -- well above the modest 2% gains the S&P 500 has made thus far. And yet, it still may not be too late to invest in the stock given the opportunities ahead. 10 stocks we like better than Teladoc Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Facebook, Netflix, Roku, and Teladoc Health. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-01-28,88.3225,92.2425,87.625,91.7225,
DXCM,2021-01-29,90.6425,94.765,89.95,93.7125,
DXCM,2021-02-01,94.0875,96.6475,93.25,95.655,"Bullish Two Hundred Day Moving Average Cross - DXCM In trading on Monday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $382.15, changing hands as high as $384.94 per share. DexCom Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $182.07 per share, with $456.23 as the 52 week high point — that compares with a last trade of $382.95. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-02-02,96.8075,100.412,96.3,98.6575,"Healthcare Investors Will Want to Hear This Industry Expert's Advice In a sector full of confusing scientific data, seemingly endless clinical trials, and hefty competition, it can be difficult to pick the healthcare stocks that will soar. But there are some trends that investors can follow -- think telehealth services offered by companies like Teladoc Health (NYSE: TDOC) and American Well (Amwell) (NYSE: AMWL), as well as at-home monitoring solutions from diabetes-focused Dexcom (NASDAQ: DXCM) -- that might just lead you toward riches down the road. Ruby Gadelrab is CEO and Founder of MDisrupt, a platform that connects digital health companies to the scientists and healthcare industry experts they need to build, commercialize, and scale health products quickly and responsibly. Ruby joined Olivia Zitkus and Corinne Cardina of Fool.com's Healthcare and Cannabis Bureau on a Jan. 22 episode of Fool Live, where she gave her advice to healthcare investors for 2021. 10 stocks we like better than Teladoc Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Corinne Cardina: Can you share three takeaways for investors thinking about buying healthcare stocks in 2021? Ruby Gadelrab: Yes, look at the trends, I think we talked about the trends before, but they are telemedicine, virtual care, COVID solutions for back to work, at-home testing and monitoring solutions, behavioral and mental health, and fintech. The one thing I would say as well if I was to give one tip from our experience here is look at health companies or digital health companies, where they have a good balance of medical folks, scientific folks, and tech folks because it's the combination of all of those things together that is going to get a health product to market safety, quickly, and responsibly. Corinne Cardina owns shares of Teladoc Health. Olivia Zitkus has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-02-03,98.1175,98.75,95.7648,97.9225,
DXCM,2021-02-04,98.87,102.025,98.21,100.812,
DXCM,2021-02-05,102.005,103.06,101.0,102.758,
DXCM,2021-02-08,103.695,103.75,100.654,100.825,
DXCM,2021-02-09,101.438,102.0,99.4525,100.258,"[""2 Investors Share Their Biggest Investing Mistakes Buying great stocks is only the first step to building wealth, and it's probably the easiest part. Once you have solid companies in your portfolio, holding them for the long term can be challenging for investors. It's tempting to sell out of stocks after some early gains, but \""locking in\"" your gains may shortchange your future wealth. Two Fool.com contributors, Brian Withers and Brian Feroldi, share their biggest investing mistakes on this Motley Fool Live episode, recorded on Jan. 17, and discuss how doing nothing is often the best course of action for investors. Find out why Netflix is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* Tom and David just revealed their ten top stock picks for investors to buy right now. Netflix is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of November 20, 2020 Brian Withers: All right. Well, selling too soon can be hazardous to your returns, to your wealth. A little story about Netflix (NASDAQ: NFLX). I was an early buyer. I became a customer in 2004, 2005-ish time and you can see the prices that I bought Netflix at. Just unheard of at this point. Although, when I bought them, the stock had split since then, so it wasn't those prices that I bought it at. I bought a bunch, seven times there. Also, during that process, it became the No. 1 holding in my portfolio at about 23%. That really freaked me out a little bit. I was still early in investing and as the stock ran up in 2009 and 2010 out of the financial crisis, it was really just taking off. The business was doing very, very well. There'd be a certain dollar amount that I was like, if it goes above this, I'm going to sell some, and it went above that, and I sold some down to that dollar amount and then it went up again. So I did that for a little while, and then eventually, it was just like, I can't deal with this anymore. But prices that I got were tremendous. There was gains all along the way. Some were, I think close to even a 20-bagger along the way. But you guys know what happened to Netflix since then. Just absolutely incredible run. This was a multi-million-dollar mistake. Had I even just kept a few shares, I would've been much much better off today. Brian Feroldi: Started with a painful one right out of the gate, yeah? Withers: Get that one out of the way. Feroldi: Now let me ask this, Brian. Obviously, knowing what you know now, you would go back and put 100% of your portfolio in Netflix and make it the only stock that you own again and again and again. Withers: Yeah. I don't know. Feroldi: That's the wonderful thing about hindsight, right? Withers: Yeah. Well, you can see even after I sold out, here was the Qwikster debacle, I missed that whole thing altogether. I can't imagine holding through that. Even some of these gyrations in here, Netflix has been a tough one to hold if you watch it [the stock price] too often. Feroldi: Well, let me ask you this. So this was 23% of your portfolio in 2007? Withers: Yeah. Feroldi: Again, doing nothing was the right thing to do. Withers: Yeah. Feroldi: Wouldn't this be 99% of your portfolio now? Withers: Yeah. These holdings, eclipsed my entire portfolio by at least double. Feroldi: There you go. Withers: Yeah. Feroldi: I 100% agree with the lesson there, but there's also the risk balancing. We're looking at this with the benefit of hindsight and saying, obviously, you should have just held. When you're going through day-by-day, it's tricky. I'm going to revisit this lesson later. [laughs] Withers: Yeah. I think the biggest thing for me, I totally get trimming a large position. I know if it climbed up to 50 and 75% of my portfolio, I never would've been able to hold that. But the fact that I sold out everything all together, I think that was really the waste in that one. Feroldi: All right, well, Brian, bared with his soul about his worst investing decisions, here's mine, I bought American Tower at 60. Withers: You sold it at 60. Feroldi: Excuse me. Yes. I bought American Tower at like 20, 25, 30, and I think at a Motley Fool recommendation, it went to 60. Brian, it had a high price-to-earnings ratio, I was like, \""Time to get out of this thing.\"" Thesis done. And then it four-bagged. The worst mistake I ever made is with Dexcom. With my previous job, I had a ton of exposure to Dexcom. I saw its product firsthand. I saw how fast that it was selling, and I bought a couple of shares, and then I sold them later that same year in a 20% profit. Oops, [laughs] because that has been a 50-bagger since selling. I've made the same mistake with Microsoft. Microsoft is an eight-bagger from when I sold it. I mean, that's a remarkable thing to say. Microsoft, because that was like 2012, 2011 that I sold it. Something like that. Paychex, Insulet, and Waste Management. Patience is your biggest edge. Withers: Do you have Dexcom now? Feroldi: I don't. Withers: My sister recently bought some just because it's doing all sorts of pioneering stuff and still has plenty of runway. Feroldi: Agreed. It's [laughs] interesting, it's the super fast-growing company. To me, Dexcom is my example of when expertise can be [a] bad thing. Because I know all of the reasons that I know Dexcom's competition so well and I know all of the reasons that it shouldn't work, that I've never been interested in rebuying, and I should have. Because of my expertise in diabetes, I also missed Livongo. Withers: Wow. Feroldi: I listened to some industry insiders who are like, this is like snake oil salesman, this business model has been tried. It doesn't work. Livongo was an eight-bagger in seven months, something like that. That's where expertise can work around you. But the key point here is, your biggest edge as an individual investor is patience. It's a massive edge that you have over the rest of other investors. You are not beholden it to anybody else, so you do not have to buy or sell on any given time frame other than your own. Patience is your biggest edge. If you found a high-quality company, just own it. Withers: There you go. Be patient not to lock in gains or even just sell that and move on to something else, right? Feroldi: That's right. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool\u2019s board of directors. Brian Feroldi owns shares of American Tower, Microsoft, and Netflix. Brian Withers owns shares of Livongo Health Inc and Netflix. The Motley Fool owns shares of and recommends American Tower, Microsoft, and Netflix. The Motley Fool recommends DexCom, Insulet, and Waste Management. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can DexCom Stock Gain More After A 10% Rise In Last 5 Days? The stock price of DexCom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has risen by 10% over the last five trading days. Earlier in January, the company reported strong preliminary numbers for Q4, with an estimated top-line growth over 20% y-o-y. The company will report its Q4 and full year results on Thursday, February 11. However, what has kept the stock buzzing over the past week was its first ever commercial for Super Bowl, starring Nick Jonas. The commercial calls for better care for people with diabetes without pricking fingers to measure their glucose levels. The commercial is aimed to increase awareness of DexCom\u2019s G6 CGM at one of the most watched sports events in the U.S. The 10% rise in DXCM stock compares with just 2% growth seen in the broader S&P 500 index. Now, is DXCM stock poised to gain further? We think so. We believe that DexCom will continue to benefit from its advanced CGM systems with ease of monitoring at home, compared to clinic visits or other CGM devices that require finger pricking. There is a 61% chance of a rise in DXCM stock over the next month (twenty one trading days) based on our machine learning analysis of trends in the stock price over the last five years. See our analysis on DexCom Stock Chances of Rise for more details. Curious about the possibility of rising over the next quarter? Check out the DXCM Stock AI Dashboard: Chances Of Rise And Fall for a variety of scenarios on how DXCM stock could move. 5D: DXCM 9.9%, vs. S&P500 2.4%; Outperformed market (7% likelihood event) DexCom stock rose 9.9% over a five-day trading period ending 2/4/2021, compared to the broader market (S&P500) rise of 2.4% A change of 9.9% or more over five trading days is a 7% likelihood event, which has occurred 94 times out of 1256 in the last five years 10D: DXCM 9.7%, vs. S&P500 0.7%; Outperformed market (30% likelihood event) DexCom stock rose 9.7% over the last ten trading days (two weeks), compared to broader market (S&P500) rise of 0.7% A change of 9.7% or more over ten trading days is a 30% likelihood event, which has occurred 380 times out of 1240 in the last five years While DXCM stock could gain more, 2020 has also created many pricing discontinuities which can offer attractive trading opportunities. For example, you\u2019ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. See all Trefis Price Estimates and Download Trefis Data here What\u2019s behind Trefis? See How It\u2019s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Team The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-02-10,101.608,101.608,99.045,99.86,
DXCM,2021-02-11,101.155,102.765,99.7875,102.55,"[""Dexcom Inc (DXCM) Q4 2020 Earnings Call Transcript Image source: The Motley Fool. Dexcom Inc (NASDAQ: DXCM) Q4 2020 Earnings Call Feb 11, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Dexcom Fourth Quarter and Full Year 2020 Earnings Release Call. My name is Daryl, and I'll be your operator for today's call. [Operator Instructions] I will now turn the call over to Sean Christensen. Sean, you may begin. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Thank you, operator, and welcome to DexCom's fourth quarter and full year 2020earnings call Our agenda begins with Kevin Sayer, DexCom's Chairman, President, and CEO, who'll provide a summary of the quarter and full year 2020, followed by a financial review and outlook from Quentin Blackford, our COO and CFO, and then a strategic update from Steven Pacelli, our Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we'll open the call up for your questions. At that time, we ask analysts to limit themselves to one question, so we can provide an opportunity for everyone participating today. Please note that, there are also slides available related to our fourth quarter performance on the DexCom Investor Relations website, on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof, based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP, with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our fourth quarter and full year earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Sean, and thank you everyone for joining us today. Let me start by summarizing, some of the things that DexCom accomplished in 2020. Total revenue grew 31% over 2019, driven by a record number of new patient additions. This translates to more than $415 million in absolute dollar growth and other high watermark for DexCom. We doubled G6 capacity in the first six months of the year. Our team has done a great job to meet the ambitious plans that we outlined nearly two years ago to scale G6 capacity, leaving the company in the best inventory position that we have been in since the launch of G6. The scaleup led to strong gross margin expansion in 2020 even as we increasingly shift our business to the pharmacy channel. We closed the full year 2020 with our highest gross margin since 2017. Our enhanced capacity puts us in position to aggressively pursue our growth initiatives. This includes the expansion of our sales force, which we announced in October and have nearly completed, as well as our efforts around product sampling and direct-to-consumer advertising in the U.S. and international markets. Many of you have seen our most recent effort to drive category awareness as we kicked off a new campaign around one of our DexCom warriors Nick Jonas, including our ad during the Super Bowl. This bold effort should give you a sense for our belief about the market opportunity ahead of us. We received great feedback from the campaign so far and look forward to joining forces with Nick and diabetes advocacy groups in the coming months, to drive greater awareness of the benefits of CGM. At the heart of the pandemic's first wave, we established a new effort in a matter of days to support hospitals needing to preserve personal protective equipment and utilize our remote monitoring technology. We've made significant progress in our work to bring Dexcom's CGM to people with type 2 diabetes, including both those on intensive insulin therapy and those who are not. We also announced several new initiatives in 2020 that we believe will position us to meet the kinds of patient growth that we expect over the next several years. Building on the success of our team in Manila, where we strengthened our customer service metrics across the board, we announced a new global business services unit in Lithuania that will help serve our international operations. We also announced that we will be building our third manufacturing site and first international manufacturing site in Malaysia. This state-of-the-art facility will be key to scaling our G7 capacity and provide logistical advantages as we look to serve our growing international base. Speaking of G7, 2020 saw us initiate and complete the first G7 pivotal trial. We're very happy with these results, and the feedback we've received from participants and clinicians involved in the trial, has been outstanding. Our clinical work is continuing as we progress with the regulatory path in 2021 to support our goal to launch G7 in the second half of the year. In any given year, these are accomplishments that we would be proud of. But in 2020. our teams accomplished these goals during a global pandemic. I want to use this forum again to say how proud I am of the DexCom employees who have embraced our mission to empower people to take control of diabetes in a year of very unique challenges. It is a privilege to both lead and learn from such a talented team. And rest assured, our team is focused on the growth opportunity ahead of us as we're now well on our way in 2021. This is shaping up to be another exciting year for the Company featuring our continued momentum as we look to bring G6 to many potential customers yet to use CGM. The ongoing manufacturing scaleup and launch of G7 and investing in several other key initiatives related to the growth pillars that we outlined at our recent Investor Day. We believe there is still a huge growth opportunity ahead and we are investing to ensure that the Company is positioned to deliver CGM as a mass market technology for greater health outcomes. The pandemic has contributed to the structural changes in the way healthcare is delivered with DexCom CGM, a valuable asset in the growing digital health and a remote monitoring healthcare ecosystems, yet a majority of people with diabetes in the world continue to rely on finger stick technology. It is because of these developing landscapes and our belief in what DexCom CGM offers that we're announcing the formation of DexCom Ventures today, which Steve Pacelli will lead. With this entrance into the venture capital space, we believe we will be able to accelerate development for innovative companies to share our commitment to empowering greater health outcomes for customers and their clinicians. This may include technologies with use cases that can be combined with our CGM system, as well as independent technology platforms. To summarize, we are very proud of what we accomplished in 2020 and are moving forward with the same commitment to our users and the growth in DexCom well into the future. With that, I will turn it over to Quentin for a review of the fourth quarter financials and discussion of the 2021 outlook. Quentin? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. We reported worldwide revenue of $568.9 million for the fourth quarter, compared to $462.8 million for the fourth quarter of 2019, representing growth of 23%. Our team did a great job maintaining momentum with new patient additions in the fourth quarter and accelerating our shift of the business into the pharmacy channel. Even with the increasing COVID lockdown as the quarter progressed, new patients for the fourth quarter were in line with our original expectations for the year, a new record and a great achievement for our team. U.S. revenue grew 20% over the fourth quarter of 2019 totaling $451 million. We were able to drive more volume into the pharmacy channel than we originally expected, closing the year approaching 50% of our total U.S. commercial volume. This means that we are making excellent progress to position the Company for long-term growth in the U.S. in an efficient operating model for the Company. And while there is channel mix causing lower revenue per patient in the pharmacy channel, the underlying strength of the business saw fourth quarter unit volumes grow significantly more than our revenue growth rate in the U.S. Our international business reached a new high watermark of $117 million in the fourth quarter of 2020 growing 35% over the fourth quarter of 2019. This growth includes strong performance in both our direct and distributor markets. We began an international DTC campaign in several of our markets in the fourth quarter and we'll continue to drive awareness of the benefits of our technology, knowing that CGM market penetration internationally remains even less than in the U.S. Our fourth quarter gross profit was $399.1 million or 70.2% of revenue compared to 66.8% of revenue in the fourth quarter of 2019. The 70.2% of revenue represents our highest gross margin quarter in the past five years. This is another demonstration of the ability of our team to navigate our strategic shift to the pharmacy channel while delivering strong profitability across the organization. As Kevin noted, our successful scaleup of G6 has been a key driver of this margin expansion, while also placing us in our strongest inventory position to date, allowing us to more aggressively target new users as we continue 2021. Operating expenses were $294.7 million for Q4 2020 compared to $205.7 million in Q4 2019. The year-over-year expense growth in the fourth quarter consists of several key areas of strategic investment, which includes roughly $15 million of nonrecurring spend related to enhancing our software development efforts and automation of our production capabilities. We also increased spending related to our DTC programs, product sampling and the expansion of our U.S. sales force. Even with significant investments throughout 2020 to prepare Dexcom for future growth and efficiency, total operating expense growth for the year totaled 26%, well below our 31% revenue growth for the year. Operating income was $104.4 million or 18.4% of revenue in the fourth quarter of 2020 compared to $103.6 million or 22.4% of revenue in the same quarter of 2019. For the year, we delivered more than 500 basis points of operating margin expansion with full-year 2020 operating margin of 16.6%, exceeding our most recent guidance. Adjusted EBITDA was $159.2 million or 28% of revenue for the fourth quarter, compared to $141.7 million or 30.6% of revenue for the fourth quarter of 2019. Our full-year adjusted EBITDA margin of 26.3% also exceeded our most recent guidance and came in more than 300 basis points better than our original 2020 guidance. As our margin progress shows the significant steps that we have taken over the past few years are having a great impact on our ability to translate revenue growth into profitability. We are confident that the trend will continue over the long term as we move toward the five-year targets that we laid out for you at our recent Investor Day, while simultaneously taking opportunities that arise to invest in the growth ahead of us. Net income for the fourth quarter was $90.4 million or $0.91 per share. We significantly increased operating cash flow in 2020 and remain in a strong cash position, with greater than $2.7 billion of cash and cash equivalents on the balance sheet as we exit the year. This gives us the flexibility to pursue the strategic investments that we believe will allow us to maintain a leadership position in our field. These include some of the investments we discussed related to our fourth quarter activities. Turning to 2021 guidance. As we stated early last month, we anticipate full year revenues of $2.21 billion to $2.31 billion, representing growth of 15% to 20%. We expect new patient growth to continue to exceed our revenue growth rate again in 2021 with our team, extending their efforts to drive U.S. commercial business into our preferred pharmacy channel. We've also contemplated potential benefits from our efforts to drive category awareness through our expanded sales force, DTC advertising, product sampling and integrated systems as well as general considerations around the competitive environment. Turning to margins, we have several considerations in 2021 as we position the business for efficient growth and long-term margin expansion in line with what we outlined at our recent Investor Day. For 2021, we anticipate gross margins of approximately 65% in line with our long-term expectations. This anticipates a slight shift from our 67% full year 2020 result, which we expect to be driven by the success of our pharmacy channel initiative as well as our 2021 investments in infrastructure related to our G7 scaleup and our U.S. manufacturing facility in Malaysia. We expect operating margins of approximately 13% reflecting our gross margin outlook as well as various investments we've contemplated in 2021. As you know, Dexcom has advanced its profitability profile at a much faster pace than originally anticipated over the past few years while at the same time building the infrastructure to scale the business profitably. With the diabetes market still under-penetrated, we're going on the offense with these investments. We are continuing to invest in the growth of the business via DTC, sampling, new markets and the launch of new products that we mentioned at our Investor Day, including G7. We are also making a significant investment in the global sales force, including doubling the size of our U.S.-based commercial field team. We will also continue to work on advanced research and development, which is looking into future generations of products and sensing capability. We're making these investments to accelerate our ability to bring CGM to those in need. Additionally, we believe these investments will support the long-term profitability objectives that we set at Investor Day, while at the same time yielding significant returns for our shareholders. However, in the near term, we want to be prudent about incurring these upfront cost in our guidance and let the benefits play out. We expect that adjusted EBITDA margins will be approximately 23% for 2021. Finally, with the release of the valuation allowance on income taxes in 2020, in 2021, we will start to have a tax rate that is applicable to earnings. We expect that rate, absent any changes in tax laws, to be in the low to mid 20% range. With that I will now turn the call over to Steve for a strategic update. Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Thanks, Quentin. As Kevin mentioned, our team did a great job executing on our strategic priorities throughout 2020. We quickly adapted to changes brought about by COVID, and ensured not only that our existing patients could rely on their DexCom supplies, but that thousands of new patients could benefit from the use of G6. In fact, we closed the year with greater than 900,000 customers globally up more than 38% over the end of 2019. We are excited by this growth knowing the life-changing impact that CGM and the software tools that we provide with it can have on our patients. Just last month, we published three peer-review studies in diabetes technology and therapeutics, that showed a greater than one point A1C reduction for customers new to DexCom's CGM in as little as three months. This study includes both type 1 and type 2 intensive insulin users, and the result validated the kind of outcomes we have seen before. But we took it one step further. We also saw a significant quality of life improvement for these patients as measured in terms of anxiety, emotional distress and burden of disease management. Results that affirm our corporate mission to empower our users. We also demonstrated that the software tools we are building around our sensors are driving improved outcomes. Across our base, we see increased time and range for our users of real-time share and Follow Apps, we see increased time and range for users who engaged with our CLARITY software, and we see increased time and range for users who take advantage of our integration with Apple's Siri virtual assistant. In 2021, we will continue to work aggressively to expand our customer base so that more and more people can experience these improved outcomes with DexCom. As we outlined in our recent Investor Day and at the conference presentation last month, we prioritized three pillars of growth in the near term and look forward to progress on all three fronts in 2021, while we also lay the foundation for longer-term market expansion. In our core business, which we defined as people with type 1 diabetes and type 2 diabetes on intensive insulin therapy, we have several initiatives under way. In the U.S., we are nearing completion of our sales force expansion, which will enhance our footprint across the country, including our reach into primary care offices. We'll continue our push to prioritize the pharmacy channel, which is the most efficient channel for our patients, clinicians and DexCom. And we'll continue our efforts to drive greater access on the awareness of the benefits that DexCom offers, including the DTC campaigns that we've been driving in both the U.S. and international markets. Outside the U.S., we continue to advocate for greater access in several key markets and look forward to broadening our reach in places where we have had little presence to date. This includes our expansion in France building from a positive recent reimbursement decision as well as the launch of G6 in Japan with Terumo as our distribution partner. For our third pillar, expanding the use of CGM in non-intensive type 2 diabetes, we are extending our efforts with Level 2 and kicking off commercial pilots with multiple partners on the digital health side. Our work with other providers continues as well as we make the case for the clinical value of DexCom CGM in the broader type 2 population. Recently, Everside Health, one of the nation's largest providers of onsite health clinics, announced that their health debt unit will make DexCom CGM available to their members with type 2 diabetes. This is a nice extension of our previous work with Healthstat following up on our pilot efforts that utilize CGM in an onsite health screening program. We remain increasingly confident in the market opportunity ahead for DexCom, and on this basis, today we announced the formation of DexCom Ventures. We have a chance to identify and accelerate the development of amazing technologies. Technologies that can truly make an impact to global health outcomes via innovation. I could not be more excited to lead this effort. I believe we are well positioned to advance our strategies and build connections that will make DexCom stronger in the years ahead. Look for much more from us on this front over the next several years. And in the meantime, I couldn't be more pleased to pass the torch on our day-to-day strategy and corporate development efforts to Quentin and his team. With that, I'll turn it back to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Steve. I think we've all grown tired of the 2020 superlative, so I'll keep this one brief. We're proud of what we accomplished in 2020 and we are pressing forward with excitement for the year ahead in 2021. Much of the discussion this week is centered around our recent Super Bowl ad. We were incredibly pleased by the public response, which drove 11 times greater search volume compared to the average 2021 Super Bowl commercial, the highest of any brand that advertised this year. This is why we did the ad, to drive awareness and ultimately bring CGM to more and more people who stand to benefit from this technology. There may be more people talking about diabetes this week than any other time in recent memory, a conversation that includes healthcare providers, insurance providers and people with diabetes themselves. We welcome these conversations and look forward to advancing these discussions for greater access for all people with diabetes. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions and Answers: Operator [Operator Instructions] And our first question comes from Robbie Marcus from J.P. Morgan. Go ahead, Robbie. Robert Marcus -- J.P. Morgan Chase & Co. -- Analyst Great, thanks for taking the question. So I'm going to use my one, Quentin. The guidance came in a little lower on the margin side for 2021. Can you walk us through what's the delta on gross margin and those expenses? I realized a long-term guide is 65%. But I think people were thinking a little bit higher in 2021 here. And then, it seems like to get to 13% you're going to need a pretty big step-up in SG&A. So maybe just help us walk through SG&A and R&D and what you're expecting in terms of investment, how much DTC will be net -- 2021 versus 2020, and any other notable expenses that we should be thinking about. Thanks. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Sure. Thanks, Robbie. Look, I think the first thing I would mention is, we've made incredible progress from a profitability perspective over the last couple of years. If you think back to our original Analyst Day, we set an expectation to be at a 25% EBITDA margin by the year 2023 and we delivered 26% EBITDA margin in the year 2020. So we've made incredible progress. And I would say progress even accelerated or went beyond what our original expectations were. But we've always known there are investments we've got to make in this business to open-up some of these incredible market opportunity that's sitting in front of us. And I think more than anything, the fact that we're making these investments ought to be a testament to the fact that we now believe in and we're seeing that these are going to be real opportunities for us. So we're excited about making that investment. On the gross margin side, there's a few things to point out this year that makes 2021 a little bit unique. One, we will continue to drive the normal efficiencies and leverage through the gross margin that we have in the last several years. And I I would expect there's a couple hundred basis points of efficiencies to continue to take out of it over the course of '21. But there's two headwinds that we have to navigate through. One continues to be the move to the pharmacy channel, we expect that we'll see a significant move over the course of this year. We've seen that pickup in terms of its momentum in the back part of last year. The other one is, we're making significant investment in standing up our first international manufacturing capability in Malaysia. We broke ground there. We have teams there as we speak, starting to build out that capability, which is going to take what is tens of millions of units of production capacity and turns it into hundreds of millions of units of production capacity for us, which we believe is going to be necessary as we open up these markets and begin to really see results from them. So that's what's going to play out on the gross margin side that that results in a couple of hundred basis points of headwind from the 67% back to 65%. On the opex side, I think it's important. G&A is going to continue to lever nicely for us. Where the investment is going is purely into sales expense and then the R&D and there's really a few drivers that drive it. There's the doubling of the U.S. commercial field force that we've talked about. That's pretty much done as we sit here today. Those resources are going to be in place, and able to start to contribute over the course of the year, but they obviously bring with it an expense load. We're also turning up the DTC efforts. We've never been better positioned from an inventory perspective to really turn the dials on DTC and sampling and giving our commercial team the tools they need to be as effective as possible. So we're excited to be able to do that. And then, finally, I'll just remind you. Over the course of this year, we've got all the G7 expenses that are going on. We got the trial expenses, we got the filing expenses and then we've got the commercial launch behind that as well. So all those things together drive the incremental investment from an opex perspective. But that's all going to show up in R&D and selling expense, you will see leverage in G&A. So hope that answers the question for you. Operator And our next question comes from Jeff Johnson from Baird. Go ahead, Jeff. Jeffrey Johnson -- Robert W. Baird & Co. -- Analyst Thanks, guys. Good evening. Just wanted to follow-up, it's really going back even to the Analyst Day. Quentin, at the time, you talked about seven to eight points of channel headwinds kind of through 2022, seven to eight points annually. I don't think you really talked about whether that would be front-end loaded, back-end loaded, how even loaded that might be over the two years. So one, how much channel headwind are we thinking this year? I think you might have said 10% last quarter for 2021. I just want to check that. And does that then -- if that's the right number, does that imply a fall-off in those channel headwinds then going into '22? If you could just help us out there, understand gating. Thank you. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, great question. 10% -- 10 points of headwinds is the right way to think about it, primarily driven by that pharmacy channel mix shift that continues to move toward the direction that is important for us to be able to scale the business over the long-term. I'd remind you profit dollars are higher in that channel. But yes, there is some gross margin pressure that comes with it. But from a top-line perspective, that's what's driving it is that pharmacy channel, call it roughly 10 points. I do think you'll see that evolve a little bit over the course of the year. Keep in mind, in the first part of last year, we weren't into the pharmacy channel to the same degree that we were as we exited the year. So you've got a tougher comp in Q1 and Q2 and you see that in the growth rates as well. You're going to see tougher growth comps in the first half of '21 that will start to subside in the back half of the year. So I do think that you'll see that evolve a bit as we start to anniversary some of the pharmacy shift that we saw on the back part of '20, into the back part of '21. As we head into '22, look, we'll talk about that as we get out there around that time frame. But I do think there's a couple of years here of stepping through it. Once we're through it, I think you're going to see the unit volume growth of this business is going to be much more reflective of the overall dollar growth. Unit volume growth continues to be incredibly strong. We were up 40% in units in the fourth quarter by the time everything settled out and our unit volume growth in '21 is right around that 25% to 30% growth, so very strong unit growth continue to drive the business. Operator And our next question comes from Margaret Kaczor from Blair, William Blair. Go ahead, Margaret. Margaret Kaczor -- William Blair & Company, L.L.C. -- Analyst Hey, good afternoon guys. Thanks for taking my question. So I'd like to shift maybe a little bit into the non-intensely managed type 2 patients and the consumer health wellness patients. I guess upfront, do you guys have any sense of utilization or annual revenue per patient among these groups? And I guess as you look at the different types of products or devices that these patients might need, is it different than what you've got right now and is that one of the goals I guess with the new venture fund or are there some internal efforts around that as well? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer You know what, Margaret, this is Kevin. I'll take that. The annual revenue profile per patient we think is going to vary based on condition in use case. We believe internally or at least what we discussed internally is for a type 2 non-intensive patient for example, even with a full time use the revenue per year per patient is going to be a lower number, because we're solving a different problem. We're not managing the lives and the health and safety of these patients. But we are making them healthier. And we are giving a better experience and they have and ultimately we will take cost from the system. As far as what that number is going to be, I don't have a number and completely we have numerous models and many of those depend upon the final use cases. I've also said numerous times and I'll stick to this as well. I think the ultimate use case and the way where ultimately price it will be for full-time use for these patients and if they choose to use it left off -- less off then that will be their choice. On their health and wellness side again, many, many more patients, lower annual revenue number, but more interactions with more different people and a completely different distribution channel. With respect to the product, certainly the core technology of sensing glucose from our perspective -- the glucose side will remain the same. As those of you who listened to our Investor Da9y heard when I had my chat with Dr. Peter Attia, we talked about accuracy. And he said, it's actually more important for his patients because if they only go between 70 and 120, 20 points off is a big deal and they'd be making a wrong decision as far as their health and what they eat nutrition wise etc. within accuracy. So we know that fundamental core technology needs to remain accurate. Where we get into different products is the experience that we create, possibly even different wearables based on the category, different places to receive the data. Then, as you look at the new ventures unit that Steve will be working in, then you look at software experiences for patients, data platforms to get data to these platforms, there are possibly other things we could sensor, measure and add to glucose. So we believe these markets are going to require something different. At the end of the day, one-size-fits-all is not going to work for us. As we try and expand and hit the goals we've laid out for everybody in the future, we're going to have numerous experiences for these patient groups. Operator And our next question comes from Matthew O'Brien from Piper Sandler. Go ahead Matthew. Matthew O'Brien -- Piper Sandler Companies -- Analyst Thanks for taking the question. So I guess just to follow up a little bit more, Quentin on the operating margin side of things. I know you're running ahead of expectations on the operating margin side of things, but I think everybody is looking at the guidance here and saying, OK, you're making all these investments in a lot of different things, the sales force and DTC. First of all, how do you measure what's most effective between the two? And then, how does it not just -- you're making these investments basically just to kind of run at the same pace that you've already laid out versus we're making these investments because we think we can even [Technical Issues] potentially a little bit better? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, well, I think we're incredibly excited and bullish on the future opportunities, but at the same time, our approach has always been, we want to see those start to pan out and contribute, and at that point, we'll start to reflect them into guidance. So as we open up some of these new markets and validate that we're able to generate the revenue from them, then hopefully, we've got some very positive updates for you guys over time. I don't think we could be more excited around where we're making these investments. We know for a fact the type 2 intensive space for example, is going to come on to CGM therapy. We're seeing it happen in our results right now. We're starting to see some of it with the non-intensives. As a matter of fact, if you look at our new patient figures, it's led by type 2 patients. So we're starting to see some of that be validated. But in order to reach those patients for example on the sales force side, we've got to be in the primary care physician offices. That's where those patients are seen and that's where our current commercial force does not really play. And so as we've added those resources, that is going to be their primary focus, their primary target. Similarly, on the DTC side, I'll continue to reiterate, there is not a better investment that we make inside the four walls of DexCom today than our DTC efforts. And the returns that we see with the new patients that come out of it, we're very confident that that that's the best investment we can possibly make. Now, will that return on investment per individual per patient start to step down into the future? It may, as they get harder to bring on. Basically, for the time being, we've been very encouraged by that return that we've seen and will continue to pour resources in there until we see that change. So I don't think there's a better place for us to be focusing our efforts right now than to really be building out the commercial force to see the right individuals where the patients are at and to continue to create awareness for these patients as well. Operator And our next question comes from Matt Taylor from UBS. Go ahead, Matt. Matt Taylor -- UBS -- Analyst Hi, thank you for taking the question. So my question is about the international investments really stepping up with the support center and the new investments in Malaysia. I guess, can you talk about the arc at that opportunity, if you could frame anything in France, Japan, and what that means for kind of the future expansion in international, that would be really helpful. Kevin Sayer -- Chairman, President and Chief Executive Officer Thanks for the question. We laid out international as one of our three primary pillars in our Investor Conference. And as you look at the progress we've made, I recently prepared a speech for the sales guys, we're up 10 times where we were five years ago. From $40 million plus to over $400 million for 2020. And by every indicator, one would say, wow, that is fabulous. And in our mind as we look at it, the opportunity is bigger than what we've addressed. And we do need to build infrastructure and we also need to look at doing things more creatively. I think, for example, the Japan partnership with Terumo, whereby we're really letting a partner take our business in that country, that is a medical technology leader in that geography is going to be a great business model for us to watch and looked at. In France, If we get reimbursement for a group of patients, we will invest some there. But we have other international models we're looking at. We literally break down every country and the type of bucket. There is great reimbursement here, here is how we need to attack this one, there is no reimbursement here, and we're making plans across all the geographies. Another key investment internationally is going to be our e-commerce platform. We've had great results every place we've launched it. So in geographies where we're not, where we go, we'll probably go first with an e-commerce platform going forward. And so we're investing on all fronts there. The Malaysia factory is truly an investment in scale for us. It will -- it's going to be ultra modern as is our Arizona manufacturer, so you don't get me wrong, but we learned a tremendous amount in building at Arizona that we can apply to Malaysia, and really put ourselves in a position to whereby we can go after these businesses. One of the things that we often discuss as we sit and discuss the would have, the should have, the could is. And for the better part of a year-and-a-half, as far as capacity, we are selling everything we built. With the opportunity now, with the inventory we have and our ops team being able to build as much as they can, we're thinking we can much more aggressively go after these international markets just on a commercial strategy basis as well, and we're going to going forward. Operator And our next question comes from Jayson Bedford from Raymond James. Go ahead. Jayson. Jayson Bedford -- Raymond James Financial, Inc. -- Analyst Thanks, and good afternoon. You mentioned -- I think Kevin mentioned, the goal is to launch G7 in the second half of this year. Historically you've referred to launching G7 in some markets in '21 and other markets in '22. You didn't say that this time maybe it was implied, but is the expectation that the G7 launch in the second half is a worldwide launch? I'm just wondering what's changed around your G7 launch plans Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Really, Jayson, nothing has changed. We are operating on schedule. We -- as I said, we completed our first pivotal study, and that in turn will provide us enough data to file for CE Mark. We do not have enough data to file in the U.S. for ICGM approval and we're working on that with the studies we have ongoing and that will continue to go on for a while. Much of this is a function of regulatory timeframe studies, COVID letting us into clinic shifts or no. There's still some uncertainty around just pulling out the execution necessary to get the submissions prepared, the abilities of the entities to review it. So, we're marching to our schedule. At the end of the day. We've never been more bullish on the product. I've spoken with investigators and patients who were on our first studies and they're -- like they're done with G6 now. Hey, they do not want to -- to wear it anymore, and we've told them, they have to go back. It is everything that we'd hoped it would be. Anything that G6 does, G7 will do better. And for now. It's just a question of timing, commercial availability, manufacturing, and we're pretty tight-lipped on these milestones as well. I'm just not going to lay out the yellow brick road for everybody to know and see and prepare for, we kind of like to surprise a few people. Operator And our next question comes from David Lewis from Morgan Stanley. Go ahead, David. David Lewis -- Morgan Stanley -- Analyst Good afternoon, thanks for taking the question. Just, Quentin, a quick one from me. You obviously talked about the 10 points of headwinds here in '21, which obviously implies 25% to 30% volume growth. One of your competitors here -- only competitor basically, is talking about 40% growth here in '21, and I just want to think about, given the size of their business, which is a little larger from a volume perspective, and I think about the major investments you're making in DTC, the major commercial investments. How should investors react to your sort of 25% to 30% volume number relative to your larger competitor who's saying they can go 40%? Thanks so much. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, David. Thanks for the question. Look, I think -- my take away is -- I think we all see the market opportunity exactly the same way. There's incredible runway sitting in front of us. There's a lot of adoption yet to be had in the intensive segments of the market and the non-intensive is going to open up as well. Our approach to guidance is probably a little bit different and unique, which is, we're very bullish on some of these new market opportunities and in contributions that can come from them, but we're not going to get ahead of ourselves with respect to those expectations as they play out over time. If that happens in '21, then fantastic, it's going to be a terrific result. If it comes a bit later in '22, it's still going to be a great result. At the end of the day, we're very confident in what this ultimately has the potential look at -- look like, and we're going to make the investments to ensure it's a reality for us. But at the same time, we're not going to get ahead of ourselves. So I think more than anything, you've got two players in this space, who are incredibly bullish on the opportunity which just validates there's a lot of runway here and a lot of opportunity for all of us to have success together. Operator And our next question comes from Marie Thibault from BTIG. Go ahead Marie. Marie Thibault -- BTIG Research -- Analyst Hi. Thank you for taking the questions this evening. My question has to do with the doubling of the sales force. It's certainly an impressive move, so I'm curious about what it means for the legacy sales force in terms of the culture with so many new folks coming on. And are those new folks concentrated in any specific geographies? I know reimbursement is so important to targeting the type 2 patient market. Thank you. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. Thank you. That's a great question. And we have worked very hard to preserve that legacy and that culture and hire the same quality of individuals. I'm actually preparing for our Virtual National Sales Meeting coming up here in a couple weeks. In 2010, we had 26 territories and we're going to 260. And of those 26 territories, you'd be amazed at how many of those people are still here. So they're still a big influence on our Company, on our culture and training, and teaching the new people to come in what's important to DexCom and what or of our values. At the same time, as the business is expanding rapidly, our culture's had to change from time to time. We've made moves over the years, for example, if I go back, we did away with having trainers in every territory in addition to a rep, which was different than everybody else in the industry, but we made that move and it proved very successful. As we go to the pharmacy channel more, as we get access easier, the job of our reps continues to evolve and change, and it's our job to provide them with tools to whereby these jobs are meaningful and rewarding, and they want to stay and they want to be with us. And we're working very hard on that INS expansion, and we're being very thoughtful about it. We had many thousand candidates for these jobs and really feel we picked some fantastic people, not only for the field positions but for some of the leadership positions that were opened up as well. We look forward to meeting with the group and being with them and we have high expectations. Operator And our next question comes from Danielle Antalffy from SVB. Danielle Antalffy -- SVB Leerink -- Analyst Yeah, hi, good afternoon, everyone. Thanks so much for taking the question. And Kevin, I just wanted to clear something up that, it sounds like after the Super Bowl ad, which by the way I thought was a great ad -- I also do love Nick Jonas, but... Kevin Sayer -- Chairman, President and Chief Executive Officer So do we. Danielle Antalffy -- SVB Leerink -- Analyst But there were some controversy, it sounds like -- or I don't know if you'd call it controversy. But just some chatter, it sounds like around, we can't even afford insulin, how can we afford this technology? And we spent a lot of time with you guys at the Analyst Day, talking about how affordable actually, the technology is. Is there just a misunderstanding out there in the market around accessing this technology or where is the disconnect there? Kevin Sayer -- Chairman, President and Chief Executive Officer Well, I don't even know that's the disconnect, Danielle, and we've talked about this a lot, before we decided to run the ad. And we decided that running the ad -- and I'm going to give to this little bit in my closing remarks, but running the ad creating more awareness, getting more people on the technology and more demand would actually lead to more accessibility and ultimately lower cost for patients and get more product to them. But if you look at the life of our patients buying insulin, buying CGM, if they have an automated -- an insulin delivery system, these people spend a lot of money and it's a large percent of their income and it's hard. It's just hard. We empathize with those people. We've done our best with our pharmacies here, for example. And when we gave some of these statistics at Investor Day, I think somewhere about 30% of our pharmacy patients have zero co-pay, and another group of them have less than $60 a month on the co-pay. So, we've done what we can to bring cost down on our side and we've not only done it bringing cost down, but we've done it while improving our margins. So we've really done the best we can here, we do think it is important to acknowledge the community and listen to them, but we also have to run a business and ultimately we felt by making more people aware, we'd have a much more positive effect than negative. Operator And our next question comes from Larry Biegelsen from Wells Fargo. Go ahead Larry. Lawrence Biegelsen -- Wells Fargo -- Analyst Good afternoon. Thanks for taking the question. Kevin, can you talk a little bit about the venture fund, specifically the amount of funding, how broad the focus will be? It sounds like it's going to be broader than diabetes, and when could we see an impact? Thanks for taking the question. Kevin Sayer -- Chairman, President and Chief Executive Officer Well, I'm going to hold Steve to the standard of when he made the investment in tandem many years ago. And our return was several times. No, I'm just kidding. We will focus on diabetes technologies a bit because that's what we do. And there are things in this diabetes or in this healthcare world that can utilize our technology that we don't have time to develop, that we need to look at and be friendly with and we have capital that we can invest. We will also look at other things that could fit into our business and our technology, I don't see us going and acquiring shared interest in 50 different companies that are all over the place, but I do see us with a very focused approach. As far as the level of funding as I've chatted with our board, we're going to leave that open right now for the opportunities that we see, and dip our foot in the water and get going. But we think we have some really good opportunities to give us platforms to expand our business over time and help some of these companies grow. Steve, I don't know if you want to add anything else? Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Yeah, no, the only thing I would comment on is that we're very much approaching this as corporate venture capital or I would tell you kind of strategic venture capital. So certainly while returns are important, although Kevin's holding me to a ridiculous standard out of [Indecipherable], returns aside, look, you're going to see us investing in opportunities that are not only seeking our financial returns, but could have some sort of a technology development piece or an in-licensing of technology piece or potentially commercial aspect to it. So, it'll all make sense. Many of you guys won't actually have a visibility into unless and until we disclose them, but it's an exciting next step for me. Operator And our next question comes from Joanne Wuensch from Citi Bank. Joanne Wuensch -- Citi -- Analyst Good afternoon, everybody and thank you for taking the question. I have one, which is, can you comment if there are any changes on -- or any observations on the competitive landscape and in any particular region that may have shifted slightly more positively or slightly more negatively? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Joanne, I would just say it is a competitive landscape and we remain competitive. We're both us, AVID and quite frankly, Medtronic, every -- all companies are aggressive here. We'll continue to push. We've done very well in all of our markets, we see opportunities to do better. We see opportunities for improvement across the board. We'll continue to do that. I think our Super Bowl ad really achieved the result that we were looking for as far as creating awareness. I mean you heard, 11 times more searches than the average ad. We have an opportunity to drive some awareness and we will do that. But it is a very competitive landscape and it is not -- it's not going to change and we're up for it. We have no problem with that, it makes everybody better. Operator And our next question comes from Mathew Blackman from Stifel. Go ahead Mathew. Mathew Blackman -- Stifel, Nicolaus & Co. Inc. -- Analyst Good afternoon, everybody. Thanks for taking the question. I wanted to touch on the sales force expansion and -- just remind us how quickly those new reps could start to contribute to revenues. And also remind us how's the sales force going to be structured? Are these reps going to call on all clinicians or will somehow be bifurcated between PCPs and and Endos and specialists? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer The way we structure the teams out in the field is very much based upon the number of people with diabetes and intensive insulin users that they see. And that information is readily available through the IQVIA data as far as insulin prescriptions in the various territories. And we use that those geographies in that data to determine how we structure the territories and where we put our people. The people in their territories will be responsible for all of the medical professionals within that group and they will continue to do that. Trying to think, is there -- there is another part to his question. Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development How we structure it. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. And we structure it similar to how we've done in the past, where regions and districts within the sales organization, we've increased the number of districts, the number of regions from two to four. And -- so similar structure that way, and then we've worked out a comp plan that we think is very fair for everybody, and our guys are willing to live with. I think the most interesting piece for me in laying out the whole sales force expansion was how it was received by our team in the beginning. You're always wary of that when you start, and instead the team raised their hands and said, we need more help, we need more exposure here, this is a good thing. They're people we don't call on. So we look forward to it. And as far as time, it takes everybody time to get acclimated to a new position, a new territory. For those who have diabetes relationships and for example, if you hire somebody from an insulin company or insulin pump company, they can go back to offices they've already been to, and they're up and running quite quickly. For others, it takes more time and that's why we have our district managers and our regional managers to help with those relationships and train those people. So there is a time. It varies based on the experience level of the rep before they start with us. Some hit the ground running and go faster than the one before. Others, it takes a little time and we monitor that, we watch and go give those more training, that need it. So it'll be fun to watch unfold. Operator And our next question comes from Ravi Misra. Ravi Misra -- Berenberg Capital Markets -- Analyst Hi, thank you for taking the question. So just wanted to go back to the gross margin and the kind of capex investments and scaleup that you're looking to make. I'm trying to figure out Quentin, and Kevin, you're building all this capacity presumably for the next, I'm guessing decade or so. How do we think about that plan -- sort of plans coming online in terms of -- what level of volume do you think you need to be when it comes to the kind of sales numbers that you put out there for the long term to kind of really truly get those plans to lever the fixed cost investments they've made? I guess, what I'm trying to ask is, our sales ramp faster than we've kind of modeled here. Is there upside to your gross margin conversely, if it's kind of in line with the long-term guidance, what gets that 65 hires that contemplate these capex investments? Kevin Sayer -- Chairman, President and Chief Executive Officer You go first and I'll go after you. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, well I would, Ravi, it's a great question, I'd remind you know the $4 billion to $4.5 billion revenue figure we put out there out in 2025 or so was more or less our base case. That's how we qualified that to you folks and it started to open up a bit of the type 2 non-intensive opportunity. But there's a massive market that sits in front of us, and as we open that up in bigger ways, as you start to open up things like hospital or gestational or get further upstream into the diabetes condition and get into pre-diabetes, those volume numbers are incredible. And so I mentioned earlier, we're talking about going from tens of millions of units to hundreds of millions of units of capability over time and we're beginning to make those investments as we speak. In terms of the capex investment, I think you're going to see roughly double this year what we've seen the last couple of years. We've seen about $200 million of capex in the last two years, each year. I think that is going to be north of $400 million probably as we stand up this building and build out the capability, that will then service for years to come into the future. How quickly we're ramping that is really going to be predicated on how quickly we open up some of these markets. What we're not going to do and we've been very clear about this after having learned from the experience ourselves and we launched G6. We're not going to put ourselves in a position again to where we don't have the inventory to deliver to the patient and create a DexCom experience that is one that we want them to have. And so we are investing ahead of that curve. But we're very confident that the curve is ultimately going to be realized. I think that the question is just nailing down that timing and know exactly what that's going to look like. From our perspective, we're going to be ready when it's ready to go. We're not going to be behind it, so. Kevin Sayer -- Chairman, President and Chief Executive Officer Thanks, Quentin. Let me add just a bit, as I look at volumes and why hundreds of millions rather than tens. As we look at the use of CGM for example as a diagnostic for somebody who may have pre-diabetes, but may not be sure as part of their annual checkup, there is hundreds of millions of people in the U.S. who would need that check up every year. As you look at 30 million people with type 2 diabetes in the U.S. -- I don't know if my 30 millions is right, but it's close. If just 10% of those people went on sensors full-time, you're looking at 60 to 90 million sensors we'd be selling on an annual basis. These opportunities are going to require scale, and we've just made the decision going at this in a manner whereby we do it gradually and hope we have enough when we get there, it's not going to work. The opportunities are too big and the investment is required. That's why we've raised the money, that's why we've made the plans, that's why we've designed the product and set the relationships that we have. We need to go after this. When you look at the size of the investment versus the size of the price, size of the price is way bigger than the size of the investment. Operator And our next question comes from Steven Lichtman from Oppenheimer. Go ahead Steven. Steven Lichtman -- Oppenheimer & Co. -- Analyst Thanks. Hi guys. The increased focus on the primary care office here near term with your sales force expansion, I assume means targeting non-intensive type 2's sooner rather than later. I guess first, how should we think about the ramp in this patient population before reimbursement models are established broadly for these patients? And second, do you have the back office capability yet, I know you're building out some more here to handle those patients over the next few years? Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, this is Kevin, I'll take that one too. Their focus will initially be on insulin using patients who have reimbursement for the technology. The non-insulin users will in fact tag along as they become aware and there are situations where some of these patients who have coverage. On the type 2 non-intensive patient, we've been very clear from the beginning that we're going to go about that in this market four different ways, through programs, payers, clinicians and then directly to patients. And over the course of 2021, you will see those four initiatives unfold as we gather more data and launch more initiatives. And so awareness will grow, as Quentin said earlier and Steve, a very reasonable number of our leads from the Super Bowl ad have been tied to non-intensive patients. Whether we can serve them or not with reimbursement today remains to be seen, but we certainly have a database of these names and people we can call on as soon as we have the product offering, we want to get in that space ready. So I think we're preparing and getting ready for that. More importantly though, as we make these clinicians aware, they can look for cases where they can make it available to their patients, they can look at situations where somebody can appeal for coverage if they have type 2 diabetes and out of control and those appeals have been successful. So we're looking forward to going there and -- but these guys will focus on our core markets and where we play with reimbursement first and foremost. Operator And our next question comes from Kyle Rose from Canaccord. Kyle Rose -- Canaccord Genuity, Inc. -- Analyst Great, thank you for taking the question. So I just wanted to ask a little bit more about just the investments in the SG&A side in in 2021. I think the sales force investments are well understood. But maybe just help us understand specifically on DTC and sampling, how does that change the cost and the timeline of a customer acquisition and then also maybe the capture rate and the retention? Could you just give us some metrics to understand how to evaluate those investments in 2021? Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, well, I think when you look at the overall investment in the areas you identified, the most significant increase is likely going to show up in doubling the size of that commercial field force, and then right behind it is DTC and sampling. Sampling is a bit new to us. We've never sampled historically, we just started to roll that out in the fourth quarter, and very early in seeing what that looks like. But that's a pretty easy one for us to measure. We're not going to give you the specific results of what that looks like. Although, the fact that we're going to continue to double down on it should tell you that we're incredibly happy with what we're seeing. But that's as easy as knowing exactly where we're dropping the samples in the field and knowing exactly what patients are utilizing those samples and ultimately turn into recurring purchase for us, so those are easy measures. And on the DTC side with social media and the leads that get created from that, that ultimately turn into patients that becomes relatively easy to measure as well. One of the things that I think was just really fascinating coming out of the Super Bowl ad is that we had five times more impressions in the last four days than we had it for the entire year of 2020 on the heels of that. I think it's just remarkable, the type of reach that we're finding with our DTC effort. So we're going to continue to monitor those things and measure those and hold ourselves accountable to them and as long as the return is there, we're going to continue to invest aggressively there. If we see the returns start to drop down then we'll start to think differently. But we're not going to give specific return measures those sorts of things, but the fact that we're doubling down in these efforts, I think, got to convey the confidence we have in these investments and what they bringing to us. Operator And our next question comes from Bob Hopkins from Bank of America. Go ahead, Bob. Bob Hopkins -- Bank of America -- Analyst Well, thank you very much, and I appreciate the opportunity to ask you a question. It's getting late so Quentin, I'll just ask a quick one of you. And you may have just answered this in response to the last question, but you said several times in this call how strong in inventory a position your in right now and -- I'm just curious if you could talk a little bit specifically about what you're able to do in 2021 that you weren't able to do in 2020 as a result of that very strong inventory position? Thank you. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Well, look, Bob, I think it's a good question. But historically, I think we've seen opportunities sit in front of us and we knew they were available to us, but we couldn't aggressively pursue them because we knew we couldn't get patient to the -- our product to the patient once they became aware of the opportunity. So what you didn't want to do is create all this awareness and then be in a back order situation immediately. And if you go back to 2019, we operated through most all of '19 in a back order situation and we came out of that early in '20, which has now allowed us to build inventories and put ourselves in a position where we can start to get more aggressive with these things. So I think it enables a whole lot of opportunities for us to get a whole lot more strategic than where we could historically just because those opportunities weren't real, we couldn't serve the patient at that point in time. Now we can. Operator And our next question comes from Chris Pasquale from Guggenheim. Go ahead, Chris. Christopher Pasquale -- Guggenheim Securities -- Analyst Thanks. I wanted to follow up on the question about non-intensive type 2s. Back at the analyst meeting, you set a pretty ambitious goal for that segment to contribute 15% of sales by 2025. Can you tell us what that was in 2020, just as a baseline, and what the gating factors might be for starting to provide more visibility into how you're tracking toward that goal? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. We really can't lay that out for 2020. I think the way you'll get more visibility from us as our programmatic approaches take off, you'll -- we'll be able to speak about revenues from the programs. Additionally, as you look out to 2023, it's my belief and intention '23, '24 and '25, this will see a product that is distributed through our typical distribution channels, and there will be visibility that way. When we have meaningful revenues to report, we'll certainly let you know that that's going on. But we don't -- right now, these are more investments than they are our revenue opportunities. We need to gather data, we need to show that this works, we need to create relationships like we have in Intermountain Healthcare for example, where they're running a study right now to look at CGM in these patients in a couple of different ways. The program we talked about that we ran down in Florida internally, that's now part of one of our programs where Healthstat's offering CGM to their type 2 patients. Up to this point, even though there's been volumes created here, a lot of this stuff has just been really to invest and to learn, similar to what we did in the hospital businesses this year as well. It can take a while for these markets to develop, but eventually we'll break it down in our report more, but for now we're just not ready to. Operator And our next question comes from Raj Denhoy from Jefferies. Go ahead Raj. Anthony Petrone -- Jefferies Financial Group Inc. -- Analyst Great. This is Anthony for Raj. My question would be on gross margin. I'm wondering in the 65% guide for '21, how much trapped overhead actually is in there from the Malaysian plan as that gets up and running? But as you look out and that plant gets up to scale, I'm wondering where the cost per sensor will trend for units coming out of that facility again once it gets up to scale. Thanks. Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Yeah, good question. In 2021, there's about 200 basis points of pressure that we're going to realize from the investments in standing up that Malaysia operating capability. So I think that quantifies for you very clearly what it will be. As we look out into the future, we've said, we believe we can get the cost profile to less than $10 per day in a 10-day use case. So think about that as less than $1 per day. Malaysia will certainly be below that offset by where we're at in the States. So, it certainly is a very attractive profile for us and as we continue to think about ways to innovate there with automation, we are hopeful to take it even further. But that's a big enabler of ultimately getting our cost profile down to those ranges we've discussed both here today and in the past. Operator And we have no more questions at this time. I would like to turn the call back to Kevin Sayer for final comments. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you. I did a bit of math while we were doing this call. This is my 40th call with Steve. And as he moves into a new role, I just need to acknowledge what a wonderful job he's done with our investors over the years. I think back at our calls in the early years where we'd sit around and go, OK, what is it we're going to say today, and what is it that we have to report? This Company has changed so much over those 40 calls, but a marvelous effort and some incredible work. And he'll still be here, but he's going to have some different investors to please, and we're excited about that. I do want to thank everybody for being on the call today. As you can tell, we remain extremely bullish about our opportunities going forward. One of our executives was having a conversation with me here one day and he said -- the way he described DexCom is, just as soon as we climb one mountain and we get to the top of it, and on the other side, there's a bigger one, and we start another climb. And I think as Quentin detailed our financial plans and what we have going on, what we see is a great big mountain and a great big climb, and we're preparing to do that. We think we can do it very effectively. We are very bullish about the future. Over the past several days, a lot of the talk has been around the Super Bowl commercial here, and I have gotten numerous pictures, videos, emails, text messages from our patients and their parents or their caregivers saying, thank you for creating awareness. Kids in school are telling everybody, remember that commercial? I wear that. And I have that and this is how I manage my diabetes. We've seen such a positive reception to this and the positive energy has just been amazing. So kudos to our marketing team, to Nick Jonas and everybody for getting this done. Our hospital initiatives and the new initiatives we've talked about, as I said they're investments, but now we're getting numerous physicians reaching out saying you've got to get this everywhere. It needs to be all throughout the hospital and they should be worn by the patients when they go home. We can't have them coming back, and monitoring glucose can be very important. We'll continue to go after those efforts. Our new market efforts are very strong. And last, I'll go to the intensive type 2s as well. As I said, we created some awareness here. I recently had a conversation. I've had several conversations with people with type 2 diabetes absolutely struggling with what to do. What can I possibly do to take care of myself, because they just don't know. And CGM tells them. It tells then what to do, it tells them about foods, it tells them about exercise, it tells them about stress and sleep and everything else. And we are really excited for this opportunity. You'll see us have a lot of good things come to pass in 2021 on all these fronts. But thanks everybody for continuing to listen, and great day, great year for DexCom and our team. Thanks everybody. Operator [Operating Closing Remarks] Duration: 67 minutes Call participants: Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Kevin Sayer -- Chairman, President and Chief Executive Officer Quentin Blackford -- Chief Financial Officer and Chief Operating Officer Steven R. Pacelli -- Executive Vice President, Strategy and Corporate Development Robert Marcus -- J.P. Morgan Chase & Co. -- Analyst Jeffrey Johnson -- Robert W. Baird & Co. -- Analyst Margaret Kaczor -- William Blair & Company, L.L.C. -- Analyst Matthew O'Brien -- Piper Sandler Companies -- Analyst Matt Taylor -- UBS -- Analyst Jayson Bedford -- Raymond James Financial, Inc. -- Analyst David Lewis -- Morgan Stanley -- Analyst Marie Thibault -- BTIG Research -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Lawrence Biegelsen -- Wells Fargo -- Analyst Joanne Wuensch -- Citi -- Analyst Mathew Blackman -- Stifel, Nicolaus & Co. Inc. -- Analyst Ravi Misra -- Berenberg Capital Markets -- Analyst Steven Lichtman -- Oppenheimer & Co. -- Analyst Kyle Rose -- Canaccord Genuity, Inc. -- Analyst Bob Hopkins -- Bank of America -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst Anthony Petrone -- Jefferies Financial Group Inc. -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable Thursday Option Activity: DXCM, MO, DMRC Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 3,520 contracts has been traded thus far today, a contract volume which is representative of approximately 352,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.2% of DXCM's average daily trading volume over the past month, of 814,095 shares. Particularly high volume was seen for the $450 strike call option expiring February 19, 2021, with 383 contracts trading so far today, representing approximately 38,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $450 strike highlighted in orange: Altria Group Inc (Symbol: MO) saw options trading volume of 34,021 contracts, representing approximately 3.4 million underlying shares or approximately 42.9% of MO's average daily trading volume over the past month, of 7.9 million shares. Especially high volume was seen for the $50 strike call option expiring June 18, 2021, with 4,979 contracts trading so far today, representing approximately 497,900 underlying shares of MO. Below is a chart showing MO's trailing twelve month trading history, with the $50 strike highlighted in orange: And Digimarc Corp (Symbol: DMRC) saw options trading volume of 725 contracts, representing approximately 72,500 underlying shares or approximately 42.9% of DMRC's average daily trading volume over the past month, of 169,170 shares. Especially high volume was seen for the $55 strike call option expiring February 19, 2021, with 370 contracts trading so far today, representing approximately 37,000 underlying shares of DMRC. Below is a chart showing DMRC's trailing twelve month trading history, with the $55 strike highlighted in orange: For the various different available expirations for DXCM options, MO options, or DMRC options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for February 11, 2021 : DIS, ILMN, DLR, DXCM, SGEN, DDOG, VRSN, NET, EXPE, HUBS, AEM, BIO The following companies are expected to report earnings after hours on 02/11/2021. Visit our Earnings Calendar for a full list of expected earnings releases. Walt Disney Company (DIS) is reporting for the quarter ending December 31, 2020. The media company's consensus earnings per share forecast from the 14 analysts that follow the stock is $-0.45. This value represents a 129.41% decrease compared to the same quarter last year. DIS missed the consensus earnings per share in the 1st calendar quarter of 2020 by -27.71%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DIS is 135.45 vs. an industry ratio of 34.50, implying that they will have a higher earnings growth than their competitors in the same industry. Illumina, Inc. (ILMN) is reporting for the quarter ending December 31, 2020. The biomedical (gene) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.21. This value represents a 28.82% decrease compared to the same quarter last year. ILMN missed the consensus earnings per share in the 2nd calendar quarter of 2020 by -13.89%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ILMN is 100.22 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. Digital Realty Trust, Inc. (DLR) is reporting for the quarter ending December 31, 2020. The reit company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.52. This value represents a 6.17% decrease compared to the same quarter last year. DLR missed the consensus earnings per share in the 1st calendar quarter of 2020 by -0.65%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for DLR is 24.07 vs. an industry ratio of 19.10, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM) is reporting for the quarter ending December 31, 2020. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.91. This value represents a 20.87% decrease compared to the same quarter last year. In the past year DXCM has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 46.88%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for DXCM is 130.54 vs. an industry ratio of 33.20, implying that they will have a higher earnings growth than their competitors in the same industry. Seagen Inc. (SGEN) is reporting for the quarter ending December 31, 2020. The biomedical (gene) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.81. This value represents a 468.18% increase compared to the same quarter last year. In the past year SGEN has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 4475%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for SGEN is 53.09 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. Datadog, Inc. (DDOG) is reporting for the quarter ending December 31, 2020. The internet software company's consensus earnings per share forecast from the 8 analysts that follow the stock is $-0.02. This value represents a 0.00% decrease compared to the same quarter last year. DDOG missed the consensus earnings per share in the 3rd calendar quarter of 2020 by -100%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for DDOG is -5777.50 vs. an industry ratio of -463.10. VeriSign, Inc. (VRSN) is reporting for the quarter ending December 31, 2020. The internet software company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.29. This value represents a 2.38% increase compared to the same quarter last year. In the past year VRSN has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 18.25%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for VRSN is 36.67 vs. an industry ratio of -33.20, implying that they will have a higher earnings growth than their competitors in the same industry. Cloudflare, Inc. (NET) is reporting for the quarter ending December 31, 2020. The internet software company's consensus earnings per share forecast from the 9 analysts that follow the stock is $-0.08. This value represents a 20.00% increase compared to the same quarter last year. In the past year NET has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2020 Price to Earnings ratio for NET is -293.26 vs. an industry ratio of -463.10, implying that they will have a higher earnings growth than their competitors in the same industry. Expedia Group, Inc. (EXPE) is reporting for the quarter ending December 31, 2020. The internet company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-2.02. This value represents a 326.97% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2020 Price to Earnings ratio for EXPE is -16.64 vs. an industry ratio of -1.00. HubSpot, Inc. (HUBS) is reporting for the quarter ending December 31, 2020. The internet software company's consensus earnings per share forecast from the 8 analysts that follow the stock is $-0.42. This value represents a 4300.00% decrease compared to the same quarter last year. In the past year HUBS has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 30.61%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for HUBS is -311.36 vs. an industry ratio of -463.10, implying that they will have a higher earnings growth than their competitors in the same industry. Agnico Eagle Mines Limited (AEM) is reporting for the quarter ending December 31, 2020. The gold mining company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.64. This value represents a 72.97% increase compared to the same quarter last year. In the past year AEM has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 14.71%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for AEM is 39.90 vs. an industry ratio of -3.40, implying that they will have a higher earnings growth than their competitors in the same industry. Bio-Rad Laboratories, Inc. (BIO) is reporting for the quarter ending December 31, 2020. The medical products company's consensus earnings per share forecast from the 1 analyst that follows the stock is $3.10. This value represents a 33.62% increase compared to the same quarter last year. BIO missed the consensus earnings per share in the 4th calendar quarter of 2019 by -5.69%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for BIO is 65.76 vs. an industry ratio of 55.10, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Looking For The Best Software Stocks To Buy In February? 3 Reporting Earnings Today Are These The Top Software Stocks To Buy Today? Software stocks have seen a meteoric rise in valuation recently. As more companies go digital and move their infrastructures to the cloud, top software stocks will no doubt enjoy substantial growth. We see how software companies like Zoom (NASDAQ: ZM) and Adobe (NASDAQ: ADBE) have grown over the last year thanks to a spike in demand for their software and services. In fact, the industry enjoyed such growth that many software companies decided to go public amid the pandemic. Software companies with a focus on work-from-home products have been beneficiaries of the global pandemic. The reality is that our demand for software and its related services will still be on a high for the months and possibly years to come. As companies begin to adapt to this pandemic era, the likelihood of going back to how things were pre-pandemic is getting slimmer. Therefore, investors who are looking for the best software stocks to buy [or sell] now so they can capitalize on this market momentum. With that in mind, here are the top software stocks to consider buying this month. Top Software Stocks To Buy [Or Sell] Now Cloudflare Inc. (NYSE: NET) Twitter Inc. (NYSE: TWTR) Datadog Inc. (NASDAQ: DDOG) Dexcom Inc. (NASDAQ: DXCM) Cloudflare Inc. Cloudflare is a web infrastructure and website security company that is based in California. The company specializes in providing content delivery network services, DDoS mitigation, and internet security to name a few. Also, the company claims that approximately 16% of Fortune 1,000 are paying Cloudflare customers. Cloudflare will announce its fourth-quarter fiscal today. With NET stock up over 20% this year, investors clearly have much to look forward to. In the company\u2019s third-quarter financials, it posted total revenue of $114.2 million, which is a 54% increase year-over-year. Cloudflare also reported a strong large customer growth, adding a record of roughly 100 net larger enterprise customers in the quarter, in addition to its first $10 million annual recurring revenue (ARR) customer. The company also ended the quarter with $1.05 billion in cash. Source: TD Ameritrade TOS \u201cOur third quarter represented many significant milestones including surpassing $100M in revenue, crossing 100,000 paying customers, and releasing more than a dozen new products and features,\u201d said Matthew Prince, co-founder & CEO of Cloudflare. With such impressive financials, will you consider buying NET stock ahead of its financials? Read More Best Stocks To Buy For 2021? 4 Fintech Stocks To Watch Are These The Best Tech Stocks To Buy In February? 4 Names To Watch Twitter Inc. Twitter is a microblogging and social networking service in which users can post and interact with messages known as \u201ctweets\u201d. The company is an open service that is home to a world of diverse people, perspectives, ideas, and information. TWTR stock rose by 13% on Wednesday. This came after the company announced its fourth-quarter fiscal on Tuesday. In it, the company reported that its monetizable daily active usage increased by 27% year-over-year at 192 million users. Twitter also reported a strong finish to the year with a revenue of $1.29 billion, up by 28% in the same period. It reflects better-than-expected performance across all its major products and geographies. In the quarter, the company also made significant progress in its brand and direct response products. Source: TD Ameritrade TOS Its strong ad revenue came from mobile app promotion as it brings a new ad format, stronger attribution, and improved targeting. This resulted in a 31% year-over-year increase in total ad revenue. Twitter also said that growth from product improvements reached an all-time high, with additional benefit from an increased global conversation around the coronavirus, the run-up to the U.S. elections, and other current events. With so many good things happening to the company, is TWTR stock a top software stock to buy? [Read More] 4 Top Semiconductor Stocks To Watch Now Amid A Global Chip Shortage Datadog Inc. Datadog offers a monitoring and security platform for cloud applications. The company provides end-to-end traces, metrics, and logs to help make applications, infrastructure, and third-party services entirely observable. These capabilities would then help businesses secure their systems, avoid downtime, and ensure customers are getting the best user experience. DDOG stock has been up by over 25% year-to-date. The company will report its fourth-quarter fiscal today. How has the company been doing financially? In its latest quarter financials posted in November, the company reported that its revenue grew by 61% year-over-year to $155 million. The company also saw its larger customers ($100,000+) grow by over 52% to 1,107 compared to a year earlier. The company certainly demonstrates continued high growth at scale. Source: TD Ameritrade TOS As the pandemic has driven organizations globally and across industries to prioritize their digital operations like never before, Datadog will continue to be a trusted partner in enabling this digital transformation and cloud migration. All things said, will you add DDOG stock to your portfolio? [Read More] Looking For The Best Health Care Stocks To Buy This Month? 4 To Consider Dexcom Inc. Dexcom is a company that develops and manufactures monitoring systems for diabetes management. In detail, the company is based in California and integrates its software and products for patients to have a real-time look at their glucose readings. Through its continuous glucose monitoring systems, allows for easier diabetes management decisions and will provide crucial information for patients. Dexcom will post its fourth-quarter financials after today\u2019s closing bell as well. Source: TD Ameritrade TOS Last month, the company reported its preliminary and unaudited revenue for its fourth quarter. The company says that it will meet or exceed $567 million, which is an increase of 23% year-over-year. For its fiscal 2020, the company\u2019s total preliminary revenue is expected to meet or exceed $1.925 billion, a 30% increase from a year ago. CEO Kevin Sayer had this to say, \u201cDexcom demonstrated its resilience in the face of the unique challenges of 2020, delivering revenue growth of nearly $450 million over 2019 and making several significant steps to extend our growth opportunity well into the future. I am incredibly proud of the work of our teams and want to express my gratitude to our employees for prioritizing the care of our customers and service to our communities throughout the year.\u201d Will you consider buying DXCM stock for these reasons? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-02-12,96.995,103.585,95.2625,103.14,
DXCM,2021-02-16,102.75,103.15,100.078,101.095,"Nasdaq 100 Movers: NTES, PDD In early trading on Tuesday, shares of Pinduoduo topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.5%. Year to date, Pinduoduo registers a 17.9% gain. And the worst performing Nasdaq 100 component thus far on the day is NetEase, trading down 3.8%. NetEase, is showing a gain of 32.7% looking at the year to date performance. Two other components making moves today are DexCom, trading down 2.4%, and JD.com, trading up 3.9% on the day. VIDEO: Nasdaq 100 Movers: NTES, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-02-17,101.57,104.322,100.048,103.53,
DXCM,2021-02-18,103.105,103.355,100.66,102.71,"4 Growth Stocks to Buy if the Stock Market Crashes Ready or not, a stock market crash may be brewing. We can't predict what will cause a crash, how steep the decline might be, or how long it will last. However, we know from history that crashes and corrections are normal parts of the investing cycle. Over the past 71 years, the widely followed S&P 500 has undergone a crash or correction totaling at least 10% on 38 separate occasions. Image source: Getty Images. But there's good news. Every single crash or correction over the past seven decades has been an opportunity for investors to buy into great companies at a discounted price. The only question is which high-quality businesses you should buy. When the next stock market crash rears its head, investors would be wise to consider growth stocks. Although value stocks have outperformed growth stocks over the very long-term, growth stocks have been running circles around value stocks since the end of the Great Recession. An eight-decade low for corporate tax rates and historically low lending rates have created the perfect conditions for growth stocks to aggressively hire, innovate, and acquire. When the next crash arrives, consider buying into the following top-notch growth stocks. Image source: Getty Images. CrowdStrike Holdings If a market crash gives you the opportunity to scoop up shares of cybersecurity stock CrowdStrike Holdings (NASDAQ: CRWD) at a discount, you should absolutely jump on that opportunity. Cybersecurity has almost become a basic need. No matter the state of the U.S. economy, hackers and robots don't take time off. Whether the system is on-premises or cloud-based, businesses need protection. The fact that more businesses than ever are pushing online in the wake of the pandemic is music to the ears of cybersecurity stocks. CrowdStrike is unique for its cloud-native Falcon platform. Built in the cloud, Falcon can respond to threats faster and more affordably than on-premises solutions. Falcon also stands out for using artificial intelligence to improve at identifying threats over time. Over the past 3.5 years, CrowdStrike has seen the percentage of clients that have at least four cloud module subscriptions jump from 9% to 61%. This leap suggests that CrowdStrike's products are well liked and that it's having no trouble scaling with its clients. Getting these existing customers to spend more is how the company has already achieved its long-term subscription gross margin target of 75% to 80%. Image source: Getty Images. DexCom Another historically pricey stock that would be perfect to buy at a discount during a market crash is medical device company DexCom (NASDAQ: DXCM). Medical devices are traditionally a commoditized, mediocre-margin part of the healthcare sector. However, DexCom isn't traditional. It focuses on the development of continuous glucose monitoring (CGM) systems for people with diabetes. Patients no longer have to prick their fingers several times daily; instead, they can have DexCom's subcutaneous sensor implanted to send real-time blood-glucose readings to a preferred wireless device. DexCom's CGM also links up with select insulin pumps to improve glycemic balance. Beyond just saving lives, DexCom provides Clarity -- web-based software that allows patients and healthcare professionals to review blood-glucose readouts. It's personalized medicine without the doctor's office visit. Innovation aside, the bull thesis is all in the numbers. According to the Centers for Disease Control and Prevention, 34.2 million people have diabetes in the U.S., and another 88 million are exhibiting symptoms consistent with prediabetes. Both figures continue to grow, which means DexCom's potential patient pool is on the rise. Image source: Getty Images. Innovative Industrial Properties The marijuana industry should offer some of the most impressive growth prospects this decade. If a crash or correction arises, consider putting money to work in fast-growing ancillary marijuana stock, Innovative Industrial Properties (NYSE: IIPR). Innovative Industrial Properties is a cannabis-focused real estate investment trust (REIT). In simpler words, it buys cannabis cultivation and processing sites and leases them out for long periods. This allows IIP to earn rental income. It also generates modest organic growth via annual rental increases and a property management fee. As of Feb. 8, Innovative Industrial Properties owned 67 properties in 17 legalized states, with 100% of its 5.8 million square feet leased out. The weighted-average remaining lease on these 67 properties is a cool 16.7 years. IIP is going to reap the rewards of highly predictable rental income for a long time to come. Perhaps the company's top growth catalyst is its sale-leaseback program. Since U.S. multistate operators (MSOs) don't always have easy access to capital, IIP acquires property from MSOs for cash, and immediately rents it back to the seller. This sale-leaseback program has allowed IIP to rapidly grow its asset portfolio with reliable renters. Image source: Amazon. Amazon Lastly, should things go south with the stock market, back up the truck and buy into the company that's dominating the retail space: Amazon (NASDAQ: AMZN). Nearly everyone knows Amazon, the third-largest publicly traded company in the U.S. by market cap. The company is expected to control 39.7% of all U.S. e-commerce in 2021, according to eMarketer. That's $0.40 of every $1 spent online in the U.S. going to Amazon this year. Retail margins tend to be slim, but Amazon makes up for this with its Prime memberships. More than 150 million people worldwide have enrolled in Prime, supplying fee revenue that Amazon uses to help undercut brick-and-mortar retailers. This subscription model also helps keep consumers loyal to the Amazon ecosystem of products and services. Amazon is also a top-tier cloud infrastructure provider. Amazon Web Services (AWS) grew sales by 30% in 2020, and the $12.7 billion in revenue generated in the fourth quarter implies an annual sales run-rate of $51 billion. Cloud margins absolutely trounce retail margins, which is why Amazon's cash flow is expected to triple by 2023 or 2024. In other words, one of the world's biggest companies still has plenty of room to run. 10 stocks we like better than Amazon When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Amazon. The Motley Fool owns shares of and recommends Amazon, CrowdStrike Holdings, Inc., and Innovative Industrial Properties. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-02-19,102.965,105.85,101.635,104.735,
DXCM,2021-02-22,104.188,105.565,102.2,103.015,
DXCM,2021-02-23,101.642,102.932,99.1225,101.695,
DXCM,2021-02-24,100.795,101.831,99.9325,101.41,
DXCM,2021-02-25,101.41,101.454,97.6675,98.8675,"Analysts Expect 10% Upside For QQQM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco NASDAQ 100 ETF (Symbol: QQQM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $146.39 per unit. With QQQM trading at a recent price near $133.24 per unit, that means that analysts see 9.87% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of QQQM's underlying holdings with notable upside to their analyst target prices are Verisk Analytics Inc (Symbol: VRSK), DexCom Inc (Symbol: DXCM), and eBay Inc. (Symbol: EBAY). Although VRSK has traded at a recent price of $167.53/share, the average analyst target is 16.17% higher at $194.62/share. Similarly, DXCM has 12.78% upside from the recent share price of $405.64 if the average analyst target price of $457.47/share is reached, and analysts on average are expecting EBAY to reach a target price of $66.95/share, which is 12.75% above the recent price of $59.38. Below is a twelve month price history chart comparing the stock performance of VRSK, DXCM, and EBAY: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Invesco NASDAQ 100 ETF QQQM $133.24 $146.39 9.87% Verisk Analytics Inc VRSK $167.53 $194.62 16.17% DexCom Inc DXCM $405.64 $457.47 12.78% eBay Inc. EBAY $59.38 $66.95 12.75% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-02-26,99.1975,100.622,96.53,99.445,
DXCM,2021-03-01,100.1,100.498,98.2462,99.1675,"Nasdaq 100 Movers: MRNA, PDD In early trading on Monday, shares of Pinduoduo topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.9%. Year to date, Pinduoduo registers a 1.0% gain. And the worst performing Nasdaq 100 component thus far on the day is Moderna, trading down 3.5%. Moderna is showing a gain of 42.9% looking at the year to date performance. Two other components making moves today are DexCom, trading down 1.1%, and Zoom Video Communications, trading up 4.4% on the day. VIDEO: Nasdaq 100 Movers: MRNA, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-02,99.0,99.615,96.79,97.9775,
DXCM,2021-03-03,96.6975,96.6975,91.15,92.175,"Wednesday Sector Laggards: Technology & Communications, Healthcare In afternoon trading on Wednesday, Technology & Communications stocks are the worst performing sector, showing a 1.7% loss. Within that group, Etsy Inc (Symbol: ETSY) and ServiceNow Inc (Symbol: NOW) are two large stocks that are lagging, showing a loss of 12.1% and 5.1%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 2.0% on the day, and up 0.07% year-to-date. Etsy Inc, meanwhile, is up 17.74% year-to-date, and ServiceNow Inc, is down 5.29% year-to-date. NOW makes up approximately 1.2% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 1.4% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Idexx Laboratories, Inc. (Symbol: IDXX) are the most notable, showing a loss of 6.5% and 5.7%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.8% in midday trading, and down 0.58% on a year-to-date basis. DexCom Inc, meanwhile, is down 0.86% year-to-date, and Idexx Laboratories, Inc., is down 0.12% year-to-date. Combined, DXCM and IDXX make up approximately 1.9% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, six sectors are up on the day, while three sectors are down. SECTOR % CHANGE Energy +3.0% Financial +1.1% Consumer Products +0.7% Industrial +0.5% Materials +0.5% Services +0.2% Utilities -0.9% Healthcare -1.4% Technology & Communications -1.7% 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-04,91.97,92.945,88.035,89.0675,
DXCM,2021-03-05,90.3775,91.8625,86.8075,91.0225,
DXCM,2021-03-08,90.4075,91.74,87.1925,88.015,
DXCM,2021-03-09,89.235,91.3475,89.235,90.735,
DXCM,2021-03-10,92.44,92.97,89.095,89.0975,
DXCM,2021-03-11,88.965,91.7762,88.7425,91.695,
DXCM,2021-03-12,89.8075,90.141,88.1475,89.4325,
DXCM,2021-03-15,88.44,90.745,87.76,90.4825,
DXCM,2021-03-16,91.7425,91.885,88.25,88.6625,"What's Going On With Tech Stocks? Banner results from 2020 darlings haven't turned into strong 2021 returns. In this episode of Industry Focus: Tech, we talk about the tech landscape in 2021 and how a recovery economy affects high-growth businesses, and we look at earnings results from MercadoLibre (NASDAQ: MELI), Zoom (NASDAQ: ZM), and Cloudflare (NYSE: NET). To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video. 10 stocks we like better than MercadoLibre When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and MercadoLibre wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 This video was recorded on March 5, 2021. Dylan Lewis: It's Friday, March 5, and we're talking about the dip in tech stocks. I'm your host Dylan Lewis. I'm joined by fool.com's daft day-to-day delinquent of drawdown deep dives, Brian Feroldi. Brian, how are you doing? Brian Feroldi: I'm doing great, Dylan. How are you? Lewis: I'm doing OK. How is your portfolio doing? I think that's probably the better question to kick off the show with. Feroldi: Well, it really depends on what time frame you're talking about. Over the last 10 days, not so good. Over the last 10 years, pretty good. I prefer to focus on the latter, not the former. Lewis: I think that's a great way to put it, Brian. Yes, I think it's shocking to log in, and I don't know about our listeners and our members, but I am someone who checks my brokerage account every day. I don't activate every day. I'd say in any given year I'm maybe doing something in my brokerage account in terms of transactions 10 to 15 days. But I check every day and to see a 5% or 10% swing in a couple of days is drastic and [laughs] it does give you pause like, huh, I thought those first couple of numbers started differently [laughs] last time I was in here. Feroldi: That's how it goes with investing and that's how it goes with stocks and start picking like us. If you're going to invest in some of the greatest companies, the most dynamic, the biggest innovators, big drawdowns are going to come and they're going to come swiftly. Lewis: They are. We lose sight of it sometimes, particularly during rosy periods, when we talk about the S&P returning 7%-10% annualized, that's an average number. You're working to that annualized figure based on overall movements over long periods of time. It doesn't have that consistent march that some of those calculators and retirement calculators will have you believe. Feroldi: That's exactly right. If you look at the historic returns for the S&P 500, they are truly all over the map. You see +20%, +30%, -20%, -30%, you average it all out over long periods of time, you get a pretty satisfactory return. But when you're looking day to day, week to week, month to month, anything can happen. Lewis: Yeah, anything can happen and you will see even larger swings with some particularly high-growth stocks. We're going to be talking about that in the middle of the show. I think maybe just to start things off, why don't we set the stage for folks that have maybe been tuning in and out of the news a little bit? Just with what's been going on in the market and then specifically in the tech space over the last two or three weeks. Feroldi: Yes. So, the stock markets started out 2021 pretty good. They were up double-digits in mid-February. Over the last few weeks, there has been a relatively modest sell-off. But if you look at the Dow and the S&P 500, they've barely budged. They are only down a few percent from their all-time highs. But the Nasdaq is down more than 10% from its February high. So the Nasdaq is officially in ""correction territory"". But even that doesn't really tell the whole story. Because while the Nasdaq is predominantly tech, certain sectors of the technology market are down even more. A couple of ETFs that I track to look at Cloud stocks and SaaS stocks are doing, which we love talking about on Industry Focus are the SKYY and the CLOU, which are just two ETF that hold a whole bunch of SaaS stocks. Those are down 17% and 18% from their February highs, and a couple of other ETFs, notably the ARK ETFs -- ARK has a group of active ETFs that have really caught fire over the last couple of years. They've become hugely popular with investors. Two of their bigger funds, the ARK Innovation ETF and the ARK Internet ETF, both of which are very focused on high growth tech stocks, are down 28% and 26%. Again, these are just the averages. We've seen lots of stocks that are down much more than that. So, it's been rocky over the last couple of weeks. Lewis: I know that a lot of our listeners are Fool members or people that generally follow the Fool investing philosophy. That means that they're probably a little overweight tech. I imagine that their portfolio probably looks a little bit like mine, where there's a little bit of an overweight to growth oriented businesses, a little bit more tech in the portfolio. So, when that's the case, and we see that with some of these specific ETFs, you're going to have some outsized movements. Definitely the case in 2020 for me. Also, the case in 2021 for me. Feroldi: Yeah. Exactly. As you said at the top of the show. When you're investing in high growth areas of the tech market, you have to think of them that they generally are going to move at a step change market in general. When the market goes up a little bit, these stocks are going to go up a lot. When the market goes down a little bit, these stocks are going to go down a lot. That is the downside to the upside of owning high growth businesses. Lewis: I think one of the confusing things, Brian, for people that have been following the market is, you look at 2020 and you say, boy, just a rough year all around. A really tough year for a lot of Americans and a lot of people all over the world. Tough year in terms of how you would look at most economic indicators. Pretty solid year for the stock market, even with the massive sell-off that we saw. I think the S&P on a total return basis is about 17%, 18%, and personally, one of the best years I have ever had investing. There was a massive disconnect between what we have seen with the market and the economy. What's odd is, you look at 2021 and I think some of the major news that's moving these companies and it's the flip. We're seeing some positive signs and that's great, but it's actually not particularly good news for a lot of these high growth businesses. Feroldi: A lot of the high growth stocks that you said really prospered in 2020, in many ways, were prospering because of COVID. So much of how we live our day to day lives was disrupted in 2020 and that forced us to live differently. People were working from home, they were shopping from home like never before, so it made complete sense that companies like Amazon, Microsoft, Google, Facebook, companies that thrive in a work from home, shop from home world, that their stocks just absolutely took off. The worst news was at the time, the more drive there was for people to use their products and services. Now that we're on the flip side of things and the world is getting better faster than we would have thought, it does make some sense that investors are actually rotating out of those stocks and into some of the stocks that have been left behind. Lewis: There have been a lot of positive movements, a lot of positive news on that front recently. You go back to January and we were looking at triple digit new case counts every single day in the United States and we're down to about 50,000-60,000 in recent days. That's a good thing. We're seeing the Johnson & Johnson one-shot vaccine was approved. That's a good thing. We're seeing positive signs on the supply for Americans with the vaccine. That's another good thing. These are all things that I think we're generally rooting for. Unfortunately, it creates a spot where the valuations for some of these higher growth businesses are going to suffer. Feroldi: Which just again proves to me that it's so hard to try and predict what the market is going to do based on the headlines. Would you ever have predicted that terrible headlines in 2020 would lead to great returns in the stock market. Now, we're seeing great headlines in terms of the vaccine being rolled out faster than anticipated and new supply coming on market and that's leading to the decline in the market. This is why I never try to guess what's going to happen next with the market, just focus on buying awesome businesses. Lewis: Yeah, we joked in 2020 several times. I could tell you the headline a week in advance and you could try to trade off of it and almost every time you'd be wrong. [laughs] It didn't matter where the jobs numbers were, or the new case numbers were, it just seemed to always be the polar opposite of what you expected to happen. Feroldi: That's exactly right, and that's nothing new, to be honest. If you've been investing for a long time, I can't tell you how many times I've seen a company report just great earnings, like, everything in the earnings report looks fantastic and the stock fell. I've also seen companies report terrible earnings, just everything was bad across the board, and the stock rose. Even if you have the news ahead of time, you can't necessarily predict what's going to happen next. Lewis: We talked a little bit about the dynamics with 2020 stay at home stocks and how they really benefited that pushed up valuation. I do think it's worth taking one step back and looking a little bit at long term forces at play here because I think there's a little bit of this too where, Brian, we have basically had low interest rates in terms of modern history, unprecedented amounts of time. The Fed funds rate, which is basically our baseline rate for all other debt in the economy, has been so low for so long. You look at the chart over the last 60 years, it has never been this low for this long. That creates a lot of movement of money within the economic system. It pushes a lot of people to more of a risk-on environment where they are willing to put money into stocks, willing to put money into real estate because they're looking for a return, they're looking for yields, and they're not able to get it as much in the debt markets. Within that category of equity investments, people looking for outsized returns are going to be putting money into growth stocks. That's where the money is going to flow. On top of what we have generally seen over the last year or so, I think there's probably a decade long trend of money flowing in one direction and at some point people deciding maybe I'm going to take some profits and take a little bit of that risk off the table as well. Feroldi: Which makes sense. To your point about just what's happening at the macro level economically, yeah, interest rates have been terrible now for over 10 years. If you need to generate an income from your portfolio, you can't really do that from bonds. You can't do that from savings. There's a whole bunch of money that is chasing returns out there. It does make sense in an environment like that, the asset prices get pushed up. When you combine that with the fact that the stock market has been roaring now for basically 11 years in a row, and couple that with the fact that a whole bunch of people were forced to stay at home and many of them took up investing for the first time as a hobby, it does make sense that stocks have had a tremendous run and that now we're seeing the reversal of that. Lewis: Brian, we want to talk about a couple of specific names that are very relevant to our Fool audience, ones that our members and our followers probably hold pretty widely. Because if you look, we're not talking about necessarily 10% drops. In some cases, we're looking at businesses that had been high-flying that are now 30% off highs. I think that's something there if you're a recent buyer, probably creates some high blood pressure for you and it might be the first time that you're really going through this. I think maybe it makes sense for us to talk a little bit about the results from some of these companies and just philosophically, how both of us are approaching this investing landscape. Feroldi: Sure. One of the things I try to hammer home all the time is that there's a difference between a business and its stock. A business sometimes can produce fantastic results and its stock can go down. A business can sometimes produce terrible results, and its stock can go up. We have a couple of examples here that really highlight that. Cloudflare, the ticker symbol there is a NET, is a company that I've really started to get to know over the last couple of months. This is a company that has done tremendously well both prior to Covid-19, as well as basically throughout the pandemic. We haven't really talked about this on the show much, but Cloudflare at a high level provides web infrastructure and security services to the Internet. Their products and services will reach 99% of the world's Internet users, within 100 milliseconds. Cloudflare is a way to speed up and get Internet content to people faster. If you look at this company's 2020 results and their Q4 results, wow, are they having a great time. In the fourth quarter alone, they added 10,000 new customers. That was up 10% sequentially to their customer ground, and they now have 110,000 total customers. 92 customers in the fourth quarter alone will spend $100,000 or more with Cloudflare. That brings their total up to 828. Their DBNR, dollar based net retention rate, retention, the good one, was 119%. When you add it all up, revenue grew 50%, gross margin was 78%, and their adjusted net loss fell by about half to $8 million. Every single thing that I just said says, wow, they are crushing it, adding 10,000 customers in a quarter. Yet, this company, since reporting earnings, is down 31%. Lewis: It's incredible. Brian, just as a side, whenever I hear you say, retention the good one, I always think of the evil twins, dollar based net expansion and dollar based net retention, how maybe expansion is the evil twin. But those are incredible numbers. What I think is hard is like, we knew 2020 was going to be good. We're seeing the lagging results coming in and then we're looking backwards. Unfortunately, we know that the market is always looking forward. What we see in terms of the market price is basically an aggregate of future value assessments of what could happen. But I see all of that and I see a business that seems to be doing just fine. I don't really see too many reasons for concerns. Feroldi: The reason there has to do mostly with valuation. All three of the stocks we're about to talk about just had a heck of a run in 2020. While their businesses improved mildly, you could make the argument that the stock prices got ahead of the business fundamentals, and not only were they pricing in great growth, they were pricing in even better growth than the growth that we've seen. This could just be a case of valuation reset. But this is why I try really hard to always focus on the business. If you just focus on the business and ask how Cloudflare is doing, it's very clear that they're executing brilliantly. Lewis: I think focus on the business is the thing you have to remind yourself for stock No. 2 here, that's MercadoLibre. Even in a world where COVID didn't happen, focus on the business was going to be a huge part of the way you talk about this company, because we've talked about this company at length on the show before. But they work in, I think, 13, maybe 14 different countries. Different currencies, they repatriate back to dollars. There's a lot of crazy stuff that happens with foreign exchange and having to denominate all their results in dollars. Already this is one where you got to look at the business metrics. You can't look at the revenue quite as much, and the numbers have been stellar. In their case, year-over-year growth for them recently has been somewhere in the 50%-60% range. [laughs] Final quarter of 2020, Brian, 97% year-over-year growth, which is bonkers. I know I said don't focus too much on the dollar figures, but I have to highlight that one. The user numbers and what they're seeing in terms of usage on their platform is incredible, 70% user growth, now at 74 million. Items sold for their e-commerce platform up 100% year-over-year. Total payment volume almost $16 billion for this last quarter, 84% growth in U.S. dollars. To highlight that disconnect there, 135% foreign exchange neutral basis, which is just insane. Those are great, great numbers, and yet this is a company that is down almost 30% since late January. Feroldi: Very similar to Cloudflare. It's like you would dig through their earnings report and you're like, ""That looks good, that looks good, that looks good."" The business is executing flawlessly, but the stock has not responded since January. Now again, if you back up and look at how they did throughout 2020, the company had a tremendous run. This is again, more of a valuation reset and a sector rotation among investors as opposed to something going wrong with the core business. Lewis: MercadoLibre shares since January 1st, 2020, up 150%. I think anyone who bought back then, even with this dip, probably felt OK. What is hard is if you're one of the newer buyers. I think in Cloudflare's case, those returns are about 270% since January 1st, which is market stumping. One of the other elements I guess which we probably touch on, Brian, 2020 set really hard expectations for new investors. The idea that you could buy something and six months later have it be worth two or three times what it once was, that doesn't usually happen. It was happening for a lot of names, particularly a lot of very popular names in the market. Feroldi: Exactly. 2020 was the weirdest year of investing I've ever been through. If you only started paying attention to the market anytime from March 2020 until now, the only thing that you've known is instant success; buy any company and it instantly goes up and you are instantly rewarded for buying and holding. Whether it was a week, a month, or three month period, that's what you experienced. For a lot of people that have started investing over the last year, what they're seeing now is really the first time that that hasn't worked and that they've actually experienced what can happen when you invest in the market. It's really challenging for anybody that's got started over the last year. Lewis: Maybe the story of 2021 with Zoom. [laughs] If you didn't know Zoom because your company used it, you learned it quickly because a friend or a family member wanted to use it. The video communication app just saw incredible adoption in 2020. I think they jumped about four, five years in growth adoption with where things were last year. Feroldi: Totally. Zoom had the year of years, and how many earnings reports did we go through and said, ""Is this the greatest earnings report of all time?"" ""Is the beat that came out here the greatest that we've ever seen?"" The fourth quarter was just more of the same. The number of Zoom customers that have 10 or more employees that are signed up grew 470% to 467,000. The number of customers that will spend more than $100,000 with Zoom over the next year grew 156%. The dollar base net retention rate, retention, the good one, that was above 130% for the 11th quarter in a row. What does that mean for the financial statements? Revenue growth of 369%, adjusted net income growth of 839%, and management issued some pretty bullish guidance for fiscal year 2022. For the full fiscal year, they expect to generate a revenue of $3.77 billion. That would represent growth of 42% off of the stellar numbers that we just started reading off, and they expect to grow their profits, although at a much, much slower rate. Keep in mind, every time that Zoom has issued guidance, it's blown it away. The company has established a culture of issuing low guidance and then blasted off. The numbers out of Zoom have just been phenomenal. There's no other word, phenomenal. Yet, the stock is down 41% from its October 2020 high and 26% since January. Yet another case of the business executing brilliantly and the stock going down. Lewis: If you are a recent shareholder, maybe a little bit more concerned, if you've owned it since the beginning of 2020, you're looking at close to 400% returns, which I don't have the words for. [laughs] We're not really used to seeing anything quite like that. I think what is hard for people is if you got your initial slug for any of these companies, your first buy for any of these companies recently, you are looking at this downturn a lot differently than someone who has been a long term shareholder. In my case, I'm a MercadoLibre shareholder, I've been for years. I'm sitting on multi-bagger returns to the stock. It's not as concerning to see a 30% dip. It's a little bit harder to hear this if you bought your first share in the last couple of weeks. Feroldi: That's exactly right. That just reinforces to me that you have to take a multi-year outlook with any of these stocks, because what the stock does and what the business does over the short term are completely different from each other. As we've seen with all three these companies, great results, terrible stock returns. But if you zoom out and look over longer periods of time, great business results always lead to great stock results. You just have to give the market time to recognize that because there are so many forces that play in the short term. That's why we always talk about how the business is doing, do we like this business over the next three, five, and 10 years. I've owned MercadoLibre since 2010 or 2011. MercadoLibre, I have seen go through so many ups and downs. This is a kind of stock that doubles and then falls 60% and then goes up 150% and then falls 50%, and then goes up and then trades sideways, and it just goes all over the map. But if you zoom out and look at the long term picture, it's been one of my biggest winners ever. Whenever I buy it and whenever I own, I just have to say, I own this business for a long period of time and I just accept that I have no clue what's going to happen over the next day, week, month, or year. Lewis: Brian, you are a must follow on Twitter for a variety of reasons. You are a nice calming voice when things are going a little crazy, but you're also excellent with graphics. I think one of my favorite things that I've seen come out of your Twitter account was a look at, I think they were all stocks that have 10-bagged or stocks that basically put up multi-bagger or 1,000% returns and the declines that they have all experienced at various points. I don't remember all the stocks off-hand, but I think it was Amazon, Netflix, and several others. It's a good reminder. [laughs] Highly disruptive businesses wind up going through some really sharp corrections from time to time. Feroldi: What's really interesting about that is not only do highly disruptive businesses do that, really stable boring businesses often do that. Warren Buffett has pointed out that Berkshire Hathaway, top tech to bottom tech, has fallen 50% four times since he's become chairman and taken over. Four separate times, Berkshire Hathaway, a big stable conglomerate as reliable as it gets, has also seen its share price get cut in half. What do you expect of high growth companies like Netflix, of Amazon, of Tesla? Their stocks are going to be even more volatile than that. If you are going to buy individual stocks or if you're going to put money into the market, the price that you pay for long term returns is occasional, short term volatility. You just have to be willing to pay that if you want to generate great returns. Lewis: We know if you're thinking of this way as you're going into your buys, it's a little bit easier. You can be planned and you can say, ""I'm going to be buying into this over time. Going to maybe build out the position in three, four, five purchases, spread it out, dollar-cost average. Keep a cash position on the side in the event that there are some interesting buying opportunities."" I think a lot of people are looking at things right now and saying, ""Interesting buying opportunity."" It's nice to get something on sale. If you happen to be in that position, I think this is a much easier thing to encounter. The thing I will say to folks that are relatively new to the market or maybe are new investors in some of these high growth businesses that have really taken a whack, the core thing I come back to is think about whether the thesis is intact. That's the easiest shorthand thing I can come back to when I see a lot of red in my portfolio. In the case of MercadoLibre, is e-commerce going to continue to build out really across the world in a new market where they own it? Yes. Digital payments, is that can continue to build out over the next couple of years? Yes. Are they going to be the market leader? Most likely. Even though there's a 30% dip there, everything that made me originally buy that company is still there for that business. Feroldi: That's exactly it. When I'm going over the earnings report, the question I'm always asking myself is; is the thesis on track? Is the management team executing? Are they adding more customers? Are their margins stable or improving? Is revenue growing? Are they launching new products and new services? When you dig through all three of those earnings reports that we just talked about, the answer is yes, yes, yes, yes. Across the board, all three of those companies are just executing brilliantly. If they can continue doing that for a long, long period of time, I'm 100% convinced that all three of those stocks will be higher in three years and in five years and in 10 years than they are today. That's why you have to focus exclusively on the business and do your best to ignore the stock. Lewis: I think what is immensely helpful is we talk about investing journals all the time and the idea of tracking thoughts. There are a lot of different ways that you can do that. You can have a physical journal, you can have a notepad. Some people use Twitter as their diary for that kind of stuff because there's public accountability, that's awesome. I think with anything you own, I think in two sentences, have the summary of why you own it. As long as that continues to be true, it's a really simple way to gut check yourself when you see scary headlines or where you see a lot of red in your portfolio. As long as those things continue to be true, you're on the right track especially if you're thinking three, five, 10 years. Feroldi: I love that. Yes, I've been using an investing journal for several years. Exactly what you just said, whenever I'm about to buy a stock, I go through and I write down what's the price today, what are the few reasons why I'm buying that stock versus all the other stocks that exist, and then I periodically go back and look at my past decisions. When I view some of my past decisions and I know the outcome, like, boy, that was a dump stock to buy. It's useful to go back and see why I was thinking what I was thinking then, because it's easy to tell yourself if something doesn't work out that you made a mistake, but when you're actually reading your rationale, it can prevent you from making that same mistake again. Lewis: One layer I'll add to that Brian is if you really want to hold yourself accountable, write down why you sell stuff when you sell it. I know that we don't really talk about selling things too often, but [laughs] one thing I have noticed is pretty much everything I have sold, it's been the wrong decision. [laughs] What I haven't done is track the new money that I put it in and really what the opportunity cost was of doing that. But there are businesses like Chipotle and Costco where I kneecap to what would have been pretty strong results and pretty good returns, just because I was interested in other ideas and I had limited money. In addition to understanding why you buy, if you're looking to improve over time and just holistically improve your investing process, understand why you sell and remember why you sell as well. Feroldi: Totally. All my biggest most blunderous mistakes have been selling and I've bought a whole bunch of bad stocks. I bought a lot of bad stocks over time, but I sold DexCom for $8. That company is over $400 today. So every other good selling decision that I make was overwhelmingly -- the amount of money that I missed out on by selling Dexcom for $8 has not been made up by all my good selling decisions. So yes, like you, all of my worst decisions usually have the word ""sell"" in them. [laughs] Lewis: Those are some good humble brags there, Brian. [laughs] I mentioned the selling stuff because I'm sure there are some people that are thinking about that right now and are looking at the declines and are thinking, it might make sense for me to move out of these. These aren't performing the way I expect them to. Look at the long term charts for some of these businesses. I think MercadoLibre in particular does a great job of illustrating the dips that come with the long term appreciation. But if you think the thesis is intact, if you think the mega trends that are pushing those companies forward are going to stay there, and I think for all these businesses we talked about today, that's certainly the case. I don't think that we're moving away from e-commerce, I think we're only becoming more dependent on Internet infrastructure. Companies have seen the value of Zoom. The web meeting is here to stay and we're increasingly getting decentralized with our workforce. You're probably in OK shape. Feroldi: Exactly. MercadoLibre is one of my largest holdings, if not my largest holdings, it depends on the day, what's happening with MercadoLibre essentially. I've owned the stock for many, many years. Yes, I'm down from what it was worth a few weeks ago, but like you just said, I have no plans to sell this company. Everything that I see when I dig through their earnings report says the thesis is on track and I want to own this company for a long time. Lewis: Same for me. If you're sitting there holding MercadoLibre, even if you're in the red, you're a fellow shareholder along with Brian and I. That's the power of the community. I think that's also one of the things as we wrap up here Brian, I'll mention last is just it's helpful to have supportive voices and I find Twitter surprisingly good for that. For all of the things that Twitter brings into the world, I think the Fool investing community and then some of the other folks on Twitter that are really long term oriented are great reinforcement for that. We try to do that here at The Fool and I think selfishly we get to do that with our colleagues a little bit more, because we're talking all the time about stocks. I know that some of our members may not have their voices so available to them, but that's what we're here for. Feroldi: There's nothing like a good community around you. If you are interacting and engaging with a strong community of like-minded people that also buy and hold great companies for long periods of time, they can help to talk you off the ledge if you are having a bad day in the market. Whenever I see big time red and I'm feeling down, I fire up Fool Live and I see what other people are saying. I go on Twitter and send out messages to people I know and respect. I go on the Motley Fool's discussion boards and read posts from some of my favorite people. Every single time it helps me feel better and refocuses me on the long term. Totally, don't invest alone, invest with other good people. Lewis: We're just lucky enough, Brian, to get paid to talk about it together and get to enjoy that community as part of our jobs. I'm always happy to have you on and always happy to talk about stuff with you. Feroldi: Always love being here, Dylan. Thanks for having me. Lewis: Listeners, that's going to do it for this episode of Industry Focus. If you have any questions or you want to reach out and say ""Hey,"" shoot us an email at industryfocus@fool.com or you can tweet us @MFIndustryFocus. If you're looking for more of our stuff, subscribe on iTunes or wherever you get your podcasts. As always, people on the program may own companies discussed on the show and The Motley Fool may have formal recommendations for or against stocks mentioned, so don't buy or sell stocks based solely on what you hear. Thanks to Tim Sparks for all his work behind the glass today and thank you for listening. Until next time, Fool on! John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Dylan Lewis owns shares of Alphabet (A shares), Amazon, and MercadoLibre. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Chipotle Mexican Grill, Cloudflare, Inc., Costco Wholesale, DexCom, Facebook, MercadoLibre, Microsoft, Netflix, Tesla, and Zoom Video Communications. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-17,88.39,88.39,85.29,87.925,"2 Hot Growth Stocks That Could Be Millionaire-Makers The television show Who Wants to Be a Millionaire? features contestants who can win up to a million dollars -- in a matter of hours -- by answering a series of trivia questions. Earning a million dollars by investing in stocks isn't usually as quick as that, but it is possible. To do so, you need lots of patience and the ability to pick quality stocks. The former is necessary to implement a buy-and-hold strategy successfully. And choosing the right stocks is obviously a prerequisite: Shares of poor companies will deliver below-average returns (at best) in the long run. Let's take a look at two companies that have what it takes to shatter the broader market for many years to come: Tandem Diabetes Care (NASDAQ: TNDM) and Pinterest (NYSE: PINS). Here's why both of these stocks could be millionaire-makers, or at least could vastly outperform the market in the long run. TNDM data by YCharts 1. Tandem Diabetes Care The percentage of the U.S. population with diabetes has been increasing in the past few decades. In 1958, this group made up just 0.93% of the country, but by 2018, that number had risen to 10%. If this trend continues, an estimated 33% of the population could have diabetes by 2050. There are scores of companies that help patients with this chronic health condition manage their illness. Tandem Diabetes does so by providing insulin pumps, an important tool in a diabetic patient's arsenal. The company's t:slim X2 insulin pump -- sales of which generate the bulk of its revenue -- can be used as a standalone device or in combination with DexCom's G6 continuous glucose monitoring (CGM) system. This helps patients monitor and automatically adjust insulin levels for an easier and more efficient way to manage their diabetes. For evidence of the t:slim X2 pump's popularity, consider that Tandem Diabetes ran a customer survey last year during which its crown jewel had a satisfaction score of more than 90%. That said, consumers best express their approval for a product by spending their money on it -- and on that front, the results are also impressive. During the fourth quarter ending Dec. 31, the company recorded sales of $168.1 million, representing a 55% year-over-year increase. Tandem Diabetes Care shipped 32,685 pumps during the quarter, 67% higher than the year-ago period. For the full fiscal year 2020, Tandem's sales jumped by 38% year over year to $498.8 million. Image source: Getty Images. Tandem is well-positioned to keep growing. Management estimates that only 35% of its addressable U.S. market (type 1 diabetes patients) use pumps, whereas the rest still rely on pesky and painful multiple daily injections (MDIs). There is an even bigger opportunity abroad; the company estimates that in its core international markets, just 400,000 of the 4 million type 1 diabetes patients eligible for pumps have made the switch. According to CEO John Sheridan, ""Since launching outside the United States just two years ago, we now have crossed approximately 45,000 people using the Tandem pump in nearly 20 different countries. By comparison, it took us more than four years to reach this level of installed base domestically."" Tandem Diabetes plans on having 500,000 worldwide customers in its installed base by 2024. For context, the company said it had over 200,000 customers in its ecosystem at the end of 2020. And management has several ways to broaden its customer base in the long run. Last year, the company announced a partnership with Abbott Laboratories -- a notable entity in the diabetes care devices segment. The two businesses are looking to develop solutions to integrate Tandem's insulin delivery systems with Abbott's CGM technology. This project, if successful, would expand Tandem's pool of potential clients. With solid long-term growth opportunities at its disposal, this healthcare company looks like a potential millionaire-maker stock, and certainly one that investors shouldn't ignore. 2. Pinterest Facebook and Twitter may be the most famous names in social media, but that doesn't mean there's not room for Pinterest. This company isn't just a pale copy of competing platforms, either; Pinterest has a more visual flavor than its peers. The company helps users discover and generate ideas thanks to ""pins,"" which are Pinterest's version of bookmarks. This business model is clearly working wonders for the company -- it's hard to find an important metric in the financials that hasn't improved in recent years. During the fourth quarter of its fiscal 2020, which ended Dec. 31, the company's revenue jumped by about 76% year over year to $705.6 million. Pinterest had 459 million monthly active users at the end of the year, representing an increase of 37% compared to the previous fiscal year. The company's average revenue per user for Q4 grew 29% year over year to $1.57. Pinterest's net income for the quarter was $207.8 million, a big leap up from the net loss of $35.7 million it recorded during the fourth quarter of the previous fiscal year. There are good reasons to think Pinterest has a lot of growth left in its engine. The company's strategy can be nicely summed up in the following quote from CEO Ben Silbermann: People need a place to dream and be optimistic, away from politics and bad news, they need a space to focus on themselves based on what they want to do, not what other people will like. And businesses want to reach people early in the planning process before they decide what to buy for their lives. Image source: Getty Images. By providing ""a place to dream,"" Pinterest is betting that it can attract more users to its platform, then keep them coming back for more by continually improving its website. For instance, the company has bettered its search functionality, beefed up its recommendations, introduced more content on its platform, etc. And on the other side, Pinterest is making it easier for companies to advertise on its platform, as well. In October, management announced a suite of tools including a way for merchants to update their catalogs more easily on the website, a storefront profile for merchants that helps facilitate discovery, and new analytical tools to better gauge customer conversion metrics. According to research firm Mordor Intelligence, the digital advertising space is projected to reach $982.8 billion in 2025, up from $304 billion in 2019, expanding at a compound annual growth rate (CAGR) of 21.6% in this period. And it won't stop there. In an increasingly digital world, online ads represent a juicy long-term trend. There are many players in this segment, but Pinterest has carved out a niche for itself. In short, Pinterest certainly has what it takes to shatter the market in the long run. 10 stocks we like better than Tandem Diabetes Care When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny owns shares of Facebook. The Motley Fool owns shares of and recommends DexCom, Facebook, Pinterest, and Twitter. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-18,87.0,87.29,84.285,84.7875,"Roblox Goes Public, and the Future of CRISPR and Gene Editing In this episode of Motley Fool Money, host Chris Hill is joined by Motley Fool Analysts Jason Moser and Emily Flippern to discuss Ulta Beauty's (NASDAQ: ULTA) CEO stepping down, and the declines of Docusign (NASDAQ: DOCU) and JD.com (NASDAQ: JD) on earnings. Also, Bumble (NASDAQ: BMBL) bounces higher and Roblox (NYSE: RBLX) has a big debut. They'll also discuss the outlook for the sports betting industry, and share two stocks on their radar. Plus, best-selling author Walter Isaacson talks about his new book, The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video. 10 stocks we like better than Walmart When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks Stock Advisor returns as of 2/1/20 This video was recorded on March 12, 2021. Chris Hill: We've got the latest headlines from Wall Street, best-selling author Walter Isaacson is our guest, and as always, we've got a couple of stocks on our radar. But we begin with some big shoes to fill. Ulta Beauty's fourth-quarter earnings report took a back seat to the news that CEO Mary Dillon is stepping down in June. She will transition to executive chair of Ulta's board and stay there for a year. Company President Dave Kimbell will take over as CEO. Shares of Ulta were down 8% on Friday, Emily, because Mary Dillon has been the CEO since 2013. She has done a great job leading this business, and the new guy has a tough act to follow. Emily Flippen: That's an understatement, Chris. What's really interesting is back in December, Ulta actually reorganized its leadership team. They brought in four new leaders for things like international operations and merchandising. All while keeping the CEO, now CEO Dave Kimbell, in his role as president. This transformation, I guess, was precursored by the transformation in the leadership team back in December, but it certainly still took me as a shareholder and the market by surprise because of what an excellent job Mary Dillon has done. Now, she will be staying on for the next year, helping the transition, helping the new CEO, Dave Kimbell, take over his role. But he certainly is going to have a challenging 2021 because when you look at Ulta's quarter, just their earnings this quarter, their same-store sales fell nearly 5%, revenue fell just nominally year over year, they stopped their expansion into Canada -- all of these negative effects coming out of the COVID pandemic. They still have a lot of initiatives that they need to prove out over the next few years to say, ""Hey, Mary Dillon, she did some great things for the company over the past eight years, but here comes Dave, and Dave can still deliver that same return for shareholders."" Hill: I think about all the success that business has had, Jason. This is something you and I have talked about before. The building up of the Ulta Beauty and Salon loyalty program, the tens of millions of people that got into that. It's one of those things that shouldn't be overlooked in terms of Mary Dillon's legacy as a leader. Jason Moser: No, not at all. I think you're absolutely right. I think the loyalty program plus the progress they've made on the mobile front, I think has been phenomenal. I think they've really embraced the changes in technology. Not only the move to mobile, clearly mobile is the thing, [laughs] it's not a fad. They saw that early on and made the investments, I think the appropriate investments for a business like that to bring in technology like augmented reality, allowing folks to be able to try on different products without necessarily having to even be in the stores. I think you put it all together, it really is just a phenomenal job that Ms. Dillon has done. I think she will be sorely missed as the CEO. However, it's nice to know that she will be holding that executive chairman role still. Hill: Real quick, Emily, before we move on, if you look at the performance of the stock, up I think in the neighborhood of 250% during her leadership, the stock falling on Friday, do you look at Ulta Beauty as a strong enough underlying business that this represents a great buying opportunity? Like, ""Hey, the stock is almost 10% cheaper?"" Or is this a little bit of a wait and see? Flippen: I tend to lean on the cheaper side, but I will say that hesitantly, because some of the numbers that we've seen for Ulta need to move in the right direction to really make this a good buying opportunity. In particular, the focus that the business has put on their loyalty sales -- loyalty members actually fell 10% year over year, which is exactly the opposite of what Mary Dillon was trying to do, which was transform this company into something that had a character, had a loyalty program, and had lots of people shopping online through these augmented reality initiatives. Two-thirds of their users, of Ulta buyers, are still in-store shoppers only. Those numbers, the loyalty numbers, and the online shopper numbers need to continue to climb to justify buying today. Hill: Shares of DocuSign falling 7% on Friday, despite the fact that fourth-quarter sales came in higher than expected, capping a year in which overall revenue came in at $1.5 billion. Jason, DocuSign's up 200% over the past year. It's not a cheap stock, but when you look at billings, when you look at the way they're adding customers, it seems like the business is growing in the ways that you would want. Moser: Oh, yes, it's growing in the ways that we would want. [laughs] Chris, as a shareholder and myself, I am very happy with this quarter. I think if you're looking for a stock to buy and hang onto for years to come, it's one that should be at the top of your list. At the end of this year, this is going to be a $2 billion revenue business, and to your point, not a cheap stock but hey listen, that puts these shares that are refreshing 20 times forward sales in a world where 40 times sales now seems to be the norm. DocuSign maybe looks like a deal, but I think the metrics that matter really do tell the tale for this company -- revenue growth, 57%, billings growth of 46%. They brought in more than 70,000 new customers for the quarter, now have just under 900,000 customers worldwide and saw their strongest expansion in upsell rates yet, actually driving their dollar net retention rate to 123%, highest it's ever been. This is a business right now, today it's generating positive operating cash flow even after you back out the stock based compensation. GAAP profitability is still a ways away, but at this point, I'd argue they don't have to worry about that given the numbers they continue to lob up. They grew enterprise in commercial customers by 50,000 for the year. International revenue grew 83%, it's now 21% of total revenue. They have a pretty cut-and-dried strategy -- it really all just centers around this idea of being the go-to platform for the agreement process, pre- and post-signature, and it seems to be working. They're building out some pretty strong technology that is resonating with customers and there's an interesting data point on the call. I think this is really a testament to the decisions that they're making and the strategies that they're employing. They added nearly the same number of customers this past year, approximately 303,000, as they actually had in total at the time the company went public in 2018. Clearly, it's a business that's benefited from tailwinds of the pandemic. I would argue that the pandemic -- notwithstanding this is a business that is still doing all the right things -- maybe that hastened the growth a little bit. But I think the guidance for the coming year is strong. They took a little bit of a target-like tone there in a conservative nature, noting that the ongoing impacts from coming out of the pandemic make operating expenses a little bit difficult to fully forecast, but all things considered, this is a business that just continues to do all the right things, it seems. Hill: Fourth-quarter revenue for JD.com rose 31%, profits were also higher than expected, but shares of the Chinese e-commerce company falling more than 5% over the past week. Emily, it seems like it was a nice cap to a strong fiscal year though. Flippen: Extremely strong year for JD. If anything, the fall today is just a contraction in valuation because of what a great 2020 it was for JD. When you look forward to what 2021 could be for this business, even thinking about 2022, it's important to differentiate JD versus its other competitors in China, in particular, Alibaba and Pinduoduo. Part of the reason why JD is going to have a tough time living up to their comps in 2020 is because virtually every other e-commerce platform in China had to suspend their delivery services during the lockdown. This is where the difference in business model comes into play, because JD owned their own logistics network, they own the warehouses, they own the distribution, they were able to stay in business, while Alibaba's T-mall, Taobao, and Pinduoduo struggled. A lot of customers actually transformed to becoming JD customers, paying that a little bit premium to get the white-glove service that JD offers just so they could get food and other items delivered to their house during the pandemic. It will be really interesting to see how many of these customers JD is able to retain heading into 2021 versus how many churn back to the cheaper platforms. Hill: Bumble's first earnings report as a public company was a hit. Shares of the online dating company up more than 10% this week. Bumble is a growth company, Jason, and revenue grew more than 30%. Moser: Yeah, hey, listen, [laughs] I'm clearly not the target demo here, but a women-first dating app, as founder Whitney Wolfe Herd describes it, I think there's a possibility that my daughters will be using this platform at some point or another. I appreciate her perspective, and I'm rooting for this company, to be honest with you. To the numbers, 31% revenue growth that was, I think, impressive. Most of that growth came from the Bumble app. The Badoo app, which is the one more international focus, a little bit slower growth there and about 10.5% of overall growth there. But fourth-quarter total paying users grew 32% to 2.7 million users. Total ARPU of $20.02 versus just under $20, it grew 4% sequentially, 3% year over year. The company's calling for $164 million at the midpoint for the current quarter here. That represents 38% growth from a year ago. I was a little surprised at the optimistic reception, given that call for full-year revenue of $720 million, that's around 24% growth. It's not a company that maybe it's growing like a number of those other tech-heavy SaaS business models that we've become so familiar with over the past year. But again, I go back to DocuSign, talking about seeing stocks at a bit more of a refreshing valuation. That pegs this stock at around 11 times forward sales, which I think is actually pretty reasonable given that it seems like it's really just getting started. They've introduced the new Bumble Premium subscription, introducing ancillary services and Bumble BFF for platonic relationships. Bumble Biz, which is for professional relationships, I'd be interested to see where they take that. Hill: Poshmark's (NASDAQ: POSH) first earnings report as a public company was not a hit on Wall Street. Revenue looked good, but the online seller of secondhand clothes issued soft guidance for the current quarter, and shares of Poshmark down nearly 20% on Friday, Emily. Flippen: There is a lot of inherent skepticism about the concept of Poshmark, which is a community, again, mostly aimed at female users for people looking to resell their clothes. But if you look at just the numbers that management provided in this quarter, there were actually a lot of good things. We can start with gross merchandise volume, GMV, that was up 28% to just under $400 million for the quarter. Pretty strong growth coming out of the year that was really light for the apparel industry overall. They posted adjusted EBITDA of over $4 million, so increasingly becoming more profitable, at least on an adjusted basis. But more importantly, they kept nearly an 18% take rate on all the orders placed on their platform, that is top tier for online sellers, and even more impressive, when you consider the huge backlog of deliveries and the issues that we saw delivering for the holidays over the past season. Where their issues came in, as you mentioned, was actually guidance. The company is guiding for 32% to 36% revenue growth over the next quarter, which was below expectations. Perhaps more importantly, they only provided guidance for that first quarter, not throughout 2021, which also could have worried some investors. I'll provide the caveat that this is the first quarter Poshmark has had as a public company. We don't know anything about management. Are they sandbagging? We don't have those expectations already set. We'll have to see if this is a struggling retailer in terms of growing revenue in 2021, or a management team that just likes to beat expectations. Hill: Roblox went public on Wednesday at $45 a share. For those unfamiliar, Roblox is an online game platform for children that is wildly popular. Shares of Roblox quickly shot up to more than $75. [laughs] Jason, we've seen some frothy IPOs over the past year. Does this seem crazy, or given the market as a whole, does this seem reasonable to you? Moser: Well, it feels like we've got a little bit of a theme going on here, in regard to valuation. We've talked about it with a few of these other stories. I think with Roblox, a very big debut, trading at around 40 times sales. Now, that seems like the norm for a lot of these companies that are just coming to the public markets, and we still don't know enough about it. But what we do know, it is obviously a very popular platform in the gaming world for children. My kids, I guess, are a little bit older, they don't use it, I've never used it, so I'm not very familiar with it. But in studying the business and understanding how it works, it's for creators as well as players. It reminded me, they have an American Express-like closed-loop thing going on here, in allowing folks to both create and play games. It gives them a lot of control over that data. I think that really offers the potential for some very compelling network effects over time, and gaming obviously is a massive market opportunity. While this is something that's still relatively new to the market, I do understand the enthusiasm there. It's a direct listing, of course, so no new shares were actually created, and then the IPO didn't raise any capital, it just gave folks the opportunity to invest in the business. They report having just under 33 million daily active users at the end of 2020. That was up 85% from a year ago. I think it will be noteworthy to see how that active user growth continues on through 2021 and beyond. But to that user growth, revenue followed in line, revenue growth of 82% was just under $1 billion for the year. Again, a lot to learn about the business. I do understand the enthusiasm behind it, though. Hill: Shares of Dick's Sporting Goods (NYSE: DKS) up a bit this week, fourth-quarter profits and revenue came in higher than expected. Emily, this is another company with some tough comps coming up in 2021, but over the past year, this is a stock up 175%. Flippen: Tough comps is the perfect description of what 2021 is going to be for Dick's Sporting Goods. This quarter, they had a 66% increase in earnings per share with their record-setting 10% increase in same-store sales growth, but next quarter is when COVID kicks in. If you actually rewind to the fourth quarter of 2020, so last year or 2019, I should say, it was a completely different picture. They had guided for flat to 2% same-store sales growth in 2020, so that will be a critical number to watch. Hill: Funko (NASDAQ: FNKO) is one of the leading creators of licensed pop-culture products, and shares of Funko rose 25% this week after a strong fourth quarter report. Jason, people aren't just watching the Mandalorian, they're also buying Mandalorian Funko pops. Moser: Many may call this a toy company, but really, they call themselves a pop-culture consumer products company. While that may seem on the surface like semantics, I think it's really not. Looking at the numbers, fourth-quarter sales in the U.S., they had a great holiday season. Sales were up 18% to $171 million. That offset weakness internationally. When you look at what this company sells, to that pop culture nature, it really does feel like a lot of what they're selling is straight out of a Simpsons episode. You're talking about things like Snapsies and Funko Vinyl Soda, and pop items, and Stitch Shoppe, and board games. But they're best known I think for their figures, specifically bobbleheads. To that point, non-figure products represented almost 23% of the company's sales today. They're trying to go beyond being just the bobblehead company, so to speak, and it seems like it's working. They are building out a direct-to-consumer business. Those sales grew 80% over $50 million represent about 8% of the business now, versus about 4% a year ago. In just an interesting note there in the call of that, there's a New York toy fair that's held annually. Because of obvious reasons, they hosted their first ever virtual Funko Fair, where they partnered with licensors and retailers to engage. That event led to nearly 1.5 million units being pre-sold to fans through their retail partners, and many of those products still don't ship. They're not even going to be released for six to nine months. You can see, they obviously have a pretty popular line of products there that the consumers seem to not get enough of, and for the year, they're calling for sales growth of 25% to 30%. Hill: Walter Isaacson is an award-winning writer and best-selling author who is definitely a fan of innovation. Start with the fact that he's written biographies on da Vinci, Albert Einstein, and Steve Jobs, so it makes sense that his latest book would explore one of the most interesting parts of science and the Nobel Prize winner at its forefront. The book is The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race. Earlier this week, Isaacson talked with my colleague Corinne Cardina about gene editing, starting with how CRISPR technology works. Walter Isaacson: CRISPR is a pretty simple system. Bacteria have been using it for more than a billion years. It's how they fight off viruses, which is of course a useful talent to have as we face all these pandemics. What CRISPR is, is a system in bacteria that can remember the genetic code of viruses that attack them. Then, they see that genetic code again, they take an enzyme, a scissors that will cut up that invading genetic code. What Jennifer Doudna and her team did is said, ""We can turn that into a scissors that will cut our own DNA at some place we've chosen."" If we want to get rid of a bad gene like the mutation that causes sickle cell anemia, or if we want to create healthier children, we can use this system to just take a target that we want to cut in our DNA, and to use a guide that will take an enzyme scissors there and cut it there. Corinne Cardina: Within the gene-editing space, there is a major difference between what is called somatic gene editing and germline gene editing. I'll give you my understanding [laughs] and you can check me on this. With somatic gene editing, you're altering the genes within a particular person. There's either the ex-vivo method, removing their cells, engineering them in a lab, putting them back in the body, or the in-vivo method, in which you inject gene-editing molecules into the body. Somatic, it means body. It changes the person's genes and how their body creates certain proteins, but it does not impact how they pass on those original genes to their offspring. That brings us to germline editing, also called inheritable edits, in which the edits to the gene can be passed on to the offspring. You say that germline editing holds more promise, but more peril. Can you explain some of the big ethical questions that scientists are grappling with about germline editing and why it's such a big jump from somatic gene editing, which has largely already become accepted? You mentioned sickle cell anemia, plenty of trials going on with the somatic side. Isaacson: Yes, we've already cured sickle cell anemia this past year in a patient named Victoria Gray in Mississippi, using somatic editing. Meaning her stem cells were taken out of her body, edited, returned to her body. We've also used CRISPR in a far more controversial way. Just two years ago, a Chinese scientist who had been to Jennifer Doudna's seminars used CRISPR to edit the embryos which became two twin girls in China. They had been edited so that they didn't have a receptor that allows them to get the virus that causes AIDS. By doing it in an early-stage embryo, in theory, it means you're not just editing those twin girls, you're editing all their descendants, you're editing the human race. The moral question becomes, should we hack our own evolution? It's like Prometheus snatching fire from the gods. We now have the power to design our children and all of our descendants not to have certain traits, or maybe to enhance certain traits like height, or hair color, or IQ, whatever you may do in the future. That becomes ethically questionable to some people. Certainly we want to do it in order to fight off dreaded diseases like Huntington's or cystic fibrosis or sickle cell, but should the rich be allowed to buy better genes for their kids to make them taller or make them smarter or give them greater muscle mass? Not something we could do right now, but in the next few decades, that will be possible. Will we want to edit out some of the diversity of our species? Behind me is my balcony overlooking the French Quarter in New Orleans. I look at the passing parade of all sorts of types of people that add to the richness of our society. If we start editing our children, are we going to lose some of our diversity? Are we going to lose this notion that we're all created equal? These are the things that Jennifer Doudna, actually she makes this discovery, she has a nightmare that somebody wants to learn about it, and when she goes into the room to meet the person in her nightmare, it's Adolf Hitler. The book not only talks about the science of this, but it talks about how Jennifer Doudna went on a journey, went on a mission to enlist scientists around the world to say, ""What rules are we going to have in place for using this new technology?"" Cardina: That's where the role of public policy comes into the book. You discussed the very valid concerns about genetically encoding inequality. Of course, right now we have lots of financial inequality in the world. But if parents are able to go to the ""genetic supermarket"", it's not going to be free. You discuss references to Brave New World, 1984 -- how do you see the role of public policy in gene editing, and maybe how does Jennifer see it as well? Isaacson: I think initially, Jennifer Doudna and myself flinched at the notion of creating genetically modified children. It's like we all flinch maybe the first time we talk about GMOs in our food. But like GMOs in our food, we have to figure out, well, when can it be good and when can it be bad? At a certain point, I began to think, and so did Jennifer Doudna, that there are certain times where it would be immoral not to use this technology to alleviate suffering, to try to stop brutal diseases like Huntington's disease. But the way we're going to have to figure it out, it's not just delegated to the politicians or delegated to the scientists. I think we all have to be involved in thinking this new technology through. And by ""we,"" I mean you and me, Corinne, and you and me, all the listeners of this show, are going to have to say, we should be discussing this as a society. It's the largest moral issue we're going to face. And in order to discuss it, it helps to know a little bit about it. So by telling the story of Jennifer Doudna, I hope I make it very easy to understand what the possibilities are. In that way, all of us can engage in this discussion, whether it's at the dinner table or in our political lives, with what are we going to do with this newfound fire that we've snatched from the gods? Cardina: It's not just scientists in labs necessarily who are doing and experimenting with gene editing. I want to talk a little bit about what you call the rebels or the troublemakers. You quote Steve Jobs' famous Apple ad from '97 that celebrated the rebels and troublemakers who pushed the human race forward. We talked a little bit about the Chinese scientist who created CRISPR babies without getting approval from the greater scientific community. He actually got in trouble, he served time in prison, he's not allowed to do science in China anymore. Can you tell us about some of the troublemakers that you discussed in the book that have forced us into a new era of gene editing? Isaacson: The most prominent was this scientist in China, He Jiankui, who decided in sort of a rogue experiment to just make the first designer babies. People say, ""Well, it's science fiction it can't happen."" Well, it's already happened. He pushed it forward. I think he did it in a very irresponsible way, which is why he's under house arrest in China. Because it wasn't medically necessary. You can prevent AIDS in other ways. It was done in a sloppy fashion. But the question becomes, ""What happens when it can be done in a safe way? What happens when it is medically necessary?"" It's not that hard to do. In the book, I describe going to Jennifer Doudna's lab in Berkeley, and within two days, with just two graduate students helping me, I was able to edit human genes. Now, don't worry, we took them after I edited the cells and we mixed it with chlorine and killed them and flushed them down the drain. I didn't unleash them on the world. But it's going to be something that in the next couple of decades will become easy enough for any graduate student to do, and eventually, people will be able to do it like they create webcasts in their own house. We have to learn what the rules should be. Cardina: I want to talk a little bit about entrepreneurship. Jennifer occupies a really interesting, a huge spectrum from basic science, researcher, and really just curiosity-driven digging into things because she is curious, all the way to being a founder of multiple companies. The race to develop CRISPR technology led to three companies formed by the cast of characters that you chronicled. There's Intellia (NASDAQ: NTLA), Editas Medicine (NASDAQ: EDIT), and CRISPR Therapeutics (NASDAQ: CRSP). Of course, there are more gene-editing companies now, but these are the three that we've familiarized ourselves with, the founders of, by the end of your book. So at The Motley Fool, we're investors. Many of our audience members may have heard of some of these companies, and some may have invested in one or all three. What would you say generally to anyone thinking about putting their money behind companies focused on gene-editing applications? Isaacson: Well, first of all, it's both useful but also joyful to actually understand what these technologies do. That's what my book is about: What is CRISPR Therapeutics? How does that work? Now, that's a good company to invest in. It was just very successful in helping cure sickle cell anemia and a blood disease over in Europe. Likewise, things like Mammoth Biosciences, which was founded by Jennifer Doudna and her graduate students, and its rival group, Sherlock Biosciences, which was founded by the MIT Harvard people like Feng Zhang and his graduate students -- those have done things like use CRISPR and RNA to detect viruses. Well, that's become very useful these days. I think that it's always a problem when you invest based on whims and hunches. It's useful to understand the product. It's useful to understand what these companies do. That's why I spend a lot of time in my book showing how they form these companies and then looking at how everything from coronavirus to cancer, to the sickle cell, are being affected by the technologies these scientists first discovered and then decided to commercialize when they form companies. Hill: The book is The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of The Human Race. It was released this week as the No. 1 best seller on Amazon. [...] Welcome back to Motley Fool Money, Chris Hill here with Jason Moser and Emily Flippen. Our email address is radio@fool.com. We got an email from Steven Lee in Stillwater, Oklahoma. He writes, ""I'm always looking for opportunities for long-term buy-and-hold stocks. An idea I've been looking at for about a year now has been in the area of sports betting. Fewer than half of the states in America have actually legalized it, so it looks like a growth opportunity. I recently bought a basket of Penn National (NASDAQ: PENN), DraftKings (NASDAQ: DKNG), and MGM (NYSE: MGM), as these companies already have a strong stake in the sports betting market. I'd love to hear your thoughts on the industry's future, as well as if you think a basket similar to this is a good long-term buy-and-hold."" Jason, I'll just start with you. I love the fact that we're headed out of the gate, Steven has the right mindset in terms of looking for long-term buy-and-hold stocks. Moser: Yeah, totally agree. I absolutely do believe this is a terrific long-term opportunity. I'm a proponent of legalizing sports betting. I enjoy laying down a little cash here and there myself. I mean, a lot of states haven't even really been brought into the fold yet, but that is just a matter of time, I think. When it comes to finding the companies that will prosper from this opportunity, I think you have to look to clearly the bigger companies, companies like Penn that afford partnerships with media companies like Barstool Sports for example. I mean, they are going to be able to utilize a lot of data that they get from their users. Size really does matter, I think, in this industry. Sports betting is a tough business, but the companies that do it well, I think stand a benefit. I don't think you can put that toothpaste back in the tube. I think we're only going to see more and more states legalize it, and I like the basket approach. Hill: Emily, what do you think? Flippen: I think this listener should definitely give themselves a pat on the back for approaching a really volatile industry the correct way. While it is a growth industry when you think about the opportunity for sports betting, it also has a lot of risks. Trying to take a single winner in this space whose regulations haven't even fully developed, is a recipe for disaster. I agree with the idea of buying a basket, spreading your bets across. But in this case, I would just recommend this listener and everybody listening to think about what's driving the growth in the businesses that you're adding to your basket. It can be easy to over-involve yourself with casino companies, for instance, when you're trying to get exposure to sports betting. Don't forget about businesses like FuboTV, which offers a platform, or Gan Limited, which offers the back-end technology for sports betting. There's lots of ways to play the space. Hill: Let's get to the stocks on our radar. Our man behind the glass, Dan Boyd, is going to hit you with a question, Jason Moser, you're up first. What are you looking at this week? Moser: Taking a look at a company called Dexcom (NASDAQ: DXCM), ticker is DXCM. This is a medical device company that focuses on the design, development, and commercialization of continuous glucose monitoring, that's called CGM. Those are systems for folks with diabetes. If you look at some of the data, it's astounding. I mean, the International Diabetes Federation estimates that in 2019, 463 million adults around the world had diabetes. You look at the CDC data, estimates were that in 2018 they had about 34 million people with diabetes, of which 26.9 million people that were actually diagnosed. Dexcom has focused on building medical devices for these folks to be able to monitor their diabetes, and tech and connectivity investments are bringing remote patient monitoring to reality. This is really an Internet of Medical Things play -- partnerships with platforms like Livongo to bring data to that ecosystem, ergo Teladoc Health ecosystem because Teladoc Health acquired Livongo. I think that just really opened up a world of opportunities for a company like Dexcom, and to that point, they've grown revenue at a 37% annualized rate over the last five years. A lot to like about this one and I'm enjoying digging into it. Hill: Dan, question about Dexcom? Dan Boyd: Chris, less of a question, more of a comment. I can't even remember the last time we did a Motley Fool Money without a medical stock on stocks on our radar. Moser: I like that comment. I think that's an astute observation, and I would just reply with the idea that it is a massive, massive market opportunity where technology is just really making things more possible today than we ever would have imagined. Hill: Emily Flippen, what are you looking at this week? Flippen: I'm looking at a business called Coupang (NYSE: CPNG). The ticker is CPNG. It's often called the Amazon of Korea. They went public on March 11, so brand new company. It's a really interesting play on e-commerce in Korea. Amazing, huge addressable market, over $530 billion in addressable market expected by 2024, of which Coupang has the largest at 20% market share. Hill: Dan, question about Coupang? Boyd: Yes, I generally don't really like IPOs, to be honest. It's not something that I invest in too much. Emily, is there something about this IPO that's got you extra excited? Flippen: Absolutely not. I love the business, but I agree with you about IPOs, which is why this is a radar stock and not a recommendation. Hill: Two very different businesses, Dan. You've got one you want to add to your watch list? Boyd: Yeah, Chris, like I said, I'm not into IPOs, so I'm going Dexcom. Hill: [laughs] I like that your disdain for IPOs overcomes your disdain for the number of times we get medical companies. Boyd: It's not disdain for medical companies, it's just that you hear about them week in and week out on this show, at least. Hill: Jason Moser, Emily Flippen, thanks so much for being here. Flippen: Thanks, Chris. Hill: That's going to do it for this week's edition of Motley Fool Money. The show is mixed by Dan Boyd, our producer is Mac Greer. I'm Chris Hill, thanks for listening. We'll see you next week. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Chris Hill owns shares of Amazon, DocuSign, and Teladoc Health. Corinne Cardina owns shares of Teladoc Health. Emily Flippen owns shares of DocuSign, Pinduoduo Inc., Teladoc Health, and Ulta Beauty. Jason Moser owns shares of Amazon, DocuSign, and Teladoc Health. The Motley Fool owns shares of and recommends Alibaba Group Holding Ltd., Amazon, Apple, CRISPR Therapeutics, DexCom, DocuSign, Editas Medicine, JD.com, Teladoc Health, and Ulta Beauty. The Motley Fool recommends fuboTV, Inc and recommends the following options: short March 2023 $130 calls on Apple, long January 2022 $1920 calls on Amazon, long March 2023 $120 calls on Apple, and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-19,84.9225,86.93,84.47,86.1575,
DXCM,2021-03-22,85.88,90.53,85.7068,89.955,"Monday Sector Leaders: Technology & Communications, Healthcare Looking at the sectors faring best as of midday Monday, shares of Technology & Communications companies are outperforming other sectors, higher by 1.8%. Within that group, Enphase Energy Inc. (Symbol: ENPH) and KLA Corp (Symbol: KLAC) are two large stocks leading the way, showing a gain of 5.5% and 5.0%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is up 2.1% on the day, and up 1.80% year-to-date. Enphase Energy Inc., meanwhile, is down 6.84% year-to-date, and KLA Corp is up 19.06% year-to-date. Combined, ENPH and KLAC make up approximately 0.8% of the underlying holdings of XLK. The next best performing sector is the Healthcare sector, up 1.0%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Catalent Inc (Symbol: CTLT) are the most notable, showing a gain of 4.5% and 3.4%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.4% in midday trading, and up 1.86% on a year-to-date basis. DexCom Inc, meanwhile, is down 2.58% year-to-date, and Catalent Inc is up 5.37% year-to-date. Combined, DXCM and CTLT make up approximately 1.2% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, five sectors are up on the day, while four sectors are down. SECTOR % CHANGE Technology & Communications +1.8% Healthcare +1.0% Services +0.3% Consumer Products +0.1% Industrial +0.1% Materials -0.1% Energy -0.6% Financial -0.7% Utilities -1.2% 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-03-23,88.22,91.675,88.22,91.0425,
DXCM,2021-03-24,90.6675,90.6675,88.6125,88.9325,
DXCM,2021-03-25,88.9475,89.3525,85.0838,87.0475,
DXCM,2021-03-26,86.7325,88.3625,85.1112,88.1825,
DXCM,2021-03-29,88.22,88.7125,86.325,87.3425,
DXCM,2021-03-30,86.645,87.6038,85.3175,86.8,
DXCM,2021-03-31,87.5,90.875,87.0,89.8475,
DXCM,2021-04-01,90.6025,92.6615,90.2525,91.375,"3 Overlooked Healthcare Stocks to Buy Right Now In times like these, investing is exciting. Some stocks are up several hundred percent since their March 2020 lows, and it seems like the same high-flying growth stocks are in everyone's portfolios. However, it's often the stocks that consistently grow but don't get any hype that are the best long-term performers. Align Technology (NASDAQ: ALGN), Repligen (NASDAQ: RGEN), and DexCom (NASDAQ: DXCM) are three companies that have been growing sales and cash flow at impressive rates for years. In a world where that predictability isn't exciting enough to garner headlines in the financial media, investors ignoring them could be missing a great opportunity to build wealth over time. Image source: Getty Images 1. Align Technology For the maker of Invisalign clear teeth straighteners, investors looking back at financial statements years from now will do a double take when they see 2020. In the five years prior, the company had been growing sales and earnings per share at 26% annually. At the height of the pandemic, during the fiscal second quarter, sales dropped a truly abysmal 41% year over year. For the full year, revenue was up 3% to $2.5 billion. That's a testament to how quickly management was able to leverage its digital platform and expand its virtual care offerings. The company also continued to invest in brand awareness and acquired a company that makes software to design dental products. These moves have positioned Align to exit the pandemic stronger than it was when it went in, and that's a high bar. The company has essentially no debt, and prior to the pandemic was generating about $0.21 to $0.25 cents of operating profit for every dollar of sales. That's impressive for a device maker. For context, Apple's profit has been between $0.24 and $0.27 cents per sales dollar for the past several years. Unlike the $2 trillion iPhone maker, Align has a lot of room to grow. It only has a $43 billion market capitalization. Management estimates that approximately 500 million people globally could benefit from straighter teeth, and only 15 million begin treatment annually. Many of those people may get help sooner than anticipated. In the fourth quarter, revenue growth accelerated to 28%. Align isn't giving guidance for 2021 yet, but has mentioned that the year started off exceptionally strong. That's likely to continue as pent-up demand from people who have spent the last year looking at their own teeth on Zoom all day drives sales. With accelerating revenue, high profit margins, no debt, and a huge market opportunity, Align doesn't get nearly the attention it deserves. With the stock down about 12% from its recent highs, now may be a great time to pick up shares. 2. Repligen Repligen makes flow systems, membranes, resins, and other tools for the development of biologic drugs. As you'd expect, business accelerated with the pandemic. COVID-related programs accounted for 13% of its $366 million in sales for 2020. That portion increased through the year, culminating in 22% of fourth-quarter revenue. Even before the pandemic, business was booming, the previous five years had seen sales compound at 33% annually. Management expects revenue this year to be 37% to 43% higher than in 2020. Further, CEO Tony Hunt has set a target for $1 billion in revenue by 2025. That's still a fraction of the $3.7 billion addressable market he estimates. So far, the company is on track to achieve it. COVID will continue to be a tailwind for Repligen this year, accounting for between 12% and 15% of growth. Hunt is focused on expanding to meet the elevated demand. Last year, the company made three strategic acquisitions, enhancing its portfolio of single-use filtration and chromatography systems, as well as silicon assemblies. The focus on single-use processing is allowing the company to take share from competitors as customers move away from using stainless steel in their labs. That old way is less efficient because it requires intensive cleaning between batches to reduce the risk of contamination. Management has also been focused on the growing gene therapy market, where it now boasts of 75 meaningful accounts using Repligen technology. With management's own guidance implying 22% annual top-line growth over the next five years, and a track record of capitalizing on opportunities through product development and strategic acquisitions, Repligen has a proven formula. Shareholders would agree after enjoying a 5,000% gain over the past decade. With a current market capitalization of only $10 billion, there is still plenty of room for explosive growth to reward those who don't own shares yet. 3. DexCom DexCom makes small, wearable transmitters that send glucose measurements to a smart device every five minutes. The customizable alerts and ability to share data have allowed diabetes patients to better manage the disease without having to endure painful fingersticks. The company essentially invented the continuous glucose monitor market 21 years ago, and its reputation for precision has fended off competition from AbbVie and Medtronic. Even so, the market is big enough for more than one winner. The percentage of Americans with diabetes stands at 11%, more than double the 4.4% in 2000. Globally, it is estimated that 700 million people will have the disease by 2045. DexCom's leadership position in that large and expanding market has produced massive growth. The company has increased sales 45% on average each year over the past decade, and shares are up 2,100% during that time. Although DexCom only became profitable in 2019, it's been producing positive cash flow since 2014. After the company posted $1.9 billion in 2020 revenue, management is guiding for 15% to 20% growth for the coming year. That's a significant slowdown from the 31% increase in 2020. However, it forecasts 25% to 30% unit volume growth, attributing the difference to the lower-priced pharmacy channel. Another drag may be the new G7 product, which will be introduced at a lower price sometime in the second half of this year after being delayed last summer. The confounding factors should work themselves out over the next few years. The company believes sales will more than double by 2025 to between $4.0 billion and $4.5 billion. The lower price point and delay of the G7 are two reasons the stock is down 20% since its all-time high last August. For investors willing to take a longer view, the diabetes innovator is likely to reward their patience. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Jason Hawthorne owns shares of Align Technology and Zoom Video Communications. The Motley Fool owns shares of and recommends Align Technology, Apple, DexCom, Repligen, and Zoom Video Communications. The Motley Fool recommends the following options: long March 2023 $120.0 calls on Apple and short March 2023 $130.0 calls on Apple. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-05,91.875,92.2925,90.385,92.04,
DXCM,2021-04-06,90.8725,94.675,90.8725,93.25,
DXCM,2021-04-07,93.3925,93.4212,91.6475,92.35,
DXCM,2021-04-08,94.33,95.5675,93.045,94.595,
DXCM,2021-04-09,94.6,95.7925,93.275,95.7225,"Senseonics Stock Will Likely Rise on the Same Trajectory As DexCom InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senseonics (NYSEAMERICAN:SENS) is a nascent continuous glucose monitoring (CGM) company that is likely to follow a similar trajectory as DexCom (NASDAQ:DXCM). As such, SENS stock is likely to move up quite a bit soon. Source: Minerva Studio / Shutterstock.com DexCom is a much larger company whose stock has risen over 21 times in the past 10 years. It brought to market its CGM products over successive iterations during that period. As a result SENS stock is likely to move up 5 to 10 times in the next five years, assuming it receives Food and Drug Administration (FDA) approval for its CGM devices. Liquidity Fears Allayed However, in the past month and a half, SENS stock has dropped like a rock. It fell from a peak of $5.27 on Feb. 16 to around $2.60 today, Apr. 5. That is a heavy 50% tumble that makes it look like there is a problem with the company. But that is not the case. Recently Senseonics released its earnings on Mar. 4 where it said that the company now has $187.3 million in cash on its balance sheet as of Jan. 31. This is up from $18.2 million at the end of 2020. Cash went up as a result of equity financings completed during the first quarter of 2021. Here is what President and CEO Tim Goodnow said during theearnings callabout the company’s liquidity: “the existing cash and cash equivalent should be sufficient to fund the business through cash flow breakeven from operations and the commercial launch.” This relates to its 365 days sensor designed to be calibrated only once per week, called the Eversense XL. The company is already “collaborating” with a Swiss company, Ascensia, in marketing its 90 days and 180 days sensor throughout Europe. 7 Great Stocks to Buy Under $10 Last year Senseonics burnt through about $65.5 million in negative free cash flow, based on its Cash Flow Statement on page 90 of its recent 10-K filing. This implies that with $187 million, Senseonics now has the cash to last at least several years. In fact, analysts seem to believe that the FDA will review by early fall its most recent product, the Eversense XL. However, its commercialization seems to be already on track in Europe since Senseonics is using Ascensia in Europe to market its products. What This Means For Senseonics Therefore, investors can expect to see SENS stock move higher as the company rolls through these sets of catalysts. In addition, doctors are freer to schedule surgical implants of its diabetes monitoring devices. This will allow Senseonics’ revenue to climb out of the hole it is in. Last year, the company generated just $4.85 million in sales, down from $21.3 million in 2019. But now analysts surveyed by Seeking Alpha expect to see sales to more than double to $12.85 million in 2021. But by 2022 revenue is forecast to go up by over 6 times to $32.90 million. At a market cap of $974 million SENS stock trades for 30 times forward revenue multiple. But consider this. One of its main competitors, DexCom now has a $35 billion market cap and trades at 15 times 2021 forecast sales of $2.81 billion. Moreover, as I pointed out above, this stock has risen over 21 times in the past 10 years, including 4.4 times in the last 5 years. DexCom, like Senseonics, also has a cloud-based diabetes monitoring sensor product. This allows the recipient to not have to use lancers to prick their fingers while they monitor their blood sugar levels. What To Do With SENS Stock The average analyst either has a hold on the stock, according to TipRanks.com and at Yahoo Finance. Or else they have an average price target of $1.69, according to Marketbeat. However, I suspect these ratings are from before the company’s recent earnings release where they announced their jump in liquidity. If you look at the pathway that DexCom took over its history in the past 5 to 10 years, you can see that the market will warm up to Senseonics. Look to take advantage of the recent dip in SENS stock with a view toward its potential long-term trajectory. On the date of publication, Mark R. Hake did not hold a long or short position in any of the securities in this article. Mark Hake writes about personal finance on mrhake.medium.com and runs the Total Yield Value Guide which you can review here. The post Senseonics Stock Will Likely Rise on the Same Trajectory As DexCom appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-12,95.0675,97.16,94.2188,96.7875,"Bullish Two Hundred Day Moving Average Cross - DXCM In trading on Monday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $383.62, changing hands as high as $388.64 per share. DexCom Inc shares are currently trading up about 1.1% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $270.11 per share, with $456.23 as the 52 week high point — that compares with a last trade of $387.15. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-13,96.075,97.5475,95.685,97.025,
DXCM,2021-04-14,97.26,98.37,96.495,97.775,"Did DexCom, Inc. (NASDAQ:DXCM) Insiders Sell Shares? It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in DexCom, Inc. (NASDAQ:DXCM). What Is Insider Selling? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information. We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But it is perfectly logical to keep tabs on what insiders are doing. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise'. The Last 12 Months Of Insider Transactions At DexCom Over the last year, we can see that the biggest insider sale was by the Executive Chairman, Kevin Sayer, for US$14m worth of shares, at about US$362 per share. That means that an insider was selling shares at slightly below the current price (US$388). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 31% of Kevin Sayer's holding. In the last year DexCom insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! NasdaqGS:DXCM Insider Trading Volume April 14th 2021 I will like DexCom better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying. DexCom Insiders Are Selling The Stock The last three months saw significant insider selling at DexCom. Specifically, insiders ditched US$18m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all. Insider Ownership of DexCom I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that DexCom insiders own 0.6% of the company, worth about US$220m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. So What Does This Data Suggest About DexCom Insiders? Insiders haven't bought DexCom stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. But it is good to see that DexCom is growing earnings. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 4 warning signs for DexCom (1 doesn't sit too well with us) you should be aware of. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-15,98.5775,100.265,98.2325,99.8725,
DXCM,2021-04-16,100.142,100.412,98.41,100.01,
DXCM,2021-04-19,99.15,99.7525,97.9112,98.26,
DXCM,2021-04-20,97.4525,98.895,95.8162,97.2275,
DXCM,2021-04-21,97.8325,100.9,97.1875,100.405,"3 Unstoppable Growth Stocks You Can Hold for Decades Although many stocks are trading at or near their 52-week highs right now, that doesn't mean that they will run out of steam or that they are due for a crash. By focusing on long-term growth opportunities involving healthcare, e-commerce, and technology, investors won't need to worry about short-term price movements or earnings performances alone. DexCom (NASDAQ: DXCM), FedEx (NYSE: FDX), and Adobe (NASDAQ: ADBE) may not be terribly cheap picks today, but they could still make for solid long-term investments that you can buy and hold for years. Image source: Getty Images 1. DexCom Medical device company DexCom makes life a little bit easier for people living with diabetes. Its G6 continuous glucose monitoring (CGM) system sends users real-time glucose readings. It doesn't require finger sticks, either. With convenience and ease of use in mind, the CGM has quickly become the company's flagship product. Earlier this year, DexCom partnered with Teladoc Health (NYSE: TDOC) to help provide users of its platform with reports and information to help manage their blood glucose levels, at no additional cost. Telehealth is a great way to integrate data from DexCom's devices, and it could open up a new avenue for the company to accelerate its growth. For proof of that, you only need to look at Teladoc's impressive numbers. In 2020, the company reported 10.6 million total visits, which was a year-over-year increase of 156% as more people opted for virtual physician visits over in-person ones due to the pandemic. But in addition to telehealth, there's a significant need for better diabetes management in general. The Centers for Disease Control and Prevention previously forecasted that by 2050, one in three U.S. adults could have diabetes, up from just one in 10 in 2010. And diabetes isn't a disease patients can simply stop treating. DexCom's business has proven resilient amid the public health crisis. The company reported sales of $1.9 billion in 2020, up 31% from the previous year. And in 2021, it expects its top line to continue to grow by up to 20%. For patients with a chronic disease like diabetes, the ongoing need for care ensures that there will be plenty of demand for DexCom's products for the foreseeable future. In the past 12 months, the healthcare stock has risen 37% and has underperformed the S&P 500 and its 50% gains. But over the long term, that isn't a trend that I would expect to continue as there are too many growth opportunities for DexCom to slow down its ascent. That is also why I wouldn't worry about the stock's hefty price-to-earnings (P/E) multiple of 77, which is well above the 27 times earnings the average stock in the Health Care Select Sector SPDR Fund trades at. With long-term growth in mind, DexCom is a great buy and investors shouldn't be too bothered with how the company has performed over just the past four quarters. 2. FedEx One positive consequence of the pandemic is that companies have been improving their online capabilities to better adapt to the possibility that consumers aren't able to visit their storefronts, especially amid lockdowns. And while lockdowns may be a thing of the past once the pandemic is over, that doesn't mean consumers won't be ready to give up that convenience. This makes logistics another hot sector to invest in. A report from Allied Market Research projects that the global logistics market will be worth approximately $13 trillion by 2027, growing at a compounded annual growth rate (CAGR) of 6.5% until then. And it's hard to go wrong with a top company like FedEx to take advantage of those opportunities. For the nine-month period ending Feb. 28, FedEx's sales of $61.4 billion grew 18.4% from the previous year. Lower fuel costs and greater efficiencies have also helped Fedex's bottom line double during that time to $3.4 billion. Although the stock has been on a run this year, rising 140% in value, it still may not be too late to invest in the business. As companies like Amazon, Shopify, and Etsy rise in popularity and generate more revenue on their platforms, that is only going to fuel more growth for logistics and timely shipping. In 2020, online spending in the U.S. rose 44% from the previous year -- the highest annual growth rate in decades. And as e-commerce grows, so too will the demand for logistics. Although Fedex's stock isn't dirt cheap, at a P/E multiple of 25, it is still lower than the 29 times earnings the average stock in the SPDR S&P 500 ETF Trust trades at. 3. Adobe On March 23, Adobe released its first-quarter results for fiscal 2021 where sales for the period ending March 5 were a record $3.9 billion and grew an impressive 26.3% year over year. What I love about Adobe is that the bulk of its business is subscription-based and recurring. During the past quarter, 91.8% of sales came from subscription revenue. That's even higher than the 88.4% it accounted for a year ago. The global software as a service (SaaS) market is rising rapidly, and analysts from KBV research project that it will be worth $185.8 billion by 2024, rising at a CAGR of 21.4% until then. With a popular and versatile suite of products, including Photoshop and Publisher, there's little reason to doubt that Adobe won't be able to tap into that growth as its software is essential for many industry professionals. Strong growth prospects, accompanied by impressive gross margins that typically come in at 85% or better, put Adobe in a fantastic position to continue generating great results for a long time. In 12 months, shares of this tech stock have risen by 58%. Today, the stock trades at 44 times earnings, which is well above the S&P 500 average. However, you shouldn't expect to catch it at much of a discount anytime soon, as its business looks to be as strong as ever. 10 stocks we like better than Adobe Systems When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Adobe Systems wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Adobe Systems, Amazon, DexCom, Etsy, FedEx, Shopify, and Teladoc Health. The Motley Fool recommends the following options: long January 2022 $1920.0 calls on Amazon and short January 2022 $1940.0 calls on Amazon. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-22,100.785,103.405,100.785,102.595,"Top Stocks 2021: If you Only Buy One IOT Stock, It Better Be Splunk InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note: This article is a part of our “If You Only Buy One Stock” series where we look at 2021’s most popular investing trends and have our top financial journalists make their very best pick. Click here to see more names for your must-buy list. If you’ve ever used a Nest thermostat, or asked Alexa to check the weather, then you have embraced the world of IoT (Internet of Things). IoT is basically a smart network—a way to connect internet-enabled devices with each other so they can make decisions and act upon them. Source: Michael Vi / Shutterstock.com With tens of billions of “things” connected, from home appliances and vending machines to livestock and factory machines, the IoT ecosystem is a computing behemoth that feeds on itself every second of every minute of every hour of every day. The IoT not only becomes bigger with each new touchpoint, it also brings people — and machines — closer. Given this is expected to be a $1.6 trillion market by 2025, investors won’t want to miss out. Ripple Effect Investing A quick Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) search of “Top IoT” stocks will point you to some of the most obvious winners. These companies mostly focus on the connectivity piece of the IoT network — whether we’re talking about early tech innovators like CalAMP (NASDAQ:CAMP), or more industry-specific players like Dexcom (NASDAQ:DXCM) and Alarm.com (NASDAQ:ALRM) in medical and security systems. There are also more diversified ways to play the theme, like buying into enterprise networking and chip giants like Cisco (NASDAQ:CSCO) and Intel (NASDAQ:INTC), or even the Global X IoT Index (NASDAQ:SNSR) exchange-traded fund. The connectivity piece of IoT is a big, big market — but a lot of players are going after it, and valuations look stretched. ALRM, for example, trades just 14% from its all-time high. Investors looking to get into this space can still jump in though, by thinking about it another way. The secret: invest in the “ripple effect” of IoT technology. Because you know who else loves IoT? Hackers. The bigger and more connected the ecosystem, the more breachable it is. Consider that everyone in your workplace has a PC, a phone and a bunch of other digital devices. All of these connect at some point or another to your corporate network. Those same devices are also being used on home networks and public WiFI networks. That means every time you connect onto the network, whether it’s from home, from work, or while sipping your soy latte at Starbucks (NASDAQ:SBUX), you have opened up a path for a hacker to steal the digital crown jewels. And now we’re connecting more “lowly” devices like thermostats to the same network as more sensitive information. That makes it easy for the bad guys. Case in point: hackers were able to break into a casino database by tapping into a smart thermostat in the lobby fish tank. If You Could Buy Only One: SPLK Stock EVERY device connected to an IoT network needs to be smart in order to be secure. And that’s why, if you could buy one IoT stock, the stock to buy is Splunk (NASDAQ:SPLK). This software company — which got its name from spelunking, or the exploration of caves — mines for information within corporate networks in real-time. Splunk’s focus is on real-time data analytics. The company’s technology helps customers improve computer network performance and provides insights into security and compliance. Now, the company is setting its sights on industrial IoT. Splunk’s software collects, analyzes and visualizes real-time and historical machine data from any source. This includes computing devices, control systems, sensors, or anything else connected by industrial networks. Given the company’s software and cloud focus, Splunk’s business model has several appealing characteristics. Growth investors will appreciate strong recurring revenue (up 40% year-over year), expanding operating margins (13% in the most recent quarter), and a mix shift toward higher-margin products. Valuation is also reasonable, with SPLK stock having pulled back over 30% from its summer highs. Finally, with cloud giants Amazon (NASDAQ:AMZN) and Microsoft (NASDAQ:MSFT) integrating more analytics and security features into their services, a specialized company like Splunk could also make an attractive acquisition target. On the date of publication, Joanna Makris did not have (either directly or indirectly) any positions in the securities mentioned in this article. Joanna Makris is a Market Analyst at InvestorPlace.com. A strategic thinker and fundamental public equity investor, Joanna leverages over 20 years of experience on Wall Street covering various segments of the Technology, Media, and Telecom sectors at several global investment banks, including Mizuho Securities and Canaccord Genuity. The post Top Stocks 2021: If you Only Buy One IOT Stock, It Better Be Splunk appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-23,102.138,104.148,102.0,103.75,
DXCM,2021-04-26,103.958,104.75,102.604,104.692,
DXCM,2021-04-27,104.21,105.75,104.21,105.425,"Can This Popular Reddit Stock Make You Rich? There were few better zero-to-hero penny stocks in 2020 than that of continuous glucose monitor (CGM) manufacturer Senseonic Holdings (NYSEMKT: SENS). In July 2020, its stock was worth $0.40 cents per share. By February 2021, however, its share price shot up to over $5.50 thanks in part to Reddit-fueled speculation. Despite a 60% plunge from highs, the company still has an impressive market cap of $907 million, considering its precarious revenue situation. Because of competition concerns, Senseonic has also attracted a dedicated base of traders betting against its success, with over 18% of the entire float sold short. Can Senseonic beat the naysayers and continue its momentum? Image source: Getty Images. The bull case for Senseonic Back in September, Senseonic received a life-saving $35 million cash infusion from Ascensia to resume the commercialization of its GCM device, Eversense. The company had halted sales of these CGMs as patients with chronic illnesses deferred medical procedures (such as CGM implants) that put them at risk of exposure to COVID-19. Sales resumed that month. There are currently only four companies making CGMs in the U.S., and Senseonic's device has been reported to have the best accuracy and last the longest. Senseonic is awaiting a decision by the U.S. Food and Drug Administration (FDA) on its Eversense 180 CGM. If successful, the company's glucose sensors would only require replacement every six months, compared to three months for its current device. Senseonic also anticipates the launch of Eversense 365 in 2023 and an improved version with real time glucose updates and storage to arrive on the scene in 2024. This year, the company expects to generate between $12 million and $15 million in revenue. By 2025, it believes that its Eversense sales could skyrocket to upwards of $200 million per year. The bear case for Senseonic There is no doubt that these projections are very rosy. However, the future looks far bleaker after evaluating products from Senseonic's competitors. The Eversense monitors are largely first-generation medical devices with sensors that require surgical implants into a patient's body (at a clinic, doctor's office, or hospital). At the moment, sixth-generation CGMs, such as the Dexcom G6 (made by the namesake company, Dexcom), come with self-serve insertion bots for their sensors. The Dexcom G6 also allows for real-time monitoring of glucose levels, with a mean measurement error of 9% compared to Eversense's 8.5%. The best part is its affordability. Each Dexcom G6 sensor lasts for 10 days, while its transmitter lasts for about three months. All combined, the CGM has an upkeep of $6,100 per year plus a one-time $365 fee for the receiver. Meanwhile, the current Eversense CGM sensor lasts 90 days, costs $2,147 for a first-time insertion, and $1,279 for every subsequent removal and reinsertion. The annual upkeep of the CGM is around $5,984. Since the cost is dependent on the number of procedures, it will fall as the sensor life increases. It's estimated to be just $3,426 for Eversense 180 and far less for Eversense 365, if the devices are approved. But we cannot look at just cost when comparing the devices. It's far more convenient for patients to get self-insertion CGMs through the mail rather than have them implanted at a doctor's office. Between 2018 and 2020, Senseonic generated a meager $8.3 million in product revenue. It cannot manage to break even in terms of gross margin. Since its inception in 1996, the company has lost $648.5 million. Before its $175 million equity infusion in Q1 2021, the company had just $35.9 million in assets to offset $177.2 million in liabilities. What's the verdict? The best word I can think of to describe the Eversense CGM series is ""fragile."" Sure, the device lasts longer and has marginally better accuracy, but its surgical implant requirement is a huge drawback, which has become especially evident during the pandemic. What's more, the high cost of innovation makes Senseonic's business model unsustainable. Its peers, such as Abbott Laboratories (NYSE: ABT), Dexcom, and Medtronic (NYSE: MDT), are all better capitalized and farther ahead in their technology. By the time Senseonic launches Eversense 365, its competitors will likely have moved on to seventh or eighth-generation CGMs. It's typically not a good idea to go long on stocks of a healthcare company that can only play catch-up. 10 stocks we like better than Senseonics Holdings, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-04-28,104.568,106.655,104.292,106.442,
DXCM,2021-04-29,107.0,107.235,104.662,105.425,"[""Dexcom Inc (DXCM) Q1 2021 Earnings Call Transcript Image source: The Motley Fool. Dexcom Inc (NASDAQ: DXCM) Q1 2021 Earnings Call Apr 29, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom First Quarter 2021 Earnings Release Conference Call. My name is Adrienne, and I'll be your operator for today's call. [Operator Instructions]. I'll now turn the call over to Sean Christensen. Sean, you may begin. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Thank you, operator, and good afternoon everyone. Welcome to Dexcom's First Quarter 2021 Earnings Call. Our agenda begins with Kevin Sayer, Dexcom's Chairman, President, and CEO, who'll provide a summary of our progress, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. And then an update from Quentin Blackford, our Chief Operating Officer on the company's strategic initiatives and scaling progress. Following our prepared remarks, we will open up the call for your questions. At that time, we ask analysts to limit themselves to one question, so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our first quarter performance on the DexCom Investor Relations website on the events and presentations page. With that, let's review our Safe Harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof, based on information currently available to Dexcom are subject to various risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements, and factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's Annual Report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call we will discuss certain financial measures that have not been prepared in accordance with GAAP, with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our first quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Sean, and thank you everyone for joining us. Today, we reported strong first quarter results for total revenue growth of 25% over the first quarter of 2020. As I often tell our employees, our ability to thrive as a company ultimately comes down to solving significant problems with a great product, and that is what we continue to see with G6. We hear incredible stories of improved glucose control, reduced disease burden, and people being empowered, and those responses have only increases with enhanced tools to better drive our customer experiences. These stories are coming from multiple sources as well, whether it is coming from G6 users or their family members who are getting better control on their glucose levels to real-time data, or clinicians who are empowered by the ability to gather unique insights into the diabetes treatment of their Type 1 or Type 2 patients and optimize therapy accordingly. And even new settings like nurses and doctors and the inpatient setting who are deploying CGM and learning about its potential to optimize workflows, and benefit from our remote monitoring technology. New customer additions are off to a great start in 2021, especially in the U.S., as we continue to see growth across all channels, building from the increased access that we've gained over the past several years. This includes continued traction for people with Type 1 diabetes and Type 2 intensively managed diabetes, both of which have continued the strong growth momentum that we've seen over the past couple of years. We're also seeing a growing number of Type 2 non-intensive customers on G6, not only through our partnerships like UnitedHealthcare's Level 2 program, but also including the other innovative programs and providers that are establishing early access to Dexcom CGM. We are also progressing our strategic commercial efforts with the remainder of our commercial sales force expansion completed in the first quarter and our direct-to-consumer marketing efforts generating new levels of brand awareness. The Super Bowl commercial featuring Nick Jonas was a highlight for the company in the first quarter. We were able to generate significant excitement for our employees and customers, many of whom have sent us pictures and stories of their pride in feeling represented during one of the biggest annual events in the world. We also contribute to a broader conversation in the diabetes community that we hope will help facilitate broader access to CGM in the future. The ad drove a record number of visitors to our website, a record for a single day new customer leads and significantly more media impressions than we generated in all of 2020, and we are confident that there will be ongoing benefits that will come from the ad, in fact according to an independent Harris Poll, Dexcom led all Super Bowl advertisers in brand equity growth. Overall, it was a great investment for the company, and I'm really proud of our team for pulling it together. Our commercial efforts also include a strong push from our teams to expand access to Dexcom CGM technology internationally both deeper and existing markets as well into new geographies. With Dexcom in the strongest majority position in the company's history as a result of our scaling initiatives, we are aggressively advocating for broader access to our G6 systems for people with Type 1 diabetes, and intensively managed Type 2 diabetes, similar to what we have done here in the United States. Since we last reported in February, we have received confirmation from three additional Canadian provinces that they will begin covering Dexcom CGM. This is a great step forward in expanding access for people with diabetes. There is significant demand from customers and clinicians, and we are optimistic that we will continue this positive momentum in Canada with both the public and private payers over the coming months. In certain reimbursed markets we are proactively lowering price to significantly expand access through incremental customer populations. This positions us well continue to grow sensor volume significantly now and into the future, and we believe the incremental volumes will more than offset the impact of price in the near-term. In conjunction with our commercial initiatives and the growing CGM category awareness, we are advancing the clinical and regulatory path for our next-generation G7 CGM system. As a reminder, we expect G7 to improve all aspects of the current customer experience offered with G6, in a disposable wearable that is less than half the size. We are working to prepare the submission for CE Mark in accordance with New Medical Device Reporting Standard in the EU. At this point, we remain on track for our target launch of G7 in the second half of 2021. We also plan to present preliminary data on G7 performance at the upcoming ATTD Conference in early June. Our trial that will support our U.S. ICGM filing is also well under way. And we have received outstanding feedback from the investigators and patients involved. We expect to complete that trial in the current quarter and we'll keep you updated as we progress toward regulatory approvals and launch. Even as we advance our strategic plans and have seen continued customer growth over the past year, the evidence of the global pandemic remains with us. We continue to navigate certain closures and territories that have seen cases spike, and our team remains focused on the three priorities that we have emphasized throughout the past year. The health and safety of our employees, continued supply of our customers and service to our communities. Towards this end, we were pleased to recently work with the State of Arizona to open the first indoor mass vaccination facility in Arizona to help the community as it transitions to the heat of the summer months. This facility rests within our Mesa distribution facility and has the capacity to support several thousand appointments per day. I am proud to lead a company whose employees are so dedicated to the service of our customers and willing to think creatively about what it means to be a leader in the communities that we serve. As we come back to first quarter results, I want to welcome a new voice to ourearnings call very familiar to many of you already. Last month, we announced the promotion of Jereme Sylvain to the role of Chief Financial Officer, and I'm pleased to have Jereme joined Quentin and I for his first Dexcomearnings callthis afternoon. Jereme? Jereme Sylvain -- Cheif Financial Officer Thank you, Kevin. I'm excited to be with you today and in the new role as we advance our work together for people with diabetes. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found on today's earnings release as well as on our IR website. For the first quarter of 2021, we reported worldwide revenue of $505 million, compared to $405 million for the first quarter of 2020, representing growth of 25% on a reported basis and 23% on a constant currency basis. This is our 7th consecutive quarter of revenue growth of $100 million or more. Impressively, our revenue performance came against our toughest quarterly comparison in 2020 for both our U.S. and international businesses as the first quarter of 2020 was largely unaffected by the COVID-19 pandemic. We also saw a nearly 40% global unit volume growth in the quarter, demonstrating the continued customer growth in the business, U.S. revenue totaled $381 million for the first quarter compared to $292 million for the first quarter in 2020, representing growth of 30%. Our U.S. business was the primary driver of growth in the first quarter with our commercial efforts in rising CGM awareness, driving solid volumes and an acceleration from our fourth quarter growth percentage. We believe that we are well-positioned to continue this momentum. Our DTC efforts and driving awareness of Dexcom CGM. we have new connected systems coming to market that build from years of collaborative work with our partners and we have an expanded field sales force, equipped with the product that our customers love. Our international business reached another quarterly high watermark with a revenue of $124 million, or 10% growth on a reported basis compared to the first quarter of 2020. As we saw in the final three quarters of 2020, the impact of COVID-19 lockdowns has had a greater impact on new customer growth in certain international markets, which has a compounding effect on our reoccurring revenue model. Nevertheless, we delivered growth against our toughest quarterly comp of 2020, or international revenue grew 61% before the pandemic. We continue to see strong growth across a number of our markets, particularly in countries with the administrative requirements to access CGM are minimized via our e-commerce channel or via broad reimbursement. As many of you have seen, we've successfully reduced our manufacturing costs and intentionally increased sensor production capacity. Through these manufacturing efficiencies and increased capacity we are no longer restricted to focusing on high-risk, high reimbursement populations. With this increased commercial flexibility we are executing on our strategy to broaden access to our CGM technology by pushing deeper into existing markets we previously could not address. Through the incremental volumes generated by these efforts, we believe we will offset the near-term price impact, while better positioning the company for long-term growth. Our first quarter gross profit was $343.9 million or 68.1% of revenue compared to 63.9% of revenue in the first quarter of 2020. The fact that we are driving margin expansion despite absorbing the channel mix impact associated with the acceleration of our U.S. business to the pharmacy channel is a testament to the work of our teams to drive down material and production costs. Operating expenses were $297.5 million for the first quarter of 2021 compared to $215.4 million for the first quarter of 2020. The increase in operating expenses as a percentage of sales in the first quarter of 2021 is a result of several of the key initiatives that we outlined in our original 2021 guidance in February. This includes our expanded commercial efforts with the doubling of our U.S. sales force and increased global DTC marketing efforts, both reflected in the quarterly results. In addition, the first quarter research and development expense includes costs associated with our large U.S. ICGM trial for G7, which will continue into the second quarter as we generate the data necessary to support our regulatory filing. Offsetting those strategic investments, we continue to gain leverage in our general and administrative expenses in the quarter demonstrating the benefits of our scaling initiatives. To that end, as we've previously indicated, we have launched a global business services facility in Lithuania, which is now officially live and servicing our customers. Operating income was $46.4 million, or 9.2% of revenue in the first quarter of 2021 compared to $43.3 million, or 10.7% of revenue in the same quarter of 2020, with the 150 basis point decrease resulting from our strategic investments, offset by our gross margin improvement. Adjusted EBITDA was $94.4 million or 18.7% of revenue for the first quarter, compared to $77.8 million or 19.2% of revenue for the first quarter of 2020. Net income for the first quarter was $32.8 million or $0.33 per share. We remain in a great financial position, closing the first quarter with more than $2.6 billion in cash and cash equivalents and well-positioned to continue our G7 scale up and remain opportunistic as we look to expand our growth opportunities. Turning to guidance. We expect some impact to new customer starts to continue during the ongoing global vaccine roll-out, particularly in certain international markets as well as continued higher than usual volumes in our U.S. Medicaid channel as the economy recovers. With the strong first quarter performance, as well as the currency benefit that we saw in the first quarter and continue to anticipate, we are pleased to be in a position to raise our full-year 2021 revenue guidance. We now expect 2021 revenue to be between $2.26 billion to $2.36 billion, representing growth of 17% to 22% over 2020. This growth continues to factor in strong unit growth volumes which are offsetting the impact of lower revenue per customer channels and our recent efforts to broaden access to G6 in international markets as well as the impact of currency. Turning to margins, we are affirming the full-year 2021 targets previously established on our fourth quarter call. This includes non-GAAP results to be approximately at the following levels. Gross profit margins of approximately 65%, operating margins of approximately 13%. We continue to expect that adjusted EBITDA margins to be approximately 23% and finally, as you may have noticed, from a tax perspective we have transitioned to profitability and will have a tax rate applicable to earnings going forward. Our expectation [Technical Issues] the call over to Quentin for a scale and strategy update. Quentin Blackford -- Chief Operating Officer Thank you, Jereme. It's been a pleasure to work alongside Jereme for the last 7 years of our careers, and I am thrilled for him as he now steps into the CFO role. I look forward to watching him take this next step in his career and look forward to the many contributions that he will make in his new role, while I'm also excited by the opportunity to turn my attention much more broadly to our strategic and scaling efforts across the organization. Our teams remain incredibly focused on our strategic initiatives and are making great progress on several fronts. As Kevin mentioned, we are advancing our regulatory and clinical efforts for G7 and we'll present the first set of G7 data at the upcoming ATTD Conference in early June. As we press forward toward our G7 goals, we are making steady progress in our effort to scale G7 manufacturing to support our launches and the continued growth of our global customer base. In the near term, this includes the lines that we are building in our San Diego and Mesa, Arizona facilities. We've also broken ground on our manufacturing site in Malaysia, which we expect will enable us to significantly scale our G7 production capacity to serve meaningful more customers as we continue to grow our business in the years to come. Even with G7 on the horizon, we remain committed to building on the leading customer experience that we have established for users of our G6 system. Following the December regulatory approval in the U.S., we rolled out an update to the G6 algorithm in the first quarter. We believe this update will drive further reductions to times in which data is temporarily unavailable. And I've seen excellent results from the initial launch of this updated algorithm in Canada in 2020. These are the kinds of incremental improvements that we are always looking to provide, and they are contributing to our strong customer retention and satisfaction levels reflected in our industry-leading net promoter scores. On the insulin delivery front, we were encouraged to see the great results from the Omnipod 5 pivotal trial presented at ENDO 2021, and look forward to the upcoming launch of that system for our Dexcom customers using the Omnipod pump. With this launch in Omnipod's differentiated patch pump form factor, as well as Tandem's continued market traction with their Dexcom connected Control-IQ, we believe that we are very well-positioned to continue to benefit from the growing appreciation for these automated insulin delivery systems. Similarly, we continue to advance our development with Eli Lilly, Novo Nordisk and more recently Ypsomed leaving us in a strong position in future years as people with diabetes stand to benefit from greater variety in their choices for Bluetooth connected insulin delivery options that integrate Dexcom CGM. We've discussed the excellent first quarter performance in our U.S. IIT market, as well as some of the key strategic initiatives that we are undertaking to expand access in our international markets. We are also making excellent progress in our effort to drive the 3rd pillar of near-term growth that we highlighted at our 2020 Investor Day, the non-intensive Type 2 market. As we've mentioned before, we are taking multi-channel approach to enabling access to Dexcom CGM in the absence of widespread reimbursement. This involves direct work with payers, digital health programs, healthcare providers and integrated networks, as well as the patients themselves. The early roll-out of Level 2 is progressing well, as we continue to see that program expand and our teams are working well with the UnitedHealthcare team to optimize the experience for members using our G6 system as part of that program. We also worked with several partners to expand their use of G6 and their respective Type 2 populations in the first quarter. This includes the initiation of commercial pilots with Teladoc Health Livongo for Diabetes platform, as well as with Welldoc. Everside Health also announced that it will offer G6 to its members with Type 2 diabetes in its Healthstat business unit, and we are proceeding there now in a pilot phase. This relationship builds from our initial work with Healthstat over the previous 2 years, including the use of Dexcom CGM in a pilot for health screenings at on-site clinics. Each of these relationships is expanding the approval of customers who can access our technology, while generating evidence of the utility of Dexcom CGM for the broader Type 2 market that we believe will drive access and awareness in the future. Beyond these core growth initiatives, our teams continue to advance innovative research and product development that we feel will contribute to long-term growth for Dexcom. This includes the hospital market, where we are generating data via our patient registry, and receiving great feedback as many hospitals across America continue to take advantage of the FDA's temporary allowance to use Dexcom CGM in the inpatient setting during the pandemic. This also includes several clinical studies assessing the use of Dexcom CGM for better management of gestational diabetes, a solution that we believe can enhance the outcomes for both the mother and the child. And finally, we continue to access next-generation technologies that we believe can build from the sensor platform that we've established with G6 and G7. We look forward to updating you as we progress. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thanks, Quentin. As you can see, we're off to a great start to the year, and working hard to execute on the strategic pathway that we laid out for 2021. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time, and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions and Answers: Operator Thank you. [Operator Instructions]. And our first question comes from Jeff Johnson from Baird. Your line is open. Jeffrey Johnson -- Baird -- Analyst Thank you. Good afternoon, guys. Let me, I'll put it into a multi-part question I guess but. Kevin, I think it's officially one question. But on the channel mix headwinds that we've been talking about here the last 6 to 8 quarters or so, is it still fair to be thinking around $200 million plus or minus this year, and given the exit rate from 4Q of '20, still fair to think a little bit of that as front-end loaded? And then when I look at your 30% U.S. growth, it would seem like, if I axe out the channel headwinds, the pricing headwinds there volumes must have grown well north of 40%. So if you could just kind of confirm that from a pricing versus volume mix in 1Q U.S. number that would be helpful as well. Thanks guys. Kevin Sayer -- Chairman, President and Chief Executive Officer Jereme. Will you take that one, Jeff. Jereme Sylvain -- Cheif Financial Officer Yeah, Jeff. To your question on what the channel mix headwinds are, we'll just tell you what the numbers were for the quarter, it was about $50 million for the quarter, and if you recall, we talked about it being a little bit more straight lined over the course of 2021 due to comps. The one thing we have talked about and Kevin referred to it on the call, as did I, is that we are going to be a little more aggressive in international markets, and so because of that we're raising what we call channel mix/pricing headwinds to about $250 million on the year, and that obviously takes into account the aggressive steps were taken outside the U.S. In terms of your question in terms of growth and unit volume, we talked about unit volume approaching 40% on a global basis. When you take the channel mix headwinds we talked about, you are correct. The U.S. unit volume growth was well in excess of that and obviously being the stronger point of the quarter from a growth perspective. So you are seeing that performance on the quarter. Operator And our next question comes from Joanne Wuensch from Citibank. Your line is open. Joanne Wuensch -- Analyst Thank you very much. Can we go back to what you just said please, to be clear, the $50 million in the quarter, how much of that was U.S. versus OUS? Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, so Joanne, we generally don't break down the two. what we did talk about was $50 million is the global, now a majority of that has traditionally been the channel mix from pharmacy or from DME into pharmacy, but when we give that number we give a global numbers that was $50 million globally on the quarter, again heavily weighted U.S. Joanne Wuensch -- Analyst Okay. I'm going to sneak one more in, because that was a clarification, is there any reason that is not possible for G7 to be in the U.S., by the end of this year? Kevin Sayer -- Chairman, President and Chief Executive Officer We're not giving any G7 timelines, other than we will launch it by the end of the year. As I said in the earlier portion of our remarks, our U.S. pivotal study will conclude this quarter, and then we'll file. We're working on our filing in Europe under MDR rules for CE Mark. And we'll go from there. Time will tell, but everything is going well. We're happy with the progress of the product. We're extremely happy with the feedback we've gotten from clinicians and patients; in fact, one clinician called me this morning, and between our our prep for this call will tell me how great the product was. So we're very happy with it, but we're not going to give any other timelines than what we have so far. Operator And our next question comes from Robbie Marcus from JP Morgan. Robert Marcus -- Analyst Great. Congrats on a nice quarter and thanks for taking the question. I wanted to talk about the guidance raise, it was more than the beat you had in the first quarter. So maybe walk us through your new patient assumptions and what's driving that U.S. versus OUS? And if you could comment at all on how the early trends of the Super Bowl and increased DTC spend and sales force doubling has benefited the company so far, and what to expect in 2021? Thanks. Jereme Sylvain -- Cheif Financial Officer Sure. Yes, we can walk you through it. The guidance raise was approximately $25 million of it was currencies, we referenced some of the foreign currency tailwinds associated with and the other half was related to volume growth expected both in the first quarter and on the balance of the year. In terms of what we saw in terms of new patient adds in the first quarter, new patient adds were slightly ahead of expectations, and so that's really as we look to the balance of the year, certainly those repeat customers obviously play through in the balance of revenue for the year. And so we've added that to the guidance. We still are bullish on the year, we still expect to have a very strong year. I think, there was any question there. And I think if you see the performance in the U.S. results, I think you're obviously seeing a lot of to your second question, a lot of the DTC while the Super Bowl ads as well as the new sales force ads starting to really play through, not to mention the fact that we have a sampling program that's out there that is starting to allow our folks to trial the product, which we think is garnering interest as well. So that's all been contemplated in the guidance. as we lay it out, and I think what you'd say is for the balance of the year. I do think you are seeing the momentum continue to support raising what we raised it by. Kevin Sayer -- Chairman, President and Chief Executive Officer And Robbie, I would just, the one thing I'd add to that is as Jereme laid out in the prepared remarks, our decision on the international markets with respect to opening up access, I do expect you're going to see that new patient number continue to perform very nicely in the back half of the year as we're accessing markets that are 5 to 6 times larger than what we had coming end of the year in some of these markets. So, very excited about where that new patient number potentially goes to. Operator And your next question comes from Matthew O'Brien from Piper Sandler. Your line is open. Matthew O'Brien -- Analyst Afternoon, and thanks for taking the question. Just a follow-up on the pricing commentary. The $200 million to $250 million, it's obviously a pretty meaningful increase, we've got Libre 3 over in Germany. Now, you're talking about being more aggressive in terms of lowering pricing OUS I think from access. I mean, does that, is it a function of Libre 3 you're trying to be aggressive in front of a more broad launch there with G6 over there? Is that a reason why you're increasing the pricing concessions right now, and then what does that say about when 3 comes to the U.S. and how can G7 can offset that? Kevin Sayer -- Chairman, President and Chief Executive Officer We've not made our decisions based on Libre 3, Matt. We've looked at what we accomplished in the U.S. here, what we've done is we've increased access by going to the pharmacy channel by looking at Medicare approval for example, which came in at a lower price to what our DME price was before, as we've set up Medicaid pricing structures in the U.S. that are yet once again a pricing structure lower than what we had before, but to increase access to a number of patients. We then have looked at our OUS business in several of our key geographies and said, you know what, our access is not broad enough, our access is very much focused on very intensively managed Type 1, oftentimes just children or adults with pumps or adults with incredibly bad hyperglycemia awareness or something along those lines. And it's more important to us to reach more patients. So we've taken the strategy we've used in the U.S. and we're deploying it in other places as well to increase our access. We won't let Libre 3 drive our decisions, we will drive our own. Jereme Sylvain -- Cheif Financial Officer I think one important thing to note there is the pricing point, it's always been part of our global pricing strategy, and the level that we're going to is still very much in line with where we're at in the U.S. pharmacy channel, to be honest with you. So we're just stepping down as we've had inventory availability now. We're in the best position we've ever been in from that perspective, we know we got to reduce the burdens to get on the product. We're in a position now to continue to execute against that global pricing strategy. So this is very much part of where we were heading. It doesn't create risk elsewhere globally, like I mentioned, it's right line with our U.S. pharmacy pricing, if you get into the comps. So excited about what this has the potential to create for us. Operator And our next question comes from Bob Hopkins from Bank of America. Bob Hopkins -- Analyst Great. Thank you and good afternoon. I just wanted to ask a question on G7. I was wondering if you could comment on 2 things. First thing, I just want to clarify, when do you expect to file CE Mark in Europe? I thought that was something that was going to happen or might have happened already. And then secondly, I was wondering if you just could comment on the upcoming data that we're going to see on G7, just maybe help give us a sense of just what we're going to see and how meaningful it might be. And just a little more detail there would be great. Thank you. Kevin Sayer -- Chairman, President and Chief Executive Officer Well G7. We have not filed yet. We will file it in the not too distant future. We want to, we need all our ducks in a row. For example, we want to file both the Android and the iOS app at the same time, not file one and then do another filing. So making sure our software is validated and verified is really one of the bigger task. The clinical data is and we're ready with that part of the filing and we've had direct discussions with our authorities over there and we feel we're in good shape, but we'll file when we're ready. We don't want to do it twice and spend a lot of time answering questions. With respect to the data that we will present here in the summer, it will be on some of the smaller studies that we've done, it will not be on any of the U.S. pivotal data obviously, but you'll see how the product performs and how consistent and how happy we are with it. Obviously I'm happy with the data and as is our team. I've made the comment on several times when all said and done everything you love about G6, you're going to love more about G7, and when that product comes to market, that's exactly how we're going to feel about it. Not only from the smaller wearable and the easier insertion and all the other wonderful patient, ease of use features we're putting in there, but the software, the app and the performance of the system, we believe is going to be spectacular. And again, set a real standard for people to go over. Operator And our next question comes from Kyle Rose from Canaccord. Your line is open. Kyle Rose -- Analyst Great, thank you very much. I wanted to talk about a few of the commercial initiatives in the U.S., I mean obviously still early in the sampling program, you've just completed the doubling of the sales force, and kind of shifting some of the focus to more on the primary care. So maybe just help us understand how some of those initiatives have played out in the early days with respect to the Q1 or early in the Q2? And just, are there any metrics or is there any sort of goalposts you can help me frame the early execution on those initiatives for us, and then how do we think about that as we move through '21? Jereme Sylvain -- Cheif Financial Officer Sure, I'll take a quick shot at the sampling, and then hand it over to Kevin here. There aren't any metrics that we're going to disclose particular to sampling in and of itself, although I will tell you the early response to this program has been beyond our expectations, both from a physicians perspective of just how easy we've enabled these PCPs to get product into the hands of our patients, and then also from a patient perspective when they realize just how easy it is to use the Dexcom product. So the sampling program has been beyond what we imagine coming out of the gate. It will continue to be a big part of what we do into the future, but in terms of giving specific metrics around it, that's not something we will do. I will tell you, it's one of the better investments that we look to make at this point. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, I'd agree with that. With respect to the sales force, we've added everybody we were going to add, everybody is in place and everybody is getting up to speed, and some of the people came from a diabetes background. So they get up to speed easier, because they have relationships already established in these offices possibly from another company. Others it's going to take a little while longer and we plan for that as we do this expansion. But as far as calling on more voices, we are learning that in all fairness, we've been under-served with respect to our ability to call on people, there is a great story we heard from down in Texas. One of our reps called on a physician, and talked to him about our product, and the doctor said, I know nothing about your product. I put people on your competitor's product because they come and ask me for it. So again, using the sample program that Quentin described with Hello Dexcom, we put this patient on the system and introduced the physician to it and now he is prescribing Dexcom all the time, because of the experience that patient have. We needed a deeper reach, we will get that deeper reach with what we've done and we'll continue to evaluate over time, and we've got tremendous metrics on our sales people. We have an incredible commercial organization that monitors that. But we also very much understand it takes a while to get up to speed. The other great thing, I can tell you about this expansion, we literally have thousands of people apply for these jobs, and a lot of very, very qualified people that we did not hire. This is a place that people want to work and a product that they really want to represent and we want to continue that culture and maintain that. Operator And our next question comes from Mathew Blackman from Stifel. Your line is open. Mathew Blackman -- Analyst Hi, good afternoon, everybody. Thanks for taking my question. I wanted to follow up on the OUS pricing strategy, and sort of a multipart question here, but is the incremental $50 million headwind you called out isolated to 2021, or will these price headwinds continue beyond 2021 outside the U.S? And then if I think about the full-year guidance range raise of about $50 million I think, about half of that, you said is underlying our performance. But that's also in the face of another $50 million headwind on price. So is it fair to say that the guidance range, is that raise is actually closer to call it $75 million ex-FX on an underlying basis? Thanks. Jereme Sylvain -- Cheif Financial Officer Yeah, so a good question. So let's go step by step. So in terms of your question on the international pricing, a majority of the raise is our strategy outside the U.S. And so what you are seeing is we are taking an incremental $50 million of call it mix headwinds. As a result of going into there, and we still, yes, you're right, we did raise guidance in the face of that by $50 million of which $25 million was currency. So absent that incremental, yes, you would have seen a $75 million, now we are going to be taking those pricing headwinds, and we're going to be taking those pricing headwinds and making up for it in incremental volume. So it's obviously net neutral to the full year guide, but you are correct, absent taking on that strategy or because of that strategy, we expect to add new patients to the point where it increases our full year outlook. Operator And our next question comes from Matt Taylor from UBS. Your line is open. Matt Taylor -- UBS -- Analyst Hi. thanks for taking the question. Okay. So I'd like to ask one just about the U.S. momentum improvement that was impressive and you called out the factors. Is it possible for you to say which of the DTC sampling and sales force you think contributed more to that and which of those is still more to come, or is it just all equal? Kevin Sayer -- Chairman, President and Chief Executive Officer I think they're all more to come and I think they're relatively equal. As I called that on the call, the effect of the Super Bowl ad was more than just short-term sales growth in our minds, the awareness we generated, the text messages I was getting during the Super Bowl from industry and technology executives that I've met over the years made it all worth it. I'm just sitting on the couch saying, hey, this is really cool. It really created a lot of awareness for our company, awareness we hadn't had before, and that was really the goal as we talked about we developed more brand equity from our ad than anybody else. So that was important to us. The DTC remains important, as you watch our ads you'll see certainly more with Nick and certainly other campaigns as well and then on top of that having more feet on the street is good. We need it, but it will take time to develop those relationships. I think of the three, I couldn't quantify one of them, but I think ultimately the sales force expansion will be extremely helpful in this. We probably got less bang out of that just because we were ramping it up in the first quarter, but the DTC work and the Super Bowl ad that was probably the biggest and then Hello Dexcom and the reps will come more throughout the rest of the year. Operator And our next question comes from Jayson Bedford from Raymond James. Jayson Bedford -- Raymond James Financial Incorporated -- Analyst Hi, good afternoon. Somewhat similar to the last question, the first quarter strength in the U.S. much better than historical seasonality. I'm just wondering, is this more a function of just the channel shifts going on in the business or a function of the new momentum that you've seen kind of perhaps from some of these new initiatives? I know it's a tough question, but if there is any way to parse that out, that would be helpful. Jereme Sylvain -- Cheif Financial Officer Sure. yeah, so a good question. Anyhow some of that is a bit of a change in shift in dynamics and you're absolutely right, as more and more goes to the pharmacy, I think you are seeing that neutralization if you will, of the Q4, Q1 dynamic. One thing we did see this quarter, and we thought it was certainly a testament to the work that our customer experience team is doing, is we saw a slight decline in attrition and a slight increase in utilization. And so as you think about the customer experience that we're trying to create here, we've been talking about increases in net promoter scores, that's starting to play through in customer utilization habits. So, that's certainly something we saw a little bit of. And then I think what we also saw is just a little bit of incremental performance. We saw some of the performance outpace expectations, so I think it will be talked about as an expectation of new patient growth, slightly outpacing it, as a result of increased awareness, as a result of DTC. So I think all three of those coming together. Operator And our next question comes from Christopher Pasquale from Guggenheim. Your line is open. Christopher Pasquale -- Guggenheim Securities -- Analyst Thanks. Two quick questions for Jereme on the margin front. First is, given how strong gross margin was in 1Q, I was hoping you could talk about why 65% is the right number for the full year. And then your audio cut out a little bit when you were talking about the tax rate, if you could just go back to that and what you're expecting for an overall tax rate this year, that would be great. Thanks. Jereme Sylvain -- Cheif Financial Officer Sure, I'll start with the latter first, we expect the tax rate for the year to be between, a non-GAAP tax rate between 23% and 25%. Back to your question on margins, we did have a great quarter in Q1. Certainly, we're very proud of the 68%. The one thing we do want to do is, first off, it's the first quarter. So we think about it from a first quarter and really thinking about before taking a look at changing anything being mindful that we won't see things play out over time, but there's really two components you have to be aware of. We do expect to take on incremental channel mix headwinds in our international markets for the back half of the year. So we have to contemplate that in light of some of the efficiencies you're starting to see. And then getting back to our previous discussions about the drivers, when we set guidance is in the back half of the year, it's when we're going to launch G7 and when we launch G7, the yield that you get on some of these lines generally is a little lower. You saw it also happen with our launch of G6. There is a little bit of step back, as you start to work out the kinks of these lines and the yield start to play out. So as those play out in the back half of the year, that's why we don't -- we feel comfortable, very comfortable with our guidance, but we didn't feel any need to raise it at this point and let the year play-out. Operator And our next question comes from Cecilia Furlong from Morgan Stanley. Cecilia Furlong -- Morgan Stanley -- Analyst Great, thanks for taking our questions. So I just wanted to go back to the pricing headwinds, but just in light of increasing ex-U.S. headwinds, should we expect your 2Q ex-U.S. results just more like they did in 2019, just in terms of relatively flat sequential performance, or can you really still grow ex-U.S. revenues quarter over quarter before G7? Quentin Blackford -- Chief Operating Officer Yeah, I don't think we're going to get into details of providing specific guidance around U.S. versus OUS, particularly at a quarterly level, I think we're incredibly bullish on where the international business can go. There's so much runway that continues to sit in front of us. A big part of that is continuing to step into this global pricing strategy that we've laid out over a multi-year basis and really what you're seeing with the pricing decisions today is that we're in a position now where we can pull some of those decisions forward, where we couldn't have historically and a lot of that comes down to having inventory available to us, being highly confident in the ability to continue to grow and scale the levels of production as we go into the future. So I'm confident you're going to see terrific results coming out of that international business over time and with some of these decisions that we've made, we are now opening up access to patient volumes that are 5 or 6 times larger than what we were really addressing historically. So I think all of that sets up very well for a very strong international business here into the future. Operator And our next question comes from Danielle Antalffy from SVB Leerink. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hey, good afternoon, everyone. Thanks so much for taking the question. I was Just wondering if you could talk a little bit about the potential impact from doubling the sales force and specifically as it relates to the primary care physician, I'm curious if you guys have this detail as to what percentage of your prescribing physicians are coming from primary care today, so we can sort of have a sense of, with the sales force doubling and better calling on the primary care, how many more physicians you could potentially capture? Thanks so much. Kevin Sayer -- Chairman, President and Chief Executive Officer Well, this is Kevin. I'll take that. Very little comes from that channel right now. That's why we added them and that's why we've expanded. If you take a look at the Type 2 intensive insulin users, most of them are found in those offices and that's why we needed to get out there. Over time, this will certainly increase, we expect it to and those are the expectations of the team we brought on board. We're hearing good anecdotal stories and things are starting to heat up, but in all reality and with a large book of business we already have in the recurring orders from our current patients, we got a ways to go. We think that will do great and we'll monitor it, if we see great returns, we'll just keep giving them tools to get great returns, is the best way to describe it. And I think, Hello Dexcom is going to be the best one that we have for that group. Operator And our next question comes from Ravi Misra from Berenberg Capital. Your line is open. Ravi Misra -- Berenberg Capital Markets -- Analyst Hi, thanks for taking the questions. Good evening. Congrats Jereme and Quentin, on the -- there's lot of management changes over at Dexcom or rotations I guess in the last year so. The question I had, I guess I wanted to go after the gross margin and pricing commentary from maybe a different angle. When you have the similar type of pricing impact in the U.S., when you started going in the pharma channel, we really saw a pretty strong level of uptake through that arena, albeit the pricing headwind continues. I guess, what I'm trying to ask is, do you -- does the guidance factor in that type of kind of immediate impact from the price cut, I guess, in Europe, and do you think that $50 million is the kind of extent of it as we kind of go forward here? Thanks. Jereme Sylvain -- Cheif Financial Officer Yes, sure, I can take that. So, our gross margins, certainly contemplates the impact of -- pricing impacts in our international markets, and so I wouldn't expect any changes there. In terms of the extent of it, as we go after these incremental markets and open up access, we almost look at that as new patients. And so when we go after our new patients and new markets, certainly pricing is going to change over time. So there could be impacts that drag out over time into future years as a result of just going after incremental pockets of patients, and any sort of knock along impact. Certainly, not anything that we would expect to be significant, but that will always be contemplated in our guidance and it'll all be something that we certainly talk to on these calls, I wouldn't expect anything that we provide hasn't been thought through and contemplated in any of the targets that we provide to you guys. Operator And our next question comes from Marie Thibault from BTIG. Your line is open. Marie Thibault -- BTIG -- Analyst Hi, good evening. Thanks for taking the questions and congrats to you as well, Jereme. I wanted to ask a question on OUS. I understand that the impact of COVID last year obviously having an impact on revenue this year but curious if you're still seeing a COVID impact in this Q1 quarter as well as the existing quarter here in terms of that still affecting new patient starts. We certainly heard from other companies that Europe is lagging on the vaccine roll-out. So we'd love to hear if that's been contemplated in guidance. And if so, how you expect that to change over the year? Thanks. Jereme Sylvain -- Cheif Financial Officer Yeah, I think from our perspective, all that we know right now is kind of the environment we operate within with respect to COVID, which we know from an international perspective has certainly created some incremental pressure in pockets of that business, particularly those that require in-clinic visit to get onto the product or some of those administrative hurdles that have been put there. In other channels where we have e-commerce, for example, we're seeing incredible results. And so I think one thing to point out on that first quarter international result is that when you look at it from a 2-year growth perspective, it's an incredibly strong number, last year was an absolute record growth for us in that first quarter from an international perspective. So I think you got to normalize that when you're looking at that first quarter growth. But in terms of the remainder of the year on an international basis and patient adoption, a big part of stepping price down in line with kind of our global pricing strategy, was the fact that we had to see administrative requirements reduced or eliminated all together to get patients onto the product, and so in these markets where we've done that, the hurdle to get onto the product has been removed. And so we absolutely would expect to see patient -- new patient acquisition become much easier for us and see that start to take off in a very positive way. So I do think you're going to see that uptick over the course of the year, even in the COVID environment with of course the caveat being that it kind of stays stable to where it's at today. If it were to get worse in some case, then we might have to think about that differently, but we're trying to look at the future based upon what we see today and how it's impacted the markets here in the moment. Operator And our next question comes from Larry Biegelsen from Wells Fargo. Your line is open. Lawrence Biegelsen -- Analyst Hey guys, thanks for taking the question. So on pricing once G7 and Libre 3 are competing with each other, how much of a price premium do you think is sustainable? And how close do you think you are to that premium today in the U.S. and outside the US. And do you see the opportunity to price G6 as a value brand? Thanks for taking the question. Kevin Sayer -- Chairman, President and Chief Executive Officer Larry. Thanks for your question. We have numerous opportunities here. But I'm not going to give our pricing strategy on theearnings call we are very thoughtful about this. We run several models. We know what our technology is worth and we know what great benefit we provide at what prices accordingly, but we're also going to price our products in a manner whereby our patients have access to it as well. And I think our commercial team combined with our finance team and everybody has done a wonderful job balancing that, we'll continue to balance, but we will continue to grow as well. I mean, look at the volume growth versus our our dollar growth this quarter and we already said, our U.S. volumes were in excess of the overall volume growth. We've managed it extremely well and we'll continue to do so. Operator And our next question comes from Anthony Petrone from Jefferies. Your line is open. Anthony Petrone -- Analyst Thanks. A couple of questions, one on G7, and one of margins as well. So G7 trying to get a sense when you look at U.S. timing to entry and efforts at ICGM, do you think the market actually behaves differently, in other words, new patient starts potentially slow a bit as the new form factor is coming to market? And then, our margins taking the other side, the COGS side specifically breaking down and breaking ground in Malaysia. Maybe just an update on timing as to when FDA inspections will take place for that facility. And just a recap of what that can do on the COGS side for sensors on a per unit basis? Thanks a lot. Jereme Sylvain -- Cheif Financial Officer I'll take the latter part of that. With respect to Malaysia, we're clearly well into that project making great progress. We have a building in place as we exit the year with plans in place to have a clean room up and ready for validation right at the turn of the year into the first quarter. Sorry, first quarter of next year. So the expectation is, we'll be producing product out of that in the first half of next year there in Malaysia. So very excited about what we're seeing there. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah. And I'll take the G6, G7 and the cut over question. Again, with respect to U.S. timing, we've not disclosed anything. One of our great learnings on G6 was have enough product ready to go when you go, and really be fully ready for launch. And we've made that commitment to our customers that we will be ready when we do launch this product that we will be able to literally flip the switching over. As far as patients, slowing their purchases of G6, in particular in the pharmacy channel, you're buying one month of product at a time. So it's not like you're going in there and loading up with 3 to 6 months, as we did in the past, and the DME channel and even in the DME channel today there is less of that loading up by patients with G6, then there wasn't in G5 and G4 prior to debt. We don't view that people will quit purchasing their G6 is when G7 is announced, because in all fairness, our customers can't live without it. And when we have the opportunity to take care of them all, what we will do is as organized with as rapid migration as we possibly can. And as far as G6 future plans, we do see a lot of opportunity here, but we really haven't disclosed anything. Operator And our next question comes from Steven Lichtman from Oppenheimer. Your line is open. Steven Lichtman -- Analyst Great, thanks for taking our questions. I just had a question on your international expansion efforts. What are some of the key countries and focus for you here over the near-term? And are you anticipating any contribution from these new regions in this year's guidance or is that more really more of a driver for 2022? Thank you. Kevin Sayer -- Chairman, President and Chief Executive Officer Yeah, I think that will be more of a driver for future years. We've talked about our launch in Japan which Terumo, and that's scheduled to happen in the second half of the year. We got reimbursement in France, as many of you know, so we do expect France to be a bigger part of our business than it has in the past, but the law of large numbers in our businesses, things have gotten so big, they can give us a whole lot that moves the needle when we start. Hence, the discussion we've had about increasing access in our more mature markets and looking at how we follow similar paths in these other geographies with the operating capability we have now there is no sense in going through and selling just the top end of this market, we want to get more aggressive and be more broad. So I think you'll see as we go into these geographies over time, we'll start as we started in the past, but we are going to get more reimbursement and try to get more patients more rapidly. Operator And our next question comes from Brandon Vazquez from William Blair. Your line is open. Brandon Vazquez -- Analyst Hi, thanks for taking the question. I just wanted to go back to one of the comments made during the prepared remarks and it sounded like there was maybe a little hinting at new connected systems coming this year. So curious if you could talk about those, and specifically what those kinds of products, I'm thinking is there something outside of the regular hardware upgrades that we see maybe somewhere on the software side, that could be a catalyst maybe for growth within maybe some of the TAM expansion opportunities like the Type 2 non-intensives, or gestational diabetes or anything like that. So is there anything we're kind of not thinking out-of-the-box here from the normal hardware that will be important in the coming 12 months or so? Jereme Sylvain -- Cheif Financial Officer I don't think that there is anything that you guys are missing in terms of the prepared remarks and speaking to some of those systems. The one thing that we certainly are excited about, has to be the Omnipod 5 product in the back half of the year, and we'll let Insulet speak to the exact timing of when we're ready to put that product into the marketplace, but having connectivity into a product like that is something that we're very excited about and believe that they'll have success with and will have success with as well. I think with respect to the whole Type 2 population and the opportunity there, we couldn't be more bullish on the opportunity that sits in front of us, and I think by the day we learn more-and-more of that increases that bullishness for us in the confidence that there's going to be some real opportunity there to create value coming from it, and you're going to see a study a little bit later this year, mid-year at some of the mid-year society meetings, that's going to start to really lay out the benefit of using CGM relative to BGM in this Type 2 population, particularly the non-intensive population that just demonstrates the sort of impact we can have on patients that are on basal only and that's a 4 million patient population in the U.S. So I think that sort of data starts to really accumulate in favor of opening up a whole another market segment that doubles the existing core U.S. intensive market today that we're very excited about. So you'll see that data here, mid-year, but I think all of it starts to point to the fact that this Type 2 space is going to open up in a significant way and we are well-positioned to take advantage of it. Operator And that concludes the question-and-answer session. I will turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, and thanks everybody for participating. As we wrap up our call today, I want to take a minute to acknowledge some very important recognition that Dexcom received this week. Forbes recently published their 100 company list of America's Best Employers for Diversity. Dexcom was honored to be Number 66 on that list. While we consider this a perpetual journey, we're very happy to have been recognized for some of the work that we've done so far. As far as our outlook on the business going forward our great quarter fuels, our continue believe that the best is yet to come. I recently caught up with a friend who is a longtime healthcare industry executive and the gist of his message to me was very simple, everything important in diabetes care is going to revolve around CGM. For example, there are numerous instant delivery devices and algorithms available for automated insulin delivery, but there is only one CGM commercially capable of delivering the patient experience and outcomes that we've all envisioned for a very long time, and that's only the beginning. There are incredible new compounds, treatments and program stepping forward for the treatment of Type 2 diabetes and we are very confident that the right CGM experience will become an integral part of all these solutions and we haven't even started talking about the difference we can make as part of a pre-diabetes program. We've never been more excited and engaged in our opportunity than we are today. Thank you again everyone and have a great day. Operator [Operator Closing Remarks] Duration: 58 minutes Call participants: Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Kevin Sayer -- Chairman, President and Chief Executive Officer Jereme Sylvain -- Cheif Financial Officer Quentin Blackford -- Chief Operating Officer Jeffrey Johnson -- Baird -- Analyst Joanne Wuensch -- Analyst Robert Marcus -- Analyst Matthew O'Brien -- Analyst Bob Hopkins -- Analyst Kyle Rose -- Analyst Mathew Blackman -- Analyst Matt Taylor -- UBS -- Analyst Jayson Bedford -- Raymond James Financial Incorporated -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst Cecilia Furlong -- Morgan Stanley -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Ravi Misra -- Berenberg Capital Markets -- Analyst Marie Thibault -- BTIG -- Analyst Lawrence Biegelsen -- Analyst Anthony Petrone -- Analyst Steven Lichtman -- Analyst Brandon Vazquez -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool owns shares of and recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for April 29, 2021 : AMZN, GILD, VRTX, TWTR, KLAC, DLR, DXCM, SWKS, FTNT, TEAM, RMD, AJG The following companies are expected to report earnings after hours on 04/29/2021. Visit our Earnings Calendar for a full list of expected earnings releases. Amazon.com, Inc. (AMZN) is reporting for the quarter ending March 31, 2021. The internet company's consensus earnings per share forecast from the 15 analysts that follow the stock is $9.75. This value represents a 94.61% increase compared to the same quarter last year. AMZN missed the consensus earnings per share in the 1st calendar quarter of 2020 by -21.23%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for AMZN is 70.89 vs. an industry ratio of -33.70, implying that they will have a higher earnings growth than their competitors in the same industry. Gilead Sciences, Inc. (GILD) is reporting for the quarter ending March 31, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.06. This value represents a 22.62% increase compared to the same quarter last year. GILD missed the consensus earnings per share in the 2nd calendar quarter of 2020 by -23.97%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for GILD is 8.93 vs. an industry ratio of -6.30, implying that they will have a higher earnings growth than their competitors in the same industry. Vertex Pharmaceuticals Incorporated (VRTX) is reporting for the quarter ending March 31, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.38. This value represents a 7.69% increase compared to the same quarter last year. VRTX missed the consensus earnings per share in the 4th calendar quarter of 2020 by -4.72%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for VRTX is 22.10 vs. an industry ratio of -6.30, implying that they will have a higher earnings growth than their competitors in the same industry. Twitter, Inc. (TWTR) is reporting for the quarter ending March 31, 2021. The internet software company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.00. This value represents a no change for the same quarter last year. TWTR missed the consensus earnings per share in the 2nd calendar quarter of 2020 by -920%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for TWTR is 182.50 vs. an industry ratio of 1.00, implying that they will have a higher earnings growth than their competitors in the same industry. KLA Corporation (KLAC) is reporting for the quarter ending March 31, 2021. The electrical instrument company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.59. This value represents a 45.34% increase compared to the same quarter last year. In the past year KLAC has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.89%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for KLAC is 24.04 vs. an industry ratio of 22.30, implying that they will have a higher earnings growth than their competitors in the same industry. Digital Realty Trust, Inc. (DLR) is reporting for the quarter ending March 31, 2021. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.59. This value represents a 3.92% increase compared to the same quarter last year. DLR missed the consensus earnings per share in the 1st calendar quarter of 2020 by -0.65%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DLR is 22.71 vs. an industry ratio of 19.20, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM) is reporting for the quarter ending March 31, 2021. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.31. This value represents a 29.55% decrease compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DXCM is 188.39 vs. an industry ratio of 70.00, implying that they will have a higher earnings growth than their competitors in the same industry. Skyworks Solutions, Inc. (SWKS) is reporting for the quarter ending March 31, 2021. The semi-radio frequency company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.08. This value represents a 85.71% increase compared to the same quarter last year. SWKS missed the consensus earnings per share in the 1st calendar quarter of 2020 by -5.88%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for SWKS is 21.28 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. Fortinet, Inc. (FTNT) is reporting for the quarter ending March 31, 2021. The security company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.48. This value represents a 23.08% increase compared to the same quarter last year. In the past year FTNT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 16.9%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for FTNT is 73.88 vs. an industry ratio of -30.90, implying that they will have a higher earnings growth than their competitors in the same industry. Atlassian Corporation Plc (TEAM) is reporting for the quarter ending March 31, 2021. The internet software company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.00. This value represents a 100.00% increase compared to the same quarter last year. TEAM missed the consensus earnings per share in the 1st calendar quarter of 2020 by -16.67%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for TEAM is 3932.67 vs. an industry ratio of 1.00, implying that they will have a higher earnings growth than their competitors in the same industry. ResMed Inc. (RMD) is reporting for the quarter ending March 31, 2021. The medical products company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.22. This value represents a 5.43% decrease compared to the same quarter last year. In the past year RMD has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 15.57%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for RMD is 39.87 vs. an industry ratio of 12.60, implying that they will have a higher earnings growth than their competitors in the same industry. Arthur J. Gallagher & Co. (AJG) is reporting for the quarter ending March 31, 2021. The insurance brokers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.83. This value represents a no change for the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 14.29%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for AJG is 28.41 vs. an industry ratio of 25.20, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-04-30,100.0,100.79,96.205,96.525,"[""Notable Friday Option Activity: DXCM, CHTR, NVDA Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 4,316 contracts have traded so far, representing approximately 431,600 underlying shares. That amounts to about 77% of DXCM's average daily trading volume over the past month of 560,205 shares. Particularly high volume was seen for the $440 strike call option expiring May 21, 2021, with 1,608 contracts trading so far today, representing approximately 160,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $440 strike highlighted in orange: Charter Communications Inc (Symbol: CHTR) options are showing a volume of 6,730 contracts thus far today. That number of contracts represents approximately 673,000 underlying shares, working out to a sizeable 74.9% of CHTR's average daily trading volume over the past month, of 898,580 shares. Particularly high volume was seen for the $550 strike put option expiring June 11, 2021, with 432 contracts trading so far today, representing approximately 43,200 underlying shares of CHTR. Below is a chart showing CHTR's trailing twelve month trading history, with the $550 strike highlighted in orange: And NVIDIA Corp (Symbol: NVDA) saw options trading volume of 57,438 contracts, representing approximately 5.7 million underlying shares or approximately 70.5% of NVDA's average daily trading volume over the past month, of 8.1 million shares. Especially high volume was seen for the $610 strike call option expiring April 30, 2021, with 4,125 contracts trading so far today, representing approximately 412,500 underlying shares of NVDA. Below is a chart showing NVDA's trailing twelve month trading history, with the $610 strike highlighted in orange: For the various different available expirations for DXCM options, CHTR options, or NVDA options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Is Dropping Today What happened? Shares of medical devices company DexCom (NASDAQ: DXCM) are dropping sharply on Friday after the company announced its first-quarter 2021 financial results on Thursday afternoon. As of 11:29 a.m. EDT today, DexCom's stock was down 6.3%. So what It isn't immediately clear why the market is reacting the way it is following DexCom's quarterly update. The company's revenue of $505 million -- representing a 25% year-over-year increase -- came in above the average analyst estimate for roughly $482.6 million. Also, DexCom's adjusted earnings per share of $0.33 came in above the $0.31 consensus analyst estimate, although it dropped noticeably from the $0.44 adjusted EPS it reported during the prior-year quarter. Image source: Getty Images. With DexCom's top and bottom lines beating analyst projections, why are some investors running for the hills today? One possible explanation is that the company's top-line guidance for the full fiscal year 2021 isn't impressive. DexCom expects to record revenue between $2.26 billion and $2.36 billion during the current fiscal year, which at the midpoint is slightly below the $2.33 billion analysts are looking for. Now what It's important for investors to remain focused on the long term. Whatever reason the market has for sending DexCom's stock lower today doesn't matter nearly as much as the company's investment thesis. And there was nothing in DexCom's quarterly update that indicated a change in its prospects. DexCom remains one of the leaders in diabetes care thanks to its G6 continuous glucose monitoring (CGM) system. And with the CGM space set to grow rapidly in the coming years, this healthcare stock is still worth serious consideration. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-05-03,96.525,96.6362,93.875,95.1425,"Analysts Forecast 11% Gains Ahead For IWY Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell Top 200 Growth ETF (Symbol: IWY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $159.22 per unit. With IWY trading at a recent price near $144.06 per unit, that means that analysts see 10.52% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IWY's underlying holdings with notable upside to their analyst target prices are Centene Corp (Symbol: CNC), eBay Inc. (Symbol: EBAY), and DexCom Inc (Symbol: DXCM). Although CNC has traded at a recent price of $61.74/share, the average analyst target is 26.50% higher at $78.10/share. Similarly, EBAY has 20.17% upside from the recent share price of $55.79 if the average analyst target price of $67.05/share is reached, and analysts on average are expecting DXCM to reach a target price of $462.76/share, which is 19.86% above the recent price of $386.10. Below is a twelve month price history chart comparing the stock performance of CNC, EBAY, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET iShares Russell Top 200 Growth ETF IWY $144.06 $159.22 10.52% Centene Corp CNC $61.74 $78.10 26.50% eBay Inc. EBAY $55.79 $67.05 20.17% DexCom Inc DXCM $386.10 $462.76 19.86% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-05-04,94.6575,94.7425,91.5562,92.855,
DXCM,2021-05-05,92.9975,93.5338,90.1875,91.485,
DXCM,2021-05-06,90.1875,90.72,87.6612,89.335,
DXCM,2021-05-07,90.6425,92.595,89.625,89.685,"DexCom, Inc.'s (NASDAQ:DXCM) Business Is Trailing The Market But Its Shares Aren't With a price-to-earnings (or ""P/E"") ratio of 66.4x DexCom, Inc. (NASDAQ:DXCM) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ratios under 20x and even P/E's lower than 11x are not unusual. However, the P/E might be quite high for a reason and it requires further investigation to determine if it's justified. Recent times have been advantageous for DexCom as its earnings have been rising faster than most other companies. The P/E is probably high because investors think this strong earnings performance will continue. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason. NasdaqGS:DXCM Price Based on Past Earnings May 7th 2021 Keen to find out how analysts think DexCom's future stacks up against the industry? In that case, our free report is a great place to start. Is There Enough Growth For DexCom? There's an inherent assumption that a company should far outperform the market for P/E ratios like DexCom's to be considered reasonable. If we review the last year of earnings growth, the company posted a terrific increase of 233%. Although, its longer-term performance hasn't been as strong with three-year EPS growth being relatively non-existent overall. So it appears to us that the company has had a mixed result in terms of growing earnings over that time. Shifting to the future, estimates from the analysts covering the company suggest earnings growth is heading into negative territory, declining 5.8% each year over the next three years. With the market predicted to deliver 14% growth per year, that's a disappointing outcome. In light of this, it's alarming that DexCom's P/E sits above the majority of other companies. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock at any price. There's a very good chance these shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the negative growth outlook. The Bottom Line On DexCom's P/E Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company. Our examination of DexCom's analyst forecasts revealed that its outlook for shrinking earnings isn't impacting its high P/E anywhere near as much as we would have predicted. When we see a poor outlook with earnings heading backwards, we suspect the share price is at risk of declining, sending the high P/E lower. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable. It is also worth noting that we have found 4 warning signs for DexCom (1 can't be ignored!) that you need to take into consideration. Of course, you might also be able to find a better stock than DexCom. So you may wish to see this free collection of other companies that sit on P/E's below 20x and have grown earnings strongly. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-05-10,89.8175,89.8175,85.605,85.6725,"[""Advantage the Drift in Senseonics Stock Before It Recovers on FDA Nod InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senseonics (NYSEAMERICAN:SENS) is an $808 million market cap medical device company that is waiting for Food and Drug Administration (FDA) approval. Until that happens, SENS stock looks like a bargain. Source: Minerva Studio / Shutterstock.com Senseonics is seeking approval for its latest implantable continuous glucose monitoring (CGM) product called the Eversense XL. The company has said it might take until the fall. The market can\u2019t or won\u2019t wait. SENS stock has been drifting down. Take advantage of this weakness to build your position. Comparison With DexCom I wrote about these developments last month in my article, \u201cSenseonics Will Likely Rise On the Same Trajectory as DexCom.\u201d Since then, SENS stock has slid from $2.34 to $1.89, down 17.2%. Daunting as this may seem, this allows long-term investors to take advantage. 7 Stocks Most at Risk of a Capital Gains Tax Selloff My thesis is that SENS stock will take the same trajectory that DexCom (NASDAQ:DXCM) has taken. It is a similar CGM company, albeit with $2.34 billion in sales. It has a cloud-based monitoring product that excludes the need for lancers that prick the skin to test blood sugar levels. DexCom has a $34.7 billion market capitalization and trades for 14.8 times sales and 158 times earnings for 2021. Over the last 10 years, DXCM stock has risen over 21 times in the past 10 years. This includes a gain of 4.4 times in the last 5 years. My thesis is that SENS stock will recover once the FDA allows Senseonics to start selling its device in the U.S. Analysts will be able to project out revenue and earnings, along the same lines that they do for DXCM stock. Investing in SENS stock requires a long-term view, perhaps as long as 5 years for a long-term, patient value investor. However, even if takes 5 years and the stock rises 10 times over that period, the average annual return will be 58.5% each year on a compound basis. That is a great ROI for most investors. But you can see that this requires patience and a long-term view. It also requires the investor to average cost down as SENS stock falls. Where This Leaves SENS Stock Analysts that cover the stock tend to agree with my optimism. For example, TipRanks says that 5 analysts already cover SENS stock, offering 12-month targets on it in the last 3 months. Their average target price is $3.17. This represents a potential gain of 74% over today\u2019s price. Yahoo! Finance reports that 4 analysts have an average target price of $2.30. That\u2019s 26% above today\u2019s price. However, Marketbeat indicates that 6 analysts have an average target of $1.69, or 7% below today\u2019s price. So the range of analyst target prices is from $1.69 to $3.17. The midpoint of these analyst aggregation sites\u2019 target price is $2.39. This represents a potential gain of 31% for investors at today\u2019s price. Sales Forecasts Justify the High Valuation One analyst on Seeking Alpha calls Senseonics \u201cone of the most compelling growth stories in the market.\u201d He calls SENS stock a \u201cpotential multi-bagger.\u201d He argues that the market is giving investors a \u201csecond chance\u201d to buy into SENS stock. He believes that Senseonics will disrupt the CGM market through its partnership with Swiss-based Ascensia Diabetes Care. Ascensia has 10 million customers in over 125 countries. The 2020 partnership with Ascensia has led to financing assistance and the prospect of spending $250 million on behalf of Senseonics over the next several years. But everyone is waiting on the FDA to act. During the March 4 conference call with analysts, the CEO said that the FDA was going to start reviewing their application by April 15. He also said that he expects approval by the third or fourth quarter. This is the basis for analysts\u2019 expectations of $12.9 billion in sales this year (up from $5 billion last year). Moreover, in 2022 they forecast $32.9 billion. That represents a 155% rise in sales year over year. It also puts SENS stock on a forward price-to-sales (P/S) multiple of 24.6 times. But this is if sales keep doubling. Bottom line: take advantage of this lull in SENS stock by averaging down. On the date of publication, Mark R. Hake did not hold a position in any security mentioned in this article. Mark Hake writes about personal finance on mrhake.medium.com and runs the Total Yield Value Guide which you can review here. The post Advantage the Drift in Senseonics Stock Before It Recovers on FDA Nod appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Can Dexcom Stock Rebound After The Recent 11% Drop? The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom\u2019s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company\u2019s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It\u2019s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back. While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn\u2019t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it\u2019s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott. Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn\u2019t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days). Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details. Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market (3% likelihood event) Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7% A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. While DXCM stock can see a rebound, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons. See all Trefis Price Estimates and Download Trefis Data here What\u2019s behind Trefis? See How It\u2019s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-05-11,84.38,88.745,84.045,87.0,
DXCM,2021-05-12,86.0,86.0,82.39,83.37,
DXCM,2021-05-13,84.085,84.5,79.6125,80.99,"[""Oversold Conditions For DexCom (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.96, after changing hands as low as $318.45 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 51.4. A bullish investor could look at DXCM's 29.96 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $305.63 per share, with $456.23 as the 52 week high point \u2014 that compares with a last trade of $323.96. Free Report: Top 7%+ Dividends (paid monthly) Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Top Growth Stocks on Sale After Earnings The stock market doesn't always make sense, and that's especially true when focusing on a relatively short period. Shares of great companies can prove volatile in the short run, sometimes for no good reason. But in the long run, winners keep winning, and the market rewards those winners. The lesson for investors is clear: Buying shares of excellent stocks on the dip is always a good idea. With that in mind, let's look at two growth stocks that recently dropped after releasing their first-quarter earnings reports: DexCom (NASDAQ: DXCM) and Netflix (NASDAQ: NFLX). Here is why both companies are worth buying and holding onto for a while. DXCM data by YCharts 1. DexCom The past 12 months have been great for DexCom and its shareholders. In 2020, the company's revenue jumped -- along with its stock price -- even amidst the COVID-19 pandemic. Key to this performance was DexCom's G6 Continuous Glucose Monitoring (CGM) system, which helps diabetes patients keep track of their blood glucose levels without relying on painful fingersticks. DexCom generates most of its revenue by selling these devices and accompanying accessories (sensors and transmitters) that need to be replaced periodically. Last year, the company reported revenue of $1.93 billion, 31% higher than in fiscal 2019. DexCom credited \""a record number of new patient additions\"" for this performance. And based on its first-quarter earnings report, the company doesn't seem to be slowing down much. DexCom's top line in the first quarter ending March 31 came in at $505 million, 25% higher than the year-ago period. This performance was, once again, driven by strong customer addition. Further, DexCom's earnings per share (EPS) for the quarter jumped to $0.41, up from $0.21. Image source: Getty Images. Despite the company's solid quarter, DexCom's shares dropped on the day it released its update. But that means very little in the grand scheme of things. More importantly, its prospects remain strong. The company notes that the number of diabetes patients worldwide has increased significantly in the past few decades. It is projected to reach 700 million people by 2045, up from 463 million people in 2019. The CGM market remains underpenetrated, both in the U.S. and abroad. As one of the leaders in this space, DexCom is looking at an exciting growth opportunity. The company is also working on a successor to the G6, appropriately named the G7. According to DexCom, this next-gen device will be 60% smaller than its predecessor and will combine the sensor and the transmitter into a single wearable, among other perks. Growing diabetes care expenditure, coupled with increasing CGM awareness, will continue to boost DexCom's financial performance. Thanks to these factors, this healthcare stock is well positioned to continue beating the market in the long run. 2. Netflix Netflix released mixed first-quarter earnings on April 20. Perhaps the most disappointing number in the company's quarterly update was its subscriber growth. The streaming service added roughly 4 million new paying members during the quarter, which came up short of its own projection of 6 million net new subscribers. It isn't difficult to see why investors were dissatisfied, since Netflix makes its money thanks to its paying subscribers. And even though the company's revenue of $7.2 billion jumped by 24.2% year over year, Netflix's stock sank after its earnings release. Despite this hiccup, Netflix's shares are still worth buying. First, you'd be hard-pressed to find a single publicly traded company that's been around for as long as Netflix has without ever missing its own projections. The fact that Netflix came up short on its first-quarter subscriber guidance is hardly conclusive evidence that the company's growth will slow to a crawl from here on out. Also, let's not forget that Netflix's member count got a boost last year because of the pandemic. It had close to 40 million net additions in 2020, which was a record. Can Netflix's growth resume during the second quarter and beyond? The company is looking to replace traditional television, and as CEO Reed Hastings noted, \""Pay television peaked at about 800 million households.\"" Image source: Getty Images. Netflix ended the first quarter with 208 million members, which means there are still hundreds of millions of potential customers out there. Elsewhere, estimates of the growth of the digital streaming market look impressive. Research firm Grand View Research thinks it will expand at a compound annual growth rate (CAGR) of 21% between 2021 and 2028. Another potential area of improvement for Netflix: viewing time. The company currently trails YouTube, which it considers to be one of its biggest competitors, in this area. Netflix's (not so) secret weapon to attract an expanding audience and increase its viewing time will be original content. It is difficult to deny the tech giant's success in this sphere. Netflix had 37 nominations during this year's Oscars, up from the 24 it had last year and the 14 it had in 2019. The company's rich library will continue to be a major growth driver moving forward and will help it fend off competing platforms such as Disney's Disney+. Netflix has continued to thrive since the launch of this and other high-profile streaming services, and with still a large worldwide audience to capture, the company's future still looks bright. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 11, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends DexCom, Netflix, and Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-05-14,81.675,84.095,81.1475,83.3125,
DXCM,2021-05-17,82.8,83.42,80.4825,81.35,
DXCM,2021-05-18,82.4965,84.37,82.2175,82.5275,
DXCM,2021-05-19,80.8675,83.225,80.75,83.0725,
DXCM,2021-05-20,84.02,86.44,83.425,86.075,"3 Top Healthcare Stocks to Buy Right Now Just as it doesn't make much sense to sail directly into the wind, investors need to be sure they're aligned with long-term trends. In the healthcare space, Dexcom (NASDAQ: DXCM), CVS Health (NYSE: CVS), and Medpace Holdings (NASDAQ: MEDP) all have momentum and strong fundamentals on their side. Dexcom, which makes wearable continuous glucose monitoring devices and the software for them, has the rise of the number of diabetes patients worldwide fueling its growth. CVS, known as a drug store company but firmly established as a medical insurer thanks to its purchase of Aetna, is helped by increased foot traffic in its stores as vaccination rates increase in the U.S. Medpace has benefited as companies turn to clinical research organizations to more seamlessly run their drug trials and approval processes for new medical therapies and devices. All three companies have raised their earnings guidance for the year, giving investors one more reason to be excited about their stocks. Image source: Getty Images. Dexcom's success is worth monitoring Dexcom, a maker of continuous glucose monitoring (CGM) devices for diabetics, is down more than 10% this year and more than 20% over the past 12 months. Looking at that, you would think the company's fundamentals were in trouble, but that's not the case. In the first quarter, the San Diego company reported revenue of $505 million, up 25% year over year. Net income was $40.3 million, or $0.41 per diluted share, compared with $19.9 million, or $0.21 per diluted share, for the same period in 2020. On top of that, the company raised its forecast for yearly revenue growth to between 17% and 22%, or between $2.26 billion and $2.36 billion. In the company's first-quarter earnings call, Dexcom CFO Jereme Sylvain said Dexcom has had seven consecutive quarters of revenue growth of $100 million or more. And Dexcom's business is riding a trend that continues to expand. According to the American Diabetes Association's most recent numbers from 2018, 34 million people in the United States -- roughly 10.5% of the population -- have diabetes. The World Health Organization's figures showed that the numbers of people worldwide with diabetes more than quadrupled between 1980 and 2014. CVS is in the right place at the right time CVS stock is up more than 29% this year and more than 38% over the past 12 months. Vaccination rates in the U.S. have risen, which is leading more people back to their local drugstores. In fact, as of April, 6.5 million people had gotten their COVID-19 shots at CVS drugstores. Another 23 million had received COVID-19 tests at CVS. The extra foot traffic is helping the company's bottom line as well as introducing potential future customers. The Rhode Island-based company reported revenue of $69 billion in the first quarter, up 3.5% year over year. Earnings per share were $1.68 in the quarter, up 6.8% over the same period in 2020. The company's biggest growth was in its healthcare benefits segment, which showed $20.4 billion in revenue, up 6.7% over the first quarter in 2020. Revenue also grew in its other two segments, with pharmacy services showing 3.8% growth and retail up 2.3%. And the company increased its outlook -- it now expects annual adjusted per-share earnings between $7.56 and $7.68. On top of that, CVS pays a consistent quarterly dividend of $0.50 a share, which equals a 2.37% yield at current prices. It hasn't raised its dividend since 2017, using the money instead to pay down its debt (including $3 billion in 2020 alone, dropping its still formidable debt from $67.7 billion to $63.6 billion) and invest in its growth. The company has reduced its debt-to-equity ratio by more than 37% over the past three years. DXCM Revenue (Quarterly) data by YCharts Medpace Holdings serves a unique niche Medpace Holdings is a clinical research organization (CRO), a company that helps pharmaceutical companies and medical device companies run their trials and ease the process of U.S. Food and Drug Administration approval. The Cincinnati company's stock is up more than 17% this year and more than 88% over the past 12 months. It has shown revenue growth of 145.1% over the past three years. In the first quarter, the company reported revenue of $260 million, up 12% year over year, and net income of $43.3 million, up from $29 million in the same period last year. The company also grew EBITDA by 32.1% to $53.6 million. Though business slowed during the pandemic because so much focus was spent on finding vaccines for COVID-19, there is a growing trend in the direction of CROs. Clinical trials are complex, and specialization in this area makes sense, particularly for smaller companies that don't yet have the full staff for clinical trials. The demand for tighter timelines has led to more companies outsourcing research to CROs. A report by Grand View Research puts the compound annual growth rate for the global CRO market at 6.6% from 2021 to 2028, reaching $66.1 billion by that time. Management raised the lower end of 2021 guidance in its first-quarter earnings report, saying it expects yearly earnings of $4.24 to $4.42 per share on revenue of $1.09 billion to $1.15 billion. The earlier guidance put the earnings between $4.08 and $4.50 per share with revenue of $1.075 billion to $1.175 billion. A three-point play with opportunities Of the three healthcare stocks, I like CVS the most because it appears to be the most underpriced, with a forward price-to-earnings ratio of 11, compared with 34 for Medpace and 146 for Dexcom. CVS also has a more dependable, albeit slower, rate of growth. I think the company has a lot to gain as the economy opens up, and its healthcare benefits segment is well situated to grow for years as the company should continue to add Medicare and Medicaid patients. Similarly, I like Medpace's spot as a business that can use its expertise to make medical trials more efficient for companies. Dexcom may be the most overpriced of the trio, but it's hard to deny the growth that's in store for CGMs. 10 stocks we like better than CVS Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and CVS Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 11, 2021 Jim Halley owns shares of CVS Health. The Motley Fool owns shares of and recommends DexCom and Medpace Holdings, Inc. Common Stock. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-05-21,86.1475,87.875,85.39,85.5225,
DXCM,2021-05-24,86.685,90.7525,85.935,88.8475,"[""Why DexCom Stock Jumped Today What happened Shares of DexCom (NASDAQ: DXCM) had jumped 5% as of 3 p.m. EDT on Monday after rising as much as 6.1% earlier in the day. The diabetes-care technology company didn't announce any news. Instead, DexCom's rise appears to be due to the positive momentum for growth stocks in general. So what When the overall stock market moves up (or down), it's not unusual for DexCom to move in tandem. The old saying that \""a rising tide lifts all boats\"" is often true with stocks. DexCom G6 glucose monitoring devices and related apps. Image source: DexCom. The more important thing to look at with DexCom, though, is the underlying business prospects that could potentially drive long-term growth. The company expects revenue to jump between 17% and 22% for full-year 2021 thanks to sustained high demand for its G6 continuous glucose monitoring (CGM) devices. Much of the demand for the G6 CGM comes from individuals with type 1 diabetes. But DexCom continues to see increasing use of the device by individuals with type 2 diabetes. Now what DexCom expects to launch its newest CGM device, the G7, in the second half of this year. The G7 CGM could prove to be even more attractive to customers with a size that's less than half that of the already popular G6. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 11, 2021 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Monday Option Activity: JBHT, LB, DXCM Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in J.B. Hunt Transport Services, Inc. (Symbol: JBHT), where a total volume of 7,767 contracts has been traded thus far today, a contract volume which is representative of approximately 776,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 150.9% of JBHT's average daily trading volume over the past month, of 514,870 shares. Especially high volume was seen for the $170 strike put option expiring June 18, 2021, with 2,530 contracts trading so far today, representing approximately 253,000 underlying shares of JBHT. Below is a chart showing JBHT's trailing twelve month trading history, with the $170 strike highlighted in orange: L Brands, Inc (Symbol: LB) saw options trading volume of 28,278 contracts, representing approximately 2.8 million underlying shares or approximately 70.6% of LB's average daily trading volume over the past month, of 4.0 million shares. Particularly high volume was seen for the $68 strike call option expiring June 11, 2021, with 10,112 contracts trading so far today, representing approximately 1.0 million underlying shares of LB. Below is a chart showing LB's trailing twelve month trading history, with the $68 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 6,219 contracts, representing approximately 621,900 underlying shares or approximately 67.2% of DXCM's average daily trading volume over the past month, of 924,875 shares. Particularly high volume was seen for the $300 strike put option expiring June 18, 2021, with 4,610 contracts trading so far today, representing approximately 461,000 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $300 strike highlighted in orange: For the various different available expirations for JBHT options, LB options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Monday's ETF with Unusual Volume: PHDG The Invesco S&P 500\u2014 Downside Hedged ETF is seeing unusually high volume in afternoon trading Monday, with over 295,000 shares traded versus three month average volume of about 104,000. Shares of PHDG were up about 0.5% on the day. Components of that ETF with the highest volume on Monday were Ford Motor, trading off about 1.4% with over 58.1 million shares changing hands so far this session, and Apple, up about 1.7% on volume of over 28.9 million shares. Dexcom is the component faring the best Monday, up by about 5.5% on the day, while Cabot Oil & Gas is lagging other components of the Invesco S&P 500\u2014 Downside Hedged ETF, trading lower by about 5.2%. VIDEO: Monday's ETF with Unusual Volume: PHDG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-05-25,88.6975,89.805,88.2075,88.3125,
DXCM,2021-05-26,87.3975,89.495,87.23,88.6725,
DXCM,2021-05-27,88.405,90.75,87.02,90.4775,"Investing $5,000 in These 2 Stocks Could Make You a Fortune Not all stocks have the potential to deliver consistent market-beating returns, but you don't have to look far to find these investment gems. The reality is that few investments will make you rich overnight, and the best way to build and maintain stock market wealth is to invest for the long term. In that vein, let's look at two stocks that have serious wealth-building potential and could provide winning catalysts to your portfolio for decades to come. Image source: Getty Images. 1. Netflix As the world goes digital, people are increasingly choosing streaming platforms to enjoy their favorite movies, television shows, and other forms of entertainment. According to Grand View Research, the video streaming market attained a global valuation of more than $50 billion in 2020, and is projected to maintain a 21% compound annual growth rate (CAGR) in the 2021-2028 period. Netflix (NASDAQ: NFLX) is one of the pre-eminent players in the worldwide streaming market, and has seen exponential growth over the past year. Shares of the company are trading about 20% higher than one year ago, and current analyst price targets give the stock as much as a 130% upside. It's no surprise that Netflix's business and balance sheet both exploded during the pandemic. In the age of extended lockdowns, millions of people around the world turned to digital streaming platforms to stay occupied at home. But Netflix's growth isn't limited to the pandemic era. And the rapid growth that the industry is expected to deliver in the years ahead portends that this streaming media giant is just getting started. In 2020, Netflix's revenue surged 24% year over year, and its operating profits rose 76%. The company welcomed 37 million new paid members to its platform last year, with nearly 9 million paid net additions occurring in the fourth quarter alone. When Netflix released its first-quarter results on April 20, shares fell by roughly 8% even though the company reported stellar increases to both its top and bottom lines. The reason behind this share price drop was Netflix's rate of subscriber growth for the quarter. Although the company expanded its paid member count to 208 million subscribers during the three-month period, this was slightly behind Netflix's original forecast of 210 million. Should investors be concerned? Not at all. Fluctuations in subscriber growth are to be expected, particularly after the banner year Netflix delivered in 2020. Management also noted that ""paid membership growth slowed due to the big COVID-19 pull forward in 2020 and a lighter content slate in the first half of this year, due to COVID-19 production delays."" And it's worth noting that Netflix's paid membership base still grew a healthy 14% in the first quarter from the year-ago period. In addition to these figures, first-quarter revenue surged 24% year over year while its net income grew by a whopping 140%. Netflix is expecting to deliver year-over-year revenue growth of 19% in the second quarter. Management is also forecasting a spike in its membership base in the latter part of the year as it builds on its slate of original releases with new seasons of fan favorites like Money Heist and The Witcher. Analysts are expecting great things from Netflix. They project that the company can keep up average annual earnings growth of around 45% or higher for the next five years alone. With shares trading slightly lower than a few months ago, now's an excellent time to buy this winning stock on sale to set up your portfolio for exceptional long-term returns. 2. DexCom While DexCom (NASDAQ: DXCM) may not be the most glamorous of healthcare stocks, its leadership in the production of continuous glucose monitoring (CGM) devices has helped it flourish as a high-growth company in all sorts of market environments. This makes it a compelling play for investors searching for a long-term portfolio winner. DexCom's flagship product is its G6 CGM system for individuals with type 1 or type 2 diabetes. The system features a one-touch applicator, a sensor and transmitter that computes and conveys the user's glucose levels, and a display device to read the results. The G6 sensor has a 10-day wear time. DexCom is planning to release its new and improved G7 system later this year, which is expected to not only be smaller than the G6 but have extended wearability as well. In the full-year 2020, DexCom reported 31% revenue growth, and its operating income surged by 590 basis points from the prior year. The company was also extremely profitable in 2020, reporting that its net income increased by nearly 400%. DexCom's first-quarter earnings showed an impressive start to 2021. Revenue surged 25% year over year during the three months, and its net income registered a 103% increase from the year-ago period. Management is expecting the company to deliver between 17% and 22% overall revenue growth for the full-year 2021. And analysts are projecting that the company can maintain a similar rate of average annual earnings growth over the next half-decade. While shares of the company have retraced from highs during the pandemic, analysts still give DexCom an upper price target of $540, which would represent as much as a 53% upside from where it's trading now. If you, like many other investors at the moment, are concerned about the current volatility of the market, now's the perfect time to fill your basket of stocks with reliable companies primed for stable, long-term growth. According to the website Research and Markets, the CGM device industry had a global valuation of more than $4 billion as of 2019, and is expected to achieve a 17.3% CAGR in the 2020-2025 period alone. DexCom has a momentous opportunity for market expansion in the years ahead, and its dominant position in its marketplace has consistently translated to meaningful balance-sheet growth throughout the pandemic and subsequent economic crisis. This makes the stock a fantastic choice to add to your buy list right now. 10 stocks we like better than Netflix When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Netflix wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 11, 2021 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends DexCom and Netflix. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-05-28,93.75,94.61,92.0062,92.3475,"[""Friday Sector Leaders: Utilities, Healthcare The best performing sector as of midday Friday is the Utilities sector, higher by 0.4%. Within the sector, CenterPoint Energy, Inc (Symbol: CNP) and Dominion Energy Inc (Symbol: D) are two large stocks leading the way, showing a gain of 0.9% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 0.5% on the day, and up 4.59% year-to-date. CenterPoint Energy, Inc, meanwhile, is up 18.44% year-to-date, and Dominion Energy Inc is up 1.98% year-to-date. Combined, CNP and D make up approximately 8.2% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, higher by 0.3%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Boston Scientific Corp. (Symbol: BSX) are the most notable, showing a gain of 1.9% and 1.6%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.4% in midday trading, and up 9.29% on a year-to-date basis. DexCom Inc, meanwhile, is down 0.22% year-to-date, and Boston Scientific Corp. is up 18.57% year-to-date. Combined, DXCM and BSX make up approximately 2.1% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, six sectors are up on the day, while three sectors are down. SECTOR % CHANGE Utilities +0.4% Healthcare +0.3% Financial +0.3% Technology & Communications +0.3% Consumer Products +0.2% Industrial +0.1% Services -0.1% Energy -0.1% Materials -0.2% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Makes Bullish Cross Above Critical Moving Average In trading on Friday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $375.26, changing hands as high as $378.44 per share. DexCom Inc shares are currently trading up about 3.6% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $305.63 per share, with $456.23 as the 52 week high point \u2014 that compares with a last trade of $374.23. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Sponsored Links The US States People Are Fleeing And The Ones They Are Moving To Forbes Read More Click here to find out which 9 other stocks recently crossed above their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Have DexCom, Inc. (NASDAQ:DXCM) Insiders Been Selling Their Stock? Some DexCom, Inc. (NASDAQ:DXCM) shareholders may be a little concerned to see that insider Sumi Shrishrimal recently sold a substantial US$518k worth of stock at a price of US$355 per share. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 9.8%. The Last 12 Months Of Insider Transactions At DexCom Over the last year, we can see that the biggest insider sale was by the Executive Chairman, Kevin Sayer, for US$14m worth of shares, at about US$362 per share. So what is clear is that an insider saw fit to sell at around the current price of US$362. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive). Insiders in DexCom didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! NasdaqGS:DXCM Insider Trading Volume May 28th 2021 For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Insider Ownership Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. DexCom insiders own about US$208m worth of shares (which is 0.6% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. What Might The Insider Transactions At DexCom Tell Us? Insiders sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. But it is good to see that DexCom is growing earnings. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for DexCom (1 doesn't sit too well with us!) that we believe deserve your full attention. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-06-01,92.8,93.5812,90.395,91.4175,
DXCM,2021-06-02,91.3275,93.1025,90.7475,92.7475,
DXCM,2021-06-03,91.7475,94.7175,91.7475,94.185,"Analysts Anticipate RPG Will Reach $191 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 500— Pure Growth ETF (Symbol: RPG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $190.99 per unit. With RPG trading at a recent price near $170.07 per unit, that means that analysts see 12.30% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RPG's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Monolithic Power Systems Inc (Symbol: MPWR), and Etsy Inc (Symbol: ETSY). Although DXCM has traded at a recent price of $370.99/share, the average analyst target is 25.02% higher at $463.82/share. Similarly, MPWR has 24.55% upside from the recent share price of $343.63 if the average analyst target price of $428.00/share is reached, and analysts on average are expecting ETSY to reach a target price of $215.56/share, which is 23.08% above the recent price of $175.14. Below is a twelve month price history chart comparing the stock performance of DXCM, MPWR, and ETSY: Combined, DXCM, MPWR, and ETSY represent 5.69% of the Invesco S&P 500— Pure Growth ETF. Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Invesco S&P 500— Pure Growth ETF RPG $170.07 $190.99 12.30% DexCom Inc DXCM $370.99 $463.82 25.02% Monolithic Power Systems Inc MPWR $343.63 $428.00 24.55% Etsy Inc ETSY $175.14 $215.56 23.08% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-04,94.88,96.9875,93.75,95.7275,
DXCM,2021-06-07,96.0025,98.0525,95.19,96.745,
DXCM,2021-06-08,97.0725,98.3275,96.155,97.4875,
DXCM,2021-06-09,98.75,99.5375,97.3912,97.5075,
DXCM,2021-06-10,97.6,99.92,96.6246,99.745,"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: ""It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges."" Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly. Image source: Getty Images. Meme stocks can be speculative binges While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ: OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million. Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month. Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ: DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time. Safe investments may be boring, but they don't put you at significant risk Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease. DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen. Similarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time. The bottom line Malkiel mentions in his book that some investors like to make ""castles in the air"" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality. Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio. 10 stocks we like better than Ocugen, Inc. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Ocugen, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-11,100.272,100.478,99.13,100.048,
DXCM,2021-06-14,100.078,102.43,99.7975,102.272,"Notable Monday Option Activity: TDG, DXCM, GILD Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in TransDigm Group Inc (Symbol: TDG), where a total volume of 3,586 contracts has been traded thus far today, a contract volume which is representative of approximately 358,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 110.5% of TDG's average daily trading volume over the past month, of 324,565 shares. Especially high volume was seen for the $600 strike put option expiring July 16, 2021, with 3,442 contracts trading so far today, representing approximately 344,200 underlying shares of TDG. Below is a chart showing TDG's trailing twelve month trading history, with the $600 strike highlighted in orange: DexCom Inc (Symbol: DXCM) saw options trading volume of 7,550 contracts, representing approximately 755,000 underlying shares or approximately 102.4% of DXCM's average daily trading volume over the past month, of 737,540 shares. Particularly high volume was seen for the $450 strike call option expiring July 16, 2021, with 5,326 contracts trading so far today, representing approximately 532,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $450 strike highlighted in orange: And Gilead Sciences Inc (Symbol: GILD) saw options trading volume of 66,043 contracts, representing approximately 6.6 million underlying shares or approximately 95.5% of GILD's average daily trading volume over the past month, of 6.9 million shares. Especially high volume was seen for the $60 strike call option expiring June 18, 2021, with 20,007 contracts trading so far today, representing approximately 2.0 million underlying shares of GILD. Below is a chart showing GILD's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for TDG options, DXCM options, or GILD options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-15,102.5,103.902,101.0,101.275,"This Underappreciated Healthcare Stock Is on Sale: Should You Buy? Medical devices giant Abbott Laboratories (NYSE: ABT) was on fire last year for one simple reason: Even though many of its business segments suffered due to the pandemic, the company established itself as one of the leaders in the COVID-19 testing market. Abbott Laboratories sold several hundred million coronavirus test kits last year, which helped keep the company's revenue and earnings afloat. In the fiscal year 2020, ending Dec. 31, Abbott Laboratories recorded sales of $34.6 billion -- an 8.5% year over year increase. However, the healthcare giant's coronavirus testing tailwinds seem to be coming to an end. The company recently lowered its guidance because it anticipates a decline in demand for COVID-19 tests. This new development sent Abbott Laboratories' stock tumbling by more than 7%. And for the year, the company's shares are up by a measly 0.48%, compared with gains of 12.86% for the S&P 500. Should you buy Abbott Laboratories' stock on the dip? ABT data by YCharts A closer look at Abbott Laboratories' new guidance The worldwide efforts to vaccinate as many people as possible against COVID-19 continue. And while that's great news for the public -- which is anxious to put this pandemic in the rearview mirror once and for all -- it also means less need for diagnostic tests for the disease. This will obviously affect Abbott Laboratories' testing revenue, and it explains why the company decided to update its guidance for the full fiscal year 2021. The company now expects earnings per share (EPS) based on generally accepted accounting principles (GAAP) between $2.75 and $2.95, which compares unfavorably to its previous guidance of at least $3.74. The company also expects non-GAAP (adjusted) EPS between $4.30 and $4.50, lower than its previous projection of non-GAAP EPS of at least $5 for the year. Image source: Getty Images. Should investors worry? A lower guidance than previously announced is never good news -- for any company. However, it's important to look at things in perspective. First, note that the company's non-GAAP EPS would represent a 20.5% increase at the midpoint compared to the previous fiscal year. Abbott Laboratories' adjusted EPS increased by a lower 12.7% year over year in 2020. Second, Abbott Laboratories' medical devices business will also benefit from the reopening of the economy. During the first quarter ending March 31, the company's medical devices sales grew by 13.1% to $3.3 billion. Meanwhile, in 2020, revenue from this same segment decreased by 3.7% to $11.8 billion. Lastly, and perhaps most importantly, Abbott Laboratories boasts several exciting growth opportunities. One of these is its market-leading MitraClip System -- a device for the treatment of mitral regurgitation. In the first quarter, sales of this product jumped by more than 15%. The company also expanded Medicare reimbursement coverage for the MitraClip back in January, which broadened the potential client base for this product. The MitraClip will continue to provide a boost to Abbott Laboratories' financial results. The company is also betting big on its diabetes care segment, which has been one of its best performing to date. In the first quarter, the medical devices giant reported sales of $980 million from this business, representing an increase of 30.2% compared to the first quarter of 2020. Abbott Laboratories' greatest weapon in this segment is its Continuous Glucose Monitoring (CGM) device, the FreeStyle Libre, which brought in nearly $830 million in sales during the quarter. With companies such as DexCom and others, the CGM market is competitive. But in my view, there is more than enough space for multiple big players. And what's more, this market is poised to continue growing. According to Grand View Research, the CGM market will expand at a compound annual growth rate (CAGR) of 12.7% through 2027. In short, Abbott Laboratories's prospects do not rely exclusively -- or even primarily -- on the market for COVID-19 diagnostic test kits. It isn't too surprising that investors chose to send its stock tumbling after it reported its updated guidance; the company's shares had benefited a great deal from its coronavirus efforts before that. Still, Abbott Laboratories' future remains bright, and given its recent dip, now is a great time to open a position in this healthcare stock. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-16,101.45,102.18,99.4675,100.938,
DXCM,2021-06-17,100.705,104.355,100.02,103.112,
DXCM,2021-06-18,102.978,104.798,102.78,104.572,
DXCM,2021-06-21,104.572,106.07,101.905,105.758,
DXCM,2021-06-22,105.22,106.898,104.385,106.878,
DXCM,2021-06-23,106.962,108.275,105.815,107.93,"Did You Miss DexCom's (NASDAQ:DXCM) Whopping 441% Share Price Gain? Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality companies can see their share prices grow by huge amounts. To wit, the DexCom, Inc. (NASDAQ:DXCM) share price has soared 441% over five years. This just goes to show the value creation that some businesses can achieve. On top of that, the share price is up 23% in about a quarter. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During the last half decade, DexCom became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). NasdaqGS:DXCM Earnings Per Share Growth June 23rd 2021 It is of course excellent to see how DexCom has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time. A Different Perspective DexCom provided a TSR of 8.4% over the last twelve months. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 40% per year for five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with DexCom (including 1 which is a bit unpleasant) . We will like DexCom better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-24,108.3,109.905,106.122,106.25,"Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well. The Centers For Medicare & Medicaid Services (CMS) recently announced that there is no longer a requirement for a minimum of four self-monitoring blood glucose tests per day to have the continuous glucose monitoring (CGM) devices covered. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking. Furthermore, Dexcom expects to launch its newest CGM device – G7 – later this year, and given that the new device will use a new and improved application, while it will also be 60% smaller in size compared to the current G6, making it the smallest CGM device available in the market. It has several other benefits over the current version, such as, its transmitter and sensor will be combined, making it a single fully disposable unit. It is also expected to have a longer wear time. As such, the G7 CGM will likely be more attractive to customers, and bolster Dexcom’s sales growth after its launch. However, now that DXCM stock has seen a rise of 23% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in DXCM stock over the next month. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 99 out of 184, or about 54% chance of a rise in DXCM stock over the coming month. Also, despite the recent rally, DXCM stock is up only 4% from the levels it was trading at a year ago. See our analysis on Dexcom Stock Chances of Rise for more details. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom’s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company’s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It’s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back. While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it’s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott. Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn’t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days). Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details. Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market (3% likelihood event) Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7% A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. While DXCM stock can see a rebound, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons. See all Trefis Price Estimates and Download Trefis Data here What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-06-25,106.4,107.62,104.906,107.59,
DXCM,2021-06-28,107.872,107.895,105.612,106.79,
DXCM,2021-06-29,106.438,106.842,104.65,106.7,
DXCM,2021-06-30,106.135,106.971,105.618,106.75,
DXCM,2021-07-01,106.248,107.005,105.185,106.71,
DXCM,2021-07-02,107.115,108.25,106.55,107.898,
DXCM,2021-07-06,108.012,110.65,107.031,110.162,"Wait For a Pullback Before Taking a Position In Senseonics InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of medical device maker Senseonics (NYSE:SENS) have been rallying in the past month. SENS stock has generated over 90% return since mid-May. Positive study results from its glucose monitoring system and an elevated short interest propelled the stock to new highs. Source: Minerva Studio / Shutterstock.com There’s no denying the potential of its glucose monitoring systems, but it’s best to wait for a pullback before investing in SENS stock. Senseonics specializes in the development of implantable glucose monitoring diabetic patients. It recently released results from an internal study, which showed that its Eversense system showed a hypoglycemic alert detection rate of over 90% for both its primary and secondary sensors. According to estimates, the market for Contour Glucose Management (CGM) is likely to surpass $12 billion by 2026. Hence, despite the competition in the sector, there is enough depth in the market for Senseonics to generate a massive amount of revenue. Let’s look at Senseonics in a little more detail to assess its prospects. Ascensia Partnership Ascensia Diabetes Care is a major name in the global diabetic care market. With its agreement with Senseonics, it will handle the distribution of the company’s Eversense XL device in Europe and sales support. Moreover, Eversense is currently the only CGM product that the Food and Drug Administration has approved for use in the U.S. The opportunity for Senseonics is incredible if it comes to fruition. Ascensia has the expertise and experience that will enable the company to establish its presence in Europe. The Swiss company was established back in 2016, and it has been fixated on improving the lives of diabetic patients. It has several noteworthy alliances with major health care companies, including Medtronic (NYSE:MDT). For example, it is working with Medtronic in developing and supplying CGMs that connect to MiniMed Paradigm and 6 Series Pump systems for insulin dosing. Competition and Financial Positioning Few CGM devices are currently prevalent in the U.S. market from Abbott (NYSE:ABT), Medtronic, and DexCom (NASDAQ:DXCM). Senseonics has the edge over its competition by being the first long-term implantable glucose monitor. The Eversense device sensors can remain in place in place for close to three months, which comfortably exceeds the typical wear time of three to 14 days. Additionally, with stronger product and expansion marketing efforts in the European market and the growing U.S. market, Senseonics could witness double-digit growth in the long run. From a financial standpoint, the company appears to be moving in the right direction. It generated revenues of $2.85 million, which grew over 7,000% on a year-over-year basis. Moreover, its cash and cash equivalents are at a healthy $178.6 million, with outstanding indebtedness at $110.6 million. Looking ahead, Senseonics expects revenues to fall in the range of $12 million to $15 million. Therefore, the company has a fantastic growth runway ahead in the fast-growing diabetes market. Final Word On SENS Stock SENS stock has been moving in the right direction in the past year, generating healthy shareholder returns. Senseonic’s Eversense CGM system is a robust product that could be a novelty in the diabetic care market. It has some unique features which give it the edge over its competition. Moreover, the market’s sheer size is such that it has ample room for Senseonics to establish its position. Additionally, its efforts to grow its presence in Europe will also solidify its positioning in the market. However, I feel it’s best to wait for a pullback before scooping up SENS stock. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. The post Wait For a Pullback Before Taking a Position In Senseonics appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-07-07,111.12,112.286,109.282,111.88,
DXCM,2021-07-08,110.158,111.832,108.855,111.742,
DXCM,2021-07-09,111.28,111.372,109.072,110.182,"[""Friday Sector Laggards: Utilities, Healthcare In afternoon trading on Friday, Utilities stocks are the worst performing sector, not showing much of a gain. Within that group, Alliant Energy Corp (Symbol: LNT) and Dominion Energy Inc (Symbol: D) are two large stocks that are lagging, showing a loss of 0.8% and 0.8%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.2% on the day, and up 4.23% year-to-date. Alliant Energy Corp, meanwhile, is up 10.99% year-to-date, and Dominion Energy Inc is up 1.88% year-to-date. Combined, LNT and D make up approximately 8.4% of the underlying holdings of XLU. The next worst performing sector is the Healthcare sector, up 0.4%. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and DexCom Inc (Symbol: DXCM) are the most notable, showing a loss of 2.8% and 1.9%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.3% in midday trading, and up 14.22% on a year-to-date basis. Biogen Inc, meanwhile, is up 46.57% year-to-date, and DexCom Inc is up 18.54% year-to-date. Combined, BIIB and DXCM make up approximately 2.0% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, eight sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Financial +2.3% Energy +2.1% Materials +1.9% Services +1.6% Consumer Products +1.4% Industrial +1.4% Technology & Communications +1.0% Healthcare +0.4% Utilities -0.0% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: DXCM, DFS In early trading on Friday, shares of Discover Financial Services topped the list of the day's best performing components of the S&P 500 index, trading up 5.5%. Year to date, Discover Financial Services registers a 34.4% gain. And the worst performing S&P 500 component thus far on the day is DexCom, trading down 1.9%. DexCom is showing a gain of 18.7% looking at the year to date performance. Two other components making moves today are Intuit, trading down 1.8%, and The Gap, trading up 5.0% on the day. VIDEO: S&P 500 Movers: DXCM, DFS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-07-12,111.355,112.215,110.382,111.442,"Interesting DXCM Put And Call Options For December 17th Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the December 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 158 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new December 17th contracts and identified one put and one call contract of particular interest. The put contract at the $440.00 strike price has a current bid of $43.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $440.00, but will also collect the premium, putting the cost basis of the shares at $396.50 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $443.43/share today. Because the $440.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 57%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 9.89% return on the cash commitment, or 22.83% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $440.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $450.00 strike price has a current bid of $43.40. If an investor was to purchase shares of DXCM stock at the current price level of $443.43/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $450.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 11.27% if the stock gets called away at the December 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $450.00 strike highlighted in red: Considering the fact that the $450.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 47%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 9.79% boost of extra return to the investor, or 22.60% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 42%, while the implied volatility in the call contract example is 43%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $443.43) to be 40%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-07-13,111.345,112.455,110.508,111.598,
DXCM,2021-07-14,112.122,112.435,109.711,110.122,
DXCM,2021-07-15,109.735,110.542,108.478,110.355,
DXCM,2021-07-16,110.638,112.858,110.242,112.172,
DXCM,2021-07-19,111.03,112.867,107.99,108.762,"First Week of September 17th Options Trading For DexCom Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new September 17th contracts and identified one put and one call contract of particular interest. The put contract at the $440.00 strike price has a current bid of $26.10. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $440.00, but will also collect the premium, putting the cost basis of the shares at $413.90 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $443.18/share today. Because the $440.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 55%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.93% return on the cash commitment, or 36.09% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $440.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $450.00 strike price has a current bid of $24.70. If an investor was to purchase shares of DXCM stock at the current price level of $443.18/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $450.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.11% if the stock gets called away at the September 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $450.00 strike highlighted in red: Considering the fact that the $450.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.57% boost of extra return to the investor, or 33.90% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example, as well as the call contract example, are both approximately 40%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $443.18) to be 39%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-07-20,108.72,112.832,107.788,111.925,"First Week of DXCM August 20th Options Trading Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the August 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new August 20th contracts and identified one put and one call contract of particular interest. The put contract at the $430.00 strike price has a current bid of $19.40. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $430.00, but will also collect the premium, putting the cost basis of the shares at $410.60 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $434.95/share today. Because the $430.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.51% return on the cash commitment, or 53.12% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $430.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $440.00 strike price has a current bid of $18.90. If an investor was to purchase shares of DXCM stock at the current price level of $434.95/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $440.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 5.51% if the stock gets called away at the August 20th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $440.00 strike highlighted in red: Considering the fact that the $440.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 52%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.35% boost of extra return to the investor, or 51.16% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 45%, while the implied volatility in the call contract example is 44%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $434.95) to be 40%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-07-21,112.372,112.45,109.25,111.745,
DXCM,2021-07-22,112.19,113.189,111.535,112.722,
DXCM,2021-07-23,113.162,115.805,112.592,115.18,
DXCM,2021-07-26,114.698,114.698,112.684,113.145,
DXCM,2021-07-27,113.072,113.646,111.318,112.145,
DXCM,2021-07-28,112.14,115.25,111.9,114.98,
DXCM,2021-07-29,114.91,116.551,113.852,114.012,"[""DexCom Inc (DXCM) Q2 2021 Earnings Call Transcript Image source: The Motley Fool. DexCom Inc (NASDAQ: DXCM) Q2 2021 Earnings Call Jul 29, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom Second Quarter 2021 Earnings Release Conference Call. My name is Dow, and I'll be your operator for today's call. [Operator Instructions] I will now turn the call over to Sean Christensen. You may begin. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Sean Christensen -- Head of Investor Relations Thank you, operator, and welcome to DexCom's Second Quarter 2021 Earnings Call. Our agenda this afternoon includes comments on the company's recent performance and strategic initiatives from Kevin Sayer, DexCom's Chairman, President and CEO; Jereme Sylvain, our Chief Financial Officer; and finally, an update from Quentin Blackford, our Chief Operating Officer. Following our prepared remarks, we will open the call up for questions. Please note that there are also slides available related to our second quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, and are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to our tables in our earnings release and the slides accompanying our second quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President And Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Today, we reported great results for our second quarter with 32% revenue growth for the quarter compared to the second quarter of 2020, as well as solid execution on our key strategic initiatives that we will discuss throughout the call today. The $143 million in absolute dollar revenue growth compared to the second quarter in 2020 represents the highest quarterly increase in DexCom's history. We continue to believe that we are early in our story with the potential to drive a far greater impact on global health. Our growth performance is closely related to the progress we've made to advance access on our CGM systems for people with diabetes. And because there is often so much misinformation spread about access to DexCom's CGM in the field, while the cost of our products for people with diabetes. Let me point out several key points that our investors, clinicians and current and potential customers should know. We've advanced pharmacy access in the U.S., where more than 70% of our commercial customers have a monthly out-of-pocket cost of less than $60 per month, and nearly 1/3 of our customers have 0 out-of-pocket costs for their G6 sensors. According to IQVIA, this is less than the comparable out-of-pocket cost for our nearest competitor. The latest research from diabetes market research firm, Seagrove Partners, confirms our conclusion. With DexCom having the lowest customer co-pays of the three largest CGM suppliers in the U.S. for customers on intensive insulin therapy, we've significantly expanded coverage for people with intensively managed type two diabetes, with the overwhelming majority of these patients now having coverage for DexCom CGM in the U.S. We also continue to advocate for equitable access to our CGM supplies for populations that are often underserved. As of July 2021, there are now 43 State Medicaid programs providing coverage for DexCom CGM, including a growing number of states providing access through their pharmacy channel for both type one and type two intensive users. We are building even more on those advocacy efforts in collaboration with several key nonprofit organizations that support the diabetes community. In June, we launched the global movement for time and range to broaden awareness of time and range and its benefits for people with diabetes and their healthcare providers. And we hope that this collaboration effort will lead to future solutions for improved CGM access. Our teams have taken a leading role to drive the removal of administrative barriers that prevent people with diabetes from accessing the benefits of real-time CGM. Along these lines, we are pleased to see the update from CMS in the second quarter to remove the requirement of at least four daily finger sticks for Medicare customers. This will simplify the CGM onboarding process for both customers and clinicians. We've also made solid progress internationally, building from our position of operational strength to advocate for broader reimbursement for G6. This initiative is moving forward according to plan with several geographies publicly announcing enhancements to their coverage of DexCom CGM in the second quarter. Despite these developments, a majority of people on mealtime insulin continue to manage their diabetes with finger sticks. Even in the U.S., a leader in CGM adoption, we continue to believe that the type one market remains less than 50% penetrated and the type two intensive market is less than 25% penetrated. So there remains a great opportunity ahead of us, even in the markets that we currently serve. At the same time, we are generating a growing evidence base for the use of DexCom CGM. And at the ATTD and ADA industry conferences in June, we presented exciting research affirming the benefits of our product platform, including the ALERTT1 trial. This randomized controlled trial was simultaneously published in the Lancet, showing superior health outcomes associated with the use of DexCom CGM relative to our nearest competitor, Flash Glucose Monitor. These conferences also featured several presentations on the use of CGM for people of type two diabetes, including those not using mealtime insulin as well as use in women who are pregnant used in the hospital setting and even conclusions applicable to health and wellness using CGM data. Perhaps the most significant of these presentations was the long-awaited readout of our MOBILE trial, which was also published in the Journal of the American Medical Association. MOBILE is another rigorous randomized controlled trial assessing the value of DexCom CGM compared to the current standard of care, finger sticks, for people of type two diabetes treated with basal insulin. Importantly, the study looked at a diverse user base representative of the U.S. population, and it assess these people in a primary care clinical environments where they are traditionally served. So what did we see? We saw clinically significant A1c reductions for users of our DexCom CGM systems. And perhaps even more telling, we saw a 16% time and range increase for the CGM cohort, which is four additional hours per day spent in the target glucose range. These were results produced with DexCom CGM and DexCom software. We designed the trial with the goal of changing the standard of care for these basal insulin users, a group that we believe includes between three million and four million people in the U.S. alone. With these results, we feel that MOBILE and DexCom have the potential to do just that, and our teams look forward to driving better awareness and access based on the study outcomes and the JAMA publication. We also made great progress in the second quarter to advance the clinical and regulatory pathway for our next-generation G7 CGM system. At ATTD in June, we provided an update on the performance of G7 drawn from our recent clinical trials. Based on the data shown, we expect that G7 will continue the excellent clinical and real world performance and reliability that we have established with our G6 brand. And it will do so with several factors that we believe will enhance our customer experience, including a fully disposable sensor and transmitter, a redesigned app experience and a market-leading 30-minute warmup period. Our G7 continues to progress according to our plans. During the second quarter, we concluded our U.S. clinical trial that will support our iCGM filing and our teams have now shifted to processing the data and working toward preparing the regulatory filing. In addition, we've recently submitted G7 for CE Mark approval. As we previously discussed, we believe that this timing places us on track to begin the G7 launch by the end of 2021. These are incredible achievements and advances from the quarter and a nice step forward to fulfill the promise presented by our CGM technology. And this is just the beginning. There are several additional areas of progress that Jereme and Quentin will discuss based on the great work of our teams in the past several months. So with that said, let me turn it over to Jereme for a review of our second quarter financial performance. Jereme? Jereme Sylvain -- Executive Vice President, Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the second quarter of 2021, we reported worldwide revenue of $595 million compared to $452 million for the second quarter of 2020, representing growth of 32% on a reported basis and 30% on a constant currency basis. As Kevin noted, this represents a record for absolute dollar growth in a quarter year-over-year. U.S. revenue totaled $462 million in the second quarter compared to $367 million in the second quarter of 2020, representing growth of 26%. Our momentum and market leadership position in the U.S. remains strong, and we have been very encouraged with the continued interest in CGM in the marketplace. With the combination of greater depth in our sales force, solid results from our direct-to-consumer marketing campaigns and expanded ability to allow for patients and clinicians to trial the G6 experience, we are beginning to see preliminary results in our effort to further expand our presence into primary care offices and position the company to extend our customer base. International business grew about 58% in the second quarter, totaling $134 million. While the second quarter comp benefited from the impact of COVID on our second quarter 2020 results, we saw good sequential growth momentum as the business once again achieved a new high watermark. The international growth was broad-based across all markets, including core markets like Germany, the U.K., Canada, Australia and the Nordic region. Our shift to the pharmacy channel and sales initiatives in the U.S. and our market expansion initiatives internationally are all progressing according to plan, driving high volume growth in both regions. Volume growth for the second quarter came in around the mid-40% range on a global basis. Perhaps the greatest examples of the international effort during the quarter came from Canada, where we saw public announcements of provincial coverage for G6 from two of the largest Canadian provinces: Quebec, where coverage of G6 was established for people with type one diabetes; and British Columbia, which became the first Canadian province to cover G6 for people with type one diabetes and intentionally manage type two diabetes. These public announcements are representative of our broader strategy to advance access to our technology for people with diabetes. We are leveraging the increasing strength of our operations and driving a meaningful expansion to the total number of patients that we can address via reimbursed pathways. Our second quarter gross profit was $417.1 million or 70.1% of revenue compared to 64.1% of revenue in the second quarter of 2020. We're very proud of the effort that's gone into these results. The 600 basis points of gross margin expansion is another great validation of the growing efficiencies that we've achieved through product design and efficient manufacturing operations. It is these types of efforts that drive the strategic flexibility to expand our addressable market that I just referenced. Operating expenses were $315.6 million for Q2 2021 compared to $213 million for Q2 2020. These results reflect what we previously noted in our discussion of our 2021 plans. We have several areas of investment that we are pursuing, which account for the increase in operating expenses as a percentage of sales relative to the second quarter of 2020. These include the costs associated with our expanded field sales force, the pivotal trial in support of our U.S. G7 regulatory submission, the G7 manufacturing scale-up and global direct-to-consumer marketing. Our strategic investments have also included our efforts to efficiently scale and lower the cost to serve our customers as we envision a future in which we serve meaningfully more people than we do today. Our global business services operations in Lithuania and the Philippines are key examples of those initiatives that are driving great customer service while leveraging our G&A spend. Operating income was $101.5 million or 17.1% of revenue in the second quarter of 2021 compared to $76.7 million or 17% of revenue in the same quarter of 2020. The 10 basis point year-over-year improvement was driven by strong improvements to our gross margin, resulting from the design of our products and the manufacturing efficiencies that come there through. These improvements more than offset the strategic investments that we've made during the year. Adjusted EBITDA was $156.6 million or 26.3% of revenue for the second quarter compared to $122.6 million or 27.1% of revenue for the second quarter of 2020. Net income for the second quarter was $75.4 million or $0.76 per share. We remain in a great financial position, closing the second quarter with approximately $2.6 billion in cash and cash equivalents and great financial flexibility to drive our strategic initiatives. Turning to guidance. We continue to expect solid volume growth across all of our regions in the back half of the year with momentum driven by growing CGM awareness globally. Based on our second quarter performance, we are pleased to be in a position to once again raise our full year 2021 revenue guidance. We now expect 2021 revenue to be between $2.35 billion to $2.4 billion, representing growth of 22% to 25% over 2020. This increase comes on top of our expectations for approximately $10 million of unfavorable currency impact in the back half relative to prior guidance. This revenue increase is primarily a reflection of our continued growth momentum as well as the ongoing impact of our channel mix and international access expansion strategies. We will see a greater revenue per patient impact to our existing base from our international access initiatives in the second half of the year, but we continue to expect the incremental volume driven by these efforts to offset those pressures in our base this year alone. More importantly, this will leave us in a much better position in the years to come. Turning to margins. We are increasing our full year 2021 targets. This includes non-GAAP results to be approximately at the following levels: gross profit margins of approximately 67%, operating margins of approximately 14% and adjusted EBITDA margins of approximately 24%. With that, I will now turn the call over to Quentin for a scale and strategy update. Quentin Blackford -- Chief Operating Officer Thank you, Jereme. As Kevin and Jereme indicated, we made great progress on our key strategic initiatives during the second quarter. It is hard not to be excited about the market potential for CGM after seeing the depth of research using DexCom technology at the recent ATTD and ADA industry conferences. We saw well over a dozen presentations from DexCom's insulin delivery partners, highlighting the clinical utility of their DexCom integrated systems and DexCom's leadership in the field of interoperable solutions. Outside of the MOBILE and ALERTT publications that Kevin mentioned, we also saw several presentations from our DexCom team members as well as independent investigators with outcomes that are very promising for the continued growth of DexCom CGM. In one study presented by our health economics team, we looked at real world evidence, documenting the cost savings for a significant number of patients with type two diabetes using G6, including both the intensive insulin therapy and those who are not treated with mealtime insulin. The results were compelling with the magnitude of cost savings generated for the G6 users being nearly identical to the cost savings we've seen in several of our other pilots. This is yet another data point supporting economic benefits associated with the better glucose control for our customers, and we are excited to leverage this growing evidence base into broader access for people with diabetes around the world. We also continue to innovate our software solutions to enable differentiated user experiences that meet the needs of the diverse customer bases that we serve. Most recently, in mid-July, we received FDA clearance on a real-time API software solution. This is, to our knowledge, one of the first, if not the first real-time API clearance in the medical device sector that enables integration with third-party apps. As many of you likely know, prior to the clearance of our real-time API, our various digital health partners were limited to the display of CGM data on a 3-hour delayed basis through our retrospective API. With this new API, partners who are now invited by DexCom have the ability to integrate real-time DexCom CGM data into the respective apps and devices. This is another great win for our customers, who will now benefit from the ability to see real-time glucose levels in a variety of new displays according to their needs. At the time of the approval, we announced Garmin and Teladoc Health Livongo for diabetes program as early users of the new API solution. In addition, Welldoc and UnitedHealthcare's Level2 are also utilizing our real-time connectivity solutions and their integrated offerings. This is an exciting innovation for us and an example of how we are leveraging our leadership in software connectivity to advance our market position in the growing digital health landscape. On the commercial front, we remain well positioned to drive growth in broader DexCom market penetration in several locations. In addition to the significant access expansion efforts that we began to implement last quarter to enable multiples of growth in our core markets, we are growing our presence in locations that are relatively new to our team. This includes Japan, where we've recently sent our first shipment of G6 systems to our local distributor. Although we have had a minor presence in Japan through the use of our G4 professional CGM, these G6 systems represent the expanded use of our product to serve people with diabetes with our core ambulatory solution. We are incredibly excited to bring our CGM technology to empower people with diabetes in Japan and look forward to developing that as a nice growth market for DexCom. In addition to the strong G7 performance data showed at ATTD in the clinical and regulatory updates that Kevin provided, our operations team is continuing according to plan in our G7 manufacturing development and scaling efforts. We have automated lines producing G7 product as we speak, with a steady cadence of additional lines scheduled to be delivered through the back half of this year and throughout 2022. In addition, the vendors in our supply chain are scaling up G7 capabilities alongside us as we sit here today. We will take what we have learned from these automated lines in San Diego and Mesa and use them to quickly replicate and scale in our new manufacturing facility in Malaysia. As we've said before, this effort will be critical to our ability to serve significant customer populations that we think can benefit from our CGM technology, giving us a clear runway to produce more than 200 million sensors per year and a much stronger presence in a key growth region for us. Our team is doing a great job to advance our efforts in what continues to be a challenging environment to navigate because of the impact of the pandemic globally. We are currently building out the manufacturing facility while also scaling our supply chain, putting us on track to be ready for production in 2022. As you can see from our 70% gross margin this quarter, we're making this progress on G7, while also advancing our efforts toward operational excellence, resulting in even greater improvements in efficiencies to our G6 manufacturing, procurement and distribution capabilities. Overall, as I think Kevin and Jereme would agree, we are very proud of the work of our teams to execute on the ambitious plans that we set forth in 2021. With that, I'll pass the call back to Kevin. Kevin Sayer -- Chairman, President And Chief Executive Officer Thanks, Quentin. I agree with that message as we are all very pleased with the progress that we made during the quarter. To be able to raise guidance across the board, including another revenue raise, with $65 million added to the midpoint of guidance is a great result for the company. We're excited to continue that momentum into the second half of the year. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions and Answers: Operator [Operator Instructions] And our first question comes from Robbie Marcus. Robbie, go ahead. Robbie Marcus -- JPMorgan -- Analyst Great.I want to congratulate you guys on a really nice quarter. If I can ask, I think we're all interested in updated G7 approval timing sounds like you haven't filed in the U.S. yet. And you had a great international number. I'd love if you could provide just any examples or tangible examples of how the expansion of benefit is already helping you? And how it might continue to help you the rest of this year and next year? Kevin Sayer -- Chairman, President And Chief Executive Officer Well, I'll start with G7, then I'll let Quentin and Jereme take over the benefit expansion. With respect to G7, we're very deliberate about what we disclose. We have filed for CE Mark and we are on schedule for that. We hit our goal there. And we are now gathering the data from the U.S. pivotal study. It was a much larger study than the data that was presented at ATTD. However, the trial was run under actually what we think are improved protocols from what we ran before. So we have no reason to not expect great data. We believe the product will be very robust. We will make sure that we deliver that file in a very pristine manner. We hear a lot of things about FDA delays and things of that nature. We don't want to create any delays. It's been our experience over time when we deliver what the FDA expects, they move very quickly and are very cooperative with us. We have no reason to believe the file we're preparing isn't going to meet those expectations. We're moving along those lines. So again, with the CE Mark filing, we're on track for an OUS launch later this year, and we'll update you more on the U.S. as time goes on. Quentin? Quentin Blackford -- Chief Operating Officer Yes, Robbie. With respect to your question or comment on the OUS business, look, there was strength really across the board in that entire portfolio of ours. So we're very encouraged by what we're seeing there, primarily on the heels of awareness just continuing to grow. To be honest with you, I don't think we've seen the benefit yet of the increased access that we spoke to really back in the first quarter. And the team has made incredible progress and working with the payers and negotiating these contracts, I'd say we're through 90% or so of those all landing in favorable positions where we probably increased or improved access for nearly one million patients in the first half of the year alone in that OUS business. But the reality is that benefit is not going to show up until the back half of the year. So the strength in the second quarter, I wouldn't attribute that to the increased access just yet, but we're very excited about how we're positioned as we go into the back half of the year around those access efforts. Robbie Marcus -- JPMorgan -- Analyst Great. Appreciate the thought. Operator And our next question comes from Bob Hopkins. Bob, go ahead. Bob Hopkins -- BofA Securities -- Analyst Great. Thank you. Okay. Just to maybe a comment on two quick things. First Quentin, I think this is what you're referencing in terms of the access piece, but I'm just curious if there's any more detail on just how that the process of the price cuts and negotiating better access, just how you feel that's going? I think and I apologize if that's kind of what you were referencing with that last question. And then, Kevin, I'd love you to just give a quick update on -- just a little more time has passed since the MOBILE trial. Just curious as to kind of what you're hearing from insurance partners or other important parties in terms of the potential impact on that data on facilitating greater reimbursement for a broader range of patients going forward? Quentin Blackford -- Chief Operating Officer Sure. So I'll jump on that first one, Bob. We are talking the exact same thing there in terms of the fact that we've negotiated or worked through the majority of those negotiations through the course of the second quarter, more than 90% or so of them behind us, all landing in favorable positions relative to improving the access for the patients, reducing the administrative burdens that were there, so that folks get on the technology a whole lot easier. So very bullish around where we're at and creating incremental access for our patients and how that sets up into the back half of the year. The pricing assumptions have come right in line with what we expected as we were going into it. No surprises there. So from our perspective, all is very positive on that front. Kevin Sayer -- Chairman, President And Chief Executive Officer And Bob, with respect to the MOBILE study, obviously, we're very excited about it. just a little time has passed here. We also have a bunch of other analyses on this data, that are coming that will support our position on basal insulin reimbursement for these patients. It's time to get the word out now. I think one of the big areas here is going to be CMS discussions down the line because a lot of these patients fall into the Medicare bucket, haven't done any of that yet, but we are looking forward and we are preparing because this data is just really -- is very, very strong. Bob Hopkins -- BofA Securities -- Analyst Thank you. Operator And our next question comes from Jeff Johnson. Go ahead, Jeff. Jeff Johnson -- Baird -- Analyst Yeah. Thanks. Good afternoon, guys. Just staying on maybe the international side for a second. Jereme, last quarter, you talked about a $50 million incremental headwind. From Quentin's comments, it sounds like maybe those really haven't started to flow in yet. So do we think about that $50 million headwind kind of a next 12-month number? Is that how to think about it? And then those initial $200 million headwinds that we kind of were expecting heading into this year, the first quarter kind of straight-lined in right at about $50 million. Did it straight line again in the second quarter at about the $50 million on the U.S. side and still thinking about the international then $50 million over the next 12 months? Jereme Sylvain -- Executive Vice President, Chief Financial Officer Sure. So the full year guidance around pricing or channel mix headwinds is still the same. And so the $200 million on what we call the original shift mix primarily in the U.S. is still the same. And in the second quarter, it came in a little bit lighter than the first quarter, but generally in line. And so I think we're seeing that stable. And we talked about it at the beginning of year being pretty stable throughout the course of the year. To your point on the international incremental headwinds about the access for price conversation, that has started. It is back half loaded. We certainly will have some of those in the first half of next year as we anniversary some of those contracts. So the $250 million we talked about was really the impact on 2021. And so you'll see the $50 million in the back half of the year. There will be a little of that into 2022. We'll go into that in the future, but that will happen over a 12-month period. Jeff Johnson -- Baird -- Analyst Thank you. Operator And our next question comes from Matthew O'Brien. Go ahead, Matthew. Matthew O'Brien -- Piper Sandler -- Analyst Good afternoon. Thanks for taking the question. I know traditionally, DexCom has been pretty conservative with their outlook. But I think, Jereme, you just said the pricing concessions are going to be impactful in the back half. But as I look at the model, the back half of the year has easier comps than the first half, and you just put up a monster in Q2, especially in the U.S. So is there something specifically you're trying to call out as far as incremental pressure in the back half of the year that we should be aware of? Jereme Sylvain -- Executive Vice President, Chief Financial Officer Yes. No, thanks for the question. Certainly, nothing that we're trying to call out. I think when we thought about guidance, we certainly talked about the performance in the first half of the year and certainly thinking about that patient base and how that plays out for the balance of the year. So that's contemplated in the guidance. And look, we raised the guidance, $65 million at the midpoint and $75 million when you exclude the impact of currency. So we've certainly raised it and passed through some of that for the balance of the year. As we think about the back half of the year, we simply don't want to get ahead of ourselves. We talked about the impact, and you pointed out the international access, but there still is COVID out there and the delta variant is out there. And so rather than increase it and get bullish and get ahead of ourselves, we want to see how it plays through for the balance of the year. We do hear instances out there outside the U.S. where primary care physicians are taking their practice and ultimately using their time to administer vaccinations. While we've done a great job navigating through those thus far this year, we do want to be prudent and make sure that we are contemplating. And look, if we can deliver more than that, we certainly will, and we'll talk to it if we are able to. Matthew O'Brien -- Piper Sandler -- Analyst Thank you. Operator And our next question comes from Mathew Blackman. Go ahead, Mathew. Mathew Blackman -- Stifel -- Analyst Good afternoon, everyone. Thanks for taking my question. Jereme, I just was curious about the second half cadence and whether we should be thinking about sort of a typical third quarter or fourth quarter cadence? Or are we sort of at the point or approaching the point where things like increasing pharmacy access may make the year somewhat less 4Q weighted as we've seen historically? Any help there would be appreciated. Jereme Sylvain -- Executive Vice President, Chief Financial Officer Yes. Sure. Absolutely happy to take it. So the way to think about Q3 and by default, you'll back into Q4. Q3 generally is not that impacted by changing in shifts and dynamic. In fact, I think for the past few years, you've generally seen it right around that 26% of full year revenue. And we expect the same to happen this year. So I think that will help you at least think about Q3 and the balance of the year. We do expect Q4 to have less of a weighting you saw in Q1 as a result of the move to the pharmacy where the year gets a little bit less seasonal. I think you'll expect the same in Q4, where you don't have folks in the DME channel rushing to meet benefits. So I do think you'll see, as we've talked about before, as we make more and more moves to the pharmacy, less heavy weighting on Q4 and less light weighting on Q1 and start to move out of that seasonality. But hopefully I gave you some context. Q3 in the near term, we do expect Q3 to mirror that of prior periods, which is generally in that 26% seasonality. Operator And our next question comes from Matt Taylor. Go ahead, Matt. Matt Taylor -- UBS -- Analyst Thank you. So I wanted to ask one on the margins here. I guess the way I'll ask it is, you showed significant progress. Quentin, you talked about a lot of the scaling and automation activities you're doing in these facilities. Has the results that you've had so far in being able to raise guidance changed your view on the longer term potential for margins at all to the positive versus the LRP? Quentin Blackford -- Chief Operating Officer Yes. What I would say is, look, our confidence level continues to increase and our ability to keep it in that mid-60s range that we've guided to long term. Is there the opportunity to take it north of there over time? If so, you can bet on it that we're going to flow that through and give that up, if possible. But look, we're in the midst of evaluating a lot of different potential business models. As you look at the whole type two non-intensive space as it opens up, we're looking at the international business continue to expand in a significant way. Pharmacy access continues to grow. All of these things are going to continue to put a bit of pressure on the gross margin profile. But if you saw the way that we were able to take cost out of the product from a design perspective and improve the process efficiencies around manufacturing this, your confidence level only increases and where we can keep that gross margin over time. So we're incredibly excited by what we're seeing. A lot of that doesn't contemplate the fact that over time, you probably see us move into a 15-day where cycle on the product itself, and so there's significant benefits that come there also. So again, a bit back to Jereme's point earlier, this is not an area that we're going to get ahead of ourselves, but we feel like we have the flexibility we need to really get after the market opportunities that present themselves and still deliver a very attractive gross margin profile in this business. Matt Taylor -- UBS -- Analyst Great. Thanks for the comments and congrats on a good results. Quentin Blackford -- Chief Operating Officer Yes. Thanks Matt. Operator And our next question comes from Margaret Kaczor. Go ahead, Margaret. Margaret Kaczor -- William Blair -- Analyst Hey, good afternoon guys. Thanks for taking my question. I wanted to follow up a little bit on the real-time APIs and you guys got approval for. And it seems like to me like it could be one of the next evolutions for the business. So I was curious if you could talk to us how important it is today versus three years from now, what it can facilitate both clinically and commercially? I guess, just to round it out, what's been the reaction from the potential partners to the API so far? Quentin Blackford -- Chief Operating Officer Well, maybe I'll start with the reaction. The reaction has been incredibly positive. I think folks understand and desire to see the real-time information coming into their tools and being able to put that into the hands of the patients. The more real time that information is, the more reactive, the patient can be to that information and improve their outcomes over time. And I think we're incredibly bullish in the sense that we believe we have the capability and a platform to build these tools off of, and that's exactly where we want to be. We want to provide as much input to these tools as we possibly can and work with as many partners as possible. I think from the very beginning, we've always had a bit of a different approach to the value of information, data and software, in particular. And what you're seeing play out right now is part of that vision that we've had there and the approval of the real-time API. We've invested heavily in the ability to produce this capability. We understand the importance of interoperability, the importance of putting information in the hands of the patients. That's who DexCom is. And you're going to continue to see us invest in that area and really use it as a differentiator. In terms of how that evolves into the future and is there opportunity to create value in that monetization of the data stream or the real-time API. Those are all things we'll evaluate over time. That's not our strategy today. Today, it's all about improving outcomes for patients that's going to show up in the way of incremental sensor sales over time, and we're very happy with that approach. But it leaves us with some great flexibility. Margaret Kaczor -- William Blair -- Analyst Great. Thanks. Operator And our next question comes from Travis Steed. Go ahead, Travis. Travis Steed -- Barclays -- Analyst Hi. Congratulations on a good quarter. I know you talked about the OUS launch of G7 here in the back half. And just curious if you could put some context on expectations for how we should think about that launch? And which countries if you're willing to share that? And you've also got probably 40 million to 50 million G6 sensors that you're making a year. And just curious what you're going to do with the G6 capacity as G7 launches? Kevin Sayer -- Chairman, President And Chief Executive Officer That's a great question. I'll take that one. We're not going to give you color on the specific countries because we don't want to -- for competitive reasons, we don't want to release the playbook, but we are on track for that. And as we look going forward, it is a very interesting question for us and one for us to debate how do we use our G6 capacity while we're bringing up G7 lines at the same time because the two don't intersect. We believe we'll have a market for G6 for quite some time. While we're going to do a global launch and go very quickly, there will be places where G7 isn't going to be available immediately. Our partners are going to take a while to catch up on the automated insulin delivery side. We're working with them now on G7, but we've got -- we've still got some G6 room to grow there. And there are some countries where we aren't yet or some geographies where we need to get started, where we can offer G6 in those areas while we sell G7 and others. So we are planning this. It's one of our areas of great debate, and I think we'll manage as best we can. We won't be bashful about taking down G6 lines if G7 is ready to go and is the home run we think it's going to be. And we've got several -- in all fairness, Quentin and his operating relations team, along with our R&D guys have developed some absolutely spectacular manufacturing methods for G7 that can give us a tremendous amount of flexibility to expand their very, very quickly and very thoughtfully. So we'll monitor that very closely. That's a really good question and something we think about a lot here. Operator And our next question comes from Danielle Antalffy. Go ahead, Danielle. Danielle Antalffy -- SVB Leerink -- Analyst Hey, good afternoon, everyone. Thanks for taking the question. I'll echo everyone's congrats on a really strong quarter. I'm not sure who this question is for. But it's on the DTC initiative, you guys had a very successful Super Bowl ad campaign. Just curious if there's any way to quantify what you're seeing from a return perspective yet? I mean this quarter, what seemed exceptionally strong to me. I'm wondering if we're seeing any benefit from that, not sure if you can even tell or if you can tell us. But if so, we'd love to hear even qualitative feedback there. Quentin Blackford -- Chief Operating Officer Sure. Yes, we'll take that question. And I think there's probably two data points that we can give you that will help you get your arms around the feedback we're seeing. First off, Q2 was a record quarter for new patient adds. So we're continuing to see record new patient adds. No doubt in many ways driven by the work we're doing around DTC and sales force as well as samples. So I think you've got certainly a data point that's helpful. The other piece is, over the past 18 months, we've doubled the active prescribers of our product. And no doubt, as we get out and get into the field and see endocrinologists, but also primary care physicians, the work we're doing around expanding that access has yielded really incredible benefits for the amount of prescribers that are out there that are: one, aware; and two, prescribing our product. I think those two things are just clear indications of the investments we're making in the awareness, in the DTC, in the sales force is paying off. And hopefully, that gives you some context, of course, looking at the quarter's revenue performance also helps as well. So those all data points, I think, really give you some color as to why we think it's still an incredible investment and why we think the returns still are some of the best in the business. Operator And our next question comes from Jayson Bedford. Go ahead, Jayson. Jayson Bedford -- Raymond James -- Analyst Thanks. Just a quick one. I wanted to get back to the gross margin line of questioning. What weighs on gross margin in the second half of the year to get to the 67% for the year? Is it international pricing? Is the buildup of Malaysia? And just if you can comment on -- it seems like a large portion of these costs may be transitory. Any color there would be helpful. Quentin Blackford -- Chief Operating Officer Sure. Yes. So there's two that are the biggest. The first one is some of the international pricing. You're correct. If some of that plays through, we'll have a little bit of pressure on margin. The other one is the launch of G7. When we launch G7, those lines won't be at full capacity and they won't be at full yield. Just like when we launched G6 and we launched some of the automation around G6, it took a little bit of time to work through some of the kinks on these automated lines. And while we still expect incredible output right out the gate, that's going to cost us a little bit more. And so I think what you're seeing is some of the international access, but then when we launched G7 and those lines start to appreciate, the cost of producing those in that shorter period are going to be a little bit higher. To your question is that transitory, all the work that the team is doing around the capability of manufacturing at high capacity as well as high yields, all of that will bounce back and play through. And if this quarter is any demonstration of how good they are, you can see the margins that you see this quarter have shown that this team does an incredible job of yielding out these lines over time. And we expect that to turn around with G7 into the future. But there will be some time as we launch G7 as we get those lines up and running, where there will be a little bit of weight just similar to what we had with G6 that we're going to have to navigate through. But again, I think we're still super bullish on the capability, and we're super proud of the team and really expecting that team to do an incredible job as we launch G7. Operator And our next question comes from Joanne Wuensch. Go ahead, Joanne. Joanne Wuensch -- Citigroup -- Analyst Thank you. Nice quarter. Two questions. Was there any stocking in the quarter either in the U.S. or the OUS market? And then you gave a sort of a blended volume price number. Could you sort of parse that out for the U.S. and for the international sales dynamic? Jereme Sylvain -- Executive Vice President, Chief Financial Officer Yes. So there was no stocking in the quarter, nothing out of the normal. Everybody was at normal levels. In terms of your question on a blended number, I'm not sure what you're referring to. Certainly, we have a price dynamic of around the $250 million. When we say price, it's really more channel, but we want to make sure we're very clear. It's really that shift in channel as well as the international access. We also talked about unit volumes, and I'm not sure if you're referencing that, but our unit volumes on the quarter, the growth year-over-year were in the mid-40% range. And so certainly a strong unit volume growth quarter. So hopefully that answers your question. And if you have any others, certainly follow-up, we can happy to be -- happy to clarify. Joanne Wuensch -- Citigroup -- Analyst Actually, it's a unit volume number, that mid-40%, that's what I call a blended number. What is that number in the U.S. and international? Jereme Sylvain -- Executive Vice President, Chief Financial Officer We don't break it out. That's our global number, but we can tell you that the growth on unit volume was strong in both the U.S. and outside the U.S. Joanne Wuensch -- Citigroup -- Analyst Okay. Thank you very much. Operator And our next question comes from Steve Lichtman. Go ahead, Steve. Steve Lichtman -- Oppenheimer -- Analyst Thank you. Hi, guys. Kevin, you talked about momentum in intensive type 2. Where do you think U.S. penetration into that market can go over the next two years? Are there any hurdles to drive penetration? Or are you feeling good now where awareness and payer coverage are to continue to drive penetration there? Kevin Sayer -- Chairman, President And Chief Executive Officer We feel very good about coverage we have there. On the commercial side, it's up over 80% of the intensive type two patients now covered for commercial payers plus the Medicare coverage that we have that covers a number of these patients already. So access for these patients isn't going to be a problem. It's now all about awareness. We went and doubled the size of our sales force at the beginning of this year, so we get access to more primary care physicians who do see a lot of the insulin using type two patients. And we've seen great results from that team. We've had a huge increase in the number of prescribers of our product over the course of this year. So that is a big win. For us, it's about getting to him and explaining to him what technology is available. We think this market will be every bit as penetrated as type one at some point. We view it as a very strong opportunity. Steve Lichtman -- Oppenheimer -- Analyst Great. Thanks Kevin. Operator Our next question comes from Anthony Petrone. Go ahead, Anthony. Anthony Petrone -- Jefferies -- Analyst Great. Congratulations. Great quarter. And hope everyone is doing well on the team. Maybe a quick one on Malaysia and G7. Is it safe to assume G7 will exclusively be manufactured out of there? And if so, what does that mean for the margin of that product? And then maybe a quick update on the integrated device partnerships, Control-IQ and eventually Omnipod 5, just how you see those partnerships in those product cycles evolving over the next 24 months? Quentin Blackford -- Chief Operating Officer Yes, I'll speak to the Malaysia question. Kevin will jump on the last part of that. With respect to Malaysia, it will not be exclusive -- G7 will not be exclusive to that location. We will start with G7 here in the States, both in San Diego and Mesa. As a matter of fact, lines are there as we speak, and we'll continue to ramp up there into the back part of this year and into next year as well. As Malaysia comes online and the buildings up out of the ground, and we validated the clean room and the capability there, we'll begin to build out the G7 capability there as well. So we'll have G7 in both locations over time, that's going to give us an opportunity to produce north of 200 million sensors altogether. And when you think about the distribution of those sensors and where they're going, both in the U.S. and internationally speaking, I think it makes a lot of sense to continue to have a capability here in the States as well in Malaysia, particularly when you start to look at the logistical distribution costs associated with moving that product around in the volumes that we're talking. So it will exist in both locations. I do think over time, the lower cost profile will come out of that Malaysia business. That's a big part of the value proposition there, but that's going to let us serve a lot of those international markets very effectively and efficiently. Kevin Sayer -- Chairman, President And Chief Executive Officer Yes. And with respect to the integrated systems, we're very excited for these opportunities. I actually made it out in the field last week. There is a whole bunch of pent-up demand for Omnipod 5. People are very ready for it. They've been ready for it for a long time, and we're looking forward to that day as well. On the Tandem side, we know they're working on new products and have new projects. I think the best thing I can talk about with Tandem is just a recent story. I got to know it on my computer, somebody wanted to give me a Facebook message, and it was a person who told me he spent 22 years on Medtronic systems and is now on Tandem Control-IQ with DexCom and he has never been healthier, never had a lower A1c, never had better -- he said my whole life has changed. He goes, this system is amazing. So we believe the integrated systems driven by DexCom sensors are game changers. People get accurate sensor information that can take these sophisticated algorithms and make proper decisions. We're very bullish and optimistic on the -- on both of these opportunities going forward. Very excited. Anthony Petrone -- Jefferies -- Analyst Thank you. Operator Our next question comes from Ravi Misra. Go ahead, Ravi. Ravi Misra -- Berenberg -- Analyst Hi. Thanks for taking the questions. Just on the DexCom API. Can you talk a little bit about how you chose some of the partners that you're working with? I understand Livongo, of course, but with Garmin. And then just more on that. Just walk us through kind of how you envision this being separate or integrated with CLARITY in the future? Just curious why this is for industry rather than kind of providers itself? Kevin Sayer -- Chairman, President And Chief Executive Officer Yes. This is Kevin. I'll handle the CLARITY piece. With the live API, the patient still has to run the DexCom app in the background. So the data will go straight to CLARITY, and it will be there as is. Now the better question is, will we ever have a CLARITY type system for those who don't have the same needs as intensive insulin users. And I think over time, you'll see us migrate our tools to that platform. Hence, you heard these guys talk about software investments over the last half of the year. And as we look at 2022, we see the same. We are quickly becoming a software company in addition to a sensor company It's very exciting there. Quentin, do you want to talk? Quentin Blackford -- Chief Operating Officer Yes, in terms of the partners, I mean you think about the Teladoc Livongo's diabetes program, the UnitedHealth, the Welldoc and Garmin, these are partners that we've established relationships with in the past. There is a little bit of integration work that goes into providing the real-time API and the connection into their systems. These were the easy ones out of the gate that really sync up with and get the programs going with. But I think the important thing is we want to be a foundation that we can provide this sort of information into many programs out there and really improve the outcomes for the patients themselves. And I don't think we could be better positioned to be able to do that right now. So incredibly thrilled with where it's at and expect more partners to be lining up. Operator And our next question comes from Marie Thibault. Go ahead, Marie. Marie Thibault -- BTIG -- Analyst Thank you. Congrats on the nice quarter and thanks for the time today. Just a quick follow-up, I think, on the comments around the sales force. I know that you doubled the sales force this year. So I just want to get an update on where they are in their productivity ramp? I know we typically think of at least six to nine months to get to a more normal productivity level. So I would love to hear kind of a status update on that. Kevin Sayer -- Chairman, President And Chief Executive Officer I think you're right on target. It does take about six to nine months for everybody to get up to speed. The one thing we are saying if I can just give you one trend, though, as we try and expand our coverage into the PCP offices where we haven't been before. It's a lot of work. We haven't been there. And as we knock on doors, it's taken these guys a while to get appointments. Once they get in, we're finding the physicians do not know a whole lot about DexCom. And if anything, we've totally validated our assumptions in this expansion. We had to get out there. We had to get more feet on the street and more faces to be as competitive as we wanted to and to achieve our goals. Marie Thibault -- BTIG -- Analyst Thank you. Operator And our next question comes from Gibran Ahmed. Go ahead. Kyle Rose -- Canaccord -- Analyst Hi. This is actually Kyle Rose on from Canaccord. So I just wanted to -- obviously, you made some big investments on the commercial side this year with DTC, doubling the sales force and the trialing. I'm just trying to understand, if you had to call out maybe one of those as a bigger driver rather than the other, which one would it be? Just trying to understand how far into realizing some of the productivity gains on the sales force we might really be seeing from the primary care channel? Quentin Blackford -- Chief Operating Officer Yes, I can take that. So at first, there's -- these all really needed to be done in conjunction. But the immediate one that you get returns on is obviously awareness. And awareness comes in many forms and factors, but clearly through DTC. I think at this point, they all go hand in hand because you're making folks aware, you're getting out into the physician's office, you're making the physician aware certainly through your rep. And through the Hello DexCom program, people are getting the opportunity to trial it. And so we all -- we did them all together. So maybe early out the gate, DTC was the immediate shot in the arm. But at this point, they're all really contributing in conjunction. And so that's the way we think about it. Over the longer haul, you think that feet on the street are going to be incredibly important as these physicians need to have relationships with folks in conjunction with all the other offerings that we provide. We have to validate that over time. Kevin referenced it as we get in front of these doctors, we're educating them. But the way I think about it is DTC was the immediate -- is the immediate more quick return. But I think at this point, they're all contributing equally. Operator And we have no more questions at this time. I'd like to turn it back to Kevin Sayer for closing comments. Kevin Sayer -- Chairman, President And Chief Executive Officer Thank you very much, and thank you, everybody, for participating in and listening to our earnings report today. In summary, this was a quarter of tremendous accomplishment, just under $600 million in revenue for this quarter with our highest ever absolute revenue dollar increase when compared to the previous year's quarter. Our worldwide field and access expansion efforts are working exactly the way we planned, positioning us very well for the rest of 2021 and beyond. 70% gross margins during a period of continued planned annual revenue per patient reductions to increase global access for all diabetes customers, new record operating income during a period of increased investment in what I believe is the most robust product pipeline we've ever had. G7 progress continues. Very important measurable milestones have been achieved on schedule this quarter. And there's nothing like being around here as we approach a deadline. It is just energizing. Other projects here made great progress as well. And finally, we are laying the groundwork for our future growth with irreputable fact-based clinical evidence. This technology will have a major impact in healthcare all over the world. Thanks, everybody, and have a great day. Operator [Operator Closing Remarks] Duration: 53 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President And Chief Executive Officer Jereme Sylvain -- Executive Vice President, Chief Financial Officer Quentin Blackford -- Chief Operating Officer Robbie Marcus -- JPMorgan -- Analyst Bob Hopkins -- BofA Securities -- Analyst Jeff Johnson -- Baird -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Mathew Blackman -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst Margaret Kaczor -- William Blair -- Analyst Travis Steed -- Barclays -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Jayson Bedford -- Raymond James -- Analyst Joanne Wuensch -- Citigroup -- Analyst Steve Lichtman -- Oppenheimer -- Analyst Anthony Petrone -- Jefferies -- Analyst Ravi Misra -- Berenberg -- Analyst Marie Thibault -- BTIG -- Analyst Kyle Rose -- Canaccord -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for July 29, 2021 : AMZN, TMUS, GILD, EW, TWLO, VRTX, KLAC, DXCM, FTNT, DLR, PINS, RSG The following companies are expected to report earnings after hours on 07/29/2021. Visit our Earnings Calendar for a full list of expected earnings releases. Amazon.com, Inc. (AMZN)is reporting for the quarter ending June 30, 2021. The internet company's consensus earnings per share forecast from the 13 analysts that follow the stock is $12.22. This value represents a 18.64% increase compared to the same quarter last year. In the past year AMZN has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 61.95%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for AMZN is 63.41 vs. an industry ratio of 21.90, implying that they will have a higher earnings growth than their competitors in the same industry. T-Mobile US, Inc. (TMUS)is reporting for the quarter ending June 30, 2021. The wireless (national) company's consensus earnings per share forecast from the 15 analysts that follow the stock is $0.52. This value represents a 14.75% decrease compared to the same quarter last year. In the past year TMUS has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 67.27%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for TMUS is 66.88 vs. an industry ratio of 54.50, implying that they will have a higher earnings growth than their competitors in the same industry. Gilead Sciences, Inc. (GILD)is reporting for the quarter ending June 30, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.76. This value represents a 58.56% increase compared to the same quarter last year. GILD missed the consensus earnings per share in the 2nd calendar quarter of 2020 by -23.97%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for GILD is 9.87 vs. an industry ratio of -1.40, implying that they will have a higher earnings growth than their competitors in the same industry. Edwards Lifesciences Corporation (EW)is reporting for the quarter ending June 30, 2021. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.55. This value represents a 61.76% increase compared to the same quarter last year. EW missed the consensus earnings per share in the 4th calendar quarter of 2020 by -5.66%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for EW is 49.80 vs. an industry ratio of 37.90, implying that they will have a higher earnings growth than their competitors in the same industry. Twilio Inc. (TWLO)is reporting for the quarter ending June 30, 2021. The internet software company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.69. This value represents a 53.33% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2021 Price to Earnings ratio for TWLO is -153.91 vs. an industry ratio of 68.70. Vertex Pharmaceuticals Incorporated (VRTX)is reporting for the quarter ending June 30, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.25. This value represents a 0.44% decrease compared to the same quarter last year. VRTX missed the consensus earnings per share in the 4th calendar quarter of 2020 by -4.72%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for VRTX is 21.40 vs. an industry ratio of -1.40, implying that they will have a higher earnings growth than their competitors in the same industry. KLA Corporation (KLAC)is reporting for the quarter ending June 30, 2021. The electrical instrument company's consensus earnings per share forecast from the 6 analysts that follow the stock is $3.94. This value represents a 44.32% increase compared to the same quarter last year. In the past year KLAC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 7.24%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for KLAC is 22.43 vs. an industry ratio of 16.10, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending June 30, 2021. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.43. This value represents a 45.57% decrease compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DXCM is 212.93 vs. an industry ratio of 37.90, implying that they will have a higher earnings growth than their competitors in the same industry. Fortinet, Inc. (FTNT)is reporting for the quarter ending June 30, 2021. The security company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.62. This value represents a 6.90% increase compared to the same quarter last year. In the past year FTNT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 18.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for FTNT is 99.16 vs. an industry ratio of -33.80, implying that they will have a higher earnings growth than their competitors in the same industry. Digital Realty Trust, Inc. (DLR)is reporting for the quarter ending June 30, 2021. The reit company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.58. This value represents a 2.60% increase compared to the same quarter last year. In the past year DLR has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 5.03%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DLR is 23.68 vs. an industry ratio of 25.60. Pinterest, Inc. (PINS)is reporting for the quarter ending June 30, 2021. The internet software company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.11. This value represents a 35.29% increase compared to the same quarter last year. In the past year PINS has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for PINS is 851.67 vs. an industry ratio of 68.70, implying that they will have a higher earnings growth than their competitors in the same industry. Republic Services, Inc. (RSG)is reporting for the quarter ending June 30, 2021. The waste removal company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.94. This value represents a 16.05% increase compared to the same quarter last year. In the past year RSG has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 8.14%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for RSG is 29.96 vs. an industry ratio of -18.10, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-07-30,119.175,131.078,118.31,128.878,"[""These 2 Winning Stocks Came Out of Nowhere Friday Wall Street closed the week on a down note, with major market benchmarks giving up ground on Friday to finish the month. The Dow Jones Industrial Average (DJINDICES: ^DJI) held up the best, while progressively worse performances for the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) still amounted to no more than a modest pullback overall. INDEX PERCENTAGE CHANGE POINT CHANGE Dow (0.42%) (149) S&P 500 (0.54%) (24) Nasdaq Composite (0.71%) (106) Data source: Yahoo! Finance. During much of the week, high-profile earnings reports dominated the news. On Friday, however, the two biggest gainers in the S&P 500 were stocks that many investors don't know at all. Below, we'll look more closely at why DexCom (NASDAQ: DXCM) and KLA (NASDAQ: KLAC) found themselves atop the market leaderboard. DexCom looks healthy Shares of Dexcom rose 13% on Friday. The maker of glucose monitoring systems saw strong performance in its most recent financial report. Dexcom saw dramatic sales growth in its business during the quarter. Revenue rose 32% from year-ago levels to $595 million. Sales in the U.S. were up 26% year over year, while international revenue jumped an even stronger 58%. Dexcom remained profitable, although adjusted earnings of $0.76 per share were down $0.03 from year-earlier numbers. Image source: Getty Images. The future prospects for Dexcom also look attractive. Trial data suggest that the company's continuous glucose monitoring platforms are leading to superior outcomes for users, and Dexcom is excited about potential upgrades like the next-generation G7 monitor to give patients even more effective equipment for help in treating diabetes. Millions of people need glucose monitoring, and Dexcom's solutions have real advantages compared to traditional methods for measurement. It's true that the company faces competition from some much bigger players in the market. However, Dexcom has demonstrated a surprising ability to hold off some of its larger rivals and keep building market share. Even after today's big jump in the stock price, Dexcom has a long way to go before it has fully tapped into its fast-growing market. KLA keeps chipping away Meanwhile, shares of KLA finished higher by 9%. The semiconductor equipment manufacturer reported solid fiscal fourth-quarter results amid favorable conditions in its industry. KLA reported revenue of $1.93 billion, which was up 32% from the same quarter a year ago. Adjusted net income soared by more than half, resulting in adjusted earnings of $4.43 per share, which dramatically surpassed expectations. Shareholders also got their rewards for sticking with KLA. The company announced a 17% boost in its quarterly dividend, which will now be $1.05 per share. Moreover, KLA now has the ability to spend as much as $2 billion on stock buybacks. That's consistent with the company's previous track record of returning capital to shareholders, who received $1.5 billion during fiscal 2021. KLA is optimistic that the good times will continue for a while to come. Fiscal first-quarter guidance calls for revenue of $1.92 billion to $2.12 billion, with adjusted earnings between $4.01 and $0.89 per share. That's a pretty wide range, but the ongoing growth that the guidance implies bodes well for those who've been increasingly nervous that the semiconductor market would have to go through a cyclical downturn at some point in the not-too-distant future. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Shares of Dexcom Are Gaining This Morning What happened Shares of continuous glucose monitor (CGM) maker Dexcom (NASDAQ: DXCM) are up more than 9% this morning after reporting sales and earnings that beat analyst estimates. Management also increased its full-year guidance for both metrics. Image source: Getty Images. So what Revenue grew 32% year over year in the period. That was the fastest pace of expansion since the same quarter last year. It has Wall Street excited that any impact from the pandemic is in the rearview mirror. QUARTER REVENUE YOY GROWTH Q2 2021 $595 million 32% Q1 2021 $505 million 25% Q4 2020 $569 million 23% Q3 2020 $501 million 26% Q2 2020 $452 million 34% Data source: Dexcom. After a quarter of its value was erased during the broad market sell-off in May, shares are back at an all-time high. The stock got a boost after management presented positive data for its next-generation CGM in June. DXCM data by YCharts Now what Theglobal marketfor CGMs is roughly $5 billion and is projected to grow faster than 10% for most of this decade. CEO Kevin Sayer has said the penetration of CGMs in the U.S. is still low. He cites type 1 diabetes penetration under 50% and type 2 penetration less than 25%. He's expecting the company's innovative products to push that number higher. Investors will now look to the much-anticipated release of the company's next-generation monitor, the G7. The device was initially anticipated to launch early this year, but trials were hampered by the pandemic. Sayer confirmed the G7 will still launch in 2021, which was music to Wall Street's ears. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: SWKS, KLAC In early trading on Friday, shares of KLAC topped the list of the day's best performing components of the S&P 500 index, trading up 10.0%. Year to date, KLAC registers a 35.7% gain. And the worst performing S&P 500 component thus far on the day is Skyworks Solutions, trading down 9.1%. Skyworks Solutions is showing a gain of 17.0% looking at the year to date performance. Two other components making moves today are Amazon.com, trading down 6.8%, and DexCom, trading up 7.2% on the day. VIDEO: S&P 500 Movers: SWKS, KLAC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-08-02,129.298,129.305,124.375,127.838,"DXCM Crosses Above Average Analyst Target In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $486.89, changing hands for $515.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 18 different analyst targets within the Zacks coverage universe contributing to that average for DexCom Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $380.00. And then on the other side of the spectrum one analyst has a target as high as $550.00. The standard deviation is $40.342. But the whole reason to look at the average DXCM price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $486.89/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $486.89 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: RECENT DXCM ANALYST RATINGS BREAKDOWN » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 16 16 15 15 Buy ratings: 1 1 1 1 Hold ratings: 2 2 2 1 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 1 Average rating: 1.26 1.26 1.28 1.39 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM — FREE. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-08-03,128.09,130.702,127.808,130.305,"2 Top Growth Stocks That Could Help Your Portfolio Shine One of the hardest things about investing is waiting. Waiting for the magic of compounding to do its thing is a particularly useful skill every investor should possess. But this skill will do you no good unless you pick the right stocks to add to your portfolio. By contrast, the combination of time and investing in great businesses remains one of the best ways to grow your wealth over the long term. And if that's your goal, then two companies that can help you reach it are DexCom (NASDAQ: DXCM) and Pinterest (NYSE: PINS). Let's see why both stocks are worth investing in. DXCM data by YCharts. 1. DexCom The future of DexCom, a maker of medical devices, is tied to the unfortunate rise in the number of people who have diabetes. The company's G6 continuous glucose monitoring (CGM) system -- the sales of which generate the bulk of its revenue -- simplifies the life of diabetes patients by helping them keep track of their blood glucose levels in real time, eliminating the need for painful finger sticks. DexCom's G6 CGM system is associated with better health outcomes for diabetes patients. In its latest quarterly update, the company reported the results of a randomized trial pitting G6 users against diabetes patients on finger sticks, which are the current standard of care. The study showed that G6 users spent an additional four hours per day in the target glucose range compared to finger-stick users, among other positive results. Increased adoption of CGM technology has been a key growth driver for DexCom in the past. And any technology that improves health outcomes is bound to have some success. Image source: Getty Images. However, there remains a long runway for growth in this market. Estimates vary, as they always do, but they all point in the same direction: rapid growth of the CGM market. Research company Mordor Intelligence sees the industry expanding at a compound annual growth rate of 14% through 2026. Meanwhile, DexCom is developing the G7, a newer, better, and smaller device. The company has also worked hard to integrate its CGM systems with automatic insulin delivery devices, such as Tandem Diabetes Care's t:slim X2 insulin pump. As DexCom continues to find new and better ways to serve patients with diabetes, the company's financial results -- and its stock price -- will continue rising. And although its shares have underperformed the market in the past year, the company has provided market-beating returns when looking at a longer period. I wouldn't bet against DexCom from here on out. In fact, I fully expect the healthcare company to beat the market, which is why I think its stock is a buy right now. 2. Pinterest Shares of social media platform Pinterest fell sharply after the company reported its financial results for its second quarter, which ended on June 30. On the one hand, it isn't hard to understand why. Although Pinterest's revenue soared by 125% year over year to $613.2 million, its monthly active users (MAUs) in the U.S. -- its most important market -- dropped by 5% to 91 million. What's more, Pinterest warned investors of slower revenue growth in the third quarter. It's not too surprising that some of these metrics spooked the market. But in my view, Pinterest remains a top growth stock worth buying. First, its business got a boost last year as a result of the pandemic. At some point, this tailwind was always going to come to a halt. As CEO Ben Silbermann said: The pandemic was an unprecedented and unique global event. In past earnings calls, we talked about how stay-at-home orders significantly increased usage of Pinterest. And for the past year, we've highlighted how people came to Pinterest for inspiration to reinvent their lives during such a difficult time. Now as the world opens up, we're seeing the similar effect in the opposite direction. Image source: Getty Images. As the pandemic gradually fades into the rearview mirror, Pinterest user growth in the U.S. should pick up. Meanwhile, the company is constantly looking for ways to please users on its platform and businesses that come looking for customers. On the user side, Pinterest provides a unique experience among social media platforms. Pinners, as they are called, express themselves primarily through pictures and videos, which they can organize and save. Pinterest even has a visual search tool to help users find what they are interested in without going through the trouble of typing a description of the item. For businesses, Pinterest provides analytic tools for the performance of ads (conversion rates and the like), ad automation tools, and more. The company's efforts to attract both individuals and businesses to its platform have worked so far, and in my view, they will continue to bear fruit. This will translate to continuous top-line growth for the company, and while it is not yet profitable, I believe it is worth overlooking the red ink on the bottom line for now. In the long run, this tech stock looks more than likely to deliver market-beating returns. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Prosper Junior Bakiny owns shares of Pinterest. The Motley Fool owns shares of and recommends Pinterest. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-08-04,130.2,131.775,128.288,128.632,
DXCM,2021-08-05,128.352,131.342,127.065,130.982,
DXCM,2021-08-06,129.812,130.528,126.5,129.16,
DXCM,2021-08-09,129.46,130.962,128.181,129.395,
DXCM,2021-08-10,129.245,129.564,124.762,124.985,"3 Growth Stocks to Buy and Hold Regardless of What Happens With the Delta Variant If you're a long-term investor, you don't need to worry about short-term trends. And while it's true the pandemic is turning out to be anything but a short-term problem, it's also not likely to keep the economy under lockdown for a decade, either. Although it's troubling to see COVID-19 case numbers rise due to the delta variant, that doesn't mean you need to drastically reconfigure your portfolio to maximize your returns under the current conditions. Plenty of growth stocks are safe bets to generate great numbers over the long haul, regardless of what happens with COVID-19 in the next year or two. Three stocks that can be solid investments to hang on to for years, possibly even decades, are DexCom (NASDAQ: DXCM), Facebook (NASDAQ: FB), and FedEx (NYSE: FDX). Image source: Getty Images. 1. DexCom In 2018, 10.5% of the U.S. population had diabetes, and each year, 1.5 million more Americans are diagnosed with it. It's a growing area of concern for physicians and patients, as diabetes is a leading cause of death in the country. Patients couldn't neglect a chronic condition like diabetes during the pandemic, even though they may not have been able to see their doctors in person -- especially because contracting COVID-19 could also lead to more serious complications. That makes DexCom's continuous glucose monitoring (CGM) systems incredibly valuable tools: People with diabetes don't have to use finger sticks with a CGM, and it can help users easily stay on top of their glucose levels, sending them real-time readings. Although many hospitals deferred procedures during the early stages of the pandemic, DexCom continued to generate strong sales numbers in 2020. Sales rose during the year by 31% to $1.9 billion from 2019's tally of $1.5 billion. Since 2018, the top line has risen by 87%. For 2021, the company projects that its revenue could top $2.4 billion, which would be a further 25% improvement from last year. DexCom has also been working on a new version of its CGM. The G7 is smaller than the current G6, has a shorter warm-up period, and allows users to access their readings on an Apple Watch or have Siri read them out. Between the company's new products and a growing need for better glucose monitoring, DexCom is a stock that looks poised for much more growth in the years ahead. 2. Facebook Facebook's business is versatile enough that it can do well regardless of the state of the pandemic. The company's revenue in 2020 totaled $86 billion, which was up 22% from the previous year; that growth rate was down only 5 percentage points from the 27% generated a year earlier, when sales came in at $70.7 billion. In Facebook's most recent quarterly results, for the period ending June 30, its revenue of $29.1 billion grew at an even faster rate of 56% as the company benefited from greater demand for advertising. However, management cautions that this rate will ""decelerate significantly,"" as future quarters will go up against some stronger numbers from last year. But with a 7% increase in monthly active users, now hitting 2.9 billion, it's still building off last year's already strong numbers -- that metric rose by 12% in the prior-year period. There's some risk here related to antitrust lawsuits, which could lead to the eventual breakup of Facebook, Instagram, and WhatsApp. But with cash on hand of more than $64 billion as of the end of Q2, Facebook would have plenty of options to explore other growth opportunities if it needed to. This is not a stock I would worry about, as the business is as strong as ever. 3. FedEx During the pandemic, consumers have been spending more money online than in stores. Data from Digital Commerce 360 shows that during 2020, consumer spending online with U.S. merchants totaled $861 billion. And the annual growth rate of 44% was the highest in more than two decades. Those kinds of numbers will be hard to repeat if the economy fully reopens and people return to shopping inside brick-and-mortar stores. However, there's still lots of growth ahead; analysts from Grand View Research project theglobal marketfor third-party logistics -- including the delivery services that bring online orders to real-life people -- will continue to rise by a compound annual growth rate of 8.5% until 2028, when it will be worth just under $1.7 trillion. In June, FedEx reported its year-end numbers for fiscal 2021, in which sales grew 21% year over year to $84 billion. While investors have been selling off the stock in recent months amid fears that shipments will decline as stores reopen, that won't negate the overall upward trend in online shopping and logistics. A surge in delta cases and more restrictions may boost the company's deliveries in the short term. But either way, FedEx will continue growing over the long haul -- and that's why this is another stock you can just buy and forget about. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple, Facebook, and FedEx. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-08-11,125.505,126.006,122.135,122.565,"[""RSP, CMG, ENPH, DXCM: Large Outflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500\u2014 Equal Weight ETF (Symbol: RSP) where we have detected an approximate $146.7 million dollar outflow -- that's a 0.5% decrease week over week (from 187,410,000 to 186,460,000). Among the largest underlying components of RSP, in trading today Chipotle Mexican Grill Inc (Symbol: CMG) is up about 0.2%, Enphase Energy Inc. (Symbol: ENPH) is trading flat, and DexCom Inc (Symbol: DXCM) is up by about 0.1%. For a complete list of holdings, visit the RSP Holdings page \u00bb The chart below shows the one year price performance of RSP, versus its 200 day moving average: Looking at the chart above, RSP's low point in its 52 week range is $103.48 per share, with $155.02 as the 52 week high point \u2014 that compares with a last trade of $154.88. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Free Report: Top 7%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Senseonics Could Go Higher, Especially if It Nabs FDA Approval InvestorPlace - Stock Market News, Stock Advice & Trading Tips Back in May, I wrote that Senseonics (NYSEAMERICAN:SENS) stock was likely to rise from $1.80 to over $3.00 per share. Now this has happened; on Aug. 9, SENS stock closed at $3.25 per share. Yet, it still looks like a good buy from here. Source: Minerva Studio / Shutterstock.com Why? Well, for the past three months, SENS stock has had a nice run-up. The stock bottomed out on May 13 at $1.71. Since then, though, it has spiked 90% to that Aug. 9 price. Plus, much of that gain has happened since Jul. 15, when SENS stock briefly bottomed again at $2.77. So, here\u2019s why I believe there\u2019s a case for SENS today. Where Things Stand with SENS Stock Senseonics makes long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Apart from its technology, though, one reason SENS stock has risen is that the company recently reported that it raised $50 million gross from an at-the-market (ATM) equity offering program. Now, it has $69.75 million in cash on the balance sheet. 7 Stocks to Sell In August Before It's Too Late This is important since the company burnt through $30.4 million in the last six months. This can be seen on in its recent 10-Q filing, in the Unaudited Condensed Consolidated Statement of Cash Flows (Page 6). This shows that the GAAP net income loss of $429 million for the six-month period actually was just $30.4 million in negative cash costs from an operating cash flow standpoint. Given that its first-quarter cash flow loss was $16.3 million, this implies that Q2 had a slightly lower $14.1 million cash burn. This also implies that its annual run-rate cash burn is just $56.4 million going forward. So, theoretically, it has enough cash ($69.75 million) to cover a similar cash burn over the next 12 months. However, that won\u2019t likely happen. If the U.S. Food and Drug Administration (FDA) begins to approve its CGM system, the company can start selling it in the United States. No doubt, that will greatly improve its cash burn and likely result in positive free cash flow (FCF) within the first year. For example, analysts estimate average revenue of $13.82 million this year. And for next year? They forecast $33 million in sales. Where This Leaves Senseonics This represents a fairly high multiple for the stock. For example, Yahoo! Finance recently indicated a market capitalization of $1.39 billion for SENS stock. If its 2022 sales forecast of $33 million comes through, then SENS stock trades for 42 times forward sales (i.e., $1.39 billion /$33 million). That\u2019s a little high, but given that its sales are likely to keep rising each year, it might be reasonable. I postulated in my previous article that, just as Dexcom (NASDAQ:DXCM) has performed well over the last five years, Senseonics will likely have a similar track record. For example, Seeking Alpha has a survey from analysts forecasting $160 million in sales by 2025. That is 4.5 years from now and its present value at 10% is worth 65.1% of that amount, or $104 million. That puts SENS stock on a forward P/S multiple of just 13 times \u2014 not so unreasonable. Moreover, let\u2019s assume that by then the company can make a 25% FCF margin. That puts its gross FCF then at $40 million, or $26 million in present value terms. But using a 1.5% FCF yield (i.e., dividing $26 million by 1.5%) its target market value would be $1.73 billion. That implies that SENS stock is still worth 24% more (i.e., $1.73 billion / $1.39 billion) using its recent market capitalization. This puts the stock\u2019s value at $4.03 per share. What to Do with SENS Stock The point here is that there\u2019s still plenty of room for the stock to move significantly higher. Here\u2019s an example. If we divide the $26 million in present value FCF estimate by 1.0%, the market value should be $2.6 billion. That is 87% higher than the Aug. 9 price, or $6.08 per share. So, depending on when the FDA approval comes in \u2014 and how fast the company can roll out its implantable CGM systems \u2014 SENS stock is likely to move much higher. My best guess is that it\u2019s worth at least $4.03 and that it could be worth as much as $6.08 per share. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That\u2019s because these \u201cpenny stocks\u201d are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com\u2019s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks \u2014 How to Profit Without Getting Scammed On the date of publication, Mark R. Hake did not hold (either directly or indirectly) any positions in any of the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Mark Hake writes about personal finance on mrhake.medium.com and runs the Total Yield Value Guide which you can review here. The post Senseonics Could Go Higher, Especially if It Nabs FDA Approval appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-08-12,123.065,124.832,122.565,123.212,
DXCM,2021-08-13,122.815,123.85,121.75,122.852,
DXCM,2021-08-16,123.042,126.818,122.212,126.545,"[""Monday Sector Leaders: Healthcare, Utilities In afternoon trading on Monday, Healthcare stocks are the best performing sector, up 0.7%. Within that group, DexCom Inc (Symbol: DXCM) and DENTSPLY SIRONA Inc (Symbol: XRAY) are two large stocks leading the way, showing a gain of 2.5% and 2.2%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.7% on the day, and up 19.48% year-to-date. DexCom Inc, meanwhile, is up 36.30% year-to-date, and DENTSPLY SIRONA Inc is up 14.94% year-to-date. Combined, DXCM and XRAY make up approximately 1.2% of the underlying holdings of XLV. The next best performing sector is the Utilities sector, up 0.3%. Among large Utilities stocks, Duke Energy Corp (Symbol: DUK) and Southern Company (Symbol: SO) are the most notable, showing a gain of 1.4% and 1.2%, respectively. One ETF closely tracking Utilities stocks is the Utilities Select Sector SPDR ETF (XLU), which is up 0.5% in midday trading, and up 11.57% on a year-to-date basis. Duke Energy Corp, meanwhile, is up 20.59% year-to-date, and Southern Company is up 11.17% year-to-date. Combined, DUK and SO make up approximately 15.8% of the underlying holdings of XLU. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, four sectors are up on the day, while five sectors are down. SECTOR % CHANGE Healthcare +0.7% Utilities +0.3% Services +0.1% Industrial +0.1% Consumer Products -0.1% Financial -0.2% Technology & Communications -0.2% Materials -0.7% Energy -1.7% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: MRNA, EBAY In early trading on Monday, shares of eBay topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.7%. Year to date, eBay registers a 51.3% gain. And the worst performing Nasdaq 100 component thus far on the day is Moderna, trading down 7.3%. Moderna is showing a gain of 245.8% looking at the year to date performance. Two other components making moves today are NetEase, trading down 5.0%, and DexCom, trading up 1.1% on the day. VIDEO: Nasdaq 100 Movers: MRNA, EBAY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-08-17,126.09,127.89,125.492,127.56,"Revenue Acceleration Will Lift Senseonics InvestorPlace - Stock Market News, Stock Advice & Trading Tips At a short interest of over 30%, Senseonics Holdings (NYSE:SENS) enjoyed a short-squeeze rally in early June. Since then, volume dried up. SENS stock does not have any positive catalysts on the way to send the stock flying higher again. Source: Andrew_Popov / Shutterstock.com Without any directions to move the stock, why should shareholders continue holding the stock? SENS Stock Added to Index On June 28, Senseonics joined the Russell 3000 index. Because it is widely followed by investment managers and exchange-traded funds, crowded buyers lifted the stock at the time. So, why are bears with a 29% short float so confident that the stock will drop back to the 35-cent low not seen since 2020? Senseonics’ addition to the index gave the stock a one-time boost. Unless investors continue buying ETFs and funds that follow the index, SENS stock will not benefit from buying demand. Still, as long as indexes hold SENS, minimal selling pressure will prevent the stock from falling by much. On June 3, Senseonics announced the results of the Promise study. It demonstrated strong accuracy of the 180-day Eversense continuous glucose monitoring (or CGM) system. For the primary sensor of over 49,000 paired points, SENS reported an overall mean absolute relative difference against the reference value of 9.1%. The SBA sensor had an 8.5% MARD value on over 12,000 paired points. Senseonics did not report any serious adverse events. Just more than 1% of patients had a mild infection at the procedure site. Dr. Satish Garg, the principal investigator, said, “The accuracy profile demonstrated by Eversense in the PROMISE Study validates the role that long-term implantable CGM systems can play in helping people manage their glucose levels.” Senseonics is waiting to hear from the U.S. and European regulatory agencies for its pre-market submissions of data. Any good news from the agencies is potential catalysts for the ailing stock. While it waits, SENS will continue to offer the Eversense CGM systems through its commercialization partner, Ascensia Diabetes Care. Since Senseonics’ Eversense is more accurate than DexCom (NASDAQ:DXCM) or Medtronics, shareholders should not expect any bad news. Opportunity and Risks SENS is not getting any analyst coverage. Analysts last rated the stock three months ago (per Tipranks). The company only needs to raise its outlook to re-ignite investor interest. In the first quarter, Senseonics reported a decrease in operating losses, to $32.52 million. The company highlighted a $50 million cash raise through an equity offering. For 2021, it reiterated a global net revenue forecast in the range of $12 million to $15 million. SENS ended the quarter with $215 million in cash and cash equivalents in the second quarter. At first glance, this would reduce the risk. It has enough cash to cover expenses and is unlikely to issue more shares. Conversely, the company reported a $249.51 million loss, or 68 cents a share. Chief Financial Officer Nick Tressler said that SENS worked through most of the inventory that it wrote down last year. In the second quarter and for the second half of the year, he expected a gross margin of -25% to -35% for the full year. Net revenue for the year will be between $12 million and $15 million. As it expands its relations with existing prescribers, SENS may re-establish its strength one territory at a time. This may involve hiring more sales representatives to increase product awareness with prescribers. The U.S. lifting restrictions is another tailwind. Sales staff may have in-office visits and training. The company did not forecast new sales momentum offsetting last year’s write-down. Also, it began the preparatory investments to increase capacity. Once it gets its sales team efforts at a full schedule, it may ramp up sales. For now, investors should not expect a positive operating margin until next year at the earliest. Your Takeaway Investors looking for exposure in the health care equipment space should consider a small, speculative position in SENS stock. The company worked through inventory issues last year and is increasing its promotional sales efforts from here. This will lead to improving margins over the longer term. SENS stock is not without risk. The company is centering its efforts on research and development, manufacturing, and clinical and regulatory activities. Those are near-term costs. In addition, as it commercializes Eversense, its partner, Ascensia is ready to distribute the product globally. When that happens, the revenue will come. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed On the date of publication, Chris Lau did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. The post Revenue Acceleration Will Lift Senseonics appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-08-18,127.2,128.537,127.13,127.385,
DXCM,2021-08-19,126.538,128.113,126.005,126.388,
DXCM,2021-08-20,126.275,130.711,125.758,129.748,
DXCM,2021-08-23,129.49,129.49,127.278,128.18,"[""Monday Sector Laggards: Utilities, Healthcare In afternoon trading on Monday, Utilities stocks are the worst performing sector, showing a 1.2% loss. Within the sector, NextEra Energy Inc (Symbol: NEE) and Ameren Corp (Symbol: AEE) are two large stocks that are lagging, showing a loss of 2.4% and 2.0%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 1.4% on the day, and up 11.46% year-to-date. NextEra Energy Inc, meanwhile, is up 10.10% year-to-date, and Ameren Corp is up 13.91% year-to-date. Combined, NEE and AEE make up approximately 19.5% of the underlying holdings of XLU. The next worst performing sector is the Healthcare sector, higher by 0.4%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Idexx Laboratories, Inc. (Symbol: IDXX) are the most notable, showing a loss of 1.6% and 1.5%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.2% in midday trading, and up 21.04% on a year-to-date basis. DexCom Inc, meanwhile, is up 38.16% year-to-date, and Idexx Laboratories, Inc. is up 34.45% year-to-date. Combined, DXCM and IDXX make up approximately 2.1% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, eight sectors are up on the day, while one sector is down. SECTOR % CHANGE Energy +4.2% Technology & Communications +1.4% Industrial +1.2% Materials +1.2% Services +1.0% Financial +0.8% Consumer Products +0.6% Healthcare +0.4% Utilities -1.2% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy ETF Outflows: IWP, IDXX, DOCU, DXCM Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $85.3 million dollar outflow -- that's a 0.5% decrease week over week (from 140,350,000 to 139,600,000). Among the largest underlying components of IWP, in trading today Idexx Laboratories, Inc. (Symbol: IDXX) is off about 0.6%, DocuSign Inc (Symbol: DOCU) is up about 2.7%, and DexCom Inc (Symbol: DXCM) is lower by about 1.2%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $81.44 per share, with $116.02 as the 52 week high point \u2014 that compares with a last trade of $114.88. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Free Report: Top 7%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-08-24,127.0,130.615,127.0,128.825,
DXCM,2021-08-25,128.6,129.798,127.925,129.39,"[""Noteworthy Wednesday Option Activity: NSC, DXCM, CNC Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Norfolk Southern Corp (Symbol: NSC), where a total of 4,876 contracts have traded so far, representing approximately 487,600 underlying shares. That amounts to about 47.4% of NSC's average daily trading volume over the past month of 1.0 million shares. Especially high volume was seen for the $272.50 strike call option expiring September 17, 2021, with 770 contracts trading so far today, representing approximately 77,000 underlying shares of NSC. Below is a chart showing NSC's trailing twelve month trading history, with the $272.50 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 3,076 contracts thus far today. That number of contracts represents approximately 307,600 underlying shares, working out to a sizeable 44.5% of DXCM's average daily trading volume over the past month, of 691,570 shares. Particularly high volume was seen for the $270 strike put option expiring June 17, 2022, with 385 contracts trading so far today, representing approximately 38,500 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $270 strike highlighted in orange: And Centene Corp (Symbol: CNC) saw options trading volume of 15,283 contracts, representing approximately 1.5 million underlying shares or approximately 43.9% of CNC's average daily trading volume over the past month, of 3.5 million shares. Particularly high volume was seen for the $70 strike call option expiring December 17, 2021, with 5,554 contracts trading so far today, representing approximately 555,400 underlying shares of CNC. Below is a chart showing CNC's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for NSC options, DXCM options, or CNC options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Senseonics Can Move Higher, but Competitive Concerns Abound InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally speaking, I\u2019m not the biggest fan of discussing publicly traded companies with a strong social media following. In many cases, you\u2019re just dealing with the hype of the moment. However, Senseonics (NYSEAMERICAN:SENS) stock offers a sound basis for justification if you\u2019re interested in gambling. To provide some quick background, Senseonics gained fame for Eversense, its long-term continuous glucose monitor (CGM) product, offering diabetes patients greater flexibility in their day-to-day lives and improving overall outcomes. Better yet, the company has positioned itself as one of the top innovators in the field, which theoretically offers much upside for SENS stock. Primarily, demand for CGM solutions will likely grow significantly from here on out, particularly as society gradually moves past the novel coronavirus pandemic. 7 Mega-Cap Stocks to Buy That Have Stable Dividends According to Grand View Research, the market value of the CGM device industry this year is approximately $5.28 billion. But by the end of 2028, it could almost double to $10.36 billion, representing a compound annual growth rate of 10.1% during the stated years. Further, Senseonics\u2019 CGM devices offer key advantages over the competition. As the company\u2019s website states, one of the advantages of going with Eversense is its on-body vibration alerts. According to Diatribe.org, Eversense \u201cis the first CGM to provide on-body vibration alerts! In the event of highs and lows, the transmitter will vibrate to notify the user, even if the phone is out of range \u2013 a particularly useful feature for individuals who are visually impaired or have trouble hearing.\u201d Inherently, that feature gives Senseonics a leg up on the competition. As well, if you were a patient with compromised capabilities, having on-body vibration alerts is a major plus. While this would seemingly tip the needle in favor of SENS stock, you should also consider what could go wrong. After all, CGM is a very competitive market. SENS Stock Is in for a Tough Battle Although Senseonics\u2019 product offerings are intriguing \u2014 especially because of their long-term use profile \u2014 the company isn\u2019t the only CGM device manufacturer in town. With DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) in the mix, Senseonics will be plying its trade in contested territory. That\u2019s not to say that investors should give up on SENS stock, but when you\u2019re competing against established blue chips, you should be prepared for potential volatility. Now on paper, Senseonics has more of a fighting chance because of its innovations such as the aforementioned on-body alerts. But it got me thinking, just how in-demand would this feature be? To get a better idea, I looked up the prevalence of diabetes sufferers with visual problems (the key market for those who would want on-body alerts). According to a research paper from BMJ Journals, an analysis on diabetes patients with visual impairments revealed the following statistics: Of the patients assessed at the time of the diabetes diagnosis the prevalence of moderate to severe visual impairment and blindness was 5.4% (95% CI 4.1 to 6.7) and 0.9% (95% CI 0.4 to 1.4), respectively. Among the patients alive and with a valid determination of visual acuity 6 years after the diagnosis, the prevalence of moderate to severe visual impairment and blindness was 6.7% (95% CI 5.0 to 8.4) and 2.4% (95% CI 1.3 to 3.4), respectively. While these are significant numbers, they pale in comparison to the number of those who don\u2019t monitor their blood sugar levels. \u201cAn American Diabetes Association survey found that 21 percent of adults with Type 1 diabetes never checked their blood glucose. Of those with insulin-treated Type 2 diabetes, 47 percent never monitored. And among those with Type 2 diabetes who were not using insulin, 76 percent never checked.\u201d Therefore, while the vibration alerts are innovative, they might not be the gamechanger for SENS stock that some proponents are hoping for. Fingersticks Might Hurt the Cause According to Diatribe.org, \u201cEversense is very accurate, but it does requires two fingerstick calibrations per day, unlike the no-calibration Dexcom G6 and Abbott FreeStyle Libre.\u201d That could be an underappreciated problem for SENS stock. As Diabetes Self-Management points out, many folks don\u2019t like the discomfort associated with finger-sticking. Due to the sizable number of patients not checking their glucose levels, this could be a much bigger issue than the visual impairment issue that would support demand for on-body alerts. Since Dexcom and Abbott CGM devices require no calibration, patients who are tired of constant fingersticks might opt for these two options based on their individual cost-benefit analysis. Again, that\u2019s not to say that SENS stock is completely irrelevant. However, if you\u2019re interested in buying shares, you may want to do some investigating yourself before making a decision. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That\u2019s because these \u201cpenny stocks\u201d are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com\u2019s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks \u2014 How to Profit Without Getting Scammed On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. The post Senseonics Can Move Higher, but Competitive Concerns Abound appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-08-26,129.31,132.075,128.603,129.265,
DXCM,2021-08-27,129.652,131.198,128.607,130.178,"Dexcom Inc Shares Near 52-Week High - Market Mover Dexcom Inc (DXCM) shares closed today at 1.9% below its 52 week high of $527.10, giving the company a market cap of $50B. The stock is currently up 40.0% year-to-date, up 20.3% over the past 12 months, and up 471.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.3%, and the S&P 500 rose 2.2%. Trading Activity Trading volume this week was 64.2% lower than the 20-day average. Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. MACD, a trend-following momentum indicator, indicates a downward trend. The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 213.8% The company's stock price performance over the past 12 months beats the peer average by 36.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -36.6% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-08-30,130.398,131.738,129.425,130.385,
DXCM,2021-08-31,130.887,132.61,129.508,132.355,"IWP, IDXX, DOCU, DXCM: ETF Outflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $53.3 million dollar outflow -- that's a 0.3% decrease week over week (from 139,600,000 to 139,150,000). Among the largest underlying components of IWP, in trading today Idexx Laboratories, Inc. (Symbol: IDXX) is off about 0.8%, DocuSign Inc (Symbol: DOCU) is off about 2.8%, and DexCom Inc (Symbol: DXCM) is up by about 1%. For a complete list of holdings, visit the IWP Holdings page » The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $81.44 per share, with $118.94 as the 52 week high point — that compares with a last trade of $117.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-01,132.975,136.882,131.735,136.23,
DXCM,2021-09-02,136.452,138.75,134.462,134.928,"[""S&P 500 Analyst Moves: DXCM The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #44 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. Looking at the stock price movement year to date, DexCom is showing a gain of 48.6%. VIDEO: S&P 500 Analyst Moves: DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Senseonic Stock Is Climbing After Bouncing Back From a Disappointing Q2 InvestorPlace - Stock Market News, Stock Advice & Trading Tips After a steep plunge, Senseonics (AMEX:SENS) stock is now close to its 52-week highs. SENS stock has nearly doubled since its bottom in June. The main driver of this move is the attention it has been receiving in the Reddit forums. Reddit hype or no, the company\u2019s Q2 report failed to move Senseonics meaningfully following its Aug. 9 release. The company reported a Q2 2021 loss of $0.42. That number was much higher than analyst expectations of a loss of $0.03. SENS stock fell about 8% after disclosing earnings. However, after digesting these results the stock rebounded quite nicely. SENS stock is up nearly 25% since reporting. This volatility in the price action of SENS stock is an example of Wall Street\u2019s short-sightedness. Senseonics\u2019 larger-than-expected earnings loss was somewhat understandable. In Q2 2021 Research and Development expenses rose by $3.31 million to $7.11 million. General and Administrative expenses increased as well to $7.53 million a year-over-year increase of $3.09 million. It should be noted however that the bulk of these increases were non-cash, stock-based compensation, and personnel-related expenses. A Closer Look at SENS Stock For a company in growth mode, increases in fixed costs are a necessary expense. The company needs to build out its personnel in order to properly scale the business. Senseonics revenue for Q2 2021 was $3.29 million compared to $0.26 million at the same time last year. However, this was still lower than its revenue of $4.6 million pre-pandemic indicating that the company still has ways to go. 8 Tech Stocks to Buy Offering Solid Dividends Senseonics has enough liquidity to fund its expansion needs. The company had cash and equivalents of $215 million against $109.9 million in debt. It also reiterated its revenue guidance of $12 to $15 million in 2021. A key aspect of the company\u2019s expansion plans is its partnership with Ascensia Diabetes Care. Under the terms of this strategic partnership, Ascensia will become the exclusive worldwide distributor of Senseonics Eversense CGM system, handling the marketing and commercialization of Eversense starting this year. The Switzerland-based Ascensia is a leader in the distribution of blood glucose monitoring systems. The company has a presence in over 125 countries worldwide with more than 10 million patients using their products. I believe that Ascensia\u2019s existing sales and marketing infrastructure will accelerate the market adoption of Senseonics\u2019 products. We can see the fruits of this partnership already beginning to bear fruit. In the Q2 2021 results, Senseonics saw its sales and marketing expenses decrease by $1.5 million. The decrease was due to Ascensia taking over marketing responsibilities. According to a press release, Ascensia ran a wide-ranging marketing campaign, raising awareness about Eversense and generating new leads for the company\u2019s sales force. This ought to translate to a bump in future revenue. Investor Takeaway Senseonics is only getting started. The Ascensia partnership is a game-changer for the company. I fully expect revenues to scale up quickly in the next few quarters. The company\u2019s technology has the potential to disrupt the diabetic industry. Now with a competent business partner in tow, the execution risk just got a lot smaller. Senseonic has a market cap of roughly $1.65 billion. This is minuscule compared to industry leader DexCom (NASDAQ:DXCM) which has a market cap of close to $50 billion. The disparity only underscores the potential upside of SENS stock if the company is able to execute well. Growth investors should consider SENS stock. On the date of publication, Joseph Nograles held a LONG position in SENS. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Joseph Nograles is a part-time freelance copywriter focused on the financial industry. He has worked in a wide variety of industries from tech to consulting with one of the \u201cbig four.\u201d He has always enjoyed analyzing businesses and has been a CFA charterholder for nearly a decade now. The post Senseonic Stock Is Climbing After Bouncing Back From a Disappointing Q2 appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-09-03,134.03,136.094,133.032,135.608,
DXCM,2021-09-07,136.352,138.74,135.688,137.915,
DXCM,2021-09-08,136.468,139.58,136.25,137.638,
DXCM,2021-09-09,135.34,139.608,134.565,138.165,
DXCM,2021-09-10,139.582,139.938,137.27,137.345,
DXCM,2021-09-13,135.368,135.712,131.792,135.108,"[""Here's Why iRhythm Technologies Stock Is Making Big Gains Today What happened Shares of iRhythm Technologies (NASDAQ: IRTC), a company that makes wearable heart monitors, are posting big gains today. Investors fired up about the appointment of Quentin Blackford as CEO pushed the stock 33.8% higher as of 12:25 p.m. EDT on Monday. So what The stock crashed earlier this year when the company failed to secure a favorable reimbursement rate from Medicare for the Zio XT, its heart arrhythmia detection device for high-risk patients. Despite the setback, the company expects total revenue to rise about 22% year over year to $323 million in 2021. Blackford previously served as the chief operating officer of DexCom, a highly successful manufacturer of wearable blood glucose monitors that had reimbursement issues of its own. DexCom's operations turned strongly profitable last year, and it looks as if investors expect him to do the same for iRhythm in the years ahead. Image source: Getty Images. Now what Sales of iRhythm's devices are growing, but they would grow a lot faster with a national pricing determination from the Centers for Medicare and Medicaid Services. It's hoped that Blackford can make more progress on this front than his predecessor once he officially takes the helm on Oct. 4. Before a Medicare contractor slashed the reimbursement price for the Zio XT, iRhythm's market cap had risen past $7 billion. This company is still the only manufacturer of simple, wearable solutions for detecting life-threatening heart arrhythmias. It's probably just a matter of time before the stock reaches a new peak. 10 stocks we like better than iRhythm Technologies, Inc. Common Stock When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and iRhythm Technologies, Inc. Common Stock wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Chief Operating Officer of DexCom, Inc. (NASDAQ:DXCM), Quentin Blackford, Just Sold 98% Of Their Holding We wouldn't blame DexCom, Inc. (NASDAQ:DXCM) shareholders if they were a little worried about the fact that Quentin Blackford, the Chief Operating Officer recently netted about US$5.0m selling shares at an average price of US$545. Probably the most concerning element of the whole transaction is that the disposal amounted to 98% of their entire holding. DexCom Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider sale was by the Executive Chairman, Kevin Sayer, for US$14m worth of shares, at about US$362 per share. That means that even when the share price was below the current price of US$549, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was only 31% of Kevin Sayer's holding. In the last year DexCom insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! NasdaqGS:DXCM Insider Trading Volume September 13th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. Insider Ownership of DexCom Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. DexCom insiders own about US$271m worth of shares (which is 0.5% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. So What Do The DexCom Insider Transactions Indicate? An insider sold DexCom shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. But it is good to see that DexCom is growing earnings. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for DexCom (1 is a bit unpleasant!) that we believe deserve your full attention. Of course DexCom may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Monday Option Activity: DXCM, MAR, NOW Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 2,860 contracts has been traded thus far today, a contract volume which is representative of approximately 286,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60.3% of DXCM's average daily trading volume over the past month, of 474,215 shares. Particularly high volume was seen for the $540 strike call option expiring October 15, 2021, with 496 contracts trading so far today, representing approximately 49,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $540 strike highlighted in orange: Marriott International, Inc. (Symbol: MAR) saw options trading volume of 9,436 contracts, representing approximately 943,600 underlying shares or approximately 54.9% of MAR's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $139 strike call option expiring September 17, 2021, with 1,066 contracts trading so far today, representing approximately 106,600 underlying shares of MAR. Below is a chart showing MAR's trailing twelve month trading history, with the $139 strike highlighted in orange: And ServiceNow Inc (Symbol: NOW) options are showing a volume of 5,102 contracts thus far today. That number of contracts represents approximately 510,200 underlying shares, working out to a sizeable 51.6% of NOW's average daily trading volume over the past month, of 988,005 shares. Particularly high volume was seen for the $620 strike put option expiring October 15, 2021, with 1,009 contracts trading so far today, representing approximately 100,900 underlying shares of NOW. Below is a chart showing NOW's trailing twelve month trading history, with the $620 strike highlighted in orange: For the various different available expirations for DXCM options, MAR options, or NOW options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-09-14,135.642,137.43,135.032,135.558,
DXCM,2021-09-15,136.164,138.448,134.032,137.918,"2 Sizzling Hot Stocks to Buy Right Now Hot stocks can be found across all industries and sectors, but whether or not these high-flying companies are worth the price of admission is often another story. If you're a long-term investor searching for stocks that can lend some serious growth to your portfolio in the coming years and also demonstrate resilience in a variety of market environments, keep on reading. The following two stocks are absolutely sizzling right now, but they also both boast superior businesses with strong competitive advantages that generate and sustain consistent demand and robust profits. Let's take a closer look. Image source: Getty Images. 1. DexCom Medical device maker DexCom (NASDAQ: DXCM) may not be a household name for many investors, but it should be. The company has a track record of generating notable cash flow growth year after year, and its shares have appreciated swiftly in kind. Over the past six months alone, the stock has shot up by about 50%. And over the past five years ago, it has popped an incredible 480%. That's because DexCom is one of a very small handful of companies with an FDA-approved continuous glucose monitoring (CGM) device on the market. The company's sole and flagship product is its G6 CGM system. It's also currently working on the next-generation G7 system, which should be launched later this year. According to the latest stats from Grand View Research, the global CGM device market is on track to reach more than $10 billion in size by 2028. The company certainly isn't without competition. Its most notable rival is Abbott Laboratories' FreeStyle Libre system. However, this industry is far from overcrowded and demand is constant. DexCom has managed to carve out and maintain a substantial piece of the pie for itself and has proven its staying power in this industry time and time again with consistent, above-average earnings growth. In its most recent quarter ended June 30, the company grew revenue by 32% and net income by 36% over the same period last year. Despite DexCom's rapid growth, the company continues to build up its liquidity while keeping its debt levels manageable. At the end of the second quarter, the company boasted $2.6 billion in cash, cash equivalents, and marketable securities compared to about $601 million in short-term liabilities. Admittedly, the stock has had a good run of late. But if you're looking for a super-charged healthcare stock that can lend substantial growth to your portfolio over a period of years, DexCom is a pick that continues to hit the bullseye. 2. Nvidia Semiconductor stock Nvidia (NASDAQ: NVDA) is known for its computer-graphics processors used by companies of all sizes across a broad spectrum of industries. In fact, it is one of the world's top manufacturers of these processors (known as GPUs) -- ranking third at just a little over 15% of the global PC GPU market, according to Statista. The company boasts some pretty big names on its client list, including the likes of Microsoft and Facebook. It's no wonder then that Nvidia delivered another series of record results in its most recent quarter. Not only did the company's total revenue spike 68% year over year, but its net income jumped by an eye-popping 282% from the year-ago quarter. Nvidia's four divisions -- automotive, professional visualization, data center, and gaming -- generated respective year-over-year revenue increases of 37%, 156%, 35%, and 85%. Shares of Nvidia have picked up some serious steam in recent months. The stock is trading about 66% higher than it was just six months ago -- and over the trailing five years, the stock has appreciated by a whopping 1,300%. Yet, the stock may still have considerable runway. From autonomous vehicles to artificial intelligence, Nvidia's products are an ideal solution for companies operating in both established and emerging industries. The stock may be sizzling now, but there's no reason to think it can't explode even higher in the coming years. 10 stocks we like better than Nvidia When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Nvidia wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Rachel Warren owns shares of DexCom. The Motley Fool owns shares of and recommends Facebook, Microsoft, and Nvidia. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-16,139.0,141.952,138.95,141.282,
DXCM,2021-09-17,140.0,141.2,138.952,140.785,"Vanguard Mid-Cap ETF Experiences Big Inflow Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $774.6 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 210,592,288 to 213,744,868). Among the largest underlying components of VO, in trading today Idexx Laboratories, Inc. (Symbol: IDXX) is off about 0.5%, Chipotle Mexican Grill Inc (Symbol: CMG) is trading flat, and DexCom Inc (Symbol: DXCM) is lower by about 0.8%. For a complete list of holdings, visit the VO Holdings page » The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $168.17 per share, with $249.85 as the 52 week high point — that compares with a last trade of $244.24. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Free Report: Top 7%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-20,140.112,141.555,136.78,139.44,"Notable Monday Option Activity: RCEL, DXCM, ALLK Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AVITA Medical Inc (Symbol: RCEL), where a total volume of 996 contracts has been traded thus far today, a contract volume which is representative of approximately 99,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 94.5% of RCEL's average daily trading volume over the past month, of 105,350 shares. Particularly high volume was seen for the $17.50 strike put option expiring October 15, 2021, with 956 contracts trading so far today, representing approximately 95,600 underlying shares of RCEL. Below is a chart showing RCEL's trailing twelve month trading history, with the $17.50 strike highlighted in orange: DexCom Inc (Symbol: DXCM) options are showing a volume of 4,693 contracts thus far today. That number of contracts represents approximately 469,300 underlying shares, working out to a sizeable 93.3% of DXCM's average daily trading volume over the past month, of 502,905 shares. Particularly high volume was seen for the $600 strike call option expiring October 15, 2021, with 1,673 contracts trading so far today, representing approximately 167,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $600 strike highlighted in orange: And Allakos Inc (Symbol: ALLK) options are showing a volume of 2,169 contracts thus far today. That number of contracts represents approximately 216,900 underlying shares, working out to a sizeable 92.3% of ALLK's average daily trading volume over the past month, of 234,960 shares. Especially high volume was seen for the $80 strike put option expiring January 21, 2022, with 715 contracts trading so far today, representing approximately 71,500 underlying shares of ALLK. Below is a chart showing ALLK's trailing twelve month trading history, with the $80 strike highlighted in orange: For the various different available expirations for RCEL options, DXCM options, or ALLK options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-21,140.392,140.878,138.335,138.448,
DXCM,2021-09-22,141.038,144.312,138.0,142.605,
DXCM,2021-09-23,143.32,144.75,142.002,143.182,
DXCM,2021-09-24,142.728,143.01,139.5,140.185,"Should You Take the ""Basket Approach"" to Investing in Tech Stocks? Thanks to technology, large industries are being remade for the 21st century and growing at a rapid pace. Picking the right stock from a very large segment of the economy can be tough, though. That's where the ""basket approach"" comes into play. In this video from the Motley Fool Live program ""The 5,"" recorded Sept. 16, Fool.com contributors Jason Hall, Clay Bruning, and Nicholas Rossolillo discuss this investment style. 10 stocks we like better than Walmart When our award-winning analyst team has an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now… and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks Stock Advisor returns as of 6/15/21 Jason Hall: Richard O., this is good. I like what he's saying and I think it applies pretty broadly, he says, ""Gotta love medical devices, basket approach, Intuitive Surgical, ShockWave Medical, DexCom"" -- the huge winner in diabetes testing -- ""InMode, Inari Medical"" -- getting into some that are a little more up-and-comers -- ""Stryker, Medtronic, Abbott Laboratories, riding the wave."" Sometimes one of the great ways to invest is to find trends. We talked about the aging trend, talked about the middle-class trend internationally. For healthcare, it's a great opportunity. But I think for a lot of these cloud companies, that basket approach works really well, too, Clay. Clay Bruning: This is how I operate in my portfolio rather than buying an ETF in a theme that I really like. I looked at that ETF or I do some research of those underlying names and I try to find the ones that I think has the highest probability of placing in terms of being one of those top two, top three players. I'm with you there, and I do that in multiple themes and multiple industries. Personally, it's the way I attack it so obviously I think it's a good way to go about. Hall: Sometimes your biased and you are also right. That's OK. Nick, what are your thoughts here? Rossolillo: Yes, I do the same thing as Clay does. Especially if it's a new company or a new industry that I'm not super familiar with, one of the first things I like to do is, see who they compete with, what's the competitive landscape look like? Oftentimes you find multiple companies that have these great growth stories. Rather than picking, which one is going to be the best growth story over the next two decades, the basket purchase, fantastic. It allows you some leeway because if a couple of them don't work out, you still have those few that are the real gems that maybe early on you couldn't tell which one was going to ultimately come out on top. Hall: I think the important thing to remember here too, is that a lot of time as you see a big trend and there are a lot of moving parts to it. You think about the Cloud, for example, or just determine like SaaS. You might have 50 companies that do 45 different things and trying to pick one or two or 10 out of that group that are going to be the ones to perform best out of all of these companies benefiting from a larger, secular tailwind. Sometimes it's just like I call it the precision fallacy here. There's no bonus points for getting too cute and picking the perfect company. Sometimes you just want a margin of safety. Rossolillo: Yes, absolutely. Especially if a movement like the Cloud, like you said, if it's that big, we're talking about hundreds of billions of dollars in incremental spending every year. For years to come there's not going to be just one winner. In fact, some of those companies that are going to ultimately be the biggest winners, they're still going to have their down-year. Taking the basket approach helps get you some more consistent growth year-in and year-out from these really massive secular growth trends. Hall: Right. You can have individual companies that went in particular areas, so you might have like a Zscaler that's showing itself is like the dominance in zero-trust and the kind of area that they live in, but then a related area of Cloud security, you've got another big winner like CrowdStrike. They're not really going head-to-head on a lot of stuff. There's some overlap. But you find all the horses in all the races, and you bet broadly and you can do pretty well. Clay Bruning owns shares of Abbott Laboratories and CrowdStrike Holdings, Inc. Jason Hall owns shares of Intuitive Surgical and Zscaler. Nicholas Rossolillo owns shares of CrowdStrike Holdings, Inc. and Intuitive Surgical. The Motley Fool owns shares of and recommends CrowdStrike Holdings, Inc., InMode Ltd., Intuitive Surgical, ShockWave Medical, and Zscaler. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-27,139.288,139.61,135.26,137.268,
DXCM,2021-09-28,135.235,135.628,130.73,134.235,"[""Ignore GameStop: Here Are 2 Better Stocks The COVID-19 pandemic shifted much of retail activity to online marketplaces, much to the chagrin of traditional brick-and-mortar stores like GameStop. The gaming retailer has had a tough past 18 months even as its stock performance over this period seems to tell a different story. Shares of GameStop have soared more than 1,900% in the past year. But this showing is largely due to the gamma squeeze we witnessed earlier this year than with the company's actual financial results. There remains a long road ahead before GameStop can recover from its woes. In the meantime, investors would do well to put their money in safer, better stocks. Two that come to mind are DexCom (NASDAQ: DXCM) and Netflix (NASDAQ: NFLX). NFLX data by YCharts. 1. DexCom There are about 34 million diabetes patients in the U.S., representing 10.5% of the country's total population. Managing this chronic illness requires a lot of discipline. DexCom helps make this task easier with its G6 Continuous Glucose Monitoring (CGM) system. Many diabetes patients still use traditional blood glucose meters (BGMs) that rely on fingersticks. There are at least two serious drawbacks to BGMs. First, they only read a patient's blood glucose level at a single point in time. Second, fingersticks can be painful. By contrast, CGMs like DexCom's use tiny sensors that test the glucose almost continually -- a process that is associated with better health outcomes. In a U.S. clinical trial that compared diabetes patients using DexCom's G6 to those using more traditional competitors, G6 patients spent an average of four additional hours per day within their target glucose range. Image source: Getty Images. Technology that improves the health of its target market -- and also happens to be more convenient than alternatives -- is likely to be highly successful. That's what we're witnessing with CGMs in general and with DexCom's G6 in particular. DexCom currently generates the bulk of its revenue from the G6 and accompanying accessories. As a result, the company's revenue continues to grow rapidly. In the second quarter ended June 30, DexCom's top line grew by 32% year over year to $595.1 million. And with the diabetes population predicted to increase in the coming years, that trend should continue. Even if the population of diabetes patients were to stay the same, there remains significant room for growth, said DexCom CEO Kevin Sayer recently: A majority of people on mealtime insulin continue to manage their diabetes with finger sticks. Even in the U.S., a leader in CGM adoption, we continue to believe that the type one market remains less than 50% penetrated and the type two intensive market is less than 25% penetrated. With that in mind, I believe DexCom is still relatively early in its growth story. I expect the healthcare company to continue beating the market in the long run, making it an excellent stock to consider adding to your portfolio. 2. Netflix It seems like such a long time ago when Netflix was still a DVD rental service. The company's decision to switch to streaming proved a shrewd one. The tech-giant's performance over the past decade speaks for itself. And even though the streaming industry is much more competitive than it used to be, I believe Netflix can continue to thrive. The company had a little more than 209 million paid members on its platforms as of the end of the second quarter, up 8.4% from the same period last year. Netflix uses the information it gathers from its customers -- from age and gender to content-viewing patterns -- to make personalized recommendations and keep users engaged. The company also uses this data to create its own TV shows and movies. Here's some evidence that this strategy is bearing fruit: Netflix's creations are highly successful. The company had 36 Oscar nominations this year and took home seven awards, beating out every other studio. Image source: Getty Images. Netflix's growing content library is a powerful reason why it will retain the bulk of its customers even if it loses some to competitors. The company can also continue to grow its user base. There remains significant opportunity in many developing nations where internet penetration is much lower. But even in the U.S., there's still some room to grow for the tech giant. According to data from global information and measurement company Nielsen, linear cable still controls 63% of the total television viewing time in the U.S. Netflix is looking to replace linear TV. To quote the company's co-CEO, Reed Hastings: \""There's plenty of room to grow without taking it away from the other streamers.\"" The slowdown in subscriber growth Netflix experienced recently should not be a worry. After all, the company's user base grew more quickly than anticipated in 2020 as a result of the pandemic. In the long run, Netflix looks well-positioned to dominate an ever-increasing share of television viewing time while adding new subscribers to its already large base. That's what makes the company an excellent investment option to consider today. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Netflix. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will Dexcom Stock Continue To Make Fresh Highs? [Updated: 9/24/2021] DXCM Stock Update A few months back we discussed that going by its historical performance Dexcom Stock (NASDAQ: DXCM) may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last one month close to its all-time high levels of $579. The company\u2019s Q2 earnings of $0.76 per share on an adjusted basis were much better than $0.43 street estimate. The revenue growth of 32% during the quarter also reflected strong y-o-y growth. Dexcom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require finger prick and data can be self-monitored easily. Given the limited competition, and a wide pool of diabetic patients (over 34 million in the U.S. alone), the company is likely to see strong growth over the coming years. DXCM stock has also seen a large appreciation of 60% year-to-date, and more than 500% over the last five years. But now that DXCM stock has seen a 11% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 702 instances in the last ten years that DXCM stock saw a twenty-one day rise of 11% or more, 414 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 414 out of 702, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details. Also, you can understand how Dexcom\u2019s revenues have changed over the years along with trends in revenues for its closest peers in a separate dashboard analysis. Calculation of \u2018Event Probability\u2018 and \u2018Chance of Rise\u2018 using last ten years data After moving 1.3% or more over a five-day period, the stock rose in the next five days on 57% of the occasions. After moving 3.6% or more over a ten-day period, the stock rose in the next ten days on 60% of the occasions After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 59% of the occasions. Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well. The Centers For Medicare & Medicaid Services (CMS) recently announced that there is no longer a requirement for a minimum of four self-monitoring blood glucose tests per day to have the continuous glucose monitoring (CGM) devices covered. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking. Furthermore, Dexcom expects to launch its newest CGM device \u2013 G7 \u2013 later this year, and given that the new device will use a new and improved application, while it will also be 60% smaller in size compared to the current G6, making it the smallest CGM device available in the market. It has several other benefits over the current version, such as, its transmitter and sensor will be combined, making it a single fully disposable unit. It is also expected to have a longer wear time. As such, the G7 CGM will likely be more attractive to customers, and bolster Dexcom\u2019s sales growth after its launch. However, now that DXCM stock has seen a rise of 23% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in DXCM stock over the next month. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 99 out of 184, or about 54% chance of a rise in DXCM stock over the coming month. Also, despite the recent rally, DXCM stock is up only 4% from the levels it was trading at a year ago. See our analysis on Dexcom Stock Chances of Rise for more details. Calculation of \u2018Event Probability\u2018 and \u2018Chance of Rise\u2018 using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom\u2019s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company\u2019s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It\u2019s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back. While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn\u2019t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it\u2019s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott. Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn\u2019t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days). Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details. Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market (3% likelihood event) Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7% A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. While DXCM stock can see a rebound, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons. Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-09-29,134.995,138.5,134.7,136.395,"1 Supercharged Healthcare Stock to Buy Right Now The best healthcare stocks can lend sustainable returns and stable growth to investors' portfolios for many years, and large-cap company Dexcom (NASDAQ: DXCM) is no exception. In this segment of Backstage Pass, recorded on Sept. 20, Fool contributors Brian Withers, Rachel Warren, and Toby Bordelon discuss why the company is such an attractive investment despite its high valuation. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: Rachel, we got another healthcare stock that I bet a lot of folks know, Dexcom. Tell us about that one. Rachel Warren: I think Dexcom, it's another company that I've written about quite a lot. It's one I found really interesting because I think it has a very unique competitive advantage. It's one of the leaders in the continuous glucose monitoring device market. Primarily used by individuals with type 1 diabetes. So it fills this very important need for a huge population of healthcare consumers. And so, the demand it faces is really very consistent no matter what's happening with the market or the economy. It's interesting because it has one product which is its current generation of its CGM device. It's called the G6 system. It's currently working on an upgrade to that, the G7 system, which is supposed to be, I think a lot smaller, have a longer wear time. But the market in which it operates, so continuous glucose monitoring devices, that market is supposed to grow at a compound annual growth rate of 10% in the 2020-2028 period, which is pretty impressive when you consider that Dexcom is one of the key presences within that market. I know several years ago it had a market share hovering around 50%, I haven't seen a recent data since then. But another interesting thing to bear in mind, in the U.S. alone, about 1.6 million individuals that have type 1 diabetes, but only one in four of the potential individuals who might qualify for, you know insulin-requiring diabetes, actually use these devices. There's a huge untapped portion of the market as of yet, that Dexcom can reach in the coming years. The stock is one of those, another multi-bagger, I believe it's up about 500% over the last five years. [laughs] It has definitely seen a lot of gains and it continually reports really high revenue increases as well, year-over-year and quarter after quarter. It's one of those that you can depend on for consistent growth and a clear competitive advantage, which are two big things to look for when investing in healthcare stocks. Toby Bordelon: Yes. This is the company, again, I don't personally own myself, but I've thought about it a lot already. It's come up, I think, Brian, in a couple of things we've done with Brian Feroldi. Brian Withers: Yeah. Toby Bordelon: Some of the three-minute stocks or whatever. This has been there a lot. I've been thinking about it. One concern I have is that, man, what is my concern Brian, it looks expensive. [laughs] I know I keep coming back to that, but this one, you said it's up 500% from where it was five years ago. Brian Withers: Yeah, it's got a price-to-sales ratio higher than Zoom. Toby Bordelon: Yeah. I remember [laughs] even Brian Feroldi who loves this company agree that, yeah, a little bit pricey. So, my question for you, as a share-owner, does that concern you at all? If I'm a new investor coming in, let's say I don't own any shares, if I'm a new investor coming in, can I still jump in this company right now and expect to see some growth down the line? Or is it just one of those things where you shouldn't touch it right now? Rachel Warren: I think so. I mean, I hope so [laughs] as I'm invested in it. No, I do really believe that it has a lot of room left to grow. For some of the reasons I had mentioned, it's in this very robust market space, that still has a lot of untapped growth potential. And although past performance is not an indicator of future performance, it has historically led to these really consistent share price gains. I do think it definitely can continue in that direction. I personally believe that it will. But that's also something kind of great about fractional investing, is if you look at a stock like this and say, wow this is a lot for a healthcare stock, you know, it's OK to just put whatever amount one is comfortable with in that stock and then see how it performs, and then maybe add more to it later depending on what you're comfortable with. But, I do personally think it can definitely continue to grow even though it's have this massive gains. Toby Bordelon: Cool. Well maybe I'll have to give it even more thought. I'm still on the fence on this one. But again, what they're doing, it's cool. I like the technology no questions about that. You cannot really criticize the product they got out there on the market. Brian Withers has no position in any of the stocks mentioned. Rachel Warren owns shares of DexCom. Toby Bordelon has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-09-30,136.252,138.065,135.688,136.715,"2 Unstoppable Stocks to Buy and Hold Forever The stock market has been on a fantastic run in the past year and a half. Since bottoming out in late March 2020 following the coronavirus-fueled market crash, the S&P 500 has doubled in value. This performance underscores the power of the buy-and-hold strategy. Even when the market is experiencing downturns, staying the course -- as opposed to panic selling -- is the right thing to do. The longer you hold onto shares of great companies, the juicier your returns will be. With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. Abbott Laboratories The history of medical devices specialist Abbott Laboratories dates back more than 100 years. As a publicly-traded company, it has soundly outperformed the market over the past several decades. Of course, past performance isn't a guarantee of future success. But Abbott's long-standing habit of delivering solid results is a significant strength. Having been a major player in the medical devices space for a long time, the company benefits from a strong reputation. Physicians, like most consumers, are inclined to stick to what they know works. In addition, with the healthcare sector having significant barriers to entry, the chances of new entrants with similar expertise and industry knowledge are minimal. Furthermore, the company's rich lineup of approved devices is protected by scores of patents and copyrights, which help insulate them from competition. One of the company's key growth drivers is the FreeStyle Libre, a continuous glucose monitoring (CGM) system that helps diabetic patients track their blood glucose levels. CGMs significantly reduce the need for painful fingersticks, making them the more attractive option for patients. The increased adoption of this technology continues to spearhead sales growth for Abbott's crown jewel. Image source: Getty Images. During the second quarter ending June 30, Abbott's diabetes care revenue came in at $1.1 billion, 40% higher than the year-ago period. The company had the FreeStyle Libre to thank for this performance. And while it competes with several other companies in this space -- most notably Medtronic and DexCom (NASDAQ: DXCM) -- this market will only continue to grow. According to the U.S. Centers for Disease Control and Prevention, more than 34 million Americans have diabetes, a number that is set to increase drastically in the coming years. This trend is unfortunate, but it underscores the need for innovative technologies to help diabetes patients manage this illness. Note that in 2020, sales of Abbott's Freestyle Libre came in at $2.6 billion, compared to DexCom's total revenue of $1.9 billion (DexCom generates revenue from the sale of its G6 CGM System as well as instruments and accessories that go along with it). Abbott looks well-placed to remain a key player in this market which, in my view, is more than enough to accommodate two or more big players. The company does have other devices that can drive growth, including the MitraClip, which treats mitral regurgitation (a condition in which blood doesn't flow from the heart properly), and its Tricuspid Repair System, a non-invasive device to help repair the tricuspid valve. Lastly, Abbott's business extends beyond its medical devices unit. The company's nutritional products and established pharmaceuticals segments add diversification. Abbott Laboratories is trading at 26.8 times forward earnings, compared to the average forward price to earnings (PE) ratio of 17.3 in the healthcare sector. That makes shares of the medical devices company expensive, but in my view, it is worth paying a premium for the company. Business is still booming for this established healthcare giant, and it will be tough for competitors to knock it off its pedestal anytime soon. That makes Abbott Laboratories' stock worth parking in your portfolio for many years to come. 2. Visa Visa is one of those companies whose services people use daily. Many of us carry around debit or credit cards that proudly display its logo. Visa helps facilitate transactions between consumers and merchants. It does not issue credit or debit cards itself -- that's what banks are for. Rather, Visa provides the transaction processing network that supports debit and credit card purchases. The company charges fees for every transaction conducted with a card that bears its name. Visa's stock has performed exceptionally well since its IPO in 2008, easily beating the market from then to now. There are two main reasons why the company can continue to perform well. First, Visa's business benefits from the network effect. That is, the value of its services increases as more people use it. The company's payment network becomes more attractive to merchants as more consumers join in. And as the number of merchants increases, more consumers are likely to use Visa for payment. This dynamic ensures that it will be challenging to eat into Visa's market share. Meanwhile, Visa's network will only continue to grow. This brings us to the second reason why the company will continue to beat the market: Exciting opportunities ahead. According to a report published by the management consulting company McKinsey, cash transactions accounted for about 28% of total transactions by volume in the U.S. in 2020. This figure is more or less in line with that of other developed nations, but cash is still king for developing countries. The digital payments market is projected to continue expanding rapidly. Image source: Getty Images. With one of the largest payment networks in the world, Visa is well-equipped to benefit. And as the financial services industry continues to evolve, it is looking to expand its reach. In June, the company announced the acquisition of Sweden-based fintech start-up Tink, which allows banks and other institutions to access financial data to build personalized banking and financial tools for consumers. The acquisition is valued at 1.8 billion Euros (roughly $2.1 billion). Visa's shares aren't cheap either -- they currently trade for 46.05 past and 39.13 times forward earnings. But note that Visa's closest competitor, Mastercard (NYSE: MA), has a PE and forward PE ratio of 49.34 and 43.62, respectively. While those two companies dominate the industry, Visa holds the edge. For the fiscal year 2019, Visa had a higher payment volume ($8.9 billion vs. $4.8 billion), higher total transactions (207 billion vs 122 billion), and more cards to its name (3.4 million vs. 2.2 million). Visa also generates higher revenue and profits. For their latest reported quarters, Visa's top line came in at $6.13 billion -- higher than Mastercard's $4.53 billion. Visa's shares aren't that expensive when put into context. And given the company's competitive advantage and growth prospects, it will continue delivering strong financial results, thereby pushing its share price ever higher. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Mastercard and Visa. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-01,137.895,138.088,134.235,137.48,
DXCM,2021-10-04,136.25,136.378,130.252,131.608,
DXCM,2021-10-05,132.055,136.306,132.055,135.098,
DXCM,2021-10-06,134.308,136.38,133.13,135.458,
DXCM,2021-10-07,136.25,137.54,134.184,134.798,
DXCM,2021-10-08,135.0,136.122,132.137,132.275,
DXCM,2021-10-11,131.102,134.318,130.27,132.195,
DXCM,2021-10-12,134.658,136.438,133.182,134.615,"Got $1,000? These 2 High-Growth Stocks Are Screaming Buys Right Now If you have $1,000 to invest in the stock market this month, you might already be thinking of the companies you want to add to your buy basket. But if you still haven't decided which ones might be the best use of that $1,000 investment or are searching for new stocks to buy, I have two companies I'd like to suggest for your consideration. The following two businesses -- one a popular marijuana-related stock and the other a red-hot healthcare stock -- have seen strong success over the past few years. The good news is that both of these companies operate in high-growth industries that give them ample runway left to explore, and they're doing just that. Let's take a closer look. Image source: Getty Images. 1. GrowGeneration Farm supplies company GrowGeneration (NASDAQ: GRWG) operates a chain of garden centers across the U.S. Marijuana growers depend on the products that GrowGeneration sells to cultivate the substance, so it should come as no surprise that business is booming. With garden centers located across Oregon, California, Colorado, Nevada, and Florida -- and rapidly expanding in these and other high-growth marijuana markets -- GrowGeneration has plenty of opportunity ahead. The company is already the top hydroponics supplier in the U.S, and it's seen incredible financial growth throughout the pandemic as demand has continued to soar. In the second quarter of this year, the company reported a 190% year-over-year increase in revenue and a 60% increase in same-store sales. The business is benefiting from both its in-person and online presence: e-commerce revenue jumped 264% year-over-year in the second quarter. The company is also having marked success with its private-label products, which accounted for 7% of its revenue in the second quarter vs. just 1% in the same quarter of 2020. Admittedly, the shares have been a bit volatile of late -- up 31% over the past year and down 57% in the past six months. But that can happen in businesses connected to new industries. With the increasing expansion of marijuana legalization around the country, there's abundant room for an established company like GrowGeneration to accumulate more market share and grow its customer base. Right now is an excellent time to consider buying this marijuana stock on sale. 2. DexCom Medical device company DexCom (NASDAQ: DXCM) is known for its market leadership in the continuous glucose monitoring industry. The company's current product is its G6 CGM system, but it expects to launch a new-and-improved G7 system later this year, which will be smaller and have a longer wear time, among other improvements. Most CGM users are Type 1 diabetics. At the end of 2020, DexCom reported that more than 900,000 customers worldwide were wearing its CGM devices. And in the U.S. alone, there are some 1.6 million Type 1 diabetics. So in short, DexCom has an immense amount of room left to tap into a potential customer base that could benefit from its life-saving technology. So far, so good. The company consistently reports exceptional financial numbers. Case in point: In its most recent quarter, revenue shot up 32% over the prior-year period, operating income surged just shy of 50%, and net income was up 36%. Meanwhile, shares of the company have popped more than 5,000% since it became publicly traded 16 years ago. And year-to-date, the stock has gained more than 40%. For those seeking a healthcare company that consistently reports above-average earnings and revenue growth and a stock that has performed strongly, DexCom is a strong contender to consider. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Rachel Warren owns shares of DexCom. The Motley Fool owns shares of and recommends GrowGeneration Corp. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-13,136.385,137.882,135.444,137.012,"[""Notable Wednesday Option Activity: DXCM, TWTR, WBA Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 2,996 contracts have traded so far, representing approximately 299,600 underlying shares. That amounts to about 57.8% of DXCM's average daily trading volume over the past month of 518,730 shares. Especially high volume was seen for the $560 strike call option expiring November 19, 2021, with 562 contracts trading so far today, representing approximately 56,200 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $560 strike highlighted in orange: Twitter Inc (Symbol: TWTR) saw options trading volume of 63,514 contracts, representing approximately 6.4 million underlying shares or approximately 56.2% of TWTR's average daily trading volume over the past month, of 11.3 million shares. Especially high volume was seen for the $62 strike call option expiring October 15, 2021, with 6,934 contracts trading so far today, representing approximately 693,400 underlying shares of TWTR. Below is a chart showing TWTR's trailing twelve month trading history, with the $62 strike highlighted in orange: And Walgreens Boots Alliance Inc (Symbol: WBA) options are showing a volume of 27,386 contracts thus far today. That number of contracts represents approximately 2.7 million underlying shares, working out to a sizeable 54.5% of WBA's average daily trading volume over the past month, of 5.0 million shares. Especially high volume was seen for the $46 strike put option expiring October 15, 2021, with 2,958 contracts trading so far today, representing approximately 295,800 underlying shares of WBA. Below is a chart showing WBA's trailing twelve month trading history, with the $46 strike highlighted in orange: For the various different available expirations for DXCM options, TWTR options, or WBA options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom (NASDAQ:DXCM) A Risky Investment? The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies DexCom, Inc. (NASDAQ:DXCM) makes use of debt. But the more important question is: how much risk is that debt creating? When Is Debt Dangerous? Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company's use of debt, we first look at cash and debt together. What Is DexCom's Net Debt? As you can see below, DexCom had US$1.71b of debt, at June 2021, which is about the same as the year before. You can click the chart for greater detail. However, its balance sheet shows it holds US$2.58b in cash, so it actually has US$874.2m net cash. NasdaqGS:DXCM Debt to Equity History October 13th 2021 How Strong Is DexCom's Balance Sheet? According to the last reported balance sheet, DexCom had liabilities of US$600.7m due within 12 months, and liabilities of US$1.91b due beyond 12 months. Offsetting this, it had US$2.58b in cash and US$483.5m in receivables that were due within 12 months. So it actually has US$562.2m more liquid assets than total liabilities. This state of affairs indicates that DexCom's balance sheet looks quite solid, as its total liabilities are just about equal to its liquid assets. So while it's hard to imagine that the US$52.1b company is struggling for cash, we still think it's worth monitoring its balance sheet. Succinctly put, DexCom boasts net cash, so it's fair to say it does not have a heavy debt load! Importantly, DexCom grew its EBIT by 33% over the last twelve months, and that growth will make it easier to handle its debt. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine DexCom's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts. Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. DexCom may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. During the last three years, DexCom produced sturdy free cash flow equating to 53% of its EBIT, about what we'd expect. This free cash flow puts the company in a good position to pay down debt, when appropriate. Summing up While it is always sensible to investigate a company's debt, in this case DexCom has US$874.2m in net cash and a decent-looking balance sheet. And we liked the look of last year's 33% year-on-year EBIT growth. So is DexCom's debt a risk? It doesn't seem so to us. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. We've identified 3 warning signs with DexCom (at least 1 which is a bit concerning) , and understanding them should be part of your investment process. At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-10-14,138.088,140.291,137.772,138.628,
DXCM,2021-10-15,138.92,139.029,135.78,136.118,"Nasdaq 100 Movers: BIIB, MAR In early trading on Friday, shares of Marriott International, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.2%. Year to date, Marriott International, registers a 20.3% gain. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 1.6%. Biogen is showing a gain of 14.6% looking at the year to date performance. Two other components making moves today are DexCom, trading down 1.3%, and MercadoLibre, trading up 2.0% on the day. VIDEO: Nasdaq 100 Movers: BIIB, MAR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-18,134.215,135.51,132.995,135.32,"FDA Approval for Senseonics’ Glucose Monitor Could Double the Stock Price InvestorPlace - Stock Market News, Stock Advice & Trading Tips During the Senseonics Holdings (NYSEAMERICAN:SENS) Q2 conference call on Aug. 9, CEO Tim Goodnow updated investors on the U.S. Food and Drug Administration approval process for its Eversense product. Eversense is designed to be a continuous glucose monitoring (CGM) device for diabetes patients. Once the FDA approval comes in for its 180-day version of Eversense, Senseonics can market it extensively in the U.S. That should provide a huge boost to SENS stock. Source: Andrew_Popov / Shutterstock.com This could not come at a better time for the stock price. It has been on a downward drift since it closed on Feb. 16 at $5.27 per share. As of the close of Oct. 15, SENS stock was down to $3.30, or a drop of over 37%. In mid-June and then again at the end of August, the stock rose over $4 per share. It’s almost as if the stock is waiting to hear from the FDA before it will move higher. Where Things Stand With the FDA CEO Tim Goodnow indicated that they are working closely with the FDA in the approval process. He indicated that the product was assigned to a lead reviewer in the FDA on April 15. 7 A-Rated Stocks to Buy Under $50 for 2022 Since then, the company has been in discussions with the lead reviewer. Mr. Goodnow indicated how he feels: “We continue to expect the approval of the product by the end of 2021. Though the constantly evolving situation with the pandemic and its impact on FDA workload, make it hard to precisely estimate regulatory timelines.” Moreover, Senseonics has a global marketing partner. Ascensia Diabetes Care was signed up in Aug. 2020 as its exclusive worldwide strategic partner to distribute its Eversense CGM. Ascensia is now marketing Eversense in Europe, which is how Senseonics is already starting to produce most of its revenue. Ascensia is a Swiss-based private company that also has its own blood glucose monitoring (BGM) Contour products. Ascensia will begin marketing the 180-day version of Eversense in the U.S., once the FDA approval comes through. Where This Leaves Senseonics Stock I have written that SENS stock could follow the same trajectory that DexCom (NASDAQ:DXCM) has taken. It is a similar CGM company, albeit with an estimated $2.4 billion in sales for 2021. DexCom has a cloud-based monitoring product that excludes the need for lancers to prick the skin for blood sugar tests. DexCom has a $52.68 billion market capitalization and trades for 22 times sales and 219 times earnings for 2021. Over the last 10 years, DXCM stock has risen 37.5 times. This includes a gain of 5.75 times in the last 5 years. The idea is that SENS stock could take a similar trajectory once its 180-day CGM Eversense device comes through with FDA approval. It could easily begin a multi-year trajectory just like DXCM stock has had in the last five years. What SENS Stock Is Worth For example, right now SENS is forecast to reach $32.7 million in sales by the end of 2022. This is up 134% from forecast sales for 2021 of $14 million. And that is up from 2020 sales of $4.95 million. But given that sales are forecast to reach $238 million by 2026 in five years, this implies a much higher stock price. First, we have to bring back those future sales and reduce them to their present value. Using a 10% discount rate over five years the discount factor works out to 62.1% (1 / (1.1^5)). That puts the present value at 147.8 million. Then using DexCom’s price-to-sales-(P/S) multiple of 22 times gives Senseonics a potential market value of $3.252 billion. That is 121% over today’s market value of $1.469 billion for Senseonics, according to Yahoo! Finance. What to Do With SENS Stock TipRanks says that 5 analysts have an average target price of $4.13. This represents a potential gain of 25% over today’s price. Moreover, Seeking Alpha has a survey of 8 analysts that cover the stock and they have an average price of $3.46, or 4.8% higher than today. The problem I have with these price targets is that they have risen as the stock has gone up. Analysts don’t want to be seen as not recommending the stock. But they don’t seem to have a long-term target or valuation for Senseonics stock. That is why I like my target price better. Investors who believe that Senseonics could follow DexCom’s trajectory might want to take a look now at SENS stock. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed On the date of publication, Mark R. Hake did not hold a position in any security mentioned in the article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Mark Hake writes about personal finance on mrhake.medium.com and runs the Total Yield Value Guide which you can review here. The post FDA Approval for Senseonics’ Glucose Monitor Could Double the Stock Price appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-19,136.26,138.196,135.758,137.512,
DXCM,2021-10-20,138.65,140.068,137.285,139.135,
DXCM,2021-10-21,138.445,142.288,137.5,142.025,"2 Unstoppable Stocks to Buy and Hold for Decades If you invest for the long term, you don't need to worry about short-term fluctuations in the market or what retail investors are betting on today. But in order to be able to just buy and forget, it's important to look at businesses that are both sound financially and likely to enjoy strong demand for its products for many years. Two stocks that fall into that category are DexCom (NASDAQ: DXCM) and Microsoft (NASDAQ: MSFT). They're good buys today and look even better over the long haul. Image source: Getty Images 1. DexCom Diabetes is, unfortunately, a growing problem in the world. One in three Americans could have the illness by 2050, according to the Centers for Disease Control and Prevention. Luckily, DexCom and its continuous glucose monitoring devices can help patients manage the issue. Using small sensors that can be inserted under a person's skin, they make it easy to obtain glucose values and can relay and share those readings through an app. And the devices don't require finger pricks. Demand for the company's products is likely to be around for a very long time, making Dexcom a sound long-term investment. The business itself has impressive margins and consistently posts strong profits. Its gross margin is a steady 69% of revenue over the trailing 12 months. Unsurprisingly, with that much left over after cost of goods sold, DexCom has also banked a 24% profit margin. The business has become more efficient over the years in keeping its expenses down (with respect to revenue), and if it can maintain these types of margins, there will be tons of profit growth in the future as sales continue to rise. Through the first six months of 2021, DexCom reported $1.1 billion in revenue, which grew 28% year over year. Its net profit of $103 million rose by 56%. For the full year, the healthcare company projects that revenue will come in between $2.35 billion and $2.4 billion, growing at least 22% from 2020. But over the long term, there will undoubtedly be even more growth, and that's what makes DexCom an excellent option for investors who want a great stock they can buy and forget about. 2. Microsoft Microsoft is an easy investment to justify over the long term. It's been a big name in its industry for decades, and that's unlikely to change. With so many different businesses that it can tap into for growth, Microsoft is versatile enough that it can change and adapt to ongoing trends. One example is in the growing popularity of videoconferencing. Zoom Video Communications (NASDAQ: ZM) has experienced significant growth since the start of the pandemic, with people stuck at home and relying on its videoconferencing software for meetings (whether it was for business or any other reason). Since the beginning of 2020, the stock soared more than 300% while the S&P 500 increased by 40%. That wasn't an area of focus for Microsoft, but that has quickly changed for the tech company. Now, Microsoft includes videoconferencing capabilities in its Teams communication platform, which is designed to help businesses stay connected. Plus, it added a ""Meet Now"" option right within its Windows 10 operating system. Microsoft is such a force that once it spots a trend, it can pour money into an area of its business to take advantage of it. With deep pockets (last fiscal year alone, it banked more than $61 billion in profit) and 1.3 billion devices that are currently using its Windows 10 software, it has the capability to easily reach users and deploy tools that can rival just about anything that's available in the marketplace today. And with so many different products and services, Microsoft is a safe bet to meet the needs of its users for the long term. From gaming to office software to cloud computing, Microsoft has many segments in its business. In its most recent quarter, for the period ending June 30, the company posted revenue of $46 billion, which rose 21% year over year, and its net income of $17 billion rose by 42%. And more importantly, many of its segments experienced growth rates of more than 10%. With stellar numbers, a solid user base, and diverse offerings, Microsoft is a company that is likely to be a relevant player in tech for a long time to come. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now… and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Microsoft and Zoom Video Communications. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-22,142.5,142.5,140.308,141.642,"Why Senseonics Holdings Stock Popped This Week What happened Shares of Senseonics Holdings (NYSEMKT: SENS) rose by nearly 10% by the end of trading Thursday afternoon this week, according to data from S&P Global Market Intelligence. Senseonics is a small-cap player in the high-value and ultra-high growth continuous glucose monitoring (CGM) system market. What sparked the stock's upswing this week? While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. Senseonics applied for a premarket approval to the U.S. Food and Drug Administration to extend the wearable life of the Eversense CGM system to 180 days on Sept. 30. Image source: Getty Images. So what Senseonics might be targeting one of the fastest growing areas in all of healthcare. But its Eversense CGM devices are fighting for market share against entrenched competitors from the likes of Abbott Laboratories, DexCom, and Medtronic. As a direct result of this exceedingly intense competition, Wall Street only expects Senseonics to generate about $14 million in total sales this year. That's not a whole lot of revenue for a company with a market cap north of $1.59 billion at the time of writing. Investors, for their part, are hoping that this six-month version of the Eversense CGM system will make the company far more competitive against these industry giants in 2022 and beyond. Now what FDA PMA reviews can take around a year to complete. Armed with this insight, investors appear to be buying this small-cap biotech stock right now in the hopes of catching lightning in a bottle, so to speak. A six-month implantable CGM device, after all, could be a game changer for the company in terms of its top-line growth. Therefore, risk-tolerant investors may want to consider buying this speculative medical device stock ahead of this potentially explosive catalyst. 10 stocks we like better than Senseonics Holdings, Inc. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2021 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-25,141.75,143.412,140.233,142.085,
DXCM,2021-10-26,141.94,142.72,140.309,141.41,
DXCM,2021-10-27,140.932,141.882,138.388,139.635,
DXCM,2021-10-28,140.425,142.802,139.116,142.58,"DexCom Inc (DXCM) Q3 2021 Earnings Call Transcript Image source: The Motley Fool. DexCom Inc (NASDAQ: DXCM) Q3 2021 Earnings Call Oct 28, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom Third Quarter 2021 Earnings Release Conference Call. My name is Darryl, and I will be your operator for today's call. [Operator Instructions]. I will now turn the call over to Sean Christensen. Sean, you may begin. Find out why DexCom is one of the 10 best stocks to buy now Our award-winning analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of October 20, 2021 Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Thank you, operator, and welcome to DexCom's Third Quarter 2021 Earnings Call. Our agenda begins with Kevin Sayer, DexCom's Chairman, President and CEO, who will provide a summary of our progress on our third quarter highlights and strategic initiatives; followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we'll open the call up for your questions. Our Chief Technology Officer, Jake Leach, will also be present with us for the Q&A period. [Operator Instructions] Please note that there are also slides available related to our third quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, expectations and assumptions about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertaintiesand and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Today, we reported another strong quarter for DexCom with third quarter revenue growth of 30% compared to the third quarter of 2020 and 28% growth on an organic basis. This revenue growth rate represents continued momentum from DexCom CGM adoption around the world, as we once again achieved a record quarter of new customer growth. The third quarter also saw several strategic accomplishments across our teams that lay the foundation for our future growth opportunities. In the U.S., we received FDA clearance for two key software solutions that continue to differentiate our connected products from those of our competitors and position us as a partner of choice across a healthcare and wearables ecosystem. First, in July, we received FDA clearance for our real-time API. For those of you who are unaware, an API is the tool that allows one app to connect with another app. Prior to this clearance, our customers and clinicians could only utilize our retrospective API, which integrated DexCom data into third-party apps on a 3-hour delayed basis. We believe that by putting the power of choice at our users' fingertips with real-time data, we can help ease the daily burden of diabetes management and significantly improved quality of life for our customers. This tool will be available to partners invited by DexCom, and we already have several that have begun the development process to enable real-time displays for their communities. This includes Garmin, which became the first partner to launch apps connected to our real-time API two weeks ago, bringing DexCom readings into their portfolio of wearables and cycling computers. Second, on the heels of the real-time API clearance, we received FDA clearance in August for the DexCom app, an app module. This module was specifically designed for people with nonintensive type two diabetes and can directly integrate into another third-party healthcare app. With the integrated DexCom app, it is now even easier for our partners to access and display our CGM data, enabling single app solutions that simplify the experiences for DexCom users. UnitedHealth Group became our first partner to launch the integrated DexCom app in app module in late September, bringing the embedded app into their Level two diabetes care program. Our connectivity, software and data infrastructure solutions are our core strength of DexCom. These two recent FDA clearances reflect the increased investment that we put into software development and we believe increase our competitive advantages moving forward. In late September, we also announced the launch of DexCom one in four international markets where we previously had no presence. Bulgaria, Latvia, Lithuania and Estonia. DexCom one leverages the G6 hardware platform and a completely redesigned software experience that focuses on simplicity, and ease of use for our customers. This is the first product launch in our history that started exclusively through the DexCom e-commerce platform, a platform that has been embraced by our customers in Canada and the U.K. over the past two years. With the proven performance of our CGM systems, the new software experience and efficient e-commerce solution and affordable pricing plans, we believe that DexCom one will be an important product for us as we drive the business toward our long-term targets. Most importantly, this differentiated product is a key step for us to bring DexCom CGM to significantly more people with diabetes who previously did not have access to our products. Early feedback around the product has been very favorable, and we look forward to seeing the full results from these launches as we leverage the full breadth of our expanding product portfolio to achieve our 2020 Investor Day goal of tripling our international addressable market by the end of 2023. Building from the strength of our mobile trial that was published in the Journal of the American Medical Association in June, investigators published the results from the extension phase of the trial in Diabetes care during the third quarter. In this extension phase, we rerandomized the population who are initially on CGM to see if the benefits would be retained for those who stayed on CGM compared to those who returned to fingerstick monitoring. Once again, the results were clear. Those who stayed on our G6 systems maintain greater time and range improvements over the 6-month extension phase compared to those who did not. The results confirmed that for the significant population of people with type two diabetes on basal insulin, there is significant benefit in continuous CGM use to optimize therapy and support behavior modifications. Our teams are working hard to leverage the conclusions from mobile into greater access to our technology for people with type two diabetes. And this is just one area in which we are building the foundation for our long-term growth. We are advancing our pilot efforts with UnitedHealth Level two, Teladoc's Livongo for Diabetes, WellDoc, Onduo and others. We are generating strong clinical evidence for expanded indications for CGM use in inpatient settings and for women who are pregnant. We continue to leverage our advantages in connectivity by gaining new customers and progressing our pipeline of solutions with our leading insulin delivery partners. Finally, we continue to advance our G7 scale-up and regulatory efforts during the quarter. We've had excellent communication with our notified body in Europe and believe that we remain on track to begin the launch of our G7 system in the fourth quarter upon receiving CE Mark clearance. In the U.S., we've made great progress in preparation for our regulatory submission. I believe that we are now in the final stages of that effort. We look forward to the comprehensive G7 510(k) submission, including G7 hardware and full Android and iOS software to the FDA in the next few weeks. As you can see, our teams are working very hard and making great progress to advance our core strategic efforts, whether it is in expanding our product portfolio, creating differentiated user experiences or laying the foundation for new market opportunities that will drive our future growth. So with that said, let me turn it over now to Jereme for a review of our third quarter financial performance. Jereme? Jereme Sylvain -- Executive Vice President-Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. For the third quarter of 2021, we reported worldwide revenue of $650 million compared to $501 million for the third quarter of 2020, representing growth of 30% on a reported basis and 28% on an organic basis. In late July, we were proud to complete the acquisition of our distributor in Australia and New Zealand. With this acquisition, we began generating revenue for certain non-CGM healthcare products, which we have categorized as inorganic growth for the quarter. This non-CGM distribution revenue contributed approximately 2% to our reported growth for the third quarter. The transition from distributor markets to direct sales is one of several important strategic initiatives that we outlined at our 2020 Investor Day as we seek to significantly grow our international presence. We believe a larger direct international footprint will give us greater control to leverage our marketing strength, invest in accelerating our growth and ensure that the direction of these core markets is aligned to our strategic interest. In terms of the financial impact of the third quarter acquisition, we expect the transaction to be approximately neutral to our operating margin for the full year as it was in the third quarter. U.S. revenue totaled $490 million in the third quarter compared to $399 million in the third quarter of 2020, representing growth of 23%. We continue to see good momentum in the U.S. where we are benefiting from the increased market access and field presence that we've enabled over the past year. New customer growth remains strong across all segments of the population including people with type one diabetes, intensively manage people with type two diabetes where we have significantly expanded market access in the past year and even early adopters in the type two non-intensive population. Our international business grew 57% in the third quarter, totaling $161 million. Excluding the impact of non-CGM distribution revenue generated by our acquisition of our distributor in Australia and New Zealand, growth for our international business was 46% in the third quarter. We continue to see very encouraging growth across the board in our international markets with the majority of our markets delivering record sales in the third quarter. Although it is still early, we believe that our strategic moves to broaden access in several markets have been very successful thus far and have left us well positioned to expand our growth profile internationally, and you see that in the reflected current quarter results. Along those lines, our global volume growth in the third quarter remained strong, exceeding 40% for the quarter. This is well above our 28% organic revenue growth rate and supports the momentum behind DexCom CGM globally, as we aggressively seek to advance access to our technology and drive better health outcomes and quality of life for people with diabetes. As Kevin mentioned, the launch of DexCom one adds to our product portfolio and provides another key element of our strategy to expand access to CGM globally. As we continue to scale our business in conjunction with our ambitious plans for customer growth, we are creating tools that allow us to serve our growing base in an efficient manner, and the use of our e-commerce platform for the initial DexCom one launch is a good example of that focus. Our third quarter gross profit was $446.9 million or 68.7% of revenue compared to 68% of revenue in the third quarter of 2020. The year-over-year gross margin expansion is an impressive result, especially when you factor in our strategic efforts this year to drive greater mix to the pharmacy channel and expanded international access. This is a credit to our teams who have innovated and embrace change where necessary to drive efficiencies and position us to maximize our strategic opportunities. We continue to demonstrate the ability to leverage both our manufacturing operations and R&D teams to be ever more efficient in the delivery of our products. Operating expenses were $323.1 million for Q3 2021 compared to $245.7 million in Q3 2020. Operating expenses, as a percentage of sales were relatively flat year-over-year as we offset investments in software development, G7 scale-up and our expanded global commercial sales force with strong leverage of our general and administrative functions. Operating income was $123.8 million in the third quarter of 2021 compared to $95 million in the same quarter of 2020, holding flat 19% of revenue. As this result indicates we've been able to retain much of our operating margin this year even as we have significantly reinvested in our business. Adjusted EBITDA was $173.5 million or 26.7% of revenue for the third quarter compared to $146.9 million or 29.3% of revenue for the third quarter of 2020. Net income for the third quarter was $89.5 million or $0.89 per share. We closed the quarter with approximately $2.7 billion in cash and cash equivalents, giving us great financial flexibility to drive our strategic initiatives. This includes the continued build-out of our manufacturing facility in Malaysia and G7 scale-up in Mesa, Arizona as well as opportunities that are relying on our business objectives, such as our recent distributor acquisition. Turning to guidance. Our third quarter performance has placed us in a position to once again raise our full year 2021 outlook for revenue and margins as we look to wrap up another excellent year. We now expect 2021 revenue to be between $2.425 billion and $2.450 billion, representing growth of 26% to 27% over 2020. This guidance includes approximately 100 basis points of non-CGM inorganic growth related to our recent distributor acquisition. Turning to margins. We are increasing our full year 2021 targets. This includes non-GAAP results to be approximately at the following levels, which include a neutral impact from our distributor acquisition. Gross profit margins of approximately 68%, operating margins of approximately 16%, and adjusted EBITDA margins of approximately 25%. With that, I will now turn the call back to Kevin. Kevin Sayer -- Chairman, President and Chief Executive Officer There are a number of things that we could celebrate, and I'd like to take the time now to thank all of the teams at DexCom and specifically highlight a few things that we are proud of. First, to our new DexCom team members in Australia and New Zealand, we are absolutely thrilled to have you with us on our journey to empower people to take control of diabetes. We look forward to working together and learning from you as we bring our technology to those in need in these key markets. Our operations team has provided another highlight in the third quarter as our G6 manufacturing yields reached all-time highs, and our warranty rates reached all-time lows. Those are the kind of metrics that lead to the margin improvements that we've seen and reflect countless hours of work from our talented employees. And finally, our R&D team continues to innovate with several updates to our sensor pipeline as well as our leadership in data and software solutions. The two FDA clearances this quarter are a testament to those efforts and a nice validation of the strategy that we discussed to leverage software as a competitive advantage and a key area of investment. As Sean mentioned at the start of the call, we've invited Jake Leach, our Chief Technology Officer, to join us for the Q&A portion of the call in order to address any questions around these clearances and our product innovation. I would now like to open the call up for Q&A. Sean? Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations [Operator Instructions] Operator, please provide the Q&A instructions. Questions and Answers: Operator [Operator Instructions] And our first question comes from Jeff Johnson from Baird. Go ahead, Jeff. Jeff Johnson -- Baird -- Analyst Thank you. Good afternoon, guys. I know we focused so much on T1 and intensive T2 most of the time, but I wanted to ask this time maybe on the nonintensive in the prediabetes markets. I guess I'm wondering more than anything your latest thoughts on how big those two markets could be over the next year or two, especially with so many we see all these behavioral services popping up with levels and super Sapiens and others in prediabetes and obviously, Level two and some of the others on the commercial side. it feels like your real-time APIs and your app and app approvals would be helpful for some of those programs. So just kind of how do you see those two markets developing in the short run kind of one to two years in your market share in those two areas, maybe over the next couple of years as well? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, Jeff. This is Kevin. I'll take that one. We think those markets can develop nicely. We have some work to do on the product labeling side and some work to do with the FDA as we migrate down that path, and we've had some of those discussions. But the results are spectacular as we've seen people use this product. In fact, we recently got an email from a physician. And again, this is in the type two world, nonintensive, but was telling us about a recent experience with a patient who had gone from an A1c in the 12 down to no medications and an A1c of 5.5 or something like that. It works there. It works there. It works also very much on the -- just the metabolic front-end general, anybody who wears a CGM and watches that data, and particularly if you set those lines narrow between like 70 and 120, if you go above the 120 mark, you ask yourself what you ate. You can usually figure out and go back to something that you could do different, the effects of exercise, the effects of poor sleep, the effect of stress of anearnings callis going to be demonstrated in CGM graph. I think it's a wonderful market opportunity. The data has to be presented properly. That's where the Live API and the approvals we talked about today come in. The API is a quick way to get there. And Jay knows the technical stuff better than me, but the API also requires a person to run a DexCom app and the other app. With the other -- the app in app module that we talked about today, some of these larger programs, again, like Level two with UnitedHealth Group, you have one app experience with like a DexCom button or a DexCom experience right in the middle of it. So if you're branding a wellness situation and really want that to be your focal point, we can resign in that app and you can have that experience. So we think both solutions, they offer speed, but they also offer different experiences. And then we'll pick the partners we want to work with on both sides. Those that have the best need for one versus the other. So we're excited for both of them, Jeff. We're very excited for these markets, and it's long been part of our long-term strategy. but we need the technology to get there, and our product pipeline truly supports going there over time. Operator And our next question comes from Robbie Marcus from JPMorgan. Go ahead, Robbie. Lilia Lozada -- JPMorgan -- Analyst Hi. This is actually Lilia on for Robbie. Can you talk briefly about dynamics that you're seeing in Europe right now? You guys had a great quarter there. So any tangible stories of success from the increased patient access efforts that you've implemented over the last few months? Any color on that you could share would be helpful. Thanks. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Sure. Yes. Thanks for the question. What you see in Europe, and certainly, it's really in all the markets we've gone in with our access strategy as we've moved into various countries and obviously, exchange price for access to populations that we historically haven't been able to get to. And what you see in the quarter, I think we talked a little bit about on the call is it was a record revenue quarter in most of our international markets. So I think you see it playing through on the revenue front. I think you saw a 46% organic growth rate outside the U.S., which again, another incredibly strong quarter fueled by a lot of the access that we've been able to create. And then you look at the new patient growth. It's another record quarter for new patient adds in this quarter, again, all pointing to some of the access that we've created outside the U.S. So I think some of the examples, I think we talked a little bit about them publicly last quarter with Canada, for example, in multiple different provinces allowing us access to those publicly reimbursed channels. And I think in those channels, you're seeing just that. A lot of people now have the access to DexCom CGM technology, and they're taking advantage of that. So we'll continue to expect that to play through. It's why we ultimately made the decision to do it. And I think you've seen it play through in the financial results and our expectation is you continue to see it play through over the long haul. Operator And our next question comes from Danielle Antalffy from SVB Leerink. Go ahead, Danielle. Danielle Antalffy -- SVB Leerink -- Analyst Hey. Good afternoon. Thanks so much for taking my question. Congrats on a really strong quarter. Jereme, just a question for you. You guys have been investing pretty significantly in direct-to-consumer marketing and ramping up the sales force initiatives around primary care physicians. I'm wondering if you can talk, now we're three quarters into this sort of more concerted effort in the U.S. And whether we're -- we can really talk about how you're seeing a return on that investment as far as incremental new patient adds and maybe just where we are from a primary care physician coverage perspective? Thanks so much. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Sure. And absolutely. So where we sit today, and we talked a little bit about it last quarter, but I want to reiterate it is, in the U.S., we've doubled our covering prescriber coverage over the past 18 months. And so what I mean by that is the amount of physicians that are writing DexCom's scripts has doubled in 18 months. That's a testament to the work that's being done by the U.S. commercial team, which has been fueled by multiple things, certainly, direct-to-consumer advertising, doubling the size of the sales force, those all really play into folks adopting the technology. Just a couple of tangible things, which I think are helpful to see, again, another record quarter for new patient adds. I think you can see that playing through. And in many ways, that's driven by the sales force. So you see that continued momentum. I'd say the one thing that we have noticed that hasn't prevented us from being at completely full effectiveness is some of the impacts of the Delta variant. I think that's probably the only thing that we've seen that's been a challenge, and that's just getting access to some of these offices when they're no longer seeing folks in person. And so you've seen a lot of physicians opening up in those locations we're doing incredibly well. So there's more to work through, and that's a function of just navigating through these COVID landscapes more than anything else. So I think in short, you're seeing the performance, you're seeing the growth, seeing the new patient adds, and we've ramped up very nicely. It's been an incredible year for us thus far and very bullish on what it means for next year. So I think that's really the feedback thus far. And again, as we get more and more data, we'll continue to share it as it becomes available. Operator And our next question comes from Matthew Blackman from Stifel. Go ahead, Matthew. Matthew Blackman -- Stifel -- Analyst Good afternoon everybody. Thanks for taking my question. I wanted to ask about the G6 rollout in Japan. Just any commentary on early trends there. Could you also just remind us the sizing of the incremental opportunity in Japan? And how meaningful a contributor do you think it could be to either worldwide growth or OUS growth, how would you want to frame it as we move into 2022? Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer Yes. This is Kevin. We're early on in that launch with our partner, Terumo. We've got some good traction. But literally with launch happening in earlier this summer, we're in a position of educating physicians, getting samples out there really teaching people about our product. We think over time, the Japan market could be a very good one for us. While there's not a tremendous amount of type one diabetes, there's also -- there is a large amount of type two diabetes. If we can get across that broad spectrum with our product offerings, we can see this being one of our -- certainly one of our top eight markets, possibly even a top four or five in the world as time goes on. We also know from a technological perspective, the physicians we've spoken with are very bullish on the performance of our product and tremendously value the accuracy and precision of what we do and the connectivity and all of those things. So we believe we have the right system for the market. But we're in early phases right now. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Yes. And just to give you -- I know you asked for the size of the market, that's a market of around 300,000 to 400,000 intensively managed patients across type one and type two. So it's a large market with a lot of folks, a smaller prevalence of T1, but obviously, a market that can be an incredible landing spot for us in that space. Operator And our next question comes from Margaret Kaczor from William Blair. Go ahead, Margaret. Margaret Kaczor -- William Blair -- Analyst Hey, good afternoon guys. Thanks for taking the question. So the question is a little bit more of a theme and an expansion maybe on some of the partnerships that you referenced and just getting a better sense around how many of your patients out today, for example, may come from these partnerships. And when we talk about expanding them, is that in the form of covered lives? Is it something else? And just as a follow-on since Jake on the call, I guess, the products and subscription services that you guys may offer these partnerships, how do those evolve, I guess, over time? And could that potentially accelerate some of the capabilities that DexCom offers or the new products that they offer away from pure technology that you've been in the past toward some of these other software or other potential offerings we have? Thanks. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Sure. Yes. So let me start with maybe the financials side and how that migrates over time. And then Jake is obviously here. He'll take you through the technical aspect of it and why we're so excited about it. So today, these partnerships are a combination of expanding TAM and expanding people that would want to access CGM technology over time. And today, it's in the form of sensors. But over time, and as we've demonstrated with a couple of other software features, we've obviously added over the past six months or so, software can be a part of that package. And so we're really -- the monetization of that will come over time. Today, it's about how do we get as many folks as possible on sensors to realize the value of CGM. So that's how we expand it. Jake, maybe you can take it through just kind of the general theme of where we're going in that space. Jacob Leach -- Executive Vice President-Chief Technology Officer Yes, sure, Jereme. Thanks for the question. So really, the way we think about it is the technology that we are bringing to market through these software features is really about providing unique experiences for customer segments. And so if you think about the type one segment or the type two segment nonintensive. You really -- you're solving different types of problems in those. And so what these software tools such as our Live API provide is a way for our partners to serve those needs with DexCom CGM and a connection to our product. The real-time API is a real advancement in our cloud strategy, and we're really excited about the list of partners that are working to integrate that into their systems to provide their customers with unique experiences. Operator And our next question comes from Matthew O'Brien from Piper Sandler. Go ahead, Matthew. Matthew O'Brien -- Piper Sandler -- Analyst Thanks and thanks for the question. So a lot of moving parts here, and I'm not sure if I'm doing the math right, but I'm getting like $60 million to $70 million of a pricing headwind this quarter. And I'm not sure what the distributor conversion, if that's right or not. I guess I'm just asking, is that about right? Are we seeing a little bit more of the pricing headwind this quarter than we've seen over the last couple. So we'll see maybe a little less next year. It's getting pulled forward to the '21-- And then the reason I'm asking is that the increase sequentially from Q3 to Q4 is a little bit below trend line. Is that because you're expecting more of the pricing headwinds to be seen here in '21 versus '22? Jereme Sylvain -- Executive Vice President-Chief Financial Officer Yes. So there's a couple of pieces. So I'll first and foremost, reiterate, the total pricing expectation for the year, the $250 million is still the expectation. If anything, we might come a little bit light on that, but that still is the expectation. And so then the pricing in Q3 was generally in line with prior quarters, a little bit elevated, but it's not a material step change. And that's a function of some of those OUS contracts kicking in. So really, that's where we come from a pricing perspective. So it's not necessarily pulling anything in. We've often talked about 2022 being relatively similar to 2021, and we're still on that trajectory. So I wouldn't necessarily expect any of that. To your question on how Q4 plays out in the guide and doing the math there, and you're doing the math right. One of the things we're mindful of, and there's really two pieces to it, as you think about it. There's the piece we talked about a little bit earlier, which is the Delta variant and getting into new primary care offices and making sure that we're seeing that over time before we count on it. So that's the first piece of it, and we're mindful of that. And then the second piece of it as more and more of our product is fulfilled through the pharmacy, the historical trends over time, you're going to see start to migrate just a little bit. You saw it start this year in Q1. If you look back to Q1, our sequential pullback from prior year Q4 into Q1 was a bit mooted. And you're going to see the same thing in this Q4, which means as more and more goes to the pharmacy, you no longer have folks in the DME space than on they have the high deductible health plans, where folks are maximizing benefits at the end of the year. So we expect a little bit less seasonality as we progress. And in turn, we expect a little seasonality in Q1 of next year. So that's what you're reading into it. That's ultimately what comes through in the guide. So you're doing the math right, but those are some of the expectations that went into it. Operator And our next question comes from Travis Steed from Barclays. Go ahead, Travis. Travis Steed -- Barclays -- Analyst Hi. Thanks for taking the question, Jereme, just a follow-up on the distributor. It sounds like the revenue impact this quarter was $13 million, all in the OUS line. And just kind of curious how to model that going forward, is that about $13 million a quarter for three more quarters and then it gets into the base and how to think about, like, is there a pricing benefit here without the distributor margin? Just a little more color on the distributor acquisition, if you will. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Sure. So we'll -- so the pricing, we don't necessarily break down the pricing USO, U.S. and the overall number. And so at the end of the day, we're on the trajectory of the total company we talked about. And so obviously, you guys will do the math. But at the end of the day, we're on that same trajectory. In terms of your question on the distributor, the impact of the distributor acquisition on growth in the quarter in our CGM business, it rounds to 0%. And so it's because there was two months in the quarter and that markup on the margin in the distributor market is relatively small. The question is, well, why do you do it? And what do you -- it's our ability to control penetrating deeper into these markets, and that's ultimately why we do it. It's not to try to get a margin uplift. It's actually to try to control investment. We're a company that has cash on the balance sheet. We're willing to invest in these markets, and we want to continue to invest in these markets. So as we take them direct, the goal is then to reinvest and make sure that we're driving adoption. So the impact of the distributor really nominal on our organic growth rate, like I said, it rounds to 0. So the 28% is the organic growth rate, even including that. So hopefully, that helps you around the acquisition. There isn't much there that changes the results this quarter. Operator And our next question comes from Matt Taylor from UBS. Go ahead, Matt. Matt Taylor -- UBS -- Analyst Great. Thanks for taking question. Excuse me. I was hoping you could give me more color on how things are going in the primary care channel. Could you give us any sense for how the sales force is maturing, how productive they are and if there's more to go there. Kevin Sayer -- Chairman, President and Chief Executive Officer Yes, this is Kevin. I'll take that. There's still more to go, but it is going very well. Our targets are going very well as far as we call on. We've also learned there are some we have not had on the target list, and we're expanding that coverage as well. We've had numerous situations where it's taken our person several attempts to get into an office. But once they get in, and once we get a person on a DexCom, the response is so good based on the quality of the product that we get more. But it is a progressive effort. And it doesn't -- we don't walk in and all of a sudden get, hey, here's 50 new patients this month. It takes a little time, and we have to build a lot of credibility. But the primary care audience, particularly for those on insulin, it's gone very well so far, but it is a process, and it does take some time. Operator And our next question comes from Joanne Wuensch from Citi. Go ahead, Joanne. Joanne Wuensch -- Citi -- Analyst Thank you very much for taking my questions. It seems to me like the increasing clinical evidence that you're building is going to really help the type two population. But could you give us sort of an update on where you think or what you think you'll need to get into the non-intensive type 2s? Kevin Sayer -- Chairman, President and Chief Executive Officer This is Kevin. I'll take that. We've taken a several-pronged approach to get in there, and we're not going to deviate from that approach. We're working with healthcare professionals who are prescribing product for non-intensive type two site right now and getting great outcomes. We work with the payer network. For example, the Level two program at UnitedHealth that's produced some very good results for them and very visible in their marketing materials and their efforts. The programs and with the technologies Jake outlined, that we got approved today, the app in the app and the interfaces that will be great for partners because they do want to control that experience for patients and ultimately getting to people directly. We've been very successful in our DTC campaigns for the intensive insulin users. There will come a time when we'll be able to go direct to those consumers in the type two and IT, as we call it, nonintensive insulin therapy or not on insulin therapy, get to these guys as well. And we have a high level of confidence in the products we're designing and the things we're planning, combined with the ability of our team to reach these markets once we turn them loose once we have the opportunity to do so. So we'll go through all those steps. We'll continue on all four fronts. We're not going to back off on one of them. Operator And our next question comes from Cecilia Furlong from Morgan Stanley. Go ahead, Cecilia. Cecilia Furlong -- Morgan Stanley -- Analyst Hey. Thank you for taking our question. I wanted to ask just on gross margin. As you think about 4Q is implied with your updated guidance step down, but just what you're factoring in from the international access component versus G7 initial launch, not quite being at scale? And how we should think about the trajectory heading into '22? Thank you. Jereme Sylvain -- Executive Vice President-Chief Financial Officer Sure. So the gross margin in Q4, we do expect to take a bit of a step back. Some of it is the international access as that ramps up. And the other piece, to your point, is the launch of G7 and turning on all of the machine, the depreciation, and therefore, the yields. A majority of that is going to be the G7 launch. And the reason why is we're not at full capacity at that point. Now once we get to full capacity, there's no reason why we don't get back to our long-term gross margin guide, and we'll get into 2022 when we get there. But there's nothing structurally in those lines that would prevent us from meeting what we had talked about from our long-term gross margin guide. There may be ebbs and flows quarter-by-quarter as we ramp up. But I don't expect there to be any issues there. So if you're kind of asking the question, well, how would I wait the two, most of the impact is upon the launch of G7 and turning on those machines and the depreciation associated with it. As we get into 2022 and volumes start to build on those machines and you're able to absorb those fixed costs there's nothing structurally that can't get us back to the gross margin profiles that we've set for an organization. Operator And our next question comes from Jayson Bedford from Raymond James. Go ahead, Jayson. Pavel Molchanov -- Raymond James -- Analyst Hi. This is Pavel on for Jason. I have two quick questions here. First, will we see G7 clinical data before U.S. approval? And the second one is how close are you guys to getting to the 75% of commercial payers into the pharmacy channel? Jacob Leach -- Executive Vice President-Chief Technology Officer Yes. So thanks for the question, this is Jake. So the -- we presented actually earlier this year, we presented at ATTD G7 data, showing an MARD of sub-9% and a very strong clinical accuracy better than G6 in fact. So we're very excited and happy with the result of the U.S. pivotal, and we'll be releasing that in the future. Kevin Sayer -- Chairman, President and Chief Executive Officer Yes. So now that you've seen that data, I think you have a feel for it. And obviously, that data -- as these -- as more products launch over time, you'll get access to it. But I think some folks ask, well, how do I know what it's going to look like before there is public data available at ATD that should set kind of North Star. In terms of the transition, the migration in the pharmacy, we talked about this glide path from approximately 50% turning into 2021 or at the end of 2020 into really 75% by the end of 2022. We're on that glide path right now. And so we're making headways. We haven't given a specific update as a percentage. But as you're charting that course, we're right where we'd be expected and right where you'd expect from a linear transition over time. So hopefully, that helps. Operator Our next question comes from Larry Biegelsen from Wells Fargo. Go ahead, Larry. Nathan Treybeck -- Wells Fargo -- Analyst Hi. This is Nathan Treybeck on for Larry. Can you just provide us an update on how you're thinking about CGM for hospital and gestational diabetes? Jacob Leach -- Executive Vice President-Chief Technology Officer Yes. This is Jake. So let's start on the hospital first. So the way we're thinking about that is that really with the accuracy and reliability that we have built into the G6 and G7 systems that it's a great CGM platform to then build a purpose-built hospital product. So we're in the early stages of understanding what is the exact CGM that meets the needs in the hospital. We've seen good success with G6 under times of COVID use in the hospital. It is really serving a need, but it's not exactly the right workflow for the hospitals. And so what we want to do is better understand how do we build a CGM that really meets the needs of that segment. On the pregnancy side, we're very excited about the building in pregnancy functionality and providing information that's important for expected mothers into the G7 product. And so that's part of our road map, and we're actively working on building that into the G7. Operator And our next question comes from Steven Lichtman from Oppenheimer. Go ahead, Steven. Steven Lichtman -- Oppenheimer -- Analyst Thank you. Hi guys. Kevin, you mentioned earlier all the work you continue to do on non-intensive with partners, payers and collecting data. Wondering what your latest thoughts are on potential revenue per patient in that population or utilization overall for the nonintensive. Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer At this point in time, the total revenue amount per year is still something we model out on a number -- in a number of cases. What we've learned and what the data that we've seen most recently supports and we'll continue to talk about is continuous use of the system provides much better healthcare outcomes than intermittent or sporadic use the things that patients learn with this technology, having that feedback full time provides a much better outcome. With respect to the long-term revenue model, and again, I'm speculating a bit here, but I'll just repeat what I say to the team internally, we're solving a much different problem for somebody who's not on insulin. It is not a life-and-death decision for them. So I can see the revenue per patient being lower for this group over time even in continuous use, but I don't know how much yet. There will certainly be intermittent use models that might be available and lead to good outcomes. But one of the mistakes that a lot of these programs make in the beginning is they try and minimize the number of sensors because they're worried about the costs, they're trying to control. And in reality, the benefits to these patients and these customers who use the systems get -- are derived from CGM data. So we have to balance those things and balance that against our current business model as well. But we do believe it's going to be a very good population and there was long a belief that all these patients won't want to wear it all the time. No, they do. They very much enjoy the data and really like knowing where they are. That has not been a problem at all. Operator And our next question comes from Ravi Misra from Berenberg. Go ahead, Ravi. Ravi Misra -- Berenberg -- Analyst Hi, thanks for taking the questions. So I guess I'll use my one question on the New Zealand, Australian distributor. Just curious, how quickly can you basically get through this, I guess, inorganic revenue in terms of the impact to guidance? Like is there still kind of non-CGM revenue that we assume in quarter 4? And maybe help us think about, I guess, what the market size that you think you're able to kind of go after with this acquisition? Or do you need to do more in this arena, this country or continent space to really get access to the population? Thank you. Jacob Leach -- Executive Vice President-Chief Technology Officer Sure, I can take that. So when we acquired the distributor, the distributor had multiple different product lines. And they have sales reps that cover these multiple different product lines. And so -- and ultimately, a distributor is about people, and it's an incredible group of people. And so the key here is making sure we keep everybody together. So we'll stay in that line. What we tried to identify for you is the contributions to the overall guide in basis points. And so in our guide, we talked about 100 basis points on the full year. You'll do the math and figure out what the approximate impact is in Q4. And I think you'll have a pretty good feel for it. We'll make sure that we isolated out over the long haul, so that you're able to identify what is and what isn't out there. So I think you can feel comfortable there, provided it's material. In terms of the actual acquisition itself, and being able to get into the market, this was -- this is a group of folks who have done an incredible job with CGM adoption in that country. And so when we get into these countries, we want to make sure, one, we have the team. We make sure that there's nothing in their way from continuing to develop CGM awareness and develop CGM adoption. So there's nothing that prevents us under the structure. The only thing we mentioned in terms of investment is very similar to the way you've thought about our organization in the U.S. We know that investment in DTC and in sales reps where it makes sense and in sampling. And all of the things that we've put in place makes great sense in other markets. You've seen us do some of that in Europe. And certainly, we've done some in Canada. And we expect to do more of that. And when we take it direct, we can do a little bit more of that. And so that's really what we're talking about. So there's nothing structurally that prevents us from taking the acquisition and continuing to proliferate CGM adoption in those countries. Kevin Sayer -- Chairman, President and Chief Executive Officer Yes. This is Kevin. I would just add to that. One of the reasons we do things of this nature, take a look at our direct business in Canada and the wins we just had with the provinces and reimbursement there. With our financial muscle at the corporate level, we can take much more risk than a distributor could on their own. And so we view this investment in Australia and New Zealand as one where we're going to be able to go after a broader market increased access reimbursement and really make an impact those -- this team needed our muscle to do that financially and we needed their talent to do it as well. So it works for both of us. Operator And our next question comes from Marie Thibault from BTIG. Go ahead, Marie. Marie Thibault -- BTIG -- Analyst Hi. Yes, thank you for taking the questions. Spending a little bit of time on the DexCom one site. It strikes me as a very consumer-friendly website. And I'm just curious, whether this is sort of a glimpse at the future. I know it's been launched into some Eastern European countries. But is this a model that you would look at in terms of sort of flexible pricing and subscription plans and bulk order discounts? Is this something that's sort of a preview of the broader appeal of CGM may be into prediabetes and end consumer markets? Kevin Sayer -- Chairman, President and Chief Executive Officer Yes, this is Kevin. This is a very important launch for us. It's the first time we've launched a product on a new software platform and had a new product launch. We're in a position now of volume and manufacturing wise that we want to get this product to as many people as we can. And what DexCom one represents is really an opportunity where we can get DexCom technology into a geography easier than we could if we went through our traditional means with our G Series product. So we're offering this. And yes, as you talked about, flexible pricing plans, subscription models and things of that nature to get this product to this patient group. It definitely can be a precursor of things we can do in the future to take advantage of the scale that we've created within the business with our ability to manufacture more and again, while the website is very easy to use, I assure you the app that Jake's team and our marketing team have developed is every bit as easy to use as the website. This truly is a step-up for us from a product experience, and then we'll evaluate those opportunities over time, where we have a market where we can increase our volumes and gain more traction with this type of product offering rather than our traditional G Series, we will explore that. Operator And our next question comes from Josh Jennings from Cowen. Go ahead, Josh. Neil Chatterji -- Cowen -- Analyst Hi. This is actually Neil on for Josh. We've had some consultants recently talked about the potential for monitoring other analytes. I was just wondering if you could maybe share any updates there in terms of any development plans or program for extending monitoring analytes outside of glucoses like ketones. Kevin Sayer -- Chairman, President and Chief Executive Officer Sure. Yes. The wearable platform that we've developed with the electrochemical sensors can be extended to other analytes, and we do have active research programs within DexCom and also with some of our university colleagues that are researching other analytes that we could use on our platform. Today, we're not talking about exactly which ones, but we do feel that this platform can be extended to multiple analytes and provide more value around the CGM component. Operator Our next question comes from Anthony Petrone from Jefferies. Go ahead, Anthony. Anthony Petrone -- Jefferies -- Analyst Great. Thanks. And I hope everyone is doing well. Two quick questions. One would be on supply chain constraints. Just wondering how that is expected to play out into 2022, hearing a lot about inflationary upward pressure on cost of goods sold. So wondering how that's playing out for DexCom and what the offsets are. And then as we look into the '05 launch, just maybe an update on what percent of existing Omnipod users are currently not users of DexCom solutions? Thank you. Kevin Sayer -- Chairman, President and Chief Executive Officer Sure. So I'll go ahead and take the inflationary and supply chain. So I think everybody is -- nobody is immune to certain products and certain areas that do have pressure based on supply chain -- supply and demand. One of the things I think our team has done, there's two pieces of it. One, do you have enough product? And two, can you manage the cost? And I think our team has done an incredible job in lining up the product. Now that doesn't mean everybody is out of the woods, that everybody's got supply chains they're naturally running through. But this team got ahead of it very early and has been working collaboratively with all of our suppliers well in advance to make sure that we're properly communicating the value of our product and making sure that we're working with them to secure supply. And that's ongoing, but that work has been done well in advance of everybody else kind of jumping on it. So we're very proud of that team. In terms of the inflationary measures, we're in a bit of a unique environment. There have been absolutely inflationary measures, but we're also making a lot more product. And so you kind of get economies of scale and purchasing power, which offset some of the challenges associated with inflation. So our expectation is we're able to navigate both of those and it will not impact kind of our longer-term gross margins because of that nature. So -- hopefully that answers your question. Maybe I could turn it over to... Jacob Leach -- Executive Vice President-Chief Technology Officer Well, I can answer the Omnipod questions. So with Pod Five, there are a decent amount of folks using it. There's some studies out there I don't want to quote them just because I don't know how accurate they are. We generally have a good feel for it, although we haven't put it out there publicly. We can let Omnipod do that if they want to. But we do know once Omnipod five is launched and the integration associated with DexCom, it could provide a catalyst certainly for us. The one thing we will say is when we continue to say it all the time, is CGM first. And so we do believe that a lot of folks do come to CGM and then ultimately could choose to go on to an integrated system. And -- Most folks that do get on to our product today now are MDI. And so a lot of those are out there. That all being said, another AID system with one is novel as Omnipod. I think it's certainly something that's interesting. And for patients that like patch pumps, I think this is an incredible opportunity for folks to get on that platform. Operator And our next question comes from Kyle Rose from Canaccord. Go ahead, Kyle? Kyle Rose -- Canaccord -- Analyst Great. Thank you for taking the question. I just wanted to maybe ask another question on DexCom One. I mean you've -- you talked a couple of times just about patient experience being different and having a different app. And I understand that the software is obviously completely different on the e-commerce side, but maybe help us understand just what specifically is different from a patient-facing perspective with DexCom one versus what we've seen historically with G6 and the previous generation products? Thank you. Jacob Leach -- Executive Vice President-Chief Technology Officer Yes, it's Jake. I'll take that one. Yes, DexCom one from the beginning, our intent around the design of that product was to make it simple. And so that kind of flows through as you mentioned, the e-commerce experience, but into the app, the mobile app itself. It's a new -- completely new app architecture for us. So it's a new piece of software. And the first part that users will see that's quite different is the onboarding module. So we basically spent a lot of time studying human factors and how users use the products, particularly in those -- when they're first learning how to use it. So what the onboard module does is really walks them through a simple process in how to get up and running quickly on their CGM. The other thing about it that's different than G6 is it has a simplified alert scheme -- So it doesn't have some of the more sophisticated predictive alerts that G6 does it. It has a very simple, easy-to-use approachable alert scheme. The other thing that we added is with our current G6 system, a lot of the kind of data over time statistics are built into our Clarity software with DexCom One, we've actually incorporated that into the DexCom one app. So typical statistics like average glucose time and range estimated A1C. That's all built into the single DexCom One. And then finally, in that vein of simplicity, there's no AID connectivity for DexCom One. It also doesn't have the share remote monitoring feature. So it's really about bringing a simple CGM product to people who've never had access to DexCom CGM and haven't experienced life without fingersticks. Operator And our next question comes from Chris Pasquale from Guggenheim. Go ahead, Chris. Chris Pasquale -- Guggenheim -- Analyst Thanks. I want to piggyback on that last question because I think that answer was instructive in terms of some of the differences here. And so it leads me to wonder who you're targeting specifically with this platform? It sounds like with the loss of sharing and predictive alerts, this is probably not going to be a type one or a pediatric product. Do you see this as a way to get more into the type two population specifically? Is it a way to approach some emerging market territories where reimbursement may not be in place? I would just love some thoughts on where you see this going over time and who this product is really for. Thanks. Kevin Sayer -- Chairman, President and Chief Executive Officer It's all of those things. Certainly, you look at the four countries we launched in, they're not huge countries, but they're markets where we've never been before. So with the e-commerce platform and the creative pricing structures we have for subscription plans and things of that nature. It gives a group of people access to our technology that have never had it before. And as far as they're not sharing and they're not connecting to the ID systems, you're exactly right. It is a lower level of technology with respect to net than what we offer. And so it is targeted different people. Certainly, we'll have access to more type two patients and access to insulin users. But again, some of these geographic plays in countries where there isn't anything, -- We felt this simpler solution is a better product to offer out of the gate than the other one. And then we'll evaluate over time what products we offer where. So you were right on point with pretty much all your observations. Operator And we have no more questions at this time. I'd like to turn it back to Kevin Sayer for final comments. Kevin Sayer -- Chairman, President and Chief Executive Officer Thank you, and thank you, everyone, for your questions and continued interest and support of DexCom. We've once again reported a number of important developments to position DexCom for the future on top of outstanding financial performance and continued growth. I'm going to wax a bit philosophical today, but my father passed away in late 2020, but he never missed anearnings call And our routine after the calls was very simple. He'd call me up and he'd say, this is what you guys were trying to say, and he was pretty much always right on point. So I'm preparing my closing remarks today, let me reiterate what we're trying to tell you. Leverage and growth continue. Our 28% revenue growth achieved through sensor volume growth in excess of 40% demonstrates the continued commitment and talent of our commercial organization. Profitability continues to improve as well, yet we remain mindful of the investments we need to make in the future. Our global access strategy is working. We continue to achieve the numbers we've achieved while we've expanded access to our product globally through strategically shifting our customers to channels, which was sold in reduced revenue per customer annually and yet margins have increased. Next, G7 is on schedule, and it's coming. All of the efforts related to G7 are moving at a frenetic pace around here. I've never seen our people so engage in a single-minded purpose. And finally, our software development and data platform commitments are going to be critical in the future and you saw big steps this quarter. We've spent a great deal of time talking about software as a differentiator today and we haven't over the past several months. you're beginning to see -- you're seeing the beginning of a great change with DexCom one and the data sharing and experience-enhancing technologies recently approved by the FDA also demonstrate this. It's only the beginning. Our long-term focus has always been for the data generated from our devices to be consumed in a way that really makes an impact on people's lives and on their healthcare in general. Thanks, and everybody, have a great day. Operator [Operator Closing Remarks] Duration: 59 minutes Call participants: Sean Christensen -- Director of Corporate Affairs and Head of Investor Relations Kevin Sayer -- Chairman, President and Chief Executive Officer Jereme Sylvain -- Executive Vice President-Chief Financial Officer Jacob Leach -- Executive Vice President-Chief Technology Officer Jeff Johnson -- Baird -- Analyst Lilia Lozada -- JPMorgan -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Matthew Blackman -- Stifel -- Analyst Margaret Kaczor -- William Blair -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Travis Steed -- Barclays -- Analyst Matt Taylor -- UBS -- Analyst Joanne Wuensch -- Citi -- Analyst Cecilia Furlong -- Morgan Stanley -- Analyst Pavel Molchanov -- Raymond James -- Analyst Nathan Treybeck -- Wells Fargo -- Analyst Steven Lichtman -- Oppenheimer -- Analyst Ravi Misra -- Berenberg -- Analyst Marie Thibault -- BTIG -- Analyst Neil Chatterji -- Cowen -- Analyst Anthony Petrone -- Jefferies -- Analyst Kyle Rose -- Canaccord -- Analyst Chris Pasquale -- Guggenheim -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-10-29,145.0,156.99,138.098,155.802,"[""Friday Sector Leaders: Healthcare, Technology & Communications The best performing sector as of midday Friday is the Healthcare sector, higher by 0.4%. Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.8% on the day, and up 18.92% year-to-date. DexCom Inc, meanwhile, is up 67.08% year-to-date, and AbbVie Inc is up 11.89% year-to-date. Combined, DXCM and ABBV make up approximately 5.0% of the underlying holdings of XLV. The next best performing sector is the Technology & Communications sector, higher by 0.3%. Among large Technology & Communications stocks, Verisign Inc (Symbol: VRSN) and eBay Inc. (Symbol: EBAY) are the most notable, showing a gain of 5.7% and 5.5%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is up 0.3% in midday trading, and up 24.69% on a year-to-date basis. Verisign Inc, meanwhile, is up 2.95% year-to-date, and eBay Inc. is up 53.11% year-to-date. VRSN makes up approximately 0.2% of the underlying holdings of XLK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, three sectors are up on the day, while six sectors are down. SECTOR % CHANGE Healthcare +0.4% Technology & Communications +0.3% Industrial +0.2% Consumer Products -0.1% Financial -0.4% Services -0.6% Utilities -0.8% Materials -1.2% Energy -1.6% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable Friday Option Activity: WMT, FE, DXCM Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Walmart Inc (Symbol: WMT), where a total volume of 79,960 contracts has been traded thus far today, a contract volume which is representative of approximately 8.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 122.4% of WMT's average daily trading volume over the past month, of 6.5 million shares. Particularly high volume was seen for the $155 strike call option expiring November 12, 2021, with 30,414 contracts trading so far today, representing approximately 3.0 million underlying shares of WMT. Below is a chart showing WMT's trailing twelve month trading history, with the $155 strike highlighted in orange: FirstEnergy Corp (Symbol: FE) options are showing a volume of 23,682 contracts thus far today. That number of contracts represents approximately 2.4 million underlying shares, working out to a sizeable 77.4% of FE's average daily trading volume over the past month, of 3.1 million shares. Especially high volume was seen for the $41 strike call option expiring December 17, 2021, with 18,144 contracts trading so far today, representing approximately 1.8 million underlying shares of FE. Below is a chart showing FE's trailing twelve month trading history, with the $41 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 3,391 contracts, representing approximately 339,100 underlying shares or approximately 75.2% of DXCM's average daily trading volume over the past month, of 450,800 shares. Particularly high volume was seen for the $600 strike call option expiring November 19, 2021, with 336 contracts trading so far today, representing approximately 33,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $600 strike highlighted in orange: For the various different available expirations for WMT options, FE options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-11-01,156.818,158.625,153.13,156.818,
DXCM,2021-11-02,157.662,160.395,155.11,159.91,"4 Top Health Care Stocks For Your November 2021 Watchlist Do You Have These Top Health Care Stocks On Your Watchlist Right Now? As investors look for the top stocks to buy in thestock market today the relevance of an industry to our daily lives plays an important factor. Health care stocks will likely be as relevant as it is today a decade from now. After all, people seek medical attention for various reasons. Whether it is a life-threatening disease or a motor vehicle accident, we would need health care providers to come to our aid. For most parts, it serves to improve our quality of life so that we can live our lives to the fullest. Now that we are still facing one of the most severe pandemics the world has ever seen, the importance of health care could not be understated. Due to this catastrophic development, health care companies have been in the limelight. Earlier today, Pfizer (NYSE: PFE) reported its third-quarter financials. Revenue for the quarter was $24.1 billion, reflecting 130% operational growth. Impressively, vaccines contributed more than half of that revenue. Separately, news such as the U.S. rolling out vaccines by Pfizer and BioNTech (NASDAQ: BNTX) for children aged 5 to 11 continues to attract the attention of investors. With that in mind, here is a list of the top health care stocks in the stock market this week. Best Health Care Stocks To Watch This Month Intuitive Surgical, Inc (NASDAQ: ISRG) Ocugen Inc (NASDAQ: OCGN) Novavax, Inc (NASDAQ: NVAX) DexCom, Inc (NASDAQ: DXCM) Intuitive Surgical So, let us start the list with the surgical robotics company, Intuitive Surgical. In detail, it develops, manufactures, and markets the da Vinci surgical system and Ion endoluminal system. Besides that, it also provides a comprehensive suite of services, training, and education programs. Within the surgical robotics space now, ISRG stock would be one of the top picks among investors. It has risen more than 55% over the past year. Last month, the company announced its third-quarter business update. Worldwide da Vinci procedures increased approximately 20% year-over-year. Also, the company shipped 336 da Vinci Surgical Systems for the quarter, an increase of 72% compared with 195 in the prior year’s quarter. Naturally, the company’s revenue also grew to $1.40 billion, representing an increase of 30% year-over-year. Overall, Intuitive appears to be firing on all cylinders to end the year on the high. It is worth noting that there were also some executive leadership changes moving forward. Intuitive has created two new functional organizations, Strategy and Growth, and Global Business Services. Mr. Marshall Mohr will be assuming the role of Executive Vice President of Global Business Services. Meanwhile, Mr. Dave Rosa will assume the role of Executive Vice President and Chief Strategy & Growth Officer. These strategic moves reflect the company’s growth and plans for advancing minimally invasive care globally. Given these considerations, would you add ISRG stock to your watchlist? [Read More] 5 Metaverse Stocks To Watch In November 2021 Ocugen Another health care company on the rise lately would be Ocugen. This is a biopharmaceutical company that focuses on developing gene therapies to cure blind diseases. In light of the pandemic, it has also been developing a vaccine for COVID-19 along with Bharat Biotech. OCGN stock has more than doubled its value over the past month. Last week, the company announced that it has submitted an Investigational New Drug application with the U.S. Food and Drug Administration to evaluate its COVAXIN™ as a vaccine candidate outside the U.S. The Phase 3 trial conducted in India by Bharat Biotech showed a result of 93.4% efficacy against severe COVID-19 disease. In addition, the efficacy against symptomatic patients was 77.8% and 63.6% against asymptomatic disease. Investors appear to be optimistic regarding the vaccine candidate’s chance of securing emergency use listing (EUL) from the World Health Organization. Should it materialize, this would be an important milestone for the vaccine. All things considered, would OCGN stock be worth watching now? [Read More] Top Reddit Stocks To Buy Right Now? 5 For Your Late 2021 Watchlist Novavax Another top health care stock trending this week would be Novavax. The company is a clinical-stage vaccine company that specializes in recombinant nanoparticle vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it is able to produce candidates to respond to both known and newly emerging diseases. NVAX stock has risen more than 25% over the past week. Yesterday, the company announced the completion of its rolling submission to Health Canada for authorization of its coronavirus vaccine candidate. Also, it has completed the submission of all data to the European Medicines Agency (EMA) to support the final regulatory review of its dossier. So, the final step would be an invitation from the EMA to file for Conditional Marketing Authorization. The company and many investors alike believe that it will bring the first protein-based coronavirus vaccine to the world. In fact, the vaccine has already been granted emergency use authorization (EUA) in Indonesia. It will be manufactured by Serum Institute of India (SII) in India and marketed by SII in Indonesia under the brand name COVOVAX™. This could be the first of many authorizations that Novavax expects in the coming weeks for its vaccine globally. Given these exciting developments, would you consider NVAX stock a top health care stock to watch? [Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know DexCom To sum it up, we will be looking at a medical device company, Dexcom. Put simply, it focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. These are particularly for use by people with diabetes and by health care providers. Its products include Dexcom G6 and Dexcom Share. Impressively, DXCM stock has more than doubled its value within the past year. Last Friday, the company provided us with its third-quarter earnings report. Dexcom posted revenue of $650.2 million, an increase of 30% year-over-year. Out of which, U.S. revenue grew by 23% and international revenue grew by 57%. Moreover, its GAAP net income was $70.9 million, or $0.71 per diluted share for the quarter. Overall, the company surpassed most analysts’ expectations and has caught the attention of many investors. Dexcom continues to progress its goal of broadening access and advancing its leadership position in CGM-driven solutions. In light of this, it raised its full-year revenue guidance for 2021 to the range of $2.425 billion to $2.450 billion. Prospective investors will also be watching out for the upcoming launch of its highly anticipated Dexcom G7 system. With all these in mind, do you think DXCM stock will have more room to grow? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-11-03,161.762,162.385,153.812,154.935,"What's Happening With Dexcom Stock? [Updated: 11/1/2021] DXCM Stock Rise The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen a rise of 10% last week, while it is up 14% in a month. The recent rise can be attributed to upbeat Q3 results. Dexcom reported revenues of $650 million and EPS of $0.89, comfortably above the $619 million sales and $0.65 EPS as per the consensus estimates. The company stated that sales growth was driven by new customer additions, amid rising awareness of CGM devices. Looking forward, the company expects to receive the CE mark for its new improved and smaller in size CGM device – G7 – in Q4 of this year. Dexcom also revised its full-year outlook upward with revenue now estimated to be in the range of $2.42-$2.45 billion, compared to its earlier guidance of $2.35-$2.40 billion. The company also revised its EBITDA margin outlook to 25% (vs. 24% earlier). A solid Q3 performance cheered investors and DXCM stock surged over 9% in a single day on Friday, October 29. But now that DXCM stock has seen a 14% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 546 instances in the last ten years that DXCM stock saw a twenty-one day rise of 14% or more, 324 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 324 out of 546, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details. [Updated: 9/24/2021] DXCM Stock Update A few months back we discussed that going by its historical performance Dexcom Stock (NASDAQ: DXCM) may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last one month close to its all-time high levels of $579. The company’s Q2 earnings of $0.76 per share on an adjusted basis were much better than $0.43 street estimate. The revenue growth of 32% during the quarter also reflected strong y-o-y growth. Dexcom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require finger prick and data can be self-monitored easily. Given the limited competition, and a wide pool of diabetic patients (over 34 million in the U.S. alone), the company is likely to see strong growth over the coming years. DXCM stock has also seen a large appreciation of 60% year-to-date, and more than 500% over the last five years. But now that DXCM stock has seen a 11% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 702 instances in the last ten years that DXCM stock saw a twenty-one day rise of 11% or more, 414 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 414 out of 702, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details. Also, you can understand how Dexcom’s revenues have changed over the years along with trends in revenues for its closest peers in a separate dashboard analysis. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data After moving 1.3% or more over a five-day period, the stock rose in the next five days on 57% of the occasions. After moving 3.6% or more over a ten-day period, the stock rose in the next ten days on 60% of the occasions After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 59% of the occasions. Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well. The Centers For Medicare & Medicaid Services (CMS) recently announced that there is no longer a requirement for a minimum of four self-monitoring blood glucose tests per day to have the continuous glucose monitoring (CGM) devices covered. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking. Furthermore, Dexcom expects to launch its newest CGM device – G7 – later this year, and given that the new device will use a new and improved application, while it will also be 60% smaller in size compared to the current G6, making it the smallest CGM device available in the market. It has several other benefits over the current version, such as, its transmitter and sensor will be combined, making it a single fully disposable unit. It is also expected to have a longer wear time. As such, the G7 CGM will likely be more attractive to customers, and bolster Dexcom’s sales growth after its launch. However, now that DXCM stock has seen a rise of 23% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in DXCM stock over the next month. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 99 out of 184, or about 54% chance of a rise in DXCM stock over the coming month. Also, despite the recent rally, DXCM stock is up only 4% from the levels it was trading at a year ago. See our analysis on Dexcom Stock Chances of Rise for more details. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom’s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company’s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It’s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back. While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it’s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott. Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn’t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days). Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details. Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market (3% likelihood event) Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7% A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. While DXCM stock may continue to rise, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons. What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016. Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-11-04,154.891,158.23,154.048,157.455,
DXCM,2021-11-05,158.265,160.6,156.869,158.865,
DXCM,2021-11-08,159.352,160.74,157.368,159.272,
DXCM,2021-11-09,158.53,161.998,158.0,159.262,
DXCM,2021-11-10,157.98,159.46,154.732,155.105,
DXCM,2021-11-11,155.615,159.762,155.158,159.348,
DXCM,2021-11-12,159.99,162.152,158.612,161.64,"Here's Why We Think DexCom (NASDAQ:DXCM) Is Well Worth Watching For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. And in their study titled Who Falls Prey to the Wolf of Wall Street?' Leuz et. al. found that it is 'quite common' for investors to lose money by buying into 'pump and dump' schemes. In contrast to all that, I prefer to spend time on companies like DexCom (NASDAQ:DXCM), which has not only revenues, but also profits. Now, I'm not saying that the stock is necessarily undervalued today; but I can't shake an appreciation for the profitability of the business itself. Conversely, a loss-making company is yet to prove itself with profit, and eventually the sweet milk of external capital may run sour. DexCom's Improving Profits Over the last three years, DexCom has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base. So I don't think the percent growth rate is particularly meaningful. As a result, I'll zoom in on growth over the last year, instead. Like a firecracker arcing through the night sky, DexCom's EPS shot from US$2.48 to US$5.46, over the last year. Year on year growth of 120% is certainly a sight to behold. That could be a sign that the business has reached a true inflection point. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. DexCom maintained stable EBIT margins over the last year, all while growing revenue 27% to US$2.3b. That's progress. The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart. NasdaqGS:DXCM Earnings and Revenue History November 12th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. So why not check this interactive chart depicting future EPS estimates, for DexCom? Are DexCom Insiders Aligned With All Shareholders? We would not expect to see insiders owning a large percentage of a US$62b company like DexCom. But we do take comfort from the fact that they are investors in the company. Notably, they have an enormous stake in the company, worth US$300m. This suggests to me that leadership will be very mindful of shareholders' interests when making decisions! Should You Add DexCom To Your Watchlist? DexCom's earnings have taken off like any random crypto-currency did, back in 2017. That EPS growth certainly has my attention, and the large insider ownership only serves to further stoke my interest. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So yes, on this short analysis I do think it's worth considering DexCom for a spot on your watchlist. However, before you get too excited we've discovered 3 warning signs for DexCom (1 can't be ignored!) that you should be aware of. Although DexCom certainly looks good to me, I would like it more if insiders were buying up shares. If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-11-15,162.5,163.498,158.79,160.488,
DXCM,2021-11-16,160.992,163.862,160.112,162.008,
DXCM,2021-11-17,161.822,163.76,158.752,162.815,
DXCM,2021-11-18,164.258,164.863,161.63,162.102,
DXCM,2021-11-19,163.395,163.51,158.485,160.295,
DXCM,2021-11-22,159.662,160.895,154.5,154.515,
DXCM,2021-11-23,153.065,154.515,146.25,147.5,
DXCM,2021-11-24,147.498,150.202,145.002,149.645,
DXCM,2021-11-26,149.232,152.615,147.362,147.99,
DXCM,2021-11-29,147.988,149.515,142.235,142.752,
DXCM,2021-11-30,143.0,145.088,140.158,140.648,
DXCM,2021-12-01,141.852,142.618,136.7,137.088,
DXCM,2021-12-02,137.08,140.421,136.266,140.055,
DXCM,2021-12-03,140.268,140.268,128.632,129.872,
DXCM,2021-12-06,129.398,132.83,127.622,131.108,
DXCM,2021-12-07,134.568,139.902,133.84,139.6,"Noteworthy Tuesday Option Activity: DE, C, DXCM Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Deere & Co. (Symbol: DE), where a total of 9,206 contracts have traded so far, representing approximately 920,600 underlying shares. That amounts to about 49.8% of DE's average daily trading volume over the past month of 1.8 million shares. Especially high volume was seen for the $370 strike call option expiring December 10, 2021, with 471 contracts trading so far today, representing approximately 47,100 underlying shares of DE. Below is a chart showing DE's trailing twelve month trading history, with the $370 strike highlighted in orange: Citigroup Inc (Symbol: C) saw options trading volume of 97,590 contracts, representing approximately 9.8 million underlying shares or approximately 46% of C's average daily trading volume over the past month, of 21.2 million shares. Especially high volume was seen for the $55 strike put option expiring December 17, 2021, with 14,306 contracts trading so far today, representing approximately 1.4 million underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $55 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 3,086 contracts thus far today. That number of contracts represents approximately 308,600 underlying shares, working out to a sizeable 41.5% of DXCM's average daily trading volume over the past month, of 744,015 shares. Particularly high volume was seen for the $420 strike put option expiring January 21, 2022, with 1,068 contracts trading so far today, representing approximately 106,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $420 strike highlighted in orange: For the various different available expirations for DE options, C options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-12-08,140.0,143.188,138.992,141.212,
DXCM,2021-12-09,141.178,143.752,140.0,140.038,
DXCM,2021-12-10,140.218,142.137,139.425,141.625,"My Take: 4 Strong Growth Stocks To Buy This Week Has the omicron-fueled sell-off already run its course? Maybe or maybe not. Given Tuesday's sharp rebound, at the very least it's clear that investors aren't willing to simply throw in the towel at the first sign of trouble. The market is open for business as usual -- even if the current volatility is a bit unusual. Yet not all stocks have fully recovered. Here are four great growth companies that were beaten down a bit by the recent market sell-off, making them relative bargains to new investors. Palantir Technologies It's not a household name, but Palantir Technologies (NYSE: PLTR) plays a crucial role in helping organizations handle the deluge of digital data they've been collecting for years now. A bunch of competitors operate in this arena, but Palantir's solutions are more than a means of turning information into insights. They go further, melding digital data with front-line activities like product deliveries, resource allocation, and even medical care. Palantir's target market isn't just companies. It actually offers the sort of solutions that governments and their agencies need to be fully effective. For instance, the UK's National Health Service tapped Palantir to help manage its response to the COVID-19 pandemic, including the execution of its mass-vaccination effort. This sort of higher-level capability can be utilized by a wide array of organizations, and they're increasingly doing so. Analysts see sales growing nearly 30% next year following this year's 40% increase. While the company is not profitable yet, progress is being made on that front -- making the shares' 26% slide this past month an even more compelling reason to consider jumping in. Fortinet Palantir may not be turning a profit yet, but cybersecurity specialist Fortinet (NASDAQ: FTNT) certainly is. The company has produced $435 million worth of operating income through the first three fiscal quarters of 2021, up 20% year over year, and is en route to what analysts expect will be a 17% gain in full-year earnings. Next year could be even better with forecasts of 19% revenue growth. At the same time, earnings per share are projected to reach $3.91 this year and $4.61 in 2022. Image source: Getty Images. With cybersecurity concerns abounding, there's little reason to think demand for these products will stop growing anytime soon. In fact, it could accelerate as the scope of the true risk continues to come into view. Cybersecurity Ventures estimates that cybercrime will cost the world around $6 trillion this year alone and -- assuming nothing is done to mitigate it -- that cost will grow at an annual pace of 15% to $10.5 trillion by 2025. In other words, nobody can afford to simply do nothing; the world will have to invest in cyberdefense. So organizations will increasingly need solutions like Fortinet's zero trust network, which ensures that remote employees are connecting to a network securely, or its network firewall, which has earned the Gartner consultancy's top accolades for 12 years in a row. And that's just a sampling of how Fortinet has managed to grow its sales and profits so well. While the shares have rebounded somewhat, they are still down 10% from their high last month. Enphase Energy Speaking of technologies the world is going to need for many years to come, add Enphase Energy (NASDAQ: ENPH) to your list. The solar power outfit is in the right place at the right time -- namely, on the cusp of explosive demand for renewable energy with solar at the forefront. The Solar Energy Industries Association predicts that in the United States alone solar-power production capacity will more than triple over the next 10 years, making it the country's fastest-growing source of electricity over that time frame. That said, it's important to note that Enphase Energy's value isn't as a solar panel manufacturer; for better or worse, that area has evolved into a commodity-type business. Rather, Enphase's edge within the fast-growing solar power market is its technology. The company's combination of power inverters, system management apps, and power-storage solutions solves many of the biggest problems that corporations and consumers will face as they transition to solar power. Plus, Enphase has over 400 patents or pending patents to help keep it (and its hardware) ahead of the competition. So with the stock down some 20% from its high, investors would do well to take a closer look. DexCom Finally, investors on the hunt for growth stocks may want to consider DexCom (NASDAQ: DXCM), a maker of continuous glucose monitoring systems (GMS) used by diabetics. The stock is anything but cheap, trading at nearly 200 times this year's expected per-share profits. But this is a company that deserves premium pricing. That's because of its technology. While it's not the market leader -- that honor still belongs to Abbott Laboratories -- never say never. DexCom's G6 system is the world's ""first real-time, integrated CGM that is authorized to work interoperably with a range of connected insulin pen and closed loop system partners."" Translation: It's a very flexible device that allows users to integrate other tech and help diabetics better manage their condition. With its leading-edge G6 system, DexCom should be able to grow at a healthy pace in the highly fragmented and fast-growing glucose monitoring field. Global Market Insights estimates this segment will grow at a 10% annual clip through at least 2027 as more and more diabetics graduate from using the much less convenient finger pricks and paper test strips. Analysts expect DexCom's revenue will grow 27% this year and 22% next year. That, together with a stock that is still 15% off the highs it reached in mid-November, makes for an investment well worth investors' attention. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 10, 2021 James Brumley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Palantir Technologies Inc. The Motley Fool recommends DexCom and Fortinet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-12-13,140.982,143.147,137.321,137.402,
DXCM,2021-12-14,136.788,138.302,132.431,133.835,
DXCM,2021-12-15,134.595,136.322,131.94,135.322,"Understanding Dexcom’s Risk Factors Amid Climate Change California-based Dexcom (DXCM) is a global medical device company that makes glucose monitoring systems for people with diabetes. It recently introduced a new product named Dexcom ONE to expand access to healthcare for people suffering from diabetes. Additionally, the company recently received FDA clearance for two software solutions that enhance its products. With this in mind, we used TipRanks to take a look at the latest financial performance and newly added risk factors for Dexcom. (See Top Smart Score Stocks on TipRanks) Q3 Financial Results Dexcom reported revenue of $650.2 million for Q3 2021, compared to $500.9 million in the same quarter last year. It posted EPS of $0.71, beating the consensus estimate of $0.63 but declining from $0.73 in the same quarter last year. Dexcom ended Q3 with $2.7 billion of liquidity, consisting of cash and a revolving credit facility. The company ended the quarter with $1.7 billion in long-term debt tied to senior convertible notes. For full-year 2021, the company anticipates revenue in the band of $2.43 billion to $2.45 billion. (See Dexcom stock charts on TipRanks). Risk Factors According to the new TipRanks Risk Factors tool, Dexcom’s main risk category is Finance and Corporate, representing 33% of the total 75 risks identified for the stock. The company recently added a new risk factor under the Macro and Political category, which accounts for 5% of its total risks. The company informs investors that it has manufacturing sites in California and Arizona and that these states have experienced annual wildfires and intensifying drought. It notes that these challenges could make it difficult for its employees to commute to work, and those working from home may experience connectivity problems due to power outages. Dexcom further says that it has major operations in Malaysia and the Philippines and that extreme weather events in these regions could damage important infrastructure and disrupt its operations. Therefore, the company wants investors to know that climate change may have a long-term adverse effect on its business. In an updated Legal and Regulatory risk factor, Dexcom reminds investors that it believes the way it markets and promotes its products comply with regulatory requirements. However, its marketing activities may be branded as misleading and it cautions that such could result in injunctions and significant penalties. The Finance and Corporate risk factor’s sector average is 29%, compared to Dexcom’s 33%. The Legal and Regulatory risk factor’s sector average is 20%, compared to Dexcom’s 27%. Dexcom’s stock has gained about 45% year-to-date. Analysts’ Take Following Dexcom’s Q3 earnings report, Piper Sandler analyst Matthew O'Brien reiterated a Buy rating on Dexcom stock and raised the price target $750 from $675. O'Brien’s new price target suggests 40.10% upside potential. Consensus among analysts is a Strong Buy based on 10 Buys and 3 Holds. The average Dexcom price target of $649 implies 21.23% upside potential to current levels. Related News: Robinhood Snaps Up Crypto Trading Platform Cove Markets — Report Canaccord Genuity Acquires Punter Southall Wealth CP Rail Completes KCS Acquisition; Shares Pop The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-12-16,135.058,136.122,131.742,132.34,"Here's Why Investors Should Consider DexCom Stock Healthcare stock DexCom (NASDAQ: DXCM) has a track record of tremendous business growth and share price appreciation that has remained consistent and robust during the pandemic. In fact, shares are up 50% over the trailing 12 months. In this segment of Backstage Pass, recorded on Dec. 1, Fool contributors Rachel Warren and Brian Feroldi discuss the stock's recent earnings, its high valuation, and its long-term growth prospects. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 10, 2021 Rachel Warren: This is another company I talk about fairly frequently and it's a healthcare stock I really like. For anyone who's not familiar, DexCom develops and manufactures continuous glucose monitoring systems used by type 1 and type 2 diabetics around the world. DexCom's customer base includes both individual patients as well as providers. The company remains one of the top players in the multi-billion-dollar CGM market even though it has faced increased competition in recent years. The current model that it sells is its G6 continuous glucose monitoring device. This features a sensor with a 10-day wear time that users insert beneath the skin with a one-touch applicator. It only releases one generation of its system at a time. The next one the G7 is expected to be launched as soon as this quarter. Shares of DexCom. This has been a high-flying stock. It's gained about 780% over the trailing-five-year period, more than 50% over the past six months alone. This is a stock that I think a lot of investors including myself are very excited about. Just a quick highlight of the third-quarter performance revenue was up 30% year over year for a total of $650 million, U.S. revenue growth was up 23% year over year while its international revenue in the third quarter were up 57% year over year. Its gross profits on a GAAP basis totaled almost 69% of its revenue for the third-quarter. Net income was down slightly although operating income grew to $118 million compared to $94 million in the third-quarter of last year. The company has a really strong cash position. It closed the most recent quarter with about $2.7 billion in cash, cash equivalents, and marketable securities compared to $735 million in total current liabilities. This is a great company with a really strong growth trajectory in a very lucrative industry. I think its next-generation CGM system, which is about to release is also going to be very key for it to remain competitive. One of the company's top competitors at Abbott with its FreeStyle Libre, which notably has a longer wear time. Wear time translates to expense for the consumer. So that also translates to more customers, or less customers for Dexcom so I'm very excited to see where this company is headed in the next few years. Brian Feroldi: Brian just mentioned selling Apple in 2010. I sold DexCom in 2006 for about $7 per share. It's currently $560 so oops. [laughs] But DexCom has done really well. It's been one of the best-performing stocks in the market over the last 10 plus years. Today, this stock trades at 151 times forward earnings. In your opinion, is the price-to-earnings ratio a good metric to look at to judge this company's value? Warren: I think it's a great metric to look at. I don't think it tells the entire story for this company. I think DexCom is one of those healthcare stocks that's had an astronomical track record of share price growth. It trades at a very high valuation. There's definitely no doubt about that, particularly for a healthcare stock. I think this comes down to a few things. I think there's a lot of robust investor sentiment around the stock and I think the fact that this is a company that essentially dominates the space that it's in. This is a company that grew its revenue 43% in 2019, 31% in 2020. It operates in an industry and leads an industry that generates consistent demand and has plenty of untapped growth potential left. There was a study done in 2020 by a company called Bigfoot Biomedical and it reported that only one in four potential CGM users actually use this device, which means that DexCom has a lot of runway left to tap into users it hasn't yet reached, potential customers within the CGM industry. I think if you weigh all of these factors as well as DexCom's leadership in this industry, it's P/E ratio makes more sense. It's high, but to me it's worth it for this company. Brian Feroldi: OK. Thank you. Brian Feroldi has no position in any of the stocks mentioned. Rachel Warren owns Apple and DexCom. The Motley Fool owns and recommends Apple. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2021-12-17,132.815,140.345,131.962,138.835,"[""Friday Sector Leaders: Healthcare, Technology & Communications Looking at the sectors faring best as of midday Friday, shares of Healthcare companies are outperforming other sectors, higher by 0.8%. Within that group, DexCom Inc (Symbol: DXCM) and Moderna Inc (Symbol: MRNA) are two large stocks leading the way, showing a gain of 5.6% and 4.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is flat on the day on the day, and up 23.63% year-to-date. DexCom Inc, meanwhile, is up 51.20% year-to-date, and Moderna Inc is up 182.45% year-to-date. Combined, DXCM and MRNA make up approximately 2.8% of the underlying holdings of XLV. The next best performing sector is the Technology & Communications sector, up 0.7%. Among large Technology & Communications stocks, Cerner Corp. (Symbol: CERN) and PTC Inc (Symbol: PTC) are the most notable, showing a gain of 13.9% and 4.7%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is down 0.2% in midday trading, and up 30.39% on a year-to-date basis. Cerner Corp., meanwhile, is up 16.23% year-to-date, and PTC Inc is up 1.14% year-to-date. PTC makes up approximately 0.1% of the underlying holdings of XLK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, three sectors are up on the day, while six sectors are down. SECTOR % CHANGE Healthcare +0.8% Technology & Communications +0.7% Services +0.2% Materials -0.1% Utilities -0.4% Industrial -0.4% Consumer Products -0.5% Financial -0.8% Energy -1.4% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""VO, DXCM, MSCI, SNPS: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $985.5 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 218,743,061 to 222,721,814). Among the largest underlying components of VO, in trading today DexCom Inc (Symbol: DXCM) is up about 0.5%, MSCI Inc (Symbol: MSCI) is off about 1.8%, and Synopsys Inc (Symbol: SNPS) is lower by about 0.9%. For a complete list of holdings, visit the VO Holdings page \u00bb The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $201.879 per share, with $261.53 as the 52 week high point \u2014 that compares with a last trade of $246.11. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-12-20,137.59,138.082,133.863,136.222,
DXCM,2021-12-21,137.422,141.575,136.92,141.475,
DXCM,2021-12-22,140.938,143.322,140.938,143.198,
DXCM,2021-12-23,143.75,144.962,143.002,143.002,
DXCM,2021-12-27,143.572,143.782,141.43,142.47,
DXCM,2021-12-28,142.75,143.068,132.2,132.375,"[""Nasdaq 100 Movers: DXCM, ATVI In early trading on Tuesday, shares of Activision Blizzard, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.4%. Year to date, Activision Blizzard has lost about 27.8% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 3.4%. DexCom is showing a gain of 48.9% looking at the year to date performance. Two other components making moves today are JD.com, trading down 2.8%, and Moderna, trading up 2.4% on the day. VIDEO: Nasdaq 100 Movers: DXCM, ATVI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tuesday Sector Laggards: Technology & Communications, Healthcare In afternoon trading on Tuesday, Technology & Communications stocks are the worst performing sector, showing a 0.7% loss. Within that group, Etsy Inc (Symbol: ETSY) and Epam Systems, Inc. (Symbol: EPAM) are two large stocks that are lagging, showing a loss of 3.9% and 2.6%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 0.7% on the day, and up 35.77% year-to-date. Etsy Inc, meanwhile, is up 24.09% year-to-date, and Epam Systems, Inc. is up 89.38% year-to-date. EPAM makes up approximately 0.3% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 0.5% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Moderna Inc (Symbol: MRNA) are the most notable, showing a loss of 6.8% and 3.0%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.5% in midday trading, and up 25.19% on a year-to-date basis. DexCom Inc, meanwhile, is up 43.65% year-to-date, and Moderna Inc is up 129.13% year-to-date. Combined, DXCM and MRNA make up approximately 2.7% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, seven sectors are up on the day, while two sectors are down. SECTOR % CHANGE Utilities +0.8% Materials +0.5% Consumer Products +0.3% Industrial +0.3% Services +0.2% Financial +0.2% Energy +0.1% Healthcare -0.5% Technology & Communications -0.7% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Monster Growth Stocks in the Making Those who invested early in such companies as Amazon and Netflix and held their shares for a while are undoubtedly happy they did so. Both tech giants have delivered market-shattering returns in the past 20 years. Both companies still look attractive today, but getting in on the ground floor would have been even better. Unless you have a time machine, though, that's not an option. Thankfully, there are other rising companies that could go on to become giants -- at least, in their respective industries -- and handsomely reward shareholders in the process. Two such companies that deserve consideration are Tandem Diabetes Care (NASDAQ: TNDM) and Planet 13 Holdings (OTC: PLNH.F). TNDM data by YCharts 1. Tandem Diabetes Care As a company seeks long-term success, it helps to be a leader in an industry ripe for growth. That description fits Tandem Diabetes Care. The company focuses on developing innovative insulin pumps for diabetes patients. Tandem's crown jewel, the t:slim X2 insulin pump, prides itself on ease of use and an automatic insulin delivery system (when paired with DexCom's G6 continuous glucose monitoring system), among other perks. There is no denying the growth opportunities in this market. In the U.S., 64% of type 1 diabetes patients currently rely on painful and multiple daily injections (MDIs) instead of insulin pumps. In other words, while insulin pumps continue to make headway in the country, there remains a sizable portion of the patient population to win over, which is good news for Tandem. Note that the percentage of the population with diabetes is projected to continue growing. While that's not great news, it means there will be an increasing need for products like the t:slim X2. Image source: Getty Images. Tandem continues to increase its top line at a good clip. In the third quarter, it recorded sales of $179.6 million, 45% higher than the year-ago period. That was on the back of 31,558 pumps shipped for the quarter, a 43% increase over last year. Tandem ended the quarter with nearly 300,000 customers worldwide. On the bottom line, the company's net income came in at $5.8 million compared to the net loss of $9.4 million it reported in Q3 of last year. For the fourth quarter, Tandem expects sales of $685 million to $695 million, which would represent year-over-year growth of 37% to 39%. In other words, business is going well for the company. There is more to look forward to ahead. The company is now aggressively expanding its operations abroad to approximately 110 territories. While these efforts could increase expenses and shrink the bottom line in the short run, they are well worth it in the long run. An even greater opportunity is outside the U.S., where penetration in this market stands at a mere 12%. Tandem also has to deal with competition, but it's doing well on that front; roughly 50% of its consumers switched from a competitor's insulin pump, not to mention first-time pump users who have switched from daily injections. Tandem looks like it has the tools to provide excellent returns for many years to come. 2. Planet 13 Holdings The pot market is another lucrative, long-term opportunity. According to some estimates, the industry will expand at a compound annual growth rate of 13.9% through 2026. Planet 13 Holdings takes a slightly different approach than most of its peers in this sector. Like others, the company sells various marijuana products, including cannabis flower, edibles, vape products, and more. But it also seeks to make cannabis shopping more of an experience with its superstore, which is strategically located on the Las Vegas strip. In this entertainment complex, as Planet 13 calls it, visitors can observe the company's cannabis production process, grab a bite to eat or a cup of coffee, and take part in other activities. Planet 13 justifies its approach with the following statistic: 74% of Americans prioritize experiences over products. That's why superstores of the kind it runs in Las Vegas feature squarely in Planet 13's long-term strategy. In June, the company opened its second store in Orange County, California. This store is touted as California's largest cannabis dispensary complex. The company's master plan is to open at least eight such stores in various attractive markets in the U.S. in the next five years. It also plans to open smaller \""neighborhood stores\"" across the country. For the third quarter, Planet 13 reported revenue of $33 million, a 45% increase over the year-ago period. The company isn't consistently profitable yet -- it recorded a net loss of $10.2 million in the quarter vs. net income of $0.2 million in the third quarter of 2020. Most pot companies are currently unprofitable, and that's one thing that makes the sector highly volatile to practically every bit of news. That said, given Planet 13 Holdings' unique strategy in the cannabis industry as well as the sector's growth potential, it is reasonable to be patient with the red ink, at least for now. The more immediate challenge for Planet 13 -- and so many other businesses -- is the pandemic, which affected foot traffic in its Las Vegas superstore in 2020. But the company was able to smooth out the losses due to the outbreak by taking advantage of curbside pickup and delivery options for its products. As a result, it navigated last year relatively well with its revenue rising 10.8% to $70.5 million. The first half of this year has been strong again. In March, Planet 13 reported sales of $9.7 million, a record for any single month. It went on to beat that record in April and then again in May. However the stock has been sinking in recent months. With new variants of the coronavirus popping up in the second half of the year, investors may be worried that as the pandemic drags on, it will continue to affect Planet 13's business. But given that the company has already shown it can navigate current conditions, this need not be cause for too much concern. Planet 13's long-term plan isn't guaranteed to work. The company is still looking to establish a stronger presence across the U.S. It's also still a pretty small company with a market cap of just over $600 million and a stock price hovering at $3.15 per share. That makes this marijuana company a bit risky, but the upside could be enormous too, especially for investors who get in on the action at current levels. 10 stocks we like better than Tandem Diabetes Care When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns and recommends Planet 13 Holdings Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: DXCM, CCL In early trading on Tuesday, shares of Carnival topped the list of the day's best performing components of the S&P 500 index, trading up 3.4%. Year to date, Carnival has not really moved. And the worst performing S&P 500 component thus far on the day is DexCom, trading down 3.3%. DexCom is showing a gain of 49.1% looking at the year to date performance. Two other components making moves today are Nucor, trading down 1.5%, and Moderna, trading up 2.9% on the day. VIDEO: S&P 500 Movers: DXCM, CCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2021-12-29,133.995,133.995,131.689,133.85,
DXCM,2021-12-30,133.175,136.938,132.975,135.328,
DXCM,2021-12-31,136.038,136.804,134.095,134.238,
DXCM,2022-01-03,132.95,133.198,128.25,130.197,"S&P 500 Movers: MRNA, TSLA In early trading on Monday, shares of Tesla topped the list of the day's best performing components of the S&P 500 index, trading up 8.7%. Year to date, Tesla registers a 8.7% gain. And the worst performing S&P 500 component thus far on the day is Moderna, trading down 7.8%. Moderna is lower by about 7.8% looking at the year to date performance. Two other components making moves today are DexCom, trading down 4.2%, and ViacomCBS, trading up 6.4% on the day. VIDEO: S&P 500 Movers: MRNA, TSLA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-01-04,129.275,129.95,125.738,128.068,
DXCM,2022-01-05,126.835,128.583,121.915,121.952,"[""DexCom Becomes Oversold (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $487.87 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 50.3. A bullish investor could look at DXCM's 28.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $318.45 per share, with $659.4518 as the 52 week high point \u2014 that compares with a last trade of $487.81. Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Implied Analyst 12-Month Target For IYH Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $325.82 per unit. With IYH trading at a recent price near $292.98 per unit, that means that analysts see 11.21% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are United Therapeutics Corp (Symbol: UTHR), Bruker Corp (Symbol: BRKR), and DexCom Inc (Symbol: DXCM). Although UTHR has traded at a recent price of $199.08/share, the average analyst target is 18.04% higher at $235.00/share. Similarly, BRKR has 14.44% upside from the recent share price of $79.14 if the average analyst target price of $90.57/share is reached, and analysts on average are expecting DXCM to reach a target price of $573.06/share, which is 11.87% above the recent price of $512.27. Below is a twelve month price history chart comparing the stock performance of UTHR, BRKR, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET iShares U.S. Healthcare ETF IYH $292.98 $325.82 11.21% United Therapeutics Corp UTHR $199.08 $235.00 18.04% Bruker Corp BRKR $79.14 $90.57 14.44% DexCom Inc DXCM $512.27 $573.06 11.87% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-01-06,121.532,123.609,120.1,120.75,
DXCM,2022-01-07,120.75,123.0,117.788,117.872,
DXCM,2022-01-10,111.042,115.748,108.868,115.585,"[""IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today InvestorPlace - Stock Market News, Stock Advice & Trading Tips Irhythm Technologies (NASDAQ:IRTC) stock is rising higher Monday alongside heavy trading of the shares. Source: ESB Professional/Shutterstock.com Let\u2019s dive into that news, as well as what else traders need to know about IRTC stock below! First off, the company\u2019s roughly 2 million shares of its stock change hands as of this writing. That\u2019s already above the company\u2019s daily average trading volume of about 477,000 shares. This comes despite any official news from the company. Instead, it looks like holders of ITRC stock have Novitas Solutions to thank for today\u2019s rise. Novitas Solutions is a Medicare Administrative Contractor (MAC). BTIG analyst Marie Thibault says that Novitas recently updated its reimbursement rates. That includes External Electrocardiographic Recording CPT codes 93243 and 93247. The new rates are $222 and $232 and retroactively go into effect on Jan. 1, 2022. 7 Safe Stocks for Your Retirement For the record, the old rates were $103 and $115 and were set back in April 2021. While iRhythm has yet to comment on the matter, this looks like good news for IRTC stock. Irhythm Technologies is a digital healthcare company focused on cardiac arrhythmias. This has it seeking to be a leader in the ambulatory electrocardiogram space. It plans to do so through its \u201cwearable biosensing technology with cloud-based data analytics and machine-learning capabilities.\u201d The company was founded in 2008 and is based out of San Francisco, Calif. Quentin Blackford leads the company as president and CEO and has been with it since last year. Prior to that, he was the COO at DexCom (NASDAQ:DXCM). Irhythm Technologies market capitalization is $3.764 billion. IRTC stock is up 25.7% as of Monday afternoon. There\u2019s morestock market newsfor investors to sink their teeth into below! We\u2019ve got all the most recent stock coverage that traders need to know about for Monday. That includes sports betting stocks falling, PayPal (NASDAQ:PYPL) crypto plans, and FuboTV (NYSE:FUBO) earnings. You can get up to speed on these subjects at the following links! More Stock Market News for Monday Sports Betting Stocks Alert: A Big Catalyst Is Underway for RSI, PDYPY, CZR, DKNG Stocks PayPal Coin May Come Soon as the Payment Company Embraces Crypto fuboTV Just Reported Q4 Results: 7 Things to Know as FUBO Stock Slips On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. The post IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 01/10/2022: APR, OMI, BMRN, DXCM, XLV, IBB Health care stocks were slipping premarket Monday with the Health Care SPDR (XLV) declining by 0.35% and the iShares Biotechnology ETF (IBB) recently down by 0.46%. Apria (APR) was gaining 25% after Owens & Minor (OMI) said it agreed to acquire the company in a deal worth about $1.6 billion. Under the terms of the deal, the Virginia-based medical distributor will pay a consideration of $37.50 per share of Apria common stock, representing an equity value of about $1.45 billion, plus the assumption of debt. BioMarin Pharmaceutical (BMRN) was up more than 3% after saying its investigational valoctocogene roxaparvovec drug reduced the annual bleeding rate in hemophilia A patients, based on data from its global late-stage trial. DexCom (DXCM) said it expects Q4 and full-year 2021 revenue of roughly $698 million and $2.45 billion, respectively. Analysts polled by Capital IQ anticipate revenue of $696 million for Q4 and $2.45 billion for 2021. DexCom was recently retreating by more than 8%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-01-11,116.018,120.675,115.572,120.292,
DXCM,2022-01-12,121.615,125.349,120.912,122.595,
DXCM,2022-01-13,122.29,122.29,113.808,113.945,"[""Thursday Sector Laggards: Technology & Communications, Healthcare The worst performing sector as of midday Thursday is the Technology & Communications sector, showing a 1.0% loss. Within that group, ServiceNow Inc (Symbol: NOW) and Lumen Technologies Inc (Symbol: LUMN) are two of the day's laggards, showing a loss of 7.2% and 6.3%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 1.3% on the day, and down 4.26% year-to-date. ServiceNow Inc, meanwhile, is down 18.01% year-to-date, and Lumen Technologies Inc, is down 0.80% year-to-date. NOW makes up approximately 1.0% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 0.5% loss. Among large Healthcare stocks, Bio-Techne Corp (Symbol: TECH) and DexCom Inc (Symbol: DXCM) are the most notable, showing a loss of 5.8% and 4.8%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.9% in midday trading, and down 4.05% on a year-to-date basis. Bio-Techne Corp, meanwhile, is down 21.99% year-to-date, and DexCom Inc, is down 13.09% year-to-date. Combined, TECH and DXCM make up approximately 1.2% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Thursday. As you can see, seven sectors are up on the day, while two sectors are down. SECTOR % CHANGE Consumer Products +0.9% Services +0.9% Industrial +0.6% Utilities +0.5% Materials +0.5% Financial +0.4% Energy +0.3% Healthcare -0.5% Technology & Communications -1.0% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: LUMN, SEDG In early trading on Thursday, shares of SolarEdge Technologies topped the list of the day's best performing components of the S&P 500 index, trading up 5.7%. Year to date, SolarEdge Technologies has lost about 1.7% of its value. And the worst performing S&P 500 component thus far on the day is Lumen Technologies, trading down 6.0%. Lumen Technologies is lower by about 0.5% looking at the year to date performance. Two other components making moves today are DexCom, trading down 3.2%, and Lam Research, trading up 5.6% on the day. VIDEO: S&P 500 Movers: LUMN, SEDG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-01-14,113.28,116.442,109.492,111.835,
DXCM,2022-01-18,109.702,110.74,107.138,107.468,"Vanguard Mid-Cap ETF Experiences Big Inflow Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $979.5 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 222,721,814 to 226,733,710). Among the largest underlying components of VO, in trading today Marvell Technology Inc (Symbol: MRVL) is off about 2.2%, Xilinx, Inc. (Symbol: XLNX) is down about 1.8%, and DexCom Inc (Symbol: DXCM) is lower by about 1.8%. For a complete list of holdings, visit the VO Holdings page » The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $204.371 per share, with $261.53 as the 52 week high point — that compares with a last trade of $240.52. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-01-19,108.765,112.11,108.558,108.808,"Is DexCom, Inc. (NASDAQ:DXCM) Worth US$430 Based On Its Intrinsic Value? Today we will run through one way of estimating the intrinsic value of DexCom, Inc. (NASDAQ:DXCM) by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. What's the estimated valuation? We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars: 10-year free cash flow (FCF) estimate 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 Levered FCF ($, Millions) US$246.5m US$415.5m US$724.4m US$944.1m US$1.11b US$1.25b US$1.37b US$1.47b US$1.56b US$1.63b Growth Rate Estimate Source Analyst x3 Analyst x3 Analyst x1 Analyst x1 Est @ 17.56% Est @ 12.88% Est @ 9.6% Est @ 7.31% Est @ 5.71% Est @ 4.58% Present Value ($, Millions) Discounted @ 5.9% US$233 US$370 US$609 US$750 US$832 US$887 US$918 US$930 US$928 US$916 (""Est"" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF) = US$7.4b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 5.9%. Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$1.6b× (1 + 2.0%) ÷ (5.9%– 2.0%) = US$42b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$42b÷ ( 1 + 5.9%)10= US$24b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$31b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$430, the company appears reasonably expensive at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. NasdaqGS:DXCM Discounted Cash Flow January 19th 2022 The assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at DexCom as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.9%, which is based on a levered beta of 0.906. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Looking Ahead: Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to ""what assumptions need to be true for this stock to be under/overvalued?"" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value lower than the current share price? For DexCom, we've compiled three further elements you should explore: Risks: We feel that you should assess the 3 warning signs for DexCom (1 is significant!) we've flagged before making an investment in the company. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for DXCM's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-01-20,109.502,113.738,108.488,108.66,
DXCM,2022-01-21,108.61,108.61,105.295,105.525,"First Week of September 16th Options Trading For DexCom (DXCM) Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new September 16th contracts and identified one put and one call contract of particular interest. The put contract at the $410.00 strike price has a current bid of $51.60. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $410.00, but will also collect the premium, putting the cost basis of the shares at $358.40 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $425.28/share today. Because the $410.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 61%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 12.59% return on the cash commitment, or 19.30% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $410.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $430.00 strike price has a current bid of $57.90. If an investor was to purchase shares of DXCM stock at the current price level of $425.28/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $430.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.72% if the stock gets called away at the September 16th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $430.00 strike highlighted in red: Considering the fact that the $430.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 45%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 13.61% boost of extra return to the investor, or 20.88% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 49%, while the implied volatility in the call contract example is 48%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $425.28) to be 38%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-01-24,103.849,106.888,100.648,106.708,"[""Notable Monday Option Activity: DXCM, TWTR, WFC Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 5,568 contracts have traded so far, representing approximately 556,800 underlying shares. That amounts to about 68.1% of DXCM's average daily trading volume over the past month of 817,260 shares. Especially high volume was seen for the $440 strike call option expiring March 18, 2022, with 821 contracts trading so far today, representing approximately 82,100 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $440 strike highlighted in orange: Twitter Inc (Symbol: TWTR) options are showing a volume of 91,757 contracts thus far today. That number of contracts represents approximately 9.2 million underlying shares, working out to a sizeable 62% of TWTR's average daily trading volume over the past month, of 14.8 million shares. Especially high volume was seen for the $32 strike put option expiring January 28, 2022, with 10,119 contracts trading so far today, representing approximately 1.0 million underlying shares of TWTR. Below is a chart showing TWTR's trailing twelve month trading history, with the $32 strike highlighted in orange: And Wells Fargo & Co (Symbol: WFC) saw options trading volume of 181,988 contracts, representing approximately 18.2 million underlying shares or approximately 61.4% of WFC's average daily trading volume over the past month, of 29.6 million shares. Particularly high volume was seen for the $53 strike put option expiring January 28, 2022, with 10,636 contracts trading so far today, representing approximately 1.1 million underlying shares of WFC. Below is a chart showing WFC's trailing twelve month trading history, with the $53 strike highlighted in orange: For the various different available expirations for DXCM options, TWTR options, or WFC options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""This Insider Has Just Sold Shares In DexCom, Inc. (NASDAQ:DXCM) We wouldn't blame DexCom, Inc. (NASDAQ:DXCM) shareholders if they were a little worried about the fact that Kevin Sayer, the Executive Chairman recently netted about US$8.6m selling shares at an average price of US$435. That sale reduced their total holding by 24% which is hardly insignificant, but far from the worst we've seen. DexCom Insider Transactions Over The Last Year In fact, the recent sale by Kevin Sayer was the biggest sale of DexCom shares made by an insider individual in the last twelve months, according to our records. So we know that an insider sold shares at around the present share price of US$422. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign. DexCom insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! NasdaqGS:DXCM Insider Trading Volume January 24th 2022 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them). Does DexCom Boast High Insider Ownership? For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that DexCom insiders own 0.5% of the company, worth about US$203m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. So What Does This Data Suggest About DexCom Insiders? Insiders haven't bought DexCom stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. But it is good to see that DexCom is growing earnings. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that DexCom is showing 3 warning signs in our investment analysis, and 1 of those is a bit concerning... But note: DexCom may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-01-25,104.0,104.68,99.79,101.558,"2 Growth Stocks I'd Buy Right Now Concerns surrounding interest rate hikes and frothy valuations have turned the market against growth stocks, and many of these companies are suffering as a result. But amid these headwinds, it's more important than ever for investors to keep a long-term mindset. Even if they lag the market in the coming months, some growth stocks have what it takes to deliver above-average returns in the next decade and beyond. Let's look at two such promising stocks: Tandem Diabetes Care (NASDAQ: TNDM) and Fiverr International (NYSE: FVRR). TNDM data by YCharts 1. Tandem Diabetes Care Tandem Diabetes Care develops medical devices to help make the lives of diabetes patients a bit easier. Diabetes is, of course, a severe chronic health condition, but worse, the number of patients suffering from this illness is projected to continue growing rapidly. That means there will be an increasing need for the types of products Tandem Diabetes makes. The company's crown jewel at the moment is the t:slim X2 insulin pump, which makes up the lion's share of its sales. There are three reasons why this product is attractive to diabetes patients. First, insulin pumps are much less painful than injections, the primary alternative way for people with diabetes to manage their blood sugar levels. Second, there is evidence that insulin pumps help diabetes patients achieve better health outcomes. Third, the t:slim X2 insulin pump is smaller than competing products, and it boasts other innovative features such as the ability to be paired up with DexCom's continuous glucose monitoring system, the G6, for automatic insulin delivery. Image source: Getty Images. These factors help explain why Tandem Diabetes continues to deliver solid revenue growth. In the third quarter (ended Sept. 30), the company's sales jumped 45% year over year to $179.6 million. The company's worldwide pump shipment grew by 43% year over year to 31,558. Further, Tandem Diabetes turned the net loss of $9.4 million it recorded during the year-ago period into a net income of $5.8 million this time around. Tandem Diabetes hasn't been profitable for that long, and it is still not consistently so. But the massive opportunities at its disposal in the diabetes market will help on that front. In the U.S., only 36% of patients with type 1 diabetes use insulin pumps. That number is only 12% abroad, which shows that there remains significant room for growth in this market. That's why the stock market's recent worries shouldn't stop investors from buying shares of this exciting healthcare stock. 2. Fiverr International Fiverr helps connect freelancers to those who need professional services. The company's success -- and future -- are tied to the rise of the gig economy, which experienced a boom during the pandemic. But this isn't just a pandemic trend. Both freelancers and the businesses who seek their services benefit from this rising megatrend. For a company, it is easier, cheaper, and faster to hire a freelancer as opposed to an employee. In other words, it helps the business save time and money. And naturally, Fiverr helps professionals easily and quickly start a side gig. The company makes money by charging transaction fees to both buyers and sellers on its platform. In the third quarter (ended Sept. 30), Fiverr's revenue jumped by 42% year over year to $74.3 million. Notably, the number of active buyers on the platform continues to grow -- registering a 33% year-over-year increase in the third quarter to 4.1 million. Image source: Getty Images. However, attaining profitability is still a challenge. The company recorded a net loss of $14.3 million during the third quarter, which was much worse than the net loss of $454,000 reported during the year-ago period. The red ink on the bottom line may be a worry for some investors, especially considering current market conditions. Those companies that remain unprofitable are likely to get hit harder by whatever the market has in store for growth stocks. Fiverr's shares are already down by almost 70% in the past year, mainly because the increased activity it experienced at the peak of the pandemic cooled down significantly. But once again, what matters is the company's long-term thesis. The online gig economy is arguably still in its infancy. Fiverr estimates its addressable market to be $115 billion. And one thing that will help the company capture even a fraction of this market is its growing competitive edge. Buyers seeking top freelancers will tend to gravitate toward those platforms with the largest pool of potential workers to choose from, one of which is Fiverr. Meanwhile, freelancers seeking a vast clientele will turn to the most popular online marketplace, and so forth, in a powerful demonstration of the network effect. That should help Fiverr produce increasingly strong financial results, turn the losses into earnings, and perform better than the broader market over the long run. 10 stocks we like better than Tandem Diabetes Care When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns and recommends Fiverr International. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-01-26,103.335,104.4,97.5025,98.9575,
DXCM,2022-01-27,100.038,100.47,95.505,95.88,
DXCM,2022-01-28,96.74,103.5,95.51,103.348,"[""Friday Sector Leaders: Services, Healthcare Looking at the sectors faring best as of midday Friday, shares of Services companies are outperforming other sectors, up 0.9%. Within that group, Discovery Inc (Symbol: DISCA) and Discovery Inc - Series C (Symbol: DISCK) are two of the day's stand-outs, showing a gain of 6.3% and 6.2%, respectively. Among the largest ETFs, one ETF closely following services stocks is the iShares U.S. Consumer Services ETF (Symbol: IYC), which is up 0.4% on the day, and down 14.26% year-to-date. Discovery Inc, meanwhile, is up 13.95% year-to-date, and Discovery Inc - Series C is up 14.74% year-to-date. Combined, DISCA and DISCK make up approximately 0.2% of the underlying holdings of IYC. The next best performing sector is the Healthcare sector, up 0.7%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) are the most notable, showing a gain of 5.9% and 4.7%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.7% in midday trading, and down 8.57% on a year-to-date basis. DexCom Inc, meanwhile, is down 24.37% year-to-date, and Vertex Pharmaceuticals, Inc. is up 8.84% year-to-date. Combined, DXCM and VRTX make up approximately 2.0% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, four sectors are up on the day, while five sectors are down. SECTOR % CHANGE Services +0.9% Healthcare +0.7% Utilities +0.5% Technology & Communications +0.5% Industrial -0.1% Financial -0.2% Consumer Products -0.5% Materials -0.6% Energy -1.1% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Insulet Stock Is Jumping Higher on Friday What happened Shares of Insulet (NASDAQ: PODD), a medical device company, are jumping in response to regulatory approval of a new product. Investors excited about the company's new automated insulin delivery system pushed the stock 15% higher as of 11:57 a.m. ET on Friday. So what Today the company announced the FDA has finally approved OmniPod 5 after several long delays. Omnipod 5 is the first tubeless automated insulin delivery system that integrates with a popular continuous glucose monitor from DexCom (NASDAQ: DXCM). Image source: Getty Images. The FDA granted Omnipod clearance for type 1 diabetes patients age 6 or older. Together with a smartphone, the new device allows patients and their parents to manage blood sugar levels without injections, tubes, or finger sticks. Now what Every five minutes, Omnipod 5 receives a reading from the DexCom glucose monitor and injects insulin accordingly. This allows for heaps more time in a safe blood sugar range. Omnipod 5 isn't cheap, but it's going to be a lot less expensive than trips to the emergency room when patients' blood sugar levels spike or crash. Constant glucose monitoring is so popular with patients and their health plans that finger pokes and strips of paper are quickly becoming a thing of the past. As the first tubeless automated insulin delivery system, Omnipod 5 could become Insulet's most successful product yet, but we probably won't see strong sales in the first quarter of 2022. The company's planning a limited market release until it's worked out any potential kinks. 10 stocks we like better than Insulet When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Insulet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-01-31,103.75,108.062,103.75,107.62,"EXCLUSIVE-U.S. diabetes deaths top 100,000 for second straight year, federal panel urges new strategy By Chad Terhune and Robin Respaut Jan 31 (Reuters) - More than 100,000 Americans died from diabetes in 2021, marking the second consecutive year for that grim milestone and spurring a call for a federal mobilization similar to the fight against HIV/AIDS. The new figures come as an expert panel urges Congress to overhaul diabetes care and prevention, including recommendations to move beyond a reliance on medical interventions alone. A report released earlier this month calls for far broader policy changes to stem the diabetes epidemic, such as promoting consumption of healthier foods, ensuring paid maternal leave from the workplace, levying taxes on sugary drinks and expanding access to affordable housing, among other areas. In 2019, diabetes was the seventh-leading cause of death in America and claimed more than 87,000 lives, reflecting a long-running failure to address the illness and leaving many more vulnerable when the COVID-19 pandemic hit, creating new hurdles to accessing care. Since then, the nation’s toll from diabetes has increased sharply, surpassing 100,000 deaths in each of the last two years and representing a new record-high level, according to a Reuters analysis of provisional death data compiled by the Centers for Disease Control and Prevention (CDC). Diabetes-related deaths surged 17% in 2020 and 15% in 2021 compared to the prepandemic level in 2019. That excluded deaths directly attributed to COVID-19. The CDC concurred with the Reuters analysis and said additional deaths from 2021 are still being tallied. ""The large number of diabetes deaths for a second year in a row is certainly a cause for alarm,"" said Dr. Paul Hsu, an epidemiologist at UCLA's Fielding School of Public Health. ""Type 2 diabetes itself is relatively preventable, so it's even more tragic that so many deaths are occurring."" In a new report, the National Clinical Care Commission created by Congress said that the United States must adopt a more comprehensive approach to prevent more people from developing type 2 diabetes, the most common form, and to help people who are already diagnosed avoid life-threatening complications. About 37 million Americans, or 11% of the population, have diabetes, and one in three Americans will develop the chronic disease in their lifetime if current trends persist, according to the commission. ""Diabetes in the U.S. cannot simply be viewed as a medical or health care problem, but also must be addressed as a societal problem that cuts across many sectors, including food, housing, commerce, transportation and the environment,"" the commission wrote in its Jan. 5 report to Congress and the U.S. Department of Health and Human Services (HHS). The federal panel recommended Congress create an Office of National Diabetes Policy that would coordinate efforts across the government and oversee changes outside health policy. It would be separate from HHS and could be similar to the White House Office of National AIDS Policy, according to Dr. William Herman, commission chairman and a professor of internal medicine and epidemiology at the University of Michigan. ""We aren’t going to cure the problem of diabetes in the United States with medical interventions,"" Herman told Reuters. ""The idea is to pull something together across federal agencies, so they are systematically talking to one another."" U.S. Senator Patty Murray, a Democrat from Washington who chairs the Senate health committee, helped create the commission in 2017 and said she is studying the recommendations closely. ""People with diabetes and other chronic illnesses were already facing challenges well before the pandemic hit, and COVID has only made these problems worse,"" Murray said in a statement to Reuters. ""It is absolutely crucial to research and find solutions to better support diabetes patients and get them the care they need."" MORE CASES, WORSE PROGNOSIS As Reuters reported last year in a series, diabetes represents a major public health failure in the United States. The number of Americans with the disease has exploded in recent decades, and their prognosis has worsened, even though spending on new treatments has soared. The pandemic has proven especially deadly for people with diabetes. People with poorly controlled diabetes have at least a two-fold greater risk of death from COVID-19, according to the report. And diabetes and its complications are more common in low-income Americans and people of color, longstanding disparities that were further exposed during the pandemic. Dr. Shari Bolen, a commission member and an associate professor of medicine at Case Western Reserve University and the MetroHealth System in Cleveland, said the staggering number of diabetes deaths is ""disheartening but also a call to action."" The federal panel's report marked the first such review on diabetes since 1975. During that time, the prevalence of diabetes among U.S. adults has increased from 5.3% in the late 1970s to 14.3% in 2018, it said. Direct medical costs related to diabetes were $237 billion in 2017, and there was an estimated $90 billion lost to lower productivity in the United States. High costs for doctor's visits, medications and supplies force many diabetes patients to forgo or delay routine care. Many patients and U.S. lawmakers have expressed outrage at the rising price of insulin, which type 1 diabetes patients must take their entire lives and which is sometimes required to keep type 2 patients’ disease under control. The commission endorsed proposals such as capping insulin price increases to the rate of inflation and government negotiation of drug prices. Murray and other lawmakers have pushed for a provision in the Biden administration's proposed Build Back Better legislation that would cap the cost of insulin at $35 for many patients. To further ease financial barriers, the panel recommended that patients’ out-of-pocket costs be waived for other ""high-value"" treatments, including certain diabetes drugs, continuous glucose monitors, basic supplies and diabetes education. The commission also highlighted the risks of overtreatment in older adults with type 2 diabetes. Reuters wrote about that risk in November and how a drug industry campaign for an aggressive treatment target led to an epidemic of potentially lethal incidents of low blood sugar, or hypoglycemia. The panel asked federal health officials to track overtreatment among Medicare patients to ""reduce the incidence of severe hypoglycemia and improve patient safety."" The commission said the United States should better promote the purchase of fruits and vegetables in food assistance programs and ensure mothers have paid family leave to aid breastfeeding, which can help reduce the risk of diabetes in mothers and is associated with a reduced risk of obesity and diabetes in children. The panel also recommended imposing taxes on sugary drinks that would raise their shelf price by 10% to 20% and using the revenue to expand access to clean drinking water and fund similar programs. HHS deferred comment to Herman. In a statement, the CDC said the report's recommendations offer a detailed roadmap to ""addressing rising health-care costs attributed to diabetes, and reducing racial, ethnic, and income-related disparities in diabetes outcomes."" (Reporting by Chad Terhune and Robin Respaut; Editing by Daniel Wallis) ((Chad.Terhune@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-01,108.525,109.678,106.172,108.76,
DXCM,2022-02-02,109.75,110.412,106.46,108.918,
DXCM,2022-02-03,107.855,109.522,104.12,104.682,"Earnings Preview: DexCom (DXCM) Q4 Earnings Expected to Decline DexCom (DXCM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 10. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This medical device company is expected to post quarterly earnings of $0.86 per share in its upcoming report, which represents a year-over-year change of -5.5%. Revenues are expected to be $696.68 million, up 22.5% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 6.17% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for DexCom? For DexCom, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.13%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that DexCom will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that DexCom would post earnings of $0.62 per share when it actually produced earnings of $0.89, delivering a surprise of +43.55%. Over the last four quarters, the company has beaten consensus EPS estimates three times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. DexCom doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Just Released: Zacks Top 10 Stocks for 2022 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022? From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-04,103.532,106.211,103.128,105.088,"DexCom (DXCM) to Report Q4 Earnings: What's in the Cards? DexCom, Inc. DXCM is scheduled to release fourth-quarter 2021 results on Feb 10, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 43.6%. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and matched once, the average surprise being 31.7%. Q4 Estimates Currently, the Zacks Consensus Estimate for fourth-quarter revenues is pegged at $696.7 million, suggesting growth of 22.5% from the year-ago reported figure. The consensus mark for earnings stands at 86 cents per share, indicating a decline of 5.5% from the prior-year quarter. Factors to Note DexCom’s fourth-quarter top line is likely to reflect an increase in volumes, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (“CGM”). In fact, per the preliminary announcement, DexCom — the leader in CGM — anticipates fourth-quarter 2021 revenues to be around $698 million (up 23% from the year-ago quarter). Per the third-quarter 2021earnings call the company continues to progress with its G7 scale-up and regulatory efforts and is on track to commence the launch of the system on receiving CE mark clearance. The company has managed to make substantial progress related to preparation for the regulatory submission in the United States. During the third quarter, the company launched Dexcom ONE, which is an important addition to its portfolio as DexCom continues to focus on widening access to healthcare for people with diabetes worldwide. DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote Per the third quarter of 2021 earnings release, the company completed the buyouts of its distributor in Australia and New Zealand, thereby advancing its strategy to transfer certain international markets from distributors to direct sales. During the same period, the company announced that its G6 CGM System is now covered by the Non-Insured Health Benefits (“NIHB”) program for diabetics aged between two and 19 requiring intensive insulin therapy. The expanded coverage is expected to provide a wider pool of First Nations, and Inuit children and adolescents access to the system, thereby potentially enabling them to better manage the life-long chronic illness. In September 2021, Dexcom announced that people with type 1 diabetes who are of 25 years of age or below may now be eligible for provincial coverage of the Dexcom G6 CGM System via Manitoba Health and Seniors Care. In the same month, the company announced that its G6 CGM System is now covered by the NIHB program for diabetics aged between two and 19 requiring intensive insulin therapy. These developments may have positively impacted the company’s performance in the to-be-reported quarter. DexCom has ample prospects in international markets backed by demographic trends and lifestyle in countries outside the United States and Europe. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In third-quarter 2021, international revenues (25% of total revenues) surged 57% year over year to $160.6 million. The momentum is likely to have continued in the fourth quarter, thanks to broad-based growth throughout all markets. However, an increase in operating expenses and intense competition may have weighed on the to-be-reported quarter’s performance. What Our Quantitative Model Suggests Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see. Earnings ESP: DexCom has an Earnings ESP of +1.13%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #4 (Sell). Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. AMN Healthcare Services, Inc. AMN has an Earnings ESP of +10.29% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. The company’s earnings yield of 5.5% compares favorably with the industry’s 0.8%. Henry Schein, Inc. HSIC has an Earnings ESP of +1.94% and a Zacks Rank of 2. Henry Schein’s long-term earnings growth rate is estimated at 11.8%. The company’s earnings yield of 5.9% compares favorably with the industry’s 4.1%. Laboratory Corporation of America Holdings LH, also popularly known as LabCorp, has an Earnings ESP of +9.21% and a Zacks Rank of 3. LabCorp’s long-term earnings growth rate is estimated at 10.6%. The company’s earnings yield of 6.8% compares favorably with the industry’s 4.3%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How to Profit from Trillions on Spending for Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-07,104.848,108.11,104.092,105.215,
DXCM,2022-02-08,104.5,106.698,103.29,106.382,"[""PDP's Underlying Holdings Could Mean 20% Gain Potential Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Momentum ETF (Symbol: PDP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $97.33 per unit. With PDP trading at a recent price near $81.08 per unit, that means that analysts see 20.04% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PDP's underlying holdings with notable upside to their analyst target prices are Masimo Corp. (Symbol: MASI), Coty, Inc. (Symbol: COTY), and DexCom Inc (Symbol: DXCM). Although MASI has traded at a recent price of $221.49/share, the average analyst target is 44.17% higher at $319.33/share. Similarly, COTY has 42.77% upside from the recent share price of $8.58 if the average analyst target price of $12.25/share is reached, and analysts on average are expecting DXCM to reach a target price of $566.33/share, which is 34.57% above the recent price of $420.86. Below is a twelve month price history chart comparing the stock performance of MASI, COTY, and DXCM: Below is a summary table of the current analyst target prices discussed above: Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Invesco DWA Momentum ETF PDP $81.08 $97.33 20.04% Masimo Corp. MASI $221.49 $319.33 44.17% Coty, Inc. COTY $8.58 $12.25 42.77% DexCom Inc DXCM $420.86 $566.33 34.57% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Unstoppable Growth Stocks to Buy in 2022 and Beyond While the market hasn't been in the best shape so far in 2022, that doesn't mean these woes will continue for the rest of the year. And even if they do, history tells us that the market eventually recovers from corrections. These otherwise stressful events create opportunities to buy shares of great companies for a discount. That's why investors shouldn't shy away from purchasing stocks right now. On that note, let's look at two companies that would be great additions to your portfolio this year and beyond: DexCom (NASDAQ: DXCM) and Visa (NYSE: V). DXCM data by YCharts. 1. DexCom Despite a recent sell-off, medical devices specialist DexCom has a bright future. The company currently makes most of its money from the sale of its G6 continuous glucose monitoring (CGM) system and accessories, which help diabetes patients keep track of their blood glucose levels. In recent years, the rapid adoption of this technology has been the driving force behind DexCom's revenue growth. For the full 2021 fiscal year, it expects to report revenue of $2.4 billion, an increase of about 27% compared to a year ago. Analysts expect the company's revenue to grow 18.5% annually through the next five years. Here are two reasons DexCom can continue performing well: First, it is currently working on the G7, a successor to the G6. According to the company, this new model will be 60% smaller and result in even better health outcomes for diabetes patients. DexCom has submitted an application to regulators in the U.S. for the G7, and the device could earn clearance sometime this year. Image source: DexCom. Given the success of the G6, investors can reasonably expect DexCom's next-gen device to see similar levels of enthusiasm within its target population. Second, the company has a massive market to tap. In the U.S., the company estimated that the type 1 diabetes market is less than 50% penetrated while the market for type 2 diabetes patients on intensive insulin is less than 25% penetrated. Last year, DexCom entered into countries in which it previously had no presence, including Bulgaria, Latvia, Lithuania, and Estonia. The company expects its ventures into these new countries and others to significantly increase its addressable population outside the U.S. to roughly 19 million people -- up from 6 million people -- by the second half of 2023. Keep in mind, the U.S. is a leader in CGM penetration, meaning there is an even greater potential in these other countries. The number of people with diabetes is also on an upward trend that will only propel CGM sales even higher. According to some estimates, the CGM market will expand at a compound annual rate (CAGR) of 10.1% through 2028. Investors looking to benefit from this rapid increase can hardly do better than this healthcare stock. 2. Visa Visa helps process and facilitate credit card transactions, and the company makes money by charging transaction fees. The company's business benefits from the network effect. That is, the value of its services increases as more people use it. The more that customers join Visa's payment network, the more it attracts businesses onto this network, and vice versa. While a few companies compete with Visa in this area -- most notably Mastercard -- Visa's strong network effect practically guarantees that it will remain one of the dominant players in this market for the foreseeable future. The company continues to deliver solid financial results, too. In the first quarter, the company saw net revenue grow 24% year over year to $7.1 billion. That was on the back of a 20% year-over-year increase in payments volume and a 21% year-over-year increase in processed transactions. Meanwhile, net income grew 27% to $4 billion compared to the year-ago period. Image source: Getty Images. Visa's business did suffer during the pandemic as payment volume decreased, but the company's rebound from these issues has been relatively strong. More important, though, is the company's long-term thesis. As card payments continue to overtake other methods -- including cash and check -- companies like Visa will benefit. And despite the seeming ubiquity of card payments in many parts of the world, Visa believes there remains significant room for card transactions to replace cash ones. During the company's first-quarterearnings conference call CEO Al Kelly said the following: While cash displacement is certainly a reality, global personal consumption expenditure of cash and check grew at a CAGR of 2% over the 10 years ending in 2019. When we look at the opportunity ahead, if you assume global cash grows at 1% annually, industrywide digital penetration of personal consumption expenditure wouldn't reach 90% for several decades. The company currently sees an $18 trillion opportunity for card payments to replace payments by cash and check. Visa isn't alone in trying to tap into this opportunity, but as an undisputed leader in the field with a solid competitive edge, the company can be expected to grab a decent slice of this market. That's why it remains an excellent stock to buy and hold through this tumultuous year and beyond. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns and recommends Mastercard and Visa. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-02-09,107.692,112.576,107.692,111.97,"[""Nasdaq 100 Movers: AMGN, DXCM In early trading on Wednesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.0%. Year to date, DexCom Inc has lost about 17.5% of its value. And the worst performing Nasdaq 100 component thus far on the day is Amgen, trading down 2.1%. Amgen is showing a gain of 4.8% looking at the year to date performance. Two other components making moves today are Marvell Technology, trading down 0.7%, and JD.com, trading up 4.0% on the day. VIDEO: Nasdaq 100 Movers: AMGN, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH The latest Earnings Preview reflects a stable quarterly performance for the Medical sector so far this reporting cycle. Going by the sector\u2019s scorecard, 33.9% of the companies in the Medical sector, constituting nearly 53.7% of the sector\u2019s market capitalization, reported earnings till Feb 2. Of these, 63.2% beat earnings estimates and 57.9% beat the same for revenues. Earnings increased 10% year over year on 12.1% higher revenues. This scorecard reflects stability in the United States on the gradual reopening of the economy even amid the rise of the Omicron variant cases through the months of the fourth quarter. However, supply chain-related disruption along with hospital staffing shortages were prominent across many geographies. Also, many parts of the COVID-affected international market are still suffering due to lower cash flows and difficult economic conditions. Overall, fourth-quarter earnings for the Medical sector are expected to rise 18.4% on a 12.8% sales increase. This compares with Q3\u2019s reported earnings growth of 29.7% and revenue growth of 15.7%. Medical Device Quarterly Synopsys The dynamic nature of the COVID-19 crisis is fast transforming the medical products industry\u2019s landscape. Integral to the broader Medical sector, Medical Device or Zacks-defined Medical Products companies\u2019 collective business growth improved significantly in Q4, driven by the gradual lifting of restrictions. But the Q4 reporting cycle so far has shown a steep sequential decline in terms of the legacy base business of the companies due to the emergence of the new Omicron variant of COVID-19, which has once again put the non-COVID medical procedures on the back foot. On the other hand, with the increase in the number of cases, testing, vaccine and therapeutic makers witnessed huge market adoption of their COVID-related healthcare support products and services in Q4. MedTech companies like Bio-Rad BIO, DexCom DXCM and LabCorp LH are likely to have been impacted from these factors in Q4. More specifically, the fourth-quarter results of the medical product stocks so far have shown temporary retraction of the base business compared to the third quarter. At the same time, diagnostic testing stocks, picked up momentum in Q4, in line with industry trends. The Zacks Medical Product sector currently carries a Zacks Sector Rank in the bottom 40% (152 of 254 industries). Let\u2019s take a sneak peek into how the aforementioned MedTech stocks are poised prior to their fourth-quarter earnings on Feb 10. Bio-Rad: The company has been witnessing substantial strength in end markets with a rebound in demand across both life science and diagnostic markets. However, we remain wary about the persistent supply-chain challenges, particularly in terms of the supply and cost of plastic raw materials, electronic components as well as rising logistics costs that have been limiting Bio-Rad\u2019s ability to meet customer demand. Bio-Rad\u2019s Life Science segment has been registering robust revenue growth since the past few quarters. We expect this growth momentum to have continued in the fourth quarter on the back of sustained growth in the company\u2019s Polymerase Chain Reaction (PCR), Droplet Digital PCR (dPCR) and Process Media businesses. (Read more: Bio-Rad to Report Q4 Earnings: What's in the Cards?) The Zacks Consensus Estimate for Bio-Rad\u2019s fourth-quarter earnings per share is pegged at $2.87. Revenues are expected to be $737.1 million. Bio-Rad does not have the right combination of the two key ingredients \u2014 a positive Earnings ESP and a Zacks Rank #3 (Hold) or better \u2014 which increases the odds of an earnings beat. The company has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. BioRad Laboratories, Inc. Price and EPS Surprise BioRad Laboratories, Inc. price-eps-surprise | BioRad Laboratories, Inc. Quote DexCom: DexCom\u2019s fourth-quarter top line is likely to have witnessed an increase in volumes, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). In fact, per the preliminary announcement, DexCom \u2014 the leader in CGM \u2014 anticipates fourth-quarter 2021 revenues to be around $698 million (up 23% from the year-ago quarter). (Read more: DexCom to Report Q4 Earnings: What's in the Cards?) The Zacks Consensus Estimate for the fourth quarter of fiscal 2022 is pegged at earnings per share of 86 cents. Revenues are expected to be $696.7 million. DexCom has an Earnings ESP of +1.13% and a Zacks Rank #4 (Sell). DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote LabCorp: Over the past few months, LabCorp has been witnessing continued sales rebound in the base business for both Diagnostics and Drug Development. Just like the previously-reported quarter, LabCorp\u2019s fourth-quarter base-business performance is expected to have registered a recovery despite a spike in COVID-19 cases as patients and providers continue to return to routine healthcare checkups and pharmaceutical clients resume their important research activities. (Read more: LabCorp to Report Q4 Earnings: What's in the Cards?) The Zacks Consensus Estimate for the fourth quarter is pegged at earnings per share of $5.90. Revenues are expected to be $3.94 billion. LabCorp has an Earnings ESP of +9.94% and a Zacks Rank #3. Laboratory Corporation of America Holdings Price and EPS Surprise Laboratory Corporation of America Holdings price-eps-surprise | Laboratory Corporation of America Holdings Quote 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioRad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-02-10,108.57,113.808,106.805,110.568,"After-Hours Earnings Report for February 10, 2022 : ILMN, DXCM, RSG, MTD, NET, EXPE, HUBS, VRSN, FE, SSNC, MPWR, BIO The following companies are expected to report earnings after hours on 02/10/2022. Visit our Earnings Calendar for a full list of expected earnings releases. Illumina, Inc. (ILMN)is reporting for the quarter ending December 31, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.50. This value represents a 59.02% decrease compared to the same quarter last year. In the past year ILMN has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 16.94%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ILMN is 64.99 vs. an industry ratio of -1.30, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending December 31, 2021. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.86. This value represents a 5.49% decrease compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for DXCM is 159.39 vs. an industry ratio of -12.30, implying that they will have a higher earnings growth than their competitors in the same industry. Republic Services, Inc. (RSG)is reporting for the quarter ending December 31, 2021. The waste removal company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.01. This value represents a 1.00% increase compared to the same quarter last year. In the past year RSG has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.77%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for RSG is 30.83 vs. an industry ratio of 52.70. Mettler-Toledo International, Inc. (MTD)is reporting for the quarter ending December 31, 2021. The scientific instrument company's consensus earnings per share forecast from the 4 analysts that follow the stock is $10.07. This value represents a 8.75% increase compared to the same quarter last year. In the past year MTD has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 5.7%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for MTD is 46.52 vs. an industry ratio of 27.30, implying that they will have a higher earnings growth than their competitors in the same industry. Cloudflare, Inc. (NET)is reporting for the quarter ending December 31, 2021. The internet software company's consensus earnings per share forecast from the 9 analysts that follow the stock is $-0.09. This value represents a 12.50% decrease compared to the same quarter last year. NET missed the consensus earnings per share in the 1st calendar quarter of 2021 by -10%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for NET is -347.91 vs. an industry ratio of -46.30. Expedia Group, Inc. (EXPE)is reporting for the quarter ending December 31, 2021. The internet company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.54. This value represents a 118.49% increase compared to the same quarter last year. Zacks Investment Research reports that the 2021 Price to Earnings ratio for EXPE is -255.78 vs. an industry ratio of -22.10. HubSpot, Inc. (HUBS)is reporting for the quarter ending December 31, 2021. The internet software company's consensus earnings per share forecast from the 9 analysts that follow the stock is $-0.36. This value represents a 89.47% decrease compared to the same quarter last year. In the past year HUBS has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 2.5%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for HUBS is -350.91 vs. an industry ratio of -46.30. VeriSign, Inc. (VRSN)is reporting for the quarter ending December 31, 2021. The internet software company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.38. This value represents a no change for the same quarter last year. VRSN missed the consensus earnings per share in the 2nd calendar quarter of 2021 by -0.76%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for VRSN is 40.43 vs. an industry ratio of 26.70, implying that they will have a higher earnings growth than their competitors in the same industry. FirstEnergy Corp. (FE)is reporting for the quarter ending December 31, 2021. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.52. This value represents a 62.50% increase compared to the same quarter last year. FE missed the consensus earnings per share in the 4th calendar quarter of 2020 by -36%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for FE is 16.17 vs. an industry ratio of 24.10. SS&C Technologies Holdings, Inc. (SSNC)is reporting for the quarter ending December 31, 2021. The computer software company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.17. This value represents a 9.35% increase compared to the same quarter last year. In the past year SSNC has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 10.62%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for SSNC is 17.57 vs. an industry ratio of 62.70. Monolithic Power Systems, Inc. (MPWR)is reporting for the quarter ending December 31, 2021. The semiconductor company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.31. This value represents a 45.56% increase compared to the same quarter last year. In the past year MPWR has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for MPWR is 85.42 vs. an industry ratio of 42.10, implying that they will have a higher earnings growth than their competitors in the same industry. Bio-Rad Laboratories, Inc. (BIO)is reporting for the quarter ending December 31, 2021. The medical products company's consensus earnings per share forecast from the 1 analyst that follows the stock is $2.87. This value represents a 28.43% decrease compared to the same quarter last year. In the past year BIO has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 61.3%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIO is 41.57 vs. an industry ratio of 8.90, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-11,106.52,111.755,104.402,105.14,"[""Noteworthy Friday Option Activity: VLO, DXCM, SSD Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Valero Energy Corp (Symbol: VLO), where a total of 18,738 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 44% of VLO's average daily trading volume over the past month of 4.3 million shares. Particularly high volume was seen for the $100 strike call option expiring March 18, 2022, with 2,093 contracts trading so far today, representing approximately 209,300 underlying shares of VLO. Below is a chart showing VLO's trailing twelve month trading history, with the $100 strike highlighted in orange: DexCom Inc (Symbol: DXCM) saw options trading volume of 3,986 contracts, representing approximately 398,600 underlying shares or approximately 44% of DXCM's average daily trading volume over the past month, of 906,565 shares. Especially high volume was seen for the $260 strike put option expiring February 18, 2022, with 406 contracts trading so far today, representing approximately 40,600 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $260 strike highlighted in orange: And Simpson Manufacturing Co., Inc. (Symbol: SSD) options are showing a volume of 1,055 contracts thus far today. That number of contracts represents approximately 105,500 underlying shares, working out to a sizeable 43.8% of SSD's average daily trading volume over the past month, of 241,105 shares. Especially high volume was seen for the $125 strike call option expiring February 18, 2022, with 1,045 contracts trading so far today, representing approximately 104,500 underlying shares of SSD. Below is a chart showing SSD's trailing twelve month trading history, with the $125 strike highlighted in orange: For the various different available expirations for VLO options, DXCM options, or SSD options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 02/11/2022: ORPH,PRQR,DXCM,CDAK Health care stocks continued to shed their prior gains this afternoon, with the NYSE Health Care Index slipping 1.4% and the SPDR Health Care Select Sector ETF (XLV) down 1.0%. The Nasdaq Biotechnology index was dropping 0.8%, reversing a midday advance. In company news, Orphazyme (ORPH) shares rose 8.4% after the Danish biotech company Friday said it plans to resubmit the new drug application for its arimoclomol product candidate to treat Niemann-Pick disease. The company previously filed a marketing application for arimoclomol with European regulators in November and said Friday it expects an advisory panel will issue its recommendation for the medication before the end of March. Codiak BioSciences (CDAK) added 3.7% after Goldman Sachs Friday began coverage of the biopharmaceuticals company with a buy investment recommendation and a $19 price target. Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com To the downside, DexCom (DXCM) slid 4.8% after reporting Q4 results trailing analyst expectations, and the continuous glucose monitors company projected FY22 revenue also lagging analyst estimates. Dexcom is projecting revenue this year in a range of $2.82 billion to $2.94 billion compared with the Capital IQ consensus looking for $2.97 billion in FY22 revenue. ProQR Therapeutics (PRQR) plunged Friday, recently sinking over76% to a record low of $1.33 a share, after saying its sepofarsen drug candidate failed to meet its primary and secondary endpoints of restoring vision in patients 8 years old and older with the Leber congenital amaurosis 10 eye disorder during phase II/II testing. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 02/11/2022: PRQR,DXCM,CDAK Health care stocks turned moderately lower this afternoon, with the NYSE Health Care Index slipping 0.6% and the SPDR Health Care Select Sector ETF (XLV) down 0.3%. The Nasdaq Biotechnology index, however, was climbing 0.5%. In company news, ProQR Therapeutics (PRQR) plunged Friday, at one point sinking almost 76% to a record low of $1.37 a share, after saying its sepofarsen drug candidate failed to meet its primary and secondary endpoints of restoring vision in patients 8 years old and older with the Leber congenital amaurosis 10 eye disorder during phase II/II testing. DexCom (DXCM) slid 3.2% after reporting Q4 results trailing analyst expectations and the continuous glucose monitors company projected FY22 revenue also lagging analyst estimates. Dexcom is projecting revenue this year in a range of $2.82 billion to $2.94 billion compared with the Capital IQ consensus looking for $2.97 billion in FY22 revenue. Codiak BioSciences (CDAK) rose 5.3% after Goldman Sachs Friday began coverage of the biopharmaceuticals company with a buy investment recommendation and a $19 price target. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates DexCom, Inc. DXCM reported fourth-quarter 2021 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate of 86 cents by 20.9%. The bottom line declined 25.3% on a year-over-year basis. For full-year 2021, the company reported an adjusted EPS of $2.66, down 14.2% from the previous year. The figure lagged the consensus mark by 5.3%. GAAP loss per share in the quarter was 20 cents, against the year-ago quarter\u2019s net income per share of $3.48. Revenue Details Total revenues grew 23% to $698.2 million on a year-over-year basis and outpaced the Zacks Consensus Estimate by 0.03%. Rising volumes across all channels, along with strong new customer additions owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring (CGM), contributed to the upside. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote For full-year 2021, the company reported revenues of $2.45 billion, up 27% on a reported basis and 26% on an organic basis. The figure came in-line with the consensus mark. Segmental Details Revenues at the Sensor and other revenues segment (86% of total revenues) climbed 29% on a year-over-year basis to $598.6 million. Hardware revenues (14%) fell 4% year over year to $99.6 million. Geographical Details U.S. revenues (74% of total revenues) increased 15% on a year-over-year basis to $517.1 million. International revenues (26%) surged 54% year over year to $181.1 million. Margin Analysis Adjusted gross profit in the quarter under review totaled $472.6 million, up 18.4% year over year. DexCom generated an adjusted gross margin (as a percentage of revenues) of 67.7%, which contracted 250 basis points (bps) year over year. Research and development expenses amounted to $149.8 million in the quarter, up 25.7% year over year. Selling, general and administrative expenses totaled $235.1 million in the reported quarter, up 33.7% year over year. The company reported total operating expenses of $472 million, up 59.9% year over year. The company reported an operating income of $0.6 million, compared with the year-ago quarter\u2019s figure of $104 million. Operating margin (as a percentage of revenues) of 0.1% contracted 1820 bps year over year. Financial Position The company exited the fourth quarter with $2.73 billion in cash, cash equivalents and marketable securities, compared with $2.70 billion in the preceding quarter. Total assets in the fourth quarter amounted to $4.86 billion, compared with $4.78 billion on a sequential basis. 2022 Guidance DexCom has decided to reiterate 2022 guidance for revenues, while issuing guidance for full-year adjusted gross margin and adjusted operating margin. The company expects revenues to be $2.82-$2.94 billion, reflecting growth of 15-20% from the previous year. The Zacks Consensus Estimate for the same stands at $2.94 billion. While adjusted gross margin is anticipated to be about 65%, adjusted operating margin is estimated to be around 16%. Wrapping Up DexCom exited the fourth quarter on a mixed note, wherein earnings missed the Zacks Consensus Estimate but revenues beat the same. Impressive contribution from the Sensor segment, and domestic and international revenue growth were key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, DexCom ended the quarter with new patient additions as well. Nevertheless, contraction in both gross and operating margins is a woe. Apart from this, cut-throat competition in the market for blood & glucose monitoring devices remains a concern. Zacks Rank Currently, DexCom has a Zacks Rank #4 (Sell). Key Picks Some better-ranked stocks that are supposed to report earnings soon are West Pharmaceutical Services, Inc. WST, Baxter International Inc. BAX and AMN Healthcare Services, Inc. AMN. The Zacks Consensus Estimate for West Pharmaceutical\u2019s fourth-quarter 2021 adjusted EPS is currently pegged at $1.92. The consensus estimate for fourth-quarter 2021 revenues stands at $709.1 million. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. West Pharmaceutical has an estimated long-term growth rate of 27.6%. WST\u2019s return on equity stands at 30.4% compared with the industry\u2019s 14.4%. Baxter currently has a Zacks Rank #2. The Zacks Consensus Estimate for its fourth-quarter 2021 adjusted EPS is currently pegged at $1.03. The consensus mark for fourth-quarter revenues stands at $3.35 billion. Baxter has an estimated long-term growth rate of 9.5%. BAX\u2019s earnings yield of 4.9% compares favorably with the industry\u2019s negative yield. AMN Healthcare currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its fourth-quarter 2021 adjusted EPS currently stands at $2.58. The consensus estimate for its revenues stands at $1.28 billion. AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN\u2019s earnings yield of 6.7% compares favorably with the industry\u2019s 1.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How to Profit from Trillions on Spending for Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q4 2021 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q4 2021 Earnings Call Feb 10, 2022, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom fourth quarter 2021 earnings release conference call. My name is Adrian, and I'll be your operator for today's call. [Operator instructions] Please note, this conference call is being recorded. I'll now turn the call over to Sean Christensen. Sean, you may begin. Sean Christensen -- Investor Relations and Corporate FP&A Thank you, operator, and welcome to DexCom's fourth quarter and full year 2021earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will provide a summary of our fourth quarter and full-year highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. [Operator instructions] Please note that there are also slides available related to our fourth-quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, expectations, and assumptions about future events, strategies, competition, product, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 20, 2022 The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our fourth quarter and full-year earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. I want to take time at the start to highlight some of DexCom's key accomplishments in 2021 that reflect our progress relative to the priorities that we established at the start of the year and our long-term goals. Total revenue grew 26% on an organic basis over the prior year, with rising CGM awareness and DexCom brand loyalty, leading to another year of record new patient additions. This translates to nearly $500 million of organic growth for the year, leading us to exceed the midpoint of our original guidance for the year by more than $160 million. We laid the foundation for the significant expansion of our addressable markets in the future with differentiated product solutions and clinical evidence. In June, we presented results from the MOBILE randomized controlled trial for people with type two diabetes being managed with basal insulin. The results were clear. DexCom CGM can do significantly more to help these people manage diabetes. And with this conclusion being validated in the Journal of the American Medical Association as well as in the recently updated ADA standards of care, we are hopeful that we can bring access to our technology for the estimated 3 million people on basal insulin therapy in the U.S. and many more outside the U.S. Alongside the MOBILE clinical evidence, we drove several updates to our product portfolio to broaden the ways that customers can engage with our technology. We've consistently spoken about our investments in software and data infrastructure as a significant competitive advantage. In the third quarter, we received two key FDA clearances for DexCom software tools that reflect this commitment and strength. Our real-time API allows us to directly integrate Dexcom CGM data in real time to the displays of approved third-party apps. And our app in-app solution creates an FDA-cleared DexCom app experience that can be integrated directly with the app of a DexCom partner. Both of these creative solutions have already been rolled out with DexCom Partners, and we believe they position us well to provide extensive options for our customers, partners, and potential partners as CGM use continues to expand into new populations. We again strengthened our product portfolio through differentiated software with the CE Mark and the launch of our Dexcom ONE product in the fourth quarter of 2021. In a relatively short period since launch, we've already seen strong adoption in both type one and type two customers, and the health systems in two of our four launch countries established reimbursement. With the focus on ease of use and affordable price point, we believe Dexcom ONE will be a significant part of our story as we look to extend CGM access globally. Perhaps most importantly, in 2021, we completed the pivotal trials in support of our next-generation G7 system and submitted the results for both CE Mark and FDA clearance. As many of you recently saw in our January presentation and will soon see in a publication, the performance of the G7 system is outstanding, achieving performance levels relative to the FDA's iCGM special controls. Even with customers on our G6 system expressing record Net Promoter Scores at the end of 2021, we are incredibly excited for them to experience G7. We believe that we are very close to receiving CE Mark and navigating the final stages of that review. In the meantime, our teams continue to work to prepare the manufacturing scale-up and commercial efforts in anticipation of G7 launches throughout the year as well as launches with some of our partners on their upcoming connected insulin delivery devices. On that front, we were excited to see the news of the FDA's recent clearance of Insulet's Omnipod 5, the first tubeless automated insulin delivery pump. With this clearance for Insulet and the ongoing success of Control-IQ for tandem Diabetes, we believe that we are enabling automated insulin delivery for the best tubeless pump on the market and the best-tethered pump. The outcomes that customers are seeing with these DexCom integrated systems are outstanding, and we are proud that our commitment to connectivity is helping advance the market and enhance the quality of life for our customers. These accomplishments align with the strategic priorities that we established at the start of last year, showing the resilience and execution of the DexCom teams in a challenging environment. And these accomplishments are not merely 2021 events, but they are the foundation that we will continue to build on as we press forward in 2022 and beyond. Many of you likely saw the recent update to the IDF estimates for global diabetes prevalence and cost. There are now greater than 500 million adults with diabetes globally, and cost to treat the disease alone are estimated to be approximately $1 trillion per year. In addition, the CDC now estimate that 38% of adults in America or 96 million people have prediabetes. There is a real opportunity here for DexCom to do something great to address this epidemic and power diabetes management and down the road even work toward diabetes prevention and better health outcomes broadly. The future for DexCom is bright. With that, I will turn it over to Jereme for a review of the fourth quarter financials and discussion of the 2022 outlook. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as on our IR website. In line with our January pre-announcement, we reported worldwide revenue of $698 million for the fourth quarter, compared to $569 million for the fourth quarter of 2020, representing growth of 23% on both a reported and constant currency basis and 20% on an organic basis. The organic revenue excludes non-CGM revenue that we generated in the fourth quarter following our acquisition of our distributor in Australia and New Zealand. U.S. revenue totaled $517 million in the fourth quarter, compared to $451 million in the fourth quarter of 2020, representing growth of 15%. Unit volume growth, which is a general representation for the growth of our user base, remained in the high 30% range compared to the fourth quarter of 2020, and we continue to see the strength in our strategic shift to the pharmacy channel. Our teams continue to work very hard to broaden our prescriber base and take advantage of the significant reimbursement access that we have driven in the past two years in both the U.S. and international markets. The uptick in COVID cases has created some challenges for us in the fourth quarter and into the early first quarter, but it is a credit to the resilience of our field team and the strength of the category that global new customers remain near record levels in the fourth quarter. Our international business executed very well in the fourth quarter, with revenue growing 54%, totaling $181 million. Excluding non-CGM revenue that resulted from our 2021 distributor acquisition, international growth was 41% in the fourth quarter. The international result reflected broad-based strength, including record results in all of our direct markets. This growth continues to validate the strategic moves that we made over the course of 2021, most notably the progress that we made to broaden access to our technology through advocacy, flexibility gained from operating efficiencies, and a differentiated product portfolio. We look forward to extending this momentum now as we progress into 2022. Our fourth-quarter gross profit was $472.6 million or 67.7% of revenue, compared to 70.2% of revenue in the fourth quarter of 2020. The fourth-quarter gross margin was slightly above our expectations as certain costs related to the G7 scale-up and commercial preparation remain in our R&D costs until we receive CE Mark. We made excellent progress to drive efficiencies across our product design, procurement, manufacturing, and logistics functions leading to a full year 2021 gross margin that finished 360 basis points above our original 2021 guidance. Operating expenses were $373.6 million for Q4 2021, compared to $294.7 million in Q4 2020. The increase in operating expenses as a percentage of revenue relative to the fourth quarter of 2020 was primarily a result of development and operational costs incurred in preparation for the launch of G7 as well as investments to support our global commercialization efforts. Operating income was $99 million in the fourth quarter of 2021, compared to $104.4 million in the same quarter of 2020. As a reminder, when we provided the outlook for 2021, we determined it was in the best interest to make investments in the business continue to fuel CGM growth and awareness. As we wrap the year, we are proud to report that we outpaced our initial 2021 operating margin guidance by more than 200 basis points, all of which came despite significant investments to solidify our software advantages, advance the G7 clinical, regulatory, and manufacturing programs, significantly expand our global sales force presence and significant efforts to build brand awareness. And we are committed to driving further leverage in the years to come as we strike the right balance between investing to maximize our growth opportunity and turning that opportunity into cash flow generation for the business and our stakeholders. Adjusted EBITDA was $154.5 million or 22.1% of revenue for the fourth quarter, compared to $159.2 million or 28% of revenue for the fourth quarter of 2020. Net income for the fourth quarter was $69 million or $0.68 per share. As many of you also saw in our press release and our GAAP reconciliations, we also recognized an $87 million expense associated with contingent milestone under the 2018 collaboration and license agreement with Verily Life Sciences. Terms of our amended contract with Verily are available in the SEC filings that were originally published in November 2018 and updated in November 2021. We closed the quarter with greater than $2.7 billion in cash and cash equivalents. We have demonstrated the ability to generate positive cash flow. And going forward, we remain in a very flexible position to continue to advance strategic initiatives and opportunities. Most notably, we will continue our development of our manufacturing facility in Malaysia as we expect to have that facility validated for production by the end of 2022. Turning to 2022 guidance. As we stated last month, we anticipate full-year total revenues of $2.82 billion to $2.94 billion, representing growth of 15% to 20%. Given the success of our strategic transition to the pharmacy channel over the past three years, we anticipate that 2022 will be the final year where we see a significant shift of our existing base from the durable medical equipment channel to pharmacy. With this ongoing shift as well as the majority of our new customers now coming through the pharmacy channel in the U.S., our expectations for customer growth in 2022 are again higher than our revenue growth rate, continuing to reflect the large end markets we serve and the growing demand for DexCom CGM worldwide. We have several scenarios built in conjunction with our plan G7 launches. And factoring in the respective regulatory approvals and competitive environment, we will provide updates as the year progresses. Turning to margins. We are establishing the following guidance for 2022. We expect gross profit margins of approximately 65% for the year, in line with the expectation that we established for our 2025 long-range plan. The slight step back relative to our 2021 results is primarily related to the launch of our G7 system during the year as we begin production at lower volumes and gradually scale in conjunction with our launches. Despite that step back in gross margin, we expect to offset that impact completely with approximately 400 basis points of operating expense leverage. We anticipate our operating margins of 2022 of approximately 16%. This factors in the ongoing investments that are driving significant returns for DexCom and setting us up for sustainable growth, including our DTC marketing efforts and investments in our product portfolio pipeline. We are making these investments with the discipline throughout the organization, driving toward the margin expansion that we've established in our long-range plan. Finally, we expect adjusted EBITDA margins of approximately 25% in 2022. With that, I will turn the call back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. To summarize, we set out in 2021 with a few key goals in mind: to complete the clinical and regulatory process for G7 and prepare for significant launches, to validate health and economic outcomes for DexCom CGM beyond the intent of insulin using population, to broaden access to DexCom CGM globally through evidence, advocacy and leveraging our growing scale and efficiency and to strengthen our product portfolio for future growth through differentiated software capabilities. Our progress on all these initiatives contributed to a great 2021 and have us looking forward to a big year ahead in 2022. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Investor Relations and Corporate FP&A Thank you, Kevin. [Operator instructions] Operator, please provide the Q&A instructions. Questions & Answers: Operator Thank you. [Operator instructions] And our first question comes from Matthew O'Brien from Piper Sandler. Your line is open. Matthew O'Brien -- Piper Sandler -- Analyst Afternoon. Thanks for taking the question. I do have -- it's a G7 question has two parts, but they're kind of interwoven. So for starters, Kevin, just talk about the data and the importance of the data when you commercialize G7 versus just like a -- and how much is the price of it? And then the second part of it is on the gross margin side, it's a big step back that we're seeing, it looks like it's entirely because of G7. So what are you anticipating as far as the impact from the G7 rollout? Like what does that say for the timing in Europe, specifically for a month or two months, and then the time of approval here at the state? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer There's many parts to your two-part question. I'll deal with some of them, and then I'll give them to Jereme, Matt, but thanks. Let me talk about the data first. DexCom has long built its legacy on having the best product in the market with respect to performance and a product that everybody can rely on. And time and time again, we've launched products where we published great clinical performance and real-life experience always ends up better than what we published. I've been looking at glucose sensors since the mid-'90s. This data is better than anything I've ever seen. And I think from a marketing perspective and from a customer experience perspective, it's absolutely critical that we remain top of the industry. And this data puts us in there and it demonstrates really the thought and effort that's gone into this product. Let's not forget, we've changed pretty much everything. There's a new algorithm, new hardware, new electronics, new app you name it, new receiver, everything in here is different than what we've had before. So this has been a monumental effort that's taken a lot of time and to be able to produce this type of clinical results we think just show the diligence of the effort. And with respect to approvals, we think it's also very important that we not leave room for error or room for doubt with the data that we submitted, which is exactly what we've done when you look at the size of that study. And of 39,000-some matched pairs, there's really no room for doubt that this product is ready for prime time from a performance perspective. On the approval time lines, as I said in the prepared remarks, we're down to the last steps for CE Mark literally procedural type discussions with documentation that will take place in the near term. We're very confident that we'll get CE Mark very soon, and then we will start our wanted launch in Europe and then roll out to the full launch after that. We've had initial dialogue with the FDA and our submission. And so far, those discussions go well. We currently are not anticipating a delay, but we don't control that any more than we controlled the CE Mark delays either that we've just experienced. By providing great clinical data, though, that certainly takes a large element out of the process. I couldn't be more excited about G7 though, Matt. I'll kick it over to Jereme for the financial ramifications. Jereme Sylvain -- Chief Financial Officer Sure. Yes. So it's a good question on the margins. We exited 2021 north of 68% with our G6, right? So we are certainly seeing G6 firing on all cylinders from an efficiency perspective. And so your question is, well, how does the sequencing and timing of G7 work? How does that impact the margin in relation to the timing throughout the course of the year? And it's a little bit of an insulation. So if it rolls out a little bit slower, certainly, the cost to produce G7 are higher, but that means we're ultimately selling more G6. And so you have this little bit of this transition, where as you think about it from a multitude of different scenarios, it really zones back in on the 65% margin, and that's the reason why we feel comfortable with the guidance there. I'll give you the opposite scenario of G7 is able to come out a little bit faster. The regulatory approval happens quicker. Certainly, we'll be selling more of it, and we'll be able to leverage the fixed-cost infrastructure and certainly improve yields. And so you ultimately get to that end goal a little bit quicker. So I think under both scenarios, whether regulatory approval and launches sooner or later, I think that 65% gross margin really speaks to the entirety of the year. Operator And the next question comes from Danielle Antalffy from SVB Leerink. Your line is open. Danielle Antalffy -- SVB Leerink -- Analyst Hey. Good afternoon, everyone. Thanks so much for taking the question. Kevin and Jereme, my question is around how to think about Q1 and potential COVID impact that you're seeing thus far? And also kind of if you could opine on what you have factored in? Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme, go ahead. Jereme Sylvain -- Chief Financial Officer Sure. Yes, I'll take that one. Yes. Sorry about that. We cut a little bit in and out there, but I think I got the question, which is how we thought about it. And I'd say for the full-year guidance, we have factored in the impact of COVID and how that would impact us. Now we did talk a little bit about it on the call. And I think you saw this really across, especially in the United States, really where omicron was pretty strong throughout the course of January, and we see it starting to dissipate here in February. So we will see that as car ability to get in front of primary care physicians and access new patients, but it's not a question of if, it's more a question of when. And so that was all contemplated in the guidance. And as we think about the full year, there's a lot of other things that we think are certainly interesting but it's as we think about certainly Dexcom ONE and the launch, as Kevin referred to of G7 with the incredible data. So we've really contemplated all of those in the guidance. But certainly, we know that as we exited January, certainly, there were some primary care physicians that were closed outside participants, but we are starting to see some of that though as we move to February. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. I'd even add to that. I actually got out in the field here earlier this week, and I heard from the rep and the teams out there that they've not had the access they wanted here in the first quarter, but it is starting to open up a little bit. Time will tell. Operator And the next question comes from Jeff Johnson from Baird. Your line is open. Jeff Johnson -- Baird -- Analyst Thank you. Good afternoon, guys. Kevin, now that you've got the MOBILE data published and the ADA standards has been published and updated, how should we think about maybe the pathway to U.S. coverage for non-intensive basal only just at the CMS level and maybe expanding commercial encouraging? Could you just remind us ballpark how many commercial payers right now or in some form or another reimburse basal-only or non-intensive T2? Kevin Sayer -- Chairman, President, and Chief Executive Officer There is some limited reimbursement for basal only and some non-intensive type twos, but it's not a very big number, Jeff, it's kind of on a haphazard basis. And it's not something that -- actually, we sell to or market to because they're just not that much of it out there. The pathway for approval will be similar to what we've done in the past. Given this mobile data, we're certainly presenting this on the commercial side and working to get couch at various payers. And hopefully, some of those will drop over the course of the year. On the CMS side, now that we have really good data, we have a good CMS plan to work with and go with them, make them more aware. Unless we forget, we did lead the charge for Medicare approval for CGM in general as a company here. So we have experience on this front, and we'll continue to push it. But it takes time, and there's always variables. In all fairness, I was completely wrong on Medicare approval before. It was approved 18 months earlier than I said I was going to come. So when I made a commitment there. So I'm rather having to make any commitments on that front. We're just going to keep pushing. The most important thing, though, is the outcomes are there. I got a note from a patient not long ago, who is a type two patient in this category. And while the patient got put on a new drug, she attribute her four-month A1C drop in six months to being out of DexCom, not to new drug because he knew what her glucose values were, and we've seen this time and time again. And we're very confident this is how this plays out over time. Operator And the next question comes from Robbie Marcus from J.P. Morgan. Your line is open. Robbie Marcus -- J.P. Morgan -- Analyst Great. Thanks for taking the question. I wanted to see if you could speak to the commercial launch strategy here. It sounds like you're spending a lot in fourth quarter and 2022 ahead of G7. You have Omnipod 5 launching. You also have Medtronic in a tight spot with the warning letter with a lot of patients potentially moving over to partner therapies here. So maybe just talk to us about the strategy, how you're going to be spending your DTC dollars, how we should think about those ramping up? And what the competitive message from your reps will be this year? Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, our competitive message from our reps is going to be the same it's always been, we're the best. And you're right, Robbie, we have a tremendous opportunity on the integrated system front with our partners to go grab as many of these users as we possibly can, and we are in talks with both Tandem and Insulet to let's go make a lot of sunshine can get as many as we possibly can as those individuals rotate off warranty and have an opportunity to get into a new system. I think it speaks to our connectivity strategy and partnering with others now we have two options. And we know a big driving factor for both those partners, the fact that they pair with the best product on the marketplace. So we will aggressively work with our partners on that front and make sure we have a joint message together. With respect to our own DC undrawn direct-to-consumer marketing, we have specific messages literally down to the geography standpoint, where in some states, we target Medicare patients more than others. In other states, we target pediatrics and others. And then we analyze the effectiveness of those adds, the return on those investments, and then adjust from there. I think 2022, we're in an interesting year because we're going through a product launch. That really isn't going to affect our behavior. We have to get more users on the six systems as we go. And then some of those ads will ultimately shift over to G7. But we're not going to slow down, and we're not going to create anticipation. We'll market what we have and sell what we have. And then as time comes, we'll pull the switch and go over. Operator And our next question comes from Matt Taylor from UBS. Matt Taylor -- UBS -- Analyst Hi. Thank you for taking the question. So I just wanted to ask you more about the dynamics of Dexcom ONE, and we're hearing about Libre 3 being rolled out more broadly. Are you seeing anything different on the competitive front? And maybe talk about how you're going more head to head with Dexcom? I'd love you to just flush out those dynamics and the opportunities it's creating for you now that you didn't have before? Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, again, let's remind everybody our original Dexcom ONE launch is for relatively small countries. The results have been very good. We've launched it as only an e-commerce platform, and two of the four countries have now put the standards in place to reimburse for it because of these and the acceptance of that product and the price point. So Dexcom ONE does give us an opportunity, first of all, to expand in new geographies where there may not be reimbursement, where the path to reimbursement would be difficult, and there's a lot of integrated systems. We look forward to that as a geographical expander, where we don't have infrastructure. The other opportunity we have with Dexcom ONE in all honesty is looking at a possible two-product strategy in some geographies where we believe we can support our G-Series for those in tens of insulin users, particularly those who are on partner systems and integrated systems and those who need all the share and follow function, pediatrics in particular, and there's another population that may not need all those features. And in those geographies, we believe Dexcom ONE is an excellent product offering that could round out our portfolio very nicely. As far as Libre 3 rolling out, we haven't seen that much of it so far. I know there's been a lot of announcements, that was approved several years ago. So we'll see how that rollout goes. Operator And our next question comes from Larry Biegelsen from Wells Fargo. Larry Biegelsen -- Wells Fargo Securities -- Analyst Good afternoon. Thanks for taking the question. Just one for me on G7 and the OUS launch. Kevin, I heard you say initially, it will be a limited launch. What does that look like? How many markets? How long is the limited launch? And how should we think about the ramp of G7 once it is approved? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Our limited launch will be a relatively short period of time and really focus on one geography primarily. And after that, we'll then roll it out to really the larger markets, the larger, more reimbursed markets, and the larger markets where we can get reimbursement very quickly and then go down to the smaller ones. So we, again, have the geographies divided up in tiers. Tier one countries, tier two, and tier three and along those lines. And that will roll out over the course of 2022, certainly to the larger markets then the other geographies will come after that. Operator And your next question comes from Joanne Wuensch from Citibank. Joanne Wuensch -- Citi -- Analyst Thank you very much. I just want to double-check two things. I want to make sure I saw either at the earlier presentation in January today. Your patient volumes in the United States were up 30%. Is there a similar number you can share outside the United States? Jereme Sylvain -- Chief Financial Officer Yes. So what we had mentioned is in the U.S., they were in the high 30s, and globally, they were also in the high 30s. And so that's the two numbers. So we gave you the global one, certainly in early January. And then today, we mentioned the U.S. was also in the high 30s as well. Joanne Wuensch -- Citi -- Analyst OK. And could you remind us what your view is on pricing headwinds for this year and if and/or they roll into next year? Jereme Sylvain -- Chief Financial Officer Sure. Yes. So this year, our pricing headwinds, we had talked about is really what we call channel mix was really around $250 million, $200 million in the U.S. and about $50 million outside the U.S. We came in a little bit light of that this year, but generally in line with that. And we expect similar type mix headwinds into 2022 and then dissipating significantly as we move into 2023. Operator And the next question comes from Jayson Bedford from Raymond James. Jayson Bedford -- Raymond James -- Analyst Good afternoon. I wanted to ask about the U.S. business in the fourth quarter. It's been about a month since you last updated investors. You mentioned COVID a couple of times on the call. But is there anything else you could share with us with respect to kind of U.S. growth, which was obviously a bit slower than the prior three quarters? Jereme Sylvain -- Chief Financial Officer Sure. Yes. Thanks, Jason. Appreciate the call. So what we saw from a growth perspective is about 15%. It was a little bit slower from a growth revenue dollars perspective. Now we did see unit volumes in the high 30%, which indicates that the underlying patient base continues to be strong. I think the one thing that we did see, and I think you referenced it earlier in your question, was didn't hit our new patient targets. It was still -- we still had near a record new patient add. And so it was still a solid addition, and we're still very happy -- but we did have some challenges getting into the primary care physician offices. And Kevin alluded to it earlier. He was out in the field. And when omicron was really running at a tight, a lot of those offices were really not seeing outside visitors. And so that creates a little bit of a challenge as you're ultimately getting to know these physicians and getting them to ultimately understand how to use the product. That was the predominant driver of what you saw in the Q4. And in our early calls when we kind of released early numbers, we have mentioned that, and we've confirmed that over the next -- over the past few weeks is that was predominantly the driver. And As we -- as omicron dissipates and we're able to get back in front of these primary care physicians, we remain bullish that folks will ultimately adopt the technology similar to what you've seen prior to that. But that was really the predominant driver, nothing really beyond that. Kevin Sayer -- Chairman, President, and Chief Executive Officer And the only thing I'd add to that, Jason, again, these volume numbers still remain very high. So again, as channel mix shifts, the growth rate is lower than the volume numbers. Add to that the fact that our NPS scores are higher than they've ever been. So patients are very happy and satisfied with the DexCom experience, which leads to them staying on the system and also being on the system more time. So as you look at revenue factors going forward, two of the biggest ones are patient retention, utilization, and we're doing very well on that front. And so that pretty much sums it up. Operator And the next question comes from Matthew Blackman from Stifel. Your line is open. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thanks for taking the question. I've got one for Jereme on the operating leverage you're guiding to in '22. How should we think about where that leverage manifests in the P&L? Is it disproportionate to the SG&A side because you're scaling into those large sales force addition? Or is it skewed to R&D because G7 costs are rolling off? Just any help on how to think about the moving parts there? Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yes. No. It's a fair question. And it's split about 50-50. I think what you're going to see is you're going to see us leveraging mostly the G&A line and the SG&A line. We'll continue to make sure that we're allocating funds to sales and marketing, but you're going to see us leveraging the G&A line and continuing to do so. And then you will see some of the falloffs on some of the R&D side as we leverage R&D. And as we post G7 launch, we don't have to incur as many costs associated with a launch establishment. So think about it 50-50 across both of those and G&A, not S&M and R&D. Operator And the next question comes from Marie Thibault from BTIG. Marie Thibault -- BTIG -- Analyst Hi. Thank you so much for taking the questions. I wanted to ask a question about the sales force progress. I think it was about a year ago that you doubled the sales force. And obviously, outside of the omicron challenges here more recently, I would like to hear how their progress has been and what else might be needed at this point? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer We're really happy with the efforts of the sales team. And again, I got out in the field for the first time this week and just had a couple of meetings with some regional teams. I'm very impressed with the quality of the people we were able to bring on. DexCom is a name here in the U.S. has one that attracted great candidates. And literally, there were thousands of people that applied for these jobs. We very much had our pick of the cream of the crop. They're all getting very much up to speed. I'm very also impressed with the diversity of the group with respect to experiences. And what we've learned is they brought from their companies. You have some from pharma, some from devices, some from diabetes, some of who used to be clinicians. So you have a very different team with very good ideas to go about this. We're confident the team is making very good progress. We missed the opportunity in all fairness to have them all together, and I am in particular, to get to know more of them. The growth in new patient starts has not been linear with the expansion of the sales force. But as we get down into these other markets, we can't expect it to be the same because they don't see as many of the people with diabetes is in our traditional endocrinology market. But we're happy with the growth that they've achieved. We have very ambitious targets for next year. What might be needed in the future is something we debate a great deal internally. We're happy with what we have now, and let's let this play out for a while longer before we make any changes. I don't see anything changing right now. If anything, again, this is all about awareness on our side. And if what we need to generate more awareness has more feet on the street, that's the direction we would go. For right now, we don't feel that way, but we may in the future. So we'll see. We're never adverse to trying pilot programs in specific geographies to see if another option come work and we will do that all throughout 2022. And if something sticks, we'll move in that direction. Operator And your next question comes from Chris Pasquale from Guggenheim. Your line is open. Chris Pasquale -- Guggenheim Partners Thanks. I wanted to follow up on the factors impacting 4Q and what lessons we should take from that as we look at 1Q? So you said COVID was the main headwind, but your channel mix has also changed a lot over the past couple of years. Do you think that's resulting in less seasonality than you used to see in the year end? And then the corollary to that would be, should we expect the typical step down in 1Q could it be more muted because of that reduced seasonality? Or did was COVID more of a factor in January than it was in December? Can you just help us sort of balance those different factors? Jereme Sylvain -- Chief Financial Officer Sure. Yes. No, I'm happy to walk through it. So you are correct. As time moves on, the move of the commercial business certainly more and more to pharmacy then DME should give us more of a situation where Q1 and Q4 are less pronounced. And so you are 100% correct there. And over the longer haul, that's where we expect to go. In terms of seasonality for this quarter, we do expect it to be relatively similar to last year. And again, that's just more of us trying to navigate through, one, that migration; two, the omicron variant this year was certainly more than we saw in January of last year. And so we're really comparing year over year. And so I think it's fair to say that. So we would expect that those two things really offset each other. So you see a little bit of a seasonality in this of 2022 similar to that you've seen in the past. Longer term, you are correct, and we will expect absent all macro factors that ultimately impact people's ability for movement and seeing physicians, etc., it will migrate to more of that situation. But we'll keep you posted as years get forward about that seasonality. For now, that's our expectation. Operator And our next question comes from Margaret Kaczor from William Blair. Brandon Vazquez -- William Blair -- Analyst Hi, everyone. This is Brandon on for Margaret. I just wanted to ask you a question on the type two basal population and maybe some of the non-intensive patients. I can appreciate you guys are still early there, but you're pretty far in with the MOBILE data. So maybe you've talked to some -- gone out in the field and talk to some endos or some other physician. And maybe you have a few patients already on DexCom that are using. And so I'm curious what early feedback you're getting from those less intensive type two patients in terms of either utilization, pricing or demand? Anything that kind of early there that we can read through that what the commercialization might look like going forward? Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, I'll start with basal insulin because the ADA and their recent guidelines came out and recommended CGM continuous use for people on basal insulin, which is a far departure from where we were in the past. This is very encouraging for us because the -- the fact that this group has now recommended that is a for us going forward. And as far as that population utilization in our MOBILE study and even in the other things that we've heard, they have no problem here in CGM all the time. For non-intensive patients, we've had our program with Level 2 at United Healthcare. We've had other programs with Intermountain Health, Onduo, Welldoc, a number of them. and the results remain the same over and over again. Patients on CGM do better than those who are not. And the information provided by CGM enables them to make the proper changes to have better overall health very much like I said in my prepared remarks earlier. We see A1Cs go down because people know what the consequences of their meds, of their exercise, of their diets, of sleep of all these factors has on their overall health. With respect to the pricing and the business model, we've often said we are solving a different problem when we're going after type two less intensive diabetes. And we, therefore, think the pricing model will be different than the current product that we have. And we are working on what that optimal solution is right now, and you'll hear more from us on that front over the course of 2022. Operator And the next question comes from Cecilia Furlong from Morgan Stanley. Cecilia Furlong -- Morgan Stanley -- Analyst Good afternoon, and thank you for taking the question. I wanted to ask on Dexcom ONE again. Just how you're thinking about further geographic expansion in 2022 as well as expectations for relative contributions to the patient volumes, OUS in 2022? And where you think this can go over the longer term? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer I'll start, and Jereme can maybe have some more specific numbers after I'm done if he's got any. Again, as I said earlier, there are two great uses for Dexcom ONE. The first one is those geographies where we're not and where we don't have infrastructure or a distribution arrangement with a distributor or another distribution partner lined up. We can drop an e-commerce platform in there and have cash pay payments patients, and we can get them on the system and we can go. Our results in our four initial countries have been outstanding. And so we'll have other new geographies up over the course of the year like that. They will not have major contributions to our revenue, but they do expand our footprint and do position us ultimately to get reimbursement in those countries. Again, as we've seen in the first four where we launched it, we now have reimbursement and process for two of those. The other opportunity for Dexcom ONE is in many of the major established markets, particularly OUS. We have an opportunity with Dexcom ONE to implement a dual-product strategy. Our G-Series does a lot more than our Dexcom ONE product with connectivity. [Inaudible] the predictive alerts and all the other things that we have in that system, we believe it merits a different price point. Again, it solves a different problem. It's a different use case. We will very opportunistically pick geographies where we could launch Dexcom ONE and augment our business in those geographies, again, adding more patient volume and more revenue to the process. As far as giving you numbers or plans, I'm not going to give you all of that. That's on the strategy side and something for us not to unwind to the world. But suffice it to say, those plans are in progress. I don't know, Jereme, if you have anything to add? Jereme Sylvain -- Chief Financial Officer I think the safe bet is just to assume multiple country entries with Dexcom ONE. And we'll get you a little bit more color once we're into those countries, hold those back for a strategic purpose. Operator And our next question comes from Kyle Rose from Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you for taking the questions. So a lot has been asked, but I think I'd like to just touch on the longer-term product pipeline. And I mean, look, I realize you haven't launched G7 yet. So it's you're probably not going to be thrilled with me asking about what's next. But with G7 launching over the course of the next 12 to 18 months globally, you've got Dexcom ONE scaling as well, what should investors expect from a product development and a product launch perspective? Is it -- is it combination products? Is there different analytes that you're going to be testing for? Just trying to really understand what the medium to longer term your hardware type of product pipeline looks like here? Kevin Sayer -- Chairman, President, and Chief Executive Officer I love what's next question, but these guys are cut me off after 15 minutes, so I'd have to stop. First of all, let's look at G7 and everything that's changed. We have plans in place to modify and make everything with G7 better already. We have, for example, a major cost initiative to reduce our manufacturing costs even where they are. You can expect us to be very diligent in efforts to get that up to a 15-day life from a product perspective because that certainly has a big impact on our P&L. We have, for example, alternative electronic structures, all those types of things going on. We've never stopped improving our sensor technology. So all of these things, we continue to work on our core business. At some point in time, there may be some diminishing returns, particularly given the accuracy of the data on the current system. So we balance that. But a lot of these efforts, again, we focus on our product development, performance, patient experience, our customer satisfaction and cost. And we look at all those buckets, I can tell you there will be a lot of software initiatives here going forward with the G7 platform. We believe with Dexcom ONE, we've merely scratched the surface of our ability to differentiate products through different software experiences, again, creating different business models and expanding our reach. With respect to their analyses, we continue to study that. We've studied that for quite some time. What we have to determine is what are real commercial markets for us? And in all fairness, we haven't found anything that compares to glucose yet. And we have a lot of things then we need to conquer on the glucose side. But we do have studies going on for some of the other analytes that you certainly be familiar with that you've heard others talk about. It just becomes a question I've asked for when and do we have the right platform and what changes we need to make to get there. So there are numerous things in the pipeline. Don't ever think we've stopped here. It's going. Operator And our next question comes from Steven Litchman from Oppenheimer. Your line is open. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Kevin, maybe building on that, you talked today about the steps you're taking now on basal only with the MOBILE data and ADA recommendations in hand. Last ATD, we saw some positive data on non-insulin type two. What are the next steps here in 2022 in terms of going after that opportunity and even prediabetes? Kevin Sayer -- Chairman, President, and Chief Executive Officer It is part of our strategy, and we build our pillar around four -- we call it the four Ps here. You've got the physicians, you've got programs, you've got all the clinics who do this, and you got the patients themselves. And we're attacking on all four fronts with these programs. We've had positive data from Level 2. We have other companies. We know we'll be reporting positive data in the near term and using this product on type two patients who are not on insulin and the outcomes remain strong. We're going to attack it on all four fronts. We believe the experience for these customers. Again, there's going to be a different experience than those who are intensively using insulin. And it's an opportunity for us to use our software capabilities to design a different experience for them that will keep them engaged. The key to any technology as far as providing a good outcome is engagement. And one of the things we've been very successful at, if you look at all of our studies, where we have these incredible outcomes, the users of our systems remain tremendously engaged, and we are trying to build a type two solution around that level of engagement, and that's why we're taking some time as we look at this product opportunity. So you'll see us attack on all fronts. I don't know, Jereme, if you have anything to add to that, you're welcome to? Jereme Sylvain -- Chief Financial Officer No. I think one of the things that if you think about this opportunity that we really prepared ourselves for, even beyond our product and our engagement there is some of the software with connectivity that we've built. And so the real-time API, for example, is our way of trying to move into this market and think about, well, if you're building an app and your app is built around whatever that happens to be, whether it is, to your point, health and wellness, we want to be able to be the partner of choice. Now we have to work on labels and things around those lines, which we'll absolutely do over the long haul. But we've really set ourselves up to be what we believe is the partner of choice, and we'll continue to do so. So that's another way we're going about it, which I think you'll continue to see us push down that path as well. Operator And our next question comes from Josh Jennings from Cowen. Josh Jennings -- Cowen and Company -- Analyst Hi. Good evening. Thanks for taking the questions \u2013 question, I should say. I just wanted to ask about gross margins and just the outperformance in 2021? And if you could just run through maybe Jereme, just some of the drivers of the outperformance relative to your initial guidance? And why we -- some of those drivers couldn't repeat in 2022? And I'm assuming that it's part of it is the G7 launch timing in 2022. But I also wanted to just -- was curious about how the acquisition of the international distributors contributed to the margin performance in 2022 and then really just thinking about a bit there's upside to this initial guidance range for 2022? Thanks so much. Jereme Sylvain -- Chief Financial Officer Yes. Absolutely. So let's think about 2021. And just as you think about that overperformance, really, there's a couple of real drivers of it. It's one, we've built a lot of automated machinery. And as a result of that, yields have gone up over time. And so you've seen the team has done an incredible job of building those yields, really driving those through. And that -- the reduction of waste and the increase efficiency and the increase of the absorption of those fixed costs really was an incredible step forward. Also through our experience with G6, we've reduced our warranty exposure. And as you have warranties, you're sending out replacements, you're sending those out, we're starting to maximize our logistics departments and reducing those freight costs ultimately in fulfilling it. So all of those things were all hitting on and maximizing those for G6. Now when you launch G7, you've got brand-new machinery. You've got -- so you've got to go through the yields process again. It's a new product. And so you actually -- you have to work through the warranty and how you ultimately navigate that. And so when you get to the question, well, what happened in 2021? That's exactly what happened. The team is doing an incredible job. And in 2022, as we launch G7, we're going to go through that journey. And as you saw with the step back that you saw when we launched G6, there was a step back and then we were able to navigate our way through it. We expect to be able to do the same with G7. However, in the year of launch, we know we're going to have to navigate through them. And so what could be potential upside to that could be effective if we're able to navigate through either yields or warranties quicker than expected, which again dovetails into how quick regulatory approvals happen, etc. So that's the primary driver. Over the long haul, there's no reason to believe that we can't continue to be more efficient over time. G7 was designed with efficiency in mind. And we have tons of different workstreams that are going on around how to maximize -- and Kevin referred to it earlier on how to maximize the cost potential within that line. And so we'll continue to do that over time. We'll get to 2023 when we get there. But over the course of 2022, we're very excited about launching G7 and then going through the improvements. Operator And our next question comes from Frank Pinal from Jefferies. Your line is open. Frank Pinal -- Jefferies -- Analyst Hi. Thank you for taking the question. I guess just looking at your user base, it looks like you've grown that by three to four times over the last several years. I'm wondering to what degree that's sustainable given G7, Dexcom ONE, prediabetes, type two -- obviously, a lot of things on the slate. And is there a point that you see where OUS revenues eclipse U.S. revenues? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer In our long-term plans, we certainly show OUS revenues becoming a larger portion of our overall revenue picture than they are today. We don't have them eclipsing U.S. revenues in our current 5-year plan because we have so much opportunity in the U.S. market. I think the user base is a great question. Because over time, the characteristics of that user base changes as we are into more, for example, Dexcom ONE type products where it's an e-commerce platform. We don't know how sticky those patients are going to be right now. We have developed a great model for stickiness with respect to our current user base. And we are designing our products and our software experiences to maintain that type of engagement in a model where people can afford to pay for the product. For many years, the No. 1 reason an individual could be using DexCom was cost. And we are trying to knock that barrier down more and more as we speak. We need to make sure we address those issues going forward. Our customer experience team has been fabulous identifying things we can do to make our product better and increase that base and have them stay. It's not just getting them. Getting the users is one task, but maintaining them is another one. And our record is unlike anybody else is in this industry, we're really good at this. Jereme Sylvain -- Chief Financial Officer Yes. And I think just to your question in terms of how is it repeatable over time in terms of the patient base. Look, I mean, the majority of DexCom's existence has been really focused on the intensive insulin user. But we know that there's an unmet need as you move into a basal user, and that's with the MOBILE study. And that's a large increase in addressable population. We also know that the type two space, there's a huge demand for that product there, but it's a question, as Kevin referred to, ultimately, how do we go to market in there? And we have some great ideas about how it should look, and we're working through those. So I think we're in a pretty good spot. But we're navigating through that. And then to your point, the prediabetes population and health and wellness population is huge. And so it's really a matter of us getting the right product into those folks' hands. And I think that's what you see us doing over time. All the investment in software and platforms is really designed around how do we engage not only our existing population and engage them better but also engage these new population, which means the TAM for this potential product is incredibly large. Operator And that concludes our question-and-answer session. I will turn the call back over to Kevin Sayer for final remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks a lot, operator. As we spend today, looking back at 2021, I just want to spend a minute and acknowledge our teams today. We have a commercial team who generated 26% revenue growth and volumes that far exceeded that in a time when we're putting through rapid expansion efforts as we doubled the U.S. sales force, acquired distributors, and did a number of things to make it more difficult. We have an operations and quality group who're doing all this time when the world has talked about component shortages and not being able to produce product has delivered every single month. In addition to delivering, we've opened a large regional distribution center in Arizona, and we're building our factory in Malaysia, and we're hitting our schedules and time frames there. You look at the innovation at this company from R&D, clinical and quality groups with respect to the work and efforts on G7 as we got those filings in and those filings are person with respect to the data that we presented. And we're getting up and ready to scale on the upside. And then just from a day-to-day basis, our HR group has walked us through thousands of hires literally in the past year. And the finance guys haven't missed a beat. And IT as we move to home, we've not had any trouble. This has been a great year for DexCom. And a lot of people have contributed. It's never just one group or one thing. So I just wanted to thank everybody, acknowledge everybody's accomplishments, and we look forward to a great year next year. Thanks. Operator [Operator signoff] Duration: 57 minutes Call participants: Sean Christensen -- Investor Relations and Corporate FP&A Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Matthew O'Brien -- Piper Sandler -- Analyst Danielle Antalffy -- SVB Leerink -- Analyst Jeff Johnson -- Baird -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Matt Taylor -- UBS -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Joanne Wuensch -- Citi -- Analyst Jayson Bedford -- Raymond James -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Marie Thibault -- BTIG -- Analyst Chris Pasquale -- Guggenheim Partners Brandon Vazquez -- William Blair -- Analyst Cecilia Furlong -- Morgan Stanley -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Josh Jennings -- Cowen and Company -- Analyst Frank Pinal -- Jefferies -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-02-14,104.51,105.884,100.98,101.75,
DXCM,2022-02-15,103.8,105.47,102.725,104.378,
DXCM,2022-02-16,104.13,104.13,100.75,103.408,"Should You Buy Dexcom Stock After Its Downbeat Q4? The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen a drop of 8% over the last month, while it was down 5% on Friday, Feb 11, due to the company’s downbeat Q4 results. Dexcom’s revenue of $698.5 million was slightly above the consensus estimate of $697.5 million. Revenue growth was driven by continued new customer additions, amid rising awareness of CGM devices. However, the company’s adjusted EPS of $0.68 was well below the $0.87 consensus estimate. The earnings were impacted by a 27% rise in operating expenses, owing to increased development and operational costs for the preparation of its new CGM system – G7 – launch. Looking forward, the company’s 2022 revenue guidance of $2.88 billion also fell short of $2.96 billion figure per the consensus estimate. Downbeat earnings as well as the 2022 guidance didn’t sit well with the investors, resulting in a dip in its stock. But now that DXCM stock has seen a 8% fall over the last month, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a good chance of a rise in DXCM stock over the next month. Out of 434 instances in the last ten years that DXCM stock saw a twenty-one day fall of 8% or more, 278 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 278 out of 434, or about a 64% chance of a rise in DXCM stock over the coming month, implying that the stock may see higher levels in the near term. See our analysis on Dexcom Stock Chance of Rise for more details. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data After moving -0.1% or lower over a five-day period, the stock rose in the next five days on 56% of the occasions. After moving -2.3% or more over a ten-day period, the stock rose in the next ten days on 59% of the occasions After moving -7.7% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 64% of the occasions. This pattern suggests that DXCM stock has higher chances of a rise in next five days, ten days, as well as next month. Dexcom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: PODD highest at 2.3%; ILMN lowest at -7.9% Ten-Day Return: BSX highest at 0.5%; ILMN lowest at -5.1% Twenty-One Day Return: BSX highest at 2.3%; ILMN lowest at -17.2% While DXCM stock is likely to move higher in the near term, it is helpful to see how Dexcom Peers fare on metrics that matter. You will find other useful comparisons for companies across industries at Peer Comparisons. What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016. Returns Feb 2022 MTD [1] 2022 YTD [1] 2017-22 Total [2] DXCM Return -2% -22% 604% S&P 500 Return -2% -7% 97% Trefis MS Portfolio Return 1% -9% 259% [1] Month-to-date and year-to-date as of 2/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-17,102.66,103.392,96.7275,96.8125,
DXCM,2022-02-18,96.75,97.9925,94.75,95.31,"Scared of the Bear? Buy These 3 Healthcare Stocks So far in 2022, the stock market has been ugly, and stocks have been hammered across the board, including healthcare stocks. Is it possible to find some future winners in this bear market? Sure. When the world turns awful, healthcare is usually a bright spot. Upheaval in Ukraine means more healthcare, not less. COVID-19 is awful for humanity, but drug companies fighting the disease remain strong. And while bad economies can sometimes cripple healthcare stocks, the practice of medicine remains a basic necessity. Here's why three Fool.com contributors think right now is a great time to buy Doximity (NYSE: DOCS), Amgen (NASDAQ: AMGN), and Novocure (NASDAQ: NVCR). Image source: Getty Images. You want to stomp the bear? Buy Doximity Taylor Carmichael (Doximity): A couple of weeks ago, I suggested that readers might want to buy shares of Doximity, the telehealth giant that was trading 60% off its highs. The company reported earnings a few days after my article, and Doximity just smacked it out of the park. METRIC ANALYST ESTIMATES Q3 ACTUAL NUMBERS Q3 Revenue (up 67%) $86 million $97 million Earnings (up 119%) $0.19 a share (high estimate) $0.26 a share Profit margin N/A 57% Net revenue retention rate N/A 171% Data sources: Yahoo! Finance and company reports. Since the company came public last year, it has surprised analysts every quarter. Nobody expects a high-growth tech stock to already have achieved profitability. Doximity beat analysts' profit estimates by 37% in its first quarter as a public company, trounced them by 90% in its second quarter, and then stomped them by 123% in Q3. Sooner or later, it seems to me, analysts might want to dramatically increase their Doximity profit estimates for 2022. While the bear has been ravaging most of my highfliers so far this year, Doximity has escaped with minimal damage. In fact, the stock is actually up 16% this year. Doximity dominates much of the virtual healthcare space, and thanks to the network effect, it would be quite difficult for any competitor to broach its moat. Eighty percent of American doctors are already on its platform, as are 90% of med students. You want to find a job in a healthcare field? Go to Doximity. You want to market your pharmaceutical to cardiologists? Go to Doximity. Do you want to visit with your patients online? Go to Doximity. This company has already done the hard work of capturing all those medical eyeballs. Now it's finding various ways to monetize its massive upscale audience of physicians and healthcare providers. This is a no-brainer pick in the healthcare space, and it's got an irrationally cheap price right now. A deeply undervalued dividend stock George Budwell (Amgen): Biotech pioneer Amgen, like most of its peers, hasn't been a great investing vehicle this year. Since the turn of the calendar year, for instance, Amgen's shares have dipped by 1.5%. This recent weakness, however, shouldn't frighten away investors. In fact, Amgen's tepid start to the new year is arguably a great buying opportunity for investors with a long-term outlook. What does Amgen stock have to offer? First off, Amgen's shares are currently trading well under fair value, according to multiple analyst estimates. What's more, the biotech sports a healthy 3.49% annualized dividend yield at current levels. So, from a surface level perspective, this blue chip biotech stock already ticks important boxes on the valuation and passive income fronts. The real reason to buy Amgen's stock, though, lies in its proven ability to bring important new medicines to market in a timely fashion. Speaking to this key point, Amgen earned regulatory approvals for the novel cancer drug Lumakras and the AstraZeneca-partnered asthma medication Tezspire last year. Each of these products is forecast to generate sales well in excess of $1 billion at peak. Amgen's top-tier innovation engine is thus expected to fuel high single-digit levels of revenue growth for the company starting as soon as 2023. Its growing top line, in turn, ought to support regular dividend hikes, share repurchases, and investments in value-creating business development deals. All told, Amgen is a fundamentally sound company with a strong outlook. These two facts should help the biotech weather this moody market in the short term, and to deliver healthy returns on capital over the long term. Tremendous growth potential at a reasonable valuation Patrick Bafuma (Novocure): If you are scared of the bear, oncology medical device company Novocure has a promising cave where you can seek shelter. While it has cooled down by 60% from its June 2021 highs, it is beating the S&P 500 for the year, down less than 2% versus more than 8% for the index. And the medical wearables maker offers big potential in the near future. Data from Novocure's phase 3 pivotal trial for non-small cell lung cancer (NSCLC) should be around the corner, adding a massive tailwind for the company. The oncology company believes there are approximately 46,000 NSCLC patients in the U.S. alone that are candidates for its treatment. The Optune device is a cancer-fighting wearable vest that uses electric fields to disrupt cancer cell division but has not been shown to affect normal cells in the body. Optune's potential indications in the NSCLC market are over four times its current addressable market for a rare type of brain cancer called glioblastoma. Positive NSCLC data could send the stock soaring, not to mention that it has a full stable of ongoing trials. With data pending in ovarian, hepatic, gastric, and pancreatic cancer, it's hard to believe growth has stalled out at Novocure. For a company with such large potential tailwinds, this oncology stock looks reasonably priced, too. It has a price-to-sales (P/S) ratio of about 15. This is similar to continuous glucose monitoring device maker DexCom at a P/S ratio of about 16, as well as a P/S ratio of about 18 for surgical robotics company Intuitive Surgical. With a comparable valuation to its peers, an incredible 79% gross margin, $938 million in cash at the end of 2021, plus huge growth potential in the near future, Novocure looks like a safe place for your money in today's bear market. 10 stocks we like better than Doximity, Inc. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Doximity, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Patrick Bafuma has no position in any of the stocks mentioned. George Budwell has no position in any of the stocks mentioned. Taylor Carmichael owns Doximity, Inc. and Intuitive Surgical. The Motley Fool owns and recommends Doximity, Inc., Intuitive Surgical, and Novocure. The Motley Fool recommends Amgen and DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-22,96.165,100.135,95.145,97.74,"[""Tuesday Sector Leaders: Utilities, Healthcare In afternoon trading on Tuesday, Utilities stocks are the best performing sector, losing just 0.3%. Within that group, PPL Corp (Symbol: PPL) and CenterPoint Energy, Inc (Symbol: CNP) are two large stocks leading the way, showing a gain of 2.2% and 1.9%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.4% on the day, and down 7.82% year-to-date. PPL Corp, meanwhile, is down 11.28% year-to-date, and CenterPoint Energy, Inc, is down 2.28% year-to-date. Combined, PPL and CNP make up approximately 3.9% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, losing just 0.5%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Medtronic PLC (Symbol: MDT) are the most notable, showing a gain of 2.4% and 2.3%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.7% in midday trading, and down 10.17% on a year-to-date basis. DexCom Inc, meanwhile, is down 27.32% year-to-date, and Medtronic PLC, is down 0.58% year-to-date. Combined, DXCM and MDT make up approximately 3.7% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, none of the sectors are up on the day, while nine sectors are down. SECTOR % CHANGE Utilities -0.3% Healthcare -0.5% Financial -1.1% Consumer Products -1.6% Industrial -1.6% Materials -1.6% Technology & Communications -1.8% Energy -2.8% Services -2.9% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tuesday's ETF with Unusual Volume: PWB The Invesco Dynamic Large Cap Growth ETF is seeing unusually high volume in afternoon trading Tuesday, with over 162,000 shares traded versus three month average volume of about 46,000. Shares of PWB were down about 0.7% on the day. Components of that ETF with the highest volume on Tuesday were Advanced Micro Devices, trading up about 1.2% with over 59.5 million shares changing hands so far this session, and Apple, down about 1.5% on volume of over 35.8 million shares. Dexcom is the component faring the best Tuesday, higher by about 2.5% on the day, while Coinbase Global is lagging other components of the Invesco Dynamic Large Cap Growth ETF, trading lower by about 6.7%. VIDEO: Tuesday's ETF with Unusual Volume: PWB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: HD, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 3.9%. Year to date, DexCom has lost about 26.2% of its value. And the worst performing S&P 500 component thus far on the day is Home Depot, trading down 4.7%. Home Depot is lower by about 20.4% looking at the year to date performance. Two other components making moves today are Best Buy, trading down 3.4%, and Advanced Micro Devices, trading up 3.5% on the day. VIDEO: S&P 500 Movers: HD, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-02-23,99.425,99.6825,93.8475,94.0775,
DXCM,2022-02-24,92.2225,102.716,91.4325,102.18,"Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar? Launched on 06/28/2004, the iShares Morningstar MidCap ETF (IMCB) is a passively managed exchange traded fund designed to provide a broad exposure to the Mid Cap Blend segment of the US equity market. The fund is sponsored by Blackrock. It has amassed assets over $805.43 million, making it one of the average sized ETFs attempting to match the Mid Cap Blend segment of the US equity market. Why Mid Cap Blend Compared to large and small cap companies, mid cap businesses tend to have higher growth prospects and are less volatile, respectively, with market capitalization between $2 billion and $10 billion. Thus, companies that fall under this category provide a stable and growth-heavy investment. Blend ETFs usually hold a mix of growth and value stocks as well as stocks that exhibit both value and growth characteristics. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.04%, making it the least expensive products in the space. It has a 12-month trailing dividend yield of 1.21%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 19.70% of the portfolio. Industrials and Consumer Discretionary round out the top three. Looking at individual holdings, Dexcom Inc (DXCM) accounts for about 0.64% of total assets, followed by Airbnb Inc Class A (ABNB) and Marvell Technology Inc (MRVL). The top 10 holdings account for about 3.93% of total assets under management. Performance and Risk IMCB seeks to match the performance of the MORNINGSTAR US MID CAP INDEX before fees and expenses. The Morningstar US Mid Cap Index comprises of mid-capitalization U.S. equities. The ETF has lost about -10.49% so far this year and is up roughly 4.50% in the last one year (as of 02/24/2022). In the past 52-week period, it has traded between $59.56 and $72.78. The ETF has a beta of 1.10 and standard deviation of 26.15% for the trailing three-year period. With about 570 holdings, it effectively diversifies company-specific risk. Alternatives IShares Morningstar MidCap ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, IMCB is a reasonable option for those seeking exposure to the Style Box - Mid Cap Blend area of the market. Investors might also want to consider some other ETF options in the space. The Vanguard MidCap ETF (VO) and the iShares Core S&P MidCap ETF (IJH) track a similar index. While Vanguard MidCap ETF has $51.04 billion in assets, iShares Core S&P MidCap ETF has $62.20 billion. VO has an expense ratio of 0.04% and IJH charges 0.05%. Bottom-Line While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares Morningstar MidCap ETF (IMCB): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report iShares Core S&P MidCap ETF (IJH): ETF Research Reports Vanguard MidCap ETF (VO): ETF Research Reports Airbnb, Inc. (ABNB): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-02-25,102.18,103.101,99.5425,102.835,"[""Notable Friday Option Activity: MSFT, FCX, DXCM Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Microsoft Corporation (Symbol: MSFT), where a total volume of 228,288 contracts has been traded thus far today, a contract volume which is representative of approximately 22.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 58.5% of MSFT's average daily trading volume over the past month, of 39.0 million shares. Especially high volume was seen for the $300 strike call option expiring February 25, 2022, with 31,567 contracts trading so far today, representing approximately 3.2 million underlying shares of MSFT. Below is a chart showing MSFT's trailing twelve month trading history, with the $300 strike highlighted in orange: Freeport-McMoran Copper & Gold (Symbol: FCX) saw options trading volume of 95,475 contracts, representing approximately 9.5 million underlying shares or approximately 50% of FCX's average daily trading volume over the past month, of 19.1 million shares. Especially high volume was seen for the $45 strike call option expiring February 25, 2022, with 8,751 contracts trading so far today, representing approximately 875,100 underlying shares of FCX. Below is a chart showing FCX's trailing twelve month trading history, with the $45 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 4,145 contracts thus far today. That number of contracts represents approximately 414,500 underlying shares, working out to a sizeable 46.6% of DXCM's average daily trading volume over the past month, of 888,620 shares. Especially high volume was seen for the $480 strike call option expiring March 18, 2022, with 1,175 contracts trading so far today, representing approximately 117,500 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $480 strike highlighted in orange: For the various different available expirations for MSFT options, FCX options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar? The iShares Morningstar MidCap Growth ETF (IMCG) was launched on 06/28/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Mid Cap Growth segment of the US equity market. The fund is sponsored by Blackrock. It has amassed assets over $1.16 billion, making it one of the average sized ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Compared to large and small cap companies, mid cap businesses tend to have higher growth prospects and are less volatile, respectively, with market capitalization between $2 billion and $10 billion. Thus, companies that fall under this category provide a stable and growth-heavy investment. Qualities of growth stocks include faster growth rates compared to the broader market, as well as higher valuations and higher than average sales and earnings growth rates. Something to keep in mind is the higher level of volatility that is affiliated with growth stocks. Even though growth stocks are more likely to outperform their value counterparts in strong bull markets, value stocks have a record of delivering better returns in almost all markets than growth stocks. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.06%, making it the least expensive products in the space. It has a 12-month trailing dividend yield of 0.49%. Sector Exposure and Top Holdings ETFs offer a diversified exposure and thus minimize single stock risk but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 30.90% of the portfolio. Industrials and Healthcare round out the top three. Looking at individual holdings, Dexcom Inc (DXCM) accounts for about 1.25% of total assets, followed by Airbnb Inc Class A (ABNB) and Marvell Technology Inc (MRVL). The top 10 holdings account for about 7.61% of total assets under management. Performance and Risk IMCG seeks to match the performance of the MORNINGSTAR US MID CAP BROAD GROWTH INDX before fees and expenses. The Morningstar US Mid Cap Broad Growth Index comprises of mid-capitalization U.S. equities that exhibit growth characteristics. The ETF has lost about -14.11% so far this year and is down about -5.63% in the last one year (as of 02/25/2022). In the past 52-week period, it has traded between $59.71 and $76.33. The ETF has a beta of 1.08 and standard deviation of 24.92% for the trailing three-year period. With about 375 holdings, it effectively diversifies company-specific risk. Alternatives IShares Morningstar MidCap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IMCG is an outstanding option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The Vanguard MidCap Growth ETF (VOT) and the iShares Russell MidCap Growth ETF (IWP) track a similar index. While Vanguard MidCap Growth ETF has $10.70 billion in assets, iShares Russell MidCap Growth ETF has $13.33 billion. VOT has an expense ratio of 0.07% and IWP charges 0.23%. Bottom-Line Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares Morningstar MidCap Growth ETF (IMCG): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report iShares Russell MidCap Growth ETF (IWP): ETF Research Reports Vanguard MidCap Growth ETF (VOT): ETF Research Reports Airbnb, Inc. (ABNB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-02-28,102.338,103.62,100.818,103.478,
DXCM,2022-03-01,103.745,107.506,100.975,102.102,
DXCM,2022-03-02,103.388,106.0,102.604,105.02,
DXCM,2022-03-03,106.5,108.3,105.205,105.988,
DXCM,2022-03-04,105.735,108.748,105.262,108.015,"[""Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation DexCom, Inc. DXCM recently received the FDA\u2019s Breakthrough Device Designation for the Dexcom continuous glucose monitoring (\u201cCGM\u201d) system\u2019s use in the hospital setting. The designation is expected to offer a more efficient and streamlined review pathway to enable Dexcom CGM technology to faster expand the company\u2019s footprint the hospital market. With the latest regulatory recognition, Dexcom is expected to solidify its foothold in the global CGM business. Significance of the Recognition Dexcom CGM utilizes a small wearable sensor and transmitter that continuously measures and sends glucose levels wirelessly to a smart device. This enables the receipt of real-time glucose data without the need for fingersticks. This apart, the system also offers customizable alerts and alarms to aid in avoiding potentially dangerous low and high blood sugar events. Per a medical personnel accustomed to the use of the Dexcom CGM in the hospital setting, the device was found to improve control over glucose levels without any increased risk in hypoglycemia (lower-than-normal blood sugar level). The receipt of the FDA\u2019s Breakthrough Device Designation is likely to be transformative for using CGM for in-patient care in hospitals. Per Dexcom\u2019s management, the Dexcom CGM was allowed by the FDA for use in hospitals during the pandemic to help healthcare providers manage patient glucose levels. This usage demonstrated its potential as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction. Industry Prospects Per a report by Grand View Research, the global CGM device market size was valued at $3,929.7 million in 2019 and is expected to reach $10.4 billion by 2027 at a CAGR of 12.7%. Factors like rising cases of diabetes and increasing adoption of CGM devices are likely to drive the market. Given the market potential, the latest coverage announcement is expected to provide a significant boost to Dexcom\u2019s business globally. Notable Developments Last month, Dexcom announced its fourth-quarter 2021 results, where it recorded robust uptick in the overall top line as well as across geographies. The company also confirmed submitting a comprehensive 510(k) pre-market notification to the FDA for regulatory review of the Dexcom G7 CGM System in accordance with the integrated CGM or iCGM Special Controls. The same month, the company announced that diabetics under the age of 18 and requiring ongoing use of insulin or insulin pump therapy are eligible for public coverage of the Dexcom G6 CGM System through Alberta Health. Price Performance Shares of the company have gained 16.4% in the past year against the industry\u2019s 1.4% fall. The S&P 500 has risen 13.6% in the same time frame. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, Dexcom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Henry Schein, Inc. HSIC, Allscripts Healthcare Solutions, Inc. MDRX and AMN Healthcare Services, Inc. AMN. Henry Schein, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 11.8%. HSIC\u2019s earnings surpassed estimates in the trailing four quarters, the average beat being 25.5%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Henry Schein has gained 39.4% compared with the industry\u2019s 11.6% growth over the past year. Allscripts has an estimated long-term growth rate of 16.3%. MDRX\u2019s earnings surpassed estimates in the trailing four quarters, the average beat being 64.8%. It currently carries a Zacks Rank #2 (Buy). Allscripts has gained 38.9% against the industry\u2019s 47.7% fall over the past year. AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN\u2019s earnings surpassed estimates in the trailing four quarters, the average beat being 20%. It currently sports a Zacks Rank #1. AMN Healthcare has gained 47.6% against the industry\u2019s 54.7% fall over the past year. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How to Profit from Trillions on Spending for Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allscripts Healthcare Solutions, Inc. (MDRX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Vanguard MidCap ETF (VO) Be on Your Investing Radar? The Vanguard MidCap ETF (VO) was launched on 01/26/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Mid Cap Blend segment of the US equity market. The fund is sponsored by Vanguard. It has amassed assets over $53 billion, making it one of the largest ETFs attempting to match the Mid Cap Blend segment of the US equity market. Why Mid Cap Blend Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. Thus, companies that fall under this category provide a stable and growth-heavy investment. Blend ETFs are aptly named, since they tend to hold a mix of growth and value stocks, as well as show characteristics of both kinds of equities. Costs Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Annual operating expenses for this ETF are 0.04%, making it the least expensive products in the space. It has a 12-month trailing dividend yield of 1.24%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 22.30% of the portfolio. Industrials and Healthcare round out the top three. Looking at individual holdings, Dexcom Inc. (DXCM) accounts for about 0.77% of total assets, followed by Marvell Technology Inc. (MRVL) and Msci Inc. (MSCI). Performance and Risk VO seeks to match the performance of the CRSP US Mid Cap Index before fees and expenses. The CRSP US Mid Cap Index targets inclusion of the U.S. companies that fall between the top 70%-85% of investable market capitalization. The ETF has lost about -8.78% so far this year and is up about 8.30% in the last one year (as of 03/04/2022). In the past 52-week period, it has traded between $214.97 and $261.20. The ETF has a beta of 1.09 and standard deviation of 24.35% for the trailing three-year period, making it a medium risk choice in the space. With about 381 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard MidCap ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VO is a great option for investors seeking exposure to the Style Box - Mid Cap Blend segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares Russell MidCap ETF (IWR) and the iShares Core S&P MidCap ETF (IJH) track a similar index. While iShares Russell MidCap ETF has $29.09 billion in assets, iShares Core S&P MidCap ETF has $64.75 billion. IWR has an expense ratio of 0.19% and IJH charges 0.05%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How to Profit from Trillions on Spending for Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard MidCap ETF (VO): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report MSCI Inc (MSCI): Free Stock Analysis Report iShares Core S&P MidCap ETF (IJH): ETF Research Reports iShares Russell MidCap ETF (IWR): ETF Research Reports To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-03-07,109.172,109.942,104.67,105.202,"Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar? Looking for broad exposure to the Mid Cap Growth segment of the US equity market? You should consider the Vanguard MidCap Growth ETF (VOT), a passively managed exchange traded fund launched on 08/17/2006. The fund is sponsored by Vanguard. It has amassed assets over $10.61 billion, making it one of the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth With market capitalization between $2 billion and $10 billion, mid cap companies usually contain higher growth prospects than large cap companies, and are considered less risky than their small cap counterparts. Thus, companies that fall under this category provide a stable and growth-heavy investment. While growth stocks do boast higher than average sales and earnings growth rates, and they are expected to grow faster than the wider market, investors should note these kinds of stocks have higher valuations. Something to keep in mind is the higher level of volatility that is affiliated with growth stocks. When you consider growth versus value, growth stocks are usually the clear winner in strong bull markets but tend to fall flat in nearly all other environments. Costs When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal. Annual operating expenses for this ETF are 0.07%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.40%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 34.70% of the portfolio. Healthcare and Industrials round out the top three. Looking at individual holdings, Dexcom Inc. (DXCM) accounts for about 1.46% of total assets, followed by Marvell Technology Inc. (MRVL) and Msci Inc. (MSCI). The top 10 holdings account for about 10.28% of total assets under management. Performance and Risk VOT seeks to match the performance of the CRSP U.S. Mid Cap Growth Index before fees and expenses. The CRSP U.S. Mid Cap Growth Index measures the investment return of mid-capitalization growth stocks. The ETF has lost about -15.36% so far this year and it's up approximately 3.86% in the last one year (as of 03/07/2022). In the past 52-week period, it has traded between $204.75 and $265.79. The ETF has a beta of 1.10 and standard deviation of 25.11% for the trailing three-year period, making it a medium risk choice in the space. With about 187 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard MidCap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VOT is a great option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P MidCap 400 Growth ETF (IJK) and the iShares Russell MidCap Growth ETF (IWP) track a similar index. While iShares S&P MidCap 400 Growth ETF has $7.35 billion in assets, iShares Russell MidCap Growth ETF has $13.08 billion. IJK has an expense ratio of 0.17% and IWP charges 0.23%. Bottom-Line While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard MidCap Growth ETF (VOT): ETF Research Reports DexCom, Inc. (DXCM): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report MSCI Inc (MSCI): Free Stock Analysis Report iShares Russell MidCap Growth ETF (IWP): ETF Research Reports iShares S&P MidCap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-08,102.915,104.101,98.25,100.2,
DXCM,2022-03-09,101.032,103.07,100.002,103.06,"These 2 Millionaire-Maker Stocks Still Promise Solid Returns To be a millionaire investor, you don't need to go looking at high-risk penny stocks to invest in. While that can be a quick way to turn a profit, it can also be a surefire way to lose all your money. Sometimes, all that's required to make a big profit is patience and investing in established businesses with proven business models. If you invested in either Amazon (NASDAQ: AMZN) or DexCom (NASDAQ: DXCM) a decade ago, both could have made you rich; a $100,000 investment in either stock would have been more than enough to make you a millionaire today. But are both of these stocks still good buys right now? Image source: Getty Images. 1. Amazon Online retailer Amazon wasn't a trillion-dollar business a decade ago. It wasn't even worth $100 billion. In March 2012, its valuation was right around $82 billion. And at the time, the company was already one of the world's top growth stocks. Net sales of $48.1 billion in 2011 grew by 41% year over year and were close to double 2009's tally of $24.5 billion. This past year, revenue topped $469.8 billion -- nearly 10 times its revenue from a decade ago. And while its growth rate slowed down to 22% in 2021, the business continues to dominate retail as an easy one-stop-shop for electronics, groceries, and just about anything that consumers can buy online. Over 10 years, the stock has risen by more than 1,400%. That would turn a $100,000 investment into $1.5 million. Whether this already incredibly successful stock can do that again is a tough question. The boost it received from pandemic-driven demand over the past two years may not be sustainable. But with more than $110 billion in cash from its operating activities during that time, I'm confident that the business won't run out of opportunities to pursue more growth in the future. So while it may not jump by another 1,000% in the next 10 years, Amazon still looks like a promising growth stock to buy and hold for the long run. 2. DexCom DexCom is a medical device company that makes it easier for people with diabetes to manage their glucose levels. Rather than having to rely on pricking themselves with finger sticks all the time, people can use the company's continuous glucose monitoring system (CGM), which can easily display readings on an ongoing basis. And so it's no surprise that with rising diabetes cases over the years, DexCom's products have been in high demand. This past year, the company's revenue of $2.4 billion grew by 27% year over year. In 2011, its sales were just $65.9 million, as the business was still in its early growth stages. It was also unprofitable then, reporting a net loss of $44.7 million. Now, it's coming off a year where its net income was $154.7 million -- more than double its sales from 10 years ago. And so it's easy to see why, over the past decade, the stock has been red-hot, soaring more than 4,000%. A $100,000 investment here would have made you a multimillionaire, with those shares now worth close to $4.2 million. It has been a terrific growth story for DexCom, which has evolved its products over that time to be more intuitive and easy to use for its customers. Its newest CGM, the G7 (still to be released), will be 60% smaller than the current version (G6) and continues to improve on its ""best-in-class accuracy,"" as the company calls it. It will remain an important product for the healthcare industry, as the number of people with diabetes will only grow. The Centers for Disease Control projected back in 2010 that by 2050, one in three U.S. adults could be living with the disease (up from just one in 10 at the time). Although it's an unfortunate projection, DexCom's devices can make living with diabetes much more manageable. And that's why although the stock has already risen so much over the past decade and trades at a hefty price-to-earnings multiple of more than 270, the growth potential for its business is what still makes DexCom a promising long-term buy. 10 stocks we like better than Amazon When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now… and Amazon wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 3, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns and recommends Amazon. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-10,100.318,102.495,100.302,101.395,
DXCM,2022-03-11,103.422,103.738,97.515,97.565,"The Implied Analyst 12-Month Target For SPHB Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 500— High Beta ETF (Symbol: SPHB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $95.71 per unit. With SPHB trading at a recent price near $71.30 per unit, that means that analysts see 34.23% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPHB's underlying holdings with notable upside to their analyst target prices are Mohawk Industries, Inc. (Symbol: MHK), DexCom Inc (Symbol: DXCM), and BlackRock Inc (Symbol: BLK). Although MHK has traded at a recent price of $132.76/share, the average analyst target is 44.31% higher at $191.58/share. Similarly, DXCM has 35.21% upside from the recent share price of $405.58 if the average analyst target price of $548.39/share is reached, and analysts on average are expecting BLK to reach a target price of $942.36/share, which is 35.16% above the recent price of $697.20. Below is a twelve month price history chart comparing the stock performance of MHK, DXCM, and BLK: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Invesco S&P 500— High Beta ETF SPHB $71.30 $95.71 34.23% Mohawk Industries, Inc. MHK $132.76 $191.58 44.31% DexCom Inc DXCM $405.58 $548.39 35.21% BlackRock Inc BLK $697.20 $942.36 35.16% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-14,97.1,104.25,97.0925,101.822,"[""Health Care Sector Update for 03/14/2022: DXCM,NKTR,BMY,MRNA,ABCM Health care stocks were moderately higher this afternoon, with the NYSE Health Care Index rising 0.6% and the SPDR Health Care Select Sector ETF (XLV) up 0.5%. The Nasdaq Biotechnology index was sinking 1.6%. In company news, DexCom (DXCM) added 5.5% after European regulators issued a CE mark for the company's G7 continuous glucose monitoring system for use by diabetes patients aged two years old and older, including pregnant women. The product is expected to launch throughout the European Economic Area the next several weeks. Moderna (MRNA) climbed 6.9% after the biopharmaceuticals company Monday said it has dosed the first patient in a trial of its mRNA-1574 vaccine candidate for human immunodeficiency virus. The early-stage study will evaluate the safety and immunogenicity of the messenger RNA-based vaccine in HIV-negative adults and measure its ability to produce autologous neutralizing antibodies. Abcam (ABCM) rose 4.8% after the life sciences company Monday reported 315.4 million British pounds in revenue for the 12 months ended Dec. 31, up 17.1% over its 269.3 million pounds in FY20 revenue and topping the Capital IQ consensus expecting 313.9 million pounds in FY21 revenue. Among decliners, Nektar (NKTR) slumped nearly 61% after saying it was discontinuing enrollment and ending analysis from a phase III study comparing a combination of its bempegaldesleukin drug candidate with Bristol-Myers Squibb's (BMY) Opdivo and Opdivo alone in patients with previously untreated unresectable or metastatic melanoma after the drug combination failed to meet the primary trial endpoints. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario Dexcom, Inc. DXCM recently announced that the Ontario government will offer coverage for the Dexcom G6 continuous glucose monitoring (CGM) System effective Mar 14, 2022. The government is going to offer this coverage through its Assistive Devices Program (ADP) for people staying in the province living with type one diabetes and are over two years of age and fulfill the coverage criteria. It is noteworthy to mention that the back of the upper arm insertion site is for ages 18 and above. Ontario now joins six other provinces or territories, most recently Alberta, providing public coverage for CGM systems under provincial health plans. The expanded public coverage for CGM can help more people to access this standard-of-care technology, thereby enabling them to manage a life-long chronic illness more efficiently. This announcement is likely to boost Dexcom\u2019s already strong leadership in CGM connected solutions space. More on the News Per management at Dexcom, the company remains committed to bringing substantial value to the Ontario healthcare system through its G6 CGM System by working closely with governments throughout Canada. This in turn is likely to ensure that each and every person living with diabetes has access to the care required. Image Source: Zacks Investment Research It is important to mention here that Dexcom CGM use is proven to enhance glycemic control and can lower the risk of costly long-term diabetes-related complications in comparison to fingerstick monitoring. Market Prospects Per a report by Grand View Research, the global CGM device market size was valued at $4.7 billion in 2020 and is estimated to witness a CAGR of 10.1% from 2021 to 2028. The growing incidence of diabetes coupled with the increasing geriatric population prone to diabetes is the primary factor driving this market\u2019s growth. Hence, this announcement is well-timed for Dexcom. Recent Developments This month, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. The designation is expected to offer a more efficient and streamlined review pathway to enable Dexcom CGM technology expand the company\u2019s footprint in the hospital market faster. Last month, Dexcom announced that people with diabetes under 18 years of age who need ongoing use of insulin or insulin pump therapy are eligible for public coverage of the Dexcom G6 CGM System via Alberta Health. Price Performance Shares of the company have gained 7.8% in the past year against the industry\u2019s 10.1% fall. Zacks Rank & Key Picks Currently, Dexcom carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. AMN, Henry Schein, Inc. HSIC and McKesson Corporation MCK. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcare\u2019s long-term earnings growth rate is estimated at 16.2%. AMN\u2019s earnings yield of 8.8% compares favorably with the industry\u2019s 0.3%. Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 25.5%. The company currently sports a Zacks Rank #2 (Buy). Henry Schein\u2019s long-term earnings growth rate is estimated at 11.8%. HSIC\u2019s earnings yield of 5.6% compares favorably with the industry\u2019s 4.1%. McKesson surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.6%. The company currently carries a Zacks Rank #2. McKesson\u2019s long-term earnings growth rate is estimated at 11.8%. MCK\u2019s earnings yield of 8.8% compares favorably with the industry\u2019s 4.1%. Just Released: Zacks Top 10 Stocks for 2022 In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022? Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don\u2019t miss your chance to get in on these long-term buys Access Zacks Top 10 Stocks for 2022 today >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-03-15,103.102,104.55,100.822,104.02,"DexCom (DXCM) to Boost Diabetes Management With New Approval DexCom, Inc. DXCM recently announced the receipt of CE Mark for its G7 Continuous Glucose Monitoring (CGM) System in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app. It is important to mention here that the company anticipates unveiling a launch of DexCom G7 in Europe in the next several weeks. Apart from this, the company has plans to introduce an updated CGM algorithm in 2022, thereby driving the next step forward in CGM sensor performance. This announcement is likely to boost Dexcom’s already strong leadership in CGM connected solutions space. More on the News Per management, the receipt of this approval marks a huge milestone for DexCom and for people with diabetes in Europe. This new platform provides an extremely powerful CGM that is easy to use, thereby helping the company’s users with insightful glucose data on one screen. This in turn reduces the time in managing diabetes. Image Source: Zacks Investment Research The company is collaborating with its insulin pump partners to combine Dexcom G7 into current and future automated insulin delivery systems as quickly as possible. Market Prospects Per a report by Grand View Research, the global CGM device market size was valued at $4.7 billion in 2020 and is estimated to witness a CAGR of 10.1% from 2021 to 2028. The growing incidence of diabetes coupled with the increasing geriatric population prone to diabetes is the primary factor driving this market’s growth. Hence, this announcement is well-timed for Dexcom. Recent Developments This month, the company announced that the Ontario government will offer coverage for the Dexcom G6 continuous glucose monitoring (CGM) System effective Mar 14, 2022. The government is going to offer this coverage through its Assistive Devices Program (ADP) for people staying in the province living with type 1 diabetes and are over two years of age and fulfill the coverage criteria. Also, this month, the company received the FDA’s Breakthrough Device Designation for the Dexcom CGM system’s use in the hospital setting. The designation is expected to offer a more efficient and streamlined review pathway to enable Dexcom CGM technology expand the company’s footprint in the hospital market faster. Last month, Dexcom announced that people with diabetes under 18 years of age who need the ongoing use of insulin or insulin pump therapy are eligible for public coverage of the Dexcom G6 CGM System via Alberta Health. Price Performance Shares of the company have gained 14.8% in the past year against the industry’s 9.2% fall. Zacks Rank & Key Picks Currently, Dexcom carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. AMN, Henry Schein, Inc. HSIC and McKesson Corporation MCK. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. AMN’s earnings yield of 8.8% compares favorably with the industry’s 0.3%. Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 25.5%. The company currently sports a Zacks Rank #2 (Buy). Henry Schein’s long-term earnings growth rate is estimated at 11.8%. HSIC’s earnings yield of 5.6% compares favorably with the industry’s 4.1%. McKesson surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.6%. The company currently carries a Zacks Rank #2. McKesson’s long-term earnings growth rate is estimated at 11.8%. MCK’s earnings yield of 8.8% compares favorably with the industry’s 4.1%. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-16,105.502,109.769,105.09,109.33,"2 Growth Stocks With More Upside Than Shiba Inu Last year, Shiba Inu (CRYPTO: SHIB) experienced a meteoric rise, but the meme coin has mostly been southbound since the beginning of 2022. Like most other cryptocurrencies, Shiba Inu faces several risks. Limited real-world uses coupled with an uncertain regulatory outlook do not make Shiba Inu the most stable asset to hold, to say the list. For long-term investors looking to build serious wealth, the stock market remains one of the best ways to do so. With that said, let's look at two stocks that have significant upside potential: Tandem Diabetes Care (NASDAQ: TNDM) and Planet 13 Holdings (OTC: PLNH.F). While Shiba Inu is unlikely to repeat its performance from last year, these two stocks have a bright future ahead. 1. Tandem Diabetes Care Medical devices specialist Tandem Diabetes Care makes the bulk of its revenue from the sale of its t:slim X2 insulin pump, an innovative device to help improve the lives of diabetes patients. Increased adoption of the company's crown jewel has worked wonders for its financial results. In 2021, Tandem Diabetes Care reported revenue of $702.8 million, 41% higher than the previous fiscal year. The company ended the year with nearly 330,000 customers worldwide, a solid increase from the roughly 200,000 it had at the end of 2020. While not yet consistently profitable, Tandem Diabetes Care reported a net income of $15.6 million in 2021, which was substantially better than the net loss of $34.4 million reported in 2020. While the company has not avoided this year's sell-off, there is a bright future ahead. Tandem Diabetes Care's t:slim X2 insulin pump boasts many advantages over competing pumps. For instance, it's claimed to be up to 38% smaller than other similar devices. Image source: Getty Images. It can also be combined with a continuous glucose monitoring device, namely DexCom's G6, for automatic insulin delivery to ensure that patients stay within their target glucose range. These perks should continue to help Tandem Diabetes Care attract new patients. The company estimates that its target market in the U.S. remains underpenetrated, with 64% of type 1 diabetes patients still relying on painful multiple daily injections (MDIs). The population of type 1 diabetes patients still using MDIs stands at 88% in the company's markets outside the U.S. These metrics are even lower for type 2 diabetes patients. In other words, Tandem Diabetes Care still has significant growth potential. Given that the diabetes patient population will continue to increase in the coming years, its device will become even more in need. That's why Tandem Diabetes Care's upside looks so high. The company has been more consistent in delivering quarterly profits in the past year, and given the massive opportunities at its disposal, there is likely more where that came from. Patient investors shouldn't pass up the opportunity to purchase shares of this healthcare stock on the dip. 2. Planet 13 Holdings Nevada-based Planet 13 Holdings looks like a risky bet. The company's shares have dropped in the past year and currently sit at $2 apiece as of this writing -- that's penny stock territory. It's always important to be careful when investing in stocks, but it is even more so with companies in which the market seems to have little faith. Still, there are reasons to be very optimistic about Planet 13 Holdings. First, the company's performance on the market is as much due to industrywide worries as it is to its own financial results. Planet 13 Holdings' stock has fallen in the past 12 months along with the Horizons Marijuana Life Sciences Index ETF, an industry benchmark. Data by YCharts. Planet 13 Holdings has actually done a pretty good job at managing the COVID-19 pandemic's effect on foot traffic in its stores. The company's business also rebounded nicely as many government-imposed measures to stop the spread of the disease subsided and vaccines became widely available. In the three months ending Sept. 30, the company's revenue soared by 45% year over year to $33 million. It's worth noting that Planet 13 Holdings' year over year revenue growth rates have been dropping, while margins have been squeezed as well. Here is why the company could reasonably address these issues. First, the marijuana sector has a bright future in North America. According to some estimates, the industry will expand at a compound annual growth rate of 16.6% through 2028. Second, Planet 13 Holdings has managed to differentiate itself from its competitors, giving it the ability to be one of the winners in the cannabis market in the coming years. The company's superstores offer a whole experience to customers, who can grab a bite to eat, shop for souvenirs, and witness the company's cannabis production process. Planet 13 Holdings' first superstore is strategically located in the heart of the Las Vegas strip. The company opened a second one in another touristy location in California last year. Planet 13 Holdings expenses have increased following the opening of its superstore in Florida, but the company has not gotten its return on investment so far. That's due in large part to low tourist activity in the state driven by the continued impact of the pandemic. As the outbreak subsides, expect things to pick up in the company's California superstore. Meanwhile, Planet 13 Holdings plans to open more of these in major cities in the next half-decade. Third, the company has expanded its presence elsewhere. For instance, it acquired a cannabis license in Florida late last year where it plans to open a network of neighborhood stores. While Planet 13 Holdings remains unprofitable, expect the company's revenue to continue growing, especially as the pandemic subsides and the company takes advantage of the new opportunities at its disposal should. That coupled with its unique business model among its peers will be instrumental in helping it show green on the bottom line eventually. Patient investors won't be disappointed with this cannabis stock. 10 stocks we like better than Tandem Diabetes Care When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns and recommends Planet 13 Holdings Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-17,108.855,114.166,108.644,113.682,"Stellar Sales Growth Trend Makes DexCom Stock A Wise Bet We believe that DexCom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, currently is an attractive pick over Amedisys stock (NASDAQ: AMED), a home health and hospice company with a similar revenue base, despite Dexcom’s comparatively higher valuation. DXCM stock trades at 16.3x trailing revenues, compared to 2.3x for AMED stock. We believe that this valuation gap is justified, given DexCom’s superior revenue growth and profitability, and better prospects. Looking at stock returns, AMED, with -16% returns over the last six months, has fared better than DXCM, which is down 26%. This compares with a 7% fall in the broader S&P500 index. However, there is more to the comparison, and we believe DexCom stands out with higher expected returns than Amedisys, as discussed in the sections below. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis – Amedisys vs. DexCom: Which Stock Is A Better Bet? Parts of the analysis are summarized below. 1. DexCom’s Revenue Growth Has Been Stronger Both companies managed to see sales growth over the recent quarters. Still, DexCom has witnessed comparatively faster revenue growth of 27% over the last twelve months versus 7% for Amedisys. Looking at a longer time frame, DexCom’s sales grew at a CAGR of 33.6% to $2.4 billion over the last twelve-month period, compared to $1.0 billion in 2018, while Amedisys’ sales grew at a CAGR of 10.1% to $2.2 billion from $1.7 billion over the same period. DexCom’s revenue growth over the recent quarters is being driven by continued new customer additions amid rising awareness of CGM devices. DexCom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require a finger prick, and data can be self-monitored easily. Given the limited competition and a vast pool of diabetic patients (over 34 million in the U.S. alone), the company will likely see strong revenue growth over the coming years. DexCom will soon launch its much-anticipated G7 CGM system in the U.S. this year, and it is expected to bolster the overall sales growth. Amedisys’ revenues were adversely impacted during the pandemic, with a decline in home health and hospice services due to social distancing and restrictions on movement. Now that most of the restrictions are behind us, Amedisys will likely see steady revenue growth. Amedisys completed the acquisition of AseraCare in June 2020, strengthening its hospice care business. Our DexCom Revenue and Amedisys Revenue dashboards provide more details on the companies’ revenues. The table below summarizes our revenue expectation for both the companies over the next three years and points to a CAGR of 20.8% for DexCom and 8.2% for Amedisys. Note that we have different methodologies for companies negatively impacted by Covid and for companies not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed in the three years before Covid to simulate return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months. 2. DexCom Is More Profitable, And It Comes With Lower Risk DexCom’s operating margin of 15% over the last twelve-month period is better than 12% for Amedisys. This compares with 13% and 10% figures seen in 2019, before the pandemic, respectively. DexCom’s free cash flow margin of 18.1% is also better than 8.5% for Amedisys. Our DexCom Operating Income and Amedisys Operating Income dashboards have more details. Looking at financial risk, DexCom trumps Amedisys. Its 4.5% debt as a percentage of equity is lower than 8.9% for Amedisys, while its 21.6% cash as a percentage of assets is higher than 2.3% for the latter, implying that DexCom has a better debt position and cash cushion. 3. The Net of It All We see that the revenue growth and profitability have been better for DexCom, and it also offers lower financial risk than Amedisys. However, Amedisys is trading at a comparatively lower valuation. Looking at prospects, using P/S as a base due to high fluctuations in P/E and P/EBIT, we find DexCom to be a better bet of the two. The table below summarizes our revenue and return expectation for DXCM and AMED over the next three years and points to a significant expected return of 93% for DXCM over this period vs. 47% expected return for AMED stock, implying that both the stocks are good investment opportunities currently, but if one has to choose one of the two, DXCM will likely turn out to be a better bet, based on Trefis Machine Learning analysis – Amedisys vs. DexCom – which also provides more details on how we arrive at these numbers. While DXCM stock may be a better pick over AMED, the Covid crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs. Logitech. What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016. Returns Mar 2022 MTD [1] 2022 YTD [1] 2017-22 Total [2] AMED Return -11% -11% 236% DXCM Return -2% -24% 582% S&P 500 Return -5% -13% 85% Trefis MS Portfolio Return -6% -15% 233% [1] Month-to-date and year-to-date as of 3/15/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-18,113.822,117.358,112.5,117.012,"Masimo's (MASI) New Product Expansion to Boost Patient Outcome Masimo Corporation MASI recently announced a major expansion of its leading hospital remote patient-monitoring and clinician notification platform — Masimo Patient SafetyNet. The expansion includes the addition of secure telehealth capabilities, thereby making the solution more adaptable and comprehensive. Telehealth for Patient SafetyNet is available for existing Patient SafetyNet systems via software upgrade and can be effortlessly integrated into view stations. The latest expansion of its Patient SafetyNet is a major stepping stone for Masimo’s Hospital Automation Platform across the world. Significance of the Expansion Telehealth for Patient SafetyNet provides secure, end-to-end, multi-way audio and visual communication between the point of care (in the room or at the bedside) to central command rooms and remote clinicians. This aids in improving clinical workflows and communication efficiency across the care continuum without interfering with the remote monitoring of patient data. The system also integrates TODA transcoding technology from LM Labs, which ensures the availability of the best quality live audio and video reproduction. These capabilities can be hosted within existing hospital infrastructure and can also exist in the cloud, thereby helping hospitals manage resources and comply with IT requirements while supporting fast deployment and flexible scaling. Telehealth for Patient SafetyNet offers a bunch of additional advanced features designed to further improve workflow efficiency and accommodate various communication and patient scenarios. The platform, which supports multiple simultaneous audio and visual streams, allows several clinicians and specialists to communicate and collaborate in real time, irrespective of location. Additionally, users can also securely chat via text, transfer files, share their screens and use collaborative digital whiteboards. This provides seamless access to patient data, notes and discussions in the most suitable medium for each case. Per management, telehealth for Patient SafetyNet is expected to allow clinicians to collaborate and communicate in advanced but intuitive and efficient ways. This is likely to ultimately lead to improvements in patient outcomes and reduce the cost of care. Industry Prospects Per a report by MarketsAndMarkets, the global patient-monitoring devices market is projected to reach $55.1 billion by 2025 from $36.4 billion in 2020 at a CAGR of 8.6%. Factors like technological advancements and growing preference for telehealth services amid the pandemic are expected to drive the market. Given the market potential, the latest addition of features to its Patient SafetyNet is likely to provide a significant boost to Masimo’s business globally. Notable Developments Last month, Masimo received the FDA’s clearance for SedLine brain function monitoring for pediatric patients (one to 17 years of age) and the SedLine Pediatric EEG (electroencephalogram) Sensor. The latest clearance expands access to SedLine for all patients above the age of one year in the United States. Also in February, Masimo announced robust fourth-quarter 2021 results, wherein it registered a solid uptick in the top line. The company also recorded a strong rebound in sensor sales (on the back of solid demand for set sensors) and robust order shipments. In the same month, MASI announced a major expansion of Masimo SafetyNet that brings robust, secure video conferencing to the remote patient management and connectivity platform to offer a comprehensive telehealth and telemonitoring solution. This is expected to provide a better patient experience. Comparison With Peers This month, Masimo’s patient-monitoring peer, DexCom, Inc. DXCM, received the CE Mark for the Dexcom G7 Continuous Glucose Monitoring (“CGM”) system for diabetics in Europe aged two years and above, including pregnant women. The same month, DXCM received the FDA’s Breakthrough Device Designation for the Dexcom CGM system’s use in the hospital setting. Another renowned name in patient-monitoring, Allscripts Healthcare Solutions, Inc.’s MDRX business unit, Veradigm, announced an agreement with the U.S. Social Security Administration (“SSA”). The agreement will allow SSA to electronically request and receive electronic health records through MDRX's Veradigm Network solution, Veradigm eChart Courier, thereby eliminating the need to allocate time and resources for manual medical record requests. Another popular peer of Masimo in the patient-monitoring space is Veeva Systems Inc. VEEV. This month, the company reported solid fourth-quarter fiscal 2022 results, wherein it continued to derive benefits from its flagship Vault platform. Veeva Commercial Cloud’s continued strength and robust adoption of Veeva Vault PromoMats and other products were other quarterly highlights. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How to Profit from Trillions on Spending for Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allscripts Healthcare Solutions, Inc. (MDRX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-21,116.255,116.77,111.915,115.085,
DXCM,2022-03-22,113.802,117.119,113.668,116.178,
DXCM,2022-03-23,114.995,114.995,111.21,112.328,"Is DexCom a Buy? Medical device companies can be excellent investments thanks to their unique mix of innovation-driven development, solid margins, and massive appreciation potential. Still, investors would do well to avoid businesses that feature some of the industry's bugbears like indebtedness, overly high valuations, and small addressable markets. On that note, DexCom (NASDAQ: DXCM) has some of the trappings that can make for a winner. Its returns have crushed the market over the last five years, with its shares rising by more than 487% against the market's rise of nearly 106%. Could it repeat this feat in the future? In my view, it's possible, but that doesn't necessarily make it the right stock for everyone. Image source: Getty Images. Why this stock might be a good pick for your portfolio To appreciate why this company is worth considering for purchase, it's key to understand its product: continuous glucose monitors (CGMs). DexCom's CGMs help people with type 2 diabetes to measure and therefore regulate their body's glucose levels. Using a CGM instead of a traditional pin-prick blood test is preferable for several reasons, starting with patient comfort. People who wear the company's disposable CGMs don't need to repeatedly poke themselves to keep their blood glucose levels in their target range. Plus, CGMs take more measurements than someone with a finger prick test would be willing to do throughout the day, which means that patients get alerted to issues sooner than they would otherwise. And they might even be saving money on insulin by using one of the company's CGMs, too. Obviously, those benefits are appealing enough to attract new customers in droves. Over the last five years, its annual sales have ballooned 241%, and in 2022 management expects to bring in as much as $2.9 billion. There's no guarantee of an encore, but investors can take heart that the company is still operating with the same successful business model as before. In fact, there's a strong argument to be made that it's actually becoming more efficient with that business model over time, which is appealing. Over the last three years, its annual cost of goods sold (COGS) and its selling, general, and administrative (SG&A) expenses have both fallen as a share of annual revenue, which drove its total expenses to also shrink as a proportion of sales. In the same period, its annual investments in research and development (R&D) grew significantly as a percentage of revenue, suggesting that management is judiciously using the cost savings to reinvest for future growth. DXCM Cost of Goods Sold (% of Annual Revenues) data by YCharts And all of the above are big green flags for investors. Don't overlook competitors and valuation risks The bear case against DexCom is that it's competing in an increasingly crowded industry that includes significantly more powerful competitors. For example, healthcare giant Abbott Laboratories is making headway into the market for CGMs as are many others. Though it has the benefit of focusing entirely on CGMs rather than other medical devices like some of its adversaries, DexCom still faces a fight for market share once the market is saturated. Given that management is expecting its total addressable market (TAM) of eligible patients to triple by the second half of 2023, however, saturation probably isn't coming soon. Nonetheless, with its narrow profit margin of 6.3%, there isn't much slack for management to work with to actually win the market share fight when it occurs. But there's always the hope of the margin improving in the next few years -- once the company concludes the manufacturing scale-up of its latest CGM. The other trouble with this stock is that its valuation is currently in the stratosphere. Its price-to-earnings (P/E) ratio is above 293, putting it massively higher than the industry's average of about 42. In one sense, that's a plus because it means the market has high expectations for the company's growth. For price-sensitive investors, such a high multiple is a dealbreaker. And even for those who prefer to chase growth stocks, multiples that high are a major red flag as they leave the stock vulnerable to a collapse in the event of a flight to value. At its current valuation, even a relatively minor earnings miss might leave a few serious dents in your investment. Therefore, while I've taken more than one stance in favor of purchasing the stock in the past, it's valued too expensively for me at the moment. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Alex Carchidi owns Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-24,113.282,117.49,110.523,117.098,
DXCM,2022-03-25,120.38,121.664,118.932,120.242,"[""Nasdaq 100 Movers: MRNA, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.5%. Year to date, DexCom Inc has lost about 10.6% of its value. And the worst performing Nasdaq 100 component thus far on the day is Moderna, trading down 5.4%. Moderna is lower by about 33.0% looking at the year to date performance. Two other components making moves today are Atlassian, trading down 4.2%, and Meta Platforms, trading up 2.0% on the day. VIDEO: Nasdaq 100 Movers: MRNA, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stock Market Today: Dow Jones, S&P 500 Opens Higher; Cannabis Stocks On The Rise Stock Market Today Mid-Morning Updates On Friday, the Dow Jones Industrial Average is up by 60 points. This comes as the U.S. and European Union (EU) announced a new partnership to reduce Europe\u2019s reliance on Russian energy, the start of a years-long effort to further isolate Russia after it began its invasion of Ukraine in February. With the new partnership, the U.S. and other nations will increase liquified natural gas exports to Europe by 15 billion cubic meters this year. Larger shipments will be delivered in the future as well. Today, DexCom (NASDAQ: DXCM) has announced a 4-for-1 stock split of its common shares. It will see the company\u2019s outstanding shares increasing to 800 million from the current 200 million shares. The EU also agreed on landmark new antitrust regulations that could reshape how tech giants like Meta Platforms (NASDAQ: FB) and Amazon (NASDAQ: AMZN) conduct business in the bloc. The regulation aims to prevent Big Tech from abusing its market position to harm smaller rivals. Among the Dow Jones leaders, shares of Apple (NASDAQ: AAPL) are up by 0.22% today while Microsoft (NASDAQ: MSFT) is down by 0.14%. Meanwhile, Disney (NYSE: DIS) and Nike (NYSE: NKE) are trading higher on Friday. Among the Dow financial leaders, Visa (NYSE: V) is up by 0.58% while Goldman Sachs (NYSE: GS) is also up by 1.03%. Shares of EV leader Tesla (NASDAQ: TSLA) are down by 0.85% on Friday. Rival EV companies like Rivian (NASDAQ: RIVN) are also down by 1.32%. Lucid Group (NASDAQ: LCID) is down by 2.90% today. Chinese EV leaders like Nio (NYSE: NIO) and Xpeng Motors (NYSE: XPEV) opened lower today. Dow Jones Today: Russia Proposes Bitcoin Payments For Oil & Energy Exports Following the stock market opening on Friday, the S&P 500 and Dow are trading higher at 0.08% and 0.21% respectively. The Nasdaq however, is trading lower at 0.32% today. Among exchange-traded funds, the Nasdaq 100 tracker Invesco QQQ Trust (NASDAQ: QQQ) is down by 0.32% while the SPDR S&P 500 ETF (NYSEARCA: SPY) is up by 0.08%. The 10-year Treasury yield remains elevated at nearly 2.37% today. U.S. oil prices, however, dipped by 2% to around $110 per barrel. This comes as concerns are easing on expectations that crude exports would resume from Kazakhstan\u2019s CPC terminal. Russia on Thursday announced that it is considering accepting bitcoin as payment for its oil and gas exports. It also says that when it comes to \u201cfriendly\u201d countries like China or Turkey, Russia will be more flexible with payment options. The price of Bitcoin is up by 1.97% today and currently trades at $44,883. [Read More] Top Stock Market News For Today March 25, 2022 Cannabis Stocks On A Roll Following Talks Of Federal Legalization Weed stocks are making headlines yet again this week as the topic of federal legalization is back on the table. This is apparent as some of the top cannabis firms in thestock market todayare seeing notable gains. Just this week, companies such as Tilray (NASDAQ: TLRY) and Sundial Growers (NASDAQ: SNDL) are up by over 20%. Diving in, all this is likely due to the U.S. House of Representatives setting another date to vote on a bill. Should this bill receive complete approval across bodies of government, it would see the nationwide legalization of marijuana. In theory, this would provide a massive bump in addressable markets for cannabis businesses. Going into the specifics, the House will be looking into the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act. As before, the bill will need to make it past voting on the House floor followed by clearance in the U.S. Senate. The latter of which was where a similar bill was blocked back in December 2020. Accordingly, this version of the bill is also pushing for the delisting of cannabis as a federally controlled substance. Moreover, the promotion of social equity throughout a legitimate industry is also another key focus of the bill. Because of all this, investors are understandably looking out for the best cannabis stocks to buy now. Not to mention, companies in the space are actively expanding their offerings. Just this week, both Aurora Cannabis (NASDAQ: ACB) and Cresco Labs (OTCMKTS: CRLBF) made notable acquisitions. For starters, Aurora purchased Thrive Cannabis for $38 million. Following that, Cresco Labs took over Columbia Care for $2 billion. As such, weed stocks would be attractive plays for some now. [Read More] Stocks To Invest In Right Now? 4 Consumer Tech Stocks In Focus Bed Bath & Beyond Stock Gains Following New Of Board Shake-Up Deal With Ryan Cohen In other news, former meme stock Bed, Bath & Beyond (NASDAQ: BBBY) or BBBY for short is in focus today. Evidently, the company\u2019s shares are now trading higher by over 6% at today\u2019s opening bell. By and large, this follows the latest news regarding the company\u2019s dealings with activist investor Ryan Cohen. As of today, three directors from Cohen\u2019s investment firm, RC Ventures will be joining the company\u2019s board. They will act as independent directors. Notably, this comes at a crucial time for the home furnishings company as it is amidst a turnaround effort. This being the case as the firm looks to refine its operations. Speaking on this latest development is BBBY CEO Mark Tritton. He notes, \u201cAs we move forward, our goals will continue to focus on delivering value for our shareholders, enhancing experiences for our customers, executing on the transformation throughout our business, and creating new and exciting opportunities for our dedicated employees across all our banners.\u201d For one thing, Ryan Cohen and his team seem to have plenty of ideas for how BBBY could shake things up. Earlier this month, after revealing his 9.8% stake in the company, Cohen suggested that a sale of BBBY\u2019s baby products business would be a good play. Regardless, with Cohen getting more involved in the company, investors appear to be keen on BBBY stock. Source: TradingView If you enjoyed this article and you\u2019re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!! The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-03-28,119.695,123.836,119.695,123.77,"Here's Why You Should Hold on to DexCom (DXCM) Stock Now DexCom, Inc. DXCM is well-poised for growth, backed by a robust product portfolio and a strong international presence. However, supply constraints remain a concern. Shares of the Zacks Rank #3 (Hold) company have gained 37.7% against the industry’s decline of 1.2% in a year’s time. Meanwhile, the S&P 500 Index has rallied 14.9%. DexCom — with a market capitalization of $46.69 billion — is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). It anticipates earnings to improve by 3.4% over the next five years. The company beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 26.5%. Key Catalysts Per the fourth-quarter 2021earnings call the company strengthened its product portfolio via differentiated software with the CE Mark and the launch of its Dexcom ONE product in the quarter under discussion. Since the launch of this product, the company has already witnessed strong adoption in both type one and type two customers, and the health systems in two of its four launch countries established reimbursement. During the third quarter, the company launched Dexcom ONE, which will be an important addition to its portfolio as DexCom progresses to widen access to healthcare for people with diabetes worldwide. Apart from this, DexCom received FDA clearance for two crucial software solutions that will help bolster its connected ecosystem. The first one is the DexCom real-time API, which makes it possible for third-party developers to incorporate real-time CGM data into their digital health apps and devices. This, in turn, offers Dexcom users a wide array of options when it comes to engagement with their glucose data. The second one is the company’s app-in-app module that directly integrates with third-party healthcare apps, thereby making managing diabetes easier for Type 2 Non-intensive insulin therapy (NIIT) users by enabling a convenient, single-app experience. Image Source: Zacks Investment Research In fourth-quarter 2021, international revenues (26% of total revenues) surged 54% year over year to $181.1 million. During the fourth quarter, international growth was broad-based throughout all markets, with all these markets delivering record sales in the quarter under review. DexCom’s market expansion initiatives internationally are all progressing according to plan, thereby driving high volume growth. Thus, international growth remains strong and presents future prospects, courtesy of improving global access and awareness. Factor Hurting the Stock DexCom relies on third parties for an assured steady supply of inputs. Thus, the capacity constraint for the production of its offerings might dampen the company’s growth prospects. Estimates Trend The Zacks Consensus Estimate for first-quarter 2022 revenues is pegged at $619.9 million, suggesting growth of 22.7% from the year-ago reported number. The same for earnings stands at 52 cents, indicating an improvement of 57.6% from the prior-year quarter. Stocks to Consider Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. AMN, Henry Schein, Inc. HSIC and McKesson Corporation MCK. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. AMN’s earnings yield of 8.8% compares favorably with the industry’s 0.3%. Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 25.5%. The company currently sports a Zacks Rank #1. Henry Schein’s long-term earnings growth rate is estimated at 11.8%. HSIC’s earnings yield of 5.6% compares favorably with the industry’s 4.1%. McKesson surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.6%. The company currently carries a Zacks Rank #2 (Buy). McKesson’s long-term earnings growth rate is estimated at 11.8%. MCK’s earnings yield of 8.8% compares favorably with the industry’s 4.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers ""Most Likely for Early Price Pops."" Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-03-29,125.0,129.0,124.57,128.822,"[""DexCom (DXCM) Shares Cross Above 200 DMA In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) crossed above their 200 day moving average of $500.59, changing hands as high as $510.84 per share. DexCom Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $318.45 per share, with $659.4518 as the 52 week high point \u2014 that compares with a last trade of $506.41. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Announces 4-for-1 Stock Split. Here's What Investors Need to Know. DexCom (NASDAQ: DXCM) has revolutionized the lives of people suffering from diabetes. The company introduced the first real-time continuous glucose monitoring (CGM) system back in 2006, raising the standard of care for a generation of patients. DexCom's robust business performance is reflected in its surging stock price. Over the past year, shares have climbed by roughly 38%. That's impressive in its own right, but zooming out highlights even stronger growth: shares are up 482% over the past five years and have gained a mind-boggling 4,550% over the course of the past decade. On Friday, DexCom announced plans to split its shares for the first time in company history. The announcement came on the heels of 20-for-1 stock split announcements from tech giants Alphabet and Amazon. The news is causing some investors to take a fresh look at the medical device maker. Let's recap just how a stock split works and what it means for existing and potential DexCom investors. Image source: Getty Images. The details DexCom's board of directors approved a 4-for-1 stock split. If supported by shareholders at the company's annual meeting on May 19, the split will amend DexCom's Restated Certificate of Incorporation and increase the total number of shares from 200 million to 800 million. Assuming the measure passes, shareholders of record as of May 19 will receive three additional shares of stock for each share they own. DexCom is currently trading at roughly $480 per share; post-split, investors will hold four shares worth roughly $120 each. The stock is expected to begin trading on a split-adjusted basis on June 10. Investors won't have to take any other action in order to receive their additional DexCom shares. Brokerages handle all the details behind the scenes so that additional shares will simply appear in investors' accounts. It's worth noting that the newly issued shares might not be available immediately on June 10. Timetables can vary slightly from brokerage to brokerage, so it can often take several days for the new post-split shares to be reflected in investors' accounts. How do investors benefit from a stock split? From a mathematical standpoint, the total value of shares held by each investor will not change. One share of DexCom stock currently fetching $480 will be worth the same amount as four post-split shares priced at $120 (4 x $120 = $480). Imagine a pizza: it doesn't matter whether it's sliced into eight or 16 pieces, so long as the size of underlying pie remains the same. Common thinking on Wall Street suggests that stock splits increase demand for a company's shares. This comes down to investor psychology: some potential buyers who are hesitant to shell out nearly $500 for a single stock may be more willing to pick up shares that trade closer to $100. History suggests, however, that the long-term impact of stock splits are outweighed by a company's actual performance. The good news for investors is that DexCom's business performance is impressive. Does this mean DexCom stock is a buy? Investors shouldn't buy DexCom stock simply because the company has initiated a stock split. But there are other reasons to consider investing in this medical device maker. The company's most recent financial report lays out a pretty compelling case. In 2021, DexCom generated revenue of $2.45 billion, up 27% year over year. At the same time, its adjusted operating income of $266 million was consistent with numbers from the year prior. These results came even as the company invested heavily in the launch of its hospital-based CGM system, which was granted a breakthrough device designation earlier this month by the Food and Drug Administration. DexCom appears poised to continue its growth. In mid-March, the company's most recent CGM device, the DexCom G7, received the Conformit\u00e8 Europ\u00ebenne (CE) Mark, allowing for sales within the European Union. The company plans to launch the DexCom G7 in Europe within the next several weeks. The Centers for Disease Control and Prevention reports that more than 415 million people worldwide are living with diabetes. That number is expected to exceed 500 million by 2040. DexCom pioneered CGM technology, becoming a global medical leader in the process. Given the large and growing market of patients who could benefit from its devices, DexCom lands squarely in the buy column. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 3, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Danny Vena owns Alphabet (A shares) and Amazon. The Motley Fool owns and recommends Alphabet (A shares) and Amazon. The Motley Fool recommends Alphabet (C shares) and DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-03-30,128.387,130.607,126.7,129.755,
DXCM,2022-03-31,129.992,130.19,127.08,127.9,
DXCM,2022-04-01,130.625,134.135,129.335,132.892,"S&P 500 Movers: ODFL, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 3.7%. Year to date, DexCom has lost about 1.2% of its value. And the worst performing S&P 500 component thus far on the day is Old Dominion Freight Line, trading down 3.5%. Old Dominion Freight Line, is lower by about 19.6% looking at the year to date performance. Two other components making moves today are Qualcomm, trading down 3.2%, and Wynn Resorts, trading up 2.5% on the day. VIDEO: S&P 500 Movers: ODFL, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-04,132.622,134.765,130.222,130.55,
DXCM,2022-04-05,130.455,130.86,126.565,129.105,"DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management DexCom, Inc. DXCM recently announced that the new Dexcom ONE Continuous Glucose Monitoring System (CGM) would be introduced in the U.K. in May. This new system is an easy-to-use real-time CGM (rt-CGM) and is more accessible and affordable for people suffering from diabetes in the country. Presently, Dexcom ONE is in review to be added to drug tariffs throughout the U.K. regions. It is worth mentioning that Dexcom ONE will become part of the broad range of products offered by the company for people with diabetes in the U.K., including the Dexcom G6 CGM system and the upcoming Dexcom G7 CGM system. Dexcom ONE has similar innovative sensing hardware like Dexcom G6 and is appropriate for people with Type 1 or Type 2 diabetes using insulin. This announcement is likely to strengthen DexCom’s robust product portfolio further. More on the News Per management, the diabetes community comprises a dynamic and inspiring group of individuals, and DexCom is committed to offering such individuals with innovative and impactful technology by expanding access to CGM technologies. This helps in driving enhanced health outcomes. In fact, the upcoming launch of Dexcom ONE signifies a crucial step forward in diabetes management, while inclusion in the drug tariff can lead to more people benefiting from this life-altering technology. Image Source: Zacks Investment Research It is imperative to mention that Dexcom ONE is a wearable sensor and transmitter that helps people to be in control of their diabetes. This innovative technology helps eliminate the need for painful finger pricks on the back of continuous glucose level monitoring and sending real-time values wirelessly to a compatible smart device via the Dexcom ONE mobile app. Further, a range of modified alerts can aid users in avoiding potentially dangerous high or low glucose events. Interestingly, this news comes on the heels of the National Institute for Health and Care Excellence (NICE) new guidelines for adults and children managing Type 1 diabetes. Per the new guidance, NICE recommends that adults with Type 1 diabetes be offered a choice of glucose sensors, including rt-CGM, while all children with Type 1 diabetes be offered rt-CGM, along with education for them as well as their families and/or caregivers on how to use their devices. Market Prospects Per a report by Grand View Research, the global CGM device market size was valued at $4.7 billion in 2020 and is estimated to witness a CAGR of 10.1% from 2021 to 2028. The growing incidence of diabetes and the increasing geriatric population prone to diabetes are the primary factors driving this market’s growth. Hence, this announcement is well-timed for DexCom. Recent Developments In March, DexCom announced the receipt of CE Mark for its G7 CGM system in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app. In the same month, the company announced that the Ontario government would offer coverage for the Dexcom G6 CGM system effective Mar 14, 2022. The government is going to offer this coverage through its Assistive Devices Program (ADP) for people staying in the province living with type 1 diabetes who are over two years of age and fulfill the coverage criteria. Price Performance Shares of the company have gained 40% in the past year compared with the industry’s growth of 2.6%. Zacks Rank & Key Picks Currently, Dexcom carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Edwards Lifesciences Corporation EW and Henry Schein, Inc. HSIC. AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare has gained 39.3% against the industry’s decline of 54.1% over the past year. Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.5%. Edwards Lifesciences has gained 40.8% compared with the industry’s 1.5% growth over the past year. Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2. Henry Schein has gained 27.1% compared with the industry’s rally of 8.3% over the past year. Just Released: The Biggest Tech IPOs of 2022 For a limited time, Zacks is revealing the most anticipated tech IPOs expected to launch this year. Concerns about Federal interest rates and inflation caused many private companies to stay on the bench- leading to companies with better brand recognition and higher growth rates getting into the game. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. See the complete list today. >>See Zacks Hottest IPOs Now Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-06,127.155,127.972,125.205,127.385,"Notable ETF Outflow Detected - IWP, DXCM, IDXX, FTNT Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $100.2 million dollar outflow -- that's a 0.7% decrease week over week (from 137,900,000 to 136,900,000). Among the largest underlying components of IWP, in trading today DexCom Inc (Symbol: DXCM) is off about 2.3%, Idexx Laboratories, Inc. (Symbol: IDXX) is off about 3.1%, and Fortinet Inc (Symbol: FTNT) is lower by about 3.8%. For a complete list of holdings, visit the IWP Holdings page » The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $88.97 per share, with $123.45 as the 52 week high point — that compares with a last trade of $97.41. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-07,126.07,130.178,125.591,128.13,
DXCM,2022-04-08,127.502,128.702,125.472,126.498,
DXCM,2022-04-11,124.688,125.455,122.502,123.122,"Why DexCom Surged 23.6% in March What happened Shares of DexCom (NASDAQ: DXCM) surged by 23.6% in March, according to data provided by S&P Global Market Intelligence. The rise has brought the diabetes management company's shares to nearly the same level as they were at the beginning of this year. Image source: Getty Images. So what DexCom reported a 27.1% year-over-year jump in revenue to $2.4 billion for fiscal year 2021 but operating income declined by 11.3% year over year due to higher research and development expenses. The company sounded an optimistic note for 2022, guiding for revenue of $2.88 billion, up 18% year over year, as it continues to advance on its business development initiatives. In line with the good results, the board of directors approved a 4-for-1 stock split. During the month, DexCom's G7 continuous glucose monitoring (CGM) system received the CE Mark, which will allow it to be sold in within the European Economic Area, for diabetes patients age 2 and above, including pregnant patients. This new product not only offers a list of customizable alerts that can warn users of high or low blood glucose levels, but also has the fastest sensor warmup in the market with no finger pricks or scanning required. In addition, DexCom is working with insulin pump partners to eventually integrate the G7 system into automated insulin delivery systems. Now what According to the World Health Organization, around 422 million people worldwide suffer from diabetes and the number of cases and prevalence has been steadily increasing over the last few decades. DexCom estimates that by 2045, around 783 million adults ages 20 to 79 will have this condition. Theglobal marketfor diabetes diagnostics is estimated at $30.8 billion this year and will rise by 8% per year to hit $42.4 billion by 2026. These numbers demonstrate that there are ample growth opportunities for DexCom to increase its market share to capture a slice of this lucrative pie. The company had indicated that the expansion into new markets where DexCom has little current commercial presence can triple its patient total addressable market by the second half of 2023. Just last week, the company announced its new DexCom One CGM system that will launch in the United Kingdom by May. The device has a wearable sensor and transmitter that allows users to monitor their glucose levels and send these values in real time to their smart devices for tracking. With the G7 receiving CE approval and the launch of its newest product, DexCom looks poised to report better numbers going forward and investors can also look forward to more innovative products in the pipeline. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Royston Yang has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-12,125.292,127.195,122.128,122.608,"Analysts See 10% Gains Ahead For RXL Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Health Care ETF (Symbol: RXL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $116.28 per unit. With RXL trading at a recent price near $105.86 per unit, that means that analysts see 9.84% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RXL's underlying holdings with notable upside to their analyst target prices are Boston Scientific Corp. (Symbol: BSX), DexCom Inc (Symbol: DXCM), and Insulet Corp (Symbol: PODD). Although BSX has traded at a recent price of $44.22/share, the average analyst target is 12.62% higher at $49.80/share. Similarly, DXCM has 12.48% upside from the recent share price of $492.49 if the average analyst target price of $553.94/share is reached, and analysts on average are expecting PODD to reach a target price of $286.86/share, which is 11.12% above the recent price of $258.14. Below is a twelve month price history chart comparing the stock performance of BSX, DXCM, and PODD: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET ProShares Ultra Health Care ETF RXL $105.86 $116.28 9.84% Boston Scientific Corp. BSX $44.22 $49.80 12.62% DexCom Inc DXCM $492.49 $553.94 12.48% Insulet Corp PODD $258.14 $286.86 11.12% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-13,123.398,125.728,123.37,124.7,
DXCM,2022-04-14,124.85,125.0,121.88,123.028,"[""DexCom (DXCM) G6 CGM System Now Available to TRICARE Members DexCom, Inc. DXCM recently announced that its G6 continuous glucose monitoring (\u201cCGM\u201d) System will be available to diabetic military members, their families and retirees as a TRICARE brand-name formulary pharmacy benefit. This will be effective from mid-April 2022 and is expected to provide faster and more convenient access to the Dexcom G6 CGM System to TRICARE members. With the latest availability to a wider patient pool, DexCom is expected to solidify its foothold in the global CGM business. A Few Words on Dexcom G6 CGM Dexcom G6 is equipped with a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device or receiver. This offers patients real-time glucose data without finger pricking. The system also provides customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that helps patients to share their glucose data in real time with up to 10 followers. Significance of the Availability Once effective, diabetic military TRICARE members will be eligible for Dexcom G6 through the military treatment facility pharmacies at zero copayment, the TRICARE retail pharmacy network or through mail order or home delivery. The pharmacy benefit provides a faster process and more consistent copayments for members. Earlier, Dexcom G6 was available via the TRICARE medical benefit by durable medical equipment suppliers where copayment amounts could vary depending on the plan. Per management, the pharmacy benefit will enable the diabetic TRICARE beneficiaries to utilize the technology to take better and real-time decisions concerning their health, with little to no out-of-pocket costs. Industry Prospects Per a report by Grand View Research, the global CGM device market size was valued at $3,929.7 million in 2019 and is expected to reach $10.4 billion by 2027 at a CAGR of 12.7%. Factors like rising cases of diabetes and increasing adoption of CGM devices are likely to drive the market. Given the market potential, the latest availability is expected to provide a significant boost to DexCom\u2019s business globally. Recent Developments This month, the company announced that the new Dexcom ONE CGM System will be launched in the United Kingdom in May. Last month, the company received CE Mark (Conformit\u00e9 Europ\u00e9enne) for the Dexcom G7 CGM System for diabetics in Europe aged two years and above, including pregnant women. The same month, DexCom announced that effective Mar 14, 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario\u2019s Assistive Devices Program for people in the province living with type 1 diabetes above the age of 2 years and meeting coverage criteria. Price Performance Shares of the company have gained 24.9% in the past year against the industry\u2019s 4.4% fall. The S&P 500 has risen 6.9% in the same time frame. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, DexCom carries a Zacks Rank #3 (Hold). A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Abiomed, Inc. ABMD and Henry Schein, Inc. HSIC. AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN\u2019s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcare has gained 37.3% against the industry\u2019s 57.1% fall over the past year. Abiomed, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 20%. ABMD\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.2%. Abiomed has lost 9.8% compared with the industry\u2019s 4.4% fall over the past year. Henry Schein has an estimated long-term growth rate of 11.8%. HSIC\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2. Henry Schein has gained 29.7% compared with the industry\u2019s 6.2% growth over the past year. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why DexCom (DXCM) is a Strong Momentum Stock It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on. The Style Scores are broken down into four categories: Value Score Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks. Growth Score Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time. Momentum Score Momentum investors, who live by the saying \""the trend is your friend,\"" are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. VGM Score What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier. #1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day. With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey. That's where the Style Scores come in. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Momentum investors should take note of this Medical stock. DXCM has a Momentum Style Score of A, and shares are up 14.1% over the past four weeks. Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2022, while the Zacks Consensus Estimate has increased $0.03 to $3.39 per share. DXCM also boasts an average earnings surprise of 26.5%. With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DXCM should be on investors' short list. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-18,122.47,122.998,119.028,120.158,
DXCM,2022-04-19,119.472,123.998,119.472,122.948,"[""Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think \"" Yes \"" Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. DexCom (DXCM) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy). While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below: Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 98%, investors should actually focus on the projected growth. The company's EPS is expected to grow 27.5% this year, crushing the industry average, which calls for EPS growth of 7.5%. Impressive Asset Utilization Ratio Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric shows how efficiently a firm is utilizing its assets to generate sales. Right now, DexCom has an S/TA ratio of 0.53, which means that the company gets $0.53 in sales for each dollar in assets. Comparing this to the industry average of 0.5, it can be said that the company is more efficient. While the level of efficiency in generating sales matters a lot, so does the sales growth of a company. And DexCom is well positioned from a sales growth perspective too. The company's sales are expected to grow 18.8% this year versus the industry average of 10.5%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. There have been upward revisions in current-year earnings estimates for DexCom. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month. Bottom Line DexCom has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination positions DexCom well for outperformance, so growth investors may want to bet on it. Just Released: Zacks' 7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year. These 7 were selected because of their superior potential for immediate breakout. See these time-sensitive tickers now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Hold on to CONMED (CNMD) Stock Now CONMED Corporation CNMD is well-poised for growth, courtesy of a robust product portfolio and strength in the General Surgery business. However, data security threats remain a concern. Shares of this currently Zacks Rank #3 (Hold) company have gained 11.5% compared with the industry\u2019s growth of 5.6% over the past year. The S&P 500 Index has rallied 6.3% in the same time frame. CONMED \u2014 with a market capitalization of $4.19 billion \u2014 is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring. It anticipates earnings to improve by 12.5% over the next five years. The company has a trailing four-quarter earnings surprise of 16.7%, on average. Key Catalysts CONMED offers a broad line of surgical products. CONMED\u2019s product portfolio consists of several new devices in the Orthopedic, Laparoscopic, Robotic, Open Surgery, Gastroenterology, Pulmonary and Cardiology sections. Innovative products like Hi-Fi Tape and Hi-Fi suture interface represent a critical component of repair security in rotator cuff repair space. Other notable offerings include the MicroFree platform in Orthopedics, the TruShot, the Y-Knot Pro and the CRYSTALVIEW Pump. Of the unique products under General Surgery, the Anchor Tissue Retrieval bag deserves mention. This is one of the major platforms in CONMED\u2019s specimen bag portfolio. With increased product offerings, the company can accelerate its top-line growth. Image Source: Zacks Investment Research General surgery comprises a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. CONMED\u2019s unique products and solutions within the General Surgery segment have been providing it a competitive edge in the MedTech space. In the fourth quarter of 2021, the General Surgery segment\u2019s revenues improved 12.2% at a constant exchange rate (CER). Domestically, General Surgery sales rose 6.8% year over year on a reported basis, while international sales climbed 25.3% at CER. According to the company\u2019s investor presentation, global General Surgery products are anticipated to grow at above-market rates on a long-term basis on the back of additional sales representatives and improving customer engagement. Primary Concern CONMED relies extensively on information technology (IT) systems for the storage, processing and transmission of its electronic, business-related information assets used in or necessary to conduct business. The data that the company stores and processes may include customer payment information and other types of sensitive business-related information. Numerous evolving cybersecurity threats pose potential risks to the security of the company\u2019s IT systems, networks and services, as well as the confidentiality, availability and integrity of its data. Estimates Trend For 2022, the consensus mark for adjusted earnings per share stands at $1.09, suggesting an improvement of 8.2% from the previous year. The Zacks Consensus Estimate for 2022 revenues is pegged at $3.70 billion, indicating growth of 15.3% from the year-ago reported figure. Stocks to Consider Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. AMN, DexCom, Inc. DXCM and Abiomed, Inc. ABMD. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcare\u2019s long-term earnings growth rate is estimated at 16.2%. AMN\u2019s earnings yield of 8.9% compares favorably with the industry\u2019s (0.3%). DexCom beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 26.5%. The company currently carries a Zacks Rank #2 (Buy). DexCom\u2019s long-term earnings growth rate is estimated at 17.6%. DXCM\u2019s earnings yield of 0.7% compares favorably with the industry\u2019s (6.7%). Abiomed surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.2%. The company currently carries a Zacks Rank #2. Abiomed\u2019s long-term earnings growth rate is estimated at 20%. ABMD\u2019s earnings yield of 1.5% compares favorably against the industry\u2019s (6.4%). Just Released: Zacks' 7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year. These 7 were selected because of their superior potential for immediate breakout. See these time-sensitive tickers now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-20,122.935,125.632,120.748,124.098,
DXCM,2022-04-21,124.78,125.945,117.552,118.102,"[""DexCom (DXCM) Earnings Expected to Grow: Should You Buy? DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 28. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This medical device company is expected to post quarterly earnings of $0.50 per share in its upcoming report, which represents a year-over-year change of +51.5%. Revenues are expected to be $619.67 million, up 22.7% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for DexCom? For DexCom, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +9.06%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that DexCom will most likely beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that DexCom would post earnings of $0.86 per share when it actually produced earnings of $0.68, delivering a surprise of -20.93%. Over the last four quarters, the company has beaten consensus EPS estimates three times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. DexCom appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Baxter (BAX) to Report Q1 Earnings: What's in the Offing? Baxter International Inc. BAX is scheduled to release first-quarter 2022 results on Apr 28, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 0.9%. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.1%. Q1 Estimates Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $3.67 billion, indicating an improvement of 24.4% from the prior-year period. The consensus mark for earnings stands at 80 cents per share, suggesting growth of 5.3% from the year-ago quarter. Factors to Note Increased demand for acute therapies products due to the COVID-19 resurgence and continuous renal replacement therapies (CRRT), devices and associated consumables are likely to have driven Baxter\u2019s Acute Therapies business\u2019 first-quarter performance. The company\u2019s robust product portfolio and the planned launch of therapies and products might get reflected in the first-quarter revenues. In the fourth quarter, Baxter announced the global launch of PrisMax 2 \u2014 the latest version of Baxter\u2019s leading-edge critical care technology that has been developed to streamline the delivery of CRRT and other organ support therapies. The PrisMax 2 system features new solutions within the company\u2019s TrueVue digital health portfolio and the PrismaLung+ blood-gas exchanger. Baxter International Inc. Price and EPS Surprise Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote Per the fourth-quarter 2021 earnings release, the company announced the FDA approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine) \u2014 a cardiovascular medication indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure). Interestingly, Baxter\u2019s formulation of norepinephrine is the first and only manufacturer-prepared ready-to-use formulation available. These developments might have favored the company\u2019s performance in the to-be-reported quarter. Global growth in patient volume drove the company\u2019s PD businesses, leading to higher sales with respect to Baxter\u2019s Renal Care segment in the fourth quarter. This momentum is likely to have continued in the first quarter as well. In the fourth quarter, all three of the company\u2019s global regions performed well and contributed to the quarter\u2019s favorable results. In Americas, Baxter reported revenues of $1.76 billion, up 4% on a year-over-year basis and 5% at cc. In EMEA, revenues totaled $815 million, up 2% from the year-ago quarter and 5% at cc. In APAC, revenues of $732 million improved 5% from the prior-year quarter and 6% at cc. Sustained recovery from the pandemic across all three regions contributed to the improvement. Baxter\u2019s wide geographic presence provides balance and stability, thereby enabling it to counter risks stemming from overexposure to a more limited range of geographies. This momentum is likely to have continued in the first quarter as well. What Our Quantitative Model Suggests Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Baxter has an Earnings ESP of -3.62%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: Baxter carries a Zacks Rank #3. Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. Zimmer Biomet Holdings, Inc. ZBH has an Earnings ESP of +0.67% and a Zacks Rank of 3. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Zimmer Biomet\u2019s long-term earnings growth rate is estimated at 5.8%. The company\u2019s earnings yield of 5% compares favorably with the industry\u2019s 0.4%. Haemonetics Corporation HAE has an Earnings ESP of +0.84% and a Zacks Rank of 3. Haemonetics\u2019 long-term earnings growth rate is estimated at 10%. The company\u2019s earnings yield of 4.8% compares favorably with the industry\u2019s 0.4%. DexCom, Inc. DXCM has an Earnings ESP of +9.06% and a Zacks Rank of 3. DexCom\u2019s long-term earnings growth rate is estimated at 17.6%. The company\u2019s earnings yield of 0.7% compares favorably with the industry\u2019s (6.5%). Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-22,116.725,116.958,109.864,110.162,"[""Nasdaq 100 Movers: ISRG, PDD In early trading on Friday, shares of Pinduoduo topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.0%. Year to date, Pinduoduo has lost about 36.8% of its value. And the worst performing Nasdaq 100 component thus far on the day is Intuitive Surgical, trading down 10.7%. Intuitive Surgical is lower by about 26.8% looking at the year to date performance. Two other components making moves today are DexCom, trading down 3.3%, and JD.com, trading up 5.3% on the day. VIDEO: Nasdaq 100 Movers: ISRG, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stryker (SYK) to Report Q1 Earnings: What's in the Cards? Stryker Corporation SYK is scheduled to release first-quarter 2022 results on Apr 28, after the closing bell. In the last reported quarter, the company delivered a negative earnings surprise of 0.4%. Q1 Estimates The Zacks Consensus Estimate for first-quarter earnings per share is pegged at $1.93, flat year over year. The same for revenues stands at $4.20 billion, suggesting growth of 6.2% from the prior-year quarter. Factors to Note Despite disruptions that stemmed from COVID-19 resurgence during the fourth quarter of 2021, Stryker's MedSurg and Neurotechnology segment witnessed substantial sales growth on the back of improvement across all its subsegments. This momentum is likely to have continued in the first quarter. With respect to the Orthopaedics & Spine segment, growth across Trauma and Extremities, as well as Knees subsegments, is likely to have favored the segment's first-quarter performance. Stryker is committed to the sustained expansion of Mako. This growth reflects the demand for its differentiated Mako robotic technology. The company witnessed both domestic and international growth (in Japan, Korea and emerging markets) in the fourth quarter of 2021. Hence, robust demand for Mako is likely to have contributed to Orthopaedics & Spine segment's performance in the to-be-reported quarter. Stryker Corporation Price and EPS Surprise Stryker Corporation price-eps-surprise | Stryker Corporation Quote On Feb 23, 2022, Stryker completed the acquisition of all the issued and outstanding shares of the common stock of Vocera Communications. Per management, the buyout will enable Stryker to enter the fast-growing digital care coordination and communications segment. Per the fourth-quarter 2021earnings call the company is above one year into the integration process (Wright Medical deal) and continues to see progress across all regions and functions despite COVID-19-induced headwinds. These developments are likely to have contributed to the company's performance in the to-be-reported quarter. Unfavorable pricing may have weighed on Stryker's first-quarter performance. What Our Quantitative Model Suggests Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see. Earnings ESP: Stryker has an Earnings ESP of -1.25%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Stryker carries a Zacks Rank #3. Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. Zimmer Biomet Holdings, Inc. ZBH has an Earnings ESP of +0.67% and a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. Zimmer Biomet's long-term earnings growth rate is estimated at 5.8%. The company's earnings yield of 5% compares favorably with the industry's 0.4%. Haemonetics Corporation HAE has an Earnings ESP of +0.84% and a Zacks Rank of 3. Haemonetics' long-term earnings growth rate is estimated at 10%. The company's earnings yield of 4.8% compares favorably with the industry's 0.4%. DexCom, Inc. DXCM has an Earnings ESP of +9.06% and a Zacks Rank of 3. DexCom's long-term earnings growth rate is estimated at 17.6%. The company's earnings yield of 0.7% compares favorably with the industry's (6.5%). Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-25,109.985,112.529,108.838,110.622,"DexCom (DXCM) to Report Q1 Earnings: What's in the Cards? DexCom, Inc. DXCM is scheduled to release first-quarter 2022 results on Apr 28, after the closing bell. In the last reported quarter, the company delivered a negative earnings surprise of 20.9%. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 26.5%. Q1 Estimates Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $619.7 million, suggesting growth of 22.7% from the year-ago reported figure. The consensus mark for earnings stands at 50 cents per share, indicating an improvement of 51.5% from the prior-year quarter. Factors to Note DexCom’s first-quarter top line is likely to reflect an increase in volume, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (“CGM”). During the fourth quarter of 2021, the company continued to make progress with respect to its objective of expanding access and accelerating its leadership in CGM-connected solutions and customer choice. Per the fourth-quarter 2021earnings call the company strengthened its product portfolio via differentiated software with the CE Mark and the launch of its Dexcom ONE product in the third quarter. DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote Per the third quarter of 2021 earnings release, the company completed the buyouts of its distributors in Australia and New Zealand, thereby advancing its strategy to transfer certain international markets from distributors to direct sales. In March 2022, the company’s received the FDA’s Breakthrough Device Designation for the Dexcom CGM system’s use in the hospital setting. These developments may have favored the company’s performance in the to-be-reported quarter. DexCom has ample prospects in international markets backed by demographic trends and lifestyles in countries outside the United States and Europe. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In fourth-quarter 2021, international revenues (26% of total revenues) surged 54% year over year to $181.1 million. The momentum is likely to have continued in the first quarter, thanks to broad-based growth throughout all markets. However, an increase in operating expenses and intense competition may have weighed on the to-be-reported quarter’s performance. What Our Quantitative Model Suggests Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see. Earnings ESP: DexCom has an Earnings ESP of +9.06%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3. Other Stocks Worth a Look Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter. Zimmer Biomet Holdings, Inc. ZBH has an Earnings ESP of +0.36% and a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. Zimmer Biomet's long-term earnings growth rate is estimated at 5.8%. The company's earnings yield of 5.2% compares favorably with the industry's 0.9%. Haemonetics Corporation HAE has an Earnings ESP of +0.84% and a Zacks Rank of 3. Haemonetics' long-term earnings growth rate is estimated at 10%. The company's earnings yield of 5.1% compares favorably with the industry's 0.9%. Hologic, Inc. HOLX has an Earnings ESP of +0.65% and a Zacks Rank of 3. Hologic's long-term earnings growth rate is estimated at 12.8%. The company's earnings yield of 6.9% compares favorably with the industry's (7%). Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Just Released: Zacks' 7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year. These 7 were selected because of their superior potential for immediate breakout. See these time-sensitive tickers now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-04-26,109.07,109.45,104.936,105.875,"[""Noteworthy Tuesday Option Activity: LEN, DXCM, BLL Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Lennar Corp (Symbol: LEN), where a total of 13,901 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 44.2% of LEN's average daily trading volume over the past month of 3.1 million shares. Especially high volume was seen for the $80 strike put option expiring May 20, 2022, with 2,607 contracts trading so far today, representing approximately 260,700 underlying shares of LEN. Below is a chart showing LEN's trailing twelve month trading history, with the $80 strike highlighted in orange: DexCom Inc (Symbol: DXCM) saw options trading volume of 2,675 contracts, representing approximately 267,500 underlying shares or approximately 42.8% of DXCM's average daily trading volume over the past month, of 625,515 shares. Particularly high volume was seen for the $550 strike call option expiring May 20, 2022, with 1,244 contracts trading so far today, representing approximately 124,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $550 strike highlighted in orange: And Ball Corp (Symbol: BLL) saw options trading volume of 6,678 contracts, representing approximately 667,800 underlying shares or approximately 40.5% of BLL's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $85 strike put option expiring May 20, 2022, with 3,012 contracts trading so far today, representing approximately 301,200 underlying shares of BLL. Below is a chart showing BLL's trailing twelve month trading history, with the $85 strike highlighted in orange: For the various different available expirations for LEN options, DXCM options, or BLL options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards? PerkinElmer, Inc. PKI is slated to release first-quarter 2022 results on May 3, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 19.1%. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 23.8%. Q1 Estimates Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $1.18 billion, suggesting a decline of 9.7% from the year-ago reported figure. The consensus mark for earnings stands at $2.08 per share, indicating a decrease of 44.1% from the prior-year quarter. Diagnostics Revenues: A Key Catalyst In the fourth quarter of 2021, with respect to business, Diagnostics, which represents 52% of total sales, grew 14% on a non-COVID basis with all three franchises growing double-digits, driven by Applied Genomics. This trend is likely to have continued in the first quarter. In April 2022, the company announced the expansion of its in vivo imaging portfolio with the introduction of the Vega imaging system. This system is a first-of-its-kind ultrasound platform that integrates hands-free, automated technology with a high-throughput ability to advance non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more. In the same month, PerkinElmer launched two ready-to-use Homogenous Time Resolved Technology (HTRF) and AlphaLISA no-wash assay kits. These kits have been created to quickly and easily identify and quantify CHO host cell protein (HCP) impurities during biopharmaceutical manufacturing. PerkinElmer, Inc. Price and EPS Surprise PerkinElmer, Inc. price-eps-surprise | PerkinElmer, Inc. Quote In December 2021, the company launched the research use only NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next-generation sequencing (NGS) solution will enable laboratories to boost sequencing throughput and make reliable variant identifications. These developments are likely to have positively impacted the company\u2019s Diagnostics segment in the first quarter. This, in turn, might get reflected in the company\u2019s to-be-reported quarter\u2019s results. Other Factors to Note The company\u2019s Discovery product portfolio may have witnessed strong demand, courtesy of sustained robust performance by life sciences. Productivity initiatives, volume leverage and strict cost control measures are likely to have contributed to the company\u2019s first-quarter gross and operating margins. New product introductions are likely to have improved product mix and thereby gross margin. However, PerkinElmer\u2019s exposure to the international markets increases the risk of foreign exchange volatility. The fluctuations in currency exchange rates might have weighed on the company\u2019s international sales in the to-be-reported quarter. Here\u2019s What the Quantitative Model Suggests Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here as you will see below. Earnings ESP: PerkinElmer has an Earnings ESP of -0.40%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: PerkinElmer carries a Zacks Rank #3. Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. Zimmer Biomet Holdings, Inc. ZBH has an Earnings ESP of +0.36% and a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. Zimmer Biomet's long-term earnings growth rate is estimated at 5.8%. The company's earnings yield of 5.2% compares favorably with the industry's 0.9%. Haemonetics Corporation HAE has an Earnings ESP of +0.84% and a Zacks Rank of 3. Haemonetics' long-term earnings growth rate is estimated at 10%. The company's earnings yield of 5.1% compares favorably with the industry's 0.9%. DexCom, Inc. DXCM has an Earnings ESP of +9.06% and a Zacks Rank of 3. DexCom's long-term earnings growth rate is estimated at 17.6%. The company's earnings yield of 0.8% compares favorably with the industry's (7%). Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Bitcoin, Like the Internet Itself, Could Change Everything Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the \u201cInternet of Money\u201d and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we\u2019re still in the early stages of this technology, and as it grows, it will create several investing opportunities. Zacks\u2019 has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. See 3 crypto-related stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store? AmerisourceBergen Corporation ABC is scheduled to release second-quarter fiscal 2022 results on May 4, before the opening bell. In the last reported quarter, the company delivered a negative earnings surprise of 0.4%. Its earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 2.3%. Q2 Estimates The Zacks Consensus Estimate for second-quarter fiscal 2022 revenues is pegged at $57.21 billion, indicating an improvement of 16.4% from the prior-year quarter. The consensus mark for earnings stands at $2.99, suggesting growth of 18.2% from the year-ago reported figure. Factors to Note Sustained growth in specialty product sales, including COVID-19 treatments and overall market growth, at this U.S. Healthcare Solutions segment may have favored the fiscal second-quarter performance. With respect to this segment, revenues are expected in the band of $207 billion to $212 billion in fiscal 2022, representing growth of 2-5%. Consequently, this may get reflected in the fiscal second-quarter results. Solid organic growth rates in the U.S. pharmaceutical market and population demographics might have contributed to the to-be-reported quarter\u2019s performance. In fiscal 2022, operating income at this segment is anticipated between $2.38 billion and $2.45 billion, reflecting growth of 5-9%. This, in turn, is likely to get reflected in the fiscal second-quarter results. AmerisourceBergen Corporation Price and EPS Surprise AmerisourceBergen Corporation price-eps-surprise | AmerisourceBergen Corporation Quote Apart from this, the World Courier unit is likely to have exhibited solid performance in the fiscal second quarter. In fact, World Courier\u2019s impressive track record as an international leader in specialty logistics has enabled AmerisourceBergen to lend support to customers globally despite a challenging COVID-19 induced environment and additional operational challenges. Going forward, World Courier will continue to design and deploy patient-centric and forward-thinking transport services in new areas like in-home clinical trials, making treatments in patients\u2019 home possible in virtually every therapeutic area. Per management, AmerisourceBergen continues to play a crucial role as the distributor of antiviral and antibody therapies used to treat COVID-19. These aforementioned trends are likely to have sustained in the fiscal second quarter as well. Per the fiscal 2022 guidance, operating income at the International Healthcare solutions segment is estimated to improve in the range of $685 million to $715 million. This, in turn, is likely to get reflected in the fiscal second-quarter results. However, higher adjusted operating expenses may have weighed on the company\u2019s to-be-reported quarter performance. What Our Quantitative Model Suggests Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see. Earnings ESP: AmerisourceBergen has an Earnings ESP of -2.81%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: It carries a Zacks Rank #4 (Sell). Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. Zimmer Biomet Holdings, Inc. ZBH has an Earnings ESP of +0.36% and a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. Zimmer Biomet's long-term earnings growth rate is estimated at 5.8%. The company's earnings yield of 5.2% compares favorably with the industry's 0.9%. Haemonetics Corporation HAE has an Earnings ESP of +0.84% and a Zacks Rank of 3. Haemonetics' long-term earnings growth rate is estimated at 10%. The company's earnings yield of 5.1% compares favorably with the industry's 0.9%. DexCom, Inc. DXCM has an Earnings ESP of +9.06% and a Zacks Rank of 3. DexCom's long-term earnings growth rate is estimated at 17.6%. The company's earnings yield of 0.8% compares favorably with the industry's (7%). Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Bitcoin, Like the Internet Itself, Could Change Everything Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the \u201cInternet of Money\u201d and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we\u2019re still in the early stages of this technology, and as it grows, it will create several investing opportunities. Zacks\u2019 has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. See 3 crypto-related stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-27,106.36,107.655,102.755,103.255,"[""Is a Surprise Coming for DexCom (DXCM) This Earnings Season? Investors are always looking for stocks that are poised to beat at earnings season and DexCom, Inc. DXCM may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because DexCom is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings \u2014 with the most up-to-date information possible \u2014 is a pretty good indicator of some favorable trends underneath the surface for DXCM in this report. In fact, the Most Accurate Estimate for the current quarter is currently at 54 cents per share for DXCM, compared to a broader Zacks Consensus Estimate of 50 cents per share. This suggests that analysts have very recently bumped up their estimates for DXCM, giving the stock a Zacks Earnings ESP of +9.06% heading into earnings season. DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here). Given that DXCM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Clearly, recent earnings estimate revisions suggest that good things are ahead for DexCom, and that a beat might be in the cards for the upcoming report. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""MedTech Stocks' Apr 28 Earnings Roster: ABMD, SYK & More The quarterly performance of the companies belonging to the MedTech industry has witnessed improvement on a year-over-year basis so far. Accelerated base business growth during the first quarter was reflected in the results of the majority of the stocks, courtesy of the waning of COVID-19 impact despite the emergence of new virus variants. However, the first-quarter performance of the majority of the companies witnessed a decline on a sequential basis. A number of MedTech players encountered severe staffing shortages and supply-chain hazards in the Q1 months, thanks to the emergence of the new COVID variants. Integral to the broader Medical sector, MedTech or Zacks-defined Medical Products companies have adapted well to changing consumer preferences and are experiencing a sustained uptrend in their stock prices. In the second half of the first-quarter reporting cycle, MedTech players saw a strong rebound in base sales volumes with the companies reaching their pre-pandemic legacy business level on the back of a substantial reduction in COVID-led fatality throughout the United States and other developed markets. Gradual lifting of restrictions and people getting back to pre-pandemic normalcy has led to a noticeable rebound in non-COVID and elective legacy businesses of the companies. Companies belonging to the MedTech sector have delivered an encouraging quarterly performance so far this reporting cycle. According to the latest Earnings Preview, this sector\u2019s first-quarter earnings are expected to improve 10.3% on 13.3% revenue growth. Let\u2019s take a look at four MedTech stocks that are scheduled to announce results on Apr 28. Abiomed, Inc. ABMD: Abiomed is likely to have registered a solid uptick in its U.S. revenues in the fourth quarter of fiscal 2022 on the back of strong growth in patient utilization and a favorable sales mix. Strength across the company\u2019s broad base portfolio was recorded, with robust growth in Impella CP, Impella RP and Impella 5.5 in the fiscal third quarter. This momentum is expected to have continued in the fiscal fourth quarter as well, given the gradual recovery of hospital-based procedures and patient utilization, thereby driving revenues. During the fiscal third-quarter 2022earnings call Abiomed confirmed that clinical feedback for its Breethe OXY-1 System has been favorable. This positive feedback is likely to have continued in the fiscal fourth quarter, leading to robust product adoption and sales. (Read more: Abiomed to Report Q4 Earnings: What\u2019s in the Cards?) ABIOMED, Inc. Price and EPS Surprise ABIOMED, Inc. price-eps-surprise | ABIOMED, Inc. Quote Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case for Abiomed. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. The company has a Zacks Rank #2 and an Earnings ESP of 0.00%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Stryker Corporation SYK: With respect to Stryker\u2019s Orthopaedics & Spine segment, growth across Trauma and Extremities, as well as Knees subsegments, is likely to have favored the segment's first-quarter 2022 performance. Stryker is committed to the sustained expansion of Mako. This growth reflects the demand for its differentiated Mako robotic technology. The company witnessed both domestic and international growth (in Japan, Korea and emerging markets) in the fourth quarter of 2021. Hence, robust demand for Mako is likely to have contributed to Orthopaedics & Spine segment's performance in the to-be-reported quarter. (Read more: Stryker to Report Q1 Earnings: What\u2019s in the Cards?) Stryker Corporation Price and EPS Surprise Stryker Corporation price-eps-surprise | Stryker Corporation Quote Stryker has a Zacks Rank #3 and an Earnings ESP of -1.44%. Baxter International Inc. BAX: Increased demand for acute therapies products due to the COVID-19 resurgence and continuous renal replacement therapies (CRRT), devices and associated consumables are likely to have driven Baxter\u2019s Acute Therapies business\u2019 first-quarter 2022 performance. The company\u2019s robust product portfolio and the planned launch of therapies and products might get reflected in the to-be-reported quarter\u2019s revenues. (Read more: Baxter to Post Q1 Earnings: What's in the Offing?) Baxter International Inc. Price and EPS Surprise Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote Baxter has a Zacks Rank #3 and an Earnings ESP of -3.62%. DexCom, Inc. DXCM: DexCom\u2019s first-quarter 2022 top line is likely to reflect an increase in volume, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). In March 2022, the company\u2019s received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. Per the third quarter of 2021 earnings release, the company completed the buyouts of its distributors in Australia and New Zealand, thereby advancing its strategy to transfer certain international markets from distributors to direct sales. These developments may have favored the company\u2019s performance in the to-be-reported quarter. (Read more: DexCom to Report Q1 Earnings: What\u2019s in the Cards?) DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote DexCom has a Zacks Rank #3 and an Earnings ESP of +9.06%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-28,103.75,104.418,99.5675,103.308,"[""DexCom (DXCM) Misses Q1 Earnings Estimates DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -36%. A quarter ago, it was expected that this medical device company would post earnings of $0.86 per share when it actually produced earnings of $0.68, delivering a surprise of -20.93%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $628.8 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.47%. This compares to year-ago revenues of $505 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have lost about 23.1% since the beginning of the year versus the S&P 500's decline of -12.2%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.75 on $698.89 million in revenues for the coming quarter and $3.38 on $2.91 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Intersect ENT (XENT), is yet to report results for the quarter ended March 2022. This maker of absorbable nasal implants is expected to post quarterly loss of $0.34 per share in its upcoming report, which represents a year-over-year change of +33.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Intersect ENT's revenues are expected to be $25.85 million, up 6.3% from the year-ago quarter. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for April 28, 2022 : AAPL, AMZN, INTC, SYK, GILD, KLAC, LHX, DLR, DXCM, AJG, TEAM, RMD The following companies are expected to report earnings after hours on 04/28/2022. Visit our Earnings Calendar for a full list of expected earnings releases. Apple Inc. (AAPL)is reporting for the quarter ending March 31, 2022. The computer company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.43. This value represents a 2.14% increase compared to the same quarter last year. In the past year AAPL has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AAPL is 25.46 vs. an industry ratio of -0.90, implying that they will have a higher earnings growth than their competitors in the same industry. Amazon.com, Inc. (AMZN)is reporting for the quarter ending March 31, 2022. The internet company's consensus earnings per share forecast from the 11 analysts that follow the stock is $8.73. This value represents a 44.71% decrease compared to the same quarter last year. AMZN missed the consensus earnings per share in the 3rd calendar quarter of 2021 by -32.75%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AMZN is 56.23 vs. an industry ratio of 19.60, implying that they will have a higher earnings growth than their competitors in the same industry. Intel Corporation (INTC)is reporting for the quarter ending March 31, 2022. The semiconductor company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.80. This value represents a 42.45% decrease compared to the same quarter last year. In the past year INTC has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 21.11%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for INTC is 13.03 vs. an industry ratio of 18.50. Stryker Corporation (SYK)is reporting for the quarter ending March 31, 2022. The medical products company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.93. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for SYK is 25.63 vs. an industry ratio of -15.70, implying that they will have a higher earnings growth than their competitors in the same industry. Gilead Sciences, Inc. (GILD)is reporting for the quarter ending March 31, 2022. The biomedical (gene) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.77. This value represents a 14.90% decrease compared to the same quarter last year. GILD missed the consensus earnings per share in the 4th calendar quarter of 2021 by -54.9%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for GILD is 9.42 vs. an industry ratio of -13.10, implying that they will have a higher earnings growth than their competitors in the same industry. KLA Corporation (KLAC)is reporting for the quarter ending March 31, 2022. The electrical instrument company's consensus earnings per share forecast from the 8 analysts that follow the stock is $4.80. This value represents a 24.68% increase compared to the same quarter last year. In the past year KLAC has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.95%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for KLAC is 15.46 vs. an industry ratio of -5.20, implying that they will have a higher earnings growth than their competitors in the same industry. L3Harris Technologies, Inc. (LHX)is reporting for the quarter ending March 31, 2022. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.02. This value represents a 5.03% decrease compared to the same quarter last year. In the past year LHX has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.54%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for LHX is 17.76 vs. an industry ratio of 18.70. Digital Realty Trust, Inc. (DLR)is reporting for the quarter ending March 31, 2022. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.67. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DLR is 21.58 vs. an industry ratio of 7.80, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending March 31, 2022. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.50. This value represents a 51.52% increase compared to the same quarter last year. DXCM missed the consensus earnings per share in the 4th calendar quarter of 2021 by -20.93%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DXCM is 122.20 vs. an industry ratio of -25.10, implying that they will have a higher earnings growth than their competitors in the same industry. Arthur J. Gallagher & Co. (AJG)is reporting for the quarter ending March 31, 2022. The insurance brokers company's consensus earnings per share forecast from the 6 analysts that follow the stock is $2.77. This value represents a 37.13% increase compared to the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 5.38%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AJG is 22.52 vs. an industry ratio of 19.20, implying that they will have a higher earnings growth than their competitors in the same industry. Atlassian Corporation Plc (TEAM)is reporting for the quarter ending March 31, 2022. The internet software company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.20. This value represents a 322.22% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for TEAM is -477.76 vs. an industry ratio of -114.30. ResMed Inc. (RMD)is reporting for the quarter ending March 31, 2022. The medical products company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.44. This value represents a 10.77% increase compared to the same quarter last year. In the past year RMD has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for RMD is 35.37 vs. an industry ratio of -15.70, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-04-29,103.095,107.87,101.305,102.145,"[""DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates DexCom, Inc. DXCM reported first-quarter 2022 adjusted earnings per share (EPS) of 32 cents, which missed the Zacks Consensus Estimate of 50 cents by 36%. The bottom line declined 3% on a year-over-year basis. GAAP net income per share in the quarter was 93 cents, compared with the year-ago quarter\u2019s figure of 56 cents per share. Revenue Details Total revenues grew 25% (22% on an organic basis) to $628.8 million on a year-over-year basis and outpaced the Zacks Consensus Estimate by 1.5%. Rising volumes across all channels, along with strong new customer additions owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring (CGM), contributed to the upside. Segmental Details Revenues at the Sensor and other revenues segment (86% of total revenues) climbed 28% on a year-over-year basis to $543.2 million. Hardware revenues (14%) rose 6% year over year to $85.6 million. Geographical Details U.S. revenues (72% of total revenues) increased 18% on a year-over-year basis to $451.2 million. International revenues (28%) surged 43% year over year to $177.6 million. Margin Analysis Gross profit in the quarter under review totaled $398.1 million, up 15.8% year over year. DexCom generated an adjusted gross margin (as a percentage of revenues) of 63.3%, which contracted 480 basis points (bps) year over year. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Research and development expenses amounted to $135.9 million in the quarter, up 24.2% year over year. Selling, general and administrative expenses totaled $220.9 million in the reported quarter, up 17.1% year over year. The company reported total operating expenses of $356.8 million, down 10% from the prior-year figure. Operating margin (as a percentage of revenues) of 6.6% contracted 250 bps year over year. Financial Position The company exited the first quarter with $2.69 billion in cash, cash equivalents and marketable securities, compared with $2.73 billion in the preceding quarter. Total assets in the first quarter amounted to $5.06 billion, compared with $4.86 billion on a sequential basis. 2022 Guidance Reaffirmed DexCom has decided to reiterate 2022 guidance for revenues, adjusted gross margin and adjusted operating margin. The company expects revenues to be $2.82-$2.94 billion, reflecting growth of 15-20% from the previous year. The Zacks Consensus Estimate for the same stands at $2.91 billion. While adjusted gross margin is anticipated to be about 65%, adjusted operating margin is estimated to be around 16%. Wrapping Up DexCom exited the first-quarter 2022 on a mixed note, wherein earnings missed the Zacks Consensus Estimate but revenues beat the same. Impressive contribution from the Sensor segment, and domestic and international revenue growth were key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, DexCom ended the quarter with new patient additions as well. Nevertheless, contraction in both gross and operating margins is a woe. Apart from this, cut-throat competition in the market for blood & glucose monitoring devices remains a concern. Zacks Rank Currently, DexCom has a Zacks Rank #3 (Hold). Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Qiagen N.V. QGEN, UnitedHealth Group Incorporated UNH and Alkermes plc ALKS. Qiagen, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 80 cents, which beat the Zacks Consensus Estimate by 12.7%. Revenues of $628.4 million outpaced the consensus mark by 6.5%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Qiagen has an estimated long-term growth rate of 11.5%. QGEN\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 11.7%. UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%. UnitedHealth has an estimated long-term growth rate of 14.8%. UNH\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%. Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1. Alkermes has an estimated long-term growth rate of 23.8%. ALKS\u2019 earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom Stock a Buy Now? If you were to strictly look at earnings multiples, you could easily miss a top growth stock like DexCom (NASDAQ: DXCM). Initially, value investors might scoff at the whopping 200+ times earnings that it trades at right now. But that wouldn't tell you the whole story. The reality is that DexCom makes some highly coveted continuous glucose monitoring (CGM) devices that can be game-changers for people with diabetes, allowing them to easily stay on top of their glucose levels. And that can lead to some significant growth down the road. Should investors worry about the stock's seemingly high valuation or look past it? Image source: Getty Images. DexCom has been rapidly growing its sales in recent years In 2021, Dexcom's top line came in at over $2.4 billion, representing year-over-year growth of 27%. And compared to two years ago, when sales were just under $1.5 billion, the company's top line has expanded by 66%. What's promising about the healthcare business beyond just its growth rate is that it generates great margins. At roughly $1.7 billion, the company's gross margin was nearly 70% of revenue in 2021. At that high of a rate, that means close to $0.70 of every dollar of revenue could cover the company's operating expenses. For a growth-oriented company like DexCom, that can translate into long-term profit growth as its products reach more people. The P/E multiple may not always be helpful DexCom's profit this past year was less than half of what it was in 2020, and that has weighed down its price-to-earnings (P/E) multiple. One reason for the decline is the business incurring a non-cash collaborative research and development fee of $87.1 million that wasn't there in previous years. The company also spent more on research and development. And as opposed to an income tax benefit of $268.6 million that propped up its earnings a year earlier, in 2021, the company incurred tax expenses of $19.2 million. When looking at adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), which factors out non-recurring and unusual items, the company's bottom line in 2021 actually rose by 14% to $578.9 million, or 24% of revenue. This year, the company anticipates up to 20% revenue growth and a slightly higher adjusted EBITDA margin of 25%. However, even with a modest earnings boost, that likely wouldn't have been enough to make DexCom look cheap by any stretch. The reality is that for fast-growing companies like DexCom, a P/E multiple may not always be a useful way for investors to evaluate its share price. To assess a company's value, especially over the very long term, investors need to consider the opportunities ahead for the business, not just a P/E ratio that a good or bad earnings result can quickly skew. There's plenty of growth on the horizon According to estimates from Vantage Market Research, theglobal marketfor CGM devices is growing at a compound annual growth rate of 10.8% and will be worth more than $13.2 billion by 2028 -- more than twice the size it is today ($5.1 billion). One of DexCom's key initiatives is to roll out its devices to more international markets, which could generate significant growth in the years ahead. In 2021, international revenue grew at a rate of 44% year over year, while U.S. revenue rose at a more modest 23%. Meanwhile, international sales account for just one-quarter of DexCom's business. By expanding around the world, DexCom can quickly strengthen its top line and overall financials. DexCom is a solid buy for long-term investors According to an estimate from the Centers for Disease Control and Prevention in 2010, the number of Americans with diabetes could triple by 2050. The need to manage the disease will only be more important in the future as the number of patients rises. Whether it grows internationally or domestically, there will be no shortage of opportunities for DexCom to generate significant growth for just not years but potentially decades. That type of growth can be difficult to capture in just a snapshot like a P/E multiple that looks at where the business is right now. And with strong gross margins, as DexCom's business grows, so will its profitability, which means its valuation will look more reasonable in the future. DexCom may look expensive today, but if you're in it for the long haul (e.g., more than just a couple of years), this could be one of the best investments to put in your portfolio. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 7, 2022 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-05-02,102.24,103.448,99.38,101.785,
DXCM,2022-05-03,101.355,101.882,98.2575,98.85,"[""Relative Strength Alert For DexCom Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.96, after changing hands as low as $393.48 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 40.4. A bullish investor could look at DXCM's 29.96 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $318.45 per share, with $659.4518 as the 52 week high point \u2014 that compares with a last trade of $396.58. Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom: Wall Street Expects This \u201cStrong Buy\u201d Stock to Rebound Dexcom (NASDAQ: DXCM), a leading maker of continuous glucose monitoring (CGM) systems, announced mixed Q122 results last week and reaffirmed its full-year guidance. Shares are down 24% year-to-date. However, Wall Street analysts continue to be bullish on Dexcom given its ability to capture further business in an underpenetrated CGM market and the rapid rise in diabetes across the globe. Financial Snapshot Dexcom\u2019s Q122 revenue grew 25% year-over-year to $628.8 million, beating analysts\u2019 estimates of $624.47 million. It\u2019s worth noting that a substantial portion of the company\u2019s revenue is recurring in nature. Disposable sensor and other revenue accounted for nearly 86% of Q122 revenue, while reusable hardware revenue contributed the remaining 14%. Meanwhile, Q122 adjusted EPS declined 3% to $0.32 and lagged the Street\u2019s estimate of $0.52. Marketing and growth investments as well as an unfavorable channel mix impacted the company\u2019s profitability. Dexcom continues to expect 2022 revenue of $2.82 billion-$2.94 billion, reflecting growth in the range of 15%-20%. It expects adjusted gross margins of about 65% and adjusted operating margins of nearly 16% in 2022. Wall Street\u2019s Take Reacting to Dexcom\u2019s Q1 results, Stifel analyst Mathew Blackman stated that most of the headwinds experienced by the company seem \u201ctransient in nature.\u201d Blackman noted that while Dexcom\u2019s U.S. performance was a bit softer-than-expected, its growth accelerated sequentially, unlike rival Abbott (ABT). The analyst also pointed out that the lower-than-anticipated Q122 margins were due to certain one-time items that will fade or reverse over the course of the year, as emphasized by the company\u2019s reaffirmed full-year gross margin and EBITDA (Earnings before Interest, Tax, Depreciation, and Amortization) guidance. Blackman is also optimistic about the launch of G7 in additional Tier 1 countries following its roll-out in the UK. Dexcom\u2019s G7 CGM received CE Mark approval in March, following which it initiated a limited launch of G7 in the UK in the subsequent weeks. Blackman lowered his price target on Dexcom to $520 from $555 but maintained a Buy rating. SVB Leerink Partners analyst Danielle Antalffy also lowered her price target on DexCom to $500 from $565 while maintaining a Buy rating following the Q122 results. The analyst feels that the adverse impact of channel mix, labor challenges, and currency headwinds might persist for the next few quarters. That said, Antalffy continues to believe that Dexcom\u2019s long-term revenue guidance of $4 billion-$4.5 billion by 2025 could be conservative. Overall, 11 analysts have a Buy rating on Dexcom, while one has a Hold rating. That adds up to a Strong Buy consensus rating. The average Dexcom price target of $526.75 implies 29.38% upside potential from current levels. Conclusion Despite the recent earnings miss and growing competition from Abbott, Wall Street continues to be bullish on Dexcom based on its dominant position in the CGM space and the rising adoption of CGM in the diabetes market. Discover new investment ideas with data you can trust Read full Disclaimer & Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-05-04,99.3375,102.432,94.49,101.508,
DXCM,2022-05-05,100.248,102.209,93.075,94.8225,
DXCM,2022-05-06,93.0525,93.4494,86.92,87.9725,
DXCM,2022-05-09,85.6925,87.1375,80.5,82.505,
DXCM,2022-05-10,85.155,86.4362,79.6825,81.8575,
DXCM,2022-05-11,81.8,84.4875,78.345,78.735,"2 Unstoppable Growth Stocks to Buy in 2022 and Beyond So far, 2022 has been a pretty hectic year for the market. But successful investors will know to ignore all the volatility and noise and focus on what matters most. The market will recover in the long run, and those individual companies whose prospects remain intact will bounce back. That means the recent downturn has a bit of a silver lining: Opportunistic investors can buy shares of great companies on the dip. Let's look at two top stocks that have performed worse than the broader market this year: DexCom (NASDAQ: DXCM) and Microsoft (NASDAQ: MSFT). Here is why both are worth buying now and holding on to for a while. DXCM data by YCharts Image source: Getty Images. 1. DexCom Shares of medical devices specialist DexCom have dropped by 39% year to date. On one hand, investors may rightfully be worried about the company's declining top-line growth rates. Of course, marketwide issues -- including geopolitical tensions and interest rate hikes in the U.S. -- did not help either. But there are good reasons to be optimistic about DexCom. It is one of the leaders in the market for continuous glucose monitoring (CGM) systems. These devices help diabetes patients automatically keep track of their blood glucose levels. Using CGM systems is associated with better health outcomes for diabetics. DexCom's own G6 CGM system continues to be highly successful. In the first quarter, the company's revenue -- which it generates through the sale of the G6 and accessories -- increased by 25% year over year to $629 million. DexCom's top line has grown at a good clip in recent years, thanks to the continued adoption of the G6. But we haven't seen the best of DexCom just yet. Here are three reasons why. First, the company estimates that there remains significant room to grow in the CGM market -- even in the U.S., a leader in the adoption of this technology. Meanwhile, it is currently expanding into international markets, and by the second half of 2023, these efforts should triple its total addressable market. Second, the company is currently working on a successor to the G6, namely the G7. This device will be an improvement over its predecessor in terms of achieving better health outcomes. The G7 recently received regulatory clearance in Europe. DexCom submitted the new device for review to authorities in the U.S. in the fourth quarter of 2021, and a regulatory nod from there could drop before the end of the year. Third, the diabetes population is projected to continue growing rapidly.This unfortunate reality means that innovative companies like DexCom that help diabetes patients live better lives will be in even higher demand. Given the growth opportunities ahead, investors should look past DexCom's declining revenue growth rates as the company has plenty of fuel to continue delivering solid financial results for years. And considering how much its shares have dropped recently, now is a great time to initiate a position in this healthcare stock. 2. Microsoft Microsoft has also been subject to the recent sell-off that particularly impacted growth stocks. Thankfully, the tech giant is arguably as robust as ever. Those who have held shares of Microsoft for a while have been handsomely rewarded. The company long-ago established a dominant spot in the market for computer operating systems and applications -- and built an incredibly valuable brand in the process. In 2021, Microsoft was the fourth-most valuable brand in the world, according to Statista. The company will almost certainly continue to thrive thanks to the services it offers, many of which have now become integral parts of the day-to-day lives of individuals and businesses. For instance, Microsoft's productivity tools, including Word, Excel, Teams, and Outlook, continue to be used by millions of people worldwide. The company has also become a giant in cloud computing thanks to Microsoft Azure, coming in second in terms of market share as of the fourth quarter of 2021. Microsoft has more recently expanded its footprint in the gaming industry with the planned acquisition of Activision Blizzard in an all-cash transaction valued at $68.7 billion. With a host of long-term opportunities to grab onto -- both the gaming and cloud computing industries are still growing rapidly -- and the cash flow it generates, Microsoft is more than capable of rebounding from the poor stock performance it has so far shown this year. Patient investors should ride out the storm and stick with this tech giant. Find out why DexCom is one of the 10 best stocks to buy now Our award-winning analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of April 7, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Activision Blizzard and Microsoft. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-05-12,77.4,80.1963,75.6525,77.88,
DXCM,2022-05-13,79.125,84.4201,79.12,83.685,"10 Substantial Stock Splits to Put on Your Radar 2022 is shaping up to be a busy year for stock splits. Stock splits occur when a company divides up its shares to lower the price and increase the overall number of shares available. Companies typically split their stock when the share price has gotten very high. While stock splits are cosmetic events that shouldn't impact a company's market value since nothing fundamental to the business is changed, there is plenty of anecdotal evidence that suggests they create wealth. SEE MORE The 22 Best Stocks to Buy for 2022 Take Nvidia (NVDA) for instance. The chipmaker said in May 2021 that it was splitting its stock 4-for-1. Shares rallied 20% between the May 21 announcement and July 19, the date the actual split occurred. There are several theories that attempt to explain why share prices often rise following a stock split. The first is that splitting a high-priced stock makes it more affordable to retail investors, which in turn creates new demand that fuels price gains. Another is that stock splits send a signal to the market that a company's share price has been rising. New investors may jump in because they assume this growth will continue. A third hypothesis is that managers declare stock splits to convey favorable information about the company's unrealized value and growth prospects. Investors respond to this signal from insiders by stepping up share purchases. Whatever the reason, there are plenty of examples of companies experiencing share price gains after a stock split. Today, we look at 10 companies that have announced or already undergone stock splits in 2022. Not every name featured here is a recommendation, but this list of firms that are splitting their shares might be a good jumping-off point for interested investors. SEE MORE 12 of Wall Street's Newest Dividend Stocks Data is as of May 11. Stock split stocks are listed in alphabetical order. Getty Images ACM Research Market value: $716.4 million Stock split: 3-for-1 Kicking off our list of stock split stocks is ACM Research (ACMR, $11.63), which develops and manufactures semiconductor processing equipment for wafer-level production applications. The company primarily supplies single-wafer cleaning equipment and considers its cleaning tools best-in-class, offering higher yields and greater efficiency than competitor equipment. ACMR's technology is protected by more than 350 issued patents. The company ramped production of new products in 2021 and is on track to double its addressable market opportunity by adding two new product categories. ACM Research's revenues rose 66% year-over-year in 2021 and earnings per share (EPS) grew 73%. However, in April, the company warned that March quarter results were likely to fall short of guidance due to COVID-related restrictions in Shanghai that have impacted employee access, production and logistics and ACMR's ability to ship finished products to customers. March quarter revenues fell 4% year-over-year and the firm posted an adjusted per-share loss of 1 cent versus earnings of 12 cents per share one year ago. Another risk is ACM Research's heavy reliance on customers in China, who purchase most of its semiconductor manufacturing equipment. Worsening trade relationships with China could adversely impact the company's financial results, but ACMR hopes to mitigate trade risk by finding new customers for its equipment outside of the mainland. ACMR declared a 3-for-1 stock dividend in March that was paid to investors on March 23. ""We are implementing this stock split to make stock ownership more accessible to employees and investors,"" said Dr. David Want, CEO of ACM Research, at the time the stock split was announced. Shares are down roughly 59% so far in 2022 as investors have digested increased risk and reduced guidance. Despite these risks, the semiconductor stock is well-liked by most of the 10 Wall Street analysts covering it, with five calling ACMR a Buy and four saying it's a Strong Buy. SEE MORE 5 Big Data Stocks to Buy for Big Long-Term Growth Getty Images Alphabet Market value: $1.50 trillion Stock split: 20-for-1 Alphabet (GOOGL, $2,272.05) which is the parent company to Google, is a worldwide leader in digital platforms. Its offerings include Chrome, Android, Google Search, Google Maps, Gmail, YouTube and a slew of other aps and services. The company's three business segments are Google Services, Google Cloud and Other Bets, a combination of earlier-stage businesses that are not yet individually material to results. One of Wall Street's few mega-cap stocks, Alphabet has generated steady double-digit revenue and EPS growth over the past decade. GOOGL shares have returned approximately 150% over the last five years, far exceeding the roughly 80% S&P 500 total return for the same period. Alphabet said sales were up 23% year-over-year in the March quarter, its slowest growth rate since 2020. GOOGL attributed the slowdown to rising inflation, supply-chain disruptions and the Ukraine war, which are reducing spending by brand advertisers, especially in Europe. Net income declined 8% and fell short of analyst estimates due in part to tough year-over-year comparisons and the company's decision to suspend operations in Russia. Google Cloud Services, while still unprofitable, remains a growth area for Alphabet, with sales up 44% during the March quarter. And GOOGL also plans to build its capacities in cybersecurity by spending $5.4 billion to acquire Mandiant (MNDT). Deutsche Bank analyst Benjamin Black recently reiterated his Buy rating on GOOGL stock. Black noted positives for the March quarter that include strong margins, a good performance from Google Search and growing interest in YouTube Shorts, a new service competing with TikTok. Alphabet announced a 20-for-1 stock split in February that will be issued on July 15. The Google stock split requires shareholder approval and will be put to a vote on June 1. The company also recently announced a new stock buyback program, with plans to repurchase up to an additional $70 billion of its own shares. Stock splits often make high-priced shares more attractive to retail investors and this could certainly be the case for GOOGL. Based on its most recent close, Alphabet stock would trade at about $113 per share post-split – much more accessible than the $2,272 per share it's priced at now. SEE MORE Hedge Funds' 25 Top Blue-Chip Stocks to Buy Now Getty Images Amazon.com Market value: $1.07 trillion Stock split: 20-for-1 Amazon.com (AMZN, $2,107.44) has been a growth stock for over two decades; big reinvestments in its core e-commerce business have paid off handsomely for investors with consistent double-digit sales and EPS gains. The company is best-known for its e-commerce site, but derives an increasing percentage of its profits from web services and digital ad segments. The company's growth has slowed to single-digit rates in 2022 due to the impact of labor shortages, supply chain issues and rising costs. In addition, Amazon's ongoing investments in logistics, the cloud and related areas are pressuring near-term profits. During the first quarter of 2022, Amazon posted 7% year-over-year sales growth and operating income down nearly 60% from one year ago. Second-quarter guidance looks for 3%-7% sales gains and could include an operating loss. Despite the company's strong historic growth, Amazon's stock returns have underperformed the S&P 500 over the last three years. In an effort to attract new retail investors, Amazon announced a 20-for-1 stock split effective June 3 that will drop the share price from roughly $2,100 to $101 (based on current levels). Stock splits are not common for AMZN, and this is the first one for the company since 1999. The split was announced at the same time as a new $10 billion share repurchase. Citi analyst Ronald Josey recently called Amazon one of the best-positioned companies he covers. He has a Buy rating on AMZN stock, and expects the company to benefit from improved efficiencies due to new fulfillment centers and rising profit contributions from its web service and digital ad segments. SEE MORE Warren Buffett's Inflation Plan: Buy, Buy, Buy Getty Images Dexcom Market value: $30.9 billion Stock split: 4-for-1 Diabetes care company Dexcom (DXCM, $314.94) makes glucose monitoring systems that are sold worldwide. Its novel implantable devices enable continuous glucose monitoring that are optimal for successful management of diabetes and also eliminate the need for painful finger sticks. Global expenditures for diabetes care were estimated at $966 billion in 2021, according to research firm Statista. And the International Diabetes Federation projects the number of diabetic adults will rise from 537 million last year to 783 million by 2045, creating a huge growing market for the DXCM's products. Dexcom became a leader in this market with its G6 continuous glucose monitor (CGM) and recently launched Dexcom One, a simpler and less expensive model that is helping the company build share in emerging markets such as Eastern Europe. DXCM also plans to introduce the G7, a next-generation version of its leading device that is more convenient, 60% smaller and offers better performance than its predecessor. The G7 device has already secured approval in Europe and was submitted to the U.S. Food and Drug Administration (FDA) for approval during the December quarter. Dexcom grew revenues 25% year-over-year in the March quarter, but adjusted EPS declined slightly due to higher expenses for research and development, collaborative fees and sales and marketing. The company is guiding for 15%-20% revenue growth in 2022 and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margins of approximately 25%. UBS recently added Dexcom to its list of stocks expected to rebound when market volatility subsides. In addition, earlier this year Wells Fargo raised DXCM stock to Overweight from Equal Weight (the equivalents of Buy and Hold, respectively), citing the upcoming G7 launch as a major growth driver. The Wells Fargo team thinks the company can potentially double the addressable market for CGM devices. Dexcom found its way on this list of stock split stocks after announcing a 4-for-1 adjustment in late March. The split will increase its share count from 200 million to 800 million, effective June 10. Using the current $315 price, this will reduce DXCM's share price to roughly $74. SEE MORE The Best (And Worst) Stocks for Rising Prices Getty Image Napco Security Technologies Market value: $580.4 million Stock split: 2-for-1 Napco Security Technologies (NSSC, $15.80) makes electronic security devices for commercial and residential properties. Its products are sold in the U.S. via a network of 200+ distributors, 10,000+ independent dealers and 2,000+ independent integrators who install alarm systems in airports, office buildings, schools and hospitals. In May, the company announced fiscal third-quarter results that included a 27% year-over-year rise in sales, while recurring revenues rose 35% during the three-month period to account for 33% of total revenues. While supply-chain constraints on electronic products have increased backlogs and weighed on its bottom line, Napco is benefiting from rising demand for school security as COVID-related lockdowns have ended. Based on its survey of 136,300 schools and average spending of $75,000 per school, Napco envisions a $10 billion school market opportunity. Napco also sees a $4.9 billion market opportunity tied to obsolete phone land lines and alarm systems across 5 million commercial buildings and 120 million residences in the U.S. Its cellular-based systems not only replace but upgrade, and create a recurring revenue run rate of $49.9 million annually as of April 2022. NSSC became one of the first stock splits of 2022 after announcing a 2-for-1 adjustment late last year. The stock split went into effect on Jan. 4. Four of the five analysts that cover NSSC rate the stock Buy or Strong Buy. Bullish investors point to the company's rising recurring revenues and the upcoming upgrade cycle in the school market as reasons to invest. SEE MORE 7 Defense Stocks to Buy as Geopolitical Risks Rise Getty Images RH Market value: $6.9 billion Stock split: 3-for-1 Home furnishings retailer RH (RH, $279.45) – a member of the Berkshire Hathaway equity portfolio – sells high-end furniture, lighting, textiles and home decor through a network of 67 retail galleries and 38 outlet stores across 30 U.S. states and Canada. Growth initiatives that include new gallery openings, global expansion, and new products and collections paid off handsomely for the company in 2021, fueling 32% sales gains and 46% adjusted EPS growth. However, the company warns that red-hot inflation and rising interest rates during 2022 could soften demand and is guiding for just 5%-7% sales growth this year. RH announced plans for a 3-for-1 stock split in March, and it's expected to be executed in the spring. Considering stock splits reduce the share price, the company said it seemed like an appropriate time given the runup RH has seen on the charts since its 2012 initial public offering (IPO), where it was priced at $24. Gordon Haskett analyst Chuck Grom expects the company to use the $2.0 billion of cash on its balance sheet to aggressively repurchase shares or debt, noting that the price of RH shares has fallen precipitously in 2022 (down about 48% for the year-to-date). Despite the cautious outlook provided by RH management, Wells Fargo analyst Zachary Fadem remains positive on the retail stock. He thinks the company's sales guidance will ultimately prove conservative, is maintaining his 2022 EPS estimate, and thinks the valuation is attractive for those with a long-term view. SEE MORE 15 Stock Picks That Billionaires Love Getty Images Shopify Market value: $40.2 billion Stock split: 10-for-1 Shopify (SHOP, $318.59) sailed high during the pandemic, but shares have plummeted in 2022 along with other e-commerce names amid worries of slowing growth. The company provides essential internet infrastructure for retailers seeking to build online sales. Its platform enables merchants to display, manage and market products across various sales channels, including web and mobile storefronts, and support order processing and fulfillment, inventory management, payment processing and customer relationship building. A potential threat to Shopify comes from Amazon.com's recent launch of Buy with Prime, which is seen as a direct competitor as it allows third-party websites to tap into its fulfillment and delivery network. Shopify presently holds a 10.3% share of the U.S. retail ecommerce market, second only to Amazon's 41% share. In a bid to expand its fulfillment services and compete more effectively against Amazon, Shopify in early May said it is buying Deliverr – a San Francisco-based startup that specializes in technologies for building fulfillment networks. The cash-and-stock deal is valued at $2.1 billion. Shopify is also partnering with digital payment platform Strike to accept Bitcoin payments on its network. Shopify generated 22% year-over-year revenue gains in its March quarter, but significantly lower adjusted EPS compared to the year-ago period. The company also warned of slower revenue growth in fiscal 2022 due in part to tough year-over-year comparisons. As part of its March quarter update, SHOP unveiled a 10-for-1 stock split that shareholders will vote at the company's annual meeting in June. Stifel analyst Scott Devitt has a Buy rating on Shopify, but is cautious that inflationary headwinds are more likely to affect Shopify merchants versus those using Amazon.com due to differences in product mix. Citi, meanwhile, issued a negative catalyst watch on SHOP stock after its Q1 report, citing concerns that consensus analyst forecasts underestimate the market headwinds in place. SEE MORE 5 Stocks to Sell or Avoid Now Getty Images SMART Global Holdings Market value: $1.1 billion Stock split: 2-for-1 SMART Global Holdings (SGH, $21.59) makes specialty solutions for the computing, memory and LED markets worldwide. The company manufactures RAM modules for computers and smartphones, embedded and removable flash memory and flash component products, and LED products for lighting, video screens and specialty lighting applications. Mobile/PCs and advanced lighting products comprise nearly half of the company's total sales and SMART Global is experiencing growth across all of its businesses. Last year's acquisition of Cree LED brought new offerings to the product mix that are fueling revenue and margin gains in this business. Overall, SMART Global generated 48% revenue growth during the March quarter while delivering its eightH consecutive quarter of year-over-year sales gains. And adjusted EPS nearly doubled from the year-ago period to come in above analysts' consensus estimate. There's more where that came from, with Wall Street analysts forecasting 23.4% revenue and 35% EPS growth this year. The company also announced a multi-year engagement with Meta Platforms (FB) that bodes well for future growth. SMART Global will provide AI-optimized architecture and managed services for Meta's ultra-scale AI computer and important new memory solution products for its data center and cloud applications. SMART Global was another one of the early stock split stocks in 2022. The company announced a 2-for-1 stock split in early January that became effective Feb. 1. SGH also unveiled a $75 million share repurchase authorization. SGH is well-liked by the analyst community too. All six of the Wall Street pros currently following the stock rate it either Buy or Strong Buy. SEE MORE 5 Great Green Stocks Making a Direct Impact Getty Images Tesla Market value: $760.4 billion Stock split: Amount not yet determined Elon Musk is making headlines for his takeover of Twitter (TWTR). But the wealth engine that supports Musk's Twitter deal is Tesla (TSLA, $734.00), the electric vehicle (EV) company he helped start in the early 2000s. Tesla has quickly grown to become the world's largest electric vehicle maker with a worldwide EV market share estimated at 21%, according to research firm InsideEVs. Tesla is a standout in the EV market because of the large number of models it offers (16), and its technological innovations that include Autopilot driverless assist and over-the-air software updates to improve the vehicle's range, power, braking and other features. The company is ramping up capacity to meet anticipated demand. Tesla opened its Gigafactory in Texas earlier this year that is expected to produce 500,000 of its Model Y SUVs per year, as well as its Gigafactory in Berlin, Germany. To improve control over its supply chain, Tesla is also bringing some battery production in-house, a move expected to increase flexibility and improve margins. Tesla delivered more than 310,000 EVs during the March quarter, up 68% year-over-year – and it believes it can grow this figure by an average of 50% annually over the next few years. Increased vehicle deliveries and higher sales prices during the March quarter generated 81% revenue growth for TSLA and more than tripled adjusted EPS. The company retains plenty of powder to fund future growth with $17.5 billion of cash on its balance sheet. In late March, Tesla announced plans for a stock split. The stock split ratio has not yet been disclosed and the action will require a shareholder vote, which is likely to occur in October. As far as stock splits go, this would mark the second one for Tesla in as many years, with the last occurring in 2020 when the company split its shares 5-for-1. The shares went on to rally 80% from the time of the announcement through the actual split. Wedbush Securities analyst Dan Ives recently reiterated his Outperform (Buy) rating on TSLA stock, citing the company's excellent March quarter results and his confidence that Tesla can deliver 1.5 million EVs in 2022. Most Wall Street analysts were impressed by the company's better-than-expected March quarter results, although some are cautious on valuation and supply-chain headwinds. SEE MORE 5 Stock Picks With Bulletproof Profit Margins Getty Images W.R. Berkley Market value: $17.7 billion Stock split: 3-for-2 W.R. Berkley (WRB, $66.66) specializes in commercial insurance products that includes excess and surplus lines, worker's compensation, professional liability and reinsurance. The company operates through 56 independently managed units, each serving territories, market segments or product types that require specialized knowledge. Over the past decade, this consistent performer has delivered steady 7% annual growth in revenues and nearly 15% yearly EPS growth on a trailing 12-month basis. WRB achieved record underwriting income and net income last year, while net premiums rose 22% and earnings per share nearly doubled. These impressive results occurred as the company benefited from rate increases in nearly all of its lines of business, margin gains and a further reduction in its expense ratio. W.R. Berkley also returned more than $478 million to its investors via $265 million of special dividends, $90 million of regular dividends and $122 million of share repurchases. The company has paid cash dividends without interruption since 1976 and grown its dividend 11% annually over the past 16 years. Without providing specific financial guidance, W.R. Berkley recently shared that it is well-positioned to prosper during an inflationary environment and anticipates another great year in 2022. March quarter results support this thesis, showing 18% year-over-year premium gains, 158% EPS growth and a 35.5% return on equity. Wells Fargo analyst Elyse Greenspan sees 2022 shaping up as a solid year for commercial line insurers in general and has made WRB stock one of her top picks in this sector. W.R. Berkley announced a 3-for-2 stock split in February that went into effect in March. SEE MORE 65 Best Dividend Stocks You Can Count On in 2022 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-05-16,83.695,84.7975,80.7725,81.15,
DXCM,2022-05-17,83.4225,84.5375,80.3475,83.04,"VO, SNPS, DXCM, CNC: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $754.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 229,741,108 to 233,332,550). Among the largest underlying components of VO, in trading today Synopsys Inc (Symbol: SNPS) is up about 1.7%, DexCom Inc (Symbol: DXCM) is down about 0.6%, and Centene Corp (Symbol: CNC) is lower by about 0.1%. For a complete list of holdings, visit the VO Holdings page » The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $201.98 per share, with $261.53 as the 52 week high point — that compares with a last trade of $211.89. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Free Report: Top 7%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-05-18,81.765,82.275,76.7225,77.1225,
DXCM,2022-05-19,77.75,80.3638,76.2525,79.03,"[""Here's Why You Should Hold on to DexCom (DXCM) Stock Now DexCom, Inc. DXCM is well-poised for growth, backed by a robust product portfolio and a strong international presence. However, supply constraints remain a concern. Shares of the Zacks Rank #3 (Hold) company have lost 10.4% compared with the industry\u2019s decline of 15% in a year\u2019s time. Meanwhile, the S&P 500 Index has fallen 2.1%. DexCom \u2014 with a market capitalization of $30.27 billion \u2014 is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). It anticipates earnings to improve by 17.4% over the next five years. The company beat earnings estimates in two of the trailing four quarters and missed twice, the average surprise being 15.8%. Key Catalysts On the basis of business growth and expanding patient base, the extension of G7 into all the core markets might extend to 2022 as the company ramps up manufacturing to lend support to the markets in an efficient manner. In April 2022, DexCom announced that the new Dexcom ONE CGM System would be introduced in the U.K. in May. This new system is an easy-to-use real-time CGM (rt-CGM) and is more accessible and affordable for people suffering from diabetes in the country. Presently, Dexcom ONE is in review to be added to drug tariffs throughout the U.K. regions. It is worth mentioning that Dexcom ONE will become part of the broad range of products offered by the company for people with diabetes in the U.K., including the Dexcom G6 CGM system and the upcoming Dexcom G7 CGM system. Image Source: Zacks Investment Research In March 2022, DexCom announced that the Ontario government would offer coverage for the Dexcom G6 CGM System effective Mar 14, 2022. The government is going to offer this coverage through its Assistive Devices Program (ADP) for people staying with type one diabetes in the province living and are over two years of age and fulfill the coverage criteria. It is worth mentioning that the back of the upper arm insertion site is for ages 18 and above. In the same month, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM System\u2019s use in the hospital setting. The designation is expected to provide a more efficient and streamlined review pathway to enable Dexcom CGM technology to rapidly strengthen the company\u2019s footprint in the hospital market. In first-quarter 2022, international revenues (28% of total revenues) surged 43% year over year to $177.6 million, owing to the widening of commercial footprint. DexCom\u2019s market expansion initiatives internationally are all progressing according to plan, thereby driving high volume growth. Thus, international growth remains strong and presents future prospects, courtesy of improving global access and awareness. Factor Hurting the Stock DexCom relies on third parties for an assured steady supply of inputs. Consequently, the capacity constraint for the production of its offerings might dampen the company\u2019s growth prospects. Estimates Trend The Zacks Consensus Estimate for 2022 revenues is pegged at $2.91 billion, suggesting growth of 18.8% from the year-ago reported number. The same for earnings stands at $3.28, indicating an improvement of 23.3% from the prior-year quarter. Stocks to Consider Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Masimo Corporation MASI and Veeva Systems, Inc. VEEV. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcare\u2019s long-term earnings growth rate is estimated at 1.1%. The company\u2019s earnings yield of 11.4% compares favorably with the industry\u2019s (0.8%). Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2 (Buy). Masimo\u2019s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company\u2019s earnings yield is pegged at 3.8% against the industry\u2019s (8.5%). Veeva Systems surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.6%. The company currently carries a Zacks Rank #2. Veeva Systems\u2019 long-term earnings growth rate is estimated at 18.1%. The company\u2019s earnings yield of 2.4% compares favorably with the industry\u2019s 0.2%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Are Options Traders Betting on a Big Move in DexCom (DXCM) Stock? Investors in DexCom, Inc. DXCM need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 17, 2022 $290.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for DexCom shares, but what is the fundamental picture for the company? Currently, DexCom is a Zacks Rank #3 (Hold) in the Medical - Instruments industry that ranks in the Bottom 28% of our Zacks Industry Rank. Over the last 30 days, two analysts have increased their earnings estimates for the current quarter, while six have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 75 cents per share to 71 cents in that period. Given the way analysts feel about DexCom right now, this huge implied volatility could mean there\u2019s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-05-20,81.175,81.4638,77.3075,80.3075,
DXCM,2022-05-23,80.6925,81.405,77.91,80.98,
DXCM,2022-05-24,74.0825,76.62,70.7325,72.0325,"[""Health Care Sector Update for 05/24/2022: INMB.PODD,DXCM,CUTR Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both were down 0.6%. The Nasdaq Biotechnology index was sinking 1.8%. In company news, INmune Bio (INMB) Tuesday was plunging almost 29% after saying the US Food and Drug Administration late last week placed a clinical hold on phase II testing of the company's XPro1595 drug candidate and requested additional information on the chemistry, manufacturing and controls for the prospective treatment for Alzheimer's disease. Cutera (CUTR) declined almost 14% after the medical device company Tuesday disclosed plans for a $200 million private placement of convertible senior notes due 2028. Insulet (PODD) rose 5.1% amid reports Dexcom (DXCM) is pursuing a potential acquisition of the medical device company. A deal could be reached \""in the coming weeks,\"" unnamed sources told Bloomberg, although they also cautioned the talks could still fall apart. DexCom shares were dropping over 12% this afternoon. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Tuesday Option Activity: ALGM, SIG, DXCM Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Allegro MicroSystems Inc (Symbol: ALGM), where a total volume of 5,614 contracts has been traded thus far today, a contract volume which is representative of approximately 561,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 85.3% of ALGM's average daily trading volume over the past month, of 657,770 shares. Particularly high volume was seen for the $20 strike put option expiring June 17, 2022, with 5,524 contracts trading so far today, representing approximately 552,400 underlying shares of ALGM. Below is a chart showing ALGM's trailing twelve month trading history, with the $20 strike highlighted in orange: Signet Jewelers Ltd (Symbol: SIG) options are showing a volume of 9,125 contracts thus far today. That number of contracts represents approximately 912,500 underlying shares, working out to a sizeable 75.5% of SIG's average daily trading volume over the past month, of 1.2 million shares. Particularly high volume was seen for the $50 strike put option expiring October 21, 2022, with 3,000 contracts trading so far today, representing approximately 300,000 underlying shares of SIG. Below is a chart showing SIG's trailing twelve month trading history, with the $50 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 6,630 contracts, representing approximately 663,000 underlying shares or approximately 72.1% of DXCM's average daily trading volume over the past month, of 919,775 shares. Particularly high volume was seen for the $310 strike put option expiring June 17, 2022, with 948 contracts trading so far today, representing approximately 94,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $310 strike highlighted in orange: For the various different available expirations for ALGM options, SIG options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 05/24/2022: ROIV,INMB,CUTR,PODD,DXCM Health care stocks were narrowly higher this afternoon, with the NYSE Health Care Index climbing less than 0.1% and the SPDR Health Care Select Sector ETF (XLV) rising 0.3%. The Nasdaq Biotechnology index, however, was sinking 1.5%. In company news, Roivant Sciences (ROIV) climbed 6.9% after saying the US Food and Drug Administration cleared the company's Vtama topical cream to treat plaque psoriasis in adults. Insulet (PODD) rose 7.2% amid reports Dexcom (DXCM) is pursuing a potential acquisition of the medical device company. A deal could be reached \""in the coming weeks,\"" unnamed sources told Bloomberg, although they also cautioned the talks could still fall apart. DexCom shares were dropping 11% this afternoon. Cutera (CUTR) declined more than 17% after the medical device company Tuesday disclosed plans for a $200 million private placement of convertible senior notes due 2028. INmune Bio (INMB) was plunging over 25% after saying the US Food and Drug Administration late last week placed a clinical hold on phase II testing of the company's XPro1595 drug candidate and requested additional information on the chemistry, manufacturing and controls for the prospective treatment for Alzheimer's disease. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: FB, BBY In early trading on Tuesday, shares of Best Buy topped the list of the day's best performing components of the S&P 500 index, trading up 3.7%. Year to date, Best Buy has lost about 25.9% of its value. And the worst performing S&P 500 component thus far on the day is Meta Platforms, trading down 9.0%. Meta Platforms is lower by about 46.9% looking at the year to date performance. Two other components making moves today are DexCom, trading down 8.7%, and Nordson, trading up 2.2% on the day. VIDEO: S&P 500 Movers: FB, BBY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 05/24/2022: DXCM, PODD, PHGE, CUTR, XLV, IBB Health care stocks were mixed premarket Tuesday. The Health Care SPDR (XLV) was 0.39% lower, and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive. DexCom (DXCM) is in talks to acquire of Insulet (PODD) and a deal could be reached \""in the coming weeks,\"" Bloomberg reported, citing unnamed sources familiar with the matter. DexCom was down more than 9%, while Insulet was recently advancing by more than 7%. BiomX (PHGE) was gaining more than 10% in value after saying it will reduce its workforce by 50% in a corporate restructuring plan aimed to preserve its capital resources. Cutera (CUTR) said it is proposing a $200 million private offering of convertible senior notes due 2028. Cutera was more than 4% lower recently. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: FB, ORLY In early trading on Tuesday, shares of O'Reilly Automotive, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.9%. Year to date, O'Reilly Automotive, has lost about 16.4% of its value. And the worst performing Nasdaq 100 component thus far on the day is Meta Platforms, trading down 9.7%. Meta Platforms is lower by about 47.3% looking at the year to date performance. Two other components making moves today are DexCom, trading down 9.3%, and PepsiCo, trading up 1.2% on the day. VIDEO: Nasdaq 100 Movers: FB, ORLY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-05-25,71.9512,75.7975,66.8925,70.33,"[""Wednesday Sector Laggards: Healthcare, Utilities Looking at the sectors faring worst as of midday Wednesday, shares of Healthcare companies are underperforming other sectors, showing a 0.8% loss. Within that group, DexCom Inc (Symbol: DXCM) and Waters Corp. (Symbol: WAT) are two large stocks that are lagging, showing a loss of 4.8% and 3.8%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.8% on the day, and down 7.29% year-to-date. DexCom Inc, meanwhile, is down 48.92% year-to-date, and Waters Corp., is down 18.04% year-to-date. Combined, DXCM and WAT make up approximately 0.9% of the underlying holdings of XLV. The next worst performing sector is the Utilities sector, showing a 0.6% loss. Among large Utilities stocks, WEC Energy Group Inc (Symbol: WEC) and CMS Energy Corp (Symbol: CMS) are the most notable, showing a loss of 2.4% and 1.8%, respectively. One ETF closely tracking Utilities stocks is the Utilities Select Sector SPDR ETF (XLU), which is down 0.6% in midday trading, and up 3.45% on a year-to-date basis. WEC Energy Group Inc, meanwhile, is up 10.43% year-to-date, and CMS Energy Corp is up 9.65% year-to-date. Combined, WEC and CMS make up approximately 5.1% of the underlying holdings of XLU. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, four sectors are up on the day, while four sectors are down. SECTOR % CHANGE Services +1.5% Energy +0.8% Consumer Products +0.5% Technology & Communications +0.4% Financial -0.0% Materials -0.1% Industrial -0.2% Utilities -0.6% Healthcare -0.8% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Comparing Binance Coin Versus DexCom Reveals New Low Here at CryptocurrenciesChannel.com, we find it interesting to track various ETF and stock prices versus various digital assets over time. We noticed that as of 5/25/2022, Binance Coin ($BNB) can buy you the most amount of DexCom shares, in the past year. For example, if you had 1 Binance Coin coin and wished to buy shares of DXCM(Symbol: DXCM) with the proceeds, you would now be able to buy 1.17 shares of DXCM. That's versus a low amount of 0.59 share over the trailing twelve months. Here's how this relationship looks charted, over the past year: The main driver of the above bar chart has, of course, been the performance of DexCom shares, relative to the performance of Binance Coin; and here's how the two compare over the past year on a total return basis: Check out our Binance Coin historical price chart and DexCom vs Crypto pages for additional charts. Note that any stock splits and/or dividends are included when we calculate the DXCM returns. Be sure to follow us at CryptocurrenciesChannel.com for more interesting stock market vs. digital asset comparisons! The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-05-26,71.1325,71.1325,68.145,70.1575,
DXCM,2022-05-27,71.4075,72.43,69.585,72.27,
DXCM,2022-05-31,76.4175,81.235,73.94,74.485,"[""S&P closes lower after last week's rally with inflation in focus By Sin\u00e9ad Carew and Anisha Sircar May 31 (Reuters) - The S&P 500 closed lower on Tuesday after a three-session rally as volatile oil trading kept soaring inflation in focus and investors reacted to hawkish comments from a Federal Reserve official. After outperforming earlier in the session, the S&P's energy sector .SPNY lost ground as oil prices reversed course after a report that some OPEC members were exploring the idea of suspending Russia from an oil-production deal, potentially paving the way for other producers to pump significantly more crude. O/R Federal Reserve policy was also top of mind for investors as U.S. President Joe Biden and Fed Chair Jerome Powell met on Tuesday to discuss inflation, which Biden said ahead of the meeting was his \""top priority.\"" This was after Fed Governor Christopher Waller said on Monday the U.S. central bank should be prepared to raise rates by a half percentage point at every meeting from now on until inflation is decisively curbed. \""The market's trying to figure out the endgame for the Fed,\"" said Jack Janasiewicz, portfolio manager at Natixis Investment Management solutions. And while lower commodity prices would be good news for equities in the longer term, the impact of the report about OPEC and Russia on the energy sector may have spooked the broader market a little on Tuesday. \""That's the sort of thing that has the market on edge,\"" said Janasiewicz. \""When we started out, the sector leading us higher was energy.\"" According to preliminary data, the S&P 500 .SPX lost 24.52 points, or 0.59%, to end at 4,133.72 points, while the Nasdaq Composite .IXIC lost 48.62 points, or 0.40%, to 12,082.51. The Dow Jones Industrial Average .DJI fell 190.80 points, or 0.57%, to 33,006.27. All three indexes had rallied last week to snap a decades long losing streak. .N \""There're too many concerns at the moment for markets to do a sharp V-bottom,\"" said Carol Schleif, deputy chief investment officer at BMO Family Office, who sees equities trading sideways for some time due to uncertainties including the Russia-Ukraine war, the global economy and inflation, as well as Fed policy. \""A piece of it is energy prices because at the margin those really impact people's propensity to spend. People are really noticing the higher prices at the grocery store,\"" she said. Earlier in the day, data showed U.S. consumer confidence eased modestly in May amid persistently high inflation and rising rates, while a separate reading showed U.S. home price growth unexpectedly heated up to record levels in March. Other key data due this week is the monthly non-farm payrolls numbers for cues on the labor market. U.S.-listed shares of Yamana Gold Inc AUY.N climbed after South African miner Gold Fields Ltd GFIJ.J, GFI.N agreed to buy the Canadian miner in a $6.7 billion all-share deal. Dexcom Inc DXCM.O jumped after the glucose monitoring systems maker denied a report on merger talks with insulin pump maker Insulet Corp PODD.O. (Reporting by Sin\u00e9ad Carew, Anisha Sircar, Devik Jain and Sruthi Shankar in Bengaluru; Editing by Marguerita Choy) ((sinead.carew@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 05/31/2022: PODD,DXCM,MLAB,FBIO Health care stocks still were mostly lower this afternoon, with the NYSE Health Care Index sinking 0.9% and the SPDR Health Care Select Sector ETF (XLV) down 1.2%. The Nasdaq Biotechnology index was down 1.6% in recent trading. In company news, Insulet (PODD) declined 9.9% on Tuesday after DexCom (DXCM) tried to squash market speculation it was pursuing a potential acquisition of the insulin-delivery device manufacturer, stating it was \""not in active discussions regarding a merger transaction at this time.\"" Insulet shares rose 8.5% last week after Bloomberg, citing unnamed sources, said a deal was possible \""in the coming weeks.\"" Dexcom was rising 4.5% this afternoon. Mesa Laboratories (MLAB) fell 3.3% after the medical disposables company reported a net loss of $0.34 per share for its Q4 ended March 31, reversing a $0.74 per share profit during the year-ago quarter and trailing the three-analyst mean expecting Q4 earnings of $0.48 per share on a GAAP basis. Fortress Biotech (FBIO) rose 1.6% after Tuesday saying it dosed the first patient in a phase I trial of its Dotinurad drug candidate to treat gout. Fortress struck a licensing deal in May 2021 with Fuji Yakuhin to commercialize Dotinurad in North America and Europe after Japanese regulators in 2020 approved it as a once-daily oral therapy for gout and hyperuricemia. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wall Street pulls back after last week's rally with inflation in focus By Sin\u00e9ad Carew and Anisha Sircar May 31 (Reuters) - Wall Street's three major indexes closed lower on Tuesday, following a rally last week, as volatile oil markets kept soaring inflation in focus and investors reacted to hawkish comments from a Federal Reserve official. After outperforming earlier in the session, the S&P's energy sector .SPNYlost ground after a report that some producers were exploring the idea of suspending Russia's participation in the OPEC+ production deal. O/R Federal Reserve policy was also top of mind for investors as U.S. President Joe Biden and Fed Chair Jerome Powell met on Tuesday to discuss inflation, which Biden said ahead of the meeting was his \""top priority.\"" This was after Fed Governor Christopher Waller said on Monday the U.S. central bank should be prepared to raise rates by a half percentage point at every meeting from now on until inflation is decisively curbed. \""The market's trying to figure out the endgame for the Fed,\"" said Jack Janasiewicz, portfolio manager at Natixis Investment Management solutions. And while lower commodity prices would be good news for equities in the longer term, the impact of the report about OPEC and Russia on the energy sector may have spooked the broader market a little on Tuesday. \""That's the sort of thing that has the market on edge,\"" said Janasiewicz. \""When we started out, the sector leading us higher was energy.\"" By the session's close, the biggest decliner among the S&P's 11 major industry sectors was energy, down 1.6%. The only sector gainers were consumer discretionary .SPLRCD, up 0.8%, with Amazon.com AMZN.O the S&P's biggest boost from a single stock on the day, and communications services .SPLRCL, up 0.4%, as Google GOOGL.O was the S&P's next biggest contributor. The Dow Jones Industrial Average .DJI fell 222.84 points, or 0.67%, to 32,990.12, the S&P 500 .SPX lost 26.09 points, or 0.63%, to 4,132.15 and the Nasdaq Composite .IXIC dropped 49.74 points, or 0.41%, to 12,081.39. All three indexes had rallied last week to snap a decades-long losing streak. With Tuesday's decline, the S&P and the Dow were essentially unchanged for May. The Nasdaq showed a monthly decline of 2%. \""There're too many concerns at the moment for markets to do a sharp V-bottom,\"" said Carol Schleif, deputy chief investment officer at BMO Family Office, who sees equities trading sideways for some time due to uncertainties including the Russia-Ukraine war, the global economy and inflation, as well as Fed policy. \""A piece of it is energy prices because at the margin those really impact people's propensity to spend. People are really noticing the higher prices at the grocery store,\"" she said. Earlier in the day, data showed U.S. consumer confidence eased modestly in May amid persistently high inflation and rising rates, while a separate reading showed U.S. home price growth unexpectedly heated up to record levels in March. Other key data due this week is the monthly non-farm payrolls numbers for cues on the labor market. U.S.-listed shares of Yamana Gold Inc AUY.N climbed 3.7%after South African miner Gold Fields Ltd GFIJ.J, GFI.N agreed to buy the Canadian miner in a $6.7 billion all-share deal. Dexcom Inc DXCM.O closed up 3% after the glucose monitoring systems maker denied a report on merger talks with insulin pump maker Insulet Corp PODD.O. Declining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.44-to-1 ratio favored decliners. The S&P 500 posted four new 52-week highs and 29 new lows; the Nasdaq Composite recorded 53 new highs and 58 new lows. On U.S. exchanges 15.52 billion shares changed hands on Tuesday, compared with the 20-day moving average of 13.25 billion. (Reporting by Sin\u00e9ad Carew, Anisha Sircar, Devik Jain and Sruthi Shankar in Bengaluru; Editing by Marguerita Choy) ((sinead.carew@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US STOCKS-S&amp;P edges down after last week's rally with inflation in focus By Sin\u00e9ad Carew and Anisha Sircar May 31 (Reuters) - The S&P 500 fell slightly on Tuesday after a three-session rally as volatile trading in oil prices kept soaring inflation in focus and investors reacted to hawkish comments from a Federal Reserve official. Eight of the 11 major S&P 500 .SPX sectors were declining and after outperforming earlier in the session, energy .SPNY lost ground and was last down 0.8% in late afternoon trading as oil prices turned negative. This was after a report that some OPEC members were exploring the idea of suspending Russia's participation in an oil-production deal, potentially paving the way for other producers to pump significantly more crude. O/R Healthcare .SPXHC and real estate .SPLRCR were the biggest laggards for the session so far. Fed Governor Christopher Waller said on Monday the U.S. central bank should be prepared to raise rates by a half percentage point at every meeting from now on until inflation is decisively curbed. Waller's comments sparked a sell-off in bond markets, with the benchmark 10-year U.S. Treasury yield US10YT=RR climbing to a one-week high, as traders scaled down expectations that the Fed might pause for breath after hikes in June and July. US/ \""There're too many concerns at the moment for markets to do a sharp V-bottom,\"" said Carol Schleif, deputy chief investment officer at BMO Family Office, citing uncertainty about the Russia-Ukraine war, the global economy and inflation, as well as Fed policy. \""A piece of it is energy prices because at the margin those really impact people's propensity to spend. People are really noticing the higher prices at the grocery store.\"" Investors were not fretting so much about Tuesday's meeting between U.S. President Joe Biden and Fed Chair Jerome Powell, according to Schleif who saw Biden's urging the Fed to keep its focus on inflation as \""a message to markets that inflation fighting has shifted to the highest priority of the Fed\u2019s dual mandates versus getting to full employment.\"" By 2:40 p.m. ET (1840 GMT), the Dow Jones Industrial Average .DJI fell 47.54 points, or 0.14%, to 33,165.42, the S&P 500 .SPX lost 0.89 points, or 0.02%, to 4,157.35 and the Nasdaq Composite .IXIC added 20.74 points, or 0.17%, to 12,151.87. All three indexes had rallied last week to snap a decades long losing streak. .N Boosted by last week's rally, the S&P 500 was up 0.5% for the month of May while the Dow was up 0.4% for the month. The tech-heavy Nasdaq was set for a 1.7% decline for the month. Data showed U.S. consumer confidence eased modestly in May amid persistently high inflation and rising rates, while a separate reading showed U.S. home price growth unexpectedly heated up to record levels in March. Other key data due this week is non-farm payrolls numbers for cues on the labor market. U.S.-listed shares of Yamana Gold Inc AUY.N climbed after South African miner Gold Fields Ltd GFIJ.J, GFI.N agreed to buy the Canadian miner in a $6.7 billion all-share deal. Dexcom Inc DXCM.O jumped after the glucose monitoring systems maker denied a report on merger talks with insulin pump maker Insulet Corp PODD.O. The CBOE volatility index .VIX snapped a three-day decline and was last up at 37 points. Declining issues outnumbered advancing ones on the NYSE by a 1.66-to-1 ratio; on Nasdaq, a 1.30-to-1 ratio favored decliners. The S&P 500 posted four new 52-week highs and 29 new lows; the Nasdaq Composite recorded 46 new highs and 41 new lows. (Reporting by Sin\u00e9ad Carew, Anisha Sircar, Devik Jain and Sruthi Shankar in Bengaluru; Editing by Marguerita Choy) ((sinead.carew@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US STOCKS-Wall St mixed amid inflation fears; Powell-Biden talks in focus By Anisha Sircar May 31 (Reuters) - U.S. stocks traded mixed on Tuesday as soaring oil prices and hawkish comments from a Federal Reserve official spooked investors, with focus on talks between U.S. President Joe Biden and Fed Chair Jerome Powell later in the day. Seven of the 11 major S&P 500 .SPX sectors declined. Communication services .SPLRCL and energy .SPNY stocks outperformed, both rising 1.2%, with the latter tracking Brent crude LCOc1 that rose above $120 a barrel after the European Union agreed to a partial ban on Russian oil. O/R Fed Governor Christopher Waller said on Monday the U.S. central bank should be prepared to raise rates by a half percentage point at every meeting from now on until inflation is decisively curbed. Waller's comments sparked a sell-off in bond markets, with the benchmark 10-year U.S. Treasury yield US10YT=RR climbing to a one-week high, as traders scaled down expectations that the Fed might pause for breath after hikes in June and July. US/ \""The market is on very high alert for anything Fed officials say before the meetings and is digesting several mixed signals from the economy,\"" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey. \""Until the picture is clearer, this market is going to have a strong bias to high volatility.\"" The meeting between U.S. President Joe Biden and Fed Chair Powell is scheduled at 1:15 p.m. (1715 GMT). Data on Tuesday showed U.S. consumer confidence eased modestly in May amid persistently high inflation and rising rates, while a separate reading showed U.S. home price growth unexpectedly heated up to record levels in March. Market participants are now awaiting readings on ISM manufacturing and non-manufacturing data and factory orders to assess the health of the economy, as well as non-farm payrolls data for cues on the labor market. At 12:35 p.m. ET, the Dow Jones Industrial Average .DJI was down 91.62 points, or 0.28%, at 33,121.34, the S&P 500 .SPX was down 5.76 points, or 0.14%, at 4,152.48. The Nasdaq Composite .IXIC was up 21.32 points, or 0.18%, at 12,152.45, led by gains in shares of Amazon.com AMZN.O and Alphabet Inc GOOGL.O. Boosted by a sharp rally last week, the S&P 500 and the Dow were up 0.4% for the month. The tech-heavy Nasdaq was down 1.4% and likely to fall for a second straight month as high-growth stocks tend to underperform when interest rates rise. U.S.-listed shares of Yamana Gold Inc AUY.N climbed 5.6% after South African miner Gold Fields Ltd GFIJ.J, GFI.N agreed to buy the Canadian miner in a $6.7 billion all-share deal. Dexcom Inc DXCM.O jumped 5.8% after the glucose monitoring systems maker denied a report on merger talks with insulin pump maker Insulet Corp PODD.O. The CBOE volatility index .VIX snapped a three-day losing streak and was last up at 26.28 points. Declining issues outnumbered advancers for a 1.83-to-1 ratio on the NYSE and for a 1.37-to-1 ratio on the Nasdaq. The S&P index recorded four new 52-week highs and 29 new lows, while the Nasdaq posted 43 new highs and 37 new lows. (Reporting by Anisha Sircar, Devik Jain and Sruthi Shankar in Bengaluru; Editing by Shounak Dasgupta and Vinay Dwivedi) ((Anisha.Sircar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Makes DexCom Stock A Better Pick Over This Insulin Pump Maker? We think that DexCom stock (NASDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom\u2019s better prospects and comparatively lower valuation. DXCM stock trades at a P/S ratio of 11x, compared to 14x for PODD stock. We believe that this gap in the valuation of these two companies does not make sense, given that DexCom has demonstrated better revenue growth and profitability than Insulet. This doesn\u2019t imply that Insulet isn\u2019t a good pick. In fact, we find both stocks a good buying opportunity, as discussed below, Looking at stock returns, Insulet\u2019s -16% return is comparatively better than DexCom\u2019s -21% change over the last twelve months. This compares with a -5% change in the broader S&P 500 index. Note that DexCom saw its stock fall 10% in the last five days after media reports of DexCom planning to acquire Insulet surfaced. While DexCom makes continuous glucose monitors, Insulet develops Insulin pumps that can be connected to CGMs. If the acquisition is successful, it will make DexCom a large player in overall diabetes management. While both the companies are likely to see continued top-line expansion, DexCom is expected to outperform. There is more to the comparison, and in the sections below, we discuss why we believe DXCM stock will offer better returns than PODD stock in the next three years. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of DexCom vs. Insulet: Which Stock Is A Better Bet? Parts of the analysis are summarized below. 1. DexCom\u2019s Revenue Growth Has Been Stronger Both companies posted sales growth over the last twelve months. Still, DexCom\u2019s revenue growth of 26.9% is higher than 14.4% for Insulet. Looking at a longer time frame, DexCom\u2019s sales grew at an average growth rate of 33.6% to $2.4 billion in 2021, compared to $1.0 billion in 2018, while that of Insulet grew at 25.0% to $1.1 billion in 2021, compared to $0.6 billion in 2018. Continued new customer additions are driving DexCom\u2019s revenue growth over the recent quarters amid rising awareness of CGM devices. DexCom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require a finger prick, and data can be self-monitored easily. Given the limited competition and a vast pool of diabetic patients (over 34 million in the U.S. alone), the company will likely see strong revenue growth over the coming years. DexCom\u2019s future sales growth will likely be bolstered by the launch of its much-anticipated G7 CGM system in the U.S. Market share gains for its Omnipod system have buoyed Insulet\u2019s revenue growth. The aging population in the U.S. and its rising awareness about diabetes products have aided the demand for Insulet\u2019s products. Our DexCom Revenue and Insulet Revenue dashboards provide more insight into the companies\u2019 sales. Looking forward, both the companies are expected to see their revenue expand at a solid pace over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 20.8% for DexCom, compared to an 18.5% CAGR for Insulet, based on Trefis Machine Learning analysis. Note that we have different methodologies for companies negatively impacted by Covid and for companies not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to forecast recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed in the three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months. 2. DexCom Is More Profitable, And It Has A Better Debt Position DexCom\u2019s operating margin of 13.7% over the last twelve-month period is much better than 4.4% for Insulet. This compares with 13.4% and 1.8% figures seen in 2019, before the pandemic, respectively. DexCom\u2019s free cash flow margin of 18.9% is also better than -4.3% for Insulet. Our DexCom Operating Income and Insulet Operating Income dashboards have more details. Looking at financial risk, DexCom\u2019s 7.0% debt as a percentage of equity is lower than 9.4% for Insulet, while its 14.2% cash as a percentage of assets is lower than 35.0% for the latter, implying that DexCom has a better debt position and Insulet has more cash cushion. 3. The Net of It All We see that DexCom has demonstrated better revenue growth, is more profitable, and has a better debt position. On the other hand, Insulet is available at a comparatively lower valuation and has a higher cash cushion. Now, looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe DexCom is currently the better choice of the two. The table below summarizes our revenue and return expectations for DexCom and Insulet over the next three years and points to an expected return of 98% for DexCom over this period vs. a 79% expected return for Insulet, based on Trefis Machine Learning analysis \u2013 DexCom vs. Insulet \u2013 which also provides more details on how we arrive at these numbers. Although this implies that DXCM is a better pick over PODD, both appear to be very good investment opportunities at their current levels. While both DXCM and PODD stock may see strong growth, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you\u2019ll be surprised how counter-intuitive the stock valuation is for Medtronic vs. Masco. What if you\u2019re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016. Returns May 2022 MTD [1] 2022 YTD [1] 2017-22 Total [2] DXCM Return -31% -48% 371% PODD Return -7% -17% 488% S&P 500 Return -4% -17% 78% Trefis Multi-Strategy Portfolio -5% -21% 209% [1] Month-to-date and year-to-date as of 5/26/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: ILMN, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.2%. Year to date, DexCom has lost about 41.2% of its value. And the worst performing Nasdaq 100 component thus far on the day is Illumina, trading down 5.5%. Illumina is lower by about 35.9% looking at the year to date performance. Two other components making moves today are Constellation Energy, trading down 5.2%, and JD.com, trading up 5.8% on the day. VIDEO: Nasdaq 100 Movers: ILMN, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Is Jumping Today What happened Shares of DexCom (NASDAQ: DXCM) were jumping 4.5% as of 10:49 a.m. ET on Tuesday after rising as much as 12.4% earlier in the day. The gain came after the company issued a public statement about reports that it's in discussions about a potential merger with Insulet (NASDAQ: PODD). DexCom stated that its policy is usually \""not to comment on rumors or speculation.\"" But in this case, the company confirmed that it \""is not in active discussions regarding a merger transaction at this time.\"" So what Investors appeared to breathe a sigh of relief that DexCom isn't considering merging with Insulet. The primary concern with a potential transaction would have been the timing. DexCom's shares were down 46% year to date before today's public statement. The healthcare stock is still more than 50% below its 52-week high. Using stock to fund a merger transaction with Insulet would have been much more problematic than if a deal was made when DexCom's shares were flying high. However, aside from the poor timing, a merger between DexCom and Insulet does make sense. The two companies have already integrated DexCom's continuous glucose monitor with Insulet's OmniPod insulin delivery system. Their businesses would be complementary to each other. Image source: Getty Images. Now what DexCom's confirmation that it's not in talks with Insulet means that investors can return to focusing on the company's underlying business. Despite the dismal performance of its stock, DexCom continues to execute well operationally. The company expects to grow revenue in 2022 by between 15% and 20%. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 27, 2022 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: STX, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 9.3%. Year to date, DexCom has lost about 41.1% of its value. And the worst performing S&P 500 component thus far on the day is Seagate Technology Holdings, trading down 6.5%. Seagate Technology Holdings is lower by about 27.0% looking at the year to date performance. Two other components making moves today are Illumina, trading down 5.7%, and Marathon Oil, trading up 6.0% on the day. VIDEO: S&P 500 Movers: STX, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom Confirms It Is Not In Active Discussions Regarding Merger Transaction (RTTNews) - In response to recent media and market speculation on Tuesday, DexCom, Inc. (DXCM) said its Board and management team regularly review opportunities like many companies to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. However, Dexcom confirmed that it is not in active discussions regarding a merger transaction at this time. It added that it is generally its policy not to comment on rumors or speculation and do not intend to comment further on this topic. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-01,74.78,75.4325,69.725,70.9625,"[""Wednesday Sector Laggards: Healthcare, Consumer Products In afternoon trading on Wednesday, Healthcare stocks are the worst performing sector, showing a 2.0% loss. Within that group, Intuitive Surgical Inc (Symbol: ISRG) and DexCom Inc (Symbol: DXCM) are two large stocks that are lagging, showing a loss of 5.8% and 5.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 1.6% on the day, and down 7.38% year-to-date. Intuitive Surgical Inc, meanwhile, is down 40.33% year-to-date, and DexCom Inc, is down 47.62% year-to-date. Combined, ISRG and DXCM make up approximately 2.2% of the underlying holdings of XLV. The next worst performing sector is the Consumer Products sector, showing a 1.2% loss. Among large Consumer Products stocks, Archer Daniels Midland Co. (Symbol: ADM) and Royal Caribbean Group (Symbol: RCL) are the most notable, showing a loss of 4.7% and 4.1%, respectively. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is down 1.5% in midday trading, and up 0.16% on a year-to-date basis. Archer Daniels Midland Co., meanwhile, is up 29.28% year-to-date, and Royal Caribbean Group, is down 27.57% year-to-date. ADM makes up approximately 2.5% of the underlying holdings of IYK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, one sector is up on the day, while eight sectors are down. SECTOR % CHANGE Energy +2.1% Utilities -0.5% Technology & Communications -0.7% Industrial -1.0% Materials -1.0% Consumer Products -1.2% Services -1.2% Financial -1.2% Healthcare -2.0% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""RSI Alert: DexCom (DXCM) Now Oversold Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 27.0, after changing hands as low as $281.21 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 49.1. A bullish investor could look at DXCM's 27.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $267.57 per share, with $659.4518 as the 52 week high point \u2014 that compares with a last trade of $281.30. Find out what 9 other oversold stocks you need to know about \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-02,71.25,78.2425,70.2525,77.9575,"[""DexCom (DXCM) to Boost Diabetes Management With New Coverage DexCom, Inc. DXCM recently announced that people living with type 1 and type 2 diabetes age two and above on multiple daily injections of insulin (three or above) or who are dependent on an insulin pump may now become eligible for public coverage of the Dexcom G6 continuous glucose monitoring (CGM) System through Prince Edward Island\u2019s Diabetes Glucose Sensor Program. In fact, Prince Edward Island joins British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Yukon, and the Non-Insured Health Benefits Program (NIHB) in offering publicly funded coverage for Dexcom CGM. Apart from this, Prince Edward Island is one of the only two government programs (along with BC PharmaCare) to offer public coverage for eligible children and adults having either type 1 or type 2 diabetes. It is noteworthy to mention that the back of the upper arm insertion site is for ages 18 and above. This announcement is likely to reinforce DexCom\u2019s already strong leadership position in CGM connected solutions space. More on the News It is worth mentioning here that the DexCom G6 CGM offers users real-time alerts, which include a predictive Urgent Low Soon warning while alerting the user in advance of hypoglycemia, thereby giving them time to take proper action before it occurs. Image Source: Zacks Investment Research Per management at DexCom, this announcement marks a critical advancement toward the goal of achieving better access to real-time CGM technology for all Canadians living with diabetes. On a daily basis, managing diabetes can pose a challenge, irrespective of an individual\u2019s age. However, through Prince Edward Island\u2019s Diabetes Glucose Sensor Program, eligible people can effectively manage their diabetes more confidently. Market Prospects Per a report by Grand View Research, the global CGM device market size was valued at $4.7 billion in 2020 and is estimated to witness a CAGR of 10.1% from 2021 to 2028. The growing incidence of diabetes and the increasing geriatric population prone to diabetes are the primary factors driving this market\u2019s growth. Hence, this announcement is well-timed for DexCom. Recent Developments In April, DexCom announced that the new Dexcom ONE CGM would be introduced in the U.K. in May. This new system is an easy-to-use real-time CGM (rt-CGM) and is more accessible and affordable for people suffering from diabetes in the country. In March, the company announced that the Ontario government would offer coverage for the Dexcom G6 CGM System effective Mar 14, 2022. The government is going to offer this coverage through its Assistive Devices Program (ADP) for people in the province living with type one diabetes who are over two years of age and fulfill the coverage criteria. Price Performance Shares of the Zacks Rank #3 (Hold) company have lost 24.6% in the past year compared with the industry\u2019s decline of 13.3%. Stocks to Consider Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Masimo Corporation MASI and Patterson Companies, Inc. PDCO. AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcare\u2019s long-term earnings growth rate is estimated at 1.1%. The company\u2019s earnings yield of 11.4% compares favorably with the industry\u2019s (0.8%). Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2 (Buy). Masimo\u2019s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company\u2019s earnings yield is 3.8% against the industry\u2019s (8.5%). Patterson Companies surpassed earnings estimates in three of the trailing four quarters and missed once, the average surprise being 2.7%. The company currently carries a Zacks Rank #2. Patterson Companies\u2019 long-term earnings growth rate is estimated at 9.9%. The company\u2019s earnings yield of 7.1% compares favorably with the industry\u2019s 4.2%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 of the Nasdaq's Best Long-Term Buys Right Now The Nasdaq is falling and in bear market territory. That much is obvious. What may not be so obvious, however, is which stocks on the exchange are likely to bounce back from their steep sell-offs. Many growth stocks on the Nasdaq were trading at inflated premiums for far too long, and a correction was likely overdue. But there are a couple of stocks that stand out as potential bargains over the long run. DexCom (NASDAQ: DXCM) and Nvidia (NASDAQ: NVDA) both have promising futures beyond just this year and the next. Their potential in the years ahead is what makes these stocks among the best buys out there for long-term investors. Image source: Getty Images. 1. DexCom Diabetes company DexCom has fallen by more than 40% since the start of this year, putting its losses far steeper than the S&P 500, which is down 14%. DexCom's high price-to-earnings (P/E) ratio of 150 may have something to do with the sell-off as investors have been shedding high-valued stocks this year. More recently, there was news that the company was looking to merge with insulin pump maker Insulet. News of a merger can send a stock down because it usually means shares will be issued to fund the deal (i.e. dilution for existing shareholders), and investors may not necessarily be on board with the transaction itself or the price tag. However, on Tuesday, DexCom squashed those rumors, saying that it \""is not in active discussions regarding a merger transaction at this time,\"" which gave the stock a bit of a bounce in price. DexCom's business doesn't need a big merger; the company is generating some good growth that's going to continue for years. Its continuous glucose monitoring devices (CGMs) help people manage their glucose levels and have become essential tools for many people with diabetes. That's evident in how resilient the company's performance has been. Through the first three months of 2022, DexCom's sales totaled $628.8 million and rose 25% year over year. The necessity of ongoing diabetes care along with the overall growth potential in the market is what makes DexCom an incredibly attractive investment for the long haul. Analysts at Grand View Research estimate that theglobal marketfor CGMs will grow at a compound annual rate (CAGR) of 10.1% until 2028. And with DexCom as a leader in that segment, there should be no shortage of opportunities for the business to get bigger. The healthcare company's high gross margin of more than 60% also means that its profits should rise along with that growth, potentially bringing down its P/E multiple over time. 2. Nvidia Chipmaker Nvidia reported its latest earnings report last week, which helped give the stock a bit of a boost. However, since the start of the year, shares of Nvidia remain deep in the red, down 37%. In the earnings report, Nvidia reported revenue of $8.3 billion for the period ending May 1, which grew 46% year over year. For the next quarter, the company anticipates that its top line will fall slightly to $8.1 billion, citing a drop in sales in Russia and China as the reasons for the declining numbers. Nvidia is another stock that has typically traded at high multiples of earnings. A year ago, investors were paying 90 times the company's profits. Today, that ratio is closer to 50. As with DexCom, Nvidia's gross margins are fairly high at 67%. Long-term investors know that as long as the growth opportunities are there, the P/E multiple shouldn't be a deterrent as profit growth looks inevitable. And growth opportunities are not something Nvidia lacks. The chip shortage in the world today affects multiple industries as more and more things are being digitized and connected to the internet. The global semiconductor market will grow by a CAGR of 9.2% until 2029, according to projections from Fortune Business Insights. Nvidia's omniverse platform, which is effectively the metaverse but for software engineers, could unlock even further opportunities down the road for the business. The company previously estimated that there could be \""up to 40 million virtual world creators and designers\"" who could seek access to the platform. The growth potential the company has combined with its great margins are why Nvidia's potential remains massive, and why investors should take advantage of the growth stock's fall in value this year. It's one of the smartest tech stocks to buy and hold. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 27, 2022 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool recommends DexCom, Insulet, and Nasdaq. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-03,77.005,77.005,72.95,73.1975,"[""Friday Sector Laggards: Technology & Communications, Healthcare Looking at the sectors faring worst as of midday Friday, shares of Technology & Communications companies are underperforming other sectors, showing a 1.8% loss. Within the sector, Micron Technology Inc. (Symbol: MU) and Etsy Inc (Symbol: ETSY) are two large stocks that are lagging, showing a loss of 7.2% and 5.8%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 2.3% on the day, and down 19.28% year-to-date. Micron Technology Inc., meanwhile, is down 24.66% year-to-date, and Etsy Inc, is down 62.46% year-to-date. MU makes up approximately 0.9% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 1.4% loss. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Illumina Inc (Symbol: ILMN) are the most notable, showing a loss of 6.1% and 5.8%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 1.0% in midday trading, and down 7.37% on a year-to-date basis. DexCom Inc, meanwhile, is down 45.47% year-to-date, and Illumina Inc, is down 38.50% year-to-date. Combined, DXCM and ILMN make up approximately 1.4% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, one sector is up on the day, while eight sectors are down. SECTOR % CHANGE Energy +0.8% Utilities -0.3% Industrial -0.7% Consumer Products -1.0% Materials -1.1% Financial -1.2% Services -1.3% Healthcare -1.4% Technology & Communications -1.8% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is It Time to Buy the S&P 500's 3 Worst-Performing May Stocks? If you're a bargain-minded investor, there's certainly no shortage of stocks priced at a discount right now. Last month was more or less a breakeven for the broad market thanks to last week's big bounce. For more than a few tickers though, the selling didn't ease. Before simply plowing into even the best of these beaten-down names from the S&P 500 index just because they're beaten down, take a moment, take a step back, and take a breath. This is no longer the simple \""buy-on-the-dlp\"" environment we all came to know and love for the better part of 2021. Everyone needs to weigh things more carefully now, appreciating that the market may be trying to tell us something by rewarding some stocks while upending others. Image source: Getty Images. Why they're the worst of the worst Overall, stocks as a whole did all right last month. The S&P 500 essentially ended May where it started it, finally stopping -- at least for the time being -- what's turned into a sizable sell-off for the year. Not every S&P 500 constituent followed suit, however. A handful of names lost a lot of ground. The worst of the worst performers? Under Armour (NYSE: UAA) (NYSE: UA), Target (NYSE: TGT), and DexCom (NASDAQ: DXCM), which fell nearly 32%, 29%, and 27% (respectively) in May. UA data by YCharts The bulk of DexCom's weakness stems from speculation it was mulling an acquisition of indirect rival Insulet -- a rumor that DexCom has since officially debunked. The combination of DexCom's glucose monitoring technology and Insulet's insulin pumps has its obvious upside. The timing of such a pairing was suspect, however, and the union of the two companies could present more complications than potential synergies. Under Armour's stock is down largely in response to news that current CEO Patrik Frisk is stepping down from the role, presenting uncertainty regarding the athletic apparel brand's future. Adding to this investor angst is the fact that well-loved founder and former CEO Kevin Plank assured investors that he won't be taking the helm again. COO Colin Browne is serving as interim president and CEO while the search for a permanent head begins. Although Browne is capable enough, it's arguably the worst possible time for Under Armour to be without permanent, decisive leadership. And as for Target, while the retailer is surviving a tough inflationary environment, it's hardly thriving in it. Shares suffered their worst single-day setback in years in the middle of May following an unexpected dip in last quarter's earnings -- from $3.69 per share to $2.19 -- which also fell short of analysts' estimates of $3.07 per share. While rival Walmart's lackluster quarterly report partially prepared investors for Target's cost-crimped numbers, the market's come to expect better from the smaller, nimbler company. To buy or not to buy? So are any of these tickers worth buying after last month's setbacks? To be clear, if you already own or end up purchasing any (or all) of these three names, you'll probably be OK. These companies have all earned their way into the S&P 500; they're clearly doing at least some things well. Don't be too eager to dig into these stocks solely because last month's stumbles seem so over the top, however. It can't be stressed enough -- last year's sweeping bullishness isn't the norm. While initially viewed in a bearish light, in retrospect the pandemic was more stimulative than stagnating. Consumers not only kept consuming but had to spend differently to adapt to lockdowns. Certain slivers of the economy that aren't often boosted suddenly experienced strong demand (personal computers, streaming services, logistics, cybersecurity, etc.), while other areas didn't exactly suffer as a result. This particular rising tide ended up lifting all boats more or less equally, making stock picking a relatively easy endeavor. This year has not only been a reminder to never take such bullishness for granted but also marks the beginning of a great decoupling. Rather than buying any and all stocks indiscriminately, investors are now opting for reliable performers and finally steering clear of companies with fuzzier futures. While DexCom's something of an exception, there's little doubt that Target and Under Armour are not only facing unexpected challenges but facing challenges that could linger for far longer than most investors care to wait. The recent selling is in many ways a warning of what's to come. And it's not just these S&P 500 stocks waving red flags regarding their foreseeable futures. A bunch of other high-profile stocks suffered similar setbacks in May for comparable, longer-lived reasons that could weigh on investors' minds for the foreseeable future. This isn't to say these three stocks can never climb again. But it does say a sharp sell-off alone isn't a good enough reason right now to dive into any stock. The moral of the story is: Know your environment -- we're back in a so-called stock picker's market. 10 stocks we like better than Target When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Target wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 27, 2022 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Target and Under Armour (C Shares). The Motley Fool recommends DexCom, Insulet, and Under Armour (A Shares). The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-06,75.3925,75.8012,72.5125,74.08,
DXCM,2022-06-07,73.2175,77.425,73.2175,77.1,
DXCM,2022-06-08,76.9375,77.7125,76.1275,76.4725,"[""2 Beaten-Down Stocks With 80% to 113% Upside, According to Wall Street It isn't easy to know what will transpire in the stock market in the next 12 months. The COVID-19 pandemic isn't over, and the world faces uncertainty regarding various economic and geopolitical issues. However, some companies have what it takes to perform exceptionally well in the next year, at least according to Wall Street. Let's look at two stocks whose average price targets by Wall Street analysts imply substantial upsides over their current levels: DexCom (NASDAQ: DXCM) and Tandem Diabetes Care (NASDAQ: TNDM). Is the Street right about these two diabetes-focused companies? DXCM data by YCharts. 1. DexCom DexCom's shares fell along with the broader market in the past 12 months. While issues outside the company's control contributed to its struggles, DexCom faces its own problems. Perhaps most notably, the company's top-line growth rate has declined in recent quarters. Also, DexCom's shares look pricey, with a forward price-to-earnings (P/E) ratio of 91.3 compared to the healthcare sector's average forward P/E of 16. Still, DexCom's average price target of $540.38 (according to Yahoo! Finance) represents a potential upside of 80.6%. Could DexCom's shares rise that much in the next year? Image source: DexCom. On the one hand, there are great reasons to be optimistic about the company's future in the next 12 months and beyond. DexCom is currently awaiting regulatory clearance in the U.S. for its newest continuous-glucose-monitoring (CGM) device, the G7. The company's current crown jewel, the G6, helped it grow its revenue and earnings in the past few years as CGM technology has grown in adoption. That's not surprising since CGM devices are associated with better health outcomes for diabetes patients. The G7 should help patients achieve even better outcomes than its predecessor, in addition to being smaller. The launch of this new gadget could help DexCom make even more headway within its target market. As the company argued last year, the CGM market remains underpenetrated even in the U.S., which is a worldwide leader in the technology. So there remains plenty of room to grow within the current population of diabetes patients in the U.S. and especially abroad. Further, diabetes is expected to become even more prevalent in the coming decades. This unfortunate trend will likely help propel CGM adoption. And as one of the leaders in the field, DexCom is well-positioned to benefit. I do not foresee the company's shares soaring by 80% in the next year, but that's no reason to avoid the stock. And although DexCom shares look expensive, the company will justify its valuation in the long run, at least for those investors willing to be patient. DexCom's revenue increased by 25% year over year to $628.8 million in the first quarter. Its adjusted earnings per share decreased to $0.32, down from $0.33. Despite the issues it has encountered lately, I expect DexCom to deliver market-beating returns in the long run, and that's why I think the company is worth buying today. 2. Tandem Diabetes Care Could Tandem Diabetes Care's shares more than double? Wall Street's average price target for the insulin pump manufacturer is $136.58, representing an impressive upside of 113%. In my view, Tandem is unlikely to live up to this target in the next 12 months. But regardless, the company's shares are worth considering. Tandem Diabetes Care's crown jewel is the t:slim X2 insulin pump. One nifty feature this device boasts is that it can be paired with DexCom's G6 to completely automate patients' insulin delivery process and help them remain within their target glucose range. Performing this task manually -- with the possibility of human error complicating things -- is far less convenient than having it done automatically. Despite its innovative insulin pump, Tandem Diabetes Care has faced many of the same issues that have plagued DexCom. The company's revenue growth rates have been on a downward trend, and it is not profitable. In the first quarter, the company's top line increased by 25% year over year to $175.9 million. And its net loss per share came in at $0.23, much worse than the $0.08 it reported during the year-ago period. Declining revenue growth rates, coupled with worsening losses, is a bad combination in any economic environment -- especially our current, challenging one. Is there any hope for Tandem Diabetes Care? The answer is yes. The company still has miles of potential growth ahead. In the U.S., only 36% of type 1 diabetes (T1D) patients use insulin pumps while the remaining 64% still rely on painful and multiple daily injections (MDIs). Abroad, the percentage of T1D patients using insulin pumps is just 12%. There are also plenty of opportunities in the type 2 diabetes market. Tandem Diabetes Care has set a goal to achieve an installed base of 1 million diabetes patients. That would represent a significant upside from its current installed base of 350,000 as of the first quarter. To put things in context, Tandem had an installed base of about 240,000 customers at the end of the first quarter of 2021. The company's ability to grow its installed base should work wonders for its revenue and profits in the years ahead. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will a Stock Split Help Rally These 2 Underperforming Nasdaq Stocks? Shares of tech stock Amazon officially split this week, and there are more stock splits coming. Many fast-growing companies have been deploying stock splits as a way to bring down their prices and thus be more accessible to a wider pool of investors. Stock splits can also generate some excitement around the businesses. A couple of stocks that would relish the opportunity to benefit from some much-needed excitement include DexCom (NASDAQ: DXCM) and Alphabet (NASDAQ: GOOG). Both stocks are going to split soon, and the hope for investors is that it puts them back into the spotlight and sends their shares surging as a result. Image source: Getty Images. 1. DexCom Lost in all the excitement about Amazon's stock split is that DexCom is also splitting its shares this week. Last month, shareholders voted in favor of a four-for-one stock split. The split is set to go into effect on June 10 and should bring the price of the stock down to less than $75. DexCom, the diabetes company that's known for its continuous glucose monitoring devices, could badly use any kind of catalyst to garner attention to its business. Year to date, its shares have fallen by 45% even though the company remains sound. Investors as a whole have been moving away from growth stocks over the past several months. DexCom, however, has been one of the worst-performing stocks on the S&P 500 thus far, possibly due to its sky-high price-to-earnings (P/E) multiple that at the start of the year was over 300. The index itself isn't doing well, but at 13%, its losses look mild in comparison to DexCom's. What's encouraging is that there is starting to be more activity around the stock as its 30-day average volumes have been rising of late: DXCM 30-Day Average Daily Volume data by YCharts Although that hasn't coincided with a rising share price, more attention on the stock could inevitably lead to a rally. For a business that has quadrupled its revenue in a span of just four years to $2.5 billion and with more growth on the way as it reaches more people with diabetes, there's tremendous value here over the long run. A high earnings multiple shouldn't distract investors from the promising opportunities DexCom possesses in the years ahead. 2. Alphabet Alphabet's drop in value in 2022 hasn't been as bad as DexCom's, but with a loss of 19%, it has also been underperforming the markets as a whole. Concerns about a potential slide in ad spending, along with some less-than-exciting quarterly earnings numbers, have put Alphabet's stock under pressure of late. The company behind the popular Google search engine reported revenue of $68 billion for the first three months of the year, which was up 23% year over year -- slower than the 34% growth it achieved in the prior-year period. And ad revenue from its video-hosting platform YouTube fell well short of analyst expectations during the period. As a result, the stock has been slumping and recently hit a 52-week low of $2,044. And even though the tech stock has rebounded a bit from that level, it still trades at a P/E multiple of 21, which is around its lowest level ever. GOOG PE Ratio data by YCharts Alphabet's shareholders recently approved the company's mammoth 20-for-1 split, which won't go into effect until the middle of next month. That gives investors plenty of time to consider whether the stock is a buy before then. While the spotlight is on Amazon right now, Alphabet's time will come in a month. And if the growth stock keeps on falling, it could be a prime time to load up on its shares, which after the split, could be trading at less than $120. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-09,75.505,76.2125,74.05,74.1125,
DXCM,2022-06-10,73.0425,73.685,72.29,73.4625,"DexCom (DXCM) Stock Moves -0.88%: What You Should Know In the latest trading session, DexCom (DXCM) closed at $293.85, marking a -0.88% move from the previous day. This change was narrower than the S&P 500's daily loss of 2.91%. Meanwhile, the Dow lost 2.73%, and the Nasdaq, a tech-heavy index, lost 0.25%. Coming into today, shares of the medical device company had lost 4.84% in the past month. In that same time, the Medical sector gained 2.04%, while the S&P 500 gained 0.84%. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. The company is expected to report EPS of $0.72, down 5.26% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $695.8 million, up 16.92% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $3.28 per share and revenue of $2.92 billion, which would represent changes of +23.31% and +19.18%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom currently has a Zacks Rank of #3 (Hold). In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 90.49. This represents a premium compared to its industry's average Forward P/E of 28.79. We can also see that DXCM currently has a PEG ratio of 2.92. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 1.99 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 33% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-06-13,70.83,71.82,67.64,68.06,"[""Surprising Analyst 12-Month Target For MMLG Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Large Growth ETF (Symbol: MMLG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.36 per unit. With MMLG trading at a recent price near $17.69 per unit, that means that analysts see 54.65% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of MMLG's underlying holdings with notable upside to their analyst target prices are 10x Genomics Inc (Symbol: TXG), Etsy Inc (Symbol: ETSY), and DexCom Inc (Symbol: DXCM). Although TXG has traded at a recent price of $40.39/share, the average analyst target is 141.40% higher at $97.50/share. Similarly, ETSY has 100.42% upside from the recent share price of $75.84 if the average analyst target price of $152.00/share is reached, and analysts on average are expecting DXCM to reach a target price of $532.64/share, which is 81.26% above the recent price of $293.85. Below is a twelve month price history chart comparing the stock performance of TXG, ETSY, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET First Trust Multi-Manager Large Growth ETF MMLG $17.69 $27.36 54.65% 10x Genomics Inc TXG $40.39 $97.50 141.40% Etsy Inc ETSY $75.84 $152.00 100.42% DexCom Inc DXCM $293.85 $532.64 81.26% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: DXCM, CSCO In early trading on Monday, shares of Cisco Systems topped the list of the day's best performing components of the Nasdaq 100 index, trading down 0.5%. Year to date, Cisco Systems has lost about 31.7% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 76.0%. DexCom is lower by about 86.9% looking at the year to date performance. Two other components making moves today are CrowdStrike Holdings, trading down 9.8%, and PepsiCo, trading down 0.5% on the day. VIDEO: Nasdaq 100 Movers: DXCM, CSCO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: DXCM, DRE In early trading on Monday, shares of Duke Realty topped the list of the day's best performing components of the S&P 500 index, trading up 2.0%. Year to date, Duke Realty has lost about 22.6% of its value. And the worst performing S&P 500 component thus far on the day is DexCom, trading down 76.0%. DexCom is lower by about 86.9% looking at the year to date performance. Two other components making moves today are Signature Bank, trading down 12.1%, and Comerica, trading up 0.4% on the day. VIDEO: S&P 500 Movers: DXCM, DRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-14,68.97,70.02,67.155,69.31,"3 Humbled Nasdaq Stocks Ready to Bounce Back It's been a rough few weeks for stocks. The Nasdaq Composite (NASDAQINDEX: ^IXIC) now sits more than 30% below its November high after dropping to a new multi-month low this week. And the composite is a weighted average of every Nasdaq-listed ticker. For some stocks, the declines have been much, much worse. As tough as it may be to believe right now, however, there are long-term opportunities among the most beaten-down names. You just have to find the guts to step in even knowing that this bear market may not be at its cyclical bottom just yet. Here's a closer look at three of your best bets right now from this humbled group of stocks. Lyft Say what you want about the fallout from the budget-slashing initiative Lyft (NASDAQ: LYFT) announced last month -- just don't say the ride-hailing business model is fatally flawed. There are enough consumers out there who don't own cars (or don't want to drive one to a particular destination), and the market is slowly but surely figuring out how many rideshare drivers it needs, as well as the right price for their service. Lyft made huge bottom-line progress last quarter, and on an adjusted basis actually produced a net operating profit. It still needs more scale to convincingly get over the profit hump once and for all, mind you. But that looks like it's coming. Analysts' expectations for top-line growth of 31% this year followed by 25% next year should be enough to lift the company to non-GAAP earnings of $0.32 per share in 2022, and then further upward to $1.10 per share in 2023. Investors haven't been pricing this prospective upside into the stock of late. Lyft shares have slid more than 70% in the course of the past 12 months, and set a new 52-week low earlier this week. It's possible the market could be concerned about the prospect of a recession as well as the unknowns of sky-high oil prices. As contractors, Lyft drivers pay for their own gasoline, making driving in this environment an expensive endeavor. The sheer severity of the sell-off, however, arguably overstates the depth of the challenges Lyft actually faces. Tandem Diabetes Care Tandem Diabetes Care (NASDAQ: TNDM) offers solutions that help diabetics control and combat their condition. While it competes with much bigger companies such as DexCom and moderately bigger ones like Insulet, Tandem's customers still appreciate the power of its t:slim X2 insulin pump and its accompanying software. It can be used by itself or along with a continuous glucose monitoring system, but more than that, the X2 works with mobile devices and can connect to the web to make it even more functional. This year's projected revenue growth of 22% and next year's expectation for sales growth of 20% speak volumes about the demand for the t:slim X2 insulin pump. The thing is, the opportunity at hand is so much bigger than just the next couple of years' worth of above-average growth. The International Diabetes Federation says 9.3% of the world suffered from diabetes as recently as 2019, but fears that figure could swell to 10.2% of the worldwide population by 2030, and to 10.9% by 2045. Beyond that expanding prevalence, bear in mind that the global population itself is on pace to grow from just a little less than 8 billion now to more than 8.5 billion in 2030 en route to 9.5 billion by 2044, according to forecasts from Worldometer. Yet the market hasn't been impressed by Tandem Diabetes' long-term growth prospects recently. The stock's down more than 60% year to date, and like Lyft, touched a new 52-week low this week. This weakness, however, looks more driven by the lousy market environment than Tandem's solid past and projected results. DraftKings Finally, add DraftKings (NASDAQ: DKNG) to your list of humbled Nasdaq stocks ready to bounce back. Its shares are down by more than 80% just since September, with each rebound effort since then quickly being followed by a drop to an even lower low. Sooner than later though, one of these recovery moves is going to get traction. If you're not familiar, DraftKings' roots are in the fantasy sports arena, although it has evolved into a full-blown sports-betting platform. Professional baseball, basketball, football, and hockey are all in its app-based wagering wheelhouse, but it can offer betting on more obscure events such as darts, tennis, and cycling, just to name a few. It also offers a lot of different kinds of betting options beyond simply picking a team or athlete to win or cover the spread. There has arguably never been a better time to be in the business. Although the U.S. Supreme Court lifted the long-standing ban on sports betting back in 2018, most of the industry's growth still lies ahead of it. Market research outfit Technavio estimates the worldwide sports betting business will grow by 10% per year between 2020 and 2025, ending that stretch more than $100 billion bigger than where it began it. One of the key drivers of this growth -- again according to Technavio -- will be the digitalization of the highly fragmented business. This plays right into DraftKings' hands, as evidenced by the numbers. The company's top line more than doubled to $1.3 billion last year, and the analyst community is calling for revenue growth of 62% this year. While it's still in the red, this sales growth is chipping away at its losses, and the company won't necessarily even need to turn a net profit before the stock starts to climb again. It just needs to convince the majority of investors that it's moving in that direction ... which it is. 10 stocks we like better than DraftKings Inc. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DraftKings Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-06-15,70.37,73.33,69.6436,71.51,
DXCM,2022-06-16,69.23,70.17,67.11,67.99,
DXCM,2022-06-17,67.8,70.3,67.74,68.81,
DXCM,2022-06-21,70.05,71.8,69.56,70.46,
DXCM,2022-06-22,69.95,72.66,69.62,71.52,
DXCM,2022-06-23,72.55,75.58,71.87,75.21,"Why Investors Should Focus on Abbott's Medical Devices Diversified healthcare company Abbott Laboratories (NYSE: ABT) has been front and center in the news this year. Given the headlines surrounding the infant formula debacle and the influx of cash from COVID-19 diagnostics, it's easy to overlook the company's innovation in medical devices. But this segment provides a stable backbone that is integral to future growth. Abbott Labs's diabetes products The American Diabetes Association claims that diabetes is the most common chronic disease in the U.S., with 1.4 million Americans newly diagnosed each year. Abbott is a leader in the field, offering one of the most widely used continuous glucose monitors. The sensor tracks blood glucose and warns if the level gets too high or low, providing more convenient and reliable care than finger-prick tests. In May, the FDA approved the Freestyle Libre 3, which Abbott claims achieves the most accurate measurement among the line-up of 14-day continuous monitoring systems. At about the size of two pennies, the sensor is also the smallest and thinnest. Abbott intends to maintain a similar price point as previous versions, substantially undercutting rival Dexcom's (NASDAQ: DXCM) G7 CGM System. While still expensive, Illinois recently passed legislation that forces insurance to cover these devices, and demand may increase if other states follow suit. Abbott continues to innovate in this area, having recently partnered with CamDiab and YpsoMed to develop an automated insulin delivery device. This system will integrate Abbott's diagnostic sensor, CamDiab's mobile app, and YpsoMed's insulin pump to automatically deliver the correct amount of insulin to the patient. The companies expect to complete development by the end of this year. The company is also working on a combined glucose-ketone sensor that will detect rising ketone levels so that the patient can take preventative measures that forestall diabetic ketacidosis. Ketone monitoring is often overlooked because it is a cumbersome and costly extra step. Pivotal trials on the technology are planned for next year. Abbott Labs's cardiovascular products Cardiovascular disease is Abbott's second primary focus in the medical device segment. The company supplies equipment for rhythm management, electrophysiology, heart failure, vascular, and structural heart indications. Two recent FDA approvals will expand the addressable market for cardiac devices. Abbott's CardioMEMS HF System monitors pressure in the pulmonary artery so that doctors can manage a patient's treatment and prevent heart failure from progressing. The device has been available since 2014, but the FDA expanded the indication in February to allow the sensor to be implanted during an earlier stage of the disease. Heart failure is the leading cause for hospitalization within the elderly population, and more than 6.2 million Americans experience the disease.Abbot estimates that the new label increases the addressable market by 1.2 million Americans. In April, the FDA approved Abbott's Aveir VR leadless pacemaker for patients with slow heart rhythms. The system offers a longer battery life, as well as a mapping capability to simplify implantation and retrieval processes. Although demand for pacemakers slowed during the height of the pandemic, COVID-19 has been linked to heart damage. At least one-in-five hospitalized COVID-19 patients experience heart irregularities, possibly caused by the viral infection of specialized cells within the heart that regulate its rhythm. Electronic pacemakers may be necessary to replace lost function. What the future holds for Abbott Abbott reported fantastic first-quarter results, with overall sales increasing 17.5% from the previous year to $11.9 billion. However, COVID-19 diagnostics tests accounted for $3.3 billion, almost one-third of total revenue. Future demand for pandemic products is uncertain, but management expects that much of the sales for the year may have already been realized. With COVID-19 sales on the decline, the medical device segment becomes the dominant source of revenue. After removing COVID-19 sales, the $3.6 billion in medical device sales accounts for about 40% of total revenue. This compares to $2.0 billion from diagnostics, $1.9 billion from nutritionals, and $1.1 billion from established pharmaceuticals. Furthermore, the growing prevalence of diabetes and heart disease promises reliable growth. The overall medical device segment grew 7%, on par with the growth from the established pharmaceutical segment but with a 50% higher operating margin. Meanwhile, nutritionals experienced a 7% decline due to the infant recall and production shut-down. The diagnostics division continues to be productive, recently unveiling a multi-pronged test for sexually transmitted diseases and monkeypox, but these will not come close to filling the hole as demand for COVID-19 screening falls. While its missteps in manufacturing infant formula are certainly troubling, Abbott remains a well-diversified Dividend King with a dominant market position in several high-growth fields. Its price-to-earnings ratio of 24 is its lowest in the past three years, and in line with competitors. Overall revenue is likely to drop in upcoming quarters, and this may carry over into the stock price; keep an eye out for potential bargain opportunities. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Natalie Forbes has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-06-24,76.32,77.73,75.14,77.67,"Will Alphabet Soar After Its Stock Split? Here's What History Shows The days of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock trading above $2,000 are numbered. And the magic number is 21. That's how many days remain before the technology giant's 20-for-1 stock split scheduled for July 15. Investors often eagerly anticipate stock splits because they think shares could take off after the split. But will Alphabet soar after its upcoming stock split? Here's what history shows. Not much to go on Let's first address the significance (or lack thereof) of stock splits. They don't change anything about a company's business. They don't change a company's overall value. However, lower share prices can attract more retail investors to a stock. That's the only real reason why Alphabet's stock split matters. With Alphabet's share price in the dumpster so far this year, the stock definitely needs a positive catalyst. Will the stock split on the way in a few weeks be just what investors want? History can sometimes be a guide. Unfortunately, there isn't much history when it comes to Alphabet stock splits. The company has conducted only one stock split since its initial public offering in 2004. On March 27, 2014, Alphabet (then known as Google) split its stock 2-for-1. There was considerable controversy surrounding this stock split. Google didn't just double its number of shares. Instead, the company created an entirely separate class of shares -- class C shares with no voting power. What happened after this unusual stock split? Not much. Both Google class A and class C shares rose by around 2% over the next few days. However, the gains quickly evaporated. By the end of April 2014, both stocks had fallen by at least 4%. GOOGL data by YCharts There were more ups and downs to come in 2014. However, it's questionable that the stock split impacted the moves. Google went on to finish the year down close to 5%. Recent precedents We really can't learn much from the one stock split in Alphabet's history. But maybe recent precedents of other stock splits this year might help. Amazon.com (NASDAQ: AMZN) stands out as the most highly anticipated stock split in the past month or so. The online shopping and cloud-hosting leader conducted a 20-for-1 stock split on June 6, 2022. However, Amazon stock didn't take off after its split. Instead, shares fell. Why? Amazon's stock split came during a time when the overall market was struggling. The company also faces some challenges with its supply chain and rising inflation. AMZN data by YCharts Another previous highflier, DexCom (NASDAQ: DXCM), also recently conducted a 4-for-1 stock split. The healthcare stock enjoyed an immediate bump. However, it was only a temporary one. DXCM data by YCharts Again, the overall stock market weakness appears to be the biggest culprit holding DexCom back. The company's business is performing well with the international launch of DexCom's G7 continuous glucose monitoring device underway. Three predictions Based on these admittedly limited historical precedents, the safest prediction is that Alphabet stock won't soar after its stock split next month. There's a big caveat with that prediction, though. If the overall stock market rebounds in a major way before then, Alphabet's stock split could serve as a bigger catalyst than expected. But here are two more predictions. One is that most investors will quickly forget all of the stock splits of 2022 that have received a lot of attention, including Alphabet's upcoming 20-for-1 split. The other prediction is that Alphabet will deliver solid gains over the next decade regardless of any stock splits. Actually, Alphabet ranks as one of my three highest-conviction growth stocks right now. I like the company's business moat. I think it also has multiple growth drivers, notably Google Cloud and the Waymo self-driving car unit. Maybe Alphabet's share price will never top $2,000 again. However, I don't expect the stock to stay near the $100 level for very long after the stock split in July. 10 stocks we like better than Alphabet (A shares) When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet (A shares) wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet (A shares) and Amazon. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-06-27,77.44,77.89,75.57,76.6,"DexCom's Stock Split Is Complete: Is It Time to Buy? DexCom (NASDAQ: DXCM) is a medical device company focused on the development and commercialization of glucose monitoring systems. On March 25, its stock got a nice little 10% bounce after it announced a pending 4-for-1 stock split. But as commonly happens in such cases (and this has been especially true during this bear market) that pop shortly thereafter turned into a decline. Investors may benefit if they jump into a stock the moment a split is announced, but oftentimes, between that point and the day the split takes place, the stock price can slide again, and those drops can last for months. Splits get some investors excited, but the reality is they don't change the value of the stock, the company, or its outlook. So what can we expect from DexCom stock now that its split is complete? Timing can be important -- and hard to know It's almost as though stock splits have become a mind game for those willing to take on more risk, or for those who might be less educated about investing. The thought process is, apparently: ""The stock will split; more people will be able to buy it after it becomes less expensive; I'll get my shares now before the split."" But in cases where the company might have no other positive news to accompany the split, that's less investing and more like gambling. DexCom's split was completed on June 10. Investors who owned shares worth $296 each when they went to bed on June 9 had four times as many shares in their portfolios, worth $74 apiece, when the market opened on June 10. The total value of their holdings didn't change. But for those who bought the stock between March 25 through April 1 -- just after its run-up -- and have held onto the shares ever since, it's a different story. They are sitting on an average unrealized loss of roughly 39%. Although that's not always the case, it's an example of what can happen when investors make ill-timed purchases based on hype. But will the now-completed split help lift DexCom's stock? The short answer is, a rally is underway, but it's not connected to the stock split. Long-term investors have more fundamental reasons to be excited. Good news for DexCom investors One look at DexCom's website and you know the company has something going for it -- pop star Nick Jonas is front and center as a spokesperson. But in all seriousness, the product he helps promote is the company's G6 continuous glucose monitor system, which allows diabetes sufferers to better manage their disease and maintain healthier lifestyles. Sales of the G6 during the first quarter helped the company improve its revenue by 25% year over year, driven by volume growth and the addition of new customers. For the full year, the company expects to grow revenue by 15% to 20%. The first quarter also provided two more reasons to get excited about DexCom's pipeline. First, the company received the CE Mark for its G7 system -- the European Union's certification that it meets the bloc's health, safety, and environmental requirements, and can be sold there. This more advanced version of the G6 is 60% smaller, accommodating less obvious insertion locations, and offers more rapid response with improved data accuracy. The launch of the G7 in Europe is underway, and when the company reports its Q2 earnings in late July or early August, it could shed some light on how well it is being adopted by patients and medical personnel. CEO Kevin Sayer anticipates the G7 having a growing impact in the second half of this year through international launches. He has also stated that he expects FDA approval for the device this year. The second product in the pipeline for 2022 is DexCom ONE. This system is similar to the G6 and G7 systems in that it uses a sensor in lieu of painful fingersticks to read blood sugar levels. DexCom ONE also has a water-resistant sensor that transmits data to a connected smartphone every five minutes. The main difference is that this system uses an app without the bells and whistles of the G6 and G7. A user can program alerts, but it does not allow for sharing data in real-time with family members or healthcare providers. The lower-priced offering should help expand DexCom's user base. The company's strategy includes expanding DexCom ONE into more countries beyond Spain and the U.K., where it is already available. In addition, the company is hoping for an FDA device designation that will bring the CGM system into the inpatient setting of hospitals, which would provide it with a new path to boost revenue. Is it time to buy? I'm less concerned about whether DexCom's pipeline and strategy can justify buying the stock now, and more concerned about when the market will provide the best opportunity. If you're an investor who buys and holds for the long term, it's worth noting that DexCom's stock price is down 52% since Nov. 8 to a level not seen since spring 2020. It's possible the share price could creep still lower during this bear market, but the glucose monitoring device market is expected to grow at a compound annual rate of 8.8% for the next eight years, and regardless of economic conditions, foregoing medical care for chronic conditions is not an option that many will choose. That should mean that as DexCom launches multiple products and expands its footprint, it should prosper, and so should its stock. If analysts' price targets are any indication, that could lead to a 56% gain from the current $77 price. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jeff Little has positions in Amazon. The Motley Fool has positions in and recommends Amazon. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-06-28,77.15,78.72,74.48,74.7,"Nasdaq Lux Health Tech Index: A Novel Portfolio Construction Reflecting the Growth in Health Technology Read Full Report The health care industry is thriving, so it is no surprise that investors have flocked toward opportunities in this sector. Yet, most investment vehicles focus primarily on the large-cap incumbents and marginalize new innovators. In July 2021, Nasdaq teamed up with Lux Capital, a $4 billion venture capital firm focused on innovation and health care technology, to develop an index that fills the gap: the Nasdaq Lux Health Tech Index™ (NQHTEC™). Many companies develop products that rely on technology to prevent, diagnose, treat and rehabilitate illnesses and diseases. The traditional players tend to specialize in medical devices and diagnostics as well as data, software, hardware and robotics. The average age of the top 10 largest medical device companies is about 96 years old, and they have survived the ups and downs of many market cycles. They are analog businesses that have adapted over time, but they are not digitally native. On the other hand, dozens of newer companies – many of which have listed on the Nasdaq Stock Market within the last 20 years - have integrated disruptive technology into their products to deliver new functionality and value to the health care industry. NQHTEC is designed to capture exposure to both the historically stable incumbents as well as many of the smaller, innovative, high-growth companies. “What we tried to do with the weighting of this index is make sure that investors get direct exposure to true innovation in health care,” Peter Hebert, Co-Founder and Managing Partner at Lux Capital, explains. “It doesn’t just reflect the S&P health care components. Instead, it’s designed to capture the integration of modern technology into the health care system. In our view, it’s new and unique, and arguably one of the largest secular trends in the coming decades.” The index’s 59 constituents are predominantly high-growth companies that focus on disruptive technology in health care. About 83% of the index weight comes from the sub $50 billion market cap contingent, and around 61% of the weight comes from the top 10 names. It is modified market cap-weighted: the top five names are capped at 8%, and the rest are capped at 4%. The companies come from not only the U.S. but also the Netherlands, Sweden and China. Importantly, there is a revenue growth contingent. New additions to the index must show they have grown their revenues at least 10% in each of the last two years prior to admission. To stay in the index, they must grow their revenues by 7% in at least one of the last two years. “The index is designed to capture businesses that have revenue growth,” says Hebert. “We methodically screen for higher-quality companies that represent this theme, not companies that have certain industry codes that reflect this theme.” Medical equipment is the largest subsector, representing almost 50% of the index weight. Biotechnology and health care services are the next two biggest subsectors. A few of the constituents are in the medical supplies and medical services business, and others offer software. “This structure differentiates NQHTEC from other health care and life sciences indexes that are either focused on large-cap pharma or biotech,” says Hebert. “Those companies generally have not captured the same benefits of digital technology.” NQHTEC’s top holdings include Intuitive Surgical (ISRG), a pioneer in robotic surgery and creator of the da Vinci® Surgical System. Known for its Invisalign® product, Align Technology (ALGN) was one of the first companies to apply additive manufacturing and 3-D printing to dentistry. Veeva Systems (VEEV) provides electronic health records software, which is transforming health care systems, and Illumina (ILMN) specializes in genetic sequencing. DexCom (DXCM) offers continuous glucose monitoring, and Insulet (PODD) provides the Omnipod® injectable drug delivery system. Admittedly, the life sciences sector has been in a bear market since 2021, and the general technology sector peaked in November 2021 and then took a downturn. That said, NQHTEC may be attractive to investors who are interested in a long holding period. They can take advantage of the opportunity via the First Trust Nasdaq Lux Digital Solutions ETF (EKG), which tracks the index. “NQHTEC is not designed to be a market timing exercise, and one should expect volatility given the overall market and risks that people perceive in rising interest rates,” Hebert points out. “Like a lot of other high growth opportunities, there’s risk inherent in it. But in our view, this is a novel way of constructing a portfolio to reflect the secular growth in health technology.” Nasdaq®, is a registered trademark of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. © 2022. Nasdaq, Inc. All Rights Reserved."
DXCM,2022-06-29,74.74,75.68,72.41,75.45,"[""DexCom (DXCM) Gains As Market Dips: What You Should Know DexCom (DXCM) closed at $75.45 in the latest trading session, marking a +1% move from the prior day. This change outpaced the S&P 500's 0.07% loss on the day. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.02%. Coming into today, shares of the medical device company had gained 0.29% in the past month. In that same time, the Medical sector lost 5.47%, while the S&P 500 lost 7.99%. Investors will be hoping for strength from DexCom as it approaches its next earnings release. The company is expected to report EPS of $0.16, down 15.79% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $695.8 million, up 16.92% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.74 per share and revenue of $2.92 billion. These totals would mark changes of +10.45% and +19.18%, respectively, from last year. Investors might also notice recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.48% lower. DexCom is currently a Zacks Rank #3 (Hold). Digging into valuation, DexCom currently has a Forward P/E ratio of 100.76. For comparison, its industry has an average Forward P/E of 27.19, which means DexCom is trading at a premium to the group. Also, we should mention that DXCM has a PEG ratio of 3.26. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 1.92 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 162, putting it in the bottom 36% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""With Stock Splits Underway, These 2 Beaten-Down Stocks Are Buys Now Stock splits are all the rage these days, with several prominent companies resorting to this move over the past few months. Unsurprisingly, splits haven't been enough to rescue some of these companies in the market. After all, this corporate strategy does nothing to change the fundamental value of a company. And with stocks still experiencing some turmoil due to economic and geopolitical issues -- and individual corporations facing specific headwinds as well -- it's been a tough year all around. Even with these caveats, there are brighter days ahead for some companies that recently resorted to stock splits. Let's consider two of them: DexCom (NASDAQ: DXCM) and Shopify (NYSE: SHOP). DXCM data by YCharts 1. DexCom Medical devices specialist DexCom announced a 4-for-1 stock split in March, which it completed on June 10. While the move did generate plenty of headlines for DexCom, the leader in continuous glucose monitoring (CGM) systems will need more than that to turn things around. CGM devices allow diabetes patients to track their blood glucose levels continuously throughout the day, and DexCom is still riding the wave of greater CGM adoption. However, the company's year-over-year revenue growth rate has decreased in recent quarters. That's not what investors want to see in a growth stock, especially not in a tricky global environment in which stocks are getting hammered for anything that resembles a good reason. Still, DexCom's prospects lie in the growth that the CGM industry will continue to experience. According to the U.S. Centers for Disease Control and Prevention (CDC), diabetes is an epidemic in the country, and it will only get worse in the coming decades. This means innovative companies like DexCom that continue to come up with ways to help diabetes patients manage this chronic illness will be in demand. DexCom currently makes most of its sales from the G6 CGM system and accessories, but it is awaiting U.S. regulatory clearance for its next-generation product, the G7; that device has already earned regulatory clearance in Europe. The G7 knocked it out of the park in studies. DexCom ran a clinical trial that enrolled more than 300 diabetes patients and compared over 39,000 blood-glucose level readings taken with blood glucose meters with those taken with the G7. The CGM device fell within 20% of the confirmed glucose range 93% of the time. The overall performance of the G7 in this trial proved its superiority over the G6, according to management. The G7 will also be 60% smaller than its predecessor. DexCom is betting on this device to help it make headway in the under-penetrated U.S. CGM market as well as the international market where CGM penetration is even lower. In the first quarter, DexCom reported revenue of $628.8 million, 25% higher than the year-ago period. The company's adjusted net income decreased slightly to $32.3 million, compared to the $32.5 million reported during the first quarter of 2021. Despite its poor performance on the market this year, DexCom's leadership in the CGM space -- coupled with the fact that the industry still boasts plenty of white space -- bode well for the future of this healthcare company. 2. Shopify Shopify has had a challenging year as its pandemic-related tailwind ended. Also, the company reported a massive net loss per share of $11.70 in the first quarter. Shopify recorded a net income per share of $9.94 in the comparable period of the previous fiscal year. It's not too surprising, then, that investors are running for the hills despite its planned 10-for-1 stock that will take effect on June 29. Still, things may not be as bad as they seem for Shopify. The company's red ink in the first quarter mostly had to do with $1.6 billion worth of losses related to equity investments it made in Affirm Holdings, a fintech company, and Global-e Online, an e-commerce platform. Shopify's adjusted net income for the quarter was a much more respectable $25.1 million, while its top line increased by 22% year over year to $1.2 billion. However, the adjusted earnings were still much lower than the $254.1 million that Shopify reported during the year-ago period. Still, the e-commerce industry in which Shopify competes has a long and bright future ahead. According to some estimates, this market will expand at a compound annual growth rate of 14.7% through 2027. It likely won't stop there as the world increasingly goes digital. Shopify provides almost everything businesses need to start online storefronts. The company's App Store boasts hundreds of applications that help merchants customize their online businesses. The suite of complimentary services it offers arguably makes Shopify's platform sticky. Imagine having spent countless hours, not to mention plenty of money, building a perfect online store thanks to Shopify's offerings. Switching to another provider would be difficult to contemplate since it would take even more time and money -- which could be better spent attracting customers. What does that mean for Shopify? The company should be able to continue attracting new customers while keeping many of its existing ones. And as the e-commerce platform maintains its momentum, Shopify's revenue and earnings will rise, even as it deals with near-term headwinds. While the past few months have been difficult for the tech company, it's too early to jump ship. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Prosper Junior Bakiny has positions in Shopify. The Motley Fool has positions in and recommends Affirm Holdings, Inc., Global-e Online Ltd., and Shopify. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-06-30,74.93,75.47,73.71,74.53,"3 Recent Stock Splits That Are Begging to Be Bought After benefiting from years of outsize gains, many companies have turned to stock splits to make shares appear more affordable. Stock splits do not directly add to shareholder wealth. One hundred shares at $100 per share hold the same value as 1,000 shares at $10 per share. However, lower nominal stock prices can increase liquidity and make whole shares more affordable to small investors. This increased interest could give an added boost to Amazon (NASDAQ: AMZN), DexCom (NASDAQ: DXCM), and Shopify (NYSE: SHOP). Long-term investors should pounce on this mega-cap mainstay while it's on sale Jake Lerch (Amazon): For Americans today, it's almost impossible to pass 24 hours without interacting with an item that was delivered, marketed, built, or otherwise supported by Amazon's various business segments. The tech behemoth's annual revenue of $477 billion ranks second only to Walmart's $576 billion. However, despite its size and significance, Amazon has experienced a dismal 2022, driven by numerous setbacks: Poor first-quarter earnings results. Slowing growth. Macroeconomic headwinds. Nevertheless, investors shouldn't dismiss Amazon as past its prime. True, the stock is down 33% year to date, and the U.S. economy could well be headed for a recession in the not-too-distant future. Yet, some prospective catalysts might help Amazon turn things around later this year, including: Its recent stock split. Amazon Web Services' robust growth rate. Increasing ad revenue. Positive impacts due to cost-cutting. Improving economic conditions brought on by lower inflation rates and revitalized supply chains. Aside from the stock split, none of these is a given. But even if these scenarios don't revive the stock's fortunes in 2022, Amazon still remains a mainstay of the American economy. In fact, I've argued that Amazon is a proxy for the U.S. economy. And despite all the challenges that beset the U.S. economy today, I do not doubt it (and Amazon) will bounce back. What makes Amazon even more attractive is that it's cheap by historical standards. Its current price-to-earnings ratio is 54.7 -- well below its long-term average and near its all-time low of 42, set earlier this year. Moreover, Wall Street is raising earnings estimates for 2023. Over the last 30 days, six firms have revised their EPS estimates higher, with only one lowering guidance. Investors would be wise to consider Amazon now, with the stock still trading much cheaper than where it started the year. Say goodbye to painful and messy fingersticks Justin Pope (DexCom): More than 500 million adults worldwide live with diabetes, a number that could grow to more than 780 million by 2045. Unfortunately, rising worldwide obesity rates have made diabetes increasingly prevalent. Measuring blood sugar traditionally requires a fingerstick to draw a drop of blood, which can be painful and inconvenient for patients. DexCom sells a continuous glucose monitoring system consisting of a sensor that patients wear for up to 10 days, which measures glucose levels and sends the data to a smart device every five minutes. Traditional blood testing only measures glucose at the moment; continuous monitoring is much more telling, like using video versus a photograph to tell a story. You can see below how smooth DexCom's growth has been; it turns out that delivering a superior alternative in a big market creates good business outcomes. The company is also profitable, generating cash profits via free cash flow and bottom-line profit (net income). DXCM Revenue (TTM) data by YCharts DexCom won't blow investors away with hypergrowth; the company's revenue grew 25% year over year in the first quarter of 2022 to $629 million. Instead, the business is a steady grower, poised for years of double-digit growth. Remember how more than half a billion adults live with diabetes? DexCom sells to just 1.25 million, leaving an ocean of growth ahead. Management recently completed a 4-for-1 stock split, dropping the share price to roughly $76 per share. Remember that stock splits make shares more affordable, but don't change the fundamental valuation of the stock itself. Therefore, metrics like the price-to-sales ratio (P/S) are helpful to look at. DexCom trades at a P/S of 12, about average for the company over the past decade. DXCM PS Ratio data by YCharts It might not be a screaming bargain, but there should be plenty of room for investors with a long-term approach willing to let that double-digit growth pile up over the coming years. This bull case hinges on more than just a stock split Will Healy (Shopify): Shopify's 10-for-1 stock split should increase the stock's appeal to small investors. However, investors shouldn't buy simply for the low nominal price. Shopify has managed to stand out among e-commerce platforms with superior products and a large ecosystem. It invests in technology to deliver fast, reliable service and offers numerous task-related tools such as a logo maker and a QR code generator. Its vast ecosystem includes tools such as a payments platform that accommodates transactions on all Shopify-supported sites. Its inventory management tools will also monitor inventories of goods sold both online and offline, making it more useful to many of its clients. Furthermore, Shopify Capital can provide its clients with funding when necessary. Still, the ecosystem addition that may pull it permanently ahead of most peers is the Shopify Fulfillment Network (SFN). The SFN will store, package, and ship goods. Since most peers are tied to an identity as a software company, most will not follow Shopify into the fulfillment business. At best, they may contract fulfillment to an outside party, similar to Wix.com's arrangement with Amazon. According to Oberlo, this ecosystem helped give Shopify a 32% market share among e-commerce platforms in the U.S., making it the No. 1 e-commerce platform in the country. But despite Shopify's potential, the stock has lost nearly 80% of its value since November as growth rates slowed. The company brought in $1.2 billion in the first quarter of 2022, and the 22% year-over-year increase slowed from the 57% revenue growth in 2021. Also, Q1 losses came in at $1.5 billion due largely to $1.7 billion in unrealized equity losses. However, Shopify expects a recovery in revenue growth in the second half of 2022. Additionally, the 10 P/S ratio is near a six-year low, making the stock more attractive to new investors. As Shopify continues to stand out with its tools and ecosystem, it looks more like a stock to buy now. Find out why Amazon is one of the 10 best stocks to buy now Our award-winning analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Amazon is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of June 2, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jake Lerch has positions in Amazon. Justin Pope has no position in any of the stocks mentioned. Will Healy has positions in Shopify. The Motley Fool has positions in and recommends Amazon, Shopify, and Wix.com. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-01,74.26,78.03,74.23,77.63,
DXCM,2022-07-05,77.25,78.89,74.75,78.46,"DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know DexCom (DXCM) closed at $78.46 in the latest trading session, marking a +1.07% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.16%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq added 0.17%. Coming into today, shares of the medical device company had gained 4.79% in the past month. In that same time, the Medical sector lost 1.13%, while the S&P 500 lost 6.79%. DexCom will be looking to display strength as it nears its next earnings release, which is expected to be July 28, 2022. In that report, analysts expect DexCom to post earnings of $0.16 per share. This would mark a year-over-year decline of 15.79%. Meanwhile, our latest consensus estimate is calling for revenue of $695.8 million, up 16.92% from the prior-year quarter. DXCM's full-year Zacks Consensus Estimates are calling for earnings of $0.74 per share and revenue of $2.92 billion. These results would represent year-over-year changes of +10.45% and +19.18%, respectively. Investors might also notice recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.58% lower within the past month. DexCom is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, DexCom currently has a Forward P/E ratio of 104.71. This valuation marks a premium compared to its industry's average Forward P/E of 27.75. It is also worth noting that DXCM currently has a PEG ratio of 3.38. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DXCM's industry had an average PEG ratio of 1.96 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 38% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. How to Profit from the Hot Electric Vehicle Industry Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits. See Zacks' Top Stocks to Profit from the EV Revolution >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-06,78.96,79.88,77.4,78.35,
DXCM,2022-07-07,78.01,82.06,77.52,81.92,
DXCM,2022-07-08,80.21,82.85,79.11,81.24,
DXCM,2022-07-11,80.1,80.465,77.65,78.43,"2 Dividend Stocks You Can Confidently Buy in a Bear Market Did you know that a bad market technically isn't a bear market until the benchmark S&P 500 index is at least 20% below its latest peak? We're not quite there at the moment. After recovering from steep losses for a few days, the index is about 19% below the high water mark it set in January. We may have emerged from a bear market already but it would be pretty irresponsible of us not to prepare for more rough weather ahead. These two giants of the healthcare sector are about as reliable as businesses get. Here's why you can count on steadily growing dividend payments from these two healthcare stocks. Abbott Laboratories You've more than likely seen some of Abbott Laboratories' (NYSE: ABT) COVID-19 diagnostic products. If you've been having a hard time finding baby formula you're also aware of this company's nutrition business. What you probably don't know is that Abbott Laboratories recently paid its 394th consecutive quarterly dividend. The company's also raised the payout for 50 consecutive years. If you're one of an estimated 37.3 million Americans living with diabetes, it's just a matter of time before you're also familiar with the most important new product Abbott Laboratories has launched in a long time. In May, the Freestyle Libre 3 received clearance from the FDA to monitor blood sugar levels 24 hours a day for 14 days at a time. The device is about the size of two pennies stacked on top of each other which is a little smaller than the constant glucose monitor (CGM) it could end up competing with, the new G7 from Dexcom (NASDAQ: DXCM). Dexcom developed the G7 for just 10 days of use at a time and it still hasn't received clearance from the FDA. Without a significant competitor for the Freestyle Libre 3 in the U.S., Abbott's CGM sales could shoot through the roof and easily offset slackening demand for COVID-19 tests. Shares of Abbott are about 23% below the peak they reached in January even though the Freestyle Libre 3 seems destined to gain and maintain a leading share of the lucrative CGM market. Abbott Laboratories shares offer a 1.7% yield at recent prices. While this yield isn't very tempting at first glance, CGM sales could help it grow the payout by leaps and bounds. Johnson & Johnson If you're willing to trade slower growth in the future for a higher yield in the present, consider Johnson & Johnson (NYSE: JNJ). With a AAA credit rating and a 60-year record of consecutive dividend raises, this healthcare conglomerate is a dividend investor's dream come true. Right now is a particularly good time to buy Johnson & Johnson because in 2023 it will spin off its consumer goods segment into a separate new business. This means existing shareholders will end up with two dividend-paying stocks in their portfolio for the price of one. The company's consumer goods segment hasn't been a major source of growth in a long time but its pharmaceutical business is stronger than ever. For example, Tremfya is a recently launched psoriasis treatment with sales that rose 41% year over year in the first quarter and it's already on pace to generate $2.4 billion in revenue this year, Johnson & Johnson's quarterly payouts have risen about 35% over the past five years. The stock currently offers a 2.5% yield and after it spins off its consumer segment, both stocks will pay dividends that meet or exceed the payments investors are currently receiving. Without a stodgy consumer health segment holding it back, J&J's soon-to-be streamlined operation could deliver impressive growth in 2023 and beyond. That makes it a solid addition now for just about any income-seeking investor's portfolio. 10 stocks we like better than Johnson & Johnson When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Johnson & Johnson. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-12,78.93,80.67,77.38,78.05,"DexCom (DXCM) Stock Moves -0.48%: What You Should Know In the latest trading session, DexCom (DXCM) closed at $78.05, marking a -0.48% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.92%. Meanwhile, the Dow lost 0.62%, and the Nasdaq, a tech-heavy index, added 0.05%. Coming into today, shares of the medical device company had gained 15.24% in the past month. In that same time, the Medical sector gained 3.13%, while the S&P 500 lost 1%. DexCom will be looking to display strength as it nears its next earnings release, which is expected to be July 28, 2022. On that day, DexCom is projected to report earnings of $0.16 per share, which would represent a year-over-year decline of 15.79%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $697.57 million, up 17.22% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.75 per share and revenue of $2.92 billion. These totals would mark changes of +11.94% and +19.28%, respectively, from last year. Any recent changes to analyst estimates for DexCom should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.03% lower. DexCom is currently sporting a Zacks Rank of #3 (Hold). In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 104.02. Its industry sports an average Forward P/E of 28.61, so we one might conclude that DexCom is trading at a premium comparatively. Meanwhile, DXCM's PEG ratio is currently 3.36. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DXCM's industry had an average PEG ratio of 1.89 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 132, putting it in the bottom 48% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-13,76.26,78.44,75.04,76.35,
DXCM,2022-07-14,75.81,77.03,73.93,76.5,
DXCM,2022-07-15,77.95,79.575,77.32,79.14,"Is DexCom Stock Too Pricey to Buy? If you've had sticker shock while perusing the grocery store recently and decided not to buy something you normally would, DexCom (NASDAQ: DXCM) might not be the stock for you. The medical device company's status as a solid growth stock is much the same as it ever was, but it's not exactly the good deal that it might have been a few years ago. Yet, there are a few reasons to believe that its high price tag could be justifiable for some investors. Let's break down this company's valuation and take a look at its growth prospects to see if buying a few shares could be a good financial decision for you. There's no doubt that it's an expensive stock If you're just learning about DexCom for the first time, it develops and sells continuous glucose monitors (CGMs), which people with type 2 diabetes use to control their blood sugar levels more effectively and comfortably than with traditional finger-stick tests that need to be done several times per day. It's also a company that's been great for investors with a total return of around 2,400% over the past 10 years. But after a run-up like that, it's no surprise to see a loss of momentum. The trouble with DexCom's valuation is that it's currently at jaw-dropping levels. Take its price-to-earnings (P/E) ratio of around 196, for example. For reference, the average P/E multiple of a company in the medical devices industry is a grand total of a hair over 34. Could DexCom really be worth paying more than five and a half times per dollar of net income compared to an average stock in its industry? For most investors, the answer to that question depends on how much growth they expect to get from their purchase. On that front, DexCom isn't half bad, but there are a couple of warning signs. Over the last two years (through the latest quarter), its net income fell by 8.3% to $211.7 million while revenue rose by 41.3%. Both of those are a far cry from the period between the start of 2018 and the start of 2020 when its sales jumped 105.4%. Competition could be to blame since powerful competitors like Abbott Laboratories are busy trying to steal market share, putting pressure on margins in the process. Over the last three years, DexCom's selling, general, and administrative (SG&A) expenses shot up significantly as a share of its quarterly revenue as did its total quarterly expenses as a share of revenue. Given that the company doubled its U.S. sales force over the course of 2021 amid a major push with its direct-to-consumer sales operations, neither of the above is surprising, but it does indicate that the days of easy and relatively low-cost growth may be approaching an end. And if margin pressure continues, it could drive the company into a few unprofitable quarters or worse, which would be an additional headwind on its stock price. It could still keep growing and growing Despite the recent slowdown in growth, it would be a big mistake to count DexCom out. For this year, management predicts that it'll make between $2.8 billion and a bit over $2.9 billion. Aside from the health and convenience benefits that patients love about its CGMs, they also tend to save money on glucose testing supplies to the tune of around $424 per month, according to management. Though competing products likely also offer significant savings compared to traditional glucose testing methods, competitors like Abbott Labs don't focus exclusively on making CGMs. DexCom should be able to continue expanding into international markets and additional diabetes market segments more aggressively, even if chasing that growth is going to be slightly more expensive than in the past. In particular, its DexCom One monitor and software package is seeing significant traction in Lithuania, Latvia, Estonia, and Bulgaria, where more than 1% of the eligible patients in the market purchased the package within the first two months of it hitting the market. Rapid growth like that sure looks like a justification for the stock's high valuation. But that doesn't mean it's a great pickup for everyone. Growth-hungry investors will find what they're looking for in DexCom, at least for the next few years. On the other hand, price-sensitive investors or traditional value investors should probably steer clear as it's a fact of life that the stock's rich valuation leaves it vulnerable to downward corrections during bear markets -- like the one we're in right now. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Alex Carchidi has positions in Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-18,79.29,79.91,76.2,76.99,
DXCM,2022-07-19,78.27,80.77,76.6097,80.64,"3 Beaten-Down S&P 500 Stocks Ready to Bounce Back Down 20% from its January high and within reach of new 52-week lows, the S&P 500 (SNPINDEX: ^GSPC) may be ready to recover -- or maybe not. We just don't know. What we do know is a slew of S&P 500 constituents have suffered even bigger setbacks and are primed to bounce back with or without the broader market's help. Let's take a closer look at three of the most beaten-down names long-term investors can go ahead and add to their portfolios now -- even if stocks as a whole haven't yet found their ultimate bottom. 1. Dexcom Dexcom (NASDAQ: DXCM) makes continuous glucose monitors for people with diabetes. In fact, its ""G"" series of devices are among the market's most popular, giving the company control of more than half the United States' glucose monitor market, as well as the biggest worldwide market share, according to numbers from iData. The fact that its monitors can be managed with a smartphone app and can integrate with some insulin pumps is proving compelling to people afflicted with Type 2 diabetes. This is apparent in Dexcom's financial results: Last year's top line was up 27%, and earnings are growing at a corresponding rate. Don't look for this trend to slow down anytime soon, either. Thanks to a combination of poor diets and an obesity epidemic, the International Diabetes Federation forecasts that 10.9% of the planet's growing population will be diagnosed with diabetes by 2045, up from 2019's tally of 9.3%. Given the outlook for global population growth during that time, the number of people with diabetes should increase from a little over 700 million to almost 1 billion. Not all of them will need glucose monitors, but many will, and it's arguable that many diabetes patients aren't using glucose monitors right now but should be. That's part of the reason this year's and next year's revenue are both projected to grow on the order of 20%, with comparable profit growth in the cards. None of this has mattered much to investors lately; the stock has been cut in half since November. As the post-pandemic dust settles, though, look for the market to start pricing in the underlying growth story again. 2. General Electric The timing of General Electric's (NYSE: GE) turnaround couldn't have been any less lucky. Just when it looked like its balance sheet problems and a business mix that was more distracting than diversified were about to be resolved, COVID-19 hit. It became difficult to figure out which weak points were the company's and which were attributable to the global supply chain's breakdown. As is the case with Dexcom, though, with the dust of the pandemic finally settling, we're getting a clearer picture of where GE is -- and the outlook looks good. With a tighter focus on areas like renewable energy, healthcare, and aircraft parts after getting out of the oil and gas business, as well as selling its aircraft leasing operation, the company is now looking for free cash flow of between $5.5 billion and $6.5 billion this year, en route to $7 billion for 2023. That's up from last year's $5.1 billion, suggesting General Electric is on the right track. And its focus is only set to improve going forward. After seeing fiscal success by divesting businesses that don't quite fit in anymore, the company is planning to split its current self into three more stand-alone entities. The time frame for the divvying has yet to be finalized, but the move should ultimately add net value simply by facilitating transparency and allowing investors to pick and choose which pieces of the current organization they'd like to own (or not). The prospect hasn't excited any investors lately, with GE stock falling more than 30% just since the end of last year. Give it time, though. The breakup is a much-needed move that should unlock pent-up value trapped by the company's still-complicated framework. 3. Walt Disney Finally, after a 12-month 47% rout that dragged shares to new 52-week lows just last week, Walt Disney (NYSE: DIS) is an attractive long-term buy. Yes, the entertainment giant is facing myriad challenges right now. These include a sudden slowing in signups for its streaming services that will likely leave it shy of its previous goal of at least 230 million streaming subscribers by 2024, as well as calls for boycotts in response to the company's stances on some political issues. Lingering economic weakness, of course, also works against Disney by making travel to its theme parks and hotels a relatively tougher sell to prospective vacationers. Except the worst-case scenario may already be priced into the stock ... and then some. Take its film business as an example. With all studios and theaters effectively shuttered during the latter half of 2020 and much of 2021, it wasn't clear if the sharp growth of the streaming industry during the heart of the coronavirus pandemic would ever let the movie business return to what it was prior to the public health crisis. But it's doing just that. Data from Box Office Mojo indicates that ticket sales during this year's Independence Day weekend topped revenue from the comparable weekend of 2019. Ditto for the following weekend's take, led by Disney's Thor: Love and Thunder, pushing the theatrical film business ever closer to its pre-pandemic revenue. Better still for Disney shareholders, of this year's 10 highest-grossing films thus far, three of them are Disney flicks. And as for its parks and hotels, while an economic headwind certainly seems like it could take a toll on the company, Morgan Stanley analyst Benjamin Swinburne sees things from a different perspective. In light of nearly two years' worth of pandemic lockdowns (effectively, even if not officially), Swinburne said he believes ""pent-up demand is clearly playing a role in the current Parks strength, which along with Disney's yield management investments may allow the business to grow even in a modest recession."" Only time can truly tell how things will shake out, but with the stock more than halved since early last year, the risk-versus-reward ratio is long on reward and short on risk. 10 stocks we like better than General Electric When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and General Electric wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Walt Disney. The Motley Fool recommends DexCom and recommends the following options: long January 2024 $145 calls on Walt Disney and short January 2024 $155 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-20,80.77,83.24,79.935,82.185,"DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know In the latest trading session, DexCom (DXCM) closed at $82.19, marking a +1.92% move from the previous day. This move outpaced the S&P 500's daily gain of 0.59%. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, added 0.07%. Coming into today, shares of the medical device company had gained 14.45% in the past month. In that same time, the Medical sector gained 8.26%, while the S&P 500 gained 7.25%. Investors will be hoping for strength from DexCom as it approaches its next earnings release, which is expected to be July 28, 2022. In that report, analysts expect DexCom to post earnings of $0.16 per share. This would mark a year-over-year decline of 15.79%. Meanwhile, our latest consensus estimate is calling for revenue of $697.01 million, up 17.12% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $0.76 per share and revenue of $2.92 billion, which would represent changes of +13.43% and +19.26%, respectively, from the prior year. It is also important to note the recent changes to analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.67% higher. DexCom currently has a Zacks Rank of #3 (Hold). Looking at its valuation, DexCom is holding a Forward P/E ratio of 105.98. This represents a premium compared to its industry's average Forward P/E of 29. We can also see that DXCM currently has a PEG ratio of 3.42. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DXCM's industry had an average PEG ratio of 1.85 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers ""Most Likely for Early Price Pops."" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-21,82.43,84.2759,81.8,83.99,"[""3 Biotech Stocks to Buy on the Dip InvestorPlace - Stock Market News, Stock Advice & Trading Tips With a rebound likely, investors are looking for biotech stocks to buy on the dip. According to Investor\u2019s Business Daily, there\u2019s been a collective 22.5% surge among the biotech stocks they\u2019re tracking. Still, the sector is well below its 2021 highs, making this a great time to buy biotech stocks on the dip. Moreover, the sector\u2019s stocks are well-positioned to keep climbing for a long time. That\u2019s because the key factor that had been pushing them down for a long time \u2013fears of sky-high interest rates \u2013is receding. 7 Cheap Stocks That Are Trading at a Discount This situation has arisen because core inflation appears to have peaked and gasoline prices are retreating. As a result, overall inflation is about to drop, and the Fed will not have to raise rates tremendously. With that in mind, these are the three biotech stocks to buy on the dip: GSK GSK $20.47 Dexco DXCM $82.18 Schrodinger SDGR $32.67 GSK (GSK) Source: Willy Barton / Shutterstock.com Trial results of the GSK (NYSE:GSK) dostarlimab drug suggest that the product is well-positioned to become \u201ca blockbuster\u201d cancer treatment. In an unprecedented occurrence, all 18 rectal cancer patients who took the drug appeared to be completely cured. And they did not have any major side effects. Consequently, I believe there is an excellent chance of dostarlimab generating hundreds of billions of dollars fir GSK. Also importantly, analysts, on average, predict that GSK\u2019s earnings per share will come in at $3.48 in 2023, up from their mean estimate of $3.22 for this year and the company\u2019s actual EPS of $3.11 in 2021. And GSK\u2019s forward price-earnings ratio is less than 12, while it has a hefty dividend yield of 4.9. Dexcom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com Dexcom (NASDAQ:DXCM) provides products that help diabetes patients. In a note to investors on July 15, Bernstein analyst Lee Hambright began covering Dexcom with a $105 price target and an \u201coutperform\u201d rating. According to the analyst, Dexcom\u2019s Continuous Glucose Monitoring (CGM) product is the most precise CGM offering available and can interface with insulin pumps. 7 Cheap Semiconductor Stocks to Buy Now Additionally, he believes that Dexcom has a long runway. Hambright claims the company has only scratched the surface of its core market. He is also very bullish on the company\u2019s upcoming G7 CGM product, which has been approved in Europe and he thinks that it is likely to be approved by the FDA. According to another source, that approval could occur soon. Analysts, on average, expect the company\u2019s EPS to climb to $1.17 in 2023 next year from 82 cents this year. In 2021, Dexcom reported EPS of 67 cents. Schrodinger (SDGR) Source: Billion Photos / Shutterstock Schrodinger (NASDAQ:SDGR) obtained approval from the FDA \u201cto study its computer-designed therapy for non-Hodgkin lymphomas in an early-phase trial.\u201d That was the first time that the agency agreed to allow the company itself to study one of its drugs derived from AI in a clinical trial. Schrodinger used its technology to develop and select the drug in ten months. The company reports that its technology enables it to examine \u201cbillions of molecules per week with a high degree of accuracy,\u201d versus the roughly \u201c1,000 compounds\u201d evaluated using traditional techniques. The company added that \u201cOur approach enables discovery of high-quality, novel molecules more rapidly, at lower cost, and we believe with a higher likelihood of success compared to traditional methods.\u201d Validating Schrodinger and its technology, the company is partnering with multiple, large pharmaceutical companies, and Bill Gates\u2019 trust had nearly 7 million shares of SDGR stock as of the trust\u2019s last report. On the date of publication, Larry Ramer was long SDGR stock. The post 3 Biotech Stocks to Buy on the Dip appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Hold On to DexCom (DXCM) Stock Now DexCom DXCM is well-poised for growth, backed by a robust product portfolio and a strong international presence. However, supply constraints remain a concern. Shares of this Zacks Rank #3 (Hold) company have lost 38.8% compared with the industry\u2019s decline of 28.9% so far this year. Meanwhile, the S&P 500 Index has fallen 24.1%. Image Source: Zacks Investment Research DexCom \u2014 with a market capitalization of $31.65 billion \u2014 is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). It anticipates earnings to improve 31% over the next five years. The company beat earnings estimates in two of the trailing four quarters and missed twice, the average surprise being 15.84%. Key Catalysts On the basis of business growth and expanding patient base, the extension of G7 into all the core markets might extend to 2022 as the company ramps up manufacturing to lend support to the markets in an efficient manner. In May 2022, DexCom introduced the Dexcom ONE CGM System in the U.K. This new system is an easy-to-use real-time CGM (rt-CGM) and is more accessible and affordable for people suffering from diabetes in the country. Presently, Dexcom ONE is in review to be added to drug tariffs throughout the U.K. regions. It is worth mentioning that Dexcom ONE will become part of the broad range of products offered by the company for people with diabetes in the U.K., including the Dexcom G6 CGM system and the upcoming Dexcom G7 CGM system. In March 2022, DexCom announced that the Ontario government offered coverage for the Dexcom G6 CGM System. The government will offer this coverage through its Assistive Devices Program (ADP) to people living with type one diabetes in the province and are over two years of age and fulfill the coverage criteria. It is worth noting that the back of the upper arm insertion site is for ages 18 and above. In the same month, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM System\u2019s use in the hospital setting. The designation is expected to provide a more efficient and streamlined review pathway to enable Dexcom CGM technology to rapidly strengthen the company\u2019s presence in the hospital market. In first-quarter 2022, international revenues (28% of total revenues) surged 43% year over year to $177.6 million, owing to the widening of commercial footprint. DexCom\u2019s market expansion initiatives internationally are all progressing according to plan, thereby driving high-volume growth. Thus, international growth remains strong, courtesy of improving global access and awareness. Primary Headwind DexCom relies on third parties for an assured steady supply of inputs. Consequently, the capacity constraint for the production of its offerings might dampen the company\u2019s growth prospects. Estimates Trend The Zacks Consensus Estimate for 2022 revenues is pegged at $2.92 billion, suggesting growth of 19.3% from the year-ago reported number. The same for earnings stands at 76 cents, indicating an improvement of 13.4% from the prior-year quarter. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks from the broader medical space are AMN Healthcare Services, Inc. AMN, Patterson Companies, Inc. PDCO and ShockWave Medical, Inc. SWAV. AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN\u2019s earnings surpassed the Zacks Consensus Estimate in all four trailing quarters, the average being 15.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. AMN Healthcarehas gained 13.8% against the industry\u2019s 32.7% fall in the past year. Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.6%. PDCO\u2019s earnings surpassed estimates in all the trailing four quarters, the average being 16.5%. Patterson Companies has lost 1.8% compared with the industry\u2019s 10.5% fall over the past year. ShockWave Medical, sporting a Zacks Rank of 1 at present, has an estimated growth rate of 44.9% for 2023. SWAV\u2019s earnings surpassed estimates in all the trailing four quarters, the average being 189.9%. ShockWave Medical has gained 7.9% against the industry\u2019s 24.4% fall over the past year. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report ShockWave Medical, Inc. (SWAV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Do Options Traders Know Something About DexCom (DXCM) Stock We Don't? Investors in DexCom, Inc. DXCM need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 16, 2022 $95.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for DexCom shares, but what is the fundamental picture for the company? Currently, DexCom is a Zacks Rank #3 (Hold) in the Medical - Instruments industry that ranks in the Top 39% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimate for the current quarter, while three have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 18 cents per share to 16 cents in that period. Given the way analysts feel about DexCom right now, this huge implied volatility could mean there\u2019s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-07-22,83.85,86.06,82.55,83.78,
DXCM,2022-07-25,83.07,83.72,81.305,82.6,
DXCM,2022-07-26,82.82,83.4984,80.78,82.7,"[""Is a Beat Likely for DexCom (DXCM) This Earnings Season? DexCom, Inc. DXCM is scheduled to release second-quarter 2022 results on Jul 28, after the closing bell. In the last reported quarter, the company delivered a negative earnings surprise of 36.00%. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed the same twice, the average surprise being 15.84%. Q2 Estimates Currently, the Zacks Consensus Estimate for second-quarter revenues is pegged at $697.01 million, suggesting growth of 17.1% from the year-ago reported figure. The consensus mark for earnings stands at 16 cents per share, indicating a decline of 15.8% from the prior-year quarter. Factors to Note DexCom\u2019s second-quarter top line is likely to have been aided by an increase in volume, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). During the first quarter, the company continued to make progress with respect to its objective of expanding access and accelerating its leadership in CGM-connected solutions and customer choice. The company launched differentiated software with the CE Mark and Dexcom ONE product in the second half of 2022. DexCom is likely to have launched Dexcom ONE product in the United Kingdom and Spain during the second quarter. These developments are likely to have benefited customer growth during the soon-to-be-reported quarter. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote In March 2022, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. During the first quarter, DexCom secured the CE mark for the Dexcom G7 CGM System for monitoring people with diabetes aged two years and older and also initiated a limited launch of the system in Europe. DexCom expanded coverage for Dexcom CGM to include type 1 diabetes in Ontario, Canada during the first quarter. Moreover, TRICARE added Dexcom G6 as a brand-name formulary pharmacy benefit. These developments may have favored the company\u2019s performance in the to-be-reported quarter. DexCom has ample prospects in international markets backed by demographic trends and lifestyles in countries outside the United States and Europe. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In first-quarter 2022, international revenues (28.2% of total revenues) surged 43% year over year to $177.6 million. The momentum is likely to have continued in the second quarter, thanks to broad-based growth throughout all markets. However, an increase in operating expenses and intense competition may have weighed on the to-be-reported quarter\u2019s performance. Earnings Beat Likely Our proven model predicts an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (17 cents per share) and the Zacks Consensus Estimate (16 cents per share), is +9.15%. Zacks Rank: DexCom carries a Zacks Rank #3. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Other Stocks to Consider Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle: Alkermes plc ALKS has an Earnings ESP of +300.00% and a Zacks Rank of 1. ALKS has an estimated long-term growth rate of 25.1%. Alkermes\u2019 earnings surpassed estimates in all the trailing four quarters, with the average surprise being 350.5%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. STERIS plc STE has an Earnings ESP of +1.85% and is a Zacks #1 Ranked stock. STE has an earnings yield of 4% against the industry\u2019s negative yield. STERIS\u2019 earnings surpassed estimates in all the trailing four quarters, with the average surprise being 9.2%. Cano Health CANO has an Earnings ESP of +53.85% and a Zacks Rank of 2 at present. CANO has an earnings yield of (0.77%), which compares favorably with the industry\u2019s yield of (1.42%). In the last reported quarter, Cano Health delivered an earnings surprise of 30.00%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. This Little-Known Semiconductor Stock Could Lead to Big Gains for Your Portfolio The significance of semiconductors can't be overstated. Your smartphone couldn't function without it. Your personal computer would crash in minutes. Digital cameras, washing machines, refrigerators, ovens. You wouldn't be able to use any of them without semiconductors. Disruptions in the supply chain have given semiconductors tremendous pricing power. That's why they present such a tremendous opportunity for investors. And today, in a new free report, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most. It's yours free and with no obligation. >>Give me access to my free special report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report STERIS plc (STE): Free Stock Analysis Report Cano Health, Inc. (CANO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth Avanos Medical (AVNS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This medical technology company is expected to post quarterly earnings of $0.39 per share in its upcoming report, which represents a year-over-year change of +85.7%. Revenues are expected to be $208.35 million, up 11.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.92% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Avanos Medical? For Avanos Medical, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +6.49%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Avanos Medical will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Avanos Medical would post earnings of $0.24 per share when it actually produced earnings of $0.26, delivering a surprise of +8.33%. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Avanos Medical doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. An Industry Player's Expected Results Among the stocks in the Zacks Medical - Instruments industry, DexCom (DXCM) is soon expected to post earnings of $0.16 per share for the quarter ended June 2022. This estimate indicates a year-over-year change of -15.8%. This quarter's revenue is expected to be $697.01 million, up 17.1% from the year-ago quarter. The consensus EPS estimate for DexCom has been revised 0.2% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -3.69%. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that DexCom will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. This Little-Known Semiconductor Stock Could Lead to Big Gains for Your Portfolio The significance of semiconductors can't be overstated. Your smartphone couldn't function without it. Your personal computer would crash in minutes. Digital cameras, washing machines, refrigerators, ovens. You wouldn't be able to use any of them without semiconductors. Disruptions in the supply chain have given semiconductors tremendous pricing power. That's why they present such a tremendous opportunity for investors. And today, in a new free report, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most. It's yours free and with no obligation. >>Give me access to my free special report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-07-27,82.78,85.83,82.78,85.8,"2 Reasons Why DexCom Stock Could Be a Smart Buy This Week Don't let DexCom's (NASDAQ: DXCM) drop of 38% this year fool you: This business is teeming with growth, and it's still fully capable of being a great long-term investment, especially starting this week. The medical device manufacturer will report its second-quarter earnings after the market closes on Thursday, July 28, and in doing so it'll provide a lot of new information that's likely to power movement in its stock. In particular, the company's foray into international markets will be in sharp focus, and investors will get key updates about how quickly they should expect its presence to expand. If you're thinking about buying a few shares, take the next step and consider another pair of arguments for why it could be a wise decision. 1. It'll be reporting on successes with its recent product launches DexCom's wearable continuous glucose monitor (CGM) is its primary product, and it's always working to add more features and launch new devices that make life easier for people with diabetes. Last quarter, the company started to sell a limited number of units of its new CGM, the G7, and it also initiated the sale of its DexCom One system in Spain and the U.K. The One product combines its older G6 monitors with a new software suite, thereby helping customers track and control their blood glucose levels in real-time more effectively than they might otherwise. When DexCom One was recently launched in Latvia, Lithuania, Estonia, and Bulgaria, it penetrated more than 1% of the addressable market in those countries within the first 60 days. That's especially impressive when considering that patients in those markets paid out of pocket for their systems. And if the business shows that it did an encore performance in the new markets it just launched in, it'll be a strong positive for the stock. Likewise, if it reports that sales of its G7 monitors are hot right in the months after it launched in the U.S., it'll set the stage for an equally successful rollout in international markets down the line. If the new launches power its Q2 revenue to grow by more than 25% year over year, which is how rapidly the top line grew in Q1 when quarterly sales were $629 million, it'll be especially favorable. 2. Its international operations are leading to massive growth, and efforts to drive even more are probably on the way The second reason DexCom might be a smart buy this week is closely related to the first. Thanks to its effective product and new launches, it's getting a significant amount of global traction. In its fiscal 2021, its revenue from markets outside of the U.S. grew by 44%, hitting $599.1 million. At the time, it only derived 24% of its total revenue from international markets, but after the first quarter of this year, those same markets are worth 28% of its quarterly intake. In other words, its overall growth rate is becoming less dependent on success in the U.S., which is a positive sign because competition is likely to be the fiercest there. And there's a good chance the company is going to lean into its early successes internationally, just like it did domestically. Management anticipates that its total addressable market outside of the U.S. will triple before the end of 2023. While it gains market share in developed markets in the E.U. and Asia, the next step will be to enter developing markets. Capturing growth might well require a scale-up of its sales organization; in the U.S. last year, it opted to double its sales force. Doing that for its ex-U.S. sales operations would ultimately imply a significant amount of additional selling, general, and administrative (SG&A) expenses, but it would also pave the way for more rapid market penetration and nearer-term gains for investors too. Buying shares of DexCom before it explicitly announces another massive sales scale-up will ensure that investors get the full benefit of price appreciation in the aftermath, not to mention the benefit from any reporting of strong earnings. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-07-28,86.06,87.28,84.11,86.99,"[""DexCom (DXCM) Q2 2022 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q2 2022 Earnings Call Jul 28, 2022, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Dexcom second quarter 2022 earnings release conference call. My name is Darryl, and I'll be your operator for today's call. [Operator instructions] As a reminder, this conference is being recorded. I will now turn the call over to Sean Christensen. Sean, you may begin. Sean Christensen -- Head of Investor Relations Thank you, operator, and welcome to Dexcom's second quarter 2022earnings call Our agenda begins with Kevin Sayer, Dexcom's chairman, president and CEO, who will summarize our recent highlights and ongoing strategic initiatives; followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. [Operator instructions] Please note that there are also slides available related to our second quarter performance on the Dexcom investor relations website on the events and presentations page. With that, let's review our safe harbor statement. Statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs and expectations about future events, strategies, competition, products, operating plans and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q and other filings with the Securities and Exchange Commission. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2022 Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our second quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measures. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Today, we reported another strong quarter for Dexcom with second quarter organic revenue growth of 16% compared to the second quarter of 2021. Momentum for global CGM adoption remains high, and we once again achieved worldwide record new customer starts in the second quarter. Following some disruption early in the year related to the Omicron wave, office access has continued to improve. And we experienced a return to a more normalized customer journey, which helped us deliver this record. Customer satisfaction also continues to reach new levels as our U.S. Net Promoter Score hit another all-time record in the second quarter. Our customers value the differentiated experience that Dexcom provides with consistent praise for our real-world accuracy, connectivity, actionable features and customer support. Product performance has been a hallmark for Dexcom throughout our history. Customers and caretakers alike rely upon the accuracy of Dexcom CGMs and can be confident in performance across all aspects of glucose management, backed by numerous clinical trials and borne out by real-world experience. We have long viewed software as an avenue to differentiate, enabling unique user experiences, supporting greater connectivity and enhancing our ability to move more seamlessly into new markets. In support of this vision, we have invested significantly in building our software infrastructure in recent years and now spend more of our R&D budget on software than hardware. A tangible example of this can be found in our rollout of Dexcom ONE. This product leverages our G6 hardware and will use our G7 platform in the future, but uses software to provide a different experience than our G Series systems. This has allowed us to meaningfully expand our market presence in recent months, entering new markets and winning tenders internationally that were previously not available to our G Series product. This is just the beginning of our journey on leveraging software to great products that meet the needs of our end users. Our software infrastructure has also positioned us to be the partner of choice for technology companies looking to build new and innovative experiences around CGM data. Our list of real-time API partners continues to grow as we're the only company that can provide partners real-time CGM data in an FDA-regulated solution. Our software capabilities are also laying the foundation for our success beyond the intensively managed population. For example, two partners focused on the use of CGM for weight management and metabolic health, Signos and Levels Health, have clinical trials underway that are leveraging our real-time API capabilities. We are excited to see the outcome from these trials as they provide a glimpse into the future for CGM technology that could serve as a much broader end market than today. The second quarter saw a number of strategic accomplishments in international markets that continue to strengthen our competitive position. The excitement continues to grow for our portfolio of CGM systems, G6, G7 and Dexcom ONE, and we've made significant strides in both direct and distributor markets to broaden access to our technology. We launched Dexcom ONE in both Spain and the U.K. and have secured reimbursement for key segments of the population. Opening large parts of these markets have previously lacked reimbursement for Dexcom CGM. We also announced a partnership with Roche to distribute Dexcom ONE in Italy. This relationship will allow us to leverage Roche's well-established commercial infrastructure to bring Dexcom ONE to a much larger Italian market. In Australia, the government recently committed to providing subsidized access to our G6 system for all people living with type 1 diabetes, which is a significant improvement in coverage and a great win for Australians deserving access to CGM technology. Our limited launch of G7 in the U.K. continues to be met with significant enthusiasm from our customers who have provided consistently positive feedback on product size, ease of use, the shorter warm-up time, the app experience and more. Many customers shared that they would often forget they were even wearing their G7 during their session and indicated they can't wait to continue wearing the product full time in the future. The period has proven to be incredibly valuable, allowing us to assess the functionality of the sensor and app in a real-world setting and providing feedback on ways to refine our support system to make the broader rollout as streamlined as possible. We are excited to get G7 in the hands of more customers and plan to expand our launch in the third quarter, starting in the U.K. In the U.S., our 510(k) submission for G7 remains under review with the FDA. As part of this process, we are making a subtle change to the G7 software based on feedback from the FDA, slightly delaying our expected time lines for clearance and U.S. launch. We expect FDA clearance and limited launch later this year and a large commercial launch in the U.S. in the first quarter of 2023. Encouragingly, our preliminary discussions with payers have progressed very well. They understand what this product will mean for our customers and people with diabetes broadly, giving us increasing confidence in the ability to ramp up commercial coverage quickly. Finally, we were very proud to showcase our expanded CGM portfolio at two of the largest diabetes conferences of the year, ATTD in Barcelona and ADA in New Orleans. These events provide us an opportunity to connect with thought leaders across the diabetes space, and we continue to see a clear consensus on real-time CGM being the standard of care in diabetes management and a growing appreciation of the health and economic benefits of extending the use of this technology beyond the intensively managed population, including the broader type 2 population and use in the hospital. Between these two events, there were dozens of presentations, abstracts and posters highlighting success stories of CGM to date and what the future could hold for this technology. I started attending diabetes conferences almost 30 years ago. As I look back even two or three years ago, these types of conversations around the broad potential of CGM were nonexistent. Now it's become very apparent that CGM data will become the basis of where diabetes management and glucose control in the future is headed. We're very excited about the opportunities ahead for Dexcom. And with that, I'll turn it over to Jereme for a review of the second quarter financials. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the second quarter of 2022, we reported worldwide revenue of $696 million, which included $12 million of unfavorable foreign currency impact. This is compared to $595 million for the second quarter of 2021, which represents growth of 16% on an organic basis. We have slightly changed our definition of organic revenue based on feedback from our stakeholders to exclude currency and acquisition-related revenue in the trailing 12-month period. Volume growth for the second quarter came in around the mid-30% range on a global basis. U.S. revenue totaled $511 million for the second quarter, compared to $462 million in the second quarter of 2021, representing growth of 11%. Customer demand remained strong in the U.S., and our unit volume growth continued to grow at a very healthy clip this quarter, relatively in line with recent quarters. We have been launching a number of new tools for our sales force in the U.S. that leverage technology to make each physician visit more efficient and effective. These tools inform our team what each doctor is prescribing, the makeup of their payer mix and even compare the out-of-pocket cost for each customer. This data can make each visit more impactful and help us continue to address the competitive mix that still exist in the market. We continue to see an ongoing impact on revenue growth from our strategic shift to the pharmacy channel. But as discussed previously, we believe this will ultimately set us up to serve meaningful, more customers over time. International revenue grew 39%, totaling $185 million in the second quarter. Organic revenue growth was 34% for the second quarter. Our positive momentum continued this quarter as the number of global initiatives we implemented in the past year has significantly improved our competitive position in international markets. In addition to the Dexcom ONE new market wins Kevin highlighted before, we also continue to drive greater reimbursement in our initial launch countries in Eastern Europe this quarter. While we previously announced that patient reimbursement in Bulgaria and Estonia, Latvia and Lithuania have now established full or partial reimbursement for individuals with type 1 diabetes. This is a great example of how our CGM portfolio strategy can help us enter completely new markets and be a catalyst for access. Through new product launches and reimbursement efforts over the past 18 months, we are happy to share that we have increased the reimbursed access to our product by more than 3 million customers and look forward to getting this much-needed technology in the hands of as many people as possible. Our second quarter gross profit was $449.5 million or 64.6% of revenue compared to 70.1% of revenue in the second quarter of 2021. Given the initial launch of G7 in the U.K., this is the first quarter where G7 development costs started to flow through COGS, accounting for some of the expected year-over-year step down in gross margin. Additionally, there were greater than 50 basis points of impact from currency in the quarter. Our second quarter gross margin was a nice step-up from the first quarter and leaves us on track to hit our margin targets for the full year. Operating expenses were $347.6 million for Q2 of 2022, compared to $315 million in Q2 of 2021. Similar to last quarter, we generated meaningful operating expense leverage despite incremental investment to support the G7 launch. We saw opex as a percentage of sales this quarter drop by 310 basis points year over year as we continue to leverage our R&D and G&A expense lines. Operating income was $101.9 million or 14.6% of revenue in the second quarter of 2022, compared to $101.5 million or 17.1% of revenue in the same quarter of 2021 as a tough year-over-year gross margin comp was partially offset by operating leverage in the quarter. Adjusted EBITDA was $175.5 million or 25.2% of revenue for the second quarter, compared to $156.6 million or 26.3% of revenue for the second quarter of 2021. Net income for the second quarter was $69.5 million or $0.17 per share. We remain in a great financial position, closing the quarter with approximately $2.8 billion worth of cash and cash equivalents. This provides us the flexibility to continue to invest in our organic growth opportunity, including the ongoing build-out this year of our Malaysia manufacturing facility and to assess any compelling strategic investments that present themselves. Along those lines, we announced today a $700 million share repurchase program, which will allow us to offset the dilutive impact from our 2023 convertible notes. We are always assessing the best uses of our capital. And given the recent market pressure, we view this as a great time to invest in our own business as we remain incredibly bullish on the sizable opportunity ahead for Dexcom. Turning to guidance. We are updating our full year 2022 revenue guidance to a range of $2.86 billion to $2.91 billion. For margins, we are reaffirming our prior full year guidance of gross profit margins of approximately 65%, operating margins of approximately 16% and adjusted EBITDA margins of approximately 25%. This guidance factors in a significant uptick in currency headwinds relative to the expectations we shared a quarter ago. We now expect around $40 million of foreign currency headwinds for the full year relative to our prior estimate of around $15 million to $20 million. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. As I look at this quarter, our underlying fundamentals remain incredibly strong. We experienced another quarter of solid volume growth, achieved worldwide record new customer starts, recorded our highest-ever customer satisfaction rating. These results were before any material contribution from G7, which we expect to improve the customer experience in every way. We advanced our CGM portfolio outside the United States with a wider rollout of Dexcom ONE, helping us reach more reimbursed lives and serving more new customers. For G7, the feedback from our limited launch in the U.K. has been fantastic, leaving us incredibly excited for a broader global launch in the coming weeks. And in the U.S., we now have clear visibility to the finish line on G7 clearance. And our preliminary payer discussions are setting the stage for a big launch early next year. Despite all the macroeconomic challenges that exist today, runaway inflation, supply chain challenges, FX headwinds, we reiterated our margin guidance, continue to have no delivery delays across our business and remain committed to driving additional operating leverage in the coming years. And finally, we announced a $700 million share repurchase plan today. This will allow us to offset the dilutive impact of our 2023 convertible notes and also provides us an opportunity to send a clear message. We're betting on ourselves and the massive opportunity ahead of us. We're optimistic as we've ever been about our future. With that, I'd now like to open up the call for Q&A. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. [Operator instructions] Operator, please provide the Q&A instructions. Questions & Answers: Operator [Operator instructions] And our first question comes from Robbie Marcus from JPMorgan. Go ahead, Robbie. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks for taking my question. It was -- when you filed G7 last year, you had a pretty high degree of confidence in the completeness of the filing. So one, wondering if we could get a little more on what it is with the software, what you have to change, and how different it's going to be from the European version? What gives you that level of confidence in how to think about U.S. sales growth until we get a G7 launch? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Robbie, this is Kevin. I'll take the G7 questions. The software revisions relate to the management of the alerts and alarms in the U.S. app. FDA had some questions about some of the things that we've done and put in it. We discussed several options that we had. We decided the best option at this time was to revise the software and file it differently, and we've added a few other features to it as well based on our discussions with them. We're in the middle of revising the software for that and have to run it through the complete validation and verification process and resubmit. We're not done with it yet, but we're working very quickly to get done with that. And that's really our big major issue. We've talked through everything else. We did have a strong level of confidence and we still do in our relationships and our discussions with the FDA on G7. The one thing we figured out as we've been through this process is we changed absolutely everything. We changed the algorithm. We changed the insertion techniques. We changed every manufacturing procedure that we have and completely rewrote the entire app and the software experience, which is a lot for them to digest and a lot for us to submit. If I look at learnings for us over time, I think we'll probably do things a little more incrementally going forward rather than as big as this one was, and we can get things through faster. But we're in a good spot. We have a lot of clarity as to where we need to go going forward. And I'll let Robbie handle the growth issues regarding G6 because we're still doing extremely well with that product. Not Robbie -- Jereme, go ahead. Jereme Sylvain -- Chief Financial Officer Yeah. Hey, how you doing, Robbie? And thanks for the question. So in the U.S., look, the quarter here, we had about 11% growth. That's generally due to some of what we talked about in prior quarters, us getting into physicians' offices. And as those new patients didn't hit those record levels, you ultimately see that recur -- on a recurring business model such as ours, it plays through. What gives us a lot of confidence for the back half of the year is Q2 was a record, and we're back on that record track and we do expect strength for the rest of the year to the point where we expect U.S. growth rates to accelerate in Q3 and Q4 as we come off of this quarter where we see these record new patient starts. And quite frankly, we expect to have record new patient starts going forward for the balance of the year, even without G7. So I hope that gives you that question. We're very confident in G6, and obviously, we're even more confident in G7 once that launches. Operator And our next question comes from Jeff Johnson from Baird. Go ahead, Jeff. Jeff Johnson -- Robert W. Baird -- Analyst Thank you. Kevin, I just want to go back on your comments about revising some of the software on the alerts and alarms on the G7 product. So it sounds like to me, you're still in the process of that. But I think you also said in your prepared remarks that you were comfortable that you would still have a limited launch in the fourth quarter and a fuller launch in the first quarter of 2023 in the U.S. So one, can I just confirm that's what you said? Two, do you have some better certainty on all the other aspects of the filing from the FDA that gives you that ability to draw that line in the sand? Or at least where is your confidence on that time line? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer We do have great certainty on the other components of the filing with the FDA. We've talked through all the other questions and things that we've discussed, and we're very, very comfortable with that. So really, the outstanding major item is revision and filing of the revised software after we validate and verify it, all of that. So we are very, very comfortable with that. And yes, what I did say is we are anticipating a limited launch in the fourth quarter in the U.S. and then the full-on rollout in -- early in the year in 2023. One of the things I said in my prepared remarks is we're very bullish about the progress we've made with the payers as far as getting the G7 reimbursed because they can see how important it's going to be for our patient base. So on the one hand, while we have the delay in the approval and the launch that -- look, none of us -- we'd all like to be faster, the other thing we're seeing on the other side is a lot of cooperation in the payer community and just in the channel in getting this thing positioned for reimbursement very quickly after approval. So we can get the launch out in not too different of a time frame on a reimbursed basis from what we expected in the beginning. So those two factors together, again, add to where we think we are. Operator And our next question comes from Margaret Kaczor from William Blair. Go ahead, Margaret. Margaret Kaczor -- William Blair & Company -- Analyst Hey, good afternoon, guys. Thanks for taking the question. I wanted to maybe dive a little bit further into kind of this new patient add growth just because it's important as we get into '23 as well. But any details that you can give in terms of how it looks like within T1, T2 intensive and others? And if there have been any changes, I guess, in the last six to 12 months? Are things getting harder or easier? And what kind of efforts you guys put in place to reaccelerate more meaningfully those new patient adds? Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yeah, I can answer that. And thank you for the question. What we saw, and I think this is -- we've really talked about it is we found our folks are most effective when they're able to get into physicians' offices. That's always been the case, and it's continued to show itself time and time again. And so what we found is it rises all tides once we're able to do so. But the predominance of where our new patient adds are coming, if you want to kind of see what the more accelerate is, it's really in the type 2 intensive space. As we get into more primary care physicians' offices, these are folks we've called on really for the first time as we've expanded our sales force in 2021, getting there in-person has really unlocked that market, and that's what you continue to see. And so now our focus is -- and we talked about it a little bit in the prepared remarks. Now that we're in these offices, a record new patient quarter this quarter, certainly, that's encouraging. But we're also seeing that all of these tools that have been put in place means every call, every visit, every time we're in the office, we're able to be more effective about what might be the prescribers' decision-making around that particular patient. And through doing that, whether it's debunking myths around co-pays and what the out-of-pocket is and making sure folks understand the cost, whether it's the ease of use and showing folks that a majority of our patients are able to put it on and use either training online or simple training in the box to ultimately put it on their body. What we're really finding is we're breaking down all of those myths out there, and our sales force continues to get more and more effective. So we're going to continue to do that over time. And we're seeing that continue to play out as better prescriber patterns, more prescriptions per provider and more providers coming over to prescribing Dexcom. So all of those are playing out, which is what gives us confidence for acceleration in the U.S. in the back half of the year. Operator And our next question comes from Joanne Wuensch from Citigroup. Go ahead, Joanne. Joanne Wuensch -- Citi -- Analyst Good evening or afternoon, and thank you. I'm a little bit curious about some of the reimbursement landscape and things which may or may not have changed. Where do you think reimbursement is for bolus? And are you seeing any other changes as it relates to prior authorization or one product versus or another or anything else that we really should be aware of? Thank you. Jereme Sylvain -- Chief Financial Officer Thanks, Joanne. Yeah, I can take the question. So in terms of basal, we continue to make progress there. So as you think about where we're having the conversations, the conversations are both on the government in the U.S., CMS, as well as the U.S. commercial providers. We're having conversations with both. And our access team has submitted the data. They've submitted both clinical data, economic data, as well as clinician recommendations. And so we are going through those conversations. So it's been submitted. Discussions are ongoing. Timing is hard to peg in all of these, but we are continuing to advance it forward in terms of conversations. So that's basal. We'll certainly be -- as that progresses forward, we'll continue to give you line of sight as to how that goes. In terms of other areas, so existing coverage in areas around prior authorizations or otherwise, we haven't seen a lot of that. Now there are occasionally plans that have a prior authorization pop up or pull out, our goal is through all of the renegotiations that take place to limit those prior authorizations. And as we continue to show how CGM can improve patient outcomes, it's becoming very clear that prior authorizations -- we see payers starting to pull those down over time, a better way to put it. And so we continue to expect to see and keep pushing that. We have not seen a material change in any form or factor. In fact, for the most part, we see them coming down, and we'll expect to see that over time in the intensive space. Operator And our next question comes from Matthew O'Brien. Go ahead, Matt. Matthew O'Brien -- Piper Sandler -- Analyst Great. Thanks for taking the question. Can we just -- as I look at the stock, down 18% in the aftermarket, that's $6 billion-ish in lost market cap, even a little bit more than that. So I think it'd be helpful -- I don't know if the reduction of the top line guidance from 20% down to 19% or maybe it's a little bit more is largely because of G7. But I'm thinking it's like a $60 million headwind, maybe something like that this year versus not getting the approval. So is it about $100 million of incremental pressure you're going to see next year and not having the approval earlier this year that you can't get all the marketing activities up and going next year? Just how do we frame up some of this modest delay? It seems like on the payer side, things are better. But just frame up what this modest delay may do to the top line as we look forward. Jereme Sylvain -- Chief Financial Officer Sure. I can talk about at least for 2022 and how it operates, and we can maybe not get too, too much into 2023, but it can help that conversation. So a lot of the guidance and the pull down of guidance is related to currency. So it's not necessarily related to the G7 and the timing associated with that. So as you look at where we're going and where we pulled that down, currency has, especially outside the U.S., has played a large impact on reported growth rates. And that's one of the reasons why we've shifted in how we talk about organic growth. As you zoom back into the U.S., the G7 delay does have a little bit of an impact on guidance. And so certainly, we would recognize that we had some impact in there and assumed it would launch. The longer-term impact is really determined on how fast we get commercial coverage and how fast we can roll it out. And so what we believe is by working alongside our coverage teams and trying to get access as fast as possible and while we're working through getting formal approvals, partnering with folks to get quicker access and quicker coverage, we believe we can work on getting those patients back in quicker and faster to where we don't believe it's going to be a material impact on 2023 and beyond. And so a little bit in 2022. Certainly, it could have a little bit of tick in 2023. But for the most part, we're doing all the work now to make sure that we have a major launch where it doesn't impact longer-term growth rates. Operator And our next question comes from Jayson Bedford from Raymond James. Go ahead, Jayson. Jayson Bedford -- Raymond James -- Analyst Good afternoon. Just two questions that require quick answers. Just a clarification. I get the sense that it was a record for new patient starts in both the U.S. and worldwide, if you could just confirm that? And then the second question is, you mentioned expanding the G7 launch in Europe over the coming weeks. And I wasn't clear whether you're going into new countries? Or is this just more expansive in the U.K.? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah, this is Kevin, I'll start. Yes, it was record new patients OUS and in our U.S. markets as well. Both teams had new patient add records during this quarter. With respect to the rollout of G7 in Europe, what we had indicated was our first rollout will be in the U.K., and we expect we will add other geographies before the end of the year. Operator And our next question comes from Travis Steed from Bank of America. Go ahead, Travis. Travis Steed -- Bank of America Merrill Lynch -- Analyst Hey, thanks for taking the question. One quick clarification. The pricing mix versus volume growth this quarter. And then as you look ahead to next year, will we start to see volume and revenue growth to start to match up a bit more? And I'm thinking about the basal opportunity, is that an opportunity where you're going to have to lower price to get the volume? Or is the basal pricing probably pretty similar to the intensive market? Thank you. Jereme Sylvain -- Chief Financial Officer Sure. So I can take those questions. In terms of pricing and what I'd say is more channel mix, but the delta between the two, it was about the same this quarter as it was in prior quarter, which is what we had signaled at the start of the year. We still expect to migrate in the U.S. channel as we move more DME to pharmacy. That continues as expected. And then we had the OUS pricing where we took down pricing in exchange for access. We expected that to run through the end of Q2 before we lapped our strategy. So it's all gone and aligned with expectations. It was right around $70 million on the quarter. In terms of basal and beyond, look, basal coverage, we believe, is out there. In terms of what the pricing is, at this point, a lot of the conversations are about category coverage. And currently, category coverage is already relatively defined, defined in pricing today. And so what that means is it could be the same, but would we be willing to talk to folks about increasing access in exchange for price? We'd absolutely entertain the conversation. It'd have to make sense for us for both the returns that we would expect on our performance, as well as for our shareholders, but nothing to this point has indicated it would be lower. However, we understand that as more and more folks get access, we will be having those conversations. Operator And our next question comes from Marie Thibault from BTIG. Go ahead, Marie. Marie Thibault -- BTIG -- Analyst Hi. Good evening. Thanks for taking the questions. I wanted to go back to something Kevin said earlier about the new software and app experience for the patient with G7 in the U.S. Can you give us a hint of how meaningful that new app experience might be for patient willingness to try the G7, to switch to the G7, and what it might do for patient demand? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer One of the best features of the limited launch in the U.K. has been getting feedback on the software and people absolutely love the app. From the very beginning, when you start, it is much easier to fire it up and get on the system and understand what CGM is going to do for you and how it's going to work. So for a new user, this is a much, much easier experience and much, much easier start. The other thing that's very obvious in the software is another feature that our patients love. It's a 30-minute warmup that actually ends up being about 25 minutes once you put the sensor on. I was speaking with a patient just last week, and I asked her what is your favorite and what is your worst thing about G6? And the two-hour warmup, this very frequently comes up -- was what came up. And so this half hour warmup is going to be a feature. But the software itself, in addition to the typical graph and the sensor reading and the arrows, we also have CLARITY data built into the app that gives you feedback about how you're doing over one day, three days, seven days or even a month. So someone can go down and look and see exactly how they're doing and what their trends are, how much time they are spending in range. So it's much more of a full experience for somebody under diabetes care, and our patients all like it tremendously. We'll be ready to go on Android and iOS in launch. We're not going to hold either of them back. The other thing with the app, and it's not really on the app, but it's a feature of this product that's been very well accepted as well, I didn't talk much about. We have a new receiver coming. The patients absolutely have loved and are using it very well. And while -- I figured when we went to the phone in the beginning, everybody would immediately migrate to the phone. There's a very large percentage of our customers who use that receiver. They will be greatly enhanced in their experience by going to the next receiver with us. And on the good news front as well, that new receiver, while a better experience, is a much lower cost offering. So I'll get stuff there on the app. Operator And our next question comes from Mathew Blackman. Go ahead, Mathew. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thanks for taking my question. International growth did step up even though you had a tougher comp. Is that the broader G7 rollout? Dexcom ONE? Some combination of those two? And I'm also really curious about Germany, in particular, where I think you are going head-to-head versus the newest sensor from your competitor. Just any commentary about sort of geographic performance within that international number. Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yeah, we can absolutely answer that. And it's interesting, Dexcom ONE and G7 really haven't contributed all that much to this point. So certainly, it's an exciting future contributor, and we're very, very bullish on both G7 and the opportunity in Dexcom ONE. Dexcom ONE really is in the BELL countries and hasn't contributed all that much and G7 was limited launch. And so what you're seeing is G7 with a more meaningful launch and Dexcom ONE with a more meaningful launch in bigger countries in Q3 and beyond. So what you saw in Q2 was really a continuation of our access and going deeper into countries where we had our G Series. And really, it was broad-based. And it's a continuation of broad-based performance outside the U.S., really across all of our countries, including Germany, where we do go head-to-head with Libre 3. And so I think what you can say is that business is doing incredibly well, and there's new catalysts to ultimately support it for upcoming periods. So we are very excited about that international business. And like I said, in countries where we're going up head-to-head with our competitors' most recent product, we continue to do very well and take share. So very, very bullish on our opportunity going forward. Operator And our next question comes from Josh Jennings from Cowen. Go ahead, Josh. Unknown speaker Hi. This is Brian here for Josh. Are you currently seeking or planning to seek CE Mark approval for the software changes you're making in the U.S.? And if so, could you share the projected time line there? Thanks for taking the question. Kevin Sayer -- Chairman, President, and Chief Executive Officer We already have the software approved for CE Mark in Europe, and we do not plan immediately on implementing the changes that we're putting into the U.S. app. We'll consider that over time. We'll -- we have the app and the software configured to whereby we can launch the product with what we're doing in Europe to sell it and support it there. And if we feel the need to in some period of time, we can implement those changes into the other software and upgrade patient's apps on the phone, but not immediately, no. Operator Our next question comes from Steven Lichtman from Oppenheimer. Go ahead, Steven. Steve Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. As you're moving G7 to full launch in the U.K., where you now also have Dexcom ONE, just wondering how will those two offerings be marketed relative to each other. Should we assume that over time, they sort of merge? And with G7 becoming the primary hardware there, obviously, that's going to happen in more and more countries over time. So wondering if you could talk to your thoughts on that. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer No, I appreciate that question. We launched Dexcom ONE in Europe, and we're launching in the U.K. because there are many reimbursement opportunities we've not been able to participate in. Our G Series, our G6 and G7 products, are regarded as very high-end sensors for intensive insulin management, integration with insulin pumps. A lot of pediatrics, they share, they follow the other features that have made our products so endeared to our users. The Dexcom ONE app has -- doesn't have many of those features. It's much more simple, and it falls into a different reimbursement category in many of these geographies. In the U.K., for example, our Dexcom ONE system will literally be -- will go through the pharmacy channel for broad-based distribution and broad-based accessibility for everybody. Whereas our G Series, it requires more documentation, more approval and very specific conditions. As we look at these geographies, we think we have an opportunity with Dexcom ONE to sell a different product and a different system with different features that really won't step over onto our G Series that is fully integrated with other systems and offers all these other features. Ultimately, as I said on the call, we want our Dexcom ONE product to be on the G7 platform, as well as we simplify our operating structure over time, but that will take a little while. And so G6 for Dexcom ONE platform, we think, will do very well. And our initial user feedback has been very good. The software for Dexcom ONE, I would also add, has been designed on the same platform as the G7 software. So it looks and feels a little more -- much more like G7 than it does G6. So our users will have a great experience there. As long as there are two reimbursement categories, we do not see these two products coming together from a reimbursement perspective. They might look more alike physically and be on the same platform once we get G7 enough capacity to transfer to the other Dexcom ONE platform. But they won't be the same experience. It won't be reimbursed at the same rates. Operator And our next question comes from Larry Biegelsen from Wells Fargo. Go ahead, Larry. Nathan Treybeck -- Wells Fargo Securities -- Analyst Hi. This is Nathan on for Larry. Can you comment on what drives the margin improvement in the second half, given the launch of G7? And how should we think about margins into 2023? Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Let me talk about the second half, and we won't get too, too much into 2023 specifically other than we all have -- our long-range plan is 65%. And so that's the way we generally think about things. In terms of the back half of the year, typically, what happens is as we go typical seasonality, as we go through the course of the year, and part of this has to do with who's ultimately purchasing the product, margins typically get better. Now that was thrown on its head a little bit as we were launching G7. I mean we had some timing things about when that would launch and what countries that would go into. So what you're finding is, is for the first half of the year, we obviously had a few different unique items that impacted margins. What you're really finding is the run rate for our margin for the first half of the year, absent these, was just below 65%. Back half of the year, we expect it to be just the opposite, just north of 65% as we hit that typical seasonality. We will have a little bit of pressure from the launch of G7 outside the U.S. However, that will clearly be offset through the G6 throughput that you ultimately see. And the reason to tick up in the back half of the year in some ways is due to -- with the G7 launch in a meaningful way outside -- inside the U.S. sliding into Q1 of next year, you do see that performance on that G6 platform, which continues to have nice margins play through over the course of the rest of the year. So we have a lot of confidence, 65% for the year, even despite all of the macroeconomic conditions. Operator We have no more questions at this time. I'll turn it back to the speakers for closing comments. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, again, thanks, everybody, for participating on the call. One of the great things that's happened in the second quarter has been my own ability to get out and talk and meet with people going to ADA and also some other conferences where I've spoken. And I've never seen Dexcom more respected and more visible than we are now. Our customer satisfaction scores, as I talked earlier, have never been higher, and that's what you hear in real life. People are absolutely thrilled with the performance of our product and the problem that we solve for them. It's never been a better time here. We have a number of Dexcom ONE launches coming out over the next few quarters on top of that with G7 as well, both presenting great revenue and growth opportunities for us. And our operations are running very efficiently and smoothly. Everybody, have a great day, and thanks for participating on the call. Operator [Operator signoff] Duration: 0 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Jeff Johnson -- Robert W. Baird -- Analyst Margaret Kaczor -- William Blair & Company -- Analyst Joanne Wuensch -- Citi -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Jayson Bedford -- Raymond James -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Marie Thibault -- BTIG -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Unknown speaker Steve Lichtman -- Oppenheimer and Company -- Analyst Nathan Treybeck -- Wells Fargo Securities -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Matches Q2 Earnings Estimates DexCom (DXCM) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical device company would post earnings of $0.13 per share when it actually produced earnings of $0.08, delivering a surprise of -38.46%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $696.2 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.12%. This compares to year-ago revenues of $595.1 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have lost about 36.1% since the beginning of the year versus the S&P 500's decline of -15.6%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $761.56 million in revenues for the coming quarter and $0.82 on $2.92 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022. This company is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of +8.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Delcath Systems, Inc.'s revenues are expected to be $1.26 million, up 132.4% from the year-ago quarter. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Delcath Systems, Inc. (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for July 28, 2022 : AAPL, AMZN, INTC, EW, KLAC, LHX, DLR, AJG, DXCM, SGEN, CLR, EIX The following companies are expected to report earnings after hours on 07/28/2022. Visit our Earnings Calendar for a full list of expected earnings releases. Apple Inc. (AAPL)is reporting for the quarter ending June 30, 2022. The computer company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.14. This value represents a 12.31% decrease compared to the same quarter last year. In the past year AAPL has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AAPL is 25.75 vs. an industry ratio of 3.10, implying that they will have a higher earnings growth than their competitors in the same industry. Amazon.com, Inc. (AMZN)is reporting for the quarter ending June 30, 2022. The internet company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.15. This value represents a 80.26% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AMZN is 108.01 vs. an industry ratio of 14.30, implying that they will have a higher earnings growth than their competitors in the same industry. Intel Corporation (INTC)is reporting for the quarter ending June 30, 2022. The semiconductor company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.69. This value represents a 46.09% decrease compared to the same quarter last year. In the past year INTC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 8.75%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for INTC is 11.61 vs. an industry ratio of 8.40, implying that they will have a higher earnings growth than their competitors in the same industry. Edwards Lifesciences Corporation (EW)is reporting for the quarter ending June 30, 2022. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.63. This value represents a 1.56% decrease compared to the same quarter last year. EW missed the consensus earnings per share in the 4th calendar quarter of 2021 by -7.27%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for EW is 41.25 vs. an industry ratio of 21.20, implying that they will have a higher earnings growth than their competitors in the same industry. KLA Corporation (KLAC)is reporting for the quarter ending June 30, 2022. The electrical instrument company's consensus earnings per share forecast from the 10 analysts that follow the stock is $5.46. This value represents a 23.25% increase compared to the same quarter last year. In the past year KLAC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.87%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for KLAC is 17.29 vs. an industry ratio of -1.00, implying that they will have a higher earnings growth than their competitors in the same industry. L3Harris Technologies, Inc. (LHX)is reporting for the quarter ending June 30, 2022. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.16. This value represents a 3.07% decrease compared to the same quarter last year. In the past year LHX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.31%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for LHX is 16.52 vs. an industry ratio of -12.50, implying that they will have a higher earnings growth than their competitors in the same industry. Digital Realty Trust, Inc. (DLR)is reporting for the quarter ending June 30, 2022. The reit company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.64. This value represents a 6.49% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DLR is 18.89 vs. an industry ratio of 21.70. Arthur J. Gallagher & Co. (AJG)is reporting for the quarter ending June 30, 2022. The insurance brokers company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.68. This value represents a 43.59% increase compared to the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.44%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AJG is 22.36 vs. an industry ratio of 20.70, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending June 30, 2022. The medical instruments company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.17. This value represents a 10.53% decrease compared to the same quarter last year. The last two quarters DXCM had negative earnings surprises; the latest report they missed by -38.46%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DXCM is 104.63 vs. an industry ratio of 21.20, implying that they will have a higher earnings growth than their competitors in the same industry. Seagen Inc. (SGEN)is reporting for the quarter ending June 30, 2022. The biomedical (gene) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $-0.82. This value represents a 74.47% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for SGEN is -50.66 vs. an industry ratio of -0.50. Continental Resources, Inc. (CLR)is reporting for the quarter ending June 30, 2022. The oil (us exp & production) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.17. This value represents a 248.35% increase compared to the same quarter last year. CLR missed the consensus earnings per share in the 3rd calendar quarter of 2021 by -3.23%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for CLR is 5.66 vs. an industry ratio of 5.70. Edison International (EIX)is reporting for the quarter ending June 30, 2022. The electric power utilities company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.90. This value represents a 4.26% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for EIX is 14.41 vs. an industry ratio of 11.50, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is Abbott Laboratories a Buy? If you're interested in buying a stock that's safe enough to recommend for your grandma or your grandchildren alike, Abbott Laboratories (NYSE: ABT) has a lot to offer. The healthcare juggernaut is capably led, fully diversified, and constantly expanding -- and it has proven quite profitable to hold over long periods. Nonetheless, one person's favorite stable stock is another person's market-underperforming clunker. Let's take a look at the company's benefits and drawbacks as an investment so that you can judge whether or not it's a good buy for you. Steady, long-term growth for patient investors Abbott Labs has a handful of factors that make it a strong anchor for retirement savings and other long-term investing purposes. The single most critical factor is that the business has a very long history of successfully developing new products to chase new growth opportunities like coronavirus diagnostic testing, while also retaining its substantial base of revenue derived from sales of relatively evergreen products like baby formula and disposable surgical tools. In 2021, these products provided more than $43 billion in revenue. For those wondering, the company has been operating in some form or another for more than 130 years, which attests to its enduring ability to compete. Most recently, its medical device division has been pioneering in-demand products like continuous glucose monitors for diabetes management. It's also developing even more sophisticated things like deep brain stimulation hardware for severe depression. Consistent innovation like that has a cost, though. Its trailing 12-month research and development (R&D) expenses topped $2.8 billion, which works out to around 6.2% of its revenue. But over the past five years, its proportion of R&D expenses to revenue has fallen, and net income has risen by 307% to reach more than $8.5 billion. So it's clear that R&D expenses are quite sustainable. That's another point in its favor for long-term investors, as it demonstrates that Abbott can secure tons of earnings growth even if it doesn't divert any additional slices of its revenue pie to developing new products. And that's also part of the reason why it can afford to treat its shareholders with a metronome-like beat of stock buybacks and dividend payments for years on end. In fact, it's a Dividend King, which is a distinction it earned by increasing its dividend payout every year for the last half century. Investors can probably count on the company to keep raising its dividend and maintain that record. So if you're willing to hold its shares for the next 50 years, you'll likely see your dividend income grow by many times over. Such growth is unlikely to make your total return from Abbott Labs approach that of a bona fide growth stock, but the point is that it won't require you to take on growth stock levels of risk to get a solid gain. Don't expect riches to come quickly As great as Abbott's product mix and dividend policies are, it isn't about to consistently outperform the market. With a market cap in excess of $191 billion, it's one of the world's largest businesses. It's incredibly hard to post rapid revenue growth at that size even with a constant supply of new products, at least for companies outside the software industry. Furthermore, it has plenty of competition in most of its segments, so there isn't much hope for any instances of trouble-free market penetration. Medical device manufacturers like DexCom are staunch competition for Abbott's glucose monitors, and they're also likely to expand more rapidly in that market thanks to their smaller size and tighter focus. So if you're looking for a conservative stock that'll appreciate in value steadily over time without too many bumps in the road, Abbott Labs could be a profitable addition to your portfolio. On the other hand, it it may not be the right pick for people wishing to take on higher levels of risk for larger returns, and it also may not be a good option for those who dislike paying taxes on their dividend income. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Alex Carchidi has positions in Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-07-29,78.25,85.86,77.51,82.08,"[""Why DexCom Stock Is Falling Today What happened Shares of DexCom (NASDAQ: DXCM) were falling 5.2% lower as of 11:15 a.m. ET on Friday after sinking as much as 10.9% earlier in the day. The decline came after the diabetes-care technology company announced its second-quarter financial results after the market close on Thursday. DexCom reported Q2 revenue of $696.2 million, up 17% year over year. However, the total was a little below the consensus Wall Street revenue estimate of $698.6 million. The company announced Q2 net income of $50.9 million, or $0.12 per diluted share, based on generally accepted accounting principles (GAAP). This result was lower than the GAAP earnings of $78.4 million, or $0.19 per diluted share, in the prior-year period. DexCom posted non-GAAP (adjusted) earnings of $69.5 million, or $0.17 per diluted share. The average analysts' estimate was for non-GAAP earnings of $0.19 per share. Also, DexCom narrowed its full-year revenue guidance from between $2.82 billion and $2.94 billion to between $2.86 billion and $2.91 billion. The upper end of this revised range is slightly below the consensus full-year revenue estimate of $2.92 billion. So what Overall, DexCom delivered solid results in Q2. Those results just weren't quite up to what Wall Street expected. This shouldn't concern long-term investors. The company also had a good reason for revising its revenue guidance. DexCom now expects roughly $40 million in foreign currency headwinds in 2022 compared with its previous estimate of between $15 million and $20 million. Now what The most important thing for investors to focus on is DexCom's future prospects, especially with its new G7 continuous glucose monitor (CGM). There's good news and bad news on that front. The bad news is that the company said that it's \""making a subtle change to the G7 software based on feedback from the FDA.\"" This will delay the company's U.S. launch of the product. The good news is that DexCom still expects to conduct a limited launch of the G7 CGM later in 2022 with a larger launch in early 2023. In addition, the company said that its preliminary talks with payers are going well. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2022 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Friday Sector Laggards: Healthcare, Services The worst performing sector as of midday Friday is the Healthcare sector, showing a 0.4% loss. Within the sector, DexCom Inc (Symbol: DXCM) and Edwards Lifesciences Corp (Symbol: EW) are two of the day's laggards, showing a loss of 6.4% and 6.1%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.7% on the day, and down 5.66% year-to-date. DexCom Inc, meanwhile, is down 39.35% year-to-date, and Edwards Lifesciences Corp, is down 22.25% year-to-date. Combined, DXCM and EW make up approximately 1.9% of the underlying holdings of XLV. The next worst performing sector is the Services sector, showing a 0.2% loss. Among large Services stocks, Comcast Corp (Symbol: CMCSA) and Warner Bros Discovery Inc (Symbol: WBD) are the most notable, showing a loss of 5.8% and 5.1%, respectively. One ETF closely tracking Services stocks is the iShares U.S. Consumer Services ETF (IYC), which is up 2.0% in midday trading, and down 22.19% on a year-to-date basis. Comcast Corp, meanwhile, is down 24.69% year-to-date, and Warner Bros Discovery Inc, is down 37.17% year-to-date. WBD makes up approximately 0.8% of the underlying holdings of IYC. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, six sectors are up on the day, while two sectors are down. SECTOR % CHANGE Energy +2.7% Industrial +1.4% Financial +1.1% Utilities +1.0% Materials +0.9% Technology & Communications +0.8% Consumer Products -0.0% Services -0.2% Healthcare -0.4% 10 ETFs With Stocks That Insiders Are Buying \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: INTC, AMZN In early trading on Friday, shares of Amazon.com topped the list of the day's best performing components of the Nasdaq 100 index, trading up 11.9%. Year to date, Amazon.com has lost about 18.0% of its value. And the worst performing Nasdaq 100 component thus far on the day is Intel, trading down 9.4%. Intel is lower by about 30.1% looking at the year to date performance. Two other components making moves today are DexCom, trading down 8.2%, and Datadog, trading up 3.2% on the day. VIDEO: Nasdaq 100 Movers: INTC, AMZN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss DexCom, Inc. DXCM reported second-quarter 2022 adjusted earnings per share (EPS) of 17 cents, in line with the Zacks Consensus Estimate. The bottom line declined 10.5% on a year-over-year basis. GAAP net income per share in the quarter was 12 cents, compared with the year-ago quarter\u2019s figure of 19 cents per share. Revenue Details Total revenues grew 17% (16% on an organic basis) to $696.2 million on a year-over-year basis but missed the Zacks Consensus Estimate by 0.1%. Rising volumes across all channels, along with strong new customer additions owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring (CGM), contributed to the upside. Segmental Details Revenues at the Sensor and other revenues segment (86% of total revenues) climbed 21% on a year-over-year basis to $597.7 million. Hardware revenues (14%) declined 2% year over year to $98.5 million. Geographical Details U.S. revenues (73% of total revenues) increased 11% on a year-over-year basis to $511 million. International revenues (27%) surged 39% year over year to $185.2 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Margin Analysis Gross profit in the quarter under review totaled $449.5 million, up 7.8% year over year. DexCom generated a gross margin (as a percentage of revenues) of 64.6%, which contracted 550 basis points (bps) year over year. Research and development expenses amounted to $121.7 million in the quarter, down 5.7% year over year. Selling, general and administrative expenses totaled $248.9 million in the reported quarter, up 33.5% year over year. The company reported total operating expenses of $372.5 million, up 17.8% from the prior-year figure. Operating margin (as a percentage of revenues) of 11.1% contracted 590 bps year over year. Financial Position The company exited the second quarter with $2.75 billion in cash, cash equivalents and marketable securities, compared with $2.69 billion in the preceding quarter. Total assets in the second quarter amounted to $5.2 billion, compared with $5.06 billion on a sequential basis. 2022 Guidance Reaffirmed DexCom tightened its revenue guidance for 2022 from $2.82-$2.94 billion to $2.86-$2.91 billion. The Zacks Consensus Estimate for the same stands at $2.92 billion. The company reiterated the 2022 guidance for adjusted gross margin and adjusted operating margin. While adjusted gross margin is anticipated to be about 65%, adjusted operating margin is estimated to be around 16%. Wrapping Up DexCom exited second-quarter 2022 on a decent note, wherein earnings met the Zacks Consensus Estimate and revenues missed the same slightly. Impressive contributions from the Sensor segment and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as the non-intensive diabetes management space, the hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, DexCom ended the quarter with new patient additions as well. The company launched its latest CGM, DexCom ONE, in the United Kingdom and Spain during the second quarter. It also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available to international markets. These developments are likely to support the future growth of the company. Nevertheless, contraction in both gross and operating margins is a woe. Apart from this, cut-throat competition in the market for blood & glucose monitoring devices remains a concern. Zacks Rank and Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the pharma/biotech sector include Lantheus LNTH, ShockWave Medical SWAV and Alkermes ALKS. While Lantheus and ShockWave Medical sport a Zacks Rank #1 (Strong Buy), Alkermes carries a Zacks Rank of 2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Lantheus have improved from earnings of $3.04 to $3.08 for 2022 and $3.33 to $3.62 for 2023 in the past 30 days. LNTH has surged 156.6% so far this year. Lantheus delivered an earnings surprise of 77.82%, on average, in the last four quarters. ShockWave Medical\u2019s earnings per share estimates have improved from $1.84 to $2.02 for 2022 and from $2.82 to $2.95 for 2023 in the past 30 days. SWAV has declined 19.1% so far this year. ShockWave Medical delivered an earnings surprise of 189.99%, on average, in the last four quarters. Alkermes\u2019 earnings per share estimates have improved from breakeven to 4 cents for 2022 and from 56 cents to 59 cents for 2023 in the past 30 days. ALKS has gained 19.6% so far this year. Alkermes delivered an earnings surprise of 350.48%, on average, in the last four quarters. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report ShockWave Medical, Inc. (SWAV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-08-01,82.61,86.21,82.45,83.83,
DXCM,2022-08-02,84.03,90.23,83.73,88.3,"[""Tuesday Sector Leaders: Utilities, Healthcare In afternoon trading on Tuesday, Utilities stocks are the best performing sector, up 0.4%. Within that group, Edison International (Symbol: EIX) and Eversource Energy (Symbol: ES) are two large stocks leading the way, showing a gain of 2.9% and 1.6%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 0.5% on the day, and up 5.34% year-to-date. Edison International, meanwhile, is up 3.02% year-to-date, and Eversource Energy is up 1.06% year-to-date. Combined, EIX and ES make up approximately 5.4% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, up 0.2%. Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and DexCom Inc (Symbol: DXCM) are the most notable, showing a gain of 5.6% and 5.2%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.2% in midday trading, and down 5.91% on a year-to-date basis. Intuitive Surgical Inc, meanwhile, is down 32.81% year-to-date, and DexCom Inc, is down 34.30% year-to-date. Combined, ISRG and DXCM make up approximately 2.4% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, four sectors are up on the day, while four sectors are down. SECTOR % CHANGE Utilities +0.4% Healthcare +0.2% Energy +0.2% Services +0.1% Technology & Communications -0.0% Industrial -0.1% Financial -0.3% Materials -0.5% Consumer Products -0.8% 25 Dividend Giants Widely Held By ETFs \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: NTES, DXCM In early trading on Tuesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.4%. Year to date, DexCom Inc has lost about 34.8% of its value. And the worst performing Nasdaq 100 component thus far on the day is NetEase, trading down 4.3%. NetEase is lower by about 14.0% looking at the year to date performance. Two other components making moves today are Idexx Laboratories, trading down 3.7%, and Intuitive Surgical, trading up 4.4% on the day. VIDEO: Nasdaq 100 Movers: NTES, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-08-03,88.29,91.23,86.84,90.39,
DXCM,2022-08-04,90.24,90.78,87.875,89.54,"2 Growth Stocks That Just Hit Setbacks: Are They Buys? Earnings season always brings good news to some corporations and bad news to others. And the stakes are that much higher when equity indexes are down, and the world faces significant macroeconomic headwinds, including inflation. With that said, it's important to remember that quarterly earnings reports -- even disappointing ones -- only cover a relatively short period of a company's history. As a rule, long-term investors should avoid decisions based on just one bad quarterly update. Let's look at two companies that failed to impress Wall Street with their most recent financial results: DexCom (NASDAQ: DXCM) and Meta Platforms (NASDAQ: META). Should investors take the opportunity to buy shares of these companies on the dip? DXCM data by YCharts. 1. DexCom Revenue growth has been dropping for this diabetes-focused medical devices specialist, although it continues to progress thanks to the increased adoption of continuous glucose monitoring (CGM). CGM devices allow diabetes patients to continuously track their blood glucose levels, an essential task for those with this chronic health condition. DexCom's revenue in the second quarter came in at $696.2 million, 17% higher than a year ago. DXCM revenue (quarterly growth). Data by YCharts. YOY = year over year. That's not awful growth, but it is below DexCom's standards, and the market tends to be less forgiving with stocks that carry a forward price-to-earnings (P/E) ratio of about 114, like DexCom, compared to the healthcare industry's 16.2. On the bottom line, adjusted net earnings per share (EPS) dropped to $0.17, down from the $0.19 during the year-ago period. However, there were encouraging signs in the earnings release, too. Most notably, DexCom is rolling out new products. While its G6 CGM system (and accessories) continue to be its main moneymaker, it launched the DexCom One and the G7 system in various international markets, including some parts of Europe, in the first half of the year. The DexCom One and the G7 have many of the same CGM features as the G6, but the former is more user-friendly, more affordable, and comes with software that (unlike the G6) does not allow users to share their data with healthcare providers automatically through the associated app. The G7 is 60% smaller and has proved in clinical trials to help achieve even better health outcomes than its predecessor within DexCom's G series, the G6. DexCom's newer devices will allow it to make even more headway with the diabetic population worldwide -- including entering new territories and securing reimbursement from more third-party payers. The company is still awaiting clearance for its G7 in the U.S. Although CGM devices have gained traction, there is still plenty of room to grow with the worldwide population of diabetes patients. DexCom's revenue growth is slowing, but the long-term prospects are still bright. Patience will be required, but those willing to hold shares for five or more years should still strongly consider this healthcare stock. 2. Meta Platforms During the second quarter, Facebook parent Meta Platforms did something it had never done as a publicly traded company: It recorded a year-over-year revenue decline. Revenue for the period came in at $28.8 billion, 1% lower than a year ago. Meta is dealing with a range of issues. Macroeconomic headwinds such as inflation have impacted ad spending, and competition from other platforms is likely stealing a lot of its thunder. Quarterly EPS declined 32% year over year to $2.46. But there is good news: The company grew its family daily active users (i.e., users of Facebook, Instagram, Messenger, and/or WhatsApp) by 4% year over year to 2.88 billion. That's impressive considering Meta Platforms' network is already second to none in the social media space. And that's one of the main reasons to remain bullish on this company. Most of Meta's users are unlikely to go anywhere because it benefits from the network effect. Those looking to connect with family and friends will gravitate toward social media websites with the most users. The more people join, the more likely that it will attract future would-be social media users. Meta Platforms' ecosystem is too attractive for businesses to ignore. Even though macroeconomic headwinds are harming the advertising business, they won't last forever. Online advertising provides benefits such as cost-efficiency and the ability to analyze the impact of ad campaigns more easily. According to some estimates, the industry will be worth $786.2 billion by 2026, up from $350 billion in 2020. It's always wise to take such estimates with a grain of salt, but there is a general upward trend here. Meta Platforms can find other ways to monetize its massive ecosystem, including the company's e-commerce efforts and the metaverse, which could be an enormous opportunity. With a forward P/E of about 17, it seems relatively cheap when looking at its three-year average. I'd say now is an excellent time to purchase its shares. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2022 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Meta Platforms, Inc. The Motley Fool has positions in and recommends Meta Platforms, Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-08-05,87.4,90.42,87.25,89.09,
DXCM,2022-08-08,89.56,94.6,89.5,91.4,
DXCM,2022-08-09,90.67,91.237,85.02,85.12,
DXCM,2022-08-10,88.0,90.1,87.58,89.73,
DXCM,2022-08-11,89.84,91.95,87.84,88.24,"This Stock-Split Stock Is Up 30% Since Splitting Its Shares Big tech companies haven't benefited much from their stock splits this year. And understandably so since stock splits themselves don't add value for investors, nor do they make a stock a better buy. It's purely an aesthetic move in an effort to potentially reach investors who can't buy fractional shares. But by and large, it shouldn't change your outlook for a company. Stock splits may have been a good way to build up hype while investors were buying up meme stocks last year. But now, as there's been a shift more toward value, this type of move hasn't been paying off for companies in the ways they may have hoped it would. Of course, there are always exceptions. Let's look at one. A split that exceeds expectations There wasn't much excitement around medical device maker DexCom (NASDAQ: DXCM) splitting its shares in June. It certainly wasn't on the same level as either Amazon and Shopify deploying stock splits. But following its 4-for-1 stock split, DexCom's stock closed at $68. Today it's around $91, an increase of 34%. The healthcare stock's rally over the past few months has been gradual and the gains aren't likely due to the stock split. Investors have likely been gravitating toward safe growth stocks (e.g. other than big tech) with more definitive long-term potential, and the need to manage diabetes is only going to increase as more people live with the disease. DexCom's continuous glucose monitoring devices are popular among people with diabetes, as they make it easy to stay on top of glucose levels. The growth was evident in the company's second quarter, ended June 30, when sales rose 17% year-over-year to $696.2 million. The company has been expanding its business globally, with product launches in the U.K. and Spain recently unlocking new opportunities for the business. Overall, the company's business looks promising, and although DexCom trades at a forward price-to-earnings multiple of more than 100, it's still a profit-generating business with loads of long-term potential; that multiple could come down over the years as DexCom continues to grow. For long-term investors, this remains a promising stock to buy and hold. Big tech hasn't been doing nearly as well Amazon deployed a massive 20-for-1 stock split in early June. The day of the split, it closed at a price of $124.79. Now at $144, its shares are up 15%, but that was due to the company's recent earnings report, which got investors excited. Prior to that, the stock was trading at around $120, and was down since its stock split. Another big stock split came from Shopify, which split its shares on a 10-for-1 basis in late June. At just over $33, it has climbed to a value of more than $42, for a gain of 27%. But here, too, the stock was trailing lower before the release of its latest earnings report, which may have not been as bad as what investors were expecting. Prior to that, the stock was trading at around $37, and even dipped to less than $32 on news that it was laying off 10% of its employees. Focus on fundamentals, not stock splits The performance of these stocks over the past few months suggests that investors are looking at deeper reasons to buy and sell shares of Amazon, Shopify, and DexCom. Earnings reports and news of layoffs have had much bigger impacts on Amazon and Shopify than their stock splits. DexCom's steady increase over the past few months also doesn't show that it benefited from a surge due to its stock split. Stock splits don't improve a company's prospects or make it look like a better deal. While the share price may be lower, that doesn't mean a stock offers better value than before the split. For investors, this serves as an important reminder not to get caught up in the hype surrounding stock splits, or anything else that has a negligible effect on a business. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Shopify. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-08-12,88.62,89.9,87.6,89.83,
DXCM,2022-08-15,89.91,92.74,89.71,92.295,
DXCM,2022-08-16,91.38,91.89,88.875,90.79,
DXCM,2022-08-17,89.4,89.88,87.65,88.14,
DXCM,2022-08-18,88.22,88.53,86.77,87.53,
DXCM,2022-08-19,86.67,87.72,84.12,85.11,
DXCM,2022-08-22,83.23,85.8,83.23,84.3,
DXCM,2022-08-23,84.21,84.6,82.2101,83.63,
DXCM,2022-08-24,84.11,87.23,84.07,85.92,
DXCM,2022-08-25,86.99,88.43,86.11,88.37,
DXCM,2022-08-26,87.73,88.88,84.23,84.49,
DXCM,2022-08-29,83.5,84.62,83.2,83.38,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 35.2% compared with 30.3% fall of the industry and 11.7% decline of the S&P 500. The renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $32.92 billion. The company projects 31.4% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimates in one of the trailing four quarters, missed the same in two and broke even in one, delivering an earnings surprise of -3.4%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM (rt-CGM) System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. In June, DexCom announced its plans to showcase its expanded global portfolio of rt-CGM systems at the Scientific Sessions of the American Diabetes Association conference. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. In March, DexCom announced that effective Mar 14, 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria. Strong Q2 Results: DexCom’s solid second-quarter 2022 revenues buoy optimism. Rising volumes across all channels and strong new customer additions contributed to the upside. Impressive contributions from the Sensor segment, and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available to international markets. Downsides Reimbursement Risk: Reimbursement risk is somewhat high due to the efforts to control healthcare expenses. The company has noted that most Type 1 patients (above 65) pay 100% of their CGM costs out of their own pockets. Unless payers (both government and private insurers) provide sufficient coverage and reimbursement, commercial success for DexCom will be limited, in our view. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market, and collectively account for substantially all of the worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.7% south to 79 cents. The Zacks Consensus Estimate for the company’s third-quarter 2022 revenues is pegged at $751.3 million, suggesting a 15.5% improvement from the year-ago quarter’s reported number. Key Picks Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Patterson Companies, Inc. PDCO and McKesson Corporation MCK. AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%. You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare has lost 5.9% compared with the industry’s 34.9% fall in the past year. Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 7.9%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%. Patterson Companies has lost 5.1% compared with the industry’s 12.4% fall over the past year. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%. McKesson has gained 77.4% against the industry’s 12.4% fall over the past year. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers ""Most Likely for Early Price Pops."" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-08-30,83.515,85.275,82.16,82.74,"Tesla Stock Split: 3 Stock-Split Stocks That Are Far Better Buys Than Tesla It's been quite the year for Wall Street and everyday investors. The S&P 500 and Nasdaq Composite have plunged into a bear market; the U.S. inflation rate hit its highest level in more than 40 years; and the U.S. appears to be near a recession following back-to-back quarters of gross domestic product (GDP) declines. Yet amid these challenges, investors have found a silver lining with stock-split stocks. A stock split is what allows a publicly traded company to alter its share price and outstanding share count without impacting its market cap or operations. A forward stock split makes shares more nominally affordable for everyday investors who might not have access to fractional-share purchases with their online broker. Image source: Getty Images. The reason investors seem to love stock splits so much is because a company's share price wouldn't be high enough to merit a split if it weren't doing something right. Companies that announce and enact stock splits are often profitable, highly innovative, and maintain some level of competitive edge over their competition. The Tesla stock split is now complete, and other stock-split stocks look more attractive One of this year's most-anticipated stock splits was enacted last week. Electric-vehicle (EV) manufacturer Tesla (NASDAQ: TSLA), which announced its intention to split in June, moved forward with a 3-for-1 forward split on Aug. 25. Retail investors who can't buy fractional shares now only have to save up a little less than $300 to purchase a single share, as opposed to about $900 prior to the split. Tesla has long been a popular stock because of its production ramp -- the company is on pace to top 1 million EVs produced and delivered in 2022 -- and its push to recurring profitability. Tesla shareholders have also embraced outspoken CEO Elon Musk. Under Musk's leadership, Tesla has expanded its revenue stream to include energy products and solar panel installation and introduced four EV models that are currently in production. But not even a stock split can hide Tesla's biggest liability, which happens to be Elon Musk. As I recently opined, Musk brings significant legal, financial, and operating risks to the table that make Tesla an extremely risky stock to own at a nosebleed forward-year valuation of 54 times Wall Street's forecast earnings per share. While Musk has led Tesla to mass production, few of the future-looking statements about new product or service unveils have come true. That's a serious problem, given that Tesla's premium valuation hinges on these innovations becoming reality in a timely manner. All this being said, here are three recent stock-split stocks that I believe are far better buys than Tesla right now. Alphabet An argument can easily be made that FAANG stock Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is the top stock-split stock to buy at the moment. Alphabet is the parent company of internet search engine Google, streaming platform YouTube, and autonomous car company Waymo, among other subsidiaries. It completed a 20-for-1 forward split on July 18. There's been a lot of recent concern about an advertising slowdown, which would certainly impact Alphabet's ad-driven business model. But these worries overlook the fact that economic contractions and/or recessions don't last very long. Alphabet's ad-focused model thrives because of its competitive advantages and the fact that the U.S. and global economy spend a disproportionate amount of time expanding. Alphabet's foundation continues to be Google, which has accounted for between 91% and 93% of worldwide internet search share over the past two years, according to GlobalStats. With a veritable monopoly in internet search, it's not hard for the company to command significant ad-pricing power with merchants. However, Alphabet's future growth prospects are brightest with its ancillary operating segments. While Google should remain a cash-flow kingpin for a long time to come, investors are really excited about YouTube growing into the second-most-visited social site in the world, and Google Cloud becoming the third-largest cloud infrastructure services provider globally. Though Google Cloud is currently a money-losing operating segment for Alphabet, cloud service margins are usually considerably higher than advertising margins. By mid-decade, Google Cloud should be playing a key role in lifting Alphabet's operating cash flow. The cherry on top is that Alphabet has never been cheaper on the basis of forward-year earnings and future cash flow than it is now. This makes it a screaming buy for patient, growth-seeking investors. Image source: Getty Images. DexCom A second stock-split stock that would be a much smarter buy than Tesla right now is medical device company DexCom (NASDAQ: DXCM). DexCom, which is known for its continuous glucose monitoring (CGM) systems, enacted a 4-for-1 forward stock split on June 13. The biggest knock against DexCom is its valuation. During bear markets, Wall Street and investors quickly lose interest in companies that are valued at nosebleed multiples to sales and/or profits. In DexCom's case, the company is trading at north of 100 times Wall Street's forecast earnings in 2022. So why should DexCom receive a pass for its premium valuation and not Tesla? There are a few good reasons. First, healthcare stocks are highly defensive, whereas EVs aren't. No matter how poorly the stock market or U.S. economy perform, or how high inflation flies, people are still going to need prescription drugs, medical devices, and healthcare services. Just because Wall Street had a bad couple of months doesn't mean diabetics stop requiring care. To build on this point, DexCom's potential pool of patients keeps growing. The most recent update from the Centers for Disease Control and Prevention (CDC) shows that 37.3 million Americans have diabetes. Further, an estimated 96 million people have prediabetes, which can lead to diabetes if left untreated. This means almost half the adult population in this country is a potential future client, based on these figures. DexCom has also maintained the No. 1 or No. 2 spot in global CGM share for many years. Between its innovation -- the company has introduced numerous generations of CGMs -- and the growing number of diabetes cases worldwide, DexCom has had no trouble sustaining a 20% growth rate. Although DexCom shares come with a premium, this premium is well deserved. Amazon The third stock-split stock that's a far better buy than Tesla is e-commerce giant (and FAANG stock) Amazon (NASDAQ: AMZN). Amazon completed a forward 20-for-1 stock split on June 6. Most people are familiar with Amazon because of its leading online marketplace. A March 2022 report from eMarketer estimates that Amazon will bring in almost 40% of all retail sales in the U.S. this year. That's more than five times higher than the share of its next-closest competitor and over eight percentage points more than its 14 closest competitors on a combined basis. While it's great news that the company's marketplace is having no trouble attracting shoppers, Amazon's future is all about its ancillary sales channels. That's because the operating margins associated with online retail tends to be razor thin. For example, the lure of Amazon's marketplace has helped the company sign up more than 200 million Prime members. These are folks paying $139 annually, or $14.99 monthly, for Prime. In return for shipping perks and access to proprietary content, Amazon is netting nearly $35 billion on an annual run-rate basis in high-margin subscription revenue. This cash flow allows the company to reinvest in its rapidly growing logistics network, as well as other high-margin initiatives. While Alphabet's Google Cloud holds an estimated 8% of global cloud-service market share, Amazon Web Services (AWS) is anchoring the industry with a whopping 31% share of worldwide cloud-service spending in the second quarter, based on a report from Canalys. Despite accounting for just a sixth of Amazon's net sales, AWS has consistently generated well over half of Amazon's operating income. AWS looks to be the company's ticket to tripling its cash flow over the next four years. And just like Alphabet, Amazon has never been cheaper as a publicly traded company on the basis of future cash flow projections. 10 stocks we like better than Tesla When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Tesla wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet (A shares) and Amazon. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), Amazon, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-08-31,83.5,84.19,81.7614,82.21,"Worried About a Volcker-Style Recession? Buy These 2 Safe Haven Stocks Federal Reserve Chairman Jerome Powell's decision to continue ramping up interest rates in order to curtail inflation is setting off alarm bells across Wall Street. Since Powell's commentary last Friday, the SPDR S&P Biotech ETF and the Technology Select Sector SPDR Fund have both lost over 2.2% of their value. What's important to understand is that these two innovation-oriented exchange-traded funds are key indicators of investors' appetite for risk. Prior to this sudden downturn, the SPDR S&P Biotech ETF and the Technology Select Sector SPDR Fund were both up by double-digits since the start of July, as bargain hunters scoured the market for deals on the belief that the worst of the 2022 bear market had passed. Image source: Getty Images. Powell's remarks, however, sent bottom fishers back into hiding over fears that a Volcker-style recession may be on the horizon. The Volcker recession refers to the period covering July 1981 to November 1982 when the U.S. economy dipped into a prolonged economic downturn as the result of Paul Volcker -- the Federal Reserve chairman at the time -- making a series of aggressive interest rate hikes in response to record-setting levels of inflation. While slowing economic growth and rising interest rates aren't the end of the world, investors are growing increasingly concerned about the possible ramifications from these dual headwinds. Volcker's strict monetary policies, after all, are widely considered to be the cause of 1982's nearly 11% unemployment level. The big deal is that unemployment, consumer spending, and corporate earnings are all linked via a positive feedback loop. In short, rising levels of unemployment lead to less consumer spending, which ultimately shrinks corporate profits. Now, the 2022 bear market has so far centered on global supply chain issues, overhangs from the COVID-19 pandemic, geopolitical turmoil, and skyrocketing levels of inflation. But Powell's insistence on tamping down inflation via interest rate hikes could cause history to repeat itself (i.e., higher levels of unemployment leading to slimmer corporate profits). Fortunately, there are a handful of safe haven stocks that investors can rely on to weather such an economic downturn. Amazon (NASDAQ: AMZN), DexCom (NASDAQ: DXCM), and Johnson & Johnson (NYSE: JNJ) are three must-own stocks in the event the Federal Reserve's tighter monetary policies push the U.S. economy into a Volcker-like recession. Here's why. Amazon: A pivot to price The e-commerce titan Amazon is one stock that ought to shine in a recession. As household budgets contract, consumers will undoubtedly become laser-focused on prices. Its no secret that Amazon, through its state-of-the-art supply chain and logistics platform, has been able to crush most of its competitors from a pricing standpoint for the better part of the last two decades. While Walmart has been able to close the gap to a degree by developing a virtual storefront of its own, and the online pet supply retailer Chewy is competitive with Amazon in terms of pricing within its particular field, Amazon's flagship Prime membership subscription service gives it a nearly insurmountable advantage over its peer group. Amazon Prime membership keeps consumers locked into its ecosystem by offering faster and cheaper shipping on a variety of items, access to a galaxy of streaming content, and marketing campaigns tailored to individual consumers. In sum, Amazon's first class e-commerce ecosystem should prove to be a big hit with consumers in a more cost-conscious world. DexCom: A fundamental diabetes platform Over 11% of the U.S. population currently has diabetes, according to a report by the Centers for Disease Control (CDC). What's more, the CDC estimates that a whopping 38% of U.S. adults presently have prediabetes. As a direct result of these staggering incident rates, the diabetes care market is one of the fasting-growing spaces within all of healthcare. Continuous glucose monitor (CGM) sales, for instance, are expected to rise at a compound annual growth rate of 27.3% over the period from 2019 to 2026, per a market analysis by Research and Markets. These favorable market dynamics make DexCom a must-own stock right now. DexCom sports one of the best-selling CGM franchises in the market today. While the company's stock is trading at over 100 times forward-looking earnings at current levels, this rich premium is arguably well deserved. After all, DexCom's stock may actually be trading at as little as 2.6 times 2026 sales, thanks to this blistering growth rate across the CGM landscape as a whole. What makes DexCom a particularly strong stock to own in a recessionary environment? DexCom's CGM devices are a fundamental part of the diabetes management landscape. An economic downturn isn't going to change this fact. As a result, the medical device company ought to be able to easily weather even a severe economic recession. 10 stocks we like better than Amazon When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Chewy, Inc., and Walmart Inc. The Motley Fool recommends DexCom and SPDR S&P Biotech. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-01,81.685,83.15,79.37,83.08,
DXCM,2022-09-02,84.47,85.46,81.28,82.0,"DexCom (DXCM) Dips More Than Broader Markets: What You Should Know DexCom (DXCM) closed the most recent trading day at $82, moving -1.3% from the previous trading session. This change lagged the S&P 500's 1.07% loss on the day. At the same time, the Dow lost 1.07%, and the tech-heavy Nasdaq lost 0.03%. Coming into today, shares of the medical device company had lost 7.21% in the past month. In that same time, the Medical sector lost 4.02%, while the S&P 500 lost 3.49%. DexCom will be looking to display strength as it nears its next earnings release. In that report, analysts expect DexCom to post earnings of $0.24 per share. This would mark year-over-year growth of 9.09%. Meanwhile, our latest consensus estimate is calling for revenue of $751.27 million, up 15.54% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $0.79 per share and revenue of $2.89 billion, which would represent changes of +17.91% and +18.16%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for DexCom. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.37% lower within the past month. DexCom is currently sporting a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that DexCom has a Forward P/E ratio of 105.77 right now. Its industry sports an average Forward P/E of 28.09, so we one might conclude that DexCom is trading at a premium comparatively. Also, we should mention that DXCM has a PEG ratio of 3.36. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.01 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 38% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-06,82.04,83.13,81.2,82.03,
DXCM,2022-09-07,82.56,88.5999,82.105,88.37,
DXCM,2022-09-08,87.32,91.64,87.21,91.59,
DXCM,2022-09-09,91.6,93.24,91.6,92.89,
DXCM,2022-09-12,92.99,94.3,92.68,94.18,"[""Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now? Let's talk about the popular DexCom, Inc. (NASDAQ:DXCM). The company's shares led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock\u2019s share price. However, could the stock still be trading at a relatively cheap price? Let\u2019s take a look at DexCom\u2019s outlook and value based on the most recent financial data to see if the opportunity still exists. What's The Opportunity In DexCom? The stock is currently trading at US$92.89 on the share market, which means it is overvalued by 34% compared to my intrinsic value of $69.55. This means that the opportunity to buy DexCom at a good price has disappeared! If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since DexCom\u2019s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. Can we expect growth from DexCom? NasdaqGS:DXCM Earnings and Revenue Growth September 12th 2022 Future outlook is an important aspect when you\u2019re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it\u2019s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to more than double over the next couple of years, the future seems bright for DexCom. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. What This Means For You Are you a shareholder? DXCM\u2019s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. At this current price, shareholders may be asking a different question \u2013 should I sell? If you believe DXCM should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed. Are you a potential investor? If you\u2019ve been keeping tabs on DXCM for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there\u2019s no upside from mispricing. However, the optimistic prospect is encouraging for DXCM, which means it\u2019s worth diving deeper into other factors in order to take advantage of the next price drop. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. At Simply Wall St, we found 1 warning sign for DexCom and we think they deserve your attention. If you are no longer interested in DexCom, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market We've all heard that you shouldn't judge a book by its cover, but income-seeking investors sometimes forget this lesson when it comes to picking stocks. Dividend Aristocrats are stocks in the S&P 500 index with at least 25 consecutive years of payment increases under their belts, and most of them get more attention than they deserve. Reliable dividend-paying stocks are a great way to generate a passive income. If you're determined to stick with the elite group of Dividend Aristocrats, though, at least stick with ones that have a good chance of outperforming the overall market. Image source: Getty Images. This pair of related healthcare companies have been paying and raising their quarterly dividends for five long decades. Best of all, their best days could lie ahead. 1. Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified healthcare conglomerate with a hand in diagnostics, medical devices, and nutrition. A diverse collection of businesses helped it increase its dividend payout for the 50th consecutive year last December. Abbott got a lot of unflattering attention when the closure of one of its baby food manufacturing plants led to a national shortage of specialty formulas. Investors seeking steadily rising payouts will be glad to know the specialty nutrition market isn't the only reliable industry where the company has an advantage. At recent prices, Abbott shares offer a 1.7% yield. That isn't too enticing now, but its payout could grow by leaps and bounds over the next several years. In May, the FDA cleared Abbott's next-generation constant glucose monitoring (CGM) device. The tiny Freestyle Libre 3 is smaller than CGMs from its nearest competitor, the G7 from Dexcom. Abbott's device also has a head start. The FDA still hasn't cleared the G7 and it isn't expected to begin a U.S. launch until 2023. With more than one reliable revenue stream Abbott has been able to raise its payout by 77% over the past five years, and it could start growing even faster. The U.S. Centers for Disease Control think there are more than 37 million Americans with diabetes right now, and Abbott has what could be the leading CGM for the foreseeable future. 2. AbbVie AbbVie (NYSE: ABBV) was spun off from Abbott Laboratories in 2013 to shield Abbott's shareholders from the impending end of market exclusivity for the world's top-selling anti-inflammatory drug, Humira. Sales of Humira plus a growing roster of younger drugs have helped the company raise its payout a stunning 120% over the past five years. Now, AbbVie shares offer an above-average dividend yield of 4% because investors are worried the company's bottom line can't keep growing. In the U.S. this spring, Humira began competing with lower-cost biosimilar versions, and sales will most likely drop significantly in the second half of the year. U.S. sales of Humira that reached $4.7 billion in the second quarter were responsible for 32% of total revenue. Luckily, AbbVie has new drugs that could more than offset the losses. In 2019, the FDA approved Skyrizi, a psoriasis injection, and Rinvoq, an arthritis drug. This pair is on pace to record $7.3 billion in combined sales this year, and AbbVie thinks they can pass $15 billion in 2025. U.S. Humira sales that drop faster than AbbVie's younger product lineup could make growth hard to achieve over the next year or two. Investors who appreciate steady dividend raises will be glad to know the company can meet and raise its payout even if Humira sales start plummeting. Over the past year, AbbVie used just 43.5% of the free cash flow its operations generated to meet its dividend obligation. With a well-funded dividend program and new growth drivers to fill in for Humira's impending losses, this stock has a good chance of outperforming over the long run. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-09-13,89.92,90.6532,88.56,89.17,"[""Why DexCom, Teladoc Health, and Veeva Systems Shares Are Slumping Today What happened The U.S. Department of Labor announced its latest data on inflation this morning. According to the report, the Consumer Price Index rose by an unsightly 8.3% in August relative to the same period a year ago. U.S. stocks, as a result, are mostly in the red Tuesday morning. Growth-dependent healthcare stocks are taking this news particularly hard today. As of 10:54 a.m. ET on Tuesday, shares of the continuous glucose monitoring giant DexCom (NASDAQ: DXCM) were down by 5.95%, the telemedicine services company Teladoc Health (NYSE: TDOC) saw its stock decline by 6.75%, and the healthcare-software company Veeva Systems (NYSE: VEEV) was lower by 3.55%. So what What's the common thread connecting these disparate healthcare stocks today? Wall Street is deeply concerned that red-hot inflation will curtail consumer spending in 2023, even for vital goods and services such as diabetes care, doctor visits, and clinical studies for important new drugs. Inflationary fears have weighed on the shares of DexCom, Teledoc Health, and Veeva Systems all year long. DexCom's stock is now down by 33% for the year, while Teledoc Health's stock price has sunk by 65.7%, and Veeva Systems shares have plunged by 31.9% over this same period. Now what Should bargain hunters take advantage of this prolonged weakness in these shares? Among these three growth healthcare stocks, DexCom jumps off the page as the most compelling buy. Its continuous glucose monitoring devices have become a fundamental component of diabetes care; so much so that the diabetes specialist's shares might be trading as low as 2.5 times 2026 sales right now. That's dirt cheap for a company with double-digit sales growth. As for Teladoc Health, Wall Street still isn't convinced that this telemedicine company can thrive in a post-pandemic world. That doesn't mean that Wall Street is correct in its dire take. Teladoc's shares are now trading at a mere 1.8 times 2023 estimated sales. Nonetheless, it could be a while before sentiment around this former high-flying stock changes. Lastly, Veeva Systems' stock could continue to falter as investors take profits on premium-laden equities. Underscoring this point, the healthcare company's shares have been trading at over 11 times 2024 projected sales of late. The healthcare-oriented software company does have a bright outlook over the long term, but this premium-heavy healthcare play could struggle in the short term in this increasingly risk-averse environment. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health and Veeva Systems. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stocks Billionaires Are Buying as the Market Plunges Runaway inflation and rising interest rates are making bears out of investors and keeping stock markets under pressure this year. Despite sliding stock prices across the board, some billionaire money managers kept confidently buying as the market plunged in the second quarter of this year. Blindly following successful investors isn't advisable, but there's nothing wrong with riding on their coattails. Here's what you should know about three stocks that billionaire hedge-fund managers were buying while the overall stock market was tanking. Image source: Getty Images. 1. Dexcom Steven Cohen and Point72 Asset Management bought over 900,000 shares of Dexcom (NASDAQ: DXCM) during the second quarter. The medical-device stock has risen around 18.6% since the end of June and could climb even higher. Dexcom markets continuous glucose-monitoring (CGM) devices that are increasingly popular among diabetic patients. An estimated 37 million Americans have diabetes, and providing them with CGMs that they regularly replace could lead to an earnings windfall. Dexcom's new lead product, the G7, is racking up sales in Europe, where regulators have already granted clearance. In the U.S., the Food and Drug Administration (FDA) is expected to clear the G7 late this year because some last-minute software changes delayed the application process. With the G7 launch underway in Europe, second-quarter international sales surged 39% year over year. Launching the much-anticipated G7 in the U.S. could make 2023 a very memorable year for Dexcom and its stock price. 2. Salesforce David Tepper and Appaloosa Management opened a new position in Salesforce (NYSE: CRM) during the second quarter. The customer relationship-management (CRM) stock now makes up more than 2% of Appaloosa's portfolio. Salesforce operates the world's most popular cloud-based customer relationship-management (CRM) solution, and its competitors aren't even close. In the latest software-tracker survey from industry analyst IDC, Salesforce's23.8% share of the worldwide CRM market was larger than its top four competitors combined. Salesforce shares rallied this summer, only to fall hard in August along with most of the stock market. Now you can scoop up the stock at just 33.1 times forward-looking earnings estimates. That's a low price to pay for a company that expects total revenue to climb 17% this year. 3. Walt Disney In the second quarter, Daniel Loeb and Third Point Capital opened a new position in Walt Disney (NYSE: DIS). The value-driven fund confidently bought 1 million shares of the media giant. Shares of Disney have risen around 19% since the end of June, but the stock trades at around 29.1 times forward-earnings expectations. With its amusement parks full of tourists again and subscription services that keep outperforming expectations, Disney was able to report second-quarter revenue that soared 23% year over year. There were concerns that Netflix's subscriber-count backslide would extend to Disney's streaming operation. Now it looks like Disney is at least partly responsible for its competitor's lack of growth. Disney+ added 7.9 million subscribers in the second quarter, which raised total streaming subscriptions to 205 million. Disney has a strong chance to become the global streaming-service leader. It also has a collection of profitable theme parks and some of the most recognizable entertainment brands on the planet. Put it all together, and the stock looks like a buy now, despite a lofty valuation. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now\u2026 and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Netflix, Salesforce, Inc., and Walt Disney. The Motley Fool recommends DexCom and recommends the following options: long January 2024 $145 calls on Walt Disney and short January 2024 $155 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-09-14,89.43,90.94,87.29,90.57,
DXCM,2022-09-15,90.62,93.02,90.31,90.98,"1 Widely Held Stock-Split Stock That Could Plunge 92%, According to Wall Street Investing in 2022 has been challenging. Since the year began, the widely followed S&P 500 and growth-driven Nasdaq Composite have each fallen into a bear market. These sizable declines come on the heels of historically high inflation, ongoing global energy supply chain problems, and back-to-back quarterly retracements in U.S. gross domestic product. Although periods of heightened volatility in the stock market can be unnerving, investors have managed to navigate to one clear source of inspiration amid the turmoil: stock-split stocks. Image source: Getty Images. Stock-split mania has been investors' saving grace in a tumultuous year A stock split is a mechanism that allows a publicly traded company to alter its share price or outstanding share count without affecting its market cap or operations. A forward stock split reduces a company's share price to make it more nominally affordable for everyday investors. This is the type of split that tends to get investors most excited, because it's enacted by companies that have been out-innovating and out-executing their competition and have seen their share prices rise substantially over time. Since the beginning of the year, six high-profile forward stock splits have taken place. In no particular order: Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): Announced its intent to split in February, and completed a 20-for-1 forward split in mid-July. Amazon (NASDAQ: AMZN): Declared a 20-for-1 stock split in March, which was enacted in early June. Tesla (NASDAQ: TSLA): Announced its intent to conduct a split in June, with shareholders approving, and the company enacting, a 3-for-1 split in August. DexCom (NASDAQ: DXCM): Declared a 4-for-1 stock split in late March, which the company completed in June. Shopify (NYSE: SHOP): Announced a 10-for-1 stock split in April that was ultimately enacted by late June. Palo Alto Networks (NASDAQ: PANW): Notified investors of its intent to split 3-for-1 in August and completed said split earlier this week. Aside from splitting their shares to make them more nominally affordable for retail investors who might not otherwise have access to fractional-share purchases through their online broker, these six companies share another thing in common: clear-cut competitive advantages. The primary reason these half-dozen stocks have outperformed and seen their share prices soar is because they offer sustainable edges over their competition. For example, Alphabet subsidiary Google controls more than 91% of global internet search market share; Amazon's online marketplace should account for nearly 40% of U.S. online retail sales in 2022; and Tesla is the leading electric-vehicle (EV) manufacturer in North America. Meanwhile, DexCom is no worse than the No. 2 global provider of continuous glucose monitoring systems; Shopify is enjoying sustained e-commerce platform subscription growth; and Palo Alto Networks is playing a key role in the evolution of next-generation cybersecurity software. Not surprisingly, most Wall Street analysts have favorable views of these six stock-split stocks. But the key word here is ""most,"" not all. A Tesla Model S, Model 3, Model X, and Model Y at a supercharger station. Image source: Tesla. One Wall Street analyst sees this stock-stock split stock losing over 90% of its value Whereas the bulk of Wall Street's consensus price targets for the aforementioned six stock-split stocks are higher than where they closed on Sept. 12, one analyst is forecasting nothing short of doom and gloom for one company. In mid-July, Gordon Johnson, the CEO and founder of GLJ Research, reiterated a sell rating on EV maker Tesla and (get this...) raised his firm's price target from $67 to $73. Keep in mind that both price targets are pre-split figures. This means Johnson's recently raised split-adjusted price target on Tesla is just $24.33/share. With Tesla shares topping $304 earlier this week, it implies that GLJ Research expects an up to 92% decline in shares of the company. Johnson, a longtime Tesla bear, has cited numerous reasons for his pessimistic take. For starters, he doesn't believe Tesla can justify its $954 billion valuation without adding 100,000 new EVs on an incremental quarterly basis. Although the opening of the Austin, Texas, and Berlin, Germany, gigafactories earlier this year will certainly help Tesla ramp up its quarterly and annual output, it's unclear how the company will sustain EV production growth without regularly opening new gigafactories. To add to the above, production at the Shanghai gigafactory has been adversely impacted by semiconductor chip shortages and China's zero-COVID strategy. With China accounting for a significant portion of Tesla's profits and sporadic production shutdowns remaining a possibility, it leaves the company in a potentially precarious situation. Additionally, Gordon Johnson has frequently harped on Tesla's accounting practices as a reason its shares could head significantly lower. Tesla accounts for Elon Musk's sizable stock-based compensation underselling, general, and administrative expenses, which have a tendency to ebb and flow from quarter to quarter. Johnson believes Tesla's true expenses, and therefore its operating efficiency, aren't being transparently accounted for in its quarterly filings. Could Tesla really plunge to $24.33 per share? Gordon Johnson's pessimism begs the question: Could Tesla really nosedive and lose 92% of its value? On one hand, it's important to recognize that Tesla wouldn't have become the fifth-largest publicly traded company by market cap if it wasn't doing something right. The company has become profitable on a recurring basis without the help of selling renewable energy credits to other automakers. It's also on track to hit 1 million EVs delivered in 2022 despite the aforementioned shortage of semiconductor chips and persistent global supply chain issues caused by the COVID-19 pandemic. Furthermore, Tesla has led with innovation, which is an easy way to get on Wall Street's good side. With Elon Musk as CEO, Tesla has brought four EVs into production and aims to bring both the Cybertruck and Semi into production as soon as next year. Tesla is the only automaker to have, thus far, successfully built itself from the ground up to mass production in over a half-century. However, Gordon Johnson's analysis isn't lacking for facts either. Based on market cap, Tesla is worth more than every other automaker on a combined basis, yet it's contending with the same supply chain issues as other automakers. Trying to justify a multiple of 57 times Wall Street's forecast earnings for the upcoming year in an industry where single-digit price-to-earnings ratios are commonplace when selling a commoditized product simply can't be done. I believe Johnson is also right in assuming that Tesla's market share is going to decline over time. Although the company has clear competitive advantages at the moment, we're already beginning to see new and legacy automakers challenge the range of Tesla's flagship sedan, the Model 3. Plus, as I've recently pointed out, Elon Musk has become a significant liability to Tesla's stock. Although a 92% decline would likely be excessive, considering Tesla's profitability and the brand-name recognition it holds with consumers and investors, I do believe ""lower"" is the direction that Tesla ultimately heads over the next one to three years. 10 stocks we like better than Tesla When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Tesla wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet (A shares) and Amazon. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-16,89.79,90.45,88.03,90.09,"Stock Market Sell-Off: 2 Reliable Dividend Stocks to Buy On the Dip These days, when it rains on Wall Street, it really pours. Stocks across the board have been sliding in response to another inflation report that could convince the Federal Reserve to raise interest rates even further. Rising interest rates could push stocks even lower, or we could be near the start of a long market recovery. At uncertain times like these, it's best to stick with the most reliable stocks the market has to offer. Image source: Getty Images. Here are two healthcare companies that are poised to produce rising profits even if the overall economy doesn't feel like cooperating. CVS Health Shares of CVS Health (NYSE: CVS) are slightly down this year, even though things are looking up for the healthcare conglomerate. Strong growth from a diverse collection of businesses allowed it to raise its dividend payout by 10% earlier this year. Now the stock offers a 2.2% yield, and investors can expect more raises in the years ahead. CVS Health is one of the most reliable dividend stocks that you won't find on the Dividend Aristocrats list. That's because the company held its payout steady from 2017 through 2021 to help pay for its $69 billion acquisition of Aetna. This is a health insurer that collects insurance premiums from an estimated 35 million members. You're more than likely familiar with this company's chain of over 9,000 retail pharmacies. Many of those pharmacies have physicians and nurse practitioners on staff. Sending Aetna members to a CVS pharmacy for care or a prescription lowers costs for CVS Health. Combining a health insurance business with thousands of retail locations capable of providing healthcare services is also boosting profits. The company expects earnings per share to climb about 22% this year. As the only major U.S. insurer that also handles day-to-day healthcare services for its members at retail locations, the advantages allowing CVS Health to outperform seem extremely durable. Abbott Laboratories Abbott Laboratories (NYSE: ABT) stock skyrocketed last year in response to soaring sales of its COVID-19 tests. Test kits that are no longer flying off the shelves, and a market fearful of rising interest rates, have been a bad combination for Abbott's stock price. The stock is down around 25% from the peak it reached late last year. Shares of Abbott offer a dividend that has risen 77% over the past five years, and the next five could be even better. The 1.8% yield this stock offers now could make big gains, thanks to a tiny device for diabetic patients. In May, the FDA granted clearance to the company's new continuous glucose monitor (CGM), the Freestyle Libre 3. Abbott's new CGM is about the size of two stacked pennies, and it sticks to the back of a patient's upper arm for two weeks at a time. It's both smaller and longer-lasting than its nearest competitor, the G6 from DexCom. DexCom's long-delayed G7 device could provide some competition in 2024. By then, patients and physicians already comfortable with Abbott's device will be hesitant to switch. In addition to diagnostics and devices for diabetic patients, Abbott builds heart replacement valves and other devices to keep our clocks ticking. In August, a clinical trial showed the company's HeartMate 3 heart pump raised the five-year survival rate for patients with advanced heart failure to 58%. This survival rate is in line with what cardiologists would expect from similar patients following a tricky transplant procedure. Inflation or a recession can cause folks to spend less on a lot of things, but not the devices that keep them out of the hospital. Reliable cash flows make Abbott a great stock to buy on the dip and hold for the long run. 10 stocks we like better than CVS Health When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and CVS Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health, CVS Health Corporation, and DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-19,88.62,89.14,85.42,87.94,"[""Nasdaq 100 Movers: MRNA, CEG In early trading on Monday, shares of Constellation Energy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.8%. Year to date, Constellation Energy registers a 107.3% gain. And the worst performing Nasdaq 100 component thus far on the day is Moderna, trading down 6.6%. Moderna is lower by about 49.3% looking at the year to date performance. Two other components making moves today are DexCom, trading down 4.2%, and Dollar Tree, trading up 1.6% on the day. VIDEO: Nasdaq 100 Movers: MRNA, CEG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: MRNA, AAL In early trading on Monday, shares of American Airlines Group topped the list of the day's best performing components of the S&P 500 index, trading up 3.4%. Year to date, American Airlines Group has lost about 20.8% of its value. And the worst performing S&P 500 component thus far on the day is Moderna, trading down 5.9%. Moderna is lower by about 49.0% looking at the year to date performance. Two other components making moves today are DexCom, trading down 3.8%, and Mosaic, trading up 3.3% on the day. VIDEO: S&P 500 Movers: MRNA, AAL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-09-20,87.28,88.425,85.62,87.37,
DXCM,2022-09-21,87.835,88.64,84.42,84.46,"3 Highly Profitable Stocks That Are Super Cheap Right Now Bear markets are never fun. Downtrodden equity markets are, however, a great time for investors with a long-term mindset to buy stocks. Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities. Cosmetic surgery company InMode (NASDAQ: INMD), Swiss pharma giant Novartis (NYSE: NVS), and diabetes care behemoth DexCom (NASDAQ: DXCM) are three highly profitable companies that have been unfairly punished by this irrational market. Read on to find out more about these top stocks in healthcare. Image source: Getty Images. InMode looks set to soar Taylor Carmichael (InMode): How cheap is InMode stock right now? The stock has a price-to-sales ratio of 7, and a price-to-earnings ratio of 16. A year ago, those multiples were 23 and 53, respectively. When we emerge from this bear market, the multiples of growth stocks will expand back to norms, and I expect the market will again pay a premium for InMode's amazing numbers. InMode has introduced radio frequency (RF) devices to the world of cosmetic surgery. These procedures are noninvasive, like lasers, except they have applications to the entire spectrum of ""body contouring."" (Lasers are largely limited to superficial tasks like hair removal.) InMode's devices direct RF waves into the body. For its ""body contouring services,"" InMode says the ""treatments use radiofrequency energy to coagulate fat, tone muscles, remodel skin and address cellulite and imperfections such as vascular lesions, spider veins, port wine stains, and leg veins."" The upshot is that InMode's devices open the door to noninvasive body sculpting without the dangers of surgery. This tech breakthrough has made InMode highly profitable, with a 42% profit margin. And the company is still growing fast, with sales soaring 30% in its most recent quarter.What's beautiful about this business is that InMode has over 14,000 installed devices around the world and every device is a platform creating continuing revenue streams for the company as the device is used. In the most recent quarter, InMode reported $15 million in revenue from consumables and service, a 59% year-over-year jump. While that's a small portion of the $113 million in total revenue, the number will grow. The noninvasive aesthetic market was valued at $53 billion last year and InMode management is optimistic about the opportunity to convert those using lasers to its RF machines. InMode is already on the way to becoming the dominant medical device maker in cosmetic surgery. The shares are dramatically on sale now, even though the company has seen nothing but good news. Over the next several years, I expect the stock to surpass its highs and go a lot higher. At $33, this stock is a steal right now. An underappreciated $190 billion company Patrick Bafuma (Novartis): When it comes to profitability on sale, pharma giant Novartis tops my list. The Swiss drugmaker generated core operating income margin of 33% of net sales in the first half of 2022. In the same time period, it generated $4.2 billion in free cash flow, resulting in $19.8 billion in cash on hand. With such a large sum in the bank and free cash flow solid, Novartis' dividend -- which is currently yielding 4% -- looks safe. Not to mention the yield is higher than those of other pharma behemoths like Merck and Pfizer, which offer 3.2% and 3.46%, respectively. Plus, Novartis' price-to-earnings (P/E) ratio of only 8 is less than either of the other two pharmas, with Pfizer at 9 and Merck at 13.2. Compared to its peers, Novartis seems undervalued. And the future seems steady. Blockbuster drug Cosentyx, which is prescribed for certain types of autoimmune diseases such as psoriasis, generated sales of $1.3 billion for the most recent quarter, up 12% from a year ago. The monoclonal antibody therapy is expected to generate over $7 billion in peak annual sales and has patent protection until at least 2029. Sales of heart failure medication Entresto were up 33% from a year ago to $1.1 billion for the quarter. And the company sees multibillion-dollar annual potential from the drugs Zolgensma, Kisquali, Kesimpta, and Leqvio -- all of which have U.S. exclusivity protection until at least 2031. With a pile of cash, several therapies blossoming into blockbusters, and an inexpensive valuation, income investors may want to look closer at Novartis. Don't miss out on this opportunity George Budwell (DexCom): DexCom is a continuous glucose monitor (CGM) juggernaut. The medical device specialist's CGM franchise, spearheaded by its DexCom G6 CGM system, has yielded enormous levels of revenue growth for the company over the past several years. DexCom's top line is on track to rise by a healthy 18.2% this year, and another 20.2% in 2023. What's more, this CGM titan posted a gross profit of a whopping $449.5 million in the second quarter of 2022. Still, the bear market hasn't been kind to this medical device giant lately, with the company's shares down by a whopping 44% from their 52-week high right now. Why are investors dumping this top growth stock? In an odd twist of events, DexCom's own success has spurred this prolonged sell-off in its stock. Prior to the start of the bear market in healthcare stocks in late 2021, DexCom's shares were trading well north of 200 times earnings estimates. The bear market has taken a hatchet to nearly every healthcare stock with a premium valuation in 2022 -- with DexCom being no exception. Speaking to this point, most of the medical device maker's key financial metrics, such as revenue, gross profit, and adjusted earnings before interest, taxes, depreciation, and amortization, have all been headed in the right direction in 2022. Investors have probably taken things way too far, however. DexCom's core target market is still growing by leaps and bounds. In fact, the medical device titan's stock could be trading at well under three times 2026 sales following this sharp decline, depending on how the global CGM market evolves over the next few years. So if you're looking for a bargain, DexCom stock ought to be at the top of your list. 10 stocks we like better than InMode Ltd. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and InMode Ltd. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 George Budwell has no position in any of the stocks mentioned. Patrick Bafuma has no position in any of the stocks mentioned. Taylor Carmichael has positions in InMode Ltd. The Motley Fool has positions in and recommends InMode Ltd. and Merck & Co. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-22,83.64,83.85,79.71,80.96,"Nasdaq Bear Market: 3 of the Best Growth Stocks to Buy Today The Nasdaq is down 27% this year, and that can be incredibly discouraging for growth investors. However, the tech-heavy index has still delivered impressive growth over a longer time frame. Over the past five years, the index remains up 77% vs. 54% for the S&P 500. The moral of the story is that long-term investors should not ignore the Nasdaq. Three Nasdaq-based stocks that are full of potential today are DexCom (NASDAQ: DXCM), Meta Platforms (NASDAQ: META), and Comcast (NASDAQ: CMCSA). They're all down 30%, but here's why they're still good buys. 1. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help diabetes patients control their blood sugar levels. The stock has taken a beating this year, falling 35%. But focusing on the short term could be a costly mistake for investors as this has the potential to be a phenomenal long-term buy. What I like most about the business, beyond its potential to meet an important need in a growing diabetes market, is that it generates incredible margins. Over the past four quarters, DexCom's gross margin of $1.8 billion has been 66% of its revenue ($2.7 billion). And while its profits may be relatively minimal, just $168 million in the past year, they should improve as the business continues to expand into more markets -- thanks to its strong margins. This year, DexCom projects that its top line could rise by as much as 19%. Another positive is that the business has also generated positive free cash flow in three of the past four quarters. DexCom's solid financials, strong margins, and promising growth opportunities all make the healthcare stock an attractive buy at its discounted price. 2. Meta Platforms Shares of Meta Platforms haven't been this low since the 2020 market crash. Down 57% this year, it has been an all-out disaster for what still remains a top growth stock. Investors have been in panic mode as the company's sales of $28.8 billion for the period ended June 30 were down 1% from the prior-year period. However, it's hard to blame that on the company. Issues in the macro environment are more at fault; advertisers are pulling back on spending amid inflation and concerns of a looming recession. This isn't a problem that's likely to persist, and it has weighed on other tech stocks beyond just Meta. The company still has more than 3.6 billion monthly active users across its social media sites (Facebook, Instagram, WhatsApp), which is a 4% increase from a year ago. That makes it likely that when companies get back to spending on ads, Meta will attract a lot of those dollars. Meta is still an incredibly successful business, generating $119.4 billion in sales over the past four quarters and netting a profit of $33.6 billion on that amount. At a ridiculously low 12 times earnings (the average tech stock trades at a multiple of 23), this is a stock that investors shouldn't pass up the opportunity to buy today. 3. Comcast Another growth stock trading at a low earnings multiple is Comcast. Investors are currently paying just 11 times earnings for the telecom business after the shares fell 32% this year -- the smallest decline of the stocks listed here. And it's easy to make a case for why the stock could do better in the future. Comcast's revenue topped $30 billion last quarter (ended June 30) and rose 5% year over year. A big reason for the boost: sales at its theme parks, which have skyrocketed 65% year over year as people emerge from their homes begin traveling again. The company could do even better, however, as it continues to grow its streaming business, Peacock. At just 13 million paid subscribers, the service is still scratching the surface in terms of potential; both Disney and Netflix have subscriber numbers in excess of 200 million. Comcast is also becoming more aggressive in its wireless business, rolling out cheaper plans to customers that could drive growth there. In addition to growth potential, Comcast also pays investors a dividend yield of 3.1%, which is notably higher than the S&P 500 average of 1.7%. For long-term investors, Comcast offers a bit of everything and is yet another solid stock to consider buying today. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. David Jagielski has positions in Meta Platforms, Inc. The Motley Fool has positions in and recommends Meta Platforms, Inc., Netflix, and Walt Disney. The Motley Fool recommends Comcast and DexCom and recommends the following options: long January 2024 $145 calls on Walt Disney and short January 2024 $155 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-23,80.39,80.78,79.03,80.66,
DXCM,2022-09-26,80.64,81.74,79.12,80.35,
DXCM,2022-09-27,81.54,81.74,78.94,79.64,
DXCM,2022-09-28,80.66,83.94,80.4,83.33,"Better Growth Stock: Intuitive Surgical vs. DexCom Growth stocks have received much of investors' ire throughout the current market downturn. With economic problems such as inflation lurking, investors are increasingly investing their money in safer companies rather than growth-oriented ones. The latter seem overvalued and sometimes generate no profits. Yet, many growth companies still have bright futures. Let's look at two excellent examples: Intuitive Surgical (NASDAQ: ISRG) and DexCom (NASDAQ: DXCM). These two medical device giants have both performed poorly over the past year, but which is more likely to outperform the other in the long run? ISRG data by YCharts. The case for Intuitive Surgical Intuitive Surgical is the leader in the robotic-assisted surgery (RAS) market, thanks to its crown jewel, the da Vinci surgical system. This machine allows physicians to perform minimally invasive surgeries that are much easier on patients than traditional operations. The great thing about Intuitive Surgical's business is the growth potential that the RAS market boasts. Minimally invasive surgeries still make up a small fraction -- only 3% as of last year -- of the total performed. That proportion will surely rise in the coming decades, providing plenty of fuel to fire up Intuitive Surgical's growth engine. And the company can remain a leader in this space, given the competitive edge it has already built. The da Vinci system costs between $500,000 and $2.5 million, a hefty sum for many healthcare facilities. Combining that cost with the time investment of training medical personnel on the machine, hospitals that have already bought da Vinci systems are reluctant to switch to a competing RAS system. Also, breaking into the industry is highly capital-intensive. Furthermore, the medical devices specialist boasts intangible assets -- in the form of patents -- that protect its devices and accessories from the competition. These factors are why Intuitive Surgical should remain a leader in the RAS market. Investors might be concerned about some of Intuitive's top executives recently selling some of their shares. The market often sees such moves as a bad sign. But unless they're related to a change in the company's fundamentals -- and we have no reason to believe they are -- then these recent sales mean little to Intuitive Surgical's long-term thesis. And as things stand, the company's prospects look attractive, thanks to its leadership in an expanding industry. That's why I think Intuitive Surgical is a buy. The case for DexCom DexCom is a leader in continuous glucose monitoring (CGM) systems. These innovative devices allow people with diabetes to perform an important task more efficiently: keeping track of their blood glucose levels. Diabetes patients typically rely on blood glucose meters, which are painful to use and can only read a blood glucose level at a particular time. CGMs are much better. These devices don't rely on painful finger sticks, and continuously keep tabs on patients' blood glucose levels. CGM devices can make up to 288 readings every day, or one every five minutes. The growth in the use of CGM systems has helped DexCom increase its revenue over the years, but the company still has a bright future ahead. Consider that the percentage of the population with diabetes is growing. By 2050, about 1 in 3 adults in the U.S could have diabetes, compared to just 11.3% of the population now. That gives DexCom plenty of room to increase its revenue and profits as its CGMs make their way deeper into this growing population. Even within the current pool of diabetes patients, CGM technology still has substantial room to grow. DexCom will also improve its prospects as it develops newer devices. The company has already launched the G7, the successor to its very successful G6, in some parts of Europe, and the G7 awaits clearance in the U.S. As a leader in CGM technology, DexCom is in an ideal position to benefit from the long-term opportunity this market presents. Two robust companies In my view, Intuitive Surgical and DexCom both seem like solid picks due to the opportunities ahead for both. Which one should investors pick? At first glance, DexCom may look like the better growth stock. DexCom has generally grown its top line (on a year-over-year basis) faster than Intuitive Surgical in the past five years. However, Intuitive's revenue as of the latest period is still more than twice that of DexCom. And that's in addition to Intuitive Surgical's much higher bottom line: ISRG Revenue (Quarterly) data by YCharts. However, DexCom's higher revenue in recent memory also puts a premium on its shares, with its forward price-to-earnings ratio coming in much higher than Intuitive Surgical's. DexCom's shares could become much more volatile due to its steeper valuation metrics, especially since its revenue growth has slowed. That's one of the reasons why, if I had to make a choice, I'd think Intuitive Surgical was the better pick. Another argument in favor of Intuitive is its (in my opinion) stronger moat. The combination of high switching costs and its intangible assets, coupled with high barriers to entry into the market, makes it nearly impossible to topple Intuitive Surgical from its leadership position in this space. With that said, both of these growth stocks look like solid long-term winners, and investors can't go wrong with either one. 10 stocks we like better than Intuitive Surgical When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Intuitive Surgical wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-09-29,82.31,82.9,80.61,82.1,
DXCM,2022-09-30,81.79,83.98,80.36,80.54,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. So far this year, this Zacks Rank #3 (Hold) stock has lost 38.9% compared with 35.5% decline of the industry and a 22.7% decline of the S&P 500. The renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $32.92 billion. The company projects 31.4% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and matched estimates in one, delivering a negative earnings surprise of 3.4%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM (rt-CGM) System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. In June, DexCom announced its plans to showcase its expanded global portfolio of rt-CGM systems at the Scientific Sessions of the American Diabetes Association conference. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. In March, DexCom announced that effective Mar 14, 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria. Strong Q2 Results: DexCom’s solid second-quarter 2022 revenues buoy optimism. Rising volumes across all channels and strong new customer additions contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available to international markets. Downsides Reimbursement Risk: Reimbursement risk is somewhat high due to the efforts to control healthcare expenses. The company noted that most Type 1 patients (above 65) pay 100% of their CGM costs out of their own pockets. Unless payers (both government and private insurers) provide sufficient coverage and reimbursement, commercial success for DexCom will be limited, in our view. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all of the worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 1.3% south to 79 cents. The Zacks Consensus Estimate for the company’s third-quarter 2022 revenues is pegged at $751.3 million, suggesting a 15.5% improvement from the year-ago quarter’s reported number. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are ShockWave Medical SWAV, AMN Healthcare Services AMN and McKesson MCK. While ShockWave Medical and AMN Healthcare Services sport a Zacks Rank #1 (Strong Buy), McKesson carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Estimates for ShockWave Medical’s earnings per share rose from $2.02 to $2.57 for 2022 and from $2.95 to $3.42 for 2023 in the past 60 days. SWAV has gained 54.6% so far this year. ShockWave Medical delivered an earnings surprise of 180.14%, on average, in the last four quarters. Estimates for AMN Healthcare Services have improved from earnings of $10.41 to $11.26 for 2022 and $7.94 to $8.30 for 2023 in the past 60 days. AMN stock has declined 13% so far this year. AMN Healthcare Services delivered an earnings surprise of 15.66%, on average, in the last four quarters. McKesson’s earnings per share estimates increased from $23.27 to $24.42 for fiscal 2023 and $25.41 to $26.04 for fiscal 2024 in the past 60 days. MCK has gained 37.6% so far this year. McKesson delivered an earnings surprise of 13.00%, on average, in the last four quarters. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report ShockWave Medical, Inc. (SWAV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-03,81.47,85.54,81.06,84.98,
DXCM,2022-10-04,87.64,91.57,87.63,90.97,"Why DexCom Was Such a Healthy Stock Today What happened There's nothing like a strategic product rollout to push the price of a stock higher. This was the case with medical device maker DexCom (NASDAQ: DXCM), which on news of international expansion saw its share price zoom more than 7% higher on Tuesday. That trounced even the robust 3%-plus gain of the S&P 500 index on the day. So what DexCom, which specializes in continuous glucose monitoring (CGM) solutions for diabetics, announced earlier in the day that it is expanding into new markets. Specifically, the company's current-generation G7 GCM System is now available for diabetes patients two years of age and older in the U.K., Germany, Austria, and Hong Kong. Other rollouts are being planned. DexCom said that it is working to launch the G7 in South Africa and New Zealand in the coming weeks. A wider expansion is currently being planned, although the company did not identify any of these markets. The G7 is worn on the body, and provides real-time glucose level readings that are sent to a user's device. In its press release trumpeting the latest rollout, the healthcare device maker quoted its CEO Kevin Sayer as saying that the company's CGM offerings have ""become the gold standard of care for diabetes, and bringing our technology to more and more people around the world continues to be a top priority."" Now what The U.K. and Germany are particularly ripe markets, as they are populous and relatively affluent countries. Investors are clearly excited about DexCom's prospects there, and looking forward to additional rollouts in the very near future. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-05,89.31,92.13,89.31,91.08,"[""DexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL \u2013 October 5, 2022 \u2013 Zacks Equity Research shares DexCom, Inc. DXCM as the Bull of the Day and Papa John's International PZZA as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Align Technology ALGN, SmileDirectClub SDC and DENTSPLY SIRONA XRAY. Here is a synopsis of all five stocks: Bull of the Day: DexCom, Inc. is a medical device/wearables company focused on helping people monitor and manage their diabetes. DexCom's top-line growth has been stellar and its addressable market is massive considering how widespread diabetes is in the U.S. and elsewhere. DexCom shares got caught up in the post-covid lockdown growth-buying wave that began to unwind last fall. The glucose monitoring company is now trading at far more reasonable levels and DXCM shares have been trending upward since the middle of June. Now might be time for investors to add DexCom stock at these levels for long-term growth upside. Connected Health Revolution DexCom makes continuous glucose monitoring systems designed for people with diabetes. The San Diego, California-based firm allows people with diabetes the chance to place a small sensor just beneath their skin\u2014most often on their abdomens\u2014to help them continuously monitor their glucose levels. DexCom's readings and data come through on companion devices or via an app on compatible smartphones, smartwatches and other devices, including offerings from Apple, Google, and others. DexCom's systems have become widely popular because they don't require people to prick themselves throughout the day in order to measure their glucose levels. DexCom's internet-connected, data-sharing devices are also helpful because they enable family, friends, and healthcare providers to receive data remotely in order to help the users make the proper medical decisions. The company's continuous glucose monitoring or CGM systems are part of a connected health revolution that's still in the very early days and might be poised to be the standard form of medical care and treatment in the decades to come. DexCom's CGM monitors systems are more beneficial for patients, caregivers, and healthcare professionals compared to more traditional/old school blood glucose meters that check glucose levels at a single moment in time. Addressable Market and Growth The simple facts are on DexCom's side as diabetes becomes far more common in the U.S. Over 37 million Americans or about 1 in 10 have diabetes, while 1 in 3 or nearly 100 million Americans have \""prediabetes,\"" according to the CDC's 2021 report. Worse still, diabetes is the 8th leading cause of death in the U.S. Rising diabetes rates, mostly type-2, is not just a U.S. problem, with roughly 540 million adults, or 1 in 10 people around the world living with diabetes. The International Diabetes Federation predicts that the number could climb to 645 million by 2030 and nearly 800 million by 2045. One of the nearby charts shows DexCom's strong revenue expansion over the past decade. The firm has averaged 34% sales growth in the past five years to climb from $719 million in 2017 to $2.5 billion in FY21. Zacks estimates call for DXCM to post another 18% revenue growth in FY22 and 21% higher in fiscal 2023 to hit $3.5 billion\u2014this is a case where the percentage change slowdown might cloud the fact that DexCom is set to add another $1 billion to its top line between 2021 and 2023. DexCom is still firmly investing in its growth. Yet, its adjusted earnings are projected to climb 18% this year and another 40% next year to come in at $1.10 per share. DXCM's upward earnings revisions help it land a Zacks Rank #1 (Strong Buy) right now. And the firm has topped EPS estimates for five years running outside of two recent misses. Price Performance and Valuation DexCom shares have skyrocketed roughly 2,300% in the past 10 years to blow away the S&P 500's 170% and its Zacks Medical Products Market's 25%. This run includes stretches of sideways movement and even drops. DXCM's outperformance has remained during the past five years. As we mentioned at the outset, the stock had tumbled off its November 2021 peaks alongside nearly every growth-focused stock. DXCM is trading around 45% below its records at around $91 per share and it still has 23% more room to run before it hits its current average Zacks price target. And the stock has already made a bit of a comeback off its mid-June lows, up over 30%. DexCom is hardly what anyone would call cheap, but Wall Street is buying it for stellar value. DXCM shares have been impacted by rising interest rates, with investors not willing to pay up as much for future earnings with rates off their rock-bottom levels. DXCM has, in turn, been recalibrated. Its forward PEG ratio (P/E ratio divided by its growth rate) is back at 2.6 vs. its recent highs of a whopping 41.9. These levels put the stock not too far off its industry's 2.2 despite its huge outperformance. Bottom Line DexCom might not be the safest near-term play amid the uncertainty about the interest rate environment. Still, investors with long-term outlooks might want to consider starting a position in the diabetes-focused connected medical products company for its long-term upside. DexCom should benefit from the growing prevalence of diabetes and it could possibly expand into new areas of the connected health world given its strong balance sheet and rising cash position. Plus, 12 of the 14 brokerage recommendations Zacks has are \""Strong Buys.\"" Bear of the Day: Papa John's International is a pizza delivery powerhouse that's facing tough-to-compete against periods, a growing assortment of food delivery options, and other headwinds. Possible Pizza Fatigue? Papa John's is the world's third-largest pizza delivery company with over 5,500 restaurants in roughly 50 countries and territories. Papa John's competes against Domino's Pizza, other local chains, and higher-end places in the take-out pizza market. Papa John's and other companies benefited from the stay-at-home covid boost over the last few years, as well as a willingness from consumers to eat out during a period of economic growth and positivity. PZZA's earnings revisions have been trending in the wrong direction lately amid a shifting economic and consumer spending landscape. Papa John's executive team last quarter pointed to higher labor costs and commodity prices as a reason for its subdued outlook, alongside lower international sales, specifically \""softening economic conditions in the UK.\""The pizza maker's FY22 and FY23 consensus estimates have dropped 6% and 7.5%, respectively over the last 60 days and slightly more if we go back a bit farther. Zacks estimates call for PZZA's 2022 revenue to climb by 2% and then pop around 5% in FY23. These estimates follow 14% revenue growth last year and 12% in FY20. Papa John's is projected to see its adjusted earnings slip by 15% in 2022 to $2.99 per share, before bouncing back to just under its FY21 total next year. The company's overall downward earnings estimate revisions help it land a Zacks Rank #5 (Strong Sell) at the moment. Bottom Line Papa John's shares have fallen over 40% in 2022 even as its broader industry dropped just 14%. PZZA's 2022 tumble roughly matches its rival Domino's, with Papa John's now down 9% over the last two years and DPZ 22% lower. Wall Street appears worried about the possibility of pizza delivery fatigue and the sustained challenges from many other restaurants who have found success through food delivery apps such as Uber Eats. All told, investors might want to stay away from Papa John's stock right now amid slowing consumer spending, high inflation, and growing non-pizza competition in the at-home delivery industry. Additional content: 3 Stocks from the Growing Orthodontics Space in Focus The pandemic-led crisis spanning two and a half years forced the dental industry to incline toward digital treatment options. The industry bore the brunt of the closure of dental practices and lower patient visits due to the risk of exposure to the virus and more focus on COVID-related treatments. However, digital orthodontics has been gaining traction lately. It offers advanced teeth straightening options while safeguarding dentists from the contagious virus. This subsegment of dental treatment entails the improvement of the arrangement and appearance of protruding, crowded or crooked teeth. It also pertains to correcting problems related to misaligned bites. Growing Trend Going by a Fortune Business Insights report, the global clear aligners market size was $2.41 billion in 2020, exhibiting lower growth of 4.4% compared with the average year-over-year growth from 2017 to 2019. However, the market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022. Apart from this, rising dependence on Artificial Intelligence (AI) & Robotics and teledentistry and an increase in the number of patient visits are likely to help the industry thrive in the near term. The latest technologies are helping orthodontic surgeons in carrying out minimally-invasive procedures that ensure precision and efficiency, thereby reducing patients' trauma. The industry players actively promote digital workflows for general dentistry and dental specialties. Further, dental 3D printers are revolutionizing dentistry. These reduce time and cost through efficient utilization of orthodontics and dental practices. Accordingly, going by the same report, this industry is projected to grow from $2.85 billion in 2021 to $10.04 billion in 2028 at a CAGR of 19.7% in the forecast period 2021-2028. Orthodontics players like Align Technology, SmileDirectClub and DENTSPLY SIRONA are likely to gain from the changing opportunities within the orthodontic space. Stocks to Watch Align Technology: In September 2022, Align introduced Invisalign Virtual Care AI, its next-generation remote monitoring solution with new artificial intelligence-assisted capabilities that streamline workflows for doctors and their staff. It has features like patient enrollment, setup, and review directly on the Invisalign Doctor Site without the need to use separate standalone solutions. Prior to this, the company announced its new Invisalign systems innovations for the Align Digital Platform. These latest innovations include ClinCheck Live Update for 3D controls, the Invisalign Practice App, Invisalign Personalized Plan, or IPP, and the Invisalign Smile Architect. In terms of 3D scanners, in the last-reported second quarter of 2022, the number of intraoral digital scans used for Invisalign case submissions reflected the continued adoption of digital scanners and a larger installed base. Total worldwide intraoral digital scan submitted to start an Invisalign case in Q2 increased to 88.4% from 82.2% in the year-ago period. SmileDirectClub: Realizing the enormous prospects of this space, SmileDirectClub has extended its teledentistry platform to dental and orthodontic offices through a collaborative model, designed specifically for dentists who currently do not offer an orthodontic product to patients, and an office-directed model, designed for orthodontists and dentists as a traditional in-office clear aligner product. The company is currently providing a doctor-directed digital end-to-end experience in teledentistry, with 24/7 access to orthodontic care and the back end of a lifetime smile guarantee. The company continues to see favorable industry dynamics with broader acceptance of telehealth and specifically, teledentistry. The company continues to see growth in the adoption and use of teledentistry by the dental and orthodontic industries. This is further boosted by the expansion of the company's professional partnerships and well-established and respected national DSOs, which demonstrate the adoption of telehealth by the dental community. DENTSPLY SIRONA: In a bid to revolutionize digital-implant workflow in dental care, DENTSPLY's single tooth replacement solution \u2014 Azento \u2014 needs special mention. It revolutionizes the digital implant workflow by restructuring implant-planning service, purchase and delivery. Management remains optimistic about the long-term potential of the company's digital dentistry and workflow management as it is well positioned with respect to the diagnostic expertise of its X-ray portfolio, which is critical for implants. DENTSPLY has been witnessing a rising trend in dental offices, upgrading from 2D to 3D units, which has also been observed in all global markets. In the last fiscal, digital diagnostic devices like Primescan, Axeos and Orthophos delivered solid growth. In three years, the company scaled its clear aligners from having no presence in the digital diagnostic space to a business that delivered $274 million in 2021. Why Haven't You Looked at Zacks' Top Stocks? Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 https://www.zacks.com Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks \""Terms and Conditions of Service\"" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release. Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They\u2019re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation. >>Show me how I could profit from the metaverse! Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Papa John's International, Inc. (PZZA): Free Stock Analysis Report SmileDirectClub, Inc. (SDC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Beaten-Down Stocks That Could Be Great Long-Term Buys Investing in equities during a downturn can be challenging. Not every beaten-down stock is worth investing in, and investors must spend time separating the wheat from the chaff. But the benefits can be enormous for those who pick the right companies. A bull market will come eventually, and if history is any guide, it will last longer than the current downturn, giving investors plenty of time to recoup the money they have lost recently. With that in mind, let's examine two stocks that have lagged the market this year but could be significant winners in the long run: HCA Healthcare (NYSE: HCA) and DexCom (NASDAQ: DXCM). HCA data by YCharts 1. HCA Healthcare Here's the thing about healthcare stocks -- medical services are always in demand. And with the world's aging population, the need for medical services will only increase. HCA Healthcare is one of the largest hospital chains in the U.S., with dozens of facilities spread out across the country -- although the company has an especially strong presence in Florida and Texas. Why has HCA been a loser in the market recently? First, it encountered pandemic-related issues. Occupancy levels in its facilities decreased during the worst of the outbreak, and physicians delivered fewer services to their patients -- two key ingredients for HCA Healthcare's top line. Second, the company's operating costs rose as a result of economic issues such as inflation and labor shortages. These issues have affected dozens of companies, including some of HCA Healthcare's competitors. But these problems will subside eventually. The trouble would be if HCA Healthcare was losing ground compared to other players in this market. The opposite seems to be true. The company's market share has increased from 26.5% in 2019 (before the pandemic hit) to about 28% as of earlier this year. In the second quarter, HCA Healthcare's revenue increased by about 2.7% year over year to $14.8 billion, not an unimpressive jump. The company's earnings per share (EPS) dropped by 10.6% year over year to $3.90. HCA Healthcare's results should improve as we move beyond the pandemic and it adjusts to the economic challenges we face. The company is great at attracting increasingly more physicians and patients onto its network, notably by pouring money into more and better clinical equipment that allows doctors to serve their patients' needs better. HCA Healthcare has made it a habit to grow its revenue, earnings, and market share in the past, and thanks to the growing healthcare sector, the company will almost certainly continue to do so. Investors only need to be patient and ride out the current storm with this healthcare giant. 2. DexCom DexCom is looking to serve the needs of another growing patient population: those with diabetes. According to estimates, about one American adult in three could be diabetic by 2050. Currently, 11.3% of the U.S. population is diabetic. One of the most critical tasks for diabetes patients is to keep track of their blood glucose levels. Blood glucose meters that use fingersticks come with severe limitations. First, they can be painful to use. Second, they can only read a patient's blood glucose level at one point in time. And, of course, they introduce the genuine possibility of human error. That's where DexCom comes in. The company offers alternative options known as continuous glucose monitoring (CGM) systems. CGM devices typically do away with (or at least substantially decrease) the need for fingersticks while continuously monitoring patients' blood glucose levels with up to 288 readings per day. In other words, CGM systems address the shortcomings of their main competition. DexCom currently makes most of its revenue from its G6 CGM device. Revenue growth rates have dropped for the company, though. DXCM Revenue (Quarterly YoY Growth) data by YCharts That partly explains the medical device's recent struggles. DexCom's revenue jumped by 17% year over year in the second quarter to $696.2 million. The company's EPS decreased to $0.12 from $0.19. DexCom's inconsistent profit growth is probably another reason the market hasn't been kind to the company lately. Thankfully, there are bright spots for DexCom. The company has already launched its next-gen device, the G7, in various parts of Europe. It is awaiting clearance in the U.S. The G7 helped diabetes patients achieve even better outcomes than the G6 in clinical trials. With the adoption of CGM systems on the rise, DexCom's next crown jewel should help it make even more headway. There is still plenty of potential demand within the current patient population, as the CGM market remains underpenetrated even in the U.S. And as already stated, this is a growing market, unfortunately. As one of the leaders in CGM devices, all those factors signal a strong future for DexCom. 10 stocks we like better than HCA Healthcare When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and HCA Healthcare wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and HCA Healthcare. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq Bear Market: 2 Top Stocks You Can Buy With $200 Right Now So far, this year has been a lousy one for investors who hold a lot of tech stocks. The Nasdaq Composite has tumbled a frightening 31% since the beginning of 2022, and nobody knows when the carnage will end. While it's been a difficult time to hold stocks, it's a great time to be a buyer. That's because, at times like these, the best stocks fall just as easily as ones that you should probably avoid in the first place. Image source: Getty Images. Every bear market in history has been wiped away by subsequent recovery periods. We don't know when the next rally will occur, but we can be fairly confident that these two stocks will come roaring back when it does. These stocks have been beaten down so far that a modest sum of just $200 is more than enough to buy shares of both. If you do have an extra $200 that you won't need to pay bills, and your emergency fund is adequate, these two look like smart buys to make right now. 1. Doximity Shares of Doximity (NYSE: DOCS) surged following its market debut in 2021. Unfortunately, it's fallen around 70% from its previous high-water mark. Doximity is a social media business specifically geared toward doctors and other healthcare professionals. It's also, in effect, a leading provider of telehealth services. In addition to a curated social media feed, Doximity operates a service called Dialer. The Dialer platform gives care providers a way to contact their patients' smartphones in a setting that complies with privacy laws. It's hyper-popular because physicians can use Doximity Dialer on their personal devices without sharing any personal contact information. Providing a social media experience tailored to the highly regulated medical field isn't just a neat idea. Doximity's already generating a sustainable and growing profit. During the company's fiscal first quarter ended June 30, 2022, net income more than doubled year over year to $22.4 million. Doximity's stock price is down now, but its position as the leading social media application for physicians is stronger than ever. The company's membership roster already includes around four out of five U.S. medical professionals. In these uncertain times, it's good to stick with businesses that can perform well in any economic condition. Investors have lots to be worried about, but we can be sure that physicians will continue doing their jobs even if the global economy sinks into a deep recession. 2. DexCom DexCom (NASDAQ: DXCM) stock surged to a new peak in 2021, but it's since fallen around 48% from that high-water mark. The stock's plunge has enticed some of the world's most famous investors, and it's not that hard to see why. DexCom makes continuous glucose-monitoring devices for diabetic patients, and there are a lot of patients to serve. The U.S. Centers for Disease Control and Prevention thinks there are around 37 million Americans living with diabetes right now. DexCom's new lead product, the G7, is a tiny transmitter that patients stick to their upper arms for 10 days before it needs to be replaced. Constantly communicating with patients' smartphones, the CGM helps patients keep their blood sugar levels in a safe range. The devices aren't cheap, but they're a lot less expensive than hospitalizations that occur due to poor blood sugar management. Healthcare plan sponsors eager to lower their diabetes-related expenses are driving up sales of the G7 in Europe, where regulators cleared the device this March. International sales soared 39% year over year in the second quarter. DexCom expects the U.S. Food and Drug Administration to grant the G7 clearance before the end of 2022. With a full-scale U.S. launch to drive growth, 2023 could be a very exciting year for this company and its stock price. 10 stocks we like better than Doximity, Inc. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Doximity, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Cory Renauer has positions in Doximity, Inc. The Motley Fool has positions in and recommends Doximity, Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Bull of the Day: DexCom, Inc. (DXCM) DexCom, Inc. DXCM is a medical device/wearables company focused on helping people monitor and manage their diabetes. DexCom\u2019s top-line growth has been stellar and its addressable market is massive considering how widespread diabetes is in the U.S. and elsewhere. DexCom shares got caught up in the post-covid lockdown growth-buying wave that began to unwind last fall. The glucose monitoring company is now trading at far more reasonable levels and DXCM shares have been trending upward since the middle of June. Now might be time for investors to add DexCom stock at these levels for long-term growth upside. Connected Health Revolution DexCom makes continuous glucose monitoring systems designed for people with diabetes. The San Diego, California-based firm allows people with diabetes the chance to place a small sensor just beneath their skin\u2014most often on their abdomens\u2014to help them continuously monitor their glucose levels. DexCom\u2019s readings and data come through on companion devices or via an app on compatible smartphones, smartwatches and other devices, including offerings from Apple, Google, and others. DexCom\u2019s systems have become widely popular because they don\u2019t require people to prick themselves throughout the day in order to measure their glucose levels. DexCom\u2019s internet-connected, data-sharing devices are also helpful because they enable family, friends, and healthcare providers to receive data remotely in order to help the users make the proper medical decisions. The company\u2019s continuous glucose monitoring or CGM systems are part of a connected health revolution that\u2019s still in the very early days and might be poised to be the standard form of medical care and treatment in the decades to come. DexCom\u2019s CGM monitors systems are more beneficial for patients, caregivers, and healthcare professionals compared to more traditional/old school blood glucose meters that check glucose levels at a single moment in time. Image Source: Zacks Investment Research Addressable Market and Growth The simple facts are on DexCom\u2019s side as diabetes becomes far more common in the U.S. Over 37 million Americans or about 1 in 10 have diabetes, while 1 in 3 or nearly 100 million Americans have \u201cprediabetes,\u201d according to the CDC\u2019s 2021 report. Worse still, diabetes is the 8th leading cause of death in the U.S. Rising diabetes rates, mostly type-2, is not just a U.S. problem, with roughly 540 million adults, or 1 in 10 people around the world living with diabetes. The International Diabetes Federation predicts that the number could climb to 645 million by 2030 and nearly 800 million by 2045. One of the nearby charts shows DexCom\u2019s strong revenue expansion over the past decade. The firm has averaged 34% sales growth in the past five years to climb from $719 million in 2017 to $2.5 billion in FY21. Zacks estimates call for DXCM to post another 18% revenue growth in FY22 and 21% higher in fiscal 2023 to hit $3.5 billion\u2014this is a case where the percentage change slowdown might cloud the fact that DexCom is set to add another $1 billion to its top line between 2021 and 2023. DexCom is still firmly investing in its growth. Yet, its adjusted earnings are projected to climb 18% this year and another 40% next year to come in at $1.10 per share. DXCM\u2019s upward earnings revisions help it land a Zacks Rank #1 (Strong Buy) right now. And the firm has topped EPS estimates for five years running outside of two recent misses. Image Source: Zacks Investment Research Price Performance and Valuation DexCom shares have skyrocketed roughly 2,300% in the past 10 years to blow away the S&P 500\u2019s 170% and its Zacks Medical Products Market\u2019s 25%. This run includes stretches of sideways movement and even drops. DXCM\u2019s outperformance has remained during the past five years. As we mentioned at the outset, the stock had tumbled off its November 2021 peaks alongside nearly every growth-focused stock. DXCM is trading around 45% below its records at around $91 per share and it still has 23% more room to run before it hits its current average Zacks price target. And the stock has already made a bit of a comeback off its mid-June lows, up over 30%. DexCom is hardly what anyone would call cheap, but Wall Street is buying it for stellar value. DXCM shares have been impacted by rising interest rates, with investors not willing to pay up as much for future earnings with rates off their rock-bottom levels. DXCM has, in turn, been recalibrated. Its forward PEG ratio (P/E ratio divided by its growth rate) is back at 2.6 vs. its recent highs of a whopping 41.9. These levels put the stock not too far off its industry\u2019s 2.2 despite its huge outperformance. Image Source: Zacks Investment Research Bottom Line DexCom might not be the safest near-term play amid the uncertainty about the interest rate environment. Still, investors with long-term outlooks might want to consider starting a position in the diabetes-focused connected medical products company for its long-term upside. DexCom should benefit from the growing prevalence of diabetes and it could possibly expand into new areas of the connected health world given its strong balance sheet and rising cash position. Plus, 12 of the 14 brokerage recommendations Zacks has are \u201cStrong Buys.\u201d Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They\u2019re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation. >>Show me how I could profit from the metaverse! Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-06,91.18,95.31,90.38,95.21,
DXCM,2022-10-07,103.63,105.33,100.11,102.14,"[""Why DexCom Stock Popped on Friday, Even as the Market Crumbled What happened Shares of DexCom (NASDAQ: DXCM) surged higher on Friday, rising as much as 10.6%. At the end of the trading day, the stock was still up 7.3%, even as the broader market indexes crumbled. The catalyst that sent the medical device maker higher was a pending decision by Medicare that could be a game changer. So what Piper Sandler analyst Matt O'Brien raised his price target on DexCom to $120, up from $110, while maintaining an overweight (buy) rating on the shares. This would represent a 17% gain compared to Thursday's closing price. The analyst cited a proposed local coverage determination (LCD) that appeared on the Centers for Medicare and Medicaid Services website. If finalized, it would provide coverage for basal insulin patients and others. O'Brien estimates this determination would expand the total addressable market for continuous glucose monitoring (CGM) for diabetes patients in the U.S. by two times, increasing the market by roughly $2 billion in domestic revenue. Furthermore, he posits that DexCom \""will reclaim its position as the highest multiple name in diabetes following this announcement.\"" Stifel analyst Mathew Blackman came to a similar conclusion, boosting his price target on DexCom to $120, up from $112, while maintaining a buy rating. He noted that the LCD \""appears to pave the way\"" for near-term CGM coverage for basal insulin users. He views the news as \""an unequivocally positive development\"" for DexCom and Abbott Laboratories (NYSE: ABT), its rival in the space. Now what A local coverage determination is a decision made by a Medicare Administrative Contractor regarding coverage of a specific item or service in its jurisdiction, based on whether it is considered \""reasonable and necessary.\"" It's worth noting that this is a proposal and not a final determination, and it will still be some time before a decision is reached. That said, this is no doubt a positive development for DexCom, which has long been one of the leading providers of CGM technology. Increasing the market by $2 billion would be a big deal, particularly in light of the fact that DexCom's full-year revenue in 2021 was roughly $2.5 billion. Investors shouldn't buy the stock solely based on this development, but there are plenty of other reasons to believe DexCom is a buy. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Danny Vena has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: AMD, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.3%. Year to date, DexCom has lost about 23.9% of its value. And the worst performing Nasdaq 100 component thus far on the day is Advanced Micro Devices, trading down 8.1%. Advanced Micro Devices is lower by about 56.7% looking at the year to date performance. Two other components making moves today are Marvell Technology, trading down 6.8%, and AstraZeneca, trading up 1.1% on the day. VIDEO: Nasdaq 100 Movers: AMD, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 10/07/2022: TLRY,TLRY.TO,CANO,DXCM Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.8% and the SPDR Health Care Select Sector ETF (XLV) down 1.9%. The Nasdaq Biotechnology index also was sinking 1.8%. In company news, Tilray Brands (TLRY) dropped over 17% after the medical marijuana company reported a non-GAAP net loss of $0.08 per share for its fiscal Q1 ended August 31, improving on a $0.13 per share adjusted loss during the same quarter last year but still missing the Capital IQ consensus looking for a $0.07 per share loss. Revenue fell 8.8% from year-ago levels to $153.2 million, also trailing the $156.9 million analyst mean. Cano Health (CANO) climbed 6.1% after a Bloomberg report that the primary care chain was in exclusive talks with CVS Health (CVS) about a potential takeover. The Wall Street Journal previously said CVS and Humana (HUM) have been considering making offers for Cano in a bid to bolster their primary-care operations, with Humana holding a right of first refusal on any sale under a 2019 agreement with Cano. CVS was sinking 9.8% this afternoon while Humana shares were fractionally higher. Dexcom (DXCM) rose 9.5% after Piper Sandler raised its price target for the medical device firm by $10 to $120 and reiterated its overweight stock rating, joining Stifel, which also increased its price target for Dexcom shares by $8 to $120 while keeping its buy rating for the continuous glucose monitors company. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Pre-market Movers: ATXI, NVIV, PRTC, IVA, ARBK\u2026 (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.30 A.M. ET). In the Green InVivo Therapeutics Holdings Corp. (NVIV) is up over 23% at $9.84 Inventiva S.A. (IVA) is up over 15% at $4.80 Aehr Test Systems (AEHR) is up over 13% at $15.79 DexCom, Inc. (DXCM) is up over 7% at $102.34 Credit Suisse Group AG (CS) is up over 7% at $4.61 BRC Inc. (BRCC) is up over 6% at $7.20 IDT Corporation (IDT) is up over 5% at $29.55 In the Red Avenue Therapeutics, Inc. (ATXI) is down over 54% at $2.86 PureTech Health plc (PRTC) is down over 18% at $25.41 Argo Blockchain plc (ARBK) is down over 14% at $3.55 Atlis Motor Vehicles, Inc. (AMV) is down over 6% at $22.86 Lantheus Holdings, Inc. (LNTH) is down over 5% at $70.79 Advanced Micro Devices, Inc. (AMD) is down over 5% at $63.95 Dingdong (Cayman) Limited (DDL) is down over 5% at $3.61 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-10,101.905,102.77,99.66,100.22,"[""Company News for Oct 10, 2022 Shares of Levi Strauss & Co. LEVI plummeted 11.7% after the company lowered its full year sales and profit projections owing to supply-chain issues and strong U.S. dollar. Shares of Advanced Micro Devices Inc. AMD plunged 13.9% after the company revealed disappointing third-quarter 2022 preliminary results with an expected revenue shortfall. DexCom Inc.\u2019s DXCM shares jumped 7.3% after the Centers for Medicare and Medicaid Services updated a local coverage determination related to glucose monitoring devices. Cano Health Inc.\u2019s CANO shares climbed 9.1% following news that CVS Health Corp. CVS is in exclusive talk to acquire the company. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Levi Strauss & Co. (LEVI): Free Stock Analysis Report Cano Health, Inc. (CANO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Soars 7.3%: Is Further Upside Left in the Stock? DexCom DXCM shares soared 7.3% in the last trading session to close at $102.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4% gain over the past four weeks. DexCom recorded a strong price increase after the Centers for Medicare and Medicaid Services (CMS) issued a proposed local coverage determination related to continuous glucose monitoring (CGM) devices last week. The CMS coverage currently applies to patients who take at least three doses of insulin a day. The proposal, which is yet to be finalized, will likely expand CGM use beyond the limited population. This is expected to provide a significant market opportunity to DexCom to serve a wider patient pool. Also, DexCom\u2019s latest announcement of the Dexcom G7 CGM System being now available for diabetics above the age of age two and above in the U.K., Ireland, Germany, Austria and Hong Kong raise optimism about the stock. This medical device company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $751.27 million, up 15.5% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For DexCom, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DXCM going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> DexCom belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, KORU Medical Systems Inc. KRMD, closed the last trading session 2.7% higher at $2.29. Over the past month, KRMD has returned -10.8%. For KORU Medical Systems Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.05. This represents a change of -150% from what the company reported a year ago. KORU Medical Systems Inc. currently has a Zacks Rank of #3 (Hold). 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report KORU Medical Systems Inc. (KRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-11,100.45,101.73,97.33,99.68,"2 Top Stocks to Buy in October and Hold Forever If you're looking for the best stocks to buy this month that you can hold in your portfolio -- and add to again and again -- you've come to the right place. While the stock market may be facing a turbulent environment at the moment, it's always a good time to invest in wonderful companies with great businesses that can generate prolonged portfolio returns. With the current state of the market, you're not alone if you're searching for investments that can provide a solid path to growth and whose products or services aren't prone to cyclicality or changes in consumer spending. Today, we're going to take a look at two such stocks which fit that bill. Let's dive in. 1. AbbVie: A no-brainer for income investors If you're not familiar with pharmaceutical giant AbbVie (NYSE: ABBV), you're likely familiar with one of its star products, Humira. The world's top-selling drug raked in $20.7 billion in revenue for the company in 2021 alone. Now, with patent exclusivity on the drug set to expire in the U.S. in 2023, you'll be glad to learn that Abbvie also has other highly lucrative products on which to rely for future revenue and profits. AbbVie's products focus on areas ranging from neuroscience to immunology to oncology to virology. In the second quarter alone, six of its top-selling products -- Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox Cosmetic, and Botox Therapeutic -- brought in respective revenues of $1.3 billion, $592 million, $1.1 billion, $505 million, $695 million, and $678 million. In total, the company's second-quarter revenue rose 5% year over year, while diluted earnings per share (EPS) jumped 21%. That follows revenue and diluted EPS growth of 23% and 137%, respectively, in 2021. Taking a step back and looking at the healthcare stock's financial performance over the much longer period of five years, the company has boosted its annual revenue, net income, and cash from operations by 100%, 117%, and 129%, respectively. Beyond the diverse streams of growth that AbbVie can tap into from its current portfolio, it also boasts an impressive pipeline of candidates that target diseases from rheumatoid arthritis to Alzheimer's to small cell lung cancer. AbbVie's wide-ranging portfolio and robust financials tick multiple boxes for healthcare investors, but that's not all the stock has to offer. There's also its dividend, which currently yields 4.1%. One final note: the Dividend King has delivered a total return of 93% for investors over the past five years alone. That leaves the S&P 500's total return of 56% in the same period well and truly in the dust. 2. DexCom: A market leader with a record of growth According to the Centers for Disease Control and Prevention, nearly one in 10 Americans has diabetes. That's more than 37 million people in the U.S. alone. For many people with diabetes, a continuous glucose monitoring (CGM) device is a daily part of life, and in some cases, can truly make the difference between life and death. DexCom (NASDAQ: DXCM) is one of the top companies in the world that develops and makes CGM devices. Its leadership in the CGM market is no small feat -- this is a space that's on track to hit a global valuation of $13.2 billion by 2028, according to Vantage Market Research. DexCom has had incredible success with its flagship product, the G6 CGM system. The rollout of the next version, the G7 -- which is billed as 60% smaller than the G6 and features a faster sensor -- is expected in the U.S. soon and is already underway in multiple international markets including the U.K., Ireland, Germany, Austria, and Hong Kong. In the most recent quarter, DexCom's revenue increased 17% from the year-ago period, while U.S. revenue jumped 11% and international revenue growth surged 39%. The company is also profitable, reporting $50.9 million in net income for the three-month period. The company had $2.8 billion in cash, cash equivalents, and marketable securities on its balance sheet at the end of the quarter. Looking back over the past five years, DexCom has grown its annual revenue and net income by 66% and 53%, respectively. It's also delivered a total return of 255% during that period, more than four times that of the S&P 500 during the same window. DexCom's continued leadership in the CGM device market, despite growing competition, provides a compelling path forward to growth. Long-term investors can capitalize on this and reap the rewards of its success. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Rachel Warren has positions in AbbVie and DexCom. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-12,100.68,100.92,97.54,98.32,
DXCM,2022-10-13,95.41,103.41,94.65,101.72,"Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks. What if you'd invested in DexCom (DXCM) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today? DexCom's Business In-Depth With that in mind, let's take a look at DexCom's main business drivers. San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom’s monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company’s monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels. Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024. 2021 at a Glance For the full-year 2021, the company reported adjusted EPS of $2.66, down 14.2% from 2020. Full-year 2021 revenues came in at $2.45 billion, up 27% year over year. Sensor & other revenue were $2.07 billion (84% of net revenues). Hardware revenues were $383.2 million (16% of net revenues). Highlights The first quarter of 2021 marked the company’s seventh consecutive quarter of revenue growth of $100 million or more. Moreover, the company witnessed about 40% global unit volume growth in the quarter, thereby indicating sustained customer growth in the business. Bottom Line Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For DexCom, if you bought shares a decade ago, you're likely feeling really good about your investment today. According to our calculations, a $1000 investment made in October 2012 would be worth $28,917.65, or a gain of 2,791.76%, as of October 13, 2022, and this return excludes dividends but includes price increases. In comparison, the S&P 500 gained 150.39% and the price of gold went up -8.27% over the same time frame. Analysts are anticipating more upside for DXCM. DexCom exited second-quarter 2022 on a mixed note, wherein earnings meet the Zacks Consensus Estimate, but revenues beat the same. Impressive contribution from the Sensor segment, and domestic and international revenue growth were key catalysts. DexCom’s prospects in alternative markets bode well. The company made continued advancements with respect to key strategic objectives and ended the quarter with new patient additions. Its slew of tie-ups and buyouts are encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. However, the company faces stiff competition in the market for blood & glucose monitoring devices. Reimbursement risk and supply constraints are other headwinds. Over the past six months, DexCom has underperformed its industry. The stock is up 8.56% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2022. The consensus estimate has moved up as well. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-14,102.81,103.97,97.26,97.41,
DXCM,2022-10-17,99.41,101.6,98.24,99.73,
DXCM,2022-10-18,102.31,103.13,96.06,96.93,"Tuesday Sector Laggards: Healthcare, Energy Looking at the sectors faring worst as of midday Tuesday, shares of Healthcare companies are underperforming other sectors, higher by 1.1%. Within that group, Moderna Inc (Symbol: MRNA) and DexCom Inc (Symbol: DXCM) are two of the day's laggards, showing a loss of 4.3% and 2.7%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.7% on the day, and down 9.00% year-to-date. Moderna Inc, meanwhile, is down 47.55% year-to-date, and DexCom Inc, is down 27.69% year-to-date. Combined, MRNA and DXCM make up approximately 1.8% of the underlying holdings of XLV. The next worst performing sector is the Energy sector, higher by 1.2%. Among large Energy stocks, ConocoPhillips (Symbol: COP) and APA Corp (Symbol: APA) are the most notable, showing a loss of 0.4% and 0.3%, respectively. One ETF closely tracking Energy stocks is the Energy Select Sector SPDR ETF (XLE), which is up 0.9% in midday trading, and up 52.00% on a year-to-date basis. ConocoPhillips, meanwhile, is up 68.80% year-to-date, and APA Corp is up 50.07% year-to-date. Combined, COP and APA make up approximately 5.6% of the underlying holdings of XLE. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, nine sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Materials +2.3% Industrial +2.2% Utilities +2.0% Services +1.8% Technology & Communications +1.5% Financial +1.4% Consumer Products +1.3% Energy +1.2% Healthcare +1.1% 25 Dividend Giants Widely Held By ETFs » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-19,95.69,97.1,94.59,96.84,"Ready to Buy the Dip? This Healthcare Stock Is a Smart Buy This bear market may not exactly put you in the mood for investing. But now is actually a great time to scoop up shares of solid companies. Why? Because many are trading at a discount. Yet their long-term outlooks remain bright. This is the case for DexCom (NASDAQ: DXCM). The company specializes in continuous glucose monitoring (CGM) systems. The business is doing well today -- and is set to keep on growing. At the same time, DexCom shares have dropped 25% this year. So, if you're ready to buy the dip, this stock is one to consider. Let's take a closer look at why you may want to add DexCom to your portfolio. Three systems to monitor blood sugar DexCom sells the G6, G7, and DexCom One CGM systems to diabetes patients so they can keep track of their blood sugar levels. These systems are efficient because a sensor implanted just under the skin monitors levels on a continual basis. And they're easy for users because, unlike finger-stick testing, they don't involve pricking a person's finger with a needle. The G6 and G7 offer a full suite of capabilities such as sharing readings with others -- for instance, a family member or friend. The DexCom One is a simpler, less expensive option for those who don't need all of the elements offered by the G6 and G7. This allows DexCom to reach a wide range of people living with diabetes -- as well as others who need to monitor their blood sugar levels. DexCom's G6 is available in the U.S. And the company aims to launch the updated G7 -- already available in several other countries -- in the U.S. in the first quarter of next year. As for DexCom One, the company recently rolled out the product in the U.K. and Spain. And DexCom has partnered with big pharma company Roche to distribute the DexCom One in Italy. Over time, DexCom has demonstrated its ability to generally grow revenue and free cash flow. And the share price has followed. DXCM Revenue (Annual) data by YCharts. The resources to grow Today, as the company launches the G7 and DexCom One in various countries, it has the resources it needs to grow. DexCom reported $2.75 billion in cash and equivalents in the second quarter. And it hasn't drawn on its revolving credit facility. For the full year, DexCom predicts revenue in the range of $2.86 billion to $2.91 billion. That represents year-over-year growth of 17% to 19%. Here's why I'm optimistic DexCom can achieve this growth and more over time. First, things are looking good when it comes to attracting users. In the second quarter, DexCom reached record quarterly new customer additions. And in DexCom One's first 60 days of sales in Bulgaria, Estonia, Latvia, and Lithuania, more than 1% of the insulin intensive population paid out of pocket for access to the product. Since, those countries have each set up partial or full reimbursement for type 1 diabetes. At the same time, diabetes is a growing problem worldwide. About 537 million adults live with diabetes. And this number is expected to rise to 643 million by 2030. Room for more than one success story DexCom's big competitor is Abbott Laboratories. That company makes the popular Freestyle Libre CGM system. But that's just one product among Abbott's diversified portfolio of medical devices and other businesses. DexCom could maintain strength in the market through its specialization in CGM systems. There's room for more than one company to win in this market. DexCom's shares have slipped just a bit more than the S&P 500 Index this year. I don't see this decline as a reflection of the company's outlook. Instead, it looks like the stock has followed the general market movement. The stock may not rebound overnight. But the company has what it takes to spur stock performance over time. I'm thinking about the growth opportunities for DexCom just ahead and farther into the future. So it could be a very good idea to buy this innovative player right now -- on the dip. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-20,95.93,97.45,93.79,94.36,"[""AFLAC Moves Up In Market Cap Rank, Passing DexCom In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, AFLAC Inc (Symbol: AFL) has taken over the #188 spot from DexCom Inc (Symbol: DXCM), according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much \u2014 that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true \""apples-to-apples\"" comparison of the value of two stocks. In the case of AFLAC Inc (Symbol: AFL), the market cap is now $37.38 billion, versus DexCom Inc (Symbol: DXCM) at $37.04 billion. Below is a chart of AFLAC Inc versus DexCom Inc plotting their respective size rank within the S&P 500 over time (AFL plotted in blue; DXCM plotted in green): Below is a three month price history chart comparing the stock performance of AFL vs. DXCM: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers \u2014 much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and \""tosses out\"" the biggest 100 companies so as to focus solely on the 400 smaller \""up-and-comers\"" (which in the right environment can outperform their larger rivals). So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at The Online Investor find value to putting together these rankings daily. Examine the full AFL market cap history vs. the full DXCM market cap history. At the closing bell, AFL is down about 1.6%, while DXCM is off about 2.6% on the day Thursday. The 20 Largest U.S. Companies By Market Capitalization \u00bb The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is a Beat Likely for DexCom (DXCM) This Earnings Season? DexCom, Inc. DXCM is scheduled to release third-quarter 2022 results on Oct 27, after the closing bell. In the last reported quarter, the company\u2019s earnings met the Zacks Consensus Estimate. Its earnings missed the Zacks Consensus Estimate in two of the trailing four quarters, beat once and met the same once, the average negative surprise being 3.35%. Q3 Estimates Currently, the Zacks Consensus Estimate for third-quarter revenues is pegged at $752.67 million, suggesting growth of 15.8% from the year-ago reported figure. The consensus mark for earnings stands at 24 cents per share, indicating an improvement of 9.1% from the prior-year quarter. Factors to Note DexCom\u2019s third-quarter top line is likely to have been aided by an increase in volume, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). Potential robust contributions from the Sensor segment and domestic and international revenue growth are likely to be the key catalysts for third-quarter results. During the first half of 2022, the company continued making progress with respect to its objective of expanding access and accelerating its leadership in CGM-connected solutions and customer choice. DexCom launched the Dexcom ONE product in the United Kingdom and Spain during the second quarter. These developments are likely to have benefited customer growth during the soon-to-be-reported quarter. In March 2022, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. During the first quarter, DexCom secured the CE mark for the Dexcom G7 CGM System for monitoring people with diabetes aged two years and older and also initiated a limited launch of the system in Europe. DexCom expanded coverage for Dexcom CGM to include type 1 diabetes in Ontario, Canada during the first quarter. Moreover, TRICARE added Dexcom G6 as a brand-name formulary pharmacy benefit. These developments may have favored the company\u2019s performance in the to-be-reported quarter. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote DexCom has been benefiting from demographic trends and lifestyles in countries outside the United States and Europe . Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In second-quarter 2022, international revenues (27% of total revenues) surged 39% year over year to $185.2 million. The momentum is likely to have continued in the third quarter, thanks to broad-based growth. The Zacks Consensus Estimate for U.S. and International revenues is pegged at $552 million and $197 million, respectively, for the third quarter. However, an increase in operating expenses and intense competition may have weighed on the to-be-reported quarter\u2019s performance. Earnings Beat Likely Our proven model predicts an earnings beat for DexCom this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (26 cents per share) and the Zacks Consensus Estimate (24 cents per share), is +7.00%. Zacks Rank: DexCom sports a Zacks Rank #1. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Other Stocks Worth a Look Here are some medical stocks worth considering as these also have the right combination of elements to post an earnings beat this quarter. Baxter International BAX has an Earnings ESP of +1.31% and a Zacks Rank of 3. Baxter\u2019s stock has declined 27.5% so far this year. BAX missed earnings estimates in the last reported quarter. Baxter has a four-quarter earnings surprise of 6.15%, on average. McKesson MCK has an Earnings ESP of +0.27% and a Zacks Rank of 2. McKesson\u2019s stock has gained 41.9% so far this year. MCK beat earnings estimates in the last reported quarter. McKesson has a four-quarter earnings surprise of 13.00%, on average. AmerisourceBergen ABC has an Earnings ESP of +0.61% and a Zacks Rank of 3. AmerisourceBergen\u2019s stock has gained 5.8% so far this year. ABC topped earnings estimates in the last reported quarter. AmerisourceBergen has a four-quarter earnings surprise of 2.63%, on average. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards? Baxter International Inc. BAX is scheduled to release third-quarter 2022 results on Oct 27, before the opening bell. In the last reported quarter, the company delivered a negative earnings surprise of 1.14%. Its earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 6.15%. Q3 Estimates Currently, the Zacks Consensus Estimate for third-quarter revenues is pegged at $3.77 billion, indicating an improvement of 17% from the prior-year period. The consensus mark for earnings stands at 82 cents per share, suggesting a decline of 19.6% from the year-ago quarter. Factors to Note Baxter anticipates total revenues to grow by mid-teen percentage points year over year in the third quarter. However, excluding unfavorable currency impact, sales are likely to grow by mid-20s percentage points. The recovery in rates of hospital admissions is likely to have continued in the third quarter, driving sales of Baxter\u2019s Medication Delivery segment. Moreover, a continued rise in elective surgical procedures is likely to have fueled strong growth in Advanced Surgery sales. The Zacks Consensus Estimate for Medication Delivery segment and Advanced Surgery segment is pegged at $715 million and $261 million, respectively, for the third quarter. However, Renal Care segment sales declined in the first half of 2022 and the trend is likely to have continued in the third quarter. The Zacks Consensus Estimate for the segment stands at $962 million. The company has multiple collaborations to help manufacture COVID-19 vaccines. However, sales growth of the BioPharma Solutions segment is likely to have been hurt by challenging year-over-year comparisons resulting from prior-year COVID-related sales. Sales at Acute Therapies segment is also likely to have faced a similar impact in the soon-to-be-reported quarter. The Zacks Consensus Estimate for the BioPharma Solutions segment and the Acute Therapies segment is pegged at $178 million and $179 million, respectively. Baxter International Inc. Price and Consensus Baxter International Inc. price-consensus-chart | Baxter International Inc. Quote Sales of the Pharmaceutical segment are likely to have been hurt by generic competition for certain molecules and supply constraints that impacted product availability. The Zacks Consensus Estimate for the segment stands at $584 million. In the second quarter, Americas and EMEA of the company\u2019s global regions performed weakly, hurt by unfavorable currency movements. In the Americas, Baxter reported revenues of $1.65 billion, up 1%. In EMEA, revenues totaled $738 million, down 6% from the year-ago quarter. In APAC, revenues of $647 million were down 6% year over year. The trend is likely to have continued in the soon-to-be-reported quarter. Meanwhile, three new product categories added with the Hillrom buyout in December last year are likely to have brought additional sales during the third quarter. These product categories generated $715 million in the second quarter. Earnings Beat Likely Our proven model predicts an earnings beat for Baxter this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (83 cents per share) and the Zacks Consensus Estimate (82 cents per share), is +1.31%. Zacks Rank: Baxter carries a Zacks Rank #3. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Other Stocks Worth a Look Here are some medical stocks worth considering as these also have the right combination of elements to post an earnings beat this quarter. DexCom DXCM has an Earnings ESP of +7.00% and a Zacks Rank of 1. DexCom\u2019s stock has declined 27.5% so far this year. DXCM missed earnings estimates in the last reported quarter. DexCom delivered a four-quarter negative earnings surprise of 3.35%, on average. McKesson MCK has an Earnings ESP of +0.27% and a Zacks Rank of 2. McKesson\u2019s stock has gained 41.9% so far this year. MCK beat earnings estimates in the last reported quarter. McKesson came up with a four-quarter earnings surprise of 13.00%, on average. AmerisourceBergen ABC has an Earnings ESP of +0.61% and a Zacks Rank of 3. AmerisourceBergen\u2019s stock has gained 5.8% so far this year. ABC topped earnings estimates in the last reported quarter. AmerisourceBergen delivered a four-quarter earnings surprise of 2.63%, on average. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 27, 2022, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This medical device company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $752.67 million, up 15.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.79% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for DexCom? For DexCom, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +7%. On the other hand, the stock currently carries a Zacks Rank of #1. So, this combination indicates that DexCom will most likely beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that DexCom would post earnings of $0.17 per share when it actually produced earnings of $0.17, delivering no surprise. Over the last four quarters, the company has beaten consensus EPS estimates just once. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. DexCom appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. An Industry Player's Expected Results Another stock from the Zacks Medical - Instruments industry, Integra LifeSciences (IART), is soon expected to post earnings of $0.74 per share for the quarter ended September 2022. This estimate indicates a year-over-year change of -14%. Revenues for the quarter are expected to be $380.64 million, down 1.6% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Integra has been revised 0.8% down to the current level. Nevertheless, the company now has an Earnings ESP of 2.70%, reflecting a higher Most Accurate Estimate. When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Integra will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-21,94.18,96.74,91.62,95.68,"Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money If you're investing in the stock market right now, you know how challenging an environment it's been for investors of all trading styles lately. Whether you gravitate toward growth-oriented stocks, value stocks, or a mixture of both, few companies have been spared the volatility hitting the broader markets. At the same time, great companies with fantastic businesses that can ride out the storm to the other side continue to make themselves known. If you have $1,000 to invest in the stock market right now, here are three great companies you may want to consider for your buy list. 1. DexCom DexCom (NASDAQ: DXCM) may not be a household name, but the products and services the company provides are not only constantly in demand but in many cases are lifesaving for its customers. DexCom manufactures and sells continuous glucose monitoring (CGM) devices and has maintained a leading share of this market through the years. These devices are used primarily by individuals with type 1 diabetes. In the U.S. alone, there are roughly 1.5 million individuals who have been diagnosed with type 1 diabetes. Beyond the broad cohort of potential users with type 1 diabetes that can continue to benefit from DexCom's products and services, CGM adoption by type 2 diabetics is another key area for growth that is yet largely untapped. Case in point: A recent study conducted by a diabetes management platform called One Drop found that 90% of participants know about CGM devices and are open to potentially using them, but an eye-popping 83% had still never leveraged this kind of technology. When you consider that type 2 diabetics comprise upwards of 95% of all diabetes cases in the U.S. alone, the prospects for growth in this market are absolutely exponential. DexCom recorded a solid 2021 with revenue up 27% overall to about $2.5 billion. International markets were particularly strong, surging 44% vs. a gain of 23% in the U.S. In the latest quarter, the company reported a 17% increase in overall revenue over the year-ago period. With DexCom's broad grip on the global CGM market -- and the much-anticipated released of its new and improved CGM system, the G7 -- the future continues to look bright for this innovative company. At its current share price, a $1,000 investment would get you about 10 shares of DexCom. 2. Lululemon Lululemon Athletica (NASDAQ: LULU) may not be the first company that comes to mind if you're thinking to invest in the stock market in the current environment. And if Lululemon were a typical apparel brand, given fears of a recession and the current macroeconomic state of things, I might be inclined to agree. One of the key defining factors about Lululemon that sets it apart from your average retail stock is the specific industry in which the company operates. Athleisure is a multibillion-dollar market in which Lululemon remains at the forefront. The point of athleisure is that you can wear these items from the gym to home to the store to anywhere in between. This versatility lends a certain level of non-cyclicality to the demand a company like Lululemon faces. Bear in mind that the global athleisure market hit a stunning valuation of $411 billion last year. By 2028, it's estimated that this market will realize a valuation of $793 billion. Lululemon's continued expansion of its brick-and-mortar as well as online footprints -- the company opened 53 net new stores in 2021 alone and recently launched a new e-commerce site and stores in Spain -- coupled with its execution of targeted plans to realize future growth are all green flags for this growth stock. Earlier this year, Lululemon announced its five-year growth plan to double its 2021 revenue to $12.5 billion by the year 2026. Considering that the company did exactly that from 2018 to 2021 -- reporting annual revenue of $3.3 billion at the beginning of that period and closing with $6.3 billion at the end of the period -- this isn't a far-flung goal for Lululemon to achieve. Its fast-growing digital and in-store presences, along with its expansion into men's athleisure -- a segment for which it hit its targeted growth goals two years ahead of schedule -- all bode well for the future of this stock. At its current share price, a $1,000 investment would leave you with about three shares of Lululemon. 3. Airbnb Airbnb (NASDAQ: ABNB) is a marketplace for matching travelers with homeowners who want to rent out their space -- and it's a stock I write about often. As one who isn't particularly thrilled by the travel sector as an investment space in general, that should emphasize just how much faith I have in Airbnb's ability to realize tremendous growth. Any way you slice it, Airbnb simply isn't your average travel stock. While this business isn't totally impervious to the global factors that have impacted the travel industry in recent years, Airbnb's recovery and ever-expanding market share have revealed that it simply doesn't respond the same way that other travel stocks do to the forces of cyclicality, macroeconomic factors, and the changing habits of travelers as a whole. In a recent interview with Quartz magazine, Airbnb's co-founder and chief strategy officer, Nate Blecharczyk, laid out why the company is built to withstand a recession and beyond -- should one hit. He noted that not only was Airbnb launched at the beginning of the Great Recession, but that the platform could have a particular draw for individuals seeking to generate an extra source of income in a tough economic environment now as it did then. Blecharczyk also noted that for travelers, the ability to find accommodation for any budget in a wide range of areas would continue to have appeal -- even if these economic concerns become a reality in the near future -- and that people will still want to get away for trips even if a recession does hit. This train of thought certainly bears up if you look at Airbnb's recent financial reports. Even as record-high inflation and virtually endless talk of a recession persist, Airbnb has continued to expand its market share, all while reporting superior business growth. Revenue and nights/experiences booked on the platform shot up 73% and 24%, respectively, in the most recent quarter compared to the same period in 2019. It was also the most profitable second quarter Airbnb has ever had, with net income totaling $379 million for the three-month period. Plus, long-term rather than short-term travelers continue to rank as Airbnb's fastest-growing cohort of customers. In the most recent quarter alone, long-term stays of 28 days or more were up a whopping 90% from the same quarter in 2019. At its current share price, a $1,000 investment in Airbnb would give you about eight shares. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Airbnb, Inc. and Lululemon Athletica. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-24,96.325,99.27,94.85,98.97,"DexCom Moves Up In Analyst Rankings, Passing Horton In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, DexCom Inc (Symbol: DXCM) has taken over the #45 spot from Horton Inc (Symbol: DHI), according to ETF Channel. Below is a chart of DexCom Inc versus Horton Inc plotting their respective rank within the S&P 500 over time (DXCM plotted in blue; DHI plotted in green): Below is a three month price history chart comparing the stock performance of DXCM vs. DHI: DXCM is currently trading up about 1.4%, while DHI is up about 0.7% midday Monday. Favorites » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-10-25,99.305,102.77,99.305,100.95,
DXCM,2022-10-26,101.54,104.796,101.255,102.61,"[""Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More This earnings season so far has reflected a strong revenue momentum for companies within the Medical sector. Earnings have also increased year over year, albeit, at a slower pace than revenues. Inflationary headwinds, supply chain challenges and labor shortages however continued for the sector, hurting the bottom line amid recovering demand for medical products and services. Per the latest Earnings Preview, 8.9% of the companies in the Medical sector, comprising 29.8% of the sector\u2019s market capitalization, reported earnings till Oct 19. Of these, 80% beat earnings estimates while all of them surpassed revenue estimates. Earnings increased 3.8% year over year on 8.9% higher revenues. This scorecard highlights the Medical sector\u2019s continued resilience amid an uncertain macroeconomic environment. Throughout the third quarter, most players in the industry were reeling under the greater-than-anticipated surge in inflationary pressure across the world. Mounting raw material costs, labor-supply constraints and supply-chain disruptions hampered the entire production and distribution process. Despite the challenging situation, the consistent opening up of economies, with countries lifting COVID-19 restrictions, might have favored the growth process in Q3. Overall, third-quarter earnings of the Medical sector are expected to decline 7.6%, while sales are expected to increase 3.8%. This compares with the second-quarter reported earnings growth of 6.5% and revenue growth of 9.9%. Medical Device Quarterly Synopsys Integral to the broader Medical sector, the Medical Device companies\u2019 collective business growth is likely to have recorded an improvement compared with the last year, with a significant reduction in COVID-led fatality across the United States and other developed countries. Added to this, notable Medical Device players have been undertaking consistent efforts to mitigate staffing shortages that have disrupted business growth since the pandemic\u2019s beginning. These factors are likely to have been advantageous for the base businesses of the Medical Device stocks. Yet, Medical Device companies continue to be burdened by the global shortage of semiconductors chips that produce life-saving medical equipment like pacemakers, blood-pressure monitors, insulin pumps and defibrillators. This ongoing challenge is expected to have significantly hampered performance across several businesses in the Medical Device industry in Q3. Overall, the rebound in the base business through the months of the third quarter is expected to have been impressive. Medical Device companies like Laboratory Corporation of America Holdings LH or LabCorp, Bio-Rad Laboratories, Inc. BIO, Baxter International BAX, DexCom DXCM and West Pharmaceutical Services WST are likely to have been positively influenced by the abovementioned factors in Q3, despite continuing challenges in the macroeconomic front. Let\u2019s take a look at the Medical Device players scheduled to announce results on Oct 27. LabCorp: LabCorp has been registering an ongoing sales rebound in the base business for both Diagnostics and Drug Development segments. However, as the severity of the pandemic has declined, we expect the demand for COVID-19 testing services and vaccines to have been lower than the year-ago period, impacting the third-quarter sales performance. Added to this, the ongoing inflationary pressure, a strengthening U.S. dollar and supply chain issues are expected to have adversely impacted LabCorp\u2019s third-quarter performance (Read more: LabCorp to Report Q3 Earnings: What's in the Cards?) Per our proven model, a stock with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates. LH has an Earnings ESP of -1.41% and carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Laboratory Corporation of America Holdings Price and Consensus Laboratory Corporation of America Holdings price-consensus-chart | Laboratory Corporation of America Holdings Quote Bio-Rad: Bio-Rad\u2019s Life Science segment has been registering robust revenue growth over the past few quarters. We expect this growth momentum to have continued in the third quarter on the back of sustained sales gains in the company\u2019s Polymerase Chain Reaction (PCR), Droplet Digital PCR (dPCR), Process Media businesses and Western Blot. The company has also been witnessing strong growth in the biopharma market for the Droplet Digital PCR platform, which is expected to have made significant contributions to the third-quarter top line. However, due to the Russia-Ukraine war situation, supply chain constraints are likely to have impacted instrument placements. (Read more: Bio-Rad to Report Q3 Earnings: What's in the Cards?) BIO has an Earnings ESP of 0.00% and a Zacks Rank #3. BioRad Laboratories, Inc. Price and Consensus BioRad Laboratories, Inc. price-consensus-chart | BioRad Laboratories, Inc. Quote Baxter International: Increased demand for acute therapies products due to the resurgence of COVID-19 and continuous renal replacement therapies, devices and associated consumables are likely to have driven Baxter\u2019s Acute Therapies business\u2019 third-quarter 2022 performance. The company\u2019s robust product portfolio and the planned launch of therapies and products are expected to have impacted the to-be-reported quarter\u2019s revenues. However, the sales growth of the BioPharma Solutions segment is likely to have been hurt by challenging year-over-year comparisons, resulting from prior-year COVID-related sales. (Read more: Baxter to Report Q3 Earnings: Is a Beat in the Cards?) Baxter has a Zacks Rank #4 (Sell) and an Earnings ESP of +1.31%. Baxter International Inc. Price and Consensus Baxter International Inc. price-consensus-chart | Baxter International Inc. Quote DexCom: DexCom\u2019s third-quarter 2022 top line is likely to have been impacted by an increase in volume, courtesy of new patients across all channels and rising global awareness regarding the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). DexCom launched the Dexcom ONE product in the United Kingdom and Spain during the second quarter. These developments are likely to have benefited customer growth during the soon-to-be-quarter. In March, the company\u2019s received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. DexCom has been benefiting from demographic trends and lifestyles in countries outside the United States and Europe. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. These developments may have favored the company\u2019s performance in the to-be-reported quarter. (Read more: Is a Beat Likely for DexCom This Earnings Season?) DexCom has an Earnings ESP of +7.00% and a Zacks Rank #3. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote West Pharmaceutical Services: West Pharmaceutical\u2019s Proprietary Products business continues to exhibit sustained strength and has been an important contributor to the company\u2019s top-line growth. In the first half of 2022, sales improved significantly on the back of double-digit growth in high-value products (HVP). The trend is likely to have continued in the third quarter. Apart from this, the company is likely to have witnessed margin expansion in the aforementioned segment in the to-be-reported quarter, owing to a favorable mix of products sold (stemming from the demand in HVP), production efficiencies and higher sales price. However, the company\u2019s business is exposed to foreign currency exchange rate fluctuations, which is likely to have adversely impacted the company\u2019s third-quarter performance. (Read more: What's in Store for West Pharmaceutical in Q3 Earnings?) West Pharmaceutical Services has an Earnings ESP of -1.51% and a Zacks Rank #4. West Pharmaceutical Services, Inc. Price and Consensus West Pharmaceutical Services, Inc. price-consensus-chart | West Pharmaceutical Services, Inc. Quote Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioRad Laboratories, Inc. (BIO): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should You Buy Dexcom (DXCM) Ahead of Earnings? Investors are always looking for stocks that are poised to beat at earnings season and Dexcom, Inc. DXCM may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Dexcom is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings \u2014 with the most up-to-date information possible \u2014 is a pretty good indicator of some favorable trends underneath the surface for DXCM in this report. In fact, the Most Accurate Estimate for the current quarter is currently at 26 cents per share for DXCM, compared to a broader Zacks Consensus Estimate of 24 cents per share. This suggests that analysts have very recently bumped up their estimates for DXCM, giving the stock a Zacks Earnings ESP of +7.00% heading into earnings season. DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here). Given that DXCM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Clearly, recent earnings estimate revisions suggest that good things are ahead for Dexcom, and that a beat might be in the cards for the upcoming report. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-27,102.18,103.25,99.33,101.25,"[""DexCom (DXCM) Q3 2022 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q3 2022 Earnings Call Oct 27, 2022, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Hello, and welcome to the Dexcom third-quarter 2022 earnings release conference call. My name is Michelle, and I will be your operator for today's conference. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator instructions] As a reminder, today's conference is being recorded. I will now turn the call over to Mr. Sean Christensen. Sir, you may begin. Sean Christensen -- Head of Investor Relations Thank you, operator, and welcome to Dexcom's third-quarter 2022earnings call Our agenda begins with Kevin Sayer, Dexcom's chairman, president, and CEO, who will summarize our recent highlights and ongoing strategic initiatives; followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. Following our prepared remarks, we'll open the call up for your questions. At that time, we ask analysts to limit themselves to one question, so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter performance on the Dexcom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to Dexcom and are subject to various risks and uncertainties. And actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third-quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us today. Today, we reported another strong quarter for Dexcom with third-quarter organic revenue growth of 20% compared to the third quarter of 2021. Our teams executed incredibly well as we work to advance our strategic initiatives while preparing for the largest product launch in our company's history. In the U.S., we saw continued momentum after our strong second quarter new customer starts with ongoing loyalty among endocrinologists and growing traction with primary care physicians. We are finding these physicians eager to engage with our teams as they learn more about the clinical benefits and superior outcomes that Dexcom CGM can provide their patients. While we expect these primary care relationships to be critical to our long-term customer aspirations, they also help us better serve the intensive insulin-using population in the U.S. today. The domestic core market still has a long runway of growth ahead as we expect the vast majority of the population to adopt CGM to help them better manage their health. Outside the U.S., our team continued to deliver customer access wins this quarter. One example, in August, the NHS announced the inclusion of Dexcom ONE on prescription via the England, Wales, Scotland, and Northern Ireland drug tariff for everyone with type 1 diabetes and type 2 intensively managed diabetes. This announcement meaningfully expanded access to Dexcom within these markets as our previous reimbursement was generally limited to a smaller population of higher-risk individuals. Importantly, this is a clear example of how we can leverage our portfolio strategy to reach many more people with diabetes across the globe. Whether we use Dexcom ONE to enter new geographies or to improve access within existing markets, there is a large opportunity to expand our reach. In many cases, these are segments of the market that have lacked product choice for customers. So, providing Dexcom's leading real-time CGM solution is being welcomed enthusiastically from customers and health systems alike. As many of you have seen, we were also very excited to initiate our full OUS launch of G7 following a successful limited launch. G7 is now available in the United Kingdom, Ireland, Germany, Austria, and Hong Kong. We have been looking forward to this day for a long time as we view G7 is not only a major step forward for Dexcom but for the entire diabetes technology market. This is a game-changing launch. As we often say, G7 takes everything about G6 and makes it better. It has a 60% smaller form factor, 30-minute warm-up time, 12-hour grace period to allow customers to choose a convenient time to change sensors, an improved app experience, and more. All of this while building upon the product performance and accuracy that has earned the trust of our customers and clinicians. These advancements were specifically designed to improve the lives of our customers, and that is being recognized by our earliest G7 users. The feedback from our launch has been incredibly positive, which adds to our confidence that this product will take Dexcom to the next level. We are moving quickly to make this life-changing technology available broadly around the world, and we'll be rolling out G7 across a steady cadence of additional geographies over the next several months. In the U.S., we have responded to the FDA, and our G7 regulatory pathway is tracking in line with expectations we shared last quarter. We completed the necessary software changes in response to the feedback we received from the agency and subsequently validated the data to ensure the software is operating as designed. These efforts position us well to receive G7 clearance before the end of the year. This is a very exciting time for us. We believe this is the product of the future for Dexcom, and we are working diligently to make that product accessible to a much broader population, not only the intensive insulin-using population but moving into people with type 2 diabetes on basal insulin only, noninsulin-using type 2s, gestational, hospital, metabolic health, and beyond. Along those lines, there is a growing body of evidence demonstrating outcomes beyond the intensive insulin-using population, including a recently published study in Diabetes Technology and Therapies. This study assessed the benefits of Dexcom CGM for a population of predominantly noninsulin-using type 2 individuals. Similar to our MOBILE study, it demonstrated meaningful reductions in A1C levels and improvements in time and range across the study group. Notably, the largest improvements in time and range came from the cohort being treated with one or less medication per day. This suggests that a sizable opportunity exists to help individuals earlier in their diabetes journey, potentially preventing escalation of the disease. This has meaningful long-term health implications for those starting on CGM and also holds promise to reduce the economic burden on our health system associated with progression of diabetes. CMS clearly recognized this potential in 2017 when they became one of the first global payers to cover CGM for people with intensively managed type 2 diabetes, and they appear ready to lead yet again in customer care. In early October, CMS published a proposed local coverage determination that would again meaningfully expand CGM for the Medicare population. Once finalized, this proposal would expand Medicare coverage to include the basal-only population, as well as noninsulin-using individuals that have experienced hypoglycemia. This proposal is in direct response to the clinical outcomes demonstrated in our MOBILE trial, where Dexcom proved to meaningfully improve time and range for this population. Since publishing that data, we have been expecting a reimbursement decision and applaud CMS for taking the lead. Coverage for the basal-only population alone would allow us to help significantly more people in the U.S. as we size that population approximately 3 million individuals. This will be the first major reimbursement expansion beyond the intensively managed space and one that we expect to be the first of many. Historically, CMS has often led commercial payers on coverage decisions, and we anticipate the same dynamic to occur here. However, we're not stopping there. We will continue to advocate for the millions of additional individuals that could benefit from access to real-time CGM. There is a massive opportunity ahead for Dexcom. With that, I'll turn it over to Jereme for a review of the third-quarter financials. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the third quarter of 2022, we reported worldwide revenue of $770 million, compared to $650 million for the third quarter of 2021, representing growth of 20% on an organic basis. As a reminder, our definition of organic revenue excludes currency in addition to non-CGM revenue acquired in the trailing 12 months. U.S. revenue totaled $573 million for the third quarter, compared to $490 million in the third quarter of 2021, representing a growth of 17%. Momentum continues to grow in our U.S. business. We saw initial signs of an inflection in late Q1 and have been encouraged to see those positive customer trends continue in the months that followed. This resulted in a reacceleration in revenue growth in the third quarter. The investments we have made in our salesforce over the past year are starting to pay off. We instituted new salesforce tools earlier this year to make calls more efficient. And today, our team is yielding productivity metrics in line with our high expectations. We have also taken steps recently to simplify access for people in the United States by creating multiple cash-pay options. We are seeing growing demand coming from outside our current reimbursement landscape, including the type 2 nonintensive space. So, we established these programs to help serve these customers as we work to broaden access. International revenue grew 22%, totaling $196 million in the third quarter. International organic revenue growth was 28% for the third quarter. Our international business continues to deliver impressive results as access initiatives completed over the past year are helping us gain market share. For example, in Australia, we are seeing very positive response to the recently expanded reimbursement for G6. Within weeks, we saw an uptick in demand. And currently, our new customers are trending around three times higher than prior to this expanded access. We have seen this dynamic play out again and again, where broader access can serve as an almost immediate catalyst to demand. As a result, we will continue to prioritize our efforts to make Dexcom CGM accessible to many more people across the globe. Our third-quarter gross profit was $494.2 million or 64.2% of revenue, compared to 68.7% of revenue in the third quarter of 2021. Similar to last quarter, the launch of G7 creates a difficult year-over-year comparison on gross margin as G7 development costs are now included in COGS. This dynamic accounts for some of the expected step-down compared to 2021. Additionally, there were 70 basis point negative impact on gross margin from currency. Absent this, gross margin would have been approximately 65%. Operating expenses were $333 million for the third quarter of 2022, compared to $320 million in the third quarter of 2021. Our focus on cost management was on full display this quarter as we generated over 600 basis points of operating expense leverage despite ongoing investment to support our growth. We drove leverage in every category of spend this quarter, while simultaneously offsetting inflationary pressures. Our focus will continue to be on generating leverage in nonvariable expenses while reinvesting those savings into our global commercial infrastructure. Operating income was $160.8 million or 20.9% of revenue in the third quarter of 2022, compared to $123.8 million or 19% of revenue in the same quarter of 2021 as our significant operating expense leverage more than offset gross margin declines in the quarter. Adjusted EBITDA was $226.6 million or 29.4% of revenue for the third quarter, compared to $173.5 million or 26.7% of revenue for the third quarter of 2021. Net income for the third quarter was $111.9 million or $0.28 per share. We remain in a great financial position, closing the quarter with approximately $2.4 billion worth of cash and cash equivalents. We reached a new high watermark in terms of free cash flow this quarter, generating over $180 million of free cash. This provides us the flexibility to support our ongoing growth opportunity while also assessing any strategic uses of capital on an ongoing basis. Our largest use of capital continues to be the buildup of our Malaysia manufacturing plant. Construction continues to progress on schedule, and we expect this facility to be producing commercial product by mid-next year. This facility will provide us the necessary scale and manufacturing efficiency to support our long-term cost targets. During the third quarter, we also executed our previously announced accelerated share repurchase program, purchasing over 550 million of outstanding shares. This allowed us to reduce the dilution associated with our 2023 convertible notes while buying back our shares at what we viewed as an attractive price point. Turning to guidance. We are updating our full-year 2022 revenue guidance to a range of $2.88 billion to $2.91 billion. For margins, we are updating our full-year guidance to the following. We are reducing our gross profit margin guidance to approximately 64%, down from 65% previously. And we are maintaining our previous operating margin and adjusted EBITDA margin guidance at 16% and 25%, respectively. This guidance factors in another sizable uptick in currency headwinds relative to expectations we shared a quarter ago. We now expect approximately $55 million of foreign currency headwinds for the full year relative to our prior estimate of around $40 million. This currency impact is the primary reason we found it prudent to reduce our gross margin guidance for 2022. However, we reiterated our operating margin guidance as we expect to offset the additional foreign exchange pressure through ongoing operating expense leverage. We have been able to navigate through a shifting economic environment well to date, but we are certainly not immune to macro pressure. Leading economic indicators continue to point to additional uncertainty in the coming quarters. So, we are working proactively to offset these impacts where we can. All these dynamics could create incremental challenges to work through in the near term. We are as bullish as ever about our underlying business and the opportunity ahead for Dexcom. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. Our third quarter was characterized by sharp execution and delivering results in line with what we said we were going to do. We're committed to launching G7 internationally in the third quarter, and now we have G7 in five different countries with more following closely behind. We said that our growth rates in the U.S. would reaccelerate as the underlying trends in the business remain strong, and we delivered on an acceleration in the growth rate. We committed to advancing our G7 regulatory process in the U.S., and our efforts this quarter leaves us on track for a clearance before the end of the year. We said that the basal-only coverage would be a matter of when, not if. Now we have more clarity around when. We will continue to operate with this type of focus on execution going forward. Finally, as we move into Q&A, we have Jake Leach with us. We recently announced the promotion of Jake to the role of chief operating officer, providing him with end-to-end responsibility for product. With almost two decades of experience at Dexcom and serving most recently as our chief technology officer, nobody knows G7 and our product road map better than Jake. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions & Answers: Operator Thank you, sir. We will now begin the question-and-answer session. [Operator instructions] Sir, we do have questions in the queue. The first question comes from Jeff Johnson with Baird. Your line is open. Please proceed. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. Kevin, I thought I'd start with a question on your international business. You guys have been benefiting in the last few quarters from recent access wins. You talked about those in the prepared remarks. One of your competitors this quarter was dealing with some company-specific issues. So, it's kind of hard to get a good feel for what's going on maybe underlying demand trends outside the U.S. So, I guess the questions are, are you seeing anything tied to macro uncertainties in your international markets? And with a lot of your international markets paid for through nationalized healthcare systems, do you consider international to be more or less, I guess, macro sensitive compared to your U.S. business? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer You know, Jeff, I may ask Jereme to help me on that. I'll take a first pass. We have learned in our U.S. markets getting access and getting reimbursement through these government agencies is absolutely critical and key to driving growth. As we've had wins in the U.K., we've had wins in Spain. We've continued to have wins in Germany as we've shifted price to create more access. That's what's driving our growth. We're getting access to more people who can use our technology and use our better product. For right now, we haven't seen any macro trends that would make us feel that this isn't going to continue. As we get more access, we will continue to grow and do well. Dexcom ONE is going to be a home run for us. G7 is doing very well out of the gate. We look very much forward to a great year internationally in '23. I don't know, Jereme, if you want to add to that. Jereme Sylvain -- Chief Financial Officer Jeff, you know, outside the U.S., historically, there's been a cost-sensitive approach toward care, healthcare. And that's where Dexcom ONE has really played a major role for us of winning some additional access outside the U.S. So, we do believe that providing these opportunities around multiple systems to address the need both more acute and less acute, it provides us really a differentiation. So, we continue to expect to do well there. And we'll keep you posted if we start to see anything change in terms of macroeconomic demand starting to dampen individual access. But for now, what we see is a great opportunity and an opportunity given our product portfolio do very, very well there. Operator Thank you, sir. The next question in the queue comes from Robbie Marcus with JPMorgan. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks for taking the questions, and congrats on a really good quarter. Maybe I'll ask about the basal opportunity, and this is really exciting here. I just want to try and set expectations for how we should think about updates to the model. First off, when do you think this can really start to -- when should it start to impact the model and add new patients? And I realize it's about a third of patients are Medicare. And then expectations, if you have them for reimbursement, should this be at the normal Medicare rate, meaning higher than the pharmacy right now? And when should we start to think about commercial plans coming online? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what, I'll start with the big picture things. We're starting commercial plans and talking about this now. This is such a big event for us and such a big win that we'd be stupid not to. So, we are thinking about this now. Our product offerings, our distribution strategy, and all those things, Robbie, as far as when it's exactly going to hit and go into your models, that's something we'll discuss later. We know the time frame for this can be anywhere from like four, five to nine months out as we work through this. But we're confident we're going to get through it. We're just thrilled with the ruling, and we are thrilled that we could be part of this. Our data from the MOBILE study was a large component in pushing this initiative across the finish line because we saw how well those people did. Jereme, if you want to get into more specifics on the numbers side, go ahead. Jereme Sylvain -- Chief Financial Officer Sure. Absolutely. So, Robbie, the way we're thinking about it now is really -- it's likely a second-half 2023 event just given the time. And so, expect that, but we'll give you more clarity as to how much the contribution is as we guide for 2023. In terms of commercial payers following, we do expect to see that as you certainly think of Medicare Advantage plans. But even as you have folks really progressing throughout their journey, we know that this product ultimately reduces cost from the system, improves lives and outcomes. And so, we do expect those to come along as well. In terms of reimbursement, the way that CMS typically reverses it is based on qualification, and this is an expansion of the category of qualification. And so, thus far, it looks like it's reimbursed in line with the existing qualifications. And at the end of the day, it's incumbent upon us, and we think we continue to show it that the economic benefits of putting somebody on CGM far outweigh the costs. And so, it's on us to continue to show that evidence, and we think we can continue to prove that as more and more evidence comes. So, we'll get back to you a little bit later in terms of the expectations of 2023 contribution. But that should give you a feel for what we expect over the coming year. Operator Thank you, sir. The next question in the queue comes from Matthew Blackman with Stifel. Your line is open. Please proceed. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thank you for taking my question. I have another question on basal. Also, as we try to think about modeling the annual value of these less than five patients, what is a reasonable way to think about where frequency for a basal patient? We've heard varying feedback from clinicians. And frankly, it's been tracking higher than we would have thought, maybe a 20-plus days per month, but I can't tell if there's any early adopter SKU in that. Just any thoughts there would be helpful. Appreciate it. Jereme Sylvain -- Chief Financial Officer Yeah. I'll maybe draw you back to the MOBILE study, which the MOBILE study was really targeted at folks wearing it full time, which was the basis for CMS coverage. And so, I think what we would see is as folks get on to therapy, we would expect a relatively similar utilization. There might be dips in between it for here and there, a day here or there, a day here and there as product is coming in. But for the most part, we expect full-time wear, and that's how we've seen folks get the most benefit. So, I'd expect it from there. Clearly, this is a new market for us, but all the early work we've done around patient satisfaction, patient results, these folks have wanted to wear it. They wanted to wear it full-time. And so, we expect that to be the baseline going forward. Operator Thank you, sir. The next question in the queue comes from Margaret Kaczor with William Blair. Margaret Kaczor -- William Blair -- Analyst Hey, good afternoon, guys. Thanks for taking the questions. Yeah. I wanted to talk a little bit about U.S. growth. Obviously, you saw a really nice acceleration from Q2 to where we are in Q3. So, can you provide any context around the growth in new patient adds, how that's trended going into Q3 and more specifically in Q4? And I know you'll love this, but going into '23, all of this growth is coming in advance of G7 in basal. So, why shouldn't we assume even more of an acceleration to occur for several quarters from now? Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yeah. Happy to talk about the patient trends. So, what we saw kind of rewind back Q2, a record for us. Q3, early feedback is it's at least equivalent of that of Q2, and we'll even get more data here soon. So, Q3 was another very strong new patient add quarter for us. And so, when we talked last about and expecting a reacceleration, that was on Q2 and an expectation of a strong Q3. I think we had a very, very strong Q3. And quite frankly, we expect a strong Q4. That's where you see that reacceleration in the U.S. So, very bullish on that particular opportunity. And you are right, that is with G6. And so, we obviously are very excited about the ability to offer G7 to the U.S. population. As it pertains to momentum and moving into '23, we'll talk about that as we give guidance in 2023. But I think the takeaway here is we are still very bullish on this business, very bullish on the opportunity, and ecstatic about the opportunity to offer G7. Operator Thank you, sir. The next question in the queue comes from Matthew O'Brien with Piper Sandler. Your line is open, sir. Matthew O'Brien -- Piper Sandler -- Analyst Great. Thanks for taking the question. Maybe, Jereme, just if you could put a little bit finer point on basal for next year? I know you said second half of next year, and you're expecting a lot of wear. But it's going to be pretty early days. A lot of things got to work through. So, is it fair to think of it as a fairly modest contributor next year? And then this might be a kind of a silly question, but you have G7 coming out next year, and then you're going to have new basal patients. Just talk about manufacturing for all these products you're going to need over the next several years, I guess. Jereme Sylvain -- Chief Financial Officer Sure. Yeah. Let me start with the -- maybe the model expectation. We have Jake here. And I think it will be good for him to talk through the manufacturing. So, in terms of how to model it out, Kevin alluded to it earlier. Generally, there's about a six- to nine-month period where look, there's a proposal, and things have to go through. And so, as folks start to open up coverage, that's why we expect that coverage to really start in the back half. And again, this is a recurring revenue business. So, there will be a contribution we expect in 2023. How material, we're going to size that up, and we'll make sure that we -- as we size it up for you, we'll give you the context for how we're guiding to it in 2023, so you understand our assumptions. If things come earlier or things go faster or slower, we'll certainly give you that clarity so that you have it. But our expectation is there's a contribution. How material, it's going to take a little bit of time as that grows, but still a contribution and really momentum exiting '23 into 2024. But in terms of capacity, maybe let me turn it over to Jake to give you some context there. Jake Leach -- Chief Operating Officer Yeah. Thanks, Jereme. So, from a capacity perspective, we've been gearing up for this G7 launch for quite a while. So, we've got G7 lines installed here in San Diego, as well as in Mesa. And so, we feel really good about our position to meet the needs of our full G7 U.S. launch, as well as the international launches that will continue throughout the year. Also, to remind you that we've got our Malaysia plant coming online the next year. So, that should also help boost our capacity. And so, I feel really good about the ability to both provide G6 and G7 product. Operator Thank you. The next question in the queue comes from Joanne Wuensch with Citi. Your line is open. Joanne Wuensch -- Citi -- Analyst [Inaudible] Sorry, I don't know if you heard any of that. But -- Kevin Sayer -- Chairman, President, and Chief Executive Officer Let's start over. Joanne Wuensch -- Citi -- Analyst Good evening, and thank you for taking the question. Dexcom ONE launched in -- I think you said six geographies outside the United States. How is that ramping? How should we think about that contributing? Because I was starting to put together in my mind like your core base business, you layer on top of that G7 benefit. You layer on top of that Dexcom ONE and, of course, basal. What's the layer for Dexcom ONE? Kevin Sayer -- Chairman, President, and Chief Executive Officer I'm not going to get into numbers, and we'll get into models later, Joanne. I can tell you, again, I'll reiterate our comments on the call. There are many geographies where CGM is accepted where we have been isolated to higher-risk patients, patients on pumps, or severe hypoglycemia. And we were reimbursed more, but we were narrowly viewed. In many of these geographies now with Dexcom ONE with our lower-cost offering, but with real-time CGM and the accuracy and other features we deliver, we're now able to go compete for those customers. That will be a very important level of business for us, particularly in Europe going forward and other countries and other places where we need to launch it. That will be a layer -- I mean, our core business, our core G Series product is going to be our primary source of revenue for a while. But over time, you will see all these elements grow bigger and take a bigger piece of the pie. And Jereme, you build the models. You -- why don't you add a little more? Jereme Sylvain -- Chief Financial Officer Yeah. So, Joanne, I completely understand the question and how to model it. I think what I would say is in 2022, this is a business just getting started. So, it's not a material contributor in 2022. However, we understand the challenge. And so, we will make sure that we're able to identify what the contribution looks like as we start to give forward-looking guidance over time. So, just rest assured, as that business gets bigger, we'll start to give you line of sight into that. For now, what's most important is we've unlocked an incredible amount of TAM. And that's super important as we think about how many new patients we're certainly going to be bringing in. So, more to come there. We'll certainly help you with models going forward. But for now, just know Dexcom ONE is a relatively small contributor this year, and we'll talk about 2023 here in a few months. Operator Thank you. The next question in the queue comes from Jayson Bedford with Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Good afternoon. Thanks. Just a quick one. I may have missed this, but did you talk about volume growth in the quarter? And if not, can you? And maybe comment on any geographic differences. Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yeah. So, we were in the unit volume in the mid- to upper 30s globally. In terms of the performance, the U.S. was slightly below that but still in the mid-30s, and OUS was slightly above that in the upper 30s. And so, really just continued strong momentum in that patient cohort or that underlying patient volume. Operator Thank you, sir. The next question in the queue comes from Larry Biegelsen with Wells Fargo. Nathan Treybeck -- Wells Fargo Securities -- Analyst Good evening. This is Nathan Treybeck on for Larry. In terms of your comments around G7 U.S. launch timing by year-end, is there anything that still needs to be done? And then how soon after the approval do you expect a full launch? And how should we think about the ramp? Is there any reason why it should be different than the G6? Thanks. Jake Leach -- Chief Operating Officer Yeah. Thanks for the question. This is Jacob. I'll take that one. So, yes, we responded to the FDA in Q3 with the answers to their final questions. And so, we feel really good about how that positions us for approval in Q4, so before the end of the year. We're really planning our launch to occur in Q1. So, that will be a full launch, and the -- our status with the FDA is we've gone back and forth. We're feeling really good about this being kind of the end of the review period. And so, we're very confident in that Q4 approval timing and a Q1 U.S. launch. Operator Thank you, sir. The next question in the queue comes from Matt Taylor with Jefferies. Your line is open. Matt Taylor -- Jefferies -- Analyst Hi. Thanks very much for taking the question. I actually wanted to double-click on some of your commentary on Dexcom ONE and thinking about your portfolio strategy as you get G7 out there. I guess, can you talk a little bit more about how you're going to use G7, G6, and ONE together to kind of meet customers where they're at in different markets around the world? What are some of the different flavors or different ways you could use that portfolio? Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah. This is Kevin. I'll take that at a high level. Certainly, our G Series product, our G7 is going to be our flagship product, we roll it out. And that will be -- we're very comfortable with that being a home run. There will be some countries where G6 is so new. It's not going to be prudent to go rush G7 into those geographies. We can let that customer base grow while we expand others. So, we look at G6 and G7 in a very similar light as far as their features, the connectivity, and all the things that they do. With Dexcom ONE currently on a G6 platform, we have areas where we need to grow, and we need to get there fast. And that product will remain on the G6 platform. We're not ready to move it to G7 anyway. We're going to use our existing G7 capacity to sell G7s in the beginning and strengthen ourselves in our current business and where we are doing very well now with our partners and everybody else ultimately Dexcom ONE will shift to that platform. And we'll roll out that way. So, as you look at Dexcom ONE, we've said many times that product is for two major purposes. The first one is to go into new geographies where we can do an online e-commerce type business and launch it as we have in those first four countries, in countries where CGM is reimbursed. But again, we have this situation where there are two types of CGMs they will pay for the -- that for the high-risk patient and connectivity and with those features that we've always had on the G Series. And then the other area, we are using Dexcom ONE as a vehicle to get into those markets and utilize our capacity to go sell sensors and serve customers there and give them a better experience than they've ever had before. And that is the plan for right now. Operator Thank you, sir. The next question in the queue comes from Marie Thibault with BTIG. Go ahead, ma'am. Marie Thibault -- BTIG -- Analyst Thank you so much for taking the questions. I wanted to ask one here on your comments on cash pay in the U.S. Unless I'm mistaken, I believe that's a recent shift or a new shift for Dexcom strategy? Would love to hear a little bit more about how that's being rolled out and how patients and providers are hearing about that cash pay option. Thanks so much. Jereme Sylvain -- Chief Financial Officer Yeah, sure. Thanks for the question. This is Jereme. It's a bit of a change. I'd say it's an addition or an augment to an existing strategy. So, we've always believed that access is incredibly important. And we believe that over the long term, access is at the basis of adoption. However, there are some certain populations out there that have high interest in the product that continue to want to use the product to manage their diabetes. And we felt that this was a way to allow them to do so while we work on that access. And so, what we are doing is we're launching multiple different versions of cash pays. We'll have those being promoted here shortly to targeted populations. And what the goal here is that folks don't have coverage, while we work in the background to get coverage, basal is a good opportunity, a good example, I should say. They can't get the product for a discount price. And the price is less than 50% of what -- the cost of them is 50% less than what it historically would have been. So, real good opportunity, multiple different options, multiple different ways we're going to be rolling it out. You'll see some marketing materials around it soon. But I would -- I think this is a great thing for access. I think it's a great thing for folks who have been looking to get on a Dexcom that, for whatever reason, haven't been able to allow them to do so. Operator Thank you, sir. The next question in the queue comes from Kyle Rose with Canaccord. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you for taking the question. So, obviously, the G7 launch, you're starting in a few countries now, going to move into the U.S. in the Q1 next year. Just how should we be thinking about gross margins when we -- when you turn on those facilities and then, in particular, the Malaysia facility coming online as well? Just how should we think about the COGS line over the course of the next 18 months? Jereme Sylvain -- Chief Financial Officer Yeah. So, the best way -- good question. The best way to think about it is in the first quarter in which we turn on lines, you generally have a dip in gross margin. And that's the initial set up the yields. We'll give you guys a little bit more line of sight into cadence as we get into 2023 guidance. But as you turn on those lines, the first sets, the yields are a little bit lower. You're absorbing in depreciation, and then as those yields start to improve, you start to get a better gross margin run on those. So, I think the expectation is, is you'll have some blips there in the periods in which we launch into certain countries, specifically U.S. And then as more and more folks transition off of G6 to G7, and those increase, you're going to see those margins improve. Longer term, G7, we can make at a lower cost than G6. And so, it's just this transitory. We'll help you out on the modeling as we get into 2023 guidance, but as you're trying to get your head around what the cadence looks like when we turn online, that's the expectation of when you'll have the dip and then a recovery after that. Operator Thank you, sir. And the next question in the queue is Steven Lichtman with Oppenheimer. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. You know, as we think about some of these new opportunities from the LCD, I'm wondering in the near term how things are progressing on the intensive type 2 side. With -- given the comments you made in terms of primary care doc progress, as well as the work you've done on coverage, can you update us on where you guys -- do you think the market is in terms of penetration, intensive type 2s? And are the pieces in place for that just to continue to expand meaningfully in the coming couple of -- two years? Jereme Sylvain -- Chief Financial Officer Yeah. Thanks for the question. We continue to do very, very well. So, if you think about kind of where that type 2 intensive penetration is, it's surpassing 35%. In terms of how we're doing, I think couple of maybe data points, which I think is helpful. First off, record new patients, Q2. Q3 is in line with that based on early feedback, could even be a little bit higher. And so, you're seeing patients coming in, which is just an indication of more and more folks adopting where a good majority of those are coming from that type 2 intensive population. It's our fastest-growing segment. I think you also think about it from a context of who we call on. And as we look at our sales team, we talk about productivity, more than three-quarters of the calls we make are now to primary care physicians. And that's because that's where we're looking to expand over time. So, I think what we've done in expanding the salesforce last year and really focusing on those sales tools, thinking about the type 2 intensive and then beyond, basal and beyond, I think you're really seeing that play out. And you're seeing some very strong growth in that type 2 intensive segment, and it sets us up well for that basal segment. Operator Thank you, sir. The next question in the queue comes from Matt Miksic with Barclays. Matt Miksic -- Barclays -- Analyst Hi. Great. Thanks so much for taking the question. Maybe just a follow-up on some of the questions about how the ramp-up of G7, it is a little bit of a modeling question, not really at all sort of a guidance question. But just in terms of how the portfolio comes together and works maybe following up on Kyle's question on ramping up these new lines. Can you talk a little bit about channel, how the sort of middle of the P&L might respond or flex as you kind of get into some of the opportunities you're talking about? Is there a channel synergy across all of these? Do you expect to have to kind of spend into some of these opportunities and then get leverage over time? Maybe if you could talk a little bit about that, that would be super helpful. Thank you. Jereme Sylvain -- Chief Financial Officer Yeah, sure. So, the line -- the way you think about the lines, and this is the way we've set it up is Dexcom ONE physical form factor cost to manufacture, not necessarily cost to support and how we service it, but really the physical product. Dexcom ONE is very similar to G6. There are other features that G6 has, but hardware is very similar. And it's very similar in G7. G7 lines and eventually Dexcom ONE will migrate to a G7 line. And so, as you think about these products, then it becomes a question of price point and then how we ultimately service the patient there. So, that's the way to think about it. Over time, as we go into certain markets depending on price point, it's got much less to do with what I would say is the physical product itself. We grow into those markets over time through economies of scale. And so, that's one of the reasons we believe with Dexcom ONE, there's a real great opportunity here. The economies of scale for us are massive. And by going into those markets, we certainly can grow into that profitability profile. So, as you think down the middle of the P&L, certainly, as you go into Dexcom ONE, there could be a slight margin differentiation, but those economies of scales help offset it. We also look at the service model, and we're able to manage the service model in a different way. So, the ultimate operating margin contribution is the same. So, that's how we think about it. And so, as you're modeling it through, that's how I would think about it. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yes. I'd just add to that. And I don't want this lost on the call. Take a look at our operating performance this quarter. Record cash flows as a former CFO is something I love to hear. And so, we have managed our business very tightly. As we look at these workstreams and these new product lines, your question is very appropriate. And we do have work streams about our cost to serve our patients, our cost to develop our new products, our manufacturing costs given all these new things we're doing. We are looking at the cost structure of the company every bit as much as we're looking at the product launches. So, we can make sure that when we get to the end of this road with these launches and with these products and new markets and new products that we have operating margins that are acceptable to us as we increase our customer base dramatically. Operator Thank you, sir. The next question in the queue comes from Joshua Jennings with Cowen. Joshua Jennings -- Cowen and Company -- Analyst Hi. Thanks for taking the questions. I wanted to just ask about the sequential acceleration in 3Q of revenue growth. And either if you could quantify or just qualitatively describe the contributions from your new pump partner. And just on that topic, if you can just remind us the requirements once G7 is approved to integrate G7 into the Tandem insulin pumps. Any steps that you can highlight and what your expectations are on that front? And can anything be done in front of G7 approval with your partners? Thanks for taking the question. Jereme Sylvain -- Chief Financial Officer Sure, I'll start with the contribution. And let me turn it over to Jake, who is our maestro on product development and understanding products. In terms of contribution, look, we're very excited about both Tandem and Insulet products. And as they launch more and more products that we are obviously integrated with, we expect it to contribute. Now, quantifying that and having those contributions, it's a little bit difficult to do given some products -- some folks were already on Dexcom CGM who bring in a pump, and some folks pull over. So, as time moves on, we'll be able to really tease that apart. But I think what we would say is we're still bullish on the opportunity of folks ultimately using our product with these incredible pump partners. I'll leave it at that just because it gets hard to contribute. Again, we'll be able to retrospectively give feedback as time moves on. But let me give it to Jake in terms of the connectivity and the timelines on G7. Jake Leach -- Chief Operating Officer Yeah. Thanks, Jereme. So, on G7 integration with our pump partners, basically, the steps are to make a few updates on the pump side to take advantage of the new features that are within G7 such as the fast warm-up, as well as the grace period. And so, those groups are already -- they have been already working on that for quite a while. And so, we do see great progress on those integrations. They've gone through kind of final steps of development and validation. So, a lot of that work can be, to your point, done ahead of time. And so, when it comes to a specific timing of approvals and launches, we'll leave that to our pump partners. But we're progressing very rapidly, and we do expect them to be integrated soon. One thing I'll note is that on our other side on the digital health partners, for example, in Europe where we have G7 out, those that are connected up to our real-time API already have G7 integrations. For example, Sugarmate is a group that's already consuming G7 data within their app at the beginning of the launch. So, very excited about the opportunity to bring more to the ecosystem with G7. Operator Thank you, sir. We have no further questions at this time. I will turn the call over to Mr. Sayer for closing remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks a lot, everybody. This was a great quarter for us with growth, with excitement related to our product launches, expanding global access, and performance on the bottom line as well. In a time when the world is in a lot of chaos, we've done what we said we were going to do yet again. Our teams are just executing very well as we press toward the end of the year and look to build momentum next year. I want to thank our team members for their hard work to strive toward these goals. It is all hands on deck to get G7 done, to get Dexcom ONE out in these markets, and do all the things that we are trying to do. But I want to close with a special note. I want to thank all the members of the diabetes community that have been working together to help improve access to CGM technology. The recent CMS proposal represents a big win for people with diabetes, and we're only one member of a large group advocating for this result. This was a collective effort from the diabetes community on behalf of the diabetes community. We want to acknowledge all the hard work that led to this proposal, both inside and outside of Dexcom, and share our excitement to help so many more people with diabetes in the U.S. live healthier lives, and it's only the beginning. Thanks a lot, everybody. Operator [Operator signoff] Duration: 0 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Jeff Johnson -- Robert W. Baird and Company -- Analyst Robbie Marcus -- JPMorgan Chase and Company -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Margaret Kaczor -- William Blair -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Jake Leach -- Chief Operating Officer Joanne Wuensch -- Citi -- Analyst Jayson Bedford -- Raymond James -- Analyst Nathan Treybeck -- Wells Fargo Securities -- Analyst Matt Taylor -- Jefferies -- Analyst Marie Thibault -- BTIG -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Matt Miksic -- Barclays -- Analyst Joshua Jennings -- Cowen and Company -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates DexCom (DXCM) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this medical device company would post earnings of $0.17 per share when it actually produced earnings of $0.17, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $769.6 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 2.25%. This compares to year-ago revenues of $650.2 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have lost about 23.6% since the beginning of the year versus the S&P 500's decline of -19.6%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.30 on $816.03 million in revenues for the coming quarter and $0.79 on $2.89 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 46% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Neuronetics (STIM), is yet to report results for the quarter ended September 2022. The results are expected to be released on November 8. This medical device company focused on psychiatric disorders is expected to post quarterly loss of $0.44 per share in its upcoming report, which represents a year-over-year change of -41.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Neuronetics' revenues are expected to be $14.79 million, up 7.2% from the year-ago quarter. This Little-Known Semiconductor Stock Could Be Your Portfolio\u2019s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that\u2019s just the tip of the iceberg), you have a need for semiconductors. That\u2019s why their importance can\u2019t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation. >>Yes, I Want to Help Protect My Portfolio During the Recession Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis Report Neuronetics, Inc. (STIM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for October 27, 2022 : AAPL, AMZN, TMUS, INTC, GILD, VRTX, PXD, EW, LHX, RSG, DXCM, COF The following companies are expected to report earnings after hours on 10/27/2022. Visit our Earnings Calendar for a full list of expected earnings releases. Apple Inc. (AAPL)is reporting for the quarter ending September 30, 2022. The computer company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.26. This value represents a 1.61% increase compared to the same quarter last year. In the past year AAPL has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AAPL is 24.44 vs. an industry ratio of 5.30, implying that they will have a higher earnings growth than their competitors in the same industry. Amazon.com, Inc. (AMZN)is reporting for the quarter ending September 30, 2022. The internet company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.22. This value represents a 29.03% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for AMZN is 124.37 vs. an industry ratio of 13.20, implying that they will have a higher earnings growth than their competitors in the same industry. T-Mobile US, Inc. (TMUS)is reporting for the quarter ending September 30, 2022. The wireless (national) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.53. This value represents a 3.64% decrease compared to the same quarter last year. In the past year TMUS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 248.78%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for TMUS is 71.49 vs. an industry ratio of 6.80, implying that they will have a higher earnings growth than their competitors in the same industry. Intel Corporation (INTC)is reporting for the quarter ending September 30, 2022. The semiconductor company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.34. This value represents a 80.12% decrease compared to the same quarter last year. INTC missed the consensus earnings per share in the 2nd calendar quarter of 2022 by -57.97%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for INTC is 12.42 vs. an industry ratio of 32.30. Gilead Sciences, Inc. (GILD)is reporting for the quarter ending September 30, 2022. The biomedical (gene) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.44. This value represents a 45.66% decrease compared to the same quarter last year. GILD missed the consensus earnings per share in the 4th calendar quarter of 2021 by -54.9%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for GILD is 10.83 vs. an industry ratio of 0.20, implying that they will have a higher earnings growth than their competitors in the same industry. Vertex Pharmaceuticals Incorporated (VRTX)is reporting for the quarter ending September 30, 2022. The biomedical (gene) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $3.31. This value represents a 1.85% increase compared to the same quarter last year. VRTX missed the consensus earnings per share in the 1st calendar quarter of 2022 by -0.32%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for VRTX is 24.64 vs. an industry ratio of 0.20, implying that they will have a higher earnings growth than their competitors in the same industry. Pioneer Natural Resources Company (PXD)is reporting for the quarter ending September 30, 2022. The oil (us exp & production) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $7.43. This value represents a 79.90% increase compared to the same quarter last year. In the past year PXD has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.24%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for PXD is 8.32 vs. an industry ratio of 6.30, implying that they will have a higher earnings growth than their competitors in the same industry. Edwards Lifesciences Corporation (EW)is reporting for the quarter ending September 30, 2022. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.62. This value represents a 14.81% increase compared to the same quarter last year. EW missed the consensus earnings per share in the 4th calendar quarter of 2021 by -7.27%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for EW is 34.57 vs. an industry ratio of 31.00, implying that they will have a higher earnings growth than their competitors in the same industry. L3Harris Technologies, Inc. (LHX)is reporting for the quarter ending September 30, 2022. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.44. This value represents a 7.17% increase compared to the same quarter last year. In the past year LHX has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.22%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for LHX is 18.60 vs. an industry ratio of 4.10, implying that they will have a higher earnings growth than their competitors in the same industry. Republic Services, Inc. (RSG)is reporting for the quarter ending September 30, 2022. The waste removal company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.21. This value represents a 9.01% increase compared to the same quarter last year. In the past year RSG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 11.86%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for RSG is 28.07 vs. an industry ratio of 18.50, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending September 30, 2022. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.24. This value represents a 9.09% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DXCM is 129.89 vs. an industry ratio of 31.00, implying that they will have a higher earnings growth than their competitors in the same industry. Capital One Financial Corporation (COF)is reporting for the quarter ending September 30, 2022. The financial services company's consensus earnings per share forecast from the 11 analysts that follow the stock is $5.03. This value represents a 26.68% decrease compared to the same quarter last year. COF missed the consensus earnings per share in the 2nd calendar quarter of 2022 by -3.31%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for COF is 5.12 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-28,113.72,121.88,109.89,120.87,"[""Health Care Sector Update for 10/28/2022: DXCM,NUVL,GILD,DVA Health care stocks were moderately higher compared with most other sectors this afternoon, with the NYSE Health Care Index rising 1.1% and the SPDR Health Care Select Sector ETF (XLV) up 1.6%. The iShares Biotechnology ETF (IBB) was climbing 3.6%. In company news, DexCom (DXCM) gained nearly 20% after the blood-glucose monitors manufacturer exceeded Wall Street expectations with its Q3 results and raised the bottom end of its FY22 revenue guidance by $200 million over its previous forecast range. Excluding one-time items, it earned $0.28 per share during the three months ended Sept. 30, while revenue grew 18% year-over-year to $769.6 million. Analysts, on average, had been expecting Dexcom earning $0.24 per share on $751 million in revenue during the three months ended Sept. 30. Nuvalent (NUVL) rallied Friday, at one point climbing 84% to a new, all-time high of $40.43 a share, after saying its NVL-520 drug candidate showed encouraging preliminary signs of activity across all five dosing levels during the dose-escalation portion of phase 1/2 testing, with 48% of the patients with advanced ROS1-positive non-small cell lung cancer demonstrating partial responses. Nuvalent shares recently were 52% higher, with the company also saying more than three-quarters of the 21 response-evaluable patients were continuing their NVL-520 treatments. Gilead Sciences (GILD) gained nearly 13% after late Thursday reporting Q3 results topping analyst estimates for the three months ended Sept. 30 and the specialty drug maker also raising its guidance for non-GAAP FY22 net income above Wall Street expectations. It also increased its forecast for product sales this year to a new range of $25.9 billion to $26.2 billion compared with its prior view expecting between $24.5 billion to $25 billion in FY22 sales, straddling the $26 billion analyst mean. To the downside, DaVita (DVA) was slumping 27%, staying within close range of its lowest share price in nearly two years, after the kidney dialysis chain reported fiscal Q3 results trailing analyst estimates for the September quarter and also cut its 2022 earnings forecast below Wall Street expectations. Excluding one-time items, the company is projecting net income this year in a range of $6.20 to $6.70 per share, down from $7.50 to $8.50 per share previously and trailing the Capital IQ consensus looking for an adjusted FY22 profit of $7.77 per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised DexCom, Inc. DXCM reported third-quarter 2022 adjusted earnings per share (EPS) of 28 cents, beating the Zacks Consensus Estimate of 24 cents by 16.7%. The bottom line also improved 27.3% on a year-over-year basis. GAAP net income per share in the quarter was 24 cents, compared with the year-ago quarter\u2019s figure of 21 cents per share. Revenue Details Total revenues grew 18% (20% on an organic basis) to $769.6 million on a year-over-year basis and beat the Zacks Consensus Estimate by 2.2%. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring (CGM), contributed to the upside. Segmental Details Revenues at the Sensor and other revenues segment (87% of total revenues) climbed 21.7% on a year-over-year basis to $666.6 million. Hardware revenues (13%) increased 0.7% year over year to $103 million. Geographical Details U.S. revenues (75% of total revenues) increased 17.1% on a year-over-year basis to $573.4 million. International revenues (25%) improved 22.2% year over year to $196.2 million. Margin Analysis Gross profit in the quarter under review totaled $494.2 million, up 10.6% year over year. DexCom generated a gross margin (as a percentage of revenues) of 64.2%, which contracted 450 basis points (bps) year over year. Research and development expenses amounted to $110.3 million in the quarter, down 14.4% year over year. Selling, general and administrative expenses totaled $234.6 million in the reported quarter, up 18.2% year over year. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote The company reported total operating expenses of $346.7 million, up 5.5% from the prior-year figure. Operating margin (as a percentage of revenues) of 19.2% expanded 100 bps year over year. Financial Position The company exited the third quarter with $2.37 billion in cash, cash equivalents and marketable securities, compared with $2.75 billion in the preceding quarter. Total assets in the third quarter amounted to $4.9 billion, compared with $5.2 billion on a sequential basis. 2022 Guidance Updated DexCom raised the lower end of its revenue guidance for 2022 and expects revenues to be in the range of $2.88-$2.91 billion compared with the previous range of $2.86-$2.91 billion. The Zacks Consensus Estimate for the same stands at $2.89 billion. The company lowered the 2022 guidance for adjusted gross margin while maintaining the same for adjusted operating margin. While the adjusted gross margin is anticipated to be about 64% (down from 65% previously expected), the adjusted operating margin is estimated to be around 16%. Wrapping Up DexCom exited third-quarter 2022 on a strong note, wherein earnings and revenues beat the Zacks Consensus Estimate. Impressive contributions from the Sensor segment and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, DexCom ended the quarter with new patient additions as well. It launched an updated sensor algorithm in five countries during the third quarter, making the latest G7 sensor technology available to international markets. The company anticipates FDA clearance for G7 sensor technology before the end of 2022. These developments are likely to support the future growth of the company. Nevertheless, the contraction in gross margin is a woe, reflecting the rising cost of sales. Apart from this, cut-throat competition in the market for blood & glucose monitoring devices remains a concern. Zacks Rank and Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. ELV, Medpace Holdings, Inc. MEDP and Accuray ARAY. Elevance Health, carrying a Zacks Rank #2 (Buy), reported third-quarter 2022 adjusted EPS of $7.53, which beat the Zacks Consensus Estimate by 6.1%. Revenues of $39.63 billion outpaced the consensus mark by 1.3%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Elevance Health has an earnings yield of 5.5% against the industry\u2019s (2.3%). ELV\u2019s earnings surpassed estimates in all the trailing four quarters, the average being 4.1%. Medpace Holdings, having a Zacks Rank #1, reported third-quarter 2022 adjusted EPS of $2.05, which beat the Zacks Consensus Estimate by 39.5%. Revenues of $384 million outpaced the consensus mark by 8.1%. Medpace Holdings has an estimated growth rate of 22.7% for 2022. MEDP\u2019s earnings surpassed estimates in the trailing four quarters, the average being 22.04%. Accuray reported fourth-quarter fiscal 2022 adjusted loss per share of 4 cents, which surpassed the Zacks Consensus Estimate by 33.3%. Fourth-quarter revenues of $110 million outpaced the Zacks Consensus Estimate by 4.9%. It currently has a Zacks Rank #2. Accuray has an estimated growth rate of 100% for fiscal 2023. ARAY\u2019s earnings surpassed estimates in three of the trailing four quarters and lagged the same in one, the average surprise being 20.8%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accuray Incorporated (ARAY): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Is Soaring Today What happened Shares of DexCom (NASDAQ: DXCM) were trading up by 13.9% as of 11:55 a.m. ET Friday. The big gain came after the diabetes-care technology company announced its third-quarter results following the market close on Thursday. DexCom reported Q3 revenue of $769.6 million, up 18% year over year. It posted earnings of $101.2 million, or $0.24 per diluted share, based on generally accepted accounting principles (GAAP). In the prior-year period, it recorded GAAP earnings of $87.3 million, or $0.21 per diluted share. Analysts' consensus estimate for DexCom's Q3 non-GAAP earnings had been $0.24 per share. It easily beat those expectations with non-GAAP earnings of $111.9 million, or $0.28 per diluted share. In addition, the company tweaked its full-year guidance. For 2022, DexCom now projects revenue of between $2.88 billion and $2.91 billion. It previously forecast revenue in the range of $2.86 billion to $2.91 billion. However, it now expects its non-GAAP gross profit margin to be around 64%, slightly lower than the previous outlook of 65%. So what DexCom's Q3 update could help convince investors that the company can navigate an uncertain macroeconomic environment better than most. There's one especially important key to DexCom's success: the new G7 continuous glucose monitoring (CGM) system. The company launched the G7 device in the United Kingdom, Ireland, Germany, Austria, and Hong Kong in the third quarter. The only negative for DexCom in Q3 was the strong U.S. dollar. The company's small decrease in its gross profit margin guidance was primarily due to currency-exchange headwinds. Now what DexCom CEO Kevin Sayer said in the Q3 conference call that the G7 could receive U.S. regulatory clearance before the end of 2022. That should position the company well to continue delivering strong growth in 2023 and beyond. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: AMZN, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 14.7%. Year to date, DexCom has lost about 13.5% of its value. And the worst performing Nasdaq 100 component thus far on the day is Amazon.com, trading down 10.3%. Amazon.com is lower by about 40.3% looking at the year to date performance. Two other components making moves today are Datadog, trading down 5.8%, and Intel, trading up 9.0% on the day. VIDEO: Nasdaq 100 Movers: AMZN, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook (RTTNews) - The following are some of the companies belonging to the healthcare sector that reported quarterly financial results on Thursday. Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), which reported lower-than-expected financial results for the third quarter, has reiterated FY 2022 net product revenue guidance. Revenue grew to $264.3 million in Q3 2022, from $187.6 million in Q3 2021, but fell short ofanalysts' estimate of $291.75 million. On a GAAP basis, net loss for the third quarter of 2022 widened to $405.9 million or $3.32 per share, from last year's $204.5 million or $1.72 per share. Analysts polled by Thomson Reuters expected a loss of $1.77 million. On a non-GAAP basis, the net loss was $193.6 million or $1.58 per share in Q3 2022 compared to a net loss of $189.8 million or $1.59 per share in Q3 2021. The company has four marketed products ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Alnylam reiterated its previous net product revenue guidance for the fiscal year 2022, to be in the range of $870-$930 million. The company has a couple of clinical trial catalysts to watch in the coming months. A phase 1 study of ALN-XDH in patients with gout is ongoing, with preliminary results expected in late 2022. In early 2023, Alnylam expects initial data from a phase I study of ALN-APP in patients with early-onset Alzheimer's Disease. The company does not plan to conduct the optional interim analysis for the HELIOS-B phase III study in patients with ATTR amyloidosis with cardiomyopathy. The study remains on track for topline results in early 2024. On Sep.30, 2022, cash, cash equivalents, and marketable securities totaled $2.27 billion. ALNY has traded in a range of $117.58 to $236.8 in the last 52 weeks. The stock closed Thursday's trading at $194, down 3.49%. DexCom Inc. (DXCM), reported better-than-expected earnings for the third quarter ended Sep.30, 2022 and raised its revenue outlook for the full year. In Q3 2022, revenue grew 18% to $769.6 million from $650.2 million in the same quarter of the prior year. On GAAP basis, net income grew to $101.2 million, or $0.24 per share, in the third quarter of 2022, from $87.3 million, or $0.21 per diluted share, in the same quarter of 2021. On a non-GAAP basis, the net income improved to $111.9 million, or $0.28 per share in the third quarter of 2022 from $89.3 million or $0.22 per share in the same quarter of 2021. Wall Street analysts were expecting earnings of $0.24 per share. The company raised its revenue outlook for the fiscal year 2022, to be in the range of $2.88 - 2.91 billion from the previous range of $2.86 - 2.91 billion. Analysts estimate the revenue for FY 2022 to be $2.89 billion. Revenue was $2.45 billion last year. Dexcom ended Q3 2022, with $2.37 billion in cash, cash equivalents, marketable securities, and undrawn credit facility. DXCM has traded in a range of $66.89 to $164.86 in the last 52 weeks. The stock closed Thursday's trading at $101.25, down 1.33%. Travere Therapeutics Inc. (TVTX) has reported a wider loss and lower revenue for the third quarter ended September 30, 2022. This biopharmaceutical company is developing therapies for rare kidney, liver, and metabolic diseases Revenue is generated from the following approved products. -- Chenodal indicated for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. -- Cholbam for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. -- Thiola and Thiola EC prescribed for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Revenue for the third quarter of 2022 declined to $50.8 million, from $54.2 million in the same period in 2021. In Q3 2022, the net loss widened to $69.7 million, or $1.09 per share from $35.6 million, or $0.59 per share in Q3 2021. Wall Street analysts expected the company to incur a loss of $0.86 per share. The most advanced product in Travere's pipeline is Sparsentan, an investigational dual-acting angiotensin, and endothelin receptor antagonist proposed for the treatment of IgA nephropathy (IgAN). Sparsentan is under FDA review, with a decision expected on February 17, 2023. In the European Union also, this product is under the European Medicines Agency (EMA) review for conditional marketing authorization, with a decision expected in the second half of 2023. The company is also exploring Sparsentan in Focal Segmental Glomerulosclerosis and a phase III trial in this indication, dubbed DUPLEX, is underway. Topline data from this study is expected in the first half of 2023. As of September 30, 2022, the company had $506.3 million in cash, cash equivalents, and marketable securities. TVTX has traded in a range of $20.49 to $31.65 in the last 52 weeks. The stock is trading at $24.65, up 9.65% in Thursday's after-hours session. Zynex, Inc. (ZYXI), which reported revenue growth of 19% for the third quarter of 2022, expects revenue to grow 23% in the fourth quarter. In the third quarter of 2022, the company's revenue increased to $41.5 million from $34.7 million in the third quarter of 2021. Net income declined to $4.9 million or $0.13 per share in Q3 2022, from $6.1 million or $0.16 per share in the third quarter of 2021, but came in just above analysts' consensus estimate of $0.12 per share. The company provided revenue guidance for the fourth quarter of 2022 along with FY 2022. For the fourth quarter, the company expects revenue to be in the range of $48 million to $51 million, with the analysts' consensus estimate being $49.18 million. Revenue was $40.37 million in the fourth quarter of 2021. For FY 2022, the company anticipates revenue to be in the range of $157.4 million to $160.4 million, in line with Wall Street analysts' estimate of $158.45 million. Revenue was $130.3 million in FY 21. The company ended the third quarter of 2022 with $23.5 million in cash reserves. ZYXI has traded in a range of $4.97 to $15.66 in the last 52 weeks. The stock closed Thursday's trading at $9.21, up 0.66%. Insmed Incorporated (INSM) has reported a wider loss for the third quarter of 2022 even as revenue climbed nearly 45% . In the third quarter of 2022, revenue grew to $67.7 million, from for the third quarter of 2021. In Q3 2022, Insmed's net loss widened to $131.1 million, or $1.09 per share on revenue of $67.7 million. This compared with a net loss of $112.7 million or $0.96 per share and revenue of $46.8 million in the year-ago period. Wall Street analysts' expected the earnings to be $0.89 per share. Anticipated events: By the end of 2022, the company expects to report topline data from the phase II pharmacokinetic/pharmacodynamic study of Brensocatib in patients with cystic fibrosis. The company intends to share data from the ARISE post-marketing confirmatory trial of ARIKAYCE in patients with nontuberculous mycobacterial lung disease caused by Mycobacterium Avium Complex (MAC), over the course of 2023. In the second quarter of 2024, the company expects topline data from the phase III ASPEN Trial of Brensocatib for the treatment on-Cystic Fibrosis Bronchiectasis. Insmed ended the third quarter of 2022, with $513.3 million in cash, cash equivalents, and marketable securities. INSM has traded in a range of $16.41 to $34.44 in the last 52 weeks. The stock closed Thursday's trading at $16.98, down 4.12%. Aargenx SE's (ARGX), Vyvgart, which was approved last December for Myasthenia Gravis, a rare, chronic, autoimmune, neuromuscular disease, has generated net product sales of $131.3 million for the third quarter ended Sep.30, 2022. Efgartigimod, the active ingredient in Vyvgart, is also being explored in a couple of indications. A registrational trial of SC efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy, dubbed ADHERE, is underway, with topline data expected in the first quarter of 2023. The company expects topline data from the second registrational ADVANCE-SC trial of SC efgartigimod for primary immune thrombocytopenia (ITP) in the second half of 2023. In the second half of 2023, the company expects topline data from the registrational ADDRESS trial of SC efgartigimod for Pemphigus Vulgaris and Foliaceus. ARGX has traded in a range of $249.5 to $403.77 in the last 52 weeks. The stock closed Thursday's trading at $372.24, down 2.97%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-10-31,120.0,122.02,116.41,120.78,
DXCM,2022-11-01,121.58,123.36,118.45,119.04,
DXCM,2022-11-02,118.33,121.41,115.48,115.95,"Is DexCom a Good Healthcare Stock to Buy Now? Shares of the medical device maker DexCom (NASDAQ: DXCM) shot about 50% higher in October. Unfortunately, the stock is still around 25% below the peak it reached in late 2021. Investors who have seen DexCom soar in the past only to come crashing down are justifiably nervous about adding the stock to their own portfolios. Let's look below the surface to see if it has any more fuel in the tank. Why DexCom soared in October On Oct. 28, DexCom stock jumped in response to a third-quarter earnings report that beat expectations on the top and bottom lines. Analysts expected adjusted earnings of $0.24 per share and were pleasantly surprised when the company reported a profit of $0.28 per share. Image source: Getty Images. DexCom specializes in constant blood-glucose monitors (CGMs) for diabetic patients. Earlier this year, the company began offering an older device called DexCom One at a lower cost in price-sensitive regions, and the strategy is working. International sales jumped 22% year over year, or 28% if you adjust for the strengthening U.S. dollar. Reasons to buy DexCom now Roughly 1 in 10 Americans are living with diabetes. Keeping blood sugar concentrations in an ideal range helps keep them out of the hospital and saves healthcare systems heaps in the process. Despite discounting some older products, DexCom's overall business is getting more profitable. Third-quarter adjusted earnings came in at 20.9% of total revenue, which was 1.9% better than the previous year's period. Investors can reasonably expect DexCom to become significantly more profitable over the next several quarters. In early October, the company launched its next-generation CGM called DexCom G7 in the United Kingdom, Germany, and other important markets around the world. DexCom sent its application for clearance of the G7 device to U.S. regulators in late 2021, but some last-minute changes to the associated smartphone application have held up the process. DexCom has already responded to the FDA's concerns and expects G7 clearance in the important U.S. market by the end of the year. Top reasons to remain cautious DexCom isn't the only company marketing CGMs to diabetic patients. Its biggest rival, Abbott Laboratories (NYSE: ABT), received FDA clearance for its next-generation CGM, FreeStyle Libre 3, in May. A long lead isn't the only reason DexCom could have a hard time competing with the much larger company's device. Abbott's inconspicuous device is the size of two stacked pennies, and it doesn't need to be replaced for 14 days at a time. The G7 is significantly larger and needs to be replaced every 10 days. The diabetic patient population is probably big enough to drive strong demand for both Abbott's and DexCom's devices. That said, expectations for the G7 are extremely high. At recent prices, the stock costs more than 150 times the company's forward-looking earnings forecast. This means anything less than an ultra-successful launch could lead to heavy losses for investors who buy the stock at its present valuation. A buy now? Smaller size and a longer life span could be significant advantages for Abbott's CGM. With an arguably inferior product, growing into its ultra-high valuation won't be easy for DexCom. It's probably best to watch this stock from a safe distance -- at least until we see how well the G7 launch progresses. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-03,114.79,117.33,112.41,112.6,
DXCM,2022-11-04,114.0,116.0,111.59,114.88,"Is It Too Late to Buy DexCom Stock? October was a good month for the stock market. The S&P 500 rose 8% after earnings season didn't turned out to be as disastrous as investors and analysts had feared. One stock that did exceptionally well last month was DexCom (NASDAQ: DXCM), which soared by a whopping 50%. At around $120 per share, the stock hasn't been this high since April. Has DexCom's stock risen too sharply in value for it to still be a good buy right now, or can it continue rising and build off its recent gains? A surge after its latest earnings report On Oct. 27, DexCom released its third-quarter earnings results, which showed excellent growth and beat analyst expectations. After consecutive quarters of missing Wall Street estimates, the company reported adjusted earnings per share (EPS) of $0.28, which soundly exceeded analyst projections of $0.24. DexCom, which is known for its continuous glucose monitoring (CGM) devices that help people with diabetes monitor their glucose levels, reported strong revenue growth of 18% for the period ended Sept. 30. Sales totaled $769.6 million as the company launched its new G7 device in five countries. Although it isn't cleared for use in the U.S. just yet, CEO Kevin Sayer said on the company's earnings call that he expects the Food and Drug Administration to give it the green light before the year is over. DexCom also reiterated its guidance for the year, calling for revenue growth of between 18% and 19%, which would see its revenue come in at about $2.9 billion. The day after the release of the results, shares of DexCom jumped to more than $120, gaining 19% in just a single session. The stock was already gradually rising during the month, benefiting from the general recovery in the markets. Has DexCom's stock become too expensive? The biggest drawback of DexCom's stock is that it can appear to be trading at too hefty of a premium. In today's bear market, that can give investors an incentive to short it or simply steer clear of it and wait for a dip in the price. In Q3, the company's unadjusted EPS was $0.24. If it were to maintain that pace for over a full year, its EPS would total $0.96. At the stock's current price tag, that would still put DexCom's price-to-earnings ratio at a whopping 125. In terms of revenue, the stock's valuation has come down and it's not absurd when compared to other diabetes specialists: DXCM PS Ratio data by YCharts Is DexCom stock a buy today? Investors have been accustomed to paying a premium for DexCom's stock simply because of its growth potential. Diabetes, unfortunately, is a growing problem in the world. In the U.S., close to 100 million people have pre-diabetes, which, without significant lifestyle changes, can eventually lead to diabetes. And according to the Centers for Disease Control and Prevention, up to 80% of people aren't aware they have the condition. DexCom's CGMs can make life easier for people with diabetes, and that's why investors see significant value in the business over the long term. And so while the healthcare stock did surge last month, it's not at all-time highs and its valuation isn't obscene given where some other top diabetes stocks are trading. As long as you're comfortable with buying and holding DexCom for years, this can still be a solid investment to buy today. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-07,115.94,116.63,113.41,115.33,"[""2 Reasons to Buy DexCom, and 1 Reason to Sell A struggling economy, rising interest rates, and negative results from high-profile corporations continue to drag the stock market down. And although medical device specialist DexCom (NASDAQ: DXCM) hasn't entirely escaped the bloodbath, the company has been doing much better in the past few months. Now, investors want to know whether DexCom can continue riding that wave for a while -- and there are good reasons why it might. However, there is also at least one major worry with this healthcare company. Are its shares a buy? Let's briefly look at both sides of the argument. DXCM data by YCharts. Reason to buy #1: Massive whitespace ahead DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients with an essential function: tracking their blood sugar levels. Being too high or too low can lead to severe -- and sometimes life-threatening -- complications. CGM devices like DexCom's G6 compete with blood glucose meters (BGM) in helping people with diabetes with this critical task. And it seems clear which method has the advantage. CGM devices take up to 288 readings per day -- one every five minutes. They also do not rely on painful fingersticks. By contrast, BGMs do rely on fingersticks and must be used manually to read a patient's glucose level at specific times. That's why CGM devices have been associated with better health outcomes for diabetes patients. And yet, they continue to lag behind their BGM counterparts. The company's CEO, Kevin Sayer, recently said: \""The domestic core market still has a long runway of growth ahead as we expect the vast majority of the population to adopt CGM to help them better manage their health.\"" But notice that the U.S. leads most other countries in CGM adoption. That means if there is plenty of room for DexCom to grow domestically, there is even more room internationally. And that's before we get into long-term trends in the number of diabetes patients increasing in the coming years. DexCom isn't the only player in this industry. Perhaps its most notable competitor is Abbott Laboratories, whose device, the FreeStyle Libre, has also been successful. But the market can accommodate multiple winners, especially as there seems to be enough room for them to grow. Reason to buy #2: A new coverage plan One barrier preventing many patients from enjoying CGM technology is third-party payers' unwillingness to cover it. Fortunately, a potential decision in the U.S. could expand those eligible for CGM coverage under Medicare. The existing coverage standards only include patients taking at least three insulin doses daily. But in October, the U.S. Center for Medicare and Medicaid Services (CMS) proposed a new plan. Under the new guidelines, even patients not on intensive insulin therapy would be eligible for CMS coverage, provided they have a history of problematic hypoglycemia (when blood glucose levels drop below a specific threshold) or take at least one insulin dose daily. According to Wells Fargo analyst Larry Biegelsent, this change could double the U.S. CGM market opportunity to eight million patients. That's not trivial, and as a leader in this field, DexCom would be one of the primary beneficiaries. True, the CMS still needs to finalize this decision, and until it does, anything could happen. But realistically speaking, these proposed plans generally look very much like the finalized ones. So there is an excellent chance the change in CGM Medicare coverage will become official. That's great news for DexCom. Reason to sell: Rich valuation Despite DexCom's seemingly bright prospects, one could argue that much of its future success is already baked into its stock price. The company's current forward price-to-earnings (P/E) ratio of 142 is substantially higher than the S&P 500's P/E of about 18.6 and the healthcare industry's average of 16.4. Failure to live up to its lofty expectations could send its stock price off a cliff. Should investors purchase shares of DexCom despite this risk? In my view, it depends on each person's investment timeline. For those willing to stay the course for five years or more, DexCom is positioned to justify its high valuation metrics. In addition to an underpenetrated and rapidly growing industry, DexCom is developing newer devices to help diabetes patients achieve even better health outcomes. The company has already begun the launch of its G7 in Europe and expects it to earn clearance in the U.S. by the end of the year. DexCom has a solid history of innovation, and we can expect the company to continue rolling out better devices down the road. That should help it increase its revenue and profits as it enrolls more diabetes patients, providing solid returns to investors in the process. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now\u2026 and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Sponsored Links The US States People Are Fleeing And The Ones They Are Moving To Forbes Read More Wells Fargo is an advertising partner of The Ascent, a Motley Fool company. Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Stock-Split Stocks That Are Crushing the Bear Market of Late Every so often, Wall Street sends investors a not-so-subtle reminder that stocks don't move up in a straight line (even if 2021 made you believe they did). This has been one of those years. Since hitting their all-time highs, the iconic Dow Jones Industrial Average, benchmark S&P 500, and tech-heavy Nasdaq Composite have respectively lost as much as 22%, 28%, and 38% of their value. This entrenches all three major U.S. stock indexes in a bear market. Image source: Getty Images. Stock splits have been Wall Street's silver lining in a trying year But in spite of burgeoning pessimism and double-digit percentage declines across most sectors and industries in 2022, investors have still found a silver lining with stock-split stocks. A \""stock split\"" is an event that allows a public traded company to alter its share price and outstanding share count without having any impact on its market cap or underlying operations. Although stock splits are a two-way street (i.e., a company's share price can be adjusted in either direction), what investors tend to be most excited about are forward stock splits. More than a half-dozen widely owned stocks have conducted forward stock splits this year. This type of split reduces the share price of a company's stock to make it more nominally affordable for everyday investors. Instead of having to save up hundreds or perhaps thousands of dollars to buy a single share of stock (assuming an investor has no access to fractional-share purchases), forward stock splits make single-share purchases easier to come by. Forward stock splits can also act as a signal that alerts investors to top-performing stocks. Companies splitting their shares have often delivered strong or sustained sales and profit growth, and in many instances are out-innovating their competition. In other words, these are the types of businesses with a chance to shine, even during a bear market. Though there have been few outperformers on a year-to-date basis, two stock-split stocks have been handily crushing the bear market of late. Shopify: 27% gain during the month of October The first stock-split stock that's been absolutely running circles around the bear market in recent weeks is cloud-based e-commerce platform Shopify (NYSE: SHOP). Shares of Shopify logged a healthy 27% gain during the month of October, albeit this followed an absolute shellacking since hitting its all-time high in November 2021. Shopify, which conducted a 10-for-1 forward stock split on June 29, 2022, has been riding high since reporting its third-quarter operating results. Although its recent resurgence is based on a smaller-than-expected quarterly loss and a \""revenue beat\"" relative to what Wall Street had expected the company to report in the September-ended quarter, it's the company's key performance indicators that deserve a closer look. To begin with, it's worth noting that Shopify's total sales were hurt by a historically strong U.S. dollar during the third quarter. Removing currency movements from the equation would yield 24% revenue growth from the prior-year period. Even accounting for high inflation, which is driving consumers to spend more, the takeaway is that Shopify is gobbling up retail commerce share in multiple channels. To add to this point, Shopify is picking up market share in brick-and-mortar stores. Shopify President Harley Finkelstein noted in an interview with CNBC following the release of his company's operating results that physical retail gross merchandise volume rose 35% in the latest quarter from the prior-year period. Innovation is playing a key role in continuing to move the needle for Shopify as well. The introduction of buy now, pay later service Shop Pay in 2021 provides its merchants with another tool they can use to grow their business. Shopify stated last year that small businesses represent a $153 billion addressable opportunity for the company. However, the retail environment will, undoubtedly, remain challenged for the foreseeable future. Historically high inflation is pinching the wallets of low-earning consumers and making small businesses think twice about upgrading to Shopify's higher-margin subscription services. With Shopify choosing to grow its point-of-sale market share and spending fairly aggressively on innovation in the near-term, it wouldn't be surprising to see bottom-line losses extend into 2023. But over longer run, where periods of economic expansion last disproportionately longer than contractions and recessions, this decision should benefit Shopify and its shareholders. DexCom's continuous glucose monitors provide a way for diabetes patients to monitor their blood glucose level without regular finger pricks. Image source: Getty Images. DexCom: 50% gain during the month of October The second stock-split stock that's completely crushed the bear market of late is medical-device company DexCom (NASDAQ: DXCM). During the month of October, shares of DexCom rocketed higher by a cool 50%. DexCom, which completed a 4-for-1 forward stock split on June 10, 2022, has been flying for the exact same reason as Shopify: better-than-expected quarterly results. Both the company's sales and adjusted earnings per share surpassed the consensus of analysts. And like Shopify, there are bigger things at work here than just headline numbers topping Wall Street's expectations. For starters, continuous glucose monitoring (CGM) system developer DexCom benefits from the generally defensive nature of healthcare stocks. No matter how poorly the stock market or U.S. economy perform, people don't suddenly stop getting sick or requiring medical care. There's a relatively safe demand floor beneath most prescription-drug and medical-device developers. More specific to DexCom, its prospective patient pool continues to grow. According to the Centers for Disease Control and Prevention, 37.3 million Americans have diabetes and 96 million additional U.S. adults have prediabetes, which can turn into full-blown diabetes if left untreated. These figures have been steadily climbing over the years, suggesting that DexCom's CGM systems have an ever-growing use case. Similar to Shopify, DexCom has been lifted by innovation. The company has introduced multiple generations of CGM's for diabetes patients, the latest of which is known as the G7. This continued innovation has led DexCom to become one of the world's two-largest CGM manufacturers and is sustaining annual sales growth of nearly 20%. The one and only blaring knock against DexCom is its valuation. Most investors are unwilling to pay a premium for stocks during bear market declines. Following its run-up, shares of DexCom are priced at 102 times Wall Street's forecast earnings for 2023. While the company's sustained growth and addressable market have certainly earned it a premium, it's not clear if a triple-digit forward price-to-earnings ratio will be sustainable in a bear market. 10 stocks we like better than Shopify When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Shopify wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-11-08,115.33,117.76,112.22,115.35,"[""Got $2,000? 2 Fantastic Stocks to Buy No Matter What the Market Does Next From rampant inflation to interest rate increases and supply chain disruptions, companies across nearly every sector are facing a unique set of challenges now. However, when you're training your focus on quality businesses that you intend to buy and hold for at least three to five years -- if not much longer -- even the current pain investors are feeling shouldn't keep you from faithfully building your portfolio. If you have $2,000 to invest in stocks right now, here are two fantastic contenders to consider for your buy list. 1. DexCom DexCom (NASDAQ: DXCM) is one of the preeminent forces in the continuous glucose monitoring (CGM) device industry, controlling a roughly 50% share of this multi-billion-dollar space. The great advantage of DexCom's CGM devices is that users don't need finger sticks and can instead rely on a one-touch applicator paired with a small sensor and transmitter to keep track of their glucose levels. The latest generation of DexCom's CGM device -- the G7, which has been approved in Europe, U.K, and Hong Kong, and is currently awaiting approval in the U.S. -- is 60% smaller than its G6 system and is ready to use in half an hour instead of two. In the U.S. alone, it's estimated that 29 million people have been diagnosed with diabetes -- and another 9 million could have diabetes and not be aware of it. CGM devices allow individuals with Type 1 or Type 2 diabetes to keep track of their glucose levels on a 24/7 basis and potentially avoid a life-threatening medical event. It's no wonder that adoption of CGMs continues to expand at a rapid clip. By the 2028, it's estimated that the global CGM market will be worth $10.4 billion, as estimated in a recent report from Grand View Research. According to the same report, \""Key factors driving this market are the rising incidence of diabetes, coupled with the increasing geriatric population prone to diabetes.\"" Over the past decade, DexCom has delivered a total return of nearly 300% for investors. This has been driven by the continued success of its CGM devices and robust revenue growth paired with consistent profitability. In that same trailing-10-year period, DexCom's annual revenue has increased 66%, while its net income has grown by more than 53%. In the first nine months of 2022, DexCom's total revenue jumped 20% compared to the same period in 2021, while its net income rose by a clip of 12%. At its current price, a $2,000 investment in DexCom would leave you with about 17 shares. 2. Pfizer Pfizer (NYSE: PFE) caught the attention of many investors in the earlier days of the pandemic. Comirnaty, the blockbuster COVID-19 vaccine that it developed with BioNTech, reached nearly $37 billion in sales in 2021. Its coronavirus antiviral medication Paxlovid hit $76 million in sales last year despite only gaining Emergency Use Authorization from the U.S. Food and Drug Administration in December. Now, with an inevitable decline in sales of Pfizer's coronavirus products expected, and some of its core products losing patent exclusivity soon, some investors might wonder whether the thesis for this healthcare giant still holds true. I would maintain that it does, and I'll tell you why. First of all, let's take a look at Pfizer's financial track record over a much broader period than its pandemic-era successes. It's true, balance sheet growth occurred at a much more conservative clip pre-pandemic -- not at all unusual for one of the world's largest pharmaceutical companies -- with revenue increasing by about 2% operationally in both 2018 and 2019. However, looking back over the trailing-10-year period, the company has increased both its revenue and net income by around 50%, and its operating cash flow has risen by approximately 95%. While Pfizer reported revenue growth to the tune of 92% in 2021 (largely driven by its coronavirus vaccine and antiviral pill sales), excluding these products, revenue still jumped by a 6% clip compared to 2020. This is more on par with what investors would expect from a mature business like Pfizer's in a normal environment. In the most recent quarter, eye-popping performance in the year-ago period combined with a decline in coronavirus vaccine sales meant that on a year-over-year comparison, overall revenue actually decreased by 2%. However, taking out Pfizer's COVID-19 products, revenue actually grew 2% on a year-over-year basis. Pfizer is continuing to see strong growth from its existing broad portfolio of drugs, which include blockbusters like blood thinner Eliquis, its Prevnar family of vaccines, and cardiomyopathy drugs Vyndaqel/Vyndamax. As for its pipeline, CEO Albert Bourla noted in the third-quarter earnings report that \""over the next 18 months, we expect to have up to 19 new products or indications in the market ... the majority were discovered in-house, and nearly all would be for indications outside of COVID-19.\"" Pfizer's incredible successes with its COVID-19 products has also added a tremendous amount of cash to its balance sheet, which it has used to fuel its research and development pipeline and ramp up its M&A activity. Both strategies could pay off big time for its business over the next five to 10 years, and for investors as well. In 2022 alone, Pfizer has made a series of well-placed acquisitions that have brought a range of promising candidates and therapies into the fold, including Arena Pharmaceuticals (known for its treatments for immuno-inflammatory disorders, among a range of other disease areas), ReViral Pharmaceuticals (known for its RSV therapies), and Biohaven Pharmaceuticals (known for its preventative migraine treatment). Beyond Pfizer's track record of blockbuster successes, another factor that may draw investors is its dividend. The healthcare stock features a yield of 3.4%, considerably more than the 2% of the average stock trading on the S&P 500. Pfizer's dividend has also increased by more than 80% over the past decade alone. To give context, Pfizer first started paying its dividend in 1938 (yes, you read that right), and has paid a dividend every quarter since. At Pfizer's current price, a $2,000 investment would add about 43 shares to your portfolio. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Rachel Warren has positions in DexCom. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Got $1,000? 2 Bear Market Stocks to Jump On Right Now Stocks have dipped in and out of bear market territory multiple times in recent months, and more volatility could still lie ahead for investors. With all the major indexes trading down since the beginning of 2022, you're in good company if your portfolio has taken a bit of a beating. Lots of investors are in the same boat. Here's the good news: While investments across a range of industries may be trading down, solid businesses with great leadership and strong, long-term growth prospects can recover from these doldrums. Investors who continue to put their capital into these types of companies can be well-positioned for this recovery when it does come. On that note, if you have $1,000 to invest in the market -- not money you'll need for bills, but cash you can leave in your portfolio for several years at least -- here are two such stocks to consider buying in the near future. 1. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) has been dealing with industry headwinds lately -- specifically, lower procedure volumes in certain markets that are still seeing lingering impacts from the pandemic. These headwinds have impacted its financial results, which explains the stock's precipitous dip of nearly 35% over the past 12 months. Still, Intuitive Surgical has continued to report profitable quarter after quarter despite these factors. What's my point here? It's so, so important for investors to look beyond headlines and even share-price fluctuations to discern whether a stock represents a company in peril or a compelling buy opportunity in a down market. I would maintain that Intuitive Surgical falls into the latter category, and the factors that have impacted its recent quarterly reports aren't related to issues with the actual business itself. The company's da Vinci surgical system is one of the premier surgical robotics systems in the world. It's used in a wide variety of procedures including colorectal, cardiac, thoracic, and general surgeries, to name a few. To date, the da Vinci system has facilitated more than 10 million procedures globally. In 2021, Intuitive Surgical grew its total revenue 31% from the prior year to $5.7 billion, with net income rising 62% year over year to $1.7 billion. In the third quarter, Intuitive Surgical's total revenue rose 11% year over year to $1.4 billion, while total procedures using the da Vinci system jumped 20% from the year-ago period. Even as fluctuating procedure volumes from ongoing spikes in COVID-19 cases in certain markets caused its net income to drop slightly from the same quarter last year, Intuitive Surgical still reported earnings of $324 million. The company also ended the three-month period with cash, cash equivalents, and investments of $7.4 billion. It's also worth pointing out that Intuitive Surgical has increased its annual cash position by more than 130% over the trailing decade alone. At Intuitive Surgical's current price, a $1,000 investment would leave you with about four shares. 2. DexCom While shares of DexCom (NASDAQ: DXCM) are still trading down by about 30% from one year ago, the stock has risen by nearly that amount over the last month alone. Why do investors appear to be increasingly bullish about DexCom? There are a few factors that have driven the healthcare stock's recent journey skyward. For one, there's the company's robust third-quarter earnings, which it reported on Oct. 27. Its results beat Wall Street's estimates on both the top and bottom lines. There's also the company's pending approval of its new G7 system, the latest generation of its flagship continuous glucose monitoring (CGM) system, which is expected to occur imminently in the U.S. and has already received the green light in the U.K. and Europe. In the third quarter, DexCom's overall revenue jumped 18% from the year-ago period to $770 million, driven by 17% growth in the U.S. and 22% internationally. Meanwhile, the company's operating income surged by 100 basis points year over year, coming in just shy of $150 million. Bear in mind, this follows revenue growing 27% to $2.5 billion in 2021, paired with total operating income of $266 million. To give you an idea of DexCom's tremendous market footprint, the global CGM device industry hit a valuation of $5.3 billion last year. DexCom's revenue accounted for roughly half of that total. DexCom certainly isn't without rivals in this space. Abbott and its FreeStyle Libre 3 CGM system is by far one of the most prominent. However, I would contend that there is room for more than one winner here. Moreover, DexCom's longstanding leadership in this space and control of a vast slice of thisglobal marketbode well for the continued rollout of its G7 system and the growth its business can deliver for both its balance sheet and investors over the long term. Investing $1,000 in DexCom stock at its current price would add approximately nine shares to your investment portfolio. 10 stocks we like better than Intuitive Surgical When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Intuitive Surgical wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-11-09,114.12,115.4,112.51,113.15,
DXCM,2022-11-10,118.99,120.75,117.04,119.84,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. So far this year, this Zacks Rank #3 (Hold) stock has lost 15.7% compared with a 33.7% decline of the industry and a 20.9% decline of the S&P 500. This renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $44.55 billion. The company projects 31.4% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and matched estimates in one, delivering a negative earnings surprise of 10.07%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in five countries during the third quarter, making the latest G7 sensor technology available for international markets. The company anticipates FDA clearance for G7 sensor technology before 2022-end. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. DexCom’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria in March. Strong Q3 Results: DexCom’s solid third-quarter 2022 revenues buoy optimism. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available for international markets. Downsides Reimbursement Risk: Reimbursement risk is somewhat high due to the efforts to control healthcare expenses. The company noted that most type 1 patients (above 65) pay 100% of their CGM costs from their own pockets. Unless payers (both government and private insurers) are provided with sufficient coverage and reimbursement, commercial success for DexCom will be limited, in our view. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a positive estimate revision trend for 2022. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved 1.3% north to 80 cents. The Zacks Consensus Estimate for the company’s fourth-quarter 2022 revenues is pegged at $810.3 million, suggesting a 16.1% improvement from the year-ago quarter’s reported number. The same for earnings per share stood at 28 cents, implying 64.7% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are ShockWave Medical SWAV, AMN Healthcare Services AMN and McKesson MCK, all carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for ShockWave Medical’s earnings per share is stable at $2.57 for 2022 and rose from $3.42 to $3.56 for 2023 in the past 60 days. SWAV has gained 43.1% so far this year. ShockWave Medical delivered an earnings surprise of 146.1%, on average, in the last four quarters. Estimates for AMN Healthcare Services have improved from earnings of $11.26 to $11.43 for 2022 and $8.30 to $8.39 for 2023 in the past 60 days. AMN stock has declined 1.6% so far this year. AMN Healthcare Services delivered an earnings surprise of 10.96%, on average, in the last four quarters. McKesson’s earnings per share estimates increased from $24.42 to $24.75 for fiscal 2023 and $26.04 to $26.40 for fiscal 2024 in the past 60 days. MCK has gained 55.2% so far this year. McKesson delivered an earnings surprise of 4.79%, on average, in the last four quarters. Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation. >>Send me my free report on the top 5 EV stocks Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report ShockWave Medical, Inc. (SWAV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-11,119.12,122.28,114.59,115.96,"3 No-Brainer Growth Stocks to Buy for 2023 and Beyond InvestorPlace - Stock Market News, Stock Advice & Trading Tips When searching for growth stocks to buy, investors should first ascertain what growth means to them. It varies from person to person. I might define growth stocks as companies growing sales by 20% annually. You might feel the “true” growth stock is growing earnings by 15% annually. There’s no single definition that can be found in the Merriam-Webster dictionary. If I’m searching for three no-brainer growth stocks to buy for 2023 and beyond, my first criterion should be a company that pays no dividends and repurchases very little of its stock. Beyond that, there are many directions I could turn. So, to speed up this process, I’ve decided to find my stocks in the S&P 500 Pure Growth ETF. This ETF tracks the performance of the S&P 500 Pure Growth Index, a collection of stocks from the S&P 500 that exhibit strong growth characteristics. The ETF’s prospectus says the following about finding pure-growth stocks: “The ‘growth score’ is measured using three factors: three-year sales per share growth rate, the ratio of the three-year net change in earnings per share to current price per share, and momentum (the 12-month percentage change in price).” Invesco’s ETF currently has 58 stocks (57 if you exclude the double entry for Alphabet). These are the three no-brainer stocks to buy for 2023 and beyond that I think are the best of the bunch. ENPH Enphase Energy $309.25 DXCM Dexcom $119.84 EPAM EPAM Systems $350.45 Enphase Energy (ENPH) Source: IgorGolovniov / Shutterstock.com A quick look at the Morningstar.com financial statements page for Enphase Energy (NASDAQ:ENPH) is all investors need to classify this company as a high-growth stock. The renewable energy company grew its revenue from $624.3 million at the end of 2019, to $2.02 billion as of Sept. 30, 2022, a cumulative growth rate of 223%. Its operating income over the same period grew 232%. I’d say that’s healthy growth. The world’s leading supplier of microinverter-based solar and battery systems reported excellent Q3 2022 results at the end of October. These results included record quarterly revenue of $634.7 million, 20% higher than Q2 2022 and 81% above Q3 2021. Notably, the company’s non-GAAP gross margin also increased 210 basis points to 42.9%. Enphase finished the third quarter with $1.42 billion in cash, $1.29 billion in total debt, and a net cash position of $130 million. Free cash flow, a metric I’m always looking for in my stocks to buy, was $545 million for the trailing 12 months ended Sept. 30, up significantly from a year ago. By most valuation metrics, ENPH stock isn’t cheap. However, when you’re buying quality, especially in these difficult times, investors will pay up. Dexcom (DXCM) Source: Andrew_Popov / Shutterstock.com Dexcom (NASDAQ:DXCM) completed a 4-for-1 stock split on June 27. The maker of glucose monitoring systems went public in April 2005 at $12 a share, selling 4.7 million shares to investors. If you bought IPO shares and are still holding, you’ve seen your investment appreciate 3,672% over 17.5 years, a compound annual growth rate of 23.1%. The S&P 500, over the same period, had a 2.2% CAGR. That’s a resounding beat if I’ve ever seen one. Dexcom reported its Q3 2022 earnings at the end of October. It beat on both the top line ($769.6 million vs. the consensus estimate of $752.7 million) as well as the bottom line, delivering 28 cents per share in earnings, four cents higher than analyst expectations. Of the 20 analysts covering DXCM stock, 16 rate it overweight or an outright buy. The analysts’ average target price is $122.33, roughly 2% higher than where it’s currently trading. Like Enphase, Dexcom carries a net cash position. The company finished the third quarter with $2.37 billion in cash on its balance sheet against $2.13 billion in total debt, for $240 million in net cash. What stands out for me in the company’s Q3 2022 report is the balance building between its sales in the U.S. and those internationally. The launch of its Dexcom G7 continuous glucose monitoring device in five countries during the quarter, including the UK and Germany, has bolstered its international presence. These international clients now account for approximately 27% of Dexcom’s revenue, up from 24% a year ago. Currently, DXCM stock currently trades around 16.2-times sales. It hasn’t been this low since 2019. EPAM Systems (EPAM) Source: Tricky_Shark / Shutterstock.com EPAM Systems (NYSE:EPAM) has been getting crushed in 2022. Its stock is down more than 52% year-to-date and 55% over the past 52 weeks. While the company’s stock might be getting hammered, the software engineering and IT consulting services business provider is doing just fine. In Q3 2022, its revenues jumped 24.1% to $1.23 billion, while its non-GAAP EPS increased 28.1% to $3.10. EPAM generated at least $100 million in quarterly revenue from six different verticals, including Travel & Consumer, which experienced tremendous growth in the quarter. This segment in particular grew 42% year-over-year to $280 million. An example of how far the company has come over the past three years is its growth in its number of employees. At the end of the third quarter, EPAM had 60,300 employees. At the end of 2019, it had 32,561 employees. Thus, in less than three years, this company almost doubled its headcount. Analysts like EPAM stock. All nine of the analysts covering it, according to Tipranks, rate it a buy with a target price of $418.44, 19% higher than its current share price. It’s not a flashy business, but it gets the job done. On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. The post 3 No-Brainer Growth Stocks to Buy for 2023 and Beyond appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-14,115.75,115.75,112.47,112.99,
DXCM,2022-11-15,115.1,116.99,113.7,116.31,
DXCM,2022-11-16,116.84,117.0,114.43,114.89,"2 Unstoppable Growth Stocks to Buy in 2022 and Beyond While growth stocks aren't attracting the interest from investors that they were a few years ago, not all businesses that fall into this category of investments have dealt with the same headwinds as many former pandemic favorites. Today, we're going to take a look at two top healthcare stocks with growth-driven businesses that have a robust track record of rewarding investors. Here's why you might want to consider investing in these two stocks for your long-term buy-and-hold portfolio. 1. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is a name known to many healthcare investors for its profitable and fast-growing surgical robotics business, which has led it to deliver a total return of about 345% to investors over the past decade. There are several key factors that have enabled the company to generate robust top- and bottom-line growth in a wide variety of market environments and over a prolonged period of time. For one, the company controls the vast majority of the surgical robotics market. As of 2021, it was estimated that its market footprint stood at a noteworthy 80%. The company's da Vinci Surgical System is used in millions of procedures from general to thoracic to cardiovascular surgery. Roughly 1.6 million procedures were performed using the da Vinci Surgical System in 2021. Resurgences of COVID-19 cases in certain markets have limited procedure volume to a certain extent in recent quarters. But most people aren't going to put off having an important medical procedure regardless of what's happening in the wider environment, much less with the stock market. Intuitive Surgical also has a very sticky business model. It sells its systems as well as accompanying instruments and software to medical providers, but the company also generates recurring revenue from the cost of replacing certain components of its surgical robotics systems after wear and use. It's no wonder that the company has boosted its annual revenue, profits, and cash flow by 162%, 160%, and 157%, respectively, over the past 10 years. Long-term investors looking for a healthcare company that has ridden out many market cycles and possesses a powerhouse noncyclical business might wish to take a second look at this top healthcare stock. 2. DexCom DexCom (NASDAQ: DXCM) has delivered investors an incredible total return of nearly 3,600% in the trailing decade. The company's core business model centers around revenue and profits from its continuous glucose monitoring (CGM) devices. CGM devices not only face consistent demand, but they are essential for many type 1 and type 2 diabetes patients worldwide. In short, even if the macroeconomic situation were to worsen, patients are still going to use (and often require) these devices as a part of daily life. DexCom's CGM devices don't need patients to use a finger jab, instead, it allows them to measure glucose readings through a one-touch applicator that conveys the data to their smartphone or other integrated devices. In this way, someone with type 1 or type 2 diabetes can track glucose readings in real-time, which can inform more consistent habits such as diet and physical activity that will keep blood sugar levels in check. Today, around 1 million people globally wear a CGM device made by DexCom. The release of DexCom's latest CGM device, the G7, is already underway in Europe, the U.K, and Asia, and is expected in the U.S. shortly. This latest model is 60% smaller than the G6 model and features a sensor that warms up in just a half-hour, which DexCom says is the fastest of any on the market. DexCom's market leadership, elevated and stable demand for its products, and strong financial track record (revenue and profits are up 66% and 53%, respectively, over the past three years alone) are all notable reasons for investors to consider scooping up this healthcare stock before year's end. 10 stocks we like better than Intuitive Surgical When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Intuitive Surgical wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-17,112.67,114.76,111.73,112.64,
DXCM,2022-11-18,114.6,115.36,112.615,113.72,"3 Stocks to Buy for Long-Term Growth Upside Today’s episode of Full Court Finance at Zacks dives into the stock market and takes a look at the next likely market catalysts as we near Thanksgiving. Despite the recent dip, the market has been on a strong run during the first half of the fourth quarter. With this in mind, let’s look at three stocks—JinkoSolar (JKS), GlobalFoundries (GFS), DexCom (DXCM)—that investors might want to buy for long-term growth potential from three different parts of the economy that become more important by the day. Wall Street posted a slightly downbeat week as investors learned a lot more about the current state of the U.S. consumer via reports from Walmart, Target, Home Depot, and others. The reports highlight that consumers are pulling back on discretionary spending. The outlook for S&P 500 earnings continues to decline for fiscal 2023, with the aggregate total down over 8% from the peak. Still, overall S&P 500 earnings are projected to be up 2.8% in 2023 on 2.5% higher revenue. This is expected to follow 4.9% earnings expansion this year on 10.2% stronger sales. Wall Street has been actively pricing in falling earnings and rising rates. But the market could have gotten slightly ahead of itself with last week’s post-CPI release surge. Jay Powell and the Fed aren’t likely to pull back on their efforts just yet. Therefore, the next major market catalysts will likely be November’s CPI data and the Fed’s December FOMC meeting. That said, time in the market often beats market timing, especially for long-term investors. And Wall Street is always ahead of Mainstreet. Therefore, investors might want to consider buying stocks after the strong first half of the fourth quarter. Today, we explore three stocks that are set to expand within three crucial growth industries. JinkoSolar JKS JinkoSolar is one of the largest solar panel manufacturers on the planet. JinkoSolar has grown its revenue at an impressive and mostly steady rate over the last decade. The Chinese solar firm topped Zacks Q3 estimates in early November, as its global module shipments doubled year-over-year. JKS lands a Zacks Rank #1 (Strong Buy) right now and its top and bottom-line outlook is impressive. (It’s worth pointing out that I bought JKS stock as part of Zacks' newest trading service – Alternative Energy Innovators). GlobalFoundries GFS GlobalFoundries is a U.S.-based chip manufacturer that’s poised to gain momentum and market share as those in power realize the U.S. must play a larger role in the actual manufacturing of semiconductors. GlobalFoundries is exposed to growth in mobile devices, data centers, the auto industry, and beyond. GFS topped our Q3 estimates on November 8, and its positive bottom-line revisions help it land a Zacks Rank #2 (Buy). DexCom, Inc. DXCM DexCom’s continuous glucose monitoring systems for people with diabetes have grown in popularity because they enable users, families, and healthcare providers to receive data constantly to help make the best medical decisions. DexCom stock has skyrocketed over the last 10 years as diabetes becomes more prevalent. DexCom topped our Q3 estimates and the stock still trades 30% below its highs. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JinkoSolar Holding Company Limited (JKS): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report GlobalFoundries Inc. (GFS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-11-21,112.62,113.55,112.12,112.66,
DXCM,2022-11-22,113.67,113.88,110.31,111.01,
DXCM,2022-11-23,111.67,113.335,110.6,112.92,
DXCM,2022-11-25,112.91,113.02,110.65,112.0,
DXCM,2022-11-28,111.62,114.75,111.62,112.57,
DXCM,2022-11-29,112.3,113.71,110.134,110.39,
DXCM,2022-11-30,110.67,116.36,110.285,116.28,
DXCM,2022-12-01,116.39,119.98,116.25,118.03,"[""2 Monster Stocks to Buy Without Any Hesitation When you're investing in companies with sticky businesses and compelling products and/or services that generate durable demand in a wide range of environments, you can set your portfolio up for success over the long-term. While there is no such thing as a perfect investment, there are many great businesses trading at discounts right now that fit the bill. Investors with the capital on hand may wish to consider taking advantage of these bargains, provided they have a long-term buy-and-hold time horizon and fully understand the businesses they are putting their hard-earned cash into. With that, let's take a look at two top growth stocks to consider adding to your portfolio before the year is out. 1. DexCom The incidence of diabetes is on the rise globally, and it's a chronic condition that impacts nearly 1 in 10 people in the U.S. alone. For millions of individuals around the world, in addition to lifestyle and dietary changes, a key element of managing the disease is wearing a continuous glucose monitoring (CGM) device. The global CGM industry was valued at $6 billion in 2021, and is set to hit a $16 billion valuation by 2030. DexCom (NASDAQ: DXCM) controls roughly 50% of this entire industry with its top-selling CGM products. The company is currently rolling out the latest model of its flagship CGM product, the G7. The release of the G7 is expected in the U.S. as soon as the first quarter of 2023, while distribution is already underway in certain European and Asian markets, as well as in the U.K. This latest CGM is not only 60% smaller than the G6 model, but has the shortest warm-up time of any such device on the market today. DexCom's vast industry footprint, coupled with rising diagnoses of diabetes and favorable legislative tailwinds continuing to expand patient coverage for CGMs through Medicare and Medicaid, all bode well for the long-term growth of this company. From a simple market-analysis standpoint, DexCom services a growing and constant medical need that impacts a substantial (and increasing) swath of the global population, and it does so at a massive scale. DexCom has grown its revenue by roughly 2,400% over the trailing decade. And just in the past three years, its annual net income has shot up by more than 53%. Investors can benefit from this top healthcare stock, which can steadily grow its business, revenue, and profits, even in an otherwise volatile economic environment. 2. Etsy Etsy (NASDAQ: ETSY) may no longer be the e-commerce stock that investors were rushing to buy at the beginning of the pandemic, but that doesn't mean its growth story is a thing of the past. On the contrary, Etsy stands to benefit considerably from the consumer-driven tailwinds driving prolonged growth in the global e-commerce market, a space on track to hit a valuation of roughly $63 trillion by the year 2030. Etsy's advantage lies in the fact that it doesn't compete directly with most well-known e-commerce companies. It controls a unique parcel of the e-commerce space with its focus on specialty, unique, vintage, and handmade goods. Not only would you be hard-pressed to find a competitor that occupies this exact e-commerce niche, but there are virtually none that do so at the scale and size that Etsy does. In fact, a study the company conducted last year found that 87% of buyers say that the Etsy platform sells products they can't find elsewhere, while 72% concur that \""there is no other store or website similar to Etsy.\"" Etsy certainly saw accelerated balance sheet gains at the height of the pandemic, with revenue surging 111% in 2020. While this growth moderated to 35% in 2021, this was right in line with its pre-pandemic year-over-year revenue increases of 27% in 2018 and 36% in 2019. Etsy's revenue grew by a healthy 12% year-over-year in the most recent quarter. Although it reported a net loss, this was largely comprised of a $1.1 billion non-cash impairment charge from pandemic-era acquisitions. Etsy also reported $168 million on an adjusted EBITDA basis, and had accumulated a hefty stockpile of cash and investments to the tune of $1.1 billion at the end of the quarter. Investors will likely need to be patient with this stock as growth normalizes from the pandemic and it works back toward GAAP profitability. However, Etsy's strong position in its large and growing addressable market -- one that management estimates is worth a whopping $2 trillion -- could bring strong balance sheet and investor returns in the years to come. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Rachel Warren has positions in DexCom and Etsy. The Motley Fool has positions in and recommends Etsy. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Top Research Reports for Walmart, Toyota Motor & Schlumberger Thursday, December 1, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Toyota Motor Corp. (TM) and Schlumberger Ltd. (SLB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today\u2019s research reports here >>> Walmart's shares are in line with the Zacks Retail - Supermarkets industry over the past year (+12.5% vs. +12.4%). The company has been benefiting from its robust omnichannel operations due to its efforts to enhance both store and online experience. Walmart has been particularly gaining from its efforts to boost delivery services through acquisitions and partnerships. The company\u2019s U.S. comp sales continued to benefit from an increased market share in grocery in the third quarter of fiscal 2023, wherein the top and bottom lines surpassed the Zacks Consensus Estimate and increased year over year. A robust third-quarter show encouraged management to raise its overall guidance for fiscal 2023. However, its consolidated operating income and earnings per share view still suggest a decline from the year-ago period figures. The company is encountering cost inflation, and expects it to remain elevated. (You can read the full research report on Walmart here >>>) Shares of Toyota Motors have declined -19.4% over the past year against the Zacks Automotive - Foreign industry\u2019s decline of -40.1%. The company is facing supply-chain disruptions, logistical challenges and manufacturing inefficiencies are likely to dent profits. Operating income is projected to decline 19.8% year over year. High capex and R&D expenses are also likely to dent cash flows. Also, Toyota's rising debt pile raises concerns. As such, investors are advised to wait for a better entry point. However, the Japan-based carmaker is one of the world\u2019s leading automakers, with an array of brands, including Toyota, Lexus and Scion, offering solid prospects. Toyota\u2019s electrification push is a major tailwind. It is deepening its focus on manufacturing electric and fuel-cell vehicles, which will bolster the company\u2019s product competitiveness. The company's raised sales view for fiscal 2023 sparked optimism. Investor-friendly moves also instill confidence. (You can read the full research report on Toyota Motor here >>>) Schlumberger\u2019s shares have outperformed the Zacks Oil and Gas - Field Services industry over the past year (+75.9% vs. +20.1%). The company is the single largest oilfield services player, with a presence in every energy market across the globe. Being the leading provider of technology for complex oilfields, the company is well-poised to take up new offshore projects in international markets. The significant increase in oil prices is aiding its overall business. Increased participation in growth of drilling and completion activities across the world brightened the company\u2019s outlook. Also, it boasts of becoming the first company in the energy service industry to add Scope 3 emissions ambition in the net-zero emission target. However, the company\u2019s balance sheet has massive debt exposure compared with the composite stocks in the industry. Also, the aggressive capital spending budget remains a headwind for the company. As such, the stock warrants a cautious stance. (You can read the full research report on Schlumberger here >>>) Other noteworthy reports we are featuring today include Lululemon Athletica Inc. (LULU), DexCom, Inc. (DXCM), and Enphase Energy, Inc. (ENPH). Mark Vickery Senior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Walmart (WMT) Benefits from Impressive E-Commerce Operations Electrification Drive Aids Toyota Motor (TM) Amid Inflation Schlumberger (SLB) to Gain on Rising Oilfield Service Demand Featured Reports Strong Product Portfolio Aids DexCom (DXCM) Fight Competition Per the Zacks analyst, DexCom strong product portfolio targeting the large and growing diabetes market is helping the company fight intensifying competition with entry new competing products. Solid Adoption of ESG Solution Aids MSCI's (MSCI) Progress Per the Zacks analyst, MSCI is benefiting from strong demand for custom and factor index modules and the increasing adoption of the ESG solution into the investment process. Atlassian (TEAM) Gains On Rising Remote Working Tool Demand Per the Zacks analyst, Atlassian is benefiting from the COVID-19 pandemic-led work-from-home wave, which is spurring demand for offsite-working software and hardware tools. Old Dominion (ODFL) Rides on Dividends & Buyback, Expenses Ail The Zacks analyst likes the shareholder-friendly measures adopted by Old Dominion. However, rising operating expenses are concerning as they are likely to keep the bottom line under pressure. Willis Towers (WTW) Rides on Buyouts & Strong Balance Sheet Per the Zacks analyst, a number of buyouts have helped Willis Towers expand its geographical footprint and ramp up product portfolio. Its healthy balance sheet enables it to fulfill debt obligations. Global Reach Buyout Benefits FLEETCOR (FLT), Liquidity Low Per the Zacks analyst, Global Reach buyout strengthens FLEETCOR's global position as a non-bank cross-border provider by increasing its scale of payments. However, low current ratio is a headwind. United Therapeutics (UTHR) Dependence on PAH Drugs A Woe United Therapeutics is a leader in treating pulmonary arterial hypertension (PAH) and markets four drugs. However the lack of product and pipeline diversification beyond PAH concerns the Zacks Analyst New Upgrades lululemon (LULU) Tracks Well with E-commerce Expansion Plans Per the Zacks analyst, lululemon is heavily investing in e-commerce capabilities like developing sites, transactional omni functionality and fulfilment options to capture the growing online demand. Expanding Solar Market to Boost Enphase Energy (ENPH) Growth Per the Zacks analyst, the expanding solar market that has set the stage for the solar microinverter market's boom tends to benefit Enphase as it remains a leading U.S. manufacturer of microinverters. RPM International (RPM) Gains From Buyouts & Strategic Plans Per the Zacks analyst, RPM benefits from the implementation of MAP 2025 operational improvement initiatives as well as various acquisitions. New Downgrades Macro Headwinds, Component Shortages Drag Down Seagate (STX) Per the Zacks analyst, Seagate's performance is likely to be affected by uncertainty prevailing over global macroeconomic conditions along with non-HDD component shortages in the near term. Strong Product Portfolio Aids DexCom (DXCM) Fight Competition Per the Zacks analyst, DexCom strong product portfolio targeting the large and growing diabetes market is helping the company fight intensifying competition with entry new competing products. Dismal Visitation Likely to Hurt MGM Resorts (MGM) Prospects Per the Zacks analyst, MGM Resorts is experiencing limited visitation in Macau owing to coronavirus crisis. Also, lack of frictionless travel between Macau and Mainland China is a concern. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Toyota Motor Corporation (TM) : Free Stock Analysis Report Schlumberger Limited (SLB) : Free Stock Analysis Report Walmart Inc. (WMT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report lululemon athletica inc. (LULU) : Free Stock Analysis Report Enphase Energy, Inc. (ENPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Supercharged Growth Stocks to Buy for 2023 If you're looking for stocks that can put up big gains next year, you've got more than a few viable options. Soaring interest rates have decimated growth stocks of all shapes and sizes in 2022, and some are poised to come roaring back. During bear markets like the one we're experiencing, shares of great businesses can fall just as easily as shares of stocks that are best avoided. Here's why these three stocks look like excellent options to buy now and hold through 2023 and beyond. Image source: Getty Images. 1. DexCom DexCom (NASDAQ: DXCM) is a niche medical device company that specializes in constant blood glucose monitors. These are battery-powered stickers that send blood sugar readings to smartphones and other devices connected to the internet. Keeping blood sugar in an ideal range doesn't just lead to better health outcomes; it can save healthcare plan sponsors a bundle. Regular use of a CGM goes a long way toward reducing costly hospitalizations that become necessary when a diabetic patient's blood sugar rises too high or falls too low. Shares of DexCom have recovered from low points over the summer, but the stock is still 31% below the all-time high it reached in 2021. Next year could be one to remember because the company's next-generation CGM is expected to earn a long-awaited approval from the U.S. Food and Drug Administration by the end of 2022. DexCom reported third-quarter revenue that rose 18% year over year in the third quarter. With the ability to market a smaller, more advanced CGM in the U.S. soon, 2023 could be another year of rapid growth for this company and its shareholders. 2. SoFi Technologies SoFi Technologies (NASDAQ: SOFI) is an all-digital bank that got started around a decade ago as the first company to refinance student loans. Now, it's a full-service consumer bank and a technology provider for a large cross-section of smaller fintech businesses. SoFi's membership roster has more than tripled in size over the past two years to reach 4.7 million at the end of September. Its business-to-business operation is also growing at a rapid clip. The number of accounts enabled by its technology platform soared 40% year over year to 124 million. This January, the company obtained a national banking charter, Now, it can use its members' savings and checking account deposits to fund lucrative auto loans and personal loans. As a result, its operation is rapidly heading toward profitability. Earnings before interest, taxes, depreciation, and amortization (EBITDA) are expected to reach 8% of total revenue this year. That's up from just 3% last year and negative territory in 2020. 3. InMode According to Grand View Research, theglobal marketfor medical aesthetics reached a whopping $99 billion in 2021, and it's expected to more than triple by 2030. Buying some shares of InMode (NASDAQ: INMD) looks like a smart way to take advantage of this trend. InMode develops and markets minimally invasive devices that contour and shape various parts of the human anatomy using its proprietary radiofrequency technology. Instead of relying on sales of the devices themselves, the company sees an increasing percentage of total revenue coming from sales of consumables accessories that need to be replaced before each procedure. Despite macroeconomic headwinds, total revenue from services and consumables soared 53% year over year in the third quarter, and operations are already strongly profitable. Adjusted earnings are expected to come in around at around 48% of total revenue this year. At recent prices, you can scoop up the stock at just 15.6 times this year's adjusted earnings expectations. With a unique business that keeps gaining a share of the enormous, rapidly growing medical aesthetics market, this stock looks like an unbelievable bargain. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Cory Renauer has positions in InMode Ltd. and SoFi Technologies, Inc. The Motley Fool has positions in and recommends InMode Ltd. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Best Stocks to Invest $20,000 in Right Now With so many companies across a wide variety of sectors suffering the wrath of volatile investor sentiment, it's easy to feel discouraged about the prospects of your portfolio in the current moment. However, when you're investing in quality stocks for five years, 10 years, 15 years -- or even longer -- the near-term environment is just a blip on the radar when compared to the broader scope of your investment journey. If you have $20,000 to invest long-term in stocks, here are three to consider putting at least some of that money toward today. 1. DexCom DexCom (NASDAQ: DXCM) may not be a household name like some other healthcare stocks, but its products are a regular fixture of everyday life in millions of households globally. The company's business model is simple. It manufactures and sells continuous glucose monitoring devices (CGMs). These devices are used by both type 1 and type 2 diabetics to track glucose levels and mitigate adverse blood sugar events. Not only do these products generate robust demand by nature of the patients they serve, but DexCom wields control of roughly half of the entire CGM market worldwide. This has proven a catalyst for strong investor returns, not to mention revenue and profits. Looking at the company's growth over the past three years, DexCom's annual revenue and net income have jumped by 66% and 53%, while the stock has generated an eye-popping total return of nearly 100%. With the growing prevalence of diabetes and the need for effective CGM devices on the rise, DexCom is ideally suited to meet this expanding need and increase its share of this lucrative market. 2. Amazon Amazon (NASDAQ: AMZN) may be struggling against the headwinds of a volatile global economy and negative sentiment against tech stocks, but that doesn't mean this household name has exhausted its growth potential. Stepping back from the events of the past few quarters, the company still dominates two of the most profitable, rapidly expanding industries on the planet. Of course, I'm referring to its share of the multi-trillion-dollar e-commerce industry -- Amazon boasts a 14% share globally and a 50% share in the U.S. Plus, Amazon leads the global cloud computing industry -- a $217 billion market, of which it currently controls 34%. Even in the current environment, investors who held on to Amazon over the past five years would have experienced a total return of about 56%, with the company growing its top and bottom line by 164% and 1,000% during that same period. This is a company that has ridden out more than its fair share of market and economic storms. Amazon's notable presence in the e-commerce and cloud computing spaces, not to mention its diverse collection of businesses that span industries from healthcare to entertainment, all bode well for its durable growth story in the years ahead. 3. Airbnb Before the pandemic, Airbnb (NASDAQ: ABNB) controlled roughly 20% of the vacation rental market in the U.S. alone and has successfully increased its share since that time. Meanwhile, in 2021, the global vacation rental space hit a valuation of $75 billion. Taking Airbnb's 2021 revenue of $6 billion -- which includes experiences booked but largely stems from vacation rental fees -- would give the company a roughly 8% share of the global vacation rental market. Given that this fast-growing space is on track to hit a valuation of $119 billion by 2030, this certainly portends well for Airbnb's future growth prospects. Not only has the high-growth business rapidly moved to profitability -- the third quarter was its most profitable ever, to the tune of $1.2 billion -- but it continues to grow revenue at a rapid clip. Its third-quarter revenue jumped 30% compared to the year-ago period. Beyond the favorable tailwinds driving the vacation rental industry, the fact that Airbnb caters to a much broader consumer base than short-term travelers (20% of all gross bookings are stays of 28 days or more) bodes well for its ability to deliver sustained returns over the long term through a variety of market cycles. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 7, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool\u2019s board of directors. Rachel Warren has positions in Amazon and DexCom. The Motley Fool has positions in and recommends Airbnb, Inc. and Amazon. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-12-02,116.28,118.51,115.305,118.11,
DXCM,2022-12-05,117.6,119.88,115.5,116.56,
DXCM,2022-12-06,115.82,119.13,115.08,116.83,
DXCM,2022-12-07,116.31,119.19,116.31,117.91,
DXCM,2022-12-08,123.7,125.55,119.16,122.67,
DXCM,2022-12-09,121.65,122.33,116.01,116.46,"Have $1,000? 2 Smart Stocks to Buy in a Nasdaq Bear Market With the Nasdaq Composite still firmly entrenched in bear market territory, if you're feeling discouraged about the state of your portfolio and the performance of some of your favorite stocks, you're certainly not alone. However, even in volatile markets, compelling buying opportunities remain for forward-thinking, patient investors. That said, in this type of environment, it's even more important than usual to differentiate between businesses that have clear paths to growth and are simply trading down amid tough macro conditions, and those that are seeing their shares decline for valid reasons that suggest they'll face long-term headwinds. Two stocks that in my view belong firmly in the former category are DexCom (NASDAQ: DXCM) and Procter & Gamble (NYSE: PG). 1. DexCom If you're searching for a non-cyclical company with products that are consistently in demand, regardless of the macro environment or consumer sentiment, DexCom could be a no-brainer contender for your portfolio. It's a leading developer and manufacturer of continuous glucose monitoring (CGM) devices in the world. Its devices are worn by millions of Type 1 and Type 2 diabetics globally. With aglobal marketshare of roughly 50% in the CGM space, it's fair to say that DexCom has considerable room to grow even in a tough economic environment. The company is currently in the process of launching the latest generation of its flagship CGM device, the G7. The G7 system is much smaller and lighter than its predecessor, and has the fastest warm-up time of the CGM devices on the market. In the third quarter, DexCom delivered year-over-year revenue growth of 18% to $770 million while its bottom line grew by 16% to $101 million. Over the past decade, its annual revenue have grown by more than 2,400%, while the stock has delivered an astonishing total return of 3,300%. CGMs are not discretionary products. These devices can make a life-or-death difference in the health of their users. It's also worth noting that a growing number of private insurers have expanded their coverage to include CGM devices, and Medicare and Medicaid last year adjusted their rules in ways that expanded their coverage for those devices. As such, DexCom's total addressable market continues to expand, and demand for its products should continue to grow. In fact, the American Diabetes Association estimates that 1.4 million Americans are diagnosed with diabetes annually. At its current share price, a $1,000 investment in DexCom would add about nine shares to your portfolio. 2. Procter & Gamble Speaking of non-cyclical businesses, Procter & Gamble is another compelling stock for long-term investors to consider, and one that is a Dividend King to boot. At its current share price, its payout yields 2.5% for investors, and it has raised its dividend annually for 66 straight years. Over the past decade alone, management has boosted the dividend by more than 60%, helping the stock to deliver a total return of 188% for investors. Not bad for a consumer staples stock that might get a bad rap among some investors for being a ""boring"" business. Often, it's those-value oriented businesses, even the ones that can be considered boring, that can deliver the most sustainable returns in a wide variety of environments. Procter & Gamble's products span a wide range of consumer needs, from personal care products to oral health to hair care to home care. Household names like Pampers, Downy, Tide, Bounty, Charmin, Always, Tampax, Gillette, Herbal Essences, Pantene, and Old Spice are all part of its family of brands. In the most recently reported quarter, Procter & Gamble grew its organic sales by percentages in the mid-to-upper single digits across each of its five core business segments. Overall, organic sales (which exclude the impacts of currency exchange fluctuations) rose 7% from the prior-year period. Even with foreign currency headwinds factored in, total net sales still rose 1% year over year to $21 billion. The company also reported net earnings of about $4 billion for the quarter. And over the past five years, Procter & Gamble has grown its top and bottom lines by 20% and 51%, respectively. A $1,000 investment in Procter & Gamble at its current share price would add approximately seven shares to your portfolio. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-12,118.0,118.38,115.17,116.78,
DXCM,2022-12-13,120.5,121.54,118.81,119.56,"Notable ETF Inflow Detected - IWP, SNPS, DXCM, CDNS Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $183.6 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 139,000,000 to 141,100,000). Among the largest underlying components of IWP, in trading today Synopsys Inc (Symbol: SNPS) is up about 2.8%, DexCom Inc (Symbol: DXCM) is up about 3.3%, and Cadence Design Systems Inc (Symbol: CDNS) is higher by about 3.3%. For a complete list of holdings, visit the IWP Holdings page » The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $74.75 per share, with $116.70 as the 52 week high point — that compares with a last trade of $88.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » Also see: • Stock MACD • Funds Holding XMVM • ETFs Holding AVD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-14,119.72,124.11,118.85,121.49,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. So far this year, this Zacks Rank #3 (Hold) stock has lost 11% compared with a 25.9% decline of the industry and a 17.7% decline of the S&P 500. This renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $45.11 billion. The company projects 32.9% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and matched estimates in one, delivering a negative earnings surprise of 10.07%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in five countries during the third quarter, making the latest G7 sensor technology available for international markets. The company anticipates FDA clearance for G7 sensor technology before 2022-end. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. DexCom’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria in March. Strong Q3 Results: DexCom’s solid third-quarter 2022 revenues buoy optimism. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available for international markets. Downsides Reimbursement Risk: Reimbursement risk is somewhat high due to the efforts to control healthcare expenses. The company noted that most type 1 patients (above 65) pay 100% of their CGM costs from their own pockets. Unless payers (both government and private insurers) are provided with sufficient coverage and reimbursement, commercial success for DexCom will be limited, in our view. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a negative estimate revision trend for 2022. In the past 30 days, the Zacks Consensus Estimate for its earnings has declined from 80 cents to 79 cents. The Zacks Consensus Estimate for the company’s fourth-quarter 2022 revenues is pegged at $805.5 million, suggesting a 15.4% improvement from the year-ago quarter’s reported number. The same for earnings per share is 26 cents, implying 52.9% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Key Picks Some better-ranked stocks from the broader medical space are ShockWave Medical SWAV, Merit Medical Systems MMSI and HealthEquity HQY, each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for ShockWave Medical’s earnings per share has been stable at $2.57 for 2022 and has risen from $3.42 to $3.56 for 2023 in the past 60 days. SWAV has rallied 25.2% so far this year. ShockWave Medical delivered an earnings surprise of 146.1%, on average, in the last four quarters. Estimates for Merit Medical Systems have improved from earnings of $2.47 to $2.57 for 2022 and $2.77 to $2.82 for 2023 in the past 60 days. MMSI stock has risen 19.4% so far this year. Merit Medical Systems delivered an earnings surprise of 25.35%, on average, in the last four quarters. HealthEquity’s earnings per share estimates have increased from $1.28 to $1.29 for fiscal 2023 and $1.76 to $1.79 for fiscal 2024 in the past 60 days. HQY has rallied 36.7% so far this year. HealthEquity’s earnings are anticipated to improve 26.3% over the next five years. Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3. Be First to New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-15,119.57,119.9,115.775,116.24,"2 Breakout Growth Stocks to Buy for the Long Haul Growth stocks aren't all the same, and it's fair to say that some may not recover from the period of volatility investors have witnessed over the past year. However, companies with strong businesses and industry tailwinds that can drive growth forward in the future are still abundant, even in the current market. Let's take a look at two such stocks today that you may want to add to your buy list before the year is out. 1. DexCom DexCom (NASDAQ: DXCM) is an established leader in the diabetes care space, with a company history that spans more than three decades. Even as the S&P 500 has edged up by 7% in the past six months, DexCom has seen shares jump by more than 70% over that period. The stock's strong performance in such a volatile environment goes back to the consistent demand for its products, its non-cyclical business, and a series of successive wins of which investors have taken note. The most recent was the long-awaited approval of the latest generation of its continuous glucose monitoring devices, the G7. The company announced the U.S. Food and Drug Administration's approval of the G7 on Dec. 8, with the official launch set to follow in early 2023. The approval covers all people aged two and up in the U.S. with Type 1 or Type 2 diabetes. This FDA green light follows on the heels of ongoing regulatory approvals for the G7 globally and launches underway in the U.K., Hong Kong, Ireland, Austria, and Germany. The launch of DexCom's latest continuous glucose monitoring device portends well for its future growth. The combination of an aging population and increased prevalence of diabetes expands the market over which it already wields a generous foothold. This follows on the heels of a decade of remarkable growth for DexCom, during which its annual revenue increased by roughly 2,400% and it delivered a total return of 3,300% for investors. The company first became profitable in 2014. Since that time, it has been consistent in the black. Over the past three years alone, its annual earnings have risen by more than 50%. With analysts estimating that DexCom can grow its annual revenue by an average of more than 30% over the next five years, now looks like a wonderful time to capitalize on the healthcare stock's long-term growth story before the stock soars higher. 2. Fiverr Fiverr (NYSE: FVRR) has followed the trajectory of many growth-oriented businesses recently, with the stock trailing down about 74% over the past year. However, this decline isn't tied so much to alarm bells about the underlying business, but rather to broader investor sentiment around growth stocks and concerns about the effect a challenging macro environment could have on the business. Fiverr's bread and butter is derived from transaction fees. These fees are a cut of the total task amount earned by the millions of freelancers on its platform who sell gigs to Fiverr's vast network of buyers. The good news is, Fiverr continues to steadily increase its ""take"" rate even in the current environment. In the most recent quarter, Fiverr's take rate rose to 30%, a 160-basis-point improvement from the year-ago period. This was fueled by growing adoption of two newer Fiverr programs: Promoted Gigs, which allows freelancers to pay to advertise their services to clients, and Seller Plus, a paid, invite-only subscription service that enhances freelancer opportunities to grow their businesses. Meanwhile, Fiverr's revenue, active buyers, and average spending per buyer all rose by respective amounts of 11%, 3%, and 12%, year over year. While the company is still not profitable, its net loss shrank considerably in the three-month period, with Fiverr reporting a net loss of $11.4 million, compared to a net loss of $42 million in the prior quarter. The booming gig economy is set to realize a valuation of $455 billion next year. The reality is that even in a recessionary environment, businesses are more likely to see the benefit of hiring freelance talent even as they scale back on hiring initiatives. Wall Street seems optimistic about the company's long-term potential as well, with analysts estimating that Fiverr could grow its annual revenue by more than 120% over the next five years. This would also bode extremely well for the stock, and long-term shareholders can benefit from this growth trajectory. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Fiverr International. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-16,114.11,115.41,113.4,114.63,"DexCom (DXCM) Dips More Than Broader Markets: What You Should Know DexCom (DXCM) closed the most recent trading day at $114.63, moving -1.39% from the previous trading session. This change lagged the S&P 500's 1.11% loss on the day. Elsewhere, the Dow lost 0.85%, while the tech-heavy Nasdaq added 0.1%. Heading into today, shares of the medical device company had gained 3.2% over the past month, lagging the Medical sector's gain of 3.73% and outpacing the S&P 500's loss of 2.19% in that time. Investors will be hoping for strength from DexCom as it approaches its next earnings release. In that report, analysts expect DexCom to post earnings of $0.26 per share. This would mark year-over-year growth of 52.94%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $805.5 million, up 15.37% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.79 per share and revenue of $2.9 billion. These totals would mark changes of +17.91% and +18.45%, respectively, from last year. Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.68% lower. DexCom is currently a Zacks Rank #3 (Hold). Looking at its valuation, DexCom is holding a Forward P/E ratio of 146.8. This valuation marks a premium compared to its industry's average Forward P/E of 28.5. Meanwhile, DXCM's PEG ratio is currently 4.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DXCM's industry had an average PEG ratio of 2.17 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-19,114.14,114.29,110.63,112.23,
DXCM,2022-12-20,111.99,114.43,110.21,113.15,"The Best Stocks to Invest $5,000 in Right Now Investing in stocks in the current market isn't for the faint of heart. The volatility that investors have been witnessing in recent months has shaken even the most stalwart of portfolios, and more bumps in the road may be ahead. However, if you have money to invest in stocks -- cash that you won't soon need for bills or other expenses -- it's always a great time to buy shares of wonderful businesses with durable long-term growth potential. If you have $5,000 to invest, here are two such stocks to consider adding to your portfolio ASAP. 1. Teladoc Teladoc Health (NYSE: TDOC) came to the forefront of many investors' radars early in the pandemic when usage of telehealth services surged to an all-time high. However, the healthcare stock was a well-established presence in this space and marking strong business growth before the pandemic happened. For example, in 2018 and 2019, Teladoc's revenue increased by 79% and 32%, respectively. Looking at these pre-pandemic levels of growth, Teladoc's revenue growth of 86% in 2021 followed by 20% growth in the first nine months of 2022, while a deceleration, might be seen as a normalization to a more stable growth trajectory. While the company is still operating at a net loss, this shrank to just $74 million in the most recent quarter after the prior two quarters saw the company take on nearly $10 billion in impairment charges related to its 2020 Livongo acquisition. Meanwhile, Teladoc's platform visits rose 14% year over year in the third quarter, while total paid memberships jumped 10% from the year-ago period. The company also produced free cash flow to the tune of $20 million during the three-month period, with nearly $1 billion in cash and investments on its balance sheet at the close of the quarter. With its net losses going down as the demand for quality telehealth services surges, Teladoc's future growth story is anything but a foregone conclusion. The company remains a prominent leader in an industry set to witness phenomenal growth in the years ahead as cutting-edge technology adoption widens in the broader healthcare industry. This strong position makes Teladoc ideally situated to capitalize on the durable trends driving the telehealth industry forward while expanding upon its established market footprint. If you invested $2,500 in Teladoc at its current share price, you'd walk away with about 93 shares for your portfolio. 2. DexCom DexCom (NASDAQ: DXCM) is one of those stocks you can buy, hold, and add to again and again in any market environment. The company is a leading developer and manufacturer of continuous glucose monitoring (CGM) devices, relied on by type 1 and type 2 diabetics around the world to monitor and manage blood sugar levels. The demand for the products DexCom makes isn't just consistent, but it's also growing. It's estimated that roughly 1.4 million people are diagnosed with diabetes every year in the U.S. alone. Globally, there are an estimated 537 million people living with diabetes, and that leaves out a large number of the population that may already be living with the disease but have not yet been formally diagnosed. The massive CGM industry has a global addressable market of $5 billion as of 2022, set to double to $10 billion by 2030. DexCom's ability to land grab in this space, where it already dominates with a market share of close to half, is exponential. DexCom just received the green light from the U.S. Food and Drug Administration for its G7 CGM, the latest generation of its flagship product. It's 60% smaller than the G6 and has the fastest warm-up time of any CGM sold commercially. The company is expected to officially launch the G7 in the U.S. in the early part of 2023, while product launches are already underway across the U.K., Europe, and Asia. DexCom's track record of revenue growth and profitability has attracted significant investor attention over the years. The stock has delivered a total return of 750% in the trailing-five-year period alone. Meanwhile, analysts estimate that DexCom can deliver average annual revenue growth at a clip of 33% in the five years ahead, and put 12-month price targets for the stock as high as 30% from its current share position. For investors searching for a durable healthcare business to buy and hold for the long term, DexCom fits the bill. At its current share price, a $2,500 investment in DexCom would add approximately 61 shares to your portfolio. 10 stocks we like better than Teladoc Health When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom and Teladoc Health. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-21,113.87,116.13,112.06,114.76,
DXCM,2022-12-22,113.78,114.76,111.6,113.68,"DexCom (DXCM) Stock Moves -0.94%: What You Should Know DexCom (DXCM) closed the most recent trading day at $113.68, moving -0.94% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.45%. Meanwhile, the Dow lost 1.05%, and the Nasdaq, a tech-heavy index, lost 5.88%. Coming into today, shares of the medical device company had gained 1.63% in the past month. In that same time, the Medical sector gained 3.1%, while the S&P 500 lost 1.68%. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. In that report, analysts expect DexCom to post earnings of $0.26 per share. This would mark year-over-year growth of 52.94%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $805.5 million, up 15.37% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $0.79 per share and revenue of $2.9 billion, which would represent changes of +17.91% and +18.45%, respectively, from the prior year. Any recent changes to analyst estimates for DexCom should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that DexCom has a Forward P/E ratio of 144.93 right now. This valuation marks a premium compared to its industry's average Forward P/E of 30.35. It is also worth noting that DXCM currently has a PEG ratio of 4.41. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.12 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 35% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3. Be First to New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-23,114.47,114.47,111.041,111.44,
DXCM,2022-12-27,111.45,111.6,108.68,109.88,"Sum Up The Parts: IYH Could Be Worth $313 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $312.76 per unit. With IYH trading at a recent price near $283.90 per unit, that means that analysts see 10.16% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Biogen Inc (Symbol: BIIB), and Moderna Inc (Symbol: MRNA). Although DXCM has traded at a recent price of $111.44/share, the average analyst target is 12.17% higher at $125.00/share. Similarly, BIIB has 10.88% upside from the recent share price of $279.16 if the average analyst target price of $309.54/share is reached, and analysts on average are expecting MRNA to reach a target price of $220.50/share, which is 10.76% above the recent price of $199.08. Below is a twelve month price history chart comparing the stock performance of DXCM, BIIB, and MRNA: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET iShares U.S. Healthcare ETF IYH $283.90 $312.76 10.16% DexCom Inc DXCM $111.44 $125.00 12.17% Biogen Inc BIIB $279.16 $309.54 10.88% Moderna Inc MRNA $199.08 $220.50 10.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » Also see: • Monthly Dividend Paying Stocks • EXAM Insider Buying • MDA Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2022-12-28,110.48,111.96,109.46,109.77,"[""DexCom (DXCM) Stock Moves -0.1%: What You Should Know In the latest trading session, DexCom (DXCM) closed at $109.77, marking a -0.1% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.2%. At the same time, the Dow lost 1.1%, and the tech-heavy Nasdaq lost 2.86%. Prior to today's trading, shares of the medical device company had lost 0.46% over the past month. This has lagged the Medical sector's gain of 0.3% and was narrower than the S&P 500's loss of 4.77% in that time. Investors will be hoping for strength from DexCom as it approaches its next earnings release. The company is expected to report EPS of $0.26, up 52.94% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $805.5 million, up 15.37% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $0.79 per share and revenue of $2.9 billion, which would represent changes of +17.91% and +18.45%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that DexCom has a Forward P/E ratio of 138.77 right now. Its industry sports an average Forward P/E of 28.27, so we one might conclude that DexCom is trading at a premium comparatively. Investors should also note that DXCM has a PEG ratio of 4.22 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.13 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Growth Stocks to Invest $1,500 in Before the End of 2022 Looking to add to your basket of stocks before the year is out? Even a relatively modest amount of investment capital like $1,500 can help you build a meaningful starter position in stocks you love. If you're hunting for great companies to add to your portfolio before 2023 hits, here are two wonderful growth stocks that are no-brainer buys right now. 1. DexCom Healthcare has proven over the years to be a particularly resilient sector in a wide variety of market environments. One of the key reasons for this is that healthcare companies tend to sell products and services that consumers need no matter what the economy or the market is doing. This is certainly true in the case of DexCom (NASDAQ: DXCM), a company that has delivered a total return nearly 700% for investors over past five years alone. DexCom is a medical device company, focused exclusively on the area of diabetes care. Its continuous glucose monitoring (CGM) devices, which are used by millions of type one and type two diabetics around the world, are designed to help consumers keep constant watch on blood sugar levels and avoid unwanted blood sugar spikes. Every few years, DexCom releases the latest generation of its CGM device. The most recent update to its flagship product is the G7, which just garnered approval from the U.S. Food and Drug Administration in December and is already launching in various international markets, including in Asia and Europe. The latest model features a range of improvements compared to the previous one, including a device structure that is 60% lighter and has a much faster warm up time. DexCom has built a strong financial foundation due to consistent and growing demand for its products. Over the trailing decade, the healthcare company's revenue has increased by an incredible 2,400% while growing its cash position by about 13,000% in that same stretch. The company has also been consistently profitable in recent years, with net income rising by 53 % just since 2020. A $1,500 investment in DexCom would add 14 shares to your portfolio right now. 2. Ulta Beauty Even as many retailers are dealing with declining margins and decelerating growth in the current environment, Ulta Beauty (NASDAQ: ULTA) continues to go from strength to strength. The company boasts a strong in-store retail presence as well as a booming online business through which it continues to derive both strong revenue growth as well as consistent profits. While the beauty industry might not be one that investors think of first when considering recession-resilient ways to park their cash, this space has had a tendency to buck unfavorable macroeconomic trends and still garner plenty of consumer spending even in recessionary environments. This idea goes back to something known as the lipstick index, a term that was coined two decades ago during the financial crisis. In essence, the idea is that even as consumer spending declines when economic conditions are difficult, people still want to spend money on little things to treat themselves. And beauty products (like lipstick) are one of them. In the most recent quarter, Ulta Beauty reported net sales of $2.3 billion and net income of $275 million, representing respective increases of 17% and 28% from the year-ago quarter. Over the trailing decade, Ulta Beauty has grown its annual revenue and earnings by eye-popping amounts of 290% and 471%. For investors who have held onto the stock throughout the entire past 10 years, they have benefited from an incredible total return of nearly 380%. As of 2021, the company's management estimated that its total addressable market was a whopping $92 billion, while it had currently penetrated just around 7% of the total industry. While that figure is no small feat, this also means that the company has tremendous runway left to explore in the years ahead. Ulta's growing share of the lucrative beauty market as well as its strong core financials have established a solid foundation on which it can deliver continued growth and enrich investors while moving beyond any challenges posed by the current market environment. A $1,500 investment in Ulta Beauty would add 3 shares to your portfolio right now. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Ulta Beauty. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2022-12-29,110.92,113.355,109.72,112.07,
DXCM,2022-12-30,110.93,113.33,109.456,113.24,"[""DexCom (DXCM) Gains As Market Dips: What You Should Know DexCom (DXCM) closed the most recent trading day at $113.24, moving +1.04% from the previous trading session. This change outpaced the S&P 500's 0.25% loss on the day. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 5.91%. Prior to today's trading, shares of the medical device company had lost 5.05% over the past month. This has lagged the Medical sector's gain of 1.77% and the S&P 500's loss of 2.59% in that time. DexCom will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.26, up 52.94% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $805.5 million, up 15.37% from the prior-year quarter. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.79 per share and revenue of $2.9 billion. These totals would mark changes of +17.91% and +18.45%, respectively, from last year. Investors should also note any recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, DexCom currently has a Forward P/E ratio of 141.54. Its industry sports an average Forward P/E of 28.95, so we one might conclude that DexCom is trading at a premium comparatively. Meanwhile, DXCM's PEG ratio is currently 4.3. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.18 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Have $2,000 to Invest? 2 Top Stocks That Could Go Parabolic While 2022 was a tough year for investors across a wide variety of sectors, history has shown that those who remain in the market through its ups and downs can reap the rewards of the best days it delivers. The thing is, investors can't predict when those days will be. Rather than jumping in and out of the market to try to capture the best or worst market moments, building your strategy on the basis of consistent investments in wonderful companies can help you generate and build upon portfolio returns through the years. If you have $2,000 to invest in the stock market right now -- money that you don't need for bills or other near-term expenses -- here are two top stocks to consider that could go parabolic in the years ahead. 1. Palantir Despite being launched nearly two decades ago, Palantir (NYSE: PLTR) has remained a mystery to many until recently. The company cut its teeth on lucrative contracts for highly secretive government agencies, and counts the Department of Defense, the Central Intelligence Agency, the National Security Agency, the Pentagon, the U.K. Ministry of Defense, and the Federal Bureau of Investigation among its clients. Palantir is a big data analytics company, whose software is used by everyone from the world's largest intelligence agencies to corporate clients to comb through data sets and promote effective decision outcomes. The company describes its mission in this way \""Our products serve as the connective tissue between an organization's data, its analytics capabilities, and operational execution.\"" Palantir still derives the bulk of its revenue from government agencies, which rely on its Gotham operating system that was designed specifically for the types of secretive projects these clients require. However, the company is increasingly expanding its stable of commercial clients with its second major offering, its Foundry platform. Some of its well-known commercial clients include names like Merck and Kinder Morgan. So, why is Palantir trading down by nearly 70% over the last year? There are a few reasons. For one, the company has not been immune to the impact of factors like inflation and weak foreign currency. Palantir is also not currently profitable on a generally accepted accounting principles (GAAP) basis, and stock-based compensation remains high. Investors are also concerned about Palantir's stream of unprofitable special purpose acquisition company (SPAC) investments. While Palantir scaled back this program earlier this year, it had previously invested in a sea of SPACs for multiyear software contracts. However, as start-ups have broadly struggled over the past year in a low-liquidity environment, the value of many of these investments has notably waned. It also didn't help that one well-known SPAC, Fast Radius, in which Palantir invested $20 million, filed for bankruptcy in November. Even still, Palantir continues to grow its base of powerhouse clients while margins expand and revenue grows. The most recent quarter represented its eighth in a row of positive adjusted free cash flow. Gross profits have risen 140% over the trailing three-year period. The company is also growing increasingly less reliant on government contracts alone. Plus, its opportunity in a vast, total addressable market, which management estimates at $119 billion and increasing, remains unmatched. Most of Palantir's clients are locked into lengthy, multiyear contracts as well. Considering that a single month's subscription to its software platform Foundry carries a roughly $1 million price tag, it's safe to say that when its clients make a commitment, they're usually in it for the long haul. In the most recent quarter, Palantir reported total revenue of $478 million, a 22% increase from the year-ago period. Its total customer count rose 66% year over year, driven by a 124% increase in its slate of U.S.-based commercial clients. Meanwhile, U.S. commercial revenue represented a 53% increase from the same period in 2021, while revenue from U.S. government clients rose 23% year over year. Wall Street currently estimates that the stock could realize a potential upside as high as 130% over the next 12 months alone. For investors with a healthy appetite for risk, the long-term potential of Palantir's innovative and sticky business model could pose an opportunity that's too good to pass up. A $2,000 investment in Palantir would add about 333 shares to your portfolio right now. 2. DexCom DexCom (NASDAQ: DXCM) is a medical device stock with a huge competitive advantage as an undefeated leader in the global continuous glucose monitoring (CGM) device market. CGM devices are used by both type one and type two diabetics. These devices keep track of patients' glucose levels in order to reduce the risk of adverse blood sugar events and promote effective health decisions. The total addressable market for these devices is not only massive but growing as the prevalence of diabetes and broader adoption of these devices rise worldwide. In fact, it's estimated that the global CGM market could hit a valuation of $10 billion by the year 2028. To give you an idea of the company's vast footprint, the CGM market hit a worldwide valuation of about $5 billion in 2020, $2 billion of which represented revenues produced by DexCom. DexCom is not only growing revenue at a rapid clip, but it is profitable as well. The most recent quarter saw its revenues increase by 20% from a year ago to $770 million, while the company generated net income in the amount of $112 million. DexCom also generated free cash flow to the tune of $180 million in the three-month period. The essential nature of CGM devices gives DexCom's business notable resilience even in a challenging macro environment. The company also just reported another major win with the approval of its latest CGM device, the G7, in the United States. The rollout of this device, which is already occurring in key markets across Europe, the U.K., and Asia, will further fuel Dexcom's growth in the quarters and years ahead. Given the company's impressive foothold on the CGM device market, coupled with the fast-growing total addressable market it operates in, it's definitely no stretch of the imagination that DexCom could soar significantly higher from here. Bear in mind, the stock has delivered a total return of about 3,300% over the trailing decade. Currently, Wall Street estimates place the stock with a potential upside as high as 3% over the next 12 months. A $2,000 investment in the healthcare stock would add 18 shares to your portfolio right now. 10 stocks we like better than Palantir Technologies When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Palantir Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Kinder Morgan, Merck, and Palantir Technologies. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-01-03,114.3,116.16,112.61,114.73,
DXCM,2023-01-04,116.79,117.54,113.39,114.33,
DXCM,2023-01-05,113.26,114.28,110.87,111.69,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. In the past six months, this Zacks Rank #3 (Hold) stock has gained 45.7% compared with a 2.3% increase of the industry and against a 1.2% decline of the S&P 500. This renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $44.32 billion. The company projects 32.9% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and matched estimates in one, delivering a negative earnings surprise of 10.07%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in five countries during the third quarter, making the latest G7 sensor technology available for international markets. The company received FDA clearance for G7 sensor technology last month. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. DexCom’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria in March. Strong Q3 Results: DexCom’s solid third-quarter 2022 revenues buoy optimism. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available in international markets. Downsides Reimbursement Risk: Reimbursement risk is somewhat high due to the efforts to control healthcare expenses. The company noted that most type 1 patients (above 65) pay 100% of their CGM costs from their own pockets. Unless payers (both government and private insurers) are provided with sufficient coverage and reimbursement, commercial success for DexCom will be limited, in our view. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a stable estimate revision trend for 2023. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained unchanged at $1.06. The Zacks Consensus Estimate for the company’s fourth-quarter 2022 revenues is pegged at $805.5 million, suggesting a 15.4% improvement from the year-ago quarter’s reported number. The same for earnings per share stands at 26 cents, implying 52.9% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Mesa Laboratories MLAB and Cardinal Health CAH. AMN Healthcare, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.96%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. AMN Healthcare has gained 52.7% compared with the industry’s 2.3% increase in the past six months. Mesa Laboratories, sporting a Zacks Rank #1 at present, has an estimated growth rate of 28.9% for fiscal 2023. MLAB’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average beat being 16.56%. Mesa Laboratories has declined 15.9% against the industry’s 2.2% increase in the past six months. Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.2%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average beat being 3.04%. Cardinal Health has gained 46.8% compared with the industry’s 4.1% increase over the past six months. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-01-06,113.03,117.01,110.78,115.82,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised) DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. In the past six months, this Zacks Rank #3 (Hold) stock has gained 42.5% compared with a 4% increase of the industry and against a 1% decline of the S&P 500. This renowned medical devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $44.32 billion. The company projects 32.9% growth for the next five years and expects to maintain its strong performance. DexCom’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and matched estimates in one, delivering a negative earnings surprise of 10.07%, on average. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in five countries during the third quarter, making the latest G7 sensor technology available for international markets. The company received FDA clearance for G7 sensor technology last month. The company, in August, announced the availability of the easy-to-use Dexcom ONE real-time CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. DexCom’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people with type 1 diabetes living in the province who are above the age of 2 years and meet coverage criteria in March. Strong Q3 Results: DexCom’s solid third-quarter 2022 revenues buoy optimism. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. DexCom also received CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available in international markets. Downsides Rising Costs: DexCom's gross margin contracted during the third quarter, reflecting the rising cost of sales. The company also lowered the 2022 guidance for adjusted gross margin. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom’s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems, currently. Estimate Trend DexCom is witnessing a stable estimate revision trend for 2023. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained unchanged at $1.06. The Zacks Consensus Estimate for the company’s fourth-quarter 2022 revenues is pegged at $805.5 million, suggesting a 15.4% improvement from the year-ago quarter’s reported number. The same for earnings per share stands at 26 cents, implying 52.9% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Mesa Laboratories MLAB and Cardinal Health CAH. AMN Healthcare, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.96%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. AMN Healthcare has gained 52.7% compared with the industry’s 2.3% increase in the past six months. Mesa Laboratories, sporting a Zacks Rank #1 at present, has an estimated growth rate of 28.9% for fiscal 2023. MLAB’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average beat being 16.56%. Mesa Laboratories has declined 15.9% against the industry’s 2.2% increase in the past six months. Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.2%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average beat being 3.04%. Cardinal Health has gained 46.8% compared with the industry’s 4.1% increase over the past six months. (We are reissuing this article to correct a mistake. The original article, issued on January 5, 2023, should no longer be relied upon.) Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-01-09,112.46,113.69,107.46,110.06,"Notable Monday Option Activity: SMCI, DG, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Super Micro Computer Inc (Symbol: SMCI), where a total of 6,887 contracts have traded so far, representing approximately 688,700 underlying shares. That amounts to about 45.9% of SMCI's average daily trading volume over the past month of 1.5 million shares. Especially high volume was seen for the $105 strike call option expiring January 20, 2023, with 1,319 contracts trading so far today, representing approximately 131,900 underlying shares of SMCI. Below is a chart showing SMCI's trailing twelve month trading history, with the $105 strike highlighted in orange: Dollar General Corp (Symbol: DG) options are showing a volume of 8,750 contracts thus far today. That number of contracts represents approximately 875,000 underlying shares, working out to a sizeable 45.6% of DG's average daily trading volume over the past month, of 1.9 million shares. Particularly high volume was seen for the $245 strike call option expiring January 20, 2023, with 3,537 contracts trading so far today, representing approximately 353,700 underlying shares of DG. Below is a chart showing DG's trailing twelve month trading history, with the $245 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 11,462 contracts, representing approximately 1.1 million underlying shares or approximately 45.5% of DXCM's average daily trading volume over the past month, of 2.5 million shares. Especially high volume was seen for the $115 strike call option expiring January 20, 2023, with 2,409 contracts trading so far today, representing approximately 240,900 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $115 strike highlighted in orange: For the various different available expirations for SMCI options, DG options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » Also see: • Cheap Consumer Shares • ICCM Average Annual Return • GOL Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-01-10,108.79,111.94,107.84,110.88,"[""DexCom (DXCM) Announces Solid Preliminary Q4 Revenues DexCom, Inc. DXCM recently announced preliminary revenues for the fourth quarter and full-year 2022. The robust preliminary results drove down the shares of the company by 0.3% in the after-hours trading session. The company is scheduled to release fourth-quarter results on Feb 9 after the closing bell. Per the preliminary report, fourth-quarter 2022 revenues are estimated to be $815 million, reflecting an increase of 17% year over year on a reported basis. The Zacks Consensus Estimate of $805.5 million lies below the preliminary figure. On an organic basis (excluding non-continuous glucose monitoring or non-CGM revenue acquired in the trailing twelve months and the impact of foreign exchange), fourth-quarter revenues are estimated to reflect an uptick of 20% year over year. The company\u2019s U.S. revenues are expected to be approximately $606 million, representing a year-over-year uptick of 17%. International revenues are expected to be $209 million, indicating an improvement of 15% from the prior-year period on a reported basis and 26% on an organic basis. Per management, the to-be-reported quarter\u2019s solid results have been driven by significant growth in Dexcom\u2019s global customer base and key regulatory clearances of its next-generation G7 CGM system. Management is also upbeat about its continued strength in 2023 on the back of its CGM access expansion, thus raising our optimism about the stock. Full-Year Prelim Results Per Dexcom, its full-year total revenues are likely to be $2.91 billion, reflecting an increase of 19% over comparable 2021 reported figures both on a reported and organic basis. The Zacks Consensus Estimate of $2.90 billion lies below the preliminary figure. 2023 Guidance Dexcom has initiated its financial outlook for the full-year 2023. The company anticipates its total revenue to be within $3.35 billion-$3.49 billion, representing an expected growth of approximately 15-20% over comparable 2022 reported figures. The Zacks Consensus Estimate for the same is currently pegged at $3.47 billion. Per management, the outlook for 2023 includes sensor volume growth driven by increasing CGM awareness for diabetics, the launch of the Dexcom G7 CGM system in the United States and its continued rollout in international markets, further international expansion and overall market dynamics. A Brief Q4 Analysis Last month, Dexcom announced its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 real-time CGM System combined with virtual diabetes coaching support. The same month, Dexcom announced the FDA had cleared the next-generation Dexcom G7 CGM System for people with all types of diabetes aged two years and above. Dexcom has been observing a robust adoption of its products over the past few months. During the third-quarterearnings callin October 2022, management confirmed that the NHS announced the inclusion of Dexcom ONE on prescription via the England, Wales, Scotland and Northern Ireland drug tariff for everyone with type 1 diabetes and type 2 intensively managed diabetes. Management is also optimistic about vast opportunities for its Dexcom ONE in new geographies as well as in existing markets. The company\u2019s preliminary projection of robust improvement in revenues on the back of strength in its business lifts our confidence in the stock. Price Performance Shares of the company have gained 40.6% between Oct 1, 2022 and Dec 31, 2022 compared with the industry\u2019s 14.1% rise and the S&P 500\u2019s 6.3% growth. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, Dexcom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Cardinal Health, Inc. CAH and Merit Medical Systems, Inc. MMSI. AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. AMN Healthcare has lost 2.9% against the industry\u2019s 4.9% rise between Oct 1, 2022 and Dec 31, 2022. Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.7%. CAH\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 3%. Cardinal Health has gained 15.3% compared with the industry\u2019s 12.5% rise between Oct 1, 2022 and Dec 31, 2022. Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI\u2019s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%. Merit Medical has gained 24.9% compared with the industry\u2019s 12.5% rise between Oct 1, 2022 and Dec 31, 2022. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade Even if your retirement is many decades away, it's never too soon to start planning for a better financial life in your future. However, if you're aiming for the value of your retirement portfolio to hit the $1 million mark in the next decade, you would need to invest a much higher amount to begin with in order to reach this goal in that time frame. Turning an initial $300,000 investment into seven figures in a decade may seem like a lofty aspiration, but it would require an annualized return of just around 13% to make that happen. Considering that the S&P 500 has delivered total returns of 220% over the past decade, which works out to 12.3% on an annualized basis, this begins to look like a much more attainable goal. Many investors set a goal of having a $1 million nest egg when they retire. However, the way in which you work toward that milestone -- and how long it takes you to get there -- will be specific to your investment preferences, risk tolerance level, the types of stocks you buy, how much you invest, and how regularly you invest, among other factors. It's also wise to diversify your investments across various stocks and asset classes, as a more balanced portfolio promotes favorable returns in a wider range of markets. With all that being said, if you have $300,000 available to invest right now, here are three powerhouse stocks to consider adding at least part of that amount to as you work toward your retirement goals, each of which has the potential to double or more over the next 10 years. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) has built an impressive track record of growth, profitability, and returns for investors throughout the years, all thanks to its portfolio of cystic fibrosis therapies. The market for treatments for that genetic disease is expanding as more cystic fibrosis patients are living longer, increasing the number of people who might use Vertex's therapies globally. Given that Vertex Pharmaceuticals is the undeniable leader in this space, it has not exhausted its total addressable market opportunity here. Management said that, while roughly 83,000 individuals have been diagnosed with the genetic disease in North America, Europe, and Australia alone, roughly one-third of the patients who could benefit from taking a triple-combination therapy (such as the company's top-selling treatment, Trikafta) are not yet doing so. Of course, this also leaves room for expansion into many other markets that are still underpenetrated and could benefit from access to Vertex's slate of therapies in the years ahead. Beyond the multibillion-dollar cystic fibrosis treatment market, Vertex Pharmaceuticals also has its eye on other rare disease indications. Its pipeline includes treatment candidates for acute pain, Duchenne muscular dystrophy, and sickle cell disease, to name a few. Over the past 10 years, Vertex Pharmaceuticals delivered a total return of more than 280% to investors while growing its top and bottom lines by 204% and 789%, respectively. Meanwhile, Wall Street is estimating that the healthcare stock could grow its revenue by an average of about 10% annually over the next five years alone. Among the analysts who cover the company, the one with the highest price target expects it to rise by about 50% in the next 12 months. The company has a dominant position in the cystic fibrosis treatment market. It is also working to expand into other rare disease drug markets with needs that remain largely unmet by the broader healthcare community. These factors both bode well for its ability to deliver enviable returns for investors in 2023 as well as throughout the next decade. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) built an incredibly lucrative business on its razor-and-blades business model. The company develops, manufactures, and sells robotic surgical systems -- its most well-known being the da Vinci Surgical system -- but it also sells services and disposable products for those devices that serve as a reliable, continuing source of revenue. Healthcare institutions that buy Intuitive Surgical's robotic surgical systems will also need to buy a steady stream of replacement parts and accessories that they use up during medical procedures. Intuitive Surgical even sells full-service plans for medical providers that include access to everything from customer service and technical support staff to on-call maintenance teams and integrated software solutions. All of this generates ongoing revenue beyond the initial sale of these systems, which on their own cost anywhere from around $600,000 to $2 million each. Bear in mind, Intuitive Surgical controls more than three-quarters of the surgical robotics market globally. Intuitive Surgical's trailing 10-year return currently sits at around 390%. During that same time frame, both its annual revenue and earnings grew by roughly 150%. Analysts think the company can grow its revenue by an average of 9% annually over the next five years. It also doesn't seem like a stretch of the imagination that Intuitive Surgical's share price could double or more over the next 10 years considering that Wall Street is targeting a 12-month upside for the stock of 12.5% (with one analyst going as high as 21%). 3. DexCom Last but not least is DexCom (NASDAQ: DXCM), a leader in diabetes care known for its top-selling continuous glucose monitoring (CGM) devices. The global CGM market is on track to surpass $10 billion by the year 2028. DexCom generated nearly half of all revenues from sales of CGM devices globally in 2021, giving it a market share of right around 50%. There are many factors driving the growing adoption of CGM, including the rising prevalence of diabetes around the world and the increasing usage of these devices by both type 1 and type 2 diabetics. Both public and private insurers continue to expand their coverage to include these devices, giving more diabetics access to a technology that can, in some cases, make a life-or-death difference in their ability to monitor for blood sugar spikes and related adverse events. DexCom just picked up another huge win with U.S. regulatory approval of its new-and-improved CGM system, the G7. The launch of the G7 in the U.S. is to take place in the months ahead and is already underway in key international markets. DexCom delivered a total return of about 300% in the trailing decade, spurred on by annual revenue growth of approximately 66% and annual earnings growth of about 53%. Analysts are not only estimating that the company can grow its revenue by 33% annually over just the next five years, but are targeting a median potential upside for the stock of approximately 18% in the next year (with a top target of 34%). Considering DexCom's continued leadership in the diabetes care market, and its ongoing growth on the top and bottom lines, the stock looks like it has plenty of room to run for the next decade and beyond. 10 stocks we like better than Vertex Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Intuitive Surgical and Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-01-11,112.41,112.69,105.04,106.16,"Nasdaq 100 Movers: ISRG, TEAM In early trading on Wednesday, shares of Atlassian topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.8%. Year to date, Atlassian registers a 9.7% gain. And the worst performing Nasdaq 100 component thus far on the day is Intuitive Surgical, trading down 5.1%. Intuitive Surgical is lower by about 2.9% looking at the year to date performance. Two other components making moves today are DexCom, trading down 3.6%, and Lucid Group, trading up 5.7% on the day. VIDEO: Nasdaq 100 Movers: ISRG, TEAM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-01-12,105.44,108.48,103.67,107.14,"[""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know DexCom (DXCM) closed the most recent trading day at $107.14, moving +0.92% from the previous trading session. This change outpaced the S&P 500's 0.34% gain on the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 8.98%. Prior to today's trading, shares of the medical device company had lost 12.62% over the past month. This has lagged the Medical sector's loss of 0.28% and the S&P 500's gain of 1% in that time. DexCom will be looking to display strength as it nears its next earnings release. In that report, analysts expect DexCom to post earnings of $0.26 per share. This would mark year-over-year growth of 52.94%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $811.18 million, up 16.18% from the year-ago period. Investors should also note any recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.93% lower within the past month. DexCom currently has a Zacks Rank of #3 (Hold). In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 100.91. This valuation marks a premium compared to its industry's average Forward P/E of 25.38. Also, we should mention that DXCM has a PEG ratio of 3.07. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.23 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 141, putting it in the bottom 45% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""IWP, SNPS, CDNS, DXCM: Large Outflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $65.4 million dollar outflow -- that's a 0.5% decrease week over week (from 140,950,000 to 140,200,000). Among the largest underlying components of IWP, in trading today Synopsys Inc (Symbol: SNPS) is down about 0.7%, Cadence Design Systems Inc (Symbol: CDNS) is off about 1%, and DexCom Inc (Symbol: DXCM) is higher by about 1%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $74.75 per share, with $108.13 as the 52 week high point \u2014 that compares with a last trade of $87.20. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb Also see: \u0095 MGIC YTD Return \u0095 CLRO Historical Stock Prices \u0095 PWP Average Annual Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-01-13,106.16,108.6,105.19,108.47,"2 Best Stocks to Buy in January and Hold Forever The start of a new year may or may not signal the recovery of the broader stock market, but great businesses are staying largely above the fray even if share prices remain volatile. From healthcare to consumer goods, quality companies continuing to build upon a track record of growth that possess sticky business models and strong core financials can see share prices recover in the future. Investors who continued to buy into these businesses at lower-than-usual valuations could be positioned well for this recovery when it does occur. If you're going stock shopping in January, here are two unstoppable stocks to buy right now and hold for the long haul. 1. DexCom DexCom (NASDAQ: DXCM) is a diabetes care giant, known for its continuous glucose monitoring (CGM) devices. Both Type 1 and Type 2 diabetics use these devices to track blood sugar levels, observe blood sugar trends, and monitor for signs of spikes that could portend a hypoglycemic or hyperglycemic event. Currently, the company controls around 50% of the global CGM market. According to the World Health Organization, the global population of individuals with diabetes has risen significantly over the past few decades, from roughly 108 million in 1980 to 422 million in 2014. As of 2022, the Centers for Disease Control and Prevention estimated that roughly 130 million individuals have diabetes in the U.S. alone. Meanwhile, a 2019 survey found that only 38% of Type 1 diabetics in the U.S. used a CGM device, with most of these individuals falling in the 26 to 50 age group. In short, not only are there large portions of the existing diabetes population that are still not using CGM devices, but as the incidence of diabetes rises, DexCom has significant opportunity build upon its existing footprint and tap into a growing total addressable market. DexCom is in the process of executing the global launch of the latest generation of its CGM devices, the G7. The launch of this new-and-improved version of its flagship product -- which is 60% smaller than the prior generation with the fastest warm-up time on the market -- is expected to boost DexCom's revenue by as much as 20% in fiscal-year 2023 alone. The company also just released its unaudited preliminary results for full-year 2022 (the full version of which is due out on Feb. 9), reporting revenue of $2.9 billion, up 19% compared to 2021. An investment in this steadily growing and profitable healthcare stock (it reported net income of $101 million in the the third quarter of 2022) could reap generous portfolio returns in the years ahead as it expands its market share and builds on its existing track record. 2. Starbucks Starbucks (NASDAQ: SBUX) is a name that needs no introduction. The chain of coffeehouses and roasteries is a favorite with consumers around the world. Even in the currently challenging macro environment, where consumer discretionary spending is broadly in flux, Starbucks is still marking business wins and has a solid foundation it can build upon to launch itself to future growth well after any recessionary storm has passed. In the company's fiscal 2022, which ended Oct. 2, it reported an 8% increase in global comparable-store sales, helped by a 12% increase in comparable-store sales in North America. While international sales declined by 24% compared to fiscal 2021, a large part of this was due to continued COVID-19-related closures in China. Outside of the U.S., China is the single-largest market in which Starbucks operates, with more than 6,000 stores open across the country. Even so, Starbucks reported consolidated net revenue of $32 billion for fiscal 2022, a surge of 13% on a constant-currency basis from the prior year, with net earnings of $3.3 billion for the 12-month period. The company is currently in the process of building out its three-year financial growth strategy called the Reinvention plan, which was announced in September 2022. These initiatives include targeting global revenue growth of 10% to 12% annually between fiscal 2023 and fiscal 2025, and increasing its global store count by 7% annually in that forecast period. Management also noted in the announcement: In China, Starbucks expects outsized comparable store sales performance in fiscal 2023 and fiscal 2024, as the market laps the severe impact of COVID-related lockdowns, with growth normalizing in the new range of 4% to 6% in fiscal 2025, an increase from the prior range of 2% to 4%, reflecting an increased digital capability and confidence in the vast opportunity ahead in this key growth market. Discretionary spending may shift in the coming months, but the loyalty and rapport consumers have with the Starbucks brand and its products can continue to drive growth over the long term, rewarding the business and its shareholders as the company works toward these initiatives and continues to expand its global footprint. For dividend investors, it's worth noting that Starbucks yields 2% based on current share prices. The stock has also has seen its dividend rise by roughly 400% over the trailing decade. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 9, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Starbucks. The Motley Fool recommends DexCom and recommends the following options: short January 2023 $92.50 puts on Starbucks. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-01-17,107.17,109.63,106.05,109.51,
DXCM,2023-01-18,109.95,110.26,106.54,106.63,
DXCM,2023-01-19,106.0,107.67,105.96,106.2,
DXCM,2023-01-20,106.2,108.0,104.99,107.86,
DXCM,2023-01-23,107.86,108.86,106.0,106.4,
DXCM,2023-01-24,105.24,106.51,103.72,106.03,
DXCM,2023-01-25,103.75,105.05,102.5,104.0,
DXCM,2023-01-26,105.44,107.03,104.13,106.65,
DXCM,2023-01-27,106.36,107.742,105.04,106.72,
DXCM,2023-01-30,106.12,106.94,105.08,105.49,
DXCM,2023-01-31,106.06,107.56,105.74,107.09,"Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar? Looking for broad exposure to the Mid Cap Growth segment of the US equity market? You should consider the iShares Russell Mid-Cap Growth ETF (IWP), a passively managed exchange traded fund launched on 07/17/2001. The fund is sponsored by Blackrock. It has amassed assets over $12.05 billion, making it the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. These types of companies, then, have a good balance of stability and growth potential. While growth stocks do boast higher than average sales and earnings growth rates, and they are expected to grow faster than the wider market, investors should note these kinds of stocks have higher valuations. Also, growth stocks are a type of equity that carries more risk compared to others. Even though growth stocks are more likely to outperform their value counterparts in strong bull markets, value stocks have a record of delivering better returns in almost all markets than growth stocks. Costs Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Annual operating expenses for this ETF are 0.23%, putting it on par with most peer products in the space. It has a 12-month trailing dividend yield of 0.72%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 28% of the portfolio. Healthcare and Industrials round out the top three. Looking at individual holdings, Synopsys Inc (SNPS) accounts for about 1.49% of total assets, followed by Dexcom Inc (DXCM) and Cadence Design Systems Inc (CDNS). Performance and Risk IWP seeks to match the performance of the Russell MidCap Growth Index before fees and expenses. The Russell Midcap Growth Index measures the performance of the mid-capitalization growth sector of the U.S. equity market. It is a subset of the Russell Midcap Index, which measures the performance of the mid-capitalization sector of the U.S. equity market & approximately 47% of the total market value of the Russell Midcap Index. The ETF return is roughly 6.63% so far this year and is down about -6.74% in the last one year (as of 01/31/2023). In the past 52-week period, it has traded between $75.41 and $103.82. The ETF has a beta of 1.09 and standard deviation of 30.05% for the trailing three-year period, making it a medium risk choice in the space. With about 406 holdings, it effectively diversifies company-specific risk. Alternatives IShares Russell Mid-Cap Growth ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, IWP is a good option for those seeking exposure to the Style Box - Mid Cap Growth area of the market. Investors might also want to consider some other ETF options in the space. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the Vanguard Mid-Cap Growth ETF (VOT) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.33 billion in assets, Vanguard Mid-Cap Growth ETF has $9.96 billion. IJK has an expense ratio of 0.17% and VOT charges 0.07%. Bottom-Line An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports DexCom, Inc. (DXCM) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report Cadence Design Systems, Inc. (CDNS) : Free Stock Analysis Report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-01,107.16,108.57,104.44,107.71,
DXCM,2023-02-02,109.17,110.5,106.59,108.03,"DexCom (DXCM) Gains But Lags Market: What You Should Know DexCom (DXCM) closed at $108.03 in the latest trading session, marking a +0.3% move from the prior day. The stock lagged the S&P 500's daily gain of 1.47%. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, added 7.94%. Coming into today, shares of the medical device company had lost 5.79% in the past month. In that same time, the Medical sector lost 0.48%, while the S&P 500 gained 7.41%. Investors will be hoping for strength from DexCom as it approaches its next earnings release, which is expected to be February 9, 2023. On that day, DexCom is projected to report earnings of $0.26 per share, which would represent year-over-year growth of 52.94%. Our most recent consensus estimate is calling for quarterly revenue of $811.79 million, up 16.27% from the year-ago period. Any recent changes to analyst estimates for DexCom should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.95% lower within the past month. DexCom is currently sporting a Zacks Rank of #3 (Hold). Investors should also note DexCom's current valuation metrics, including its Forward P/E ratio of 102.94. For comparison, its industry has an average Forward P/E of 29.27, which means DexCom is trading at a premium to the group. It is also worth noting that DXCM currently has a PEG ratio of 2.95. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.31 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-03,107.18,109.98,106.21,108.43,"2 Unstoppable Growth Stocks to Buy in 2023 and Beyond Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. But some growth-oriented companies managed to buck the trend. Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM). These two stocks aren't one-hit wonders, either. There are good reasons why they performed as well as they did in 2022, and there are equally solid reasons to think they can produce similarly robust returns in the long run. Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals is entering an important stretch. Over the past 10 years, the company has generated growing revenue and earnings thanks to its medicines that treat cystic fibrosis (CF), a rare genetic condition. Now, the drugmaker looks to be on the verge of marketing a product in a different therapeutic area. Last year, Vertex said it planned on submitting exa-cel to regulatory authorities in the U.S. and Europe by the end of the first quarter of 2023. Exa-cel is a potential gene-editing treatment that Vertex is developing with CRISPR Therapeutics for a duo of rare blood-related illnesses -- sickle cell disease and beta-thalassemia. Vertex could launch exa-cel early next year if all goes according to plan. Vertex Pharmaceuticals is also set to make pipeline progress elsewhere. Consider the company's VX-548, a potential therapy for acute and neuropathic pain. Last year, Vertex said it would start a phase 3 study for this medicine in treating acute pain in Q4, although it hasn't officially announced the start of this trial. Still, investors should expect a word or two from management regarding VX-548 pretty soon. Late last year, Vertex started a phase 2 study for VX-634 as a potential treatment for Alpha-1 antitrypsin deficiency. This inherited condition can lead to liver disease. Some of Vertex's other candidates target type 1 diabetes and APOL1-mediated kidney disease. Vertex's programs are making meaningful clinical progress, and exa-cel is inching closer to approval. Together, they provide the company with multiple short-term catalysts that could boost its stock price. More importantly, they will help the drugmaker expand its line up of medicines and generate even stronger revenue and earnings growth for a long time before they run into patent cliffs, the dreaded obstacles that sometimes sink biotech companies. Vertex's CF products are far from finished driving solid financial results. The company won't release its Q4 update for about another week, but we saw plenty more evidence of the resilience of Vertex's CF franchise throughout last year. In the first nine months of 2022, the company's revenue increased by 20.5% year over year to $6.6 billion, while its net income soared by 59.2% year over year to $2.5 billion. Expect Vertex Pharmaceuticals to continue delivering similarly robust financial results as it strengthens its portfolio of drugs through new approvals. Having produced market-beating returns in the past, Vertex can likely do it again for investors willing to be patient. 2. DexCom DexCom focuses on helping diabetes patients with its continuous glucose monitoring (CGM) devices that enable patients to take blood glucose measurements. The company today primarily markets its G6 CGM, but last year, it launched its next-gen device, the G7, in Europe. The G7 proved even more effective than the G6 in helping diabetes patients achieve excellent health outcomes. DexCom's G7 was cleared in the U.S. in December, and the company will launch it this year. The DexCom ONE is another CGM device DexCom launched in Europe last year; it is a more affordable option that targets more price-sensitive patients. DexCom's newer devices will help it expand the pool of CGM patients, a demographic that is already growing. The adoption of CGM technology is being driven by the fact that these devices continuously monitor blood glucose levels throughout the day, allowing diabetes patients to make better, healthier decisions. The blood glucose meters against which CGMs compete are limited in that they can only tell a person's blood glucose levels at a specific point during the day. The increased use of CGM has led to growing revenue for DexCom. DXCM Revenue (Quarterly) data by YCharts Furthermore, the company could soon benefit from a regulatory decision in the U.S. that would expand the pool of patients eligible for reimbursement by Medicare. The growing population of people with diabetes should also lead to a greater need for DexCom's devices. As a leader in CGM with a long history of developing newer and innovative products, DexCom looks set to remain at the forefront of efforts to combat this chronic illness -- and to handsomely reward its shareholders in the process. 10 stocks we like better than Vertex Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 9, 2023 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-06,108.09,109.065,106.44,106.73,"[""DexCom (DXCM) to Report Q4 Earnings: What's in the Cards? DexCom, Inc. DXCM is scheduled to release fourth-quarter 2022 results on Feb 9, after the closing bell. In the last reported quarter, the company\u2019s earnings beat the Zacks Consensus Estimate by 16.67%. Its earnings missed the Zacks Consensus Estimate in two of the trailing four quarters, beat once and met the same once, the average negative surprise being 10.07%. Q4 Estimates Currently, the Zacks Consensus Estimate for DexCom\u2019s fourth-quarter revenues is pegged at $811.8 million, indicating growth of 16.3% from the year-ago reported figure. The consensus mark for earnings stands at 26 cents per share, indicating an improvement of 52.9% from the prior-year quarter. Factors to Note DexCom\u2019s fourth-quarter top line is likely to have been aided by continued increase in volume, courtesy of new patients across all channels and rising global awareness about the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). Potential robust contributions from the Sensor segment and domestic and international revenue growth are likely to be the key catalysts for fourth-quarter results. The company\u2019s preliminary results for the fourth quarter estimated total revenues to be $815 million, implying an increase of 17% year over year on a reported basis. During the first nine months of 2022, the company continued with expanding access and accelerating its leadership in CGM-connected solutions and customer choice. DexCom continues to launch the Dexcom ONE product in new countries. These developments are likely to have benefited customer growth during the soon-to-be-reported quarter. Last year, the company received the FDA\u2019s Breakthrough Device Designation for the Dexcom CGM system\u2019s use in the hospital setting. DexCom also secured the CE mark for the Dexcom G7 CGM System for monitoring people with diabetes aged two years and older, and initiated a limited launch of the system in Europe in 2022. DexCom expanded coverage for Dexcom CGM to include type 1 diabetes in Ontario, Canada. Moreover, TRICARE added Dexcom G6 as a brand-name formulary pharmacy benefit. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote These developments may have favored the company\u2019s performance in the to-be-reported quarter. On an organic basis (excluding non-continuous glucose monitoring or non-CGM revenue acquired in the trailing 12 months and the foreign exchange impact), fourth-quarter revenues are likely to have witnessed an uptick of 20% year over year. DexCom has been benefiting from demographic trends and lifestyles in countries outside Europe and the United States. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In third-quarter 2022, international revenues (25% of total revenues) surged 22.2% year over year to $196.2 million. U.S. revenues (75% of total revenues) were up 17.1% in the same period. The momentum is likely to have continued in the fourth quarter, thanks to broad-based growth. The company\u2019s preliminary U.S. revenues in the fourth quarter are estimated to be approximately $606 million, indicating a year-over-year uptick of 17%. Preliminary International revenues are estimated to be $209 million, implying an improvement of 15% from the prior-year period on a reported basis and 26% on an organic basis. The Zacks Consensus Estimate for U.S. and International revenues is pegged at $590 million and $215 million, respectively, for the fourth quarter. However, an increase in operating expenses and intense competition might have weighed on the to-be-reported quarter\u2019s performance. What Our Quantitative Model Suggests Our proven model does not conclusively predict an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that's not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. Zacks Rank: DexCom carries a Zacks Rank #3. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Stocks Worth a Look Here are some medical instrument stocks worth considering as these have the right combination of elements to post an earnings beat this quarter. Hologic HOLX has an Earnings ESP of +1.32% and a Zacks Rank of 1. Hologic\u2019s stock has gained 16.3% in the past six months. HOLX topped earnings estimates in the last reported quarter. It has a four-quarter earnings surprise of 30.60%, on average. IDEXX Laboratories IDXX has an Earnings ESP of +1.04% and a Zacks Rank of 2. IDEXX Laboratories\u2019 stock has gained 18.6% in the past six months. IDXX beat earnings estimates in the last reported quarter. It has a four-quarter earnings surprise of 5.19%, on average. ShockWave Medical SWAV has an Earnings ESP of +4.40% and a Zacks Rank of 2. ShockWave Medical\u2019s stock has declined 15.5% in the past six months. SWAV beat earnings estimates in the last reported quarter. It has a four-quarter earnings surprise of 146.10%, on average. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They\u2019re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation. >>Show me how I could profit from the metaverse! Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now? Launched on 01/26/2011, the SPDR S&P Health Care Equipment ETF (XHE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific market segment or the market as a whole, have traditionally dominated the ETF industry. Market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns, and are a good option for investors who believe in market efficiency. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta. By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such. Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results. Fund Sponsor & Index The fund is sponsored by State Street Global Advisors. It has amassed assets over $480.89 million, making it one of the average sized ETFs in the Health Care ETFs. XHE, before fees and expenses, seeks to match the performance of the S&P Health Care Equipment Select Industry Index. The S&P Health Care Equipment Select Industry Index represents the health care equipment segment of the S&P Total Market Index. Cost & Other Expenses Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Operating expenses on an annual basis are 0.35% for XHE, making it one of the least expensive products in the space. XHE's 12-month trailing dividend yield is 0.03%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. For XHE, it has heaviest allocation in the Healthcare sector --about 100% of the portfolio. Taking into account individual holdings, Abiomed Inc. (ABMD) accounts for about 2.05% of the fund's total assets, followed by Dexcom Inc. (DXCM) and Intuitive Surgical Inc. (ISRG). XHE's top 10 holdings account for about 18% of its total assets under management. Performance and Risk The ETF return is roughly 10.99% and is down about -1.78% so far this year and in the past one year (as of 02/06/2023), respectively. XHE has traded between $79.20 and $114.46 during this last 52-week period. XHE has a beta of 0.93 and standard deviation of 29.53% for the trailing three-year period, which makes the fund a medium risk choice in the space. With about 83 holdings, it effectively diversifies company-specific risk. Alternatives SPDR S&P Health Care Equipment ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the iShares U.S. Medical Devices ETF (IHI) tracks Dow Jones U.S. Select Medical Equipment Index. First Trust Indxx Medical Devices ETF has $2.08 million in assets, iShares U.S. Medical Devices ETF has $6.37 billion. MDEV has an expense ratio of 0.70% and IHI charges 0.39%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. Bottom Line To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-07,105.71,109.75,104.66,109.5,"2 Stock-Split Stocks to Buy Without Hesitation in 2023 While stock splits aren't value-creating vehicles per se, these events can allow more investors access to stocks that otherwise have risen to such steep prices that buying even one or two shares may be out of reach. There were several well-known stock splits that took place in 2022, and the current market environment has discounted some of these companies even further. If you're bargain-hunting for wonderful businesses that fit this bill in the 2023 market environment, here are two recent stock-split stocks that are primed to deliver sustainable growth for investors in the next decade and beyond. 1. Shopify Shopify (NYSE: SHOP) executed a 10-for-1 stock split on June 28, 2022. Although shares of Shopify are still trading up by double digits since the beginning of 2023, the stock is still down by roughly 40% from where it was trading 12 months ago. Shopify continues to prove its advantage as a leading e-commerce platform and is continuing to grow market share and build out its business even as share prices have remained highly volatile. According to data from BuiltWith, of the roughly 13 million e-commerce sites that are live in the U.S. alone, 25% of those are built on Shopify's software. That gives Shopify the leading market share of any e-commerce platform provider in the country. Shopify has made it easier than ever, even for someone with little to no business experience, to build a brand from the ground up with a suite of tools, applications, and integrations that enable everything from seamless product sourcing, billing, and supply chain management to workflow automation and payroll. It should come as no surprise that Shopify's merchant base is only expanding. Merchant solutions revenue jumped 26% year over year in the third quarter of 2022 -- driving a 22% year-over-year increase in total revenue -- while rising 340% on a three-year clip. And, with the addition of fulfillment company Deliverr to its existing fulfillment network, Shopify is closing the gap on an area that can be an integral make-or-break factor for any company in its industry: supply chain management. As of the third quarter of 2022, management noted that the company was seeing a 75% year-over-year jump in merchant inventory processing through Deliverr cross docks. In September 2022, approximately two-thirds of all packages delivered in the U.S. experienced just a two-business-day delivery time. Besides more efficient and fast fulfillment processes, Shopify is continuing to find new ways to increase merchant growth and retention. For example, the company finished launching Shop Promise in the third quarter, which is a badge that brands leveraging the Shopify Fulfillment Network can display on their store page to let customers know they offer a smooth and swift delivery process. Management said that merchants who displayed a Shop Promise badge on their store had increased buyer conversion by as much as 9% since the initiative was launched. Shopify also launched an all-in-one point-of-sale hardware device for merchants called POS Go in the third quarter, as well as Shopify Markets Pro, which enables seamless cross-border selling. As the multitrillion-dollar e-commerce industry continues to grow in the years ahead, Shopify's vast array of offerings for sellers can continue to fuel strong merchant growth and enable an entirely new generation of brands to capitalize on future waves of consumer spending. This creates a compelling buying proposition for long-term investors with the risk tolerance to put capital into this type of growth-oriented business. 2. DexCom DexCom (NASDAQ: DXCM) carried out a 4-for-1 stock split on June 10, 2022. While the stock is down slightly year to date, shareholders are still looking at a trailing-three-year total return of nearly 80%. On the whole, the healthcare industry has long been seen as a resilient place to invest capital, largely because the products and services that come out of this industry tend to face strong demand in a wide variety of markets. Dexcom is certainly no exception. The company is one of the leading developers and manufacturers of continuous glucose monitoring (CGM) devices in the world. Over the past decade, the company has seen revenue grow by more than 1,400%. CGM devices are an essential part of daily life for many individuals with diabetes to monitor their blood sugar levels on a consistent basis. DexCom is in the process of launching its latest CGM device, the G7. The system not only has the fastest warm-up time of any CGM device on the market but also is 60% lighter than the G6 model. Currently, most CGM device users are type 1 diabetics. In a recent interview with MedTech Dive, CEO Kevin Sayer gave some insight into some additional potential use cases for DexCom's products in the future when asked about the expansion of these devices into the type 2 diabetes and even prediabetes consumer markets. He noted: It's the learnings from the CGM that can be very beneficial. We find over and over again, when patients with type 2 diabetes on compounds -- not insulin -- wear a CGM, they see a vast improvement in their health. Because of the CGM, they have a dataset whereby they can change their behavior and their lives. On the prediabetes side, it's every bit as visible. If you wear a CGM and see you're having meal spikes above a certain amount and your average glucose is too high, you can see what's coming. According to the Centers for Disease Control and Prevention, roughly 11% of Americans have diabetes, which translates to about 37 million individuals, based on current figures. And roughly 1.4 million Americans are newly diagnosed with diabetes every year. Bear in mind that these figures don't take into account individuals outside the U.S., nor do they include individuals that have diabetes but have not been diagnosed or are at risk of developing diabetes. In short, there is a tremendous ongoing market opportunity here for DexCom and its products. For long-term shareholders, a buy-and-hold investment in this stock could yield generous returns in the years ahead. 10 stocks we like better than Shopify When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Shopify wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of January 9, 2023 Rachel Warren has positions in DexCom and Shopify. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends DexCom and recommends the following options: long January 2023 $1,140 calls on Shopify and short January 2023 $1,160 calls on Shopify. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-08,109.5,110.9,108.74,109.84,
DXCM,2023-02-09,110.02,110.71,106.82,107.24,"[""DexCom (DXCM) Q4 2022 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q4 2022 Earnings Call Feb 09, 2023, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, welcome to the Dexcom fourth quarter 2022 earnings release conference call. My name is Abby, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator instructions] As a reminder, the conference is being recorded. And I will now turn the call over to Sean Christensen, vice president of finance and investor relations. Sean, you may begin. Sean Christensen -- Head of Investor Relations Thank you, Abby, and welcome to Dexcom's fourth quarter 2022earnings call Our agenda begins with Kevin Sayer, Dexcom's chairman, president, and CEO, who will summarize our recent highlights and ongoing strategic initiatives; followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. [Operator instructions] Please note that there are also slides available related to our fourth quarter performance on the Dexcom investor relations website on the events and presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our fourth quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. I'd like to start by reviewing some of Dexcom's key accomplishments in 2022. Total revenue grew 20% on an organic basis driven by another year of record new customer starts. This translates into more than $475 million of organic revenue growth compared to last year as we saw another step forward for CGM awareness and Dexcom brand loyalty. We added nearly 450,000 Dexcom users to our base in 2022 and ended the year with close to 1.7 million customers globally. Our team did a great job generating this customer engagement and growth while simultaneously enhancing the scale and efficiency of our organization. Our operations team demonstrated world-class performance this year, ensuring adequate supply in a difficult macro environment and providing on-time delivery rates of greater than 99%. We drove over 500 basis points of operating expense leverage in 2022 despite broad inflationary pressure. This was not the result of reactionary cost cutting. Instead, it reflects decisions made years ago at our company to foster a culture of cost discipline as we grow. From a strategic perspective, we will look back at 2022 as a pivotal year for our company. We advanced several of our most important initiatives, including multiple new product launches, significant access wins, new market development, and a further extension of our market-leading performance in connectivity. Everything we achieved this past year helps build a foundation for years of sustainable growth ahead. For example, in October, CMS published a proposed local coverage determination that would meaningfully expand access to CGM technology for the Medicare population. This proposal would broaden coverage to include people with type 2 diabetes using basal insulin only, as well as certain non-insulin-using individuals that experience hypoglycemia. This result was led by the publication of Dexcom's MOBILE study and furthered by a strong partnership with the diabetes community. We heard broad support and enthusiasm from key stakeholders during the comment period and expect the ruling to be finalized in the coming months. As a reminder, we size the basal-only type 2 population at 3 million people in the United States. Between this Medicare ruling and broader commercial coverage, which we expect to follow shortly, this population has the potential to nearly double our addressable reimbursed market in the United States. Outside the United States, our team has been equally focused on building greater access. We drove many positive coverage decisions from Mobile payers over the course of 2022. These access wins were in response to the strong clinical evidence we continue to generate, as well as the introduction of our portfolio strategy in many of these markets. 2022 was the first time that we brought multiple Dexcom products to a single market, and this strategy has enabled us to significantly extend our reach. By offering multiple products, we can provide a unique value proposition that meets the specific needs of our diverse base of customers, clinicians, and payers. A great example is in the U.K., where Dexcom ONE was added to the national formulary for all people with intensively managed diabetes. Collectively, our international access initiatives have helped us expand our reimbursed coverage by 3.5 million lives over the past 18 months. 2022 will also be remembered as the year of G7. We received both CE Mark and FDA regulatory clearance for G7 and initiated a full launch outside the United States. The feedback from our customers has been everything we'd hoped for. We are hearing consistent praise for the new features, such as the 60% smaller form factor, shorter warm-up period, and more engaging and consumer-friendly app. Perhaps the most encouraging is that 97% of initial users surveyed have found G7 easy to use. We designed this product to simplify the lives of our customers, and we are thrilled to see that emphasis resonating. All of this leaves us incredibly excited to bring G7 to the U.S. In fact, we began shipping this week into our U.S. distribution channels to support our rollout. We have quickly ramped up production capacity to support the launch with our automated G7 lines already capable of producing more than 100,000 sensors a day. We want to get G7 into the hands of as many people as possible. So, in conjunction with our launch, we've established a bridge program to simplify access for our early adopters. This program will provide new and existing customers access to G7 immediately and allow us to go to market in a broad and expedited manner. Behind the scenes, we continue to advance our discussions with payers to build reimbursement. Our conversations have progressed very well, and we are well on track with our G7 coverage plans. More importantly, we are not going to be bashful about what we think of this product. G7 is the new gold standard in diabetes technology. This is the most accurate, easy-to-use, and accessible CGM ever produced, and we want to share this message with the world. As a result, we will be releasing our second-ever Super Bowl commercial this Sunday. We're again teaming up with one of our most recognizable Dexcom warriors, Nick Jonas, to announce the G7 is here. This is a great opportunity to connect not only with our loyal G6 users but with the millions of people with diabetes that still do not use CGM. We want these individuals, their caregivers, and their loved ones to know that Dexcom can help them live healthier lives. With that, I'll turn it over to Jereme for a review of the fourth quarter financials. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the fourth quarter of 2022, we reported worldwide revenue of $815 million compared to $698 million for the fourth quarter of 2021, representing growth of 20% on an organic basis. As a reminder, our definition of organic revenue excludes currency in addition to non-CGM revenue acquired in the trailing 12 months. U.S. revenue totaled $606 million for the fourth quarter compared to $517 million in the fourth quarter of 2021, representing growth of 17%. Our recent momentum in the U.S. continued into Q4 as we delivered another strong quarter of volume growth and solid new customer starts. We were very encouraged by the prescribing trends we saw in the fourth quarter, and we closed the year with around 75% of our commercial scripts going through the pharmacy channel. This represents the endpoint of a multiyear channel journey. And we believe our current structure maximizes access for our users as the most covered CGM and supports greater customer choice in how they access the most accurate CGM. International revenue grew 15%, totaling $209 million in the fourth quarter. International organic revenue growth was 27% for the fourth quarter. We continue to take share in international markets as the introduction of new products and access wins over the past year leave us in a wonderful position to compete for new users. For example, in response to the sizable U.K. coverage decision we received last August, our revenue growth has accelerated over the past two quarters in that region. Even though this was already one of our largest OUS markets, there has been a clear uptick in demand following this broad expansion of access. Our fourth quarter gross profit was $544 million or 66.7% of revenue compared to 67.7% of revenue in the fourth quarter of 2021. Foreign currency was an 80-basis-point negative impact on gross margin in the quarter. Operating expenses were $372 million for the fourth quarter of 2022 compared to $461 million in the fourth quarter of 2021. You may recall that in the fourth quarter of 2021, we recognized an $87 million expense associated with the contingent milestone under the 2018 collaboration and license agreement with Verily Life Sciences. Absent this, our operating expenses for the fourth quarter of 2022 would have been relatively flat year over year. This represents another quarter of very disciplined cost management as we generated 800 basis points of opex leverage. Operating income was $172.1 million or 21.1% of revenue in the fourth quarter of 2022 compared to $12 million or 1.7% of revenue in the same quarter of 2021. Even excluding the Verily charge from 2021, this highlights incredibly strong operating expense leverage in our current year, which more than offsets our step backwards in gross margin. Adjusted EBITDA was $237.1 million or 29.1% of revenue for the fourth quarter compared to $67.3 million or 9.6% of revenue for the fourth quarter of 2021. Net income for the fourth quarter was $136.3 million or $0.34 per share. We remain in a great financial position, closing the quarter with approximately $2.5 billion worth of cash and cash equivalents. This cash level provides organizational flexibility to support our organic growth opportunity and assess strategic uses of capital on an ongoing basis, such as the accelerated share repurchase program we executed in 2022 and ongoing development of our Malaysia manufacturing facility. Turning to 2023 guidance. As we stated last month. We anticipate total revenue to be in the range of $3.35 billion to $3.49 billion, representing growth of 15% to 20%. This reflects another year of strong underlying volume growth, which will again exceed our revenue growth rate for the year. To help provide some insight into the makeup of our guidance this year, we recently provided some additional color around our expectations. First, earlier on this call, Kevin discussed our plans to support our initial G7 customers with a bridge program. We expect this program to impact our revenue per customer early in the year as we provide G7 access at an affordable cash rate as we build reimbursement. We expect this impact to narrow over the course of the year as broader coverage is secured. Internationally, we estimate that around 1/3 of our new customer starts will come in through the Dexcom ONE platform. Therefore, this business will start to have a more material impact on numbers this year as that customer base builds. For the type 2 basal opportunity, we anticipate CMS reimbursement to be finalized for this population by midyear and begin contributing to our results in the second half of 2023. We expect this population to contribute approximately 1% of our total revenue in 2023. Turning to margins. We expect gross profit margin to be in the range of 62% to 63%. This assumed year-over-year decline is primarily related to the impact of the broader G7 launch. As with any launch, we will initially be running at lower production volumes, and it will take some time for our new manufacturing lines to scale. Importantly, this is a temporary dynamic, and we still expect G7 product costs to be less than G6 at scale. Despite the step backwards in gross margin, we are guiding for operating margins to be relatively flat year over year at 16.5%, which reflects another 150 to 250 basis points of operating expense leverage in 2023. This is the result of ongoing cost initiatives at our organization, which continue to drive leverage even as we allocate greater investment to support our global commercial infrastructure and G7 launch. Finally, we expect adjusted EBITDA margins of approximately 26% in 2023. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. To summarize, we are incredibly excited about the opportunity ahead with G7, and we're rolling out product to our distributors as we speak, and we're ready for a big launch in the U.S. I would now like to open up the call for Q&A. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Abby, please provide the Q&A instructions. Questions & Answers: Operator Thank you. And we will now begin the question-and-answer session. [Operator instructions] And we will pause for just one moment to compile the Q&A roster. We will take our first question from Jeff Johnson with Baird. Your line is open. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. Let me ask you just a two-part question on G7, if I could. Kevin, on your website, you talk about adding more commercial coverage for G7 every day. I guess, could you give us a number of what percentage of covered lives or lives are covered currently in the commercial channel for G7 and where you expect that to go maybe over the next quarter or two? And I think Libre 3 has now been in the pharmacy channel for about four months or so in the U.S. Obviously, your business looks like it's probably safe with the AID users in the Medicare channel. But for your stand-alone T1 users, have you seen any change in your attrition rate? Anything as we kind of look at that Libre 3 versus G6 dynamic that has changed in the last few months that Libre 3 has been out there? Thank you. Jereme Sylvain -- Chief Financial Officer Thanks, Jeff. Yes, I appreciate that. This is Jereme. So, to your question on coverage, we're still in the throes of the commercial DME and the Medicare coverage. We talked about on G7 taking about 90 days. But on the pharmacy side, we're actually a little bit ahead of schedule. Kevin referenced, we're well on track to the point where I talked about a $30 million-ish hit in Q1 as a result of our bridge program. That number is more like $15 million now, and that's because some of those pharmacy contracts are coming in earlier. So, we are making great progress, and we continue to get that every day. And the signs lead to more and more contracts coming over, maybe even ahead of schedule. In terms of the question then on competitive dynamics, maybe I can start and then Kevin will obviously have a few thoughts there. We had a record new patient start in Q4. If that gives you any context, we had another solid new patient quarter. So, while we have seen competitive product out there, we continue to do very, very well with G6 to the point where we have seen incredible strength there. And that's, of course, on the heels of a G7 launch, which as we referenced, is coming out here in the next coming days. Kevin, I don't know if you have anything else to add there. Kevin Sayer -- Chairman, President, and Chief Executive Officer No. I would tell you what we're also hearing is a great deal of excitement from our user base for G7. So, with respect to your question regarding how our G6 users doing, they're very anxious to get G7 and very excited to go. So, we're feeling good about where we are right now. Jeff Johnson -- Robert W. Baird and Company -- Analyst Understood. Thank you. Operator We will take our next question from Larry Biegelsen with Wells Fargo. Your line is open. Larry Biegelsen -- Wells Fargo Securities -- Analyst Good afternoon. Thanks for taking the question. Kevin, I wanted to ask about the ramp in the type 2 basal population. I think people were a little surprised you only expected 1% growth contribution in '23. I guess, that would be about $60 million on an annual run rate. At the last investor meeting, you said you expect $700 million in revenues in 2025 from sources other than insulin-intensive patients, and I think this was mostly type 2 basal. So, the question is, do you still expect $700 million by 2025 from these non-intensive sources? And how do you see the ramp in the type 2 basal population? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, Larry, our -- I'm going to talk for a bit. I'll turn it over to Jereme. Our initial estimates, it's 1% of our total revenues would come from that. And that's a reasonably sized number. We plan for July, second half of the year, approval and rolling it out from there. It may go faster than that, but we've been conservative in our estimates, and we will make every attempt to beat those. As we look out to 2025, that non-intensive insulin space is not just basal users. We believe our CGM product will be very valuable among a number of markets in the type 2 space and also in metabolic health. So, it's not just basal users there. It's a lot more than that. And many of the basal users, as you well know, move up to be intensive insulin users as well. So, we view that population as moving and shifting with us as they go. Jereme, you have anything else to add? Jereme Sylvain -- Chief Financial Officer Sure. Yeah. Larry, so the $60 million number you're referencing would assume, say, everybody started on July 1 and they went through the end of the year. The reality is that some folks will start in July, some folks will start in December. And so really, the exit velocity is much higher than that on a run rate perspective. If you were to blend it, average it over the course of the year, you're really only getting three months of revenue contribution. And so you kind of do the math there, and the exit rate is a little bit higher than I think what you're implying. So, we are really, really bullish on it. But it is a recurring revenue business. So, what we need to do is get those -- get that coverage out there, get the scripts in. And so, look, I understand the question. It's a big, big market with a big, big opportunity. We plan on playing in it, and we plan on playing it in a big way. But obviously, we want to be prudent around guidance. And certainly, if things go better than that, then we'll always try to do so. We'll report back to everybody. Operator We will take our next question from Margaret Kaczor with William Blair. Your line is open. Margaret Kaczor -- William Blair and Company -- Analyst OK. Good afternoon, everyone. Thanks for taking the questions. I wanted to maybe take Larry's question a step further and just kind of talk about the potential pace of adoption within type 2 basal, maybe not just this year, but really more over an 18-month, 24-month period. And is it fair at all to compare it to, I guess, what the attritional type of insulin diabetic population is? Is it going to be easier, harder, I guess, to drive adoption or are there guardrails on penetration? And then just because you brought up metabolic health to non-insulin diabetics, 2025 is just around the corner. So, should we expect, I guess, a more meaningful impact from here as early as next year? Thanks. Jereme Sylvain -- Chief Financial Officer Yeah. So, let me start on the base, and then I can turn it over to Kevin from that perspective. And so, the ramp in basal is going to be a bit interesting. We'll give you kind of the way we think about it. Think about it as -- I generally start with type 2 intensive, and you think about that ramp, and you think about coverage and how that takes place. And if the coverage takes place over a similar time, you'd expect a relatively similar ramp. Now I'd caveat that by saying there's more awareness today. And hence, the Super Bowl commercial is a good opportunity for us to continue to raise that awareness. However, the place in which the basal patients cede is a wider swath of physicians. And so, we don't have an exact crystal ball here. If you're using prior analogs, the best analog is type 2 intensive would be about the adoption rate. But I think as time moves on, we'll be able to give you a little bit more color. But that's kind of our best crystal ball. And then maybe, Kevin, if you want to give just some general thoughts about metabolic health and the opportunities there. Kevin Sayer -- Chairman, President, and Chief Executive Officer No. As we look out to the future, Margaret, particularly with our easy-to-use G7 platform that we're launching today, we believe our future is very bright as we deal with metabolic health. We've changed our mission statement to help people control their health, not just diabetes anymore. We continue to see very positive results from several programs who are using sensors to assist people in these endeavors. And over time, and particularly with type 2 management and all the type 2 drug alternatives on the horizon, we believe CGM becomes a very important part of that health equation. And we're continuing to work on product offerings and business models. So, it will be differentiated from what we do today and geared toward that population. We're really excited about the opportunity. And it will continue to mature over 2023, and then we'll see what happens in 2024. We've got a lot of basal patients to reach first. So, let's go after them, and then we'll continue to move to the other areas as well. Operator And we will take our next question from Robbie Marcus with J.P. Morgan. Your line is open. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Oh, great, and congrats on a nice quarter. Wanted to ask about the European or OUS experience. And it looks like you're gaining share, you're doing well. How much of that is being driven by G7? And what's the feedback there? And any head-to-head color you could give us versus Libre 3 in the markets where it participates? And then also sort of same question on Dexcom ONE and the impact you're seeing there. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer I will start off. With respect to the sales and the revenue numbers, G7 and Dexcom ONE are still early enough in their launch life cycle that while they're additive, they're not what's driving a lot of the adoption, a lot of the growth that we've seen in European markets. A lot of that's been what we've established with G6, the additional coverage that we've obtained, as I talked about in the prepared remarks, in 18 months, we've added 3.5 million more reimbursed lives. That being said, initial response to G7 has been everything we'd hoped for. People love the app. They love the receiver. Again, in many of these markets, the receiver is a very, very strong tool. My most recent conversation with the G7 user focused completely around the half-hour warm-up. A half-hour warmup has eliminated 90 minutes of the longest two hours of somebody's life who ever used the G6. And certainly, in the comparative front compared to the hour warm-up, again, it is a much better experience. The majority of our G6 users are new to Dexcom. They're not Dexcom upgrade -- I mean G7 users, I apologize. The majority of our G7 users are new to Dexcom. Some of them come from the competition. Some of them have not used CGM before, but they're all finding it very easy to use and having great experiences. So, we're very happy with the product to this point in time. We've done very well. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks a lot. Operator We will take our next question from Joanne Wuensch with Citibank. Your line is open. Joanne Wuensch -- Citi -- Analyst Good evening and thank you for taking the question. So, I'd like to spend just a minute on the gross margin and how you anticipate those ramping throughout the year. And then while I know we're sort of early to be thinking about 2024, I do think people are looking at that as sort of a more normalized margin rate, and if you could sort of shed any light on how to think about that. Thank you. Jereme Sylvain -- Chief Financial Officer Sure. Thanks, Joanne. Appreciate that. And you start off with, obviously, the fourth quarter. We had a really strong gross margin. I think it's a demonstration of what's to come with what our teams can do when you give them time with a new product launch. So, I think as you think about the year, the cadence for 2023, we do expect in the first half of the year margins to be a little bit lower. And that's because of, as Kevin referenced earlier, the bridge program. Certainly, that has an impact. But most importantly, it's the launch of G7. Volumes won't be where they would have been, say, in a more mature launch, and we'll still be going through some of those early manufacturing scrap and yield challenges we always see. But what we've proven time and time again is if you give our engineering and R&D team time with these lines, they continue to get yields better over time. And so, our expectation is as we start to exit the year in 2023, we start to come closer back to that long-term guide of 65% gross margins. And there's nothing longer term, structurally, that we don't believe, especially as G7 gets to scale, that gets us back to those long-term guides that we've originally provided. So, we'll continue to work toward that. Think about 2023 as the first half of the year as a little bit lower. As we ramp up those lines in the back half, you start to tackle some of that absorption of those fixed overheads. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Terrific. Thank you. Operator We will take our next question from Matthew O'Brien with Piper Sandler. Your line is open. Matthew O'Brien -- Piper Sandler -- Analyst Good afternoon. Thanks for taking that question. Just on the bridging program, can you tease out a little bit more, maybe, Jereme, on expectations there? I think you had said $20 million to $30 million. You said you're trending better than that for Q1, which is great to hear. But I don't think you ever said how much the bridging program is going to cost you for the full year. It seems like it's going to be even better than expected overall versus maybe what you were thinking starting off '23. But then also bridging is supposed to be more of a headwind on the gross margin side, too. And if it's less of a headwind, maybe that helps out the gross margin profile a little bit more, maybe sooner than expected. So, I'm just wondering like based on all these things on the bridging program specifically being better than expected, should we start to creep up a little bit more as far as our expectations for top-line growth and then even gross margins for the full year? Thanks. Jereme Sylvain -- Chief Financial Officer Sure. Yeah. I don't think we're at a point where we'd necessarily change our guidance. But let me take your question head on, which is in isolation, what does this do? So, certainly, what the bridging program, what this effectively means is we have contracts in place a little bit more ahead of when we ultimately expected. And so, ASPs will be a little bit higher, and that's as a result of most folks going through coverage as opposed to the bridging program. So, that does a couple of things. Certainly, it does help revenue and it does help margin. That all being said, we're not changing guidance for the year. But I think what this does mean is, one, it's a great thing for patients who want to access the product. We talked about coverage being a key strategy. That's wonderful. It does help longer term for those margin profiles. And while I wouldn't necessarily guide you outside of our ranges, you are correct. It does help on revenue and gross margin on the full year. And the other question was how much for the full year. We expected a majority of it, almost all of the $20 million, $30 million, in the first quarter. We do expect a nominal amount in Q2. We haven't expected any of it beyond Q2. Really, a majority of your concern would be in Q1. Matthew O'Brien -- Piper Sandler -- Analyst Got it. Thank you. Operator And we will take our next question from Marie Thibault with BTIG. Your line is open. Marie Thibault -- BTIG -- Analyst Hi, good afternoon. Thank you for taking the questions and congrats on a strong quarter. Wanted to ask a little bit more on kind of the backlog around the Medicare decision-making. I'm very curious how physicians and patients, how aware they are of that decision, whether we might see a bolus of patients sort of come on once that Medicare coverage took place. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks for the question. It will be up to us to drive awareness in that community to make sure people are aware of that decision. There will certainly be those very familiar with Dexcom and with continuous glucose monitoring will be aware of it and will pick it up quickly. But it will be up to us to drive awareness in both communities. the physicians and users of the product to go and ask for it and to create that environment. So, we're not going to sit back and wait. We're going to have to push. Matthew O'Brien -- Piper Sandler -- Analyst OK. Thank you very much. Operator We'll take our next question from Travis Steed with Bank of America. Your line is open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Hi. Thanks for taking the question. So, U.S. growth the last couple of quarters has been around 17%. So, second half of the year, I think, was record patient growth for both quarters. So, trying to think about ex the [Inaudible] for the bridge program if we should be seeing an acceleration here in the first quarter and the U.S. growth specifically and how that builds over the course of the year. And then on the Super Bowl ad, what kind of impact did you see on U.S. new patient starts last time you did that? Thank you. Jereme Sylvain -- Chief Financial Officer Sure. Yes. So, I'll start with how we're thinking about Q1. And the way we've generally thought about Q1 is in terms of full year contribution, absent any sort of bridging program, to be a very similar contributor as a percentage of total year revenue in the first quarter. So, that's total company, not just U.S. total company. And then you add the bridging program and then you pull it down from there. And that's generally how we think about the quarter, which is just an indication of continued strong new patient growth. Clearly, we'll be working through driving new patients and driving growth over the course of the year. In terms of the Super Bowl and then how to think about the Super Bowl and how that contributes, last time we did it, there were hundreds and hundreds of thousands of inbound leads. Not all of those obviously translated into patients, but there was a lot of interest. One of the challenges, though, if you rewind the clock a couple of years, is there wasn't as much coverage there. And so, I think what we're hoping this time around is, one, the awareness is the most important thing. And the awareness, as that gets out there, will be very, very helpful. But as coverage starts to come through and we have this bridging program in place, it's a real opportunity to take advantage of it. We're not ready to give exact patient numbers out there other than to say that the return on capital is a very strong investment. And so, you should expect we do that math before we sign up for this. And we wouldn't be doing if we didn't expect a return on investment that was commensurate with what you and we would expect. Travis Steed -- Bank of America Merrill Lynch -- Analyst Great. Thank you. Operator We will take our next question from Jayson Bedford with Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Hi. Good afternoon. Just maybe an opex question. It looks like it's a bit bigger of a step up implied in '23. I know the Super Bowl ad is a contributor. But just wondering if you can comment on what are the sources of the opex growth and maybe hit on any planned changes to the sales force in support of G7. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jayson. This is Kevin. I'll take it, rather big picture. We'll continue to invest in R&D. Our spend will grow some but not as rapidly as it has in other years. And quite honestly, as a percentage of revenue, it's probably come down a little bit. Same with -- on the G&A side, we'll continue to invest in infrastructure and build things out for our continued growth. But a lot of that investing has been done. Our biggest dollar investment, our biggest increases are going to be on the commercial side and in all areas, create awareness in the sales force, marketing across the board, we'll be spending on the commercial side. Those expenditures will -- could adjust and move over the course of the year as we learn more. We've always been very adept at channeling those dollars where they can be the most effective. We're analyzing some of that now. We certainly have a plan, but we've never been afraid to deviate from it if it makes more sense. And so, we're looking at all those things. A lot of international investment this year, quite honestly, as a percentage of our investment. International is getting a bigger piece of it than they have in the past because we really look at these opportunities. We've got G7 and several of these companies combined with the Dexcom launch and all those covered lives we've added. We think there's great growth opportunities over there, but we've got to invest in that infrastructure. Jereme Sylvain -- Chief Financial Officer Yeah. And just to kind of add to that one, Jayson, just to give you some context. We launched outside the U.S. with Dexcom ONE and G7, call it, in the first couple of phases. But we have more phases to go. And so, we're going to make the marketing push obviously with G7 in the U.S, but there's also a second phase of G7 launchings outside the U.S. and a second and third phase of Dexcom ONE outside the U.S. So, sales and marketing is really where we want to put our investment, and we'll get leverage elsewhere. But hopefully, that gives you kind of some context for how we're thinking about that spend in 2023. Jayson Bedford -- Raymond James -- Analyst Got it. Operator And we will take our next question from Matt Taylor with Jefferies. Your line is open. Matt Taylor -- Jefferies -- Analyst Hey, guys. Thanks for taking the question. So, I just want to get some thoughts on gross margin longer term. I know you touched on this year. And obviously, with the new product launch, there's some initial depression, and then you get spring loaded with leverage over time. So, help us think about G7 over the next couple of years. Does that expand? How can that impact gross margins with and without the potential for a longer-wear label? Jereme Sylvain -- Chief Financial Officer Yeah. I can start there. You're 100% right. I mean, obviously, there's the levers to get the actual cost of the product, and we've been very transparent about it. We want to get to basically $1 per day and a 10-day sensor or a $10 sensor. And then we want to go even beyond that. But that has always been kind of our public goal. Then, of course, as you move to a 15-day sensor, that cost is spread out over a longer period. So, we have intentions over the long haul of doing all of that. Now the math, if you do that, would indicate there's some real opportunities in gross margin even beyond potential long-term guide. The one thing we want to be mindful of is we don't want to shortchange ourselves and other opportunities to either partner or otherwise over the long haul. So, while the long-term guide remains intact, there are certainly levers and opportunities for us to do well there. And so I think you're hitting on all the right points. That all being said, we really hold to that long-term 65% gross margin. That's what we'll work too. And if there's other opportunities to get fill you in on some other things we're doing in the future, we'll certainly do so. Matt Taylor -- Jefferies -- Analyst Yeah. Thanks, Jereme. Operator We will take our next question from Mathew Blackman with Stifel. Your line is open. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thank you for taking my question. Jereme, just curious, I appreciate all the inputs that you gave us that roll up to the 15% to 20% guide. I'm just curious, have you contemplated in that 15% to 20% range any competitive pressures in the event that your competitor gets approved to integrate with a pump sometime in 2023? Thanks. Jereme Sylvain -- Chief Financial Officer Yeah. Thanks for the question, Matt. Yes, we do. We've considered all of that when providing that guidance. I mean, when we think about all the competitive pressures and then we think about all the opportunities ahead of us, we consider all that in the guidance. And you are right, there is the potential out there, at least according to some of the commentary, that there could be some potential pressure out there. I would say that we've contemplated it. At the same time, we feel very confident in our product offering and what it ultimately does, how it integrates, and the safety features that people rely on our product for the accuracy, the ease of use. So, I think we feel very confident about it. But yes, we did contemplate that in our guide. Mathew Blackman -- Stifel Financial Corp. -- Analyst Appreciate it. Thank you. Operator We will take our next question from Chris Pasquale with Nephron. Your line is open. Chris Pasquale -- Nephron Research -- Analyst Thanks. Love the update on how you guys are thinking about price. You said in the past, your U.S. channel mix could start to stabilize once you hit 75% of the pharmacy. You're there now. But you also have D1 making a bigger portion of the OUS starts, which I would imagine might pull down your international ASP a bit. So, can you tell us what impact price had on revenue in '22 and then how you're thinking about the potential impact this year? Jereme Sylvain -- Chief Financial Officer Yeah. So, we'll talk about 2022 since we gave kind of a guide there, which was around $200 million in the U.S. and around $50 million outside the U.S. And the full year of 2022 was generally in line with that. It was, I think, just south of $200 million in the U.S. and just south of $50 million outside the U.S. So, basically right in line with that. So, I think you can feel good about what guidance we gave there. Going forward, the expectation is in the G Series, that delta -- that price-volume delta starts to come down over time. What we would expect to see is -- and we're not going to give a specific number for 2023 since most of that migration is done, but we will have to lap the 2022 migration. And then if there's drift, say, 75 say drifts to 80, you wouldn't expect material moves there. But those are all things we've contemplated in those figures. To your point, and I think you're hitting out the way we model the business, we model the business as a G Series and a Dexcom ONE. And I would suggest you do that going forward. And then to your point, Dexcom ONE modeled as a percentage of total business will allow you to then understand the contributions to ASP there, which is why it was important for us to give you our expectation of new patient starts in 2023 that one-third of them outside the U.S. will be on Dexcom ONE. So, I think the way you're thinking about the model is exactly the way we model it internally, and that's the way I'd go about doing that for 2023 and beyond. Operator And we will take our next question from Kyle Rose with Canaccord. Your line is open. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you very much. I wanted to ask an additional question just on the commercial strategy moving forward. I understand the DTC advertising, and you doubled the sales force a few years ago. But just as you prepare for basal approval in the U.S., how does the focus or the call point of the actual sales force need to change? Do you need to make additional investments in people? Just help us understand how the targeting goes moving forward. Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah. This is Kevin. I'll take that. Jereme gave us a bit of color earlier. 75% of our calls already by our U.S. sales force are in the PCP arena. And I think you'll continue to see that expand as our team spends more of their time addressing that marketplace, at the same time, not ignoring the places where we've been so successful in the past with the intensive management diabetes. So, we will look at that structure in great detail. On a geographical basis, even within the U.S., there may be some places where we need to expand geographically versus large expansion across the entire country. We'll analyze that in great detail as we go. We're in the process of doing that now. We just brought on a new chief commercial officer, as many of you will remember, in early January. And she's deep in the middle of that today as we manage those thoughts and the launch and everything else going on. But we'll look at it very strongly. Operator We will take our next question from Steve Lichtman with Oppenheimer. Your line is open. Steve Lichtman -- Oppenheimer and Company -- Analyst Thank you. Evening, guys. Question on Dexcom ONE outlook. Can you talk about any major new geographic regions you expect to roll out the platform this year? And should we expect to see any movement in bringing Dexcom ONE onto the G7 platform this year? Or is that a longer-term play? Jereme Sylvain -- Chief Financial Officer Yeah. It's a fair question. Let me just say, we're not necessarily going to give the playbook as to what countries we are going into. Now we have launched recently in Croatia, Romania, and Greece for Dexcom ONE. That is out there now. So, hopefully, that gives you some context, but we will be launching in more countries. But rather than give the playbook publicly, we'll let our commercial team execute that and give you that feedback. But just know, we will go into more countries. So, hopefully, that gives you at least some context. We will go. In terms of the movement from Dexcom ONE to the G7 form factor, we are absolutely going to be moving to that factor. It's going to take a little bit of time, and the reason it's going to take a little bit of time is, as we get economies of scale on G6, which we have today across the existing user base, as well as Dexcom ONE, as well as a lot of opportunity for new users on G7, we want to make sure we prioritize G7 and that form factor for those patients coming on to therapy on the G Series. Make no mistake, though, as soon as possible, right after that, we will be moving Dexcom ONE to that G7 form factor. Stay tuned. We'll have some updates as the years progress on. But you're thinking about it the right way. We will move there in relatively short order. Steve Lichtman -- Oppenheimer and Company -- Analyst Thanks, Jereme. Operator We will take our next question from Josh Jennings with Cowen. Your line is open. Joshua Jennings -- Cowen and Company -- Analyst Hi. Good afternoon. I was hoping to follow up on the pricing question. And I'm not sure if you've given a recent update just on how investors should think about the average reimbursement Dexcom receives in the U.S. for a G6 or a G Series patient. And then just a follow-up on that is, will that change with the G7 introduction for one? And then two, is it important the share shifts in the pump market just considering the reimbursement Dexcom gets to the DME channel with the Tandem pump versus the pharmacy channel with the Insulet pump? Thanks for taking the questions. Thank you. Jereme Sylvain -- Chief Financial Officer Yes. It's a good question. Look, I think the way to think about the ASP is it's really more about channel than it is about version. And so as you think about where folks and who folks -- who gets access, but the general way to think about it is Medicare, which is publicly out there, I think after the increase, it's around 250 a month. There's a delta there which goes to the distributor who ultimately fulfills that. So, the net price to us is south of that. But ultimately, that would be our price in that range. That's publicly available. Generally, commercial DME is higher than that and pharmacy is lower than that number. And so that's the way to think about it. In terms of then how ASP moves over time, think about it less of generation of product and think about it more as where folks want to get their product. And so I think you're thinking about it the right way. As we talked about, 75% of our lives covered in commercial. Seventy-five percent of those patients, those patients obviously then come through at a lower price point. If that drifts to, say, 80%, you could see that having a potential tick on there. Again, most of that is behind us, but that's the way to think about the split there. And then in terms of pump partners and how folks ultimately access it, it really depends again consumer preference. You're right, Tandem is generally accessed through the DME and Insulet's generally access to the pharmacy. So, it makes sense that folks get their CGMs through that channel. That all being said, it's ultimately consumer preference. And we believe the consumer experience through the pharmacy is great. We have some really great DME partners. They do a wonderful job fulfilling product through that DME channel. And so we believe that, that folks can be fulfilled either way. Joshua Jennings -- Cowen and Company -- Analyst Great. If I could sneak in just a quick follow-up. Just thinking about your CGM platform attached to pumps, is there a premium reimbursement that Dexcom receives in that scenario versus stand-alone? Or is it all consistent across the board? It just depends on the channel, as you said. Thank you. Sorry about that. Kevin Sayer -- Chairman, President, and Chief Executive Officer No. Right now, there's one class of CGM products, and reimbursement is consistent across the board. Operator We will take our next question from Cecilia Furlong with Morgan Stanley. Your line is open. Cecilia Furlong -- Morgan Stanley -- Analyst Good afternoon and thank you for taking the question. I was hoping to follow up. You talked, though, the last quarter just about rolling out cash pay models in the U.S. Just curious if you could provide more color as you're thinking about that opportunity today. And then for 2023, specifically, how we should think about potential incremental contributions from that? And thank you for taking the question. Kevin Sayer -- Chairman, President, and Chief Executive Officer You bet. This is Kevin. I'll take it. Big picture, our cash pay program for G7 to start with is going to be our bridging program. And people will be able to pay cash for G7 that way. Ultimately, as we get access and coverage of G7, when people's co-pays will be significantly lower than the bridging program cost, we'll phase that out and have a cash pay program on G7 that individuals will be able to access. We continue our cash pay program on G6, but that is not a major portion of our revenues. It's just a piece of them. We do this to create access primarily where people's insurance doesn't cover it, and they can't get access through the federal or the other governmental channels as well. It's not a huge percentage of our revenues. We need to continue to be cognizant of it and address those patients' needs. And that's why we have it there. Operator We will take our next question from Matt Miksic with Barclays. Your line is open. Matt Miksic -- Barclays -- Analyst Thanks so much. If I could, just two quick follow-ups on some of the topics that were covered earlier. So, on ramping production for G7 to the gross margins and the impact and improving on scrap rates and all that. And just wondering, by the end of the year, we're sort of hitting what you say about your manufacturing and sort of representative margins maybe in the facilities that you have. And the other was just on the comment you had on contemplation or competition on the pump integration front this year. And if that were not to come, I'm just wondering, not to put you in a tough spot or anything like that or credit margin the guidance range. But if that were not to come, does that -- is that sort of a slight tailwind to the top end of your guided range, or how to think about that? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer This is Kevin. I'll take that bigger picture. Jereme has been very familiar with the numbers, but I'll give you a bit of my perspective. With respect to no competition in the pump integration point, we may pick up more, we may not. What I do know is everybody using those pumps integrated systems right now uses a Dexcom. And they're achieving remarkable results with the technology we've developed over the years, and we'll continue to receive such. It is our position that the experience that they're going to have with algorithms based upon Dexcom's CGM that have been developed through the data and the performance of our sensor will continue to make us the leader in that space regardless of who the competing sensor is. And so we're very confident there that we will continue to have a very strong product offering going forward. With respect to the margin change over the course of the year, there's a couple of factors in there. Obviously, Jereme has talked about the bridging program in the first half of the year bringing margins down a bit because the revenue per patient will be a bit lower there when we start. But as we see that pick up, we'll pick that up on the revenue side. Then you have basal come in, and Medicare reimbursement is strong. So, that will help on pricing. The flip side of that is it's sometimes lost on folks, everything we do with G7 is different. All these lines are completely different. All the capacity is different. But the only thing that's the same is we're building in Arizona, and we're building it in San Diego. And that's not going to be the same for a good portion of the year because we expect the factory in Malaysia to be up and running in the second half and producing product there. So, you have a number of variables with respect to scrap, with respect to purchasing components, with respect to how these lines run as we get them up and running and functioning at full speed versus where they are today and then bringing on a new factory. We have tried to contemplate every one of those variables as we've started, and we'll update you as to how things are going as time goes on. But whenever you do a product launch, particularly when this significant because when we did our last big G6 product launch, we had similar margin activity, but it was on a much smaller scale because we're so much bigger than we were before, there's just more variables that we have to plan for. We've tried to be conservative and thoughtful in our guidance based on the performance we expect of our teams. We also expect our teams to be better than this too. We don't ever lower the bar for them, as they will tell you. But we've looked at all -- every one of those things and contemplating that, and we meet on this literally every day to make sure we're covering all of our bases. This launch is really important to us as are our margins. But it's really important to get product out to all the users that want it. Matt Miksic -- Barclays -- Analyst Thanks for the color. Operator And we will take our last question from Michael Polark with Wolfe Research. Your line is open. Michael Polark -- Wolfe Research -- Analyst Good evening. Thank you. I just wanted to follow up on first quarter to make sure I have my modeling square. Jereme, I heard in response to prior question using the full year guide, you're thinking about 1Q consistent with seasonal patterns. The last three years, I have 21% of full year revenue in the first quarter. If I use the midpoint of your range this year, that's $720 million. But then you made the comment about the bridge program down from there. So, that would be another, say, $15 million or $20 million for the quarter. So, I'd be at $700 million or $705 million. Have I put this together correctly? If not, can you help? Thank you so much. Jereme Sylvain -- Chief Financial Officer Sure. Yeah. I mean you're not far directionally off. I mean you are right, we do expect the Q1 contribution and really the sequential decline from Q4 into Q1 to be very similar to what you've seen in the past. And so that will help you get a little bit closer as you think about sequential decline as well from Q4 into Q1. That will put you into a ballpark. And then from there, you're right. We updated our number. It's about $15 million now as a result of the bridging program as opposed to the $20 million to $30 million. But that will get you in the ballpark. You're not far off, but there's probably a little bit of tweaking to do around the edges there. But use that 21% contribution, but think also 10% sequential. Those little rounding differences ultimately matter in there. Hopefully, that gives you the context you need though. Michael Polark -- Wolfe Research -- Analyst Yup. Thank you. Operator And ladies and gentlemen, with no further questions at this time, I will turn the call back to Kevin Sayer for any additional or closing remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you very much, and thanks, everybody, for joining us today. We spent a lot of time in our fourth quarter call talking about 2023. I want to just step back again and thank all of our great people here at this company for their hard work in a year where we delivered on our revenue targets, we controlled our costs. At the same time, we've advanced our technologies, our infrastructure, and we've advanced coverage and accessibility for our product all over the world to enhance people's lives. But we are very excited for this launch. This is my fourth major launch here at Dexcom. And every single time, it's taken our company to another level. The first time was G4, and that was when accuracy really came to bear. And we truly established what accuracy standard should be for CGM, and we will remain the most accurate system in the world. G7 is going to be a better experience than G6. Every time we try to make the product easier to use, and this is the biggest ease-of-use advancement we've ever had as we look at the responses from our users so far. And as always, we will make this product as accessible as we can. Dexcom has always been the most accessible brand CGM as far as coverage, and we will continue to do so. That's our commitment to drive that very hard for our end users. It is going to be a busy and great 2023. I am very confident we'll be sitting here a year from now and I'll be able to say the same things. Thanks, everybody, and have a great day. Operator [Operator signoff] Duration: 0 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Jeff Johnson -- Robert W. Baird and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Margaret Kaczor -- William Blair and Company -- Analyst Robbie Marcus -- JPMorgan Chase and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Marie Thibault -- BTIG -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Jayson Bedford -- Raymond James -- Analyst Matt Taylor -- Jefferies -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Chris Pasquale -- Nephron Research -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Steve Lichtman -- Oppenheimer and Company -- Analyst Joshua Jennings -- Cowen and Company -- Analyst Cecilia Furlong -- Morgan Stanley -- Analyst Matt Miksic -- Barclays -- Analyst Michael Polark -- Wolfe Research -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates DexCom (DXCM) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 30.77%. A quarter ago, it was expected that this medical device company would post earnings of $0.24 per share when it actually produced earnings of $0.28, delivering a surprise of 16.67%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $815.2 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 0.02%. This compares to year-ago revenues of $698.2 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have lost about 3% since the beginning of the year versus the S&P 500's gain of 7.3%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.15 on $735.4 million in revenues for the coming quarter and $1.05 on $3.44 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Integra LifeSciences (IART), has yet to report results for the quarter ended December 2022. The results are expected to be released on February 22. This medical device maker is expected to post quarterly earnings of $0.90 per share in its upcoming report, which represents a year-over-year change of +7.1%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. Integra LifeSciences' revenues are expected to be $397.83 million, down 1.9% from the year-ago quarter. Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you \u2013 and it\u2019s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation. >>Send me my free report on the top 5 EV stocks Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Thursday Option Activity: CRM, GMED, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Salesforce Inc (Symbol: CRM), where a total of 97,670 contracts have traded so far, representing approximately 9.8 million underlying shares. That amounts to about 105.1% of CRM's average daily trading volume over the past month of 9.3 million shares. Especially high volume was seen for the $195 strike call option expiring April 21, 2023, with 8,238 contracts trading so far today, representing approximately 823,800 underlying shares of CRM. Below is a chart showing CRM's trailing twelve month trading history, with the $195 strike highlighted in orange: Globus Medical Inc (Symbol: GMED) options are showing a volume of 3,948 contracts thus far today. That number of contracts represents approximately 394,800 underlying shares, working out to a sizeable 95.1% of GMED's average daily trading volume over the past month, of 415,325 shares. Especially high volume was seen for the $70 strike call option expiring March 17, 2023, with 1,035 contracts trading so far today, representing approximately 103,500 underlying shares of GMED. Below is a chart showing GMED's trailing twelve month trading history, with the $70 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 22,934 contracts, representing approximately 2.3 million underlying shares or approximately 93.2% of DXCM's average daily trading volume over the past month, of 2.5 million shares. Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 5,033 contracts trading so far today, representing approximately 503,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $105 strike highlighted in orange: For the various different available expirations for CRM options, GMED options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 ACIM Historical Stock Prices \u0095 CSL Split History \u0095 MLAB YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for February 9, 2023 : PYPL, MSI, DXCM, EQR, VRSN, VTR, EXPE, NET, REG, BAP, G, NWSA The following companies are expected to report earnings after hours on 02/09/2023. Visit our Earnings Calendar for a full list of expected earnings releases. PayPal Holdings, Inc. (PYPL)is reporting for the quarter ending December 31, 2022. The internet software company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.98. This value represents a 6.52% increase compared to the same quarter last year. PYPL missed the consensus earnings per share in the 1st calendar quarter of 2022 by -6.9%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for PYPL is 25.31 vs. an industry ratio of -15.70, implying that they will have a higher earnings growth than their competitors in the same industry. Motorola Solutions, Inc. (MSI)is reporting for the quarter ending December 31, 2022. The wireless equipment company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.20. This value represents a 20.30% increase compared to the same quarter last year. In the past year MSI has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 5.68%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for MSI is 27.95 vs. an industry ratio of 8.00, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending December 31, 2022. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.26. This value represents a 52.94% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for DXCM is 139.04 vs. an industry ratio of 42.20, implying that they will have a higher earnings growth than their competitors in the same industry. Equity Residential (EQR)is reporting for the quarter ending December 31, 2022. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.94. This value represents a 14.63% increase compared to the same quarter last year. EQR missed the consensus earnings per share in the 1st calendar quarter of 2022 by -3.75%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for EQR is 18.53 vs. an industry ratio of 17.70, implying that they will have a higher earnings growth than their competitors in the same industry. VeriSign, Inc. (VRSN)is reporting for the quarter ending December 31, 2022. The internet software company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.53. This value represents a 3.38% increase compared to the same quarter last year. In the past year VRSN has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 0.64%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for VRSN is 34.93 vs. an industry ratio of -24.20, implying that they will have a higher earnings growth than their competitors in the same industry. Ventas, Inc. (VTR)is reporting for the quarter ending December 31, 2022. The reit company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.72. This value represents a 1.37% decrease compared to the same quarter last year. In the past year VTR has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for VTR is 17.41 vs. an industry ratio of 13.30, implying that they will have a higher earnings growth than their competitors in the same industry. Expedia Group, Inc. (EXPE)is reporting for the quarter ending December 31, 2022. The internet company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.43. This value represents a 146.55% increase compared to the same quarter last year. EXPE missed the consensus earnings per share in the 1st calendar quarter of 2022 by -34.78%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for EXPE is 21.13 vs. an industry ratio of 46.40. Cloudflare, Inc. (NET)is reporting for the quarter ending December 31, 2022. The internet software company's consensus earnings per share forecast from the 9 analysts that follow the stock is $-0.09. This value represents a 30.77% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for NET is -145.18 vs. an industry ratio of -15.70. Regency Centers Corporation (REG)is reporting for the quarter ending December 31, 2022. The reit company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.98. This value represents a 2.97% decrease compared to the same quarter last year. REG missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -1.05%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for REG is 16.15 vs. an industry ratio of 13.10, implying that they will have a higher earnings growth than their competitors in the same industry. Credicorp Ltd. (BAP)is reporting for the quarter ending December 31, 2022. The bank (foreign) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $3.76. This value represents a 13.94% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for BAP is 9.13 vs. an industry ratio of 8.80, implying that they will have a higher earnings growth than their competitors in the same industry. Genpact Limited (G)is reporting for the quarter ending December 31, 2022. The outsourcing company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.59. This value represents a 34.09% increase compared to the same quarter last year. G missed the consensus earnings per share in the 4th calendar quarter of 2021 by -2.22%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for G is 19.51 vs. an industry ratio of 16.70, implying that they will have a higher earnings growth than their competitors in the same industry. News Corporation (NWSA)is reporting for the quarter ending December 31, 2022. The movie/tv production company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.25. This value represents a 43.18% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NWSA is 36.00 vs. an industry ratio of -8.00, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-10,112.65,120.0,111.21,117.89,"[""DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong DexCom, Inc. DXCM reported fourth-quarter 2022 adjusted earnings per share (EPS) of 34 cents, beating the Zacks Consensus Estimate of 26 cents by 30.8%. The company had recorded an adjusted loss of 1 cent per share in the prior-year quarter. GAAP net income per share in the quarter was 22 cents, against the year-ago quarter\u2019s loss of 1 cent per share. Revenue Details Total revenues grew 17% (20% on an organic basis) to $815.2 million on a year-over-year basis and beat the Zacks Consensus Estimate by 2.2%. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring (CGM), contributed to the upside. Segmental Details Revenues at the Sensor and other revenues segment (88% of total revenues) climbed 19% on a year-over-year basis to $714.8 million. Hardware revenues (12%) increased 1% year over year to $100.4 million. Geographical Details U.S. revenues (74% of total revenues) increased 17% on a year-over-year basis to $606.4 million. International revenues (26%) improved 15% year over year to $208.8 million. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Margin Analysis Gross profit in the quarter under review totaled $541.3 million, up 14.5% year over year. DexCom generated a gross margin (as a percentage of revenues) of 66.4%, which contracted 130 basis points (bps) year over year. Research and development expenses amounted to $116.3 million in the quarter, down 22.4% year over year. Selling, general and administrative expenses totaled $297.8 million in the reported quarter, up 27.4% year over year. The company reported total operating expenses of $415.9 million, down 11.9% from the prior-year figure. It reported an operating margin (as a percentage of revenues) of 15.4%, expanding significantly year over year. Full-Year Results DexCom reported revenues of $2.91 billion for the full-year 2022, up 19% reportedly and 20% organically from prior-year. The company\u2019s adjusted EPS improved 77.6% year over year to 87 cents. Revenues in the United States were up 16%. International revenues were up 28% and 31% reportedly and organically, respectively. Financial Position The company exited the fourth quarter with $2.46 billion in cash, cash equivalents and marketable securities, compared with $2.37 billion in the preceding quarter. Total assets in the fourth quarter amounted to $5.39 billion, compared with $4.9 billion on a sequential basis. 2023 Guidance DexCom issued its revenue and earnings guidance for 2023. The company expects revenues to be in the range of $3.35-$3.49 billion, implying 15-20% year-over-year growth. The Zacks Consensus Estimate for the same stands at $3.44 billion. The company expects adjusted gross margin to be 62-63% and operating margin to be approximately 16.5%. Wrapping Up DexCom exited fourth-quarter 2022 on a strong note, wherein earnings and revenues beat the Zacks Consensus Estimate. Impressive contributions from the Sensor segment and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Apart from making continued advancements with respect to its key strategic objectives, DexCom also ended the quarter with new patient additions. It launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available to international markets. The company received FDA clearance for G7 sensor technology in December 2022. These developments are likely to support the company\u2019s future growth. Nevertheless, the contraction in gross margin is a woe, reflecting the rising cost of sales. Apart from this, cut-throat competition in the market for blood & glucose monitoring devices remains a concern. Zacks Rank and Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Cardinal Health, Inc. CAH, McKesson Corporation MCK and Hologic, Inc. HOLX. Cardinal Health, carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2023 adjusted EPS of $1.32, beating the Zacks Consensus Estimate by 16.8%. Revenues of $51.47 billion outpaced the consensus mark by 2%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Cardinal Health has a long-term estimated growth rate of 11.6%. CAH\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 6.4%. McKesson, having a Zacks Rank #2, reported third-quarter fiscal 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 8.8%. Revenues of $70.49 billion outpaced the consensus mark by 0.02%. McKesson has a long-term estimated growth rate of 10.4%. MCK\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 3.4%. Hologic reported first-quarter fiscal 2023 adjusted earnings of $1.07 per share, beating the Zacks Consensus Estimate by 18.9%. Revenues of $1.07 billion surpassed the Zacks Consensus Estimate by 9.5%. It currently sports a Zacks Rank #1. Hologic has a long-term estimated growth rate of 15.2%. HOLX\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 30.6%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: JD, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.6%. Year to date, DexCom Inc registers a 2.8% gain. And the worst performing Nasdaq 100 component thus far on the day is JD.com, trading down 4.2%. JD.com is lower by about 5.4% looking at the year to date performance. Two other components making moves today are Airbnb, trading down 3.5%, and PayPal Holdings, trading up 4.4% on the day. VIDEO: Nasdaq 100 Movers: JD, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: NWS, DXCM In early trading on Friday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 9.4%. Year to date, DexCom registers a 3.6% gain. And the worst performing S&P 500 component thus far on the day is News Corp, trading down 8.8%. News Corp is showing a gain of 3.1% looking at the year to date performance. One other component making movesis Global Payments, trading up 5.3% on the day. VIDEO: S&P 500 Movers: NWS, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-13,119.69,121.11,118.01,118.28,"[""2 Growth Stocks That Could Help Make You a Fortune Many stocks are still shifting between sharp highs and lows these days, but wonderful businesses continue to impress investors even in the current environment. Looking beyond share price, you don't have to search hard to find compelling businesses with abundant growth opportunities that boast strong financials to boot. Here are two such stocks to consider adding to your portfolio right now. 1. DexCom DexCom (NASDAQ: DXCM) is one of the world's leading developers and manufacturers of continuous glucose monitoring (CGM) devices, which help people monitor and manage their blood sugar levels. While primarily used by the type 1 diabetes population, and increasingly, those with type 2 diabetes, there could be use cases for these products in individuals with prediabetes as well. All of these markets are still underpenetrated, though. Let's look at the U.S. market, for example, where the population has one of the highest rates of diabetes in the world and where DexCom generates the majority of its revenue. Roughly 34 million people -- about 11% of the U.S. population -- have diabetes. Approximately 7 million of them have diabetes but have not received a formal diagnosis. As of 2021, it was estimated that only 2.4 million diabetics in the U.S. were using a CGM. And only about 3% to 4% of individuals with type 2 diabetes use a CGM. The company is currently launching the latest generation of its CGM device, the G7, which is 60% smaller and has a quicker warm-up time than its predecessor (which management says is the fastest of any such product on the market). This follows a robust year of growth in 2022, in which DexCom's revenue rose by 19% to $2.9 billion. The company reported 16% growth in U.S. revenue, while international revenue jumped 28%. And it generated net income of $341 million for the year, up 57% compared to 2021. Considering that roughly 422 million people have diabetes worldwide, DexCom's market leadership (estimated to be around 50% globally) bodes well for its continued growth in its vast and steadily widening total addressable market. Investors who buy in on the dip now could be primed for enviable returns in the years to come. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is coming off of several quarters of fluctuating procedure volumes as COVID-19 surges in the U.S. and Europe earlier in 2022, and later spikes in cases in Asia all put the brakes on some elective surgeries. While these kinds of events could persist for the next few quarters, these aren't long-term trends, and they aren't related to deficiencies in Intuitive Surgical's actual business. As such, this could be an intriguing opportunity to buy the stock, which is still sitting on a five-year return of about 100%. In that period, the company has grown its top line by about 70%, while net income has risen by approximately 20%. And the company has grown its cash from operations by a total of 80% over that period. Intuitive Surgical remains a leader in the rapidly growing multibillion-dollar surgical robotics market. Its portfolio consists of its flagship da Vinci surgical suite and its Ion system. The former can be used in a wide range of minimally invasive surgeries, while the Ion is specifically for minimally invasive lung biopsies. These devices, plus the instruments, accessories, replacement parts, software solutions, and other services for them that the company sells, brought in $6.2 billion in revenue in 2022, and net income of $1.3 billion. Meanwhile, the company closed the year holding $6.7 billion in cash and investments. Intuitive Surgical remains well-positioned to capitalize on the continued growth of its industry as the adoption of surgical robotics systems widens, and as it finds ways to further diversify its revenue streams. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Top Healthcare Stocks to Buy for the Long Haul The healthcare industry may not be the most exciting place to invest at first glance. However, it's often these very companies that have businesses primed to weather market and economic storms because of the non-cyclicality of their products and services. If you're looking for two superior healthcare stocks to put cash into this month, here are two no-brainer buys to consider building positions in or adding to right now. 1. DexCom DexCom (NASDAQ: DXCM) is in the process of launching its latest product in both domestic and international markets, the G7 continuous glucose monitoring device. This device is the most upgraded version of its flagship CGM product and has the fastest warm-up time of any such device that has been commercialized to date. In December, the G7 was given the green light by the Food and Drug Administration for all diabetics aged two and up. DexCom's CGM is the most covered and reimbursed CGM currently on the market, and is now covered for reimbursement by over 97% of private insurers nationwide. For all of 2022, DexCom delivered top-line growth of 19%, while its bottom line grew nearly 60% compared to 2021. In total, the healthcare company reported revenue of $3 billion and earnings of $341 million for the 12-month period. It also closed out the year with cash and investments on its balance sheet in the amount of about $2.5 billion. Expanding coverage options and the rising prevalence of diabetes worldwide create a massive and growing addressable market opportunity that DexCom is well-positioned to continue deriving strong results from in the years ahead. Bear in mind this is a company that has increased its annual revenue by 140% over the trailing five years alone. Meanwhile, its stock has delivered a total return of more than 700%. For reference, that is nearly 10 times the return the S&P 500 has delivered in that same period. 2. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) is another stock that has rewarded investors with generous returns over the years. Over the trailing five-year period, the stock has delivered a total return in the amount of 94%. The S&P 500's trailing five-year return currently sits right around 74%. The company also has a respectable track record of growing revenue and profits. 2022 was a continuation of that trend. Vertex's four approved products (all of which treat cystic fibrosis) brought in a combined revenue of $9 billion, representing a hike of 18% from full-year 2021. Trikafta continues to be the top performer for the company. The drug, which is approved to treat more than 90% of all individuals with cystic fibrosis in the U.S. alone, raked in total product revenue of $7.7 billion for the 12-month period. Vertex Pharmaceuticals also raked in profits of $3.3 billion for the 12-month stretch. Meanwhile, management estimates that there are still as many as 20,000 cystic fibrosis patients who could benefit from its products but are not yet taking them. COO Stuart Arbuckle noted in the 2022earnings callthat \""the growth in the CF population can be attributed to more patients coming forward to receive treatment, better data capture in patient registries, and perhaps most importantly, people with CF are living longer due to improvements in patient care and the availability of truly effective therapies.\"" Considering that Vertex Pharmaceuticals is the only company with approved CFTR modulators on the market -- these are drugs that work to correct the underlying cause of cystic fibrosis -- the company is both a direct instigator and a direct beneficiary of these tailwinds. That fact, along with Vertex's robust pipeline, which includes a new rare blood disorder therapy that could be on the cusp of approval, bodes particularly well for the company's growth over the next five to 10 years and well beyond. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-14,117.5,119.79,116.62,118.55,"June 2024 Options Now Available For DexCom (DXCM) Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading today, for the June 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 493 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new June 2024 contracts and identified one put and one call contract of particular interest. The put contract at the $115.00 strike price has a current bid of $18.10. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $115.00, but will also collect the premium, putting the cost basis of the shares at $96.90 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $118.22/share today. Because the $115.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 15.74% return on the cash commitment, or 11.65% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $115.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $120.00 strike price has a current bid of $25.60. If an investor was to purchase shares of DXCM stock at the current price level of $118.22/share, and then sell-to-open that call contract as a ""covered call,"" they are committing to sell the stock at $120.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 23.16% if the stock gets called away at the June 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 21.65% boost of extra return to the investor, or 16.03% annualized, which we refer to as the YieldBoost. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $118.22) to be 53%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 » Also see: • Stocks Insiders Are Buying But Hedge Funds Are Selling • Top Ten Hedge Funds Holding TGE • Top Ten Hedge Funds Holding OGCP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-15,118.66,120.28,118.0,120.17,
DXCM,2023-02-16,118.49,119.39,117.08,117.26,"Community Health (CYH) Q4 Earnings Beat on Strong Admissions Community Health Systems, Inc. CYH reported fourth-quarter 2022 adjusted net earnings of $1.50 per share, which surpassed the Zacks Consensus Estimate of 41 cents per share. Additionally, the bottom line climbed 30.4% year over year. Net operating revenues slid 2.8% year over year to $3,142 million in the quarter under review. Also, the top line fell shy of the consensus mark of $3,170 million and our estimate of $3,142.5 million. The quarterly results benefited on the back of improved admissions and adjusted admissions. An increase in the count of surgeries also contributed to the quarterly results. However, the upside was partly offset by an elevated expense level. Community Health Systems, Inc. Price, Consensus and EPS Surprise Community Health Systems, Inc. price-consensus-eps-surprise-chart | Community Health Systems, Inc. Quote Quarterly Operational Update At the fourth-quarter end, the hospital count for Community Health stood at 80, which lagged both the Zacks Consensus Estimate and our estimate of 81. Patient days tumbled 7.5% year over year. The average length of stay fell 9.8% year over year, while the occupancy rate of 50% deteriorated 150 basis points year over year. Admissions grew 1.9% year over year. Meanwhile, adjusted admissions advanced 5.2% year over year in the quarter under review. On a same-store basis, admissions and adjusted admissions improved 4.4% and 8.2%, respectively, from their corresponding prior-year quarter’s reported figures. Licensed beds of CYH totaled 12,832 as of Dec 31, 2022, which indicates a decrease of 457 beds from the 2021-end level. The reported figure missed both the consensus mark and our estimate of 13,333. Total operating costs and expenses increased 3.7% year over year to $2,914 million in the fourth quarter, lower than our estimate of $2,968.7 million. The increase was mainly due to higher salaries and benefits and other operating expenses. Meanwhile, net interest expenses of $205 million declined 6.8% year over year. Community Health reported a net income of $446 million, which doubled year over year. Adjusted EBITDA dropped 25.2% year over year to $404 million in the quarter under review primarily due to reduced acuity of inpatient admissions, unfavorable changes in payor mix and lower pandemic relief funds recognized. Financial Update (as of Dec 31, 2022) Community Health exited the fourth quarter with cash and cash equivalents of $118 million, which declined more than four-fold from the figure in 2021 end. Total assets of $14,669 million fell 3.6% from the 2021-end level. Long-term debt amounted to $11,614 million, which decreased 4.1% from the figure as of Dec 31, 2021. Current maturities of long-term debt came in at $21 million. During 2022, CYH generated operating cash flows of $300 million. Net cash used in operating activities came in at $131 million in 2021. 2023 View Net operating revenues are anticipated to lie between $12,200 million and $12,600 million this year, the mid-point of which indicates a rise of 1.5% from the 2022 reported figure of $12,211 million. Adjusted EBITDA is estimated to lie within $1,475-$1,625 million. The mid-point of the guidance implies a 5.7% rise from the 2022 figure of $1,466 million. Net loss per share is forecasted to lie between 65 cents and 5 cents in 2023. Community Health reported a net loss of $1.38 per share in 2022. Depreciation and amortization are predicted within $510-$530 million. Net interest expense is estimated to lie in the $815-$835 million band. Net cash provided by operating activities is anticipated between $675 million and $825 million in 2023. Capital expenditures are expected within $450-$500 million. Diluted weighted-average shares outstanding is estimated within 130-131 million. Zacks Rank Community Health currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Other Medical Sector Releases Of the other Medical sector players that have reported fourth-quarter results so far, the bottom lines of DexCom, Inc. DXCM, Tenet Healthcare Corporation THC and Ecolab Inc. ECL beat the Zacks Consensus Estimate. DexCom reported fourth-quarter 2022 adjusted earnings per share of 34 cents, beating the Zacks Consensus Estimate of 26 cents by 30.8%. The company had recorded an adjusted loss of 1 cent per share in the prior-year quarter. Total revenues grew 17% (20% on an organic basis) to $815.2 million on a year-over-year basis and beat the Zacks Consensus Estimate by 2.2%. The gross profit of DXCM totaled $541.3 million, up 14.5% year over year. It generated a gross margin (as a percentage of revenues) of 66.4%, which contracted 130 basis points (bps) year over year. Tenet Healthcare’s fourth-quarter 2022 adjusted earnings of $1.96 per share surpassed the Zacks Consensus Estimate by 54.3%. However, the bottom line dropped 27.4% year over year. Net operating revenues improved 2.6% year over year to $4,990 million in the quarter under review. The top line beat the consensus mark by 1.7%. Adjusted net income from continuing operations of THC of $213 million slid 27.5% year over year. Adjusted EBITDA dipped 11.8% year over year to $897 million. Ecolab reported fourth-quarter 2022 adjusted earnings per share of $1.27, down year over year by a penny. The bottom line, however, beat the Zacks Consensus Estimate by 1.6%. Revenues grossed $3.67 billion in the reported quarter, up 9.1% year over year. The metric surpassed the Zacks Consensus Estimate by 0.04%. ECL’s fixed-currency sales increased 15.3%, and acquisition-adjusted fixed-currency sales increased 12% from the prior-year period’s level. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-17,116.39,117.03,113.4,114.76,"Validea Daily Guru Fundamental Report for DXCM - 2/17/2023 Below is Validea's daily guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: PASS Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper ""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-02-21,113.59,114.79,112.79,114.01,"[""My 3 Biggest Stock Market Predictions for March I don't have a crystal ball, but some trends you can see continuing from a mile away. If you're looking for performance in what has been a volatile year so far for the markets, following these three trends might help in March. 1. Lithium mining stocks will continue to rise Albemarle (NYSE: ALB) just came out with its full-year and fourth-quarter earnings, and the mining company's decision to raise prices for lithium is paying off. Knowing that automakers increasingly need lithium for the batteries in electric vehicles, the move was simply a case of higher demand raising prices. Albemarle's fourth-quarter and full-year numbers were edifying. The company reported fourth-quarter revenue of $2.6 billion, up 193% year over year. Full-year revenue was $7.3 billion, up 119%. Earnings per share (EPS) for the quarter were $9.60, up 753% over the same period last year, while full-year EPS was $22.84, a huge leap from $1.06 last year. The company sees continued growth for 2023 with full-year revenue forecast between $11.3 billion and $12.9 billion. Albemarle's success also bodes well for other Lithium stocks, including Lithium Americas (NYSE: LAC), which isn't even producing lithium or revenue yet. Lithium Americas is proceeding with construction on its Thacker Pass mine in Humboldt County, Nevada, after what it said was a favorable ruling against those opposing the mine. The company also is close to launching operations in the Cauchar\u00ed-Olaroz mine in Jujuy, Argentina, and said it expects to begin producing lithium in the first half of this year. Lithium Americas holds a 44.8% interest in the Cauchar\u00ed-Olaroz mine, with Chinese lithium company Ganfeng Lithium holding the rest. Lithium Americas is already lining up customers for its lithium and struck a supply agreement regarding the Thacker Pass mine with General Motors on Jan. 31. Another Lithium mining stock to watch is Sociedad Qu\u00edmica y Minera de Chile (NYSE: SQM). It reports full-year and fourth-quarter earnings on March 1. Through the first nine months, it had $7.57 billion in revenue, up 326%, year over year. Net income was $2.76 billion, up 944% over the same period, while EPS through nine months was $9.65 compared to $0.92 in the same period last year. LAC data by YCharts 2. Look for continued success for home healthcare stocks The trend toward providing more healthcare services at home isn't likely to slow down. While it was given a push during the pandemic, several factors are likely to drive increased use of delivering medical services in the home. The most obvious is a reduced cost, both to insurers and to patients, of having healthcare in the home or an outpatient facility, rather than in a hospital. This is particularly true for people with chronic conditions such as diabetes, chronic obstructive pulmonary disease, and kidney disease. Another trend that will increase home healthcare is the increased digitization of patient monitoring, including health monitoring trackers. A study by ReportLinker indicates home healthcare spending will rise, with a compound annual growth rate of 8.3% through 2028, becoming a $405.6 billion market by that time. The last trend toward more home healthcare is an increasing desire by the growing senior population to age in place. One negative factor the industry is facing is increased labor costs, but that trend is affecting healthcare companies in general. Two companies that benefit from this trend are Addus HomeCare (NASDAQ: ADUS) and DexCom (NASDAQ: DXCM). Addus, which provides home healthcare and hospice services, has seen its shares rise more than 45% over the past year. Through the first nine months of last year, the company reported revenue of $704.1 million, up 10% year over year, though net income was down slightly to $31.3 million, compared to $32.1 million in the same period a year ago. DexCom, which makes continuous glucose monitoring devices (CGMs) for diabetes patients, has seen its shares rise more than 22% over the past year. The company got Food and Drug Administration (FDA) clearance for its latest CGM device, the G7, last year and should see the benefit of increased sales this year. In 2022, the company reported revenue of $2.91 billion, up 19%, and net income of $341.2 million, up 57% over 2021. 3. There may be a winner in the race for an RSV vaccine Several companies are fighting to be the first to have an approved vaccine to fight respiratory syncytial virus (RSV), which hospitalizes 60,000 to 12,000 older adults (those 65 and older) each year and kills between 6,000 and 10,000 of them, according to the Centers for Disease Control and Prevention. There are 11 RSV vaccines that are currently being studied, according to data from PATH, a non-profit health organization, but only two are in phase 3 trials. Both of these RSV vaccines, one by GSK (NYSE: GSK) and one by Pfizer (NYSE: PFE), are for people 60 and older. Pfizer's vaccine, RSVpreF, was shown to be 85.7% effective on patients 60 and older, according to the company. The FDA accepted priority review for a biologics license application (BLA) for the vaccine in December. The Prescription Drug User Fee Act (PDUFA) goal date for a decision is in May, but it could come sooner, considering the importance of an RSV vaccine. The candidate from GSK (formerly GlaxoSmithKline), RSVPreF3 OA, was effective on 83% of patients 60 and older in stopping symptomatic illness and was 94% effective in preventing severe illness in the group, according to a study published Feb. 16 in the New England Journal of Medicine. GSK, in its fourth-quarter report, said it anticipates approval of its BLA in the first half of this year as well. It's possible that both vaccines could be approved, but the first one with an FDA nod would likely give its company at least a short-term edge in 2023 sales. 10 stocks we like better than Albemarle When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Albemarle wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Jim Halley has positions in GSK, Lithium Americas, and Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends DexCom, GSK, and General Motors. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Healthcare Stocks to Buy and Hold for the Next 10 Years The healthcare industry has long proven itself to be a resilient place for investors to park their cash. If you're looking for tried-and-true companies that have a robust track record of enriching shareholders and delivering favorable financials in a wide range of environments, you don't have to look far. Here are three such stocks to consider adding to your buy basket this month, each of which you can hold for the long haul. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) has continued to report explosive financial growth from its core portfolio of products, all while expanding its pipeline into new disease areas ripe for disruption. And the healthcare stock has enriched investors in the process. It's delivered a total return of 24% over the past year, compared to the S&P 500's negative return of 7% in that same period. The company recently released its financial results for 2022. During the 12-month period, Vertex Pharmaceuticals generated revenue of $9 billion, net income of $3.3 billion, and operating income of $4.3 billion. These figures increased 18%, 42%, and 55%, respectively, from 2021. Vertex also closed out the period with cash and investments on its balance sheet to the tune of $11 billion. The company's resilience against a difficult economic backdrop goes back to the demand for its products; they all not only treat cystic fibrosis, but also are the only approved therapeutics designed to target the root cause of the genetic illness. This class of drugs is known as CFTR (cystic fibrosis transmembrane conductance regulator) modulators. Bear in mind that the cystic fibrosis therapeutics market is on track to be worth an estimated $32 billion by the year 2027. Despite Vertex's considerable footprint in this field, management estimates that there are as many as 20,000 individuals who could take its existing portfolio of drugs but are not doing so, while there are another 5,000 cystic fibrosis patients who need treatment but can't take CFTR modulators. Vertex Pharmaceuticals is already working on a new drug for the latter cystic fibrosis population with Moderna; it also has a budding pipeline that includes candidates targeting type 1 diabetes, sickle cell disease, acute pain, and APOL1-mediated kidney disease. Vertex's pipeline could see numerous approvals coming down the pike in the next five years, and one approval as soon as this year. This potential, combined with its robust portfolio of top-selling cystic fibrosis medicines that continue to drive strong revenue growth and profitability, make a compelling argument for a long-term buy-and-hold position in this top healthcare stock. 2. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) has generally been known for more steady and moderate returns, but even so, investors who have stayed with the stock through at least the last five years are looking at a total return of about 40%. A more compelling draw for this stock is its dividend, which currently yields 2.8% and which Johnson & Johnson has raised every year for 60 years and counting. When the company spins off its consumer health division as Kenvue later this year. Shareholders of the current company will remain invested in both Kenvue (the new consumer-health business) and Johnson & Johnson (the combined pharmaceutical and medical-devices business) at the time of the split, and receive dividends from each. The consumer-health business has historically grown slower; this is not surprising due to the margins these types of products generate, and the company's broad, mature footprint in this sector. However, with brands like Tylenol, Band-Aid, Listerine, and Aveeno included in this business, it's safe to say there's a continued road for growth ahead. And its spinoff will also ease constraints on the growth trajectories of the other two businesses. Johnson & Johnson's pharmaceutical division covers everything from immunology to cardiovascular ailments to infectious diseases, while its medical devices encompass everything from joint replacements to sports medicine solutions to spinal-care devices to heart pumps. Management is estimating that its pharmaceutical division alone will hit the $60 billion revenue mark by the year 2025. Johnson & Johnson's consumer-health division delivered operational sales growth of 4% in 2022, while its pharmaceutical and medical-devices divisions yielded sales growth of 7% and 6%, respectively. Total sales and earnings for the year came in at $94 billion and $21 billion. As of 2022, Johnson & Johnson was the second largest pharmaceutical and healthcare company in the world by revenue, second only to Pfizer. The company is one of only two public entities that have garnered the highest credit rating (AAA) awarded by S&P Global Ratings. If you're looking for stability, steady growth, and a reliable dividend, Johnson & Johnson seems like a no-brainer healthcare stock to buy and hold for the long haul. 3. DexCom DexCom (NASDAQ: DXCM) has experienced some of the market pressure afflicting growth-oriented stocks over the last year. But it's beaten the market with a total return of about 13% over the trailing 12 months, and investors are still looking at a five-year total return of about 720%. The company is currently celebrating another huge business win, with the launch of its latest product, the G7 continuous glucose monitoring (CGM) device. DexCom's CGM products are used by about 1.7 million people worldwide as of the end of 2022, and are the most widely covered and reimbursed of any such products on the market. Despite DexCom's broad footprint, there's plenty of room left for the company to expand in the years ahead, as the addressable market for CGM wearers isn't just underpenetrated but growing. People with both Type 1 and Type 2 diabetes can wear CGMs, and there's growing evidence that there could be benefits for those with prediabetes as well. It's estimated that there are more than 537 million individuals living with diabetes worldwide, and more than 1 million people are diagnosed with the disease in the U.S. alone each year. Meanwhile, another 541 million individuals globally are at high risk for developing Type 2 diabetes, which accounts for the lion's share of all diabetes cases. DexCom continues to work aggressively with private and public entities to expand coverage for CGM wearers, another key catalyst for long-term adoption of these devices. And in the company's 2022earnings call Chief Executive Officer Kevin Sayer noted that \""Collectively, our international access initiatives have helped us expand our reimbursed coverage by 3.5 million lives over the past 18 months.\"" The company saw revenue pop 19% in 2022 to $3 billion, while raking in earnings of $341 million, a 57% increase year over year. With its considerable and expanding market opportunity, profitable business, and clear, consistent demand for its products, DexCom looks like a compelling choice to add to a diversified basket of stocks. 10 stocks we like better than Vertex Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom and Johnson & Johnson. The Motley Fool has positions in and recommends Pfizer, S&P Global, and Vertex Pharmaceuticals. The Motley Fool recommends DexCom, Johnson & Johnson, and Moderna. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-22,114.54,114.98,104.2,111.65,
DXCM,2023-02-23,111.61,112.1,109.35,111.87,
DXCM,2023-02-24,110.42,111.48,109.35,110.09,"[""Better Buy: Abbott Laboratories or DexCom Stock? Americans are getting heavier and have been for a while. According to the Centers for Disease Control and Prevention, U.S. obesity prevalence has increased since 1999, from 30.5% to 41.9%, with severe obesity growing from 4.7% to 9.2%. With all that extra weight comes an increased likelihood of certain obesity-related conditions, such as heart disease, strokes, certain cancers, and type 2 diabetes. According to MarketStudyReport, a market research firm, the global diabetes care devices market was $23.3 billion in 2022 and is projected to reach $32.7 billion by 2028, representing a compound annual growth rate of 4.95% over this period. Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) are both poised to benefit from increased spending on diabetes care devices as they manufacture continuous glucose monitoring devices used by diabetes patients. Which healthcare company is the better buy? Let's see. The case for Abbott Laboratories Abbott Laboratories stock is down over 4% in 2023 and more than 10% over the past 12 months. What's hurting it lately is news that the Securities and Exchange Commission and Federal Trade Commission are investigating Abbott in connection with its infant formula business. The company had a voluntary recall and manufacturing shutdown of certain infant formulas at its plants a year ago after U.S. Food and Drug Administration (FDA) investigators found cronobacter sakazakii bacteria at the company's Sturgis, Michigan plant. At least two dozen families are suing Abbott over allegedly contaminated formula. Abbott's big advantage over DexCom is its size and scope, which makes it easier to adapt to changing market conditions, or to overcome legal judgments. It has more than 115,000 employees, compared to roughly 8,000 for DexCom. Abbott operates in four segments: nutrition, diagnostics, medical devices, and established pharmaceuticals. Abbott reported full-year and fourth-quarter earnings on Jan. 25. 2022 revenue totaled $43.7 billion, up 1.3%, with earnings per share of $3.91, down 0.8%. In the fourth quarter, the company reported revenue of $10.1 billion, down 12% year over year, thanks mostly to reduced COVID-19 testing sales. Earnings per share (EPS) were $0.59, down 46.8% compared to Q4 2021. One big bright spot for Abbott was diabetes care sales of $4.8 billion for the year, up 9.9%. Within those sales, the company's Freestyle Libre continuous glucose monitors (CGMs) reported sales of $1.1 billion in Q4, up 40% year over year. This was thanks in part to the FDA's 2022 clearance of the Freestyle Libre 3 model, said to be the world's smallest CGM. Another positive sign for Abbott was its diagnostics sales, which, excluding COVID testing sales, were $16.6 billion in 2022, up 6%. Diagnostics was led by rapid diagnostics products, whose sales were $10.2 billion in 2022, up 19%. Abbott's guidance points to a down year in 2023, saying it expected EPS between $3.15 and $3.25, down 18%. The company is a favorite of income investors because it has increased its quarterly dividend for 51 consecutive years, That includes an 8.5% boost in December 2022 to $0.51 per share, equal to a yield of around 1.97%, slightly above the S&P 500 average dividend. DXCM Revenue (Annual) data by YCharts The case for DexCom DexCom's stock is up only slightly in 2023, but up more than 19% over the past year. The company's sole products are CGMs and CGM-related peripherals. DexCom's price-to-earnings ratio (P/E) of 140 makes it appear less of a buy than Abbott's P/E of about 26. But the reason the stock is more expensive is DexCom's continued growth and its profit margin of 64.7%, compared to Abbott's profit margin of 56.1%. The company reported $2.91 billion in revenue in 2022, up 19%, and EPS of $0.82, up 54.7%. In Q4, that growth didn't slow down, with revenue of $815.2 million, up 17% year over year, and EPS of $0.22, compared to an EPS loss of $0.01 in the same period a year ago. This could be another big year for DexCom. The DexCom G7, its latest CGM, was cleared by the FDA last year and just launched on Feb. 17. The company made a big splash with an ad during the Super Bowl for the product featuring singer Nick Jonas, who has type 1 diabetes. The G7 is covered by Medicare. The device's sensor is only slightly larger than Abbott's Freestyle Libre 3, and also operates in conjunction with a phone app. In its 2023 guidance, the company said it expects revenue of between $3.35 billion and $3.49 billion, up 15% to 20%, and a non-GAAP gross profit margin of between 62% and 63%. Making a solid choice Choosing between these stocks may depend on what kind of investor you are. While both are good long-term choices, Abbott has a longer track record as a company and more diversity in its revenue streams. And because of its dependable dividend, it may be better for income-oriented investors. However, its infant formula issues could also be a drag on the company's stock price for a while, and the company's own guidance points to lower EPS in 2023. DexCom has a less diverse business model. However, the company's revenue and EPS growth and better margins make it the better play for growth-oriented investors with a longer window of investing. And in the short term, it may be the better choice because it isn't facing lawsuits or investigations. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Jim Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Stock-Split Stocks with Explosive Potential to Buy in 2023 Stock splits don't actually do anything to augment the values of the companies that perform them, but they can make a stock that has reached a particularly bloated price more accessible to the average investor again. 2022 saw its fair share of stock splits from large companies across a range of sectors. While a stock split shouldn't induce you to buy or sell a stock in and of itself, there's no denying that the volatile nature of the current market environment has revealed compelling investment opportunities in companies primed for long-term growth despite near-term market pressures. Here are two such stocks with explosive long-term growth potential to consider adding to your buy basket right now. 1. Amazon Amazon (NASDAQ: AMZN) underwent a 20-for-1 stock split on June 3, 2022. The company has remained a mainstay for investors, consumers, and everyone from small to large businesses over the years with its diverse selection of high-growth segments and its penchant for expanding into and disrupting lucrative markets. The company is known for its market-leading e-commerce platform and its rapidly growing cloud business, while it continues to innovate in other sectors from healthcare to grocery to entertainment. In recent quarters, its growth has decelerated as the aggressive investments it made to build out its operations earlier in the pandemic have been left to contend with a more sluggish economic environment. Against that backdrop, Amazon slashed its corporate employee base by about 6% to reduce its operating costs although these layoffs will only trim its overall workforce by around 1%. Even as its e-commerce business is being impacted by headwinds from shifting consumer spending patterns, Amazon is still retaining its footprint and growth trajectory in key markets. For example, CEO Andy Jassy said the following in the 2022earnings callregarding the company's rapidly evolving international e-commerce footprint: We're very enthusiastic about the business we're building there. I think, just perspective, if you look at the compounded annual growth rate from 2019 to '21, in the U.K., it was over 30%; in Germany, it was 26%; in Japan, it was 21%. And the fact that we haven't given back that growth, and these are all net of FX .... a meaningful amount of market segment share has shifted to our global established e-commerce territories, and we're excited about that. The company controls a roughly 40% share of the e-commerce industry in the U.S. It is also continuing to grow overall net revenue steadily, with Amazon Web Services alone surging 30% in 2022 despite greater caution by enterprise customers to part with their money than in times past. And its painful annual net loss last year was mostly a paper one, stemming from declines in its common stock investment in beleaguered electric vehicle maker Rivian Automotive. Imminent changes in consumer and enterprise spending may continue to impact Amazon in the short term. However, the company's generous market footprints and established core businesses have faced many a storm in their time and carried on. There's no reason to think this period will be any different. 2. DexCom DexCom (NASDAQ: DXCM) executed a 4-for-1 stock split on June 10, 2022. The company remains a leader in the diabetes care industry with its continuous glucose monitoring (CGM) devices. Bear in mind, theglobal marketfor CGMs is rapidly growing both as the incidence of diabetes rises and the adoption of these devices expands in the patient population. According to an analysis by Grand View Research, the global CGM market is expected to reach a valuation of $11 billion by 2030, compared to its 2022 valuation of $7.8 billion. To give you an idea of the scale of DexCom's footprint in that market, the company reported revenue just shy of $3 billion in 2022, giving it an estimated market share of about 40% globally. And as of the end of 2022, roughly 1.7 million people around the world were using DexCom's CGM devices, a whopping increase of nearly half a million individuals compared to 2021. DexCom has built a steadily growing and profitable business around its CGM devices, and is in the process of releasing the latest version of its flagship product, the G7. The new G7 CGM was just officially launched in the U.S. and has already been launched in key international markets including Europe, the U.K., and Asia. The product is billed as being 60% smaller than its predecessor, and with recent coverage expansion by Medicare, remains the most covered and reimbursed device of its kind. 2022 saw the company report earnings to the tune of $341 million, a 57% increase from 2021. DexCom's revenue rose 19% year over year, driven by revenue increases of 16% in the U.S. and 28% in international markets. Meanwhile, the healthcare company's operating income of $391 million represented a 250-basis point hike from 2021. Another successful product launch and a strong track record of growth portend well for this market leader's continued expansion in the years ahead. Long-term shareholders can benefit in the process. 10 stocks we like better than Amazon.com When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Rachel Warren has positions in Amazon.com and DexCom. The Motley Fool has positions in and recommends Amazon.com. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-02-27,110.98,111.68,109.02,110.58,
DXCM,2023-02-28,111.694,112.52,109.88,111.01,"[""Billionaire Israel Englander Is Making Huge Bets on These 2 \u2018Strong Buy\u2019 Stocks After the year\u2019s early rally appeared to hit a brick wall in recent times, the markets seem uncertain which direction to take next, making the seesawing conditions not easy for investors to navigate. Against such a backdrop, maybe the best solution for investors is to follow in the footsteps of legendary Wall Street names - ones like Israel Englander. The Millennium Management Chairman and CEO founded the hedge fund in 1989 with $35 million and now the firm is an almost $53 billion going concern, so he knows a thing or two about investing. Recently, Englander has been busy padding the portfolio with some big buys, and we\u2019ve tracked down two of his recent purchases. Do these choices sit well with the Street\u2019s stock experts? Turns out they certainly do. According to the TipRanks database, both are rated as Strong Buys by the analyst consensus. So, let\u2019s see why these names are drawing plaudits right now. Dexcom Inc (DXCM) The first Englander-backed stock we\u2019ll look at is medical device maker Dexcom. The San Diego, California-based company makes continuous glucose monitoring (CGM) systems to be used by diabetes patients. The company\u2019s solutions include wearables the Dexcom G6 and the more recent Dexcom G7, a small wearable sensor that every 5 minutes sends real-time glucose readings to a user\u2019s smartphone and which the FDA recently cleared for usage by people with all types of diabetes ages two years and older. The company touts the product as the most accurate CGM offering on the market. Diabetes is not only a chronic disease but an increasingly prevalent one too. Dexcom\u2019s products have been growing in popularity as seen by the steady sales gains made by the company. This was evident again in the latest quarterly statement \u2013 for 4Q22. Dexcom dialed in revenue of $815.2 million, amounting to a 16.8% year-over-year increase and meeting Street expectations. There was a conclusive beat on the bottom-line as adj. EPS of $0.34 came in ahead of the $0.28 forecast. The company also stuck to its previous 2023 guidance that calls for 15%-20% growth on the topline and gross margins of 62%-63%. Englander obviously sees plenty to like here. In Q4, he upped his stake in the company by more than 200% with the purchase of 2,658,077 shares. He now holds a total of 3,890,649 shares, which at the current share price are worth $431.9 million. Mirroring Englander\u2019s confidence, Piper Sandler analyst Matt O'Brien says Dexcom is a 'favorite name for 2023' and highlights several reasons to get on board. \u201cWhile DXCM has continued to trade sideways since November following its strong Q3 earnings, we think there is room for significant appreciation from the domestic G7 rollout, continued OUS expansion and the basal opportunity (Basal-IQ Tech uses a Dexcom G6 sensor) leading the way. Better than expected volumes and strong GM leverage give DXCM the opportunity in our view to be a beat and raise story as we move through 2023,\u201d O'Brien opined. Unsurprisingly, then, O\u2019Brien rates DXCM shares an Overweight (i.e. Buy), backed by a $150 price target. This target brings the upside potential to 35%. (To watch O\u2019Brien\u2019s track record, click here) Most agree with O\u2019Brien\u2019s thesis. Based on 10 Buys, vs. 3 Holds, the stock claims a Strong Buy consensus rating. Going by the $129.92 average target, the shares will climb 17% higher in the year ahead. (See DXCM stock forecast) SBA Communications (SBAC) On to our next Englander-endorsed name is SBA Communications (SBAC), a real estate investment trust (REIT) but a unique one at that. The Boca Raton, Florida-based company owns and operates wireless communications infrastructure and in fact is one of the largest providers of communication tower space in the United States, as well as having operations in Central America, and Brazil, Africa, and the Philippines. Its main focus is geared toward leasing of antenna space on its communications sites to a host of wireless service providers, including Verizon, AT&T, and T-Mobile. SBAC's solid position is reflected in the company\u2019s steadily rising revenues and earnings over the past few quarters. In the most recently reported quarter, for 4Q22, revenue rose by 15.3% from the same period a year ago to $686.1 million, beating the Street\u2019s call by $4.81 million. However, while net income increased significantly from $48.9 million in 4Q21 to $102.6 million and resulting in $0.94 per share, the figure fell short of the $1.11 expected by the analysts. Englander enters the frame here via a big increase to his holdings in Q4. He purchased 594,994 shares in the quarter, upping his stake by almost 300% and now holds a total of 797,089 shares, at present worth north of $206 million. Englander is obviously upbeat about SBAC\u2019s future and so is Raymond James analyst Ric Prentiss, who writes: \u201cSBAC is our current preferred tower stock due to its: 1) larger exposure to U.S. towers; 2) higher quality AFFO; 3) longer runway for strong dividend growth (the company currently pays a quarterly cash dividend of $0.85 per share); and 4) proven ability to opportunistically allocate capital including stock buybacks.\u201d Based on that assessment, Prentiss rates SBAC a Strong Buy and has a price target set at $334. Should that figure be met, investors will be sitting on returns of ~29% a year from now. (To watch Prentiss\u2019s track record, click here) Turning now to the rest of the Street, where SBAC gets plenty of support. Barring two skeptics, all 10 other recent analyst reviews are positive, making the consensus view here a Strong Buy. Shares are expected to appreciate by ~27% in the year ahead, considering the average target stands at $328.82. (See SBAC stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks\u2019 Best Stocks to Buy, a newly launched tool that unites all of TipRanks\u2019 equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Analysts Anticipate UPRO To Hit $40 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares UltraPro S&P500 ETF (Symbol: UPRO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $40.50 per unit. With UPRO trading at a recent price near $35.75 per unit, that means that analysts see 13.30% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of UPRO's underlying holdings with notable upside to their analyst target prices are Intuitive Surgical Inc (Symbol: ISRG), Martin Marietta Materials, Inc. (Symbol: MLM), and DexCom Inc (Symbol: DXCM). Although ISRG has traded at a recent price of $231.74/share, the average analyst target is 16.53% higher at $270.06/share. Similarly, MLM has 14.44% upside from the recent share price of $359.94 if the average analyst target price of $411.93/share is reached, and analysts on average are expecting DXCM to reach a target price of $126.06/share, which is 14.00% above the recent price of $110.58. Below is a twelve month price history chart comparing the stock performance of ISRG, MLM, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET ProShares UltraPro S&P500 ETF UPRO $35.75 $40.50 13.30% Intuitive Surgical Inc ISRG $231.74 $270.06 16.53% Martin Marietta Materials, Inc. MLM $359.94 $411.93 14.44% DexCom Inc DXCM $110.58 $126.06 14.00% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb Also see: \u0095 Institutional Holders of GBNY \u0095 RWR Videos \u0095 BWS Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Abbott and DexCom Investors Be Worried About Apple's Latest News? Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) enjoy symbiotic relationships with Apple (NASDAQ: AAPL). The two companies' popular continuous glucose monitoring (CGM) devices used by many patients with diabetes connect to iPhones and Apple Watches. Patients can easily monitor their glucose and receive alerts when thresholds are exceeded on their smart devices. But that relationship could be about to change significantly in a way that isn't helpful to the two big CGM makers. Bloomberg reported last week about one of Apple's major development efforts. Should Abbott and DexCom investors be worried about Apple's latest news? Image source: Getty Images. From partner to competitor The CGM market is already huge and continues to grow rapidly. Abbott posted sales of $1.1 billion for its FreeStyle Libre in the fourth quarter of 2022, a year-over-year jump of more than 40%. DexCom's Q4 sales for its CGM devices topped $815 million, up 17% year over year. Apple wants to take a bite of its own out of this big market opportunity. Bloomberg cited anonymous sources that revealed Apple has a secret project called E5 to measure glucose without pricking the skin to obtain blood. The tech giant's goal is to launch its own CGM tied to its Apple Watch, according to Bloomberg's sources, who are familiar with Apple's efforts. The two current market leaders in CGM use patches that are inserted into the skin of a person's arm. These patches must be replaced regularly -- every 10 days for DexCom's G7 and every 14 days for Abbott's FreeStyle Libre. However, Apple is using a much different method to measure glucose. The company's approach is to use lasers to bounce light off of areas beneath the skin that contain interstitial fluids that leak from capillaries. These interstitial fluids are absorbed by glucose in the blood. Apple's process, known as optical absorption spectroscopy, measures the reflected light to determine an individual's concentration of glucose. This concentration can then be used to calculate the blood glucose level. Immediate jolts It's understandable that Apple's potential entrance into the CGM market immediately caught the attention of Abbott's and DexCom's shareholders. The two healthcare stocks took a hit after the news broke about Apple's secret E5 project. Abbott's share price fell nearly 3% immediately after the Bloomberg story was published on Feb. 22. The stock bounced back quickly, however. Still, though, Abbott's shares remain nearly 2% lower than they were prior to the revelation of Apple's CGM development efforts. DexCom stock was hit even harder. Shares sank as much as 8% on Feb. 22 before recovering later in the day. The stock has continued to claw its way back this week but is still a little lower than it was before the Apple project was reported. A long way to go Should Abbott and DexCom investors really be worried about Apple's CGM efforts? Yes. The growth trajectories for both companies could be negatively impacted if Apple becomes a direct rival. The competition would likely hurt DexCom the most. While Abbott has many other products other than FreeStyle Libre, all of DexCom's revenue is generated from its CGM systems. However, Abbott would definitely be affected if Apple is able to carve out a significant market share. Perhaps the best news for Abbott and DexCom is that Apple still has a long way to go to perfect its CGM technology. Apple is only at the proof-of-concept stage at this point, according to Bloomberg's sources. The company could take several years before it could potentially launch a CGM product. And it's possible that Apple's efforts will fail. Bloomberg also reported that Apple is working on a prototype device that's roughly the size of an iPhone. Abbott's and DexCom's current CGM patches are much smaller and could be preferred by many people with diabetes. In the meantime, both Abbott and DexCom continue to invest in research and development to build better CGM technology. The companies could be able to out-innovate Apple. The bottom line is that Apple could be a formidable rival in the CGM market at some point in the future. For now, however, Abbott and DexCom should continue to deliver solid growth with their respective CGM products. 10 stocks we like better than Apple When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Apple wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Keith Speights has positions in Apple. The Motley Fool has positions in and recommends Abbott Laboratories and Apple. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-01,110.51,111.31,109.32,110.76,
DXCM,2023-03-02,112.51,121.37,112.38,121.24,"[""Nasdaq 100 Movers: TSLA, DXCM In early trading on Thursday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.9%. Year to date, DexCom registers a 2.6% gain. And the worst performing Nasdaq 100 component thus far on the day is Tesla, trading down 6.0%. Tesla is showing a gain of 54.8% looking at the year to date performance. Two other components making moves today are Lucid Group, trading down 4.6%, and PDD Holdings, trading up 2.9% on the day. VIDEO: Nasdaq 100 Movers: TSLA, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Where to Invest $1,000 in a 2023 Nasdaq Bear Market The bear market of the past year has kept investors on their toes. While stocks across a variety of sectors feel the pain, few have been hit as hard as those on the growth-centric Nasdaq Composite index. Many of these growth stocks have seen some improvement in 2023. Still, there's no telling whether the bear is finally giving way to a bull market, or if further discounting will take hold. The index itself is still down by double-digit percentages from its all-time high. Turbulent market or not, if you have $1,000 that isn't needed to pay monthly bills, bolster an emergency fund, or pay off credit card debt, there are plenty of superior companies begging to be invested in. Here are two to consider. 1. Upstart Upstart (NASDAQ: UPST), is an artificial intelligence-based lending platform that partners with financial institutions to provide consumer loans using non-traditional creditworthiness assessment. The company isn't getting the praise from investors that it did in prior years, largely because the overall lending environment is constrained, with loan volume broadly depressed in the current economy. It's also being dinged for keeping a higher-than-usual number of loans on its balance sheet. Investors are shying away from the stock over short-term losses, which could be shortsighted. Granted, Upstart still has work to do to right itself in the current economic environment, making the stock a somewhat risky investment at the moment. But it's vital to understand how Upstart got here and that the underlying business still has great potential. Upstart uses artificial intelligence (AI) to provide a growing range of loan types (including personal and auto loans) by using nontraditional data points aside from Fair Isaac's FICO scores to assess an applicant's creditworthiness. Its platform expands access to credit for consumers, including those rejected based only on their FICO score, while also lowering the risk of default and losses for partner institutions. Upstart is still in the relatively early stages of growth (the company is just over a decade old), but its model has proven resilient over time. Until recently, the lion's share of loans facilitated through the platform got purchased by its network of institutional partners. This lessened the risk to Upstart's balance sheet and allowed it to continue fueling rapid growth. The troubled economy changed the lending landscape, and the changes are beyond Upstart's immediate control. With interest rates so high, consumers are less likely to apply for loans, and institutional investors are more reluctant to fund them. The loans that are approved generally carry higher interest rates. These factors raised expenses and elevated the default risk generally, worrying Upstart's partners. This led to Upstart keeping more loans on its own balance sheet. It had about $1 billion in loans on the balance sheet at the end of 2022 (compared to $704 million in the third quarter). Upstart's AI platform is constantly adjusting to the risk variance in the current economy, which means it's approving fewer loans and further depressing loan volume. That's why loan volume and revenue are down, and the company is now unprofitable. So, what's Upstart doing about it? Management indicated in the latestearnings callthat it is working on the loan-buying synergy between Upstart and its institutional partners. It aims to make that relationship less subject to such immediate economic shifts that hit the company's financials. One way the company tries to do this is by marketing its Upstart Macro Index to others. The service aims to provide real-time data allowing lenders to make more accurate decisions about lending rather than using quickly outdated information. Upstart is also playing the waiting game. As the economy improves, Upstart's lending volume should recover, and its institutional partners should be more amenable to buying its loans again. While it waits, it continues to expand its network. The company ended the year with 778 dealers in its auto loan network, and 92 credit union and bank partners. These figures represented increases of 90% and 120%, respectively, from the year-ago period. Lenders might be scaling back originations right now, but Upstart continues to aggressively build out its partner network, a sign that it remains confident in its platform's technology. For long-term investors with a minimum buy-and-hold horizon of three to five years, this -- coupled with the company's continued potential as a disruptor in the multitrillion-dollar lending market -- could warrant even a modest position in this growth stock. 2. DexCom DexCom (NASDAQ: DXCM), a leader in the diabetes care market, is far less volatile than Upstart. The company develops and sells continuous glucose monitoring (CGM) devices, which track blood sugar levels. These devices can be extremely beneficial for type 1 and type 2 diabetics, and potentially even those with pre-diabetes. But adoption remains relatively low. For DexCom, with a market share of around 40% globally at the time of this writing, this creates a notable growth opportunity while it continues to generate recurring revenue from its existing users. CGM products aren't a one-and-done purchase. Its products have sensors and transmitters that require regular replacement. As such, DexCom's revenue and earnings revolve around a subscription-based business in which users are regularly sent a new supply of products. The G7, DexCom's most recent version of its flagship CGM product, has a wear time of 10 days, for example. The full-year 2022 saw DexCom grow its revenue to $3 billion, a 19% increase from 2021. This figure was driven by 16% revenue growth in the U.S., while international revenue jumped 28% in 2022. Some reductions in R&D expenses and more efficient operations helped boost the non-GAAP bottom line nearly 60% to $341 million for the year. Also key to CGM adoption is the expansion of insurance coverage, which DexCom is aggressively working on. For example, in the 2022earnings call CEO Kevin Sayer said that an anticipated Medicare ruling and broader commercial coverage, \""which we expect to follow shortly ... has the potential to nearly double our addressable reimbursed market in the United States.\"" By the end of 2022, DexCom had grown its user base to 1.7 million, adding 450,000 people in the year. It's estimated that there are as many as 37 million diagnosed diabetics in the U.S. alone and roughly 15 times that number globally. And it's forecast that there will be more than 780 million diabetics globally by 2045. So there is a broad and growing opportunity for DexCom, domestically and internationally. For investors, now could be a compelling opportunity to invest in a fast-growing healthcare business with a long runway for growth, profitability, and a steady share in a competitive market. And that's whether or not another full-fledged bear market appears. 10 stocks we like better than Upstart When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Upstart wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Upstart. The Motley Fool recommends DexCom and Fair Isaac. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-03,120.525,123.14,119.89,122.92,"[""DexCom (DXCM) Gains But Lags Market: What You Should Know In the latest trading session, DexCom (DXCM) closed at $122.92, marking a +1.39% move from the previous day. This change lagged the S&P 500's 1.62% gain on the day. Elsewhere, the Dow gained 1.17%, while the tech-heavy Nasdaq added 12.91%. Coming into today, shares of the medical device company had gained 12.23% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 4.54%. DexCom will be looking to display strength as it nears its next earnings release. In that report, analysts expect DexCom to post earnings of $0.15 per share. This would mark year-over-year growth of 87.5%. Meanwhile, our latest consensus estimate is calling for revenue of $720.74 million, up 14.62% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $1.06 per share and revenue of $3.46 billion, which would represent changes of +21.84% and +18.75%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.96% higher. DexCom is currently sporting a Zacks Rank of #3 (Hold). Looking at its valuation, DexCom is holding a Forward P/E ratio of 114.77. This represents a premium compared to its industry's average Forward P/E of 25.9. Investors should also note that DXCM has a PEG ratio of 2.94 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.24 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Guru Fundamental Report for DXCM - 3/3/2023 Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 100% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: PASS Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Factor-Based Stock Portfolios Factor-Based ETF Portfolios Harry Browne Permanent Portfolio Ray Dalio All Weather Portfolio About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 High-Flying Growth Stock With 19% Upside, According to Wall Street Medical device specialist DexCom (NASDAQ: DXCM) has been on fire over the past year, significantly outperforming the broader market. The healthcare company can thank several tailwinds for its performance, including the continued adoption of the technology it has helped pioneer -- continuous glucose monitoring (CGM) -- and the launch of new products. But DexCom still has some upside left, at least if we go by Wall Street's predictions. The company's current average price target of $132.22 (according to Yahoo! Finance) represents a 19% upside over its stock price of about $111 as of this writing. Should investors follow the Street's advice and buy DexCom's shares? Let's dig in and find out. The advantage of continuous glucose monitoring CGM devices give diabetes patients a much better option to keep track of their blood sugar levels. Typically, those with diabetes have to draw blood with a device sometimes called a glucometer that measures the amount of sugar in the blood sample. But this method is painful and suffers from one other major drawback: It only tells patients their blood glucose levels at a specific point when they measure it. Enter CGM options, like DexCom's G6. The G6 system has a small sensor inserted under the skin that measures blood glucose levels once every five minutes. That's 12 times per hour and 288 times per day. Having access to this much data can allow patients to better navigate the day-to-day challenges of living with diabetes. The G6 also sends alerts to compatible devices if blood glucose levels go above or below a predetermined threshold. This option is superior. And it has helped DexCom make serious headway in the diabetes market. The company currently serves an estimated 1.7 million patients worldwide, and its G6 is the most popular CGM system in the world. Further DexCom's revenue has grown. Last year, the company's top line jumped by 19% year over year to $2.91 billion. But there is plenty of upside left. There are 37.3 million diabetes patients in the U.S. alone. According to the World Health Organization, there are 422 million of them globally. DexCom's installed base of 1.7 million is just a minuscule portion of that. The company does have several competitors, but it leads this market with Abbott Laboratories, whose CGM devices franchise, the FreeStyle Libre, generated $4.3 billion in revenue in 2022. DexCom has been able to continue to increase its revenue and its installed base despite the competition from the much larger Abbott Laboratories. Even if there is a combined 20 million CGM users worldwide (an unlikely number), there is still massive room to grow globally. And that's before we add the fact that the population of patients with diabetes will maintain an upward trajectory for decades. Meanwhile, DexCom has released the G7, an updated CGM system whose sensor is smaller than that of the G6. It started launching it in Europe last year and should do so in the U.S. this year. The DexCom ONE is another device that focuses on simplicity and accessibility (in terms of price). These newer devices will help DexCom as it continues to gain new users. A solid buy despite the risks All companies face risks. DexCom is no exception to this iron rule. Let's consider two potential headwinds for investors to consider before initiating a position in this healthcare company; the first is valuation. DexCom's shares look richly valued, with a forward price-to-earnings ratio of 106. That looks high by almost any standard. By comparison, the S&P 500's forward P/E is just 20. DexCom's valuation is likely a reflection of the company's prospects and the fact that it has historically grown its revenue very rapidly. In the past five years, DexCom's top line has increased by an average of 42.5% per year. Companies with impressive revenue growth and attractive opportunities often command much higher premiums. However, DexCom could be vulnerable to heightened volatility in the short term, especially if it fails to live up to investors' expectations which are, to some extent, already baked into its stock price. Another problem for DexCom could be increased competition from Apple, which has been developing non-invasive ways to measure patients' blood glucose levels. It could eventually integrate this feature into some of its devices like the Apple Watch. According to recent reports, Apple has reached the proof-of-concept phase of its work in this area. What should investors think of these potential problems for DexCom? Let's start with the second. It's important to note that the proof-of-concept stage is a fancy way of saying, there is real promise here, but there is still a long way to go. It could be five years or more before this technology sees the light of day if it does at all. And while valuation is an issue, DexCom could justify its rich premium over the long run, given the massive opportunity ahead in the diabetes market. Will the healthcare company meet the Street's predictions in the next year? My view is that it will. But even if it doesn't, DexCom still looks like an excellent long-term bet. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Apple. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-06,114.1,116.079,112.44,113.25,"[""Nasdaq 100 Movers: DXCM, ENPH In early trading on Monday, shares of Enphase Energy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.7%. Year to date, Enphase Energy has lost about 13.3% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 6.4%. DexCom is showing a gain of 1.6% looking at the year to date performance. Two other components making moves today are Dollar Tree, trading down 2.6%, and Rivian Automotive, trading up 4.5% on the day. VIDEO: Nasdaq 100 Movers: DXCM, ENPH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""5 Stocks That Powered Nasdaq ETF Last Week Wall Street ended the week on a positive note despite volatility. The tech-heavy Nasdaq Composite Index outperformed once again, gaining 2.6%, while the S&P 500 and the Dow Jones were up 1.9% and 1.7%, respectively. In this regard, Invesco QQQ QQQ, which serves as a proxy to the Nasdaq Index, gained 2.9%. As such, we have highlighted the five best-performing stocks of QQQ from last week that led the way higher in the portfolio. These include DexCom Inc. DXCM, Align Technology ALGN, Verisk Analytics VRSK, Atlassian TEAM, and Adobe Inc. ADBE. The outperformance came on the heels of a return of the risk factor at the end of the week. This is especially true as the rally in yields eased after comments from Fed officials calmed fears over red-hot inflation and higher-for-longer interest rates. Atlanta Fed President Raphael Bostic said that he's \""very firmly\"" in favor of a quarter-point hike for now, adding that it's important for the central bank to move cautiously. The 10-year yields clawed back below 4% after topping the highest levels in four months. As the tech sector relies on borrowing for superior growth, it is cheaper to borrow more money for further initiatives when interest rates are low (read: Inverse Treasury ETFs Soar as Yields See Big Monthly Gain). Let\u2019s take a closer look at the fundamentals of QQQ. QQQ in Focus Invesco QQQ provides exposure to the 101 largest domestic and international non-financial companies listed on the Nasdaq. Information technology accounts for 50.7% of the assets, while communication services and consumer discretionary make up for a 16.2% and 15.5% share, respectively. Invesco QQQ is one of the largest and most-popular ETFs in the large-cap space, with AUM of $154.5 billion and an average daily volume of around 46.4 million shares. Invesco QQQ charges investors 20 bps in annual fees and has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook. Below, we have highlighted the above-mentioned five stocks in the ETF with their respective positions in the fund\u2019s basket. Top-Performing Stocks in QQQ DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The stock jumped 11.2% last week and its earnings are expected to grow 21.8% this year. DexCom makes up for 0.39% of assets in QQQ and has a Zacks Rank #3 (Hold). It has a Growth Score of B. Align Technology manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The stock climbed 10% and accounts for 0.2% in the fund\u2019s basket. Align Technology has an expected earnings growth rate of 2.8% for this year. It has a Zacks Rank #3. Verisk Analytics is one of the leading data analytics providers serving customers in the insurance, energy and specialized markets, and financial services. The stock makes up for 0.2% of assets in the QQQ portfolio (read: Old Economy Investing is Back: Sector ETFs to Win). Verisk Analytics gained 8.7% last week and has an expected earnings growth rate of 8.4% for this year. VRSK has a Zacks Rank #3. Atlassian is a global leader and innovator in the enterprise collaboration and workflow software space. The company offers a suite of cloud-based software solutions, which help organizations, collaborate and manage their workforce such that the teams work better together. Shares of TEAM were up 7.8% last week. Atlassian has an estimated earnings growth rate of 29.01% for the fiscal year (ending June 2024). Atlassian accounts for a 0.21% share in QQQ and has a Zacks ETF Rank #3. It has a Growth Score of B (read: Best Tech ETFs In Nasdaq's Worst Week Since December). Adobe is one of the largest software companies in the world. It picks up licensing fees from customers, which form the bulk of its revenues. Adobe gained 6.7% last week and accounts for 1.3% in the fund\u2019s basket. Adobe is expected to see an earnings growth of 11.3% for the fiscal year (ending Nov 2023). It has a Zacks Rank #3 and a Growth Score of A. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Adobe Inc. (ADBE) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report Atlassian Corporation PLC (TEAM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-07,113.24,115.375,112.12,113.81,
DXCM,2023-03-08,113.51,114.015,111.86,112.74,
DXCM,2023-03-09,113.26,116.65,111.87,112.08,"[""DexCom (DXCM) Stock Moves -0.59%: What You Should Know In the latest trading session, DexCom (DXCM) closed at $112.08, marking a -0.59% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.85%. Meanwhile, the Dow lost 1.66%, and the Nasdaq, a tech-heavy index, lost 10.91%. Prior to today's trading, shares of the medical device company had gained 2.64% over the past month. This has outpaced the Medical sector's loss of 3.72% and the S&P 500's loss of 2.85% in that time. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. In that report, analysts expect DexCom to post earnings of $0.15 per share. This would mark year-over-year growth of 87.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $720.74 million, up 14.62% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.06 per share and revenue of $3.46 billion. These totals would mark changes of +21.84% and +18.8%, respectively, from last year. Any recent changes to analyst estimates for DexCom should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.96% higher. DexCom is holding a Zacks Rank of #3 (Hold) right now. Investors should also note DexCom's current valuation metrics, including its Forward P/E ratio of 106.72. This valuation marks a premium compared to its industry's average Forward P/E of 25.25. Investors should also note that DXCM has a PEG ratio of 2.74 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DXCM's industry had an average PEG ratio of 2.04 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Just Released: Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500\u2019s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don\u2019t miss your chance to still be among the first to get in on these just-released stocks. See New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Top Stocks to Buy in March and Hold Forever If you're looking for more great stocks to add to your portfolio this month, you don't have to look far to find quality businesses with compelling growth stories. Provided you have the capital on hand to invest right now that you can put into your portfolio and leave alone for the next few years, even the current choppy waters of the market are still presenting investors with wonderful opportunities to buy great companies. Here are two names to consider adding to your portfolio in the near future and holding for years. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) has remained the premier presence in the cystic fibrosis treatment space for over a decade now since its first therapy to treat the underlying factors that cause the genetic disease was given the green light by the U.S. Food and Drug Administration. Since that time, Vertex has seen its portfolio of CFTR modulators -- the class of drugs that work to correct the root cause of cystic fibrosis -- expand to four approved therapies, and it remains the only company with approved CFTR modulators on the market at the time of this writing. While its portfolio of top-selling therapies faces consistent and growing demand -- management estimates that as many as 20,000 cystic fibrosis patients could take its CFTR modulators but aren't yet doing so -- Vertex is looking toward future sources of growth to spur its business and financials forward in the years ahead. Its current pipeline includes a non-opioid drug candidate for acute pain, a cystic fibrosis drug for patients who can't take CFTR modulators (management estimates that more than 5,000 patients fit this category), and a potential one-time functional care for two rare blood disorders, for which it's in the process of undergoing regulatory submissions. The company is also wading into the lucrative diabetes care market. Last year, Vertex finished its acquisition of ViaCyte, a company that is working on stem cell therapies to treat type 1 and type 2 diabetes. The cystic fibrosis treatment market is set to reach a valuation of $32 billion by the year 2027, achieving a compound annual growth rate of more than 24% from its 2019 valuation of about $5 billion. However, the broad opportunities within this space are just the tip of the iceberg for the long-term potential that Vertex appears to have as it continues to explore lucrative yet underpenetrated segments of the rare-disease drug market. For investors searching for a healthcare stock in which to retain a multi-year, buy-and-hold investment, Vertex looks like a compelling choice to consider. 2. DexCom DexCom (NASDAQ: DXCM) has constructed a robust revenue-producing and profitable business in the lucrative diabetes care market with its industry-leading continuous glucose monitoring (CGM) devices. The company recently saw the latest generation of its flagship CGM device, the G7, receive the green light from the FDA, and launches of the product are already underway in key global markets, including Europe and Asia. The G7 device is being marketed as having the fastest warmup time of any such device to date, at only 30 minutes total. It's also 60% smaller than its predecessor, DexCom's top-selling CGM, the G6. Like the G6, the G7 CGM doesn't require any finger sticks, and it sends readings to the wearer's compatible device every five minutes in order to enable seamless tracking of blood sugar levels and trends. Although the launch is only in its early days, management said in the 2022earnings callthat \""97% of initial users surveyed have found the G7 easy to use.\"" Moreover, as of the end of 2022, 1.7 million people around the globe were wearing a DexCom device, an increase of an incredible 450,000 lives compared to 2021. DexCom's revenue shot up 20% in 2022, while earnings surged nearly 60%. Given the ongoing expansion of public and private coverage for current and prospective CGM wearers -- including a recent U.S. ruling extending G7 coverage to Medicare beneficiaries who meet eligibility -- DexCom still has a broad, growing addressable market to tap into today. There are millions of type 1 and type 2 diabetics around the globe who could benefit from such a device but are not yet wearing one. And the prevalence of diabetes is on the rise. There's also data to indicate that pre-diabetics may benefit from wearing CGMs. In short, there's a lot of growth runway left for DexCom here, and investors who stay with this stock for the long haul could tap into this growth story, too. 10 stocks we like better than Vertex Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever You don't need to have a lot of cash on hand to start investing in the stock market. Even if you've only got a few hundred dollars to put to work, there are still plenty of wonderful companies that you can add to your portfolio, particularly in a time where most brokerages allow investors to purchase fractional shares of just about any business. Remember, price doesn't tell you anything about a stock other than what the market values it at during a given point in time. A \""cheap\"" or \""expensive\"" share price alone shouldn't be the reason you buy a stock. However, if you're looking for stocks to buy right now for less than $120 a pop, here are two names to consider with wonderful businesses that look well-positioned to deliver growth and returns for investors in the years ahead. 1. DexCom DexCom (NASDAQ: DXCM) is one of the leading makers of continuous glucose monitoring (CGM) systems in the world. As of the end of 2022, 1.7 million people globally were using its CGM products. Furthermore, the company generated about 40% of all CGM-related revenue worldwide last year. Not only does this massive market footprint bode well for DexCom's continued growth in this space -- approximately 1.4 million people are diagnosed with diabetes each year in the U.S. alone -- but this would also indicate a significant, still untapped market opportunity for the diabetes care leader. In 2022, the company reported revenue of $3 billion, along with net income of $341 million. These two figures increased 20% and 60%, respectively, from the prior-year period. Meanwhile, over the trailing five years alone, DexCom has seen its annual revenue soar by 100%, while earnings have risen by 240%. Right now, DexCom is in the middle of launching its latest product, the G7 CGM. Marketed as 60% smaller than its predecessor, with the fastest warm-up time of any such device on the market, and as part of the most-covered and reimbursed CGM brand commercialized to date, the G7 should be the latest in a long line of strong growth catalysts for DexCom. For investors looking for a resilient healthcare business with products that not only face consistent demand in a wide range of markets, but growing demand, DexCom hits the mark on all counts. 2. Chewy Chewy (NYSE: CHWY) may seem like an average pet care company at first glance, but a deeper look reveals a rapidly diversifying business infrastructure that is working to penetrate virtually all aspects of the multibillion-dollar pet industry. The e-commerce giant carries thousands of pet-oriented brands that feature everything from bedding to toys to sofas to cat trees, but that just barely scratches the surface of this growing company. The company has its own telehealth service for pets, which allows pet owners to contact a licensed veterinarian and be connected via chat or text in moments. It has a growing selection of pet health insurance plans, thanks to partnerships with well-known companies Lemonade and Trupanion. Chewy's online pharmacy dispenses a range of prescription medications, and pet owners can also access compounded medications through this service. There's also the non-prescription pet wellness slice of the industry, which management estimates could be valued at more than $2 billion. Chewy recently entered the space with the release of its own branded line of pet supplements. In an environment where smooth fulfillment and streamlined operating costs are more essential than ever, the company is also making strides with its growing network of automated fulfillment centers, which now process 30% of all its shipping volume. Chewy expects to open two more in the coming months alone. In the nearly four years since its initial public offering, Chewy has seen its annual revenue grow by more than 80%. At the end of the third quarter, the business had 20.5 million active customers on its platform, a 9% increase in gross customer additions compared to the same period in 2019 (before the pandemic supercharged its growth). While the pet industry is a space not wholly untouched by recessionary headwinds, it's more resilient than many retail categories because people largely continue to spend money on their pets in all economic environments. If you're looking to invest in the growth potential of the pet industry -- and in a profitable business at that (Chewy recorded $2.3 million in net income in the third quarter of 2022) -- this top stock may be worth adding to your list of buys this month. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Chewy, Lemonade, and Trupanion. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-10,112.28,112.28,107.28,107.77,
DXCM,2023-03-13,106.27,112.94,106.16,110.66,
DXCM,2023-03-14,111.86,113.71,111.3,113.16,
DXCM,2023-03-15,112.08,114.33,111.185,113.72,"DexCom (DXCM) Gains As Market Dips: What You Should Know In the latest trading session, DexCom (DXCM) closed at $113.72, marking a +0.49% move from the previous day. This change outpaced the S&P 500's 0.7% loss on the day. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq added 2.77%. Heading into today, shares of the medical device company had lost 4.55% over the past month, lagging the Medical sector's loss of 4.27% and outpacing the S&P 500's loss of 5.06% in that time. DexCom will be looking to display strength as it nears its next earnings release. On that day, DexCom is projected to report earnings of $0.15 per share, which would represent year-over-year growth of 87.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $720.74 million, up 14.62% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.06 per share and revenue of $3.46 billion. These totals would mark changes of +21.84% and +18.8%, respectively, from last year. Any recent changes to analyst estimates for DexCom should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, DexCom currently has a Forward P/E ratio of 107.12. For comparison, its industry has an average Forward P/E of 24.42, which means DexCom is trading at a premium to the group. Also, we should mention that DXCM has a PEG ratio of 2.75. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments was holding an average PEG ratio of 2.02 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-16,113.06,115.36,112.39,114.56,"Noteworthy Thursday Option Activity: ADI, NOC, DXCM Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Analog Devices Inc (Symbol: ADI), where a total volume of 17,165 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.3% of ADI's average daily trading volume over the past month, of 3.6 million shares. Especially high volume was seen for the $175 strike put option expiring March 24, 2023, with 4,083 contracts trading so far today, representing approximately 408,300 underlying shares of ADI. Below is a chart showing ADI's trailing twelve month trading history, with the $175 strike highlighted in orange: Northrop Grumman Corp (Symbol: NOC) options are showing a volume of 4,452 contracts thus far today. That number of contracts represents approximately 445,200 underlying shares, working out to a sizeable 46.8% of NOC's average daily trading volume over the past month, of 951,865 shares. Particularly high volume was seen for the $440 strike put option expiring March 17, 2023, with 623 contracts trading so far today, representing approximately 62,300 underlying shares of NOC. Below is a chart showing NOC's trailing twelve month trading history, with the $440 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) saw options trading volume of 11,964 contracts, representing approximately 1.2 million underlying shares or approximately 46.3% of DXCM's average daily trading volume over the past month, of 2.6 million shares. Particularly high volume was seen for the $75 strike put option expiring September 15, 2023, with 6,191 contracts trading so far today, representing approximately 619,100 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $75 strike highlighted in orange: For the various different available expirations for ADI options, NOC options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » Also see: • Top Ten Hedge Funds Holding LBCC • GOAC Options Chain • IXP YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-17,114.5,115.45,113.055,113.93,
DXCM,2023-03-20,113.95,117.43,113.95,117.21,
DXCM,2023-03-21,117.6,119.29,116.74,118.98,"DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know DexCom (DXCM) closed the most recent trading day at $118.98, moving +1.51% from the previous trading session. The stock outpaced the S&P 500's daily gain of 1.3%. Meanwhile, the Dow gained 0.98%, and the Nasdaq, a tech-heavy index, added 7.48%. Coming into today, shares of the medical device company had gained 2.13% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 2.95%. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. The company is expected to report EPS of $0.15, up 87.5% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $720.74 million, up 14.62% from the year-ago period. DXCM's full-year Zacks Consensus Estimates are calling for earnings of $1.07 per share and revenue of $3.46 billion. These results would represent year-over-year changes of +22.99% and +18.82%, respectively. It is also important to note the recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.95% higher. DexCom currently has a Zacks Rank of #3 (Hold). Looking at its valuation, DexCom is holding a Forward P/E ratio of 109.92. For comparison, its industry has an average Forward P/E of 24.38, which means DexCom is trading at a premium to the group. Investors should also note that DXCM has a PEG ratio of 2.82 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DXCM's industry had an average PEG ratio of 2.05 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-22,118.93,119.235,114.92,115.0,"[""Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)? If you're interested in broad exposure to the Healthcare - Medical Devices segment of the equity market, look no further than the SPDR S&P Health Care Equipment ETF (XHE), a passively managed exchange traded fund launched on 01/26/2011. An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors. Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Medical Devices is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 6, placing it in top 38%. Index Details The fund is sponsored by State Street Global Advisors. It has amassed assets over $503.17 million, making it one of the larger ETFs attempting to match the performance of the Healthcare - Medical Devices segment of the equity market. XHE seeks to match the performance of the S&P Health Care Equipment Select Industry Index before fees and expenses. The S&P Health Care Equipment Select Industry Index represents the health care equipment segment of the S&P Total Market Index. Costs Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same. Annual operating expenses for this ETF are 0.35%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.02%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at individual holdings, Abiomed Inc. (ABMD) accounts for about 2.05% of total assets, followed by Dexcom Inc. (DXCM) and Intuitive Surgical Inc. (ISRG). The top 10 holdings account for about 18% of total assets under management. Performance and Risk The ETF has added roughly 3.66% and is down about -14.02% so far this year and in the past one year (as of 03/22/2023), respectively. XHE has traded between $79.20 and $114.46 during this last 52-week period. The ETF has a beta of 0.93 and standard deviation of 27.99% for the trailing three-year period, making it a medium risk choice in the space. With about 83 holdings, it effectively diversifies company-specific risk. Alternatives SPDR S&P Health Care Equipment ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, XHE is an outstanding option for investors seeking exposure to the Health Care ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well. First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the iShares U.S. Medical Devices ETF (IHI) tracks Dow Jones U.S. Select Medical Equipment Index. First Trust Indxx Medical Devices ETF has $1.95 million in assets, iShares U.S. Medical Devices ETF has $5.93 billion. MDEV has an expense ratio of 0.70% and IHI charges 0.39%. Bottom Line To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar? Designed to provide broad exposure to the Mid Cap Growth segment of the US equity market, the Vanguard Mid-Cap Growth ETF (VOT) is a passively managed exchange traded fund launched on 08/17/2006. The fund is sponsored by Vanguard. It has amassed assets over $9.86 billion, making it one of the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. Thus they have a nice balance of growth potential and stability. While growth stocks do boast higher than average sales and earnings growth rates, and they are expected to grow faster than the wider market, investors should note these kinds of stocks have higher valuations. Something to keep in mind is the higher level of volatility that is affiliated with growth stocks. They are likely to outperform value stocks in strong bull markets but over the longer-term, value stocks have delivered better returns than growth stocks in almost all markets. Costs Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Annual operating expenses for this ETF are 0.07%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.73%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 29.20% of the portfolio. Healthcare and Industrials round out the top three. Looking at individual holdings, Amphenol Corp. (APH) accounts for about 1.65% of total assets, followed by Cadence Design Systems Inc. (CDNS) and Dexcom Inc. (DXCM). The top 10 holdings account for about 15.26% of total assets under management. Performance and Risk VOT seeks to match the performance of the CRSP U.S. Mid Cap Growth Index before fees and expenses. The CRSP U.S. Mid Cap Growth Index measures the investment return of mid-capitalization growth stocks. The ETF has gained about 5.86% so far this year and is down about -12.69% in the last one year (as of 03/22/2023). In the past 52-week period, it has traded between $165.84 and $229. The ETF has a beta of 1.10 and standard deviation of 26.31% for the trailing three-year period, making it a medium risk choice in the space. With about 172 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard Mid-Cap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VOT is an outstanding option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the iShares Russell Mid-Cap Growth ETF (IWP) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.15 billion in assets, iShares Russell Mid-Cap Growth ETF has $11.81 billion. IJK has an expense ratio of 0.17% and IWP charges 0.23%. Bottom-Line Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports Amphenol Corporation (APH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Cadence Design Systems, Inc. (CDNS) : Free Stock Analysis Report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-03-23,116.26,116.87,113.32,114.5,"Have $1,000? 2 Stock-Split Companies to Add to Your Buy Basket Right Now. Modern investing has made buying into great companies more accessible than ever, particularly with so many brokerages offering fractional shares. Another way that high-flying stocks can become more accessible to the average investor is through stock splits. A stock split doesn't add value for existing investors, but rather divides their holdings up into more shares at correspondingly lower prices. So a split can also make a stock more palatable for investors with more-moderate capital. As always, share price alone shouldn't affect your choices one way or the other. The underlying business and how it fits your portfolio's objectives are what matter. If you have $1,000 to put into the market right now, here are two companies that recently underwent stock splits to consider holding for years. 1. DexCom DexCom (NASDAQ: DXCM) executed a 4-for-1 split on May 19 of last year. The diabetes-care specialist had a banner 2022 with stunning revenue growth and profits. It also marked a significant win just before the start of the new year with approval from the Food and Drug Administration for its G7 continuous glucose monitoring (CGM) device, the latest generation of its flagship product. Distribution is now underway in the U.S. and in markets including Europe and Asia. DexCom significantly augmented its CGM user base in 2022, closing the year with 1.7 million active users globally, an increase of 450,000 from the end of 2021. Revenue was $3 billion in 2022, with earnings at $341 million for the full year -- approximate increases of 20% and 60%, respectively, from 2021. Several factors are driving the continued adoption of CGMs and the growth of their total addressable market. In some cases, they can make a life-saving difference for the wearers. The expansion of insurance coverage for CGMs -- with DexCom products remaining the most-covered on the market -- and the rising incidence of diabetes worldwide are two other key catalysts. What's more, the potential addressable market for CGM wearers is still heavily underpenetrated, with some estimates showing that only up to 4% of individuals in the U.S. with Type 2 diabetes, the most commonly diagnosed form of the disease, now wear these devices. Moreover, beyond Type 1 and Type 2 diabetics, there are potential uses even for pre-diabetics. The growth runway for DexCom isn't anywhere close to ended, which is good news for the business and could make it a particularly compelling choice for long-term investors. 2. Alphabet Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) executed a 20-for-1 stock split on July 1 of last year. The company has an impressive record of rewarding long-term investors, with a total return of 250% to 260% over the past decade (depending on whether you own class A or class C shares). Its top and bottom lines have grown 409% and 371%, respectively, in that same 10-year period. Even so, the fluctuating sentiment around growth and tech stocks, as well as the constrained ad spending environment, has perhaps made some investors wary of the company. And with the launch of Microsoft's new-and-improved Bing search engine incorporating ChatGPT, there seems to be some concern about Alphabet's long-term sway over the search engine market, a multibillion-dollar space in which its Google has long been the indomitable leader. The current economy has forced companies to pull back on ad spending. But this isn't a long-term trend, and ad spending will recover. Few brands today can survive without a robust, consistent digital presence. Roughly half of all ad spending globally is controlled by Alphabet and fellow tech giant Meta Platforms. Alphabet also continues to see steady growth in its cloud infrastructure business, Google Cloud, and has about an 11% share of this multibillion-dollar market at the time of this writing. Google has roughly 85% of the global search engine market; Microsoft's Bing controls about 9%. Alphabet recently executed a somewhat bumpy launch for Bard, its own competitor to ChatGPT, at a time when AI promises to revolutionize a range of industries including the search engine space. This stumble doesn't mean that the Sun has set on the tech giant. AI-based tools are far from perfect, and Bard is still a work in progress. While the search market could change in the future, it doesn't mean that Google can't adapt to AI, something Alphabet is already working on with the rollout of Bard. The company has other fast-growing businesses to rely on, too, including its cloud segment and YouTube. Revenue totaled $283 billion and earnings reached $60 billion in 2022, with cash and investments on its balance sheet of $114 billion. Alphabet offers investors with a multi-year investment horizon, an established name with a tremendous global footprint, and a long history of profitability. And that sets it up to continue to seize market share as its toolkit of services and technologies evolves to keep pace with the digital age. The stock still looks like an intriguing buy, particularly at its currently discounted price. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Rachel Warren has positions in Alphabet and DexCom. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, and Microsoft. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-24,114.26,115.21,112.79,114.09,"Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada Dexcom, Inc. DXCM announced that its Dexcom G6 CGM System would be available for all eligible patients with type 1 and type 2 diabetes in the Canadian province, Manitoba, irrespective of their age. It would be effective from Mar 14. The company’s real-time continuous glucose monitoring (CGM) system is currently the standard of care in diabetes management. Patients on both basal and bolus insulin or using an insulin pump will be eligible for the Dexcom G6 CGM System, through the Manitoba Pharmacare program. The system uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device. This provides patients with real-time glucose data without the need to scan or prick their fingers routinely. It will also help patients to set customizable and predictive alerts, and an urgent low alarm to help avoid potentially dangerous hypoglycemic events. The users (patients) will also be able to share their glucose information with up to ten followers, enabling remote monitoring. The system will allow connectivity through integrations with leading insulin delivery systems and digital health apps. The G6 CGM system is likely to enable self-management of diabetes at home, improve patient experience and preserve vital health system capacity. It will do so by reducing the risk of severe hypoglycemia that may result in emergency care for patients. The system will not require an application for a preapproval of coverage in Manitoba, which will improve access for patients and reduce the workload for prescribers. The ease of access to real-time CGM systems is now raising the bar for other jurisdictions across Canada to follow suit, thereby leading to greater access to the system in the country. Recent Developments Last month, the company reported fourth-quarter 2022 adjusted earnings per share (EPS) of 34 cents, beating the Zacks Consensus Estimate by 30.8%. Total revenues grew 17% (20% on an organic basis) to $815.2 million on a year-over-year basis. Rising volumes across all channels, along with strong new customer additions, contributed to the upside. This was due to the increasing global awareness of the benefits of real-time CGM. U.S. revenues (74% of total revenues) increased 17% on a year-over-year basis to $606.4 million. International revenues (26%) improved 15% year over year to $208.8 million. In February, Dexcom launched its G6 system in Singapore for diabetic patients aged two years and older, including pregnant women. The same month, Dexcom launched its next-generation Dexcom G7 CGM System in the United States. The company also gained coverage for the G7 system by Medicare beneficiaries. The glucose monitoring market presents significant commercial opportunities for the company. DXCM’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Stocks to Consider Dexcom currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Becton, Dickinson and Company BDX, Henry Schein HSIC and The Cooper Companies COO. Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months. Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%. HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months. The Cooper Companies, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 11%. Its earnings missed estimates in three of the trailing four quarters and beat the same once, the average negative surprise being 1.82%. COO’s shares have gained 11.3% compared with the industry’s 0.8% growth in the past six months. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-27,115.75,117.95,115.04,116.07,"Nasdaq 100 Movers: PDD, TSLA In early trading on Monday, shares of Tesla topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.7%. Year to date, Tesla registers a 58.8% gain. And the worst performing Nasdaq 100 component thus far on the day is PDD Holdings, trading down 3.4%. PDD Holdings is lower by about 12.4% looking at the year to date performance. Two other components making moves today are Moderna, trading down 3.0%, and DexCom, trading up 2.4% on the day. VIDEO: Nasdaq 100 Movers: PDD, TSLA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-28,117.32,117.99,113.141,113.815,
DXCM,2023-03-29,114.83,115.75,113.07,113.96,"UBS Initiates Coverage of DexCom (DXCM) with Buy Recommendation On March 29, 2023, UBS initiated coverage of DexCom with a Buy recommendation. Analyst Price Forecast Suggests 18.96% Upside As of March 28, 2023, the average one-year price target for DexCom is $135.40. The forecasts range from a low of $111.10 to a high of $157.50. The average price target represents an increase of 18.96% from its latest reported closing price of $113.82. See our leaderboard of companies with the largest price target upside. The projected annual revenue for DexCom is $3,546MM, an increase of 21.86%. The projected annual non-GAAP EPS is $1.10. What are Large Shareholders Doing? Baillie Gifford & holds 17,303K shares representing 4.48% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm decreased its portfolio allocation in DXCM by 47.75% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.01% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.04% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase & holds 10,647K shares representing 2.76% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.45% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. What is the Fund Sentiment? There are 1891 funds or institutions reporting positions in DexCom. This is an increase of 134 owner(s) or 7.63% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.47%, an increase of 17.12%. Total shares owned by institutions increased in the last three months by 0.56% to 443,061K shares. The put/call ratio of DXCM is 1.18, indicating a bearish outlook. Dexcom Background Information (This description is provided by the company.) Sponsored Links This Is The Highest Rated Hearing Aid In The US hear.com DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-30,114.27,115.0,112.62,114.4,"AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates AngioDynamics (ANGO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this medical device maker would post a loss of $0.01 per share when it actually produced earnings of $0.01, delivering a surprise of 200%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. AngioDynamics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $80.71 million for the quarter ended February 2023, missing the Zacks Consensus Estimate by 2.28%. This compares to year-ago revenues of $73.97 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. AngioDynamics shares have lost about 9.4% since the beginning of the year versus the S&P 500's gain of 4.9%. What's Next for AngioDynamics? While AngioDynamics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for AngioDynamics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.06 on $93.32 million in revenues for the coming quarter and $0.01 on $342.87 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, DexCom (DXCM), has yet to report results for the quarter ended March 2023. This medical device company is expected to post quarterly earnings of $0.15 per share in its upcoming report, which represents a year-over-year change of +87.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. DexCom's revenues are expected to be $719.86 million, up 14.5% from the year-ago quarter. Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit) The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries. Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks. See Stocks Now Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-03-31,115.02,116.87,114.52,116.18,"[""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know In the latest trading session, DexCom (DXCM) closed at $116.18, marking a +1.56% move from the previous day. This change outpaced the S&P 500's 1.44% gain on the day. At the same time, the Dow added 1.26%, and the tech-heavy Nasdaq gained 5.21%. Prior to today's trading, shares of the medical device company had lost 5.64% over the past month. This has lagged the Medical sector's gain of 2.17% and the S&P 500's gain of 2.28% in that time. DexCom will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.15, up 87.5% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $719.86 million, up 14.48% from the prior-year quarter. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.07 per share and revenue of $3.46 billion. These totals would mark changes of +22.99% and +18.82%, respectively, from last year. It is also important to note the recent changes to analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.95% higher within the past month. DexCom currently has a Zacks Rank of #3 (Hold). In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 107.28. Its industry sports an average Forward P/E of 26.1, so we one might conclude that DexCom is trading at a premium comparatively. Also, we should mention that DXCM has a PEG ratio of 2.75. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments was holding an average PEG ratio of 2.13 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 All-Weather Stocks to Buy Without Hesitation Right Now Market volatility tends to affect every industry in unique ways. While there are always exceptions, healthcare has continually proven to be one of the most resilient sectors in a wide variety of market environments. If you have cash to add to stocks right now, here are two healthcare names to buy without hesitation before the month is out. 1. DexCom DexCom (NASDAQ: DXCM) has long been known as a leader in diabetes care, with its industry-dominating portfolio of continuous glucose monitoring (CGM) devices, led by its flagship G series of products. Its latest CGM device, the G7, was just approved in the U.S. at the end of 2022, and launches are underway across the nation, as well as in international markets spanning Europe to the U.K. to Asia. Early feedback about the G7 from users has already been promising. CEO Kevin Sayer noted in the fourth-quarter 2022 earnings call: We are hearing consistent praise for the new features, such as the 60% smaller form factor, shorter warm-up period, and more engaging and consumer-friendly app. Perhaps the most encouraging is that 97% of initial users surveyed have found G7 easy to use. Despite the fact that CGMs can be valuable and even lifesaving tools for both type 1 and type 2 diabetics (and there are indications that there could potentially be valuable use cases for pre-diabetics), there are still millions of people with diabetes all over the world that do not utilize one. This fact, combined with the growing prevalence of diabetes worldwide, creates a vast and growing addressable market opportunity for DexCom, an opportunity that it is well-positioned to seize upon, given its broad footprint in this space. The enhancement of both private and public coverage options are also factors driving CGM adoption by the consumer populace. DexCom has not only been at the forefront of advocating for change on the government level and working alongside private insurers to effect this end, but its products are currently the most covered on the market. The company saw its user base skyrocket by an incredible 450,000 lives in 2022, with DexCom ending the year with about 1.7 million users around the world. Bear in mind that it's estimated that there are about half a billion people with diabetes globally. DexCom raked in profits of $341 million and operating income of $391 million in 2022 alone. If you're looking for a profitable business with a firm foothold on a fast-growing and highly non-cyclical industry, DexCom meets the mark on all counts. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) has built a thriving, multibillion-dollar business around its long-standing leadership in the surgical robotics industry. The company has been a trailblazer in this space and boasts the distinction of having first-mover market advantage, since its flagship product, the da Vinci Surgical System, was approved more than two decades ago. While the da Vinci Surgical System was initially approved for use in general laparoscopic surgery, it has since garnered approval for a range of other use cases, including prostate, gynecological, bladder, and kidney surgeries, to name a few. In recent quarters, Intuitive Surgical has exhibited somewhat of a growth deceleration, but this isn't because the company is losing its edge or due to underlying issues with the business. It goes back to a wave of COVID-19 resurgences throughout 2022 across markets that provide key sources of revenue and profits for Intuitive Surgical in Europe and Asia, which inevitably caused a delay in procedures and impacted procedure volume. However, even several quarters of fluctuating procedure volumes shouldn't deter investors looking at a multi-year, buy-and-hold position in this stock. Notably, the procedures that Intuitive Surgical's systems support are not usually elective in nature, which lends an overall resilience to the business. Even as year-over-year growth comparisons have been somewhat more moderate, Intuitive Surgical is continuing to witness stable revenue acceleration, remains profitable, and its installed base of systems continues to grow. The company ended the year with an installed base of 7,544 systems globally, up 12% from 2021 and 35% from 2019. Intuitive Surgical doesn't just generate revenue from how many systems it sells and installs for medical providers. It makes even more revenue -- and recurring revenue at that -- from the range of services, software, tools, and instruments that go along with these systems. This is a company with a strong history of profitability. Just looking back over the past few years, Intuitive Surgical generated profits of $1.3 billion in 2022, $1.7 billion in 2021, and $1.1 billion in 2020. The company controls a roughly 80% share of the surgical robotics industry, a space that represents a vast and expanding addressable market as use cases for and adoption of surgical robotics systems grows. For healthcare investors, that can create a golden opportunity in any market environment. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-03,116.03,116.03,113.25,115.24,"What Investors Need to Know About the Growing Digital Health Space A s the world continues to shift towards digitalization, a revolutionary transformation is happening in healthcare. Patients and providers are increasingly adopting digital solutions to improve delivery and patient outcomes while reducing costs. Given the demographic challenges facing much of the developed world, this shift could not come at a better time. In this piece, we will look at how big the digital health space is, as well as who the major players are. What is Digital Health? Digital healthcare is the application of technology to healthcare services, making them more accessible and efficient. Digital health companies use a wide range of technologies, including electronic health records (EHRs), telemedicine, artificial intelligence (AI), mobile health (mHealth) and wearable devices, to enhance patient care. Smartphones and connected devices can improve communication and create innovative ways to monitor health better. These technologies can help diagnose earlier, possibly even prevent disease and improve chronic condition management. Demographic Tailwinds The good news is that life expectancy is rising. The bad news is that with falling fertility rates, populations are skewing older. By 2030, every Baby Boomer will be 65 or older, putting 20% of the U.S. population at retirement age. Europe is already there. In 2022, 21.1% of EU citizens were 65 or older, and there were just over three working-age persons for every person over 65. Aside from the challenges for the labor pool, healthcare spending increases dramatically with age. In the U.S. in 2019, 35% of total health spending was for those 65+ (which accounted for just 17% of the population) and 21% for the 55-64 years of age (13% of the population). Less than one-third (30%) of the population accounted for well over half (56%) of healthcare costs. With an aging population, demand for healthcare is growing as the working-age population shrinks as a percent of the total. We need to do more with less, a strong tailwind for digital healthcare. The Growing Digital Health Market The digital health market is estimated to be growing at a compound annual growth rate of around 25% from 2019 to 2025. Investor funding in the total digital health industry worldwide has rapidly risen from $1.1 billion in 2010 to $22.9 billion in 2020. The pandemic led to a massive boost in 2021 to $44.8 billion in funding. Even with the steep decline to $23.3 billion, 2022 remains the second-highest annual investment level in history, leaving the growth trend intact outside the 2021 bubble. Mobile health apps are becoming ubiquitous. In Q3 2022, there were 41,517 healthcare apps on the Apple Appstore, up from 36,949 in Q3 2015. In Q3 2022, there were 54,546 healthcare apps on the Android Appstore, up from 27,417 in Q3 2015. In Q3 2022, there were 2,380 healthcare apps on the Amazon Appstore, up from 15 in Q3 2015. The most downloaded health and fitness app in 2022 was Sweatcoin, with 52 million downloads, followed by the Blood Pressure App at 51 million. The global telemedicine market has also experienced incredible growth rates from $49.9 billion in 2019 to a projected $149.1 billion in 2023 and is expected to reach $459.8 billion by 2030. The electronic health records (EHR) market worldwide was estimated to be $29.16 billion in 2020 and is expected to grow to $27.25 billion by 2027. According to data from Statista, artificial intelligence (AI) in the healthcare market reached around $11.1 billion worldwide in 2021 and is forecasted to grow at a compound annual growth rate of 37% from 2022 to 2030, reaching $188 billion. Global smartwatch shipments have grown from 37 million in 2016 to 232 million in 2021 and are expected to reach 402 million by 2026. Digital Fitness & Wellbeing Devices are expected to reach $68 billion in 2023, with revenue growing at a compound annual growth rate of 9.9%, they will reach $99.1 billion by 2027. Big Tech and Retailers Moving Into Digital Healthcare Some of the major players in the digital health revolution are unsurprisingly big tech leaders or major consumer brands. Given the current economic climate with high interest rates and tightening credit conditions, bigger companies will have an advantage over smaller ones, which means further tailwinds for the big guys and an increased likelihood of acquisitions. Amazon (AMZN) has spent years and made considerable investments in healthcare and recently announced that it will be working with JP Morgan (JPM) and Berkshire Hathaway (BRK.A) to cut healthcare costs. Here are just a few examples of its activity in the sector. In 2018, Amazon acquired PillPack using the provider to launch a pharmacy service. AWS joined the National Institutes of Health’s Science and Technology to help researchers worldwide work together more effectively. In 2019, it launched an app-based health service for employees that it later offered to other companies. In 2019, Amazon rolled out the first HIPAA-compliant Alexa skills. In 2021, it announced two new programs for its Alexa device focused on healthcare and retirement homes, and its Alexa Fund invested in Cognixion. Its headset users will be able to interface directly with Alexa from anywhere to control smart devices, access news, or for those with severe speech impediments, use Alexa to speak for them. In February 2023, Amazon completed its acquisition of One Medical and its parent in a $3.9 billion deal, launching its digital health platform. The deal gives the e-commerce behemoth over 200 brick-and-mortar doctors’ offices and around 815,000 One Medical members. In January 2023, the company launched RxPass, a $5 prescription subscription service for Prime members who take multiple medications in addition to its existing pharmacy service. Alphabet (GOOG) has been busy in the healthcare space as well. In the AI space, Google announced earlier this month a new open-source program called Open Health Stack for developers to build health-related apps. It has been working with the Mayo Clinic on how AI can help radiotherapy. For consumers, Google’s conversation AI technology, Duplex, can confirm if providers receive specific Medicaid plans in their state. It is also making Medicaid re-enrollment information easier to find on Search since a pandemic-induced break on re-enrolling expires March 2023. It will also surface neighborhood health centers that offer free or low-cost healthcare. In January, Google and DeepMind launched MedPaLM, an open-source large language model designed to generate safe and helpful answers in the medical field. The current iteration, med-PaLM 2, consistently performed at an “expert” doctor level on medical exam questions, scoring 85%, surpassing similar AI models. The company has invested in or partnered with various AI-related healthcare companies including BenchSci, Dyno, Insitro, Temaya, Sonofi, Hyperfine, Varian, Infinitus and Klara. In addition, it has also acquired Drug R&D firms such as SignalPath and invested in Encodia, EQRx and InstaDeep. It has also invested in multiple companies working on gene therapy solutions, genomics, reproductive health and healthcare supply chain solutions. Apple (AAPL)’s watch is already one of the most widely used health monitoring devices with over 100 million users, and its Airpods could be the company’s next health monitoring device. In late February, Bloomberg’s Mark Gurman reported that Apple had recently hit some significant milestones in its E5 project to provide noninvasive continuous blood glucose monitoring through its watch using laser spectrometry. The company has worked on the CGM system for over 12 years and is considered at the proof-of-concept stage. The market for this is massive. According to the CDC, 10% of adult Americans have diabetes, and 20% of those who have it don’t know they do. Over one-third of adult Americans have prediabetes, and 80% are not aware they do. An estimated 10.5% or 536.6 million of the world’s population (20 to 79 years of age) have diabetes, with more than half unaware. Apple Watch can currently take electrocardiograms, monitor blood oxygen levels, assist in elder care with issues like fall detection and provide hearing assistance, sleep monitoring and body temperature for women’s health tracking. Third parties have been developing apps for the watch to address various health conditions, including neurological problems. In June 2022, Rune Lab’s Apple Watch-based Parkinson’s disease tracker received FDA clearance. It automatically tracks tremors and lets patients report symptoms and medication usage. NightWare developed an app for the watch to help those suffering from post-traumatic stress-related nightmares. It is the first and only digital therapeutic developed to treat nightmares that is cleared by the FDA. There are also over 150 million Airpod owners and given the number of patents Apple has been filing for sensors in the devices, they could very well be the next consumer wellness device. Microsoft (MSFT) is involved in a wide range of healthcare offerings, many of which leverage its investment in OpenAI and ChatGPT. A 2013 study in the Journal of Graduate Medical Education found that over a two month timeframe, 92% of healthcare providers reported that documentation obligations are excessive, 90% reported that it compromises the amount of time spent with patients and 73% reported the amount of documentation negatively impacts patient care. Earlier this month, Nuance Communications, a Microsoft company, announced Dragon Ambient eXperience (DAXTM) Express, which will use OpenAI’s newest model, GPT-4, to reduce the time providers spend taking notes by using generative AI to summarize medical conversations. DAX Express automatically and securely creates draft clinical notes in seconds for immediate review and completion after each patient visit, physical or virtual. Data supports the profound impact AI can have on provider care. For example, a MedTech Europe survey in 2020 found that the time physicians in Europe spent with patients rose from 50% to 67% with the implementation of AI, and consequently time spent on administrative tasks dropped from 50% to 33%. Microsoft platforms are being used across a wide range of healthcare providers. Teladoc (TDOC) software as a service solution is built in Microsoft Azure, and healthcare organizations are using Microsoft Teams to improve care, provide virtual visits, cut costs and improve efficiency. Walmart (WMT) currently has 32 in-store clinics with plans to grow to over 75 by the end of next year and potentially 4,000 primary care centers by 2031, which would make them the nation’s largest provider. The clinics are powered by Microsoft’s cloud service and VMWare (VMW) to access its Epic electronic medical record system. Walmart isn’t alone in its quest to expand into healthcare. In February 2023, Albertsons Companies (ACI) launched Sincerely Health, a digital health and wellness platform, now available on its grocery apps and websites of 16 of its brands, including Albertsons, Safeway, Vons, Shaw’s, Jewel-Osco, Acme and Tom Thumb. In 2022, Oracle (ORCL) made a big move into healthcare when it closed its $28 billion acquisition of Cerner Corporation, a healthcare IT systems provider. Other Major Players American Well Corp (AMWL) is an enterprise software company enabling digital care virtual primary care, post-discharge follow-up, chronic condition management and remote patient monitoring and aligns them into a single digital care operating system that aggregates all of the data from these care experiences to provide real-time insight. Dexcom Inc (DXCM) designs and commercializes continuous glucose monitoring systems (CGM), an alternative to the traditional blood glucose meter process. Its CGM systems currently integrate with insulin pumps from Insulet (PODD) and Tandem (TNDM), amongst others. Its 2022 revenue rose 19% YoY, with a 28% growth in international revenue. Tandem develops products for people with insulin-dependent diabetes and has three key insulin pump products, which account for most of its revenue. In 2022, its worldwide install base grew 29% YoY to around 420,000 customers worldwide, and renewal pump shipments in the U.S. grew 60% while non-U.S. sales rose 19%. Insulet has developed the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. The Omnipod was approved by the FDA in 2005 and has around 360,000 users worldwide. In 2022 Omnipod revenue grew 27% YoY, the seventh consecutive year of 20%+ revenue growth. Last year, rumors circulated that Dexcom was considering acquiring Insulet, which Dexcom denied. In February 2023, GE HealthCare Technologies (GEHC) announced it was acquiring Caption Health, which uses AI to assist with ultrasound scans of the heart for early disease detection. Caption Health was recognized as one of TIME’s 100 Best Inventions and a winner of Fast Company’s Next Big Things in Tech for health in 2021. The Bottom Line Sponsored Links The US States People Are Fleeing And The Ones They Are Moving To Forbes We are living longer, and a larger portion of the population than ever before will be 65+ in the coming years, which means that greater demands will be placed on healthcare with a relatively smaller labor force to provide services. Leveraging advances in digital health technologies can help people to live longer and have higher-quality lives. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-04,115.44,116.18,114.3,115.64,
DXCM,2023-04-05,115.69,115.739,112.42,112.82,"[""2 Explosive Growth Stocks to Buy in April The market has tested the patience of even the most seasoned of investors over the last year, and you're not alone if you've seen your portfolio struggle against the ongoing volatility. With even the most tried-and-true companies across a wide selection of industries seeing share prices buckle in this environment, it's more important than ever to consider where you put your investing capital to work and ensure that the underlying businesses align with your portfolio goals and risk tolerance. If you're on the hunt for two compelling businesses to add to your buy basket this month, here are two names to consider right now. 1. DexCom DexCom (NASDAQ: DXCM) continues to derive substantial revenue growth and profits from its market-leading portfolio of continuous glucose monitoring (CGM) devices. The company's latest launch of its newest generation of its flagship CGM device, the G7, is underway in the U.S. and was already launched in other key international markets before the end of 2022 in Europe, Asia, and beyond. The G7 is approved in the U.S. for all diabetics from the age of two and up, and not only is it the most covered and reimbursed brand on the market, but the CGM itself has the fastest warmup time of any such device that is currently commercialized. The G7 is also 60% smaller than the prior version, the G6, making it easier to use and far more portable than its predecessor. While the company was only in the initial phase of its U.S. launch at the time of the 2022earnings call DexCom CEO Kevin Sayer noted: We are hearing consistent praise for the new features, such as the 60% smaller form factor, shorter warm-up period, and more engaging and consumer-friendly app. Perhaps the most encouraging is that 97% of initial users surveyed have found G7 easy to use. We designed this product to simplify the lives of our customers, and we are thrilled to see that emphasis resonating. Bear in mind, the G7 sensor can be worn for a maximum of 10 days. These devices can be lifesaving and are used by both type 1 and type 2 diabetics, although there remains a massive addressable market for each that is broadly untapped. About 1.7 million people were using DexCom's devices as of the end of 2022, while nearly half a billion people globally have diabetes. Currently, only about 3% to 4% of individuals with type 2 diabetes in the U.S. alone wear a CGM. In short, not only is this a recurring revenue business, but one that enjoys a large and growing market opportunity. DexCom's revenue soared 19% in 2022, while profits jumped nearly 60%. For investors looking for a growth-oriented healthcare stock with a highly non-cyclical business -- and a profitable one to boot -- DexCom looks like a worthy contender for a multi-year buy-and-hold position. 2. Chewy Chewy (NYSE: CHWY) continues to carve out a prolonged runway to growth for itself in the lucrative pet care industry, a space that hit a valuation upwards of $280 billion globally as of 2022. There are a variety of factors driving the growth of this space, from the rise of pet ownership to the reality that consumers are not only spending more on products but on quality products for their pets. For Chewy, an online retailer with its fingers in everything from pet healthcare to pet food, pet insurance, pet supplements, pet toys, and supplies, to name just a few segments within this vast addressable market opportunity, this creates a compelling road to growth ahead. Even as consumers may be spending less on certain items in an environment that could be teetering on the brink of a recession, people are still going to spend money on their pets. Chewy's recent financial results certainly bear this concept out. And, the company is boosting its competitive edge with a growing network of automated fulfillment centers that not only slash its overhead costs but streamline the order processing and delivery timeline for customers. In 2022, Chewy reported revenue of $10 billion, while net income came in at $49 million. The company is making more and more of its revenue and profits from its subscription program, Autoship. In fact, 73% of net sales came from its Autoship program in 2022. On the whole, Autoship sales came to $7.4 billion for the 12-month period, up 18% from 2021. And, as of the final quarter of the year, net sales per active customer hit $500, a roughly 15% surge compared to the fourth quarter of 2021. Notably, Chewy generated $119 million in free cash flow in 2022, ending the year with about $677 million in cash and investments on its balance sheet. Even if consumers reel in spending in the near term given the current state of the economy, the overall trajectory of pet spending and the pet care industry on the whole bode particularly well for Chewy given the diversity of its business segments and the many different targets of pet spending its business taps into. The fact that the company is also exposed to so many sources of pet spending means that the more non-cyclical sources of revenue can balance out these more cyclical areas. For investors, that could create a worthwhile buy-and-hold opportunity in the current market and well beyond. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Chewy. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar? Designed to provide broad exposure to the Mid Cap Growth segment of the US equity market, the iShares Russell Mid-Cap Growth ETF (IWP) is a passively managed exchange traded fund launched on 07/17/2001. The fund is sponsored by Blackrock. It has amassed assets over $11.91 billion, making it the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. These types of companies, then, have a good balance of stability and growth potential. Qualities of growth stocks include faster growth rates compared to the broader market, as well as higher valuations and higher than average sales and earnings growth rates. Additionally, growth stocks have a greater level of risk associated with them. Even though growth stocks are more likely to outperform their value counterparts in strong bull markets, value stocks have a record of delivering better returns in almost all markets than growth stocks. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.23%, putting it on par with most peer products in the space. It has a 12-month trailing dividend yield of 0.74%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 26.50% of the portfolio. Industrials and Healthcare round out the top three. Looking at individual holdings, Synopsys Inc (SNPS) accounts for about 1.49% of total assets, followed by Dexcom Inc (DXCM) and Cadence Design Systems Inc (CDNS). Performance and Risk IWP seeks to match the performance of the Russell MidCap Growth Index before fees and expenses. The Russell Midcap Growth Index measures the performance of the mid-capitalization growth sector of the U.S. equity market. It is a subset of the Russell Midcap Index, which measures the performance of the mid-capitalization sector of the U.S. equity market & approximately 47% of the total market value of the Russell Midcap Index. The ETF has gained about 7.97% so far this year and is down about -11.40% in the last one year (as of 04/05/2023). In the past 52-week period, it has traded between $75.41 and $98.61. The ETF has a beta of 1.10 and standard deviation of 25.80% for the trailing three-year period, making it a medium risk choice in the space. With about 406 holdings, it effectively diversifies company-specific risk. Alternatives IShares Russell Mid-Cap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IWP is a great option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the Vanguard Mid-Cap Growth ETF (VOT) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.26 billion in assets, Vanguard Mid-Cap Growth ETF has $9.98 billion. IJK has an expense ratio of 0.17% and VOT charges 0.07%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports DexCom, Inc. (DXCM) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report Cadence Design Systems, Inc. (CDNS) : Free Stock Analysis Report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-06,112.94,112.94,111.43,112.47,"3 No-Brainer Medical Device Stocks to Buy Right Now The COVID-19 pandemic slowed business for many healthcare companies because the number of elective surgeries fell. On top of that, labor shortages for hospital staff, tightened hospital spending, and supply chain issues slowed sales of medical equipment. However, as elective procedures gradually return to where they were before the pandemic, medical equipment makers are seeing a surge in sales. Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. Let's see why investors should consider them now. Edwards has its pulse on growth Edwards Lifesciences focuses on devices for critical care monitoring and to treat structural heart disease. About 10 years ago, the company pioneered transcatheter heart valves (TAVR) that don't require open-heart surgery. It's looking forward to a boost this year thanks to the launch late last year of its next-generation TAVR, the Sapien 3 Ultra Resilia. The valve is made from cow heart tissue and has anti-calcification technology. The company's other big seller has been its HemoSphere system to monitor patients' heart functions and fluid status. Edwards should benefit as the population ages. Heart disease is the No. 1 cause of death in the U.S., according to the Centers for Disease Control and Prevention. The need for heart valves and heart monitoring is expected to grow, with Edwards saying in its latest quarterly report that it expects low double-digit growth in business between now and 2028. The company reported fourth-quarter and full-year earnings on Jan. 31. Fourth-quarter sales were up 1% year over year to $1.35 billion while yearly revenue grew 3% to $5.38 billion. Earnings also grew. In the fourth quarter, Edwards reported earnings per share (EPS) of $0.65, up 22.6% over the fourth quarter of 2021. Yearly EPS was up 2.5% to $2.44. Edwards said it expects 2023 sales of $5.6 billion to $6 billion, up 9% to 12%, and adjusted EPS between $2.45 and $2.60, compared to $2.48 in 2022. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. On Jan. 6, the FDA cleared Abbott's Navitor, its latest transcatheter aortic valve implantation (TAVI) system, to treat people with severe aortic stenosis (when a heart valve doesn't open properly) who are at high risk for open-heart surgery. Then on Jan. 26, it received FDA approval for another indication for its Proclaim XR SCS (spinal-cord stimulation) system as a non-medication pain therapy for diabetic peripheral neuropathy. Finally, on March 30, Abbott received FDA approval of its Epic Max stented tissue valve to treat patients with aortic regurgitation (when a heart valve doesn't close properly) or stenosis. Epic Max is designed for patients who can't take blood thinners but need heart valve replacements. On the financial front, Abbott reported revenue of $43.6 billion last year, up 1.3%, though EPS was down to $3.91 compared to $3.94 a year earlier. Abbott's diabetes care sales spiked by 34.8% in the U.S. last year and 9.9% overall to $4.8 billion, thanks to the introduction of the Freestyle Libre 3, the world's smallest and thinnest continuous glucose monitoring (CGM) device. One advantage Abbott has over the other two stocks here is its dividend, which it has increased for 51 consecutive years. The current quarterly dividend pays $0.51 per share, equal to an above-average yield of about 2%. The payout ratio is a conservative 42%, meaning it is well-covered by the company's cash flows. G7 launch will drive DexCom sales this year DexCom focuses on CGM systems for diabetic care -- a need that is increasing due to an aging population and increasing obesity. According to the International Diabetes Foundation, there were 537 million adults with diabetes in 2021, and that number is expected to grow to 783 million by 2045. The number could be even higher, the foundation said, because nearly one in two adults who have diabetes are undiagnosed. The company launched its latest -- and smallest -- CGM device, the G7, in February and is looking forward to another year of growth. DexCom reported fourth-quarter and full-year 2022 numbers on Feb. 9. Fourth-quarter revenue was up 17% year over year to $815 million while full-year revenue was up 19% to $2.9 billion. Net income for the year was $341 million, up about 45%, with 2023 EPS coming in at $0.82, up almost 55%. Fourth-quarter net income was $91.8 million, compared to a loss of $5.3 million in the same quarter a year ago, while EPS this quarter was $0.22 compared to an EPS loss of $0.01 in the same period a year ago. This year, thanks to the launch of the G7, the company's guidance points to revenue of between $3.35 billion and $3.49 billion, growth of 15% to 20%. 10 stocks we like better than Edwards Lifesciences When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Edwards Lifesciences wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Jim Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Edwards Lifesciences. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-10,112.52,113.07,110.9,112.53,"1 Stock-Split Stock That's a Surefire April Buy and 1 to Avoid For 15 months, investors have been taken for quite the ride, courtesy of Wall Street. Following 2021, which saw the S&P 500 endure a peak correction of just 5%, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite took a shellacking in 2022. All three fell into a bear market and generated their worst yearly returns since the Great Recession. But even in down years for the stock market, investors find bright spots to latch onto. In 2022, it was stock-split stocks. Image source: Getty Images. Stock splits take center stage A stock split is an event that allows a publicly traded company to alter its share price and outstanding share count without having any effect on its market cap or operations. A forward stock split is designed to make a company's share price more nominally affordable for everyday investors, whereas a reverse stock split increases a company's share price, which is usually done to keep it compliant with minimum listing standards for a major U.S. stock exchange. Most investors gravitate to companies enacting forward stock splits. That's because forward stock splits are undertaken by businesses whose share prices have risen significantly. For a company's share price to appreciate meaningfully over time, the underlying businesses has to be firing on all cylinders. In many instances, companies enacting forward splits are also out-innovating their competition. This makes forward splits something of a beacon for investors to locate top-tier businesses. In 2022, a half-dozen prominent stocks conducted much-anticipated forward stock splits. This includes: Amazon (NASDAQ: AMZN) completing a 20-for-1 split in June, DexCom (NASDAQ: DXCM) enacting a 4-for-1 split in June. Shopify (NYSE: SHOP) finishing its 10-for-1 split in June. Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) closing its 20-for-1 split in July. Tesla (NASDAQ: TSLA) enacting a 3-for-1 split in August. Palo Alto Networks (NASDAQ: PANW) completing its 3-for-1 split in September. Among these six high-profile stock-split stocks, one stands out as a surefire buy for patient investors in April, while another is facing mounting headwinds and is worth avoiding. The stock-split stock that's a surefire buy in April: Palo Alto Networks The stock-split stock that makes for a surefire buy this month is cybersecurity player Palo Alto Networks. Although Palo Alto is, arguably, pricier than the FAANG stocks that also split their shares (Alphabet and Amazon), its phenomenal growth rate and execution make it worth every bit of its premium. Before digging beneath the surface, I believe its important to point out that cybersecurity solutions have evolved into basic necessity services over time. In the wake of the COVID-19 pandemic, businesses of all sizes have created an online presence and moved their data into the cloud. No matter what the U.S. economy throws corporate America's way, demand for cybersecurity solutions to protect sensitive information isn't going away. With this macro tailwind in mind, the biggest company-specific catalyst in Palo Alto's sails is its ongoing transformation to a cloud-based, subscription services-driven operating model. Though it hasn't completely abandoned physical firewall solutions, emphasizing cloud-based software-as-a-service (SaaS) security solutions comes with well-defined advantages. For one, subscription services tend to be stickier when it comes to customer retention. This is to say that subscribing customers are less likely to cancel their subscription(s) than a purchaser of physical firewall products is to buy new products. It's a definite boost to long-term loyalty and gross revenue retention. To add, an SaaS-driven model should also produce predictable cash flow on a quarterly/annual basis. Without much in the way of churn, Palo Alto's management team can confidently outlay capital for innovation and acquisitions without hampering profitability. There's undeniable evidence that Palo Alto Network's shift to cloud-based SaaS is paying off. Thanks to a larger percentage of net sales coming from SaaS solutions, the company has been able to sustain a growth rate in excess of 20%. Additionally, the company raised its operating margin guidance for fiscal 2023 in February by 200 basis points to a range of 21.5% to 22%, relative to what it had forecast in November. It's not just that next-generation software sales are accelerating -- it's that sales are accelerating in all the right (i.e., higher-margin) places. What's particularly noteworthy is the growth in Prisma Cloud, the company's inline network security solution designed to protect developers in public and private clouds. As of the January-ended quarter, the number of subscribers using four or more Prisma cloud module solutions rose 114% year-over-year. The strength of next-gen solution add-on sales demonstrates why Palo Alto is firing on all cylinders. With Palo Alto Networks focused on high-margin SaaS solutions and continuing to make smart bolt-on acquisitions, its current share price premium will look like a discount when looking back in a few years. A Tesla Model S charging. Image source: Tesla. The stock-split stock you can avoid in April: Tesla But not all stock-split stocks will continue to be winners for investors. Out of last year's high-profile stock splits, it's electric-vehicle (EV) manufacturer Tesla that I'd suggest avoiding in April. Make no mistake about it, Tesla didn't reach a $587 billion valuation by accident. It's been propelled by its first-mover advantages in the EV space. It's North America's leading EV producer, with the company nearing 441,000 total EVs produced during the first quarter. Thanks to two new gigafactories coming online last year, the company believes it'll reach 1.8 million EVs produced in 2023, with some pundits on Wall Street thinking Tesla could hit 2 million. Investors have also been enamored with Tesla's profits. Based on generally accepted accounting principles (GAAP), it's delivered a profit in each of the past three years. That's in stark contrast to the EV segments for virtually every other new and legacy automaker, which are bleeding red. CEO Elon Musk has played a role in sending Tesla's stock higher, too. Musk is viewed as an innovator, and his promises of innovations to come have been built into his company's valuation. While this story has fanned the flames of bulls for years, a growing number of headwinds should have investors hitting the brakes on the world's most-valuable automaker. To begin with, Tesla's price cuts look like a clear red flag. Though some people will argue that these cuts are in response to manufacturing becoming more cost-efficient, they've corresponded with rising inventory levels for the company. Ongoing price cuts in the U.S., China, and Europe suggest Tesla's vehicle margin will contract meaningfully in 2023 (if not beyond) as competitors close the gap. Another reason to be concerned is that all of Tesla's efforts to become more than just a car company haven't yielded favorable results. Musk's acquisition of SolarCity has been a money-loser since day one. Meanwhile, the company's energy and services divisions are generating menial gross margins that ultimately turn to losses once below-the-line expenses are factored in. Ultimately, Tesla is a car company that's valued at 48 times Wall Street's consensus earnings in 2023. For context, auto stocks usually have earnings multiple of between 6 and 8. But the biggest reason to avoid Tesla stock is its leadership. Aside from the fact that Musk has found himself in potential hot water with securities regulators on more than one occasion, he's made a laundry list of promises that have failed to come to fruition. Level 5 autonomous driving has been ""a year away"" for nine years and counting, while not one of the 1 million promised robotaxis is on public roads. Everything from promised EV models to ancillary innovations are regularly delayed by Musk and his team. With a possible U.S. recession on the horizon, an exceptionally pricey (and cyclical) auto stock led by questionable management isn't where I'd want my money to be. 10 stocks we like better than Palo Alto Networks When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Palo Alto Networks wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-11,112.0,115.12,111.97,115.04,
DXCM,2023-04-12,116.134,116.68,114.57,114.82,"Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the market, the SPDR S&P Health Care Equipment ETF (XHE) is a smart beta exchange traded fund launched on 01/26/2011. What Are Smart Beta ETFs? Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy. Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a low-cost, convenient, and transparent way. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta. By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such. While this space offers a number of choices to investors, including simplest equal-weighting, fundamental weighting and volatility/momentum based weighting methodologies, not all these strategies have been able to deliver superior results. Fund Sponsor & Index XHE is managed by State Street Global Advisors, and this fund has amassed over $493.73 million, which makes it one of the average sized ETFs in the Health Care ETFs. This particular fund seeks to match the performance of the S&P Health Care Equipment Select Industry Index before fees and expenses. The S&P Health Care Equipment Select Industry Index represents the health care equipment segment of the S&P Total Market Index. Cost & Other Expenses Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. With one of the least expensive products in the space, this ETF has annual operating expenses of 0.35%. The fund has a 12-month trailing dividend yield of 0.02%. Sector Exposure and Top Holdings Most ETFs are very transparent products, and disclose their holdings on a daily basis. ETFs also offer diversified exposure, which minimizes single stock risk, though it's still important for investors to research a fund's holdings. XHE's heaviest allocation is in the Healthcare sector, which is about 100% of the portfolio. Taking into account individual holdings, Abiomed Inc. (ABMD) accounts for about 2.05% of the fund's total assets, followed by Dexcom Inc. (DXCM) and Intuitive Surgical Inc. (ISRG). The top 10 holdings account for about 18% of total assets under management. Performance and Risk The ETF has added roughly 7.70% and is down about -10.65% so far this year and in the past one year (as of 04/12/2023), respectively. XHE has traded between $79.20 and $110.32 during this last 52-week period. The fund has a beta of 0.94 and standard deviation of 26.49% for the trailing three-year period, which makes XHE a medium risk choice in this particular space. With about 83 holdings, it effectively diversifies company-specific risk. Alternatives SPDR S&P Health Care Equipment ETF is an excellent option for investors seeking to outperform the Health Care ETFs segment of the market. There are other ETFs in the space which investors could consider as well. First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the iShares U.S. Medical Devices ETF (IHI) tracks Dow Jones U.S. Select Medical Equipment Index. First Trust Indxx Medical Devices ETF has $2.05 million in assets, iShares U.S. Medical Devices ETF has $6.05 billion. MDEV has an expense ratio of 0.70% and IHI charges 0.39%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. Bottom Line To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-13,115.17,116.6,115.05,116.28,"[""2 Stocks That Turned $40,000 Into $1 Million in 10 Years Growth-oriented businesses can make for great investments because they are always reinvesting back into their operations. And if the businesses focus on areas of the economy that are continuing to grow, that can lead to some incredible returns. Two stocks that have turned $40,000 investments into more than $1 million over the past decade are DexCom (NASDAQ: DXCM) and Tesla (NASDAQ: TSLA). Here's a look at why they have done so well and whether they can still be good buys moving forward. 1. DexCom Diabetes is a growing concern for the healthcare industry as the disease is related to many other health problems. And while 28.7 million people have been diagnosed with diabetes in the U.S., according to data from the Centers for Disease Control and Prevention (CDC), there's another 8.5 million people that it estimates are undiagnosed. An estimated 38% of the adult U.S. population has pre-diabetes, which in many cases will end up resulting in diabetes. DexCom, which makes continuous glucose monitoring (CGM) devices that help people stay on top of their blood glucose levels, has made for a phenomenal growth investment over the years. In the past decade the company's top line has soared, and the business is now consistently profitable as well. DXCM Revenue (Annual) data by YCharts The company's future looks bright as DexCom is always coming out with newer, smaller devices to help make monitoring glucose levels easier than before. Late last year, the Food and Drug Administration approved the company's G7 device for use in all types of diabetes, for anyone two years of age and older. The new device is 60% smaller than the previous iteration, and DexCom calls it \""the most accurate CGM cleared by the FDA.\"" Investing $40,000 into the stock a decade ago would have been enough to get your investment to over $1 million today. It was a much riskier stock back then; in 2012, DexCom was coming off a year when sales were $100 million, and its net loss of $54.5 million was more than half of its top line. Today, DexCom is a much safer investment, and while it may not produce the same kinds of returns over the next decade, this is still a great stock to buy and hold, given the ongoing need to manage diabetes. 2. Tesla Tesla's performance over the past decade has been even more impressive than DexCom's. Investing $40,000 into the electric vehicle maker's stock would have resulted in your portfolio being worth $2.7 million today. In 2012, Tesla's revenue of $413 million had more than doubled the previous year's tally, but the problem was that the company was deeply unprofitable, with its net loss of $396 million that year being nearly as high as its revenue. Now, however, Tesla is a top company and is included within the S&P 500. Last year, it generated $81.5 billion in revenue and earned a profit of $12.6 billion, for a net margin of 15%. The company can afford to cut prices as it has done multiple times this year in order to help generate more demand. Tesla has established itself as a leading company in the electric vehicle market, and globally that industry should grow at an annualized rate of about 24% through 2028, according to estimates from Fortune Business Insights. Concerns about climate change and the need for more environmentally friendly cars are reasons why Tesla can continue to be a great growth stock in the future. Like DexCom, it may no longer be able to replicate the gains of the past decade, but it can still be a good buy. There is some risk, however, given the growing number of competitors entering the lucrative EV space, and there is also the possibility that developing fully autonomous vehicles may end up being a pipe dream. But if you're comfortable with those risks, this can still be a good buy right now, especially with the stock down 50% from its 52-week high. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 8, 2023 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust fourth-quarter 2022 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, stiff competition and reimbursement risks persist. So far this year, this Zacks Rank #3 (Hold) stock has gained 1.4% compared with a 2.3% increase of the industry and a 7.5% rise of the S&P 500. This renowned medical-devices company and provider of continuous glucose monitoring (CGM) systems has a market capitalization of $44.45 billion. The company projects 39% growth for the next five years and expects to maintain its strong performance. DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed the same in one and matched estimates in one, delivering an earnings surprise of 2.86%, on average. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available to international markets. The company received FDA clearance for G7 sensor technology in December 2022. These developments are likely to support the company\u2019s future growth. The company also launched the easy-to-use Dexcom ONE real-time CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin in 2022. DexCom\u2019s prospects in alternative markets, such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Positive Coverages: DexCom's products have been receiving increasing coverage over the past few months, raising our optimism. The company, in June 2022, announced that people with type 1 and type 2 diabetes aged two years and above on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island\u2019s Diabetes Glucose Sensor Program.DexCom ended the fourth quarter with new patient additions. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario\u2019s Assistive Devices Program. This program is for people with type 1 diabetes living in the province who are above the age of two years and meet coverage criteria in March. Strong Q4 Results: DexCom\u2019s solid fourth-quarter 2022 revenues buoy optimism. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment and domestic and international revenue growth were key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. Downsides Rising Costs: DexCom's gross margin contracted 130 basis points during the fourth quarter to 66.4%, reflecting the rising cost of sales. The company expects adjusted gross margin to be 62-63%, reflecting cost pressure to continue. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. DexCom\u2019s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems currently. Estimate Trend DexCom is witnessing an upward estimate revision trend for 2023 and 2024. In the past 30 days, the Zacks Consensus Estimate for its earnings gained 1 cent for 2023 and 2024 to $1.07 per share and $1.45 per share, respectively. The Zacks Consensus Estimate for the company\u2019s first-quarter 2023 revenues is pegged at $719.9 million, suggesting a 14.5% improvement from the year-ago quarter\u2019s reported number. The same for earnings per share is pegged at 15 cents, implying 87.5% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are Becton, Dickinson and Company BDX, Henry Schein HSIC and The Cooper Companies COO. Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. So far this year, BDX\u2019s shares have lost 0.2% against the industry\u2019s 8% growth. Henry Schein, sporting a Zacks Rank #1 at present, has an estimated long-term growth of 18.3%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average beat being 2.97%. So far this year, the HSIC\u2019s shares have gained 2.8% compared with the industry\u2019s 8% growth. The Cooper Companies, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 11%. The company\u2019s earnings missed estimates in each of the trailing four quarters, the average negative surprise being 1.82%. So far this year, the COO\u2019s shares have gained 12.7% compared with the industry\u2019s 8% growth. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-14,115.68,116.46,114.13,115.7,
DXCM,2023-04-17,117.91,120.215,117.69,118.65,"[""Notable Monday Option Activity: DXCM, TWLO, WIX Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DexCom Inc (Symbol: DXCM), where a total of 7,220 contracts have traded so far, representing approximately 722,000 underlying shares. That amounts to about 43.9% of DXCM's average daily trading volume over the past month of 1.6 million shares. Particularly high volume was seen for the $125 strike call option expiring April 21, 2023, with 2,128 contracts trading so far today, representing approximately 212,800 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $125 strike highlighted in orange: Twilio Inc (Symbol: TWLO) saw options trading volume of 14,134 contracts, representing approximately 1.4 million underlying shares or approximately 43.7% of TWLO's average daily trading volume over the past month, of 3.2 million shares. Particularly high volume was seen for the $61 strike call option expiring April 21, 2023, with 2,500 contracts trading so far today, representing approximately 250,000 underlying shares of TWLO. Below is a chart showing TWLO's trailing twelve month trading history, with the $61 strike highlighted in orange: And Wix.com Ltd. (Symbol: WIX) saw options trading volume of 2,539 contracts, representing approximately 253,900 underlying shares or approximately 43.2% of WIX's average daily trading volume over the past month, of 588,310 shares. Particularly high volume was seen for the $50 strike put option expiring July 21, 2023, with 2,000 contracts trading so far today, representing approximately 200,000 underlying shares of WIX. Below is a chart showing WIX's trailing twelve month trading history, with the $50 strike highlighted in orange: For the various different available expirations for DXCM options, TWLO options, or WIX options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Construction Dividend Stocks \u0095 BRID Split History \u0095 PSCI Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Healthcare Innovation Drives Medical Device Makers To New Highs The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector peer DexCom Inc. (NASDAQ: DXCM) is forming a constructive base. All three of those stocks are large caps, and all are part of the S&P 500 healthcare sector, tracked by the Health Care Select Sector SPDR Fund (NYSEARCA: XLV). In an April 14 report, researcher FactSet said the healthcare sector is among those with the highest percentages of companies reporting earnings above estimates. Although sector earnings are declining versus last year\u2019s first quarter, Wall Street still likes companies that exceed views. As a whole, the healthcare sector has a lot going for it, even as it goes through the normal market ebbs and flows. It\u2019s a non-cyclical sector, meaning its services are in demand regardless of the market or economic conditions. In a March article, Morgan Stanley\u2019s James Ferraioli underscored broad sector strength. Drilling down to medical devices, he wrote, \u201cIncreasingly sophisticated and connected medical devices are driving improvements in convenience and care. For example, wire-free adhesive heart monitors can now capture cardiac data and transmit it to a patient\u2019s doctor, and pacemakers can relay data wirelessly to a patient\u2019s smartphone.\u201d Here\u2019s a look at three large-cap healthcare growers. Stryker If you\u2019ve been to a medical office or hospital anytime recently, you\u2019ve undoubtedly seen some Stryker gear, even if the brand name didn\u2019t register. This is a company that\u2019s been around seemingly forever. Stryker, whose market capitalization is $110.14 billion, counts joint replacements, surgical equipment, and medical imaging systems among its most important products. Earnings growth has bounced back in the past two years, following a decline in 2020 as hospitals curtailed elective procedures. You can track Stryker\u2019s sales and net income growth using MarketBeat\u2019s earnings data for the stock. Analysts have a \u201cmoderate buy\u201d rating on the stock, with a consensus price target of $277.45, a 4.60% downside. With earnings coming up on May 1, it wouldn\u2019t be surprising to see analysts keep existing price targets in place for the moment. The stock cleared a handle buy point above $280.52 on March 31 and has been in rally mode since then, traveling higher along its 50-day moving average. It\u2019s still in buy range, having risen 3.7% above that point, but investors should use caution ahead of an earnings report, which has the potential to send a stock sharply in either direction. Boston Scientific Like other medical gear makers, Boston Scientific saw an earnings decline in 2020, but growth resumed in the past two years. Analysts expect earnings to increase by 6% this year, and by another 19% in 2024. The company has been pursuing a strategy of growth through acquisition. That\u2019s not uncommon in the medical field, where smaller companies develop treatments that are later acquired by larger firms. Among Boston Scientific\u2019s key products are devices for cardiology, urology, and endoscopy. Its cardiology products include implantable defibrillators and pacemakers, while its urology products include devices for the treatment of urinary incontinence and kidney stones. Its endoscopy products include diagnostic and treatment devices used in the gastrointestinal tract. The Boston Scientific chart shows a series of consolidations and breakouts in the past year, leading to a one-year return of 15.91%. In the past three months, shares rallied 10.68%. The company reports first-quarter results on April 26, before the opening bell, with Wall Street eyeing earnings of $0.43 per share on revenue of $3.16 billion. Those would be increases on both the top and bottom lines, as you can see using MarketBeat\u2019s earnings data. Analysts\u2019 consensus rating is \u201cbuy,\u201d with a price target of $52.18, an upside of 1.31%. Now that we are in the thick of earnings season, consider very carefully any buy ahead of a report that could move the stock significantly. If it rockets higher after the report, that\u2019s a buy signal, as it generally indicates more upside will follow. DexCom DexCom is a medical device company that specializes in continuous glucose monitoring systems for patients with diabetes. Its most important products are its G6 and G7 continuous glucose monitoring systems, which provide real-time readings and alerts to help people manage their diabetes. The ability for patients to continuously monitor glucose levels is an advancement over the old-fashioned finger sticks, which are a hassle and only provide a snapshot. In addition, DexCom's systems provide real-time alerts and trend data, allowing patients to better manage their condition and reduce the risk of glucose fluctuations. A look at DexCom\u2019s chart reveals a first-stage base that\u2019s been forming since December. The current base undercut prior structure lows. That can be bullish, as it often sets the stock up for bigger gains as investors scoop up more shares at a lower valuation. MarketBeat\u2019s analyst data for DexCom show a \u201cmoderate buy\u201d rating on the stock, with a price target of $124.06, an upside of 7.24%. The current buy point is above $125.55, but as with Stryker and Boston Scientific, it\u2019s very likely that analysts are not updating their targets ahead of DexCom\u2019s April 27 quarterly report. Wall Street expects earnings of $0.15 a share on revenue of $730.24 million. In a research note last year, Bank of America outlined its bullish case for DexCom. \u201cDXCM has durable revenue growth (annuity business model) and is recession resilient,\u201d analysts wrote. They added that they see longer-term potential in the non-invasive Type 2 diabetes patient population and other non-core markets that could significantly increase market opportunity. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-18,119.84,119.84,117.93,118.93,"[""Guru Fundamental Report for DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Factor-Based Stock Portfolios Factor-Based ETF Portfolios Harry Browne Permanent Portfolio Ray Dalio All Weather Portfolio About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BTIG Maintains DexCom (DXCM) Buy Recommendation Fintel reports that on April 17, 2023, BTIG maintained coverage of DexCom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 14.53% Upside As of April 6, 2023, the average one-year price target for DexCom is $135.87. The forecasts range from a low of $111.10 to a high of $157.50. The average price target represents an increase of 14.53% from its latest reported closing price of $118.63. See our leaderboard of companies with the largest price target upside. The projected annual revenue for DexCom is $3,546MM, an increase of 21.86%. The projected annual non-GAAP EPS is $1.10. What are Other Shareholders Doing? JHML - John Hancock Multifactor Large Cap ETF holds 6K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 6K shares, representing an increase of 0.69%. The firm decreased its portfolio allocation in DXCM by 16.37% over the last quarter. Profunds - Profund Vp Health Care holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 1.29%. The firm increased its portfolio allocation in DXCM by 26.89% over the last quarter. Ithaka Group holds 299K shares representing 0.08% ownership of the company. In it's prior filing, the firm reported owning 168K shares, representing an increase of 43.90%. The firm decreased its portfolio allocation in DXCM by 99.87% over the last quarter. TAP Consulting holds 3K shares representing 0.00% ownership of the company. No change in the last quarter. Orin Green Financial holds 5K shares representing 0.00% ownership of the company. No change in the last quarter. What is the Fund Sentiment? There are 1885 funds or institutions reporting positions in DexCom. This is an increase of 124 owner(s) or 7.04% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.48%, an increase of 18.69%. Total shares owned by institutions increased in the last three months by 0.59% to 443,799K shares. The put/call ratio of DXCM is 1.01, indicating a bearish outlook. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all DexCom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Raymond James Upgrades DexCom (DXCM) Fintel reports that on April 17, 2023, Raymond James upgraded their outlook for DexCom (NASDAQ:DXCM) from Outperform to Strong Buy . Analyst Price Forecast Suggests 14.53% Upside As of April 6, 2023, the average one-year price target for DexCom is $135.87. The forecasts range from a low of $111.10 to a high of $157.50. The average price target represents an increase of 14.53% from its latest reported closing price of $118.63. See our leaderboard of companies with the largest price target upside. The projected annual revenue for DexCom is $3,546MM, an increase of 21.86%. The projected annual non-GAAP EPS is $1.10. What are Other Shareholders Doing? Schechter Investment Advisors holds 6K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 4K shares, representing an increase of 35.54%. The firm increased its portfolio allocation in DXCM by 102.01% over the last quarter. PFPPX - MidCap Growth Fund R-3 holds 51K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 23K shares, representing an increase of 54.89%. The firm increased its portfolio allocation in DXCM by 97.21% over the last quarter. AVPUX - Vp Ultra Fund Class I holds 22K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 16K shares, representing an increase of 25.62%. The firm increased its portfolio allocation in DXCM by 96.30% over the last quarter. Seven Eight Capital holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 4K shares, representing a decrease of 42.65%. The firm decreased its portfolio allocation in DXCM by 99.85% over the last quarter. INDEX - S&P 500(R) Equal Weight No Load Shares holds 2K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing a decrease of 18.20%. The firm decreased its portfolio allocation in DXCM by 6.58% over the last quarter. What is the Fund Sentiment? There are 1885 funds or institutions reporting positions in DexCom. This is an increase of 124 owner(s) or 7.04% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.48%, an increase of 18.69%. Total shares owned by institutions increased in the last three months by 0.59% to 443,799K shares. The put/call ratio of DXCM is 1.01, indicating a bearish outlook. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all DexCom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-19,118.77,124.2,118.67,124.12,"[""Diversified Abbott Laboratories Could Reverse And Move Higher It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. What is surprising is that Abbott Laboratories' device growth is enough to drive a double-digit gain in organic sales. That\u2019s enough to offset the sudden decline in COVID-related sales and keep the guidance unchanged. This is excellent news for investors, and the stock is set up for a reversal. Another catalyst, such as an improvement in analysts' sentiment or price target, is all this market needs to move higher. \""Our first-quarter results reflect a very strong start to the year,\"" said Robert B. Ford, chairman and chief executive officer. \""Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition.\"" As it is, the analysts rate this stock a Moderate Buy with about 17% of upside potential. The bad news is that sentiment has softened over the last year, and the price target trended lower, but that trend may be over. Marketbeat.com hasn\u2019t tracked any new commentary yet, but the latest, issued days before the report, includes 1 price target increase and 1 decrease in line with the broad consensus. Assuming the analysts like the cast of Abbott\u2019s Q1 results and outlook, this should signal a bottom in sentiment, if not a rebound. Abbott Laboratories Has Solid Quarter And Reaffirms Guidance. Abbott Laboratories had a solid quarter despite the 18.5% decline in headline revenue. The revenue fell because of a 49% decline in the Diagnostics segment, primarily because of COVID. The revenue beat the consensus because of a 10% increase in organic sales driven by a 3.8% gain in Nutrition, a 3.7% gain in Established Pharmaceuticals and an 8.5% gain in Medical Devices. Sales were most robust in the US due to last year\u2019s recall of baby formula and the exiting of the pediatric business in China. The company\u2019s margin contracted because of deleveraging related to windfall sales of COVID products but not as much as expected. The top-line strength carried through to the bottom line but was offset slightly to produce $1.03 in adjusted EPS or 510 bps better than expected compared to 620. The takeaway is that earnings outpaced the consensus and led the company to reiterate its guidance for the year. The guidance expects $4.30 in adjusted EPS at the low end of the range, which compares well with the $4.39 consensus. The top end of $4.50 provides some room for outperformance, and both are sufficient to cover the dividend and repurchase shares. Abbott Laboratories Is A King Of Dividend Payers Abbott Laboratories reached Dividend King status 2 years ago and is on track to keep increasing payout for the next few years at least. The stock is yielding about 1.95%, which is better than the S&P 500 average and comes with a better track record of payments. The payout ratio is low at 50% of earnings, and the balance sheet is well-managed. Investors should expect the pace of increases to slow from the current double-digit pace to a slower one, but not for them to cease. The chart is favorable and shows a double-bottom at the $97.50 level. The Q1 release has the stock up more than 3.5% in premarket action and is on track to test resistance at the baseline of the pattern. The baseline is near $115; if crossed, the market could move much higher. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Are Medical Stocks Lagging DexCom (DXCM) This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has DexCom (DXCM) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. DexCom is a member of the Medical sector. This group includes 1150 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 1.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Our latest available data shows that DXCM has returned about 5% since the start of the calendar year. At the same time, Medical stocks have lost an average of 0.9%. This means that DexCom is performing better than its sector in terms of year-to-date returns. Another Medical stock, which has outperformed the sector so far this year, is Lantheus Holdings (LNTH). The stock has returned 78.2% year-to-date. Over the past three months, Lantheus Holdings' consensus EPS estimate for the current year has increased 15.1%. The stock currently has a Zacks Rank #1 (Strong Buy). Breaking things down more, DexCom is a member of the Medical - Instruments industry, which includes 94 individual companies and currently sits at #102 in the Zacks Industry Rank. This group has gained an average of 3.7% so far this year, so DXCM is performing better in this area. In contrast, Lantheus Holdings falls under the Medical - Products industry. Currently, this industry has 101 stocks and is ranked #153. Since the beginning of the year, the industry has moved +2.9%. Investors with an interest in Medical stocks should continue to track DexCom and Lantheus Holdings. These stocks will be looking to continue their solid performance. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-20,123.59,125.315,121.95,122.19,"Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows Thus far this year, small-cap stocks and large-cap tech have stolen the show – for differing reasons. Small caps, represented by the Russell 2000 Index ETF (IWM), have garnered attention due to their relative weakness. The demise of Silicon Valley Bank has thrown doubt at many stocks that make up the SPDR S&P Regional Banking ETF (KRE), which in turn makes up a large part of the IWM. Conversely, big-cap tech, and the Nasdaq 100 ETF (QQQ),have made an impact for the opposite reason. QQQ is up nearly 20% while underlying components such as Nvidia (NVDA) are higher by a whopping 91% or more. Image Source: Zacks Investment Research One common phenomenon in the stock market is industry group rotation, which refers to the shifting of investor preferences from one industry to another. Though the trends mentioned above show little signs of slowing, they will eventually diverge from the trend and other industries will take the limelight. Investors should be prepared should that happen. Even if it does not happen right away, it also makes sense to diversify. Today we will discuss 3 industries (and stocks within them) worth watching: Solar Energy The clean energy sector has been on a growth trajectory for years as geopolitical conflicts have disrupted the supply of fossil fuels, world governments push for clean energy agendas, and solar technology improves and becomes more efficient. The Invesco Solar ETF (TAN) is normally the best proxy for the group; however, it has moved sideways for months. As such, investors should stick to the group’s leading stock which is Zacks Rank #2 (Buy) stock First Solar (FSLR). FSLR is currently set up in a good-looking base structure ahead of its earnings which are due April 27th. Image Source: Zacks Investment Research Medical Products The medical products industry often flies under the radar. However, the group has some attractive characteristics that make it worth investing in. Generally, companies within this group tend to be recession-proof, stable, and offer long-term growth. Wednesday, surgical robotics maker Intuitive Surgical (ISRG) injected life into the industry after it beat earnings expectations. The stock shot higher by more than 10% in the session on expanding volume. Though the stock is extended in price at this juncture, investors may want to turn their attention to glucose monitoring system maker Dexcom (DXCM). DXCM is breaking out of a multi-month base ahead of its April 27th EPS report. For those who prefer more diversification, iShares US Med Device ETF (IHI) isan ETF proxy for the industry. Image Source: Zacks Investment Research Enterprise Software It’s easy to see why the Internet-Software group is a top 25% group. Whenever I see multiple stocks in an industry breaking out simultaneously, my eyes light up. It is difficult to find an industry with more momentum than the enterprise software group. Enterprise software companies Samsara (IOT) and Asure Software (ASUR) each broke out last week and are up 15% since. Now, Fastly (FSLY), a top performer this year, is giving investors another chance to jump onboard as shares into the 50-day moving average. Image Source: Zacks Investment Research Bottom Line Markets have been known to have periods of “nasty” industry group rotations, catching investors off guard. Investors should look at the three under-the-radar groups above as ways of diversifying into other parts of the market. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with ""black gold."" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report First Solar, Inc. (FSLR) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports Asure Software Inc (ASUR) : Free Stock Analysis Report iShares Russell 2000 ETF (IWM): ETF Research Reports Invesco Solar ETF (TAN): ETF Research Reports SPDR S&P Regional Banking ETF (KRE): ETF Research Reports iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Fastly, Inc. (FSLY) : Free Stock Analysis Report Samsara Inc. (IOT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-21,123.35,125.4,122.33,123.73,
DXCM,2023-04-24,124.68,125.01,123.5,123.83,"[""Sell the News? 5 Reasons Tech May Pullback Let me preface what I will say with this: I do not believe in the idea of calling tops. However, when short-term caution flags arise, I take note and heed the warning the market is sending my way by pulling back exposure. With that in mind, I do not love the action here in tech land. The price action is sluggish, and some yellow and red flags are popping up here ahead of big tech earnings, including: Weakness in Bitcoin: Bitcoin tends to provide \u201crisk on\u201d signals and has been a solid forward-looking indicator for tech. Over the past few months, it has led the Nasdaq in both directions. Could weakness in BTC be foreshadowing weakness in tech? Potential for sell the news type event: Year-to-date, the Nasdaq 100 ETF (QQQ) is up nearly 18%. The index has an open price gap below and has yet to tag its 50-day moving average since breaking out. Image Source: Zacks Investment Research Sentiment: The CNN Fear & Greed Index suggests that bullish sentiment is on the rise. Generally, bulls want to see negative or neutral sentiment so that the market can climb the proverbial \u201cwall of worry\u201d. Healthcare outperformance: When the healthcare sector is strong, it tends to act as a \u201crisk-off\u201d gauge for the general market. While tech has lagged recently, healthcare-related names such as Dexcom (DXCM), Merck (MRK), and Intuitive Surgical (ISRG) have outperformed dramatically. Image Source: Zacks Investment Research Money is moving into beaten-down sectors: At the time of this writing, the Nasdaq is down three-quarters of a percent, while the SPDR S&P Regional Bank ETF (KRE) is flat on the session. Investors may be moving money from extended technology and growth stocks to beaten-down stocks that feel like discounts. Conclusion Though the medium-term trend remains higher in tech, there are some subtle signs beneath the surface suggesting that the space may need a brief pullback. Investors should manage their portfolio exposure accordingly and look to have some fresh powder in the event tech stocks sell off post-earnings this week. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports SPDR S&P Regional Banking ETF (KRE): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead Big Tech Earnings Loom Any way you spin it, this week looks to be a busy week on Wall Street. Equities markets are heading into the heart of earnings season, and big tech names, which have recovered in 2023 and are buoying the general market, are set to report earnings. After the close on Tuesday, Microsoft (MSFT) and Alphabet (GOOGL) are expected to report earnings \u2013 the two companies account for nearly $3.5 trillion in market cap. It doesn\u2019t end there. Later in the week, social media giant Meta Platforms (META) will report Wednesday, and e-commerce king Amazon (AMZN) will report Thursday. Though Amazon\u2019s stock has lagged recently, the stock closed above its 200-day moving average for the first time in more than two months and its price-to-sales ratio is at historic lows. Expect big tech earnings to be a key driver this week. Image Source: Zacks Investment Research Economic Calendar On the economic front, the calendar is as follows: Today: Nothing. Tuesday: S&P Case-Shiller home price index (9 am EST), new home sales (10 am EST), & consumer confidence (10 am EST). Wednesday: Durable-goods orders (8:30 am EST) Thursday: GDP (8:30 am), Jobless claims (8:30 am EST), pending home sales (10:00 am EST). Friday: PCE and Core PCE index (8:30 am EST) There will be no Fed speakers this week as the Federal Reserve remains in a \u201cquiet period\u201d. Beyond the economic calendar, below are 3 things to remember this week. 3 Things to Remember Know when the key market-moving companies and the companies in your portfolio are reporting earnings: The last thing we want to do as investors is get caught flat-footed. On Zacks.com, you can check earnings dates. Image Source: Zacks Investment Research Check the Zacks ESP: The Zacks Earnings ESP (Expected Surprise Prediction) is the closest thing you can get to having earnings \u201ccrystal ball\u201d. The ESP tracks recent earnings revisions. When a stock has a positive ESP score and is ranked a Zacks #3 (Hold) or better, the underlying company tends to beat on earnings 70% of the time and outperforms the market one year forward on average. Image Source: Zacks Investment Research These days, most brokers allow you to also check the magnitude to which a company may move on earnings based on the options market. Some implied moves for earnings this week include: Microsoft (MSFT):4.1% Alphabet (GOOGL): 5.4% Meta (META): 9.1% Amazon (AMZN):7.1% Snap (SNAP): 15.8% Pinterest (PINS): 10% Cloudflare (NET):11.2% First Solar (FSLR): 7.6% Gilead Sciences (GILD): 3.5% Dexcom (DXCM): 9.7% Be Prepared for Anything: At this juncture in 2023, investors should have a plan for the market moving in either direction. For now, the general market is in a clear uptrend, with the Nasdaq 100 ETF (QQQ) higher by 20% year-to-date. Image Source: Zacks Investment Research Nevertheless, such a strong move into earnings for many companies may mean several \u201csell the news\u201d type events may be on the horizon. Also, sentiment is heating up \u2013 the CNN Fear Greed index is at its \u201cgreediest\u201d levels since the beginning of February when the general market was starting a multi-week pullback. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report First Solar, Inc. (FSLR) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report Snap Inc. (SNAP) : Free Stock Analysis Report Pinterest, Inc. (PINS) : Free Stock Analysis Report Cloudflare, Inc. (NET) : Free Stock Analysis Report Meta Platforms, Inc. (META) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Medtech Companies with Higher Future Share Prices The pandemic shook medtech companies, with procedures cut and elective surgeries pushed off until \u201clater.\u201d That later time is here and helping to drive results for several companies. Boston Scientific Corp. (NYSE: BSX), Dexcom Inc. (NASDAQ: DXCM) and Intuitive Surgical Inc. (NASDAQ: ISRG) have all gotten attention from analysts who see normalization and growth in the forecast. Boston Scientific Leads the Group Boston Scientific Corp. leads the group on good news, including results, approvals and acquisitions. The takeaway is that growth is present, acquisitions are boosting growth and new products are coming to market. The latest product approval is for LithoVue Elite, a single-use ureteroscope perfect for diagnosing kidney stones and other ailments. The kidney stone market is worth more than $2 billion, and diagnosis is a large part of the cost. What this means for the BSX stock is a series of upgrades and price target increases that set all-time highs. Boston Scientific got a triple-shot of good news when Raymond James, Truist and BTIG Research raised their price targets on the same day. Their consensus is near $57 compared to the $53 Marketbeat.com consensus, which assumes the stock is fairly valued at current levels. The takeaway is that the price target should increase, and the new targets are well into the all-time high territory. Boston Scientific reports quarter one earnings in late April and should grow revenue and earnings compared to last year. Sold results could extend the trend of price target increases and price action. Dexcom: A Medtech Dynamic Growth Story Raymond James analysts called out Dexcom after reviewing the medtech industry. The review reexamined the impact of COVID-19 on the industry, and Dexcom emerged as a dynamic growth story while also giving the nod to Boston Scientific. In their view, COVID-19 disrupted the natural growth patterns, but those are expected to return. That means 5% to 10% top-bottom line growth, and business is expected to accelerate in the second half of 2023. For Dexcom, which focuses on continuous glucose monitoring for diabetics, it means accelerated adoption of this much-needed and highly-appreciated technology. Dexcom has 13 analysts covering its stock, and they are pushing it higher. The price target is down compared to last year but up compared to last quarter and last month, positively affecting the stock price. The stock price has been trending sideways since mid-2022 but appears well-supported and ready to move higher. The first-quarter earnings report is due at the end of April and may provide the proper catalyst. Intuitive Surgical: Outperformance in the Works? Intuitive Surgical is expected to post a year-over-year gain in revenue and earnings that may underestimate the company by a wide margin. The company has been accelerating its business sequentially for four quarters and shows no signs of slowing down. The largest segment, instruments and accessories, was the primary driver of strength in the last report, and that is expected to continue with the post-COVID increase in procedure volume. Analysts have weighed on the share price over the last year, but that trend changed. The latest commentaries include boosted targets that have helped put a bottom in the stock. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) to Report Q1 Earnings: What's in the Cards? DexCom, Inc. DXCM is scheduled to release first-quarter 2023 results on Apr 27, after the closing bell. In the last reported quarter, the company\u2019s earnings beat estimates by 30.77%. The figure also beat the consensus mark in two of the trailing four quarters, missed once and met the same once, the average negative surprise being 2.86%. Q1 Estimates Currently, the Zacks Consensus Estimate for DexCom\u2019s first-quarter revenues is pegged at $719.9 million, indicating growth of 14.5% from the year-ago reported figure. The same for earnings stands at 15 cents per share, implying an 87.5% improvement from that reported in the prior-year quarter. Factors to Note DexCom\u2019s first-quarter revenues are likely to have been aided by continued increase in volume. This surge can be attributed to new patients across all channels and rising global awareness about the benefits of its real-time Continuous Glucose Monitoring (\u201cCGM\u201d). Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to be the key catalysts for the company\u2019s first-quarter results. In 2022, DexCom continued expanding access and accelerating its leadership in CGM-connected solutions and customer choice. The company continues to launch the Dexcom ONE product in new countries. These developments are expected to have benefited customer growth in the soon-to-be-reported quarter. In December 2022, DXCM received the FDA\u2019s approval for the Dexcom G7 CGM system\u2019s use in people with any type of diabetes, aged two years and older. The company also secured the CE mark for the abovementioned system for monitoring diabetic patients aged two years and older, and initiated a limited launch of same in Europe in late 2022. DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote DexCom expanded coverage for its CGM system in Ontario, Canada, to include type 1 diabetes. Moreover, in January, Non-Insured Health Benefits Program extended its coverage for Dexcom G6 to include all clients with type I diabetes in British Columbia. These developments must have favored the company\u2019s performance in the to-be-reported quarter. DXCM has been benefiting from demographic trends and lifestyles in countries outside Europe and the United States. Per the company, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In the fourth quarter of 2022, International revenues (26% of total revenues) surged 15% year over year to $208.8 million. Organically, the segment\u2019s revenues were up 27% in the last reported quarter. U.S. revenues (74% of total revenues) increased 17% in the same period. The trend is likely to have continued in the first quarter of 2023, owing to broad-based growth. The Zacks Consensus Estimate for U.S. and International revenues is pegged at $515 million and $205 million, respectively, for the first quarter. However, an increase in operating expenses and intense competition might have weighed on the company\u2019s performance in the quarter. What Our Quantitative Model Suggests Our proven model does not conclusively predict an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that's not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Earnings ESP: DexCom\u2019s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. Zacks Rank: DexCom carries a Zacks Rank #2 at present. Stocks Worth a Look Here are a few medical stocks worth considering as these have the right combination of elements to come up with an earnings beat this reporting cycle: Henry Schein HSIC has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. HSIC has an estimated long-term growth rate of 8.1%. Henry Schein\u2019s earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%. BioRad Laboratories BIO has an Earnings ESP of +0.16% and a Zacks Rank of 2 at present. BIO has an earnings yield of 3.3%, which compares favorably with the industry\u2019s negative yield of 2.9%. BioRad Laboratories\u2019 earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 27.54%. McKesson MCK has an Earnings ESP of +1.22% and a Zacks Rank #3 at present. MCK has an estimated long-term growth rate of 10.4%. McKesson\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.42%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-25,123.0,125.098,123.0,123.96,"[""2 Monster Stocks to Buy Without Any Hesitation Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM) have characteristics in common that, in my view, make them monster stocks to buy without hesitation. Over the past five years, each healthcare company has shown strong growth in revenue and earnings per share (EPS). Not coincidentally, both companies' shares are up this year, and up by triple-digit percentages over the past five years. Both companies also have major tailwinds that should help drive revenue for years. For Lilly, it's the potential in weight-loss drug Mounjaro and Alzheimer's therapy donanemab. For DexCom, profits will be driven by the trend toward greater numbers of diabetes patients and their need for continuous glucose monitoring devices (CGMs). Eli Lilly's Mounjaro could become the top-selling drug Eli Lilly has grown steadily, but it has a handful of therapies in the works that could supercharge the company's earnings. Over the past five years, Lilly has seen annual EPS climb by nearly 33% while annual revenue jumped by over 120%. So far this year, Lilly's shares are up a little more than 5%, but over the past five years, they're up by 387%. Last year, annual EPS was $6.90, up 13%, with revenue climbing only 1% to $28.5 billion. The company said it expects EPS to rise to between $7.90 and $8.10 in 2023. The real payoff, though, is on the horizon. The company's drug Mounjaro (tirzepatide) has the potential to be the world's top-selling drug -- replacing Humira, the immunology blockbuster from AbbVie. Mounjaro could be worth $25 billion annually in sales, analysts have said. Mounjaro, approved to treat type 2 diabetes, is already experiencing rising sales, possibly because it's being prescribed off-label to treat obesity. Since the drug launched last June, it did $279.2 million in sales in less than six months. It's expected to be approved by the Food and Drug Administration (FDA) to treat obesity sometime this year. Lilly's study on obese patients without diabetes showed that the highest dose (15 milligrams) could reduce a person's body weight by 22.5%, an improvement of 5% over the top-selling weight-loss drugs. If Lilly's lead Alzheimer's therapy, donanemab, is approved by the FDA, it could also be a blockbuster. Derek Asay, Lilly's senior vice president of government strategy and federal accounts, told Reuters that he expects the U.S. Centers for Medicare & Medicaid Services (CMS) to expand payment for Alzheimer's therapies beyond just those patients who are in clinical trials. Analysts have said the therapy could be worth $12 billion in annual sales. LLY Revenue (Annual) data by YCharts. The FDA rejected an accelerated approval application for donanemab, which is designed to remove amyloid plaques in the brain that are associated with Alzheimer's. But the drug is in phase 3 trials to treat patients with early Alzheimer's symptoms, and data from one of the trials is expected sometime in the second quarter. The company also has another Alzheimer's drug, remternetug, which is in a phase 3 trial. One advantage for Lilly's investors is the stock's quarterly dividend of $1.13 per share. The company has increased the dividend for nine consecutive years, including a 15% bump over the past five years. The yield is currently around 1.2%. DexCom focuses on diabetes care DexCom does one thing and does it well: developing, manufacturing, and selling continuous glucose monitoring (CGM) systems for diabetes care. The company's newest CGM systems, the DexCom G6 and G7, are compatible with most cellphones. And unlike traditional glucose readers, they don't require users to prick their fingers to draw blood for readings, because the system sensors are inserted under the skin to measure glucose levels continuously. There's plenty of competition in the CGM space, but the number of people with diabetes continues to grow, thanks to an aging population, and less-healthy diets and lifestyle choices. According to a study by Grand View Research, the market for CGMs will be around $8.3 billion in 2023; with a compound annual growth rate of 4.4%, it's expected to be worth $11.2 billion in 2023. The key for DexCom's growth is that it's somewhat noncyclical and recession-proof. People use CGMs because they have to. DXCM Revenue (Annual) data by YCharts. DexCom reported 2022 revenue of $2.9 billion, up 19%. Guidance puts 2023 revenue between $3.35 billion and $3.49 billion. Net income was $341.2 million in 2022, up 57%, and EPS for 2022 was $0.82, up 55%. Over the past five years, DexCom's revenue has climbed 97% and EPS has grown by 198%. The stock is up more than 9% this year and more than 329% over the past five years. The company launched its newest CGM device, the Dexcom G7, in February. On April 17, the device was approved for Medicare coverage; Dexcom said this will add 1.5 million more potential customers. 10 stocks we like better than Eli Lilly When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Eli Lilly wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 21, 2023 Jim Halley has positions in AbbVie. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Zacks Investment Ideas feature highlights: Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF For Immediate Release Chicago, IL \u2013 April 25, 2023 \u2013 Today, Zacks Investment Ideas feature highlights Nasdaq 100 ETF QQQ, Dexcom DXCM, Merck MRK, Intuitive Surgical ISRG and SPDR S&P Regional Bank ETF KRE. Sell the News? 5 Reasons Tech May Pull Back Let me preface what I will say with this: I do not believe in the idea of calling tops. However, when short-term caution flags arise, I take note and heed the warning the market is sending my way by pulling back exposure. With that in mind, I do not love the action here in tech land. The price action is sluggish, and some yellow and red flags are popping up here ahead of big tech earnings, including: Weakness in Bitcoin: Bitcoin tends to provide \u201crisk on\u201d signals and has been a solid forward-looking indicator for tech. Over the past few months, it has led the Nasdaq in both directions. Could weakness in BTC be foreshadowing weakness in tech? Potential for sell the news type event: Year-to-date, the Nasdaq 100 ETF is up nearly 18%. The index has an open price gap below and has yet to tag its 50-day moving average since breaking out. Sentiment: The CNN Fear & Greed Index suggests that bullish sentiment is on the rise. Generally, bulls want to see negative or neutral sentiment so that the market can climb the proverbial \u201cwall of worry.\u201d Healthcare outperformance: When the healthcare sector is strong, it tends to act as a \u201crisk-off\u201d gauge for the general market. While tech has lagged recently, healthcare-related names such as Dexcom, Merck and Intuitive Surgical have outperformed dramatically. Money is moving into beaten-down sectors: At the time of this writing, the Nasdaq is down three-quarters of a percent, while the SPDR S&P Regional Bank ETF is flat on the session. Investors may be moving money from extended technology and growth stocks to beaten-down stocks that feel like discounts. Conclusion Though the medium-term trend remains higher in tech, there are some subtle signs beneath the surface suggesting that the space may need a brief pullback. Investors should manage their portfolio exposure accordingly and look to have some fresh powder in the event tech stocks sell off post-earnings this week. Why Haven\u2019t You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports SPDR S&P Regional Banking ETF (KRE): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-26,123.0,125.18,122.919,124.93,"Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings) Economic Concerns Remain Despite Market Recovery Though equities markets have recovered thus far in 2023, many economic and macro concerns remain. Geopolitically speaking, the war in Ukraine persists with no end in sight (and potential escalations elsewhere, like Taiwan). Inflation has slowed; however, there are some signs that it may rear its ugly head again. Used car prices, which are often looked at as a leading indicator for inflation, began moving up again in March for the first time in seven months. Unforeseen Rate Hiking Problems Meanwhile, the Federal Reserve’s rate-hiking crusade against inflation has caused unanticipated problems in the regional banking sector. The SPDR Regional Bank ETF (KRE) has been under immense pressure. Silicon Valley Bank has already gone bust, and fellow regional bank First Republic Bank (FRC) is on the tipping point – down more than 90% year-to-date, with the deposits dropping rapidly. Image Source: Zacks Investment Research Technology is the Leader but is Extended Conversely, technology and the Nasdaq 100 ETF (QQQ) have been on a tear. Mega-cap tech stocks such as Apple (AAPL), Microsoft (MSFT), and Nvidia (NVDA) have been on a tear. So far this year, NVDA is up a mind-blowing 85%! Image Source: Zacks Investment Research That said, many stocks, such as Apple and Microsoft, have yet to tag their 50-day moving averages since breaking out earlier in the year. Image Source: Zacks Investment Research The 50-day tends to act similar to a rubber band. When stocks get stretched too far in one direction, they tend to snap back in the other direction. Couple that with the fact that we are heading into the historically weak period of May, and investors overleveraged in tech stocks may be in for some pain. In pre-election years, like the one we are in now, May tends to be the second weakest month of the year. Where to Hide? Like anything in the stock market, a tech pullback is not a foregone conclusion. However, investors will be best served to diversify their portfolios so that they can withstand any potential volatility in the market. Due to the regional banking crisis, many banking and small cap stocks are vulnerable. Meanwhile, investors likely do not want to chase tech here. An Essential Sector One intriguing avenue to take is to look at the healthcare sector. The most basic needs of human beings are food, water, shelter, and healthcare. Healthcare is a sector that has stood the test of time and will undoubtedly continue to into the future. Below are some reasons healthcare companies tend to do well in any economy: Healthcare is a necessity: As I mentioned above, healthcare is a non-negotiable. If you are sick, you will seek healthcare. Defensive sector: Because healthcare is a necessity, savvy investors understand they can rely on healthcare stocks for steady and stable growth. Unlike other sectors, healthcare stocks will fluctuate less based on the overall economy. An Aging Population: As the “baby boomer” generation ages, demand for healthcare services will inevitably increase, leading to a surge in healthcare expenditures. Stocks to Watch Merck (MRK) has one of the deepest pipelines in the biotech space. The company boasts more than six blockbuster drugs, including Keytruda, which is approved for treating several types of cancer. Through its in-house pipeline and strategic acquisitions over the years, the company has one of the best growth track records of any company in the market, let alone the healthcare sector. Below is a chart of the company’s EPS growth going back to the 90s. Image Source: Zacks Investment Research Beyond its impressive pipeline and earnings track record, MRK has an immaculate balance sheet. The company has over $13 billion in cash on hand and only $1.9 billion in short-term debt. MRK will report earnings Thursday. DexCom (DXCM) develops continuous glucose monitoring systems for diabetes patients. As the number of diabetes patients in the United States and around the world continues to grow, DXCM should be a primary beneficiary. DXCM is setting up in an attractive price pattern and is attempting to break out ahead of its earnings report on Thursday. Image Source: Zacks Investment Research Shockwave Medical (SWAV) is a medical device company that develops products for patients with cardiovascular disease. SWAV is one of the fastest-growing companies in the healthcare space. Last quarter, SWAV grew year-over-year EPS 232% on revenue growth of 71%. Image Source: Zacks Investment Research Other healthcare stocks, such as Intuitive Surgical (ISRG), Medtronics (MDT), and Stryker (SYK), are also very strong – illustrating the immense investor appetite for this sector currently. Conclusion Healthcare stocks are an excellent place to look in the current market environment. The sector tends to do well in almost any economy due to the aging population, the necessity of the space, and the defensive nature of the industry, which is attractive to investors. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report First Republic Bank (FRC) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports SPDR S&P Regional Banking ETF (KRE): ETF Research Reports ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-04-27,125.575,126.44,121.22,123.58,"[""DexCom (DXCM) Q1 Earnings and Revenues Beat Estimates DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.33%. A quarter ago, it was expected that this medical device company would post earnings of $0.26 per share when it actually produced earnings of $0.34, delivering a surprise of 30.77%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $741.5 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 3.01%. This compares to year-ago revenues of $628.8 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have added about 10.3% since the beginning of the year versus the S&P 500's gain of 5.6%. What's Next for DexCom? While DexCom has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.22 on $827.22 million in revenues for the coming quarter and $1.07 on $3.46 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Asensus Surgical (ASXC), another stock in the same industry, has yet to report results for the quarter ended March 2023. This maker of surgical robots and medical instruments is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Asensus Surgical's revenues are expected to be $1.2 million, up 12.2% from the year-ago quarter. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Asensus Surgical, Inc. (ASXC) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Thursday Option Activity: MRK, QLYS, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Merck & Co Inc (Symbol: MRK), where a total of 30,931 contracts have traded so far, representing approximately 3.1 million underlying shares. That amounts to about 50.9% of MRK's average daily trading volume over the past month of 6.1 million shares. Especially high volume was seen for the $115 strike call option expiring May 19, 2023, with 4,167 contracts trading so far today, representing approximately 416,700 underlying shares of MRK. Below is a chart showing MRK's trailing twelve month trading history, with the $115 strike highlighted in orange: Qualys, Inc. (Symbol: QLYS) options are showing a volume of 1,318 contracts thus far today. That number of contracts represents approximately 131,800 underlying shares, working out to a sizeable 50% of QLYS's average daily trading volume over the past month, of 263,380 shares. Particularly high volume was seen for the $125 strike call option expiring May 19, 2023, with 600 contracts trading so far today, representing approximately 60,000 underlying shares of QLYS. Below is a chart showing QLYS's trailing twelve month trading history, with the $125 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 9,055 contracts thus far today. That number of contracts represents approximately 905,500 underlying shares, working out to a sizeable 49.9% of DXCM's average daily trading volume over the past month, of 1.8 million shares. Especially high volume was seen for the $100 strike put option expiring June 16, 2023, with 1,442 contracts trading so far today, representing approximately 144,200 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $100 strike highlighted in orange: For the various different available expirations for MRK options, QLYS options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Funds Holding SPIL \u0095 PSCF Historical Stock Prices \u0095 KRYS market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for April 27, 2023 : AMZN, TMUS, AMGN, INTC, GILD, MDLZ, DXCM, AJG, RSG, SGEN, LHX, COF The following companies are expected to report earnings after hours on 04/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases. Amazon.com, Inc. (AMZN)is reporting for the quarter ending March 31, 2023. The internet company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.21. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AMZN is 76.63 vs. an industry ratio of 5.60, implying that they will have a higher earnings growth than their competitors in the same industry. T-Mobile US, Inc. (TMUS)is reporting for the quarter ending March 31, 2023. The wireless (national) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.51. This value represents a 164.91% increase compared to the same quarter last year. TMUS missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -24.53%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TMUS is 21.34 vs. an industry ratio of 66.10. Amgen Inc. (AMGN)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $3.84. This value represents a 9.65% decrease compared to the same quarter last year. In the past year AMGN has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.24%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AMGN is 13.45 vs. an industry ratio of -2.50, implying that they will have a higher earnings growth than their competitors in the same industry. Intel Corporation (INTC)is reporting for the quarter ending March 31, 2023. The semiconductor company's consensus earnings per share forecast from the 15 analysts that follow the stock is $-0.16. This value represents a 118.39% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for INTC is 52.82 vs. an industry ratio of 26.10, implying that they will have a higher earnings growth than their competitors in the same industry. Gilead Sciences, Inc. (GILD)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.63. This value represents a 23.11% decrease compared to the same quarter last year. In the past year GILD has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 11.33%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GILD is 12.21 vs. an industry ratio of -2.50, implying that they will have a higher earnings growth than their competitors in the same industry. Mondelez International, Inc. (MDLZ)is reporting for the quarter ending March 31, 2023. The food company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.80. This value represents a 4.76% decrease compared to the same quarter last year. In the past year MDLZ has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.82%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MDLZ is 23.04 vs. an industry ratio of 48.80. DexCom, Inc. (DXCM)is reporting for the quarter ending March 31, 2023. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.15. This value represents a 87.50% increase compared to the same quarter last year. DXCM missed the consensus earnings per share in the 1st calendar quarter of 2022 by -38.46%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DXCM is 116.76 vs. an industry ratio of -0.60, implying that they will have a higher earnings growth than their competitors in the same industry. Arthur J. Gallagher & Co. (AJG)is reporting for the quarter ending March 31, 2023. The insurance brokers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.00. This value represents a 6.76% increase compared to the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.67%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AJG is 23.56 vs. an industry ratio of 20.10, implying that they will have a higher earnings growth than their competitors in the same industry. Republic Services, Inc. (RSG)is reporting for the quarter ending March 31, 2023. The waste removal company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.13. This value represents a 0.88% decrease compared to the same quarter last year. In the past year RSG has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 10.78%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for RSG is 26.50 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. Seagen Inc. (SGEN)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $-0.82. This value represents a 10.81% decrease compared to the same quarter last year. SGEN missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -11.96%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SGEN is -68.27 vs. an industry ratio of -2.50. L3Harris Technologies, Inc. (LHX)is reporting for the quarter ending March 31, 2023. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.87. This value represents a 8.01% decrease compared to the same quarter last year. LHX missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -5.23%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LHX is 15.82 vs. an industry ratio of -125.20, implying that they will have a higher earnings growth than their competitors in the same industry. Capital One Financial Corporation (COF)is reporting for the quarter ending March 31, 2023. The financial services company's consensus earnings per share forecast from the 11 analysts that follow the stock is $3.80. This value represents a 32.38% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for COF is 6.59 vs. an industry ratio of 11.40. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Growth Stocks That Could Double in 5 Years As a group, growth stocks had a year to forget in 2022. And even with the market recovery we are experiencing this year, many remain in the red over the past 12 months. But there are always outliers. Some growth stocks have performed just fine recently compared to the broader market. That's true for Vertex Pharmaceuticals (NASDAQ: VRTX) and DexCom (NASDAQ: DXCM) -- and both of these companies are on solid growth paths that could continue to deliver for investors. Let's consider why both healthcare stocks could double in the next five years -- and for those keeping score at home, that amounts to a compound annual growth rate of almost 15%. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotech company best known for its lineup of medicines that treat the underlying causes of cystic fibrosis (CF), a rare genetic disease. While the drugmaker continues to dominate this area, considering it has no competition, Vertex is looking forward to important catalysts in the near and mid-term. First, Vertex is awaiting approval for exa-cel in the U.S. and Europe. Exa-cel is a potential gene editing therapy for sickle cell disease and beta-thalassemia the company developed with CRISPR Therapeutics. Beyond that, Vertex Pharmaceuticals has a pipeline of exciting medicines that it thinks will deliver five brand-new approvals in the next five years. One of the company's most advanced candidates is VX-147, a potential treatment for APOL1-mediated kidney disease. This potential medicine is undergoing a phase 2/3 study. Vertex is also working on a pain treatment called VX-548 that seeks to improve over the existing standard drugs in this area, many of which come with dangerous side effects. For instance, Acetaminophen, sold under the brand name Tylenol in the U.S., is the leading cause of acute liver failure in the country. Various opioids are also used to manage pain, but they too can have severe side effects. VX-548 is undergoing a phase 3 clinical trial. In CF, the biotech is working on medicines that could extend the pool of patients eligible for its drugs. And Vertex is going after other difficult targets, most notably type 1 diabetes. The company's programs in this area, such as VX-880, are still in the early stages of development. But VX-880 could restore patients' ability to produce insulin, something that would make this therapy highly successful if it proves effective in studies. Vertex Pharmaceuticals' revenue and earnings have generally grown at a good clip over the past five years. VRTX Revenue (Quarterly) data by YCharts Given that the company still has room to increase its sales in the CF market, and the regulatory approvals it will earn throughout the next half a decade, expect the biotech to deliver market-beating returns even beyond this period. 2. DexCom DexCom focuses on developing continuous glucose monitoring (CGM) systems for diabetes patients. The company currently generates most of its revenue from the G6, although it has started the launch of its latest device, the G7, in the U.S. and Europe. There are at least three reasons why DexCom has been and will continue to be successful. First, CGM systems are better than blood glucose meters, which can only measure a patient's sugar levels at a specific time using painful fingersticks. CGM systems don't rely on fingersticks, and keep track of people's blood sugar levels throughout the day. Second, DexCom has constantly developed newer and better versions of its G series CGM systems. The latest G7 is smaller than the G6, has a faster warmup period, and blew it out of the park in clinical studies, where it delivered even better outcomes than its predecessor. Within five years, the G7 could become DexCom's primary source of revenue. Third, the worldwide diabetes market is vast. There are 422 million diabetes patients worldwide (most of whom are of the type 2 variety), and the CGM market remains underpenetrated. This massive opportunity could allow DexCom to deliver the kinds of excellent returns it needs for its stock price to double in the next five years. As the company makes solid headway in this market, expect its financial results to continue improving. DexCom may not see its share price soar by 566% again in the next five years as it is now a more mature company, and revenue growth has slowed. DXCM Revenue (Quarterly) data by YCharts But it now generates profits in addition to positive free cash flows. That and the growing top line could allow the company to double in the next half a decade. Find out why Vertex Pharmaceuticals is one of the 10 best stocks to buy now Our analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Vertex Pharmaceuticals is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of April 24, 2023 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-04-28,119.255,122.28,117.6,121.34,"[""Stifel Maintains Dexcom (DXCM) Buy Recommendation Fintel reports that on April 28, 2023, Stifel maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 10.40% Upside As of April 24, 2023, the average one-year price target for Dexcom is 136.43. The forecasts range from a low of 111.10 to a high of $157.50. The average price target represents an increase of 10.40% from its latest reported closing price of 123.58. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1888 funds or institutions reporting positions in Dexcom. This is an increase of 118 owner(s) or 6.67% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.49%, an increase of 15.03%. Total shares owned by institutions increased in the last three months by 0.95% to 441,284K shares. The put/call ratio of DXCM is 1.14, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,303K shares representing 4.46% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm increased its portfolio allocation in DXCM by 35.81% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.00% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase holds 10,647K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.44% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all Dexcom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BTIG Maintains Dexcom (DXCM) Buy Recommendation Fintel reports that on April 28, 2023, BTIG maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 10.40% Upside As of April 24, 2023, the average one-year price target for Dexcom is 136.43. The forecasts range from a low of 111.10 to a high of $157.50. The average price target represents an increase of 10.40% from its latest reported closing price of 123.58. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1888 funds or institutions reporting positions in Dexcom. This is an increase of 118 owner(s) or 6.67% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.49%, an increase of 15.03%. Total shares owned by institutions increased in the last three months by 0.95% to 441,284K shares. The put/call ratio of DXCM is 1.14, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,303K shares representing 4.46% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm increased its portfolio allocation in DXCM by 35.81% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.00% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase holds 10,647K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.44% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all Dexcom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Canaccord Genuity Maintains Dexcom (DXCM) Buy Recommendation Fintel reports that on April 28, 2023, Canaccord Genuity maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 10.40% Upside As of April 24, 2023, the average one-year price target for Dexcom is 136.43. The forecasts range from a low of 111.10 to a high of $157.50. The average price target represents an increase of 10.40% from its latest reported closing price of 123.58. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1887 funds or institutions reporting positions in Dexcom. This is an increase of 112 owner(s) or 6.31% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.49%, an increase of 16.41%. Total shares owned by institutions increased in the last three months by 0.34% to 441,284K shares. The put/call ratio of DXCM is 1.14, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,303K shares representing 4.46% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm increased its portfolio allocation in DXCM by 35.81% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.00% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase holds 10,647K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.44% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all Dexcom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Raymond James Maintains Dexcom (DXCM) Strong Buy Recommendation Fintel reports that on April 28, 2023, Raymond James maintained coverage of Dexcom (NASDAQ:DXCM) with a Strong Buy recommendation. Analyst Price Forecast Suggests 10.40% Upside As of April 24, 2023, the average one-year price target for Dexcom is 136.43. The forecasts range from a low of 111.10 to a high of $157.50. The average price target represents an increase of 10.40% from its latest reported closing price of 123.58. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1887 funds or institutions reporting positions in Dexcom. This is an increase of 112 owner(s) or 6.31% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.49%, an increase of 16.41%. Total shares owned by institutions increased in the last three months by 0.34% to 441,284K shares. The put/call ratio of DXCM is 1.14, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,303K shares representing 4.46% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm increased its portfolio allocation in DXCM by 35.81% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.00% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase holds 10,647K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.44% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all Dexcom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong DexCom, Inc. DXCM reported first-quarter 2023 adjusted earnings per share (EPS) of 17 cents, which beat the Zacks Consensus Estimate of 15 cents by 13.3%. The same for the prior-year quarter was recorded at 7 cents. The company reported GAAP net income per share of 12 cents, declining from the year-ago quarter\u2019s figure of 23 cents. The company\u2019s shares have gained 9.1% so far this year compared with the industry\u2019s growth of 2.7%. The broader S&P 500 Index has moved up 6.1% in the same period. Image Source: Zacks Investment Research Revenue Details Total revenues grew 18% (19% on an organic basis) to $741.5 million on a year-over-year basis and beat the Zacks Consensus Estimate by 3%. Rising volumes across all channels, along with strong new customer additions, owing to increasing global awareness of the benefits of real-time Continuous Glucose Monitoring, contributed to the upside. Segmental Details Sensor and other revenues(88% of total revenues) increased 20% on a year-over-year basis to $651.9 million. Hardware revenues (12%) increased 5% year over year to $89.6 million. Geographical Details U.S. revenues (71% of total revenues) increased 17% on a year-over-year basis to $526 million. International revenues (29%) improved 21% year over year to $215.5 million. Margin Analysis Gross profit totaled $462.6 million, up 16.2% year over year. DexCom reported a gross margin (as a percentage of revenues) of 62.4%, which contracted 90 basis points year over year. Research and development expenses amounted to $119 million in the quarter, down 12.4% year over year. Selling, general and administrative expenses totaled $294.6 million, up 34.6% year over year. The company reported total operating expenses of $415.4 million, up 16.4% from the prior-year figure. Operating margin (as a percentage of revenues) was 6.4%, almost flat year over year. Financial Position The company exited the first quarter with $2.57 billion in cash, cash equivalents and marketable securities compared with $2.46 billion in the preceding quarter. Total assets amounted to $5.52 billion compared with $5.39 billion on a sequential basis. 2023 Guidance DexCom raised its revenue guidance for 2023 but reiterated the earnings outlook. The company now expects revenues in the range of $3.4-$3.515 billion, implying 17-21% year-over-year growth. The Zacks Consensus Estimate for the same stands at $3.46 billion. Previously, DXCM expected revenues in the range of $3.35-$3.49 billion. The company continues to expect an adjusted gross margin of 62-63% and an operating margin of approximately 16.5%. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Wrapping Up DexCom exited first-quarter 2023 on a strong note, wherein both earnings and revenues beat estimates. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Apart from making continued advancements in terms of its key strategic objectives, the company also recorded new patients in the quarter. DXCM launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available to international markets. It received FDA clearance for the same technology in December 2022. These developments are likely to support the company\u2019s future growth. Nevertheless, the contraction in gross margin is a woe, reflecting the rising cost of sales. Cut-throat competition in the market for blood & glucose monitoring devices remains another concern. Zacks Rank and Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Intuitive Surgical ISRG, Chemed CHE and Edwards Lifesciences EW, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Intuitive Surgical reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate of $1.19 per share. Revenues of $1.7 billion outpaced the consensus mark by 6.9%. Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 1.86%. Chemed reported first-quarter 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 0.2%. Revenues of $560 million outpaced the consensus mark by 2.6%. Chemed has a long-term estimated growth rate of 8.8%. CHE\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.12%. Edwards Lifesciences reported first-quarter 2023 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion surpassed the Zacks Consensus Estimate by 4.7%. Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 1.69%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Chemed Corporation (CHE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-05-01,121.34,121.47,117.21,118.44,"Barclays Maintains Dexcom (DXCM) Equal-Weight Recommendation Fintel reports that on May 1, 2023, Barclays maintained coverage of Dexcom (NASDAQ:DXCM) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 12.44% Upside As of April 24, 2023, the average one-year price target for Dexcom is 136.43. The forecasts range from a low of 111.10 to a high of $157.50. The average price target represents an increase of 12.44% from its latest reported closing price of 121.34. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1888 funds or institutions reporting positions in Dexcom. This is an increase of 118 owner(s) or 6.67% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.49%, an increase of 15.03%. Total shares owned by institutions increased in the last three months by 0.95% to 441,284K shares. The put/call ratio of DXCM is 1.14, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,303K shares representing 4.46% ownership of the company. In it's prior filing, the firm reported owning 18,105K shares, representing a decrease of 4.64%. The firm increased its portfolio allocation in DXCM by 35.81% over the last quarter. Sands Capital Management holds 15,514K shares representing 4.00% ownership of the company. In it's prior filing, the firm reported owning 16,693K shares, representing a decrease of 7.60%. The firm increased its portfolio allocation in DXCM by 31.54% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,746K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 11,715K shares, representing an increase of 0.26%. The firm increased its portfolio allocation in DXCM by 30.18% over the last quarter. Jpmorgan Chase holds 10,647K shares representing 2.75% ownership of the company. In it's prior filing, the firm reported owning 10,248K shares, representing an increase of 3.75%. The firm increased its portfolio allocation in DXCM by 34.10% over the last quarter. Capital Research Global Investors holds 9,462K shares representing 2.44% ownership of the company. In it's prior filing, the firm reported owning 10,530K shares, representing a decrease of 11.30%. The firm increased its portfolio allocation in DXCM by 16.21% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. See all Dexcom regulatory filings. This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-02,117.0,118.27,115.01,118.12,"[""Health Care Sector Update for 05/02/2023: VNDA, LLY, SNY, PINC, DXCM Health care stocks were declining late Tuesday afternoon, with the NYSE Health Care Index easing 0.3% and the Health Care Select Sector SPDR Fund (XLV) slipping 0.4%. The iShares Biotechnology ETF (IBB) was decreasing 1.1%. In company news, Vanda Pharmaceuticals (VNDA) said it filed a lawsuit against the US Food and Drug Administration for allegedly providing confidential details related to Hetlioz and Fanapt to generic drug manufacturers during the regulator's review of the latter's abbreviated new drug applications. Vanda shares were down 0.2%. Eli Lilly (LLY) and Sanofi's (SNY) Sanofi-Aventis US agreed to cap their insulin prices at $35 per monthly prescription for uninsured New Yorkers over the next five years, according to a statement from the New York Attorney General's office. Eli Lilly shares were down 0.2% and Sanofi was also down 0.2%. Premier (PINC) shares slumped over 18% after it lowered its fiscal 2023 earnings outlook. Dexcom (DXCM) was down 0.5% after the firm said it's planning to offer $1 billion of convertible notes in a private placement. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Analyst Moves: DXCM The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #24 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. Looking at the stock price movement year to date, DexCom is showing a gain of 2.1%. VIDEO: S&P 500 Analyst Moves: DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Notable ETF Outflow Detected - IWP, DXCM, LULU, FTNT Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $80.9 million dollar outflow -- that's a 0.7% decrease week over week (from 134,800,000 to 133,900,000). Among the largest underlying components of IWP, in trading today DexCom Inc (Symbol: DXCM) is off about 1.5%, lululemon athletica inc (Symbol: LULU) is down about 0.5%, and Fortinet Inc (Symbol: FTNT) is lower by about 1.9%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $74.75 per share, with $95.11 as the 52 week high point \u2014 that compares with a last trade of $88.34. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb Also see: \u0095 Stock Splits \u0095 MCAF market cap history \u0095 Institutional Holders of CLOU The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is Dexcom a Good Stock to Buy Now? If you're a long-term Dexcom (NASDAQ: DXCM) shareholder, congratulations. A $1,000 bet placed on this developer of blood sugar monitoring devices a decade ago is worth nearly $30,000 today. Sadly, past performance doesn't guarantee future results. If anything, Dexcom's success to date makes continued growth at its previous pace extra challenging. Shares of Dexcom recently dipped a couple of percentage points after the company shared results from the first three months of 2023. Is the stock's recent slip a sign that investors should avoid this former highflier or is it an opportunity to buy a great stock at a bargain price? Let's weigh Dexcom's strengths against its weaknesses to see if it's still a smart buy. Reasons to buy Dexcom stock now Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. At least half a dozen Wall Street analysts raised their price targets on Dexcom stock. Dexcom's new consensus price target implies a potential gain of 16% over the next 12 months if the rest of the market sees its constant blood-glucose monitor (CGM) business in the same light. This isn't the rate of return investors are used to with this stock but there's a lot less risk now than there was 10 years ago. In February, Dexcom launched its next-generation CGM device, called the G7, with help from a Super Bowl commercial. Shortly after that, a positive coverage decision for G7 from the Centers for Medicare and Medicaid Services (CMS) helped make the first weeks of its launch a success. Total first-quarter sales in the U.S. grew 17% year over year and will likely accelerate later this year. According to management, nearly 1,000 healthcare providers who had never prescribed a Dexcom device started patients on the G7 during the first quarter. In April, CMS expanded CGM coverage to diabetes patients using all types of insulin, plus non-insulin-using patients with a history of hypoglycemic events. Previously, millions of Americans with type 2 diabetes who use basal insulin weren't eligible for CGM coverage. Their new eligibility could lead to a surge in demand from folks too young for Medicare, too. Private insurers don't necessarily need to follow CMS' lead but they usually do. Reasons to remain cautious for now Dexcom isn't the only company with a fancy new CGM on the market. The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Abbott recently reported first-quarter FreeStyle Libre sales that reached $1.2 billion worldwide. This included a gain of nearly 50% year over year in the U.S. market. Dexcom is expecting its first year with G7 in the U.S. to be somewhat muted. Management's revenue outlook for 2023 implies growth between 17% and 21% this year. Dexcom's stock price has heaps of growth already baked in. The stock is trading at sky-high multiples of 149 times trailing earnings and 17.7 times sales. A very risky bet With expectations already high, investors who buy at recent prices have little to gain if the G7 device simply succeeds. The stock's valuation is so high right now that it will need to grow CGM sales faster than Abbott has to justify its valuation. Dexcom's near-term expectations for G7 sales appear way below the explosive growth the stock market is expecting. It's probably best to watch the G7 launch from a safe distance until the stock's valuation returns to a sensible level. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 24, 2023 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock That's a Surefire May Buy and 1 to Avoid Volatility is the price of admission to one of the greatest wealth creators on the planet. In 2022, investors were given a hearty serving of uncertainty and volatility, with all three major U.S. stock indexes plunging into a bear market and, ultimately, delivering their worst full-year performances in more than a decade. But the interesting thing about investors is their resilience. No matter how bleak things may appear in the short term, investors always find a way to latch onto outperformers. Over the past year, stock-split stocks have been the companies they've flocked to. Image source: Getty Images. A stock split is an event that allows a publicly traded company to alter its outstanding share count and share price without impacting its market cap or any aspect of its operations. It's a purely cosmetic move that can lower a company's share price to make it more easily tradable for everyday investors who don't have access to fractional-share purchases. A stock split can also increase a company's share price to ensure it remains listed on a major exchange. The latter move is known as a reverse stock split, while the former is a forward stock split. Most investors tend to focus on forward stock splits because they're conducted by companies with rising valuations that are almost always out-innovating and out-executing their competition. Last year, a half-dozen prominent stocks enacted forward splits, including Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG), Tesla (NASDAQ: TSLA), Shopify (NYSE: SHOP), Palo Alto Networks (NASDAQ: PANW), and DexCom (NASDAQ: DXCM). But among these top-tier stock-split stocks, there are clear standouts in May. One of these companies is historically inexpensive and ripe for the picking, while another is seeing its competitive advantages erode before our eyes. The stock-split stock that's a surefire buy in May: Alphabet Among the high-profile companies to have split their stock over the past year, the one that stands out as a phenomenal buy in May is Alphabet, the parent company of popular internet search engine Google, autonomous vehicle company Waymo, and streaming platform YouTube. Alphabet enacted a 20-for-1 forward split in mid-July. Keeping in mind that even the best stocks face challenges and headwinds, Alphabet's biggest concern at the moment has to be the growing likelihood that the U.S. economy will fall into a recession. A number of indicators have been sounding warnings for months that an economic downturn is likely. Furthermore, the minutes from the Federal Open Market Committee's March meeting officially forecast a \""mild recession\"" for later this year. Although the stock market and U.S. economy don't move in tandem, losses for equities tend to be more pronounced, historically, after a recession is declared. Alphabet generates the bulk of its revenue from advertising. Businesses aren't shy about paring back their ad budgets at the first sign of a possible recession. In other words, Alphabet could certainly endure some weaker growth prospects in the coming quarters, especially if U.S. economic growth shifts into reverse. But as I've previously pointed out, this is a two-sided coin that very much favors the patient investor. Even though recessions are inevitable, every recession after World War II has lasted just two-to-18 months. That compares to periods of expansion, which are typically measured in years. Ad-driven businesses enjoy strong pricing power a disproportionate amount of time. Alphabet's bread-and-butter operating segment continues to be its internet search engine. In March, Google accounted for 93.2% of global internet search share, according to data from GlobalStats. You have to go back to March 2015 to find the last time Google accounted for less than 90% of worldwide search. As long as Google has a roughly 90-percentage-point advantage over its next-closest competitor, it's going to maintain exceptional ad-pricing power. Yet what's really exciting is what Alphabet is doing with the cash flow it's generating from Google. One of its faster-growing initiatives is Google Cloud. Enterprise cloud-infrastructure spending is still, arguably, in its infancy, and Google Cloud has managed to gobble up 10% of global cloud infrastructure-service spending as of the fourth quarter of 2022, per Canalys. More importantly, Google Cloud generated a profit for Alphabet in Q1 2023, which reversed a sizable loss from the prior-year period. Cloud services generally offer much juicier margins than advertising. Looking years down the line, Google Cloud has an opportunity to become a core cash-flow driver for Alphabet. Lastly, don't overlook Alphabet's historically cheap valuation. Investors have the opportunity to purchase shares of Alphabet right now for just 17 times Wall Street's consensus earnings in 2024. Likewise, after averaging a price-to-cash-flow multiple of 18.4 over the past five years, it can be purchased for less than 12 times estimated cash flow for the upcoming year. Alphabet stock is ripe for the picking in May. The Model 3 is Tesla's flagship sedan. Image source: Tesla. The stock-split stock investors should avoid in May: Tesla However, not all stock-split stocks offer attractive outlooks at the moment. With a potential recession on the horizon and competition rapidly picking up, electric vehicle (EV) manufacturer Tesla is the stock-split stock to avoid in May. Tesla completed a 3-for-1 split in late August. Just as top-tier stocks have headwinds, companies to avoid have their potential catalysts. Tesla didn't get to where it is by accident. It did so by building its operations from the ground up. With four gigafactories, Tesla can mass produce in the neighborhood of 2 million EVs annually. In 2023, the company is targeting 1.8 million EVs, which would be a nice uptick from the 1.37 million EVs produced last year. Tesla has also delivered in the profit column. Whereas the EV divisions of virtually all new and legacy automakers are deeply in the red, Tesla has generated a generally accepted accounting principles (GAAP) profit in each of the past three years. This streak will likely continue in 2023. Unfortunately, many of the competitive advantages that Tesla has enjoyed are beginning to wane as new competition enters the picture. The easiest way to tell this is happening is by taking a closer look at Tesla's pricing activity. The company has reduced prices on its core EV models six separate times in 2023. While Tesla optimists claim this has to do with operating efficiencies reducing the price of its EVs, the company's rapidly rising inventory tells another story. Its vehicle inventory at the end of March 2023 stood at 15 days, which represents the highest mark since Q3 2020. Without accounting for all of these price reductions (some of which have taken place since the end of Q1), as well as excluding the benefit of $521 million in renewable energy credits (RECs), Tesla's automotive gross margin slipped to 18.3% during Q1. Whereas Wall Street was expecting $3.2 billion in free-cash flow from Tesla, the company reported an $80 million free-cash outflow, if we exclude RECs. Another problem for Tesla is that it's been unable to transform itself into more than just a car company. Yes, it has a supercharger network, offers solar panel installation, and operates an energy storage business. However, these are generally low-margin operations that lose money once below-the-line expenses are factored in. Tesla's entire GAAP profit depends on selling and leasing EVs. The reason this is noteworthy is because auto stocks traditionally trade at a multiple of 6 to 8 times earnings, with a little bit of an exception for automakers with faster growth prospects. Tesla is commanding a price-to-earnings multiple closer to 50 in 2023. That's not a multiple that makes sense for a highly cyclical industry when a potential recession is on the horizon. But the biggest issue of all for Tesla might be its CEO, Elon Musk. Musk is a visionary, but he's also a huge liability in a variety of ways. He's constantly drawing the attention of securities regulators for all the wrong reasons, and the vast majority of his innovations/promises end up delayed or scrapped. It's quite possible Tesla's share price deflates as more of Musk's innovations fail to come to fruition. For that and the many other reasons listed above, Tesla is an easy avoid in May. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 24, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-05-03,119.2,119.88,116.79,117.32,
DXCM,2023-05-04,116.5,117.87,116.03,117.42,"3 HealthTech Stocks to Watch as Digital Health Transforms the Industry InvestorPlace - Stock Market News, Stock Advice & Trading Tips Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumors, medicine makes use of many such technologies. Companies that develop technologies for the healthcare sector are referred to as healthtech companies. In this column, I will provide information about three of the best healthtech stocks available, focusing on companies that have developed non-drug technologies to combat or diagnose diseases. Another major trend in medicine is digital health. According to the FDA, “digital health technologies use computing platforms, connectivity, software, and sensors for health care and related uses.” The three names that I will discuss are also digital health stocks. Medtronic (MDT) Source: JHVEPhoto / Shutterstock.com Medtronic (NYSE:MDT) is one of the world’s top medical device makers. In the last 18 months, the company has launched a number of new, very promising products. On May 1, the FDA approved two of MDT’s “leadless pacemakers,” called Micra AV2 and Micra VR2. According to the company, the devices are “the world’s smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.” Given these devices’ many important, competitive advantages, they should boost MDT’s financial results going forward. Moreover, as I noted in a previous column, the company has launched “a robot that helps perform surgeries” using artificial intelligence. Speaking to an analyst on March 10, MDT CFO Karen Parkhill said that Hugo is “going to be a strong contributor to our revenue growth for many years to come. ” Also likely to boost Medtronic are a few moves by Washington on the diabetes front. First, the FDA last month eliminated restrictions that it had imposed on MDT’s insulin pumps. Secondly, the agency approved the company’s new insulin pump. Finally, Medtronic, which markets continuous glucose-monitoring systems, should be boosted by a recent decision by Medicare to cover the cost of such systems for some diabetes patients who don’t receive daily insulin injections. Dexcom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com Dexcom’s (NASDAQ:DXCM) main business is marketing continuous glucose monitors, including its Dexcom G7, which “delivers real-time glucose numbers to [patients’] smartphone[s].” As a result, Dexcom should benefit from Medicare’s recent decision “to cover the cost of such systems for some diabetes patients who don’t receive daily insulin injections.” Indeed, the company cited the new coverage rules, along with its strong first-quarter results, as the reasons for its decision to raise its 2023 sales guidance on April 27. Specifically, DXCM increased its full-year top-line outlook to $3.4 billion to $3.52 billion from $3.35 billion to $3.49 billion. Given how widespread diabetes is and the importance of Medicare coverage for selling devices, I think that the guidance will probably end up being conservative. In Q1, Dexcom’s top line climbed 18% year over year to $741.5 million, while its operating income, excluding some items, increased 2.6 percentage points YOY. UBS responded to the Q1 results by increasing its price target on the shares to $150 from $142 while keeping a “buy” rating on the name. The bank expects the company to deliver “beat and raise” quarterly results “throughout the year.” GE HealthCare Technologies (GEHC) Source: testing / Shutterstock.com GE Healthcare (NASDAQ:GEHC) spun off from General Electric (NYSE:GE) in January. GE Healthcare is “a leading manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals.” Among its top products are CT machines, MRIs, ultrasounds and mammograms. The company also sells many digital tools that help manage its leading products. On April 25, GEHC reported that its top line had climbed an impressive 12% year over year, excluding acquisitions and divestments, while its adjusted earnings before interest and taxes climbed to $664 million from $599 million. Moreover, the company reported that it expects its earnings per share, excluding some items, to climb 7% to 11% this year to $3.60-$3.75. Before GEHC reported its results, investment bank Piper Sandler on April 20 started coverage of the name with a $95 price target and an “overweight” rating. The bank noted that the company had a large backlog of $14 billion, and thinks that it will be able to introduce significant new products after it raised its investment in R&D. On the technology front, the company recently launched a system “designed to deliver high-performance ultrasound guidance” for multiple types of surgeries. And GEHC received an award from research firm MedTech Breakthrough for a “Best New Ultrasound Technology Solution.” Both pieces of news bode well for GEHC’s outlook as they suggest that the company is indeed on the cutting edge of medtech and an excellent healthtech stock to buy. As of the date of publication, Larry Ramer owned shares of GE. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer. The post 3 HealthTech Stocks to Watch as Digital Health Transforms the Industry appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-05,117.71,121.59,117.28,120.82,"Dexcom to build its first European factory in Ireland DUBLIN, May 5 (Reuters) - U.S. medical device company Dexcom DXCM.O plans to invest 300 million euros ($330.8 million) over the next five years to build a manufacturing site in Ireland, creating up to 1,000 jobs, it said on Friday. The plans provide some good news for the Irish economy after announcements of job cuts at other foreign-owned companies. Dexcom, which makes glucose monitoring systems for people with diabetes, said it would seek planning permission for land owned by the Irish government's investment agency (IDA) in Athenry. ""This will be one of the biggest single private sector investments ever in the West of Ireland,"" Prime Minister Leo Varadar said in a statement. Ireland is hugely reliant on multinationals that together employ more than 275,000 people, or one in nine workers, and account for a large chunk of the country's income and corporate taxes. Many of the world's leading drugmakers have operations in Ireland, including Pfizer (PFE.N), which plans to invest more than 1.2 billion euros ($1.26 billion) to expand manufacturing at its plant in Dublin. Rival Abbott Laboratories (ABT.N) said in August that it would create about 1,000 jobs with expansion of its manufacturing facilities. ($1 = 0.9069 euros) (Reporting by Graham Fahy Editing by David Goodman) ((graham.fahy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-08,120.15,120.92,118.67,120.18,
DXCM,2023-05-09,120.19,120.44,118.69,119.65,
DXCM,2023-05-10,120.8,123.13,119.85,122.57,
DXCM,2023-05-11,122.89,123.43,119.76,121.07,
DXCM,2023-05-12,121.39,122.47,120.8,121.7,
DXCM,2023-05-15,121.75,122.62,119.3,119.61,"[""Guru Fundamental Report for DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Factor-Based Stock Portfolios Factor-Based ETF Portfolios Harry Browne Permanent Portfolio Ray Dalio All Weather Portfolio About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stocks on the Verge of Breaking Out In choppy markets, combining technical and fundamental strength becomes paramount. Below are 3 stocks that hold these characteristics and are on the verge of breaking out: DXCM Dexcom (DXCM) is a medical device company that designs and develops continuous glucose monitoring (CGM) systems. CGMs are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. Unique Product Leads to Strong Growth Dexcom\u2019s unique monitoring system is used to continuously measure a patient\u2019s blood glucose level and transmit that information to a small cell phone-sized receiver in real-time. Though the blood glucose monitoring Dexcom is highly competitive, DXCM is the leader. Last quarter, EPS grew 113% year-over-year on revenue growth of 18%. Image Source: Zacks Investment Research The company\u2019s EPS of $0.17 beat Zacks estimates of 15 cents by 13.3%. The positive surprise was nothing new. DXCM has a strong history of beating estimates \u2013 in 17 out of the last 19 quarters, the company has surprised to the upside. Image Source: Zacks Investment Research \u201cThe Longer the Base, The Higher in Space\u201d A stock that has sound fundamentals and breaks out from a long base can produce robust results. DXCM fits the criteria \u2013 the stock is emerging from a consolidation dating back to October 2022. Should the breakout hold, expect fireworks to the upside in the coming weeks. Image Source: Zacks Investment Research With diabetes rates increasing in the U.S. and worldwide, DXCM should benefit from solid healthcare tailwinds. RMBS Rambus (RMBS) is an industry-leading chip producer. The company\u2019s chips are used for interface, memory, security, and display architectures for computing, gaming, graphics, and more. Strong Industry From a performance, growth, and price performance perspective, the leading industry in thestock market todayis the chip sector. Though Rambus may get less attention than Advanced Micro Devices (AMD) or Nvidia (NVDA), the company has strong growth and even more robust price and volume action. Fundamentals RMBS has grown top and bottom-line results at a double-digit clip for several quarters in a row, and the stock\u2019s strong Zacks #2 (Buy) ranking suggests that may continue. Price & Volume The most intriguing part of RMBS is its strong price and volume action. RMBS has been hugging the 50-day moving average for all of 2023. The recent post-eps pullback and subsequent rebound off the 50-day moving average is a golden opportunity, in my opinion. Image Source: Zacks Investment Research VIPS Zacks Rank #1 (Strong Buy) stock Vipshops (VIPS) is China\u2019s third largest e-commerce platform. Vipshops benefits from the massive market it serves (300 million customers) and the many companies it counts as partners (more than 20,000). The End of China\u2019s Zero-Covid Policy China had one of the most stringent COVID-19 lockdown policies in the entire world. In fact, at times, Chinese President Xi was willing to allow the Chinese economy to come to a screeching halt to tamp down coronavirus cases. Throughout this time, Vipshops and most other Chinese companies suffered. However, in the past three quarters, VIPS has turned around its EPS picture and has grown EPS by 12%, 55%, and 27%. Despite the widely publicized reopening of the Chinese economy, analysts seem slow to change course. VIPS has delivered positive surprises in four straight quarters, including big beats of 42.31% and 33.33%. Image Source: Zacks Investment Research Finally, it appears that analysts are catching on to Vipshop\u2019s renewed growth trajectory. In the past seven days, Zacks Consensus Estimates for 2023 and 2024 have been revised higher. Technical View When searching for a monster stock, two of the most powerful traits to look for are a strong uptrend and relative strength. VIPS holds both of these characteristics. Over the past year, the stock is up 91.1% while the S&P 500 Index is +2.9% - impressive when considering the volatility that occurred in global markets. Image Source: Zacks Investment Research The stock has been consolidating for the past five months and is pulling into the rising 50-day moving average \u2013 an attractive reward-to-risk zone. VIPS is scheduled to report earnings Wednesday. This Little-Known Semiconductor Stock Could Be Your Portfolio\u2019s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that\u2019s just the tip of the iceberg), you have a need for semiconductors. That\u2019s why their importance can\u2019t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation. >>Yes, I Want to Help Protect My Portfolio During the Recession Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Rambus, Inc. (RMBS) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Vipshop Holdings Limited (VIPS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-05-16,119.54,119.54,117.87,118.61,"Zacks Investment Ideas feature highlights: Dexcom, Rambus, Advanced Micro Devices, Nvidia and Vipshops For Immediate Release Chicago, IL – May 16, 2023 – Today, Zacks Investment Ideas feature highlights Dexcom DXCM, Rambus RMBS, Advanced Micro Devices AMD, Nvidia NVDA and Vipshops VIPS. 3 Stocks on the Verge of Breaking Out In choppy markets, combining technical and fundamental strength becomes paramount. Below are 3 stocks that hold these characteristics and are on the verge of breaking out: DXCM Dexcom is a medical device company that designs and develops continuous glucose monitoring (CGM) systems. CGMs are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. Unique Product Leads to Strong Growth Dexcom's unique monitoring system is used to continuously measure a patient's blood glucose level and transmit that information to a small cell phone-sized receiver in real-time. Though the blood glucose monitoring Dexcom is highly competitive, DXCM is the leader. Last quarter, EPS grew 113% year-over-year on revenue growth of 18%. The company's EPS of $0.17 beat Zacks estimates of 15 cents by 13.3%. The positive surprise was nothing new. DXCM has a strong history of beating estimates – in 17 out of the last 19 quarters, the company has surprised to the upside. ""The Longer the Base, The Higher in Space"" A stock that has sound fundamentals and breaks out from a long base can produce robust results. DXCM fits the criteria – the stock is emerging from a consolidation dating back to October 2022. Should the breakout hold, expect fireworks to the upside in the coming weeks. With diabetes rates increasing in the U.S. and worldwide, DXCM should benefit from solid healthcare tailwinds. RMBS Rambus is an industry-leading chip producer. The company's chips are used for interface, memory, security, and display architectures for computing, gaming, graphics, and more. Strong Industry From a performance, growth, and price performance perspective, the leading industry in thestock market todayis the chip sector. Though Rambus may get less attention than Advanced Micro Devices or Nvidia, the company has strong growth and even more robust price and volume action. Fundamentals RMBS has grown top and bottom-line results at a double-digit clip for several quarters in a row, and the stock's strong Zacks #2 (Buy) ranking suggests that may continue. Price & Volume The most intriguing part of RMBS is its strong price and volume action. RMBS has been hugging the 50-day moving average for all of 2023. The recent post-eps pullback and subsequent rebound off the 50-day moving average is a golden opportunity, in my opinion. VIPS Zacks Rank #1 (Strong Buy) stock Vipshops is China's third largest e-commerce platform. Vipshops benefits from the massive market it serves (300 million customers) and the many companies it counts as partners (more than 20,000). The End of China's Zero-Covid Policy China had one of the most stringent COVID-19 lockdown policies in the entire world. In fact, at times, Chinese President Xi was willing to allow the Chinese economy to come to a screeching halt to tamp down coronavirus cases. Throughout this time, Vipshops and most other Chinese companies suffered. However, in the past three quarters, VIPS has turned around its EPS picture and has grown EPS by 12%, 55%, and 27%. Despite the widely publicized reopening of the Chinese economy, analysts seem slow to change course. VIPS has delivered positive surprises in four straight quarters, including big beats of 42.31% and 33.33%. Finally, it appears that analysts are catching on to Vipshop's renewed growth trajectory. In the past seven days, Zacks Consensus Estimates for 2023 and 2024 have been revised higher. Technical View When searching for a monster stock, two of the most powerful traits to look for are a strong uptrend and relative strength. VIPS holds both of these characteristics. Over the past year, the stock is up 91.1% while the S&P 500 Index is +2.9% - impressive when considering the volatility that occurred in global markets. The stock has been consolidating for the past five months and is pulling into the rising 50-day moving average – an attractive reward-to-risk zone. VIPS is scheduled to report earnings Wednesday. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with ""black gold."" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Rambus, Inc. (RMBS) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Vipshop Holdings Limited (VIPS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-17,118.58,119.77,116.6,118.59,"Look Under The Hood: VUG Has 12% Upside Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Growth ETF (Symbol: VUG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $284.37 per unit. With VUG trading at a recent price near $254.26 per unit, that means that analysts see 11.84% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VUG's underlying holdings with notable upside to their analyst target prices are Horizon Therapeutics plc (Symbol: HZNP), Tractor Supply Co. (Symbol: TSCO), and DexCom Inc (Symbol: DXCM). Although HZNP has traded at a recent price of $96.34/share, the average analyst target is 16.93% higher at $112.65/share. Similarly, TSCO has 12.75% upside from the recent share price of $226.29 if the average analyst target price of $255.14/share is reached, and analysts on average are expecting DXCM to reach a target price of $133.35/share, which is 12.43% above the recent price of $118.61. Below is a twelve month price history chart comparing the stock performance of HZNP, TSCO, and DXCM: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Vanguard Growth ETF VUG $254.26 $284.37 11.84% Horizon Therapeutics plc HZNP $96.34 $112.65 16.93% Tractor Supply Co. TSCO $226.29 $255.14 12.75% DexCom Inc DXCM $118.61 $133.35 12.43% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » Also see: • Top Stocks Held By Louis Bacon • Institutional Holders of IGEM • DVYA YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-18,118.26,119.277,116.95,119.03,
DXCM,2023-05-19,118.81,120.53,116.97,117.13,
DXCM,2023-05-22,117.58,120.99,116.12,119.29,
DXCM,2023-05-23,118.45,119.14,114.55,115.69,"[""Noteworthy Tuesday Option Activity: DXCM, LMND, PINS Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DexCom Inc (Symbol: DXCM), where a total volume of 10,039 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.6% of DXCM's average daily trading volume over the past month, of 2.4 million shares. Particularly high volume was seen for the $115 strike call option expiring June 16, 2023, with 1,681 contracts trading so far today, representing approximately 168,100 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $115 strike highlighted in orange: Lemonade Inc (Symbol: LMND) saw options trading volume of 8,614 contracts, representing approximately 861,400 underlying shares or approximately 42.4% of LMND's average daily trading volume over the past month, of 2.0 million shares. Particularly high volume was seen for the $30 strike call option expiring September 15, 2023, with 795 contracts trading so far today, representing approximately 79,500 underlying shares of LMND. Below is a chart showing LMND's trailing twelve month trading history, with the $30 strike highlighted in orange: And Pinterest Inc (Symbol: PINS) options are showing a volume of 66,140 contracts thus far today. That number of contracts represents approximately 6.6 million underlying shares, working out to a sizeable 42.3% of PINS's average daily trading volume over the past month, of 15.6 million shares. Especially high volume was seen for the $26 strike call option expiring July 21, 2023, with 10,867 contracts trading so far today, representing approximately 1.1 million underlying shares of PINS. Below is a chart showing PINS's trailing twelve month trading history, with the $26 strike highlighted in orange: For the various different available expirations for DXCM options, LMND options, or PINS options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Mortgage REITs Hedge Funds Are Selling \u0095 EXC Price Target \u0095 AEE RSI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Investing $1,000 in These 2 Top Growth Stocks Would Be a Brilliant Move Given the market volatility over the past few years, some investors are questioning whether they should still be putting their hard-earned money into the stock market. There is substantial economic uncertainty at the moment, and we could see a recession this year. But long-term investors know that equity markets should continue to appreciate on the other side of whatever economic trouble is on the way short term. For those investors with a long-term view and with $1,000 available that isn't needed for monthly bills, paying off short-term debt, or firming up an emergency fund, there are some quality stocks available that can grow this initial sum for years to come. Let's take a closer look at two excellent growth stocks to buy right now: Teladoc Health (NYSE: TDOC) and DexCom (NASDAQ: DXCM). 1. Teladoc Health Last year was a horror show for Teladoc. Share prices of the telemedicine specialist plunged due to slowing revenue growth and deep net losses. In fairness, the red ink was due to non-cash impairment charges related to an acquisition, but investors didn't seem to care. Although these issues are real, it's important not to let them cloud the broader picture. Teladoc's prospects largely hinge on the future of telehealth and its ability to execute its master plan. Despite the headwinds, long-term investors can still be excited about the company's prospects. Let's first consider Teladoc's execution. Revenue growth slowed, but the past three years were highly unusual. Teladoc's business experienced an incredible pandemic boom that was unlikely to last forever. On the bottom line, Teladoc seems to have put the surprise impairment charges behind, at least based on its guidance for the fiscal year 2023. The company expects a net loss per share between $1.70 and $1.25, compared to a loss per share of $84.60 last year. Further, Teladoc's memberships and visits continue to move in the right direction. In the first quarter, total visits jumped by 8% year over year to 4.9 million. The company's BetterHelp therapy service had 467,000 paying members as of the end of the quarter, 22% higher than the year-ago period. Teladoc is spending a lot of money on marketing and advertising to attract customers, which is necessary at this stage of its growth and is one of the main reasons it is unprofitable. Once it becomes a more established corporation and cuts down these expenses, it will boost the bottom line, especially considering the company's high gross margins, typically in the 60% to 70% range. And there are plenty of opportunities ahead for Teladoc to grow its business further. According to some estimates, the telemedicine industry will record an impressive compound annual growth rate of 24% through 2030. Teladoc is one of the best stocks to cash in on this. Investors can acquire 41 shares of Teladoc at its current price of just under $24. Holding these shares for a while will pay rich dividends down the road. 2. DexCom DexCom is a continuous glucose monitoring (CGM) system specialist. CGM are devices that help diabetes patients keep track of their blood glucose levels throughout the day. The technology has gained traction among those with diabetes over the past decade or so. DexCom recently launched its newest device, the G7, in the U.S. and Europe. Note that the company ended 2022 with nearly 1.7 million customers globally. That sounds like a lot, but it is a mere tiny fraction of the 422 million diabetes patients worldwide. Collectively, CGM companies -- of which DexCom is one of the leaders -- have likely captured only a small percentage of this vast market. Meanwhile, the evidence that CGM technology leads to better outcomes than blood glucose meters continues to mount. DexCom recently reported the results of a study conducted in the U.K. that shows that CGM leads to cost savings for the healthcare system and improved lives for diabetes patients. Because of results like these, third-party payers will keep covering these devices, making them more accessible to the general public. The U.S. Centers for Medicare & Medicaid Services recently expanded those patients that will be covered under Medicare. The new coverage decision added non-insulin patients with a history of problematic hypoglycemia (or when blood sugar levels drop under a specific threshold). Previously, only insulin patients were eligible for Medicare reimbursement for CGM machines. Given that they are associated with better outcomes, we can expect these devices to continue gaining in popularity among those with diabetes and third-party payers, which will greatly benefit DexCom over the long run. DexCom's shares are changing hands for a little under $118 apiece right now, so investors can grab eight of them -- with change to spare -- with $1,000. Those who do so today will be glad they did in 10 years. 10 stocks we like better than Teladoc Health When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 15, 2023 Prosper Junior Bakiny has positions in Teladoc Health. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-05-24,114.89,117.07,114.31,116.73,"4 Growth Stocks to Buy and Hold Forever It's been tough to be an investor of late. Stocks are dishing out plenty of drama (and volatility) this year, making it uncomfortable to stick with them. If your time frame truly is ""forever,"" though, it doesn't really matter. There are still lots of great growth stocks you can jump into for at least the next several years regardless of their recent action. Here's a closer look at four of your best bets. DexCom DexCom (NASDAQ: DXCM) is a leading name in next-generation continuous glucose monitoring systems. The latest iteration of its flagship device -- the G7 -- offers the same game-changing feature that the prior six versions of its tech have. It has an automated means of keeping constant tabs on blood glucose levels. That's a huge deal for diabetics. And the company's numbers confirm strong demand. Last quarter's top line grew 18% year over year, following 2022's full-year top-line growth of 19%. This full year's and next year's expected revenue growth both stand in excess of 20%. This is just a taste of DexCom's likely long-term future. The International Diabetes Federation believes the worldwide number of diabetics will grow from 2021's 537 million to 643 million in 2030 and to 783 million by 2045. And that growth may understate the company's ultimate potential. Many diabetics who could benefit from a glucose monitor aren't yet using one. As they increasingly embrace such a solution, DexCom stands to benefit. Ditto for DexCom's shareholders. Dutch Bros Most fans of quick-service coffee joints are familiar with Starbucks. But that's not the only java joint out there. A much smaller chain called Dutch Bros (NYSE: BROS) enjoys its own loyal customer base. And it's growing fast. Founded in 1992, Oregon-based Dutch Bros started out as a single pushcart coffee stand. Leveraging its unique vibe and a handful of exclusive drink offerings, the company's grown to 716 stores operating in 14 different states. Most of that expansion has taken shape in just the past few years. For perspective, Starbucks operates more than 17,000 locations in North America alone. That's still only a fraction of its potential, though. Last quarter's 45 new stores and year-over-year revenue growth of nearly 30% has been roughly the norm for a while now, and it's in line with the sort of sales growth that analysts expect for the remainder of this year and next. How's this kind of growth happening in such a saturated market? Simply put, the company is capitalizing on consumers' fatigued interest in the aging and all-too-common Starbucks brand; never even mind its distracting labor woes. (Several Starbucks stores have unionized in recent months, putting a spotlight on the company's treatment of workers.) Dutch Bros doesn't face the same sort of headache. Being a smaller organization, it's better equipped to be the ""community-driven, people-first"" company it claims to be. And being a younger company, it seems more in tune with modern societal norms that matter most to consumers. ASML Holding When investors think of semiconductor stocks, ASML (NASDAQ: ASML) isn't often a name that comes to mind. Big mistake. This Netherlands-based $274 billion behemoth is not only growing fast, but many of the industry's key players would struggle to operate without ASML around. That's because the company supplies chipmakers with the equipment and supplies needed to make semiconductors. The science of manufacturing has seen several enormous evolutions since its infancy. The latest of these is also arguably the most game-changing. That's the introduction of lithography, or the use of ultraviolet light to effectively ""etch"" a semiconductor onto a circuit board. It's fast, cost-effective, and allows for the mass creation of very small (and therefore power-efficient) chips. This stock's been a lackluster performer of late, largely due to worries of a sweeping slowdown of the world's semiconductor business. But that's a short-term concern that ignores a much bigger two-part backdrop. Demand for microchips is still accelerating, and a huge number of these chips will need to be made with lithography. To this end, despite weakness in China during the first quarter, the company anticipates a big recovery of the region's chipmaking industry through the end of this year as political complications get worked out. At the same time, the United States' budding semiconductor manufacturing business is going to rely heavily on ASML's technology. Yes, this company has enough political leverage and patents to monetize both halves of the world. That's why this year's revenue is expected to soar to the tune of nearly 26%, followed by healthy 12% growth next year. Booking Holdings Finally, add to your shopping list the online travel-booking name Booking Holdings (NASDAQ: BKNG), parent of such sites as booking.com and priceline.com. There was a time not too long ago -- at the height of the pandemic -- when travel stocks were essentially untouchable. People weren't going anywhere for any reason. That's changing now. But with little more than a passing glance, it seems the recovery is a slow one. Take a closer look at the most recent headlines, however. The American Automobile Association reported last week that more Americans will be traveling by air this upcoming Memorial Day weekend than did so in pre-pandemic 2019. Specifically, the organization expects 3.4 million Americans to travel by air this holiday weekend, up 5.4% from 2019's tally. That growth follows record-breaking travel within China earlier this month during the country's equivalent to the United States' Labor Day holiday. At the same time, the World Travel & Tourism Council believes global tourism revenue will grow for a third year in a row in 2023, coming within 5% of 2019's levels en route to a full recovery by 2024. As for business travel, Deloitte says it's also on the road to recovery, and should eclipse its pre-pandemic peak by late 2024 or early 2025. Consumers are looking for new experiences again, and companies are doing more in-person business. That's why Booking's revenue is expected to improve to the tune of 20% this year. Next year's projected top-line growth of nearly 12%, meanwhile, feels conservative given the backdrop. Find out why Booking Holdings is one of the 10 best stocks to buy now Our analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Booking Holdings is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of May 15, 2023 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML, Booking Holdings, and Starbucks. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-05-25,116.66,116.66,112.27,114.61,"[""3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition and reimbursement persist. So far this year, this Zacks Rank #3 (Hold) stock has risen 3% compared with the industry\u2019s 0.5% growth. The S&P 500 Index has gained 8.3% in the same time frame. DXCM, a renowned medical-devices company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $44.45 billion. It projects 39% growth over the next five years and expects to maintain the strong performance. DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once, and met the same in another, delivering an average surprise of 2.86%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available to international markets. The company received FDA clearance for G7 sensor technology in December 2022. These developments are likely to support DXCM\u2019s future growth. In 2022, the company also launched the easy-to-use Dexcom ONE real-time CGM System on prescription for everyone with type 1 or type 2 diabetes using insulin. It did so via drug tariff in NHS England, Wales, Scotland and Northern Ireland. DexCom\u2019s prospects in alternative markets, such as non-intensive diabetes management, hospitals, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Positive Coverages: DXCM\u2019s products have been receiving increasing coverage over the past few months, raising our optimism. In June 2022, the company announced that type 1 and type 2 diabetic patients (aged two years and above) who are on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island\u2019s Diabetes Glucose Sensor Program. DexCom ended the first quarter with new patient additions. The Ontario government started coverage for the Dexcom G6 CGM System through Ontario\u2019s Assistive Devices Program. This program is for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Strong Q1 Results: DexCom\u2019s solid first-quarter 2023 revenues buoy optimism. Rising volumes across all channels, along with new customer additions due to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. Downsides Rising Costs: DexCom's gross margin contracted 90 basis points during the first quarter to 62.4%, reflecting the rising cost of sales. The company expects adjusted gross margin of 62-63%, indicating persisting cost pressure. Stiff Competition:The market for blood glucose monitoring devices is highly competitive, subject to rapid changes and new product introductions. DXCM\u2019s competitors manufacture and market products for the single-point finger stick device market and collectively account for substantially all worldwide sales of self-monitored glucose testing systems at present. Estimate Trend DexCom is witnessing a mixed estimate revision trend for 2023 and 2024. In the past 30 days, the consensus mark for earnings per share decreased 1 cent to $1.06 for 2023 and increased 1 cent to $1.47 for 2024. The Zacks Consensus Estimate for the company\u2019s second-quarter 2023 revenues is pegged at $837 million, indicating a 20.2% improvement from the year-ago quarter\u2019s reported number. The same for earnings is pinned at 22 cents per share, implying 29.4% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks from the broader medical space are Merit Medical Systems MMSI, West Pharmaceutical Services WST and Perrigo PRGO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Merit Medical Systems has an estimated long-term growth rate of 11%. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.22%. So far this year, MMSI\u2019s shares have risen 18.9% compared with the industry\u2019s 8.7% growth. West Pharmaceutical Services has an estimated long-term growth rate of 6.3%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 13.61%. So far this year, WST\u2019s shares have gained 49.1% compared with the industry\u2019s 8.7% growth. Perrigo\u2019s earnings are expected to improve 24.2% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average negative surprise being 0.79%. The company has lost 1.9% so far this year against the industry\u2019s 4.8% growth. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""The Best Stocks to Invest $500 in Right Now While some investors may be discouraged by the market volatility that has continued from last year into 2023, the fact remains that truly great businesses are still growing even in an ongoing economic maelstrom. While a full-fledged recession has the ability to hamper growth across a range of businesses and sectors, when you're looking at a multi-year buy-and-hold horizon for any stock you own, even these periods can be a short window against your overall investment period. If you're looking to put just $500 into stocks this week, here are two companies to consider when you do. 1. DexCom DexCom (NASDAQ: DXCM) has built a name for itself as a leader in diabetes care, a highly fragmented space with increasing levels of competition. However, as of 2022, the company controls roughly 40% of the global continuous glucose monitoring (CGM) device market, a space that garnered a valuation of $7.8 billion last year. In the first quarter of 2023, DexCom reported that revenue hit $742 million, up 18% from the same period in 2022. This growth rate was driven by 21% revenue growth in international markets and 17% in the U.S. in the three-month period. The company generated earnings of $49 million for the quarter, down slightly on a year-over-year basis but up 23% on a two-year basis. The company is in the process of executing the global launch of its G7 CGM, most recently in the U.S. Although it's still early days, in DexCom's first-quarter earnings report, CEO Kevin Sayer noted the following: We have seen a steady ramp of new users, and the initial feedback from both customers and clinicians has been consistently great. We have also seen this product attracting new prescribers altogether. Already in the early weeks of this rollout, nearly 1,000 healthcare providers have prescribed G7 who previously were not prescribing DexCom CGM. Bear in mind that there are millions of diabetics around the world that could still benefit from CGMs but aren't using them. There is also significant untapped potential in the type 2 diabetes market, the most frequently diagnosed version of the disease, which alone afflicts as many as 95% of all Americans with diabetes. This addressable market is not only large but expanding due to a range of factors, including the rising incidence of diabetes globally and more favorable private and public coverage options making CGMs more accessible to the patient population. When you factor in DexCom's significant leadership in this space, it would appear that the stock still has plenty of room to run. 2. Airbnb The demand for curated, unique, and long-term stays didn't originate with Airbnb (NASDAQ: ABNB), but the travel giant has taken this concept to an entirely new level in the nearly 15 years since the company's inception. Despite the fact that fears of a recession continue to linger and the travel industry is fueled by heavy levels of discretionary spending, Airbnb keeps going from strength to strength. The most recent quarter represented record growth on multiple fronts, a trend that has been building in the series of quarters that Airbnb has reported since its recovery from the travel doldrums of the pandemic. The company hit 121 million nights and experiences booked in the three-month period alone, up 19% from the prior year and 49% from the same quarter in 2019. Airbnb generated revenue of $1.8 billion and a net income of $117 million (or $151 million, excluding foreign currency fluctuations) in the first quarter of 2023. That revenue figure was up 117% on a four-year basis. Meanwhile, its earnings stand in contrast to a net loss of $19 million in the same quarter last year, representing its inaugural first quarter of profitability. Free cash flow came in at $1.6 billion for the three-month period, up 32% from one year ago and 471% from four years ago. Airbnb is regularly cultivating and upgrading its platform offerings to make them more attractive for both hosts and guests. People are increasingly looking to Airbnb as a way to earn extra cash, with active listings on the platform at the end of the first quarter representing an 18% jump on a year-over-year basis. Long-term stays of 28 days or more comprised 18% of all gross bookings completed in the three-month period, compared to just 13% in the first quarter of 2019. If a recession hits, any company with exposure to the travel industry will be affected, and Airbnb is no exception. However, the diverse types of stays, hosts, and guests that its platform caters to, and its continued record growth and profitability, are building upon a strong core business poised to withstand a storm. Investors who stay along for the ride may find it was well worth the wait. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 22, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Airbnb. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-05-26,114.32,115.56,113.55,115.05,
DXCM,2023-05-30,115.23,116.67,113.01,113.56,
DXCM,2023-05-31,113.78,117.848,113.61,117.26,"[""2 Incredible Growth Stocks to Buy Before the Next Bull Market You're not alone if you're waiting with eager anticipation for the next prolonged bull market. The stock market has clocked its fair share of up and down days in the first several months of 2023, but that doesn't mean investors should give up the ship. Strong businesses with compelling growth stories haven't gone anywhere. Even while share prices remain depressed across a range of sectors, companies that have these growth stories can be poised to deliver enviable returns in the next bull market and beyond. Here are two such names to think about adding to your buy basket right now. 1. DexCom DexCom (NASDAQ: DXCM) has continued to impress as a leader in the diabetes care space for more than two decades and counting. The stock has popped 55% over the trailing 12 months. DexCom's continuous glucose monitoring devices are used by diabetics around the world to monitor their blood sugar levels and help to avoid adverse -- and in some cases, life-threatening -- blood sugar events. The company recently came out with the latest model of its flagship CGM product, the G7, marketed as being the most accurate CGM with the fastest warm-up time of any such device currently on the market. While wear times vary, the G7 has a wear time of 10 days. The launch of the G7 is only in its relatively early stages in the U.S.; it was previously launched in key markets across Europe, the U.K., and Asia. Despite the clear benefits of CGMs for both type 1 and type 2 diabetics -- and, in some cases, pre-diabetics -- these markets are still heavily underpenetrated. DexCom has been at the forefront of working with private insurers as well as governments to expand coverage, which should further spur adoption. Just before the launch of the G7 in the U.S., DexCom announced that the U.S. Centers for Medicare & Medicaid Services had extended coverage of the device to all eligible beneficiaries, making this CGM the most covered and reimbursed of any such device on the market. In the first-quarterearnings call management noted that the CMS had also just extended coverage for CGMs to type 2 diabetics using basal insulin as well as certain hypoglycemic patients who do not use insulin. CEO Kevin Sayer noted that this represented \""the largest single expansion of access to CGM in our industry's history,\"" adding, \""we size the basal-only type 2 population alone at around 3 million people in the U.S. with around half being of Medicare age.\"" The expansion of coverage options for wearers, and the reality that the incidence of both type 1 and type 2 diabetes is only growing, creates a vast and growing market opportunity that DexCom is continuing to readily tap. While the diabetes care space is fragmented, DexCom's market-leading devices should allow it to continue growing even as other competitors enter this space. Profits over the trailing 12 months alone totaled $293 million, making this look like a compelling investment to buy and hold for the long haul. 2. Etsy Etsy (NASDAQ: ETSY) is still trading down about 25% since the beginning of 2023. Yet, while a long-awaited recession forecast by many economists may or may not be in the offing, consumers are still continuing to shell out cash on discretionary expenditures. In addition, the segment of the e-commerce market that Etsy targets -- which revolves around unique, handmade, and specialty items -- may be just the types of products that consumers might be more inclined to purchase in a cash-constrained environment rather than name-brand products from larger stores. In the most recent quarter, Etsy reported consolidated gross merchandise sales of $3.1 billion across its family of brands. The Etsy marketplace generated the lion's share of this figure, coming in at $2.7 billion for the three-month period. These figures represented a slight decline on a year-over-year basis; however, revenue for the quarter came in at $641 million, up 11% from the year-ago period. Etsy also returned to profitability in the quarter, generating earnings of about $75 million. The Etsy marketplace ended the quarter with 89.9 million active buyers, up 1% from the year-ago period. Management noted that this was \""the first time this metric has grown on a year-over-year basis since the fourth quarter of 2021.\"" The Etsy marketplace also saw 7 million new buyers flock to its platform in the three-month period, along with 21% more reactivated buyers than in the year-ago quarter. Importantly, the platform is continuing to see astonishing growth from pre-pandemic levels. Arguably, this could present a more accurate gauge of its growth story than comparisons to the height of pandemic or to recent months when consumer spending has been in flux because of a difficult economic environment. Case in point: The Etsy marketplace's cohorts of active buyers and repeat buyers were up 119% and 149%, respectively, in the first quarter of 2023 compared to the first quarter of 2019. And, its segment of habitual buyers (individuals who purchased $200 or more worth of goods over six or more purchase days in the last year) was up a whopping 238% on a four-year basis. As spending levels recover, Etsy's strong footprint in its specialty segment of the e-commerce market, and the continued growth it's seeing in an otherwise challenging spending landscape, bode well for its ability to generate meaningful returns from its family of brands over the next three to five years and well beyond. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 22, 2023 Rachel Warren has positions in DexCom and Etsy. The Motley Fool has positions in and recommends Etsy. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stock-Split Stocks Billionaires Can't Stop Buying If there's one certainty about investors as a whole, it's that they'll find the good in even the direst situations. With the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite tumbling into a bear market in 2022, investors turned to companies enacting stock splits for good news. A stock split allows a publicly traded company to alter its share price and outstanding share count without having any impact on its market cap or operations. Forward stock splits lower a company's share price while increasing its share count by the same magnitude, while a reverse stock split is designed to increase a company's share price and reduce its outstanding share count by the same factor. Image source: Getty Images. In general, forward stock splits are what tend to attract investors. Companies enacting forward splits are usually outperforming and out-innovating their competition. Reducing a public company's share price via a stock split makes it more nominally affordable for everyday investors who don't have access to fractional-share purchases with their online broker. But it's not just retail investors that have been fascinated with stock-split stocks. According to the newest round of Form 13F filings with the Securities and Exchange Commission (SEC), billionaire money managers have been buying up shares of companies that have enacted stock splits. What follows are three stock-split stocks billionaires couldn't stop buying during the first quarter. Alphabet The one stock-split stock that stands head and shoulders above all others when it comes to billionaire buying interest is Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), the parent company of internet search engine Google and streaming platform YouTube. Alphabet completed a 20-for-1 forward stock split in mid-July of last year. During the first quarter, seven billionaires added Alphabet Class A (GOOGL) shares to their respective funds, including: Dan Loeb of Third Point Philippe Laffont of Coatue Management Chase Coleman of Tiger Global Management Bill Ackman of Pershing Square Capital Management Steven Cohen of Point72 Asset Management Ray Dalio of Bridgewater Associates Israel Englander of Millennium Management In this exact order, these billionaires bought roughly 4.75 million shares, 4.64 million shares, 4.64 million shares, 2.19 million shares, 2.15 million shares, 1.56 million shares, and 1.56 million shares of Google Class A stock in the March-ended quarter. The operating segment that makes Alphabet tick is Google. Based on monthly data provided by GlobalStats, you have to go back to the first quarter of 2015 to find the last time Google didn't account for at least a 90% share of global internet search. Even with ad spending somewhat depressed in the short term as domestic fears of a recession build, Google shouldn't have any trouble remaining a cash cow with a virtually insurmountable market share lead. However, billionaires are probably buying shares of Alphabet for its ancillary business segments as much as they are for its tried-and-true internet search division. For instance, YouTube has become the second most-visited social site on the planet. More importantly, short-form videos known as Shorts are really resonating with users. Daily Shorts views have jumped to north of 50 billion from roughly 30 billion in less than a year. Google Cloud represents another intriguing opportunity for Alphabet. The first quarter saw Alphabet's cloud infrastructure service segment generate a profit while sustaining a double-digit growth rate. Keep in mind that enterprise cloud spending is still in its early stages, which should give Google Cloud plenty of opportunity to become a serious cash flow driver in the years to come. DexCom A second stock-split stock that billionaires can't stop buying is medical device company DexCom (NASDAQ: DXCM), which undertook a 4-for-1 forward split in mid-June 2022. DexCom designs and manufactures continuous glucose monitoring (CGM) devices for patients with diabetes. According to an abundance of 13F filings, five billionaire fund managers were eager buyers of DexCom shares, including: Ken Griffin of Citadel Advisors Steven Cohen of Point72 Asset Management John Overdeck and David Siegel of Two Sigma Investments Jim Simons of Renaissance Technologies In the same order as listed above, these billionaires purchased approximately 1.81 million shares, 1.36 million shares, 349,100 shares, and 212,900 shares of DexCom stock during the first quarter. The \""why?\"" behind these buys is simple: untapped opportunity. The number of people in the U.S. and globally with diabetes continues to grow. In the U.S., the number of diabetics regularly using insulin to achieve glycemic balance who qualify for a CGM is more than triple the actual number of patients currently using a CGM. There's a sustainable opportunity for DexCom to grow its sales, profits, and pricing power over time as awareness of CGMs grows domestically. But this is far from a domestic story. In 2000, 151 million people worldwide had diabetes. As of 2021, this figure had more than tripled to 537 million. By 2045, IDF Diabetes Atlas estimates 783 million people will be diabetic globally. Expanding its products into new regions and improving reimbursement access internationally should allow DexCom to sustain an annual sales growth rate of near 20% for the foreseeable future. Another reason billionaires are onboard with DexCom is the company's innovation. DexCom has developed numerous generations of CGMs, and it regularly leans on the competitive advantages of its products, such as real-time readings and wireless connectivity, to differentiate itself from its peers. Image source: Getty Images. Palo Alto Networks The third stock-split that billionaires can't stop buying is cybersecurity company Palo Alto Networks (NASDAQ: PANW). Palo Alto completed a 3-for-1 stock split last September. Based on Form 13F filings, three successful billionaire money managers took the plunge with Palo Alto, including: Steven Cohen of Point72 Asset Management Ken Griffin of Citadel Advisors Chase Coleman of Tiger Global Management As listed above, these billionaire investors purchased in the neighborhood of 571,400 shares, 355,100 shares, and 257,700 shares of Palo Alto Networks' stock during the first quarter. The great thing about cybersecurity stocks is they've evolved into basic necessity solution providers. Businesses were steadily moving their data online and into the cloud prior to the COVID-19 pandemic. But over the past three years, this shift has accelerated. No matter what's happening with the stock market or U.S. economy, businesses of all sizes with an online or cloud presence need to protect their sensitive information. That's good news for Palo Alto and its peers. What's really powered Palo Alto's growth over the past couple of years is its defined shift toward cloud-based software-as-a-service (SaaS) solutions. Although it's not abandoned physical firewall products, the percentage of net sales derived from SaaS subscriptions has grown from 61.7% in fiscal 2018 (the company's fiscal year ends July 31) to 78.3% through the first nine months of fiscal 2023. A subscription-driven operating model should enhance its gross revenue retention and provide a lift to the company's long-term operating margin. Something else that's likely raising the eyebrows of billionaire fund managers is Palo Alto's ability to land big customers and coerce add-on sales. The company now has 25 accounts generating at least $10 million in total bookings, which is more than double from where things stood at this time last year. Furthermore, the percentage of Prisma Cloud subscribers that purchased four or more modules grew 90% year over year in the fiscal third quarter. Landing the big fish and netting add-on sales is an easy way to continually trounce Wall Street's revenue and profit growth forecasts. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 22, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet and Palo Alto Networks. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wednesday Sector Leaders: Utilities, Healthcare The best performing sector as of midday Wednesday is the Utilities sector, higher by 1.0%. Within that group, Edison International (Symbol: EIX) and Eversource Energy (Symbol: ES) are two large stocks leading the way, showing a gain of 2.2% and 2.1%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 1.0% on the day, and down 7.16% year-to-date. Edison International, meanwhile, is up 5.66% year-to-date, and Eversource Energy, is down 16.04% year-to-date. Combined, EIX and ES make up approximately 5.3% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, higher by 0.3%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Edwards Lifesciences Corp (Symbol: EW) are the most notable, showing a gain of 3.1% and 2.5%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.5% in midday trading, and down 5.57% on a year-to-date basis. DexCom Inc, meanwhile, is up 2.00% year-to-date, and Edwards Lifesciences Corp is up 12.38% year-to-date. Combined, DXCM and EW make up approximately 2.0% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, two sectors are up on the day, while seven sectors are down. SECTOR % CHANGE Utilities +1.0% Healthcare +0.3% Consumer Products -0.8% Technology & Communications -0.8% Financial -1.0% Industrial -1.1% Services -1.4% Materials -1.4% Energy -1.7% 25 Dividend Giants Widely Held By ETFs \u00bb Also see: \u0095 Low Priced Dividend Stocks \u0095 FOSL Videos \u0095 Top Ten Hedge Funds Holding APRW The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-06-01,117.48,119.63,116.305,119.58,
DXCM,2023-06-02,120.0,122.84,118.68,122.57,
DXCM,2023-06-05,123.0,126.305,122.22,124.66,
DXCM,2023-06-06,125.49,126.59,124.36,125.38,"Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long Haul No investment is totally impervious to the environment in which it exists. In a time where recession concerns remain for many investors, and the market is continuing to deal with regular bouts of volatility, it can be easy to lose sight of your long-term investment horizon and get caught up in the day-to-day machinations of the market. However, if you're investing in stocks for a period from three to five years up to decades, this long-term mindset will not only help you to be highly selective in the stocks that you buy, but can also help you ride out the inevitable volatile periods with greater mental fortitude. If you're looking for two compelling businesses to invest $1,500 in this month, here are two names to consider hitting the buy button on right now. 1. Fiverr Fiverr (NYSE: FVRR) continues to help customers, from small enterprises to massive brands, connect with freelancers that meet their business needs. On the other side of that equation, Fiverr remains a leading platform for freelancing professionals with skills across hundreds of specialties to connect with clients all over the world. Even if a recession were to hit, the long-term tailwinds driving the gig economy, which is an increasingly important segment of the overall labor economy, look poised to persist well beyond any such period. The desire for flexible work options and freelance talent isn't curtailing, it's growing. The pandemic certainly promoted the rise of remote and gig work. But now more than ever, workers are looking for ways to earn money on their own terms, whether to replace their full-time job or create a supplemental stream of income. The benefits of the gig economy aren't solely tied to gig workers, either. For companies of all sizes, the advantage of being able to contract talent on an as-needed or long-term basis without hiring full-time employees is clear in any environment, and even more so in the current macro landscape where corporate belts are tightening. Fiverr's platform seamlessly engages both sides of the growing gig economy. Even in a difficult operating environment, the company's continued rollout of new digital products and services, as well as tools to help both freelancers and the clients hiring them succeed, is clearly paying off. Fiverr added 20 new gig categories in the first quarter of 2023 alone, many of which were AI-centric. For example, businesses can now hire AI artists on Fiverr or retain freelancers to construct AI-based models or apps. Fiverr reported revenue of $88 million in the first quarter, a 1.5% increase from the prior-year period, but a 30% jump on a two-year basis. Buyers of freelance services were spending 4% more on the platform as of the end of the first quarter than they were at the same time the prior year, while Fiverr closed out the three-month period with 4.3 million active buyers globally. Now Fiverr takes a 30.4% cut of all transactions completed on the platform, compared to 29.6% one year ago and 27.2% two years ago. Over the trailing 12 months, Fiverr has pulled in revenue totaling about $339 million. The company isn't profitable yet, but it shaved its net loss down in the first three months of 2023 to just around a quarter of what it was a year ago. Fiverr's business serves a vital and growing force in the broader labor economy. This could create long-term tailwinds of growth that investors may want to capitalize on. 2. DexCom DexCom (NASDAQ: DXCM) has amassed a business that now accounts for almost half of all sales generated in the continuous glucose monitoring (CGM) device market worldwide. The company is targeting revenue of approximately $3.4 billion to $3.5 billion for the full-year 2023, which would represent 17% growth on the low end and 21% growth on the high end from its 2022 revenue figure. With some analysts estimating that the CGM market will hit a valuation of $8.3 billion in 2023, that would put DexCom's slice of that total right around the 40% mark. If the company's performance in the first three months of 2023 is any indication, DexCom looks to be on a solid track to meet that goal. The first quarter saw the company rake in revenue of $742 million, up 18% from the year-ago quarter. Of that total, $652 million was derived from sales of its CGM sensors, as well as recurring subscriptions for its hardware offerings, while the remaining $90 million came from hardware sales. The company recently released its G7 CGM, marketed as being the most accurate CGM device and the most covered by private and public insurers that has been commercialized so far. The G7 launch is still underway in DexCom's largest market, the U.S., having just garnered a regulatory green light from the U.S. Food and Drug Administration at the end of last year. As of the first quarter, 71% of DexCom's revenue is derived from U.S. sales, while the remaining 29% is from international markets. In the company's year-end 2022earnings call management referenced a proposal by the U.S. Center for Medicare and Medicaid Services that would expand CGM coverage to type 2 diabetics on basal insulin, as well as certain patients not using insulin who have hypoglycemia. They said that this proposal, combined with the continued expansion of commercial coverage, stood to double DexCom's total reimbursed addressable market in the U.S. Well, that CMS proposal was approved, and coverage began for these patient populations as of April. While this is great news for any business that sells CGM devices (AbbVie is one notable example that comes to mind), DexCom's considerable market share makes it well-positioned to benefit from the generous tailwinds that coverage expansion and the rising prevalence of diabetes will provide. This is also a profitable business. DexCom's trailing 12-month earnings total $293 million at this writing. With CGM use cases spanning the type 1 and type 2 diabetes markets, and even including individuals with prediabetes in certain instances, there is a lot of room left for this healthcare stock and its shareholders to flourish. 10 stocks we like better than Fiverr International When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Fiverr International wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of May 30, 2023 Rachel Warren has positions in AbbVie and DexCom. The Motley Fool has positions in and recommends Fiverr International. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-07,125.76,126.19,117.74,119.71,"[""Vanguard Mid-Cap ETF Experiences Big Outflow Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $130.4 million dollar outflow -- that's a 0.3% decrease week over week (from 245,393,272 to 244,776,096). Among the largest underlying components of VO, in trading today DexCom Inc (Symbol: DXCM) is down about 1.7%, Amphenol Corp. (Symbol: APH) is up about 1.1%, and Arthur J. Gallagher & Co. (Symbol: AJG) is lower by about 0.6%. For a complete list of holdings, visit the VO Holdings page \u00bb The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $182.88 per share, with $228.43 as the 52 week high point \u2014 that compares with a last trade of $212.26. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb Also see: \u0095 Information Technology Services Dividend Stocks \u0095 HOME Videos \u0095 Funds Holding FULT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""SPY ETF Gains 13% YTD; Analysts See Further Upside The artificial intelligence (AI) craze and rebound in tech stocks have resulted in the SPDR S&P 500 ETF Trust\u2019s (NYSEARCA:SPY) year-to-date rally of about 13%. Interestingly, the SPY ETF stock\u2019s technical indicators and the analysts\u2019 price target suggest further upside potential from the current level. The SPDR S&P 500 ETF is designed to track the S&P 500 Index (SPX) and provides investors with a smart investment option. The ETF (Exchange Traded Funds) is highly diversified as it represents a basket of over 500 companies from across eight market sectors, including technology, health care, and more. One of the major factors worth considering is the SPY ETF\u2019s considerably low fees. The ETF has an expense ratio (cost of managing the ETF) of 0.09%, which makes it an attractive investment. Remarkably, SPY has delivered an average annualized return of 12.1% in the past decade, ending in March 2023. Moreover, SPY ETF stock pays a 1.51% annual dividend yield, which enhances investors\u2019 returns over the long run. Is SPY a Buy? It is worth mentioning that as per 6,186 analysts providing ratings on SPY\u2019s 505 holdings, the ETF is a Moderate Buy, and the average price target of $478.05 implies a 11.7% upside. Apart from the experts, TipRanks\u2019 easy-to-read technical summary signals indicate that SPY ETF stock is a Buy at current levels. Additionally, the weighted average Smart Score of the SPDR S&P 500 ETF is eight, implying it is more likely to beat the broader market averages. It is worth highlighting that more than 50% of the holdings boast an outperform Smart Score. Sponsored Links Look For Any High School Yearbook, It's Free Classmates While most of the ETF\u2019s holdings witnessed strong returns over the past year, there remain a few outperformers, having gained over 60%. Importantly, analysts see further upside potential in these stocks. Here are the 10 best-performing stocks in the SPY ETF: First Solar (FSLR) Nvidia Corporation (NVDA) Netflix, Inc. (NFLX) Fair Isaac Corporation (FICO) Axon Enterprise, Inc. (AXON) General Electric (GE) Dexcom (DXCM) Lamb Weston Holdings (LW) Las Vegas Sands (LVS) Cardinal Health (CAH) Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-06-08,119.52,121.28,118.31,121.13,"Here’s Why the QQQ ETF Could Be a Great Pick Investors looking to enjoy the rally in tech stocks may consider the Invesco QQQ Trust (NASDAQ:QQQ). So far in 2023, the QQQ ETF has advanced more than 32%, easily outperforming the 12% rise in the S&P 500 Index (SPX). Remarkably, the QQQ ETF stock has beaten the S&P 500 in nine out of the last ten years. Interestingly, analysts are optimistic about the future growth potential of this ETF, envisioning further opportunities for expansion. The QQQ ETF tracks the NASDAQ 100 Index (NDX) and provides an opportunity to hold companies in key markets such as cloud computing, artificial intelligence, streaming services, electric vehicles, and more. Additionally, the QQQ ETF stock has delivered an average annualized return of 17.7% in the past decade, ending in March 2023. Also, the ETF has a low expense ratio (cost of managing the ETF) of 0.20%, which makes it an attractive investment. Is QQQ Stock a Buy? It is worth mentioning that, as per 1,734 analysts providing ratings on QQQ’s 102 holdings, the ETF is a Moderate Buy. Its average price target of $385.11 implies a 10.4% upside. Apart from analysts’ consensus, QQQ is a Buy based on the technical indicators. Additionally, the Invesco QQQ ETF has an Outperform Smart Score of eight on TipRanks, implying it is more likely to beat the broader market averages. It is worth highlighting that more than 50% of the holdings boast an Outperform Smart Score. While most of the ETF’s holdings witnessed strong returns over the past year, there remain a few stars, having gained over 50%. Let’s take a look at the five best-performing stocks in the ETF: Nvidia Corporation (NVDA) Netflix Inc. (NFLX) Dexcom (DXCM) Mercadolibre, Inc. (MELI) Copart, Inc. (CPRT) Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-09,121.31,124.55,120.2,124.34,"Why Is Steris (STE) Down 0.9% Since Last Earnings Report? It has been about a month since the last earnings report for Steris (STE). Shares have lost about 0.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Steris due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. STERIS Q4 Earnings Beat Estimates, Gross Margin Down STERISreported fourth-quarter fiscal 2023 adjusted earnings per share of $2.30, up 12.7% from the year-ago quarter’s figure. The metric also exceeded the Zacks Consensus Estimate by 6.9%. The adjustment excludes the impacts of certain non-recurring charges like the amortization of acquired intangible assets and acquisition and integration-related charges among others. The company’s GAAP EPS was $1.88, up 75.7% from the year-ago quarter’s earnings of $1.07. Full-year adjusted EPS was $8.20, up 3.5% from fiscal 2022. Revenues in Detail Revenues of $1.38 billion increased 14% year over year in the fourth quarter. The metric beat the Zacks Consensus Estimate by 8.7%. Organic revenues at constant exchange rate or CER rose 16% year over year in the fiscal fourth quarter. In fiscal 2023, the company reported revenues of $4.96 billion, up 8.1% from fiscal 2022. Quarter in Detail The company operates through four segments — Healthcare, Applied Sterilization Technologies (AST), Life Sciences and Dental. Revenues at Healthcare rose 20% year over year to $884.6 million (up 21% on a CER organic basis). This performance reflected a 31% improvement in capital equipment revenues, a 15% increase in service revenues and a 15% rise in consumable revenues. Revenues at AST improved 7% to $239.1 million (up 10% on a CER organic basis). Revenue growth was driven by increased demand from core medical device customers, partially offset by continued reduction in demand from single-use bioprocessing customers. Revenues in the Life Sciences segment rose 10% to $157.5 million (up 11% year over year on a CER organic basis). Service revenues rose 6% and capital equipment revenues increased 8%. Consumable revenues rose 14%. The Dental segment reported revenues of $103.6 million, down 2% year over year (down 1% on a CER organic basis). Margins Gross profit in the reported quarter was $558.1 million, up 2.9% from the prior-year quarter’s gross profit. Gross margin contracted 475 basis points (bps) year over year to 42.5% in the reported quarter. STERIS witnessed a 25.9% year-over-year drop in selling, general and administrative expenses to $335.9 million. Research and development expenses rose 1.1% to $26.4 million. Adjusted operating expenses of $362.3 million declined 24.5% year over year. The adjusted operating margin expanded 871 bps to 16.3%. Financial Details STERIS exited fiscal 2023 with cash and cash equivalents of $208.4 million compared with $259.4 million at the end of the fiscal third quarter. Cumulative net cash flow from operating activities at the end of fiscal fourth quarter was $756.9 million compared with $684.8 million a year ago. Guidance STERIS provided its fiscal 2024 financial guidance. Full-year revenues are expected to increase 7-8% from fiscal 2022. Organic revenues at CER are expected to increase 6-7%. The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $5.14 billion. Adjusted earnings per share for fiscal 2023 are expected in the range of $8.55 to $8.75. The Zacks Consensus Estimate for the metric is pegged at $8.71. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -7.13% due to these changes. VGM Scores At this time, Steris has an average Growth Score of C, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Steris has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Performance of an Industry Player Steris is part of the Zacks Medical - Instruments industry. Over the past month, DexCom (DXCM), a stock from the same industry, has gained 0.1%. The company reported its results for the quarter ended March 2023 more than a month ago. DexCom reported revenues of $741.5 million in the last reported quarter, representing a year-over-year change of +17.9%. EPS of $0.17 for the same period compares with $0.08 a year ago. For the current quarter, DexCom is expected to post earnings of $0.22 per share, indicating a change of +29.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.4% over the last 30 days. DexCom has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-12,124.8,127.22,123.52,126.91,
DXCM,2023-06-13,126.98,128.02,124.68,125.95,"DarioHealth is an AI-Powered Digital Therapeutics Play DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common comorbidity conditions, including diabetes, weight loss, hypertension, musculoskeletal and behavioral health, across six domains: timing, tone, channel, content, frequency and intervention. It utilizes AI to help people with chronic conditions manage their health. It monitors a user’s condition with sensors and provides recommendations, information, and provider engagement. The app was designed to handle chronic disease management in between doctor visits. The company has nearly $67 million in contract value as it pursues B2B with employers over earlier direct-to-consumer (DTC) models. B2B now accounts for 70% of total revenues. Strategic Partnerships The company expanded strategic relationships with American Well Co.'s telemedicine platform (NASDAQ: AMWL) and the first account through national pharmacy benefits manager Sanofi. Sanofi of Dario data showed a statistically significant reduction in all-cause healthcare resource utilization, which included a (23.5%) reduction in hospitalizations. It will be offering its cardiometabolic solution will be integrated into the Amwell platform, reaching an installed base of 90 million people and 2,000 health plans. This could result in highs tens of millions in future revenues. It expects to see results near year's end. Amwell joins the strategic partners' list, including Sanofi US Services Inc., CVS Health Co. (NYSE: CVS), Virgin Pulse Inc., Solera Health Inc. and Alliant Insurance Services. DexCom Partnership The company partnered with DexCom Inc. (NASDAQ: DXCM) to integrate its continuous glucose monitoring (GCM) technology in the DarioHealth multi-chronic condition platform. This enables users to collect blood sugar readings into the app. The company also closed a new contract with a national pharmacy benefits manager (PBM) to provide its employer clients with the DarioHealth platform, starting with its diabetes solution in Q2 2023. Accelerating On May 11, 2023, DarioHealth released its fiscal first-quarter 2023 results for the quarter ending March 2023. The company reported an adjusted earnings-per-share (EPS) loss of (-$0.45), excluding non-recurring items, versus consensus analyst estimates for a loss of ($0.50), beating estimates by $0.05. Revenues fell (12.3%) year-over-year (YOY) to $7.07 million, beating analyst estimates by $361K. Gross profit margin improved 44.8%, Non-GAAP gross profit margin was 60.1% of revenues. The cash balance was $38.8 million. DarioHealth expects to bump gross margins up to 70% in 2024. Most contracts are multi-conditioned, generating more revenues than a single condition. CEO Insights DarioHealth CEO Erez Raphael commented, ""Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022. The increase in B2B share of total revenue reflects what we believe are growing trends in the market favoring Dario's single, integrated, multi-condition digital health platform.” Dario retains nearly 80% of the people who try the platform for a year. It runs the engagement data through its AI engine to better personalize user experiences in a predictive manner. An individual's disease state changes and differs from others. The platform can adjust to how its user's health priorities may change with their surroundings and activities. DarioHealth analyst ratings and price targets are on MarketBeat. Weekly Descending Triangle The weekly candlestick chart on DRIO shows it's trying to recover from a descending triangle breakdown. The weekly descending triangle commenced after topping at $7.33 in August 2022. Shares collapsed to the flat-bottom trendline area of around $3.87 in September 2022. DRIO was choppy as it slingshot back up through the descending trendline peaking at $6.87 in January 2023 before breaking down through the flat-bottom trendline of the triangle at $3.87 in April 2023. Shares fell to a new swing low of $3.13 in May 2023 before triggering a weekly market structure (MSL) low breakout attempt at the $4.09 trigger. Pullback support levels are at $3.87, $3.53, $3.13 and $2.79. Pullback support levels are $12.36, $11.39 weekly MSL trigger, $10.90 and $10.20. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-14,126.26,129.2,125.96,127.06,"Commit To Purchase DexCom At $110, Earn 8.8% Using Options Investors eyeing a purchase of DexCom Inc (Symbol: DXCM) stock, but tentative about paying the going market price of $127.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2024 put at the $110 strike, which has a bid at the time of this writing of $9.70. Collecting that bid as the premium represents a 8.8% return against the $110 commitment, or a 8.6% annualized rate of return (at Stock Options Channel we call this the YieldBoost). Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $110 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless DexCom Inc sees its shares fall 14.2% and the contract is exercised (resulting in a cost basis of $100.30 per share before broker commissions, subtracting the $9.70 from $110), the only upside to the put seller is from collecting that premium for the 8.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $110 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2024 put at the $110 strike for the 8.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 251 trading day closing values as well as today's price of $127.48) to be 44%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of StockOptionsChannel.com. Top YieldBoost Puts of the Nasdaq 100 » Also see: • Top Stocks Held By Cathie Wood • Top Ten Hedge Funds Holding TOWN • PEBO market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-15,128.32,131.24,128.1,130.98,
DXCM,2023-06-16,132.0,134.14,129.99,130.1,
DXCM,2023-06-20,129.73,130.8,127.64,129.97,
DXCM,2023-06-21,130.13,130.265,126.545,127.86,"[""Wednesday Sector Laggards: Technology & Communications, Healthcare The worst performing sector as of midday Wednesday is the Technology & Communications sector, showing a 0.9% loss. Within that group, Intel Corp (Symbol: INTC) and Advanced Micro Devices Inc (Symbol: AMD) are two large stocks that are lagging, showing a loss of 4.6% and 4.6%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 1.1% on the day, and up 38.27% year-to-date. Intel Corp, meanwhile, is up 26.75% year-to-date, and Advanced Micro Devices Inc is up 77.18% year-to-date. Combined, INTC and AMD make up approximately 4.0% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 0.2% loss. Among large Healthcare stocks, Teleflex Incorporated (Symbol: TFX) and DexCom Inc (Symbol: DXCM) are the most notable, showing a loss of 3.6% and 2.3%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.1% in midday trading, and down 2.01% on a year-to-date basis. Teleflex Incorporated, meanwhile, is down 2.17% year-to-date, and DexCom Inc is up 10.66% year-to-date. Combined, TFX and DXCM make up approximately 1.2% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, six sectors are up on the day, while two sectors are down. SECTOR % CHANGE Energy +1.3% Utilities +0.6% Materials +0.5% Industrial +0.4% Services +0.3% Consumer Products +0.1% Financial -0.0% Healthcare -0.2% Technology & Communications -0.9% 25 Dividend Giants Widely Held By ETFs \u00bb Also see: \u0095 EUMV YTD Return \u0095 APPN market cap history \u0095 CPIX Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here\u2019s Why the Invesco QQQ Trust ETF is Appealing Investors with a long-term horizon could consider investing in the Invesco QQQ Trust (NASDAQ:QQQ) ETF. This appealing ETF tracks the NASDAQ 100 Index (NDX) and provides an opportunity to hold stocks from 10 different sectors. Remarkably, the QQQ ETF has advanced more than 39% year-to-date thanks to the AI-related boom. Moreover, the ongoing rally may persist due to falling inflation, the economy's resilient recovery, and the pause on the Fed\u2019s benchmark interest rate hike. What Makes QQQ ETF Attractive? The QQQ ETF stock is a growth-focused index fund with about $197.83 billion in assets under management. Interestingly, the QQQ ETF has beaten the S&P 500 Index (SPX) in nine out of the last ten years, with the trend continuing in 2023 so far. Additionally, the QQQ ETF stock has delivered an average annualized return of 17.7% in the past decade, ending in March 2023. Also, the ETF has a low expense ratio (cost of managing the ETF) of 0.20%, which makes it a promising investment. Is Invesco QQQ a Good Buy? Per the recommendations of 1,744 analysts giving stock forecasts for the 102 holdings of the Invesco QQQ ETF, the 12-month average price target of $388.73 implies 6% upside potential from current levels. Also, the QQQ ETF has a Moderate Buy consensus rating on TipRanks. Apart from analysts\u2019 consensus, TipRanks\u2019 easy-to-read technical summary signals indicate that QQQ ETF stock is a Buy at current levels. Importantly, the Invesco QQQ ETF has an Outperform Smart Score of eight on TipRanks, suggesting it could deliver market-beating returns in the future. Top 10 Performing Stocks in QQQ ETF The rally in top technology stocks drove the index fund to a new high last month. While several of the ETF\u2019s holdings witnessed strong returns over the past year, there remain a few stars, having gained over 60%. Let\u2019s take a look at the ten best-performing stocks in the ETF: Nvidia Corporation (NVDA) Netflix Inc. (NFLX) Dexcom (DXCM) Mercadolibre, Inc. (MELI) Broadcom Inc. (AVGO) Meta Platforms, Inc. (META) Intuitive Surgical (ISRG) Copart, Inc. (CPRT) Constellation Energy Corporation (CEG) Workday (WDAY) Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-06-22,127.61,128.08,125.89,126.52,"3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio DexCom, Inc. DXCM is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition and reimbursement persist. This Zacks Rank #3 (Hold) company’s shares have risen 12.9% year to date compared with the industry’s 7.7% growth. The S&P 500 Index has gained 15.3% in the same time frame. DXCM, a renowned medical-devices company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $50.4 billion. It projects 40.4% growth over the next five years and expects to maintain the strong performance going forward. DexCom’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.19%. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Portfolio: We are upbeat about DexCom's continued strength in its CGM products. It launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available in international markets. The company received FDA clearance for this technology in December 2022. These developments are likely to support DXCM’s future growth. In 2022, the company also launched the easy-to-use Dexcom ONE real-time CGM System on prescription for everyone with type 1 or type 2 diabetes using insulin. It did so via drug tariff in NHS England, Wales, Scotland and Northern Ireland. DexCom’s prospects in alternative markets, such as non-intensive diabetes management, hospitals, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Positive Coverages: DXCM’s products have been receiving increasing coverage over the past few months, raising our optimism. In June 2022, the company announced that type 1 and type 2 diabetic patients (aged two years and above) who are on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. DexCom ended the first quarter with new patient additions. The Ontario government began coverage for the Dexcom G6 CGM System through the province’s Assistive Devices Program. This program has been designed for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Strong Q1 Results: DXCM’s solid first-quarter 2023 revenues buoy optimism. Rising volumes across all channels, along with new customer additions due to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. Downsides Rising Costs: DexCom's gross margin contracted 90 basis points during the first quarter to 62.4%, reflecting the rising cost of sales. The company expects adjusted gross margin of 62-63% for 2023, indicating persisting cost pressure. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid changes and new product introductions. DXCM’s competitors manufacture and market products for the single-point finger stick device market and collectively account for the worldwide sales of self-monitored glucose testing systems at present. Estimate Trend DexCom is witnessing a stable estimate revision trend for 2023 and 2024. In the past 30 days, the consensus mark for earnings per share remained unchanged at $1.06 for 2023 and at $1.47 for 2024. The Zacks Consensus Estimate for the company’s second-quarter 2023 revenues is pegged at $837 million, indicating a 20.2% improvement from the year-ago quarter’s reported number. The same for earnings is pinned at 22 cents per share, implying 29.4% growth year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks from the broader medical space are Merit Medical Systems MMSI, Alcon ALC and Perrigo PRGO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Merit Medical Systems has an estimated long-term growth rate of 11%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 20.22%. MMSI’s shares haverisen 17% year to date compared with the industry’s 12.1% growth. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.85%. ALC’s shares have rallied 16.9% year to date compared with the industry’s 7.7% growth. Perrigo’s earnings are expected to improve 24.6% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, delivering an average negative surprise of 0.79%. The company’s shares have lost 0.4% year to date against the industry’s 5.3% growth. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers ""Most Likely for Early Price Pops."" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-23,125.92,127.5,124.83,126.75,
DXCM,2023-06-26,125.38,126.15,123.151,124.62,"Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper ""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Large-Cap Growth Stocks Factor-Based Stock Portfolios High Momentum Stocks Dividend Aristocrats 2023 High Insider Ownership Stocks Top S&P 500 Stocks About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-27,124.62,125.48,121.79,123.5,"Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View Dexcom DXCM announced its strategy to expand the accessibility of its glucose sensing technology products to millions of other patients than currently covered. Its plan includes expansion in international markets and launch of a new product targeting diabetic patients who don’t use insulin yet. The company also stated that private payers are including its products under their coverage, earlier than expected. New Product Launch Dexcom is currently developing a new product with a 15-day sensor, designed specifically for diabetic patients who are not on insulin. The company is planning to launch the new product in the United States in 2024. DXCM estimated that almost 70% of Americans living with diabetes will likely be eligible for using the new product to track and manage their glucose levels. The product will also offer a new software experience for diabetic patients not using insulin. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote International Launch The company continues to expand its presence in new countries. Its Dexcom G7 is now available in 14 countries. DXCM launched Dexcom ONE in Argentina earlier this year, marking its entry into Latin America. Payer Coverage In April, the Centers for Medicare & Medicaid Services, administering the government’s Medicare program, expanded its coverage for continuous glucose monitoring (CGM) products to include additional patients. The added coverage now includes CGM for type II diabetic patients on basal insulin. Dexcom estimates that the expanded coverage should increase targeted patient population by millions. Per the press release, it is estimated that 3-4 million people in the United States have a history of problematic hypoglycemia and majority of them are now included under Medicare coverage. Moreover, commercial insurers or private payers are also following Medicare’s steps to cover this additional patient population. The inclusion of type II diabetic patients on basal insulin by the commercial players has been faster than expected, with 60% commercial coverage for this population already in place. The expanded coverage will provide the patient population with access to Dexcom G7, the most accurate CGM system. This should boost Dexcom’s top-line growth going forward. Dexcom Raises Long-Term Outlook Based on robust demand for its products in the last two years, DXCM has raised its guidance for 2025. The company now expects a $500 million increase in revenues (from that projected earlier). Dexcom now projects revenues of $4.6-$5.1 billion in 2025, up from the previous guided range of $4.0-$4.5 billion. The company raised its guidance for adjusted operating and EBIDTA margins by 1 percentage point to 21% and 31%, respectively. However, it continues to expect adjusted gross margin of 65%. Dexcom’s revenues are anticipated to grow 17-21% in 2023 to $3.4-$3.515 billion. The Zacks Consensus Estimate for revenues in 2023 is pegged at $3.49 billion. The bottom line is expected to improve 23% to $1.07 in the same year. Price Performance Shares of Dexcom have risen 10% year to date compared with the industry’s 7% growth. The S&P 500 Index has risen 14% in the said time frame. Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider Dexcom currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Hologic HOLX, Alcon ALC and Perrigo PRGO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Hologic has an estimated growth rate of 5% for fiscal 2024. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX’s shares have risen 8.4% year to date compared with the industry's 6.4% growth. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.85%. ALC’s shares have rallied 17.2% year to date compared with the industry’s 6.4% growth. Perrigo’s earnings are expected to improve 24.6% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, delivering an average negative surprise of 0.79%. The company’s shares have lost 1.9% year to date against the industry’s 4.8% growth. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-28,124.01,127.86,123.83,126.42,"[""Looking for a Growth Stock? 3 Reasons Why DexCom (DXCM) is a Solid Choice Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks. Our proprietary system currently recommends DexCom (DXCM) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below: Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 51.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 22.6% this year, crushing the industry average, which calls for EPS growth of 7.9%. Cash Flow Growth Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 37.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 8.7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 75.9% over the past 3-5 years versus the industry average of 9.2%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for DexCom have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.2% over the past month. Bottom Line While the overall earnings estimate revisions have made DexCom a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination indicates that DexCom is a potential outperformer and a solid choice for growth investors. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries. FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks. What if you'd invested in DexCom (DXCM) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today? DexCom's Business In-Depth With that in mind, let's take a look at DexCom's main business drivers. San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom\u2019s monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company\u2019s monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels. Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024. DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product use. It is also focusing on international markets However, market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. 2022 at a Glance For the full-year 2022, the company reported adjusted EPS of 87 cents, up 77.6% from 2021. Full-year 2022 revenues came in at $2.91 billion, up 19% year over year. Revenues in the United States were up 16%. International revenues were up 28% and 31% reportedly and organically, respectively. Bottom Line Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in DexCom ten years ago, you're likely feeling pretty good about your investment today. According to our calculations, a $1000 investment made in June 2013 would be worth $21,887.46, or a 2,088.75% gain, as of June 28, 2023. Investors should keep in mind that this return excludes dividends but includes price appreciation. The S&P 500 rose 171.41% and the price of gold increased 49.18% over the same time frame in comparison. Looking ahead, analysts are expecting more upside for DXCM. DexCom exited first-quarter 2023 on a strong note, wherein earnings and revenues beat the Zacks Consensus Estimate. Impressive contribution from the Sensor segment, and domestic and international revenue growth were key catalysts. DexCom\u2019s prospects in alternative markets bode well. The company made continued advancements with respect to key strategic objectives and ended the quarter with new patient additions. Its slew of tie-ups and buyouts are encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. So far this year, DexCom has outperformed its industry. However, the company faces stiff competition in the market for blood & glucose monitoring devices. Reimbursement risk and supply constraints are other headwinds. The stock has jumped 8.75% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 2 higher, for fiscal 2023; the consensus estimate has moved up as well. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-06-29,126.57,128.9,125.82,127.94,"DexCom (DXCM) Just Flashed Golden Cross Signal: Do You Buy? From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend. DXCM has rallied 7.8% over the past four weeks, and the company is a Zacks Rank #2 (Buy) at the moment. This combination suggests DXCM could be on the verge of another move higher. The bullish case only gets stronger once investors take into account DXCM's positive earnings estimate revisions. There have been 2 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well. Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on DXCM for more gains in the near future. Free Report: Top EV Battery Stocks to Buy Now Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to ""insane levels,"" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid. Download free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-06-30,129.76,131.76,128.202,128.51,
DXCM,2023-07-03,127.23,127.42,124.76,127.02,
DXCM,2023-07-05,126.58,128.48,125.69,128.07,"[""DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada DexCom, Inc. DXCM recently announced that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System received Health Canada\u2019s approval for people with all types of diabetes aged two years and above. The Dexcom G7 has been built on the performance of Dexcom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range. Although approved by Health Canada, Dexcom G7 is not yet available for purchase. Dexcom Canada is working to make Dexcom G7 available to diabetic Canadians by the end of 2023. Dexcom is also currently working with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems. With the latest regulatory approval, DexCom is expected to solidify its foothold in the global CGM business. Significance of the Approval Per Dexcom\u2019s estimates, diabetes affects more than 3 million Canadians, which requires around-the-clock management of glucose levels and daily treatment decisions to manage the disease. Dexcom believes that Health Canada\u2019s approval of the G7 CGM will provide access to an innovative technology that simplifies diabetes management. It has also been shown to significantly (by up to 42%) reduce hospitalizations and emergency room visits due to hypoglycemia. Per an expert familiar with the use of CGM for diabetes management, following the approval of Dexcom G7 in Canada, patients will likely have a new, simple-to-start and easy-to-use tool in their diabetes management toolbox to effectively manage their diabetes and make important health decisions backed by health data and proven results. Dexcom\u2019s management believes that the next-generation Dexcom G7 with its greater accuracy, a simplified user experience, proven results and extensive digital connectivity will likely support greater quality of life and improved outcomes for diabetics. Industry Prospects Per a report by Grand View Research, the global CGM device market size was valued at $7,816.8 million in 2022 and is expected to reach $11.2 billion by 2030 at a CAGR of 4.4%. Factors like the rising cases of diabetes and the increasing adoption of CGM devices are likely to drive the market. Given the market potential, the latest regulatory approval is expected to provide a significant boost to DexCom\u2019s business globally. Notable Developments Last month, DexCom announced that the Dexcom G6 Real-Time CGM System is the only CGM to connect to the Omnipod 5 AID System, thus helping users to protect against high and low glucose levels. In April, DexCom announced its first-quarter 2023 results, wherein it registered a solid uptick in its overall top line, both on a reported and organic basis. It also recorded robust growth in U.S. and international revenues in the quarter. During the earnings release, management confirmed the commencement of the launch of Dexcom G7 in the United States and the finalization of coverage for Dexcom G7 with the U.S. Centers for Medicare & Medicaid Services, providing Medicare beneficiaries reimbursed access to Dexcom\u2019s latest-generation technology. Price Performance Shares of the company have gained 62.1% in the past year compared with the industry\u2019s 9.8% growth and the S&P 500's 15.7% rise. Image Source: Zacks Investment Research Zacks Rank & Other Key Picks Currently, DexCom carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are Hologic, Inc. HOLX, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. Hologic, carrying a Zacks Rank #2 at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX\u2019s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Hologic has gained 12.7% compared with the industry\u2019s 9.8% rise in the past year. HealthEquity, sporting a Zacks Rank #1 at present, has an estimated long-term growth rate of 22%. HQY\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 9.1%. HealthEquity has gained 2.4% against the industry\u2019s 15.3% decline over the past year. Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX\u2019s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%. Boston Scientific has gained 42.2% against the industry\u2019s 22.2% decline over the past year. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio AmerisourceBergen Corporation ABC is well poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this currently Zacks Rank #3 (Hold) company have risen 15.2% year to date compared with the industry\u2019s 14.3% growth. The S&P 500 Index has increased 17% in the same time frame. AmerisourceBergen is one of the world\u2019s largest pharmaceutical services companies, focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. It has a market capitalization of $38.65 billion. The company\u2019s bottom line is anticipated to improve 8.7% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.14%. Image Source: Zacks Investment Research What\u2019s Driving Growth? In fiscal 2022, ABC realigned its reporting structure under two segments \u2014 U.S. Healthcare Solutions and International Healthcare Solutions. The first segment consists of the legacy Pharmaceutical Distribution Services (excluding Proforma), MWI Animal Health, Xcenda, Lash Group and ICS 3PL. It benefits from increasing volume and an expanding customer base. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the coming quarters. In the fiscal second quarter of 2023, revenues at U.S. Healthcare Solutions totaled $56.7 billion, up 11.3% year over year. This improvement was due to higher specialty product sales and overall market growth. However, this upside was partially offset by lower revenues from commercial COVID-19 treatments. Segmental operating income amounted to $756.1 million, up 3.6% year over year. Higher gross profit (which included fees earned from the distribution of government-owned COVID-19 treatments and a gross profit on sales from specialty physician practices) contributed to the upside. Revenues at the U.S. Healthcare Solutions segment are expected to grow 7-8% in fiscal 2023. Operating income is anticipated to increase 3-5%. PharmaLex is a leading provider of specialized services for the life sciences industry, owned by funds advised by AUCTUS Capital Partners AG. It has a significant footprint in Europe and the United States, and a growing presence in other parts of the world. The acquisition of this Germany-based company will enhance ABC\u2019s global portfolio of solutions to support manufacturer partners in the pharmaceutical development and commercialization journey. In 2022, ABC collaborated with TrakCel, the leading innovator of cellular orchestration solutions, to launch an integrated technology platform. The idea was to accelerate patient access to prescribed cell and gene therapies, and provide complete visibility throughout the treatment process. The acquisition of Alliance Healthcare strongly drove AmerisourceBergen\u2019s International segment revenues in fiscal 2022. Adjusted earnings per share for fiscal 2023 is estimated between $11.70 and $11.95, implying a 6-8% increase from the previous year\u2019s level. ABC estimates revenue growth of 6-8% for the same time frame. What\u2019s Hurting the Stock? AmerisourceBergen operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, global competitors and regulatory challenges. The company encounters additional competition from manufacturers, chain drugstores, specialty distributors, and packaging and healthcare technology companies. Increased competition is likely to affect its business. Estimate Trend ABC has been witnessing a positive estimate revision trend for fiscal 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has increased from $11.75 per share to $11.88. The same for fiscal third-quarter 2023 revenues is pegged at $63.41 billion, indicating a 5.6% improvement from the year-ago quarter\u2019s actual. The bottom-line estimate is pinned at $2.82, implying year-over-year growth of 8.5%. AmerisourceBergen Corporation Price AmerisourceBergen Corporation price | AmerisourceBergen Corporation Quote Stocks to Consider A few better-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 18.3% year to date compared with the industry\u2019s 8.8% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 12.8% year to date compared with the industry\u2019s 8.8% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. The company\u2019s shares have rallied 6.8% year to date compared with the industry\u2019s 8.8% growth. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock to Buy Hand Over Fist in July and 1 to Avoid Like the Plague Stock market corrections and bear markets are a normal part of the long-term investing cycle. Nevertheless, substantial downside in equities tends to catch investors off guard. The 2022 bear market, which saw the three major U.S. stock indexes deliver their worst returns since 2008, provides a perfect example. When equities head lower or uncertainty builds on Wall Street, investors will always try to find the proverbial light at the end of the tunnel. Over the past two years, stocks enacting splits have been that ray of positivity. Image source: Getty Images. Stock-split stocks have taken center stage A stock split is an event that allows a publicly traded company to alter its share price and outstanding share count without having any effect on its market cap or operations. It's a purely cosmetic change that can either lower a company's share price (known as a forward stock split) or increase a company's share price (a reverse stock split). The latter is typically done to ensure continued listing on a major stock exchange, while the former is designed to make shares more nominally affordable for everyday investors who don't have access to fractional-share purchases through their broker. Without question, it's forward stock splits that garner most of Wall Street's attention. Companies conducting forward stock splits are usually out-innovating their competition and executing on their strategic initiatives. Since July 2021, eight top-tier companies have enacted forward stocks splits, including: Nvidia (NASDAQ: NVDA), which completed a 4-for-1 split on July 20, 2021. Amazon (NASDAQ: AMZN), which executed a 20-for-1 split on June 6, 2022. DexCom (NASDAQ: DXCM), which enacted a 4-for-1 split on June 13, 2022. Shopify (NYSE: SHOP), which concluded its 10-for-1 split on June 29, 2022. Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG), which closed a 20-for-1 split on July 18, 2022. Tesla (NASDAQ: TSLA), which finished its 3-for-1 split on Aug. 25, 2022. Palo Alto Networks (NASDAQ: PANW), which finalized a 3-for-1 split on Sept. 14, 2022. Monster Beverage (NASDAQ: MNST), which fulfilled its 2-for-1 split on March 28, 2023. As we motor into the scorching-hot month of July, one of these eight stock-split stocks stands out as a phenomenal value for patient investors, while another will likely have an exceptionally difficult time generating a positive return for new buyers. The stock-split stock to buy hand over fist in July: Alphabet Despite an exceptionally strong rally to kick off the first half of 2023, Alphabet, the parent company of internet search engine Google and streaming platform YouTube, is the stock-split stock that stands head and shoulders above its peers as a top buy in July. The biggest headwind for a giant like Alphabet is that it runs an ad-reliant operating model. Advertising is a cyclical industry, with businesses typically paring back their spending months in advance of an economic downturn. With a number of economic data points and indicators suggesting a U.S. recession is growing likelier, it wouldn't be a surprise to see the ad spending environment remain challenging for the next couple of quarters. On the flip side, the U.S. economy spends a disproportionate amount of time expanding. Whereas every recession after World War II has lasted between two and 18 months, periods of expansion usually last years. That's fantastic news for an ad-driven company like Alphabet. Something else investors will appreciate is the reliability of cash flow from Google. According to data from GlobalStats, Google has accounted for between 90% and 93% of worldwide internet search share over the past eight years. It's the obvious choice of advertisers looking to target their message(s), which should translate to strong ad-pricing power for Alphabet. However, the company's long-term growth story has less to do with its foundational search engine and more to do with YouTube and cloud infrastructure service segment Google Cloud. The former is the second most-visited social media site on the planet, while the latter is the global No. 3 cloud infrastructure service provider. Google Cloud is particularly important, given that the margins associated with cloud services are usually much higher than the margins from advertising. Note: Google Cloud recorded its first quarterly profit in the March-ended quarter. Even with shares of Alphabet closing out the first half of the year with a 36% gain, the stock remains a bargain. Investors can scoop up shares right now for 19 times forward-year earnings and roughly 13 times Wall Street's consensus cash flow for 2024. Over the past five years, shares of Alphabet have averaged a forward price-to-earnings (P/E) multiple of 25.1 and a price-to-cash-flow ratio of 18.3. In all respects, Alphabet is a value play among growth stocks. Image source: Getty Images. The stock-split stock to avoid like the plague in July: Nvidia However, not all stock-split stocks are set to outperform. Among the eight prominent companies listed, semiconductor solutions specialist Nvidia is the one to avoid like the plague in July. To be fair, a lot of things have gone right since Nvidia split its stock two years ago. Topping that list is the role Nvidia is playing in the artificial intelligence (AI) revolution. Though the company does have its own suite of AI-inspired solutions, such as virtual agents for businesses, Nvidia's mark is being felt most via its AI-driven A100 and H100 graphics processing units (GPUs) used in data centers. AI solutions and systems require fast data-processing to make split-second decisions, and Nvidia's GPUs are absolutely dominating enterprise data centers According to Nvidia CEO Jensen Huang, \""accelerated computing and generative AI\"" are seemingly pulling orders forward and vastly increasing demand for the company's data center solutions. Nvidia's fiscal second-quarter sales forecast of $11 billion came in miles ahead of the $7.2 billion that Wall Street had been forecasting. While Nvidia's AI chops have, thus far, been very impressive, there are clear reasons for investors to keep their distance in July, if not well beyond. To start with, every next-big-thing investment over the past 30 years has led to some sort of bubble-popping event. Whether it's the internet, business-to-business commerce, genome decoding, 3D printing, cannabis, the metaverse, or blockchain technology, investor expectations for game-changing trends initially outpaces demand every time. While I fully expect AI to be a successful investment trend over the long run, expectations in the early going appear far too frothy. Another problem for Nvidia is the possibility that U.S. regulators will beef up regulations concerning AI chip exports to China. An export ban put into place last year on Nvidia's fastest AI GPUs coerced the company to develop a slower version of its AI GPU for China. With regulators once again considering clamping down on AI chip exports to China, a sizable percentage of Nvidia's GPU business could be at risk. There's also Nvidia's valuation, which is tough to stomach no matter how aggressive of a growth investor you are. Over the past five years, investors have been able to pick up shares of Nvidia for an average of 18 times sales, 55 times cash flow, and 41 times forward earnings. All three of these figures are pretty aggressive as-is. Currently, shares of Nvidia are going for 41 times sales, 155 times cash flow, and 55 times forward earnings. I don't foresee a scenario where Nvidia can consistently grow its top line and bottom line fast enough to merit its current valuation, let alone head even higher. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 30, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-06,126.64,128.17,125.86,127.7,"[""Notable ETF Outflow Detected - IWP, DXCM, IDXX, APO Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $96.1 million dollar outflow -- that's a 0.7% decrease week over week (from 135,200,000 to 134,200,000). Among the largest underlying components of IWP, in trading today DexCom Inc (Symbol: DXCM) is down about 1.3%, Idexx Laboratories, Inc. (Symbol: IDXX) is down about 1.5%, and Apollo Global Management Inc (new (Symbol: APO) is lower by about 2.2%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $75.88 per share, with $96.99 as the 52 week high point \u2014 that compares with a last trade of $94.38. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows \u00bb Also see: \u0095 Top Stocks Held By Paul Singer \u0095 Funds Holding DUO \u0095 VERY Historical PE Ratio The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio Stryker Corporation SYK is well poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. However, pricing pressure remains a concern. Shares of this Zacks Rank #2 (Buy) company have risen 21.6% compared with the industry\u2019s 3.6% growth so far this year. The S&P 500 Index has gained 16.9% in the same time frame. Stryker, with a market capitalization of $112.89 billion, is one of the world\u2019s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.4% in the next five years. SYK\u2019s earnings yield of 3.4% compares favorably with the industry\u2019s (3.1%). Image Source: Zacks Investment Research What\u2019s Favoring Stryker\u2019s Growth? Stryker continues to witness strong demand for Mako and a healthy order book amid recovery in procedure-demand following the COVID-19 pandemic. This is due to the platform\u2019s unique and promising features. These developments, in turn, enable the company to sustain the momentum in robotic-treatment sales. SYK is committed to the continued expansion of Mako, whose installations touched record high during the fourth quarter. It remains confident about robust growth in Mako revenues in 2023, on the back of new launches and software upgrades. The first-quarter results reflected Stryker\u2019s efforts to promote the advanced surgery platform. The company is focused on continued expansion of Mako and progressing well with it in international markets. The initiatives reflect the demand for Stryker\u2019s unique arm-assisted robotic technology. SYK also boasts a diversified product portfolio. Its wide range of products protects it against any significant sales shortfall during economic turmoil. Stryker\u2019s significant exposure to robotics and artificial intelligence for healthcare and Medical Mechatronics have helped it to stay ahead of the curve in the MedTech space. The company\u2019s portfolio includes Mako as well as products for hip and knee surgeries. On its first-quarterearnings call Stryker stated that procedural volumes continue to recover in most countries after getting adversely affected last year due to COVID-19. Although hospital staffing pressure remains in certain regions, the company expects this problem to resolve gradually. This improvement, in turn, will likely lead to higher procedures in 2023. Per management, Stryker\u2019s constant support for customers and focus on innovation poise it for growth as the effect of the pandemic subsides. In first-quarter 2023, its adjusted research and development expenses were 6.5% of net sales, highlighting its strong commitment to innovation. According to the company, this is likely to drive new product launches. In September 2022, SYK launched a new Spine Guidance Software \u2014 Q Guidance System \u2014 for spine application. The Q Guidance system has shown promising launch uptake during the first quarter. Moreover, Stryker\u2019s cost-cutting initiatives to improve margins and lessen inflationary pressure look promising. The adjusted selling, general and administrative expenses during first-quarter 2023 were 35.6% of net sales, expanding 40 basis points year over year. What\u2019s Hurting the Stock? An unfavorable currency rate fluctuation poses a persistent threat to Stryker\u2019s core businesses. Foreign currency had a 2.2% unfavorable impact on sales during the first quarter. The trend is likely to continue in the second half of 2023. The company is also facing inflationary pressure, leading to lower margins. Estimate Trend The Zacks Consensus Estimate for 2023 earnings per share is pegged at $10.16, indicating year-over-year growth of 8.8%. The same for revenues is pinned at $19.95 billion, implying an 8.1% improvement year over year. Stryker Corporation Price Stryker Corporation price | Stryker Corporation Quote Other Stocks to Consider Some other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares haverallied 18.3% year to date compared with the industry\u2019s 8.8% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 12.8% year to date compared with the industry\u2019s 8.8% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have gained 6.8% year to date compared with the industry\u2019s 8.8% growth. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-07,126.8,128.59,125.78,126.71,"Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio ShockWave Medical, Inc. SWAV is well poised for growth, backed by its research and development (R&D) efforts and focus on clinical studies. Shares of this Zacks Rank #3 (Hold) company have risen 31.5% compared with the industry’s 7% growth so far this year. The S&P 500 Index has increased 16.9% in the same time frame. With a market capitalization of $10.08 billion, this medical device company is committed to developing and commercializing products that can change the way calcified cardiovascular disease is treated. Image Source: Zacks Investment Research ShockWave Medical’s earnings yield of 1.4% compares favorably with the industry’s (6.3%). Its earnings beat estimates in each of the trailing four quarters, the average surprise being 98.84%. What’s Driving the Company’s Performance? SWAV invests in R&D efforts to accelerate its Intravascular Lithotripsy (IVL)Technology, thereby broadening and enhancing its existing product offerings. In the first quarter of 2023, the company incurred R&D expenses of $27 million, up 58.5% from the prior-year quarter’s level. For 2023, the company expects revenues in the $700-$720 million range, implying growth of 43-47% from the previous year’s number. ShockWave Medical believes in its ability to rapidly develop innovative products, owing to a dynamic product innovation process. The versatility and leveraging ability of its core technology and management philosophy continue to improve its R&D process. The company recruits and retains engineers and scientists with substantial expertise in developing medical devices. Its pipeline of products in various stages of development is anticipated to provide additional commercial opportunities. Since its inception, ShockWave Medical has been committed to generating clinical data to substantiate the safety and effectiveness of its IVL Technology. The initial studies consistently highlighted low rates of complications irrespective of the type of vessel being examined. Apart from getting regulatory approvals or clearances, data from the company’s clinical studies strengthen its ability to drive the adoption of IVL Technology throughout multiple therapies in its existing and new market segments. SWAV’s previous studies guided optimal IVL procedure technique and enriched the design of its IVL System and products under development. Management is optimistic about the continued clinical acceptance and penetration of IVL, as demonstrated by its strong results in first-quarter 2023 and a higher outlook for 2023 revenues. The company has ongoing clinical programs for several products and indications. On being successful, these will enable SWAV to expand the commercialization of its products into new geographies and indications. Shockwave Medical received regulatory approval for the Shockwave C2 Coronary IVL Catheter in Japan in 2022. Besides, the company also announced the introduction and global availability of its M5+ peripheral IVL catheter, post the receipt of the CE mark and the FDA clearance last year. What’s the Downside? Limited commercialization expertise and approved or cleared products pose a challenge in evaluating SWAV’s current business and determining future financial growth. Estimate Trend The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $715.82 million, indicating an improvement of 46.2% from the previous year’s reported figure. The same for adjusted earnings per share is pinned at $3.97. ShockWave Medical, Inc. Price ShockWave Medical, Inc. price | ShockWave Medical, Inc. Quote Stocks to Consider Some better-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC’s shares haverallied 18.3% year to date compared with the industry’s 8.8% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM’s shares have risen 12.8% year to date compared with the industry’s 8.8% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX’s shares have gained 6.8% year to date compared with the industry’s 8.8% growth. Free Report: Top EV Battery Stocks to Buy Now Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to ""insane levels,"" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid. Download free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-07-10,128.05,131.03,128.0,130.62,"[""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stryker (SYK) Launches Autonomous Guidance System for Surgeries Stryker SYK announced the launch of its fully autonomous guidance system, Ortho Q Guidance, designed specifically for its orthopedic customers. The new guidance system can be easily controlled by the surgeon from the sterile field. The Ortho Q Guidance system has new optical tracking options via a redesigned, state-of-the-art camera with sophisticated algorithms. The new camera features optical tracking options and advanced algorithms from the Ortho Guidance software, which provides improved surgical planning and guidance. The Ortho Guidance software works with Ortho Q to offer a smart and streamlined workflow for Express Knee, Precision Knee and Versatile Hip procedures, increasing speed and efficiency in the operating room. Price Performance Stryker\u2019s shares have risen 20.4% year to date compared with the industry\u2019s growth of 2.6%. The S&P 500 Index has gained 15.6% in the same time frame. Image Source: Zacks Investment Research Features of the New Guidance System One of the key features of the Ortho Q Guidance system is that it is a robotics-ready platform, which means that it can be integrated with robotic technology in the future. The platform includes dual PCs and a quick-refresh camera that ensure fast and reliable performance and data processing. Another feature of the guidance system is that it is implant agnostic, which means that it can work with any implant that the surgeon chooses. This gives the surgeon more flexibility and options, enabling the facilities to meet the needs of the entire service line using one platform. The system also supports different surgical approaches, such as anterior, posterior, or lateral hip replacement, or partial or total knee replacement. The advanced guidance system has a Triathlon implant dedicated software, designed for Stryker's Triathlon knee implants. The software provides additional clinical feedback to the surgeon, such as implant sizing, alignment, rotation and gap balancing. The Ortho Q Guidance system also features a small footprint, which means it takes up less space and is easy to move and store. This allows for use in both the operating room and the ambulatory surgery center setting, thereby increasing accessibility and convenience for both surgeons and patients. Industry Prospects Per a report by REPORTS AND DATA, the global orthopedic navigation systems market was valued at $146.5 million in 2018. It is anticipated to reach $327.9 million by 2026 at a CAGR of 10.6%. Growth in health care infrastructure and the increasing prevalence of orthopedic disorders will drive the growth of the orthopedic surgical navigation system market in this end-user segment. Given the market potential, the availability and adoption of the autonomous guidance system is likely to bolster Stryker\u2019s business globally. Recent Development In May, Stryker successfully completed the first surgical case using the Q Guidance system along with Cranial Guidance software, per an update from its Early Product Surveillance for the new system prior to its full commercial launch. The advanced technology aids surgeons in cranial surgeries by offering image-based planning and intraoperative guidance. Stryker Corporation Price Stryker Corporation price | Stryker Corporation Quote Zacks Rank & Other Stocks to Consider Stryker currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 17.7% year to date compared with the industry\u2019s 5.9% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 11.9% year to date compared with the industry\u2019s 5.9% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 3.6% year to date compared with the industry\u2019s 5.9% growth. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-11,130.77,132.11,130.095,131.23,"[""Citigroup Maintains Dexcom (DXCM) Buy Recommendation Fintel reports that on July 11, 2023, Citigroup maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 10.82% Upside As of July 6, 2023, the average one-year price target for Dexcom is 144.75. The forecasts range from a low of 116.15 to a high of $159.60. The average price target represents an increase of 10.82% from its latest reported closing price of 130.62. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 17.32%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1910 funds or institutions reporting positions in Dexcom. This is an increase of 24 owner(s) or 1.27% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.47%, a decrease of 1.19%. Total shares owned by institutions decreased in the last three months by 1.12% to 439,491K shares. The put/call ratio of DXCM is 1.36, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 17,157K shares representing 4.43% ownership of the company. In it's prior filing, the firm reported owning 17,303K shares, representing a decrease of 0.85%. The firm decreased its portfolio allocation in DXCM by 11.92% over the last quarter. Sands Capital Management holds 13,739K shares representing 3.54% ownership of the company. In it's prior filing, the firm reported owning 15,514K shares, representing a decrease of 12.92%. The firm decreased its portfolio allocation in DXCM by 20.77% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,965K shares representing 3.09% ownership of the company. In it's prior filing, the firm reported owning 11,746K shares, representing an increase of 1.83%. The firm decreased its portfolio allocation in DXCM by 3.50% over the last quarter. Jpmorgan Chase holds 10,765K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 10,647K shares, representing an increase of 1.09%. The firm decreased its portfolio allocation in DXCM by 4.14% over the last quarter. Capital Research Global Investors holds 9,275K shares representing 2.39% ownership of the company. In it's prior filing, the firm reported owning 9,462K shares, representing a decrease of 2.02%. The firm decreased its portfolio allocation in DXCM by 5.03% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Additional reading: ABOUT NON-GAAP FINANCIAL MEASURES AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL PLAN Indenture dated May 5, 2023 between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028). [Signature Page to [Base][Additional] Capped Call Confirmation] DEXCOM PRICES UPSIZED OFFERING OF $1.1 BILLION OF 0.375% CONVERTIBLE SENIOR NOTES DUE 2028 This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Integra's (IART) Codman EVD Catheter Study Data Favorable Integra Lifesciences Holdings Corporation IART recently presented promising clinical and financial results for the Codman Bactiseal External Ventricular Drain (EVD) catheter set in the treatment of hydrocephalus as a consequence of aneurysmal subarachnoid haemorrhage (aSAH) patients were presented. The real-world study was carried out at the University Hospital Gemelli in Rome, Italy, due to a separate grant from Integra. Study Details Retrospective data analysis was conducted on 100 patients who were given either the Codman Bactiseal EVD catheter or a non-impregnated silicone catheter (NISC) at random. In the management of patients with aSAH-related hydrocephalus, it sought to compare the cost-effectiveness and budgetary effects of antibiotic-impregnated silicone catheters (AISC) and non-impregnated silicon catheters. Integra has granted a dent. According to the statistics, patients who received Codman Bactiseal EVD were less likely to develop infections of the cerebrospinal fluid. Even though patients had more severe aSAHs than those with NISC treatment, the researchers saw a better rate of independence among those who received the Codman Bactiseal EVD catheter set. Using a budget impact model, the research predicted economic indicators based on the clinical outcomes. According to the findings of the financial impact analysis, the clinical outcomes for AISC translated into a four-day reduction in the typical hospital stay and a 5,730 savings per patient. Significance of the Findings The study's findings offer decision-makers who are in charge of enhancing patient care and determining cost-effective treatments tangible proof of the advantages of catheters infused with antibiotics. In addition to saving lives, the Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus. Image Source: Zacks Investment Research One of the most serious and debilitating effects of aSAH is acute hydrocephalus, which places a high demand on surgeons and patients for additional, effective treatment options. Recent clinical data provides solid support for Codman Bactiseal EVD's therapeutic and financial benefit to the customers by showing medical professionals how to lower the rates of cerebrospinal fluid infections and hospital care expenses. The advancements in sophisticated catheter technology will continue to be supported by this technology. Industry Prospects Per a report by Data Bridge Market Research, global hemorrhagic stroke treatment market market was valued at $34 billion in 2021 and it would grow up to $62.01 billion by 2029 at a CAGR of 7.8%. Progress Within CSS Segment Integra is witnessing healthy demand for its industry-leading products within Codman Specialty Surgical (CSS). The segment is benefiting from growing market acceptance of the company\u2019s global neurosurgery line-ups, including CSS management and neuromonitoring. Within CSS management, Integra is experiencing growth banking on strong market adoption of programmable valves and advanced energy (CUSA Capital and related disposables). Neuromonitoring sales are gaining traction too on new product launches. The company launched CUSA Clarity bone tip in United States, Canada, Australia and New Zealand, further expanding the global CUSA portfolio. In CereLink, Integra has made progress on resolving the electrical interference issue in its monitors and expects to relaunch it in the late third quarter of 2023. Overall, the CSS arm is expected to witness a revenue CAGR of 4.7% from 2020 through 2025. Price Performance Shares of Integra have declined 22.3% in the past one year against the industry\u2019s rise of 14%. Zacks Rank and Key Picks Integra currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon, carrying Zacks Rank #2 (Buy), has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 19.9% year to date compared with the industry\u2019s 8.1% growth. DexCom, carrying Zacks Rank # 2, has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 15.3% year to date compared with the industry\u2019s 8.1% growth. Hologic, carrying Zacks Rank #1, has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 5% year to date compared with the industry\u2019s 8% growth. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cigna (CI) to Add Three Biosimilars to NPF, Enable Cost Savings The pharmacy benefits management (\""PBM\"") unit of The Cigna Group's CI Evernorth segment, Express Scripts, recently revealed plans to include three biosimilars within the preferred product list on its National Preferred Formulary (\""NPF\""). Among the three, two of the biosimilars, Hyrimoz and Adalimumab-adaz, are manufactured by Sandoz, the generic division of the famous Swiss pharmaceutical firm Novartis NVS. The third biosimilar, Cyltezo, is the first interchangeable biosimilar with HUMIRA and is developed by the German-based drugmaker Boehringer Ingelheim. The FDA-approved biosimilars are competitive substitutes for HUMIRA as they are comparatively more affordable and have proved to be clinically effective in treating inflammatory conditions. Thereby, the introduction of more cost-effective biosimilars for inflammatory conditions is a dire need and the information furnished by Express Scripts trend data underlines the reason. The costs of inflammatory medications made up for around 25% of the overall drug spending in the commercial book of business of Express Scripts last year. The advent of varied biosimilars means increased competition in the industry, which often reduces prices and paves the way for enhanced access and choice of treatment for patients. Per Evernorth, competition created among biosimilars is forecasted to create savings between $225 billion and $375 billion for the U.S. healthcare system with regard to total pharmacy expenditures over the next decade. The role of a pharmacy benefit manager like Express Scripts is to work out rebates and fees with drug manufacturers and develop formularies for medications that are covered by insurance. The addition of cost-effective and clinically-effective biosimilars within NPF reflects Cigna\u2019s focus to generate cost savings for its clients. The same is also likely to attract more customers in buying prescription medications from the pharmacy network of CI, which in turn, might boost its pharmacy revenues. Pharmacy revenues contribute a massive chunk to Cigna\u2019s revenues and the contribution stood at 71.2% for 2022. Cigna boasts an expansive pharmacy network across the United States. On an annual basis, Express Scripts Pharmacy distributes roughly 1.6 billion adjusted prescriptions to pharmacy plan members that are managed by Express Scripts PBM. In fact, CI acquired Express Scripts back in 2018 in order to add strength to its pharmacy business. Shares of Cigna have gained 6.8% in the past three months against the industry\u2019s 11.2% decline. CI currently carries a Zacks Rank #3 (Hold). Image Source: Zacks Investment Research Stocks to Consider Some better-ranked stocks in the Medical space are Encompass Health Corporation EHC and DexCom, Inc. DXCM. While Encompass Health currently sports a Zacks Rank #1 (Strong Buy), DexCom carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Encompass Health\u2019s earnings surpassed estimates in two of the last four quarters and missed the mark twice, the average surprise being 4.88%. The Zacks Consensus Estimate for EHC\u2019s 2023 earnings indicates a 11.9% rise from the year-ago actuals. The consensus mark for EHC\u2019s 2023 earnings has moved 1.3% north in the past 60 days. The bottom line of DexCom outpaced estimates in three of the trailing four quarters and matched the mark once, the average surprise being 15.19%. The Zacks Consensus Estimate for DXCM\u2019s 2023 earnings indicates a 23% rise, while the same for revenues suggests an improvement of 20.1% from the respective year-ago actuals. The consensus mark for DXCM\u2019s 2023 earnings has moved 0.9% north in the past 30 days. Shares of Encompass Health and DexCom have gained 7.9% and 13.8%, respectively, in the past three months. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Encompass Health Corporation (EHC) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Add McKesson (MCK) to Your Portfolio McKesson Corporation MCK is well poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company\u2019s opioid-related litigation expenses are a potential threat. Shares of this Zacks Rank #2 (Buy) company have risen 10.6% year to date compared with the industry\u2019s 12.6% growth. The S&P 500 Index has risen 15.6% in the same time frame. McKesson is a healthcare services and information technology company with a market capitalization of $56.25 billion. Its earnings are anticipated to improve 10.8% over the next five years. Image Source: Zacks Investment Research The company\u2019s bottom line beat estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 4.48%. Its earnings yield of 6.4% compares favorably with the industry\u2019s 4.2%. What\u2019s Backing MCK? McKesson continues to actively pursue deals, divestitures and acquisitions to drive growth. In April 2022, the company completed the divestiture of its retail and distribution businesses in the United Kingdom to Aurelius. During fiscal 2022, MCK completed the sale of its Austrian business to Quadrifolia and the remaining share of its German joint venture to Walgreens Boots Alliance. Earlier this year, the company completed the divestiture of all of its European businesses. These divestitures will allow McKesson to focus on its key growth market \u2014 the United States. In October 2022, MCK completed formation of a joint venture with HCA Healthcare to create a fully integrated oncology research organization. Per the deal, McKesson and HCA will integrate their respective research units \u2014 U.S. Oncology Research (USOR) and Sarah Cannon Research Institute (SCRI). The newly created entity, with the combined capabilities of SCRI and USOR, is expected to boost clinical research and drug development, lead to better data and analytic capabilities, and pave the way for a wider portfolio of clinical trials. McKesson is a major player in the pharmaceutical and medical supplies distribution market. It stands to benefit from an increased generic utilization and inflation in generics, courtesy of an aging population and several patent expirations in the next few years. The Distribution Solutions segment caters to a wide range of customers and businesses. During the fiscal fourth quarter of 2023, McKesson\u2019s growth was led by strong performances across all segments, except the International segment, which was marred by unfavorable currency movement. The divestiture of the company\u2019s European business also hurt its growth. Last month, MCK launched its curated private brand of over-the-counter (OTC) health and wellness products, Foster & Thrive. The launch, expected to unify the company\u2019s private brand portfolio, consolidates Health Mart and Sunmark branded OTC products. It is also expected to significantly strengthen McKesson\u2019s Pharmacy & Healthcare Solutions business. What\u2019s Hurting the Stock? McKesson\u2019s broad settlement of opioid-related claims of states and municipalities is likely to increase its short-term expenses. Per the settlement deal, the company had to pay up to approximately $7.2 billion to the Settling Governmental Entities. Estimates Trend The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $294.48 billion, indicating a 6.4% increase from the previous year\u2019s level. The same for adjusted earnings per share is pinned at $26.51, implying a 2.2% year-over-year improvement. McKesson Corporation Price McKesson Corporation price | McKesson Corporation Quote Other Stocks to Consider Some other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 17.7% year to date compared with the industry\u2019s 5.9% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 11.9% year to date compared with the industry\u2019s 5.9% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 3.6% year to date compared with the industry\u2019s 5.9% growth. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-12,131.39,133.905,131.26,133.67,"Stryker (SYK) Launches Q Guidance System for Cranial Surgeries Stryker SYK announced the commercial launch of its Q Guidance system with Cranial Guidance software in the United States. The new navigation system will provide image-based planning and intraoperative guidance. It will assist surgeons in positioning instruments and identifying patient anatomy during cranial surgery. The software will be useful for different types of surgeries, including craniotomies, skull base and transsphenoidal procedures, shunt placements and biopsies. Price Performance Stryker’s shares have risen 21.2% year to date compared with the industry’s growth of 3.5%. The S&P 500 Index has gained 15.7% in the same time frame. Image Source: Zacks Investment Research New Software Features Stryker believes that the Q Guidance system with Cranial Guidance software has the potential to become the standard of care, and a possible means for increasing accuracy and efficiency in the operating room. The system includes a touchscreen monitor to control inside or outside the sterile field, leading to high-performance 2D-3D visualization. It is likely to provide neurosurgeons with more surgical planning and guidance capabilities than ever before, with a special focus on biopsies and shunt placements. A smooth user interface and workflow, coupled with intuitive new views like 3D targeting and the new skull stripping feature, will be helpful during surgeries. The Q Guidance system with Cranial Guidance software features a proprietary camera, the FP8000, which offers faster speed than other cameras in the market. It also has a dual PC system that allows one PC to run the applications and the other to provide real-time patient data. The system uses Diffusion Tensor Imaging and tractography to estimate and visualize the brain's axonal organization in 3D. Additionally, it has a Precision Targeting System that enables navigated biopsy of cranial tissue by using comprehensive guidance data and imaging to preplan an approach for entry point. Furthermore, it enables electromagnetic catheter placement for pinless shunt procedures. In May, Stryker successfully completed the first surgical case using the Q Guidance system with Cranial Guidance software, per an update from its Early Product Surveillance for the new system prior to this commercial launch. Industry Prospects Per a report by Expert Market Research, the cranial implant market was valued at $1.14 billion in 2022. It is anticipated to reach $2.09 billion by 2031 at a CAGR of 7%. Factors like increased geriatric population and a growing number of trauma instances are expected to contribute to this improvement. An increase in research and development activities is also aiding the aforementioned market’s growth. Given the market potential, the availability and adoption of the advanced cranial surgical technology is likely to bolster Stryker’s business globally. Recent Development Earlier this month, Stryker launched its fully autonomous guidance system, Ortho Q Guidance, designed specifically for its orthopedic customers. The Ortho Guidance software works with Ortho Q to offer a smart and streamlined workflow for Express Knee, Precision Knee and Versatile Hip procedures, increasing speed and efficiency in the operating room. Stryker Corporation Price Stryker Corporation price | Stryker Corporation Quote Zacks Rank & Other Stocks to Consider Stryker currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC’s shares have rallied 17.7% year to date compared with the industry’s 5.9% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM’s shares have risen 11.9% year to date compared with the industry’s 5.9% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX’s shares have risen 3.6% year to date compared with the industry’s 5.9% growth. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation. Yes, I Want to Help Protect My Portfolio Against Inflation >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-07-13,134.56,134.92,133.01,133.98,"[""AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top AngioDynamics, Inc. ANGO reported adjusted earnings per share (EPS) of 2 cents for fourth-quarter fiscal 2023 compared with the year-ago EPS of a penny. However, the adjusted EPS lagged the Zacks Consensus Estimate by 33.3%. GAAP loss per share was 54 cents, wider than the year-over-year loss of 16 cents per share. Full-year adjusted loss per share was 6 cents against the break-even EPS at the end of the comparable fiscal 2022 period. The figure was in line with the Zacks Consensus Estimate. Revenue Details Revenues in the fiscal fourth quarter totaled $91.1 million, up 4.7% year over year on a reported basis (up 4.9% at constant exchange rate or CER). The top line topped the Zacks Consensus Estimate by 0.4%. The company continued to see strong contributions from its Med Tech (which include the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform) and Med Device businesses during the quarter. Full-year revenues were $338.8 million, reflecting a 7.1% uptick on a reported basis from the comparable fiscal 2022 period. The figure surpassed the Zacks Consensus Estimate marginally by 0.1%. At CER, full-year revenues were up 7.5%. Geographical Analysis In the quarter under review, U.S. net revenues totaled $74.4 million, up 0.9% year over year. This figure compares to our U.S. net revenues\u2019 fiscal fourth-quarter projection of $76.2 million. International revenues came in at $16.6 million, up 25.1% from the year-ago quarter on a reported basis and up 26.2% at CER. This figure compares to our fiscal fourth-quarter International revenues\u2019 projection of $14.3 million. Segmental Analysis AngioDynamics derives revenues from two businesses \u2014 Med Tech and Med Device. The Med Tech business\u2019 net sales in the fiscal fourth quarter were $26.5 million, reflecting an uptick of 17.2% year over year. This was primarily on the back of increased net sales of Auryon amounting to $11.8 million (up 22%) and NanoKnife disposable sales of $4.6 million (up 28%) compared with the prior-year quarter. AlphaVac sales in the reported quarter were $1.8 million, up 86.9% year over year. However, the improvement in the Med Tech segment was partially offset by a decline of 8.3% in AngioVac sales which amounted to $6.1 million in the quarter. This figure compares to our fiscal fourth quarter\u2019s Med Tech business\u2019 net sales projection of $26.9 million. Med Device revenues in the fiscal fourth quarter grossed $64.6 million, up 0.3% from the year-ago period. This was primarily driven by strength in AngioDynamics\u2019 angiographic products and the dialysis business. This figure compares to our fiscal fourth quarter\u2019s Med Device business\u2019 net sales projection of $63.6 million. AngioDynamics, Inc. Price, Consensus and EPS Surprise AngioDynamics, Inc. price-consensus-eps-surprise-chart | AngioDynamics, Inc. Quote Margin Analysis In the quarter under review, AngioDynamics\u2019 gross profit fell 0.2% to $46.4 million. The gross margin contracted 250 basis points (bps) to 50.9%. We had projected 52.1% of gross margin for fourth-quarter fiscal 2023. Sales and marketing expenses fell 2% to $26.3 million year over year. Research and development expenses decreased 0.1% year over year to $7.9 million, whereas general and administrative expenses declined 7.9% year over year to $10.2 million. Adjusted operating expenses of $44.4 million decreased 3.1% year over year. The adjusted operating profit totaled $1.9 million, which surged 202.9% from the prior-year quarter. The adjusted operating margin in the fiscal fourth quarter expanded 142 bps to 2.2%. Cash Position AngioDynamics exited fiscal 2023 with cash and cash equivalents of $44.6 million compared with $28.8 million at the end of fiscal 2022. The long-term debt (net of current portion) at the end of fiscal 2023 was $49.8 million compared with $25 million at the end of fiscal 2022. Cumulative net cash provided by operating activities was $78 million against net cash used in operating activities of $7.2 million a year ago. FY24 Guidance AngioDynamics has initiated its guidance for fiscal 2024. The company expects its net sales in the range of $328 million-$333 million. The adjusted loss per share is projected to be between 28 cents and 34 cents. Our Take AngioDynamics exited the fourth quarter of fiscal 2023 with better-than-expected revenues. The quarter\u2019s adjusted EPS performance and a solid uptick in the overall top line were impressive. Robust domestic and international revenues were also encouraging. The company continued gaining from its Med Tech and Med Device businesses, which was promising. Robust sales of Auryon and NanoKnife looked encouraging. Continued positive physician feedback for both the F22 and F18 versions of AlphaVac also bodes well. The expansion of the adjusted operating margin augurs well. On the fiscal fourth-quarterearnings call AngioDynamics\u2019 management confirmed that it is currently preparing to launch a new version of the Auryon product for use in the lower extremities segment of the venous thrombectomy market. Management also confirmed that the APEX study, evaluating AlphaVac F18 as a treatment for pulmonary embolism, is more than 50% enrolled and expects to complete enrollment this winter and submit the results to the FDA in the first half of the calendar year 2024. These raise optimism about the stock. However, AngioDynamics\u2019 lower-than-expected EPS and lower revenues from AngioVac sales in the fiscal fourth quarter were disappointing. The gross margin contraction does not bode well. Continued supply chain disruptions and inflationary pressures also raise apprehension. Zacks Rank & Key Picks AngioDynamics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space that are supposed to report earnings soon are DexCom, Inc. DXCM, Becton, Dickinson and Company BDX, popularly known as BD, and Boston Scientific Corporation BSX. The Zacks Consensus Estimate for DexCom\u2019s second-quarter 2023 adjusted EPS is currently pegged at 22 cents. The consensus estimate for revenues is pegged at $837 million. DexCom currently carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has an estimated long-term growth rate of 40.4%. DXCM\u2019s earnings yield of 0.8% compares favorably with the industry\u2019s negative yield. BD currently has a Zacks Rank #2. The Zacks Consensus Estimate for its third-quarter fiscal 2023 adjusted EPS is currently pegged at $2.88. The same for revenues is pegged at $4.83 billion. BD has an estimated long-term growth rate of 10.1%. BDX\u2019s earnings yield of 4.7% compares favorably with the industry\u2019s 4.1%. Boston Scientific currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter 2023 adjusted EPS is currently pegged at 49 cents. The same for its revenues stands at $3.49 billion. Boston Scientific has an estimated long-term growth rate of 11.5%. BSX\u2019s earnings yield of 3.7% compares favorably with the industry\u2019s negative yield. Just Released: Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500\u2019s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don\u2019t miss your chance to still be among the first to get in on these just-released stocks. See New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Intuitive Surgical, Inc. ISRG is well poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by solid first-quarter 2023 results and its progress on the artificial intelligence (AI) front, is expected to contribute further. Risks pertaining to procedure adoption and stiff competition persist. Shares of this Zacks Rank #2 (Buy) company have risen 31% year to date compared with the industry\u2019s 8.4% growth. The S&P 500 Index has gained 16.5% during the same time frame. Intuitive Surgical, the pioneer of robotic-assisted surgery and the renowned provider of minimally invasive care, has a market capitalization of $118.82 billion. It projects 13% growth over the next five years and expects to maintain its strong performance going forward. The company\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed the same in the other two, delivering an average surprise of 1.9%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strength in Robotics: We are upbeat about Intuitive Surgical\u2019s robot-based da Vinci surgical system that enables minimally-invasive surgery and reduces the trauma associated with open surgery. The da Vinci System is powered by robotic technology that has provided the company with solid exposure to medical mechatronics, robotics and AI for the healthcare space. On ISRG\u2019s first-quarter 2023earnings callin April, the installed base of the da Vinci system grew approximately 12% year over year. The utilization of clinical systems in the field, measured by procedures per system, was up 13% from the prior-year quarter\u2019s level. Progress on the AI Front: We are also positive about the growing adoption of minimally-invasive robot-assisted surgeries, self-automated home-based care, the use of information technology for quick and improved patient care, and the shift of the payment system to a value-based model. These indicate the high prevalence of AI in the MedTech space. Per management, the rise of medical mechatronics, powerful computing, improved sensing, microfabrication and molecular imaging has enabled new solutions to old problems. AI has been enhancing Intuitive Surgical\u2019s product portfolio with clinical applications, diagnostic support, operational efficiency, electronic health record systems, practice workflows and supply chain management. Strong Q1 Results: The company\u2019s solid first-quarter 2023 results also buoy our optimism. The company witnessed continued growth in da Vinci procedure volume during the quarter. Downsides Risk of Procedure Adoption: Intuitive Surgical faces the risk of adoption of its procedures. This is because adoption growth takes time, as each procedure needs to gain credibility. Furthermore, the wide use of the company\u2019s products requires training of surgical teams. Market acceptance could be delayed by the time required to complete such trainings. Stiff Competition: Since the launch of its flagship device, the da Vinci System, in 2000, Intuitive Surgical used to enjoy a monopoly in the market for robots used in abdominal surgery. However, the competition for ISRG intensified following the regulatory approval of Transenterix's surgical robot for abdominal surgery in 2017. Estimate Trend Intuitive Surgical is witnessing a positive estimate revision trend for 2023. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.8% north to $5.47 per share. The consensus mark for the company\u2019s second-quarter 2023 revenues is pegged at $1.73 billion, indicating a 13.8% improvement from the year-ago quarter\u2019s reported number. Intuitive Surgical, Inc. Price Intuitive Surgical, Inc. price | Intuitive Surgical, Inc. Quote Other Stocks to Consider A few other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 22.8% year to date compared with the industry\u2019s 8.4% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 18% year to date compared with the industry\u2019s 8.4% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 5.6% year to date compared with the industry\u2019s8.4% growth. Just Released: Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500\u2019s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don\u2019t miss your chance to still be among the first to get in on these just-released stocks. See New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Gains But Lags Market: What You Should Know DexCom (DXCM) closed the most recent trading day at $133.98, moving +0.23% from the previous trading session. The stock lagged the S&P 500's daily gain of 0.85%. Elsewhere, the Dow gained 0.14%, while the tech-heavy Nasdaq added 5.61%. Heading into today, shares of the medical device company had gained 5.2% over the past month, outpacing the Medical sector's loss of 1.55% and the S&P 500's gain of 3.18% in that time. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. This is expected to be July 27, 2023. The company is expected to report EPS of $0.22, up 29.41% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $837 million, up 20.22% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $1.07 per share and revenue of $3.49 billion, which would represent changes of +22.99% and +20.08%, respectively, from the prior year. Any recent changes to analyst estimates for DexCom should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.26% higher within the past month. DexCom currently has a Zacks Rank of #2 (Buy). Looking at its valuation, DexCom is holding a Forward P/E ratio of 125.24. This valuation marks a premium compared to its industry's average Forward P/E of 31.91. It is also worth noting that DXCM currently has a PEG ratio of 3.1. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.61 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Just Released: Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500\u2019s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don\u2019t miss your chance to still be among the first to get in on these just-released stocks. See New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-14,134.5,137.62,133.984,137.32,"[""Here is Why Growth Investors Should Buy DexCom (DXCM) Now Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks. Our proprietary system currently recommends DexCom (DXCM) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. Here are three of the most important factors that make the stock of this medical device company a great growth pick right now. Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 51.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 22.7% this year, crushing the industry average, which calls for EPS growth of 10.4%. Cash Flow Growth Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 37.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 9.3%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 75.9% over the past 3-5 years versus the industry average of 8.9%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. There have been upward revisions in current-year earnings estimates for DexCom. The Zacks Consensus Estimate for the current year has surged 0.3% over the past month. Bottom Line While the overall earnings estimate revisions have made DexCom a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination indicates that DexCom is a potential outperformer and a solid choice for growth investors. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Select Medical (SEM) Up 21% Year to Date: More Room to Run? Shares of Select Medical Holdings Corporation SEM have gained 21.4% year to date against the industry\u2019s 14.9% decline. The Medical sector fell 4.8% but the S&P 500 composite index rallied 17.3% in the same time frame. With a market capitalization of $3.8 billion, the average volume of shares traded in the last three months were 0.6 million. Image Source: Zacks Investment Research Sustained top-line growth, active pursuit of buyouts and joint ventures, coupled with a strong financial stand, continue to drive Select Medical. The expected long-term earnings growth rate of SEM is pegged at 15%, better than the industry\u2019s average of 13.4%. Can SEM Retain the Momentum? The Zacks Consensus Estimate for Select Medical\u2019s 2023 earnings is pegged at $1.84 per share, indicating a 49.6% increase from the 2022 figure. The same for revenues stands at $6.5 billion, suggesting a 3.1% increase from the year-ago figure. The consensus mark for 2024 earnings is pegged at $2.34 per share, suggesting an improvement of 26.8% from the 2023 estimate. The same for revenues stands at $6.8 billion, hinting at a 4% increase from the 2023 estimate. After witnessing a 7.9% CAGR over the past decade (2012-2022), revenues of Select Medical improved 4.1% year over year in the first quarter of 2023 on the back of growing patient volumes. Increased confidence of people to opt for outpatient visits is likely to provide an impetus to the performance of its Outpatient Rehabilitation and Concentra segments. Management forecasts revenues within $6.5-$6.7 billion in 2023, the midpoint of which indicates an improvement of 4.8% from the 2022 figure. The dire need for effective rehabilitation services that empower individuals recovering from chronic illness and injuries to resume daily life activities is expected to provide SEM an opportunity to capitalize on through its rehabilitation hospitals. Select Medical resorts to an inorganic growth strategy, in which it acquires healthcare facilities or enters into joint ventures with several U.S. healthcare providers. Such initiatives build up capabilities, bolster the healthcare portfolio and expand the geographical presence of this Zacks Rank #3 (Hold) leading U.S. healthcare facility operator. SEM\u2019s care network comprised 105 critical illness recovery hospitals, 32 rehabilitation hospitals and 1,936 outpatient rehabilitation clinics spread across the United States and the District of Columbia as of Mar 31, 2023. A sound financial position provides a cushion for Select Medical to pursue uninterrupted growth-related initiatives. Its growing cash reserves and solid cash-generating abilities empower it to invest funds for boosting growth prospects as well as engage in prudent deployment of capital via share buybacks and dividends. Its dividend yield of 1.7% remains higher than the industry\u2019s average of 1.4%. Select Medical boasts an impressive VGM Score of B. VGM Score helps identify stocks with the most attractive value, the best growth and the most promising momentum. Stocks to Consider Some better-ranked stocks in the Medical space are Alcon Inc. ALC, DexCom, Inc. DXCM and HCA Healthcare, Inc. HCA. While Alcon currently sports a Zacks Rank #1 (Strong Buy), DexCom and HCA Healthcare carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Alcon\u2019s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and matched the mark once, the average beat being 8.85%. The Zacks Consensus Estimate for ALC\u2019s 2023 earnings suggests an improvement of 17.9%, while the same for revenues indicates growth of 8% from the respective year-ago reported figures. The consensus estimate for ALC\u2019s 2023 earnings has moved 0.4% north in the past 60 days. Shares of Alcon have gained 23.9% year to date. DexCom\u2019s earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and matched the mark once, the average surprise being 15.19%. The consensus estimate for DXCM\u2019s 2023 earnings indicates a rise of 23%, while the same for revenues suggests an improvement of 20.1% from the corresponding year-ago reported estimates. The consensus estimate for DXCM\u2019s 2023 earnings has moved 0.9% north in the past 30 days. Shares of DexCom have gained 20% year to date. HCA Healthcare\u2019s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 9.04%. The Zacks Consensus Estimate for HCA\u2019s 2023 earnings suggests an improvement of 7.2%, while the same for revenues indicates growth of 5.3% from the respective year-ago reported figures. The consensus estimate for HCA\u2019s 2023 earnings has moved 0.1% north in the past 30 days. Shares of HCA Healthcare have rallied 23.7% year to date. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Select Medical Holdings Corporation (SEM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow? DexCom, Inc. DXCM is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition and reimbursement persist. This Zacks Rank #2 (Buy) company\u2019s shares have risen 18.3% year to date compared with the industry\u2019s 9.9% growth. The S&P 500 Index has gained 17.3% in the same time frame. DXCM, a renowned medical-devices company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $51.82 billion. It projects 40.4% growth over the next five years and expects to maintain the strong performance going forward. DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.19%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strong Product Portfolio:We are upbeat about DexCom's continued strength in its Continuous Glucose Monitoring (CGM) products. It launched an updated sensor algorithm in multiple countries in the second half of 2022, making the latest G7 sensor technology available in international markets. The company received the FDA clearance for this technology in December 2022. Earlier this month, the G7 CGM System received Health Canada\u2019s approval for people with all types of diabetes, aged two years and above. These developments are likely to support DXCM\u2019s future growth. In 2022, the company also launched the easy-to-use Dexcom ONE real-time CGM System on prescription for everyone with type 1 or type 2 diabetes using insulin. It did so via drug tariff in NHS England, Wales, Scotland and Northern Ireland. DexCom\u2019s prospects in alternative markets, such as non-intensive diabetes management, hospitals, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. New Product Launch: Last month, Dexcom announced that is currently developing a new product with a 15-day sensor, designed specifically for diabetic patients who are not on insulin. The company is planning to launch the new product in the United States in 2024. Positive Coverages: DXCM\u2019s products have been receiving increasing coverage over the past few months, raising our optimism. Last year, the company expanded public coverage for type 1 and type 2 diabetic patients (aged two years and above) who are on multiple daily injections of insulin (three or more) or who use an insulin pump using its G6 CGM System via Prince Edward Island\u2019s Diabetes Glucose Sensor Program. DexCom ended the first quarter with new patient additions. The Ontario government began coverage for the Dexcom G6 CGM System through the province\u2019s Assistive Devices Program. This program has been designed for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Strong Q1 Results: DXCM\u2019s solid first-quarter 2023 revenues buoy optimism. Rising volumes across all channels, along with new customer additions due to increasing global awareness of the benefits of real-time CGM, contributed to the upside. Last month, the company raised its guidance for 2025, based on robust demand for its products in the previous two years. The company now expects growth of $500 million in revenues (from that projected earlier). Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. Downsides Rising Costs: The company\u2019s gross margin contracted 90 basis points during the first quarter to 62.4%, reflecting the rising cost of sales. It expects adjusted gross margin of 62-63% for 2023, indicating persisting cost pressure. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid changes and new product introductions. DXCM\u2019s competitors manufacture and market products for the single-point finger stick device market and collectively account for the worldwide sales of self-monitored glucose testing systems at present. Estimate Trend DexCom is witnessing an improving estimate revision trend for 2023 and 2024. In the past 30 days, the consensus mark for earnings per share increased from $1.06 to $1.07 for 2023 and from $1.47 to $1.50 for 2024. The Zacks Consensus Estimate for the company\u2019s second-quarter 2023 revenues is pegged at $837 million, indicating a 20.2% improvement from the year-ago quarter\u2019s reported number. The same for earnings is pinned at 22 cents per share, implying growth of 29.4% year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Other Stocks to Consider A few other top-ranked stocks from the broader medical space are Alcon ALC, Perrigo Company PRGO and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 22.8% year to date compared with the industry\u2019s 8.4% growth. Perrigo\u2019s earnings are expected to improve 24.6% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO\u2019s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, delivering an average negative surprise of 0.79%. The company\u2019s shares have lost 0.4% year to date against the industry\u2019s 5.3% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 5.6% year to date compared with the industry\u2019s 8.4% growth. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-17,136.7,138.4,136.365,137.45,"[""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom Reaches Analyst Target Price In recent trading, shares of DexCom Inc (Symbol: DXCM) have crossed above the average analyst 12-month target price of $134.53, changing hands for $137.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for DexCom Inc, but the average is just that \u2014 a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $97.00. And then on the other side of the spectrum one analyst has a target as high as $150.00. The standard deviation is $16.632. But the whole reason to look at the average DXCM price target in the first place is to tap into a \""wisdom of crowds\"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DXCM crossing above that average target price of $134.53/share, investors in DXCM have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $134.53 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover DexCom Inc: RECENT DXCM ANALYST RATINGS BREAKDOWN \u00bb Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 14 14 14 12 Buy ratings: 0 0 0 1 Hold ratings: 2 2 2 2 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.25 1.25 1.25 1.33 The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DXCM \u2014 FREE. The Top 25 Broker Analyst Picks of the S&P 500 \u00bb Also see: \u0095 DNAD YTD Return \u0095 Top Ten Hedge Funds Holding SMEZ \u0095 SJI Split History The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-18,137.07,138.17,135.51,137.93,"[""IWP, DXCM, IDXX, APO: ETF Inflow Alert Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $114.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 134,450,000 to 135,600,000). Among the largest underlying components of IWP, in trading today DexCom Inc (Symbol: DXCM) is up about 0.2%, Idexx Laboratories, Inc. (Symbol: IDXX) is down about 2.7%, and Apollo Global Management Inc (new (Symbol: APO) is up by about 0.8%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $75.88 per share, with $100.21 as the 52 week high point \u2014 that compares with a last trade of $100.15. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Free Report: Top 8%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb Also see: \u0095 Institutional Holders of VEMY \u0095 BEP Historical Stock Prices \u0095 Funds Holding RICO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now West Pharmaceutical Services, Inc. WST is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern. Shares of this Zacks Rank #1 (Strong Buy) company have risen 63% year to date compared with the industry's 15% growth. The S&P 500 Index has increased 18.5% in the same period. West Pharmaceutical, with a market capitalization of $28.59 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.3% in 2024. The company delivered a trailing four-quarter average earnings surprise of 13.61%. Image Source: Zacks Investment Research Key Catalysts The Proprietary Products business continues to exhibit sustained strength and is an important contributor to WST's top line. This segment's customers primarily comprise several of the major biologic, generic and pharmaceutical drug companies globally that incorporate components and other offerings in their injectable products. Sales improved 2.3% organically in the first quarter of 2023. High-value products (components and devices) accounted for more than 70% of segment sales and delivered mid-single digit organic sales growth. Growth in demand, especially from biologic customers, and strong performances in Generics and Pharma market units, buoy optimism. West Pharmaceutical also continues to expand high-value product manufacturing capacity for supporting rising customer demand from recent launches and anticipated drug programs in the coming years. Robust organic growth of Proprietary Products\u2019 Generics and Pharma market units is another quarterly highlight. The company maintains its research-scale production facilities and laboratories for creating new products. It also provides contract engineering design and development services to help customers with new product developments. WST continues to pursue innovative strategic platforms in prefillable syringes, injectable containers, advanced injections, and safety and administration systems. In the first quarter, the company's R&D expenses increased 17.1% from the prior-year period\u2019s level. West Pharmaceutical remains committed to seeking innovative opportunities for the acquisition, licensing, partnering or development of products, services and technologies. The company is focused on its objective of connecting dots throughout science and technology for potential value creation. Factors Hurting the Stock The growing exposure to international markets makes WST susceptible to adverse foreign exchange volatility. Unfavorable fluctuations in currency exchange rates can affect WST\u2019s international sales. On its first-quarter 2023earnings call the company projected forex headwind on revenues of $15 million for 2023. Moreover, the constant fall in the Contract-Manufactured Products segment is concerning. Lower demand for COVID-related products is also worrying. Contraction in gross and operating margins does not bode well. West Pharmaceutical\u2019s pandemic-related sales are also likely to experience a downtrend in the rest of 2023, thereby hurting Proprietary Products\u2019 revenue growth. Estimates Trend The company has been witnessing an upward estimate revision trend in 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 4.5% to $7.69 per share. The consensus estimate for 2023 revenues is pegged at $2.98 billion, indicating a 3.1% increase from the 2022 level. West Pharmaceutical Services, Inc. Price West Pharmaceutical Services, Inc. price | West Pharmaceutical Services, Inc. Quote Other Stocks to Consider Some other top-ranked stocks from the broader medical space are Hologic HOLX, Alcon ALC and DexCom DXCM. While Hologic sports a Zacks Rank #1, both Alcon and DexCom carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 5.6% year to date compared with the industry\u2019s 8.4% growth. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 22.8% year to date compared with the industry\u2019s 8.4% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 18% year to date compared with the industry\u2019s 8.4% growth. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-19,137.34,138.92,131.88,133.63,"[""NextGen (NXGN) Settles Misrepresentation Allegations for $31M NextGen Healthcare Inc NXGN agreed to pay $31 million to resolve allegations that it has misrepresented certain features of its electronic health record (EHR) software and unlawfully paid users to promote the same, U.S. authorities said on Friday. The whistleblower lawsuit was filed by Elizabeth Ringold and Toby Markowitz, two clinicians who used NextGen's software for electronic health records at the South Carolina Department of Corrections. However, the company denied any wrongdoing. The settlement does not include any admissions of liability, a NextGen spokesperson divulged in an email. Price Performance NextGen\u2019s shares have lost 9.3% year to date against the industry\u2019s growth of 54.6%. The S&P 500 Index has gained 18.8% in the same time frame. Image Source: Zacks Investment Research The Whistleblower Lawsuit Ringold and Markowitz filed their lawsuit in 2018 under seal. Federal prosecutors joined the case this week and filed their complaint along with the settlement. Prosecutors argued that NextGen fraudulently obtained a certification in 2014, allowing the providers to get incentive payments from the government for using its EHR software. The company had allegedly claimed that the software has certain capabilities required for the certification, such as recording vital signs and generating clinical summaries. Prosecutors also said that NextGen offered customers up to $10,000 for recommending the product to others, thereby violating the federal Anti-Kickback Statute. Similar Investigations NextGen\u2019s settlement is the latest in a series of similar deals between electronic health record companies and Vermont U.S. Attorney Nikolas Kerest, who has recovered more than $400 million in total. Previous cases in Vermont involving similar allegations have resulted in a $155 million settlement with eClinicalWorks; a $145 million deal with Allscripts Healthcare Solutions Inc's Practice Fusion Inc; a $57.5 million settlement with Greenway Health; and a $45 million deal with Modernizing Medicine Inc. Recent Developments at NextGen In June, Associated Urologists of North Carolina (using NextGen\u2019s Enterprise Practice Management) decided to expandthe implementation of NXGN\u2019s technologies to include Enterprise EHR. In May, the company\u2019s Behavioral Health Suite was chosen by CA-based CHE Behavioral Health to support its growing network. This suite is a comprehensive solution that provides access to a single, integrated physical and behavioral health record to treat patients. NextGenalso reported fourth-quarter results in the same month. It posted better-than-expected results with a solid uptick in its top line, along with strength in both recurring and non-recurring revenues. However, rising operating costs led to the contraction of the adjusted gross margin. In April, the company announced that Mindful Care had selected NextGen Behavioral Health Suite to support its short and long-term goals. NEXTGEN HEALTHCARE, INC Price NEXTGEN HEALTHCARE, INC price | NEXTGEN HEALTHCARE, INC Quote Zacks Rank & Other Stocks to Consider NextGen currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks from the broader medical space are Alcon ALC, DexCom DXCM and Hologic HOLX, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%. ALC\u2019s shares have rallied 17.7% year to date compared with the industry\u2019s 5.9% growth. DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. DXCM\u2019s shares have risen 11.9% year to date compared with the industry\u2019s 5.9% growth. Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. HOLX\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%. HOLX\u2019s shares have risen 3.6% year to date compared with the industry\u2019s 5.9% growth. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wall Street Believes These High-Profile Stock-Split Stocks Can Lose Up to 91% of Their Value The past two years have featured no shortage of ups and downs for the investing community. The major U.S. stock indexes climbed to all-time highs in 2021, were clobbered by the 2022 bear market, and have rebounded strongly through the first six months and change of 2023. Throughout these wild vacillations on Wall Street, investors have consistently gravitated to companies that have enacted stock splits. A stock split is an event that allows a publicly traded company to cosmetically alter its share price and outstanding share count without having any impact on its market cap or operations. Stock splits can make shares more nominally affordable for everyday investors, as with a forward stock split, or can be used to increase a company's share price to maintain minimum listing standards on a major stock exchange as is often the case with reverse stock splits. Image source: Getty Images. Although reverse stock splits do garner attention from time to time, most investors are laser-focused on forward stock splits. Companies conducting forward splits are usually out-innovating and out-executing their competition. In other words, they're top-tier businesses. Since the start of July 2021, eight high-profile stocks have enacted forward splits, including: Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021. Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022. DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022. Shopify (NYSE: SHOP): 10-for-1 split in June 2022. Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022. Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022. Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022. Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023. Although these stock-split stocks have, recently, vastly outperformed, not all Wall Street analysts are on board with the idea that additional upside awaits. What follows are three stock-split stocks that select analysts and Wall Street institutions believe could decline between 18% and 91%. Amazon: Implied downside of 18% The first ultra-popular stock-split stock that may not live up to its billing, at least according to one Wall Street analyst, is e-commerce leader Amazon. Analyst Barton Crockett of Rosenblatt has a neutral rating on shares of the company with a price target of \""only\"" $111. This would imply 18% downside to come in shares of Amazon, based on where it closed on July 14. What's arguably the biggest issue for Amazon is the expectation from investors that retail sales will slow as the Federal Reserve pushes interest rates higher. Amazon generates a sizable percentage of its sales from its flagship online marketplace. However -- and this is a pretty big \""however\"" -- Amazon's leading revenue segment isn't as important to its cash-flow generation and profitability as you might think. Despite bringing in a boatload of revenue for the company and attracting people to its website, the online marketplace is a low-margin segment. Amazon's ancillary businesses are of far greater importance, and they're continuing to fire on all cylinders. Amazon Web Services (AWS) is the world's leading cloud infrastructure services provider, with 32% of global cloud service spending share, based on estimates from Canalys, as of the end of March. Enterprise cloud spending is still in its early stages, and the operating margin associated with cloud services is considerably higher than with online retail sales. Other critical segments for Amazon include subscription services and advertising services. As of April 2021, the company had surpassed 200 million Prime subscribers and was one of the most-visited websites on the planet. Selling Prime subscriptions and maintaining strong ad-pricing power also provide Amazon with superior margins relative to online retail sales. Though Amazon may not be as much of a screaming deal as it was during the 2022 bear market, the cash-flow multiple it's trading at, relative to Wall Street's forward-year consensus, is historically cheap. Nvidia: Implied downside of 19% A second high-profile stock-split stock that one Wall Street analyst believes may have meaningful downside to come is semiconductor solutions provider Nvidia. Analyst Ruben Roy at Stifel upped his firm's price target on Nvidia to $370 per share in May, which as of the closing bell on July 14 would imply a 19% decline in the company's shares. The clearest headwind for Nvidia is going to be its valuation. Shares have more than tripled on a year-to-date basis, with the company's artificial intelligence (AI) ties driving its outperformance. Whereas Nvidia has averaged an already expensive price-to-cash-flow ratio of nearly 57 over the past five years, it's now trading at closer to 166 times cash flow. From a fundamental perspective, it's almost impossible to justify the current valuation. Another problem for Nvidia is that next-big-thing investments have a propensity to form bubbles in their early stages and pop. Dating back 30 years, the internet, business-to-business commerce, genome decoding, 3D printing, blockchain technology, and the metaverse are just some examples of next-big-thing innovations that needed time to mature. AI likely won't be the exception. Nvidia might also face tighter export restrictions to China for its AI-driven graphics processing units (GPUs). Despite developing a slower chip for its Chinese customers, U.S. regulators are looking at further limiting Nvidia's ability to export its AI GPUs to China. The one factor Nvidia does have working in its favor is its overwhelming market share in data centers. Forecasts suggest Nvidia may account for 90% of AI-focused GPUs in enterprise data centers. Unfortunately, even this may not be enough to support a valuation in excess of $1 trillion. The price of Tesla's flagship sedan, the Model 3, has been reduced multiple times this year. Image source: Tesla. Tesla: Implied downside of 91% The third high-profile stock-split stock that at least one Wall Street analyst foresees losing a significant percentage of its value is electric vehicle (EV) manufacturer Tesla. The founder and CEO of GLJ Research, Gordon Johnson, has just slapped a $24.33 price target on shares of the company after adjusting for last year's stock split. That's 91% below where Tesla shares closed on July 14. Although Tesla is the only pure-play EV company that's generating a recurring profit, and it's the first automaker to have successfully built itself from the ground up to mass production in more than 50 years, there are well-defined red flags that rightly have Wall Street analysts like Johnson cautious about the company's future. Perhaps the most front-and-center concern for Tesla is the price war it precipitated among EV producers. Tesla has reduced prices for key models in the U.S. on a half-dozen occasions since the year began. While there had been hope that these price cuts were nothing more than a ploy for Tesla to grab additional share from competitors, CEO Elon Musk noted during a question-and-answer session at the company's annual shareholder meeting that Tesla's pricing strategy is being driven by demand. If prices are declining, it's because inventory levels are rising and competition is picking up. As I've pointed out previously, Elon Musk is also a risk for existing shareholders. Musk may be innovative, but he has a knack for drawing unwanted attention from securities regulators. Far more worrying, Musk has made promises about full self-driving vehicles, innovations, and product launches that haven't been met. As these promises build and go unfulfilled, it becomes likelier that Tesla's share price could deflate. Similar to Nvidia, Tesla's valuation is problematic as well. Whereas traditional auto stocks trade at single-digit price-to-earnings (P/E) multiples, Tesla is commanding a P/E ratio of around 80. That's an issue for a company with a declining automotive gross margin that's struggled to become more than a just a car company. While there's no denying that Tesla generates investor buzz as well as any publicly traded company, sustaining its existing valuation, let alone pushing higher, will be increasingly difficult. 10 stocks we like better than Amazon.com When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 10, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-20,134.06,134.35,130.42,130.65,"Top Picks: 3 Stocks That (Almost) All Analysts Agree On InvestorPlace - Stock Market News, Stock Advice & Trading Tips Regarding the best stocks to buy, some investors look to analyst consensus stocks — companies that everyone on Wall Street fawns over. I did a quick Finviz.com screen of S&P 500 companies. The lowest rating from analysts — the lower, the better — was 1.50 for DexCom (NASDAQ:DXCM), a maker of glucose monitoring systems. The highest was a tie among four companies, each with a 3.50 rating. The top 20 companies (including those that tied) rated between 1.50 for DXCM and 1.80. Of the 36 at 1.80 or less, healthcare had the highest representation with eight companies. Ten of the sectors used by Finviz had at least one stock. The question is, which three to pick? They’re all so popular with analysts. Since it’s my article, I’ll go with stocks in the energy, industrial and financial sectors. Two of the three I’ve recommended in 2023. The other, I don’t believe I’ve ever discussed before. Targa Resources (TRGP) Source: PopTika / Shutterstock Targa Resources (NYSE:TRGP) has been a favorite energy stock of mine in 2023. I’ve recommended it on at least three occasions, the most recent in mid-July, as part of a trifecta of dividend stocks to buy for the long haul. As I said in my article, of the 19 analysts that cover its stock, 17 rated it a Buy, while the other two gave it an Overweight rating. The stock has no Hold or Sell ratings. The average target price of $99.82 is 27% higher than where it’s currently trading. The midstream energy business generates most of its revenue from the Permian Basin, quickly becoming the breadbasket of American energy production. What makes its dividend so attractive — its annualized dividend of $2 yields 2.5% — is the stability of it. The company generates 85% of its revenue from fee-based contracts, growing its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) by more than 62% over the past year. Its shares are up 52.5% over the past five years, double Exxon Mobil’s (NYSE:XOM) return over the same period. Jacobs Solutions (J) Source: Gorodenkoff/ShutterStock.com Jacobs Solutions (NYSE:J) is the stock of the three that I don’t believe I’ve ever discussed on InvestorPlace.com. I selected it because my wife owns a construction company. It makes sense that I should follow what’s happening in it. To say that Jacobs is just a construction company is like saying that Amazon (NASDAQ:AMZN) is just an e-commerce business. That couldn’t be further from the truth. Although it started in 1947 with engineer Joseph J. Jacobs, selling consulting services to construction companies and other infrastructure-type businesses, it has become a project manager with over $15 billion in revenue generated by more than 60,000 employees worldwide, working on some of the most significant and most complex projects. Of the 19 analysts that covered its stock, 12 rate it a Buy, another six rate it Overweight, and one has it as a Hold. The average target price of $148.21 is 21% higher than its current share price. Jacobs is in the middle of transforming its business to create more shareholder value. It’s trying to build higher-growth, higher-margin companies focusing on critical infrastructure projects and their sustainability. In May, it announced that it would separate itself into two companies. One would be its Critical Mission Solutions (CMS) business. It focuses on providing services to government agencies. As a result of the separation, it will become a pure-play provider of government services with $4.4 billion in annual revenue and more easily valued by investors. Chief Executive Officer (CEO) Bob Pragada and the board believe that addition by subtraction is good for shareholders. While the news has yet to excite investors, once completed, investors should expect its share price to go on its next leg higher. S&P Global (SPGI) Source: AntonSAN / Shutterstock.com S&P Global (NYSE:SPGI) stock has performed well over the past five years, up nearly 100%, but it hasn’t come without some volatility. In 2021, its share price gained 44%, only to be followed up with a 39% decline through the first 10 months of 2022. In the nine months since, it’s gained back most of 2022’s losses. For investors who don’t mind a little volatility, SPGI is the perfect stock to own for the long haul, adding to your position whenever it has one of its temporary corrections. Since Doug Peterson became CEO on Nov. 1, 2013, its stock gained 494%, considerably higher than the S&P 500. Peterson is diligently working to get the company best known for its Indices business back to generating industry-leading margins and profitability. Analysts have taken notice. In recent weeks, at least three analysts covering SPGI stock have raised their price targets. On July 12, Raymond James analyst Patrick O’Shaughnessy upped his target by $8 to $421. He has an outperform rating on the stock. A more noticeable bump in price came from UBS analyst Kramm; he raised its target price by $40 to $460, well above where it’s trading. Morgan Stanley analyst Toni Kaplan also slightly adjusted higher, increasing her target by $7, to $427, with an Overweight rating. Overall, 24 analysts cover its stock, with 22 giving it an Overweight or outright Buy, with no Sell ratings. It has an average target price of $440.71. In October 2021, I recommended investors buy SPGI for the next 15 years. Nothing’s changed. It’s still a long-term buy. On the date of publication, Will Ashworth did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. More From InvestorPlace The #1 AI Name for 2023 Could Be About to Ignite This $20.6 Trillion Wealth Shift Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post Top Picks: 3 Stocks That (Almost) All Analysts Agree On appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-07-21,130.98,132.565,130.06,130.6,"[""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know DexCom (DXCM) closed at $130.60 in the latest trading session, marking a -0.04% move from the prior day. This move lagged the S&P 500's daily gain of 0.03%. Meanwhile, the Dow gained 0.01%, and the Nasdaq, a tech-heavy index, lost 1.37%. Prior to today's trading, shares of the medical device company had gained 3.26% over the past month. This has outpaced the Medical sector's gain of 0.82% and lagged the S&P 500's gain of 3.43% in that time. DexCom will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2023. On that day, DexCom is projected to report earnings of $0.22 per share, which would represent year-over-year growth of 29.41%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $837 million, up 20.22% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.07 per share and revenue of $3.49 billion. These totals would mark changes of +22.99% and +20.08%, respectively, from last year. It is also important to note the recent changes to analyst estimates for DexCom. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.26% higher. DexCom is holding a Zacks Rank of #2 (Buy) right now. Valuation is also important, so investors should note that DexCom has a Forward P/E ratio of 122.42 right now. Its industry sports an average Forward P/E of 31.98, so we one might conclude that DexCom is trading at a premium comparatively. Also, we should mention that DXCM has a PEG ratio of 3.03. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.68 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Highly-Ranked Large Cap Stocks to Buy Before Earnings for Big Upside Today\u2019s episode of Full Court Finance at Zacks takes a look at where the market stands as big tech stocks start reporting quarterly earnings results. The episode then explores three highly-ranked large-cap stocks\u2014Honeywell, DexCom, and NextEra Energy\u2014that investors might want to buy before their upcoming earnings releases for both near-term and long-term upside. Wall Street swung between smalls declines and gains through late-afternoon trading on Friday. The more mundane session followed a rather big pullback from the Nasdaq on Thursday after investors dumped Tesla and Netflix stock to lock in some profits following the massive first-half run. The reactions to Netflix and Tesla, which spilled over into semiconductors and much of tech, could be a sign of what\u2019s to come. Some big tech names that have skyrocketed in 2023 and are trading at or near their highs might have to post big beat-and-raise quarters to keep their runs going in the near term. In fact, a profit-taking pullback in the coming weeks would possibly prove beneficial to the market. Despite the possibility of near-term volatility or selling, the bedrock supporting the bull market appears to remain solid, with inflation cooling, the Fed near the end of its hiking cycle, and the earnings picture improving (also read: Q2 Earnings Season Gets Off to a Positive Start). Honeywell (HON) is set to report its Q2 results on Thursday, July 27. Honeywell is an industrial products company that\u2019s transformed into a hybrid digital-software-industrial titan. The historic firm\u2019s portfolio spans aerospace, building technologies, energy, healthcare, utilities, logistics, and far beyond. Honeywell\u2019s diverse offerings support NASA missions all the way to high-tech temperature control systems for homes and buildings. Image Source: Zacks Investment Research Honeywell\u2019s outlook showcases solid top and bottom line growth for $140 billion market cap firm. And its improving earning outlook helps it land a Zacks Rank #2 (Buy) right now. HON\u2019s dividend yields 2% at the moment, and it has crushed the S&P 500 over the last 20 years, up 640% vs. 360%. Yet, the stock is still down YTD and trading around 10% below its records. Image Source: Zacks Investment Research Honeywell is now trading above its 50-day and 200-day moving averages and it found support at its 21-day recently, after popping off its 50-week moving average in May. And HON is trading at a 25% discount to its highs at 21.6X forward 12 month earnings, which is right near its Zacks econ sector and its own 5-year median. DexCom, Inc. (DXCM) makes continuous glucose monitoring devices designed for people with diabetes. DXCM is set to report its second quarter financial results on July 27. The connected-health firm allows people with diabetes the chance to place a small sensor just beneath their skin to help them continuously monitor their glucose levels and avoid the dreaded finger prick. Image Source: Zacks Investment Research DexCom\u2019s continuous glucose monitoring offerings are part of a connected health revolution that\u2019s still in the early days and is poised to become the standard form of medical care and treatment in the decades to come. DexCom\u2019s addressable market continues to expand, with 1 in 10 people in the U.S. currently suffering from diabetes, and far more have \u201cprediabetes,\u201d according to the CDC. Rising diabetes rates are not just a U.S. problem, with roughly 540 million adults, or 1 in 10 people around the world living with diabetes, with that figure set to keep growing. Image Source: Zacks Investment Research DexCom\u2019s revenue and earnings growth outlooks showcase the continuation of impressively large and steady top and bottom line growth. DXCM\u2019s upward earnings revisions help it land a Zacks Rank #2 (Buy). Wall Street is also very high on the stock, with 13 of the 15 brokerage recommendations Zacks has at \u201cStrong Buys.\u201d DexCom shares have skyrocketed over 2,200% in the last 10 years, yet they are currently trading 20% below their highs. Plus, DXCM has already mounted a roughly 85% comeback off of its lows last year. And DXCM currently trades above its 21-day, 50-day, and 200-day moving averages. NextEra Energy (NEE) operates one of the largest electric utilities, Florida Power & Light Company, in the U.S. and is one of the biggest producers of wind and solar energy on the planet. NextEra is a battery storage leader as well, and it is exposed to the potential long-term upside of nuclear power. The $150 billion market cap firm is also the largest holding in the Utilities Select Sector SPDR ETF XLU. NextEra\u2019s revenue is projected to grow by 30% in FY23 to $27 billion and then climb 8% higher next year to help boost its bottom line by 7% and 9%, respectively, based on Zacks estimates. Plus its earnings outlook continues to improve to help it grab a Zacks Rank #2 (Buy) heading into its earnings release on Tuesday, July 25. Image Source: Zacks Investment Research NextEra\u2019s dividend currently yields 2.5% and it has raised its payout by an average of 11% annually over the past five years. And 10 of the 13 brokerage recommendations Zacks has for NEE are \u201cStrong Buys,\u201d with no \u201cSells.\u201d NEE stock has climbed by 260% in the past decade and 890% in the last 20 years, with a total return of roughly 1,700%. This outperformance includes roughly two and a half years of choppy sideways movement, with NEE trading 15% below its records. Image Source: Zacks Investment Research NextEra could be ready to break out of its slump, with it back above its 200-week moving average, as well as its 21-day and 50-day. On the valuation front, NEE trades at a 33% discount to own its highs at 22.8X forward 12-month earnings and not too far above its decade-long median. NextEra is currently trading at its lowest valuation levels over the past three years. (Disclosure: Ben Rains own NEE in Zacks Alternative Energy Innovators and in his personal portfolio) Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Honeywell International Inc. (HON) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Utilities Select Sector SPDR ETF (XLU): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Invesco QQQ Trust ETF: What Lies Ahead? Investors looking to invest in tech stocks may consider the Invesco QQQ Trust (NASDAQ:QQQ). So far in 2023, the QQQ ETF has advanced more than 42%, easily outperforming the 18.6% rise in the S&P 500 Index (SPX). Encouragingly, the ETF\u2019s Outperform Smart Score on TipRanks indicates positive signals. Also, the analysts\u2019 average price target implies more room for the ETF to grow. The ETF might have more room to run on the back of falling inflation, the economy\u2019s resilient recovery, and the pause on the Fed\u2019s benchmark interest rate hike. QQQ ETF: Key Supporting Factors The QQQ ETF stock is a growth-focused index fund with about $208.95 billion in assets under management as of July 20. Also, the ETF has a low expense ratio (cost of managing the ETF) of 0.20%, which makes it a promising investment. Moving on, the QQQ ETF stock has beaten the S&P 500 Index in nine out of the last ten years, with the trend continuing in 2023 so far. Moreover, the stock has delivered an average annualized return of 18.93% in the past decade, ending in June 2023. Favorable Smart Score According to TipRanks\u2019 Smart Score System, QQQ has a Smart Score of 8 out of 10, which indicates that the ETF could outperform the broader market over the long term. It is worth highlighting that more than 50% of the holdings boast an Outperform Smart Score (i.e., a score of 8 or higher). The stock has a Positive signal from retail investors. Our data shows that about 10.3% of TipRank\u2019s retail investors changed their holdings of the QQQ in the last 30 days. Moreover, The SPY ETF enjoys bullish blogger sentiment on TipRanks. Is Invesco QQQ a Good Buy, According to Top Analysts? As per 1,244 top analysts providing ratings on the QQQ\u2019s 102 holdings, the ETF is a Moderate Buy, and the average price target of $415.49 implies a 10.28% upside. It is noteworthy that these top analysts have an impressive history of helping investors generate massive returns from their recommendations. QQQ ETF\u2019s Best-Performing Stocks Here are some notable companies within the QQQ ETF that have demonstrated outstanding performance in the past year: Nvidia Corporation (NVDA) Netflix Inc. (NFLX) Broadcom Inc. (AVGO) Constellation Energy Corporation (CEG) Trade Desk (TTD) Meta Platforms, Inc. (META) ON Semiconductor Corporation (ON) Paccar (PCAR) Dexcom (DXCM) Booking Holdings (BKNG) Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-24,130.58,131.74,127.44,127.72,"[""Are Medical Stocks Lagging Boston Scientific (BSX) This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Boston Scientific (BSX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Boston Scientific is a member of the Medical sector. This group includes 1119 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that BSX has returned about 14.9% since the start of the calendar year. At the same time, Medical stocks have gained an average of 0.2%. This means that Boston Scientific is outperforming the sector as a whole this year. Another stock in the Medical sector, DexCom (DXCM), has outperformed the sector so far this year. The stock's year-to-date return is 15.3%. For DexCom, the consensus EPS estimate for the current year has increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Boston Scientific belongs to the Medical - Products industry, which includes 99 individual stocks and currently sits at #121 in the Zacks Industry Rank. On average, this group has gained an average of 8.2% so far this year, meaning that BSX is performing better in terms of year-to-date returns. In contrast, DexCom falls under the Medical - Instruments industry. Currently, this industry has 96 stocks and is ranked #83. Since the beginning of the year, the industry has moved +12.1%. Investors interested in the Medical sector may want to keep a close eye on Boston Scientific and DexCom as they attempt to continue their solid performance. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) to Report Q2 Earnings: What's in the Cards? DexCom, Inc. DXCM is scheduled to release second-quarter 2023 results on Jul 27, after the closing bell. In the last reported quarter, the company\u2019s earnings beat estimates by 13.33%. The figure also outpaced the consensus mark in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%. Q2 Estimates Currently, the Zacks Consensus Estimate for DexCom\u2019s second-quarter revenues is pegged at $837 million, indicating growth of 20.2% from the year-ago quarter\u2019s reported figure. The consensus mark for earnings is pinned at 22 cents per share, implying a 29.4% improvement year over year. Factors to Note DexCom\u2019s second-quarter revenues are likely to have been aided by continued increase in volume. This surge can be attributed to new patients across all channels and rising global awareness about the benefits of its real-time Continuous Glucose Monitoring (CGM) system. Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to have been the key catalysts behind the company\u2019s second-quarter results. In April, DexCom announced that coverage for its CGM systems was expanded through Non-Insured Health Benefits program. The expanded coverage will provide access to CGM systems for all patients managing diabetes with insulin. The Medicare coverage for the company\u2019s latest CGM technology, G7 sensor, also got expanded in the same month to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events. In March, DexCom\u2019s G6 CGM System was made eligible for treatment of type II diabetes in Manitoba, Canada. It was available earlier for type I diabetes management alone. Moreover, the system will be available for patients of all ages. These developments might have boosted the demand for DXCM\u2019s CGM systems. This, in turn, is likely to have driven revenue growth in the to-be-reported quarter. The company has been benefiting from demographic trends and lifestyles in countries outside Europe and the United States. Per management, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In the first quarter, International revenues (29% of total revenues) surged 21% year over year to $215.5 million. Organically, the segment\u2019s revenues were up 27% in the last reported quarter. U.S. revenues (71% of total revenues) increased 17% in the same period. The trend is likely to have continued in the second quarter, owing to broad-based growth. The Zacks Consensus Estimate for U.S. and International revenues is pegged at $515 million and $205 million, respectively, for the second quarter. The approval for G7 CGM system in Canada in July buoys optimism. On its second-quarterearnings call the company may provide an update on the launch plan of the new system in the country. However, an increase in operating expenses and intense competition might have weighed on DXCM\u2019s performance in the quarter to be reported. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote What Our Quantitative Model Suggests Our proven model does not conclusively predict an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that's not the case here. Earnings ESP: DexCom\u2019s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: DexCom carries a Zacks Rank #2 at present. Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle. McKesson MCK has an Earnings ESP of +1.93% and a Zacks Rank of 2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The stock has gained 9.5% year to date. MCK\u2019s earnings beat estimates in the last reported quarter. It has a trailing four-quarter earnings surprise of 4.48%, on average. Avanos Medical AVNS has an Earnings ESP of +0.74% and a Zacks Rank of 3 at present. The stock has lost 3.5% year to date. AVNS\u2019 earnings missed estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 8.03%. Pacific Biosciences of California PACB has an Earnings ESP of +5.88% and a Zacks Rank of 3 at present. The stock has gained 67.3% year to date. PACB\u2019s earnings beat estimates in the last reported quarter. It has a negative four-quarter average earnings surprise of 3.66%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-25,126.9,131.11,126.81,129.96,"[""Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks Tuesday, July 25, 2023 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time update on the ongoing Q2 earnings season and new research reports on 16 major stocks, including Toyota Motor Corporation (TM), Deere & Company (DE) and Starbucks Corporation (SBUX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today\u2019s research reports here >>> Q2 Earnings Season Scorecard Including all the results that came out this morning, we now have Q2 results from 122 S&P 500 members or 24.4% of the index's total membership. Total earnings for these 122 index members are up +1.2% from the same period last year on +7.1% higher revenues, with 81.1% beating EPS estimates and 63.9% beating revenue estimates. The +1.2% earnings growth pace for this group of 122 index members is the first positive year-over-year earnings growth after 5 back-to-back quarters of declines. The 81.1% EPS beats percentage is not only above what we had seen from this group of 122 S&P 500 members in recent quarters but is also above the 5-year average of 78.7%. This is notable since Q2 estimates had suffered fewer negative revisions relative to other recent quarters. Looking at Q2 as a whole, combining the actuals that have come out with estimates for the sitll to come companies, total earnings are expected to be down -10.4% from the same period last year on -0.4% lower revenues. Excluding the Energy sector drag, Q2 earnings for the rest of the S&P 500 index would be down -4.6% on +3.3% higher revenues. Today's Featured Analyst Reports Toyota Motor shares have modestly outperformed the Zacks Automotive - Foreign industry over the past year (+7.0% vs. +5.3%). Continued demand for vehicles and robust product line-up is set to fuel sales volumes of Toyota. To capitalize on the accelerated global shift to green cars, the auto giant is deepening focus on manufacturing electric and fuel-cell vehicles, which will bolster the company\u2019s product competitiveness. The ratio of electrified vehicles sold to total sales in fiscal 2023 was 29.6% and the company expects the ratio to increase to 37% in fiscal 2024. It aims to generate 40% of its global sales from EVs by 2025 and 70% by 2030 and expand global sales of BEVs to 3.5 million units a year by 2030. The company plans to invest 4 trillion yen ($35 billion) for a line-up of 30 BEV by 2030. Its commitment to return capital to shareholders and upbeat fiscal 2024 view spark confidence. Thus, we are bullish on the stock. (You can read the full research report on Toyota Motor here >>>) Shares of Deere have outperformed the Zacks Manufacturing - Farm Equipment industry over the past year (+40.3% vs. +38.1%). The company is witnessing solid growth in order levels, which is expected to aid its top-line performance in the forthcoming quarters. Strong replacement demand will continue to boost the company's results. Demand for its construction equipment will likely benefit from anticipated growth in infrastructure investments in the United States. Even though inflated material and labor costs are anticipated to impact the company's margins, the company's effort to improve pricing will somewhat help offset this impact. Product launches equipped with the latest technology to make farming automated will continue to provide Deere with an edge over its competitors. The company is poised to benefit in the long run from rapid growth in the global population and the rising worldwide infrastructure needs. The earnings estimate for 2023 has lately moved north. (You can read the full research report on Deere here >>>) Starbucks shares have outperformed the Zacks Retail - Restaurants industry over the past year (+30.7% vs. +23.6%). The company is benefiting from solid comps growth in all its operational segments along with impressive revenue recovery from China after COVID-19. Improving customer experience with innovative new store designs and upgraded product offerings, and supply-chain efficiencies bode well for the company. Also, the company\u2019s focus on product innovation and store growth adds to its growth. For fiscal 2023, the company expects consolidated revenues and global comparable store sales to be in the range of 10-12% and the high end of 7-9%, respectively, year over year. However, earnings estimates for fiscal 2023 have moved south in the past 7 days. Increased expenses and inflation are major concerns to the company\u2019s growth trend. (You can read the full research report on Starbucks here >>>) Other noteworthy reports we are featuring today include AbbVie Inc. (ABBV), Equinor ASA (EQNR) and DexCom, Inc. (DXCM). Director of Research Sheraz Mian Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Toyota Motor's (TM) Prospects Solid on Electrification Push Deere (DE) Gains from Strong Demand and Strategic Actions Store & Comps Growth Aid Starbucks (SBUX), High Cost Ail Featured Reports AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth The Zacks analyst says that AbbVie's new drugs, Skyrizi and Rinvoq, are going strong bolstered by approvals in new indications. They can drive the top-line and make up for lost Humira sales. Equinor (EQNR) to Benefit From Rising Clean Energy Demand The Zacks analyst is impressed by Equinor's massive investments in renewable projects, comprising solar and wind energy. With this, the company can capitalize on the rising clean energy demand. Strong Product Portfolio Aids DexCom (DXCM) Fight Competition Per the Zacks analyst, DexCom strong product portfolio targeting the large and growing diabetes market is helping the company fight intensifying competition with entry new competing products. Strong Renewal Rate Change, Retention Aid Travelers (TRV) Per the Zacks analyst, Travelers is set to gain from continued strong renewal rate change and retention and increase in new business. Yet, exposure to cat loss inducing underwriting volatility ails. Verisk (VRSK) Gains From Opta Buyout, Operational Risks Stay Per the Zacks analyst, the Opta acquisition has expanded Verisk's footprint in the Canadian market. Chances of security breach remains as a concern. Investment Aid Edison International (EIX), Financial Ail Per the Zacks Analyst, Edison International's systematic capital investment strategy plan is likely to boost its growth in the long-term. However, company's weak financials remains a bottleneck. Wix.com (WIX) Benefits From Diversified Product Portfolio Per the Zacks analyst, Wix's performance is gaining from robust uptake of Wix Editor and other new e-commerce applications. Increasing partner revenues and B2B partnerships are tailwinds. New Upgrades Robust Live Events Demand Aid Live Nation Entertainment (LYV) Per the Zacks analyst, Live Nation is likely to benefit from pent-up demand for live events, solid ticket sales and sponsorship business. Also, focus on strengthening of client base bode well. Expanding Diagnosis & Treatment Portfolio Aids Philips (PHG) Per the Zacks analyst, Philips continues to benefit from growing Diagnosis & Treatment business on the back of partnerships, expanding geographical coverage and innovative solutions. Post Holdings (POST) Benefits from Solid Foodservice Segment Per the Zacks analyst, Post Holdings is benefiting from strength in the Foodservice business. During the second quarter of fiscal 2023, Foodservice sales increased 40.1% to $633.2 million. New Downgrades High Costs & Rising Rates Hurt Pool Corp (POOL) Prospects Per the Zacks analyst, Pool Corp has been negatively impacted by inflationary costs, weather-related constraints and high interest rates. Also fall in new pool construction activity remains a concern. J.B. Hunt (JBHT) Grapples With Challenging Freight Market Per the Zacks Analyst, lower revenues across all the business segments, mainly due to a combination of lower volume and customer rates, hurt J.B. Hunt's second-quarter 2023 results. High Costs & Loan Concentration to Hurt U.S. Bancorp (USB) Per the Zacks analyst, U.S. Bancorp's high costs due to high integration expenses is likely to limit bottom-line growth. Also, commercial loan concentration are concerning. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Toyota Motor Corporation (TM) : Free Stock Analysis Report Starbucks Corporation (SBUX) : Free Stock Analysis Report Deere & Company (DE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Equinor ASA (EQNR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform. The Style Scores are broken down into four categories: Value Score For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks. Growth Score Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time. Momentum Score Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying \""the trend is your friend.\"" The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. VGM Score If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day. This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio. That's where the Style Scores come in. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of A, forecasting year-over-year earnings growth of 23% for the current fiscal year. For fiscal 2023, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $1.07 per share. DXCM boasts an average earnings surprise of 15.2%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-26,129.2,131.26,129.09,130.69,
DXCM,2023-07-27,131.11,131.49,128.77,129.36,"[""Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics DexCom (DXCM) reported $871.3 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 25.2%. EPS of $0.34 for the same period compares to $0.17 a year ago. The reported revenue represents a surprise of +4.10% over the Zacks Consensus Estimate of $837 million. With the consensus EPS estimate being $0.22, the EPS surprise was +54.55%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- United States: $616.60 million versus $609.26 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +20.7% change. Revenue- International: $254.70 million compared to the $227.63 million average estimate based on six analysts. The reported number represents a change of +37.5% year over year. Revenue- Hardware: $93.30 million versus the two-analyst average estimate of $104.27 million. The reported number represents a year-over-year change of -5.3%. Revenue- Sensor and other: $778 million compared to the $730.62 million average estimate based on two analysts. The reported number represents a change of +30.2% year over year. View all Key Company Metrics for DexCom here>>> Shares of DexCom have returned +3.4% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Free Report: Top EV Battery Stocks to Buy Now Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to \""insane levels,\"" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid. Download free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates DexCom (DXCM) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 54.55%. A quarter ago, it was expected that this medical device company would post earnings of $0.15 per share when it actually produced earnings of $0.17, delivering a surprise of 13.33%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $871.3 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.10%. This compares to year-ago revenues of $696.2 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have added about 15.4% since the beginning of the year versus the S&P 500's gain of 18.9%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.32 on $924.72 million in revenues for the coming quarter and $1.07 on $3.49 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Eargo, Inc. (EAR), has yet to report results for the quarter ended June 2023. This company is expected to post quarterly loss of $0.97 per share in its upcoming report, which represents a year-over-year change of +93.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Eargo, Inc.'s revenues are expected to be $8.2 million, up 13.1% from the year-ago quarter. Free Report: Top EV Battery Stocks to Buy Now Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to \""insane levels,\"" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid. Download free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Eargo, Inc. (EAR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for July 27, 2023 : TMUS, INTC, MDLZ, CP, KLAC, F, DXCM, AJG, DLR, MTD, EIX, EQR The following companies are expected to report earnings after hours on 07/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases. T-Mobile US, Inc. (TMUS)is reporting for the quarter ending June 30, 2023. The wireless (national) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.71. This value represents a 19.58% increase compared to the same quarter last year. TMUS missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -24.53%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TMUS is 19.90 vs. an industry ratio of 21.80. Intel Corporation (INTC)is reporting for the quarter ending June 30, 2023. The semiconductor company's consensus earnings per share forecast from the 14 analysts that follow the stock is $-0.19. This value represents a 165.52% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for INTC is -180.84 vs. an industry ratio of -4.30. Mondelez International, Inc. (MDLZ)is reporting for the quarter ending June 30, 2023. The food company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.69. This value represents a 2.99% increase compared to the same quarter last year. In the past year MDLZ has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.25%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MDLZ is 23.09 vs. an industry ratio of 18.10, implying that they will have a higher earnings growth than their competitors in the same industry. Canadian Pacific Kansas City Limited (CP)is reporting for the quarter ending June 30, 2023. The transportation (rail) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.69. This value represents a 6.76% decrease compared to the same quarter last year. CP missed the consensus earnings per share in the 1st calendar quarter of 2023 by -10%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CP is 28.19 vs. an industry ratio of 16.70, implying that they will have a higher earnings growth than their competitors in the same industry. KLA Corporation (KLAC)is reporting for the quarter ending June 30, 2023. The electrical instrument company's consensus earnings per share forecast from the 9 analysts that follow the stock is $4.82. This value represents a 17.04% decrease compared to the same quarter last year. In the past year KLAC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.58%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for KLAC is 18.40 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry. Ford Motor Company (F)is reporting for the quarter ending June 30, 2023. The auto (domestic) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.51. This value represents a 25.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for F is 7.47 vs. an industry ratio of 7.20, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending June 30, 2023. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.22. This value represents a 29.41% increase compared to the same quarter last year. In the past year DXCM has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DXCM is 122.14 vs. an industry ratio of 8.60, implying that they will have a higher earnings growth than their competitors in the same industry. Arthur J. Gallagher & Co. (AJG)is reporting for the quarter ending June 30, 2023. The insurance brokers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.86. This value represents a 9.41% increase compared to the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AJG is 25.23 vs. an industry ratio of 21.90, implying that they will have a higher earnings growth than their competitors in the same industry. Digital Realty Trust, Inc. (DLR)is reporting for the quarter ending June 30, 2023. The reit company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.65. This value represents a 6.45% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DLR is 17.81 vs. an industry ratio of 14.20, implying that they will have a higher earnings growth than their competitors in the same industry. Mettler-Toledo International, Inc. (MTD)is reporting for the quarter ending June 30, 2023. The scientific instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $9.99. This value represents a 6.39% increase compared to the same quarter last year. In the past year MTD has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 0.93%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MTD is 30.45 vs. an industry ratio of 28.30, implying that they will have a higher earnings growth than their competitors in the same industry. Edison International (EIX)is reporting for the quarter ending June 30, 2023. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.95. This value represents a 1.06% increase compared to the same quarter last year. In the past year EIX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for EIX is 15.28 vs. an industry ratio of 11.30, implying that they will have a higher earnings growth than their competitors in the same industry. Equity Residential (EQR)is reporting for the quarter ending June 30, 2023. The reit company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.94. This value represents a 5.62% increase compared to the same quarter last year. EQR missed the consensus earnings per share in the 1st calendar quarter of 2023 by -1.14%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for EQR is 17.87 vs. an industry ratio of 15.50, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-28,134.4,139.55,132.1,132.38,"[""Stocks Gain as Bond Yields Fall on Signs of Cooling Inflation What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is up +0.85%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.53%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.52%. Stocks this morning are moderately higher after key measures of U.S. inflation cooled, bolstering optimism the economy can avoid a recession and that the Federal Reserve can achieve a soft landing. The U.S. Q2 employment cost index rose at the slowest pace in 2 years, and the U.S. Jun PCE core deflator, the Fed's preferred inflation gauge, rose less than expected. Also, strength in technology stocks is boosting the overall market, with Intel up more than +5% after reporting better-than-expected Q2 revenue. U.S. Jun personal spending rose +0.5% m/m, stronger than expectations of +0.4% m/m. Jun personal income rose +0.3% m/m, weaker than expectations of +0.5% m/m. The U.S. Jun PCE core deflator, the Fed's preferred gauge of inflation, eased to +4.1% y/y from +4.6% y/y in May, better than expectations of +4.2% y/y and the slowest pace of increase in 1-3/4 years. The U.S. Q2 employment cost index rose +1.0% (q/q annualized), slower than expectations of +1.1% and the smallest pace of increase in 2 years. The University of Michigan U.S. Jul consumer sentiment was revised lower to 71.6 from the initially reported 72.6. The markets are discounting the odds at 18% for a +25 bp rate hike at the September 20 FOMC meeting. Global bond yields are mixed. The 10-year T-note yield fell from a 2-1/2 week high of 4.038% and is down -4.8 bp to 3.951%. The 10-year German bund yield rose to a 2-week high of 2.585% and is up +1.0 bp at 2.485%. The 10-year UK Gilt yield rose to a 1-1/2 week high of 4.389% and is up +2.0 at 4.330%. Overseas stock markets are mixed. The Euro Stoxx 50 is up +0.25%. China\u2019s Shanghai Composite Index today closed up +1.84%. Japan\u2019s Nikkei Stock Index closed down -0.40%. Today\u2019s stock movers\u2026 T Rowe Price Group (TROW) is up more than +10% to lead gainers in the S&P 500 after reporting Q2 adjusted EPS of $2.02, well above the consensus of $1.73. Cincinnati Financial (CINF) is up more than +8% after reporting Q2 adjusted operating EPS of $1.21, stronger than the consensus of 70 cents. Digital Realty Trust (DLR) is up more than +6% after reporting Q2 adjusted Ebitda of $697 million, above the consensus of $665.8 million. Intel (INTC) is up more than +5% to lead gainers in the Dow Jones Industrials after reporting Q2 revenue of $12.90 billion, well above the consensus of $12.02 billion, and forecast Q3 revenue of $12.9 billion-$13.9 billion, the midpoint above the consensus of $13.28 billion. KLA Corp (KLAC) is up more than 5% after reporting Q4 adjusted EPS of $5.40, stronger than the consensus of $4.85. Reata Pharmaceuticals (RETA) is up more than +52% after Biogen agreed to buy the company for about $7.3 billion. Dexcom (DXCM) is up more than +6% to lead gainers in the Nasdaq 100 after reporting Q2 revenue of $871.3 million, stronger than the consensus of $840.2 million, and raising its full-year revenue forecast to $3.50 billion-$3.55 billion from a previous forecast of $3.40 billion-$3.52 billion, above the consensus of $3.50 billion. Franklin Resources (BEN) is up more than +4% after reporting Q3 net outflows of $7.1 billion, less than the consensus of $8.67 billion. Mondelez International (MDLZ) is up more than +4% after reporting Q2 net revenue of $8.51 billion, above the consensus of $8.21 billion. Procter & Gamble (PG) is up more than +3% after reporting Q4 net sales of $20.55 billion, better than the consensus of $20.06 billion. Juniper Networks (JNPR) is down more than -6% after it said it is \u201ccurrently facing some near-term order weakness from its Cloud and to a lesser degree its Service Provider customers.\u201d Ford Motor (F) is down more than -4% after it said it now expects to see losses from electric vehicles hit $4.50 billion this year, above the consensus of a -$3.25 billion loss. Centene (CNC) is down more than -5% after company executives said only 2.7% of its members are in its four-star Medicare plans and warned that number might drop to zero this year, which could eventually mean a drop in revenue from those plans. Mohawk Industries (MHK) is down more than -5% after reporting Q2 free cash flow of $146.9 million, well below the consensus of $245.7 million. AON Plc (AON) is down more than -4% after reporting Q2 adjusted EPS of $2.76, below the consensus of $2.82. Principal Financial Group (PFG) is down more than -4% after reporting Q2 adjusted operating EPS of $1.53, weaker than the consensus of $1.65. Colgate-Palmolive (CL) is down more than -2% after forecasting full-year organic sales to climb +5% to +7%, the midpoint below the consensus of +6.38%. Across the markets\u2026 September 10-year T-notes (ZNU23) today are up +15 ticks, and the 10-year T-note yield is down -4.8 bp to 3.951%. Sep T-notes today recovered from a 2-1/2 week low, and the 10-year T-note yield fell back from a 2-1/2 week high of 4.038% on signs of easing U.S. price pressures. T-notes recovered after the Q2 employment cost index and the Jun core PCE deflator rose less than expected. T-notes this morning initially dropped to a 2-1/2 week low on negative carryover from a jump in 10-year Japan JGB bond yields to a 9-year high after the BOJ adjusted its yield curve control program. The dollar index (DXY00) today is down by -0.29%. The dollar today fell back from a 2-1/2 week high posted on overnight trade and is moderately lower after weaker-than-expected U.S. inflation news knocked T-note yields lower. Also, strength in the yen weighed on the dollar after the yen climbed to a 1-1/2 week high against the dollar. EUR/USD (^EURUSD) today is up by +0.51%. The euro recovered from a 3-week low and is moderately higher on hawkish comments from ECB Governing Council member and Bundesbank President Nagel, who said, \""Core inflation is stubborn, so our monetary policy needs to be even more stubborn.\u201d The euro today initially fell to a 3-week low after German Jul CPI rose less than expected and after Eurozone Jul economic confidence fell more than expected to a 9-month low. ECB Governing Council member and Bundesbank President Nagel said, \""Core inflation is stubborn, so our monetary policy needs to be even more stubborn, and we need interest rates to be high enough and to keep them there for as long as necessary.\"" Eurozone Jul economic confidence fell -0.8 to a 9-month low of 94.5, weaker than expectations of 95.0. German Q2 GDP was unchanged q/q, weaker than expectations of +0.1% q/q. German Jul CPI (EU harmonized) eased to +6.5% y/y from +6.8% y/y in Jun, better than expectations of +6.6% y/y. France Q2 GDP rose +0.5% q/q, stronger than expectations of +0.1% q/q. USD/JPY (^USDJPY) is up by +0.60%. The yen today fell back from a 1-1/2 week high against the dollar and is moderately lower. The yen retreated on dovish comments from BOJ Governor Ueda, who said today\u2019s move by the BOJ to adjust its yield curve control was not a step toward normalization of BOJ policy and that there is a \u201clong way\u201d before the BOJ raises negative interest rates. The yen today initially rallied to a 1-1/2 week high after the BOJ tweaked its yield curve control program and effectively raised the upper limit of its 10-year JGB yield target to 1.0% from 0.5%. Also, stronger-than-expected Japanese inflation news was hawkish for BOJ policy and supportive for the yen after Tokyo Jul CPI rose more than expected. The BOJ, as expected, kept its policy balance rate unchanged at -0.1%. The BOJ also kept its target for 10-year yields at around 0% but said the 0.5% ceiling was now a reference point and that it would offer to buy 10-year debt at 1.0% each day, suggesting an effective doubling of the upper target of the yield range. Tokyo Jul CPI rose +3.2% y/y, unchanged from Jun and stronger than expectations of +2.9% y/y. Tokyo CPI ex-fresh food and energy rose +4.0% y/y, stronger than expectations of +3.7% y/y and the most in 40 years. August gold (GCQ3) today is up +12.9 (+0.66%), and Sep silver (SIU23) is up +0.048 (+0.20%). Precious metals prices this morning are moderately higher. Weakness in the dollar today is bullish for metals prices. Also, today\u2019s U.S. inflation news on the Q2 employment index and Jun core PCE deflator was weaker than expected, knocking bond yields lower and supporting precious metals. On the negative side was today\u2019s action by the BOJ to tweak its yield curve control program, which sent the 10-year JGB bond yield soaring to a 9-year high. Also, fund liquidation of long gold holdings is weighing on gold prices after long gold holdings in ETFs fell to a new 3-year low Thursday. More Stock Market News from Barchart Domino's Pizza Posts Huge Free Cash Flow Growth- Ideal for Options Traders Should You Invest in SKIN Stock? Pros & Cons Explained Is NIO the Best Chinese EV Stock to Buy Now? Why Dividend Investors Should be Cautious on Verizon and AT&T On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong DexCom, Inc. DXCM reported second-quarter 2023 adjusted earnings per share (EPS) of 34 cents, which beat the Zacks Consensus Estimate of 22 cents by 54.5%. The company reported earnings of 17 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 28 cents, up from the year-ago quarter\u2019s figure of 12 cents. Shares of DexCom were up 2.8% in after-hours trading on Jul 27, following better-than-expected quarterly results. The stock gained 61.3% year to date compared with the industry\u2019s growth of 15.5%. The broader S&P 500 Index has moved up 20.2% in the same period. Image Source: Zacks Investment Research Revenue Details Total revenues grew 25% (26% on an organic basis) to $871.3 million on a year-over-year basis and beat the Zacks Consensus Estimate by 4.1%. Strong revenue growth was driven by rising volumes on the back of increasing global awareness of the benefits of real-time Continuous Glucose Monitoring and strong customer additions. Segmental Details Sensor and other revenues(89% of total revenues) increased 30% on a year-over-year basis to $778 million. Hardware revenues (11%) decreased 5% year over year to $93.3 million. Geographical Details U.S. revenues (71% of total revenues) increased 21% on a year-over-year basis to $616.6 million. International revenues (29%) improved 38% (40% on an organic basis) year over year to $254.7 million. Margin Analysis Gross profit totaled $546.4 million, up 21.6% from the prior-year quarter\u2019s level. DexCom reported gross margin (as a percentage of revenues) of 62.7%, which contracted approximately 180 basis points year over year. Research and development expenses amounted to $119.3 million, down 2% year over year. Selling, general and administrative expenses totaled $297.3 million, up 19.4% year over year. The company reported total operating expenses of $418.3 million, up 12.3% from the prior-year period\u2019s number. Operating margin (as a percentage of revenues) was 14.7%, expanding 360 bps year over year. Financial Position DXCM exited the second quarter with $3.64 billion in cash, cash equivalents and marketable securities compared with $2.57 billion in the preceding quarter. Total assets amounted to $6.82 billion compared with $5.52 billion on a sequential basis. 2023 Guidance DexCom raised its revenue guidance for 2023 but reiterated the earnings outlook. The company now expects revenues in the range of $3.5-$3.55 billion, implying 17-21% year-over-year growth. The Zacks Consensus Estimate for the same is pegged at $3.46 billion. Previously, DXCM expected revenues in the range of $3.4-$3.515 billion. The company continues to expect adjusted gross margin of approximately 63% versus 62-63% previously. Adjusted operating margin is anticipated to be approximately 17%, up from the previous projection of 16.5%. Wrapping Up DexCom exited second-quarter 2023 on a strong note, wherein both earnings and revenues beat estimates. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. The availability of new sensors like G6 & G7 in new international markets is also boosting revenue growth. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Apart from making continued advancements in terms of its key strategic objectives, the company continued to have strong new patient additions in the quarter. The expansion of gross and operating margins buoys optimism. However, cut-throat competition in the market for blood & glucose monitoring devices remains another concern. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Zacks Rank and Other Stocks to Consider Currently, DexCom carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. Abbott, carrying a Zacks Rank of 2 at present, reported second-quarter 2023 adjusted earnings per share (EPS) of $1.08, which beat the Zacks Consensus Estimate by 3.8%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $9.98 billion outpaced the consensus mark by 2.9%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. Elevance Health reported second-quarter 2023 adjusted EPS of $9.04, which beat the Zacks Consensus Estimate by 2.5%. Revenues of $43.38 billion surpassed the Zacks Consensus Estimate by 4.5%. The company currently carries a Zacks Rank #2. ELV has a long-term estimated growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.8%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, which beat the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the consensus mark by 1.4%. The company currently carries a Zacks Rank #2. ISRG has a long-term estimated growth rate of 14.5%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 4.2%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Markets Today: Stocks Climb as U.S. Price Pressures Ease Morning Markets September E-Mini S&P 500 futures (ESU23) this morning are up +0.64%, and Sep Nasdaq 100 E-Mini futures (NQU23) are up +1.03%. Stock indexes this morning are climbing on signs of easing price pressures after the U.S. Q2 employment cost index rose at the slowest pace in 2 years and after the U.S. Jun PCE core deflator, the Fed's preferred gauge of inflation, rose less than expected. Also, strength in technology stocks is boosting the overall market, with Intel up more than +8% in pre-market trading after reporting better-than-expected Q2 revenue. U.S. Jun personal spending rose +0.5% m/m, stronger than expectations of +0.4% m/m. Jun personal income rose +0.3% m/m, weaker than expectations of +0.5% m/m. The U.S. Jun PCE core deflator, the Fed's preferred gauge of inflation, eased to +4.1% y/y from +4.6% y/y in May, better than expectations of +4.2% y/y and the slowest pace of increase in 1-3/4 years. The U.S. Q2 employment cost index rose +1.0% (q/q annualized), slower than expectations of +1.1% and the smallest pace of increase in 2 years. The markets are discounting the odds at 18% for a +25 bp rate hike at the September 20 FOMC meeting. Global bond yields are mixed. The 10-year T-note yield fell from a 2-1/2 week high of 4.038% and is down -2.8 bp to 3.971%. The 10-year German bund yield rose to a 2-week high of 2.585% and is up +0.2 bp at 2.476%. The 10-year UK Gilt yield rose to a 1-1/2 week high of 4.389% and is up +2.5 at 4.335%. Overseas stock markets are mixed. The Euro Stoxx 50 is up +0.12%. China\u2019s Shanghai Composite Index today closed up +1.84%. Japan\u2019s Nikkei Stock Index closed down -0.40%. The Euro Stoxx 50 today is slightly higher. European stocks recovered from early losses and moved higher on signs of easing price pressures in the Eurozone after German Jul consumer prices rose less than expected. A jump in global bond yields initially weighed on stocks today after the BOJ adjusted its yield curve control and effectively doubled the upper limit on its 10-year yield range to 1.0% from 0.5%. The 10-year German bund yield rose to a 2-1/2 week high of 2.585% on the news. Also, economic concerns undercut stocks after today\u2019s news showed Eurozone Jul economic confidence fell more than expected to a 9-month low. On the positive side is strength in bank stocks, led by a +5% jump in Standard Chartered Plc after it reported Q2 adjusted pretax profit of $1.6 billion, above the consensus of $1.39 billion. Also, airline stocks are higher after British Airways parent IAG SA and Air France-KLM reported better-than-expected Q2 earnings. German Jul CPI (EU harmonized) eased to +6.5% y/y from +6.8% y/y in Jun, better than expectations of +6.6% y/y. Eurozone Jul economic confidence fell -0.8 to a 9-month low of 94.5, weaker than expectations of 95.0. German Q2 GDP was unchanged q/q, weaker than expectations of +0.1% q/q. France's Q2 GDP rose +0.5% q/q, stronger than expectations of +0.1% q/q. China\u2019s Shanghai Composite today rallied to a 2-month high and closed moderately higher. Chinese stocks jumped today on signs that authorities are acting on the policy pledges made at the Politburo meeting. A report today said authorities asked China\u2019s largest technology companies to provide case studies of their most successful startup investments in consumer, telecom, and media companies, a sign that authorities are willing to grant broader leeway in backing such deals after a crackdown brought them to a halt two years ago. Also, Bloomberg News reported that the China Securities Regulatory Commission consulted securities firms for possible measures to boost stocks, including a cut in the stamp duty and a slowdown in initial public offerings to help liquidity. Japan\u2019s Nikkei Stock Index today fell to a 2-week low and closed moderately lower. Japanese stocks retreated today after Japanese bond yields soared after the BOJ tweaked its yield curve control program. The 10-year JGB bond yield jumped to a 9-year high of 0.591% after the BOJ effectively raised the upper limit of its 10-year JGB yield target to 1.0% from 0.5%. The yen also climbed to a 1-1/2 week high against the dollar on the news, undercutting exporter stocks. In addition, an increase in price pressures weighed on stocks and boosted bond yields after today\u2019s news showed Tokyo Jul consumer prices rose more than expected. Stocks recovered from their worst levels, and the yen gave up some of its gains after BOJ Governor Ueda said today\u2019s move by the BOJ to adjust its yield curve control was not a step toward normalization of BOJ policy and that there is a \u201clong way\u201d before the BOJ raises negative interest rates. The BOJ, as expected, kept its policy balance rate unchanged at -0.1%. The BOJ also kept its target for 10-year yields at around 0% but said the 0.5% ceiling was now a reference point and that it would offer to buy 10-year debt at 1.0% each day, suggesting an effective doubling of the upper target of the yield range. Tokyo Jul CPI rose +3.2% y/y, unchanged from Jun and stronger than expectations of +2.9% y/y. Tokyo CPI ex-fresh food and energy rose +4.0% y/y, stronger than expectations of +3.7% y/y and the most in 40 years. Pre-Market U.S. Stock Movers Intel (INTC) rallied more than +8% in pre-market trading after reporting Q2 revenue of $12.90 billion, well above the consensus of $12.02 billion, and forecast Q3 revenue of $12.9 billion-$13.9 billion, the midpoint above the consensus of $13.28 billion. Reata Pharmaceuticals (RETA) soared more than +51% in pre-market trading after Biogen agreed to buy the company for about $7.3 billion. Dexcom (DXCM) climbed more than +3% in pre-market trading after reporting Q2 revenue of $871.3 million, stronger than the consensus of $840.2 million, and raising its full-year revenue forecast to $3.50 billion-$3.55 billion from a previous forecast of $3.40 billion-$3.52 billion, above the consensus of $3.50 billion. Roku (ROKU) rallied more than +9% in pre-market trading after reporting Q2 net revenue of $847.2 million, well above the consensus of $774.7 million. Skechers (SKX) jumped more than +4% in pre-market trading after reporting Q2 adjusted EPS of 97 cents, well above the consensus of 53 cents, and raising its full-year EPS forecast to $3.25-$3.40 from a previous forecast of $3.00-$3.20, stronger than the consensus of $3.18. Trade Desk (TTD) rose more than +3% in pre-market trading after BTIG LLC upgraded the stock to buy from neutral. Procter & Gamble (PG) gained more than +1% in pre-market trading after reporting Q4 net sales of $20.55 billion, better than the consensus of $20.06 billion. Juniper Networks (JNPR) tumbled more than -6% in pre-market trading after it said it is \u201ccurrently facing some near-term order weakness from its Cloud and to a lesser degree its Service Provider customers.\u201d Ford Motor (F) slid more than -2% in pre-market trading after it said it now expects to see losses from electric vehicles hit $4.50 billion this year, above the consensus of a -$3.25 billion loss. Chemours (CC) dropped more than -3% in pre-market trading after reporting Q2 net sales of $1.64 billion, below the consensus of $1.70 billion. Southwest Airlines (LUV) is down more than -1% in pre-market trading after Raymond James downgraded the stock to outperform from a strong buy. Sleep Number (SNBR) plunged more than -22% in pre-market trading after reporting Q2 net sales of $458.8 million, weaker than the consensus of $471.6 million. ArcBest (ARCB) dropped more than -3% in pre-market trading after reporting Q2 adjusted EPS of $1.54, well below the consensus of $2.02. Wingstop (WING) tumbled more than -4% in pre-market trading after Wedbush downgraded the stock to neutral from outperform. Today\u2019s U.S. Earnings Reports (7/28/2023) Aon PLC (AON), Centene Corp (CNC), Charter Communications Inc (CHTR), Chevron Corp (CVX), Church & Dwight Co Inc (CHD), Colgate-Palmolive Co (CL), Exxon Mobil Corp (XOM), Franklin Resources Inc (BEN), Newell Brands Inc (NWL), Procter & Gamble Co/The (PG), T Rowe Price Group Inc (TROW). More Stock Market News from Barchart S&P Futures Climb Ahead of Key U.S. Inflation Data, Intel Surges on Upbeat Earnings Looking to Retire? What is the Ideal Retirement Age? Stocks Give Up Early Gains as the 10-Year T-note Yield Jumps Above 4% Don\u2019t Let the EV Hype Train Dissuade You From HF Sinclair (DINO) On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q2 2023 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q2 2023 Earnings Call Jul 27, 2023, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, welcome to the DexCom second quarter 2023 earnings release conference call. My name is Abby, and I will be your operator for today's call. At this time, all participants are in a listen-only mode, and later, we will conduct a question-and-answer session. [Operator instructions] As a reminder, the conference is being recorded. And I will now turn the call over to Sean Christensen, vice president of finance and investor relations. Mr. Christensen, you may begin. Sean Christensen -- Head of Investor Relations Thank you, Abby, and welcome to DexCom's second quarter 2023earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question, so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter performance on the DexCom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2023 All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP. With respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or periods of results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our second-quarter earnings presentation for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Today, we reported another great quarter for DexCom with second-quarter organic revenue growth of 26% compared to the second quarter of 2022. Demand for DexCom CGM continues to grow as access to our products is expanding faster than at any time in our company's history. In the first half of 2023 alone, we broadened our product portfolio strategy, extended our geographic reach, and meaningfully expanded reimbursed coverage for DexCom CGM. As we sit at the midpoint of this pivotal year for our company, we have a lot to be excited about. In the U.S., our launch of G7 continues to gain momentum. Customers and clinicians alike are sharing consistently or faster warm-up time and redesigned software platform, with this product, we have extended our leadership position in accuracy and product performance while taking a significant step forward in terms of simplicity. It has never been easier to use or prescribe a DexCom CGM, and we are attracting new customers and prescribers to our ecosystem as a result. Similar to last quarter, we have seen a continuation of the trend that the majority of our G7 users have been new to DexCom. Additionally, there are now 8,000 physicians writing scripts for G7 in the U.S. that were previously not prescribing DexCom. We designed G7 to hold broad market appeal, and these early prescribing trends are validating those efforts. Behind the scenes, we continue to drive reimbursement for G7. As a reminder, we established Medicare and broad commercial DME coverage during the first quarter, while rapidly progressing our commercial pharmacy contracts. We further advanced this process in the second quarter as expected, and we are excited to share that all major PBMs now cover DexCom G7. This occurred much faster than we originally anticipated and brings our total number of G7 covered lives nearly in line with our industry-leading G6 levels. This further strengthens our position as the most covered CGM brand as we prioritize keeping out-of-pocket costs low for our customers. As a reminder, the majority of our customers are paying less than $20 a month out of pocket in the pharmacy channel, which is significantly less than our nearest competitor, where the majority of customers are paying greater than $70 per month. We're also seeing G7 play a very important role for us as we move more broadly beyond intensive insulin management. We've taken a big step in that direction this year following the recent CMS decision to significantly expand coverage beyond intensive insulin use. As of mid-April, Medicare coverage officially kicked in for people with type 2 diabetes using basal insulin only, as well as certain non-insulin-using individuals that experience hypoglycemia. This resulted in a true step change in coverage for the industry. As we estimate these two populations represent around 6 million to 7 million people in the U.S. with roughly half being of Medicare age. It's also been encouraging to see commercial payers quickly follow suit. We have already established greater than 60% commercial coverage for the basal population, which we view as a validation of DexCom's value proposition by payers. We're thrilled to have this level of coverage established this quickly as it provides us much greater commercial flexibility to promote this opportunity. While still early, the initial response from the clinical community has been very encouraging. Physicians have wasted no time in prescribing DexCom to their basal patients as they recognize a clear potential for better outcomes among this population. We have also seen excitement coming directly from members of the basal community who are interested in engaging with our glucose data to make more informed lifestyle decisions. As a result, we have seen a notable uptick in demand in our Medicare business. In fact, Q2 was our highest new patient quarter within the Medicare channel in the history of our company. Considering this was only a partial quarter of expanded coverage, we view this as a very positive sign of things to come. In our international business, our share gains accelerated in the second quarter as our ongoing access initiatives and product portfolio strategy have helped us reach many more people with diabetes across the globe. We expanded our international G7 launch in the second quarter into six new markets. G7 is being met with a lot of enthusiasm in our initial launch countries, and we are excited to bring it to additional geographies in the coming months. This will include our launch of G7 into Canada, where we recently received regulatory clearance. We have plenty of inventory on hand to support this broader rollout, particularly with our Malaysia facility now producing commercial product. Another key international lever for us has been our broader rollout of DexCom ONE. DexCom ONE has proven to accelerate our entrance into new markets, broaden access within existing geographies and even serve as a catalyst for reimbursement in certain regions. Perhaps most noteworthy this past quarter is that we officially launched DexCom ONE in Argentina, which marks our initial entrants into Latin America. We expect this to only be a starting point for us in that region as we continue to extend our global reach in coming years. Finally, we came away from the American Diabetes Association's 83rd scientific sessions as excited as ever about our future. This year's event added to the growing body of evidence demonstrating DexCom CGM's ability to drive greater health and economic outcomes across the diabetes care continuum. Particularly, we are seeing more data suggesting a clear use beyond the intensive insulin population and even outside of insulin you saw all together. For example, our team presented a real-world study of more than 7,000 adults with type 2 diabetes who were not using insulin. After only three months, this cohort saw a 40% increase in time range and a clinically meaningful improvement in A1c levels. Perhaps just as important was the high level of engagement demonstrated as study participants were DexCom CGM more than 80% of the time. This was consistent with what we have seen in other broader type 2 studies, including the mobile trial where we saw high levels of utilization and a clear desire to continue to our DexCom CGM full-time. During ADA weekend, we hosted an Investor Day, where we shared our latest vision around the future of DexCom. As part of the day, we increased our LRP, provided new detail on the size of our recent access wins, and shared our plan to launch our product specifically for people not on insulin. With this product, we will leverage our G7 hardware but provide a custom software experience tailored to this broader population. We expect to launch early next year with a 15-day wear time and cash pay option. This will simplify access out of the gate for users as we build the case with payers for broader coverage. Importantly, this new product also provides a glimpse into our future where we expect to utilize software to build tailored experiences and serve much larger populations. As we said at Investor Day, we're just getting started. With that, I will turn it over to Jereme for a review of the second-quarter financials. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the second quarter of 2023, we reported worldwide revenue of $871 million compared to $696 million for the second quarter of 2022, representing growth of 26% on an organic basis. As a reminder, our definition of organic revenue excludes currency in addition to non-CGM revenue acquired in the trailing 12 months. U.S. revenue totaled $617 million for the second quarter compared to $511 million in the second quarter of 2022, representing growth of 21%. We delivered another record new customer start quarter in Q2 with continued momentum in the U.S. as our G7 launch gained additional traction and the recently finalized CMS coverage provided a new tailwind to our Medicare business. As Kevin mentioned, we continue to progress our commercial pharmacy coverage in G7 for the second quarter, which further reduced our need to utilize the Bridge program. The impact from this program was negligible in Q2, and we expect this number to remain small going forward. With broad coverage for G7 now available across all channels, there will be fewer customers that need to leverage this program to access their product. International revenue grew 38%, totaling $255 million in the second quarter. International organic revenue growth was 40% for the second quarter. We have been executing very well in international markets as our ongoing access work and product portfolio strategy continues to broaden our reach. We have seen a robust customer response to this expanded access and have consistently taken share across our footprint in recent quarters. In fact, this marks the ninth straight quarter that we have gained international market share. The U.K. continues to be a great case study for us. In the past year, we have significantly broadened our reimbursement in that market, see new clinical recommendations around real-time CGM use, and launched our newest generation product. Following these events, we have experienced an acceleration in this market. And in Q2, we posted one of our highest U.K. growth rates in recent years. We also recently expanded our connectivity leadership in this market. As Insulet extended their launch of Omnipod 5, which is powered by our G6 system to the United Kingdom, given our long track record in the pump market with over 1 million patient years of cumulative experience and the forthcoming connectivity with G7. We expect to remain the clear CGM leader for the connected insulin delivery market. Our second-quarter gross profit was $553.5 million or 63.5% of revenue compared to 64.6% of revenue in the second quarter of 2022. The year-over-year decline in gross margin was expected as we take a temporary step back to scale G7 production. It is worth noting that some of our expected ramp-up costs extended into the third quarter, which increased Q2 gross margin relative to our expectations. It takes some time for our new manufacturing lines to fully scale but the cost profile of G7 will gradually improve as we increase production volumes. Keep in mind, our Malaysia facility recently initiated commercial production. So, you should expect to see a similar dynamic occurring in the near term as we scale those lines. Operating expenses were $395.1 million for Q2 of 2023 and compared to $347.6 million in Q2 of 2022. At our recent Investor Day, we highlighted some of our key cost initiatives, which we refer to as a cost to execute. This represents our ongoing framework of how we think about operational efficiency and how we ultimately seek cost as a growth driver for our business. Our second quarter operating expense management was yet another demonstration of our commitment to this program as we generated over 450 basis points of opex leverage. We are very proud of this result as we have continued to support our ongoing investments in our global commercial efforts. We know this will ebb and flow over time based on the needs of the business, but it should serve as a reminder of this organization's ability to scale. Operating income was $158.4 million or 18.2% of revenue in the second quarter of 2023 compared to $101.9 million or 14.6% of revenue in the same quarter of 2022. Adjusted EBITDA was $232.6 million or 26.7% of revenue for the second quarter compared to $175.5 million or 25.2% of revenue for the second quarter of 2022. Net income for the second quarter was $139.4 million or $0.34 per share. We closed the quarter with greater than $3.6 billion of cash and cash equivalents, leaving us in a very strong financial position. This significant step up relative to our Q1 cash levels primarily reflects the convertible bond offering we completed early in the second quarter. With our 2023 converts coming due later this year, we saw an opportunity to refinance at very compelling terms which provides us significant financial flexibility. This supports our ongoing capital deployment goals with a primary focus on extending our organic growth opportunity. As we mentioned, we reached a key milestone during this quarter as our Malaysia facility began producing commercial product. This plant will quickly scale to become our largest operation and help support our long-term cost target of $10 per sensor. Turning to guidance. We are raising our full-year 2022 revenue guidance to a range of $3.50 billion to $3.55 billion, representing growth of 20% to 22% for the year. Our updated revenue guidance reflects an increase of over $65 million at the midpoint compared to our previous guidance. This reflects our strong start to the year, as well as our expectation to carry this momentum into the second half of 2023. From a margin perspective, we are updating our full-year non-GAAP gross margin guidance to 63%, which represents the high end of our previous guidance range. Our operating expense management has also left us well-positioned to raise operating and EBITDA margin guidance for the year. We now expect non-GAAP operating margin of approximately 17% and adjusted EBITDA margin of 26.5% for fiscal year 2023. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. Our results this quarter we like a highlight reel. Q2 was our highest revenue quarter ever and represented the largest year-over-year dollar growth in our company's history. We again delivered record new customer starts worldwide and gained market share in nearly every major reimbursed geography. Our G7 launch continued to be marked by excellent execution across the board. We have now introduced this product into 13 international markets and quickly built broad reimbursement in the U.S. Through our commercial efforts, we are bringing new physicians into our ecosystem and our manufacturing initiatives are driving process improvements ahead of expectations. Additionally, our R&D team has already enabled five flawless upgrades to our completely redesigned G7 app. In addition, we are growing in a disciplined and sustainable manner. We have delivered over 450 basis points of operating expense leverage, doubled our earnings per share year over year, and posted one of the largest free cash flow quarters in our company's history. I'm incredibly proud of our team for delivering this level of progress. When you experience results like these, it makes our stated vision much more tangible. We are truly on a mission to help people control their health through continued innovation and execution. With that, I would now like to open the call up for Q&A. We will also have Jake Leach, our chief operating officer, to join us for our question-and-answer session. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Abby, please provide the Q&A instructions. Questions & Answers: Operator Thank you. We will now begin the question-and-answer session. [Operator instructions] And we will take our first question from Robbie Marcus. I apologize, Danielle Antalffy with UBS. Your line is open. Danielle Antalffy -- UBS -- Analyst Hey, good afternoon. Sorry about that. I didn't realize I was lowering my hand, so apologies for that. But good afternoon, everyone. Thanks so much for taking the question. Guys, you saw a really nice revenue acceleration across the business this quarter. That OUS number really does stand out. It looks like one of your stronger growth quarters internationally in a while. Can you provide a little bit more color on the sources of that international strength as you think about the key regions that you've entered and extending both the G7 and the DexCom ONE launches across these different geographies? Thanks so much. Kevin Sayer -- Chairman, President, and Chief Executive Officer You bet, Danielle. This is Kevin. I'll take that. And it was a great international quarter. There are three things that have driven that international business for us. The first, the plan we launched several quarters ago to increase access across the board and make our product more accessible in all these markets. And we've seen results of that in all the geographies, particularly in Germany. Second of all, you can't underestimate the effect of G7 in many of these markets. We've launched in 13 countries, as I said, in our prepared remarks, G7 is going very well. The third piece is the portfolio strategy, where we have DexCom ONE supporting expansion into geographies where we haven't been before and broadening access into countries where we already exist. Those three strategic efforts have helped us tremendously. I don't know, Jereme, if you've got anything you want to add to that. Jereme Sylvain -- Chief Financial Officer No, I think the only thing I'd say is really across the board, all the major countries we're in, where there's reimbursement, we're taking share. And it's a common theme you're really seeing, and our portfolio approach really allows us to do that. So, a wonderful quarter, and thank you for the question. Operator Will take our next question from Robbie Marcus with JPMorgan. Your line is open. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks for the question, and congrats on a really nice quarter. Looks like you guys raised guidance for basically two times the size of the beat in the quarter. So, I'd love to just hear where the confidence is coming from. How to think about U.S. and OUS growth in third and fourth quarter as we progress and where that upside in guidance is coming from? And any color as it relates to type 2 basal within that guidance range? Thanks a lot. Jereme Sylvain -- Chief Financial Officer Sure, Robbie. Thanks. This is Jereme. I can take that. You're right. We did raise guidance, and that really comes off of the strength you're seeing outside the U.S., as well as some of the coverage and access wins we've had in the U.S. Of course, all of it buoyed in the background by the launch of G7, which, as you know, most accurate sensor and one that we're really happy about. If you think about kind of geography-wise, think about it the first half of the year to a little bit reflect the second half of the year, and that's how the split would work, which I think you'll see that. And as you kind of think about what that means, we have a bit of a more challenging comp in the U.S. in the back half of the year, at least related to the second quarter. So, we've contemplated that. And we've also contemplated outside the U.S. continuing to do well, but just being mindful of the fact that growing at a faster clip than we have in recent quarters but being mindful about growing the markets as we're expanding. If you think about where it's coming from, what the driver is in the U.S. around basal, certainly, some of it is there. While we're not giving a number around basal, basal has really now started to with the coverage we've been able to obtain it's really starting to fold into the core business. But you can assume Basal is there. And then you may ask the question, well, gee, is there opportunity? Look, we provided the guidance as what is a base case. We've increased our confidence in that base case. I think you can see that. And then, of course, we'll look to outperform as time moves on. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks a lot. Operator And we will take our next question from Jeff Johnson with Baird. Your line is open. Jeff Johnson -- Robert W. Baird and Company -- Analyst Yeah. Thank you. Good afternoon, guys. Jereme, maybe I'll follow up on your U.S. comments there on basal only. If I look back the last four or five years, you guys typically increase your U.S. revenue sequentially from 1Q to 2Q, maybe $70 to -- or $60 million to $70 million, I'm sorry, this quarter, it was a $90 million sequential improvement. So, any way to say half of that was basal or a third of that was basal. I know it was only not quite a full quarter contribution, but just help us maybe qualitatively how much of that sequential bigger-than-usual improvement, might have been basal. And then just on top of that, just in France, any movement yet on basal only. I know, obviously, your competitor has gotten that. I think you guys were working toward that. Just any updates on basal-only coverage for you in Europe. Thanks. Jereme Sylvain -- Chief Financial Officer Sure, Jeff. You know, I think what I would say is in the U.S. in the quarter, a relatively nominal contribution from basal in Q2. While we did have quite a few -- quite a robust patient ad quarter, and you know this all too well, with coverage really kicking in, in April, starting with the DME channel, it takes three to four weeks to get access to product. And so, ultimately, the contribution start to build over the course of the year. So, yes, there was contribution in the quarter. Yes, it did help, but a lot of it was driven just by taking share in existing markets. And so, we're really proud of that. In terms of France, our expectation is we have G7 out in France. We're launching DexCom ONE in France here in the near future. We expect to have a very robust coverage model. I won't speak specifically there because we are going through that process. But we do expect broad coverage to compete with that of our competitor. And I think what we're proving is in markets where we have coverage and you've seen it in our international growth over the past nine quarters taking share, we expect to do quite well and take our fair share in that country once we go live. Jeff Johnson -- Robert W. Baird and Company -- Analyst Fair enough. Thanks. Operator We will take our next question from Larry Biegelsen with Wells Fargo. Your line is open. Larry Biegelsen -- Wells Fargo Securities -- Analyst Good afternoon. Thanks for taking the question. I guess, Jereme, let me ask on the guidance. I mean, it looks like you're guiding to about similar growth in the second half as the first half. One would think -- and the comps aren't too different when you look at it first half versus second half last year. One would think that you have tailwinds, pricing coming down, the ramp of Basal and G7, is there anything you're seeing that's concerning? Or is this conservatism? And just if you could comment on just cadence. Should we expect typical seasonality? Thanks for taking the question. Jereme Sylvain -- Chief Financial Officer Yeah. Sure, Larry. There's nothing that gives us pause about the back half of the year. I'll start with that. I think if we come into this quarter, record quarter in new patients. We have no lack of confidence in saying that. And so, we do expect a good back half of the year. We raised the guidance at the midpoint by a little over $65 million. So, I know you're kind of inferring at the top end and doing the work there. Look, there's nothing that gets in the way. What we've done is we derisked the base case. You see we've done that where now the base case is 20% to 22% growth, a record patient growth quarter in Q2 obviously bullish in the back half of the year. But again, basal is new. So, we're just being prudent in how we go about that and making sure we provide that base case. Of course, if we can do better, we will do so, and we will certainly pass it along to you. In terms of cadence and seasonality, I think our expectation is at least Q3 looks to operate in a similar seasonality as to last year. At least that's how we're looking at it now globally. So, think about it that way on a global basis and I would expect that to play out -- really expect that to play out for the balance of the year, relatively similar seasonality to the past two years. Larry Biegelsen -- Wells Fargo Securities -- Analyst Thank you. Operator We will take our next question from Joanne Wuensch with Citi. Your line is open. Joanne Wuensch -- Citi -- Analyst Thank you. Is there a way to quantify the contribution of DexCom ONE in the quarter outside the United States? I'm trying to get my head around the international growth, how much of that is coming from DexCom ONE? How much from G7, if you can share? And then maybe some of it is from the opportunity to partner with insulin pumps. Like walk me through that, please? Thank you. Kevin Sayer -- Chairman, President, and Chief Executive Officer Joanne, this is Kevin. We don't break those numbers out, but our growth comes from all of the above. Certainly, Dexcom's ONE has been a factor in those countries where we've launched it, but we haven't launched it in all of our international geographies yet. Our launch, as Jereme said earlier, we're about to launch in France. We just announced we're kicking off in Latin America here in Q3, and we've launched in a few other geographies. Those geographies, that's doing well. G7 has been a strong contributor, particularly in the U.K. and Germany, where those launches are more mature. And our pump partners, particularly is automated in some delivery reimbursement has broadened in some of the geographies. That's helped us tremendously. Our direct efforts in Australia, where we acquired our distributor. That distributor performed extremely well, and they've taken good share in the Australia and New Zealand markets in addition to that. So, I mean, it's a blend of all the factors we talked about on the call. Jereme Sylvain -- Chief Financial Officer Yeah. And just to help you with the -- just to kind of triangulate some of our prior comments, you know, we talked about a third of our new patient starts coming from DexCom ONE and that's a building business over the course of the year. So, if that's a third of the new starts and it's a building business over the course of the year, Joanne, you can probably then presume where most of the new patient starts come from, they come from the G-Series and we don't necessarily distinguish between the two. We obviously know what the numbers are. The point is, it's a series in a platform. And so, a majority of the growth does come from that G-Series just based on what we've historically said, and nothing has changed since that. Operator And we will take our next question from Matt Miksic with Barclays. Your line is open. Matt Miksic -- Barclays -- Analyst Hey, thanks. Thanks so much for taking the question. So, just one follow-up on OUS growth and just a quick question on -- I just happened to see some of your more of your promotional efforts, sort of the market development to brand awareness and ads that you're putting out in television and elsewhere. I'm just wondering how you're thinking about the success of those, what the duration of those campaigns run whether U.S. or internationally, I'll just include a quick follow-up on some of the international growth questions that you're getting to try to parse out the stricter is, if you could remind us also if there's any stocking of new geographies that happened or as you're really stepping into a new area, there's some element of that that we should also think about that may not repeat next quarter, the quarter after. Thanks. Jereme Sylvain -- Chief Financial Officer Hey, thanks, Matt. Thanks for the question. And I'll start with the second one first, and then we can circle back. No significant stocking anything along those lines. This is really driven by robust patient growth. And so, I think it's just taking share, driving access, and ultimately, entering into these markets. In terms of your first question around promotional activities, we always look at what works. We use various versions of mixed marketing, mixed sales models to ultimately determine the effectiveness and the return on investment of those. And then how the response curves work and Terry and the commercial leadership team, they do a wonderful job assessing that spend, looking at what makes in, and then pivoting as needed. And so, what you can expect to see is there'll always be mixes over time, but they will change. And so, we'll have campaigns. They'll change, it will change based on what works best, and we'll continue to learn from those. And so, I would expect to see continued promotional materials. I'll continue to see demonstrating why we think DexCom is the right product for folks and making sure that they know that we are the right product for them. And so, I think you are seeing good feedback. We are seeing great returns. I mean, at the end of the day, what you see is record new patient quarters, and you see that in our acceleration of growth in the quarter. So, that's what we'll continue to do. That's where we'll invest. I don't know, Kevin, any other thoughts on promotional materials? Kevin Sayer -- Chairman, President, and Chief Executive Officer No, I just think our promotional materials continue to evolve, and you'll see those evolve over the course of the year as we have more to offer, and we direct that message more toward different markets. I think our commercial efforts have been very successful, but in all fairness, we're looking at everything really with a very close-eye right now as we plan for next year and the year after that. It's not just a one-quarter shot for us. Matt Miksic -- Barclays -- Analyst That's great. Thank you so much. Operator We will take our next question from Travis Steed with Bank of America. Your line is open. Travis Steed -- Bank of America Merrill Lynch -- Analyst Jereme, thanks for taking the question. I guess just wanted to clarify on the basal guidance. So, before it was like 1.5% of total revenue for the year. Is that changing at all or moving? And what's a fair way to think about a full year of basal, should we think about that exit rate and multiplying it by four is thinking about kind of a full run rate for basal? Thank you. Jereme Sylvain -- Chief Financial Officer Yeah. So, Travis, it's interesting. So, while we're not going to give a specific number on basal anymore just because it's now really folded into our business. There was a time when we said, hey, look, we have CMS coverage, and we don't expect Medicare Advantage to come that faster. We think commercial is going to take a little bit longer, and it's happened much, much faster. So, now it's just really part of our core business. To your question, though, is it greater than 1.5%? Absolutely. It's part of the reason we raised the guidance. It's part of the performance in the quarter, and so you'd expect it to be higher than that. The way I would think about it is just now about any other patient really population, where you ultimately want to annualize it, you'll think about attrition. So, far, there's been no differences in terms of attrition from the basal population that started today to our core population. And I think you start to annualize that exit rate. And that's the way I'd apply it and going forward and then, of course, new adds. So, I think you're thinking about it the right way, Travis. And then in terms of is it greater than 1.5%, yes, it is. Travis Steed -- Bank of America Merrill Lynch -- Analyst Good. Thank you. Operator And we will take our next question from Matt Taylor with Jefferies. Your line is open. Matt Taylor -- Jefferies -- Analyst Hi. Thank you for taking the question. I just wanted to ask you one about the competitive environment, basically ask if you're seeing anything change in terms of share or pricing or anything else notable there that we should be aware of. Kevin Sayer -- Chairman, President, and Chief Executive Officer We've been pretty clear about our share position. If we haven't been, let me reiterate it again, all in major geographies that are reimbursed, we've been gaining share and we gained share across most all of them this quarter. So, we're doing very well. G7 has been accepted the way we wanted to. The majority of our G7 users are new users to DexCom. We've seen greater increased awareness in the physician community now that they have this product with its simplicity combined with it being the best-performing product on the market. So, we're very clear there. Our pricing trends. You can see our margins have remained strong, and our pricing is where we want it to be across channels. We've been pretty clear on all those things, and there's really no other changes to report. Matt Taylor -- Jefferies -- Analyst Great. Thank you, Kevin. Operator We will take our next question from Margaret Kaczor with William Blair. Your line is open. Margaret Kaczor -- William Blair and Company -- Analyst Hey, good afternoon, everyone. Thanks for taking the questions. I wanted to maybe talk a little bit longer term and talk about basal adoption trends. Historically, and I think even your kind of maps are just the same. This coverage has expanded for intensive insulin users. We've seen like this 1,000 basis points-plus of kind of incremental market adoption, at least by our math. I know it's early at this point, so you guys are being a little bit hesitant to get ahead of yourselves, but how do you compare, I guess, the early weeks or months in basal right now versus what you saw on commercial coverage had opened up for intents of insulin users? And then, longer term, why shouldn't we see that same level or pace of acceleration in basal? I know a different market, but especially as commercial coverage has maybe come up faster than it did in those markets at that time. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Margaret, this is Kevin. I'll take it to start, and if the other guys have more to add, they can. I think as I've traveled about and spoke to physicians and stuff, we've learned a lot about basal just launching, just the journey of a basal patient. They've been on other meds for quite some time and that's septic on insulin is a big step, and it's a step that they've, in many cases, been afraid up for a long time. So, providing this group with information necessary to truly manage their condition and to see that they're getting the right dose to see what behaviors they need to use to try and not advance their type 2 diabetes fast. We think there is a tremendous market here. And I think the reception and all fairness has probably been even warmer than I thought it was going to be just as I've gone and spoken with people. We are also at a different point in time as far as CGM adoption and CGM awareness in general as CGM is much more accepted than it was when we launched in other markets. Even from a distribution perspective, when we got Medicare approval the first time, I don't want to take you all back, but a Medicare patient couldn't use the phone app. When we got Medicare approval back in 2017, if they did, we had to give all the money back to CMS, we couldn't even get distributors to take our business. So, that environment is all much, much more positive than it's been before. The flip side of this is it's new. There are a lot of them and there's still education to do and quite candidly, or with a different physician group because these people are usually primary care. While we've done everything we can or we think we've done a good job expanding to get into that market, we know there's more work to do there as well. So, we're cautiously optimistic. We've seen great results so far. We've heard great things from the patients who use it, but it's just going to have to build over time. We considered all these things as we've looked at that market. Operator We'll take our next question from Matthew O'Brien with Piper Sandler. Your line is open. Matthew OBrien -- Piper Sandler -- Analyst Good afternoon. Thanks for taking my question. Would just love to hear a little bit more about G7 specifically, those 8,000 new prescribing clinicians here in the state. Can you talk about the composition of those between PCPs and then existing endos that are higher volume folks? And then internationally, I know, Jereme, you said historically that G7 is a product where you're actually getting patients away from your competitor. Is the trajectory changing as far as the -- that dynamic as far as getting patients aware from your competitor? Just looking at that international number in the quarter. Thank you. Jereme Sylvain -- Chief Financial Officer Yeah. And thank you for the question. You know, in terms of those 8,000 prescribing physicians, those are really predominantly primary care physicians. And many of them were already writing CGM in the past. And so, you can probably surmise that change is obviously what we think is taking share. And that's quite frankly, what we're seeing. And so, those are folks that are seeing G7, they're seeing the ease of use. They're seeing expanded coverage that we've worked on for years and years and years, and that really, we've led. And so, that's really driven a lot of that change outside the U.S., and Jake alluded or Kevin alluded to it, and Jake tracks us all the time, over half of new patients starts still remain new to CGM and a good chunk of those are switchers. They're not new to CGM, I say new to DexCom, not necessarily new to CGM. And so, as you see that, and you see a good chunk of folks saying, \""Well, wow, this is a product we've been waiting for.\"" We do believe we're doing incredibly well in those international markets, both in patients that are new to CGM in all candor but also those that have decided to make the switch. And so, we're really excited about the growth. I mean, I think you can see we've been really excited about G7 for years. And I think the market feedback is following that same excitement. Operator We will take our next question from Matthew Blackman with Stifel. Your line is open. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thanks for taking my question. I wanted to ask on the PCP channel. You encountering any friction points in those offices above and beyond what you may have expected with basal? And I guess, conversely, is there anything you anticipated would be challenging that may be playing out less challenging? And also, I'm curious, is your PCP sales force finding a meaningful number of type 1s in that channel? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Yeah. This is Kevin. The challenges we're encountering or challenges we anticipated. The biggest challenge always is, particularly in the Medicare environment, document, getting the documents and getting to the proper distribution channel to serve these patients because they are pretty much, I'll go through -- those who are not in Medicare Advantage, I'll go through the DME channel. And so, Document gathering, particularly in a PCP office where they don't see all people with diabetes all the time, and the use of these documents is the biggest challenge, but we anticipated that. And we worked very closely with our distributors to streamline that process as best we can. They've done a very good job helping us get our product out and help us continue to grow. As we talked earlier, our biggest Medicare new patient that quarter ever, those folks all went through distributors. So, that's a good metric for us and shows that they're doing very well. I think it's been pretty much as planned, and we don't have a specific PCP sales force. Our reps have geographic territories, and they call on both specialty diabetes clinics and primary care physicians. So, they truly have a business to run it in their individual territories. And certainly, we know who they call on and where they spend the majority of their time, but it's their job to drive that business and bring those offices along. They do a really good job of that. Jereme Sylvain -- Chief Financial Officer I think there was one -- you asked a question on type 1s, and we find them in the PCP offices. And the answer is yes, we do. We do, and we find them as we go deeper and deeper into the primary care offices, we do find type 1s. Some of whom are not on CGM and PCP offices, where maybe CGM is a little bit less prescribed. And so, there are opportunities there in those spaces to continue to drive awareness beyond, of course, the typical endocrinologist space. Mathew Blackman -- Stifel Financial Corp. -- Analyst Thank you. Operator We will take our next question from Marie Thibault with BTIG. Your line is open. Marie Thibault -- BTIG -- Analyst Hi. Thanks for taking the questions, and congrats on a great quarter. I wanted to ask my question here. We learned recently about a competitor's DTC launch. I think in the U.K. of a wearable to monitor glucose for people without diabetes, more of a lifestyle sort of tool, with DexCom's device for non-insulin users coming next year, any early thoughts on how your device be differentiated, whether that's features, pricing, how you're targeting that market? Jake Leach -- Chief Operating Officer Yeah, this is Jake. I'll take that one. Yes, we're really excited about this new product that we're going to introduce, specifically for non-insulin users. And what I'd say about it is it's specifically designed for the needs of someone who isn't on insulin but is trying to manage their glucose and trying to improve their health condition. And so, the feature set is very unique to the needs of those users. It's not -- you're not managing insulin. You're not trying to avoid hypoglycemia. It's all about connecting the dots between diet, exercise, and how those things impact glucose. CGM is the only tool that can provide you that real-time feedback. And so, we're really excited about how it's going to play into that space. And over time, we likely will expand the patient segment for that product, but we are initially focused on the type 2 insulin -- non-insulin users. Jereme Sylvain -- Chief Financial Officer And price-wise, in those price-wise and those things, there's the time in place we'll ultimately talk about that. Today, probably not the best time. Obviously, it's information we want to keep a little bit close to our vest until it gets a little closer to launch date. But when I say we're very excited about it, it is an incredibly exciting time around here at DexCom. Marie Thibault -- BTIG -- Analyst All right. Well understood. Thank you. Operator We will take our next question from Jayson Bedford with Raymond James. Your line is open. Jayson Bedford -- Raymond James -- Analyst Hi. Good afternoon. Maybe just to follow up on the last line of questioning. I think you mentioned that you're going to launch the noninsulin device early next year, which I think is kind of news at least on timing in '24. Have you run a trial for the device? And I assume you'll file late this year, or have you filed? Jake Leach -- Chief Operating Officer Yeah. Thanks for the question. Yes. So, it's important to note, right, that product is a 15-day product or non-insulin product. And we have completed a clinical study on the G7 platform showing survivability out to 15 days with great performance. We met the iCGM criteria in that study. And so, that study is going to be used for the submission of that product. So, that's why we're confident in our ability to say we're going to launch that product next year. Jayson Bedford -- Raymond James -- Analyst OK. Thank you. Operator And we will take our next question from Steve Lichtman with Oppenheimer. Your line is open. Steve Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, everyone. I wanted to ask about basal and broader type 2 opportunity outside of the U.S., particularly in the EU, certainly another big opportunity. Are the new pieces that you were putting in place with G7 and DexCom ONE enough to really go after penetration of that patient population? Or are there additional reimbursement efforts needed there as well? Kevin Sayer -- Chairman, President, and Chief Executive Officer You know, the access strategy is an ever-evolving one, and that's why we have our product portfolio. Our portfolio approach that we've adopted, there are some geographies where DexCom ONE will absolutely be the product. We go after that basal population with other geographies where quite candidly. If they're reimbursed adequately, we can use the G-Series, and we break it down market by market in some countries, it's literally state by state and region by region, where we select the right product within our portfolio to offer and gain the access and coverage that we need. We believe we have the products that we need to go do that. We've talked a bit about this, but the DexCom ONE platform is soon going to be -- DexCom ONE is going to be on the G7 platform next year. And when that happens, that is going to be just another step forward for us. And as we look to the future, as we extend life of our sensors and things like that, as we talked about at our Investor Days, we'll just have more and more opportunities internationally. So, we have the portfolio to go attack those things. We still have to go through the process of filling out paperwork, making bids, meeting with the proper people, and building that access team out over time and that's infrastructure we built from the ground up, and we've been building over the past several years. Jereme Sylvain -- Chief Financial Officer And the one other thing I'd say to that is, remember, outside the U.S., a lot of the products are available OTC. You don't really necessarily need to go get a script. Now, you might go to a pharmacy to pick it up. The script is required for reimbursement. And so, as you think about some of these products that are coming out that are really targeted at that, you can already use them. And so, there are ways we can work around that. With the right form factor, with the right product, and as Kevin has alluded to, we think we've got the portfolio, the products, the software, the way to iterate on that to be very effective in those markets. Steve Lichtman -- Oppenheimer and Company -- Analyst Great. Thanks. Operator And we will take our next question from Josh Jennings with TD Cowen. Your line is open. Josh Jennings -- TD Cowen -- Analyst Hi. Good afternoon. I was hoping to just better understand how you've had success kind of driving the average out-of-pocket cost for patients prescribed with G6, G7 down to $20. And is that something that you can market or have been marketing to patients or physicians? And has that been a driver of share gains in the U.S.? Kevin Sayer -- Chairman, President, and Chief Executive Officer It certainly has been a driver of share gains in the U.S. because we're -- again, our focus is on that customer. And as we go for the lowest cost per customer, that's what we do. We do everything we can to keep that co-pay down. In some cases, it depends on the payer, the insurance company, what the arrangement is, but we also are able to maintain a premium price due to the strength of our product, due to the fact that it provides such great outcomes and such good retention. Our retention rates are better than they've ever been as far as people staying on our product and using it. And we know when people stay on the product, they are healthier. There's clinical data coming over the next several months from studies. That's going to show that the extended use of CGM over time leads to just much better-extended health. So, you combine all those factors, the fact that patients stay in our product, the fact that it produces great outcomes, the fact that those outcomes are documented, we can go and command a lower co-pay. And we can go, really, position ourselves to do well. Now, because of that, you have to go through, again, the access games or the access infrastructure that various payers play. One of our key initiatives right now is working on pre-authorizations and to -- if we have to keep those to make sure those are electronic to take that burden off the head of the physician's offices who prescribe our product. That's probably our biggest hurdle as far as ease of reimbursement right now, but we're working to do that as well. And we have very aggressive goals on that front over the next year. But the product and reputation and outcomes of DexCom are able to do -- enable us to do that. Jereme Sylvain -- Chief Financial Officer You know, one of the things we've talked about over the years is our strategy was to look at ways to get covered products, make the easier burden longer term. I mean, think about people impacted by diabetes, there's already a significant burden on those individuals. And now you add in a large co-pay that's a challenging thing. So, we've really worked on coverage. It's something we've known is out there, and it's something we've worked on, and you're seeing it play through. We're us working very hard on coverage relative to that perhaps our competitor has really driven us to be in a position where we can help patients better longer term because this is a long-term challenge. We want to be there throughout that. Josh Jennings -- TD Cowen -- Analyst Thank you. Operator We will take our next question from Michael Polark with Wolfe Research. Your line is open. Michael Polark -- Wolfe Research -- Analyst Hey, good afternoon. Thank you for taking the question. My question is the non -- the product for type 2 is not on insulin that's going to launch next year, the 15-day sensor. In 2024, is this largely -- is the base case expectation that this is a cash pay model in '24, and then over a multiyear period, there might be some uptake into traditional insurance channels? Or would you expect that next year, you'll have kind of early at-risk insurance coverage for this concept? Jake Leach -- Chief Operating Officer Yeah, sure. I'll take that one. So, yes, it's primarily an initial launch, it's going to be cash pay. We do feel though we're targeting this segment of customer. There's 25 million people in the U.S. who fit into this category of -- with type 2 diabetes that are on insulin. So, we should give a real opportunity to provide them with better outcomes. And we do feel that this product that's specifically designed for this group can produce an outcome that payer will pay for over time. But we've got to generate that evidence in that population. We're starting to see evidence of CGM in that population and the benefits it can provide. We feel like this custom-tailored product is going to do a great job at delivering the outcomes that we're going to need. So, it's going to take a little time, but we do feel that this is a place that ultimately will be reimbursed. Operator And this concludes our question-and-answer session for today. I will now turn the call over to Mr. Kevin Sayer for closing remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Again, thanks, everybody, for participating on our call today. Just in wrapping up, I want to acknowledge all the great efforts here at our company, our commercial team around the world has had an incredibly successful G7 launch. Not only in getting product out the door but driving access, make it available. Everything that we've asked them to do, we've done faster than we planned, and we're just very appreciative of that. Our operations team has not missed a beat from supply chain and Microchips and G6 manufacturing in addition to G7 along the way, our engineering team. Those products performed the way we wanted it to. It's done very, very well. They continue to work on making it better. You talked earlier about our outperformance. Software is not just an add-on. It is difficult. And then those five upgrades of the app in this quarter. Seamless and delivering people better features every time, you can go through the entire organization, even the bond offering this quarter, kudos to that team. It is a great time to be here. As I said earlier in my prepared remarks, we're just getting started and that's how we feel about things. So, thanks, everybody, for participating on our call today, and we look forward to talking to you again soon. Operator [Operator signoff] Duration: 0 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Danielle Antalffy -- UBS -- Analyst Robbie Marcus -- JPMorgan Chase and Company -- Analyst Jeff Johnson -- Robert W. Baird and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Joanne Wuensch -- Citi -- Analyst Matt Miksic -- Barclays -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Taylor -- Jefferies -- Analyst Margaret Kaczor -- William Blair and Company -- Analyst Matthew OBrien -- Piper Sandler -- Analyst Mathew Blackman -- Stifel Financial Corp. -- Analyst Marie Thibault -- BTIG -- Analyst Jake Leach -- Chief Operating Officer Jayson Bedford -- Raymond James -- Analyst Steve Lichtman -- Oppenheimer and Company -- Analyst Josh Jennings -- TD Cowen -- Analyst Michael Polark -- Wolfe Research -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-07-31,133.14,133.4,124.03,124.56,"[""Monday Sector Laggards: Healthcare, Utilities The worst performing sector as of midday Monday is the Healthcare sector, showing a 0.8% loss. Within the sector, DexCom Inc (Symbol: DXCM) and Johnson & Johnson (Symbol: JNJ) are two large stocks that are lagging, showing a loss of 5.6% and 4.3%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 1.1% on the day, and down 0.49% year-to-date. DexCom Inc, meanwhile, is up 8.97% year-to-date, and Johnson & Johnson, is down 4.99% year-to-date. Combined, DXCM and JNJ make up approximately 9.6% of the underlying holdings of XLV. The next worst performing sector is the Utilities sector, showing a 0.2% loss. Among large Utilities stocks, Edison International (Symbol: EIX) and Entergy Corp (Symbol: ETR) are the most notable, showing a loss of 1.5% and 1.1%, respectively. One ETF closely tracking Utilities stocks is the Utilities Select Sector SPDR ETF (XLU), which is down 0.1% in midday trading, and down 3.59% on a year-to-date basis. Edison International, meanwhile, is up 14.14% year-to-date, and Entergy Corp, is down 4.46% year-to-date. Combined, EIX and ETR make up approximately 5.0% of the underlying holdings of XLU. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, six sectors are up on the day, while three sectors are down. SECTOR % CHANGE Energy +1.2% Services +0.4% Technology & Communications +0.4% Materials +0.3% Industrial +0.2% Financial +0.1% Consumer Products -0.1% Utilities -0.2% Healthcare -0.8% 10 ETFs With Stocks That Insiders Are Buying \u00bb Also see: \u0095 Water Utilities Dividend Stocks \u0095 ROK Split History \u0095 SCOM market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Monday's ETF Movers: URA, IHI In trading on Monday, the Uranium ETF is outperforming other ETFs, up about 3.2% on the day. Components of that ETF showing particular strength include shares of Uranium Energy, up about 8.2% and shares of UR Energy, up about 5% on the day. And underperforming other ETFs today is the iShares U.S. Medical Devices ETF, down about 1% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Dexcom, lower by about 4.5%, and shares of Procept Biorobotics, lower by about 2.9% on the day. VIDEO: Monday's ETF Movers: URA, IHI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: DXCM, SIRI In early trading on Monday, shares of Sirius XM Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.5%. Year to date, Sirius XM Holdings has lost about 8.6% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 2.8%. DexCom is showing a gain of 13.6% looking at the year to date performance. Two other components making moves today are Intel, trading down 1.8%, and Atlassian, trading up 3.4% on the day. VIDEO: Nasdaq 100 Movers: DXCM, SIRI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher Glucose-monitor maker DexCom Inc. (NASDAQ: DXCM) was among the top three gainers within the healthcare sector on July 28, advancing 2.33% in the season after gapping higher at the open. The company reported second-quarter results that came in ahead of Wall Street\u2019s expectations. Earnings were 34 cents a share on revenue of $871.3 million, increases of 100% and 25%, respectively, over last year\u2019s second quarter. U.S. revenue was up 21%, but international revenue growth was even stronger, at 38%. Domestic business still constitutes the bulk of revenue, at 71%. DexCom specializes in continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM devices allow users to track their glucose levels in real-time, giving patients valuable data to manage their conditions more effectively and make better decisions about their insulin dosing and dietary choices. Rivals in the space include Abbott Laboratories (NYSE: ABT) and Medtronic plc (NYSE: MDT). The company tailors its software to address different needs for various patients\u2019 glucose control. Reducing Costs & Patient Admissions In a June investors' day presentation, DexCom said its CGM has demonstrated a 35% reduction in inpatient admissions, an approximately 50% reduction in inpatient visits, and a 14% reduction in outpatient visit costs. The company also said that it sees plenty of potential with domestic growth, but suggested the opportunity for international market share was even greater. As is the case with the U.S. market, international growth is dependent on insurance reimbursements. So far, it\u2019s received broad reimbursement for its G-series of monitors, and tiered or limited reimbursement for other products. In the U.S., according to the company, Dexcom is the most-covered CGM with the lowest out-of-pocket expenses. In 2024, the company aims to launch a glucose-sensing product designed for people with Type 2 diabetes who are not on insulin. Boosted Full-Year Revenue Guidance In its second-quarter report, DexCom boosted its full-year guidance. It expects revenue between $3.5 billion and $3.55 billion, an increase of 21% at the midpoint. Analysts\u2019 forecasts called for revenue of $3.5 billion, so investors were cheered by the slightly better-than-expected outlook. In its investors\u2019 day presentation, DexCom guided toward $4 billion to $4.5 billion in revenue for 2024, and $4.6 billion to $5.1 billion for 2025. Wall Street expects the company to grow earnings by 40% this year, to $1.22 a share, with earnings growth of 30% next year, to $1.58 per share. Immediately after the second-quarter report, five analysts boosted their price targets on the stock, as you can see using MarketBeat\u2019s DexCom analyst ratings. The consensus view is \u201cmoderate buy,\u201d with a price target of $138.50, an upside of 4.62%. For now, it appears that investors and analysts are pleased with the company\u2019s growth prospects, although price increases have been relatively slow and steady, rather than explosive. Anticipating Further Improvements In a note following the earnings report, Morningstar analyst Debbie Wang wrote that Morningstar\u2019s Debbie Wang wrote, \u201cThis quarter was a big step in the right direction, and we anticipate further improvements through 2024 as the manufacturing of G7 reaches scale.\u201d The company has been ramping up its production capabilities. It\u2019s scaling production for its G7 model in San Diego and Mesa, Arizona, as well as opening production facilities in Ireland and Malaysia. The stock has advanced 9.10% in the past three months and 16.90% year-to-date. On a one-year basis, shares are up 52.18%. In the post-earnings price action, after the stock gapped up 4.84% in the first five minutes, it made further advances in the session\u2019s first 25 minutes, then began selling off, ending the day with a gain of 2.33%, without closing the gap. On July 28, the stock cleared a short area of consolidation above the 50-day moving average before reversing lower. It remains in a buy zone, as long as it doesn\u2019t decline below its 50-day average, or unless it rallies more than 5% above its July 28 high of $139.55. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Barclays Maintains Dexcom (DXCM) Equal-Weight Recommendation Fintel reports that on July 31, 2023, Barclays maintained coverage of Dexcom (NASDAQ:DXCM) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 9.34% Upside As of July 6, 2023, the average one-year price target for Dexcom is 144.75. The forecasts range from a low of 116.15 to a high of $159.60. The average price target represents an increase of 9.34% from its latest reported closing price of 132.38. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1919 funds or institutions reporting positions in Dexcom. This is an increase of 31 owner(s) or 1.64% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.48%, a decrease of 2.79%. Total shares owned by institutions decreased in the last three months by 0.35% to 439,741K shares. The put/call ratio of DXCM is 1.31, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm decreased its portfolio allocation in DXCM by 61.58% over the last quarter. Sands Capital Management holds 13,739K shares representing 3.54% ownership of the company. In it's prior filing, the firm reported owning 15,514K shares, representing a decrease of 12.92%. The firm decreased its portfolio allocation in DXCM by 20.77% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,965K shares representing 3.09% ownership of the company. In it's prior filing, the firm reported owning 11,746K shares, representing an increase of 1.83%. The firm decreased its portfolio allocation in DXCM by 3.50% over the last quarter. Jpmorgan Chase holds 10,765K shares representing 2.78% ownership of the company. In it's prior filing, the firm reported owning 10,647K shares, representing an increase of 1.09%. The firm decreased its portfolio allocation in DXCM by 4.14% over the last quarter. Capital Research Global Investors holds 9,275K shares representing 2.39% ownership of the company. In it's prior filing, the firm reported owning 9,462K shares, representing a decrease of 2.02%. The firm decreased its portfolio allocation in DXCM by 5.03% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Additional reading: DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Non-Exclusive Distribution Agreement, dated Amendment Number Fourteen to Amended and Restated Non-Exclusive Distribution Agreement, dated April 1, 2023, by and between DexCom, Inc. and Byram Healthcare. Non-Exclusive Distribution Agreement, dated Non-Exclusive Distribution Agreement, dated This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-01,124.45,125.95,121.85,122.0,
DXCM,2023-08-02,120.83,124.25,120.46,123.81,"5 Top Stocks Likely to Beat Earnings Estimates It is not surprising that before an earnings season, every investor looks for stocks that are likely to beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature. In this regard, we ran a screener that yielded Coty COTY, BJ's Restaurants BJRI, DexCom DXCM, Livent LTHM and D.R. Horton DHI as the likely winners on the earnings beat potential. Why Is a Positive Earnings Surprise So Important? Historically, stocks of companies with solid quarterly earnings (on a nominal basis) tank if they miss or merely meet market expectations. After all, a 20% earnings rise (though apparently looks good) doesn’t tell you if earnings growth has been exhibiting a decelerating trend. Also, seasonal fluctuations come into play sometimes. If a company’s Q1 is seasonally weak and Q4 strong, then it is likely to report a sequential earnings decline. In such cases, growth rates are misleading while judging the true health of a company. On the other hand, after much brainstorming and analysis of companies’ financials and initiatives, Wall Street analysts project earnings of companies. They in fact club their insights and a company’s guidance when deriving an earnings estimate. Thus, outperforming that estimate is almost equivalent to beating the company’s own expectation as well as the market perception. And if the margin of earnings surprise is big, it typically drives the stock higher right after the release. Thus, more than anything else, an earnings surprise can push a stock higher. How to Find Stocks that Can Beat? Now, finding stocks that have the potential to beat on the bottom line may be investors’ dream but not an easy job. One way to do this is to look at the earnings surprise history of the company. An impressive track in this regard generally acts as a catalyst in sending a stock higher. It indicates the company’s ability to surpass estimates. And investors generally believe that the company will apply the same secret sauce to execute yet another earning beat in its next release. The Winning Strategy In order to shortlist stocks that are likely to come up with an earnings surprise, we chose the following as our primary screening parameters. Last EPS Surprise greater than or equal to 10%: Stocks delivering positive surprise in the last quarter tend to surprise again. Average EPS Surprise in the last four quarters greater than 20%: We lifted the bar for outperformance slight higher by setting the average earnings surprise for the last four quarters at 20%. Average EPS Surprise in the last two quarters greater than 20%: This points to a more consistent surprise history and makes the case for another surprise even stronger. In addition, we place a few other criteria that push up the chance of a positive surprise. Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) rating can get through. Earnings ESP greater than zero: A stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for an earnings beat to happen, as per our proven model. In order to zero in on those that have long-term growth potential and high trading liquidity we have added the following parameters too: Next 3–5 Years Estimated EPS Growth (Per Year) greater than 10%: Solid expected earnings growth exhibits the stock’s long-term growth prospects. Average 20-day Volume greater than 100,000: High trading volume implies that the stocks have adequate liquidity. A handful of criteria has narrowed down the universe from over 7,700 stocks to only 17. Here are five out of 17 stocks: Coty (COTY): The Zacks Rank #2 company is engaged in the manufacturing, marketing and distribution of beauty products. You can see the complete list of today’s Zacks #1 Rank stocks here. The average earnings surprise of COTY for the past four quarters is 145.0%. BJ's Restaurants (BJRI): The Zacks Rank #1 company owns and operates a chain of high-end casual dining restaurants in the United States. The average earnings surprise of BJRI for the past four quarters is 121.2%. DexCom (DXCM): The Zacks Rank #2 medical device company is focused on the design, development and commercialization of continuous glucose monitoring systems. The average earnings surprise of DXCM for the past four quarters is 28.83%. Livent (LTHM): The Zacks Rank #1 company produces and distributes lithium chemicals. The average earnings surprise of LTHM for the past four quarters is 22.07%. D.R. Horton (DHI): The Zacks Rank #2 company is one of the leading national homebuilders, which is primarily engaged in the construction and sale of single-family houses both in the entry-level and move-up markets. The average earnings surprise of DHI for the past four quarters is 23.97%. You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks’ portfolios and strategies are available at: http://www.zacks.com/performance. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with ""black gold."" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BJ's Restaurants, Inc. (BJRI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report D.R. Horton, Inc. (DHI) : Free Stock Analysis Report Coty (COTY) : Free Stock Analysis Report Livent Corporation (LTHM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-08-03,123.8,124.88,120.6,122.07,"[""These Hot ETFs Could Heat Up More in August The summer months sit squarely in the weaker six-month period for stocks, but that seasonality doesn\u2019t appear to be affecting stocks, as broad market benchmarks are currently on multi-month winning streaks. That includes the Nasdaq-100 Index (NDX), which as of the end of July, is higher by 44% year-to-date. Obviously, that\u2019s excellent news for the Invesco QQQ Trust (QQQ) and the Invesco NASDAQ 100 ETF (QQQM) -- the marquee exchange traded funds tracking the Nasdaq-100. Clearly, those ETFs are on scintillating paces this year, supported in large part by the strength of the magnificent seven. Conversely, August historically isn\u2019t the best month of the year for stocks. It\u2019s not the worst, either, but that \u201csplit decision\u201d could be confusing for newer investors. Good news: History bodes well for QQQ and QQQM in August. Some NDX Stocks Thrive in August Several QQQ and QQQM member firms, including some that have already notched big gains this year, rank among the best-performing S&P 500 stocks over the past decade. Among large QQQ/QQQM components, Nvidia (NASDAQ: NVDA) averaged an August gain of 7.55% over the past decade, according to Schaeffer\u2019s Investment Research. Even with Nasdaq\u2019s recent special rebalance of NDX, Nvidia remains the third-largest tech holding in QQQ and QQQM at a weight of 4.35%. While healthcare is often overshadowed in relation to QQQ and QQQM, the sector accounts for about 7% of the ETFs\u2019 rosters. Dexcom (NASDAQ: DXCM), one of the ETFs\u2019 healthcare holdings, is also one of the top-performing S&P 500 stocks in the eighth month of the year, averaging a stellar return of 12.52%, noted Schaeffer's. Regarding more familiar QQQ/QQQM components and August history, Facebook parent Meta Platforms (NASDAQ: META) -- hot in its own right this year -- posted an average August gain of 3.56% over the past decade. QQQ and QQQM allocate less than 5% of their weights to the industrial sector, but one of the stocks hailing from that group that also resides in the Invesco ETFs is Cintas (NASDAQ: CTAS). That stock, which accounts for 0.41% of the ETFs\u2019 portfolios, averaged an August gain of 2.73%. In potentially more good news for QQQ and QQQM, Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT), which combine for 21% of the funds\u2019 rosters, are also among the S&P 500 leaders in August. So are Netflix (NASDAQ: NFLX) and Synopsys (NASDAQ: SNPS), both of which are QQQ/QQQM holdings. For more news, information, and analysis, visit the ETF Education Channel. Read more on ETFtrends.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock to Buy Hand Over Fist in August and 1 to Avoid Like the Plague When examined over long stretches, history shows that Wall Street's major indexes head decisively higher. But over shorter timelines, the directional movement in stocks is no more certain than a coin flip. Over the trailing-two-year period, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have all surged to new highs, plummeted into a bear market, and are all, once again, pushing higher. When Wall Street whipsaws investors, they have a tendency to seek out time-tested businesses. In recent years, the answer for investors has been to gravitate to stocks enacting splits. Image source: Getty Images. A stock split is an event that lets a publicly traded company alter its share price and outstanding share count without having any impact on its market cap or operating performance. It's a purely cosmetic move that can make shares more nominally affordable for retail investors, as with a forward-stock split, or can boost a company's share price to meet minimum listing standards for a major exchange, as often occurs with a reverse-stock split. For all intents and purposes, most investors are seeking out companies enacting forward splits. The reason high-flying stocks are splitting their shares to make them more nominally affordable for everyday investors is usually because they're executing on their strategic initiatives and out-innovating their competition. Since the start of July 2021, eight brand-name companies have conducted forward stock splits (listed chronologically): Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022 Shopify (NYSE: SHOP): 10-for-1 split in June 2022 Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023 While these are all top-notch businesses with well-defined competitive advantages, not all stock-split stocks are alike. In August, one historically cheap stock-split stock stands out as a surefire buy for opportunistic investors, while another is facing a mountain of headwinds and would be best avoided. The stock-split stock to buy hand over fist in August: Amazon The stock-split stock that patient investors can confidently buy hand over fist in August is none other than e-commerce leader Amazon. Although shares of the company have bounced back strongly in 2023, Amazon is still well below its all-time high, set in November 2021. The primary concern skeptics share is the belief that the U.S. economy will slow in the not-too-distant future. Despite second-quarter U.S. gross domestic product expanding at a faster pace than Wall Street had expected, numerous predictive tools are screaming that a recession is on the horizon. Amazon generates most of its revenue from its world-leading online marketplace. Since retail sales are cyclical, a recession would likely lead to revenue stagnation or declines for the company's top sales segment. But the most important thing to understand about Amazon is that there's a big difference between revenue and cash flow. While it does bring in a lot of revenue from online retail sales, the margins associated with e-commerce are small. Comparatively, a handful of Amazon's other operating channels generate the bulk of its cash flow, despite not accounting for as much of its net sales. Amazon Web Services (AWS) can easily be labeled the company's most important operating segment. Even though AWS only accounts for a sixth of Amazon's net sales, it regularly produces 50% to 100% of the company's operating income. Enterprise cloud infrastructure service spending is still in the early stages of ramping up, and AWS currently controls almost a third of the global cloud infrastructure service market share. Subscription services is another key segment, led by Prime. Amazon surpassed 200 million Prime subscriptions in April 2021 but hasn't updated this figure since. Considering that year-over-year subscription services revenue growth hasn't dipped below 13% on a currency-neutral basis in any of the past six quarters (through the end of March), it's a good bet that Amazon's pricing power and aggregate Prime subscriber count are climbing. The point is that the segments vital to Amazon's operating cash flow are still growing by a sustained double-digit percentage. Even if online retail sales weaken, it won't have much of an impact on the operating metric that truly matters to Amazon. During the 2010s, Amazon closed out every year with a price-to-cash-flow ratio of between 23 and 37. Based on Wall Street's consensus estimate, investors can scoop up shares of Amazon right now for a multiple of 17x forecast 2023 cash flow, less than 13x forward-year cash flow, and just 9x projected cash flow in 2026. Amazon stock is cheaper now than it's ever been as a publicly traded company. Image source: Getty Images. The stock-split stock to avoid like the plague in August: Nvidia However, not all stock-split stocks are going to deliver for their shareholders. Out of the eight high-profile companies to have split their shares since July 2021, it's graphics processing unit (GPU) giant Nvidia that's worth avoiding like the plague in August. Just as all great businesses have headwinds to contend with, stocks to avoid have catalysts that can push them higher. For Nvidia, there's no bigger catalyst than the artificial intelligence (AI) revolution. Based on an estimate from PwC, AI can provide a $15.7 trillion lift to the global economy by 2030. While there's plenty of excitement with regard to AI software and system solutions, Nvidia's role is primarily as the backbone of high-compute data centers. It provides the lion's share of the GPUs currently deployed in AI-driven data centers. Though additional competition is undoubtedly coming, Nvidia's first-mover advantages and superior GPUs have put it in the driver's seat. Unfortunately, even first-mover advantages in AI may not be enough to support the company's otherworldly valuation. One problem for Nvidia is that history isn't on its side. Every next-big-thing investment or hot growth trend over the past 30 years has gone through a boom-then-bust phase. I'm talking about the internet, genome decoding, cannabis, 3D printing, blockchain technology, the metaverse, and much more. Though companies involved in next-big-thing investments can be wildly successful over the long run, history has shown that Wall Street and investors tend to overestimate the adoption of new technology. Supply chain constraints are another concern for Nvidia. As I discussed earlier this week, the limited supply of high-bandwidth memory and chip on wafer on substrate are holding back giants like Nvidia from truly taking advantage of AI euphoria. Another potential problem for Nvidia is that U.S. regulators are considering even more stringent standards regarding shipments of its AI GPUs to China. Last year, regulators restricted the export of Nvidia's high-powered, AI-inspired A100 and H100 GPUs to China, which inspired the company to develop the slower A800 and H800 GPUs. But even these toned-down solutions may, eventually, be restricted. When initial restrictions were put in place last year, Nvidia warned it could lose up to $400 million in quarterly sales. Lastly, valuation is a front-and-center concern. If U.S. economic growth does slow in the second half of 2023 or early 2024, investors are going to be far less willing to pay more than 170 times cash flow and 243 times trailing-12-month earnings for shares of the company. 10 stocks we like better than Amazon.com When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of July 27, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-04,122.14,122.83,119.89,120.33,
DXCM,2023-08-07,121.0,122.1,120.135,120.97,"Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper ""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-08-08,120.3,120.3,107.07,110.19,"[""DXCM Makes Notable Cross Below Critical Moving Average In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) crossed below their 200 day moving average of $117.14, changing hands as low as $108.12 per share. DexCom Inc shares are currently trading off about 10.4% on the day. The chart below shows the one year performance of DXCM shares, versus its 200 day moving average: Looking at the chart above, DXCM's low point in its 52 week range is $78.94 per share, with $139.55 as the 52 week high point \u2014 that compares with a last trade of $108.35. The DXCM DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed below their 200 day moving average \u00bb Also see: \u0095 Funds Holding ANGI \u0095 NXZ Historical Stock Prices \u0095 PCT market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Tuesday Option Activity: UPS, DXCM, IFF Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in United Parcel Service Inc (Symbol: UPS), where a total volume of 62,651 contracts has been traded thus far today, a contract volume which is representative of approximately 6.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 183.8% of UPS's average daily trading volume over the past month, of 3.4 million shares. Especially high volume was seen for the $175 strike put option expiring August 11, 2023, with 6,532 contracts trading so far today, representing approximately 653,200 underlying shares of UPS. Below is a chart showing UPS's trailing twelve month trading history, with the $175 strike highlighted in orange: DexCom Inc (Symbol: DXCM) saw options trading volume of 28,859 contracts, representing approximately 2.9 million underlying shares or approximately 95.2% of DXCM's average daily trading volume over the past month, of 3.0 million shares. Particularly high volume was seen for the $125 strike call option expiring August 18, 2023, with 3,613 contracts trading so far today, representing approximately 361,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $125 strike highlighted in orange: And International Flavors & Fragrances Inc. (Symbol: IFF) saw options trading volume of 18,192 contracts, representing approximately 1.8 million underlying shares or approximately 76.3% of IFF's average daily trading volume over the past month, of 2.4 million shares. Especially high volume was seen for the $60 strike put option expiring August 18, 2023, with 1,669 contracts trading so far today, representing approximately 166,900 underlying shares of IFF. Below is a chart showing IFF's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for UPS options, DXCM options, or IFF options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Transportation Dividend Stock List \u0095 Institutional Holders of NFX \u0095 DDG Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom is Now Oversold (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $112.932 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 46.0. A bullish investor could look at DXCM's 29.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $78.94 per share, with $139.55 as the 52 week high point \u2014 that compares with a last trade of $112.94. Find out what 9 other oversold stocks you need to know about \u00bb Also see: \u0095 VPV Insider Buying \u0095 PINE Videos \u0095 SONA Insider Buying The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y Inogen, Inc. INGN incurred an adjusted loss per share of 25 cents for second-quarter 2023, wider than the adjusted loss per share of 2 cents in the year-ago period. However, the Zacks Consensus Estimate was pegged at a loss of 64 cents per share. GAAP loss per share for the quarter was 42 cents, wider than the year-earlier loss of 15 cents per share. Revenues in Detail Inogen registered revenues of $83.6 million for the second quarter, down 19.1% year over year. The figure lagged the Zacks Consensus Estimate by 10.3%. On a constant-currency basis, total revenues for the reported quarter decreased 18.5%. Per management, the year-over-year decrease in the top line primarily resulted from lower international and direct-to-consumer sales. However, this was partially offset by an increase in domestic business-to-business sales and rental revenues. Segmental Details Inogen derives revenues from two sources \u2014 rental and sales. Rental revenues for the reported quarter grossed $15.3 million, up 8.6% from the year-ago period. Per management, continued growth in rental patients on service and higher Medicare reimbursement rates resulted in the upside. However, this was partially offset by rental revenue adjustments, which were part of Inogen\u2019s work to improve collections processes and clean up aged receivables. This figure compares to our Rental revenues\u2019 second-quarter projection of $14.9 million. Sales revenues were $68.3 million, down 23.5% from the prior-year quarter. This figure compares to our Sales revenues\u2019 second-quarter projection of $78.4 million. Revenues by Region & Category Domestic business-to-business sales for second-quarter 2023 amounted to $18.3 million, up 62.9% on a year-over-year basis. Our projection for the same was $18.7 million. International business-to-business sales for the reported quarter amounted to $23.3 million, down 37.8% year over year on a reported basis. Our model estimate for the metric was $30.1 million. Domestic direct-to-consumer sales decreased 34.1% year over year to $26.8 million for the quarter. Our estimate for the same was $29.7 million. Inogen, Inc Price, Consensus and EPS Surprise Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote Margins For the quarter under review, Inogen\u2019s adjusted gross profit fell 23.9% from the year-ago period to $37.3 million. The adjusted gross margin contracted 280 basis points to 44.6%. Sales and marketing expenses decreased 11.5% from the year-ago quarter to $26.9 million. Research and development expenses decreased 29.2% year over year to $4.3 million, while general and administrative expenses increased 15.2% to $14.6 million. Adjusted operating expenses of $45.8 million decreased 6.8% year over year. Adjusted operating loss totaled $8.5 million compared with the prior-year quarter\u2019s adjusted operating loss of $0.2 million. Financial Position Inogen exited second-quarter 2023 with cash and cash equivalents of $167.7 million compared with $164.1 million at the end of first quarter. The company ended the quarter with no debt on its balance sheet. Cumulative net cash used in operating activities at the end of second-quarter 2023 was $2.3 million compared with $12.6 million a year ago. Guidance Inogen has provided its outlook for the full year. The company expects its total revenues to be between $315 million and $320 million. The Zacks Consensus Estimate for the same currently stands at $381.9 million. Our Take Inogen exited the second quarter of 2023 with better-than-expected earnings. The robust year-over-year uptick in rental revenues and domestic business-to-business sales was impressive. Last month, Inogen entered into a definitive agreement to acquire Physio-Assist SAS with the aim of diversifying its Respiratory Product portfolio and expanding market opportunities in the rest of the world and potentially in the United States. During the quarter, Inogen introduced Rove 6 in the United States, a portable oxygen concentrator now with an eight-year expected service life. These developments look promising for the stock. Yet, lower-than-expected revenues and dismal year-over-year top-line and bottom-line performances were worrying. A decline in international business-to-business and domestic direct-to-consumer sales was concerning as well. The contraction of adjusted gross margin was worrying. Inogen continued to incur operating losses for the second quarter, which did not bode well. Zacks Rank and Stocks to Consider Inogen currently has a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom, Inc. DXCM, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. DexCom, carrying a Zacks Rank of 2 (Buy), reported second-quarter 2023 adjusted EPS of 34 cents, beating the Zacks Consensus Estimate by 54.6%. Revenues of $871.3 million outpaced the consensus mark by 4.1%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 42.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.8%. Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, beating the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the Zacks Consensus Estimate by 1.4%. It currently carries a Zacks Rank #2. Intuitive Surgical has a long-term estimated growth rate of 15.7%. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.2%. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Insulet (PODD) Stock for Now Insulet Corporation PODD is likely to gain in the coming quarters, backed by its revolutionary offering, the Omnipod 5 Automated Insulin Delivery (\u201cAID\u201d) system. The company achieved record U.S. and total Omnipod new customer starts for the first quarter. Further, Insulet is making good headway in the developmental work to integrate Omnipod 5 with DexCom\u2019s G7 and Abbott\u2019s Libre systems. The advancement of the company\u2019s diabetes business sounds encouraging. However, a highly competitive environment and economic uncertainty are concerning for the company. In the past year, this Zacks Rank #3 (Hold) stock has decreased 0.8% compared with the 4.4% fall of the industry and an 8.4% rise of the S&P 500 composite. The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $18.34 billion. Insulet projects a long-term estimated earnings growth rate of 35.1% compared with 14% of the industry. PODD\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 80.2%. Let\u2019s delve deeper. Upsides Omnipod\u2019s Market Access Expansion Continues: Insulet delivered a record first quarter for the U.S. revenue growth of 49% and 35% for total Omnipod and another record for new customer starts both domestically and globally for any first quarter. U.S. Omnipod revenue growth surpassed the company\u2019s expectations, driven by the annuity-based model with cumulative record new customer starts and growing U.S. pharmacy volumes. This includes an increasing contribution from Omnipod 5 and a premium for the Omnipod 5 and Omnipod DASH pods in the U.S. pharmacy. Image Source: Zacks Investment Research International Omnipod revenue growth also benefited from the strong Omnipod DASH adoption. Per the first-quarter update, Insulet expects to introduce Omnipod 5 in the United Kingdom mid-year and Germany in the fall. Additionally, the company is building its new manufacturing facility in Malaysia, which will further strengthen its global capabilities. Omnipod 5 Transforms Diabetes Management: Per the first-quarter earnings update, Omnipod 5 continues to be a driving force of strong growth in the United States, representing almost 95% of U.S. new customer starts. The system\u2019s ease of use, simplified access, quality of life, strong clinical outcomes and execution have positioned Insulet to continuously win across all market segments. At the 16th International Conference on Advanced Technologies & Treatments for Diabetes, real-world evidence presented by the company with data from more than 31,000 Omnipod 5 users is unmatched by competitors. Further, PODD noted that the development work to integrate Omnipod 5 with DexCom\u2019s G7 and Abbott\u2019s Libre systems and iOS integration efforts have been progressing well. Diabetes Market Boom: The global diabetes device market is expected to witness a CAGR of 7.5% by 2030, led by an increase in technological advancements, the increasing adoption of insulin delivery devices and the rising prevalence of diabetes and obesity. Insulet has been making significant investments of late to advance its diabetes business. In February 2023, Insulet acquired the assets of Automated Glucose Control LLC \u2014 a company in Palo Alto, CA, focused on developing and commercializing best-in-class AID technology. In the same month, Insulet acquired assets related to Bigfoot\u2019s pump-based AID technologies. Insulet paid $25M for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy. Downsides Tough Competitive Pressure: Insulet operates in a highly competitive environment dominated by firms ranging from large multinational corporations with significant resources to start-ups. Also, competitive and regulatory conditions in the markets where the company operates limit Insulet\u2019s ability to switch to strategies like price increases and other drivers of cost increases. PODD\u2019s Omnipod System primarily competes with Medtronic\u2019s market-leading MiniMed, a division of Medtronic. MiniMed boasts a major part of the conventional insulin pump market share in the United States. Other suppliers in the United States include Tandem Diabetes Care, Inc. Economic Uncertainty Hampers Growth: Weaker global economic conditions may reduce the demand for Insulet\u2019s products, intensify competition, exert pressure on prices, dent supply and lengthen the sales cycle. Insulet is also exposed to the risk of a reduction in healthcare spending in the United States, Canada and Europe due to an economic slump. Per the first-quarter 2023earnings call Insulet expects an unfavorable product mix, U.S. manufacturing ramp, inflation and supply-chain headwinds to continue to impact business results for the next few years. Estimate Trend The Zacks Consensus Estimate for Insulet\u2019s 2023 earnings per share (EPS) has remained constant at $1.38 in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $1.57 billion. This suggests a 20.3% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Intuitive Surgical ISRG. Haemonetics has an earnings yield of 3.98% against the industry\u2019s -3.55%. Haemonetics\u2019 earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 12.21%. Its shares have risen 29.2% against the industry\u2019s 4.4% decline in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 42.9% compared with the industry\u2019s 15.8%. Shares of the company have rallied 32.4% against the industry\u2019s 2.9% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 23.8%. Intuitive Surgical, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 15.7%, almost in line with the industry. Shares of ISRG have risen 29.4% compared with the industry\u2019s 2.9% growth over the past year. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 4.19%. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-09,110.71,114.66,109.8,110.96,"[""Noteworthy ETF Inflows: VO, MSI, DXCM, CTAS Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mid-Cap ETF (Symbol: VO) where we have detected an approximate $172.2 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 247,506,850 to 248,281,420). Among the largest underlying components of VO, in trading today Motorola Solutions Inc (Symbol: MSI) is up about 0.6%, DexCom Inc (Symbol: DXCM) is up about 1.8%, and Cintas Corporation (Symbol: CTAS) is higher by about 0.4%. For a complete list of holdings, visit the VO Holdings page \u00bb The chart below shows the one year price performance of VO, versus its 200 day moving average: Looking at the chart above, VO's low point in its 52 week range is $182.88 per share, with $229.34 as the 52 week high point \u2014 that compares with a last trade of $222.64. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Free Report: Top 8%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb Also see: \u0095 FANH Videos \u0095 Institutional Holders of NRDS \u0095 CLR YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 26 cents in the second quarter of 2023, down by 88.9% year over year. The figure topped the Zacks Consensus Estimate by a penny. The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others. Supplemental combined adjusted EPS for the quarter was also 26 cents, down 87.7% year over year. GAAP loss per share for the quarter was 80 cents against the year-earlier EPS of 36 cents. Revenues in Detail QuidelOrtho registered revenues of $665.1 million in the second quarter, which increased 8.4% year over year. The figure surpassed the Zacks Consensus Estimate by 7.3%. In the reported quarter, supplemental combined revenues of $665.1 million were down 26% on a reported basis and down 25.9% at constant exchange rate (CER). In the second quarter, Respiratory revenues were $89 million (down 73.8% on both reported basis and at CER), while Non-Respiratory revenues were up $576.1 million (up 3% and 4.1% on reported basis and at CER, respectively). Segments in Detail QuidelOrtho now derives revenues from four business units \u2014 Labs, Transfusion Medicine (TM), Point-Of-Care (POC) and Molecular Diagnostics (MDx). In the second quarter, Labs revenues were $361.4 million, up 5.7% and 7% on a reported basis and at CER, respectively. This compares to our second-quarter projections of $248.6 million. TM revenues were $163.3 million in the second quarter, down 3.3% and 2.5% on a reported basis and at CER, respectively. This compares to our second-quarter projections of $118.6 million. POC revenues amounted to $134.2 million in the second quarter, reflecting a decline of 63.4% and 63.5 % on a reported basis and at CER, respectively. This compares to our second-quarter projections of $239.5 million. MDx revenues totaled $6.2 million in the second quarter, down 70% both on a reported basis and at CER. This compares to our second-quarter projections of $11.3 million. Geographical Distribution Geographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China and Other regions (which includes Latin America, Japan and other Asia-Pacific markets). Revenues from North America amounted to $378.8 million, reflecting a decline of 36.4% and 36.1% on a reported basis and at CER, respectively. This compares to our second-quarter projections of $421.3 million. EMEA revenues amounted to $80.6 million, reflecting a decline of 2.8% on a reported basis and down 2.5% at CER. This compares to our second-quarter projections of $57.1 million. Revenues from China amounted to $81.3 million, reflecting a decline of 15.4% on a reported basis and 13.4% at CER. This compares to our second-quarter projections of $55.5 million. Revenues from Other regions amounted to $124.4 million, reflecting an uptick of 0.5% on a reported basis and 1.1% at CER. This compares to our second-quarter projections of $84.1 million. QuidelOrtho Corporation Price, Consensus and EPS Surprise QuidelOrtho Corporation price-consensus-eps-surprise-chart | QuidelOrtho Corporation Quote Margin Trend In the quarter under review, QuidelOrtho\u2019s gross profit declined 12.2% to $296.4 million. The gross margin contracted by a huge 1046 basis points (bps) to 44.6%. We had projected 42.9% of gross margin for the second quarter. Selling, marketing and administrative expenses rose 51.3% to $179.1 million. Research and development expenses went up 83.6% year over year to $62.8 million. Adjusted operating expenses of $241.9 million surged 58.5% year over year. Adjusted operating profit totaled $54.5 million, reflecting a 70.5% decline from the prior-year quarter\u2019s level. Adjusted operating margin in the second quarter contracted a huge 2195 bps to 8.2%. Financial Position QuidelOrtho exited second-quarter 2023 with cash and cash equivalents of $178.6 million compared with $353.9 million at the end of first quarter. Total debt (including short-term debt) at the end of second-quarter 2023 was $2.52 billion compared with $2.59 billion at the first-quarter end. Cumulative net cash flow from operating activities at the end of second-quarter 2023 was $158.3 million compared with $725.6 million a year ago. Guidance QuidelOrtho has revised its financial outlook for 2023. Total revenues are now expected to lie within $2.88 billion-$3.08 billion, narrowed from the earlier guidance of $2.87 billion-$3.18 billion. The Zacks Consensus Estimate for the same stands at $2.99 billion. Non-respiratory revenues are now expected to be between $2.27 billion and $2.31 billion (up 5-6.5% at CER from 2022 levels), narrowed from the earlier projections of $2.26 billion and $2.31 billion (up 4.5-6.5% at CER from 2022 levels). Respiratory revenues for the full year are now expected to lie in the range of $610 million-$775 million, narrowed from the earlier projections of $610 million-$875 million. The respiratory revenues now include COVID-related revenues of $300 million to $400 million, narrowed from the earlier projections of $300 million-$500 million. Adjusted EPS is now expected to lie between $4.85 and $5.30, lowered from the prior guidance of $5.15-$5.70. The Zacks Consensus Estimate for the same stands at $5.28. Our Take QuidelOrtho ended the second quarter of 2023 with better-than-expected results. An uptick in the company\u2019s overall top line and Non-Respiratory revenues was impressive. The company registered robust revenues from its Labs segment and Other region, which were encouraging. The company also recorded solid revenues from its Instrument revenue category, which was promising. The continued uptick in Sofia non-COVID pull-through and growth in QuidelOrtho\u2019s integrated installed base and automation were encouraging. During the quarter, QuidelOrtho completed the Savanna Emergency Use Authorization and 510(k) FDA submissions, including 510(k) for the instrument in both RVP4 and HSV VZV lesion panels. These look promising for the stock. However, dismal bottom-line results and lower supplemental combined revenues were disappointing. The decline in the majority of its business units and geographies was discouraging. The decline in QuickVue and Recurring revenues was also worrying. The contraction of both margins also does not bode well. Zacks Rank and Other Key Picks QuidelOrtho currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are DexCom, Inc. DXCM, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. DexCom, carrying a Zacks Rank of 2, reported second-quarter 2023 adjusted EPS of 34 cents, beating the Zacks Consensus Estimate by 54.6%. Revenues of $871.3 million outpaced the consensus mark by 4.1%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 42.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.8%. Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, beating the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the Zacks Consensus Estimate by 1.4%. It currently carries a Zacks Rank #2. Intuitive Surgical has a long-term estimated growth rate of 15.7%. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.2%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QuidelOrtho Corporation (QDEL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""PacBio (PACB) Inks Research Collaboration for Genome Sequencing Pacific Biosciences of California PACB, popularly known as PacBio, entered into a research collaboration with the University of Washington. As a part of the research collaboration, PACB, along with GeneDx WGS, the leading provider of genomic and clinical insights, will study the capabilities of HiFi long-read whole genome sequencing (\u201cWGS\u201d) in pediatric patients with genetic conditions for better diagnostic rates. The study \u2014 SeqFirst \u2014 will use both short and long-read WGS to find out whether some genetic conditions are caused by novel variants that are not accessible via short-read sequencing technologies. The study is a collaboration between GeneDx and Seattle Children\u2019s Hospital, a hub for genomic research and precision medicine. GeneDx will sequence and analyze the genomes of 350 people, including 120 patients from Seattle Children\u2019s Hospital and their biological parents, if available. Price Performance Shares of PacBio have risen 46.5% year to date compared with the industry\u2019s growth of 2%. The S&P 500 Index has gained 19% in the same time frame. Image Source: Zacks Investment Research Significance of the Collaboration The researchers hope to discover new insights into the genetic basis of rare and complex diseases from the SeqFirst study, which is sponsored by GeneDx and partly funded by the Brotman Baty Institute. This institute brings together experts from UW Medicine, Seattle Children\u2019s Hospital and Fred Hutchinson Cancer Center. The long-read sequencing has the potential to provide new insights into human genomes and discover novel variants that may help understand the causative variation in DNA in patients with certain genetic conditions. GeneDX will use PacBio\u2019s popular Revio sequencing system to perform long-read WGS sequencing and analysis in the new study. The study aims to find out if the Revio system can improve the diagnosis of rare and complex diseases by providing more accurate, longer and methylation-sensitive reads. The study will share the sequencing data, including the novel variants and their frequencies, with the Consortium of Long Read Sequencing (CoLoRS) database to help advance the scientific knowledge of variant prevalence and classification. Previous Collaborations PacBio has been collaborating with leading research hospitals, health-organizations and technology companies in both technology and research fields over the past two years. One of its key collaborations is with Google, a subsidiary of Alphabet GOOGL, to implement the latter\u2019s deep learning method, DeepConsensus, in Revio. The partnership also provides access to Alphabet\u2019s DeepVariant, potentially helping in improving long-read WGS performance. PacBio\u2019s collaborations, especially with GOOG, will likely help it in discovering real applications in healthcare to aid critical and complex cases with the use of artificial intelligence. Notable Developments Earlier this month, PacBio announced second-quarter 2023 results, wherein there was a robust increase in its overall revenues, including strong revenues from Instrument and Consumables. Solid performances in the Asia-Pacific and Europe, the Middle East and Africa regions were also witnessed. In June, PacBio announced that the leading provider of clinical diagnostics and genomic services, Bioscientia, in Europe, has adopted its Revio long-read sequencing system. The company also announced a clinical research study with Radboud University Medical Center (Radboudumc) in the same month to explore the causes of rare and genetic diseases. Pacific Biosciences of California, Inc. Price Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote Zacks Rank & Stock to Consider PacBio currently carries a Zacks Rank #3 (Hold). DexCom DXCM is a better-ranked stock from the same sector, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has an estimated growth rate of 42.9% over the next five years. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 28.83%. DXCM\u2019s shares have lost 2.7% year to date against the industry\u2019s 2% growth. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise Masimo Corporation MASI delivered adjusted earnings per share (EPS) of 62 cents in the second quarter of 2023, down 54.1% year over year. The figure missed the Zacks Consensus Estimate by 27.9%. The adjustments include acquisition, integration and related costs, and litigation-related expenses, settlements and awards, among others. GAAP EPS for the quarter was 29 cents, down 12.1% from the year-earlier figure. Revenues in Detail Masimo registered revenues of $455.3 million in the second quarter, down 19.5% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimate by 0.2%. The year-over-year decline in revenues primarily resulted from lower revenues from its healthcare and non-healthcare segments. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, were 64,100 in the second quarter of 2023. Segmental Details Masimo derives its revenues from two business sources \u2014 Healthcare and Non-healthcare. Healthcare revenues in the second quarter were $281.1 million, representing a decrease of 21.3% on a reported basis and 20.7% at constant exchange rate (CER). This compares to our projection of $354.6 million of Healthcare revenues in the second quarter. Non-healthcare revenues in the second quarter were $174.2 million, reflecting a decline of 17% both on a reported basis and at CER. This compares to our projection of $196.8 million of Non-healthcare revenues in the second quarter. Masimo Corporation Price, Consensus and EPS Surprise Masimo Corporation price-consensus-eps-surprise-chart | Masimo Corporation Quote Margin Analysis In the quarter under review, Masimo\u2019s gross profit fell 14.3% to $221.2 million. However, the gross margin expanded 291 basis points (bps) to 48.6%. We had projected 52.9% of gross margin for the second quarter. Selling, general & administrative expenses decreased 19.4% to $151.7 million. Research and development expenses declined 15.9% year over year to $40.2 million. Total operating expenses of $191.9 million decreased 18.7% year over year. Total operating profit amounted to $29.3 million, reflecting a 32.6% uptick from the prior-year quarter. The operating margin in the second quarter expanded 253 bps to 6.4%. We had projected 9.8% of operating margin for the second quarter. Financial Position Masimo exited second-quarter 2023 with cash and cash equivalents of $150.7 million compared with $174.1 million at the end of first quarter. Long-term debt at the end of second-quarter 2023 was $888.8 million compared with $897.5 million at the first-quarter end. Cumulative net cash flow from operating activities at the end of second-quarter 2023 was $24 million compared with $25.6 million a year ago. Guidance Masimo has provided its outlook for the third quarter and revised the same for 2023. For the third quarter, total revenues are projected to be in the range of $475 million-$525 million. The Zacks Consensus Estimate for the metric is currently pegged at $569.9 million. Healthcare revenues are expected to lie within $305 million to $335 million (reflecting a decline of 7% to growth of 2% on both reported basis and at CER), while Non-healthcare revenues are expected to be between $170 million and $190 million. Adjusted EPS for the third quarter is projected to be in the range of 50-64 cents. The Zacks Consensus Estimate for the same is pegged at $1.14. For the full year, total revenues are now projected to be in the range of $2,100 million-$2,200 million, lowered from the previous outlook of $2,415 million-$2,460 million. The Zacks Consensus Estimate for the metric is currently pegged at $2.12 billion. Healthcare revenues are now expected to lie within $1,300 million-$1,350 million (reflecting a decline of 3% to growth of 1% on both reported basis and at CER). The outlook for Healthcare revenues was in line with the outlook provided when Masimo released its preliminary results in July. Non-healthcare revenues for the year are continued to be expected in the range of $800 million-$850 million, in line with Masimo\u2019s outlook in its preliminary results. Adjusted EPS for 2023 is now projected within $3.35-$3.55, lowered from the previous projections of $4.70-$4.80. The Zacks Consensus Estimate for the same is pegged at $4.43. Our Take Masimo exited the second quarter of 2023 with better-than-expected revenues. The expansion of the company\u2019s installed base was impressive. Management confirmed that the company gained new hospital customers during the quarter at a record level, which was encouraging. The expansion of both margins in the quarter bodes well. On the second-quarterearnings call Masimo\u2019s management confirmed that its Non-healthcare segment\u2019s Hearables category (including headphones and earbuds) was scaled up in the second half of 2022 with the introduction of the Bowers & Wilkins PI7, PX7 and PX8 headphone models. The company has also been witnessing steady growth in its Hearables category on the back of the launch of Denon PerL earbuds with automatic customization of the sound spectrum for personalized listening experience in June. These look promising for the stock. On the flip side, lower-than-expected earnings and the dismal top-line and bottom-line performances were disappointing. The decline in its Healthcare and Non-healthcare segmental revenues was worrying. Masimo\u2019s lower-than-expected sensor orders during the reported quarter were discouraging. Zacks Rank & Key Picks Masimo currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom, Inc. DXCM, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. DexCom, carrying a Zacks Rank of 2 (Buy), reported second-quarter 2023 adjusted EPS of 34 cents, beating the Zacks Consensus Estimate by 54.6%. Revenues of $871.3 million outpaced the consensus mark by 4.1%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 42.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.8%. Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, beating the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the Zacks Consensus Estimate by 1.4%. It currently carries a Zacks Rank #2. Intuitive Surgical has a long-term estimated growth rate of 15.7%. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.2%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly. But with an abundance of options to choose from, it can be challenging to separate the wheat from the chaff. For those needing inspiration, let's consider two stocks worth investing in: HCA Healthcare (NYSE: HCA) and DexCom (NASDAQ: DXCM). If you have a spare $1,000 that isn't being saved for something important -- such as bills or an emergency -- here is why putting that money into these companies would be worthwhile. 1. HCA Healthcare HCA Healthcare runs a business that most people will have to interact with at some point. The company is one of the largest hospital chains in the U.S. It ended the second quarter with 182 hospitals, unchanged from the previous year's comparable period. The inevitability of people needing HCA Healthcare services is one of the factors that make it an attractive stock. Even during challenging times, people are unlikely to skip the medical care they need; it's one of the last things they'll skimp on. So the occupancy levels that are one of the sources of HCA Healthcare's revenue should remain somewhat stable regardless of economic conditions. Still, that doesn't mean the company is immune to economic challenges, as the past couple of years have shown. HCA Healthcare has had to deal with rising expenses due to inflation and labor issues, among other problems. However, the stock has delivered solid returns throughout the ebbs and flows. One reason is that HCA continues to post financial results that are robust, though not always blowout-level. In the second quarter, revenue increase by 7% year over year to $15.9 billion. Key metrics were also on the rise, including same-facility admissions and emergency room visits. Earnings per share (EPS) of $4.29 jumped by 10% year over year. Here's another reason to like HCA: The company has continued to gain market share against its competitors. It did so during the pandemic, going from 26.5% before the outbreak started to 28% as of the second quarter of last year. Market share gains of 1.5 percentage points in three years are meaningful in an industry this competitive. Although the past is not a guarantee, HCA's ability to capture market share is a good sign. It has done so by improving its clinical capabilities, thus giving physicians more options to treat their patients, a win-win situation. It's a good bet that it can continue doing the same. With its entrenched position in many communities around the country -- and the high barriers to entry in the healthcare industry (steep up-front costs and legal obstacles) -- HCA should remain a leader in its field for a while, making the company a solid buy-and-hold option. At current levels, $1,000 would get investors about three shares of HCA Healthcare at current levels. 2. DexCom DexCom is helping fight the diabetes epidemic by developing continuous glucose monitoring (CGM) systems that allow people with this chronic illness to keep their blood glucose levels in check. Blood sugar significantly out of range can lead to serious, sometimes life-threatening complications for a diabetic. CGM systems are superior to blood glucose meters (BGMs) since the former automatically make measurements throughout the day, as often as every five minutes. BGMs are manual, rely on painful jabs in the finger, and can only tell blood sugar levels at a point in time. That's why DexCom's devices, such as its flagship G6 system, have been linked with better health outcomes. Adoption of this technology has helped DexCom push its revenue and earnings higher, even with fierce competition from Abbott Laboratories' FreeStyle Libre system. In the second quarter, DexCom's revenue increased 25% year over year to $871.3 million and its adjusted EPS doubled to $0.34. Over the past year, DexCom has launched two new devices: the G7, successor to its G6, and the DexCom ONE. These are helping the company make progress in its existing geographies and break into new ones. For instance, the company entered the Latin American market in the second quarter (specifically Argentina) with the DexCom ONE, a cheaper CGM option that can help attract price-sensitive customers and make headway in regions with low CGM penetration. And there is still a massive addressable market ahead, with 37.3 million diabetes patients in the U.S. alone. DexCom ended 2022 with an installed base of 1.7 million customers. Since it is one of the leaders in the field, this metric shows that there is ample white space ahead if the company continues doing what has helped it succeed: innovate and raise awareness for better ways to address diabetes, including CGM devices. That should lead to solid financial results and stock market performance for a while. Investors can get about eight shares of DexCom with $1,000 -- money well spent. 10 stocks we like better than HCA Healthcare When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and HCA Healthcare wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2023 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and HCA Healthcare. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-10,112.25,115.94,112.15,113.27,"[""Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates Avanos Medical, Inc. AVNS reported second-quarter 2023 adjusted earnings per share (EPS) of 24 cents, down 7.7% year over year. The bottom line missed the Zacks Consensus Estimate by 29.4%. GAAP loss per share in the quarter under review was 9 cents against the year-ago period\u2019s EPS of 10 cents. Revenues Revenues grossed $169.4 million in the reported quarter, down 0.9% year over year. The metric lagged the Zacks Consensus Estimate by 12.6%. Per management, the top line was hampered by a lower volume in the Pain Management and Recovery portfolio, primarily from lower hyaluronic acid portfolio (HA) sales. However, this was offset by a higher volume in the Digestive Health portfolio. Excluding both the negative impact of foreign exchange and the $5 million impact related to Avanos\u2019 previously announced decision to eliminate revenues that were not meeting its returns criteria, organic growth was 2.6% in the quarter. Segmental Analysis Avanos provides a portfolio of innovative product offerings that focuses on Pain Management and Recovery and Digestive Health. Pain Management and Recovery\u2019s net revenues of $76.4 million decreased 15.8% year over year on a reported basis. At constant exchange rate (CER), revenues were down 11%. The segment saw soft results across the Interventional pain, Game Ready and 5-shot HA product categories, each of which was down in the second quarter versus the prior-year period. The surgical pain pump business was also flat during the quarter. This figure compares to our second-quarter projection of $83.3 million. Digestive Health\u2019s net revenues of $93 million improved 15.9% year over year. At CER, revenues were up nearly 17%, owing to strength in the med product line. The business saw continued strong execution for NeoMed. Avanos\u2019 legacy intra-feeding product line grew in double digits globally, primarily driven by the continued expansion of its U.S. CORTRAK standard of care offering. This figure compares to our second-quarter projection of $78.7 million. Avanos Medical, Inc. Price, Consensus and EPS Surprise Avanos Medical, Inc. price-consensus-eps-surprise-chart | Avanos Medical, Inc. Quote Margin Analysis In the quarter under review, Avanos\u2019 gross profit fell 3.7% to $97.8 million. The gross margin contracted 172 basis points (bps) to 57.7%. Selling and general expenses rose 11.8% to $93 million. Research and development expenses decreased 10.5% year over year to $6.8 million. Adjusted operating expenses of $99.8 million increased 9.9% year over year. Adjusted operating loss totaled $2 million against the prior-year quarter\u2019s adjusted operating profit of $10.8 million. Financial Update The company exited second-quarter 2023 with cash and cash equivalents worth $81.8 million compared with $95.7 million at the end of first quarter. Total debt at the second-quarter end was $209.5 million compared with $210.9 million at the first-quarter end. Cumulative net cash used in operating activities at the end of second-quarter 2023 totaled $9.4 million against net cash provided by operating activities of $28.8 million in the prior-year period. Guidance Avanos has adjusted its 2023 guidance for divestiture. The company estimates its revenues for the full year in the range of $675 million-$685 million. The Zacks Consensus Estimate for the same currently stands at $802.4 million. Avanos now anticipates 2023 adjusted EPS between $1.05 and $1.15, lowered from its previous outlook of $1.60-$1.80. The Zacks Consensus Estimate for the same currently stands at $1.63. Our Take Avanos\u2019 strength in the Digestive Health segment in the second quarter of 2023 was encouraging. The robust growth in NeoMed and CORTRAK was promising. On theearnings call management confirmed that TriVisc, Avanos\u2019 3-shot offering, continues to meet its internal performance expectations. This raises our optimism about the stock. Yet, Avanos\u2019 lower-than-expected results in the quarter were disappointing. The year-over-year decline in the top and bottom lines and lower revenues from Pain Management and Recovery segment were also discouraging. Management also confirmed during theearnings callthat although supply-chain disruptions have lessened, Avanos continued to experience ongoing product supply challenges and the effects of inflation throughout its supply chain. These raise our apprehension. The contraction of gross margin does not bode well. Zacks Rank and Key Picks Avanos currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom, Inc. DXCM, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. DexCom, carrying a Zacks Rank of 2 (Buy), reported second-quarter 2023 adjusted EPS of 34 cents, beating the Zacks Consensus Estimate by 54.6%. Revenues of $871.3 million outpaced the consensus mark by 4.1%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 42.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.8%. Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, beating the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the Zacks Consensus Estimate by 1.4%. It currently carries a Zacks Rank #2. Intuitive Surgical has a long-term estimated growth rate of 15.7%. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.2%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates Accuray Incorporated ARAY reported loss per share of 3 cents for the fourth quarter of fiscal 2023, narrower than the year-ago period\u2019s loss of 4 cents per share. However, the metric lags the Zacks Consensus Estimate of a breakeven earnings per share (EPS). Full-year adjusted loss per share was 10 cents, wider than the loss of 6 cents per share at the end of the comparable fiscal 2022 period. The loss per share was also wider than the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues in Detail Accuray registered revenues of $118.3 million in the fourth quarter of fiscal 2023, up 7.5% year over year. However, the figure lagged the Zacks Consensus Estimate by 2.6%. The overall top-line growth was aided by robust segmental revenues and performances by the majority of geographies. At constant exchange rate (CER), net revenues were $120.1 million, representing a 9.1% increase from the prior-year period. Full-year revenues were $447.6 million, reflecting a 4.1% improvement from the comparable fiscal 2022 period. However, the figure lagged the Zacks Consensus Estimate by 0.7%. Segmental Details Accuray derives revenues from two sources \u2014 Products and Services. In the fiscal fourth quarter, Product revenues improved 7.6% from the year-ago quarter to $62.5 million. This figure compares to our Product revenues\u2019 fiscal fourth-quarter projection of $65.2 million. At CER, Product revenues improved 9%. Services revenues rose 7.4% from the year-ago quarter to $55.8 million. This figure compares to our Services revenues\u2019 fiscal fourth-quarter projection of $56.9 million. At CER, Services revenues were up 9%. Gross product orders totaled $88.4 million, up 0.1% year over year. This figure compares to our gross orders\u2019 fiscal fourth-quarter projection of $99.5 million. Accuray Incorporated Price, Consensus and EPS Surprise Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote Margin Trend In the quarter under review, Accuray\u2019s gross profit fell 12.4% to $37.7 million. Gross margin contracted 725 basis points to 31.9%. Selling and marketing expenses fell 25.7% to $10.7 million. Research and development expenses fell 2.6% year over year to $14.2 million, while general and administrative expenses went up 10.3% year over year to $13.3 million. Total operating expenses of $38.1 million decreased 6.9% year over year. Operating loss totaled $0.5 million in the fiscal fourth quarter against the prior-year quarter\u2019s operating profit of $2 million. Financial Position Accuray exited fiscal 2023 with cash and cash equivalents of $89.4 million compared with $88.7 million at the end of fiscal 2022. Total debt (including short-term debt) at the end of fiscal 2023 was $177.3 million compared with $180.5 million at the fiscal 2022-end. FY24 Guidance Accuray has initiated its outlook for fiscal 2024 based on current expectations. The company expects its fiscal year revenues to be $460 million-$470 million, reflecting year-over-year growth of 3-5%. The Zacks Consensus Estimate for the same is pegged at $474.9 million. Our Take Accuray ended the fourth quarter of fiscal 2023 with solid overall top-line results, which were encouraging. Robust Product and Services revenues and performances in the majority of geographies were impressive. The uptick in gross orders and the global installed base also look promising. Continued strong demand for Accuray\u2019s Radixact innovations, including ClearRT, Synchrony and VitalHold, buoy optimism. During the reported quarter, Accuray booked several strategic and multi-system orders from key institutions globally. Per Accuray\u2019s management, the company entered several strategic partnerships over the past few months. These look promising for the stock. However, lower-than-expected results and dismal bottom-line performances were disappointing. The fall in revenues from Japan was also worrying. The gross margin contraction also does not bode well. The current global supply-chain shortages and geopolitical and inflationary pressure are other challenges the company is navigating through, which is another concern. Zacks Rank and Key Picks Accuray currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom, Inc. DXCM, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. DexCom, carrying a Zacks Rank of 2 (Buy), reported second-quarter 2023 adjusted EPS of 34 cents, beating the Zacks Consensus Estimate by 54.6%. Revenues of $871.3 million outpaced the consensus mark by 4.1%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 42.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.8%. Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. Intuitive Surgical reported second-quarter 2023 adjusted EPS of $1.42, beating the Zacks Consensus Estimate by 7.6%. Revenues of $1.76 billion surpassed the Zacks Consensus Estimate by 1.4%. It currently carries a Zacks Rank #2. Intuitive Surgical has a long-term estimated growth rate of 15.7%. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.2%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accuray Incorporated (ARAY) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Are the Best Companies to Invest in Now? Our 3 Picks for August InvestorPlace - Stock Market News, Stock Advice & Trading Tips Uncertainty from geopolitical tensions within the Ukraine war and China issues has led to slower United States labor market growth. In this environment of uncertainty, the United States labor market has displayed a degree of resilience but at a notably slower pace of growth. On the other hand, this has led to the rise of the best companies to invest in. Recent data released by the Labor Department underscores this cautious trend, as it\u2019s revealed that U.S. employers added 187,000 jobs in July, reflecting a tampered pace compared to previous periods of economic expansion. However, even as geopolitical tensions continue to shape the economic landscape, other sectors are experiencing unique growth trajectories, and these three companies are the best to invest in for long-term returns. Taiwan Semiconductor Manufacturing (TSM) Source: ToyW / Shutterstock Taiwan Semiconductor Manufacturing Company (NYSE:TSM) is a semiconductor manufacturer, producing 60% of the world\u2019s semiconductor supply. TSM stock is up 29.89% YTD and Yahoo! Finance reported 11 analysts having a mean 1-year price target of $112.01, ranging from $85.00 to $135.00. The majority of notable firms rated TSM as a \u201cbuy.\u201d The global semiconductor industry is projected to grow at a 12.2% CAGR through 2029, from $573.44 billion in 2022 to $1.38 trillion by 2029. TSMC reported Q2 financials that are recovering, with revenue of $15.68 billion beating expectations by 300 million, diluted EPS of $7.01 down 23.3%, and net income of $5.925 billion. TSMC is poised to benefit from the increase in artificial intelligence use, with the company forecasting that CPUs, GPUs, and other AI-related technology will grow at a 50% CAGR in the next 5 years, doubling revenue. The company also recently announced a new R&D center in Taiwan having 300,000 meters of floor space, which will be used to develop process technology at the 2-nanometer generation and beyond. TSMC has been quick to relocate to this center, as everything will be ready for a full staff of 7,000+ by September. In Arizona, TSMC is continuing to build its first fab to support U.S. semiconductor infrastructure, where the production schedule of N4 process technology is expected to be complete by 2025. In Japan, TSMC is building a specialty technology factory, with volume production utilizing 12,16, 22, and 28 process technologies on track for late 2024. TSMC is also engaging with customers and partners in Europe, to evaluate building a specialty fab in Germany, with a focus on automotive-specific technologies. Lastly, in China, TSM is expanding the production of its 28-nanometer process chips TSM\u2019s dedication to diversifying its customer base showcases its commitment to expanding its global manufacturing footprint, making it a great stock pick with enormous growth potential. Dexcom Incorporated (DXCM) Source: aslysun / Shutterstock.com Dexcom Incorporated (NASDAQ:DXCM) is an American biotechnology (biotech) company that manufactures medical devices to monitor diseases such as diabetes. Dexcom boasts strong financials with Q2 2023 revenue of $871.3 million beating analyst expectations by $30.3 million and growing at a 19.6% CAGR. Dexcom demonstrates excellent profitability with a 63.9% gross profit margin well above the sector median, a 13.7% levered FCF margin, and a high 16.41% ROCE. Dexcom has had successes with international expansion this year alone. The company gained approval in Canada to sell its newest generation glucose monitoring system to Canadian citizens, the Dexcom G7, by Health Canada. Dexcom also planned to invest $330.8 million over 5 years for the development of its first European factory in Ireland, with the G7 having gained approval in the EU in late 2022. This international expansion from device approvals and factory developments allows Dexcom to capitalize on the international market and gain new customers with its newest generation device. This makes it one of those best companies to invest in. Dexcom has also partnered with key companies. Dexcom is collaborating with DarioHealth Corporation to integrate the data from Dexcom\u2019s CGM systems into DarioHealth\u2019s chronic condition platform. Dexcom also entered a similar partnership with MedNow to integrate CGM system data into MedNow\u2019s virtual diabetes management platform. Dexcom\u2019s unique partnership with South-Korean-based Kakao Health combines Dexcom\u2019s software and Kakao\u2019s software and AI capabilities into a product for the South Korean market coming in 2024. Dexcom has been able to further expand its reach in the international market with its Kakao Health partnership, as well as finding a new revenue stream by integrating its data into software platforms. With DXCM up 6.2% YTD, strong buy ratings from analysts, and an average predicted 12-month upside of 25.8%, Dexcom is a definite buy in August because of its strong financials, its international expansion, and advantages from the partnerships mentioned above. Wells Fargo (WFC) Source: Ken Wolter / Shutterstock.com Wells Fargo (NYSE:WFC) is a bank with loans ranging from commercial real estate to consumer mortgages. WFC stock is up 7.32% YTD. Macroeconomic factors have recently hurt the banking sector. As the Federal Reserve increased interest rates, Mortgage Loan Origination decreased from $37.9 billion to $6.6 billion from Q1 2022 to Q1 2023 as fewer consumers were looking for a mortgage. The decrease in interest rates will likely bolster growth, as the number of people seeking mortgages will increase. As a result, the banking sector will grow at a CAGR of 11.85% until 2031. In its latest earnings, Wells Fargo ended with a revenue of $18.82 billion which increased 14.34% YoY, net income of $4.94 billion increased by 57.16% YoY, and diluted EPS of $1.25 grew 66.67%. All in all, it\u2019s one of those best companies to invest in. Moreover, with a P/E ratio of only 11, investors will likely snap it up as the Fed eases on interest rate hikes Additionally, in the long term, Wells Fargo will resolve and move on from its previous scandals, boosting growth as management can focus on new innovations and products for consumers. Yahoo! Finance reports 23 analysts\u2019 having 12-month price targets that range from $43.75 to $65.00, and the average being $50.89. These are optimistic price targets as the stock\u2019s current price is just $44.85. WFC stock is undervalued, and macroeconomic factors with the passage of time push to boost growth. On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here\u2019s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn\u2019t matter if you have $500 or $5 million. Do this now. The post What Are the Best Companies to Invest in Now? Our 3 Picks for August appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain National Vision (EYE) Stock Now National Vision Holdings, Inc. EYE is likely to gain in the coming quarters, backed by impressive adjusted comparable store sales growth. The company is progressing in its initiatives toward the improvement of exam capacity, including deploying remote medicine capabilities. Investing in AI start-ups like Toku fortifies the future of optical care, enabling people to have affordable access to potentially life-saving health data in an easily accessible, non-invasive test. Meanwhile, escalated expenses and operating in a highly competitive space appear worrisome for National Vision. In the past year, this Zacks Rank #3 (Hold) stock has declined 33.4% compared with the 4.3% fall of the industry and a 9.5% rise of the S&P 500 composite. The leading optical retailer has a market capitalization of $1.62 billion. The company projects long-term estimated earnings growth of 21.9% compared with the industry\u2019s 14.1%. National Vision surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an earnings surprise of 69.9%, on average. Let\u2019s delve deeper. Upsides Future Strategies Look Promising: In terms of store expansion, National Vision continues to see a sizable new opportunity with growth for many years to come. The company\u2019s planned store openings of approximately 65 to 70 new stores in 2023 remain on track, having opened eight new stores in the first quarter. National Vision continued to execute initiatives to thrive in the post-pandemic new normal business environment toward improved sales and profitability. The company\u2019s retention, recruitment and remote medicine efforts are likely to deliver an improved exam capacity. Image Source: Zacks Investment Research In addition, the digitization of stores, corporate offices and marketing efforts are expected to drive productivity improvements. Investments in improved patient care and optometric experience, including investments in AI, are expected to pay off in the long term. National Vision\u2019s merchandising and distribution teams continue to execute well and are confident that the current inventory levels are sufficient to support continued growth in 2023. Overall, the company continues to utilize its strong balance sheet and cash flow to invest in strategic initiatives to enhance customer experience and strengthen its market position. Technological Investments: National Vision recently invested in an early-stage healthcare, AI start-up, Toku, alongside Topcon Healthcare. Through the investment, EYE is strengthening the future of optical care in which more people are able to have affordable access to potentially life-saving health data on an easily accessible, non-invasive test. A Bullish First-Quarter Performance: In the last reported quarter, National Vision delivered better-than-expected revenues and earnings. Amid an uncertain macro environment, National Vision delivered positive comparable sales growth in the first quarter, primarily driven by strength in its managed care business. During the quarter, National Vision opened four new America's Best and four Eyeglass World stores. The combined unit growth of America's Best and Eyeglass World brands increased 5% over the total store base last year, having ended the quarter with 1,357 stores. Further, the company is also continuing to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas. Per the company\u2019s first-quarter update, it is on track with the expansion into at least an additional 200 remote-enabled stores in 2023. Downsides Mounting Expenses: EYE reported a significant year-over-year decline in first-quarter earnings. Escalating expenses caused a contraction in the gross and adjusted operating margins. The company is facing demand headwinds across its network of stores, given the current macro environment and supply challenges in a smaller subgroup of stores due to constraints on eye exam capacity. Tough Competition: National Vision operates in a highly competitive optical retail industry. Companies within the industry generally compete based on the recognition of the brand name, price, convenience, selection, service and product quality. National Vision competes with national retailers like LensCrafters, Pearle Vision and Visionworks in the broader optical retail industry. Competition exists in physical retail locations along with e-commerce platforms. The company also faces a competitive threat from online sellers of contact lenses and eyewear. Many firms are focused on selling eyeglasses in the online market like Warby Parker and Zenni Optical. Estimate Trend The Zacks Consensus Estimate for EYE\u2019s 2023 earnings per share (EPS) has moved up from 50 cents to 55 cents in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $2.12 billion. This suggests a 5.6% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Intuitive Surgical ISRG. Haemonetics has an earnings yield of 3.98% against the industry\u2019s -3.24%. Haemonetics\u2019 earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have risen 33.7% against the industry\u2019s 4.3% decline in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 42.9% compared with the industry\u2019s 15.9%. Shares of the company have rallied 30.6% against the industry\u2019s 2.1% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.83%. Intuitive Surgical, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 15.7%, almost in line with the industry. Shares of ISRG have risen 30.6% against the industry\u2019s 2.1% fall over the past year. ISRG\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 4.19%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-11,112.35,112.7,110.55,111.69,"[""Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients The Cigna Group\u2019s CI health benefits business, Cigna Healthcare, collaborated with the global digital-first health and well-being engagement company, Virgin Pulse. The tie-up aims to provide an advanced digital platform, which can be accessed at myCigna by specific employer-sponsored plan clients of Cigna Healthcare from the very beginning of 2024. The new platform is an initiative to extend a connected and more customized experience to bring enhanced whole-person well-being for around 11 million customers of Cigna. And taking the help of Virgin Pulse seems to be an apt move on the part of CI since the former leverages AI-powered technology and behavior change science, which imparts clients the ability to manage their mental, physical and social health. Subsequently, an individual can make better health choices, set attainable targets and earn financial rewards. The platform empowers users with the flexibility to connect a compatible fitness device or input some basic daily metrics, like weight or number of hours slept, and consequently, keep a check on their progress. On the basis of the customers\u2019 information, preferences and claims experience, myCigna will direct them to other suitable programs of Cigna Healthcare linked with pre-diabetes management or behavioral health services. The latest initiative reflects Cigna\u2019s ardent endeavor to extend advanced digital solutions to its health plan clients. This, in turn, might lure more plan sponsors and clients to opt for Cigna Healthcare\u2019s plans and thereby, provide an impetus to the segment in the days ahead. Through this unit, Cigna serves customers of U.S. Commercial, U.S. Government and International Health businesses. An increase in the customer base is expected to fetch higher premiums for Cigna, which remain the most significant contributor to any health insurer\u2019s top line. Total medical customers of CI increased 9.5% year over year as of Jun 30, 2023. The health insurance marketplace frequently witnesses launches of advanced digital health solutions by multiple healthcare providers to meet the surge in demand for virtual care since the advent of the COVID pandemic. Therefore, the move to bring an enhanced digital platform seems aptly timed by Cigna. Apart from the Cigna Healthcare unit, the Evernorth business of Cigna has also put its foot forward to capitalize on the trend to go digital and boost customer base. Last year, the unit added five app- based programs to its clinical platform, Digital Health Formulary. The offerings comprised authenticated and trustworthy health apps devised to achieve better health outcomes. Shares of Cigna have gained 12.6% in the past three months compared with the industry\u2019s 1.6% growth. CI currently carries a Zacks Rank #3 (Hold). Image Source: Zacks Investment Research Stocks to Consider Some better-ranked stocks in the Medical space are Amphastar Pharmaceuticals, Inc. AMPH, DexCom, Inc. DXCM and HCA Healthcare, Inc. HCA. Amphastar Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), and DexCom and HCA Healthcare carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Amphastar Pharmaceuticals\u2019 earnings surpassed estimates in three of the last four quarters and matched the mark once, the average surprise being 35.98%. The Zacks Consensus Estimate for AMPH\u2019s 2023 earnings indicates a rise of 36.6%, while the same for revenues suggests an improvement of 28.5% from the respective year-ago actuals The consensus mark for AMPH\u2019 2023 earnings has moved 5.1% north in the past 30 days. DexCom\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.83%. The Zacks Consensus Estimate for DXCM\u2019s 2023 earnings indicates a rise of 36.8%, while the same for revenues suggests an improvement of 21.3% from the respective year-ago actuals. The consensus mark for DXCM\u2019s 2023 earnings has moved 11.2% north in the past 30 days. The bottom line of HCA Healthcare outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 5.42%. The Zacks Consensus Estimate for HCA\u2019s 2023 earnings indicates a rise of 8.6%, while the same for revenues suggests an improvement of 6.1% from the respective year-ago actuals. The consensus mark for HCA\u2019s 2023 earnings has moved 1.3% north in the past 30 days. The Amphastar Pharmaceuticals stock has gained 28.3% in the past three months. However, shares of DexCom and HCA Healthcare have lost 7% and 2.8%, respectively, in the same time frame. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI) : Free Stock Analysis Report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Syneos Health (SYNH) to Go Private, Reports Q2 Performance Syneos Health SYNH recently announced that its stockholders have approved the company\u2019s merger agreement with a private investment consortium at a special meeting held on Aug 2, 2023. The consortium affiliates include Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As announced on SYNH\u2019s May 10 release, the all-cash transaction represents a 24% premium to the company\u2019s unaffected closing stock price on Feb 13, 2023, which is the last trading day before media speculation regarding the company. The transaction is expected to be completed in the second half of 2023, subject to the satisfaction of customary closing conditions and regulatory approvals. More on the News Upon the closing of the agreement, Syneos Health\u2019s Class A common stock shares will no longer trade on the Nasdaq Stock Market LLC and will be deregistered under the Securities Exchange Act of 1934 as amended. Henceforth, the company will operate as a private company. Image Source: Zacks Investment Research Per SYNH, the definitive agreement reflects the comprehensive review of available opportunities, including interests from multiple parties, backed by the assistance of independent financial and legal advisors. The partnership with the consortium will enable the company to accelerate its growth strategy, enhance customer delivery and evolve the organization toward a tech-enabled future. Q2 2023 Earnings Performance Parallel to the merger news, Syneos Health declared second-quarter 2023 financial results within the latest quarterly SEC filing. The company reported GAAP diluted earnings per share (EPS) of 1 cent compared with 75 cents in the prior-year quarter. Revenues in the second quarter increased 0.4% year over year to $1.37 billion and also exceeded the Zacks Consensus Estimate by 9.6%. Segment-wise, the Clinical Solutions segment recorded revenues of $1.02 billion in the second quarter, down 0.4% year over year on a reported basis. This exceeded our model\u2019s projected revenues of $940 million in this segment. Commercial Solutions revenues were $344.3 million in the reported quarter, up 2.8% year over year. This compares with our model\u2019s segmental projection of $263.3 million. In the quarter under review, the gross margin contracted 237 basis points (bps) to 21.6%, with a 3.5% increase in the cost of revenues. The adjusted operating margin (excluding depreciation, amortization and restructuring and other expenses) contracted 552 bps from the year-ago quarter to 8.2%. SYNH reported cash, cash equivalents and restricted cash of $82.3 million at the second quarter-end. Per the update given on 10-Q, the company has incurred approximately $23 million in costs in connection with the Merger and expects to continue to incur significant costs and expenses, including fees for professional services and other transaction costs. Price Performance In the past six months, SYNH shares have increased 23.1% against the industry\u2019s fall of 9.3%. Zacks Rank and Other Key Picks Syneos Health currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and SiBone SIBN. Haemonetics sports a Zacks Rank #1 (Strong Buy), while DexCom and SiBone each carry a Zacks Rank #2. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019stock has risen 23.7% in the past year. Earnings estimates for Haemoneticshave increased from $3.56 to $3.58 in 2023 and $3.96 to $3.98 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.32%. In the last reported quarter, it posted an earnings surprise of 38.16%. Estimates for DexCom\u2019s 2023 EPS have increased from $1.07 to $1.19 in the past 30 days. Shares of the company have increased 26% in the past year against the industry\u2019s fall of 3.7%. DXCM\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.83%. In the last reported quarter, it posted an earnings surprise of 54.55%. Estimates for SiBone\u2019s2023 loss have narrowed from $1.42 to $1.40 per share in the past 30 days and to $1.27 in the past seven days. Shares of the company have increased 23.3% in the past year against the industry\u2019s fall of 4.1%. SIBN\u2019s earnings beat estimates in all of the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBonedelivered an earnings surprise of 26.83%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Syneos Health, Inc. (SYNH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-14,111.82,116.01,111.54,115.76,"[""Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport Abbott\u2019s ABT branded generics and international diabetes businesses continue to drive growth for the company. Yet, the business environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold). Shares of Abbott have outperformed the industry over the past year. The stock has lost 5.8% compared with the industry\u2019s 7.3% decline. Abbott is expanding its Diagnostics business foothold (consisting of nearly 30% of the company\u2019s total revenues in the second quarter of 2023). Although, over the past few quarters, there has been a decline in demand for Abbott\u2019s rapid diagnostic tests to detect COVID-19, it is largely being offset by higher growth across other businesses. Particularly, in the United States and Europe, Abbott is experiencing increased demand for routine diagnostic testing. Further, Abbott\u2019s Established Pharmaceuticals Division (EPD) business operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America. The company recently noted that banking on the successful execution of its Branded Generic operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Following the massive setback related to the voluntary recall and production stoppage of certain infant powder formula products manufactured at its facility in Sturgis, MI last year, Abbott\u2019s Nutrition business has started showing signs of recovery since the beginning of 2023. Per the last update on the second-quarterearnings call the company has made good progress in increasing manufacturing production. It has now recovered approximately 75% of the market share in the infant formula business. Adult nutrition is also gaining momentum, backed by the strong global sales performance of Abbott's complete and balanced nutrition brand, Ensure. On the flip side, during the COVID-19 public health emergency, Abbott\u2019s diagnostic tests witnessed stupendous revenue growth backed by increasing demand for testing as well as government-enacted favorable policies to expedite or promote access to healthcare in order to slow down or stop the spread of the virus. However, through the last few months of 2022 and following the official ending of the public health emergency in May, Abbott experienced a continuous decline in COVID testing-related demand. Meanwhile, Abbott, while trying to expand its nutrition business in emerging markets, is facing weakness in Greater China on challenging market dynamics. Especially in pediatric nutrition, the company is apprehensive about the new food safety regulations and a consequent oversupply of products in the market. Accordingly, in December 2022, Abbott initiated steps to exit its pediatric nutrition business in China. The withdrawal of business from the Chinese market, which holds a significant share of Abbott\u2019s pediatric nutrition sales, is going to significantly impact Abbott\u2019s overall Nutrition business in the coming period. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Intuitive Surgical ISRG. Haemonetics sports a Zacks Rank #1 (Strong Buy), while DexCom and Intuitive Surgical carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 tock has risen 23.7% in the past year. Earnings estimates for Haemoneticshave increased from $3.56 to $3.58 for 2023 and from $3.96 to $3.98 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.32%. In the last reported quarter, it posted an earnings surprise of 38.16%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.07 to $1.19 in the past 30 days. Shares of the company have risen 26% in the past year against the industry\u2019s fall of 3.7%. DXCM earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.83%. In the last reported quarter, it posted an earnings surprise of 54.55%. Estimates for Intuitive Surgical\u2019s 2023 earnings per share have increased from $5.47 to $5.56 in the past 30 days. Shares of the company have risen 29% in the past year against the industry\u2019s fall of 3.8%. ISRG\u2019s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 4.19%. In the last reported quarter, Intuitive Surgical delivered an earnings surprise of 7.58%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Retain Quest Diagnostics (DGX) Stock for Now Quest Diagnostics Inc. DGX is well-poised for growth in the coming quarters, backed by stronger base volume trends and growth from acquisitions. In the second quarter of 2023, Quest Diagnostics\u2019 earnings and revenues were well ahead of estimates. The highly specialized Advanced Diagnostics portfolio represents a key pillar for the company to support faster growth across all customer segments. However, COVID-19 testing revenues and a competitive landscape are concerning for DGX. In the past year, this Zacks Rank #3 (Hold) stock has decreased 4.3% compared with the industry\u2019s 11.1% fall and a 4.2% rise of the S&P 500 composite. The renowned provider of diagnostic information services has a market capitalization of $15.15 million. Quest Diagnostics has an earnings yield of 6.44% compared with the industry\u2019s yield of 4.08%. The company\u2019s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 4.92%. Let\u2019s delve deeper. Tailwinds Q1 Performance: Quest Diagnostics exceeded the Zacks Consensus Estimates for both earnings and revenues in the second quarter of 2023. The robust base business performance reflected the company\u2019s ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care. The M&A strategy continues to be a key growth driver for DGX, with the integration of Haystack Oncology remaining well on track. The acquisition positions the company to enter the high-growth area of minimal residual disease or MRD testing. Across the health system business, the Professional Lab Services (\u201cPLS\u201d) business had a very strong quarter, reflecting growth from new and existing PLS relationships. Further, an updated outlook for the full year boosts optimism while operating in a tight labor market. Image Source: Zacks Investment Research The Base Volume Improves: Across Physician Lab Services, a large number of strategic partnerships with health plans involve value-based arrangements, which are leading to faster growth and share gains than traditional relationships. Within Hospital labs, progress in terms of partnerships with Northern Light Health, Lee Health and Tower Health is particularly encouraging in the PLS business, which delivered a strong second quarter. In Consumer Health, the company also recorded strong base business growth on its digital platform \u2014 questhealth.com. The initial uptake of the company\u2019s first-ever consumer-initiated genetic health test, Genetic Insights, is promising. The Strong Potential of Advanced Diagnostics: Within this segment, the QuestAD-Detect Alzheimer's blood test is adding to Neurology\u2019s growth trends, fortifying the company\u2019s position in the rapidly evolving Alzheimer\u2019s landscape. In addition, Quest Diagnostics continues to hold growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services. Downsides COVID-19 Testing Revenues Drop: In the second quarter, the company\u2019s COVID-19 testing revenues declined significantly, leading to lower contributions from Diagnostic Information Services than the prior-year quarter. Further, the year-over-year decline in the top and bottom lines are discouraging. A Competitive Landscape: Quest Diagnostics faces intense competition, primarily from LabCorp, other commercial laboratories and hospitals. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including the accurate and rapid turnaround of testing results. As a result, DGX and other commercial labs compete with hospital-affiliated labs, primarily based on the quality of service. Estimate Trend The Zacks Consensus Estimate for Quest Diagnostics\u2019 2023 earnings per share (EPS) has moved up from $8.69 to $8.70 in the past 30 days. The consensus estimate for the company\u2019s 2023 revenues is pegged at $9.16 billion. This suggests a 7.3% decline from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Penumbra PEN. Haemonetics has an earnings yield of 4.10% against the industry\u2019s -3.18%. Haemonetics\u2019 earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have risen 20.3% against the industry\u2019s 7.3% decline in the past year. HAE sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DexCom, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 42.9% compared with the industry\u2019s 15.9%. Shares of the company have rallied 21% against the industry\u2019s 6% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.83%. Penumbra, sporting a Zacks Rank #1 at present, has an estimated earnings growth rate of 56.6% for 2024, compared with the industry\u2019s 23.8%. Shares of Penumbra have risen 41.7% against the industry\u2019s 6% fall over the past year. PEN\u2019s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 94.24%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-15,115.0,117.25,114.26,114.51,"Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year? Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Caribou Biosciences, Inc. (CRBU) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Caribou Biosciences, Inc. is a member of the Medical sector. This group includes 1114 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Caribou Biosciences, Inc. is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for CRBU's full-year earnings has moved 18.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Our latest available data shows that CRBU has returned about 6.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 1.9% on average. This means that Caribou Biosciences, Inc. is performing better than its sector in terms of year-to-date returns. Another stock in the Medical sector, DexCom (DXCM), has outperformed the sector so far this year. The stock's year-to-date return is 2.2%. Over the past three months, DexCom's consensus EPS estimate for the current year has increased 12.7%. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Caribou Biosciences, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 535 individual companies and currently sits at #98 in the Zacks Industry Rank. On average, stocks in this group have lost 11.7% this year, meaning that CRBU is performing better in terms of year-to-date returns. DexCom, however, belongs to the Medical - Instruments industry. Currently, this 96-stock industry is ranked #104. The industry has moved +0.2% so far this year. Caribou Biosciences, Inc. and DexCom could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Caribou Biosciences, Inc. (CRBU) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-08-16,114.84,115.42,110.99,111.16,"[""Here's Why You Should Invest in Edward Lifesciences (EW) Now Edwards Lifesciences Corporation (EW) is well-poised to grow in the coming quarters due to its robust second-quarter 2023 performance. The increased adoption of the company\u2019s life-saving therapies aided the top line. TMTT (Transcatheter Mitral and Tricuspid Therapies) sales were driven by overall transcatheter edge-to-edge repair procedure growth as well as the ongoing launch and growing adoption of the PASCAL Precision system in Europe and the United States. At the second quarter-end, the company had sufficient liquidity to meet its debt obligations. However, a contraction of margins and operating in a competitive landscape are concerning for the company. In the past year, this Zacks Rank #3 (Hold) stock has decreased 20.5% compared with the 3.2% fall of the industry and a 5.5% rise of the S&P 500 composite. The renowned global medical device company has a market capitalization of $48.96 billion. Edward Lifesciences has an earnings yield of 3.17% compared to the industry\u2019s -7.09%. EW\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 1.62%. Let\u2019s delve deeper. Upsides A Solid Second-Quarter Performance: The company recently posted second-quarter 2023 results, surpassing both earnings and revenue estimates. Across TAVR, sales were aided by improved hospital staffing levels and the continued successful launch of SAPIEN 3Ultra RESILIA. Internationally, sales grew on a constant-currency basis from all regions, including a broad-based adoption of the SAPIEN platform in Europe. The adoption of the company\u2019s premium RESILIA-based products across all regions is encouraging. Critical Care sales growth was led by the Smart Recovery technology portfolio and the strong uptake of the Acumen IQ sensor. Image Source: Zacks Investment Research TMTT Portfolio Holds Potential: The TMTT segment benefitted from continued strong overall procedure volumes, the adoption of the PASCAL Precision platform and the opening of new centers across the United States and Europe. The company continued enrollment in the Class IIF pivotal trial for functional mitral patients. Within Surgical, patient enrollment continued for the MOMENTIS clinical study, which is designed to demonstrate the durability of the RESILIA tissue in the mitral position. In Critical Care, the HemoSphere monitoring platform also remained positive in the second quarter with a healthy pipeline of future opportunities. Strong Solvency and Capital Structure: At the second quarter-end, the company had cash and cash equivalents and short-term investments of $1.51 billion compared with $1.22 billion recorded at the end of the fourth quarter of 2022. The long-term debt was $596.7 million, which remained much lower than the quarter\u2019s cash and cash equivalents and short-term investments level. This suggests a strong solvent position. Downsides Escalated Expenses: The contraction of both margins in the second quarter is discouraging. A year-over-year increase in SG&A expenses reflected performance-based compensations and investments in transcatheter field-based personnel in support of the company\u2019s growth strategy. A Competitive Landscape: The medical device industry is highly competitive with the presence of several competent players. In Heart Valve Therapy, Edwards Lifesciences primarily competes with Medtronic and Sorin Group, whereas players such as ICU Medical, Pulsion Medical Systems AG, LiDCO Group and Becton, Dickinson offer competition across other segments. With CoreValve (especially on the transfemoral side), Medtronic and Boston Scientific are tough competitors for Edwards Lifesciences in the TAVR market. Estimate Trend The Zacks Consensus Estimate for Edwards Lifesciences\u2019 2023 earnings per share (EPS) has remained constant at $2.55 in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $6.01 billion. This suggests an 11.7% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Penumbra PEN. Haemonetics has an earnings yield of 4.10% against the industry\u2019s -3.18%. Haemonetics\u2019 earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have risen 20.3% against the industry\u2019s 7.3% decline in the past year. HAE sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DexCom, carrying a Zacks Rank #2 (Buy) at present, has a long-term estimated earnings growth rate of 42.9% compared with the industry\u2019s 15.9%. Shares of the company have rallied 21% against the industry\u2019s 6% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 28.83%. Penumbra, sporting a Zacks Rank #1 at present, has an estimated earnings growth rate of 56.6% for 2024 compared with the industry\u2019s 23.8%. Shares of Penumbra have risen 41.7% against the industry\u2019s 6% fall over the past year. PEN\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 94.24%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Outperformer Poised to Be the Next Stock-Split Stock, and 2 High-Flying Stocks Unlikely to Split Their Shares Investing on Wall Street comes with its ups and downs. Although 2023 has been a banner year for optimists, this entire decade has been nothing short of a roller-coaster. We've witnessed two bear markets (2020 and 2022) and a seemingly unstoppable bull market that took all three major indexes to new all-time highs less than two years ago. When volatility picks up on Wall Street, investors have a tendency to seek out tried-and-true outperformers. Over the past couple of years, companies enacting stock splits certainly fit the bill. Image source: Getty Images. A stock split is an event where a publicly traded company alters both its share price and share count by the same magnitude, without having any impact on its market cap or operating performance. It's a purely cosmetic change that can make a company's nominal share price more affordable for everyday investors, as with a forward stock split, or can increase its share price to maintain minimum listing standards on a major exchange, as with a reverse stock split. Most investors pay close attention to companies conducting forward stock splits. If a company is reducing its share price, there's a good chance it's a highflier that's outperformed its competition on both an operating and innovative basis. Since July 2021, eight high-profile stocks have conducted stock splits (listed in chronological order): Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022 Shopify (NYSE: SHOP): 10-for-1 split in June 2022 Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023 The $64,000 question is: Which publicly traded companies are next to join this illustrious group of stock-split stocks? At the moment, one high-flying stock stands out as a surefire candidate to become the next stock-split stock. Meanwhile, two other widely owned outperformers, which are seemingly long overdue for a split, have very good reasons to avoid becoming the next stock-split stock. The logical next stock-split stock: Costco Wholesale If there's one publicly traded company that makes for the most-logical stock-split candidate, it's warehouse club Costco Wholesale (NASDAQ: COST). Although Costco has split its shares three times (not including its spin-off of Price Enterprises in 1994) since becoming a public company, it's been 23 years since it last made its shares more nominally affordable for everyday investors. Shares ended at just shy of $563 on Aug. 11, 2023. The reason shares of Costco have powered higher by more than 1,000% (not including dividends paid) since the company's last split in January 2000 has to do with its array of competitive advantages. Over the very long-term, these competitive edges are likely to lift Costco's shares even more. For example, Costco's size and deep pockets allow it to purchase goods in bulk. Typically, the more of a product it buys, the lower the per-unit cost. Costco is able to pass along these cost-savings to its members, especially in grocery aisles. This helps it consistently undercut major grocery chains and local shops on price, which is a big lure to attracting new customers and retaining existing members. Selling low-margin groceries is just one way Costco's operating model thrives. Each of the company's warehouse clubs contains an assortment of discretionary goods that sport substantially higher margins than groceries. If consumers just buy a handful of these discretionary items, Costco's operating margin moves higher. But at the heart of Costco's success is its membership program. Consumers and businesses paying $60 or $120 annually for a membership is a high-margin revenue channel that gives the company even more room to undercut its peers on pricing. Plus, paying for a membership makes it likelier that consumers will choose Costco over other local stores. After all, members are going to want to get the most bang for their $60/$120 annual fee. Costco Wholesale splitting its stock and making shares more nominally affordable would almost certainly ignite interest in a company that's well-known among everyday investors. Highflier No. 1 that has good reason not to be the next stock-split stock: UnitedHealth Group However, a high share price doesn't guarantee that a publicly traded company is going to split its stock. Healthcare company UnitedHealth Group (NYSE: UNH), whose shares closed at $508.01 on Aug. 11, serves as a prime example. Although UnitedHealth Group has split its stock on five previous occasions as a public company, it hasn't done so since the end of May 2005. One factor, in particular, makes it highly unlikely that UnitedHealth's board will seek a split: its inclusion in the Dow Jones Industrial Average (DJINDICES: ^DJI). The Dow Jones is a 127-year-old index comprised of 30 historically profitable, time-tested, multinational businesses. But unlike the other major indexes, the Dow is a share price-weighted index. In other words, the higher a component's share price, the more influence it holds within the Dow Jones Industrial Average. UnitedHealth Group's $508 share price is, by far, the highest in the Dow, which gives it the most sway within the index. The company's board would be wise not to lose this distinction. But just because UnitedHealth Group's stock is unlikely to split, it doesn't mean its share price can't head even higher. Though its health insurance segment is prone to higher payouts from time to time, the company's premium pricing power is actually quite strong. Sustained mid-single-digit growth for UnitedHealth's insurance segment has pretty much become the expectation. What's arguably even more exciting is Optum, the company's considerably faster-growing healthcare services subsidiary. Optum is composed of three segments that handle everything from pharmacy services to the software healthcare institutions rely on. The generally higher operating margin associated with Optum is what has the potential to lift UnitedHealth Group's earnings per share by a double-digit percentage each year. Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool. Highflier No. 2 that has good reason not to be the next stock-split stock: Berkshire Hathaway (Class A) The other high-flying stock that's virtually guaranteed not to split, even though it's seemingly decades overdue for one, is conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), the company run by billionaire CEO Warren Buffett. Specifically, I'm talking about the Class A shares (BRK.A), which have never split and would set an investor back a cool $542,900, as of Aug. 11. As long as Warren Buffett is running Berkshire Hathaway, it's a virtual certainty that the Class A shares won't be split. We know this, because the Oracle of Omaha plainly told investors so during the company's 1995 annual shareholder meeting. For context, this is the same year that Berkshire announced its intent to create its Class B shares. Despite Buffett referring to Berkshire's Class A share price as \""awkward to disadvantageous\"" in 1995, he also noted that if a stock split were performed \""we are almost certain we would get a shareholder base that would not have the level of sophistication and the synchronization of objectives with us that we have now.\"" The Oracle of Omaha also opined that Berkshire's Class A share price and the company's intrinsic value would be out of sorts if a split were introduced, \""because then people would think about other possibilities that might give the stock a temporary boost.\"" Even though stock splits are off the table at Berkshire Hathaway, it hasn't stopped Berkshire's Class A shares from gaining close to 4,400,000%, in aggregate, since Warren Buffett became CEO. Buffett's love of dividend stocks, cyclical businesses, and his penchant for portfolio concentration, have all played key roles. In particular, dividend stocks have a knack for handily outpacing the returns of non-paying companies over multidecade periods. In 2023, Berkshire Hathaway is set to collect north of $6 billion in dividend income. Likewise, packing the company's investment portfolio with cyclical stocks allows Buffett and his investing team to take advantage of long-winded economic expansions and bull markets. Even though bear markets are an inevitable part of the investing cycle, the typical bull market has lasted 3.5 times longer than the average bear market, since September 1929. 10 stocks we like better than Costco Wholesale When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Costco Wholesale wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 1, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Berkshire Hathaway, Costco Wholesale, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom and UnitedHealth Group. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-17,111.1,111.5,107.625,107.81,"[""A Bull Market Is Coming: 2 Beaten-Down Stocks to Buy and Hold After last year's downturn, investors are finally witnessing a solid performance by equity markets. The S&P 500 has technically been in a bull market since June 8, when it closed 20% up from its most recent low. And given that bull runs last for an average of 2.6 years (according to some research), this could only be the beginning. There are plenty of excellent stocks to consider buying to ride this upward wave. Let's consider two solid candidates: Teladoc (NYSE: TDOC) and Tandem Diabetes Care (NASDAQ: TNDM). These stocks remain down over the trailing-12-month period, but here is why they could move in the opposite direction in the long run. 1. Teladoc Slowing revenue growth and worsening net losses are a bad combination for any company. That's what Teladoc dealt with last year, but the company has improved, at least somewhat, on one of those fronts in 2023. Teladoc is recording much better bottom lines than in 2022, although it remains unprofitable. TDOC Net Income (Quarterly) data by YCharts. To deliver stronger performances on the stock market, Teladoc will have to improve on both the top and bottom lines, and there are good reasons to believe it has what it takes. First, some general considerations about the telemedicine market. Telehealth visits with a licensed medical professional can often serve the same purpose as in-person visits. But the former are much more convenient for patients and physicians and likely result in lower costs for both. For doctors, receiving patients in an office carries more overhead costs than doing it virtually, while patients can save on trip-related expenses. So, expect telemedicine to grow as health systems shift some medical care to virtual channels. Teladoc's revenue growth should benefit; it has built a solid brand name and arguably benefits from the network effect. That is to say, the value of its platform increases with use. Patients will seek out telemedicine networks with the highest number of physicians, specialties, etc., and the more patients join a platform, the more it becomes attractive to medical professionals. Teladoc ended the second quarter with 85.9 million U.S. integrated care members (where it connects patients with a range of health professionals, from general practitioners to specialists). That was an increase of 7% year over year. That's in addition to the company's mental health unit, BetterHelp, which had 476,000 members in the second quarter, 17% higher than the year-ago period. And Teladoc's chronic care unit (for chronic illnesses) had about 1.1 million members, a 7% year-over-year jump. Teladoc has plenty of room to grow across all three segments, especially in mental health, an area with a dire need following the pandemic-induced increase in depression and anxiety. BetterHelp charges lower fees than traditional on-site therapy, so it is helping make it more accessible. On the bottom line, Teladoc isn't that far off from breaking even. The company's margins have grown over time and currently sit above 70%. The company has been trimming its workforce to cut costs. But Teladoc's highest expenses tend to come from marketing and advertising, which should decrease as it becomes better established. That's why profitability isn't that far off for the company. And although its shares remain down, patient investors who get in now should be rewarded down the road. 2. Tandem Diabetes Care Tandem Diabetes Care develops and markets innovative insulin pumps. It makes most of its money from its t:slim X2 pump, a device with plenty of perks. It is small and discreet, user-friendly (it can be updated remotely and charged with a run-of-the-mill micro USB charger), and convenient when paired with a continuous glucose monitoring device such as DexCom's G6 to automate insulin delivery and eliminate the use of painful fingersticks. Tandem's crown jewel has shown some success, although the company's growth rate is also declining. In the second quarter, Tandem Diabetes Care's revenue of $195.9 million dropped by about 2.2% year over year. The company's pump shipment of 29,500 was lower than the 32,000 thousand reported in the year-ago period. It ended the quarter with an installed base of 437,000 patients, 16% higher than the prior-year quarter. Challenging economic conditions, including inflation, have affected the company's business, and that's what we are seeing unravel as its top line and pump shipment decline. But Tandem Diabetes Care still has a long runway for growth. Diabetes is a worsening problem. The company estimates that there are about 8.1 million eligible patients for its pumps where it does business, most of whom have yet to make the switch from painful multiple daily injections. Further, as its installed base expands, it will make more money from selling accessories that accompany its pump (such as cartridges) and pump renewals. Tandem estimates a renewal cycle of five years. The company's revenue growth should bounce back with these opportunities as the economy improves and as it launches its newest device, the Tandem Mobi Insulin Pump. The U.S. Food and Drug Administration recently cleared it, and it is the \""world's smallest durable insulin delivery system,\"" according to the company. Tandem's newest device will help decrease its expenses, as it estimates that the Mobi is 10% to 15% cheaper to manufacture, while its cartridges cost 20% less to make than that of the t:slim X2 pump. The company expects its gross margins to rise to 65% as the Tandem Mobi gains traction. TNDM Gross Profit Margin data by YCharts. These developments should work wonders for Tandem Diabetes Care's revenue and earnings over the medium term, and even as it remains unprofitable, it looks like a stock worth buying and keeping for a while. 10 stocks we like better than Teladoc Health When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 14, 2023 Prosper Junior Bakiny has positions in Teladoc Health. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cohen\u2019s Point72 Cuts Broadcom, Meta, Google to Push Into Microsoft, NVIDIA and Micron Hedge fund Point72 Asset Management recently unveiled its trading report for the June quarter. Its value stood at $33.63 billion at quarter\u2019s close, showing 4.15% growth during the second quarter of 2023, up from $32.29 billion in March. Steven Cohen, renowned for his keen investment insights and iconic presence on Wall Street, has built a financial colossus that commands respect from even the most seasoned players in finance. His balanced blend of caution and audacity has steered Point72 through the tumultuous tides of the market, establishing the Stamford, Connecticut-based fund as a symbol of financial triumph. However, for Cohen, it's more than just about impressive numbers; it's the pursuit of a philosophy that goes beyond conventional wisdom. He's shaped Point72 into a hub for innovative thinking, fostering an environment of insatiable curiosity and a team that dares to challenge the norm. Innovating, Adapting Cohen once remarked, \u201cMy belief is if you\u2019re not innovating and not adapting, then you\u2019re dying.\u201d During the recent quarter, the number of holdings managed by the fund saw a dip of 3.7%, going from 2,187 at the quarter's start to 2,105 disclosed positions, encompassing shares, bonds, exchange-traded funds, and more. The chart below illustrates the fund's value trajectory over the last 10 years. The fund's reported market value is currently at all-time highs despite choppy and volatile equity markets. The top five positions in the fund by portfolio weight are: Put options on the SPDR S&P 500 ETF (US:SPY), at a 3.35% weighting; NVIDIA Corp (US:NVDA), at 2.07%; Microsoft Corporation (US:MSFT), 1.85%; Amazon.com (US:AMZN), 1.18%; and, Adobe (US:ADBE), 1.10%. Along with the fund\u2019s next 95 largest holdings, the heat map below provides a snapshot of the broader portfolio and the relative weight of each position. What Steve Cohen\u2019s Team Bought Cohen\u2019s Point 72 revealed its notable positions for the most recent quarter, with buys in sectors ranging from tech to healthcare and logistics, highlighting the fund\u2019s management team\u2019s dynamic investment strategy. Microsoft stood out as a significant play with the fund capitalizing on the tech giant's consistent growth. The position in MSFT stock reached a market value of $620.79 million by quarter's end. This translated to a 1.85% portfolio weight, an impressive jump of 1.45% during the quarter as Cohen rotated out of other FAANG players. NVIDIA, another leader in the tech sector, saw its position in Point 72's holdings grow to a value of $695.03 million. NVDA stock occupied 2.07% of the portfolio, marking an allocation growth of 1.22%. The position was aided by a 50% rise in the share price after NVDA made its single-largest earnings expansion in its history during the quarter, helping the chip maker reach the $1 trillion market cap level. An intriguing put position was initiated in UnitedHealth Group (US:UNH), worth $211.34 million at the quarter's close. This strategic move represents 0.63% of the portfolio, with a significant bet on a stock that has traded broadly sideways since the beginning of 2022. Point 72 took a fresh interest in Micron Technology (US:MU), allocating a new position that grew to $178.29 million or 0.53% of the portfolio, suggesting bullish sentiment in the memory chip industry. A newly initiated position in Union Pacific (US:UNP) was also evident as the holdings swelled to $172.76 million, accounting for 0.52% of the fund's allocation. In the creative software realm, the fund\u2019s position in Adobe was expanded to $370.11 million. ADBE stock claimed 1.10% of the portfolio, with an allocation growth of 0.50%. The stock has continued its rally post close of the quarter. Other new notable positions in the fund during the quarter with; Cigna Group (US:CI) with a $167.27 million position, biotech sector stock Immunogen (US:IMGN) seeing a new investment worth $164.4 million, energy sector stock Southern Company (US:SO) with a $158.81 million position and logistics heavyweight Fedex (US:FDX) worth $158.38 million by quarter's end. What Steve Cohen\u2019s Team Sold Atop the list of Point 72 sale transactions is Broadcom (US:AVGO). At quarter\u2019s end, the AVGO stock position stood at a value of $56.36 million, reflecting 0.17% of the fund's total allocation, down from 1.24% from the previous quarter. A striking reduction was seen in Alphabet (US:GOOGL), with its value plummeting to a mere $0.91 million. Representing less than 0.01% of the portfolio, this position could well likely disappear. The fund's put position in SPDR S&P 500 ETF Trust (US:SPY) stood at a colossal $1,13 billion. Even with its sizable value, the position saw an allocation decline of 0.93%, ending at 3.35% of the portfolio, hinting at a bearish outlook on the broader market. Despite its rebranding and dynamic market moves, Meta Platforms (US:META) faced a reduction in the fund's allocation, closing at $240.32 million or 0.71% of the portfolio, marking a decline of 0.91% during the quarter. Intel (US:INTC), a key player in the semiconductor space, saw its position at Point 72 reduced to $59.86 million, reflecting 0.18% of the total portfolio and a decline of 0.89%. Arista Networks (US:ANET) witnessed a contraction in its allocation, ending the quarter with a value of $88.91 million or 0.26% of the portfolio, marking a decrease of 0.85%. Salesforce (US:CRM), despite being a cloud computing heavyweight, saw its portfolio presence dwindle to a mere $0.67 million, accounting for only 0.002% of the portfolio by the quarter's end. Retail titan Walmart (US:WMT) saw its position value stand at $179.15 million by the quarter's end, translating to 0.53% of the portfolio. The allocation shrank by 0.75%, suggesting a cautious approach towards the retail sector. The ADRs of Alibaba Group (US:BABA), grappling with regulatory pressures, saw its position in the fund reduce to $80.13 million or 0.24% of the portfolio, marking a decline of 0.60% in fund allocation. In the healthcare tech segment, Dexcom (US:DXCM), a pioneer in continuous glucose monitoring, ended the quarter with a miniscule position of $2.69 million, translating to 0.008% of the portfolio, falling from an 0.5% weight at the beginning of the quarter. How Steve Cohen\u2019s \u2018Other\u2019 Team is Doing We would be remiss if we didn\u2019t mention the Point 72 chief\u2019s other team, the New York Mets. Perhaps New York Post columnist Mike Vaccaro summed it up best in his Aug. 16 piece: \u201cOne more time, we are reminded that meaningless games are never entirely meaningless to everyone, even in a Mets season that has felt lost since Memorial Day or so, and unrelentingly meaningless since Aug. 1,\u201d read the article\u2019s lede paragraph. That\u2019s with a team on which Cohen splurged $806 million in last winter\u2019s free-agent player transactions. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-18,107.41,107.79,105.75,106.05,
DXCM,2023-08-21,106.0,106.5,104.45,104.68,"[""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Best Stocks to Buy Now, 8/21/2023, According to Top Analysts Which stocks are best to buy now? According to top Wall Street analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating today and has a significant upside as well. To find more stocks like these, take a look at TipRanks\u2019 Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by top-ranking analysts. Here are today\u2019s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. Palo Alto Networks (NASDAQ:PANW) \u2013 Palo Alto Networks offers an enterprise cybersecurity platform. Today, Barclays analyst Saket Kalia maintained a Buy rating on the stock with a price target of $275. 19 out of the 20 top analysts who recently rated the stock gave it a Buy. Collectively, their 12-month price targets imply an upside of nearly 27%. Dexcom (NASDAQ:DXCM) \u2013 Dexcom makes continuous glucose monitoring (CGM) systems. Today, Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on the stock with a price target of $130. 12 out of the 13 top analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of nearly 44%. Advanced Drainage Systems (NYSE:WMS) \u2013 Advanced Drainage Systems manufactures water drainage structures and supplies. Today, KeyBanc analyst Jeffrey Hammond reaffirmed a Buy rating on the stock with a price target of $160. WMS stock has received Buy ratings from six out of the seven top analysts who have recently rated it. Overall, the consensus 12-month price target suggests an increase of about 22%. Sponsored Links Look For Any High School Yearbook, It's Free Classmates Who are the Top Analysts? TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. See real-time analyst rankings and learn more about the performance of top analysts on TipRanks\u2019 Top Wall Street Analysts page. Disclosure The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stock-Split Stocks Billionaires Are Selling and the 1 Surprising Stock-Split Stock They're Piling Into There are a lot of ways to make money on Wall Street. Over the past couple of years, gravitating to stocks enacting splits has been one of the more profitable strategies. A stock split is an event that allows a publicly traded company to change its share price and outstanding share count (by the same magnitude) without having any impact on its market cap or operating performance. It's a cosmetic move that can make shares more nominally affordable for everyday investors, as with a forward stock split, or can increase a company's share price to avoid delisting from a major exchange, as with a reverse stock split. Image source: Getty Images. Since July 2021, investors have flocked to eight prominent, profitable, and time-tested businesses that have conducted forward stock splits. Listed in the chronological order of when they conducted their respective splits, these companies are: Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022 Shopify (NYSE: SHOP): 10-for-1 split in June 2022 Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023 The success of these stock-split stocks isn't lost on Wall Street's most-successful money managers, either. Based on the latest round of 13F filings with the Securities and Exchange Commission, billionaire investors were actively moving their money into or out of some very widely owned stock-split stocks. Stock-split stock No. 1 billionaires were busy selling in the second quarter: Amazon The stock-split stock that saw what can be described as the most-aggressive selling from billionaire fund managers during the second quarter is e-commerce company Amazon. Eight prominent billionaires were big-time sellers, including: Jim Simons at Renaissance Technologies (8,999,016 shares sold) Chase Coleman at Tiger Global Management (5,989,891 shares) Ole Andreas Halvorsen at Viking Global Investors (3,226,907 shares) Stephen Mandel at Lone Pine Capital (1,709,767 shares) John Overdeck and David Siegel at Two Sigma Investments (1,443,520 shares) Israel Englander at Millennium Management (1,159,561 shares) Steven Cohen at Point72 Asset Management (994,294 shares) This selling pressure probably has to do with Amazon being cyclical, as well as the company's lofty valuation, based on traditional fundamental metrics. Amazon generates a majority of its sales from its world-leading online marketplace. With economic uncertainty taking center stage throughout much of 2023, the expectation would be for weaker consumer spending in the months and quarters to come. Meanwhile, Amazon's stock is commanding a price-to-earnings (P/E) ratio of 61, based on Wall Street's earnings consensus for this year. That's well over double the P/E of the benchmark S&P 500. However, valuing Amazon based on traditional metrics has never been a smart move. Since the company reinvests so much of its cash flow back into the business, operating cash flow is a far better valuation measurement for Amazon. After trading at 23 to 37 times year-end cash flow between 2010 and 2019, Amazon can be purchased for 15 times forecast cash flow for this year and about 9 times estimated cash flow in 2026. In other words, Amazon is, arguably, cheaper than it's ever been as a publicly traded company. Stock-split stock No. 2 billionaires were busy selling in the second quarter: Alphabet A second stock-split stock billionaire money managers ran away from during the June-ended quarter is Alphabet, the parent company of internet search engine Google and the second most-popular social media site globally, YouTube. The three highly successful billionaires that meaningfully reduced their exposure to Alphabet's Class A shares (GOOGL) include: Chase Coleman of Tiger Global Management (4,551,949 shares sold) Dan Loeb of Third Point (3,325,000 shares) Steven Cohen of Point72 Asset Management (3,299,177 shares) The likeliest reason for this selling is the expectation of economic weakness. Even though the U.S. economy has proved more resilient than anticipated, multiple datapoints and predictive indicators suggest weakness to come. Since Alphabet is reliant on advertising for a significant percentage of its revenue, and advertisers tend to pare back their spending at the first signs of trouble, billionaires may have been playing it safe by paring down their exposure. Ultimately, I believe this is a move Coleman, Loeb, and Cohen will regret. Though ad spending is cyclical, Google is a practical monopoly in the internet search space. Based on data from GlobalStats, Google held a 92.1% share of the global internet search market in July 2023, and hasn't accounted for less than 90% of worldwide search share since March 2015. Further, Alphabet's fast-growing ancillary segments are really coming into their own. YouTube Shorts (short-form videos usually lasting less than a minute) have grown from 6.5 billion daily views to north of 50 billion over the past two years. Meanwhile, Google Cloud has become the world's No. 3 cloud infrastructure service provider, and has delivered back-to-back quarters of operating income. Thanks to its fast-growing ancillary divisions, Alphabet looks to be on the verge of a big uptick in operating cash flow. Stock-split stock No. 3 billionaires were busy selling in the second quarter: Tesla The third stock-split stock that saw significant cash outflows from billionaires during the June-ended quarter is electric-vehicle (EV) manufacturer Tesla. The three top-notch billionaires that were busy selling Tesla shares include: Israel Englander at Millennium Management (2,457,514 shares sold) Jim Simons at Renaissance Technologies (1,933,244 shares) Jeff Yass at Susquehanna International (759,457 shares) Unlike Amazon and Alphabet, there are a couple of very clear catalysts that likely precipitated this selling. For starters, Tesla has reduced the sales price of its EV lineup on at least a half-dozen occasions this year. During Tesla's first-quarter conference call, CEO Elon Musk addressed the company's pricing strategy and noted that it had everything to do with EV demand. If Musk's company is reducing prices by a double-digit percentage, it reflects weaker demand, growing competition, and weaker automotive gross margins to come. Billionaire investors may also be growing tired of the theatrics that come with having Elon Musk as CEO. While there's little denying that he's an innovator, Musk has a habit of attracting negative attention from regulators. He's made numerous promises that haven't been kept, as well. For instance, his claim that fully autonomous Tesla vehicles are \""one year away\"" has been made for the past decade. Lastly, Tesla's valuation could be a prime reason for billionaires to sell. Despite the company's other revenue channels (e.g., supercharger network, energy storage, and services), it's overwhelmingly reliant on selling and leasing EVs to generate a profit. Most auto stocks trade at high-single-digit P/E ratios. Comparatively, Tesla is commanding a P/E of 66, based on Wall Street's consensus for 2023, which doesn't look sustainable. Image source: Getty Images. The stock-split stock billionaires absolutely piled into during the second quarter: Nvidia On the other side of the aisle is the one stock-split stock billionaire money managers absolutely piled into during the June-ended quarter: Nvidia. The manufacturer of graphics processing units (GPUs) had 11 (yes, 11!) prominent billionaires buy shares, including: Jeff Yass of Susquehanna International (5,401,204 shares purchased) Jim Simons of Renaissance Technologies (1,852,712 shares) Israel Englander of Millennium Management (1,023,518 shares) David Tepper of Appaloosa Management (870,000 shares) Steven Cohen of Point72 Asset Management (662,385 shares) Stephen Mandel of Lone Pine Capital (641,649 shares) John Overdeck and David Siegel of Two Sigma Investment (629,072 shares) Chase Coleman of Tiger Global Management (584,700 shares) Dan Loeb of Third Point (500,000 shares) Ole Andreas Halvorsen of Viking Global Investors (312,400 shares) The catalyst behind this aggressive collection of billionaire buys is undeniably artificial intelligence (AI). AI involves using software and systems to handle tasks that would normally be assigned to humans. Based on a report issued earlier this year by PwC, AI is estimated to add $15.7 trillion to the global economy by 2030, with its impact being most-pronounced in China and North America. The reason these 11 billionaires chose Nvidia is simple: Nvidia accounts for the lion's share AI-driven GPUs found in high-compute data centers. With businesses not wanting to be left behind as Wall Street's next big trend takes shape, Nvidia is seeing otherworldly demand for its A100 and H100 AI GPUs. But not everything is perfect for this Wall Street darling. For instance, U.S. officials are considering additional curbs on what AI-driven GPU's Nvidia can export to China. The world's No. 2 economy generates a sizable amount of annual revenue for Nvidia. The other potential issue for Nvidia is its valuation. Although the ramp-up in its growth rate from AI has been jaw-dropping, so is the company's multiple relative to its cash flow -- 226 times trailing-12-month cash flow. An argument can be made that Nvidia has never been pricier, which may limit its upside moving forward. 10 stocks we like better than Amazon.com When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 14, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-22,104.38,107.46,104.14,106.98,"[""Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar? Launched on 07/17/2001, the iShares Russell Mid-Cap Growth ETF (IWP) is a passively managed exchange traded fund designed to provide a broad exposure to the Mid Cap Growth segment of the US equity market. The fund is sponsored by Blackrock. It has amassed assets over $12.64 billion, making it the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. These types of companies, then, have a good balance of stability and growth potential. Growth stocks have higher than average sales and earnings growth rates. While these are expected to grow faster than the broader market, they also have higher valuations. Further, growth stocks have a higher level of volatility associated with them. Compared to value stocks, growth stocks are a safer bet in a strong bull market, but don't perform as strongly in almost all other financial environments. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.23%, putting it on par with most peer products in the space. It has a 12-month trailing dividend yield of 0.69%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 22.40% of the portfolio. Healthcare and Industrials round out the top three. Looking at individual holdings, Dexcom Inc (DXCM) accounts for about 1.67% of total assets, followed by Idexx Laboratories Inc (IDXX) and Apollo Global Management Inc (APO). The top 10 holdings account for about 8.32% of total assets under management. Performance and Risk IWP seeks to match the performance of the Russell MidCap Growth Index before fees and expenses. The Russell Midcap Growth Index measures the performance of the mid-capitalization growth sector of the U.S. equity market. It is a subset of the Russell Midcap Index, which measures the performance of the mid-capitalization sector of the U.S. equity market & approximately 47% of the total market value of the Russell Midcap Index. The ETF has added roughly 11.57% so far this year and was up about 2.43% in the last one year (as of 08/22/2023). In the past 52-week period, it has traded between $77.40 and $100.32. The ETF has a beta of 1.10 and standard deviation of 24.28% for the trailing three-year period, making it a medium risk choice in the space. With about 340 holdings, it effectively diversifies company-specific risk. Alternatives IShares Russell Mid-Cap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IWP is an outstanding option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the Vanguard Mid-Cap Growth ETF (VOT) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.85 billion in assets, Vanguard Mid-Cap Growth ETF has $10.62 billion. IJK has an expense ratio of 0.17% and VOT charges 0.07%. Bottom-Line Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Apollo Global Management Inc. (APO) : Free Stock Analysis Report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Revolutionary Stocks I'd Buy Right Now Without Hesitation The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized returns over long periods (which describes most investors) would do well to consider shares of innovative companies such as CRISPR Therapeutics (NASDAQ: CRSP), Sarepta Therapeutics (NASDAQ: SRPT), and DexCom (NASDAQ: DXCM). Let's find out why these three revolutionary stocks are worth buying. 1. CRISPR Therapeutics Gene-editing specialist CRISPR Therapeutics currently has no products on the market. But the company's candidates all use the CRISPR (hence its name) gene-editing technique that earned the researchers who pioneered it a Nobel Prize for their trouble. So far, this groundbreaking technology hasn't led to any approvals. However, the U.S. Food and Drug Administration (FDA) and its counterpart agency in Europe are currently considering exa-cel for approval in treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). These two rare blood diseases have proved difficult to treat. But exa-cel, discovered by CRISPR Therapeutics and developed in collaboration with Vertex Pharmaceuticals, represents significant progress in these areas -- it could be a one-time curative option for both. If it earns approval, CRISPR Therapeutics' stock should rise, literally and figuratively, given the addressable market at exa-cel's disposal. The first U.S. approval could land by Dec. 8. Being a clinical-stage biotech, CRISPR Therapeutics doesn't generate much revenue. It also isn't profitable. But at this stage, investors shouldn't focus on that. Having proven its innovative capabilities with exa-cel, the company should generate enough money from this success to make solid headway with the more than half a dozen products in its pipeline, still using the Nobel Prize-winning technique that helped it develop exa-cel. CRISPR Therapeutics qualifies as a revolutionary stock and could deliver excellent returns to patient investors. 2. Sarepta Therapeutics Sarepta Therapeutics is a biotech company focusing much of its effort on targeting just one illness: Duchenne muscular dystrophy (DMD), a progressive genetic disease accompanied by symptoms such as muscle degeneration. Treatments have been hard to come by, but Sarepta has produced four of them. It earned its latest FDA approval in June for arguably its most important product yet. Called Elevidys, it is the first gene therapy for DMD approved by the agency. While Sarepta's other products help manage symptoms of DMD, Elevidys treats the underlying cause of the disease at the genetic level. Sarepta developed it in collaboration with Roche, and the two companies expect peak annual sales of $4 billion for Elevidys. Sarepta Therapeutics is already delivering solid top-line growth. In the second quarter, the company's revenue was $261.2 million, almost 12% higher than the prior-year quarter. The biotech does remain unprofitable, although it's improving on that front. Its second-quarter net loss per share of $0.27 was much better than the $2.65 reported in the year-ago period. With a new source of revenue under its belt, things should continue to improve. Sarepta Therapeutics has more DMD products in development and is targeting other rare diseases. The company has more than 40 programs in its pipeline. The focus on DMD alone could be highly lucrative -- Vertex Pharmaceuticals has found incredible success in becoming the leader in the cystic fibrosis market. Whether within DMD or beyond it, though, Sarepta Therapeutics' ability to generate new groundbreaking therapies is an excellent sign for investors. 3. DexCom DexCom is a leader in the market for continuous glucose monitors (CGMs). This technology offers diabetecs a better way to perform the crucial task of keeping track of their blood-sugar levels. Blood glucose meters (BGMs) have been the most popular options but are limited. BGMs are manual devices that use painful finger sticks and can only read blood glucose levels at a specific time. CGMs are automatic, work constantly, and do away with the need for finger sticks. DexCom has been one of the pioneers of CGM technology -- and results have been moving in the right direction. For the second quarter, revenue came in at $871.3 million, 25% higher than in the prior-year period, and adjusted net income doubled to $0.34 per share. Although it has been progressing in the CGM market for a while, DexCom still has plenty of room for more growth. Armed with two new devices -- the G7, the latest in its flagship G series of CGM options, and the DexCom One -- the company plans to continue making headway in countries where CGM penetration is low, which is almost everywhere. DexCom has been expanding its reach internationally and recently entered Latin America -- specifically Argentina -- for the first time. Diabetes is a global health crisis affecting some 422 million people. While DexCom doesn't do business all over the world, it ended 2022 with an installed base of just 1.7 million. There should be millions more who are ready to make the switch to CGM -- and DexCom will be one of the primary companies positioned to help them. 10 stocks we like better than CRISPR Therapeutics When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and CRISPR Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 14, 2023 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool recommends DexCom and Roche. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-23,107.15,107.68,103.99,104.38,
DXCM,2023-08-24,104.99,105.01,100.78,100.98,
DXCM,2023-08-25,100.92,102.11,99.015,100.76,
DXCM,2023-08-28,102.07,103.29,98.75,99.29,"1 Stock-Split Stock Billionaires Are Buying Hand Over Fist and 1 Unexpected Stock-Split Stock They're Selling If you want to make money investing in the stock market, there's an endless array of popular strategies. Scooping up stocks before they split their shares is one strategy that's worked out well in recent years. From time to time, shares of successful companies rise so high that everyday investors begin to shun them for no other reason than their high share price. Stock splits allow companies to lower their stock prices to levels within reach of everyday investors by turning one share into 10, for example. Image source: Getty Images. In theory, multiplying the number of outstanding shares by a specific amount should lower the price by an equal magnitude In practice, though, the extra attention that surrounds stock splits tends to drive their prices higher. A little over two years ago, investors began flocking to Nvidia (NASDAQ: NVDA) after it enacted a 4-for-1 split. Since then, at least a dozen successful companies saw their prices soar after joining the stock-split party, including: Intuitive Surgical (NASDAQ: ISRG): a 3-for-1 split announced in August 2021 Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL): a 20-for-1 split announced in February 2022. Amazon (NASDAQ: AMZN): a 20-for-1 split announced in March 2022. Dexcom (NASDAQ: DXCM): a 4-for-1 split announced in March 2022. Shopify (NYSE: SHOP): a 10-for-1 split announced in April 2022. Palo Alto Networks (NASDAQ: PANW): a 3-for-1 split in August 2022. Some of the most successful money managers Wall Street's ever known are paying attention to these stock-split stocks, too. With the latest round of disclosures institutional investors are required to make each quarter, we know which ones billionaires are buying hand over fist. We can also see what they're selling, and you might be surprised. Nvidia is a stock-split stock billionaires are buying with both hands During the three months that ended June 30, billionaire money managers were tripping over each other on their way to buy shares of Nvidia. Jeff Yass and Susquehanna International, the fund he manages, bought more than 5.4 million shares of the graphics processing unit (GPU) designer. James Simons of Renaissance Technologies acquired 1.9 million shares. John Overdeck and David Siegel of Two Sigma Advisers bought 1.6 million shares. Israel Englander of Millennium Management added more than 1 million shares, raising the company's holdings in the GPU designer past $1 billion. David Tepper and Appaloosa added 870,000 Nvidia shares to its portfolio. Artificial intelligence (AI) means different things to different people. In the end, though, AI applications generally need GPUs to function. Nvidia sells the vast majority of GPUs used to power AI applications, and the recent proliferation of services such as ChatGPT has translated into soaring sales and profits for its investors. In the second quarter, Nvidia reported data center sales that soared 171% year over year to $10.3 billion. As the leading producer of GPUs that power AI applications, Nvidia has a lot of pricing power, and this advantage shows on its bottom line. The company earned $8.2 billion in the first half of 2023, a 262% gain over the previous-year period. Shares of Nvidia are currently trading at around 42.5 times Wall Street's forward-looking earnings estimate. A multiple this high would be difficult for almost any stock to overcome, but Nvidia's pricing power is probably strong enough that investors buying at recent prices could realize market-beating gains over the long run. Stock-split stock that billionaires sold heavily in the second quarter: Dexcom One stock-split stock that saw aggressive selling from billionaire fund managers in the second quarter was Dexcom, the manufacturer of continuous blood-glucose monitors. A slew of prominent billionaires dumped the stock in the second quarter, including: Ken Griffin at Citadel Advisors (sold 3,780,330 shares). Steven Cohen at Point72 Asset Management (sold 1,541,082 shares). Israel Englander at Millennium Management (sold 771,329 shares). John Overdeck and David Siegel at Two Sigma Investments (sold 196,180 shares). Dexcom's next-generation CGM, the G7, earned FDA approval last December. Strong uptake of the new device in the U.S. and abroad is driving growth. Second-quarter sales surged 25% year over year, and plenty of revenue is filtering down to the bottom line. According to generally accepted accounting principles (GAAP), operating income during the second quarter came in at $128.1 million, or 14.7% of revenue. Sales of Dexcom's G7 device are pushing its needle forward, but Abbott Laboratories had a long head start in the U.S. market with FreeStyle Libre 3, a CGM the size of two stacked pennies, significantly smaller than Dexcom's G7 device. Despite the challenge Abbott's CGM presents, Dexcom is trading for the lofty multiple of 82.7 times forward earnings estimates. While its business is likely to continue growing at a healthy pace, expecting it to maintain a pace that justifies such a lofty valuation seems unreasonable given the competition. If I were holding this stock, I'd continue to do so. However, I wouldn't criticize anyone for following the lead of billionaires who recently trimmed their richly valued positions. 10 stocks we like better than Nvidia When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Nvidia wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 21, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon.com and Shopify. The Motley Fool has positions in and recommends Abbott Laboratories, Alphabet, Amazon.com, Intuitive Surgical, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-08-29,99.3,101.65,98.02,100.58,"Nasdaq 100 Movers: PCAR, PDD In early trading on Tuesday, shares of PDD Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 17.4%. Year to date, PDD Holdings registers a 16.3% gain. And the worst performing Nasdaq 100 component thus far on the day is PACCAR, trading down 4.2%. PACCAR is showing a gain of 23.6% looking at the year to date performance. Two other components making moves today are DexCom, trading down 1.1%, and MercadoLibre, trading up 3.7% on the day. VIDEO: Nasdaq 100 Movers: PCAR, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-08-30,101.03,106.95,100.75,103.42,"[""Notable Wednesday Option Activity: VTLE, NKE, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vital Energy, Inc (Symbol: VTLE), where a total of 2,543 contracts have traded so far, representing approximately 254,300 underlying shares. That amounts to about 44.5% of VTLE's average daily trading volume over the past month of 571,050 shares. Especially high volume was seen for the $40 strike put option expiring October 20, 2023, with 1,040 contracts trading so far today, representing approximately 104,000 underlying shares of VTLE. Below is a chart showing VTLE's trailing twelve month trading history, with the $40 strike highlighted in orange: Nike (Symbol: NKE) saw options trading volume of 30,881 contracts, representing approximately 3.1 million underlying shares or approximately 43.2% of NKE's average daily trading volume over the past month, of 7.2 million shares. Especially high volume was seen for the $111 strike call option expiring September 22, 2023, with 2,001 contracts trading so far today, representing approximately 200,100 underlying shares of NKE. Below is a chart showing NKE's trailing twelve month trading history, with the $111 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 16,588 contracts thus far today. That number of contracts represents approximately 1.7 million underlying shares, working out to a sizeable 43.1% of DXCM's average daily trading volume over the past month, of 3.8 million shares. Especially high volume was seen for the $105 strike call option expiring September 15, 2023, with 3,784 contracts trading so far today, representing approximately 378,400 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $105 strike highlighted in orange: For the various different available expirations for VTLE options, NKE options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Earnings History \u0095 Institutional Holders of SWIR \u0095 Funds Holding CNDO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: HPQ, PODD In early trading on Wednesday, shares of Insulet topped the list of the day's best performing components of the S&P 500 index, trading up 6.9%. Year to date, Insulet has lost about 31.2% of its value. And the worst performing S&P 500 component thus far on the day is HPQ, trading down 10.2%. HPQ is showing a gain of 4.9% looking at the year to date performance. Two other components making moves today are Brown-Formam, trading down 4.1%, and DexCom, trading up 3.1% on the day. VIDEO: S&P 500 Movers: HPQ, PODD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is Trending Stock DexCom, Inc. (DXCM) a Buy Now? DexCom (DXCM) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this medical device company have returned -17.6% over the past month versus the Zacks S&P 500 composite's -1.7% change. The Zacks Medical - Instruments industry, to which DexCom belongs, has lost 6% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Revisions to Earnings Estimates Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, DexCom is expected to post earnings of $0.34 per share, indicating a change of +21.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.3% over the last 30 days. The consensus earnings estimate of $1.23 for the current fiscal year indicates a year-over-year change of +41.4%. This estimate has changed +5.2% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $1.59 indicates a change of +29.1% from what DexCom is expected to report a year ago. Over the past month, the estimate has changed +2.6%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for DexCom. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of DexCom, the consensus sales estimate of $936.02 million for the current quarter points to a year-over-year change of +21.6%. The $3.54 billion and $4.26 billion estimates for the current and next fiscal years indicate changes of +21.7% and +20.3%, respectively. Last Reported Results and Surprise History DexCom reported revenues of $871.3 million in the last reported quarter, representing a year-over-year change of +25.2%. EPS of $0.34 for the same period compares with $0.17 a year ago. Compared to the Zacks Consensus Estimate of $837 million, the reported revenues represent a surprise of +4.1%. The EPS surprise was +54.55%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Valuation No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. DexCom is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about DexCom. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-08-31,103.53,105.06,100.9,100.98,"Oversold Conditions For DexCom (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.99, after changing hands as low as $101.205 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 56.7. A bullish investor could look at DXCM's 29.99 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $78.94 per share, with $139.55 as the 52 week high point — that compares with a last trade of $101.27. Find out what 9 other oversold stocks you need to know about » Also see: • SPRB Stock Predictions • Top Ten Hedge Funds Holding BKD • Top Ten Hedge Funds Holding UMAR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-01,102.32,102.695,100.51,101.895,"DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know DexCom (DXCM) closed at $101.90 in the latest trading session, marking a +0.91% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.18%. At the same time, the Dow added 0.33%, and the tech-heavy Nasdaq lost 0.02%. Heading into today, shares of the medical device company had lost 17.28% over the past month, lagging the Medical sector's loss of 0.91% and the S&P 500's loss of 1.63% in that time. DexCom will be looking to display strength as it nears its next earnings release. On that day, DexCom is projected to report earnings of $0.34 per share, which would represent year-over-year growth of 21.43%. Our most recent consensus estimate is calling for quarterly revenue of $936.02 million, up 21.62% from the year-ago period. DXCM's full-year Zacks Consensus Estimates are calling for earnings of $1.23 per share and revenue of $3.54 billion. These results would represent year-over-year changes of +41.38% and +21.74%, respectively. It is also important to note the recent changes to analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.83% higher. DexCom currently has a Zacks Rank of #3 (Hold). In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 84.02. Its industry sports an average Forward P/E of 30.54, so we one might conclude that DexCom is trading at a premium comparatively. We can also see that DXCM currently has a PEG ratio of 1.96. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.21 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 99, putting it in the top 40% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-05,101.94,102.97,99.93,100.33,"[""Why DexCom (DXCM) is a Top Growth Stock for the Long-Term For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform. The Style Scores are broken down into four categories: Value Score For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks. Growth Score Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time. Momentum Score Momentum traders and investors live by the saying \""the trend is your friend.\"" This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. VGM Score What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier. It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day. This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio. That's where the Style Scores come in. To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of B, forecasting year-over-year earnings growth of 41.4% for the current fiscal year. For fiscal 2023, 11 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.16 to $1.23 per share. DXCM boasts an average earnings surprise of 28.8%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why Analysts Say GE's Healthcare Spinoff Has $20 Upside Of the 19 U.S. corporate spinoffs that have occurred in 2023, GE HealthCare Technologies Inc. (NASDAQ: GEHC) may be the most intriguing. With the market\u2019s attention on a wave of media spinoffs, the growth opportunities at General Electric\u2019s new standalone healthcare business are well worth tuning in to. In its first year as a separate publicly traded entity, GE HealthCare is delivering some impressive results. First-half revenue and earnings per share (EPS) are up 8% and 22% year-over-year, respectively. The results reflect a healthy underlying demand for advanced medical devices that screen, diagnose, treat and monitor patients. Management\u2019s full-year guidance hike signals a confident leadership team that is exceeding expectations despite a challenging economic climate. The strong financial performance, however, has been overshadowed by a 25 million share secondary offering that took place June 7th, 2023. GE HealthCare\u2019s stock has slid 14% since then. Yet, given the growth that could be generated from the capital infusion, Wall Street is calling it an opportunity. Within the last 30 days, three research groups started covering GE HealthCare. Wells Fargo cited the company\u2019s potential role in Alzheimer\u2019s disease in issuing an Overweight rating. Argus Research applauded GEHC\u2019s leading positions across several target markets in calling the stock a Buy. Bank of America started with a Neutral rating, but its $82 target price has become quite bullish. Overall, the Street\u2019s early opinions of GE HealthCare have been skewed to the bullish side. The current $87 consensus target suggests the stock will advance roughly $20 from here and return to its April 2023 peak. The positive analyst sentiment is about more than GEHC\u2019s association with a 130-year-old light bulb company founded by Thomas Edison, J.P. Morgan and other legendary American industrialists. What Does GE HealthCare Technologies Do? GE HealthCare offers a range of medical technologies and pharmaceutical diagnostics to health care clinicians. More than four million of the company\u2019s imaging, ultrasound and other diagnostic units are installed worldwide. Along with other patient care solutions and services, they generated $18.3 billion in revenue last year. Backed by the trusted GE brand name, the products represent value to customers because they improve provider productivity and patient outcomes. At its core, GE HealthCare is aiming to be a key driver of two of the industry\u2019s hottest trends \u2014 precision medicine and digital care. Precision, or personalized, medicine tailors medical decisions and products to the individual based on his or her unique history and risk factors. The company\u2019s latest innovations are being built around this concept rather than the traditional \u201cone size fits all\u201d approach. Meanwhile, its digital healthcare solutions cover the scope of today\u2019s medical buzzwords, from advanced visualization and virtual care to cardiology IT and even cybersecurity. What Is GE HealthCare\u2019s Growth Strategy? A major component of the growth story is M&A. GE HealthCare has already announced a pair of acquisitions since making its Nasdaq debut earlier this year. In January 2023, the company acquired French computed tomography (CT) interventional guidance specialist IMACTIS. A month later, it purchased privately held Caption Health, a creator of artificial intelligence-based imaging software for early disease detection. Given the plentiful resources, these and future acquisitions stand to boost the company\u2019s tech capabilities and growth prospects. Not surprisingly, the Caption buyout isn\u2019t GE HealthCare\u2019s only bet on artificial intelligence (AI). In June 2023, the company launched an FDA-cleared AI deep learning tool called Sonic DL that makes the MRI imaging process up to 12 times faster. The technology is expected to be particularly beneficial to heart patients who have trouble holding their breath during an MRI. In May 2023, it received FDA clearance for Precision DL, a deep-learning technology that enhances image quality in PET/CT scans. With additional deep learning solutions in its portfolio, GE HealthCare\u2019s use of AI could lead to more informed clinical decision-making \u2014 and more robust financial results. For 2023, management is forecasting adjusted EPS of $3.70 to $3.85. At the midpoint, this implies 11.5% profit growth from 2022 and a solid first-year performance as a standalone company. It also means the stock is trading at a modest 18x earnings. This places GEHC in the bottom quartile of large-cap healthcare equipment providers. Edwards Lifesciences, for example, trades at 30x this year\u2019s earnings. Dexcom goes for 82x. GE HealthCare does pay a dividend, but it only amounts to a 0.2% annual yield. Investors shouldn\u2019t be dissuaded by this, though because 1) profits are better off going to product innovation and acquisitions at this stage of the growth trajectory, and 2) as the business matures, there will be a lot of room for dividend increases. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany DexCom, Inc. DXCM, announced that its DexCom G6 continuous glucose monitoring (CGM) system can now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. The Omnipod 5 AID system, developed by Insulet Corporation (PODD), is the first tubeless AID system that integrates with the DexCom G6 CGM system in Germany to automatically adjust insulin delivery and manage glucose levels both day and night. The DexCom G6 CGM system is approved for people with type 1 and type 2 diabetes, aged 2 years and older. The Insulet Corporation\u2019s Omnipod 5 AID system is cleared for individuals with type 1 diabetes, aged 2 years and older. Insulet Corporation achieved clearance for Omnipod 5 AID system based on clinical studies where the system achieved clinically meaningful health outcomes only when it is connected to DexCom CGM. DexCom added Omnipod AID to its CGM ecosystem in the U.K. in June. Price Performance Shares of DexCom have lost 10% year to date against the industry\u2019s 0.3% growth. The S&P 500 Index has gained 18.6% in the same time frame. Image Source: Zacks Investment Research DexCom Advantage The compatibility of the DexCom G6 CGM system and the PODD\u2019s Omnipod 5 AID system offer a new option in Germany for people with diabetes who want to simplify their diabetes management and improve their health outcomes. The combination of these two devices can help users achieve better glucose control, lower A1C, reduce hypoglycemia and hyperglycemia, and increase time in range. Users can also benefit from the convenience, discretion, and flexibility of these tubeless and wireless devices. With the Omnipod 5 AID system, DexCom strengthens its position as the world\u2019s most connected CGM, providing patients in Germany with more choice and flexibility for observing glucose data and delivering insulin. The benefits are likely to drive demand higher for DexCom G6 CGM system going forward, boosting the company\u2019s top line. Notable Developments In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada\u2019s approval for people with all types of diabetes, aged two years and above. The DexCom G7 has been built on the performance of DexCom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range. Although approved by Health Canada, DexCom G7 is not yet available for purchase. DexCom Canada is working to make DexCom G7 available to diabetic Canadians by the end of 2023. The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth. Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. The company\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Stocks to Consider DexCom currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Align Technology ALGN, HealthEquity, Inc. HQY and McKesson Corporation MCK. Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. ALGN\u2019s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company\u2019s shares have risen 77.8% year to date compared with the industry\u2019s 14.1% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%. The company\u2019s shares have rallied 7.8% year to date against the industry\u2019s 9.4% decline. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. The stock has rallied 9.9% year to date compared with the industry\u2019s 14.1% growth. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's Next For DexCom Stock After A 17% Fall In A Month? DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index. This underperformance can be attributed to the reduced risk of cardiovascular events for obesity drugs of Novo Nordisk and likely Eli Lilly. Investors are concerned about the possible wider applications of obesity drugs and their impact on medical devices used to manage diabetes. In the longer term, DXCM stock is up 89% from levels seen in late 2019, far better than the S&P 500 index, up around 35%. Interestingly, DexCom stock has had a Sharpe Ratio of 0.7 since early 2017, higher than 0.6 for the S&P 500 Index over the same period. This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds. This 89% rise for DexCom stock since late 2019 can primarily be attributed to 1. DexCom\u2019s revenue growth of 117% to $3.2 billion over the last twelve months, compared to $1.5 billion in 2019, partly offset by 2. the company\u2019s P/S ratio falling 9% to 12.5x revenues vs. 13.7x in 2019, and 3. a 5% rise in its total shares outstanding to 388 million. This has meant that the company\u2019s revenue per share metric has risen 107% to $8.24 now, compared to $3.98 in 2019. Our dashboard on Why DexCom Stock Moved has more details. New customer additions are leading the revenue growth for DexCom amid rising awareness of CGM devices. DexCom is among the few players with regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require a finger prick, and data can be self-monitored easily. Given the limited competition and a vast pool of diabetic patients (over 37 million in the U.S. alone), the company will likely see strong revenue growth over the coming years. DexCom\u2019s future sales growth will likely be bolstered by its G7 CGM system in the U.S., which secured regulatory approval in December 2022. The company expects its revenue to rise 21% to $3.5 billion in 2023 and $4.9 billion in 2025 (at the mid-point of the provided range). Not only has the company seen stellar revenue growth, but it also saw its margin expand from 9.4% in 2019 to 14.0% now. Our DexCom Operating Income Comparison dashboard has more details. After its recent fall, DXCM stock looks attractive. It currently trades at 12x revenues compared to its last five-year average of 21x, implying that the stock is undervalued. Our DexCom Valuation Ratios Comparison dashboard has more details. The company continues to see strong sales growth and also expand its operating margin. The concerns over the broader application of obesity drugs and its impact on DexCom also appear to be stretched. A CGM device will be a helpful tool to monitor the effectiveness of the drugs on a patient. A massive 40% cut in P/S multiple for DexCom isn\u2019t justified in our view. Overall, investors can use the current dip in DXCM stock for likely solid gains in the long run. Returns Aug 2023 MTD [1] 2023 YTD [1] 2017-23 Total [2] DXCM Return -17% -9% 593% S&P 500 Return -2% 18% 102% Trefis Reinforced Value Portfolio -4% 32% 576% [1] Month-to-date and year-to-date as of 8/31/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-06,105.446,108.28,104.22,106.88,"[""Wednesday Sector Leaders: Utilities, Healthcare The best performing sector as of midday Wednesday is the Utilities sector, up 0.2%. Within the sector, Xcel Energy Inc (Symbol: XEL) and Entergy Corp (Symbol: ETR) are two large stocks leading the way, showing a gain of 1.3% and 1.2%, respectively. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 0.1% on the day, and down 10.97% year-to-date. Xcel Energy Inc, meanwhile, is down 18.15% year-to-date, and Entergy Corp, is down 11.14% year-to-date. Combined, XEL and ETR make up approximately 5.5% of the underlying holdings of XLU. The next best performing sector is the Healthcare sector, losing just 0.3%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and Insulet Corp (Symbol: PODD) are the most notable, showing a gain of 7.8% and 5.2%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.5% in midday trading, and down 2.15% on a year-to-date basis. DexCom Inc, meanwhile, is down 5.70% year-to-date, and Insulet Corp, is down 31.34% year-to-date. Combined, DXCM and PODD make up approximately 1.1% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, one sector is up on the day, while eight sectors are down. SECTOR % CHANGE Utilities +0.2% Healthcare -0.3% Services -0.4% Industrial -0.4% Consumer Products -0.5% Technology & Communications -0.6% Energy -0.6% Financial -0.7% Materials -0.8% 10 ETFs With Stocks That Insiders Are Buying \u00bb Also see: \u0095 ADES YTD Return \u0095 PKE Dividend History \u0095 Funds Holding INIS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Fall as Economic Strength May Keep Interest Rates Higher for Longer What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) Wednesday closed down -0.70%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.57%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.88%. Stocks on Wednesday posted moderate losses, with the S&P 500 and Nasdaq 100 posting 1-week lows and the Dow Jones Industrials posting a 1-1/2 week low. Stocks opened lower Wednesday on negative carryover from a fall in the Euro Stoxx 50 to a 1-1/2 week low on weaker-than-expected Eurozone economic news. Stocks extended their losses as bond yields jumped after Wednesday\u2019s Aug ISM services report expanded more than expected, bolstering speculation the Fed will keep interest rates higher for longer. The U.S. Aug ISM services index unexpectedly rose +1.8 to a 6-month high of 54.5, stronger than expectations of a decline to 52.5. The U.S. Jul trade deficit widened to -$65.0 billion from -$63.7 billion in June, a smaller deficit than expectations of -$68.0 billion. The Fed Beige Book was neutral for stocks as it stated U.S. economic activity was modest during July and August, and most districts said price growth slowed overall. Also, job growth was subdued across the U.S. during the survey period. Boston Fed President Collins said it's \""too early\"" to say if inflation is on a sustained path to 2%, and further tightening may be warranted depending on the data. She added that the Fed will \""need to hold rates at restrictive levels for some time\"" as while demand is moderating, it continues to outpace supply, adding to price pressures. The markets are discounting the odds at 7% for a +25 bp rate hike at the September 20 FOMC meeting and 50% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields Wednesday moved higher. The 10-year T-note yield rose to a 2-week high of 4.302% and finished up +2.8 bp at 4.288%. The 10-year German bund yield rose to a 2-week high of 2.664% and finished up +4.2 bp at 2.653%. The 10-year UK gilt yield rose to a 2-week high of 4.559% and finished up +0.8 bp at 4.533%. Overseas stock markets Wednesday settled mixed. The Euro Stoxx 50 closed down -0.72%. China\u2019s Shanghai Composite Index closed up +0.12%. Japan\u2019s Nikkei Stock Index closed up +0.62%. Eurozone July retail sales fell -0.2% m/m, right on expectations and the first decline in four months. German July factory orders fell -11.7% m/m, weaker than expectations of -4.3% m/m and the biggest decline in 3-1/4 years. ECB Governing Council member Kazimir said the ECB needs to raise interest rates one more time to make sure inflation returns to 2%, and a September rate hike is \""preferable\"" to a later increase. ECB Governing Council member Knot said investors betting against an ECB rate hike next week are \""maybe\"" underestimating the likelihood of it happening. Today\u2019s stock movers\u2026 Apple (AAPL) closed down more than -3%, leading losers in the Dow Jones Industrials after the Wall Street Journal reported that Chinese government agencies had barred staff from using the iPhone and other foreign-branded devices at work. Losses in Apple accelerated on technical selling after the stock fell below its 50-day moving average. MarketAxess Holdings (MKTX) closed down more than -5% after Morgan Stanley and Keefe Bruyette & Woods said overall average daily credit trading volume in August tracked below estimates. Albemarle (ALB) closed down more than -5% after global lithium prices fell -14% m/m in August. Lithium products account for about 70% of the company\u2019s total revenue. Lockheed Martin (LMT) closed down more than -4% after it pushed back the delivery timing of the new F-35 jet to April 2024 from this December due to testing issues. Nvidia (NVDA) closed down more than -3% after Research Affiliates said the stock is \u201ca textbook story of a Big Market Delusion,\u201d and with shares trading around 110 times earnings, the stock is priced beyond perfection. Regional bank stocks retreated Wednesday and weighed on the overall market. Comerica (CMA) closed down more than -4%. Also, Zions Bancorp (ZION) and KeyCorp (KEY) closed down more than -3%. In addition, Citizens Financial Group (CFG), Huntington Bancshares (HBAN), and Truist Financial (TFC) closed down more than -2%. Southwest Airlines (LUV) closed down more than -2% after it said that due to surging jet fuel costs, revenue for each seat flown mile would fall -5% to -7% from a year earlier compared with an earlier outlook for a drop of -3% to -7%. Tesla (TSLA) closed down more than -1% after Indonesian Coordinating Maritime Affairs and Investment Minister Panjaitan said Tesla CEO Musk is concerned about the state of the global economy and possible overcapacity in the EV market and shelved expansion plans in Indonesia. Gilead Sciences (GILD) closed down more than -1% after HSBC initiated coverage of the stock with a recommendation of reduce and a price target of $71. Dexcom (DXCM) closed up more than +6% to lead gainers in the S&P 500 and Nasdaq 100 after Jeffries said the use of obesity drugs appears to increase the use of type 2 diabetes continuous glucose monitors, which Dexcom manufactures. Zimmer Biomet Holdings (ZBH) closed up more than +4% after CEO Tornos said he sees demand for GLP-a weight-loss drugs as \u201cdefinitely a tailwind\u201d for the company in the short term. Salesforce (CRM) closed up more than +1% to lead gainers in the Dow Jones Industrials after it said it added new artificial intelligence (AI) capabilities and automation improvements. AeroVironment (AVAV) closed up more than +20% after reporting Q1 revenue of $152.3 million, better than the consensus of $128.5 million, and raising its 2024 revenue forecast to $635 million-$675 million from a previous forecast of $630 million-$660 million, stronger than the consensus of $656 million. NexGen Healthcare (NXGN) closed up more than +14% after Thoma Bravo agreed to acquire the company for $23.95 a share. Trade Desk (TTD) closed up more than +2% after William Blair initiated coverage on the stock with an outperform recommendation. Nasdaq Inc (NDAQ) closed up more than +1% after reporting August equity options volume rose +8.8% y/y to 298 million contracts. Across the markets\u2026 December 10-year T-notes (ZNZ23) on Wednesday closed down -8.5 ticks, and the 10-year T-note yield rose +2.8 bp to 4.288%. Dec T-notes Wednesday gave up an early advance and fell to a 1-1/2 week low, and the 10-year T-note yield rose to a 2-week high of 4.302% on stronger-than-expected U.S. economic news after the Aug ISM services index unexpectedly expanded by the most in 6 months. Also, comments Wednesday from Boston Fed President Collins weighed on T-note prices when she said it is \""too early\"" to say if inflation is on a sustained path to 2% and further tightening may be warranted depending on the data. In addition, an increase in inflation expectations weighed on T-notes after the 10-year breakeven inflation rate Wednesday rose to a 1-week high of 2.33%. More Stock Market News from Barchart Dollar Follows Bond Yields Higher Retirees: Does it Make Economic Sense to Move Into a 55+ Community? Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value 3 Hot Stocks Under $10 for Your September Watchlist On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""UBS Maintains Dexcom (DXCM) Buy Recommendation Fintel reports that on September 6, 2023, UBS maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 51.85% Upside As of August 31, 2023, the average one-year price target for Dexcom is 152.36. The forecasts range from a low of 131.30 to a high of $183.75. The average price target represents an increase of 51.85% from its latest reported closing price of 100.33. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1920 funds or institutions reporting positions in Dexcom. This is an increase of 19 owner(s) or 1.00% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.46%, a decrease of 1.79%. Total shares owned by institutions increased in the last three months by 0.37% to 437,989K shares. The put/call ratio of DXCM is 1.15, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in DXCM by 172.17% over the last quarter. Sands Capital Management holds 13,103K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 13,739K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in DXCM by 0.57% over the last quarter. Jpmorgan Chase holds 12,673K shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 10,765K shares, representing an increase of 15.06%. The firm increased its portfolio allocation in DXCM by 825.09% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,102K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 11,965K shares, representing an increase of 1.14%. The firm increased its portfolio allocation in DXCM by 3.23% over the last quarter. VFINX - Vanguard 500 Index Fund Investor Shares holds 9,229K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 9,017K shares, representing an increase of 2.31%. The firm increased its portfolio allocation in DXCM by 2.55% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Additional reading: Dexcom Appoints Rimma Driscoll to Board of Directors DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Non-Exclusive Distribution Agreement, dated Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: WBD, DXCM In early trading on Wednesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.5%. Year to date, DexCom has lost about 7.4% of its value. And the worst performing Nasdaq 100 component thus far on the day is Warner Bros Discovery, trading down 3.8%. Warner Bros Discovery is showing a gain of 18.1% looking at the year to date performance. Two other components making moves today are Tesla, trading down 3.0%, and PDD Holdings, trading up 2.3% on the day. VIDEO: Nasdaq 100 Movers: WBD, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: WBD, DXCM In early trading on Wednesday, shares of DexCom topped the list of the day's best performing components of the S&P 500 index, trading up 4.5%. Year to date, DexCom has lost about 7.4% of its value. And the worst performing S&P 500 component thus far on the day is Warner Bros Discovery, trading down 3.8%. Warner Bros Discovery is showing a gain of 18.1% looking at the year to date performance. One other component making moves today is Marketaxess Holdings trading down 3.7% on the day. VIDEO: S&P 500 Movers: WBD, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Strength in U.S. Economic News Boosts Bond Yields and Weighs on Stocks What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is down -0.83%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.52%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.03%. Stock indexes this morning are moderately lower, with the S&P 500, Dow Jones Industrials, and Nasdaq 100 indexes falling to one-week lows. Stocks opened lower this morning on negative carryover from a fall in the Euro Stoxx 50 to a 1-1/2 week low on weaker-than-expected Eurozone economic news. Losses in stocks accelerated as bond yields jumped after today\u2019s Aug ISM services report expanded more than expected, bolstering speculation the Fed will keep interest rates higher for longer. The U.S. Aug ISM services index unexpectedly rose +1.8 to a 6-month high of 54.5, stronger than expectations of a decline to 52.5. The U.S. Jul trade deficit widened to -$65.0 billion from -$63.7 billion in June, a smaller deficit than expectations of -$68.0 billion. Boston Fed President Collins said it's \""too early\"" to say if inflation is on a sustained path to 2%, and further tightening may be warranted depending on the data. She added that the Fed will \""need to hold rates at restrictive levels for some time\"" as while demand is moderating, it continues to outpace supply, adding to price pressures. The markets are discounting the odds at 8% for a +25 bp rate hike at the September 20 FOMC meeting and 54% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields are higher. The 10-year T-note yield rose to a 2-week high of 4.296% and is up +2.6 bp at 4.286%. The 10-year German bund yield rose to a 2-week high of 2.654% and is up +4.1 bp at 2.653%. The 10-year UK gilt yield rose to a 2-week high of 4.559% and is up +1.1 bp at 4.536%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.74%. China\u2019s Shanghai Composite Index closed up +0.12%. Japan\u2019s Nikkei Stock Index closed up +0.62%. Today\u2019s stock movers\u2026 Nvidia (NVDA) is down more than -3% after Research Affiliates said the stock is \u201ca textbook story of a Big Market Delusion,\u201d and with shares trading around 110 times earnings, the stock is priced beyond perfection. Apple (AAPL) is down more than -3%, leading losers in the Dow Jones Industrials as higher T-note yields weigh on tech stocks. Losses in Apple accelerated on technical selling after the stock fell below its 50-day moving average. Warner Bros Discovery (WBD) is down more than -3% after it forecasted full-year Ebitda of $10.5 billion-$11.0 billion, down about $500 million from a previous estimate due to the impact of strikes from actors and writers. Tesla (TSLA) is down more than -3% to lead losers in the Nasdaq 100 after Indonesian Coordinating Maritime Affairs and Investment Minister Panjaitan said CEO Musk is concerned about the state of the global economy and possible overcapacity in the EV market and shelved expansion plans in Indonesia. Gilead Sciences (GILD) is down more than -2% after HSBC initiated coverage of the stock with a recommendation of reduce and a price target of $71. Olin Corp (OLN) is down more than -2% after Goldman Sachs downgraded the stock to neutral from buy. Southwest Airlines (LUV) is down more than -1% after Airlines it said that due to surging jet fuel costs, revenue for each seat flown mile would fall -5% to -7% from a year earlier compared with an earlier outlook for a drop of -3% to -7%. Dexcom (DXCM) is up more than +5% to lead gainers in the S&P 500 and Nasdaq 100 after Jeffries said the use of obesity drugs appears to increase the use of type 2 diabetes continuous glucose monitors, which Dexcom manufactures. Nasdaq Inc (NDAQ) is up more than +2% after reporting August equity options volume rose +8.8% y/y to 298 million contracts. Salesforce (CRM) is up more than +1% to lead gainers in the Dow Jones Industrials after it said it added new artificial intelligence (AI) capabilities and automation improvements. American Airlines Group (AAL) is up more than +2% after BNP Paribas Exane upgraded the stock to outperform from neutral with a price target of $20. AeroVironment (AVAV) is up more than +27% after reporting Q1 revenue of $152.3 million, better than the consensus of $128.5 million, and raising its 2024 revenue forecast to $635 million-$675 million from a previous forecast of $630 million-$660 million, stronger than the consensus of $656 million. NexGen Healthcare (NXGN) is up more than +14% after Thoma Bravo agreed to acquire the company for $23.95 a share. Gitlab (GTLB) is up more than +4% after reporting Q2 revenue of $139.6 million, above the consensus of $129.9 million, and raising its 2024 revenue forecast to $555 million-$557 million from a previous forecast of $541 million-$543 million, better than the consensus of $542.9 million. Trade Desk (TTD) is up more than +1% after William Blair initiated coverage on the stock with an outperform recommendation. Across the markets\u2026 December 10-year T-notes (ZNZ23) today are down -7 ticks, and the 10-year T-note yield is up +2.6 bp at 4.286%. Dec T-note prices today gave up an early advance and fell to a 1-1/2 week low, and the 10-year T-note yield rose to a 2-week high of 4.296% on stronger-than-expected U.S. economic news after the Aug ISM services index unexpectedly expanded by the most in 6 months. Also, comments today from Boston Fed President Collins weighed on T-note prices when she said it is \""too early\"" to say if inflation is on a sustained path to 2% and further tightening may be warranted depending on the data. The dollar index (DXY00) today is up +0.06% and posted a 5-1/2 month high. The dollar recovered from overnight losses and moved higher as T-note yields climbed on the stronger-than-expected Aug ISM services report. Also, hawkish comments from Boston Fed President Collins supported the dollar. In addition, Chinese economic concerns weighed on the yuan, which fell to a 10-month low against the dollar today. EUR/USD (^EURUSD) is down by -0.06% and dropped to a 2-3/4 month low. The euro gave up overnight gains and turned lower after the dollar rebounded from early losses and moved higher. Also, weakness in Eurozone economic news weighed on the euro after Eurozone July retail sales fell for the first time in four months and after German Jul factory orders fell by the most in 3-1/4 years. EUR/USD today initially moved higher on hawkish ECB comments after ECB Governing Council member said the markets are underplaying the risks of an ECB rate hike next week, and Governing Council member Kazimir said a September rate hike is preferable to a later increase. Eurozone July retail sales fell -0.2% m/m, right on expectations and the first decline in four months. German July factory orders fell -11.7% m/m, weaker than expectations of -4.3% m/m and the biggest decline in 3-1/4 years. ECB Governing Council member Kazimir said the ECB needs to raise interest rates one more time to make sure inflation returns to 2%, and a September rate hike is \""preferable\"" to a later increase. ECB Governing Council member Knot said investors betting against an ECB rate hike next week are \""maybe\"" underestimating the likelihood of it happening. USD/JPY (^USDJPY) is down -0.10%. The yen today recovered from a 10-month low against the dollar and is slightly higher. Comments from Japan\u2019s top currency official, Masato Kanda, sparked short covering in the yen when he said he wouldn\u2019t rule out any options if forex moves continue. The yen gave up some of its gains after T-note yields rose. October gold (GCV3) today is down -8.8 (-0.45%), and Dec silver (SIZ23) is down -0.433 (-1.81%). Precious metals prices this morning are moderately lower, with gold dropping to a 1-week low and silver falling to a 2-week low. Today's rally in the dollar index to a 5-1/2 month high is bearish for metals. Also, rising global bond yields are negative for precious metals prices. In addition, hawkish central bank comments undercut precious metals when Boston Fed President Collins said it is \""too early\"" to say if inflation is on a sustained path to 2% and further tightening may be warranted, and ECB Governing Council member Kazimir said the ECB needs to raise interest rates one more time to make sure inflation returns to 2%. More Stock Market News from Barchart Rent the Runway Alert: Options Traders Are Placing Big Bets on RENT Stock Peloton Stock: Should You Buy the Dip or Dodge the Value Trap? Markets Today: Stocks Slip as Weak Eurozone Economic News Fuels Growth Concerns Ride to Multi-Month Highs With These Top Barchart Opinion Stocks! On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-07,106.75,107.59,100.76,104.91,"Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength? DexCom DXCM shares soared 6.5% in the last trading session to close at $106.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9% loss over the past four weeks. DexCom recorded a strong price increase after it allayed concerns that popular weight-loss drugs, like Wegovy, would tamp down usage of its diabetes devices. Per a company presentation on Sep 5, Dexcom confirmed that across all segments of patients with type 2 diabetes, use of continuous glucose monitors increased after beginning treatment with GLP-1 drugs. This medical device company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of +21.4%. Revenues are expected to be $936.02 million, up 21.6% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For DexCom, the consensus EPS estimate for the quarter has been revised 4.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DXCM going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> DexCom belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Integer ITGR, closed the last trading session 0.7% lower at $80.74. Over the past month, ITGR has returned -8.5%. For Integer, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.07. This represents a change of +12.6% from what the company reported a year ago. Integer currently has a Zacks Rank of #2 (Buy). Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-08,104.92,107.14,104.175,104.35,
DXCM,2023-09-11,104.35,108.09,103.95,107.29,"Stocks Settle Higher as Tesla’s Surge Powers Gains in Tech Stocks What you need to know… The S&P 500 Index ($SPX) (SPY) Monday closed up +0.67%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.19%. Stocks on Monday settled moderately higher. Strength in technology stocks Monday boosted the overall market, with Tesla closing up more than +10% after Mogan Stanley upgraded the stock. Also, Qualcomm closed up more than +3% after Apple extended its contract with the company to provide it with modem semiconductor chips for three more years. In addition, M&A activity supported stocks after JM Smucker agreed to acquire Hostess Brands for $5.6 billion. Higher T-note yields Monday limited gains in stocks. Comments on Sunday from U.S. Treasury Secretary Yellen were bullish for stocks when she said she's ""feeling very good"" about the case for a soft landing in the U.S. as ""every measure of inflation is on the road down,"" and she's increasingly confident that the U.S. will be able to contain inflation without major damage to the job market. U.S. and European stocks garnered carryover support Monday from a +0.84% rally in China’s Shanghai Composite on positive Chinese credit and inflation news. The markets are discounting the odds at 7% for a +25 bp rate hike at the September 20 FOMC meeting and 44% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields Monday moved higher. The 10-year T-note yield rose +1.6 bp to 4.280%. The 10-year German bund yield rose +2.8 bp to 2.638%. The 10-year UK gilt yield rose +4.8 bp to 4.472%. Overseas stock markets on Monday settled mixed. The Euro Stoxx 50 closed up +0.40%. China’s Shanghai Composite Index closed up +0.84%. Japan’s Nikkei Stock Index closed down -0.43%. China Aug CPI rose +0.1% y/y from a -0.3% y/y decline in July, right on expectations. China Aug PPI eased to -3.0% y/y from -4.4% y/y in July, weaker than expectations of -2.9% y/y. China Aug new yuan loans were 1.36 trillion yuan, above expectations of +1.25 trillion yuan. Aug aggregate financing, the broadest measure of credit growth, rose +3.12 trillion yuan, stronger than expectations of +2.69 trillion yuan. The European Commission cut its 2023 Eurozone GDP forecast to +0.8% from an earlier projection of +1.1%. It also cut its 2023 Eurozone inflation forecast to +5.6% from a previous forecast of +5.8%. Today’s stock movers… Tesla (TSLA) closed up more than +10% to lead gainers in the S&P 500 and Nasdaq 100 after Morgan Stanley upgraded the stock to overweight from equal weight and said Tesla’s Dojo supercomputer may add as much as $500 billion to the company’s market value through faster adoption of robotaxis and network services. CVS Health Corp (CVS) closed up more than +4% after Wolfe Research projected that the company would regain its four-star quality rating on its Medicare Advantage contract for 2025 after losing it in 2024. Qualcomm (QCOM) closed up more than +3% after Apple extended its modem chip contract with the company for three more years. M&T Bank (MTB) closed up more than +3% after analysts said the company gave a positive update on its guidance at the Barclays Global Financial Services Conference. Kenvue (KVUE) closed up more than +3% after Deutsche Bank raised its recommendation on the stock to buy with a price target of $27. Dexcom (DXCM) closed up more than +2% after Bloomberg Intelligence said that the company generated $287 million in August for its continuous glucose monitoring devices, up +64% y/y, which positions the stock to beat Q3 earnings estimates. Crinetics Pharmaceuticals (CRNX) closed up more than +63% after it said its oral, once-daily Paltusotine achieved positive results and met the primary endpoint and all secondary goals to treat people living with acromegaly and neuroendocrine tumors. Hostess Brands (TWNK) closed up more than +19% after JM Smucker agreed to acquire the company for $5.6 billion. RTX Corp (RTX) closed down more than -7% to lead losers in the S&P 500 after cutting its full-year sales forecast to $67.5 billion-$68.5 billion from a previous estimate of $73 billion-$74 billion, weaker than the consensus of $73.64 billion. JM Smucker (SJM) closed down more than -7% after it agreed to acquire Hostess Brands for $5.6 billion. Newell Brands (NWL) closed down more than -6% and added to last week’s -6% fall ahead of its demotion to the S&P SmallCap 600 Index from the S&P 500 due to take effect before the market opening on Sep 18. VF Corp (VFC) closed down more than -6% after it was ordered to pay $505 million in taxes related to its reorganization of TBL Licensing LLC. Ovintiv Inc (OVV) closed down more than -3% after announcing a sale of 15 million shares of the company’s common stock by a holder. AstraZeneca Plc (AZN) closed down more than -2% after data released from a Phase III trial of its Tagrisso drug combined with chemotherapy showed the efficacy benefit of the drug came with a cost of added toxicity from the chemo regimen. Evergy Inc (EVRG) closed down more than -2% after Wolfe Research downgraded the stock to peer perform from outperform. Brunswick Corp (BC) closed down by more than -1% after JPMorgan Chase downgraded the stock to neutral from overweight. Across the markets… December 10-year T-notes (ZNZ23) on Monday closed down -4.5 ticks, and the 10-year T-note yield rose +1.6 bp to 4.280%. Dec T-notes on Monda posted moderate losses on negative carryover from a slump in Japanese government bonds. The 10-year JGB bond yield soared to a 9-1/2 year high Monday after BOJ Governor Ueda said an end to negative interest rates is possible by year-end. Also, an increase in inflation expectations weighed on T-notes after the 10-year inflation breakeven rate rose to a 2-week high Monday at 2.355%. In addition, a rally in stocks Monday curbed safe-haven demand for T-notes. Prices climbed from their worst levels on solid demand for the Treasury’s $44 billion auction of 3-year T-notes with a bid-to-cover ratio of 2.75, above the 10-auction average of 2.70. More Stock Market News from Barchart Dollar Falls as Yen and Yuan Strengthen Looking to Invest in Pickleball? Consider These 2 Stocks 2 Beaten-Down Stocks Worth Buying at Multi-Year Lows Oracle Stock Is Still Cheap - All Eyes Today on its Results and FCF Margins On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-12,106.56,107.34,103.4,104.86,"[""Tuesday Sector Laggards: Technology & Communications, Healthcare In afternoon trading on Tuesday, Technology & Communications stocks are the worst performing sector, showing a 0.8% loss. Within that group, Oracle Corp (Symbol: ORCL) and Adobe Inc (Symbol: ADBE) are two large stocks that are lagging, showing a loss of 14.7% and 3.6%, respectively. Among technology ETFs, one ETF following the sector is the Technology Select Sector SPDR ETF (Symbol: XLK), which is down 1.6% on the day, and up 39.18% year-to-date. Oracle Corp, meanwhile, is up 29.92% year-to-date, and Adobe Inc is up 61.49% year-to-date. Combined, ORCL and ADBE make up approximately 5.2% of the underlying holdings of XLK. The next worst performing sector is the Healthcare sector, showing a 0.4% loss. Among large Healthcare stocks, HCA Healthcare Inc (Symbol: HCA) and DexCom Inc (Symbol: DXCM) are the most notable, showing a loss of 3.7% and 3.1%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is flat on the day in midday trading, and down 1.10% on a year-to-date basis. HCA Healthcare Inc, meanwhile, is up 8.43% year-to-date, and DexCom Inc, is down 9.42% year-to-date. Combined, HCA and DXCM make up approximately 2.0% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, three sectors are up on the day, while five sectors are down. SECTOR % CHANGE Energy +2.0% Financial +1.1% Utilities +0.1% Materials -0.0% Consumer Products -0.1% Industrial -0.1% Services -0.2% Healthcare -0.4% Technology & Communications -0.8% 10 ETFs With Stocks That Insiders Are Buying \u00bb Also see: \u0095 HTZ Options Chain \u0095 Funds Holding NTZO \u0095 CTW Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Rises 7% in One Week: What's Driving It? DexCom's DXCM shares have risen 6.9% since Tuesday last week, while yesterday\u2019s after-market movement took the rally to nearly 8%. Last week, the company presented a positive picture for its continuous glucose monitoring (CGM) devices, allaying investors\u2019 fears about rising competition from GLP-1 drugs like Wegovy, Ozempic and Mounjaro. These GLP-1 drugs, which were first approved for treating type II diabetes, are currently gaining popularity as obesity treatment. Some analysts believed that total addressable markets for CGM devices is cut meaningfully with the rising adoption of these drugs. The potential rise in competition from GLP-1 drugs is an overhang for CGM-makers like DexCom, with analysts assuming negative impact over the next six months to a year. However, DexCom stated in its presentation last week that it has surveyed and observed rising adoption of its CGM devices among patients initiating GLP-1 therapy, contradicting the assumptions. This caused DXCM\u2019s shares to rise in the previous week. Price Performance Shares of DexCom have lost 5.3% year to date compared with the industry\u2019s 4.8% decline. The S&P 500 Index has gained 17.2% in the same time frame. Image Source: Zacks Investment Research DexCom Findings While GLP-1 are drugs that are prescribed with specific doses within regular intervals, CGM devices are worn on the body and can measure blood sugar in real time. These devices are often paired with insulin pumps. DexCom presented that the use of CGMs have increased across all segments of patients with type II diabetes after beginning treatment with GLP-1 drugs. Per the data provided, use of these monitoring devices doubled on average for patients on intensive insulin while the same was up 3.8 times for patients on basal insulin alone. The use of CGMs also increased in patients on non-insulin therapy by 4.2 times. The company believes that the use of CGMs help patients to achieve dose titration for therapeutic regimen, as recommended in GLP-1 labeling. The simplicity of CGM systems is supporting its accelerated adoption, even for patients on GLP-1 therapy. Moreover, the use of these devices help increase the durability of health outcomes. The presented facts imply that adoption of CGM devices is likely to continue going forward. With rising adoption of DexCom devices by GLP-1 users, the potential impact of GLP-1 competition is likely to diminish. However, investors should keep a watch on sales figure for these devices to get a clear picture of the competition landscape. Industry Prospects Per a report by Grand View Research, the CGM devices market was valued at $7.82 billion in 2022 and is anticipated to witness a CAGR of 4.4% from 2023 to 2030. Factors like the growing cases of diabetes, coupled with the increasing adoption CGM devices, are expected to drive the market. Given the market potential and increased adoption among GLP-1 users, DexCom\u2019s CGM business is likely to perform well in the future. Notable Developments Earlier this month, DexCom announced that its DexCom G6 CGM system will now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. The company had added Omnipod AID to its CGM ecosystem in the U.K. in June. In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada\u2019s approval for people with all types of diabetes, aged two years and above. Although approved by Health Canada, DexCom G7 is not yet available for purchase. DexCom Canada is working to make DexCom G7 available to diabetic Canadians by the end of 2023. The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Stocks to Consider DexCom currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Align Technology ALGN, HealthEquity, Inc. HQY and McKesson Corporation MCK. Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. ALGN\u2019s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company\u2019s shares have risen 58.9% year to date compared with the industry\u2019s 12% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%. The company\u2019s shares have rallied 13.6% year to date against the industry\u2019s 10.6% decline. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. The stock has rallied 13% year to date compared with the industry\u2019s 12% growth. Free Report: Top EV Battery Stocks to Buy Now Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to \""insane levels,\"" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid. Download free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wall Street Has Found Its Next High-Flying Stock-Split Stock. Here's Why I'm Not Buying the Hype. Wall Street has been nothing short of a roller-coaster ride since the start of 2020. Investors experienced the quickest bear market decline in history during the COVID-19 crash in 2020, as well as a period of unfettered exuberance in 2021, which sent all three major indexes to record-closing highs. This was followed by another bear market in 2022, and a big-time rally in megacap growth stocks this year. When volatility and unpredictability rule the roost, professional and everyday investors have a tendency to seek the safety of longtime outperformers. Companies enacting stock splits certainly meet that definition. Image source: Getty Images. Investors can't get enough of stocks enacting splits A stock split is an event that allows a publicly traded company to alter both its share count and share price without having any effect on its market cap or operating performance. This purely cosmetic change can make a company's shares more nominally affordable for everyday investors, or can boost a company's share price to ensure it meets the minimum continued listing requirements of a major stock exchange. Most investors tend to focus their attention on forward stock splits, which are the type of split designed to reduce a company's nominal share price while increasing its outstanding share count by the same magnitude. Businesses conducting forward splits are usually firing on all cylinders, out-executing their peers, and handily out-innovating their competition. Since the start of July 2021, eight high-flying companies have conducted forward stock splits, including (listed in chronological order by effective date of split): Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022 Shopify (NYSE: SHOP): 10-for-1 split in June 2022 Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023 NVDA data by YCharts. What these businesses offer is an abundance of competitive advantages. Without going through every example, you have Nvidia accounting for around 90% of the graphics processing units used in high-compute data centers, Amazon leading the charge in cloud infrastructure services and U.S. online retail sales, Tesla being the world's leading producer of electric vehicles, and Alphabet's Google amassing a virtual monopoly in global internet search share. In other words, there are good reasons these eight stock-split stocks have outperformed. Wall Street has its next great stock-split stock With only Monster Beverage taking the plunge among industry-leading businesses in 2023, investors have been eager to pile into the next great stock-split stock -- and it would appear their wish has been granted. In August, Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) announced it would be conducting a 2-for-1 forward split on Sept. 20, 2023. This'll mark the fifth split in the company's storied history, and its first since a 5-for-1 split took place in January 2014. To say that Novo Nordisk is on fire would be an understatement. Shares of the company have tripled over the trailing three-year period, and they're up more than 500% over the trailing decade. Earlier this month, the company surpassed luxury retailer LVMH to become Europe's largest publicly traded company by market cap. Investors don't have to dig deep to find the catalysts behind this move. Four brand-name therapies have fueled Novo Nordisk's double-digit sales and profit growth: injectable glucagon-like peptide-1 (GLP-1) drugs Ozempic (type 2 diabetes), Saxenda, and Wegovy (Saxenda and Wegovy are both used for chronic weight management), as well as oral type 2 diabetes drug Rybelsus. These four drugs combined for roughly 63% of the $15.45 billion Novo Nordisk recorded in first-half sales in 2023, with respective sales growth of 58%, 36%, 367%, and 97%, from Ozempic, Saxenda, Wegovy, and Rybelsus, from the prior-year period. What's made GLP-1 drugs such a hot commodity is their ability to induce weight loss in users. GLP-1 receptor agonists like Ozempic (keep in mind that Ozempic isn't approved as a weight-loss therapy), Saxenda, and Wegovy cause the stomach to empty more slowly, which helps users feel fuller and eat less. Further, it signals to the brain that there's still food in the stomach, which can reduce a person's appetite. As of 2017, the Centers for Disease Control and Prevention estimated that nearly 42% of Americans were obese. In short, Novo Nordisk could be sitting on a gold mine with its GLP-1 injectable therapies. Wall Street seems to agree. Based on the consensus estimate of analysts in 2026, Novo Nordisk is on track to grow its earnings per share by 116%, and its sales by 87%, compared to what it reported in 2022. Image source: Getty Images. This stock-split stock can stay on the pharmacy shelf While investors have fallen head over heels for stock-split stocks in recent years, this is one upcoming split that I have no intention of grabbing from the pharmacy shelf. I'm certainly not slighting Novo Nordisk one bit for capitalizing on the success of its GLP-1 injectable products. The U.S. Food and Drug Administration hasn't approved many drugs for chronic weight management, which gives Novo Nordisk a clear path to sustained double-digit sales growth. I fully agree with Wall Street's assessment that the company can deliver double-digit top-line growth in each of the next four years. Rather, my concerns with Novo Nordisk boil down to two factors: competition and valuation. To begin with, it'd be foolish (small f) to consider Novo Nordisk as the only player in the GLP-1 receptor agonist space. While it does have three blockbuster therapies growing at a rapid pace, other GLP-1 drugs are being developed that could easily eat into Novo Nordisk's share. This includes orforglipron, an oral nonpeptide GLP-1 receptor agonist from Eli Lilly (NYSE: LLY), as well as danuglipron, which is an oral GPL-1 receptor agonist from Pfizer (NYSE: PFE), to name a few. A mid-stage study of Lilly's experimental oral GLP-1 drug led to 14.7% mean weight reduction at the 36-week mark in adults who were obese or overweight. Lilly's drug is also being studied for type 2 diabetes. Meanwhile, Pfizer's twice-daily oral GLP-1 candidate produced a reduction in HbA1c levels of up to 1.16% in mid-stage trials, and is also being examined as a weight-loss therapy. Though not all GLP-1 candidates are going to be successful in late-stage trials, Novo Nordisk's bread and butter will, undoubtedly, face competitive pressures in the years to come. Novo Nordisk's trailing-12-month price-to-sales (P/S) ratio is at an all-time high. NVO PS Ratio data by YCharts. The other issue for Novo Nordisk is its valuation. While the company's price/earnings-to-growth ratio (PEG ratio) of 1.72 suggests it may still be somewhat cheap relative to its future growth prospects, Wall Street's sales forecasts tell a different story. Although there is no concrete rule on how to value pharmaceuticals and biotech stocks, given the ever-changing nature of drug pricing and peak sales potential, my personal rule of thumb with drugmakers is that they're fully valued at 6 times forward-looking sales. There may be some exceptions for rare-disease drugmakers that don't have a lot of competition, but that doesn't apply to Novo Nordisk and its type 2 diabetes and obesity drug lines. Using Wall Street's consensus revenue estimate for 2026, Novo Nordisk is on track for $47.5 billion in annual sales. However, it's already sporting a $437 billion market cap. Investors today are paying 9.2 times sales...in 2026! Things would have to go flawlessly for this valuation to make sense. I don't expect perfection from any publicly traded company, which is why I wouldn't touch this high-flying stock-split stock. 10 stocks we like better than Novo Nordisk When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 5, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Pfizer, Shopify, and Tesla. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-13,104.99,106.96,104.78,105.22,"[""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know In the latest trading session, DexCom (DXCM) closed at $105.22, marking a +0.34% move from the previous day. This change outpaced the S&P 500's 0.12% gain on the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 0.29%. Heading into today, shares of the medical device company had lost 8.43% over the past month, lagging the Medical sector's loss of 0.98% and the S&P 500's gain of 0.09% in that time. DexCom will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.34, up 21.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $936.02 million, up 21.62% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.54 billion. These totals would mark changes of +41.38% and +21.74%, respectively, from last year. Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DexCom is currently a Zacks Rank #3 (Hold). Investors should also note DexCom's current valuation metrics, including its Forward P/E ratio of 85.19. For comparison, its industry has an average Forward P/E of 27.54, which means DexCom is trading at a premium to the group. We can also see that DXCM currently has a PEG ratio of 1.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.08 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 45% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""November 17th Options Now Available For DexCom (DXCM) Investors in DexCom Inc (Symbol: DXCM) saw new options become available today, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new November 17th contracts and identified one put and one call contract of particular interest. The put contract at the $105.00 strike price has a current bid of $6.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $105.00, but will also collect the premium, putting the cost basis of the shares at $98.50 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $105.67/share today. Because the $105.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.19% return on the cash commitment, or 34.74% annualized \u2014 at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $105.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $5.00. If an investor was to purchase shares of DXCM stock at the current price level of $105.67/share, and then sell-to-open that call contract as a \""covered call,\"" they are committing to sell the stock at $110.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.83% if the stock gets called away at the November 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.73% boost of extra return to the investor, or 26.55% annualized, which we refer to as the YieldBoost. The implied volatility in the call contract example above is 45%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $105.67) to be 42%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 \u00bb Also see: \u0095 DXC Technology shares outstanding history \u0095 Funds Holding AUUD \u0095 Molson Coors Beverage market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-14,106.23,106.6,100.93,101.55,"Here's Why You Should Retain DexCom (DXCM) Stock for Now DexCom, Inc. DXCM is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist. This Zacks Rank #3 (Hold) company’s shares have fallen 7.1% year to date compared with the industry’s 4.9% decline. The S&P 500 Index has gained 17.3% in the same time frame. DXCM, a renowned medical-devices company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $40.67 billion. It projects 42.9% growth over the next five years and expects to maintain the strong performance going forward. DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 28.83%. Image Source: Zacks Investment Research Let’s delve deeper. Strong Product Demand: We are upbeat about DexCom's continued strength in its Continuous Glucose Monitoring (CGM) products. The company continues to expand its product portfolio with the addition of new products like DexCom One and G7 sensor. This has helped accelerate its growth. Sales of these products have reflected strong demand since their launch late last year. Moreover, DXCM’s focus on expanding into new geographies is also boosting the business. Earlier this month, the company launched its latest device, DexCom One, in France with reimbursement coverage. Accurate and effective product performance, coupled with simplicity of use, is driving adoption of new CGM devices in the company’s portfolio. DexCom stated that 8,000 physicians prescribed its CGM devices (who had previously not done so) during the second quarter. Meanwhile, the company’s plan to expand its product portfolio beyond intensive insulin use will further benefit the top line going forward. New Product Launch: In June, Dexcom announced that it is currently developing a new product with a 15-day sensor, designed specifically for diabetic patients who are not on insulin. The company is planning to launch the new product in the United States in 2024. Positive Coverages: DXCM’s products have been receiving increasing coverage over the past few months, raising our optimism. The company’s G7 CGM System is already covered by all major pharmacy benefit managers in the United States following the launch late last year. In 2022, the company expanded public coverage for type 1 and type 2 diabetic patients (aged two years and above) who are on multiple daily injections of insulin (three or more) or who use an insulin pump leveraging its G6 CGM System via Prince Edward Island’s Diabetes Glucose Sensor Program. DexCom ended the second quarter with new patient additions. The Ontario government began coverage for the Dexcom G6 CGM System through the province’s Assistive Devices Program. This program has been designed for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Strong Q2 Results: DXCM’s solid second-quarter 2023 revenues buoy optimism. Rising volumes across all channels, along with new customer additions due to increasing global awareness of the benefits of real-time CGM, contributed to the upside. In June, the company raised its guidance for 2025, based on robust demand for its products in the previous two years. The company now expects additional $500 million in revenues (from that projected earlier). Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. Downsides Rising Costs: The company’s gross margin contracted 180 basis points during the second quarter to 62.7%, reflecting the rising cost of sales. It expects adjusted gross margin of approximately 63% for 2023, indicating persisting cost pressure. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid changes and new product introductions. DXCM’s competitors manufacture and market products for the single-point finger stick device market and collectively account for the worldwide sales of self-monitored glucose testing systems at present. Estimate Trend DexCom is witnessing an improving estimate revision trend for 2023 and 2024. In the past 60 days, the Zacks Consensus Estimate for earnings per share has increased from $1.07 to $1.23 for 2023 and from $1.50 to $1.59 for 2024. The consensus mark for the company’s third-quarter 2023 revenues is pegged at $936 million, indicating a 21.6% improvement from the year-ago quarter’s reported number. The same for earnings is pinned at 34 cents per share, implying growth of 21.4% year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are Align Technology ALGN, HealthEquity, Inc. HQY and McKesson Corporation MCK. Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 53.1% year to date compared with the industry’s 11.5% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%. The company’s shares have rallied 13.8% year to date against the industry’s 10.3% decline. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. The stock has rallied 12.1% year to date compared with the industry’s 11.5% growth. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with ""black gold."" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-15,101.85,102.33,95.855,96.35,"[""Health Care Sector Update for 09/15/2023: LXRX, RYZB, PTCT, DXCM Health care stocks were declining late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) was decreasing 0.7%. In corporate news, Lexicon Pharmaceuticals (LXRX) shares rose 8.2% a day after a regulatory filing showed Chief Financial Officer Jeffrey Wade increased his stake in the biopharmaceutical firm. RayzeBio (RYZB) shares jumped almost 33% after debuting on Nasdaq earlier in the day. PTC Therapeutics (PTCT) shares tumbled 30% after Raymond James downgraded the company's stock to underperform from outperform. DexCom (DXCM) shares fell 5.3% after Raymond James lowered its price target to $131 from $154 while keeping the strong buy rating. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Slump as Tech Stock Weakness Weighs on the Overall Market What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) Friday closed down -1.22%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.83% and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.75%. Stocks on Friday closed moderately lower, with the S&P 500 and Nasdaq 100 posting 1-week lows. An increase in T-note yields on Friday undercut technology stocks and weighed on the overall market. Also, chipmaker stocks were under pressure after Reuters reported that Taiwan Semiconductor Manufacturing Co asked its major suppliers to delay shipment of high-end chipmaking equipment. Stocks extended their losses Friday after the University of Michigan U.S. Sep consumer sentiment fell more than expected. Friday\u2019s quarterly triple witching options event may have added fuel to the decline in stocks. Derivatives contracts tied to stocks, index options, and futures for September expired on Friday, prompting traders to roll over their existing positions or start new ones. A positive factor for stocks Friday was signs that China\u2019s economy rebounded in August after consumer spending and factory output strengthened. China Aug industrial production rose +4.5% y/y, stronger than expectations of +3.9% y/y and the biggest increase in 4 months. Also, China Aug retail sales rose +4.6% y/y, stronger than expectations of +3.0% y/y. Bank of America said EPFR Global data shows investors poured $26.4 billion into U.S. equities in the week ended September 13, the biggest weekly inflow since March 2022. Also, global stocks attracted $25.3 billion of inflows. The U.S. import price index ex-petroleum was unchanged m/m for a second month, right on expectations. The U.S. Sep Empire manufacturing survey general business conditions rose +20.9 to 1.9, stronger than expectations of -10.0. The University of Michigan U.S. Sep consumer sentiment fell -1.8 to 67.7, weaker than expectations of 69.0. The University of Michigan U.S. Sep 1-year inflation expectations unexpectedly eased to a 2-1/2 year low of 3.1%, better than expectations of no change at 3.5%. Also, the Sep 5-10-year inflation expectations eased to a year low of 2.7%, better than expectations of no change at 3.0%. The markets are discounting the odds at 4% for a +25 bp rate hike at the September 20 FOMC meeting and 33% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields Friday moved higher. The 10-year T-note yield rose +3.6 bp to 4.322%. The 10-year German bund yield rose +8.2 bp to 2.675%. The 10-year UK gilt yield rose +7.7 bp to 4.358%. Overseas stock markets Friday settled mixed. The Euro Stoxx 50 closed +0.36%. China\u2019s Shanghai Composite Index closed -0.28%. Japan\u2019s Nikkei Stock Index closed +1.10%. Today\u2019s stock movers\u2026 Nucor (NUE) closed down more than -6% to lead losers in the S&P 500 after reporting Q3 preliminary EPS of $4.10-$4.20, weaker than the consensus of $4.56. Dexcom (DXCM) closed down more than -5% after Raymond James cut its price target on the stock to $131 from $154. Chip stocks retreated Friday after Reuters reported that Taiwan Semiconductor Manufacturing Co asked its major suppliers to delay shipment of high-end chipmaking equipment. As a result, KLA Corp (KLAC) and Lam Research (LRCX) closed down more than -5%. Also, Applied Materials (AMAT), ASML Holding NV (ASML), Advanced Micro Devices (AMD), and Globalfoundries (GFS) closed down more than -4%. In addition, Nvidia (NVDA), ON Semiconductor (ON), and Microchip Technology (MCHP) closed down more than -3%. Adobe (ADBE) closed down more than -4% after reporting Q3 earnings results that beat expectations but gave an outlook that analysts see as conservative. Insulet (PODD) closed down more than -2% to lead losers in the S&P 500 after Raymond James cut its price target on the stock to $228 from $299. Homebuilders moved lower after Lennar forecast Q4 new orders of 16,200 to 17,200, the midpoint below the consensus of 16,591. As a result, Toll Brothers (TOL) and PulteGroup (PHM) closed down more than -3%, and Lennar (LEN) and DR Horton (DHI) closed down more than -2%. DoorDash (DASH) closed down more than -2% after MoffettNathanson downgraded the stock to market perform from outperform. Charles Schwab (SCHW) closed down more than -2% after reporting August client assets of $8.09 trillion, down -2% from July. Truist Financial (TFC) closed down more than -1% after Piper Sandler downgraded the stock to neutral from overweight. Walt Disney (DIS) closed up more than +1% to lead gainers in the Dow Jones Industrials after Bloomberg reported the company had held exploratory talks about selling its ABC network and TV stations to Nexstar Media Group. Moderna (MRNA) closed up more than +1% to lead gainers in the Nasdaq 100 after the UK\u2019s Medicines and Healthcare Products Regulatory Agency approved the company\u2019s Covid-19 vaccine Spikevax. Host Hotels & Resorts (HST) closed up more than +2% after the company raised its regular quarterly cash dividend to 18 cents per share, above forecasts of 15 cents. AT&T (T) closed up more than +1%, adding to Thursday\u2019s +2% gain after it said it is confident in its full-year guidance and expects Q3 free cash flow in the range of $4.5 billion-$5.0 billion. JB Hunt Transport Services (JBHT) closed up more than +1% after it announced that it had entered into a definitive agreement to buy the brokerage operations of BNSF Logistics LLC. Warner Bros Discovery (WBD) closed up nearly +1% after the CFO said the company is looking at potential sales of some of its \u201cnon-core\u201d assets and that it expects to raise prices on monthly Max subscriptions. Across the markets\u2026 December 10-year T-notes (ZNZ23) on Friday closed down -7.5 ticks, and the 10-year T-note yield rose +3.6 bp to 4.322%. T-notes were under pressure Friday on negative carryover from a fall in European government bonds after hawkish ECB comments pushed European bond yields higher. Also, Friday\u2019s stronger-than-expected U.S. economic news on Sep Empire manufacturing activity and Aug industrial production was bearish for T-notes. Prices recovered from their worst levels after the University of Michigan Sep consumer sentiment and inflation expectations fell more than expected. More Stock Market News from Barchart Dollar Slips on Weak U.S. Consumer Sentiment Crude Prices Finish Higher on Dollar Weakness and Chinese Energy Demand Optimism Nat-Gas Prices Edge Lower on the Outlook for Cooler U.S. Temps Grain Markets: Will Wheat, Soybean, and Corn Prices Rebound? On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom Stock Dove by 5% Today What happened A notable price target cut from an analyst was followed by a dip in the price of DexCom (NASDAQ: DXCM) stock on Friday. Investors traded out of the specialty medical device maker, reducing its value by more than 5%. That was a far steeper decline than the 1.2% slide of the benchmark S&P 500 index. So what Raymond James prognosticator Jayson Bedford was the person behind the chop. Before market open, he snipped his DexCom price target to $131 per share from its preceding level of $154. That was the bad news. The good news was that he maintained his strong buy recommendation on the healthcare stock. Bedford isn't the only analyst who has trimmed his expectations on DexCom lately. Last week, Danielle Antalffy of UBS also lowered her price target significantly, reducing it to $138 from her previous $175. Like Bedford, she remained bullish on the stock, leaving her buy recommendation intact. In spite of those cuts, optimism is still in the air for DexCom due to the company's position on the market. It is a leader in the lucrative niche segment of continuous blood glucose monitoring. Last last year, it launched a new device, the G7, which it claims is the most accurate monitoring product on the market. It also boasts the fastest warm-up time, according to the company. Now what Collectively, the analysts currently tracking DexCom are anticipating growth both this and next year. They're modeling a nearly 22% improvement in revenue for 2023 over the previous year, and an almost 43% leap in per-share profitability. In 2024, those metrics are projected to grow by 20% and 30%, respectively. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 11, 2023 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Raymond James Maintains Dexcom (DXCM) Strong Buy Recommendation Fintel reports that on September 15, 2023, Raymond James maintained coverage of Dexcom (NASDAQ:DXCM) with a Strong Buy recommendation. Analyst Price Forecast Suggests 50.03% Upside As of August 31, 2023, the average one-year price target for Dexcom is 152.36. The forecasts range from a low of 131.30 to a high of $183.75. The average price target represents an increase of 50.03% from its latest reported closing price of 101.55. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1923 funds or institutions reporting positions in Dexcom. This is an increase of 23 owner(s) or 1.21% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.46%, a decrease of 1.84%. Total shares owned by institutions decreased in the last three months by 0.15% to 437,992K shares. The put/call ratio of DXCM is 1.10, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in DXCM by 172.17% over the last quarter. Sands Capital Management holds 13,103K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 13,739K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in DXCM by 0.57% over the last quarter. Jpmorgan Chase holds 12,673K shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 10,765K shares, representing an increase of 15.06%. The firm increased its portfolio allocation in DXCM by 825.09% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,102K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 11,965K shares, representing an increase of 1.14%. The firm increased its portfolio allocation in DXCM by 3.23% over the last quarter. VFINX - Vanguard 500 Index Fund Investor Shares holds 9,229K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 9,017K shares, representing an increase of 2.31%. The firm increased its portfolio allocation in DXCM by 2.55% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 09/15/2023: RYZB, PTCT, DXCM Health care stocks were declining Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%. The iShares Biotechnology ETF (IBB) was decreasing 0.3%. In company news, RayzeBio (RYZB) shares jumped 37% after debuting on Nasdaq earlier in the day. PTC Therapeutics (PTCT) shares tumbled 30% after Raymond James downgraded the company's stock to underperform from outperform. DexCom (DXCM) shares fell 4.2% after Raymond James lowered its price target to $131 from $154 while keeping the strong buy rating. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Tumble on Higher Bond Yields and Tech Stock Weakness What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is down -0.93%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.55%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.50%. Stock indexes this morning are moderately lower, with the Nasdaq 100 falling to a 1-week low. An increase in T-note yields today is undercutting technology stocks and weighing on the overall market. Also, chipmaker stocks are under pressure after Reuters reported that Taiwan Semiconductor Manufacturing Co asked its major suppliers to delay shipment of high-end chipmaking equipment. Stocks extended their losses after the University of Michigan U.S. Sep consumer sentiment fell more than expected. Market activity today may be volatile due to the triple witching options event. Derivatives contracts tied to stocks, index options, and futures for September are scheduled to expire today, prompting traders to roll over their existing positions or start new ones. Stocks have support on signs that China\u2019s economy rebounded in August after consumer spending and factory output strengthened. China Aug industrial production rose +4.5% y/y, stronger than expectations of +3.9% y/y and the biggest increase in 4 months. Also, China Aug retail sales rose +4.6% y/y, stronger than expectations of +3.0% y/y. Bank of America said EPFR Global data shows investors poured $26.4 billion into U.S. equities in the week ended September 13, the biggest weekly inflow since March 2022. Also, global stocks attracted $25.3 billion of inflows. The U.S. import price index ex-petroleum was unchanged m/m for a second month, right on expectations. The U.S. Sep Empire manufacturing survey general business conditions rose +20.9 to 1.9, stronger than expectations of -10.0. The University of Michigan U.S. Sep consumer sentiment fell -1.8 to 67.7, weaker than expectations of 69.0. The University of Michigan U.S. Sep 1-year inflation expectations unexpectedly eased to a 2-1/2 year low of 3.1%, better than expectations of no change at 3.5%. Also, the Sep 5-10-year inflation expectations eased to a year low of 2.7%, better than expectations of no change at 3.0%. The markets are discounting the odds at 4% for a +25 bp rate hike at the September 20 FOMC meeting and 37% for that +25 bp rate hike at the November 1 FOMC meeting. Global bond yields are higher. The 10-year T-note yield is up +3.2 bp at 4.318%. The 10-year German bund yield is up +7.6 bp at 2.669%. The 10-year UK gilt yield is up +7.0 bp at 4.351%. Overseas stock markets are mixed. The Euro Stoxx 50 is up +0.26%. China\u2019s Shanghai Composite Index closed -0.28%. Japan\u2019s Nikkei Stock Index closed +1.10%. Today\u2019s stock movers\u2026 Insulet (PODD) is down more than -4% to lead losers in the S&P 500 after Raymond James cut its price target on the stock to $228 from $299. Homebuilders are falling today after Lennar forecast Q4 new orders of 16,200 to 17,200, the midpoint below the consensus of 16,591. As a result, Lennar (LEN) is down more than -4%. Also, DR Horton (DHI), Toll Brothers (TOL), and PulteGroup (PHM) are down more than -3%. Charles Schwab (SCHW) is down more than -4% after reporting August client assets of $8.09 trillion, down -2% from July. Adobe (ADBE) is down more than -4% to lead losers in the S&P 500 after reporting Q3 earnings results that beat expectations but gave an outlook that analysts see as conservative. Dexcom (DXCM) is down more than -4% after Raymond James cut its price target on the stock to $131 from $154. Chip stocks are moving lower after Reuters reported that Taiwan Semiconductor Manufacturing Co asked its major suppliers to delay shipment of high-end chipmaking equipment. As a result, Applied Materials (AMAT), ASML Holding NV (ASML), and KLA Corp (KLAC) are down more than -3%. Also, Advanced Micro Devices (AMD), Globalfoundries (GFS), and Lam Research (LRCX) are down more than -2%. DoorDash (DASH) is down more than -3% after MoffettNathanson downgraded the stock to market perform from outperform. Nucor (NUE) is down more than -2% after reporting Q3 preliminary EPS of $4.10-$4.20, weaker than the consensus of $4.56. DocuSign (DOCU) is down more than -2% after HSBC initiated coverage of the stock with a recommendation of reduce and a price target of $42. Truist Financial (TFC) is down more than -2% after Piper Sandler downgraded the stock to neutral from overweight. Estell Lauder (EL) is up more than +2% to lead gainers in the S&P 500 after Redburn Atlantic upgraded the stock to neutral from sell. Media stocks are climbing today after the Alliance of Motion Picture & Television Producers agreed to hold talks next week aimed at ending a strike by writers that started in May. As a result, Paramount Global (PARA) is up more than +4%. Also, Fox Corp (FOXA) is up more than +1%. Walt Disney (DIS) is up more than +1% to lead gainers in the Dow Jones Industrials after Bloomberg reported the company has held exploratory talks about selling its ABC network and TV stations to Nexstar Media Group. Warner Bros Discovery (WBD) is up more than +2% to lead gainers in the Nasdaq 100 after the CFO said the company is looking at potential sales of some of its \u201cnon-core\u201d assets and that it expects to raise prices on monthly Max subscriptions. Host Hotels & Resorts (HST) is up more than +1% after the company raised its regular quarterly cash dividend to 18 cents per share, above forecasts of 15 cents. Across the markets\u2026 December 10-year T-notes (ZNZ23) today are down -7 ticks, and the 10-year T-note yield is up +3.2 bp at 4.318%. T-notes are under pressure today on negative carryover from a fall in European government bonds on hawkish ECB comments. Also, today\u2019s stronger-than-expected U.S. economic news on Sep Empire manufacturing activity and Aug industrial production is bearish for T-notes. Prices recovered from their worst levels after the University of Michigan Sep consumer sentiment and inflation expectations fell more than expected. The dollar index (DXY00) today is down by -0.19%. The dollar is under pressure after today\u2019s news showed the University of Michigan Sep consumer sentiment and inflation expectations fell more than expected, which is dovish for Fed policy. Also, hawkish ECB comments today boosted EUR/USD at the dollar\u2019s expense. Higher T-note yields today are limiting losses in the dollar. EUR/USD (^EURUSD) is up by +0.27%. Hawkish ECB comments today are lifting the euro. ECB President Lagarde said the ECB is not discussing interest rate cuts and ECB Governing Council member Vasle said he wouldn\u2019t exclude further ECB interest rate hikes. Eurozone Q2 labor costs eased to +4.5% y/y from +5.2% y/y in Q1. ECB President Lagarde said the level of borrowing costs and the length of time they stay elevated \""will matter significantly\"" and that the ECB is not discussing interest rate cuts. ECB Governing Council member Vasle said core inflation is still \""relatively high\"" and \""I wouldn't exclude that further interest rate hikes might be necessary.\"" USD/JPY (^USDJPY) is up +0.12%. The yen today fell to a 10-1/4 month low against the dollar. Today\u2019s rally in the Nikkei Stock index to a 1-1/4 month high has reduced the safe-haven demand for the yen. Also, higher T-note yields today are weighing on the yen. In addition, the yen fell on a report that said the BOJ sees a discrepancy between BOJ Governor Ueda\u2019s recent comments and how traders interpreted the remarks, saying Ueda\u2019s reference to a potential to end negative rates was a general statement rate rather than a policy signal. The Japan Jul tertiary industry index rose +0.9% m/m, stronger than expectations of +0.3% m/m. October gold (GCV3) today is up +18.6 (+0.97%), and Dec silver (SIZ23) is up +0.521 (+2.27%). Precious metals prices this morning are moderately higher, with silver climbing to a 1-week high. The dollar\u2019s weakness today is supportive for metals. Also, stock weakness today has boosted the safe-haven demand for precious metals. In addition, silver garnered support after a report on China Aug industrial production was stronger than expected, a bullish factor for industrial metals demand. Bearish factors included higher global bond yields and the continued liquidation of gold holdings by funds after long gold holdings in ETFs fell to a 3-1/3 year low Thursday. More Stock Market News from Barchart Why Netgear (NTGR) May Finally Make Good on Its Discount Markets Today: Stocks Slip on Higher Bond Yields and Chip Stock Weakness Stock Index Futures Slide as Investors Look Ahead to Fed Decision, UAW Walkout in Focus Stocks Close Higher on Optimism the U.S. Economy is Headed for a Soft Landing On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-18,95.69,96.64,94.85,95.295,"[""Interesting DXCM Put And Call Options For March 2024 Investors in DexCom Inc (Symbol: DXCM) saw new options begin trading this week, for the March 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 179 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new March 2024 contracts and identified one put and one call contract of particular interest. The put contract at the $90.00 strike price has a current bid of $7.80. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $90.00, but will also collect the premium, putting the cost basis of the shares at $82.20 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $94.86/share today. Because the $90.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 65%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.67% return on the cash commitment, or 17.67% annualized \u2014 at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $90.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $100.00 strike price has a current bid of $10.00. If an investor was to purchase shares of DXCM stock at the current price level of $94.86/share, and then sell-to-open that call contract as a \""covered call,\"" they are committing to sell the stock at $100.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 15.96% if the stock gets called away at the March 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 47%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 10.54% boost of extra return to the investor, or 21.50% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 45%, while the implied volatility in the call contract example is 43%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $94.86) to be 43%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 \u00bb Also see: \u0095 Gas Utilities Dividend Stocks \u0095 Funds Holding EQCN \u0095 Institutional Holders of SCHG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stock-Split Stocks Billionaire Investors Can't Stop Buying Volatility has been readily apparent on Wall Street for more than three years. Investors have been taken for quite the ride, which has included two bear markets (2020 and 2022), as well as a period where the stock market appeared virtually unstoppable (2021). When equities get whipsawed, professional and everyday investors often turn to companies that have a history of outperforming. Over the past two years, companies enacting stock splits fit the bill perfectly. A \""stock split\"" is an event which allows a publicly traded company to change both its share price and outstanding share count while having no effect on its market cap or operating performance. This purely cosmetic change can make a company's shares more nominally affordable for investors who lack access to fractional-share purchases, or can lift a company's share price to ensure it meets the minimum requirements for continued listing on a major exchange. Image source: Getty Images. Most investors tend to gravitate to forward-stock splits, which are the type that reduce a company's share price while increasing its share count by the same factor. Companies enacting forward splits are usually highfliers with phenomenal long-term growth prospects. Since the start of July 2021, eight high-profile stocks have enacted forward splits, with a ninth on the way later this week (listed in chronological order by date of split): Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022 Shopify (NYSE: SHOP): 10-for-1 split in June 2022 Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL): 20-for-1 split in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023 Novo Nordisk (NYSE: NVO): 2-for-1 split to be effective on Sept. 20, 2023 The outperformance of these nine stock-split stocks isn't lost on Wall Street's billionaire investors. Based on the latest round of Form 13F filings, billionaires couldn't stop buying three stock-split stocks. Stock-split stock No. 1 billionaires can't stop buying: Nvidia Despite its share price shooting to the heavens since the year began, billionaire money managers have had no hesitation piling into semiconductor solutions specialist Nvidia. The June-ended quarter saw 11 billionaire fund managers buy into the Nvidia growth story or add to their existing positions, including (total shares purchased in the second quarter in parenthesis): Jeff Yass of Susquehanna International (5,401,204 shares) Jim Simons of Renaissance Technologies (1,852,712 shares) Israel Englander of Millennium Management (1,023,518 shares) David Tepper of Appaloosa Management (870,000 shares) Steven Cohen of Point72 Asset Management (662,385 shares) Stephen Mandel of Lone Pine Capital (641,649 shares) David Siegel and John Overdeck of Two Sigma Investments (629,072 shares) Chase Coleman of Tiger Global Management (584,700 shares) Dan Loeb of Third Point (500,000 shares) Ole Andreas Halvorsen of Viking Global Investors (312,400 shares) The impetus behind this overwhelming conviction is the rise of artificial intelligence (AI). AI involves using software and systems to cover tasks normally assigned to humans. With machine learning, AI solutions have the ability to learn, evolve, and become more efficient at their tasks over time. Nvidia is effectively powering the AI revolution. Its high-powered graphics processing units (GPUs) are being used in a majority of AI-accelerated data centers. Nvidia's A100 and H100 GPUs are believed to account for around 90% of high-compute GPUs in enterprise data centers. The thing is, Nvidia is just getting started. Production of the A100 and H100 have been constrained by chip on wafer on substrate (CoWos) capacity at chip fabrication giant Taiwan Semiconductor Manufacturing Company, which is commonly known as \""TSMC.\"" With TSMC doubling its CoWoS capacity, Nvidia should be able to vastly increase its output of A100 and H100 GPUs in 2024, and likely well beyond. What remains to be seen is if Nvidia can hold its monstrous year-to-date gains. Competition is set to pick up in a big way from the likes of Advanced Micro Devices and Intel over the next two years. Additionally, increasing output is expected to be detrimental to Nvidia's pricing power. As scarcity is removed and businesses reassess their AI needs, Nvidia could see its calendar year 2024 gross margin come under serious pressure. Stock-split stock No. 2 billionaires can't stop buying: Novo Nordisk A second stock-split stock that Wall Street's billionaire investors simply can't get enough of is pharmaceutical giant Novo Nordisk, which is splitting its shares this coming Wednesday. Four prominent billionaire fund managers mashed the buy button on Novo Nordisk during the second quarter (total shares purchased in the second quarter in parenthesis): Chase Coleman at Tiger Global Management (634,500 shares) David Siegel and John Overdeck at Two Sigma Investments (301,341 shares) Israel Englander at Millennium Management (95,273 shares) The catalyst behind this optimism from billionaires primarily has to do with Novo Nordisk's injectable glucagon-like peptide-1 (GLP-1) drugs Ozempic, Saxenda, and Wegovy. The former is used to treat type 2 diabetes, with the latter two are approved by the U.S. Food and Drug Administration for chronic weight management. Ozempic is Novo Nordisk's shining star, with sales totaling nearly $6 billion in the first-half of 2023, up 58% from the prior-year period. GPL-1 therapies are a potential game-changer for those seeking/needing to lose weight. GLP-1 receptor agonists cause the stomach to empty more slowly, as well as signal to the brain that there's still food in the stomach, which collectively leads to less desire to eat. Considering that close to 42% of American adults were estimated to be obese in 2017, per the Centers for Disease Control and Prevention, a potentially massive opportunity awaits Novo Nordisk. However, it won't be walk in the park for Novo Nordisk, even if it does have a head start with its lineup of GLP-1 receptor agonists. New competition is on the horizon that could eventually give Ozempic a run for its money. Likewise, Novo Nordisk is being priced for perfection. After 25 years of investing on Wall Street and studying drug developers, I can assure you that virtually nothing ever goes according to plan. Image source: Getty Images. Stock-split stock No. 3 billionaires can't stop buying: Shopify The third stock-split stock that billionaires seemingly can't stop buying is cloud-based e-commerce platform Shopify. The June-ended quarter saw five billionaires pile into Shopify stock, including (total shares purchased in the second quarter in parenthesis): Ken Griffin of Citadel Advisors (1,704,417 shares) Steven Cohen of Point72 Asset Management (1,510,804 shares) David Siegel and John Overdeck of Two Sigma Investments (872,211 shares) Israel Englander of Millennium Management (605,022 shares) The fuel behind billionaires' interest in Shopify looks to be a combination of better-than-expected economic data, as well as better-than-anticipated growth for the company. With regard to the former, we've witnessed the Federal Reserve remove prior forecasts of a U.S. recession, and have seen the U.S. unemployment rate remain steadily below 4%. Since the retail industry is highly cyclical, an improving macroeconomic outlook bodes well for retailers and the company (Shopify) they're using to create and manage their online retail presence. As for Shopify, it's used the power of its platform to pass along hefty price hikes to its monthly and annual subscribers. As my Foolish colleague Danny Vena laid out in January, monthly subscription prices rose by 33% or 34%, while annual subscription costs nearly doubled for those who took advantage of a 50%-off promotion for their first year of service. Having the ability to raise prices by this magnitude has solidified Shopify's strong double-digit growth rate. However, it's worth pointing out that U.S. real retail sales -- retail sales growth less the rate of inflation -- has been negative on a year-over-year basis in each of the past 10 months. While Shopify's price hikes are hitting home, consumer sentiment is still shaky, at best. Similar to Nvidia and Novo Nordisk, Shopify is also aggressively priced for growth. But with forecast earnings in 2023 that would place its price-to-earnings ratio in the triple-digits, it's fair to question if the company's sizable year-to-date gain can hold up under potential macro pressures. 10 stocks we like better than Nvidia When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Nvidia wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 11, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet, Amazon.com, and Intel. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends DexCom, Intel, and Novo Nordisk and recommends the following options: long January 2023 $57.50 calls on Intel and long January 2025 $45 calls on Intel. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-19,95.29,95.31,92.77,94.16,"[""DexCom (DXCM) Dips More Than Broader Markets: What You Should Know DexCom (DXCM) closed at $94.16 in the latest trading session, marking a -1.19% move from the prior day. This change lagged the S&P 500's daily loss of 0.22%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq lost 0.23%. Prior to today's trading, shares of the medical device company had lost 8.97% over the past month. This has lagged the Medical sector's loss of 2.99% and the S&P 500's gain of 2.08% in that time. Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. In that report, analysts expect DexCom to post earnings of $0.34 per share. This would mark year-over-year growth of 21.43%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $936.02 million, up 21.62% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.54 billion. These totals would mark changes of +41.38% and +21.74%, respectively, from last year. Investors might also notice recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 77.42. Its industry sports an average Forward P/E of 28.63, so we one might conclude that DexCom is trading at a premium comparatively. Meanwhile, DXCM's PEG ratio is currently 1.8. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.07 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 112, which puts it in the top 45% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""First Week of DXCM December 15th Options Trading Investors in DexCom Inc (Symbol: DXCM) saw new options become available this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 87 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DXCM options chain for the new December 15th contracts and identified one put and one call contract of particular interest. The put contract at the $90.00 strike price has a current bid of $5.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $90.00, but will also collect the premium, putting the cost basis of the shares at $84.50 (before broker commissions). To an investor already interested in purchasing shares of DXCM, that could represent an attractive alternative to paying $93.62/share today. Because the $90.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.11% return on the cash commitment, or 25.63% annualized \u2014 at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $90.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $95.00 strike price has a current bid of $7.60. If an investor was to purchase shares of DXCM stock at the current price level of $93.62/share, and then sell-to-open that call contract as a \""covered call,\"" they are committing to sell the stock at $95.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.59% if the stock gets called away at the December 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DXCM shares really soar, which is why looking at the trailing twelve month trading history for DexCom Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DXCM's trailing twelve month trading history, with the $95.00 strike highlighted in red: Considering the fact that the $95.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 46%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 8.12% boost of extra return to the investor, or 34.04% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 44%, while the implied volatility in the call contract example is 43%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $93.62) to be 43%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of the Nasdaq 100 \u00bb Also see: \u0095 Insider Buying \u0095 TXMD YTD Return \u0095 XLV Average Annual Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Vanguard Mid-Cap ETF (VO) Be on Your Investing Radar? Designed to provide broad exposure to the Mid Cap Blend segment of the US equity market, the Vanguard Mid-Cap ETF (VO) is a passively managed exchange traded fund launched on 01/26/2004. The fund is sponsored by Vanguard. It has amassed assets over $53.73 billion, making it one of the largest ETFs attempting to match the Mid Cap Blend segment of the US equity market. Why Mid Cap Blend Mid cap companies, with market capitalization in the range of $2 billion and $10 billion, offer investors many things that small and large companies don't, including less risk and higher growth opportunities. These types of companies, then, have a good balance of stability and growth potential. Blend ETFs usually hold a mix of growth and value stocks as well as stocks that exhibit both value and growth characteristics. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.04%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 1.62%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Industrials sector--about 16.30% of the portfolio. Information Technology and Financials round out the top three. Looking at individual holdings, Motorola Solutions Inc. (MSI) accounts for about 0.81% of total assets, followed by Dexcom Inc. (DXCM) and Amphenol Corp. (APH). The top 10 holdings account for about 5.87% of total assets under management. Performance and Risk VO seeks to match the performance of the CRSP US Mid Cap Index before fees and expenses. The CRSP US Mid Cap Index targets inclusion of the U.S. companies that fall between the top 70%-85% of investable market capitalization. The ETF has gained about 6.53% so far this year and was up about 6.72% in the last one year (as of 09/19/2023). In the past 52-week period, it has traded between $186.57 and $228.23. The ETF has a beta of 1.09 and standard deviation of 19.30% for the trailing three-year period, making it a medium risk choice in the space. With about 341 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard Mid-Cap ETF holds a Zacks ETF Rank of 1 (Strong Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VO is an outstanding option for investors seeking exposure to the Style Box - Mid Cap Blend segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares Russell Mid-Cap ETF (IWR) and the iShares Core S&P Mid-Cap ETF (IJH) track a similar index. While iShares Russell Mid-Cap ETF has $28.37 billion in assets, iShares Core S&P Mid-Cap ETF has $72.64 billion. IWR has an expense ratio of 0.19% and IJH charges 0.05%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard Mid-Cap ETF (VO): ETF Research Reports Amphenol Corporation (APH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Motorola Solutions, Inc. (MSI) : Free Stock Analysis Report iShares Core S&P Mid-Cap ETF (IJH): ETF Research Reports iShares Russell Mid-Cap ETF (IWR): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Will DexCom Stock Recover To Its Pre-Inflation Shock Highs of $160? DexCom stock (NASDAQ: DXCM) currently trades at $102 per share, about 36% higher than the level seen in early June 2022, just before the Fed started increasing rates, compared to 19% gains for the S&P 500 during this period. The rally in the stock over recent months has been driven by a steady decline in the inflation rate in response to the Fed\u2019s aggressive rate hike plan \u2013 although investors still have concerns about a potential recession. The notable increase in DexCom\u2019s revenues over recent quarters has also contributed to the stock recovery. Interestingly, DexCom stock has had a Sharpe Ratio of 0.7 since early 2017, higher than 0.6 for the S&P 500 Index over the same period. This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds. Despite its outperformance over the last twelve months or so, DXCM stock is still much lower than its pre-inflation shock high of $163, seen in late 2021. It has seen an 11% decline in the last month or so. This can be attributed to the reduced risk of cardiovascular events for obesity drugs of Novo Nordisk and likely Eli Lilly. Investors are concerned about the possible broader applications of obesity drugs and their impact on medical devices used to manage diabetes. Returning to the pre-inflation shock level means that DXCM stock will have to gain more than 60% from here. We believe that will materialize over time. DXCM currently trades at 13x revenues compared to its last five-year average of 21x, implying that the stock is undervalued. Our DexCom Valuation Ratios Comparison dashboard has more details. Our detailed analysis of DexCom\u2019s upside post-inflation shock captures trends in the company\u2019s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock\u2019s performance during the 2008 recession. 2022 Inflation Shock Timeline of Inflation Shock So Far: 2020 \u2013 early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up. Early 2021: Shipping snarls and worker shortages from the coronavirus pandemic continue to hurt supply. April 2021: Inflation rates cross 4% and increase rapidly. Early 2022: Energy and food prices spike due to the Russian invasion of Ukraine. Fed begins its rate hike process. June 2022: Inflation levels peak at 9% \u2013 the highest level in 40 years. The S&P 500 index declined more than 20% from peak levels. July \u2013 September 2022: Fed hikes interest rates aggressively \u2013 resulting in an initial recovery in the S&P 500 followed by another sharp decline. Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses. In contrast, here\u2019s how DXCM stock and the broader market performed during the 2007/2008 crisis. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index. 9/1/2008 \u2013 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08). 3/1/2009: Approximate bottoming out of S&P 500 index. 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008). DexCom And S&P500 Performance During 2007-08 Financial Crisis DXCM stock saw a 61% decline from $3 in September 2007 (pre-crisis peak) to $1 in March 2009 (as the markets bottomed out). It recovered sharply post the 2008 crisis to levels of around $2 in early 2010, rising about 100% between March 2009 and January 2010. The S&P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to reach levels of 1,124. DexCom\u2019s Fundamentals Over Recent Years DexCom\u2019s revenue rose 117% to $3.2 billion over the last twelve months, compared to $1.5 billion in 2019. New customer additions are leading the revenue growth for DexCom amid rising awareness of CGM devices. DexCom is among the few players with regulatory approvals for its wearable continuous glucose monitoring (CGM) device. Not only has the company seen stellar revenue growth, but it also saw its margin expand from 9.4% in 2019 to 14.0% now. Our DexCom Operating Income Comparison dashboard has more details. Does DexCom Have A Sufficient Cash Cushion To Meet Its Obligations Through The Ongoing Inflation Shock? DexCom\u2019s total debt increased from $1.1 billion in 2019 to $2.0 billion in 2022, while its cash increased from around $0.4 billion to $0.6 billion. The company also garnered $0.7 billion in cash flows from operations in 2022. Given its solid cash cushion, the company is in a good position to service its near-term obligations. Conclusion With the Fed\u2019s efforts to tame runaway inflation rates helping market sentiment, we believe DXCM stock has the potential for gains once fears of a potential recession are allayed. That said, the concerns over the broader application of obesity drugs and its impact on DexCom remain a key risk factor for realizing these gains. While DXCM stock looks like it can see higher levels over time, it is helpful to see how DexCom\u2019s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons. Returns Sep 2023 MTD [1] 2023 YTD [1] 2017-23 Total [2] DXCM Return 1% -10% 580% S&P 500 Return 0% 17% 101% Trefis Reinforced Value Portfolio -2% 29% 564% [1] Month-to-date and year-to-date as of 9/15/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-20,95.37,95.81,92.36,92.63,"3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its own. DexCom (NASDAQ: DXCM), Eli Lilly (NYSE: LLY), and West Pharmaceutical Services (NYSE: WST) are three stocks that have each turned $100,000 investments into $1 million over the past 10 years. Let's take a closer look at why these three businesses have done so well and better understand whether their stocks are still good buys. 1. DexCom Diabetes company DexCom has been hugely successful over the years. It makes continuous glucose monitoring (CGM) devices that help people with diabetes manage their glucose levels. And like with any device, there are always innovations and improvements that give users an incentive to upgrade to the latest iteration. DexCom's newest CGM, the G7, is smaller than the previous model and has a more discrete design, requires less warm-up time, and the company says it is ""the most accurate CGM."" As the number of people with diabetes increases, so too does the potential user base for one of DexCom's CGMs. Plus, as the company makes enhancements to those products, that can also drive more revenue growth for the business. The company's revenue totaled $2.9 billion last year, growing by 19% year over year. With profit margins of around 12%, the business's bottom line is also in good shape to rise along with revenue. Over the past 10 years, DexCom has turned a $100,000 investment into its business into more than $1.5 million today. Although it's a pricey stock to own at more than 100 times its trailing earnings, given the long-term growth opportunities the business possesses, it could still make for a great healthcare stock to buy for the long haul. 2. Eli Lilly Pharmaceutical giant Eli Lilly has been a great investment to own, as it would have turned a $100,000 investment 10 years ago into approximately $1.1 million today. Its top line wasn't all that impressive last year, as revenue of $28.5 billion was only slightly higher than the $28.3 billion that it generated in the previous year. But it's the company's future growth prospects that have investors bullish about the business. Diabetes drug Mounjaro generated just under $1 billion in revenue last quarter, for the period ending June 30. It's a promising drug that analysts have high hopes for, with some estimating that its peak annual sales could top $100 billion. The potential comes from its ability to be a highly effective weight-loss treatment. In clinical trials, some patients lost as much as 26% of their body weight over a 20-month timeframe. And with many weight-related illnesses that it could potentially help treat, the opportunities for the drug are through the roof. Eli Lilly is a great example of when earnings multiples may be of little use, given how much upside there may be in the long run. While the stock looks expensive, trading at around 80 times its profits, it could still look cheap if Mounjaro gets close to hitting its potential. If you're willing to buy and hold for years, Eli Lilly is still a stock worth buying right now. 3. West Pharmaceutical Services Another top healthcare stock to own over the past decade has been West Pharmaceutical Services. The company designs and makes drug delivery and packaging systems. Its products include seals, vials, and stoppers. It has benefited from the pharmaceutical industry's growth as its revenue has doubled over the past decade, and its bottom line has increased at an even faster rate. WST Revenue (Annual) data by YCharts. This year, the company expects sales to come in at just under $3 billion, reflecting no more than 4% revenue growth as a drop in demand for COVID-19 products is weighing down the business. But in the long run, there's still much more growth potential ahead for the business. At nearly 60 times earnings, West Pharmaceutical Services is technically the cheapest stock on this list. Although investors might still find it expensive, if you're hanging on for the long term, this can also be a good investment as the business is relatively stable and it reports strong profit margins of 18%. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 18, 2023 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-21,92.34,92.38,88.85,89.08,"3 Unstoppable Nasdaq 100 Stocks Just Waiting to Be Bought InvestorPlace - Stock Market News, Stock Advice & Trading Tips A remarkable 30-year bull run for the Nasdaq 100 saw it gain nearly 4,000% by 2020. But, the party came to a screeching halt when the pandemic hit. Within a matter of weeks the tech-heavy index lost a third of its value and plunged deep into a bear market. Yet just as quickly, it made a U-turn and more than doubled again over the next 18 months. While that roller coaster ride was intense, it’s been a bit rocky since, and the Nasdaq 100 still hasn’t regained those former highs. It is within striking distance, though, sitting just 7% below its former peak. For investors with a long-term mindset, this means bargains still abound. What follows are three unstoppable Nasdaq stocks to buy right now. DexCom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com Medical device manufacturer DexCom (NASDAQ:DXCM) specializes in continuous glucose monitors (CGM) used by diabetics and is the second largest player behind Abbott Labs (NYSE:ABT). In the market for Type 1 diabetes, though, DexCom is the leader by a better than 2-to-1 margin. According to a UBS (NYSE:UBS) analysis, 83% of people with Type 1 diabetes will use a CGM, suggesting DexCom’s lead will continue to grow. However, Type 2 diabetes could be the place of growth for the medical device specialist’s future. UBS expects just 30% of Type 2 diabetics will use a CGM at the start of the next decade. But the number of people taking basal insulin, the slow-release type that regulates blood sugar throughout the day, is expected to grow to 50% of the diabetic population. Further, 21 million Type 2 diabetics don’t take insulin at all. Analysts see that as the biggest opportunity for CGM sales. And once DexCom taps the international market, it will realize additional continued market share increases. The medical device company raised full-year revenue forecasts from a range of 17% to 21% growth to one of 20% to 22% growth. That is largely the due to sales outside of the U.S. Even so, the market slashed DexCom’s stock by a third. Two analysts also recently cut their price targets, though they left their buy recommendations intact. DexCom’s stock is not cheap on a price-to-earnings, price-to-sales, or free cash flow basis, but the long and broad runway of opportunity it faces makes it worth the premium. Palo Alto Networks (PANW) Source: Sundry Photography / Shutterstock.com Premiere cybersecurity company Palo Alto Networks (NASDAQ:PANW) is enjoying significant growth in recent years. Cybersecurity is an essential component of doing business these days, thanks to the growing number of threats to privacy. The Identity Theft Research Center says data breaches are on a record-breaking run this year. There were 951 incidents of compromised data in Q2 and over 1,390 events in the first six months of 2023. That’s driving their billings higher, which saw a 23% increase in fiscal 2023. Equally important, the cybersecurity expert is able to dramatically increase its production of free cash flow. FCF this year was more than $2.6 billion, a 47% increase over 2022 and nearly double from the year prior. Palo Alto Networks just split its stock 3-for-1 on Sept. 14 indicating a very bullish sentiment by management. Although shares are up 72% year to date (YTD), this industry’s fast-growing business has no ceiling. Sirius XM Holdings (SIRI) Source: Shutterstock A decade or so ago Sirius XM Holdings (NASDAQ:SIRI) wasn’t that good of an investment. However, the business has improved. Sirius investors only gained a 19% total return over the past ten years. The S&P 500 tripled in value in that time frame while the Nasdaq 100 grew five-fold. So why buy Sirius now? Shares are down 30% YTD on fears of ad revenue drying up and a recession taking a toll on new vehicle sales. First, the auto industry is coming out of its slump. New car sales surged 15% higher in August year over year (YOY), which should increase new subscription sales where actually makes most of its money. Q2 revenue was $2.25 billion with subscriptions accounting for $1.73 billion worth. Most of Sirius’ ad revenue came from the music streaming service Pandora that it acquired four years ago. Also, SIRI still produces a lot of cash. Management forecasts it will end the year with $1.2 billion of free cash flow. The stock trades at just 12 times next year’s earnings estimates, less than twice its sales, and a deeply discounted 12 times FCF. Yet over the past decade, it solidified its finances and now offers an attractive valuation. On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L’Express, and numerous other news outlets. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post 3 Unstoppable Nasdaq 100 Stocks Just Waiting to Be Bought appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-22,88.4,89.0,87.14,87.5,
DXCM,2023-09-25,87.13,87.22,85.31,86.06,"[""Markets Today: Stocks Lower on Concern about Hawkish Global Central Banks Morning Markets December E-Mini S&P 500 futures (ESZ23) are down -0.32%, and the Dec Nasdaq 100 E-Mini futures (NQZ23) are down -0.33%. Stock index futures this morning are mildly lower, following losses in European stocks, on speculation global central banks will keep interest rates higher for longer to combat inflation. European stocks are under pressure after the 10-year German bund yield jumped to a 12-year high today of 2.811%, and the 10-year T-note yield rose to a new 16-year high of 4.509%. The stock market is also concerned about a possible U.S. government shutdown this Sunday when the fiscal year begins on Oct 1. U.S. and European stocks are also under pressure on concerns that China\u2019s property debt crisis is worsening after China Evergrande Group canceled a creditor meeting today and said it must revisit its restructuring plan. The ongoing debt crisis in China threatens to derail the country\u2019s growth prospects and drag down the global economy. Today\u2019s news showed the U.S. Aug Chicago Fed national activity index fell -0.23 -0.16, weaker than expectations of 0.10. Morgan Stanley warned today that risks are rising for U.S. consumer stocks on \""slowing consumer spending, resumption of student loan payments, rising delinquencies in certain household cohorts, higher gasoline prices, and weakening data in the housing sector.\"" Also, 44% of stocks in the consumer discretionary sector are trading below their 200-day moving averages, pointing to additional weakness. The markets are discounting a 19% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 47% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields today are higher. The 10-year T-note yield rose to a new 16-year high of 4.509% and is up +6.7 bp at 4.501%. The 10-year German bund yield climbed to a 12-year high of 2.811% and is up +5.6 bp at 2.795%. The 10-year UK gilt yield is up +5.5 bp at 4.304%. Overseas stock markets are mixed today. The Euro Stoxx 50 is down -1.15%. China\u2019s Shanghai Composite Index closed -0.54%. Japan\u2019s Nikkei 225 today closed +0.85%. The Euro Stoxx 50 today tumbled to a 5-3/4 month low on speculation global central banks will keep interest rates higher for longer to combat inflation. European government bonds retreated and weighed on stocks as the 10-year German bund yield rose to a 12-year high today. Weakness in mining stocks and metals producers are leading the overall market lower as China\u2019s worsening property problems weighed on the outlook for commodities. On the positive side, today\u2019s economic news showed the Sep German IFO business climate index fell less than expected. ECB Governing Council member Kazaks said the ECB's \""very appropriate\"" +25 bp interest rate hike in September may allow for a pause in October. The Sep German IFO business climate index fell by -0.1 to 85.7, stronger than expectations of 85.2. China\u2019s Shanghai Composite Stock Index today closed moderately higher. Weakness in Chinese property developers led the overall market lower today on concerns that China\u2019s property debt crisis is worsening. China Evergrande Group today scrapped a creditor meeting and said it must revisit its restructuring plan. Also, China Oceanwide Holdings Ltd. disclosed it is facing liquidation after a Bermuda court issued a winding-up order against the company and involved a $175 million loan principal that wasn\u2019t paid. In addition, concerns are growing that Chian Country Garden Holdings may suffer an imminent default. There are fears that China\u2019s property debt crisis will next hit China\u2019s commercial banks and keep home prices under pressure, further hurting consumer confidence. Japan\u2019s Nikkei Stock Index today posted moderate gains as weakness in the yen sparked a rally in exporter stocks. The Japanese yen fell to a 10-3/4 month low against the dollar on negative carryover from last Friday after the BOJ held monetary policy steady, and BOJ Governor Ueda said the distance from being able to adjust the negative rate hasn't changed much. Also, BOJ Governor Ueda said today that the BOJ needs to continue with monetary easing as uncertainties around wage gains and inflation are high, and therefore, the goal of achieving 2% inflation accompanied by wage gains hasn\u2019t yet \u201ccome in sight.\u201d Pre-Market U.S. Stock Movers Footwear companies are retreating today after Jeffries downgraded Nike, Foot Locker, and Urban Outfitters to hold from buy, citing slower spending by U.S. students and ongoing Chinese headwinds. As a result, Foot Locker (FL) and Urban Outfitters (URBN) are down more than -2%, and Nike (NKE) is down more than -1%. Dexcom (DXCM) is down more than -1% in pre-market trading after a weekend article in Barron\u2019s said the emergence of GLP-1 drugs to treat obesity has already started to hurt shares of companies treating obesity complications. HP Inc (HPQ) dropped more than -1% in pre-market trading after an SEC filing showed holder Berkshire Hathaway sold $129 million of shares over the past three sessions. Morphic Holding (MORF) tumbled more than -4% in pre-market trading after BTIG downgraded the stock to neutral from buy. Film and entertainment stocks rallied in pre-market trading after striking screenwriters reached a tentative labor agreement with Hollywood Studios. As a result, Warner Bros Discovery (WBD) and Paramount Global (PARA) are up more than +2%. Also, Walt Disney (DIS) and Netflix (NFLX) are up more than +1%. Dow Inc (DOW) gained more than +1% in pre-market trading after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $55. CarMax (KMX) climbed more than +2% in pre-market trading after Wedbush upgraded the stock to outperform from neutral with a price target of $90. Earnings Reports (9/25/2023) Thor Industries Inc (THO), Waldencast Plc (WALD). More Stock Market News from Barchart Market Heat Check: Top 10 Stocks Riding High on Implied Volatility Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Fed Speak 3 Spinoff Companies That Are Seriously Undervalued GDP, Consumer Confidence and Other Can't Miss Items This Week On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Recover Early Losses on Soft Landing Optimism for the U.S. Economy What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.40%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.46%. Stocks on Monday recovered from early losses and closed moderately higher as short-covering emerged on comments from Chicago Fed President Goolsbee, who said it's possible for the U.S. to avoid a recession and have a soft landing. Stocks on Monday initially opened lower, with the S&P 500 falling to a 3-1/2 month low, the Dow Jones Industrials posting a 2-1/2 month low, and the Nasdaq 100 dropping to a 5-week low. Stocks were under early pressure Monday on speculation global central banks will keep interest rates higher for longer to combat inflation. The 10-year German bund yield jumped to a 12-year high Monday of 2.812%, and the 10-year T-note yield climbed to a new 16-year high of 4.546%. The stock market is also concerned about a possible U.S. government shutdown this Sunday when the fiscal year begins on Oct 1. Another negative for stocks is the concern that China\u2019s property debt crisis is worsening after China Evergrande Group canceled a creditor meeting on Sunday and said it must revisit its restructuring plan. The ongoing debt crisis in China threatens to derail the country\u2019s growth prospects and drag down the global economy. Monday\u2019s U.S. economic news was weaker than expected and bearish for stocks. The Aug Chicago Fed national activity index fell -0.23 -0.16, weaker than expectations of 0.10. Also, the Aug Dallas Fed manufacturing outlook level of general business activity unexpectedly fell -0.9 to -18.1, weaker than expectations of an increase to -14.0. Morgan Stanley warned Monday that risks are rising for U.S. consumer stocks on \""slowing consumer spending, resumption of student loan payments, rising delinquencies in certain household cohorts, higher gasoline prices, and weakening data in the housing sector.\"" Also, 44% of stocks in the consumer discretionary sector are trading below their 200-day moving averages, pointing to additional weakness. The markets are discounting a 19% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 46% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields Monday moved higher. The 10-year T-note yield rose to a new 16-year high of 4.546% and finished up +10.4 bp at 4.538%. The 10-year German bund yield climbed to a 12-year high of 2.812% and finished up +5.8 bp at 2.798%. The 10-year UK gilt yield rose +7.4 bp to 4.323%. Overseas stock markets Monday settled mixed. The Euro Stoxx 50 closed -0.95%. China\u2019s Shanghai Composite Index closed -0.54%. Japan\u2019s Nikkei 225 today closed +0.85%. Today\u2019s stock movers\u2026 Sealed Air Corp (SEE) closed up more than +3% to lead gainers in the S&P 500 after Citigroup upgraded the stock to buy from neutral. Dow Inc (DOW) closed up more than +1% to lead gainers in the Dow Jones Industrials after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $55. Nvidia (NVDA) closed up more than +1% after Morgan Stanley said the recent drop in the stock has created \u201canother buying opportunity.\u201d Amazon.com (AMZN) closed up more than +1% after the company said it would invest as much as $4 billion in AI startup Anthropic and Wedbush said that investment \u201cshould ease investor concerns that Amazon has been less proactive than its peers in its approach to generative AI.\u201d Steel Dynamics (STLD) and Cleveland-Cliffs (CLF) closed up more than +3% after Citigroup upgraded both stocks to buy from neutral. CarMax (KMX) closed up more than +1% after Wedbush upgraded the stock to outperform from neutral with a price target of $90. Cruise line operators retreated Monday on rising interest rates after the 10-year T-note yield rose to a 16-year high. The higher rates may reduce the profitability of the companies that rely on borrowing costs to finance their operations and fleet expansion. As a result, Carnival (CCL), Norwegian Cruise Line Holdings (NCLH), and Royal Caribbean Cruises (RCL) closed down more than -1%. Packaged food stocks and food producers moved lower Monday with Conagra Brands (CAG), Kellog (K), Keurig Dr Pepper (KDP), Campbell Soup (CPB), McCormick & Co (MCK), Coca-Cola (KO), and Modelez International (MDLZ) closing down more than -1%. Morphic Holding (MORF) closed down more than -36% after BTIG downgraded the stock to neutral from buy. MarketAxcess Holdings (MKTX) closed down more than -2% after Citigroup placed the stock on a 30-day downside catalyst watch, citing its Q3 EPS estimate that is already 13% below consensus. Dexcom (DXCM) closed down more than -1% after a weekend article in Barron\u2019s said the emergence of GLP-1 drugs to treat obesity has already started to hurt shares of companies treating obesity complications. HP Inc (HPQ) closed down more than -1% after an SEC filing showed holder Berkshire Hathaway sold $129 million of shares over the past three sessions. Across the markets\u2026 December 10-year T-notes (ZNZ23) Monday closed down -16.5 ticks. The 10-year T-note yield rose +10.4 bp to 4.538%. Dec T-notes Monday sold off to a 16-year nearest-futures low, and the 10-year T-note yield soared to a 16-year high of 4.546%. Carryover pressure from a slide in German bunds weighed on T-note prices as the 10-year German bund yield Monday rose to a 12-year high of 2.812%. Also, supply pressures are undercutting T-note prices as the Treasury readies to sell $158 billion of T-notes and floating-rate notes this week, starting with Tuesday\u2019s $48 billion auction of 2-year T-notes. In addition, a rebound in stocks on Monday reduced the safe-haven demand for T-notes. More Stock Market News from Barchart Dollar Climbs on Rising Bond Yields Crude Prices Settle Lower on Dollar Strength and Chinese Energy Demand Concerns Nat-Gas Prices Little Changed on a Mixed U.S. Weather Outlook HTZ Stock: Navigating the Crossroads of Revenge Travel and Market Volatility On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Mixed as Global Bond Yields Climb The S&P 500 Index ($SPX) (SPY) today is up +0.23%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.02%, and the Nasdaq ($IUXX) (QQQ) is up +0.26%. Stocks are mixed, with the S&P 500 earlier in the day falling to a 3-1/2 month low, the Dow Jones Industrials posting a 2-1/2 month low, and the Nasdaq 100 dropping to a 5-week low. There is speculation global central banks will keep interest rates higher for longer to combat inflation. European stocks are under pressure after the 10-year German bund yield jumped to a 12-year high today of 2.812%, and the 10-year T-note yield rose to a new 16-year high of 4.531%. The stock market is also concerned about a possible U.S. government shutdown this Sunday when the fiscal year begins on Oct 1. U.S. and European stocks are also under pressure on concerns that China\u2019s property debt crisis is worsening after China Evergrande Group canceled a creditor meeting today and said it must revisit its restructuring plan. The ongoing debt crisis in China threatens to derail the country\u2019s growth prospects and drag down the global economy. Today\u2019s U.S. economic news was weaker than expected and bearish for stocks. The Aug Chicago Fed national activity index fell -0.23 -0.16, weaker than expectations of 0.10. Also, the Aug Dallas Fed manufacturing outlook level of general business activity unexpectedly fell -0.9 to -18.1, weaker than expectations of an increase to -14.0. Morgan Stanley warned today that risks are rising for U.S. consumer stocks on \""slowing consumer spending, resumption of student loan payments, rising delinquencies in certain household cohorts, higher gasoline prices, and weakening data in the housing sector.\"" Also, 44% of stocks in the consumer discretionary sector are trading below their 200-day moving averages, pointing to additional weakness. The markets are discounting a 19% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 44% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields today are higher. The 10-year T-note yield rose to a new 16-year high of 4.531% and is up +8.3 bp at 4.517%. The 10-year German bund yield climbed to a 12-year high of 2.812% and is up +5.7 bp at 2.797%. The 10-year UK gilt yield is up +8.51bp at 4.3294%. Overseas stock markets are mixed today. The Euro Stoxx 50 is down -1.31%. China\u2019s Shanghai Composite Index closed -0.54%. Japan\u2019s Nikkei 225 today closed +0.85%. Today\u2019s stock movers\u2026 Airline stocks are under pressure today on signs of weakened travel demand after data from Bloomberg Second Measure shows the observed sales decline among airlines for the week ending Sep 17 averages more than -7% from a year earlier. As a result, United Airlines Holdings (UAL), American Airlines Group (AAL), Delta Air Lines (DAL), Alaska Air Group (ALK), and Southwest Airlines (LUV) are down more than -1%. Cruise line operators are falling on rising interest rates today as the 10-year T-note yield rose to a 16-year high. The higher rates may reduce the profitability of the companies that rely on borrowing costs to finance their operations and fleet expansion. As a result, Carnival (CCL) is down more than -2% to lead losers in the S&P 500. Also, Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Cruises (RCL) are down more than -1%. Footwear companies are retreating today after Jeffries downgraded Nike, Foot Locker, and Urban Outfitters to hold from buy, citing slower spending by U.S. students and ongoing Chinese headwinds. As a result, Foot Locker (FL) is down more than -4%, Urban Outfitters (URBN) is down more than -1%, and Nike (NKE) is down -0.5%. Morphic Holding (MORF) is down more than -14% after BTIG downgraded the stock to neutral from buy. Dexcom (DXCM) is down more than -1% after a weekend article in Barron\u2019s said the emergence of GLP-1 drugs to treat obesity has already started to hurt shares of companies treating obesity complications. MarketAxcess Holdings (MKTX) is down more than -1% after Citigroup placed the stock on a 30-day downside catalyst watch, citing its Q3 EPS estimate that is already 13% below consensus. HP Inc (HPQ) is down -0.5% after an SEC filing showed holder Berkshire Hathaway sold $129 million of shares over the past three sessions. Sealed Air Corp (SEE) is up more than +3% to lead gainers in the S&P 500 after Citigroup upgraded the stock to buy from neutral. Nvidia (NVDA) is up more than +1% after Morgan Stanley said the recent drop in the stock has created \u201canother buying opportunity.\u201d Amazon.com (AMZN) is up more than +1% after the company said it would invest as much as $4 billion in AI startup Anthropic and Wedbush said that investment \u201cshould ease investor concerns that Amazon has been less proactive than its peers in its approach to generative AI.\u201d Dow Inc (DOW) is up more than +1% to lead gainers in the Dow Jones Industrials after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $55. CarMax (KMX) is up more than +1% after Wedbush upgraded the stock to outperform from neutral with a price target of $90. Steel Dynamics (STLD) and Cleveland-Cliffs (CLF) are up more than +1% after Citigroup upgraded both stock to buy from neutral. Across the markets\u2026 December 10-year T-notes (ZNZ23) today are down -12 ticks, and the 10-year T-note yield is up +8.3 bp at 4.517%. Dec T-notes today sank to a 16-year nearest-future slow, and the 10-year T-note yield jumped to a 16-year high at 4.531%. Carryover pressure from a slide in German bunds is weighing on T-note prices as the 10-year German bund yield today rose to a 12-year high of 2.812%. Also, supply pressures are undercutting T-note prices as the Treasury readies to sell $158 billion of T-notes and floating-rate notes this week. The dollar index (DXY00) today is up by +0.26% and posted a new 6-1/2 month high. The dollar has support today on rising bond yields, with the 10-year T-note climbing to a 16-year high. Also, the weakness in stocks today has boosted the liquidity demand for the dollar. In addition, the dollar has carryover support from last Wednesday when the Fed signaled one more +25 bp rate hike this year and projected the fed funds rate next year +50 bp higher than they projected back in June. EUR/USD (^EURUSD) today is down by -0.54% and dropped to a 6-1/2 month low. Dollar strength today is weighing on the euro along with dovish ECB comments. ECB Governing Council member Kazaks said the ECB's 25 bp rate hike this month may allow for a pause at its October meeting. Losses in EUR/USD were limited after the Sep German IFO business climate fell less than expected. ECB President Lagarde said, \""Our future decisions will ensure that the key ECB interest rates will be set at sufficiently restrictive levels for as long as necessary.\"" ECB Governing Council member Kazaks said the ECB's \""very appropriate\"" 25 bp interest rate hike in September may allow for a pause in October. The Sep German IFO business climate fell by -0.1 to 85.7, stronger than expectations of 85.2. USD/JPY (^USDJPY) is up +0.28%. The yen today tumbled to a 10-3/4 month low against the dollar. The yen is under pressure today on dovish comments from BOJ Governor Ueda, who said the BOJ needs to continue with monetary easing as uncertainties around wage gains and inflation are high, and therefore, the goal of achieving 2% inflation accompanied by wage gains hasn\u2019t yet \u201ccome in sight.\u201d October gold (GCV3) today is down -3.2 (-0.17%), and Dec silver (SIZ23) is down -0.189 (-0.79%). Precious metals prices today are moderately lower. Today\u2019s rally in the dollar index to a 6-1/2 month high is undercutting metals prices. Also, soaring global government bond yields are bearish for precious metals after the 10-year German bund yield today rose to a 12-year high and the 10-year T-note yield rose to a 16-year high. Losses in precious metals are limited as weakness in stocks today has boosted some safe-haven demand for precious metals. More Stock Market News from Barchart 2 Undervalued Dividend Stocks with 5% Yields To Buy Near 52-Week Lows Markets Today: Stocks Lower on Concern about Hawkish Global Central Banks Market Heat Check: Top 10 Stocks Riding High on Implied Volatility Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Fed Speak On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked... Volatility has been the name of the game on Wall Street since this decade began. The major indexes have vacillated between bear and bull markets since the start of 2020, which has encouraged investors to seek out the safety of companies that have long track records of outperformance. While the FAANG stocks have been a popular choice for ages, it's stocks enacting splits that have really drawn investors' attention over the past two years. Image source: Getty Images. Investors can't get enough of stock-split stocks A stock split is an event which allows a publicly traded company to alter its share price and outstanding share count without having any impact on its market cap or operating performance. This purely cosmetic change can make shares more nominally affordable for investors without access to fractional-share purchases, or can be used to increase the share price of a publicly traded company to ensure it meets the minimum listing standards for major exchanges. Most investors tend to pile into companies enacting forward-stock splits, which reduces a company's share price and increases its outstanding share count by the same factor. Businesses enacting forward splits are usually out-executing and out-innovating their competition. Since the start of July 2021, nine high-profile companies have enacted stock splits (listed in chronological order by the effective date of their split): Nvidia (NASDAQ: NVDA): 4-for-1 split conducted in July 2021 Amazon (NASDAQ: AMZN): 20-for-1 split conducted in June 2022 DexCom (NASDAQ: DXCM): 4-for-1 split conducted in June 2022 Shopify (NYSE: SHOP): 10-for-1 split conducted in June 2022 Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split conducted in July 2022 Tesla (NASDAQ: TSLA): 3-for-1 split conducted in August 2022 Palo Alto Networks (NASDAQ: PANW): 3-for-1 split conducted in September 2022 Monster Beverage (NASDAQ: MNST): 2-for-1 split conducted in March 2023 Novo Nordisk (NYSE: NVO): 2-for-1 split conducted in September 2023 NVDA data by YCharts. These are all businesses that offer well-defined competitive advantages and/or sustained double-digit growth catalysts -- and their share price performance reflects this. Nvidia accounts for around 90% of all graphics processing units used in artificial intelligence (AI)-accelerated data centers. Amazon's e-commerce marketplace brought in nearly $0.40 of every $1 spent in U.S. online retail sales in 2022. DexCom is one of the two leading providers of continuous glucose monitoring systems. Shopify holds approximately 28% of e-commerce platform market share in the U.S. Alphabet's Google has totaled no less than 90% of worldwide monthly internet search share since March 2015. Tesla is the leading electric-vehicle (EV) manufacturer in North America, and the only profitable pure-play EV producer. Palo Alto Networks is one of only two cybersecurity companies to have a greater than 20% share of the network security space. Monster Beverage is No. 2 in U.S. energy drink market share, with just over 30%, as of 2022. Novo Nordisk's glucagon-like peptide-1 (GLP-1) drugs (Ozempic, Saxenda, and Wegovy) appear to be game-changers in the weight-loss department. However, these nine high-profile stock-split stocks sport very different valuations. Image source: Getty Images. Which stock-split stock is the cheapest? Traditionally, the price-to-earnings (P/E) ratio or forward P/E ratio -- which divides a company's current share price into Wall Street's forecast earnings per share (EPS) for the upcoming year -- are used to determine whether or not a stock is a good value. While the forward P/E ratio can be particularly useful for mature businesses, it can sometimes fail to tell the full story with growth stocks that are regularly reinvesting their operating cash flow. With few exceptions, the stock-split stocks listed above tend to aggressively reinvest their operating cash flow into high-growth initiatives. For this reason, forward-year cash flow, not forward-year EPS, is the better value determinant among these nine high-profile stock-split stocks. What you see below is the forward-year multiple to cash flow for each of the nine high-profile stock-split stocks: Amazon: 12.5 Alphabet (Class A shares, GOOGL): 14.62 Palo Alto Networks: 23.52 Nvidia: 24.77 Monster Beverage: 30.94 DexCom: 34.49 Tesla: 42.5 Novo Nordisk: 61.52 Shopify: 75.75 There are certainly surprises in this list. For instance, Nvidia and Palo Alto Networks aren't as pricey as their traditional P/E ratio suggests. By comparison, Tesla, Novo Nordisk, and Shopify are quite expensive, compared to the other stock-split stocks. But the biggest shock of all is that Amazon is the cheapest stock-split stock, when based on forward-year cash flow. Here's why Amazon is a phenomenal value I'll be the first to admit that Amazon's forward-year P/E ratio of 44 isn't flattering. The company's desire to reinvest in high-growth operating segments and logistics can, at times, lead to some disappointing bottom-line results. But make no mistake about it, Amazon is a phenomenal value, and it's because of the company's rapidly growing operating cash flow. Most investors are familiar with Amazon because of its world-leading e-commerce platform. While it's true that Amazon generates a sizable percentage of its annual sales from online retail, this is actually a low-margin segment for the company. The bulk of Amazon's operating cash flow comes from three fast-growing ancillary divisions: Amazon Web Services (AWS), advertising services, and subscription services. AWS is, without question, the most-important puzzle piece to Amazon's success. Tech analysis company Canalys pegged AWS's global share of cloud infrastructure service spending at 30%, as of the end of June. That's world-leading market share with enterprise cloud spending still in its very early innings. Despite accounting for around a sixth of Amazon's net sales, AWS is frequently responsible for the lion's share of the company's operating income. Amazon is also one of the most-visited websites in the world. From November 2022 through April 2023, it drew between 2.2 billion and 2.7 billion monthly visits. Garnering this many eyeballs, many of which are actively looking to purchase something, is a lure that advertisers simply can't resist. Excluding currency movements, advertising services have grown by at least 21% on a year-over-year basis in each of the past eight quarters. Lastly, Amazon has delivered sustained double-digit, currency-neutral sales growth from its subscription services segment. The popularity of its online retail marketplace, as well as its exclusive rights to Thursday Night Football, have lifted its global Prime subscriber count above 200 million, as of April 2021. Amazon should have little issue raising annual Prime subscription prices given the value proposition it offers members. Amazon is a well-oiled machine that's on track to more than triple its operating cash flow between 2022 ($4.59/share, reported) and 2026 ($14.88/share, estimated). If it can hit Wall Street's consensus forecast in 2026, it'll be valued at just 9 times cash flow. That's considerably below the multiple of 23 to 37 times cash flow it traded at from 2010 through 2019, and it demonstrates how much of a value Amazon stock is right now. 10 stocks we like better than Amazon.com When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 18, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool recommends Alphabet, Amazon.com, DexCom, Monster Beverage, Novo Nordisk, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Under Pressure as Global Bond Yields Climb The S&P 500 Index ($SPX) (SPY) today is down -0.14%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.17%. Stocks this morning are moderately lower, with the S&P 500 falling to a 3-1/2 month low, the Dow Jones Industrials posting a 2-1/2 month low, and the Nasdaq 100 dropping to a 5-week low. Stocks are falling today on speculation global central banks will keep interest rates higher for longer to combat inflation. European stocks are under pressure after the 10-year German bund yield jumped to a 12-year high today of 2.812%, and the 10-year T-note yield rose to a new 16-year high of 4.531%. The stock market is also concerned about a possible U.S. government shutdown this Sunday when the fiscal year begins on Oct 1. U.S. and European stocks are also under pressure on concerns that China\u2019s property debt crisis is worsening after China Evergrande Group canceled a creditor meeting today and said it must revisit its restructuring plan. The ongoing debt crisis in China threatens to derail the country\u2019s growth prospects and drag down the global economy. Today\u2019s U.S. economic news was weaker than expected and bearish for stocks. The Aug Chicago Fed national activity index fell -0.23 -0.16, weaker than expectations of 0.10. Also, the Aug Dallas Fed manufacturing outlook level of general business activity unexpectedly fell -0.9 to -18.1, weaker than expectations of an increase to -14.0. Morgan Stanley warned today that risks are rising for U.S. consumer stocks on \""slowing consumer spending, resumption of student loan payments, rising delinquencies in certain household cohorts, higher gasoline prices, and weakening data in the housing sector.\"" Also, 44% of stocks in the consumer discretionary sector are trading below their 200-day moving averages, pointing to additional weakness. The markets are discounting a 19% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 44% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields today are higher. The 10-year T-note yield rose to a new 16-year high of 4.531% and is up +8.3 bp at 4.517%. The 10-year German bund yield climbed to a 12-year high of 2.812% and is up +5.7 bp at 2.797%. The 10-year UK gilt yield is up +8.51bp at 4.3294%. Overseas stock markets are mixed today. The Euro Stoxx 50 is down -1.31%. China\u2019s Shanghai Composite Index closed -0.54%. Japan\u2019s Nikkei 225 today closed +0.85%. Today\u2019s stock movers\u2026 Airline stocks are under pressure today on signs of weakened travel demand after data from Bloomberg Second Measure shows the observed sales decline among airlines for the week ending Sep 17 averages more than -7% from a year earlier. As a result, United Airlines Holdings (UAL), American Airlines Group (AAL), Delta Air Lines (DAL), Alaska Air Group (ALK), and Southwest Airlines (LUV) are down more than -1%. Cruise line operators are falling on rising interest rates today as the 10-year T-note yield rose to a 16-year high. The higher rates may reduce the profitability of the companies that rely on borrowing costs to finance their operations and fleet expansion. As a result, Carnival (CCL) is down more than -2% to lead losers in the S&P 500. Also, Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Cruises (RCL) are down more than -1%. Footwear companies are retreating today after Jeffries downgraded Nike, Foot Locker, and Urban Outfitters to hold from buy, citing slower spending by U.S. students and ongoing Chinese headwinds. As a result, Foot Locker (FL) is down more than -4%, Urban Outfitters (URBN) is down more than -1%, and Nike (NKE) is down -0.5%. Morphic Holding (MORF) is down more than -14% after BTIG downgraded the stock to neutral from buy. Dexcom (DXCM) is down more than -1% after a weekend article in Barron\u2019s said the emergence of GLP-1 drugs to treat obesity has already started to hurt shares of companies treating obesity complications. MarketAxcess Holdings (MKTX) is down more than -1% after Citigroup placed the stock on a 30-day downside catalyst watch, citing its Q3 EPS estimate that is already 13% below consensus. HP Inc (HPQ) is down -0.5% after an SEC filing showed holder Berkshire Hathaway sold $129 million of shares over the past three sessions. Sealed Air Corp (SEE) is up more than +3% to lead gainers in the S&P 500 after Citigroup upgraded the stock to buy from neutral. Nvidia (NVDA) is up more than +1% after Morgan Stanley said the recent drop in the stock has created \u201canother buying opportunity.\u201d Amazon.com (AMZN) is up more than +1% after the company said it would invest as much as $4 billion in AI startup Anthropic and Wedbush said that investment \u201cshould ease investor concerns that Amazon has been less proactive than its peers in its approach to generative AI.\u201d Dow Inc (DOW) is up more than +1% to lead gainers in the Dow Jones Industrials after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $55. CarMax (KMX) is up more than +1% after Wedbush upgraded the stock to outperform from neutral with a price target of $90. Steel Dynamics (STLD) and Cleveland-Cliffs (CLF) are up more than +1% after Citigroup upgraded both stock to buy from neutral. Across the markets\u2026 December 10-year T-notes (ZNZ23) today are down -12 ticks, and the 10-year T-note yield is up +8.3 bp at 4.517%. Dec T-notes today sank to a 16-year nearest-future slow, and the 10-year T-note yield jumped to a 16-year high at 4.531%. Carryover pressure from a slide in German bunds is weighing on T-note prices as the 10-year German bund yield today rose to a 12-year high of 2.812%. Also, supply pressures are undercutting T-note prices as the Treasury readies to sell $158 billion of T-notes and floating-rate notes this week. The dollar index (DXY00) today is up by +0.26% and posted a new 6-1/2 month high. The dollar has support today on rising bond yields, with the 10-year T-note climbing to a 16-year high. Also, the weakness in stocks today has boosted the liquidity demand for the dollar. In addition, the dollar has carryover support from last Wednesday when the Fed signaled one more +25 bp rate hike this year and projected the fed funds rate next year +50 bp higher than they projected back in June. EUR/USD (^EURUSD) today is down by -0.54% and dropped to a 6-1/2 month low. Dollar strength today is weighing on the euro along with dovish ECB comments. ECB Governing Council member Kazaks said the ECB's 25 bp rate hike this month may allow for a pause at its October meeting. Losses in EUR/USD were limited after the Sep German IFO business climate fell less than expected. ECB President Lagarde said, \""Our future decisions will ensure that the key ECB interest rates will be set at sufficiently restrictive levels for as long as necessary.\"" ECB Governing Council member Kazaks said the ECB's \""very appropriate\"" 25 bp interest rate hike in September may allow for a pause in October. The Sep German IFO business climate fell by -0.1 to 85.7, stronger than expectations of 85.2. USD/JPY (^USDJPY) is up +0.28%. The yen today tumbled to a 10-3/4 month low against the dollar. The yen is under pressure today on dovish comments from BOJ Governor Ueda, who said the BOJ needs to continue with monetary easing as uncertainties around wage gains and inflation are high, and therefore, the goal of achieving 2% inflation accompanied by wage gains hasn\u2019t yet \u201ccome in sight.\u201d October gold (GCV3) today is down -3.2 (-0.17%), and Dec silver (SIZ23) is down -0.189 (-0.79%). Precious metals prices today are moderately lower. Today\u2019s rally in the dollar index to a 6-1/2 month high is undercutting metals prices. Also, soaring global government bond yields are bearish for precious metals after the 10-year German bund yield today rose to a 12-year high and the 10-year T-note yield rose to a 16-year high. Losses in precious metals are limited as weakness in stocks today has boosted some safe-haven demand for precious metals. More Stock Market News from Barchart 2 Undervalued Dividend Stocks with 5% Yields To Buy Near 52-Week Lows Markets Today: Stocks Lower on Concern about Hawkish Global Central Banks Market Heat Check: Top 10 Stocks Riding High on Implied Volatility Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Fed Speak On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-26,85.62,88.74,85.34,88.62,"Tuesday Sector Leaders: Healthcare, Consumer Products In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, losing just 0.5%. Within that group, ResMed Inc. (Symbol: RMD) and DexCom Inc (Symbol: DXCM) are two of the day's stand-outs, showing a gain of 3.2% and 2.0%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.7% on the day, and down 2.95% year-to-date. ResMed Inc., meanwhile, is down 31.10% year-to-date, and DexCom Inc, is down 23.47% year-to-date. Combined, RMD and DXCM make up approximately 1.1% of the underlying holdings of XLV. The next best performing sector is the Consumer Products sector, losing just 0.7%. Among large Consumer Products stocks, Smith (A O) Corp (Symbol: AOS) and Mondelez International Inc (Symbol: MDLZ) are the most notable, showing a gain of 1.9% and 1.5%, respectively. One ETF closely tracking Consumer Products stocks is the iShares U.S. Consumer Goods ETF (IYK), which is down 1.6% in midday trading, and down 5.37% on a year-to-date basis. Smith (A O) Corp, meanwhile, is up 13.07% year-to-date, and Mondelez International Inc is up 8.00% year-to-date. MDLZ makes up approximately 4.5% of the underlying holdings of IYK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, none of the sectors are up on the day, while nine sectors are down. SECTOR % CHANGE Healthcare -0.5% Consumer Products -0.7% Energy -0.8% Services -0.9% Industrial -1.3% Technology & Communications -1.4% Materials -1.4% Financial -1.5% Utilities -2.1% 25 Dividend Giants Widely Held By ETFs » Also see: • KRO Dividend History • Funds Holding MVBF • Institutional Holders of DYAX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-09-27,89.56,92.94,89.56,92.09,"[""DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring DexCom, Inc. DXCM and privately-held RxFood Corporation have entered into an agreement to bring their respective expertise together and introduce an improved digital health solution for those with diabetes. The companies have partnered to introduce such services currently in Canada. RxFood is a leading company in the medical nutrition therapy segment. It uses powerful Artificial Intelligence models that help in dietary assessments and recommendations leveraging images of foods consumed by the users. The company is trying to create an impression of personalized nutrition and food as medicine. RxFood app has been primarily tested on families with diabetic children. Clinical data demonstrated that the app has helped reduce the time associated with day-to-day diabetes management for children by parents. The company\u2019s technology enables personalized care recommendations by providing more complete food records with higher accuracy (compared to manual entries) to clinicians. Price Performance Shares of DexCom have lost 21.7% year to date compared with the industry\u2019s 8.9% decline. The S&P 500 has witnessed 14.2% growth in the said time frame. Image Source: Zacks Investment Research Significance of the Deal DexCom is already providing a cutting-edge technology through its continuous glucose monitoring (CGM) systems like G6, G7 and others that is leading to better management of diabetes. The company\u2019s CGM technology has made it a leader in the diabetes care technology segment. DXCM has always focused on bringing industry-leading technology to improve and transform day-to-day management of diabetes. It will now introduce automatic food and nutrition tracking (with the help of RxFood app\u2019s image-recognition technology) to its CGM users. The company believes that continuous glucose monitoring is a key part of diabetes management but type, amount and timing of food intake are also important. The partnership will provide unified, time-matched food and glucose data reports. The addition of RxFood app to DexCom\u2019s CGM universe will help seamless recording of dietary metrics, which when combined with glucose data will enable personalized nutritional guidance at scale. The combined system will be available to Canadians with diabetes, following the commercial launch of Dexcom G6 CGM system or the Dexcom G7 CGM system. Currently, the RxFood app, featuring the Dexcom CGM glucose data integration, is available to health care program stakeholders across Canada including hospitals, insurers and employers. We note that DXCM is also partnering with automated insulin delivery makers like Insulet Corporation\u2019s PODD. The company\u2019s progress with its services will likely lead to the creation of an ecosystem, which will lead to more seamless diabetes management for patients through glucose monitoring, dietary assessment and insulin delivery, all without manual intervention. An efficient diabetes management system should lead to the accelerated adoption of DXCM\u2019s products. Notable Developments Earlier this month, DexCom announced that its G6 CGM system can now connect with the Insulet Corporation\u2019s Omnipod 5 Automated Insulin Delivery (AID) system in Germany. Insulet\u2019s Omnipod 5 automatically adjusts insulin delivery and manages glucose levels both day and night. Insulet\u2019s Omnipod 5 AID system is cleared for individuals with type 1 diabetes, aged 2 years and older. In July, DexCom announced that its next-generation G7 CGM system received Health Canada\u2019s approval for people with all types of diabetes, aged two years and above. The DexCom G7 has been built on the performance of DexCom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Other Key Picks DexCom currently carries a Zacks Rank #2 (Buy). A couple of other top-ranked stocks in the broader medical space are Align Technology ALGN and McKesson Corporation MCK. Align Technology, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. ALGN\u2019s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company\u2019s shares have risen 41.8% year to date compared with the industry\u2019s 11.5% growth. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. The stock has rallied 18.1% year to date compared with the industry\u2019s 11.5% growth. Just Released: Zacks Top 10 Stocks for 2023 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500\u2019s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don\u2019t miss your chance to still be among the first to get in on these just-released stocks. See New Top 10 Stocks >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar? If you're interested in broad exposure to the Mid Cap Growth segment of the US equity market, look no further than the Vanguard Mid-Cap Growth ETF (VOT), a passively managed exchange traded fund launched on 08/17/2006. The fund is sponsored by Vanguard. It has amassed assets over $10.23 billion, making it one of the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth With market capitalization between $2 billion and $10 billion, mid cap companies usually contain higher growth prospects than large cap companies, and are considered less risky than their small cap counterparts. Thus, companies that fall under this category provide a stable and growth-heavy investment. Qualities of growth stocks include faster growth rates compared to the broader market, as well as higher valuations and higher than average sales and earnings growth rates. Further, growth stocks have a higher level of volatility associated with them. They are likely to outperform value stocks in strong bull markets but over the longer-term, value stocks have delivered better returns than growth stocks in almost all markets. Costs Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Annual operating expenses for this ETF are 0.07%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.74%. Sector Exposure and Top Holdings Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 27.20% of the portfolio. Industrials and Healthcare round out the top three. Looking at individual holdings, Motorola Solutions Inc. (MSI) accounts for about 1.64% of total assets, followed by Dexcom Inc. (DXCM) and Amphenol Corp. (APH). The top 10 holdings account for about 14.26% of total assets under management. Performance and Risk VOT seeks to match the performance of the CRSP U.S. Mid Cap Growth Index before fees and expenses. The CRSP U.S. Mid Cap Growth Index measures the investment return of mid-capitalization growth stocks. The ETF has added about 7.18% so far this year and it's up approximately 13.49% in the last one year (as of 09/27/2023). In the past 52-week period, it has traded between $165.84 and $213.93. The ETF has a beta of 1.11 and standard deviation of 23.36% for the trailing three-year period, making it a medium risk choice in the space. With about 160 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard Mid-Cap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VOT is a great option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the iShares Russell Mid-Cap Growth ETF (IWP) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.32 billion in assets, iShares Russell Mid-Cap Growth ETF has $12.24 billion. IJK has an expense ratio of 0.17% and IWP charges 0.23%. Bottom-Line Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports Amphenol Corporation (APH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Motorola Solutions, Inc. (MSI) : Free Stock Analysis Report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-28,92.09,96.17,91.63,95.46,"[""Dynatronics Corporation (DYNT) Reports Q4 Loss, Tops Revenue Estimates Dynatronics Corporation (DYNT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -85.29%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.36, delivering a surprise of -125%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Dynatronics Corporation, which belongs to the Zacks Medical - Instruments industry, posted revenues of $8.44 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.02%. This compares to year-ago revenues of $11.19 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Dynatronics Corporation shares have lost about 63.2% since the beginning of the year versus the S&P 500's gain of 11.3%. What's Next for Dynatronics Corporation? While Dynatronics Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Dynatronics Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $9.4 million in revenues for the coming quarter and -$0.68 on $36.25 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, DexCom (DXCM), is yet to report results for the quarter ended September 2023. This medical device company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of +21.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. DexCom's revenues are expected to be $936.02 million, up 21.6% from the year-ago quarter. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dynatronics Corporation (DYNT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: WDAY, DXCM In early trading on Thursday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, DexCom has lost about 15.7% of its value. And the worst performing Nasdaq 100 component thus far on the day is Workday, trading down 7.8%. Workday is showing a gain of 27.1% looking at the year to date performance. Two other components making moves today are Micron Technology, trading down 5.5%, and Advanced Micro Devices, trading up 2.4% on the day. VIDEO: Nasdaq 100 Movers: WDAY, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: KMX, ALB In early trading on Thursday, shares of Albemarle topped the list of the day's best performing components of the S&P 500 index, trading up 4.1%. Year to date, Albemarle has lost about 21.9% of its value. And the worst performing S&P 500 component thus far on the day is Carmax, trading down 11.4%. Carmax is showing a gain of 16.0% looking at the year to date performance. Two other components making moves today are Accenture, trading down 5.0%, and DexCom, trading up 3.3% on the day. VIDEO: S&P 500 Movers: KMX, ALB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-09-29,97.37,97.58,93.13,93.3,"[""Buy this Tech Stock on the Dip in October for 50% Upside? DexCom, Inc. (DXCM) is a connected medical device standout that has posted steadily massive YoY growth as more people in the U.S. and globally suffer from diabetes. DexCom posted an impressive second quarter and provided upbeat guidance once again, yet its stock tumbled since its release as Wall Street took profits following a huge run off its lows. DXCM stock is currently down over 40% from its 2021 highs and trading 51% below its average Zacks price target even though it stands out in the connected health world that\u2019s likely to become standard medical practice. Vital Tech in a Growing Market DexCom makes continuous glucose monitoring systems designed for people with both type 1 and type 2 diabetes. The connected-health firm allows people with diabetes the opportunity to place a small sensor on their bodies to help them continuously monitor their glucose levels in real-time and avoid the dreaded finger prick. Users, caregivers, and others can monitor key levels via various compatible smart devices and wearables. DexCom\u2019s goal is to help its users \u201cmake better decisions in the moment with the most accurate CGM\u201d device to help \u201cmanage your diabetes with confidence\u201d and \u201clive a healthier, more confident life.\u201d Image Source: Zacks Investment Research DexCom\u2019s continuous glucose monitoring systems are part of a connected health revolution that appears poised to become the standard form of care and treatment in the future. DexCom\u2019s addressable market is growing rapidly even though 1 in 10 people in the U.S. already have diabetes, according to the CDC. Far more people currently have \u201cprediabetes\u201d in the U.S. Plus, rising diabetes rates are not just a U.S. issue considering that 1 in 10 people globally are living with diabetes and counting. The DexCom G6 and DexCom G7 are currently covered by Medicare for people who meet certain criteria. The company is also expanding its reach far beyond the U.S. Growth Outlook DXCM is projected to post roughly 20% sales growth in 2023 and 2024 to reach $4.26 billion next year, based on Zacks estimates. This top line growth follows 26% average expansion during the trailing three years and even stronger sales growth prior to that stretch. Meanwhile, Zacks estimates call for DexCom to grow its adjusted earnings by 41% this year and 30% higher next year. DXCM boasts an impressive history of bottom line beats and its positive earnings outlook helps it earn a Zacks Rank #2 (Buy) right now. Other Fundamentals DexCom shares have soared over 3,600% during the past 20 years and 1,200% over the last 10 years vs. the S&P 500\u2019s 164% and Zacks Tech Sector\u2019s 230%. More recently, DXCM is up 183% over the past five years, which includes roughly sideways movement in the trailing 36 months. DexCom has gone on a wild ride over the last three years, tumbling off its November 2021 highs alongside the Nasdaq. The stock then skyrocketed between June 2022 and the end of July 2023. Wall Street then utilized its earnings release as a chance to start cashing in. Image Source: Zacks Investment Research DXCM shares are currently trading 40% below their highs and 51% under their average Zacks price. The stock is trading below its 50-day and 200-day moving averages. But it could be set to find support around its 50-month moving average, which it has only broken below a few times over the last 15 years. Buyers also seem to be nibbling after it recently fell below its 200-week moving average. And DexCom is trading at some of its most historically oversold RSI levels. DXCM trades at a 22% discount to the Zacks Tech sector and 50% below its own three-year median, with a PEG ratio of 1.5. That said, one of the glaring drawbacks for DexCom in the new interest rate environment is that it is still trading at 63.7X forward 12-month earnings vs. Tech\u2019s 22.7X. Bottom Line Wall Street is still super high on the stock, with 15 of the 17 brokerage recommendations Zacks has at \u201cStrong Buys.\u201d Therefore, investors who can handle some risk might want to consider taking a chance on DexCom in the fourth quarter. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: BKR, ZS In early trading on Friday, shares of Zscaler topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.2%. Year to date, Zscaler registers a 41.9% gain. And the worst performing Nasdaq 100 component thus far on the day is Baker Hughes, trading down 1.3%. Baker Hughes is showing a gain of 22.4% looking at the year to date performance. Two other components making moves today are DexCom, trading down 1.0%, and Micron Technology, trading up 4.5% on the day. VIDEO: Nasdaq 100 Movers: BKR, ZS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Morgan Stanley Maintains Dexcom (DXCM) Equal-Weight Recommendation Fintel reports that on September 29, 2023, Morgan Stanley maintained coverage of Dexcom (NASDAQ:DXCM) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 59.60% Upside As of August 31, 2023, the average one-year price target for Dexcom is 152.36. The forecasts range from a low of 131.30 to a high of $183.75. The average price target represents an increase of 59.60% from its latest reported closing price of 95.46. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1939 funds or institutions reporting positions in Dexcom. This is an increase of 30 owner(s) or 1.57% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.46%, a decrease of 2.96%. Total shares owned by institutions increased in the last three months by 0.11% to 439,011K shares. The put/call ratio of DXCM is 1.06, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in DXCM by 172.17% over the last quarter. Sands Capital Management holds 13,103K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 13,739K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in DXCM by 0.57% over the last quarter. Jpmorgan Chase holds 12,673K shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 10,765K shares, representing an increase of 15.06%. The firm increased its portfolio allocation in DXCM by 825.09% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,102K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 11,965K shares, representing an increase of 1.14%. The firm increased its portfolio allocation in DXCM by 3.23% over the last quarter. VFINX - Vanguard 500 Index Fund Investor Shares holds 9,229K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 9,017K shares, representing an increase of 2.31%. The firm increased its portfolio allocation in DXCM by 2.55% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-02,92.86,96.18,91.8015,94.55,"[""DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know In the latest trading session, DexCom (DXCM) closed at $94.55, marking a +1.34% move from the previous day. This move outpaced the S&P 500's daily gain of 0.01%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%. Coming into today, shares of the medical device company had lost 8.44% in the past month. In that same time, the Medical sector lost 4.56%, while the S&P 500 lost 4.45%. Investors will be hoping for strength from DexCom as it approaches its next earnings release, which is expected to be October 26, 2023. In that report, analysts expect DexCom to post earnings of $0.34 per share. This would mark year-over-year growth of 21.43%. Meanwhile, our latest consensus estimate is calling for revenue of $936.02 million, up 21.62% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $1.23 per share and revenue of $3.54 billion, which would represent changes of +41.38% and +21.74%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for DexCom. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DexCom is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, DexCom currently has a Forward P/E ratio of 75.8. This valuation marks a premium compared to its industry's average Forward P/E of 25.41. Also, we should mention that DXCM has a PEG ratio of 1.77. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.07 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 10/02/2023: DXCM, APLS, CI, XLV, IBB Health care stocks were mixed premarket Monday with the iShares Biotechnology ETF (IBB) recently inactive while the Health Care Select Sector SPDR Fund (XLV) was down 0.4%. DexCom (DXCM) was 1.5% higher after saying its continuous glucose monitoring system improved glycohemoglobin levels in type 1 diabetes patients, based on real-world data from a seven-year study. Apellis Pharmaceuticals (APLS) was up 2.6% after saying the US Food and Drug Administration has approved the Empaveli injector designed to support self-administration of Empaveli, which is approved for adults with paroxysmal nocturnal hemoglobinuria, a blood disorder. Cigna Group (CI) said it has agreed to pay approximately $172 million to settle long-running legal disputes related to \""certain past Medicare Advantage risk adjustment practices.\"" Cigna Group was declining 0.02% pre-bell. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-03,93.67,94.36,90.24,90.94,"Nasdaq 100 Movers: ABNB, NFLX In early trading on Tuesday, shares of Netflix topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.6%. Year to date, Netflix registers a 32.4% gain. And the worst performing Nasdaq 100 component thus far on the day is Airbnb, trading down 3.4%. Airbnb is showing a gain of 54.3% looking at the year to date performance. Two other components making moves today are DexCom, trading down 2.0%, and Intel, trading up 2.2% on the day. VIDEO: Nasdaq 100 Movers: ABNB, NFLX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-10-04,91.16,91.39,85.54,87.7,"[""Nasdaq 100 Movers: DXCM, ASML In early trading on Wednesday, shares of ASML Holding topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.7%. Year to date, ASML Holding registers a 7.2% gain. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 3.1%. DexCom is lower by about 22.2% looking at the year to date performance. Two other components making moves today are Moderna, trading down 2.8%, and Tesla, trading up 2.5% on the day. VIDEO: Nasdaq 100 Movers: DXCM, ASML The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock to Buy Hand Over Fist in October and 1 to Avoid When volatility and uncertainty rule the roost on Wall Street, investors often seek out industry-leading, time-tested businesses with a rich history of outperforming the broader market. Since July 2021, companies enacting stock splits have been at the top of the list. A stock split is an event that allows a publicly traded company to alter both its share price and outstanding share count while having no impact on its market cap or operating performance. Consider it a purely cosmetic change designed to make a publicly traded company's shares more nominally affordable, as with a forward-stock split, or to increase a public company's share price to ensure it meets the minimum listing standards for a major stock exchange, as with a reverse-stock split. Image source: Getty Images. Companies conducting forward-stock splits are what investors tend to hone in on. That's because businesses angling to make their shares more nominally affordable for everyday investors are usually firing on all cylinders and outpacing their peers in the innovation department. Since the start of July 2021, nine companies that are dominant within their respective industries have conducted forward-stock splits: Nvidia (NASDAQ: NVDA): 4-for-1 split in July 2021. Amazon (NASDAQ: AMZN): 20-for-1 split in June 2022. DexCom (NASDAQ: DXCM): 4-for-1 split in June 2022. Shopify (NYSE: SHOP): 10-for-1 split in June 2022. Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split in July 2022. Tesla (NASDAQ: TSLA): 3-for-1 split in August 2022. Palo Alto Networks (NASDAQ: PANW): 3-for-1 split in September 2022. Monster Beverage (NASDAQ: MNST): 2-for-1 split in March 2023. Novo Nordisk (NYSE: NVO): 2-for-1 split in September 2023. These are all profitable businesses with well-defined growth catalysts. However, their outlooks differ quite a bit. As we push forward into October, one stock-split stock stands out as being historically cheap, while another widely owned stock-split stock is worth avoiding as headwinds mount. The stock-split stock to buy hand over fist in October: Amazon Among the nine high-profile stock-split stocks listed above, the one that makes for a phenomenal buy in October is e-commerce behemoth Amazon. The most popular online retailer saw its shares pressured last week after the Federal Trade Commission (FTC), along with 17 states, sued the company. The FTC and involved states allege that Amazon is using its online-marketplace dominance to inflate its prices and bully competition out of the picture. Additionally, there are concerns that Amazon's stock could be adversely impacted by a U.S. or global economic slowdown. A multitude of predictive indicators and economic datapoints do suggest a heightened likelihood of a U.S. recession. Amazon generates a large chunk of its net sales from its online marketplace. While these headwinds are both fresh and palpable, they're not game changers, nor do they alter Amazon's growth strategy or addressable opportunities. Although Amazon accounts for nearly 40% of online retail sales in the U.S., the company's online marketplace isn't what generates the bulk of its operating cash flow. In other words, even if online retail sales were to slow due to an economic slowdown or recession, it's not going to have much impact on Amazon's cash flow -- and that's what matters. Where Amazon generates its veritable gold mine of cash flow is from Amazon Web Services (AWS), subscription services, and advertising services. AWS is the world's leading cloud-infrastructure service provider (30% of global cloud-infrastructure service sales in the second quarter, according to Canalys). More importantly, enterprise cloud spending is still ramping up, which bodes well for sustained double-digit growth for AWS. Even though AWS only accounts for around a sixth of Amazon's net sales, it often generates 50% or more of the company's operating income. Amazon's subscription-services segment is playing a key role, too. In April 2021, the company surpassed 200 million Prime subscribers. Since then, Amazon's online marketplace has grown larger, and it's secured the rights to Thursday Night Football. Amazon has phenomenal pricing power with Prime, and it's encouraging users to remain loyal to its growing portfolio of high-margin products and services. But what stands out most about Amazon is its valuation. On the surface, its trailing price-to-earnings (P/E) ratio of 100 might look downright scary. But using the traditional P/E ratio isn't the best way to value a growth company that's constantly reinvesting in its operations. Instead, measuring Amazon's multiple relative to its cash flow yields a far different take. Whereas Amazon had regularly traded at between 23 and 37 times its year-end cash flow from 2010 through 2019, it can be purchased right now for just 11.5 times forward-year operating cash flow based on Wall Street's consensus. With the exception of the 2022 bear-market lows, this is the cheapest Amazon has ever been as a publicly traded company. The Model 3 is Tesla's flagship electric sedan. Image source: Tesla. The stock-split stock to avoid in October: Tesla However, the sun may not shine on all nine of these top-performing stock-split stocks. In particular, electric vehicle (EV) manufacturer Tesla appears poised for a breakdown. Before digging into what ails Tesla, let's give it credit for becoming the first automaker in more than a half-century to build itself from the ground up to mass production. Tesla looks to be on track to hit its production target of 1.8 million EVs in 2023 and could potentially surpass 2 million EVs annually based on the capacity of its four existing gigafactories. Furthermore, Tesla is the only EV pure play that's profitable on a recurring basis. The company has generated three consecutive years of generally accepted accounting principles (GAAP) profits and looks to be well on its way to making it four in a row in 2023. Nevertheless, there are still plenty of reasons for investors to hit the brakes. Let's start with the price war that Tesla kicked off to begin 2023. Some of the company's EV models have seen more than a half-dozen price cuts since the year began. CEO Elon Musk has been very clear that his company's pricing strategy has everything to do with demand. In short, Tesla continuing to slash the selling price on Models 3, S, Y, and X suggests that competition is picking up and inventory levels remain stubbornly high. Tesla's operating margin has been nearly halved since the end of September 2022, and it'll likely worsen as price cuts continue. To build on this point, Tesla is far from the only show in town. While it still holds the No. 1 spot in North American market share, legacy automakers are beginning to hit their stride. Keep in mind that giants like General Motors and Ford Motor Company not only have deep pockets, but they possess more than a century of brand power that Tesla simply can't match. Meanwhile, BYD looks to be doing donuts around Tesla in China. Another problem with Tesla is its leadership. To be frank, Elon Musk has a habit of overpromising and underdelivering. Whether its new innovations, such as Level 5 autonomy for the company's EVs, or the introduction of a new model, such as the Cybertruck, Musk and his company almost always fail to deliver new innovations or products in a timely fashion. While it's perfectly fine to try and fail, Tesla's valuation assumes nothing but success, which has been far from the case. This brings me to my final point: Tesla's valuation makes no sense. Most auto stocks trade at a high single-digit earnings multiple. Tesla is commanding a P/E ratio of roughly 74 based on Wall Street's consensus-earnings forecast for this year. While some folks might point to Tesla's ancillary operations as reasons for this premium, the company's ancillary operations are either losing money hand over fist (e.g., solar) or generating relatively low margins (e.g., supercharger network). Tesla has struggled to become more than a car company, which means valuing it like a game-changing tech stock makes no sense. 10 stocks we like better than Amazon.com When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 25, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, BYD, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom, General Motors, and Novo Nordisk and recommends the following options: long January 2025 $25 calls on General Motors. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-05,88.1,88.1,80.8,84.0,"[""Notable Thursday Option Activity: FSLY, DXCM, SAFE Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Fastly Inc (Symbol: FSLY), where a total of 9,790 contracts have traded so far, representing approximately 979,000 underlying shares. That amounts to about 43.8% of FSLY's average daily trading volume over the past month of 2.2 million shares. Especially high volume was seen for the $20 strike call option expiring November 17, 2023, with 1,145 contracts trading so far today, representing approximately 114,500 underlying shares of FSLY. Below is a chart showing FSLY's trailing twelve month trading history, with the $20 strike highlighted in orange: DexCom Inc (Symbol: DXCM) saw options trading volume of 20,771 contracts, representing approximately 2.1 million underlying shares or approximately 43.7% of DXCM's average daily trading volume over the past month, of 4.7 million shares. Especially high volume was seen for the $100 strike call option expiring November 17, 2023, with 2,795 contracts trading so far today, representing approximately 279,500 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $100 strike highlighted in orange: And Safehold Inc (Symbol: SAFE) options are showing a volume of 2,913 contracts thus far today. That number of contracts represents approximately 291,300 underlying shares, working out to a sizeable 41.9% of SAFE's average daily trading volume over the past month, of 695,305 shares. Especially high volume was seen for the $15 strike put option expiring January 19, 2024, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of SAFE. Below is a chart showing SAFE's trailing twelve month trading history, with the $15 strike highlighted in orange: For the various different available expirations for FSLY options, DXCM options, or SAFE options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 Department Stores Dividend Stocks \u0095 EML Videos \u0095 EDAP YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Add Up The Pieces: VOT Could Be Worth $231 Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Mid-Cap Growth ETF (Symbol: VOT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $231.41 per unit. With VOT trading at a recent price near $191.41 per unit, that means that analysts see 20.90% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VOT's underlying holdings with notable upside to their analyst target prices are Burlington Stores Inc (Symbol: BURL), DexCom Inc (Symbol: DXCM), and Caesars Entertainment Inc (Symbol: CZR). Although BURL has traded at a recent price of $127.04/share, the average analyst target is 64.42% higher at $208.88/share. Similarly, DXCM has 62.72% upside from the recent share price of $87.70 if the average analyst target price of $142.71/share is reached, and analysts on average are expecting CZR to reach a target price of $71.67/share, which is 61.63% above the recent price of $44.34. Below is a twelve month price history chart comparing the stock performance of BURL, DXCM, and CZR: Below is a summary table of the current analyst target prices discussed above: NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET Vanguard Mid-Cap Growth ETF VOT $191.41 $231.41 20.90% Burlington Stores Inc BURL $127.04 $208.88 64.42% DexCom Inc DXCM $87.70 $142.71 62.72% Caesars Entertainment Inc CZR $44.34 $71.67 61.63% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets \u00bb Also see: \u0095 EBF Historical PE Ratio \u0095 Top Ten Hedge Funds Holding KGRO \u0095 ETFs Holding INXN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-06,82.55,83.6902,81.07,83.22,"DexCom Enters Oversold Territory (DXCM) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $81.07 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 39.1. A bullish investor could look at DXCM's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DXCM shares: Looking at the chart above, DXCM's low point in its 52 week range is $80.80 per share, with $139.55 as the 52 week high point — that compares with a last trade of $81.90. Free Report: Top 8%+ Dividends (paid monthly) Find out what 9 other oversold stocks you need to know about » Also see: • IPOs • IEC Videos • IDTI Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-10-09,82.49,83.32,80.8,83.09,"[""DexCom (DXCM) to Launch Latest CGM System G7 in Canada Dexcom, Inc. DXCM recently announced that its next-generation real-time continuous glucose monitoring (rtCGM) system, DexCom G7, will be available in Canada from Oct 10, for people with any type of diabetes, aged two years and older, including those who are pregnant. Per the company, DexCom G7 is the most accurate CGM on the Canadian market that will offer users a new way to gain greater control over their diabetes. The system will provide insightful health information about food, activity and treatment, leading to informed decisions. We note that Dexcom G7 CGM was approved in July by the Health Canada for people with any type of diabetes, aged two years and above. It has been built based on the performance of Dexcom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range. Price Performance Shares of DexCom have lost 26.5% year to date compared with the industry\u2019s 9.4% decline. The S&P 500 Index has risen 13.6% in the same time frame. Image Source: Zacks Investment Research Key Features of G7 DexCom\u2019s next-generation G7 CGM system has several features that will likely aid faster adoption by users. The system is the smallest sensor developed by DexCom that makes it comfortable and discreet to wear. It also provides a one-push applicator with an all-in-one sensor that helps in simple and painless insertion. The DexCom G7 can send glucose readings to compatible devices in real-time, improving the decision-making process. Its predictive alarm feature alerts users up to 20 minutes in advance of severe hypoglycemia. There is no requirement for routine finger sticks, scanning, or calibration. The device also provides options to create personalized alerts to effortlessly match a user\u2019s lifestyle and needs. It will also help in remote monitoring of patients as it supports sharing of glucose data with up to 10 followers. The DexCom G7 system will be the first waterproof CGM device available in Canada with protection for 24 hours when submerged in eight feet of water. Industry Prospects Per a report by Grand View Research, the global CGM device market size was valued at $7,816.8 million in 2022 and is expected to reach $11.2 billion by 2030 at a CAGR of 4.4%. Factors like the rising cases of diabetes and the increasing adoption of CGM devices are likely to drive the market. Given the market potential, the latest regulatory approval is expected to provide a significant boost to DexCom\u2019s business globally. Notable Developments In September, DXCM and the privately-held RxFood Corporation have entered into an agreement to combine their respective expertise and introduce an improved digital health solution for diabetic patients. The companies have partnered to introduce such services currently in Canada. Last month, DexCom announced that its G6 CGM system can now connect with the Insulet Corporation\u2019s Omnipod 5 Automated Insulin Delivery (AID) system in Germany. Insulet\u2019s Omnipod 5 automatically adjusts insulin delivery and manages glucose levels both day and night. The Omnipod 5 AID system is cleared for individuals with type 1 diabetes, aged 2 years and older. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Zacks Rank & Stocks to Consider DXCM currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Align Technology ALGN, McKesson Corporation MCK and Medpace MEDP. Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. ALGN\u2019s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company\u2019s shares have risen 35% year to date compared with the industry\u2019s 38% growth. McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. The stock has gained 18.7% year to date compared with the industry\u2019s 38% growth. Medpace, carrying a Zacks Rank #2 at present, has an estimated growth rate of 16.2% for 2024. MEDP\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 22.28%. The company\u2019s shares have rallied 15.9% year to date against the industry\u2019s 12.5% decline. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know DexCom (DXCM) closed the latest trading day at $83.09, indicating a -0.16% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.63%. At the same time, the Dow added 0.59%, and the tech-heavy Nasdaq gained 0.39%. Shares of the medical device company have depreciated by 20.25% over the course of the past month, underperforming the Medical sector's loss of 1.62% and the S&P 500's loss of 3.39%. The investment community will be paying close attention to the earnings performance of DexCom in its upcoming release. The company is slated to reveal its earnings on October 26, 2023. The company's earnings per share (EPS) are projected to be $0.34, reflecting a 21.43% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $936.02 million, reflecting a 21.62% rise from the equivalent quarter last year. DXCM's full-year Zacks Consensus Estimates are calling for earnings of $1.23 per share and revenue of $3.54 billion. These results would represent year-over-year changes of +41.38% and +21.74%, respectively. Investors should also note any recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DexCom presently features a Zacks Rank of #3 (Hold). With respect to valuation, DexCom is currently being traded at a Forward P/E ratio of 67.61. For comparison, its industry has an average Forward P/E of 25.02, which means DexCom is trading at a premium to the group. Also, we should mention that DXCM has a PEG ratio of 1.58. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.08 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 100, finds itself in the top 40% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why DexCom (DXCM) is a Strong Growth Stock Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on. The Style Scores are broken down into four categories: Value Score For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks. Growth Score While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. Momentum Score Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying \""the trend is your friend.\"" The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. VGM Score If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. #1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day. This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio. That's where the Style Scores come in. To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible. Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy. A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of B, forecasting year-over-year earnings growth of 41.4% for the current fiscal year. Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.04 to $1.23 per share. DXCM also boasts an average earnings surprise of 28.8%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-10,82.91,86.4,81.115,85.21,"[""Tuesday Sector Leaders: Services, Healthcare In afternoon trading on Tuesday, Services stocks are the best performing sector, up 1.2%. Within that group, Target Corp (Symbol: TGT) and Dollar Tree Inc (Symbol: DLTR) are two of the day's stand-outs, showing a gain of 4.4% and 4.4%, respectively. Among the largest ETFs, one ETF closely following services stocks is the iShares U.S. Consumer Services ETF (Symbol: IYC), which is up 1.3% on the day, and up 19.38% year-to-date. Target Corp, meanwhile, is down 25.05% year-to-date, and Dollar Tree Inc, is down 22.07% year-to-date. Combined, TGT and DLTR make up approximately 1.5% of the underlying holdings of IYC. The next best performing sector is the Healthcare sector, higher by 1.2%. Among large Healthcare stocks, DexCom Inc (Symbol: DXCM) and DaVita Inc (Symbol: DVA) are the most notable, showing a gain of 3.6% and 3.4%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.7% in midday trading, and down 1.90% on a year-to-date basis. DexCom Inc, meanwhile, is down 24.95% year-to-date, and DaVita Inc is up 22.22% year-to-date. Combined, DXCM and DVA make up approximately 0.8% of the underlying holdings of XLV. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday. As you can see, nine sectors are up on the day, while none of the sectors are down. SECTOR % CHANGE Services +1.2% Healthcare +1.2% Materials +1.2% Financial +1.1% Consumer Products +1.0% Utilities +0.9% Technology & Communications +0.9% Industrial +0.9% Energy +0.7% 10 ETFs With Stocks That Insiders Are Buying \u00bb Also see: \u0095 Technology Dividend Stock List \u0095 Institutional Holders of ICG \u0095 OIBR Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: DXCM, LCID In early trading on Tuesday, shares of Lucid Group topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.5%. Year to date, Lucid Group has lost about 23.7% of its value. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 1.4%. DexCom is lower by about 27.6% looking at the year to date performance. Two other components making moves today are Amgen, trading down 1.1%, and Enphase Energy, trading up 3.2% on the day. VIDEO: Nasdaq 100 Movers: DXCM, LCID The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-11,84.31,85.02,77.91,78.97,"[""Stocks Settle Higher as Bond Yields Fall on Dovish Fed Comments What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.43%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.72%. Stocks on Wednesday closed moderately higher on a decline in bond yields after dovish Fed comments bolstered speculation the Fed is heading toward a pause in interest rate hikes. Late Tuesday, San Francisco Fed President Daly said tighter financial conditions might mean the Fed \""doesn't have to do as much\"" on interest rates. Also, Fed Governor Waller said Wednesday that the Fed is finally getting very good inflation we wanted and is in a position to \""watch and see\"" on interest rates. M&A activity also supported equities after Exxon Mobil agreed to buy Pioneer Natural Resources for $59.5 billion. Bearish factors for stocks included the stronger-than-expected U.S. PPI report and concern the Israel-Hamas war could expand after Hezbollah militants launched missiles into Israel from Lebanon. U.S. Sep PPI final demand rose +0.5% m/m and +2.2% y/y, stronger than expectations of +0.2% m/m and +1.6% y/y. Also, Sep PPI ex-food and energy rose +0.3% m/m and +2.7% y/y, stronger than expectations of +0.2% m/m and +2.3% y/y. The minutes of the Sep 19-20 FOMC meeting were slightly hawkish as they stated that \""Participants generally judged that with the stance of monetary policy in restrictive territory, risks to the achievement of the committee's goals had become more two-sided.\"" The minutes also noted that \""a majority\"" of Fed officials saw one more rate increase \""would likely be appropriate,\"" while \""some\"" said \""no further increases would be warranted.\"" Fed Governor Bowman said, despite recent improvements, \""inflation remains well above the FOMC's 2% target. Domestic spending has continued at a strong pace, and the labor market remains tight. This suggests that the policy rate may need to rise further and stay restrictive for some time to return inflation to the FOMC's goal.\"" U.S. MBA mortgage applications rose +0.6% w/w in the week ended October 6. The mortgage purchase sub-index rose +0.7%, and the refinancing sub-index rose +0.3%. The average 30-year fixed mortgage rate rose +14 bp to 7.67%, the highest in almost 23 years. The markets are discounting an 8% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 31% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields Wednesday moved lower. The 10-year T-note yield fell to a 1-1/2 week low of 4.542% and finished down -7.0 bp at 4.583%. The 10-year German bund yield fell to a 2-1/2 week low of 2.706% and finished down -5.7 bp at 2.718%. The 10-year UK gilt yield fell to a 2-week low of 4.317% and finished down -9.8 bp at 4.328%. Overseas stock markets Wednesday settled mixed. The Euro Stoxx 50 closed down -0.11%. China\u2019s Shanghai Composite Index closed up +0.12%. Japan\u2019s Nikkei 225 today closed up +0.60%. Today\u2019s stock movers\u2026 Amgen (AMGN) closed up more than +4% to lead gainers in the Dow Jones Industrials and Nasdaq 100 after Leerink Partners upgraded the stock to outperform from market perform with a price target of $318. Coherent (COHR) closed up more than +5% after B. Riley Securities upgraded the stock to buy from neutral with a price target of $51. Adobe (ADBE) closed up more than +3% after releasing new features for generative AI models at the Max conference in Los Angeles. Ventas (VTR) closed up more than +2% after BNP Paribas Exane initiated coverage on the stock with an outperform recommendation and a price target of $47. Caesars Entertainment (CZR) closed up more than +2% after Stifel raised its price target on the stock to $80 from $74, and Wells Fargo Securities said the company\u2019s 2024 outlook is \u201cupbeat.\u201d Boeing (BA) closed up more than +1% after UBS initiated coverage on the stock with a buy recommendation. Cava Group (CAVA) closed up more than +1% after Morgan Stanley upgraded the stock to overweight from equal weight. Dialysis providers and makers of devices that treat diabetes are under pressure after Norvo Nordisk said its Ozempic medication showed effectiveness surprisingly early in a kidney failure trial. As a result, Davita (DVA) closed down more than -16% to lead losers in the S&P 500. Also, Baxter International (BAX) closed down more than -12%, and Dexcom (DXCM) closed down more than -7% to lead losers in the Nasdaq 100. In addition, Insulet (PODD) closed down more than -8%, and ResMed (RMD) closed down more than -4%. Norwegian Cruise Line Holdings (NCLH) closed down more than -5% after it sold $790 million of junk bonds to refinance debt. Exxon Mobil (XOM) closed down more than 3% after agreeing to buy Pioneer Natural Resources for $59.5 billion, or $253 per share. Keurig Dr Pepper (KDP) closed down more than -3% after Barclays cut its price target on the stock to $34 from $40. Portillo\u2019s (PTLO) closed down more than -6% after Morgan Stanley downgraded the stock to equal weight from overweight. RXO Inc (RXO) closed down more than -2% after JPMorgan Chase downgraded the stock to underweight from neutral. Arista Networks (ANET) closed down more than -1% after Piper Sandler downgraded the stock to neutral from overweight. Across the markets\u2026 December 10-year T-notes (ZNZ23) Wednesday closed up +7 ticks, and the 10-year T-note yield fell -7.0 bp to 4.583%. Dec T-notes Wednesday climbed to a 1-1/2 week high, and the 10-year T-note yield fell to a 1-1/2 week low of 4.542%. T-notes found support on dovish Fed comments after San Francisco Fed President Daly said tighter financial conditions may mean the Fed \""doesn't have to do as much\"" on interest rates. Also, Fed Governor Waller said the Fed is in a position to \""watch and see\"" on interest rates. In addition, concerns the Middle East conflict may spread boosted safe-haven demand for T-notes after Hezbollah militants launched missiles into Israel from Lebanon. T-notes maintained their gains on strong demand for the Treasury\u2019s $35 billion 10-year T-note auction with a bid-to-cover ratio of 2.50, better than the 10-auction average of 2.46. Gains in T-notes were limited after U.S. producer prices rose more than expected in September. Also, hawkish comments from Fed Governor Bowman were negative for T-note prices when she said still high inflation may mean the Fed will need to keep the policy rate higher and for longer. In addition, strength in stocks curbed the safe-haven demand for T-notes. More Stock Market News from Barchart 11 Steps to Take If You Get Laid Off or Lose Your Job 3 Breakout Small-Cap Stocks Outperforming the Market Dollar Falters as Bond Yields Decline I Think You'll Like These 2 Five-Day Losers On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Mixed as Dovish Fed Comments Knock Bond Yields Lower What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%. Stocks are mixed on a decline in bond yields after dovish Fed comments bolstered speculation the Fed is heading toward a pause in interest rate hikes. Late Tuesday, San Francisco Fed President Daly said tighter financial conditions might mean the Fed \""doesn't have to do as much\"" on interest rates. Also, Fed Governor Waller today said the Fed is finally getting very good inflation we wanted and is in position to \""watch and see\"" on interest rates. M&A activity is also supporting equities after Exxon Mobil agreed to buy Pioneer Natural Resources for $59.5 billion. Bearish factors for stocks include the stronger-than-expected U.S. PPI report and concern the Israel-Hamas war could expand after Hezbollah militants launched missiles into Israel from Lebanon. U.S. Sep PPI final demand rose +0.5% m/m and +2.2% y/y, stronger than expectations of +0.2% m/m and +1.6% y/y. Also, Sep PPI ex-food and energy rose +0.3% m/m and +2.7% y/y, stronger than expectations of +0.2% m/m and +2.3% y/y. Fed Governor Bowman said, despite recent improvements, \""inflation remains well above the FOMC's 2% target. Domestic spending has continued at a strong pace, and the labor market remains tight. This suggests that the policy rate may need to rise further and stay restrictive for some time to return inflation to the FOMC's goal.\"" U.S. MBA mortgage applications rose +0.6% w/w in the week ended October 6. The mortgage purchase sub-index rose +0.7%, and the refinancing sub-index rose +0.3%. The average 30-year fixed mortgage rate rose +14 bp to 7.67%, the highest in almost 23 years. The markets are discounting a 14% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 33% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are lower. The 10-year T-note yield fell to a 1-1/2 week low of 4.542% and is down -6.6 bp at 4.587%. The 10-year German bund yield fell to a 2-1/2 week low of 2.706% and is down -4.3 bp at 2.731%. The 10-year UK gilt yield fell to a 2-week low of 4.317% and is down -6.9 bp at 4.357%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.09%. China\u2019s Shanghai Composite Index closed up +0.12%. Japan\u2019s Nikkei 225 today closed up +0.60 %. Today\u2019s stock movers\u2026 Caesars Entertainment (CZR) is up more than +3% to lead gainers in the S&P 500 after Stifel raised its price target on the stock to $80 from $74, and Wells Fargo Securities said the company\u2019s 2024 outlook is \u201cupbeat.\u201d Amgen (AMGN) is up more than +3% to lead gainers in the Dow Jones Industrials and Nasdaq 100 after Leerink Partners upgraded the stock to outperform from market perform with a price target of $318. Boeing (BA) is up more than +2% after UBS initiated coverage on the stock with a buy recommendation. Ball Corp (BALL) is up more than +2% after Barclays upgraded the stock to overweight from equal weight with a price target of $59. Adobe (ADBE) is up more than +2% after releasing new features for generative AI models at the Max conference in Los Angeles. Coherent (COHR) is up more than +6% after B. Riley Securities upgraded the stock to buy from neutral with a price target of $51. Cava Group (CAVA) is up more than +1% after Morgan Stanley upgraded the stock to overweight from equal weight. Dialysis providers and makers of devices that treat diabetes are under pressure after Norvo Nordisk said its Ozempic medication showed effectiveness surprisingly early in a kidney failure trial. As a result, Davita (DVA) is down more than -16% to lead losers in the S&P 500. Also, Baxter International (BAX) is down more than -8%, and Dexcom (DXCM) is down more than -5% to lead losers in the Nasdaq 100. In addition, Insulet (PODD) is down more than -5%, and ResMed (RMD) is down more than -4%. Exxon Mobil (XOM) is down more than 4% after agreeing to buy Pioneer Natural Resources for $59.5 billion, or $253 per share. Arista Networks (ANET) fell more than -1% in pre-market trading after Piper Sandler downgraded the stock to neutral from overweight. Portillo\u2019s (PTLO) is down more than -4% after Morgan Stanley downgraded the stock to equal weight from overweight. RXO Inc (RXO) is down more than -3% after JPMorgan Chase downgraded the stock to underweight from neutral. Keurig Dr Pepper (KDP) is down more than -2% after Barclays cut its price target on the stock to $34 from $40. Texas Instruments (TXN) is down nearly -1% after Oppenheimer downgraded the stock to market perform from outperform. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are up +10 ticks, and the 10-year T-note yield is down -6.6 bp at 4.587%. Dec T-notes today climbed to a 1-1/2 week high, and the 10-year T-note yield fell to a 1-1/2 week low of 4.542%. T-notes found support on comments late Tuesday from San Francisco Fed President Daly, who said tighter financial conditions may mean the Fed \""doesn't have to do as much\"" on interest rates. Also, concerns the Middle East conflict may spread boosted safe-haven demand for T-notes after Hezbollah militants launched missiles into Israel from Lebanon. Gains in T-notes are limited after U.S. producer prices in September rose more than expected. Also, hawkish comments from Fed Governor Bowman were negative for T-note prices when she said still high inflation may mean the Fed will need to keep the policy rate higher and for longer. In addition, supply pressures are weighing on T-notes as the Treasury will auction $35 billion of 10-year T-notes later today as part of this week\u2019s $101 billion T-notes and T-bonds auction package. The dollar index (DXY00) today is down by -0.14% and posted a 2-week low. Today's decline in bond yields is undercutting the dollar as the 10-year T-note yield fell to a 2-week low. Also, strength in stocks is curbing liquidity demand for the dollar. Losses in the dollar are limited after U.S. Sep PPI final demand rose more than expected, a hawkish factor for Fed policy. EUR/USD (^EURUSD) today is up by +0.08% and climbed to a 2-week high. Dollar weakness today is supporting the euro. Also, an increase in the ECB\u2019s monthly consumer expectations for August is hawkish for ECB policy and bullish for EUR/USD. The euro fell back from its best levels on dovish comments from ECB Governing Council member and Bundesbank President Nagel, who said \u201cpausing could be an option\u201d for the ECB at its next policy meeting later this month. The ECB\u2019s Aug 1-year CPI expectations rose +0.1 to 3.5%, and the Aug 3-year CPI expectations rose +0.1 to 2.5%. USD/JPY (^USDJPY) today is up by +0.20%. The yen today is moderately lower on reduced safe-haven demand after the Nikkei Stock Index today climbed to a 1-week high. Also, a decline in Japanese government bond yields weighed on the yen after the 10-year JGB bond yield fell to a 1-week low of 0.766%. In addition, weak economic news undercut the yen after Japan Sep machine tool orders fell for the ninth consecutive month. Losses in the yen are limited due to a decline in T-note yields, which is bullish for the yen. Japan Sep machine tool orders fell -11.2% y/y, the ninth consecutive month machine tool orders have declined. December gold (GCZ3) today is up +8.2 (+0.44%), and Dec silver (SIZ23) is up +0.132 (+0.60%). Precious metals prices this morning are moderately higher, with gold posting a 1-1/2 week high and silver posting a 1-week high. A weaker dollar today is bullish for metals prices. Also, a decline in global bond yields is supportive of precious metals. In addition, concerns that the Middle East turmoil may spread have boosted safe-haven demand for precious metals after Hezbollah militants launched missiles into Israel from Lebanon. Finally, today\u2019s stronger-than-expected U.S. Sep PPI final demand report boosted demand for gold as an inflation hedge. Gains in metals are limited as today\u2019s stock rally has curbed the safe-haven demand for precious metals. More Stock Market News from Barchart Markets Today: Stocks Move Higher as Bond Yields Fall Despite Strong U.S. PPI Short Straddle Screener Results For October 11th S&P Futures Climb Ahead of FOMC Meeting Minutes and U.S. PPI Data Stocks End Higher on an Improved Outlook for a Fed Pause On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Push Higher as Dovish Fed Comments Knock Bond Yields Lower What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is up +0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.21%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.32%. Stocks this morning are mildly higher on a decline in bond yields after dovish Fed comments bolstered speculation the Fed is heading toward a pause in interest rate hikes. Late Tuesday, San Francisco Fed President Daly said tighter financial conditions might mean the Fed \""doesn't have to do as much\"" on interest rates. Also, Fed Governor Waller today said the Fed is finally getting very good inflation we wanted and is in position to \""watch and see\"" on interest rates. M&A activity is also supporting equities after Exxon Mobil agreed to buy Pioneer Natural Resources for $59.5 billion. Bearish factors for stocks include the stronger-than-expected U.S. PPI report and concern the Israel-Hamas war could expand after Hezbollah militants launched missiles into Israel from Lebanon. U.S. Sep PPI final demand rose +0.5% m/m and +2.2% y/y, stronger than expectations of +0.2% m/m and +1.6% y/y. Also, Sep PPI ex-food and energy rose +0.3% m/m and +2.7% y/y, stronger than expectations of +0.2% m/m and +2.3% y/y. Fed Governor Bowman said, despite recent improvements, \""inflation remains well above the FOMC's 2% target. Domestic spending has continued at a strong pace, and the labor market remains tight. This suggests that the policy rate may need to rise further and stay restrictive for some time to return inflation to the FOMC's goal.\"" U.S. MBA mortgage applications rose +0.6% w/w in the week ended October 6. The mortgage purchase sub-index rose +0.7%, and the refinancing sub-index rose +0.3%. The average 30-year fixed mortgage rate rose +14 bp to 7.67%, the highest in almost 23 years. The markets are discounting a 14% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 33% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are lower. The 10-year T-note yield fell to a 1-1/2 week low of 4.542% and is down -6.6 bp at 4.587%. The 10-year German bund yield fell to a 2-1/2 week low of 2.706% and is down -4.3 bp at 2.731%. The 10-year UK gilt yield fell to a 2-week low of 4.317% and is down -6.9 bp at 4.357%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.09%. China\u2019s Shanghai Composite Index closed up +0.12%. Japan\u2019s Nikkei 225 today closed up +0.60 %. Today\u2019s stock movers\u2026 Caesars Entertainment (CZR) is up more than +3% to lead gainers in the S&P 500 after Stifel raised its price target on the stock to $80 from $74, and Wells Fargo Securities said the company\u2019s 2024 outlook is \u201cupbeat.\u201d Amgen (AMGN) is up more than +3% to lead gainers in the Dow Jones Industrials and Nasdaq 100 after Leerink Partners upgraded the stock to outperform from market perform with a price target of $318. Boeing (BA) is up more than +2% after UBS initiated coverage on the stock with a buy recommendation. Ball Corp (BALL) is up more than +2% after Barclays upgraded the stock to overweight from equal weight with a price target of $59. Adobe (ADBE) is up more than +2% after releasing new features for generative AI models at the Max conference in Los Angeles. Coherent (COHR) is up more than +6% after B. Riley Securities upgraded the stock to buy from neutral with a price target of $51. Cava Group (CAVA) is up more than +1% after Morgan Stanley upgraded the stock to overweight from equal weight. Dialysis providers and makers of devices that treat diabetes are under pressure after Norvo Nordisk said its Ozempic medication showed effectiveness surprisingly early in a kidney failure trial. As a result, Davita (DVA) is down more than -16% to lead losers in the S&P 500. Also, Baxter International (BAX) is down more than -8%, and Dexcom (DXCM) is down more than -5% to lead losers in the Nasdaq 100. In addition, Insulet (PODD) is down more than -5%, and ResMed (RMD) is down more than -4%. Exxon Mobil (XOM) is down more than 4% after agreeing to buy Pioneer Natural Resources for $59.5 billion, or $253 per share. Arista Networks (ANET) fell more than -1% in pre-market trading after Piper Sandler downgraded the stock to neutral from overweight. Portillo\u2019s (PTLO) is down more than -4% after Morgan Stanley downgraded the stock to equal weight from overweight. RXO Inc (RXO) is down more than -3% after JPMorgan Chase downgraded the stock to underweight from neutral. Keurig Dr Pepper (KDP) is down more than -2% after Barclays cut its price target on the stock to $34 from $40. Texas Instruments (TXN) is down nearly -1% after Oppenheimer downgraded the stock to market perform from outperform. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are up +10 ticks, and the 10-year T-note yield is down -6.6 bp at 4.587%. Dec T-notes today climbed to a 1-1/2 week high, and the 10-year T-note yield fell to a 1-1/2 week low of 4.542%. T-notes found support on comments late Tuesday from San Francisco Fed President Daly, who said tighter financial conditions may mean the Fed \""doesn't have to do as much\"" on interest rates. Also, concerns the Middle East conflict may spread boosted safe-haven demand for T-notes after Hezbollah militants launched missiles into Israel from Lebanon. Gains in T-notes are limited after U.S. producer prices in September rose more than expected. Also, hawkish comments from Fed Governor Bowman were negative for T-note prices when she said still high inflation may mean the Fed will need to keep the policy rate higher and for longer. In addition, supply pressures are weighing on T-notes as the Treasury will auction $35 billion of 10-year T-notes later today as part of this week\u2019s $101 billion T-notes and T-bonds auction package. The dollar index (DXY00) today is down by -0.14% and posted a 2-week low. Today's decline in bond yields is undercutting the dollar as the 10-year T-note yield fell to a 2-week low. Also, strength in stocks is curbing liquidity demand for the dollar. Losses in the dollar are limited after U.S. Sep PPI final demand rose more than expected, a hawkish factor for Fed policy. EUR/USD (^EURUSD) today is up by +0.08% and climbed to a 2-week high. Dollar weakness today is supporting the euro. Also, an increase in the ECB\u2019s monthly consumer expectations for August is hawkish for ECB policy and bullish for EUR/USD. The euro fell back from its best levels on dovish comments from ECB Governing Council member and Bundesbank President Nagel, who said \u201cpausing could be an option\u201d for the ECB at its next policy meeting later this month. The ECB\u2019s Aug 1-year CPI expectations rose +0.1 to 3.5%, and the Aug 3-year CPI expectations rose +0.1 to 2.5%. USD/JPY (^USDJPY) today is up by +0.20%. The yen today is moderately lower on reduced safe-haven demand after the Nikkei Stock Index today climbed to a 1-week high. Also, a decline in Japanese government bond yields weighed on the yen after the 10-year JGB bond yield fell to a 1-week low of 0.766%. In addition, weak economic news undercut the yen after Japan Sep machine tool orders fell for the ninth consecutive month. Losses in the yen are limited due to a decline in T-note yields, which is bullish for the yen. Japan Sep machine tool orders fell -11.2% y/y, the ninth consecutive month machine tool orders have declined. December gold (GCZ3) today is up +8.2 (+0.44%), and Dec silver (SIZ23) is up +0.132 (+0.60%). Precious metals prices this morning are moderately higher, with gold posting a 1-1/2 week high and silver posting a 1-week high. A weaker dollar today is bullish for metals prices. Also, a decline in global bond yields is supportive of precious metals. In addition, concerns that the Middle East turmoil may spread have boosted safe-haven demand for precious metals after Hezbollah militants launched missiles into Israel from Lebanon. Finally, today\u2019s stronger-than-expected U.S. Sep PPI final demand report boosted demand for gold as an inflation hedge. Gains in metals are limited as today\u2019s stock rally has curbed the safe-haven demand for precious metals. More Stock Market News from Barchart Markets Today: Stocks Move Higher as Bond Yields Fall Despite Strong U.S. PPI Short Straddle Screener Results For October 11th S&P Futures Climb Ahead of FOMC Meeting Minutes and U.S. PPI Data Stocks End Higher on an Improved Outlook for a Fed Pause On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: DXCM, ADBE In early trading on Wednesday, shares of Adobe topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.5%. Year to date, Adobe registers a 62.2% gain. And the worst performing Nasdaq 100 component thus far on the day is DexCom, trading down 5.2%. DexCom is lower by about 28.7% looking at the year to date performance. Two other components making moves today are Intuitive Surgical, trading down 2.5%, and Amgen, trading up 2.1% on the day. VIDEO: Nasdaq 100 Movers: DXCM, ADBE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-12,79.69,80.14,75.04,75.49,
DXCM,2023-10-13,75.0,76.435,74.75,76.19,
DXCM,2023-10-16,77.58,80.19,76.17,78.95,"[""Leerink Partners Initiates Coverage of Dexcom (DXCM) with Outperform Recommendation Fintel reports that on October 16, 2023, Leerink Partners initiated coverage of Dexcom (NASDAQ:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 90.77% Upside As of October 5, 2023, the average one-year price target for Dexcom is 145.35. The forecasts range from a low of 98.98 to a high of $168.00. The average price target represents an increase of 90.77% from its latest reported closing price of 76.19. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1940 funds or institutions reporting positions in Dexcom. This is an increase of 30 owner(s) or 1.57% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.45%, a decrease of 4.26%. Total shares owned by institutions increased in the last three months by 0.03% to 439,570K shares. The put/call ratio of DXCM is 1.00, indicating a bearish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in DXCM by 1.57% over the last quarter. Sands Capital Management holds 13,103K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 13,739K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in DXCM by 0.57% over the last quarter. Jpmorgan Chase holds 12,673K shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 10,765K shares, representing an increase of 15.06%. The firm increased its portfolio allocation in DXCM by 825.09% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,102K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 11,965K shares, representing an increase of 1.14%. The firm increased its portfolio allocation in DXCM by 3.23% over the last quarter. VFINX - Vanguard 500 Index Fund Investor Shares holds 9,229K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 9,017K shares, representing an increase of 2.31%. The firm increased its portfolio allocation in DXCM by 2.55% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Rally on Slightly Reduced Geopolitical Risks in the Middle East What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.06%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.93%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.18%. Stocks on Monday posted moderate gains, with the Dow Jones Industrials climbing to a 3-week high. Stocks rose Monday as diplomatic efforts to contain the Israel-Hamas conflict eased geopolitical concerns and improved market sentiment. The markets are also looking to Q3 corporate quarterly earnings results that ramp up this week, with 10% of the stocks in the S&P 500 expected to report. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. President Biden is considering visiting Israel himself, and German Chancellor Scholz is expected to arrive in Israel on Tuesday. Also, Jordan King Abdullah II is in Italy, where he\u2019s expected to meet with Italian Prime Minister Meloni to discuss the crisis. Meanwhile, U.S. Security Advisor Sullivan said the U.S. had warned Iran through back-channel talks about the risk of escalation of the war. In an interview with Sky News, U.S. Treasury Secretary Yellen said higher interest rates in the U.S. may persist while also saying the U.S. economy is \""in a good place.\"" The U.S. Oct Empire manufacturing survey general business conditions fell -6.5 to -4.6, a smaller decline than expectations for a level of -6.0. The markets are discounting an 8% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 37% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields on Monday moved higher. The 10-year T-note rose +9.8 bp to 4.710%. The 10-year German bund yield rose +4.8 bp to 2.785%. The 10-year UK gilt yield rose +9.5 bp to 4.481%. In a measure to boost liquidity, the People's Bank of China (PBOC) on Monday added a net 289 billion yuan ($39.6 billion) into the financial system via the medium-term lending facility, the largest monthly injection of cash into the financial system since December 2020. Overseas stock markets on Monday settled mixed. The Euro Stoxx 50 closed up +0.33%. China\u2019s Shanghai Composite Index closed down -0.46%. Japan\u2019s Nikkei 225 today closed down -2.03%. Today\u2019s stock movers\u2026 Lululemon Athletica (LULU) closed up more than +10% to lead gainers in the Nasdaq 100 after S&P Dow Jones Indices announced the stock will replace Activision Blizzard in the S&P 500 before the opening of trading on Wednesday. News Corp (NWSA) closed up more than +4% after activist Starboard Value said it had built a \u201csizable\u201d stake in the company and plans to push for strategic and governance changes to the company. Charles Schwab (SCHW) closed up more than +4% after reporting Q3 bank deposits of $284.4 billion, above the consensus of $268.8 billion. Arista Networks (ANET) closed up more than +3% after Evercore ISI added the stock to its tactical outperform list with a price target of $200. Dexcom (DXCM) closed up more than +3% after Leerink Partners reinstated coverage of the stock with a recommendation of outperform and a price target of $110. Allstate (ALL) closed up more than +3% after Reuters reported that Trian Fund Management had built up a stake in the company. Pfizer (PFE) closed up more than +3% despite cutting its full-year revenue forecast after Leerink Partners said the company\u2019s cost-cutting measures are a positive for the stock. Hubbell Inc (HUBB) closed up more than +3% after S&P Dow Jones Indices announced the stock would replace Organon in the S&P 500 before the opening of trading on Wednesday. Microsoft (MSFT) closed up +1.5% after Piper Sandler named the company its highest conviction large-cap stock to own over the rest of the year with a price target of $400. Moderna (MRNA) closed down more than -6% to lead losers in the S&P 500 and Nasdaq 100 after Pfizer cut its full-year forecasts due to weaker-than-expected demand for its Covid-19 products. Henry Schein (HSIC) closed down more than -2% after it said some of its manufacturing and distribution units experienced a cybersecurity incident. Organon (OGN) closed down more than -2% after S&P Dow Jones Indices announced that Hubbell Inc would replace the stock in the S&P 500 before trading on Wednesday. Walgreens Boots Alliance (WBA) closed down more than -2% to lead losers in the Dow Jones Industrials after Moody\u2019s Investors Service warned it may cut the company\u2019s Baa3 investment grade rating, the lowest tier above junk, citing a continued decline in earnings. Target (TGT) closed down -0.53% after data from Bloomberg Second Nature shows observed sales for the company in the week ending Oct 8 fell -10% from a year earlier. Across the markets\u2026 December 10-year T-notes (ZNZ23) Monday closed down -16.5 ticks, and the 10-year T-note yield rose +9.8 bp to 4.710%. Dec T-notes Monday retreated lower as diplomatic efforts to contain the Israel-Hamas conflict boosted stocks and curbed safe-haven demand for T-notes. Also, hawkish comments Monday from U.S. Treasury Secretary Yellen weighed on T-notes when she said higher interest rates in the U.S. may persist for a while. In addition, the smaller-than-expected decline in the U.S. Oct Empire manufacturing general business conditions index was bearish for T-notes. Finally, an increase in inflation expectations was bearish for stocks after the 10-year breakeven inflation rate rose to a 3-week high Monday at 2.388%. More Stock Market News from Barchart Dollar Slips as Stocks Rally on Reduced Middle East Geopolitical Risks Tesla Q3 Earnings Preview: 6 Key Things to Watch In the Report 3 EV Stocks Under $10 Analysts Expect To Triple Mobileye's (MBLY) Autonomous Drive: Navigating the Road of Innovation and Skepticism On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Gain on Diplomatic Efforts to Contain the Israeli-Hamas Conflict What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is up +1.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.97%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%. Stocks this morning are moderately higher, with the Dow Jones Industrials climbing to a 3-week high. Stocks are rising today as diplomatic efforts to contain the Israel-Hamas conflict have eased geopolitical concerns and improved market sentiment. The markets are also looking to Q3 corporate quarterly earnings results that ramp up this week. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. President Biden is considering visiting Israel himself, and German Chancellor Scholz is expected to arrive in Israel on Tuesday. Also, Jordan King Abdullah II is in Italy, where he\u2019s expected to meet with Italian Prime Minister Meloni to discuss the crisis. Meanwhile, U.S. Security Advisor Sullivan said the U.S. had warned Iran through back-channel talks about the risk of escalation of the war. In an interview with Sky News, U.S. Treasury Secretary Yellen said higher interest rates in the U.S. may persist while also saying the U.S. economy is \""in a good place.\"" The U.S. Oct Empire manufacturing survey general business conditions fell -6.5 to -4.6, a smaller decline than expectations for a level of -6.0. The markets are discounting an 8% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 37% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are higher. The 10-year T-note is up +9.2 bp at 4.704%. The 10-year German bund yield is up +5.2 bp at 2.789%. The 10-year UK gilt yield is up +9.3 bp at 4.478%. In a measure to boost liquidity, the People's Bank of China (PBOC) added a net 289 billion yuan ($39.6 billion) into the financial system via the medium-term lending facility, the largest monthly injection of cash into the financial system since December 2020. Overseas stock markets are mixed. The Euro Stoxx 50 is up +0.19%. China\u2019s Shanghai Composite Index closed down -0.46%. Japan\u2019s Nikkei 225 today closed down -2.03 %. Today\u2019s stock movers\u2026 Lululemon Athletica (LULU) is up more than +9% to lead gainers in the Nasdaq 100 after S&P Dow Jones Indices announced the stock will replace Activision Blizzard in the S&P 500 before the opening of trading on Wednesday. Charles Schwab (SCHW) is up more than +6% to lead gainers in the S&P 500 after reporting Q3 bank deposits of $284.4 billion, above the consensus of $268.8 billion. Pfizer (PFE) is up more than +4% despite cutting its full-year revenue forecast after Leerink Partners said the company\u2019s cost-cutting measures are a positive for the stock. Arista Networks (ANET) is up more than +3% after Evercore ISI added the stock to its tactical outperform list with a price target of $200. Hubbell Inc (HUBB) is up more than +3% after S&P Dow Jones Indices announced the stock would replace Organon in the S&P 500 before the opening of trading on Wednesday. Veralto (VLTO) is up more than +2% after Vertical Research upgraded the stock to buy from hold with a price target of $82. Microsoft (MSFT) is up more than +2% after Piper Sandler named the company its highest conviction large-cap stock to own over the rest of the year with a price target of $400. Dexcom (DXCM) is up more than +2% after Leerink Partners reinstated coverage of the stock with a recommendation of outperform and a price target of $110. Allison Transmission Holdings (ALSN) is up more than +2% after JPMorgan Chase upgraded the stock to neutral from underweight. Colgate-Palmolive (CL) is up more than +1% after Stifel upgraded the stock to buy from hold with a price target of $81. Moderna (MRNA) is down more than -7% to lead losers in the S&P 500 and Nasdaq 100 after Pfizer cut its full-year forecasts due to weaker-than-expected demand for its Covid-19 products. Henry Schein (HSIC) is down more than -2% after it said some of its manufacturing and distribution units experienced a cybersecurity incident. Walgreens Boots Alliance (WBA) is down more than -2% to lead losers in the Dow Jones Industrials after Moody\u2019s Investors Service warned it may cut the company\u2019s Baa3 investment grade rating, the lowest tier above junk, citing a continued decline in earnings. Trade Desk (TTD) is down more than -1% on signs of insider selling after an SEC filing showed CEO Green sold $14.9 million shares last Wednesday and Friday. Target (TGT) is down nearly -1% after data from Bloomberg Second Nature shows observed sales for the company in the week ending Oct 8 fell -10% from a year earlier. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are down -14 ticks, and the 10-year T-note yield is up +9.2 bp at 4.704%. Dec T-notes today are moving lower as diplomatic efforts to contain the Israel-Hamas conflict are boosting stocks and curbing safe-haven demand for T-notes. Also, hawkish comments today from U.S. Treasury Secretary Yellen weighed on T-notes when she said higher interest rates in the U.S. may persist for a while. In addition, the smaller-than-expected decline in the U.S. Oct Empire manufacturing general business conditions survey was bearish for T-notes. The dollar index (DXY00) today is down by -0.23%. The dollar is under pressure today as geopolitical risks in the Middle East ease slightly after diplomatic efforts to contain the crisis curbed safe-haven demand for the dollar. Also, today\u2019s rally in stocks has reduced the liquidity demand for the dollar. Higher T-note yields today are limiting the downside in the dollar. EUR/USD (^EURUSD) today is up by +0.21%. A weaker dollar today is supportive of the euro. Also, an easing of Eurozone political risks us bullish for EUR/USD after exit polls showed Poland\u2019s pro-EU opposition party won a majority in parliamentary elections on Sunday. The German Sep wholesale price index eased to -4.1% y/y from -2.7% y/y in Aug, the largest decline in over three years. Dovish comments from ECB Governing Council member de Cos were bearish for the euro when he said the surge in global borrowing costs means ECB policymakers have probably done enough to tame inflation, and the September assessment that the level of interest rates was more appropriate \""is even more valid today.\"" USD/JPY (^USDJPY) today is up by +0.03%. The yen today is slightly lower as an easing of geopolitical tensions in the Middle East has reduced the safe-haven demand for the yen. The yen is also under pressure after Japan's industrial production for August was revised lower. In addition, higher T-note yields today are undercutting the yen. Losses in the yen are limited on comments today from Japanese currency chief Kanda that bolstered speculation Japan was close to intervening in currency markets to support the yen when he said, \u201cWe will take appropriate action on forex if necessary.\u201d Japan Aug industrial production was revised downward to -0.7% m/m from the initially reported unchanged m/m. December gold (GCZ3) today is down -8.5 (-0.44%), and Dec silver (SIZ23) is down -0.050 (-0.22%). Precious metals prices this morning are moderately lower as diplomatic efforts to contain the conflict between Israel and Hamas have eased geopolitical risks in the Middle East and reduced safe-haven demand for precious metals. Also, higher global bond yields today are negative for precious metals. In addition, hawkish comments from U.S. Treasury Secretary Yellen undercut precious metals when she said higher interest rates in the U.S. may persist. A weaker dollar today and the ongoing Israeli-Hamas conflict are limiting the downside in precious metals prices. More Stock Market News from Barchart Are These 2 Beaten-Down REITs Worth Buying for Their High Dividend Yields? Markets Today: Stocks Edge Higher on Hopes Israeli-Hamas Conflict Can Be Contained Option Volatility And Earnings Report For October 16 - 20 Stocks Set to Open Higher as Investors Await Powell Speech and Corporate Earnings On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Markets Today: Stocks Edge Higher on Hopes Israeli-Hamas Conflict Can Be Contained Morning Markets December E-Mini S&P 500 futures (ESZ23) are up +0.38%, and the Dec Nasdaq 100 E-Mini futures (NQZ23) are up +0.22%. Stock index futures this morning are moderately higher as the markets track diplomatic efforts to contain the Israel-Hamas conflict. The markets are also looking to Q3 corporate quarterly earnings results that ramp up this week. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. President Biden is considering visiting Israel himself, and German Chancellor Scholz is expected to arrive in Israel on Tuesday. Also, Jordan King Abdullah II is in Italy, where he\u2019s expected to meet with Italian Prime Minister Meloni to discuss the crisis. Meanwhile, U.S. Security Advisor Sullivan said the U.S. had warned Iran through back-channel talks about the risk of escalation of the war. In an interview with Sky News, U.S. Treasury Secretary Yellen said higher interest rates in the U.S. may persist while also saying the U.S. economy is \""in a good place.\"" The U.S. Oct Empire manufacturing survey general business conditions fell -6.5 to -4.6, a smaller decline than expectations of for a report of -6.0. The markets are discounting an 8% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 35% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are higher. The 10-year T-note is up +7.1 bp at 4.683%. The 10-year German bund yield is up +4.4 bp at 2.781%. The 10-year UK gilt yield is up +7.7 bp at 4.463%. Overseas stock markets are mixed. The Euro Stoxx 50 is up +0.06%. China\u2019s Shanghai Composite Index closed down -0.46%. Japan\u2019s Nikkei 225 today closed down -2.03 %. The Euro Stoxx 50 today is slightly higher as the markets focus on any new developments in the Israeli-Hamas war and what implications the war could have on the economy and interest rates. Crude prices and European government bond yields are slightly higher. Technological stock losses are weighing on the overall market after Bloomberg News reported that the U.S. is considering further restrictions on China\u2019s access to advanced semiconductors. An easing of Eurozone price pressures is supporting stocks after the German Sep wholesale price index eased to -4.1% y/y, the steepest drop in more than three years. Also, Eurozone political risks eased as exit polls showed Poland\u2019s pro-EU opposition party won a majority in parliamentary elections on Sunday. The German Sep wholesale price index eased to -4.1% y/y from -2.7% y/y in Aug, the largest decline in more than three years. ECB Governing Council member de Cos said the surge in global borrowing costs means ECB policymakers have probably done enough to tame inflation, and the September assessment that the level of interest rates was more appropriate \""is even more valid today.\"" China\u2019s Shanghai Composite Stock Index today dropped to a 7-week low and closed moderately lower. A slide in technology stocks today undercut market sentiment and weighed on the overall market after Bloomberg News reported the U.S. plans to tighten sweeping measures to restrict China\u2019s access to advanced semiconductors and chipmaking gear. The new rules aim to close loopholes from curbs announced last October and strengthen controls on selling graphic chips for artificial intelligence applications. The U.S. will also impose additional checks on Chinese firms attempting to evade export restrictions by routing shipments through other nations and add Chinese chip design firms to a trade restriction list, requiring overseas manufacturers to obtain a U.S. license to fill orders from those companies. Losses in Chinese stocks were limited after the PBOC boosted liquidity and injected the most cash into the financial system in almost three years. The People's Bank of China (PBOC) added a net 289 billion yuan ($39.6 billion) into the financial system via the medium-term lending facility, the largest monthly injection of cash into the financial system since December 2020. Japan\u2019s Nikkei Stock Index today closed sharply lower amid concern about the conflict between Israel and Hamas. Weakness in technology stocks weighed on the overall market after Bloomberg News reported the U.S. will tighten curbs on China\u2019s access to chip technology. Also, a downward revision to Japan's industrial production activity in August was negative for stocks. In addition, airlines and Industrial stocks moved lower on concerns that soaring fuel prices will undercut profits after last week\u2019s surge in crude prices. Japan Aug industrial production was revised downward to -0.7% m/m from the initially reported unchanged m/m. Pre-Market U.S. Stock Movers Lululemon Athletica (LULU) jumped more than +4% in pre-market trading after S&P Dow Jones Indices announced the stock will replace Activision Blizzard in the S&P 500 before the opening of trading on Wednesday. Hubbell Inc (HUBB) climbed more than +2% in pre-market trading after S&P Dow Jones Indices announced the stock would replace Organon in the S&P 500 before the opening of trading on Wednesday. VinFast Auto Ltd (VFS) rose more than +3% in pre-market trading after CEO Le Thi Thu Thuy said the company plans to move into Southeast Asian markets aggressively and expects to meet its target of selling 35,000 to 50,000 vehicles this year. Allison Transmission Holdings (ALSN) is up more than +2% in pre-market trading after JPMorgan Chase upgraded the stock to neutral from underweight. Dexcom (DXCM) climbed more than +2% in pre-market trading after Leerink Partners reinstated coverage of the stock with a recommendation of outperform and a price target of $110. Colgate-Palmolive (CL) rose more than +1% in pre-market trading after Stifel upgraded the stock to buy from hold with a price target of $81. Instacart (CART) gained more than +1% in pre-market trading after Barclays initiated coverage on the stock with a recommendation of overweight and a price target of $40. New Ambrx Biopharma (AMAM) surged more than +45% in pre-market trading after it released data abstract from a trial of its investigational drug for prostate cancer. Cantor Fitzgerald said the data \u201cexceeded street expectations.\u201d Apple (AAPL) fell more than -1% in pre-market trading on signs of weak Chinese demand for the new iPhone when market tracker Counterpoint Research reported sales of the new iPhone 15 are down -4.5% in China compared with the iPhone 14 over their first 17 days after release. Pfizer (PFE) dropped more than -2% in pre-market trading after cutting its full-year revenue forecast to $58 billion-$61 billion from a previous estimate of $67 billion-$70 billion. Chip equipment stocks are falling in pre-market trading after Bloomberg News reported that the U.S. plans to tighten restrictions on China\u2019s access to advanced semiconductors and chipmaking gear. As a result, Nvidia (NVDA), KLA Corp (KLAC), Applied Materials (AMAT), Lam Research (LRCX), Advanced Micro Devices (AMD), and ASML Holding NV (ASML) are down more than -1%. Trade Desk (TTD) tumbled more than -5% in pre-market trading on signs of insider selling after an SEC filing showed CEO Green sold $14.9 million shares last Wednesday and Friday. Charles Schwab (SCHW) slid nearly -1% in pre-market trading after reporting Q3 net revenue of $4.61 billion, weaker than the consensus of $4.63 billion. Earnings Reports (10/16/2023) Charles Schwab Corp/The (SCHW), CrossFirst Bankshares Inc (CFB), Enerpac Tool Group Corp (EPAC), Equity LifeStyle Properties Inc (ELS), FB Financial Corp (FBK), Guaranty Bancshares Inc/TX (GNTY), ServisFirst Bancshares Inc (SFBS), Veradigm Inc (MDRX). More Stock Market News from Barchart Option Volatility And Earnings Report For October 16 - 20 Stocks Set to Open Higher as Investors Await Powell Speech and Corporate Earnings Geopolitics, Earnings and Other Key Themes to Watch this Week From Field to Silo: Trading the Journey of Corn During the Harvest Season On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-17,77.38,82.56,76.81,80.49,"[""Why the Market Dipped But DexCom (DXCM) Gained Today In the latest trading session, DexCom (DXCM) closed at $80.49, marking a +1.95% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.01%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.25%. Prior to today's trading, shares of the medical device company had lost 17.15% over the past month. This has lagged the Medical sector's loss of 2.91% and the S&P 500's loss of 1.6% in that time. Investors will be eagerly watching for the performance of DexCom in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 26, 2023. The company is predicted to post an EPS of $0.34, indicating a 21.43% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $936.02 million, indicating a 21.62% increase compared to the same quarter of the previous year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.55 billion. These totals would mark changes of +41.38% and +21.83%, respectively, from last year. Investors should also take note of any recent adjustments to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DexCom is holding a Zacks Rank of #4 (Sell) right now. Valuation is also important, so investors should note that DexCom has a Forward P/E ratio of 64.14 right now. This expresses a premium compared to the average Forward P/E of 24.58 of its industry. We can also see that DXCM currently has a PEG ratio of 1.49. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Instruments industry had an average PEG ratio of 2.04 as trading concluded yesterday. The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 40% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Slide as Bond Yields Climb on Strong U.S. Economic Reports What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.06%. Stocks are sliding, with the Nasdaq 100 falling to a 1-week low. Bond yields jumped on this morning\u2019s stronger-than-expected U.S. Sep retail sales and Sep manufacturing reports, hawkish factors for Fed policy. Also, weakness in chip stocks is weighing on the overall market after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. A rally in medical device makers lifted the S&P 500 off its lows. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. German Chancellor Scholz is expected to arrive in Israel today, and U.S. President Biden will travel to Israel on Wednesday. President Biden will also travel to Jordan to meet with Arab leaders, including Jordan King Abdullah II, Egyptian President Abdel Fatah El-Sisi, and Palestinian Authority President Mahmoud Abbas. U.S. Sep retail sales rose +0.7% m/m and +0.6% m/m ex-autos, stronger than expectations of +0.3% m/m and +0.2% m/m ex-autos. Also, Aug retail sales were revised higher to +0.8% m/m and +0.9% m/m ex-autos from the initially reported +0.6% m/m and +0.6% m/m ex-autos. U.S. Sep manufacturing production rose +0.4% m/m, stronger than expectations of unchanged m/m. The U.S. Oct NAHB housing market index fell -4 to a 9-month low of 40, weaker than expectations of 44. The markets are discounting a 10% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 46% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are higher. The 10-year T-note yield rose to a 1-week high of 4.855% and is up +11.1 bp at 4.817%. The 10-year German bund yield rose to a 1-week high of 2.895% and is up +9.8 bp at 2.883%. The 10-year UK gilt yield rose to a 1-week high of 4.561% and is up +5.3 bp at 4.533%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.12%. China\u2019s Shanghai Composite Index closed up +0.32%. Japan\u2019s Nikkei 225 today closed up +1.20%. Today\u2019s stock movers\u2026 Chip stocks are under pressure today after the U.S. said it is restricting top-of-the-line chips used for powering artificial intelligence (AI) models, including chips Nvidia designed especially for the Chinese market. As a result, Nvidia (NVDA) is down more than -5% to lead losers in the S&P 500 and Nasdaq 100. Also, Intel (INTC) is down more than -2% to lead losers in the Dow Jones Industrials. In addition, Advanced Micro Devices (AMD), Marvell Technology (MRVL), KLA Corp (KLAC), Broadcom (AVGO), Lam Research (LRCX), and NXP Semiconductors (NXPI) are down more than -2%. Lucid Group (LCID) is down more than -3% after reporting it delivered 1,457 vehicles in Q3, below expectations of 2,100. Bank of New York Mellon (BK) is down more than -3% after reporting Q3 total average deposits of $262.11 billion, below the consensus of $269.61 billion. NetScout (NTCT) is down more than -19% after cutting its 2023 adjusted EPS forecast to $2.00-$2.20 from a prior forecast of $2.20-$2.32, weaker than the consensus of $2.27. U.S.-listed Chinese stocks are falling today after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. As a result, JD.com (JD) is down more than -3%. Also, Baidu (BIDU) and NetEase (NTES) are down more than -2%. In addition, Trip.com (TCOM) is down more than -1%. Choice Hotels International (CHH) is down more than -3% after offering to buy Wyndham Hotels for $90/share in a deal valued at $9.8 billion. Goldman Sachs (GS) is down more than -1% after reporting Q3 net interest income of $1.55 billion, weaker than the consensus of $1.86 billion. VF Corp (VFC) is up more than +6% to lead gainers in the S&P 500 after activist investor Engaged Capital took a stake in the company. Medical device companies are rallying today after Leerink Partners named Intuitive Surgical, Dexcom, and Shockwave Medical among its top buys. As a result, Dexcom (DXCM) is up more than +4% to lead gainers in the Nasdaq 100. Also, Insulet (PODD) is up more than +4%, Shockwave Medical (SWAV) is up more than +3%, and Intuitive Surgical (ISRG) is up more than +1%. Dollar Tree (DLTR) is up more than +3% after Goldman Sachs upgraded the stock to buy from neutral with a price target of $137. Wyndham Hotels & Resorts (WH) is up more than +10% after Choice Hotels International proposed to buy the company for $90 a share in a deal valued at $9.8 billion. Viasat (VSAT) is up more than +5% after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $30. Fidelity National Information Services (FIS) is up more than +1% after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $65. Air Products & Chemicals (APD) is up more than +1% after Wells Fargo Securities upgraded the stock to overweight from neutral with a price target of $345. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are down -25 ticks, and the 10-year T-note yield is up +11.1 bp at 4.817%. Dec T-notes today fell to a 1-week low, and the 10-year T-note yield climbed to a 1-week high of 4.885%. Today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports were hawkish for Fed policy and weighed on T-note prices. Also, an increase in inflation expectations is bearish for T-notes after the 10-year breakeven inflation rate today climbed to a 2-1/4 month high of 2.410%. The dollar index (DXY00) today is up by +0.16%. The dollar today recovered from overnight losses and is moderately higher. Signs of strength in the U.S. economy are boosting T-note yields and the dollar on today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports. Also, the weakness in stocks today has boosted the liquidity demand for the dollar. EUR/USD (^EURUSD) today is down by -0.09%. Strength in the dollar today is weighing on the euro. Losses in EUR/USD are limited after today\u2019s news showed the German Oct ZEW survey expectations of economic growth rose more than expected to a 6-month high. Also, hawkish comments from ECB Chief Economist Lane were supportive of the euro when he said ECB policy is far from being loosened. The German Oct ZEW survey expectations of economic growth rose +10.3 to a 6-month high of -1.1, stronger than expectations of -9.0. ECB Chief Economist Lane said monetary policy can only be loosened when ECB officials are \""sufficiently confident\"" of reaching their 2% inflation target, \""but this is quite some distance away from where we are now.\"" USD/JPY (^USDJPY) today is up by +0.17%. The yen today gave up an overnight advance and is moderately lower. A jump in T-note yields today is undercutting the yen along with weak Japanese economic news after the Aug tertiary industry index unexpectedly fell. The yen initially moved higher in overnight trade on a Bloomberg report that said the BOJ will likely discuss raising its inflation projection for fiscal 2023 and 2024 at its policy meeting later this month. The Japan Aug tertiary industry index unexpectedly fell -0.1% m/m, weaker than expectations of a +0.3% m/m increase. December gold (GCZ3) today is up +2.8 (+0.14%), and Dec silver (SIZ23) is up +0.135 (+0.592%). Precious metals prices this morning are moderately higher on increased safe-haven demand regarding the Israeli-Hamas war after Israeli defense minister Gallant said to expect a \u201clong war\u201d against Hamas. Also, an increase in inflation expectations boosted demand for gold as an inflation hedge after the 10-year U.S. breakeven inflation rate today rose to a 2-1/4 month high. Silver also found support today on the stronger-than-expected U.S. retail sales and manufacturing production reports, which were bullish for industrial metals demand. Gains in precious metals are limited today by the stronger dollar and higher global bond yields. Also, hawkish comments from ECB Chief Economist Lane weighed on precious metals when he said ECB policy is far from being loosened. More Stock Market News from Barchart Should You Buy This Warren Buffett Stock Near 52-Week Lows for Its 5% Yield? Markets Today: Stocks Slip as Bond Yields Jump after U.S. Retail Sales Tops Forecasts Navigating the Stock Market Amidst International Conflict: Opportunities in Chaos 2 Covered Call Ideas on Iron Mountain Stock. Which One is Better? On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Mixed as Bond Yields Climb on Strong U.S. Economic Reports What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.27%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.04%. Stocks this morning are mixed, with the Nasdaq 100 falling to a 1-week low. Bond yields jumped on this morning\u2019s stronger-than-expected U.S. Sep retail sales and Sep manufacturing reports, hawkish factors for Fed policy. Also, weakness in chip stocks is weighing on the overall market after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. A rally in medical device makers lifted the S&P 500 off its lows. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. German Chancellor Scholz is expected to arrive in Israel today, and U.S. President Biden will travel to Israel on Wednesday. President Biden will also travel to Jordan to meet with Arab leaders, including Jordan King Abdullah II, Egyptian President Abdel Fatah El-Sisi, and Palestinian Authority President Mahmoud Abbas. U.S. Sep retail sales rose +0.7% m/m and +0.6% m/m ex-autos, stronger than expectations of +0.3% m/m and +0.2% m/m ex-autos. Also, Aug retail sales were revised higher to +0.8% m/m and +0.9% m/m ex-autos from the initially reported +0.6% m/m and +0.6% m/m ex-autos. U.S. Sep manufacturing production rose +0.4% m/m, stronger than expectations of unchanged m/m. The U.S. Oct NAHB housing market index fell -4 to a 9-month low of 40, weaker than expectations of 44. The markets are discounting a 10% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 46% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are higher. The 10-year T-note yield rose to a 1-week high of 4.855% and is up +11.1 bp at 4.817%. The 10-year German bund yield rose to a 1-week high of 2.895% and is up +9.8 bp at 2.883%. The 10-year UK gilt yield rose to a 1-week high of 4.561% and is up +5.3 bp at 4.533%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.12%. China\u2019s Shanghai Composite Index closed up +0.32%. Japan\u2019s Nikkei 225 today closed up +1.20%. Today\u2019s stock movers\u2026 Chip stocks are under pressure today after the U.S. said it is restricting top-of-the-line chips used for powering artificial intelligence (AI) models, including chips Nvidia designed especially for the Chinese market. As a result, Nvidia (NVDA) is down more than -5% to lead losers in the S&P 500 and Nasdaq 100. Also, Intel (INTC) is down more than -2% to lead losers in the Dow Jones Industrials. In addition, Advanced Micro Devices (AMD), Marvell Technology (MRVL), KLA Corp (KLAC), Broadcom (AVGO), Lam Research (LRCX), and NXP Semiconductors (NXPI) are down more than -2%. Lucid Group (LCID) is down more than -3% after reporting it delivered 1,457 vehicles in Q3, below expectations of 2,100. Bank of New York Mellon (BK) is down more than -3% after reporting Q3 total average deposits of $262.11 billion, below the consensus of $269.61 billion. NetScout (NTCT) is down more than -19% after cutting its 2023 adjusted EPS forecast to $2.00-$2.20 from a prior forecast of $2.20-$2.32, weaker than the consensus of $2.27. U.S.-listed Chinese stocks are falling today after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. As a result, JD.com (JD) is down more than -3%. Also, Baidu (BIDU) and NetEase (NTES) are down more than -2%. In addition, Trip.com (TCOM) is down more than -1%. Choice Hotels International (CHH) is down more than -3% after offering to buy Wyndham Hotels for $90/share in a deal valued at $9.8 billion. Goldman Sachs (GS) is down more than -1% after reporting Q3 net interest income of $1.55 billion, weaker than the consensus of $1.86 billion. VF Corp (VFC) is up more than +6% to lead gainers in the S&P 500 after activist investor Engaged Capital took a stake in the company. Medical device companies are rallying today after Leerink Partners named Intuitive Surgical, Dexcom, and Shockwave Medical among its top buys. As a result, Dexcom (DXCM) is up more than +4% to lead gainers in the Nasdaq 100. Also, Insulet (PODD) is up more than +4%, Shockwave Medical (SWAV) is up more than +3%, and Intuitive Surgical (ISRG) is up more than +1%. Dollar Tree (DLTR) is up more than +3% after Goldman Sachs upgraded the stock to buy from neutral with a price target of $137. Wyndham Hotels & Resorts (WH) is up more than +10% after Choice Hotels International proposed to buy the company for $90 a share in a deal valued at $9.8 billion. Viasat (VSAT) is up more than +5% after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $30. Fidelity National Information Services (FIS) is up more than +1% after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $65. Air Products & Chemicals (APD) is up more than +1% after Wells Fargo Securities upgraded the stock to overweight from neutral with a price target of $345. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are down -25 ticks, and the 10-year T-note yield is up +11.1 bp at 4.817%. Dec T-notes today fell to a 1-week low, and the 10-year T-note yield climbed to a 1-week high of 4.885%. Today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports were hawkish for Fed policy and weighed on T-note prices. Also, an increase in inflation expectations is bearish for T-notes after the 10-year breakeven inflation rate today climbed to a 2-1/4 month high of 2.410%. The dollar index (DXY00) today is up by +0.16%. The dollar today recovered from overnight losses and is moderately higher. Signs of strength in the U.S. economy are boosting T-note yields and the dollar on today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports. Also, the weakness in stocks today has boosted the liquidity demand for the dollar. EUR/USD (^EURUSD) today is down by -0.09%. Strength in the dollar today is weighing on the euro. Losses in EUR/USD are limited after today\u2019s news showed the German Oct ZEW survey expectations of economic growth rose more than expected to a 6-month high. Also, hawkish comments from ECB Chief Economist Lane were supportive of the euro when he said ECB policy is far from being loosened. The German Oct ZEW survey expectations of economic growth rose +10.3 to a 6-month high of -1.1, stronger than expectations of -9.0. ECB Chief Economist Lane said monetary policy can only be loosened when ECB officials are \""sufficiently confident\"" of reaching their 2% inflation target, \""but this is quite some distance away from where we are now.\"" USD/JPY (^USDJPY) today is up by +0.17%. The yen today gave up an overnight advance and is moderately lower. A jump in T-note yields today is undercutting the yen along with weak Japanese economic news after the Aug tertiary industry index unexpectedly fell. The yen initially moved higher in overnight trade on a Bloomberg report that said the BOJ will likely discuss raising its inflation projection for fiscal 2023 and 2024 at its policy meeting later this month. The Japan Aug tertiary industry index unexpectedly fell -0.1% m/m, weaker than expectations of a +0.3% m/m increase. December gold (GCZ3) today is up +2.8 (+0.14%), and Dec silver (SIZ23) is up +0.135 (+0.592%). Precious metals prices this morning are moderately higher on increased safe-haven demand regarding the Israeli-Hamas war after Israeli defense minister Gallant said to expect a \u201clong war\u201d against Hamas. Also, an increase in inflation expectations boosted demand for gold as an inflation hedge after the 10-year U.S. breakeven inflation rate today rose to a 2-1/4 month high. Silver also found support today on the stronger-than-expected U.S. retail sales and manufacturing production reports, which were bullish for industrial metals demand. Gains in precious metals are limited today by the stronger dollar and higher global bond yields. Also, hawkish comments from ECB Chief Economist Lane weighed on precious metals when he said ECB policy is far from being loosened. More Stock Market News from Barchart Should You Buy This Warren Buffett Stock Near 52-Week Lows for Its 5% Yield? Markets Today: Stocks Slip as Bond Yields Jump after U.S. Retail Sales Tops Forecasts Navigating the Stock Market Amidst International Conflict: Opportunities in Chaos 2 Covered Call Ideas on Iron Mountain Stock. Which One is Better? On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Drop as Bond Yields Climb on Strong U.S. Economic Reports What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.22%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.61%. Stocks this morning are moderately lower, with the Nasdaq 100 falling to a 1-week low. Stocks are under pressure as bond yields jumped on this morning\u2019s stronger-than-expected U.S. Sep retail sales and Sep manufacturing reports, hawkish factors for Fed policy. Also, weakness in chip stocks is weighing on the overall market after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. A rally in medical device makers lifted the S&P 500 off its lows. The U.S. and its allies are ramping up diplomatic efforts to contain the conflict between Israel and Hamas. German Chancellor Scholz is expected to arrive in Israel today, and U.S. President Biden will travel to Israel on Wednesday. President Biden will also travel to Jordan to meet with Arab leaders, including Jordan King Abdullah II, Egyptian President Abdel Fatah El-Sisi, and Palestinian Authority President Mahmoud Abbas. U.S. Sep retail sales rose +0.7% m/m and +0.6% m/m ex-autos, stronger than expectations of +0.3% m/m and +0.2% m/m ex-autos. Also, Aug retail sales were revised higher to +0.8% m/m and +0.9% m/m ex-autos from the initially reported +0.6% m/m and +0.6% m/m ex-autos. U.S. Sep manufacturing production rose +0.4% m/m, stronger than expectations of unchanged m/m. The U.S. Oct NAHB housing market index fell -4 to a 9-month low of 40, weaker than expectations of 44. The markets are discounting a 10% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 46% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields are higher. The 10-year T-note yield rose to a 1-week high of 4.855% and is up +11.1 bp at 4.817%. The 10-year German bund yield rose to a 1-week high of 2.895% and is up +9.8 bp at 2.883%. The 10-year UK gilt yield rose to a 1-week high of 4.561% and is up +5.3 bp at 4.533%. Overseas stock markets are mixed. The Euro Stoxx 50 is down -0.12%. China\u2019s Shanghai Composite Index closed up +0.32%. Japan\u2019s Nikkei 225 today closed up +1.20%. Today\u2019s stock movers\u2026 Chip stocks are under pressure today after the U.S. said it is restricting top-of-the-line chips used for powering artificial intelligence (AI) models, including chips Nvidia designed especially for the Chinese market. As a result, Nvidia (NVDA) is down more than -5% to lead losers in the S&P 500 and Nasdaq 100. Also, Intel (INTC) is down more than -2% to lead losers in the Dow Jones Industrials. In addition, Advanced Micro Devices (AMD), Marvell Technology (MRVL), KLA Corp (KLAC), Broadcom (AVGO), Lam Research (LRCX), and NXP Semiconductors (NXPI) are down more than -2%. Lucid Group (LCID) is down more than -3% after reporting it delivered 1,457 vehicles in Q3, below expectations of 2,100. Bank of New York Mellon (BK) is down more than -3% after reporting Q3 total average deposits of $262.11 billion, below the consensus of $269.61 billion. NetScout (NTCT) is down more than -19% after cutting its 2023 adjusted EPS forecast to $2.00-$2.20 from a prior forecast of $2.20-$2.32, weaker than the consensus of $2.27. U.S.-listed Chinese stocks are falling today after Bloomberg News reported the U.S. is restricting the sale of chips to China that are used for AI. As a result, JD.com (JD) is down more than -3%. Also, Baidu (BIDU) and NetEase (NTES) are down more than -2%. In addition, Trip.com (TCOM) is down more than -1%. Choice Hotels International (CHH) is down more than -3% after offering to buy Wyndham Hotels for $90/share in a deal valued at $9.8 billion. Goldman Sachs (GS) is down more than -1% after reporting Q3 net interest income of $1.55 billion, weaker than the consensus of $1.86 billion. VF Corp (VFC) is up more than +6% to lead gainers in the S&P 500 after activist investor Engaged Capital took a stake in the company. Medical device companies are rallying today after Leerink Partners named Intuitive Surgical, Dexcom, and Shockwave Medical among its top buys. As a result, Dexcom (DXCM) is up more than +4% to lead gainers in the Nasdaq 100. Also, Insulet (PODD) is up more than +4%, Shockwave Medical (SWAV) is up more than +3%, and Intuitive Surgical (ISRG) is up more than +1%. Dollar Tree (DLTR) is up more than +3% after Goldman Sachs upgraded the stock to buy from neutral with a price target of $137. Wyndham Hotels & Resorts (WH) is up more than +10% after Choice Hotels International proposed to buy the company for $90 a share in a deal valued at $9.8 billion. Viasat (VSAT) is up more than +5% after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $30. Fidelity National Information Services (FIS) is up more than +1% after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $65. Air Products & Chemicals (APD) is up more than +1% after Wells Fargo Securities upgraded the stock to overweight from neutral with a price target of $345. Across the markets\u2026 December 10-year T-notes (ZNZ23) this morning are down -25 ticks, and the 10-year T-note yield is up +11.1 bp at 4.817%. Dec T-notes today fell to a 1-week low, and the 10-year T-note yield climbed to a 1-week high of 4.885%. Today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports were hawkish for Fed policy and weighed on T-note prices. Also, an increase in inflation expectations is bearish for T-notes after the 10-year breakeven inflation rate today climbed to a 2-1/4 month high of 2.410%. The dollar index (DXY00) today is up by +0.16%. The dollar today recovered from overnight losses and is moderately higher. Signs of strength in the U.S. economy are boosting T-note yields and the dollar on today\u2019s stronger-than-expected U.S. retail sales and manufacturing production reports. Also, the weakness in stocks today has boosted the liquidity demand for the dollar. EUR/USD (^EURUSD) today is down by -0.09%. Strength in the dollar today is weighing on the euro. Losses in EUR/USD are limited after today\u2019s news showed the German Oct ZEW survey expectations of economic growth rose more than expected to a 6-month high. Also, hawkish comments from ECB Chief Economist Lane were supportive of the euro when he said ECB policy is far from being loosened. The German Oct ZEW survey expectations of economic growth rose +10.3 to a 6-month high of -1.1, stronger than expectations of -9.0. ECB Chief Economist Lane said monetary policy can only be loosened when ECB officials are \""sufficiently confident\"" of reaching their 2% inflation target, \""but this is quite some distance away from where we are now.\"" USD/JPY (^USDJPY) today is up by +0.17%. The yen today gave up an overnight advance and is moderately lower. A jump in T-note yields today is undercutting the yen along with weak Japanese economic news after the Aug tertiary industry index unexpectedly fell. The yen initially moved higher in overnight trade on a Bloomberg report that said the BOJ will likely discuss raising its inflation projection for fiscal 2023 and 2024 at its policy meeting later this month. The Japan Aug tertiary industry index unexpectedly fell -0.1% m/m, weaker than expectations of a +0.3% m/m increase. December gold (GCZ3) today is up +2.8 (+0.14%), and Dec silver (SIZ23) is up +0.135 (+0.592%). Precious metals prices this morning are moderately higher on increased safe-haven demand regarding the Israeli-Hamas war after Israeli defense minister Gallant said to expect a \u201clong war\u201d against Hamas. Also, an increase in inflation expectations boosted demand for gold as an inflation hedge after the 10-year U.S. breakeven inflation rate today rose to a 2-1/4 month high. Silver also found support today on the stronger-than-expected U.S. retail sales and manufacturing production reports, which were bullish for industrial metals demand. Gains in precious metals are limited today by the stronger dollar and higher global bond yields. Also, hawkish comments from ECB Chief Economist Lane weighed on precious metals when he said ECB policy is far from being loosened. More Stock Market News from Barchart Should You Buy This Warren Buffett Stock Near 52-Week Lows for Its 5% Yield? Markets Today: Stocks Slip as Bond Yields Jump after U.S. Retail Sales Tops Forecasts Navigating the Stock Market Amidst International Conflict: Opportunities in Chaos 2 Covered Call Ideas on Iron Mountain Stock. Which One is Better? On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: NVDA, DLTR In early trading on Tuesday, shares of Dollar Tree topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.3%. Year to date, Dollar Tree has lost about 20.4% of its value. And the worst performing Nasdaq 100 component thus far on the day is NVIDIA, trading down 6.7%. NVIDIA is showing a gain of 194.4% looking at the year to date performance. Two other components making moves today are Intel, trading down 3.9%, and DexCom, trading up 1.6% on the day. VIDEO: Nasdaq 100 Movers: NVDA, DLTR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-18,81.49,85.27,81.465,84.12,"[""Can DexCom (DXCM) Keep the Earnings Surprise Streak Alive? Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM), which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. This medical device company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 33.94%. For the most recent quarter, DexCom was expected to post earnings of $0.22 per share, but it reported $0.34 per share instead, representing a surprise of 54.55%. For the previous quarter, the consensus estimate was $0.15 per share, while it actually produced $0.17 per share, a surprise of 13.33%. With this earnings history in mind, recent estimates have been moving higher for DexCom. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. DexCom currently has an Earnings ESP of +7.39%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on October 26, 2023. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Stocks Close Lower on Heightened Geopolitical Risks and Soaring Bond Yields What you need to know\u2026 The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.34%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.98%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.41%. Stocks on Wednesday closed sharply lower, with the Nasdaq 100 falling to a 1-week low. Stocks retreated Wednesday on the risks of an escalation in the Israeli-Hamas war after an explosion at a Gaza hospital complicated diplomatic efforts to contain the conflict. After the bombing, the leaders of Jordan, Egypt, and the Palestinian Authority canceled their scheduled summits with President Biden on Wednesday. Airline stocks moved lower and weighed on the overall market after United Airlines Holdings warned that the Israeli-Hamas war and higher jet fuel costs would weigh on earnings. Also, Morgan Stanley closed down more than -6% after reporting weaker-than-expected Q3 wealth management revenue. A jump in the 10-year T-note yield to a new 16-year high Wednesday was bearish for stocks. Crude prices rose more than +1% at a 2-week high, which boosted energy stocks. Crude prices jumped after Iran\u2019s foreign minister called for an oil embargo against Israel. Tuesday\u2019s U.S. housing news was mixed for stocks. U.S. Sep housing starts rose by +7.0% to 1.358 million units, which was weaker than expectations for an increase to 1.383 million. However, Sep building permits fell by -4.4% to 1.473 million units, slightly stronger than expectations for a larger decline to 1.453 million units. Weekly U.S. MBA mortgage applications fell -6.9% in the week ended Oct 13 to 166.9, the weakest reading in 28 years. The mortgage purchase sub-index fell 5.6% to its lowest level in 28 years, and the refinancing sub-index fell -9.9%. The average 30-year fixed mortgage rate rose +0.3 bp to 7.70%, the highest in 23 years. Fed comments Wednesday were mixed for T-notes and stocks. On the bearish side, NY Fed President Williams said despite inflation progress, there's still a way to go, and the Fed will need to keep interest rates restrictive \""for some time.\"" Conversely, Fed Governor Waller suggests he favors pausing Fed rate hikes when he said, \""I believe we can wait, watch, and see how the economy evolves before making definitive moves on the path of the policy rate.\"" The Fed Beige Book was slightly dovish, stating, \""The near-term outlook for the economy was generally described as stable or having slightly weaker growth, and labor market tightness continued to ease across the nation.\"" The markets are discounting a 6% chance that the FOMC will raise the funds rate by +25 bp at the next FOMC meeting that ends on November 1, and a 42% chance for that +25 bp rate hike at the following meeting that ends on December 13. The markets are then expecting the FOMC to begin cutting rates in the second half of 2024 in response to an expected slowdown in the U.S. economy. U.S. and European bond yields Wednesday moved higher. The 10-year T-note yield rose to a 16-year high of 4.926% and finished up +6.6 bp at 4.900%. The 10-year German bund yield rose to a 1-1/2 week high of 2.934% and finished up +4.3 bp at 2.924%. The 10-year UK gilt yield rose to a 2-week high of 4.664% and finished up +14.5 bp at 4.657%. Overseas stock markets on Wednesday settled mixed. The Euro Stoxx 50 closed down -1.12%. China\u2019s Shanghai Composite Index closed down -0.80%. Japan\u2019s Nikkei 225 today closed up +0.01%. Today\u2019s stock movers\u2026 Albemarle (ALB) closed down more than -9% to lead losers in the S&P 500 after Bank of America Global Research downgraded the stock to underperform from neutral. Airline stocks were under pressure Wednesday after United Airlines flagged a sharp profit decline should flights to and from Israel remain grounded due to the Israel-Hamas conflict. As a result, United Airlines Holdings (UAL) closed down more than -9%. Also, American Airlines Group (AAL)and Alaska Air Group (ALK) closed down more than -5%, and Delta Air Lines (DAL) closed down more than -4%. Lucid Group (LCID) closed down more than -9% to lead losers in the Nasdaq 100 after CFRA downgraded the stock to sell from hold with a price target of $4. JB Hunt Transport Services (JBHT) closed down more than -8% after reporting Q3 EPS of $1.80, weaker than the consensus of $1.83. Morgan Stanley (MS) closed down more than -6% after reporting Q3 wealth management net revenue of $6.40 billion, below the consensus of $6.58 billion. Northern Trust (NTRS) closed down more than -6% after reporting Q3 net interest income of $469.4 million, below the consensus of $473.3 million. Nvidia (NVDA) closed down more than -3% after it warned that new U.S. rules on chip exports to China could hinder product development and cause other difficulties. Sherwin-Williams (SHW) closed down more than -4% after Bank of America Global Research downgraded the stock to underperform from neutral. Citizens Financial Group (CFG) closed down more than -5% after reporting Q3 revenue of $2.01 billion, weaker than the consensus of $2.04 billion. Diabetes stocks rallied after better-than-expected earnings results from Abbott Laboratories eased concerns that the Ozempic weight-loss drug would curb demand for their products. As a result, Dexcom (DXCM) closed up more than +6% to lead gainers in the S&P 500 and Nasdaq 100. Also, DaVita (DVA) closed up more than +3%, and Insulet (PODD) closed up more than +2%. Abbott Laboratories (ABT) rallied +3.71% after reporting Q3 net sales of $10.14 billion, better than the consensus of $9.81 billion. Nasdaq Inc (NDAQ) closed up more than +3% after reporting Q3 net revenue of $940 million, stronger than the consensus of $933.7 million. Procter & Gamble (PG) closed up more than +2% to lead gainers in the Dow Jones Industrials after reporting Q1 organic revenue rose +7.00%, stronger than the consensus of +5.83%. Energy stocks and energy service providers moved higher, with the price of WTI crude up more than +1% at a 2-week high. As a result, Valero Energy (VLO) and Phillips 66 (PSX) closed up more than +2%. Also, Occidental Petroleum (OXY), APA Corp (APA), Exxon Mobil (XOM), and Marathon Petroleum (MPC) are up more than +1%. Floor & Decor Holdings (FND) closed up nearly +1% after S&P Dow Jones Indices said the company will replace Vicor Corp in the S&P MidCap 400, effective on Friday\u2019s open. Across the markets\u2026 December 10-year T-notes (ZNZ23) Wednesday closed down -11 ticks, and the 10-year T-note yield rose +6.6 bp to 4.900%. Dec T-notes Wednesday fell to a new 16-year nearest-futures low, and the 10-year T-note yield climbed to a 16-year high of 4.926%. An increase in inflation expectations was bearish for T-notes after the 10-year breakeven inflation rate Wednesday climbed to a 2-3/4 month high of 2.449%. Also, mediocre demand for the Treasury\u2019s $13 billion of 20-year T-bonds was negative for prices, with a bid-to-cover ratio of 2.59, below the 10-auction average of 2.67. In addition, hawkish comments from NY Fed President Williams weighed on T-notes when he said the Fed will need to keep interest rates restrictive \""for some time.\"" T-notes recovered from their worst levels Wednesday as heightened geopolitical risks in the Middle East undercut stocks and boosted safe-haven demand for T-notes. Also, dovish comments from Fed Governor Waller gave T-notes a lift when he said he favors pausing Fed rate hikes. More Stock Market News from Barchart Households Might Be Wealthier. Just Don\u2019t Tell Winnebago and the Rest of the RV Stocks Dollar Tracks T-note Yields Higher 3 Fintech Stocks Analysts Like Better Than SoFi Technologies Top AI Stocks To Watch as Wedbush Predicts Eye-Opening Q3 Earnings On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nasdaq 100 Movers: ASML, DXCM In early trading on Wednesday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.8%. Year to date, DexCom Inc has lost about 25.5% of its value. And the worst performing Nasdaq 100 component thus far on the day is ASML Holding, trading down 4.8%. ASML Holding is showing a gain of 6.0% looking at the year to date performance. Two other components making moves today are AstraZeneca, trading down 4.6%, and Palo Alto Networks, trading up 1.4% on the day. VIDEO: Nasdaq 100 Movers: ASML, DXCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""S&P 500 Movers: BIO, NDAQ In early trading on Wednesday, shares of Nasdaq OMX Group topped the list of the day's best performing components of the S&P 500 index, trading up 4.7%. Year to date, Nasdaq OMX Group has lost about 14.8% of its value. And the worst performing S&P 500 component thus far on the day is Bio-Rad Laboratories, trading down 8.5%. Bio-Rad Laboratories is lower by about 25.8% looking at the year to date performance. Two other components making moves today are United Airlines Holdings, trading down 7.7%, and DexCom, trading up 4.7% on the day. VIDEO: S&P 500 Movers: BIO, NDAQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value Diabetes care and aesthetics. Those are two areas of healthcare that should provide investors with ample growth opportunities in the long run. Two companies that are in solid positions to capitalize on that potential are DexCom (NASDAQ: DXCM) and InMode (NASDAQ: INMD). While both of these stocks are struggling this year, down more than 30%, here's why they may not just rally but potentially even double in value. 1. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes easily track their glucose levels. It can make life much easier for millions of people around the world. The company has some attractive growth potential as even people without diabetes could benefit from the devices by adjusting their eating habits if they learn they have high glucose numbers. Analysts at Grand View Research project that the market for CGMs is expanding at a compound annual rate of 4.4% and will be worth $11.2 billion by 2030. And in the long run, the market may become even larger given the need to treat diabetes may increase. One thing that is likely hurting DexCom right now is the rising popularity of weight-loss drugs. Wegovy, Mounjaro, and Ozempic (which isn't approved for weight loss but that has helped people lose weight) have been effective weight-loss treatments. And investors appear to be anticipating that those drugs could result in fewer people with diabetes and thus, less of a need for DexCom's CGMs. But that would be a premature conclusion. For starters, the list price for one month's treatment can cost over $1,000 for these drugs, and many insurance companies aren't covering them. The risk for consumers is that they can potentially gain all that weight back if they stop taking the drugs. Plus, there are also side effects to consider which may hinder their growth potential. Investors appear eager to be buying into the hype surrounding Ozempic and weight-loss drugs in general, and that could be a mistake. DexCom is a top name for CGMs, and there's still plenty of growth potential ahead for the business. It's far too early to suggest that weight-loss drugs will lead to a drastic reduction in diabetes cases. The company's sales are up 22% this year, and profits have also risen by 11%. Unfortunately, this fast-growing stock is down 30%, trading near its 52-week low. Although it's down now, this is a healthcare stock that definitely has the potential to double in value as the need to effectively manage diabetes isn't going away anytime soon. 2. InMode Another stock that weight-loss drugs can be impacting is InMode. But InMode may actually benefit from people losing weight. The company provides minimally invasive procedures that can be alternatives to plastic surgery. The treatments can help tighten skin, which can be in high demand for people who have lost weight and have sagging skin. But aesthetics in general can be a promising business, especially when the treatments are non-invasive. Analysts at Grand View Research project that the non-invasive aesthetic treatment market will be worth more than $190 billion by 2030, growing at an annualized rate of 15.4% until then. One opportunity analysts highlight is in women who are 50 years and older and who may be more concerned about their appearances. That's a growing demographic and one that could be a key market for InMode to pursue. In the short run, the company has run into some headwinds due to the challenging macroeconomic environment. Last week, InMode reduced its full-year guidance for 2023, now expecting revenue of $500 million to $510 million, which is about a $30 million reduction from its original forecast. That would imply a 10% growth rate from the $454 million it recorded in 2022. The company says interest rates are weighing on the financing of medical equipment, which is impacting its sales activity. InMode didn't mention net income in its update, but the company typically nets a high profit margin; last year, its profits were 35% of the top line. InMode's stock is down 40% this year, and the ongoing conflict between Israel and Hamas in Gaza has resulted in new concerns involving the Israeli company's safety. However, InMode says that it doesn't anticipate any production interruptions and that it is prioritizing employee safety. While this may be a challenging time for InMode for multiple reasons, it's a business that remains in good shape, and it's an investment that can double in value in the long run given the opportunities it has ahead. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 16, 2023 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends InMode. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits When the going gets tough on Wall Street, investors have a tendency to turn their attention to time-tested businesses with a history of outperformance. For the past decade, the FAANG stocks have fit this definition perfectly. But over the past two years, it's companies enacting stock splits that have been exceptionally popular during periods of market instability. A stock split is an event that allows a publicly traded company to alter both its share price and outstanding share count while having no impact on its market cap or operating performance. Think of a stock split as a purely cosmetic change to a company's share price that can make it more nominally affordable for everyday investors or can ensure that a company meets the minimum listing standards for major stock exchanges. Image source: Getty Images. Most investors tend to gravitate to companies enacting forward-stock splits -- those reducing their share price to make it more nominally affordable for retail investors. Companies conducting forward-stock splits are usually highfliers that are outperforming and outinnovating their competition. Since the start of July 2021, nine high-profile companies have conducted forward-stock splits, including: Nvidia (NASDAQ: NVDA): 4-for-1 split conducted in July 2021. Amazon (NASDAQ: AMZN): 20-for-1 split conducted in June 2022. DexCom (NASDAQ: DXCM): 4-for-1 split conducted in June 2022. Shopify (NYSE: SHOP): 10-for-1 split conducted in June 2022. Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split conducted in July 2022. Tesla (NASDAQ: TSLA): 3-for-1 split conducted in August 2022. Palo Alto Networks (NASDAQ: PANW): 3-for-1 split conducted in September 2022. Monster Beverage (NASDAQ: MNST): 2-for-1 split conducted in March 2023. Novo Nordisk (NYSE: NVO): 2-for-1 split conducted in September 2023. Among these nine stock-split stocks, a select group of Wall Street analysts and pundits have identified three they believe could rise by as much as 696%. Based on Wall Street's high-water price targets, the following three stock-split stocks offer the greatest upside. Tesla: Implied upside of 696% The stock-split stock with the most to gain, at least according to Ark Invest CEO and Chief Investment Officer Cathie Wood, is electric vehicle (EV) manufacturer Tesla. An Ark Invest report released in April calls for North America's leading EV producer to reach $2,000 per share by 2027. This would mark nearly 700% upside compared to where Tesla shares closed out this past week. Cathie Wood and Ark's researchers have made a number of assumptions to justify their $2,000 price target. Namely, they expect Tesla to generate between $200 billion (bear case) and $613 billion (bull case) in annual autonomous ride-hail revenue by 2027. Furthermore, the number of EVs Tesla sells each year is expected to catapult from a little north of 1.3 million in 2022 to between 10.3 million (bear case) and 20.7 million (bull case) come 2027. Although Tesla is the only pure-play EV producer that's currently profitable on the basis of generally accepted accounting principles (GAAP), and it's the first automaker in well over a half-century to build itself from the ground up to mass production, I'd label Wood's price target on Tesla as \""Wall Street's most ridiculous.\"" The main issue with Wood's analysis is that her and her teams' assumptions appear flawed. For instance, Tesla's four existing gigafactories likely have a maximum production capacity of a little north of 2 million units annually. For Tesla to reach at least 10.3 million EVs sold by 2027, it'd likely have to open three to four new gigafactories per year and be able to ramp up these production facilities with no issues. This scenario seems unrealistic. To build on the above, Wood's call for $200 billion to $613 billion in autonomous ride-hailing revenue within four years is borderline laughable. Tesla hasn't been able to advance beyond Level 2 autonomy for years, which means the company isn't anywhere close to having autonomous ride-hailing EVs on public roads. Worst of all, Tesla kick-started a price war with other EV manufacturers earlier this year. As a result of growing competition and rising inventory, Tesla's operating margin has been nearly halved in a nine-month stretch. Suffice it to say, I don't see Tesla getting anywhere near $2,000 per share by 2027. DexCom: Implied upside of 110% A second stock-split stock that could more than double, based on the high-water price target of one Wall Street analyst, is medical-device maker DexCom. According to senior research analyst Matt O'Brien at Piper Sandler, DexCom shares can reach $160, which would represent upside of 110% from where the company's stock ended this past week. Shares of DexCom have been absolutely clobbered since mid-July, with the primary downside catalyst being Novo Nordisk's drugs, Ozempic and Wegovy. Although the former is approved by the U.S. Food and Drug Administration (FDA) to treat type 2 diabetes, both Ozempic and Wegovy are glucagon-like peptide-1 (GLP-1) drugs that have helped users lose weight. DexCom is the one of the two largest players in continuous glucose-monitoring systems (CGMs). For the 37.3 million people in the U.S. with diabetes, weight management tends to be a common issue. The connect-the-dots thesis that explains DexCom's recent decline is that Novo Nordisk's game-changing therapies that induce weight loss could eventually lead to fewer cases of type 2 diabetes and therefore less of a need for CGMs. Admittedly, this train of thought is a bit of a stretch. Ozempic isn't approved by the FDA for weight loss, and there's nothing concrete to suggest that Novo Nordisk's GLP-1 drugs will make a dent in what's been a steady increase in diabetes cases in the United States. Based on data collected between 2017 and 2020, just shy of 42% of adults in the U.S. were obese. Given the higher instances of co-morbidities associated with people who are overweight, CGM companies like DexCom should continue to see plenty of demand for their products. But what's really allowed DexCom to shine is its innovation. While it has, clearly, benefited from a growing number of diabetes cases in the U.S. and globally, it's the evolution of DexCom's CGMs that sets it apart. The company's latest CGM, the DexCom G7, sends real-time blood glucose readings to a person's smartphone or watch, which is one of many ways it's differentiating itself from the competition. Although DexCom's forward price-to-earnings (P/E) ratio of 47 remains pricey, the company should have no trouble sustaining a double-digit growth rate. Image source: Getty Images. Nvidia: Implied upside of 142% The third stock-split stock with mouthwatering upside, based on the high-water price target of one Wall Street analyst, is semiconductor-solutions specialist Nvidia. Analyst Hans Mosesmann of Rosenblatt Securities has a $1,100 price target on Nvidia, which equates to upside of 142% relative to where shares closed out this past week. The fuel behind Mosesmann's seemingly otherworldly price target that would take Nvidia well north of a $2.5 trillion market cap is the artificial intelligence (AI) revolution. AI involves using software and systems, along with machine learning, to handle tasks that would normally be overseen by humans. What makes Nvidia special is that it's the infrastructure backbone of the AI movement. The company's A100 and H100 graphics processing units (GPUs) account for 90% (or more) of the GPUs currently being used in high-compute data centers. With chip-fab capacity maxed out for Nvidia's AI-accelerated GPUs, Nvidia has been able to command exceptional pricing power. As a result, the company's sales and profit forecasts have completely blown past even the loftiest projections by Wall Street. While there have been clear catalysts pushing Nvidia higher, the company could face an assortment of headwinds in the coming quarters. For example, production expansion will likely be a net negative for Nvidia. With chip-fabrication company Taiwan Semiconductor Manufacturing set to potentially double its chip on wafer on substrate capacity (CoWoS) by the end of 2024, there should be less scarcity of Nvidia's A100 and H100 GPUs. Less scarcity probably means less pricing power and weaker future margins. Furthermore, Nvidia will be facing increased competition. Advanced Micro Devices debuted its MI300X AI-accelerated GPU in June, with plans to really ramp up production in 2024. Meanwhile, Intel will be bringing its Falcon Shores GPU to market in 2025. Another issue for Nvidia is that every next-big-thing trend over the past 30 years has endured an initial bubble. While AI has the opportunity to be a long-term game changer, it's not yet clear if demand for AI products and solutions can meet or exceed the lofty expectations investors currently have for the technology. As I wrote earlier about Wood's price target with Tesla, I don't believe Mosesmann's price target on Nvidia has a chance of being met. Find out why Tesla is one of the 10 best stocks to buy now Our analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Tesla is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of October 13, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet, Amazon.com, and Intel. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends DexCom, Intel, and Novo Nordisk and recommends the following options: long January 2023 $57.50 calls on Intel and long January 2025 $45 calls on Intel. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is the Ozempic-Driven DexCom Selloff Overdone? Plenty of businesses, such as PepsiCo Inc. (NYSE: PEP) and Walmart Inc. (NYSE: WMT), have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nordisk A/S' (NYSE: NVO) Ozempic, and similar drugs made by Eli Lilly & Co. (NYSE: LLY). While PepsiCo and Walmart have swatted away those concerns, investors are now wondering about the prospects for DexCom Inc. (NASDAQ: DXCM). DexCom specializes in the development and manufacturing of continuous glucose monitoring systems to help diabetes patients manage blood sugar levels. DexCom's technology offers real-time, continuous data on a person's glucose levels using a small sensor placed beneath the skin, typically on the abdomen. This sensor sends the data to a compact, wearable receiver or a smartphone app, allowing users to monitor their blood sugar on a 24-hour basis. Stock Rolled Over After Q2 Report Look at the DexCom chart: The stock had been trending sideways throughout this year until rolling over into a steep and sudden correction in July. That sell-off followed its second-quarter report, which beat views by a long shot, as you can see using MarketBeat's DexCom earnings data. In theearnings conference call CEO Kevin Sawyer said, \""Q2 was our highest revenue quarter ever and represented the largest year-over-year dollar growth in our company's history.\"" He also said the quarterly results were \""like a highlight reel.\"" So what happened? Unfortunately for DexCom, investors have become concerned about the possibility of more expansive applications of obesity drugs and their impact on medical devices used to manage diabetes. In fact, Eli Lilly's Mounjaro is approved to help treat type 2 diabetes, as is Novo Nordisk's Ozempic. DexCom Not Seeing Impact of Weight-Loss Drugs Fears of people using diabetes drugs to successfully treat their condition, while ditching their subscriptions to glucose monitors, are not unwarranted. However, DexCom's sales haven't yet seen a dent from sales of Novo Nordisk's or Eli Lilly's diabetes drugs. DexCom's revenue grew at double-digit rates in each of the past eight quarters, while earnings grew at triple-digit rates in the past three quarters. The company has been profitable every year since 2018. Reassuring Investors About the Pace of Sales It's been attempting to stave off concerns about business going away due to diabetes and weight-loss drugs. In early September, in an investors' presentation, the company said it anticipated adoption of its products to continue at a rapid clip. After that news, the stock got a modest bump, but the aftereffect didn't last; shares are down 18.06% in the past month. Other medical device makers, such as Zimmer Biomet Holdings Inc. (NYSE: ZBH), have also seen selloffs due to worries about weight loss and diabetes drugs. Zimmer Biomet sells equipment to treat sleep apnea, a condition closely linked to obesity. Zimmer Biomet shares are down 26.04% in the past three months. Analysts See Upside in Price Target MarketBeat's DexCom analyst ratings show a consensus view of \""moderate-buy\"" with a price target of $129.59, a 61% upside. Think about that for a minute: That's a pretty hefty increase in expected share price, indicating that despite the 30.28% year-to-date decline, Wall Street hasn't thrown in the towel on DexCom stock, despite several analysts lowering their price targets in recent weeks. Analysts anticipate that DexCom will maintain a yearly revenue growth rate of approximately 20% through 2027. Wall Street is eyeing earnings growth of 43% this year, to $1.24 a share. Next year, that's expected to grow another 30% to $1.61 per share. If profit margins increase, earnings per share and revenue could grow at fast rates. All of that adds up to a stock that could be perceived as a good bargain right now. You could view DexCom's downturn as a \""right-sizing,\"" as the price-to-earnings ratio is still 70, firmly in growth stock territory. A high P/E can indicate an overvalued stock, but with DexCom's revenue and earnings projections, it may simply mean the stock is selling at low valuations relative to its potential. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-19,83.69,87.48,83.61,86.04,"[""Guru Fundamental Report for DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Earnings Expected to Grow: Should You Buy? DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 26, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This medical device company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of +21.4%. Revenues are expected to be $937.31 million, up 21.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.91% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for DexCom? For DexCom, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +7.39%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that DexCom will most likely beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that DexCom would post earnings of $0.22 per share when it actually produced earnings of $0.34, delivering a surprise of +54.55%. Over the last four quarters, the company has beaten consensus EPS estimates four times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. DexCom appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Expected Results of an Industry Player Thermo Fisher Scientific (TMO), another stock in the Zacks Medical - Instruments industry, is expected to report earnings per share of $5.63 for the quarter ended September 2023. This estimate points to a year-over-year change of +10.8%. Revenues for the quarter are expected to be $10.63 billion, down 0.4% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Thermo Fisher has been revised 0.7% down to the current level. Nevertheless, the company now has an Earnings ESP of -0.16%, reflecting a lower Most Accurate Estimate. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Thermo Fisher will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-20,86.02,87.35,85.48,85.97,"[""Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings? Community Health Systems, Inc. CYH is scheduled to release third-quarter 2023 results on Oct 25, after market close. Q3 Estimates The Zacks Consensus Estimate for Community Health\u2019s third-quarter loss per share is pegged at 15 cents, narrower than the prior-year quarter\u2019s loss of 52 cents per share. The consensus mark for revenues is $3,042 million, suggesting 0.6% growth from the year-ago quarter\u2019s reported number. Earnings Surprise History Community Health\u2019s bottom line beat estimates in two of the trailing four quarters and missed the mark twice, the average negative surprise being 236.37%. This is depicted in the chart below: Community Health Systems, Inc. Price and EPS Surprise Community Health Systems, Inc. price-eps-surprise | Community Health Systems, Inc. Quote Let\u2019s see how things have shaped up prior to the third-quarter earnings announcement. Expanding patient volumes, better payer mix and improved revenue per adjusted admission are likely to have boosted revenue growth in the third quarter. We expect Community Health\u2019s admissions to inch up 0.1% year over year in the to-be-reported quarter. Revenue per adjusted admission is expected to increase 0.2% year over year in the third quarter. Additionally, higher number of surgeries across an array of specialties, such as cardiovascular, colorectal, urology and gynecology, is likely to have provided an opportunity to CYH to earn greater revenues. Expansion initiatives in the form of bed addition and opening of ambulatory surgery centers and freestanding emergency departments are expected to have enabled it to gain a greater market share and subsequently, are likely to have aided the quarterly results. However, the upside is likely to have been partly offset by a decline in patient days, fall in the average length of stay and a lower occupancy rate. We expect patient days to decrease 7.4% year over year in the third quarter. Our estimate for occupancy rate is 45.4%, which indicates a deterioration of 130 basis points from the prior-year quarter\u2019s reported number. Community Health\u2019s margins are likely to have taken a hit from an escalating operating expense level in the to-be-reported quarter. We expect total operating costs and expenses to be $2,827.2 million, up 0.2% year over year. What Our Quantitative Model Predicts Our proven model does not conclusively predict an earnings beat for Community Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that\u2019s not the case here as elaborated below. Earnings ESP: Community Health has an Earnings ESP of 0.00%. You can uncover the best stocks before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: CYH currently carries a Zacks Rank of 3. Stocks to Consider While an earnings beat looks uncertain for Community Health, here are some companies from the Medical space, which according to our model, have the right combination of elements to beat on earnings this time around: DENTSPLY SIRONA Inc. XRAY has an Earnings ESP of +1.85% and a Zacks Rank of 1, currently. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for XRAY\u2019s third-quarter 2023 earnings is pegged at 48 cents per share, indicating an improvement of 17.1% from the year-ago quarter\u2019s reported figure. DENTSPLY SIRONA\u2019s earnings beat estimates in three of the trailing four quarters and missed the mark once, the average surprise being 12.51%. DexCom, Inc. DXCM has an Earnings ESP of +7.39% and a Zacks Rank of 3, currently. The Zacks Consensus Estimate for DXCM\u2019s third-quarter 2023 earnings is pegged at 34 cents per share, which implies a rise of 21.4% from the year-ago quarter\u2019s reported figure. DexCom\u2019s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 28.83%. Merck & Co., Inc. MRK has an Earnings ESP of +1.73% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for MRK\u2019s third-quarter 2023 earnings is pegged at $1.94 per share, suggesting 4.9% growth from the year-ago quarter\u2019s reported number. Merck's earnings beat estimates in each of the trailing four quarters, the average surprise being 6.05%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's in Store for West Pharmaceutical (WST) in Q3 Earnings? West Pharmaceutical Services WST is scheduled to release third-quarter 2023 results on Oct 26, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 8.21%. WST\u2019s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 12.47%. Q3 Estimates Currently, the Zacks Consensus Estimate for revenues is pegged at $746.9 million, indicating an improvement of 8.7% from the year-ago period\u2019s level. The consensus mark for earnings is pinned at $1.86 per share, indicating a deterioration of 8.4% year over year. Factors to Note West Pharmaceutical\u2019s Proprietary Products was an important contributor to its top-line growth in the first half of 2023. The segment is likely to have exhibited sustained strength in the second quarter as well. Apart from this, the company is also expected to have witnessed a margin expansion in the aforementioned segment. This is due to a favorable mix of products sold (stemming from high-value products\u2019 [HVP] demand), production efficiencies and higher sales price. WST has been witnessing a strong uptake of HVP components, which include Westar, Envision and NovaPure offerings. This trend is likely to have continued in the quarter to be reported. Although the top line declined during the second quarter, demand growth and a strong order book for 2023 are encouraging. The company\u2019s raised guidance for 2023 earnings and revenues is likely to be reflected in the third-quarter results. West Pharmaceuticals\u2019 business is exposed to foreign currency exchange rate fluctuations that is likely to have positively impacted the company\u2019s third-quarter performance. However, it expects COVID-related sales to decrease further after declining year over year in the past two quarters. West Pharmaceutical Services, Inc. Price and Consensus West Pharmaceutical Services, Inc. price-consensus-chart | West Pharmaceutical Services, Inc. Quote What Our Quantitative Model Suggests Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here as you will see below. Earnings ESP: West Pharmaceuticals has an Earnings ESP of -1.23%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. Stocks Worth a Look Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle. Insulet PODD has an Earnings ESP of +5.00% and a Zacks Rank of 2. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The company\u2019s shares have lost 53.8% year to date. PODD\u2019s earnings beat estimates in the last reported quarter. It has a four-quarter average earnings surprise of 126.94%. IQVIA IQV has an Earnings ESP of +0.51% and a Zacks Rank of 3. The stock has lost 2.9% year to date. IQV\u2019s earnings beat estimates in the last reported quarter. IQVIA has a trailing four-quarter average earnings surprise of 2.26%. DexCom DXCM has an Earnings ESP of +7.39% and a Zacks Rank of 3. The stock has lost 16% year to date. DXCM\u2019s earnings beat estimates in the last reported quarter. DexCom has a four-quarter average earnings surprise of 28.83%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-23,85.75,87.98,85.6,86.02,"[""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Stock-Split Stocks That Could Plunge Up to 89%, According to Select Wall Street Analysts During periods of heightened uncertainty on Wall Street, it's not uncommon for investors to seek safety in profitable, time-tested, outperforming businesses. While the \""FAANG stocks\"" have been somewhat of a mainstay for investors over the past decade, it's companies enacting splits that have been garnering plenty of attention over the past two years. A stock split allows a publicly traded company to alter both its share price and outstanding share count without affecting its market cap or operating performance. Think of it as a purely cosmetic change that can either make a company's shares more nominally affordable for retail investors, or increase a company's share price to ensure it meets the minimum listing standards of a major stock exchange. Image source: Getty Images. Most investors are laser-focused on forward-stock splits, which involves reducing a company's share price and increasing its share count by the same factor. Companies enacting forward-stock splits are usually highfliers that have handily outperformed and out-innovated their competition. Since the midpoint of 2021, nine industry leaders have conducted forward-stock splits, including: Nvidia (NASDAQ: NVDA): 4-for-1 split Amazon (NASDAQ: AMZN): 20-for-1 split DexCom (NASDAQ: DXCM): 4-for-1 split Shopify (NYSE: SHOP): 10-for-1 split Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split Tesla (NASDAQ: TSLA): 3-for-1 split Palo Alto Networks (NASDAQ: PANW): 3-for-1 split Monster Beverage (NASDAQ: MNST): 2-for-1 split Novo Nordisk (NYSE: NVO): 2-for-1 split However, Wall Street's outlook for these companies varies greatly. Whereas select analysts and pundits believe three of these stock-split stocks could deliver triple-digit gains, a couple of Wall Street analysts foresee sizable declines for two of these nine high-profile stock-split stocks. Tesla: Implied downside of 89% The stock-split stock that offers jaw-dropping downside, at least in the eyes of GLJ Research's Gordon Johnson, is electric-vehicle (EV) maker Tesla. Johnson, a longtime Tesla bear, has a split-adjusted price target on the world's largest automaker by market cap of $24.33. If this price target were to come to fruition, it would represent an 89% decline from where Tesla stock closed on October 19. Although Tesla is North America's leading EV manufacturer, and the company looks to be working on its fourth consecutive year of profitability -- something no other EV pure-play has come close to achieving -- there are a number of potential warning signs for current and prospective shareholders. To begin with, Tesla kick-started a price war earlier this year that's proving disastrous to its margins. The company's four production models (S, 3, X, and Y) have endured more than a half-dozen price cuts. According to CEO Elon Musk, Tesla's pricing strategy is entirely driven by demand. Multiple price cuts signal that inventory levels are rising and/or demand for EVs remains tepid. Unsurprisingly, Tesla's operating margin has plunged from 17.2% to 7.6% over the past year. As I've stated in the past, leadership is another reason to be cautious with Tesla. Despite being a visionary, Musk has also proved to be a significant liability for his company. He's drawn the unwanted attention of securities regulators on a number of occasions, and has made countless promises that simply haven't been fulfilled. For instance, Musk's pledge of Level 5 autonomy coming \""next year\"" is something we've heard for the past decade. Furthermore, Tesla has struggled to become more than a car company. Energy generation and storage revenue has practically flatlined over the past couple of quarters, while SolarCity has been a money-loser since it was acquired in 2016. This is a big problem for a company with a price-to-earnings (P/E) ratio of nearly 70, based on Wall Street's consensus earnings in 2023. By comparison, most auto stocks have P/E ratios of between 5 and 10. There's no question Tesla has broken down barriers in the auto space and used its first-mover advantages to the fullest. But with competition picking up and the company's operating margin plunging, \""down\"" is the likeliest direction Tesla stock is headed. Image source: Getty Images. Palo Alto Networks: Implied downside of 11% The other stock-split stock at least one Wall Street analyst believes could head meaningfully lower is cybersecurity company Palo Alto Networks. Though some analysts foresee Palo Alto stock rising by more than 30% from its closing price of around $253 on Oct. 19, analyst Joshua Tilton of Wolfe Research expects shares to tumble by 11% to $225. The likeliest reason Palo Alto Networks would find its shares under pressure is its valuation. During periods of economic uncertainty, investors gravitate to perceived-to-be \""cheap\"" stocks. Palo Alto certainly isn't cheap by any traditional measuring stick. Based on Wall Street's consensus earnings estimate, shares are trading at nearly 48 times forecast earnings for fiscal 2024 (Palo Alto's fiscal 2024 ends on July 31, 2024). The other potential concern would be the growing likelihood of a U.S. recession. With numerous economic datapoints and predictive tools forecasting weakness in the coming quarters, there's the worry we could see businesses pare back their spending. However, cybersecurity solutions have evolved into necessity services. No matter how well or poorly the U.S. economy is performing, businesses with an online or cloud-based presence still need to protect their sensitive information. For cybersecurity companies like Palo Alto, it's led to highly predictable cash flow in any economic climate. Furthermore, Palo Alto Networks has well-defined competitive edges in cybersecurity. Over the past five years, the company has made a concerted push toward cloud-based, artificial intelligence (AI)-driven, software-as-a-service (SaaS) solutions. A portfolio focused on cloud-based SaaS offers a number of advantages. Cloud-based SaaS is going to be nimbler and more efficient at recognizing and responding to potential threats than on-premises solutions. Likewise, a subscription-driven operating model should do a much better job of retaining customers, lifting the company's operating margin, and delivering highly predictable cash flow. In other words, this shift is providing more bang for each revenue buck that Palo Alto Networks is bringing in. Palo Alto's management has also done a fantastic job of making bolt-on acquisitions that expand its service ecosystem and move the profit needle higher. While it's always possible Palo Alto could sell off with the broader market and reach Tilton's price target, this is a company whose tools and intangibles suggest it's headed considerably higher. Find out why Tesla is one of the 10 best stocks to buy now Our analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Tesla is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of October 16, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon.com. The Motley Fool has positions in and recommends Alphabet, Amazon.com, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-24,85.4,86.84,85.26,86.35,
DXCM,2023-10-25,85.85,86.37,83.06,84.35,"[""MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More The third-quarter reporting cycle has just begun for the Medical sector (one of the 16 broad Zacks sectors within the Zacks Industry classification). Quarterly performances have been encouraging so far despite companies still recovering from inflationary pressures, supply-chain challenges and labor shortages. The latest Earnings Preview indicates that 6.6% of the companies in the Medical sector, constituting nearly 24.7% of the sector\u2019s market capitalization, reported earnings until Oct 18. Of these, 75% beat earnings and revenue estimates. Earnings increased 5.6% year over year on 7.5% higher revenues. Overall, third-quarter earnings of the Medical sector are expected to decline 15.4% despite a 5.1% sales increase. This compares with second-quarter earnings decline of 29% despite 5.7% reported revenue growth. Per the latest trends, the Medical sector is one of the spaces expected to witness lesser earnings among seven other sectors in the reporting cycle. MedTech Quarterly Synopsis Although the scorecard so far reflects encouraging results, uncertain market conditions within the United States, with the majority of the players in the Medical sector reeling under an uncertain macroeconomic environment for a while, prevail. Through the third-quarter months, the companies that are into international trade are also expected to have faced currency headwinds. However, foreign currency translation may have been a tailwind for some companies. Meanwhile, ongoing inflationary pressure and the Federal Reserve\u2019s hint of the need to raise interest rates more and a continued restrictive monetary policy depending on incoming economic data are also likely to have driven expenses higher. On a positive note, companies have been successfully addressing pent-up demand, which is likely to have led to higher year-over-year growth within the legacy base businesses. MedTech players who were very much into COVID-19-related businesses have been gradually shifting their business into non-COVID operations. This is likely to have boosted their performances during the third quarter of 2023. Overall, the July-September months were marked by strength in product portfolios and solid customer adoption of products. MedTech companies like DexCom, Inc. DXCM, West Pharmaceutical Services, Inc. WST, Merit Medical Systems, Inc. MMSI and Integer Holdings Corporation ITGR are likely to have been positively impacted by the tailwinds discussed above, despite encountering turbulence on the macroeconomic front. Let\u2019s observe the status of three MedTech players, scheduled to announce results on Oct 26, 2023. West Pharmaceutical: West Pharmaceutical\u2019s Proprietary Products segment was an important contributor to its top-line growth in the first half of 2023. The segment is likely to have exhibited sustained strength in the second quarter as well. WST has been witnessing a strong uptake of HVP components, which include Westar, Envision and NovaPure offerings. This trend is likely to have continued in the quarter to be reported. West Pharmaceuticals\u2019 business is exposed to foreign currency exchange rate fluctuations that are likely to have positively impacted the company\u2019s third-quarter performance. However, it expects COVID-related sales to decrease further after declining year over year in the past two quarters. (Read more: What's in Store for West Pharmaceutical in Q3 Earnings?) West Pharmaceutical Services, Inc. Price and EPS Surprise West Pharmaceutical Services, Inc. price-eps-surprise | West Pharmaceutical Services, Inc. Quote The Zacks Consensus Estimate for third-quarter 2023 earnings per share (EPS) is pegged at $1.86. Revenues are expected to be $746.9 million. West Pharmaceutical does not have the right combination of the two key ingredients \u2014 a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) \u2014 which increases the odds of an earnings beat. WST has an Earnings ESP of -1.23% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DexCom: DexCom\u2019s third-quarter 2023 revenues are likely to have been aided by the continued increase in volume. This surge can be attributed to new patients across all channels and rising global awareness about the benefits of its real-time Continuous Glucose Monitoring system. The company has been benefiting from demographic trends and lifestyles in countries outside Europe and the United States. Per management, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. (Read more: DexCom to Report Q3 Earnings: Is a Beat in Store?) DexCom, Inc. Price and EPS Surprise DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote The Zacks Consensus Estimate for third-quarter 2023 EPS is pegged at 34 cents. Revenues are expected to be $937.3 million. DXCM has an Earnings ESP of +7.39% and a Zacks Rank #3. Merit Medical: Merit Medical\u2019s third-quarter 2023 performance is likely to have been driven by continued strong performance by its Cardiovascular segment. Per management, the segment had exceeded the high end of its expectations for constant currency growth in second-quarter 2023. MMSI\u2019s Peripheral Intervention and Original Equipment Manufacturer products are likely to have continued to witness robust customer adoption, thereby driving up its quarterly revenues in the to-be-reported quarter. In June, Merit Medical completed the acquisition of a portfolio of dialysis catheter products and the BioSentry Biopsy Tract Sealant System from AngioDynamics. This follows its acquisition of the Surfacer Inside-Out Access Catheter System from Bluegrass Vascular Technologies, Inc. Management believes that these acquisitions will likely strengthen its position in the dialysis and biopsy markets besides expanding its growing specialty dialysis device offering. This also looks promising for the stock. Merit Medical Systems, Inc. Price and EPS Surprise Merit Medical Systems, Inc. price-eps-surprise | Merit Medical Systems, Inc. Quote The Zacks Consensus Estimate for third-quarter 2023 EPS is pegged at 65 cents. Revenues are expected to be $306.3 million. MMSI has an Earnings ESP of 0.00% and a Zacks Rank #3. Integer Holdings: Integer Holdings\u2019 second-quarter 2023 results were boosted by robust customer demand across all product lines. ITGR\u2019s robust pipeline of new products and faster-growing end markets raise our optimism about its third-quarter results. Management was encouraged by the significant supply-chain improvement in the last reported quarter. However, management continues to experience pockets of supply chain risk, raising our apprehension. Integer Holdings Corporation Price and EPS Surprise Integer Holdings Corporation price-eps-surprise | Integer Holdings Corporation Quote The Zacks Consensus Estimate for third-quarter 2023 EPS is pegged at $1.05. Revenues are expected to be $372.3 million. ITGR has an Earnings ESP of -1.91% and a Zacks Rank #3. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store? DexCom, Inc. DXCM is scheduled to release third-quarter 2023 results on Oct 25, after the closing bell. In the last reported quarter, the company\u2019s earnings beat estimates by 54.55%. The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 28.83%. Q3 Estimates Currently, the Zacks Consensus Estimate for DexCom\u2019s third-quarter revenues is pegged at $937.31 million, indicating growth of 21.8% from the year-ago quarter\u2019s reported figure. The consensus mark for earnings is pinned at 34 cents per share, implying a 21.4% improvement year over year. Factors to Note DexCom\u2019s revenues in the to-be-reported quarter are likely to have been aided by continued increase in volume. This surge can be attributed to new patients across all channels and rising global awareness about the benefits of DXCM\u2019s real-time Continuous Glucose Monitoring (CGM) system. Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to have been the key catalysts behind the company\u2019s third-quarter performance. In July, DexCom received approval for the use of its G7 sensor in Canada. In April, the company announced that the coverage for its CGM systems was expanded through the Non-Insured Health Benefits program. The expanded coverage will provide access to CGM systems for all patients managing diabetes with insulin. The Medicare coverage for the company\u2019s latest CGM technology, G7 sensor, also got expanded in the same month to include diabetic patients using all types of insulin, as well as certain non-insulin-using individuals with a history of problematic hypoglycemic events. These developments might have boosted the demand for DXCM\u2019s CGM systems. This, in turn, is likely to have driven revenue growth in the to-be-reported quarter. The company has been benefiting from demographic trends and lifestyles in countries outside Europe and the United States. Per management, international growth remains strong and presents lucrative opportunities, courtesy of improving global access and awareness. In the second quarter, International revenues (29% of total revenues) surged 38% year over year to $254.7 million. Organically, the segment\u2019s revenues were up 40% in the last reported quarter. U.S. revenues (71% of total revenues) increased 21% in the same period. The trend is likely to have continued in the third quarter, owing to broad-based growth. The Zacks Consensus Estimate for U.S. and International revenues is pegged at $683 million and $253 million, respectively, for the third quarter. However, an increase in operating expenses and intense competition might have weighed on DXCM\u2019s performance in the quarter under review. DexCom, Inc. Price and Consensus DexCom, Inc. price-consensus-chart | DexCom, Inc. Quote Earnings Beat Likely Our proven model predicts an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here, as you will see below. Earnings ESP: DexCom\u2019s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +7.39%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: DexCom carries a Zacks Rank #3 at present. Other Stocks Worth a Look Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this reporting cycle. Dentsply Sirona XRAY has an Earnings ESP of +1.85% and a Zacks Rank of 2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The stock has gained 2.5% year to date. XRAY\u2019s earnings beat estimates in the last reported quarter. It has a four-quarter average earnings surprise of 12.51%. Avanos Medical AVNS has an Earnings ESP of +3.45% and a Zacks Rank of 3 at present. The stock has lost 32.5% year to date. AVNS\u2019 earnings missed estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 0.61%. The Cooper Companies COO has an Earnings ESP of +0.32% and a Zacks Rank of 3 at present. The stock has lost 2.8% year to date. COO\u2019s earnings met estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 0.09%. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-26,84.18,84.23,80.925,81.09,"[""DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say DexCom (DXCM) reported $975 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 26.7%. EPS of $0.50 for the same period compares to $0.28 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $937.31 million, representing a surprise of +4.02%. The company delivered an EPS surprise of +47.06%, with the consensus EPS estimate being $0.34. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- United States: $713.60 million versus the six-analyst average estimate of $681.21 million. The reported number represents a year-over-year change of +24.5%. Revenue- International: $261.40 million versus $254.18 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +33.2% change. Revenue- Hardware: $101.20 million compared to the $105.87 million average estimate based on two analysts. The reported number represents a change of -1.8% year over year. Revenue- Sensor and other: $873.80 million compared to the $833.91 million average estimate based on two analysts. The reported number represents a change of +31.1% year over year. View all Key Company Metrics for DexCom here>>> Shares of DexCom have returned -8.4% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Dexcom lifts 2023 revenue view on strong demand for diabetes devices Adds comment for conference call in paragraph 3-4 Oct 26 (Reuters) - Medical device maker Dexcom DXCM.O on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more than 14% higher in extended trading. Makers of medical products such as bariatric surgery devices and CGM systemshave been trying to ease investor concerns over a potential hit to demand from the rising popularity of new GLP-1 diabetes drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Dexcom joined larger peer Abbott ABT.Nin saying the use of GLP-1 drugs among diabetes patients could end up increasing demand for CGMs, which track blood sugar levels throughout the day and can transmit glucose readings as frequently as five minutes. \""Physicians are also pursuing CGM as they add GLP-1 as diabetes therapy,\"" said Dexcom CEO Kevin Sayer, adding that the device is given to patients as a scoreboard to let them know how they're doing. Dexcom'squarterly sales rose 27% to $975 million, surpassing analysts' estimates of $939.24 million, according to LSEG data. Abbott had also posted strong sales of $1.4 billion for its CGM system FreeStyle Libre in diabetes care. Dexcom raised its annual revenue forecast to between $3.58 billion and $3.6 billion, compared with its previous range of $3.5 billion to $3.55 billion. Analysts expect annual sales of $3.55 billion. Excluding items, the company posted a profit of 50 cents for the quarter ended Sept. 30, compared with estimates of 35 cents. Shares of the California-based company rose to $93 after the bell. (Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath) ((Khushi.Mandowara@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 2023 Earnings Call Transcript Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q3 2023 Earnings Call Oct 26, 2023, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom third quarter 2023 earnings release conference call. My name is Mandeep and I will be your operator for today's call. At this time all participants are in a listen-only mode. Later, we will conduct a question-and a-answer session. [Operator instructions] As a reminder, the conference is being recorded. I will now turn the call over to Sean Christensen, vice president of finance and investor relations. Mr. Christensen, you may begin. Sean Christensen -- Head of Investor Relations Thank you, operator, and welcome to DexCom's third quarter 2023earnings call Our agenda begins with Kevin Sayer, DexCom's chairman, president, and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter performance on the DexCom investor relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some of the statements we will make in today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 23, 2023 All forward-looking statements included in this presentation are made as of the date hereof based on information currently available to DexCom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in DexCom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP with respect to our non-GAAP and cash-based results. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third quarter earnings presentation reconciliation of these measures to their most directly comparable GAAP financial measure. Now I will turn it over to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you, Sean, and thank you, everyone, for joining us. Today, we reported another great quarter for DexCom with third quarter organic revenue growth of 26% compared to the third quarter of 2022. This year is proving to be one of the most exciting periods in our company's history. Access is expanding faster than ever before, and we are seeing new levels of for our differentiated products. This can be seen firsthand in our broader rollout of G7 in the U.S. Building upon our legacy of being the most accurate sensor, G7's focus on simplicity and affordability continues to attract new customers and prescribers to our platform. Similar to last quarter, the majority of G7 customers continue to be new to DexCom, and we took yet another step forward in expanding our prescribing base. There are now nearly 18,000 physicians writing scripts for DexCom that were not prescribing our products before the G7 launch. This represents a notable increase in our prescribing community in only a short period of time as more clinicians recognize G7's unique feature set, ease of use and market-leading levels of coverage. This combination has made it incredibly easy for physicians to prescribe DexCom CGM and drive greater levels of engagement within their patient populations. Additionally, our new G7 software platform is enhancing our value proposition across all patient types. We've implemented new software updates almost monthly since launch with improvements to features like connectivity and alarm personalization. As one example, we have established new lines of communication in our app to simplify the process of engaging with our customers. We are constantly working behind the scenes to improve the customer experience, and we will continue to operate with this type of focus to ensure that we have the most user-friendly and engaging products on the market. Our customers know that when you join the DexCom ecosystem, you get all of the benefits today and tomorrow associated with our leading innovation. Our latest product cycle has also coincided with the largest expansion of coverage in our company's history, with significant reimbursement now established beyond intensive insulin use. There are more people with covered access to DexCom CGM than ever before. As a reminder, Medicare coverage went live in mid-April for people with type 2 diabetes using basal insulin only, as well as certain non-insulin individuals that experience hypoglychemia. Collectively, these two populations represent nearly 7 million people in the U.S. with approximately half being of Medicare age. Encouragingly, commercial coverage continues to build for this group. We have established market-leading levels of basal-only reimbursement as payers clearly recognize the potential for better outcomes driven by DexCom. This further supports our industry low, out-of-pocket cost for our customers. With a full quarter of broad coverage now under our belt, we continue to be very encouraged by early prescribing transfer this cohort. We noted last quarter that we experienced an immediate uptick in new patient starts once coverage went live, and we have seen a clear continuation of this trend since that time. In fact, we delivered another record Medicare new patient start quarter in Q3 as physicians have quickly adjusted their prescribing patterns to match the new reimbursement landscape. While early, basal adoption trends look very similar to those we previously experienced once broad coverage became available for intensively managed type 2 diabetes. We view this as a very positive sign of things to come. Importantly, when you combine this broader coverage with our leading sensor technology, we feel incredibly confident in our market position. Since the launch of G7, we have gained share across all reimbursed channels and patient segments in the U.S. and that trend continued this quarter. Even among non-reimbursed channels, we are seeing more and more interest in DexCom CGM. We are also seeing similar dynamics across our international footprint. We have never been better positioned to compete globally from a product to access or capacity perspective. And we once again took international share this quarter as a result. Our product portfolio continues to be a key contributor to this success. By having multiple products available, we can tailor our offerings to meet the unique needs of individual geographies and reimbursement structures. A great example of this was seen in France this past quarter, where Dexcom ONE secured reimbursement for all people on intensive insulin therapy, which represents around 0.5 million people, and we have submitted our evidence to extend that coverage to the basal population. In addition to advancing our product offerings, we've been continuously working to build greater commercial scale and flexibility to serve each market more effectively. As we discussed at our Investor Day, one way to drive scale is through the conversion of key international markets from distributor to direct operations. Historically, these conversions have been followed by a notable uptick in performance as we provide greater levels of support and focus to these markets once we oversee all facets of sales and distribution. Along those lines, we recently made the strategic decision to go direct in Japan. As a reminder, Japan became one of the first countries to establish broad reimbursement for anyone taking insulin late last year, representing more than 1 million lives. Despite this, the market remains in its very early stages, and we will continue to work to drive much greater CGM adoption over time as we initiate direct sales in the second quarter of next year. Finally, at the ASD this month, we added to our substantial base of distinctive clinical evidence with new data around long-term DexCom CGM outcomes and adherence, the impact of Dexcom ONE for type 2 diabetes and performance within the pregnancy setting. Study after study, we continue to demonstrate DexCom's position as a cornerstone within the evolving diabetes care and metabolic health landscape. Across a wide range of customers in care settings, our product plays a unique role in providing real-time information that can drive behavior change, greater patient accountability, and more informed therapy decisions. Like everyone else, we have also been interested to see the latest data behind new drug therapies. We believe these drugs play an important role in the care continuum, and it is encouraging to see new solutions emerging and a growing appreciation around the need for better and earlier care. Data continues to demonstrate that clinicians prefer to use CGM together with these drugs to drive the best possible outcomes. In fact, we shared claims data this quarter that showed prescribing trends for CGM increase once someone has initiated GLP-1 therapy, as clinicians favor DexCom for its protective features and ability to support lifestyle management. As an update, we looked at trailing 12-month data through August 2023 would suggest this dynamic is even more pronounced among the newest generation of these drugs. The data clearly show that CGM usage grows faster in GLP-1 users than those who are not on therapy. This further demonstrates the complementary nature of DexCom CGM across all therapy regimes in diabetes. As we look forward, we continue to ensure that we advance our unique role within the ecosystem of care as we progress our mission of empowering people to take control of help. This will include launching new products such as our non-insulin product coming next summer, as well as advancing our ongoing clinical work across much broader populations. We are still very early in our story in terms of potential impact and the number of lives we can ultimately touch. Our future is incredibly bright. With that, I will turn it over to Jereme for a review of the third quarter financials. Jereme? Jereme Sylvain -- Chief Financial Officer Thank you, Kevin. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release, as well as on our IR website. For the third quarter of 2023, we reported worldwide revenue of $975 million, compared to $770 million for the third quarter of 2022, representing growth of 27% on a reported basis and 26% on an organic basis. As a reminder, our definition of organic revenue excludes currency in addition to non-CGM revenue acquired or divested in the trailing 12 months. U.S. revenue totaled $714 million for the third quarter, compared to $573 million in the third quarter of 2022, representing growth of 24%. Between the ongoing success of our G7 launch and significant expansion of coverage for DexCom this year, our U.S. business is really hitting its stride. This is particularly noticeable when looking at our new customer start trends, which again outpaced our expectations for this quarter. This dynamic has now played out for several quarters in a row, and we are seeing the direct result of that continued momentum. In the third quarter, we saw revenue growth accelerate compared to last quarter, and we delivered our fastest quarterly growth rate in over two years. International revenue grew 33%, totaling $261 million in the third quarter. International organic revenue growth was 30% for the third quarter. We continue to execute incredibly well in our international markets. Our product portfolio strategy, ongoing access work, and growing commercial traction helped us again gain share this quarter. We had a particularly strong quarter across our European footprint as we saw our growth remain similar to the accelerated level we saw in the second quarter. An item of note is we did have slower growth coming from our non-CGM business, as well as relatively flat performance in Japan as we work with our distributor partner to start the process of transitioning to direct sales. As a reminder, when we made our distributor acquisition in 2021, we also inherited a business that distributed products outside the diabetes space. We recently made the decision to spin off this unit to focus entirely on our CGM and diabetes technologies in this region, which we think will enhance our execution in the market. We expect the deal to close in early 2024, and we want to thank our employees for their continued strong work through the transition in the space. Our third quarter gross profit was $630 million or 64.7% of revenue, compared to 64.2% of revenue in the third quarter of 2022. We are very proud of our gross margin performance in the quarter. This is another testament to the top tier work our operations team continues to deliver this year. Despite managing through a new product launch, we have improved yields on both the G6 and G7 platforms. In addition, Q3 gross margins benefited from a stronger-than-expected mix of G6 customers as our pump users eagerly await G7 AID integration. When this transition starts in the coming weeks, we expect an acceleration in our base shift to G7. While G7 currently has a higher unit cost profile than G6 and will over the near term, we expect this to become our highest margin product as we drive greater volumes and economies of scale over the course of 2024 and beyond. Operating expenses were $392 million for Q3 of 2023, compared to $333 million in Q3 of 2022. Our focus on cost management again stood out this quarter as we delivered over 300 basis points of operating expense leverage. This now marks the seventh straight quarter that we have generated at least 250 basis points of year-over-year operating expense leverage. We will continue to invest in the growth of the business while finding ways to be even more efficient. Operating income was $238.9 million or 24.5% of revenue in the third quarter of 2023, compared to $160.8 million or 20.9% of revenue in the same quarter of 2022. This margin represents a new quarterly record for DexCom. Adjusted EBITDA was $345 million or 32.3% of revenue for the third quarter, compared to $226.6 million or 29.4% of revenue for the third quarter of 2022. This margin also represents a new quarterly record for DexCom. Net income in the third quarter was $203 million or $0.50 per share. We remain in a very strong financial position as we closed out the quarter with greater than $3.2 billion of cash and cash equivalents. Our ability to generate consistent and growing free cash flow is becoming more apparent every quarter, and we delivered the highest free cash flow quarter in our company's history in Q3. This provides us a lot of flexibility to be thoughtful and opportunistic in our capital allocation decisions. Along those lines, we are excited to announce a $500 million share repurchase program today. Given our very strong underlying fundamentals and outlook, we see this as a great time to step into the market and buy back our stock. This program also provides the added benefit of more than offsetting any remaining dilution related to our 2023 convertible notes as the remainder of these are reaching maturity in the coming weeks. Turning to guidance. We are raising our full year 2023 revenue guidance to a range of $3.575 billion to $3.6 billion, representing growth of 23% to 24% for the year. Our updated revenue guidance reflects an increase of over $60 million at the midpoint compared to our previous guidance. It is more than $165 million higher than where we guided to start the year. From a margin perspective, we are raising our full year non-GAAP gross margin guidance to approximately 64%. We are also increasing our non-GAAP operating and adjusted EBITDA margin guidance for the year to approximately 19% and 28%, respectively. With that, I will pass it back to Kevin. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thanks, Jereme. I would now like to open up the call for Q&A. We also have Jake Leach, our chief operating officer; and Teri Lawver, our chief commercial officer, joining us for our question-and-answer session. Sean? Sean Christensen -- Head of Investor Relations Thank you, Kevin. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions. Questions & Answers: Operator Thank you. We will now begin the question-and-answer session. [Operator instructions] We will take our first question from Robbie Marcus with JPMorgan. Please go ahead. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Great. Thanks for taking the question and congrats on an absolutely fantastic quarter. There is a lot to talk about here, but just keeping it to one question. What really showed just so much upside was the U.S. number this quarter, along with the profitability. So, question really is, one, how much of that do we ascribe to the new basal indication with growth from both Medicare and commercial patients? And we started to see this in France and Japan, and I hear that a lot of European countries might, over the course of '24, start covering for basal. So, the question is really how much is basal contributing today? And how big can it be over the coming years if all of Europe starts to bring on enhanced reimbursement, something that would have been unimaginable just 12 months ago? Thanks a lot. Jereme Sylvain -- Chief Financial Officer Hey, thanks, Robbie. This is Jereme. Appreciate the comments. I can take that one and address it from there. In terms of what the contribution was this quarter from basal, obviously, we had a really strong quarter this quarter, record new patients once again and obviously raised the guide on the year. Now some of that does come from basal. There's no question there. As we continue to open up reimbursement, the new patients are coming along. And Kevin mentioned it. We're starting to see basal follow similar patterns to type 2 intensive, which when you think about coming into this year, it's about 40% to 45% adoption, but really the curve is starting to follow that. So, we're very excited about the opportunity there. And so, that's in the U.S. And certainly, clearly, that's playing out here. In terms of OUS, it's a great opportunity. One of the things we've seen outside the U.S. is as access is created, creates significant opportunities for growth. And you've seen our actions over the course of the past few years. We've created a lot of access for our products. And in turn, our international markets have grown incredibly well. And there's a large population outside the U.S. that this would ultimately apply it to once you have basal coverage. So, it could be an absolute tailwind for us for years and years to come. It's something obviously we're very excited about. We don't want to get ahead of ourselves, right? We have to get that coverage in place. But the bullish issue here about the U.S. experience is what we would expect to see as more and more coverage comes. And so, we leave very excited about what the future holds. Robbie Marcus -- JPMorgan Chase and Company -- Analyst Thanks a lot. Operator Our next question comes from Margaret Kaczor Andrew with William Blair. Please go ahead. Malgaret Kaczor Andrew -- William Blair and Company -- Analyst Hey, good afternoon, guys. Thanks for taking the question. Obviously, a lot of talk in the quarter, and I'm sure a lot of people will get to that. But one of the things that I wanted to ask here was there any dialogue you may be having with clinical society and where CGM fits within the treatment paradigm specifically focused on non-insulin users? And I asked because, obviously, there could be a change in guidelines with TLPs right now. And so, can you use some of those discussions to pull forward CGM use as well? And again, if not now, when or does it even matter? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Hey, Margaret, this is Kevin. I'll take that. We have had discussions with the societies on expanding coverage for people with type 2 diabetes not on insulin. And those discussions continue. We've seen a gradual uptick, for lack of a better word, in the guidelines of CGM use from all professional societies over the last several years. And as we gather more data and as we see more data coming from studies we're aware of over the next 12 months, we believe we can continue to build a better case. Every time we are in a study or look at a study from this population in this group, people on CGM do better. It's just simple. They have better outcomes. They're more adherent to their meds. They have a feedback loop that they don't have any other way. We're very excited about this opportunity. That's why we're going with the product where we've talked about filing before the end of this year and launching next year, our product is designed for people not on insulin. And we think it's going to be a great product offering on this front going forward. So, we're looking forward to it, and I think we'll be able to write the script the same way we've written the script in our industry so far. Operator Our next question comes from Larry Biegelsen with Wells Fargo. Please go ahead. Larry Biegelsen -- Wells Fargo Securities -- Analyst Good afternoon. Thanks for taking the questin. And I'll reiterate my congratulations on a really strong quarter here. Jereme, I wanted to ask about the guidance and any comments on next year. The math, if I'm doing it correctly, it implies Q4 growth slows by about 400 basis points, and you don't get the same quarter-over-quarter lift you typically see. And so why is that? And any reason why the momentum for sales growth would slow next year? And anything we should think about on the margin such as the implications from Japan? Thank you. Jereme Sylvain -- Chief Financial Officer Yeah. So, thanks for the question, Larry. So, in terms of where the guide goes, I think you're right, it does imply a tad of a decel. Most of that, I would say, is related to really comps historically over time. And Larry, you've tracked us for a while. So, as we move more out of commercial DME and into pharmacy, typically, we have an uptick into Q4 in those DME environments. As more and more of our folks go through the retail channel, you kind of lose some of that. So really, you're playing about -- it's really about seasonality within the course of the year. So, we're not trying to imply anything. Really, what we're trying to say is this is the trajectory we see it going with seasonality. This is our, again, our base case as we start to look at guidance over the course of the year. And so, the trends -- underlying trends, there's nothing to say there. I mean, the underlying trends in this business remains strong. I don't think we're trying to imply anything other than that. We do expect, you kind of referenced Japan, there could be around the fringes until we go direct a little bit of a stable as opposed to necessarily growing story around Japan. And so, that is around the fringe, but that represents a really small piece of the business on the international side. Really, what you're seeing is just us being mindful about seasonality in our base case. And then certainly, if we can outperform, we'll do what we traditionally do, we just try to do so. Larry Biegelsen -- Wells Fargo Securities -- Analyst Thank you. Operator Our next question comes from Danielle Antalffy with UBS. Please go ahead. Danielle Antalffy -- UBS -- Analyst Hey, good afternoon, guys. Thanks so much for taking the question, and I will also say congrats on a really great quarter. I was just curious. So, Jereme, you alluded to the fact that basal seems to be starting to ramp similar to how the insulin-intensive type 2 did when you got coverage there. What about from a utilization perspective? Any color you can give on how these basal patients are adopting technology? Is it similar to what you saw in the mobile study? I know it's early, but we should have had some reorders by now. So just curious what you're seeing. Thanks so much. Jereme Sylvain -- Chief Financial Officer Yeah. Really -- and I appreciate the congrats. Thanks. What we see is -- and Teri is here. So, what I can do is I can give you kind of what we're seeing maybe numbers-wise, but maybe Teri can kind of take you into the day-tod-day interaction with patients. Number-wise, we haven't seen much of a change at this point. The population does -- has reorders relatively in the same capacity as in the past. And so that's a good early indicator. But maybe Teri can take you through what he's hearing and seeing in the field around the excitement around basal and who wants to use it. Teri Lawver -- Chief Commercial Officer Sure. Thanks, Jereme, and thanks, Danielle. The trends, as Kevin referenced, that we see in basal in terms of uptake and intention to prescribe from the physicians mirror what we've seen in other segments of the marketplace. And the coverage is certainly a big driver of that. We track coverage very closely for DexCom for the industry. And in basal, as with the rest of the market, DexCom continues to be the most covered CGM with the lowest out-of-pocket co-pay. We also have the benefit of being out in front of the payers and the healthcare providers with the mobile study, demonstrating the benefit and the outcomes that DexCom drives for this population. So we see a nice trajectory, I think, in line with what we would expect, and we expect that to continue. Danielle Antalffy -- UBS -- Analyst Thank you. Operator Our next question comes from Matt Taylor with Jefferies. Please go ahead. Matt Taylor -- Jefferies -- Analyst Hey, thanks for taking the question and congrats on the results. I guess I wanted to ask you, Kevin, you talked a bit more here about the basic combination therapy or benefit that CGMs see with GLP-1s. And I was wondering if you had thought about partnering with the pharma companies, maybe running studies to show that over time there is a benefit to using CGM with the drugs, things like that, that might give investors even more confidence longer term in the future of CGM in the GLP world. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, certainly, we think about partnering with the drug companies, but they're doing so well right now. They're very busy. We do have relationships with them and have had discussions. With respect to studies, we certainly talk about some of those internally. We saw clinical evidence over at the EASD meeting recently where that was a large topic of discussion that the team brought back, and we're very aware of studies coming out over the first half of 2024 that are going to show some of these data for the use of these new drugs in CGM in combination and how that works for people. So we know there's evidence coming in investigator-initiated studies, and we're looking at some of our own right now. I think the data will continue to support it. Matt Taylor -- Jefferies -- Analyst Great. Thank you very much. Operator Our next question comes from Matthew O'Brien with Piper Sandler. Please go ahead. Matthew O'Brien -- Piper Sandler -- Analyst Afternoon. Thanks for taking the question. Can you -- maybe, Jereme, you mentioned this, but you talked about the G7 integration that's upcoming here in the next few weeks. Is that literally sometime in November, we'll start to see that? And then just talk about what that's going to do in terms of trying to access new patients, but also convert existing G6 users over to G7. Any kind of disruption that that could cause in Q4 than early next year? Thanks. Jereme Sylvain -- Chief Financial Officer Yeah. Hey, Matt. We have Jake here right now who is intimately familiar. Jake, what do you think? Jake Leach -- Chief Operating Officer Yeah, sure. Som we are very excited about transitioning our G6 end users over to G7 once those pump partners have compatibility. That's coming very rapidly. And we really think it's going to be important for those users to be able to access the benefits of G7. It's the most accurate sensor. So having that driving those AID systems, we're really looking forward to seeing that out in the marketplace. No real disruption. Those users will basically just switch over for Tandem. It's a firmware update to the pump, and they'll just sort of G6 -- or to G7 once they get -- their G6 supplies are utilized and they get the new prescription for G7. So very much looking forward to that product being in the field. Matthew O'Brien -- Piper Sandler -- Analyst Thank you. Operator Our next question comes from Mathew Blackman with Stifel. Please go ahead. Mathew Blackman -- Stifel Financial Corp. -- Analyst Good afternoon, everybody. Thanks for taking my question. So, we did a big CGM survey last month. And one of the most interesting takeaways were very positive early expectations for the non-insulin opportunity. Many docs expecting peak penetration over time to approach the 50-plus percent range and with a pretty steep adoption curve. So, really does seem somewhat similar to the type 2 intensive rollout. Just hoping for any color on how that tracks versus your expectations for non-insulin assuming some reimbursement over time? Just any color there would be helpful. Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer You know what, I'll take that one, and I appreciate the question. It's long been our view. And in fact, one of the things I tell the guys here frequently as well, it took us many years to build the intensive insulin market and get this technology adopted rapidly. I don't believe the curve is going to be near that long in this type 2 world once people start using this product, and we gear an experience toward what will be meaningful to them because what is meaningful to them is different than what's meaningful to our current patients, again, driven by the performance of our product, and they have accurate data. But once we gear an experience that enhances their lives with respect to the performance of the medications, performance -- what exercise does, what their various nutrition does in their lives and can add other insights from other sensors, we think we can create a tremendous healthcare experience in this market. And we do think we can ultimately push toward reimbursement and possibly even creation of a new product category altogether for those individuals. We're pretty thrilled about it. I think it's going to be a great, great opportunity. Jereme Sylvain -- Chief Financial Officer Yeah. And Matt, it's -- and thank you for that study. Obviously, we saw it as well. In terms of timing, I think one of the things that is our obligation as a management team is just to make sure, as we start to see it and as we launch products that are geared to this population, we keep you in line with what we see, so we can have a collective understanding about where that market is going over time. So, we should be assured, as we start to get more line of sight into it, obviously, you can tell we're very bullish on the opportunity. We'll make sure we communicate that as quarters proceed Mathew Blackman -- Stifel Financial Corp. -- Analyst Thank you. Appreciate it, everybody. Operator Our next question comes from Joanne Wuensch with Citibank. Please go ahead. Joanne Wuensch -- Citi -- Analyst Thank you very much for taking the question and let me also say quite the quarter. One of the things that really stuck out to me this quarter was margins and operating margins, of course, the two are tied. But even your SG&A was well contained. Does this create a new, I don't know, go-forward rate? Or how do I think about this? Because that's where -- that's quite nice. Jake Leach -- Chief Operating Officer Yes. Thanks for the question. I'll take the portion on the gross margin and then Jereme can talk about operating margins. So, with gross margin, we're really thrilled with the results this quarter. It's really a testament to how well our operations teams are executing across both G6 and G7. Our yields on the G7 scale up or a little ahead of where we planned, which is a fantastic thing to place to be. As we look at the transition from the AID patients from G6 to G7, one of the things that is implied in our guide there for gross margin for the year and into next year, as we look in the long range, we are going to be switching those patients over to G7, which G7 today is at a slightly lower gross margin, just based on where it is in its product life cycle. G6 is a higher-margin product today. Over time, as we do switch our base all over to G7 and continue to scale that product, we have a very good path to getting to lower costs than G6 on that over time. But we're trying to be on that guide as transparent around the margin -- gross margin for the product just as we do that transition. Jereme Sylvain -- Chief Financial Officer Yeah. And then to your question on operating margin and how our spend profile lays out, certainly a great quarter. And I think we're really happy with it. At the end of the day, we raised our full year guidance to 19% on the op margin perspective, and that's on the back of some of the work we're doing around it. Investor Day, we talked about a cost to execute initiative, and a lot of that was around driving profitability. So, I think you can expect us to continue to look at driving operating margin over time. There will be ebbs and flows as we invest in the business for growth. And so, I think it's reasonable to expect ebbs and flows. But I'll kind of rewind back to where we started the year, right? Around J.P. Morgan, we issued guidance of around 16.5% operating margin. And now we're talking about exiting the year at 19%. And that's just all around the work of just being highly efficient around how we deliver service, how we deliver support, how we look to acquire customers. All of the things that we try to do. You can tell we are absolutely focused on making sure we do so in an efficient manner while continuing to reinvest in the business. Joanne Wuensch -- Citi -- Analyst Thank you very much. Operator Our next question comes from Jeff Johnson with Baird. Please go ahead. Jeff Johnson -- Robert W. Baird and Company -- Analyst Thank you. Good afternoon, guys. I will admit, I missed most of the prepared comments. I jumped on right as Matt O'Brian was asking his question. But it was a G7 integration question from Matt. And Jake, from your answer, I just wanted to ask one follow-up question, I guess, quickly. We started here just in the last week or two that maybe there's a maybe newer version of G7 that have to come along to fully integrate with Control-IQ. Just if you can clarify what I'm hearing in the field or help me understand what I'm hearing in the field and that that newer version of G7 is only going to be available for the first couple of months here in the DME channel and eventually in pharmacy as of January 1. So, what's going on there? And is that anything at all from an investor perspective, we need to think about, worry about, impact numbers at all? It doesn't sound like to me, but just would love the insight there. Thanks. Jake Leach -- Chief Operating Officer Yeah. Thanks for the question, Jeff. So yeah, as we continually scale the G7 platform, we've actually made several enhancements to the product, both on the software side, but also on the hardware side. And so, we actually recently made an update to the Bluetooth capability on the product, both increasing the frequency that it can reconnect to a device, as well as the performance of the Bluetooth radio itself. So, that product is compatible with the Tandem pump and is already shipping globally, both here in the U.S. and internationally, and we don't expect there to be any issue with people being able to upgrade their Tandem pumps to the G7 compatibility. Jereme Sylvain -- Chief Financial Officer Yeah. And Jeff, no margin concerns, no question. This is really par for the course in what we do in terms of iterations over time. A lot of times, you don't necessarily hear about it. We went through this with G6, you'll remember it. We had a transmitter swapout, which ultimately came through at a lower cost, higher performance. I would expect more of these types of changes over time, whether it's software and hardware as we continue to make improvements to the platform over time as part of just continuous improvement. Jeff Johnson -- Robert W. Baird and Company -- Analyst The DME only availability through the end of this year, is that just a control kind of access initially or just anything I'm missing there? Jereme Sylvain -- Chief Financial Officer No, there's nothing you're missing there. There's product that will be out in all channels. And so really, I think what you're hearing is timing questions about when you burn through things. That's, I think, more anecdotal than anything else. Everybody is going to be able to have access to this thing in short order. It might start through the DME just because that's the channel that you can generally start through. But this product will be available everywhere. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, that also accommodates a lot of our Tandem pumpers because they get a lot of their supplies through the DME channel, too, Jeff. So, this has been well thought out. Jeff Johnson -- Robert W. Baird and Company -- Analyst Perfect. Thanks. Operator Our next question comes from Travis Steed with Bank of America. Please go ahead. Travis Steed -- Bank of America Merrill Lynch -- Analyst Congrats everybody on the good quarter. Maybe just talk about the buyback, the thought process for the buyback, how much of that's related to the convert versus just seeing your stock at an attractive valuation and is buyback something we should think about you doing more going forward now that you've got your free cash flow at a good level? Jereme Sylvain -- Chief Financial Officer Yeah. So, we think about the buybacks in multiple different ways. Certainly, we want to limit dilution, and that's something we always think about as we launch converts. One of the other things we do when we launch converted, obviously, they come at a lower cash cost. And so, when we have the opportunity to take the incremental cash that we're making through those and give that back to shareholders, we certainly do so. And then look, at the end of the day, while it's not for us to comment on share price, that's certainly for others. We are highly, highly, highly bullish on our business over the long term. And so, when we see an opportunity to invest in our business, either in the form of investment in capabilities or by purchasing stock back, we certainly want to take those opportunities. Whether or not we do these all the time, look, it's been two consecutive years we've done that. So, it's something we'll certainly always look at. You can tell we're not shy about it. But we'll always take a look at it and make sure that we're opportunistic around it, as well as representing the bullishness we have in our business. Travis Steed -- Bank of America Merrill Lynch -- Analyst Great. Thank you. Operator Our next question comes from Marie Thibault with BTIG. Please go ahead. Marie Thibault -- BTIG -- Analyst Great quarter. Thanks for taking the question. I hope you could just expand on the comment in the prepared remarks about even more pronounced dynamic of complementary between CGM use in the GLP-1s. Just curious to get more details on the magnitude of that? And any thoughts on why that would be even more pronounced with the latest generation? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Well, this is Kevin. I'll have Jereme jump in, too, because he's more familiar with the underlying data than I am, but the underlying data as we research this as much as we can, indicates with the new compounds. The physicians are also prescribing CGM for the GLP-1 users as they add GLP-1 to diabetes therapies. They're already existing. They want to give these patients a scoreboard to let them know how they're doing and they're seeing very good results from the GLP-1s in combination with other therapies they're on. And then you add a sensor to it, you can see, \""OK, I've taken this drug and look how my habits have changed. Look how my average glucose has changed over the course of a week or a month versus where it was before.\"" And so, we think we're a vital tool and a very good tool. And the underlying data that we're seeing in prescriptions supports that. I don't know, Jereme, if you have anything else to add? Jereme Sylvain -- Chief Financial Officer No, that's exactly it. And you're asking kind of why the reason, Marie, I mean, we have clinicians tell us all the time. To administer drugs as potent as these are and ultimately to ensure that they are effective, both while they're on the drug and while they're coming off the drug and how they ultimately engage going forward, there is a high correlation of interest in CGM. The more and more folks we speak to, they're saying, why wouldn't you want to understand what's going on in the body as to how to better understand, one, to titrate the drug, but then how to change behaviors and get folks off the drugs over the long haul. So you're just seeing more and more of that, and the script data proves it. Marie Thibault -- BTIG -- Analyst All right. Good. Thank you. Operator Our next question comes from William Plovanic from with Canaccord. Please go ahead. Unknown speaker This is Caitlin on for Bill Plovanic. Congrats on a great quarter. Just maybe touch on the non-insulin product. I think you mentioned it was going to come out next summer. Any more color you can provide on the specific product features that you haven't talked about before? And any updates kind of on the price point or where you are with payer conversations. Thank you. Jake Leach -- Chief Operating Officer Yeah, this is Jake. I'll take the first part about the process. Yes, we're extremely excited about it. We've already finished the clinical trial required for that submission before the end of this year for the product. It's a 15-day meet iCGM criteria. So, really excited about it. The product is all about helping people really engage with their health. So, it is a different -- completely different software experience than what our G-Series and DexCom ONE products are. I'm not going to get into all the specific features yet, but rest assured, our focus is to ensure that people get the benefit of CGM and basically helping them connect the dots to their other lifestyle. And it's really an important tool to help them learn about no matter what therapy they're on and how their metabolic health can be improved. And so, really excited. Team is just finishing up validations in the product. We're looking forward to launching it next year. Teri Lawver -- Chief Commercial Officer Caitlin, hi, it's Teri. Thanks for the question. This product, like all of our products, starts with unique insights into the needs of our customers. So, we're really excited to bring a product to the market that is designed specifically for those who are not on insulin. This is a highly motivated group, but who have different needs, different health needs, different lifestyle needs, and different product and feature needs versus those who are on insulin. So, we've designed the product specifically for that group, understanding what additional medications they might be on, and we are excited to bring this to the market probably in summer of next year is what we're tracking to. Kevin Sayer -- Chairman, President, and Chief Executive Officer And over time, we'll look for reimbursement. We've talked about this as a cash pay option to start, and that's how we'll do it. As far as the exact pricing, that remains to be determined when we launch. We're not going to give that out yet. So, we're excited, as you can tell. Operator Our next question comes from Jayson Bedford with Raymond James. Please go ahead. Jayson Bedford -- Raymond James -- Analyst Thanks, and good afternoon. So, two questions that require one-word answer. What's the timeline on basal coverage in France? And then maybe for Jereme, what's the annual revenue contribution from that business that you expect to sell off in the first half of '24? Jereme Sylvain -- Chief Financial Officer Yeah. So easy answer is basal expected 2024 in France. Timing exactly will depend on the government bodies, but we expect it in the first half of 2024. And the approximate contribution from the business being spun off is $30 million annual run rate. Jayson Bedford -- Raymond James -- Analyst Thank you. Operator Our next question comes from Michael Polark with Wolfe Research. Please go ahead. Michael Polark -- Wolfe Research -- Analyst Good afternoon. Thank you for taking the question. In the prepared remarks, you mentioned you believe you gained share across all reimbursement channels and segments and then added even in non-reimbursed channels. I'm curious, I mean, clearly, we know about the innovation work here and the product launch and that might be the answer. But is there anything commercially you're doing different in the cash pay market today that's influencing that comment? Kevin Sayer -- Chairman, President, and Chief Executive Officer No. We do have a cash pay program right now with G7, but we've not done anything significant. I'll go back mainly to our coverage. I mean G7 coverage has come at a rate much faster than anything we've done before, not just on the basal side but also on the intensive insulin side in every place else. So, we're widely covered, and people find it very easy to get and very easy to pick it up in the channel that they choose to pursue. And we offer the cash pay program and that there are people taking advantage of it. They like G7. They like the different form factor, the ease of use and the things that we offer. So, we have seen an increase there. But it's not something we're pushing really hard. Michael Polark -- Wolfe Research -- Analyst Thank you. Operator Our next question comes from Steve Lichtman with Oppenheimer and Company. Please go ahead. Steve Lichtman -- Oppenheimer and Company -- Analyst Thank you. Congrats, guys. Obviously, a lot of focus on basal as expected but you do, of course, have coverage now for non-insulin hypo at risk, which is a sizable population in its own right. Can you talk about what you're hearing from physicians on the use of CGM there? And are you hearing anything in the field that changed your initial view on how big that opportunity can be in particular? Teri Lawver -- Chief Commercial Officer Thanks, Steve. It's Teri. We're only about six months in since the implementation of that CMS decision. So, still an evolving landscape for the problematic hypoglycemia group. But we see a real opportunity to continue to build coverage with the payers to continue to educate them and to build education with the HCP community, keeping in mind that this is a population where, historically, we haven't thought a lot about CGM use in utilization, but the data that we now have that supported the CMS decision and that we'll continue to build to bring the payers is really compelling. So, we see a tremendous opportunity here and one that's still quite nation with a lot of upside in the future. Steve Lichtman -- Oppenheimer and Company -- Analyst Thank you. Operator Our next question comes from Josh Jennings with TD Cowen. Please go ahead. Josh Jennings -- TD Cowen -- Analyst Hi, thanks for taking the questions. I know you have a lot in front of you with type 2 basal and the cash pay product being launched next year, but you did mention that you're pursuing reimbursement, Kevin, for type 2 and non-insulin using patients. I was just hoping to better understand the road map of the clinical development program and should we -- investors be thinking two to three years for that potential reimbursement to come in or three to five years? And then just on top of that, just what's giving you optimism that you can show a clinically meaningful and statistically segment reduction [Inaudible] seeing that type 2 non-insulin using population. I think you had some registry data. I know you had some registry data at ADA this year, but any other signals and drivers of your confidence? Thanks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Look, we've done numerous studies and every time we introduce CGM to this population, we see lower A1c, higher time in range, and all the other vital signs of these patients get better. And so, we're confident that we have positive impact. I'll add a couple of other things that we've heard in my own travels and travels of the group. One of the things everybody is concerned about is adherence to meds. With CGM, we can -- patients can see what happens when they're inherent to their meds and when they take them, be it whichever type 2 therapy they're on. They can see what happens, and they take their metformin every morning or their SGLT2 pill or even the effect of their GLP-1 injection every week. They can see what happens. And that adherence to drugs leads to better health on an overall basis. So, let's be clear, it's not like diabetes growth has slowed down anywhere. Diabetes still continues to grow rapidly and the cost of diabetes care, as great as all of our technologies have been, continues to increase. So, if we can be a cog in that wheel to whereby we add an element of cost, it's not that significant when you look at the grand scheme of things, but can reduce many other costs and reduce complications that they spend on other things and possibly slow down the train on some of the meds people have to move to. We think we have a great role to play here. And that's how we look at it. I don't think it's going to take five years. I think this is more a two- to three-year journey. But you know what, that's the gospel according to me. I don't have anything else to base that on, but you'll see data continue to pile up in this segment, particularly as we launch a cash pay product to start and then get some basic reimbursement from that from others. We're making our case -- obviously, building a case with CMS, like we did for mobile on basal, that was data produced by DexCom. We're pretty good at that. So, we'll keep pushing. Josh Jennings -- TD Cowen -- Analyst Great. Thanks so much. Operator Our next question comes from Matt Miksic with Barclays. Please go ahead. Matt Miksic -- Barclays -- Analyst Hey, good afternoon, and congrats on the quarter and appreciate all the color today on the call. If I could follow up on a comment you made, Kevin, earlier about the number of new prescribers post driven by the G7 launch and get some color if you could share it around is that sort of getting further into the sort of simple user segment of the market? Is it linked in any way to the basal coverage? What's your assessment of what's been driving that? And other than G7 just being great. But -- and then also maybe the implications for share trends in the U.S., if that continues? Jereme Sylvain -- Chief Financial Officer Hey, Matt, this is Jereme. I can take this. And by the way, it's all intentional, right? We have a commercial team that's done an incredible job of identifying areas to go and doctors to really certainly focus on where we can come in with the product, demonstrate obviously, it's the most accurate. Certainly, it's easy to use. And with the coverage we have, I think it really demonstrates to the physicians and their prescribing patterns. Look, we can -- we have the lowest out-of-pockets for these patients, and we can ultimately keep them on therapy and adherence for a much longer period. So, I think that in addition to obviously G7 and all the features it has inherent in it has allowed these physicians to make the change. But it's so wonderful product, wonderful coverage, and absolutely intentionality by the sales team. I mean, just a great job by those -- that team identifying who those targets are going out there and addressing it. So, it's no coincidence. And 18,000 incremental prescribers, a significant amount in the PCP space and a lot of folks are switching. These PCPs are switching from who they prescribed today and moving over to DexCom. So, we're really proud of it. And obviously, it was 1,000 in the first quarter, 8,000 in the second quarter, and another 9,000 this quarter. So, it is -- the message is getting out, and it's meaningful. Matt Miksic -- Barclays -- Analyst Great. Thank you for the color. Operator Our next question comes from Mike Kratky with Leerink Partners. Please go ahead. Mike Kratky -- Leerink Partners -- Analyst Yeah. Hi, everyone. Thanks for taking our question. Just going back to basal only, what's the latest basal-only commercial coverage you have in place? And how are you thinking about both the cadence and what's needed to bridge that gap to get more full coverage? Teri Lawver -- Chief Commercial Officer Yeah. This is Teri. Happy to take that one. We track coverage very closely for DexCom and for the industry, and DexCom is the most covered CGM with the lowest out-of-pocket co-pay. That is true for the overall population in U.S. commercial lives, and it's also true for the basal population. And I would say, keep in mind that we were out with the mobile study in front of the payers even before the CMS decision came through. So, we continue to -- we'll continue to lead in the coverage for this population. Jereme Sylvain -- Chief Financial Officer Yeah. And then your question was how much -- what more do we need to go? The answer is it's not warm. A lot of commercial payers are already really covering this. You now -- Teri referenced, we have the most wide coverage on basal. It's really now just -- it's time. It takes time to get in front of payers, Medicaid payers, government payers. And so, it's just canvassing. And by the way, this is not something that we didn't face with type 1. It's not something we didn't face with type 2 intensive. And so, just give us time, but a majority of people walking around with using basal insulin now have access to CGM technology. It's a wonderful thing for the population. Mike Kratky -- Leerink Partners -- Analyst Understood. Thanks very much. Operator This concludes our question-and-answer session for today. I will now turn the call over to Mr. Kevin Sayer for closing remarks. Kevin Sayer -- Chairman, President, and Chief Executive Officer Thank you. This was truly a banner quarter for us. This was our first quarter with over $200 million in year-over-year quarterly growth and the second consecutive quarter of record financial performance and market share gains on all fronts. Our G7 launch remains in its early stages. There's tremendous amount of momentum left in this launch with our plan upgrades to the system and also our upcoming AID integrations. In addition to continuing to perform in these traditional metrics, our company's growth as a world-class organization on a number of fronts continues to be recognized. DexCom was recognized by Forbes as one of the top 5 organizations to work for in the state of California. By the way, three of the top 5 were universities. So, we're one of two companies in that group. We are recognized by Newsweek as one of the 300 top green organizations and acknowledging our great work of our teams to advance our sustainability initiatives, and we are considering this very thoroughly in all of our product development efforts going forward. Finally, we've been recognized by FAST Technologies as one of the brands that matters. Great honors for our company. I want to thank everybody here at DexCom who makes these great things happen and thank everybody for your continued support. Thank you. Operator [Operator signoff] Duration: 0 minutes Call participants: Sean Christensen -- Head of Investor Relations Kevin Sayer -- Chairman, President, and Chief Executive Officer Jereme Sylvain -- Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Malgaret Kaczor Andrew -- William Blair and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Danielle Antalffy -- UBS -- Analyst Teri Lawver -- Chief Commercial Officer Matt Taylor -- Jefferies -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst Jake Leach -- Chief Operating Officer Mathew Blackman -- Stifel Financial Corp. -- Analyst Joanne Wuensch -- Citi -- Analyst Jeff Johnson -- Robert W. Baird and Company -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Marie Thibault -- BTIG -- Analyst Unknown speaker Jayson Bedford -- Raymond James -- Analyst Michael Polark -- Wolfe Research -- Analyst Steve Lichtman -- Oppenheimer and Company -- Analyst Josh Jennings -- TD Cowen -- Analyst Matt Miksic -- Barclays -- Analyst Mike Kratky -- Leerink Partners -- Analyst More DXCM analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Best Healthcare Stocks to Buy Right Now The healthcare industry may not be as hot with investors as artificial intelligence or other high-flying industries, but the range of essential needs these businesses serve provides opportunities ripe for investor cash in a range of market environments. From life-saving medicines to medical devices, people require these products and services no matter what is happening with the broader economy. For long-term investors, that can pose a tempting buying proposition in both bull and bear market environments. If you're looking for top healthcare stocks to add cash to this month, here are two names to consider when you do. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) is one of those healthcare businesses that has proven its ability to penetrate, expand, and disrupt markets where patients have historically had few to no options to treat rare medical conditions. Over the last decade, Vertex has seen profits and cash rise by respective amounts of about 1,200% and 530%. This goes back to the success of its core business, a franchise of medicines that target the underlying genetic cause of cystic fibrosis. Even though Vertex is the only company with drugs on the market that serve that function, management still estimates that there are tens of thousands of patients globally who could benefit from its current drugs but aren't taking them yet. These aren't one-and-done treatments either, but drugs that patients generally need to take twice daily. Now, Vertex is looking to replicate its success with its cystic fibrosis drug franchise in other lucrative markets. It's working on a stem-cell-based therapy for type 1 diabetes with the goal of developing a functional cure for the condition. Bear in mind, there are close to 3 million people with Type 1 diabetes in Europe and North America alone. The company is also developing what would be the first functional cure for the rare kidney disorder APOL1-mediated kidney disease. The condition afflicts more than 100,000 people just in the U.S. and Europe. While both of these candidates each represent multi-billion-dollar opportunities for Vertex, investors should be watching in the coming months for the much-anticipated regulatory decisions on exa-cel, its rare blood disorder candidate that would be the first functional cure for both sickle cell disease and transfusion-dependent beta thalassemia. The U.S. Food and Drug Administration is expected to release its review decision about approving the drug to treat sickle cell disease by Dec. 8. Because this profitable business has its fingers in so many pies, it could easily be first to market in multiple other underpenetrated sectors besides cystic fibrosis. Long-term investors may find this growth story warrants a long, hard second look. 2. DexCom DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring (CGM) systems that it sells to healthcare providers and people living with diabetes. Last year, the company launched the latest generation of its flagship CGM device, the G7, marketed as being the most accurate as well as the most widely insured of any such device on the market. Approvals for the device have expanded globally over the last year from the U.S. to Europe to Asia to Africa. For example, the G7 was just approved in Canada in early October for all diabetics aged two and up. There are roughly 12 million people living with diabetes or prediabetes in Canada alone. As regulatory approvals for the G7 have continued, DexCom has raked in revenue and profits at a rapid clip, building on a strong track record of financial growth. DexCom's revenue for the first half of 2023 totaled $1.6 billion, while net income came in at $165 million. Those figures represented respective increases of 22% and 11% from the same period in 2022. The company ended the most recent quarter with about $3.6 billion in cash and investments on its balance sheet. The demand for effective diabetes management tools isn't going anywhere, even as therapeutic options to manage the disease hit the market. In fact, CGMs are often used in conjunction with diabetes drugs like Eli Lilly's Mounjaro. If you were to look at DexCom's stock alone, its roughly 25% decline from the start of the year might give you pause. But a closer look at the continued demand for its products -- which has translated to impressive balance sheet gains -- could tell a different story. Find out why Vertex Pharmaceuticals is one of the 10 best stocks to buy now Our analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed their ten top stock picks for investors to buy right now. Vertex Pharmaceuticals is on the list -- but there are nine others you may be overlooking. Click here to get access to the full list! *Stock Advisor returns as of October 23, 2023 Rachel Warren has positions in DexCom. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""After-Hours Earnings Report for October 26, 2023 : AMZN, INTC, CMG, AJG, RSG, F, DLR, COF, LHX, DXCM, HIG, VRSN The following companies are expected to report earnings after hours on 10/26/2023. Visit our Earnings Calendar for a full list of expected earnings releases. Amazon.com, Inc. (AMZN)is reporting for the quarter ending September 30, 2023. The internet company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.58. This value represents a 190.00% increase compared to the same quarter last year. AMZN missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -9.09%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AMZN is 54.19 vs. an industry ratio of 20.00, implying that they will have a higher earnings growth than their competitors in the same industry. Intel Corporation (INTC)is reporting for the quarter ending September 30, 2023. The semiconductor company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.03. This value represents a 94.92% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for INTC is -364.78 vs. an industry ratio of -16.70. Chipotle Mexican Grill, Inc. (CMG)is reporting for the quarter ending September 30, 2023. The restaurant company's consensus earnings per share forecast from the 15 analysts that follow the stock is $10.46. This value represents a 9.99% increase compared to the same quarter last year. CMG missed the consensus earnings per share in the 4th calendar quarter of 2022 by -6.64%. Arthur J. Gallagher & Co. (AJG)is reporting for the quarter ending September 30, 2023. The insurance brokers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.94. This value represents a 12.79% increase compared to the same quarter last year. In the past year AJG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.15%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AJG is 26.56 vs. an industry ratio of 19.10, implying that they will have a higher earnings growth than their competitors in the same industry. Republic Services, Inc. (RSG)is reporting for the quarter ending September 30, 2023. The waste removal company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.41. This value represents a 5.22% increase compared to the same quarter last year. In the past year RSG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.02%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for RSG is 27.59 vs. an industry ratio of 12.30, implying that they will have a higher earnings growth than their competitors in the same industry. Ford Motor Company (F)is reporting for the quarter ending September 30, 2023. The auto (domestic) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.40. This value represents a 33.33% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for F is 5.71 vs. an industry ratio of 6.10. Digital Realty Trust, Inc. (DLR)is reporting for the quarter ending September 30, 2023. The reit company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.62. This value represents a 2.99% decrease compared to the same quarter last year. DLR missed the consensus earnings per share in the 4th calendar quarter of 2022 by -1.79%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DLR is 17.72 vs. an industry ratio of 10.50, implying that they will have a higher earnings growth than their competitors in the same industry. Capital One Financial Corporation (COF)is reporting for the quarter ending September 30, 2023. The financial services company's consensus earnings per share forecast from the 13 analysts that follow the stock is $3.23. This value represents a 23.10% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for COF is 7.71 vs. an industry ratio of 7.90. L3Harris Technologies, Inc. (LHX)is reporting for the quarter ending September 30, 2023. The aerospace and defense company's consensus earnings per share forecast from the 9 analysts that follow the stock is $3.06. This value represents a 6.13% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LHX is 14.30 vs. an industry ratio of 5.30, implying that they will have a higher earnings growth than their competitors in the same industry. DexCom, Inc. (DXCM)is reporting for the quarter ending September 30, 2023. The medical instruments company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.34. This value represents a 21.43% increase compared to the same quarter last year. In the past year DXCM has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 54.55%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DXCM is 68.58 vs. an industry ratio of 19.70, implying that they will have a higher earnings growth than their competitors in the same industry. Hartford Financial Services Group, Inc. (HIG)is reporting for the quarter ending September 30, 2023. The insurance company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.95. This value represents a 35.42% increase compared to the same quarter last year. In the past year HIG has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for HIG is 9.20 vs. an industry ratio of 10.30. VeriSign, Inc. (VRSN)is reporting for the quarter ending September 30, 2023. The internet software company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.74. This value represents a 10.13% increase compared to the same quarter last year. In the past year VRSN has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.29%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for VRSN is 29.41 vs. an industry ratio of -11.70, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates DexCom (DXCM) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 47.06%. A quarter ago, it was expected that this medical device company would post earnings of $0.22 per share when it actually produced earnings of $0.34, delivering a surprise of 54.55%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $975 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 4.02%. This compares to year-ago revenues of $769.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. DexCom shares have lost about 25.5% since the beginning of the year versus the S&P 500's gain of 9%. What's Next for DexCom? While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.39 on $995.17 million in revenues for the coming quarter and $1.23 on $3.55 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Nemaura Medical, Inc. (NMRD), another stock in the same industry, has yet to report results for the quarter ended September 2023. This company is expected to post quarterly loss of $0.10 per share in its upcoming report, which represents a year-over-year change of +41.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Nemaura Medical, Inc.'s revenues are expected to be $0.1 million, up 42.9% from the year-ago quarter. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Nemaura Medical, Inc. (NMRD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-27,92.73,92.988,86.27,89.29,"[""Health Care Sector Update for 10/27/2023: APLM, ICU, PTCT, DXCM Health care stocks fell late Friday afternoon with the NYSE Health Care Index dropping 2% and the Health Care Select Sector SPDR Fund (XLV) declining 1.9%. The iShares Biotechnology ETF (IBB) fell 2.4%. In corporate news, Apollomics (APLM) shares surged 80%, a day after the company said its experimental treatment vebreltinib was found to benefit a person with brain tumor. SeaStar Medical (ICU) shares jumped 28% after the company withdrew its Sept. 8 registration statement, opting not to pursue the sale of securities due to current market conditions. PTC Therapeutics (PTCT) slumped 22% after the company posted a Q3 diluted loss of $1.76 per share, widening from a loss of $1.53 a year earlier. Analysts polled by Capital IQ expected a loss of $1.06. DexCom (DXCM) shares gained 9.7% after analysts increased their price targets on the company following better-than-expected Q3 results. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Noteworthy Friday Option Activity: MS, CUBI, DXCM Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Morgan Stanley (Symbol: MS), where a total of 41,208 contracts have traded so far, representing approximately 4.1 million underlying shares. That amounts to about 40.5% of MS's average daily trading volume over the past month of 10.2 million shares. Particularly high volume was seen for the $71 strike put option expiring November 17, 2023, with 3,224 contracts trading so far today, representing approximately 322,400 underlying shares of MS. Below is a chart showing MS's trailing twelve month trading history, with the $71 strike highlighted in orange: Customers Bancorp Inc (Symbol: CUBI) options are showing a volume of 962 contracts thus far today. That number of contracts represents approximately 96,200 underlying shares, working out to a sizeable 40.5% of CUBI's average daily trading volume over the past month, of 237,315 shares. Particularly high volume was seen for the $35 strike put option expiring December 15, 2023, with 226 contracts trading so far today, representing approximately 22,600 underlying shares of CUBI. Below is a chart showing CUBI's trailing twelve month trading history, with the $35 strike highlighted in orange: And DexCom Inc (Symbol: DXCM) options are showing a volume of 23,051 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 40.5% of DXCM's average daily trading volume over the past month, of 5.7 million shares. Especially high volume was seen for the $65 strike put option expiring November 17, 2023, with 3,283 contracts trading so far today, representing approximately 328,300 underlying shares of DXCM. Below is a chart showing DXCM's trailing twelve month trading history, with the $65 strike highlighted in orange: For the various different available expirations for MS options, CUBI options, or DXCM options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 \u00bb Also see: \u0095 ZFOX Average Annual Return \u0095 Top Ten Hedge Funds Holding DVN \u0095 Crown Castle Historical Earnings The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 10/27/2023: ICU, DXCM, PTCT Health care stocks were weaker Friday afternoon, with the NYSE Health Care Index falling 1.7% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.6%. The iShares Biotechnology ETF (IBB) fell 1.9%. In corporate news, SeaStar Medical (ICU) shares jumped past 22% after it withdrew its Sept. 8 registration statement. The company said it has chosen not to pursue the sale of securities due to current market conditions. PTC Therapeutics (PTCT) slumped 22% after it posted a Q3 diluted loss of $1.76 per share, widening from a loss of $1.53 a year earlier. Analysts polled by Capital IQ expected a loss of $1.06. DexCom (DXCM) shares gained 10% after analysts increased their price targets on the company, following better-than-expected Q3 results. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Morgan Stanley Maintains Dexcom (DXCM) Equal-Weight Recommendation Fintel reports that on October 27, 2023, Morgan Stanley maintained coverage of Dexcom (NASDAQ:DXCM) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 79.25% Upside As of October 5, 2023, the average one-year price target for Dexcom is 145.35. The forecasts range from a low of 98.98 to a high of $168.00. The average price target represents an increase of 79.25% from its latest reported closing price of 81.09. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Dexcom is 3,546MM, an increase of 4.20%. The projected annual non-GAAP EPS is 1.10. What is the Fund Sentiment? There are 1922 funds or institutions reporting positions in Dexcom. This is an increase of 5 owner(s) or 0.26% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.45%, a decrease of 5.64%. Total shares owned by institutions increased in the last three months by 0.01% to 439,849K shares. The put/call ratio of DXCM is 0.99, indicating a bullish outlook. What are Other Shareholders Doing? Baillie Gifford holds 16,723K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 17,157K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in DXCM by 1.57% over the last quarter. Sands Capital Management holds 13,103K shares representing 3.38% ownership of the company. In it's prior filing, the firm reported owning 13,739K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in DXCM by 0.57% over the last quarter. Jpmorgan Chase holds 12,673K shares representing 3.27% ownership of the company. In it's prior filing, the firm reported owning 10,765K shares, representing an increase of 15.06%. The firm increased its portfolio allocation in DXCM by 16.16% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,102K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 11,965K shares, representing an increase of 1.14%. The firm increased its portfolio allocation in DXCM by 3.23% over the last quarter. VFINX - Vanguard 500 Index Fund Investor Shares holds 9,229K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 9,017K shares, representing an increase of 2.31%. The firm increased its portfolio allocation in DXCM by 2.55% over the last quarter. Dexcom Background Information (This description is provided by the company.) DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits. Sponsored Links The US States People Are Fleeing And The Ones They Are Moving To Forbes Read More Click to Learn More This story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Health Care Sector Update for 10/27/2023: SNY, PTCT, DXCM, XLV, IBB Health care stocks were gaining premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was up 0.2% and the iShares Biotechnology ETF (IBB) was 0.3% higher recently. Sanofi (SNY) was slipping past 16% as it reported Q3 earnings of 2.55 euros ($2.69) per share, down from 2.88 euros a year earlier. PTC Therapeutics (PTCT) was retreating by 18% after it posted a Q3 diluted loss of $1.76 per share, widening from a loss of $1.53 a year earlier. Analysts polled by Capital IQ expected a loss of $1.06. DexCom (DXCM) was advancing by more than 16% after it reported a Q3 non-GAAP net income of $0.50 per diluted share, up from $0.28 a year earlier. Analysts polled by Capital IQ expected $0.33. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Revolutionary Stocks I'd Buy Right Now Without Hesitation Investor Jim Rogers, who co-founded the Quantum Fund with George Soros, once famously said, \""Bottoms in the investment world don't end with four-year lows, they end with 10- or 15-year lows.\"" Yet, it's virtually impossible for investors to know for certain when markets are going to hit bottom -- or top out for that matter. The good news is, if you're consistently putting cash into companies that are well-positioned for long-term, competitive growth, you don't need to divine when bear markets will veer into bull territory, or vice versa. Instead, you can focus on buying wonderful businesses that can compound your returns with time. If you're in a position to put cash into stocks right now -- money that you don't need for household expenses or other bills -- there are plenty of intriguing stocks begging to be bought. Here are three names to consider. 1. DexCom DexCom (NASDAQ: DXCM) is known for its continuous glucose monitoring (CGM) devices, which can be used by both Type 1 and Type 2 diabetics to track blood sugar levels and ensure more accurate insulin management. There are also potential use cases for pre-diabetics that could expand the potential patient population in the years ahead. Roughly half a billion adults have diabetes globally. That number is expected to balloon to roughly 643 million by the beginning of the next decade. The point being, the market opportunity for a leader like DexCom is not only substantial but expanding. The company has a history of revenue growth and profitability. DexCom turned a profit for the first time over a decade ago. In the last five years alone, it's increased revenue by around 97%, while net income has grown in the ballpark of 240%. A key impetus for its continued growth story has come in the form of the latest generation of its CGM systems, the G7. The device has been approved in the U.S., Europe, the U.K., and Canada, as well as in certain markets in Asia and Africa. The U.S., which is the largest diabetes market in North America and accounts for more than two-thirds of the company's revenue, remains a core area of focus for DexCom. Since the G7 was approved in the U.S. last December, there are 8,000 physicians now prescribing the CGM that had not prescribed a DexCom product before. DexCom recently announced that all the leading pharmacy benefit managers in the U.S. cover the G7, and patients prescribed the CGM through a pharmacy pay around $20 a month compared to patients using a competitor CGM, who pay around $70. Importantly, since the Centers for Medicare and Medicaid Services widened CGM coverage beyond intensive insulin use to individuals who use basal insulin or don't use insulin but have hypoglycemia; this has expanded DexCom's total addressable market in the U.S. alone by up to 7 million individuals. The potential for this business remains strong, and for investors seeking a profitable healthcare company with a wide moat and considerable runway left to explore, DexCom looks like a worthy contender. 2. Airbnb Airbnb (NASDAQ: ABNB) isn't just a destination for people to book vacation homes. In the 16 years since the company was launched, the platform has grown to serve a wide variety of travel use cases, from business trips to weekend trips to leisure bookings, to people looking for a place to live and work for extended periods of time. There's no denying that the travel industry as a whole has seen a notable rebound from the doldrums of the pandemic. And even as broader economic worries persist, people are spending money on experiences like travel, which is having a trickle down effect on many companies with broad exposure to the travel space. However, the travel resurgence is far from the only factor driving Airbnb's growth story. The diversity of stays offered on its platform, and the fact that it facilitates both side of an accommodation transaction, mean that it benefits from many types of travel as well as the continued surge in people looking to list their homes on Airbnb. Airbnb has introduced a range of upgrades to its platform in past months, from more user-friendly price-setting tools for hosts to discounts on long-term stays to more affordable stay options. After introducing discounts for stays of three months or more and adjusting Airbnb's interface to make long-term stays easier to find, management said that there was a notable surge in guests booking these types of reservations. In June alone, nights reserved for three months or more comprised one-quarter of all monthly stays. Airbnb brought in revenue of $4.3 billion in the first six months of 2023, with profits totaling $767 million for the first half of the year. The company also generated cash from operating activities to the tune of about $2.5 billion in that six-month window. If you're looking to invest in travel stocks, a business like this that is exposed to many types of travel spending and is building a store of cash and profits looks like a no-brainer choice. 3. Amazon Amazon (NASDAQ: AMZN) needs no introduction, and this mainstay company has dealt with its share of economic highs and lows through the years. After a bumpy few quarters, Amazon slashed its workforce, which was among a range of aggressive moves to cut costs and get back to profitability. Not only did that approach, while painful, achieve what management was aiming for, but the company's leadership in the core sectors it operates in gives it a considerable competitive advantage in multiple lucrative markets. In the first half of 2023, Amazon generated net sales of $262 billion across its family of businesses, while profits for the six-month period totaled a healthy $10 billion. Of that net sales figure, $116 billion was derived from product sales (i.e. sales on its flagship e-commerce platform) while the remaining $146 billion was derived from services sales (i.e., Amazon Web Services, Prime, etc.). In other words, Amazon is raking in most of its revenue and profits from subscription-based services, which are not only higher-margin businesses but sources of recurring income. Trailing-12-month operating cash flow hit $62 billion as of the end of the second quarter, a 74% increase from one year ago. As Amazon has done in the past, it continues to expand beyond its cloud computing and e-commerce markets into other lucrative areas, like artificial intelligence. The company recently started building its own AI chips and is investing billions into a top competitor of ChatGPT. Investors who want in on the next era of growth for Amazon may want to scoop up some shares of the stock in the near future. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 23, 2023 Sponsored Links Help Pay Down Balances Instead Of Interest Credit Karma Learn More John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Rachel Warren has positions in Amazon.com and DexCom. The Motley Fool has positions in and recommends Airbnb and Amazon.com. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook DexCom, Inc. DXCM reported third-quarter 2023 adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 22 cents by 47.1%. The company reported earnings of 28 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 29 cents, up from the year-ago quarter\u2019s figure of 24 cents. Shares of DexCom rose 17% in after-hours trading on Oct 26, following better-than-expected quarterly results. However, the stock has lost 28.4% year to date compared with the industry\u2019s 15.5% decline. The broader S&P 500 Index has moved up 10% in the same period. Image Source: Zacks Investment Research Revenue Details Total revenues grew 27% (26% on an organic basis) to $975 million on a year-over-year basis and beat the Zacks Consensus Estimate by 4%. Strong revenue growth was driven by rising volumes on the back of increasing global awareness of the benefits of real-time Continuous Glucose Monitoring and strong customer additions. Segmental Details Sensor and other revenues(90% of total revenues) increased 31% on a year-over-year basis to $873.8 million. Hardware revenues (10%) decreased 2% year over year to $101.2 million. Geographical Details U.S. revenues (73% of total revenues) increased 24% on a year-over-year basis to $713.6 million. International revenues (27%) improved 33% (30% on an organic basis) year over year to $261.4 million. Margin Analysis Gross profit totaled $623.3 million, up 26.1% from the prior-year quarter\u2019s level. DexCom reported a gross margin (as a percentage of revenues) of 62.7%, which contracted approximately 30 basis points year over year. Research and development expenses amounted to $131.4 million, up 19.1% year over year. Selling, general and administrative expenses totaled $284.7 million, up 21.4% year over year. The company reported total operating expenses of $417.8 million, up 20.5% from the prior-year period\u2019s recorded number. Operating margin (as a percentage of revenues) was 21.1%, up 190 bps year over year. Financial Position DXCM exited the third quarter with $3.24 billion in cash, cash equivalents and marketable securities compared with $3.64 billion in the preceding quarter. Total assets amounted to $6.6 billion compared with $6.82 billion on a sequential basis. 2023 Guidance DexCom raised its guidance for 2023 revenues and also raised its adjusted gross and operating margin outlook. The company now expects revenues in the range of $3.575-$3.6 billion, implying 23-24% year-over-year growth. The Zacks Consensus Estimate for the same is pegged at $3.55 billion. Previously, DXCM expected revenues in the range of $3.5-$3.55 billion. DXCM now expects an adjusted gross margin of approximately 64% versus 63% previously. Adjusted operating margin is projected to be approximately 19%, up from the previous guidance of 17%. DXCM also announced a share repurchase program worth $500 million. Wrapping Up DexCom exited third-quarter 2023 on a strong note, wherein both earnings and revenues beat their respective estimates. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, the expansion of coverage for CGM systems during the quarter supported growth. This trend is likely to continue for the rest of 2023. The availability of new sensors like G6 & G7 in new international markets is also boosting revenue growth. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Apart from making continued advancements in terms of its key strategic objectives, the company continued to have strong new patient additions in the quarter. The expansion of gross and operating margins buoys optimism. However, cut-throat competition in the market for blood & glucose monitoring devices remains another concern. DexCom, Inc. Price, Consensus and EPS Surprise DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote Zacks Rank and Stocks to Consider Currently, DexCom carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Edwards Lifesciences EW. Abbott, carrying a Zacks Rank of 2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. Elevance Health reported third-quarter 2023 adjusted EPS of $8.99, which beat the Zacks Consensus Estimate by 6.4%. Revenues of $42.5 billion were in line with the Zacks Consensus Estimate. The company currently carries a Zacks Rank #2. ELV has a long-term estimated growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.91%. Edwards Lifesciences reported third-quarter 2023 adjusted EPS of 59 cents and revenues of $1.48 billion, both in line with their respective Zacks Consensus Estimate. It currently carries a Zacks Rank #2. EW has a long-term estimated growth rate of 8%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.62%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Pre -market Movers: NKGN, ICU, PTCT, ENPH, DXCM\u2026 (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). In the Green NKGen Biotech, Inc. (NKGN) is up over 38% at $5.25. SeaStar Medical Holding Corporation (ICU) is up over 28% at $1.02. DexCom, Inc. (DXCM) is up over 16% at $94.55. reAlpha Tech Corp. (AIRE) is up over 10% at $55.00. Intel Corporation (INTC) is up over 7% at $34.91. LianBio (LIAN) is up over 5% at $3.96. In the Red PTC Therapeutics, Inc. (PTCT) is down over 22% at $18.45. Enphase Energy, Inc. (ENPH) is down over 20% at $76.00. Sanofi (SNY) is down over 16% at $44.35. Jaguar Global Growth Corporation I (JGGC) is down over 9% at $6.32. NatWest Group plc (NWG) is down over 9% at $4.58. Cognition Therapeutics, Inc. (CGTX) is down over 9% at $1.01. Next.e.GO N.V. (EGOX) is down over 7% at $1.01. BioVie Inc. (BIVI) is down over 5% at $3.05. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-10-30,90.16,90.59,84.71,84.91,"Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4% Shares of The Ensign Group, Inc. ENSG gained 2.4% since it reported third-quarter 2023 results on Oct 25, 2023. The quarterly results benefited on the back of higher managed care revenues and improved occupancies. A hiked adjusted earnings per share (EPS) for this year may have boosted investors’ sentiment about the stock. However, the upside was partly offset by an elevated expense level. ENSG reported a third-quarter 2023 adjusted EPS of $1.20, which surpassed the Zacks Consensus Estimate by 1.7%. The bottom line improved 15.4% year over year. Operating revenues climbed 22.2% year over year to $940.8 million in the quarter under review. The top line beat the consensus mark by a whisker. The Ensign Group, Inc. Price, Consensus and EPS Surprise The Ensign Group, Inc. price-consensus-eps-surprise-chart | The Ensign Group, Inc. Quote Q3 Update ENSG’s adjusted net income of $69 million advanced 16.6% year over year in the third quarter and came higher than our estimate of $67.8 million. Same-store occupancy improved 290 basis points (bps) year over year while transitioning occupancy expanded 270 bps year over year. Total expenses rose 23.8% year over year to $861 million, higher than our estimate of $854.9 million. The year-over-year increase was due to higher cost of services, rent-cost of services and general and administrative expenses. Segmental Update Skilled Services: The segment recorded revenues of $903 million, which grew 22.1% year over year in the third quarter. The figure matched the Zacks Consensus Estimate but surpassed our estimate of $902.3 million. Segment income improved 15.8% year over year to $117.8 million. Skilled nursing and campus operations of the segment totaled 258 and 26, respectively, at the third-quarter end. Standard Bearer: Rental revenues advanced 12% year over year to $21 million in the quarter under review but fell short of our estimate of $22.2 million. Segmental income of $7.2 million grew 3.2% year over year. Funds from Operations totaled $13.6 million in the third quarter, which rose 8.7% year over year. Financial Update (as of Sep 30, 2023) Ensign Group exited the third quarter with cash and cash equivalents of $467.9 million, which climbed 47.9% from the level at 2022 end. It had a leftover capacity of $593.3 million under its line of credit at the third-quarter end. Total assets of $4,082 million increased 18.2% from the 2022-end figure. Long-term debt-less current maturities were $146.5 million, down 1.9% from the figure as of Dec 31, 2022. Current maturities of long-term debt amounted to $3.9 million. Total equity of $1,465.4 million advanced 17.3% from the figure at 2022 end. ENSG generated net cash from operations of $291.4 million in the first nine months of 2023, which rose 31.1% from the prior-year comparable period. Capital-Deployment Update Ensign Group did not buy back shares in the third quarter. It paid out a quarterly dividend of 5.75 cents per share. 2023 Outlook Updated Revenues are projected to lie within $3.72-$3.73 billion compared with the prior guidance of $3.69-$3.73 billion. The midpoint of the updated outlook implies a 23.1% rise from the 2022 figure. Adjusted EPS is estimated to be between $4.73-$4.79 for 2023, up from the earlier view of $4.70-$4.78. The midpoint of the revised guidance indicates an improvement of 15% from the 2022 figure. The weighted average common shares outstanding is estimated to be around 57.7 million and the tax rate is assumed at 25% for this year. Zacks Rank Ensign Group currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Other Medical Sector Releases Of the Medical sector players that have reported third-quarter 2023 results so far, the bottom-line results of Encompass Health Corporation EHC, Merit Medical Systems, Inc. MMSI and DexCom, Inc. DXCM beat the respective Zacks Consensus Estimate. Encompass Health reported third-quarter 2023 adjusted EPS of 86 cents, which surpassed the Zacks Consensus Estimate by 11.7%. The bottom line advanced 28.4% year over year. Net operating revenues of EHC rose 10.8% year over year to $1,206.9 million in the quarter under review. The top line beat the consensus mark by a whisker. Net patient revenue per discharge of Encompass Health improved 3.3% year over year in the third quarter. Total discharges increased 7.3% year over year. Adjusted EBITDA was $237.5 million, which rose 21.6% year over year in the third quarter. It added 26 beds to its existing hospitals in the quarter under review. Merit Medical’s third-quarter 2023 adjusted EPS of 75 cents rose 17.2% year over year. The figure also surpassed the Zacks Consensus Estimate by 15.4%. MMSI registered revenues of $315.2 million in the third quarter, up 9.8% year over year. The figure surpassed the consensus estimate by 2.9%. The Cardiovascular unit reported third-quarter revenues of $306.1 million, up 9.7% both on a reported basis and at constant exchange rate (CER) year over year. Endoscopy devices’ revenues totaled $9.1 million, up 11.2% year over year both on a reported basis and at CER. Adjusted operating profit totaled $35.7 million, reflecting an 82.4% jump from the prior-year quarter. The adjusted operating margin in the third quarter expanded 451 bps to 11.3%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate of earnings of 22 cents per share by 47.1%. The company reported earnings of 28 cents per share in the prior-year quarter. Total revenues of DXCM grew 27% (26% on an organic basis) to $975 million on a year-over-year basis and beat the Zacks Consensus Estimate by 4%. Sensor and other revenues (90% of total revenues) increased 31% on a year-over-year basis to $873.8 million. Hardware revenues (10%) decreased 2% year over year to $101.2 million. Operating margin (as a percentage of revenues) was 21.1%, up 190 bps year over year. Zacks Names ""Single Best Pick to Double"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Encompass Health Corporation (EHC) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-10-31,85.73,89.47,85.41,88.83,"[""Nasdaq 100 Movers: ON, GEHC In early trading on Tuesday, shares of GE HealthCare Technologies topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.5%. Year to date, GE HealthCare Technologies registers a 13.1% gain. And the worst performing Nasdaq 100 component thus far on the day is ON Semiconductor, trading down 4.6%. ON Semiconductor is lower by about 0.1% looking at the year to date performance. Two other components making moves today are Amgen, trading down 4.0%, and DexCom, trading up 2.9% on the day. VIDEO: Nasdaq 100 Movers: ON, GEHC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Reasons Growth Investors Will Love DexCom (DXCM) Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. DexCom (DXCM) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below: Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 49.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 55.2% this year, crushing the industry average, which calls for EPS growth of 11.9%. Cash Flow Growth While cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 37.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 75.9% over the past 3-5 years versus the industry average of 7.7%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. There have been upward revisions in current-year earnings estimates for DexCom. The Zacks Consensus Estimate for the current year has surged 9.7% over the past month. Bottom Line DexCom has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination positions DexCom well for outperformance, so growth investors may want to bet on it. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What Makes DexCom (DXCM) a New Buy Stock DexCom (DXCM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for DexCom basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. For DexCom, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of Earnings Estimate Revisions Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>. Earnings Estimate Revisions for DexCom This medical device company is expected to earn $1.35 per share for the fiscal year ending December 2023, which represents a year-over-year change of 55.2%. Analysts have been steadily raising their estimates for DexCom. Over the past three months, the Zacks Consensus Estimate for the company has increased 13.9%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of DexCom to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-01,88.26,94.405,87.8101,94.13,"DXCM Factor-Based Stock Analysis Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper ""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-11-02,94.84,95.8299,92.07,93.67,"[""Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up Nevro Corp. NVRO reported a loss per share of 65 cents for the third quarter of 2023, against the year-ago quarter\u2019s earnings per share (EPS) of $2.22. However, the loss per share was narrower than the Zacks Consensus Estimate of a loss of 77 cents. Revenues in Detail Nevro registered worldwide revenues of $103.9 million in the third quarter, up 3.4% year over year on a reported basis. The figure topped the Zacks Consensus Estimate by 7.8%. At constant exchange rate (CER), revenues were up 3% year over year. Painful Diabetic Neuropathy (PDN) indication sales represented approximately $20.8 million (20%) of worldwide permanent implant procedures and increased 56% year over year. Quarterly Highlights In the quarter under review, international revenues were $14.1 million, down 1.4% year over year on a reported basis and 6% at CER. This figure compares to our third-quarter projection of $13.3 million. U.S. revenues for the quarter totaled $89.8 million, up 4.3% year over year. This figure compares to our third-quarter projection of $82.2 million. Total U.S. permanent implant procedures increased 7%, while U.S. trial procedures increased 4%. U.S. PDN trial procedures, representing approximately 24% of total U.S. trial volume, jumped 41% from the prior-year quarter. Nevro Corp. Price, Consensus and EPS Surprise Nevro Corp. price-consensus-eps-surprise-chart | Nevro Corp. Quote Margin Trend In the quarter under review, Nevro\u2019s gross profit rose 0.3% to $69.5 million. However, the gross margin contracted 205 basis points to 66.9%. We had projected 67.7% of gross margin for the third quarter. Sales, general & administrative expenses increased 3.8% to $81.2 million. Research and development expenses decreased 0.8% year over year to $13.9 million. Total adjusted operating expenses of $95.1 million increased 3.1% year over year. The total adjusted operating loss in the reported quarter totaled $25.6 million compared with a total adjusted operating loss of $22.9 million in the year-ago quarter. Financial Position Nevro exited the third quarter of 2023 with cash and cash equivalents and short-term investments of $320.3 million compared with $329.9 million at the end of the second quarter. Long-term debt at the end of third-quarter 2023 was $187.8 million compared with $187.5 million at the second-quarter end. As of Sep 30, 2023, 36,869,962 shares were issued and 36,187,046 shares were outstanding. Cumulative net cash used in operating activities at the end of third-quarter 2023 was $49.9 million compared with cumulative net cash provided by operating activities of $38.1 million a year ago. Guidance Nevro has provided its financial outlook for the fourth quarter and raised its financial outlook for 2023. For the fourth quarter, Nevro expects its worldwide revenues to be in the range of $108 million-$110 million, reflecting a decline of 4-6% year over year at CER. The Zacks Consensus Estimate is pegged at $110.9 million. The company now expects its 2023 worldwide revenues in the range of $417 million-$419 million, reflecting growth of 3% from the comparable figure of 2022 both on a reported basis and at CER. This is up from the prior outlook of $410 million-$415 million, reflecting growth of 1-2% from the comparable figure of 2022 both on a reported basis and at CER. The Zacks Consensus Estimate is pegged at $412.4 million. Our Take Nevro exited the third quarter of 2023 with better-than-expected results and a solid improvement in overall top-line results. The company\u2019s robust domestic revenues were also impressive. An uptick in total U.S. permanent implant procedures and U.S. trial procedures was promising. The improvement in U.S. PDN trial procedures was also encouraging. During the quarter, Nevro announced favorable 24-month data from the SENZA PDN Randomized Controlled Trial. The data, published in Diabetes Research and Clinical Practice, demonstrated the long-term efficacy of high-frequency 10 kHz spinal cord stimulation to treat refractory PDN. On theearnings call management confirmed that the HFX iQ and its ability to deliver personalized pain relief continue to receive positive feedback. These look promising for the stock. On the flip side, dismal bottom-line performances and international revenues were disappointing. The sustained operating loss incurred by Nevro also raises our apprehension. The contraction of the gross margin also does not bode well. Zacks Rank and Key Picks Nevro currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Nevro Corp. (NVRO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom (DXCM) Might be Well Poised for a Surge Investors might want to bet on DexCom (DXCM), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this medical device company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008. For DexCom, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year. Current-Quarter Estimate Revisions The earnings estimate of $0.43 per share for the current quarter represents a change of +26.47% from the number reported a year ago. Over the last 30 days, eight estimates have moved higher for DexCom compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 12.5%. Current-Year Estimate Revisions For the full year, the earnings estimate of $1.41 per share represents a change of +62.07% from the year-ago number. There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, 10 estimates have moved up for DexCom versus no negative revisions. This has pushed the consensus estimate 14.92% higher. Favorable Zacks Rank Thanks to promising estimate revisions, DexCom currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. Bottom Line DexCom shares have added 7.3% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business Baxter International Inc. BAX reported third-quarter 2023 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 66 cents by 3%. However, the bottom line declined 4% from the year-ago quarter\u2019s level. On a GAAP basis, the EPS was 9 cents against a loss of $5.94 in the prior-year quarter. The company recorded $2.79 billion as goodwill impairment in the prior-year quarter. On its third-quarterearnings call Baxter announced that it completed the divestment of its BioPharma Solutions (BPS) business at the end of the third quarter. In May, it had signed an agreement to divest the business for $4.25 billion. The company reported BPS business as discontinued operations this quarter. Moreover, it completed the restructuring of its operating model by integrating its diverse product categories under four global segments \u2014 Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals and Kidney Care. Adjusted EPS, including discontinued operations during the third quarter, was 82 cents, flat year over year. Revenue Details Revenues from continued operation totaled $3.71 billion, up 3% on a reported basis and 2% at constant currency (cc). Revenues from discontinued operations (BPS business) amounted to $191 million. The Zacks Consensus Estimate for total sales is pegged at $3.69 billion. Shares of BAX were up 2.3% in pre-market trading following better-than-expected results and the completion of divestment. The company\u2019s shares have lost 35.7% year to date compared with the industry\u2019s decline of 13%. The broader S&P 500 Index has moved up 11.4% in the same period. Image Source: Zacks Investment Research Segmental Details As part of its transformation plan announced in February, Baxter established its new operating model, integrating its prior matrixed structure of nine businesses operating across three geographic regions into the aforementioned four verticalized global segments. The company started reporting under a new model, beginning third-quarter 2023. Medical Products & Therapies The segment includes Advanced Surgery and a new category, Infusion Therapies & Technologies. Total sales at this segment during the third quarter were $1.26 billion, up 5% year over year reportedly and 4% at cc. Infusion Therapies and Technologies\u2019 sales totaled $1 billion, up 5% year over year, reportedly, and 4% at cc. Advanced Surgery category sales amounted to $255 million, up 3% year over year reportedly as well as at cc. Healthcare Systems and Technologies The segment includes the Front Line Care category. It also includes Patient Support Systems and Surgical Solutions categories, which are clubbed as the Care & Connectivity Solutions category. Total sales at this segment during the third quarter were $744 million, up 1% year over year reportedly and flat at cc. Front Line Care category sales totaled $301 million, up 8% year over year, reportedly, as well as at cc. Care & Connectivity Solutions category sales amounted to $443 million, down 3% year over year reportedly and 4% at cc. Pharmaceuticals The segment was reported as one of the product categories till last quarter. This segment\u2019s report presently includes two product categories \u2014 Injectables & Anesthesia and Drug Compounding. Total sales during the third quarter were $580 million, up 10% year over year reportedly and 9% at cc. Injectables and Anesthesia category sales totaled $351 million, up 8% year over year reportedly and 7% at cc. Drug Compounding category sales amounted to $229 million, up 15% year over year reportedly and 13% at cc. Kidney Care This segment includes BAX\u2019s Renal Care category, which is now reported under the Chronic Therapies category. The segment also includes the Acute Therapies category. Total sales at this segment during the third quarter were $1.1 billion, up 1% year over year reportedly and flat at cc. Chronic Therapies category sales totaled $921 million, up 8% year over year reportedly and 7% at cc. Acute Therapies category sales amounted to $188 million, up 13% year over year reportedly and 12% at cc. Baxter plans to spin-off this segment, which will trade as an independent, publicly-traded company under the proposed tradename of Vantive. The spin-off is expected to be completed by July 2024. Other Revenues at the segment amounted to $17 million, down 63% on a year-over-year basis and 61% at cc. Margin Analysis Baxter reported an adjusted gross profit of $1.55 billion for the third quarter, up 1% year over year. As a percentage of revenues, the gross margin declined 70 basis points (bps) to 41.7% in the same quarter. Selling, general and administrative expenses amounted to $1 billion, up 6.5% from the year-ago quarter\u2019s figure. Research and development expenses totaled $166 million, up 9.9% on a year-over-year basis. Adjusted operating income from continuing operations totaled $347 million, down 4.9% year over year. As a percentage of revenues, the operating margin contracted 70 bps to 9.4%. Adjusted income from discontinued operations, net of tax, amounted to $71 million during the reported quarter. Guidance Updated For fourth-quarter 2023, Baxter anticipates sales from continuing operations to grow approximately 1-2% on a reported basis and 1% at cc. The Zacks Consensus Estimate for the same is pegged at $3.84 billion, implying a decline of 1.3% reportedly. Adjusted EPS from continuing operations is expected between 85 cents and 88 cents. The Zacks Consensus Estimate for the same is pegged at 84 cents. For full-year 2023, sales growth for continuing operations is expected to be 1-2% on a reported basis and 2% at cc. Adjusted EPS from continuing operations is projected in the band of $2.57-$2.60. During the last quarter, BAX anticipated revenues to be flat to 1% growth on a reported basis and 1% at cc. EPS was anticipated in the range of $2.54-$2.62. Baxter International Inc. Price, Consensus and EPS Surprise Baxter International Inc. price-consensus-eps-surprise-chart | Baxter International Inc. Quote Zacks Rank and Other Stocks to Consider Currently, Baxter carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Baxter International Inc. (BAX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract Avanos Medical, Inc. AVNS reported third-quarter 2023 adjusted earnings per share (EPS) from continuing operations of 30 cents, up 25% year over year. The bottom line topped the Zacks Consensus Estimate by a penny. GAAP loss per share from continuing operations in the quarter under review was 19 cents against the year-ago period\u2019s EPS of 23 cents. Revenues Revenues grossed $171.3 million in the reported quarter, down 0.6% year over year. The metric beat the Zacks Consensus Estimate by 3.8%. Per management, the top line was hampered by lower hyaluronic acid portfolio (HA) sales. Lower revenues from the Pain Management and Recovery portfolio also weighed on the top line. However, this was offset by a higher volume in the Digestive Health portfolio and slightly favorable pricing and foreign currency translation effects. Excluding currency and the impact of products no longer sold, organic growth was flat. Segmental Analysis Avanos provides a portfolio of innovative product offerings that focus on Pain Management and Recovery and Digestive Health. Pain Management and Recovery\u2019s net revenues of $76.3 million decreased 11.7% year over year on a reported basis. At constant exchange rate (CER), revenues were down 10%. Although the segment benefited from Diros revenues, the negative impact of foreign exchange and Avanos\u2019 previously-announced decision to discontinue certain low-growth, low-margin products dragged the revenues. Management also confirmed witnessing continued softness across the Game Ready and HA product categories during the reported quarter. This figure compares to our third-quarter projection of $69.7 million. Digestive Health\u2019s net revenues of $95 million improved 10.6% year over year. At CER, revenues were up nearly 10.5%. The business saw continued strong execution for NeoMed. Avanos also recorded continued expansion of its U.S. CORTRAK standard of care offering. This figure compares to our third-quarter projection of $86 million. Avanos Medical, Inc. Price, Consensus and EPS Surprise Avanos Medical, Inc. price-consensus-eps-surprise-chart | Avanos Medical, Inc. Quote Margin Analysis In the quarter under review, Avanos\u2019 gross profit fell 4.7% to $95.5 million. The gross margin contracted 240 basis points (bps) to 55.8%. Selling and general expenses rose 0.5% to $78.7 million. Research and development expenses decreased 14.1% year over year to $6.1 million. Adjusted operating expenses of $84.8 million decreased 0.7% year over year. Adjusted operating profit totaled $10.7 million, reflecting a 27.7% decline from the prior-year quarter\u2019s level. Adjusted operating margin in the third quarter contracted 234 bps to 6.2%. Financial Update The company exited third-quarter 2023 with cash and cash equivalents worth $107.1 million compared with $81.8 million at the end of second quarter. Total debt at the third-quarter end was $264.5 million compared with $209.5 million at the second-quarter end. Cumulative net cash provided by operating activities at the end of third-quarter 2023 totaled $19.7 million compared with $57.2 million in the prior-year period. Guidance Avanos has reiterated its 2023 continuing operations guidance. The company continues to estimate its revenues for the full year in the range of $675 million-$685 million. Avanos continues to anticipate 2023 adjusted EPS between $1.05 and $1.15. The Zacks Consensus Estimate currently stands at $1.14. Our Take Avanos\u2019 ended the third quarter of 2023 with better-than-expected results. Its continued strength in the Digestive Health segment in the quarter was encouraging. The robust growth in NeoMed and CORTRAK was promising. On theearnings call management confirmed that the early performance of Avanos\u2019 newly acquired Trident product line has been solid. Management is also upbeat about the U.S. market launch, which commenced recently. This raises our optimism about the stock. Management also confirmed during theearnings callthat it anticipates a continued reduction in supply-chain disruptions and strong demand for Avanos\u2019 products. This also looks promising for the stock. Yet, Avanos\u2019 year-over-year decline in the top line and lower revenues from the Pain Management and Recovery segment were disappointing. Management also confirmed during theearnings callthat its efforts to reduce inventory negatively impacted fixed cost absorption. The company\u2019s third-quarter performance was also hampered by the ongoing inflationary pressure on electronic components. These raise our apprehension. The contraction of both margins does not bode well. Zacks Rank and Key Picks Avanos currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y Glaukos Corporation GKOS reported a third-quarter 2023 adjusted loss of 50 cents per share, 10.7% narrower than the Zacks Consensus Estimate of a loss of 56 cents.The figure, however, was wider than the year-ago quarter\u2019s adjusted loss of 45 cents per share. The GAAP loss per share was 63 cents compared with the prior-year quarter\u2019s reported loss of 58 cents. Revenue Details Glaukos registered revenues of $78 million in the third quarter, up 10% year over year on a reported basis and 9% at constant currency. The figure also surpassed the Zacks Consensus Estimate by 3.4%. Quarter in Detail The company recorded net sales of $58.3 million and $19.7 million for Glaucoma and Corneal Health, respectively, which were up 9% and 12% year over year. Margin Trend Gross profit increased 9.4% to $59.5 million in the reported quarter. The gross margin was flat at 76%. Selling, general and administrative expenses rose 15.1% to $54.2 million. Research and development expenses totaled $33.3 million, up 15.3% year over year. Total operating expenses were $87.5 million, up 15% from that recorded in the prior-year period. The operating loss amounted to $28 million compared with $21.6 million in the year-ago period. The adjusted operating loss was $21.8 million, wider than the year-ago quarter\u2019s reported loss of $15.3 million. Financial Update Glaukos exited third-quarter 2023 with cash and cash equivalents, and short-term investments of $307 million compared with $310 million at the end of the last reported quarter. 2023 Guidance The company updated its guidance for 2023 revenues. It expects net sales in the range of $307-$310 million compared with the previously stated $304-$308 million, reflecting improving currency translational rates. Glaukos Corporation Price, Consensus and EPS Surprise Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote Our Take Glaukos exited the third quarter of 2023 with decent results, wherein both earnings and revenues beat their respective estimates. Management is excited regarding the company\u2019s return to top-line growth in the reported quarter. GKOS has launched several products, including iPrime, iAccess and iStent, in the past few quarters, which are aiding its revenue growth. The company has been focused on delivering improved outcomes for patients suffering from chronic eye diseases. It does so by continuing to develop a pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care. One of the advanced pipeline candidates, iDose TR, has been successfully tested in a phase III study. Glaukos filed a new drug application with the FDA in February and a decision regarding the same is expected later this year. The company stated that the targeted population is 3 million in the United States every year. However, GKOS\u2019 operating loss in the reported quarter amid rising costs and expenses raised our apprehension. Its operation in a stiff, competitive market is also worrisome. Zacks Rank and Stocks to Consider Currently, Glaukos carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Growth Stocks That Could Help Set You Up for Life The stock market has tested even the most resilient of investors over the last two years, as bouts of volatility followed by surges across multiple sectors have become common. That's why most investors are better off buying stock in quality companies and holding it longer term (at least five years) and continuing to add to their investments in those businesses in both up and down markets. A few years of volatility shouldn't make or break your investing thesis. If you are looking for growth stocks to buy right now in order to hold long-term, here are two names to consider for your shortlist. 1. DexCom DexCom (NASDAQ: DXCM) makes and sells continuous glucose monitoring (CGM) devices, which have broad utility for both Type 1 and Type 2 diabetics, and can offer life-saving benefits for some users. The company has been rolling out the newest generation of its flagship CGM this year, the G7. The G7 continues to gain approval in key markets around the world. Canada, which has a diabetic and pre-diabetic population that numbers around 12 million, is one of the latest. Moreover, broadening access to DexCom's products through growing commercial pharmacy coverage, its new and existing relationships with insurers, and coverage by sponsored national healthcare systems domestically and abroad are making its CGMs within the reach of record swaths of customers. One example is a recent decision by the U.S. Centers for Medicare and Medicaid this past spring. The gist of the decision is that CGMs are now covered for Type 2 diabetics who take basal insulin, as well as some people who have hypoglycemia but do not use insulin. This means that 7 million people can now use DexCom's products who couldn't before. In the third quarter of 2023, DexCom brought in total revenue of $975 million, a 27% increase from the prior-year period. Profits for the quarter totaled $121 million, up 20% from one year ago. The company also hit a gross profit margin of about 65% in the quarter. It finished out the quarter with cash and investments on its balance sheet to the tune of about $3 billion. The company's financials look great, and the business is serving a need that is not only essential but growing as the incidence of diabetes rises globally. Investors with even a modest amount of cash to invest right now may want to consider a position in this top healthcare stock. 2. Etsy Etsy (NASDAQ: ETSY) is known for its marketplace where sellers from around the world can list vintage, unique, handmade, and specialty goods. The business occupies a very specific space in the multi-trillion-dollar world of e-commerce, one that few companies focus on at the scale that Etsy does. Management has estimated that its total online addressable market is about $466 billion, with Etsy controlling about a 3% slice. There's a lot of room for this company to grow, even if the space becomes more crowded in the years ahead. It's true that Etsy's growth has slowed from pandemic levels, and this has discouraged some investors. However, it's important to recognize that a slowdown of pandemic-era growth was inevitable at some point, and the difficult macroeconomic backdrop of the last few years only compounded that reality. As consumer spending recovers, a wide range of companies that make money from non-essential purchases can benefit, including Etsy. Speaking of the current spending landscape, in September, consumer spending rose 0.7% month over month when adjusting for food and energy prices. That figure was up 3.7% from one year ago. There's also an argument to be made that people might be inclined to spend on generally more affordable items like secondhand or handmade goods, as opposed to retail items from big-box stores in tight spending environments. This is another area where Etsy can benefit. Even with spending levels remaining depressed from pandemic highs, Etsy still brought in profits of $136 million on revenue of $1.3 billion in the first half of 2023. As of the end of the second quarter of 2023, the Etsy marketplace saw repeat buyers soar 140% from four years ago. Habitual buyers (customers that spent at least $200 in six or more purchase days in the last 12 months) were up 218% on a four-year basis and accounted for about 43% of all gross merchandise sales generated on the platform. Patience will be required with this stock, and with any stock that has high exposure to discretionary consumer spending, but it might be a miscalculation to think that Etsy is down for the count. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 30, 2023 Sponsored Links Look For Any High School Yearbook, It's Free Classmates Rachel Warren has positions in DexCom and Etsy. The Motley Fool has positions in and recommends Etsy. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wall Street Analysts Think DexCom (DXCM) Could Surge 36.81%: Read This Before Placing a Bet DexCom (DXCM) closed the last trading session at $94.13, gaining 7.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $128.78 indicates a 36.8% upside potential. The mean estimate comprises 18 short-term price targets with a standard deviation of $15.31. While the lowest estimate of $101 indicates a 7.3% increase from the current price level, the most optimistic analyst expects the stock to surge 64.7% to reach $155. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for DXCM, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts. However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces. That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Here's Why There Could be Plenty of Upside Left in DXCM Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 14.9%, as 10 estimates have moved higher compared to no negative revision. Moreover, DXCM currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DXCM could gain, the direction of price movement it implies does appear to be a good guide. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DexCom (DXCM) Just Reclaimed the 50-Day Moving Average After reaching an important support level, DexCom (DXCM) could be a good stock pick from a technical perspective. DXCM surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend. The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend. DXCM has rallied 7.3% over the past four weeks, and the company is a Zacks Rank #2 (Buy) at the moment. This combination suggests DXCM could be on the verge of another move higher. The bullish case solidifies once investors consider DXCM's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 10 higher, while the consensus estimate has increased too. With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on DXCM for more gains in the near future. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 90 cents in the third quarter of 2023, down by 51.4% year over year. The figure topped the Zacks Consensus Estimate by 100%. The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others. GAAP loss per share for the quarter was 19 cents against the year-earlier EPS of 28 cents. Revenues in Detail QuidelOrtho registered revenues of $744 million in the third quarter, which decreased 5.1% year over year both on a reported basis and at constant exchange rate (CER). The figure surpassed the Zacks Consensus Estimate by 14.2%. In the third quarter, Respiratory revenues were $185.4 million (down 21.5% on both reported basis and at CER), while Non-Respiratory revenues were $558.6 million (up 2% on both reported basis and at CER). Segments in Detail QuidelOrtho now derives revenues from four business units \u2014 Labs, Transfusion Medicine (TM), Point-Of-Care (POC) and Molecular Diagnostics (MDx). In the third quarter, Labs revenues were $341.4 million, up 2% on both reported basis and at CER. This compares to our third-quarter projections of $288.4 million. TM revenues were $163.9 million in the third quarter, up 0.5% and 0.4% on a reported basis and at CER, respectively. This compares to our third-quarter projections of $134.3 million. POC revenues amounted to $233.1 million in the third quarter, reflecting a decline of 13.8% on both reported basis and at CER. This compares to our third-quarter projections of $218.6 million. MDx revenues totaled $5.6 million in the third quarter, down 63.6% and 63.7% on a reported basis and at CER, respectively. This compares to our third-quarter projections of $9.6 million. Geographical Distribution Geographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China and Other regions (which includes Latin America, Japan and other Asia-Pacific markets). Revenues from North America amounted to $465.2 million, reflecting a decline of 10.1% and 9.7% on a reported basis and at CER, respectively. This compares to our third-quarter projections of $428.6 million. EMEA revenues amounted to $74.5 million, reflecting an uptick of 1.1% on a reported basis but down 2.4% at CER. This compares to our third-quarter projections of $64.9 million. Revenues from China amounted to $81.1 million, reflecting an improvement of 0.4% on a reported basis and 5.5% at CER. This compares to our third-quarter projections of $60.9 million. Revenues from Other regions amounted to $123.2 million, reflecting an uptick of 10.3% on a reported basis and 7% at CER. This compares to our third-quarter projections of $96.6 million. QuidelOrtho Corporation Price, Consensus and EPS Surprise QuidelOrtho Corporation price-consensus-eps-surprise-chart | QuidelOrtho Corporation Quote Margin Trend In the quarter under review, QuidelOrtho\u2019s gross profit declined 9.7% to $368.1 million. The gross margin contracted 251 basis points (bps) to 49.5%. We had projected 49.9% of gross margin for the third quarter. Selling, marketing and administrative expenses fell 4.9% to $194.1 million. Research and development expenses declined 4.9% year over year to $62.4 million. Adjusted operating expenses of $256.5 million decreased 4.9% year over year. Adjusted operating profit totaled $111.6 million, reflecting an 18.9% decline from the prior-year quarter\u2019s level. Adjusted operating margin in the third quarter contracted 257 bps to 15%. Financial Position QuidelOrtho exited third-quarter 2023 with cash and cash equivalents of $149.3 million compared with $178.6 million at the end of second quarter. Total debt (including short-term debt) at the end of third-quarter 2023 was $2.47 billion compared with $2.52 billion at the second-quarter end. Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $199.8 million compared with $715.9 million a year ago. Guidance QuidelOrtho has reiterated its financial outlook for 2023. Total revenues are continued to be expected to lie in the range of $2.88 billion-$3.08 billion (down 29-24% a CER). The Zacks Consensus Estimate stands at $2.97 billion. Non-respiratory revenues are continued to be expected between $2.27 billion and $2.31 billion (up 5-6.5% at CER from 2022 levels). Respiratory revenues for the full year are continued to be expected to lie in the range of $610 million-$775 million. Per management, from the fourth quarter onward, QuidelOrtho will be including COVID-19 revenues as part of its overall respiratory business as it is in an endemic state. Adjusted EPS is continued to be expected to lie between $4.85 and $5.30. The Zacks Consensus Estimate stands at $4.90. Our Take QuidelOrtho ended the third quarter of 2023 with better-than-expected results. An uptick in the company\u2019s Non-Respiratory revenues was impressive. The company registered robust revenues from its Labs and TM segments and China and Other regions, which were encouraging. QuidelOrtho also recorded strong revenue growth in the EMEA region on a reported basis, which buoys optimism. The company also recorded solid revenues from its Instrument and Recurring revenue categories, which were promising. The continued uptick in Sofia instruments and growth in QuidelOrtho\u2019s integrated installed base and automation were encouraging. In September, QuidelOrtho received a CLIA Waiver from the FDA, which applies to its new Sofia 2 SARS Antigen+ FIA (fluorescent immunoassay). The test, intended for prescription use only, can be used in CLIA-waived point-of-care settings. This looked promising for the stock. However, dismal top-line and bottom-line results were disappointing. Lower Respiratory revenues during the quarter were also not promising. The decline in its POC and MDx segments and geographically in North America was discouraging. The decline in QuickVue revenues was also worrying. The contraction of both margins also does not bode well. Zacks Rank and Key Picks QuidelOrtho currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QuidelOrtho Corporation (QDEL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance DENTSPLY SIRONA Inc. XRAY reported third-quarter 2023 adjusted earnings per share (EPS) of 49 cents, which beat the Zacks Consensus Estimate of 48 cents by 2.1%. The bottom line improved 19.6% on a year-over-year basis. On a GAAP basis, the company incurred a loss of $1.25 per share compared with a reported loss of $5.01 in the year-ago quarter. Revenues Revenues in the reported quarter totaled $947 million, which missed the Zacks Consensus Estimate by 2.6%. The top line was flat year over year but declined 0.3% on an organic basis. Lower demand for implant and imaging products, mainly in the U.S. market, along with soft demand for technology and dental solutions in Europe, led to the decline. However, strong international growth, caused by the recovery in China, helped offset the decline partially. Business Details As a part of its restructuring plan, XRAY changed its reporting structure from Apr 1, 2023. The company reported third-quarter results under four new segments \u2014 Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. While the Connected Technology Solutions segment consists of equipment, instruments and CAD/CAM business, the Orthodontic and Implant Solutions segment includes the implant systems and aligner solutions. These businesses were formerly part of the erstwhile Technologies and Equipment segment. The Essential Dental Solutions unit includes endodontic, restorative and preventive consumables businesses, earlier part of the former Consumables segment. The Wellspect Healthcare segment includes urology catheters business, earlier part of Technologies & Equipment, and other healthcare-related consumable businesses, previously under the Consumables segment. Connected Technology Solutions Revenues in this segment totaled $276 million, down 3.8% year over year and 4.6% on an organic basis. CAD/CAM demand improved in the U.S. market while recessionary concerns led to softer demand in Europe. Orthodontic and Implant Solutions Sales in this segment amounted to $252 million, up 2.2% year over year. On an organic basis, net sales improved 0.9%. The growth was driven by SureSmile and Byte sales, coupled with implant growth in China, partially offset by lower lab sales. Essential Dental Solutions Sales in this segment amounted to $377 million, down 0.3% year over year. On an organic basis, net sales declined 0.9%. The decline was primarily led by lower volume in Europe, partially offset by the rising demand in international markets. Wellspect Healthcare Sales in this segment amounted to $72 million, up 9.9% year over year. On an organic basis, net sales improved 6.8%. Sales were driven by growth across all regions, along with additional revenues from new products. Revenues by Geography In the United States, revenues decreased 0.9% year over year organically to $356 million. Rest of World (ROW) revenues increased 4.5% organically to $237 million on a year-over-year basis. Revenues in Europe, however, declined 2.7% to $354 million, organically, during the same time frame. Margin Analysis Gross profit in the reported quarter totaled $495 million, down 2.7% on a year-over-year basis. The gross margin came in at 52.2%, which contracted 150 basis points. Selling, general and administrative expenses totaled $372 million, down 7.2% from the year-ago quarter\u2019s level. Research and development expenses amounted to $46 million, up 12.2% from the prior-year quarter\u2019s number. Operating loss totaled $236 million compared with $1.22 billion in the year-ago period. Financial Condition DENTSPLY SIRONA exited the third quarter of 2023 with cash and cash equivalents of $309 million compared with $295 million at the end of the last reported quarter. The cumulative net cash provided by operating activities totaled $217 million compared with $375 million in the year-ago period. DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise DENTSPLY SIRONA Inc. price-consensus-eps-surprise-chart | DENTSPLY SIRONA Inc. Quote 2023 Guidance Updated DENTSPLY SIRONA updated its guidance for 2023 earnings and revenues based on declining sales performance in the third quarter. The company lowered its earlier revenue guidance from organic growth of nearly 3% to 1%. It now expects sales in the band of $3.90-$3.94 billion compared with the previously projected range of $3.98-$4.02 billion. The Zacks Consensus Estimate for the same is pegged at $4 billion. The lowered guidance includes a forex headwind of $25 million. XRAY now expects adjusted EPS in the band of $1.80-$1.85, down from the previously anticipated range of $1.92-$2.02. The Zacks Consensus Estimate for the same is pegged at $1.97. Our Take XRAY\u2019s third-quarter adjusted earnings as well as revenues declined year over year. However, earnings beat the market expectation by a cent. Lower-than-expected revenues raise apprehension. The company also provided a lowered guidance for both top and bottom lines, reflecting a challenging macro-environment, particularly in Germany and the United States. Soft demand in Europe may act as a headwind for the rest of 2023. Recovery of demand in China will be a key driver of top line going forward. Sales improved 20% during the third quarter in the country following a strong second quarter, reflecting recovery after a prolonged period of weak demand. Moreover, strong demand for aligners and CAD/CAM in the U.S. market will support top-line growth going forward. Zacks Rank and Stocks to Consider Currently, DENTSPLY SIRONA has a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View McKesson Corporation (MCK) reported second-quarter fiscal 2024 adjusted earnings per share (EPS) of $6.23, which beat the Zacks Consensus Estimate of $6.11 by 2%. The bottom line also improved 3% on a year-over-year basis. GAAP EPS was $4.92, down 23.8% from the year-ago quarter\u2019s level. The significant decline was due to the provision of bad debts worth $210 million for uncollected trade accounts receivable related to the bankruptcy of Rite Aid Corporation. Revenue Details Revenues of $77.22 billion beat the Zacks Consensus Estimate by 1.8%. The top line also increased 10% year over year, reflecting strong growth in the United States. This was partially offset by lower international sales due to divestitures of its European businesses. Q2 Segmental Analysis Revenues at the U.S. Pharmaceutical segment totaled $69.8 billion, up 16% year over year. Per management, the upside was primarily driven by higher volume of specialty products, including an increase in volume from retail national account customers. However, branded-to-generic conversions partially offset the upside. The U.S. Pharmaceutical and Specialty Solutions segment reported an adjusted operating profit of $815 million, up 8% from the prior-year quarter\u2019s level. This was due to growth in the distribution of specialty products to providers and health systems, and increased contributions from our generics program, partially mitigated by lower demand for COVID-19 vaccine distribution. The adjusted metric for the segment was up 15% year over year, excluding the impact of the abovementioned vaccine\u2019s distribution. At the International segment, revenues amounted to $3.5 billion, down 43% year over year. This was due to divestitures of McKesson\u2019s European businesses. Adjusted operating profit at the segment totaled $93 million, down 32% from the year-ago quarter\u2019s figure. Revenues at the Medical-Surgical Solutions segment totaled $2.8 billion, flat year over year. Sales were primarily hurt by lower COVID-19-related sales. The Medical-Surgical segment reported an adjusted operating profit of $254 million, down 17% year over year. Excluding the impact of COVID-related items, the adjusted metric was up 5%. Revenues at the Prescription Technology Solutions segment totaled $1.1 billion, up 12% from that recorded a year ago. The improvement can be attributed to higher technology services revenues and an increase in prescriptions from third-party logistics. Adjusted operating profit amounted to $209 million at the segment, up 48% from the prior-year quarter\u2019s level. Margins Gross profit in the reported quarter was $3.07 billion, down 1% on a year-over-year basis. The figure accounted for 4% of net revenues. The company reported an operating income of $977 million, down 25% from the year-ago quarter\u2019s figure. Operating margin accounted for 1.3% of net revenues. Financial Update Cash and cash equivalents totaled $2.52 billion compared with $2.64 billion in the previous quarter. Cumulative net cash used in operating activities amounted to $87 million against net cash provided by operating activities of $166 million in the year-ago period. Fiscal 2024 Guidance McKesson raised its adjusted earnings guidance for fiscal 2024. It now projects adjusted EPS in the range of $26.80-$27.40, up from the previous guidance of $26.55-$27.35. The Zacks Consensus Estimate for the same is pegged at $27.21. The company now expects revenues to grow 8-12% versus 7-12% as estimated previously. McKesson Corporation Price, Consensus and EPS Surprise McKesson Corporation price-consensus-eps-surprise-chart | McKesson Corporation Quote Summing Up McKesson exited the fiscal second quarter of 2024 on a strong note, wherein both earnings and revenues beat their respective estimates. The outperformance reflects strong demand for its pharmaceuticals and prescription technology solutions. A strong earnings outlook for the year raises optimism. However, lower COVID-19-related sales and divesture of European businesses hurt top as well as bottom-line growth for the Medical-Surgical Solutions and International segments, respectively. Meanwhile, price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space remain as headwinds. Zacks Rank and Other Key Picks McKesson currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank of 2 at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-03,96.57,99.01,96.07,97.46,"[""Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates Inari Medical, Inc. NARI delivered earnings per share (EPS) of 5 cents in the third quarter of 2023 against the year-ago period\u2019s loss of 19 cents per share. However, the figure surpassed the Zacks Consensus Estimate of a breakeven EPS. Revenues in Detail Inari Medical registered revenues of $126.4 million in the third quarter, up 31.4% year over year. The figure surpassed the Zacks Consensus Estimate by 3.6%. Q3 Highlights On the third quarterearnings call Inari Medical\u2019s management confirmed that 68% of its revenues were derived from the sale of FlowTriever Systems and 32% from the sale of ClotTriever and other systems. On the same call, management also continued to make progress across the six products that are in full market release in the second half of 2023. Three of these products, REVCORE, InThrill and ProTrieve, add direct incremental revenue opportunities. Management also confirmed gaining good initial traction and is receiving excellent clinical feedback across all three products. Per management, Inari Medical witnessed another quarter of record case and revenue production outside of the United States. Its performance was driven primarily by increased adoption in Western Europe, complemented by solid case growth in its early-stage markets in Latin America, Canada and Asia-Pacific. The company continues to make good progress in both China and Japan and anticipates beginning to treat patients in both these markets in 2024. Management expects its international business could represent greater than 20% of total revenues over time on the back of unmet needs. During the reported quarter, NARI launched two new products \u2014 RevCore and T16 Curve catheter \u2014 both targeting patients with venous thromboembolism. Inari Medical, Inc. Price, Consensus and EPS Surprise Inari Medical, Inc. price-consensus-eps-surprise-chart | Inari Medical, Inc. Quote Margin Trend In the quarter under review, Inari Medical\u2019s gross profit improved 31.4% to $111.9 million. The gross margin expanded 4 basis points (bps) to 88.5%. We had projected 86.2% of gross margin for the third quarter. Selling, general and administrative expenses rose 16.4% to $88.3 million. Research and development expenses increased 12.5% year over year to $21.5 million. The operating expenses of $109.8 million increased 15.6% year over year. The operating profit totaled $2.1 million against the operating loss of $9.8 million in the year-ago period. Financial Position Inari Medical exited third-quarter 2023 with cash and cash equivalents and short-term investments of $351.3 million compared with $337.5 million at the end of the second quarter. Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $23.7 million compared with cumulative net cash used in operating activities of $25.2 million a year ago. Guidance Inari Medical has raised its financial outlook for the full year 2023. For the full year, the company now expects revenues to be $490 million-$493 million, up from the prior-year outlook of $482 million-$492 million. The Zacks Consensus Estimate stands at $488.9 million. Our Take Inari Medical exited the third quarter of 2023 with better-than-expected results. The uptick in overall revenues was impressive. The company continued to make impressive progress with respect to its product portfolio, which saw robust product adoption. Geographical performances were also impressive. The gross margin expansion bodes well for the stock. However, Inari Medical\u2019s dismal bottom-line performances were disappointing. The company incurred an operating loss during the quarter, which raises our apprehension. Zacks Rank and Other Key Picks Inari Medical currently sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates AMN Healthcare Services, Inc. AMN delivered adjusted earnings per share (EPS) of $1.97 in the third quarter of 2023, which declined 23.3% year over year. However, the figure surpassed the Zacks Consensus Estimate by 20.1%. GAAP EPS for the quarter was $1.39, reflecting a 33.8% plunge from the year-ago figure. Revenues in Detail AMN Healthcare registered revenues of $853.5 million in the third quarter, down 25% year over year. However, the figure surpassed the Zacks Consensus Estimate by 0.3%. Segment Details AMN Healthcare conducts its business via three reportable segments \u2014 Nurse and Allied Solutions, Physician and Leadership Solutions and Technology and Workforce Solutions. In the third quarter of 2023, the Nurse and Allied Solutions segment\u2019s revenues totaled $573.4 million, down 30.8% year over year. Travel nurse staffing revenues were down 34% year over year, whereas Allied revenues declined 12% year over year. This figure compares to our Nurse and Allied Solutions segment\u2019s third-quarter projection of $570.7 million. The Physician and Leadership Solutions segment\u2019s revenues totaled $159.6 million, down 8.9% year over year despite a 6% uptick in locum tenens revenues, which amounted to $113 million. Interim leadership revenues were down 35% year over year. Physician and leadership search businesses saw revenue decline by 25% year over year. This figure compares to our Physician and Leadership Solutions segment\u2019s third-quarter projection of $169.7 million. The Technology and Workforce Solutions segment\u2019s revenues totaled $120.5 million, down 10.8% year over year. Language interpretation services business revenues came in at $66 million in the quarter (up 20% year over year), while the vendor management systems business saw a 37% year-over-year revenue decline to reach $38 million. This figure compares to our Technology and Workforce Solutions segment\u2019s third-quarter projection of $109.7 million. AMN Healthcare Services Inc Price, Consensus and EPS Surprise AMN Healthcare Services Inc price-consensus-eps-surprise-chart | AMN Healthcare Services Inc Quote Margin Trend In the quarter under review, AMN Healthcare\u2019s gross profit fell 24.8% to $289.5 million. However, the gross margin expanded 11 basis points (bps) to 33.9%. We had projected 33.4% of gross margin for the third quarter. Selling, general & administrative expenses fell 24.1% to $163.4 million. Adjusted operating profit totaled $126.1 million, reflecting a 25.7% decline from the prior-year quarter. The adjusted operating margin in the third quarter contracted 12 bps to 14.8%. Financial Position AMN Healthcare exited third-quarter 2023 with cash and cash equivalents of $29.4 million compared with $7 million at the end of the second quarter. Total debt at the end of third-quarter 2023 was $945 million compared with $1 billion at the end of the second quarter. Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $413.3 million compared with $538.4 million a year ago. Guidance AMN Healthcare has provided its financial outlook for the fourth quarter of 2023. For the fourth quarter, the company expects revenues to be $ $790 million-$810 million, reflecting a decline of 28-30% compared with the prior-year figure. The Zacks Consensus Estimate stands at $847.1 million. With respect to the Nurse and Allied Solutions segment, the company expects revenues to decline 33-35% from the prior-year figure. The Technology and Workforce Solutions segment\u2019s revenues are expected to decline 18% from the prior-year figure. The company projects third-quarter revenues at the Physician and Leadership Solutions segment to decline 12-14% from the prior-year figure. Our Take AMN Healthcare exited the third quarter of 2023 with better-than-expected results. The uptick in locum tenens revenues and Language interpretation services revenues was impressive. The gross margin expansion bodes well for the stock. Management confirmed that its definitive agreement to acquire MSDR will likely bolster AMN Healthcare\u2019s presence in the robust locum tenens market. On theearnings call management confirmed that the company had strengthened its ability to deliver multifaceted tech-enabled workforce solutions to simplify labor management and provide a variety of options for making the labor force more flexible and cost effective. Additionally, management believes that clients would be able to access AMN Healthcare\u2019s full set of solutions via our better-integrated sales and service organization. These look promising for the stock. However, AMN Healthcare\u2019s dismal top-line and bottom-line performances were disappointing. The decline in all the segmental revenues during the reported quarter was worrying. The contraction of the adjusted operating margin raises our apprehension about the stock. AMN Healthcare expects to register a decline in its overall top line and all its segments in the fourth quarter of 2023, which is concerning. Zacks Rank and Stocks to Consider AMN Healthcare currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View Cardinal Health, Inc. CAH reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.73, which beat the Zacks Consensus Estimate of $1.40 by 23.6%. The bottom line also improved 44.2% year over year. GAAP EPS in the quarter was 2 cents compared with the year-ago period\u2019s level of 40 cents. The significant decline was led by a goodwill impairment charge of $537 million in the Medical segment. Revenue Details Sales improved 10.4% on a year-over-year basis to $54.76 billion. The top line also outpaced the Zacks Consensus Estimate by 0.4%. Segmental Analysis Pharmaceutical Segment In the reported quarter, pharmaceutical revenues increased 11% to $51 billion on a year-over-year basis. The performance highlights branded pharmaceutical sales growth from existing Pharmaceutical Distribution and Specialty Solutions customers. Pharmaceutical profit totaled $507 million, up 18% from the year-ago quarter\u2019s level. The upside was driven by generics program performance and higher contributions from brand and specialty products. Medical Segment Revenues at this segment totaled $3.8 billion, flat year over year, as lower PPE volumes and pricing were completely offset by at-home Solutions growth. The segment reported a profit of $71 million against a loss of $8 million in the year-ago quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives. Margin Analysis Gross profit increased 9.5% year over year to $1.77 billion. As a percentage of revenues, the gross margin in the reported quarter was 3.2%, almost flat on a year-over-year basis. Distribution, selling, general and administrative expenses totaled $1.2 billion, flat year over year. Operating loss amounted to $14 million against the year-ago quarter\u2019s operating income of $137 million. The company recorded Impairments and loss on disposal of assets of $537 million compared with $153 million in the prior-year quarter. Financial Update The company exited the reported quarter with cash and cash equivalents of $3.85 billion compared with $4.04 billion in the fiscal fourth quarter of 2023. Cumulative net cash provided by operating activities totaled $545 million compared with $23 million in the year-ago period. 2024 Guidance Raised Cardinal Health raised its fiscal 2024 guidance for earnings. The company anticipates adjusted EPS between $6.75 and $7.00, up from the previous guidance of $6.50-$6.75. The Zacks Consensus Estimate for the same is pegged at $6.66. CAH also raised its guidance for the Pharmaceutical segment\u2019s profit. It now expects growth in the band of 7-9% compared with the earlier projection of 4-6%. Cardinal Health, Inc. Price, Consensus and EPS Surprise Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote Conclusion Cardinal Health exited the fiscal first quarter on a strong note with better-than-expected earnings and revenues. The company also witnessed revenue growth in its Pharmaceutical segment. Recovery in the Medical segment is encouraging. However, intense competition and customer concentration are concerning. Zacks Rank and Stocks to Consider Cardinal Health carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up Fresenius Medical Care AG & Co. KGaA FMS reported third-quarter 2023 adjusted earnings per share (EPS) of 31 cents, which missed the Zacks Consensus Estimate of 37 cents by 16.2%. The bottom line declined 22.5% year over year. Revenue Details Revenues of $5.37 billion (EUR 4,936 million) missed the Zacks Consensus Estimate by 1%. The company reported a revenue decline of 3% year over year and 7% at constant currency (cc) as well as on an organic basis. Segmental Details Fresenius Medical implemented a new operating model during the first quarter and started reporting under two new segments \u2014 Care Delivery and Care Enablement. Previously, the company reported under the Health Care Products and Health Care Services segments. The Care Delivery segment primarily consists of products earlier reported under the Health Care Services segment. Care Delivery The segment\u2019s revenues declined 4% on a year-over-year basis but gained 6% at cc and 7% on an organic basis. Revenues in the U.S. markets declined 3% but gained 4% at cc and 5% on an organic basis. Sales were hurt by the negative exchange rate effect and a decrease in dialysis days. However, the favorable impact from the value-based care business, reimbursement rate increases and a favorable payor mix helped partially offset the decline. FMS stated that the annualization effect of COVID-19-related excess mortality in the late-stage chronic kidney disease (CKD) and end-stage renal disease (ESRD) population continues to hurt treatment growth in the U.S. market. International sales declined 7% reportedly but gained 14% at cc and 16% on an organic basis. A negative exchange rate effect and the impact of closed or sold clinics led to the decline, partially offset by a significant effect of hyperinflation in various markets. Care Enablement The segment\u2019s revenues decreased 3% year over year, but rose 5% at cc as well as on an organic basis. Sales declined due to the unfavorable impact of currency movement, partially offset by higher sales of in-center disposables, machines for chronic treatment and home hemodialysis products as well as higher average sales prices. Margins Operating income, excluding special items and U.S. Provider Relief Funding, was up 14% from that reported in the prior-year quarter. The metric also gained 20% at cc. Operating margin, excluding the aforementioned items, was 8.7%, up 130 bps from the year-ago quarter\u2019s actual. 2023 Outlook Fresenius Medical maintained its outlook for revenues in 2023. The company expects revenues to grow at a low-to-mid single-digit percentage rate. However, it raised its operating income guidance following favorable earnings growth in the first nine months of 2023. The metric is now estimated to grow at a low-single-digit percentage rate (previously remained flat or declined by up to a low-single-digit percentage rate). Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote Summing Up Although FMS exited the third quarter on a dismal note, its results reflected strong organic growth on the back improving treatment volumes as well as a stabilizing labor environment in the United States. A potential continuation of improvement in these two key factors will be beneficial for the company in the rest of 2023. Overall price improvements also supported growth in the Care Enablement segment. Meanwhile, FMS\u2019 newly implemented operating model led to operational improvements. The bottom line was hurt by inflationary cost increases in energy, material and personnel. These headwinds are likely to improve over the year, which also gets reflected in the company\u2019s operating outlook. In the first nine months, FMS generated EUR 232 million in savings by implementing initiatives under its FME25 transformation program. The company targets savings in the range of 250-300 million euros by 2023-end, and 650 million euros by 2025-end. These are likely to continue to improve the operating margin going forward. The company\u2019s plans to divest its noncore and dilutive assets look promising as they will help it to focus on its core and growing categories as well as boost its cash resource. Zacks Rank and Stocks to Consider Currently, Fresenius Medical carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand Prestige Consumer Healthcare Inc. PBH delivered second-quarter fiscal 2024 diluted earnings per share (EPS) of $1.07, an increase of 4.9% from the year-ago period\u2019s figure. However, the metric came in line with the Zacks Consensus Estimate. Revenues Total revenues in the second quarter fell 1% year over year to $286.3 million but topped the Zacks Consensus Estimate by 0.4%. The revenue performance for the quarter was led by Cough & Cold and Ear & Eye Care category performances in North America and strong year-over-year growth in the International OTC segment, offset by declines in certain other categories and the planned strategic exit of private-label revenues. Excluding currency impacts, revenues decreased 0.7% compared to the prior- year quarter. Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote Segments in Detail The company conducts its operations through two reportable segments \u2014 North American OTC Healthcare and International OTC Healthcare. Revenues in the North American OTC Healthcare segment were $244.4 million, down 3% from the year-earlier quarter. Our model projected the segment\u2019s revenues to be $246.6 million in the third quarter. The revenue performance for the quarter was driven by lower sales in Women\u2019s Health and certain other categories and the strategic exit of private labels, partially offset by strong performance in the Cough & Cold and Ear & Eye Care categories. Revenues in the International OTC Healthcare segment were $41.9 million, up 12.6% from the year-ago quarter\u2019s figure. The increase in revenues was driven by strong Eye & Ear Care and Women\u2019s Health sales, partially offset by a $0.7 million currency headwind. Our model\u2019s projected revenues from this segment were $38.7 million. Margins The gross profit in the fiscal second quarter decreased 0.6% year over year to $162 million. Meanwhile, the gross margin expanded 27-basis points (bps) year over year to 56.6% due to a 1.6% decrease in the cost of sales (excluding depreciation). During the quarter, Advertising and marketing expenses fell 8.5% to $40 million, while General and administrative expenses decreased 1.7% to 26 million. The adjusted operating income (excluding depreciation and amortization) in the quarter under review was $95.9 million, highlighting an increase of 3.5%. The adjusted operating margin expanded 147 bps to 33.5%. Financial Update Prestige Consumer exited the fiscal second quarter of 2024 with cash and cash equivalents of $60.1 million compared with the $54.6 million recorded at the end of the first quarter. The long-term debt totaled $1.26 billion, sequentially down from $1.32 million at the first-quarter end. The cumulative net cash provided by operating activities in the second quarter was $110.5 million compared to $115.8 million in the prior-year comparable period. The adjusted free cash flow in the quarter was $59.5 million compared with $55.2 million at the end of the prior period\u2019s quarter. In the fiscal first quarter, PBH repurchased nearly 0.4 million shares for $25 million, concluding its previously authorized share repurchase program. Guidance The company reaffirmed its fiscal 2024 outlook, which was originally announced during the fiscal 2023 fourth-quarter earnings call. Revenues for the full year are anticipated in the range of $1.135 billion-$1.140 billion (unchanged) compared with the $1.128 billion reported in fiscal 2023. Organic revenue growth for the full year is anticipated to be 1%-2%. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $1.14 billion. Prestige Consumer Healthcare expects fiscal 2024 diluted EPS in the range of $4.27-$4.32 (same as earlier). In fiscal 2023, the company posted a loss of $1.65 per share and an adjusted EPS of $4.21. The Zacks Consensus Estimate for fiscal 2024 EPS stands at $4.31. Free cash flow for the full year is likely to be $240 million or more (unchanged). Our Take PBH exited the fiscal second quarter of 2024 with revenues beating and earnings matching estimates. The top-line performance was driven by the company\u2019s ongoing brand-building efforts and growth in multiple categories, including Cough & Cold and Ear & Eye Care, and the international segment. Both the gross and adjusted operating margins expanded during the quarter, which is highly promising. In a continued dynamic macro environment, the company\u2019s diverse portfolio of brands comes as an advantage to generate long-term shareholder value. Meanwhile, the North American OTC Healthcare segment saw a decline in revenues due to lesser sales of Women\u2019s Health products and the strategic exit of private labels. Zacks Rank and Key Picks Prestige Consumer Health currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 1.5%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down Omnicell, Inc. OMCL reported third-quarter 2023 adjusted earnings per share (EPS) of 62 cents, down 38% year over year. However, the metric beat the Zacks Consensus Estimate of 45 cents. Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs, severance-related expenses and others. GAAP EPS was 12 cents in the quarter under review compared with 37 cents in the prior-year quarter. Revenues in Detail Revenues in the third quarter totaled $298.7 million, down 14.2% year over year. The decline was mainly due to lower point-of-care revenues as a result of ongoing health systems and capital budget and labor constraints. However, the figure beat the Zacks Consensus Estimate by 1.4%. Omnicell, Inc. Price, Consensus and EPS Surprise Omnicell, Inc. price-consensus-eps-surprise-chart | Omnicell, Inc. Quote Segmental Details On a segmental basis, Product revenues dropped 23.4% year over year to $188.8 million in the reported quarter. This compares with our model\u2019s estimate of $186.4 million for the third quarter. Service and other revenues climbed 8.3% year over year to $109.9 million, which also exceeded our model\u2019s segmental projection of $107.4 million. Operational Update In the quarter under review, the gross profit declined 17.1% to $132 million. The gross margin contracted 152 basis points (bps) to 44.2%. Operating expenses were $128.3 million in the third quarter, down 8.8% year over year. The operating profit in the quarter totaled $3.7 million, down 79.9% year over year. In the third quarter, the adjusted operating margin contracted 406 bps to 1.2%. Financial Update Omnicell exited the third quarter of 2023 with cash and cash equivalents of $446.8 million compared with $399.5 million at the end of the second quarter. The cumulative cash flow provided by operating activities at the end of the third quarter was $142.7 million compared to the cumulative net cash outflow of $4.4 million in the comparable period last year. 2023 Outlook Omnicell provided an updated outlook for the full-year 2023. Total revenues for 2023 are expected in the range of $1.135 billion-$1.155 billion (previously $1.160 billion-$1.200 billion). Of this, product revenues are expected in the range of $705 million-$715 million (earlier $740 million-$760 million) and service revenues in the band of $430 million-$440 million (earlier $420 million-$440 million). The Zacks Consensus Estimate for total revenues is pegged at $1.18 billion. The adjusted EPS for the full year is expected in the range of $1.65-$1.80, down from the previous guidance in the band of $1.75-$2.00. The Zacks Consensus Estimate is pegged at $1.76. For the fourth quarter of 2023, Omnicell expects revenues in the range of $247-$267 million, including anticipated product revenues in the band of $142-$152 million and service revenues in the range of $105-$115 million. The Zacks Consensus Estimate for fourth-quarter 2023 revenues is pegged at $298.3 million. The adjusted EPS for the fourth quarter is anticipated in the range of 7-22 cents. The Zacks Consensus Estimate is pegged at 36 cents. Our Take Omnicell ended the third quarter of 2023 with better-than-expected earnings and revenues. The company delivered strong cost management and operational discipline and also plans to take actions related to cost containment across the business. The steps are intended to better align with Omnicell\u2019s anticipated top-line performance as it heads into 2024 while positioning the company for continuous investment in innovation. Omnicell\u2019s Central Pharmacy Dispensing Service appears to be gaining momentum in the market, which is encouraging. Moreover, health systems are opting for the company\u2019s management services expertise to help drive financial and clinical outcomes in the rapidly growing healthcare industry. Meanwhile, both earnings and revenues were down compared to the year-ago quarter. Omnicell reduced its 2023 financial guidance as weakness in demand prevails. The company is also struggling in terms of its gross and adjusted operating margins, both of which contracted during the quarter. Zacks Rank and Other Key Picks Omnicell currently sports a Zacks Rank #1 (Strong Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4.0%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock to Buy Hand Over Fist in November, and 1 to Avoid Don't look now, but Wall Street's broadest stock indexes, the benchmark S&P 500 and growth-focused Nasdaq Composite, are back in correction territory, as of the closing bell on Oct. 27. Typically, when the sledding gets tough on Wall Street, investors seek the safety of profitable, time-tested, outperforming businesses. Over the past two years, this definition has perfectly encompassed a handful of companies enacting stock splits. A stock split is an event that allows a publicly traded company to cosmetically alter its share price and outstanding share count without having any impact on its market cap or operating performance. A forward-stock split reduces a company's share price, thereby making it more affordable for everyday investors who don't have access to fractional-share purchases with their online broker. Meanwhile, reverse-stock splits increase a publicly traded company's share price, usually with the purpose of ensuring it meets the minimum listing standards for a major stock exchange. Image source: Getty Images. Forward-stock splits are what tend to garner the attention of investors. That's because companies enacting forward splits are often industry leaders and top-notch innovators whose high-flying stock price reflects this outperformance, relative to their peers. Since the start of July 2021, nine high-flying companies have conducted forward-stock splits: Nvidia (NASDAQ: NVDA): 4-for-1 split Amazon (NASDAQ: AMZN): 20-for-1 split DexCom (NASDAQ: DXCM): 4-for-1 split Shopify (NYSE: SHOP): 10-for-1 split Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split Tesla (NASDAQ: TSLA): 3-for-1 split Palo Alto Networks (NASDAQ: PANW): 3-for-1 split Monster Beverage (NASDAQ: MNST): 2-for-1 split Novo Nordisk (NYSE: NVO): 2-for-1 split While all nine of these businesses bring easily identifiable competitive advantages to the table, their outlooks over the next five to 10 years differ greatly. As we move into November, one of these nine stock-split stocks is effectively cheaper than it's ever been as a publicly traded company -- while another stock-split stock looks completely avoidable as it contends with mounting headwinds. The stock-split stock to buy hand over fist in November: Alphabet The screaming bargain in November, among the aforementioned nine stock-split stocks, is Alphabet. This is the parent company of familiar internet search engine Google and streaming platform YouTube, among other ventures. If there's a weakness in Alphabet's armor, it's that the company is cyclical. Nearly 78% of the $76.7 billion in total sales reported in the September-ended quarter derived from its advertising services. Advertising is notoriously cyclical, with businesses not shy about paring back their spending at the first signs of economic weakness. Given that a handful of economic data points and predictive tools are signaling a coming recession, it's possible that Alphabet's primary revenue driver could weaken in the coming quarters. But this is a two-sided coin -- and the two sides aren't remotely equal. Even though U.S. recessions are a perfectly normal part of the economic cycle, they're traditionally short-lived. Just three of the 12 recessions following World War II lasted at least 12 months, and none of the remaining three surpassed 18 months. Meanwhile, most periods of expansion have extended beyond one year. In other words, the ad industry is poised to thrive over long stretches. Few businesses are more perfectly positioned to take advantage of long-winded economic expansions than Alphabet. Google accounted for close to 92% of worldwide internet search share in September 2023, and it's amassed at least a 90% monthly share of global internet search dating back to April 2015. It's the unquestioned go-to for businesses looking to advertise, which means Google possesses exceptionally strong ad-pricing power. Beyond its bread-and-butter cash-flow driver, Alphabet should enjoy meaningful growth from YouTube and Google Cloud. The former is the second most-visited site globally, and has seen daily views of short-form videos, known as Shorts, catapult higher over the past two years. Google Cloud is a particularly intriguing long-term growth catalyst. Enterprise cloud spending is still in its early stages, and Google Cloud already accounts for an estimated 9% of cloud infrastructure service spending, based on a second-quarter report from tech analysis firm Canalys. Although Google Cloud's year-over-year growth rate has \""slowed\"" to 22.5%, as of the September-ended quarter, it's generated three consecutive quarters of operating profits following years of losses. Most importantly, this unquestioned industry leader is pretty much cheaper than it's ever been as a publicly traded company. Shares of Alphabet can be purchased right now for less than 13 times consensus cash flow per share in 2024. By comparison, shares of the company have averaged a multiple of just over 18 times year-end cash flow between 2018 and 2022. Alphabet is a surprisingly cheap stock that patient investors can confidently buy hand over fist. The Model 3 is Tesla's top-selling sedan. Image source: Tesla. The stock-split stock to avoid in November: Tesla However, past performance is no guarantee of future success. In November, electric-vehicle (EV) manufacturer Tesla stands out as the clear stock-split stock worth avoiding. Tesla has done a number of things right in order to be valued as the world's largest automaker by market cap. It became the first auto company to build itself from scratch to mass production in well over 50 years, and is currently the only pure-play EV maker that's generating a recurring profit, based on generally accepted accounting principles (GAAP). Even though legacy automakers are quite profitable, the EV divisions of legacy auto companies are bleeding red. Likewise, Tesla is sitting on a veritable mountain of cash. It closed out the September-ended quarter with $26.1 billion in cash, cash equivalents, and investments. With a reasonably minimal amount of debt, Tesla has more flexibility to innovate and potentially diversify its operations than its peers. But Tesla also has plenty of drawbacks as an investment. For example, it lacks brand power. It's a relatively young brand that takes a clear back seat to the likes of General Motors and Ford Motor Company, to name a few. These stalwarts have more than a century of history in their sails, and they can easily cross generational gaps to connect with and engage previous and future buyers. Tesla also appears to have a pretty serious inventory problem. Since the end of the first quarter of 2022, days of supply -- i.e., ending new car inventory divided by the relevant quarters' deliveries -- has jumped from three days to 16 days, as of Sept. 30. CEO Elon Musk has previously stated that Tesla's pricing strategy is dictated by demand for its EVs. With more than a half-dozen price cuts across its four production models since 2023 began, the implication is clear that inventory is a problem. Not surprisingly, these price cuts have more than halved the company's operating margin over the past year -- 17.2% to 7.6%. Tesla's attempts to become more than just a car company aren't exactly hitting home, either. The SolarCity acquisition has been a money-loser for Tesla for seven years, while the remainder of Tesla's ancillary operations are generally low margin. In fact, sales in the company's Energy Generation and Storage segment have been relatively flat since the first quarter of this year. To build on the above, 41% of Tesla's pre-tax profit in the latest quarter can be traced to interest income on its cash and automotive regulatory credits, which it sells to other automakers. These renewable energy credits are given to Tesla for free by governments. This is a sizable amount of pre-tax income that has nothing to do with selling and leasing EVs. Finally, Tesla's valuation makes little sense. Auto companies typically trade at price-to-earnings (P/E) ratios in the mid-to-high single-digits. Tesla is commanding a P/E ratio, based on consensus 2023 earnings, of well over 60. With its operating margin declining, Tesla looks to be at risk of serious downside. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 30, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom, General Motors, and Novo Nordisk and recommends the following options: long January 2025 $25 calls on General Motors. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-06,97.78,98.91,94.34,94.84,"[""QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays QIAGEN\u2019s QGEN business is expected to get a boost from its growing molecular diagnostic market and expanded test menu. Yet, QIAGEN faces a tough competitive landscape and foreign exchange headwinds. The stock carries a Zacks Rank #3 (Hold). QIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. The range of assays for diseases and biomarkers speeds up and simplifies laboratory workflow and standardizes many lab procedures. Meanwhile, the molecular diagnostics space is fast gaining share in theglobal marketwhile catering to the rapidly growing treatment areas of oncology, infectious diseases and immune monitoring. Molecular testing is the most dynamic segment of the global in vitro diagnostics market. QIAGEN has built a position as a preferred partner to co-develop companion diagnostics paired with targeted drugs. It is consistently creating a rich pipeline of molecular tests that are transforming the treatment of cancer and other diseases. QGEN has more than 25 master collaboration agreements with pharmaceutical industry customers, some with multiple co-development projects. QIAGEN\u2019s Molecular Diagnostics customers accounted for $1.1 billion in sales in 2022. In terms of the latest development, QIAGEN\u2019s market-leading QuantiFERON latent TB test delivered an outstanding third quarter of 2023, generating 25% CER growth and delivering a significant milestone, with quarterly sales rising above $100 million for the first time. The company continues to see a very healthy conversion trend from the tuberculin skin test. The QIAcuity digital PCR system delivered over 40% sales growth at CER, driven by new placements and increasing biopharma consumable sales. The QIAstat diagnostic syndromic testing platform also did well this quarter with a combination of growth in consumables, driven by double-digit CER gains in noncoding testing and placements above the same level achieved in the third quarter of last year. QIAGEN N.V. Price QIAGEN N.V. price | QIAGEN N.V. Quote QIAGEN\u2019s long-term business strategy involves strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commercialization, marketing and distribution of certain of their existing and potential products. In October 2023, QIAGEN and Myriad Genetics collaborated to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market and providing distributable companion diagnostic test kits for theglobal market On the flip side, QIAGEN currently markets products in more than 100 countries. Its international operations are subject to a variety of risks arising from the economy, political outlook, language and cultural barriers in the countries it operates. In many of these emerging markets, QIAGEN faces several risks. These include economies that may be dependent on only a few products and are therefore subject to significant fluctuations, weak legal systems that may affect the company\u2019s ability to enforce contractual rights, exchange controls, unstable governments, and privatization or other government actions affecting the flow of goods and currency. In the quarter under review, the Asia Pacific/Japan region reported revenue decline in low single-digit CER rates for non-COVID sales. Non-COVID sales in China declined at a low single-digit CER rate as well. Revenues from Europe, the Middle East and Africa (30.5% of sales) reportedly fell 6%. The overall sales declined 11% at CER due to significant COVID-19 sales in the third quarter of 2022. Recording more than 50% of its revenues from the international market, QIAGEN is highly exposed to the risk of foreign currency movement. The situation may worsen with the strengthening of the domestic currency against high-focus nations. Any unanticipated currency headwinds in high-focus markets may drag the top and the bottom line further in the future. Foreign currency transactions resulted in a net loss of $9.0 million and $4.1 million in the years ended Dec 31, 2021 and 2020, respectively. Over the past year, shares of QIAGEN have plunged 21.4% compared with 21% fall of the industry. Key Picks Some better-ranked stocks in the broader medical space are DexCom DXCM, Insulet PODD and Haemonetics HAE, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term expected earnings growth rate of 33.6%. Earnings estimates for 2023 have increased from $1.23 to $1.41 in the past 30 days. DXCM\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. In the last reported quarter, it posted an earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.62 to $1.65 in the past 30 days. PODD has a long-term expected earnings growth rate of 41.5%. Insulet\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 126.94%. In the last reported quarter, it delivered an earnings surprise of 58.33%. Estimates for Haemonetics\u2019 fiscal 2024 earnings have remained constant at $3.82 in the past 60 days. HAE has a long-term expected earnings growth rate of 10%. Haemonetics\u2019 earnings beat estimates in each of the trailing four quarters, with the average beat being 19.39%. In the last reported quarter, it delivered an earnings surprise of 38.16%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up Bruker Corporation BRKR delivered adjusted earnings per share (EPS) of 74 cents in the third quarter of 2023, up 12.1% year over year. The figure exceeded the Zacks Consensus Estimate by 17.5%. The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others. GAAP EPS for the quarter was 60 cents, reflecting a 1.7% rise from the year-earlier figure. Revenues in Detail Bruker registered revenues of $742.8 million in the third quarter, up 16.3% year over year. The figure topped the Zacks Consensus Estimate by 3.3%. Excluding the positive impacts of 2.1% from acquisitions and 3.3% from changes in foreign currency rates, the company witnessed organic revenue growth of 10.9%. Bruker Corporation Price, Consensus and EPS Surprise Bruker Corporation price-consensus-eps-surprise-chart | Bruker Corporation Quote On a geographic basis, the United States witnessed a 10.1% year-over-year rise in revenues to $211.1 million. Our model projected the region\u2019s revenues to be $191.1 million. Europe revenues increased 23.8% year over year to $252 million, while revenues in the Asia Pacific rose 16.6% to $229.3 million. For both these regions, our model\u2019s projected revenues for the third quarter were $247.3 million. The Other category\u2019s revenues moved up 7.7% year over year to $50.4 million. This exceeded our model\u2019s projected revenues from this segment of $33.3 million. Segmental Analysis Bruker reports results under two segments \u2014 BSI (comprising BioSpin and CALID and Nano) and Bruker Energy & Supercon Technologies (\u201cBEST\u201d). BSI Within this segment, BioSpin Group\u2019s revenues rose 12.9% from the year-ago quarter to $198.3 million. Our model\u2019s projected revenues in this segment were $199.2 million. CALID\u2019s revenues increased 15.3% year over year to $239.3 million in the third quarter. This compares with our model\u2019s projected revenues of $221.3 million in this segment. Organic revenues grew in the high-single-digit percentage, driven by the strong performance of the microbiology business. Revenues of the Nano group climbed 19.9% to $238.7 million. Our model projected revenues for this segment to be $228.9 million. Nano\u2019s organic revenues grew in the mid-teens-percentage range, driven by strength in Nano's industrial research, AI-driven semiconductor and advanced packaging metrology, as well as academic markets. BEST In the third quarter, the BEST segment\u2019s revenues were $70.6 million, up 19.1% year over year. This compares with our model\u2019s segmental projection of $73.7 million. Margin Trend In the quarter under review, Bruker\u2019s gross profit rose 14.2% to $382.8 million. The gross margin contracted 95 basis points (bps) to 51.5%, on an 18.6% rise SG&A expenses rose 22.7% to $177.6 million. R&D expenses went up 26.7% year over year to $71.3 million. Adjusted operating expenses of $248.9 million increased 23.8% year over year. The adjusted operating profit totaled $133.9 million, reflecting a 0.3% fall from the prior-year quarter. Meanwhile, the adjusted operating margin in the third quarter contracted 299 bps to 18%. Financial Position Bruker exited the third quarter of 2023 with cash and cash equivalents of $363.6 million compared with $574.8 million at the second-quarter end. The total long-term debt (including the current portion) at the end of the third quarter was $1.10 billion, sequentially down from $1.24 billion at the end of the second quarter. At the third quarter-end, the cumulative net cash flow from operating activities was $44.1 million compared with $69.5 million during last year\u2019s comparable period. 2023 Guidance Bruker provided an updated outlook for 2023. For the full year, the company expects revenues in the range of $2.88-$2.91 billion (previously $2.85-$2.90 billion). This indicates year-over-year revenue growth of 14%-15% (earlier 12.5%-14.5%) on a reported basis and growth of 11.5%-12.5% (previously 9.5%-11.5%) on an organic basis. The Zacks Consensus Estimate for revenues is pegged at $2.88 billion. BRKR expects its full-year 2023 adjusted EPS in the range of $2.48-$2.53 (or 6%-8% growth year over year). Previously, the guidance for the metric was $2.55-$2.60, representing 9%-11% year-over-year growth. The Zacks Consensus Estimate is pegged at $2.55 per share. Our Take Bruker ended the third quarter of 2023 with earnings and revenues beating estimates. Year to date, the company has delivered three consecutive quarters of double-digit organic revenue growth and demonstrated great resiliency in challenging market conditions due to its innovation strategy. Bruker\u2019s strong growth is attributed to its fundamental commitment to innovations and delivering high-value solutions for customers and the ongoing portfolio transformation. BRKR recently completed the acquisition of PhenomeX, whose platforms are highly complementary to Bruker\u2019s existing cellular and sub-cellular analysis tools, including the CellScape spatial biology platform. Also, the expansion of the gross margin is encouraging. Meanwhile, the gross and adjusted operating margins resulted in a contraction in the quarter. Throughout fiscal 2023, Bruker continued to accelerate investments in its transformative Project Accelerate 2.0 initiatives, and operational excellence and productivity. Zacks Rank & Key Picks Bruker currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-07,95.8097,97.62,95.09,95.19,"[""3 Standout Growth Stocks to Own for 2024 The Fed's ongoing rate hike campaign has pressured many growth stocks over the past year, as these companies often rely on debt to finance future expansion. Now, however, as recent data points suggest the Fed may be nearing the end of its tightening cycle - and the U.S. economy may actually manage a soft landing - growth stocks are once again back in favor. And as interest rates eventually decline back toward more typical levels, growth stocks in particular should benefit from lower borrowing costs. With this in mind, here's a look at three stocks that are top-rated by analysts, and expected to outpace their peers on key growth metrics. Dexcom We start with San Diego-based Dexcom (DXCM), a medical device company that designs, develops, and commercializes continuous real-time glucose monitoring (CGM) systems for people with diabetes. Founded in 1999, DexCom's CGM systems are used by people with all types of diabetes, including type 1, type 2, and gestational diabetes. With a market cap of $36.6 billion, Dexcom stock is down 15% in 2023 so far. www.barchart.com Dexcom posted a strong set of numbers for Q3 2023, marked by significant growth in both revenue and earnings. Revenues of $975 million represented a yearly growth of 26.7% while EPS of $0.50 grew by an even sharper 78.6%. The latter came in above the consensus estimate of $0.34, continuing a trend of topping analysts' expectations. The company's operational strength is also reflected in the 14.5% yearly improvement in its net cash from operating activities to $614.9 million, with a cash balance of $3.24 billion at the end of the quarter. Meanwhile, the global release of Dexcom's new G7 product and the expansion of Dexcom ONE into new geographies could potentially contribute to greater adoption of its CGM technology within a significantly larger patient population. Looking ahead, analysts have penciled in above-average revenue and EPS growth rates for Dexcom, with forward revenue growth at 20.71% (vs. the industry median of 9.14%) and EPS growth of 36.41% (vs. 4.12%). Overall, analysts have a \u201cStrong Buy\u201d rating for Dexcom stock, with a mean target price of $128.78. This denotes an upside potential of roughly 34% from current levels. Out of 18 analysts covering the stock, 16 have a \u201cStrong Buy\u201d rating and two have a \u201cHold\u201d rating. www.barchart.com Synopsys Founded in 1986, Synopsys (SNPS) is a software development company that provides tools and services for the design and verification of electronic systems. The company has also made significant investments in artificial intelligence (AI) and machine learning (ML) to develop new tools that can help designers automate more of the design process. With more than 4,000 customers worldwide, Synopsys currently commands a market cap of $74.51 billion. The share price for Synopsys has rallied 55.7% on a YTD basis. www.barchart.com In Q3 2023, Synopsys reported revenues of roughly $1.5 billion, up 19.2% from the year-ago period. EPS grew by 37.1% from the previous year to $2.88, coming in above the consensus estimate of $2.74. The company's EPS has surpassed expectations in each of the past five quarters. The company ended the quarter with a cash balance of about $1.7 billion and an almost flat year-on-year net cash from operating activities of $1.38 billion. In terms of future growth catalysts, SNPS has a market-leading position in the Electronic Design Automation industry with a 32% share. A wider tailwind in the form of customer preference for integrated EDA tools - such as the one offered by Synopsys - due to its cost- and time-saving features is also expected to drive the company's revenues higher. Further, the company's bet on AI to be a large driver of revenues in the future has also found traction. Although Synopsys' valuation may appear to be on the higher side after its rally this year, analysts are forecasting above-average growth rates for the company. The consensus is looking for forward revenue and EPS growth of 16.13% and 22.83% compared to the sector medians of 8.65% and 7.87%, respectively, for Synopsys. Overall, analysts have a \u201cStrong Buy\u201d rating on SNPS with a mean target price of $526.64. This represents an upside potential of about 5.6% from current levels. Out of 12 analysts covering the stock, 10 have a \u201cStrong Buy,\u201d one has a \u201cModerate Buy,\u201d and one has a \u201cHold\u201d rating. www.barchart.com ServiceNow We conclude our list with another software company, ServiceNow (NOW). Founded in 2003 and based out of Santa Clara, Calif., ServiceNow is a cloud-based software company that provides IT service management (ITSM), customer service management (CSM), and other digital workflow solutions. Its platform helps companies automate and streamline their business processes, improve customer service, and increase efficiency. Currently commanding a market cap of $124.89 billion, ServiceNow stock is up more than 55% on a YTD basis. www.barchart.com In Q3 2023, ServiceNow's revenues came in at $2.3 billion, up 25% from the year prior, while EPS of $2.92 rose 49% from the year-ago period. Quarterly earnings comfortably outpaced the consensus estimate of $2.56, just like in the previous four quarters. Operationally relevant metrics for a platform company, such as current remaining performance obligations ($7.43 billion, up 27% YoY) and $1 million+ annual contract value customers (1,789, up 17% YoY), improved during the quarter - indicating healthy demand for its products. ServiceNow's diverse customer base, headlined by 19 federal deals over $1 million in the latest quarter, makes it less vulnerable to sector-specific shocks. Notably, in Q3, ServiceNow clocked in 100% YoY growth in the transportation and logistics, education, manufacturing, and CMC sectors. Also, the company recently launched its generative AI-powered Now Assist platform, which has already elicited interest from over 300 customers. Further, the company is leveraging the power of AI to improve its workflow automation platform, Creator Workflows. Analysts are expecting ServiceNow to report industry-beating revenue and EPS growth. While forward revenue growth is pegged at 22.46% (vs. the industry median of 8.65%), EPS growth is expected at 61.37% (compared to the sector average of 6.97%). Overall, analysts have a \u201cStrong Buy\u201d rating on the stock, with a mean target price of $638.71 - indicating an upside potential of about 3% from current levels. Out of 32 analysts covering NOW stock, 28 have a \u201cStrong Buy\u201d rating, two have a \u201cModerate Buy\u201d rating, and two have a \u201cHold\u201d rating. www.barchart.com On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top OPKO Health, Inc. OPK delivered a loss per share of 11 cents in the third quarter of 2023, flat compared with the year-ago period\u2019s loss per share. However, the figure was wider than the Zacks Consensus Estimate of a loss of 9 cents per share. Revenues in Detail OPKO Health registered revenues of $178.6 million in the third quarter, down 0.6% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 2.1%. Lower revenues from services dragged the overall top line. Segmental Revenues OPKO Health manages its operations through two reportable segments \u2013 Diagnostics and Pharmaceuticals. Within the Diagnostics arm, revenues from services amounted to $131.7 million in the reported quarter, down 7.8% year over year, primarily due to lower COVID-19 testing volume and reimbursement. Clinical test reimbursement also decreased due to the mix of testing ordered, partially offset by an increase in clinical test volume. This compares to our projection of $131.3 million from services revenues in the third quarter. Within the Pharmaceuticals arm, revenues from products rose 25.6% to $40.7 million, primarily on the back of higher sales in OPKO Health\u2019s international operating companies and increased revenues from RAYALDEE sales. This compares to our projection of $41.6 million from product revenues in the third quarter. Revenues from sales of RAYALDEE in the third quarter of 2023 were $7.3 million, up 5.8% from the prior-year period. Revenues from the transfer of intellectual property and other totaled $6.2 million, up 37.8% from the prior-year period. This compares to our projection of $8 million of revenues from the transfer of intellectual property and other in the third quarter. OPKO Health, Inc. Price, Consensus and EPS Surprise OPKO Health, Inc. price-consensus-eps-surprise-chart | OPKO Health, Inc. Quote Margin Analysis In the quarter under review, OPKO Health\u2019s gross profit rose 52.4% to $47.7 million. The gross margin expanded by a huge 929 basis points to 26.7%. Selling, general and administrative expenses fell 9.3% to $72.3 million. Research and development expenses climbed 3.2% year over year to $19.4 million. Adjusted operating expenses of $91.7 million decreased 6.9% year over year. Adjusted operating loss totaled $44 million compared with the prior-year quarter\u2019s adjusted operating loss of $67.2 million. Financial Position OPKO Health exited third-quarter 2023 with cash and cash equivalents of $138.6 million compared with $108.1 million at the second-quarter end. Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $10.1 million against cumulative net cash used in operating activities of $63.6 million a year ago. Guidance OPKO Health has provided its financial outlook for the fourth quarter of 2023. For the fourth quarter, it expects total revenues between $170 million and $180 million. The Zacks Consensus Estimate currently stands at $191.3 million. OPKO Health expects its revenues from services to lie between $126 million and $132 million and revenues from product sales to be in the range of $33 million-$36 million. Other revenues are expected to be between $8 million and $12 million, inclusive of the estimated Pfizer gross profit share of $8 million to $10 million. Our Take OPKO Health exited the third quarter of 2023 with better-than-expected revenues. OPKO Health\u2019s confirmation that NGENLA (somatrogon) has been approved in 48 markets, including the United States, Japan, EU Member States, Canada and Australia, looks promising. Also, its continued sales by Pfizer in more than 23 countries, including all priority global markets, raises our optimism about OPKO Health. In September, BARDA awarded a contract to OPKO Health\u2019s company, ModeX Therapeutics Inc., to advance a platform and specific therapeutic candidates designed to address a range of public health threats in viral infectious diseases. The same month, OPKO Health\u2019s subsidiary, OPKO Biologics, Inc., entered into a Research Collaboration Agreement with Entera Bio Ltd. to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes. During the quarter, ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies. This month, OPKO Health presented positive late-breaking clinical data on RAYALDEE extended-release calcifediol. These look promising for the stock. Robust results from the Pharmaceuticals segment, with solid sales of RAYALDEE, are impressive. The company\u2019s continued strength in its oncology business and management\u2019s confirmation that it has finalized new service agreements with several new-launch clients starting in the fourth quarter also augur well. The expansion of the gross margin bodes well. However, the wider-than-expected loss per share and dismal top-line and bottom-line performances were concerning. Lower Diagnostics revenues were also worrying. The persistent operating loss for OPKO Health also does not bode well for the company. Zacks Rank and Key Picks OPKO Health currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y Shockwave Medical, Inc. SWAV reported third-quarter 2023 earnings per share (EPS) of 92 cents, which beat the Zacks Consensus Estimate of 81 cents by 13.6%. The company reported an EPS of 68 cents in the year-ago quarter. Revenue Details Revenues totaled $186 million, up a massive 42% from the prior-year period\u2019s level. The top line also beat the Zacks Consensus Estimate by 0.6%. The growth was primarily driven by an increase in the purchase volume of products, both in the United States and abroad. Revenues from coronary products grew nearly 50% during the third quarter, while peripheral product sales improved approximately 30%. Coronary franchise sales were driven by the strong adoption of new coronary device C2+ in international markets. The device was launched in the U.S. market during the third quarter. While U.S. revenues were up 33% year over year, International revenues grew 88%. Internationally, SWAV\u2019s sales were boosted by strong momentum in Germany, the United Kingdom, Italy, Spain and France. Q3 Highlights In August, the Centers for Medicare & Medicaid Services (CMS) created new Medicare Severity Diagnosis Related Group (MS-DRG) codes and payments for coronary Intravascular Lithotripsy (IVL) in the hospital inpatient setting. Per the new codes, new coronary IVL-specific MS-DRGs are associated with higher payments than the MS-DRG payments for other Percutaneous Coronary Intervention procedures. Again, the CMS established a Category I Current Procedural Terminology add-on code for procedures involving coronary earlier this month. Under this new category, physicians will get a 20-30% increase in remuneration for the additional work associated with performing coronary IVL. In September, SWAV appointed Nick West as the Associate Chief Medical Officer (CMO), who will likely succeed Dr. Dawkins as CMO in mid-2024. Margins Gross profit in the reported quarter was $161.5 million, up 42.3% year over year. As a percentage of revenues, the gross margin in the quarter was 87%, up 100 basis points year over year. Sales and marketing expenses amounted to $56.9 million, up 35.2% from the prior-year quarter\u2019s level. Research and development expenses totaled $39.5 million, up 95.9% on a year-over-year basis. Operating income totaled $43.6 million compared with the year-ago quarter\u2019s level of $36.8 million. Financial Position Shockwave Medical exited the third quarter with cash, cash equivalents and investments of $917.3 million compared with $258.6 million in the previous quarter. Total assets amounted to $1.47 billion compared with $786.6 million at the end of the second quarter of 2023. 2023 Revenue Outlook For 2023, Shockwave Medical continues to expect revenues in the band of $725-$730 million. The projected top line implies growth of 48-49% from the prior-year period\u2019s level. The Zacks Consensus Estimate for the same is pegged at $729.8 million. ShockWave Medical, Inc. Price, Consensus and EPS Surprise ShockWave Medical, Inc. price-consensus-eps-surprise-chart | ShockWave Medical, Inc. Quote Wrapping Up SWAV ended the third quarter on a positive note, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. The company exhibited significant revenue growth in the same quarter. Strong top-line growth across all categories is also encouraging. The expansion in gross margin buoys optimism as it will likely boost earnings going forward. Management is optimistic about the continued clinical acceptance and penetration of IVL. Considering the fact that the C2+ device holds a strong demand in the international market, the launch of the same in the United States looks promising. This is due to the technology\u2019s strong results in the quarter under review as well as a higher outlook for 2023 revenues. Moreover, higher pay rates for physicians for IVL procedure is likely to benefit the adoption of SWAV\u2019s products, thereby boosting its top-line growth. However, an increase in operating expenses is a concern. Zacks Rank and Other Key Picks Currently, Shockwave Medical carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Abbott, carrying a Zacks Rank #2 at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2. DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2. ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 (Strong Buy). Insulet is witnessing continued uptake of Omnipod through the U.S. pharmacy channel. Insulet continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign in the United States and across select international markets. Omnipod is specifically designed for individuals on multiple daily insulin injections. The company is driving pump penetration across all age groups in both the Type 1 and Type 2 markets, while also gaining in market share. Omnipod 5 continues to be a driving force behind U.S. and international growth. In the United States, Omnipod 5 represented the vast majority of new customer starts in the third quarter. Customer retention remains strong. In the United States, Omnipod's new customer starts from multiple daily injections and legacy tubed pumps witnessed a 80-20% split in the third quarter, in line with the company\u2019s historical mix. Further, Insulet\u2019s sales and marketing strategies and international expansion efforts are aligned with its long-term growth profile. The company is focused on advancing its initiatives. Insulet will continue to expand access to Omnipod 5 as well as increase the total addressable market for the Omnipod platform. During the second quarter, Insulet commercially launched Omnipod 5 in the United Kingdom and in August, the device reached Germany commercially. Insulet Corporation Price Insulet Corporation price | Insulet Corporation Quote Earlier in 2023, Insulet received FDA clearance for its basal-only Pod named Omnipod GO, a unique product for the type 2 market. The company is bringing this innovation to market in 2024. According to Insulet, by the end of 2024, it targets Omnipod 5 to be available for the majority of its European customers. Further, Omnipod DASH continues to be the leading insulin pump for use in the Type 2 market. While the company is yet to progress with Omnipod 5 Automated Insulin Delivery in the Type 2 market, the underlying demand for Omnipod DASH in the said market is encouraging. In third-quarter 2023, Insulet registered quarter-over-quarter growth with Omnipod DASH. On the flip side, Insulet is incurring higher costs associated with Omnipod 5 production. Added to this, higher production costs due to global inflation as well as supply chain disruptions and labor shortages continue to put pressure on margins. During the third quarter, selling, general & administrative expenses rose 28.7% while research and development expenses rose 28.4% year over year. Weaker global economic conditions may reduce demand for Insulet\u2019s products, intensify competition, exert pressure on prices, dent supply and lengthen the sales cycle. Moreover, a number of countries in Western Europe are facing liquidity crunch. Insulet is also exposed to the risk of a reduction in healthcare spending in the United States, Canada and Europe due to an economic slump. Insulet currently expects unfavorable product mix, U.S. manufacturing ramp, inflation and supply chain headwinds to continue to impact business results for the next few years. Over the past year, PODD shares have declined 46.4% compared with 6.4% decline of the industry. Other Stock Picks Some other top-ranked stocks in the broader medical space are HealthEquity HQY, DexCom DXCM, and Haemonetics HAE. While HQY carries a Zacks Rank #1 currently, DXCM and HAE carry a Zacks Rank #2 (Buy) each. HealthEquity, at present, has an estimated long-term growth rate of 26.7%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters and missed once, delivering an average surprise of 13.03%. The company\u2019s shares have risen 4.1% year to date against the industry\u2019s 14.7% decline. DexCom has a long-term expected earnings growth rate of 33.6%. Earnings estimates for 2023 have increased from $1.23 to $1.41 in the past 30 days. DXCM\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. In the last reported quarter, it posted an earnings surprise of 47.1%. Estimates for Haemonetics\u2019 fiscal 2024 earnings have remained constant at $3.82 in the past 60 days. HAE has a long-term expected earnings growth rate of 10%. Haemonetics\u2019 earnings beat estimates in each of the trailing four quarters, with the average beat being 19.39%. In the last reported quarter, it delivered an earnings surprise of 38.16%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research QIAGEN N.V. QGEN recently announced the launch of the Microbiome WGS (whole-genome sequencing) SeqSets \u2014 a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research. The SeqSets are enabled for diverse microbiome research applications, including studies of gut health, soil microbiology, antibiotic resistance and others. The latest development further expands the growing portfolio of QIAGEN microbiome solutions within the Sample Technologies product group. Significance of the News In recent years, microbiome research has gained prominence, exploring the relationship between microorganisms such as bacteria, fungi and viruses and their hosts. The goal is to better understand their impact on health, diseases and ecological processes to develop novel diagnostic and therapeutic strategies. Image Source: Zacks Investment Research Against this backdrop, QIAGEN\u2019s Microbiome WGS SeqSets provide a complete Sample to Insight solution. The workflow streamlines the process steps involving sample extraction and NGS (next-generation sequencing) library preparation to prepare the sample for processing in an NGS sequencer, followed by user-friendly bioinformatics analysis designed for researchers without expertise in the field. News in Detail The QIAamp PowerFecal Pro WGS SeqSets and the DNeasy PowerSoil Pro WGS SeqSets offer unified solutions for gut and soil samples. The workflow begins with DNA extraction using the DNeasy PowerSoil Pro or QIAamp PowerFecal Pro DNA Kits, which efficiently isolate high yields of DNA and identify greater bacterial diversity than other commercial kits. Following extraction, the QIAseq Normalizer Kit streamlines library normalization, enabling easy pooling for high-throughput sequencing. The QIAseq FX DNA Library Kit enables rapid 2.5-hour NGS library preparation for whole genome metagenomic analysis, creating sequencing libraries with minimal bias through enzymatic fragmentation and adapter ligation. Finally, bioinformatics analysis is conducted using the Microbial Analysis Portal \u2014 an intuitive web-based platform. It enables the taxonomic identification of microbes, provides a detailed breakdown of microbial species and supports antimicrobial resistance analysis for identifying antibiotic resistance genes. Industry Prospects Per a research report, the global microbiome sequencing services market was $1.37 billion in 2022 and is expected to register a CAGR of 10.9% by 2030. Recent Highlights of Sample Technologies QIAGEN\u2019s market-leading sample technology portfolio continues to make progress in automation upgrades with the recent launch of TissueLyser III instruments. Another example is the next update that will come with the release of an upgraded version of QIAsymphony. The platform will onboard connectivity elements and additional features to even better enable high-volume applications, such as liquid biopsies. Moreover, QIAGEN leverages its deep sample prep expertise through some of the more dynamic growth applications, such as expanding the microbiome portfolio. The company\u2019s extensive range of microbiome solutions also includes downstream processing technologies such as NGS, digital PCR (dPCR) or quantitative PCR (qPCR), all complemented by robust bioinformatics tools for seamless digital analysis. Another notable sample tech expansion highlighted by QGEN is the launch of kits in QIAwave\u2019s portfolio. QIAwave RNeasy and multianalyte DNA RNeasy kits were added to the collection of the alternative version of the most popular QIAGEN kits, which have been redesigned to use considerably less plastic and cardboard. Price Performance In the past six months, shares of the company have declined 14.9% compared with the industry\u2019s fall of 15.6%. Zacks Rank and Key Picks QIAGEN currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.85 in 2023 and $4.07 to $4.09 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.63 to $1.65 in the past seven days. Shares of the company have decreased 49% in the past year compared with the industry\u2019s decline of 18%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 126.9%. In the last reported quarter, it delivered an average earnings surprise of 58.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.41 in the past seven days. Shares of the company have fallen 18.9% in the past year compared with the industry\u2019s decline of 14.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Tandem Diabetes (TNDM) Now Tandem Diabetes Care, Inc. TNDM is well-poised for growth in the coming quarters due to innovative product offerings, which continue to gather remarkable enthusiasm. The upcoming scaling of multiple new products is expected to be a huge catalyst for the company\u2019s growth and ability to lead diabetes management. A strong solvency is an added upside. However, Tandem Diabetes\u2019 operations are highly dependent on the market acceptance of insulin pumps and related products. Competitive pressures are concerning too. In the past year, this Zacks Rank #3 (Hold) stock has declined 60.1% compared with the 3.6% fall of the industry and a 15.3% rise of the S&P 500 composite. The renowned medical device company has a market capitalization of $1.02 billion. Tandem Diabetes projects an estimated earnings growth rate of 37.6% for 2024 compared with the 23.2% of the industry. In the trailing four quarters, TNDM delivered an average earnings surprise of 18.3%. Let\u2019s delve deeper. Tailwinds Impressive Product Innovation Continues: Tandem Diabetes is currently undergoing a transitional time as it prepares for the next phase of growth through its innovative portfolio. The anticipation around the launch of Tandem Mobi has started to build and is already generating incredible interest among healthcare providers, people using multiple daily injections (MDI) and current pumpers. The company\u2019s flagship product, the t:slim X2 with Control-IQ technology, continues to stand out as the number-one rated automated insulin delivery (AID) system. Also, TNDM made great progress in the early release phases of the DexCom G7 integrated system to the market. Management is also working to bring the t:slim X2 with Abbott\u2019s FreeStyle Libre 2 sensor to the United States in the late fourth quarter. Image Source: Zacks Investment Research Strong Solvency: On the liquidity front, Tandem Diabetes looks well-placed. The company exited the third quarter of 2023 with cash and cash equivalents and short-term investments of $498.2 million, while it did not report any short-term payable debt. The total debt of $285 million at the third quarter-end was also much less than the corresponding cash balance. Bright Prospects of the Diabetes Market: An aging population, unhealthy lifestyle, rising awareness and higher expenditure on health care are likely to continue driving the highly competitive diabetes market. Tandem Diabetes' near and long-term strategy focuses on meaningfully expanding the adoption of the insulin pump by people with type 1 diabetes across all its markets and producing more evolved products and services to attract people living with type 2 diabetes who use insulin-intensive therapy. Headwinds Heavy Dependence on Insulin Pumps: Tandem Diabetes generates a large portion of revenues from the sale of insulin pumps. Hence, any factors that negatively impact the sale of these products or result in sales increasing at a much slower pace could adversely affect the company\u2019s business, financial condition and operating results. In the third quarter of 2023, pump sales accounted for 43% of Tandem Diabetes\u2019 total sales worldwide. Tough Competitive Pressure: TNDM operates in a highly competitive environment dominated by firms ranging from large multinational corporations with significant resources to start-ups. Also, competitive and regulatory conditions in the markets where the company operates limit its ability to switch to strategies like price increases. In addition, several companies have been developing and marketing their insulin delivery systems and related software applications, including insulin pumps and Bluetooth-enabled insulin pens, to support MDI therapy. Estimate Trend The Zacks Consensus Estimate for Tandem Diabetes\u2019 2023 loss per share has moved from $1.81 to $2.03 in the past 30 days and to $2.10 in the past seven days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $761.3 million. This suggests a 4.9% fall from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 27.1% for fiscal 2024 compared with the industry\u2019s 17.2%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have rallied 5.3% against the industry\u2019s 6.3% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 41.5% compared with the industry\u2019s 12.2%. Shares of the company have decreased 48% compared with the industry\u2019s 6.4% decline over the past year. PODD\u2019s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 126.9%. In the last reported quarter, it delivered an average earnings surprise of 58.3%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 14.3%. Shares of DXCM have fallen 18% compared with the industry\u2019s 3.6% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-08,95.22,95.57,91.485,92.76,"[""Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y Inogen, Inc. INGN incurred an adjusted loss per share of 36 cents for third-quarter 2023, wider than the adjusted loss per share of 18 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 57 cents per share. GAAP loss per share for the quarter was $1.97, wider than the year-earlier loss of 42 cents per share. Revenues in Detail Inogen registered revenues of $83.9 million for the third quarter, down 20.3% year over year. The figure surpassed the Zacks Consensus Estimate by 3.8%. On a constant-currency basis, total revenues for the reported quarter decreased 21.5%. Per management, the year-over-year decrease in the top line primarily resulted from lower domestic business-to-business sales and lower direct-to-consumer revenues. However, this was partially offset by strong growth in rental and international business-to-business sales. Segmental Details Inogen derives revenues from two sources \u2014 rental and sales. Rental revenues for the reported quarter grossed $15.9 million, up 8.7% from the year-ago period. Per management, an increase in the total number of rental patients on service resulted in the upside. This figure compares to our Rental revenues\u2019 third-quarter projection of $13.1 million. Sales revenues were $67.9 million, down 25% from the prior-year quarter. This figure compares to our Sales revenues\u2019 third-quarter projection of $67.2 million. Revenues by Region & Category Domestic business-to-business sales for third-quarter 2023 amounted to $17.3 million, down 59.4% on a year-over-year basis. Our projection for the same was $34.7 million. International business-to-business sales for the reported quarter amounted to $25.6 million, up 69.8% year over year on a reported basis and up 62% on a constant-currency basis. Our model estimate for the metric was $15.2 million. Domestic direct-to-consumer sales decreased 24.1% year over year to $25.1 million for the quarter. Our estimate for the same was $17.3 million. Inogen, Inc Price, Consensus and EPS Surprise Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote Margins For the quarter under review, Inogen\u2019s adjusted gross profit fell 18.6% from the year-ago period to $37.1 million. However, the adjusted gross margin expanded 96 basis points to 44.2%. Sales and marketing expenses decreased 22.7% from the year-ago quarter to $26.1 million. Research and development expenses decreased 2% year over year to $4.5 million, while general and administrative expenses increased 15.1% to $17 million. Adjusted operating expenses of $47.6 million decreased 10.4% year over year. Adjusted operating loss totaled $10.5 million compared with the prior-year quarter\u2019s adjusted operating loss of $7.5 million. Financial Position Inogen exited third-quarter 2023 with cash and cash equivalents of $124.6 million compared with $167.7 million at the second-quarter end. The company ended the quarter with no debt on its balance sheet. Cumulative net cash used in operating activities at the end of third-quarter 2023 was $0.1 million compared with $22.1 million a year ago. Guidance Inogen has reiterated its revenue outlook for the full year. The company continues to expect its total revenues between $315 million and $320 million. The Zacks Consensus Estimate currently stands at $317.7 million. Our Take Inogen exited the third quarter of 2023 with better-than-expected revenues. The robust year-over-year uptick in rental revenues and international business-to-business sales was impressive. The expansion of the adjusted gross margin also bodes well. In September, Inogen completed the acquisition of Physio-Assist SAS, which expanded its global respiratory care presence by addressing a sizeable, growing and underserved airway clearance market opportunity. On theearnings call management confirmed that it secured the reimbursement approval for Rove 6 in France in August. Inogen is currently focused on introducing Rove 6 to key customers in that market. These developments look promising for the stock. Yet, wider-than-expected loss per share and dismal year-over-year top-line and bottom-line performances were worrying. A decline in domestic business-to-business and domestic direct-to-consumer sales was concerning as well. Inogen continued to incur operating losses for the third quarter, which did not bode well. Zacks Rank and Key Picks Inogen currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top Accuray Incorporated ARAY reported loss per share of 3 cents for the first quarter of fiscal 2024, narrower than the year-ago period\u2019s loss of 6 cents per share. The metric was in line with the Zacks Consensus Estimate. Revenues in Detail Accuray registered revenues of $ 103.9 million in the first quarter of fiscal 2024, up 7.7% year over year. The figure topped the Zacks Consensus Estimate by 6.3%. The overall top-line growth was aided by robust Products revenues. At constant exchange rate (CER), net revenues were $102.7 million, representing a 6.5% increase from the prior-year period. Segmental Details Accuray derives revenues from two sources \u2014 Products and Services. In the fiscal first quarter, Product revenues improved 19.6% from the year-ago quarter to $53.4 million. This figure compares to our Product revenues\u2019 fiscal first-quarter projection of $50.6 million. At CER, Product revenues improved 15%. Services revenues declined 2.6% from the year-ago quarter to $50.5 million. This figure compares to our Services revenues\u2019 fiscal first-quarter projection of $47 million. At CER, Services revenues were down 1%. Gross product orders totaled $63.7 million, down 8.8% year over year. This figure compares to our gross orders\u2019 fiscal first-quarter projection of $76.2 million. Accuray Incorporated Price, Consensus and EPS Surprise Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote Margin Trend In the quarter under review, Accuray\u2019s gross profit rose 14.2% to $39.5 million. Gross margin expanded 216 basis points to 38%. Selling and marketing expenses fell 5.1% to $10.2 million. Research and development expenses fell 0.6% year over year to $14 million, while general and administrative expenses went up 9.5% year over year to $13 million. Total operating expenses of $37.3 million increased 1.4% year over year. Operating profit totaled $2.2 million in the fiscal first quarter against the prior-year quarter\u2019s operating loss of $2.2 million. Financial Position Accuray exited first-quarter fiscal 2024 with cash and cash equivalents of $76.9 million compared with $89.4 million at the end of fiscal 2023. Total debt (including short-term debt) at the end of first-quarter fiscal 2024 was $176 million compared with $177.3 million at the fiscal 2023-end. Cumulative net cash used in operating activities at the end of third-quarter 2023 was $8.6 million against cumulative net cash provided by operating activities of $0.1 million a year ago. FY24 Guidance Accuray has reiterated its outlook for fiscal 2024 based on current expectations. The company continues to expect its fiscal year revenues to be $460 million-$470 million, reflecting year-over-year growth of 3-5%. The Zacks Consensus Estimate is pegged at $465.7 million. Our Take Accuray ended the first quarter of fiscal 2024 with an in-line loss per share and better-than-expected revenues. The company\u2019s solid overall top-line results and robust Product revenues were encouraging. Geographically, Accuray\u2019s performance was strong in EIMEA (Europe, India, the Middle East and Africa), China and Japan, which was impressive. The expansion in the global installed base also looks promising. Continued strong demand for Accuray\u2019s CyberKnife, Radixact and TomoTherapy platforms buoy optimism. The gross margin expansion also bodes well. On theearnings call management confirmed that with the addition of Cenos, the Radixact system will likely ensure that treatments change per the requirement to minimize dose to healthy tissue and personalize treatment. Management also stated that in early October Accuray gained regulatory clearance for its domestic manufactured Tomo C platform focused on the Type B segment in China. These look promising for the stock. However, dismal bottom-line performances and a decline in gross orders were disappointing. The fall in revenues from the Americas and Asia Pacific (excluding China) and Services revenues were also worrying. The current global geopolitical and inflationary pressure are other challenges the company is navigating through, which is another concern. Zacks Rank and Stocks to Consider Accuray currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.85 in the third quarter of 2023, up 37% sequentially. The figure topped the Zacks Consensus Estimate by 48.4%. GAAP EPS for the quarter was $2.62, reflecting a surge of 131.9% year over year. Revenues in Detail Revenues of $3.12 billion in the third quarter were up by 5.9% year over year. The figure surpassed the Zacks Consensus Estimate by 3.7%. The top line was driven by solid performances of DaVita\u2019s dialysis patient service revenues and Other revenues. Segment Details The company\u2019s dialysis patient service revenues were $2.95 billion, up by 3.7% year over year. This figure compares to our dialysis patient service revenues\u2019 third-quarter projection of $2.89 billion. Other revenues were $169.4 million, up 65.7% from the year-ago quarter\u2019s figure. This figure compares to our third-quarter projection of $111.9 million. Per management, the total U.S. dialysis treatments for the third quarter were 7,306,948 or 92,493 per day, on average. This represents a per-day decrease of 0.2% on a sequential basis. Normalized non-acquired treatment growth in the third quarter of 2023 was 0.5% year over year. As of Sep 30, 2023, DaVita provided dialysis services to around 249,100 patients at 3,053 outpatient dialysis centers, of which 2,694 were U.S. centers while 359 were located across 11 other countries. During the third quarter of 2023, the company opened a total of five new dialysis centers and closed 15 dialysis centers in the United States. It also acquired two dialysis centers and opened four new dialysis centers outside the United States in the same period. DaVita Inc. Price, Consensus and EPS Surprise DaVita Inc. price-consensus-eps-surprise-chart | DaVita Inc. Quote Margin Details In the quarter under review, DaVita\u2019s gross profit rose 22.1% to $1.05 billion. The gross margin expanded 450 basis points (bps) to 33.8%. We had projected 31.9% of gross margin for the third quarter. General & administrative expenses climbed 3.1% to $376.9 million. Adjusted operating profit totaled $677.1 million, reflecting a 36.1% uptick from the prior-year quarter\u2019s level. Adjusted operating margin in the third quarter expanded 482 bps to 21.7%. Financial Position DaVita exited the third quarter of 2023 with cash and cash equivalents and short-term investments of $461.2 million compared with $339.9 million at the second-quarter end. Total debt (including the current portion) at the end of third-quarter 2023 was $8.39 billion compared with $8.69 billion at the second-quarter end. Cumulative net cash flow from operating activities at the end of third-quarter 2023 was $1.57 billion compared with $1.22 billion a year ago. 2023 Guidance DaVita has raised its adjusted EPS outlook for 2023. Adjusted EPS from continuing operations for the full year is now projected to be in the range of $7.80-$8.30, up from the prior outlook of $7.00-$7.80. The Zacks Consensus Estimate currently stands at $7.39. Our Take DaVita ended the third quarter of 2023 with better-than-expected results. The uptick in the company\u2019s overall top line and dialysis patient service and Other revenues during the period was impressive. The sequential improvement of DaVita\u2019s bottom line was also encouraging. The opening of several dialysis centers within the United States and overseas was promising. The expansion of both margins bodes well for the stock. DaVita raising its EPS outlook for the year also raises our optimism. However, the decline in total U.S. dialysis treatments during the quarter due to a decrease in hospital inpatient revenues was discouraging. The company faced continued cost inflationary pressure, a tight labor market and low unemployment during the reported quarter, which was further concerning. Zacks Rank and Other Key Picks DaVita currently carries a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger Chemed\u2019s CHE VITAS business has been registering robust performance over the past few quarters. However, seasonality in business, competitive landscape and dependence on government mandates are concerns. The stock carries a Zacks Rank #3 (Hold). Chemed\u2019s VITAS segment is being driven by the strong adoption of its advanced hospice and palliative care services through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. In the third quarter, VITAS net revenues were up 12.5% year over year on a significant increase in days of care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.7%. Further, Roto-Rooter is currently the nation\u2019s leading provider of plumbing, drain cleaning service and water restoration, reaching more than 90% of the U.S. population. Chemed believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment\u2019s market share, banking on the company\u2019s core competitive advantages in terms of brand awareness, customer response time and 24/7 call centers and Internet presence. A notable e-marketing initiative by Roto-Rooter is to expand brand awareness among younger audiences by placing advertisements and content on various social media platforms, including Facebook, Instagram and YouTube. Chemed Corporation Price Chemed Corporation price | Chemed Corporation Quote In the third quarter, Roto-Rooter branch commercial revenues inched up 1.5% from the last year on 1.8% growth in excavation revenues and a 2% hike in commercial water restoration revenues. On the flip side, in recent times, Chemed\u2019s margin performance has been affected by the inflationary trend, increased logistics costs and higher employee-related expenses. In the third quarter, the company noted that full-year 2023 revenue growth is expected to be negatively impacted by 75 basis points as a result of the sequestration relief in the first half of 2022 compared to a full year of sequestration in 2023. In the third quarter of 2023, the company registered a year-over-year increase of 35.8% in the cost of products and services by 4.5%. Added to this, the market for sewer, drain and pipe cleaning and plumbing repair businesses is highly competitive. Competition is fragmented in most markets, with local and regional firms providing much of the competition. Besides, Hospice care in the United States is competitive as hospice services are generally uniform. As the hospice care industry is highly fragmented, VITAS competes with a large number of organizations on the basis of its ability to deliver quality, responsive services. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, DexCom DXCM and Haemonetics HAE. While PODD carries a Zacks Rank #1 (Strong Buy) currently, DXCM and HAE carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DexCom has a long-term expected earnings growth rate of 33.6%. Earnings estimates for 2023have increased from $1.23 to $1.41 in the past 30 days. DXCM\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. In the last reported quarter, it posted an earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.62 to $1.65 in the past 30 days. PODD has a long-term expected earnings growth rate of 41.5%. Insulet\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 126.94%. In the last reported quarter, it delivered an earnings surprise of 58.33%. Estimates for Haemonetics\u2019 fiscal 2024 earnings have remained constant at $3.82 in the past 60 days. HAE has a long-term expected earnings growth rate of 10%. Haemonetics\u2019 earnings beat estimates in each of the trailing four quarters, with the average beat being 19.39%. In the last reported quarter, it delivered an earnings surprise of 38.16%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Chemed Corporation (CHE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But there are a couple of medical device makers that are still seeing strong demand for their products even amid the rising popularity of weight-loss treatments. DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. Here's why they could continue to be good buys for the foreseeable future. 1. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes track their glucose levels. But investors have been concerned that with the rising popularity of drugs that can help with weight loss, including Wegovy and Ozempic, there will be less of a need for CGMs, and that will hurt the growth prospects of a company like DexCom. But the numbers don't suggest that at all. DexCom reported its third-quarter numbers last month, and revenue of $975 million for the period ended Sept. 30 was up 27% year over year. For the full year, DexCom anticipates that its top line will come in around $3.6 billion, which would represent a year-over-year increase of approximately 24%. It also projects that its adjusted operating margin will be a fairly healthy 19% of revenue. On the company's earnings call, CEO Kevin Sayer also indicated that a rise in weight-loss drugs that help to curb appetite (also known as GLP-1 drugs) isn't hurting business. \""The data clearly show that CGM usage grows faster in GLP-1 users than those who are not on therapy.\"" Whether this pattern continues is the big question, but for now weight-loss drugs may be helping to encourage people to track their glucose levels. DexCom is down more than 30% from its 52-week high. Now could be a potentially good time for investors to buy shares of this healthcare stock. 2. Abbott Laboratories A big rival for DexCom is Abbott Laboratories, which also makes CGMs. The company's medical device segment, specifically diabetes care products, is a key source of growth. For the period ended Sept. 30, Abbott reported revenue of $4.2 billion in its medical device segment, which grew at a rate of nearly 17% -- the highest among all of its segments. Sales of its FreeStyle Libre CGM devices were especially strong, coming in at $1.4 billion and growing at a rate of 31%. Abbott's management sees a similar to trend with respect to CGMs and weight-loss treatment: They are going hand-in-hand with one another. CEO Robert Ford said on the company's earnings call last month that \""a recent analysis of our U.S. user base showed that a growing number of Libre users are using Libre in combination with GLP-1 medications as part of a companion therapy approach for managing their diabetes.\"" The early signs are encouraging for both DexCom and Abbott, indicating that perhaps GLP-1 treatments aren't going to bad news for their respective businesses. But with both stocks down more than 13% this year, investors don't appear to be convinced just yet. Which stock is the better option for investors? Trading at 33 times its trailing earnings, Abbott is the more modestly priced stock of the two right now -- DexCom's price-to-earnings multiple is at more than 100, but that should come down as the business continues to grow over the years. Abbott is also the more diversified of the two businesses, with pharmaceutical, nutritional products, diagnostics, and other medical devices also contributing to its top line. Both stocks could make for good long-term investments, but if you prefer a more pure-play diabetes stock, then DexCom may be the better buy. However, if you want a more diversified healthcare investment, then Abbott could be the optimal choice for your long-term investing strategy. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 6, 2023 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down STERIS plc STE reported second-quarter fiscal 2024 adjusted earnings per share (EPS) of $2.03, up 2% from the year-ago quarter\u2019s figure. However, the metric missed the Zacks Consensus Estimate by 1%. The adjustment excludes the impacts of certain non-recurring charges like the amortization of acquired intangible assets and acquisition and integration-related charges, among others. The company\u2019s GAAP EPS was $1.16 compared to the loss of $3.15 per share in the year-ago quarter. Revenues in Detail Revenues of $1.34 billion increased 11.8% year over year in the second quarter. The metric beat the Zacks Consensus Estimate by 4.1%. Organic revenues at the constant exchange rate or CER rose 8% year over year in the fiscal second quarter. STERIS plc Price, Consensus and EPS Surprise STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote Quarter in Detail The company operates through four segments \u2014 Healthcare, Applied Sterilization Technologies (\u201cAST\u201d), Life Sciences and Dental. Revenues at Healthcare rose 18.7% year over year to $870.1 million (up 14% on a CER organic basis). This performance reflected a 20% improvement in capital equipment revenues, a 13% increase in service revenues and a 24% rise in consumable revenues. Going by our model, the projected revenues for the Healthcare segment in the fiscal second quarter was $797.7 million. Revenues at AST improved 1.2% to $235.1 million (down 1% on a CER organic basis). Underlying service growth continues to be impacted by Medtech Customer inventory management and the reduction in demand from bioprocessing Customers. Our model estimated revenues for this business to be $239.4 million in the second quarter. Revenues in the Life Sciences segment increased 5.8% to $133.1 million (up 5% year over year on a CER organic basis). This performance reflected an 18% increase in capital equipment revenues and a 3% increase in consumable revenues, while service revenues were flat compared with the second quarter last year. Our model\u2019s projection was $138.7 million. The Dental segment reported revenues of $104.2 million, down 4.9% year over year (down 6% on a CER organic basis). The reported figure also missed our model\u2019s projected revenues of $107.9 million. Margins The gross profit in the reported quarter was $593.5 million, up 11.5% from the prior-year quarter. However, the gross margin contracted 13 basis points (bps) year over year to 44.2% on a 12.1% rise in the cost of revenues. STERIS witnessed a 17.8% year-over-year rise in selling, general and administrative expenses to $380.7 million. Research and development expenses rose 8.5% to $27 million. Adjusted operating expenses of $407.7 million rose 17% year over year. The adjusted operating margin contracted 150 bps to 13.8%. Financial Details STERIS exited the second quarter of fiscal 2024 with cash and cash equivalents of $213.8 million compared with $208.6 million at the end of the fiscal first quarter of 2024. Cumulative net cash flow from operating activities at the end of the fiscal second quarter was $427.2 million compared with $335.6 million at the end of the prior year\u2019s comparable period. Further, the company has a five-year annualized dividend growth rate of 8.51%. Guidance STERIS reaffirmed its fiscal 2024 guidance, which was originally provided on the fiscal first-quarter earnings call. STERIS expects fiscal 2024 revenues to increase 9-10% from fiscal 2023 (unchanged). Organic revenue expectation at CER also remains unchanged at 6-7%. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $5.42 billion, implying 9.3% growth from fiscal 2023. Adjusted earnings per share for fiscal 2024 are now expected in the range of $8.60-$8.80 (same as earlier). The Zacks Consensus Estimate for the metric is pegged at $8.73. Our Take STERIS exited the fiscal second quarter of 2024 with earnings missing and revenues beating estimates. The bottom line was up year over year. The ongoing momentum in the Healthcare segment is encouraging, with the chances of outperforming the company\u2019s original expectations for the current fiscal year. Moreover, the integration of the surgical instrumentation business purchased from BD during the quarter continues to progress as planned. Meanwhile, escalating expenses do not bode well for the stock. Both margins resulted in a contraction in the quarter, raising our concern. Zacks Rank & Key Picks STERIS currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-09,93.27,95.29,91.71,92.4,"[""Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform. The Style Scores are broken down into four categories: Value Score Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks. Growth Score Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time. Momentum Score Momentum traders and investors live by the saying \""the trend is your friend.\"" This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. VGM Score If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier. #1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day. This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio. That's where the Style Scores come in. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of A, forecasting year-over-year earnings growth of 62.1% for the current fiscal year. 10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.18 to $1.41 per share. DXCM also boasts an average earnings surprise of 36.4%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Earnings Winners Poised to Outperform the Market InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sound financial performance indicates that a company may be a good investment choice. The earnings season provides investors another window of opportunity to see which reporting companies exceeded expectations with solid financials and positive outlooks. These earnings winners present new and experienced investors with opportunities to get in on a company with strong growth potential. That is why investing in earnings season winners is one of the best thematic strategies investors can use to rebalance their portfolios, ride the winners\u2019 momentum or mitigate the long-term risk from companies that poorly performed during the previous quarter. If you are in the market to complete your portfolio or deploy some trading capital, these three winners might be worth checking out before the rest of the market jumps in. Dexcom (DXCM) Source: FOOTAGE VECTOR PHOTO / Shutterstock.com Dexcom (NASDAQ:DXCM) designs and manufactures medical devices focused on continuous glucose monitoring (CGM) systems used by healthcare providers and diabetes patients. It has an integrated system product called Dexcom G6, which allows it to work with electronic interfaces and medical devices that collectively help automate insulin pumps, insulin dosing systems and other diabetes management devices. Its other products include Dexcom Real-time API for third-party health applications integration and its Clarity system for cloud integration in mobile devices. DXCM\u2019s revenue grew by 27% year-over-year (YoY), and organic GAAP operating income also increased by 190 basis points YoY. Plus, earnings beat analyst expectations by 47.06%, a giant leap from last year\u2019s non-GAAP earnings. The company recently received regulatory clearance for a Dexcom G7 launch in the Canadian Market. Dexcom also raised its FY 2023 revenue guidance to 23% to 24% growth and a 28% increase in EBITDA margin. That makes DXCM one of our top choices in this quarter\u2019s earnings winners. Emcor Group (EME) Source: ARMMY PICCA/ShutterStock.com Emcor Group (NYSE:EME) is a specialty contractor for mechanical and electrical construction, infrastructure and building services that offer the design, integration and maintenance of electrical power transmissions, generation and distribution service systems. These services cater to critical infrastructure systems in virtually every economic sector. Emcor also offers services that cover facility environments, such as lighting, air conditioning, fire protection, specialty welding and power generation systems. EME is also in a definitive acquisition agreement with ECM Holding Group. ECM is one of the leading providers of efficiency retrofit services for weatherization, lighting, water and airflow management solutions. This transaction, once completed, is expected to add further expanded services to Emcor Group\u2019s specialized offerings. On the earnings front, EME reported a record quarterly revenue of $3.21 billion, a 13.5% increase YoY. The company also reported a $3.61 EPS, exceeding analyst estimates by 33.21%. The revenue growth has been driven mainly by its U.S. construction segment. Its strong performance year to date led to the company upgrading its 2023 revenue guidance to $12.5 billion and its non-GAAP diluted EPS to $12.25 to $12.65 from its previous $10.75 to $11.25 guidance. That makes EME another top investment contender in this quarter\u2019s earnings winner. AppFolio (APPF) Source: Pavel Kapysh / Shutterstock.com AppFolio (NASDAQ:APPF) is a cloud business management solution that caters to the real estate industry and helps businesses automate, streamline and digitally transform critical operations. The company\u2019s platform is aimed to help the real estate industry have a platform interconnected in a singularly growing ecosystem. That includes property owners, real estate investment managers, property managers and residents. APPF\u2019s solutions, AppFolio Property Manager Plus, AppFolio Property Manager and AppFolio\u2019s platform, provide various services, including payments, tenant screening and insurance. AppFolio made a comeback in its financial results for the quarter. Revenue grew by 32% for Q3 2023, and EPS beat analysts\u2019 estimates with its reported earnings of 225% surprise. The AppFolio Property Manager platform grew to 7.8 million units, a 9.85% increase YoY. The company\u2019s continued focus on creating exceptional shareholder value has paid off with its stellar quarter. No wonder Analysts see it as a Strong Buy. With a potential turnaround recovery for the end of the year, we see APPF as a strong contender in our list of earnings release winners. On the date of publication, Rick Orford did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News. More From InvestorPlace Musk\u2019s \u201cProject Omega\u201d May Be Set to Mint New Millionaires. Here\u2019s How to Get In. The #1 AI Investment Might Be This Company You\u2019ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post 3 Earnings Winners Poised to Outperform the Market appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.42 in the fourth quarter of fiscal 2023, up 24.4% year over year. The figure was in line with the Zacks Consensus Estimate. The adjustments include expenses related to purchase accounting adjustments and integration costs, among others. GAAP EPS for the quarter was 53 cents, reflecting a decline of 42.4% from the year-earlier figure. Full-year adjusted EPS was $12.21, up 7.6% compared with that at the end of the comparable fiscal 2022 period. The figure lagged the Zacks Consensus Estimate by 0.2%. Revenues in Detail BD registered revenues of $5.09 billion in the fiscal fourth quarter, up 6.8% year over year. The figure surpassed the Zacks Consensus Estimate by 1.4%. At constant exchange rate (CER), revenues climbed 5.9%. The top-line improvement primarily resulted from robust performances by BD\u2019s segments. Base revenues were $5.07 billion in the fiscal fourth quarter, up 7.3% year over year on a reported basis and 6.3% at CER. Base organic revenue growth for the fiscal fourth quarter was 7% at CER. Full-year revenues were $19.37 billion, reflecting a 2.7% improvement from the comparable fiscal 2022 period. The figure surpassed the Zacks Consensus Estimate by 0.4%. Segment Details BD\u2019s operations consist of three worldwide business segments \u2014 BD Medical, BD Life Sciences and BD Interventional. For the quarter under review, BD Medical reported worldwide revenues of $2.55 billion, up 7.5% from the year-ago quarter on a reported basis and 6.2% at CER. Per management, this upside can be attributed to strong double-digit growth in Medication Management Solutions and Pharmaceutical Systems (PS) business units. This compares to our projection of fiscal fourth-quarter segmental revenues of $2.45 billion. Worldwide revenues in the BD Life Sciences segment totaled $1.33 billion, up 3.3% year over year on a reported basis and up 2.2% at CER. The segment\u2019s performance reflected solid growth in the base business and an expected decline in COVID-only testing revenues. The fiscal fourth-quarter revenues compare to our estimate of $1.34 billion. BD Interventional segment generated worldwide revenues of $1.20 billion, up 9.7% from the year-ago quarter on a reported basis and 9.6% at CER. This was owing to strong growth across the segment. The fiscal fourth-quarter revenues compare to our estimate of $1.22 billion. Geographic Results In the fourth quarter of fiscal 2023, revenues in the United States improved 6.3% to $2.88 billion. This compares to our estimate of $2.87 billion. International revenues grossed $2.21 billion, up 7.6% from the year-ago quarter on a reported basis and 5.3% at CER. This compares to our estimate of $2.13 billion. Becton, Dickinson and Company Price, Consensus and EPS Surprise Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote Margin Analysis In the quarter under review, BD\u2019s gross profit declined 18.1% to $1.70 billion. The gross margin contracted a huge 1017 basis points (bps) to 33.4%. Selling and administrative expenses decreased 3.8% to $1.14 billion. Research and development expenses decreased 6.3% year over year to $281 million. Adjusted operating expenses of $1.42 billion declined 4.3% year over year. Adjusted operating profit totaled $283 million, reflecting a 52.4% plunge from the year-ago quarter. The adjusted operating margin in the fiscal fourth quarter contracted 691 bps to 5.6%. Financial Position BD exited fiscal 2023 with cash and cash equivalents and short-term investments of $1.42 billion compared with $1.01 billion at the fiscal 2022-end. Total debt (including current debt obligations) at the end of fiscal 2023 was $15.88 billion compared with $16.07 billion at the fiscal 2022-end. Cumulative net cash flow from continuing operating activities at the end of fiscal 2023 was $2.99 billion compared with $2.47 million a year ago. Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 4.23%. Fiscal 2024 Guidance BD has initiated its financial outlook for fiscal 2024. BD projects its full fiscal year revenues to be in the range of $20.1 billion-$20.3 billion. The Zacks Consensus Estimate is pegged at $20.32 billion. For fiscal 2024, organic revenue growth is expected to be between 5.25% and 6.25%, while revenue growth at CER is expected to be in the range of 4.5-5.5%. For the full fiscal year, adjusted EPS is anticipated in the range of $12.70-$13.00, representing growth of 4-6.5%. The Zacks Consensus Estimate is pegged at $13.49. Our Take BD exited the fourth quarter of fiscal 2023 with in-line earnings and better-than-expected revenues. Solid top-line and bottom-line results, along with improvements in the overall base revenues, were impressive. Robust performances by all its segments and both geographic regions were encouraging. Strength in BD\u2019s segment\u2019s business units during the reported quarter was also promising. This month, BD\u2019s Medication Delivery Solutions (MDS) business unit launched its next-generation needle-free blood draw technology, the new PIVO Pro Needle-free Blood Collection Device. In August, BD received the FDA\u2019s 510(k) clearance for the BD Respiratory Viral Panel for the BD MAX System. These developments also raise our optimism. However, lower COVID-only testing revenues in the quarter were discouraging from a business perspective. MDS unit\u2019s softness in China, driven by market dynamics (including volume-based procurement) and the PS unit\u2019s slowdown in China exports of anticoagulants, were also concerning. Rising product costs put pressure on the margins, leading to the contraction of both margins, which do not bode well. Zacks Rank and Key Picks BD currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y Surmodics, Inc. SRDX delivered adjusted earnings per share (EPS) of 53 cents in the fourth quarter of fiscal 2023 against the year-ago quarter\u2019s loss of 26 cents per share. The metric topped the Zacks Consensus Estimate by a huge 231.3%. GAAP EPS for the quarter was 47 cents against the year-earlier loss of $1.06 per share. Full-year adjusted EPS was 16 cents against the loss of 95 cents per share at the end of the comparable fiscal 2022 period and the Zacks Consensus Estimate of a loss of 22 cents per share. Revenues in Detail Surmodics registered revenues of $27.9 million in the fiscal fourth quarter, up 7.6% year over year. The figure surpassed the Zacks Consensus Estimate by 7.6%. The top line was boosted by solid year-over-year product sales growth from both the Medical Device and In Vitro Diagnostics (IVD) businesses. Excluding SurVeil drug-coated balloon (DCB) license fee revenues, total revenues increased 12.6% year over year to $26.9 million. Full-year revenues were $132.6 million, reflecting a 32.6% improvement from the comparable fiscal 2022 period. The figure surpassed the Zacks Consensus Estimate by 1.5%. Segmental Analysis Surmodics operates via two reportable segments \u2014 Medical Device and IVD. In the reported quarter, sales in the Medical Device segment summed $21 million, up 7.9% from the year-ago quarter. Excluding SurVeil DCB license fee revenues, Medical Device revenues increased 14.9% to $20 million year over year. Medical Device revenue growth was primarily driven by increased performance coating royalties and significant contributions to product sales from the Pounce thrombectomy device platform. However, this was partly offset by a decrease in proprietary specialty catheter product sales due to the completion of a customer development program. This figure compares to our Medical Device fiscal fourth-quarter revenue projection of $19.7 million. In the quarter under review, IVD sales improved 6.8% to $6.9 million, primarily driven by strong customer demand for microarray slide/surface products and favorable order timing for distributed antigen products. This figure compares to our IVD fiscal fourth-quarter revenue projection of $6.3 million. The company also derives revenues from three primary sources \u2014 Product sales, Royalties and license fees and Research, development and other fees. In the quarter under review, Product sales were $15.4 million, up 6.7% from the prior-year quarter. This figure compares to our fiscal fourth-quarter revenue projection of $14.9 million. Royalties and license fees revenues totaled $10.1 million, up 5.7% from the prior-year quarter. This figure compares to our fiscal fourth-quarter revenue projection of $11.1 million. Research, development and other revenues were $2.6 million, up 22.6% year over year. Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. price-consensus-eps-surprise-chart | Surmodics, Inc. Quote Margin Trend In the quarter under review, Surmodics\u2019 gross profit increased 2.6% to $20.9 million. However, the gross margin contracted 363 basis points to 74.8%. We had projected 80.0% of gross margin for the fiscal fourth quarter. Selling, general & administrative expenses declined 7.1% to $12.8 million. Research and development expenses declined 20.9% year over year to $9.7 million. Adjusted operating expenses of $22.5 million declined 13.6% year over year. Adjusted operating loss totaled $1.6 million compared with the prior-year quarter\u2019s adjusted operating loss of $5.6 million. Financial Position Surmodics exited fiscal 2023 with cash and cash equivalents of $41.4 million compared with $18.9 million at the end of fiscal 2022. Total debt (including short-term debt) at the end of fiscal 2023 was $29.4 million compared with $10 million at the fiscal 2022-end. Cumulative net cash provided by operating activities at the end of fiscal 2023 was $10.5 million against cumulative net cash used in operating activities of $17.2 million a year ago. Fiscal 2024 Guidance Surmodics has initiated its financial outlook for fiscal 2024. The company projects fiscal year 2024 revenues in the range of $116 million-$121 million, representing a decrease of 13-9% over the comparable prior-year period. The Zacks Consensus Estimate currently stands at $121.2 million. Excluding SurVeil DCB license fee revenues, Surmodics expects fiscal 2024 total revenues between $112 million and $117 million, representing an increase of 9-14% compared to fiscal 2023. Adjusted loss per share for fiscal 2024 is expected to be in the range of $1.32-97 cents. The Zacks Consensus Estimate currently stands at a loss of 67 cents per share. Our Take Surmodics exited the fourth quarter of fiscal 2023 with better-than-expected results. The solid uptick in the overall top line and bottom line was impressive. The company registered robust revenues from both segments and its primary sources, which was encouraging. During the quarter, Surmodics advanced the initial commercialization of its Pounce arterial thrombectomy and Sublime radial access platforms. This looks promising for the stock. In October, Surmodics launched its Preside medical device coating technology, providing improved lubricity and durability to a broader range of complex device applications. This raises our optimism about the stock. However, the gross margin contraction does not bode well for Surmodics. Its operation in a competitive and evolving field and reliance on third parties also raise our apprehension. Zacks Rank and Other Key Picks Surmodics currently sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now IDEXX Laboratories, Inc. IDXX is well-poised to grow confidence, backed by solid gains in CAG (Companion Animal Group) Diagnostics\u2019 recurring revenues. Strong momentum in the expansion of the ProCyte One installed base buoys optimism. The expansion of its commercial footprint has been a key element of the company\u2019s customer engagement strategy, which is highly promising. However, IDEXX\u2019s operations are prone to macroeconomic challenges. Also, unfavorable solvency does not bode well. In the past year, this Zacks Rank #4 (Sell) stock has increased 2.8% against the 8.9% decline of the industry and an 11.5% rise of the S&P 500 composite. The renowned medical device company has a market capitalization of $35.1 billion. IDEXX has an estimated long-term earnings growth rate of 18% compared with the industry\u2019s 14.2%. IDXX\u2019s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 7.64%. Let\u2019s delve deeper. Upsides CAG Continues to Perform Well: The company\u2019s long-term success in the continuing growth of CAG\u2019s recurring diagnostic products and services depends on growing volumes at existing customers by increasing their utilization of existing and new test offerings, acquiring new customers, maintaining high customer loyalty and retention and realizing modest annual price increases. Once again, in the third quarter of 2023, IDEXX's CAG Diagnostics recurring revenues remained solidly above sector growth levels. In the United States, volume growth was supported by new business gains, high customer retention levels and continued increases in diagnostic frequency and utilization per clinical visit at the practice level. Image Source: Zacks Investment Research ProCyte One, a Long-Term Growth Component: IDEXX\u2019s innovative, customer-friendly hematology analyzer, ProCyte One, has been a key driver of strong premium hematology placements since its launch in 2021. Additionally, ProCyte One supports the company\u2019s long-term growth goal in international markets, where most veterinarians are qualified to perform hematology testing when determining a patient's general health. At the third quarter-end, the global installed base exceeded more than 12,000 instruments. Strong Global Performance: IDEXX\u2019s increased commercial presence as a result of seven international commercial expansions since 2020 helped drive solid double-digit year-over-year gains in the international premium instrument installed base across platforms in the third quarter of 2023. Globally, IDEXX continues to achieve strong organic revenue growth across its modalities. In the third quarter, consumable gains were aided by 11% growth in the global premium instrument installed base, reflecting solid gains across its Catalyst, Premium Hematology and SediVue platforms. In addition, IDEXX\u2019s premium instrument placements continue to benefit from the international launch of ProCyte One. Downsides Macroeconomic Concerns: During the third quarter, IDXX\u2019s sales and marketing expenses rose primarily due to higher personnel-related costs, partially offset by lower meeting and conference costs. General and administrative expenses also increased 6.3%, driven by higher personnel-related and outside services costs. Headwinds from ongoing capacity management challenges at U.S. clinics impacted software trends and caused a relative slowdown in wellness visits in the quarter. Debt Profile: At the end of the third quarter of 2023, IDEXX reported a short-term debt of $400 million against the corresponding cash and cash equivalents of $331.7 million. With unfavorable solvency, the company is likely to face a challenge in repaying its obligations. Estimate Trend The Zacks Consensus Estimate for IDEXX\u2019s 2023 earnings per share (EPS) has moved down from $9.81 to $9.80 in the past 30 days and increased to $9.82 in the past seven days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $3.65 billion. This suggests an 8.3% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 27.1% for fiscal 2024 compared with the industry\u2019s 17.2%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have rallied 3.8% against the industry\u2019s 9.2% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 41.5% compared with the industry\u2019s 12.2%. Shares of the company have decreased 49.2% compared with the industry\u2019s 9.2% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 126.9%. In the last reported quarter, it delivered an average earnings surprise of 58.3%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 14.3%. Shares of DXCM have fallen 22.5% compared with the industry\u2019s 8.9% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down Phibro Animal Health PAHC delivered adjusted earnings per share (EPS) of 14 cents in the first quarter of fiscal 2024, down 33.3% from the year-ago quarter\u2019s adjusted figure. The metric also missed the Zacks Consensus Estimate by 33.3%. Without adjustments, the GAAP loss per share in the fiscal first quarter was 20 cents compared to the EPS of 10 cents in the year-ago quarter. Net Sales In the quarter under review, net sales totaled $231.3 million, a 0.5% decrease from the year-ago quarter. The figure also missed the Zacks Consensus Estimate by 4.4%. Segmental Sales Breakup The company conducts its operations via three segments \u2014 Animal Health, Mineral Nutrition and Performance Products. In the first quarter of fiscal 2024, Animal Health\u2019s net sales increased 3.6% to $160.5 million. Our model\u2019s projected revenues were $164.3 million. Phibro Animal Health Corporation Price, Consensus and EPS Surprise Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote Within the segment, net sales of medicated feed additives (MFAs) and others reflected 1% year-over-year growth. The uptick was driven by increased sales of the company\u2019s processing aids used in the ethanol fermentation industry. Within Animal Health, nutritional specialty product sales rose 3%, with increased volumes in poultry customers, primarily domestic. Also, net vaccine sales showed a year-over-year rise of 14% due to poultry product introductions in Latin America and growth in the U.S. swine sector, partially offset by the timing of deliveries in other international regions. Net sales in the Mineral Nutrition segment fell 6% year over year due to declines in average selling prices and reduced volumes due to reduced demand. Per our model, revenues from this segment were expected to be $57.7 million in the fiscal first quarter. Net sales in the Performance Products segment fell 17.8% to $14.8 million as a result of the lower demand for the ingredients used in personal care products. Our model projected the segment to report $18.5 million in revenues. Margins Phibro\u2019s fiscal first-quarter gross profit fell 1.3% year over year to $67.7 million. The gross margin contracted 24 basis points (bps) to 29.3% on a 0.2% rise in the cost of goods sold to $163.6 million. SG&A expenses in the reported quarter were $68.5 million, up 24.6% from the year-ago quarter\u2019s levels. The operating profit fell a staggering 106% year over year to $0.8 million, while the operating margin contracted 620 bps to 0.3% in the quarter under review. Financial Update The company exited the fiscal 2024 first quarter with cash and short-term investments of $91.2 million compared with $81.3 million at the end of the fourth quarter of fiscal 2023. Cumulative net cash provided by operating activities at the end of the first quarter was $16.2 million compared with net cash outflow of $10.7 million in the prior year\u2019s comparable period. Guidance Phibro provided updated guidance for fiscal 2024. The company expects net sales between $980 million to $1.02 billion (earlier $1 billion-$1.05 billion). The Zacks Consensus Estimate for the metric is pegged at $1.02 billion. Adjusted EPS is expected in the range of $1.04-$1.16 (previously $1.12-$1.27). The Zacks Consensus Estimate is pegged at $1.18. Our Take Phibro exited the first quarter of fiscal 2024 on a disappointing note, with lower-than-expected revenues and earnings. Both Mineral Nutrition and Performance Products businesses witnessed reduced sales in the quarter, partly because of customers rationalizing their inventory levels and timing issues. The stark decline in the operating profit is highly concerning. On a positive note, Phibro\u2019s core Animal Health business demonstrated continued growth. Double-digit sales growth in the vaccines product group benefited from the strong customer acceptance of poultry vaccines recently launched in Latin America. Phibro\u2019s ongoing investment in the companion animal pipeline is promising. Zacks Rank & Key Picks Phibro currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag Inspire Medical Systems, Inc. INSP delivered a loss of 29 cents per share in third-quarter 2023, narrower than the year-ago loss of 60 cents. The metric was also narrower than the Zacks Consensus Estimate of a loss of 53 cents. Revenues in Detail Inspire Medical registered revenues of $153.3 million in the third quarter, up 40.4% year over year. However, the figure lagged the Zacks Consensus Estimate by 1.8%. Per management, the top-line growth was driven by higher utilization at existing sites. The addition of new implanting centers and U.S. sales territories also complimented the improvement. The top line also benefited from strength in U.S. revenues and revenues outside the United States (All other countries). Segment Details Inspire Medical\u2019s operations consist of two geographic regions \u2014 the United States and All other countries. For the quarter under review, U.S. revenues of $147.5 million reflected an increase of 38.8% from the year-ago quarter on a reported basis. Per management, this upside was primarily driven by higher utilization at existing centers. Other growth drivers included the addition of new implanting centers, Inspire Medical\u2019s continuing direct-to-consumer marketing and a higher number of territory managers. During the reported quarter, Inspire Medical activated 62 new U.S. centers, thus bringing the total to 1,107 U.S. medical centers providing Inspire therapy. The company also created 13 new U.S. sales territories in the quarter, bringing the total to 274 U.S. sales territories. Revenues from outside the United States totaled $5.8 million, up 99% year over year on a reported basis. Inspire Medical Systems, Inc. Price, Consensus and EPS Surprise Inspire Medical Systems, Inc. price-consensus-eps-surprise-chart | Inspire Medical Systems, Inc. Quote Margin Analysis In the third quarter, Inspire Medical\u2019s gross profit increased 44.2% to $128.9 million. The gross margin expanded 222 basis points to 84.1%. Selling, general and administrative expenses jumped 32.3% to $113.2 million. Research and development expenses increased 38.8% year over year to $29.1 million. Operating expenses of $142.4 million increased 33.6% year over year. Operating loss totaled $13.5 million compared with the prior-year quarter\u2019s operating loss of $17.2 million. Financial Position INSP exited third-quarter 2023 with cash and cash equivalents and short-term investments of $464.2 million compared with $467.1 million at the second-quarter end. Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $7.4 million against cumulative net cash used in operating activities of $7.7 million a year ago. Outlook Inspire Medical has upped its revenue outlook for 2023. The company now projects revenues in the range of $608 million-$612 million (reflecting growth of 49-50% from 2022 levels), up from the earlier projection of $600 million-$610 million (reflecting growth of 47-50% from 2022 levels). The Zacks Consensus Estimate is pegged at $612.3 million. INSP continues to plan to activate 52-56 new U.S. medical centers providing Inspire therapy and add 12-14 new U.S. sales territories during the fourth quarter of 2023. Our Take Inspire Medical exited the third quarter of 2023 with narrower-than-expected loss per share. The robust improvement of the top line was impressive. Strength in year-over-year geographic results was promising. The gross margin expansion, despite rising product costs, also looks promising. The activation of new U.S. centers and the creation of new U.S. sales territories during the reported quarter also look encouraging. Management\u2019s expectations of activating more U.S. medical centers and adding new U.S. sales territories during the fourth quarter of 2023 also raise our optimism about the stock. During the quarter, Inspire Medical\u2019s management confirmed making significant progress with market access by expanding coverage policies with several large national health plans to include the company\u2019s recently expanded indications. Management also stated that the company continued to make investments in its clinical research, as reflected by the PREDICTOR study results. These also look promising for the stock. However, lower-than-expected revenues and dismal bottom-line results were disappointing. Rising operating costs weighed on the company\u2019s performance and resulted in continued operating loss. This also raises apprehension. Zacks Rank and Key Picks Inspire Medical currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-10,93.61,95.07,91.59,94.05,"[""National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall National Vision Holdings, Inc. EYE delivered adjusted earnings per share (EPS) of 15 cents for the third quarter of 2023, flat year over year. The figure topped the Zacks Consensus Estimate by 150%. The adjustment excludes the impact of certain non-recurring charges like stock compensation expenses, asset impairment and the amortization of acquisition intangibles, among others. GAAP loss in the quarter was 94 cents per share, marking a significant decline from the prior-year figure of 15 cents. Revenues in Detail Revenues in the third quarter totaled $532.4 million, surpassing the Zacks Consensus Estimate by 1.1%. The top line rose 6.6% from the year-ago quarter\u2019s number, led by an increase in adjusted comparable store sales growth, new store sales growth and higher revenues from the company's AC Lens business. This was partially offset by the impact of unearned revenues in the third quarter of 2023 compared with the prior-year quarter. In the third quarter, comparable store sales growth was 3.8%. Adjusted comparable store sales growth was 4.3%. National Vision opened 21 new stores to reach a store count of 1,402 at the end of the quarter. Overall, the store count rose 5.3% year over year. Segment Analysis Till the end of 2023, National Vision will continue to provide its principal products and services through two reportable segments \u2014 Owned & Host and Legacy. However, the termination of the longstanding Walmart contract (announced in July) will lead to a full dilution of the company\u2019s Legacy business, effective 2024. National Vision Holdings, Inc. Price, Consensus and EPS Surprise National Vision Holdings, Inc. price-consensus-eps-surprise-chart | National Vision Holdings, Inc. Quote Margins The gross profit in the reported quarter was $280.3 million, up 5.2% from the prior-year quarter\u2019s levels. The gross margin of 52.7% contracted 71 basis points (bps). SG&A expenses rose 10.9% to $249.7 million. The adjusted operating margin was 5.8%, contracting 254 bps year over year. Financial Position National Vision exited the third quarter of 2023 with cash and cash equivalents of $265.8 million compared with $254.6 million at the end of the second quarter. The cumulative net cash flow from operating activities at the end of the quarter was $153.3 million compared with $121.3 million a year ago. 2023 Outlook National Vision updated its full-year 2023 guidance. For 2023, net revenues are expected in the range of $2.115-$2.125 billion (the previous outlook was $2.075-$2.135 billion). The Zacks Consensus Estimate for the metric is currently pegged at $2.12 billion. Adjusted EPS is estimated in the band of 53-58 cents (42-60 cents). The Zacks Consensus Estimate for the same is currently pegged at 54 cents. Adjusted comparable store sales are expected at around 2% (0%-3%). Our Take National Vision reported third-quarter 2023 results with better-than-expected earnings and revenues. The performance reflected strength in the managed care business supported by the continued progress with expanding eye exam capacity, particularly within America's Best. Adjusted comparable store sales growth was driven by an increase in average ticket and customer transactions. In July, National Vision announced the termination of the Walmart partnership in 2024, positioning the company to focus on core strategic initiatives to grow its freestanding brands \u2014 America\u2019s Best and Eyeglass World. Planned new store openings of around 65-70 this year remain well on track. Meanwhile, the contraction of both margins is worrisome. Higher SG&A expenses in the quarter reflected increases in performance-based incentives and stock-based compensation. Zacks Rank and Key Picks National Vision currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut Illumina Inc. ILMN reported adjusted earnings per share (EPS) of 33 cents in the third quarter of 2023, beating the Zacks Consensus Estimate of 13 cents by a staggering margin. However, the bottom line declined 3% from the year-ago quarter\u2019s figure. The adjustments exclude the impact of GRAIL pre-acquisition net operating losses on GILTI, the utilization of U.S. foreign tax credits and incremental non-GAAP tax expenses, among others. Including one-time items, the company\u2019s GAAP loss per share was $4.8 compared with the year-ago quarter\u2019s loss of $24.3. Revenues In the quarter under review, Illumina\u2019s revenues were $1.12 billion, up 0.4% year over year (up 1% at CER). The top line missed the Zacks Consensus Estimate by 1%. Segment Details Post the acquisition of GRAIL on Aug 18, 2021, Illumina has two reportable segments, Core Illumina and GRAIL. Core Illumina sequencing service and other revenues were $142 million (up 15% year over year). This was driven primarily by higher instrument service contract revenues on a growing installed base, as well as an increase in lab services revenues. Illumina, Inc. Price, Consensus and EPS Surprise Illumina, Inc. price-consensus-eps-surprise-chart | Illumina, Inc. Quote Sequencing Instrument revenues for Core Illumina of $179 million grew 10% year over year. The increase was primarily led by strength in NovaSeq X shipments, which more than offset the decline in NovaSeq 6000 shipments. Core Illumina sequencing service and other revenues were $142 million (up 15% year over year). This was driven primarily by higher instrument service contract revenue on a growing installed base, as well as an increase in lab services revenue. GRAIL contributed $21 million to revenues during the reported quarter compared with $10 million in the year-ago period. Margins The adjusted gross margin (excluding amortization of acquired intangible assets) was 65.3% in the reported quarter, highlighting a contraction of 310 basis points (bps) year over year. The decline is attributed to product mix and less fixed cost leverage on lower manufacturing volumes, as well as lower instrument margins and higher field service and installation costs due to the NovaSeq X launch. Research and development expenses decreased 3.1% year over year to $315 million, whereas SG&A expenses came in at $303 million compared with $146 million in the year-ago quarter. Adjusted operating costs increased 31.2% to $618 million. The adjusted operating profit in the quarter was $113 million, down 61.3% year over year. Financial Update Illumina exited the third quarter of 2023 with cash and cash equivalents plus short-term investments of $933 million compared with $1.56 billion at the end of the second quarter of 2023. The company did not repurchase any common stock in the quarter. Cumulative net cash provided by operating activities at the end of the third quarter of 2023 was $254 million compared with $245 million in the last year\u2019s comparable period. 2023 Guidance Illumina updated its 2023 outlook. The company expects 2023 consolidated revenues to decrease 2-3% (the earlier guidance was nearly 1% growth) compared with the previous year. The Zacks Consensus Estimate for the same is currently pegged at $4.60 billion. Adjusted EPS for 2023 is expected in the range of 60 cents to 70 cents (the previous guidance was 75 cents to 90 cents). The Zacks Consensus Estimate for the same is currently pegged at 78 cents. Core Illumina revenues are now expected to decrease 3-4% year over year (earlier projection was flat revenue growth). GRAIL revenues are anticipated to be at the low end of the $90 million to $110 million range (earlier projection, between $90 million-$110 million). Key Announcements Throughout the third quarter, Illumina headlined on many occasions. Notably, the company launched TruSight Oncology 500 (TSO 500) ctDNA Version 2, a liquid biopsy assay that enables comprehensive genomic profiling of circulating tumor DNA. Major improvements include a faster turnaround time of less than four days, higher sensitivity with lower input requirements and a more streamlined workflow. The company also announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India, to grow the genomics market in the most populous country in the world. The expansion will help unlock opportunities for advancing healthcare and combat the effects of climate change in South Asia. Our Take Illumina delivered better-than-expected third-quarter 2023 earnings, while revenues were a miss. Core Illumina\u2019s performance across all regions was affected by tighter funding and budget pressures impacting customers\u2019 purchasing power, as well as the high-throughput customers transitioning to NovaSeq X. Contraction in margins, as well as a reduced full-year outlook, is also discouraging. On a positive note, Illumina has been executing well in its plan to reduce the analyzed run rate expenses, having reduced by approximately $175 million, which is ahead of the original projection of more than $100 million. This appears promising. Zacks Rank & Key Picks Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-13,96.8,100.57,94.5501,98.35,"[""US STOCKS-S&P 500 takes a pause ahead of U.S inflation data By Sin\u00e9ad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly lower as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month. The CPI reading, along with labor market, \""are clearly in the driver's seat for what matters to financial markets, because it dictates where Fed policy goes from here,\"" said Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company in Milwaukee, Wisconsin. \""The market has the expectation the Fed is done with interest rate hikes and for that to be true, you need to have continued progress on the inflation front,\"" along with labor market cooling, he said. Traders have priced in a nearly 86% chance the Fed holds interest rates steady in December, according to the CME Group's FedWatch tool. While the CPI reading was the key issue keeping investors \""in a holding pattern\"" on Monday, Michael O\u2019Rourke, chief market strategist at JonesTrading in Stamford, Connecticut said they were also digesting a weaker U.S. credit outlook issued. Moody's late on Friday lowered its outlook on the U.S. credit rating to \""negative\"" from \""stable\"", citing large fiscal deficits and a decline in debt affordability. This added to investor reluctance to make big decisions ahead of a weekend deadline that could potentially result in a U.S. government shutdown, O'Rourke said. U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress. However on Monday afternoon, top U.S. Senate Democrat Chuck Schumer expressed tentative support for Johnson's short-term funding bill that would keep the government open past the weekend. The Dow Jones Industrial Average .DJI rose 54.77 points, or 0.16%, to 34,337.87, the S&P 500 .SPX lost 3.69 points, or 0.08%, to 4,411.55 and the Nasdaq Composite .IXIC dropped 30.37 points, or 0.22%, to 13,767.74. The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak. Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer, ending up 0.7% while utilities .SPLRCU was the biggest loser, falling 1.2%. Helping keep the Dow afloat, Boeing BA.N rallied 4% on Monday after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft. And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday. The S&P healthcare index .SPXHC was the benchmark's second biggest percentage gainer, adding 0.6%. It's biggest percentage gainer was dialysis company Davita Inc DVA.N, which rose 6.5%. Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. While Tesla TSLA.O shares, finishing up more than 4%, added some support to the consumer discretionary index .SPLRCD declines in heavyweight stocks such as Apple AAPL.O and Microsoft MSFT.O helped weigh down the S&P 500 technology index .SPLRCT. Advancing issues outnumbered declining ones on the NYSE by a 1.08-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored decliners. The S&P 500 posted 24 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 52 new highs and 227 new lows. On U.S. exchanges 9.34 billion shares changed hands compared with the 10.97 billion after for the last 20 sessions. (Reporting by Sin\u00e9ad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis) ((sinead.carew@thomsonreuters.com; +13322191897;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Humana's (HUM) CenterWell Unit Plans Expansion in Indiana Humana Inc.\u2019s HUM brand CenterWell recently announced its expansion plans across Indiana, which include the inauguration of four senior-focused primary care centers in the Indianapolis city of the state all throughout 2023 and 2024. This marks the brand\u2019s first entry into the city and the strength of CenterWell centers can only solidify the brand\u2019s presence throughout Indianapolis. The opening of its first center, CenterWell Irvington, in Indianapolis is scheduled for Nov 16 of this year. The center has already started treating patients last month along with CenterWell Indy West, CenterWell Eagledale and CenterWell Pendleton Pike, the inauguration dates of which have not yet been disclosed. The abovementioned four CenterWell Senior Primary Care locations will offer patients easy access to a certified care team specially trained to cater to the unique needs of the senior population. The team comprises physicians, nurse practitioners, behavioral health specialists, social workers and referral specialists. The CenterWell centers will also have activity centers, the benefits of which can be reaped by the entire aging populace of the Indianapolis area. The CenterWell brand holds promising expansion plans and a significant motive behind such plans is to offer greater convenience to seniors of different U.S. communities by making primary care available at locations close to their homes. This will eliminate hindrances to care for the medically vulnerable population and subsequently, serve their physical, mental, emotional and social needs. Thereby, expansion plans that actually result in a growing number of senior-focused primary care centers may attract more senior patients to avail its highly beneficial lucrative services. The CenterWell facilities of Indiana treat patients covered under varied Medicare Advantage or Original Medicare health plans. Therefore, access to the centers\u2019 services can be made possible by enrolling in the abovementioned plans. The resultant benefit of such enrollment may be reaped in the form of growing membership for Humana, which boasts a solid Medicare business. Contract wins and renewals from federal and state authorities or fruitification of expansion plans keep on bolstering membership growth and fetch improved premiums, which are the most significant contributor to a health insurer\u2019s top line. As of Sep 30, 2023, its Medicare Advantage membership rose 14.7% year over year. CenterWell Senior Primary Care, along with Conviva Care Center, forms the Primary Care Organization of Humana, which serves 285,000 seniors across roughly 300 centers situated in 15 states as of Sep 30, 2023. An aging U.S. population also substantiates the timeliness of CenterWell\u2019s promising expansion plans. Shares of Humana have declined 5.6% in the past six months against the industry\u2019s 10.1% growth. HUM currently carries a Zacks Rank #3 (Hold). Image Source: Zacks Investment Research Stocks to Consider Some better-ranked stocks in the Medical space are Ligand Pharmaceuticals Incorporated LGND, DexCom, Inc. DXCM and Encompass Health Corporation EHC. While Ligand Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), DexCom and Encompass Health carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Ligand Pharmacueticals\u2019 earnings outpaced estimates in each of the trailing four quarters, the average surprise being 67.19%. The Zacks Consensus Estimate for LGND\u2019s 2023 earnings indicates a rise of 6.5% from the year-ago reported figure. The consensus mark for LGND\u2019s 2023 earnings has moved 2.4% north in the past 60 days. The bottom line of DexCom beat estimates in each of the trailing four quarters, the average surprise being 36.43%. The Zacks Consensus Estimate for DXCM\u2019s 2023 earnings indicates a rise of 62.1% surge, while the same for revenues suggests an improvement of 23.5% from the corresponding year-ago reported figures. The consensus mark for DXCM\u2019s 2023 earnings has moved 14.6% north in the past 30 days. Encompass Health\u2019s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 17.33%. The Zacks Consensus Estimate for EHC\u2019s 2023 earnings indicates a rise of 22.8% from the year-ago reported figure. The consensus mark for EHC\u2019s 2023 earnings has moved 1.4% north in the past 30 days. The Encompass Health stock has gained 4.4% in the past six months. However, shares of Ligand Pharmaceuticals and DexCom have declined 28.2% and 17.4%, respectively, in the same time frame. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Encompass Health Corporation (EHC) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US STOCKS-S&P 500 takes a pause ahead of U.S inflation data By Sin\u00e9ad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month. The CPI reading, along with labor market, \""are clearly in the driver's seat for what matters to financial markets, because it dictates where Fed policy goes from here,\"" said Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company in Milwaukee, Wisconsin. \""The market has the expectation the Fed is done with interest rate hikes and for that to be true, you need to have continued progress on the inflation front,\"" along with labor market cooling, he said. While the CPI reading was the key issue keeping investors \""in a holding pattern\"" on Monday, Michael O\u2019Rourke, chief market strategist at JonesTrading in Stamford, Connecticut said they were also digesting a weaker U.S. credit outlook issued. Moody's late on Friday lowered its outlook on the U.S. credit rating to \""negative\"" from \""stable\"", citing large fiscal deficits and a decline in debt affordability. This added to investor reluctance to make big decisions ahead of a weekend deadline that could potentially result in a U.S. government shutdown, O'Rourke said. U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress. According to preliminary data, the S&P 500 .SPX lost 4.03 points, or 0.09%, to end at 4,411.51 points, while the Nasdaq Composite .IXIC lost 30.36 points, or 0.22%, to 13,767.74. The Dow Jones Industrial Average .DJI rose 49.76 points, or 0.15%, to 34,332.86. The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak. Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer during the session, while utilities .SPLRCU was the biggest loser. Helping keep the Dow afloat, Boeing BA.N rallied on Monday after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft. And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday. Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. (Reporting by Sin\u00e9ad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis) ((sinead.carew@thomsonreuters.com; +13322191897;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US STOCKS-Wall Street wavers after rally, focus on inflation data By Sin\u00e9ad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a rally on Friday investors turned their focus to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month. \""Everyone's kind of in a holding pattern waiting to see what happens with the inflation data in morning,\"" Michael O\u2019Rourke, chief market strategist at JonesTrading in Stamford, Connecticut. While the CPI reading was likely the biggest concern, O'Rourke said that investors were also still digesting Moody's weaker U.S. credit outlook issued after market close on Friday. Friday Moody's lowered its outlook on the U.S. credit rating to \""negative\"" from \""stable\"", citing large fiscal deficits and a decline in debt affordability. This added to investor reluctance to make big decisions ahead of a weekend deadline that could result in a U.S. government shutdown, O'Rourke said. U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress. The Dow Jones Industrial Average .DJI rose 52.18 points, or 0.15%, to 34,335.28, the S&P 500 .SPX lost 0.82 points, or 0.02%, to 4,414.42 and the Nasdaq Composite .IXIC dropped 12.31 points, or 0.09%, to 13,785.80. The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak. Traders have priced in a nearly 86% chance that the Fed will hold interest rates in December, according to the CME Group's FedWatch tool. Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer, up 0.7%, while utilities .SPLRCU was the biggest loser, down more than 1%. While Tesla TSLA.O shares, up more than 4%, added some support to the consumer discretionary index .SPLRCD declines in heavyweight stocks such as Apple AAPL.O and Microsoft MSFT.O helped weigh down the S&P 500 technology index .SPLRCT. Helping keep the Dow afloat, Boeing BA.N climbed 4.3% after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft. And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday. Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. Advancing issues outnumbered declining ones on the NYSE by a 1.08-to-1 ratio; on Nasdaq, a 1.02-to-1 ratio favored decliners. The S&P 500 posted 23 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 44 new highs and 199 new lows. (Reporting by Sin\u00e9ad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Wall Street wavers after rally, focus on inflation data By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - The main U.S. stock indexes were mixed on Monday as investors awaited a crucial inflation reading this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. The cautious mood followed a strong session on Wall Street on Friday, when a rally in megacap stocks lifted the tech-heavy Nasdaq .IXIC to a two-month peak and the benchmark S&P 500 .SPX to a near eight-week closing high. Investors will focus on a slew of economic data and speeches from Fed officials this week for clues on the trajectory of U.S. interest rates amid growing expectations that the Fed is done hiking borrowing costs. Data on Tuesday is expected to show headline consumer prices eased to 3.3% in October from 3.7% in September. However, core prices are seen unchanged from the previous month. \""The concern is that if you get hot CPI data, that puts the prospect of Fed raising rates at the next meeting back on the table,\"" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. \""Given the healthy slate of retail earnings that we have this week, along with the CPI data tomorrow, there's clearly risk to the rally's strength.\"" The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak. Traders have priced in a nearly 86% chance that the Fed will hold interest rates in December, according to the CME Group's FedWatch tool. Adding to jitters on Monday, Moody's lowered its outlook on the U.S. credit rating to \""negative\"" from \""stable\"", citing large fiscal deficits and a decline in debt affordability. U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a government shutdown on Friday, but the measure quickly ran into opposition from lawmakers from both parties in Congress. At 12:12 p.m. ET, the Dow Jones Industrial Average .DJI was up 81.50 points, or 0.24%, at 34,364.60, the S&P 500 .SPX was down 1.13 points, or 0.03%, at 4,414.11, and the Nasdaq Composite .IXIC was down 28.99 points, or 0.21%, at 13,769.12. Helping keep the Dow afloat, Boeing BA.N climbed 4.6% after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft. Meanwhile, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday. Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 1.9% and 6.9% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. Advancing issues outnumbered decliners by a 1.12-to-1 ratio on the NYSE. Declining issues outnumbered advancers for a 1.05-to-1 ratio on the Nasdaq. The S&P index recorded 22 new 52-week highs and seven new lows, while the Nasdaq recorded 41 new highs and 182 new lows. (Reporting by Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel) ((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medical device stocks rise in relief after Wegovy heart benefits data Adds fresh analyst comments in paragraphs 3, 10; updates share movement Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. \""We believe key findings could be seen as a marginal positive for some, but not all, verticals within MedTech, especially given currently depressed sentiment,\"" said Baird analyst Jeff Johnson. The data, for instance, showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. That lifted shares of Penumbra PEN.N, which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. The $4.64 billion iShares US Medical Devices ETF IHI.P rose 2.3% on Monday, eyeing its biggest one-day percentage gain since April. The ETF is down about 13% this year, through Friday's close. Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. Monday's moves are the latest sign that investors across industries are closely looking at developments with the popular new class of weight-loss and diabetes drugs called GLP-1s such as Wegovy and Eli Lilly's LLY.N Mounjaro and Zepbound. \""The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold,\"" said Leerink analyst Mike Kratky. ANALYSIS-Healthcare companies counter investor worries over Wegovy effect (Reporting by Leroy Leo and Medha Singh in Bengaluru; Editing by Sriraj Kalluvila) ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain CVS Health (CVS) Stock for Now CVS Health Corporation CVS is well-poised for growth, backed by the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services that instill optimism. The acquisition of Oak Street Health advances its care delivery strategy for consumers, which is likely to boost future growth. However, stiff competition and poor macroeconomic conditions are a concern. In the past year, this Zacks Rank #3 (Hold) stock has declined 30.3% compared with the industry\u2019s 35.1% fall and the S&P 500\u2019s 12.2% rise. The pharmacy innovation company, with integrated offerings across the entire spectrum of pharmacy care, has a market capitalization of $87.09 billion. The company has a long-term estimated earnings growth rate of 4.5%. Let\u2019s delve deeper. Tailwinds Health Care Benefit Shows Potential: Following the colossal acquisition of health insurance giant Aetna, CVS Health has introduced its Health Care Benefits business arm. Medical membership in the third quarter of 2023 grew to 25.7 million, an increase of 1.4 million members versus the prior year, reflecting growth across multiple product lines, including individual exchange, Medicare, and commercial. CVS Health demonstrated strong growth led by significant progress made in restoring its Medicare Advantage Star ratings. Medicare Advantage is a key strategic growth area for its business. During the third quarter earnings update, the company stated that Aetna continues to be a leader in zero-dollar premium products and approximately 84% of Medicare eligibles will have access to Aetna plans in this category in 2024. Health Services Business Gaining Traction: CVS Health continues to gain traction within Health Services (previously known as the Pharmacy segment) driven by pharmacy claims growth, specialty pharmacy and brand inflation. Within Health Service, both Signify Health and Oak Street Health continue to deliver strong business performance consistent with expectations. Image Source: Zacks Investment Research As Oak Street expands to additional geographies, these opportunities to drive higher patient growth will continue to increase. By the end of 2023, CVS Health expects to have Oak Street clinics in 25 states, up from 21 at the close of the transaction. The company expects to build 50-60 clinics next year. Strong Solvency and High Return to Investors: CVS Health ended third-quarter 2023 with cash and cash equivalents of $16.19 billion compared with $16.88 billion at the end of second-quarter 2023. Long-term debt came up to $59.78 billion compared with $61.41 billion at the end of second-quarter 2023. Although the total year-end debt was much higher than the corresponding cash and cash equivalent level, the near-term payable debt is at $2.1 million, lower than the short-term cash level. This is positive news in terms of solvency level as, at least during the economic downturn, the company is holding sufficient cash for debt repayment. Downsides Competitive Landscape: In spite of significant new client wins in the course of a strong selling season, intense competition and harsh industry conditions are major impediments for CVS Health. Big competitors such as Walgreens, Target and Wal-Mart are expanding their pharmacy businesses. Exposure to International Market Risks: CVS Health\u2019s international operations present political, legal, compliance, operational, regulatory, economic and other risks. These risks vary widely by country and include several regional and geopolitical business conditions and demands, government intervention and censorship, discriminatory regulation, climate change regulation, nationalization or expropriation of assets and pricing constraints. Estimate Trends In the past 90 days, the Zacks Consensus Estimate for its fiscal 2023 earnings has moved down from $8.62 to $8.59 per share. The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $352.9 billion, suggesting a 9.5% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), posted adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service Quest Diagnostics Incorporated DGX recently launched Quest Mobile \u2014 which enables patients nationwide to have a specimen collected for laboratory testing more easily and conveniently. By the end of 2023, Quest Mobile's 5,000 skilled mobile phlebotomists will be operating in 44 states. The latest development is likely to broaden Quest Diagnostics' laboratory services offering. More on Quest Mobile The Quest Mobile service will be accessible in 44 states and is based on the most easily accessible mobile collecting healthcare network in the United States. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their homes. Patients will be required to pay a $55 mobile collection fee at the time of scheduling and Quest Mobile does not bill health insurance. The business is actively arranging commercial pricing with healthcare systems, health insurance and providers to remove the need for patients to pay out-of-pocket. Significance of Latest Launch Healthcare, particularly lab testing, is becoming more and more centered around the patient's choice and convenience. People may now get important testing services on their own schedules and from a reputable provider of quality and customer care by using Quest Mobile. The service is a manifestation of Quest Diagnostics\u2019 approach to advance and leverage its scale and expertise to cater to the changing demands of its clientele, which encompasses a growing need for at-home care services. Quest Diagnostics\u2019 network of 5,000 trained mobile phlebotomists is believed to be the largest in the industry. The new service complements the company's current service options, which include online appointment scheduling and walk-in visits at one of Quest's 2,100 patient service centers and in-office phlebotomy at some health provider sites. With the launch of Quest Mobile, the company can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing, allowing them to work together for a healthier world \u2014 one life at a time. Industry Prospects Per a report by Grand View Research, the global clinical laboratory service market size was estimated at $217.53 billion in 2022 and is expected to expand at a CAGR of 3.2% from 2023 to 2030. The industry is witnessing growth due to factors such as the increasing burden of chronic diseases and the growing demand for early diagnostic tests. Progress Within Laboratory Business In October 2023, Quest Diagnostics inked a strategic lab services agreement with Neway. The agreement aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD). Image Source: Zacks Investment Research The same month, Quest Diagnostics was granted FDA Breakthrough Device Designation for its adeno-associated virus called AAV companion diagnostic (CDx), developed in collaboration with Sarepta Therapeutics for the Duchenne muscular dystrophy gene therapy. Per terms of the agreement, Diadem has licensed exclusive U.S. rights to the intellectual property of its AlzoSure Predict blood-based prognostic technology to Quest Diagnostics for the purpose of developing, validating and marketing a laboratory-developed test service for providers and patients in the United States. Price Performance In the past year, shares of DGX have declined 11.7% compared with the industry\u2019s 3.2% fall. Zacks Rank and Other Key Picks Quest Diagnostics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""US STOCKS-Wall St falls as megacaps drag ahead of inflation data By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. Megacap growth stocks were a big drag, as the benchmark U.S. 10-year Treasury yield US10YT=RR rose. Shares of Microsoft MSFT.O, Amazon.com AMZN.O and Apple AAPL.O fell between 0.5% and 1.5% in early trade. Eight of the 11 major S&P 500 sectors were in the red, with rate-sensitive real estate stocks .SPLRCRdown 1.2% and leading declines. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. A report on Tuesday is expected to show headline consumer prices eased to 3.3% in October from 3.7% in September. However, core prices are seen unchanged from the previous month. \""If the year-over-year (number) continues to show a decline, then that seals the fact that the Fed is not going to raise in December and most likely they're done with the hiking campaign,\"" said Peter Cardillo, chief market economist at Spartan Capital Securities. The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and on hopes that U.S. interest rates are near their peak. The benchmark S&P 500 .SPX closed at near eight-week highs on Friday, while the tech-heavy Nasdaq .IXIC hit a two-month peak. Traders have priced in a nearly 86% chance that the Fed will hold interest rates in December, but have pushed back bets of rate cuts to June from May, according to the CME Group's FedWatch tool. Adding to the cautious mood, Moody's lowered its outlook on the U.S. credit rating to \""negative\"" from \""stable\"", citing large fiscal deficits and a decline in debt affordability. \""With the absence of macro news and the strong rally that we had on Friday, the downgrade and the anticipation of the inflation data is inducing some selling this morning,\"" Cardillo said. U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a government shutdown on Friday, but the measure quickly ran into opposition from lawmakers from both parties in Congress. At 9:41 a.m. ET, the Dow Jones Industrial Average .DJI was down 20.28 points, or 0.06%, at 34,262.82, the S&P 500 .SPX was down 19.10 points, or 0.43%, at 4,396.14, and the Nasdaq Composite .IXIC was down 96.40 points, or 0.70%, at 13,701.71. Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. Cushioning the Dow, Boeing BA.N climbed 5.1% after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft. The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows. (Reporting by Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel) ((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis IDEXX Laboratories, Inc. IDXX recently announced the upcoming launch of the SNAP Leish 4Dx Test \u2014 a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The test will be available in Europe and Asia starting February 2024. IDEXX provides diagnostic capabilities that meet veterinarians\u2019 diverse needs through the CAG (Companion Animal Group) Diagnostics segment. The latest development demonstrates the company\u2019s commitment to expanding the vector-borne disease offering to support veterinarians worldwide in their mission to deliver a higher standard of care for pets. Significance of the News Parasites and vector-borne diseases like leishmaniosis are an increasing risk to pets\u2019 health globally. Commonly found in the tropical and subtropical regions of Europe, Asia, Africa and South and Central America, the zoonotic disease is transmitted by sand flies to dogs living in or traveling to these endemic regions. Image Source: Zacks Investment Research However, the disease could be potentially fatal if left untreated. With the chances of one in 10 dogs testing positive in Leishmania-endemic areas globally (according to IDEXX\u2019s cited data), the infected dogs can remain asymptomatic for months to years. This makes leishmaniosis an essential component of annual wellness screens. News in Detail IDEXX\u2019 SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis and anaplasmosis. By replacing Lyme disease detection with the detection of leishmaniosis, which is a more prevalent endemic disease in certain regions of the world, the SNAP Leish 4Dx Test supports vector-borne disease diagnosis globally. The rapid diagnostic test provides veterinarians with an end-to-end solution for vector-borne disease testing, including the ability to screen for heartworm disease, ehrlichiosis, anaplasmosis and leishmaniosis with a single sample during the patient visit. It also offers streamlined reference laboratory follow-up testing for the quantification of SNAP positives and the opportunity to perform additional follow-up testing in the clinic or at IDEXX Reference Laboratories. In addition, the Test checks compatibility with the SNAP Pro Analyzer, which supports an efficient practice workflow by automatically activating and interpreting test results and facilitating seamless charge capture. Ongoing support and education are also offered to keep veterinary staff up-to-date with the latest resources to help protect pets and their families. Industry Prospects Per a Research report, the Leishmaniasis treatment market is expected to witness a CAGR of 8.4% up to 2029. Strong Prospects of the CAG Segment Diagnostics has remained one of the fastest-growing areas of the veterinary clinic since the determination of a patient's health status, and the best treatment path very often requires testing. The company\u2019s long-term success in the continuing growth of CAG recurring diagnostic products and services depends on growing volumes at existing customers by increasing their utilization of existing and new test offerings, acquiring new customers, maintaining high customer loyalty and retention and realizing modest annual price increases. In the third quarter of 2023, IDEXX's CAG Diagnostics recurring revenues increased 9% organically, which remained solidly above sector growth levels. The results, supported by the sustained benefits of execution drivers, reflected high-single-digit organic revenue growth in the United States, while international regions posted double-digit organic growth. Price Performance In the past year, shares of IDEXX have increased 0.2% against the industry\u2019s decline of 11.7%. Zacks Rank and Key Picks IDEXX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 10.9% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.32%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.85 to $1.90 in the past seven days. Shares of the company have decreased 46.6% in the past year compared with the industry\u2019s decline of 10.5%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 16.8% in the past year compared with the industry\u2019s decline of 11.8%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medical device makers rise on relief after Wegovy obesity trial data Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. \""In our view, several bullets were dodged here,\"" Jefferies analyst Matthew Taylor said in a note. The heart protective benefits of Wegovy obesity treatment are due to more than weight loss alone, according to presented by Novo at a major medical meeting on Saturday. Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. \""Investors had feared a significant reduction in strokes. That didn't materialize,\"" J.P. Morgan analyst Robbie Marcus said in a note. Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Inari Medical NARI.O, which also produces surgical equipment, were up 6% in morning trade. The iShares US Medical Devices ETF IHI.P rose 2.3%, eyeing its biggest one-day percentage gain since April, days after the fund hit a more than three-year low. (Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila) ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-14,100.0,103.85,99.26,101.38,"[""Here's Why You Should Retain Penumbra (PEN) Stock for Now Penumbra, Inc. PEN is well poised for growth in the coming quarters driven by the company\u2019s vascular and neuro businesses. Penumbra\u2019s Immersive Healthcare business, too, is making significant progress. Its robust estimate for 2023 revenues reflects continued demand for its products. Yet, currency movements and a challenging competitive landscape affect the top line. In the past year, the Zacks Rank #3 (Hold) stock has gained 11.2% compared with the industry\u2019s 13.3% fall and the S&P 500\u2019s 6.5% rise. The global healthcare provider company has a market capitalization of $8.72 billion. It surpassed estimates in the trailing four quarters, the average surprise being 56.7%. Key Growth Catalysts Robust Vascular Business Growth: Penumbra is demonstrating strong growth within the company\u2019s Vascular business, banking on the rapid increase in sales of the company\u2019s vascular thrombectomy products in the United States. In this region, the company is benefiting from sales of new products and further market penetration of existing products. Despite supply-related issues, the Lightning Flash launch earlier in 2023 exceeded Penumbra\u2019s expectations, becoming the biggest product launch in its history. Lightning Flash and Lightning Bolt are also accelerating in Penumbra\u2019s U.S. vascular thrombectomy franchise, which increased 42% year over year in the third quarter. The company expects to see a robust growth trajectory in the Vascular arm in the next five years and beyond. Improving Neuro Trend: Within the Neuro franchise, Penumbra is witnessing growth in the stroke business. It is experiencing strong customer uptake of RED 72 (with the proprietary SENDit technology), RED 43 and BMX81. According to Penumbra, coupled with the recently launched BMX81, these products will continue to increase the company\u2019s growth and market share in Neuro, particularly as physicians continue to realize the trade-off with oversized aspiration catheters in the market in the past several years. Image Source: Zacks Investment Research In the third quarter, a strong increase in the company\u2019s Neuro product sales was driven by an increase in sales of neuro thrombectomy products and neuro access products. Upbeat 2023 Guidance: For the fourth quarter of 2023, the company projects total company revenue growth to accelerate to 28%-31% year over year. This correlates to the midpoint of the 2023 annual guidance of $1.05-$1.07 billion, suggesting a 24%-26% improvement from 2022 levels. The Zacks Consensus Estimate for fourth-quarter and full-year 2023 revenues is pegged at $290.2 million and $1.06 billion, respectively. Downsides Foreign Exchange Impacts Sales: A significant portion of Penumbra\u2019s sales and costs are exposed to changes in foreign exchange rates. In 2022, approximately 30.2% of the company's consolidated revenues came from the non-U.S. markets. Its operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact sales, cost of sales and expenses, and consequently, net income. Tough Competitive Landscape: The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Penumbra competes with a number of manufacturers and distributors of neuro and vascular medical devices. The company\u2019s most notable competitors are Boston Scientific, Inari, Medtronic, Stryker, Terumo, AngioDynamics and several private companies. Estimate Trends In the past 90 days, the Zacks Consensus Estimate for its fiscal 2023 earnings has moved up 13.7% to $1.99. The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $1.06 billion, indicating a 25.2% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure Bio-Rad BIO is currently grappling with industry-wide softness, global macroeconomic headwinds, competitive pressure and adverse currency impacts. The stock carries a Zacks Rank #5 (Strong Sell), at present. Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller biopharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has been experiencing. Management stated that biopharma softness resulted in the Life Science Segment\u2019s decelerated growth. In the third quarter of 2023, negative BioPharma macro trends persisted. Bio-Rad experienced reduced demand from biopharma customers for its process chromatography resins and from both biopharma and smaller biotech customers for the Life Science research projects products. Bio-Rad experienced weaker demand from government accounts in China due to softening macroeconomic conditions. On the third-quarterearnings call management stated that the situation might have a potentially larger impact on the company\u2019s BioPharma business than initially communicated. This takes into account a core revenue guidance cut of 200 basis points related to the third-quarter revenue shortfall due to weakness in BioPharma and softer demand in China. In recent times, Bio-Rad\u2019s margin performance has been affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses. In the third quarter, the company\u2019s gross margin was additionally impacted by an unfavorable product mix, with a higher-than-anticipated percentage of instrument sales versus reagents, as well as lower-than-projected revenues in the Life Science Group. Bio-Rad Laboratories, Inc. Price Bio-Rad Laboratories, Inc. price | Bio-Rad Laboratories, Inc. Quote These macroeconomic factors, particularly the ongoing labor unrest, rising wage and raw material costs, along with ongoing geopolitical unrest, are leading to a significant escalation in the company\u2019s operating expenses. Bio-Rad posted a 3.9% year-over-year decline in operating profit in the third quarter. Added to this, Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit Bio-Rad\u2019s ability to switch to strategies like price increases and other drivers of cost increases. Further, the extension of the public tender commitments to multiple years by the government, resulting in a reduced number of annual tenders, has led to aggressive tender pricing by Bio-Rad\u2019s competitors. Thus, Bio-Rad faces pricing pressure resulting from increased competition, which makes it difficult for the company to manage operational, financial and business conditions efficiently. Over the past year, shares of BIO have plummeted 28.1% compared with the industry\u2019s 10.5% drop. On a positive note, following the acquisition of Dropworks in 2021, Bio-Rad has been consistently developing its foothold in the rapidly growing digital PCR space to address additional opportunities in the PCR market. The pipeline of Bio-Rad\u2019s QX600 Droplet Digital PCR platform is currently robust and growing. Backed by the tremendous customer response, the company continues to ramp up production capacity to accommodate the ongoing demand. In the third quarter, within Life Science Group, academic and government sales of Life Sciences were strong in the Americas, encouraged by several noteworthy announcements involving ddPCR. On the clinical testing front, the Bio-Rad QX ONE platform has been selected for SMA testing for all newborns in Hong Kong and in the United States. Geneoscopy announced it had published the results of the pivotal CRC-PREVENT clinical trial, reporting the highest sensitivity for detecting colorectal cancer among similar tests powered by BIO\u2019s QXDx ddPCR platform. In the United States, Verily won a major multi-year national wastewater testing contract from the CDC based on Bio-Rad\u2019s QX600 platform. Management views these as contributors to future growth and a strong reinforcement of the versatility and the impact of the technology. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 for third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 for third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Buy Alcon (ALC) Stock Right Now Alcon ALC is well-poised for growth in the coming quarters, backed by the encouraging performance of the Surgical business. Strength in contact lenses and ocular health business is highly optimistic for the Vision Care segment. Further, a sound financial position bodes well for the stock. Meanwhile, macroeconomic challenges and the adverse effects of intense competition remain concerning for the company. In the past year, this Zacks Rank #2 (Buy) stock has increased 13.7% against the 13.3% fall of the industry and an 11.2% rise of the S&P 500 composite. The renowned pharmaceutical and medical device manufacturer has a market capitalization of $35.94 billion. Alcon projects a long-term estimated earnings growth rate of 14.9% compared with 13.9% of the industry. ALC\u2019s earnings surpassed estimates in three of the trailing four quarters and were breakeven in one, delivering an average surprise of 8.03%. Let\u2019s delve deeper. Upsides Surgical Business Ascends: Alcon\u2019s Surgical business continues to gain from the company\u2019s diverse portfolio and incremental innovation. In Implantables, excluding the impact of the Korea PCIOL reimbursement change, the company is seeing strong growth, banking on the Vivity rollout in select international markets, including Japan and Canada. With Vivity and PanOptix, Alcon currently continues to lead the ATIOL category in the United States and international market. In the second quarter, Alcon remained encouraged by the resilience of global ATIOL penetration, which was up 80 basis points year over year and up 60 basis points sequentially, primarily driven by strength in international markets. Image Source: Zacks Investment Research Vision Care Returns to Growth: Within this segment, Alcon is registering solid growth, banking on strong sales of its contact lenses and ocular health products. In contact lenses, the company is successfully executing its strategy of investing in fast-growing market segments where it has significant share opportunities. Within reusable lenses, TOTAL30 and TOTAL30 for astigmatism are witnessing strong market acceptance. In terms of Daily Lenses, the company is benefiting from the strong performance of Toric lenses, including Precision1 and DAILIES TOTAL1 Toric. In Ocular health, SYSTANE and Pataday are particularly registering strong growth. Stable Solvency Structure: Alcon exited the second quarter with cash and cash equivalents of $0.66 billion against the corresponding short-term payable debt of $100 million. This is an indication of favorable solvency. The total debt was $4.68 billion compared with $4.69 billion at the end of the first quarter.Moreover, the company\u2019s second-quarter interest coverage stood at 4.2%, sequentially up from the first-quarter interest coverage of 4.1%. Downsides Macroeconomic Pressure Persists: Alcon is experiencing inflationary pressures and supply-chain challenges, which are likely to continue throughout 2023. The cost of net sales in the second quarter was up 4.1% year over year. Selling, general and administration expenses rose 3.6% year over year. A Tough Competitive Landscape: With the ophthalmology industry being highly competitive, Alcon faces intense competition in the Surgical and Vision Care businesses. In the Surgical business, the mixture of competitors ranges from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of specialized products. ALC also faces competition from the providers of alternative medical therapies such as pharmaceutical companies that have the potential to disrupt the core elements of its business. Estimate Trend The Zacks Consensus Estimate for Alcon\u2019s 2023 earnings per share has remained constant at $2.75 in the past 60 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $9.48 billion. This suggests a 9.5% rise from the year-ago reported number. Other Key Picks Some other top-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 27.1% for fiscal 2024 compared with the industry\u2019s 17.2%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have rallied 11.1% against the industry\u2019s 11.5% fall in the past year. HAE carries a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 41.5% compared with the industry\u2019s 12.2%. Shares of the company have decreased 46.5% compared with the industry\u2019s 11.5% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 126.9%. In the last reported quarter, it delivered an average earnings surprise of 58.3%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 14.3%. Shares of DXCM have fallen 15.4% compared with the industry\u2019s 13.3% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut Henry Schein, Inc. HSIC registered adjusted earnings per share (EPS) of $1.32 in the third quarter of 2023, up 2.3% from the year-ago period\u2019s adjusted EPS. However, the metric missed the Zacks Consensus Estimate by 0.8%. Revenues in Detail Henry Schein reported net sales of $3.16 billion in the third quarter, up 3.1% year over year. However, the metric lagged the Zacks Consensus Estimate by 0.9%. The year-over-year increase included a 1.2% decrease in local currencies, 3.2% growth from acquisitions and a 1.1% increase in net sales related to foreign currency exchange. Henry Schein, Inc. Price, Consensus and EPS Surprise Henry Schein, Inc. price-consensus-eps-surprise-chart | Henry Schein, Inc. Quote Sales of personal protective equipment (PPE) and COVID-19 test kits in the third quarter were $175 million compared with $244 million in the prior-year period. Excluding sales of PPE and COVID-19 test kits, third-quarter internal sales growth in local currencies was 1.1% year over year. On a geographic basis, the company recorded sales of $2.36 billion in North America, down 0.5% year over year. Sales totaled $799 million in the International market, up 15.3% year over year. Our model projected sales in North America and International regions to be $2.40 billion and $799.7 million, respectively. Segmental Analysis Henry Schein derives revenues from three operating segments \u2014 Dental, Medical and Technology and Value-Added Services. Dental In the third quarter, the company recorded $1.88 billion in global Dental sales, up 5.4% year over year. This compares with our model\u2019s projected revenues of $1.93 billion. The segment\u2019s revenues included an internally generated sales decrease of 0.2% in local currencies and reflected a 0.9% decrease in North America and 0.9% growth internationally and an increase of 0.3% in local currencies, excluding sales of PPE products. Medical Global Medical revenues declined 3.3% year over year to $1.07 billion. Our model projected the segment\u2019s revenues to be $1.08 billion. The segment\u2019s revenues included an internally generated sales increase of 0.8% in local currencies and continued to be impacted by a difficult prior-year comparison of 9.3% sales growth and a product mix shift to generic pharmaceuticals and corporate brand products. Technology and Value-Added Services Revenues from global Technology and Value-Added Services rose 19.3% to $210 million. Our model\u2019s projection was $187.2 million. The figure included 9.6% internal sales growth in local currencies and 8.6% growth from acquisitions, including Large Practice Sales LLC. Margin Trend In the reported quarter, the gross profit totaled $995 million, reflecting an 8.9% increase year over year. The gross margin expanded 167 basis points (bps) to 31.5%. SG&A expenses rose 11.9% to $725 million in the quarter under review. The adjusted operating profit in the third quarter was $270 million, an increase of 1.5% year over year. Meanwhile, the adjusted operating margin contracted 13 bps year over year to 8.5%. Liquidity Position In the third quarter of 2023, HSIC repurchased nearly 660,000 shares of its common stock for $50 million. The company had approximately $315 million authorized and available for future stock repurchases at the end of the reported quarter. 2023 Guidance Henry Schein provided an updated outlook for 2023, which considers the current continuing operations and recently announced acquisitions. The guidance also assumes that present foreign currency exchange rates will prevail and end markets will remain consistent with current market conditions. For 2023, the company expects adjusted EPS in the range of $4.43-$4.71, narrowing the previous guidance range ($5.18-$5.35) for the underlying business to the $5.18-$5.26 band. The Zacks Consensus Estimate for the metric is currently pegged at $5.26. For 2023, Henry Schein expects sales growth of nearly 1%-3% lower compared with the 2022 figure (the earlier outlook was 1%-3% sales growth). The Zacks Consensus Estimate for revenues is currently pegged at $12.82 billion. Our Take Henry Schein ended the third quarter of 2023 with both earnings and revenues missing estimates. However, the metrics increased year over year despite continued lower sales of PPE products and COVID-19 test kits. The company\u2019s profitability benefitted from technology, value-added services and dental specialty products while progressing toward the goal of achieving 40% of operating income from sales of high-growth, high-margin products. The gross margin expansion sounds promising. Meanwhile, Henry Schein lowered its outlook for the full year, which reflected softening macroeconomic conditions and an estimated impact due to business interruption from the recent cybersecurity incident. Management updated that the incident has now been contained, which primarily affected the dental and medical distribution businesses. The company is making significant progress in resuming normal-course operations. Zacks Rank & Key Picks Henry Schein currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DexCom DXCM, Medpace MEDP and The Ensign Group ENSG. DexCom, carrying a Zacks Rank of 2 (Buy), reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million outpaced the consensus mark by 4%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Medpace reported a third-quarter 2023 adjusted EPS of $2.22, beating the Zacks Consensus Estimate by 8.8%. Revenues of $492.5 million surpassed the Zacks Consensus Estimate by 3.4%. It currently carries a Zacks Rank #2. Medpace has an estimated earnings growth rate of 16.2% for the next year. MEDP\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 14.6%. The Ensign Group reported a third-quarter 2023 adjusted EPS of $1.20, beating the Zacks Consensus Estimate by 1.7%. Revenues of $940.8 million surpassed the Zacks Consensus Estimate by 0.2%. It currently carries a Zacks Rank #2. The Ensign Group has a long-term estimated growth rate of 15%. ENSG\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 1.5%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-15,101.38,104.245,100.86,102.11,"[""Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth Prestige Consumer\u2019s PBH brand-building strategy, market share gains in its leading brands as well as higher demand in certain categories and channels are major upsides. The stock carries a Zacks Rank #2 (Buy). Prestige Consumer owns and markets a diverse portfolio of well-recognized consumer brands, a few of which date back more than 100 years. The products are further supported by significant marketing, which is designed to enhance sales growth and long-term profitability across major and core brands. The majority of the company\u2019s core brands, including Monistat, Summer's Eve, Nix, TheraTears and Dramamine, together accounted for approximately 81.9% of total revenues in fiscal 2023. The company has leveraged these wide arrays of diversified brands across many categories. These have delivered record revenues and consistent EBITDA margins. In the second quarter of fiscal 2024, Prestige Consumer\u2019s strong top-line performance translated into superior earnings and cash flows. Prestige Consumer emphasizes brand-building and product innovation in niche consumer healthcare categories to improve the lives of its consumers. Its long-term brand-building efforts, combined with efficient marketing, channel development and innovation that drive long-term brand and category growth, have led the company\u2019s brands to continually hold the leading market share position. Prestige Consumer Healthcare Inc. Price Prestige Consumer Healthcare Inc. price | Prestige Consumer Healthcare Inc. Quote In this regard, Goody\u2019s headache powders have grown more than three times more than the overall analgesic category in the fiscal year to date. Having acquired the brand more than 10 years ago, the company successfully leveraged insights from consumers and expanded with targeted offerings, like Goody's Hangover, to meet ever-evolving product needs and preferences. These highly successful products were helped by distinct marketing tactics to attract new customers while strengthening connections with existing ones. Over the past year, shares of Prestige Consumers have risen 1.2% against the industry\u2019s 9.7% decline. On the flip side, economic conditions in both the United States and globally have been and will continue to be volatile due to several factors, such as supply-chain constraints, rising interest rates, a high inflationary environment and geopolitical events. These uncertainties could put pressure on prices and supply and potentially affect the demand for Prestige Consumer\u2019s products. In the first half of fiscal 2024, the gross margin was slightly down due to cost inflation, as anticipated. Prestige Consumer generally relies on brokers and distributors for the sale of its products in foreign countries, having generated approximately 14% of fiscal 2023 revenues from its international business. Hence, fluctuating foreign exchange rates remain a concern. Key Picks Some top-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2, Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 12.1% in the past year. Estimates for Haemonetics\u2019 2023 earnings have increased from $3.82 to $3.86 in the past 30 days while the same for 2024 have risen from $4.07 to $4.11. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 42.2% in the past year compared with the industry\u2019s decline of 9.4%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 11.8% in the past year compared with the industry\u2019s decline of 11.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""QIAGEN (QGEN) Launches QIAcuity Kits and Software Update QIAGEN N.V. QGEN recently announced the launch of three new kits for use on its QIAcuity systems and a major new software update. These are designed to expand the portfolio of applications for the use of digital PCR (Polymerase Chain Reaction) technology in areas like cell and gene therapies, DNA and RNA quantification, as well as food and pharmaceutical safety. The recent developments will strengthen QIAGEN\u2019s QIAcuity digital PCR platform. The highly versatile QIAcuity is one of the company\u2019s five pillars of growth, belonging to the PCR/Nucleic acid amplification product group. More About QIAcuity Digital PCR Kits The new QIAcuity Mycoplasma Quant Kit offers researchers an accurate and precise way to detect mycoplasma contaminants in all steps of research and manufacturing of cell and gene therapies. The unique and sensitive workflow of the kit has been validated by a third party and also complies with the mycoplasma testing frameworks provided by the United States, the EU and the Japanese Pharmacopeia, thereby reducing validation efforts in-house. Image Source: Zacks Investment Research Another one from the pipeline, the QIAcuity OneStep Advanced EG Kit, allows researchers the highly sensitive quantification of RNA or RNA alongside DNA in one reaction. The kit uses intercalating dye technology that makes procedures easier to design and more cost-efficient than those used in fluorescent-probe-based PCR. With the launch of QIAcuity mericon Food Testing Kits, QIAGEN extended its large food-safety testing portfolio from traditional quantitative PCR, providing increased precision and sensitivity and ensuring dependable data analysis and interpretation. Currently, these are the only ready-to-use digital PCR food tests in the market, which enable researchers to fight product adulteration through the target-specific authentication of food and animal feed ingredients. News on Software Update Additionally, QIAGEN plans to launch the QIAcuity Software 2.5 update in November. It is designed to help researchers determine two key features of digital PCR analyses. Using the functionality of a temperature gradient, the software will allow them to determine the precise temperature at which their experiment should run. This will save them the need to put the sample through an external thermocycler during the development of tests to target specific genetic building blocks. Industry Prospects Per a research report, the global digital PCR market was valued at $5.96 billion in 2022 and is expected to register a CAGR of 9.14% by 2032. Recent Performance of PCR/Nucleic Acid Amplification Product Group QIAGEN\u2019s PCR/Nucleic acid amplification involves research and applied PCR solutions and components. In the third quarter of 2023, the segment\u2019s sales were affected by a sharp drop-off in sales of OEM products used by third-party companies in their products. However, QIAcuity digital PCR continued to deliver growth above 40% at the constant exchange rate and is tracking well toward the 2023 goal of at least $70 million of annual sales. Per management, growth is coming from a combination of increasing consumables pull-throughs along with solid trends in new placements. Price Performance In the past six months, shares of QIAGEN have declined 12.6% compared with the industry\u2019s fall of 17.6%. Zacks Rank and Key Picks QIAGEN currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 12.1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past thirty days. Shares of the company have decreased 42.2% in the past year compared with the industry\u2019s decline of 9.4%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past thirty days. Shares of the company have fallen 11.8% in the past year compared with the industry\u2019s decline of 11.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase Alcon, Inc. ALC delivered core earnings per share (EPS) of 66 cents in the third quarter of 2023, up 32% from the year-ago quarter\u2019s figure (up 41% at the constant exchange rate or CER). The figure missed the Zacks Consensus Estimate by 1.5%. Alcon\u2019s \u201ccore\u201d results are based on non-IFRS (International Financial Reporting Standards) measures. In the third quarter, the company\u2019s diluted EPS were 41 cents, up 78% from the prior-year quarter\u2019s figures. Revenues in Detail Alcon\u2019s net sales to third parties in the third quarter were $2.30 billion, missing the Zacks Consensus Estimate by 1.6%. The top line increased 8.4% from the year-ago quarter\u2019s levels (up 9% at CER). Quarter in Detail Alcon reports operations through two reportable segments \u2014 Surgical (comprising Implantables, Consumables and Equipment/Other) and Vision Care (comprising Contact Lenses and Ocular Health). Surgical In the third quarter, Surgical sales amounted to $1.28 billion, up 5% year over year and 6% at CER. Our estimate projected a year-over-year improvement of 12.8%. Net sales in Implantables increased 2%, led by demand for advanced technology intraocular lenses in the international market. Our estimate projected a year-over-year increase of 17.2% for the third quarter. Consumables increased 7.7%, while Equipment/Other was up 4% from the prior-year quarter\u2019s levels. Our estimate projected an improvement of 10.8% and 9.5% for consumables and equipment/other, respectively. Vision Care The segment reported total sales of $1.00 billion, up 13% year over year on a reported and CER basis. Our model projected a year-over-year rise of 8.6%. Net sales of Contact Lenses increased 10% year over year, driven by product innovation, including toric modalities of Precision1, Total30 and Dailies Total1, outpacing declines in legacy lenses. Our model projected an improvement of 9.1% in this segment. Ocular Health sales increased 19% year over year, primarily driven by the portfolio of eye drops, including acquired ophthalmic pharmaceutical products and price increases. Margins The cost of net sales in the third quarter was $1.02 billion, up 6.7% year over year. The core gross profit rose 10.6% to $1.31 billion in the reported quarter. The core gross margin expanded 88 basis points (bps) to 56.1% in the third quarter of 2023. The core operating margin expanded 103 bps in the third quarter to 13.2%. The upside was primarily driven by a higher gross margin and improved underlying operating leverage from higher sales. Financial Position Alcon exited the third quarter of 2023 with cash and cash equivalents of $1.05 billion compared with $661 million at the end of the second quarter. The cumulative net cash flow from operating activities at the end of the third quarter was $937 million compared with $872 million a year ago. Free cash flow totaled $592 million at the end of the third quarter of 2023, compared with a cash inflow of $475 million a year ago. 2023 Outlook Alcon provided an updated outlook for the full year. The company anticipates 2023 net sales in the range of $9.3-$9.4 billion (previously $9.3-$9.5 billion). The revised range suggests growth of 10-11% at CER from 2022, up from the earlier projected growth of 9-11%. The Zacks Consensus Estimate for ALC\u2019s revenues is pegged at $9.48 billion. Alcon Price, Consensus and EPS Surprise Alcon price-consensus-eps-surprise-chart | Alcon Quote Core EPS for the full year is expected in the range of $2.70-$2.75 (previously $2.70-$2.75). This indicates growth of 31-33% at CER from 2022 levels, up from the earlier projected growth of 28-32%. The Zacks Consensus Estimate for Alcon\u2019s 2023 earnings is currently pegged at $2.75 per share. Our Take Alcon delivered lower-than-expected earnings and revenues in the third quarter of 2023. However, the registered year-over-year increase in both revenues and EPS front. A competitive product portfolio, favorable market conditions, strong commercial execution and selective price increases drove the robust performance. During the reported quarter, the company witnessed strong demand for advanced technology intraocular lenses in international markets. The double-digit Vision Care growth reflects strength in contact lenses and eye drops, including acquired products and pricing. The expansion of both margins bodes well. Within Implantables, international growth was partially offset by unfavorable currency impacts. Escalating costs are discouraging, too. Zacks Rank and Other Key Picks Alcon currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2, reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-16,102.0,105.19,102.0,104.77,"[""Paragon 28 (FNA) New Staple System Expands Ankle Device Line Paragon 28, Inc. FNA recently launched its JAWS Great White Staple System. This development is expected to strategically fortify its position in the field of midfoot and hindfoot solutions. According to Paragon 28, this advanced system offers increased strength and stability of the osteotomy or fusion site compared to conventional staple systems. More on the News The JAWS Great White Staple System has an ultra-low-profile bridge with an expanded surface area. This is expected to enhance stability while minimizing soft tissue irritation. The staple's design incorporates shoulders that seamlessly align with the inserter, ensuring full seating before compression activation and eliminating the need for additional tampering. Superiority Over Traditional System The JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions. Additionally, it provides a remarkable 169% increased compressive force compared to the average two-prong nitinol staple in the market. These attributes redefine the benchmark for strength and durability in midfoot and hindfoot solutions. Image Source: Zacks Investment Research Strategic Expansion of Portfolio This latest addition, the JAWS Great White Staple System, broadens Paragon 28's comprehensive hindfoot solutions offering that includes the Gorilla Ankle Fracture Plating System, APEX 3D Total Ankle Replacement, Silverback Ankle Fusion Plating System, Phantom TTC Nail System and Phantom ActivCore Nail System. With this detailed portfolio, Paragon 28 is poised to capture the huge orthopedic and ankle solution market targeting trauma, arthritis, and limb salvage. Industry Prospects Going by a Business Wire report, the global foot and ankle devices market, valued at $1.4 billion in 2022, is poised for substantial growth, with a projected CAGR of 7.3% to reach $2.3 billion by 2029. Key segments encompass primary ankle replacement, total ankle fusion, midfoot fixation, bunion treatment, hindfoot device, foot digit implant, hammertoe device and syndesmotic repair. Share Price Performance Shares of Paragon 28 have plunged 46.6% over the past year compared with an 8.8% decline of the industry. Zacks Rank and Key Picks FNA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 41.6% in the past year compared with the industry\u2019s decline of 6.7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics' stock has risen 13.2% in the past year. Estimates for Haemonetics\u2019s 2023 earnings have increased from $3.82 to $3.86 in the past 30 days, while the same for 2024 have increased from $4.07 to $4.11. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 9.4% in the past year compared with the industry\u2019s decline of 7.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Paragon 28, Inc. (FNA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes Omnicell OMCL is gaining from the expansion of advanced services solutions and prudent cost management. Persistent inflationary pressures pose a threat to Omnicell\u2019s cost-saving actions. The stock carries a Zacks Rank #3 (Hold). Omnicell is progressing well with its three-legged strategy that covers market expansion through delivery of differentiated, innovative solutions, expansion into new markets, primarily outside the United States, and expansion through strategic partnerships and acquisition of new technologies. In 2020, the company expanded its autonomous pharmacy portfolio with the strategic and accretive acquisition of PSG's 340B Link business, now called Omnicell 340B. 340B is a significant part of an increasingly complex pharmacy supply chain, requiring solutions designed to help providers manage compliance and reporting while capturing drug cost savings. Omnicell has also accelerated a shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service (formerly Omnicell One) and Central Pharmacy Dispensing Services. In the third quarter of 2023, several of the company\u2019s health system partners extended their sole-source agreements, including a Florida-based health system, which plans to replace its existing point-of-care footprint with Omnicell XT systems. One of Georgia's largest healthcare networks has contracted Omnicell's inventory optimization service to help strengthen its pharmacy supply chain. Omnicell, Inc. Price Omnicell, Inc. price | Omnicell, Inc. Quote Earlier in 2023, a major southern health system customer expanded the service to nearly 20 hospitals across its health system for increased digitization, visibility and insights. Omnicell\u2019s recently-acquired ReCept has been rebranded as Omnicell specialty pharmacy services and was introduced to the market in late 2022. In 2023, the company\u2019s focus has been on integrating customer success functions into its broader organizational structure. On the flip side, similar to its healthcare system partners, the company\u2019s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components\u2019 raw materials and freight. In the third quarter of 2023, gross profit declined 17.1%, resulting in a year-over-year contraction in the gross margin of 152 basis points. The operating profit also decreased 79.9% compared to the third quarter of 2022. For full-year 2023, management anticipates the cost-savings measures to be partially offset by year-over-year increases in compensation and vendor price increases. Further, Omnicell\u2019s operations are subjected to continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, including price competition, industry and competitor consolidation, competitor brand recognition and relationships with suppliers and current and potential customers. This increased competition could result in pricing pressure and a reduced margin, which would have an adverse impact on the company\u2019s performance. Over the past year, shares of Omnicell have declined 38.3% against the industry\u2019s 14% growth. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 41.6% in the past year compared with the industry\u2019s decline of 6.7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 13.2% in the past year. Estimates for Haemonetics\u2019s 2023 earnings have increased from $3.82 to $3.86 in the past 30 days, while the same for 2024 have increased from $4.07 to $4.11. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 9.4% in the past year compared with the industry\u2019s decline of 7.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Could DexCom Stock Help You Become a Millionaire? Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend stocks to generate some solid recurring income. Either way, you would have plenty of options to consider to make the most of that money. But the important piece of the puzzle is how to get to $1 million in 10, 20, or 30 years from now. One way can be to invest in a growing business with lots of potential in the future. DexCom (NASDAQ: DXCM), which is a big name in diabetes care, is a possible option. Below, I'll look at whether the stock could help make you a millionaire. The need for diabetes care could rise significantly DexCom makes continuous glucose monitoring (CGM) devices, which help people with diabetes stay on top of their glucose levels. And demand for those devices should rise as the number of people with diabetes increases. While not every diabetic will need or use a CGM, there should certainly be a significant uptick in demand. By 2050, analysts estimate that there will be 1.3 billion people living with diabetes, which is more than double the 529 million who had the disease in 2021. And by 2030, the market for CGMs could be worth an estimated $11.2 billion, according to data from Grand View Research. It's currently growing at a compound annual rate of 4.4%. That's not terribly fast, but it does suggest steady growth ahead for the company. In fact, the recent past has seen DexCom's revenue grow quite robustly -- from just under $1.5 billion in 2019 to more than $2.9 billion in 2022 -- doubling within a span of three years. Could GLP-1 drugs derail the growth? The big concern on the minds of many investors these days is whether glucagon-like peptide 1 (GLP-1) drugs such as Wegovy and Ozempic could have a negative impact on the growth potential for DexCom. GLP-1 drugs have been effective in helping people lose weight by suppressing their appetite. They can help improve blood sugar levels as well, which may potentially diminish demand for CGMs. As of now, it's a bit early to tell whether that will be the case or not. The early signs are that the people who have been using GLP-1 drugs have been using CGMs more. DexCom CEO Kevin Sayer stated on the company's earnings call last month, \""The data clearly show that CGM usage grows faster in GLP-1 users than those who are not on therapy.\"" DexCom's sales for the most recent quarter, which ended on Sept. 30, rose by 27% to $975 million. The company also reported a high operating profit of $205.5 million, which was 21% of the top line. While DexCom's growth rate has been slowing down over the years, in recent quarters it has been trending upward: DXCM Revenue (Quarterly YOY Growth) data by YCharts. However, it's a bit early to tell what the impact of GLP-1 drugs will be. While people may be using CGMs to monitor the effectiveness of the drugs, that may not necessarily be a trend that holds up over the long haul, especially if concerns over blood sugar levels subside over time. Can DexCom deliver strong returns long term? If you had invested $10,000 in DexCom 10 years ago, your investment would be worth more than $115,000 right now. That's some solid growth, but you would need to do much better than that to get to $1 million -- unless you're investing six figures into the healthcare stock, which most investors can't afford to do. Suppose you invest at the age of 35 and have 30 investing years to go before retirement. That's a good number of years left, but if you're investing only $10,000, you would need your investment to effectively be not only a 10-bagger but a 100-bagger. For a stock to grow to 100 times its value, it would need to average an annual growth rate of approximately 16.6% over a 30-year period. That's well above the S&P 500 average over the long run, which is around 10%. The market for CGMs is only growing at a rate of 4.4%, according to analysts -- and that could diminish if GLP-1 drugs have a negative impact on demand. Let's say you decide to invest more money. At $25,000, your investment would need to grow to 40 times its value. Then, the CAGR would need to be 13.1%. That's lower, but it's still notably higher than the broader market average. Based on the growth rates needed and the threat GLP-1 drugs pose to CGMs, it's hard to make a case that you could end up becoming a millionaire from owning shares of DexCom without making a substantial investment in the company. Should you invest in DexCom stock anyway? Shares of DexCom are down 13% this year as concerns relating to its future growth mount despite the company's strong performance. Another problem is the stock's hefty price-to-earnings multiple, which stands at over 100, meaning that investors are paying a significant premium for the shares right now. This can still be a good long-term investment given the ongoing need for diabetes care and earnings that continue to rise, but investors should temper their expectations for the stock as its gains ahead may not be as impressive as they have been over the past decade, given the potential headwinds that the company is facing. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 6, 2023 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Omnicell (OMCL) Stock Now Omnicell OMCL is well-poised for growth in the coming quarters, backed by its ongoing efforts to automate and modernize the global medication management infrastructure. The company is building on its expense containment initiatives to bring the cost structure in line with near-term revenue expectations. Stable solvency is highly encouraging. Meanwhile, the impacts of inflationary challenges can dent Omnicell\u2019s performance. Intense competition from its peers further adds to the concern. In the past year, this Zacks Rank #3 (Hold) stock has declined 37.2% against the 16% rise of the industry and the 14.4% growth of the S&P 500 composite. The renowned healthcare technology company has a market capitalization of $1.50 billion. It has an earnings yield of 5.3% compared with the industry\u2019s -7.8%. Omnicell surpassed estimates in all the trailing four quarters, delivering an average negative earnings surprise of 216.3%. Let\u2019s delve deeper. Tailwinds Robust Pipeline of Advanced Services Portfolio: Over the past few years, OMCL has made three key acquisitions \u2014 ReCept (later rebranded as Omnicell Specialty Pharmacy Services), FDS Amplicare and MarkeTouch Media, LL \u2014 intended to enhance advanced services offerings. Throughout the third quarter of 2023, the company continued to focus on executing the go-to-market strategy with these acquisitions, building on its momentum from the first half of the year. Further, central pharmacy dispensing services continued to gain market traction, with several health systems choosing to automate their central pharmacy inventory and dispensing operations. In EnlivenHealth, Omnicell appears to be gaining momentum with cross-selling and upselling communication solutions to existing customers. Image Source: Zacks Investment Research Anticipated Benefits of Cost-Containment Measures: Last year, Omnicell introduced several restructuring initiatives to enhance and streamline certain engineering functions for its domestic operations and realign its international sales organization to better serve its customers in various international markets. Earlier in 2023, the company committed to further reducing its headcount across many of its functions and also reducing its real estate footprint to align with its broader hybrid work strategy to lower costs. Moreover, management recently stated that more expense containment initiatives are underway to address ongoing macroeconomic headwinds. Strong Liquidity and Capital Structure: Omnicell exited the third quarter of 2023 with cash and cash equivalents of $446.8 million, while short-term debt on its balance sheet was nil. This is indicative of a sound solvency position. Further, debt-to-capital at the third-quarter end was sequentially down by 0.4% to 32.4%. Downsides Rising Expenses May Strain Margins: Similar to its healthcare system partners, the company\u2019s operations continue to be affected by persisting labor shortages and increased inflationary costs related to components\u2019 raw materials and freight. In the third quarter of 2023, Omnicell reported a year-over-year decrease in both gross and operating profit. For the full year 2023, management anticipates cost-savings measures to be partially offset by year-over-year increases in compensation and vendor price increases. A Competitive Landscape: Omnicell\u2019s operations are subjected to continued and increased competition from current and future competitors in the medication management automation solution market and the medication adherence solution market, including price competition, industry and competitor consolidation, competitor brand recognition and in terms of relationships with the suppliers and current and potential customers. This increased competition could result in pricing pressure and a reduced margin, which may have an adverse impact on the company\u2019s performance. Estimate Trend The Zacks Consensus Estimate for OMCL\u2019s 2023 earnings per share has remained constant at $1.76 in the past 60 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $1.14 billion. This suggests an 11.7% fall from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 27.1% for fiscal 2024 compared with the industry\u2019s 17.2%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have rallied 13.2% against the industry\u2019s 6.7% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 41.5% compared with the industry\u2019s 12.2%. Shares of the company have decreased 41.6% compared with the industry\u2019s 6.7% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 126.9%. In the last reported quarter, it delivered an average earnings surprise of 58.3%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 14.3%. Shares of DXCM have fallen 9.4% compared with the industry\u2019s 7.2% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Illumina (ILMN) Launches Initiative on Pathogen Sequencing Illumina, Inc. ILMN recently launched the Global Health Access Initiative to support the acceleration of pathogen sequencing in low and middle-income countries (LMICs). The program aims to provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply-chain challenges. Expanding sequencing capabilities in LMICs has been a long-term focus for Illumina and forms the foundation of collaborations with organizations like FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria. The recent development will also boost the company\u2019s core business. Backdrop According to Illumina\u2019s head of Global Health, enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness and allows countries to manage their priority health threats. It also avoids costly and time-consuming shipment of samples abroad and leads to faster response times. Image Source: Zacks Investment Research Currently, pricing for sequencing instruments and consumables can vary by country or region, which is challenging for funders and donors and can limit broad implementation. Illumina\u2019s representative quotes that the countries or regions whose public health preparedness will most benefit from genomics often lack the resources to implement it sustainably. The New Initiative in Detail Developed with guidance from customers, funders, and market facilitators, including the nonprofit FIND, Illumina's new Global Health Access Initiative is a step forward to address these challenges. The program will provide discounted prices for a range of sequencing applications, including drug resistance profiling in tuberculosis, whole-genome sequencing of emerging and reemerging viruses to monitor virus evolution and support outbreak response, broad respiratory pathogen detection for influenza-like illness surveillance, wastewater and other environmental surveillance applications to track pathogens and antimicrobial resistances at the population level. To simplify budgeting and procurement, Illumina's key components for these applications are available as single-part-number combination kits, encompassing library preparation reagents, sequencing reagents and data analysis tools. More on the News Of late, significant advances have been made in global genomic sequencing capacity. The data cited by Illumina shows that as of December 2022, 84% of World Health Organization member states are capable of sequencing SARS-COV-2, while more than 16 million SARS-CoV-2 genomes have been deposited in the GISAID repository as of October 2023. However, geographic disparities in the ability to monitor pathogens beyond SARS-CoV-2 lead to significant gaps in the detection of emerging threats, putting global health security at risk. The Global Health Access initiative is an evolution of Illumina\u2019s efforts during the pandemic in providing global health access pricing for SARS-CoV-2 genomic surveillance. Industry Prospects Per a Research report, the global genomics market size was valued at $28.1 billion in 2022 and is expected to witness a CAGR of 16.5% up to 2030. Recent Performance of the Core Illumina Segment Core Illumina\u2019s products and services serve customers in the research, clinical and applied markets and enable the adoption of a variety of genomic solutions. In the third quarter of 2023, sequencing instrument revenues grew 10% year over year, driven primarily by NovaSeq X. Core Illumina sequencing service and other revenues were up 15%, led by higher instrument service contract revenues on a growing installed base and an increase in lab services revenues. However, the segment\u2019s performance across all regions was impacted by macroeconomic conditions on customers' purchasing power and the impact of high-throughput customers transitioning to NovaSeq X. Price Performance In the past six months, shares of Illumina have decreased 49.3% compared with the industry\u2019s decline of 15.9%. Zacks Rank and Key Picks Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 13.2% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 41.6% in the past year compared with the industry\u2019s decline of 6.7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 9.4% in the past year compared with the industry\u2019s decline of 7.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-17,104.93,106.74,104.31,104.97,"[""Neogen's (NEOG) Innovation Aids, Currency Headwind Stays Neogen NEOG is well positioned to gain from its extensive global foothold and diverse product mix. However, a tough competitive landscape weighs on the stock. Neogen carries a Zacks Rank #3 (Hold) currently. Neogen, in its mission to be the leading company in the development and marketing of solutions for food and animal safety, follows a vision or a growth strategy consisting of the following elements \u2014 increasing sales of existing products, introducing products and product lines, expanding international sales, and acquiring businesses and forming strategic alliances. Going by the first part of the growth strategy, Neogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal first quarter, the Bacterial and General Sanitation business saw its highest growth, with particularly strong sales of Clean-Trace Hygiene Monitoring products. Within worldwide genomics, the company registered solid growth in international beef markets. As far as the second part of the growth strategy is concerned, Neogen has been progressing well with its R&D activities. During the fiscal first quarter, Neogen R&D\u2019s expenses were $6.7 million, up 37.2% year over year. With respect to the third aspect of international growth, the company is expanding well in other geographies. It is also forming strategic alliances. In terms of the latest developments, acquisitions added 73.5% to total revenues during the fiscal second quarter. Neogen Corporation Price Neogen Corporation price | Neogen Corporation Quote Earlier, Neogen had completed the strategic bolt-on acquisition of Corvium, a SaaS provider behind its Neogen Analytics Platform. The buyout accelerated the company\u2019s organic data strategy. Further, following the completion of the 3M Food Safety Division merger, its integration is currently on track. According to the company, the relocation of the former 3M pathogen and sample handling product lines in the Neogen facilities remains on track for completion in the third quarter of fiscal 2024. Over the past year, shares have risen 2.2% against the industry\u2019s 5.8% dip. On the flip side, Neogen\u2019s international business continues to be impacted by currency movements. During the pandemic, there was a move toward the safety of the U.S. dollar, which negatively impacted local currencies in the company\u2019s international locations, particularly those where the outbreaks were less controlled. Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company\u2019s competitors, which could affect the marketability and profitability of its products. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 41.6% in the past year compared with the industry\u2019s decline of 6.7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 13.2% in the past year. Estimates for Haemonetics\u2019 2023 earnings have increased from $3.82 to $3.86 in the past 30 days, while the same for 2024 have increased from $4.07 to $4.11. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 9.4% in the past year compared with the industry\u2019s decline of 7.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now DexCom, Inc. DXCM is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist. This Zacks Rank #2 (Buy) company\u2019s shares have lost 7.5% year to date compared with the industry\u2019s 8.6% decline. The S&P 500 Index has risen 18.3% in the same time frame. DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $39.45 billion. It projects 33.6% growth over the next five years and expects to maintain the strong performance going forward. Image Source: Zacks Investment Research DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 36.43%. Let\u2019s delve deeper. Strong Product Demand: We are upbeat about DexCom's continued strength in its Continuous Glucose Monitoring (CGM) products. The company continues to expand its product portfolio with the addition of new products like DexCom One and G7 sensor. This has helped accelerate its growth. Sales of these products have reflected strong demand since their launch late last year. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, the expansion of coverage for CGM systems during the quarter supported growth. This trend is likely to continue for the rest of 2023. The availability of new sensors like G6 & G7 in new international markets is also boosting revenue growth. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom\u2019s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. New Product Launch: In June, Dexcom announced that it is currently developing a new product with a 15-day sensor, designed specifically for diabetic patients who are not on insulin. The company is planning to launch the new product in the United States in 2024. Positive Coverages: DXCM\u2019s products have been receiving increasing coverage over the past few months, raising our optimism. The company\u2019s G7 CGM System is already covered by all major pharmacy benefit managers in the United States, following its launch late last year. In 2022, the company expanded public coverage for type 1 and type 2 diabetic patients (aged two years and above) who are on multiple daily injections of insulin (three or more) or who use an insulin pump leveraging its G6 CGM System via Prince Edward Island\u2019s Diabetes Glucose Sensor Program. DexCom ended the third quarter with new patient additions. The Ontario government began coverage for the Dexcom G6 CGM System through the province\u2019s Assistive Devices Program. This program has been designed for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Strong Q3 Results: DXCM\u2019s solid third-quarter 2023 revenues buoy optimism. Rising volumes across all channels, along with new customer additions due to increasing global awareness of the benefits of real-time CGM, contributed to the upside. In October, the company raised its guidance for 2025 based on robust demand for its products in the previous two years. The company now expects an additional $3.55 billion in revenues compared with the earlier projected band of $3.5-$3.55 billion. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. Downsides Rising Costs: The company\u2019s gross margin contracted 30 basis points during the third quarter to 62.7%, reflecting the rising cost of sales. It expects an adjusted gross margin of approximately 64% for 2023, indicating persisting cost pressure. Stiff Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid changes and new product introductions. DXCM\u2019s competitors manufacture and market products for the single-point finger stick device market and collectively account for the worldwide sales of self-monitored glucose testing systems at present. Estimate Trend DexCom is witnessing an improving estimate revision trend for 2023 and 2024. In the past 60 days, the Zacks Consensus Estimate for earnings has increased from $1.23 per share to $1.43 for 2023 and from $1.59 to $1.68 for 2024. The consensus mark for the company\u2019s fourth-quarter 2023 revenues is pegged at $1 billion, indicating a 23.3% improvement from the year-ago quarter\u2019s reported number. The same for earnings is pinned at 42 cents per share, implying growth of 23.5% year over year. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Other Stocks to Consider Some other top-ranked stocks from the same medical industry are Cardinal Health CAH, Biodesix BDSX and Patterson Companies PDCO, each carrying a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Cardinal Health has an estimated long-term growth rate of 15.2%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.67%. CAH\u2019s shares have rallied 35.4% year to date. Biodesix has an estimated growth rate of 22.7% for 2024. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 9.76%. BDSX\u2019s shares have lost 44.8% year to date. Patterson Companies has an estimated long-term growth rate of 9.2%. PDCO\u2019s earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.47%. PDCO\u2019s shares have risen 8.8% year to date. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Charles River (CRL) Widens CliniPrime GMP Suite With New Launch Charles River Laboratories International, Inc. CRL recently announced the launch of CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing. All CliniPrime products meet regulatory guidelines for clinical trial development and commercial manufacturing of advanced therapies. The recent development expands the CliniPrime suite of Good Manufacturing Practice (\u201cGMP\u201d)-compliant offerings. This will also boost the Cell Solutions business of the company\u2019s Research Models and Services (\u201cRMS\u201d) segment. News in Detail With the continued advancement in gene-modified cell therapies, there is also a growing need for reliable and consistent sources of GMP-compliant, donor-derived cellular starting material. Cryopreserved leukopaks play a critical role in the research and development continuum and have become an ideal option for many cell therapy developers. Cryopreservation shortly after leukopak collection maximizes cellular viability, product consistency and long-term availability. These factors can help simplify logistics and mitigate risks throughout the supply chain of donor-derived cellular starting materials. Image Source: Zacks Investment Research The launch of CliniPrime Cryopreserved Leukopaks completes an already robust portfolio of GMP-compliant leukopaks from Charles River. CliniPrime leverages the company\u2019s established production processes to provide advanced therapy programs with a high-quality product offering that supports both clinical trial development and commercialization while reducing client resource investment and risk. Per CRL\u2019s representative, the product offers a solution to the growing industry\u2019s need for reliable and consistent sources of cellular starting material. This will help clients work in the development of potentially life-saving modalities of treatment. Industry Prospects Per a Research report, the global cell and gene therapy market was valued at $22.7 billion in 2023 and is expected to witness a CAGR of 28.7% by 2030. Recent Highlights of the RMS Segment Through RMS, CRL provides foundational tools for the discovery of new molecules by supplying research models to the drug development industry, along with a variety of related services. In the last reported third quarter of 2023, robust client demands from global biopharma clients and academic institutions drove the segment\u2019s revenue growth. However, sales were modestly impacted by the timing of NHP (non-human primates) shipments within China and slower demand from mid-tier clients, including biotechs and CROs (contract research organizations). In October, the company introduced an important digital innovation in the business, offering clients real-time access to research model availability and pricing and immediate order confirmation. The intuitive experience enables collaboration between researchers and procurement teams to search inventory by name, species, strain code or therapeutic area and configure their request based on research model specifications, matching their study requirements and schedule. Price Performance Over the past six months, Charles River shares have decreased 4.9% compared with the industry\u2019s fall of 7.8%. Zacks Rank and Key Picks Charles River carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""4 Best Stocks Exhibiting Solid Earnings Growth A company always aims to make money sooner or later. Therefore, earnings growth is the main priority for any organization. So, what\u2019s earnings growth? Study a company\u2019s revenues over a given period, subtract the production cost, and you have earnings. Incidentally, this is the most important variable manipulating its share price. But, expectations of earnings play a significant role. Earnings Estimates & Share Price Movements Frequently, we have seen a decline in the stock price despite earnings growth and a rally in price following an earnings decline. This is largely the result of a company\u2019s earnings failing to meet market expectations. Earnings estimates embody analysts\u2019 opinions on factors such as sales growth, product demand, competitive industry environment, profit margins, and cost control. Thus, earnings estimates serve as a valuable tool, while making investment decisions. Earnings estimates also help analysts assess the cash flow to determine the fair value of a firm. Thus, investors should be on the lookout for stocks ready to make a big move. Hence, investors need to buy stocks with historical earnings growth and are seeing a rise in quarterly and annual earnings estimates. Screening Measures: To shortlist stocks that have striking earnings growth and positive estimate revisions, we have added the following parameters: Zacks Rank less than or equal to 2 (Only Zacks' 'Buys' and 'Strong Buys' are allowed. With the Zacks Rank proving itself to be one of the best rating systems out there, this is a great way to start things off.) 5-Year Historical EPS Growth (%) greater than X-Industry (stocks with a strong EPS growth history). % Change EPS F(0)/F(-1) greater than or equal to 5 (companies that saw year-over-year earnings growth of 5% or more in the last reported fiscal). % Change Q1 Estimates over the last 4 weeks greater than zero (stocks that have seen their current quarter earnings estimates revised higher in the last 4 weeks). % Change F1 Estimates over the last 1 week greater than zero (stocks that have seen their annual earnings estimates revised higher in the last 1 week). % Change F1 Estimates over the last 4 weeks greater than zero (stocks that have seen their annual earnings estimates revised higher in the last 4 weeks). The above criteria narrowed the universe of around 7,839 stocks to only eight. Here are the top four stocks that stand out: DexCom DXCM is a medical device company. DexCom has a Zacks Rank #2 (Buy). DXCM\u2019s expected earnings growth rate for the current year is 64.4%. You can see the complete list of today\u2019s Zacks #1 (Strong Buy) Rank stocks here. Arthur J. Gallagher & Co. AJG provides insurance brokerage and consulting services. Arthur J. Gallagher has a Zacks Rank #2. AJG\u2019s expected earnings growth rate for the current year is 13.6%. Limbach LMB provides building systems. Limbach has a Zacks Rank #1. LMB\u2019s expected earnings growth rate for the current year is 173.4%. The Hartford Financial Services Group HIG is a major multi-line insurance and investment company in the United States. Hartford Financial Services has a Zacks Rank #2. HIG\u2019s expected earnings growth rate for the current year is 7.9%. You can sign up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors, and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks\u2019 portfolios and strategies are available at: https://www.zacks.com/performance. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Hartford Financial Services Group, Inc. (HIG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Arthur J. Gallagher & Co. (AJG) : Free Stock Analysis Report Limbach Holdings, Inc. (LMB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Nemaura (NMRD) to Expand in UK With Metabolic Health Program Nemaura Medical NMRD has made a move to expand into the U.K. market with its Metabolic Health Program. Under this initiative, the company has integrated continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This strategic move also marks a significant advancement in addressing metabolic health, obesity and diabetes. More on the News This latest program leverages Nemaura\u2019s world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics. Participants, by using CGM for just two days per month, can monitor the impact of GLP-1 agonists, lifestyle changes, diet modifications and exercise on their blood glucose profiles. Favorable Outcome Preliminary studies with the United Kingdom\u2019s National Health Service (NHS) have demonstrated promising results. Even without the use of GLP-1 agonists, the integrated program has shown positive responses. The incorporation of behavioral change programs, focusing on education, personalized exercise regimens and lifestyle adjustments, complements CGM's data-driven approach, providing individuals with comprehensive tools for long-lasting change. According to Nemaura, the integrated approach aims to kick-start weight loss initiatives using pharmaceutical interventions and sustain them through education and behavioral change. Image Source: Zacks Investment Research Users can now subscribe directly through the Miboko website. This marks a turning point in Nemaura's history and promises a new era in metabolic health and personalized weight management. Industry Prospects Going by a recent DataHorizzon Research report, the global metabolic testing market, valued at $575.3 million in 2022, is set to reach $1,19 billion by 2032 at a CAGR of 7.7%. Increased awareness about lifestyle disorders like diabetes and obesity is driving the demand for metabolic testing equipment. Integration into smart gadgets and the COVID-19 pandemic further accelerate the market, particularly in the context of monitoring oxygen levels. The market's future appears promising, propelled by the growing need for effective metabolic health monitoring. Share Price Performance Shares of NMRD have plunged 87.8% over the past year compared with the industry\u2019s 6.2% dip. Zacks Rank and Key Picks Nemaura currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 41.6% in the past year compared with the industry\u2019s decline of 6.7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019stock has risen 13.2% in the past year. Estimates for Haemonetics\u2019 2023 earningshave increased from $3.82 to $3.86 in the past 30 days, while the same for 2024 have increased from $4.07 to $4.11. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 9.4% in the past year compared with the industry\u2019s decline of 7.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Nemaura Medical, Inc. (NMRD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""What's in the Cards for Medtronic (MDT) in Q2 Earnings? Medtronic plc MDT is scheduled to report second-quarter fiscal 2023 results on Nov 21, before the opening bell. In the last reported quarter, the company\u2019s earnings exceeded the Zacks Consensus Estimate by 8.1%. Medtronic surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 3.37%. Let\u2019s see how things have shaped up prior to this announcement. Factors at Play Similar to the last few quarters, Medtronic's business is expected to have registered growth. The upside is likely to have been fueled by procedure volume recovery, supply improvements and innovative product introductions. In cardiac rhythm management within the broader Cardiovascular, the company continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family as it enters new geographies and expands penetration in existing markets. In May 2023, Medtronic received FDA approval for Micra AV2 and VR2, which extend the battery life by 40% to a projected 16-17 years, respectively. The ICDs (Implantable cardioverter-defibrillator) within cardiac rhythm management are gaining in terms of market share following the latest CE Mark for the Aurora Extravascular ICD. We believe these developments to have boosted the company\u2019s second-quarter revenues. Per our model, we project the Medtronic Cardiovascular segment to register growth of 3.9% in the fiscal second quarter. Within Medtronic\u2019s Neuroscience portfolio, the Cranial Spinal technologies business registered robust growth in recent quarters. In the fiscal first quarter, this segment benefitted from increased sales of Spine & Biologics products in the United States based on the continued adoption of the Aible spinal ecosystem. The company's ENT business within the Specialty Therapies division in the Neuroscience portfolio continues to contribute positively. The Specialty Therapies business is gaining from the strong performances of the company\u2019s hemorrhagic stroke flow diversion products. We expect these trends to have continued through the fiscal second quarter, thus adding to the top line. Per our model, we project Medtronic\u2019s Neuroscience segment to register growth of 2% in the fiscal second quarter. Medtronic PLC Price and EPS Surprise Medtronic PLC price-eps-surprise | Medtronic PLC Quote Within Medtronic\u2019s MedSurg portfolios, the rollout of differentiated Hugo robotic systems in many international markets and the United States will likely drive revenues in the to-be-reported quarter. Medtronic is likely to have registered strong performance within Advanced Energy and Barrx, primarily driven by improved supply and continued growth in GI Genius and PillCam in the second quarter of fiscal 2024. We project Medtronic\u2019s MedSurg segment to register an increase of 8.9% in the fiscal second quarter. In Diabetes, Medtronic continues to see significant growth in markets outside the United States, led by the increasing user base of the MiniMed 780G insulin pump combined with the Guardian 4 sensor. During the fiscal first quarter, the company launched 780G and Guardian 4 sensors. We believe these launches will contribute to the company\u2019s fiscal second-quarter performance owing to strong customer adoption. In September 2023, Medtronic received CE Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple, two-step insertion process. We believe this development will contribute to the company\u2019s top line in the quarter to be reported. According to our model, Medtronic\u2019s overall Diabetes is expected to rise 0.7% in the fiscal second quarter. Q2 Estimates The Zacks Consensus Estimate for Medtronic\u2019s fiscal second-quarter total revenues of $7.92 billion suggests a 4.4% rise from the prior-year reported number. The consensus mark for earnings is pegged at $1.18 per share, suggesting a 9.2% decline from the year-ago reported figure. What Our Quantitative Model Predicts Our proven model does not conclusively predict an earnings beat for Medtronic this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. Earnings ESP: Medtronic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: Medtronic currently carries a Zacks Rank #3 (Hold). Stocks Worth a Look Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Abbott, carrying a Zacks Rank of 2, reported adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Abbott has a long-term estimated growth rate of 5.1%. ABT\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. DexCom reported adjusted EPS of 50 cents in third-quarter 2023, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2. DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-20,104.39,109.2,104.06,108.96,"[""DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks. DexCom (DXCM) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy). While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below: Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 49.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 64.1% this year, crushing the industry average, which calls for EPS growth of 7.6%. Cash Flow Growth Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 37.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 75.9% over the past 3-5 years versus the industry average of 7%. Promising Earnings Estimate Revisions Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. There have been upward revisions in current-year earnings estimates for DexCom. The Zacks Consensus Estimate for the current year has surged 15.7% over the past month. Bottom Line DexCom has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination positions DexCom well for outperformance, so growth investors may want to bet on it. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""National Vision's (EYE) Market Expansion Aids, Inflation Ails National Vision EYE continues to gain market share on improving consumption patterns. The company\u2019s strong focus on opening new stores is also encouraging. Legacy business termination might mar growth. The stock carries a Zacks Rank #3 (Hold). National Vision\u2019s four subsegments within Owned and Host are consistently gaining market share, banking on several growth drivers. Diminishing eyesight with increasing age causes new customers to buy corrective eyewear. Meanwhile, there\u2019s a steady and consistent replacement cycle in place as customers replace or purchase new eyewear for a variety of reasons, including changes in prescriptions, fashion trends and necessity. America's Best and Eyeglass World are particularly driving revenues. The company is expanding sales through the continued rollout of its remote medicine technology. National Vision is deploying remote medicine technology in tandem with electronic health record technology to drive expanded capacity, improve in-store efficiencies and improve patient experience. The combination of these initiatives is resulting in added exam capacity in sales that the company would not have had otherwise. Per the company\u2019s third-quarter update, National Vision opened 70 new America\u2019s Best and Eyeglass World stores. Unit growth in America\u2019s Best and Eyeglass World brands increased 5.3% on a combined basis over the total store base last year. The company ended the quarter with 1402 stores and is on track to open between 65 stores and 70 stores in 2023. It is also on track with the expansion into at least an additional 200 remote-enabled stores in 2023. National Vision plans to continue executing its core growth initiatives and further invest in strengthening competitive advantages. In terms of store expansion, the company continues to see a sizable new opportunity with growth for many years to come. National Vision Holdings, Inc. Price National Vision Holdings, Inc. price | National Vision Holdings, Inc. Quote Per National Vision, marketing continues to be a key factor in driving traffic to its stores, given the infrequent purchase cycle for eyeglasses. In the current environment of high inflation, the company continues to focus on marketing efficiency this year. Year to date, National Vision has invested $82 million in capital expenditures, primarily focused on new store openings and investment in labs, distribution centers and customer-facing technology. The company currently remains on track for 2023 CapEx in the range of $115 million to $120 million to support key growth initiatives. The company\u2019s merchandising and distribution teams continue to execute well and are confident that the current inventory levels are sufficient to support continued growth in 2023. Overall, National Vision continues to utilize its strong balance sheet and cash flow to invest in strategic initiatives to enhance customer experience and strengthen its market position. On the flip side, in July 2023, National Vision announced that its long-term partnership with Walmart is going to terminate on Feb 23, 2024. National Vision, in this regard, noted that this impending termination may significantly impact the company\u2019s business. The transition period, including Walmart\u2019s solicitation period under the agreements, may cause disruption to the business, including a reduction in sales, productivity and focus, and may make it harder to retain associates and optometrists, which in turn could adversely impact the company\u2019s financial condition and results of operations. Due to these factors, the costs to retain associates and optometrists during the transition period may increase. Added to this, rising inflation is resulting in increased costs and expense pressure for National Vision. The company anticipates that pressure from increases in raw materials prices could have an impact on its costs applicable to revenues in 2023. Wage investments as a result of inflation and an increasingly competitive recruiting market for vision care professionals due to the pandemic and related effects have had and may continue to have, an impact on the company\u2019s profitability. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.1% in the past year compared with the industry\u2019s decline of 6.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and from $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry\u2019s decline of 6.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Myriad Genetics (MYGN) Expands Pharma Services With New Pact Myriad Genetics, Inc. MYGN entered into a non-exclusive collaboration with Personalis through which Myriad will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners. Financial terms of the deal were not disclosed. The collaboration will expand Myriad Genetics pharma services. More on the News Personalis' ImmunoID NeXT technology, which the top 20 worldwide biopharma companies have used, is the most discriminating platform for powering drug development biomarker initiatives. It offers high-quality exome/transcriptome assays for FFPE cancer tissues. Strategic Efforts Several companion diagnostic pharmaceutical partners are requesting whole exome and whole transcriptome testing on the tumors of their patients. Myriad Genetics' goal is to provide its customers with complete menu access and the company is thrilled to enhance its offering by leveraging Personalis' high-quality assays. Through this collaboration, partners will utilize the MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoiceCDx cancer tests. Industry Prospects Per a report by Reports And Data, the global precision oncology market is expected to reach $99.72 billion in 2027 from $49.98 billion in 2019 at a CAGR of 9.9%. Factors like rising cancer incidences and growing awareness pertaining to molecular-level diagnosis and treatment are likely to drive the market for the same. Progress Within Testing Menu During third-quarter earnings update, Myriad Genetics talked about continuous gain in share in the hereditary cancer market, with volumes rising 18% year over year in the third quarter. This was driven by competitive account wins and increased adoption by providers of myRisk. Image Source: Zacks Investment Research In the third quarter, hereditary cancer testing volumes from the oncology business rose 15% year over year, well above the estimated industry growth, reflecting enduring franchise and improving its brand reputation. Prolaris \u2014 the prostate cancer test \u2014 continued its momentum, with third-quarter revenues up 18% year over year. In September 2023, Myriad Genetics announced two key milestones in its strategic partnership with Illumina. The collaboration brings together Myriad\u2019s MyChoice CDx homologous recombination deficiency (HRD) technology and Illumina\u2019s expertise in comprehensive genomic profiling to broaden clinical research opportunities and drive CDx development for gene-based therapies. Price Performance In the past year, MYGN\u2019s shares have declined 7.6% compared with the industry\u2019s fall of 25%. Zacks Rank and Key Picks Myriad Genetics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost Medtronic plc MDT gained FDA approval for its Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. Following this win, the commercialization of the therapy will begin immediately. The latest development represents a milestone for physicians and patients in the treatment of hypertension. The approval, which is a culmination of ten years of clinical research and development of the Medtronic renal denervation technology, will boost the company\u2019s Cardiovascular portfolio. Significance of the News Hypertension, or high blood pressure, is the leading modifiable cause of heart attack, stroke and death, and its prevalence is notably worse among the underserved communities in the United States. Despite the available medications and lifestyle interventions, control rates remain low. These challenges boast the possibility that patients may benefit from an adjunctive treatment option to better manage their blood pressure. Image Source: Zacks Investment Research For Medtronic, the potential of this therapy has led to forming close partnerships with leading experts in the clinical community who could help deliver this technology to the people who need it most. According to the company\u2019s representative, the promise of this therapy enabled Medtronic to keep going, even when others exited the renal denervation space. News in Detail The Medtronic Symplicity blood pressure procedure is innovative and minimally invasive, delivering radiofrequency to nerves near kidneys that can become overactive and contribute to high blood pressure. After sedation, doctors insert a single thin tube (known as a catheter) into the artery leading to the kidney. Once the tube is in place, doctors administer energy to the system to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind. Patient preference and shared decision-making have been identified as critical components of developing a hypertension care plan, including the Symplicity blood pressure procedure. The results from a Medtronic-led patient preference study demonstrated that one-third of patients were likely to choose the interventional treatment when presented with an interventional treatment with blood pressure reduction and potential risks in line with those of the Symplicity blood pressure procedure. Industry Prospects Per a Research report, the hypertension drug market was valued at $31.76 billion in 2022 and is expected to witness a CAGR of 4.0% by 2030. Notable Highlights in the Cardiovascular Space Last month, Medtronic received the FDA approval for the Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. The approval was supported by global pivotal trial results showing the system's safety and effectiveness, which were published in The New England Journal of Medicine. In the same month, the company announced four-year results from the Evolut Low Risk Trial, wherein the Medtronic Evolut transcatheter aortic valve replacement (TAVR) system demonstrated exceptional outcomes and sustained valve performance, proven by significantly better hemodynamics than surgical aortic valve replacement (SAVR). The data were presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) conference and simultaneously published in the Journal of the American College of Cardiology. Price Performance In the past six months, MDT shares have lost 16.4% compared with the industry\u2019s decline of 14.7%. Zacks Rank and Key Picks Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have lost 40.1% in the past year compared with the industry\u2019s decline of 6.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry\u2019s decline of 6.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics Paragon 28, Inc. FNA has taken a significant stride in advancing its biologics offerings with the recent launch of BEAST Cortical Fibers. It is engineered to provide an osteoinductive porous structure for cellular attachment and osteoinductive potential, aiding in cellular differentiation and bone formation. Paragon 28 claims this advancement will enhance surgical flexibility. More on the News The flexibility of BEAST Cortical Fibers upon hydration facilitates application in challenging fusion locations in the foot and ankle. It enables surgeons to address complex cases efficiently. The loose cortical matrix absorbs bioactive fluids, including bone marrow aspirate, fostering cellular infiltration and promoting efficient bone remodeling. The BEAST Cortical Fibers\u2019 advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation. Image Source: Zacks Investment Research Comprehensive Biologics Portfolio The launch of BEAST Cortical Fibers complements Paragon 28's already robust biologics product offering for reconstruction and trauma. From the PRESERVE Bone Wedge System to the V92 and V92-FC+ Cellular Bone Matrices, MgNum Bone Void Filler, Paraderm Dermal Matrix, BEAST Demineralized Bone Matrices to Pro3 Placenta and Cord Regenerative Tissue Matrices, the company provides a comprehensive suite of innovative solutions for reconstruction and trauma. Industry Prospects Going by a Future Market Insights report, the global orthopedic trauma devices market is poised for a surge from $10.7 billion in 2023 to more than $21.2 billion by 2033. Based on a number of growth factors, such as an aging population, a rise in orthopedic diseases and an increase in road accidents and sports injuries, the demand for orthopedic trauma medical devices is set to escalate. Recent Update Earlier this month, the company launched its JAWS Great White Staple System. According to Paragon 28, this advanced system offers increased strength and stability of the osteotomy or fusion site compared to conventional staple systems. This development is expected to strategically fortify its position in the field of midfoot and hindfoot solutions. Share Price Performance Shares of Paragon 28 have plunged 46.6% over the past year compared with a 6.6% decline of the industry. Zacks Rank and Key Picks Paragon 28 currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy). Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.1% in the past year compared with the industry\u2019s decline of 6.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and from $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry\u2019s decline of 6.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Paragon 28, Inc. (FNA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How. Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to manage blood glucose levels in hand, patients may not have as much of a need for the glucose monitors and insulin pumps they formerly relied on, so the fearful argument goes. And newer drugs like Eli Lilly's Mounjaro are likely to exacerbate the same trend. But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Here's how that might work, and how much it could help their share prices over the next few years. Effective type 2 diabetes and weight loss medicines: Friend or foe for device makers? Therapies made by Novo Nordisk and Eli Lilly like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound treat diabetes and also obesity by prompting the patient's body to produce more insulin after they eat food, thereby lowering their blood glucose level after meals to within healthy ranges. Persistently high blood glucose levels, as occurs in untreated type 2 diabetes, are a major risk factor for developing cardiovascular illness. Separately, even in people who do not have diabetes, obesity is also a major risk factor for cardiovascular disease. So it isn't all that surprising to learn that those same medicines have been proven in a handful of different scientific investigations to reduce people's cardiovascular disease risks as a consequence of lowering their blood glucose levels and helping them to shed their excess weight. But if your company makes devices that might get used by patients a lot less when Ozempic is easily available, there's clearly a potential problem. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. In the third quarter alone, Abbott brought in $1.4 billion from sales of its FreeStyle Libre CGM, 30% more than a year prior. In the same period, DexCom's revenue of $975 million from its lineup of CGMs and accessories was up 27% compared to last year. So much for Ozempic usage being a headwind at the moment. In fact, per an analysis of insurance claims data by DexCom, patients on intensive insulin regimens increased their use of the company's monitors by double when they started on medicines in the same class as Ozempic. For those on non-insulin treatments, usage quadrupled. Simply checking the data from the monitor more won't necessarily drive more revenue, but it suggests that patients will not be in any hurry to stop buying the disposable sensors they need to make their monitor work. A similar analysis by Abbott also reached favorable conclusions, finding that patients on the medications wore their monitor's sensors more days of the week than they did before. Furthermore, patients experienced significant improvements in their blood glucose levels beyond what they'd achieved with Ozempic, too. Wearing the sensor more frequently means needing to replace it more frequently. And that points to more spending, not less. This issue is far from being settled The rationale for why patients seem to increase their glucose monitor use when taking these drugs doesn't have to be complicated. Just as patients need to know when their blood glucose levels are too high so that they can moderate them by taking insulin, they need to know when their levels are too low so that they can avoid hypoglycemia. Taking these medicines is what opens the door to that possibility where it was improbable before. And that's why they aren't actually a threat to Abbott or DexCom. Based on the available data, it looks like both businesses are picking up a brand new tailwind for sales of their CGMs. As DexCom's entire game is to sell CGMs and accessories, the additional revenue growth from this trend will probably be more significant for shareholders than it will be for Abbott Labs, as diabetes care devices are only a small portion of its colossal catalog of healthcare products. At the moment, it's hard to say exactly how much additional revenue Mounjaro and Ozempic could generate over the coming years, as they're still early on in their history of use. Nonetheless, if you were thinking about buying either DexCom or Abbott Labs, be aware that there's now another point in their favor. 10 stocks we like better than Novo Nordisk When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 15, 2023 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist When challenges arise on Wall Street, investors have a tendency to turn to profitable, time-tested companies that have handily outperformed their peers. While the FAANG stocks have been the popular/logical choice for the past decade, it's companies enacting stock splits that have endeared investors over the past two years. A stock split is an event that allows a publicly traded company to cosmetically alter its share price and share count without having any impact on its market cap or operations. Forward-stock splits reduce a company's share price to make it more nominally affordable for everyday investors, while a reverse-stock split is employed to increase a company's share price to ensure it remains compliant with listing rules at major exchanges. Image source: Getty Images. Without question, most of Wall Street gravitates to companies enacting forward-stock splits. That's because companies enacting forward splits are very clearly outperforming and out-innovating their competition. Since the start of July 2021, nine well-known, high-flying stocks have conducted forward-stock splits: Nvidia (NASDAQ: NVDA): 4-for-1 split Amazon (NASDAQ: AMZN): 20-for-1 split DexCom (NASDAQ: DXCM): 4-for-1 split Shopify (NYSE: SHOP): 10-for-1 split Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split Tesla (NASDAQ: TSLA): 3-for-1 split Palo Alto Networks (NASDAQ: PANW): 3-for-1 split Monster Beverage (NASDAQ: MNST): 2-for-1 split Novo Nordisk (NYSE: NVO): 2-for-1 split But not even stock-split stocks are created equally. Based on the latest round of Form 13F filings, there are clear winners. More specifically, billionaire money managers are scooping up shares of very specific members of this stock-split group. What follows are three stock-split stocks billionaires bought hand over fist during the September-ended quarter. Alphabet (Class A shares, GOOGL) The first stock-split stock billionaire investors can't seem to get enough of is Alphabet (specifically, the Class A shares, GOOGL). Alphabet is the parent company of familiar internet search engine Google, streaming platform YouTube, and autonomous vehicle company Waymo, among others. All told, nine billionaires were busy mashing the buy button during the third quarter, including (total shares purchased in parenthesis): Stephen Mandel of Lone Pine Capital (3,113,001 shares) Bill Ackman of Pershing Square Capital Management (2,169,824 shares) Chase Coleman of Tiger Global Management (1,523,000 shares) Ken Griffin of Citadel Advisors (1,498,213 shares) John Overdeck and David Siegel of Two Sigma Investments (1,195,541 shares) Ken Fisher of Fisher Asset Management (1,023,535 shares) Israel Englander of Millennium Management (602,822 shares) Steven Cohen of Point72 Asset Management (544,495 shares) The likeliest reason these billionaire money managers have piled into Alphabet is the overreaction investors have had to the potential for economic weakness. Since Alphabet generates nearly 78% of its revenue from advertising, and U.S. gross domestic product grew by a healthy 4.9% during the third quarter, it would appear fears of a meaningful ad slowdown have proved incorrect. Billionaires likely also value Alphabet's foundational operating segment, Google. In October, Google claimed close to 92% of worldwide internet search share. Moreover, it hasn't accounted for less than a 90% share of monthly internet search over the past 8.5 years. It's the undisputed best way for advertisers to target users, and that's going to afford Google exceptional pricing power for a long time to come. But the most-exciting growth catalyst for Alphabet is its cloud segment. Google Cloud is the global No. 3 in cloud infrastructure service spending, and enterprise cloud spending is still, arguably, in its infancy. After years of operating losses, Google Cloud is now generating a profit. Though Wall Street wasn't thrilled with Google Cloud growing by \""only\"" 22.5% year-over-year in the September-ended quarter, it's hard to argue against a decisive shift to recurring profitability from a potentially high-margin segment. Amazon A second stock-split stock that billionaires bought hand over fist during the third quarter is e-commerce behemoth Amazon. A grand total of 10 billionaires added to their respective funds' existing stakes, including (total shares purchased in parenthesis): Jeff Yass of Susquehanna International (5,042,696 shares) Ole Andreas Halvorsen of Viking Global Investors (4,348,680 shares) Steven Cohen of Point72 Asset Management (1,171,081 shares) John Overdeck and David Siegel of Two Sigma Investments (883,205 shares) Ken Fisher of Fisher Asset Management (665,738 shares) David Tepper of Appaloosa Management (587,500 shares) Dan Loeb of Third Point (580,000 shares) Stephen Mandel of Lone Pine Capital (569,245 shares) Chase Coleman of Tiger Global Management (239,760 shares) Not to sound like a broken record, but the optimism with Amazon probably has a lot to do with the resilience of the U.S. economy. Amazon generates an outsized percentage of its revenue from its world-leading online marketplace. When economic downturns occur, it's not uncommon for consumers to spend less, thereby stalling a significant portion of Amazon's top-line growth. A healthy U.S. economy reduces near-term concerns about a retail sales slowdown. However, the smartest investors on Wall Street are aware that Amazon is far more than an online retailer. Whereas Google Cloud is the world's No. 3 cloud infrastructure service, Amazon Web Services (AWS) is No. 1, with approximately 30% ofglobal marketshare. AWS is pacing more than $92 billion in annual run-rate revenue, as of the end of September, and its exceptionally high margins (relative to online retail sales) mean this segment accounts for the lion's share of Amazon's operating income. Amazon's subscription services are also extremely important to its long-term success. In April 2021, the company surpassed 200 million global Prime subscribers, according to then-CEO Jeff Bezos. With exclusivity to Thursday Night Football and an ever-growing online marketplace and logistics network, it's a fair assumption that this subscriber count, along with Amazon's subscription pricing power, have both increased since April 2021. Although Amazon isn't cheap based on the traditional price-to-earnings (P/E) ratio, it's historically inexpensive relative to its cash flow potential over the coming years. Deliveries for Tesla's Cybertruck will begin at the end of November. Image source: Tesla. Tesla The third stock-split stock that billionaires are buying hand over fist is the most-owned stock among retail investors. I'm talking about electric-vehicle (EV) maker Tesla, which was purchased by four prominent billionaires during the third quarter, including (total shares purchased in parenthesis): John Overdeck and David Siegel of Two Sigma Investments (644,638 shares) Jeff Yass of Susquehanna International (603,898 shares) Israel Englander of Millennium Management (407,695 shares) Billionaires have long latched onto Tesla stock because it's in the driver's seat (sorry, the most obvious pun had to be used) in the EV space. It's North America's leading EV manufacturer; the only automaker to build itself from the ground-up to mass production in more than a half-century; and the only pure-play EV company that's generating a recurring profit. These billionaires continue to view Tesla as a disruptive force in the automotive space. But while Amazon and Alphabet are historically cheap, at least relative to their cash flow, Tesla is on the opposite end of the spectrum. Despite its struggles to meaningfully expand beyond selling and leasing EVs, it's trading at a nosebleed valuation in relation to other auto stocks. This is a potential problem given the headwinds the company is encountering. Specifically, Tesla kicked off a price war with other EV makers earlier this year. Though optimists had hoped Tesla selling its EVs for a lower price was a sign of its improved production efficiency, CEO Elon Musk stamped out this belief during his company's annual shareholder meeting by noting that Tesla's pricing strategy is dictated by demand. The more than half-dozen price cuts across Tesla's production models in 2023, which have more than halved the company's operating margin over the trailing year (as of Sept. 30, 2023), are due to rising inventory and/or weaker demand. These billionaires might may also be playing with fire given Musk's history of failing to deliver. Despite overseeing the rollout of four current production models -- soon to be five with the Cybertruck -- Tesla's chief has a habit of overpromising and underdelivering. If many of Musk's unfulfilled promises are backed out of Tesla's valuation, its stock could head meaningfully lower. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 15, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-21,108.42,109.65,107.81,108.96,"[""Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up Medtronic plc MDT reported adjusted earnings per share (EPS) of $1.25 in second-quarter fiscal 2024 compared with the year-ago quarter\u2019s EPS of $1.30. The figure moved down 4% but beat the Zacks Consensus Estimate by 5.9%. Without certain one-time adjustments \u2014 including restructuring and associated costs, amortization and acquisition-related costs, among others \u2014 GAAP EPS was 68 cents, surging 112.5% from the year-ago quarter\u2019s reported figure. Total Revenues Worldwide revenues in the reported quarter grossed $7.98 billion, up 5.3% year over year on a reported basis and 5% on an organic basis. The top line exceeded the Zacks Consensus Estimate by 0.9%. The company's organic revenue results reflect broad strength across businesses and geographies, benefiting from durable fundamentals. Segment Details The company generates revenues from four major segments, namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. In the fiscal second quarter, Cardiovascular revenues increased 5.9% at CER to $2.92 billion, with all three divisions reporting organic growth this quarter. This compares with our model projection of $2.87 billion for the fiscal second quarter. Cardiac Rhythm & Heart Failure sales totaled $1.49 billion, up 5.3% year over year at CER. Revenues from Structural Heart & Aortic were up 8.2% at CER to $819 million. Coronary & Peripheral Vascular revenues were up 5% year over year to $613 million. In Medical Surgical, worldwide sales totaled $2.14 billion, up 7% year over year at CER. The Surgical & Endoscopy revenue grew 8.5%, while Patient Monitoring & Respiratory Interventions revenues rose 2.5%. This compares with our model projection of $2.18 billion for the Surgical segment for Q2. Medtronic PLC Price, Consensus and EPS Surprise Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote In Neuroscience, worldwide revenues of $2.29 billion were up 4.7% year over year and 4.2% organic, with a high-single-digit organic increase in CST and low-single-digit organic increases in Specialty Therapies and Neuromodulation. This compares with our model projection of $2.23 billion for the Neuroscience segment for the said quarter. Revenues in the Diabetes group rose 9.7% at CER and 6.7% on organic to $610 million. The company registered mid-teens growth in non-U.S. developed markets on continued MiniMed 780G system adoption and increased CGM attachment rates on the strength of the Guardian 4 sensor. This compares with our model projection of $560.2 million for the fiscal second quarter for the Diabetes segment. Margins Gross margin in the reported quarter contracted 116 basis points (bps) to 65.4% on an 8.9% rise in cost of revenues. Research and development expenses rose 3.3% year over year at $698 million. Selling, general and administrative expenses rose 2.6% to $2.69 billion. Adjusted operating margin contracted 13 bps year over year to 23%. Guidance Medtronic raised fiscal 2024 guidance. Fiscal 2024 organic revenue growth is expected to be 4.75% (up from the earlier guidance of 4.5%). The organic revenue growth guidance excludes the impact of foreign currency and revenue related to certain businesses reported as Other. If foreign currency exchange rates as of the beginning of November hold, fiscal 2024 revenue growth on a reported basis would be approximately 2.6%. The Zacks Consensus Estimate for the company\u2019s fiscal 2024 worldwide revenues is pegged at $32.13 billion. The full-year adjusted EPS is now expected in the range of $5.13-$5.19 (previous guidance was $5.08- $5.16). The Zacks Consensus Estimate for the year\u2019s adjusted earnings is $5.12. Our Take Medtronic recorded earnings and revenue beat in the fiscal second quarter. The company's organic revenue results reflect broad strength across businesses and geographies, benefiting from durable fundamentals. During the quarter, the company received the FDA approval for the Aurora EV-ICD system and Symplicity Spyral renal denervation (RDN) system. Within Neuroscience, CST delivered high-single-digit Core Spine growth on implant pull-through fueled by continued adoption of the AiBLE ecosystem. Within Diabetes, non-U.S. developed markets rose in the mid-teens on continued MiniMed 780G system adoption and increased CGM attachment rates on the strength of the Guardian 4 sensor. The raised fiscal 2024 guidance looks encouraging. However, macroeconomic headwinds related to persistent inflation and unfavorable foreign currency movements continue to challenge the company\u2019s earnings performance. Zacks Rank & Other Key Picks Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced their quarterly results are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now Myriad Genetics MYGN is well poised for growth in coming quarters, backed by a strong improvement in testing volume across all its businesses. The recent collaboration with QIAGEN looks impressive. Yet, foreign exchange headwinds and stiff competition are a concern. In the past year, this Zacks Rank #3 (Hold) stock has declined 9.6% compared with 25.4% fall of the industry and a 13.3% rise of the S&P 500 composite. The renowned genetic testing and precision medicine company has a market capitalization of $1.62 billion. Myriad Genetics surpassed estimates in two of the trailing four quarters and missed the same in the other two, delivering an average negative earnings surprise of 24.24%. Let\u2019s delve deeper. Tailwinds Huge Potential in Oncology Testing: As a leader in genetic testing and precision medicine, Myriad Genetics provides insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. The company believes that the expansion of companion diagnostics, market expansion through new clinical guidelines and providing new offerings are key opportunities to boost its Oncology business. In the third quarter of 2023, hereditary cancer testing volumes from the oncology business rose 15% year over year, well above the estimated industry growth, reflecting enduring franchise and improving its brand reputation. Prolaris \u2014 the prostate cancer test \u2014 continued its momentum, with third-quarter revenues up 18% year over year. Product Launches: Myriad Genetics launched a slew of products in recent months. In August 2023, Myriad Genetics announced enhancements to the GeneSight Psychotropic test \u2014 a pharmacogenomic test for mental health medications. The GeneSight report will now include information on how a patient's smoking status may impact their body's metabolism of certain medications. Image Source: Zacks Investment Research The same month, Myriad Genetics announced the integration of Absolute Risk Reduction (ARR) into the Prolaris Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. Strategic Partnerships to Drive Growth: In September 2023, Myriad Genetics entered into a research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The partnership will study the use of minimal residual disease (MRD) testing in breast cancer by using Myriad\u2019s MRD testing platform. This tumor-informed high-definition assay uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA (ctDNA). During the third quarter, Myriad Genetics collaborated with QIAGEN to develop kit-based companion diagnostic tests, combining its strengths in assay development, clinical testing and regulatory approvals. The opportunity to better serve pharma partners, but we hope that this collaboration sets the stage for advanced analysis and accessibility of MRD and HRD assays to improve cancer treatment decision-making potentially. Downsides Foreign Exchange Headwinds: Myriad Genetics receives a considerable portion of its revenues and pays an amount of its expenses in foreign currencies. As a result, the company remains at risk of exchange rate fluctuations between foreign currencies and the U.S. dollar. Increasing Competition: With the entry of new players, imminent price competition is a concern. Per management, Myriad Genetics is currently facing competition in its key BRACAnalysis market. The company expects competition to intensify in its current fields with recently observed advancements in technology. Estimate Trend The Zacks Consensus Estimate for MYGN\u2019s 2023 loss per share has moved up from 31 cents to 30 cents in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $750. 7 million. The projection suggests a 10.7% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Quantitative Stock Analysis Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt Zimmer Biomet's ZBH strategic focus on emerging markets and stabilizing market trends bolster our confidence in this stock. However, factors like macroeconomic uncertainties and competitive pressurecontinue to adversely impact Zimmer Biomet's sales. The stock carries a Zacks Rank #3 (Hold). The company is witnessing a rebound in its business for the past few quarters despite macroeconomic challenges. Per ZBH, procedure recovery continues successfully, aided by no meaningful impact of COVID-19 or staffing challenges. Accordingly, the company is enjoying a tailwind from increased provider capacity, resulting in a backlog pull-through in the recent quarters. In the third quarter, U.S. sales rose 6%, with elective procedure volumes recovering. Further, sales growth in the S.E.T. category, together with strong capital sales, improved the overall performance in this region. International sales grew 2.9% year over year. All regions benefited from the continued recovery of elective procedures, backlog recapture, strong commercial execution and new product uptake. In terms of business category, Global Knees grew 7.3%, driven by the strong execution of the company\u2019s 4-pillars strategy centering on a very strong Persona portfolio, combined with the benefits of the ROSA robotics platform. Further, excluding the unfavorable impacts of tough comps in China and headwinds in Russia, the international Hip business demonstrated growth in the low double digits. Over the recent past, Zimmer Biomet has been working to strengthen its foothold in emerging markets that provide long-term opportunities for growth. The company's strategic investments in these regions over the past several quarters to improve operational and sales performance are yielding results. Zimmer Biomet Holdings, Inc. Price Zimmer Biomet Holdings, Inc. price | Zimmer Biomet Holdings, Inc. Quote While the integration of Biomet is over, the combined company has started to benefit from a strong presence in emerging markets with an extended portfolio that includes upper and lower joints. According to the combined company, this will help develop the extremities and trauma business going forward. Zimmer Biomet expects to establish critical mass in both spine and dental that will position the company to compete effectively and gain a share in these significant markets. The market opportunity is expected to grow to $66.6 billion by 2025 for orthopedic implants globally. Within emerging markets, we note that strength in the Asia Pacific market has continued to drive strong revenue growth so far. As the COVID-19 severity is over now, banking on a cadence of product launches and strong customer adoptions, Zimmer Biomet is successfully expanding its presence in the emerging market. In the third quarter of 2023, Zimmer Biomet\u2019s international sales grew 2.9%, driven by faster recovery and strength across both developed and emerging markets. Over the past year, shares of Zimmer Biomet have declined 2.5% compared with the industry\u2019s 8% plunge. Meanwhile, although Zimmer Biomet is gradually coming out of the impact of the two-and-a-half-year-long healthcare crisis, the ongoing industry-wide trend of staffing shortages and supply chain-related hazards is denting growth. Deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor costs, freight charges and rising interest rates, have put the dental treatment space (which is highly elective) in a tight spot. Within the Hip category, headwinds in Russia are disproportionately impacting the outside U.S. business. Further, within the S.E.T. category, Zimmer Biomet is facing challenges in the form of reimbursement headwinds, particularly in the Restorative Therapies business. In addition, the company also noted experiencing acute supply challenges within Sports and Trauma. All these are creating significant pressure on the company\u2019s operating profit. During the last reported third quarter, ZBH witnessed a 3.1% increase in SG&A expenses and a 14.9% rise in R&D expenses. The presence of a large number of players has made the medical device market intensely competitive. The orthopedic industry, in particular, is highly competitive with the presence of players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew and Medtronic. Zimmer Biomet needs to constantly introduce or acquire new products to withstand competitive pressure and maintain its market share. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.1% in the past year compared with the industry\u2019s decline of 6.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and from $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry\u2019s decline of 6.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Retain STERIS (STE) Stock for Now STERIS plc STE is well-poised for growth in the coming quarters, backed by the strong momentum in the Healthcare business. The Becton, Dickinson and Company deal will strengthen, complement and expand the company\u2019s Healthcare product offerings. Encouraging signs of the Medtech demand recovery also buoy optimism for the AST (Applied Sterilization Technologies) business. However, STERIS\u2019 operations are subjected to macroeconomic pressures and currency fluctuations, which may adversely affect its performance. In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 12.3% against the industry\u2019s 7.5% fall and the S&P 500\u2019s 13.3% rise. The renowned provider of infection prevention and other procedural products and services has a market capitalization of $19.78 billion. The company has an earnings yield of 4.35% compared to the industry\u2019s -8.65%. In the trailing four quarters, STE delivered an average earnings surprise of 1.13%. Let\u2019s delve deeper. Factors at Play Upsides Promising Healthcare Business: The Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. In the second quarter of fiscal 2024, capital equipment, consumables and services demonstrated consistent double-digit growth. The backlog reduced sequentially, and replacement orders represented 65% of the total orders in Healthcare in the first half of the fiscal year. Given the performance, the company sees potential for the segment to outperform its expectations for the fiscal year, offsetting the macro challenges impacting demand in other segments. Image Source: Zacks Investment Research Strong Rebound Prospects of the AST Segment: Since the beginning of the fiscal 2023 third quarter, STERIS customers were left stranded with a bulk of inventory, possibly caused by vaccine reluctance or vaccine production in general. However, the MedTech inventory pullback was earlier noted as temporary and is not expected to continue beyond the first half of the year. Raising optimism, the company seemingly witnessed positive signs of recovery in the MedTech demand in the fiscal second quarter. Markets across the United States reflected an improving procedure environment and the burndown of customer inventory, resulting in solid growth. On the bioprocessing side, despite tough comparisons with a vaccine spike in the year-ago period leading to a slowdown in market demand, management remains bullish on sequential growth to return in the second half of the year. Benefits of the BD Acquisition: In August 2023, the company purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company or BD. The acquisition strengthens, complements and expands STERIS\u2019 Healthcare product offerings with renowned brands like V. Mueller, Snowden-Pencer and Genesis. Per the latest update, the integration is progressing as planned. Downsides Mounting Expenses May Strain the Bottom Line: Challenging macroeconomic conditions in the form of supply-chain constraints, higher material costs, ongoing labor inflation and lower productivity continue to weigh significantly on STERIS\u2019 margins. These macroeconomic factors are also resulting in a significant escalation in the company\u2019s operating expenses. In the first half of fiscal 2024, the gross profit was affected by the unfavorable impacts of productivity and inflationary cost increases for materials and labor, which exceeded the benefits of pricing and mix. Foreign Currency Risks: With nearly 30% of STERIS\u2019 revenues and cost of revenues being generated outside the United States, foreign currency exchange rate fluctuations can significantly impact its financial position, results of operations and competitive position. For instance, the ongoing geopolitical instability, including as a result of Russia\u2019s invasion of Ukraine, has negatively impacted and can potentially further impact the global and U.S. economies. This has led to volatility in capital markets and foreign currency exchange rates, rising interest rates and heightened cybersecurity risks. Estimate Trends In the past 30 days, the Zacks Consensus Estimate for STERIS\u2019 fiscal 2024 earnings has moved south from $8.74 to $8.70. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $5.43 billion, suggesting 9.5% growth from the fiscal 2023 reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 27.4% for fiscal 2024 compared with the industry\u2019s 14.1%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have increased 0.3% against the industry\u2019s 6.3% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 37.4% compared with the industry\u2019s 6.2% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have fallen 1.9% compared with the industry\u2019s 7.5% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Top 5 ChatGPT Stocks Revealed Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. Today you can invest in the wave of the future, an automation that answers follow-up questions \u2026 admits mistakes \u2026 challenges incorrect premises \u2026 rejects inappropriate requests. As one of the selected companies puts it, \u201cAutomation frees people from the mundane so they can accomplish the miraculous.\u201d Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Growth Stocks to Buy With $1,000 Right Now Do you have some idle cash you want to put to work, but aren't sure how? This is a tricky market environment, to be sure. Earnings have been hit-and-miss of late, and while stocks as a whole have been roaring, the rally effort somehow feels a bit hollow. There are a handful of tickers out there, however, begging to be bought up. Their underlying companies are enjoying trends that can defy any brewing economic headwinds. One of these prospective picks is hiding in plain sight, while a couple of others are down for no good reason. Here's a rundown of three of these stocks you may want to add to your portfolio sooner than later. 1. Alphabet The rhetoric surrounding Google parent Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) has been anything but encouraging of late. Not only are investors waiting to hear the court's decision on the antitrust lawsuit levied by the U.S. Department of Justice (DOJ) against the company, but the release of its AI-powered ChatGPT rival has just been delayed until next year. There's a reason Alphabet shares are still holding up, however: This seemingly alarming news just doesn't matter much. That's not to say investors don't have reason to be concerned or frustrated. Neither of these developments rattle the company's core business, though. That's advertising. It's still doing just fine on this front. Ad revenue was up more than 9% year over year for the quarter ending in September, while its cloud computing revenue jumped 22%. Operating income grew accordingly. And all of this growth extends well-established (even if occasionally erratic) trends. GOOG Revenue (TTM) data by YCharts Don't misread the message: Alphabet needs to establish a better presence than Microsoft's Bard in the budding artificial intelligence space. Its legal battle with the DOJ could change the way Google ensures it remains the United States' most-used search engine. Legal headaches are nothing new for the company, however; it's survived plenty of them in the past. In the meantime, although Google's next-generation conversational AI platform isn't quite ready for prime time, the market isn't exactly ready for these tools either -- at least not in a meaningful way. Many consumers and corporations alike are still trying to figure out exactly how commercial versions of these tools are of benefit. It could take years to establish a marketable level of trust and understanding of artificial intelligence technologies, by which time Alphabet's entries in the AI race will be ready. Until then, the world's need to search the web still leaves Google in the enviable position of its gatekeeper -- with or without the promotional strategies the Department of Justice dislikes. GlobalStats reports the search engine still fields more than 90% of worldwide search queries. 2. DexCom If you keep regular tabs on glucose monitor maker DexCom (NASDAQ: DXCM), you likely already know why the stock stumbled so much in the middle of the year. If the company's not on your watch list though, know that it's not so much market-wide weakness as it's been the growing excitement surrounding weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, the latter of which was just recently approved by the U.S. Food and Drug Administration. Investors are assuming weight loss will reduce the growing prevalence of type 2 diabetes, thus crimping the need for DexCom's glucose monitors. Investors are increasingly realizing, however, that the theory doesn't hold quite as much water as first presumed. Oh, there's something to the idea, to be sure. The Cleveland Clinic reports that obese individuals are six times more likely to develop diabetes than people at a healthier weight are. But while losing weight can reduce or even eliminate diabetic conditions, it isn't necessarily the only cause of diabetes. Then there's the update from Novo Nordisk on the matter posted earlier this month. As it turns out, while there's clear benefit from its Wegovy (and presumably Lilly's comparable Zepbound), such drugs don't dramatically negate the need for glucose monitors. Leerink Partners' analysts also point out that \""discontinuation rates [of weight loss drugs] remain high in a real-world setting,\"" meaning the advent of Zepbound and the continued growth of Wegovy should have only a \""limited impact\"" on DexCom's business. That's why Leerink initiated coverage of DexCom with an \""outperform\"" rating. And most of the rest of the analyst community agrees. Still well down from July's peak, 18 of the 24 analysts following this stock rate it as bullishly as they can, sporting a consensus price target of $124.65. That's nearly 20% above the stock's present price. You might want to take the hint. 3. HubSpot Finally, add HubSpot (NYSE: HUBS) to your list of stocks to buy if you've got an extra $1,000 lying around. With a market cap of $24 billion, HubSpot is possibly one of the biggest companies you've never heard of. Give it time, though. This software company's growing like a weed, with this year's projected top-line growth of 24% expected to be followed by nearly 19% worth of improvement next fiscal year. Earnings are growing accordingly. HubSpot's specialty is customer relationship management (or CRM) software. It's a category dominated by its much bigger rival, Salesforce. As is so often the case, however, Salesforce's sheer size makes it a difficult big boat to steer. HubSpot is smaller and therefore nimbler, allowing it to win contracts bigger competitors look past. The company's doing a great deal on the artificial intelligence front, too, helping its clients solve problems they didn't even realize they had. The impending acquisition of ClearBit will bolster HubSpot's customers' ability to turn customer data into actionable information. In the meantime, the company's keeping its clients abreast of all the potential advantages and disadvantages of AI tools they may be interested in using. Website assessments, content creation guides, and marketing campaign managers are all also in its wheelhouse, further adding value to its software packages. This value and the customer interest it's causing isn't going unnoticed either. For a third year in a row, technology market research outfit Gartner rates HubSpot as a leader of the B2B (business to business) marketing automation software market, highlighting the company's capacity to help marketers adapt in a quickly changing business environment. HubSpot may never be as big as Salesforce. It doesn't have to become that big, however, to become a tremendous growth investment. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now\u2026 and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool\u2019s board of directors. James Brumley has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, HubSpot, Microsoft, and Salesforce. The Motley Fool recommends DexCom, Gartner, and Novo Nordisk. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-22,110.0,112.045,109.415,110.8,"[""Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening Quest Diagnostics Incorporated DGX entered into a strategic collaboration with Universal DX (UDX) aimed to advance colorectal cancer screening in the United States, for which over 110 million people may be eligible. In the United States, colorectal cancer is the third most commonly diagnosed cancer and the third highest cause of cancer death in men and women. According to the American Cancer Society, 153,020 people will be diagnosed with colorectal cancer in the United States in 2023, with 52,550 dying from the disease. The latest move will expand Quest Diagnostics\u2019 portfolio of cancer services, fortifying the Diagnostic Solutions business. More on Collaboration Under the terms of the commercial agreement, Quest Diagnostics intends to perform and offer clinical laboratory services to providers and patients in the United States based on UDX's Signal-C, an advanced colorectal cancer screening blood test, assuming premarket approval in the United States. To gather clinical evidence for the test, UDX will enroll patients in a 15,000-patient study, including over 100 investigator sites, to support a submission to the FDA for premarket approval. Once the FDA approves the test, Quest will have exclusive rights to provide clinical laboratory services in the United States. Additionally, UDX declared the first close of its nearly $70 million series B financing round from investors, which included Quest Diagnostics. Strategic Implications The partnership intends to bring together Quest's national scale and experience in the United States, along with UDX's cutting-edge liquid biopsy screening technology. This includes nearly 2,100 patient service centers for blood draws, extensive connectivity between health plans and electronic health records and more. Image Source: Zacks Investment Research With its national reach and superior oncology knowledge, Quest Diagnostics is well-positioned to use UDX Signal-C technology and make it widely available across the United States. This partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer. Industry Prospects Per a report by Fortune Business Insights, the global colorectal cancer screening market size is projected to reach from $17.05 billion in 2023 to $23.03 billion by 2030, witnessing a CAGR of 4.4%. The major factors for growth of the colorectal cancer screening market include the advent of efficacious genetic tests, an increase in the prevalence of colorectal cancer and increasing cancer prevention initiatives. Recent Developments In July 2023, Quest Diagnostics launched a novel prostate cancer biomarker test through its subspecialty pathology business unit, AmeriPath. The laboratory test is developed in collaboration with Envision Sciences \u2014 an Australia-based clinical diagnostics company with a focus on oncology diagnostics and prognostics in tissue and blood. In June 2023, Quest Diagnostics acquired Haystack Oncology. The acquisition is intended to improve patient outcomes through early, accurate detection of residual or recurring cancer. Based on circulating tumor DNA (ctDNA), Haystack Oncology created a highly sensitive minimal-residual disease (\u201cMRD\u201d) testing tool to help with the early detection of residual or reoccurring cancer and to guide treatment choices better. Quest Diagnostics will use this MRD technology to create new blood-based clinical lab services for solid tumor cancers that will be made available starting in 2024. Price Performance In the past year, DGX shares have declined 9.5% against the industry\u2019s rise of 3.7%. Zacks Rank and Key Picks Quest Diagnostics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Abbott (ABT) Benefits From Innovation Amid FX Headwinds Abbott\u2019s ABT new product launches and geographic expansion should boost sales. Low diagnostic testing demand continues to dent sales. The stock carries a Zacks Rank #3 (Hold). Abbott is expanding its Diagnostics business (consisting of 24% of the company\u2019s total revenues in the third quarter of 2023). Although, over the past few quarters, there has been a significant decline in demand for Abbott\u2019s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses. Within Established Pharmaceuticals Division (EPD), in September, Abbott entered into an agreement with global biotech leader mAbxience to commercialize several biosimilars in emerging markets. This collaboration will help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases to people in countries that have historically lacked access to these treatment options. Abbott\u2019s EPD sales in the third quarter increased 11.1% year over organically. In key emerging markets, organic sales improved 8.8% year over year, led by growth in several geographies and therapeutic areas, including gastroenterology, women's health and central nervous system/pain management. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Further, following a slew of developments, the Diabetes Care business achieved organic sales growth of 24.5% in the third quarter of 2023. This was led by FreeStyle Libre, which contributed $1.4 billion in revenues in the reported quarter. At the end of the third quarter, the global Libre user base exceeded 5 million people, with nearly 2 million in the United States, where the Libre user base has nearly doubled in the last two years. Over the past year, shares of Abbott have lost 2.8% compared with the industry\u2019s 5.4% fall. On the flip side, Abbott has been experiencing a continuous decline in COVID testing-related demand. In the third quarter of 2023, Abbott\u2019s Rapid Diagnostics sales decreased 59.2% from the year-ago period due to lower demand for COVID-19 tests. Further, foreign exchange is a major headwind for Abbott as a considerable percentage of its revenues comes from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company\u2019s performance in the international markets. In the third quarter, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.1% in the past year compared with the industry\u2019s decline of 6.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and from $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry\u2019s decline of 6.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry Teleflex TFX recently announced the enrollment of the first patient in the ACCESS-MANTA Registry. The international, multicenter, prospective, observational, single-arm clinical registry intends to examine and collect data on the outcomes of the contemporary on-label use of the MANTA Vascular Closure Device (\u201cVCD\u201d) in standard-of-care transcatheter aortic valve replacement (TAVR) procedures, including appropriate patient selection and proper vascular access. The MANTA VCD \u2014 one of the primary product offerings of the company\u2019s Interventional product category \u2014 is the first commercially available biomechanical VCD designed specifically for large-bore femoral arterial access site closure. The latest development comes as a boost for the segment. Significance of the ACCESS-MANTA Registry The ACCESS-MANTA Registry is set to enroll at least 250 patients in up to 15 major TAVR institutions across the United States and Canada. It will employ the primary objectives of safety defined by VCD large-bore access site-related Valve Academic Research Consortium-3 (VARC-3) major and minor vascular complications within 30 days of the TAVR procedure and effectiveness defined by time to hemostasis or the elapsed time between MANTA Device deployment and the first observed and confirmed arterial hemostasis. Image Source: Zacks Investment Research The study will also evaluate technical success, treatment success, ambulation success, discharge readiness and procedure time. Since its first implantation in 2014, receiving its CE mark in 2016 and FDA approval in 2019, the MANTA Device has been well-studied in more than 10,000 patients and more than 70 publications. News in Detail Per TFX\u2019s spokesperson, large-bore access site complications are recognized as morbid, driving increased costs and prolonged length of stay. Hence, percutaneous cardiac and peripheral procedures, such as TAVR, which are performed through large-bore arteriotomies, need dedicated closure technology that is safe, effective and procedurally efficient. The MANTA Device demonstrated these attributes in the pivotal SAFE MANTA IDE Clinical Trial \u2014 the largest prospective, multi-center study of a purpose-designed large-bore femoral arterial access site closure device to date in the United States. However, the TAVR practice has since evolved to embrace routine access site imaging, awake procedures, somewhat smaller delivery systems and sheaths, lower-risk patients and considerably higher per-operator experience. Against this backdrop, the ACCESS-MANTA Registry will allow Teleflex to understand the degree to which these changes, coupled with a dedicated device that is optimally deployed, may improve large-bore outcomes. Industry Prospects Per a Research report, the global VCD market was valued at $1.5 billion in 2022 and is expected to witness a CAGR of nearly 6.5% by 2032. Recent Highlights of the Interventional Business In the last reported third quarter of 2023, Teleflex\u2019s interventional business reported meaningful contributions from balloon pumps, access and closure in the 22.4% year-over-year growth. The company continued to build momentum in the complex PCI (Percutaneous Coronary Interventions) and emerging structural heart portfolios. TFX perceives MANTA as being on the trajectory for strong double-digit growth in 2023. Earlier in June 2023, Teleflex expanded its Structural Heart portfolio with the Wattson Temporary Pacing Guidewire \u2014 the first commercially available bipolar temporary pacing guidewire designed specifically for use during TAVR and balloon aortic valvuloplasty. The full market release of the same is anticipated later this year. Price Performance In the past six months, TFX shares have decreased 8.7% compared with the industry\u2019s decline of 8.7%. Zacks Rank and Key Picks Teleflex currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 2% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have dropped 38% in the past year compared with the industry\u2019s decline of 6.4%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 3.4% in the past year compared with the industry\u2019s decline of 7.3%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Teleflex Incorporated (TFX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-24,110.8,113.81,110.44,112.95,"[""Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut Shares of Orthofix Medical OFIX have plunged 4.5% since the release of its third-quarter earnings on Nov 8. The company delivered third-quarter 2023 adjusted earnings per share (EPS) of 7 cents, down 76.7% from a year ago. However, the figure beat the Zacks Consensus Estimate of a loss of 75 cents. The one-time adjustments include expenses associated with long-term income tax rate adjustment, strategic investments and the amortization of acquired intangibles, and medical device regulation charges, among others. For the third quarter, GAAP loss per share was 77 cents compared with a loss of 53 cents in the year-ago period. Total Revenues Quarterly revenues totaled $184 million, up 61.4% year over year on a reported basis and 8% at Constant Exchange Rate (CER). Yet, the metric missed the Zacks Consensus Estimate by a marginal 0.8%. Segmental Details Across product categories, Bone Growth Therapies\u2019 revenues reached $53.4 million, up 14.7% year over year and at CER. The rise was driven by growth in both spine and fracture portfolios. Revenues from Spinal Implants, Biologics and Enabling Technologies were $101 million, up 154.7% year over year (154.5% at CER). The Global Spine business' revenues increased 79.1% year over year to $154.4 million. The Global Orthopedics business' revenues climbed 6.6% year over year (up 0.7% at CER) to $29.7 million. Margins In the reported quarter, gross profit rose 43.6% year over year to $119.8 million. The gross margin contracted 809 basis points to 65.1%. Sales and marketing, general and administrative, and research and development expenses escalated 71.2%, 40.4% and 55.4% year over year to $94.9 million, $27.1 million and $18.6 million, respectively. ORTHOFIX MEDICAL INC. Price, Consensus and EPS Surprise ORTHOFIX MEDICAL INC. price-consensus-eps-surprise-chart | ORTHOFIX MEDICAL INC. Quote Adjusted operating loss for the quarter was $20.9 million compared with $3.3 million in the prior-year period. Operational Update The company exited third-quarter 2023 with cash and cash equivalents of $33.6 million compared with $38 million at the end of second-quarter 2023. Cumulative net cash used in operating activities at the end of third quarter was $39.1 million against the prior-year period\u2019s cash flow of $13.9 million. Cumulative capital expenditure incurred by OFIX at third-quarter end was $46.9 million compared with $17.3 million at second-quarter end. Accordingly, cumulative free cash flow at the end of third quarter was ($86.1) million. It reported free cash outflow of $31.1 million at the prior-year end. 2023 Outlook Orthofix updated its guidance for 2023. The guidance is based on current foreign-currency exchange rates and do not take into account any additional potential exchange rate changes that may occur this year. For 2023, management expects net sales in the $739-$744 million band (previous guided range was $752-$758 million).The Zacks Consensus Estimate is pegged at $742.2 million. Our Take Orthofix exited the third quarter of 2023 with better-than-expected earnings, while revenues lagged estimates. It registered year-over-year revenue growth on the back of strength in global spine business. During the quarter, it witnessed very strong growth across multiple business segments and product lines. Orthofix\u2019s complementary portfolio is driving even further incremental cross-selling opportunities. However, a contraction in both margins does not bode well. The increase in sales and marketing expense is primarily driven by integration-related severance, retention costs, stock-based compensation associated with the merger and higher commissions as a result of the achievement of certain sales objectives. The company lowered its 2023 sales outlook, raising apprehension. Zacks Rank Orthofix currently has a Zacks Rank #2 (Buy). Other Key Picks Some other top-ranked stocks in the broader medical space are Haemonetics HAE,Insulet PODD and DexCom DXCM. While Haemonetics and DexCom currently carry a Zacks Rank #2 each, Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Estimates for Haemonetics\u2019 2023 and 2024 EPS have increased from $3.82 to $3.86 and $4.07 to $4.11, respectively, in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 EPS have jumped from $1.61 to $1.90 in the past 30 days. The stock has fallen 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 EPS have ascended from $1.23 to $1.41 in the past 30 days. Shares of DXCM have dipped 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it reported earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal Labcorp LH recently announced the completion of the comprehensive laboratory relationship with Legacy Health. Under the terms of the agreement, Labcorp will acquire the select assets of its outreach laboratory business in the Northwest United States, including laboratory facilities and equipment. The collaboration allows Labcorp to bring its leading diagnostics capabilities to patients across Legacy's service area. The company currently manages Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply-chain services and laboratory support. News in Detail The locally owned, non-profit healthcare system, Legacy Health offers comprehensive healthcare services across its communities in Portland, Southwest Washington and Oregon's mid-Willamette Valley. It includes a six-hospital health system with a full-service children's hospital, a 24-hour behavioral health center and more than 80 primary care, specialty and urgent care clinics. Image Source: Zacks Investment Research Connecting two mission-driven organizations, the partnership expands access to Labcorp's industry-leading laboratory services and diagnostic testing to benefit communities in Oregon and Southwest Washington. Per Labcorp\u2019s representative, the closing of this deal reinforces the company\u2019s commitment to providing access to high-quality testing throughout the region by building on Legacy Health's longstanding history of serving communities. Upon the completion of full integration, healthcare providers and patients throughout the region will have more direct and convenient access to Labcorp's full range of laboratory services. However, Legacy continues to maintain the ownership and licensure of its hospital laboratories. Industry Prospects Per a research report, the global diagnostic testing market was valued at $165.6 billion in 2021 and is expected to witness a CAGR of 8.6% by 2030. Strategic Partnerships Expand Diagnostics Capabilities Labcorp sees strength across its diagnostic laboratories and biopharma laboratory service businesses. The company has been driving exceptional growth by expanding the base business, finalizing and integrating hospital and health systems and local and regional laboratory transactions. Labcorp owes this significant momentum to its leadership in science and technology to deliver superior solutions to patients and to its commitment to quality and efficiency. The latest partnership announcement with Baystate Health builds on their existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing. The company will acquire the outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. In August 2023, the company expanded Diagnostic Testing and Laboratory Services in Eastern Massachusetts via an agreement with the leading integrated academic health system, Tufts Medicine. Price Performance In the past six months, Labcorp shares have declined 0.8% against the industry\u2019s 1.6% growth. Zacks Rank and Key Picks LH currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 1.9% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have dropped 36.6% in the past year compared with the industry\u2019s decline of 5.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 1.1% in the past year compared with the industry\u2019s decline of 5.8%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Labcorp (LH) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-27,112.07,115.09,112.03,113.98,"[""Here's Why Investors Should Retain Labcorp (LH) Stock for Now Laboratory Corporation of America Holdings LH, or Labcorp, is well-poised to grow in the coming quarters, backed by its efforts to advance its leading position in high-growth strategic areas, especially specialty testing. The planned spin-off has resulted in two independent companies, each poised for strong, sustainable growth. In addition, Labcorp is on the way to realize the expected savings from the Launchpad initiative, buoying optimism. However, the significant drop in COVID-19 testing revenues continues to hinder the company\u2019s operational results. Increased competition from other players in the industry remains a concern. In the past year, this Zacks Rank #3 (Hold) stock has decreased 10.8% against the 11.8% rise of the industry and a 15.5% increase of the S&P 500 composite. The renowned healthcare diagnostics company has a market capitalization of $18.06 billion. In the trailing four quarters, the company delivered an average negative earnings surprise of 0.86%. Let\u2019s delve deeper. Factors at Play Targeted Development in High-Growth Areas: In its efforts to further expand, Labcorp is focusing more on primary areas, such as oncology, woman\u2019s health, autoimmune disease and neurology. In addition, the company is well-positioned for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business. Labcorp remains at the forefront of driving better patient outcomes in oncology following the acquisition of Personal Genome Diagnostics Inc. (PGDx) in early 2022. In May 2023, the company teamed up with Forge Biologics for adeno-associated virus (AAV) gene therapy development and collaboration. In addition, the company is investing in innovation and technology that supports diagnostic and drug development testing across disease areas, including cancer, Alzheimer\u2019s and other diseases. Image Source: Zacks Investment Research Spin-Off of the CDSS Business to Add More Value: In June 2023, Labcorp completed the planned spin-off of its wholly owned Clinical Development and Commercialization Services (\u201cCDCS\u201d) business. Fortrea now operates as a global contract research organization (CRO) providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations. The resulting spin-off is expected to provide Labcorp with strengthened strategic flexibility and an operational focus to pursue specific market opportunities and better meet customer needs, focused capital structures and capital allocation strategies to drive innovation and growth, a more targeted investment opportunity for different investor bases and the ability to align its particular incentive compensation with its financial performance. LaunchPad Initiative on Track: To enhance shareholder value, Labcorp previously implemented a new LaunchPad business process improvement initiative, targeting savings of $350 million over the next three years ending 2024. We are pleased to see that the company is on track to deliver its targeted cost savings. Earlier, LH was set to implement actions in the third quarter of 2023 to take out $25 million of annualized stranded costs throughout the enterprise as a result of the spin-off. On the third-quarterearnings call management hinted that it is on track to take out the cost by the end of the year. Moreover, at the recently hosted Investors Day, the company talked about a $100 million-$125 million reduction through Launchpad. Downsides Lower COVID-19 Testing Sales & Supply Challenges: As the severity of the pandemic continues to weaken, Labcorp has been witnessing a significant decline in COVID-19 PCR testing volumes for some quarters. In the third quarter of 2023, testing revenues were down 87%. LH\u2019s operations are also subject to the effects of macroeconomic factors in the United States and globally, such as significant economic fluctuations as a result of the disturbed geopolitical situation and inflation, all leading to an increase in the cost of goods and services. Competitive Landscape: Labcorp faces intense competition from its major competitor, Quest Diagnostics, and other commercial laboratories and hospitals. With pricing being an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including an accurate and rapid turnaround of testing results. As a result, Labcorp and other commercial labs compete with hospital-affiliated labs, primarily on the basis of the quality of service. Estimate Trend In the past 30 days, the Zacks Consensus Estimate for Labcorp\u2019s 2023 earnings has moved south from $13.66 to $13.57. The Zacks Consensus Estimate for 2023 revenues is pegged at $12.14 billion, suggesting an 18.4% drop from the 2022 comparable figure. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.3%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have decreased 0.9% compared with the industry\u2019s 3.1% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 35.7% compared with the industry\u2019s 3.1% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have increased 0.4% against the industry\u2019s 3.7% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Labcorp (LH) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Investing $5,000 in These 3 Stocks Could Make You Rich You've probably heard the expression \""Beauty is in the eye of the beholder.\"" I think the same sentiment can be applied to wealth. One person's threshold for being rich is likely to differ from another person's level. There's also another old adage you've likely heard: \""Don't count your chickens before they hatch.\"" This is a good one for investors to heed. Just because a stock appears to have a great chance of generating impressive returns doesn't mean that it will. Why do I bring up those two old sayings? I believe that investing $5,000 in three specific stocks could make you rich. But your version of rich might be different from mine -- and there's no guarantee that these stocks will be big winners. With that in mind, here are the stocks I'm so bullish about. 1. Alphabet I understand why some might be skeptical that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) can still make anyone rich. After all, the company's Google Cloud is losing share to Microsoft's Azure platform. There are questions about whether or not artificial intelligence presents an existential threat to Google Search. My take, though, is that Google Cloud's slump is overblown. Alphabet's cloud unit actually grew revenue by 22.5% year over year in the third quarter. More importantly, the company has what could be a game-changer on the way with its Gemini AI models. Research company SemiAnalysis estimates that Gemini is five times more powerful than the most advanced version of OpenAI's GPT-4. With Alphabet preparing to incorporate Gemini into its cloud platform next year, I expect that Google Cloud will soon get its groove back. What about the possibility that AI will make Google Search obsolete? I suspect that AI will instead add to Alphabet's search revenue over time. CEO Sundar Pichai hinted recently that offering subscription models of Google Search integrated with generative AI could be on the table. I predict that Alphabet will be among the biggest winners from AI over the next decade and beyond. Google Cloud should continue to grow robustly. There's a huge opportunity in the robotaxi market for Alphabet's Waymo unit. Don't overlook the possibility that the company could also achieve a breakthrough in quantum computing. 2. Amazon Amazon (NASDAQ: AMZN) is another \""Magnificent Seven\"" stock that some might think has diminishing returns ahead. I disagree. Amazon's best days could be on the way. AI should serve as a major tailwind for Amazon. Like Alphabet, Amazon is developing a new large language model that should be competitive with GPT-4. I think that CEO Andy Jassy was exactly right when he stated in the company's Q3 call, \""Customers want to bring the models to their data, not the other way around.\"" He added -- correctly -- that a lot of that customer data resides in the Amazon Web Services (AWS) cloud platform. Jassy believes that the current paradigm for the cloud market will change dramatically over the next decade or so. Today, over 90% of global IT spending is on-premises with the remainder in the cloud. Jassy thinks those numbers will flip. If he's right (and I think he is), AWS should be a huge beneficiary. Don't ignore Amazon's e-commerce opportunities, though. The company recently announced plans to begin selling cars online. There's still a lot of room to run with e-commerce making up only 15.6% of total U.S. retail sales in Q3. 3. UiPath It isn't just AI giants that offer an opportunity to make you rich. I think that UiPath (NYSE: PATH), an up-and-comer with a market cap of under $10.5 billion, also stands out as a great stock to buy. UiPath is a pioneer in robotic process automation (RPA). Its technology helps customers use AI to automate their business processes. The company has nearly 11,000 customers, including well-known ones such as Deloitte, DexCom, and Uber. Cathie Wood's Ark Invest believes that UiPath could be part of \""AI's sleeper wave\"" of smaller companies that haven't attracted as much attention from Wall Street. While there are others in the RPA market, Ark Invest views UiPath's low-code and no-code interfaces as superior to the competition. Others are taking note of UiPath, too. Everest Group named the company as the only Star Performer in its recent Intelligent Document Processing Products report. Gartner ranked UiPath as a leader for the fifth consecutive year in the RPA category. Granted, UiPath is less of a known quantity than Alphabet and Amazon. However, I think this rising AI star could be a massive winner down the road. 10 stocks we like better than UiPath When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and UiPath wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2023 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, Uber Technologies, and UiPath. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-28,113.37,113.77,111.29,112.2,"[""Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite Smith & Nephew SNN recently entered into a definitive agreement to acquire CartiHeal, developer of Agili-C, to expand its range of sports medicine technologies. The transaction is likely to close in the first quarter of 2024. Per terms of the agreement, Smith & Nephew will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance. The acquisition will be financed from existing cash and debt facilities. More on the News CartiHeal was formed as a university spin-off in 2009. It maintains a small factory near Tel Aviv and a sales office in New Jersey. CartiHeal has a considerable amount of raw material in the United States and will have enough U.S. stock by the closure of the transaction to support a full commercial launch. All CartiHeal workers will be transferred to Smith+Nephew. Agili-C is a one-step, over-the-counter treatment for osteochondral (bone and cartilage) lesions that has a broader indication than current treatments. It is approved to treat a wide range of patients, including those with lesions in their knees due to mild to moderate osteoarthritis. Agili-C is a porous, biocompatible and resorbable scaffold that facilitates spontaneous articular cartilage regeneration and subchondral bone replacement. Agili-C received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) in 2020 and Premarket Approval (PMA) in March 2022. Strategic Implications The acquisition of this revolutionary technology complements Smith & Nephew's goal of investing in its thriving Sports Medicine company. With the demonstrated commercial expertise in high-growth biologics and Agili-C's exceptional clinical performance, Smith & Nephew can achieve additional success with this attractive therapy choice. Image Source: Zacks Investment Research Smith & Nephew is the right new home for Agili-C as a leader in sports medicine and with a thorough understanding of biologics. Agili-C is an excellent addition to the company\u2019s portfolio. It is looking forward to leveraging its experience to improve patient cartilage repair outcomes. Industry Prospects Per a report by Grand View Research, the global sports medicine market size was valued at $ 5.08 billion in 2022 and is estimated to witness a CAGR of 8.2% from 2023 to 2030. The demand for sports medicine has gained traction in recent years, owing to the rising incidences of sports injuries and growing participation in sports and fitness-related activities by people. A gradual shift from proactive care to preventive care with respect to sports injuries is projected to drive the market. Recent Launches In October 2023, Smith & Nephew launched REGENETEN Bioinductive Implant, allowing access to thousands of patients in Japan. With more than 100,000 procedures completed globally since its introduction in the United States and Europe, REGENETEN has had a transformative impact on the way surgeons approach rotator cuff repair. In August 2023, Smith & Nephew launched the OR3O Dual Mobility System for use in primary and revision hip arthroplasty in India. Compared with traditional solutions, dual mobility implants have a small diameter femoral head that locks into a larger polyethylene insert \u2014 increasing stability, reducing dislocation risk and offering improved range of motion. Price Performance In the past year, SNN has declined 0.6% compared with the industry\u2019s fall of 3.1%. Zacks Rank and Key Picks Smith & Nephew carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Teleflex (TFX) Stock for Now Teleflex TFX is well-poised to grow in the coming quarters, backed by the strength of its Vascular business. The company\u2019s Interventional segment continues to outperform in some of its key product portfolios, including balloon pumps. Further, a favorable solvent position also buoys optimism. However, mounting expenses and a competitive space remain concerning for the company. In the past year, this Zacks Rank #3 (Hold) stock has decreased 3.3% compared with the 3.3% fall of the industry and the 15.7% rise of the S&P 500 composite. The global provider of med-tech products has a market capitalization of $10.34 billion. The company has an earnings yield of 6.06% against the industry\u2019s -7.83%. Teleflex surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.98%. Let\u2019s delve deeper. Tailwinds Vascular Business Grows: Following the $976-million acquisition of Vascular Solutions, there has been accelerated growth within Teleflex\u2019s vascular product portfolio. Despite the third quarter facing a negative impact of the previously announced Endurance catheter recall, the segment managed to grow 0.3% in revenues. Over the long term, TFX remains positioned for dependable growth with category leadership in Central Venous Catheters and midlines, anticipated share gains with a novel coated PICC portfolio and new product introductions. Image Source: Zacks Investment Research In June 2023, Teleflex\u2019s Arrow EZ-IO Needle became the first and only Intraosseous (IO) Needle to receive FDA 510(k) clearance for MR Conditional labeling. A critical component of the Arrow EZ-IO Intraosseous Vascular Access System, The EZ-IO Needle, has a patented diamond tip designed for fast, precise and steady insertion. Solid Momentum in Interventional: In the third quarter of 2023, the segment\u2019s diversified portfolio generated 22.4% revenue growth. Balloon pumps, right heart catheters and access and closure and MANTA, the Vascular Closure device, all contributed meaningfully. MANTA continues on the trajectory for strong double-digit growth in 2023. Earlier this year, Teleflex received FDA clearance for Wattson Temporary Pacing Guidewire, expanding the Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement and balloon aortic valvuloplasty. Per the latest update, the company is in the final stages of completion for the commercial launch. Strong Solvency With High Leverage: Teleflex exited the third quarter of 2023 with cash and cash equivalents of $881.5 million against the corresponding near-term payable of $87.5 million. With such an insignificant comparison, the company holds a sound financial position, even during times of economic slowdown. The long-term debt amounted to $1.95 billion at the end of the third quarter, higher than $1.47 billion at the second-quarter end. Meanwhile, times interest earned for the company stands at 7.2%, down from 7.6% in the second quarter. Downsides Escalating Expenses Put Pressure on the Bottom Line: Teleflex has been grappling with escalated expenses for a while. Deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor costs, as well as freight charges and rising interest rates, all have put the medical device space in a tight spot. In the third quarter of 2023, Teleflex\u2019s gross margin contracted 134 basis points (bps) to 55.8%. SG&A expenses rose 1.7%, while research and development expenses increased 0.5%. Increasing Competition: Teleflex competes with companies ranging from small start-up enterprises to larger and more established companies that have access to significantly greater financial resources. Moreover, competitors having clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support and cost-effectiveness can be a disadvantage for the company. Estimate Trend The Zacks Consensus Estimate for TFX\u2019s 2023 earnings per share (EPS) has moved north from $13.27 to $13.33 in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $2.96 billion. This suggests a 6.2% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.3%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have decreased 1.3% compared with the industry\u2019s 3.1% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 34.9% compared with the industry\u2019s 3.1% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have increased 3.3% against the industry\u2019s 3.3% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Teleflex Incorporated (TFX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom (DXCM) is a Top Growth Stock for the Long-Term It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform. The Style Scores are broken down into four categories: Value Score Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks. Growth Score While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. Momentum Score Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying \""the trend is your friend.\"" The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. VGM Score If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier. It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day. This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio. That's where the Style Scores come in. To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible. The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank. Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: DexCom (DXCM) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of A, forecasting year-over-year earnings growth of 64.4% for the current fiscal year. 10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.20 to $1.43 per share. DXCM also boasts an average earnings surprise of 36.4%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Penumbra's (PEN) Expansion Moves, New Launches Aid Growth Penumbra PEN is gaining traction in the international markets on strong customer uptake. Strategic innovation is an added positive. The stock carries a Zacks Rank #2 (Buy). Penumbra is still in the early stages of its journey to bring its proprietary thrombectomy technologies to patients in the United States and around the world. The company\u2019s consistent revenue growth momentum is being driven by the extraordinary outcomes witnessed in patients treated with Lightning Flash, Lightning Bolt 7 and RED 72 with SENDit technology. Penumbra derives a significant portion of its revenues internationally (30.2% in 2022). It expects to materially increase both revenues and profitability in the company\u2019s international business in the next three years and beyond. During this period, the company expects to bring its franchise products like RED catheters and CAT RX together with its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams. Internationally, the company projects early success with the launch of its first-generation computer-aided products in Europe. Penumbra has plans to expand access to its most advanced thrombectomy products to its international vascular teams over the next few years. In addition, the company\u2019s international teams and partners believe in its enormous potential to expand its leadership in stroke intervention outside the United States with SENDit and Thunderbolt in the coming years. Among the recent developments, in 2023, the company launched the RED catheter for stroke and the first-generation computer-orchestrated thrombectomy products, Lightning 12 and 7 in Europe. Penumbra, Inc. Price Penumbra, Inc. price | Penumbra, Inc. Quote In terms of pipeline, on the third-quarterearnings call the company stated that over the next 18 months, it plans to launch four new computer-assisted vacuum thrombectomy (CAVT) products in the United States. Combined with Flash and Bolt 7, Penumbra expects its CAVT portfolio to drive market share and market growth in deep vein thrombosis, pulmonary embolism and arterial. In addition, the company has made significant advancements with next-generation technology that could expand both the scope and dominance of its CAVT platform over the long term. Added to this, the company successfully launched the Lightning Bolt 7 arterial thrombectomy system in June following its FDA clearance in March 2023. Lightning Flash and Lightning Bolt are also driving an acceleration in Penumbra\u2019s U.S. vascular thrombectomy franchise, which grew 42% year over year in the third quarter. The company expects to see a robust growth trajectory in the Vascular arm in the next five years and beyond. On the flip side, though the pandemic is over, its impact on global supply chains and labor markets lingers. It resulted in cost inflation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra\u2019s profitability. In the third quarter of 2023, Penumbra reported an 18.9% rise in cost of revenues. Selling, general and administrative expenses rose 15.9%. Total operating expenses were up 13.1% year over year. Further, a significant portion of Penumbra\u2019s sales and costs are exposed to changes in foreign exchange rates. In 2022, approximately 30.2% of the company's consolidated revenues came from the non-U.S. markets. The company\u2019s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income. Key Picks Other top-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Estimates for Haemonetics\u2019 2023 earnings have increased from $3.82 to $3.86 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Philips (PHG) Bolsters Diagnostic Imaging With New Launches Philips PHG announced a slew of AI-enabled innovations at RSNA23 to focus on patient care through enhanced efficiency. Notably, Philips introduced next-generation ultrasound systems, namely EPIQ Elite 10.0 and Philips Affiniti, to simplify clinical workflows with a single user interface, shared transducers and automated tools, enhancing user experience. Further, the company showcased the world\u2019s first helium-free mobile magnetic resonance imaging system, BlueSeal MR Mobile, which is designed to enhance diagnostic imaging and requires only seven liters of liquid helium, offering cost and up-time advantages. Additionally, Philips introduced HealthSuite Imaging, an AI-enabled cloud-based Picture Archiving and Communication System, which offers high-speed remote diagnostic reading, integrated reporting and AI-powered workflow orchestration, enhancing operational efficiency and patient care. Also, the company launched the \u2018care means the world' campaign at the event, emphasizing the connection between human and environmental health. Philips is expected to gain solid traction across diagnostic centers and other healthcare providers on the back of its latest move. Koninklijke Philips N.V. Price and Consensus Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote Expanding Diagnosis & Treatment Portfolio The latest move is in sync with the company\u2019s deepening focus to bolster its Diagnosis & Treatment offerings. Notably, Philips collaborated with Quibim on an integrated solution using AI-based QP-Prostate software to automate real-time prostate gland segmentation in MR images. This will enhance diagnostic confidence, personalized treatment and better outcomes for patients requiring MR exams, thereby reducing the need for manual procedures. Further, the company unveiled Philips Ultrasound Compact 5500CV at the 2023 American Society of Echocardiography Event. This portable, compact system offers high-quality image and echocardiography workflows in cart-based systems, providing a single point of access for diagnosing and treating cardiac disease. Additionally, Philips will showcase its latest Digital X-ray innovations, including the Philips Radiography 7000 M, at RSNA, aiming to improve patient care and operational efficiency. Growth Prospects We believe that all the above-mentioned endeavors will likely aid the company in strengthening its footprint in the global diagnostic imaging market. Per a Markets and Markets report, the global diagnostic imaging market is expected to reach $34.6 billion by 2028, exhibiting a CAGR of 5.5% between 2023 and 2028. A Mordor Intelligence report indicates that the global diagnostic imaging market will witness a CAGR of 6.1% during the forecast period of 2023-2028. Strong prospects in the promising diagnostic imaging market will likely instill investor optimism in the stock. Philips has gained 43.2% on a year-to-date basis against the industry\u2019s decline of 5.8%. Moreover, the aforementioned launches are expected to solidify the company\u2019s Diagnosis & Treatment business. In the third quarter of 2023, Philips reported Diagnosis & Treatment revenues of \u20ac2.2 billion, registering growth of 6% from the year-ago quarter. Philips expects the 2023 Diagnosis & Treatment segment\u2019s revenues to witness high-single-digit to double-digit growth. Strength in the underlined segment will likely aid the company\u2019s overall financial performance in the near term. Philips expects 2023 comparable sales growth in the band of 6-7%. Zacks Rank & Stocks to Consider Currently, Philips carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical market sector are DaVita DVA, DexCom DXCM and Fate Therapeutics FATE. While DaVita sports a Zacks Rank #1 (Strong Buy), DexCom and Fate Therapeutics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita shares have gained 33.1% in the year-to-date period. The long-term earnings growth rate for DVA is currently projected at 18.25% DexCom shares have gained 0.7% in the year-to-date period. DXCM\u2019s long-term earnings growth rate is currently projected at 33.59%. Fate Therapeutics shares have lost 77.4% in the year-to-date period. The long-term earnings growth rate for FATE is currently projected at 29.49%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Fate Therapeutics, Inc. (FATE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System Bruker Corporation BRKR recently announced a collaboration and quality agreement with the medical device company, Accelerate Diagnostics Inc. AXDX. The agreement enables the validation of Bruker\u2019s MALDI Biotyper sirius instruments and Sepsityper software with Accelerate Diagnostics' Arc system for subsequent registration in the United States and the EMEA markets. Bruker\u2019s MALDI Biotyper solution is designed for in-vitro diagnostic (IVD) use in clinical microbiology markets. The recent development will also fortify the company\u2019s Microbiology division, which belongs to the BSI (Bruker Scientific Instruments) CALID segment. Significance of the Arc System A leading IVD company, Accelerate Diagnostics, Inc. is dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Arc system \u2014 which includes the Accelerate Arc Module and BC kit \u2014 is an innovative, automated positive blood culture sample preparation platform that was launched and commercialized in 2022. Image Source: Zacks Investment Research Tailored for clinical laboratories, the Arc system enables the on-demand processing of samples without the need for an overnight culture incubation, reducing the wait time for identification results. The system is designed to compete with molecular positive blood culture identification solutions. News in Detail Using Bruker's MALDI Biotyper system, the Arc system\u2019s simple load-and-go workflow automates directly from positive blood culture sample preparation for downstream microbial identification. Labs will be able to leverage the breadth of their Bruker MALDI-Biotyper identification library in combination with rapid phenotypic antibiotic susceptibility results using the Accelerate Pheno system and the Accelerate WAVE system, which is currently under development and planned for future release. Per the company\u2019s representative, Bruker's MALDI Biotyper with Accelerate Diagnostics' Arc system to automate positive blood culture sample preparation and rapid microbial identification will be a valuable addition to many laboratories. In particular, the combination offers the potential to reduce the likelihood of cross-reactivity and false positive results that come with rapid molecular tests. The collaboration marks an important step as both companies are committed to helping laboratories in the important fight against sepsis with their leading products. Industry Prospects Per a research report, the global microbial identification market was valued at $3.2 billion in 2020 and is expected to witness a CAGR of 12.2% by 2025. Other Developments of the BSI CALID Segment One of CALID Group\u2019s divisions, Bruker Optics, designs, manufactures and distributes research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy and imaging technologies. The segment headlined on a few occasions recently. Last month, BRKR announced a majority investment in the Swiss high-tech company, Miro Analytical AG, complementing the Bruker Optics gas-analysis spectroscopy portfolio with fast, compact, highest-precision QCL (Quantum Cascade Laser) multi-trace gas analyzers. The combined expertise will advance climate research and environmental pollution analysis as well as industrial trace-gas monitoring solutions. The company also had a notable tender win in September 2023, wherein the largest German airport, FRA, will modernize passenger security with up to 220 Bruker high-performance explosives trace detector (ETD) systems DE-tector flex. These will replace the earlier-generation Bruker ETD systems at the Frankfurt airport. Price Performance In the past year, shares of BRKR have decreased 0.8% compared with the industry\u2019s decline of 18.8%. Zacks Rank and Key Picks Bruker currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE and DexCom DXCM, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Haemonetics\u2019 stock has decreased 1.3% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have increased 3.3% in the past year compared with the industry\u2019s decline of 3.3%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Connect Biopharma Holdings Limited Sponsored ADR (CNTB) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Connect Biopharma Holdings Limited Sponsored ADR is a member of our Medical group, which includes 1087 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Connect Biopharma Holdings Limited Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for CNTB's full-year earnings has moved 39.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the most recent data, CNTB has returned 29.1% so far this year. Meanwhile, the Medical sector has returned an average of -7.6% on a year-to-date basis. As we can see, Connect Biopharma Holdings Limited Sponsored ADR is performing better than its sector in the calendar year. One other Medical stock that has outperformed the sector so far this year is DexCom (DXCM). The stock is up 0.7% year-to-date. The consensus estimate for DexCom's current year EPS has increased 16.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Connect Biopharma Holdings Limited Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, which includes 528 individual stocks and currently sits at #47 in the Zacks Industry Rank. On average, stocks in this group have lost 22.4% this year, meaning that CNTB is performing better in terms of year-to-date returns. DexCom, however, belongs to the Medical - Instruments industry. Currently, this 94-stock industry is ranked #72. The industry has moved -4.9% so far this year. Investors interested in the Medical sector may want to keep a close eye on Connect Biopharma Holdings Limited Sponsored ADR and DexCom as they attempt to continue their solid performance. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Connect Biopharma Holdings Limited Sponsored ADR (CNTB) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-29,113.38,117.44,113.0,116.18,"[""Here's Why You Should Retain Zimmer Biomet (ZBH) for Now Zimmer Biomet ZBH is well-poised for growth in the coming quarters, backed by its efforts to expand its global presence to address the huge demand in the musculoskeletal space. Zimmer Biomet\u2019s business recovery continues. However, stiff competition and foreign exchange headwinds are a concern. In the past year, this Zacks Rank #3 (Hold) stock has declined 5.8% compared with the 5.2% fall of the industry and the 12% rise of the S&P 500 composite. The leading musculoskeletal healthcare company has a market capitalization of $23.63 billion. The company has an earnings yield of 6.60% against the industry\u2019s -1.81%. Zimmer Biomet surpassed estimates in all of the trailing four quarters, delivering an average earnings surprise of 5.09%. Let\u2019s delve deeper. Tailwinds Business Recovery Continues: Zimmer Biomet has witnessed a rebound in its business in the past few quarters despite macroeconomic challenges. According to the company, procedure recovery continues successfully, aided by no meaningful impact from COVID or staffing challenges. Accordingly, the company is enjoying a tailwind from increased provider capacity, resulting in backlog pull-through in the recent quarters. In Q3, U.S. sales rose 6%, well ahead of the company\u2019s expectations, with elective procedure volumes recovering. Sales growth in the S.E.T. category, together with strong capital sales, improved the overall performance in this region. International sales grew 2.9% year over year. All regions benefited from the continued recovery of elective procedures, backlog recapture, strong commercial execution and new product uptake. Focus on Emerging Markets to Drive Growth: Over the recent past, Zimmer Biomet has been working to strengthen its foothold in emerging markets that provide long-term opportunities for growth. The company's strategic investments in these regions over the past several quarters to improve operational and sales performance are yielding results. Image Source: Zacks Investment Research Market opportunities for orthopedic implants globally are expected to grow to $66.6 billion by 2025. Within emerging markets, strength in the Asia Pacific market continued to drive strong revenue growth so far. As the COVID-19 severity is over now, banking on a cadence of product launches and strong customer adoptions, Zimmer Biomet is successfully expanding its presence in the emerging market. Gradually Stabilizing Market: Despite challenging market conditions in the form of pricing pressure, the last few quarters witnessed gradual stability in the global musculoskeletal market with better-than-expected sales growth in certain geographies, banking on improved procedural volume. In line with this, in the third quarter of 2023, the company witnessed strong growth driven by continued procedure recovery, strong execution, and solid momentum with the new innovation. The company saw another positive quarter of year-over-year momentum in large joints, with the overall global knee and S.E.T. business growing 7.3% and 2.8%, respectively. Downsides Competitive Landscape: The presence of a large number of players has made the medical devices market intensely competitive. The orthopedic industry, in particular is highly competitive with the presence of players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew and Medtronic. Exposed to Currency Movement: A substantial portion of Zimmer Biomet\u2019s foreign revenues is generated in Europe and Japan. Significant increases in the value of the U.S. Dollar relative to the Euro, the Japanese Yen, the Swiss Franc or other currencies are having adverse effects on the company\u2019s operations. Estimate Trend The Zacks Consensus Estimate for Zimmer Biomet\u2019s 2023 earnings per share (EPS) has been constant at $7.51 in the past 90 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $7.38 billion. This suggests a 6.4% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine Quest Diagnostics Incorporated DGX entered into a multi-pronged collaboration with Scipher Medicine intended to expand patient access to diagnostic services, advancing precision medicine for rheumatoid arthritis (RA). The collaboration leverages Quest Diagnostics\u2019 sequencing and specimen collection expertise with Scipher's precision medicine technology. Using an analysis of molecular profiles, Scipher's PrismRA test determines which RA patients are unlikely to benefit from TNF medications. The PrismRA test helps identify patients who can be provided an effective alternative therapy to save needless drug cycles or dose escalations by evaluating their molecular signature. More on Collaboration As part of a multi-year partnership, Quest Diagnostics will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test. The test is called a blood-based molecular signature response classifier (MSRC). Its goal is to predict how a patient will react to medication consisting of TNF inhibitors (TNFi), which is frequently recommended for RA patients. Quest Diagnostics will facilitate courier logistics services, which include patient specimen transportation between Quest Diagnostics and Scipher laboratories and provider sites. The collaboration focuses on Quest Diagnostics' advanced laboratory in Marlborough, Massachusetts, which has next-generation sequencing capabilities. Quest Diagnostics will extract and sequence RNA from PrismRA blood specimens to uncover about two dozen molecular features related to TNFi therapy response. Strategic Efforts The PrismRA is a breakthrough in RA precision medicine diagnostics because it helps enable the early, personalized treatment so critical to favorable outcomes for this often-disabling disease. Through its collaboration with Scipher, Quest Diagnostics extends its capabilities in autoimmune diagnostic services, including services to aid clinical decisions with biologics. Image Source: Zacks Investment Research The collaboration with Scipher supports Quest Diagnostics' genomics strategy and investments, particularly in next-generation sequencing and scale in blood-specimen logistics. Quest Diagnostics is enabling clinical innovators like Scipher to realize the potential of precision medicine to treat huge, underserved patient populations by providing these distinct assets. Industry Prospects Per a report by Precedence Research, the global precision medicine market size was valued at $73.49 billion in 2022 and is expected to reach $175.64 billion by 2030 at a CAGR of 11.5% by 2030. Increased adoption of emerging genomic technologies, such as NGS and high-density microarray, coupled with favorable government initiatives, is expected to fuel the global gene therapy market and, in consequence, the precision medicine market. Recent Developments In November 2023, Quest Diagnostics entered into a strategic collaboration with Universal DX (UDX) aimed to advance colorectal cancer screening in the United States, for which over 110 million people may be eligible. The partnership intends to bring together Quest's national scale and experience in the United States along with UDX's cutting-edge liquid biopsy screening technology. This includes nearly 2,100 patient service centers for blood draws, extensive connectivity between health plans and electronic health records and more. In July 2023, Quest Diagnostics launched a novel prostate cancer biomarker test through its subspecialty pathology business unit, AmeriPath. The laboratory test is developed in collaboration with Envision Sciences \u2014 an Australia-based clinical diagnostics company with a focus on oncology diagnostics and prognostics in tissue and blood. Price Performance In the past year, DGX\u2019s shares have declined 10.6% against the industry\u2019s rise of 1.9%. Zacks Rank and Key Picks Quest Diagnostics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has increased 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have dropped 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Factor-Based Stock Analysis Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics Accelerate Diagnostics, Inc. AXDX has initiated a collaboration and quality agreement with Bruker Corporation BRKR. The deal will help the company advance in vitro diagnostics in microbiology. With this latest collaboration, Accelerate Diagnostics will be able to strengthen its foothold in the U.S. and EMEA markets. More on the News As part of this collaboration, Accelerate Diagnostics' cutting-edge Arc system will integrate with Bruker's MALDI Biotyper sirius instruments and Sepsityper software. The Arc system, which is an automated positive blood culture sample preparation platform, streamlines positive blood culture sample preparation, eliminating the need for overnight culture incubation. This drastically reduces the wait time for identification results. By leveraging Bruker's MALDI Biotyper system, AXDX addresses cross-reactivity issues associated with rapid molecular tests, offering accuracy and reliability. Image Source: Zacks Investment Research A Strategic Deal The utilization of Bruker's Biotyper system, in conjunction with the Arc system, is likely to reduce the likelihood of cross-reactivity and false positive results that come with rapid molecular tests. According to the company, the platform economics are more favorable with the Arc system as compared to on-market molecular platforms, especially when laboratories consider that approximately 30% of results are blood culture contaminants resulting in wasted expense. Further, the total cost to rapidly identify organisms from positive blood cultures is significantly lower than what labs are paying today for a rapid molecular ID solution. With an ongoing clinical trial and regulatory submission on the horizon, Accelerate Diagnostics is on the right track, given the demand for FDA-cleared devices. Market Prospects Going by a Markets and Markets report, the global in vitro diagnostics market was estimated to be worth $117.8 billion in 2022 and is poised to reach $138.4 billion by 2027, at a CAGR of 3.3%. Share Price Performance Shares of AXDX have plunged 50% over the past year compared with the industry's 3.6% decline. Zacks Rank & Other Key Picks Accelerate Diagnostics currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Insulet PODD and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), DexCom carries a Zacks Rank #2. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Bruker Corporation (BRKR) : Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal Charles River Laboratories International, Inc. CRL recently announced a collaboration with an Australian non-profit foundation, Genetic Cures for Kids Inc. (\u201cGC4K\u201d). Under the partnership, the company will perform plasmid DNA production in support of GC4K\u2019s early phase trials for Hereditary Spastic Paraplegia Type 56 (\u201cSPG56\u201d). Charles River\u2019s contract development and manufacturing organization business provides comprehensive contract development and manufacturing solutions for cell and gene therapies. The latest collaboration with GC4K will also boost the company\u2019s Biologics Solutions business within the Manufacturing segment. About GC4K and SPG56 Founded in 2021, the Australian not-for-profit charity raises funds that explicitly go to rare disease research programs and clinical trials to find cures for rare diseases. GC4K\u2019s lead campaign, Our Moon\u2019s Mission, has been dedicated to the pursuit of innovative gene therapy solutions for SPG56 \u2014 a rare neurodegenerative disease with no treatment presently. Image Source: Zacks Investment Research SPG56 is progressive and is characterized by varying degrees of spasticity and muscle weakness, which typically begins with motor and cognitive regression in childhood and continuously worsens through life. Additional clinical manifestations include intellectual disability, dystonia, cerebellar ataxia, subclinical peripheral neuropathy, seizures and visual impairment. In addition, limited access to genetic testing has pertained to diagnoses that are hard to achieve, and as such, fewer than one in one million people have ever been diagnosed with SPG56 globally. The foundation is not only committed to developing a cure for SPG56 but also to creating a replicable framework that paves the way to develop treatments for some of the 7,000 other genetic diseases in the world. More on the News Through the partnership, GC4K will leverage Charles River\u2019s established plasmid platform, eXpDNA, and premier expertise in plasmid DNA production, including High-Quality (HQ) plasmid, which combines key features of good manufacturing practice manufacture with a rapid turnaround to accelerate time to clinic. Plasmid DNA is a critical starting material for many cell and gene therapy therapeutics, and demand continues to outstrip supply. In response to this, the company opened a state-of-the-art HQ plasmid manufacturing center of excellence in 2022 to address these supply shortages and support the growing needs of the cell and gene therapy field. Industry Prospects Per a Research report, the global cell and gene therapy market was valued at $22.7 billion in 2023 and is expected to witness a CAGR of 28.7% by 2030. Other Developments in Biologics Solutions In recent years, the company has significantly broadened its cell and gene therapy portfolio with several acquisitions and recent expansions to simplify complex supply chains and meet the growing global demand for plasmid DNA, viral vector and cell therapy services. Combined with the company\u2019s legacy testing capabilities, Charles River offers a comprehensive \u201cconcept-to-cure\u201d advanced therapies solution. In September 2023, the company announced the launch of its lentiviral vector manufacturing platform, Lentivation, which can reduce lentiviral vector production timelines from 18 months to less than seven months. CRL\u2019s collaboration with INADcure Foundation will also leverage its market-leading CDMO expertise in HQ plasmid DNA production to manufacture its leading candidate for Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy. Price Performance Over the past six months, Charles River shares have decreased 0.4% compared with the industry\u2019s fall of 2.1%. Zacks Rank and Key Picks Charles River carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 4.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have dropped 37.9% in the past year compared with the industry\u2019s decline of 5.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 3.5% in the past year compared with the industry\u2019s decline of 5.8%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar? If you're interested in broad exposure to the Mid Cap Growth segment of the US equity market, look no further than the Vanguard Mid-Cap Growth ETF (VOT), a passively managed exchange traded fund launched on 08/17/2006. The fund is sponsored by Vanguard. It has amassed assets over $10.83 billion, making it one of the largest ETFs attempting to match the Mid Cap Growth segment of the US equity market. Why Mid Cap Growth With market capitalization between $2 billion and $10 billion, mid cap companies usually contain higher growth prospects than large cap companies, and are considered less risky than their small cap counterparts. These types of companies, then, have a good balance of stability and growth potential. Qualities of growth stocks include faster growth rates compared to the broader market, as well as higher valuations and higher than average sales and earnings growth rates. Further, growth stocks have a higher level of volatility associated with them. Compared to value stocks, growth stocks are a safer bet in a strong bull market, but don't perform as strongly in almost all other financial environments. Costs Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.07%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.71%. Sector Exposure and Top Holdings It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 27.30% of the portfolio. Industrials and Healthcare round out the top three. Looking at individual holdings, Amphenol Corp. (APH) accounts for about 1.64% of total assets, followed by Microchip Technology Inc. (MCHP) and Dexcom Inc. (DXCM). The top 10 holdings account for about 14.4% of total assets under management. Performance and Risk VOT seeks to match the performance of the CRSP U.S. Mid Cap Growth Index before fees and expenses. The CRSP U.S. Mid Cap Growth Index measures the investment return of mid-capitalization growth stocks. The ETF has added roughly 13.04% so far this year and it's up approximately 9.87% in the last one year (as of 11/29/2023). In the past 52-week period, it has traded between $176.22 and $213.93. The ETF has a beta of 1.10 and standard deviation of 23.29% for the trailing three-year period, making it a medium risk choice in the space. With about 163 holdings, it effectively diversifies company-specific risk. Alternatives Vanguard Mid-Cap Growth ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, VOT is an excellent option for investors seeking exposure to the Style Box - Mid Cap Growth segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares S&P Mid-Cap 400 Growth ETF (IJK) and the iShares Russell Mid-Cap Growth ETF (IWP) track a similar index. While iShares S&P Mid-Cap 400 Growth ETF has $7.49 billion in assets, iShares Russell Mid-Cap Growth ETF has $13.09 billion. IJK has an expense ratio of 0.17% and IWP charges 0.23%. Bottom-Line Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want key ETF info delivered straight to your inbox? Zacks\u2019 free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vanguard Mid-Cap Growth ETF (VOT): ETF Research Reports Amphenol Corporation (APH) : Free Stock Analysis Report Microchip Technology Incorporated (MCHP) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report iShares Russell Mid-Cap Growth ETF (IWP): ETF Research Reports iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-11-30,116.94,117.26,114.86,115.55,"[""Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering Thermo Fisher Scientific, Inc. TMO extended its ongoing partnership with Flagship Pioneering to develop and commercially scale multiproduct platforms on an accelerated basis. This partnership has been expanded to include Flagship's network of businesses through the newly-formed strategic partnership, which makes use of the companies' knowledge in the fields of life science tools, diagnostics and services. The recent development will fortify the Life Science Solutions segment. More on Collaboration Flagship Pioneering is a biotechnology firm that creates and develops platform businesses, each with the capacity to produce several goods that revolutionize sustainability or human health. The collaboration between Thermo Fisher and Flagship aims to establish new platform firms that concentrate on innovative tools and capabilities to enhance the biotech ecosystem and expedite the development of first-in-class medicines. Thermo Fisher and Flagship have been suppliers for many years. Strategic Implications As the industry's go-to partner, working together on innovation is a crucial step in the development of the businesses' enduring partnership. Through this partnership, Flagship Pioneering aims to accelerate the impact of Thermo Fisher's strong scientific experience and broad commercial skills on future discoveries that they bring to market. Realizing the full potential of innovative new modalities for human and environmental health requires complementing competencies and ecosystem aspects. TMO\u2019s in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering's creative company creation approach in this cooperation, which aims to create revolutionary capabilities for the ecosystem. Industry Prospects Per a report by Grand View Research, the global life science tools market size was valued at $144.08 billion in 2022 and is expected to expand at a CAGR of 10.8% from 2023 to 2030. The growth in revenue is mainly due to rapid advancements by the life science tools companies in sequencing, MS, chromatography, NMR, and other various products. Moreover, investments and funding for the development of advanced therapeutics, along with consistent demand for novel medicine and treatments due to rising incidence of diseases such as cancer, kidney and thyroid disorders and diabetes, will drive the market. Recent Partnerships In October 2023, Thermo Fisher entered into a companion diagnostic (CDx) partnership with Boehringer Ingelheim to support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations. In September 2023, Thermo Fisher collaborated with the National Minority Quality Forum (NMQF) to help bring clinical research to historically underserved patient populations through NMQF\u2019s Alliance for Representative Clinical Trials (ARC). The NMQF and Thermo Fisher's clinical research division will increase community health clinics' capacity to participate in clinical studies. Through systematic training and continuous involvement as investigator sites in clinical studies, the agreement will include ARC clinics in the clinical research process. Price Performance In the past year, TMO shares have decreased 12.7% compared with the industry\u2019s fall of 8.3%. Zacks Rank and Key Picks Thermo Fisher carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. The company\u2019s shares have declined 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Hold Humana (HUM) Stock for Now Humana Inc. HUM is aided by an expanding membership base, a robust 2023 business outlook, buyouts and collaborations, and a notable financial position. Zacks Rank & Price Performance Humana currently carries a Zacks Rank #3 (Hold). The stock has gained 4.5% in the past three months compared with the industry\u2019s 12.2% rise. The Zacks Medical sector has dipped 5.8% against the S&P 500 Composite\u2019s gain of 0.9% in the same time frame. Image Source: Zacks Investment Research Favorable Style Score HUM boasts an impressive VGM Score of A. VGM Score helps identify stocks with the most attractive value, the best growth and the most promising momentum. Robust Growth Prospects The Zacks Consensus Estimate for Humana\u2019s 2023 earnings is pegged at $28.29 per share, suggesting growth of 12.1% from the prior-year reported figure. The consensus mark for 2024 earnings is pegged at $31.42 per share, indicating an improvement of 11.1% from the prior-year estimate. Impressive Earnings Surprise History HUM\u2019s bottom line outpaced estimates in each of the trailing four quarters, the average surprise being 5.5%. Strong 2023 Outlook Management forecasts adjusted revenues to be within $100.7-$102.7 billion this year, the midpoint of which suggests 9.4% growth from the 2022 figure. Adjusted earnings per share are anticipated to be a minimum of $28.25 in 2023, which indicates an improvement of 11.9% from the 2022 level. Key Drivers Humana gains on the back of an expanding customer base, which it earns through distributing cost-effective health insurance plans across different U.S. communities and making efforts to upgrade such plan offerings from time to time. Humana recently announced its Medicare Advantage plans for 2024, aiming to expand to 39 new counties in 2024. Overall, its Medicare HMO offerings are targeted to reach 140 counties in 2024, while its Medicare LPPO plans are likely to be available across 80 counties in the same time frame. The strength of these plans should fetch numerous contract wins and renewed agreements from federal or state authorities. An increase in membership fetches the resultant benefit of improved premiums, the most significant contributor to a health insurer\u2019s top line. An aging U.S. population is likely to sustain the solid demand for Humana\u2019s Medicare plans. Management expects individual Medicare Advantage membership will witness a minimum membership growth of 860,000 in 2023. In order to cater more effectively to the aging population, HUM has the CenterWell brand in place. This August, the health insurer introduced the CenterWell Primary Care Anywhere program to provide enhanced primary care to seniors at home across specific Louisiana and Georgia locations. In November 2023, CenterWell announced its expansion plans across Indiana, which will help the brand solidify its presence in the region. A series of acquisitions undertaken over the years have enhanced Humana\u2019s capabilities, diversified income streams, expanded its global presence and widened its customer base. HUM often resorts to collaborations with well-reputed organizations to launch new plans or upgrade features within the existing ones. In October 2023, Humanapartnered with Denver Health to offer enhanced care access and convenience for its Medicare Advantage customer base across the Denver area. Humana boasts a solid cash position and cash-generating abilities, with the support of which it can undertake uninterrupted growth-related initiatives. As of Sep 30, 2023, its cash and cash equivalents of $15.1 billion were way higher than the short-term debt of $2.2 billion. In the first nine months of 2023, HUM generated operating cash flows of $11.1 billion, which increased 14.4% year over year. Stocks to Consider Some better-ranked stocks in the Medical space are Integer Holdings Corporation ITGR, Centene Corporation CNC and DexCom, Inc. DXCM. Integer Holdings sports a Zacks Rank #1 (Strong Buy), while Centene and DexCom carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The bottom line of Integer Holdings surpassed estimates in each of the last four quarters, the average surprise being 12%. The Zacks Consensus Estimate for ITGR\u2019s 2023 earnings and revenues indicates 18.6% and 14.9% growth, respectively, from their corresponding prior-year actuals. Centene Corporation\u2019s earnings beat estimates in two of the trailing four quarters and missed twice, the average surprise being 5.6%. The Zacks Consensus Estimate for CNC\u2019s 2023 earnings and revenues indicates 15.2% and 4.4% growth, respectively, from the prior-year actuals. DexCom\u2019s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 36.4%. The Zacks Consensus Estimate for DXCM\u2019s 2023 earnings indicates a rise of 64.4%, while the consensus mark for revenues suggests an improvement of 23.5% from the corresponding year-ago reported figures. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe Charles River CRL continues to gain from strong organic growth on robust demand from biotech and pharmaceutical clients. The Research Models and Services (RMS) arm continues to gain from the Charles River Accelerator and Development Labs (CRADL) initiative. However, the global Discovery and Safety Assessment (DSA) business environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold). At present, Charles River is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. The company is gaining from its extensive expertise in the discovery of preclinical candidates and the design, execution and reporting of safety assessment studies for numerous types of compounds, including cell and gene therapies and small- and large-molecule pharmaceuticals. The demand for these services is driven by the needs of large global pharmaceutical companies that continue to transition to an outsourced drug development model, in addition to mid-size and emerging biotechnology companies, industrial and agrochemical companies and non-governmental organizations that rely on outsourcing. In the third quarter, organic revenue growth of 5.3% was mainly driven by broad-based strength in the Safety Assessment business on contributions from base pricing and study volume. The DSA backlog decreased to $2.6 billion in the third quarter from $2.8 billion at the end of the second quarter. The company\u2019s RMS business line is in high demand among clients in the field of basic research and screening of non-clinical drug candidates. These service offerings provide greater flexibility for clients\u2019 research and also support increased scientific complexity. The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Charles River Laboratories International, Inc. Price Charles River Laboratories International, Inc. price | Charles River Laboratories International, Inc. Quote In 2023, the company has witnessed strong growth within the insourcing solutions business led by the CRADL initiative. These days, clients are increasingly adopting CRADL\u2019s flexible model to access laboratory space without having to invest in internal infrastructure. To support client demand, Charles River is consistently expanding CRADL\u2019s footprint organically and through the acquisition of Explora BioLabs (done in 2022), a provider of contract vivarium research services. According to Charles River, in the third quarter, the CRADL sites, or the flexible vivarium rental space, remained well utilized overall and continued to generate significant year-over-over revenue growth. Over the past year, shares of Charles River have lost 13.7% compared with the industry\u2019s 14.7% decline. On the flip side, since the beginning of 2023, although Discovery Services revenues demonstrated steady growth, the rate of growth remained at a moderate level, which is reflective of the current market environment and the shorter-term nature of both discovery projects and business backlog. Impacted by a more cautious spending environment from biopharmaceutical clients, the DSA backlog consistently declined on a sequential basis through the quarters of 2023. Meanwhile, the current Cambodian NHP supply constraints and the corresponding impact on its Safety Assessment business are expected to reduce consolidated revenue growth by approximately 200 basis points to 400 basis points in 2023. Foreign exchange is a major headwind for Charles River, as a considerable percentage of its revenues comes from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company\u2019s performance in the international markets. Going by our model, the impact of foreign currency translation is projected to reduce reported revenue growth by 0.5% in 2023. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it came up with an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Inspira (IINN) Expands in Life Support Space With New Deal Inspira Technologies OXY IINN has announced a partnership with Ennocure MedTech, a player in the field of bio-electronic wound dressing. This collaboration aims to integrate bio-electronic technology into Inspira's INSPIRA ART, a cutting-edge approach to oxygenating blood directly to replace traditional mechanical ventilation. Financial terms of the deal have not been disclosed. Addressing Unmet Needs of Bloodstream Infection Care This collaboration particularly aims to address a persistent global healthcare challenge, with an estimated 250,000 bloodstream infections linked to intravenous lines annually. These infections not only result in prolonged hospital stays but also increase healthcare costs significantly. Inspira's plan is to incorporate Ennocure's bio-electronic technology into its INSPIRA ART, creating a preventive approach to reduce complications and combat bloodstream infections. Strategic Implications According to Inspira, the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions will help the company improve patient outcomes in ICUs. This will, therefore, pave the way for safer and more effective life support treatments. Image Source: Zacks Investment Research Market Prospects Going by a Data Bridge Market Research report, the global life support equipment market, valued at $4.25 billion in 2022, is projected to reach $6.96 billion by 2030, at a CAGR of 7.20%. Dominated by hospitals, the market's growth will be fueled by technological advancements, increasing healthcare expenditure and a rise in chronic diseases. Factors such as continuous innovation, improving healthcare infrastructure, and strategic collaborations are likely to further expand opportunities in this vital healthcare sector. Share Price Performance Over the past year, shares of IINN have lost 10.8% compared with the industry\u2019s 8% decline. Zacks Rank and Key Picks Inspira currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it came up with an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have lost 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Inspira Technologies OXY B.H.N. Ltd. (IINN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Retain Quest Diagnostics (DGX) Stock for Now Quest Diagnostics Inc. DGX is likely to grow in the coming quarters, backed by its robust strength in the base business. The company is enabling growth across its customer channels through advanced diagnostics, with an intense focus on faster-growing clinical areas, including molecular genomics and oncology. Continuous progress in terms of operational and productivity improvements is highly encouraging. However, the company\u2019s solvency level and competitive disadvantages remain a concern. In the past year, this Zacks Rank #3 (Hold) stock has decreased 11.4% against the industry\u2019s 1.1% growth and 12.1% rise of the S&P 500 composite. The renowned provider of diagnostic information services has a market capitalization of $15.26 billion. Quest Diagnostics has an earnings yield of 6.42% compared with the industry\u2019s yield of 4.68%. The company\u2019s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 3.07%. Let\u2019s delve deeper. Tailwinds Strong Potential of Advanced Diagnostics: A key pillar of the company\u2019s strategy is to support faster growth across all customer segments through highly specialized advanced diagnostics. Within the segment, the QuestAD-Detect Alzheimer's blood test is adding to Neurology\u2019s growth trends, fortifying the company\u2019s position in the rapidly evolving Alzheimer\u2019s landscape. Image Source: Zacks Investment Research In the third quarter, Quest also reported strong demand for the Alzheimer's cerebral spinal fluid panel. The company was granted FDA Breakthrough Device Designation for its adeno-associated virus called AAV companion diagnostic, developed in collaboration with Sarepta Therapeutics for the Duchenne muscular dystrophy gene therapy. Further, DGX continues to hold growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services. Volume Rebound in the Base Business: Quest Diagnostics\u2019 collaborations with health plans, hospitals and physicians have elevated the demand for services, which shows continued return to care. In the third quarter, the company successfully completed negotiations for all strategic health plan renewals scheduled for 2023, positioning it to build on growth opportunities. Across Physician Lab Services, a large number of strategic partnerships with health plans involve value-based arrangements, which are leading to faster growth and share gains than traditional relationships. Within Hospital labs, progress in terms of partnerships with Northern Light Health, Lee Health and Tower Health is particularly encouraging in the Professional Lab Services (\u201cPLS\u201d) business. In Consumer Health, the company generated solid base business revenue growth from the consumer-initiated testing channel in the third quarter. A Strategic Imperative to Drive Operational Excellence: In terms of driving operational excellence, the company focuses on improving its operational quality, service and costs, thereby driving productivity gains. The Invigorate initiative, which consists of several flagship programs with individually structured plans, was designed to reduce its cost structure and improve performance. Quest Diagnostics is committed to achieving its savings and productivity improvements of approximately 3% annually via this initiative. Earlier in 2023, the company implemented an automated microbiology solution in Lenexa, KS, with Lewisville, TX, being the next in line. Post completion, Quest\u2019s four major laboratories will use automated microbiology lines with artificial intelligence embedded, identifying positive and negative cases leading to improved quality and productivity. In addition, Quest Diagnostics finds great potential in generative AI to deliver insights and content to better target and serve customers and create innovations that help standardize its lab operations. Downsides Escalating Debt Level: As of Sep 30, 2023, the long-term debt was $3.95 billion, while the cash and cash equivalent balance was only $143 million. The current portion of the debt also stood much higher at $304 million. A higher debt level induces higher interest payments, which come with the risk of failure to pay the same. The times interest earned for the company stands at 8%, a sequential drop from 8.7% at the end of the second quarter. Competitive Landscape: Quest Diagnostics faces intense competition, primarily from LabCorp, other commercial laboratories and hospitals. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including the accurate and rapid turnaround of testing results. As a result, Quest Diagnostics and other commercial labs compete with hospital-affiliated labs, primarily based on the quality of service. Estimate Trend The Zacks Consensus Estimate for Quest Diagnostics\u2019 2023 earnings per share (EPS) has moved up from $8.69 to $8.71 in the past 30 days. The consensus estimate for the company\u2019s 2023 revenues is pegged at $9.21 billion. This suggests a 6.8% decline from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.3%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have decreased 5.1% compared with the industry\u2019s 6.5% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 38.6% compared with the industry\u2019s 6.5% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have decreased 1.5% compared to the industry\u2019s 9.1% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-01,114.24,117.5,113.01,116.62,"[""Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Nevro (NVRO). Shares have added about 15.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Nevro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Nevro Q3 Earnings Top Estimates, FY23 Revenue View Up Nevro reported a loss per share of 65 cents for the third quarter of 2023, against the year-ago quarter\u2019s earnings per share of $2.22. However, the loss per share was narrower than the Zacks Consensus Estimate of a loss of 77 cents. Revenues in Detail Nevro registered worldwide revenues of $103.9 million in the third quarter, up 3.4% year over year on a reported basis. The figure topped the Zacks Consensus Estimate by 7.8%. At constant exchange rate (CER), revenues were up 3% year over year. PDN indication sales represented approximately $20.8 million (20%) of worldwide permanent implant procedures and increased 56% year over year. Quarterly Highlights In the quarter under review, international revenues were $14.1 million, down 1.4% year over year on a reported basis and 6% at CER. U.S. revenues for the quarter totaled $89.8 million, up 4.3% year over year. Total U.S. permanent implant procedures increased 7%, while U.S. trial procedures increased 4%. U.S. PDN trial procedures, representing approximately 24% of total U.S. trial volume, jumped 41% from the prior-year quarter. Margin Trend In the quarter under review, Nevro\u2019s gross profit rose 0.3% to $69.5 million. However, the gross margin contracted 205 basis points to 66.9%. Sales, general & administrative expenses increased 3.8% to $81.2 million. R&D expenses decreased 0.8% year over year to $13.9 million. Total adjusted operating expenses of $95.1 million increased 3.1% year over year. The total adjusted operating loss in the reported quarter totaled $25.6 million compared with a total adjusted operating loss of $22.9 million in the year-ago quarter. Financial Position Nevro exited the third quarter of 2023 with cash and cash equivalents and short-term investments of $320.3 million compared with $329.9 million at the end of the second quarter. Long-term debt at the end of third-quarter 2023 was $187.8 million compared with $187.5 million at the second-quarter end. As of Sep 30, 2023, 36,869,962 shares were issued and 36,187,046 shares were outstanding. Cumulative net cash used in operating activities at the end of third-quarter 2023 was $49.9 million compared with cumulative net cash provided by operating activities of $38.1 million a year ago. Guidance Nevro has provided its financial outlook for the fourth quarter and raised its financial outlook for 2023. For the fourth quarter, Nevro expects its worldwide revenues to be in the range of $108 million-$110 million, reflecting a decline of 4-6% year over year at CER. The Zacks Consensus Estimate is pegged at $110.9 million. The company now expects its 2023 worldwide revenues in the range of $417 million-$419 million, reflecting growth of 3% from the comparable figure of 2022 both on a reported basis and at CER. This is up from the prior outlook of $410 million-$415 million, reflecting growth of 1-2% from the comparable figure of 2022 both on a reported basis and at CER. The Zacks Consensus Estimate is pegged at $412.4 million. How Have Estimates Been Moving Since Then? It turns out, estimates revision have trended upward during the past month. The consensus estimate has shifted 11.32% due to these changes. VGM Scores Currently, Nevro has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Nevro has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Performance of an Industry Player Nevro belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, DexCom (DXCM), has gained 23.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2023. DexCom reported revenues of $975 million in the last reported quarter, representing a year-over-year change of +26.7%. EPS of $0.50 for the same period compares with $0.28 a year ago. For the current quarter, DexCom is expected to post earnings of $0.42 per share, indicating a change of +23.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for DexCom. Also, the stock has a VGM Score of B. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nevro Corp. (NVRO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection Neogen Corporation NEOG recently introduced an advanced Veratox VIP assay for detecting walnuts. It is the third assay in Neogen's Veratox VIP line of enhanced quantitative ELISA products. The recent launch will bolster Neogen\u2019s Food Safety business. More on the News The new Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach. This novel quantitative test has good specificity down to 0.15 ppm walnut protein, which is one of the lowest detection limits for an ELISA kit. It can test samples from a wide range of product kinds and processing settings, including heat-processed and complex samples. Veratox VIP for Walnut has a best-in-class time-to-result of 30 minutes and ready-to-use reagents. Benefits of New Launch Per management, as tree nuts continue to be one of the most frequent allergens, Neogen must provide solutions that make it easier for producers to detect potential contamination and reinforce their allergen control measures. Given the highly sensitive nature of the new Veratox VIP for Walnut test, producers can be confident in Neogen's strong commitment to food safety and quality. Industry Prospects Per a report by Coherent Market Insight, the global food allergen testing market size was valued at $774.2 Million in 2022 and is anticipated to witness a CAGR of 8.4% from 2023 to 2030. The global food allergen testing market is expected to witness significant growth over the forecast period due to rising consumer awareness. Consumers are demanding fresh and healthier foods for which manufacturers are adopting stringent food safety standards. Progress Within Food Safety Arm The Neogen Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. Image Source: Zacks Investment Research Regarding the latest development, revenues in the Food Safety segment in the fiscal first quarter increased 157.2% compared to the prior year, including core growth of 4.5%. Core growth within this segment was led by the Bacterial & General Sanitation product category, which benefited from new microbiological testing business in the United States and the U.K. and solid growth in the Natural Toxins and Allergens product category. Price Performance In the past year, NEOG\u2019s shares have increased 3.3% against the industry\u2019s fall of 6.3%. Zacks Rank and Key Picks Neogen carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging Philips PHG unveiled three new ultra-lightweight magnetic resonance (MR) Smart Fit coils, namely Smart Fit TorsoCardiac 1.5T, Smart Fit 1.5T shoulder and Smart Fit Knee 3.0T at RSNA 2023. Notably, the Smart Fit TorsoCardiac 1.5T coil is a versatile, thin, flexible and lightweight device designed for cross-sectional images of the head, body or extremities. It can bend over 90 degrees and be used for difficult anatomies. The Smart Fit 1.5T shoulder coil is designed to enhance radiology productivity by 10%, whereas The Smart Fit Knee 3.0T coil is versatile and easy to use with a wide range of patients. Additionally, all three coils offer enhanced flexibility, reduced patient setup time and improved image quality resolution with SmartSpeed AI solution. Philips is expected to gain solid traction across healthcare providers on the back of its latest move. Koninklijke Philips N.V. Price and Consensus Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote Growth Prospects The latest move is in sync with the company\u2019s deepening focus on strengthening its position in the global magnetic resonance imaging (MRI) market. This, in turn, will solidify its footing in the global diagnostic imaging market. Per a Fortune Business Insights report, the global MRI imaging equipment market is expected to reach $11.5 billion by 2030, exhibiting a CAGR of 6.3% between 2023 and 2030. A Mordor Intelligence report indicates that the global diagnostic imaging market will witness a CAGR of 6.1% during the forecast period of 2023-2028. We believe the company\u2019s growing prospects in these promising markets will likely instill investor optimism in the stock. Philips has gained 36.2% on a year-to-date basis against the industry\u2019s decline of 5.4%. Diagnosis & Treatment Segment in Focus The company\u2019s growing efforts to bolster its Diagnosis & Treatment segment are evident from its product releases at RSNA 2023. Notably, Philips has showcased BlueSeal MR Mobile, the world\u2019s first helium-free mobile MRI system, at RSNA 2023. The new MRI system, featuring a lightweight 1.5T fully sealed magnet and requiring only 7 liters of liquid helium, offers cost and up-time advantages for diagnostic imaging. Further, the company introduced Philips HealthSuite Imaging, a cloud-based Picture Archiving and Communication System, enhancing patient care, operational efficiency and IT management by providing high-speed remote diagnostic reading, integrated reporting and AI-enabled workflow orchestration. Additionally, Philips introduced next-generation ultrasound systems, namely EPIQ Elite 10.0 and Philips Affiniti, to simplify clinical workflows with a single-user interface, shared transducers and automated tools, enhancing user experience. All the above-mentioned endeavors are expected to enhance the underlined segment\u2019s performance in the upcoming period. In the third quarter of 2023, Philips reported Diagnosis & Treatment revenues of \u20ac2.2 billion, registering growth of 6% from the year-ago quarter. Philips expects the 2023 Diagnosis & Treatment segment\u2019s revenues to witness high-single-digit to double-digit growth. Strength in the underlined segment will likely aid the company\u2019s overall financial performance in the near term. Philips expects 2023 comparable sales growth in the band of 6-7%. Zacks Rank & Stocks to Consider Currently, Philips carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical market sector are DaVita DVA, DexCom DXCM and Fate Therapeutics FATE. While DaVita sports a Zacks Rank #1 (Strong Buy), DexCom and Fate Therapeutics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita shares have gained 35.9% in the year-to-date period. The long-term earnings growth rate for DVA is currently projected at 18.25%. DexCom shares have gained 2% in the year-to-date period. DXCM\u2019s long-term earnings growth rate is currently projected at 33.59%. Fate Therapeutics shares have lost 75.3% in the year-to-date period. The long-term earnings growth rate for FATE is currently projected at 29.49%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Fate Therapeutics, Inc. (FATE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Walgreens (WBA) Launches Rx Savings Finder Digital Tool Walgreens Boots Alliance WBA recently announced the launch of Rx Savings Finder \u2014 a simple-to-use digital tool designed to help customers save money on prescription medications. The new tool consolidates free, third-party discount cards, providing patients with a quick and easy way to find lower prices on their Walgreens medications. Rx Savings Finder has been introduced in collaboration with RxSense, a high-growth healthcare technology company providing industry-leading solutions for pharmacy benefits and prescription savings. The latest development will enhance Walgreens\u2019 evolving suite of Pharmacy Solutions within the U.S. Retail Pharmacy segment. Significance of the Launch Per Walgreens\u2019 chief pharmacy officer, rising inflationary trends can have serious implications on health as well, alongside the usual price increases. The company expresses concern by referencing published data, which shows that more than one-third of Americans have avoided a prescription refill to reduce costs, with more than 131 million Americans taking at least one prescription medication. Image Source: Zacks Investment Research Against this backdrop, Walgreens\u2019 new digital tool helps alleviate cost concerns for patients by offering savings on thousands of medications and providing transparent pricing before they reach the checkout counter. By consolidating the search process across multiple discount card websites, the company makes efforts to save the patient\u2019s valuable time and reduce the cost of vital medications. Alongside empowering customers to find lower deals at Walgreens, the company is taking an important step in alleviating the workload of pharmacists. For its pilot program, WBA received an overwhelmingly positive response, with both customers and pharmacy staff reporting significant time and cost savings. Walgreens\u2019 officer shares a promising instance involving a pharmacist\u2019s recent account, wherein the Rx Savings Finder tool has helped a customer save more than $75 on prescriptions during a single visit. More on the News The Rx Savings Finder tool is currently available at all Walgreens pharmacies nationwide at no cost. Patients can access the discount card prices by text messages or emails, which can be presented to a Walgreens pharmacy team member so that the savings can be applied to the price of their prescription medications. While Rx Savings Finder cannot be combined with or applied to prescription drug insurance, the prices available through prescription coupons can be less expensive than a copay. On an impressive note, WBA\u2019s digital innovations, spanning telepharmacy, micro-fulfillment and cutting-edge technologies, align with the evolving needs of patients and pharmacists. Beyond the conventional role of medication dispensing, Walgreens\u2019 vision encompasses fostering meaningful patient connections, looking at their holistic health profiles and forging collaborations with healthcare partners for a more comprehensive and community-centric approach to healthcare. Industry Prospects Per a Research report, the global pharmacy market was valued at $1.01 trillion in 2020 and is expected to witness a CAGR of 4.3% up to 2028. Recent Performance of the US Retail Pharmacy Segment Walgreens\u2019 trusted brand, deep community relationships and convenience form the foundation of its pharmacy business and the platform for growth as it expands throughout other areas of health care. In September, the company exited fiscal 2023 with Pharmacy and Retail components comprising 74% and 26%, respectively, of the U.S. Retail Pharmacy segment\u2019s fiscal sales. In the fourth quarter of fiscal 2023, U.S. Pharmacy comp sales increased 9.2%, driven by brand inflation, mix impacts and comp script growth. A weaker-than-normal respiratory season and the impact of Medicaid redeterminations have resulted in a weaker overall prescription market during the quarter. Moreover, the U.S. Retail business was impacted by a weaker-than-normal respiratory season and a continued shift in consumer behavior, driven by a challenging macroeconomic environment. These factors led to the comparable sales decline of 3.3% in the fourth quarter. Price Performance In the past six months, WBA shares have decreased 36.1% compared with the industry\u2019s fall of 11.5%. Zacks Rank and Key Picks Walgreens currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 6.1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 38.6% in the past year compared with the industry\u2019s decline of 6.5%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have fallen 2.2% in the past year compared with the industry\u2019s decline of 7.8%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""2 Strong Stocks Trading 30% Below Their Highs to Buy in December Today\u2019s episode of Full Court Finance at Zacks dives into where the stock market stands to start December and where we could be headed as we close out 2023. The episode then discusses why investors might want to consider buying Global Payments (GPN) and DexCom (DXCM) stock right now for long-term growth, with both trading at least 30% below their record highs. The Nasdaq slipped slightly on Thursday, though its slide doesn\u2019t appear to warrant too much alarm following two weeks of sideways movement after the massive run since the end of October. Some selling is comforting since it helps cool things down to start the final month of 2023. The market could face more selling pressure in the near term, with the Nasdaq sliding below overbought RSI levels after failing to break above its summer 2023 highs. Markets never go straight up, and there will always be reversions back toward key moving averages such as the 21-day, 50-day, and 200-day throughout bullish periods. Image Source: Zacks Investment Research Thankfully, it appears that more investors are attempting to position themselves on the right side of a possible rally toward all-time highs in the coming months as Wall Street looks ahead to rate cuts. Global Payments (GPN) Global Payments is a top payments technology firm that operates three reportable business segments: Merchant Solutions, Issuer Solutions, and Consumer Solutions. The company\u2019s various offerings do everything from enabling its customers to accept card and digital-based payments to helping manage their card portfolios and beyond. The firm has made various acquisitions over the years, including its roughly $4 billion deal to buy EVO Payments, which closed in March 2023. Image Source: Zacks Investment Research GPN lands a Zacks Rank #3 (Hold) right now, with its earnings revisions moving sideways. But Global Payments beat our Q3 earnings estimate on Halloween. Current Zacks estimates call for its adjusted earnings to climb 12% in FY23 and then jump another 14% in FY24 on the back of 7% higher revenue growth each year. Global Payments has climbed 267% over the last 10 years vs. the Zacks tech sector\u2019s 242%. This outperformance came even though GPN shares haven\u2019t recovered much ground after their prolonged tumble. GPN stock is still down around 45% from its 2021 highs and up only 17% in 2023 vs. Tech\u2019s 45%. Image Source: Zacks Investment Research Global Payments trades 21% below its average Zacks price target and it is back above its 200-day and its 50-day moving averages. GPN is also crucially trading above its 50-week moving average. On top of that, the stock trades at a 65% discount to its 10-year highs, 50% below its median, and 60% under the Zacks tech sector at 10.6X forward 12-month earnings. GPN is currently trading near its decade-long lows on the forward earnings front. GPN also pays a dividend and 80% of the brokerage recommendations Zacks has are \u201cStrong Buys.\u201d DexCom, Inc. (DXCM) DexCom makes continuous glucose monitoring systems for people with diabetes. DexCom\u2019s addressable market is expanding even though 1 in 10 Americans already have diabetes because far more currently have prediabetes, according to the CDC. Diabetes is also on the rise outside of the U.S. Overall, DexCom\u2019s devices are part of a wave of connected health technologies that should become standard care. Image Source: Zacks Investment Research DXCM boasts an impressive history of EPS beats, including a 47% beat on October 26. Its positive earnings outlook helps it earn a Zacks Rank #2 (Buy) right now. DXCM is projected to post 24% sales growth in 2023 and another 18% in FY24 to hit $4.24 billion next year, which comes on top of 26% average expansion during the trailing three years. On the bottom line, DexCom is projected to grow its adjusted earnings by 64% and 18%, respectively. DexCom stock has skyrocketed over the last 20 years and soared 1,200% in the last 10 years vs. the S&P 500\u2019s 160%, which includes a 240% run during the past five years. Still, DXCM trades roughly 30% under its peaks and 15% below its summer 2023 highs. The stock found support around its 50-month moving average not too long ago and climbed back above that long-term level recently. DexCom shares have also mounted a comeback above their 200-week and 50-week moving averages, as well as their 200-day and 50-day. Image Source: Zacks Investment Research DXCM trades at a 20% discount to its three-year median at a PEG ratio of 2.1 and near the Tech sector\u2019s 1.9. DexCom also announced a $500 million share repurchase program when it reported its Q3 results. Investors with a long-term outlook might appreciate that it has a strong balance sheet, and 17 of the 19 brokerage recommendations Zacks has are \u201cStrong Buys.\u201d Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Global Payments Inc. (GPN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-04,116.25,118.79,116.2,118.24,"[""Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue? Exact Sciences Corporation\u2018s EXAS shares have surged 35.4% year to date against the industry\u2019s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a market capitalization of $12.12 billion. The upside in the Screening and Precision Oncology segments is likely to have driven this Zacks Rank 2 (Buy) stock. Its earnings are expected to have surged by 58.2% in the next year. Will the Upside Continue? The Zacks Consensus Estimate for EXAS\u2019 2023 earnings indicates a 58.2% increase from the year-ago reported figure. The consensus estimate for 2023 revenues is pegged at $2.48 billion, indicating a year-over-year improvement of 19.1%. Exact Sciences is focusing on three areas to enhance Cologuard growth. Building the best and most effective commercial organization in healthcare by investing in the leadership team, training and sales force effectiveness is the first strategy. Improving the customer experience by making it simpler to order Cologuard electronically and continue rescreening patients every three years is the next strategy. Screening more people starting at age 45 to catch cancer earlier is the final strategy. In terms of the latest development, more than 9,000 new healthcare professionals ordered Cologuard during the second quarter and more than 321,000 have ordered since launch. About 75% of all U.S. primary care physicians have ordered Cologuard. The company\u2019s Precision Oncology portfolio guides treatment decisions for more than 200,000 cancer patients annually. The Oncotype DX test helps early-stage breast cancer patients determine whether they will benefit from chemotherapy. The OncoExTra test helps late-stage cancer patients determine their best treatment options. A consistent focus on high-quality tests, top-tier clinical evidence and physician education cemented Oncotype DX as the standard of care. In terms of the latest developments, the company has made progress in its three most impactful pipeline programs, colon cancer screening, molecular residual disease and multi-cancer screening. For Next Generation Cologuard, the data presentation at ACG in October demonstrated the pivotal head-to-head BLUE-C study is the new gold standard for evidence in colon cancer screening. The study was designed to validate a pre-specified algorithm. BLUE-C enrolled over 20,000 people, including 98 with cancer and more than 2,000 with precancerous polyps. Image Source: Zacks Investment Research Exact Sciences exited the third quarter of 2023 with cash and cash equivalents and marketable securities of $733.4 million compared with $604.4 million at the end of the second quarter of 2023. The company had no long-term debt on its balance sheet at the end of the third quarter. This is good news, particularly during an overall tough macroeconomic scenario when the company is faced with a global manufacturing and supply halt. The raised guidance is an indicator of future growth. For 2023, the company expects revenues in the range of $2.476-$2.486 billion (from the earlier-provided range of $2.441-$2.466 billion). The Zacks Consensus Estimate for the same is pegged at $2.26 billion. For 2023, the company expects its Screening revenues to be in the range of $1.820-$1.835 billion. The company expects Precision Oncology revenues in the range of $615-$625 million. Estimate Trends The Zacks Consensus Estimate for EXAS\u2019 2023 has moved from a loss of $1.90 to a loss of $1.48 in the past 90 days, reflecting analysts\u2019 optimism. Other Key Picks Some other top-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 shares have moved up 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share (EPS) have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have declined 40.9% in the past year compared with the industry\u2019s fall of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 EPS have increased from $1.23 to $1.41 in the past 30 days. The company\u2019s shares have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Validea Detailed Fundamental Analysis - DXCM Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Thermo Fisher (TMO) Advances Health Equity via New Partnership Thermo Fisher Scientific TMO recently announced a collaboration with Project HOPE, a leading global health and humanitarian organization working on the front lines of the world\u2019s health challenges. The partnership will focus on improving the well-being and treatment outcomes of adolescents and young persons living with HIV in Nigeria, the country with the second-largest HIV epidemic worldwide. The partnership builds on Thermo Fisher\u2019s collaborations with customers, governments and nonprofit organizations to create a more equitable global healthcare environment. The latest development greatly advances Project HOPE\u2019s efforts in Northwestern Nigeria by expanding access to critical community HIV testing services. About Project HOPE Founded in 1958, Project HOPE\u2019s mission lies at the epicenter of today\u2019s greatest health challenges, including infectious and chronic diseases, disasters and health crises, maternal, neonatal and child health and the policies that impact how health care is delivered. The organization currently has an operating base in more than 25 countries worldwide. Image Source: Zacks Investment Research For more than a decade, Project HOPE has been collaborating with public, private and government partners to improve health in Nigeria. With a focus on HIV/AIDS, Project HOPE strives to support government, local partners and communities to prevent new infections and enhance health outcomes for the most vulnerable populations in line with the UNAIDS targets toward achieving epidemic control. Significance of the Collaboration Nigeria currently accounts for nearly two million individuals living with HIV, contributing to approximately two-thirds of new HIV infections in West and Central Africa. Thermo Fisher\u2019s partnership with Project HOPE builds on its meaningful work in the region and allows the company to support and learn from a new cohort of essential partners to give more young people living with HIV a greater chance to explore and fulfill their life ambitions. Supported by local community partners, Project HOPE will identify and help connect more HIV-positive adolescents and young persons with appropriate treatment and essential social and economic support services, ultimately improving their well-being and quality of life. Additionally, Thermo Fisher will engage its employees in volunteer opportunities to augment the services delivered by Project HOPE. More on the News This year\u2019s World AIDS Day, observed on Dec 1 every year, celebrates the theme \u201cLet Communities Lead\u201d \u2014 a stark reminder to focus on individuals living with this disease and enable community partners on the frontline of driving local progress. Thermo Fisher\u2019s previous support for Project HOPE\u2019s initiatives in countries like Ukraine laid the foundation for the new collaboration to address infectious diseases, particularly HIV/AIDS. For instance, in 2022, the company launched an HIV drug resistance genotyping kit with global health equity pricing \u2014 an offering that has been adopted by more than 30 low and middle-income countries across Africa, Latin America, the Middle East and Asia and has helped drive health policy changes in Kenya. Industry Prospects Per a Research report, the global HIV diagnostics market was valued at $985.7 million in 2022 and is expected to witness a CAGR of 5.5% in the 2023-2030 period. Other Notable Developments Earlier this year, Thermo Scientific B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PlGF plus KRYPTOR and B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S sFlt-1 KRYPTOR novel biomarkers became the first and only immunoassays to receive breakthrough designation and FDA clearance for the risk assessment and clinical management of preeclampsia \u2014 a potentially life-threatening condition that disproportionately impacts pregnant Black women. The company also partnered with Pfizer to expand local access to next-generation-sequencing-based testing for cancer patients in low and middle-income markets across Africa, Latin America, the Middle East and Asia. Price Performance In the past six months, TMO shares have decreased 4.3% compared with the industry\u2019s fall of 6.5%. Zacks Rank and Key Picks Thermo Fisher currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 0.5% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data BiomX Inc. PHGE recently released favorable data from Part 2 of its Phase 1b/2a trial. This trial has assessed the efficacy of the novel phage cocktail, BX004, in treating chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa) in cystic fibrosis (CF) patients. The study has been addressed as a 'watershed moment' by experts demonstrating the safety and tolerability of BX004 and its advanced clinical impact. A Few Words on BX004 The study's controlled, double-blind, randomized design, coupled with the positive clinical evidence, positions phage-based therapy as a potential game-changer in addressing pulmonary infections associated with CF. More Into the Study BiomX noted that the study emphasized the improvements in pulmonary function observed after a brief 10-day treatment with BX004. The relative FEV1 improvement and positive outcomes in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain signal a breakthrough in the treatment of chronic pulmonary infections associated with CF. Endpoints included safety and tolerability, a decrease in P. aeruginosa burden, sputum pharmacokinetics, FEV1, CFQ-R (CF Questionnaire-Revised) and CFRSD-CRISS (Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score). More specifically, BX004 showcased an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment (Day 10), a stark contrast to the placebo arm's 0%. This achievement is noteworthy, especially for patients with a decade-long history of P. aeruginosa lung infections. Image Source: Zacks Investment Research Key Highlights of Part 2 Results Part 2 of the trial involved 34 CF patients. The phage cocktail exhibited positive clinical effects, particularly in patients with reduced baseline lung function. The reduction in P. aeruginosa levels, especially in patients on standard inhaled antibiotics, exceeded the outcomes observed in Part 1 of the trial. Advancing Further Banking on these favorable outcomes, BiomX is currently advancing the BX004 program to a larger, pivotal Phase 2b/3 trial. The decision is contingent on regulatory feedback and the availability of sufficient funding. Market Prospects According to an Acumen Research and consulting report, the global Chronic Obstructive Pulmonary Disease (\u201cCOPD\u201d) treatment market, valued at $16.78 billion in 2021, is projected to reach $25.37 billion by 2030, witnessing a CAGR of 4.9% from 2022 to 2030. Factors such as the increasing prevalence of COPD, continuous research and development and rising FDA approvals contribute to market expansion. Despite challenges like patent expirations and the availability of generic alternatives, the market is bolstered by a growing number of COPD cases, a surge in pharmaceutical usage in emerging nations and promising drugs in the pipeline. Share Price Performance Over the past year, shares of PHGE have improved 1.1% against the industry\u2019s 3.2% decline. Zacks Rank and Key Picks BiomX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Insulet PODD. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 0.5% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report BiomX Inc. (PHGE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague For much of the past four years, volatility has been a fixture on Wall Street. All three major stock indexes have bounced between bull and bear markets on a couple of occasions. When short-term uncertainty arises, investors have a tendency to seek out time-tested businesses with a track record of outperformance. Although the FAANG stocks have been popular with investors for the past decade, it's stocks enacting splits that have fit the bill for the past two years. A stock split is an event that allows a publicly traded company to cosmetically alter its share price and outstanding share count while having no impact on its market cap or operating performance. A forward-stock split makes a company's share price more nominally affordable for everyday investors, while a reverse-stock split increases a public company's share price, likely to ensure it maintains minimum listing standards on a major stock exchange. Image source: Getty Images. Between the two, forward-stock splits tend to get the most attention -- and with good reason. Companies enacting forward splits are typically highfliers that have out-executed and out-innovated their competition. Since mid-2021, nine top-tier businesses have completed forward-stock splits (listed in chronological order by date of split): Nvidia (NASDAQ: NVDA): 4-for-1 split Amazon (NASDAQ: AMZN): 20-for-1 split DexCom (NASDAQ: DXCM): 4-for-1 split Shopify (NYSE: SHOP): 10-for-1 split Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG): 20-for-1 split Tesla (NASDAQ: TSLA): 3-for-1 split Palo Alto Networks (NASDAQ: PANW): 3-for-1 split Monster Beverage (NASDAQ: MNST): 2-for-1 split Novo Nordisk (NYSE: NVO): 2-for-1 split All nine of these companies are leaders within their respective industries. However, the outlooks for these highfliers in the years to come vary quite a bit. As we push into December and ready to close the curtain on 2023, one stock-split stock remains historically cheap despite a sizable year-to-date rally, while another top performer appears set to face a slew of headwinds in 2024 (and beyond). The stock-split stock to buy hand over fist in December: Alphabet Among the nine prominent stock-split stocks listed above, the one that stands out as the best value in December -- even with a 50% year-to-date gain -- is Alphabet. This is the parent company of internet search engine Google and streaming platform YouTube, among other ventures. The primary reason shares of Alphabet tumbled more than 40% during the 2022 bear market was the growing fear that the U.S. would fall into a recession. Alphabet generated nearly 78% of its total revenue from advertising during the September-ended quarter, and advertisers usually pare back their spending at their first signs of economic weakness. Since ad revenue is so important to Alphabet's cash flow, the company's stock became a victim of \""what if?\"" thinking. But here's the important thing to know about recessions: Although we can never predict when they'll occur, history shows they're short-lived. Of the 12 U.S. recessions that have occurred following World War II, nine have lasted less than a year, and none have surpassed 18 months. That compares to a handful of expansions that lasted between four and 12 years over the same timeline. These lengthy periods of expansion provide Alphabet with plenty of ad-pricing power. Something else Alphabet brings to the table is the utter dominance of its internet search engine. Based on data provided by GlobalStats, Google accounted for 91.55% of worldwide internet search share in October. It's held a monthly share of 90% or greater in global internet search for more than eight years. Merchants are well aware that Alphabet's search engine provides them the best chance to reach a broad audience with their message(s). However, Google isn't Alphabet's only source of long-term ad growth. Streaming platform YouTube has over 2.7 billion monthly active users (MAUs), which places it behind only Meta Platforms' Facebook in total MAUs. In particular, the rapid growth of Shorts (short-form videos often lasting less than 60 seconds) from 6.5 billion daily views to north of 50 billion in two years has the potential to meaningfully lift the organic growth rate for YouTube and parent Alphabet. An even stronger long-term growth driver than YouTube is cloud infrastructure service platform Google Cloud. According to tech-analysis company Canalys, Google Cloud commands 10% of worldwide cloud infrastructure service spending, which is a big deal considering that enterprise cloud spending is still in the very early innings. Following multiple years of losses, Google Cloud has delivered three consecutive quarters of profits. With cloud margins often outpacing advertising margins, Google Cloud may become Alphabet's leading cash-flow driver by the latter half of the decade. And, as promised, Alphabet remains historically inexpensive. Over the trailing-five-year period, Alphabet has traded at an average of 18 times its year-end cash flow. Opportunistic investors can snag shares of this industry leader in December for less than 14 times forward-year cash flow. It's a low-water mark for a top-tier business. Image source: Getty Images. The stock-split stock to avoid like the plague in December: Nvidia Although all nine of the highlighted stock-split stocks have vastly outperformed over the long run, the one that could struggle to deliver superior returns moving forward is semiconductor giant Nvidia. When November came to a close, shares of Nvidia were 220% higher from where they began 2023. The fuel behind this phenomenal performance is the artificial intelligence (AI) revolution. Based on estimates from PwC, AI has the potential to boost worldwide gross domestic product by $15.7 trillion come 2030. Nvidia's role in the ascension of AI is as the infrastructure backbone of high-compute data centers. The company's A100 and H100 graphics processing units (GPUs) likely account for between 80% and 90% of the GPUs currently being used in AI-accelerated data centers. With A100 and H100 production set to expand in 2024, and Nvidia's sales and profits skyrocketing, it's easy to understand why Nvidia has outperformed. There are, however, a handful of factors that suggest the hottest stock in AI is going to have a difficult 2024. One of the more ironic challenges Nvidia could contend with in the coming year or two is its production expansion. Selling more A100 and H100 GPUs likely sounds fantastic from an investment and operating perspective. But the bulk of Nvidia's data center sales growth through the first nine months of its current fiscal year can be traced to phenomenal pricing power amid GPU scarcity. Being able to increase its sales capacity will almost certainly weigh on its pricing power. To add to the above, Nvidia will be facing growing competition in the AI-GPU space in the coming quarters. Advanced Micro Devices debuted its MI300X AI-GPU in the second half of 2023, with plans to meaningfully ramp production next year. Brand-name chipmaker Intel also expects to dive headfirst into the high-growth AI-GPU market in 2025 with its Falcon Shores GPU. It's hard to envision a scenario where Nvidia doesn't lose significant pricing power and/or market share over the next 12 to 24 months. Another problem for Nvidia is that U.S. regulators have continued to limit exports of high-powered chips to China. The world's No. 2 economy generates in the neighborhood of 20% to 25% of Nvidia's net sales. With a lower growth ceiling in China, Nvidia could have an even tougher time meeting Wall Street's lofty growth expectations in the coming quarters. History is the final concern for Nvidia. Every next-big-thing investment dating back 30 years has navigated its way through an initial bubble, and AI is unlikely to be the exception to the rule. All technologies need time to mature, which makes it unlikely that Nvidia's rapid valuation expansion is sustainable. 10 stocks we like better than Alphabet When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 29, 2023 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Sean Williams has positions in Alphabet, Amazon, Intel, and Meta Platforms. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Meta Platforms, Monster Beverage, Nvidia, Palo Alto Networks, Shopify, and Tesla. The Motley Fool recommends DexCom, Intel, and Novo Nordisk and recommends the following options: long January 2023 $57.50 calls on Intel and long January 2025 $45 calls on Intel. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-05,116.37,117.82,115.64,117.2,"[""West Pharmaceutical's (WST) New Launch to Expand Portfolio West Pharmaceutical Services, Inc. WST recently announced the receipt of the FDA\u2019s 510(k) clearance and the subsequent launch of its Vial2Bag Advanced 13mm admixture device. The admixture device is indicated for adolescent and adult patients only. The latest regulatory clearance and launch is expected to significantly expand West Pharmaceutical\u2019s administration systems portfolio with a new smaller-size needle-free admixture device for immediate use IV (intravenous) drug transfer to maximize the benefits of point-of-care nursing. The administration systems are part of the company\u2019s Proprietary Products segment. Significance of the Launch The addition of the Vial2Bag Advanced 13mm admixture device will likely complement West Pharmaceutical\u2019s existing Vial2Bag Advanced 20mm admixture device. The two products are expected to provide options for the reconstitution and transfer of a drug using either a 13mm or 20mm vial and an IV bag before administration to the patient. The device is needle-free and has a dual channel design to provide dedicated fluid pathways into and out of the IV bag and a vial spike design for connection to the drug vial. Per West Pharmaceutical\u2019s management, the 13mm product, a key addition to its portfolio, will likely address the critical need for more drug preparation and delivery options at the point of care. Industry Prospects Per a report by Data Bridge Market Research, the global injectable drug delivery market was valued at $17.13 billion in 2021 and is anticipated to reach $46.84 billion by 2029 at a CAGR of 13.4%. Factors like the increasing incidence of chronic diseases, the rising number of elderly population and technological advancements are likely to drive the market. Given the market potential, the latest announcement is expected to significantly strengthen West Pharmaceutical\u2019s business worldwide. Another Notable Development In October, West Pharmaceutical announced its third-quarter 2023 results, wherein it registered a solid uptick in its net sales and organic net sales. Its bottom-line performance was also solid. The company's Proprietary Products segment\u2019s net sales and organic net sales growth were also robust. The segment\u2019s high-value product (HVP) organic net sales growth was led by customer demand for HVP components such as FluroTec, Daikyo and Envision and HVP devices such as self-injection systems and administration systems. Price Performance The stock has gained 49.3% over the past year compared with the industry\u2019s 10.9% rise and the S&P 500's 16.1% growth. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, West Pharmaceutical carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 44.4% compared with the industry\u2019s 5.7% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 1.2% against the industry\u2019s 3.3% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 24.7% against the industry\u2019s 3.3% decline in the past year. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why You Should Retain UnitedHealth Group (UNH) Stock Now UnitedHealth Group Incorporated UNH is aided by a well-performing government business, owing to increasing premiums and numerous contract wins. The pursuit of buyouts, a solid financial position and a robust 2023 outlook are other tailwinds. Zacks Rank & Price Performance UnitedHealth Group currently carries a Zacks Rank #3 (Hold). The stock has gained 15% in the past three months compared with the industry\u2019s 11.8% rise. Image Source: Zacks Investment Research Rising Estimates The Zacks Consensus Estimate for UnitedHealth Group\u2019s 2023 earnings and revenues is pegged at $24.95 per share and $368.9 billion, respectively, indicating an improvement of 12.4% and 13.8% from the year-ago reported figures. UNH boasts an impressive surprise record. Its earnings outpaced estimates in each of the trailing four quarters, the average being 2.7%. Return on Equity UnitedHealth Group\u2019s efficiency in utilizing shareholders\u2019 funds can be substantiated by its trailing 12-month return on equity of 26.6%, which remains higher than the industry\u2019s average of 23.4%. Robust Outlook UnitedHealth Group anticipates revenues between $357 billion and $360 billion, the mid-point of which indicates an improvement of 10.6% from the 2022 reported figure. It expects 2024 revenues between $400 billion and $403 billion. Adjusted net earnings per share (EPS) are estimated to be between $24.85 and $25 for the year. The mid-point of the updated guidance suggests 12.3% growth from the 2022 figure. It expects adjusted net EPS in the range of $27.5-$28 in 2024. Business Tailwinds Revenues of UnitedHealth Group continue to benefit from solid contributions from its UnitedHealthcare and Optum businesses. Premiums contributed 78.3% to the company\u2019s total revenues in the third quarter. It is expected to rise further as UnitedHealth Group continues to serve more people through Medicare and Medicaid Advantage plans. Through the UnitedHealthcare unit, UNH devises effective Medicare and Medicaid businesses, as well as integrates lucrative features within them from time to time. The top line of UnitedHealthcare segment is expected to benefit as the company grows its existing Medicaid markets and serves more people through fee-based and risk-based commercial offerings. The company expects to add more than 1 million members to its Medicare Advantageplan this year, expanding its membership base and fetching higher premiums. The Medicaid business is set to grow as it continues to support states in initiating redeterminations. The company aims to reach 96% of all Medicare customers with its 2024 Individual Medicare Advantage Plan. Optum Health segment will continue to gain from more people served under value-based care arrangements and consistent strengthening of care delivery services. Optum Insight and Optum Rx are expected to benefit from enhanced capabilities and new sales and opportunities. However, excellent customer retention should also favor Optum Rx results. The company expects to serve nearly 900,000 additional patients in value-based care arrangements through the end of 2023. It aims to generate 1.5 billion scripts through OptumRx by 2023. UnitedHealth Group has been pursuing collaborations with renowned healthcare providers to bolster its capabilities and solidify its nationwide presence. Its acquisition of Amedisys should enhance and expand its in-home capabilities and fuel growth in the Optum Health segment. Moreover, UNH will get access to Amedisys\u2019s Medicare customers, thus enhancing its benefits business in the future. The company\u2019s launch of Price Edge and zero-cost life-saving drugs should help retain more customers in the future. Its partnership with ProHealth Care should also aid Optum\u2019s results in the future. The company also earns through investment income. The metric increased nearly 94.3% in the third quarter. A high-interest rate environment should boost this metric in the future. A solid financial position is a dire need for companies that keep an eye on continued business investments. Apart from growth-related initiatives, a sound financial stand instills confidence in UNH in the tactical deployment of capital through share buybacks and dividend payments. The company returned $11.5 billion to shareholders in the first nine months of 2023 through share repurchases and dividends. Its dividend yield of 1.4% remains higher than the industry\u2019s figure of 1.3%. UNH expects operating cash flow in the range of $27-$28 billion in 2023. UNH currently carries an impressive Value Score of B. Key Concerns The health insurer has been experiencing an increase in operating expenses due to higher medical and operating costs and the cost of goods sold. Such expenses continue to weigh on the margin expansion. We expect total operating costs to rise 13.3% in 2023. Nevertheless, we believe that a systematic and strategic plan of action will drive growth in the long term. Stocks to Consider Some better-ranked stocks in the Medical space are Amphastar Pharmaceuticals, Inc. AMPH, DexCom, Inc. DXCM and Medpace Holdings, Inc. MEDP. Amphastar Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), and DexCom and Medpace carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Amphastar Pharmaceuticals earnings surpassed estimates in each of the last four quarters, the average surprise being 52.1%. The Zacks Consensus Estimate for AMPH\u2019s 2023 earnings indicates a surge of 62.4% from the prior-year tally. The consensus mark for revenues suggests an improvement of 28.4% from the year-ago actual. The consensus mark for AMPH\u2019s 2023 earnings has moved 17.6% north in the past 30 days. The bottom line of DexCom beat estimates in each of the trailing four quarters, the average beat being 36.4%. The Zacks Consensus Estimate for DXCM\u2019s 2023 earnings indicates a surge of 64.4% from the year-ago figure. The consensus mark for revenues suggests an improvement of 23.5% from the prior-year tally. The consensus mark for DXCM\u2019s 2023 earnings has moved 16.3% north in the past 30 days. Medpace\u2019s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 14.6%. The Zacks Consensus Estimate for MEDP\u2019s 2023 earnings indicates an improvement of 18.8% from the year-ago actual. The consensus mark for revenues suggests 29.4% growth from the year-ago actual. The consensus mark for MEDP\u2019s 2023 earnings has moved 3.1% north in the past 60 days. Shares of Amphastar Pharmaceuticals, DexCom and Medpace have gained 107.9%, 1.2% and 37.2%, respectively, in the past year. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Integra Gains From New Product Launches, Mounting Costs Ail Integra LifeSciences IART is gaining from a series of product introductions, acquisitions and strong overseas expansion. However, product recall issues dent growth. The stock carries a Zacks Rank #3 (Hold). Integra sees healthy demand for its industry-leading products within Codman Specialty Surgical (\u201cCSS\u201d). The segment is benefiting from the growing market acceptance of the company\u2019s global neurosurgery line-ups, including CSS management and neuromonitoring. Within CSS management, Integra is experiencing growth, banking on the strong market adoption of programmable valves and advanced energy (the key revenue-generating products are CUSA Capital, Mayfield, DuraGen, Certas Plus programmable valves, Bactiseal catheters and instruments). The company has expanded the international reach of the CUSA platform and registered DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America. Also, Integra's Tissue Technologies business is continuously gaining traction on efficient growth strategies and a better price management policy. The wound reconstruction subcategory within Tissue Technologies is rebounding fast, banking on robust sales in Integra Skin and SurgiMend. Integra LifeSciences Holdings Corporation Price Integra LifeSciences Holdings Corporation price | Integra LifeSciences Holdings Corporation Quote Further, the ACell franchise is driving better results. In the Tissue Technologies division, the company launched NeuraGen 3D, a unique mid-cap nerve repair product. However, the challenging macroeconomic scenario, specifically in the Asia Pacific and Europe, is driving higher-than-anticipated inflation in terms of raw materials and labor costs. These could also result in broader economic impacts and security concerns, affecting the company\u2019s business through 2023. Higher freight costs, ongoing labor inflation and manufacturing and supply-chain inefficiencies continued to put significant pressure on Integra\u2019s margins in recent times. IART\u2019s SG&A expenses rose 12.6% in the third quarter of 2023. In the quarter, the unfavorable product and geographic mix and Boston recall issue-related expenses laid significant pressure on the company\u2019s margins. Our estimates indicate 6.9% and 2.3% increases in SG&A expenses for 2023 and 2024, respectively. In May 2023, Integra had to voluntarily recall the manufacturing of its key products like PriMatrix, SurgiMend, Revize and TissueMend from its Boston, MA, manufacturing facility. In the second quarter of 2023, the company reported a decline in global revenues, primarily as the result of this recall, which affected both Domestic and International sales. Further, due to the voluntary recall, the company recorded a $24.1 million write-off of inventory that could no longer be sold. In June, Integra submitted an initial response to the audit findings but currently expects the matter to get resolved not before 2023 end. Over the past year, shares of IART have declined 27.4% compared with the industry\u2019s 4.7% drop. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Insulet PODD. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 0.5% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails Boston Scientific BSX is gaining traction in emerging markets. Innovative prowess, FDA approvals and accretive acquisitions bode well for long-term growth. However, the unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In 2022, 40% of the company\u2019s consolidated revenues came from international regions. Within its international regions, BSX is putting additional efforts to expand its foothold in emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada) that hold strong growth potential based on their economic conditions, healthcare sectors and global capabilities. In the EMEA too, Boston Scientific is successfully expanding its base banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand. Within the Asia Pacific (\u201cAPAC\u201d), Boston Scientific is particularly registering strong growth in Japan and China. Within Japan, the company is benefitting from new product launches like AGENT DCB, Rezum, POLARx FIT and WATCHMAN FLX. In China, BSX is gaining from the Imaging and Complex PCI portfolio. Additionally, following the pandemic-led mayhem, Boston Scientific is consistently registering fast recovery within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options. Particularly, the company is gaining market share with its biliary franchise led by the AXIOS Stent and Delivery System and hemostasis, single-use imaging and metal stent franchises. In the third quarter of 2023, BSX reported strong organic growth contributions from single-use imaging and AXIOS technologies. Endoscopy demonstrated notable strength in the United States, Latin America and APAC, with new product momentum and healthy procedure demand during the third quarter. The company recently received U.S. marketing authorization for an expanded indication of the AXIOS stent to include gallbladder drainage, increasing access to more patients with this platform. Over the past year, shares of Boston Scientific have increased 20.6% against the industry\u2019s 3.2% decline. Boston Scientific Corporation Price Boston Scientific Corporation price | Boston Scientific Corporation Quote Meanwhile, the industry-wide trend of challenging macroeconomic conditions in the form of inflation, disruptions in economic activity, global supply chains and labor markets, volatile financial market dynamics and significant volatility in price and availability of goods and services is putting pressure on BSX\u2019s profitability. Further, international conflicts, including the Russia-Ukraine war and tension between China and Taiwan, have increased cybersecurity risks globally. With sustained macroeconomic pressure, the company may struggle to keep in check its cost of revenues and operating expenses. In the third quarter of 2023, the company reported a 12.5% rise in the cost of products sold and a 9.7% rise in SG&A expenses. For 2023, 2024 and 2025, our model projects the cost of products sold to grow by 7.2%, 10.1% and 7.4%, respectively, over the prior year. Further, with Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players too. In 2023, the company expects an approximate 100-basis point headwind from foreign exchange on revenues. The presence of a large number of players has made the medical device market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Insulet PODD. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 0.5% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal Henry Schein\u2019s HSIC dental laboratory business \u2014 Zahn Dental \u2014 recently entered into an exclusive agreement to distribute the global dental manufacturing company, Myerson\u2019s newly launched Trusana Premium Denture System. Comprising three products \u2014 the Trusana Premium 3D Tooth Resin, Trusana Premium 3D Denture Base Resin and Trusana Bond Denture Adhesive \u2014 the system works together to create a premium denture with optimal physical properties and esthetics for dental laboratories. Henry Schein\u2019s Zahn Dental is focused on delivering products and services that help foster the adoption of digital solutions in dentistry, specifically among lab technicians. Zahn Dental's relationship with Myerson will help Henry Schein strengthen its digital dentistry offerings. News in Detail Zahn Dental\u2019s comprehensive offering of industry-leading innovative products, breakthrough technologies, value-added services and technical support makes it a total solution provider. The business is a leading distributor of CAD/CAM equipment, digital materials, removable prosthetic teeth and traditional core supplies to dental laboratories in North America. The addition of Myerson\u2019s complete digital denture system further strengthens Zahn Dental\u2019s portfolio of dental laboratory solutions that help improve its customers\u2019 production processes and enhance patient outcomes. Image Source: Zacks Investment Research Created by a team of scientists and clinicians from around the world, Trusana\u2019s patented chemistry delivers an unfilled polymer with high-impact strength and toughness. The flexural strength, modulus, fracture toughness and wear resistance of this polymer are well beyond that of conventional 3D-printed denture materials. Trusana resins won a RadTech/UVA Emerging Technology award for additive manufacturing in 2020. The Trusana Premium Denture System\u2019s innovative science and technology help dental laboratories produce final digital dentures that maintain strength and the characteristics of a traditional denture. Together, Trusana Premium 3D printing resins result in a high-quality product while helping save time, money and materials. Industry Prospects Per a Research report, the global digital dentistry market was valued at $4.2 billion in 2021 and is expected to witness a CAGR of 13.1% by 2032. Prospects of Digital Dentistry With dentistry undergoing a significant transition to integrate high-tech digital workflow systems into the dental practice, HSIC remains a favorable choice for customers who are seeking an integrated digital clinical workflow. Earlier in 2023, North American sales of digital equipment comprising 2D and 3D digital imaging, mills and intra-oral scanners returned to growth. However, sales were lower in the third quarter, which reflected a declining average selling price for intra-oral scanners as a result of new products introduced late last year. The company closed one of its larger transactions this year with Biotech Dental, adding its comprehensive, integrated suite of planning and diagnostic software to Henry Schein\u2019s portfolio of digital dental solutions and fast-growing the portfolio of implants and clear aligners. Within Henry Schein\u2019s technology and value-added service businesses, the largest contributor\u2019s, Henry Schein One, growth continues to be driven by practice management software solutions and cloud-based solutions \u2014 Dentrix Ascend and Dentally \u2014 which provide the opportunity for dental practitioners to integrate their clinical workflow. Price Performance In the past six months, HSIC shares have decreased 8.1% against the industry\u2019s rise of 1%. Zacks Rank and Key Picks Henry Schein currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Charles River (CRL) Stock Now Charles River Laboratories International, Inc. CRL is likely to grow in the coming quarters, backed by the prospects of the DSA (Discovery and Safety Assessment) segment. Service offerings of the RMS (Research Models and Services) business continue to be in high demand among the company\u2019s clients in the field of basic research and screening of non-clinical drug candidates. A stable solvent balance sheet buoys optimism. However, the company\u2019s operations are subject to the uncertain impacts of macroeconomic conditions and intense competition from other players in the industry. In the past year, this Zacks Rank #3 (Hold) stock has declined 5% compared with the 11.5% fall of the industry and a 16.8% rise of the S&P 500 composite. Operating as a full-service, early-stage contract research organization, Charles River has a market capitalization of $10.34 billion. The company has an earnings yield of 5.24% against the industry\u2019s -1.69% yield. CRL surpassed estimates in all the trailing four quarters, delivering an average earnings surprise of 8.43%. Let\u2019s delve deeper. Upsides DSA Arm Continues to Thrive: CRL is gaining from its extensive expertise in the discovery of preclinical candidates and the design, execution and reporting of safety assessment studies for numerous types of compounds, including cell and gene therapies, and small and large molecule pharmaceuticals. The demand for these services is driven by the needs of large global pharmaceutical companies that continue to transition to an outsourced drug development model, in addition to mid-size and emerging biotechnology companies, industrial and agrochemical companies and non-governmental organizations that rely on outsourcing. Image Source: Zacks Investment Research In the third quarter, the organic revenue growth of 5.3% was mainly driven by broad-based growth in the Safety Assessment business on contributions from base pricing and study volume. RMS Business Rebounds: The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Through 2023, the company has been witnessing strong growth within the insourcing solution business led by the CRADL (Charles River Accelerator and Development Labs) initiative. Global biopharmaceutical companies, small and midsized biotechs and academic and government accounts continue to make significant contributions to the growth rate. CRL is now focused on ramping up the utilization of the new sites and continuing to add new sites. This will generate a runway for continued robust revenue growth and margin enhancement opportunities for CRADL. Stable Solvency Structure: Charles River exited the third quarter of 2023 with cash and cash equivalents of $157 million compared with $200 million at the end of the second quarter. Meanwhile, the total debt was $2.51 billion compared to $2.68 billion at the end of the second quarter. Although the third quarter\u2019s total debt was much higher than the corresponding cash and cash equivalent level, the company has no short-term payable debt on its balance sheet. This is good news in terms of the company\u2019s solvency position, particularly during the economic downturn. Downsides Macroeconomic Condition: A significant chunk of Charles River\u2019s RMS and DSA revenues is generated in China. Any trade policy-related conflict between the United States and China may accordingly hamper the company\u2019s business developments in this region. Further, the Manufacturing Solutions segment is experiencing softness across broader end markets, which, according to the company, is due to a post-COVID-19 slowdown from biopharma manufacturers, CDMOs and their suppliers. These market conditions started to impact the Microbial Solutions business more noticeably in the third quarter of 2023. According to Charles River, for Microbial Solutions, the global biopharma demand environment is affecting the Endosafe endotoxin testing product line as clients are reducing both testing volumes and investments in new instruments. Competitive Landscape: Charles River competes in the marketplace based on its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in each of its three business segments. This fiercely competitiveglobal marketimpacts the company\u2019s market capitalization scenario. Estimate Trend The Zacks Consensus Estimate for CRL\u2019s earnings has moved up from $10.49 to $10.56 in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $4.10 billion, suggesting a 3.2% increase from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.3%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have decreased 1% compared with the industry\u2019s 2.2% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 36.3% compared with the industry\u2019s 2.2% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have increased 1.2% against the industry\u2019s 3.4% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \""Most Likely for Early Price Pops.\"" Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-06,117.74,119.06,116.38,117.94,"[""Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think \""Yes\"" Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. DexCom (DXCM) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy). Here are three of the most important factors that make the stock of this medical device company a great growth pick right now. Earnings Growth Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 49.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 65.2% this year, crushing the industry average, which calls for EPS growth of 11.2%. Cash Flow Growth While cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 37.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 7.7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 75.9% over the past 3-5 years versus the industry average of 7%. Promising Earnings Estimate Revisions Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for DexCom have been revising upward. The Zacks Consensus Estimate for the current year has surged 1.9% over the past month. Bottom Line DexCom has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination indicates that DexCom is a potential outperformer and a solid choice for growth investors. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio AMN Healthcare Services, Inc. AMN is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism led by a solid third-quarter 2023 performance and its healthcare Managed Services Program (MSP) are expected to contribute further. However, healthcare industry regulations and stiff competition are major downsides. Over the past year, this Zacks Rank #3 (Hold) stock has lost 40.8% compared with the 12.3% decline of the industry. The S&P 500 has witnessed 16.5% growth in the said time frame. The renowned player in the healthcare total talent services space has a market capitalization of $2.66 billion. The company\u2019s earnings yield of 11.5% compares favorably with the industry\u2019s negative yield. AMN Healthcare surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an earnings surprise of 12.7%, on average. Image Source: Zacks Investment Research Let\u2019s delve deeper. Broad Array of Services: We are upbeat about AMN Healthcare\u2019s business\u2019 gradual evolution beyond traditional healthcare staffing. The company has become a strategic total talent solutions partner for its clients. Its suite of healthcare workforce solutions includes MSPs, vendor management systems and medical language interpretation services. In November, AMN Healthcare announced the launch of ShiftWise Flex, a next-generation vendor management system that leverages advanced features and automation to empower healthcare organizations with the ability to create a financially sustainable and agile workforce. Healthcare MSP: AMN Healthcare\u2019s unique MSP is helping the company gain market traction. Notably, the program helps streamline the entire workforce planning process, which facilitates the delivery of improved patient care. This has resulted in a large network of improved patient care and efficiency. In 2022, AMN Healthcare had approximately $5.3 billion in spend under management through its MSPs, and approximately 64% of its consolidated revenues flowed through MSP relationships. Strong Q3 Results: AMN Healthcare\u2019s third-quarter 2023 performance raises our optimism. It witnessed an uptick in locum tenens revenues and Language interpretation services revenues. The gross margin expansion bodes well for the stock. Downsides Healthcare Industry Regulations: AMN Healthcare provides talent solutions and technologies on a contractual basis to its clients who pay the company directly. Accordingly, Medicare, Medicaid and insurance reimbursement policy changes generally do not directly impact the company. Nevertheless, reimbursement changes in government programs, particularly Medicare and Medicaid, can and do indirectly affect the demand and the prices paid for AMN\u2019s services. Stiff Competition: AMN Healthcare faces significant competition in the Medical Services industry. The company competes in national, regional and local markets for healthcare organization clients and healthcare professionals. In the nurse and allied healthcare staffing business, it competes with a few national competitors, along with numerous smaller, regional and local companies. Estimate Trend AMN Healthcare has been witnessing a positive estimate revision trend for 2023. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share has moved 0.2% north to $8.09. The Zacks Consensus Estimate for fourth-quarter 2023 revenues is pegged at $795.8 million, suggesting a 29.3% decline from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 39.8% compared with the industry\u2019s 4.6% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have lost 0.6% compared with the industry\u2019s 4.9% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 22% against the industry\u2019s 4.9% decline in the past year. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""DXCM Factor-Based Stock Analysis Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper \""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis\"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios Excess Returns Investing Podcast About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail Omnicell\u2019s OMCL geographic expansion and portfolio development aid growth. However, persistent inflationary pressures pose a threat to Omnicell\u2019s cost-saving actions. The stock carries a Zacks Rank #3 (Hold). Omnicell is progressing well with its three-legged strategy that covers market expansion through the delivery of differentiated, innovative solutions, expansion into new markets, primarily outside the United States, and expansion through strategic partnerships and the acquisition of new technologies. In this line, the company earlier expanded its autonomous pharmacy portfolio with the strategic and accretive acquisition of PSG's 340B Link business, now called Omnicell 340B. 340B is a significant part of an increasingly complex pharmacy supply chain, requiring solutions designed to help providers manage compliance and reporting while capturing drug cost savings. Omnicell has also accelerated a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service (formerly Omnicell One) and Central Pharmacy Dispensing Services. In the third quarter of 2023, several of OMCL\u2019s health system partners extended their sole-source agreements, including a Florida-based health system that plans to replace its existing point-of-care footprint with Omnicell XT systems. One of Georgia's largest healthcare networks has contracted for Omnicell's inventory optimization service to help strengthen its pharmacy supply chain. Omnicell, Inc. Price Omnicell, Inc. price | Omnicell, Inc. Quote In terms of its 2025 financial roadmap, Omnicell is targeting to reach 1.9 billion to 2 billion of revenues by 2025 \u2014 a 14% to 15% compounded total annual revenue growth rate from 2021 to 2025. Over the same period, it is also targeting an expansion of the non-GAAP EBITDA margin from 21% in 2021 to 25% by 2025, representing a margin expansion of approximately 400 bps. The company is well-positioned to deliver on the 2025 total revenue growth targets, driven by factors like growing its tech service revenues, the benefits of long-term sole source customer partnerships, multi-year co-development plans and increased average deal sizes. Further, given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, Omnicell has specified its second leg of strategies for expanding into new markets. In the first half of 2023, the company\u2019s international sales represented 12% of the total sales. Meanwhile, Omnicell has adopted several strategies to drive its top line, including portfolio expansion, acquisitions and further penetration in the medication adherence market. Similar to its healthcare system partners, the company\u2019s operations continue to be affected by persisting labor shortages and increased inflationary costs related to components\u2019 raw materials and freight. In the third quarter of 2023, the gross profit declined 17.1%, resulting in a year-over-year contraction in the gross margin of 152 basis points. The operating profit also decreased 79.9% compared to the third quarter of 2022. For the full year 2023, management anticipates cost-saving measures to be partially offset by year-over-year increases in compensation and vendor price increases. Omnicell\u2019s operations are subjected to continued and increased competition from current and future competitors in the medication management automation solution market and the medication adherence solution market, including price competition, industry and competitor consolidation, competitor brand recognition and in terms of relationships with suppliers and current and potential customers. This increased competition could result in pricing pressure and a reduced margin, which may have an adverse impact on the company\u2019s performance. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, DexCom DXCM and Insulet PODD. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 0.5% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared to the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 60 cents in third-quarter fiscal 2024, which surpassed the Zacks Consensus Estimate by 22.5%. The bottom line improved 57.9% on a year-over-year basis. GAAP EPS in the fiscal third quarter was 17 cents against the year-ago quarter\u2019s loss of 2 cents. Revenues in Detail In the fiscal third quarter, the company generated revenues of $249.2 million, beating the Zacks Consensus Estimate by 2.3%. The top line improved 15.3% from the prior-year quarter. HSA Details As of Oct 31, 2023, the total number of Health Savings Accounts (HSA) for which HealthEquity served as a non-bank custodian (HSA members) was 8.3 million, up 8.4% year over year. HealthEquity reported 592,000 HSAs with investments as of Oct 31, 2023, up 11.9% year over year. Total Accounts, as of Oct 31, 2023, were 15.3 million, up 5.4% year over year. This uptick included total HSAs and 6.9 million other Consumer Direct Benefits (CDBs). Total HSA assets were $22.57 billion at the end of Oct 31, 2023, up 11.7% year over year. This included $13.97 billion of HSA cash and $8.59 billion of HSA investments. This figure compares to our fiscal third-quarter HSA cash and HSA investments projection of $14.4 billion and $8.4 billion, respectively. We had projected total HSA assets of $22.8 billion in the fiscal third quarter. Client-held funds, which are deposits held on behalf of HealthEquity\u2019s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $0.76 billion as of Oct 31, 2023. Revenue Sources HealthEquity derives revenues from three sources: Service revenues, Custodial revenues and Interchange revenues. Service revenues totaled $107.5 million in the quarter, down 0.9% year over year. This figure compares to our Service revenues\u2019 fiscal third-quarter projection of $122.5 million. Custodial revenues totaled $106.6 million, up 42.8% from the year-ago period. This figure compares to our Custodial revenues\u2019 fiscal third-quarter projection of $80.7 million. Interchange revenues totaled $35.1 million, up 6.9% year over year. This figure compares to our Interchange revenues\u2019 fiscal third-quarter projection of $38 million. HealthEquity, Inc. Price, Consensus and EPS Surprise HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote Margin Details In the quarter under review, HealthEquity\u2019s gross profit rose 24.9% to $158.4 million. The gross margin expanded 485 basis points (bps) to 63.6%. We had projected 57.4% of gross margin for the fiscal third quarter. Sales and marketing expenses climbed 19.7% to $13.9 million year over year, whereas technology and development expenses climbed 13.8% to $55.6 million. General and administrative expenses also increased 4.9% year over year to $26.4 million. Adjusted operating expenses of $101.6 million increased 11.4%. Adjusted operating profit totaled $56.8 million, improving 59.5% from the prior-year quarter. Adjusted operating margin in the quarter expanded 630 bps to 22.8%. Financial Position The company exited third-quarter fiscal 2024 with cash and cash equivalents of $334.1 million compared with $290.3 million at the fiscal second-quarter end. Total debt (net of issuance costs) at the end of third-quarter fiscal 2024 was $874.3 million compared with $873.6 million at the end of the fiscal second quarter. Cumulative net cash flow from operating activities at the end of third-quarter fiscal 2024 totaled $165.8 million compared with $95.2 million in the year-ago period. FY24 Guidance HealthEquity has upped its revenue and EPS outlook for fiscal 2024. For fiscal 2024, revenues are now projected to be between $985 million and $995 million, up from the earlier projections of $980 million and $990 million. The Zacks Consensus Estimate is currently pegged at $990.3 million. Adjusted EPS is now expected to be in the range of $2.08 to $2.16, up from the prior outlook of $1.97-$2.06. The Zacks Consensus Estimate currently stands at $2.03. Our Take HealthEquity exited third-quarter fiscal 2024 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. The top line benefited from robust contributions from the majority of its revenue sources. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. The expansion of both margins also bodes well. The company raising its revenue and adjusted EPS outlook for the fiscal year raises our optimism. However, a decline in Service revenues in the reported quarter is disappointing. The continued inflationary pressure leading to higher wage inflation issues does not bode well. Zacks Rank and Other Key Picks HealthEquity currently sports a Zacks Rank #1 (Strong Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, flaunting a Zacks Rank of 1, reported third-quarter 2023 adjusted EPS of $2.85, beating the Zacks Consensus Estimate by 48.4%. Revenues of $3.12 billion outpaced the consensus mark by 3.7%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita has a long-term estimated growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.6%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2 (Buy). DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Align Technology (ALGN) Stock Now Align Technologies ALGN is well-poised for growth in the coming quarters, backed by its global expansion to address the vast untapped demand in the malocclusion space. The company launched its first subscription-based clear aligner program DSP worldwide, which looks encouraging. Mounting expenses are putting pressure on margins. Strong FX headwind impedes growth. In the past year, this Zacks Rank #3 (Hold) stock has increased 15% compared with the 9.9% rise of the industry and 16.4% growth of the S&P 500 composite. The renowned medical device company has a market capitalization of $16.83 billion. ALGN projects a long-term estimated earnings growth rate of 17.5% compared with 12.5% of the industry. Let\u2019s delve deeper. Upsides Invisalign Portfolio Expansion: Align Technology\u2019s Invisalign portfolio offers orthodontic treatment to straighten teeth without metal braces. In the third quarter of 2023, the company continued to roll out the Invisalign Comprehensive Three and Three product in APAC, where it is available in China, Hong Kong, Korea, Taiwan and India. Instead of unlimited additional aligners within five years of the treatment end date, the latest configuration offers Invisalign comprehensive treatment with three other aligners included within three years of the treatment end date. Geographic Expansion Continues: Align Technology is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America. The company also performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others. Align Technology continues to expand its business in 2023 through investments in resources, infrastructure and initiatives that drive growth in Invisalign treatment, intraoral scanners and Exocad CAD/CAM software in existing and new international markets. Strategic Alliances: Align Technology's slew of strategic alliances looks impressive. The company has well-established relationships with many DSOs, especially in the United States, and is consistently exploring collaboration with others that drive the adoption of digital dentistry. Image Source: Zacks Investment Research In the Americas, Align Technology is focused on reaching young adults as well as teens and their parents through influencer and creator-centric campaigns in 2023. It is partnering with leading smile squad creators, including Marshall Martin, Rally Shaw and Jeremy Lin. Each of these creators shared their personal experiences with Invisalign treatment and why they chose to transform their smile with Invisalign aligners. Downsides Currency Headwinds: Foreign exchange is a major headwind for Align Technology due to a considerable percentage of its revenues coming from outside the United States (in 2022, 44% of the company\u2019s consolidated revenues came from international regions). Through the first nine months of 2023, the strengthening of the U.S. dollar against nearly every other major currency hampered Align Technology\u2019s revenues in the international markets. This was mainly due to the Fed\u2019s 10 consecutive aggressive hikes in interest rates to tackle inflation since March 2022. Competitive Landscape: Align Technology faces significant competition from traditional orthodontic appliance (or wires and brackets) players such as 3M\u2019s Unitek, Danaher Corporation\u2019s Sybron Dental Specialties and Dentsply International. The company also competes with products similar to Invisalign Technology, such as the ones from Ormco Orthodontics, a division of Sybron Dental Specialties. Estimate Trend The Zacks Consensus Estimate for Align Technologies\u2019 2023 earnings per share (EPS) has dropped from $8.77 to $8.42 in the past 90 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at 3.86 billion. The projection suggests a 3.3% rise from the year-ago reported number. Other Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 EPS have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Reveals ChatGPT \""Sleeper\"" Stock One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion. As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other \""must buys.\"" Plus more. Download Free ChatGPT Stock Report Right Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-07,118.3,119.48,117.51,118.89,"[""Here's Why You Should Retain Boston Scientific (BSX) Now Boston Scientific Corporation BSX is well poised for growth in the coming quarters. It is backed by the strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX. The 2023 guidance indicating strong growth over 2022 levels builds confidence in the stock. However, unfavorable currency movements and stiff competition are a concern. In the past year, this Zacks Rank #3 (Hold) stock has gained 20.1% compared with a 4.4% fall of the industry and a 16.5% rise of the S&P 500. The renowned manufacturer of medical devices and products has a market capitalization of $80.31 billion. The company\u2019s long-term projected growth of 12.5% compares with the industry\u2019s growth projection of 11.7%. Let\u2019s delve deeper. Factors At Play Geographic Expansion Continues: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In 2022, 40% of the company\u2019s consolidated revenues came from international regions. In Europe, the Middle East and Africa (EMEA), Boston Scientific is successfully expanding its base banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand. In the third quarter, EMEA sales increased 10.9% year over year on an operational basis, with double-digit growth in seven of the company\u2019s eight business units. Across the portfolio, Boston Scientific saw strength in new and ongoing product launches, including FARAPULSE and POLARx. Long-Term Growth Strategies: In 2019, Boston Scientific provided a review of its long-term growth strategy and offered plans for product pipeline and strategic investments. In this regard, the company has recently talked about effective scaling up of its EP and WATCHMAN sales force, which is consistently resulting in strong growth. Based on the strong execution of the company\u2019s strategic priorities, Boston Scientific, during the third-quarterearnings call stated that most of its global business units are growing in line with or faster than the respective markets. WATCHMAN, a Long-Term Growth Component: Boston Scientific\u2019s structural heart programs are fast building momentum, banking on the strong performance of the WATCHMAN left atrial appendage closure device. Image Source: Zacks Investment Research In September, Boston Scientific received the FDA approval for its next generation of WATCHMAN FLX Pro. The company expects to see continued momentum within the WATCHMAN franchise supported by this approval and other significant investments in clinical evidence. In this regard, enrollment commenced in HEAL-LAA, a post-market study of the WATCHMAN FLX Pro device in the United States. Downsides Competitive Landscape: The presence of a large number of players has made the medical devices market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies. Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it is highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players, too. In 2023, the company expects an approximate 100 basis-point headwind on revenues from foreign exchange. Estimate Trend The Zacks Consensus Estimate for Boston Scientific\u2019s 2023 earnings is pegged at $2.01 per share, indicating a 17.5% increase from the 2022 reported number. The Zacks Consensus Estimate for 2023 revenues is pegged at $14.10 billion, suggesting an 11.2% rise from the 2022 figure. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain OPKO Health (OPK) Stock for Now OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in Rayaldee. The optimism led by solid third-quarter 2023 performance and few notable agreements are expected to contribute further. However, stiff competition and concerns regarding overdependence on Rayaldee persist. Over the past year, this Zacks Rank #3 (Hold) stock has gained 18.5% against the 6.2% decline of the industry. The S&P 500 has witnessed 15.2% growth in the said time frame. The renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.24 billion. It projects 8% growth for 2024 and expects to maintain its strong performance. OPKO Health\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 26.6%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Potential in Rayaldee: We are upbeat about OPKO Health\u2019s Rayaldee business. Rayaldee is the first and only therapy approved by the FDA for the treatment of secondary hyperparathyroidism in adults with stage three or four chronic kidney disease and vitamin D insufficiency. For the nine months ended Sep 30, 2023, net product revenues from sales of Rayaldee were up 19.2%. Strategic Agreements: OPKO Health has entered into a slew of agreements over the past few months. On third-quarter 2023earnings callin November, management confirmed that GLP-2 to treat short bowel syndrome is being developed into a once-daily oral form jointly with Entera. OPKO Health\u2019s management is also considering working with Entera on one of its oxyntomodulin peptides for weight loss. Strong Q3 Results: OPKO Health\u2019s better-than-expected third-quarter 2023 revenues buoy our optimism. Its confirmation that NGENLA (somatrogon) has been approved in 48 markets, including the United States, Japan, EU Member States, Canada and Australia, looks promising. Also, its continued sales by Pfizer in more than 23 countries, including all priority global markets, raises our optimism about OPKO Health. Downsides Stiff Competition: The pharmaceutical, diagnostic and laboratory testing industries are highly competitive and require an ongoing, extensive search for technological innovation. Numerous companies, including major pharmaceutical companies, specialty pharmaceutical companies and specialized biotechnology companies, are engaged in the development, manufacture and marketing of pharmaceutical products competitive with those that OPKO Health intends to commercialize itself and through its partners. Overdependence on Rayaldee: OPKO Health\u2019s Rayaldee is the company\u2019s only pharmaceutical product approved for marketing in the United States. The company\u2019s ability to generate revenues from product sales and achieve profitability substantially depends on its ability to effectively commercialize Rayaldee. The failure to successfully commercialize Rayaldee would have a material adverse effect on the company\u2019s business. Estimate Trend OPKO Health is witnessing a negative estimate revision trend for 2023. In the past 90 days, the Zacks Consensus Estimate for its loss per share has widened from 20 cents to 25 cents. The Zacks Consensus Estimate for the company\u2019s fourth-quarter 2023 revenues is pegged at $178.3 million, suggesting a 3.8% fall from the year-ago quarter\u2019s reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 39.1% compared with the industry\u2019s 3.8% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have lost 3.9% compared with the industry\u2019s 6.2% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 18.9% against the industry\u2019s 6.2% decline in the past year. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook Veeva Systems, Inc. VEEV reported adjusted earnings per share (EPS) of $1.34 in the third quarter of fiscal 2024, reflecting an uptick of 18.6% from the year-ago EPS of $1.13. Adjusted EPS surpassed the Zacks Consensus Estimate by 4.7%. GAAP EPS in the fiscal third quarter was 83 cents, up 23.9% from the year-ago period\u2019s 67 cents. Revenues For the quarter, the company\u2019s revenues totaled $616.5 million, outpacing the Zacks Consensus Estimate by 0.1%. On a year-over-year basis, the top line improved by 11.6%. The fiscal third quarter top line was driven by Veeva Systems\u2019 robust segmental performances. Segmental Details Veeva Systems derives revenues from two operating segments \u2014 Subscription services; and Professional services and other. In the fiscal third quarter, Subscription services revenues improved 12.1% from the year-ago quarter to $494.9 million. Our projection for fiscal third-quarter revenues was $493.2 million. Professional services and other revenues were up 9.8% year over year to $121.6 million, primarily resulting from continued strength in Research and Development (R&D) Solutions services and Veeva Business Consulting. Our projection for fiscal third-quarter revenues was $122.4 million. Veeva Systems Inc. Price, Consensus and EPS Surprise Veeva Systems Inc. price-consensus-eps-surprise-chart | Veeva Systems Inc. Quote Margin Details In the quarter under review, Veeva Systems\u2019 gross profit improved 12.6% to $448.8 million. The gross margin expanded 67 basis points (bps) to 72.8%. We had projected 70.7% of gross margin for the fiscal third quarter. Sales and marketing expenses rose 3% to $96.8 million. R&D expenses went up 23.8% year over year to $161.3 million, while general and administrative expenses climbed 17.8% year over year to $62.3 million. Total operating expenses of $320.3 million increased 15.6% year over year. Operating profit totaled $128.5 million, which increased 5.8% from the prior-year quarter. However, the operating margin in the fiscal third quarter contracted 114 bps to 20.8%. We had projected 18.5% of operating margin for the fiscal third quarter. Financial Position The company exited third-quarter fiscal 2024 with cash and cash equivalents and short-term investments of $3.94 billion compared with $3.87 billion at the fiscal second-quarter end. Cumulative net cash provided by operating activities at the end of third-quarter fiscal 2024 was $853.6 million compared with $717.1 million in the year-ago period. Guidance Veeva Systems has revised its financial outlook for fiscal 2024 and provided its estimates for the fourth quarter of fiscal 2024. For the fourth quarter of fiscal 2024, the company expects total revenues between $620 million and $622 million. The Zacks Consensus Estimate is currently pegged at $623 million. Subscription revenues and Professional services and other revenues are estimated to be approximately $517 million and $103 million-$105 million, respectively, in the fiscal fourth quarter. Adjusted EPS is projected to be $1.30. The Zacks Consensus Estimate is pegged at $1.26. Veeva Systems now expects revenues for fiscal 2024 between $2,353 million and $2,355 million, lowered from the earlier outlook of $2,365 million and $2,370 million. The Zacks Consensus Estimate is currently pegged at $2.36 billion. Subscription revenues are now expected to be $1,897 million, reflecting an uptick from the earlier projection of $1.895 million. This consists of Commercial Solutions\u2019 subscription revenues of around $993 million (up from the prior projection of $985 million) and R&D Solutions\u2019 subscription revenues of approximately $904 million (down from the prior projection of $910 million). Professional services and other revenues for fiscal 2024 are now expected to be between $456 million and 458 million, lowered from the earlier outlook of $470 million and $475 million. Adjusted EPS for the year is now expected to be $4.76, indicating an increase from the previous outlook of $4.68. The Zacks Consensus Estimate is pegged at $4.68. Our Take Veeva Systems exited the third quarter of fiscal 2024 with better-than-expected results. The uptick in the overall top and bottom lines and robust performances by both segments during the quarter were impressive. The company continues to benefit from its flagship Vault platform, which is encouraging. Veeva Systems\u2019 continued strength in its Commercial Solutions with new customer additions and strong win rates in Veeva CRM looked promising. Veeva Systems registered great traction in newer areas, including LIMS and Batch Release, which augurs well. The gross margin expansion bodes well. On the flip side, the rising operating costs putting pressure on the operating margin during the quarter was concerning. On theearnings call management sounded cautious about the overall macroeconomic environment as the industry continues to navigate inflation, higher interest rates, global conflicts and the Inflation Reduction Act. Management expects this to primarily impact the outlook for Veeva Systems\u2019 Professional Services business. This raises our apprehension. Zacks Rank and Key Picks Veeva Systems currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, flaunting a Zacks Rank of 1 (Strong Buy), reported third-quarter 2023 adjusted EPS of $2.85, beating the Zacks Consensus Estimate by 48.4%. Revenues of $3.12 billion outpaced the consensus mark by 3.7%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita has a long-term estimated growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.6%. DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2 (Buy). DexCom has a long-term estimated growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay Globus Medical GMED continues to gain from the surging demand for its Musculoskeletal Solutions products. However, we are worried about the challenging pricing scenario that continues to plague Globus Medical. The stock carries a Zacks Rank #3 (Hold). Globus Medical is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. The company is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. Over the past couple of quarters, this business has registered above-market growth, driven by competitive rep recruiting from prior quarters and robotic pull-through. In September 2023, Globus Medical completed the merger with NuVasive. The combined company is expected to create a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs and improving offerings to surgeons and patients. The combination capitalizes on GMED\u2019s complementary commercial organization and should allow the company to accelerate its globalization strategies to increase customer reach and strengthen surgeon relationships. Globus Medical, Inc. Price Globus Medical, Inc. price | Globus Medical, Inc. Quote According to Globus Medical, both the companies\u2019 operational footprints are highly complementary, allowing them to better leverage each other's manufacturing and supply-chain resources to increase internal production while reducing the amount of capital investment required as stand-alone. This way, they can redirect investment and improve cash flow. In line with the company\u2019s business strategy to focus on its integrated product development, Globus Medical is consistently making efforts in research and development. Per the company, its team-oriented approach, active surgeon input and demonstrated capabilities position it to maintain a rapid rate of product launches. In September 2023, Globus Medical launched the Precice Bone Transport system commercially in the targeted areas by NuVasive Specialised Orthopaedics (\u201cNSO\u201d). The most recent addition to the less intrusive NSO portfolio received CE marking and approval, and it is now offered in a few regions. Meanwhile, like other industry players, GMED is currently grappling with negative trends in the global economy, including interest rate fluctuations, increases in inflation and financial market volatility. These factors are adversely affecting the company\u2019s operations and financial performance. Global inflation, in particular, has led to a significant rise in the cost of raw materials for GMED. In the third quarter, Globus Medical incurred a 139.6% surge in the cost of goods sold. These macroeconomic factors, along with the rising wage and raw material costs, are also leading to a significant escalation in the company\u2019s operating expenses. SG&A expenses in the reported quarter were up 46.6% from the year-ago quarter. Research and development expenses increased 56.8% year over year. Further, the presence of a large number of players made the musculoskeletal device market intensely competitive. The orthopedic industry, in particular, is highly competitive with the presence of more prominent players like Zimmer Biomet, Stryker, Johnson & Johnson\u2019s DePuy, Smith & Nephew and Medtronic. Globus Medical needs to constantly introduce or acquire new products to withstand competitive pressure and maintain its market share. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have risen from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry\u2019s decline of 3.3%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have advanced 0.1% in the past year compared with the industry\u2019s decline of 4.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain National Vision (EYE) Stock Now National Vision Holdings, Inc. EYE is well-poised to grow in the coming quarters, backed by comparable store sales growth and new store sales. The ongoing execution of strategic initiatives bodes well for the company. Further, the strong liquidity supports its robust and disciplined capital allocation plan, which is highly encouraging. Meanwhile, the company\u2019s substantial reliance on vendors and other macroeconomic pressures could pose a challenge. In the past year, this Zacks Rank #3 (Hold) stock has declined 51.2% compared with the 6% fall of the industry and a 15.7% rise of the S&P 500 composite. The leading optical retailer has a market capitalization of $1.49 billion. The company projects long-term estimated earnings growth of 14.5% compared with the industry\u2019s 11.7%. National Vision surpassed estimates in three of the trailing four quarters and missed in one, delivering an earnings surprise of 48.3%, on average. Let\u2019s delve deeper. Upsides Owned & Host Gains Market Share: All four subsegments within Owned and Host are consistently gaining market share, banking on several growth drivers. These include diminishing eyesight with increasing age, causing new customers to buy corrective eyewear, and a steady and consistent replacement cycle as customers replace or purchase new eyewear for a variety of reasons, including changes in prescriptions, fashion trends and necessity. America's Best and Eyeglass World are particularly driving revenues. National Vision is deploying remote medicine technology in tandem with electronic health record technology to drive expanded capacity, enhance in-store efficiencies and improve the patient experience. The combination of these initiatives is resulting in added exam capacity in sales that the company would not have had otherwise. Per the company\u2019s third-quarter 2023 update, National Vision opened 70 new America\u2019s Best and Eyeglass World stores. Image Source: Zacks Investment Research Future Strategies Look Promising: National Vision plans to continue executing core growth initiatives and further investing in strengthening competitive advantages. In terms of store expansion, the company continues to see a sizable new opportunity with growth for many years to come. Marketing continues to be a key factor in driving traffic to National Vision\u2019s stores, given the infrequent purchase cycle for eyeglasses. Year to date, EYE has invested $82 million in capital expenditures, primarily focused on new store openings and investment in labs, distribution centers and customer-facing technology. The company\u2019s merchandising and distribution teams continue to execute well and are confident that the current inventory levels are sufficient to support continued growth in 2023. Solvency and Capital Structure: National Vision exited the third quarter of 2023 with cash and cash equivalents of $266 million and a corresponding short-term debt of $11 million. This is good news in terms of the company\u2019s solvency position. Long-term debt came up to $552 million in the third quarter compared with $555 million at the end of the second quarter. Downsides Rising Inflation Leads to Mounting Expenses: The company anticipates that pressures from increases in raw material prices could have an impact on its costs applicable to revenues in 2023. Throughout 2023, targeted wage investments, including increases in compensation for optometrists and associates, as well as flexibility initiatives, impacted costs and SG&A expenses. Wage pressures in certain markets are likely to continue for the rest of the year. Management also apprehended that wage investment pressure and increases in raw material prices in 2023 may not be able to be fully offset by leverage from revenue growth, productivity efficiency and various pricing actions. High Dependence on Vendors: National Vision procures almost all of its merchandise from domestic and international vendors. Moreover, the company has ties with a very limited number of suppliers for the majority of its eyeglass frames, eyeglass lenses and contact lenses. Thus, high dependence on a limited number of suppliers exposes it to concentration of supplier risk. In tough times, EYE may find it difficult to look for an alternative source of procurements in a timely or cost-effective manner. Estimate Trend The Zacks Consensus Estimate for National Vision\u2019s 2023 earnings per share (EPS) has moved up from 54 cents to 55 cents in the past 30 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $2.12 billion. This suggests a 5.6% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.8%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have decreased 1.9% compared with the industry\u2019s 6% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have decreased 37.6% compared with the industry\u2019s 6% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have decreased 4% compared with the industry\u2019s 6.5% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2 Tandem Diabetes Care, Inc. TNDM recently launched the updated t:slim X2 insulin pump software with Dexcom G7 Continuous Glucose Monitoring (\u201cCGM\u201d) integration in the United States. This marks the company\u2019s flagship pump platform, t:slim X2, with the Control-IQ technology, to be the only automated insulin delivery (AID) system in the world to feature Dexcom\u2019s most advanced CGM technology. Tandem Diabetes\u2019 product innovations are helping expand its reach into different customer segments of the market beyond where it operates, providing additional choices to new and existing customers to manage their diabetes. The launch of the Tandem t:slim X2 insulin pump integrated with Dexcom G7 further demonstrates the company\u2019s commitment to continued leadership in advancing AID systems. News in Detail With the integration of Dexcom G7, t:slim X2 insulin pump, users can now spend more time in a closed loop with little to no wait time between Dexcom G7 CGM sensor sessions. The users are allowed even more choices in their diabetes management, with the option of using either a Dexcom G6 or a Dexcom G7 CGM sensor. Image Source: Zacks Investment Research The Dexcom G7 sensor is 60 percent smaller than its predecessor, Dexcom G6, and offers a range of new features. Apart from being the most accurate, the new, discreet sensor is also the fastest CGM connected to the t:slim X2 pump, with a 30-minute sensor warmup time compared to two hours previously. Dexcom G7 also features a 12-hour grace period to replace the finished sensors for a more seamless transition between sessions and flexibility when changing sensors. Tandem Diabetes will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. Pre-loaded with the updated software, t:slim X2 pumps are now being shipped to new customers. Significance of the Launch The Tandem Diabetes-Dexcom collaboration has entered its 10th year, and the company is focused on sustaining the rapid pace of innovation to further its mission of helping improve the lives of people with diabetes. With the latest offering, Tandem Diabetes now provides more than 300,000 current t:slim X2 users the ability to integrate with Dexcom\u2019s most advanced CGM technology. Outside the United States, the t:slim X2 pump with Dexcom G7 integration is expected to be launched in additional countries in early 2024. Industry Prospects Per a Research report, the AID system market was valued at $749.2 million in 2022 and is expected to witness a CAGR of 9.8% by 2030. Bright Prospects of Product Innovations It has been a transitional time for Tandem Diabetes as it prepares for its next phase of growth through the expansion of its technology offerings. The company is executing several near-term product launches while implementing scalable systems and processes to support its global operations and leverage the infrastructure. Apart from G7, Tandem Mobi is also preparing for the launch of the t:slim X2 integration with the Abbott FreeStyle Libre 2 sensor. This new integrated offering is an incredible accomplishment, bringing the benefits of AID technology to Abbott's customers in the United States for the first time. In addition, Tandem Mobi is leading the way in creating a whole new category of devices for insulin therapy. The anticipation around the novel miniaturized durable pump has started to build and is already generating incredible interest among healthcare providers, people using multiple daily injections and current pumpers. Management is set to begin Mobi\u2019s scaled launch with a limited release in the fourth quarter, followed by broad availability in early 2024. Price Performance In the past six months, TNDM shares have declined 8% compared with the industry\u2019s fall of 6.2%. Zacks Rank and Key Picks Tandem Diabetes Care currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has decreased 1.9% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.85 to $1.91 in the past 30 days. Shares of the company have dropped 37.6% in the past year compared with the industry\u2019s decline of 6%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past seven days and to $1.44 in the past 30 days. Shares of the company have decreased 4% in the past year compared with the industry\u2019s decline of 6.5%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-08,118.48,119.39,116.92,116.97,"[""AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome AMN Healthcare Services, Inc. AMN recently partnered with ALTA Language Services. Through the partnership, AMN Language Services will now likely offer language proficiency testing for hospital and healthcare systems via a new platform. The platform assesses and qualifies the bilingual staffs and full-time interpreters, thus solidifying their position as the ultimate resource for comprehensive language solutions and facilitating compliance with Section 1557 of the Affordable Care Act. However, it is worth noting that ALTA Language Services is a language and cultural solutions company that provides translation, medical interpreter training and language testing services. The latest partnership is expected to strengthen AMN Healthcare\u2019s Technology and Workforce Solutions segment. Rationale Behind the Collaboration Section 1557 of the Patient Protection and Affordable Care Act, which prohibits discrimination on any basis in federally funded health programs and activities, requires that all bilingual staff be evaluated and qualified by passing an assessment before they can render care in another language besides English. For healthcare providers, compliance with Section 1557 regulations is a legal obligation and is also crucial to addressing health disparities, improving patient outcomes and enabling care without concern of miscommunication. A recent AMN Healthcare Study showed, in an analysis of 204 million minutes of patient interpretation services, that 45 different languages are cited as being among the top 10 spoken in patient and provider encounters throughout the country. This underscored the ever-increasing complexity of these encounters. The partnership will likely boost AMN Language Service's diverse portfolio of products and simplify the language procurement process for customers by providing the convenience of streamlined invoicing and a one-stop shop for language services, including translation and language proficiency testing. AMN Healthcare\u2019s management believes that the latest partnership will likely provide solutions that give patients the ability to better communicate their needs, actively participate in their care and improve their health outcomes. Per ALTA Language Services\u2019 management, both the patient and the healthcare providers are expected to benefit from the solution as it ensures compliance, reduces risks and validates practitioners' abilities to deliver medical services in languages other than English. This, in turn, will likely enhance the quality and accessibility of healthcare services for diverse patient populations. Industry Prospects Per a report by MarketsandMarkets, theglobal marketfor natural language processing in Healthcare & Life sciences is anticipated to grow from $2.7 billion in 2023 to $11.8 billion by 2028 at a CAGR of 34.4%. Factors like the focus on enhancing clinical decision support and the rapidly increasing globalization among staff are likely to drive the market. Given the market potential, the latest partnership is expected to significantly strengthen AMN Healthcare\u2019s business. Another Notable Development Last month, AMN Healthcare announced its third-quarter 2023 results, wherein it registered a solid uptick in its Language services revenues. Price Performance The stock has lost 40.2% over the past year compared with the industry\u2019s 11.7% decline. The S&P 500 has witnessed 17.3% growth in the said time frame. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, AMN Healthcare carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 42.2% compared with the industry\u2019s 5.2% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 2.1% against the industry\u2019s 2.6% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 22.4% against the industry\u2019s 2.6% decline in the past year. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS BrainsWay Ltd. BWAY has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. This latest development is expected to address the growing demand for advanced noninvasive neurostimulation treatments. The company is encouraged by the sales growth momentum over the past few quarters. According to BrainsWay, the latest extended availability of this device is projected to elevate its installed base in the country to more than 20 Deep TMS systems, marking a significant milestone in the company's global expansion. More Into the News According to BrainsWay, the expanded access to Deep TMS aligns with its goal to address mental health globally. Deep TMS, delivered through a patented coil design within a patient-friendly helmet, targets affected brain structures with a magnetic field, stimulating crucial neural networks. The technology's success in positively impacting mental health patients in South Korea underscores its effectiveness in addressing major depressive disorders, the primary indication for which it is currently cleared in the country. Image Source: Zacks Investment Research In this regard, we note that BrainsWay's commitment to superior science is evidenced by its three FDA-cleared indications, including major depressive disorders, obsessive-compulsive disorders and smoking addiction. Global Expansion in Noninvasive Neurostimulation BrainsWay plays a prominent role in advanced noninvasive neurostimulation treatments globally. With offices in Burlington, MA, and Jerusalem, Israel, the company is dedicated to increasing global awareness and access to Deep TMS. As the technology continues to make strides in South Korea, BrainsWay solidifies its role as a transformative force in mental health, poised for continued progress and impact on a global scale. Market Prospects According to a Strategic Market Research report, the global neurostimulation device market is expected to witness a CAGR of 12.8%, reaching $5.41 billion in 2022 and is projected to soar to $50.7 billion by 2030. The market is fueled by the rising awareness of mental diseases, a surge in neurological disorders and a growing aging population globally. Non-invasive treatments, the acknowledgment of neurostimulation therapies and the prevalence of chronic pain in the elderly contribute to the increasing demand for neurostimulation devices. Share Price Performance Shares of BWAY surged 206.2% in the past year against the industry\u2019s 5.8% decline. Zacks Rank and Other Key Picks BrainsWay currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2, and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has increased 3.9% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.90 to $1.91 in the past 30 days. Shares of the company have dropped 35.6% in the past year compared with the industry\u2019s decline of 5.8%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have increased 2.1% in the past year compared with the industry\u2019s decline of 5.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Brainsway Ltd. Sponsored ADR (BWAY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden Quest Diagnostics Inc. DGX has been awarded a contract by the Centers for Disease Control and Prevention (\u201cCDC\u201d) to assess the burden of hepatitis C virus (HCV) in the United States. The multi-year agreement was granted to Quest Diagnostics following a competitive bid and marks a new phase of a decade-long collaboration between Quest Diagnostics and the CDC to improve hepatitis public health research based on insights from laboratory data. Other research collaborations between Quest Diagnostics and CDC have focused on the fentanyl drug crisis and HIV, as well as COVID-19 variant tracking using the company's next-generation sequencing. In recent times, the company has formed and expanded its strategic relationships with a slew of healthcare partners. Significance of the News According to the CDC\u2019s published estimates, approximately two million Americans are infected with hepatitis C, but most are unaware that they have it. Left untreated, the disease can progress to advanced stages, including liver cancer and death. The infection in its early stages can be identified through laboratory testing, while treatment may be curative. Image Source: Zacks Investment Research In a 2020 report, the CDC recommended one-time hepatitis C testing for all individuals aged 18 years of age or older and that all pregnant women be tested for HCV during each pregnancy. Routine periodic testing is also recommended for people with ongoing risk factors. With its comprehensive offering of hepatitis screening and monitoring assays, Quest Diagnostics has the largest private laboratory database with more than 60 billion data points. The company routinely develops research, called Quest Diagnostics Diagnostics Health Trends, based on this data with the CDC and academic experts. News in Detail Under the new agreement, Quest Diagnostics will perform both HCV antibody testing and molecular RNA testing using HIPAA-deidentified \""remnant\"" specimens randomly selected from clinical test specimens. The goal is to gain a better understanding of the burden of hepatitis C infection in the United States. Quest Diagnostics and CDC\u2019s longstanding partnership highlights the importance of strategic public-private collaborations to inform public health strategy in critical health areas. The company previously worked with the CDC to analyze laboratory test results, which healthcare providers ordered for patients with suspected hepatitis infection. In 2013, the two organizations formed an agreement to jointly analyze de-identified hepatitis C testing data for \""Baby Boomers\"" or individuals born from 1945 through 1965. Since 2012, Quest Diagnostics has supported the CDC in advancing public health by providing deidentified laboratory results for hepatitis A, B, C and E. All shared laboratory test results are deidentified and HIPAA-compliant. Industry Prospects Per a Research report, the global hepatitis C market was valued at $55.1 billion in 2022 and is expected to witness a CAGR of 14.2% by 2032. Other Recent Strategic Relationships Last month, Quest Diagnostics announced a multi-year collaboration with Scipher Medicine to scale precision medicine access for patients with rheumatoid arthritis (RA). Quest Diagnostics will provide advanced RNA extraction and next-generation sequencing services for Scipher's PrismRA \u2014 regarded as a breakthrough in RA precision medicine diagnostics. The company also entered into a strategic partnership with the biotech company, Universal DX (UDX). Under the agreement, Quest Diagnostics plans to perform and provide clinical laboratory services to providers and patients in the United States based on UDX's Signal-C \u2014 an advanced colorectal cancer screening blood test, assuming the premarket approval of the test in the United States. Price Performance In the past six months, shares of DGX have increased 0.5% compared with the industry\u2019s rise of 3.2%. Zacks Rank and Key Picks Quest Diagnostics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has increased 3.9% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.90 to $1.91 in the past 30 days. Shares of the company have dropped 35.6% in the past year compared with the industry\u2019s decline of 5.8%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have increased 2.1% in the past year compared with the industry\u2019s decline of 5.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-11,117.66,118.69,115.38,117.9,"[""Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue? Shares of Integer (ITGR) have been strong performers lately, with the stock up 6.1% over the past month. The stock hit a new 52-week high of $96.55 in the previous session. Integer has gained 37.7% since the start of the year compared to the -5.9% move for the Zacks Medical sector and the -1.8% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 26, 2023, Integer reported EPS of $1.27 versus consensus estimate of $1.05. For the current fiscal year, Integer is expected to post earnings of $4.60 per share on $1.58 billion in revenues. This represents a 18.56% change in EPS on a 14.9% change in revenues. For the next fiscal year, the company is expected to earn $5.25 per share on $1.69 billion in revenues. This represents a year-over-year change of 14.2% and 6.65%, respectively. Valuation Metrics Integer may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself. On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style. Integer has a Value Score of B. The stock's Growth and Momentum Scores are C and C, respectively, giving the company a VGM Score of B. In terms of its value breakdown, the stock currently trades at 20.5X current fiscal year EPS estimates, which is not in-line with the peer industry average of 23.2X. On a trailing cash flow basis, the stock currently trades at 14X versus its peer group's average of 13.7X. Additionally, the stock has a PEG ratio of 1.3. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Integer currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integer meets the list of requirements. Thus, it seems as though Integer shares could have potential in the weeks and months to come. How Does ITGR Stack Up to the Competition? Shares of ITGR have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is DexCom, Inc. (DXCM). DXCM has a Zacks Rank of # 2 (Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of C. Earnings were strong last quarter. DexCom, Inc. beat our consensus estimate by 47.06%, and for the current fiscal year, DXCM is expected to post earnings of $1.70 per share on revenue of $3.59 billion. Shares of DexCom, Inc. have gained 17.5% over the past month, and currently trade at a forward P/E of 82.91X and a P/CF of 90.98X. The Medical - Instruments industry is in the top 25% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ITGR and DXCM, even beyond their own solid fundamental situation. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Charles River (CRL) Expands 3D In Vitro Services Via New Deal Charles River Laboratories International, Inc. CRL entered into an agreement with German biotech company, CELLphenomics. Through the partnership, Charles River clients will have access to CELLphenomics\u2019 proprietary 3D tumor model platform, PD3D, expanding Charles River\u2019s 3D in vitro testing services to further optimize oncological approaches for its clients. The recent development will fortify the company\u2019s Discovery and Safety Assessment (DSA) segment. About CELLphenomics CELLphenomics offers the world\u2019s largest collection of complex in vitro models of rare and ultra-rare tumors like sarcomas or thymomas. The service-based biotechnology company has a continuously growing biobank, comprising more than 500 complex in vitro models from more than 20 tumor entities. Image Source: Zacks Investment Research CELLphenomics has developed a custom mid-throughput screening platform that blends complex cell culture models with advanced automation and a streamlined analysis pipeline. The proprietary, precision medicine PD3D platform offers mid-throughput efficacy testing, drug combination screening, toxicity profiling, target validation, drug sensitivity correlation with clinical response and biomarker identification. News in Detail Leveraging CELLphenomics technology, Charles River will now have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types. The agreement will also give CELLphenomics access to Charles River\u2019s genomically annotated and in vivo characterized cancer model database to develop PD3D models. The database is comprised of more than 700 tumor models, including patient-derived xenografts (PDX), cell lines and cell line-derived xenografts. These models have been extensively profiled for histological features, molecular data and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumor models for preclinical anti-cancer agent testing. The biological advantages of PDX include the retention of histological and genetic characteristics of the donor tumor and the preservation of cell-autonomous heterogeneity. The merge of both biobanks will significantly increase the translational relevance of the in vitro and in vivo platforms offered by Charles River CELLphenomics. More in the News Charles River is excited about the integration of CELLphenomics\u2019 tumor model platform into the existing portfolio of products and services of the Discovery Services business. The company offers a range of cancer cell-based assays, including PDX assays and assays representing the entire tumor microenvironment. Hence, therapies are not only tested for their effect on real patient materials but also for their interaction with the human immune system. Industry Prospects Per a Research report, the global 3D cell culture market was valued at $1.42 billion in 2022 and is expected to witness a CAGR of 14.1% by 2032. Recent Development in the DSA Segment Last month, CRL and Aitia, a leader in the application of Causal AI and Digital Twins, announced a strategic partnership, which includes the co-development of PDX Digital Twins for in vivo oncology research. Through the partnership, Aitia will have access to Charles River\u2019s Artificial Intelligence (AI) powered drug solution platform, Logica, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. In September 2023, Charles River and Related Sciences announced a multi-program collaboration agreement to apply Logica across several previously undrugged targets in Retated Sciences\u2019 portfolio, including cancer immunotherapy, autoimmunity and inflammatory diseases. Price Performance Over the past six months, Charles River shares have gained 1.6% against the industry\u2019s decline of 2.7%. Zacks Rank and Key Picks Charles River currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has gained 6.3% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have remained unchanged at $1.91 in the past 30 days. Shares of the company have dropped 36.7% in the past year compared with the industry\u2019s decline of 8.1%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have fallen 2.0% in the past year compared with the industry\u2019s decline of 7.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Pet Parents Keep Spending In this podcast, Motley Fool analyst Bill Barker and host Deidre Woollard discuss: The power of Chewy's auto-ship service. If Chewy's growth is too dependent on macro trends. What factors could lead to a Dollar General turnaround. Motley Fool host Mary Long talks with Dexcom CEO Kevin Sayer about the impact of weight loss drugs on diabetes care. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video. Should you invest $1,000 in Chewy right now? Before you buy stock in Chewy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Chewy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*. See the 10 stocks *Stock Advisor returns as of December 11, 2023 This video was recorded on Dec. 07, 2023. Deidre Woollard: Are you giving your pets gifts for the holidays? You're not alone. Motley Fool Money starts now. Welcome to Motley Fool Money. I'm Deidre Woollard here with Motley Fool Analyst Bill Barker. Bill, how's it going today? Bill Barker: It's going well. Thanks. Deidre Woollard: Glad to hear it. Well, yesterday on the show, Dylan and Bill Mann, I believe, talked about people's food. We're going to start with talking about pet food with Chewy earnings, so Bill, I got to ask you, I know you have pets. I believe you have a dog. Are you a Chewy subscriber? Bill Barker: I've seen some people rave about their Chewy's experience, but I get food delivered regularly by Amazon and haven't ever given it a thought as to why would change. Deidre Woollard: Do you have a subscription with Amazon, or do you just buy food when the bowl is empty? Bill Barker: There's a subscription for some of the food and other parts of the food when the bowl is empty. One of the dogs is on prescription food right now, so I can't just get that as easily as otherwise. But it's a problem for Chewy is that there aren't enough people like me thinking about getting multiple dogs out there. They need more customers it seems like. Deidre Woollard: I think so. Well, it's interesting because you get the subscription, but you get it through Amazon and Autoship is huge for Chewy two, it's about 76% of their business according to their earnings, and I find that interesting because I have a cat who's also on prescription food and also gets prescription medicine because he's itchy, and so we have Chewy for the medicine, but not for the food. The medicine is a big part of Chewy's business as well. Seems like a bigger part. But you're right, the earnings were, they weren't great. The customer count was down by 1% That's not great. This is a pandemic darling. But what impressed me was how much money everybody continues to spend, net sales of $543 per customer up year, every year by around 14%. They're trying to grow customers, but they also are trying to keep people spending some of that is the pharmacy part. But are they putting too much faith in how much we love our pets? I don't know if you've seen those commercials that she always been running, but they make it seem we are just ready to spend everything on our animals. Bill Barker: I guess if they're betting on an increased trend in what is termed, in some places, pet humanization, then that's one way to go. They are going to run into a limit on that before running into a limit on the possibility of acquiring more customers pointed out that there was a COVID darling. I think a lot of the growth was pulled forward. There was an interpretation of the mass adoption of pets as something that was the beginning of extended period of the growth in the pet markets rather than just a pulling forward of future growth, and the stock price reflected that in 2021 and not ever since. This is a stock that's been globeredis. Reality has been delivered rather than the fantasy that was hoped for by not just owners of this stock, but a lot of others that saw changes in behavior over a short period rather than fundamental changes in behavior over a longer period. Deidre Woollard: That is one of the things that I'm asking myself about, about this stock as well, this one, and the one we'll talk about later. Not a good year for either, but one of the things I mentioned on the call was really strong Black Friday and Cyber Monday. It's gone down now since then. But this thing about people buying pets gifts, do you buy your dogs gifts? Bill Barker: No. There have been some impulse purchases at times, but I've been asked by the kids, it's so and so's birthday. What are you getting her? I just take the cat, the dog. They don't know anything about that. They just want a little more food. That's what they really want. But certainly the opportunity to buy costumes at Halloween for your pet, it doesn't seem to be a thing that the pets want. But a lot of these gifts are things that people want more than the pets want. Deidre Woollard: Well, Chewy's betting on this idea of pet parents, or paw parents, depending on who you talk to. With this idea that your pet is family and you have to treat them like family, which I don't know. I love my cat, but I'm not sure I consider myself my cat's parent. Looking at Chewy tough here in the market, as we've mentioned, part of that losses, this is what the market really didn't like, and they're still a really young company. They're still growing. They're expanding into Canada. They're working on streamlining all of their shipping and things like that. I'm wondering, do you think the market has less tolerance for a company that isn't a tech company? Because losses seem to hurt more if you're not making software, from what I can tell. Bill Barker: Well, if you're not growing that fast and you're losing money, that's a bad combination, always has been. You can defer the making money while the growth is exceptional. But when the growth becomes something that you could measure against lots and lots of other things, and ones that are making money, you suffer by comparison. When you depart the category of 20, 30% whatever it might be, annual growth, and you wander into high single digit, very low double digit, which is about as high as you might rationally predict for Chewy. At this point, the question turns to how does that stack up in terms of profits and poorly is the answer today. Deidre Woollard: Badly yes. Bill Barker: Then you're, well, who are the most likely buyers and owners of the stock? It's people who buy the story and either have just unshakable faith in management, or think there's a hiccup going on or something like that. But you're getting into fewer and fewer buyers just when you don't have either strong growth or any profitability. Now, there's future profitability, I suppose, in this company if it focuses on that. But it's still saying that it's a good growth story. Deidre Woollard: That is the interesting thing is that it was maybe being seen as less of what it is, which is, e commerce, and seeing it more as some new type of company. The question I'm asking myself about it is, were the expectations too big? Because we've seen that with a lot of the pandemic darling is that they had growth, and we just thought, oh, the sky is the limit, and then we came back to reality. It's like maybe this is a smaller business than we thought. You mentioned earlier the idea of people need to be getting more pets. I mean, that's one of the issues that is happening. Adoption rates are down. We're not getting as many pets as we did when we were all home during the pandemic, and one of the things that I think about with this company is macro pressures. You've got the pressure of people probably will continue to spend on their pets, maybe spend a little less. You know, that's a concern. The other one that I think about which is off to the side, but the idea of household formation. My theory is if rents are more expensive, maybe people are living at home longer, maybe they're not going out and on their own and then maybe you won't get pets. With all of this stuff, is Chewy just a smaller business maybe than the market really wanted it to be? Bill Barker: Certainly than what the market wanted it to be back when the stock was 5x6x. What it is today, the growth was understood to be a function of that real step up during the pandemic, and then just stretched out as people would maintain their pets and get more insurance for them, and the pets would age and they'd have more prescription medicine and everything, and there were many new pet owners and they would become lifelong pet owners. Well, some of that has played out. The pet market is bigger today than it was in 2019, but it's still digesting a lot of people that aren't going to turn out to be longer term or lifelong pet owners, or because they don't have the choice to work from home, can't maintain their pet the way they had or the way the pet wants to be cared for. There's continued digestion of the growth that occurred, and for a company that was in the high-growth category, that's a difficult thing to navigate. Deidre Woollard: True. But the thing I do love about this is those auto ship numbers. I think that's a great thing to keep watching for this company, and as long as they keep having that and they keep growing spend, hopefully, they sort out some of the other stuff and learn to cut costs a little bit. Bill Barker: People will continue to receive the food and then the food will continue to get eaten, and it is convenient to have the autoship like a subscription? It is a subscription, so that is a more stable source of revenue than otherwise. But as the numbers this quarter showed, that's not enough to produce the top line growth that the stock needed. Deidre Woollard: I want to pivot and talk about another company that reported earnings which is Dollar General. It has not been a great year for them, either, not in the market or certainly in the court of public opinion. There was a Bloomberg cover story in September about Dollar General employees saying it's a terrible place to work. But I started getting interested in this one after that I read that story. Not a great look for them. But then they brought back their former CEO, Todd Bassos, in October. I'm starting to look at this one as a turnaround. One of the things that they announced, not on this call, but before that, was that they're investing $150 million in labor hours. They're focused more on the stores, on addressing some of those customer service problems. Some of the issues with shrink that they've had. In general, you've got a CEO coming back. How long do you give them, is it like a new CEO, where you say, it's got to be a full year. But if you've got a CEO coming back, they already know the company. Do you want to see action and results a little sooner? Bill Barker: Yeah, well, I think one of the things that you're going to see, and you saw it perhaps already, is the big bath quarter where you put a lot of the bad stuff into your first quarter, maybe two quarters of results for the CEO. Some charges, assess what you can put into the past and put it into one big bundle and then start talking about the future. I think that certainly with a returning CEO, he's going to be much more tuned to exactly where the bodies are buried for this company and a very detailed knowledge of what does and doesn't work. Not only in the industry generally, but with the company specifically. It's not a function of a company that needs, I think, a new pair of eyes to look at it. An old pair of eyes had great success, left at the right time, perhaps. But you only have to go back a year to have the stock double the price that it was that it is today. Prior to the last 12 months, it was a fairly smooth 15 years for the company. I think that the odds in the market with markets betting on is a return to the past. That's a pretty good story for shareholders, whether it develops as you say. That's a question, how much time you should give. I would say just a couple of quarters, you'll see something. Deidre Woollard: Yeah, I think what you just mentioned is why I'm interested in this one, because it was a good performers, it's a good dividends, it's been a good stock and then it's had this bad year. Now it seems maybe this is like their dominoes pizza moment where they admit that hey, there's a problem. But I think one of the things that's interesting for them, so not a great quarter, same store sales down a little bit. But they're putting a lot of their energy into growth. Maybe this is part of that, get all the cost stuff out of the way, because their real estate plans are ambitious, 800 new stores, about 1,500 remodels. You think sometimes as a CEO comes in, they want to trim costs, trims the sales. This is the opposite approach, and I'm wondering if that is because Dollar General, the Dollar stores, they have this captive audience. I think maybe they figure they increased, get more people in the stores, increase quality, maybe they increase sales. Is that something we should be looking at as part of the thesis here? Bill Barker: Well, the growth here has to be put into context, 800 stores. I think they've got 15, 17,000 right now there. Deidre Woollard: Yeah, they've got a lot of stores. Bill Barker: I'll talk about the Dollar stores in general for the category there are 37,000. To put that into a bit of pointless context, you could visit one every day for 100 years and not have yet visited them all. If that were a worthwhile thing to do with your next 100 years, I've given you that idea. [laughs] There are plenty of them out there, 800 more isn't really as big a number as you might think given the installed store base already and the availability of them. But there are probably 800 reasonable locations. When you map that out over a few years. I think the remodeling is also a big part of this and I wouldn't doubt that there are, well, more than 1,500 stores that look like they could use a little remodeling out of the entire account. I think they've got plenty to do. They've got to get by these OSHA reports and the employee safety problems and fines that they have accumulated over the years and have been back in the news this year. You know what you're getting when you go into a Dollar General. But they can up the experience, if they choose to use their money that way. They've, I think, discontinued their share buybacks so they've got some more money available to dedicate to that. Up to a point which is up to the point at which the debt becomes a problem, because this is a company that has plenty of debt. Deidre Woollard: Yeah, that's a good point. When you're assessing this as a potential, turnaround, there's just a lot of factors and I'm thinking about the Dollar stores in general, a lot lately because I'm thinking about shifting consumer behavior. What could be next? We've talked so much about consumer spending. I find it interesting looking at Dollar Tree versus Dollar General, because they're both Dollar stores, but you've got a different product mix. Dollar General is so much more tied to the grocery side of things. They're really are more in rural areas. Dollar Tree is starting to think like, OK, we're moving beyond the dollar, more expensive items. Dollar General, they're doing something different. They're putting in these DG markets. Dollar General markets, more fresh food. Looks like a grocery store, but like a very small grocery store. When you're thinking about Dollar General, what do you think about as, its role in the consumer spending cycle? Bill Barker: I think more and more embedded with the consumables and the refrigerated installations. The food that has to be refrigerated, that they're selling. They're moving more toward consumer spending that does not change over time and is not particularly vulnerable to macroeconomic factors. People are going to come in frequently for their consumables, they're putting in more produce which will bring people in more often, because that's something you buy more frequently. I think it's a good plan to get people in more frequently, give them what they need most, and layer on some impulse purchases beyond that. It's very competitive. They don't have a mote. It's extremely easy wherever there's competition. Although in some rural communities are, they go to place in many others, of any greater population size, or growing population. There's going to be competition not just from Family Dollar, Dollar Tree or Walmart, slightly larger or significantly larger locations, but there's only so much you can capture before the online sales are also a threat. Their normal purchase is I think, less or around $15 per basket. That's not something that people are most frequently getting done online. How much they can grow that basket size without finding that they're running into competition from other and bigger players? I don't know. I think that's a bit of a cap. But everything up until about 12 months ago was generally successful for this company. They had, as I said, a good more than decade long, fairly smooth, story that people would love to see repeated. Deidre Woollard: Well, I feel like both of the companies we talked about today are ones that we're going to want to see next quarter and because things have to go in a direction, at least. Thanks for your time today, Bill. Bill Barker: Okay, thank you. Deidre Woollard: If you're a regular Motley Fool money listener, you're probably well aware of how dividend stocks have the potential to really supercharge your portfolio's return. Dividends have accounted for around 40% of the total return of the S&P 500 since 1930. Of course, have been an important tool for all time greats like Benjamin Graham and Warren Buffett. Our top notch analysts at Motley Fool stock advisor certainly agree and have put together a list of five quality dividend payers that are also recommendations in our stock advisor service. The report is free to you just as a thank you for listening to our podcast. No purchase necessary. Just go to Fool.com slash dividends and we'll email it directly to your inbox. That's Fool.com slash dividends to claim your five dividend stock recommendations. Now we hear a lot about how weight loss drugs have the potential to upend more unexpected industries, airlines, gyms, apparel. But how are the leaders of medical device companies thinking about these new drugs? Up next, Mary Long talks with Kevin Sayer, CEO of Dexcom, about the future of diabetes care and the small monitor that's changing what that care looks like. Mary Long: Maybe we can start by having you give us an overview of the history of diabetes care and how Dexcom came to really be a pioneer in continuous glucose monitoring. Kevin Sayer: A great question. I personally go back in diabetes care back in the mid '90s. I started my time in diabetes at many med diabetes which Medtronic bought, and is there diabetes arm right now. With diabetes care, particularly those on insulin, there's always been several problems that need to be solved. Insulin was the first big one and what a great discovery that was then how's that insulin delivered? More importantly, what information do people use to manage their diabetes health and figure out how much insulin to deliver. Over time, the way people did that in the beginning was like urine sticks and then finger sticks where people would prick their finger and you would prick your finger and get a number and say, based on that, this is how much insulin I'm going to take or what I'm going to do, which is like watching a basketball game and looking at the score in the middle of the first quarter and deciding who's going to win, it doesn't work that way. I experienced the vision or the experience of continuous glucose monitoring way back in the '90s when I was there and then had the chance to come to Dexcom. But quite honestly, the most difficult problem to solve an intensive insulin therapy is what is the information I'm going to base that decision on. What continuous glucose monitoring gives individuals is the opportunity to look at their glucose all the time. Our numbers go directly to your phone. We want to meet people where they are. They get a new glucose value every five minutes. Then we have alerts and alarms and system features that literally enabled them to be safe and more healthy than they would ever be without it. We've gone from a position, particularly with insulin users way back in the day. I've been in Dexcom now for 12 years full time. It took a long time to get somebody to get CGM to where now we're covered by all major insurance companies where the most affordable reimbursed solution there is for glucose monitoring. Most kids, if they get diagnosed with Type I diabetes now, or insulin, they leave with a Dexcom. They're not going through what everybody went through in the past. This has evolved to really become the standard of care there. We believe we have a lot more runway in other areas going forward. Mary Long: That evolution that you mentioned, I've heard you say before that part of what Dexcom is and has been doing is really building an entirely new industry. Can you explain a bit what you might mean by that? Kevin Sayer: Yeah and again, I'll go back to the beginning. In the beginning, insurance companies really didn't even want to pay for this because it looked like we're adding more costs to the system. We had to go create models to whereby we could get this reimbursed for people to use. We decided as a company that we wanted to take this technology to the phone. We were the first medical device of this nature, of this classification to go directly to a phone. When we went to a phone, all sorts of windows opened up because we enabled people to, for example, to share data with others. We rang the Nasdaq bell a couple of weeks ago and I talked to one of we had a lot of what we call our Dexcom warriors there, people who represent our company, who use our product. One was a young woman who told me a story. She's from Australia and she was asleep in a hotel room at 04:00 in the morning when people broke down her door because her blood glucose had gone low. Her friend in Australia had seen it because she followed the data on the phone, come by the hotel and saved her life. We've created situations and things of that nature to help people in their care. We've also created an industry with respect to interoperability. We share our data with other companies. We enable insulin pumps and algorithm companies to have automated insulin delivery to give people better lives. We share our data with apps with companies, nutrition based, diabetes care based, whatever. If our data can make somebody healthier, we want people to use our data where they can. Every first in our industry has been created by our company. Mary Long: Dexcom is not the only company that makes a CGM device. Your chief rivals are Abbott, which makes the Freestyle Libre and Medtronic. Those are both large like diversified medical device companies. Dexcom, does Dexcom, end of story. How does that singular focus help you and hurt you? Kevin Sayer: I consider it an asset primarily, but let me talk about how it helps us first, that singular focus means we have to be extremely clever and innovative. The list of first I came at you with earlier, going to the phone first, the first interoperate system and our level of accuracy and performance, the reimbursement we've obtained, we have to lead this industry. We can't follow the other guys. We've always prided ourselves on having the best product and that has given us a tremendous advantage over time with respect to accuracy and performance where it's difficult. The things I think about when I think about our competitors quite candidly infrastructure as we look at new geographies go into, for example, we don't have a cardiovascular business in Bulgaria, or pick a country, we have to very selectively pick where we're going to make investments and how we're going to grow international. These other geographies, because we don't have other businesses there. We have grown very methodically, very thoughtfully, very creatively, over time, internationally, and scaled our business that way. It's lack of infrastructure, but we've built it nicely. We've more than doubled the number of employees that we have in the past three years. For example, as we've built infrastructure out again while growing profitably. Mary Long: The latest iteration generation of your CGM device is the G7, and that launched earlier this year. That rollout happened all around the world at the same time. Seems like that was a success. You raise end of your [laughs] guidance after posting your most recent results and are now targeting $3.575- 3.6 billion in revenue, which is about a 23-24% year over year growth. I'd imagine that there's a lot of planning that goes into that launch and also maybe a lot of chaos. What did you learn from that experience? Maybe what will you do differently when the G8 one day comes out? Kevin Sayer: We've learned a lot of things. That's really a good question. Our G6 launch that happened five years earlier, we weren't ready for, we were literally running out of inventory almost on a monthly basis. If you ask my team. We were holding the business together. We're still growing well and we were doing fine. But it was really tough. We plan this launch much better from a supplier and a capacity perspective, and I've had no product shortages whatsoever. We also matured our development process enough to whereby we launched this product in a much more mature manner than other ones. You always have things you can improve when you launch your product. But I think the product was launched maturely and in a very good state. The other thing we learned is about our technology in general. People love our old product because it saves their life. It's been such an integral part of their care that while the other product is smaller and more accurate and reimbursed and affordable, there's emotional difficulty sometimes in switching for people. Because again, we've been front and center in their lives, people are switching out that are on the G6 system. Most of our G7 users are new to Dexcom. They're not G6 switchers. We've been able to access a lot more physicians as far as prescription, 18,000 more physicians in the US have written Dexcom scripts than had written scripts a year ago. Because the new product has so many great features with respect to a smaller size, it's ease of use. The new app is really strong and phenomenal. I think the launch has been very successful and with G8, I think what we've learned is we'll just apply those learnings. Let's make sure the product is ready. Let's make sure it's baked. Let's make sure we identify the features that people need to put into it. I think we did a very good job of identifying what our users we're going to want. Let's figure out what that next level of features is and build on that platform. Mary Long: When you think about the future of Dexcom and future iterations of G7, G8, what have you? You seem to have a really close relationship with patients, with the custom consumers that use your products. How do you source feedback from them and then incorporate that into future iterations of this device? Kevin Sayer: We continuously pulse our customers and ask for their feedback. We monitor social media very closely. The diabetes community is not quiet, they're pretty vocal. In fact, I got some great feedback when we were in New York ringing the bell. We had a dinner. We brought a lot of, again our Dexcom warriors back. We had a luncheon form. I sat at a table to get feedback from an eleven year old, a nine year old and a seven year old. And I said, OK, tell me what you would have us do better. It's really fun to ask the question and they all had really good answers. They want us to make the product last longer and we've committed to going from a end product to a fifteen day product over time. They talked about a couple things in the app they'd like to see. These kids, imagine being seven years old and having to manage taking shots every day or an insulin pump that's giving you insulin. When you ask a seven year old that question, you'd be shocked at the maturity of their answer. I'd like a different adhesive that does X, Y and Z. Okay, we can do that. We ask directly, pulse directly. We spend time with social media. Again, you talked about us being a regulated company. We also have to recognize that whatever we do is regulated and we have to make sure people are safe and it is a wind, we balance all of that. Mary Long:Weight loss drugs have been a hot topic this year. There are plenty of bearers that are saying that this is going to change every industry, not just things that are seemingly related to weight loss drugs, but even airlines are going to change their entire set up. Perhaps unsurprisingly, part of that conversation has involved diabetes companies and companies just like yours. Yet again, you posted this amazing quarter most recently. I think even cited a study that says, well, actually use of these GLP-1, these weight loss drugs, supplements and increases use of CGM products. Can you talk a bit about how you see the future of weight loss drugs interacting with your product? Kevin Sayer: Yeah and look, this drug category is amazing. The results that have been produced have been absolutely amazing. But there's never been a time when people wouldn't need CGM as a result of everything that's been learned. The thing that we talked about was data that we've garnered through very strong data sources. That people who go on these weight loss drugs, like people who have type two diabetes, who are on basal insulin, if you added GLP-1 to their therapy. If you add CGM, their outcomes are better. The outcomes of these people all get better if you add CGM to those therapies across the board, if they're on intensive insulin therapy, basal incent therapy or just somebody with type two diabetes and you add a GLP-1 to what they're already doing because it gives you a real time scorecard, you learn throughout the course of a day. For example, if you're on one of these weight loss drugs, look I can keep my glucose at a pretty steady state because I'm not eating as much. But you also learn very quickly, and a lot of us as executors of our company, we are sensors all the time without diabetes. You learn what specific meals do to your glucose and to your health. It definitely can create a better experience. It can also create better adherence to the drugs. One of the things the payers are concerned about in reimbursing for these drugs, are the patients going to comply? You can tell very quick from a CGM if somebody is complying, because you can see how steady their glucose is and how the spikes are not as big as they used to be before they were on these drugs. I think we can be a great scorecard for this. I think over time we can use the performance of our system combined with other data such as activity data, sleep data, whatever data we can incorporate into our data ecosystem and creating experience that can help people be healthier across the board. I never thought for a minute that these drugs would exclude TGM. I think we can become a vital part of it. We just have to define that, just like we've defined our place in the insulin-using world. Now, Basil's insulin. We'll define our place in this one too and I think we'll do very well. Mary Long: This takes this a step further. But our co founder David Gardner talks a lot about the importance of investing in companies that are building the future you'd like to see. In so many ways, right, Dexcom is building a better future. But ultimately, CGM devices manage diabetes rather than cure or eliminate it. So how does Dexcom fit into this futuristic world in which maybe diabetes doesn't exist? Kevin Sayer: Well, type 1 diabetes isn't going to be affected by these drugs. There could be a cure some day. There are many programs where people are trying to get cures and that would be a tremendous outcome for everybody. Let's be very clear, but at the end of all this, you're going to need a scorecard and people are going to need to see how healthy they are. Even again, if type 2 diabetes is delayed, you learn so much from wearing a CGM. You learn more from wearing a CGM about your metabolic health than almost anything you can do. We believe we can create experiences that fit right along with all of this and as somebody has pre diabetes or for example, gestational diabetes. We had a label, we can now be used in pregnancy. Well, I have grand babies that had a gestational diabetes, I have a gestational diabetes daughter in law, and she was sticking her finger for the first couple of weeks, she called me up, can you give me one of those? It made nine day difference and my twin grand babies are here largely came when they needed to come because she wore a sensor. We have a place across this healthcare spectrum and glucose state is going to be important enough that we'll figure out where to get it in. I think this noise will eventually quiet down and will be an important part of this community. Deidre Woollard: As always, people on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. I'm Deidre Woollard, thanks for listening. We'll see you tomorrow. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool\u2019s board of directors. Bill Barker has no position in any of the stocks mentioned. Deidre Woollard has positions in Amazon.com, Dollar General, and Walmart. Mary Long has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Chewy, and Walmart. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space Terumo Medical Corporation (TRUMY) recently unveiled its AZUR HydroPack Peripheral Coil System in the United States. This marks significant progress in terms of the company's global presence as a leading player in embolotherapy solutions. The coil system boasts a soft, universal-shaped platinum and hydrogel composition, which distinguishes it prominently in the peripheral coil market. Advanced Hydrogel Technology The AZUR HydroPack\u2019s hydrogel technology creates a gel core that promotes new tissue growth, a departure from traditional platinum coils. This unique feature enhances efficiency and minimizes reperfusion, thus advancing patient outcomes. According to Terumo, the coil's versatility and efficiency provide interventional radiologists and vascular surgeons with an ideal solution for diverse peripheral embolization procedures. With a .018\"" primary wind and lengths ranging from 5 to 60 cm, it is currently the longest gel core on the market, offering flexible sizing options. According to the company, the soft coil design paired with an enhanced pusher enables ease of delivery, optimized trackability and microcatheter stability. Image Source: Zacks Investment Research A Superior Solution As the market for peripheral coil embolization expands, Terumo's AZUR HydroPack stands out with its advanced design and compatibility with microcatheters. The absence of vessel-diameter sizing requirements, except for the placement of an anchor coil, reduces inventory needs. The AZUR HydroPack complements Terumo's embolotherapy portfolio, seamlessly fitting in with the AZUR CX Peripheral Coil System and AZUR Framing Coil System. Market Prospects Going by a report from Exactitude Consultancy, the embolotherapy market size is set to witness a CAGR of 8.1% from 2023 to 2030. As chronic diseases are becoming more prevalent, the market is expanding, driven by increased incidences of liver cancer and hepatocellular carcinoma. Factors such as the demand for minimally invasive procedures, higher disposable incomes and advanced technological breakthroughs contribute to market growth. Share Price Performance Shares of TRUMY have risen 10% in the past year against the industry\u2019s 7.4% decline. Zacks Rank and Key Picks Terumo carries a Zacks Rank #4 (Sell) currently. Some better-ranked stocks in the broader medical space are Insulet (PODD), Haemonetics (HAE) and DexCom (DXCM). While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Terumo Corp. (TRUMY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes QIAGEN\u2019s QGEN business has been getting a boost from its growing molecular diagnostic market, international expansion, expanded test menu and growth-driving strategic collaborations. Yet, macroeconomic headwinds impede growth. The stock currently carries a Zacks Rank #3 (Hold). QIAGEN is progressing well with its testing menu expansion strategy, which is driving the company\u2019s growth. In October 2023, QIAGEN launched the QuantiFERON-EBV RUO (Research Use Only) assay. This new addition to the QuantiFERON portfolio of assays is designed to support research into EBV infection and EBV-related malignancies. It utilizes highly specific EBV antigens to stimulate a cell-mediated immune response, offering a dynamic view of the host\u2019s active immune engagement with the virus. In September 2023, QIAGEN added two new nucleic acid extraction kits, extending its eco-friendly QIAwave product line. The two new kits are the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit, eco-friendlier versions of the RNeasy Plus Mini Kit and the All DNA/RNA Mini Kit. QIAGEN\u2019s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commercialization, marketing and distribution of certain of their existing and potential products. In October 2023, QIAGEN and Myriad Genetics collaborated to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market and providing distributable companion diagnostic test kits for theglobal market QIAGEN\u2019s NGS portfolio has been witnessing double-digit revenue growth over the past few quarters. Management aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services. It is also working on the launch of a range of new proprietary Digital NGS technology-based gene panels within the GeneReader system. QIAGEN\u2019s latest partnerships with NHS England and Element Biosciences are expected to add further growth momentum within the genomics business. QIAGEN is one of the top three providers of human identification solutions, which have included sample preparation and PCR kits. The company is now leveraging this position as it expands into next-generation sequencing-based applications with the recent acquisition of Verogen in early 2023. The acquisition is offering new ways to solve cases and bring resolution to those affected. QIAGEN N.V. Price QIAGEN N.V. price | QIAGEN N.V. Quote On the flip side, QIAGEN currently markets products in more than 100 countries. Its international operations are subject to a variety of risks arising from the economy, political outlook, language and cultural barriers in the countries it operates. In many of the emerging markets, QIAGEN faces several risks, which include economies that may be dependent on only a few products and are, therefore subject to significant fluctuations. Weak legal systems may affect its ability to enforce contractual rights and exchange controls. Unstable governments and privatization or other government actions may affect the flow of goods and currency. In the quarter under review, overall sales declined 11% at CER due to difficult year-over-year comparisons. In the year-ago quarter, the company had witnessed strong COVID-19 sales. QIAGEN records more than 50% of its revenues from the international market. As a result, it is highly exposed to the risk of foreign currency movement. The situation may worsen with the strengthening of the domestic currency against high-focus nations. Any unanticipated currency headwinds in high-focus markets may drag down the top and bottom lines further in the future. Foreign currency transactions resulted in a net loss of $9.0 million and $4.1 million in 2021 and 2020, respectively. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Medtronic (MDT) Expands AI-Driven Care With New Partnership Medtronic plc MDT entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This strategic collaboration advances the use of AI in endoscopic care and strengthens Medtronic's leadership in AI-integrated healthcare solutions. In accordance with the terms of this extended contract, Medtronic will give Cosmo an upfront payment of $100 million, in addition to a double-digit royalty on net sales that are comparable to market rates and a potential milestone payment of $100 million. The payment is anticipated to be attained by the end of 2024. Medtronic will have exclusive worldwide marketing rights, with Cosmo Pharmaceuticals being the exclusive manufacturer. More on Collaboration Through this AI-driven collaboration, GI GeniusTM's intelligent endoscopy module successes will be furthered, providing scalable healthcare improvements and ongoing innovation to patients and caregivers worldwide. With the help of this unique international collaboration, Medtronic and Cosmo Pharmaceuticals are dedicated to transforming endoscopy and utilizing AI to enhance patient outcomes. The collaboration's emphasis on cutting-edge and scalable AI platforms, such as AI AccessTM, exemplifies an innovative approach to healthcare and provides a wider range of diagnostic tools and treatment options. AI AccessTM is designed to host multiple third-party AI applications to allow for faster innovation and streamline the AI development process across medical AI applications. Strategic Efforts The expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in Medtronic's quest to use AI to improve patient care. This is in line with Medtronic's business goals of providing cutting-edge solutions to customers while also raising patient care standards in the fight against gastrointestinal illnesses. Image Source: Zacks Investment Research Medtronic and Cosmo Pharmaceuticals' expanded partnership demonstrates Cosmo's capacity to develop the GI Genius platform into a transformative force in healthcare. The continued cooperation with Medtronic, the world's leading medtech business, is critical in enabling the GI Genius platform to offer advanced AI solutions and improved clinical outcomes to patients worldwide. This relationship is expected to provide tremendous value, representing a big step forward in our journey toward healthcare innovation. Industry Prospects The company\u2019s latest move positions it well to capitalize on growth prospects in the AI market. Per a report by Grand View Research, the global AI in cancer diagnostics market size was $93.2 million in 2021 and is expected to witness a CAGR of 28.0% by 2030. Early detection of cancer is possible through the use of AI for screening and diagnosis of cancer, which is expected to boost market growth. Progress in AI-Driven Solution Medtronic\u2019s digitization is transforming the competitive landscape in the spine and with Aible, the company is leading the way. It is currently the only solution with integrated AI-based surgical planning with unit adaptive spine intelligence. Within Medtronic\u2019s Medical Surgical Portfolios, the company is gaining from the positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets. At the end of the fiscal second quarter, the company noted that adoption of Hugo remained positive, with surgeons appreciating its feature of Touch Surgery Enterprise Digital Technology. The company is progressing well to bring Hugo to the United States. Recently, the company received the FDA nod to start the U.S. Hernia indication pivotal trial for Hugo. Price Performance In the past year, MDT\u2019s shares have increased 1.6% against the industry\u2019s fall of 6.9%. Zacks Rank and Key Picks Medtronic carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook Edwards Lifesciences Corporation EW recently highlighted its strategy for longer-term growth, provided an update on its technology pipeline and shared financial guidance. The company noted that the future of TAVR remains strong, driven by greater awareness, patient activation, advances in new technologies such as RESILIA and indication expansion and increased global adoption. The PROGRESS pivotal trial is anticipated to conclude enrollment in early 2024 and is investigating the treatment of patients with moderate aortic stenosis. In 2024, the TCT Conference is anticipated to host the presentation of data from EARLY TAVR, a critical trial examining the management of individuals with severe aortic stenosis sans symptoms. Global SAPIEN 3 Ultra RESILIA acceptance is strong and early 2024 CE Mark clearance is anticipated. Within TMTT, Edwards Lifesciences stated that the EVOQUE tricuspid valve is being commercialized in Europe and U.S. certification is anticipated by mid-2024 CE. By the end of 2025, SAPIEN M3 is anticipated to be marked. The company's primary goal is to help patients live longer, healthier and more active lives by identifying and addressing important unmet needs in cardiac surgery. Edwards will keep pushing for the widespread use of INSPIRIS RESILIA, its flagship surgical aortic heart valve that is setting a new benchmark for tissue durability in 2024. EW anticipates that the global launch of its MITRIS RESILIA valve in 2024 will accelerate its leadership in surgical mitral repair. Strategic Spin-Off By the end of 2024, Edwards plans to have a tax-free spin-off of Critical Care completed. As Edwards seeks increased potential for TAVR, TMTT, and surgical patients and additional investments in interventional heart failure technology, the proposed separation will allow for a sharper focus. Image Source: Zacks Investment Research With the help of the spin-off, Critical Treatment will be able to focus better and adapt to the changing needs of millions of patients worldwide, consolidating its position as the industry leader in advanced patient monitoring and revolutionizing treatment with AI-powered smart monitoring solutions. Outlook For 2023, the company expects total sales in the range of $5.9-$6.1 billion. Adjusted EPS is expected to be in the range of $2.47-$2.53. The company also provided guidance for 2024 Total sales are expected in the range of $6.3-$6.6 billion, representing constant currency (CC) growth of 8-10%. Adjusted EPS is expected in the range of $2.70- $2.80, representing CC growth of 9%-11%. Long-Term Growth Strategy Edwards Lifesciences expects to maintain its leadership position in the global TAVR market through an increased focus on expanding patient access by actively leveraging current valve platforms for additional indications. This includes developing next-generation valve platforms and maintaining trusted relationships with clinicians, payers and regulators. With patients and clinicians increasingly preferring TAVR and based on the substantial body of compelling clinical evidence along with strong adoption of its TAVR devices, management remains optimistic about the long-term growth opportunity its transcatheter therapies offer in theglobal market Edwards Lifesciences also remains committed to aggressively investing in structural heart disease and critical care technologies. At the annual Investor Conference held in December 2022, Edwards Lifesciences upheld the global TAVR opportunity to increase to $10 billion by 2028, driven by greater awareness and advances in new technologies, as well as indication expansion and increased global adoption. Also, management projects TMTT\u2019sglobal marketopportunity to increase $5 billion by 2028. Price Performance In the past six months, Edwards Lifesciences shares has declined 19.2% compared with the industry\u2019s decline of 7.4%. Zacks Rank and Other Key Picks Edwards Lifesciences currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why You Should Retain Merit Medical (MMSI) Stock for Now Merit Medical Systems, Inc. MMSI is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by solid third-quarter 2023 performance and its continued spend on research and development (R&D) are expected to contribute further. However, headwinds due to higher consolidation in the healthcare industry and stiff competition persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 5.3% against a 7.8% rise of the industry and 16% growth of the S&P 500. The renowned medical device provider has a market capitalization of $4.03 billion. The company projects 11.5% growth for the next five years and expects to maintain its strong performance. It has delivered an earnings surprise of 14.4% for the past four quarters, on average. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strong Product Portfolio: Merit Medical has continued to gain significant momentum on the back of new products. The company is upbeat about the product pipeline, including radio and electrophysiology products, raising investors\u2019 optimism. In October, the company announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures. In September, Merit Medical announced the U.S. commercial release of its Aspira Bottle. Continued Spend on R&D: Merit Medical\u2019s R&D operations have been central to its historical growth and are believed to be critical to its continued growth. In recent years, the company\u2019s focus on innovation has led to the introduction of several new products, improvements to its existing products, and expansion of its product lines, as well as enhancements and new equipment in its R&D facilities. This raises our optimism. Strong Q3 Results: Merit Medical\u2019s robust third-quarter 2023 results buoy optimism. The company witnessed a year-over-year uptick in the top and bottom lines. The company also saw revenue growth in both its segments and across all the product categories within its Cardiovascular unit. Robust performances in the United States and outside were also registered. The expansion of both margins bodes well for the stock. Downsides Higher Consolidation in the Healthcare Industry: Healthcare costs have risen significantly over the past decade. Thus, to provide healthcare solutions at a cheaper rate and eradicate competition, large-cap MedTech behemoths have started consolidating with mid-cap and small-cap companies. This enables the availability of healthcare products at cheap prices in the market. Per management, such trends compel Merit Medical\u2019s customers to ask for price concessions on its products, which act against the ongoing business strategies. This may also exert a solid downward pressure on the prices of Merit Medical\u2019s products and reduce the customer base. Stiff Competition: Merit Medical operates in highly competitive markets, where it faces competition from many companies with greater resources. Such resources and market presence may enable the competitors to market competing products more efficiently or at reduced prices to gain market share. Estimate Trend Merit Medical is witnessing a positive estimate revision trend for 2023. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2.8% north to $2.96. The Zacks Consensus Estimate for the company\u2019s fourth-quarter 2023 revenues is pegged at $314.9 million, suggesting a 7.3% rise from the year-ago quarter\u2019s reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 43.7% compared with the industry\u2019s 5.7% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 0.2% against the industry\u2019s 6.2% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 28.4% against the industry\u2019s 6.2% decline in the past year. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""McKesson (MCK) Announces Availability of FDA-Approved Drug McKesson Corporation\u2019s MCK Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEO (nirogacestat). OGSIVEO is a gamma-secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO was approved by the FDA on Nov 27, 2023. The availability of the FDA-approved drug is expected to significantly solidify McKesson\u2019s foothold in the global desmoid tumors treatment space and boost its Specialty Pharmacy Solutions business. Significance of the Availability Per McKesson, desmoid tumors (also referred to as aggressive fibromatosis) are locally invasive and slow-growing soft tissue tumors. Although these tumors are considered benign due to their inability to metastasize, they can cause significant morbidity and, occasionally, mortality in patients. OGSIVEO is the first drug to be approved for this rare type of non-cancerous tumor. McKesson\u2019s management believes that OGSIVEO will likely provide a new therapy option for patients affected by desmoid tumors, which is a unique, rare, and sometimes unpredictable disease. Industry Prospects Per a report by Coherent Market Insights, the global desmoid tumors market was estimated to be valued at $2,494.1 million in 2022 and is anticipated to exhibit a CAGR of 7.3% between 2022 and 2023. Factors like the increasing incidences of the disease and the related demand for effective and sophisticated chemotherapeutic drugs are expected to drive the market. Given the market potential, the recent drug availability is expected to strengthen McKesson\u2019s position in the global desmoid tumors care space. Recent Developments in Specialty Pharmacy Solutions This month, McKesson announced that Biologics by McKesson was selected by AstraZeneca as a specialty pharmacy provider for TRUQAP (capivasertib). Last month, McKesson announced that Biologics by McKesson was selected by Takeda as a specialty pharmacy provider for FRUZAQLA (fruquintinib). The same month, McKesson reported its second-quarter fiscal 2024 results, wherein it recorded a solid uptick in its overall top line. The revenue uptick was primarily driven by growth in the U.S. Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail national account customers, specialty products, and GLP-1 medications. Price Performance Shares of the company have gained 21.2% in the past year compared with the industry\u2019s 7.8% rise and the S&P 500's 16% growth. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, McKesson carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 43.7% compared with the industry\u2019s 5.7% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 0.2% against the industry\u2019s 6.2% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 28.4% against the industry\u2019s 6.2% decline in the past year. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Illumina (ILMN) Expands Globally Despite Macroeconomic Woes Illumina\u2019s ILMN market opportunities continue to expand, driven by accelerated demand from clinical and larger customer transition to NovaSeq X. Yet, regulatory issues surrounding GRAIL dent growth. The stock carries a Zacks Rank #3 (Hold). Illumina is currently keeping up well with its goals to strengthen its foothold in the multi-billion gene sequencing worldwide market with some highly competitive products in its existing portfolio and pipeline. Further, the company is developing sample-to-answer solutions to catalyze adoption in the clinical setting, including in reproductive and genetic health and oncology. In reproductive health, the company primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally through technology, which identifies fetal chromosomal abnormalities by analyzing cell-free DNA in maternal blood. The market adoption of the NGS technology is also accelerating the research for rare and undiagnosed diseases to discover the genetic causes of inherited disorders by assessing many genes simultaneously. In the United States, Louisiana, Michigan, North Carolina, Rhode Island and Tennessee updated their state Medicaid coverage for NIPT in all pregnancies. Across Europe, NIPT is currently available for all pregnancies in the Netherlands and has been approved for broader coverage in Italy. This year, the company also announced a partnership with Henry Ford Health, to assess the impact of comprehensive genomic testing in cardiovascular disease, particularly in diverse and underserved populations. Illumina, Inc. Price Illumina, Inc. price | Illumina, Inc. Quote In the third quarter of 2023, clinical sequencing consumables grew 10% year over year, led by continued momentum in oncology and genetic disease testing. Illumina opened a new office and state-of-the-art Solutions Center in Bengaluru, India, to grow the genomics market in the most populous country in the world, unlocking opportunities for advancing health care and combating the effects of climate change in South Asia. The NovaSeq X launch has further strengthened Illumina's competitive position in high-throughput sequencing. The sophisticated platform includes the most comprehensive end-to-end software the company has released to date. The strong global interest in the NovaSeq X series has led to its rollout occurring at a strong magnitude and pace. During the third quarter, Illumina saw encouraging trends across both its research and clinical high-throughput customers who have a NovaSeq X installed. On both quarter-over-quarter and year-over-year basis, these customers have shown higher overall growth in sequencing output than high-throughput customers who are yet to adopt NovaSeq X. The company exited the quarter with more than 310 orders since launch, with the total installed base being 273 instruments. On the flip side, Illumina\u2019s acquisition of GRAIL remains subject to ongoing legal and regulatory proceedings in the United States and the European Union. As of Oct 1, 2023, Illumina\u2019s accrued liabilities included $458 million and also comprised related foreign currency gains. In addition, the company also remains at risk of further fines, penalties, remedies or restrictions from the European Commission, the FTC and/or other governmental or regulatory authorities. Currently, GRAIL is held and operated separately and independently from Illumina pursuant to the transitional measures ordered by the European Commission in the EC Divestment Decision, which prohibited the company\u2019s acquisition of GRAIL under the EU Merger Regulation. Other than the uncertainty surrounding GRAIL integration, these regulatory complications are raising the legal expenses for Illumina, thereby building pressure on the bottom line. Further, the current macroeconomic scenario, including the armed conflict between Russia and Ukraine, which began in 2022, and the sanctions imposed by the United States and other countries have impacted the company\u2019s ability to ship products to affected regions and customers. Furthermore, the slowdown of COVID-19 surveillance and macroeconomic factors, such as inflation, exchange rates and competitive challenges in China, have impacted both Illumina\u2019s business performance and customers\u2019 behavior. In the near term, management does not expect these headwinds to lessen. In the third quarter, total sequencing consumable revenues were also impacted by COVID-19, Russia and China factors, as well as macroeconomic conditions on customers' purchasing power and project planning. On a combined basis, the decrease in COVID-19 surveillance and the effect of sanctions in Russia represented approximately a 3.5%-point reduction in Core Illumina revenues. Over the past years, shares of ILMN have plunged 45.8% compared with the industry\u2019s 23% decline. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it delivered an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY Walgreens Boots Alliance\u2019s WBA wholly-owned subsidiary \u2014 AllianceRx Walgreens Pharmacy \u2014 will now distribute Tarsus Pharmaceuticals-manufactured XDEMVY (lotilaner ophthalmic solution) 0.25%. AllianceRx Walgreens is one of the four specialty pharmacies selected to distribute the FDA-approved treatment for Demodex blepharitis (DB), a highly prevalent eyelid disease, which impacts almost 25 million eye care patients in the United States. The addition of XDEMVY brings the specialty pharmacy\u2019s number of LDDs (Limited Distribution Drugs) to more than 240, among the highest of specialty pharmacies in the United States. Walgreens offers specialty pharmacy services, among others, through its U.S. Retail Pharmacy Segment. Significance of the Launch Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasites found on human skin. Patients can easily overlook symptoms of Demodex blepharitis due to similarities with other eye conditions like dry eye or allergies. When left untreated, Demodex blepharitis can have clinical manifestations like inflammation of the lid and conjunctiva and corneal manifestations. Image Source: Zacks Investment Research Tarsus Pharmaceuticals\u2019 novel prescription eye drop, XDEMVY, is designed to target and eradicate the Demodex mite infestation. The active ingredient in XDEMVY is lotilaner, a well-characterized agent that eradicates Demodex mites by selectively inhibiting the GABA-Cl channels. News in Detail AllianceRx Walgreens is excited to be selected as part of the network to offer Tarsus\u2019 sought-after medication for patients. Per a representative, winning access to a limited distribution drug is all about the way the company takes care of patients, supports providers and builds services around patients and therapies. Access to these medications, along with the personalized support of the company\u2019s Specialty360 Therapy Teams, are both integral to patients throughout their treatment. Apart from XDEMVY, AllianceRx Walgreens also avails a few other LDDs, including Braeburn\u2019s Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), indicated for the treatment of moderate-to-severe opioid use disorder and Genentech\u2018s Columvi (glofitamab), which treats adults with certain types of diffuse large B-cell lymphoma or large B-cell lymphoma that has come back (relapsed), or that did not respond to previous treatment (refractory), and who have received two or more prior treatments for their cancer. Also included in the list is Argenx-manufactured Vyvgart Hytrulo (efgartigimod alfa-fcab), a subcutaneous injection (delivered beneath the skin) for adults with anti-AChR antibody-positive generalized myasthenia gravis, a chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles. Industry Prospects Per a Research report, the global pharmacy market was valued at $1.01 trillion in 2020 and is expected to witness a CAGR of 4.3% up to 2028. Other Developments in the U.S. Retail Pharmacy Segment Over the past two years, Walgreens has acquired and launched new businesses in several arenas, including specialty pharmacy services, all of which build upon its strong foundation in retail pharmacy to tap into high-growth healthcare services. In the fourth quarter of fiscal 2023, U.S. Pharmacy comp sales increased 9.2%, driven by brand inflation, mix impacts and comp script growth. A weaker-than-normal respiratory season and the impact of Medicaid redeterminations have resulted in a weaker overall prescription market during the quarter. The U.S. Retail business was also impacted by a weaker-than-normal respiratory season and a continued shift in consumer behavior driven by a challenging macroeconomic environment. These factors led to a comparable sales decline of 3.3% in the fiscal fourth quarter. Last month, Walgreens launched a simple-to-use digital tool that is designed to help customers save money on prescription medications. Rx Savings Finder finds free third-party discount cards, providing patients with a quick and easy way to find lower prices on their Walgreens medications. Price Performance In the past six months, WBA shares declined 26.8% compared with the industry\u2019s fall of 2.1%. Zacks Rank and Key Picks Walgreens currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has gained 3.8% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.91 to $1.91 in the past 30 days. Shares of the company have dropped 35.3% in the past year compared with the industry\u2019s decline of 6.9%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have gained 0.1% in the past year against the industry\u2019s decline of 6.2%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Exact Sciences (EXAS) Stock Now Exact Sciences Corporation EXAS is likely to register growth in the coming quarters, led by the broad-based momentum in Cologuard adoption. The company is progressing well with its strategic prioritization, which is likely to drive the company\u2019s future growth. The raised 2023 guidance is an indication of consistent growth. Heavy dependence on the Cologuard test and operating in a highly-competitive space are a concern for the company. In the past year, this Zacks Rank #3 (Hold) stock has surged 43.9% against a 23.7% decline of the industry and a 16.2% rise of the S&P 500 composite. The renowned global medical device company has a market capitalization of $11.65 billion. The company has an expected earnings growth rate of 41.1% for the next year compared with the industry\u2019s 11.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 25.12%. Let\u2019s delve deeper. Key Drivers Strong Cologuard Adoption: The company is focusing on three areas to enhance Cologuard growth. Building the best and most effective commercial organization in healthcare by investing in the leadership team, training and sales force effectiveness is the first strategy. Secondly, improving the customer experience by making it simpler to order Cologuard electronically and continue rescreening patients every three years; and third, screening more people starting at age 45 to catch cancer earlier. In terms of the latest development, more than 9,000 new healthcare professionals ordered Cologuard during the second quarter and more than 321,000 have ordered since launch. About 75% of all US primary care physicians have ordered Cologuard. Advancing New Solutions: With regard to the third priority of advancing new solutions, Exact Sciences is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need. In August 2023, Exact Sciences presented new data confirming Exact Sciences' approach to multi-cancer early detection (MCED), real-world outcomes using the Oncotype DX Breast Recurrence Score and modeling comparisons between Cologuard and potential blood-based screening tests for colorectal cancer. Image Source: Zacks Investment Research In June 2023, Exact Sciences entered into a separate collaboration with two renowned healthcare organizations at the forefront of cancer research. The agreements aim to improve patient care by increasing access to genomic information. Raised 2023 Guidance: The company raised its 2023 revenue guidance to $2.476-$2.486 billion (from the earlier range of $2.441-$2.466 billion). The Zacks Consensus Estimate for the same is pegged at $2.26 billion. For 2023, the company expects its Screening revenues to be in the range of $1.820-$1.835 billion. The company expects Precision Oncology revenues in the range of $615-$625 million. Downsides Reliance on Cologuard Test: Exact Sciences\u2019 financial results continue to be highly vulnerable to the performance of its leading Cologuard test. Per management, its ability to generate revenues will depend very substantially on the commercial success of its Cologuard and Oncotype DX breast cancer tests for at least the next 12 months. In case the company is unable to continue to boost sales of Cologuard and Oncotype DX breast cancer tests or if it is delayed or limited in doing so, EXAS\u2019 business prospects, financial condition and results of operations will be affected. A Tough Competitive Landscape: Given the large market for colorectal cancer screening, Exact Science faces numerous competitors, some of which possess significantly greater financial and other resources and development capabilities than the company. Estimate Trend In the past 30 days, the Zacks Consensus Estimate for Exact Sciences\u2019 loss for 2023 has dropped from $1.90 per share to $1.48. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.48 billion, suggesting a 19.1% rise from the 2022 reported number. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-12,118.54,120.11,116.81,119.16,"[""Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes Myriad Genetics MYGN has been benefiting from strategic alliances and a strong product portfolio. However, rising expenses have been denting profits. The stock carries a Zacks Rank #3 (Hold) currently. As a leading name in genetic testing and precision medicine, Myriad Genetics believes that the key opportunities to grow its Oncology business are the expansion of companion diagnostics, market expansion through new clinical guidelines and new offerings. The company is looking to cash in on the vast potential in the breast cancer screening market. Also, per a report by Grand View Research on Medium, the breast cancer screening market in the United States is expected to reach roughly $6.8 billion by 2028. In the third quarter of 2023, hereditary cancer testing volumes from the oncology business rose 15% year over year, well above the estimated industry growth, reflecting an enduring franchise and improved brand reputation. Prolaris \u2014 the prostate cancer test \u2014 continued its momentum, with third-quarter revenues up 18% year over year. Myriad Genetics, Inc. Price Myriad Genetics, Inc. price | Myriad Genetics, Inc. Quote The company entered into a collaboration with Memorial Sloan Kettering Cancer Center to study the use of minimal residual disease (MRD) testing in breast cancer. The research project will use Myriad Genetics' MRD testing platform. This tumor-informed high-definition assay uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA (ctDNA). Myriad Genetics' MRD test was selected for its anticipated higher sensitivity and specificity than many other ctDNA offerings. Myriad Genetics' progress across the globe with respect to myChoiceCDx test seems impressive. The company continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test. In September 2023, Myriad Genetics announced two key milestones in its strategic partnership with Illumina. The collaboration brought together Myriad\u2019s MyChoice CDx homologous recombination deficiency technology and Illumina\u2019s expertise in comprehensive genomic profiling to broaden clinical research opportunities and drive CDx development for gene-based therapies. On the flip side, Myriad Genetics has been grappling with escalated expenses for a while. Although the company is gradually coming out of the impact of the two-and-a-half-year-long healthcare crisis, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor costs, as well as freight charges and rising interest rates, has put the medical device space in a tight spot. In the third quarter of 2023, Myriad Genetics\u2019 Research and development expenses rose 17.1% year over year to $24 million. SG&A expenses increased 4.3% to $136.1 million in the reported quarter. Myriad Genetics receives a considerable portion of its revenues and pays a portion of its expenses in foreign currencies. As a result, the company remains at risk of exchange rate fluctuations between foreign currencies and the U.S. dollar. If the dollar strengthens against foreign currencies, the translation of foreign currency-denominated transactions will result in decreased revenues, operating expenses and net income. Management fears this may not be significantly offset by increased revenues. Moreover, management does not currently utilize hedging strategies to mitigate foreign currency risk. The strengthening of the dollar has affected many U.S. companies trading in foreign currencies lately. In the year ended Dec 31, 2022, MYGN\u2019s revenues were negatively impacted by nearly $10.4 million due to foreign currency fluctuations. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has DexCom (DXCM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. DexCom is a member of the Medical sector. This group includes 1088 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for DXCM's full-year earnings has moved 16.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Our latest available data shows that DXCM has returned about 8% since the start of the calendar year. In comparison, Medical companies have returned an average of -4%. As we can see, DexCom is performing better than its sector in the calendar year. Exscientia PLC Sponsored ADR (EXAI) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.1%. The consensus estimate for Exscientia PLC Sponsored ADR's current year EPS has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #71 in the Zacks Industry Rank. This group has gained an average of 1.6% so far this year, so DXCM is performing better in this area. On the other hand, Exscientia PLC Sponsored ADR belongs to the Medical - Drugs industry. This 194-stock industry is currently ranked #71. The industry has moved -3.2% year to date. Investors with an interest in Medical stocks should continue to track DexCom and Exscientia PLC Sponsored ADR. These stocks will be looking to continue their solid performance. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Exscientia PLC Sponsored ADR (EXAI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Integra (IART) to Advance ENT Division With New Buyout Deal Integra Lifesciences Corporation IART signed a definitive agreement to acquire Acclarent for $275 million in cash at closure. The is subject to normal acquisition price adjustments and an additional $5 million upon the completion of specific regulatory milestones from Johnson & Johnson MedTech firm Ethicon. It is worth mentioning that Integra will be among the top suppliers of ENT products and technologies following closure. Acclarent is a leading player in ENT procedures. Financial Details After the acquisition closes, Integra anticipates providing comprehensive guidance on its financial effects. It is anticipated that the transaction will be concluded by the second quarter of 2024, subject to usual closing conditions and regulatory clearances. Transition services, including transition manufacturing services, will be offered for a maximum of four years after the closing. Significance of the Acquisition The transaction will be integrated into Integra's Codman Specialty Surgical (CSS) business unit. The neurosurgery section is greatly enhanced by the ear, nose and throat (ENT) category, which is a crucial area of strategic importance. This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. The ENT segment is an anatomical adjacency to neurosurgery. The acquisition will offer opportunities for ENT and neurosurgeons to collaborate closely on tumor care using skull base approaches. Image Source: Zacks Investment Research The acquisition offers a unique chance to expand and take the lead in the desirable ENT device market thanks to Acclarent's well-established commercial scale, well-known brand, distinctive portfolio and active innovation pipeline. Industry Prospects Per a report by Grand View Research, the global ENT devices market size was valued at USD 23.0 billion in 2022 and is expected to witness a CAGR of 5.74% from 2023 to 2030. Increasing penetration of minimally invasive ENT procedures, growing prevalence of ENT-related disorders and rising geriatric population are key trends stimulating market growth. Technological advancements also play an important role in the market\u2019s growth. Progress Within the CSS Arm Integra sees healthy demand for its industry-leading products within Codman Specialty Surgical (CSS). The segment is benefiting from growing market acceptance of the company\u2019s global neurosurgery line-ups, including CSS management and neuromonitoring. Within CSS management, Integra is experiencing growth banking on strong market adoption of programmable valves and advanced energy (key revenue-generating products are CUSA Capital, Mayfield, DuraGen, Certas Plus programmable valves, Bactiseal catheters and instruments). The company expanded the international reach of the CUSA platform and registered DuraGen, DuraSeal, Mayfield and Duo LED lighting in EMEA and Latin America. The company also launched DuraGen Plus in China. In CereLink, Integra made progress on resolving the electrical interference issue in its monitors and relaunched it in the international market in the third quarter of 2023. The company also filed an updated 510(k) in the United States in mid-September, with an expected launch of the product early in the first quarter of 2024. Overall, the CSS arm is expected to witness a revenue CAGR of 6.9% from 2021 through 2025. Price Performance In the past year, IART\u2019s shares have declined 24.5% compared with the industry\u2019s fall of 2.5%. Zacks Rank and Key Picks Integra carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Tandem Diabetes (TNDM) Avails Tandem Source in the United States Tandem Diabetes Care, Inc. TNDM recently announced the full U.S. launch of its diabetes management platform, Tandem Source. The global data management application targets clinicians and expands the capabilities of the Tandem Diabetes\u2019 t:connect data management application available for customers in the United States. The innovation enhances clinical data visualization and provides added interface customization for health care providers (HCPs) to manage their patient's care better, whether remotely or in person. The platform is available for all Tandem pump users and their HCPs in the United States, with international availability expected in 2024. News in Detail Tandem Source is designed to integrate the features of Tandem\u2019s legacy t:connect, t:connect HCP and t:connect Portal offerings with new comprehensive data reporting in one central, scalable platform. The company began a scaled global launch of Tandem Source earlier in the second quarter of 2023. Feedback from the early adopters of the application in the United States has been overwhelmingly positive. Image Source: Zacks Investment Research The platform provides access to important therapy data and introduces convenient ways for pump users to reorder supplies and update their pump software. For HCPs, Tandem Source provides the tools necessary to seamlessly view critical patient data, identify trends and help their patients better manage their diabetes. Both HCPs and pump users also have access to three new Tandem Source reports in the platform. Tandem Source features a new web-based pump uploader that offers faster data transfers to the cloud with no computer software to install or update. It automatically transfers data from users\u2019 pumps using the t:connect mobile app, keeps online data current and removes the need for manual pump uploads. Tandem Source offers three easy-to-use reports that consolidate all the information required for HCPs to make impactful clinical recommendations. Industry Prospects Per a Research report, the AID system market was valued at $749.2 million in 2022 and is expected to witness a CAGR of 9.8% by 2030. Other Notable Highlights It has been a transitional time for Tandem Diabetes, preparing for the next phase of growth through an innovative portfolio that reduces the burden of diabetes management. The company is executing multiple near-term product launches while implementing scalable systems and processes to support its global operations and leverage the infrastructure. Last week, TNDM introduced the highly-anticipated t:slim X2 insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States. The company\u2019s number-one rated automated insulin delivery (AID) system with Control-IQ technology is the only AID option in the world today to use Dexcom\u2019s most advanced CGM technology. In July 2023, Tandem Mobi, distinguished as the world\u2019s smallest durable AID system, received FDA clearance. Mobi sets a new paradigm with the features of multiple wearability options, detachable infusion sets and the discretion of its mobile app operation. A limited release of Tandem Mobi is expected to start in late 2023, with full commercial availability planned for early 2024. Price Performance In the past six months, TNDM\u2019s shares have declined 6.6% compared with the industry\u2019s fall of 9.5%. Zacks Rank and Key Picks Tandem Diabetes Care currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019stock has increased 13.9% in the past year. Earnings estimates for Haemoneticshave increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.80 to $1.91 in the past 30 days. Shares of the company have dropped 33.6% in the past year compared with the industry\u2019s decline of 6%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.43 to $1.44 in the past 30 days. Shares of the company have increased 5.3% in the past year against the industry\u2019s decline of 2.5%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""IWP, APO, DXCM, IDXX: Large Inflows Detected at ETF Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Mid-Cap Growth ETF (Symbol: IWP) where we have detected an approximate $173.8 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 136,650,000 to 138,350,000). Among the largest underlying components of IWP, in trading today Apollo Global Management Inc (new (Symbol: APO) is off about 0.8%, DexCom Inc (Symbol: DXCM) is up about 2.7%, and Idexx Laboratories, Inc. (Symbol: IDXX) is up by about 0.1%. For a complete list of holdings, visit the IWP Holdings page \u00bb The chart below shows the one year price performance of IWP, versus its 200 day moving average: Looking at the chart above, IWP's low point in its 52 week range is $81.975 per share, with $103.93 as the 52 week high point \u2014 that compares with a last trade of $103.40. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average \u00bb. Free Report: Top 8%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows \u00bb Also see: \u0095 Live Ventures Historical Earnings \u0095 Funds Holding EXFO \u0095 RALS YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Boston Scientific (BSX) Hits 52-Week High: What's Aiding It? Shares of Boston Scientific Corporation BSX scaled a new 52-week high of $56.55 on Dec 13, before closing the session marginally lower at $56.48. Over the past year, this Zacks Rank #3 (Hold) stock has gained 21.9% against a 4.1% decline of the industry. The S&P 500 has witnessed 19.7% growth in the said time frame. Over the past five years, the company registered earnings growth of 5.9% compared with the industry\u2019s 7.4% rise. The company\u2019s long-term expected growth rate of 12.5% compares with the industry\u2019s growth projection of 11.8%. Boston Scientific\u2019s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 4.3%. Boston Scientific is witnessing an upward trend in its stock price, prompted by its impressive market share gain in the MedSurg segment. The optimism led by a solid third-quarter 2023 performance and continued geographical expansion are expected to contribute further. However, a competitive landscape and exposure to currency movement continue to concern the company. Image Source: Zacks Investment Research Let\u2019s delve deeper. Key Growth Drivers Geographic Expansion: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States, raising investors\u2019 optimism. Within its international regions, the company is putting additional efforts to expand its foothold in emerging markets, which are holding strong growth potentials based on their economic conditions, healthcare sectors, and global capabilities. In the third quarter of 2023, despite the ongoing weaknesses in Russia, emerging markets registered sturdy growth, primarily banking on strong performance in China. During this period, emerging markets net sales grew 19% on an operational basis, year over year. MedSurg Market Share Gain Impressive: Investors are upbeat about Boston Scientific\u2019s consistent fast recovery within its MedSurg segment following the pandemic-led mayhem. The Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options. In third-quarter 2023, the company reported strong organic growth contributions from single-use imaging and AXIOS technologies. Endoscopy demonstrated notable strength in the United States, Latin America and Asia-Pacific, with new product momentum and healthy procedure demand during the third quarter. Strong Q3 Results: Boston Scientific\u2019s robust third-quarter 2023 results raise optimism. The company registered a strong year-over-year improvement in organic sales, indicating a solid rebound in the legacy business even amid several macroeconomic issues. Organic and operational revenues at its core business segments and geographies were also up in the reported quarter. Downsides Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players too. Competitive Landscape: The presence of a large number of players has made the medical devices market highly competitive. The company participates in several markets, including Cardiovascular, Cardiac Rhythm Management, Endosurgery and Neuromodulation, where it faces competition from large and well-capitalized companies, apart from several other smaller companies. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, HealthEquity, Inc. HQY and DexCom, Inc. DXCM. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 49.1% compared with the industry\u2019s 7.8% rise in the past year. HealthEquity, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 27.5%. HQY\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 16.5%. HealthEquity has gained 9.4% against the industry\u2019s 9.1% decline over the past year. DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 5.2% against the industry\u2019s 2.5% decline in the past year. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Glaukos (GKOS) Stock for Now Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have rallied 36.6% year to date against the industry\u2019s 5.4% decline. The S&P 500 Index has also increased 16.6% in the same time frame. Glaukos, with a market capitalization of $3.05 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 8.3% for 2024 and anticipates to maintain its strong performance in terms of revenues. The company has an average four-quarter earnings surprise of 5.72%. Image Source: Zacks Investment Research Key Catalysts Glaukos\u2019 sales returned to growth following a declining trend in 2022, reflecting an improving macro environment coupled with the launch of several new products in the past few quarters. Continued strong demand across international Glaucoma and Corneal Health franchises will be the key top-line in 2024. Moreover, the commercial launch of iStent infinite in 2023 is boosting the U.S. glaucoma franchise, which will drive growth in the upcoming few quarters. The company\u2019s raised outlook for revenues on its third-quarterearnings calllooks promising. Meanwhile, the new local coverage determinations proposed in June 2023 are likely to remove certain ophthalmic goniotomy and canaloplasty procedures from coverage. This will likely have a positive impact on the iStent business. GKOS has launched several products like iPrime, iAccess and iStent in the past few quarters, which are aiding its revenue growth. The company has been focused on delivering improved outcomes for patients suffering from chronic eye diseases. It does so by continuing to develop a pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care. One of the advanced pipeline candidates, iDose TR, has been successfully tested in a phase III study. Glaukos filed a new drug application with the FDA in February and a decision regarding the same is expected later this year. The company stated that the targeted population is 3 million in the United States every year. A potential approval for the candidate will substantially boost Glaukos\u2019 revenues. Per top-line data from two pivotal studies, GKOS announced that its targeted injectable implant candidate, iDose TR, for glaucoma patients,achieved excellent tolerability and a favorable safety profile last year. The candidate achieved non-inferior reductions in intraocular pressure in three months from its baseline compared with the timolol ophthalmic solution. What\u2019s Hurting GKOS? Glaukos\u2019 competitors include medical companies, academic and research institutions, as well as others that develop new drugs, therapies, medical devices or surgical procedures to treat glaucoma. Thus, intense competition continues to weigh on the company\u2019s overall performance. Moreover, the U.S. Centers for Medicare & Medicaid Services significantly reduced physician payment rates in 2022, which led to lower U.S. Glaucoma sales volume in the year. With no significant change in payment rates in 2023, the impact continued through the year and will continue to adversely impact sales in the last quarter. Estimate Trend The bottom-line estimate for GKOS is pegged at a loss of $2.20 per share for 2023, 0.9% wider than the previous year\u2019s reported loss of $2.18. The Zacks Consensus Estimate for 2023 revenues is pinned at $308.47 million, indicating growth of 9.1% from that recorded in the previous year. Glaukos Corporation Price Glaukos Corporation price | Glaukos Corporation Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Retain Baxter International (BAX) in Your Portfolio Baxter International BAX is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern. Shares of this Zacks Rank #3 (Hold) company have lost 28% year to date compared with the industry's 6.3% decline. The S&P 500 Index has increased 16.6% in the same time frame. BAX, with a market capitalization of $18.61 billion, is a global medical technology company providing items such as kidney-dialysis equipment, infusion pumps and intravenous solutions. The company has an earnings yield of 7.1% compared with the industry's (1.8%). It anticipates earnings to improve 5.2% over the next five years. Image Source: Zacks Investment Research What's Driving the Performance? Baxter Internationalended third-quarter 2023 with an improvement in both earnings and revenues. Sales across all product categories were strong except for a decline in the Care & Connectivity Solutions category, led by lower rental revenues and hospital capital spending. The company expects the demand for its medically essential products to continue amid stabilizing macroeconomic conditions and the healthcare marketplace. BAX stated that the ongoing transformational actions, announced earlier this year, will likely boost its performance going forward. The transformational actions, which include realigning its businesses and operations into four vertically integrated global business segments, are likely to be completed by July 2024. Baxter Internationalis also progressing with the proposed spin-off of its Kidney Care segment, comprising of Renal Care and Acute Therapies product categories, into an independent, publicly traded company. This is also a part of BAX\u2019s transformational actions. On its third-quarterearnings call Baxter Internationalannounced that it completed the divestment of its BioPharma Solutions (BPS) business at the end of the third quarter. In May, it had signed an agreement to divest the business for $4.25 billion. As part of its transformation, BAX established its new operating model, integrating the prior matrixed structure of its nine businesses operating across three geographic regions into the aforementioned four verticalized global segments. The company started reporting under a new model, beginning third-quarter 2023. Revenues from continued operations totaled $3.71 billion in the third quarter, up 3% on a reported basis and 4% organically. Notable Developments In June, Baxter Internationalannounced the U.S. launch of its new Hillrom Progressa+ bed for the intensive care unit. Progressa+, which offers new technology and features, has been designed to make it easier for nurses to care for patients and support patient recovery. What's Weighing on the Stock? Although recovering, the company continues to face pressure for services related to hospital admissions and procedural volumes. Supply-chain disruptions continue to hurt growth albeit slowly compared with the last few quarters. Lower rental revenues and reduced hospital capital spending continue to impact top-line growth. A decline in sales in China due to the implementation of value-based procurement initiatives is likely to continue in the country. Although gross profit improved 1%, operating profit declined 4.9% year over year in the third quarter, reflecting inflationary pressure. Both gross and operating margins contracted during the same time frame. Estimates Trend The Zacks Consensus Estimate for 2023 revenues is pegged at $14.75 billion, indicating a 2.4% decline from the previous year\u2019s level. However, revenues are likely to witness an estimated growth rate of 4% in 2024. The consensus mark for adjusted EPS is pinned at $2.60, indicating a 25.7% decrease from the year-ago reported number. The consensus estimate for adjusted EPS has improved 1.2% in the past 30 days. However, EPS is likely to witness an estimated growth rate of 14.5% in 2024. Baxter International Inc. Price Baxter International Inc. price | Baxter International Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. The New Gold Rush: How Lithium Batteries Will Make Millionaires As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%. Download the brand-new FREE report revealing 5 EV battery stocks set to soar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Thermo Fisher (TMO) Launches New Solutions for Clinical Labs Thermo Fisher Scientific TMO introduced new sample preparation solutions to simplify and automate respiratory diagnostic testing. The company launched the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens. The recent development will further strengthen the company\u2019s Life Science Solutions segment. About Thermo Scientific KingFisher Apex Dx Clinical laboratories that perform respiratory testing need to generate the highest quality results. To meet their needs, the high-throughput, versatile KingFisher Apex Dx system enables scientists\u2019 labs to recover quality nucleic acids for sensitive downstream applications with maximum consistency, reproducibility, and reliability. The system is designed to be part of a modular sample preparation to real-time PCR analysis workflow, providing precise results, accurate data management and robust security features that meet cybersecurity and diagnostic regulatory standards. Image Source: Zacks Investment Research The KingFisher Apex Dx system automates the extraction of up to 24 or 96 DNA, RNA, protein, or cell samples and transitions from clinical research to diagnostics by offering research use only and IVD software modes. It can be integrated with a Laboratory Information Management System or Laboratory Information System via Diomni Enterprise Software for enhanced data management and workflow optimization. About Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit The MagMAX Dx Viral/Pathogen NA Isolation kit offers advanced formulation to ensure reproducible results and is automation-compatible with the KingFisher Apex Dx. The solution offers a new advanced formulation to maximize nucleic acid yield from routinely tested respiratory pathogens such as S. aureus, M. tuberculosis, influenza, RSV and SARS-CoV-2. This kit also helps laboratories meet greener policies with REACH-compliant components and responsibly sourced packaging. Currently, the kit is available in in North America and coming soon to other regions. More on the News The KingFisher Apex Dx system builds on decades of product expertise and innovations, which have placed customers\u2019 trust in the KingFisher instrument line. Per Thermo Fisher\u2019s representative, the combination of the Apex Dx system and the MagMAX Dx Viral/Pathogen NA Isolation Kit further simplifies sample preparation for clinical labs so they can have confidence in downstream results when testing for respiratory diseases. Together, these products provide laboratories with an in vitro diagnostic and in vitro diagnostic regulation approved automated sample preparation solutions for increased confidence in downstream results. Industry Prospects Per a Research report, the global life science tools market was valued at $144.1 billion in 2022 and is expected to witness a CAGR of 10.8% in the 2023-2030 period. Recent Highlights in the Life Science Solutions Segment Last month, Thermo Fisher and Flagship Pioneering expanded their ongoing strategic partnership to develop and commercially scale multi-product platforms on an accelerated basis. Together, the companies aim to create a new platform focused on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies. Price Performance In the past six months, TMO shares have decreased 5.9% compared with the industry\u2019s fall of 9.1%. Zacks Rank and Key Picks Thermo Fisher currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has gained 4.1% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have remained unchanged at $1.91 in the past 30 days. Shares of the company have dropped 37.7% in the past year compared with the industry\u2019s decline of 8.1%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have decreased 1.4% in the past year compared with the industry\u2019s decline of 7.7%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Add Cardinal Health (CAH) to Your Portfolio Now Cardinal Health Inc. CAH is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern. Shares of this Zacks Rank #2 (Buy) company have risen 39.2% year to date compared with the industry's 7.7% growth. The S&P 500 Index has increased 20.7% in the same time frame. CAH, with a market capitalization of $22.35 billion, is a nationwide drug distributor and service provider to pharmacies, healthcare providers and manufacturers. The company has an earnings yield of 7.3% compared with the industry's 4.7%. It anticipates earnings to improve 14.3% over the next five years. Image Source: Zacks Investment Research What's Driving CAH\u2019s Performance? Diversified Product Portfolio: Investors are upbeat about Cardinal Health\u2019s Medical and Pharmaceutical offerings, which provide the company with a competitive edge in the niche space. This month, the company announced the U.S. launch of its SmartGown EDGE Breathable Surgical Gown with ASSIST Instrument Pockets to provide surgical teams with safe and convenient instrument access in the operating room. In September, Cardinal Health announced the U.S. launch of its Kangaroo OMNI Enteral Feeding Pump, designed to help provide enteral feeding patients with more options to meet their personalized needs throughout their enteral feeding journey. Distribution Centers: Investors are optimistic about Cardinal Health\u2019s opening of a few distribution centers in strategic areas over the past few months. This month, the company announced its plans to build a new distribution center in Greenville, SC, to support its at-Home Solutions business, a home healthcare medical supplies provider serving people with chronic and serious health conditions in the United States. In May, Cardinal Health Canada announced its plans to open a new distribution center in the Greater Toronto Area, thus expanding its distribution footprint to better meet the medical and surgical product demands of the Canadian healthcare system. Strong Q1 Results: Cardinal Health\u2019s impressive first-quarter fiscal 2024 results buoy optimism. The company\u2019s robust top-line results and solid performance in the Pharmaceutical segment were encouraging. Per management, the segmental performance was driven by brand and specialty pharmaceutical sales growth from existing customers. Notable Developments In November, CAH announced the launch of SmartGown EDGE Breathable Surgical Gown with ASSIST Instrument Pockets in the United States. The new surgical gown will provide surgical teams with safe and convenient instrument access in the operating room. In September, the company announced the launch of its next-generation Kangaroo OMNI enteral feeding pump in the country. The new pump\u2019s design will provide more options to patients to meet their personalized needs for enteral feeding. Per CAH, the Kangaroo OMNI is the first and only attitude-independent enteral feeding system launched so far in the United States. The device is designed for portability with an option for delivery of a wider variety of enteral formulas. The new pump has a familiar user interface to the earlier Kangaroo pumps. This should help facilitate a smooth transition for patients as well as caregivers across hospital and home-based care. What's Weighing on the Stock? The company continues to face high costs to support sales as well as rising operating expenses. Although there is an improving trend for costs and expenses, these are likely to hurt margins in fiscal 2024, especially in the first half. Meanwhile, rising interest rates are a key area of concern amid high Capex plans. In the first quarter of fiscal 2023, gross margin remained flat year over year. This implies that rising costs are being offset by cost-saving initiatives. Cardinal Health\u2019s Monoject syringes get unfavorable FDA recommendations following reports of delay in therapy as well as inaccurate therapy (overdose or underdose) when used with a syringe pump or a patient-controlled analgesia pump. Any further regulatory setback may raise concerns. Estimates Trend The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $226.17 billion, indicating a 10.3% improvement from the previous year\u2019s level. The same for adjusted EPS is pinned at $6.89, indicating a 19% increase from the year-ago reported number. The consensus estimate for adjusted EPS has improved 1.2% in the past 60 days. Cardinal Health, Inc. Price Cardinal Health, Inc. price | Cardinal Health, Inc. Quote Other Stocks to Consider Some other top-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Masimo's (MASI) ORi Favored by Study for PaO2 Information Masimo Corporation MASI recently announced the findings of a retrospective study in which researchers assessed the association between Masimo ORi (Oxygen Reserve Index) and the arterial partial pressure of oxygen (PaO2) in patients who underwent non-cardiac thoracic surgery during one-lung ventilation (OLV). The findings were published in the Journal of Anesthesia. In the United States, ORi has been granted a De Novo by the FDA to be used in patients undergoing surgery as an adjunct to SpO2 for increased monitoring resolution of elevated hemoglobin oxygen saturation levels. The ORi feature is indicated for the monitoring of hemoglobin oxygen saturation levels in patients 18 years and above on supplemental oxygen during no-motion conditions perioperatively in hospital environments. The latest study demonstrating a significant correlation between the two parameters during OLV is a major stepping stone for Masimo\u2019s real-time patient monitoring business and is likely to solidify its position in the niche space on a global scale. Significance of the Study The researchers noted the importance of striving to prevent hyperoxemia and hypoxemia, especially during surgery requiring OLV, due to the risk of pulmonary complications. Hence, they sought to evaluate a non-invasive, continuous method of predicting imminent over- or under-oxygenation to overcome the drawbacks of invasive blood gas analysis alone, using Masimo ORi. The researchers found that ORi values were significantly correlated with PaO2 measured simultaneously. They also concluded that ORi could provide useful information on arterial oxygenation even during OLV. ORi is expected to provide clinicians with additional visibility, as a complement to SpO2 monitoring with Masimo SET pulse oximetry, into when oxygenation is increased into, or decreased out of, moderate hyperoxia in real time. Hyperoxia is a state of excess supply of oxygen in tissues and organs. Industry Prospects Per a report by Mordor Intelligence, the global patient monitoring market is anticipated to reach from $43,808.29 million in 2023 to $62,571.34 million by 2028 at a CAGR of approximately 7.4%. Factors like the rising burden of chronic diseases due to lifestyle changes, growth in the elderly population, increasing preference for home and remote monitoring and the ease of use of portable devices are expected to drive the market. Given the market potential, the latest study outcome is likely to provide a significant boost to Masimo\u2019s business. Recent Developments Last month, Masimo announced the receipt of the FDA\u2019s 510(k) clearance for over-the-counter and prescription use of the Masimo W1 medical watch. The same month, Masimo announced a joint agreement with GE HealthCare. The collaboration is expected to integrate Masimo SET pulse oximetry into GE HealthCare\u2019s Portrait Mobile wireless and wearable patient monitoring solution. Also, in November, Masimo reported its third-quarter 2023 results. Per management, its healthcare business is transitioning away from COVID-era conditions. Also, management is beginning to see customer behavior and sensor purchasing patterns shifting back to the pre-pandemic growth trend line. Price Performance Shares of Masimo have lost 32% in the past year compared with the industry\u2019s 6.9% decline. The S&P 500 has witnessed 15.5% growth in the said time frame. Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider Currently, Masimo carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 42.5% compared with the industry\u2019s 4.6% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have lost 1.4% compared with the industry\u2019s 6.9% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 31.4% against the industry\u2019s 6.9% decline in the past year. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why Investors Should Retain ResMed (RMD) Stock for Now ResMed Inc. RMD is well-poised for growth in the coming quarters, backed by the strength of the SaaS (Software-as-a-Service) business. It is progressing across several digital health technology initiatives further to increase the value proposition for its connected healthcare ecosystem. Further, its performance across the international markets also garners appreciation. However, global economic uncertainties, as well as competitive disadvantages, may pose challenges to the company\u2019s results of operations. In the past year, this Zacks Rank #3 (Hold) stock has decreased 26.9% compared with the 8.1% decline of the industry and a 15.2% rise of the S&P 500 composite. The renowned medical device company has a market capitalization of $23.96 billion. RMD has an earnings yield of 4.46% against the industry\u2019s yield of -1.80%. The company\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in another. It has an average earnings surprise of 1.80%. Let\u2019s delve deeper. Upsides Strategic Pacts to Boost SaaS Business: The business is considered an essential part of ResMed\u2019s growth strategy, complementing the software and device solutions across the company\u2019s core sleep apnea and respiratory care businesses. The most recent addition to the portfolio, MEDIFOX DAN, continues to surpass the company\u2019s initial expectations with an accelerated contribution. Image Source: Zacks Investment Research Meanwhile, the Home Medical Equipment (\u201cHME\u201d) SaaS business under the Brightree brand is growing at a very rapid pace. The sustained high single-digit organic growth in the SaaS business is driven by strength in the HME segment and stability as well as increased tech adoption by customers in the facilities segment. Further, ResMed\u2019s recent acquisition of Somnoware complements its current ecosystem of software solutions, including AirView for providers and physicians and Brightree for home care providers. Potential in Digital Health: ResMed is leading the market in digital health technology, with more than 16 billion nights of medical data in the cloud and nearly 22.5 million cloud-connectable medical devices on people's bedside tables in 140 countries worldwide. The company is liberating this data to the cloud, unlocking value for patients, providers, physicians, payers and entire healthcare systems. Further, ResMed\u2019s key global customer-facing software products \u2014 AirView and myAir \u2014 are 100% in the cloud. In the coming quarters, the company is introducing several artificial intelligence-driven coaching features in the AirView system and on the myAir app that will provide personalized suggestions to increase patient therapy adherence and ultimately improve patient outcomes. Increased Focus on International Markets: ResMed continues to invest and expand its presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe. Across Europe, Asia and other markets, device organic sales have been benefiting from the strong demand and continued availability of AS10 and AS11 cloud-connected devices. In Europe, Asia and other markets, device sales increased by 20% in constant currency terms in the fiscal first quarter of 2024, reflecting strong demand and significantly improved availability of cloud-connected devices. There are huge opportunities for greater adoption of digital health technologies worldwide, with more than 2 billion people suffering from sleep apnea, COPD and asthma combined. Downsides Macroeconomic Challenges: Global macroeconomic conditions, including supply chain disruptions, fluctuations in foreign currency exchange rates and volatility in capital markets, could continue to affect ResMed\u2019s operations results adversely. Decline in the global economic environment may reduce demand for the company\u2019s products, resulting in lower sales, lower product prices and reduced reimbursement rates by third-party payers while increasing the cost of operating the business. Furthermore, with the sustained inflationary pressures in the future, the company may struggle to keep in check its operating expenses as a percentage of net revenues. We are worried that this might adversely dent ResMed\u2019s profitability. Competitive Landscape: The market for SDB (sleep-disordered breathing) products is highly competitive with respect to product price, features and reliability. ResMed's primary competitors include Philips BV, DeVilbiss Healthcare, Fisher & Paykel Healthcare Corporation Limited and regional manufacturers, among others. The disparity between the company's resources and those of its competitors may increase due to consolidation in the healthcare industry. Estimate Trend The Zacks Consensus Estimate for RMD\u2019s fiscal 2024 earnings per share (EPS) has moved down from $7.30 to $7.26 in the past seven days. The Zacks Consensus Estimate for the company\u2019s fiscal 2024 revenues is pegged at $4.68 billion, up 10.9% from the year-ago reported figure. Key Picks Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics has an estimated earnings growth rate of 28.4% for fiscal 2024 compared with the industry\u2019s 15.3%. HAE\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 16.1%. Its shares have declined 5.1% compared with the industry\u2019s 6.5% fall in the past year. HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Insulet, sporting a Zacks Rank #1 at present, has a long-term estimated earnings growth rate of 39.2% compared with the industry\u2019s 11.7%. Shares of the company have lost 38.6% compared with the industry\u2019s 6.5% decline over the past year. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 33.6% compared with the industry\u2019s 13.8%. Shares of DXCM have lost 1.5% compared to the industry\u2019s 9.1% decline over the past year. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Surmodics (SRDX) Stock for Now Surmodics, Inc. SRDX is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid fourth-quarter fiscal 2023 performance and its consistent efforts to boost research and development (R&D) are expected to contribute further. Yet, regulatory headwinds and data security threats persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 7.5% compared with the 7.4% decline of the industry. The S&P 500 has witnessed 15.5% growth in the said time frame. The renowned medical device and in-vitro diagnostics technology provider has a market capitalization of $484.3 million. Surmodics projects 71% growth for fiscal 2025 and is expecting to maintain its strong performance. SRDX\u2019s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 121.1%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Consistent Efforts to Boost R&D: Surmodics\u2019 solid efforts to improve its R&D stature have been a key growth driver, which raises our optimism. The company\u2019s whole product solutions pipeline and sirolimus-based below-the-knee drug-coated balloon program deserve mention. Surmodics has been making progress using its internally developed .014 balloon platform. In fiscal 2023, Surmodics\u2019 R&D expenses were 35.1% of total revenues and were largely associated with its investments in vascular intervention product development, costs associated with the SurVeil drug-coated balloon (DCB) and regulatory infrastructure, facilities and personnel. Thrombectomy Prospects Bright: Surmodics\u2019 aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. On the fourth quarter of fiscal 2023earnings callin November, management confirmed that the feedback received from new and existing physician customers during the past quarter demonstrated the advantages of Surmodics\u2019 Pounce and Sublime products. In June, Surmodics received the FDA\u2019s approval for the SurVeil DCB. Strong Q4 Results: Surmodics registered a solid uptick in the overall top and bottom lines in the fourth quarter of fiscal 2023. The company recorded robust revenues from both segments and its primary sources. During the quarter, Surmodics advanced the initial commercialization of its Pounce arterial thrombectomy and Sublime radial access platforms. This looked promising for the stock. Downsides Regulatory Headwinds: Surmodics\u2019 facilities and procedures are subject to periodic inspections by the FDA to determine compliance with the latter\u2019s requirements. On account of non-compliance with applicable laws or regulations, the FDA could ban such medical devices. Any adverse regulatory action can potentially have a negative impact on Surmodics' business practices and operations. Data Security Threats: Surmodics collects and stores sensitive data, including its proprietary business information, on its networks. The secure maintenance of this information is critical to its operations and business strategy. Despite Surmodics\u2019 security measures, its information technology and infrastructure may be vulnerable to attacks by hackers, resulting from employee error or other disruptions. Estimate Trend Surmodics is witnessing a negative estimate revision trend for fiscal 2024. In the past 90 days, the Zacks Consensus Estimate for its loss per share has widened from 67 cents to $1.00. The Zacks Consensus Estimate for the company\u2019s first-quarter fiscal 2024 revenues is pegged at $29.7 million, suggesting a 19.2% improvement from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 42.5% compared with the industry\u2019s 4.6% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have lost 1.4% compared with the industry\u2019s 6.9% decline in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 31.4% against the industry\u2019s 6.9% decline in the past year. 4 Oil Stocks with Massive Upsides Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with \""black gold.\"" Zacks Investment Research has just released an urgent special report to help you bank on this trend. In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. Download your free report now to see them. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-13,119.14,122.38,118.425,122.29,"[""Here's Why You Should Retain Catalent (CTLT) Stock for Now Catalent, Inc. CTLT is well-poised for growth in the coming quarters, courtesy of strength in its products and services portfolio. The optimism led by its preliminary first-quarter fiscal 2024 performance, along with its technology foundation, is expected to contribute further. Catalent\u2019s operation in a competitive landscape and customer dependency pose threats. Over the past year, this Zacks Rank #3 (Hold) stock has lost 6.6% against 1.2% growth of the industry and 22.9% rise of the S&P 500. The renowned global developer and supplier of better treatments has a market capitalization of $7.47 billion. Catalent projects 27.8% growth for the next five years and expects to maintain its strong performance. CTLT\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, the average earnings surprise being 9.2%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Products and Services: We are upbeat about Catalent\u2019s product and service launches over the past few months. On the preliminary first-quarter fiscal 2024earnings call Catalent\u2019s management stated that its non-COVID non-Sarepta Biologics business is expected to grow in the low- to mid-teens in fiscal 2024 as the company launches GLP-1 production and bring on incremental capacity and improve productivity. In June, the company announced that it had expanded its integrated development, manufacturing and supply solution, OneBio Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies and mRNA. Technology Foundation: Catalent is equipped with broad and diverse technology platforms that are supported by extensive know-how and nearly 1,300 patents and patent applications worldwide across advanced delivery technologies, drug and biologics formulation, and manufacturing, buoying our optimism. Its leading softgel platforms and modified release technologies provide formulation expertise to solve complex delivery challenges for its customers. Catalent offers advanced technologies for the delivery of small molecules and biologics via respiratory, ophthalmic and injectable routes, including the blow-fill-seal unit dose technology and prefilled syringes. Strong Q1 Results: Catalent\u2019s preliminary first-quarter fiscal 2024 results buoy optimism. The company registered a year-over-year improvement in the Pharma and Consumer Health segment and the Biologics segment\u2019s non-COVID revenues. Management\u2019s confirmation regarding Catalent\u2019s strength in its non-COVID Biologics portfolio and continued progress in improving its operational performance raise our optimism. Downsides Customer Dependency: Catalent\u2019s customers are engaged in the research, development, production and marketing of pharmaceutical, biotechnology and consumer health products. The amount of customer spending on these activities and the outcomes of such activities have a large impact on Catalent\u2019s sales and profitability. Available resources, the need to develop new products and consolidation in the industries in which its customers operate may have an impact on such spending. Stiff Competition: Catalent operates in a highly competitive market, wherein it competes with multiple companies, including those offering advanced delivery technologies and outsourced dose form or biologics manufacturing. The company also competes in some cases with the internal operations of pharmaceutical, biotechnology and consumer health customers with manufacturing capabilities and chooses to source these services internally. Estimate Trend Catalent has been witnessing a negative estimate revision trend for fiscal 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 10.9% south to 73 cents. The Zacks Consensus Estimate for the company\u2019s second-quarter fiscal 2024 revenues is pegged at $1.01 billion, suggesting an 11.7% decline from the year-ago quarter\u2019s reported number. Key Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA\u2019s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 36.6%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. DaVita\u2019s shares have gained 48% compared with the industry\u2019s 10.1% rise in the past year. DexCom, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 33.6%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, with an average of 36.4%. DexCom\u2019s shares have gained 7.4% compared with the industry\u2019s 2.8% rise in the past year. Integer Holdings, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%. Integer Holdings\u2019 shares have rallied 54.4% compared with the industry\u2019s 2.8% rise in the past year. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Catalent, Inc. (CTLT) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain McKesson (MCK) Stock for Now McKessonCorporation MCK is well-poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company\u2019s opioid-related litigation expenses are a potential threat. Shares of this currently Zacks Rank #3 (Hold) company have risen 24.1% year to date compared with the industry\u2019s 7.9% growth. The S&P 500 Index has increased 16.2% in the same time frame. McKesson is a healthcare services and information technology company with a market capitalization of $61.47 billion. Its earnings are anticipated to improve 10.5% over the next five years. Image Source: Zacks Investment Research The company\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.87%. Its earnings yield of 5.9% compares favorably with the industry\u2019s 4.9%. Key Growth Drivers Strength in Biologics: Investors are optimistic about McKesson\u2019s robust Biologics business. Independent specialty pharmacy, Biologics by McKesson, has been making impressive progress lately. The pharmacy was chosen by AstraZeneca and SpringWorks Therapeutics as the distribution partner for their respective drugs, TRUQAP (capivasertib) and OGSIVEO (nirogacestat), earlier this month. Last month, the pharmacy was selected by Takeda as a specialty pharmacy provider of FRUZAQLA (fruquintinib). In September, it was chosen by GSK as a specialty pharmacy provider of OJJAARA (momelotinib). In August, Biologics was selected by Daiichi Sankyo, Inc. as a specialty pharmacy provider of VANFLYTA (quizartinib). Strength in Distribution Market: McKesson is a major player in the pharmaceutical and medical supplies distribution market that raises investors\u2019 optimism. The Distribution Solutions segment caters to a wide range of customers and businesses. It also stands to benefit from increased generic utilization and inflation in generics, driven by several patent expirations in the next few years and an aging population. Per management, the uptick in the company\u2019s U.S. Pharmaceutical and Medical-Surgical Solutions segment\u2019s adjusted operating profit was driven by growth in the distribution of specialty products to providers and health systems, higher contribution from generics and growth of GLP-1 medication in the first quarter of fiscal 2024. Strong Q2 Results: McKesson\u2019s robust second-quarter fiscal 2024 results buoy optimism. The company recorded strong top and bottom-line performances and strength in its U.S. Pharmaceutical, Medical-Surgical Solutions and Prescription Technology Solutions segments. Downsides Weak Trends: McKesson distributes generic pharmaceuticals, which are subject to price fluctuations. The Distribution Solutions segment continues to experience a weaker generic pharmaceutical pricing trend. Continued volatility, unfavorable pricing trends, reimbursement of generic drugs and significant fluctuations in the nature, and frequency and magnitude of generic pharmaceutical launches could have an adverse impact on McKesson. Stiff Competition: Distribution Solutions faces stiff competition both in terms of price and service from various full-line, short-line and specialty wholesalers, service merchandisers, self-warehousing chains, manufacturers engaged in direct distribution, third-party logistics companies and large-payer organizations. Moreover, MCK depends on fewer suppliers for its products. As a result, it is not in a position to negotiate pricing. Estimates Trend The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $304.19 billion, indicating a 9.9% increase from the previous year\u2019s level. The consensus mark for adjusted earnings per share is pinned at $27.23, implying a 5% year-over-year improvement. McKesson Corporation Price McKesson Corporation price | McKesson Corporation Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It\u2019s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is \u201cWill you get into the right stocks early when their growth potential is greatest?\u201d Zacks has released a Special Report to help you do just that, and today it\u2019s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Why DexCom (DXCM) Dipped More Than Broader Market Today DexCom (DXCM) ended the recent trading session at $122.59, demonstrating a -0.41% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.01%. Elsewhere, the Dow saw an upswing of 0.15%, while the tech-heavy Nasdaq appreciated by 0.36%. The medical device company's shares have seen an increase of 17.5% over the last month, surpassing the Medical sector's gain of 5.79% and the S&P 500's gain of 5.21%. Analysts and investors alike will be keeping a close eye on the performance of DexCom in its upcoming earnings disclosure. In that report, analysts expect DexCom to post earnings of $0.43 per share. This would mark year-over-year growth of 26.47%. In the meantime, our current consensus estimate forecasts the revenue to be $1 billion, indicating a 23.26% growth compared to the corresponding quarter of the prior year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.44 per share and a revenue of $3.59 billion, signifying shifts of +65.52% and +23.47%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for DexCom. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.7% higher. DexCom presently features a Zacks Rank of #2 (Buy). With respect to valuation, DexCom is currently being traded at a Forward P/E ratio of 85.65. Its industry sports an average Forward P/E of 24.28, so one might conclude that DexCom is trading at a premium comparatively. Meanwhile, DXCM's PEG ratio is currently 2.55. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Instruments industry currently had an average PEG ratio of 2.69 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain Globus Medical (GMED) Stock Now Globus Medical, Inc. GMED is well-poised for growth in the coming quarters, backed by growth across its U.S. spine and trauma portfolios. The Enabling Technologies business benefits from the continued uptake of EGPS and E3D systems. However, several macroeconomic issues are denting the company\u2019s profit margins. In the past year, this Zacks Rank #3 (Hold) stock has increased 31.2% compared with the 1.4% rise of the industry and a 23.1% increase of the S&P 500 composite. The renowned medical device company has a market capitalization of $6.81 billion. Globus Medical projects a long-term estimated earnings growth rate of 11.5% compared with 13.3% of the industry. GMED\u2019s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 5.44%. Let\u2019s delve deeper. Upsides Musculoskeletal Prospects Strong: In the third quarter, Legacy Globus's musculoskeletal revenues rose 10.7%. Earlier, Globus Medical launched three new products \u2014 REFLECT, MARVEL and Ossifuse. The company continues to make significant progress in launching its prone, lateral patient positioning system. As Globus Medical moves into the second half of 2023 and into 2024, the company anticipates a strong cadence of product launches throughout the Musculoskeletal portfolio. Steady Pace of Product Development: In line with the company\u2019s business strategy to focus on its integrated product development, Globus Medical is consistently making efforts in research and development. In September 2023, Globus Medical launched the Precice Bone Transport system commercially in the targeted areas by NuVasive Specialised Orthopaedics (NSO). The most recent addition to the less intrusive NSO portfolio recently received CE marking and approval, and it is now offered in a few regions. Image Source: Zacks Investment Research In Q3, the company launched Hydrone, an interior 3D printed interbody fusion device and Strato wiring system for trauma. Management noted that Surgeons would soon start gaining access to its broader expandable offerings, 3D printed interbody portfolio, cervical disc, robotic prone, lateral system, EGPS E3D and neuromonitoring solutions, improved retractors, Magic and the precise family of limb-lengthening products. Strong Liquidity, Solvency and Capital Structure: Globus Medical exited the third quarter of 2023 with cash and cash equivalents and short-term marketable securities of $468.9 million compared with $612.8 million at the end of the second quarter. The company finished the quarter with no debt on its balance sheet. Downsides Macroeconomic Concerns Curb Profit: Like other industry players, Globus Medical is currently grappling with negative trends in the global economy, including interest rate fluctuations, increases in inflation, and financial market volatility. These factors are affecting the company\u2019s operations and financial performance. Global inflation, in particular, led to a significant rise in the cost of raw materials for companies. In the third quarter, the company incurred a 139.6% surge in the cost of goods sold. Exposure to Currency Movement: In the last nine months, Globus Medical generated 17.1% of its sales from the international market. A significant portion of the company\u2019s foreign revenues and expenses is generated in Japan, the Eurozone, the U.K. and Australia. This makes it highly vulnerable to currency fluctuations. For 2022, the company reported a foreign currency transaction loss of $1.02 million. Estimate Trend The Zacks Consensus Estimate for 2023 earnings per share (EPS) moved from $2.32 to $2.30 in the past 90 days. The Zacks Consensus Estimate for the company\u2019s 2023 revenues is pegged at $1.56 billion. This suggests a 52.1% rise from the year-ago reported number. Key Picks Some beter-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 shares have increased 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Neogen (NEOG) to Advance Feline DNA Testing With New Pact Neogen Corporation NEOG recently collaborated with the Cat Fanciers' Association (CFA). With the goal of expanding the genomic products available to CFA members through marketing, education and promotion of Neogen technology and products, the partnership is centered around Neogen's My CatScanTM DNA testing services. The recent development will enable Neogen to continue offering advanced genomic solutions and strengthen its global foothold. About Cat Fanciers' Association Since 1906, the world's most significant pedigreed cat registry and a not-for-profit network of member clubs \u2014 the Cat Fanciers' network \u2014 has been devoted to conserving, honoring and safeguarding cats. The goals of CFA are to protect and advance cat breeds with a strong pedigree and to improve the welfare of all cats. Millions of cat owners worldwide are encouraged by CFA to receive appropriate care, education and responsible cat keeping. Strategic Implications This strategic alliance will expand feline DNA testing and strengthen Neogen's relationship with the kitty community. Neogen and CFA are looking forward to a generative relationship that will spur innovation and raise awareness in the field of feline genetics. Preservation breeding is all about making deliberate choices based on ancestry and, most importantly, health and genetic features. My CatScan by Neogen scans for more than 120 feline health concerns and genetic features, providing breeders with the information they need to build new generations of pedigreed cats meticulously. Industry Prospects Per a report by Grand View Research, the global pet DNA testing market size is estimated to reach USD 322.02 million in 2022. It is expected to witness a compound annual growth rate (CAGR) of 9.20% over the forecast period. The market growth is propelled by factors like increasing pet adoption rates, rising consumer genomics, increasing R&D activities by key companies & academic researchers and growing awareness & sales of pet DNA testing kits. Recent Developments Neogen\u2019s Animal Safety segment is gaining from strong performances of a complete line of consumable products marketed to veterinarians and animal health product distributors. Its genomic identification and related interpretive bioinformatics services are showing strong prospects, too. The Animal Safety business continues to grow, led by sales of vet instruments and disposables and a new line of business with a large retail customer. Within the biosecurity portfolio, Neogen continues to grow solidly in cleaners, disinfectants and rodenticides. In terms of the latest development, within worldwide genomics, the company registered solid growth in international beef markets and companion animal testing during the fiscal first quarter. Image Source: Zacks Investment Research In June 2023, Neogen launched My CatScan 2.0, an incredibly refined and improved version of the test. The extended analysis offered by My CatScan 2.0 gives cat owners, feline breeders and veterinarians a deeper level of knowledge to provide insights into the health and well-being of their feline pets. Price Performance In the past year, NEOG\u2019s shares have increased 28.1% against the industry\u2019s fall of 3%. Zacks Rank and Other Key Picks Neogen carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. While Haemonetics and DexCom carry a Zacks Rank #2, Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have declined 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Align Technologies (ALGN) Secures Updated Medical Device License Align Technologies ALGN received an updated medical device license from Health Canada for its Invisalign Palatal Expander system for broad patient applicability, including growing children, teens and adults (with surgery or other techniques). The system was unveiled at the company\u2019s 2023 Investor Day in September and is presently available on a limited basis in Canada. The Invisalign Palatal Expander system is pending the FDA\u2019s 510(k) submission and is not yet available in the United States. ALGN is revolutionizing digital dentistry through the Align Digital Platform, an integrated suite of proprietary technologies and services designed to deliver a seamless, end-to-end solution for patients and consumers, orthodontists, general practitioners (GP) dentists and lab partners. About the Invisalign Palatal Expander System The Invisalign Palatal Expander is designed based on the company\u2019s proprietary and patented technology. The modern, innovative direct 3D printed orthodontic appliance provides a safe, comfortable and clinically effective alternative to traditional palatal expanders that require manually turning a screw in the device in the mouth daily to achieve expansion. These are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during the treatment of patients. Image Source: Zacks Investment Research The system consists of a series of removable devices staged in small increments of movement to expand a patient\u2019s narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient\u2019s unique anatomy based on an iTero intraoral digital scan. Following this, a palatal expansion treatment plan and device design are developed using Align Technology\u2019s proprietary AI-driven orthodontic software. The Invisalign Palatal Expander system is expected to be available in other markets pending regulatory approvals beginning 2024. Strategic Advantages With the launch of Invisalign Palatal Expanders, ALGN intends to increase market opportunity in the teen market by addressing a portion of cases that were otherwise not possible to treat without these devices. The system eases the usual challenges associated with palatal expansion, including maintaining proper hygiene, emergency appointments, turning the screw and the parents\u2019 fear of causing pain to their child in treatment. Combined with Invisalign First aligners, Invisalign Palatal Expanders provides doctors with a full early intervention treatment solution for Phase 1 treatment, which makes up 20 percent of orthodontic cases starting each year. The early interceptive treatment is typically done at ages six through ten, through arch expanders or partial metal braces, before all permanent teeth have erupted. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years. Industry Prospects Per a Research report, the 3D printing market is valued at $15 billion in 2023 and is expected to witness a CAGR of 18.1% till 2028. Other Notable Developments The company is transforming orthodontic treatment through the adoption of next-generation tools and customized treatment plans based on years of research and intelligence from millions of patients treated with the Invisalign System. At the foundation of this goal lies the Align Digital Platform, which utilizes the Align Digital Workflow, comprising dedicated tools and capabilities for each stage of the Invisalign treatment journey. In September 2023, ALGN introduced the Plan Editor tool in the Plan stage of the Align digital workflow. This enables enhanced flexibility and customization in Invisalign treatment planning for Invisalign-trained orthodontists and GP dentists. The company also launched new software innovations \u2014 the Align Oral Health Suite and iTero-exocad Connector \u2014 to accelerate digital practice transformation. Price Performance In the past six months, ALGN shares have lost 22.1% compared with the industry\u2019s fall of 2.2% Zacks Rank and Key Picks Align Technologies currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Haemonetics HAE, Insulet PODD and DexCom DXCM. Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each, while Insulet sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Haemonetics\u2019 stock has gained 13.3% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.80 to $1.91 in the past 30 days. Shares of the company have lost 30.9% in the past year compared with the industry\u2019s decline of 1.2%. PODD\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.43 to $1.44 in the past 30 days. Shares of the company have gained 7.4% in the past year compared with the industry\u2019s growth of 2.9%. DXCM\u2019s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Here's Why You Should Retain CONMED (CNMD) Stock for Now CONMED Corporation (CNMD) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid third-quarter 2023 performance and a potential General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist. This currently Zacks Rank #3 (Hold) company\u2019s shares have risen 29.6% year to date compared with the industry\u2019s 10.7% growth. The S&P 500 Index has increased 23.1% during the same time frame. CONMED, the renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $3.42 billion. The company projects 28.5% growth over the next five years and expects to maintain its strong performance going forward. Image Source: Zacks Investment Research Its earnings surpassed estimates in three of the trailing four quarters and missed the same once, delivering a negative average surprise of 7.84%. Let\u2019s delve deeper. Potential in General Surgery: The segment consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. CONMED\u2019s unique products and solutions within the General Surgery segment have been providing a competitive edge in the MedTech space. One of these products, the Anchor Tissue Retrieval bag, deserves a special mention. It is one of the major platforms in the company\u2019s specimen bag portfolio. Broad Product Spectrum: CONMED offers a broad line of surgical products, including several new devices in the Orthopedic, Laparoscopic, Robotic, Open Surgery, Gastroenterology, Pulmonary and Cardiology sections. Products like the Hi-Fi Tape and Hi-Fi suture interface are critical components of repair security in the rotator cuff repair space. During the third quarter, CNMD remained focused on the introduction of a delivery system for MIS rotator cuff repair. Other notable offerings are the MicroFree platform in Orthopedics, the TruShot, the Y-Knot Pro and the CRYSTALVIEW Pump. The Anchor Tissue Retrieval bag is a unique product under the General Surgery arm. Solid Recurring Revenue Base: Approximately 80% of CONMED\u2019s revenues are recurring, derived from the sale of disposable single-use products. The remaining 20% comes from sales of capital equipment (such as powered drills and saws for surgery, electrosurgical generators, video-imaging cameras, fluid control systems and surgical hand-pieces). This, in turn, creates demand for complementary single-use items. Hospitals and clinics are expanding the use of single-use, disposable products. This endeavor is aimed at reducing expenses related to sterilizing surgical instruments and products following surgery. CONMED\u2019s revenues totaled $304.6 million in third-quarter 2023, up 10.7% year over year. Additional sales from newly acquired businesses contributed approximately 40 basis points of growth. Downsides Regulatory Requirements: Substantially, all CONMED products are classified as class II medical devices, subject to regulations from numerous agencies and legislative bodies worldwide. As a manufacturer of medical devices, the company\u2019s manufacturing processes and facilities are subject to on-site inspection and constant review by the FDA for compliance with the Quality System Regulations. Supply Constraints and FX Impact: Although CONMED recorded strong growth across all segments in the third quarter, the legacy orthopedic business was hurt by supply-chain constraints. The supply disruption continues to pose a headwind for the company during the fourth quarter of 2023. CNMD expects supply-chain issues to improve from the first quarter of 2024. Moreover, revenues were hurt by unfavorable currency movement during the third quarter. The company continues to expect foreign exchange to have an unfavorable impact on its top-line growth by 150-200 basis points in 2023. Currency rates are expected to negatively impact earnings by 20-25 cents per share. Estimate Trend CONMED is witnessing a positive estimate revision trend for 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has improved from $3.47 per share to $3.50. The same for the company\u2019s fourth-quarter revenues is pegged at $332.94 million, indicating a 32.7% improvement from the year-ago quarter\u2019s reported number. The bottom-line estimate for the fourth quarter is expected to improve 164.3% from the year-ago period\u2019s level of $1.11. CONMED Corporation Price CONMED Corporation price | CONMED Corporation Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Reasons to Retain Inari Medical (NARI) in Your Portfolio Now Inari Medical, Inc. NARI is well-poised for growth, backed by a huge market opportunity for products and its commitment to understand the venous system. However, its dependency on the adoption of products is concerning. Shares of this currently Zacks Rank #3 (Hold) company have risen 4% year to date compared with the industry\u2019s 1.4% growth. The S&P 500 Index has risen 23.1% in the same time frame. NARI, with a market capitalization of $3.7 billion, is a commercial-stage medical device company. It seeks to develop products for treating and changing the lives of patients suffering from venous diseases. Image Source: Zacks Investment Research The company\u2019s earnings yield of 0.1% compares favorably with the industry\u2019s (7.8%). Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.16%. What\u2019s Driving NARI\u2019s Performance? Inari Medical is spearheading the creation and commercialization of devices that are purposefully built, keeping in mind the specific characteristics of the venous system, its diseases and unique clot morphology. The company\u2019s in-depth knowledge of its target market and commitment to understand the venous system have allowed it to figure out the unmet needs of patients as well as physicians. This, in turn, has enabled NARI to quickly innovate and improve its products while updating its clinical and educational programs. In November, NARI acquired LimFlow, a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). The minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins in no-option CLTI patients who are facing major amputation and have exhausted all other therapeutic options. LimFlow recently received FDA\u2019s approval for its Transcatheter Arterialization of Deep Veins system. The acquisition adds a highly differentiated growth platform to Inari Medical\u2019s portfolio that is likely to provide multiple opportunities for expansion, including expansion in CLTI patient population. In June, Inari Medical launched two new purpose-built products \u2014 the RevCore thrombectomy catheter and the Triever16 Curve catheter. RevCore is currently the first mechanical thrombectomy device designed to address venous in-stent thrombosis. Triever16 Curve is the latest addition to NARI\u2019s FlowTriever platform. The latest launches are expected to significantly solidify the company\u2019s foothold in the Venous Stent Thrombosis and Venous Thromboembolism (VTE) treatment space globally. In May, NARI announced the planned enrollment of the PEERLESS II trial, its third randomized controlled trial (RCT) in VTE. PEERLESS II is a prospective, global, multi-center RCT, comparing the outcomes of intermediate-risk pulmonary embolism (PE) patients treated with the FlowTriever system versus anticoagulation alone. Strong procedural growth across both its product lines, ClotTriever and FlowTriever, continues to drive the company\u2019s top line in the first half of 2023, a trend that is likely to be reflected in the second-half results. Moreover, NARI has expanded its product portfolio with new launches this year. It continues to progress well with the launch of Protrieve and InThrill. Continued adoption of FlowSaver \u2014 a device designed to be used with the FlowTriever System to reduce blood loss \u2014 will boost European sales. During the second quarter, the company launched two new products \u2014 RevCore and T16 Curve \u2014 targeting patients with venous thromboembolism. The launch of new products looks promising for NARI\u2019s long-term growth. The company reported total revenues of $126.4 million for the third quarter, indicating a 31.4% improvement year over year.It expanded its territories to more than 275 in 2022. Inari Medical expects total revenues in the range of $490-$493 million for 2023, indicating growth of approximately 27.8-28.6% from the previous year\u2019s reported actual. What\u2019s Weighing on the Stock? Most of NARI\u2019s product sales come from a limited number of hospitals. The company\u2019s growth and profitability mainly depend on its ability to boost awareness of its products among physicians and patients. These also depend on how keen physicians and hospitals are to adopt its products and perform catheter-based thrombectomy procedures on patients suffering from venous thromboembolism. Inari Medical\u2019s inability to validate the benefits of its products and catheter-based thrombectomy procedures will result in limited adoption of the same. Moreover, it might not happen as quickly as expected. These factors, in unison, might negatively impact NARI\u2019s business and financial condition. Estimates Trend The Zacks Consensus Estimate for the company\u2019s revenues is pegged at $492.8 million for 2023, indicating a 28.5% increase from the previous year\u2019s reported number. The bottom-line estimate is pinned at 8 cents, implying a 114.6% improvement from that recorded a year ago. The same has improved to 8 cents in 2023 from 4 cents in 2022 in the past 60 days. Inari Medical, Inc. Price Inari Medical, Inc. price | Inari Medical, Inc. Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DexCom DXCM, HealthEquity, Inc. HQY and Biodesix BDSX. DexCom, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 33.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. DXCM\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%. The company\u2019s shares have risen 4.2% year to date compared with the industry\u2019s 3.8% growth. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 26.8%. HQY\u2019s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.5%. The company\u2019s shares have rallied 15% year to date against the industry\u2019s 9.9% decline. Biodesix, carrying a Zacks Rank #2 at present, has an estimated growth rate of 32.3% for 2024. BDSX\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.76%. The stock has fallen 30.9% year to date compared with the industry\u2019s 9.9% decline. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s credited with a \u201cwatershed medical breakthrough\u201d and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."", ""Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger Align Technology\u2019s ALGN robust product line and consistent focus on international markets to drive growth bolster our confidence in the stock. However, we remain concerned about the current economic uncertainty, which continues to cast a negative impact on Align Technology\u2019s dental procedures. The stock carries a Zacks Rank #3 (Hold). Align Technology is strategically capturing the growing malocclusion market, one of the most prevalent clinical dental conditions in the world. According to Align Technology\u2019s May 2023 data, it is currently affecting approximately 60% to 75% of the global population. Per the company, there are approximately 500 million people globally with malocclusion. However, most of them do not seek orthodontic treatment mainly due to negative perceptions of metal braces, affordability of treatment and accessibility to doctors in certain markets and geographies. Align Technology is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America. By the end of 2022, the company sold directly or through authorized distributors in more than 100 countries. With the opening of its third clear aligner fabrication facility in Wroclaw, Poland, the company now has a manufacturing facility in each of its operating territories \u2014 Americas (Mexico), APAC (China) and EMEA (Poland). The company also performs digital treatment planning and interpretation for restorative cases worldwide, including in Costa Rica, China, Germany, Spain, Poland and Japan, among others. Align Technology has been expanding its business in 2023 through investments in resources, infrastructure and initiatives that help drive growth in Invisalign treatment, intraoral scanners and Exocad CAD/CAM software in existing and new international markets. According to the company, by establishing and expanding its key operational activities in locations closer to customers, it can address local and regional needs in a better way. Image Source: Zacks Investment Research Further, the company\u2019s slew of strategic alliances looks impressive. It has well-established relationships with many dental service organizations, especially in the United States, and is continuously exploring collaborations with others that drive the adoption of digital dentistry. In 2023, in the Americas, Align Technology focused on reaching young adults as well as teens and their parents through influencer and creator-centric campaigns, partnering with leading smile squad creators, including Marshall Martin, Rally Shaw and Jeremy Lin. Each of these creators shared their personal experiences with Invisalign treatment and why they chose to transform their smile with Invisalign aligners. Over the past year, shares of ALGN have gained 27.2% compared with an 11.8% rise of the industry. On the flip side, although Align Technology is gradually coming out of the impact of the two-and-a-half-year-long healthcare crisis, the ongoing industry-wide trend of staffing shortages and supply chain-related hazards is denting growth. Deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor costs as well as freight charges and rising interest rates, has put the dental treatment space (which is highly-elective) in a tight spot. Added to this, Align Technology is also concerned about the military conflict between Russia and Ukraine that is likely to continue. The company noted that while it continues to employ research and development personnel in Russia as well as limited post-sales support and administrative personnel, its total number of employees in Russia was materially reduced in 2022. Align Technology anticipates increasing headwinds from macroeconomic uncertainty and potential supply issues related to the war in the Middle East in the upcoming period. The company expects fourth-quarter GAAP operating margin to be down sequentially from the third quarter of 2023 due to restructuring, primarily related to severance as the company adjusts headcount for this environment. Further, foreign exchange is a major headwind for Align Technology due to a considerable percentage of its revenues coming from outside the United States (in 2022, 44% of the company\u2019s consolidated revenues came from international regions). Through the first nine months of 2023, the strengthening of the U.S. dollar against nearly every other major currency hampered Align Technology\u2019s revenues in the international markets. This was mainly due to the Fed\u2019s 10 consecutive aggressive rate hikes to tackle inflation since March 2022. Key Picks Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Estimates for Insulet\u2019s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry\u2019s decline of 7%. PODD\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%. Haemonetics\u2019 stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days. HAE\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%. Estimates for DexCom\u2019s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry\u2019s decline of 7.1%. DXCM\u2019s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%. Zacks Names \""Single Best Pick to Double\"" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It\u2019s a little-known chemical company that\u2019s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks\u2019 Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.""]"
DXCM,2023-12-14,123.42,126.37,122.335,123.1,"DXCM Quantitative Stock Analysis Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. DEXCOM, INC. (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. BOOK/MARKET RATIO: PASS RETURN ON ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS: PASS CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS RETURN ON ASSETS VARIANCE: PASS SALES VARIANCE: PASS ADVERTISING TO ASSETS: PASS CAPITAL EXPENDITURES TO ASSETS: PASS RESEARCH AND DEVELOPMENT TO ASSETS: FAIL Detailed Analysis of DEXCOM, INC. DXCM Guru Analysis DXCM Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper ""Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis"" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
DXCM,2023-12-15,123.02,123.57,121.08,122.59,
DXCM,2023-12-18,121.85,124.5,119.55,123.35,
DXCM,2023-12-19,123.63,124.58,122.91,123.29,
DXCM,2023-12-20,122.48,123.29,115.64,116.64,
DXCM,2023-12-21,118.59,122.92,118.36,122.8,
DXCM,2023-12-22,122.38,122.61,120.23,122.17,
DXCM,2023-12-26,123.3,123.86,121.88,123.55,
DXCM,2023-12-27,124.02,124.25,122.264,123.73,
DXCM,2023-12-28,124.31,125.72,123.51,124.16,
DXCM,2023-12-29,123.78,124.78,123.65,124.09,
DXCM,2024-01-02,123.15,126.225,122.4,123.09,
DXCM,2024-01-03,123.44,123.44,119.645,120.27,
DXCM,2024-01-04,120.03,122.8,119.86,121.83,
DXCM,2024-01-05,121.27,124.99,120.5,123.98,
DXCM,2024-01-08,125.71,130.32,123.67,129.63,
DXCM,2024-01-09,128.81,132.03,128.38,129.7,
DXCM,2024-01-10,130.04,130.74,127.97,128.0,
DXCM,2024-01-11,127.97,130.3,126.72,128.93,
DXCM,2024-01-12,128.93,130.0,124.06,125.0,
DXCM,2024-01-16,123.59,124.94,121.29,124.46,
DXCM,2024-01-17,123.0,125.53,122.54,125.45,
DXCM,2024-01-18,126.26,128.0,125.297,127.45,
DXCM,2024-01-19,127.12,127.99,125.06,127.29,
DXCM,2024-01-22,129.2,130.31,128.65,129.29,
DXCM,2024-01-23,129.15,129.319,125.388,127.12,
DXCM,2024-01-24,128.1,128.56,125.74,127.42,
DXCM,2024-01-25,129.14,129.39,125.24,126.505,
DXCM,2024-01-26,126.07,126.39,119.71,121.96,
DXCM,2024-01-29,121.88,124.26,119.55,124.25,
DXCM,2024-01-30,123.14,123.24,120.6,120.79,
DXCM,2024-01-31,121.23,123.06,120.12,121.35,
DXCM,2024-02-01,122.15,123.87,119.92,122.6,
DXCM,2024-02-02,122.21,122.45,119.63,120.96,
DXCM,2024-02-05,120.71,121.802,119.6,121.23,
DXCM,2024-02-06,121.81,124.98,120.43,124.92,
DXCM,2024-02-07,124.92,127.13,124.275,126.61,
DXCM,2024-02-08,127.2,127.37,125.21,127.05,
DXCM,2024-02-09,123.0,124.987,120.29,120.47,
DXCM,2024-02-12,119.53,120.5,117.14,118.42,
DXCM,2024-02-13,116.52,120.24,116.26,117.03,
DXCM,2024-02-14,117.03,117.7,114.96,116.75,
DXCM,2024-02-15,117.08,118.51,116.05,117.69,
DXCM,2024-02-16,116.83,118.805,116.32,117.05,
DXCM,2024-02-20,116.73,119.095,116.73,117.87,
DXCM,2024-02-21,117.0,117.96,115.3,116.39,
DXCM,2024-02-22,117.55,118.0,115.36,117.5,
DXCM,2024-02-23,117.13,118.49,116.01,116.26,
DXCM,2024-02-26,116.35,118.19,115.852,116.17,
DXCM,2024-02-27,116.25,116.415,114.55,115.32,
DXCM,2024-02-28,115.61,115.71,113.05,114.22,
DXCM,2024-02-29,115.09,115.56,114.03,115.07,
DXCM,2024-03-01,114.37,122.23,113.69,121.74,
DXCM,2024-03-04,121.76,124.3,120.51,122.3,
DXCM,2024-03-05,123.08,123.91,120.9,121.78,
DXCM,2024-03-06,126.1,133.94,124.12,133.72,
DXCM,2024-03-07,135.6,137.93,132.26,133.24,
DXCM,2024-03-08,134.0,136.25,132.33,135.25,
DXCM,2024-03-11,134.65,136.4,133.01,133.04,
DXCM,2024-03-12,133.0,136.73,130.74,135.38,
DXCM,2024-03-13,136.1,137.46,131.53,131.68,
DXCM,2024-03-14,132.44,133.0,128.72,129.5,
DXCM,2024-03-15,130.95,131.819,128.62,130.46,
DXCM,2024-03-18,131.682,135.58,131.51,134.72,
DXCM,2024-03-19,133.83,134.33,131.635,134.17,
DXCM,2024-03-20,134.87,135.81,131.31,132.53,
DXCM,2024-03-21,133.48,136.449,133.15,133.41,
DXCM,2024-03-22,133.54,134.38,131.36,133.18,
DXCM,2024-03-25,133.39,140.88,133.39,140.1,
DXCM,2024-03-26,140.69,142.0,138.495,139.93,
DXCM,2024-03-27,141.55,141.865,138.115,139.48,
DXCM,2024-03-28,139.98,140.8,138.515,138.7,
DXCM,2024-04-01,138.79,139.62,136.98,137.94,
DXCM,2024-04-02,136.33,137.99,135.21,136.65,
DXCM,2024-04-03,136.73,139.96,136.585,138.51,
DXCM,2024-04-04,139.56,139.71,133.23,133.34,
DXCM,2024-04-05,133.13,139.11,131.74,138.93,
DXCM,2024-04-08,139.74,140.91,137.47,139.96,
DXCM,2024-04-09,140.78,141.99,138.525,140.45,
DXCM,2024-04-10,138.81,140.65,137.42,140.32,
DXCM,2024-04-11,140.1,141.25,138.15,139.62,
DXCM,2024-04-12,138.02,138.77,134.28,136.14,
DXCM,2024-04-15,137.81,138.015,134.5,134.56,
DXCM,2024-04-16,135.29,137.825,133.21,136.52,
DXCM,2024-04-17,136.07,136.64,132.875,133.86,
DXCM,2024-04-18,134.36,135.99,133.58,134.3,
DXCM,2024-04-19,134.64,134.98,129.17,130.745,
DXCM,2024-04-22,131.26,132.36,129.74,131.52,
DXCM,2024-04-23,131.47,135.31,131.0,134.0,
DXCM,2024-04-24,132.79,138.5,132.47,137.87,
DXCM,2024-04-25,138.91,139.24,134.39,138.01,
DXCM,2024-04-26,132.5,138.805,124.08,124.34,
DXCM,2024-04-29,125.15,128.51,123.075,125.81,
DXCM,2024-04-30,126.25,128.65,125.08,127.39,
DXCM,2024-05-01,126.21,128.74,123.515,125.88,
DXCM,2024-05-02,127.03,127.88,124.61,126.65,
DXCM,2024-05-03,127.22,129.22,126.91,128.37,
DXCM,2024-05-06,128.52,129.94,127.79,129.65,
DXCM,2024-05-07,129.6,130.32,128.99,130.1,
DXCM,2024-05-08,130.18,130.36,127.04,127.42,
DXCM,2024-05-09,128.17,130.48,127.62,128.14,
DXCM,2024-05-10,128.14,129.3,126.72,127.05,
DXCM,2024-05-13,128.225,128.225,124.745,124.95,
DXCM,2024-05-14,125.03,126.576,124.25,125.97,
DXCM,2024-05-15,126.58,130.22,126.0,129.71,
DXCM,2024-05-16,129.79,132.2,129.28,131.91,
DXCM,2024-05-17,131.72,132.26,130.16,131.36,
DXCM,2024-05-20,131.69,132.09,129.69,130.69,
DXCM,2024-05-21,131.1,131.56,129.91,130.84,
DXCM,2024-05-22,130.73,131.76,130.1,130.53,
DXCM,2024-05-23,129.97,129.97,125.365,125.6,
DXCM,2024-05-24,125.82,128.24,124.54,127.37,
DXCM,2024-05-28,126.7,128.04,125.15,127.38,
DXCM,2024-05-29,126.82,128.63,126.19,127.64,
DXCM,2024-05-30,127.61,127.61,117.2,118.4,
DXCM,2024-05-31,120.15,121.473,116.26,118.77,
DXCM,2024-06-03,118.16,118.38,114.33,115.23,
DXCM,2024-06-04,115.63,117.06,114.68,116.71,
DXCM,2024-06-05,116.77,120.48,116.06,118.08,
DXCM,2024-06-06,117.5,118.175,114.2,115.3,
DXCM,2024-06-07,114.73,116.58,114.242,115.79,
DXCM,2024-06-10,115.05,116.96,114.62,116.57,
DXCM,2024-06-11,116.92,118.12,115.72,116.9,
DXCM,2024-06-12,116.6,118.8,115.96,117.121,
DXCM,2024-06-13,115.16,116.33,113.67,113.78,
DXCM,2024-06-14,113.55,116.01,113.24,115.95,
DXCM,2024-06-17,115.18,117.91,114.75,116.53,
DXCM,2024-06-18,116.53,117.49,116.13,116.64,
DXCM,2024-06-20,116.94,117.12,115.49,116.1,
DXCM,2024-06-21,117.18,117.27,114.22,116.64,
DXCM,2024-06-24,116.41,116.6,109.751,110.61,
DXCM,2024-06-25,111.36,111.82,108.74,110.31,
DXCM,2024-06-26,110.28,113.83,110.16,113.5,
DXCM,2024-06-27,112.69,114.97,112.56,114.54,
DXCM,2024-06-28,114.29,114.58,111.86,113.38,
DXCM,2024-07-01,113.0,115.295,111.0,112.17,
DXCM,2024-07-02,112.17,113.08,111.01,112.49,
DXCM,2024-07-03,112.4,112.49,109.81,110.91,
DXCM,2024-07-05,111.17,113.83,110.03,113.7,
DXCM,2024-07-08,113.5,113.5,110.63,110.97,
DXCM,2024-07-09,111.32,111.519,110.44,110.84,
DXCM,2024-07-10,110.84,111.29,109.42,110.79,
DXCM,2024-07-11,111.125,113.8,110.8,112.58,
DXCM,2024-07-12,112.65,115.34,111.67,114.1,
DXCM,2024-07-15,113.54,114.77,112.05,113.04,
DXCM,2024-07-16,112.93,116.12,112.27,116.06,
DXCM,2024-07-17,116.04,117.19,114.58,114.59,
DXCM,2024-07-18,114.49,116.345,110.66,110.7,
DXCM,2024-07-19,111.73,112.14,110.04,111.66,
DXCM,2024-07-22,112.76,113.25,110.75,111.65,
DXCM,2024-07-23,111.65,113.28,110.441,112.13,
DXCM,2024-07-24,111.97,113.08,110.0,111.96,
DXCM,2024-07-25,111.17,112.55,107.56,107.85,
DXCM,2024-07-26,66.0,67.44,62.34,63.99,
DXCM,2024-07-29,65.03,68.93,64.1701,67.48,
DXCM,2024-07-30,68.54,70.79,67.82,69.7,
DXCM,2024-07-31,69.9,70.88,67.0,67.8,
DXCM,2024-08-01,68.15,71.23,68.11,70.34,
DXCM,2024-08-02,69.45,72.61,68.91,72.32,
DXCM,2024-08-05,69.16,75.1498,69.16,72.435,
DXCM,2024-08-06,72.92,77.32,72.75,75.25,
DXCM,2024-08-07,72.0054,73.2,69.07,69.32,
DXCM,2024-08-08,69.8,71.76,69.795,71.5,
DXCM,2024-08-09,71.56,72.34,69.62,69.76,
DXCM,2024-08-12,69.76,72.12,69.01,71.27,
DXCM,2024-08-13,71.01,72.15,70.37,71.02,
DXCM,2024-08-14,70.4,71.02,69.655,70.05,
DXCM,2024-08-15,70.97,72.46,69.9,72.36,
DXCM,2024-08-16,72.55,74.73,72.51,74.65,
DXCM,2024-08-19,74.78,77.77,74.5,77.69,
DXCM,2024-08-20,76.0,77.58,72.39,72.85,
DXCM,2024-08-21,73.75,73.75,72.15,73.2,
DXCM,2024-08-22,73.67,74.56,72.18,72.28,
DXCM,2024-08-23,72.35,75.195,72.08,74.07,
DXCM,2024-08-26,73.66,75.0,73.51,73.67,
DXCM,2024-08-27,74.14,74.31,71.95,72.24,
DXCM,2024-08-28,72.06,72.22,70.31,70.48,
DXCM,2024-08-29,71.15,71.5,69.45,69.62,
DXCM,2024-08-30,70.0,70.43,68.99,69.34,
DXCM,2024-09-03,68.91,73.28,68.91,72.36,
DXCM,2024-09-04,71.45,71.71,69.33,69.82,
DXCM,2024-09-05,69.655,69.8,67.52,69.05,
DXCM,2024-09-06,69.24,69.27,66.95,68.61,
DXCM,2024-09-09,68.87,71.56,68.74,69.71,
DXCM,2024-09-10,69.83,70.01,68.06,68.55,
DXCM,2024-09-11,68.38,68.56,66.86,68.46,
DXCM,2024-09-12,68.47,69.3,67.3441,68.82,
DXCM,2024-09-13,68.97,69.9,68.17,69.51,
DXCM,2024-09-16,70.42,71.52,69.93,70.09,
DXCM,2024-09-17,69.85,70.97,68.59,68.94,
DXCM,2024-09-18,69.4,70.63,69.08,69.46,
DXCM,2024-09-19,70.88,72.34,70.2671,71.905,
DXCM,2024-09-20,71.91,71.91,69.71,70.44,
DXCM,2024-09-23,70.47,70.92,69.61,69.7,
DXCM,2024-09-24,69.86,69.9999,68.5544,68.66,
DXCM,2024-09-25,68.61,68.68,66.32,66.73,
DXCM,2024-09-26,67.0,67.71,66.33,67.53,
DXCM,2024-09-27,68.43,68.6,67.14,67.29,
DXCM,2024-09-30,67.77,68.27,66.495,67.04,
DXCM,2024-10-01,67.39,67.39,65.29,66.0,
DXCM,2024-10-02,65.7,67.19,64.78,67.1,
DXCM,2024-10-03,66.82,67.1499,65.58,65.69,
DXCM,2024-10-04,66.45,68.99,66.22,68.11,
DXCM,2024-10-07,68.025,69.5717,67.81,68.61,
DXCM,2024-10-08,68.86,69.63,68.57,69.4,
DXCM,2024-10-09,69.17,69.725,68.83,69.62,
DXCM,2024-10-10,69.16,70.0,68.57,69.54,
DXCM,2024-10-11,69.96,70.02,69.06,69.21,
DXCM,2024-10-14,69.18,69.18,68.2,69.18,
DXCM,2024-10-15,68.85,69.09,67.04,67.1,
DXCM,2024-10-16,67.585,69.96,67.585,69.9,
DXCM,2024-10-17,69.9,70.4,69.2033,69.55,
DXCM,2024-10-18,69.5,72.4,69.26,72.38,
DXCM,2024-10-21,71.87,73.79,71.81,72.61,
DXCM,2024-10-22,72.1,73.12,71.84,73.08,
DXCM,2024-10-23,72.32,73.23,72.2,72.48,
DXCM,2024-10-24,73.21,75.13,73.03,74.85,
DXCM,2024-10-25,73.4,76.06,70.88,73.44,
DXCM,2024-10-28,73.48,74.6,71.6,72.09,
DXCM,2024-10-29,72.25,72.58,70.88,72.24,
DXCM,2024-10-30,72.1,72.56,71.09,71.8,
DXCM,2024-10-31,71.1651,71.61,69.74,70.48,
DXCM,2024-11-01,70.1,71.08,69.88,70.35,
DXCM,2024-11-04,70.88,71.01,69.65,69.7,
DXCM,2024-11-05,69.0,69.0,68.37,69.0,
DXCM,2024-11-06,69.635,70.25,67.895,68.61,
DXCM,2024-11-07,68.79,68.98,67.695,68.91,
DXCM,2024-11-08,68.9,70.99,68.735,69.96,
DXCM,2024-11-11,70.135,72.04,69.71,70.315,
DXCM,2024-11-12,69.46,75.47,69.23,74.36,
DXCM,2024-11-13,74.455,74.55,71.84,72.51,
DXCM,2024-11-14,72.6,75.78,71.75,74.68,
DXCM,2024-11-15,75.51,77.96,75.13,75.88,
DXCM,2024-11-18,75.88,78.16,75.69,76.27,
DXCM,2024-11-19,75.7,76.61,74.65,74.88,
DXCM,2024-11-20,74.73,75.31,72.94,75.24,
DXCM,2024-11-21,74.83,75.76,74.17,74.46,
DXCM,2024-11-22,74.85,75.286,72.51,72.83,
DXCM,2024-11-25,74.215,78.22,73.3,77.83,
DXCM,2024-11-26,78.65,79.38,76.9401,77.94,
DXCM,2024-11-27,78.43,78.62,77.21,78.1,
DXCM,2024-11-29,78.31,79.37,77.89,77.99,
DXCM,2024-12-02,78.19,80.18,77.5001,79.31,
DXCM,2024-12-03,79.085,81.11,78.0901,80.91,
DXCM,2024-12-04,80.86,82.26,80.69,81.01,
DXCM,2024-12-05,80.91,81.0,78.06,78.92,
DXCM,2024-12-06,78.71,79.5,77.33,77.72,
DXCM,2024-12-09,78.09,79.11,77.55,78.41,
DXCM,2025-01-27,88.58,89.59,87.35,87.53,
DXCM,2025-01-28,87.01,89.0,86.6501,88.35,
DXCM,2025-01-29,88.15,88.31,86.04,86.43,
DXCM,2025-01-30,86.61,88.7,86.61,87.62,
DXCM,2025-01-31,86.87,88.29,86.59,86.83,
DXCM,2025-02-03,88.0,88.42,86.79,87.05,
DXCM,2025-02-04,85.002,87.95,85.002,87.46,
DXCM,2025-02-05,87.46,88.86,87.01,88.78,
DXCM,2025-02-06,88.85,89.58,87.66,88.32,
DXCM,2025-02-07,88.52,88.72,87.595,88.08,
DXCM,2025-02-10,88.38,88.425,85.6044,88.27,
DXCM,2025-02-11,87.52,88.02,86.28,86.38,
DXCM,2025-02-12,85.07,85.29,83.78,83.87,
DXCM,2025-02-13,83.96,84.58,83.2,84.09,
DXCM,2025-02-14,86.03,89.84,86.0,89.07,
DXCM,2025-02-18,90.0,93.25,89.57,90.53,
DXCM,2025-02-19,90.77,91.74,89.115,89.68,
DXCM,2025-02-20,89.45,89.84,88.36,89.34,
DXCM,2025-02-21,88.6,89.87,87.56,88.78,
DXCM,2025-02-24,88.82,91.22,88.5,90.81,
DXCM,2025-02-25,90.71,91.87,87.93,88.34,
DXCM,2025-02-26,87.68,90.66,86.41,89.91,
DXCM,2025-02-27,89.44,89.96,87.73,87.82,
DXCM,2025-02-28,87.84,88.6,86.88,88.37,
DXCM,2025-03-03,88.67,88.74,85.64,86.02,
DXCM,2025-03-04,85.65,86.14,81.85,82.42,
DXCM,2025-03-05,82.61,83.54,81.5,81.96,
DXCM,2025-03-06,80.44,81.745,79.09,79.51,
DXCM,2025-03-07,79.7,80.29,76.82,77.84,
DXCM,2025-03-10,74.74,74.92,70.47,70.71,
DXCM,2025-03-11,71.15,71.45,69.02,70.27,
DXCM,2025-03-12,70.915,72.3,69.86,70.76,
DXCM,2025-03-13,70.7,70.715,68.48,68.48,
DXCM,2025-03-14,68.59,70.77,68.59,70.67,
DXCM,2025-03-17,70.31,71.99,70.3,71.35,
DXCM,2025-03-18,71.25,71.35,69.92,70.7,
DXCM,2025-03-19,70.71,74.42,70.71,73.38,
DXCM,2025-03-20,72.9,76.27,72.52,75.11,
DXCM,2025-03-21,74.17,74.485,72.73,73.84,"3 Stocks That May Be Trading Below Estimated Value In March 2025 As the U.S. stock market navigates a period of mixed performance, with major indices like the Dow Jones and S&P 500 experiencing fluctuations amid economic uncertainties and tariff concerns, investors are keenly observing potential opportunities that may arise from these volatile conditions. In this environment, identifying stocks that are trading below their estimated value can be crucial for those looking to capitalize on potential market inefficiencies while considering factors such as inflation projections and Federal Reserve policies. Click here to see the full list of 197 stocks from our Undervalued US Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: DexCom, Inc. is a medical device company that specializes in designing, developing, and commercializing continuous glucose monitoring systems globally, with a market cap of approximately $27.63 billion. Operations: The company's revenue is primarily derived from its Patient Monitoring Equipment segment, which generated $4.03 billion. Estimated Discount To Fair Value: 35.5% DexCom is trading 35.5% below its estimated fair value of US$113.71, suggesting it may be undervalued based on cash flows. Despite a recent FDA warning letter concerning manufacturing processes, the company continues to project robust growth with anticipated 2025 revenue of US$4.60 billion and earnings expected to grow at 19.1% annually, outpacing the broader market. The appointment of Renée Galá as a director could bolster strategic leadership amid these challenges. The analysis detailed in our DexCom growth report hints at robust future financial performance. Take a closer look at DexCom's balance sheet health here in our report. Overview: Atlassian Corporation, with a market cap of approximately $57.50 billion, designs, develops, licenses, and maintains various software products worldwide through its subsidiaries. Operations: The company's revenue primarily stems from its Software & Programming segment, which generated approximately $4.79 billion. Estimated Discount To Fair Value: 33.9% Atlassian is trading at US$229.86, significantly below its estimated fair value of US$347.81, which highlights potential undervaluation based on cash flows. The company has shown consistent revenue growth, with recent quarterly earnings revealing a revenue increase to US$1.29 billion from the previous year's US$1.06 billion despite ongoing net losses. Analysts expect Atlassian to achieve profitability within three years, with anticipated high returns on equity and robust revenue growth surpassing market averages. Upon reviewing our latest growth report, Atlassian's projected financial performance appears quite optimistic. Click here and access our complete balance sheet health report to understand the dynamics of Atlassian. Overview: Smurfit Westrock Plc, along with its subsidiaries, is involved in the manufacturing, distribution, and sale of containerboard, corrugated containers, and other paper-based packaging products with a market cap of $23.43 billion. Operations: The company's revenue segments include North America at $10.09 billion, Latin America at $1.71 billion, and Europe, the Middle East and Africa, and Asia-Pacific collectively at $9.58 billion. Estimated Discount To Fair Value: 48.9% Smurfit Westrock, trading at US$46, is significantly undervalued with an estimated fair value of US$89.98. Despite recent insider selling and profit margins declining to 1.5% from 6.8%, the company forecasts strong earnings growth of 26% annually, outpacing the market average. However, its dividend yield of 3.75% isn't well-covered by free cash flows, and debt coverage by operating cash flow remains a concern amidst ongoing board changes and acquisition pursuits. According our earnings growth report, there's an indication that Smurfit Westrock might be ready to expand. Unlock comprehensive insights into our analysis of Smurfit Westrock stock in this financial health report. Investigate our full lineup of 197 Undervalued US Stocks Based On Cash Flows right here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:DXCM NasdaqGS:TEAM and NYSE:SW. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"
DXCM,2025-03-24,75.045,75.81,74.67,75.32,
DXCM,2025-03-25,75.24,76.01,72.52,73.55,
DXCM,2025-03-26,73.25,73.3965,71.47,72.13,
DXCM,2025-03-27,71.895,72.47,69.41,69.47,
DXCM,2025-03-28,69.5,69.89,67.37,67.74,
DXCM,2025-03-31,67.22,68.75,66.25,68.26,
DXCM,2025-04-01,67.85,68.4,66.32,67.32,
DXCM,2025-04-02,66.32,68.52,66.32,68.14,
DXCM,2025-04-03,64.875,65.0,61.48,61.8,
DXCM,2025-04-04,59.63,60.97,57.59,59.83,
DXCM,2025-04-07,58.03,62.9,58.0,61.63,
DXCM,2025-04-08,62.5,63.86,59.97,60.76,
DXCM,2025-04-09,60.09,67.63,59.62,66.81,
DXCM,2025-04-10,72.8,73.5,66.46,67.36,
DXCM,2025-04-11,67.385,67.6599,64.99,66.14,
DXCM,2025-04-14,67.66,68.07,66.48,67.39,
DXCM,2025-04-15,67.4,69.32,66.978,69.23,
DXCM,2025-04-16,68.865,69.56,67.75,68.73,"Tariffs, Trump, and Turmoil In this podcast, Motley Fool analysts talk about economic uncertainty, airlines, building materials, and assorted spirits. Motley Fool analyst Asit Sharma caught up with Martín de los Santos, the CFO of MercadoLibre, at The Motley Fool's Market Volatility Summit. They talked about how MercadoLibre became resilient, and the long-term opportunities for the company. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy. A full transcript is below. Before you buy stock in MercadoLibre, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MercadoLibre wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $526,499!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $687,684!* Now, it’s worth noting Stock Advisor’s total average return is 818% — a market-crushing outperformance compared to 156% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of April 14, 2025 This video was recorded on April 11, 2025 Ron Gross: T is for tariffs, Trump and Turmoil. Motley Fool money starts now. From fool Global headquarters. This is Motley Fool Money. It's the Motley Fool Money Radio Show. I'm Ron Gross sitting in for Dylan Lewis. Joining me today, our senior analyst, Emily Flippen and Matt Argersinger fools, how you doing? Matt Argersinger: Ron. Emily Flippen: Doing all right. Matt Argersinger: Doing all right. Ron Gross: Glad to hear it. Today, we're going to talk banks and assorted spirits, but we must, once again, begin with the big macro and, oh, boy, what a week it has been following several very rough days in the stock market, on Wednesday, the Trump administration put a 90-day pause on its so-called reciprocal tariff policy, sending the market soaring for its biggest one day gain since 2008. Then, on Thursday, inflation data came in tamer than expected and just for good measure, on Thursday, we saw another sell-off in stocks. Emily, I am truly exhausted. But let's dig in. Where are we now from an economic markets perspective? I know you don't have a crystal ball, but where do you think we're going? Emily Flippen: If financial media has anything to say about it, it's straight to hell on a handbasket here for American consumers and investors. I'm teasing here because I really don't necessarily think that is going to be the case. While we still have a lot of economic data that is not coming out as favorably as I think some investors want, and that's leading to some of that volatility we're seeing in the market, the earlier inflation metrics that we got earlier this week, we're actually very encouraging. It was a sign that some of the concerns that I think we had around stagflation may be coming down a bit. Now, that is the core PPI, the producer price index that excludes food and energy, but it's the Fed's favored inflation metric here. That actually fell nominally month over month. And it wasn't just a matter of, Okay, this is lower than expected, but still rising inflation, but an actual month-over-month decline here. Of course, if we add food and energy, the story changes. But this is a little bit of a silver lining that I think investors need to say, OK, we have a lot of data that's pointing in the wrong direction right now. Here is something that continues to say, it may not be as bad as we expect. But of course, the emphasis is, of course, on this was the case. Inflation metrics are a lagging indicator. We're always forward-looking. Some of the policies that we've seen since this data has come out over the course of the past month, I think, are pretty clearly indicating that inflation is expected to heat up substantially. But I'll take this when for this week. Ron Gross: What about from the markets? Do you think the markets are just nervous, don't like uncertainty? That's what we typically say. Markets hate uncertainty, and there's so much uncertainty around here nowadays. Do you think that's why we're seeing the volatile the big sharp moves? Emily Flippen: I don't think it's just uncertainty. I think there's genuine concern about the business impacts that these tariffs, if they stay in place, will have both on companies that are supplying, manufacturing, as well as consumers looking to make purchases. This has wide-ranging implications for the performance of the broader economy as a whole. It's not just a matter of uncertainty because I think if we came out tomorrow and said, Okay, we are certain, 100% sure. The tariffs, as they are today, are going to stick this way for the next 12 months for certain, for example. That would be certainty. But I'll tell you what, I bet the stock market would sell off. Ron Gross: Oh. Understood. Matt, US consumer sentiment is now worse than during the Great Recession. New data just came out. Anything here for an individual investor to do other than sit back and just watch it unfold? Matt Argersinger: Sitting back is very good advice. Watching it unfold, I don't know. You're better off just turning everything off and maybe going away for a week. But look, we're investors. I know that's impossible. It's definitely impossible for me. But here's what I think if you're an investor, what you can or should pay attention to, and that is interest rates. The Trump administration only really blinked this past week when the 10 yield crossed about 4.5%. But guess where we are today as we tape on Friday, back above 4.5%, Ron. If you go back to April 2nd, which was Liberation Day, as the administration called it, the 10-year was just above 4%. We're up 50 basis points in a week, and that's through all this market dislocation. It usually doesn't work that way. Usually, investors are buying treasuries as a safe haven during times like this. That's just not happening right now and I think that is where the real danger lies, and I think Emily hinted at this. I mean, if countries like China and, Japan UK, various members of the EU stop buying our treasuries, either because they're exporting less as a result of these tariffs, and they don't have as many US dollars to invest anyway, or much worse, guys, they willfully decide to stop buying treasuries in favor of other safe-haven assets or currencies. I mean, just look at the Swiss franc as of the past week. If that happens, it will almost certainly send treasury yields much higher. And I think that would spell huge trouble for the housing market, which we already know is suffering from high mortgage rates. Imagine mortgage rates not at six or 7% as they are now, but 8, 9, 10%. I think it also spells big trouble for small, midsize businesses who don't have as much flexibility with their balance sheets and where they source their products. It's bad for auto manufacturers, bad for commercial real estate and then to consumers to Emily's point. Consumers are sitting on record credit card debt and if interest rates move higher that situation gets a lot worse. I think it really could mean bad news for the economy. If you're going to watch anything at all, sit back and watch this shake out, watch treasury yields. If they keep moving higher, I expect that could trigger a response by the administration. To be less aggressive with these tariffs, maybe come to the table, that'll be the trigger point. Ron Gross: I was going to say one silver lining may be we do have anecdotal evidence that the administration does keep an eye on the bond market, and on interest rates, that could very well be the reason we got the 90 day pause. We don't necessarily have proof of that, but that certainly could be. I would encourage them to keep an eye on the yields, so we don't get into too much trouble, as you outlined. But speaking of interest rates, on Friday, many of the larger banks reported pretty solid results for the first quarter, and Matt, lots of data, plenty of commentary from the CEOs. What's set out to you in these reports? Matt Argersinger: Results you said, Ron, the results were actually really solid. The problem is no one really cares about that right now. It's really all about guidance and how these CEOs are thinking about the environment, post tariffs, post-liberation Day and what they see going forward. Here's what they're saying. If you look at CEO Jamie Diamond, CEO of the largest US bank, JP Morgan, he's been pretty vocal this past week about the dangers of tariffs, even saying he believes that a recession is all but unavoidable now. And then he said this after his bank reported quarter results, ""The economy is facing considerable turbulence, potential negatives of tariffs and trade wars,"" ongoing sticking inflation, high fiscal deficits, and still rather high asset prices and volatilities. What else he said? Wells Fargo's CEO, Charlie Sharf, ""We support the administration's willingness to look at barriers to fair trade to the United States. Though there are certainly risks associated with such significant actions, a timely resolution, which benefits the US, would be good for businesses, consumers, and the markets. We expect continued volatility and uncertainty and are prepared for a slower economic environment in 2025"" Then Larry Fink, CEO of Blackrock, which I think is now the world's largest ass manager, ""The sweeping tariff announcements went further than I could have imagined in my 49 years in finance."" Then in an interview on CNBC, he also said, ""I think we're very close if not in a recession now,"" talking about, of course, the US economy. Ron Gross: Thanks for cheering us up, Matt. Matt Argersinger: Well, there you go. Let me sum it up, too. These tarifs are dangerous. If not resolved quickly, the risks are high, expect continued uncertainty, which we keep talking about, and we may already be in a recession. Remember, these are the banks and financial institutions that have a pulse, I think, in a lot of areas of the economy, which is from housing to credit, consumer spending. Wait until we start hearing from industrial companies or consumer discretionary companies, especially those that make and sell products all around the world. What will be their reactions and guidance when they report in the coming weeks? I think this is just the first Salvo, and it's sobering when you look at it, in terms of what they're seeing. Ron Gross: On Wednesday, Constellation Brands reported fourth-quarter results that beat expectations, but a week full-year earnings outlook that focused on the impact of, yes, tariffs was the focus. Emily, how did the quarter look to you? Is it possible for us to remove tariffs from this conversation and focus on the business, or they are so intertwined, just can't do that. Emily Flippen: I actually think that tariffs are maybe the least interesting thing happening to Constellation Brands business today. I understand why the narrative was around tariffs. It's like you can open up an Internet browser without being slapped across the face with news about tariffs and how they're going to be impacting companies. Certainly, Constellation Brands did say in the quarter that they're expecting a low single-digit increase in their total cost of goods that's associated with the tariffs and sourcing, of course, aluminum cans and other bottling items for the beers and the accessories, I'll say, for the wine and spirits business that they sell. But all of this stuff is happening to Constellation Brands. Meanwhile, Constellation Brands as a business itself, is actually doing a pretty decent job of a turnaround, especially considering the overall beer market. I think it's a disappointment that there's not more discussion around how strong this business has been in an incredibly weak environment for alcohol sales. If you compare their performance against other large beer makers, Boston Beer, with Sam Adams being a great example, which has seen declining depletions, declining shipments, declining profitability and sales, Constellation Brands is growing and growing pretty solidly because the beer brands that it is continuing to focus on just have continued to resonate with a consumer that's a little bit more niche, that is a bit more loyal, and that has led to pretty incredible market share gains really consistently for this company in otherwise weak environment. I love that Constellation Brands has performed so well. I'm disappointed that the narrative is, Oh, no, that small single-digit increase associated with the tariffs. But I actually think fast forwarding five years from now, we're probably looking at a better business than today. Ron Gross: They're selling some of their wine brands, Cooks, Miomi, that a good movie? You like that? Emily Flippen: I do. They're actually almost entirely divesting of their wine and spirits business. And if you look at their performance on earnings per share, non-adjusted basis for the quarter, you'll see the impact of that nearly $3 billion in goodwill write-offs associated with the sale of that business, which has been an underperformer for them for a while. That is obviously a ding on them. Some of the investments this company has made historically just haven't panned out. But they're really focusing on cost energies right now and focusing on what works, which is obviously the Corona, the Medello, the Pacificos. Those have an audience that are way more loyal than not to be offensive to Miomi, which I love their wine is a bit more loyal. Ron Gross: Coming up, we'll talk airlines, building materials, and used cars. You're listening to Motley Fool Money. ... Ron Gross: Welcome back to Motley Fool Money. I'm Ron Gross here with Emily Flippen and Matt Argersinger. On Wednesday, Delta reported that revenue growth stalled a bit in the first quarter and the company did not reaffirm its full year guidance, citing headwinds from the economic uncertainty around global trade. Matt, seems to me it wasn't the quarterly results, but the lack of full year guidance that spooked investors. Shares were up big on Wednesday as Trump paused tariffs, but the stock got smacked on Thursday as investors continued to digest what it all means. As I asked Emily with constellation, I'd love to strip out the economic noise here and talk about the business. Can we do that? Matt Argersinger: Well, let's try, Ron. It was actually a record quarter for Delta in terms of revenue. Pretty surprising, revenue was up 3.3% year over year, 13 billion, and growth was particularly strong in the premium segment of the business. So first class, business class, revenue there was up 7% year over year. International revenue was also pretty strong, and even corporate revenue was higher year over year, and Delta generated 1.3 billion in free cash flow in the quarter, paid down about 500 million in long term debt. All fairly positive and aligned with what CEO Ed Bastian said near the beginning of the year, which was that 2025 was going to be Delta's best financial year in our history. That is not really working out. Ron Gross: Maybe not so much. Matt Argersinger: Because even if you go back a month ago, Delta had actually guided for 6-8% revenue growth this quarter. That's a big comedown from that. According to Bastion, things actually started to slow back in February. Well, before these tariff announcements or any hint of them, the company slashed its first quarter forecast. It did maintain its full year outlook back then, though. As you mentioned, Ron, that has now changed. They're not reaffirming that year outlook anymore. The company has pulled its guidance. It's still expecting to be profitable this year, but a far cry from where the company thought things would be coming into the year. I think you have to worry a lot about the state of the consumer here. What travel demand is going to look like, say, over the next 6-9 months, you mentioned the consumer sentiment numbers at the top of the show. One thing that's got to be helping Delta a little bit, though, over the past week is the fall in energy prices that we've seen. It's a big cost input for every airline including Delta. That will undoubtedly help Delta's margins and probably help the company remain profitable for the year if not growing. Ron Gross: On Thursday, CarMax reported worse than expected fourth quarter results, and while it said it was making progress toward its financial goals, it will remove the timelines associated with them due to the potential impact of broader macro factors. Emily, I know I sound like a broken record here, but the macro environment is hard to escape. Do your best. Tell me how CarMax's business is doing. Emily Flippen: I actually think the business is doing a lot better than people expect, especially, again, given the narrative right now. I understand that the market is in part selling off CarMax for a few different factors. Of course, one aspect of the tariff implication for CarMax and any other business that is operating in the auto parts industry is that the used car parts that it needs in order to fix and resell vehicles on its platform, those are likely to increase, and that's likely to hurt margins at least in that narrow perspective. There's also an element of, Okay, used car prices are likely to increase with the tariffs as well, and that could hurt demand for used cars. That could certainly pride some people out of market, and management was so uncertain of this environment that they did pull that guidance for vehicle sales, which is concerning to investors adding to the uncertainty. You can make the logical argument there for the interim of like, Okay, I understand what's happening here to CarMax. But I actually think that a little bit longer term, taking it one step further, we're likely to see similarly to what we saw during the pandemic that used car prices are likely to go up and that could price some people out of the market. But it's actually a boon for a lot of leaders in this space like CarMax, when the prices of used cars go up, especially in comparison to something like a new vehicle 'cause a new vehicles will also increase making used cars look relatively more attractive for consumers who can make a purchase plus higher cost means higher fees for CarMax. All of that is to say, I actually think they could make up some of the margin here, and the future may not be as negative for CarMax as some investors are pricing in today. Ron Gross: All things considered, does CarMax go on your radar or you still go away? Emily Flippen: If I had a radar stock this month that I thought was an attractive value that I could make a 22nd, 32nd pitch for it, CarMax would certainly be up there. Digging into it this morning and in preparation for our show here, it reminded me this is an incredibly strong, profitable company, market share leader with a lot of tailwinds if you're willing to hold and overlook some of the near term uncertainty. Ron Gross: Sounds good. On Tuesday, RPM International reported fiscal third quarter results that came in weaker than expected, and the maker of Deglo and Rustleum blamed unfavorable weather conditions and said that sales would be flat in the fourth quarter. Matt, RPM does a lot of business overseas, so it's got the trade situation plus the weather to contend with. How the quarter look to you, and does it tell us anything about industrial activity in general? Matt Argersinger: Well, lots of headwinds for RPM and lots of headwinds in general for industrial activity, even coming into this quarter and all the tariff news. Really two big challenges for them. They had record results last year in last year's fiscal third quarter, so comparisons are tough. But weather was a big problem in the quarter. If you don't know RPM, they serve primarily in the construction industry, and in much of the country, you had a fairly lengthy winter and then a lot of unusual storm activity in the south and the West, which really affected them. Slow housing market also continues to have an impact. That's been a story for a few years now. Until that picks up, RPM's consumer business is really going to struggle. Sales were down 3% overall. Pre tax operating profits, this is a business with high operating leverage we're down around 30%. With regard to tariffs, though, the good news for RPM is that they tend to be fairly insulated. For the most part, the company manufactures products in the countries or regions where it sells them. They do small amount of cross border activity. It sounds like a situation for RPM, where sales may be slightly down for the year with lower margins, but here is something, Ron, you and Emily can be excited about. RPM is acquiring the pink stuff. Ron Gross: The pink. Matt Argersinger: Which I'm sure, if you've ever done an industrial cleaning of a bathroom, you've definitely use or at least should use. So the pink stuff joins other cleaning products within RPM's portfolio, including Crud Cutter, Mean Green, and Contobum, if I'm pronouncing that correctly. That guy sounds like the 1927 Yankees when it comes to cleaning portfolio lineup. Ron Gross: I love it. Alright, fools. We'll see you a little bit later in the show. Up next, an interview with Martin de los Santos. He's the CFO of Mercado Libre, E-commerce giant and the largest company in Latin America. You're listening to Motley Fool Money. Welcome back to Motley Fool Money. I'm Ron Gross. Molly Fool senior analyst Asit Sharma caught up with Martin de los Santos, the CFO of Mercado Libre, a few weeks ago at our Market Volatility Summit. In this clip, you'll hear how Mercado Libre became resilient in the long term opportunities for Meli. Motley Fool members can access the full interview and replays from the event at live.fool.com. Asit Sharma: Martin, I wanted to start. Just looking at this company in general, Mercado Libre has such a history of dealing with formidable challenges from hyperinflation and geopolitical events within Latin America to providing fintech and lending services to populations that often are new to the banking and credit systems. What makes Mercado Libre such a resilient business? Martin de los Santos: Yes, we were founded back in '99, and we turned 25 years in 2024. With those 25 years, as you can imagine, in Latin America, operating in 19 different countries, we've seen it all. Things going sour very rapidly. Maybe Mezuela as an example, hyperinflation in Argentina, then things coming back as we are seeing it today, Brazil, Mexico. I think we went through a lot during those years. I would highlight a couple of things. First, we operate in commerce and Fintech in a region where there's a lot to be done in those two fronts. Production of commerce continues to be very low compared to other places. We are riding a secular trend of people moving online. The same with Fintech, I think the banks have done a really poor job of including financially, most of the population in Latin America, so that generates an opportunity for us. That's one thing. I will also highlight the culture of the company. Our CEO, our chairman continues to be Marcos Galbrin, who was the founder of the company. Not only him, a lot of people were with him at the beginning continues to be with the company. We have a very strong culture of entrepreneurship, willingness to take risks. Many times in the history of our company, we have to reinvent ourselves or take big bets, and that's a big part of our success, a culture of excellence, execution, bringing good talent, teamwork internally while competing because we operating in very competitive markets to the outside. I think I would say that we operate in a region that has tremendous opportunities, both commerce and Fintech, and we also have a culture of executing and operating in Latin America that has helped us to be resilient and to be successful in this. Latin America, we came from being a start-up of five people in the garage 25 years ago to last year we became the most valuable company in Latin America, and we have done that I think by culture and execution and the quality of people that we brought into our team. Asit Sharma: I liked one thing that you mentioned between the culture and the execution, which is the ability to take a risk, to take those big bets. How are things different now that you sit in the chair of a CFO to make sure that the bets have a commensurate payoff for the risk and also maybe in some cases to be the person who's encouraging the company to take those risks? Martin de los Santos: It's not only my role. I think it's the role of the senior management team. We keep on thinking about the trade off between growth and profitability. In fact, we have a name for that within Meli we call it grow fit because we operating many different verticals have tremendous growth opportunities, but at the same time, they require investments. If you look at the history of the past five, six years, we improve significantly the profitability of our business. While at the same time, we continue to deliver very high growth in both in commerce, Fintech, advertising at the different verticals. However, when we look forward, we don't shy away from investing, even if in the short term, that might put some pressure on margins because the main thing for us is to make sure that we do capture those opportunities that we had ahead of us and not necessarily to maximize short term profits. We do have a long term perspective on the business, but that's a trade off that we do it all the time, deciding where to invest and sacrifice a little bit of margins to capture opportunities in the future, and the whole company and the whole senior management team is thinking in those terms. Then it does risk taking, I think it's the nature of our business. You mentioned I used to run the credit business, which we started back in 2017. That's probably the ultimate one that you need to manage and to deal with risk, and we're very cautious in the way we manage that risk. But in other cases in the history of our company, maybe 15 years ago, we took a big bet on adapting our platform to mobile, and that required lot of risk and a mindset of really changing the way we were doing things. If we didn't do that, we wouldn't have a company today. Ten years ago, we started with logistics, which is critical for e-commerce solution. If you think about it ten years ago, we didn't touch one single package. Today, last year, we have 1.8 billion packages delivered through our own fulfillment infrastructure or logistic infrastructure. I think those type of beds that when you need to do when you need to take risk and make sure that you invest behind the long term growth opportunities, that's what differentiates mainly from other companies that might not be willing to take those risks. Asit Sharma: I wanted to ask you about some overall metrics that you use as you look at the business. I used to work for a company where while we had so many drill down metrics, the owner would come in every day, and he said, I just need one number to run this business. Now, that wasn't true. You need more than one number to run a business. But it taught me something that people like yourself often Kean on a few metrics almost on a daily basis. How do you gauge the health of Mercado Libre from day to day? Martin de los Santos: Yeah, we are a very data oriented company. Business reviews that are so deep in terms of analysis and data that is true. It's hard to keep up with all the businesses. It's very complex Mercado Libre today. So it's important to have some, big picture views, and then you can drill down whenever you see something that we want to go into more detail. Many different businesses, 19 different countries. You can imagine that the metrics are hundreds. But I would say that obviously, top line metric GMB on our commerce business is very important. Users, last year, I mentioned we have 100 million users, or 100 million buyers on our commerce platform. In terms of engagement, transactions per user is a metric that we follow very closely. That's on the commerce side. On the Fintech side, obviously number of users, 61 million monthly active users last quarter. TPV for the acquiring business, then credit book, asset and the mansion that has been growing more than 100% year and years, is a metric that is very important to see engagement with our platform and then frequency of use. In Fintech is very important to have principality. We're seeing people who have engaged with more than one product and how often they engage with different products. That's something that we pay a lot of attention. Then the credit business, obviously, the traditional metrics, MPLs, the spreads of our books, the different books, and so on the repayment of our credit card, for instance, which is a product that you need to invest to build a cohort, I would say those. Obviously, financial metrics at the end of the quarter, at the end of each month are very important to see top line growth, as well as profit margins are the two ones, the two metrics that tells us how we are doing in terms of growth feed rate profitability, as well as growth. Asit Sharma: Strategically, where you sit, where are you focusing the organization to create the most value when we look out over a very long time horizon? Is there a specific activity or investment that's going to create the greatest yield as we look beyond, say, the medium term that you like to talk about within the management team and encourage employees to think about? Martin de los Santos: Very important to have an owner's mentality team. We operate. We are fortunate to operate in a platform in a company. That has, as we like to say, has more doors to be open, that has to open them. We have opportunities everywhere we see. In commerce, we're just getting started. Penetration is very low. We continue to grow at a very rapid pace north of 30% year and year, twice the speed of the market, so we're continuing to gain market share. Even after 25 years, we're growing at start-up rates. On Fintech in Mexico, less than half the population have a bank account. Less than 15% have a credit card. The opportunity is immense as well to continue growing. Advertising, we mentioned it before, everywhere you look at mainly there are opportunities. We are fortunate to have a lot of resources to take on those opportunities. 18,000 developers, a very well, very strong balance sheet to invest. We generate lots of cash, even though we are investing in our business as well. I think the big challenge is when you don't have a clear constraint is how to make sure that you are investing in the right things. That represents not only choosing what to invest, but also choosing what not to do, not to get and also to make sure that you are investing on things that really have a good payout, and they actually result in growth going forward. That's something that continuously my team and my colleagues at the sea level are continuously looking at, at the end of the day is maintaining this growth feed mentality that we have been operating. We want to make sure that we hit the growth targets. While, not shying away from investing, even if in the short term, we might put some pressure on margins. We don't mind. We don't run the business on a quarter by quarter basis. We run the business for the next 25 years. Ron Gross: Coming up after the break, Emily Flippen and Matt Argersinger return with a couple of stocks on their radar. Stay right here. You're listening to Motley Fool Money. As always, people on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against. Don't buy r sell stocks based solely on what you hear. All personal finance content follows Motley Fool editorial standards and are not approved by advertisers. The Motley Fool only picks products that it would personally recommend to friends like you. Welcome back to Motley Fool Money Ron Gross here with Emily Flippen and Matt Argersinger Fools, we've got time for two quick stories before we hit stocks on our radar. Let's start with the Walmart news on Wednesday, Walmart withdrew its earnings guidance, citing uncertainty surrounding the Trump administration's newly imposed tariffs specifically on China. Emily, the health of Walmart can tell us a lot about the health of the consumer and, frankly, the economy as a whole. What did you take away from these actions by Walmart management? Emily Flippen: Unfortunately, my takeaway is that things will likely get worse before they get better. The silver lining to this is that Walmart did reaffirm its sales guidance. They actually are perceived to have a little bit more clarity into how consumers are behaving versus what their bottom line may look like, which is obviously heavily impacted by things like tariffs and any negotiations there. Not only does Walmart really act as that bellwether for how consumers are behaving, but it's also really easy to forget that Walmart's a little bit of a bellwether and a leader for other businesses that look to Walmart for guidance. So many companies are likely watching Walmart's decision here to pull back guidance on their bottom line, and they could potentially adopt a very similar wait-and-see approach here as it applies to their own guidance. And that can almost turn into a self-fulfilling prophecy of economic slowing and leading to a market sell-off all because of the cautiousness around things like earnings guidance. Now, I think that could be a dramatic interpretation, of course, and I'll just quickly mention that Walmart does have much more complex supply lines than a lot of other small businesses. Their certainty and clarity there could be more opaque than other companies. But the fact that they are a bellwether for both consumers, which we focus on, as well as other businesses is a bit of a red flag. Ron Gross: The new Superman movie is scheduled to hit theaters this July. As listeners know, I am a Superman fanatic, really looking forward to it. Admittedly, the movies haven't always been so super, but there is a new sneak peek out there. I know you have both seen it, so I'm curious to ask. Do we have a hit on our hands or a dud? Did you have a favorite part of the sneak peek? I'll go to you first Matt. Matt Argersinger: Well, how can you not love Krypto coming in there, Krypto the super dog, coming in to rescue Superman from whatever ails him in that particular scene. But no, look, I think it looks awesome. I think Gunn did a fantastic job with the Guardians of Galaxy movies. I like that he's bringing a lot of interesting characters into the Superman movie, including looks like Hawk Man's in there. Looks like Guy Gardner, the Green Lantern characters in there. I'm excited. I'm going to go see it with my son, for sure. Emily, a hit or a dud? Emily Flippen: Well, let's put it this way. You're barking up the wrong tree, because I am not a superhero movie watcher. But I will say this. I watched the trailer at your bequest, and I didn't know the creepy CGI dog had a name. Nice to know. Matt Argersinger: You don't know Krypto? A creepy CGI dog. Emily Flippen: There's a lot of CGI in that trailer. CGI has come a long way. I don't know what I'm talking about, as it applies to CGI. I will say, it was obviously CGI, though. I do think it's a little bit of a red flag if you're having to bring in other superheroes to attract excitement. What does that say about Superman? Ron Gross: Well, I am hopeful, and my favorite part is when the Fortress of solitude rises out of the snow as Superman gets closer, almost like it could sense where he was. I love that part. Very cool. Alright, Fools, a quick personal note before we hit stocks on our radar. This will be my last Motley Fool Money radio show. It has been the joy of my career to play a small part in the financial journey of as Chris Hill would say, our dozens of listeners. Thank you for letting me share my thoughts with you for 16 wonderful years. Thank you all very much. I really appreciate it. Matt Argersinger: Ron, can I just say? Ron Gross: Yes, Matt. Matt Argersinger: Sixteen years, actually, 17 years with the Motley Fool. You've been a colleague, a mentor, a leader, most of all, a friend. I wish you the very best in retirement, and we will do our very best. It will be a lot harder now, but we will do our very best to keep this show firing on all cylinders. Ron Gross: [laughs] I appreciate that. Thanks, Martin. Very nice. Fools, we have time for a couple of stocks on our radar, so let's close out the show that way, and I will bring in our man Dan Boyd, to ask a question and pick his favorite. Emily, you're up first. What have you got? Emily Flippen: I'm looking at Dexcom this week. It's nice to have a little bit of positive news in a world that is changing around us so rapidly. Some of the excitement here for Dexcom did get drowned out by tariff talk. But Dexcom did see a little bit of a revival this week because they did get FDA approval for their newest continuous glucose monitor that is a Dexcom G7. It could be worn for up to 15 days so that extending the life versus their previous model, it puts them in more direct competition with Abbott, who is one of their competitors, which also has the FreeStyle Libre, which can be worn up to 15 days. Ahead of Metronic. I definitely move in the right direction here for Dexcom. CGM penetration for diabetics worldwide is still so much lower than what it should be, considering the health benefits that it can bring. I will say, though, I always have in the back of my head, just the fear around a couple of things. One is weight loss drugs, leading to a decline in type 2 diabetes that could eat up some of the market here for Dexcom, as well as actually a potential cure for something like diabetes. That's further down the line, but a lot of research and time is being spent into it, considering it is such a deadly and expensive disease. Ron Gross: Dan, you got a question or a comment? Dan Boyd: Dexcom it's one of these companies that the name doesn't really match up with what they do. The name, to me, is, like, something out of Superman, very sinister. But what they do very good for society. I don't know what to do here, Emily. Emily Flippen: That's a good point. I will say Abbott sharing its name with Abbott Elementary. Sounds like the friendlier of the options, but I like Dexcom more, despite the name. Ron Gross: Matt, you're up. What have you got? Matt Argersinger: Ron, I'm looking at RobinHood Markets. Ticker H-O-O-D. This is an unusual one for me. I just want to stress, this is a true radar stock, a company I'm just beginning to take a look at. But I heard a great interview with Robin Hood's chief brokerage officer last week. If you look at where young people, I'm talking mainly Emily's age, where they're going to open up brokerage accounts. It's not Fidelity. It's not Charles Schwab. It's certainly not Interactive Brokers where I tend to toil. It's Robin Hood. Nearly 26 million funded customers, many, I think most of which are in their 20s and 30s. When that large cohort of investors matures, starts opening retirement accounts, trust accounts, getting mortgages, doing more sophisticated trading. I think Robin Hood is really growing its offerings to like, a whole range of financial services. They also have the Robin Hood Gold membership, which is approaching three million accounts. It offers members higher levels of market data, greater margin access, could be dangerous, and then higher interest on cash and accounts. I have to say, I'm a shareholder in Schwab and I will probably be a shareholder in Schwab for a long time. But if I'm going to make a long term bet on a brokerage company, I might also want to have exposure to a brokerage company that has the most young people coming to it because it's likely to prosper right alongside that growth over time. Ron Gross: Dan, got a question? Dan Boyd: Yeah, when I hear Robin Hood, I associate it with meme stocks like GameStop and AMC and all that jazz. Is this a company that actually has legs, or is it just something that's going to be a flash in the pan? Matt Argersinger: Dan, I thought the same thing. It's the meme stock brokerage. But the fact that they have 26 million funded customers, and that has continued growing way past the GameStop and AMC stuff that we saw several years ago, that gives you confidence that has long term staying power. Ron Gross: I, too, am a Charles Schwab shareholder, not a Robin Hood one, but I'll take a look. Could be interesting. Dan, you got a favorite fear watch list? Dan Boyd: Well, it really seems like Dexcom is, like, the smart choice, but Robin Hood, I feel like is the more interesting choice. Can I do both on your last day, Ron? Ron Gross: You can do whatever you want, Dan. Both it is. Dan Boyd: That's awesome. Ron Gross: Emily Flippen and Matt Argersinger, thanks for being here, my friends. That's going to do it for this week's Motley Fool Money. Our tremendous engineer is Dan Boyd. I am Ron Gross. Thanks for listening. The Motley Fool Money Radio Show, we'll see you next week. JPMorgan Chase is an advertising partner of Motley Fool Money. Charles Schwab is an advertising partner of Motley Fool Money. Wells Fargo is an advertising partner of Motley Fool Money. Asit Sharma has no position in any of the stocks mentioned. Dan Boyd has no position in any of the stocks mentioned. Emily Flippen, CFA has positions in Constellation Brands and MercadoLibre. Matthew Argersinger has positions in Boston Beer, Charles Schwab, MercadoLibre, and RPM International and has the following options: short May 2025 $45 puts on Delta Air Lines. Ron Gross has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Boston Beer, CarMax, Interactive Brokers Group, JPMorgan Chase, MercadoLibre, and Walmart. The Motley Fool recommends Charles Schwab, Constellation Brands, Delta Air Lines, DexCom, and RPM International and recommends the following options: long January 2027 $65 calls on DexCom, short January 2027 $75 calls on DexCom, and short June 2025 $85 calls on Charles Schwab. The Motley Fool has a disclosure policy. Tariffs, Trump, and Turmoil was originally published by The Motley Fool"
DXCM,2025-04-17,66.99,68.78,66.53,68.605,
DXCM,2025-04-21,68.07,68.12,65.11,66.11,
DXCM,2025-04-22,67.09,67.305,65.53,66.33,
DXCM,2025-04-23,68.5,70.21,66.81,66.9,
DXCM,2025-04-24,67.79,70.98,67.545,70.78,
DXCM,2025-04-25,70.85,72.28,70.355,71.66,
DXCM,2025-04-28,72.3,72.6,70.5731,71.18,
DXCM,2025-04-29,71.275,71.46,70.29,71.3,
DXCM,2025-04-30,70.29,71.57,69.75,71.36,
DXCM,2025-05-01,71.38,71.71,69.7,70.26,
DXCM,2025-05-02,75.26,81.88,75.175,81.62,
DXCM,2025-05-05,81.525,81.96,80.0018,80.242,
DXCM,2025-05-06,79.232,82.48,78.5501,81.53,
DXCM,2025-05-07,81.53,83.885,80.5,83.35,
DXCM,2025-05-08,84.0,85.74,83.48,85.34,
DXCM,2025-05-09,85.0,85.71,84.23,84.67,
DXCM,2025-05-12,87.02,87.02,84.31,85.05,"Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns Health and fitness companies focus on improving and maintaining physical well-being through products and services including gym memberships, fitness equipment, nutritional supplements and wellness programs. Here we recommend five stocks from the Health and Fitness space with a favorable Zacks Rank to enhance your portfolio returns. Their favorable Zacks Rank indicates more upside in the near term. These are: Sprouts Farmers Market Inc. SFM, DexCom Inc. DXCM, Hims & Hers Health Inc. HIMS, United Natural Foods Inc. UNFI and GoodRx Holdings Inc. GDRX. Health and fitness companies benefit from consistent demand on growing global awareness of health issues and the importance of physical fitness. This trend is supported by rising rates of lifestyle-related diseases and a growing emphasis on preventive healthcare. The space’s growth is backed by diverse revenue streams, which include subscriptions, product sales and services, making it attractive to investors seeking long-term gains. Moreover, technological advancements, such as fitness trackers and wearable fitness devices, provide new opportunities for growth and drive further consumer engagement and revenue potential. However, the market is highly competitive. Economic downturns can impact consumer spending on non-essential health and fitness products. Rapid changes in consumer preferences and health trends can make it challenging for companies to continuously lure customers. The chart below shows the price performance of our five picks year to date. Image Source: Zacks Investment Research Sprouts Farmers’ focus on product innovation, emphasis on e-commerce, expansion of private label offerings and targeted marketing with everyday great pricing bodes well. SFM has been lowering operational complexity, optimizing production, improving in-stock position and updating to smaller-format stores. These efforts helped SFM post better-than-expected fourth-quarter 2024 results, wherein both top and bottom lines grew year over year. Buoyed by the performance, Sprouts Farmers provided a decent 2025 view. SFM expects net sales to rise between 10.5% and 12.5% with comps anticipated to increase in the range of 4.5-6.5%. SFM’s strong sales growth, margin expansion and disciplined financial management position it as a compelling investment opportunity. SFM currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Sprouts Farmers has an expected revenue and earnings growth rate of 13.7% and 33.6%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.2% over the last seven days. DexCom has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth have acted as the key catalysts. DXCM’s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DexCom made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM’s slew of tie-ups with AID systems is encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom currently carries a Zacks Rank #2 (Buy). DexCom has an expected revenue and earnings growth rate of 14.3% and 23.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings remained same over the last seven days. Zacks Rank #2 Hims & Hers Health addresses a vast unmet healthcare market, leveraging a $360M U.S. TAM across specialties like mental health, weight loss, and dermatology. HIMS’ personalized product offerings drive subscriber growth, with 2M+ subscribers contributing to rising recurring revenues. Targeting $100M from new categories by 2025, HIMS invests in GLP-1 weight-loss solutions, advanced tech, and compounding pharmacies to scale. While new launches temporarily pressure margins, Hims & Hers focuses on efficiency and long-term profitability. Competing with players like Teladoc, HIMS differentiates through personalized care, proprietary tech, and vertical integration. Hims & Hers Health has an expected revenue and earnings growth rate of 58.5% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 9.4% over the last seven days. Zacks Rank #2 United Natural Foods has continued to demonstrate strong growth and operational discipline, supported by wholesale momentum and sustained demand for natural and organic products. UNFI’s strategic initiatives such as customer base expansion, network optimization, investment in automation, and adoption of lean management practices have driven notable gains in efficiency, cost savings and service quality. UNFI raised its full-year fiscal 2025 outlook following solid second-quarter results. That said, challenges remain in the form of softness in retail, pressure on gross margins due to product mix and pricing strategies, and higher industry competition. UNFI’s continued focus on execution, digital capabilities, margin improvement and retail repositioning will be critical to sustaining momentum and long-term shareholder value creation. United Natural Foods has an expected revenue and earnings growth rate of 1.9% and more than 100%, respectively, for the current year (ending July 2025). The Zacks Consensus Estimate for current-year earnings has improved 7.9% over the last 60 days. Zacks Rank #2 GoodRx Holdings offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. GDRX operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. GDRX also offers other healthcare products and services, including subscriptions and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, GDRX provides healthcare products and solution for dogs, cats, and other pets. GDRX serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings has an expected revenue and earnings growth rate of 4% and 14.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings remained the same over the last 60 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report Sprouts Farmers Market, Inc. (SFM) : Free Stock Analysis Report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-05-13,84.65,85.54,83.84,84.11,"The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx Chicago, IL – May 13, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sprouts Farmers Market Inc. SFM, DexCom Inc. DXCM, Hims & Hers Health Inc. HIMS, United Natural Foods Inc. UNFI and GoodRx Holdings Inc. GDRX. Health and fitness companies focus on improving and maintaining physical well-being through products and services including gym memberships, fitness equipment, nutritional supplements and wellness programs. Here we recommend five stocks from the Health and Fitness space with a favorable Zacks Rank to enhance your portfolio returns. Their favorable Zacks Rank indicates more upside in the near term. These are: Sprouts Farmers Market Inc., DexCom Inc., Hims & Hers Health Inc., United Natural Foods Inc. and GoodRx Holdings Inc. Growing Demand for Health and Fitness Companies Health and fitness companies benefit from consistent demand on growing global awareness of health issues and the importance of physical fitness. This trend is supported by rising rates of lifestyle-related diseases and a growing emphasis on preventive healthcare. The space’s growth is backed by diverse revenue streams, which include subscriptions, product sales and services, making it attractive to investors seeking long-term gains. Moreover, technological advancements, such as fitness trackers and wearable fitness devices, provide new opportunities for growth and drive further consumer engagement and revenue potential. However, the market is highly competitive. Economic downturns can impact consumer spending on non-essential health and fitness products. Rapid changes in consumer preferences and health trends can make it challenging for companies to continuously lure customers. Sprouts Farmers Market Sprouts Farmers’ focus on product innovation, emphasis on e-commerce, expansion of private label offerings and targeted marketing with everyday great pricing bodes well. SFM has been lowering operational complexity, optimizing production, improving in-stock position and updating to smaller-format stores. These efforts helped SFM post better-than-expected fourth-quarter 2024 results, wherein both top and bottom lines grew year over year. Buoyed by the performance, Sprouts Farmers provided a decent 2025 view. SFM expects net sales to rise between 10.5% and 12.5% with comps anticipated to increase in the range of 4.5-6.5%. SFM’s strong sales growth, margin expansion and disciplined financial management position it as a compelling investment opportunity. SFM currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Sprouts Farmers has an expected revenue and earnings growth rate of 13.7% and 33.6%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.2% over the last seven days. DexCom DexCom has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth have acted as the key catalysts. DXCM’s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DexCom made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM’s slew of tie-ups with AID systems is encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom currently carries a Zacks Rank #2 (Buy). DexCom has an expected revenue and earnings growth rate of 14.3% and 23.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings remained same over the last seven days. Hims & Hers Health Zacks Rank #2 Hims & Hers Health addresses a vast unmet healthcare market, leveraging a $360M U.S. TAM across specialties like mental health, weight loss, and dermatology. HIMS’ personalized product offerings drive subscriber growth, with 2M+ subscribers contributing to rising recurring revenues. Targeting $100M from new categories by 2025, HIMS invests in GLP-1 weight-loss solutions, advanced tech, and compounding pharmacies to scale. While new launches temporarily pressure margins, Hims & Hers focuses on efficiency and long-term profitability. Competing with players like Teladoc, HIMS differentiates through personalized care, proprietary tech, and vertical integration. Hims & Hers Health has an expected revenue and earnings growth rate of 58.5% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 9.4% over the last seven days. United Natural Foods Zacks Rank #2 United Natural Foods has continued to demonstrate strong growth and operational discipline, supported by wholesale momentum and sustained demand for natural and organic products. UNFI’s strategic initiatives such as customer base expansion, network optimization, investment in automation, and adoption of lean management practices have driven notable gains in efficiency, cost savings and service quality. UNFI raised its full-year fiscal 2025 outlook following solid second-quarter results. That said, challenges remain in the form of softness in retail, pressure on gross margins due to product mix and pricing strategies, and higher industry competition. UNFI’s continued focus on execution, digital capabilities, margin improvement and retail repositioning will be critical to sustaining momentum and long-term shareholder value creation. United Natural Foods has an expected revenue and earnings growth rate of 1.9% and more than 100%, respectively, for the current year (ending July 2025). The Zacks Consensus Estimate for current-year earnings has improved 7.9% over the last 60 days. GoodRx Holdings Zacks Rank #2 GoodRx Holdings offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. GDRX operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. GDRX also offers other healthcare products and services, including subscriptions and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, GDRX provides healthcare products and solution for dogs, cats, and other pets. GDRX serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings has an expected revenue and earnings growth rate of 4% and 14.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings remained the same over the last 60 days. Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report Sprouts Farmers Market, Inc. (SFM) : Free Stock Analysis Report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-05-14,83.64,86.565,83.64,86.52,"Top Health & Fitness Stocks to Buy for the Wellness Boom An updated edition of the March 24, 2025 article.The health and fitness space has transformed into a thriving industry, fueled by growing public interest in leading healthier lives. More people are prioritizing wellness, pushing up demand for gyms, supplements, and holistic services. Tech has played a big role here — wearable devices and digital platforms have made it easier than ever to monitor progress and stay motivated. At the same time, rising concerns around obesity, chronic illness, and mental health are prompting even more individuals to adopt fitness-focused lifestyles.Tech giants like Apple AAPL and Amazon AMZN are leaning into this shift. Apple’s ecosystem includes the Apple Watch and its Fitness+ service, offering users real-time health data and guided workouts. Amazon is also making moves in healthcare with acquisitions like One Medical, combining artificial intelligence (AI)-powered tools with virtual care. These efforts are reshaping how people manage their health, and in turn, accelerating industry growth.Looking ahead, the global health and wellness market is expected to hit around $1.1 trillion by 2034, at a steady 7.33% CAGR from 2025. Emphasis on preventive care, alongside corporate wellness programs and government-backed initiatives, is keeping the momentum strong. The rise of boutique fitness and premium wellness clubs is also opening the door for more specialized offerings. Consumers are shifting toward a more integrated view of health — where fitness, nutrition, and mental well-being go hand in hand — creating multiple revenue streams for brands in the space. Companies like Sprouts Farmers Market SFM, Hims & Hers Health HIMS and DexCom DXCM are the leading players in this movement.For investors, this trend presents a compelling long-term opportunity. As wellness becomes a top priority for more consumers, demand for fitness, nutrition, and digital health services is expected to grow. Our Health & Fitness Screen is designed to put the spotlight on high-potential stocks — like the four above — making it easier to find strong opportunities in this expanding market.Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity. Sprouts Farmers Market has carved out a strong niche in the specialty grocery space, putting fresh, natural, and organic products front and center. Its store design revolves around an open-market concept, where produce takes the spotlight. Surrounding it is a handpicked assortment of organic, plant-based, and gluten-free goods tailored to health-conscious shoppers. From fresh meats and dairy alternatives to vitamins and supplements, Sprouts offers lifestyle-focused choices. Its private-label Sprouts Brand has gained serious traction — generating over 23% of revenue in 2024 — by delivering exclusive, high-quality items at value-driven prices.Now operating 440 stores across 24 states, Sprouts continues to expand with a focus on smaller-format locations that bring fresh, premium food closer to communities. A key part of its strategy lies in logistics: the Zacks Rank #1 (Strong Buy) company is optimizing its supply chain by placing distribution hubs within 250 miles of most stores. This boosts produce freshness and supports local sourcing. At the same time, Sprouts is leaning into digital innovation with app-based ordering, delivery options, and personalized marketing, all contributing to a seamless omnichannel shopping experience.You can see the complete list of today’s Zacks #1 Rank stocks here.Sustainability is more than a buzzword for Sprouts — it’s woven into the company’s mission. In 2024, organic products made up 30% of total sales, while plant-based offerings climbed 27%. The company continues to prioritize responsible sourcing, food waste reduction, and carbon footprint management. Through its Sprouts Healthy Communities Foundation, over $35 million has been invested since 2015 in nutrition education and food access programs. By combining eco-conscious practices with a commitment to health and wellness, Sprouts is reinforcing its role as a go-to grocer for mindful consumers. Hims & Hers Health has steadily evolved into a broad-based digital health and wellness platform, offering personalized solutions for conditions like hair loss, mental health, dermatology, weight loss, and sexual wellness. Their services are primarily delivered via telehealth, where customers access licensed providers through the company’s platform. These providers prescribe medications—both branded and compounded — which are fulfilled through Hims & Hers-affiliated pharmacies. In addition to prescription products, the company also offers over-the-counter health, skincare, and supplement items, many under their own brand, available online or through retail partnerships.Hims & Hers’ fitness and wellness offerings have expanded significantly in recent years, with notable moves into weight management. The Zacks Rank #2 (Buy) company launched compounded semaglutide in mid-2024 and later added branded versions, tying into its broader telehealth weight loss program. New capabilities like a peptide manufacturing facility and a lab testing business (acquired in early 2025) aim to support long-term growth in this segment. These additions enhance their ability to provide medically-backed, personalized treatments for conditions such as obesity, testosterone imbalance, and sleep disorders — areas often tied to physical fitness and overall well-being.Underlying this expansion is a scalable tech platform that supports recurring subscription models and end-to-end care, from virtual consultation to medication delivery. Their approach reduces barriers like stigma and access limitations, particularly for first-time healthcare seekers. The platform’s structure allows Hims & Hers to respond quickly to growing demand for lifestyle-related care, positioning the company as a consumer-first health partner with a strong foothold in the digital fitness and wellness space.DexCom’s health and fitness-related business centers around continuous glucose monitoring (CGM) systems designed to support people managing diabetes and those focused on improving metabolic health. Its core products — G6, G7, and the newly launched Stelo biosensor — offer real-time glucose tracking, mobile connectivity, and seamless data sharing via wearables like Apple Watch. The G7 system, with a smaller sensor and faster warm-up time, offers advanced alerts and an intuitive mobile app, while the over-the-counter Stelo targets adults with prediabetes and non-insulin-dependent Type 2 diabetes, broadening Dexcom’s reach into wellness and preventive care.Over the years, Dexcom has expanded beyond insulin-dependent users through strategic product development and partnerships. Its CGM systems are now integrated with insulin pumps and smart pens, allowing for semi-automated insulin delivery. More recently, Dexcom has collaborated with digital health players and consumer technology brands to make CGM data available in fitness platforms, extending usage beyond clinical diabetes management. These efforts are aligned with Dexcom’s broader vision of helping a wider population manage glucose levels and gain insights into their metabolic health.Dexcom’s platform continues to evolve, with development aimed at people who are obese, pregnant, or hospitalized. Their CGM systems are built for continuous use, replacing traditional finger-stick methods and offering wearable comfort and connectivity. Dexcom’s real-time APIs allow developers to integrate glucose data into various health and fitness applications. Through its advanced biosensors, predictive alerts, and growing focus on general health, #2 Ranked Dexcom is positioning itself as not just a diabetes tech leader but also a key player in the evolving health and fitness ecosystem. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN) : Free Stock Analysis Report Apple Inc. (AAPL) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Sprouts Farmers Market, Inc. (SFM) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-05-15,86.21,86.85,84.76,85.7,"[""Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest Quarterly earnings results are a good time to check in on a company\u2019s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst performers in the patient monitoring industry. Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges. The 5 patient monitoring stocks we track reported a strong Q1. As a group, revenues beat analysts\u2019 consensus estimates by 2.2% while next quarter\u2019s revenue guidance was 0.9% below. Luckily, patient monitoring stocks have performed well with share prices up 17.3% on average since the latest earnings results. Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. ResMed reported revenues of $1.29 billion, up 7.9% year on year. This print was in line with analysts\u2019 expectations, but overall, it was a mixed quarter for the company with EPS and constant currency revenue in line with analysts\u2019 estimates. \u201cOur positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for our best-in-class products and software solutions,\u201d said Resmed\u2019s Chairman and CEO, Mick Farrell. ResMed delivered the weakest performance against analyst estimates and slowest revenue growth of the whole group. Interestingly, the stock is up 15.2% since reporting and currently trades at $246.99. Is now the time to buy ResMed? Access our full analysis of the earnings results here, it\u2019s free. Revolutionizing diabetes care with its tubeless \""Pod\"" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line. Insulet reported revenues of $569 million, up 28.8% year on year, outperforming analysts\u2019 expectations by 4.8%. The business had an exceptional quarter with a solid beat of analysts\u2019 constant currency revenue and EPS estimates. Insulet delivered the biggest analyst estimates beat and fastest revenue growth among its peers. The market seems happy with the results as the stock is up 25.3% since reporting. It currently trades at $322. Is now the time to buy Insulet? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1989 to solve the \""unsolvable problem\"" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement. Masimo reported revenues of $372 million, up 9.5% year on year, exceeding analysts\u2019 expectations by 1.1%. Still, it was a mixed quarter as it posted a significant miss of analysts\u2019 full-year EPS guidance estimates. Masimo delivered the weakest full-year guidance update in the group. As expected, the stock is down 3.5% since the results and currently trades at $155. Read our full analysis of Masimo\u2019s results here. Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. iRhythm reported revenues of $158.7 million, up 20.3% year on year. This print surpassed analysts\u2019 expectations by 3.3%. It was a strong quarter as it also logged full-year revenue guidance beating analysts\u2019 expectations. iRhythm pulled off the highest full-year guidance raise among its peers. The stock is up 27% since reporting and currently trades at $138.38. Read our full, actionable report on iRhythm here, it\u2019s free. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. DexCom reported revenues of $1.04 billion, up 12.5% year on year. This result beat analysts\u2019 expectations by 1.8%. Taking a step back, it was a satisfactory quarter as it also produced a solid beat of analysts\u2019 organic revenue estimates but a miss of analysts\u2019 EPS estimates. The stock is up 22.3% since reporting and currently trades at $85.95. Read our full, actionable report on DexCom here, it\u2019s free. In response to the Fed\u2019s rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed\u2019s 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump\u2019s presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here."", ""5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which market watchers expect will take the healthcare industry by storm. Since the beginning of 2023, the industry has been witnessing mass adoption of AI and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healthcare settings. GenAI has begun to showcase its proficiency across a range of healthcare fields, from time-consuming administrative tasks to critical areas such as technological discovery and clinical trials. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. At this stage, it should be prudent to invest in stocks from the Zacks-defined Medical Instrument industry with a favorable Zacks Rank. We have selected five such stocks that have provided double-digit returns in the past month during which Wall Street suffered severe volatility. These stocks are: DexCom Inc. DXCM, IDEXX Laboratories Inc. IDXX, NeuroPace Inc. NPCE, Fresenius Medical Care AG FMS and ClearPoint Neuro Inc. CLPT. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The chart below shows the price performance of our five picks in the past month. Image Source: Zacks Investment Research DexCom has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth have acted as the key catalysts. DXCM\u2019s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DXCM made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM\u2019s slew of tie-ups with AID systems is encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom has an expected revenue and earnings growth rate of 14.3% and 23.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.5% over the last 60 days. IDEXX Laboratories\u2019 robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. This underscores the consistent growth in the CAG international business, supported by volume gains and global premium instrument placements. IDXX\u2019s software solutions are facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Also, the consumable business boosts IDXX\u2019s top line. IDXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. IDEXX Laboratories has an expected revenue and earnings growth rate of 5.8% and 14%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.4% over the last seven days. NeuroPace operates as a medical device company in the United States. NPCE develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. NPCE\u2019s RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, NPCE provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. NPCE sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace has an expected revenue and earnings growth rate of 18.1% and 15.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 12.2% over the last 60 days. Fresenius Medical Care has been benefiting from strong organic growth on the back of improving treatment volumes as well as a stabilizing labor environment in the United States. Continued improvement in these two key factors should be beneficial for FMS in 2025. Overall pricing momentum also supported growth in the Care Enablement segment. FMS\u2019 newly implemented operating model led to operational improvements. FMS generated 221 million euros in savings in 2024 by implementing initiatives under the FME25 transformation program. FMS\u2019 continued divestment of its noncore and dilutive assets seems promising. Fresenius Medical Care has an expected revenue and earnings growth rate of 1.6% and 28.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.4% over the last seven days. ClearPoint Neuro operates as a medical device company primarily in the United States. CLPT develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. CLPT offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. ClearPoint Neuro has an expected revenue and earnings growth rate of 24.1% and 11.4%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.6% over the last 30 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report ClearPoint Neuro, Inc. (CLPT) : Free Stock Analysis Report NeuroPace, Inc. (NPCE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-05-16,85.88,86.0,84.68,85.48,"[""Dexcom CEO says CGMs fit MAHA agenda \u2018very nicely\u2019; Tandem preps for new products This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom CEO Kevin Sayer touted the company\u2019s recent efforts to expand coverage of CGMs for people with Type 2 diabetes. On a May 1 earnings call, the CEO told investors that all three major U.S. pharmacy benefit managers now cover the company\u2019s G7 glucose monitor for anyone with diabetes. Dexcom expects to have coverage for nearly 6 million people with Type 2 diabetes who don\u2019t take insulin by the end of the year. \u201cWhile this still represents only a portion of this 25 million-person population in the U.S., we often see smaller and customized plans quickly follow suit of the larger PBM formularies,\u201d Sayer said. Dexcom will seek coverage from Medicare for people with diabetes who don\u2019t take insulin. The company is working to gather evidence from a randomized controlled trial to submit a request to the Centers for Medicare and Medicaid Services, Sayer said. Wolfe Research analyst Mike Polark on the earnings call noted comments by Health and Human Services Secretary Robert F. Kennedy Jr. supporting CGMs. Food and Drug Administration Commissioner Martin Makary has also suggested making the devices more widely available. \u201cWe\u2019re very pleased with the comments of the administration,\u201d Sayer said, adding that the company thinks its devices \u201cfit the Make America Healthy agenda very nicely.\u201d Dexcom reported revenue of $1.04 billion in the first quarter, a 12% increase year over year. Tandem is seeking Europe\u2019s CE mark for its newer, smaller Mobi insulin pump, CEO John Sheridan said in an April 30 earnings call. Tandem received FDA clearance for the device in 2023. The company plans to launch Mobi outside of the U.S. with multiple sensor integrations by the year\u2019s end, Sheridan said. In February, Tandem received an expanded FDA indication for its Control-IQ+ algorithm for Type 2 diabetes. The algorithm pairs data from glucose monitors with the company\u2019s insulin pumps for automated dosing. Tandem hopes to launch the newer version of that algorithm internationally by the end of the year, pending regulatory approval, Sheridan said. The CEO also provided an update on Tandem\u2019s efforts to develop an insulin patch pump. The company is working on a tubeless feature for its Mobi pump that is now in verification testing and manufacturing buildout, Sheridan said. Meanwhile, the company has moved development of the Sigi patch pump that it acquired in 2022 to San Diego. Insulet, which received an expanded indication last year for its Omnipod 5 patch pump, said people with Type 2 diabetes represent a growing portion of new patients. Eric Benjamin, chief product and customer experience officer, told investors on May 8 that people with Type 2 diabetes made up more than 30% of new starts in the first quarter, an increase from 25% in the fourth quarter. The company grew revenue by nearly 29% to $569 million in the first quarter, compared to the year-ago period, and named longtime medtech executive Ashley McEvoy as CEO. Insulet estimated in February that the Type 2 indication expands the total addressable market for its patch pumps in the U.S. to more than 5.5 million people with Type 2 diabetes who take insulin. About 2.5 million of those people take multiple daily injections of insulin. Insulet estimated the market is less than 5% penetrated. Benjamin expects the company could double or triple that number, telling investors, \u201cRight now, we're making that market.\u201d Recommended Reading New Insulet CEO Ashley McEvoy sets priorities"", ""DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook Medical device company DexCom (NASDAQ:DXCM) beat Wall Street\u2019s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year\u2019s revenue to be around $4.6 billion, close to analysts\u2019 estimates. Its non-GAAP profit of $0.32 per share was in line with analysts\u2019 consensus estimates. Is now the time to buy DXCM? Find out in our full research report (it\u2019s free). Revenue: $1.04 billion vs analyst estimates of $1.02 billion (12.5% year-on-year growth, 1.8% beat) Adjusted EPS: $0.32 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $230.4 million vs analyst estimates of $251.9 million (22.2% margin, 8.5% miss) The company reconfirmed its revenue guidance for the full year of $4.6 billion at the midpoint Operating Margin: 12.9%, up from 11% in the same quarter last year Free Cash Flow Margin: 9.3%, down from 16.5% in the same quarter last year Organic Revenue rose 13.8% year on year (24.8% in the same quarter last year) Market Capitalization: $33.93 billion DexCom\u2019s first quarter results reflected ongoing momentum in its core continuous glucose monitoring (CGM) business, with management attributing growth to expanded commercial reach, increased patient starts\u2014particularly among type 2 non-insulin users\u2014and new product enhancements. CEO Kevin Sayer cited record levels of new customer acquisition, driven by broadened prescriber activity and new payer access wins, as well as the recent launch of Stelo, DexCom\u2019s over-the-counter biosensor, and updates to the G7 platform. Looking forward, management underscored the importance of continued payer coverage expansion, particularly with all three major pharmacy benefit managers (PBMs) now committed to covering DexCom\u2019s G7 for wider patient populations. CFO Jereme Sylvain emphasized the company\u2019s focus on managing supply chain costs and margin pressures, while maintaining investment in product innovation and operational efficiency. Sayer stated, \u201cWe believe we can continue to demonstrate our value time and time again,\u201d highlighting DexCom\u2019s efforts to secure broader access, data-driven outcomes, and regulatory clearances. DexCom\u2019s management provided detailed context on the drivers of first quarter performance and addressed several business-critical developments impacting the outlook for 2025. Type 2 Diabetes Access Gains: Management emphasized that recent wins with large PBMs have accelerated adoption among type 2 non-insulin users. The company saw a notable uptick in new patient starts from this population, which is now a material portion of overall new additions. Stelo Launch and Uptake: The over-the-counter Stelo sensor, targeting type 2 diabetes, prediabetes, and wellness users, continues to attract new customers. Stelo\u2019s app enhancements and expanded distribution, including availability on Amazon, have driven over 200,000 downloads to date. 15-Day G7 System Clearance: DexCom secured FDA approval for a 15-day wear G7 sensor, increasing convenience and potentially improving margins. The product is slated for launch in the second half of the year, with work underway to ensure compatibility with insulin pumps and payer coverage. Operational and Supply Dynamics: The company navigated short-term supply constraints by expediting shipments and working closely with distribution partners. Management acknowledged incremental freight costs but confirmed that manufacturing output and product quality have stabilized. FDA Warning Letter Response: DexCom addressed an FDA warning letter received in March, implementing corrective process controls without impacting new product approvals or ongoing distribution. Management expects to resolve outstanding issues while continuing to prioritize innovation. Management\u2019s outlook for 2025 centers on broadening access for DexCom\u2019s CGM products, scaling adoption among type 2 diabetes patients, and improving operational efficiency amid cost pressures. Broader Payer Coverage: Coverage expansion among major PBMs is expected to drive growth in the type 2 non-insulin segment, unlocking a larger addressable market and supporting continued high rates of new patient acquisition. Product Pipeline Execution: The upcoming launch of the 15-day G7 sensor and ongoing software enhancements\u2014such as Stelo app updates and integration with third-party wellness platforms\u2014are positioned to support retention, differentiation, and margin improvement over time. Margin Management and Cost Controls: Management highlighted ongoing programs to offset elevated freight costs and inflationary pressures, including leveraging prior investments in automation, AI, and sales force expansion. The ability to balance investment with efficiency is seen as key to maintaining operating margins despite external headwinds. Matt Taylor (Jefferies): Asked about the closure of the gap between volume and revenue growth. Management confirmed inventory normalization and record new patient starts, indicating that volume growth remains robust and consistent with earlier trends. Larry Biegelsen (Wells Fargo): Questioned why full-year guidance was unchanged despite strong Q1 organic growth. CFO Jereme Sylvain said it was too early to adjust guidance after one quarter, emphasizing a commitment to deliver on full-year targets. Danielle Antalffy (UBS): Sought insight on DexCom\u2019s resilience in a potential recession. Management cited strong payer coverage and the cost-saving value of CGM to health systems, expressing confidence in the company\u2019s positioning relative to peers. Jeff Johnson (Baird): Inquired about gross margin cadence and whether manufacturing issues persisted. Management stated margin improvement is expected later in the year and indicated that manufacturing output and quality are on track, with no ongoing process issues. Jayson Bedford (Raymond James): Probed on international revenue softness and supply dynamics. Management noted localized strength in Japan and France but acknowledged timing variability in international coverage wins, resulting in some quarterly choppiness. Looking ahead, the StockStory team will monitor (1) execution of the 15-day G7 system launch and its adoption rates, (2) continued expansion of coverage for type 2 non-insulin diabetes patients among payers, and (3) the pace at which supply chain costs normalize and margins recover. Additional signposts include data readouts from the type 2 diabetes randomized controlled trial and further growth in Stelo\u2019s user base. DexCom currently trades at a forward P/E ratio of 40\u00d7. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report. Donald Trump\u2019s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today."", ""Here's Why You Should Add DexCom Stock to Your Portfolio Now DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. However, risks related to stiff competition persist. This Zacks Rank #2 (Buy) company\u2019s shares have gained 10.1% year to date compared to the industry\u2019s 8.8% decline. The S&P 500 Index has declined 0.4% in the same time frame. DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $33.93 billion. It projects a 23.1% growth rate over the next five years and anticipates maintaining a strong performance going forward. DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, the average surprise being 0.47%. Image Source: Zacks Investment Research Let\u2019s delve deeper. Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. In the first quarter, Dexcom\u2019s G7 system continued its robust momentum. Accelerated conversion of the installed base for G7 manufacturing is driving strong revenue performance and improving gross margins. Both the U.S. and international markets benefited from enhanced reimbursement and access wins, underscoring the system\u2019s clinical value. In Europe, Dexcom\u2019s One+ system performed strongly. The company finalized the basal coverage for One+ in France during the fourth quarter. These trends underscore DexCom\u2019s growing market presence and the effectiveness of its innovative solutions in diabetes management and metabolic health. Internationally, Dexcom has seen pockets of strength in key markets, such as Japan and France, where recent type 2 diabetes coverage expansions have driven growth. New Product Launch: Dexcom plans to launch a 15-day G7 sensor in the second half of 2025, which is expected to bolster margins and enhance user experience. Additionally, efforts are underway to integrate AI-driven analytics, which deliver personalized insights and support improved patient care. DXCM is actively developing its next-generation sensor, G8, as its new hardware platform across its product portfolio. Building on the insights gained from G7, G8 will be a smaller, more advanced wearable that incorporates multi-analytic capabilities, enhancing its diagnostic potential. Key product innovations included the launch of Stelo, the first over-the-counter continuous glucose monitor (CGM), which is now available through Amazon's storefront. Dexcom also implemented several software and connectivity updates, including a 180-day data look-back feature, which enhances customer experience and supports wider user engagement. Stelo adoption is growing steadily, particularly among type 2, prediabetes and health-conscious consumers. In December, DXCM announced the launch of a proprietary Generative AI (GenAI) platform, making it the first CGM manufacturer to integrate GenAI into glucose biosensing technology. In November, DexCom inked a partnership with OURA with plans to expand its services into smart ring technology, a trending health tracker device. The collaboration is aimed at revolutionizing metabolic health management by integrating DexCom's glucose biosensor data with the biometric insights provided by the Oura Ring. The companies will also co-market and cross-sell each other\u2019s products. The first app integration resulting from the partnership is expected to be launched in 2025. Positive Coverages: Reimbursement expansion is also playing a crucial role in DexCom\u2019s growth, with insurance coverage extending beyond insulin users. As of January 2025, Dexcom secured coverage with two of the three largest pharmacy benefit managers (PBMs) for all people with diabetes, regardless of insulin use. This contributed to a significant uptick in new starts from the type 2 non-insulin population \u2014 the highest in the company\u2019s history. The third major PBM is set to add Dexcom G7 coverage in select formularies by mid-year, marking a transformational shift in CGM access across the United States. Strong Q1 Results: Dexcom delivered strong operational performance in the first quarter of 2025, driven by robust category demand, significant access wins and focused execution across its teams. The company reported record acceleration in demand from new customers, attributed to its expanded commercial reach following a broad prescriber base expansion in 2024. U.S. revenues (72% of total revenues) increased 15% on a year-over-year basis to $750.5 million. International revenues (28%) improved 7% (12% on an organic basis) year over year to $285.5 million. Adjusted gross profit totaled $596.2 million, up 4.8% from the prior-year quarter\u2019s level. The company reported total adjusted operating income of $143.1 million, up 2.1% from the prior-year period\u2019s recorded number. DexCom\u2019s strong revenue growth projection for 2025, driven by continued market expansion, broader access wins and advancements in its CGM technology, looks promising. The company expects revenues to be $4.6 billion, implying 14% year-over-year growth. Rebate Pressure: Dexcom is encountering notable rebate pressure in the U.S. market, which negatively impacted its revenue growth despite strong demand and improved sales force productivity. The rebate eligibility challenges resulted in a lower growth rate as reported revenue figures reflected these headwinds. Management anticipates that this pressure will become minimal throughout 2025 as efforts to stabilize the rebate channel take effect and support a more robust performance. Stiff Competition: Rising competition in the Type 1 diabetes market, particularly from pump-integrated CGM systems, adds pressure. Additionally, the leadership transition in the U.S. commercial team introduces potential risks to execution as DexCom navigates these dynamics. While challenges persist, the company\u2019s strategic initiatives and innovation-driven approach position it well for sustained growth. DexCom, Inc. price | DexCom, Inc. Quote DexCom has witnessed a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for 2025 earnings per share has moved down 1 cent to $2.02. The consensus mark for the company\u2019s second-quarter revenues is pegged at $1.12 billion, indicating an 11.8% improvement from the year-ago quarter\u2019s reported number. The consensus estimate for earnings is pinned at 45 cents per share, implying an improvement of 4.7% year over year. Some other top-ranked stocks from the same medical industry are GENEDX HOLDINGS WGS, CVS Health CVS and Cencora COR. GENEDX, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 336% for 2025. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. WGS\u2019 earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 145.82%. WGS\u2019 shares have declined 17.3% so far this year. CVS Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 12.2% for 2025. CVS\u2019 earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS\u2019 shares have risen 34.7% year to date. Cencora, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 16.7% for 2025. COR\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.00%. Its shares have gained 27.3% so far this year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-05-19,84.51,86.99,84.34,86.96,
DXCM,2025-05-20,85.875,87.6533,85.875,87.34,"[""3 Prominent Stocks Estimated To Be Trading Below Intrinsic Value By Up To 46.9% As the U.S. stock market navigates mixed performance amid rising Treasury yields and a recent credit rating downgrade, investors are keenly observing opportunities that may have been overlooked. In this environment, identifying stocks trading below their intrinsic value can be particularly appealing, as these investments might offer potential upside when market sentiment stabilizes. Click here to see the full list of 173 stocks from our Undervalued US Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: DexCom, Inc. is a medical device company that specializes in the design, development, and commercialization of continuous glucose monitoring systems both in the United States and internationally, with a market cap of approximately $33.52 billion. Operations: The company's revenue is primarily derived from its Patient Monitoring Equipment segment, which generated $4.15 billion. Estimated Discount To Fair Value: 24.6% DexCom is trading at US$85.48, significantly below its estimated fair value of US$113.33, indicating potential undervaluation based on discounted cash flows. Despite recent executive changes and a share repurchase program up to US$750 million, the company faces challenges such as an FDA warning letter regarding manufacturing processes. However, with revenue expected to grow faster than the U.S. market and earnings forecasted to rise significantly at 23.2% annually, DexCom presents a compelling case for investors focusing on cash flow valuation metrics amidst operational hurdles. Our earnings growth report unveils the potential for significant increases in DexCom's future results. Dive into the specifics of DexCom here with our thorough financial health report. Overview: Excelerate Energy, Inc. offers liquefied natural gas (LNG) solutions globally and has a market cap of approximately $3.52 billion. Operations: The company's revenue is primarily derived from its Utilities - Gas segment, which generated $966.41 million. Estimated Discount To Fair Value: 46.9% Excelerate Energy, trading at US$28.86, is significantly below its estimated fair value of US$54.34, highlighting potential undervaluation based on cash flows. The company reported strong Q1 2025 results with revenue jumping to US$315.09 million from US$200.11 million year-over-year and earnings per share doubling to US$0.48. While earnings are forecasted to grow at 17.9% annually, faster than the U.S market average, a low return on equity forecast of 12.5% could be a concern for investors focusing on profitability metrics amidst its expansion efforts such as M&A activities and strategic partnerships in LNG supply. Our comprehensive growth report raises the possibility that Excelerate Energy is poised for substantial financial growth. Click to explore a detailed breakdown of our findings in Excelerate Energy's balance sheet health report. Overview: BBB Foods Inc. operates a chain of grocery retail stores in Mexico and has a market cap of $3.45 billion. Operations: The company's revenue primarily comes from the sale, acquisition, and distribution of various products and consumer goods, totaling MX$61.89 billion. Estimated Discount To Fair Value: 16.7% BBB Foods, priced at $30.25, trades below its fair value estimate of $36.32, suggesting undervaluation based on cash flows. The company recently turned profitable and forecasts indicate significant earnings growth of 30.2% annually over the next three years, outpacing the U.S market average. Despite a net loss in Q1 2025, revenue surged to MXN 17.13 billion from MXN 12.68 billion year-over-year, reflecting strong operational performance amidst leadership changes. Insights from our recent growth report point to a promising forecast for BBB Foods' business outlook. Click here to discover the nuances of BBB Foods with our detailed financial health report. Gain an insight into the universe of 173 Undervalued US Stocks Based On Cash Flows by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:DXCM NYSE:EE and NYSE:TBBB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""3 Big Reasons to Love DexCom (DXCM) Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move. Is now still a good time to buy DXCM? Or are investors being too optimistic? Find out in our full research report, it\u2019s free. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. We can better understand Patient Monitoring companies by analyzing their organic revenue. This metric gives visibility into DexCom\u2019s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement. Over the last two years, DexCom\u2019s organic revenue averaged 19.2% year-on-year growth. This performance was fantastic and shows it can expand quickly without relying on expensive (and risky) acquisitions. We track the long-term change in earnings per share (EPS) because it highlights whether a company\u2019s growth is profitable. DexCom\u2019s EPS grew at an astounding 23.2% compounded annual growth rate over the last five years, higher than its 21% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Growth gives us insight into a company\u2019s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). DexCom\u2019s five-year average ROIC was 25%, placing it among the best healthcare companies. This illustrates its management team\u2019s ability to invest in highly profitable ventures and produce tangible results for shareholders. These are just a few reasons why DexCom ranks highly on our list, and with its shares outperforming the market lately, the stock trades at 40.6\u00d7 forward P/E (or $87 per share). Is now the right time to buy? See for yourself in our comprehensive research report, it\u2019s free. Donald Trump\u2019s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.""]"
DXCM,2025-05-21,85.93,87.0,84.5,84.89,
DXCM,2025-05-22,84.9,85.31,84.28,84.83,"Citigroup Adjusts Price Target on DexCom to $102 From $82, Maintains Buy Rating DexCom (DXCM) has an average rating of overweight and mean price target of $99.04, according to anal"
DXCM,2025-05-23,83.94,85.01,83.48,84.51,"An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued DexCom's estimated fair value is US$116 based on 2 Stage Free Cash Flow to Equity DexCom is estimated to be 27% undervalued based on current share price of US$84.83 The US$98.01 analyst price target for DXCM is 16% less than our estimate of fair value Today we will run through one way of estimating the intrinsic value of DexCom, Inc. (NASDAQ:DXCM) by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. It may sound complicated, but actually it is quite simple! Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate: (""Est"" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$13b We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.3%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$2.8b× (1 + 2.9%) ÷ (7.3%– 2.9%) = US$67b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$67b÷ ( 1 + 7.3%)10= US$33b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$46b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$84.8, the company appears a touch undervalued at a 27% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at DexCom as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.3%, which is based on a levered beta of 1.005. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for DexCom Strength Debt is not viewed as a risk. Weakness Earnings declined over the past year. Opportunity Annual earnings are forecast to grow faster than the American market. Trading below our estimate of fair value by more than 20%. Threat Revenue is forecast to grow slower than 20% per year. Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For DexCom, there are three essential elements you should look at: PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
DXCM,2025-05-27,85.44,85.7,84.6,85.33,"Prediction: These 2 Stocks Will Beat the Market in the Next Decade Eli Lilly and DexCom have been market-beaters over the past decade. Eli Lilly could ride the wave of a strong lineup and deep pipeline, especially in weight management. DexCom's devices are valuable to diabetes patients, but there's still a significant untapped opportunity. 10 stocks we like better than Eli Lilly › Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM). Eli Lilly has been one of the best-performing pharmaceutical giants in the past 10 years. Though that doesn't guarantee future success, it's worth highlighting what has led to the company's strong showing. Lilly has made significant clinical breakthroughs in recent years, none more important than tirzepatide, a medicine sold as Mounjaro in treating diabetes, and Zepbound in managing weight. It was the first dual GLP-1/GIP agonist approved by the U.S. Food and Drug Administration. Here are two ways in which that's relevant to the company's future performance. First, tirzepatide hasn't been on the market that long, having earned approval about three years ago. It will continue delivering excellent top-line growth. Second, even more clinical successes like tirzepatide could help the stock perform well. Eli Lilly recently released positive data from a phase 3 clinical trial for orforglipron, an oral GLP-1 medicine; the strong results sent the stock price soaring. The drugmaker is also working on retatrutide, which mimics the action of not just two gut hormones (as tirzepatide does), but three. Lilly dubbed it ""triple G."" Retatrutide could be yet another breakthrough. In total, the company has 11 weight loss candidates in the pipeline. Even with mounting competition in this field, Eli Lilly looks like a runaway leader compared to any company not named Novo Nordisk. And that's before we mention the rest of the pipeline. Last year, Lilly earned approval for Kisunla in treating Alzheimer's disease, another significant win considering that very few medicines have gotten the green light from regulators in this area in the past 20 years. Lilly has not performed well in 2025 due to tariff-induced volatility, and disappointing bottom-line guidance for the full year. However, the company is pivoting its manufacturing back into the U.S., something it has been doing for years -- so even if President Donald Trump's trade agenda survives his administration, the drugmaker should be fine. And while the stock's forward price-to-earnings ratio of around 33 is around twice the average of 16 for the healthcare industry, the company's better-than-average results and excellent prospects justify its valuation. Eli Lilly is a terrific dividend stock. The company has increased its payouts by 200% over the past 10 years. And the stock should deliver superior returns through 2035, especially for shareholders who opt to reinvest the dividend. DexCom specializes in developing and marketing continuous glucose monitoring (CGM) systems that help diabetes patients keep track of their blood sugar levels. The company's appeal is the superiority of its devices compared to the alternatives. With blood glucose meters, patients use a painful finger prick (or something similar) to collect a small blood sample to know their measurement at that specific point in time. In contrast, once installed, CGMs constantly monitor their status, day and night, with measurements made up to every five minutes. That's 12 per hour and 288 per day -- no manual meter can match that. Strong adoption of the technology has been a massive tailwind for DexCom. Patients are switching to CGM, and third-party payers are increasingly reimbursing for it. This has resulted in growing revenue and earnings over the past decade, and a strong, if somewhat volatile, stock-market performance. Here's more good news: DexCom has consistently pointed out that the CGM market remains underpenetrated. In the U.S., the number of diabetes patients who use CGM is much lower than the number whose use would be covered by insurance. Furthermore, the company has routinely entered new markets to expand its addressable population. DexCom does have to deal with stiff competition from Abbott Laboratories, but has remained successful nonetheless. Abbott pointed out about 18 months ago that just 1% of diabetic adults worldwide had access to CGM. So there's space for multiple winners over the long run. And while tariffs could be a threat, DexCom does significant manufacturing for U.S. consumers domestically. Management expects minimal impact from tariffs. Lastly, though DexCom's recent forward P/E of around 42 looks high, it's not far from the lowest point it has seen in years: A high-growth stock, DexCom has generally traded at high premiums and has still performed better than the broader market. Its valuation won't kill momentum in the next decade. And in the meantime, the stock should once again deliver outsize returns as DexCom makes headway into the massive CGM market. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $804,688!* Now, it’s worth noting Stock Advisor’s total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Prediction: These 2 Stocks Will Beat the Market in the Next Decade was originally published by The Motley Fool"
DXCM,2025-05-28,85.24,87.6,85.24,86.98,
DXCM,2025-05-29,87.65,87.665,84.51,84.86,
DXCM,2025-05-30,86.76,86.8,84.85,85.8,"[""Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $100.29, according to analysts p"", ""Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy Investing.com -- Goldman Sachs has initiated coverage of diabetes technology stocks Insulet (NASDAQ:PODD) and Dexcom (NASDAQ:DXCM) with Buy ratings, citing strong long-term growth prospects in both the insulin delivery and continuous glucose monitoring (CGM) markets. In a research note, Goldman Sachs described the diabetes technology market as \u201cat a crossroads,\u201d with growth shifting from its core Type 1 diabetes patient base toward the broader Type 2 diabetes population and even consumer markets. \u201cWe see Insulet as well positioned to accelerate market share capture given its unique form factor (patch vs durable), pharmacy access, and Type 2 indication,\u201d the analysts wrote. They added that the company\u2019s valuation sits \u201cat the high end of growth medtech.\u201d Dexcom also earned a Buy rating, with Goldman noting that while the stock has underperformed over the past year, falling 43% relative to the S&P 500, \u201cwe view forward estimates as appropriately re-calibrated.\u201d The analysts expect \u201cupside to 2025 top-line expectations,\u201d though they acknowledged caution on gross margins due to \u201csupply-related issues in 1H.\u201d Still, they believe \u201cmore steady execution should unlock share value from here.\u201d Goldman sees the insulin pump market growing 11.4% annually in volume and 12.7% in dollars through 2028, driven by further penetration into the Type 1 population and expansion into the Type 2 multiple daily injector segment. \u201cWe expect patch pump technology to become the primary form factor for insulin pumps,\u201d the firm said, projecting a shift from 30% patch pump share in 2024 to 40% by 2028. Goldman also initiated coverage on Beta Bionics (BBNX) with a Neutral rating and maintained existing ratings on Abbott (ABT, Buy) and Tandem (TNDM, Neutral). Related articles Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy AGCO downgraded as Citi says risk/reward now more balanced Sanofi, Regeneron shares nosedive after mixed Itepekimab results"", ""Goldman Sachs Initiates DexCom at Buy With $104 Price Target DexCom (DXCM) has an average rating of buy and mean price target of $100.29, according to analysts p"", ""2 Profitable Stocks on Our Watchlist and 1 to Turn Down While profitability is essential, it doesn\u2019t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \""Your margin is my opportunity\"". Not all profitable companies are created equal, and that\u2019s why we built StockStory - to help you find the ones that truly shine bright. That said, here are two profitable companies that generate reliable profits without sacrificing growth and one that may face some trouble. Trailing 12-Month GAAP Operating Margin: 8.9% Known for its proprietary D-U-N-S Number that serves as a unique identifier for businesses worldwide, Dun & Bradstreet (NYSE:DNB) provides business decisioning data and analytics that help companies evaluate credit risks, verify suppliers, enhance sales productivity, and gain market visibility. Why Is DNB Risky? Dun & Bradstreet\u2019s stock price of $9.02 implies a valuation ratio of 8.4x forward P/E. Read our free research report to see why you should think twice about including DNB in your portfolio, it\u2019s free. Trailing 12-Month GAAP Operating Margin: 18% Started with the invention of the steam drill, Ingersoll Rand (NYSE:IR) provides mission-critical air, gas, liquid, and solid flow creation solutions. Why Do We Like IR? At $83.05 per share, Ingersoll Rand trades at 23.8x forward P/E. Is now a good time to buy? Find out in our full research report, it\u2019s free. Trailing 12-Month GAAP Operating Margin: 15.3% Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. Why Is DXCM a Good Business? DexCom is trading at $86.15 per share, or 39.6x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it\u2019s free. Donald Trump\u2019s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free.""]"
DXCM,2025-06-02,85.44,85.88,84.1,85.51,
DXCM,2025-06-03,85.49,87.33,84.5,86.79,"Reflecting On Patient Monitoring Stocks’ Q1 Earnings: Masimo (NASDAQ:MASI) The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Masimo (NASDAQ:MASI) and the rest of the patient monitoring stocks fared in Q1. Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges. The 5 patient monitoring stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 2.2% while next quarter’s revenue guidance was 0.9% below. Luckily, patient monitoring stocks have performed well with share prices up 18.6% on average since the latest earnings results. Founded in 1989 to solve the ""unsolvable problem"" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement. Masimo reported revenues of $372 million, up 9.5% year on year. This print exceeded analysts’ expectations by 1.1%. Despite the top-line beat, it was still a mixed quarter for the company with an impressive beat of analysts’ constant currency revenue estimates but a significant miss of analysts’ full-year EPS guidance estimates. Katie Szyman, Chief Executive Officer of Masimo, said, “Since joining Masimo as CEO three months ago, I have been focused on immersing myself in our business. I have visited customers, employees, manufacturing and R&D sites, evaluated our innovation pipeline, and attended national meetings with our sales team. My key takeaways are that our technology advantage is real, we have a stellar team that is enthusiastic about the path forward at Masimo, and we have an opportunity to build and improve from a position of meaningful strength. Our first quarter results clearly demonstrate the earnings power of our core business as we delivered double-digit revenue growth and exceptional earnings growth.” Masimo delivered the weakest full-year guidance update of the whole group. The stock is up 2.3% since reporting and currently trades at $164.39. Read our full report on Masimo here, it’s free. Revolutionizing diabetes care with its tubeless ""Pod"" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line. Insulet reported revenues of $569 million, up 28.8% year on year, outperforming analysts’ expectations by 4.8%. The business had an exceptional quarter with a solid beat of analysts’ constant currency revenue and EPS estimates. Insulet achieved the biggest analyst estimates beat and fastest revenue growth among its peers. The market seems happy with the results as the stock is up 26.5% since reporting. It currently trades at $325. Is now the time to buy Insulet? Access our full analysis of the earnings results here, it’s free. Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. ResMed reported revenues of $1.29 billion, up 7.9% year on year, in line with analysts’ expectations. It was a decent quarter as it posted EPS and constant currency revenue in line with analysts’ estimates. ResMed delivered the weakest performance against analyst estimates and slowest revenue growth in the group. Interestingly, the stock is up 13.9% since the results and currently trades at $244.10. Read our full analysis of ResMed’s results here. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. DexCom reported revenues of $1.04 billion, up 12.5% year on year. This number surpassed analysts’ expectations by 1.8%. Aside from that, it was a satisfactory quarter as it also produced an impressive beat of analysts’ organic revenue estimates. The stock is up 21.2% since reporting and currently trades at $85.14. Read our full, actionable report on DexCom here, it’s free. Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. iRhythm reported revenues of $158.7 million, up 20.3% year on year. This result topped analysts’ expectations by 3.3%. Overall, it was a strong quarter as it also produced full-year revenue guidance beating analysts’ expectations. iRhythm delivered the highest full-year guidance raise among its peers. The stock is up 29% since reporting and currently trades at $140.65. Read our full, actionable report on iRhythm here, it’s free. Thanks to the Fed’s rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn’t send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump’s November win lit a fire under major indices and sent them to all-time highs. However, there’s still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate."
DXCM,2025-06-04,86.87,87.235,85.59,85.61,"Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks An updated edition of the April 14, 2025 article. The global population is aging at an unprecedented pace, reshaping healthcare systems and economic planning across nations. Longer life expectancies—fueled by medical advancements and improved living standards—have coincided with declining birth rates, leading to a demographic imbalance that is pronounced in developed and emerging economies alike. According to the World Health Organization’s October 2024 report, the number of people aged 60 and older surpassed the number of children under five back in 2020. By 2030, one in six individuals globally will be over 60, and by 2050, that figure is expected to reach 2.1 billion. Notably, 80% of these older adults will reside in low- and middle-income countries. This shift is likely to be accompanied by a steady increase in non-communicable diseases (NCDs), which will place significant pressure on healthcare infrastructure, financing, and long-term care delivery. In response to this demographic transformation, healthcare consumption patterns are shifting. Demand is rising for pharmaceuticals, medical devices, home-based care, and digital health solutions tailored for aging populations. The global geriatric care market was valued at approximately $1.2 trillion in 2025, up from around $1 trillion in 2022, with steady annual growth driven by the increasing prevalence of chronic and age-associated conditions such as cardiovascular disease, diabetes, dementia and osteoporosis. Frailty, falls and other geriatric syndromes further complicate care requirements. Healthcare giants such as Boston Scientific BSX, AbbVie ABBV, Amgen AMGN and Dexcom DXCM are all capitalizing on this evolving landscape. By enhancing operational efficiency, they are increasingly expanding their presence in the Seniors & Aging Demographics domain. Pharmaceutical companies are ramping up efforts to develop treatments for chronic conditions prevalent in older adults. Those leading the innovation in immunology, oncology and neurodegenerative disease treatments are well-positioned for sustained growth. Simultaneously, innovations in medical technology and home care services bolster the sector's attractiveness and offer strong potential for high returns on investments. Digital health solutions, artificial intelligence-driven diagnostics and home-based monitoring systems are transforming elder care, creating new revenue opportunities for healthcare firms. Another promising area that should draw niche investor interest is the Healthcare Real Estate Investment Trust (Healthcare REIT) sector. Within this space, Community Healthcare Trust CHCT and CareTrust REIT CTRE stand out for their focus on serving the aging population through specialized healthcare real estate. CHCT invests in outpatient centers and medical office buildings in underserved regions, expanding access to preventive and chronic care for seniors. CTRE, on the other hand, concentrates on post-acute and long-term care, owning skilled nursing, assisted living, and memory care facilities. Together, these companies are helping to meet the rising demand for healthcare and housing solutions driven by demographic shifts. Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity. Boston Scientific, a prominent medical device company, has developed several medical devices catering to the needs of the elderly. The company’s WATCHMAN Left Atrial Appendage Closure Device is designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation, offering an alternative to long-term anticoagulation therapy. Further, the SYNERGY Bioabsorbable Polymer Coronary Stent system has shown favorable outcomes in elderly patients, particularly those requiring shorter durations of dual antiplatelet therapy. This apart, the company’s LATITUDE NXT Remote Patient Management system and Communicator integrate features from the original LATITUDE platform with enhancements. This system supports more efficient clinic operations while enabling proactive, remote care for patients with implantable cardiac devices, many of whom are elderly. The stock currently carries a Zacks Rank #3 (Hold). AbbVie, as a pharma giant, is actively expanding its focus on the senior and aging demographic through strategic partnerships and investments. The company’s December 2024 acquisition of Aliada Therapeutics includes the latter’s lead investigational asset ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier-crossing technology, positioning it as a potential best-in-class disease-modifying therapy. In oncology, AbbVie partnered with Xilio Therapeutics in February 2025 to develop tumor-activated immunotherapies, including masked T-cell engagers, aimed at improving treatment efficacy and reducing toxicity. In January 2025, AbbVie secured rights to SIM0500, a trispecific antibody from Simcere Zaiming, expanding its hematologic oncology pipeline. The company also invested $223 million in January 2024 to expand its Singapore biologics manufacturing facility, boosting capacity to meet the aging population's needs. AbbVie’s R&D focuses on next-gen immunology, bispecifics, antibody-drug conjugates (ADCs), and therapies for neuropsychiatric and neurodegenerative disorders. The stock holds a Zacks Rank #3. Amgen, a leading biotech firm, is sharpening its focus on the aging population through targeted biopharma innovation. At the May 2024 Financial Times Biotech Summit, management reaffirmed the need for elderly-focused medicines to meet evolving health demands. In osteoporosis care, Amgen offers EVENITY for postmenopausal women at high fracture risk and Prolia, which outperforms traditional treatments in reducing fracture risk. The company is also advancing MariTide, its experimental obesity drug, which showed up to 20% weight loss at 52 weeks in trials, with added benefits for patients with Type 2 diabetes. Amgen’s broader R&D pipeline includes next-gen immunology, bispecifics, ADCs and therapies targeting neuropsychiatric and neurodegenerative diseases. The stock has a Zacks Rank #3. Dexcom, a leading provider of continuous glucose monitoring (CGM) systems, has been actively expanding its offerings to better serve seniors and the aging population. Its G7 CGM system is popular among older adults who find its sensor insertion and app setup process simple. Dexcom has also ensured that its CGM systems, including Dexcom G6 and G7, are covered by Medicare, increasing accessibility for seniors. In August 2024, Dexcom launched Stelo, the first FDA-cleared over-the-counter CGM in the United States, designed for adults aged 18 and older who do not use insulin. Stelo offers real-time glucose readings and insights into how diet and exercise affect glucose levels. Priced at $99 for a two-sensor pack or $89 via monthly subscription, Stelo features a 15-day wear time and is HSA/FSA eligible. In December 2024, Dexcom integrated a Generative AI platform into Stelo, enhancing its Weekly Insights feature to provide users with more personalized content based on glucose levels, activity and sleep. The stock holds a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report CareTrust REIT, Inc. (CTRE) : Free Stock Analysis Report Community Healthcare Trust Incorporated (CHCT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-06-05,85.78,86.54,84.87,85.75,
DXCM,2025-06-06,86.73,87.91,85.83,86.67,
DXCM,2025-06-09,86.91,86.935,85.09,85.68,"Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 23.8% year-over-year for the current fiscal year, with sales growth of 14.3%. Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0 to $2.03 per share. DXCM also boasts an average earnings surprise of 0.5%. DexCom is also cash rich. The company has generated cash flow growth of 32%, and is expected to report cash flow expansion of 9.8% in 2025. Investors should take the time to consider DXCM for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-06-10,86.05,86.45,84.305,84.82,"1 Cash-Producing Stock on Our Buy List and 2 to Be Wary Of While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning. Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here is one cash-producing company that reinvests wisely to drive long-term success and two that may struggle to keep up. Trailing 12-Month Free Cash Flow Margin: 1.9% Founded in the basement of a Boise, Idaho dental office in 1978, Micron (NYSE:MU) is a leading provider of memory chips used in thousands of devices across mobile, data centers, industrial, consumer, and automotive markets. Why Are We Wary of MU? Micron’s stock price of $111.07 implies a valuation ratio of 12.7x forward P/E. Dive into our free research report to see why there are better opportunities than MU. Trailing 12-Month Free Cash Flow Margin: 5.5% Covering 1.6 billion loaded miles in 2023 alone, Knight-Swift Transportation (NYSE:KNX) offers less-than-truckload and full truckload delivery services. Why Do We Avoid KNX? At $44.81 per share, Knight-Swift Transportation trades at 22.6x forward P/E. If you’re considering KNX for your portfolio, see our FREE research report to learn more. Trailing 12-Month Free Cash Flow Margin: 13.9% Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. Why Are We Backing DXCM? DexCom is trading at $85.31 per share, or 40x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free. Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a ""fearful"" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free."
DXCM,2025-06-11,85.01,85.49,82.901,82.99,
DXCM,2025-06-12,83.09,83.6088,82.0244,82.85,
DXCM,2025-06-13,81.69,83.17,81.3901,81.99,
DXCM,2025-06-16,82.8,83.7,82.265,83.0,"[""Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Investing.com -- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients. The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic\u2019s diabetes business, which it rates \u201cHold.\u201d Truist said the diabetes device sector is positioned for double-digit growth over the next several years, driven by expanding use in underpenetrated global markets and a shift toward more patient-centric care. Survey feedback from physicians suggested stronger adoption of pumps and CGMs in type 2 diabetes, particularly among patients using insulin. Among the large-cap names, the firm favored Dexcom and Insulet, citing strong profitability and leadership in the growing CGM and patch pump segments. While Truist said that Insulet\u2019s recent CEO change may introduce some near-term uncertainty, it said the company\u2019s growth trajectory remains intact. Dexcom, which has faced concerns following mid-2024 execution missteps and rising competition from Abbott\u2019s Libre system, still offers a favorable risk-reward, Truist said, pointing to a lower relative valuation and catalysts such as guideline updates and expanding reimbursement for type 2 diabetes. In the small-cap space, Truist preferred Beta Bionics over Tandem. It noted both firms face challenges in the slower-growing durable pump market but said Beta Bionics\u2019 iLet system has a potential ease-of-use advantage and a head start in transitioning to more profitable pharmacy distribution channels. Regarding potential volatility in shares of both Beta Bionics and Tandem, Truist said the broader diabetes device market remains one of the most attractive growth areas in medtech, supported by technology innovation, evolving reimbursement, and increased patient engagement. Related articles Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Boeing Commercial Airplanes head meets Air India chairman after fatal 787 crash Forward Air stock surges on report PE firms express acquisition interest"", ""Truist Initiates DexCom at Buy With $102 Price Target DexCom (DXCM) has an average rating of buy and mean price target of $100.36, according to analysts p""]"
DXCM,2025-06-17,82.665,83.35,81.61,81.83,"Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Top 5 Upgrades: Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term competitive dynamics in Networking and improved scale in Security. TD Cowen upgraded Celsius Holdings (CELH) to Buy from Hold with a price target of $55, up from $37. The firm expects to see continued improvement through the summer as Celsius’ comparable sales ease from 35% in May to 19% in June and 11% in July. Stifel upgraded Incyte (INCY) to Buy from Hold with a price target of $107, up from $75. This weekend’s presentation of preliminary INCA033989 dose-escalation data in essential thrombocythemia patients “represents a best-case scenario,” the firm tells investors in a research note. Wells Fargo upgraded Celanese (CE) to Overweight from Equal Weight with a price target of $66, up from $45. The firm sees potential for sequential earnings improvement on cost savings and reduced maintenance and notes its outlook assumes no demand improvement near term. Wells Fargo upgraded Wix.com (WIX) to Overweight from Equal Weight with a price target of $216, up from $173. The firm says its “strong” partner channel checks leave it confident Wix can take price in fiscal 2026 and raise bookings by 2%. Top 5 Downgrades: BofA downgraded CoreWeave (CRWV) to Neutral from Buy with a price target of $185, up from $76. Noting that the stock has run up 145% following Q1 results, the firm says it believes much of the near-term upside has been priced in. H.C. Wainwright downgraded Sarepta (SRPT) to Sell from Neutral with a $10 price target. The company announced another death due to acute liver failure in a second non-ambulatory Duchenne muscular dystrophy patient treated with Elevidys, and is suspending shipments of the drug to non-ambulatory DMD patients until an immunosuppressive regimen can be agreed upon with regulators and implemented, the firm tells investors in a research note. Piper Sandler also downgraded Sarepta to Neutral from Overweight with a price target of $36, down from $70. Baird downgraded Pros Holdings (PRO) to Neutral from Outperform with a price target of $18, down from $27. The firm says that given recent internal changes at the company, it is “increasingly concerned” about Pros’ ability to execute its long-term targets. Jefferies downgraded Packaging Corp. (PKG) to Hold from Buy with a price target of $205, down from $245. The firm still views Packaging Corp. as best in class, but sees the company’s competitive edge flattening and the stock limited by its premium valuation. Citizens JMP downgraded Angi Inc. (ANGI) to Market Perform from Outperform without a price target following a transfer of coverage. The several strategic changes underway have the potential to improve the core fundamentals of Angi’s marketplace, but competition among digital home improvement and maintenance marketplaces has intensified, the firm says. Top 5 Initiations: Barclays initiated coverage of Hinge Health (HNGE) with an Overweight rating and $43 price target. Musculoskeletal issues are expensive, and Hinge can “bend the cost curve” with digital physical therapy, the firm says. KeyBanc, Morgan Stanley, RBC Capital, Stifel, Truist, Evercore ISI, William Blair, Hinge Health, BofA, Canaccord, and Piper Sandler started coverage of the stock with Buy-equivalent ratings. Citizens JMP initiated coverage of MNTN (MNTN) with an Outperform rating and $23 price target. The firm’s positive view is based on MNTN’s ability to attract small businesses and retain and grow their advertising budgets. Evercore ISI, Raymond James, Susquehanna, Loop Capital, and Needham also started coverage of the stock with Buy-equivalent ratings, while Citi and Morgan Stanley initiated the name with Neutral-equivalent ratings. Leerink initiated coverage of Medtronic (MDT) with an Outperform rating and $110 price target. The firm sees a positive “shifting tide” for Medtronic driven by the company’s Cardiac Ablation Solutions business offering a significant and underappreciated source of upside, its recently announced decision to separate its Diabetes business, the company’s portfolio having relatively significant exposure to several other high-growth end-markets, and a clear shift in Medtronic’s M&A strategy that could help bolster its longer-term growth portfolio. Leerink also started coverage of Boston Scientific (BSX) with an Outperform rating and $118 price target. Truist initiated coverage of Insulet (PODD) with a Buy rating and $365 price target. Truist expects Insulet’s Omnipod 5 will remain the only true tubeless and fully disposable patch pump for the foreseeable future, which should allow Insulet to maintain a market leadership patch pump position within the growing Type 1 and Type 2 diabetes markets even if/when competitor patch designs begin coming to market over the next few years. The firm also started coverage of DexCom (DXCM) with a Buy and Tandem Diabetes (TNDM) with a Hold rating. UBS initiated coverage of Freshpet (FRPT) with a Sell rating and $65 price target. The firm says consensus estimates for Freshpet are too high, and that “more subdued” growth in the near-term should cause the stock’s valuation to contract further. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CSCO: Disclaimer & DisclosureReport an Issue Cisco upgraded to Buy from Hold at Deutsche Bank Cisco price target raised to $67 from $63 at Goldman Sachs AI Daily: Disney, Universal sue Midjourney for copyright infringement Saudi Arabia brings in Cisco, AMD for AI cloud project, Information says Alpha Modus Ventures files patent infringement lawsuit against Cisco"
DXCM,2025-06-18,82.01,82.43,80.23,80.998,"[""Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks Looking back on patient monitoring stocks\u2019 Q1 earnings, we examine this quarter\u2019s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers. Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges. The 5 patient monitoring stocks we track reported a strong Q1. As a group, revenues beat analysts\u2019 consensus estimates by 2.2% while next quarter\u2019s revenue guidance was 0.9% below. Luckily, patient monitoring stocks have performed well with share prices up 16.5% on average since the latest earnings results. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. DexCom reported revenues of $1.04 billion, up 12.5% year on year. This print exceeded analysts\u2019 expectations by 1.8%. Overall, it was a satisfactory quarter for the company with a solid beat of analysts\u2019 organic revenue estimates. The stock is up 16.7% since reporting and currently trades at $82. Is now the time to buy DexCom? Access our full analysis of the earnings results here, it\u2019s free. Revolutionizing diabetes care with its tubeless \""Pod\"" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line. Insulet reported revenues of $569 million, up 28.8% year on year, outperforming analysts\u2019 expectations by 4.8%. The business had an exceptional quarter with an impressive beat of analysts\u2019 constant currency revenue and EPS estimates. Insulet achieved the biggest analyst estimates beat and fastest revenue growth among its peers. The market seems happy with the results as the stock is up 18.4% since reporting. It currently trades at $304.39. Is now the time to buy Insulet? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1989 to solve the \""unsolvable problem\"" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement. Masimo reported revenues of $372 million, up 9.5% year on year, exceeding analysts\u2019 expectations by 1.1%. Still, it was a mixed quarter as it posted a significant miss of analysts\u2019 full-year EPS guidance estimates. Masimo delivered the weakest full-year guidance update in the group. As expected, the stock is down 2.3% since the results and currently trades at $157.02. Read our full analysis of Masimo\u2019s results here. Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. ResMed reported revenues of $1.29 billion, up 7.9% year on year. This print was in line with analysts\u2019 expectations. More broadly, it was a mixed quarter as it also logged EPS in line with analysts\u2019 estimates but constant currency revenue in line with analysts\u2019 estimates. ResMed had the weakest performance against analyst estimates and slowest revenue growth among its peers. The stock is up 16.7% since reporting and currently trades at $250.09. Read our full, actionable report on ResMed here, it\u2019s free. Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. iRhythm reported revenues of $158.7 million, up 20.3% year on year. This result beat analysts\u2019 expectations by 3.3%. It was a strong quarter as it also logged full-year revenue guidance beating analysts\u2019 expectations. iRhythm scored the highest full-year guidance raise among its peers. The stock is up 33% since reporting and currently trades at $144.95. Read our full, actionable report on iRhythm here, it\u2019s free. The Fed\u2019s interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump\u2019s presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate."", ""Dexcom recalls more than 700,000 CGM receivers for lack of audible alarm This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. UPDATE: June 24, 2025: This article has been updated to reflect changes in the Food and Drug Administration\u2019s recall database to the number of recalled devices in commerce. The FDA\u2019s database now shows more than 700,000 recalled receivers were distributed worldwide. A problem with Dexcom\u2019s receivers for its glucose sensors may cause people to not get an audible alert for low or high blood sugar levels, the Food and Drug Administration said in an enforcement report posted Monday. More than 700,000 devices are affected by the Class I recall, the highest risk category. The receiver, a handheld device that gives glucose readings, may not provide an audible alert due to a manufacturing problem. Dexcom said in a letter to customers that, as of May, it had received 56 reports of severe adverse events, such as seizure, loss of consciousness, and other hypoglycemic or hyperglycemic symptoms. All of the people recovered, the company said. The recall applies to receivers associated with Dexcom\u2019s G7, G6, One and One+ CGMs. Dexcom is asking users to return the affected devices and is offering replacements. Dexcom started the recall on May 12. For the G7, more than 600,000 receivers were affected globally, while for the G6, more than 36,800 devices were affected. Tens of thousands of receivers for Dexcom\u2019s One and One+ CGMs were also part of the recall. At the end of 2024, Dexcom had about 2.8 million to 2.9 million users globally, according to the company\u2019s annual report. The manufacturing problem involves defective foam or an assembly error that may cause the receiver\u2019s speaker to lose contact with the printed circuit board, according to entries posted in the FDA\u2019s recall database. The affected devices will still provide hypoglycemia or hyperglycemia alerts through other cues, such as vibration and visual prompts, according to the database entry. The recall does not affect people who use Dexcom\u2019s mobile apps to display glucose values and for alerts and alarms, who make up the majority of the company\u2019s users, Dexcom spokesperson James McIntosh wrote in an email. For the affected receivers that have been distributed, the reported incidence rate is .015%, according to the email. Dexcom said in the June 3 letter to customers that it had received 112 complaints associated with the malfunction. Dexcom is asking users to check if their receiver is affected and contact technical support to coordinate a return and receive a free replacement. The company also recommended regular testing of the speaker, regardless of whether a receiver is affected by the recall. Earlier this year, Dexcom issued a Class II recall that said in rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alerts. At the time, Dexcom told users to check CGM glucose values regularly and to turn the receiver off and on. Recommended Reading Dexcom CEO says CGMs fit MAHA agenda \u2018very nicely\u2019; Tandem preps for new products"", ""Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications.1 Dexcom Warrior Lance Bass will share first-hand experience saying \""Bye\"" to fingersticks* during panel at ADA. SAN DIEGO, June 18, 2025--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, today released its \""Dexcom State of Type 2 Report: Access and Attitudes Across the United States\"" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will present extensive clinical data that shows the benefits of CGM for those living with Type 2 diabetes as well as new outcomes from early Stelo users. Dexcom releases new State of Type 2 Report: Access and Attitudes Across the United States Earlier this year, Dexcom announced the release of its first multi-region report, detailing access and attitudes of individuals diagnosed with Type 2 diabetes and healthcare professionals across Europe and the Middle East (EMEA). The latest State of Type 2 Report now builds on those initial findings with data collected in the U.S. Topline takeaways include: Tech is believed to be an effective way to manage Type 2 diabetes: More than half (59%) of U.S. HCPs believe that better access to CGM will be the most effective way to help people with Type 2 diabetes manage their condition over the next decade.1 U.S. HCPs support CGM as \""standard of care\"": 96% of providers surveyed in the U.S. agree that CGM should be the standard of care for individuals using multiple daily insulin injections, and 94% agree that CGM should be the standard of care for those on basal insulin.1 U.S. HCPs unanimously support use of CGM in combination with GLP-1 medications: 100% of U.S. HCPs surveyed recommend CGM in combination with GLP-1 or SGLT2 medication because it has the best expected outcomes for patients, and 79% of providers in EMEA agreed.1 Better coverage, more education and training can improve understanding of CGM: HCPs believe access and understanding about the usage of CGM can be improved with additional coverage and more educational support for Americans with Type 2 diabetes, as well as more training for healthcare providers. Specifically, 60% of U.S. HCPs said additional funding or budget to cover CGM could increase usage among people with Type 2 diabetes.1 \""The findings of our State of Type 2 Report in the U.S. reaffirm what we\u2019ve always believed to be true: CGM is central to the future of Type 2 diabetes care,\"" said Jake Leach, president and chief operating officer of Dexcom. \""To help drive the greatest impact for patients, a continued focus on diabetes education and access to CGMs is needed \u2013 and Dexcom is committed to advancing these around the world.\"" Read the full Dexcom State of Type 2 Report here: https://provider.dexcom.com/future-type-2-diabetes-care Dexcom presents robust clinical data and hosts compelling presentations Conference attendees will have the opportunity to hear firsthand from Grammy-nominated singer, actor, producer and Dexcom Warrior Lance Bass about how Dexcom CGM has helped him live his best life during Dexcom\u2019s product theater on Saturday, June 21. After being diagnosed with Latent Autoimmune Diabetes in Adults (LADA), also known as Type 1.5 diabetes, Lance has been an advocate for the diabetes community, saying \u2018Bye\u2019 to fingersticks*, guesswork and uncertainty with the help of Dexcom G7 technology. Lance will be joined by experts who will also speak about how early adoption of CGM can improve diabetes management through personalized care in addition to innovations in Dexcom technology, including new features and in-app reports. Additionally, Dexcom will present clinical data at the conference that continues to support the benefits of its technology for people with diabetes of all ages and stages. Most notably, several studies looking at CGM use for those with Type 2 diabetes across various insulin therapies show numerous benefits \u2013 adding to an already extensive body of evidence \u2013 from reduced mortality risk among insulin-using people2 to reduced diabetes-related distress and improved self-management3 among non-insulin using people. In a real-world observational study of individuals with Type 2 diabetes not using insulin, Dexcom G7 use was associated with significantly reduced diabetes-related distress and increased adherence to healthy eating plans and exercise routines, supporting CGM as a powerful tool for behavior modification.3 For a detailed overview of all Dexcom presentations at ADA this year, visit: https://professional.diabetes.org/scientific-sessions. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you\u2019re made of. For more information, visit www.dexcom.com. Category: IR *Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. 1 Dexcom State of Type 2 Report (US), Dexcom data on file, 2025. 2 Blake CL, et al. \""Reduced Mortality Risk Associated with Dexcom rtCGM Compared to SMBG Among People with T2D on Any Insulin Therapy.\"" Presented at ADA 2025. 3 Crawford, MA, et al. \""Real-World Dexcom CGM Use in T2D NIT: Reduced Diabetes Distress and Improved Self-Care Behaviors.\"" Presented at ADA 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250618841089/en/ Contacts Media Relations Contact Nadia Conard mediarelations@dexcom.com Investor Relations Contact Sean Christensen sean.christensen@dexcom.com"", ""Dexcom Insider Sold Shares Worth $517,906, According to a Recent SEC Filing Nicholas Augustinos, Director, on June 13, 2025, sold 6,290 shares in Dexcom (DXCM) for $517,906. Fo""]"
DXCM,2025-06-20,81.6,82.06,79.61,80.01,"[""DXCM's Access Gains and Operational Strength Offset Margin Pressures DexCom DXCM delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth drivers are set to propel the business forward, even as the company faces operational and regulatory headwinds. Dexcom\u2019s strong commercial execution, expanding access footprint and pipeline innovation position it well for long-term growth. Yet, execution in logistics, regulatory compliance, and payer strategy will be critical for converting these tailwinds into sustainable margin expansion. This Zacks Rank #3 (Hold) company\u2019s shares have gained 18.6% quarter to date compared to the industry\u2019s 4.5% decline. The S&P 500 Index has improved 6.9% in the same time frame. DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $31.76 billion. It projects a 23.1% growth rate over the next five years and anticipates maintaining a strong performance going forward. Image Source: Zacks Investment Research DexCom\u2019s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, the average surprise being 0.47%. A major inflection point for Dexcom in 2025 is the significant expansion in reimbursement coverage for people with type 2 diabetes (T2D), particularly those who are not on insulin. As of summer 2025, Dexcom\u2019s G7 continuous glucose monitor (CGM) will be covered by all three major pharmacy benefit managers (PBMs) for anyone with diabetes, unlocking access for nearly 6 million non-insulin users. Encouragingly, the first quarter already saw a material increase in new starts from this cohort, the highest in Dexcom\u2019s history. Physician prescribing patterns are shifting in tandem with these policy changes, setting the stage for accelerating patient adoption in the back half of the year. Simultaneously, Dexcom\u2019s over-the-counter CGM, Stelo, is helping capture a broader audience, including patients with prediabetes and those interested in wellness and metabolic health. The company has rolled out app enhancements, launched on Amazon, and observed a rising subscription trend among early adopters. While still in early stages, Stelo adds a consumer-facing channel that complements the prescription-based G7 ecosystem. Image Source: dexcom.com The upcoming launch of the 15-Day G7 system marks a technological leap for Dexcom. With improved accuracy (MARD of 8.0%) and extended wear time, the device is expected to bolster gross margins and deepen product differentiation. Integration efforts with insulin pump partners and payer contracting are already underway to ensure a seamless rollout in the second half of 2025. Additionally, Dexcom continues to benefit from operational leverage. Following a major sales force expansion in 2024, the company is now optimizing reach and productivity, especially in the basal and primary care segments. Internationally, momentum is building in markets like France and Japan, aided by Dexcom ONE\u2019s growing presence and type 2 coverage wins. Dexcom\u2019s $2.7 billion cash position and the announcement of a $750 million share buyback reflect strong balance sheet health and confidence in long-term cash flow generation. Despite inflation and logistics cost headwinds, the company reaffirmed its full-year revenue and EBITDA margin guidance, highlighting effective cost control and prioritization. DexCom has witnessed a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for 2025 earnings per share has remained stable at $2.03. Image Source: Zacks Investment Research The consensus mark for the company\u2019s second-quarter revenues is pegged at $1.12 billion, indicating an 11.8% improvement from the year-ago quarter\u2019s reported number. The consensus estimate for earnings is pinned at 45 cents per share, implying an improvement of 4.7% year over year. Image Source: Zacks Investment Research However, Dexcom is not without headwinds. Gross margin guidance for fiscal 2025 was revised down to nearly 62%, primarily due to supply-chain disruptions that began in late 2024. To maintain customer continuity, Dexcom resorted to costly chartered flights and now faces a prolonged inventory rebuild. These freight-related expenses, combined with nearly 50 bps of inflation from raw material tariffs and FX volatility, are expected to weigh on profitability through the third quarter. Separately, Dexcom is addressing a warning letter from the FDA tied to 2024 inspections. While it does not restrict product approvals or sales, it demands ongoing resource allocation and operational focus. The company is cooperating with the agency and has begun implementing corrective measures. Lastly, while Dexcom is advocating Medicare coverage for non-insulin T2D users, progress hinges on a randomized controlled trial set to report results in late 2025 or early 2026. A favorable outcome could unlock another major addressable market. DexCom, Inc. price | DexCom, Inc. Quote While Dexcom leads in sensor accuracy and access, its three listed rivals \u2014 Abbott Laboratories ABT, Medtronic MDT and Senseonics SENS \u2014 are rapidly innovating, creating a more competitive and segmented CGM market landscape in 2025 and beyond. Abbott Laboratories continues to expand its CGM footprint with its FreeStyle Libre family and the recent launch of Libre Rio, an FDA-cleared OTC device targeting insulin-free Type 2 diabetes patients. Abbott Laboratories\u2019 broad portfolio and consumer wellness push with Lingo directly challenge Dexcom\u2019s Stelo strategy, especially in the growing OTC and metabolic health market. Medtronic, while spinning off its diabetes unit, remains a strong force through its MiniMed 780G system. Its integration of CGM with insulin pumps competes directly with Dexcom\u2019s G7-enabled automated delivery partnerships. The forthcoming spin-off could streamline Medtronic\u2019s focus and reinvigorate innovation. Senseonics, although smaller in scale, presents a differentiated offering with its implantable Eversense CGM. With sensor wear times of up to 365 days, it appeals to a niche segment prioritizing convenience and minimal maintenance, pressuring Dexcom to enhance G7\u2019s longevity and user comfort. As adoption grows, Senseonics\u2019 Eversense could influence payer and clinician preference dynamics, particularly among high-adherence, low-maintenance patient cohorts. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""5 things to watch at the ADA\u2019s Scientific Sessions This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. At the American Diabetes Association\u2019s Scientific Sessions, companies like Abbott, Dexcom and Beta Bionics will share the latest data on diabetes technology and new partnerships. The annual conference takes place June 20-23 in Chicago, with industry leaders gathering to discuss new developments in diabetes treatments. This year\u2019s event follows new ADA standards of care that would expand access to continuous glucose monitors, recommending that the devices be used in adults with Type 2 diabetes who are taking glucose-lowering medications other than insulin. The conference also comes during a dynamic time in the diabetes tech industry, following Medtronic\u2019s announcement to spin out its diabetes business, partnerships between competitors, plans for new CGMs and insulin pumps, and the Food and Drug Administration authorizing the first automated insulin delivery systems for people with Type 2 diabetes. Here are five topics MedTech Dive will be watching during the conference: Abbott and Dexcom are expected to share updates on their latest CGMs at the conference. Abbott is developing a dual-analyte sensor that can detect both blood glucose and ketones, and has struck partnerships with insulin pump companies for integrations with the planned device. BTIG analyst Marie Thibault wrote in an email that the CGM \u201chas the potential to be the first dual-analyte monitoring technology to come to market, pending approval.\u201d Meanwhile, Dexcom received FDA clearance in April for a 15-day version of its G7 CGM. The company has worked to line up integrations with automated insulin delivery systems, and plans to launch the new CGM in the second half of the year. Access has expanded for both CGMs and insulin pumps in the past year, as the FDA has expanded device labels, insurers have extended coverage and the ADA has updated its guidelines. Leerink Partners analyst David Risinger wrote in a research note last month that he expects the conference to be a \u201ckey catalyst\u201d for CGMs, with more of a focus on people with Type 2 diabetes who don\u2019t take insulin, as well as people with prediabetes and people who don\u2019t have diabetes. Dexcom said it will present data at ADA this year that looks at the benefits of CGM use for people with Type 2 diabetes across various insulin therapies. The company said that in an observational study of people with Type 2 diabetes not taking insulin, use of Dexcom\u2019s G7 CGM was associated with significantly reduced diabetes-related distress. Last year, the FDA granted expanded labels to Insulet and Tandem Diabetes Care for their automated insulin delivery systems to be used by people with Type 2 diabetes. Automated insulin delivery systems pair a CGM with an insulin pump, using an algorithm to predict how much insulin a person will need and automatically adjust the dose. Medtronic is working on an expanded label for its 780G pump to be used with its Simplera Sync sensor by people with Type 2 diabetes. Medtronic will present late-breaking data on this effort during the conference, Risinger wrote. Medtronic is also working on a separate automated insulin delivery system in partnership with Abbott, with Abbott developing a CGM to pair exclusively with Medtronic\u2019s insulin pumps. Medtronic said in April that it made FDA submissions for its MiniMed 780G insulin pump and its SmartGuard insulin dosing algorithm that would allow them to be used as interoperable devices, a critical step in advancing the Abbott partnership. New competitors plan to bring patch pumps to the U.S. market, where Insulet is currently the only company with a patch form factor device. Tandem Diabetes care has said it is working on a tubeless feature for its Mobi insulin pumps. The company is also developing a separate patch pump after buying AMF Medical in 2023. Meanwhile, Medtronic told investors earlier this year that the company is still working on a patch pump. It\u2019s not clear if the companies will share news on the planned devices. However, Thibault said she would be listening for updates from Tandem, Medtronic and Beta Bionics, which plans to launch a patch pump version of its automated insulin delivery system in 2027. Beta Bionics, which went public in January, said it will host a demonstration of the patch pump at a Sunday investor event. Medtronic announced last month that it plans to spin out its diabetes business into a separate, publicly traded company. The unit brought in $2.76 billion of revenue in Medtronic\u2019s 2025 fiscal year, and the medtech conglomerate hopes to separate it within 18 months. So far, the company has shared few details about the planned spinoff, other than that the new company would be named MiniMed, reflecting the original name of the company before Medtronic acquired it in 2001. The business is based in Northridge, California, and has more than 8,000 employees. Needham analyst Mike Matson wrote in a June 6 research note that the separation makes sense \u2014 allowing the diabetes company to become more nimble and responsive to customer needs and market trends \u2014 but will take time to create value. Recommended Reading Abbott\u2019s new diabetes leader on latest sensors, partnerships and Type 2 coverage""]"
DXCM,2025-06-23,79.99,80.32,77.81,79.84,
DXCM,2025-06-24,80.31,88.32,79.4,87.57,"ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Diabetes technology companies shared plans for their upcoming devices this weekend at the American Diabetes Association's Scientific Sessions. Several firms — including Medtronic, Tandem Diabetes Care and Beta Bionics — are developing insulin patch pumps, although Insulet seems poised to be the only company on the market with a fully disposable device. Meanwhile, competitors Abbott and Dexcom are working on multi-analyte sensors, with Abbott planning to launch a device next year that can detect both glucose and ketone levels. Here are the latest updates from the conference: As Medtronic plans for a spinoff of its diabetes business, operating unit president Que Dallara gave an update on two insulin pumps in development. Medtronic provided a demonstration of its next tubed pump, the MiniMed 8-series, which is about half the size of its current 780G pump, has no screen and is controlled by a phone, RBC Capital Markets analyst Shagun Singh wrote in a research note. The company expects to submit the 8-series pump for Food and Drug Administration clearance by the close of its 2026 fiscal year, which ends next April. Medtronic plans to integrate the pump with its own Simplera glucose sensor and with competitor Abbott’s Libre sensors. Medtronic also showcased a patch pump in development. Comparing Medtronic’s planned pump to Insulet’s Omnipod — a fully disposable device that created the market for insulin patch pumps — Medtronic’s patch pump has a semi-durable design with a rechargeable battery, J.P. Morgan analyst Robbie Marcus wrote in a research note. Medtronic’s patch pump would have a larger insulin reservoir, at 300 units, and a longer wear time, at seven days. Dallara did not provide a timeline for the patch pump, Marcus wrote, adding he does not expect “anything material” for roughly three more years. Singh estimated the patch pump wouldn’t be in the U.S. market earlier than 2027. Beta Bionics unveiled a new prototype for a patch pump, called Mint. The diabetes device company, which went public in January, currently sells the iLet Bionic Pancreas, an automated insulin delivery system that uses a tubed pump. The new device is a mix of disposable and reusable components, Marcus wrote, with a reusable piece that lasts for about two years and requires new batteries periodically. It is comparable to Insulet’s Omnipod in that both pumps last three days and take up to 200 units of insulin. Marcus described the device as a ""thoughtful form factor” and a better version of existing tubed devices, but expects Insulet to still have the advantage with the convenience of a fully disposable pump. Tandem discussed plans for two upcoming patch pumps and a traditional tubed pump. The company is working on its t:slim X3 pump, a successor to its line of tubed pumps, which features better processing capabilities, battery life and durability, Singh wrote. The company is also working on a tubeless option for its smaller Mobi insulin pumps and a separate patch pump called Sigi, which will be rechargeable and come with pre-filled insulin cartridges. Tandem did not share timelines for any of the three pumps, but is expected to debut the t:slim X3 first, followed by Mobi tubeless and then Sigi, Singh wrote. Abbott has struck several partnerships around a planned dual-analyte sensor that can detect glucose and ketones. The device, Abbott claims, can help people with diabetes avoid a serious condition called diabetic ketoacidosis by detecting a rise in ketones early. A panel at ADA debated the clinical need for continuous ketone monitoring. Leading up to the conference, Tandem, Sequel Med Tech and Beta Bionics said they would integrate their insulin pumps with Abbott’s planned sensor. Abbott is preparing for a commercial launch sometime next year, and expects the sensor to be integrated with all major automated insulin delivery systems, BTIG analyst Marie Thibault wrote in a research note. The company hopes to gain market share in the U.S. with the new sensor. Dexcom’s next continuous glucose monitor, the G8, is currently in human feasibility trials, J.P. Morgan’s Marcus wrote. The sensor will last for 15 days, have a smaller form factor than Dexcom’s current G7, and support multi-analyte capabilities. Dexcom has not yet said which analytes it will support, such as the ability to monitor ketone levels. Marcus expects the device could reach the market as soon as 2027 or 2028. Senseonics, which makes an implantable glucose sensor that can be worn for one year, discussed future iterations of the device at the conference. The company is working on a version called Gemini, which is fully implantable and self-powered. The company plans to start a study later this year, followed by a commercial launch in the fourth quarter of 2026, BTIG’s Thibault wrote. Further out, the company is working on a version that requires no transmitter, called Freedom. That sensor is in prototype testing, according to Thibault. The ADA conference featured a debate on the benefits and risks of over-the-counter CGMs, but developers of the devices had few updates to share at the conference. Abbott and Dexcom launched the first over-the-counter CGMs last year. Dexcom’s Stelo was geared toward people with Type 2 diabetes who don’t take insulin, although it could also be used by people who have prediabetes or don’t have diabetes. Abbott’s Lingo was more wellness-oriented, intended for people who don’t have diabetes. Abbott said last year it was also working on a separate, over-the-counter device, called Rio, intended for people with Type 2 diabetes who don’t take insulin. When asked by MedTech Dive, an Abbott spokesperson said the company does not have a timeline for launch, adding that “right now, our efforts are focused on getting more people access and coverage for our current portfolio of Libre CGMs.” Recommended Reading Insulet’s Eric Benjamin shares update on automated insulin delivery system"
DXCM,2025-06-25,87.55,87.75,84.4,84.68,"[""S&P Futures Tick Higher With Focus on Powell\u2019s Testimony September S&P 500 E-Mini futures (ESU25) are trending up +0.16% this morning, extending yesterday\u2019s gains, while investors await further testimony from Federal Reserve Chair Jerome Powell for clues on the rate outlook. The ceasefire brokered by U.S. President Donald Trump between Iran and Israel appeared to be holding on Wednesday, with both sides declaring victory in the war. Trump\u2019s Middle East envoy said late on Tuesday that talks between the U.S. and Iran were \u201cpromising\u201d and that Washington remained hopeful for a long-term peace agreement. Investors are now turning their attention back to the U.S. economy and how trade tensions and fiscal pressures could impact corporate earnings and growth. In yesterday\u2019s trading session, Wall Street\u2019s three main equity benchmarks closed higher. Chip stocks rallied, with Intel (INTC) and Advanced Micro Devices (AMD) climbing over +6%. Also, DexCom (DXCM) surged more than +9% and was the top percentage gainer on the Nasdaq 100 after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced that his agency is launching one of the largest campaigns in history to promote the use of wearable health devices. In addition, Uber Technologies (UBER) gained over +7% after the company announced that it would begin offering driverless Waymo rides to its customers in Atlanta. On the bearish side, Dollar General (DG) fell more than -1% after Goldman Sachs downgraded the stock to Neutral from Buy. Economic data released on Tuesday showed that the U.S. Conference Board\u2019s consumer confidence index unexpectedly fell to 93.0 in June, weaker than expectations of 99.4. Also, the U.S. April S&P/CS HPI Composite - 20 n.s.a. eased to +3.4% y/y from +4.1% y/y in March, weaker than expectations of +4.0% y/y. In addition, the U.S. Richmond Fed manufacturing index unexpectedly rose to -7 in June, stronger than expectations of -10. Fed Chair Jerome Powell told lawmakers on Tuesday that the central bank is not in a hurry to cut interest rates as officials await greater clarity on the economic effects of President Trump\u2019s tariffs. \u201cThe effects of tariffs will depend, among other things, on their ultimate level,\u201d Powell said in remarks before the House Financial Services Committee. \u201cFor the time being, we are well-positioned to wait to learn more about the likely course of the economy before considering any adjustments to our policy stance.\u201d Should inflation come in below expectations or the labor market weaken, Powell said, the Fed could cut rates sooner. Cleveland Fed President Beth Hammack said that interest rates are only modestly restrictive and that policymakers may keep borrowing costs steady \u201cfor quite some time.\u201d Also, New York Fed President John Williams said that \u201cmaintaining this modestly restrictive stance of monetary policy is entirely appropriate to achieve our maximum employment and price stability goals,\u201d while policymakers assess the full impact of U.S. policy changes. In addition, Boston Fed President Susan Collins said that monetary policy is in the right place, emphasizing that the \u201cmodestly restrictive\u201d stance of monetary policy is \u201cnecessary.\u201d Finally, Fed Governor Michael Barr stated that he expects tariffs to push inflation higher and voiced support for maintaining a wait-and-see approach on interest rates. Meanwhile, U.S. rate futures have priced in an 81.4% chance of no rate change and an 18.6% chance of a 25 basis point rate cut at the July FOMC meeting. Today, investors will closely watch Fed Chair Jerome Powell\u2019s semi-annual monetary policy testimony before the Senate Banking Committee. On the economic data front, investors will focus on U.S. New Home Sales data, which is set to be released in a couple of hours. Economists foresee this figure coming in at 694K in May, compared to 743K in April. U.S. Crude Oil Inventories data will be released today as well. Economists expect this figure to be -1.200M, compared to last week\u2019s value of -11.473M. On the earnings front, notable companies like Micron Technology (MU), Paychex (PAYX), General Mills (GIS), and Jefferies Financial (JEF) are set to report their quarterly figures today. In the bond market, the yield on the benchmark 10-year U.S. Treasury note is at 4.287%, down -0.07%. The Euro Stoxx 50 Index is down -0.13% this morning, taking a breather after yesterday\u2019s rally spurred by the ceasefire between Israel and Iran. Bank and media stocks underperformed on Wednesday, while automobile and defense stocks advanced. Final data from the National Statistics Institute confirmed on Wednesday that Spain\u2019s economy expanded by 0.6% in the first quarter, slightly slower than the 0.7% growth seen in the previous quarter. Separately, data showed that France\u2019s consumer confidence was unchanged in June and remained well below its long-term average. Meanwhile, investors are focusing on the NATO summit in the Netherlands, where defense spending will take center stage. The military alliance\u2019s 32 member states, except Spain, have reportedly agreed to raise their defense spending target to 5% of gross domestic product. In corporate news, Stellantis N.V. (STLAM.M.DX) gained over +4% after Jefferies upgraded the stock to Buy from Hold. Also, Babcock International Group Plc (BAB.LN) surged more than +12% after the British warship maker boosted its mid-term profit target. France\u2019s Consumer Confidence and Spain\u2019s GDP data were released today. The French June Consumer Confidence stood at 88, weaker than expectations of 89. The Spanish GDP has been reported at +0.6% q/q and +2.8% y/y in the first quarter, in line with expectations. Asian stock markets today closed in the green. China\u2019s Shanghai Composite Index (SHCOMP) closed up +1.04%, and Japan\u2019s Nikkei 225 Stock Index (NIK) closed up +0.39%. China\u2019s Shanghai Composite Index closed higher and hit a more than 6-month high today as the ceasefire between Israel and Iran appeared to hold, with sentiment further lifted by Beijing\u2019s push toward a consumer-driven economy. Brokerage and defense stocks led the gains on Wednesday. China on Tuesday issued guidelines aimed at using financial tools to stimulate consumption, with commitments to support employment and boost household incomes as part of wider efforts to strengthen the economy. The guidelines, jointly drafted by six government departments and published by the People\u2019s Bank of China, stated that China would assist eligible companies across the consumer industry chain in raising funds through stock market listings and other channels. China will \u201cguide financial institutions to strengthen financial services from both the supply and demand sides of consumption, meet the diversified financing needs of various entities and promote the expansion of high-quality consumption,\u201d the PBOC said. Meanwhile, China\u2019s Premier Li Qiang stated on Wednesday that he was confident the world\u2019s second-largest economy could sustain a \u201crelatively rapid\u201d growth pace as it shifts from a manufacturing-based model to one driven by consumption. \u201cChina\u2019s economy showed steady improvement in the second quarter,\u201d Li added. He also stated that China\u2019s consumption potential would create vast new market opportunities for global businesses. In other news, Beijing said it would take action in response to Taiwan\u2019s decision to add several Chinese firms, including Huawei, to an export-control list that restricts their access to advanced technology. In corporate news, New Oriental Education & Technology climbed over +8% in Hong Kong after JPMorgan upgraded the stock to Overweight from Neutral. Japan\u2019s Nikkei 225 Stock Index ended higher and hit a more than 4-month high today as the truce between Israel and Iran appeared to hold, buoying investors\u2019 risk appetite. Chip-related stocks outperformed on Wednesday, tracking overnight gains in their U.S. peers. Bank of Japan data released on Wednesday showed that a key gauge of Japan\u2019s service-sector inflation stood at 3.3% in May, sustaining expectations of additional interest rate hikes by the central bank. Separately, data from the Cabinet Office showed that Japan\u2019s leading economic indicators index, which gauges the economic outlook for a few months ahead based on data such as job offers and consumer sentiment, was revised upward in April. Meanwhile, a summary of opinions from the BOJ\u2019s June policy meeting showed on Wednesday that some policymakers supported holding interest rates steady for now amid uncertainty over the impact of U.S. tariffs on the Japanese economy. Others on the nine-member board said that inflation was running above expectations, with one member suggesting the BOJ might have to raise interest rates \u201cdecisively\u201d at some point, even if economic uncertainty persists. BOJ board member Naoki Tamura said on Wednesday that the central bank should consider further interest rate hikes without delay as inflation could reach its target earlier than expected despite trade uncertainty. On the trade front, Japan\u2019s tariff negotiator Ryosei Akazawa is reportedly planning his seventh trip to the U.S. for as early as June 26th, seeking to end tariffs that are weighing on Japan\u2019s economy. Investors also await Japan\u2019s retail sales and Tokyo CPI data, scheduled for release on Friday, which will help guide the BOJ\u2019s next policy decisions. The Nikkei Volatility Index, which takes into account the implied volatility of Nikkei 225 options, closed down -2.63% to 23.29. The Japanese May Corporate Services Price Index came in at +3.3% y/y, stronger than expectations of +3.1% y/y. The Japanese April Leading Index stood at 104.2, stronger than expectations of 103.4. Pre-Market U.S. Stock Movers FedEx (FDX) slumped over -5% in pre-market trading after the shipping giant issued below-consensus FQ1 adjusted EPS guidance. BlackBerry (BB) surged more than +14% in pre-market trading after the cybersecurity company posted better-than-expected Q1 results and raised its full-year sales guidance. QuantumScape (QS) jumped over +33% in pre-market trading after the company announced it had successfully integrated its advanced Cobra separator process into baseline cell production. Worthington Enterprises (WOR) rose more than +10% in pre-market trading after the maker of building and consumer products reported stronger-than-expected FQ4 results. TMC the metals company Inc. (TMC) climbed over +6% in pre-market trading after Wedbush upgraded the stock to Outperform from Neutral with a price target of $11. You can see more pre-market stock movers here Today\u2019s U.S. Earnings Spotlight: Wednesday - June 25th Micron (MU), Paychex (PAYX), General Mills (GIS), Jefferies Financial (JEF), H B Fuller (FUL), Novagold (NG), Worthington Steel (WS), Steelcase (SCS), MillerKnoll (MLKN), Winnebago Industries (WGO), Daktronics (DAKT). On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Undervalued Stock Opportunities For Savvy Investors In June 2025 The United States market has experienced a positive trend, rising 1.9% over the last week and showing a 12% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying undervalued stocks can be key for investors seeking opportunities that align with these promising growth prospects. Click here to see the full list of 173 stocks from our Undervalued US Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: AppLovin Corporation develops a software-based platform aimed at improving the marketing and monetization of content for advertisers globally, with a market cap of approximately $118.26 billion. Operations: AppLovin generates revenue through its Apps segment, which accounts for $1.43 billion, and its Advertising segment, contributing $3.70 billion. Estimated Discount To Fair Value: 21.8% AppLovin is trading at US$349.48, 21.8% below its estimated fair value of US$447.09, indicating potential undervaluation based on cash flows. Despite recent goodwill impairments of US$188.94 million and legal challenges regarding alleged fraudulent practices, the company reported robust first-quarter sales of US$1.48 billion and net income growth to US$576.42 million from the previous year\u2019s figures. Its earnings are forecasted to grow significantly over the next three years, supporting a positive outlook amidst volatility concerns. Our earnings growth report unveils the potential for significant increases in AppLovin's future results. Click to explore a detailed breakdown of our findings in AppLovin's balance sheet health report. Overview: DexCom, Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring systems globally, with a market cap of approximately $34.34 billion. Operations: The company's revenue is primarily derived from its patient monitoring equipment segment, which generated $4.15 billion. Estimated Discount To Fair Value: 25.8% DexCom, trading at US$87.57, is valued 25.8% below its estimated fair value of US$117.96, suggesting undervaluation based on cash flows. Despite ongoing legal issues with Stelo over trademark infringement and consumer confusion, DexCom's revenue is projected to grow significantly faster than the market at 12.9% annually. Earnings are expected to rise by 23.3% per year, bolstered by strategic leadership changes and a robust product pipeline in glucose monitoring technology. Upon reviewing our latest growth report, DexCom's projected financial performance appears quite optimistic. Click here to discover the nuances of DexCom with our detailed financial health report. Overview: Corpay, Inc. is a payments company that assists businesses and consumers with managing vehicle-related expenses, lodging expenses, and corporate payments across the United States, Brazil, the United Kingdom, and internationally; it has a market cap of $23.23 billion. Operations: Corpay's revenue is primarily derived from vehicle payments at $2.00 billion, corporate payments at $1.31 billion, and lodging payments at $487.52 million. Estimated Discount To Fair Value: 37.7% Corpay is trading at US$329.47, significantly below its estimated fair value of US$528.76, indicating undervaluation based on cash flows. The company's earnings are forecast to grow annually by 15.4%, outpacing the broader U.S. market's growth rate of 14.6%. Recent strategic partnerships with major entities like West Ham United and Real Madrid enhance its foreign exchange solutions footprint, while a strong cash position supports potential acquisitions to drive future growth. In light of our recent growth report, it seems possible that Corpay's financial performance will exceed current levels. Navigate through the intricacies of Corpay with our comprehensive financial health report here. Get an in-depth perspective on all 173 Undervalued US Stocks Based On Cash Flows by using our screener here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include APP DXCM and CPAY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""Entegris, Herc, Enovis, Commercial Vehicle Group, and DexCom Shares Skyrocket, What You Need To Know A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices. Additionally, dovish signals from Federal Reserve Chair Jerome Powell in his Congressional testimony, reaffirming a \""wait-and-see\"" approach on interest rates, further calmed markets, improving investors' appetite for stocks and other risk assets. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Semiconductor Manufacturing company Entegris (NASDAQ:ENTG) jumped 7%. Is now the time to buy Entegris? Access our full analysis report here, it\u2019s free. Specialty Equipment Distributors company Herc (NYSE:HRI) jumped 7.4%. Is now the time to buy Herc? Access our full analysis report here, it\u2019s free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 6.2%. Is now the time to buy Enovis? Access our full analysis report here, it\u2019s free. Heavy Transportation Equipment company Commercial Vehicle Group (NASDAQ:CVGI) jumped 5.1%. Is now the time to buy Commercial Vehicle Group? Access our full analysis report here, it\u2019s free. Patient Monitoring company DexCom (NASDAQ:DXCM) jumped 6.3%. Is now the time to buy DexCom? Access our full analysis report here, it\u2019s free. Herc\u2019s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 28 days ago when the stock gained 5.1% after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. Herc is down 32.1% since the beginning of the year, and at $126.38 per share, it is trading 47.2% below its 52-week high of $239.28 from November 2024. Investors who bought $1,000 worth of Herc\u2019s shares 5 years ago would now be looking at an investment worth $4,616. Unless you\u2019ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story."", ""Why DexCom (DXCM) is a Top Growth Stock for the Long-Term Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 23.8% year-over-year for the current fiscal year, with sales growth of 14.3%. Four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0 to $2.03 per share for 2025. DXCM boasts an average earnings surprise of 0.5%. Looking at cash flow, DexCom is expected to report cash flow growth of 9.8% this year; DXCM has generated cash flow growth of 32% over the past three to five years. DXCM should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-06-26,84.95,86.07,84.8,85.068,"[""Diabetes stocks rally after RFK comments on HHS campaign Sarah Karlin-Smith of Pink Sheet reported via X: \u201cRFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing \u201cwearable\u201d in 4 years.\u201d Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on TNDM: Disclaimer & DisclosureReport an Issue Cisco upgraded, CoreWeave downgraded: Wall Street\u2019s top analyst calls Tandem Diabetes initiated with a Hold at Truist Tandem Diabetes announces agreement with Abbott to develop diabetes solutions Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges"", ""DexCom\u2019s Q1 Earnings Call: Our Top 5 Analyst Questions DexCom\u2019s first quarter was met with a positive response from the market, as the company delivered revenue ahead of Wall Street expectations and maintained strong growth momentum. Management attributed this performance to robust demand, record new patient additions, and successful navigation of short-term supply challenges. CEO Kevin Sayer highlighted that the company\u2019s expanded commercial reach, recent product launches, and broader patient access were key to driving acceleration in new customer starts, particularly among individuals with type 2 diabetes. Sayer noted, \u201cWe experienced an acceleration in demand from new customers, which again came in at record levels during Q1.\u201d Is now the time to buy DXCM? Find out in our full research report (it\u2019s free). Revenue: $1.04 billion vs analyst estimates of $1.02 billion (12.5% year-on-year growth, 1.8% beat) Adjusted EPS: $0.32 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $230.4 million vs analyst estimates of $251.9 million (22.2% margin, 8.5% miss) The company reconfirmed its revenue guidance for the full year of $4.6 billion at the midpoint Operating Margin: 12.9%, up from 11% in the same quarter last year Organic Revenue rose 13.8% year on year (24.8% in the same quarter last year) Market Capitalization: $33.2 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Matt Taylor (Jefferies) asked about the impact of supply dynamics on revenue growth and how quickly the price-volume gap might close. CFO Jereme Sylvain said inventory levels have normalized, and new patient growth remains strong, suggesting volume growth will continue to track historical trends. Danielle Antalffy (UBS) inquired about DexCom\u2019s resilience in an economic downturn. Sylvain explained that broader coverage and the value proposition of CGM position DexCom well, though all healthcare companies face some macro risk. Jayson Bedford (Raymond James) questioned international growth variances. Sylvain pointed to strong performance in Japan and France, attributing some volatility to the timing of coverage wins in various international markets. Jeff Johnson (Baird) sought clarification on gross margin cadence and potential manufacturing issues. COO Jacob Leach stated manufacturing output was at record levels and product quality was steady, with no major process issues identified. Marie Thibault (BTIG) asked how DexCom is maintaining operating and EBITDA margin guidance despite gross margin pressures. Sylvain and Leach credited operational efficiencies, prior commercial investments, and targeted cost controls for supporting margin targets. In the quarters ahead, the StockStory team will watch (1) the pace of new type 2 diabetes patient adoption as expanded PBM coverage takes effect, (2) the rollout and patient uptake of the 15 Day G7 system and its integration with insulin pumps, and (3) progress on supply chain normalization and gross margin recovery as logistics costs decrease. Additional data releases in support of broader type 2 coverage will also be key milestones. DexCom currently trades at $84.78, up from $70.25 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it\u2019s free). The market surged in 2024 and reached record highs after Donald Trump\u2019s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we\u2019re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver\u2019s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.""]"
DXCM,2025-06-27,85.0,87.48,84.84,86.33,"Here's Why DexCom (DXCM) is a Strong Momentum Stock Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Momentum investors, who live by the saying ""the trend is your friend,"" are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. DXCM boasts a Momentum Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of DexCom has seen some interesting price action recently; the stock is up 5% over the past one week and up 0.2% over the past four weeks. And in the last one-year period, DXCM has lost 25.8%. As for the stock's trading volume, 3,401,516 shares on average were traded over the last 20 days. A company's earnings performance is important for momentum investors as well. For fiscal 2025, four analysts revised their earnings estimate higher in the last 60 days for DXCM, while the Zacks Consensus Estimate has increased $0 to $2.03 per share. DXCM also boasts an average earnings surprise of 0.5%. Investors should take the time to consider DXCM for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-06-30,85.77,87.49,85.5568,87.29,"Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push DexCom, Inc. (NASDAQ:DXCM) ranks among the best fundamental stocks to buy according to hedge funds. Oppenheimer reaffirmed its $95 price target and Outperform rating for DexCom, Inc. (NASDAQ:DXCM) on June 24 in response to remarks made by Health and Human Services Secretary RFK Jr. regarding a significant wearables campaign. At a June 24 hearing of the House Energy and Commerce Health Subcommittee, Secretary Kennedy declared that HHS would soon begin “one of the biggest advertising campaigns in HHS history” to promote wearables among Americans, emphasizing the advantages of glucose monitors. The possibility of a major government marketing campaign is encouraging for companies that provide continuous glucose monitoring (CGM), as noted by Oppenheimer, who also observed that the Secretary’s remarks may indicate interest in future coverage of over-the-counter CGMs. Oppenheimer also noted recent advancements in CGM coverage for non-insulin Type 2 diabetes, pointing to a DexCom-led randomized controlled trial that is expected to wrap up in late 2025 or early 2026 for Medicare patients with non-insulin Type 2 diabetes. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds Disclosure: None."
DXCM,2025-07-01,83.175,85.62,82.75,83.58,"[""2 \u2018Strong Buy\u2019 Stocks That the MAHA Movement AND Wall Street Love Wearables, or electronic devices worn to collect health-related data, are fast becoming a public health priority. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. told Congress that HHS will launch one of the largest advertising campaigns in its history to get wearables and continuous glucose monitors (CGMs) onto every wrist and arm in America. Stocks of companies that sell these devices have seen a surge following his commentary. Abbott Laboratories (ABT) and DexCom (DXCM), in particular, have benefitted. Both firms were already darlings of Wall Street thanks to consistent double-digit revenue growth. Kennedy\u2019s Make America Healthy Again (MAHA) push now constitutes a significant bull case that, if successful, may pull millions of new users into the wearables ecosystem. In turn, these users would add significantly to the top and bottom lines of Abbott and DexCom. Jeff Bezos Unloads $5.4B in Amazon Shares: Should You Buy or Sell AMZN Stock Now? Elon Musk\u2019s Tesla Makes History With \u2018First Time That a Car Has Delivered Itself to Its Owner\u2019 This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! This push to promote wearables is due to the argument that catching and screening diseases early would put less strain on the healthcare sector in the long run. Proponents also believe that wearables promote healthier overall lifestyles. Abbott already dominates the global CGM market with its FreeStyle Libre platform. The company also offers Lingo, an over-the-counter CGM that targets general consumers outside of its Diabetes Care segment. In the first quarter, Abbott reported total Medical Devices revenue of $4.9 billion, up 12.6% year over year. Its Diabetes Care sales within that segment were $1.7 billion, up 21.6% annually. Management continues to target $10 billion in annual sales related to Libre devices by 2028. Supporting the broad appeal and benefits of its wearables, in May, Abbott reported positive results from its REFLECT real-world studies, which found that its CGM tech \u201chelps significantly reduce the risk of hospitalization for heart complications in people with diabetes.\u201d With support from MAHA proponents and the HHS, these sales figures could get a boost. Abbott Laboratories could also gain significant pricing power if the HHS chooses to subsidize its wearables. Abbott Laboratories has already been one of the best-performing names in healthcare in the past year. The stock is up 30.9% over the past 52 weeks. Out of 26 analysts, 18 tag it as a \u201cStrong Buy,\u201d with a mean price target of $143.65. Dexcom offers several CGM products, includings its Dexcom G7, which connects directly to Apple Watches. Plus, Dexcom\u2019s Stelo, which is an over-the-counter CGM targeting wellness-focused users, has already attracted 140,000 subscribers as of the end of 2024. DexCom reported revenue of $1.04 billion for Q1, up 14% on an organic basis, which DexCom defines as excluding non-CGM revenue. Management said that Q1 marked the second straight quarter of reaccelerating revenue growth, and that the company navigated supply chain issues and expanded access and coverage to its CGMs. For the full year, DexCom forecasts revenue growth of 14%. Just like with Abbott, a decision from the HHS to subsidize or otherwise support wearables for every American could cause explosive sales growth and give DexCom more room to push prices higher. DXCM stock has been struggling ever since the stock peaked in 2021. It is still down over 47% from those highs, but the stock popped nearly 10% Kennedy\u2019s comments. If the government starts aggressively promoting wearables, this may be the catalyst that causes DXCM stock to pick up steam again. Out of 25 analysts, 20 tag it a \u201cStrong Buy,\u201d with a mean price target of $99.68. On the date of publication, Omor Ibne Ehsan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Who benefits from over-the-counter CGMs? This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The launch of the first over-the-counter glucose sensors last year has raised a debate about who benefits from these devices. The Food and Drug Administration cleared devices made by Dexcom and Abbott last year with a broad indication, allowing anyone who does not take insulin to use them. During a session at the American Diabetes Association\u2019s Scientific Sessions in June, a pharmacist and a physician debated the benefits and risks of these new devices. They both supported making CGMs more accessible to people with diabetes, but disputed the usefulness of the devices for adults without diabetes. Diana Isaacs, a pharmacist and director of education and training in diabetes tech at the Cleveland Clinic, argued in favor of over-the-counter CGMs, saying they could be helpful for people who don\u2019t have insurance coverage or who might have a hard time getting into a specialist for a prescription. David Ahn, an endocrinologist and chief of diabetes services at Hoag Hospital\u2019s Mary and Dick Allen Diabetes Center, agreed that having glucose monitors easily accessible is \u201creally exciting,\u201d but raised concerns that patients might misinterpret the data and that the devices are not designed for accuracy in a narrower glucose range. The ADA debate was part of a broader discussion that is happening after Health and Human Services Secretary Robert F. Kennedy Jr. touted CGMs at a recent Congressional hearing, saying he would like all Americans to be wearing a health wearable within four years. Currently, two over-the-counter CGMs are on the market: Dexcom\u2019s Stelo device, which is marketed to people with Type 2 diabetes who don\u2019t take insulin, and Abbott\u2019s Lingo, which is tailored to the wellness market. Abbott received FDA clearance for another over-the-counter device, called Libre Rio, which is intended for people with Type 2 diabetes, but the company has not yet shared a timeframe for launch. One key difference between over-the-counter and prescription CGMs is that the over-the-counter versions don\u2019t provide hypoglycemia alerts. They also display a narrower range of glucose values. Dexcom\u2019s G7 has a reportable glucose range of 40 to 400 milligrams per deciliter, while its Stelo app only displays ranges of 70 to 250 mg/dL. Dexcom\u2019s Stelo also provides glucose readings every 15 minutes, while its G7 sensor provides them every five minutes. Abbott\u2019s Lingo similarly provides a range of 50 to 200 mg/dL, while its Libre Rio is expected to have a measurement range in line with prescription CGMs. The over-the-counter devices focus on measuring glucose spikes, with Stelo issuing a \u201cspike alert\u201d while Lingo issues \u201cpoints\u201d for increases in glucose throughout the day. One challenge for people without diabetes who may use a CGM is that glucose spikes are not well defined, Ahn said. For example, how do you distinguish if the \u201cspike\u201d is just a response to stress versus from having a high-carb meal? It also raises the question of what the goal is for patients. \u201cIs our ultimate goal to not have any spikes at all and to have a flat line as a blood sugar?\u201d he said. \u201cSurely that\u2019s not the case.\u201d While there are strong guidelines for time in range for people with diabetes, he added, there is no consensus statement or guideline for what \u201cnormal\u201d is for people without diabetes. Ahn also said CGMs are better at detecting high and low blood sugar levels, and may be less accurate in a tighter range. He wore both Dexcom\u2019s Stelo and Abbott\u2019s Libre 2 Plus for 13 days, and had an average glucose reading of 113 mg/dL from Stelo but an average of 85 mg/dL from Libre 2 Plus. \u201cGlucose spikes and misinterpreting data can lead to confusion, anxiety, and worse, disordered eating,\u201d he said. Isaacs looked to the history of diabetes devices to build an argument for over-the-counter CGMs. At one point, finger sticks used to measure blood glucose were only available in doctors\u2019 offices. Now, they can be bought without a prescription. When the first CGMs came to market, they were only accessible for people who had the privilege of being able to afford them and get a prescription, Isaacs said. \u201cI remember very vividly, in the earlier days of CGM, we had patients with Type 1 diabetes where some healthcare providers said, \u2018Oh, I think that person is going to get too anxious seeing their numbers all of the time,\u2019\u201d Isaacs said. \u201cLet the person decide.\u201d CGMs are much more accessible today. But for people without insurance coverage or a prescription, an over-the-counter CGM would often be cheaper than paying for a prescription device with cash, Isaacs said. One area of potential benefit is for people with prediabetes, which accounted for roughly 38% of U.S. adults in 2021, according to the Centers for Disease Control and Prevention. Many people don\u2019t know they are living with this condition, Isaacs said. Even though CGMs are not intended to diagnose diabetes, the results could prompt a person to see their physician and get testing, she said. Isaacs also sees the devices as helpful for people with gestational diabetes, because many of those patients don\u2019t take insulin, which can make it harder to get insurance coverage for a CGM. For people without diabetes, Isaacs still sees CGMs as having a role in educating people about what foods and other lifestyle factors can lead to glucose excursions. \u201cWhat I would argue is that the benefit, for sure, outweighs the risk,\u201d Isaacs said. Recommended Reading Abbott\u2019s new diabetes leader on latest sensors, partnerships and Type 2 coverage"", ""Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. SAN DIEGO, July 01, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID \""9430114\"" approximately five minutes prior to the start time. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Category: IR View source version on businesswire.com: https://www.businesswire.com/news/home/20250701870316/en/ Contacts DexCom, Inc.: Sean Christensen Vice President \u2013 Finance and Investor Relations investor-relations@dexcom.com (858) 200-0200"", ""Medical device maker stocks falls after proposed Medicare payment cuts Investing.com -- Shares of medical device manufacturers tumbled on Tuesday after the Centers for Medicare & Medicaid Services (CMS) proposed significant payment reductions for home health agencies that could impact diabetes care providers. Tandem Diabetes Care Inc (NASDAQ:TNDM) fell 6.4%, DexCom Inc (NASDAQ:DXCM) dropped 4.9%, and Insulet Corporation (NASDAQ:PODD) declined 2%. The sell-off follows CMS\u2019s proposed rule for calendar year 2026 that would decrease Medicare payments to home health agencies by 6.4%, or approximately $1.135 billion compared to 2025. The proposed cuts include a permanent adjustment of -4.059% and a temporary reduction of 5.0% to recoup what CMS describes as retrospective overpayments. Investors appear concerned that the payment reductions could negatively impact diabetes device makers, as many patients using continuous glucose monitors (CGMs) and insulin pumps rely on Medicare coverage. The proposal particularly affects companies like DexCom, which manufactures CGMs, and Tandem and Insulet, which produce insulin delivery systems. The proposed rule, issued on June 30, 2025, is part of CMS\u2019s annual update to Medicare payment policies under the Home Health Prospective Payment System. While the proposal includes a 2.4% payment update ($425 million increase), this is more than offset by the proposed permanent and temporary adjustments. The rule also proposes reclassifying all continuous glucose monitors and insulin infusion pumps under the \""frequent and substantial servicing payment category,\"" which CMS says would give beneficiaries access to current technology rather than having to wait five years. CMS stated that the actions in this proposed rule \""would help improve patient care and protect the Medicare program\u2019s sustainability for future generations.\"" Related articles Medical device maker stocks falls after proposed Medicare payment cuts BofA highlights Meta\u2019s early AI gains and revenue momentum, reiterates Buy rating Wall Street analysts start bullish on Omada Health on chronic care market growth"", ""Saluda Medical Appoints Barry Regan as Chief Executive Officer Follows the Addition of Mike Mathias as Chief Commercial Officer in Late 2024 and Jim Erickson as Chief Financial Officer in Late 2023 MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the appointment of Barry Regan as President and Chief Executive Officer effective as of July 14, 2025. In his most recent roles, Mr. Regan served as Executive Vice President, Global Operations at Dexcom and Senior Vice President, Global Operations at Wright Medical. \""We are thrilled to welcome Barry to Saluda and are fortunate to augment our leadership team with his extensive experience at a critical juncture,\"" said Doug Godshall, Chairman of the Board of Directors of Saluda Medical. \""Combined with the recent appointments of Mike Mathias as Chief Commercial Officer and Jim Erickson as Chief Financial Officer, we are confident Saluda has the right team of seasoned and driven leaders in place to fully realize our vision of bringing scientifically-based spinal cord stimulation, and neuromodulation more broadly, into the future with our unparalleled dose-controlled, closed-loop platform. On behalf of the Board, we also extend our gratitude to Jim Schuermann for his contributions to the Company and wish him success in his future endeavors.\"" Bob Palmisano, Board Member of Saluda Medical and former Chief Executive Officer of Wright Medical added, \""I am excited to work with Barry again following our time together at Wright. Barry's proven track record of driving transformational change to support growth and profitability at large, global healthcare organizations, including at Wright and most recently at Dexcom, will undoubtedly benefit Saluda as the Company continues to scale commercial operations for the Evoke System.\"" \""I am thrilled to join Saluda as Chief Executive Officer at this exciting time,\"" said Barry Regan. \""I look forward to working with Mike Mathias, Jim Erickson, Doug, Bob, and the entire team to continue establishing Saluda as a new standard of care in neuromodulation and transforming the lives of patients with chronic neurological conditions.\"" About Barry Regan Mr. Regan brings more than 30 years of operations experience across both the medical device and pharmaceutical industries to his new role as President and CEO of Saluda Medical. Most recently, he served as Executive Vice President, Global Operations at Dexcom, which included responsibility for overseeing the capital investment strategy supporting the scale-up of internal and external supplier manufacturing processes for Dexcom's continuous glucose monitoring (CGM) products. Prior to Dexcom, Mr. Regan held the role of Senior Vice President, Global Operations at Wright Medical, and before that, Senior Vice President, Global Supply Chain at Smith & Nephew. Earlier in his career, Mr. Regan served as Vice President, Manufacturing & General Manager, Puerto Rico at AbbVie, and also held various positions at Abbott of increasing responsibility over a 17-year period. He holds a Bachelor of Technology from the University of Limerick and an MBA from Lake Forest Graduate School of Management. About Saluda Medical Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke\u00ae System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/. Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. Investor Contacts: Brian Johnston or Sam Bentzinger brian@gilmartinir.com sam@gilmartinir.com View original content to download multimedia:https://www.prnewswire.com/news-releases/saluda-medical-appoints-barry-regan-as-chief-executive-officer-302494895.html SOURCE Saluda Medical""]"
DXCM,2025-07-02,83.26,84.73,82.79,83.57,"[""Apple AI, Wolfspeed bankruptcy, medical device stocks Yahoo Finance anchor Brad Smith examines some of the top headlines on Wall Street as part of today's Market Minute. Apple (AAPL) is reportedly considering using an external artificial intelligence (AI) language learning model (LLM) for Siri from Anthropic (ANTH.PVT) or OpenAI (OPAI.PVT), Bloomberg reported. Wolfspeed (WOLF) stock skyrockets after the company filed for Chapter 11 bankruptcy. Medical device makers like Tandem Diabetes (TNDM), Dexcom (DXCM), and Insulet (PODD), are trading lower as the US proposes changes to Medicare rules. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute"", ""Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech."", ""How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts The agency overseeing Medicare and Medicaid proposes $4.5 billion of spending cuts for home healthcare, and new economies on diabetes devices.""]"
DXCM,2025-07-03,83.7,84.49,82.575,82.93,"[""3 Reasons Growth Investors Will Love DexCom (DXCM) Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. DexCom (DXCM) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below: Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for DexCom is 25%, investors should actually focus on the projected growth. The company's EPS is expected to grow 23.8% this year, crushing the industry average, which calls for EPS growth of 14%. Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for DexCom is 9.8%, which is higher than many of its peers. In fact, the rate compares to the industry average of -0.7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 32% over the past 3-5 years versus the industry average of 6.5%. Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. There have been upward revisions in current-year earnings estimates for DexCom. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month. DexCom has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination positions DexCom well for outperformance, so growth investors may want to bet on it. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. DexCom is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 0.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that DXCM has returned about 7.5% since the start of the calendar year. In comparison, Medical companies have returned an average of -2.9%. This shows that DexCom is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Bayer Aktiengesellschaft (BAYRY). The stock is up 59.4% year-to-date. The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 84 individual stocks and currently sits at #186 in the Zacks Industry Rank. This group has lost an average of 7.5% so far this year, so DXCM is performing better in this area. Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #53. The industry has moved -0.3% so far this year. Investors with an interest in Medical stocks should continue to track DexCom and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-07-07,82.84,83.805,82.5,82.94,"What You Need to Know Ahead of DexCom’s Earnings Release DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits data to an external receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30. Ahead of the event, analysts expect DXCM to report a profit of $0.45 per share on a diluted basis, up 4.7% from $0.43 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions. Chevron Stock's 4.6% Dividend Yield and 1.67% One Month Short Put Yield Make CVX a Buy Tariff Dealine, Fed Minutes and Other Key Thing to Watch this Week SoFi Stock Is Betting on Crypto Again. How Should You Play SOFI Stock Here? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect DXCM to report EPS of $2.03, up 23.8% from $1.64 in fiscal 2024. Its EPS is expected to rise 24.6% year over year to $2.53 in fiscal 2026. Over the past 52 weeks, DXCM’s shares have dipped 25.2%, underperforming the S&P 500’s ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund’s (XLV) 5.4% dip over the same time frame. On July 1, DexCom shares fell over 4% after the U.S. government proposed changes to payment schedules and introduced a competitive bidding program for diabetes devices, impacting the broader glucose monitoring and insulin pump sector. Nevertheless, analysts’ consensus opinion on DXCM stock is very positive, with an overall “Strong Buy” rating. Out of 25 analysts covering the stock, 20 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and four give a “Hold.” DXCM’s average analyst price target is $99.68, indicating a potential upside of 20.2% from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"
DXCM,2025-07-08,83.14,84.46,82.9241,83.76,
DXCM,2025-07-09,84.14,85.2,82.73,84.87,DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty. It was management’s execution of its strategy that caused the problem.
DXCM,2025-07-10,85.24,85.92,84.058,85.46,
DXCM,2025-07-11,83.37,83.37,83.05,83.37,
DXCM,2025-07-14,83.42,85.61,82.96,85.33,
DXCM,2025-07-15,86.03,86.14,84.67,84.78,"[""Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /CNW/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies. AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often develop unnoticed by patients and might not be detected during routine exams. By identifying these signs early, AI enhances the ability to initiate treatments promptly, significantly improving health outcomes. This proactive approach allows for timely intervention, which is crucial in preventing the progression of these eye diseases. AI enhances patient care by analyzing the risk of disease progression and the specifics of each patient's retinal condition. This analysis helps healthcare providers develop customized treatment plans, tailored to individual needs. AI can predict how diseases like AMD will progress and helps in optimizing treatment schedules. This personalized approach ensures that each patient receives the most effective care specific to their condition, potentially improving their quality of life. A report from Media.Market.us said that the Global AI-Powered Retina Image Analysis Market Size is projected to expand significantly, reaching approximately US$ 9.4 billion by 2033, up from US$ 2.65 billion in 2023. This growth, at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2033, is fueled by several pivotal developments in the field of ophthalmology, driven by advances in artificial intelligence (AI). Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Abbott (NYSE: ABT), DexCom, Inc. (NASDAQ: DXCM), iRhythm Technologies, Inc. (NASDAQ: IRTC), Tandem Diabetes Care, Inc. (NASDAQ: TNDM). Media.Market.us continued: \""Enhanced Patient Monitoring through AI: AI-powered tools are revolutionizing the monitoring of retinal diseases. These tools enable continuous observation, allowing doctors to track disease progression over time. This ongoing monitoring is crucial for chronic conditions, where timely adjustments to treatment can lead to better management of the disease. Continuous data collection provided by AI tools offers a dynamic view of the patient's condition, facilitating more informed decision-making in clinical practice. Expanding Access to Care with AI in Ophthalmology: AI technology can significantly extend the reach of specialized eye care, especially to remote or underserved communities. Through AI, high-quality diagnostic and monitoring services can be delivered remotely, eliminating the need for patients to travel to specialist centers. This capability not only saves time and resources but also ensures that more patients have access to necessary care, improving eye health outcomes across diverse populations. Supporting Research and Development in Ophthalmology: AI applications in retina image analysis contribute valuable data to the field of ophthalmology. This data aids in ongoing research, offering new insights into how retinal diseases develop and progress. Researchers can use this information to explore potential new treatments and understand disease mechanisms more deeply. AI's role in R&D not only accelerates scientific discovery but also opens up possibilities for innovative therapeutic approaches, enhancing patient care.\"" Avant Technologies, Inc. (OTCQB: AVAI) and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA - Avant Technologies, Inc. (\""Avant\"" or the \""Company\"") and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the completion of its milestone meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting allowed Ainnova and its Contract Research Organization (CRO), Fortrea, to present and discuss Ainnova's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA. Ainnova's clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. The FDA has now provided the Company with valuable guidance on its clinical protocol, the number and type of clinics Ainnova will need to conduct a successful clinical trial, the number of retinologists required to examine the images generated by Ainnova's Vision AI, etc. With the FDA's recommendations, the Company can now actively plan for the total cost of conducting this planned clinical trial through to completion. Data from Ainnova's trial will support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, \""We're truly excited about this next phase. We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous\u2014comparing our AI-based retinal screening to the readings of three retinologists. \""This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera, which we believe will be a game changer\u2014making diabetic retinal screenings faster, more accessible, and available from virtually any point of care.\"" AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's clinical trial is paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. CONTINUED\u2026 Read this and more news for Avant Technologies at: https://finance.yahoo.com/quote/AVAI/news/ In other diabetes developments and happenings in the biotech market include: Abbott (NYSE: ABT) recently announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes. This innovative product features the world's smallest1,2 glucose sensor. Glucose monitoring is key to effective diabetes management as it helps people living with diabetes understand how their body responds to food, exercise, and medications3. It empowers them to take an active role in managing their condition, which can ultimately increase confidence4 and improve health outcomes. DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, recently released its \""Dexcom State of Type 2 Report: Access and Attitudes Across the United States\"" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will present extensive clinical data that shows the benefits of CGM for those living with Type 2 diabetes as well as new outcomes from early Stelo users. Dexcom releases new State of Type 2 Report: Access and Attitudes Across the United States - Earlier this year, Dexcom announced the release of its first multi-region report, detailing access and attitudes of individuals diagnosed with Type 2 diabetes and healthcare professionals across Europe and the Middle East (EMEA). iRhythm Technologies, Inc. (NASDAQ: IRTC) recently announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)\u2014especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations. The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias\u2014often asymptomatic\u2014cluster around major disease inflection points. In T2D patients, arrhythmias were frequently identified prior to or shortly after diagnoses of CKD or major adverse cardiovascular events such as stroke or heart failure. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, recently announced the Tandem t:slim X2\u2122 insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre\u00ae 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. \""Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs,\"" said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. \""The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.\"" DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated twenty two hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains \""forward-looking statements\"" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \""Forward-looking statements\"" describe future expectations, plans, results, or strategies and are generally preceded by words such as \""may\"", \""future\"", \""plan\"" or \""planned\"", \""will\"" or \""should\"", \""expected,\"" \""anticipates\"", \""draft\"", \""eventually\"" or \""projected\"". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: editor@marketnewsupdates.com - +1(561)325-8757 View original content:https://www.prnewswire.com/news-releases/artificial-intelligence-revolutionizing-early-detection-of-diabetic-retinopathy-creating-a-multi-billion-dollar-revenue-opportunity-302505344.html SOURCE MarketNewsUpdates View original content: http://www.newswire.ca/en/releases/archive/July2025/15/c5156.html"", ""Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating DexCom (DXCM) has an average rating of Buy and mean price target of $100.84, according to analysts p"", ""Edgepark expands diabetes offerings with two new product innovations Explore the latest in diabetes management solutions, including over-the-counter offerings and first-of-their-kind products TWINSBURG, Ohio, July 15, 2025 /PRNewswire/ -- Edgepark has recently expanded its portfolio to include the latest innovations from diabetes manufacturers, including the first-ever FDA-cleared yearlong continuous glucose monitor (CGM) system, and a glucose biosensor that can be purchased without a prescription. \""Our goal is to meet patients where they are in their health journey,\"" said Anthony Alvarez, SVP and GM of Edgepark. \""Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like a one-year wearable system and blood glucose biosensors that can be used without a prescription will no doubt play a pivotal role in the well-being of the patients we serve.\"" Updates to the Edgepark diabetes product portfolio Biosensor technology: Dexcom Stelo Glucose Biosensor\u2122 System (Stelo) The first-ever FDA-cleared over-the-counter glucose biosensor, the Dexcom Stelo, is now available through Edgepark, one of the limited number of suppliers to offer it. This biosensor represents a significant leap in glucose monitoring by expanding access to this technology for adults not on insulin and who don't have a history of problematic hypoglycemia. Its groundbreaking accessibility, coupled with the ability to provide glucose insights directly to a smartphone without fingersticks, empowers a wider population to proactively understand and manage their metabolic health. This product is FSA/HSA eligible and can be ordered without a prescription from a healthcare provider here. \""While CGMs have become more accessible through insurance in recent years, there are still many people who do not qualify for coverage \u2013 that's where over-the-counter options like the Stelo biosensor come into play,\"" said Alvarez. \""At Edgepark, we are laser-focused on overcoming accessibility challenges to help patients manage overall health and make more proactive decisions throughout their day.\"" New CGM addition: Eversense\u00ae 365 Continuous Glucose Monitoring (CGM) Now available through Edgepark, Eversense 365 is the first and only FDA-cleared one-year implantable CGM system, intended for use in those living with Type 1 or Type 2 diabetes who are 18 and older. Most CGM devices are small, wearable sensors that sit on the exterior of the body, lasting around two weeks. The Eversense 365 CGM is inserted only once a year into the upper arm by a health care provider to provide continuous monitoring for 365 days. The system is comprised of three main components: An implantable fluorescence-based glucose sensor. Because it rests under the skin, it is less likely to be knocked off. A removable smart transmitter that can be taken off and on without requiring a new CGM A mobile app that displays glucose data This new CGM introduces a novel approach to continuous glucose monitoring. Eversense 365's extended-wear duration reduces potential \""wearable fatigue\"" that can be associated with frequent replacements required by traditional CGM devices. Those interested in exploring this as an option for their care journey can click here. To learn more about the Edgepark diabetes portfolio and explore all available products, visit the Edgepark website. About Edgepark Edgepark is a leading provider of supplies direct-to-home, committed to caring and providing patients solutions that make it easy to choose and receive the products needed to live their best life. Learn more at Edgepark.com. Media Contact: mediarelations@edgepark.com View original content to download multimedia:https://www.prnewswire.com/news-releases/edgepark-expands-diabetes-offerings-with-two-new-product-innovations-302504641.html SOURCE Edgepark Medical Supplies"", ""DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. As such, the Zacks rating upgrade for DexCom is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. For DexCom, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . For the fiscal year ending December 2025, this medical device company is expected to earn $2.03 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for DexCom. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.2%. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of \""buy\"" and \""sell\"" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a \""Strong Buy\"" rating and the next 15% get a \""Buy\"" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of DexCom to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Mizuho Securities Adjusts DexCom Price Target to $100 From $95, Maintains Outperform Rating DexCom (DXCM) has an average rating of Buy and mean price target of $100.84, according to analysts p""]"
DXCM,2025-07-16,85.485,85.57,83.85,84.13,
DXCM,2025-07-17,84.09,85.9,83.54,84.1,"Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month SAN DIEGO, July 17, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This year’s Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports such as football, basketball, lacrosse, track & field, soccer, and more, alongside eight returning team members. The new athletes were selected following a dynamic, first-of-its-kind nationwide open call that drew over two hundred submissions, as Dexcom searched for the next great college athletes with diabetes to join the program. To officially welcome and celebrate the newly selected Dexcom U athletes, Dexcom hosted its Signing Day Camp earlier this month in Baltimore, Maryland. The event was hosted by Mark Andrews, Baltimore Ravens tight end and Dexcom Warrior, who relies on Dexcom G7 to manage his Type 1 diabetes and perform at the highest level. Mark was joined by Mike Golic Sr., NFL legend and sports broadcaster, who uses Stelo, Dexcom’s over the counter glucose biosensor, to manage his Type 2 diabetes. The powerful, high-energy day brought together athletes with diabetes across all levels, including pro, college and youth sports, to redefine what’s possible with diabetes. Both new and returning Dexcom U team members connected with Baltimore youth athletes and celebrated the resilience and determination that unite them. ""It was incredibly inspiring to witness athletes of all ages come together at the Dexcom U Signing Day Camp to show what is possible while living with diabetes,"" said Mark Andrews, Dexcom Warrior and Baltimore Ravens tight end. ""I know how impactful it would have been to have a support system like this in the early stages of my career, so for me, getting to be the role model I never had is really special."" Dexcom U was created to elevate college athletes with diabetes who are breaking boundaries in sports and achieving their goals, despite their diagnosis. Since its inception in 2022, the program has directly impacted more than 40 college athletes across 38 schools and 19 sports. Each Dexcom U athlete relies on Dexcom continuous glucose monitoring (CGM) technology like Dexcom G7 to manage their diabetes with real-time data delivered directly to their smartphone or smartwatch,* empowering them to take control of their health and discover what they’re made of. ""This season, we set out to grow Dexcom U in ways that bring even more athletes into our Warrior community. From launching a new nationwide Open Call to hosting our first Dexcom U Signing Day Camp, we’re creating impactful opportunities for athletes with diabetes to shine,"" said Leverne Marsh, executive vice president of marketing at Dexcom. ""It’s all part of our mission to show how Dexcom’s continuous glucose monitoring technology supports performance, confidence, and connection."" The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes: New athletes: Ali Ramadan, Soccer, Creighton University Anya Tribune, Soccer, Gardner-Webb University Ari Long, Basketball, University of Oregon Breanna Corral-Vargas, Acrobatics & Tumbling, Hawaii Pacific University Clarke Byram, Track & Field, Pole Vault, University of Tennessee, Knoxville Jackson Montgomery, Baseball, Coppin State University Kya Epps, Track & Field, University of Cincinnati Michael Trepeta, Lacrosse, Johns Hopkins University Miles Byrd, Basketball, San Diego State University Nadia Nemeth, Field Hockey, Northwestern University Niamh Pfaff, Lacrosse, Yale University Nikola Parichkov, Tennis, Wake Forest University Patrick Heneghan, Football, Denison University Returning athletes: Ben Mirisch, Water Polo, University of Southern California Caleb Fauria, Football, University of Delaware Isaac Traudt, Basketball, Creighton University Jessica Walter, Softball, University of Connecticut Madison Moraja, Track & Field, North Carolina State University Nicholas Hahne, Cheerleading, University of Notre Dame Raegan Lantz, Volleyball, Miami (OH) University Shelomi Sanders, Basketball, Alabama A&M University Dexcom U athletes will receive access to Dexcom CGM, exclusive events and opportunities, and a supportive network of collegiate and professional athletes — including mentors like Seattle Sounders forward Jordan Morris and Dexcom U alum and Vegas Thrill setter Carly Graham — who support one another both on and off the field. To learn more about Dexcom U, visit www.Dexcom.com/DexcomU2025. About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com. *Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility. View source version on businesswire.com: https://www.businesswire.com/news/home/20250717183186/en/ Contacts Media Contact Aly Brandt mediarelations@dexcom.com Investor Contact Sean Christensen sean.christensen@dexcom.com"
DXCM,2025-07-18,84.7,84.775,83.23,83.89,"Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 34% Discount? The projected fair value for DexCom is US$127 based on 2 Stage Free Cash Flow to Equity DexCom is estimated to be 34% undervalued based on current share price of US$84.10 The US$98.85 analyst price target for DXCM is 22% less than our estimate of fair value In this article we are going to estimate the intrinsic value of DexCom, Inc. (NASDAQ:DXCM) by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Believe it or not, it's not too difficult to follow, as you'll see from our example! We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: (""Est"" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF) = US$14b We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.2%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = US$3.0b× (1 + 2.9%) ÷ (7.2%– 2.9%) = US$71b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$71b÷ ( 1 + 7.2%)10= US$36b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$50b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$84.1, the company appears quite undervalued at a 34% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at DexCom as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.2%, which is based on a levered beta of 0.986. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for DexCom Strength Debt is not viewed as a risk. Weakness Earnings declined over the past year. Opportunity Annual earnings are forecast to grow faster than the American market. Trading below our estimate of fair value by more than 20%. Threat Revenue is forecast to grow slower than 20% per year. Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to ""what assumptions need to be true for this stock to be under/overvalued?"" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Why is the intrinsic value higher than the current share price? For DexCom, there are three pertinent elements you should explore: PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
DXCM,2025-07-21,83.955,84.5,83.3,84.03,"Are Medical Stocks Lagging DexCom (DXCM) This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is DexCom (DXCM) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. DexCom is a member of the Medical sector. This group includes 985 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DexCom is currently sporting a Zacks Rank of #1 (Strong Buy). Over the past 90 days, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 0.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Our latest available data shows that DXCM has returned about 7.9% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.4% on a year-to-date basis. As we can see, DexCom is performing better than its sector in the calendar year. Amarin (AMRN) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 63.1%. The consensus estimate for Amarin's current year EPS has increased 54.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). To break things down more, DexCom belongs to the Medical - Instruments industry, a group that includes 84 individual companies and currently sits at #164 in the Zacks Industry Rank. Stocks in this group have lost about 11.5% so far this year, so DXCM is performing better this group in terms of year-to-date returns. On the other hand, Amarin belongs to the Medical - Biomedical and Genetics industry. This 493-stock industry is currently ranked #86. The industry has moved -2.3% year to date. Investors interested in the Medical sector may want to keep a close eye on DexCom and Amarin as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
DXCM,2025-07-22,84.49,85.65,84.25,85.12,
DXCM,2025-07-23,86.19,86.775,85.5,86.43,"Tenovi Expands Access to Glucose Data for Remote Patient Monitoring and Cardiometabolic Programs Through Dexcom Integration PORTSMOUTH, N.H., July 23, 2025--(BUSINESS WIRE)--Tenovi, a leading provider of remote patient monitoring (RPM) solutions, today announced it now supports Dexcom continuous glucose monitoring (CGM) data directly within its clinician-facing dashboard. This milestone expands Tenovi’s ability to support diabetes management programs across healthcare organizations by seamlessly displaying Dexcom CGM data within its existing virtual RPM infrastructure. Through this integration, Tenovi now supports hourly average glucose data visualization for patients using Dexcom real-time CGMs. Healthcare teams using Tenovi’s platform can view glucose trends alongside other vital health RPM metrics, without the need to distribute or manage physical inventory of CGM devices. ""Access to glucose insights is vital to managing chronic conditions such as diabetes,"" said Iftah Mashav, Chief Growth Officer at Tenovi. ""A Dexcom and Tenovi integration allows our clients to leverage CGM data in virtual care models that are flexible, scalable, and rooted in clinical outcomes."" This expansion supports Tenovi’s broader suite of telemetry solutions designed for cardiometabolic populations, an area of growing focus for health plans and employer-sponsored programs. By enabling continuous remote access to essential health data, Tenovi helps organizations improve outcomes, reduce costs, and scale value-based care. Tenovi provides secure data access via the Dexcom API, allowing health systems to onboard patients seamlessly without the burden of physical device logistics. Dexcom data access is now live on the Tenovi platform. Healthcare organizations can begin enrolling eligible patients immediately. To learn more or schedule a demo, visit www.tenovi.com. About Tenovi Tenovi is a data aggregation and automation Healthcare IoT platform that connects medical device manufacturers with remote patient monitoring programs. It provides over 40 remote patient monitoring and remote therapeutic monitoring (RTM) device point solutions that integrate with its proprietary Cellular Gateway, automating the transfer of patient vitals. Tenovi's API-driven fulfillment and automation services enable seamless deployment of remote patient and therapeutic monitoring programs. For more information, visit www.tenovi.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20250723089944/en/ Contacts Janice Murphy Media Relations jmurphy@tenovi.com"
DXCM,2025-07-24,86.54,87.14,86.055,86.74,"[""Discuss Reports Record Mid-Year Growth with AI Agentic Approach to Vibe Coding for Market Insights Seattle, Washington, July 24, 2025 (GLOBE NEWSWIRE) -- In a time where 90% of business leaders think customers highly trust their brand, while only 30% of consumers actually do (PWC), Discuss is providing a new, better way for companies to connect with and discuss everything with the people they serve. As the first company to bring together human-led and AI-led interviews in one market insights solution, called Discuss Everything, Discuss is entering the second half of 2025 with record growth driven by AI innovation, industry recognition, and market momentum. Market Momentum As the trust gap widens and customer expectations shift faster, a growing number of global brands and research agencies are turning to Discuss for a better way to stay connected with their audiences. In the first half of 2025, Discuss welcomed major brands like Nike, Nestle, Mastercard, Suntory Beverage & Food\u2019s Asian Pacific operations, and Dexcom, along with leading agencies including HumanBranding Inc. and Quadrant Strategies, who also added Discuss\u2019 new Interview Agent for AI moderation of some sessions moving forward. Midway through 2025, Discuss reports a 64% year-over-year (YoY) increase in platform usage. Discuss launched a corporate initiative to leverage GenAI across all areas of the business, which enabled it to support this increasing platform adoption while only having to expand its global workforce by 16% in the first half of the year, with team members now operating in more than 20 countries across the globe. Core Innovations Discuss continues to lead the industry through its innovative approach to vibe coding market insights, with AI agents that scale and accelerate in-depth feedback across global teams, whether the interviewer is human or AI. When using Discuss, any team can stay close to customers \u2013 especially those that have historically been at arm\u2019s length from what consumers say and do. Vibe coding makes market insights accessible to anyone, with agents that find their ideal audiences, conduct interviews, and deliver the business insights teams need in a matter of hours, turning customer understanding into a daily advantage rather than a quarterly deliverable. In May, Discuss introduced Discuss Now, a self-paced AI interview solution that delivers in-depth market insights at the speed of a survey. The same AI agents that power Discuss Now can also be integrated across the full Discuss platform with the Discuss Everything solution \u2013 the first to bring AI-led interviews and human-led conversations together in one place. Whether teams need quick-turn feedback or deep, emotionally rich insights, Discuss Everything gives them the flexibility to switch between methods, or blend both, based on their unique objectives and business needs while minimizing the need for multiple tools or vendors to support AI-led interviews and human-led interviews. Industry Recognition In the 2025 G2 Summer reports, Discuss was recognized for the 11th consecutive quarter as a Leader among 57 vendors in User Research and 18 vendors in Consumer Video Feedback. With #1 rankings for Best Results, Best Relationship, Usability and Most Implementable, Discuss continues to deliver ROI three months faster than the industry average. Customers also rated Discuss above industry benchmarks for ease of use (94%), ease of setup (92%), likelihood to recommend (94%), ease of doing business with (96%), and quality of support (96%). Beyond awards, Discuss has led conversations at major industry events including The MarTech Conference, Quirk\u2019s London, TMRE@Home, IIEX Europe, and DMWF, sharing the stage with leading brands like Danone, HP, Mastercard, and Dexcom. Discuss is excited to have its Co-Founder and Chief Growth Officer, Jim Longo, speaking with industry visionary, Stan Sthanunathan, former EVP of Consumer and Market Insights at Unilever and former VP of Marketing Strategy and Insights at The Coca-Cola Company, at Quirk\u2019s New York on why blending human intimacy with AI-driven solutions is essential for modern consumer insights. About Discuss At Discuss, we exist to shatter assumptions and bring human connection back to the heart of every decision. Our all-in-one market insights platform, complete with advanced AI Agents and coupled with key services, enables organizations to collect, analyze, and share in-depth feedback from audiences around the globe. Discuss\u2019 solutions give teams the option to choose the speed and scale of a fully agentic AI approach, the depth and nuance of human-led conversations, or a blend of both. Trusted by leading Insights, Marketing, Product, CX, and UX professionals worldwide, Discuss is the preferred choice for leading brands and agencies including 3M, Suntory Global Spirits, Mastercard, HelloFresh, Reckitt, The Standard, Mondelez, Ipsos, and Escalent. Discover how Discuss can help you make faster, smarter decisions, without losing the human touch, at www.discuss.io. CONTACT: Jill Postoak Discuss 866-557-6716 jill@discuss.io"", ""Is DexCom, Inc.'s (NASDAQ:DXCM) ROE Of 24% Impressive? One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. We'll use ROE to examine DexCom, Inc. (NASDAQ:DXCM), by way of a worked example. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Trump has pledged to \""unleash\"" American oil and gas and these 15 US stocks have developments that are poised to benefit. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) \u00f7 Shareholders' Equity So, based on the above formula, the ROE for DexCom is: 24% = US$535m \u00f7 US$2.3b (Based on the trailing twelve months to March 2025). The 'return' is the yearly profit. That means that for every $1 worth of shareholders' equity, the company generated $0.24 in profit. See our latest analysis for DexCom By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As you can see in the graphic below, DexCom has a higher ROE than the average (12%) in the Medical Equipment industry. That is a good sign. With that said, a high ROE doesn't always indicate high profitability. A higher proportion of debt in a company's capital structure may also result in a high ROE, where the high debt levels could be a huge risk . Companies usually need to invest money to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. That will make the ROE look better than if no debt was used. DexCom does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.08. While no doubt that its ROE is impressive, we would have been even more impressed had the company achieved this with lower debt. Debt does bring extra risk, so it's only really worthwhile when a company generates some decent returns from it. Return on equity is one way we can compare its business quality of different companies. Companies that can achieve high returns on equity without too much debt are generally of good quality. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE. Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company. But note: DexCom may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? DexCom, Inc. DXCM is scheduled to release second-quarter 2025 results on July 30, after the closing bell. In the last reported quarter, the company\u2019s earnings missed estimates by 3.03%. The bottom line outpaced the consensus mark in two of the trailing four quarters and missed twice, delivering an average surprise of 0.47%. Shares of DXCM have gained 11.1% so far this year against the industry\u2019s 10.2% decline. The S&P 500 Index has increased 6.9% in the same time frame. Image Source: Zacks Investment Research Currently, the Zacks Consensus Estimate for revenues is pegged at $1.12 billion, indicating growth of 11.8% from the year-ago quarter\u2019s reported figure. The consensus mark for earnings is pinned at 45 cents per share, implying 4.7% growth year over year. DexCom\u2019s second-quarter 2025 outlook remains promising, with multiple tailwinds supporting potential growth. The expansion of the U.S. prescriber base, strong international performance and the growing traction of Stelo are key factors driving optimism. Additionally, FDA approval for the 15-day G7 CGM could have provided a boost. While challenges such as competitive pressures and channel mix shifts remain, DexCom appears well-positioned to have accelerated growth and improved financial performance in the quarter. U.S. Market Dynamics DXCM\u2019s quarterly performance is likely to have been shaped by expanded coverage. The company\u2019s CGM for anybody with diabetes is covered by two of the three largest PBMs since January, which might have led to higher adoption during the soon-to-be-reported quarter. Moreover, the company's ongoing sales force expansion and efforts to stabilize its presence in the Durable Medical Equipment (\u201cDME\u201d) channel should have aided demand. DexCom reported a record number of new patient starts in the past two quarters, which signals improving commercial execution. Strong U.S. demand on the back of increasing patient base is expected to have contributed significantly in the soon-to-be-reported quarter. International Market Expansion DexCom\u2019s international segment showed resilience, growing 7% year over year in the last reported quarter, driven by coverage expansion for type 2 diabetes patients. Continued growth in Japanese business and rising adoption of Dexcom ONE in France are likely to have boosted international sales in the second quarter. Stelo: A Game-Changer for the Non-Insulin Market One of DexCom\u2019s most promising growth drivers for the second quarter is likely to have been Stelo, the over-the-counter continuous glucose monitor (CGM) for people with prediabetes and Type 2 diabetes who are not on insulin. DXCM is expanding adoption of Stelo through product iteration, broad awareness campaigns and new distribution channels, including its introduction on the Amazon storefront. The company is building on the Stelo experience through targeted partnerships that will help consolidate multiple biomarkers into its platform. This includes the recently announced relationship with ??URA, which will integrate Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from the Oura Ring to provide an even broader picture of health for our mutual customers. The company expects Stelo sales to rise 2-3% in 2025. Financial Outlook and Margin Expansion On its first-quarter earnings call, DexCom reiterated its full-year 2025 revenue guidance of $4.6 billion, representing organic growth of 14%. The company expects margin improvement to continue in 2025 as it converts more of its installed base to G7 and drives greater scale at high-volume manufacturing facilities. DXCM expects gross margin to be approximately 62% and operating margin to be 21% for 2025. The anticipated improvement in sales and margin is likely to be reflected in the upcoming quarterly results. DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below. Earnings ESP: DexCom has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2 at present. Here are a few medical stocks worth considering, as these have the right combination of elements to come up with an earnings beat this reporting cycle. GeneDx Holdings WGS has an Earnings ESP of +5.26% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on July 29. WGS\u2019 earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 145.82%. The Zacks Consensus Estimate for the company\u2019s second-quarter EPS may increase 190.9% from the year-ago quarter\u2019s figure. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is set to release third-quarter fiscal 2025 results on Aug. 6. COR\u2019s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. The Zacks Consensus Estimate for COR\u2019s fiscal third-quarter EPS may surge 13.2% from the year-ago reported figure. Cardinal Health CAH has an Earnings ESP of +0.81% and a Zacks Rank #2 at present. The company is slated to release fourth-quarter fiscal 2025 results on Aug. 12. CAH\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. The Zacks Consensus Estimate for the company\u2019s fiscal fourth-quarter EPS may increase 10.3% from the year-ago quarter figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-07-25,87.215,89.07,86.69,88.99,"3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 44.1% The United States market has shown positive momentum with a 1.7% increase over the past week and an 18% climb in the last year, alongside forecasts of a 15% annual earnings growth. In this environment, identifying stocks trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets. Click here to see the full list of 176 stocks from our Undervalued US Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: Freshpet, Inc. manufactures, distributes, and markets natural fresh meals and treats for dogs and cats across the United States, Canada, and Europe with a market cap of approximately $3.57 billion. Operations: The company generates revenue from its pet food and pet treats segment for dogs and cats, amounting to $1.01 billion. Estimated Discount To Fair Value: 44.1% Freshpet is trading significantly below its estimated fair value of US$133.26, presenting potential undervaluation based on discounted cash flows at a current price of US$74.51. Despite reporting a net loss of US$12.7 million for Q1 2025, earnings are forecast to grow substantially at 38.36% annually over the next three years, outpacing the broader market's growth expectations and suggesting strong future cash flow potential despite recent setbacks in profitability. Our earnings growth report unveils the potential for significant increases in Freshpet's future results. Unlock comprehensive insights into our analysis of Freshpet stock in this financial health report. Overview: DexCom, Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring systems with a market cap of approximately $33.38 billion. Operations: DexCom generates its revenue primarily from the Patient Monitoring Equipment segment, which accounted for $4.15 billion. Estimated Discount To Fair Value: 31.8% DexCom is trading at US$86.43, significantly below its estimated fair value of US$126.81, highlighting potential undervaluation based on discounted cash flows. Despite slower revenue growth at 13.1% annually compared to the industry benchmark, earnings are expected to grow significantly at 23.2% per year, surpassing the broader market's projections. Recent integration with Tenovi enhances DexCom's data utility in healthcare settings; however, ongoing legal challenges concerning trademark issues could impact brand perception and operations. Our expertly prepared growth report on DexCom implies its future financial outlook may be stronger than recent results. Delve into the full analysis health report here for a deeper understanding of DexCom. Overview: Corpay, Inc. is a payments company that facilitates the management of vehicle-related expenses, lodging expenses, and corporate payments for businesses and consumers across the United States, Brazil, the United Kingdom, and internationally; it has a market cap of $23.57 billion. Operations: Corpay's revenue is primarily derived from its Vehicle Payments segment at $2.00 billion, followed by Corporate Payments at $1.31 billion and Lodging Payments at $487.52 million. Estimated Discount To Fair Value: 35.3% Corpay is trading at US$344.14, significantly below its estimated fair value of US$532.1, suggesting potential undervaluation based on discounted cash flows. While revenue growth is projected at 10.3% annually, slightly above the market average, earnings are expected to grow at 17.8% per year, outpacing the broader market's expectations. Recent strategic partnerships and acquisitions enhance Corpay’s cross-border payment capabilities; however, debt coverage by operating cash flow remains a concern for financial stability. According our earnings growth report, there's an indication that Corpay might be ready to expand. Click to explore a detailed breakdown of our findings in Corpay's balance sheet health report. Delve into our full catalog of 176 Undervalued US Stocks Based On Cash Flows here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include FRPT DXCM and CPAY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"
DXCM,2025-07-28,88.99,89.76,88.63,89.53,
DXCM,2025-07-29,89.64,89.96,88.97,89.38,
DXCM,2025-07-30,89.35,89.98,88.3,89.06,"Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion in 2024, with projections pointing to continued growth through 2029. The twelfth edition of Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition highlights how decentralization of healthcare, rapid innovation, and consumer-driven demand are reshaping how and where diagnostic tests are performed—from traditional clinical settings to homes, workplaces, and remote environments. ""POC testing is no longer a fringe segment—it is a central pillar of modern diagnostics,"" said Melissa Elder, Senior Analyst at Kalorama Information. ""We see industry leaders like Abbott, Dexcom, Roche, Danaher, and Exact Sciences innovating aggressively, with POC solutions spanning blood gases, infectious disease, colon cancer, glucose monitoring, and more."" The report identifies major growth opportunities in oncology, stroke, dementia, cardiac markers, and glucose management. With transportable and handheld devices becoming more widely available, the reach of point-of-care testing is extending to urgent care centers, disaster relief zones, and at-home monitoring. While the market is recovering from the COVID-19 testing surge of 2020–2022, momentum continues thanks to emerging technologies and the expanding need for fast, accurate, and accessible diagnostics. Trends Shaping the Future of POC Diagnostics: Wearables and mobile health tools Telehealth integration CRISPR and microfluidics innovation Multiplexed and AI-enabled testing Regulatory challenges and LDT policy changes The rise of non-invasive and consumer-friendly testing China's expanding role in the global POC landscape Key Takeaways from the Report: $36 Billion in Global Revenues (2024): Driven by demand in physician offices, clinics, and mobile care, with steady mid-single-digit CAGR expected through 2029. Top Growth Areas: Oncology, stroke, dementia, cardiac, and continuous glucose monitoring (CGM). Next-Gen Tech Impact: Innovations in CRISPR diagnostics, biosensors, and AI are transforming point-of-care capabilities. POC Molecular Diagnostics Rise: Originally accelerated by COVID-19, molecular POC testing is gaining relevance in emergency care and field screening worldwide. Consumer-Led Prevention: Wearables and Bluetooth-enabled tools support proactive health monitoring. Market Leaders and Competitive Landscape ""Abbott leads the global market with over 25% share due to its expansive POC portfolio,"" said Elder. ""Dexcom and Roche are advancing CGM and coagulation testing, while Exact Sciences is driving growth in colon cancer diagnostics. Danaher's Beckman Coulter continues to deliver in blood, cancer, and infectious disease testing."" An Essential Industry Resource The report is a vital tool for product developers, investors, and healthcare strategists navigating market trends and emerging opportunities. It answers critical questions such as: Where is POC testing growing fastest? What technologies are reshaping diagnostic accessibility? How are regulations and reimbursement shaping adoption? What are the most promising new test types and applications? What's Inside: Global market forecasts through 2029 In-depth segmentation across 10+ test categories Venue analysis (hospital, clinic, retail, home) Competitive landscape profiles and regulatory updates Access the Report Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition is now available: https://kaloramainformation.com/product/worldwide-point-of-care-poc-diagnostic-tests-2025 To request the report or schedule a briefing: Sheri Davie – Kalorama Information Sales Team sheri.davie@scienceandmedicinegroup.com For media inquiries: Richa Singh – VP, Strategic & Insights Sales richa.singh@scienceandmedicinegroup.com About Kalorama Information Kalorama Information, part of Science and Medicine Group, is a leading publisher of independent market research in medical diagnostics, biotechnology, and life sciences. Our reports help global healthcare organizations, investors, and innovators make informed decisions with confidence. View original content to download multimedia:https://www.prnewswire.com/news-releases/rapid-expansion-and-innovation-drive-36-billion-global-point-of-care-diagnostics-market-says-new-kalorama-report-302516378.html SOURCE Kalorama Information"
DXCM,2025-07-31,85.7,87.0,80.46,80.81,"[""Dexcom Earnings Beat. Diabetes Device Maker Names New CEO. Dexcom stock fell late Wednesday as it reported Q2 earnings that topped expectations and named a new chief executive officer."", ""UBS Adjusts Price Target on DexCom to $106 From $105, Maintains Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Oppenheimer Adjusts Price Target on DexCom to $102 From $95, Maintains Outperform Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics For the quarter ended June 2025, DexCom (DXCM) reported revenue of $1.16 billion, up 15.2% over the same period last year. EPS came in at $0.48, compared to $0.43 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.12 billion, representing a surprise of +3.06%. The company delivered an EPS surprise of +6.67%, with the consensus EPS estimate being $0.45. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- United States: $841 million versus the six-analyst average estimate of $809.7 million. The reported number represents a year-over-year change of +14.9%. Revenue- International: $316.1 million versus the six-analyst average estimate of $311.29 million. The reported number represents a year-over-year change of +16%. Revenue- Hardware: $39.3 million versus the three-analyst average estimate of $38.99 million. The reported number represents a year-over-year change of -31.4%. Revenue- Sensor and other: $1.12 billion versus $1.08 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18% change. View all Key Company Metrics for DexCom here>>> Shares of DexCom have returned +6.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Dexcom raises sales expectations, discusses G8 plans This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $1.16 billion 15% increase year over year Q2 net income: $179.8 million 25% increase year over year Dexcom raised its sales expectations for 2025 amid expanding access to its glucose sensors for people with Type 2 diabetes. The company raised its revenue forecast to a range of $4.6 billion to about $4.63 billion for 2025, after forecasting $4.6 billion last quarter. CFO Jereme Sylvain, on a Wednesday earnings call, attributed the change to three of the major U.S. pharmacy benefit managers now covering Dexcom\u2019s continuous glucose monitors for people with Type 2 diabetes who don\u2019t take insulin. The company is also looking to adoption of its over-the-counter device, Stelo, as a growth driver. Although Dexcom does not disclose exact user numbers, outgoing CEO Kevin Sayer said the company\u2019s Stelo app has been downloaded more than 400,000 times. Dexcom launched the over-the-counter glucose sensor last year, with the intent of marketing it to people with Type 2 diabetes who don\u2019t take insulin. However, most of the recent uptake has been by people who don\u2019t have diabetes and are buying the devices for health and wellness, Sayer said. \u201cQuite candidly, that's how we designed and developed the app, because last year, at this time, we didn't have very much of any Type 2 coverage for non-insulin users,\u201d Sayer said. \u201cAs time has gone on, and now G7 has coverage by the three largest PBMs in the country, we're seeing a shift.\u201d Dexcom\u2019s main competitor, Abbott, has been working on a dual-analyte sensor that can detect both glucose and ketone levels. The company struck several planned integrations leading up to the American Diabetes Association\u2019s Scientific Sessions last month. When asked about plans for Dexcom\u2019s next flagship CGM, the G8, Chief Operating Officer Jake Leach, who will take over as CEO at the beginning of next year, said the sensor will be 50% smaller and will include a chip that supports multiple analyte sensing. He did not share the timing for the device. Leach said that there have been a lot of recent discussions around the clinical utility of measuring ketones simultaneously with glucose. Dexcom has a ketone sensor in development, \u201cand we'll bring it to the market when we feel it's appropriate,\u201d Leach said. \u201cBut at this point in time, we're very focused on features that extend safety and ease of use for both our patients as well as the prescribing physicians.\u201d Dexcom is still working with the Food and Drug Administration on resolving a warning letter the company received in March, which raised concerns with a design change Dexcom made to a component used in its sensors without submitting a premarket notification to the FDA. Dexcom had begun to produce a chemical internally for its sensor wires to add redundancy to its supply chain, but reverted back to the external supplier after the FDA requested a separate 510(k) submission, J.P. Morgan analyst Robbie Marcus wrote in March. The company has made \u201cquite a bit of progress\u201d in updating its processes and documentation to address the FDA\u2019s concerns, Leach said. Dexcom is also resolving a recall where receivers for its CGMs may not sound an audible alarm for low or high blood sugar levels. Sylvain said the company will be swapping out some receivers. The CFO said Dexcom recorded a charge in the second quarter that had a 100-basis-point impact on its quarterly results. Recommended Reading FDA clears iRhythm\u2019s second 510(k) in response to warning letter"", ""Citigroup Adjusts Price Target on DexCom to $105 From $102, Maintains Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise DexCom, Inc. DXCM reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus Estimate of 45 cents by 6.7%. The company reported earnings of 43 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 45 cents, up from the year-ago quarter\u2019s figure of 35 cents. Total revenues grew 15.2% (15% on an organic basis) to $1.16 billion year over year. Sales beat the Zacks Consensus Estimate by 3.1%. The year-over-year revenue growth was driven by continued strong category demand, focused execution and a growing contribution from recent access wins, especially for type 2 diabetes. Despite better-than-expected results, shares of DXCM declined almost 5.5% during after-hours trading on July 30. The stock has gained 9.9% year to date against a 7.3% decline in the industry. The broader S&P 500 Index has moved up 8% in the same period. Image Source: Zacks Investment Research Sensor and other revenues (97% of total revenues) increased 18% on a year-over-year basis to $1.12 billion. Hardware revenues (3%) decreased 31% year over year to $39.3 million. U.S. revenues (73% of total revenues) increased 15% on a year-over-year basis to $841 million. International revenues (27%) improved 16% (14% on an organic basis) year over year to $316.1 million. Adjusted gross profit totaled $695.9 million, up 9.1% from the prior-year quarter\u2019s level. DexCom reported an adjusted gross margin (as a percentage of revenues) of 60.1%, down 340 basis points year over year. Research and development expenses totaled $148.2 million, up 9% year over year. Selling, general, and administrative expenses totaled $328 million, down 1.4%. The company reported total adjusted operating income of $221.8 million, up 13.5% from the prior-year period\u2019s recorded number. Adjusted operating margin (as a percentage of revenues) was 19.2%, down 30 basis points year over year. DXCM exited the second quarter with cash, cash equivalents, and marketable securities worth $2.93 billion compared with $2.7 billion in the first quarter of 2025. Total assets amounted to $7.33 billion, up sequentially from $6.75 billion. DexCom raised its outlook for 2025 revenues. The company now expects revenues to be in the range of $4.6-$4.625 billion (previously $4.6 billion), implying 14-15% year-over-year growth. The Zacks Consensus Estimate was pegged at $4.61 billion. DXCM expects adjusted gross margin to be approximately 62%. Adjusted operating margin is projected to be approximately 21%. DexCom, Inc. price-consensus-eps-surprise-chart | DexCom, Inc. Quote DexCom delivered a solid second-quarter update, marked by double-digit top-line growth and a confident raise in full-year guidance, as it executes on broadening access to CGM and scaling its innovation engine. Strong new customer additions on the back of expanded reimbursement for the fast-growing type 2 non-insulin population drove U.S. sales. Meanwhile, momentum in international markets was driven by key coverage wins such as Ontario\u2019s Drug Benefit program in Canada and continued traction for the cost-effective DexCom ONE+ platform across Europe. On the product front, DexCom is leveraging both hardware and software to to keep its business afloat amid rising competition. The upcoming 15-day G7 sensor, cleared by the FDA, is set to be launched in the second half of 2025, while development on the next-gen G8 platform is underway, promising smaller, multi-analyte-ready wearables. Meanwhile, over 400,000 downloads of DexCom\u2019s new Stelo biosensor app highlight consumer adoption beyond diabetes, with integrations like Oura Ring enabling a more personalized health ecosystem. DXCM\u2019s new AI-powered Smart Food Logging feature for G7 and Stelo enables users to snap meal photos, automatically log details, and assess glycemic impact \u2014 enhancing personalization, improving dietary awareness and simplifying diabetes management. Margins faced near-term pressure, with gross margin at 60.1% due to expedited logistics costs as inventory was being rebuilt. Still, DexCom reaffirmed its 2025 gross margin guidance of 62% and raised full-year revenue guidance. Management also flagged a succession plan \u2014 current CEO Kevin Sayer will step down in early 2026, passing the reins to long-time executive Jake Leach. The transition comes as DexCom doubles down on expanding CGM access, scaling globally and integrating AI-driven features across its platforms. While CMS\u2019s proposed competitive bidding program for Medicare CGM could emerge as a future headwind, DexCom believes the 2027 start timeline and its differentiated clinical data give it a strong footing. The company\u2019s CGM sensors are now covered by the three largest pharmacy benefit managers. With access opened to approximately 6 million new lives, DexCom sees this as the first step toward a 25 million-person opportunity. With ample cash reserves and a steadily growing base of prescribers and end-users, the company appears well-positioned to maintain leadership in a rapidly expanding CGM market. DXCM carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks from the broader medical space that are expected to report earnings soon are Align Technology ALGN, Cardinal Health, Inc. CAH and Cencora, Inc. COR. The Zacks Consensus Estimate for Align Technology\u2019s second-quarter 2025 adjusted EPS is currently pegged at $2.57. The consensus estimate for revenues is pegged at $1.06 billion. ALGN currently carries a Zacks Rank #2. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Align Technology has an estimated long-term growth rate of 11.2%. However, ALGN\u2019s earnings yield is 5.1% compared with the industry\u2019s 5.4%. Cardinal Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for fourth-quarter fiscal 2025 adjusted EPS is currently pegged at $2.03 and the same for revenues is pinned at $60.67 billion. Cardinal Health has an estimated long-term growth rate of 10.9%. CAH\u2019s earnings yield of 5.7% compares favorably with the industry\u2019s 5.5%. Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pinned at $80.33 billion. Cencora has an estimated long-term growth rate of 12.8%. COR\u2019s earnings yield of 5.4% compares favorably with the industry\u2019s 4.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Baird Adjusts Price Target on DexCom to $112 From $105, Maintains Outperform Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""JPMorgan Adjusts Price Target on DexCom to $90 From $85, Maintains Neutral Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Rothschild & Co Redburn Adjusts Price Target on DexCom to $115 From $110, Maintains Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Piper Sandler Adjusts Price Target on DexCom to $100 From $90, Maintains Overweight Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Wolfe Adjusts Price Target on DexCom to $105 From $100, Maintains Outperform Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Raymond James Adjusts Price Target on DexCom to $102 From $99, Maintains Strong Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""Jefferies Adjusts Price Target on DexCom to $112 From $110, Maintains Buy Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p"", ""DexCom\u2019s (NASDAQ:DXCM) Q2 Sales Beat Estimates Medical device company DexCom (NASDAQ:DXCM) beat Wall Street\u2019s revenue expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year\u2019s revenue to be around $4.61 billion, close to analysts\u2019 estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts\u2019 consensus estimates. Is now the time to buy DexCom? Find out in our full research report. Revenue: $1.16 billion vs analyst estimates of $1.13 billion (15.2% year-on-year growth, 2.8% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.8% beat) Adjusted EBITDA: $327.6 million vs analyst estimates of $314.6 million (28.3% margin, 4.1% beat) The company slightly lifted its revenue guidance for the full year to $4.61 billion at the midpoint from $4.6 billion Operating Margin: 18.4%, up from 15.7% in the same quarter last year Organic Revenue rose 15% year on year (16.2% in the same quarter last year) Market Capitalization: $35.03 billion Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. A company\u2019s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, DexCom grew its sales at an impressive 20.2% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. DexCom\u2019s annualized revenue growth of 16% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company\u2019s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don\u2019t accurately reflect its fundamentals. Over the last two years, DexCom\u2019s organic revenue averaged 17.9% year-on-year growth. Because this number is better than its two-year revenue growth, we can see that some mixture of divestitures and foreign exchange rates dampened its headline results. This quarter, DexCom reported year-on-year revenue growth of 15.2%, and its $1.16 billion of revenue exceeded Wall Street\u2019s estimates by 2.8%. Looking ahead, sell-side analysts expect revenue to grow 15.5% over the next 12 months, similar to its two-year rate. This projection is noteworthy and implies the market is forecasting success for its products and services. Unless you\u2019ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. DexCom\u2019s operating margin might fluctuated slightly over the last 12 months but has generally stayed the same, averaging 14.7% over the last five years. This profitability was higher than the broader healthcare sector, showing it did a decent job managing its expenses. Looking at the trend in its profitability, DexCom\u2019s operating margin of 16% for the trailing 12 months may be around the same as five years ago, but it has increased by 2 percentage points over the last two years. This dynamic unfolded because its sales growth gave it operating leverage and shows it has some momentum on its side. In Q2, DexCom generated an operating margin profit margin of 18.4%, up 2.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Revenue trends explain a company\u2019s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth \u2013 for example, a company could inflate its sales through excessive spending on advertising and promotions. DexCom\u2019s EPS grew at an astounding 17.5% compounded annual growth rate over the last five years. Despite its operating margin improvement during that time, this performance was lower than its 20.2% annualized revenue growth, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. Diving into DexCom\u2019s quality of earnings can give us a better understanding of its performance. A five-year view shows DexCom has diluted its shareholders, growing its share count by 5.2%. This has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don\u2019t tell us as much about a company\u2019s fundamentals. In Q2, DexCom reported adjusted EPS at $0.48, up from $0.43 in the same quarter last year. This print beat analysts\u2019 estimates by 8.3%. Over the next 12 months, Wall Street expects DexCom\u2019s full-year EPS of $1.70 to grow 36.9%. We enjoyed seeing DexCom beat analysts\u2019 organic revenue, EPS, and EBITDA expectations this quarter. Overall, we think this was a solid quarter with some key areas of upside. The market seemed to be hoping for more, and the stock traded down 2.9% to $86.50 immediately following the results. Is DexCom an attractive investment opportunity right now? If you\u2019re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it\u2019s free."", ""Bernstein Adjusts Price Target on DexCom to $98 From $88, Maintains Outperform Rating DexCom (DXCM) has an average rating of buy and mean price target of $103.56, according to analysts p""]"
DXCM,2025-08-01,80.57,80.86,78.93,79.28,
DXCM,2025-08-04,79.9,80.215,75.94,76.259,
DXCM,2025-08-05,76.3,76.53,74.88,75.46,"Garmin announces collaborations with leading brands for Garmin Marathon Series Companies will bring exciting activations to the expo, course and finish line festival OLATHE, Kan., Aug. 5, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Brooks, Dexcom, Maurten, Shokz and Therabody will support the Garmin Marathon Series with products and programming, beginning with the inaugural races in Toledo, Ohio on Sunday, Sept. 21. ""As leaders in their respective fields, these brands are the ideal collaborators to enrich the signature experience we're creating for the Garmin Marathon Series. Each brings something unique to our events, whether they're engaging with runners at the two-day expo, providing support on the course or helping finishers recover and celebrate after the race."" – Susan Lyman, Garmin Vice President of Consumer Sales and Marketing Brooks Brooks Running creates market-leading performance running footwear, apparel, sports bras, and accessories distributed worldwide, propelled since 1914 by a never-ending curiosity with how humans move, pushing the limits of motion science, engineering, and technology to create gear that unlocks the power of energy and movement for everyone. Each participant of the Garmin Marathon Series will receive a branded Brooks running shirt to commemorate the event. Additionally, Brooks will be onsite at the expo with its latest gear and along the course at a designated cheer station. Dexcom Dexcom empowers people to take control of health through innovative glucose biosensing technology. With Dexcom G7 and Stelo by Dexcom, its first over-the-counter glucose biosensor, it is easier than ever to get started with a biosensor that best suits each user's unique needs. Dexcom G7 and Stelo transform how runners track glucose levels and understand their metabolic health. Dexcom will have a presence at the expo and finish line festival, as well as a dedicated cheer zone along the course. Maurten Known for revolutionizing sports nutrition with its debut in 2015, Maurten has gained a reputation as the world's leading nutrition brand for endurance athletes. Runners will have access to Maurten gels at designated aid stations, empowering them to stay fueled and perform their best. Maurten will also be onsite at the expo. Shokz As the pioneer and leader in open-ear listening, Shokz helps runners stay motivated, aware, and connected—without compromising on comfort or sound quality. Throughout the Garmin Marathon Series, Shokz will showcase its innovative headphones at the expo, power runners through the toughest miles with a high-energy cheer station, and join the celebration at the finish line festival. Therabody By supercharging performance with science-backed recovery devices, Therabody enables athletes to train harder, perform better and recover faster. Race participants can take advantage of an exclusive offer on Therabody recovery devices to support their training, and benefit from using them throughout race weekend in Therabody recovery zones at the expo, along the course and at the finish line festival. The Garmin Marathon Series is a bold new chapter in road running events, wholly owned and produced by Garmin, a global leader in fitness technology and pioneer of the first running smartwatch. Launching in fall 2025 with events in Toledo, Ohio, and Tucson, Arizona, the Series offers four race distances: a Boston Marathon qualifier full marathon, USATF-certified half marathon, 10K and 5K1. Registration for the Garmin Marathon Series is currently open for all race distances in Toledo and Tucson. For additional information about the cities, races, community engagement opportunities and future locations, please visit garmin.com/marathons. Engineered on the inside for life on the outside, Garmin products have revolutionized the aviation, automotive, fitness, marine and outdoor markets. Dedicated to helping people make the most of the time they spend pursuing their passions, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garmin on social, or follow our blog. 1Tucson courses are pending certification and subject to change. About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved. Notice on Forward-Looking Statements: This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 28, 2024, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983), and the Quarterly Report on Form 10-Q for the quarter ended June 28, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). Copies of such Form 10-K and Form 10-Q are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. MEDIA CONTACTS: Elliott Scott 913-397-8200 media.relations@garmin.com View original content to download multimedia:https://www.prnewswire.com/news-releases/garmin-announces-collaborations-with-leading-brands-for-garmin-marathon-series-302521839.html SOURCE Garmin International, Inc."
DXCM,2025-08-06,75.48,77.95,74.795,76.4,"DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the companies that stood stronger last week. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company’s strong earnings performance in the second quarter of the year. In a statement last week, DexCom, Inc. (NASDAQ:DXCM) named Jake Leach as its new chief executive officer (CEO) effective January 1, 2026, in addition to his post as the current president and chief operating officer. Incumbent CEO Kevin Sayer will continue to work closely with Leach during the transition period and remain executive chairman of the board of directors. Meanwhile, DexCom, Inc. (NASDAQ:DXCM) grew its net income in the second quarter of the year by 25 percent to $179.8 million from $143.5 million in the same period last year. Revenues increased by 16 percent to $1.16 billion from $1 billion year-on-year. While we acknowledge the potential of DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock."
DXCM,2025-08-07,77.12,77.95,75.59,76.4,"Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market Dexcom stands as the US leader in the continuous glucose monitoring (CGM) space as it continues to innovate and diversify its product lines to simplify blood glucose monitoring for type 2 diabetes (T2D) patients. The global diabetes population is projected to hit 643 million by 2030, as per the International Diabetes Federation (IDF). According to GlobalData analysis, the global CGM market is growing at a CAGR of 8.62% and is projected to reach a valuation of $13.6bn by 2034, up from $5.9bn in 2024. In the US, Dexcom held an estimated 74% share of the CGM market in 2024. Other major players in the CGM space include Abbott with its FreeStyle Libre CGM system and Medtronic with its MiniMed CGM. A strong constituent of Dexcom’s continued US market lead is in the diversification of its CGM technology, with smartphone integrations for its G7 CGM system, the recent roll out of over-the-counter (OTC) CGM Stelo, claimed to be the first glucose biosensor available in the US without a prescription, and recent collaborations that aim to tap into the booming wellness wearables market. According to a 2023 report from GlobalData, the wearable technology market is forecast to grow from $99.5bn in 2022 to $290.6bn in 2030. In 2024, Dexcom invested $75m into ŌURA, forging a partnership that makes Dexcom the only CGM compatible with the Finnish company’s Oura smart ring. The Oura smart ring, which measures wellness metrics such as sleep, stress, and cardiovascular data, and CGM data, has so far sold around 2.5 million units worldwide, following Dexcom’s investment. In addition, Dexcom leads in native integration with Apple Watch, standing as the only company currently offering direct-to-watch connectivity with its G7 sensor since integrating with the wearable in June 2024. Dexcom recently announced Q2 2025 revenues exceeding $1.1bn, a 15% uplift on Q2 2024. The company also revealed that from 1 January 2026, Dexcom’s chief operating officer, Jake Leach, will take over from outgoing CEO Kevin Sayer as Dexcom’s new CEO. In Dexcom’s 30 July earnings call, Sayer said: “Today’s announcement of Jake’s transition to the role of CEO reflects the Board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future.” Medical Device Network sat down with Sayer to learn more about how the company will maintain its market position and drive innovation in the CGM space in the future. This interview has been edited for length and clarity. Kevin Sayer (KS): I think we'll continue to be a leader. We have grown dramatically over the past several years, and we have no intention of slowing down. Part of maintaining our market-leading position will involve continuing to enhance our technology. We've always been a company built on product excellence, and that will continue. As we move forward, we've learned that creating an optimal customer experience is very important. Now that our CGMs are mobile-based, we continue to look at how we can make life even better for diabetes patients. Nutrition is important to people with diabetes and those without. With this in mind, we have now added an AI provision where Dexcom G7 users can more easily log their nutrient intake by photographing their food with their smartphone. This is just one area we will continue to elaborate on to further improve the patient experience. As competition goes, there's more technology coming, but at the same time, we've invested billions of dollars in scaling our business. Scaling a CGM is not a simple task. We've built out a factory in Arizona and now have a factory in Malaysia that supplies more products, and we are working on finishing a factory in Ireland that we anticipate being at full scale by 2027. The scale of a CGM business to meet patient needs is really important, and I think that's a strong advantage for our team, and one we've built with our financial muscle and resources combined with our financial success in the marketplace. KS: We are continuing to invest in the US, particularly as we have obtained much more coverage in the area of T2D for those not on insulin. We have a great market expansion opportunity in the US, and we've been able to obtain coverage from the three largest pharmacy benefit managers in the US for people with T2D who are not on insulin already. As for the rest of the world, the countries within Europe represent our next largest market, and we're continuing to focus on markets, particularly those where CGM is reimbursed. In the UK, we have Dexcom One Plus, which is lower cost, and while it doesn't connect with our automated insulin delivery system partners, it still provides patients with an optimal experience for managing their diabetes and gets reimbursed at a lower rate than our G7 product. We look at every country and the coverage available. There are other places where we've adopted an online strategy, originally, knowing there's no coverage, but if we go online and offer a cash paid product to individuals, they'll buy it. After a very long period of time, after people start buying the device online with their own money, the reimbursement authorities often come and cover the product. KS: Our next G7 product launch will be in the US, and we'll extend the device’s lifespan out to 15 days. And that will be very important. Patients want it, and they don't want to change their sensor for this if they don't have to. Initially, for adults, the 15-day product will see a limited launch in the US in Q3, with a complete rollout expected by Q4. As mentioned, with respect to G7, we are continuing to enhance the app with the aforementioned AI function, and we plan to add more analytics to it over time. One thing we've done to improve the experience for a different group of customers are physicians. We're working hard on electronic healthcare record (EHR) integration. We have more than 100 clinics in the US in the process of or having integrating Dexcom CGM data into EPIC’s EHR systems. And that'll be very important in the EU going forward, as many of the countries have talked about integrating sensor data with medical records. We have our Stelo device in the US, and we'll start rolling that out internationally in future periods. We've had great success with Stelo in the US so far, and we'll continue to expand that product offering, and again, add features and integrate more data to give people a better picture of their overall health. KS: While we have not labelled anything for these indications, there is a migration towards them. We have API Interfaces that we share with several partners, and several of those apps that work with Stelo or G7 are, in fact, geared towards wellness and putting people in better overall metabolic health. We announced a recent partnership with ŌURA, for example, and Oura users are using Stelo and that Stelo data is displayed in the Oura ring app, along with Oura ring data, and those users will have their own insights as to what they think is most important concerning glucose data and other wellness metrics provided by Oura ring. KS: That's a good question, and those things have changed over the years, given that when I started with Dexcom, our revenue the previous year was $40m, and you can see where we are at now (Dexcom achieved revenues of around $4bn in 2024). One of the things I wake up and think about sometimes is that I want to make sure that, as a leader of this company, we don't miss the opportunity to change the lives of as many people as we can by not executing on our operations and having enough infrastructure in place to do the things we need to do. I think about that, and I think we've done a good job of scaling and building the business out to meet those requirements. We have to make sure we build a business that enables us to make our products more accessible to more people, to get them the clinical benefits of CGM, and at the same time, run a profitable business that generates proper returns to our shareholders. We've balanced this well over the years and will continue to do so. ""Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market"" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site."
DXCM,2025-08-08,76.27,79.05,76.27,78.86,
DXCM,2025-08-11,78.74,79.22,77.599,77.85,
DXCM,2025-08-12,78.5,80.36,78.145,80.17,"[""ViCentra to Bring Smartphone-Based Closed Loop Therapy to People with Diabetes in Early 2026 Kaleido patch pump system with Diabeloop's DBLG2 algorithm and Dexcom G7 CGM to launch in Germany and the Netherlands in early 2026, bringing smartphone-controlled closed loop therapy to more people with diabetes UTRECHT, the Netherlands, Aug. 12, 2025 /PRNewswire/ -- ViCentra, maker of the Kaleido insulin patch pump, today announced that following the CE Mark approval of Diabeloop's DBLG2 algorithm under the EU Medical Device Regulation (MDR), its next-generation hybrid closed loop system is set to launch in Germany and the Netherlands in early 2026. The new system combines ViCentra's discreet and featherlight Kaleido patch pump with Diabeloop's DBLG2 app-based algorithm\u2014enabling automated insulin delivery controlled directly from the user's smartphone. The integration of Dexcom G7, which is 60% smaller than its predecessor and features an all-in-one sensor and transmitter, significantly enhances comfort and ease of use. \""Kaleido is built for people, not just glucose levels,\"" said Tom Arnold, CEO of ViCentra. \""This launch marks a step-change in wearable diabetes technology: beautifully designed, smartphone-controlled, and powered by a proven algorithm. Together with our partners, we're making flexible, closed loop therapy more accessible\u2014and more human.\"" ViCentra and Diabeloop will begin rolling out the new system this fall in Germany and the Netherlands. During the pre-launch they will gather real-world experience from users and healthcare professionals in preparation for the full commercial launch of the Dexcom G7 integration in early 2026. ViCentra congratulates Diabeloop on receiving CE Mark for DBLG2 and celebrates this important milestone in the companies' long-standing partnership. What's New for People with Diabetes Smartphone-based insulin automation \u2014 no separate controller required Dexcom G7 CGM \u2014 all-in-one sensor and transmitter offers powerful accuracy and a faster warm-up with no fingersticks required Kaleido patch pump \u2014 the smallest and lightest in its class, combining flexibility and performance with a lifestyle design that empowers users without reminding them of their condition About ViCentra ViCentra is on a mission to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, a flexible, discreet, and beautifully crafted alternative to traditional insulin pumps. Headquartered in Utrecht, The Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry. View original content:https://www.prnewswire.com/news-releases/vicentra-to-bring-smartphone-based-closed-loop-therapy-to-people-with-diabetes-in-early-2026-302526520.html SOURCE ViCentra"", ""Health Care Roundup: Market Talk Find insight on Novartis, Eli Lily, Dexcom and more in the latest Market Talks covering Health Care.""]"
DXCM,2025-08-13,80.67,81.56,79.87,79.949,"[""Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic, and Dexcom Inc. The segment is bolstered by urban centers like Riyadh and Jeddah, reflecting strong market potential in Saudi Arabia. Saudi Arabian Blood Glucose Device Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The \""Saudi Arabia Blood Glucose Device Market Size & Trends 2025-2033\"" report has been added to ResearchAndMarkets.com's offering. The Saudi Arabia Blood Glucose Device Market is projected to grow at US$ 143.96 Million in 2024 to US$ 259.8 Million in 2033 at a CAGR of 6.78% over the forecast period 2025-2033. The market is fueled by the increasing incidence of diabetes, increasing awareness about health, and government initiatives for early diagnosis and self-blood glucose monitoring. Recent advances in continuous glucose monitoring (CGM) systems and easy-to-use glucometers are enhancing patient compliance and results. In Saudi Arabia, blood glucose meters have become very popular as a result of the high and increasing rate of diabetes, which is one of the topmost public health problems in the country. Lifestyle issues such as lack of physical activity, high-calorie diets, and rising obesity levels have fueled this phenomenon. The government has initiated various awareness campaigns and public health programs promoting early detection and self-management. Moreover, easy access to blood glucose monitors through pharmacies and online stores, insurance coverage, and technological advances has exposed them to both urban and rural communities throughout the Kingdom. Growth Drivers in the Saudi Arabia Blood Glucose Device Market Increased Type 2 Diabetes Prevalence Saudi Arabia has a very high rate of diabetes prevalence in the world, and Type 2 diabetes is prevalent among most of the adult population. Inactive lifestyles, poor eating habits, and growing obesity levels are the key causes. With rising awareness, more people are opting for blood glucose meters for regular monitoring and early treatment. The government as well as the healthcare sector is also placing emphasis on self-care to prevent complications and healthcare expenses, thereby increasing demand further. This burden of chronic disease is likely to fuel steady expansion in the blood glucose device market during the forecast period. Over one in ten individuals in Saudi Arabia had diabetes, and the disease's prevalence was set to nearly double by the year 2045, as stated in the IDF report. The report also stated that 4.27 million individuals in Saudi Arabia, a country with a population of approximately 34.8 million, suffer from diabetes, whereas an additional 1.86 million have the condition but are not diagnosed yet. The number is predicted to rise to 5.6 million in 2030 and continue to rise to 7.5 million in 2045. Technological Advancements and User-Friendly Devices The ready availability of modern blood glucose monitors, including Continuous Glucose Monitoring (CGM) systems and Bluetooth glucometers, is transforming the management of diabetes. They are providing better accuracy, real-time monitoring, and smartphone connectivity, enabling improved diabetes management. Simple-to-use interfaces, smaller sizes, and painless testing techniques enhance their appeal to younger and older people. While global players make an entry into the Saudi market with state-of-the-art innovations, patients gain through enhanced choices that enhance compliance and enhance long-term results, fuelling adoption across age ranges. August 2023, Nemaura Medical received authorization by the Saudi Food and Drug Authority (SFDA) for its non-invasive glucose sensor wearable, sugarBEAT. Regarded as a Class IIb medicinal device with a CE mark, the device offers useful information using daylong glucose monitoring and review of daily glucose patterns. Government Programs and Public Health Campaigns Vision 2030 health sector reform is being heavily funded by the government of Saudi Arabia with a focus on disease prevention and early detection. Screening programs for diabetes, school and workplace awareness programs, and collaboration with healthcare providers are enhancing diagnosis rates and encouraging frequent glucose monitoring. Subsidies for the necessary medical equipment and insurance coverage for diabetes care have further enhanced access to blood glucose equipment. Monitoring equipment is also being more commonly installed in hospitals and primary care facilities. These forward-looking initiatives by the public sector are fast-tracking market penetration and promoting the adoption of blood glucose monitoring devices across the board. For example, in 2024, the Saudi Ministry of Health collaborated with Ithnain to improve diabetes control, launching innovative coaching for more than 10,000 patients and keeping in line with Vision 2030 to develop healthcare solutions throughout the Kingdom. This program is consistent with Saudi national health policies for Vision 2030 and reflects Saudi Arabia's increasing interest in diabetes awareness and effective management. Obstacles in the Saudi Arabia Blood Glucose Device Market Excessive Cost of Sophisticated Devices In spite of the benefits of CGMs and intelligent glucometers, their excessive cost is a deterrent for most consumers. High-tech blood glucose devices with digital capabilities or continuous monitoring features tend to have a higher cost, and not all health insurance plans provide full coverage. The premium pricing issue disproportionately targets low - and middle-income patients, making regular monitoring less accessible. Therefore, many continue to use less efficient or older monitoring devices. Without increased affordability or wider insurance cover, widespread use of high-tech blood glucose devices is a major hurdle in the Kingdom. Limited Compliance and Awareness in Rural Regions Despite good healthcare facilities and awareness campaigns in urban areas such as Riyadh and Jeddah, rural and remote areas lack proper awareness and access to diabetes care. Poor compliance due to limited understanding of the necessity for frequent glucose monitoring and how to use the devices effectively contributes to this. Some patients also lack technical competence for newer machines. These differences impact early diagnosis and continuation disease management. Widening outreach, education, and distribution to underserved communities is an essential barrier to achieving countrywide use of blood glucose monitoring technologies. Key Players Analysis (Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis) Abbott Laboratories Medtronic Dexcom Inc. B. Braun Melsungen AG DarioHealth Corp Sanofi Bionime Corporation Novo Nordisk Key Attributes: Key Topics Covered: 1. Introduction 2. Research & Methodology 2.1 Data Source 2.2 Research Approach 2.3 Forecast Projection Methodology 3. Executive Summary 4. Market Dynamics 4.1 Growth Drivers 4.2 Challenges 5. Saudi Arabia Blood Glucose Device Market 5.1 Historical Market Trends 5.2 Market Forecast 6. Market Share Analysis 6.1 By Products 6.2 By Application 6.3 By End User 6.4 By States 7. Product 7.1 Test Strips 7.2 Lancets 7.3 Blood Glucose Meters 8. Application 8.1 Type 1 Diabetes 8.2 Type 2 Diabetes 8.3 Gestational Diabetes 9. End User 9.1 Hospital Pharmacies 9.2 Retail Pharmacies 9.3 Online Sales 9.4 Diabetes Clinics & Centers 10. Top States 10.1 Dhahran 10.2 Riyadh 10.3 Khobar 10.4 Jeddah 10.5 Dammam 10.6 Others 11. Reimbursement Policy 12. Value Chain Analysis 13. Porter's Five Forces Analysis 13.1 Bargaining Power of Buyers 13.2 Bargaining Power of Suppliers 13.3 Degree of Competition 13.4 Threat of New Entrants 13.5 Threat of Substitutes 14. SWOT Analysis 14.1 Strength 14.2 Weakness 14.3 Opportunity 14.4 Threats 15. Pricing Benchmark Analysis 15.1 Abbott Laboratories 15.2 Medtronic 15.3 Dexcom, Inc. 15.4 B. Braun Melsungen AG 15.5 DarioHealth Corp 15.6 Sanofi 15.7 Bionime Corporation 15.8 Novo Nordisk 16. Key Players Analysis For more information about this report visit https://www.researchandmarkets.com/r/wjhsee About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Blood Glucose Device Market CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900"", ""5 Revealing Analyst Questions From DexCom\u2019s Q2 Earnings Call DexCom\u2019s second quarter 2025 results saw the company surpass Wall Street\u2019s revenue and earnings expectations, though the market\u2019s immediate reaction was notably negative. Management attributed the quarter\u2019s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom\u2019s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbursement for nearly 6 million type 2 non-insulin lives this year. The company also pointed to operational investments aimed at restoring inventory levels and supporting customer supply, as well as continued momentum in international markets, especially with DexCom ONE+. Collectively, these factors illustrate DexCom\u2019s ability to drive growth through access expansion, operational execution, and product innovation. Is now the time to buy DXCM? Find out in our full research report (it\u2019s free). Revenue: $1.16 billion vs analyst estimates of $1.13 billion (15.2% year-on-year growth, 2.8% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.8% beat) Adjusted EBITDA: $327.6 million vs analyst estimates of $314.6 million (28.3% margin, 4.1% beat) The company slightly lifted its revenue guidance for the full year to $4.61 billion at the midpoint from $4.6 billion Operating Margin: 18.4%, up from 15.7% in the same quarter last year Organic Revenue rose 14.6% year on year vs analyst estimates of 12.8% growth (182.3 basis point beat) Market Capitalization: $31.44 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Travis Lee Steed (Bank of America) asked about the factors supporting raised guidance, and CFO Jereme Sylvain cited strong new starts in type 2 non-insulin users and expanding PBM coverage as key drivers for confidence in higher full-year targets. Lawrence H. Biegelsen (Wells Fargo) pressed on the risks of CMS competitive bidding for Medicare, with President Jake Leach explaining that 15% of DexCom\u2019s business is Medicare fee-for-service and emphasizing the company\u2019s focus on preventing service disruption and closely monitoring proposal developments. Robert Justin Marcus (JPMorgan) inquired about gross margin trends, and Sylvain pointed to sequential improvements expected from rebuilding inventory and more efficient distribution, while noting one-time impacts from a product recall in Q2. Joanne Karen Wuensch (Citibank) asked about the G8 sensor roadmap and competitive multi-analyte sensors, with Leach highlighting DexCom\u2019s ongoing development focused on reliability and user safety, and confirming that a ketone sensor remains in the pipeline. Danielle Joy Antalffy (UBS) questioned competitive dynamics in the type 1 segment, with Sayer and Leach emphasizing DexCom\u2019s established ecosystem and ongoing feature enhancements as key differentiators. In the coming quarters, analysts will closely monitor (1) the commercial launch and adoption trajectory of the 15-day G7 sensor, (2) further expansion of PBM and international reimbursement for both prescription and over-the-counter CGM solutions, and (3) the impact of new software features and digital health integrations on patient engagement and utilization. Notably, leadership succession and any potential shifts in strategic priorities as Jake Leach prepares to assume the CEO role at the beginning of 2026 will also be under scrutiny. The ability to execute on these fronts will be critical to DexCom\u2019s growth prospects and market positioning. DexCom currently trades at $80.16, down from $89.11 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it\u2019s free). Donald Trump\u2019s April 2025 \""Liberation Day\"" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don\u2019t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street\u2019s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year\u2019s revenue to be around $4.61 billion, close to analysts\u2019 estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts\u2019 consensus estimates. Is now the time to buy DXCM? Find out in our full research report (it\u2019s free). Revenue: $1.16 billion vs analyst estimates of $1.13 billion (15.2% year-on-year growth, 2.8% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.8% beat) Adjusted EBITDA: $327.6 million vs analyst estimates of $314.6 million (28.3% margin, 4.1% beat) The company slightly lifted its revenue guidance for the full year to $4.61 billion at the midpoint from $4.6 billion Operating Margin: 18.4%, up from 15.7% in the same quarter last year Organic Revenue rose 14.6% year on year vs analyst estimates of 12.8% growth (182.3 basis point beat) Market Capitalization: $31.44 billion DexCom\u2019s second quarter 2025 results saw the company surpass Wall Street\u2019s revenue and earnings expectations, though the market\u2019s immediate reaction was notably negative. Management attributed the quarter\u2019s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom\u2019s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbursement for nearly 6 million type 2 non-insulin lives this year. The company also pointed to operational investments aimed at restoring inventory levels and supporting customer supply, as well as continued momentum in international markets, especially with DexCom ONE+. Collectively, these factors illustrate DexCom\u2019s ability to drive growth through access expansion, operational execution, and product innovation. Looking forward, DexCom\u2019s updated guidance underscores management\u2019s focus on broadening access for type 2 non-insulin users and driving global adoption of its continuous glucose monitoring (CGM) platform. The company is preparing for the commercial launch of its longer-wear 15-day G7 sensor and deepening software integration, including new AI-powered features and partnerships with digital health platforms. Incoming President Jake Leach stated that DexCom will continue to prioritize innovation, increased scale, and operational excellence. At the same time, CFO Jereme Sylvain noted that evolving reimbursement dynamics\u2014including competitive bidding proposals for Medicare and international policy changes\u2014could impact growth and margin trends in the coming years, requiring disciplined execution and adaptability. In their second quarter remarks, DexCom\u2019s management attributed the company\u2019s performance to broad-based demand, expanded insurance coverage, and the rapid rollout of new digital health features. The team also highlighted operational improvements, advances in product innovation, and a well-planned leadership transition. Their commentary throughout the call reflected a focus on building long-term relationships with prescribers, caregivers, and payers, as well as investing in technology and customer support. The management team described a multi-pronged strategy to sustain growth, improve patient outcomes, and scale DexCom\u2019s global operations\u2014even as they prepare for changes at the top of the organization. Type 2 market expansion: DexCom secured reimbursement with a third major PBM for type 2 non-insulin users, now providing coverage for nearly 6 million type 2 non-insulin lives in the U.S. This milestone helped drive significant growth in the segment and contributed to new customer adoption. Stelo traction builds: The over-the-counter Stelo glucose biosensor app surpassed 400,000 downloads, with its user base evolving from primarily type 2 non-insulin patients to increasingly wellness-focused and prediabetes segments as prescription CGM coverage broadened. International momentum: International revenue growth accelerated, fueled by expanded access for DexCom ONE+ and new public funding wins in major regions such as Ontario, Canada, and France. Management sees ongoing opportunities as more countries adopt broader access standards for CGM technology. Product innovation pipeline: DexCom emphasized a rapid cadence of development and deployment for new features, including AI-powered meal logging, direct-to-watch connectivity, and integration with third-party platforms like Oura. The company is preparing for the commercial introduction of its 15-day G7 sensor, which is anticipated to improve patient convenience and expand the addressable market. Leadership transition announced: CEO Kevin Sayer will hand over responsibilities to Jake Leach at the beginning of 2026; Leach stressed a commitment to continuity in DexCom\u2019s strategic direction and a focus on global scaling and innovation. DexCom\u2019s future performance will be shaped by the continued expansion of reimbursement, successful product launches, and ongoing investments in technology and market access. Management\u2019s strategy is centered around increasing penetration among under-served populations, introducing new hardware and software capabilities, and maintaining operational resilience in the face of evolving competitive and regulatory headwinds. The company\u2019s ability to deliver on these priorities will determine its growth trajectory and long-term market leadership. Broader access and uptake: Management underscored that increased PBM coverage and expanded international reimbursement are central to driving new patient adoption, particularly among type 2 non-insulin users. Penetrating under-served populations and building on recent access wins remain top priorities for the organization. Product releases and integration: The launch of the 15-day G7 sensor and continuous software enhancements\u2014including AI-enabled features and new digital health partnerships\u2014are expected to boost engagement, drive higher utilization rates, and strengthen retention. However, realizing these benefits will require seamless commercialization and effective payer negotiations. Potential headwinds: DexCom acknowledged early-stage uncertainty around proposed CMS competitive bidding for Medicare, which could impact pricing and margins as soon as 2027. The management team also noted that scaling operations and optimizing sales productivity is an ongoing process. Competitive activity, especially in the type 1 diabetes segment, will require the company to maintain its pace of innovation and differentiate through user experience and outcomes. In the coming quarters, analysts will closely monitor (1) the commercial launch and adoption trajectory of the 15-day G7 sensor, (2) further expansion of PBM and international reimbursement for both prescription and over-the-counter CGM solutions, and (3) the impact of new software features and digital health integrations on patient engagement and utilization. Notably, leadership succession and any potential shifts in strategic priorities as Jake Leach prepares to assume the CEO role at the beginning of 2026 will also be under scrutiny. The ability to execute on these fronts will be critical to DexCom\u2019s growth prospects and market positioning. DexCom currently trades at $80.16, down from $89.11 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it\u2019s free). Donald Trump\u2019s April 2025 \""Liberation Day\"" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don\u2019t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""FriskaAi and Dexcom Enter CGM Data Integration Agreement ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company's groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs. FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team. \""Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine,\"" says Shaji Nair, CEO of FriskaAi. \""Dexcom's pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness.\"" Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range. The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions. Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies. About FriskaAi FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients' glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai. Media Contact: Michele Nachum NPC Creative Services michele@npccs.com SOURCE: FriskaAi View the original press release on ACCESS Newswire""]"
DXCM,2025-08-14,79.74,80.205,78.86,79.96,"3 Reasons We’re Fans of DexCom (DXCM) Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation. Following the drawdown, is now an opportune time to buy DXCM? Find out in our full research report, it’s free. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks. In addition to reported revenue, organic revenue is a useful data point for analyzing Patient Monitoring companies. This metric gives visibility into DexCom’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement. Over the last two years, DexCom’s organic revenue averaged 17.8% year-on-year growth. This performance was fantastic and shows it can expand quickly without relying on expensive (and risky) acquisitions. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. DexCom’s EPS grew at an astounding 17.5% compounded annual growth rate over the last five years. This performance was better than most healthcare businesses. Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. As you can see below, DexCom’s margin expanded by 8.6 percentage points over the last five years. This is encouraging, and we can see it became a less capital-intensive business because its free cash flow profitability rose more than its operating profitability. DexCom’s free cash flow margin for the trailing 12 months was 13.3%. These are just a few reasons DexCom is a rock-solid business worth owning. With the recent decline, the stock trades at 34.3× forward P/E (or $80.25 per share). Is now a good time to buy? See for yourself in our comprehensive research report, it’s free. Donald Trump’s April 2025 ""Liberation Day"" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."
DXCM,2025-08-15,80.29,82.04,80.29,80.95,"DexCom Stock: Analyst Estimates & Ratings DexCom, Inc. (DXCM), headquartered in San Diego, California, is a global leader in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company primarily serves people with diabetes by offering advanced, real-time monitoring solutions that track glucose levels, enabling more precise and proactive diabetes management. DexCom’s flagship products include the DexCom G6 and G7 systems, which provide users with continuous, non-invasive data for better glucose control. Beyond diabetes, DexCom is expanding into areas like diabetes prevention and insulin dosing optimization, positioning itself as a key player in the evolving healthcare and medical device sectors. The company has a market capitalization of $31.36 billion. Why This Cannabis Penny Stock Could Be Wall Street’s Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Shares of this medical device company have gained 12.6% over the past 52 weeks, underperforming the broader S&P 500 Index ($SPX), which has gained 19% over the same period. This year, the stock has gained a modest 2.8%, while the S&P 500 index is up almost 10% year-to-date (YTD). To put this into perspective, we compare with the sector-specific iShares U.S. Medical Devices ETF (IHI). The ETF’s gains have more or less aligned with DexCom’s, rising by 10.3% over the past 52 weeks and 5.9% on a YTD basis. Despite DexCom’s strong second-quarter results on Jul. 30, the market's reaction was not positive, as the stock price dropped a notable 9.3% the very next trading session. The company’s revenue increased 15.2% year-over-year (YOY) to $1.16 billion. DexCom also received FDA clearance for the DexCom G7 15 Day CGM System. Its adjusted EPS increased 11.6% YOY to $0.48, surpassing the $0.45 figure expected by Wall Street analysts. For the fiscal year 2025, ending this December, Wall Street analysts expect DexCom’s bottom line to grow by 25% YOY to $2.05 per share on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in two of the trailing four quarters and missing them on two other occasions. Among the 25 analysts covering DexCom’s stock, the consensus is a “Strong Buy.” That’s based on 20 “Strong Buy” ratings, one “Moderate Buy” rating, and four “Holds.” The current configuration of the ratings is slightly more bullish than two months ago, when the stock had 19 “Strong Buy” ratings. Reflecting a stable market outlook for the company, Canaccord Genuity analyst William Plovanic maintained a “Buy” rating on the stock this month, while keeping the price target at $106. On July 31, Raymond James analyst Jayson Bedford maintained a ""Strong Buy"" rating, with the price target on the stock raised from $99 to $102. DexCom’s mean price target of $102.60 indicates a premium of 28.3% from the current market prices. The Street-high price target of $125 implies a potential upside of 56.3%. On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"
DXCM,2025-08-18,80.93,81.74,80.3227,80.82,
DXCM,2025-08-19,80.68,81.42,80.32,80.9,"Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization NEW YORK, August 19, 2025--(BUSINESS WIRE)--Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron’s Board of Directors in 2023, will transition into a full-time executive role while continuing to serve on the Board. With more than 30 years in the medical device industry, Rasdal has repeatedly led companies from breakthrough innovation to market leadership. As CEO of DexCom, Inc. (NASDAQ: DXCM), he oversaw FDA approval, IPO, and the launch of the company’s first continuous glucose monitoring system, a product that transformed diabetes management globally. He later served as founding CEO of Obalon Therapeutics, guiding the company through FDA PMA approval, IPO, and commercialization of its novel obesity treatment device. Earlier in his career, Rasdal was President of Medtronic Vascular and Vice President of Global Marketing at Arterial Vascular Engineering, acquired by Medtronic for $4.3 billion. ""Andy and Mark have built multiple billion-dollar market leaders from the ground up,"" said Dr. Tom Oxley, CEO and Founder, Synchron. ""They will be force-multipliers for Synchron. We have some groundbreaking advancements in our pipeline."" Mr. Brister joins Synchron with more than 38 years of experience pioneering medical device technologies, launching over 100 products, and holding more than 450 patents. He has held senior engineering and R&D leadership roles at Guidant Corp., Arterial Vascular Engineering, Medtronic, DexCom, and Obalon Therapeutics. Brister’s innovations have helped define multiple device categories, from vascular interventions to diabetes care and gastrointestinal devices. ""I believe Synchron is one of the most important medical device companies of this generation,"" said Rasdal. ""Synchron’s BCI has the potential to restore autonomy to millions living with motor impairment, and I’m honored to join the team full-time to help make that vision a reality."" ""What drew me to Synchron, is the chance to apply decades of product development and scale-up experience to a technology with the potential to transform millions of lives,"" said Brister. ""The Stentrode® BCI is a once-in-a-generation innovation, one that could restore independence for people with severe paralysis and redefine the connection between the brain and the digital world."" About Synchron Synchron is the category-defining brain-computer interface (BCI) company pioneering implantable neurotechnology designed to restore autonomy and improve lives. Its mission is to bring the first commercially scalable BCI to millions of people with motor impairment. Synchron has completed two human clinical trials since 2019 and is preparing for a larger-scale study. The company’s implantable BCI is now powered by Chiral AI™, a proprietary foundation model of cognition. With the BCI market projected to reach $400 billion (Morgan Stanley), Synchron is leading the field while prioritizing ethical development grounded in Cognitive Liberty and the protection of fundamental rights. Synchron is headquartered in New York. Learn more at synchron.com and follow @synchroninc. View source version on businesswire.com: https://www.businesswire.com/news/home/20250819583131/en/ Contacts Media Contact Kimberly Ha Synchron kha@synchron.com"
DXCM,2025-08-20,80.77,82.05,80.43,81.67,"[""Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management. At a time when obesity and disease threaten the well-being of millions, Signos is leading the movement to put metabolic health back into the hands of individuals. By integrating Stelo by Dexcom glucose biosensor with an AI-powered platform for deciphering unique metabolisms, Signos enables people to see how food choices, timing, activity, stress, and even sleep affect their bodies in real time \u2014 equipping them with the information required to seize their health and make decisions backed by their own biology. \""This is more than a product launch \u2014 it's a mission,\"" said Sharam Fouladgar-Mercer, CEO and Founder of Signos. \""Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen.\"" Key Features and Purpose-Driven Benefits: Igniting the Metabolic Movement with Personalized Data: By tapping into the body's own signals, Signos equips individuals with tools to improve sleep, manage weight, and reduce the risk of chronic disease \u2014 not through restriction, but through understanding. Personalized, AI-Driven Insights: Signos translates glucose fluctuations into easy-to-follow, personalized recommendations \u2014 transforming raw data into actionable guidance for building healthier everyday habits. Total Body Intelligence: Signos helps users understand how their bodies respond to meals, workouts, sleep, and stress, creating a holistic picture of personal health. Expert Metabolic Monitoring: Signos removes barriers and puts powerful glucose insights into the hands of millions without the need for prescriptions, inflated prices, or hidden hoops. It's real-time metabolic health, made truly accessible. The need for accessible, effective metabolic health solutions has never been greater. With 73.6% of U.S. adults classified as overweight or obese, 88% of Americans classified as metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, Signos offers a proactive solution grounded in science and is changing the trajectory of metabolic health by intervening early and guiding users toward meaningful, lasting lifestyle changes. The company aims to help millions monitor their metabolic health and build better habits by leveraging insights based on glucose, the body's primary energy source. Raven-Symon\u00e9, actress and advisor, shared, \""I've been using Signos for years now and no matter my mental ups and downs it is there to keep me in reality. The reality is things change, levels change, but if you keep an eye on the overall picture you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs.\"" Signos is available now, offering individuals everywhere a revolutionary way to monitor glucose, unlock personalized insights, and take control of their metabolism to build a sustainably healthier life \u2014 all from the convenience of their smartphone. For more information, visit signos.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/signos-unveils-first-ever-fda-cleared-glucose-monitoring-breakthrough-for-weight-management-enabling-millions-of-americans-to-take-control-of-their-health-302534147.html SOURCE Signos"", ""DexCom Expands Access and Innovation While Balancing Headwinds DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management\u2019s confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom\u2019s over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom\u2019s competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM\u2019s clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom\u2019s G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom\u2019s innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a \u201cconsumer technology mindset,\u201d rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom\u2019s business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % \u2014 beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche\u2019s potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic\u2019s Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic\u2019s MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. price | DexCom, Inc. Quote DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company\u2019s leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-08-21,81.45,81.93,79.83,80.639,"[""CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded HP Enterprise (HPE) to Overweight from Equal Weight with a price target of $28, up from $22. The firm believes accretion from the Juniper acquisition and multiple upside is not being priced into the shares. H.C. Wainwright upgraded CoreWeave (CRWV) to Buy from Neutral with an $180 price target. The stock's valuation \""has sunk deep enough,\"" the analyst tells investors in a research note. Arete also upgraded CoreWeave to Buy from Neutral with an $180 price target. Citi upgraded Bio-Techne (TECH) to Buy from Neutral with a price target of $70, up from $55. The firm views the company's growth and margin outlook as conservative and believes the stock is undervalued at current levels. Jefferies upgraded Enphase Energy (ENPH) to Hold from Underperform with a price target of $36, up from $28. Treasury guidance issued on Friday of last week was positive for residential solar, yet Enphase's stock is up just about 10%, notes the analyst, who perceives a market disconnect in which the buyside gives little credit for TPO sales, wrongly assuming the majority of sales are tied instead to cash/loan. UBS upgraded iQiyi (IQ) to Buy from Neutral with a price target of $3.32, up from $1.97. iQiyi's fundamentals could be bottoming out amid a more benign regulatory environment, the analyst tells investors in a research note. Top 5 Downgrades: Wedbush downgraded Instacart (CART) to Underperform from Neutral with a price target of $42, down from $55, arguing that Amazon's (AMZN) expansion of its same-day perishable grocery delivery service has intensified competition. Citi downgraded Coty (COTY) to Neutral from Buy with a price target of $4.25, down from $6.50. The company's fiscal Q4 results came in weaker than expected despite a low bar, the analyst tells investors in a research note. Wells Fargo downgraded Truist Financial (TFC) to Equal Weight from Overweight with an unchanged $47 price target after its announced 5-year strategic plan that contains \""new new metrics.\"" The company is lagging its numerous peers with this announcement after years of share loss and weak JD Power rankings, the analyst tells investors in a research note. JPMorgan downgraded Alcon (ALC) to Neutral from Overweight with a price target of $77.53, down from $105.88. The company reported another \""soft\"" quarter and cut to guidance, the analyst tells investors in a research note. BofA downgraded Monday.com (MNDY) to Neutral from Buy with a price target of $205, down from $240. Search engine optimization driven website visits to Monday.com sank by an average of 23.5% year-over-year in Q2 and declines accelerated to 25.3% in July, according to Similarweb data, reports the analyst. Top 5 Initiations: Argus initiated coverage of DexCom (DXCM) with a Buy rating and $100 price target. The firm sees the company maintaining above industry average growth with expanding customer reach across the continuous glucose monitoring for diabetes landscape and leveraging costs to enhance profitability. Morgan Stanley assumed coverage of NetApp (NTAP) with an Equal Weight rating and price target of $115, up from $106. The firm says its intra-quarter storage channel checks were most cautious for NetApp. Rosenblatt initiated coverage of PubMatic (PUBM) with a Buy rating and $17 price target. The company's Q2 earnings report unearthed a second problem in a major DSP relationship, setting the stage for a decline in adjusted EBITDA in 2026, but these operating challenges seem likely to be overcome, the analyst tells investors in a research note. BofA initiated coverage of NuScale Power (SMR) with a Neutral rating and $36 price target. The developer of small modular reactor nuclear technology's use of lightwater technology and LEU, rather than scarce HALEU, offers \""a more de-risked fuel pathway\"" than peers, but the firm's Neutral rating reflects the early commercialization stage, a lack of binding contracts, and a valuation that \""already prices in significant future success.\"" Morgan Stanley initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $18 price target. The firm sees a multi-billion dollar opportunity for Haduvio."", ""DexCom (NASDAQ:DXCM) Shareholders Will Want The ROCE Trajectory To Continue Explore DexCom's Fair Values from the Community and select yours If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. Speaking of which, we noticed some great changes in DexCom's (NASDAQ:DXCM) returns on capital, so let's have a look. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on DexCom is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) \u00f7 (Total Assets - Current Liabilities) 0.17 = US$687m \u00f7 (US$7.3b - US$3.3b) (Based on the trailing twelve months to June 2025). Therefore, DexCom has an ROCE of 17%. On its own, that's a standard return, however it's much better than the 10% generated by the Medical Equipment industry. Check out our latest analysis for DexCom Above you can see how the current ROCE for DexCom compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for DexCom . DexCom is displaying some positive trends. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 17%. Basically the business is earning more per dollar of capital invested and in addition to that, 29% more capital is being employed now too. So we're very much inspired by what we're seeing at DexCom thanks to its ability to profitably reinvest capital. For the record though, there was a noticeable increase in the company's current liabilities over the period, so we would attribute some of the ROCE growth to that. The current liabilities has increased to 45% of total assets, so the business is now more funded by the likes of its suppliers or short-term creditors. And with current liabilities at those levels, that's pretty high. All in all, it's terrific to see that DexCom is reaping the rewards from prior investments and is growing its capital base. Astute investors may have an opportunity here because the stock has declined 23% in the last five years. With that in mind, we believe the promising trends warrant this stock for further investigation. On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation for DXCM on our platform that is definitely worth checking out. For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Analyst Report: Dexcom Inc DexCom, Inc. focuses on the design, development, and commercialization of CGM systems in the United States and internationally to support the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its primary products include Dexcom G6 and Dexcom G7 integrated CGM systems; Dexcom Share, a remote monitoring system; Dexcom ONE, which is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and T2D. The company was incorporated in 1999 and is headquartered in San Diego."", ""Market Digest: AIG, AMAT, EL, MCK, DXCM Technology and the massive AI trade took it on the chin on August 19, dragging some of the major indices down and creating some developments worth monitoring. The Nasdaq dropped 1.5% and the Nasdaq 100 (QQQ) fell 1.4%, led lower by weakness in the mega-cap semiconductor and software stocks. The iShares Semiconductor ETF (SOXX) lost 1.6%, the VanEck Semiconductor ETF (SMH) declined 2%, the Dow Jones U.S. Semiconductor Index gave back 3%, the DJ U.S. Software Index was off 2%, and the iShares Tech-Software ETF (IGV) sank 2.6%. Many of the beloved IT names were whacked, including NVDA, AVGO, TSM, AMD, ARM, MSFT, ORCL, and PLTR, which all fell 1.4% to 9.4%. The QQQ as well as the SOXX and the SMH closed at or near their 21-day exponential moving averages. The software indices broke below their 50-day averages for the first time since early this year and broke down from short-term topping formations. In addition, the highflying (mostly IT) IPOs from 2025 were smacked hard. On the flipside, five of the 11 S&P 500 sectors rose between 0.6% and 1.8% -- and they were mostly defensive areas. Real Estate, Consumer Staples, and Utilities led with gains of 1% to 1.8%, while Healthcare and Materials gained 0.6%. As of this writing, the QQQ has traced out multiple bearish divergences with respect to the daily moving-average convergence/divergence (MACD) and there has been one divergence with the 14-day relative strength index (RSI). Volume was above average, creating a second distribution day. For big trouble, we need to see four to five days of heavy selling in a 10-day period. The Vortex indicator is close to turning bearish while the 21-day rate-of-change (ROC) is nearing bearish territory. (Mark Arbeter, CMT)""]"
DXCM,2025-08-22,81.01,82.36,80.475,82.26,
DXCM,2025-08-25,81.705,82.2,75.89,75.96,"DexCom Insiders Sold US$11m Of Shares Suggesting Hesitancy Many DexCom, Inc. (NASDAQ:DXCM) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In the last twelve months, the biggest single sale by an insider was when the Executive Chairman & CEO, Kevin Sayer, sold US$2.9m worth of shares at a price of US$86.91 per share. That means that an insider was selling shares at around the current price of US$82.26. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Insiders in DexCom didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! See our latest analysis for DexCom If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations. The last three months saw some DexCom insider selling. Lead Independent Director Mark Foletta sold just US$17k worth of shares in that time. Neither the lack of buying nor the presence of selling is heartening. But the volume sold is so low that it really doesn't bother us. I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that DexCom insiders own 0.3% of the company, worth about US$103m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. We did not see any insider buying in the last three months, but we did see selling. But the sales were small, so we're not concerned. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the DexCom insiders selling. Of course, the future is what matters most. So if you are interested in DexCom, you should check out this free report on analyst forecasts for the company. But note: DexCom may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
DXCM,2025-08-26,76.25,76.89,75.72,76.12,"[""3 Stocks That May Be Undervalued By As Much As 46.1% As the U.S. stock market navigates a mixed landscape, with recent rallies and shifts in major indices like the Dow Jones Industrial Average and S&P 500, investors are closely watching for opportunities amidst potential interest rate cuts and strong corporate earnings. In this environment, identifying undervalued stocks becomes crucial as they may offer significant growth potential when market conditions stabilize or improve. Click here to see the full list of 195 stocks from our Undervalued US Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: DexCom, Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring systems globally, with a market cap of approximately $32.26 billion. Operations: The company generates revenue primarily from its continuous glucose monitoring systems, with the Patient Monitoring Equipment segment contributing $4.30 billion. Estimated Discount To Fair Value: 29.7% DexCom's recent financial performance and strategic initiatives position it as a potentially undervalued stock based on cash flows. The company reported strong revenue growth, with second-quarter sales reaching US$1.16 billion, up from US$1 billion the previous year, and raised its 2025 revenue guidance to between US$4.6 billion and US$4.625 billion. Despite legal challenges regarding trademark issues, DexCom continues to innovate with AI-powered features in its glucose monitoring systems, enhancing user engagement and market reach. Insights from our recent growth report point to a promising forecast for DexCom's business outlook. Click to explore a detailed breakdown of our findings in DexCom's balance sheet health report. Overview: Old National Bancorp is a bank holding company for Old National Bank, offering consumer and commercial banking services in the United States, with a market cap of approximately $8.90 billion. Operations: The company generates revenue primarily from its Community Banking segment, which accounts for approximately $1.89 billion. Estimated Discount To Fair Value: 44.1% Old National Bancorp appears undervalued based on cash flows, trading at US$22.72, below its estimated fair value of US$40.62. The company reported a net interest income increase to US$514.79 million in Q2 2025 from the previous year's US$388.42 million, reflecting strong cash flow generation despite higher net charge-offs of US$26.53 million compared to last year\u2019s US$14.05 million and recent shareholder dilution impacting equity returns forecasts negatively. Our growth report here indicates Old National Bancorp may be poised for an improving outlook. Delve into the full analysis health report here for a deeper understanding of Old National Bancorp. Overview: UMB Financial Corporation is a bank holding company offering banking services and asset servicing both in the United States and internationally, with a market cap of $9.23 billion. Operations: The company's revenue segments include Personal Banking at $335.35 million, Commercial Banking at $965.43 million, and Institutional Banking (including Healthcare Services) at $648.57 million. Estimated Discount To Fair Value: 46.1% UMB Financial is trading at US$121.59, significantly below its estimated fair value of US$225.65, indicating potential undervaluation based on cash flows. Despite recent shareholder dilution and net charge-offs of US$15.5 million in Q2 2025, the company reported robust net interest income growth to US$467.02 million from the previous year's US$245.11 million, showcasing strong cash flow generation and an anticipated earnings growth rate surpassing the broader market expectations. Our comprehensive growth report raises the possibility that UMB Financial is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of UMB Financial. Click this link to deep-dive into the 195 companies within our Undervalued US Stocks Based On Cash Flows screener. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include DXCM ONB and UMBF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""Dexcom Announces Upcoming Conference Presentations SAN DIEGO, August 26, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you\u2019re made of. For more information, visit www.dexcom.com. Category: IR View source version on businesswire.com: https://www.businesswire.com/news/home/20250826215155/en/ Contacts DexCom, Inc. Sean Christensen Vice President \u2013 Finance and Investor Relations investor-relations@dexcom.com (858) 200-0200""]"
DXCM,2025-08-27,75.8,76.97,74.74,76.38,"Discuss Introduces “Vibe Coding” and Hybrid AI + Human Market Insight Platform New release introduces vibe coding for market insights, enabling any team to combine AI-moderated research with the depth of human-led conversations. SEATTLE, WA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- As AI-moderated interviews reshape qualitative research, many companies frame it as a choice between automation or human connection. Discuss, the only global market insights platform proven to deliver both, today announced new features that cement the hybrid model of AI-led and human-led research as the industry’s new normal. Trusted by global brands including Mastercard, Danone, Dexcom, and Suntory, Discuss enables teams to move at the speed of AI while preserving the empathy and cultural nuance that live human conversations can deliver. This release also introduces a concept Discuss is calling vibe coding for market insights. Borrowed from software development, where AI turns natural-language instructions into code, vibe coding in consumer research democratizes insight access, allowing non-researchers to stay close to customers with a platform that lets AI handle the heavy lifting from finding participants, to running interviews, to surfacing themes and insights. “AI-moderated research is here to stay, and rightly so. It has forever changed how quickly teams can gain a quick pulse on their audiences,” said Simon Glass, CEO of Discuss. “But no amount of technological advancement can replace the human bond. Speed without empathy is just noise. This release builds on what we’ve been doing for years: combining AI and human research so teams don’t have to choose. We see it less as an ‘either or’ choice and more as a practical evolution and we’re proud to be leading it.” Key Feature Highlights Turn past qual projects into a living knowledge base: The Enhanced Insights Agent leverages GenAI to automatically find answers to key questions across research, breaking down silos and making qualitative data instantly searchable. Scale consumer closeness for every use case with AI-led video interviews: Designed for real-time qual at scale, the enhanced Interview Agent now enables teams to test concepts, get UX feedback, run shop-alongs and gain consumer closeness. Find your target audience in hours, not weeks: Enhanced Project Agent is like a virtual assistant that builds screeners. It recruits from 3M+ vetted global participants representing B2B, B2C, and healthcare, with responses in under an hour. Feature Details Insights Agent: Building Knowledge Across Projects Q: How can I reuse past research without starting from scratch? For years, qualitative insights have lived in silos, forgotten after each project. With new Cross-Project Summaries, Discuss Insights Agent turns those silos into a searchable, evolving knowledge base. Teams can now synthesize insights across both AI-moderated and human-led projects, spotting consumer behavior shifts and answering new questions without repeating work. Instead of treating each study as an isolated exercise, researchers can build a living repository that grows in value over time. Interview Agent: Video Conversations With Real Human Depth Q: Can AI really conduct video interviews like a human moderator? Discuss’ enhanced Interview Agent now extends beyond audio to video, capturing not only what people say but also how they react in real time. Teams can present ads, product designs, or concepts directly within the interview, prompting instant feedback that the AI probes with smart follow-up questions. On mobile, participants can even flip their cameras for live, self-directed shop-alongs or in-home tours. It can also adapt questions in real time, run asynchronously across time zones, and engage respondents in dozens of languages. By capturing tone, expressions, and body language across dozens of languages, the Interview Agent delivers richer context at scale than surveys alone can provide. Project Agent: Rapid Access to the Right Audiences Q: How fast can I find the right consumers for an AI-led interview? The updated Project Agent makes sourcing global audiences seamless. With access to more than 3 million vetted participants across 150 countries and 100,000 job titles, brands can reach niche or global audiences in days. Whether connecting with B2B decision-makers in Berlin or Gen Z shoppers in São Paulo, insights arrive in as soon as an hour, enabling faster, more credible decisions without sacrificing quality. Why It Matters The pace of AI adoption has raised expectations for speed, but leading brands continue to rely on live, human conversations to capture nuance, empathy, and cultural context that algorithms cannot replicate. Discuss is the only market insights platform that unites AI- and human-led research, letting teams move quickly without compromise. With more than one million qualitative sessions across 100+ countries, Discuss brings a decade of proven global scale to the AI era. Its new features consolidate years of qualitative research experience into tools that anyone – not just researchers – can use to understand consumers. The bigger picture: Why does vibe coding matter to market insights? Borrowed from software development, where AI translates natural-language instructions into code, vibe coding in market insights democratizes access to research. For both AI- and human-moderated research, Discuss customers can simply describe what they want to learn, and AI agents handle everything from recruiting participants to synthesizing insights. What once required months of coordination and specialized expertise can now be achieved in hours while still offering the option of live, human-led sessions when nuance and empathy matter most. Industry Perspective The shift toward hybrid AI and human-led research is gaining traction across the industry. To highlight this evolution, Discuss is convening a live conversation with Forrester and Quadrant Strategies on August 28, 2025, featuring Rowan Curran, Principal Analyst at Forrester. The session explores how generative AI is reshaping research and the practical steps teams must take to turn disruption into opportunity. Register here. See Discuss and Meta at TMRE Discuss will take the stage with Meta at The Market Research Event (TMRE), October 28-30, 2025 in Las Vegas, NV to share how placing human-centric research at the center of UX design enabled the Meta Monetization team to surface deep behavioral insights, iterate faster, and build tools that are not just functional but meaningfully valuable to advertisers and marketers. The joint session will spotlight practical use cases and lessons learned from deploying Discuss’ market insights platform inside one of the world’s most innovative companies. See details here. Summary Launch: Discuss introduces “Vibe Coding” and hybrid AI + human market insight platform Why it matters: Redefines consumer insights research by uniting AI-moderated speed with the nuance of live human conversations Core differentiator: Only global insights platform proven to deliver both: AI agents that recruit, interview, and synthesize, plus live human moderation when empathy and cultural context matter Key innovations: Enhanced Insights Agent with cross-project summaries, Interview Agent with real-time video feedback and shop-alongs, and Project Agent sourcing 3M+ vetted participants in hours Industry validation: Discuss hosting over 1M qualitative sessions worldwide and set to present with Meta at TMRE 2025 on human-centered research in the AI era About Discuss Discuss is the leading AI-powered market insights platform, trusted by global brands and agencies to uncover authentic human understanding at scale. Built to shatter assumptions and bring human connection back to decision-making, the Discuss platform combines AI Agents, AI-moderated interviews, and live, human-led conversations in one end-to-end solution. Teams across marketing, product, UX, and consumer insights use Discuss to collect, analyze, and share in-depth feedback from audiences in more than 100 countries. With more than a million sessions conducted and recognition as a G2 Leader and GRIT Top 10 Most Innovative Technology Supplier, Discuss is the only proven market insights platform that delivers the best of both worlds: the speed and scale of AI-powered research with the nuance and trust of human-to-human insights. Customers include leading brands such as 3M, Suntory Global Spirits, Mastercard, HelloFresh, Reckitt, The Standard, Mondelez, Ipsos, and Escalent. Learn more at www.discuss.io. CONTACT: Suzame Tong Discuss PR@discuss.io"
DXCM,2025-08-28,76.26,76.36,74.21,75.08,
DXCM,2025-08-29,75.08,75.8,74.54,75.34,"[""San Diego's Dexcom lays off 350 employees Dexcom, a glucose-monitoring company based in San Diego, is laying off 350 employees. The company announced Wednesday that it was cutting 3% of its global workforce. Of the 350 laid off, 196 workers were based in San Diego. Most of the San Diego employees affected were in operations and manufacturing. \""Dexcom is taking proactive steps to position ourselves for long-term success through strategic changes to our organizational model and operating structure. This includes a reduction in force as we realign our structure to enhance our ability to deliver on our commitments,\"" a Dexcom spokesperson wrote in a statement to The Times. The layoffs follow the company\u2019s recent move to manufacture outside California. Last year, it announced a shift to centralize manufacturing in Arizona and eliminated 536 positions in San Diego. Founded in 1999, Dexcom has become a leading developer of the continuous glucose monitor. For people with diabetes, wearing a glucose monitor eliminates the need for fingerstick tests and allows their blood sugar levels to be tracked around the clock. When a patient\u2019s blood sugar shifts dangerously, Dexcom will alert them. Initially, the company's products primarily served people with Type 1 diabetes, an autoimmune disease that typically develops in adolescence. Over time, its research expanded to include those with Type 2 diabetes as well. The company also aims to expand its services to support customers with pre-diabetes and those who wish to monitor their glucose levels for wellness purposes. Most recently, it announced a new monitor that will be wearable for up to 15 days. Previously, the monitor was wearable for 10 days at most. The new version is scheduled for release in the next few months. This year, Dexcom also faced two recalls amid problems with the alerts on some of its glucose monitors. Dexcom\u2019s shares fell about 2% Thursday. The company's net income from the second quarter was $179.8 million, up from $143.5 million in the previous period last year, and revenue grew 15%, from $1.004 billion to $1.157 billion. Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights. This story originally appeared in Los Angeles Times."", ""If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the challenges, DexCom still has significant growth prospects and benefits from a moat. 10 stocks we like better than DexCom \u203a Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight months. Anything can happen in the short run that makes even the best businesses stumble. Top stocks, however, can consistently outperform broader equities over long periods, such as a decade. With that said, let's look at how DexCom has performed over the past 10 years and try to determine what kinds of returns it can deliver from here on out. DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed increased adoption over the past decade, partly thanks to DexCom's efforts. The company is a leader in this niche. DexCom's revenue has grown rapidly over this period, too, and the company managed to turn profitable. But a significant pullback over the past few years has destroyed some of its long-term gains. The result? Though DexCom's returns over the past 10 years haven't been terrible at all, they are below the performance of the S&P 500 over the same period. With a 12.99% annual return since 2015, a $1,000 investment in DexCom would be worth $3,391.56 as of the current date. That's good. But if you had invested $1,000 in an ETF that tracks the performance of the S&P 500, you'd have something close to $4,112.90. That's even better. Notably, the S&P 500's return is calculated with dividends reinvested. Without that, DexCom would still be below, but by a smaller margin. DexCom has faced slowing revenue growth over the past few years, partly due to fierce competition from Abbott Laboratories. Last year, the company also experienced lower revenue per patient, partly due to higher-than-anticipated rebate eligibility. Further, some still see the rise of GLP-1 medicines that help with obesity -- a significant risk factor for diabetes -- as a threat to DexCom's long-term prospects. However, despite these challenges, there are good reasons to be optimistic about DexCom's future. One of them is that, even though its CGM technology has experienced increased adoption, there is still a massive runway ahead. Abbott Laboratories, DexCom's main competitor, made this clear by pointing out almost two years ago that less than 1% of the world's diabetics use CGMs. Of course, this number varies from one country to another. In the U.S., penetration is higher than in most other countries. However, even in the U.S., there are more than 4.5 million patients on insulin who are eligible for third-party coverage for CGM but still aren't benefiting from the technology. DexCom ended 2024 with an installed base of approximately 2.8 to 2.9 million patients, representing a 25% increase compared to the previous fiscal year. It has already established itself as a leader in the niche and boasts a network effect thanks to its device being compatible with a host of other gadgets that help diabetes patients, including insulin pumps and pens. The company is likely to capture a decent portion of the remaining market. And again, that's only in the U.S. Over the long term, the company will benefit from other factors that should expand its addressable market. First, DexCom is constantly innovating. Last year, it launched an over-the-counter CGM device in the U.S. for diabetes patients who aren't on insulin and for people with prediabetes. The company's DexCom ONE, which it introduced a few years ago, caters to more price-sensitive customers in some regions. DexCom's innovative efforts should enable it to target a broader range of patients. Second, DexCom has benefited from increased third-party coverage worldwide for CGM technology, thanks to its constant demonstration of the benefits of its platform. That should also continue. Third, the medical device specialist can enter new markets as it has in the past. Lastly, the rise of GLP-1 therapies will not destroy DexCom's prospects. As the company has pointed out, physicians tend to prescribe weight management medicines in conjunction with CGM devices for eligible patients. The adoption of its devices remains robust among eligible GLP-1 patients. With that said, can DexCom outperform the market over the next 10 years? My view is that the company's sell-off over the past few years has gone too far, and at current levels, the stock is attractive given its position in the CGM market, its moat, and the massive whitespace remaining in the industry. DexCom still looks like a buy. Before you buy stock in DexCom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and DexCom wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $659,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,113,120!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,068% \u2014 a market-crushing outperformance compared to 185% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of August 25, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool"", ""Why Is DexCom (DXCM) Down 7% Since Last Earnings Report? It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is DexCom due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. DexCom reported second-quarter 2025 adjusted earnings per share of 48 cents, which beat the Zacks Consensus Estimate of 45 cents by 6.7%. The company reported earnings of 43 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 45 cents, up from the year-ago quarter\u2019s figure of 35 cents. Total revenues grew 15.2% (15% on an organic basis) to $1.16 billion year over year. Sales beat the Zacks Consensus Estimate by 3.1%. The year-over-year revenue growth was driven by continued strong category demand, focused execution and a growing contribution from recent access wins, especially for type 2 diabetes. Sensor and other revenues (97% of total revenues) increased 18% on a year-over-year basis to $1.12 billion. Hardware revenues (3%) decreased 31% year over year to $39.3 million. U.S. revenues (73% of total revenues) increased 15% on a year-over-year basis to $841 million. International revenues (27%) improved 16% (14% on an organic basis) year over year to $316.1 million. Adjusted gross profit totaled $695.9 million, up 9.1% from the prior-year quarter\u2019s level. DexCom reported an adjusted gross margin (as a percentage of revenues) of 60.1%, down 340 basis points year over year. Research and development expenses totaled $148.2 million, up 9% year over year. Selling, general, and administrative expenses totaled $328 million, down 1.4%. The company reported total adjusted operating income of $221.8 million, up 13.5% from the prior-year period\u2019s recorded number. Adjusted operating margin (as a percentage of revenues) was 19.2%, down 30 basis points year over year. DXCM exited the second quarter with cash, cash equivalents, and marketable securities worth $2.93 billion compared with $2.7 billion in the first quarter of 2025. Total assets amounted to $7.33 billion, up sequentially from $6.75 billion. DexCom raised its outlook for 2025 revenues. The company now expects revenues to be in the range of $4.6-$4.625 billion (previously $4.6 billion), implying 14-15% year-over-year growth. DXCM expects adjusted gross margin to be approximately 62%. Adjusted operating margin is projected to be approximately 21%. In the past month, investors have witnessed a downward trend in fresh estimates. Currently, DexCom has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, DexCom has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. DexCom belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, IQVIA Holdings (IQV), has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025. IQVIA reported revenues of $4.02 billion in the last reported quarter, representing a year-over-year change of +5.3%. EPS of $2.81 for the same period compares with $2.64 a year ago. For the current quarter, IQVIA is expected to post earnings of $2.96 per share, indicating a change of +4.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.5% over the last 30 days. IQVIA has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
DXCM,2025-09-02,74.17,75.1073,73.47,74.3,
DXCM,2025-09-03,74.32,79.51,74.0,78.92,
DXCM,2025-09-04,79.2,81.64,78.68,80.76,"Dexcom to lay off about 350 people This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom will cut about 350 jobs globally as part of a broader restructuring, the company confirmed with MedTech Dive on Thursday. Company spokesperson James McIntosh said in an email the cuts make up about 3% of Dexcom’s total workforce. About 196 of the people affected are based in San Diego, where Dexcom is headquartered. The cuts are due to changes in Dexcom’s organizational model and operating structure, McIntosh wrote. The layoffs follow a decision by Dexcom last year to move manufacturing from San Diego to Mesa, Arizona. At the time, Dexcom cut more than 500 jobs. In the latest round of cuts, Dexcom is eliminating 134 operations roles in San Diego as the company continues to transition manufacturing and operations to Arizona, McIntosh wrote. San Diego will remain the company’s product innovation center and global headquarters. The cuts cover a variety of positions, according to a California Worker Adjustment and Retraining Notification filing submitted in late August. They include manufacturing and sales jobs, as well as senior managers working in marketing, regulatory affairs, finance, mechanical engineering and other roles. The layoffs are expected to start on Nov. 3, according to the filing. Dexcom announced several changes in its most recent earnings call, including a leadership transition. Current CEO Kevin Sayer will step down in January, with Chief Operating Officer Jake Leach taking the helm. Dexcom is also preparing for the launch of a 15-day version of its G7 glucose monitor, which the company expects will start in the second half of the year, Sayer said in the July earnings call. Dexcom raised its sales expectations for 2025 in its second-quarter call. The company reported revenue of $1.16 billion, a 15% increase year over year, and net income of $179.8 million, a 25% increase. Recommended Reading Dexcom CEO Kevin Sayer to step down"
DXCM,2025-09-05,80.875,81.6,79.48,80.51,"[""Why DexCom (DXCM) Stock Is Up Today Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.3% in the afternoon session after company executives provided an optimistic outlook at the Wells Fargo Healthcare Conference on Wednesday. During the conference, management expressed confidence in achieving \""strong double-digit growth into the foreseeable future.\"" The company also noted that a new product launch is \""imminent.\"" A key catalyst highlighted was the expansion of market access, with the third quarter being the first time all three major Pharmacy Benefit Managers (PBMs) will provide coverage for its non-insulin diabetes products. The company's leadership described this expanded coverage as a \""real good opportunity,\"" signaling a positive trajectory for future sales and market penetration. After the initial pop the shares cooled down to $81.11, up 2.8% from previous close. Is now the time to buy DexCom? Access our full analysis report here, it\u2019s free. DexCom\u2019s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 6.3% on the news that the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices. Additionally, dovish signals from Federal Reserve Chair Jerome Powell in his Congressional testimony, reaffirming a \""wait-and-see\"" approach on interest rates, further calmed markets, improving investors' appetite for stocks and other risk assets. DexCom is up 3.3% since the beginning of the year, but at $81.11 per share, it is still trading 10.6% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom\u2019s shares 5 years ago would now be looking at an investment worth $814.68. Today\u2019s young investors likely haven\u2019t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next."", ""Dexcom Insider Sold Shares Worth $357,796, According to a Recent SEC Filing Jereme M Sylvain, Executive Vice President, Chief Financial Officer, on September 02, 2025, sold 4,8""]"
DXCM,2025-09-08,79.35,79.65,77.74,78.0,
DXCM,2025-09-09,77.61,79.2,77.61,78.4,
DXCM,2025-09-10,77.97,78.28,75.555,76.0,
DXCM,2025-09-11,76.24,77.93,75.85,76.0,
DXCM,2025-09-12,75.77,76.69,75.39,76.22,
DXCM,2025-09-15,76.44,78.96,75.525,75.58,
DXCM,2025-09-16,75.79,77.73,75.6,76.55,
DXCM,2025-09-17,76.99,77.84,75.5501,76.44,
DXCM,2025-09-18,72.93,75.96,71.84,75.78,
DXCM,2025-09-19,75.0,75.18,66.9,67.45,
DXCM,2025-09-22,67.69,70.5,66.57,69.51,
DXCM,2025-09-23,69.01,69.98,68.03,68.2,
DXCM,2025-09-24,68.265,70.18,67.14,67.5,
DXCM,2025-09-25,66.7,68.57,65.5,68.3,
DXCM,2025-09-26,68.05,69.25,66.71,67.1,
DXCM,2025-09-29,67.34,67.37,65.18,66.46,
DXCM,2025-09-30,66.7,67.61,66.18,67.29,
DXCM,2025-10-01,67.21,67.86,63.53,66.08,
DXCM,2025-10-02,65.79,66.82,64.67,66.44,
DXCM,2025-10-03,66.78,67.63,66.37,67.05,
DXCM,2025-10-06,67.9,68.0,66.12,66.36,
DXCM,2025-10-07,66.77,67.43,65.88,66.03,
DXCM,2025-10-08,65.96,67.88,64.9,67.78,
DXCM,2025-10-09,67.56,69.0,67.24,68.08,
DXCM,2025-10-10,68.15,68.5,65.03,65.12,
DXCM,2025-10-13,65.99,66.37,64.93,65.2,
DXCM,2025-10-14,63.85,67.29,63.195,66.22,
DXCM,2025-10-15,66.35,66.61,64.9,65.41,
DXCM,2025-10-16,66.0,66.68,64.985,66.33,
DXCM,2025-10-17,66.26,66.85,65.41,66.6,
DXCM,2025-10-20,67.05,68.47,66.7,68.43,
DXCM,2025-10-21,68.68,69.83,68.01,69.75,
DXCM,2025-10-22,70.44,71.99,69.75,70.7,
DXCM,2025-10-23,70.7,71.5,70.11,71.06,
DXCM,2025-10-24,71.14,72.08,70.31,70.33,
DXCM,2025-10-27,70.87,71.115,69.82,70.63,
DXCM,2025-10-28,70.665,70.665,66.42,69.23,
DXCM,2025-10-29,68.92,69.1,67.795,68.22,
DXCM,2025-10-30,68.36,69.17,68.0,68.17,
DXCM,2025-10-31,59.19,60.36,56.445,58.2101,
DXCM,2025-11-03,58.55,61.145,58.5,60.42,
DXCM,2025-11-04,61.09,62.39,58.88,61.18,
DXCM,2025-11-05,60.95,60.95,58.34,59.28,
DXCM,2025-11-06,58.97,60.0,56.89,58.02,
DXCM,2025-11-07,58.015,58.25,54.11,55.0,
DXCM,2025-11-10,55.16,55.895,54.22,54.84,
DXCM,2025-11-11,56.29,58.86,55.84,58.13,
DXCM,2025-11-12,58.07,59.79,57.51,59.61,
DXCM,2025-11-13,59.195,60.85,59.195,59.72,
DXCM,2025-11-14,59.05,59.47,57.92,58.06,
DXCM,2025-11-17,58.11,59.1,57.2,58.47,
DXCM,2025-11-18,58.35,60.48,58.14,60.17,
DXCM,2025-11-19,59.78,60.33,59.16,59.73,
DXCM,2025-11-20,59.72,60.755,58.285,58.41,
DXCM,2025-11-21,58.5,61.15,58.355,60.24,
DXCM,2025-11-24,60.38,62.85,60.07,62.21,
DXCM,2025-11-25,62.0,64.0,61.425,61.7,
DXCM,2025-11-26,61.36,63.085,61.31,62.54,
DXCM,2025-11-28,62.565,63.95,62.2301,63.47,
DXCM,2025-12-01,62.79,63.975,62.32,63.52,
DXCM,2025-12-02,65.09,65.315,64.36,64.45,
DXCM,2025-12-03,64.43,65.16,64.09,64.85,
DXCM,2025-12-04,65.13,65.335,64.09,65.25,
DXCM,2025-12-05,65.38,66.75,65.15,65.49,
DXCM,2025-12-08,65.26,66.04,64.0,65.62,
DXCM,2025-12-09,65.57,66.77,64.4,66.33,
DXCM,2025-12-10,66.485,68.22,65.61,67.56,
DXCM,2025-12-11,67.98,69.77,67.53,68.94,
DXCM,2025-12-12,69.025,69.31,66.675,66.96,
DXCM,2025-12-15,67.42,67.75,65.36,65.73,
DXCM,2025-12-16,66.35,67.0,65.2,66.365,
DXCM,2025-12-17,66.18,68.19,65.63,65.75,
DXCM,2025-12-18,66.31,66.67,65.56,65.89,
DXCM,2025-12-19,66.45,66.87,65.64,66.06,
DXCM,2025-12-22,66.16,67.95,66.12,67.43,
DXCM,2025-12-23,67.36,67.395,66.35,66.86,
DXCM,2025-12-24,66.92,67.51,66.75,67.42,
DXCM,2025-12-26,67.45,67.66,67.0,67.57,
DXCM,2025-12-29,67.59,68.18,67.12,67.47,
DXCM,2025-12-30,67.36,67.71,66.86,67.06,
DXCM,2025-12-31,67.1,67.15,66.0,66.37,
DXCM,2026-01-02,66.63,67.49,66.12,66.54,
DXCM,2026-01-05,66.64,67.94,65.19,67.65,
DXCM,2026-01-06,67.65,70.28,67.3,69.88,
DXCM,2026-01-07,69.76,70.92,69.12,70.1,
DXCM,2026-01-08,69.33,69.84,67.3,68.43,
DXCM,2026-01-09,68.61,68.89,65.6,67.4,
DXCM,2026-01-12,66.74,72.5,65.92,70.98,
DXCM,2026-01-13,70.89,70.92,68.465,70.25,
DXCM,2026-01-14,70.05,71.28,68.71,69.7,
DXCM,2026-01-15,69.65,70.055,68.97,69.24,
DXCM,2026-01-16,69.35,70.38,69.02,69.54,
DXCM,2026-01-20,68.77,71.3299,68.54,70.75,
DXCM,2026-01-21,71.29,72.81,70.75,72.12,
DXCM,2026-01-22,71.74,75.97,70.78,73.94,
DXCM,2026-01-23,73.05,73.51,71.66,72.86,
DXCM,2026-01-26,72.95,74.01,72.65,73.377,
DXCM,2026-01-27,73.215,73.88,71.845,73.67,
DXCM,2026-01-28,73.67,73.925,72.66,73.37,
DXCM,2026-01-29,73.32,74.205,72.34,74.03,
DXCM,2026-01-30,73.41,74.955,72.83,73.04,
DXCM,2026-02-02,72.705,73.59,72.41,72.55,
DXCM,2026-02-03,72.55,75.36,70.73,71.645,
DXCM,2026-02-04,71.86,72.275,70.48,70.83,
DXCM,2026-02-05,70.98,72.055,69.63,69.89,
DXCM,2026-02-06,70.57,70.68,68.68,69.97,
DXCM,2026-02-09,69.02,70.21,67.87,70.17,
DXCM,2026-02-10,70.18,70.34,68.12,68.16,
DXCM,2026-02-11,68.28,68.55,67.04,68.12,
DXCM,2026-02-12,68.01,69.0,64.88,65.13,
DXCM,2026-02-13,64.445,71.34,62.86,70.02,
DXCM,2026-02-17,70.25,72.19,69.81,70.41,
DXCM,2026-02-18,70.545,73.24,70.03,72.8,
DXCM,2026-02-19,72.785,73.155,71.61,72.27,